<SEC-DOCUMENT>0001564590-22-013004.txt : 20220331
<SEC-HEADER>0001564590-22-013004.hdr.sgml : 20220331
<ACCEPTANCE-DATETIME>20220331161703
ACCESSION NUMBER:		0001564590-22-013004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		138
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220331
DATE AS OF CHANGE:		20220331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celularity Inc
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38914
		FILM NUMBER:		22792776

	BUSINESS ADDRESS:	
		STREET 1:		1325 AVENUE OF THE AMERICAS
		STREET 2:		25TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		2126163700

	MAIL ADDRESS:	
		STREET 1:		1325 AVENUE OF THE AMERICAS
		STREET 2:		25TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GX Acquisition Corp.
		DATE OF NAME CHANGE:	20180912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>celu-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T18:54:27.9707388+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ccfc69a50e5a44e89f9a89b5c642c0de -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:celu="http://celularity.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
celu-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000002" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001752828_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:AmendmentFlag" contextRef="C_0001752828_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000005" name="dei:EntityCentralIndexKey" contextRef="C_0001752828_20210101_20211231">0001752828</ix:nonNumeric>
			<ix:nonNumeric id="F_000012" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001752828_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000450" name="us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear" contextRef="C_0001752828_20210101_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000493" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000494" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000931" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001055" name="us-gaap:RevenuePracticalExpedientFinancingComponent" contextRef="C_0001752828_20210101_20211231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000527" name="celu:LicenseArrangementTerm" contextRef="C_0001752828_20200806_20200806">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000534" name="celu:LicenseArrangementTerm" contextRef="C_0001752828_20210101_20211231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000809" name="celu:OptionToRenewLeaseTermPeriod" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001010" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001053" name="celu:PaymentPlansForCustomerToPayOverTimePeriod" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231">P24M</ix:nonNumeric>
			<ix:nonNumeric id="F_001052" name="celu:PaymentPlansForCustomerToPayOverTimePeriod" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231">P1M</ix:nonNumeric>
			<ix:nonNumeric id="F_001060" name="celu:LicensingArrangementTerm" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001064" name="celu:SupplyAndDistributionAgreementPeriod" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001065" name="celu:SupplyAndDistributionAgreementRenewalTerm" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001070" name="celu:SupplyAndDistributionAgreementPeriod" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001071" name="celu:SupplyAndDistributionAgreementRenewalTerm" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901">P2Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_001144" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20211231" decimals="-3">88221000</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_001148" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-3">7856000</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001752828_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001752828_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:PreferredStockValue" contextRef="C_0001752828_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000097" name="us-gaap:PreferredStockValue" contextRef="C_0001752828_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000613" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231">P4Y6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000614" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000626" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">P3Y8M1D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000620" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716" decimals="2">9.66</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000621" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716" decimals="2">10.20</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000622" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231" decimals="2">4.17</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000623" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231" decimals="2">6.95</ix:nonFraction>
			<ix:nonNumeric id="F_000627" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">P3M29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000628" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">P1Y3M29D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000632" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231" decimals="2">0.09</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000633" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231" decimals="2">0.10</ix:nonFraction>
			<ix:nonNumeric id="F_000644" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">P3Y8M1D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000638" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716" decimals="2">9.66</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000639" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716" decimals="2">10.20</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000640" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231" decimals="2">4.17</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000641" name="celu:FairValuesOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231" decimals="2">6.95</ix:nonFraction>
			<ix:nonNumeric id="F_000645" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">P3M29D</ix:nonNumeric>
			<ix:nonNumeric id="F_000646" name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">P1Y3M29D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000650" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="2">0.09</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000651" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="2">0.10</ix:nonFraction>
			<ix:nonNumeric id="F_000662" name="celu:ValuationInputForConvertiblePromissoryNoteTerm" contextRef="C_0001752828_20200101_20201231">P7M6D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000655" name="celu:PercentageOfCouponRate" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231" decimals="2">0.12</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000656" name="celu:PercentageOfCouponRate" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231" decimals="2">0.17</ix:nonFraction>
			<ix:nonNumeric id="F_000660" name="celu:ValuationInputForConvertiblePromissoryNoteTerm" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231">P8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000661" name="celu:ValuationInputForConvertiblePromissoryNoteTerm" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231">P3Y2M8D</ix:nonNumeric>
			<ix:nonNumeric id="F_000760" name="celu:IndefiniteLivedIntangibleAssetsAmortizationMethod" contextRef="C_0001752828_20210101_20211231">Indefinite</ix:nonNumeric>
			<ix:nonNumeric id="F_000767" name="celu:IndefiniteLivedIntangibleAssetsAmortizationMethod" contextRef="C_0001752828_20200101_20201231">Indefinite</ix:nonNumeric>
			<ix:nonNumeric id="F_000761" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231">P11Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000762" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000763" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231">P16Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000764" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231">P13Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000768" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231">P11Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000769" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000770" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231">P16Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000771" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231">P13Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000936" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001752828_20210101_20211231">P4Y7M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000937" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001752828_20200101_20201231">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000964" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20190101_20191231">P7Y7M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000965" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231">P7Y3M18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000966" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">P7Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000967" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">P7Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000968" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">P6Y10M24D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="celu-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001752828_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_20220325">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">celu:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">celu:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCariCordIncorporatedMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:CariCordIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CTHBiosourcingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CTHBiosourcingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CTHBiosourcingLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">celu:GXAcquisitionCorpMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXSponsorWarrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:GXSponsorWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_celuClinicalTrial">
				<xbrli:measure>celu:ClinicalTrial</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuHLICellularTherapeuticsLLCMember_20170531_20170531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:HLICellularTherapeuticsLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-05-31</xbrli:startDate>
					<xbrli:endDate>2017-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170815_20170815">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AnthrogenesisMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-08-15</xbrli:startDate>
					<xbrli:endDate>2017-08-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AnthrogenesisMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-08-01</xbrli:startDate>
					<xbrli:endDate>2017-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlliquaAPAMember_20180507_20180507">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AlliquaAPAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-05-07</xbrli:startDate>
					<xbrli:endDate>2018-05-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20180507">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-05-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCaricordMember_20181005_20181005">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:CaricordMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-05</xbrli:startDate>
					<xbrli:endDate>2018-10-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareDevelopmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_celuSegment">
				<xbrli:measure>celu:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_20200101_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20200701_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtMajorCustomersAxis_celuCustomerTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:CustomerTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlphaFirstMergerSubIncorporationMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AlphaFirstMergerSubIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuSurvivingCorporationMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:SurvivingCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:CelularityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuGXTrustAccountMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:GXTrustAccountMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:GXWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:GXWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20200806_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-06</xbrli:startDate>
					<xbrli:endDate>2020-08-06</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:MISTUltraMISTBusinessMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-06</xbrli:startDate>
					<xbrli:endDate>2020-08-06</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:MISTUltraMISTBusinessMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-06</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:MISTUltraMISTBusinessMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-06</xbrli:startDate>
					<xbrli:endDate>2020-08-06</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-06</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">celu:UltraMISTBusinessMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">celu:UltraMISTBusinessMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:PublicWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:PublicWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-16</xbrli:startDate>
					<xbrli:endDate>2021-07-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210801">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-08-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210607_20210608">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-07</xbrli:startDate>
					<xbrli:endDate>2021-06-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_celuDay">
				<xbrli:measure>celu:Day</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001752828_srtStatementGeographicalAxis_celuWarrenNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeSpaceMember_20170901_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeSpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:WarrenNewJerseyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-01</xbrli:startDate>
					<xbrli:endDate>2017-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtStatementGeographicalAxis_celuCedarKnollsNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeAndLaboratorySpaceMember_20191101_20191101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:CedarKnollsNewJerseyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-01</xbrli:startDate>
					<xbrli:endDate>2019-11-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-03-13</xbrli:startDate>
					<xbrli:endDate>2019-03-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:HLICellularTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:LLCAndAnthrogenesisMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:HLICellularTherapeuticsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:LLCAndAnthrogenesisMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210505_20210505">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-05</xbrli:startDate>
					<xbrli:endDate>2021-05-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-12-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210324_20210324">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CariCordParticipatingShareholdersMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-24</xbrli:startDate>
					<xbrli:endDate>2021-03-24</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CariCordParticipatingShareholdersMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-16</xbrli:startDate>
					<xbrli:endDate>2020-03-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-16</xbrli:startDate>
					<xbrli:endDate>2020-03-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-16</xbrli:startDate>
					<xbrli:endDate>2020-03-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBPreferredStockPurchaseAgreementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBPreferredStockPurchaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStocksMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStocksMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemablesConvertiblePreferredStocksMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemablesConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20180507">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-05-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215_20190215">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-15</xbrli:startDate>
					<xbrli:endDate>2019-02-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedAndRestatedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190529">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:AmendedAndRestatedDragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-05-31</xbrli:startDate>
					<xbrli:endDate>2019-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:AmendedDragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-11-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-11-04</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104_20191104">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-11-04</xbrli:startDate>
					<xbrli:endDate>2019-11-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109_20200109">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-09</xbrli:startDate>
					<xbrli:endDate>2020-01-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-16</xbrli:startDate>
					<xbrli:endDate>2020-03-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20200316_20200316">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-16</xbrli:startDate>
					<xbrli:endDate>2020-03-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_celuLegacyGXWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">celu:LegacyGXWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:SponsorsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:March2020SeriesBWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:PublicWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:SponsorWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20210301_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20210701_20210731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapLiabilitiesTotalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20210701_20210930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-07-01</xbrli:startDate>
					<xbrli:endDate>2021-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_20200403_20200403">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-03</xbrli:startDate>
					<xbrli:endDate>2020-04-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SanuwaveLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-06</xbrli:startDate>
					<xbrli:endDate>2020-08-06</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SanuwaveLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:ArthrexAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-05-07</xbrli:startDate>
					<xbrli:endDate>2021-05-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:EvolutionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-09-01</xbrli:startDate>
					<xbrli:endDate>2021-09-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:EvolutionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:OtherMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-13</xbrli:startDate>
					<xbrli:endDate>2020-04-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-15</xbrli:startDate>
					<xbrli:endDate>2020-10-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CURAFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CURAFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCOTAIncMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:COTAIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CryoportSystemsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CryoportSystemsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_20210608">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CVStarLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-08</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CVStarLoanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:StockPurchaseAgreementWithDirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-18</xbrli:startDate>
					<xbrli:endDate>2020-09-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MsHariniMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MsHariniMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MsHariniMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_srtCounterpartyNameAxis_celuMrPecoraMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MrPecoraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220301">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000594"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000624 F_000625"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000004" fromRefs="F_000694 F_000695"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000005" fromRefs="F_000704 F_000705"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000002" fromRefs="F_000642 F_000643"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000003" fromRefs="F_000692 F_000693"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000001" name="dei:DocumentType" contextRef="C_0001752828_20210101_20211231">10-K</ix:nonNumeric><span style="font-weight:normal;"> </span></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (Mark&#160;One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:DocumentAnnualReport" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000010" name="dei:DocumentPeriodEndDate" contextRef="C_0001752828_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000011" name="dei:DocumentFiscalYearFocus" contextRef="C_0001752828_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:DocumentTransitionReport" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number&#160;<ix:nonNumeric id="F_000019" name="dei:EntityFileNumber" contextRef="C_0001752828_20210101_20211231">001-38914</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0001752828_20210101_20211231">Celularity Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001752828_20210101_20211231">83-1702591</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressAddressLine1" contextRef="C_0001752828_20210101_20211231">170 Park Ave</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressCityOrTown" contextRef="C_0001752828_20210101_20211231">Florham Park</ix:nonNumeric>, <ix:nonNumeric id="F_000024" name="dei:EntityAddressStateOrProvince" contextRef="C_0001752828_20210101_20211231">NJ</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressPostalZipCode" contextRef="C_0001752828_20210101_20211231">07932</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric id="F_000026" name="dei:CityAreaCode" contextRef="C_0001752828_20210101_20211231">(908)</ix:nonNumeric>&#160;<ix:nonNumeric id="F_000027" name="dei:LocalPhoneNumber" contextRef="C_0001752828_20210101_20211231">768-2170</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:Security12bTitle" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231">Class A common stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:TradingSymbol" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231">CELU</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:SecurityExchangeName" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:Security12bTitle" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231">Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:TradingSymbol" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231">CELUW</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;">&#160;</p></td>
<td valign="bottom" style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000034" name="dei:SecurityExchangeName" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <span style="font-weight:bold;">None </span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes<span style="text-transform:uppercase;"> </span><span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;<ix:nonNumeric id="F_000008" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001752828_20210101_20211231">No</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.<span style="font-size:10pt;">&#160;</span>Yes <span style="font-family:Segoe UI Symbol;">&#9744;</span> <ix:nonNumeric id="F_000007" name="dei:EntityVoluntaryFilers" contextRef="C_0001752828_20210101_20211231">No</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.<span style="font-size:10pt;">&#160;</span><ix:nonNumeric id="F_000006" name="dei:EntityCurrentReportingStatus" contextRef="C_0001752828_20210101_20211231">Yes</ix:nonNumeric> <span style="font-family:Segoe UI Symbol;">&#9746;</span> No <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric id="F_000031" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001752828_20210101_20211231">Yes</ix:nonNumeric><span style="font-size:10pt;"> </span><span style="font-family:Segoe UI Symbol;">&#9746;</span> No <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000016" name="dei:EntityExTransitionPeriod" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> No <span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of Class A common stock on the Nasdaq Stock Market on June&#160;30, 2021, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="dei:EntityPublicFloat" contextRef="C_0001752828_20210630" decimals="-5" scale="6">128.1</ix:nonFraction> million. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of the registrant&#8217;s Class A common stock outstanding as of March&#160;25, 2022 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000003" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001752828_20220325" decimals="INF" format="ixt:numdotdecimal">137,720,526</ix:nonFraction>. </p><ix:nonNumeric id="F_000356" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">None.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:82.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">[Reserved]</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9C.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR"><span style="text-decoration:underline;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits, Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:82.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;16, 2021, we consummated the previously announced merger pursuant to that certain Merger Agreement and Plan of Reorganization, dated January&#160;8, 2021, or the Merger Agreement, by and among us, our wholly-owned merger subs and Celularity LLC (formerly known as Celularity Inc.), or Legacy Celularity.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, we effected the business combination through the (a) merger of our wholly-owned merger sub with and into Legacy Celularity with Legacy Celularity surviving as our wholly-owned&#160;subsidiary and (b) immediately following the first merger and as part of the same overall transaction, the merger of the Legacy Celularity, as surviving corporation of the first merger, with and into a second wholly-owned merger sub, with such second wholly-owned merger sub as the surviving entity of the second merger, which ultimately resulted in Legacy Celularity becoming our wholly-owned&#160;direct subsidiary.&#160;&#160;We refer to these mergers as the &#8220;Mergers&#8221; and, collectively with the other transactions described in the Merger Agreement, the &#8220;Business Combination&#8221;. On the Closing Date, we changed our name from GX Acquisition Corp. to Celularity Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the context indicates otherwise, references in this annual report to the &#8220;Company,&#8221; &#8220;Celularity,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Celularity Inc. (f/k/a GX Acquisition Corp.) and its consolidated subsidiaries (including Legacy Celularity). References to &#8220;GX&#8221; refer to the predecessor company prior to the consummation of the Business Combination.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Celularity logo, Celularity IMPACT, Biovance, Interfyl, Lifebank, CentaFlex and other trademarks or service marks of Celularity Inc. appearing in this annual report are the property of Celularity Inc. This annual report on Form 10-K also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">SUMMARY RISK FACTORS</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our business involves significant risks. Below is a summary of the material risks that our business faces, which makes an investment in our securities speculative and risky. This summary does not address all these risks. These risks are more fully described below under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A of this annual report on Form 10-K. Before making investment decisions regarding our securities, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could decline, and you could lose all or part of your investment. In addition, there are also additional risks not described below that are either not presently known to us or that we currently deem immaterial, and these additional risks could also materially impair our business, operations or market price of our Class A common stock.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We have incurred net losses in every period since our inception, have no cellular therapeutic candidates approved for commercial sale and we anticipate that we will incur substantial net losses in the future.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our placental-derived&#160;cellular therapy candidates represent a novel approach to cancer, infectious and degenerative disease treatments that creates significant challenges.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our historical operating results indicate substantial doubt exists related to our ability to continue as a going concern.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19&#160;pandemic and future outbreaks of the disease, in regions where we or third parties on which we rely have concentrations of clinical trial sites or other business operations.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our business is highly dependent on the success of our lead therapeutic candidates. If we are unable to obtain regulatory approval for our lead candidates and effectively commercialize its lead therapeutic candidates for the treatment of patients in approved indications, our business would be significantly harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We rely on CAR-T&#160;viral vectors from Sorrento Therapeutics, Inc., or Sorrento, for our CYCART-19&#160;therapeutic candidate and termination of this license, or any future licenses, could result in the loss of significant rights, which would harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of, or commercialize, our therapeutic candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">The U.S. Food and Drug Administration, or FDA, regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory of our therapeutic candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We may not be able to file Investigational New Drug, or IND, applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed, and if so, we may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We operate our own manufacturing and storage facility, which requires significant resources&#59; manufacturing or other failures could adversely affect our clinical trials and the commercial viability of our therapeutic candidates and our biobanking and degenerative diseases businesses.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We rely on donors of healthy human full-term&#160;post-partum&#160;placentas to manufacture our therapeutic candidates, and if we do not obtain an adequate supply of such placentas from qualified donors, development of our placental-derived&#160;allogeneic cells may be adversely impacted.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our clinical trials may fail to demonstrate the safety and/or efficacy of any of our therapeutic candidates, which would prevent or delay regulatory approval and commercialization.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">If our effort to protect the proprietary nature of the intellectual property related to our technologies are inadequate, we may not be able to compete effectively in our market.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We are, and in the future may be, party to agreements with third parties. Disputes may arise with such third parties regarding the terms of such agreements, including terms governing payment obligations, contractual interpretation, or related intellectual property ownership or use rights, which could materially adversely impact us, including by requiring the payment of additional amounts, or requiring us to invest time and money in litigation or arbitration.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our therapeutic candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We will need substantial additional financing to develop our therapeutics and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our therapeutic candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Our relationship with customers, physicians, and third-party&#160;payors are subject to numerous laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to various compliance initiatives.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.89%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the statements contained in this annual report on form 10-K constitute forward-looking statements within the meaning of <span style="Background-color:#FFFFFF;color:#000000;">Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act.&#160;</span>. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. <span style="Background-color:#FFFFFF;color:#000000;">These statements relate to our future events, including our anticipated operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to,</span><span style="color:#000000;">&#160;statements about:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the success, cost, timing and potential indications of our cellular therapy candidate development activities and clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of any approved therapeutic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our therapeutic candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability and plans to research, develop, manufacture and commercialize our therapeutic candidates, as well as our degenerative disease products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to attract and retain collaborators with development, regulatory and commercialization expertise&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the size of the markets for our therapeutic candidates, and our ability to serve those markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to successfully commercialize our therapeutic candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our expenses, future revenues, capital requirements and needs for additional financing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our use of cash and other resources&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our expectations regarding our ability to obtain and maintain intellectual property protection for our therapeutic candidates, degenerative disease products, and our ability to operate our business without infringing on the intellectual property rights of others.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify these forward-looking statements by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;outlook,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strive,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and the negative version of these words or other comparable words or phrases, but the absence of these words does not mean that a statement is not forward-looking. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this annual report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this annual report on Form 10-K and the documents that we reference in this annual report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this annual report on Form 10-K.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">Item 1. Business. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:5.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. We are developing a pipeline of off-the-shelf placental-derived allogenic cell therapy product candidates including T cells engineered with a chimeric antigen receptor, or CAR, unmodified and genetically modified natural killer, or NK cells, and mesenchymal-like adherent stromal cells, or ASCs. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. We believe that by harnessing the placenta&#8217;s unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible and affordable therapeutics. We currently have three active clinical trials and plan to submit two additional IND applications in 2022. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:5.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Celularity IMPACT platform capitalizes on the benefits of placenta-derived cells to target multiple diseases, and provides seamless integration, from bio sourcing through manufacturing cryopreserved and packaged allogeneic cells, in our purpose-built U.S.-based approximately 150,000 square foot facility. We believe the use of placental-derived cells, sourced from the placentas of full-term healthy informed consent donors, has potential inherent advantages, from a scientific and an economic perspective. First, relative to adult-derived cells, placental-derived cells demonstrate greater stemness, meaning the ability to expand and persist. Second, placental-derived cells are immunologically na&#239;ve, meaning the cells have never been exposed to a specific antigen, and suggesting the potential for less toxicity and for low or no graft-versus-host disease, or GvHD, in transplant. Third, our placental-derived cells are allogeneic, meaning they are intended for use in any patient, as compared to autologous cells, which are derived from an individual patient for that patient&#8217;s sole use. We believe this a key difference that will enable readily available off-the-shelf treatments that can be delivered faster, more reliably, at greater scale and to more patients.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:5.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From a single source material, the postpartum human placenta, we derive four allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which are used in five key cell therapeutic programs: CYCART-19, CYNK-001, CYNK-101, APPL-001, and PDA-002- that in turn are, focused on six initial indications. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor, the construct and related CARs for which are in-licensed from Sorrento Therapeutics, Inc., or Sorrento. We plan to submit an IND and to commence a Phase 1 clinical trial of CYCART-19 in the first half of 2022. CYNK-001 is a placental-derived unmodified NK cell in development for the treatment of acute myeloid leukemia, or AML, a blood cancer, and for glioblastoma multiforme, or GBM, a solid tumor cancer. CYNK-001 is currently in Phase 1 trial for AML and a Phase 1/2a trial for GBM, respectively. CYNK-101 is genetically modified version of a placental-derived NK-cell. We <span style="color:#000000;">initiated a Phase 1 trial of CYNK-101 in patients with HER2+ gastric and gastroesophageal cancers during the fourth quarter</span>. <span style="color:#000000;">CYNK-101 will be evaluated in combination with monoclonal antibodies, or mAbs, to target HER2+ (traztuzumab) and PDl-1 (pembrolizumab). </span>APPL-001 is a placenta-derived ASC being developed for the treatment of Crohn&#8217;s disease, a degenerative disease. PDA-002 is a placenta-derived ASC being developed for the treatment of Facioscapulohumeral muscular dystrophy, or FSHD.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Celularity IMPACT manufacturing process is a seamless, fully integrated process designed to optimize speed and scalability from the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific CMC, advanced cell manufacturing and cryopreservation. The result is a suite of allogeneic inventory-ready, on demand placental-derived cell therapy products. In addition, we have non-core legacy operations that are complementary to our work in placenta-derived cell therapeutics, including biobanking operations that include the collection, processing and cryogenic storage of certain birth byproducts for third-parties, and our degenerative disease business consists of the manufacture and sale of our Biovance and Interfyl products, directly and through our network of distribution partners. See &#8220;&#8212;<span style="font-style:italic;"> Commercial Businesses</span>&#8221; for more information regarding these operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current science is the product of the cumulative background and effort over two decades of our seasoned and experienced management team. We have our roots in Anthrogenesis Corporation, or Anthrogenesis, a company founded under the name Lifebank in 1998 by Robert J. Hariri, M.D., Ph.D., our founder and Chief Executive Officer, and acquired in 2002 by Celgene Corporation, or Celgene. The team continued to hone their expertise in the field of placental-derived technology at Celgene through August 2017, when we, acquired Anthrogenesis. Celularity has a robust global intellectual property portfolio comprised of over 1,500 patents and patent applications protecting our Celularity IMPACT platform, our processes, technologies and current key cell therapy programs. We believe this know-how, expertise and intellectual property will drive the rapid development and, if approved, commercialization of these potentially lifesaving therapies for patients with unmet medical needs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> Pipeline</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leveraging our Celularity IMPACT platform, we have four placental-derived allogeneic cell types: T&#160;cells, unmodified NK cells, genetically modified NK cells and ASCs. From this, we have five key therapeutic programs in clinical development focused on six initial indications.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000001.jpg" title="" alt="" style="width:674px;height:305px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Celularity IMPACT Platform</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placental-derived cell therapies offer potentially lifesaving therapies for patients with unmet medical needs. We have developed and acquired proprietary technology for collecting, processing and storing placental stem cells with potentially broad therapeutic applications across cancer, infectious and degenerative diseases.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use our proprietary Celularity IMPACT platform for the development of <span style="font-weight:bold;">I</span>mmuno-<span style="font-weight:bold;">M</span>odulatory <span style="font-weight:bold;">P</span>lacenta-derived <span style="font-weight:bold;">A</span>llogeneic <span style="font-weight:bold;">C</span>ell <span style="font-weight:bold;">T</span>herapies. We believe that by harnessing the placenta&#8217;s unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible and affordable therapeutics.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Celularity IMPACT manufacturing process is a seamless, fully integrated process that is built to optimize speed and scale from sourcing of human full term healthy postpartum donated placentas through proprietary processing methods, cell selection, product-specific CMC, advanced cell manufacturing and cryopreservation and result in allogeneic inventory-ready and on demand placental-derived cell therapy products. The fully integrated process is housed in our purpose-built manufacturing, translational research and biobanking facility.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Celularity IMPACT platform capitalizes on our integrated processes and the unique biologic characteristics of placenta-derived allogeneic cells to target multiple diseases including indications across cancer, infectious and degenerative diseases. The platform is designed to accelerate the speed at which therapies can be provided to patients while ensuring manufacturing excellence of high quality and pure placental-derived cell therapy products at a lower cost of goods. We believe cell therapy inventory should be available to physicians on demand to treat patients in need and to enable repeat dosing regimens that other cell therapy platforms will not be able to support.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman PS Std;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000002.jpg" title="" alt="" style="width:600px;height:261px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman PS Std;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000003.jpg" title="" alt="" style="width:587px;height:245px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at greater scale and quality with attractive economics. We believe achieving this goal will result in placental-derived allogeneic cell therapies becoming a standard of care in various indications across cancer, infectious and degenerative diseases, and enable us to make potentially lifesaving therapies more readily accessible to more patients throughout the world. We plan to achieve this mission by:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Leveraging the inherent advantages of placental-derived cells</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;&#160;&#160;Our cells come from the postpartum placenta donated by healthy donors who have signed an informed consent, representing a renewable, economical and highly scalable starting material collected under rigorous controls. We use those cells to produce on-demand, off-the-shelf investigational allogeneic cellular therapy products investigational medicines that are designed to sidestep treatment delays inherent to more costly autologous cell therapies and other allogeneic cell therapy approaches, all while offering the potential for greater in vivo expansion, persistence, potency and acceptance. Further, we believe the immunological na&#239;vet&#233; of placental cells may allow for potentially less toxicity.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capturing efficiencies through our integrated</span><span style="font-size:10pt;color:#000000;"> </span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Celularity IMPACT platform</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;&#160;&#160;Manufacturing allogeneic cell therapeutic candidates involves a series of complex and precise steps. We believe a critical component to our success will be to leverage our rapidly scalable, end-to-end supply chain. Applying proprietary manufacturing know-how, expertise and capacity utilizing our purpose-built U.S.-based cGMP compliant facility, we believe our fully integrated manufacturing operations and infrastructure will allow us to improve the manufacturing process, eliminate reliance on contract manufacturing organizations, or CMOs, and more rapidly advance therapeutic candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Selectively targeting indications with unmet patient need with potential for accelerated development</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;&#160;&#160;Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could provide an advantage, both in terms of development (sourcing and </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:10pt;color:#000000;">proliferation) and potential efficacy (affinity). In selecting indications, </span><span style="font-size:10pt;color:#000000;">we</span><span style="font-size:10pt;color:#000000;"> evaluate where the biological properties of placental-derived cells position them for success, as well as where there is a clearly defined regulatory pathway providing the potential for accelerated development to address unmet patient need.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Continuing to invest in basic and translational research</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;&#160;&#160;We intend to continue to invest in the discovery and development of additional pipeline cell franchises and explore other placental-derived cell opportunities. Preclinical and early clinical data demonstrating the unique biological activity and potential of placental-derived stem cells, provide potential for multiple highly effective cell therapy programs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Benefiting from collective experience of deep, seasoned management team</span><span style="font-style:italic;font-size:10pt;color:#000000;">.</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;We have a deep, seasoned management team with experience in all aspects of cellular medicine, including discovery and translational research, clinical development and product approval, manufacturing and process development and commercialization. For over two decades, the team has been at the vanguard of cellular medicine, and has collectively seen a number of programs, including one cell therapy, through FDA-approval to commercialization.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Team and Corporate History</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anthrogenesis Corporation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have our roots in Anthrogenesis, a corporation founded under the name Lifebank in 1998 by Robert&#160;J.&#160;Hariri, M.D., Ph.D., our founder and Chief Executive Officer. Like us, Anthrogenesis was focused on developing and delivering cellular therapies using placental-derived stem cells for the treatment of cancers, degenerative and infectious diseases. Celgene acquired Anthrogenesis in December 2002 in a stock-for-stock merger, and operated Anthrogenesis as Celgene Cellular Therapeutics, or CCT, a wholly-owned subsidiary of Celgene. Similarly, CCT continued to focus on the research and development of placental-derived stem cells. In 2016, Dr. Hariri formed Celularity and began acquiring the assets that form our business today. These include our degenerative disease and biobanking businesses, which Celgene had sold to Human Longevity, Inc., or HLI, a genomic-based health intelligence company co-founded by Dr. Hariri and Dr. Diamandis, one of our directors, as well as our core cellular therapeutics business, which we acquired in August 2017, when we acquired Anthrogenesis from Celgene in exchange for stock and event-driven contingent value rights, or CVRs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Celgene Corporation (acquired by Bristol Myers Squibb)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, in connection with the Anthrogenesis acquisition, we entered into a license agreement with Celgene. Pursuant to the license with Celgene, we granted Celgene a worldwide, royalty-free, fully-paid up, non-exclusive license under Anthrogenesis&#8217; intellectual property in existence as of the date of the Celgene license or as developed by Celgene in connection with any transition services activities related to the merger for preclinical research purposes, as well as to develop, manufacture, commercialize and fully exploit products and services that relate to the construction of any CAR, the modification of any T-cell or NK cell to express such a CAR, and/or the use of such CARs or T-cells or NK cells for any purpose, which commercial license is sublicensable. Either party may terminate the Celgene license upon an uncured material breach of the agreement by the other party or insolvency of the other party.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contingent Value Rights</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, in connection with the Anthrogenesis acquisition, we issued shares of our Series X Preferred Stock to Celgene as merger consideration and entered into the contingent value agreement with Celgene, or the CVR Agreement. Pursuant to the CVR Agreement, we issued one CVR in respect of each share of Series X Preferred Stock issued to Celgene in the acquisition. Such CVRs are not separable from the shares of Series&#160;X Preferred Stock other than in an initial public offering or a sale of our company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CVR Agreement entitles the holders of the CVRs to an aggregate amount, on a per program basis, of $50 million in regulatory milestones and an aggregate $125 million in commercial milestone payments with respect to certain of our investigational therapeutic programs, which would include the current CYNK-001, CYNK-101 and PDA-002 pipeline candidates and the legacy PDA-001 program (a placenta-derived adherent cells, proprietary to Anthrogenesis, that is formulated for intravenous delivery) that are no longer in development. Such payments under the CVR Agreement also expressly cover PNK-007 (which includes certain NK cells proprietary to Anthrogenesis, produced by a process proprietary to Anthrogenesis as of the closing of the Anthrogenesis transaction) and certain PNK-007 cells with a genetic modification (but not including NK cells with a chimeric receptor, including a CAR), along with any derivatives, parts, subparts, or progeny of any of the foregoing, or any therapeutic based or derived (in whole or in part) on certain related development programs as they existed as of the closing of the Anthrogenesis transaction. Accordingly, as we expand our NK cell type franchise into new indications and, as a general matter, because these payments are not payable until a later stage of development, we expect to continue to evaluate our present and future therapeutic candidates as they develop and evolve in light of the specific terms in the CVR Agreement to determine the specific therapeutics on which such amounts will be payable. In addition, with respect to each </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such program and calendar year, the CVR holders will be entitled to receive a royalty equal to a mid-teen percentage of the annual net sales for such program&#8217;s therapeutics from the date of the first commercial sale of such program&#8217;s therapeutic in a particular country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program therapeutic in such country, the expiration of marketing exclusivity with respect to such therapeutic in such country, and August 2027 (i.e., the tenth anniversary of the closing of the acquisition of Anthrogenesis). No payments under the CVR Agreement have been made to date.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investors&#8217; Rights Agreement and Investment Rights Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also entered into an investors&#8217; rights agreement and an investment rights agreement, each with Celgene and certain other parties thereto in August 2017 in connection with the Anthrogenesis acquisition. For more information regarding these agreements, see Item 13 &#8220;<span style="font-style:italic;">Certain Relationships and Related Transactions, and Director Independence &#8212; License and Other Agreements</span>&#8221; of this annual report.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allogeneic Placental-Derived Cells</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biomaterials Collection</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial source material for our four allogeneic cell types is the postpartum human placenta. We source human placental birth material used for the manufacture of our products from accredited hospitals and birth centers, with collections performed by licensed health care professionals. Eligibility for donation is determined by a donor screening process that includes education about the donor program, obtaining informed consent from the donor and completion of a detailed maternal health questionnaire and family health history. These forms are completed by the donor, with assistance from trained collection technicians as needed. Donors providing birth materials do not encounter any fees and are not renumerated. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensed health care professionals collect donor material utilizing our proprietary collection kits, which include barcode labels for biomaterials (cord blood, placenta and maternal blood samples) along with appropriate chain of custody documentation. Once collected, the donated material and a maternal blood sample are shipped in an insulated container via courier to our Florham Park, New Jersey laboratory and manufacturing facility.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon arrival at our facility, the donated material is reviewed for labeling completeness and accuracy of the barcoded kit and is electronically coded into a validated software database. If all quality criteria are met, the donated material is then individually evaluated and forwarded to the appropriate production suite for processing and manufacturing. We believe that our sourcing is rapidly scalable due to numerous established procurement relationships that provide a constant renewable supply to meet current and future manufacturing needs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unique Biology of Placenta-Derived Cells</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placental-derived cells have unique biology related to immunological na&#239;vet&#233;, stemness, persistence and proliferation that makes them a biologically preferred starting material with the potential for less toxicity and superior biological activity relative to adult bone marrow or peripheral blood-derived cells.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research has shown that the human placenta is a novel and valuable source of multipotential stem/progenitor cells of mesenchymal and hematopoietic origin, which have multiple therapeutic applications. Our characterization data show that approximately one to five percent of placental-derived cells are CD34+ hematopoietic stem cells, or HSCs, among which expression of certain markers suggests that such HSCs have more self-renewal capacity and the potential to facilitate the early engraftment of the placental-derived cells. In addition, further characterization has shown low T-cell content and immature T subpopulations. This demonstrated immunological na&#239;vet&#233; further suggests the potential for low or no GvHD in transplant. Furthermore, mesenchymal-like cells have been shown to possess other characteristics, capabilities and effects (<span style="font-style:italic;">e.g.</span>, osteogenic, chondrogenic, adipogenic differentiation capabilities and immunomodulatory effects). The high quantity of mesenchymal-like cells and Treg cells indicate that placental-derived cells can potentially contribute to prevention of GvHD and host microenvironment modulation. In summary, we believe the stemness, potential capacity of proliferation and persistence of placental-derived cells support multiple potential therapeutic applications, including those in development by us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graphic illustrates the origins of four cell-types </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that we </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">derived from the placenta, which are T cells</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> modif</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with a CAR, unmodified NK cells, genetically modified NK cells and ASC</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000004.jpg" title="" alt="" style="width:600px;height:464px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also researching placental-derived exosomes for potential therapeutic applications. Exosomes are a kind of extracellular vesicle that act as communication channels between cells and cause functional changes in recipient cells. Exosomes enable intercellular communication by transferring specific cargo contents to a recipient cell<span style="color:#000000;"> </span>and can confer epigenetic changes in the recipient cells by delivering microRNAs, or miRNAs. Exosomes have been identified as the primary factors responsible for paracrine effects detected in all types of stem cells and for the transfer of genetic material from stem cells to the tissue-specific cell that needs regeneration. Exosomes have been shown to possess powerful regenerative potential, including immune-modulatory properties and anti-inflammatory properties. We discovered a type of exosome that we call a placenta-derived adherent cell exosome, or pExo. Rich in growth factors, DNA fragments, miRNAs, and messenger RNAs, pExo exhibit particular markers that distinguish them from other exosomes that are not derived from placenta-derived adherent cells. We are investigating purified pExo formulated into pharmaceutical compositions for human administration to promote angiogenesis and/or vascularization, to modulate immune activity and to repair tissue damage.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview of CAR-T Cells</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">White blood cells are a component of the immune system and responsible for defending the body against infectious pathogens and other foreign material. T cells are a type of white blood cell and are involved in both sensing and killing infected or abnormal cells, including cancer cells, as well as coordinating the activation of other cells in an immune response.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unlike adult peripheral blood mononuclear cell, or PBMC, derived T cells, placental-derived T cells are mostly na&#239;ve and can be readily expanded while maintaining an earlier differentiation phenotype, such as greater expression of na&#239;ve/memory markers and lower expression of effector/exhaustion markers. These characteristics allow for greater proliferative potential of these cells <span style="font-style:italic;">ex vivo</span>. Placental-derived T cells are also known to have greater immune tolerance and display impaired allogeneic activation, contributing to lower incidences of severe GvHD, which makes them an attractive cell population for use as an allogeneic, adoptive cell therapy. We have developed a robust process for the isolation, transduction and expansion of placental-derived T cells to generate &#8220;off-the-shelf&#8221; allogeneic CAR-T cells.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allogeneic human placental T cells are derived from healthy donor placentas. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> separate out mononuclear cells using a mononuclear cell separation method to isolate placental T cells prior to cryopreservation. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> allogeneic CAR-T cell product begins with the thawing and activation of the isolated placental T cells, followed by viral transduction of the cancer-targeting CAR construct and an additional genetic modification step to minimize any risk of GvHD. Once transduced and transfected, the CAR-T cells are expanded to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> yield</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> large quantities </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of these cells </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior to harvest, final </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">formulation</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and cryopreservation of the cellular therapeutic.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview of NK cells &#8212; Unmodified and Genetically Modified</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NK cells are potent effector cells of the innate immune system responsible for identifying and eliminating abnormal and stressed host cells. They are equipped with NK cell-specific activating receptors that recognize conserved antigens induced by cellular stress while being simultaneously tuned with inhibitory receptors to avoid mistakenly targeting healthy cells. NK cells are particularly relevant in combating viral infections and mediating anti-tumor immunity in which normal cellular processes are stressed for the purposes of perpetuating viral infection and cancer cell proliferation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercializing NK cell therapies has been limited by the difficulty and cost to scale the production of mature NK cells for clinical dosing. Utilizing our Celularity IMPACT platform, our proprietary process has mitigated these limitations by expanding and differentiating placental-derived stem cells into NK cells over a period of 35 days. We derive the HSCs from healthy donor placentas, then propagate and differentiate these cells into NK cells. This process can produce hundreds of doses per donor placenta. We also developed technologies that can achieve high genetic modification efficiency by transducing placenta HSCs and producing downstream stable gene modified CYNK cells with enhanced cancer killing activities. These cells are then cryopreserved and available to be shipped upon request.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our genetically modified NK cells, our allogeneic modified NK cell product begins with the thawing and activation of the isolated placental NK cells. We then use a lentiviral vector transduction to augment the effector functions of the NK cells and to sustain their tumor-killing properties. We believe that our genetically modified NK cells can be used in combination with therapeutic mAbs to boost antibody-dependent cellular cytotoxicity, or ADCC, potential.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview of ASCs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placental-derived ASCs are a novel, culture-expanded mesenchymal-like cell population derived from placental tissue. <span style="font-style:italic;">In vivo</span>, we demonstrated that ASCs&#8217; immune-modulatory properties alleviate autoimmunity and possess anti-inflammatory activity. Both intravenous and intramuscular administration formulations of the first generation of ASCs have been developed and investigated in clinical studies in Crohn&#8217;s Disease, multiple sclerosis, rheumatoid arthritis, stroke, diabetic foot ulcers and diabetic peripheral neuropathy. We are developing next generation genetically modified ASCs for the treatment of degenerative diseases.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allogeneic human placental ASCs are derived from healthy donor placentas. Our allogeneic ASC product begins with the thawing and activation of the isolated placental-derived ASCs, followed by genetic modification of tissue factor to reduce potential toxicities and lower risk of adverse effects. Once modified, we expand the ASCs to large quantities prior to harvest, final formulation and cryopreservation of the cellular therapeutic.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Allogeneic Cell Therapies &#8212; an &#8220;Off-the-Shelf&#8221; Approach</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are two primary approaches to engineered cell therapies: autologous and allogeneic. Autologous therapies use engineered cells derived from the individual patient, while allogeneic therapies use cells derived from an unrelated third-party healthy donor. We believe our human placental-derived allogeneic platform is leading the next evolution of cellular medicine because we aim to deliver off-the-shelf allogeneic cellular therapies, at greater scale and quality with attractive economics, potentially making lifesaving therapies more readily accessible to more patients throughout the world.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human placenta-derived allogeneic platform currently includes placental CAR-T cells (CYCART-19), NK cells (CYNK-001 and CYNK-101) and ASCs (APPL-001 and PDA-002).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CYCART</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, autologous CAR-T products are manufactured by isolating T cells from the patient&#8217;s blood through a process known as leukapheresis. The cancer-targeting construct expressing specific CAR proteins is virally transduced into the T cells and the engineered T cells are then propagated until a sufficient number are available for infusion. The engineered T cells are then shipped back to the clinical center for administration to the patient. The process from leukapheresis to delivery to the clinical center takes approximately four weeks. While the autologous approach has been revolutionary, demonstrating compelling efficacy in many patients, we are burdened by lengthy vein-to-vein time, high production cost, variable potency and manufacturing failures.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversely, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> allogeneic placental-derived T cells are derived from healthy donors that have undergone rigorous donor screening and selection. Manufactured drug product can be deployed to patients immediately in sufficient quantities because administration is not limited by patient cell sourcing and individual drug product expansion. As an &#8220;off-the-shelf&#8221; treatment, CYCART cells also offer the potential to re-dose patients, if necessary. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">H</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ealthy births are in hundreds of millions worldwide, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the placenta provides an abundant, renewable source of healthy, ready to use lymphocytes. In addition, placental-derived T cells contain an abundance of stem cell memory T cells, which confer high proliferation and durability. Placental T cells are known be immune-privileged and have low donor to host toxicity (GvHD). </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therefore potentially a generally safer cell population. Furthermore, allogeneic placental T cells can be genetically engineered to minimize the risk of GvHD and avoid being destroyed by the patient&#8217;s immune system. Therefore, CYCART cells may possess an advantageous safety profile while delivering effective tumor eradication activity and durable persistence in patients.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CYNK</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, autologous NK cells and genetically modified autologous NK cells have been used in the setting of immuno-oncology. NK cells can directly kill cancer cells by recognizing signals of cellular stress and carry no risk of GvHD. However, autologous peripheral blood derived NK cells have limited proliferation capacity and usually require leukemia cell line-based technology to assist production. In addition, autologous CAR-NK was shown to encounter technical challenges due to low transduction efficiency of CAR vectors in the peripheral NK cells. Our NK platform propagates placenta derived HSCs and differentiates these cells into NK cells (CYNK). This process can produce hundreds of doses per placenta donor. We have also developed technologies that can achieve high genetic modification efficiency by transducing placenta HSCs and produce downstream stable gene modified CYNK cells with enhanced cancer killing activities. These cells are then frozen and can be shipped to clinical administration immediately upon request.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ASCs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Both autologous and allogeneic bone marrow or adipose tissue derived ASCs have been used in human clinical trials. Autologous ASC therapies have advantages including the absence of donor cell related adverse events and fewer regulatory hurdles since cell products are derived from a donor&#8217;s own cells. However, ASC products carry the inherited or aging-related biological defects from the donor, which may impair therapeutic value. Furthermore, in most cases, autologous cells still require cultivation before patient administration and there is a risk of manufacturing failure.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversely, allogeneic ASCs can provide an off-the-shelf product with high quality and flexibility of dosing. ASCs are regarded as immune-privileged due to their relative low-level MHC class I and II protein expression. Our placenta tissue derived ASCs are potentially more immune privileged due to their fetal origin. Clinical applications of human placenta derived ASCs have not been shown to be associated with severe adverse events. In addition, because APPL cells have higher proliferative capability, they are expected to be more suitable for genetic manipulations to engineer the cells to have specific features to enhance their functions or to mitigate risk factors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapeutic Candidate Pipeline and Development Strategy</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are researching and developing multiple placental-derived allogeneic cellular therapeutic candidates for the treatment of indications across cancer, infectious and degenerative diseases. From a single source material, the placenta, we focus on four allogeneic cell types: CAR-T cells, unmodified NK cells, genetically modified NK cells and ASCs, which have led to five key cell therapeutic </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs, CYCART-19, CYNK-001, CYNK-101</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> APPL-001</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and PDA-002</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which are focused on </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">six</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> initial indications. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product pipeline is represented in the diagram below:</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000005.jpg" title="" alt="" style="width:686px;height:310px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CYCART-19</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead therapeutic program based on our placental-derived CAR-T cell is CYCART-19, an allogeneic CAR-T cell targeting the CD19 receptor. We are granted certain rights related to the CD19 receptor construct and associated CARs utilized in CYCART-19 in the field of placenta-derived cells and/or cord blood-derived cells from Sorrento, a significant stockholder. For a description of the terms of the Sorrento license and our rights outside the field of placenta-derived cells and/or cord blood-derived cells, see the section entitled &#8220;<span style="font-style:italic;">Licensing Agreements &#8212; Sorrento Therapeutics, Inc.&#8221;.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All currently FDA-approved CAR-T cell therapies, and an estimated approximately 75% of clinical assets in development, are autologous. Autologous therapies mean the peripheral blood-derived T-cell is the immune cell vehicle used to express a CAR, making the patient their own donor. Manufacturing these autologous CAR-T cell therapies is complex and costly, with a long vein-to-vein time that, can affect therapeutic outcomes. Moreover, multiple rounds of lymphocyte depleting therapies cause inconsistent apheresis cell recovery in relapsed or refractory patients. We believe that our placental-derived CAR-T cell, CYCART-19, is a scalable solution because it does not have apheresis capacity constraints is designed to be manufactured at high volume, and is delivered as an on-demand, off-the-shelf, cryopreserved packaged product. Further, placental-derived cells contain an abundance of stem cell memory cells, which confers greater proliferative potential and increased persistence <span style="font-style:italic;">in vivo</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Data</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, placental-derived T cells, which constitute the starting material for CYCART-19, were demonstrated to consist mostly of na&#239;ve/T stem cell memory cells, or T scm, with a small proportion of central memory T cells. Following genetic modification and proliferation/expansion in the laboratory, CYCART-19 cells expressed high levels of na&#239;ve/memory markers and low levels of the immune inhibitory molecule PD-1. Furthermore, CYCART-19 cells maintained a higher proportion of T scm, as compared to PBMC-derived CD19 CAR+ T cells, which signifies greater self-renewal, proliferative potential, lymphoid homing and increased ability to persist <span style="font-style:italic;">in vivo</span>.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000006.jpg" title="" alt="" style="width:224px;height:271px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000007.jpg" title="" alt="" style="width:561px;height:262px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">In vitro<span style="font-style:normal;">, CYCART-19 cells specifically lysed CD19+ targets Daudi (Burkitt&#8217;s Lymphoma) and Nalm6 (Acute Lymphoblastic Leukemia) cell lines and secreted pro-inflammatory cytokines and effector proteins in response to these CD19+ targets.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000008.jpg" title="" alt="" style="width:600px;height:268px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000009.jpg" title="" alt="" style="width:600px;height:223px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000010.jpg" title="" alt="" style="width:554px;height:558px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000011.jpg" title="" alt="" style="width:325px;height:403px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000012.jpg" title="" alt="" style="width:315px;height:459px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As shown in the preceding graphics, in mice models, CYCART-19 demonstrated superior anti-lymphoma activities and survival, indicating greater <span style="color:#000000;">activity</span>, persistence and prolonged immune attack upon tumor recharging as compared to adult-blood derived CD19 CAR-T cells. CYCART-19 eliminated tumor and resulted in 100% survival out to 120 days. CYCART-19 &#8220;memory&#8221; characteristics were demonstrated via extended survival out to 215 days upon tumor rechallenge on day 122, longer persistence, and greater lymphoid homing to the spleen at end of study to elicit prolonged antitumor activities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Placental-derived T cells are unique in that they can contribute to reduced alloreactivity responses and can be associated with lower incidences and severity of GvHD. As shown in the following graphic, expanded placental-derived T cells did not induce xenogeneic GvHD in <span style="font-style:italic;">in vivo</span> mice models. This is evidenced by 100% survival, no weight loss, no increase in detection of any human CD3+ T cells in treated mice. PBMC-treated mice exhibited significant weight loss, death of all mice and increase of detection of human CD3+ T cells at day 28.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000013.jpg" title="" alt="" style="width:392px;height:297px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000014.jpg" title="" alt="" style="width:396px;height:296px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the lack of evidence of GvHD with expanded placental-derived T cells, we do include a CRISPR-mediated T cell receptor alpha constant, or TRAC, knock-out, or KO, step in our process as a further risk mitigation strategy to prevent GvHD. CYCART-19 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfected cells achieved 97-99% TRAC KO efficiency and demonstrated a loss of functional T cell receptor via lack of response (proliferation) to anti-CD3 restimulation.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000015.jpg" title="" alt="" style="width:394px;height:413px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000016.jpg" title="" alt="" style="width:399px;height:348px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Planned Phase 1/2 Clinical Trial </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to evaluate CYCART-19 for the treatment of B-cell malignancies (targeting the CD19 receptor) in a Phase 1/2 clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The planned Phase 1 trial will evaluate safety and dosing and will include three dose cohorts (40, 120 and 360&#160;x 106 transduced, viable CAR-T cells), in a 3x3 trial design, and will enroll up to 18 patients. The primary endpoint is to determine safety and maximum tolerated dose. Secondary endpoints are overall response rate</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ORR</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the sum of complete responses and partial responses</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CR+PR&#8221;), duration of response</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOR, progression-free survival</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PFS</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and overall survival</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OS. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also intend to explore the persistence of C</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Y</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CART-19.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The planned Phase 2 trial will evaluate efficacy of CYCART-19 and enroll 198 patients. The primary endpoint is to determine ORR (CR+PR). <span style="color:#000000;">Secondary endpoints are safety, time to response, DOR, PFS and OS. We also intend to explore the persistence of CYCART-19.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to submit an IND and commence Phase 1 of the trial in the first half of 2022. There is no assurance the IND will be <span style="color:#000000;">approved, will be approved</span><span style="color:#000000;font-size:12pt;"> </span>on the time frame contemplated or that the studies will be permitted to begin in the anticipated time frame.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CYNK-001</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead therapeutic program based on our placental-derived unmodified NK cell type is CYNK-001, an allogeneic unmodified NK cell being developed as a treatment for AML and GBM.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AML is the second most common type of leukemia in adults and children comprising about one-third of all adult leukemia cases. While most patients respond well to induction chemotherapy and achieve complete remission, two-thirds will relapse after frontline therapy. Patients who experience relapse following standard therapy (Relapse/Refractory-R/R AML) and those that achieve a complete response but have residual measurable residual disease (MRD+ AML) have poor outcomes and remain an unmet medical need for new therapies. We are evaluating CYNK-001 administered to AML patients with either R/R AML or MRD+ AML. We seek to determine if CYNK-001 following the standard of care could further reduce AML burden in R/R AML and/or MRD+ AML potentially to below measurable residual disease (&#60;0.1%) and if this translates to a clinical benefit that could lead to a registration trial. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GBM is an invasive type of glial tumor of the brain. Radiation and temozolomide chemotherapy is standard of care, but the average clinical benefit is three months and long-term remission of GBM tumors despite surgery is elusive in the majority of patients. We are investigating if CYNK-001 can home to the brain and prime anti-tumor immunity following intravenous infusion and will evaluate the feasibility and efficacy of CYNK-001 administered intratumorally. The impact on the tumor immune microenvironment and GBM tumor killing will be studied in brain biopsy sections following surgical resection.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Data</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies of CYNK-001 showed evidence of significant killing against chronic myeloid leukemia, or CML, AML and MM, cell lines and primary AML samples. CYNK-001 activation released high concentration of IFN-g, a cytokine favoring Th1 anti-tumor responses, and CYNK-001 exerted up to 60% specific lysis against primary AML samples at an effector:target (E:T) ratio of 3:1.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000017.jpg" title="" alt="" style="width:312px;height:249px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000018.jpg" title="" alt="" style="width:600px;height:265px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000019.jpg" title="" alt="" style="width:428px;height:312px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000020.jpg" title="" alt="" style="width:526px;height:225px;" /></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Single or repeated dose of CYNK-001 significantly reduced BLI signal on D25, 28 and 35 compared with PBS control</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Repeated dose significantly reduced BLI signal on D25, 28 and 35 compared with CYNK-001 single dose</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1 Trial</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed a Phase 1 dose escalation trial that enrolled 11 relapsed/refractory AML patients, treating 10 with a single dose of PNK-007, a prior formulation of CYNK-001 that was not cryopreserved. The cell therapy was generally well tolerated, with no dose-limiting toxicities, no GvHD, and no detectable HLA, allo-antibody. Eight of 10 patients were efficacy evaluable (two were not due to inadequate bone marrow for evaluation) and two of four of these patients treated with the highest dose (approximately 700 million NK cells) had evidence of a transient biologic effect.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000021.jpg" title="" alt="" style="width:319px;height:446px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently enrolling a follow-up Phase 1 trial for CYNK-001, the cryopreserved NK cell formulation equivalent of PNK-007, in patients with relapsed/refractory AML and patients in hematologic remission with minimal residual disease, or MRD. As part of the CYNK-001 Phase 1 trial, we assessed dosing of lymphodepletion to maintain serum IL-15 levels above baseline and T regulatory cells at low levels for up to 28 days (&#8220;Window of dosing opportunity&#8221;) to potentially enhance potency and persistence of NK cells. In total, 13 patients have been enrolled and treated with R/R AML and eight patients with MRD+ AML and there have been no dose limiting toxicities observed at any dose level to date including total dose levels of 1.8, 3.6 and 5.4 billion CYNK-001 cells. There has been the achievement of MRD negative status at highest CYNK-001 cell dose level with documented persistence of CYNK-001 cells in bone marrow and peripheral blood at 28 days post Day 0 Infusion. Upon completion of the 5.4 billion total dose level cohort, we intend to continue dose escalation in the MRD indication to 9.0 billion or more total CYNK-001 cells. To potentially further enhance CYNK-001 potency and persistence, the expansion arms in MRD and R/R AML an augmented lymphodepletion protocol of Cytoxan 3600 mg divided over four days (versus prior 900&#160;mg divided over three days) and fludarabine 120 mg divided over four days (versus prior 75 mg divided over three days) to increase post lymphodepletion IL-15 levels and to add subcutaneous IL-2 (six million international units administered sub-cutaneous for seven doses every other day starting with Day 0 infusion of CYNK-001). Once we identify the dose of NK&#160;cells associated with the greatest durable clinical activity, we intend to meet with the FDA to discuss a Phase 2 protocol. We expect to complete enrollment in the dose-escalation phase in the second half of 2022 for R/R AML and fourth quarter of 2022 for MRD AML, and if results are positive, this program will be advanced into Phase 2<span style="color:#000000;">.</span>&#160;&#160;In December 2021, we received fast track designation from the FDA for CYNK-001 for the treatment of AML.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000022.jpg" title="" alt="" style="width:679px;height:292px;" /><span style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000023.jpg" title="" alt="" style="width:680px;height:308px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2021, we initiated a Phase 1 dose escalation trial in recurrent GBM of intravenous and intra-tumoral bed CYNK-001 cells to evaluate dose, NK cell homing and persistence, safety, and biologic effect.&#160;&#160;We received fast track designation from the FDA for CYNK-001 for the treatment of recurrent GBM in March 2021 and received orphan drug designation from the FDA for CYNK-001 for the treatment of GBM in April 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were investigating if intravenous multi-dosing of CYNK-001 can safely facilitate the clearance of SARS-CoV-2 from patients exhibiting mild to moderate symptoms during the early phase of infection. Enhanced clearance of virus from the lung and airways is hypothesized to rescue susceptible patients from developing COVID-19 and acute respiratory distress syndrome, or ARDS, associated lung inflammation and deterioration. We are no longer enrolling patients in a Phase 1/2 clinical trial, and as of July 2021, all trial sites for the trial were closed and no additional trials are being conducted.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CYNK-101</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead therapeutic candidate based on our placental-derived genetically modified NK cell type is CYNK-101, an allogeneic genetically modified NK cell being developed as a treatment in combination with trastuzumab for HER2+ overexpressing gastric and gastroesophageal cancer, collectively gastric cancer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initially, we are pursuing CYNK-101 in combination with trastuzumab and pembrolizumab to treat first line, newly diagnosed, metastatic gastric cancer. Gastric cancers are among the most common solid tumors worldwide and are a leading cause of cancer related deaths. Gastric cancers are characterized by poor prognosis. HER2 is involved in the pathogenesis and poor outcomes in many tumors including gastric cancers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Data</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CYNK-101 demonstrated <span style="font-style:italic;">in vitro</span> and <span style="font-style:italic;">ex vivo</span> enhanced ADCC activities in combination with trastuzumab against gastric cancer cell lines. <span style="font-style:italic;">In vitro</span>, CYNK-101 in combination with trastuzumab showed significant ADCC activity against both gastric cancer cell lines. <span style="font-style:italic;">Ex vivo</span>-CYNK-101 exhibited enhanced cytotoxicity against gastric cell lines in combination with trastuzumab compared to that of IgG control. Compared to pre-infusion CYNK-101, <span style="font-style:italic;">ex vivo</span>-CYNK-101 showed not only a higher ADCC activity against gastric cancer cell lines, but also a more matured NK cell phenotype.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000024.jpg" title="" alt="" style="width:433px;height:384px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In vitro <span style="font-style:normal;">ADCC activity of CYNK-101 in combination with trastuzumab against NCI-N87 or OE19 at E:T ratio of 2:1</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman PS Std;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000025.jpg" title="" alt="" style="width:449px;height:268px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman PS Std;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000026.jpg" title="" alt="" style="width:481px;height:430px;" /></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ex vivo ADCC activity of CYNK-101 in combination with trastuzumab against NCI-N87 at E:T ratio of 2:1.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman PS Std;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000027.jpg" title="" alt="" style="width:600px;height:376px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman PS Std;font-style:normal;text-transform:none;font-variant: normal;"><img src="gizttcucplmb000028.jpg" title="" alt="" style="width:600px;height:429px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Phenotype characterization of <span style="font-style:italic;">ex vivo</span> CYNK-101</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CYNK-101 provides a platform for a variety of mAb combination therapies. Improved ADCC response was observed from CYNK-101 in combination with other mAbs (Rituximab, Elotuzumab, Daratumumab), as compared to unmodified CYNK cells against lymphoma cells lines. IND-enabling studies are ongoing to evaluate CYNK-101 in combination with mAbs in subcutaneous and orthotopic tumor models.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2a Trial</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2021, we initiated a Phase 1 trial to evaluate CYNK-101<span style="color:#000000;"> as a first-line treatment in advanced HER2/neu positive gastric and gastroesophageal junction cancer in combination with standard chemotherapy, trastuzumab and pembrolizumab.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1/2a trial will evaluate safety and dosing and will include three dose cohorts in a 3x3 trial design and will enroll up to 55 first line, newly diagnosed metastatic advanced unresectable gastric cancer overexpressing HER2. The general objective is to establish maximum tolerated dose and recommended Phase 2 dose. The primary endpoint of the Phase 1 portion of the trial is safety (maximum tolerated dose). Secondary endpoints include ORR, DOR, PFS and mOS. The primary endpoint of the Phase 2a portion (expansion) is ORR. Secondary endpoints include ORR, DOR, PFS, mOS and safety<span style="color:#000000;">. In January 2022, </span>we received fast track designation from FDA for this program.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ASCs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing the next generation cellular therapies for immune-deregulation diseases and degenerative diseases.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">APPL-001</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current lead therapeutic candidate from our placental-derived ASC type is APPL-001, a genetically modified placental-derived ASC. We are initially evaluating APPL-001 for the treatment of Crohn&#8217;s disease. In clinical studies of unmodified ASCs, over 50 patients were dosed with ASCs for the treatment of Crohn&#8217;s disease. Clinical response rates were significantly higher in treatment groups compared with the placebo group.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2a Trial Design</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The planned Phase 1/2a trial will evaluate APPL-001 in patients with moderate to severe Crohn&#8217;s disease who are refractory to corticosteroids. The primary objective is to assess the safety and tolerability and to establish recommended Phase 2 dose. The primary objective in the planned Phase 2a part of the trial will be evaluation of clinical activity by measuring clinical remission and clinical response in subjects with moderate to severe Crohn&#8217;s disease. Secondary objectives are to assess disease modifying measures such as endoscopic measurements and quality of life assessments. The planned primary endpoint is clinical remission/response at four-six weeks and after one year. Planned secondary endpoints include evaluation of mucosal healing, and, patient-reported outcome of quality of life as measured by Inflammatory Bowel Disease Questionnaire.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">PDA-002</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The second therapeutic candidate from our placental-derived ASC type is PDA-002, a placental-derived ASC being developed for the treatment of FSHD. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Phase 1/2a Trial Design</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The planned Phase 1/2a trial will evaluate PDA-002 in patients with FSHD. The primary objective is to assess the safety and tolerability and to establish recommended Phase 2 dose. The primary objective in the planned Phase 2a part of the trial will be evaluation of change from baseline in 6-minute walk test with PDA-002 in comparison to placebo. Secondary objectives include change in intramuscular fat fraction through MRI from baseline, c<span style="Background-color:#FFFFFF;color:#000000;">hanges in muscle strength assessed with Handheld Dynamometry (HHD) from baseline, </span>in comparison to placebo at 6-month time period, Quality of life change from baseline assessed by FSHD-HI scores, in comparison to placebo at 6-month time period, and change in reachable workspace from baseline, in comparison to placebo at 6-month time period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Future Pipeline Opportunities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to utilize our Celularity IMPACT platform to pursue additional targets of interest. These include the additional indications for the four allogeneic cell types currently in the pipeline as well as other targets that might be validated in the future. Our placental-derived T cell platform has potential to target other receptors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we regularly survey the scientific and industry landscape for opportunities to license, partner or acquire technologies that may help us advance current or new cell therapies for the benefit of patients.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercial Businesses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Degenerative Diseases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The National Cancer Institute defines &#8220;degenerative disease&#8221; as a disease in which the function or structure of the affected tissues or organs changes for the worse over time. Our degenerative disease business today is comprised primarily of the sale of our Biovance and Interfyl products, directly or through our distribution network. Biovance is decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. It is an intact, natural extracellular matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. Interfyl is human connective tissue matrix derived from the placenta of a healthy, full-term pregnancy. It is used by a variety of medical specialists to fill soft tissue deficits resulting from wounds, trauma, or surgery. We are investigating additional biomaterial products for use in treating degenerative diseases as well as applications in degenerative diseases for our proprietary cell therapies and possible combination therapies that use of a biomaterial or biomaterials in combination with a cell therapy. Biovance and Interfyl were developed at Anthrogenesis prior to the Celgene acquisition and sold to HLI by Celgene, and then acquired by us from HLI in May 2017, subject to marketing and distribution rights licensed by HLI to a third party, which rights were acquired by us in May 2018, along with the MIST and UltraMIST Therapy Systems. In August 2020, we entered into a five-year licensing arrangement that included: (i) an exclusive Biovance license for distribution and commercialization in the wound care market and (ii) a non-exclusive license for the distribution and commercialization of Interfyl in the wound care market worldwide, except certain Asian jurisdictions, pursuant to which we were to receive royalties based on minimum sales thresholds. <span style="color:#000000;">The license agreement with Sanuwave was terminated during the third quarter of 2021 due to an uncured material breach.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have focused our marketing and sales strategy within the Degenerative Disease segment on developing strong distribution partners for our products rather than building out our own direct sales force. On May 7, 2021, we entered into a six-year supply and distribution agreement with Arthrex, Inc., or Arthrex, that includes: (i) an exclusive Biovance, Interfyl, and Centaflex license for distribution and commercialization within the United States in the field of orthopedic surgery&#59; and (ii) an exclusive license to commercialize and distribute Interfly and Centaflex within the United States in the field of acute and chronic non-healing wound care. On September 1, 2021, we entered into a three-year supply and distribution agreement with Evolution Biologyx, LLC, or Evolution that includes an exclusive license to commercialize and distribute Interfyl in the United States within any medical specialty where Interfyl is administered in an in-office or in-patient setting and is reimbursed through Medicare Part B or any successor, equivalent or similar category established by the U.S. Department of Health and Human Services Center for Medicare Services or other government authority, except in the medical specialty of orthopedic surgery excluding trauma or spine applications in the medical specialty or orthopedic or neurologic surgery.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to invest in creating new or differentiated products for the Degenerive Disease segment to supplement sales of our mature commercial products, Biovance and Interfyl.&#160;&#160;We have created Biovance 3L, a trilayer human amniotic membrane product focused on the ocular and surgical markets.&#160;&#160;Biovance 3L will be available in both sheet and disk form depending upon the application.&#160;&#160;We have also created CentaFlex, a decellularized human placental matrix derived from the umbilical cord.&#160;&#160;CentaFlex can be used as a surgical covering, wrap or barrier to protect and support the repair of damaged tissue.&#160;&#160;We have other products based on human placental tissue under development that may follow a variety of regulatory pathways to potentially achieve commercial readiness.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biobanking</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provide a fee-based biobanking service to expectant parents who contract with the company to collect, process, cryogenically preserve and store certain biomaterial, including umbilical cord blood and placenta derived cells and tissue. We receive a one-time fee for the collection, processing and cryogenic preservation of the biomaterials, and a storage fee to maintain the biomaterials in our biobank payable annually over a period of eighteen years. We acquired our biobanking business in May 2017 from HLI, which HLI operated as LifebankUSA, along with the degenerative disease products Biovance and Interfyl, and in October 2018, we acquired CariCord Inc., or CariCord, a family cord blood bank.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an approximately 150,000 square foot purpose-built facility located in Florham Park, New&#160;Jersey, which includes a cGMP-ready manufacturing center, along with dedicated research and office spaces and space for shared services. Our facility includes nine Grade C/ISO-7 and six Grade D/ISO-8 manufacturing suites designed for commercial production of cellular therapies and advanced biomaterials. We intend to manufacture all finished product in-house at our manufacturing facility in Florham Park, New Jersey. We have invested resources to optimize our manufacturing process, including the development of improved analytical methods. We plan to continue to invest in process science, product characterization and manufacturing to improve our production and supply chain capabilities over time. We also use CMOs, as needed, on a non-exclusive basis, and may use CMOs in the future, for certain of our therapeutic candidates. For example, we use a CMO for the clinical manufacture and supply of CYNK-001. All other finished products are manufactured in-house. We are in the process of internalizing the manufacture of CYNK-001 and anticipates that all finished product will be manufactured in-house in 2022. Notwithstanding, we will engage CMOs as necessary to ensure continuous supply of clinical and commercial grade product based on demands.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cellular therapeutic candidates are designed and manufactured via a platform comprised of defined unit operations and technologies. The process is gradually developed from small to larger scales, incorporating compliant procedures to create GMP conditions. Notwithstanding this platform-based model, each therapeutic is unique and for each new therapeutic candidate, a developmental phase is necessary to individually customize each engineering step and to create a robust procedure that can later be implemented in a GMP environment to ensure the production of clinical batches. This work is performed in a research and development environment to evaluate and assess variability in each step of the process in order to define the most reliable production conditions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensing Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into license agreements in the ordinary course of our business. We have in-licensed certain technology from Sorrento that is necessary to research and develop our CYCART-19 program. Because of the broad potential applicability of our placental-derived cellular therapeutic candidates, we may also out license our technology to third parties for development for other indications that we do not intend to pursue or for certain territories. For example, in June 2017, we entered into a license agreement with Lung Biotechnology PBC. Under that license agreement, which was terminated in March 2021, we granted Lung Biotechnology an exclusive license to placental-derived stem cells in the field of pulmonary diseases and organ transplantation. We have also licensed rights to distribute our degenerative disease products, Biovance and Interfyl, to Sanuwave for a five-year period in connection with the August 2020 sale of other non-core assets, however we terminated this license in the third quarter of 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, as part of the acquisition of Anthrogenesis from Celgene, we granted Celgene a worldwide, royalty-free, fully paid up, non-exclusive license, to use certain intellectual property for both research and commercial purposes, and granted Celgene the CVRs, which provide us the right to future milestone and royalty payments in certain circumstances. See the section entitled &#8220;<span style="font-style:italic;">&#8212; Our Team and Corporate History &#8212; Celgene Corporation</span>&#8221; for a description of the ongoing relationship between us and Celgene, including the out license agreement and the CVRs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we entered into a license and transfer agreement with Sorrento to obtain rights to Sorrento&#8217;s proprietary anti-CD19 CAR-T construct and associated CARs for use in placenta-derived or cord blood-derived cells. Sorrento is a significant stockholder of ours. We are using Sorrento&#8217;s technology to genetically modify our placental-derived T-cell to create the CAR T-cell with a CD19 receptor that is our CYCART-19 therapeutic candidate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Sorrento Agreement, we obtained a worldwide license, with the right to grant sublicenses with Sorrento&#8217;s consent, under certain of Sorrento&#8217;s intellectual property rights, including patent rights that would be infringed by the use of certain CD19 CAR constructs, to research, develop, use, reproduce, modify, and create derivative works in the field of placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder, and to make, have made, use, sell, offer for sale, import, export, and distribute products for use in connection with our research, development, commercialization and exploitation of products combining Sorrento&#8217;s proprietary anti-CD19 CAR-T construct and associated CARs with placenta-derived or cord blood-derived cells. The foregoing license is exclusive with respect to a certain U.S. provisional patent application and non-exclusive with respect to all other licensed intellectual property rights of Sorrento.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento reserves the right to make, have made, use, sell, offer for sale, import, export, and otherwise research, develop, commercialize and exploit CD19 CAR-T licensed products for use outside the field of placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder and any other products or services that are not CD19 CAR-T licensed products that use or incorporate any CD19 CAR-T constructs or associated CARs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sorrento Agreement, we have sole responsibility for the development and commercialization of licensed products, subject to certain reserved rights of Sorrento with respect to CD19 CAR-T products. We are currently negotiating a supply agreement with Sorrento to obtain the continued supply of CAR constructs and licensed products under the Sorrento Agreement. Additionally, we are obligated to use commercially reasonable efforts to develop and commercialize licensed products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Sorrento Agreement, we have agreed to assign all right, title and interest in any improvements generated by us to Sorrento&#8217;s background intellectual property. Additionally, we have granted Sorrento a non-exclusive, sublicensable, fully paid-up, royalty free, worldwide license under any new inventions that relate to or cover CD19 CAR-T constructs generated by us under the Sorrento Agreement for use in connection with Sorrento&#8217;s reserved rights under CD19 CAR-T licensed products and constructs (as described above). Sorrento has the primary right to control the prosecution and maintenance of patents and patent applications arising out of or relating to the Sorrento Agreement, including any patents or patent applications covering the licensed products, while we have the secondary right to pick up prosecution of any such patents and patent applications abandoned by Sorrento.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sorrento Agreement, we are obligated to pay Sorrento a low teens double digit percentage of non-royalty sublicensing income payments received by us in connection with a grant of any sublicense for CD19 CAR-T licensed products. Additionally, we are obligated to pay Sorrento a low single-digit royalty on net sales of CD19 CAR-T licensed products in perpetuity. We will also be obligated to pay Sorrento for the supply of the CAR constructs and licensed products pursuant to the supply agreement, once finalized, which we expect to be based on the cost plus a percentage, with no guaranteed minimums. As of December 31, 2021, we have not paid Sorrento any amounts under the Sorrento Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either party may terminate the Sorrento Agreement upon an uncured material breach of the Sorrento Agreement by the other party. Additionally, after the first anniversary of the effective date of the Sorrento Agreement, we have the right to terminate the Sorrento Agreement at any time upon specified written notice to Sorrento.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for the technologies supporting our Celularity IMPACT platform, and our lead cellular therapeutic candidates, CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002 and future therapeutic candidates, as well as novel discoveries, product development technologies, and know-how. Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and applications related to our technology, inventions, and improvements that are important to the development and implementation of our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees, consultants, or other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting its commercial therapeutics and methods of using and manufacturing the same.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are actively building our intellectual property portfolio around our Celularity IMPACT platform, our four allogeneic cell types and our therapeutic candidates based on our own intellectual property as well as licensed intellectual property. We are the owner of, co-owner of, or the licensee of over 1,500 patents and patent applications in the United States and worldwide protecting our Celularity IMPACT platform, our processes, technologies and current key cell therapy programs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio includes patents and patent applications directed toward our four allogeneic placental-derived cell types: CAR-T cells, unmodified NK cells, genetically modified NK cells and ASCs as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have five utility patent families in the CAR-T technology area supporting our CYCART-19 therapeutic candidate comprising two patent families owned by us and three patent families licensed from Sorrento. These patent applications include licensed CAR-T patent families and owned placental-derived CAR-T patent families directed toward early CAR receptor technology, CAR receptor method and composition, anti-CD19 CAR receptor and product characterization. Patents issuing from these families have expected expiry dates ranging from 2039 to 2040 and include pending patent applications in the United States and under the PCT.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have approximately 15 utility patent families owned by us in the NK technology area supporting our CYNK-001 and CYNK-101 therapeutic candidates that include patents and patent applications covering process, treatment of indications, and product characterization. Patents issuing from these families have expected expiry dates ranging from 2028 to 2041 and include patents issued and pending patent applications in the United States and under the PCT, Australia, Brazil, Canada, China, Colombia, Eurasian Patent Office, European Patent Office, Hong Kong, Israel, India, Indonesia, Japan, Republic of Korea, Mexico, Malaysia, New Zealand, Russian Federation, Singapore, Taiwan R.O.C., Ukraine, Vietnam, South Africa.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We have approximately 25 utility patent families owned by us in the ASC technology area supporting our APPL-001 and PDA-002 therapeutic candidates and former PDAC candidates that include patents covering product characterization and method of production, as well as product description and indications. Patents issuing from these families have expected expiry dates ranging from 2021 to 2040 and include patents issued and pending patent applications in the United States and under the PCT, Argentina, Australia, Brazil, Canada, China, Colombia, Eurasian Patent Office, European Patent Office, Hong Kong, Israel, India, Indonesia, Japan, Republic of Korea, Mexico, Malaysia, New Zealand, Peru, Russian Federation, Singapore, Taiwan R.O.C., Ukraine, Venezuela, Vietnam, South Africa. Although patent families in this technology area began to expire in 2021, we have numerous patent families in this technology area directed to improvements in the cells and methods/indications for their use, which include recently filed applications directed towards APPL-001, a second generation, genetically modified ASC therapeutic candidate. These applications have projected expiration dates to 2041 and are expected to replace the early-expiring applications. Accordingly, we do not expect that the expiry of the early-filed ASC patents will have a material effect on our business.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More generally, our patent portfolio and filing strategy is designed to provide multiple layers of protection by pursuing claims directed toward composition of matter, methods of making, and methods of use, amongst others. We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patent protection intended to cover our technology and related technologies and uses thereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional application to which priority is claimed. In the United States, patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the United States, the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to, among other things, compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension is calculated based on the length of time we take for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be restored. Moreover, a patent can only be restored once, and thus, if a single patent is applicable to multiple products, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our products will compete with novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to existing standard of care treatments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to the promising therapeutic effect of cell therapies in clinical trials, we anticipate increasing competition from existing and new companies developing these therapies, as well as in the development of allogeneic cell therapies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potential cell therapy competitors include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;C</span><span style="font-style:italic;font-size:10pt;color:#000000;">YCART-19&#59; allogeneic CAR-T cell therapies:</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Cellectis S.A., Fate Therapeutics Inc. and Precision Biosciences, Inc.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;C</span><span style="font-style:italic;font-size:10pt;color:#000000;">YNK-101 and CYNK-001&#59; allogeneic NK cell therapies:</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;Fate Therapeutics Inc., Kiadis Pharma N.V., Century Therapeutics, Inc. and Nkarta, Inc.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A</span><span style="font-style:italic;font-size:10pt;color:#000000;">PPL-001 and PDA-002&#59; allogeneic ASC therapies:</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;Mesoblast Limited.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;C</span><span style="font-style:italic;font-size:10pt;color:#000000;">ell therapy competition:</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics PLC, Celyad S.A., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Gilead Sciences, Inc. (acquired Kite Pharma, Inc.), Poseida Therapeutics, Inc., Precision Biosciences, Inc. and Sangamo Therapeutics, Inc.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition will also arise from non-cell-based therapies pursued by small-cap biotechnology and large-cap pharmaceutical companies including Amgen Inc., AstraZeneca plc, Bristol Myers Squibb Company, Incyte Corporation, Merck &#38; Co., Inc. and F. Hoffmann-La Roche AG.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize therapeutics that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than cellular therapeutics that we may develop. Our competitors also may obtain FDA or other regulatory approval for their therapies more rapidly than it may obtain approval for ours, which could result in our competitors establishing a strong market position before it is able to enter the market or make development efforts more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and convenience.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, as well as for technologies complementary to, or necessary for, our programs.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation and Product Approval</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell therapeutics will be regulated as biologics. With this classification, commercial production of our cellular therapeutics will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a biologics license application, or BLA for marketing authorization. Our cellular therapeutic candidates are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our therapeutic candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agencies before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">centralized way, but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Product Development Process</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA regulates pharmaceutical and biological products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the Public Health Service Act, or PHSA, and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our operation and business. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before the trial is commenced&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA Advisory Committee review, if applicable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices, or GTPs, for the use of human cellular and tissue products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">FDA review and approval, or licensure, of the BLA.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including our cellular therapeutic candidates, in humans, the therapeutic candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees, or IBCs, as set forth in the National Institutes of Health, or NIH, Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, or the NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids)&#59; (ii) nucleic acid </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids)&#59; or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if we determine that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase 1.</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase 2.</span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-size:10pt;color:#000000;">Phase 3</span><span style="font-size:10pt;color:#000000;">.&#160;&#160;&#160;&#160;Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious harm to patients.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human cellular therapy products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in order to establish the safety, efficacy, purity and potency of cellular therapy products, or that the data generated in these trials will be acceptable to the FDA to support marketing approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, as amended, or PDUFA, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the therapeutic unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the therapeutic within required specifications. For cellular therapies, the FDA also will not approve the product if the manufacturer is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. In November 2017, the FDA released a guidance document entitled &#8220;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue &#8212; Based Products: Minimal Manipulation and Homologous Use &#8212; Guidance for Industry and Food and Drug Administration Staff&#8221;, which it revised and reissued in July 2020, or the Guidance. The document confirmed the FDA&#8217;s stance that sheet forms of amniotic tissue are appropriately regulated as solely Section&#160;361 HCT/Ps when manufactured in accordance with 21 CFR Part 1271 and intended for use as a barrier or covering. The primary intent of the GTP requirements is to ensure that cell and tissue-based therapeutics are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although FDA had indicated in its Guidance that the agency would&#160;&#160;exercise enforcement discretion under limited conditions with respect to the IND application and pre-market approval requirements for certain HCT/Ps, this period of enforcement discretion ended May 31, 2021.<span style="color:#000000;"> </span> Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an applicant must incur significant expenditure of time, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">money</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and effort in the areas of training, record keeping, production and quality control.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a therapeutic receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the therapeutic. Further, the FDA may require that certain contraindications, warnings or precautions be included in the labeling. The FDA may impose restrictions and conditions on distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved therapeutics that have been commercialized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any product for an indication for which orphan designation has been granted. However, if only one indication for a therapeutic has orphan designation, a pediatric assessment may still be required for any applications to market that same therapeutic for the non-orphan indication(s).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United&#160;States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a therapeutic that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the therapeutic is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the therapeutic with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, the FDA granted orphan drug designation to our non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy, CYNK-001, for the treatment of patients with malignant gliomas.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has programs intended to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of a serious or life-threatening condition. These programs include fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation. Specifically, new therapeutics are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the therapeutic and the specific indication for which it is being studied. Unique to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any therapeutic submitted to the FDA for approval, including a therapeutic with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A therapeutic is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed therapeutics. The FDA will attempt to direct additional resources to the evaluation of an application for a new therapeutic designated for priority review in an effort to facilitate the review. Additionally, a therapeutic may be eligible for accelerated approval. Therapeutics studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, for products being considered for accelerated approval, the FDA currently requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period, which could adversely impact the timing of the commercial launch of the product. In addition, breakthrough therapy designation is intended to expedite the development and review of therapeutics that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a therapeutic candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include (i) holding meetings with the sponsor and the review team throughout the development of the therapy, (ii) providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable, (iii) involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review, (iv) assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor and (v) considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same product if relevant criteria are met. If a product is designated as breakthrough therapy, FDA will expedite the development and review of such product.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2021, we received fast track designation from the FDA for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy, CYNK-001, for the treatment of adults with recurrent GBM.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any therapeutics for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physicians deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including administrative, civil and criminal sanctions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Manufacturers and other parties involved in the drug supply </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States. Accordingly, manufacturers must continue to expend time, money, and effort </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the area of</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our therapeutics under development.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Marketing Exclusivity</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act, or the BPCIA, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity may be extended by six months, for a total of 12.5 years, if the FDA requests that the innovator company conduct pediatric clinical investigations of the product.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our therapeutic candidates, some of its U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved therapeutic is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of its currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Federal and State Licenses and Registrations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The health care industry is subject to stringent regulation by a wide range of authorities. Accordingly, our business requires us to maintain certain licenses, registrations, permits, authorizations, approvals, certifications, accreditations and other types of federal, state, and local governmental permissions and to comply with various regulations in every jurisdiction in which it operates. For example, we are required to maintain licenses and registrations in several states, and has obtained biologics, tissue bank and blood bank licenses, permits and registrations in states where such licensure is required for us to market and support our products and services. Some states, such as New York, impose state law restrictions on products that have not been the subject of a BLA based upon their interpretation of guidance issued under federal law, including the FDA&#8217;s guidance on HCT/Ps, which can lead to different, and potentially conflicting, regulatory frameworks applicable to our degenerative disease products on a state by state basis. We also maintain an annual registration with the FDA as a tissue bank, and national accreditation by the American Association of Blood Banks. The failure to comply with such licensure requirements can result in enforcement actions, including the revocation or suspension of the licenses, registrations or accreditations, or subject us to plans of correction, monitoring, civil money penalties, civil injunctive action and/or criminal penalties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other U.S. Healthcare Laws and Compliance Requirement<span style="color:#000000;">s</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &#38; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (<span style="font-style:italic;">e.g.</span>, the Office of Inspector General), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, our business practices, including our research and sales, marketing and scientific/educational grant programs may be required to comply with the fraud and abuse provisions of the Social Security Act, false claims laws, anti-kickback and anti-bribery laws, the data privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, federal transparency requirements and similar state laws, each as amended.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for, either the referral of an individual for, or the purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have knowingly presented or caused to be presented a false or fraudulent claim to, among others, a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil and criminal false claims laws, including the federal civil False Claims Act, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. Pharmaceutical and other healthcare companies are being investigated or, in the past, have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, pharmaceutical and other healthcare companies also have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, imposes requirements on certain types of individuals and entities, including covered entities (<span style="font-style:italic;">i.e</span>., certain healthcare providers, health plans and healthcare clearinghouses), relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates (and their subcontractors) that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, in California, the California Consumer Protection Act, or CCPA, which went into effect on January 1, 2020, establishes a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. While clinical trial data and information governed by HIPAA are currently exempt from the current version of the CCPA, other personal information may be applicable and possible changes to the CCPA may broaden its scope. In addition, a new California ballot initiative, the California Privacy Rights Act, or CPRA, was passed in November 2020. Effective starting on January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Physician Payments Sunshine Act created under the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members. Effective January 1 2022, applicable manufacturers are required to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse-midwives.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In order to distribute therapeutics commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states and local jurisdictions have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate its business and our results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursemen<span style="color:#000000;">t</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic candidates for which we obtain regulatory approval. In the United States and certain markets in other countries, sales of any therapeutics for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or from establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessity and cost-effectiveness of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics, in addition to the costs required to obtain the FDA approvals. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a therapeutic does not assure that other payors will also provide coverage for the therapeutic. Adequate third-party reimbursement may not be available to enable </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to maintain price levels sufficient to realize an appropriate return on </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> investment in therapeutic development.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular therapeutic candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Patient Protection Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketability of any therapeutic candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. For example, actions by federal and state governments and health plans may put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement for our products if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research and development. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more therapeutics for which it receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell therapeutic candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expansion of the entities eligible for discounts under the 340B Drug Discount Program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">expansion of healthcare fraud and abuse laws, including the FCA and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">requirements to report certain financial arrangements with physicians and teaching hospitals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a licensure framework for follow on biologic products.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There remain executive, legal and political challenges to certain aspects of the Affordable Care Act. For example, in December 2017, Congress repealed the tax penalty for an individual&#8217;s failure to maintain Affordable Care Act-mandated health insurance as part of the Tax Act. Further, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act-mandated &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans and the medical device excise tax on non-exempt medical devices, and, also eliminated the health insurer tax. Moreover, the Bipartisan Budget Act of 2018, effective January 1, 2019, or BBA, among other things, amended the Affordable Care Act to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. On December 14, 2018, a Texas United States District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was effectively repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the United States Court of Appeals for the 5<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></span> Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the Affordable Care Act brought by several states without specifically ruling on the constitutionality of the Affordable Care Act. Prior to the Supreme Court's decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act.&#160;&#160;The ultimate content, timing or effect of any healthcare reform legislation on the United States healthcare industry is unclear.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Biden administration, on October 13, 2017, former President Trump signed an Executive Order terminating the cost-sharing subsidies that reimburse insurers under the Affordable Care Act. The former Trump administration concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the Affordable Care Act have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those appropriations are made. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their request for a restraining order was denied by a federal judge in California on October 25, 2017. On August 14, 2020, the U.S. Court of Appeals for the Federal Circuit ruled in two separate cases that the federal government is liable for the full amount of unpaid CSRs for the years preceding and including 2017. For CSR claims made by health insurance companies for years 2018 and later, further litigation will be required to determine the amounts due, if any. Further, on June 14, 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12 billion in Affordable Care Act risk corridor payments to third-party payors who argued the payments were owed to them. On April 27, 2020, the United States Supreme Court reversed the U.S. Court of Appeals for the Federal Circuit's decision and remanded the case to the U.S. Court of Federal Claims, concluding the government has an obligation to pay these risk corridor payments under the relevant formula.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that the Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage and the price that we receive for any approved therapeutic, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our therapeutics. Such reforms could have an adverse effect on anticipated revenue from </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutic candidates that </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may successfully develop and for which it may obtain regulatory approval and may affect </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> overall financial condition and ability to develop therapeutic candidates.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022. Then, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022 Further, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. At the federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, imposing inflation caps and supporting the development and market entry of lower-cost generic drugs and biosimilars&#59; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, to enhance the domestic drug supply chain, to reduce the price that the Federal government pays for drugs, and to address price gouging in the industry&#59; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.&#160;&#160;On December 29, 2021 CMS rescinded the Most Favored Nations rule.&#160;&#160;Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our therapeutic candidates. Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs. Individual states in the United&#160;States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, On May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional Regulation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on its business. We cannot predict, however, how changes in these laws may affect its future operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Europe/Rest of World Government Regulation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our therapeutics. Whether or not we obtain FDA approval of a therapeutic, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the therapeutic in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a Market Authorization Application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of therapeutics, operating restrictions and criminal prosecution.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 225 full-time employees and 143 non-employee leased workers. Of these employees, 27 held Ph.D. or M.D. degrees, 33 were engaged in research, 16 were engaged clinical development and 92 were engaged in technical operations. Substantially all of our employees are located in Florham Park, New Jersey. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating its existing and additional employees. The principal purposes of our incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</p>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We post our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, and any amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act, free of charge, on the Investors section of our public website (www.celularity.com) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, you can read our SEC filings over the Internet at the SEC&#8217;s website at www.sec.gov. The contents of these websites are not incorporated into this annual report on Form&#160;10-K. Further, our references to the URLs for these websites are intended to be inactive textual references only.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the following risk factors, as well as the other information in this annual report on Form 10-K, and in our other public filings. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Business and Industry</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred net losses in every period since its inception, has no cellular therapeutics approved for commercial sale and anticipates that it will incur substantial net losses in the future.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage&#160;biopharmaceutical company, has no cellular therapeutics approved for commercial sale, has not generated any revenue from cellular therapeutic sales to date, generates limited revenues from our degenerative disease and biobanking businesses, and will continue to incur significant research and development and other expenses related to its ongoing operations. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential therapeutic candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. As a result, we are not profitable and has incurred net losses in each period since our inception. We reported net losses of $100.1 million and $208.2 million the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $663.7 million.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seeks regulatory approvals for, cellular therapeutic candidates based on our four placental-derived&#160;allogeneic cell types: CAR-T&#160;cells, unmodified NK cells, genetically modified NK cells, and ASCs. Even if we succeed in commercializing one or more of its therapeutic candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional therapeutic candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue from our cellular therapeutic candidates. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our placental-derived cellular therapy candidates represent a novel approach to cancer, infectious and degenerative disease treatments that creates significant challenges.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing a pipeline of allogeneic cellular therapeutic candidates that are derived from healthy, full-term, human donor placentas, and in certain cases, are genetically modified. Allogeneic cells are intended to be &#8220;off-the-shelf&#8221; for use in any patient. Advancing these novel therapeutic candidates creates significant challenges, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">manufacturing cellular therapeutic candidates to its and regulatory specifications and in a timely manner to support its clinical trials, and, if approved, commercialization&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">biosourcing placentas and other materials and supplies for the manufacture of its therapeutic candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">any variability in placental-derived&#160;cells, or a higher-rejection&#160;rate, which could ultimately affect its ability to produce therapeutics in a reliable and consistent manner and treat certain patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">educating medical personnel regarding the potential advantages and potential disadvantages such as the side effect profile of its therapeutics, if approved, such as the potential adverse side effects related to GvHD, cytokine release syndrome, or CRS, neurotoxicity, prolonged cytopenia and neutropenic sepsis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">using medicines to manage adverse side effects of our therapeutic candidates that may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">obtaining regulatory approval, as the FDA, and other regulatory authorities have limited experience with development of allogeneic cell therapies for cancer, infectious and degenerative diseases&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">establishing sales and marketing capabilities for its therapeutic portfolio upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> historical operating results indicate substantial doubt exists related to its ability to continue as a going concern.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses and used significant cash in operating activities since inception. We have an accumulated deficit of approximately $663.7&#160;million and have cash and, cash equivalents and restricted cash of $52.1&#160;million as of December&#160;31, 2021. These factors raise substantial doubt about our ability to continue as a going concern and satisfying our estimated liquidity needs 12&#160;months from the issuance of the financial statements. If we continue to experience operating losses, and we are not able to generate additional liquidity through a capital raise or other cash infusion, we might need to secure additional sources of funds, which may or may not be available to it. Additionally, a failure to generate additional liquidity could negatively impact our ability to operate our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The gene-editing technology we use is relatively new, and if we are unable to use this technology in our intended therapeutic candidates, our revenue opportunities will be materially limited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use gene editing techniques to modify certain of the placental-derived&#160;cell types. We use these technologies to either reduce the risk of toxicity or improve the potential for efficacy. These technologies are relatively new, and may not be shown to be effective at achieving the expected effect in clinical studies, or may be associated with safety issues, either in our clinical development programs or those of others using these novel technologies. Any issues with the novel gene editing technologies, even if not experienced by us, could negatively affect our development programs. For instance, the genetic modifications may create unintended changes to the DNA such as a non-target&#160;site gene-editing, a large deletion, or a DNA translocation, any of which could lead to unwanted side-effects. The gene-editing&#160;of our therapeutic candidates may also not be successful in limiting the risk of GvHD or thrombosis or in increasing affinity.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some competitors in the allogeneic cell therapy space and more broadly in the gene therapy space have had clinical trials put on hold by the FDA.&#160;&#160;Based on findings in those clinical trials, the FDA may request additional testing, request different types of testing or even substantially revise the methodology used to evaluate clinical trials for other companies pursuing similar therapeutic avenues.&#160;&#160;We cannot control the actions of our competitors, cannot influence the results of their clinical trials and cannot know how FDA may react to a specific fact pattern arising in another clinical trial.&#160;&#160;Additional testing, different types of testing or a revised regulatory approach may delay our clinical trials, increase costs in our trials or otherwise preclude our trial from being given permission to proceed absent substantial time, effort and resources on our part.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the gene-editing&#160;industry is rapidly developing, and our competitors may introduce new technologies that render the technologies that we employ for our therapeutic candidates obsolete or less attractive. New technology could emerge at any point in the development cycle of its therapeutic candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact our programs. We also may be placed at a competitive disadvantage, and competitive pressures may force it to implement new technologies at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that we will be able to implement technologies on a timely basis or at an acceptable cost. If we are unable to maintain technological advancements consistent with industry standards, its operations and financial condition may be adversely affected.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic and future outbreaks of the disease, in regions where we or third parties on which we relies have concentrations of clinical trial sites or other business operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic&#160;and future outbreaks of the disease. For example, enrollment in clinical trials of CYNK-001&#160;for AML was delayed due to the COVID-19&#160;outbreak. Additionally, our ability to collect healthy, full-term&#160;donor placentas was limited during the height of the COVID-19&#160;pandemic in New&#160;Jersey and the tri-state&#160;area as hospital resources were diverted. Although we have reopened our offices and employees have transitioned back to working on site, there is a lack of uniformity of restrictions and requirements among its clinical trial sites, and future shelter-in-place&#160;or similar type restrictions could be reimposed, and once again, hospital personnel may not pursue donor consents. We are now also subject to risk of outbreaks at our facilities, and potential exposure to employee claims regarding workplace safety, and unanticipated shutdowns or quarantines could be imposed in the future, which would disrupt our operations. This uncertainty and the evolving nature of policies and restrictions, may negatively impact productivity, disrupt our business and further delay clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course, which could negatively impact our business, operating results and financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19&#160;pandemic, may be difficult to assess or predict, it has resulted in significant disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19&#160;could materially affect our business and the value of our Class A common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global COVID-19&#160;pandemic continues to evolve, and its ultimate impact or that of any similar health pandemic or epidemic is highly uncertain. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not yet know the full extent of potential delays or impacts on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> planned and ongoing clinical trials, the hospitals and healthcare systems or the global </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">economy as a whole</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. These effects could have a material impact on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operations, and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will continue to monitor the COVID-19&#160;situation closely.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on CAR-T viral vectors from Sorrento Therapeutics, Inc. for our CYCART-19 therapeutic candidate and termination of this license, or any future licenses, could result in the loss of significant rights, which would harm our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are dependent on patents, know-how&#160;and proprietary technology, both our own and licensed from others. In order to modify the placental-derived&#160;T cells to produce our CAR-T&#160;cell line, and our CYCART-19&#160;therapeutic candidate, we use retroviral technology licensed from, and supplied by, Sorrento. Celularity depends substantially on our license agreement with Sorrento. This license may be terminated by Sorrento for our uncured material breach. Any termination of this license could result in the loss of significant rights and could harm our ability to commercialize CYCART-19, and any future therapeutic candidates that use the licensed CAR construct. To the extent that obligations under this license agreement are not met, we may lose the benefits of the Sorrento license agreement and the CAR construct we use for CYCART-19. Further, we would need an additional license from Sorrento or access to other CAR construct technology to research and develop therapeutic candidates directed at targets not covered by our existing agreement with Sorrento. In addition, the Sorrento CAR-T&#160;retroviral technology may fail to produce viable therapeutic candidates. If we were to obtain approval of CYCART-19, there is no assurance that Sorrento would be able to supply sufficient viral vectors for commercial-scale&#160;manufacturing. If the agreement with Sorrento was terminated or we required other technology, such a license or technology may not be available to us on reasonable terms, or at all, particularly given the limited number of alternative technologies in the market. See Item 1 &#8220;<span style="font-style:italic;">Business&#160;&#8212;Licensing Agreements&#160;&#8212; Sorrento Therapeutics, Inc.</span>&#8221; for more information regarding the license from Sorrento.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also use other gene editing technology for the other cellular therapeutics in our pipeline. While certain of these technologies are available from multiple commercial vendors, were any of these vendors to refuse to supply us, it could negatively impact our development of our modified NK cells and ASCs, which depend on genetic modification to achieve the intended clinical benefits. Moreover, some gene editing technology that is currently available without license, could become patented or proprietary to a third party. If we are unable to obtain a license on commercially reasonable terms when needed, we could be forced to redesign our cellular therapeutics and or stop development. Any of these occurrences could have a material adverse effect on our business prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disputes may also arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including those related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related&#160;issues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our right to sublicense patent and other rights to third parties under collaborative development relationships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of its therapeutic candidates, and what activities satisfy those diligence obligations&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the ownership of inventions and know-how&#160;resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have licensed, or may license in the future, prevent or impair its ability to maintain its licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are generally also subject to all of the same risks with respect to protection of intellectual property that our licenses, as it is for intellectual property that we own, which are described below. If we or our current and future licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our therapeutic candidates are based on novel technologies, which makes it difficult to predict the time and cost of therapeutic candidate development and obtaining regulatory approval.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our research, development and manufacturing efforts on our placental-derived&#160;allogeneic T cell, NK cell and mesenchymal-like&#160;stromal cell types, and our future success depends on the successful development of this therapeutic approach. We have developed our Celularity IMPACT platform, which covers biosourcing through manufacturing of cryopacked cells, and continues to invest in optimizing and improving its technologies. There can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in scaling its manufacturing process when appropriate for commercialization, which may prevent us </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from completing </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> clinical studies or commercializing </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics on a timely or profitable basis, if at all. In addition, as </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the early stages of clinical development, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we do</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not know the doses to be evaluated in pivotal trials or, if approved, commercially. Finding a suitable dose for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cell therapeutic candidates may delay </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> anticipated clinical development timelines. In addition, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expectations </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with regard to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scalability and costs of manufacturing may vary significantly as </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> develop </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic candidates and understands these critical factors.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical study requirements of the FDA, European Medicines Agency, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a therapeutic candidate are determined according to the type, complexity, novelty and intended use and market of the potential therapeutics. The regulatory approval process for novel therapeutics candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other therapeutic candidates. In addition, under guidelines issued by the NIH, gene therapy clinical trials are also subject to review and oversight by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. Before a clinical trial can begin at any institution, that institution&#8217;s IRB, and its IBC assesses the safety of the research and identifies any potential risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH guidelines voluntarily follow them.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we expect reduced variability in its allogeneic cell therapeutic candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability and the use of healthy donor full-term&#160;placentas, and related screening requirements, may create separate variability challenges. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new therapeutic candidates. Moreover, our therapeutic candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous therapies that have previously been approved. For instance, allogeneic T cell therapeutic candidates may result in GvHD not experienced with autologous T cell products. While we have modified our CAR-T&#160;cell candidate to attempt to address this concern, CYCART-19&#160;may still be associated with GvHD and may not be effective in clinical trials. Even if we collect promising initial clinical data of our therapeutic candidates, longer-term&#160;data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly impact our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business is highly dependent on the success of our lead therapeutic candidates. If we are unable to obtain approval for our lead candidates and effectively commercialize our lead therapeutic candidates for the treatment of patients in approved indications, our business would be significantly harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced therapeutic candidates, including CYCART-19, CYNK-001, CYNK-101, APPL-001 and PDA-002. Because these placental-derived&#160;allogeneic cells are among the first allogeneic placental-derived&#160;cell therapies to be evaluated in the clinic, the failure of any such therapeutic candidate, or the failure of other allogeneic cell therapies, may impede our ability to develop our therapeutic candidates, and significantly influence physicians&#8217; and regulators&#8217; opinions in regards to the viability of our entire pipeline of placental-derived&#160;allogeneic cell therapies, particularly if high or uncontrolled rates of GvHD or other adverse events are observed. If significant adverse events are observed with the administration of its therapeutic candidates, or if any of the therapeutic candidates is viewed as less safe or effective than autologous therapies, its ability to develop other placental-derived&#160;allogeneic therapies may be significantly harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our therapeutic candidates, including our lead therapeutic candidates, will require additional clinical and non-clinical&#160;development, regulatory review and approval in multiple jurisdictions, substantial investment, scaled commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from sales of our cellular therapeutics. In addition, because our therapeutic candidates are all based on a similar process, our Celularity IMPACT platform, if any of the lead therapeutic candidates encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business for our therapeutics pipeline would be significantly harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our therapeutic candidates may cause undesirable side effects or have other properties that could halt our clinical development, prevent our regulatory approval, limit our commercial potential or result in significant negative consequences.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable or unacceptable side effects caused by our therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous cell therapies and those under development have shown frequent rates of CRS and neurotoxicity, and adverse events have resulted in the death of patients. Certain of our therapeutic candidates, such as CYCART-19, CYNK-101&#160;and APPL-001&#160;undergo genetic engineering. As these are novel technologies, errors may occur or may not present until used in humans in the clinic, and could cause adverse events. While we believe that placental-derived cells, including our use of NK cells and ASCs, have an inherent safety profile that may limit adverse events, there can be no assurance that this is the case as these are novel therapeutics.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> continue to evolve </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> placental-derived&#160;therapeutic programs, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may need to halt or modify development of certain candidates </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> adverse events. For example, in designing APPL-001, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> made certain modifications and adjustments, including a genetic modification due to an increased risk of thrombosis observed in a Phase 1 clinical trial of a placental-derived&#160;cell therapeutic</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> done at Celgene Cellular Therapeutics. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In any of our ongoing or planned clinical trials, patients may experience severe adverse events related to our allogeneic cell therapeutic candidates, some of which may result in death. If unacceptable toxicities arise in the development of our therapeutic candidates, we could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our therapeutic candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related&#160;side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from cell therapy are not normally encountered in the general patient population and by medical personnel. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our therapeutic candidates, which would prevent or delay regulatory approval and commercialization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approvals for the commercial sale of our cell therapeutic candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our therapeutic candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and our outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our therapeutic candidates may not be predictive of the results of later-stage&#160;clinical trials, including in any post-approval&#160;studies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is typically an extremely high rate of attrition from the failure of therapeutic candidates proceeding through clinical trials. Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most therapeutic candidates that commence clinical trials are never approved as therapeutics.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, for ongoing and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our therapeutic candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our therapeutic candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publish initial, interim or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, initial, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to submit INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit such trials to proceed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to submit INDs for additional therapeutic candidates in the future, including two planned in 2022 for CYCART-19&#160;and APPL-001. We cannot be certain that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. The manufacturing of allogeneic cell therapies remains an emerging and evolving field. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, will be a focus of IND reviews, which may delay the clearance of INDs. Additionally, even if FDA permits the initiation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that FDA will not change our requirements in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> may encounter substantial delays in </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> clinical trials or may not be able to conduct </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> trials on the timelines </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">we</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> expect.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could cause us or relevant regulatory authorities to suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and its future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">inability to generate sufficient preclinical, toxicology or other&#160;</span><span style="font-style:italic;font-size:10pt;">in vivo</span><span style="font-size:10pt;">&#160;or&#160;</span><span style="font-style:italic;font-size:10pt;">in vitro</span><span style="font-size:10pt;">&#160;data to support the initiation of clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">difficulty sourcing healthy full-term&#160;donor placentas of sufficient quality and in sufficient quantity to meet our development needs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain therapeutic candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays in reaching a consensus with regulatory agencies on study design&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays in obtaining required IRB approval at each clinical study site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays in patient recruitment, and or difficulty collaborating with patient groups and investigators, or other issues involving patient, such as completing participation or return for post-treatment&#160;follow-up, or dropping-out&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">failure by our CROs, other third parties or us to adhere to clinical study requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">failure to perform in accordance with the FDA&#8217;s good clinical practice, or GCP, requirements or applicable regulatory guidelines in other countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">issues with manufacturing of cellular therapeutics, including delays in manufacturing, testing, releasing, validating sufficient stable quantities of our therapeutic candidates for use in clinical studies or the inability to do any of the foregoing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">occurrence of adverse events associated with the therapeutic candidate that are viewed to outweigh its potential benefits&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the cost of clinical studies of our therapeutic candidates being greater than we anticipate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">negative or inconclusive results from clinical studies, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon development programs&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet its quantity or quality requirements for necessary raw materials.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ongoing&#160;COVID-19 pandemic, including the resurgence of cases relating to the spread of the Delta and Omicron variants, or future pandemics, may also increase the risk of certain of the events described above and delay our development timelines. For example, in early&#160;2020 and again in mid 2021, we experienced delays in enrolling its Phase 1 clinical trial of CYNK-001&#160;for AML as a result of the pandemic. Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair its ability to generate revenue. In addition, if we make manufacturing or formulation changes to our therapeutic candidates, we may be required to, or we may elect to conduct additional studies to bridge our modified candidates to earlier versions or may need to conduct additional studies on newly discovered candidates. Clinical study delays could also shorten any periods during which our therapeutics have patent protection and may allow our competitors to bring cell therapies to market before we do, which could impair its ability to successfully commercialize our therapeutic candidates and may harm our business and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Monitoring and managing toxicities in patients receiving therapeutic candidates is challenging, which could adversely affect </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> ability to obtain regulatory approval and commercialize </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> therapeutic candidates.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials to monitor patients for GvHD (for CYCART-19), in addition to more generally monitoring patients for adverse events who participate in its clinical trials. Even with these procedures in place, these centers and hospitals may have difficulty observing patients and treating toxicities or any other adverse events, which could lead to more severe or prolonged toxicities or even patient deaths. If there are any serious issues with GvHD or any other unanticipated events, it could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, which could jeopardize regulatory approval of our therapeutic candidates. Moreover, to the extent our cellular therapies are used outside of hospitals or medical centers, and upon any approval if our therapies are made more widely available on a commercial basis, it may become even more difficult to observe and manage adverse events. Moreover, medicines used at centers to help manage adverse side effects of our therapeutic candidates, such as any GvHD, may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials are expensive, time-consuming and difficult to design and implement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our allogeneic placental-derived&#160;cell therapeutic candidates are based on new technologies and will require the creation of inventory of mass-produced, off-the-shelf&#160;therapeutics, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with certain cancers or other targeted indications, including treating any potential side effects, could be significant. Accordingly, its clinical trial costs for its cellular therapeutic candidates are likely to be significantly higher than for more conventional therapeutic technologies or drug products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to develop additional therapeutic candidates, our commercial opportunity will be limited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of our core strategies is to pursue clinical development of additional therapeutic candidates beyond our initial five key programs, CYCART-19, CYNK-001, CYNK-101, APPL-001 and PDA-002, and to expand beyond the initial six indications targeted. Developing, obtaining regulatory approval and commercializing additional cell therapeutic candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional therapeutic candidates through the development process.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we receive FDA approval to market these or additional therapeutic candidates, we cannot assure any such therapeutic candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional therapeutic candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional therapeutic candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, therapeutic candidate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We operate our own manufacturing and storage facility, which requires significant resources&#59; manufacturing or other failures could adversely affect its clinical trials and the commercial viability of our therapeutic candidates and our biobanking and degenerative diseases businesses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a purpose-built&#160;facility located in Florham Park, New&#160;Jersey, where we process healthy full-term&#160;donor placentas for use in cell therapy and tissue products and operate our biobanking business. While we have experience managing the process for our research and existing clinical trial needs, we may not be able to mass-produce&#160;off-the-shelf&#160;placental-derived&#160;allogeneic cellular therapeutics to satisfy demands for any of our therapeutic candidates as we expand into later stage clinical trials, or for commercial production post-approval. While we believe the manufacturing and processing approaches are appropriate to support our current needs and that we have a scalable process and have secured appropriate supply from various third-parties, including Sorrento, we cannot be sure that our scaled process will result in allogeneic cells that will be safe and effective. Further, our manufacturing and storage facility, including for our biobanking and degenerative disease businesses, must comply with current good manufacturing practices, or cGMPs, which include, if applicable, the FDA&#8217;s current GTPs for the use of human cellular and tissue products. Accordingly, we are subject to ongoing periodic unannounced inspection by the FDA and other governmental agencies to ensure strict compliance with cGMPs, including GTPs as applicable, and other government regulations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our therapeutic candidates. Furthermore, if contaminants are discovered in our supply of therapeutic candidates or in the manufacturing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facilities, such supply may have to be discarded and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cannot assure any stability or other issues relating to the manufacture of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic candidates will not occur in the future.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or any other of our vendors may fail to manage the logistics of storing and shipping our raw materials, including donor placentas. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, health pandemics or epidemics, could result in the inability to manufacture therapeutics, the loss of usable therapeutics or prevent or delay the delivery of therapeutic candidates to patients and clinical trial sites. We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide its therapeutic candidates to patients would be jeopardized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently have no cellular therapeutics marketing sales force. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our therapeutic candidates once approved, we may not be able to generate product revenue.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no sales, marketing or distribution capabilities and, as a company, have no experience in marketing cellular therapeutics as our current sales force is limited to our degenerative disease and biobanking businesses. We intend to develop an in-house&#160;specialized marketing organization and sales force for our cellular therapeutic candidates, if such candidates receive regulatory approval, which will require significant expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable or decide not to establish internal sales, marketing and distribution capabilities for our cellular therapeutics once approved, we will pursue collaborative arrangements regarding the sales and marketing of cellular therapeutics&#59; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive from the sale of cellular therapeutics will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from therapeutic sales may be lower than if we had commercialized our therapeutic candidates directly, as we do for our degenerative disease products and biobanking business. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our therapeutic candidates. There can be no assurance that we will be able to develop in-house&#160;sales and distribution capabilities or establish or maintain relationships with third-party&#160;collaborators to commercialize any therapeutic that receives regulatory approval in the United&#160;States or in other markets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">A variety of risks associated with conducting research and clinical trials abroad and marketing our therapeutic candidates internationally could materially adversely affect its business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to globally develop our therapeutic candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">differing regulatory requirements in foreign countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">differing standards for the conduct of clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">increased difficulties in managing the logistics and transportation of storing and shipping therapeutic candidates produced in the United&#160;States and shipping the therapeutic candidate to the patient abroad, which may necessitate local or regional manufacture, including the need to source healthy full-term&#160;donor placentas outside the United&#160;States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">import and export requirements and restrictions, including as they pertain to donor placentas and human tissue collection and manufacture&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">foreign taxes, including withholding of payroll taxes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">difficulties staffing and managing foreign operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United&#160;States&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">differing payor reimbursement regimes, governmental payors or patient self-pay&#160;systems, and price controls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">potential liability under the FCPA or comparable foreign regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">challenges enforcing its contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United&#160;States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">production shortages resulting from any events affecting raw material supply, including obtaining sufficient donor placentas, and other issues with manufacturing abroad&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">business interruptions resulting from the COVID-19&#160;pandemic or other natural or man-made&#160;disasters, including earthquakes, tsunamis, fires or other medical epidemics, or geo-political&#160;actions, including war and terrorism.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These and other risks associated with its international operations may materially adversely affect its ability to attain or maintain profitable operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we have multiple programs and therapeutic candidates in our development pipeline and are pursuing a variety of target indications, we may expend our limited resources to pursue a particular therapeutic candidate and fail to capitalize on development opportunities or therapeutic candidates that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on the development of cellular therapeutic candidates, targeting indications across cancer, infectious and degenerative diseases. Because we have limited financial and personnel resources, we may forgo or delay pursuit of opportunities with potential target indications or therapeutic candidates that later prove to have greater commercial potential than our current and planned development programs and therapeutic candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and other future therapeutic candidates for specific indications may not yield any commercially viable future therapeutic candidates. If we do not accurately evaluate the commercial potential or target market for a particular therapeutic candidate, we may be required to relinquish valuable rights to that therapeutic candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors for our cellular therapeutics include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage&#160;companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our therapeutic candidates or may develop proprietary technologies or secure patent protection that Celularity may need for the development of its technologies and products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval of our therapeutic candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our therapeutic candidates. We may not be able to implement its business plan if the acceptance of our therapeutic candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our therapeutic candidates, or if physicians switch to other new drug or biologic products or choose to reserve our therapeutic candidates for use in limited circumstances. For additional information regarding its competition, see the section entitled &#8220;Business &#8212; Competition.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.  </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon its ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">medical personnel, including </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Founder and Chief Executive Officer, Robert Hariri, M.D., Ph.D., </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our President, Andrew Pecora, M.D.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chief Operating Officer, John Haines. The loss of the services of any of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> executive officers, other key employees, and other scientific and medical advisors, and </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> inability to find suitable replacements could result in delays in product development and harm </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, i</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n June 2021, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Chief Scientific Officer,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> retired and we have not yet replaced her and,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> there is no assurance that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will be able to find an appropriate officer to fill the role quickly or at all. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> conduct substantially </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all of</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operations at </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> facilities in New&#160;Jersey. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> market is intense and may limit </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to hire and retain highly qualified personnel on acceptable terms or at all. Despite efforts to retain valuable employees, members of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> management, scientific and development teams may terminate their employment on short notice. Although </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> employment agreements with </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> key employees, these employment agreements provide for at-will&#160;employment, which means that any of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> employees could leave employment at any time, with or without notice. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other employees. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> success also depends on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to continue to attract, retain and motivate highly skilled junior, mid-</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">level</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;and senior managers as well as junior, mid-level&#160;and senior scientific and medical personnel.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, we had 225 full-time&#160;employees and <span style="color:#000000;">143 non-employee leased workers</span>. As our development and commercialization plans and strategies develop, and as we operate as a public company following the Business Combination, we have expanded our employee base and expect to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">identifying, recruiting, integrating, maintaining and motivating additional employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our therapeutic candidates, while complying with our contractual obligations to contractors and other third parties&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">improving our operational, financial and management controls, reporting systems and procedures.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to commercialize our therapeutic candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of attention away from day-to-day&#160;activities in order to devote a substantial amount of time to managing these growth activities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop, manufacture and commercialize our therapeutic candidates and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our therapeutic candidates and any future therapeutic candidates that we may develop. Any of these relationships may require us to incur non-recurring&#160;and other charges, increase our near and long-term&#160;expenditures, issue securities that dilute stockholders or disrupt our management and business. We licensed certain intellectual property back to Celgene in connection with the Anthrogenesis acquisition. Given the broad scope of the license, Celgene could use our intellectual property to develop therapeutics that compete with us in the CAR field. Additionally, we have continuing obligations to Celgene under the CVR Agreement, under which we may be required to make certain payments to Celgene with respect to certain of our therapeutics, including CYNK-001&#160;and CYNK-101. Our payment obligations to Celgene under the CVR Agreement may limit our ability to partner such assets, were we choose to do so. See Item 1 &#8220;Business &#8212; Our Team and Corporate History &#8212; Celgene Corporation&#8221; for more information regarding the Celgene relationship.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming&#160;and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our therapeutic candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our therapeutic candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our therapeutic candidates could delay the development and commercialization of our therapeutic candidates in certain geographies for certain indications, which would harm its business prospects, financial condition and results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have in the past and in the future will continue to explore entering into new strategic alliances, collaborations, and licensing arrangements with third parties related to non-core&#160;areas. Such arrangements are entered into based on information available at the relevant time, and may not lead to long-term&#160;collaborations after initial research and development is conducted. We are party to certain agreements, and may in the future enter into new agreements, that contain non-competes&#160;or otherwise restrict our ability to operate in a particular field.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, disputes may arise under our current or future strategic alliances, collaborations, or other agreements or arrangements that include grants of intellectual property rights to or from us, or payments related thereto, including disagreements over scope of rights granted, proprietary rights, payment obligations, contract interpretation or the preferred course of research, development or commercialization. As a result of such disagreements, we may be required to pay additional amounts, there may be a reduction or delay in amounts payable to us, or there may be delays in research, development or commercialization activities, or termination of the arrangements, which could adversely impact our business and operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not realize the benefits of acquired assets or other strategic transactions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of its strategic transactions, including our license with Sorrento, and any future strategic transactions depends on the risks and uncertainties involved, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">unanticipated liabilities related to acquired companies or joint ventures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">difficulties integrating acquired personnel, technologies and operations into its existing business&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">retention of key employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">increases in our expenses and reductions in its cash available for operations and other uses&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">disruption in our relationships with collaborators or suppliers as a result of such a transaction&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">possible write-offs&#160;or impairment charges relating to acquired businesses or joint ventures.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries. Future acquisitions or dispositions could result in potentially dilutive issuances of its equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs&#160;of goodwill, any of which could harm its financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need substantial additional financing to develop our therapeutics and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to spend a substantial amount of capital in the development and manufacture of our therapeutic candidates. We will need substantial additional financing to develop our therapeutics and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our therapeutics and initiate and complete registration trials for multiple cellular therapeutics. Further, if approved, we will require significant additional amounts in order to launch and commercialize our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, we had $37.0&#160;million in cash and cash equivalents. We will need to raise additional capital to implement our plans. Further, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise a large amount of capital sooner than currently anticipated if we choose to expand more rapidly than our present plans. In any event, we will require additional capital for the further development and commercialization of our therapeutic candidates, including funding our internal manufacturing capabilities and growth of our degenerative disease business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our therapeutic candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements, including our license from Sorrento. We could be required to seek collaborators for our therapeutic candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our therapeutic candidates in markets where we otherwise would seek to pursue development or commercialization ourself. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our securities to decline.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> internal computer systems, or those used by </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of our CROs, collaborators, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach in our systems or infrastructure (including provided by third party vendors) were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our therapeutic candidates could be delayed. In addition, our increased reliance on personnel working from home could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business. As an early-stage company without significant investments in data security protection, we may not be sufficiently protected against such occurrences, and may not have the resources to allocate to such efforts.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new therapeutics and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new therapeutics can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, statutory, regulatory and policy changes, and business disruptions, such as those caused by the COVID-19&#160;pandemic. Average review times at the agency have fluctuated in recent years as a result. In addition, funding of government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA has had to furlough critical employees and stop critical activities. In addition, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold as a result of the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or disruption occurs, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the business disruptions and clinical trial delays caused by the COVID-19&#160;pandemic described above, our operations, and those of our CROs and other contractors and consultants, could be subject to other disruptions, including those caused by power shortages, telecommunications failures, water shortages, floods, hurricanes, tornadoes, fires, earthquakes, extreme weather conditions, medical epidemics and other natural or man-made&#160;disasters or business interruptions. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Our ability to manufacture our therapeutic candidates could be disrupted if our operations or those of our suppliers are affected by a man-made&#160;or natural disaster or other business interruption. Moreover, because our core operations are concentrated at our purpose-built&#160;facility in Florham Park, New Jersey, any disruptions at this site, if prolonged, could materially harm our business and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not obtain and maintain federal and state licenses and registrations required for our current and future operations, our ability to generate revenue will be limited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The health care industry is subject to stringent regulation by a wide range of authorities. Accordingly, our business requires us to maintain certain licenses, registrations, permits, authorizations, approvals, certifications, accreditations and other types of federal, state, and local governmental permissions and to comply with various regulations in every jurisdiction in which we operate. For example, we </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> required to maintain licenses and registrations in several states, and ha</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> obtained biologics, tissue bank and blood bank licenses, permits and registrations in states where such licensure is required for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to market and support </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products and services. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also maintains an annual registration with the FDA as a tissue bank, and national accreditation by the American Association of Blood Banks. The failure to comply with such licensure requirements can result in enforcement actions, including the revocation or suspension of the licenses, registrations or accreditations, or subject </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to plans of correction, monitoring, civil money penalties, civil injunctive action and/or criminal penalties. While </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believe that, given </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> current and proposed business, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not presently required to obtain additional licenses or registrations to market </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products or services, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cannot predict whether additional regulatory approval will be required in the future and, if so, whether such approval will at such time be obtained, whether for the stem cells and/or any other services that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">developing or may attempt to develop. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our f</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ailure to obtain and maintain required federal and state licenses and registration will limit </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to generate revenue.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with customers, physicians, and third-party payors are subject to numerous laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We operate in a highly-regulated&#160;industry, and our relationships with customers, physicians, and third-party&#160;payors are subject to numerous laws and regulations. See the section entitled &#8220;<span style="font-style:italic;">Business&#160;&#8212; Government Regulation and Product Approval</span>&#8221;. Healthcare providers, physicians and third-party&#160;payors in the United&#160;States and elsewhere will play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party&#160;payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may impact, among other things, our clinical research and development programs, as well as our proposed and future sales, marketing and education programs for our cellular therapeutics, as well as the sales and marketing of our degenerative disease products and biobanking business. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing&#160;and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of whom may receive stock options as compensation for service on our scientific advisory board, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourself or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties and corrective measures, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our therapeutic candidates or our degenerative disease products outside the United&#160;States will also likely subject us to an additional overlay of foreign equivalents of the healthcare laws, among other foreign laws.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies often scrutinize interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information&#59; and </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> use of data relating to personal identifier information and personal health information of U.S. citizens is restricted.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is broadly regulated by U.S. and foreign regulatory authorities, and we have both regulatory and contractual obligations with respect to such regulatory authorities concerning the handling, maintenance, and protection of data relating to personal identifier information and personal health information of U.S. citizens. Further, the collection and use of personal data in the European Union, are governed by the General Data Protection Regulation, or GDPR. Other jurisdictions, such as California, are adopting additional privacy regulations restricting the use of personal information and providing individuals certain rights with respect to their data or notices regarding use of their data. See Item 1 &#8220;Business &#8212; Government Regulation and Product Approval&#8221;. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states or other privacy rules and regulations may result in significant fines and other administrative penalties. We may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect its business, financial condition, results of operations and prospects. As our business progresses, these privacy regulations may significantly impact our business activities and exemplifies the vulnerability of our business to evolving regulatory environment related to personal data and protected health information.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against it, we may incur substantial liabilities and may be required to limit commercialization of its therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing of our therapeutic candidates and will face an even greater risk if we commercialize any cellular therapeutics, in addition to the risks from the sale of our degenerative disease products. For example, we may be sued if our therapeutic candidates or degenerative disease products cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the therapeutic or product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our therapeutic candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in a number of adverse effects, any of which could materially harm our financial condition and results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of therapeutics we develop, alone or with corporate collaborators, or negatively impact our degenerative disease business. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained and expect to obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Reliance on Third Parties</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of, or commercialize, our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials. We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for therapeutic candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of its clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory approval process. Moreover, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize its therapeutic candidates. As a result, our financial results and the commercial prospects for our therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact Celularity&#8217;s ability to meet its desired clinical development timelines.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on donors of healthy human full-term placentas to manufacture our therapeutic candidates, and if we do not obtain an adequate supply of such placentas from qualified donors, development of our placental-derived allogeneic cells may be adversely impacted.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are reliant on biosourcing healthy donor placentas to manufacture our therapeutic candidates, and on hospital personnel to obtain the necessary donor consent. Healthy donor placentas vary in type and quality, and this variation makes producing standardized therapeutic candidates more difficult and makes the development and commercialization pathway of our therapeutic candidates more uncertain. We have developed a process designed to enhance the quality and consistency of the placental-derived&#160;cells used in the manufacture of our three allogeneic cell types (CAR-T&#160;cells, NK cells and mesenchymal-like&#160;stromal cells), but our process may fail to identify suitable donors or detect all issues, and we may discover failures with the material after production. We may also have to update our specifications for new risks that may emerge, such as to screen for new viruses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have strict specifications for donor material, which include specifications required by regulatory authorities and rely on informed donor consent. If we are unable to identify and obtain donor material that satisfy specifications, agree with regulatory authorities on appropriate specifications, incentivize hospital personnel to solicit consent to donation or address variability in donor placentas, there may be inconsistencies in the therapeutic candidates we produce or we may be unable to initiate or continue ongoing clinical trials on the timelines we expect, or scale up our manufacturing process for later-stage&#160;clinical trials or commercialization, which could harm our reputation and adversely impact our business and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our therapeutic candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence from Sorrento, and other raw materials, some of which are manufactured by small companies with limited resources and experience to support a commercial therapeutic, or to deliver raw materials to our specifications. Although we are currently negotiating a supply agreement with Sorrento, we generally do not have dedicated supply contracts with many of our suppliers, and we may not be able to contract with them on acceptable terms, or at all. Many suppliers curtailed their operations during the COVID-19&#160;pandemic and our ability to source raw materials has been impacted. Further, some of our suppliers may not be able to scale-up&#160;as we move to later-stage&#160;clinical trials or commercialization. Accordingly, we may experience delays in receiving, or fail to secure entirely, key raw materials to support clinical or commercial manufacturing. Certain raw materials also require third-party&#160;testing, and some of the testing service companies may not have capacity or be able to conduct the testing that we request.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also face competition for supplies from other cell therapy companies. Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable terms or in a timely manner.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier, including to meet any regulatory requirements for such qualification, could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">we</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> or </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">third party</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> suppliers acting on </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> behalf</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">we</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> may be liable for damages.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development and manufacturing activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We are subject to federal, state and local laws and regulations in the United&#160;States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe our procedures, as well as the procedures of our third party suppliers for using, handling, storing and disposing of these materials comply with legally prescribed standards, neither we nor our third party suppliers can completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United&#160;States. We are not permitted to market any biological drug product in the United&#160;States until we receive approval of a biologics license application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the therapeutic candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the novel nature of our therapeutic candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic cell therapies. We may also request regulatory approval of future therapeutic candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the therapeutic candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our therapeutic candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also experience delays in completing planned clinical trials for a variety of reasons, including if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our therapeutic candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors. The FDA&#8217;s review of our data for ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more of our clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our therapeutic candidates, the commercial prospects for our therapeutic candidates will be harmed, and our ability to generate revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence therapeutic sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">To the extent our Biovance and Interfyl products do not qualify for regulation as HCT/P solely under Section&#160;361 of the PHSA, this could result in removal of these products from the market.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2017, the FDA released a guidance document entitled &#8220;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use&#160;&#8212; Guidance for Industry and Food and Drug Administration Staff&#8221;, which it revised and reissued in July&#160;2020. The document confirmed the FDA&#8217;s stance that sheet forms of amniotic tissue are appropriately regulated as solely Section&#160;361 HCT/Ps when manufactured in accordance with 21 CFR Part 1271 and intended for use as a barrier or covering. However, wound healing is not a homologous use of amniotic tissue, and to the extent we make claims for Biovance and Interfyl, two products in our degenerative disease business, that extend beyond homologous use, we may be subject to FDA enforcement. The Guidance stated that the FDA intends to exercise enforcement discretion under limited conditions with respect to the IND application and pre-market&#160;approval requirements for certain HCT/Ps for a period that expired on May 31, 2021. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s approach is risk-based, and the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uidance clarified that high-risk&#160;products and uses could be subject to immediate enforcement action. New&#160;York has interpreted the Guidance such that it has restricted the marketing of such products without BLA approval, notwithstanding the current exception in the Guidance, and other states may make similar determination, which would limit the market for such products until a BLA is approved.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amniotic tissue is generally eligible for regulation solely as a HCT/P under Section&#160;361 of the PHSA depending on whether the specific product at issue and the claims made for it are consistent with the applicable FDA criteria for minimal manipulation and homologous use. HCT/Ps that do not meet these minimal manipulation and homologous use criteria are subject to more extensive regulation as drugs, medical devices, biological products, or combination products. Such HCT/Ps must comply with both the FDA&#8217;s requirements for HCT/Ps and the requirements applicable to biologics, devices or drugs, including pre-market&#160;clearance or approval from the FDA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to either modify our claims or cease selling our Biovance and Interfyl products until the FDA approves a BLA, and then we will only be able to market such products for indications that have been approved in a BLA. The loss of our ability to market and sell these products would have an adverse impact on our revenues, business, financial condition and results of operations. In addition, we expect the cost to manufacture our products will increase due to the costs to comply with the requirements that apply to Section&#160;351 biological products, such as current cGMP and ongoing product testing costs. Increased costs relating to regulatory compliance could have an adverse impact on our business, financial condition and results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the FDA might, at some future point, modify its position on which current or future products qualify as Section&#160;361 HCT/Ps. Any regulatory changes could have adverse consequences for us and make it more difficult or expensive for us to conduct our business by requiring pre-market&#160;clearance or approval and compliance with additional post-market&#160;regulatory requirements with respect to those products. It is also possible that the FDA could require us to recall our Biovance and Interfyl products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect the therapeutic candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12&#160;years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for its biological products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of the therapeutic candidates we develop that are approved in the United&#160;States as a biological product under a BLA should qualify for the 12-year&#160;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject therapeutic candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory landscape that will govern our therapeutic candidates is uncertain&#59; regulations relating to more established cellular therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our therapeutic candidates or unexpected costs in obtaining regulatory approval.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we are developing novel cellular therapeutic candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene or cell therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our therapeutic candidates. Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our therapeutic candidates, further complicating the regulatory landscape.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The various committees and advisory groups involved in regulatory review, and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to perform additional studies, increase </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic candidates or lead to significant post-approval&#160;limitations or restrictions. Because the regulatory landscape for </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> placental-derived&#160;cell therapeutic candidates is new, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may face even more cumbersome and complex regulations than those for more traditional pharmaceutical or biological products. Furthermore, even if </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic candidates obtain required regulatory approvals, such approvals may later be withdrawn </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential therapeutic to market could decrease </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to generate sufficient revenue to maintain </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our cell therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we complete our planned and Phase 1 and Phase 1/2a clinical trials and obtain positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant therapeutic candidate. However, we do not have any agreement or guidance from the FDA that its regulatory development plans will be sufficient for submission of a BLA. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and its therapeutic candidates may fail to improve outcomes for such patients.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA grants us accelerated approval based on Phase 1/2a clinical trial results, if and when such trials occur, as a condition for accelerated approval, the FDA may require us to perform post-marketing&#160;studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly because our therapeutic candidates represent a novel treatment. In addition, the standard of care may change with the approval of new therapeutics in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that its therapeutic candidate is superior to the new products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical trial results may also not support approval. In addition, our therapeutic candidates could fail to receive regulatory approval for many reasons, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our therapeutic candidates are safe and effective for any of their proposed indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">We may be unable to demonstrate that our therapeutic candidates&#8217; clinical and other benefits outweigh their safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the data collected from clinical trials of our therapeutic candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United&#160;States or elsewhere&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> plan to seek orphan drug designation for some or all of </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> therapeutic candidates across various indications, but </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">we</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> revenue, if any, to be reduced.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition. In the United&#160;States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee&#160;waivers. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, but if a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances. See the section entitled &#8220;<span style="font-style:italic;">Business&#160;&#8212; Government Regulation and Product Approval</span>&#8221; for more information regarding orphan drug designation. Even though in April 2021, the FDA granted orphan drug designation to our non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy, CYNK-001, for the treatment of patients with malignant gliomas, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our therapeutic or if a subsequent applicant demonstrates clinical superiority over our product.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to seek orphan drug designation for some or all of our therapeutic candidates in specific orphan indications in which there is a medically plausible basis for the use of these therapeutics. Even if we obtain orphan drug designation, exclusive marketing rights in the United&#160;States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the therapeutic to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our therapeutics, if approved. </p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to therapeutic candidates granted breakthrough therapy or fast track designation by the FDA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to evaluate and continue ongoing discussions with the FDA on regulatory strategies that could enable it to take advantage of expedited development pathways for certain of our <span style="color:#000000;">therapeutic</span> candidates, although we cannot be certain that our <span style="color:#000000;">therapeutic</span> candidates will qualify for any expedited development pathways or that regulatory authorities will grant, or allow it to maintain, the relevant qualifying designations. Potential expedited development pathways that we could pursue include breakthrough therapy and fast track designation.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Breakthrough therapy designation is intended to expedite the development and review of <span style="color:#000000;">therapeutic</span> candidates that are designed to treat serious or life-threatening diseases when &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a <span style="color:#000000;">therapeutic</span> candidate as a breakthrough therapy provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the <span style="color:#000000;">therapeutic</span> candidate and ensure collection of appropriate data needed to support approval&#59; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers&#59; intensive guidance on an efficient drug development program, beginning as early as Phase 1&#59; organizational commitment involving senior managers&#59; and eligibility for rolling review and priority review. Fast track designation is designed for <span style="color:#000000;">therapeutic</span> candidates intended for the treatment of a serious or life-threatening disease or condition, where nonclinical or clinical data demonstrate the potential to address an unmet medical need for this disease or condition.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have received fast track designation for certain of its cell therapy candidates, we may elect not to pursue either of breakthrough therapy or fast track designation for our other therapeutic candidates, and the FDA has broad discretion whether or not to grant these designations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, even if we believe that a particular therapeutic candidate is eligible for breakthrough therapy or fast track designation, we cannot assure you that the FDA would decide to grant such designation. Breakthrough therapy designation and fast track designation do not change the standards for product approval, and there is no assurance that such designation or eligibility will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the breakthrough therapy designation or fast track designation. Thus, even if we do receive breakthrough therapy or fast track designation, the company may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw breakthrough therapy or fast track designation if it believes that the product no longer meets the qualifying criteria. our business may be harmed if we are unable to avail ourself of these or any other expedited development and regulatory pathways.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> therapeutic candidates in one jurisdiction does not mean that </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">we</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> will be successful in obtaining regulatory approval of </span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">our</span><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> therapeutic candidates in other jurisdictions.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining regulatory approval of our therapeutic candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a therapeutic candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the therapeutic candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United&#160;States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United&#160;States, a therapeutic candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United&#160;States have requirements for approval of therapeutic candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for it and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our therapeutic candidates will be harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval of our therapeutic candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our therapeutic candidates will require surveillance to monitor the safety and efficacy of the therapeutic candidate. The FDA may also require a REMS in order to approve our therapeutic candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our therapeutic candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our therapeutic candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing&#160;information and reports, registration, as well as continued compliance with cGMPs and current GCPs for any clinical trials that Celularity conducts post-approval, and compliance with applicable product tracking and tracing requirements. As such, we will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work with must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer&#160;advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as &#8220;off-label&#160;use&#8221;), limitations on industry-sponsored&#160;scientific and educational activities and requirements for promotional activities involving the internet and social media. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label&#160;uses, and a company that is found to have improperly promoted off-label&#160;uses may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label&#160;uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label&#160;use of their products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with our therapeutic candidates, including adverse events of unanticipated severity or frequency, or with our third-party&#160;suppliers, or our manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market&#160;studies or clinical studies to assess new safety risks&#59; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">restrictions on the marketing or manufacturing of our therapeutic candidates, withdrawal of the therapeutic from the market or voluntary or mandatory product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">fines, warning letters or holds on clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;">product seizure or detention, or refusal to permit the import or export of </span><span style="font-size:10pt;">our</span><span style="font-size:10pt;"> therapeutic candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our therapeutic candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United&#160;States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing or modified cells may damage public perception of our therapeutic candidates or adversely affect its ability to conduct its business or obtain regulatory approvals for our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The gene-editing&#160;technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our therapeutic candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our therapeutic candidates. In addition, given the novel nature of gene-editing&#160;and cell therapy technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies. Increased negative public opinion or more restrictive government regulations either in the United&#160;States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our therapeutic candidates or demand for such therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval of our therapeutic candidates, the cell therapies may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of engineered placental-derived&#160;cells as a potential treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. We may not be able to educate these persons on the benefits of using our therapeutic candidates for many reasons. For example, certain of the therapeutic candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous&#160;cells. It is possible that our therapeutic candidates may kill these non-cancerous&#160;cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our therapeutic candidates are accepted in the market, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the clinical indications for which our therapeutic candidates are approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">physicians, hospitals, cancer treatment centers and patients considering its therapeutic candidates as a safe and effective treatment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the potential and perceived advantages of our therapeutic candidates over alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the prevalence and severity of any side effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">product labeling or product insert requirements of the FDA or other regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">limitations or warnings contained in the labeling approved by the FDA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the timing of market introduction of our therapeutic candidates as well as competitive products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the cost of treatment in relation to alternative treatments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the availability of coverage and adequate reimbursement by third-party&#160;payors and government authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the willingness of patients to pay out-of-pocket&#160;in the absence of coverage and adequate reimbursement by third-party&#160;payors and government authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the effectiveness of our sales and marketing efforts.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our therapeutic candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our cell therapies achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our therapeutics, are more cost effective or render our therapeutics obsolete.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and reimbursement may be limited or unavailable in certain market segments for our therapeutic candidates, which could make it difficult for us to sell our cell therapies, if approved, profitably.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful sales of our therapeutic candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party&#160;payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic candidates for which we obtain regulatory approval. In addition, because our therapeutic candidates represent new approaches to the treatment of cancer, infectious and degenerative diseases, we cannot accurately estimate the potential revenue from our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients who are provided medical treatment for their conditions generally rely on third-party&#160;payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party&#160;payors is critical to new product acceptance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party&#160;payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party&#160;payor may depend upon a number of factors, including, but not limited to, the third-party&#160;payor&#8217;s determination that use of a therapeutic is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">a covered benefit under our health plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">safe, effective and medically necessary&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">appropriate for the specific patient&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">cost-effective&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">neither experimental nor investigational.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement of a therapeutic from a government or other third-party&#160;payor is a time-consuming&#160;and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness&#160;data for the use of our therapeutics. Even if we obtain coverage for a given therapeutic, if the resulting reimbursement rates are insufficient, hospitals may not approve our therapeutic for use in their facility or third-party&#160;payors may require co-payments&#160;that patients find unacceptably high. Patients are unlikely to use our therapeutic candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our therapeutic candidates. Separate reimbursement for the therapeutic itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our therapeutic is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party&#160;payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party&#160;payors and reduce the willingness of physicians to use our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United&#160;States, no uniform policy of coverage and reimbursement for products exists among third-party&#160;payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party&#160;reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to seek approval to market our therapeutic candidates in both the United&#160;States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our therapeutic candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a therapeutic candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness&#160;of a particular therapeutic candidate to currently available therapies. Other EU member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border&#160;imports from low-priced&#160;markets exert a commercial pressure on pricing within a country.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketability of any therapeutic candidates for which </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> receive regulatory approval for commercial sale may suffer if government and other third-party&#160;payors fail to provide coverage and adequate reimbursement. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party&#160;reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more therapeutics for which </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The advancement of healthcare reform may negatively impact our ability to sell its therapeutic candidates, if approved, profitably.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party&#160;payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United&#160;States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our therapeutic candidates, if approved, profitably. Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. See the section entitled &#8220;Business &#8212; Government Regulation and Product Approval&#8221; for a discussion of these laws and regulations. There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our therapeutics. Such reforms could have an adverse effect on anticipated revenue from therapeutic candidates that we may successfully develop and for which we may obtain regulatory approval and may affect its overall financial condition and ability to develop therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there has been increasing legislative and enforcement interest in the United&#160;States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. Individual states in the United&#160;States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the initiatives that may be adopted in the future. Additionally, the continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the demand for our therapeutic candidates, if we obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to set a price that it believes is fair for our therapeutics&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our ability to generate revenue and achieve or maintain profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the level of taxes that we are required to pay&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the availability of capital.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies is not adequate, we may not be able to compete effectively in our market.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success depends in large part on our ability to obtain and maintain protection of intellectual property. We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to its technologies. Any disclosure to or misappropriation by third parties of its confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. We have filed additional patent applications, and we anticipate additional patent applications will be filed in the future, both in the United&#160;States and in other countries, as appropriate. However, we cannot predict:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">if and when patents will issue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;">whether or not others will obtain patents claiming aspects </span><span style="font-size:10pt;">similar to</span><span style="font-size:10pt;"> those covered by </span><span style="font-size:10pt;">our</span><span style="font-size:10pt;"> patents and patent applications&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">whether we will need to initiate litigation or administrative proceedings, which may be costly whether we win or lose.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and enforcing biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we may fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications licensed from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that the claims in our pending patent applications will be considered patentable by the United&#160;States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United&#160;States or foreign countries. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license&#160;may fail to result in issued patents with claims that cover our therapeutic candidates or uses thereof in the United&#160;States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, which may result in such patents being canceled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect its intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our therapeutic candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our therapeutic candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our therapeutic candidates under patent protection would be reduced. Further, changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how&#160;that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure&#160;agreements and intellectual property assignment agreements, with our employees, consultants, corporate partners and, when needed, advisers. Trade secrets, however, may be difficult to protect.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps it has taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we require all of our employees to assign their inventions to us, and requires all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United&#160;States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United&#160;States and abroad. If we are unable to prevent unauthorized material disclosure of our confidential information or intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or know-how&#160;of others in their work for us, we may be subject to claims that the Company or the Company&#8217;s employees, consultants or independent contractors have inadvertently or otherwise </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">used or disclosed intellectual property, including trade secrets or other proprietary or confidential information of these third parties or </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> employees&#8217; former employers. Litigation may be necessary to defend against these claims. If </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> fail in defending such claims, in addition to paying monetary damages, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may lose valuable intellectual property rights and face increased competition to business. A loss of key research personnel work product could hamper or prevent </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to commercialize potential technologies and solutions, which could harm </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business. Even if </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> successful in defending against these claims, litigation could result in substantial cost and be a distraction to </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management team and employees.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our therapeutic candidates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on us avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our therapeutic candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that its therapeutic candidates may give rise to claims of infringement of the patent rights of others.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our therapeutic candidates may be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party&#160;patents were held by a court of competent jurisdiction to cover the manufacturing process of our therapeutic candidates, constructs or molecules used in or formed during the manufacturing process, or any final therapeutic itself, the holders of any such patents may be able to block our ability to commercialize the therapeutic candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party&#160;patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the therapeutic candidate unless we obtain a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party&#160;patent on commercially reasonable terms, or at all, our ability to commercialize our therapeutic candidates may be impaired or delayed, which could in turn significantly harm our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our therapeutic candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our therapeutic candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our therapeutic candidates, which could harm our business significantly.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presently, we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, that we believe will facilitate the development of our therapeutic candidates. In the future, we may identify third party intellectual property and technology that we may need to acquire or license in order to engage in its business, including to develop or commercialize new technologies or services, and the growth of our business may depend in part on our ability to acquire, in-license&#160;or use this technology.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be unable to acquire or in-license&#160;any third-party&#160;intellectual property rights from third parties that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> identif</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm its business. Even if </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> able to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> obtain a license, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be non-exclusive, thereby giving </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> competitors access to the same technologies licensed to </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In that event, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may be required to expend significant time and resources to develop or license replacement technology. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may need to cease use of the compositions or methods covered by such third-party&#160;intellectual property rights to the extent </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unable to maintain </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> license with any such third-party&#160;licensors.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The licensing and acquisition of third-party&#160;intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party&#160;intellectual property rights that we may consider necessary or attractive in order to commercialize our therapeutic candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If such licenses are available, we may be required to pay the licensor in return for the use of such licensor&#8217;s technology, lump-sum&#160;payments, payments based on certain milestones such as sales volumes, or royalties based on sales. In addition, our licenses may also place restrictions on our future business opportunities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize technology covered by these license agreements. If these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market products that use technologies identical to those licensed to us. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Additionally, termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in us having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more technologies that rely on such agreements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the above risks, intellectual property rights that may be licensed now or in the future could include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use sublicensed intellectual property, even if we are in compliance with all of the obligations under its license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize therapeutic candidates may be materially harmed.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we may not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce licensed and sublicensed intellectual property effectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our licensors may have relied on third-party&#160;consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents and patent applications in-licensed. If other third parties have ownership rights to patents or patent applications in-licensed&#160;by us, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other rights are found to be invalid or unenforceable. Moreover, we could encounter delays in the introduction of services while we attempt to develop alternatives. Further, defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent us from commercializing products, which could harm our business, financial condition, or results of operations and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be involved in lawsuits or other legal proceedings to protect or enforce its patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of its licensors or misappropriate or otherwise violate our intellectual property rights or the intellectual property rights of our licensors. In the future, we or our licensors may initiate legal proceedings to enforce or defend our intellectual property rights or the intellectual property rights of our licensors, to protect our trade secrets or the trade secrets of our licensors, or to determine the validity or scope of intellectual property rights we own or control.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To counter infringement or unauthorized use, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be required to file infringement claims, which can be expensive and time-consuming. Third parties may also initiate legal proceedings against </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> licensor</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to challenge the validity or scope of intellectual property rights </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> own, control or to which </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> have rights. In an infringement proceeding, a court may decide that one or more of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not valid or </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pending patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business. Additionally, many of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> adversaries or adversaries of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> licensors in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> can. In the event of a successful claim of infringement against </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringing products, which may be impossible or require substantial time and monetary expenditure.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party&#160;pre-issuance&#160;submission of prior art to the USPTO, or opposition, derivation, revocation, reexamination,&#160;<span style="font-style:italic;">inter partes</span>&#160;review or interference proceedings, or other pre-issuance&#160;or post-grant&#160;proceedings or other patent office proceedings or litigation in the United&#160;States or other jurisdictions provoked by third parties or brought by us or our licensors, may challenge or be necessary to determine the inventorship, priority, patentability or validity of inventions with respect to us or our licensor&#8217;s patents or patent applications. An unfavorable outcome could leave our technology or therapeutic candidates without patent protection, allow third parties to commercialize our technology or therapeutic candidates and compete directly with us, without payment to us, or could require us or our licensors to cease using the related technology or to obtain license rights from the prevailing party in order to be able to manufacture or commercialize our therapeutic candidates without infringing third-party&#160;patent rights.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or other legal proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United&#160;States.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. If the breadth or strength of protection provided by us or our licensor&#8217;s patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize therapeutic candidates. Moreover, the uncertainties associated with litigation could have a material adverse effect on Celularity&#8217;s ability to raise the funds necessary to continue clinical trials, continue research programs, license necessary technology from third parties, or enter into collaborations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment&#160;of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The lives of our patents may not be sufficient to effectively protect our products and business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our therapeutic candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United&#160;States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If our technologies require extended development and/or regulatory review, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents protecting </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technologies might expire before or shortly after </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> able to successfully commercialize them. If </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we do</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not have sufficient patent life to protect </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> business and results of operations will be adversely affected.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing its therapeutic candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on its business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights outside the United&#160;States. Filing, prosecuting and defending patents on therapeutic candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United&#160;States can be less extensive than those in the United&#160;States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United&#160;States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the United&#160;States or abroad, our patents and patent applications may be challenged or may fail to result in issued patents. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United&#160;States, or from selling or importing products made using its inventions in and into the United&#160;States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United&#160;States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that it initiates, or that are initiated against us, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United&#160;States and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce its intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in either the patent laws or in interpretations of patent laws in the United&#160;States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. We may not develop additional proprietary technologies that are patentable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming that other requirements for patentability are met, prior to March&#160;16, 2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States, the first to file a patent application was entitled to the patent. On or after March&#160;16, 2013, under the Leahy-Smith&#160;America Invents Act, or the America Invents Act, enacted on September&#160;16, 2011, the United&#160;States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March&#160;16, 2013, but before us, could therefore be awarded a patent covering an invention of ours, even if we have made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Because patent applications in the United&#160;States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> licensors were the first to either (</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;file any patent application related to </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technology or (ii)&#160;invent any of the inventions claimed in </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensor&#8217;s patents or patent applications.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant&#160;proceedings, including post-grant&#160;review,&#160;<span style="font-style:italic;">inter partes</span>&#160;review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United&#160;States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed&#160;patent applications and the enforcement or defense of our owned or in-licensed&#160;issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United&#160;States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered natural laws. Accordingly, the evolving case law in the United&#160;States, and abroad, may adversely affect us and our licensor&#8217;s ability to obtain new patents or to enforce existing patents and may facilitate third party challenges to any owned or licensed patents.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain any competitive advantage. For example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">others may be able to make products that are similar to any therapeutic candidates we may develop or utilize similar technology that are not covered by the claims of the patents that we license or may own in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we, or our, current or future collaborators, might not have been the first to make the inventions covered by the issued patents and pending patent applications that we license or may own in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we, or our, current or future collaborators, might not have been the first to file patent applications covering certain of our intellectual property or our inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">it is possible that our pending patent applications or those that we may own in the future will not lead to issued patents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive therapeutics for sale in our major commercial markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable therapeutic candidates or will provide us with any competitive advantages&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we cannot ensure that our commercial activities or therapeutic candidates will not infringe upon the patents of others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we cannot ensure that we will be able to successfully commercialize our therapeutic candidates on a substantial scale, if approved, before the relevant patents that we own or licenses expire&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our therapeutic candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we may not develop additional proprietary technologies that are patentable&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">the patents or intellectual property rights of others may harm our business&#59; and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">we may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Class A Common Stock </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">There may not be an active trading market for our securities, which may make it difficult to sell shares of Class A Common Stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is possible that an active trading market for our securities will not develop or, if developed, that any market will not be sustained. This would make it difficult for to sell our securities at an attractive price or at all.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our securities may be volatile, which could cause the value of an investment to decline.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The price of our securities may fluctuate significantly due to general market and economic conditions. An active trading market for our securities may not develop or, if developed, it may not be sustained. In addition, fluctuations in the price of our securities could contribute to the loss of all or part of the investment in our company. Even if an active market for our securities develops and continues, the trading price of our securities could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. Any of the factors listed below could have a material adverse effect on your investment in our securities and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factors affecting the trading price of our securities may include:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the realization of any of the risk factors presented in this annual report&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman PS Std;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family:Times New Roman;">actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us&#59;</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;changes in the market&#8217;s expectations about our operating results&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our operating results failing to meet the expectation of securities analysts of investors in a particular period&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;operating and share price performance of other companies that investors deem comparable to us&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the volume of shares of Class A common stock available for public sale&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;future issuances, sales, resales or repurchases or anticipated issuances, sales, resales or repurchases of our securities&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the commencement, enrollment or results of our ongoing and planned clinical trials of our therapeutic candidates or any future clinical trials we may conduct, or changes in the development status of our therapeutic candidates&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;adverse results or delays in clinical trials&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any delay in our regulatory filings for our therapeutic candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our failure to commercialize our therapeutic candidates&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;adverse regulatory decisions, including failure to receive regulatory approval of our therapeutic candidates&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;changes in laws or regulations applicable to our therapeutic candidates, including but not limited to clinical trial requirements for approvals&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;adverse developments concerning manufacturers or suppliers&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our inability to manufacture or obtain adequate supply for any approved therapeutic or inability to do so at acceptable prices&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our inability to establish collaborations if needed&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;additions or departures of key scientific or management personnel&#59;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;unanticipated serious safety concerns related to cellular therapies&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;introduction of new therapeutics or services offered by our competitors&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our ability to effectively manage growth&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;actual or anticipated variations in quarterly operating results&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our cash position&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;publication of research reports about us or our industry, or cellular therapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;changes in the structure of healthcare payment systems&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;changes in the market valuations of similar companies&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;overall performance of the equity markets&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;speculation in the press or investment community&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;sales of Class A common stock by us or our stockholders in the future&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the trading volume of our Class A common stock&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;changes in accounting practices<span style="font-family:Times New Roman PS Std;">&#59;</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the ineffectiveness of our internal control over financial reporting&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain or maintain patent protection for its technologies&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;significant lawsuits, including patent or stockholder litigation&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;general political and economic conditions, including health pandemics, such as COVID-19&#59; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;other events or factors, many of which are beyond our control.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our Class A common stock, regardless of its actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not intend to pay cash dividends for the foreseeable future.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-size:13.5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any cash dividends in the foreseeable future. As a result, you may only receive a return on your investment in our Class A common stock if the trading price of your shares increases.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences including:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;limited availability of market quotations for our securities&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a determination that the Class A common stock is a &#8220;penny stock&#8221; which will require brokers trading in the Class A common stock to adhere to more stringent rules&#59;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>

<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;possibly resulting in a reduced level of trading activity in the secondary trading market for shares of the Class A common stock&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a limited amount of analyst coverage&#59; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a decreased ability to issue additional securities or obtain additional financing in the future<span style="font-family:Times New Roman PS Std;">.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales and issuances of our Class A common stock or rights to purchase common stock, including pursuant to our equity plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner it determines from time to time. we may also sell our common stock as part of entering into strategic alliances, creating joint ventures or collaborations or entering into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our Class A common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our Class A common stock and may prevent or frustrate attempts by our stockholders to replace or remove its current management.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our second amended and restated certificate of incorporation&#160;&#160;and our amended and restated bylaws&#160;&#160;adopted in connection with the completion of the Business Combination contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a board of directors divided into three classes serving staggered three-year terms, such that not all members of our board of directors will be elected at one time&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a requirement that special meetings of stockholders be called only by the chairman of our board of directors, the chief executive officer, or by a majority of the total number of authorized directors&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;advance notice requirements for stockholder proposals and nominations for election to our board of directors&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation&#59; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the authority of our board of directors to issue preferred stock on terms determined by the directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our charter and bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our Class A common stock to decline.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our charter provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our charter provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any derivative claim or cause of action brought on our behalf&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any claim or cause of action against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our charter or the bylaws&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our charter or bylaws&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware&#59; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any claim or cause of action against us or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our charter provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our charter. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global credit and financial markets have experienced extreme volatility and disruptions in the past, most recently as a result of the ongoing COVID-19&#160;pandemic. These disruptions can result in severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require it to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change federal net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change income and taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2021, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we had approximately </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.4</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of U.S. federal and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.9</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million state NOL carryforwards, and these NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities, which could adversely affect our profitability. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize NOL carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in tax law could adversely affect our business and financial condition.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the U.S. Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our securities. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of changes in tax laws on an investment in our securities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Item 1B. Unresolved Staff Comments. </p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_PROPERTIES">Item 2. Properties. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We occupy approximately 150,000 square feet of office, laboratory and manufacturing space in Florham Park, New&#160;Jersey under a lease expiring in 2036, which we use as our principal place of business. We lease additional properties in New&#160;Jersey. We believe that our existing facilities and other available properties will be sufficient for our needs for the foreseeable future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_LEGAL_PROCEEDINGS">Item 3. Legal Proceedings. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 9, 2021, John Schlechtweg, a former employee, filed a complaint against us in the United States District Court for the District of Connecticut alleging breach of verbal contract and, alternatively, unjust enrichment. The complaint specifically alleges that we have refused to pay Mr. Schlechtweg additional compensation relating to his involvement in the sale of certain assets to Sanuwave. We believe the claims asserted in the action are without merit and intend to vigorously defend against them, but there can be no assurance as to the outcome of the litigation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 4, 2021, a putative class action lawsuit was filed in the Supreme Court of the State of New York by a purported&#160;&#160;stockholder in connection with the Business Combination: Spero v. GX Acquisition Corp., et al., Index No. 650812/2021 (N.Y. Sup Ct. Feb 04, 2021). On February 26, 2021, the same purported stockholder filed an amended complaint in the lawsuit removing the class action allegations and certain of the other allegations, or the Spero Complaint. On February 8, 2021, a complaint was filed with the Supreme Court of the State of New York by a purported stockholder in connection with the Business Combination: Rogalla v. GX Acquisition Corp., et al., Index No. 650877/2021 (N.Y. Sup Ct. Feb 08, 2021), or the Rogalla Complaint, and together with the Spero Complaint, the Complaints). The Complaints name our Company and members of our board of directors (prior to the Business Combination), or GX and the GX Board, respectively, as defendants. Additionally, the Rogalla Complaint named First Merger Sub, Second Merger Sub and Celularity as defendants. The Rogalla Complaint alleged breach of fiduciary duty claims against the GX Board in connection with the Business Combination and aiding and abetting the GX Board&#8217;s breaches of fiduciary duties claims against GX, First Merger Sub, Second Merger Sub and Celularity. These claims are based on allegations that the prospectus in connection with the Business Combination was materially misleading and/or omitted material information concerning the Business Combination. The Spero Complaint alleged breach of fiduciary duty claims against the GX Board in connection with the Business Combination and aiding and abetting the GX Boards&#8217; breaches of fiduciary duties claims against GX. These claims were based on the sales process and valuation of Celularity, as well as allegations that the S-4 Registration Statement related to the Business Combination was materially misleading and/or omitted material information concerning the Business Combination. The Complaints generally requested injunctive relief or rescission, unspecified damages and awards of attorneys&#8217; and experts&#8217; fees, among other remedies. On April 29, 2021, the plaintiff that filed the Spero Complaint voluntarily discontinued that action. On July 20, 2021, the plaintiff that filed the Rogalla Complaint voluntarily discontinued that action.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GX Board also received four demands from putative stockholders of GX dated February 18, 2021, March 2, 2021, March 19, 2021 and March 24, 2021, together, the Demands, alleging that GX and the GX Board have breached their fiduciary duties and violated federal securities laws because the prospectus allegedly was materially misleading and/or omitted material information concerning the Business Combination. The Demands sought the issuance of corrective disclosures in an amendment or supplement to the prospectus. While GX believed that the above allegations were all without merit, on March 29, 2021, GX filed an amended Form S-4 with the SEC that contained certain additional information that mooted the disclosure claims asserted in the Complaints and the Demands, the Supplemental Disclosures. In connection with the filing of the Supplemental Disclosures, counsel for the plaintiffs in the Complaint and the Demands agreed that, in light of the mootness of their claims, they would stand down and not take any further action with respect to the Business Combination or the prospectus, and subsequently entered into a confidential agreement with GX to resolve any and all claims that were or could have been raised in the Complaints and the Demands.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares of our Class A common stock have traded on the Nasdaq Global Select Market under the ticker symbol &#8220;CELU&#8221;. Our ticker symbol for our warrants exercisable for one share of Class A common stock at an exercise price of $11.50 per share is &#8220;CELUW&#8221;. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 24, 2022, there were approximately 147 stockholders of record of our Class A common stock and 15 holders of our warrants.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any dividends on our capital or common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance under Equity Compensation Plans</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this annual report</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, in connection with a settlement of a dispute with CTH Biosourcing LLC, or CTH, we issued 743,771 shares of Class A common stock to CariCord participating shareholders. These securities were issued under Section 4(a)(2) of the Securities Act in a transaction not involving a public offering. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:5.94%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Of the gross proceeds received from GX&#8217;s initial public offering, or IPO, and the full exercise of the option to purchase additional units, $287.5 million was placed in GX&#8217;s trust account. The net proceeds of the IPO were applied to fund the Business Combination and related expenses.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_RESERVED">Item 6. [Reserved] </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Such forward-looking statements, which represent our intent, belief, or current expectations, involve risks and uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221; &#8220;should&#8221; and similar expressions. Factors that could cause or contribute to differences in results include, but are not limited to, those set forth under Item 1.B. &#8220;Risk Factors&#8221; and elsewhere in this annual report. Except as required by law, we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:5.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. We are developing a pipeline of off-the-shelf placental-derived allogenic cell therapy product candidates including T cells engineered with a CAR, NK cells, and mesenchymal-like ASCs. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. We believe that by harnessing the placenta&#8217;s unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need for effective, accessible and affordable therapeutics. We currently have three active clinical trials and plan to submit two additional IND applications in 2022. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:5.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Celularity IMPACT platform capitalizes on the benefits of placenta-derived cells to target multiple diseases, and provides seamless integration, from bio sourcing through manufacturing cryopreserved and packaged allogeneic cells, in our purpose-built U.S.-based approximately 150,000 square foot facility. We believe the use of placental-derived cells, sourced from the placentas of full-term healthy informed consent donors, has potential inherent advantages, from a scientific and an economic perspective. First, relative to adult-derived cells, placental-derived cells demonstrate greater stemness, meaning the ability to expand and persist. Second, placental-derived cells are immunologically na&#239;ve, meaning the cells have never been exposed to a specific antigen, and suggesting the potential for less toxicity and for low or no GvHD in transplant. Third, our placental-derived cells are allogeneic, meaning they are intended for use in any patient, as compared to autologous cells, which are derived from an individual patient for that patient&#8217;s sole use. We believe this a key difference that will enable readily available off-the-shelf treatments that can be delivered faster, more reliably, at greater scale and to more patients.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:5.03%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From a single source material, the postpartum human placenta, we derive four allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which are used in five key cell therapeutic programs&#8212;CYCART-19, CYNK-001, CYNK-101, APPL-001, and PDA-002&#8212;that in turn are focused on six initial indications. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor, the construct and related CARs for which are in-licensed from Sorrento. We plan to submit an IND and to commence a Phase 1 clinical trial of CYCART-19 in the first half of 2022. CYNK-001 is a placental-derived unmodified NK cell in development for the treatment of AML, a blood cancer, and for GBM, a solid tumor cancer. CYNK-001 is currently in Phase 1 trial for AML and a Phase 1/2a trial for GBM, respectively. CYNK-101 is genetically modified version of a placental-derived NK-cell. We <span style="color:#000000;">initiated a Phase 1 trial of CYNK-101 in patients with HER2+ gastric and gastroesophageal cancers during the fourth quarter</span>. <span style="color:#000000;">CYNK-101 will be evaluated in combination with mAbs to target HER2+ (traztuzumab) and PDl-1 (pembrolizumab). </span>APPL-001 is a placenta-derived ASC being developed for the treatment of Crohn&#8217;s disease, a degenerative disease. PDA-002 is a placenta-derived ASC being developed for the treatment of Facioscapulohumeral muscular dystrophy, or FSHD. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Celularity IMPACT manufacturing process is a seamless, fully integrated process designed to optimize speed and scalability from the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific CMC, advanced cell manufacturing and cryopreservation. The result is a suite of allogeneic inventory-ready, on demand placental-derived cell therapy products. In addition, we have non-core legacy operations that are complementary to our work in placenta-derived cell therapeutics, including biobanking operations that include the collection, processing and cryogenic storage of certain birth byproducts for third-parties, and our degenerative disease business consists of the manufacture and sale of our Biovance and Interfyl products, directly and through our third-party distribution agreement. See &#8220;&#8212;<span style="font-style:italic;"> Commercial Businesses</span>&#8221; for more information regarding these operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current science is the product of the cumulative background and effort over two decades of our seasoned and experienced management team. We have our roots in Anthrogenesis, a company founded under the name Lifebank in 1998 by Robert J. Hariri, M.D., Ph.D., our founder and Chief Executive Officer, and acquired in 2002 by Celgene. The team continued to hone their expertise in the field of placental-derived technology at Celgene through August 2017, when we, acquired Anthrogenesis. Celularity has a robust global intellectual property portfolio comprised of over 1,500 patents and patent applications protecting our Celularity IMPACT platform, our processes, technologies and current key cell therapy programs. We believe this know-how, expertise and intellectual property will drive the rapid development and, if approved, commercialization of these potentially lifesaving therapies for patients with unmet medical needs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have had significant operating losses. We had net loss</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and $208.2 million for the year</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ended December&#160;31, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, respectively. We had an accumulated deficit of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">663.7</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million at </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021. Our</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> primary use of cash is to fund operations, which consist primarily of research and development expenses, and to a lesser extent, selling, general and administrative expenses. Cash used to fund operating expenses is impacted by the timing of when it pays these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and expect our research and development expenses, selling, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses and losses to increase as we continue development of, and seek regulatory approvals for, our therapeutic candidates, and begin to commercialize any approved therapeutics, as well as hire additional personnel, develop commercial infrastructure for therapeutics, pay fees to outside consultants, lawyers and accountants, and incur increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs. Our net losses may fluctuate significantly depending on the timing of our clinical trials and our expenditures on other research and development activities.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon our current operating plan, we do not believe that our existing cash and cash equivalents as of December&#160;31, 2021, along with the $46.5 million received in March 2022 related to the exercise of warrants, will be sufficient to fund our operating expenses and capital expenditure requirements through the next twelve months. To date, we have not had any cellular therapeutics approved for sale and have not generated any revenues from the sale of our cellular therapeutics. We generate limited revenues from our biobanking and degenerative disease businesses. We do not expect to generate any revenues from cellular therapeutic product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our therapeutic candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our therapeutic candidates, we expect to incur significant commercialization expenses related to therapeutic sales, marketing, manufacturing and distribution as our current commercialization efforts are limited to our biobanking and degenerative disease businesses. As a result, until such time, if ever, as we can generate substantial revenue from therapeutics, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19 Pandemic</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic resulted in increased unemployment, commodity and stock market volatility during the acute phase of the epidemic. Increases in vaccination rates and lower levels of reported cases suggest that the worst part of the pandemic may have passed. Should a new or mutated variant arise that results in further measures to combat its spread, there could be an adverse material impact to our financial condition, operating results, and timing and amounts of cash flows.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we were able to operate continuously throughout 2020 and 2021, we implemented &#8220;work from home&#8221; policies as needed following local health recommendations for non-essential employees and employees whose roles are able to be performed remotely. Management of remote workers can present special challenges and productivity may not be as high for remote workers. Because certain elements of our operations (such as processing placental tissue, certain biological assays, translational research and storage of cord blood) cannot be performed remotely, we instituted controls and protocols including mandatory temperature checking, symptom assessment forms, incremental cleaning and sanitization of common surfaces to mitigate risks to employees. Although we have not experienced any material disruption to date, there can be no assurance that our mitigation measures will continue to be effective and that there will not be a disruption to an important element of our business in the future.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to a broad decline in economic activity and restrictions on physical access to certain medical facilities, we did experience a decrease in the net revenues of our degenerative disease business due to the pandemic. As for clinical trials, we did not cancel or postpone enrollment solely due to the risks of COVID-19. However, enrollment in the clinical trial evaluating CYNK-001 for AML experienced some delays in the first half of 2020 and in mid 2021 as sites assessed their safety protocols and experienced high volumes of COVID-19 patients. We had a year-over-year increase in research and development expenses in 2021 notwithstanding the enrollment delays. </p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The extent to which COVID-19 or any other health epidemic may impact our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on our business, results of operations, financial condition, and prospects.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Segments</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the third quarter of 2020, we managed our operations as one segment. In the third quarter of 2020, we began to manage our operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to cellular therapies we are researching and developing, which are unproven and in various phases of development. All of the cell </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapy programs fall into the Cell Therapy segment. We have no approved cell therapy product and have not generated revenue from the sale of cellular therapies to date. Degenerative Disease produces, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sells</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and licenses products used in surgical and wound care markets, such as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biovance</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interfyl</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We sell products in this segment both using our own sales force as well as independent distributors. We are developing additional tissue-based products for the Degenerative Disease segment. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. We operate in the biobanking business primarily under the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LifebankUSA</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> brand. For more information about our reportable business segments refer to </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, &#8220;Segment Reporting&#8221; of our consolidated financial statements included </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elsewhere </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in this </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annual report</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisitions and Divestitures</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current operations reflect strategic acquisitions and divestures that we have made since formation. Additional details regarding the following acquisitions can be found in Note 1, &#8220;Nature of Business and Basis of Presentation&#8221; to our consolidated financial statements for the year ended December 31, 2021 included elsewhere in this annual report.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Human Longevity</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May&#160;2017, we acquired HLI CT from HLI. HLI CT operated LifebankUSA, a private umbilical cord blood stem cell and cord tissue bank that offers parents the option to collect, process and cryogenically preserve newborn umbilical cord blood stem cells and cord tissue units. The HLI CT acquisition also provided us with rights to a portfolio of biomaterial assets, including Biovance and Interfyl, as well other assets that we are no longer pursuing. In aggregate, the fair value of the consideration to acquire HLI CT was $28.9 million. The acquisition led to goodwill and intangible assets including in-process research and development, or IPR&#38;D, and a licensing agreement.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the time of the HLI CT acquisition, Biovance and Interfyl were subject to an exclusive distribution arrangement with Alliqua Biomedical, Inc., or Alliqua. In May&#160;2018, we acquired certain assets from Alliqua, including Alliqua&#8217;s biologic wound care business, which included the marketing and distribution rights to Biovance and Interfyl<span style="font-size:5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup></span>as well as a Class II medical device, the MIST and UltraMIST Therapy Systems. In connection with the Alliqua asset purchase agreement, we paid cash consideration of $29.0 million. The Alliqua acquisition led to goodwill and intangible assets.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2020, we (i) sold the assets comprising our MIST/UltraMIST business to Sanuwave Health, Inc., or Sanuwave, and (ii) entered into a five-year licensing agreement with Sanuwave for total consideration of $24.5 million, of which $20.0 million was paid at or prior to closing. The remaining $4.5 million of the purchase price was financed through a convertible promissory note due on or before August 6, 2021. The convertible promissory note can be converted into common shares of Sanuwave stock at our election any time on or after January 1, 2021 which we have not elected to do as of the date of this filing.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The five-year licensing arrangement with Sanuwave includes: (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market and (ii)&#160;a non-exclusive license for the distribution and commercialization of Interfyl in the wound care market. Under the licensing agreement, we were to receive a quarterly license fee and a defined royalty on each product sale. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. We terminated the license in the third quarter of 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anthrogenesis</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2017, we acquired Anthrogenesis, a wholly-owned subsidiary of Celgene. The Anthrogenesis acquisition included a portfolio of pre-clinical and clinical stage assets, including key cellular therapeutic assets in that we continue to develop. The Anthrogenesis acquisition gives us access to Anthrogenesis&#8217; proprietary technologies and processes for the recovery of large quantities of high-potential stem cells and cellular therapeutic products derived from postpartum human placentas, each an &#8220;Anthrogenesis Product&#8221;. As part of the&#160;Anthrogenesis&#160;acquisition, some of the inventors of the&#160;Anthrogenesis&#160;Products and other key members of the&#160;Anthrogenesis&#160;Product development team joined&#160;us. In aggregate, the fair value of the consideration to acquire&#160;Anthrogenesis&#160;was $346.4 million. The acquisition led to goodwill and intangible assets including IPR&#38;D and a licensing agreement and contingent value rights agreement. See &#8220;&#8212; Licensing Agreements&#8221; below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CariCord</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October&#160;2018, we acquired CariCord, a family cord blood bank established by ClinImmune Labs University of Colorado Cord Blood Bank and the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado School of Medicine. In the aggregate, the fair value of the consideration to acquire CariCord was $9.3 million. The acquisition led to goodwill and intangible assets.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Licensing Agreements</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, we license in intellectual property and other rights from third parties and have also outlicensed our intellectual property and other rights, including in connection with our acquisitions and divestitures, described above. Additional details regarding our licensing agreements can be found in Note 15, &#8220;License and Distribution Agreements&#8221; to our audited consolidated financial statements for the year ended December 31, 2021 included elsewhere in this annual report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sorrento</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2020, we entered into a license and transfer agreement, with Sorrento Henry Ji, Ph.D., a former member of Legacy Celularity&#8217;s board of directors, currently serves as President and Chief Executive Officer of Sorrento. Sorrento is also a significant stockholder of ours and invested in the PIPE. Pursuant to the Sorrento Agreement, we obtained a worldwide license, with the right to grant sublicenses with Sorrento&#8217;s consent, under certain of Sorrento&#8217;s intellectual property rights, including patent rights that would be infringed by the use of certain CD19 CAR constructs, to research, develop, use, reproduce, modify, and create derivative works in the field of placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder, and to make, have made, use, sell, offer for sale, import, export, and distribute products that consist of a combination of certain specified CAR constructs and placenta-derived cells and/or cord blood-derived cells in the field of placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder. The foregoing license is exclusive with respect to certain specified patent rights and non-exclusive with respect to all other intellectual property rights of Sorrento. The CD19 CAR construct licensed from Sorrento forms the basis of the genetic modification for CYCART-19.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sorrento Agreement, we have sole responsibility for the development and commercialization of licensed products, subject to certain reserved rights of Sorrento with respect to CD19 CAR-T therapeutics. Additionally, we are obligated to use commercially reasonable efforts to develop and commercialize licensed products.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sorrento Agreement, we are obligated to pay Sorrento a low double-digit percentage of non-royalty sublicensing income payments received by it in connection with a grant of any sublicense for CD19 CAR-T licensed products. Additionally, we are obligated to pay Sorrento a low single-digit royalty on net sales of CD19 CAR-T licensed products in perpetuity. <span style="color:#000000;">See Item 1 &#8220;</span><span style="font-style:italic;color:#000000;">Business &#8212; Licensing Agreements &#8212; Sorrento Therapeutics, Inc.</span><span style="color:#000000;">&#8221; for more information regarding the Sorrento Agreement and the proposed supply agreement.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Celgene (now part of Bristol Myers Squibb)</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2017, in connection with the Anthrogenesis acquisition, we entered into a license agreement, with Celgene, which has since been acquired by Bristol Meyers Squibb. Pursuant to the license, we granted Celgene a worldwide, royalty-free, fully-paid up, non-exclusive license, without the right to grant sublicenses (other than to its affiliates), under Anthrogenesis&#8217; intellectual property in existence as of the date of the license or as developed by Celgene in connection with any transition services activities related to the merger for non-commercial pre-clinical research purposes, as well as to develop, manufacture, commercialize and fully exploit products and services that relate to the construction of any CAR, the modification of any T-cell or NK cell to express such a CAR, and/or the use of such CARs or T-cells or NK cells for any purpose, which commercial license is sublicensable. Either party may terminate the license upon an uncured material breach of the agreement by the other party or insolvency of the other party.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2017, Legacy Celularity also issued shares of its Series X Preferred Stock to Celgene as merger consideration and entered into the CVR Agreement with Celgene pursuant to which we issued one CVR in respect of each share of Series X Preferred Stock issued to Celgene in connection with the Anthrogenesis acquisition. The CVR Agreement entitles the holders of the CVRs to an aggregate amount, on a per program basis, of $50 million in regulatory milestones and an aggregate $125 million in commercial milestone payments with respect to certain of our investigational therapeutic programs, which would include the current CYNK-001 CYNK-101 and PDA-002 pipeline candidates and the legacy PDA-001 program (certain placenta-derived adherent cells, proprietary to Anthrogenesis, that are formulated for intravenous delivery, that is no longer in development. Such payments under the CVR Agreement also expressly cover PNK-007 (which includes certain NK cells proprietary to&#160;Anthrogenesis, produced by a process proprietary to&#160;Anthrogenesis&#160;as of the closing of the&#160;Anthrogenesis&#160;transaction) and certain PNK-007 cells with a genetic modification (but not including NK cells with a chimeric receptor, including a CAR), along with any derivatives, parts, subparts, or progeny of any of the foregoing, or any therapeutic based or derived (in whole or in part) on certain related development programs as they existed as of the closing of the&#160;Anthrogenesis&#160;transaction. Accordingly, as&#160;we&#160;expand&#160;our&#160;NK cell type franchise into new indications and, as a general matter, because these payments are not payable until a later stage of development,&#160;we&#160;expect to continue to evaluate&#160;our&#160;present and future therapeutic candidates as they develop and evolve&#160;in light of&#160;the specific terms in the CVR Agreement to determine the specific therapeutics on which such amounts will be payable. In addition, with respect to each such program and calendar year, the CVR holders will be entitled to receive a royalty equal to a mid-teen percentage of the annual net sales for such program&#8217;s therapeutics from the date of the first commercial sale of such program&#8217;s therapeutic in a particular country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program therapeutic in such country, the expiration of marketing exclusivity with respect to such therapeutic in such country, and August 2027 (i.e., the tenth anniversary of the closing of the acquisition of&#160;Anthrogenesis). No </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments under the CVR Agreement have been made to date.&#160;We&#160;estimate the liability associated with the CVR quarterly. Changes to that liability include but are not limited to changes in&#160;our&#160;clinical programs, assumptions about the commercial value of those programs and the time value of money.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Item 1 &#8220;<span style="font-style:italic;">Business &#8212; Our Team and Corporate History &#8212; Celgene Corporation</span>&#8221; for more information regarding the Celgene license and the CVR Agreement.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Operating Results</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net revenues</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues include: (i) sales of HCT/P&#8217;s, including Biovance, Biovance 3L, Interfyl&#160;and MIST/UltraMIST&#160;Therapy System equipment and single-use applicators, collectively, Product Sales and Rentals&#59; (ii) the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services&#59; and, (iii) license fees and royalties received under our various license and distribution agreements, collectively, License, Royalty and Other. MIST/UltraMIST&#160;revenues are only included within 2020 as the business was divested in August 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of goods sold</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold consists of labor, material and overhead costs associated with our two existing commercial business segments, biobanking and degenerative disease. Biobanking costs include the cost of storage and transportation kits for newly banked materials as well as tank and facility overhead costs for cord blood and other units in storage. Degenerative disease costs include costs associated with procuring placentas, qualifying the placental material and processing the placental tissue into a marketable product. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance, Biovance 3L and Interfyl product lines. License, royalty and other costs reflect expenses incurred related to our distribution agreements.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and development expense</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses primarily relate to basic scientific research into placentally derived allogeneic cells, pre-clinical studies to support our current and future clinical programs in cellular medicine, clinical development of our NK cell programs and facilities, depreciation and other direct and allocated expenses incurred as a result of research and development activities. We incur expenses for third party CROs, that assist in running clinical trials, personnel expenses for research scientists, specialized chemicals and reagents used to conduct biologic research, expense for third party testing and validation and various overhead expenses including rent and facility maintenance expense. Basic research, research collaborations involving partners and research designed to enable successful regulatory submissions is critical to our current and future success in cell therapy. We anticipate that our research and development expenditures will increase as we engage in further clinical trials, investigate incremental CAR constructs for our allogeneic T-cell and NK cell platforms and conduct further pre-clinical studies on CYNK-101 in conjunction with various antibody candidates. The amount of increase will depend on numerous factors, including the timing of clinical trials, preliminary evidence of efficacy in clinical trials and the number of indications that we choose to pursue.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and administrative expense</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expense consists primarily of personnel costs including salaries, bonuses, stock compensation and benefits for specialized staff that support our core business operations. Executive management, finance, legal, human resources and information technology are key components of general and administrative expense and those expenses are recognized when incurred. We expect that as we engage in more clinical trials and potentially prepares for commercialization of any approved therapies that our general and administrative costs will increase over time. The magnitude and timing of any increase in general and administrative expense will depend on the progress of clinical trials, the release of new products within the degenerative disease portfolio, changes in the regulatory environment or incremental staffing needs to support the growth of the business as well as any incremental expenses associated with being a public company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration liability</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the acquisitions of Anthrogenesis from Celgene and HLI CT from HLI were accounted for as business combinations, we recognized acquisition-related contingent consideration on the balance sheet in accordance with the acquisition method of accounting. See &#8220;&#8212; Acquisitions and Divestitures&#8221; for more information. The fair value of contingent consideration liability is determined based on a probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of achieving regulatory and commercial milestone obligations and royalty obligations. The fair value of acquisition related contingent consideration is remeasured each reporting period with changes in fair value recorded in the consolidated statement of operations. Changes in contingent consideration fair value estimates result in an increase or decrease in our contingent consideration obligation and a corresponding charge or reduction to operating results. Key elements of the contingent consideration are regulatory milestone </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payments, sales milestone payments and royalty payments. Regulatory payments are due on regulatory approval of certain cell types in the United States and the European Union. Regulatory milestone payments are one time but are due prior to any potential commercial success of a cell type in a specific indication. Royalty payments are a percentage of net sales. Sales milestone payments are due when certain aggregate sales thresholds have been met. Management must use substantial judgement in evaluating the value of the contingent consideration. Estimates used by management include but are not limited to: (</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) the number and type of clinical programs that we are likely to pursue based on the quality of our preclinical data, (ii) the time required to conduct clinical trials, (iii) the odds of regulatory success in those trials, (iv) the potential number of patients treatable for the indications in which we are successful and (v) the pricing of treatments that achieve commercial status. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> these areas involve substantial judgement on the part of management and are inherently uncertain.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of&#160;Year Ended&#160;December&#160;31, 2021&#160;to&#160;December 31, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,854</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,053</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,522</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,012</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,868</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,144</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">543.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,335</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,278</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,057</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold (excluding amortization of acquired</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; intangible assets)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,528</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,247</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,281</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,649</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,294</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,355</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,476</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,085</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">533.2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,353</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,707</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,646</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,341</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,336</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,005</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127.7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,145</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,566</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,421</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,192</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,394</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,202</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,400</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(129,400</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130,394</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,203</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,059</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,925</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Net Revenue and Cost of Goods Sold</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenue for the year ended December 31, 2021 was $21.3 million, an increase of $7.1 million, or 49.4%, compared to the prior year period. The increase was due to an increase of $10.1 million in license, royalty and other revenues primarily driven by (i) recognition of previously deferred revenue as a result of the termination of the Sanuwave license agreement of $6.8 million and (ii) an increase in revenues from supply and distribution agreements recognized during 2021 of $1.4 million, partially offset by a decrease in product sales and rentals revenues of $3.1 million resulting from the sale of the MIST/UltraMIST assets in August 2020. Services revenues were flat compared to the prior period.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold for the year ended December 31, 2021 increased by $4.7 million, or 95.7%, compared to the prior year period. The increase was due to (i) higher license, royalty and other costs of $2.0 million driven by sales under new supply and distribution agreements including Arthrex and Evolution and (ii) higher services costs of $1.4 million resulting from increased labor and overhead costs as well as allocated expenses. Costs related to product sale and rentals increased by $1.2 million due to changes in product mix driven by the sale of the MIST/UltraMIST assets in August 2020, increased material and labor costs and higher allocated costs associated with higher Interfyl production volumes in the second half of the year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December 31, 2021 were $88.4 million, an increase of $35.6 million, or 67.6%, compared to the prior year period. The increase in research and development expenses was primarily due to higher stock-based compensation expense of $9.7 million related to awards granted to senior management (for more information about stock-based compensation refer to Note 13, &#8220;Stock-Based Compensation&#8221; of our consolidated financial statements included elsewhere in this annual report on Form 10-K), higher cell therapy process development and research expenses related to the CYCART-19 program, and higher personnel costs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative Expenses</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expenses for the year ended December 31, 2021 were $71.3 million, an increase of $40.0 million, or 127.7%, compared to the prior year period, primarily due to higher stock-based compensation expense of $25.9 million related to awards granted to our board of directors and senior management (for more information about stock-based compensation refer to Note 13, &#8220;Stock-Based Compensation&#8221; of our consolidated financial statements included elsewhere in this annual report on Form 10-K), a charge related to an estimated legal settlement with CTH Biosourcing LLC and higher personnel costs and professional fees as we began operating as a public company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Change in Fair Value of Contingent Consideration Liability</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021, and 2020 the fair value of the contingent consideration liability decreased resulting in net gains of $41.1 million and $55.6 million, respectively. The change in fair value of the contingent consideration liability for the year ended December 31, 2021 and 2020 resulted from changes in market-based assumptions and underlying projections (for more information about changes in the fair value of contingent consideration liability refer to Note&#160;4, &#8220;Fair Value of Financial Assets and Liabilities&#8221; of&#160;our&#160;consolidated&#160;financial statements included&#160;elsewhere in&#160;this annual report on Form&#160;10-K).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Amortization of Acquired Intangible Assets</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense for the year ended December 31, 2021 was $2.2 million, which decreased 35.4%, compared to the prior year period, primarily due to the sale of UltraMIST to Sanuwave in August&#160;2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Impairment of Acquired Intangible Assets</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, the development of PDA-001 was discontinued for an indefinite period of time as we opted to pursue an alternative clinical program. As a result, we fully impaired our IPR&#38;D asset for PDA-001&#160;(acquired from Celgene) totaling $129.4&#160;million during the third quarter of 2020 (see Note 8, &#8220;Goodwill and Intangible Assets, Net&#8221; in our consolidated financial statements included elsewhere in this annual report on Form 10-K).</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income (Expense)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">370</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10.3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,171</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,354</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(817</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34.7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on sale of business</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,434</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,434</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100.0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (expense) related to warrant liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,482</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,686</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,168</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123.0</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,682</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,096</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,778</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,961</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,008</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,969</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(114.7</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, other income (expense), net changed by $70.0 million compared to the prior&#160;year period. The change was primarily due to a gain recognized in 2021 related to our warrants to purchase common stock compared to a loss recognized in 2020, which resulted from changes in the fair value of the corresponding liabilities (see Note 4, &#8220;Fair Value of Financial Assets and Liabilities&#8221; of our consolidated financial statements included elsewhere in this annual report on Form 10-K). Other (expense) income, net for the year ended December 31, 2021 also included expense of $2.8 million resulting from the change in fair value of the convertible note receivable obtained in connection with the disposition of the UltraMIST business (see Note 4, &#8220;Fair Value of Financial Assets and Liabilities&#8221; of our consolidated financial statements included elsewhere in this annual report on Form 10-K), partially offset by net proceeds of $1.4 million from the sale of unused New Jersey net operating losses, or NOLs, and unused research and development, or R&#38;D, tax credits. Other income (expense), net for the year ended December 31, 2020 includes $3.8 million in net proceeds from the sale of unused New Jersey NOLs and unused R&#38;D tax credits and a $4.4 million loss on sale of business related to the sale of UltraMIST.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception through December&#160;31, 2021, we have raised aggregate net cash proceeds of $483.3&#160;million. As of December&#160;31, 2021, we had $37.0&#160;million of cash and cash equivalents and an accumulated deficit of $663.7 million. In March 2022, we received approximately $46.4 million of cash proceeds from the exercise of warrants to acquire an aggregate of 13,281,386 shares at $3.50 per share. Our primary use of our capital resources is funding our operating expenses, which consist primarily of funding the research and development of our cellular therapeutic candidates, and to a lesser extent, selling, general and administrative expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based upon </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> current operating plan, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we do </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not believe that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing cash and cash equivalents as of December&#160;31, 202</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, will be sufficient to fund </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> operating expenses and capital expenditure requirements through the next twelve months. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> seeking additional funding through public or private equity and/or debt financings. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may adversely affect the holdings or the rights of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> stockholders. Based on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> future operations, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> concluded that there is substantial doubt about </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to continue as a going concern.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur substantial expenses in the foreseeable future for the development and potential commercialization of our cellular therapeutic candidates and ongoing internal research and development programs. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, to complete our current and future preclinical studies and clinical trials, and to complete the process of obtaining regulatory approval for our therapeutic candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize its cellular therapeutic candidates, if approved, we may require substantial additional funding in the future.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods indicated:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash (used in)/provided by</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110,096</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(63,193</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,903</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,815</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,562</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,014</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,437</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,006</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We used $110.1&#160;million of net cash in operations for the year ended December&#160;31, 2021 as compared to $63.2&#160;million during the year ended December 31, 2020.  Cash used in operating activities in 2021 reflected our net loss of $100.1 million as well as noncash charges of $1.4&#160;million and a net change in our operating assets and liabilities of $11.3 million. Cash used in operating activities in 2020 reflected our net loss of $208.2 million, which was slightly offset by noncash charges of $141.4&#160;million and a net change in our operating assets and liabilities of $3.6 million. The noncash charges primarily consisted of depreciation and amortization, impairment charges, stock-based compensating expense, issuance of common stock to settle a liability, change in fair value of our warrants and contingent consideration. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We used $6.2 million and $27.8 million on capital expenditures during the years ended December 31, 2021 and 2020, respectively. In 2021, we received $0.3 million from the sale of a promissory note. In 2020, we received proceeds of $15.0 million from the August&#160;2020 sale of UltraMIST. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We generated $98.6 million of net cash from financing activities for the year ended December 31, 2021, which consisted of $108.8 million in cash proceeds from the merger with GX, the PIPE financing and Palantir investment, partially offset by payments for professional services related to the aforementioned transactions of $10.9 million.</span> We also received and paid back $5.0 million in short-term loans and received $0.6 million in proceeds from the exercise of stock options. We generated $102.0&#160;million of net cash from financing activities for the year ended December&#160;31, 2020, which consisted primarily of proceeds from the issuance of Series B redeemable convertible preferred stock and warrants in March&#160;2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our significant accounting policies are summarized in Note&#160;2, &#8220;Summary of Significant Accounting Policies,&#8221; included in our&#160;&#160;consolidated financial statements included elsewhere in this annual report on Form 10-K.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of our consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related to the accounting for business combinations, goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred stock warrants. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> based </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">estimates on historical experience, known trends and other market-specific&#160;or other relevant factors that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">believe to be reasonable under the circumstances. On an ongoing basis, management evaluates these estimates when there are changes in circumstances, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facts</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue when control of the products and services is transferred to our customers in an amount that reflects the consideration we expect to receive from our customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and to the extent that the transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which it expects to be entitled.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products within our Degenerative Disease segment generally do not contain multiple elements. We allow for a right of return for those products but to date returns have been minimal.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement with Sanuwave, we received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. We recognized the quarterly license fee over each quarterly term based on the actual sales occurring over the period (until we terminated the license in the third quarter of 2021). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting for Business Combinations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting for business combinations requires us to make significant estimates and assumptions, especially at the acquisition date with respect to tangible and intangible assets acquired and liabilities assumed and pre-acquisition&#160;contingencies. We use our best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date as well as the useful lives of those acquired intangible assets. Examples of critical estimates in valuing certain of the intangible assets and goodwill we have acquired include but are not limited to developed technologies and IPR&#38;D. Our estimates may also impact its deferred income tax assets and liabilities. Unanticipated events and circumstances may occur that may affect the accuracy or validity of such assumptions, estimates or actual results.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Valuation of Goodwill and Intangible Assets</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have acquired and may continue to acquire significant intangible assets in connection with business combinations, which we record at fair value. The determination of fair value requires the use of forecasts, estimates and assumptions, which requires significant judgment by management. Each of these factors are subject to uncertainty and can significantly affect the value of the intangible asset.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and indefinite-lived&#160;intangible assets are reviewed for impairment annually or when an event occurs that could result in an impairment. The impairment analysis requires the exercise of significant judgment by management and can involve both the assessment of qualitative factors (which are subject to uncertainty and can change significantly from period to period), as well as a quantitative. For our quantitative impairment tests, we use an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth rates, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions used are subject to uncertainty. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of the assets and could potentially impact our results of operations. Actual results may differ from our estimates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have acquisition-related&#160;contingent consideration, which consists of potential milestone and royalty obligations, which was recorded in the consolidated balance sheets at our acquisition-date&#160;estimated fair value. We remeasure the fair value each reporting period, with changes recorded in the consolidated statements of operations. The determination of fair value requires the exercise of significant judgment and estimates by management. These include estimates and assumptions regarding the achievement and timing of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">milestones, forecasted revenues and assumptions utilized in calculating a discount rate. If management&#8217;s assumptions prove to be inaccurate, it could result in changes to the contingent consideration liability and have a material effect on </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> results of operations.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrant Liability</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounting for liability classified warrants requires management to exercise judgment and make estimates and assumptions regarding their fair value (for more information about the material inputs and assumptions used to value the liability classified warrants refer to Note 4, &#8220;Fair Value of Financial Assets and Liabilities&#8221; of our consolidated financial statements included elsewhere in this annual report on Form 10-K). The warrant liability was initially recorded at fair value upon the date of issuance and is subsequently remeasured to fair value at each reporting date, with changes recognized in the consolidated statement of operations. Changes in the fair value of the liability classified warrants will continue to be recognized until the warrants are exercised, expire or qualify for equity classification.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Convertible Note Receivable</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a convertible note receivable from the August&#160;2020 disposition of the UltraMIST business. We use a bond valuation that employs a credit default model, which requires the use of estimates and judgement by management regarding: (i)&#160;the fair value and volatility of the issuer&#8217;s common stock, (ii)&#160;probability and timing of converting the note, and (iii)&#160;risk-free&#160;interest rate. If our assumptions and estimates prove to be inaccurate, it could result in changes to the convertible note receivable and have a material effect on our results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize compensation expense related to stock options granted to employees and nonemployees based on the estimated grant date fair value and recognizes forfeitures as they occur. We estimate the grant date fair value, and the resulting stock-based&#160;compensation expense, using the Black-Scholes&#160;option-pricing&#160;model for service-based and performance based awards. For awards with market conditions, we utilize a Monte-Carlo model to estimate the fair value of those awards. The grant date fair value of the stock-based&#160;awards is recognized on a straight-line&#160;basis over the requisite service period, which is typically the vesting period of the respective awards. The Black-Scholes&#160;option-pricing&#160;model and Monte-Carlo model requires the use of highly subjective assumptions to determine the fair value of stock-based&#160;awards. See Note 12 to our audited consolidated financial statements included elsewhere in this annual report for information concerning certain of the specific assumptions used in applying the Black-Scholes&#160;option-pricing&#160;model to determine the estimated fair value of stock options granted during the years ended December&#160;31, 2021 and 2020. Such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based&#160;compensation could be materially different.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 2 to our consolidated financial statements included elsewhere in this annual report on Form 10-K for information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent it has made one, of their potential impact on our financial condition of results of operations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JOBS Act Accounting Election</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to remain an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to use this extended transition period to enable it to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (i)&#160;is no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of business. These risks primarily include interest rate sensitivities.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest Rate Risk</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had cash and cash equivalents of $37.0 million as of&#160;December 31, 2021, which consists principally of cash held in commercial bank accounts and money market funds having an original maturity of less than three months. At December&#160;31, 2021, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We had no debt outstanding as of December 31, 2021.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Effects of Inflation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Item 8. Financial Statements and Supplementary Data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:93.33%;"></td>
<td style="width:6.67%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Page</span></p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID No. <ix:nonNumeric id="F_000036" name="dei:AuditorFirmId" contextRef="C_0001752828_20210101_20211231">34</ix:nonNumeric>)</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:underline;">Consolidated Statements of Operations</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><span style="text-decoration:underline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flow</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr style="height:1pt;">
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the stockholders and the Audit Committee of Celularity Inc.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets&#160;of Celularity Inc. (the "Company") as of December 31, 2021 and 2020, the related consolidated statements of operations, convertible preferred stock and stockholders' deficit, and cash flows, for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards&#160;of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Emphasis of Matter Regarding Going Concern</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations since inception, has an expectation of continuing operating losses for the foreseeable future, and needs to raise additional capital to finance its future operations, that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <ix:nonNumeric id="F_000037" name="dei:AuditorName" contextRef="C_0001752828_20210101_20211231">Deloitte &#38; Touche LLP</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000038" name="dei:AuditorLocation" contextRef="C_0001752828_20210101_20211231">Parsippany, New Jersey</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CELULARITY INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,240</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,311</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable, net of allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="C_0001752828_20211231" decimals="-3" scale="3">283</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">272</ix:nonFraction> as of December 31, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and December 31, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="celu:PromissoryNotesReceivable" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="celu:PromissoryNotesReceivable" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:InventoryNet" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,549</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:InventoryNet" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001752828_20211231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AssetsCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AssetsCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:Goodwill" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Goodwill" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:InventoryNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,721</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:InventoryNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" scale="3">355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:Assets" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">414,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:Assets" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">431,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of financing obligation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="celu:FinancingObligationsCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="celu:FinancingObligationsCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,677</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,621</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition-related contingent consideration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">232,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">273,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="celu:FinancingObligationsNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,085</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="celu:FinancingObligationsNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="celu:WarrantLiability" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="celu:WarrantLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_0001752828_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_0001752828_20201231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" scale="3">335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:Liabilities" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">314,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:Liabilities" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">412,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 11)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000091">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000092">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000111" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000112" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000113" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000115" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000117" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2021&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000114" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000116" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000118" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">29,484,740</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000119" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000120" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000121" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000123" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2021&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000122" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">75,088,327</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="U_xbrlishares" id="F_000124" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000126" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">41,205,482</ix:nonFraction></ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">290,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series X preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000127" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000128" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000129" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000131" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000133" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2021&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000130" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000132" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">11,953,274</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000143" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001752828_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000144" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001752828_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="U_xbrlishares" id="F_000147" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000149" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2021&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001752828_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000148" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001752828_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001752828_20201231" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction> authorized, issued and outstanding as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000096">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000097">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000135" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000136" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000137" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal">730,000,000</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="U_xbrlishares" id="F_000139" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal">124,307,884</ix:nonFraction></ix:nonFraction> issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding as of December 31, 2021&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001752828_20201231" decimals="INF" format="ixt:numdotdecimal">155,640,290</ix:nonFraction> shares authorized, <ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001752828_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001752828_20201231" decimals="INF" format="ixt:numdotdecimal">18,529,453</ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares issued and outstanding as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000098" name="us-gaap:CommonStockValue" contextRef="C_0001752828_20211231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:CommonStockValue" contextRef="C_0001752828_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treasury stock, at cost, <ix:nonFraction unitRef="U_xbrlishares" id="F_000151" name="us-gaap:TreasuryStockShares" contextRef="C_0001752828_20211231" decimals="INF">0</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000152" name="us-gaap:TreasuryStockShares" contextRef="C_0001752828_20201231" decimals="INF" format="ixt:numdotdecimal">90,834</ix:nonFraction> shares as of December 31, 2021 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:TreasuryStockValue" contextRef="C_0001752828_20201231" decimals="-3" scale="3">256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">763,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001752828_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">663,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001752828_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">563,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001752828_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">531,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">414,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">431,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CELULARITY INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold (excluding amortization of acquired intangible assets)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:CostOfRevenue" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:CostOfRevenue" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:CostOfRevenue" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:CostOfRevenue" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:CostOfRevenue" contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:CostOfRevenue" contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231" decimals="-3" scale="3">391</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">71,341</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="celu:ChangeInFairValueOfContingentConsiderationLiability" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">41,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="celu:ChangeInFairValueOfContingentConsiderationLiability" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,192</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="celu:OperatingIncomeCostsAndExpenses" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">130,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="celu:OperatingIncomeCostsAndExpenses" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">166,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">109,059</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">151,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:OtherNonoperatingIncome" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">370</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:OtherNonoperatingExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:OtherNonoperatingExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,354</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on the sale of business</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:GainLossOnSaleOfBusiness" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income (expense) related to warrant liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="celu:IncomeExpenseRelatedToWarrantLiabilities" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="celu:IncomeExpenseRelatedToWarrantLiabilities" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="celu:OtherNonoperatingIncomeExpenses" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,682</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="celu:OtherNonoperatingIncomeExpenses" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">61,008</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">100,098</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">212,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense (benefit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:NetIncomeLoss" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">100,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:NetIncomeLoss" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">208,233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per share information:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share &#8211; basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000197" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001752828_20210101_20211231" decimals="2" sign="-">1.49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000198" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001752828_20200101_20201231" decimals="2" sign="-">11.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding &#8211; basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000199" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001752828_20210101_20211231" decimals="0" format="ixt:numdotdecimal">67,057,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000200" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001752828_20200101_20201231" decimals="0" format="ixt:numdotdecimal">18,417,910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CELULARITY INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series A Redeemable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B Redeemable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series X Redeemable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Treasury Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity (Deficit)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000201" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">29,484,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000203" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">27,552,236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">206,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000205" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">11,953,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="us-gaap:SharesOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">18,421,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000209" name="us-gaap:SharesOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20191231" decimals="INF" sign="-" format="ixt:numdotdecimal">13,975</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;&#160;&#160;&#160;&#160;&#160; &#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$(<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">355,330</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$(<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">327,420</ix:nonFraction>)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000213" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">108,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">138</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000216" name="us-gaap:TreasuryStockSharesAcquired" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">76,859</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20200101_20201231" decimals="-3" scale="3">256</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">256</ix:nonFraction>)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,371</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="celu:TemporaryEquityShareIssuanceCosts" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" sign="-" scale="3">15</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000222" name="celu:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">13,620,063</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,596</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred stock in connection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with CariCord acquisition</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000224" name="celu:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCariCordIncorporatedMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">33,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCariCordIncorporatedMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="-3" scale="3">250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:ProfitLoss" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">208,233</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:ProfitLoss" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">208,233</ix:nonFraction>)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000228" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">29,484,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">184,247</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000230" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">41,205,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">290,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000232" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">11,953,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000234" name="us-gaap:SharesOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">18,529,453</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000236" name="us-gaap:SharesOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20201231" decimals="INF" sign="-" format="ixt:numdotdecimal">90,834</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$(<ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20201231" decimals="-3" sign="-" scale="3">256</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,418</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$(<ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">563,563</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$(<ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">531,400</ix:nonFraction>)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000241" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">572,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">197</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,010</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000246" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">29,484,740</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">184,247</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000248" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">41,205,482</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">290,866</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000250" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">11,953,274</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">75,000</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000252" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">94,122,408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000254" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">90,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20210101_20211231" decimals="-3" scale="3">256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">485,332</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">485,598</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to PIPE investors</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000258" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">8,340,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,400</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of liability classified legacy warrants to equity</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,398</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to Palantir</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000264" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to settle liability with CTH</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000267" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">743,771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,333</ix:nonFraction></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:ProfitLoss" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">100,118</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:ProfitLoss" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">100,118</ix:nonFraction>)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000272" name="us-gaap:SharesOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">124,307,884</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$&#160;&#160;&#160;&#160;&#160;&#160; &#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">763,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">663,681</ix:nonFraction>)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:StockholdersEquity" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">99,418</ix:nonFraction></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CELULARITY INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flow from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:NetIncomeLoss" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">100,118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:NetIncomeLoss" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">208,233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operations:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment charges</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:AssetImpairmentCharges" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for doubtful accounts</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of warrant liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of inventory step-up</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="celu:AmortizationOfInventoryStepUp" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to settle liability with CTH</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on sale of business</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:GainLossOnSaleOfBusiness" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">41,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,909</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:IncreaseDecreaseInInventories" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">643</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sale of net operating losses and research and development tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="celu:SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="celu:SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">314</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">8,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,093</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">110,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">63,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flow from investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital expenditures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the sale of business</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,019</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from promissory note</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="celu:ProceedsFromPromissoryNote" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">12,815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flow from financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="celu:ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from short term borrowings - related party</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of short term borrowings - related party</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash received from GX Acquisition Corp. on recapitalization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="celu:CashReceivedOnRecapitalization" contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from Palantir investment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="celu:ProceedsFromInvestment" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from PIPE financing</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">83,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">638</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of PIPE/SPAC related costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">98,562</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">102,014</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">26,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001752828_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">43,507</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash at end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:InterestPaidNet" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment included in accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">806</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recapitalization from GX Acquisition Corp. merger</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="celu:RecapitalizationFromMerger" contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">550,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancellation of treasury stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="celu:CancellationOfTreasuryStock" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash assets acquired from merger with GX Acquisition Corp.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="celu:NonCashAssetsAcquiredFromMerger" contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231" decimals="-3" scale="3">163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed from the merger with GX Acquisition Corp.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="celu:WarrantLiabilityAssumedFromMerger" contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock as payment for PIPE/merger related costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="celu:IssuanceOfCommonStockAsPaymentForRelatedCosts" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrant liabilities to equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="celu:ReclassificationOfWarrantLiabilitiesToEquity" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">96,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclass of offering costs paid in prior year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="celu:ReclassOfOfferingCostsPaidInPriorYear" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">153</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in PIPE/SPAC related costs in accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="celu:ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of asset and financing obligation related to facility build out</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="celu:RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" scale="3">216</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receipt of convertible note in connection with the Sanuwave Transaction</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UltraMIST systems reclass from inventory to fixed assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="celu:UltraMISTSystemsReclassFromInventoryToFixedAsset" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of warrants issued in connection with Series B preferred stock sale</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="celu:FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrants at estimated fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="celu:IssuanceOfWarrantsAtEstimatedFairValue" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of Series B convertible preferred stock in connection with CariCord acquisition</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="celu:IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CELULARITY INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">NOTES TO&#160;CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p><ix:nonNumeric id="F_000357" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000357_dcnt_b2024658-ba43-493c-b307-03f2a6e456cf">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Business and Basis of Presentation</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Celularity Inc., (&#8220;Celularity&#8221; or the &#8220;Company&#8221;), formerly known as GX Acquisition Corp. (&#8220;GX&#8221;), was a blank check company incorporated in Delaware on&#160;<ix:nonNumeric id="F_000436" name="dei:EntityIncorporationDateOfIncorporation" contextRef="C_0001752828_20210101_20211231" format="ixt:datemonthdayyearen">August 24, 2018</ix:nonNumeric>. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses</span>.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On July 16, 2021 (the &#8220;Closing Date&#8221;), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated January 8, 2021 (the &#8220;Merger Agreement&#8221;), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of GX (&#8220;First Merger Sub&#8221;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (&#8220;Second Merger Sub&#8221;), and the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (&#8220;Legacy Celularity&#8221;). Upon completion of the merger transaction, GX changed its name to Celularity Inc.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The business combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States (see Note 3). Reported shares and earnings per share available to holders of the Company&#8217;s common stock, prior to the business combination, have been retroactively restated as shares reflecting the exchange ratio established in the business combination (<ix:nonNumeric id="F_000437" name="celu:BusinessCombinationSharesExchangeRatioDescription" contextRef="C_0001752828_20210716_20210716"><ix:nonFraction unitRef="U_xbrlipure" id="F_000439" name="celu:BusinessCombinationSharesExchangeRatio" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210716_20210716" decimals="INF">1.00</ix:nonFraction>&#160;share of Legacy Celularity for approximately&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000438" name="celu:BusinessCombinationSharesExchangeRatio" contextRef="C_0001752828_20210716_20210716" decimals="INF">0.7686</ix:nonFraction>&#160;shares of Celularity</ix:nonNumeric>)</span>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Description of Business</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Celularity is a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic T cells engineered with chimeric antigen receptor (&#8220;CAR&#8221;) T cells, natural killer (&#8220;NK&#8221;) cells and mesenchymal-like adherent stromal cells (&#8220;ASCs&#8221;), targeting indications across cancer, infectious and degenerative diseases. Celularity is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (&#8220;Anthrogenesis&#8221;) in August&#160;2017 from Celgene Corporation (&#8220;Celgene&#8221;), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously, Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene&#8217;s cell therapy division. Celularity currently has&#160;<ix:nonFraction unitRef="U_celuClinicalTrial" id="F_000440" name="celu:NumberOfClinicalTrials" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;">&#160;active clinical trials and plans to submit two additional investigational new drug (&#8220;IND&#8221;) applications in 2022. The Celularity IMPACT platform capitalizes on the benefits of placenta-derived cells to target multiple diseases, and provides seamless integration, from bio sourcing through manufacturing cryopreserved and packaged allogeneic cells at its purpose-built U.S.-based&#160;<ix:nonFraction unitRef="U_utrsqft" id="F_000441" name="celu:AreaOfBuilding" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction>&#160;square foot facility. Celularity&#8217;s placental-derived cells are allogeneic, meaning they are intended for use in any patient, as compared to autologous cells, which are derived from an individual patient for that patient&#8217;s use. From a single source material, the postpartum human placenta, Celularity derives four allogeneic cell types: T cells, unmodified NK cells, genetically-modified NK cells and ASCs, which have resulted in five key cell therapeutic programs: CYCART-19, CYNK-001, CYNK-101, APPL-001 and PDA-002, focused on six initial indications. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is a placental-derived unmodified NK cell in development for the treatment of acute myeloid leukemia (&#8220;AML&#8221;), a blood cancer, and for glioblastoma multiforme (&#8220;GBM&#8221;), a solid tumor cancer. CYNK-101 is a placental-derived genetically modified NK cell in development, to be evaluated in combination with a monoclonal antibody to target HER2+ cancers, such as gastric cancer. APPL-001 is a placenta-derived ASC being developed for the treatment of Crohn&#8217;s disease</span>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage&#160;companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting&#160;capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Acquisitions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shortly after Legacy Celularity&#8217;s incorporation in 2016, it completed four business combinations. Legacy Celularity did not have any significant activities prior to its acquisitions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;31, 2017, Legacy Celularity acquired HLI Cellular Therapeutics, LLC (&#8220;HLI CT&#8221;) from Human Longevity Inc. (&#8220;Human Longevity&#8221;). HLI CT operated LifebankUSA, a private umbilical cord blood stem cell and cord tissue bank that offers parents the option to collect, process and cryogenically preserve newborn umbilical cord blood stem cells and cord tissue units. The HLI CT acquisition also provided Legacy Celularity with rights to a portfolio of biomaterial assets, including Biovance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Interfyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;as well as PSC-100, a development-stage&#160;placental stem cell program. Prior to the acquisition, Human Longevity entered into to a Supply Agreement and a License, Marketing and Development Agreement (collectively, &#8220;the HLI Agreements&#8221;) with Alliqua Biomedical Inc. (&#8220;Alliqua&#8221;). The HLI Agreements gave Alliqua exclusive rights to market and distribute Biovance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Interfyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. Rights, title and interest into the HLI Agreements transferred to the Company as a result of the HLI CT acquisition. In aggregate, the fair value of the consideration to acquire HLI CT was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuHLICellularTherapeuticsLLCMember_20170531_20170531" decimals="-3" format="ixt:numdotdecimal" scale="3">28,876</ix:nonFraction>. The acquisition led to goodwill and intangible assets including in-process&#160;research and development (&#8220;IPR&#38;D&#8221;) and a licensing agreement.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000357_dcnt_b2024658-ba43-493c-b307-03f2a6e456cf" continuedAt="F_000357_dcnt_c5b33794-5d54-44af-80a6-94fea23d5bbf">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;15, 2017, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">executed a Merger Agreement with Celgene whereupon it acquired </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wholly-owned</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;subsidiary of Celgene (the &#8220;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Merger Agreement&#8221;). The </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisition included a portfolio of pre-clinical&#160;and clinical stage assets, including key cellular therapeutic assets in immuno-oncology, inflammatory and age-related&#160;diseases, that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continues to develop. The </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisition gives </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access to </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; proprietary technologies and processes for the recovery of large quantities of high-potential&#160;stem cells and cellular therapeutic products derived from postpartum human placentas (each an &#8220;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Product&#8221;). As part of the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisition, some of the inventors of the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Products and other key members of the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Product development team joined </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In aggregate, the fair value of the consideration to acquire </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170815_20170815" decimals="-3" format="ixt:numdotdecimal" scale="3">346,430</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The acquisition led to goodwill and intangible assets including IPR&#38;D and a licensing agreement and contingent value rights (&#8220;CVR&#8221;) agreement</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, Legacy Celularity issued shares of its Series X Preferred Stock to Celgene as merger consideration and entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;) with Celgene pursuant to which it issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000444" name="celu:ContingentValueRightIssuedForEachShare" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> CVR in respect of each share of Series X Preferred Stock issued to Celgene in connection with the Anthrogenesis acquisition. The CVR Agreement entitles the holders of the CVRs to an aggregate amount, on a per program basis, of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="celu:RegulatoryMilestones" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction> in regulatory milestones and an aggregate $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="celu:CommercialMilestonePayments" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction> in commercial milestone payments with respect to certain programs. In addition, with respect to each such program and calendar year, the CVR holders will be entitled, with respect to a given calendar year and program, to receive a royalty equal to a mid-teen&#160;percentage of the annual net sales for such program, from the date of the first commercial sale of such program&#8217;s product in a particular country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program product in such country, the expiration of marketing exclusivity with respect to such product in such country, and August 2027 (i.e., the tenth anniversary of the closing of the acquisition of Anthrogenesis). Celularity estimates the liability associated with the CVR quarterly. Changes to that liability include but are not limited to changes in Celularity clinical programs, assumptions about the commercial value of those programs and the time value of money.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;7, 2018, the Company completed an Asset Purchase Agreement with Alliqua, a regenerative technologies company that commercializes regenerative medical products (the &#8220;Alliqua APA&#8221;). The Alliqua APA included the acquisition of Alliqua&#8217;s biologic wound care business, including the marketing and distribution rights to Biovance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Interfyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup>as well as a Class II medical device, the MIST<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and UltraMIST<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;Therapy Systems. In connection with the Alliqua APA, the Company paid cash consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlliquaAPAMember_20180507_20180507" decimals="0" format="ixt:numdotdecimal">29,000</ix:nonFraction>. The Alliqua acquisition led to goodwill and intangible assets. <ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" contextRef="C_0001752828_20180507" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> debt or significant liabilities were assumed by the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;5, 2018, the Company acquired CariCord Inc. (&#8220;CariCord&#8221;), a family cord blood bank established by ClinImmune Labs University of Colorado Cord Blood Bank (&#8220;ClinImmune Labs&#8221;) and the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado School of Medicine (the &#8220;University of Colorado&#8221;). In the aggregate, the fair value of the consideration to acquire CariCord was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCaricordMember_20181005_20181005" decimals="0" format="ixt:numdotdecimal">9,326</ix:nonFraction>. The acquisition led to goodwill and intangible assets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company&#8217;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While management has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company&#8217;s continuity plans will be successful.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Although the Company was able to operate continuously throughout 2020 and 2021, the Company implemented work-from-home policies as needed following local health recommendations for non-essential employees and employees whose roles are able to be performed remotely. Because certain elements of the Company&#8217;s operations (such as processing placental tissue, certain biological assays, translational research and storage of cord blood) cannot be performed remotely, the Company instituted controls and protocols including mandatory temperature checking, symptom assessment forms, incremental cleaning and sanitization of common surfaces to mitigate risks to employees.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Due to a broad decline in economic activity and restrictions on physical access to certain medical facilities, the Company did experience a decrease in the net revenues of its degenerative disease business due to the pandemic in 2021. As for clinical trials, the Company did not cancel or postpone enrollment solely due to the risks of COVID-19. However, enrollment in the clinical trial evaluating </span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000357_dcnt_c5b33794-5d54-44af-80a6-94fea23d5bbf">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">CYNK-001 for AML experienced some delays in the first half of 2020 as sites assessed their safety protocols and experienced high volumes of COVID-19 patients. Enrollment has continued in the AML trial and remains ongoing. As a result, during 2020 the Company had a year-over-year increase in research and development expenses notwithstanding the enrollment delays. The Company also initiated a clinical trial evaluating CYNK-001 in patients with COVID-19, which necessitated additional research and development and project management resources. The Company believes that it would have deployed its human and capital resources to other efforts, such as its C</span><span style="Background-color:#FFFFFF;">Y</span><span style="Background-color:#FFFFFF;">CART-19 clinical development program, had the COVID-19 pandemic not struck.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">COVID-19 did not have a material negative impact on oncology clinical trial patient accrual rates during 2021. However, screenings and enrollments in the COVID-19 trial were lower once vaccines became more widely available. During 2021, Celularity continued to utilize mandatory temperature checking and symptom assessment forms and, commencing with the third quarter of 2021, instituted additional safety protocols for unvaccinated employees. Celularity also utilized a liaison to help schedule vaccination appointments for employees.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The extent to which COVID-19 or any other health epidemic may impact the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition, and prospects.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Going Concern</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-15,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="Background-color:#FFFFFF;">, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Since its inception, Legacy Celularity funded its operations primarily with proceeds from the sales of preferred stock as well as revenues generated through its biobanking and degenerative disease commercial operations. The Company has incurred recurring losses since its inception, including net losses of </span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:NetIncomeLoss" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">100,118</ix:nonFraction><span style="Background-color:#FFFFFF;"> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:NetIncomeLoss" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">208,233</ix:nonFraction>&#160;for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001752828_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">663,681</ix:nonFraction>. The Company expects to continue to generate operating losses for the foreseeable future. As of the date these financial statements are issued, the Company expects that its cash and cash equivalents will not be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is seeking additional funding through public or private equity and/or debt financings. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p></ix:continuation><ix:nonNumeric id="F_000358" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000358_dcnt_aaa7fc1f-f217-49db-8692-d867cc91f21b">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric id="F_000377" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United&#160;States (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000378" name="us-gaap:UseOfEstimates" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000378_dcnt_123c17e2-e204-45ad-bf20-42f3b9aac831">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use&#160;of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions </p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_aaa7fc1f-f217-49db-8692-d867cc91f21b" continuedAt="F_000358_dcnt_277c4a5e-2c8e-427a-8348-4103097a07e5"><ix:continuation id="F_000378_dcnt_123c17e2-e204-45ad-bf20-42f3b9aac831">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to the Company&#8217;s goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and common </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock warrants. The Company based its estimates on historical experience, known trends and other market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facts</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p></ix:continuation><ix:nonNumeric id="F_000379" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p></td></tr></table></div></ix:nonNumeric><ix:nonNumeric id="F_000380" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December&#160;31, 2021 and 2020, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.</p></ix:nonNumeric><ix:nonNumeric id="F_000381" name="celu:RestrictedCashPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company maintained letters of credit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,836</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,202</ix:nonFraction>, respectively, for the benefit of the landlord of leased properties, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</p></ix:nonNumeric><ix:nonNumeric id="F_000382" name="us-gaap:InventoryPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inventory</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out&#160;basis. Prior to initial approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial material as research and development expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)&#160;expected to expire prior to being sold, (ii)&#160;has a cost basis in excess of its net realizable value, (iii)&#160;is in excess of expected sales requirements as determined by internal sales forecasts, or (iv)&#160;fails to meet commercial sale specifications, the inventory is written-down&#160;through a charge to cost of goods sold. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged,<span style="font-style:italic;">&#160;Biovance</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;currently has a shelf-life&#160;of five years in the United&#160;States and between two and three years outside of the United&#160;States, and Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;has a shelf-life&#160;of five years. If actual market conditions are less favorable than those projected by management, inventory write-downs&#160;may be required. Inventory, net of current portion on the Company&#8217;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_277c4a5e-2c8e-427a-8348-4103097a07e5" continuedAt="F_000358_dcnt_dc76a585-b1f3-41e9-a237-203d21a14f80"><ix:nonNumeric id="F_000383" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. <ix:nonNumeric id="F_000406" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000406_cnt_1">Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p><ix:continuation id="F_000406_cnt_1" continuedAt="F_000406_cnt_2">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:68.57%;"></td>
<td style="width:1.45%;"></td>
<td style="width:29.97%;"></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000456" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210101_20211231" format="ixt-sec:duryear">26</ix:nonNumeric> years</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000461" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_2078e9bc-a6da-4e50-977e-ae4e028cca39">5</ix:nonNumeric> - <ix:nonNumeric id="F_000462" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231" format="ixt-sec:durwordsen">7<ix:continuation id="C_2078e9bc-a6da-4e50-977e-ae4e028cca39"> years</ix:continuation></ix:nonNumeric></p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000457" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000458" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000459" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareDevelopmentMember_20210101_20211231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000460" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">shorter of the estimated useful life and the lease term</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress&#160;and depreciated once placed into service.</p></ix:nonNumeric><ix:nonNumeric id="F_000384" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Tangible Long-Lived Assets</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible long-lived&#160;assets consist of property, plant and equipment. Tangible long-lived&#160;assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived&#160;asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived&#160;asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on tangible long-lived&#160;assets during the years ended December&#160;31, 2021 and 2020.</p></ix:nonNumeric><ix:nonNumeric id="F_000385" name="us-gaap:BusinessCombinationsPolicy" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000385_dcnt_20423efb-e7f1-4f99-b72e-ea4dbf039f97">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under Accounting Standards Codification 805,&#160;<span style="font-style:italic;">Business Combinations</span>, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business. If the single asset or group of similar assets does not meet the threshold, an entity must next evaluate whether both an input and substantive process are present.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i)&#160;identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii)&#160;the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is tested for impairment at least annually. Acquired IPR&#38;D is recognized at fair value and initially characterized as an indefinite-lived&#160;intangible asset, irrespective of whether the acquired IPR&#38;D has an alternative future use. Transaction costs related to business combinations are expensed as incurred.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, the selection of valuation methodologies, estimates of future revenue and cash flows, expected long-term&#160;market growth, future expected operating expenses, costs of capital and appropriate discount rates. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and, as a result, actual results may differ materially from estimates.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_dc76a585-b1f3-41e9-a237-203d21a14f80" continuedAt="F_000358_dcnt_7b627824-a9e4-4092-9124-6dde25aecd1b"><ix:continuation id="F_000385_dcnt_20423efb-e7f1-4f99-b72e-ea4dbf039f97">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition-related&#160;contingent consideration, which consists of potential milestone and royalty obligations (see Note 11), was recorded in the consolidated balance sheets at its acquisition-date&#160;estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related&#160;contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The fair value measurement is based on significant inputs not observable by market participants and thus represents a Level 3 input in the fair value hierarchy (see Note 4).</p></ix:continuation><ix:nonNumeric id="F_000386" name="celu:AssetAcquisitionsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Asset Acquisitions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&#38;D with no alternative future use is charged to research and development expense at the acquisition date.</p></ix:nonNumeric><ix:nonNumeric id="F_000387" name="us-gaap:InProcessResearchAndDevelopmentPolicy" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Process Research and Development</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of IPR&#38;D acquired through a business combination is capitalized as an indefinite-lived&#160;intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived&#160;asset and amortized over its estimated useful life.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of an IPR&#38;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indefinite-lived&#160;IPR&#38;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived&#160;IPR&#38;D annually for impairment during the fourth quarter. In testing indefinite-lived&#160;IPR&#38;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived&#160;IPR&#38;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived&#160;IPR&#38;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived&#160;IPR&#38;D. Under either approach, if the fair value of the indefinite-lived&#160;IPR&#38;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the year ended December&#160;31, 2020, the Company recognized an impairment charge related to its indefinite-lived&#160;IPR&#38;D of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,400</ix:nonFraction>. <ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction> such charge was recognized during the year ended December 31, 2021 (see Note 8).</p></ix:nonNumeric><ix:nonNumeric id="F_000388" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000388_dcnt_4257f4cd-fca6-454f-87ec-ade661fac6d7">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the third quarter of 2020, the Company managed its operations as <ix:nonFraction unitRef="U_celuSegment" id="F_000465" name="us-gaap:NumberOfReportingUnits" contextRef="C_0001752828_20200101_20200630" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> reporting unit. In the third quarter of 2020, the Company began to manage its operations through an evaluation of <ix:nonFraction unitRef="U_celuSegment" id="F_000466" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001752828_20200701_20200930" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the change in reporting units, goodwill was required to be allocated across the operating segments under the new reporting structure. Goodwill was attributed to each reporting unit based on the acquired value, which is reflective of the relative fair value.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company&#8217;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_7b627824-a9e4-4092-9124-6dde25aecd1b" continuedAt="F_000358_dcnt_1faecd5f-c2aa-45a7-9fda-52e05454b000"><ix:continuation id="F_000388_dcnt_4257f4cd-fca6-454f-87ec-ade661fac6d7">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, not to exceed the total amount of goodwill allocated to the reporting unit.</span></p></ix:continuation><ix:nonNumeric id="F_000389" name="celu:PreferredStockWarrantsLiabilitiesPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock Warrants Liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the business combination with GX (see Notes 1 and 3), the Company classified warrants for the purchase of shares of its convertible preferred stock (see Note 12) as liabilities on its consolidated balance sheets as these warrants were freestanding financial instruments that may have required the Company to transfer assets upon exercise. The warrant liabilities, which consisted of warrants for the purchase of Series B convertible preferred stock, were initially recorded at fair value upon the date of issuance of each warrant and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liabilities were recognized as a component of other (expense) income in the consolidated statement of operations. Fair value of the preferred stock warrant liabilities were remeasured through the July 16, 2021 closing date on the consolidated statement of operations until the liability was reclassified to equity on the closing date. </p></ix:nonNumeric><ix:nonNumeric id="F_000390" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into lease agreements for its laboratory and office facilities. The Company determines if a lease arrangement is an operating lease or capital lease at inception. Rent expense is recognized on a straight-line&#160;basis over the term of the lease. Incentives granted under the Company&#8217;s facilities leases, including allowances to fund leasehold improvements and rent holidays, are recorded as a deferred rent liability and are recognized as reductions to rental expense on a straight-line&#160;basis over the remaining term of the lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the nature of the renovations and the Company&#8217;s involvement during the construction period of newly leased office space to determine if it is considered to be the owner of the construction project during the construction period. If the Company determines that it is the owner of the construction project, it is required to capitalize the fair value of the asset, including potentially the building, construction costs incurred, and capitalized interest, on its consolidated balance sheet along with a corresponding financing liability (&#8220;build-to-suit&#160;accounting&#8221;). Upon occupancy for build-to-suit&#160;leases, the Company assesses whether the circumstances qualify for sales recognition under the sale-leaseback&#160;accounting guidance. If the lease meets the sale-leaseback&#160;criteria, the Company will remove the asset and related financial obligation from the balance sheet and evaluate the lease for treatment as a capital or operating lease. If upon completion of construction, the project does not meet the sale-leaseback&#160;criteria, the leased property will be treated as a capital lease for financial reporting purposes.</p></ix:nonNumeric><ix:nonNumeric id="F_000391" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000391_dcnt_f089f770-b67c-40f2-89d2-852311cb7cb9">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>, Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;and MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;and UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term&#160;pregnancies), and license, royalty and other operations (i.e., license agreement with Sanuwave Health Inc.).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Product sales and rentals</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biovance<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is a low frequency ultrasound system used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates and bacteria. The MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System consists of a generator and treatment wand (collectively, the &#8220;MIST Equipment&#8221;) along with single-use&#160;applicators (the &#8220;MIST Applicators&#8221;) and optional accessories (e.g., roll stand and carts).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_1faecd5f-c2aa-45a7-9fda-52e05454b000" continuedAt="F_000358_dcnt_8ca3f6d0-d4fb-403d-9613-67e71a16e27e"><ix:continuation id="F_000391_dcnt_f089f770-b67c-40f2-89d2-852311cb7cb9" continuedAt="F_000391_dcnt_fac87fc6-8e4e-4eac-be0f-2e96b38c0bb0">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has the ability to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns. The Company offers product warranties which provide assurance that the product will function as expected and in accordance with specification. Customers can purchase warranties separately and these warranties give rise to a separate performance obligation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System had both software and non-software&#160;(e.g., hardware) components that function together to deliver the product&#8217;s essential functionality. In addition, the hardware sold could not be used apart from the embedded software. The MIST Equipment was obtained by the customer in three ways: (a)&#160;the purchase of the MIST Equipment outright&#59; (b)&#160;the lease of the MIST Equipment for a monthly rental fee&#59; or (c)&#160;pay-per-use&#160;arrangement whereupon the Company provided the MIST Equipment for a single pay per use fee, subject to a minimum purchase requirement of MIST Applicators. MIST Applicators were separately ordered and purchased by customers who opted to purchase or directly lease the equipment. In addition, the Company offered the MIST Equipment for a standard <ix:nonNumeric id="F_000469" name="celu:EquipmentEvaluationPeriod" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:durday">90</ix:nonNumeric>&#160;day evaluation period at <ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:EquipmentExpense" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> charge to the customer for the MIST Equipment&#59; however, MIST Applicators were required to be purchased during the evaluation term. When the Company leased or entered into a pay-per-use&#160;arrangement, it retained title to the equipment at all times.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For multiple-element&#160;arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. When the Company&#8217;s customer arrangements are multiple-element&#160;arrangements that contains a lease or pay-per-use&#160;arrangement, the Company allocates the arrangement consideration between the lease deliverable (i.e., the MIST Equipment) and non-lease&#160;deliverable (i.e., the MIST Applicators). The consideration related to the pay-per-use&#160;arrangements was allocated to the lease deliverable based on the &#8220;Minimum Volume Method&#8221;, which used the contractual minimum volume in the relative fair value calculation because the ultimate level of MIST Applicator purchases was unknown. The consideration allocated related to the lease arrangement was established in the lease arrangement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides inventory to certain customers through pre-arranged&#160;agreements on a consignment basis. Customers consigned inventory is maintained and stored by certain customers&#59; however, ownership remains with the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Services</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">License, royalty and&#160;other</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement with Sanuwave Health Inc. (&#8220;Sanuwave&#8221;) which acquired certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business (see Note 14), the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognized the quarterly license fee over each quarterly term based on the actual sales occurring over the period. The license agreement with Sanuwave was terminated during the third quarter of 2021 due to an uncured material breach.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to </p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_8ca3f6d0-d4fb-403d-9613-67e71a16e27e" continuedAt="F_000358_dcnt_638713a6-520a-4060-b255-8bf2b9f3a577"><ix:continuation id="F_000391_dcnt_fac87fc6-8e4e-4eac-be0f-2e96b38c0bb0" continuedAt="F_000391_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up&#160;basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ee Note </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for further discussion of the Company&#8217;s license agreements.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="DA_RN_3767174097100001138">For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the<span style="font-size:12pt;color:#000000;"> </span><span style="color:#000000;">consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order). </span></p></ix:continuation><ix:nonNumeric id="F_000392" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related&#160;expenses, depreciation and amortization, stock-based&#160;compensation, third-party&#160;license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p></ix:nonNumeric><ix:nonNumeric id="F_000393" name="us-gaap:AdvertisingCostsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising and Marketing Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="us-gaap:MarketingAndAdvertisingExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">252</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:MarketingAndAdvertisingExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">764</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000394" name="celu:GovernmentGrantsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Grants</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company recorded a reduction of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="celu:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">290</ix:nonFraction> to research and development expense resulting from grant awards for the year ended December&#160;31, 2020. The Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="celu:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t receive grant monies during 2021.</p></ix:nonNumeric><ix:nonNumeric id="F_000395" name="celu:PatentCostsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related&#160;costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p></ix:nonNumeric><ix:nonNumeric id="F_000396" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000396_dcnt_f28f8895-f300-4cb8-becc-bed62592361e">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures all stock-based&#160;awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based&#160;awards with only service-based&#160;vesting conditions and records the expense for these awards using a straight-line&#160;method.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company&#8217;s Board of Directors approved the award of performance-based&#160;stock options to a non-employee&#160;consultant who also serves as a director for the Company (see Note 13). The performance-based&#160;stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based&#160;awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based&#160;awards and adjusts expense accordingly on a cumulative basis.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_638713a6-520a-4060-b255-8bf2b9f3a577" continuedAt="F_000358_dcnt_6e12452c-9ccd-40c8-8317-47159e104045"><ix:continuation id="F_000396_dcnt_f28f8895-f300-4cb8-becc-bed62592361e">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes&#160;option-pricing&#160;model. The Company historically has been a private company and lacks company-specific&#160;historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted to employees is determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employee&#160;consultants is equal to the contractual term of the option award. The risk-free&#160;interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is <ix:nonFraction unitRef="U_xbrlipure" id="F_000474" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001752828_20210101_20211231" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction> based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future (see Note 13).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company awarded options to its President which have market-based vesting conditions. <span style="Background-color:#FFFFFF;font-family:Calibri;">The Company uses the Monte-Carlo model in order to calculate the fair value of the market-based awards. Also in 2021, the Company granted restricted stock units (&#8220;RSU&#8221;), the fair value of which is determined based on the stock price on the date of grant. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies stock-based&#160;compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is reversed in the period of the forfeiture.</p></ix:continuation><ix:nonNumeric id="F_000397" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric id="F_000398" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step&#160;process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not&#160;to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than <ix:nonFraction unitRef="U_xbrlipure" id="F_000475" name="celu:MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" contextRef="C_0001752828_20210101_20211231" decimals="INF" scale="-2">50</ix:nonFraction>% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).</p></ix:nonNumeric><ix:nonNumeric id="F_000399" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000399_dcnt_8ce2078c-de45-45d7-84a4-7e478402902e">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per&#160;Share</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average&#160;number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, stock options and warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average&#160;number of shares of common </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_6e12452c-9ccd-40c8-8317-47159e104045" continuedAt="F_000358_dcnt_c9282f5d-52d9-4100-b375-19a9493e7b8d"><ix:continuation id="F_000399_dcnt_8ce2078c-de45-45d7-84a4-7e478402902e">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></p><ix:nonNumeric id="F_000407" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000476" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">82,643,496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000477" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">26,533,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000478" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">17,167,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000479" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">474,700</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000480" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">42,686,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000481" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">19,811,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000482" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_20210101_20211231" decimals="0" format="ixt:numdotdecimal">69,694,763</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000483" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001752828_20200101_20201231" decimals="0" format="ixt:numdotdecimal">119,621,865</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p><ix:nonNumeric id="F_000400" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making&#160;group, in deciding how to allocate resources in assessing performance. Prior to the third quarter of 2020, the Company managed its operations as <ix:nonFraction unitRef="U_celuSegment" id="F_000484" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of <ix:nonFraction unitRef="U_celuSegment" id="F_000485" name="celu:NumberOfBusinessSegments" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December&#160;31, 2021 and 2020 in Note 18.</p></ix:nonNumeric><ix:nonNumeric id="F_000401" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Customers</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United&#160;States. During the year ended December 31, 2021, the Company had one customer (Customer A) provide for <ix:nonFraction unitRef="U_xbrlipure" id="F_000486" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="2" scale="-2">38</ix:nonFraction>% of revenue and another customer provide for <ix:nonFraction unitRef="U_xbrlipure" id="F_000488" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001752828_srtMajorCustomersAxis_celuCustomerTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="2" scale="-2">11</ix:nonFraction>% of total revenue. In the year ended December&#160;31, 2020, the Company had one customer provide for <ix:nonFraction unitRef="U_xbrlipure" id="F_000487" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">13</ix:nonFraction>% of the revenue earned. As of December&#160;31, 2021, Customer A comprised approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000489" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231" decimals="2" scale="-2">47</ix:nonFraction>% of the Company&#8217;s outstanding accounts receivable. As of December&#160;31, 2020, one of the Company&#8217;s customers comprised approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000490" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231" decimals="2" scale="-2">24</ix:nonFraction>% of the Company&#8217;s outstanding accounts receivables.</p></ix:nonNumeric><ix:nonNumeric id="F_000402" name="celu:EmergingGrowthCompanyPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging&#160;growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p></ix:nonNumeric><ix:nonNumeric id="F_000403" name="celu:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2019-12, <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span> (Topic 740) (&#8220;ASU 2019-12&#8221;). The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification 740 and clarifying existing guidance to facilitate consistent application. The standard was effective for the Company beginning on January 1, 2021. The adoption of ASU 2019-12 as of January 1, 2021 did not have a material impact on the consolidated financial statements.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_c9282f5d-52d9-4100-b375-19a9493e7b8d" continuedAt="F_000358_dcnt_192ff027-9371-4223-9119-24b028ef62c5"><ix:nonNumeric id="F_000404" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000404_dcnt_62415cd4-b055-4e19-a8d6-d6a8a3e8367e">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2020, the FASB issued ASU 2020-06, (Subtopic 470-20):&#160;<span style="font-style:italic;">Debt &#8212; Debt with Conversion and Other Options</span>&#160;(&#8220;ASU 2020-06&#8221;) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06&#160;includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity&#8217;s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06&#160;will require entities to use the &#8220;if-converted&#8221; method when calculating diluted earnings per share for convertible instruments. ASU 2020-06&#160;is effective for fiscal years beginning after December&#160;15, 2021 (fiscal year 2022 for the Company), including interim periods within those fiscal years. As <ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:LineOfCredit" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> debt is currently outstanding, the Company does not expect the impact of ASU 2020-06&#160;to have an impact on its financial position, results of operations or cash flows.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, <span style="font-style:italic;">Financial Instruments &#8212; Credit Losses</span> (&#8220;ASU 2016-13&#8221;), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02<span style="font-style:italic;">, Leases (Topic&#160;842)&#160;</span>(&#8220;ASU 2016-02&#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line&#160;basis over the term of the lease. A lessee is also required to record a right-of-use&#160;asset and a lease liability for all leases with a term of greater than 12&#160;months regardless of their classification. Leases with a term of 12&#160;months or less may be accounted for similar to existing guidance for operating leases today. The guidance is effective for the Company for annual reporting periods beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022, with early adoption permitted. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC 842 as of <ix:nonNumeric id="F_000492" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231" format="ixt:datemonthdayyearen">January 1, 2022</ix:nonNumeric> using the modified retrospective method, which did not require it to restate prior periods and did not have an impact on retained earnings. The Company has elected the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its Consolidated Balance Sheets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company will determine whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the Consolidated Balance Sheets as right-of-use assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets will be recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the right-of-use asset. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not yet finalized the impact of this new standard, however, the Company is expecting its adoption will have a material effect on the Company&#8217;s consolidated financial statements.&#160;&#160;Upon adoption, the most significant impact relates to an equity adjustment and the recognition of a new right-of-use asset and lease liability arising from the derecognition of existing assets and liabilities from the failed sale-leaseback transaction of the Company&#8217;s Florham Park, New Jersey facility.&#160;&#160;Upon adoption, the Company will derecognize the portion of the existing build-to-suit facility financing obligation and the corresponding existing asset that was recorded solely as a result of the transaction&#8217;s build-to-suit designation in accordance with Topic 840.&#160;&#160;The difference associated with this derecognition will be recorded as an adjustment to equity as of January 1, 2022.&#160;&#160;The Company will then follow the general lessee transition requirements discussed above to record the new right-of-use asset and lease liability in accordance with Topic 842.&#160;&#160;Certain Company-paid costs associated with this transaction that were capitalized will not be derecognized and thus will be carried over and </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000358_dcnt_192ff027-9371-4223-9119-24b028ef62c5"><ix:continuation id="F_000404_dcnt_62415cd4-b055-4e19-a8d6-d6a8a3e8367e">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">retained at their currently recognized balances as they would have been recognized in the absence of the build-to-suit designation.&#160;&#160;Further information regarding this transaction is discussed within Note 11.&#160;&#160;&#160;&#160; </span></p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000359" name="celu:BusinessCombinationsAndDisposalsDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000359_dcnt_7208d520-7295-4ac1-b737-15d42100e4dd">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.&#160;&#160;&#160;&#160;&#160;Business Combinations and Disposals</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Fiscal 2021</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 16, 2021, the Company consummated the previously announced merger pursuant to the Merger Agreement, by and among GX, First Merger Sub, Second Merger Sub and Legacy Celularity (see Note 1).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, a business combination between GX and Legacy Celularity was effected through the (a) merger of First Merger Sub with and into Legacy Celularity with Legacy Celularity surviving as a wholly-owned subsidiary of GX (Legacy Celularity, in its capacity as the surviving corporation of the merger, the &#8220;Surviving Corporation&#8221;) (the &#8220;First Merger&#8221;) and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the merger of the Surviving Corporation with and into Second Merger Sub, with Second Merger Sub as the surviving entity of the Second Merger, which ultimately resulted in Legacy Celularity becoming a wholly-owned direct subsidiary of GX (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Mergers&#8221; and, collectively with the other transactions described in the Merger Agreement, the &#8220;Business Combination&#8221;). On the Closing Date, the Company changed its name from GX Acquisition Corp. to Celularity Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the effective time of the Mergers (the &#8220;Effective Time&#8221;), each share of preferred stock of Legacy Celularity (the &#8220;Legacy Celularity Preferred Stock&#8221;) that was issued and outstanding was automatically converted into a number of shares of common stock of Legacy Celularity, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000495" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_20210716" decimals="INF">0.0001</ix:nonFraction> per share (the &#8220;Legacy Celularity Common Stock&#8221;) at the then-effective conversion rate as calculated pursuant to the Amended and Restated Certificate of Incorporation of Legacy Celularity, dated March 16, 2020, as amended (the &#8220;Legacy Celularity Charter&#8221;), such that each converted share of Legacy Celularity Preferred Stock was no longer outstanding and ceased to exist, and each holder of Legacy Celularity Preferred Stock thereafter ceased to have any rights with respect to such securities (the &#8220;Legacy Celularity Preferred Stock Conversion&#8221;).</p><ix:nonNumeric id="F_000498" name="us-gaap:CommonStockConversionBasis" contextRef="C_0001752828_20210101_20211231" continuedAt="F_000498_dcnt_0e1bf431-f085-4f24-88f4-ef267bbe2bf4"><p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000496" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF">0.0001</ix:nonFraction> per share (&#8220;Company Class A Common Stock&#8221;) equal to the Exchange Ratio (as defined below) (the &#8220;Per Share Merger Consideration&#8221;)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, &#8220;Legacy Celularity Capital Stock&#8221;) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">each share of First Merger Sub common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000497" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlphaFirstMergerSubIncorporationMember_20210716" decimals="INF">0.01</ix:nonFraction> per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000499" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuSurvivingCorporationMember_20210716" decimals="INF">0.0001</ix:nonFraction> per share, of the Surviving Corporation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Company Class A Common Stock (and not Celularity Capital Stock) (each, a &#8220;Converted Warrant&#8221;) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Company Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the &#8220;Celularity Warrant Shares&#8221;) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below)&#59; and (B) the per share exercise price for each share of Company Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below)&#59; and</span></p></td></tr></table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000359_dcnt_7208d520-7295-4ac1-b737-15d42100e4dd" continuedAt="F_000359_dcnt_87bfd478-2064-4af2-940f-3b613309f819"><ix:continuation id="F_000498_dcnt_0e1bf431-f085-4f24-88f4-ef267bbe2bf4">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">e)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">each option to purchase Legacy </span><span style="font-size:10pt;">Celularity</span><span style="font-size:10pt;"> Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a &#8220;Legacy </span><span style="font-size:10pt;">Celularity</span><span style="font-size:10pt;"> Option&#8221;) was assumed by GX and converted into an option to purchase shares of Company Class A Common Stock (each, a &#8220;Converted Option&#8221;).</span></p></td></tr></table></div></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Business Combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States. Under this method of accounting, GX was treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on existing Legacy Celularity stockholders comprising a relative majority of the voting power of the combined company, Legacy Celularity&#8217;s operations prior to the acquisition comprising the only ongoing operations of Celularity, the majority of Celularity&#8217;s board of directors appointment by Legacy Celularity, and Legacy Celularity&#8217;s senior management comprising a majority of the senior management of Celularity. Accordingly, for accounting purposes, the financial statements of the combined entity represented a continuation of the financial statements of Legacy Celularity with the business combination being treated as the equivalent of Legacy Celularity issuing stock for the net assets of GX, accompanied by a recapitalization. The Company recorded net assets of GX at historical costs, with <ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:OtherIntangibleAssetsNet" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> goodwill or other intangible assets recorded. Operations prior to the business combination are those of Legacy Celularity. Reported shares and earnings per share available to holders of the Company&#8217;s Class A common stock, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio established in the business combination (1.00 share of Legacy Celularity for approximately <ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000502" name="celu:BusinessCombinationExchangeRatioOfCommonStock" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="4">0.7686</ix:nonFraction> shares of Celularity Class A common stock).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net proceeds from this transaction totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="celu:BusinessAcquisitionTransactionCostsProceedsNet" contextRef="C_0001752828_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">108,786</ix:nonFraction>. These proceeds were comprised of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="celu:BusinessAcquisitionTransactionCostsProceedsNet" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuGXTrustAccountMember_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">5,386</ix:nonFraction> held in GX&#8217;s trust account, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="celu:BusinessAcquisitionTransactionCostsProceedsNet" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">83,400</ix:nonFraction> received from the completion of a concurrent private investment in public equity financing (&#8220;PIPE Financing&#8221;) and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="celu:BusinessAcquisitionTransactionCostsProceedsNet" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction> received from an investment by Palantir Technologies, Inc. The Company incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="C_0001752828_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">21,657</ix:nonFraction> in transaction costs relating to the merger with GX of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="celu:BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">10,795</ix:nonFraction> were satisfied by the issuance of Class A common stock, which has been offset against additional paid-in capital in the Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, the existing stockholders of Legacy Celularity exchanged their interests for shares of Class A common stock of Celularity. <ix:nonNumeric id="F_000509" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231">In addition, GX had previously issued public warrants and private placement warrants (collectively, the &#8220;GX Warrants&#8221;) as part of the Units in its initial public offering in May 2019</ix:nonNumeric>. None of the terms of the GX Warrants were modified as a result of the Business Combination. On the date of the Business Combination, the Company recorded a liability related to the GX Warrants of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:Liabilities" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,202</ix:nonFraction>, with an offsetting entry to additional paid-in capital. During the period from July 17, 2021 to December 31, 2021, the fair value of the GX Warrants <span style="Background-color:#FFFFFF;">decreased to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,962</ix:nonFraction>, resulting in an expense reduction of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,240</ix:nonFraction></span> in the consolidated statement of operations for the year ended December 31, 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon consummation of the Business Combination, Legacy Celularity warrants qualified for equity classification. As a result, the transaction date fair value of the Legacy Celularity warrants of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">96,398</ix:nonFraction> was reclassified from warrant liability to additional paid-in capital (see Note 12).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately following the Business Combination, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000514" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000515" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF" format="ixt:numdotdecimal">122,487,174</ix:nonFraction></ix:nonFraction> shares of Class A common stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000516" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF">0.0001</ix:nonFraction> issued and outstanding, options to purchase an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000517" name="celu:OptionToPurchaseSharesOfCommonStock" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF" format="ixt:numdotdecimal">21,723,273</ix:nonFraction> shares of Class A common stock and <ix:nonFraction unitRef="U_xbrlishares" id="F_000518" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716" decimals="INF" format="ixt:numdotdecimal">42,686,195</ix:nonFraction> warrants outstanding to purchase shares of Class A common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PIPE Financing (Private Placement)</p><ix:nonNumeric id="F_000519" name="celu:SubscriptionAgreementsDescription" contextRef="C_0001752828_20210101_20211231"><p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the &#8220;Subscribers&#8221;) purchased from Celularity an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000521" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716_20210716" decimals="INF" format="ixt:numdotdecimal">8,340,000</ix:nonFraction> shares of Class A common stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000520" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716" decimals="INF">10.00</ix:nonFraction> per share and an aggregate purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">83,400</ix:nonFraction>, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the &#8220;Subscription Agreements&#8221;). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Arrangement with Palantir Technologies Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the subscription agreement entered into by GX with Palantir Technologies Inc. (&#8220;Palantir&#8221;) on May 5, 2021, Palantir purchased <ix:nonFraction unitRef="U_xbrlishares" id="F_000523" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716_20210716" decimals="INF" format="ixt:numdotdecimal">2,000,000</ix:nonFraction> shares of Class A common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000524" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716" decimals="INF">10.00</ix:nonFraction> per share and an aggregate purchase price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction>, upon closing of the Business Combination and closing of the PIPE financing.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Fiscal 2020</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000526" name="celu:AssetPurchaseAgreementDescription" contextRef="C_0001752828_20210101_20211231">On August&#160;6, 2020, the Company executed (i)&#160;an asset purchase agreement to sell certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business to Sanuwave and (ii)&#160;a <span style="-sec-ix-hidden:F_000527">five-year</span>&#160;licensing agreement with Sanuwave for total consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">24,524</ix:nonFraction> (the &#8220;Sanuwave Transaction&#8221;), of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">20,000</ix:nonFraction> was paid at or prior to closing. The remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">4,524</ix:nonFraction> of the purchase price was financed through a convertible promissory note due on or before <ix:nonNumeric id="F_000531" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806" format="ixt:datemonthdayyearen">August&#160;6, 2021</ix:nonNumeric>. The convertible promissory note can be converted into shares of Sanuwave stock at the election of the Company any time on or after <ix:nonNumeric id="F_000532" name="us-gaap:DebtInstrumentConvertibleConversionDate" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806" format="ixt:datemonthdayyearen">January&#160;1, 2021</ix:nonNumeric>. As of December 31, 2021 the fair value of the convertible promissory note related to Sanuwave was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="celu:FairValueOfConvertiblePromissoryNote" contextRef="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">2,488</ix:nonFraction> which is included in other current assets on the consolidated balance sheet.</ix:nonNumeric> </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000359_dcnt_87bfd478-2064-4af2-940f-3b613309f819">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="-sec-ix-hidden:F_000534">five-year</span>&#160;licensing arrangement with Sanuwave includes: (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market and (ii)&#160;a non-exclusive&#160;license for the distribution and commercialization of Interfyl in the wound care market. Under the licensing agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.</p><ix:nonNumeric id="F_000408" name="celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following assets and liabilities were divested/written off in this transaction:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets Divested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" contextRef="C_0001752828_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">1,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" contextRef="C_0001752828_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">13,296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" contextRef="C_0001752828_20200806" decimals="-3" scale="3">452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" contextRef="C_0001752828_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">3,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets divested</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="C_0001752828_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">19,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total upfront consideration was allocated between both components of the Sanuwave Transaction to <ix:nonNumeric id="F_000540" name="celu:ConsiderationDescription" contextRef="C_0001752828_20210101_20211231">(i)&#160;calculate the goodwill attributed to the UltraMIST business, (ii)&#160;determine the allocation of arrangement consideration to the three performance obligations and (iii)&#160;determine the loss on sale of the UltraMIST business. The Company utilized a discounted cash flow model to value the UltraMIST business, which determined the fair value of the UltraMIST business was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,019</ix:nonFraction>. Significant inputs of this discounted cash flow model included (i)&#160;a discount rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000542" name="celu:DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231" decimals="2" scale="-2">11</ix:nonFraction>%, (ii)&#160;tax rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000543" name="celu:DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231" decimals="2" scale="-2">26</ix:nonFraction>% and (iii)&#160;a long-term&#160;growth rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000544" name="celu:DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231" decimals="2" scale="-2">2</ix:nonFraction>%. The remaining proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,505</ix:nonFraction> were allocated to the license agreement on a residual basis. During the third quarter of 2020, the Company recognized a loss on sale of UltraMIST of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,434</ix:nonFraction>, which included approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="celu:DisposalGroupIncludingDiscontinuedOperationProfessionalFees" contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231" decimals="-3" scale="3">40</ix:nonFraction> in related professional fees. Due to the Company&#8217;s tax position as of the closing date, there was no tax impact resulting from the sale of the UltraMIST business.</ix:nonNumeric></p></ix:continuation><ix:nonNumeric id="F_000360" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000360_dcnt_ce3d521b-0222-4919-8539-185f00410636">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold;">Fair Value of Financial Assets and&#160;Liabilities</span></p><ix:nonNumeric id="F_000409" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="celu:ConvertibleNoteReceivable" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="celu:ConvertibleNoteReceivable" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">232,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">232,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability - Sponsor Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="celu:WarrantLiabilitySponsorWarrants" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="celu:WarrantLiabilitySponsorWarrants" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability - Public Warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="celu:WarrantLiabilityPublicWarrants" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="celu:WarrantLiabilityPublicWarrants" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">245,822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">258,184</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents &#8211; money market funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="celu:ConvertibleNoteReceivable" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="celu:ConvertibleNoteReceivable" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">273,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">273,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="celu:PreferredStockWarrants" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="celu:PreferredStockWarrants" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">350,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">350,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2021 and 2020, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" contextRef="C_0001752828_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" contextRef="C_0001752828_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="C_0001752828_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="C_0001752828_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between Level&#160;1, Level 2 and Level 3.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000360_dcnt_ce3d521b-0222-4919-8539-185f00410636" continuedAt="F_000360_dcnt_b4acc5b7-798d-4f52-b8c3-452d93d23663">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents consisted of a money market fund. The money market fund was valued using inputs observable in active markets for similar securities, which represents a Level 1 measurement in the fair value hierarchy. The carrying values of accounts receivable, accounts payable, deferred revenue and other current liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term&#160;nature of those instruments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation&#160;of Contingent Consideration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted&#160;income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions.</p><ix:nonNumeric id="F_000410" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December&#160;31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in to (out of)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">settlements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="celu:ContingentConsiderationObligation" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">273,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">41,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="celu:ContingentConsiderationObligation" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">232,222</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in to (out of)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">settlements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="celu:ContingentConsiderationObligation" contextRef="C_0001752828_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">328,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="celu:ContingentConsiderationObligation" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">273,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the liability to make potential future milestone and earn-out&#160;payments was estimated by the Company at each reporting date based, in part, on the results of a third-party&#160;valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving specified events, discount rates, and the period of time until earn-out&#160;payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company&#8217;s consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has classified all of the contingent consideration as a long-term&#160;liability in the consolidated balance sheet as of December&#160;31, 2021 and 2020. See Note&#160;11, &#8220;Commitment and Contingencies&#8221;, for more information on contingent consideration.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation of&#160;Stock Warrant Liabilities</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The warrant liability at December 31, 2021 is composed of the fair value of warrants to purchase shares of common stock. The private placement warrants assumed upon the Business Combination (the &#8220;Sponsor Warrants&#8221;) were recorded at the Closing Date fair value based on a Black-Scholes option pricing model that utilizes inputs for: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset and (vi) maturity. The Black-Scholes option pricing model&#8217;s primary unobservable input utilized in determining the fair value of the Sponsor Warrants is the expected volatility of the Class A common stock. Inputs to the Black-Sholes option pricing model for the Sponsor Warrants are updated each reporting period to reflect fair value. The public warrants assumed upon the Business Combination (the &#8220;Public Warrants&#8221;) were recorded at the Closing Date fair value based on the close price of such warrants. Each subsequent reporting period, the Public Warrants are marked-to-market based on the period-end close price.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preferred stock warrant liability at December&#160;31, 2020 is composed of the fair value of warrants to purchase shares of Legacy Celularity Series B convertible preferred stock that were issued in 2020 and became exercisable for Class A common stock upon consummation of the Business Combination in accordance with their terms. Warrants were issued by Legacy Celularity to Dragasac Limited (&#8220;Dragasac&#8221;) in January&#160;2020 for no consideration and were recorded at fair value at the date of issuance (see Note 12). The liability associated with the warrants was recorded at fair value on the dates the warrants were issued and exercisable and was subsequently remeasured to fair value at each reporting date through the Business Combination date. The aggregate fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000360_dcnt_b4acc5b7-798d-4f52-b8c3-452d93d23663" continuedAt="F_000360_dcnt_132e9fe6-0331-486d-9586-7b566885d13a">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company used a lattice model to value the Legacy </span><span style="Background-color:#FFFFFF;">Celularity</span><span style="Background-color:#FFFFFF;"> warrants issued as the exercise price was a function of the stock price. In the application of each model, estimates and assumptions impacting the fair value measurement included the fair value per share of the underlying shares of Legacy </span><span style="Background-color:#FFFFFF;">Celularity&#8217;s</span><span style="Background-color:#FFFFFF;"> Series B convertible preferred stock, risk-free interest rate, and exercise date with considerations of the earlier of when the investor was required to exercise and the anticipated exit date. The most significant assumption in the forward contract model impacting the fair value of the preferred stock warrants was the fair value of Legacy </span><span style="Background-color:#FFFFFF;">Celularity&#8217;s</span><span style="Background-color:#FFFFFF;"> convertible preferred stock as of each remeasurement date. The Company determined the fair value per share of the underlying preferred stock by taking into consideration the most recent sales of Legacy </span><span style="Background-color:#FFFFFF;">Celularity&#8217;s</span><span style="Background-color:#FFFFFF;"> convertible preferred stock, results obtained from third-party valuations and additional factors that are deemed relevant.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2021 and December&#160;31, 2020, the fair value of the warrant liabilities was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="celu:FairValueNetAssetsLiability" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,962</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="celu:FairValueNetAssetsLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,640</ix:nonFraction>, respectively. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated remaining term of the warrants.</span></p><ix:nonNumeric id="F_000411" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s warrant liabilities for which fair values are determined using Level 3 inputs:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of warrants issued in connection with Series B</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred stock sale</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="celu:StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,954</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrant at fair value*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="celu:ProceedsFromIssuanceOfWarrant" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss recognized in earnings from change in fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="celu:GainLossRecognizedInEarningsFromChangeInFairValues" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,698</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="celu:FairValueNetAssetsLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="celu:FairValueNetAssetsLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain recognized in earnings from change in fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="celu:GainLossRecognizedInEarningsFromChangeInFairValues" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed at Closing Date (Sponsor Warrants)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="celu:WarrantLiabilityAssumedAtClosingDate" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed at Closing Date (Public Warrants)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="celu:WarrantLiabilityAssumedAtClosingDate" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Legacy Celularity Warrants to equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="celu:ReclassificationOfLegacyCelularityWarrantsToEquity" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">96,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="celu:FairValueNetAssetsLiability" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="Background-color:#FFFFFF;"><ix:footnote id="FNT_000000" xml:lang="en-US">The warrants issued at fair value were immediately charged to expense see Note 12.</ix:footnote></span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the Public Warrants was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,362</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">24,438</ix:nonFraction>&#160;as of December 31, 2021 and July 16, 2021, respectively, based on the publicly stated closing price. The fair value of the Sponsor Warrants was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,600</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">34,764</ix:nonFraction>&#160;as of December 31, 2021 and July 16, 2021, respectively.&#160;<ix:nonNumeric id="F_000412" name="celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXSponsorWarrantsMember_20210101_20211231" escape="true" continuedAt="F_000412_cnt_1">Significant inputs for the Sponsor Warrants are as follows:</ix:nonNumeric></span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><ix:continuation id="F_000412_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common share price</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000607" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231" decimals="INF">5.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000608" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716" decimals="INF">10.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000609" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231" decimals="2">11.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000610" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716" decimals="2">11.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000611" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20211231" decimals="0">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000612" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20210716" decimals="0">0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000613">4.5</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000614">5.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000615" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231" decimals="2">1.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000616" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20210716" decimals="2">0.79</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000617" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20211231" decimals="1">63.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000618" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20210716" decimals="1">50.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the warrants issued to Dragasac was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">33,435</ix:nonFraction>&#160;as of July 16, 2021. On the Closing Date, the Dragasac warrants qualified for equity classification and were reclassified accordingly.&#160;<ix:nonNumeric id="F_000413" name="celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210101_20211231" escape="true" continuedAt="F_000413_cnt_1">Significant inputs for the warrants issued to Dragasac are as follows:</ix:nonNumeric></span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p><ix:continuation id="F_000413_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.66 - 10.20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17 - 6.95</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price <sup style="font-size:85%;line-height:120%;vertical-align:top">a</sup></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000624" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716" decimals="2">6.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000625" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231" decimals="2">6.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000626">3.67</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33 - 1.33</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000629" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716" decimals="0">54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000630" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231" decimals="0">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000631" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716" decimals="2">0.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09% - 0.10%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;"><ix:footnote id="FNT_000001" xml:lang="en-US">The exercise price is the lower of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000634" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231" decimals="2">6.77</ix:nonFraction>&#160;per share or&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000635" name="celu:PercentageOfExercisePrice" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231" decimals="2" scale="-2">80</ix:nonFraction>% of either&#160;<ix:nonNumeric id="F_000636" name="celu:ClassOfWarrantExercisePriceDescription" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210101_20211231">(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</ix:nonNumeric></ix:footnote></span></p></td></tr></table></div></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000360_dcnt_132e9fe6-0331-486d-9586-7b566885d13a">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the warrants issued in connection with the Legacy Celularity Series B Preferred Stock was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="celu:FairValueOfWarrants" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716" decimals="-3" format="ixt:numdotdecimal" scale="3">62,963</ix:nonFraction>&#160;as of July 16, 2021. On the Closing Date, these warrants qualified for equity classification and were reclassified accordingly.&#160;<ix:nonNumeric id="F_000414" name="celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210101_20211231" escape="true" continuedAt="F_000414_cnt_1">Significant inputs for the warrants issued in connection with the Legacy Celularity Series B Preferred Stock are as follows:</ix:nonNumeric></span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><ix:continuation id="F_000414_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.66 - 10.20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17 - 6.95</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price <sup style="font-size:85%;line-height:120%;vertical-align:top">b</sup></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000642" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716" decimals="2">7.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000643" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="2">7.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">3.67</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33 - 1.33</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000647" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716" decimals="0">54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000648" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231" decimals="0">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000649" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716" decimals="2">0.60</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09% - 0.10%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;"></span><span style="Background-color:#FFFFFF;"><ix:footnote id="FNT_000002" xml:lang="en-US">The warrants are exercisable at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000652" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231" decimals="2">7.53</ix:nonFraction>&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</ix:footnote></span></p></td></tr></table></div></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation of the Convertible Note Receivable</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The convertible note receivable was received in connection with the disposition of the UltraMIST/MIST business. At any time on or after January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted into Sanuwave common stock at a defined rate. The convertible promissory note was to be paid on or before August 6, 2021, however, remains outstanding in full at December 31, 2021. The fair value of this note was determined using Level 3 inputs and is based on a bond valuation which employs a credit default model as of December 31, 2020. As of December 31, 2021, the Company utilized Level 3 inputs on a probability weighted model based on outcomes of a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions.</p><ix:nonNumeric id="F_000415" name="celu:ScheduleOfConvertibleNoteValuationModelTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant inputs for the convertible note valuation model are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="celu:FaceValueOfNotesReceivable" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="celu:FaceValueOfNotesReceivable" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coupon rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12% - 17%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000657" name="celu:PercentageOfCouponRate" contextRef="C_0001752828_20200101_20201231" decimals="2" scale="-2">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000658" name="celu:ValuationModelThatRelateToSanuwaveCommonStock" contextRef="C_0001752828_20211231" decimals="INF">0.17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000659" name="celu:ValuationModelThatRelateToSanuwaveCommonStock" contextRef="C_0001752828_20201231" decimals="INF">0.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.7 - 3.19</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000662">0.6</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000663" name="celu:ValuationInputForConvertiblePromissoryNote" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231" decimals="2">0.29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000664" name="celu:ValuationInputForConvertiblePromissoryNote" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20201231" decimals="2">0.09</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000665" name="celu:ValuationInputForConvertiblePromissoryNote" contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20201231" decimals="0">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000361" name="us-gaap:InventoryDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000361_dcnt_012f3cab-3fb3-4930-ac3f-4cf8d8f9c913">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.&#160;&#160;&#160;&#160;&#160;Inventory</p><ix:nonNumeric id="F_000416" name="celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s major classes of inventories were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="celu:InventoryRawMaterialsCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="celu:InventoryRawMaterialsCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in progress</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="celu:InventoryWorkInProgressCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="celu:InventoryWorkInProgressCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">460</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="celu:InventoryFinishedGoodsCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="celu:InventoryFinishedGoodsCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, gross</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="celu:InventoryGrossCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="celu:InventoryGrossCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,852</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: inventory reserves</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="celu:InventoryReserveCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" scale="3">48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="celu:InventoryReserveCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="celu:InventoryNetCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="celu:InventoryNetCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Classification:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:InventoryNet" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,549</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:InventoryNet" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:InventoryNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,721</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:InventoryNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,998</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="celu:InventoryNetCurrentAndNoncurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="celu:InventoryNetCurrentAndNoncurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000361_dcnt_012f3cab-3fb3-4930-ac3f-4cf8d8f9c913">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.</p></ix:continuation><ix:nonNumeric id="F_000362" name="celu:PrepaidExpensesDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.&#160;&#160;&#160;&#160;&#160;Prepaid Expenses</p><ix:nonNumeric id="F_000417" name="celu:ScheduleOfPrepaidExpensesTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="celu:PrepaidClinicalExpense" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,269</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="celu:PrepaidClinicalExpense" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:PrepaidInsurance" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:PrepaidInsurance" contextRef="C_0001752828_20201231" decimals="-3" scale="3">206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000363" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.&#160;&#160;&#160;&#160;&#160;Property and Equipment, Net</p><ix:continuation id="F_000406_cnt_2">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,513</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvement<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">71,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,289</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and production equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,395</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,884</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery, equipment and fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,054</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">105,404</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,086</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">90,077</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:88.89%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><ix:footnote id="FNT_000003" xml:lang="en-US">Includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:SaleLeasebackTransactionHistoricalCost" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:SaleLeasebackTransactionHistoricalCost" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,513</ix:nonFraction></ix:nonFraction> at December 31, 2021 and 2020 under financing lease resulting from a failed sale leaseback (see Note 11).</ix:footnote></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><ix:footnote id="FNT_000004" xml:lang="en-US">Includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:SaleLeasebackTransactionHistoricalCost" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,959</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:SaleLeasebackTransactionHistoricalCost" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,273</ix:nonFraction> at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</ix:footnote></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><ix:footnote id="FNT_000005" xml:lang="en-US">Includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,971</ix:nonFraction> $<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction> at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</ix:footnote></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:Depreciation" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,625</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:Depreciation" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,780</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Construction in progress</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,054</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,773</ix:nonFraction> as of December&#160;31, 2021 and 2020 primarily relates to the leasehold improvements made at the Company&#8217;s leased facilities in Florham Park, NJ.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000364" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000364_dcnt_488da60c-9918-466e-936d-4965766bdcb9">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.&#160;&#160;&#160;&#160;&#160;Goodwill and Intangible Assets, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs its annual goodwill impairment test in the fourth quarter of every year, unless a triggering event occurs prior to the impairment test. Based on the Company&#8217;s annual assessment performed during the fourth quarter of 2021, it was determined that goodwill was not impaired. </p><ix:nonNumeric id="F_000419" name="us-gaap:ScheduleOfGoodwillTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of goodwill assigned to the Company&#8217;s operating segments are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell Therapy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disease</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Biobanking</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="us-gaap:Goodwill" contextRef="C_0001752828_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">127,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of goodwill related to sale of UltraMIST business</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:Goodwill" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:Goodwill" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:Goodwill" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:88.89%;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000364_dcnt_488da60c-9918-466e-936d-4965766bdcb9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets, Net</p><ix:nonNumeric id="F_000420" name="celu:ScheduleOfIntangibleAssetsNetTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lives</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangible assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 &#8211; 16 years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,413</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000765" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20200101_20201231" format="ixt-sec:duryear"><ix:nonNumeric id="F_000758" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20210101_20211231" format="ixt-sec:duryear">10</ix:nonNumeric></ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names &#38; trademarks</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20211231" decimals="-3" scale="3">570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20201231" decimals="-3" scale="3">570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 &#8211; 13 years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquired rights</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000766" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20200101_20201231" format="ixt-sec:duryear"><ix:nonNumeric id="F_000759" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20210101_20211231" format="ixt-sec:duryear">6</ix:nonNumeric></ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000741" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20201231" decimals="-3" scale="3">906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names &#38; trademarks</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20211231" decimals="-3" scale="3">220</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20201231" decimals="-3" scale="3">165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquired rights</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,540</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,840</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,306</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,114</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,879</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-amortized intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired IPR&#38;D product rights</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="celu:AcquiredProductRights" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">108,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="celu:AcquiredProductRights" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">108,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000760">indefinite</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">123,187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">125,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense for intangible assets was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,192</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,394</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively.</p><ix:nonNumeric id="F_000421" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December&#160;31, 2021 is estimated as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,784</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,356</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2020, the Company experienced a triggering event as it discontinued development of PDA-001&#160;for an indefinite period of time and opted to pursue an alternative clinical program. As of September&#160;30, 2020, the Company determined PDA-001&#160;did not have future cash flows as the Company did not intend to further develop and commercialize the asset. The triggering event required the Company to perform a quantitative impairment test as of September&#160;30, 2020. As a result of this impairment test, the Company recorded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001752828_20200701_20200930" decimals="-3" format="ixt:numdotdecimal" scale="3">129,400</ix:nonFraction> impairment charge to write-off&#160;the entire IPR&#38;D intangible asset related to PDA-001.</p></ix:continuation><ix:nonNumeric id="F_000365" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.&#160;&#160;&#160;&#160;&#160;Accrued expenses and&#160;other current liabilities</p><ix:nonNumeric id="F_000422" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="celu:AccruedClinicalTrialExpense" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="celu:AccruedClinicalTrialExpense" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,653</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued wages, bonuses, commissions and vacation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,824</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals for construction in progress</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="celu:AccrualsForConstructionInProgress" contextRef="C_0001752828_20201231" decimals="-3" scale="3">171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001752828_20211231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0001752828_20201231" decimals="-3" scale="3">292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,661</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000366" name="us-gaap:ShortTermDebtTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000366_dcnt_d4be9309-13da-4833-b2d3-582d3a30c603">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.&#160;&#160;&#160;&#160;&#160;Short-term borrowings &#8211; related party</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On June 8, 2021, Legacy Celularity entered into a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:DebtInstrumentFaceAmount" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608" decimals="INF" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction>&#160;loan agreement with C.V. Starr &#38; Co., Inc. (&#8220;CV Starr&#8221;), a stockholder of the Company. The loan accrued interest on outstanding principal at a rate equal to (a)&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000794" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210731" decimals="INF" scale="-2">8.0</ix:nonFraction>% per year until, and including, July 31, </span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000366_dcnt_d4be9309-13da-4833-b2d3-582d3a30c603">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2021</span><span style="Background-color:#FFFFFF;"> and (b)&#160;</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000795" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210801" decimals="INF" scale="-2">10.0</ix:nonFraction></span><span style="Background-color:#FFFFFF;">% per </span><span style="Background-color:#FFFFFF;">year</span><span style="Background-color:#FFFFFF;"> commencing on, and including August 1, 2021. Accrued and unpaid interest was payable on July 31, 2021, the last day of each month thereafter, on the date of any prepayment of the loan, on the maturity date and, after the maturity date, on demand. The loan&#160;was required to be&#160;paid in full on the earlier of (</span><span style="Background-color:#FFFFFF;">i</span><span style="Background-color:#FFFFFF;">)&#160;</span><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000796" name="us-gaap:DebtInstrumentMaturityDate" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210101_20211231" format="ixt:datemonthdayyearen">June 8, 2022</ix:nonNumeric></span><span style="Background-color:#FFFFFF;">, (ii) the date of the consummation of the&#160;Business Combination&#160;and (iii) the date the outstanding principal&#160;was&#160;declared due and payable by CV Starr as remedy to an event of default (the &#8220;Maturity Date&#8221;). On the earlier of (</span><span style="Background-color:#FFFFFF;">i</span><span style="Background-color:#FFFFFF;">) the Maturity Date or (ii) the date on which the loan&#160;was&#160;repaid in&#160;full&#160;and the commitments of CV Starr&#160;were&#160;terminated,&#160;Legacy&#160;</span><span style="Background-color:#FFFFFF;">Celularity</span><span style="Background-color:#FFFFFF;">&#160;was required to&#160;pay CV Starr an exit fee in an amount equal to&#160;</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000797" name="celu:ShortTermBorrowingAmountEqualToExitFeePercentage" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210607_20210608" decimals="3" scale="-2">2.0</ix:nonFraction></span><span style="Background-color:#FFFFFF;">% of the aggregate principal amount of the loan advanced.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the terms of the loan, Legacy Celularity could not permit the aggregate amount of cash and cash equivalents to be less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction>&#160;for more than&#160;<ix:nonFraction unitRef="U_celuDay" id="F_000799" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210607_20210608" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction>&#160;consecutive business days. Legacy Celularity could not borrow an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608" decimals="INF" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction>&#160;under the loan agreement should it project that the aggregate amount of its cash and cash equivalents would be less than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction>&#160;prior to the consummation of the Business Combination.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, the Company repaid amounts outstanding under the short term borrowing arrangement with CV Starr and the arrangement was cancelled. Total amount paid to CV Starr was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="celu:RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,146</ix:nonFraction>, which included principal, accrued interest and the exit fee.</span></p></ix:continuation><ix:nonNumeric id="F_000367" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000367_dcnt_51ab6f90-f5e2-42ad-b475-9f9a1da96889">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;&#160;&#160;&#160;&#160;Commitments and&#160;contingencies</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2017, Legacy Celularity entered into an operating lease for office space in Warren, New Jersey, which expires in <ix:nonNumeric id="F_000803" name="celu:OperatingLeaseExpiryYear" contextRef="C_0001752828_srtStatementGeographicalAxis_celuWarrenNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeSpaceMember_20170901_20170930">2022</ix:nonNumeric>. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000804" name="us-gaap:RestrictedCashEquivalentsCurrent" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231" decimals="-3" scale="3">481</ix:nonFraction>, which is classified as restricted cash (non-current) on the consolidated balance sheets as of December 31, 2020. During the second quarter of 2021, the full $481 was drawn by the landlord. During the third quarter of 2021, the lease for office space in Warren, New Jersey was terminated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 10, 2019, Legacy Celularity extended the operating lease for the office and laboratory space in Cedar Knolls, New Jersey on a month-to-month basis. Beginning November 1, 2019, Legacy Celularity began paying the landlord the base annual rent and all additional rent at a <ix:nonFraction unitRef="U_xbrlipure" id="F_000805" name="celu:PercentageIncreaseInBaseAnnualRent" contextRef="C_0001752828_srtStatementGeographicalAxis_celuCedarKnollsNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeAndLaboratorySpaceMember_20191101_20191101" decimals="2" scale="-2">2</ix:nonFraction>% increase, pro-rated monthly for each month it remains in possession of the premises. Monthly lease payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000806" name="us-gaap:OperatingLeasePayments" contextRef="C_0001752828_srtStatementGeographicalAxis_celuCedarKnollsNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeAndLaboratorySpaceMember_20191101_20191101" decimals="-3" scale="3">15</ix:nonFraction> due under the lease include base rent and ancillary charges.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 13, 2019, Legacy Celularity entered into a lease agreement for a <ix:nonFraction unitRef="U_utrsqft" id="F_000807" name="celu:AreaOfBuildings" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313" decimals="0" format="ixt:numdotdecimal">147,215</ix:nonFraction> square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in <ix:nonNumeric id="F_000808" name="celu:OperatingLeaseExpiryYear" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313">2036</ix:nonNumeric>. The Company has the option to renew the term of the lease for two additional <span style="-sec-ix-hidden:F_000809">five-year</span> terms so long as the lease is then in full force and effect. The lease term commenced on <ix:nonNumeric id="F_000810" name="celu:OperatingLeaseCommencementDate" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313" format="ixt:datemonthdayyearen">March 1, 2020</ix:nonNumeric> subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly base rent is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="celu:InitialMonthlyBaseRent" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313" decimals="-3" scale="3">230</ix:nonFraction> and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000812" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,722</ix:nonFraction></ix:nonFraction> which is classified as restricted cash (non-current) on the consolidated balance sheet as of December 31, 2021 and December 31, 2020. The lease agreement allows for a landlord provided tenant improvement allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:TenantImprovements" contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313" decimals="-3" format="ixt:numdotdecimal" scale="3">14,722</ix:nonFraction> to be applied to the costs of the construction of the leasehold improvements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not the legal owner of the leased space. However, in accordance with Accounting Standards Codification 840, Leases, the Company is deemed to be the owner of the leased space, including the building shell, during the construction period because of the Company&#8217;s level of direct financial and operational involvement in the substantial tenant improvement. The lease arrangement did not meet all the criteria for sale-leaseback accounting due to the continuing involvement of the Company in the property and therefore was accounted for as a failed sale-leaseback financing obligation. As a result, as of December 31, 2019, Legacy Celularity capitalized the fair value of the building shell, the tenant improvement allowance, and ground rent expense, approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000815" name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,062</ix:nonFraction>, as construction-in-progress within property and equipment, net and recorded a corresponding build-to-suit facility lease financing obligation. As of December 31, 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000816" name="celu:FinancingObligationsNoncurrent" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,085</ix:nonFraction> related to the lease financing obligation was classified as a long-term capital lease liability on its consolidated balance sheet, while $<ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="celu:FinancingObligationsCurrent" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,051</ix:nonFraction> was classified as a current liability.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, construction costs incurred as part of the build-out and tenant improvements were capitalized as construction-in-progress within property and equipment, net. Legacy Celularity began to occupy completed portions of the facility in the first quarter of 2020. As the building was occupied, costs were moved out of construction-in-process and were placed in service. As of December 31, 2021 and 2020, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231" decimals="-3" scale="3">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,415</ix:nonFraction> of costs related the facility included in construction-in-progress, respectively. Remaining construction was completed during January 2021 and remaining construction-in-progress costs were placed in service.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes rent expense on a straight-line basis over the respective lease period and has recorded deferred rent for rent expense incurred but not yet paid. Rent expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">668</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,612</ix:nonFraction> for the years ended December 31, 2021 and 2020, respectively.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000367_dcnt_51ab6f90-f5e2-42ad-b475-9f9a1da96889" continuedAt="F_000367_dcnt_0671e349-8f17-4126-a05a-231aada8cae3"><ix:nonNumeric id="F_000423" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments inclusive of the amended lease, by year and in aggregate, under non-cancelable&#160;leases consist of the following as of December&#160;31, 2021:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,531</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000828" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,414</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Related to Business Combinations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s acquisition of HLI CT, Anthrogenesis and CariCord, the Company has agreed to pay future consideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000829" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">232,222</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">273,367</ix:nonFraction> as contingent consideration as of December&#160;31, 2021 and 2020, respectively. Due to the contingent nature of these milestone and royalty payments, there is a high degree of management estimates that determine the fair value of the contingent consideration. See note 4 for further discussion. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2021 or 2020.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Palantir Technologies Inc.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2021, Legacy Celularity executed a Master Subscription Agreement with Palantir under which it will pay $<ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="celu:PaymentsForMasterSubscriptionAgreement" contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210505_20210505" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction>&#160;over&#160;<ix:nonNumeric id="F_000832" name="celu:PaymentSubscriptionPeriod" contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210505_20210505" format="ixt-sec:durwordsen">five years</ix:nonNumeric>&#160;for access to Palantir&#8217;s Foundry platform along with certain professional services. The Company will utilize Palantir&#8217;s Foundry platform to secure deeper insights into data obtained from the Company&#8217;s discovery and process development, as well as manufacturing and biorepository operations. During the third quarter of 2021, the Company paid its first annual fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="celu:AnnualFeePaid" contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,000</ix:nonFraction>. For the year ended December 31, 2021, the Company has recorded costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,333</ix:nonFraction>&#160;on a straight-line basis related to this agreement, which was included as a component of selling, general and administrative expense in the consolidated statement of operations.</p>
<p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sirion License Agreement </p>
<p style="text-align:justify;margin-top:7pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2021, the Company entered into a license agreement (&#8220;Sirion License&#8221;) with Sirion Biotech GmbH (&#8220;Sirion&#8221;). Under the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (&#8220;Licensed Product&#8221;). As part of the Sirion License, the Company will pay Sirion $<ix:nonFraction unitRef="U_iso4217USD" id="F_000835" name="celu:UpfrontFee" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231" decimals="-3" scale="3">136</ix:nonFraction> as an upfront fee, a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000836" name="celu:AnnualMaintenanceFee" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231" decimals="-3" scale="3">113</ix:nonFraction> annual maintenance fee and may owe up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000837" name="celu:ClinicalAndRegulatoryMilestones" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,099</ix:nonFraction> million related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration of the last to expire valid claim of the patents covering such Licensed Product, and (ii) <ix:nonNumeric id="F_000838" name="us-gaap:LongtermPurchaseCommitmentPeriod" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231" format="ixt-sec:duryear">10</ix:nonNumeric> years after first Commercial Sale of a Licensed Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company for convenience upon <ix:nonNumeric id="F_000839" name="celu:LicenseAgreementNoticePeriod" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231" format="ixt-sec:durday">30</ix:nonNumeric> days written notice. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 24, 2021, CTH Biosourcing LLC (&#8220;CTH&#8221;) filed a petition and request for disclosure in the District Court of Travis County, Texas seeking declaratory relief challenging Legacy Celularity&#8217;s for-cause termination of a Tissue Procurement Agreement (&#8220;TPA&#8221;). During the year ended December 31, 2021, the Company entered into a tri-party settlement with CTH and the CariCord </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000367_dcnt_0671e349-8f17-4126-a05a-231aada8cae3">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">participating shareholders, as interested parties, in which the Company agreed to amend the TPA in exchange for a full release of all claims underlying the aforementioned litigation. In addition, the Company issued</span><span style="font-size:12pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000840" name="celu:NumberOfSharesIssuedInLegalSettlementAgreement" contextRef="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210324_20210324" decimals="INF" format="ixt:numdotdecimal">743,771</ix:nonFraction><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Celularity </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class A Common Stock to the CariCord participating shareholders</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with an estimated fair value of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="celu:EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" contextRef="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,333</ix:nonFraction><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in exchange for a full release</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This amount was recorded as a legal settlement expense within selling, general and administrative in the statement of operations for the year ended December 31, 2021. Pursuant to the settlement agreement, the CariCord participating shareholders are entitled to receive up to an additional </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000842" name="celu:NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" contextRef="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210324_20210324" decimals="INF" format="ixt:numdotdecimal">371,885</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Celularity Class A Common Stock if certain procurement targets are met by CTH under the TPA during a specified period, which was not probable of being achieved at December 31, 2021.</span><span style="font-size:12pt;"> </span></p></ix:continuation><ix:nonNumeric id="F_000368" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000368_dcnt_bbba6830-4951-404f-9c0d-f54b6dac87e4">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.&#160;&#160;&#160;&#160;&#160;Equity</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Subsequent to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000843" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231" decimals="INF" format="ixt:numdotdecimal">730,000,000</ix:nonFraction>&#160;shares of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000844" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231" decimals="INF">0.0001</ix:nonFraction>&#160;par value Class A common stock.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Voting Power</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company&#8217;s directors and all other matters requiring stockholder action. Holders of&#160;<ix:nonNumeric id="F_000845" name="us-gaap:CommonStockVotingRights" contextRef="C_0001752828_20210101_20211231">common stock are entitled to one vote per share</ix:nonNumeric>&#160;on matters to be voted on by stockholders.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Dividends</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Holders of Class A Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#8217;s board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Liquidation, Dissolution and Winding Up</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the event of the Company&#8217;s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company&#8217;s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Preemptive or Other Rights</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Election of Directors</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class serving a three-year&#160;term, except with respect to the election of directors at the special meeting held in connection with the merger with GX. Class I directors are elected to an initial one-year&#160;term (and three-year&#160;terms subsequently), the Class II directors are elected to an initial two-year&#160;term (and three-year&#160;terms subsequently) and the Class III directors are elected to an initial three-year&#160;term (and three-year&#160;terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000846" name="celu:PercentageOfSharesRequiredForVoting" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20211231" decimals="INF" scale="-2">50</ix:nonFraction>% of the shares voted for the election of directors can elect all of the directors.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Prior to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of&#160;December&#160;31, 2020, Legacy Celularity&#8217;s certificate of incorporation, as amended and restated, authorized Legacy Celularity to issue&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000847" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231" decimals="INF" format="ixt:numdotdecimal">155,640,290</ix:nonFraction>&#160;shares of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000848" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231" decimals="INF">0.0001</ix:nonFraction>&#160;par value common stock. The voting, dividend and liquidation rights of the holders of Legacy Celularity&#8217;s common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock (as set forth below).</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Each share of&#160;<ix:nonNumeric id="F_000849" name="us-gaap:CommonStockVotingRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20200101_20201231">common stock entitled the holder to one vote</ix:nonNumeric>&#160;on all matters submitted to a vote of Legacy Celularity stockholders. The holders of common stock, voting exclusively and as a separate class, were entitled to elect one director of the Legacy Celularity. Common stockholders were entitled to receive dividends, as was declared by the board of directors, if any, subject to the preferential dividend rights of Preferred Stock. Through the Closing Date, no cash dividends were declared or paid.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000368_dcnt_bbba6830-4951-404f-9c0d-f54b6dac87e4" continuedAt="F_000368_dcnt_5fd30447-b834-4550-a02f-ae48f746b37b">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December&#160;31, 2020, Legacy Celularity had&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000850" name="us-gaap:TreasuryStockShares" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231" decimals="INF" format="ixt:numdotdecimal">90,834</ix:nonFraction>&#160;of repurchased shares recorded as treasury stock. On the Closing Date, previously existing Legacy Celularity shares held in treasury were cancelled without any conversion.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Subsequent to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s Certificate of Incorporation authorized&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000851" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction>&#160;shares of preferred stock and provides that shares of preferred stock may be issued from time to time in one or more series. The Company&#8217;s board of directors is authorized to fix the voting rights, if any, designations, powers and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The Company&#8217;s board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and could have anti-takeover effects. The ability of the Company&#8217;s board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management. As of December 31, 2021, the Company does&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000852" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000853" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any outstanding preferred stock.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Prior to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Legacy Celularity issued Series A convertible redeemable preferred stock (the &#8220;Series A Preferred Stock&#8221;), Series B convertible redeemable preferred stock (the &#8220;Series B Preferred Stock&#8221;), and Series X convertible redeemable preferred stock (the &#8220;Series X Preferred Stock&#8221;). The Series A Preferred Stock, Series B Preferred Stock, and Series X Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221;. Immediately prior to closing of the Business Combination on July 16, 2021, the outstanding shares of Preferred Stock were converted into shares of Legacy Celularity common stock and then exchanged for the Company&#8217;s Class A common stock at the Effective Time. As of December&#160;31, 2020, Legacy Celularity certificate of incorporation, as amended and restated, authorized Legacy&#160;Celularity&#160;to issue a total of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000854" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">116,526,341</ix:nonFraction>&#160;shares&#160;of Preferred Stock, with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000855" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231" decimals="INF">0.0001</ix:nonFraction>&#160;per share. As of&#160;December&#160;31, 2020,&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000856" name="us-gaap:TemporaryEquitySharesSubscribedButUnissued" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>&#160;shares of Preferred Stock remained undesignated.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of Preferred Stock had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of Legacy Celularity. Therefore, the Preferred Stock was classified outside of stockholders&#8217; deficit on the consolidated balance sheet.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 16, 2020, Legacy Celularity entered into a Series B Preferred Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors and certain individual investors (collectively &#8220;Investors&#8221;). Pursuant to the terms of the Purchase Agreement, Legacy Celularity sold and issued to the Investors an aggregate of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000857" name="us-gaap:TemporaryEquitySharesIssued" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316" decimals="INF" format="ixt:numdotdecimal">13,620,063</ix:nonFraction>&#160;shares of Series B Preferred Stock and warrants to purchase up to an aggregate of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000858" name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316" decimals="INF" format="ixt:numdotdecimal">13,281,386</ix:nonFraction>&#160;shares of Series B Preferred Stock for an aggregate purchase price of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316" decimals="-3" format="ixt:numdotdecimal" scale="3">102,550</ix:nonFraction>. Legacy Celularity utilized a probability-weighted option pricing model to determine the fair value of the warrants at the issuance date with the residual proceeds allocated to the Series B Preferred Stock. Based on this valuation, Legacy Celularity determined the purchase price allocated to the Series B Preferred Stock was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316" decimals="-3" format="ixt:numdotdecimal" scale="3">84,596</ix:nonFraction>&#160;and the purchase price allocated to the warrants was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000861" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316" decimals="-3" format="ixt:numdotdecimal" scale="3">17,954</ix:nonFraction>.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Legacy Celularity&#8217;s classified Preferred Stock in accordance with Accounting Standards Codification 480,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">Distinguishing Liabilities from Equity</span><span style="Background-color:#FFFFFF;">, which required that contingently redeemable securities be classified outside of permanent stockholders&#8217; equity. Accordingly, Legacy Celularity classified all shares and classes of Preferred Stock as mezzanine equity on the accompanying consolidated balance sheets at December 31, 2021.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rights, Preferences and Privileges of the Preferred Stock</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of the Preferred Stock had the following rights and preferences except where noted:</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Voting</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of&#160;<ix:nonNumeric id="F_000862" name="us-gaap:PreferredStockVotingRights" contextRef="C_0001752828_20210101_20211231">Preferred Stock were entitled to vote</ix:nonNumeric>, together with the holders of common stock as a single class, on all matters submitted to stockholders for a vote and had the right to vote the number of shares equal to the number of shares of common stock into which each share of Preferred Stock could convert on the record date for determination of stockholders entitled to vote.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As long as there were at least&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000863" name="celu:NumberOfSharesRequiredToBeOutstandingForVoting" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBPreferredStockPurchaseAgreementsMember_20211231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction>&#160;shares of Series B Preferred Stock outstanding, the holders of Series B Preferred Stock, voting as a separate class, could elect one director of Legacy Celularity. The remaining directors were elected by holders of common stock and Preferred Stock, voting together as a single class on an as converted basis.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000368_dcnt_5fd30447-b834-4550-a02f-ae48f746b37b" continuedAt="F_000368_dcnt_a7775c6c-1977-4a77-9f5c-b7aad3df9da8">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Conversion</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Each share of Preferred Stock was convertible, at the option of the holder, at any time after the date of issuance. In addition, each share of Preferred Stock could automatically converted into shares of common stock at the applicable conversion ratio then in effect (i)&#160;upon the closing of a firm-commitment public offering resulting in at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal" scale="3">50,000</ix:nonFraction>&#160;of gross proceeds to Legacy Celularity at a price of at least $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000865" name="celu:ConversionPricePerShareOfCommonStock" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231" decimals="INF">9.41</ix:nonFraction>&#160;per share of common stock, subject to appropriate adjustment of any recapitalization (&#8220;Qualified IPO&#8221;), or (ii)&#160;upon the written consent of the holders of a majority of the then-outstanding shares of Preferred Stock, voting together as a single class.</span></p><ix:nonNumeric id="F_000869" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210101_20211231"><p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The conversion ratio of each series of Preferred Stock was determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price per share was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000866" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStocksMember_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000867" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStocksMember_20211231" decimals="INF">6.27</ix:nonFraction></ix:nonFraction>&#160;for Series A and X Preferred Stock (the &#8220;Series A and X Original Issue Price&#8221;) and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000868" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemablesConvertiblePreferredStocksMember_20211231" decimals="INF">7.53</ix:nonFraction>&#160;for Series B Preferred Stock (the &#8220;Series B Original Issue Price&#8221;), each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in Legacy Celularity&#8217;s certificate of incorporation, as amended and restated. As of December&#160;31, 2020 and the Closing Date, the Conversion Price was equal to the Original Issue Price for each series of Preferred Stock. Accordingly, as of December&#160;31, 2020 and the Closing Date, each share of each series of Preferred Stock was convertible into shares of Legacy Celularity common stock on a&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000870" name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction>-for-one basis.</span></p></ix:nonNumeric>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Dividends</span></p><ix:nonNumeric id="F_000873" name="us-gaap:PreferredStockDividendPaymentTerms" contextRef="C_0001752828_20210101_20211231"><p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000871" name="us-gaap:PreferredStockDividendRatePercentage" contextRef="C_0001752828_20210101_20211231" decimals="INF" scale="-2">6</ix:nonFraction>% of the Original Issue Price per year&#59; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date,&#160;<ix:nonFraction unitRef="U_iso4217USD" id="F_000872" name="us-gaap:DividendsPreferredStockCash" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>&#160;cash dividends were declared or paid.</span></p></ix:nonNumeric>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Liquidation</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of Legacy Celularity or Deemed Liquidation Event (as defined below), each holder of the then-outstanding Preferred Stock was entitled to receive the greater of (i)&#160;an amount equal to the Original Issue Price for each series of Preferred Stock plus any dividends declared but unpaid thereon or (ii)&#160;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event at the conversion price. In the event that the assets available for distribution to stockholders&#160;were&#160;insufficient to pay Preferred&#160;Stock holders&#160;the full amounts to which they&#160;were&#160;entitled, the assets available for distribution&#160;were to&#160;be distributed on a pro rata basis among the holders of the Preferred Stock in proportion to the respective amounts that would otherwise be payable in respect of such shares.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">After the payment of all preferential amounts to the holders of Preferred Stock, then, to the extent available, the remaining assets of Legacy Celularity were to be distributed among the holders of common stock, pro rata based on the number of shares held by each such holder.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Unless (i)&#160;the holders of Series B Preferred Stock received an amount less the Original Issue Price or (ii)&#160;the holders of majority of the then-outstanding Preferred Stock, voting together as a single class, elect otherwise, a Deemed Liquidation Event included a merger or consolidation (other than one in which stockholders of Legacy Celularity own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of Legacy Celularity.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Redemption</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Legacy Celularity&#8217;s certificate of incorporation, as amended and restated, did not provide redemption rights to the holders of Preferred Stock.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Legacy Celularity Warrants</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On May 7, 2018, Legacy Celularity granted Dragasac a warrant for the purchase of an aggregate of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000874" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20180507" decimals="INF" format="ixt:numdotdecimal">16,601,736</ix:nonFraction>&#160;shares of Series B Preferred Stock (the &#8220;Dragasac Warrant&#8221;) at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000875" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20180507" decimals="INF">7.53</ix:nonFraction>&#160;per share. On February 15, 2019, Dragasac exercised its rights under the Dragasac Warrant to purchase&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000876" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215" decimals="INF" format="ixt:numdotdecimal">6,640,695</ix:nonFraction>&#160;shares of Series B Preferred Stock, at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000877" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215" decimals="INF">7.53</ix:nonFraction>&#160;per share, for gross proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215_20190215" decimals="-3" format="ixt:numdotdecimal" scale="3">50,000</ix:nonFraction>. On May 29, 2019, Legacy Celularity amended and restated the Dragasac Warrant to provide for a reduced exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000879" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedAndRestatedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190529" decimals="INF">7.29</ix:nonFraction>&#160;for the remaining warrant shares in exchange for Dragasac agreeing to purchase&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000880" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedAndRestatedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190529" decimals="INF" format="ixt:numdotdecimal">3,431,223</ix:nonFraction>&#160;shares of Series B Preferred Stock on or before May 31, 2019. On May 31, 2019, Dragasac exercised its rights under the Dragasac Warrant to purchase&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000881" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531" decimals="INF" format="ixt:numdotdecimal">3,431,223</ix:nonFraction>&#160;shares of Series B Preferred Stock at a price per share of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000882" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531" decimals="INF">7.29</ix:nonFraction>, for gross proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531_20190531" decimals="-3" format="ixt:numdotdecimal" scale="3">25,000</ix:nonFraction>. On November 1, 2019, Legacy Celularity again amended the Dragasac Warrant to provide for a reduced exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000884" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191101" decimals="INF">6.77</ix:nonFraction>&#160;for the remaining warrant shares in exchange for Dragasac agreeing to purchase&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000885" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191101" decimals="INF" format="ixt:numdotdecimal">6,529,818</ix:nonFraction>&#160;shares of Series B Preferred Stock on or before </span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000368_dcnt_a7775c6c-1977-4a77-9f5c-b7aad3df9da8" continuedAt="F_000368_dcnt_b09672f3-d1de-460e-ac8d-8d351b2bdcf1">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">November 4, 2019. On November 4, 2019, </span><span style="Background-color:#FFFFFF;">Dragasac</span><span style="Background-color:#FFFFFF;"> exercised its right to purchase&#160;</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000886" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104" decimals="INF" format="ixt:numdotdecimal">6,529,818</ix:nonFraction>&#160;</span><span style="Background-color:#FFFFFF;">shares of Series B Preferred Stock, at a price per share of $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000887" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104" decimals="INF">6.77</ix:nonFraction></span><span style="Background-color:#FFFFFF;">, for gross proceeds of approximately $</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104_20191104" decimals="-3" format="ixt:numdotdecimal" scale="3">44,178</ix:nonFraction></span><span style="Background-color:#FFFFFF;">.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 9, 2020, Legacy Celularity issued a warrant for the purchase of an aggregate of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000889" name="us-gaap:SharesIssued" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109" decimals="INF" format="ixt:numdotdecimal">6,529,818</ix:nonFraction>&#160;shares of Series B Preferred Stock to Dragasac. The exercise price per share at which the warrant will be exercised shall be the lesser of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000890" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109" decimals="INF">6.77</ix:nonFraction>&#160;per share or&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000891" name="celu:WarrantsPerSharePercentage" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109" decimals="2" scale="-2">80</ix:nonFraction>% of either (i)&#160;the value attributed to one share of Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of the common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange. The estimated fair value of the warrant of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000892" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109_20200109" decimals="0" format="ixt:numdotdecimal">11,988</ix:nonFraction>&#160;at the issuance date was immediately charged to expense and recorded in expense related to warrant liabilities in the accompanying consolidated statements of operations. The incremental change in fair value resulting from the amendment was also immediately charged to expense and recorded in the same line item.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 8, 2021, Legacy Celularity entered into a warrant amendment agreement (&#8220;Amendment No.&#160;2&#8221;) to amend the warrant issued to Dragasac on January 9, 2020, as amended on March 16, 2020. Amendment No.&#160;2 added a cashless exercise provision and eliminated the provision that would have provided for expiration of the warrant upon consummation of the Business Combination. Any portion of the warrant that was unexercised prior to consummation of the Business Combination converted into warrants to purchase shares of the Company&#8217;s Class&#160;A common stock, with the exercise price and number of shares adjusted as per the exchange ratio and the terms of the Merger Agreement (see Note 3). This amendment did not result in any changes to the accounting for these warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 16, 2020, Legacy Celularity entered into the Purchase Agreement with the Investors. Pursuant to the terms of the Purchase Agreement, Legacy Celularity sold and issued to the Investors an aggregate of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000893" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316_20200316" decimals="INF" format="ixt:numdotdecimal">13,620,063</ix:nonFraction>&#160;shares of Series B Preferred Stock and warrants to purchase up to an aggregate of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000894" name="celu:NumberOfWarrantsIssued" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316" decimals="INF" format="ixt:numdotdecimal">13,281,386</ix:nonFraction>&#160;shares of Series B Preferred Stock for an aggregate purchase price of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20200316_20200316" decimals="-3" format="ixt:numdotdecimal" scale="3">102,550</ix:nonFraction>. The warrants are exercisable at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000896" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316" decimals="INF">7.53</ix:nonFraction>&#160;per share on the first to occur of (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering and (c)&#160;the consummation of a change of control. On January 8, 2021, Legacy Celularity entered into a warrant amendment agreement to amend the warrant issued the Investors on March 16, 2020. The warrant was amended to add cashless exercise provisions following the consummation of the Business Combination. Any portion of warrant held by the Investors that was unexercised prior to the consummation of the Business Combination converted into a warrant to purchase shares of the Company&#8217;s Class&#160;A common stock, with the exercise price and number of shares adjusted as per the exchange ratio and the terms of the&#160;Merger&#160;Agreement&#160;(see Note 3). This amendment did not result in any changes to the accounting for these warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Prior to the Business Combination, Legacy Celularity classified the warrants as liabilities on its consolidated balance sheets because the warrants were freestanding financial instruments that might have required Legacy Celularity to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and was subsequently remeasured to fair value at each reporting date with the final remeasurement occurring on the Closing Date. Changes in the fair value of the warrant liability were recognized as a component of other income (expense), net in the consolidated statement of operations. On the Closing Date, the warrants held by Dragasac and the Investors were converted into warrants to purchase shares of the Company&#8217;s Class A common stock. The aforementioned warrants qualified for equity classification on the Closing Date and were reclassified accordingly.&#160;&#160;</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Legacy GX Warrants</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Upon consummation of the Business Combination, the Public Warrants and Sponsor Warrants remain outstanding.&#160;<ix:nonNumeric id="F_000897" name="celu:DescriptionOfExercisableTerms" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_celuLegacyGXWarrantMember_20210101_20211231">The Public Warrants became exercisable on <ix:nonNumeric id="F_000898" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" format="ixt:datemonthdayyearen">August 15, 2021</ix:nonNumeric>, which is the later of (a)&#160;<ix:nonNumeric id="F_000899" name="celu:WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" format="ixt-sec:durday">30</ix:nonNumeric>&#160;days after the consummation of a Business Combination or (b)&#160;<ix:nonNumeric id="F_000900" name="celu:WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" format="ixt-sec:durmonth">12</ix:nonNumeric>&#160;months from the effective date of the registration statement relating to GX&#8217;s initial public offering.</ix:nonNumeric>&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000901" name="celu:ClassOfWarrantOrRightWarrantsExercisableForCash" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction>&#160;Public Warrants would have been exercisable for cash unless the Company has an effective and current registration statement covering the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to such common shares. Notwithstanding the foregoing, if a registration statement covering the common shares issuable upon the exercise of the Public Warrants were not effective within 90 days from the consummation of the Business Combination, the holders could have, until such time as there was an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration were not available, holders would not have been able to exercise their Public Warrants on a cashless basis. The Company filed its registration statement on August 12, 2021. The Public Warrants will expire&#160;<ix:nonNumeric id="F_000902" name="celu:WarrantExpirationTerm" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" format="ixt-sec:durwordsen">five years</ix:nonNumeric>&#160;from the consummation of the Business Combination or earlier upon redemption or liquidation.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company may call the Public Warrants for redemption (excluding the Sponsor Warrants), in whole and not in part, at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000903" name="celu:PublicWarrantsCallPrice" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20211231" decimals="INF">0.01</ix:nonFraction>&#160;per warrant:</span></p><ix:nonNumeric id="F_000905" name="celu:DescriptionOfWarrantCallProvision" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" continuedAt="F_000905_dcnt_c1ca9c28-110c-4116-ac5d-dac5227d6114"><div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">at any time while the Public Warrants are exercisable,</span></p></td></tr></table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000368_dcnt_b09672f3-d1de-460e-ac8d-8d351b2bdcf1"><ix:continuation id="F_000905_dcnt_c1ca9c28-110c-4116-ac5d-dac5227d6114">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">upon not less than&#160;<ix:nonNumeric id="F_000904" name="celu:MinimumWrittenNoticePeriodForRedemption" contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231" format="ixt-sec:durday">30</ix:nonNumeric>&#160;days&#8217; prior written notice of redemption to each Public Warrant holder, and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">if, and only if, there is a current registration statement in effect with respect to the issuance of the common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing.</span></p></td></tr></table></div></ix:continuation>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Sponsor Warrants are identical to the Public Warrants underlying the units sold in GX&#8217;s initial public offering, except that the Sponsor Warrants and the common shares issuable upon the exercise of the Sponsor Warrants were not transferable, assignable or salable until after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Sponsor Warrants are held by someone other than the initial purchasers or their permitted transferees, the Sponsor Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The exercise price and number of shares of Class A common stock issuable upon exercise of the Public Warrants and Sponsor Warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of Class A common shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In order to finance transaction costs in connection with the Business Combination, members of GX&#8217;s sponsor, GX Sponsor LLC (the &#8220;Sponsor&#8221;), entered into promissory notes with GX to provide working capital funds. In connection with the Business Combination,&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000906" name="celu:AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorsMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,499,999</ix:nonFraction>&#160;Sponsor Warrants were issued to members of the Sponsor as repayment for the working capital loans made to GX.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2021, the Company had&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000907" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231" decimals="INF" format="ixt:numdotdecimal">42,686,195</ix:nonFraction>&#160;outstanding warrants to purchase Class A common stock.&#160;<ix:nonNumeric id="F_000424" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000424_cnt_1">A summary of the warrants is as follows:</ix:nonNumeric></span></p><ix:continuation id="F_000424_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dragasac Warrant</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000908" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231" decimals="INF" format="ixt:numdotdecimal">6,529,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000913" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231" decimals="INF">6.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000917" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231" format="ixt:datemonthdayyearen">March&#160;16,&#160;2025</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2020 Series B Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000909" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231" decimals="INF" format="ixt:numdotdecimal">13,281,386</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000914" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231" decimals="INF">7.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000918" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231" format="ixt:datemonthdayyearen">March&#160;16,&#160;2025</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public Warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000910" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231" decimals="INF" format="ixt:numdotdecimal">14,374,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000915" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231" decimals="INF">11.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000919" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231" format="ixt:datemonthdayyearen">July&#160;16,&#160;2026</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsor Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000911" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231" decimals="INF" format="ixt:numdotdecimal">8,499,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000916" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231" decimals="INF">11.50</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000920" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231" format="ixt:datemonthdayyearen">July&#160;16,&#160;2026</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000912" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001752828_20211231" decimals="INF" format="ixt:numdotdecimal">42,686,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="Background-color:#FFFFFF;"><ix:nonNumeric id="F_000923" name="celu:DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20210101_20211231">The exercise price is the lessor of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000921" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231" decimals="INF">6.77</ix:nonFraction>&#160;per share or&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000922" name="celu:WarrantsPerSharePercentage" contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231" decimals="2" scale="-2">80</ix:nonFraction>% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.</ix:nonNumeric></span></p></td></tr></table></div></ix:continuation></ix:continuation><ix:nonNumeric id="F_000369" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000369_dcnt_d31bce2e-0cff-4da2-884c-8ecbf097fafe">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2021 Equity Incentive Plan</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2021, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) to employees and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The number of shares of Class A common stock initially reserved for issuance under the 2021 Plan is&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000924" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210731" decimals="INF" format="ixt:numdotdecimal">20,915,283</ix:nonFraction>. As of December&#160;31, 2021,&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231" decimals="INF" format="ixt:numdotdecimal">15,152,282</ix:nonFraction>&#160;shares remain available for future grant under the 2021 Plan. The number of shares reserved for issuance will automatically increase on January 1 of each year, for a period of&#160;<ix:nonNumeric id="F_000927" name="celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" format="ixt-sec:duryear">10</ix:nonNumeric>&#160;years, from January 1, 2022 through January 1, 2031, by&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000926" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="INF" scale="-2">4</ix:nonFraction>% of the total number of shares of Celularity capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021 Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021 Plan.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The 2021 Plan is administered by the Company&#8217;s board of directors. The Company&#8217;s board of directors, or a duly authorized committee thereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan </span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000369_dcnt_d31bce2e-0cff-4da2-884c-8ecbf097fafe" continuedAt="F_000369_dcnt_31c89905-63cb-4c14-9e8c-1e53c819926f">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of the Company&#8217;s stockholders.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2017 Equity Incentive Plan</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) adopted by Legacy Celularity&#8217;s board of directors and approved by Legacy Celularity&#8217;s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with the closing of the Business Combination and effectiveness of the 2021 Plan, no further grants will be made under the 2017 Plan.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The total number of stock options that could have been issued under the 2017 Plan was&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000928" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">32,342,049</ix:nonFraction>. Shares that expired, forfeited, canceled or otherwise terminated without having been fully exercised were available for future grant under the 2017 Plan.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The 2017 Plan is administered by the Company&#8217;s board of directors or, at the discretion of the Company&#8217;s board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy Celularity&#8217;s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could not be less than&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000929" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="INF" scale="-2">100</ix:nonFraction>% of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than&#160;<ix:nonNumeric id="F_000930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over a three or&#160;<ix:nonNumeric id="F_000932" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" format="ixt-sec:durwordsen">four year</ix:nonNumeric>&#160;period.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Stock Option Valuation</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Awards with Service Conditions</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally required judgment to determine.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the respective expected term or contractual term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">The expected dividend yield is&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000933" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001752828_20210101_20211231" decimals="2" scale="-2">0</ix:nonFraction>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock</span><span style="color:#000000;">.</span></p></td></tr></table></div><ix:nonNumeric id="F_000425" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes&#160;option-pricing&#160;model to determine the grant-date&#160;fair value of stock options granted during the years ended December&#160;31, 2021 and 2020:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000934" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">0.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000935" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">1.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000936">4.65</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000937">6.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000938" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">80.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000939" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">67.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant-date&#160;fair value per share of stock options granted during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000940" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001752828_20210101_20211231" decimals="2">4.13</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000941" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001752828_20200101_20201231" decimals="2">2.24</ix:nonFraction>, respectively.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000369_dcnt_31c89905-63cb-4c14-9e8c-1e53c819926f" continuedAt="F_000369_dcnt_cbd5bea8-968f-4a80-aa14-f2871aca372a"><ix:nonNumeric id="F_000426" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity under the 2021 Plan and the 2017 Plan:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contract life</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000942" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">13,954,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000953" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231" decimals="2">0.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000964">7.6</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000943" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,662,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000954" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="2">3.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000944" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">108,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000955" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="2">3.88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000945" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,340,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000956" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231" decimals="2">2.17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000946" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">17,167,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000957" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231" decimals="2">1.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000965">7.3</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000947" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">9,681,736</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000958" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="2">8.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000948" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">703,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000959" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="2">0.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000949" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,080,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000960" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231" decimals="2">4.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000950" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">24,064,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000961" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="2">4.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000966">7.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000971" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000951" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">24,064,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="2">4.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000967">7.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,525</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000952" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">17,840,068</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000963" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="2">3.51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000968">6.9</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,898</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In March 2021, Legacy Celularity&#8217;s board of directors approved the issuance of fully vested options to acquire&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000974" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001752828_20210301_20210331" decimals="INF" format="ixt:numdotdecimal">269,007</ix:nonFraction>&#160;shares at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000975" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="C_0001752828_20210301_20210331" decimals="2">3.83</ix:nonFraction>&#160;per share to each of its non-employee directors. During the second quarter of 2021, the grant notice was provided to the non-employee directors. Accordingly, the grant date was established in the second quarter of 2021 under ASC 718,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">Compensation &#8211; Stock Compensation</span><span style="Background-color:#FFFFFF;">&#160;and the Company recognized the commensurate expense.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the second quarter of 2021, Legacy Celularity&#8217;s board of directors approved the issuance of fully vested options to acquire a total of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000976" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001752828_20210401_20210630" decimals="INF" format="ixt:numdotdecimal">2,613,217</ix:nonFraction>&#160;shares at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000977" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="C_0001752828_20210401_20210630" decimals="2">10.21</ix:nonFraction>&#160;per share to certain members of senior management. Accordingly, the Company recognized the full expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000978" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">13,723</ix:nonFraction>&#160;during the second quarter of 2021, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,861</ix:nonFraction>&#160;was recorded to research and development expense and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630" decimals="-3" format="ixt:numdotdecimal" scale="3">6,862</ix:nonFraction>&#160;was recorded to selling, general and administrative expense on the consolidated statement of operations.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In September 2021, the Company&#8217;s board of directors approved the issuance of options to acquire a total of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000981" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">3,766,107</ix:nonFraction>&#160;shares of common stock at $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000982" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930" decimals="2">10.23</ix:nonFraction>&#160;per share to certain members of senior management as a result of the Business Combination (the &#8220;Transaction Awards&#8221; or &#8220;Performance Awards&#8221;). The Transaction Awards vested&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000983" name="celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930" decimals="2" scale="-2">50</ix:nonFraction>% on the Closing Date, with the remaining&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000984" name="celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930" decimals="2" scale="-2">50</ix:nonFraction>% vesting over&#160;<ix:nonNumeric id="F_000985" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. Accordingly, the Company recognized expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">7,186</ix:nonFraction>&#160;during the third quarter of 2021 for the shares that vested on the grant date, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,388</ix:nonFraction>&#160;was recorded to research and development expense and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000988" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">3,798</ix:nonFraction>&#160;was recorded to selling, general and administrative expense on the consolidated statement of operations. Additional expense was recognized in 2021 for the portion of the awards that vest over time. </span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2021, the Company amended two non-employee stock option awards such that any unvested awards at the time of the Business Combination would become fully vested. The Company </span><span style="color:#000000;">accelerated the recognition of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" contextRef="C_0001752828_20210701_20210731" decimals="-3" scale="3">567</ix:nonFraction> of expense related to the modification of these awards</span><span style="Background-color:#FFFFFF;">. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2021 and 2020, the aggregate intrinsic value was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000990" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,959</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000991" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">671</ix:nonFraction> for the stock options exercised, respectively. <ix:nonFraction unitRef="U_xbrlishares" id="F_000992" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">131,256</ix:nonFraction> options exercised with a value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapLiabilitiesTotalMember_20210101_20211231" decimals="-3" scale="3">441</ix:nonFraction> were classified as liabilities at December 31, 2021 until the shares are issued to the holder.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, unrecognized compensation cost for options issued was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,408</ix:nonFraction>, and will be recognized over an estimated weighted-average&#160;amortization period of <ix:nonNumeric id="F_000995" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:duryear">3.3</ix:nonNumeric>&#160;years.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Awards with Performance Conditions</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had certain performance-based stock options, which were earned based on the attainment of specified goals achieved over the performance period. During the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000996" name="celu:ExpenseRelatedToPerformanceAwards" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">31</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000997" name="celu:ExpenseRelatedToPerformanceAwards" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">21</ix:nonFraction> expense related to the performance awards in which the performance condition was probable until those awards were amended such that the entire unvested portion of the award vested upon closing of the Business Combination.&#160;&#160;The Company <span style="color:#000000;">accelerated the recognition of </span>$<ix:nonFraction unitRef="U_iso4217USD" id="F_000998" name="celu:AwardModificationExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">121</ix:nonFraction> of expense related to the modification of this award and as of December 31, 2021, the there was <ix:nonFraction unitRef="U_iso4217USD" id="F_000999" name="celu:UnrecognizedExpenseRelatedToPerformanceAwards" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> amount of unrecognized expense related to these performance awards </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000369_dcnt_cbd5bea8-968f-4a80-aa14-f2871aca372a">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Awards with Market Conditions</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company awarded options to acquire a total of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001000" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930" decimals="INF" format="ixt:numdotdecimal">2,469,282</ix:nonFraction>&#160;shares with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930" decimals="2">6.32</ix:nonFraction>&#160;to the Company&#8217;s President in connection with the commencement of his employment. The grant was comprised of four equal tranches, which award will&#160;<ix:nonNumeric id="F_001002" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231">vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date</ix:nonNumeric>, subject to his continued employment with the Company. The fair value of the President&#8217;s award was determined based upon a Monte Carlo simulation valuation model. The Company&#8217;s assumptions for expected volatility and closing price were&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_001003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930" decimals="3" scale="-2">75.0</ix:nonFraction>% and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001004" name="us-gaap:SharePrice" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210930" decimals="2">6.32</ix:nonFraction>, respectively. The aggregate estimated fair value of the President&#8217;s award was $<ix:nonFraction unitRef="U_xbrlishares" id="F_001005" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210930" decimals="INF" format="ixt:numdotdecimal">7,013</ix:nonFraction>, which is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric id="F_001006" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930" format="ixt-sec:durwordsen">four years</ix:nonNumeric>. The Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_001007" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231" decimals="-3" scale="3">514</ix:nonFraction>&#160;in share-based expense related to the President&#8217;s award for the year ended December 31, 2021. As of December 31, 2021, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001008" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,499</ix:nonFraction>&#160;of unrecognized compensation costs that the Company plans to recognize over the weighted average period of&#160;<ix:nonNumeric id="F_001009" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231" format="ixt-sec:duryear">3.7</ix:nonNumeric>&#160;years.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Restricted Stock Units</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issues restricted stock units (&#8220;RSUs&#8221;) to employees that generally vest over a <span style="-sec-ix-hidden:F_001010">two-year</span> period with <ix:nonFraction unitRef="U_xbrlipure" id="F_001011" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231" decimals="2" scale="-2">50</ix:nonFraction>% of awards vesting after 1 year and then the remaining <ix:nonFraction unitRef="U_xbrlipure" id="F_001012" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20210101_20211231" decimals="2" scale="-2">50</ix:nonFraction>% vesting after 2 years. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period.</p><ix:nonNumeric id="F_000427" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity related to RSU stock-based payment awards:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001013" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">488,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001016" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="2">7.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_001014" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">13,900</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001017" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="2">7.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001015" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="INF" format="ixt:numdotdecimal">474,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001018" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="2">7.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" decimals="-3" scale="3">222</ix:nonFraction>&#160;for the year ended December&#160;31, 2021, related to RSUs. As of December&#160;31, 2021, the total unrecognized expense related to all RSUs was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,296</ix:nonFraction>, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric id="F_001021" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231" format="ixt-sec:duryear">1.92</ix:nonNumeric>&#160;years</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p><ix:nonNumeric id="F_000428" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company recorded stock-based&#160;compensation expense in the following expense categories of its consolidated statements of operations:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001022" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20211231" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001023" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231" decimals="-3" scale="3">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001024" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001025" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001026" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001027" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001028" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">40,010</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001029" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,371</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000370" name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000370_dcnt_ba6186ac-1409-44fc-8c0c-4ba6fc1e0d58">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.&#160;&#160;&#160;&#160;&#160;Revenue Recognition</p><ix:nonNumeric id="F_000429" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000429_dcnt_42757361-1027-482c-9a1e-c5021cfd9fc5">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information about disaggregated revenue by product and services:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001030" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001031" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001032" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001033" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001034" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001035" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001036" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001037" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000370_dcnt_ba6186ac-1409-44fc-8c0c-4ba6fc1e0d58" continuedAt="F_000370_dcnt_0b686947-1c37-4574-b3a5-5a97e6a01e3d"><ix:continuation id="F_000429_dcnt_42757361-1027-482c-9a1e-c5021cfd9fc5">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000430" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides changes in deferred revenue from contract liabilities:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001038" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001039" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001752828_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferral of revenue*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001040" name="celu:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,928</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001041" name="celu:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of unearned revenue**</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001042" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001043" name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,916</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001044" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,067</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001045" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,449</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">2020 includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_001046" name="us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,505</ix:nonFraction>&#160;received in advance of performing services under a license agreement (see Note 15).&#160;&#160;The remainder of the 2020 and all of the 2021 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">During the third quarter of 2021, the Company terminated the license agreement with Sanuwave due to an uncured material breach (See Note 15). As a result, the Company recognized the remaining deferred revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001047" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20210701_20210930" decimals="-3" format="ixt:numdotdecimal" scale="3">6,754</ix:nonFraction>&#160;that was to be recognized on a straight-line basis over the non-cancelable term of the license agreement.</p></td></tr></table></div></ix:nonNumeric><ix:continuation id="F_000391_cnt_1">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying Accounting Standards Codification 606,&#160;<span style="font-style:italic;">Revenue from Contracts with Customers</span>&#160;(&#8220;ASC 606&#8221;): (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities&#59; (2)&#160;the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less&#59; (3)&#160;the Company expenses costs to obtain a contract as they are incurred in the expected period of benefit and therefore, the amortization period is one year or less&#59; (4)&#160;the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are recorded as selling, general and administrative expenses&#59; (5)&#160;the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer&#59; and (6)&#160;the Company does not disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product sales&#160;and rentals</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. For each contract, the Company considers the obligation to transfer products and services to the customer, each of which are distinct, to be performance obligations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its degenerative disease products. The goods and services listed below may not all be included in every contract. Some contracts may include all of the Company&#8217;s products and services while others may only include one product or service type.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Supply of Biovance</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Supply of Interfyl</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Supply of Biovance 3L</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Supply of MIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;and UltraMIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Supply of MIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;and UltraMIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;rental product.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Degenerative disease commercial operations revenue is generally recognized when the customer obtains control of the Company&#8217;s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Sales and other taxes collected on behalf of third parties are excluded from revenue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Variable Consideration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company is required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, discounts, and other deductions), and recognize the estimated amount as revenue, when the Company transfers control </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000370_dcnt_0b686947-1c37-4574-b3a5-5a97e6a01e3d" continuedAt="F_000370_dcnt_8493b614-466d-4552-89c1-89215d06bbf4">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the product to customers. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled. An expected value method may be an appropriate estimate of the amount of variable consideration if an entity has a large number of contracts with similar characteristics whereas the most likely amount method may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company&#8217;s anticipated performance and all information (historical, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and forecasted) that is reasonably available.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales Incentives and Other Promotional Programs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers volume-based&#160;discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer&#160;basis to estimate what levels of incentives will be earned.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Product Returns</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with industry practice, the Company maintains a returns policy that generally offers customers a right of return for products that have been purchased from the Company. To date, the Company has had minimal product returns and currently does not have an accrual for product returns. The Company will continue to assess the estimate for product returns as it gains additional historical experience.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Services</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its biobanking services:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Collection and processing services&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;">Storage services.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contracted storage periods are <ix:nonNumeric id="F_001048" name="celu:ContractedStoragePeriods" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:duryear">18</ix:nonNumeric>&#160;years and <ix:nonNumeric id="F_001049" name="celu:ContractedStoragePeriods" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:duryear">25</ix:nonNumeric>&#160;years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the 18- and the 25-year&#160;storage fees that are being recognized over the contractual storage period. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12&#160;months from the balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Significant Financing</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans (annual, <ix:nonNumeric id="F_001050" name="celu:ContractedStoragePeriods" contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:duryear">18</ix:nonNumeric>&#160;years and <ix:nonNumeric id="F_001051" name="celu:ContractedStoragePeriods" contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:duryear">25</ix:nonNumeric>&#160;years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans for customers to pay over time for a period of <span style="-sec-ix-hidden:F_001052">one to 24&#160;months</span> (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When considered over a <ix:nonNumeric id="F_001054" name="celu:PaymentPlansForCustomerToPayOverTimePeriod" contextRef="C_0001752828_20210101_20211231" format="ixt-sec:durmonth">24</ix:nonNumeric>-month&#160;period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000370_dcnt_8493b614-466d-4552-89c1-89215d06bbf4">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, the total aggregate transaction price allocated to the unsatisfied performance obligations for services was recorded as deferred revenue amounting to $<ix:nonFraction unitRef="U_iso4217USD" id="F_001056" name="us-gaap:DeferredRevenue" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,067</ix:nonFraction>, which will be recognized as revenue ratably on a straight-line&#160;basis over the contractual period of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_001057" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,196</ix:nonFraction> will be recognized as revenue over the next 12&#160;months.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales Incentives and Other Promotional Programs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer&#160;basis to estimate what levels of incentives will be earned.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allocation of Transaction Price</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company&#8217;s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License, royalty and other</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement with Sanuwave which acquired certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business, the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognize the quarterly license fee over each quarterly term based on the actual sales occurring over the period. If quarterly revenues were lower than the quarterly license fee, the Company recognized the difference during the third month of the quarterly period. Any royalties earned in excess of the quarterly license fee were recognized at the end of each quarterly period, as that is when it is probable that a significant future reversal of revenue under the arrangement will not occur. During the third quarter of 2021, the license agreement with Sanuwave was terminated due to an uncured material breach.</p></ix:continuation><ix:nonNumeric id="F_000371" name="celu:LicenseAndDistributionAgreementsTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000371_dcnt_26d7506e-5395-4c0e-9b3a-6fb1118ca3dd">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License and Distribution Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. License and Transfer Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 15, 2017, Legacy Celularity entered into a License and Transfer Agreement with TNK Therapeutics, Inc. and Sorrento Therapeutics, Inc. (collectively &#8220;Sorrento&#8221;), pursuant to which Legacy Celularity was granted an exclusive license to certain materials, patents and intellectual property related to Sorrento to develop and commercialize products for the treatment of any disease or disorder (the &#8220;2017 License Agreement&#8221;). During the first quarter of 2020, the 2017 License Agreement was mutually terminated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 26, 2020, Legacy Celularity and Sorrento entered into a binding term sheet for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells for the treatment of any disease or disorder (the &#8220;2020 Sorrento Term Sheet&#8221;). The 2020 Sorrento Term Sheet outlined various provisions to be incorporated and further negotiated in contemplation of a final license and supply agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2020, Legacy Celularity and Sorrento entered into a new License and Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder (the &#8220;2020 Sorrento License Agreement&#8221;). Celularity retains the right to sublicense the rights granted under the agreement with Sorrento&#8217;s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until terminated by either the Company or Sorrento for uncured material breach upon 90&#160;days written notice or, after the first anniversary of the effective date of the Sorrento Agreement, by the Company for convenience upon six months&#8217; written notice to Sorrento.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000371_dcnt_26d7506e-5395-4c0e-9b3a-6fb1118ca3dd" continuedAt="F_000371_dcnt_f597bc2c-99b4-4bce-88c8-c0c414bd0f82">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and Sorrento are actively negotiating a new supply agreement related to the 2020 Sorrento License Agreement. The 2020 Sorrento Term Sheet details certain aspects of this supply agreement, including pricing terms on material and/or licensed product supplied under the 2020 Sorrento License Agreement. The Company did&#160;<ix:nonFraction unitRef="U_iso4217USD" id="F_001058" name="celu:IncentivePayment" contextRef="C_0001752828_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction>t incur incentive payments related to the 2020 Sorrento Term Sheet.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lung&#160;Biotechnology PBC License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2017, Legacy Celularity entered into a license agreement with Lung Biotechnology PBC (&#8220;LB&#8221;), a wholly owned subsidiary of United Therapeutics Corporation (the &#8220;LB Agreement&#8221;), whereupon Legacy Celularity granted to LB an exclusive, worldwide sublicensable license of certain intellectual property to develop and commercialize products in the fields of thoracic and abdominal organ transplantation and pulmonary diseases (the &#8220;LB Licensed IP&#8221;). Pursuant to the LB Agreement, Legacy Celularity agreed to supply LB with placental-derived stem cells for use in the development and commercialization of products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2020, Legacy Celularity and LB agreed to expand their strategic collaborative license agreement to include treatment of COVID-19 and Acute Respiratory Distress Syndrome (&#8220;ARDS&#8221;). Under the amended collaborative agreement, the Company will seek regulatory approval for CYNK-001 in the treatment of COVID-19, and LB will seek regulatory approval for CYNK-001 in the treatment of ARDS. LB has global rights under the amended collaborative agreement to commercialize CYNK-001 in the treatment of COVID-19 and ARDS. The collaboration will be governed by a joint steering committee to oversee development and commercialization activities. LB will provide financial support as needed and requested by Legacy Celularity, subject to a maximum of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001059" name="celu:ReimbursementOfCostUnderLicenseAgreement" contextRef="C_0001752828_20200403_20200403" decimals="-3" scale="3">75</ix:nonFraction>&#160;per enrolled patient in the related clinical studies, which will be recorded as an offset to research and development expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2021, the license agreement with LB was terminated in its entirety effective April 11, 2021. The termination applies to the April 3, 2020 amendment for the treatment of CYNK-001 in COVID-19 and ARDS.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Genting&#160;Innovation PTE LTD Distribution Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;4, 2018, concurrently with Dragasac&#8217;s equity investment in the Series B Preferred Stock, the Company entered into a distribution agreement with Genting Innovation PTE LTD (&#8220;Genting&#8221;) pursuant to which Genting was granted supply and distribution rights to certain Company products in select Asia markets (the &#8220;Genting Agreement&#8221;). The Genting Agreement grants Genting limited distribution rights to the Company&#8217;s then-current&#160;portfolio of degenerative disease products and provides for the automatic rights to future products developed by or on behalf of the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Genting Agreement was renewed on January&#160;31, 2021, and automatically renews for successive twelve month terms unless: Genting provides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party for cause.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genting and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Celgene Corporation License&#160;Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Anthrogenesis acquisition, on August&#160;20, 2017, the Company entered into a license agreement with Celgene (the &#8220;Celgene Agreement&#8221;) pursuant to which the Company granted Celgene two separate licenses to certain intellectual property owned or controlled by Anthrogenesis as of the date of the Company&#8217;s acquisition of Anthrogenesis (the &#8220;Anthrogenesis IP&#8221;). The Celgene Agreement grants Celgene a royalty-free, fully-paid&#160;up, worldwide, non-exclusive&#160;license to the Anthrogenesis IP for pre-clinical&#160;research purposes in all fields and a royalty-free, fully-paid&#160;up, worldwide license, with the right to grant sublicenses, to the Anthrogenesis IP for the development, manufacture, commercialization and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte&#160;or NK cell to express such a CAR, and/or the use of such CARs or T-lymphocytes&#160;or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic uses thereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Celgene Agreement will remain in effect until its termination by either party for cause.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sanuwave Licensing Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 6, 2020, in conjunction with the sale of the UltraMIST business, Legacy Celularity entered into a&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000371_dcnt_f597bc2c-99b4-4bce-88c8-c0c414bd0f82">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001060">five-year</span></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;licensing arrangement with Sanuwave that includes (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market worldwide, except for certain Asian jurisdictions and (ii)&#160;a non-exclusive license for the distribution and commercialization of Interfyl in the wound care market worldwide, except for certain Asian jurisdictions (the &#8220;Sanuwave Licensing Agreement&#8221;). Sanuwave has the right to grant sublicenses of the exclusive Biovance license and non-exclusive Interfyl license to&#160;</span><ix:nonNumeric id="F_001061" name="celu:LicenseAgreementDescription" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20210101_20211231"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;its affiliates without the consent of the Company and (ii)&#160;any third party for the sole purpose of providing services directly to Sanuwave upon prior written consent by the Company. The Sanuwave License Agreement will automatically renew for additional one-year periods unless either party </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gives written notice of termination at least 180&#160;days prior to the expiration of the then-current term. Under the Sanuwave License Agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.</span></ix:nonNumeric><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Company may terminate the Sanuwave Licensing Agreement following the second year if annual sales of that year are less than $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001062" name="celu:AnnualSales" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">3,000</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Following the third year of the agreement, either party may terminate the Sanuwave Licensing Agreement upon 90&#160;days written notice should annual sales not exceed $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001063" name="celu:AnnualSalesNotExceed" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;in that third year or any year thereafter.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sanuwave Licensing Agreement, the Company will serve on a joint steering committee where it will oversee Sanuwave&#8217;s marketing efforts with respect to the licensed products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2021, Legacy Celularity sent a notice of deficiency to Sanuwave under the existing license agreement, where Sanuwave had until July 19, 2021 to cure a material breach. This material breach was not cured by Sanuwave and, as a result, the agreement with Sanuwave was terminated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusive Supply and Distribution Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 7, 2021, the Company entered into a&#160;<span style="-sec-ix-hidden:F_001064">six-year</span>&#160;supply and distribution agreement with Arthrex, Inc. (Arthrex) that includes (i) an exclusive Biovance, Interfyl, and Centaflex license for distribution and commercialization within the United States for the orthopedic surgery and (ii) an exclusive Interfly and Centaflex license for commercialization and distribution within the United States for the acute and chronic non-healing wound market (the &#8220;Arthrex Supply and Distribution Agreement&#8221;). The Arthrex Supply and Distribution Agreement will automatically renew for terms of  <span style="-sec-ix-hidden:F_001065">two-year</span> periods unless either party gives notice of non-renewal at least <ix:nonNumeric id="F_001066" name="celu:SupplyAndDistributionAgreementNonRenewalNoticePeriod" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> advance of the end of the then current term. At least ninety days prior to the start of each calendar quarter, the Company and Arthrex will agree in good faith to a minimum binding forecast based upon projected sales volume by Arthrex for said upcoming calendar quarter for each of the products. Upon agreement, Arthrex shall submit to the Company a purchase order to purchase products for the minimum forecasted quantities. The Company shall invoice Arthrex after the product has been issued and payments for such invoices will be <ix:nonFraction unitRef="U_xbrlipure" id="F_001067" name="celu:DiscountPercentagePaymentForInvoicesWithinTenDays" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507" decimals="2" scale="-2">2</ix:nonFraction>%, ten net <ix:nonNumeric id="F_001068" name="celu:PaymentTermNet" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507" format="ixt-sec:durwordsen">forty-five days</ix:nonNumeric> from the date of the invoice. Upon material breach of the Arthrex Supply and Distribution Agreement either party may deliver such breach to the other party and the notified party will have <ix:nonNumeric id="F_001069" name="celu:MaterialBreachContractTerminatedTerm" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507" format="ixt-sec:durwordsen">thirty days</ix:nonNumeric> to cure such breach. If the notified party fails to cure the material breach of the Arthrex Supply and Distribution Agreement the non-breaching party may terminate the respective agreement.&#160;&#160;&#160;&#160;<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Arthrex Supply and Distribution Agreement, the Company and Arthrex will establish a joint steering committee to oversee commercialization activities of the products. Membership of the joint steering committee will be comprised of an equal number of employees of each respective party. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2021, the Company entered into a&#160;<span style="-sec-ix-hidden:F_001070">three-year</span>&#160;supply and distribution agreement with Evolution Biologyx, LLC (&#8220;Evolution&#8221;) that includes an exclusive Interfyl license for the distribution and commercialization within the United States within any medical specialty where Interfyl is administered in an in-office or in-patient setting and is reimbursed through Medicare Part B or any successor, equivalent or similar category established by the Center for Medicare Services or other Government Authority, except in the medical specialty of orthopedic surgery excluding trauma or spine applications in the medical specialty or orthopedic or neurologic surgery (the &#8220;Evolution Supply and Distribution Agreement&#8221;). The Evolution Supply and Distribution Agreement will automatically renew for terms of <span style="-sec-ix-hidden:F_001071">two-year</span> periods unless either party gives notice of non-renewal at least <ix:nonNumeric id="F_001072" name="celu:SupplyAndDistributionAgreementNonRenewalNoticePeriod" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> in advance of the current term. Evolution will provide a non-binding twelve month rolling forecast to the Company. The next forecast is due October 31, 2022, and each October 31 thereafter. At least forty-five days prior to the start of each calendar quarter, the Company and Evolution will agree in good faith to a minimum binding forecast based upon projected sales volume by Evolution for said upcoming calendar quarter for each of the products. <ix:nonNumeric id="F_001077" name="celu:SupplyAndDistributionAgreementForecastDescription" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210101_20211231">The forecast may not deviate to less than 70% for the immediate following quarter, 50% two quarters out, 40% three quarters out, and 25% for full quarters from the original forecasted amount for that specific quarter set forth in the respective agreed upon binding forecast. Upon agreement, Evolution shall submit to the Company a purchase order to purchase products for the minimum binding forecasted quantities.</ix:nonNumeric> The Company shall invoice Evolution after the product has been issued and payments for such invoices will be <ix:nonFraction unitRef="U_xbrlipure" id="F_001073" name="celu:PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901" decimals="2" scale="-2">50</ix:nonFraction>% upon receipt and acceptance of purchase order and <ix:nonFraction unitRef="U_xbrlipure" id="F_001074" name="celu:RemainingDuePercentageNetFortyFivePaymentTerm" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901" decimals="2" scale="-2">50</ix:nonFraction>% <ix:nonFraction unitRef="U_xbrlipure" id="F_001075" name="celu:DiscountPercentagePaymentForInvoicesWithinTenDays" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901" decimals="2" scale="-2">2</ix:nonFraction>%, ten net <ix:nonNumeric id="F_001076" name="celu:PaymentTermNet" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901" format="ixt-sec:durwordsen">forty-five days</ix:nonNumeric> from the date of invoice. The Evolution Supply and Distribution Agreement may be terminated by (i) material breach of the Evolution Supply and Distribution Agreement and subsequent failure to cure the material breach within <ix:nonNumeric id="F_001078" name="celu:MaterialBreachContractTerminatedTerm" contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901" format="ixt-sec:durwordsen">thirty days</ix:nonNumeric> of notice of material breach and (ii) otherwise mutually agreed in writing by the Company and Evolution. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000372" name="us-gaap:DefinedBenefitPlanTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.&#160;&#160;&#160;&#160;&#160;Benefit Plans</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax&#160;basis. Matching contributions to the plan may be made at the discretion of the Company&#8217;s board of directors. During the years ended December&#160;31, 2021 and 2020, the Company made contributions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001079" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">989</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001080" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">835</ix:nonFraction>, respectively, to the plan.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000373" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000373_dcnt_07ace5c9-88ac-451e-9635-cc97adff0478">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.&#160;&#160;&#160;&#160;&#160;Income Taxes</p><ix:nonNumeric id="F_000431" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax expense (benefit):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001081" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001082" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current income tax expense (benefit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001083" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001084" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">17</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax expense (benefit):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001085" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001086" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,366</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001087" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001088" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,351</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax expense (benefit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001089" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001090" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,717</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total (benefit) from income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001091" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001092" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><ix:nonNumeric id="F_000432" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001093" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001094" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001095" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">9.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001096" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">3.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001097" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">1.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001098" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">1.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest accretion expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001099" name="celu:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">8.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001100" name="celu:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">5.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001101" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001752828_20210101_20211231" decimals="3" sign="-" scale="-2">46.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001102" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001752828_20200101_20201231" decimals="3" sign="-" scale="-2">21.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark to market warrant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001103" name="celu:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">2.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001104" name="celu:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" contextRef="C_0001752828_20200101_20201231" decimals="3" sign="-" scale="-2">5.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent items</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001105" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">2.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_001106" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="C_0001752828_20200101_20201231" decimals="3" sign="-" scale="-2">1.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001107" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001752828_20210101_20211231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001108" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001752828_20200101_20201231" decimals="3" scale="-2">2.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><ix:nonNumeric id="F_000433" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities as of years ended December&#160;31, 2021 and 2020 consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001109" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">88,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001110" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001111" name="celu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,672</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001112" name="celu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,673</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001113" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001114" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Startup costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001115" name="celu:DeferredTaxAssetsStartupCosts" contextRef="C_0001752828_20211231" decimals="-3" scale="3">697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001116" name="celu:DeferredTaxAssetsStartupCosts" contextRef="C_0001752828_20201231" decimals="-3" scale="3">729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001117" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001118" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001119" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001120" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unicap</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001121" name="celu:DeferredTaxAssetsUnicap" contextRef="C_0001752828_20211231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001122" name="celu:DeferredTaxAssetsUnicap" contextRef="C_0001752828_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imputed interest on contingent payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001123" name="celu:DeferredTaxAssetsImputedInterestOnContingentPayments" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001124" name="celu:DeferredTaxAssetsImputedInterestOnContingentPayments" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,340</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fee capitalization and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001125" name="celu:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,550</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001126" name="celu:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,587</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001127" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001128" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001129" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">121,519</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001130" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,062</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001131" name="celu:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001132" name="celu:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001133" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001134" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001135" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">92,297</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001136" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001137" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001752828_20211231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001138" name="us-gaap:DeferredTaxLiabilities" contextRef="C_0001752828_20201231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000373_dcnt_07ace5c9-88ac-451e-9635-cc97adff0478">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000434" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Benefits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001139" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001752828_20191231" decimals="-3" scale="3">786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase related to current year tax provisions</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001140" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001752828_20200101_20201231" decimals="-3" scale="3">242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001141" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,028</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase related to current year tax provisions</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001142" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001752828_20210101_20211231" decimals="-3" scale="3">242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001143" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, and 2020, the Company had U.S. federal and state net operating loss carryforwards of $88,327<span style="font-size:12pt;color:#000000;"><span style="-sec-ix-hidden:F_001144">&#160;</span></span>and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001145" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,495</ix:nonFraction>, respectively, which may be available to offset future taxable income and begin to expire in <ix:nonNumeric id="F_001146" name="celu:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20210101_20211231">2040</ix:nonNumeric>. As of December&#160;31, 2021, and 2020, the Company also had U.S. federal and state research and development tax credit carryforwards of $7,672<span style="-sec-ix-hidden:F_001148"> </span>and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001147" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,673</ix:nonFraction>, respectively, which may be available to offset future tax liabilities and begin to expire in <ix:nonNumeric id="F_001149" name="celu:TaxCreditCarryforwardsExpirationYear" contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">2032</ix:nonNumeric>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year&#160;period. A corporation that experiences an ownership change is subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term&#160;tax-exempt&#160;rate subject to additional adjustments, as required. The Company experienced an ownership change on August&#160;15, 2017. The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development credits before utilization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of deferred tax assets is dependent upon the Company&#8217;s ability to generate taxable income in future years. Accounting Standards Codification 740-10,&#160;<span style="font-style:italic;">Income Taxes,</span>&#160;requires a valuation allowance to be applied against deferred tax assets when it is considered &#8220;more likely than not&#8221; that some or all of the gross deferred tax asset will not be realized. The Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded valuation allowance against its federal and state gross deferred tax assets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company had gross unrecognized tax benefits of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001150" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,270</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001151" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,028</ix:nonFraction>, respectively. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next 12&#160;months. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_001152" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001752828_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_001153" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001752828_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company&#8217;s consolidated statements of operations. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2016 to the present&#59; however, carryforward attributes that were acquired may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sold $<ix:nonFraction unitRef="U_iso4217USD" id="F_001155" name="celu:NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,356</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001154" name="celu:NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,005</ix:nonFraction> of its net operating losses and unused R&#38;D tax credits through the New Jersey Economic Development Authority&#8217;s Technology Business Tax Certificate Transfer Program during 2021 and 2020, respectively. The income resulting from the sale of net operating losses and unused R&#38;D tax credits is recorded as a component of other income (expense) on the consolidated statement of operations.</p></ix:continuation><ix:nonNumeric id="F_000374" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000374_dcnt_20067c44-4947-46c7-bae3-cee836fada1a">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.&#160;&#160;&#160;&#160;&#160;Segment Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. Prior to the third quarter of 2020, the Company managed operations as <ix:nonFraction unitRef="U_celuSegment" id="F_001156" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001752828_20200101_20200630" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of <ix:nonFraction unitRef="U_celuSegment" id="F_001157" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001752828_20200701_20200930" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> distinct business segments: Cell Therapy, Degenerative Disease, and </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000374_dcnt_20067c44-4947-46c7-bae3-cee836fada1a">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This change was prompted by certain organizational and personnel changes. The chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001158" name="us-gaap:Assets" contextRef="C_0001752828_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">414,128</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001159" name="us-gaap:Assets" contextRef="C_0001752828_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">431,008</ix:nonFraction> as of December&#160;31, 2021 and 2020, respectively.</p><ix:nonNumeric id="F_000435" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information by segment is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="19" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative Disease</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001160" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001161" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001162" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001163" name="us-gaap:GrossProfit" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001164" name="us-gaap:GrossProfit" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001165" name="us-gaap:GrossProfit" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,682</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001166" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001167" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001168" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,450</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001169" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">64,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001170" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">159,693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment contribution</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001171" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">85,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001172" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231" decimals="-3" sign="-" scale="3">246</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001173" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001174" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">64,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001175" name="celu:SegmentContribution" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">148,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001176" name="celu:IndirectExpenses" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001177" name="celu:IndirectExpenses" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001178" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="C_0001752828_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">109,058</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a) Components of other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001179" name="celu:ChangeInFairValueOfContingentConsiderationLiability" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">41,145</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001180" name="us-gaap:AdjustmentForAmortization" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,192</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001181" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,953</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="19" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disease</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001182" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001183" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,722</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001184" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001185" name="us-gaap:GrossProfit" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,262</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001186" name="us-gaap:GrossProfit" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001187" name="us-gaap:GrossProfit" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,346</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001188" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001189" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,653</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001190" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001191" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001192" name="us-gaap:DirectOperatingCosts" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment contribution</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001193" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,470</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001194" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001195" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001196" name="celu:SegmentContribution" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">20,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001197" name="celu:SegmentContribution" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">74,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001198" name="celu:IndirectExpenses" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">77,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001199" name="celu:IndirectExpenses" contextRef="C_0001752828_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">77,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001200" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="C_0001752828_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">151,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a) Components of other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001201" name="celu:ChangeInFairValueOfContingentConsiderationLiability" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,566</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of acquired intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001202" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">129,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001203" name="us-gaap:AdjustmentForAmortization" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001204" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">77,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000375" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true" continuedAt="F_000375_dcnt_7101d80f-315e-4901-b946-d9ac47934672">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19.&#160;&#160;&#160;&#160;&#160;Related Party Transactions</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The related party transactions described below do not have any associated balances on the consolidated balance sheet as of December 31, 2021. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Consulting Agreement with Dr.&#160;Andrew Pecora</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2017, Legacy Celularity entered into a scientific and clinical advisor agreement (the &#8220;SAB Agreement&#8221;) with Dr.&#160;Andrew Pecora, a member of Legacy Celularity&#8217;s board of directors, for the provision of consulting and advisory services. The SAB Agreement was superseded by a new SAB Agreement executed by Legacy Celularity on February 1, 2019.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000375_dcnt_7101d80f-315e-4901-b946-d9ac47934672" continuedAt="F_000375_dcnt_9dd6c98f-4383-409b-a17a-82a45eb79f7f">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 13, 2020, Legacy Celularity executed the First Amendment of the SAB Agreement with Dr.&#160;Pecora. The term of the First Amendment was six months. It provided for the payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001205" name="celu:PaymentForMonth" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413" decimals="-3" scale="3">20</ix:nonFraction>&#160;per month and the issuance of a stock option to purchase&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001206" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413" decimals="INF" format="ixt:numdotdecimal">153,718</ix:nonFraction>&#160;shares of Legacy Celularity&#8217;s common stock. This consideration was in addition to consideration defined in prior agreements. Upon the execution of the agreement,&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001207" name="celu:StockOptionsVested" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413" decimals="INF" format="ixt:numdotdecimal">76,859</ix:nonFraction>&#160;of the options were vested. The remaining&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001208" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413" decimals="INF" format="ixt:numdotdecimal">76,859</ix:nonFraction>&#160;options were vested upon Dr.&#160;Pecora&#8217;s achievement of a performance objective.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 15, 2020, Legacy Celularity executed the Second Amendment to the SAB Agreement with Dr.&#160;Pecora. Under the Second Amendment, Dr.&#160;Pecora agreed to provide Legacy Celularity with strategic advice on clinical development operations and strategy and assist in establishing a long-range clinical development plan. Compensation under the arrangement includes: (i)&#160;cash consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001209" name="celu:CashConsiderationPerMonth" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015" decimals="-3" scale="3">20</ix:nonFraction>&#160;per month, (ii)&#160;a one-time cash bonus of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001210" name="celu:RelatedPartyCashBonus" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015" decimals="-3" scale="3">50</ix:nonFraction>&#160;upon consummation of a merger, combination, consolidation or similar transaction involving Legacy Celularity in relation to a transaction with GX, (iii)&#160;a non-qualified stock option to purchase&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001211" name="celu:NonqualifiedStockOptionToPurchaseSharesOfCommonStock" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015" decimals="INF" format="ixt:numdotdecimal">153,718</ix:nonFraction>&#160;shares of Legacy Celularity&#8217;s common stock. This non-qualified stock option was granted during the second quarter of 2021. The original expiration of the Second Amendment was January 31, 2021. On January 31, 2021, the Company executed the amended and restated second amendment to the SAB Agreement which extended the term of the Second Amendment to September 30, 2021, unless earlier terminated by the Company for cause.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the SAB Agreements, the Company paid Dr.&#160;Pecora $<ix:nonFraction unitRef="U_iso4217USD" id="F_001212" name="celu:PaymentsToRelatedParty" contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20210101_20211231" decimals="-3" scale="3">390</ix:nonFraction>&#160;and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001213" name="celu:PaymentsToRelatedParty" contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200101_20201231" decimals="-3" scale="3">460</ix:nonFraction>&#160;for the years ended December 31, 2021 and 2020, respectively. On September 15, 2021, the Company hired Dr. Pecora to serve as President. Upon hiring Dr. Pecora, the SAB Agreement was terminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CURA Foundation</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2021 and 2020, the Company made a contribution of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001214" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20210101_20211231" decimals="-3" scale="3">500</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001215" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20200101_20201231" decimals="-3" scale="3">375</ix:nonFraction>, respectively to the CURA Foundation in support of the International Vatican. <span style="Background-color:#FFFFFF;">Dr.&#160;Robin L. Smith serves on the Company&#8217;s Board of Directors, previously served on the board of directors of Legacy Celularity, and is the president and chairperson of the board of the CURA Foundation.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">COTA, Inc</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November&#160;2020, Legacy Celularity and COTA, Inc. (&#8220;COTA&#8221;) entered into an Order Schedule (the &#8220;Order Schedule No.&#160;2&#8221;), to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide the licensed data in connection with AML patients. The COTA Order Schedule No.&#160;2 will terminate on the one-year anniversary following the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity&#8217;s President, is the Founder and Chairman of the Board of COTA and Dr.&#160;Robin L. Smith, a member of the&#160;Company&#8217;s&#160;Board, is an investor in COTA. The Company paid COTA $<ix:nonFraction unitRef="U_iso4217USD" id="F_001216" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCOTAIncMember_20210101_20211231" decimals="-3" scale="3">149</ix:nonFraction>&#160;during the year ended December 31, 2021.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cryoport Systems, Inc</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_001217" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20210101_20211231" decimals="-3" scale="3">104</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001218" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20200101_20201231" decimals="-3" scale="3">158</ix:nonFraction> to the Cryoport Systems, Inc (&#8220;Cryoport&#8221;) for transportation of cryopreserved materials during the years ended December&#160;31, 2021 and 2020, respectively. The Company&#8217;s Chief Executive Officer and director, Dr.&#160;Robert Hariri, M.D, Ph.D., has served on Cryoport&#8217;s board of directors since September&#160;2015.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CV Starr Loan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 8, 2021, Legacy Celularity entered into a $<ix:nonFraction unitRef="U_iso4217USD" id="F_001219" name="celu:LoanAgreement" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_20210608" decimals="-3" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction>&#160;loan agreement with CV Starr.&#160;CV Starr is an investor in the Company, holding&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001220" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231" decimals="INF" format="ixt:numdotdecimal">3,320,346</ix:nonFraction>&#160;warrants to purchase Class A common stock and&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001221" name="celu:NumberOfSharesHolding" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231" decimals="INF" format="ixt:numdotdecimal">4,320,347</ix:nonFraction>&#160;shares of Class A common stock as of December 31, 2021. During the third quarter of 2021, the Company repaid amounts outstanding under the short-term borrowing arrangement with CV Starr.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Purchase Agreement with a Director</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;18, 2020, a Director of the Company exercised options to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_001222" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction>&#160;shares of common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001223" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918" decimals="2">0.21</ix:nonFraction> per share. Subsequent to the aforementioned exercise, the Company and the Director entered into a stock purchase agreement on September&#160;18, 2020 whereby the <ix:nonFraction unitRef="U_xbrlishares" id="F_001224" name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction>&#160;shares of common stock were repurchased by the Company at the then current fair market value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001225" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918" decimals="2">2.56</ix:nonFraction> per share.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employment of an Immediate Family&#160;Member</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity&#8217;s Chairman and Executive Officer, is employed by Celularity as an Executive Director, Corporate Strategy&#160;&#38; Business Development. Ms.&#160;Hariri transitioned to part-time&#160;in late 2018, and her base salary for each of the years ended December&#160;31, 2019 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001226" name="celu:RelatedPartyPartTimeBaseSalary" contextRef="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20190101_20191231" decimals="-3" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_001227" name="celu:RelatedPartyPartTimeBaseSalary" contextRef="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231" decimals="-3" scale="3">38</ix:nonFraction></ix:nonFraction> per year. In 2021, Ms.&#160;Hariri transitioned back to full-time&#160;and her base salary is $<ix:nonFraction unitRef="U_iso4217USD" id="F_001228" name="celu:RelatedPartyFullTimeBaseSalary" contextRef="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20210101_20211231" decimals="-3" scale="3">210</ix:nonFraction>. Ms.&#160;Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and conditions as applicable to unrelated employees in similar positions.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:continuation id="F_000375_dcnt_9dd6c98f-4383-409b-a17a-82a45eb79f7f">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Pecora, the son of Andrew Pecora, M.D., the Company&#8217;s President, was employed by Celularity as Manager, Clinical Supply Chain. For the year ended December&#160;31, 2020, Mr.&#160;Pecora earned $<ix:nonFraction unitRef="U_iso4217USD" id="F_001229" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="C_0001752828_srtCounterpartyNameAxis_celuMrPecoraMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231" decimals="-3" scale="3">104</ix:nonFraction> in base salary and bonus and he earned equity awards which were in line with similar roles at Celularity. </p></ix:continuation><ix:nonNumeric id="F_000376" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001752828_20210101_20211231" escape="true">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20.&#160;&#160;&#160;&#160;&#160;Subsequent Events</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events and there are no items requiring disclosure except the following:</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Warrant Amendment and Exercise</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March&#160;1, 2022, Celularity and certain of the investors amended and restated the investors&#8217; respective Legacy Celularity Warrants (the &#8220;A&#38;R Warrants&#8221;) to (i)&#160;reduce the exercise price per share from $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001230" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231" decimals="INF">7.53</ix:nonFraction> per share to $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001231" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301" decimals="INF">3.50</ix:nonFraction> per share, subject to adjustment as set forth in the A&#38;R Warrants, (ii)&#160;remove the transfer restrictions set forth in the A&#38;R Warrants, and (iii)&#160;make other changes reflecting the impact of the business combination.&#160;</span>In conjunction with the amendment, those investors exercised&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_001232" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301" decimals="INF" format="ixt:numdotdecimal">13,281,386</ix:nonFraction> of the A&#38;R Warrants in exchange for <ix:nonFraction unitRef="U_xbrlishares" id="F_001233" name="us-gaap:SharesIssued" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301" decimals="INF" format="ixt:numdotdecimal">13,281,386</ix:nonFraction> shares of the Company&#8217;s Class A common stock for gross proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001234" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220301" decimals="-3" format="ixt:numdotdecimal" scale="3">46,485</ix:nonFraction>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9A_CONTROLS_PROCEDURES">Item 9A. Controls and Procedures. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this annual report on Form 10-K, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. The term &#8220;disclosure controls and procedures&#8221;, as defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Because there are inherent limitations in all control systems, a control system, no matter how well conceived and operated, can provide only reasonable, as opposed to absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Based on our evaluation of our disclosure controls and procedures as of December 31, 2021, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date were not effective at the reasonable assurance level given the existence of the material weaknesses in our internal control over financial reporting discussed below. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Internal Control Over Financial Reporting</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:3.7%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. An internal control material weakness is a significant deficiency, or aggregation of deficiencies, that does not reduce to a relatively low level the risk that material misstatements in financial statements will be prevented or detected on a timely basis by employees in the normal course of their work. An internal control significant deficiency, or aggregation of deficiencies, is one that could result in a misstatement of the financial statements that is more than inconsequential. In making its assessment of internal control over financial reporting management used the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8201;&#8212;&#8201;Integrated Framework (2013). Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021, and determined that our internal control over financial reporting was not effective at a reasonable assurance level due to the following material weaknesses in our internal control over financial reporting: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;color:#000000;">Control Environment</span><span style="color:#000000;">: We had insufficient internal resources with appropriate accounting and finance knowledge and expertise to design, implement, document and operate effective internal controls around our financial reporting process.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;color:#000000;">Accounting for Contingent Consideration</span><span style="color:#000000;">: Our calculation of the contingent consideration liability contained inconsistent and / or incorrect assumptions resulting in identified audit adjustments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;color:#000000;">Accounting for Deferred Taxes</span><span style="color:#000000;">: Our calculation of deferred tax assets and deferred tax liabilities contained errors resulting in identified audit adjustments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iv</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;color:#000000;">Accounting for Warrants</span><span style="color:#000000;">: Our calculation of warrant liabilities contained inconsistent and / or incorrect assumptions resulting in identified audit adjustments.</span></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The material weakness related to the impairment of intangible assets previously identified by us was remediated. <span style="color:#000000;">We are currently implementing our remediation plan to address the material weaknesses identified above. Such measures include:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Hiring additional accounting personnel to ensure timely reporting of significant matters.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Designing and implementing controls to formalize roles and review responsibilities to align with our team&#8217;s skills and experience and designing and implementing formalized controls.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Designing and implementing procedures to identify and evaluate changes in our business and the impact on our internal controls.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Designing and implementing formal processes, policies and procedures supporting our financial close process.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Consolidating all recurring valuation models under one service provider.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;">Engaging an outside firm to assist with the documentation, design and implementation of our internal control environment.</span></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than in connection with executing upon the continued implementation of the remediation measures referenced above, there were no changes in our internal controls over financial reporting that occurred during the quarter ended December 31, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9B_OR_INFORMATION">Item 9B. Other Information. </p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers and Directors </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:27.99%;"></td>
<td style="width:2.05%;"></td>
<td style="width:3.83%;"></td>
<td style="width:2.05%;"></td>
<td style="width:64.08%;"></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Age*</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 1pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Position(s)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Chairman of the Board of Directors</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew L. Pecora, M.D., F.A.C.P</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David C. Beers</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stephen A. Brigido, DPM</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Degenerative Disease</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Keary Dunn, Esq.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President, General Counsel&#160;&#38; Business Development</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bradley Glover, Ph.D.</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President and Chief Technology Officer</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John R. Haines</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President and Chief Operating Officer</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anne Jones, Ph.D.</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Vice President and Chief Business Officer</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Directors</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sculley<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Bloom<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peter Diamandis, M.D.<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)(2)</sup></span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lim Kok Thay<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc Mazur<span style="font-size:8pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)(2)</sup></span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robin L. Smith, M.D., MBA</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew C. von Eschenbach, M.D.<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:77.78%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">As of March 29, 2022</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Member of the audit committee.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Member of the compensation committee.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Member of the nominating and corporate governance committee.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Executive Officers</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.<span style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Dr. Hariri is the founder of Celularity and has served as our Chief Executive Officer and Chairman of our board of directors since the Business Combination, served as President since the Business Combination through September 2021 and was our founder before the Business Combination and has previously served as our President and Chief Executive Officer and as Chairman of our board of directors since 2016. Dr. Hariri also serves as a director at Biovie since June 2020. Prior to joining us, Dr. Hariri founded and served as Chief Executive Officer of Anthrogenesis Corporation, and after its acquisition by Celgene, Dr. Hariri served as Chief Executive Officer of Celgene Cellular Therapeutics from 2005 to 2013. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri is also an Adjunct Professor of Neurosurgery and a member of the Board of Overseers at the Weill-Cornell University Medical College. He is a member of the X PRIZE Foundation scientific advisory board for the Archon X PRIZE for Genomics. Dr. Hariri is a trustee and vice-chair of the Liberty Science Center. Dr.&#160;Hariri has served as a member of the board of directors of various companies, including Myos Corporation from July 2011 to November 2020, where he served as Chairman of the board from April 2012 to November 2020, Bionik Laboratories Corp. from March 2015 to October 2017, Cryoport since 2017, Bio Vie Inc. since June 2020. Dr.&#160;Hariri obtained an A.B. in Biological Anthropology from Columbia University School of Engineering and Applied Sciences and Columbia College and an M.D. and Ph.D. from Cornell University. Our board of directors believes that Dr.&#160;Hariri&#8217;s history in building companies in biotechnology, medical devices and therapeutics, as well as his expertise and experience in life sciences, including his work in immune-oncology and cell therapeutics and his educational background, provide him with the qualifications and skills to serve on our board of directors.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Andrew L. Pecora, M.D., F.A.C.P<span style="font-style:normal;">.</span><span style="font-weight:normal;font-style:normal;"> has been serving as President since September 2021. He was a director of our wholly owned subsidiary Celularity Operations, Inc. from June 2017 through the Business Combination. He also was a consultant to Celularity Operations and Chair of its Scientific Advisory Board. Dr. Pecora has been a practicing physician since 1989 and is the founder and first president of Regional Cancer Care Associates. He also is the founder of COTA, Inc. a data analytics company, and has served as COTA&#8217;s Chairman since 2011. He also is Chairman of Outcomes Matter Innovation LLC, or OMI, and served as OMI&#8217;s Chief Executive </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:normal;">Officer from 2019 to September 2021.Prior to consulting with </span><span style="font-weight:normal;font-style:normal;">Celularity</span><span style="font-weight:normal;font-style:normal;"> Operations, Inc., Dr. Pecora served as a director of </span><span style="font-weight:normal;font-style:normal;">Caladrius</span><span style="font-weight:normal;font-style:normal;"> Biosciences, Inc., from 2011 to 2016, as Chief Medical Officer from 2011 to 2015, and as Chief Visionary Officer from 2013 to 2015. He co-founded and was Chairman and Chief Executive Officer of Progenitor Cell Therapy, or PCT, prior to its acquisition by </span><span style="font-weight:normal;font-style:normal;">Caladrius</span><span style="font-weight:normal;font-style:normal;"> </span><span style="font-weight:normal;font-style:normal;">in 2011 and served as PCT&#8217;s Chief Medical Officer from 2011 to 2015. Earlier, he founded and was Chairman of </span><span style="font-weight:normal;font-style:normal;">Amorcyte</span><span style="font-weight:normal;font-style:normal;">, Inc., a clinical-stage cell therapy company focused on developing novel treatments for cardiovascular disease. Dr. Pecora was Chairman and Director of the John </span><span style="font-weight:normal;font-style:normal;">Theurer</span><span style="font-weight:normal;font-style:normal;"> Cancer Center at Hackensack University Medical Center from 2001 to 2011. He was Vice President of Cancer Services and Chief Innovations Officer of Hackensack Meridian Health from 2011 to 2016. From 2016 to 2019, Dr. Pecora served as President Physician Enterprise, Chief Innovations Officer, and Institutional Official of Hackensack Meridian Health. Dr. Pecora is a Professor of Medicine and Oncology at Georgetown University Medical Center. He received an M.D. from the University of Medicine and Dentistry of New Jersey, graduating with honors. He went on to complete his medical education in internal medicine at New York Hospital and in hematology and oncology at Memorial Sloan-Kettering Cancer Center, both in New York City. He is board certified in internal medicine, hematology, and oncology.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">David C. Beers<span style="font-style:normal;">.</span><span style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Mr. Beers has served as our Chief Financial Officer since the Business Combination and before the Business Combination served as our Chief Financial Officer since January 2020. Mr. Beers previously served as a portfolio manager at Goldman Sachs Asset Management, or GSAM. from 2010 to 2019, where he managed the Goldman Sachs Income Builder portfolio and the Real Estate Balanced portfolio as a member of the GSAM high yield</span><span style="font-weight:normal;font-style:normal;"> </span><span style="font-weight:normal;font-style:normal;color:#000000;">team. Previously, Mr. Beers served as a technology and media analyst with T. Rowe Price from 2004 to 2010 and with Morgan Stanley Investment Management from 1996 to 2002. Mr. Beers obtained an AB from Princeton University in 1992 and an MBA from The Wharton School of Business at The University of Pennsylvania in 2004.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stephen A. Brigido, DPM<span style="font-style:normal;">.&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Mr. Brigido has served as our President, Degenerative Disease since the Business Combination and before the Business Combination, served as our President, Degenerative Disease and Biobanking since September 2019. Prior to joining us, Dr. Brigido served as Managing Partner at Venel Holdings from November 2010 to present, and at BBHP Medical LLC from October 2016 to present. Before his tenure at BBHP Medical LLC, Dr. Brigido served as President and Chief Medical Officer at Edge Orthopaedics, LLC from April 2012 to July 2016. While at Edge Orthopaedics, Dr. Brigido was responsible for the development and commercial release of over 30 FDA approved products in foot and ankle surgery. In 2016, he facilitated a sale of that company to Orthofix SRL in Verona, Italy. Dr. Brigido is a founding partner of Plazmology 4, Inc., and has served on its board of directors since 2012. From 2005-2019 Dr. Brigido was the Section Chief of Foot and Ankle Reconstruction at Coordinated Health&#59; and was Director of the Reconstructive Foot and Ankle Fellowship from 2010-2019. In addition to his duties as a surgeon, Dr. Brigido served on the Board of Directors of Coordinated Health Holding Company from 2008-2019. Dr. Brigido has published over 120 peer reviewed papers in regenerative medicine and orthopedics&#59; and has written numerous book chapters. Dr. Brigido is a Professor of Surgery at The Commonwealth Medical College in Scranton, PA, and has numerous patents involving biomaterials and orthopedic hardware. Dr. Brigido obtained a Bachelor of Science from Randolph-Macron College and a Medical Degree from Temple University.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Keary L. Dunn, Esq.<span style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Mr. Dunn has served as our Executive Vice President, General Counsel &#38; Business Development since the Business Combination and before the Business Combination served as our Executive Vice President and General Counsel since March 2020. Prior to joining us, from January 2017 to March 2020, Mr. Dunn served as Vice President, U.S. Head Legal, Novartis Global Drug Development. At Novartis, Mr. Dunn also served as General Counsel of the Cell and Gene Therapy Unit from 2014 to 2017. He also served as the Global Ethics and Compliance Officer for Novartis Oncology from 2012 to 2014. Prior to his tenure at Novartis, from 2008 to 2010, Mr. Dunn served as Senior Corporate Counsel at Sanofi-Aventis U.S. as a member of the Regulatory/Privacy/Policy and Managed Markets legal groups. Mr. Dunn holds a Juris Doctor Degree from George Mason University and a Bachelor of Science degree in biochemical pharmacology from the State University of New York at Buffalo.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bradley Glover, Ph.D.<span style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Dr. Glover has served as our Executive Vice President and Chief Technology Officer since the Business Combination and before the Business Combination served as our Executive Vice President and Chief Technology Officer since March 2021. Prior to joining us, from August 2019 to March 2021, Dr.&#160;Glover served as Vice President Corporate Development, Head of Corporate Strategy &#38; Operations at Kite Pharma, Inc., which he first joined in September 2016 and held several executive roles in corporate development and technical operations. Prior to Kite, Dr. Glover he held several roles of increasing responsibility at Genentech, Inc. (now part of the Roche Group) from 2008 through September 2016 in the areas of finance, strategy, supply chain operations and alliance management. Dr. Glover holds a Ph.D. in biochemistry and molecular genetics from the University of Colorado, an M.B.A. from the Rady School of Management at the University of California, San Diego, and a Bachelor of Science degree in biochemistry from the University of California San Diego. Dr. Glover was also a Jane Coffin Childs Medical Research Fellow at the University of California Berkeley.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">John R. Haines&#160;&#160;<span style="font-weight:normal;font-style:normal;"> </span><span style="font-weight:normal;font-style:normal;color:#000000;">Mr. Haines has served as our Executive Vice President and Chief Operating Officer since the Business Combination and before the Business Combination served as our Chief Operating Officer since October 2020, and prior to that role, Mr. Haines served as our Chief Administrative Officer since September 2017. Prior to joining us, from 2013 to 2017, Mr. Haines served as President and Chief Executive Officer at Andiscern Corporation, a private company he cofounded to develop particle accelerator-based technology to detect fissile material used to make nuclear weapons. Prior to his tenure at Andiscern, from 2009 to 2013, Mr. Haines served as President and Chief Executive Officer at Ionetix Corporation, a private company he cofounded in 2009 to commercialize </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:normal;font-style:normal;color:#000000;">superconducting cyclotron technology developed at the MIT Plasma Fusion Laboratory. Mr. Haines served as President and Chief Operating Officer of </span><span style="font-weight:normal;font-style:normal;color:#000000;">Anthrogenesis</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Corporation from July 1999 through December 2002, when it was acquired by Celgene Corporation and renamed Celgene Cellular Therapeutics. Mr. Haines obtained a Bachelor of Arts in Economics from Villanova University, a Master of Science from the University of Pennsylvania, a Master of Bioethics from the University of Pennsylvania Graduate School of Medicine, a Master of Arts from King&#8217;s College London, and a postgraduate diploma from Stanford University.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anne Jones, Ph.D.<span style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Dr. Jones has served as our Executive Vice President and Chief Business Officer since the Business Combination and before the Business Combination served as our Executive Vice President and Chief Business Officer since April 2021. Prior to joining us, Dr. Jones served as Chief Operating Officer at Genuity Science leading their core business in Ireland, Iceland, and the United States. Dr. Jones also served as the Chief Executive Officer of Genomics Medicine Ireland (GMI), leading the company on population genomics and data analytics in oncology and complex diseases. Prior to GMI, she was Vice President and General Manager for Pall Corporations Lab, Food &#38; Beverage business at U.S.-based Danaher Corp. Dr. Jones also held senior roles in strategy development and planning at Agilent Technologies where she led business development and M&#38;A activities for Agilent&#8217;s Life Sciences and Applied Markets division and developed the strategy for Agilent&#8217;s successful entry into cell analysis. Dr. Jones has also worked with Amersham Biosciences in the UK and GE Healthcare Life Sciences in the UK and USA in marketing and R&#38;D roles. Dr. Jones obtained a B.S. in Microbiology and Molecular Biology from the National University of Ireland, Galway and a Ph.D. at Cancer Research UK, studying protein biochemistry and molecular biology in DNA Repair.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-Employee Directors</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">John Sculley<span style="font-weight:normal;">.&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Mr. Sculley has served as a member of our board of directors since the Business Combination and before the Business Combination served as Vice Chairman of our board of directors since June 2017. Mr. Sculley has also served as Chairman of the Board of Directors and Chief Marketing Officer for RxAdvance Corporation, a modern Pharmacy Benefit Manager platform company, a position he has held since 2015. Mr. Sculley is the co-founder and vice chairman of Zeta Global, a personalized marketing platform, positions he has held since 2009. Mr. Sculley has also served as a member of the Board of Directors at Zeta Global since 2009 and he previously served as a member of the Board of Directors at Kaleido Biosciences, Inc. from October 2018 to January 2020. Mr. Sculley previously served as the Chief Executive Officer of Pepsi-Cola Co from 1978 to 1983. He served as the Chief Executive Officer of Apple Inc. from 1983 to 1993. Mr. Sculley was a founding Board member of MetroPCS Communications, Inc. from 1996 to 2008 and Rally Health, Inc. from 2011 to 2014. He was also a member of the Board of Directors of MDLIVE, Inc. from 2009 to 2017. Mr. Sculley obtained a Bachelor of Arts from Brown University and an MBA from the Wharton School of Business. Mr. Sculley has also been awarded ten Ph.D.s and the Ellis Island Medal of Honor. Our board of directors believes that Mr. Sculley is qualified to serve based on his experience, qualifications, attributes and skills, including his extensive experience in leadership roles at other companies.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Jay R. Bloom<span style="font-weight:normal;font-style:normal;color:#000000;"> Mr. Bloom has served as a member of our board of directors since the Business Combination. Mr. Bloom is also a Managing Partner of Trimaran, which he co-founded in 1998, serves as a Manager of Trimaran Fund II, an existing private equity fund, and serves as Co-Chairman and Chief Executive Officer and a director of GX Acquisition Corp. II. Trimaran and affiliated entities have managed, through Trimaran Fund Management, L.L.C., private equity funds, collateralized loan obligations, and hedge funds (in the case of hedge funds, as sub-advisor). Prior to Trimaran, Mr. Bloom was a Managing Director and Vice Chairman of CIBC, where he was responsible for CIBC&#8217;s United States and European Merchant Banking activities, which were conducted through the CIBC Funds. In addition, Mr. Bloom was responsible for overseeing CIBC&#8217;s United States and European Leveraged Finance businesses, which included financial sponsor coverage&#59; acquisition finance&#59; high yield origination, underwriting, sales and trading&#59; private placements&#59; and financial restructuring advisory services. Prior to CIBC, Mr. Bloom was a co-founder of Argosy, a boutique investment bank that engaged in leveraged finance activities and principal investing. Argosy was acquired by CIBC in 1995. Prior to Argosy, Mr. Bloom was a Managing Director of Drexel Burnham Lambert Inc., and before that he was an investment banker at Lehman Brothers. Mr. Bloom also practiced law at Paul Weiss Rifkind Wharton &#38; Garrison. Within the last five years, Mr. Bloom has served on the Board of Directors of El Pollo Loco, Inc. until its IPO (restaurants), KCAP Financial Inc. (fixed income investments/asset management&#59; NASDAQ: KCAP), ChanceLight, Inc. (for-profit education), Norcraft Companies, Inc. (building products) and Brite Media Group LLC (specialty advertising). He has also in the past served as a director of Accuride Corporation (heavy truck components&#59; NYSE: ACW), Consolidated Advisors, LLC (asset management), Domino&#8217;s Pizza, Inc. (restaurants), Freightcar America, Inc. (rail cars), Global Crossing Ltd. (telecommunications&#59; NYSE: GX), Heating Oil Partners, L.P. (energy), IASIS Healthcare Corporation (hospitals and insurance), Millennium Digital Media Holdings (cable/telecom), Morris Materials Handling, Inc. (capital equipment), NSP Holdings LLC (safety products), PrimeCo Wireless Communications LLC (communications), Source Financial Corporation (retail), Standard Steel, LLC (railcar components) and Transportation Technologies, Inc (heavy truck components). He serves on the Advisory Board of the Richman Center for Business, Law and Public Policy at Columbia University, has served as a member of the Cornell University Council and the Cornell University Undergraduate Business Program Advisory Council, and is an emeritus member of the Advisory Council of the Johnson Graduate School of Management at Cornell University. Mr. Bloom graduated summa cum laude from Cornell University with a B.S degree, from the Johnson Graduate School with an M.B.A degree and from Columbia University School of Law with a J.D. degree, where he was a member of the Board of Editors of the Columbia Law Review. Mr. Bloom is well qualified to serve on our board of directors due to his extensive financial, investment, operation and private and public company experience.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Peter H. Diamandis, M.D.&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Dr. Diamandis</span><span style="color:#000000;"> </span><span style="font-weight:normal;font-style:normal;color:#000000;">has served as a member of our board of directors since the Business Combination. Dr. Diamandis was</span><span style="font-weight:normal;font-style:normal;color:#000000;"> </span><span style="font-weight:normal;font-style:normal;color:#000000;">a co-founder and before the Business Combination served as a Vice Chairman of our board of directors since 2016. Dr. Diamandis is also the Founder and Executive Chairman of the XPRIZE Foundation, a non-profit foundation that has designed and operated large-scale incentive competitions and the Executive Founder of Singularity University, a graduate-level Silicon Valley institution founded in 2008 that counsels the world&#8217;s leaders on exponentially growing technologies. Dr. Diamandis is the Vice Chairman and co-Founder of Human Longevity, Inc., a company focused on extending the human lifespan. Dr. Diamandis obtained degrees in Molecular Engineering and Aerospace Engineering from MIT and an M.D. from Harvard Medical School. Our board of directors believes he is well qualified to serve on the board due to his extensive operational and management experience in the technology industry.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dean C. Kehler<span style="font-weight:normal;font-style:normal;">.&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Mr. Kehler has served as a member of our board of directors since the Business Combination. Mr. Kehler is also a Managing Partner of Trimaran, which he co-founded in 1998, serves as a Manager of Trimaran Fund II, and serves as Co-Chairman and Chief Executive Officer and a director of GX Acquisition Corp. II. Prior to Trimaran, Mr. Kehler was a Managing Director and Vice Chairman of CIBC, where he was responsible for CIBC&#8217;s United States and European Merchant Banking activities, which were conducted through the CIBC Funds. In addition, Mr. Kehler was responsible for overseeing CIBC&#8217;s United States and European Leveraged Finance businesses, which included financial sponsor coverage&#59; acquisition finance&#59; high yield origination, underwriting, sales and trading&#59; private placements&#59; and financial restructuring advisory services. Prior to CIBC, Mr. Kehler was a co-founder of Argosy. Prior to Argosy, Mr. Kehler was a Managing Director of Drexel Burnham Lambert Inc., and before that he was an investment banker at Lehman Brothers. Mr. Kehler serves on the Boards of Directors of El Pollo Loco Holdings, Inc. (restaurants&#59; NASDAQ: LOCO)&#59; Portman Ridge Finance Corporation. (investment company&#59; NASDAQ: PTMN) and Security First Corp. (cyber security and data management software), of which he is Vice Chairman. He also serves as a Member of the Board of Overseers of the University of Pennsylvania School of Nursing, and formerly served as its Chairman. Within the last five years, he has served a director of Inviva Inc. (insurance), and Graphene Frontiers, LLC (graphene). Mr. Kehler previously served as a director of Ashley Stewart Holdings, Inc. (retail)&#59; Continental Airlines Inc. (airlines&#59; NYSE: CAL)&#59; Global Crossing Ltd. (telecommunications&#59; NYSE: GX)&#59; Hills Department Stores, Inc. (retail&#59; NYSE: HDS)&#59; TeleBanc Financial Corp. (Internet banking&#59; NASDAQ: TBFC)&#59; Booth Creek Ski Group, Inc. (real estate&#59; leisure)&#59; CB Holding Corp. (restaurants)&#59; CNC Holding Corp. (retail)&#59; Heating Oil Partners, L.P. (energy)&#59; Jefferson National Financial Corporation (annuities)&#59; PrimeCo Wireless Communications, LLC (communications)&#59; Source Financing Corp. (retail)&#59; TLC Beatrice International Inc. (consumer products)&#59; and Urban Brands, Inc. (retail). In addition, Mr. Kehler previously served as a board observer of ITC Holdings, Inc. (electric transmission). Mr. Kehler previously served as a Director, Treasurer and Chair of the Finance Committee of CARE USA, one of the world&#8217;s largest private humanitarian organizations. Mr. Kehler graduated from the Wharton School of the University of Pennsylvania. Mr. Kehler is well qualified to serve on our board of directors due to his extensive financial, investment, operation and private and public company experience.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lim Kok Thay<span style="font-weight:normal;font-style:normal;">.</span>&#160;&#160;&#160;&#160;<span style="font-weight:normal;font-style:normal;color:#000000;">Tan Sri Lim has served as a member of our board of directors since the Business Combination. Before the Business Combination, Tan Sri Lim has previously served on our board of directors since 2018, and is the Chairman and Chief Executive of Genting Berhad. He is also the Deputy Chairman and Chief Executive of Genting Malaysia Berhad, the Deputy Chairman and Executive Director of Genting Plantations Berhad, the Executive Chairman of Genting Singapore Limited and the Chairman of Genting UK Plc. Tan Sri Lim has served in various positions within the Genting Group since 1976. He is a Founding Member, a Permanent Trustee and Chairman of the Board of Trustees of the charitable foundation The Community Chest, Malaysia. In addition, he is a member of the board of directors of several other companies as well as a member of the board of trustees of several charitable organizations in Malaysia. Tan Sri Lim is the Chairman and Chief Executive Officer of Genting Hong Kong Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited. Tan Sri Lim holds a Bachelor of Science in civil engineering from the University of London. He attended the Program for Management Development of Harvard Business School in 1979. Our board of directors believes that Tan Sri Lim is qualified to serve on the board based on his experience, qualifications, attributes and skills, including his extensive experience in leadership roles at other companies.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marc Mazur.&#160;&#160;&#160;&#160;<span style="font-weight:normal;font-style:normal;">Mr. Mazur has served as a member of our board of directors since the Business Combination. Mr. Mazur also serves as a director of GX Acquisition Corp. II. Mr. Mazur has served as an Industry Advisor for Brightwood Capital Advisors, LLC, a private debt fund, since 2014. From 2006 until 2008, Mr. Mazur served as the Chief Executive Officer of Brevan Howard U.S. Asset Management, a London-based global macro hedge fund, and a senior advisor of this company until 2010. From 2010 through December 2019, Mr. Mazur served as a member of the board of directors for Fibrocell Science, Inc. (NASDAQ: FCSC), an autologous cell and gene therapy company. Mr. Mazur serves as chairman of the audit committee and a member of the valuation committee of SuRo Capital Corp. (NASDAQ:SSSS), a business development company that invests in late-stage venture-backed private companies since 2017. He served a senior advisor to Tsinghua Venture Capital from 2001 to 2005. Mr. Mazur served as a Vice President at Salomon Brothers, Inc from 1984 to 1987 and served as a Vice President in the Fixed Income Division of The Goldman Sachs Group, Inc. from 1987 until 1996, and served as a consultant for Goldman from 1997 to 1999. Between 2010 and 2014, he served as a director of Staywell Health and as a director of DeVilbiss Health, private companies in the wellness and medical device fields. Mr. Mazur received his B.A. in Political Science from Columbia University and a J.D. from Villanova University School of Law. He is well qualified to serve on our board of directors due to his senior executive-level experience in finance, life science, healthcare consulting and business strategy, as well as his board experience.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Robin L. Smith, M.D., MBA</span><span style="font-style:normal;">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;">&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Dr. Smith has served as a member of our board of directors since the Business Combination. Before the Business Combination, Dr. Smith served as one of </span><span style="font-weight:normal;font-style:normal;color:#000000;">our&#160;&#160;directors</span><span style="font-weight:normal;font-style:normal;color:#000000;"> since August 2019. Dr. Smith has also served as a director of Sorrento since December 2019. She has served as partner of BRM Holdings, LLC, a consulting </span><span style="font-weight:normal;font-style:normal;color:#000000;">firm, since</span><span style="font-weight:normal;font-style:normal;color:#000000;"> March 2015. In 2007, Dr. Smith founded The Stem for Life Foundation (SFLF), a nonprofit organization, and has served as Chairman of the Board and President of the Stem for Life Foundation since its inception. The Stem for Life Foundation is now part of the </span><span style="font-weight:normal;font-style:normal;color:#000000;">Cura</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Foundation of which Dr. Smith serves as Chair of the Board and President. She has served as Vice President of the Science and Faith STOQ Foundation in Rome since 2015 and has served as a member of its Board of Directors since 2012. She also co-founded Spiritus Therapeutics, Inc. in 2018 and serves as President and Chair of the Board. From 2006 to 2015, Dr. Smith served as Chair and CEO of </span><span style="font-weight:normal;font-style:normal;color:#000000;">Caladrius</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Biosciences, Inc. (formerly </span><span style="font-weight:normal;font-style:normal;color:#000000;">NeoStem</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Inc.). She has served Chair of the board of directors of </span><span style="font-weight:normal;font-style:normal;color:#000000;">Mynd</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Analytics, Inc. since August 2015 and then its successor Emmaus Medical, Inc. until September 2019, served on the board of directors of Rockwell Medical, Inc. from June 2016 to November 2019 and served on the board of </span><span style="font-weight:normal;font-style:normal;color:#000000;">Seelos</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Therapeutics, Inc. since January 2019. Dr. Smith has been a member of the Board of Overseers at the NYU Langone Medical Center in New York since 2014, a member of the International Board of Sanford Health since 2016, co-</span><span style="font-weight:normal;font-style:normal;color:#000000;">chair of the Life Sci advisory board on gender diversity since April 2016, a member of the board of directors of Alliance for Regenerative Medicine (ARM) Foundation since 2017 and a co-founder and member of the board of directors of Unite to Prevent Cancer Foundation since 2018. She has served as a voluntary Clinical Associate Professor in the Department of Medicine at the Rutgers, New Jersey Medical School since 2017. She served on the Board of Trustees of the NYU Langone Medical Center from 2006 to 2014 and was on the board of directors of Signal Genetics, Inc. from July 2014 to February 2016, </span><span style="font-weight:normal;font-style:normal;color:#000000;">BioXcel</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Corporation from August 2015 to June 2017 and </span><span style="font-weight:normal;font-style:normal;color:#000000;">ProLung</span><span style="font-weight:normal;font-style:normal;color:#000000;"> Inc. from February 2017 to July 2018. Dr. Smith obtained her M.D. from Yale University, an M.B.A. from the Wharton School of </span><span style="font-weight:normal;font-style:normal;color:#000000;">Business</span><span style="font-weight:normal;font-style:normal;color:#000000;"> and a B.A. from Yale University. Our board of directors believes that Dr. Smith&#8217;s scientific background and her broader business development and corporate experience, qualify her to serve on the board.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Andrew C von Eschenbach, M.D.<span style="font-weight:normal;font-style:normal;">&#160;&#160;&#160;&#160;</span><span style="font-weight:normal;font-style:normal;color:#000000;">Dr. von Eschenbach has served as a member of our board of directors since the Business Combination. Before the Business Combination, Dr. von Eschenbach served as one of our directors since June 2017. Dr. von Eschenbach serves as President of Samaritan Health Initiatives since January 2010. Prior to his tenure there, from 2005 to 2009, he served as Commissioner of the Department of Health and Human Services at the U.S. Food &#38; Drug Administration. Previously, Dr. Eschenbach served as a director at the National Cancer Institute and as Executive Vice President/Chief Academic Officer and Professor of Urologic Oncology at the University of Texas MD Cancer Center. Dr. von Eschenbach obtained a B.S. from St. Joseph&#8217;s University and an M.D. from Georgetown University School of Medicine. Dr. von Eschenbach served as a Lt. Commander in the U.S. Navy Medical Corps, and after completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. Dr. von Eschenbach completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center. Our board of directors believes that Dr.&#160;von Eschenbach is qualified to serve on the board due to his extensive experience in biotechnology and his expertise in oncology.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Composition</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and affairs will be organized under the direction of o<span style="color:#000000;">ur board of directors. Our board of directors currently consists of nine members and</span>&#160;Dr.&#160;Hariri serves as Chairman of the board of directors. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to the management. The board of directors meets on a regular basis and on an&#160;<span style="font-style:italic;">ad hoc</span>&#160;basis as required.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the terms of <span style="color:#000000;">our certificate of incorporation</span> and the amended and restated bylaws, <span style="color:#000000;">the board of directors is initially divided</span> into three classes, as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Class I, which consists of Andrew C. von Eschenbach, M.D., Jay R. Bloom and Peter Diamandis, M.D., whose terms will expire at the annual meeting of stockholders to be held in 2022&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Class II, which consists of Dean C. Kehler, Robin L. Smith, M.D. and Lim Kok Thay, whose terms will expire at the annual meeting of stockholders to be held in 2023&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>Class III, which consists of Robert J. Hariri, M.D., Ph.D., John Sculley and Marc Mazur, whose terms will expire at the annual meeting of stockholders to be held in 2024.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized size of the board of directors will be fixed exclusively by resolutions of the board of directors. The authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed between the three classes so that, as nearly as possible, each class will consist of one-third&#160;of the directors. This classification of the board of directors may have the effect of delaying or preventing changes in its control or management. Our board of directors may be removed for cause by the affirmative vote of the holders of at least 66 2/3% of its voting stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Director Independence</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of the directors on the board of directors, other than Dr.&#160;Hariri, qualifies as an independent director, as defined by Rule&#160;5605(a)(2) of the Nasdaq Listing Rules and the board of directors consists of a majority of &#8220;independent directors&#8221; as defined under the rules of the SEC and Nasdaq listing rules relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Leadership Structure</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is chaired by Dr.&#160;Hariri, the Chief Executive Officer. In such role, Dr.&#160;Hariri has the authority, among other things, to call and preside over board of directors meetings, to set meeting agendas and to determine materials to be distributed to the board of directors. The board of directors believes that combining the positions of Chief Executive Officer and Board Chair helps to ensure that the board of directors and management act with a common purpose and that separating the positions of Chief Executive Officer and Board Chair has the potential to give rise to divided leadership, which could interfere with good decision-making&#160;or weaken the ability to develop and implement strategy. Instead, the board of directors believes that combining the positions of Chief Executive Officer and Board Chair provides a single, clear chain of command to execute its strategic initiatives and business plans. In addition, the board of directors believes that a combined Chief Executive Officer/Board Chair is better positioned to act as a bridge between management and the board of directors, facilitating the regular flow of information. We also believe that it is advantageous to have a Board Chair with an extensive history with and knowledge of the company (as is the case with its Chief Executive Officer) as compared to a relatively less informed independent Board Chair.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Role of the Board in Risk Oversight</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The audit committee of the board of directors are primarily responsible for overseeing its risk management processes on behalf of the board of directors. Going forward, we expect that the audit committee will receive reports from management at least quarterly regarding its assessment of risks. In addition, the audit committee reports regularly to the board of directors, which also considers our risk profile. The audit committee and the board of directors focus on the most significant risks we face and our general risk management strategies. While the board of directors oversees its risk management, management is responsible for day-to-day&#160;risk management processes, the board of directors expects management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day&#160;activities and to effectively implement risk management strategies adopted by the audit committee and the board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks it faces and that the board of directors leadership structure, which also emphasizes the independence of the board of directors in its oversight of its business and affairs, supports this approach.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Board Committees</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The board of directors has established the audit committee, compensation committee and nominating and corporate governance committee. The board of directors has adopted a charter for each of these committees, which comply with the applicable requirements of current Nasdaq rules. We intend to comply with future requirements to the extent they are applicable to us. Copies of the charters for each committee are available on the investor relations portion of our website.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Audit Committee</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee consists of Jay R. Bloom, Dean C. Kehler and, Marc Mazur. Each of the members of the audit committee&#160;&#160;satisfy the independence requirements of Nasdaq and Rule&#160;10A-3&#160;under the Exchange Act. Each member of the audit committee can read and understand fundamental financial statements in accordance with Nasdaq audit committee requirements.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler serves as the chair of the audit committee. The functions of this committee include, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit&#160;services&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>monitoring the rotation of partners of our independent auditors on our engagement team as required by law&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and discussing the statements and reports with our independent auditors and </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing, with our independent auditors and management, significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing with management and our independent auditors any earnings announcements and other public announcements regarding material developments&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>preparing the report that the SEC requires in our annual proxy statement&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and providing oversight of any related-person&#160;transactions in accordance with our related person transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management are implemented&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing on a periodic basis our investment policy&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and evaluating on an annual basis the performance of the audit committee and the audit committee charter.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of the Nasdaq Listing Rules. Our independent registered public accounting firm and the management periodically meet privately with the audit committee.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The composition and functioning of the audit committee complies with all applicable requirements of the Sarbanes-Oxley&#160;Act and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Compensation Committee</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation committee consists of Peter Diamandis,&#160;&#160;Marc Mazur and Dean C. Kehler. Marc Mazur serves as the chair of the compensation committee. Each of the members of its compensation committee are a non-employee&#160;director as defined in Rule&#160;16b-3&#160;promulgated under the Exchange Act and satisfies the Nasdaq Stock Market independence requirements. The functions of this committee include, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall compensation strategy and policies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and making recommendations to the full board of directors regarding the compensation and other terms of employment of our executive officers&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and approving (or if it deems it appropriate, making recommendations to the full board of directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluating risks associated with our compensation policies and practices and assessing whether risks arising from its compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and making recommendations to the full board of directors regarding the type and amount of compensation to be paid or awarded to our non-employee&#160;board members&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establishing policies with respect to votes by our stockholders to approve executive compensation as required by Section&#160;14A of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation, to the extent required by law&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;"></span><span style="color:#000000;"></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section&#160;10C of the Exchange </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>administering our equity incentive plans&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establishing policies with respect to equity compensation arrangements&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of its compensation policy and strategy in achieving expected benefits to us&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and making recommendations to the full board of directors regarding the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing with management and approving our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in its periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>preparing the report that the SEC requires in our annual proxy statement&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and assessing on an annual basis the performance of the compensation committee and the compensation committee charter.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The composition and functioning of the compensation committee complies with all applicable requirements of the Sarbanes-Oxley&#160;Act and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Nominating and Corporate Governance Committee</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The nominating and corporate governance committee consists of John Sculley, Lim Kok Thay, Robin Smith and Andrew C. von Eschenbach, M.D. John Sculley serves as the chair of the nominating and corporate governance committee. Each of the members of this committee satisfy the Nasdaq Stock Market independence requirements. The functions of this committee include, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>identifying, reviewing and evaluating candidates to serve on the board of directors consistent with criteria approved by the board of directors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>determining the minimum qualifications for service on the board of directors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluating director performance on the board of directors and applicable committees of the board of directors and determining whether continued service on the board of directors is appropriate&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluating, nominating and recommending individuals for membership on the board of directors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluating nominations by stockholders of candidates for election to the board of directors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>considering and assessing the independence of members of the board of directors&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>developing a set of corporate governance policies and principles, including a code of business conduct and ethics, periodically reviewing and assessing these policies and principles and their application and recommending to the board of directors any changes to such policies and principles&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>considering questions of possible conflicts of interest of directors as such questions arise&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>reviewing and assessing on an annual basis the performance of the nominating and corporate governance committee and the nominating and corporate governance committee charter.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The composition and functioning of the nominating and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley&#160;Act and all applicable SEC and Nasdaq rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Family Relationships </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><span style="font-weight:normal;">There are no family relationships among any of our executive officers or directors. </span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Code of Business Conduct and Ethics</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a written code of business conduct and ethics that applies to its directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or person performing similar functions. A current copy of the code is available on the Corporate Governance section of our website,<span style="font-style:italic;">&#160;www.celularity.com</span>. Information contained on or accessible through the website is not a part of this annual report, and the inclusion of the website address in this annual report is an inactive textual reference only. The nominating and corporate governance committee of the board of directors are be responsible for overseeing the code of conduct and must approve any waivers of the code of conduct for employees, executive officers and directors. We expect that any amendments to the code of conduct, or any waivers of its requirements, are be disclosed on our website.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Limitation of Liability and Indemnification</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="color:#000000;">certificate of incorporation</span> limits the liability of directors to the maximum extent permitted by Delaware law. Delaware law allows a corporation to eliminate the personal liability of directors of a corporation to the corporation and its stockholders for monetary damages for breach of their fiduciary duties as directors, except for liability for any:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>breach of his or her duty of loyalty to the corporation or its stockholders&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>act or omission not in good faith or that involves intentional misconduct or a knowing violation of law&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&#160;174 of the DGCL&#59; or</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>transaction from which the director derived an improper personal benefit.</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our <span style="color:#000000;">certificate of incorporation </span>does not eliminate a director&#8217;s duty of care and, in appropriate circumstances, equitable remedies, such as injunctive or other forms of non-monetary&#160;relief, will remain available under Delaware law. These limitations also do not affect a director&#8217;s responsibilities under any other laws, such as the federal securities laws or other state or federal laws. Our bylaws provide that we will indemnify our directors and executive officers and may indemnify other officers, employees and other agents, to the fullest extent permitted by law. Our bylaws also provide that we are obligated to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding and also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us. The board of directors has obtain a policy of directors&#8217; and officers&#8217; liability insurance.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our bylaws. These agreements, among other things, are expected to require us to indemnify our directors and executive officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The limitation of liability and indemnification provisions in our <span style="color:#000000;">certificate of incorporation</span> and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that these provisions in our <span style="color:#000000;">certificate of incorporation</span> and bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise disclosed in Item 3 &#8220;<span style="font-style:italic;">Legal Proceedings</span>&#8221; section of this annual report, at present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Scientific Advisory Board</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We established a scientific advisory board. We expect to regularly seek advice and input from these experienced scientific leaders on matters related to its research and development programs. Our scientific advisory board consists of experts across a range of key disciplines relevant to our programs and science. We intend to continue to leverage the broad expertise of our advisors by seeking their counsel on important topics relating to our research and development programs. Some of the members of our scientific advisory board have entered into consulting agreements with us covering their respective confidentiality, non-disclosure&#160;and proprietary rights matters and own or have owned shares of our Class A common stock or options to purchase shares of our Class A common stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delinquent Section 16(a) Reports</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.14%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 16(a) of the Exchange Act and SEC regulations require our directors, certain officers and holders of more than 10% of our Class A common stock to file reports of ownership on Form 3 and changes in ownership on Form 4 or 5 with the SEC. The reporting directors, officers and 10% stockholders are also required by SEC rules to furnish us with copies of all Section 16(a) reports they file. Based solely on our review of copies of such reports received and written representations from our directors and such covered officers, we believe that our directors and officers complied with all applicable Section 16(a) filing requirements during 2021, with the exception of one Form 4 filing by Mr. Eschenbach, dated December 2, 2021, reporting one transaction.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:12pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_11_EXECUTIVE_COMPENSATION">Item 11. Executive Compensation. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a discussion and analysis of compensation arrangements of our named executive officers. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual compensation programs that we adopt may differ materially from the currently planned programs that are summarized in this discussion. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and has elected to comply with the scaled disclosure requirements applicable to emerging growth companies. Unless the context otherwise requires, all references in this section to us refer to us and/or our subsidiaries prior to the consummation of the Business Combination and to us and our subsidiaries after the Business Combination.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain, incentivize and reward deeply talented and qualified executives who share its philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the company and align executive incentives with the long-term interests of its stockholders. This section provides an overview of our executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors , with input from our Chief Executive Officer, have historically determined the compensation for our named executive officers. <span style="color:#000000;">Our named executive officers for the year ended December&#160;31, 2021, were Dr.&#160;Hariri, our Chief Executive Officer, Dr. Pecora, our President, and Mr. Haines, our Chief Operating Officer. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 Summary Compensation Table</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information concerning the compensation of Celularity&#8217;s named executive officers for the year ended December&#160;31, 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and principal position</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Bonus</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)<sub style="font-size:85%; vertical-align:bottom">(</sub><sub style="font-size:85%; vertical-align:bottom">2)</sub></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-Equity Incentive Plan Compensation ($)<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">compensation ($)<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,214,697</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">369,250</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,809</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,819,756</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">845,845</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,809</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,681,654</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Pecora, M.D., F.A.C.P.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262,506</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,398,741</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389,750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,050,997</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">John Haines</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">420,625</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,464,957</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99,110</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,435</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,026,127</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Executive Vice President and Chief Operating Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:88.89%;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">Salary amounts represent actual amounts earned during 2021. For Dr. Pecora, amount is pro-rated reflecting his September 15, 2021 start date. For Mr. Haines, reflects an increase in salary effective July 16, 2021.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">Dr. Pecora was advanced a $300,000 bonus in 2021 (the first installment of an aggregate $1,200,000 award) in connection with his September 2021 employment as President, but such bonus is not deemed earned until September 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">Amounts reported represent the aggregate grant date fair value of the stock options granted to the named executive officers, computed in accordance with the Financial Accounting Standards Board&#8217;s, or FASB. Accounting Standards Codification, or ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 11 to our audited consolidated financial statements included elsewhere in this annual report. This amount does not reflect the actual economic value that may be realized by the named executive officer, which will depend on factors including the continued service of the executive and the future value of our stock. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">Represents performance-based cash bonuses awarded to our named executive officers.&#160; See &#8220;Narrative Disclosures to the Summary Compensation Table &#8212;Bonus Compensation&#8221; below for a description of this compensation.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">This column reflects the aggregate value of other categories of payment, consisting of (i)&#160;for Dr.&#160;Hariri, in 2020, $11,200 for 401(k), $24,069 for health insurance coverage and $540 for life insurance coverage&#59; and in 2021 $11,200 for 401(k), $30,381 for health insurance coverage and $540 for life insurance coverage (ii) for Dr. Pecora $389,750 of fees paid for services as a consultant to us and fees paid for services as a member of the Legacy Celularity board of directors prior to the Business Combination&#59; and (iii), for Mr. Haines, $11,200 for 401(k), $29,695 for health insurance coverage and $540 for life insurance coverage.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Narrative Disclosure to Summary Compensation Table</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Base Salary is provided below.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.26%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021 Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022 Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Salary</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,200,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Pecora, M.D., F.A.C.P.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900,000 (1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:72.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Haines</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">420,625 (2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">445,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Dr. Pecora was appointed President in September 2021.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Mr. Haines&#8217; salary was increased from $400,00 to $445,000 effective July 16, 2021, the Closing Date of the Business Combination. </span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The base salary of our executive officers is generally determined and approved by its compensation committee of our board of directors in connection with the executive officer&#8217;s commencement of employment. The annual base salaries of our named executive officers are generally reviewed, determined and approved by our compensation committee periodically in order to compensate its named executive officers for the satisfactory performance of duties to us. Annual base salaries are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Bonus Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time the board of directors or compensation committee may approve bonuses for our executive officers based on individual performance, company performance or as otherwise determined appropriate. In 2020, Dr.&#160;Hariri was entitled to a target bonus equal to 100% of his base salary, and in 2021, pursuant to his new employment agreement, such amount was 75%.&#160;&#160;In 2021, Mr. Haines was entitled to a target bonus equal to 40% of his base salary.&#160;&#160;Dr. Pecora will be entitled to a short-term discretionary performance bonus beginning with calendar year 2022, with a target bonus percentage equal to 60% of his then current base salary.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity-Based Incentive Awards</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our equity-based incentive awards are designed to align our interests and those of our stockholders with those of our employees and consultants, including our executive officers. The board of directors is responsible for approving equity grants. As of the date of this annual report, stock option awards were the only form of equity awards we have granted to any of our executive officers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically used stock options as an incentive for long-term compensation to its executive officers because the stock options allow its executive officers to profit from this form of equity compensation only if its stock price increases relative to the stock option&#8217;s exercise price, which exercise price is set at the fair market value of our common stock on the date of grant. We may grant equity awards at such times as our board of directors determines appropriate. our executives generally are awarded an initial grant in the form of a stock option in connection with their commencement of employment. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All stock options prior to the Business Combination were granted pursuant to the 2017 Plan. We now grant<span style="color:#000000;"> </span>equity incentive awards under the 2021 Plan.<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All options are granted with an exercise price per share that is no less than the fair market value of our common stock on the date of grant of such award. Stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See &#8220;&#8212; Outstanding Equity Awards at Fiscal Year-End.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Named Executive Officers and Potential Payments Upon Termination of Employment or Change in Control</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of Dr.&#160;Hariri and Mr. Haines, as summarized below, has entered into amended and restated employment agreements (which we refer to as the &#8220;employment agreements&#8221;) that took effect upon completion of the Business Combination, and Dr. Pecora entered into an employment agreement in connection with his appointment as President, all of which are filed as exhibits hereto to this annual report on Form 10-K. The material terms of each of these agreements are described below. For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see the descriptions below that summarize the potential payments provided for in their respective employment agreements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into an employment agreement dated<span style="color:#000000;"> </span>as of the Closing Date, setting forth the terms of Dr.&#160;Hariri&#8217;s employment as our Chief Executive Officer. The employment agreement incorporates our Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, which Dr. Hariri signed in connection with the employment agreement. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the employment agreement, Dr. Hariri is entitled to an initial annual base salary of $1,200,000. Dr.&#160;Hariri&#8217;s employment agreement also provides for an annual target bonus of up to 75% of his base salary. Receipt of an annual bonus is subject to achievement of individual and company-wide annual performance goals, as set by us and confirmed by our board of directors. On September 9, 2021, as contemplated by such agreement, <span style="color:#000000;"> </span>Dr. Hariri was granted an option to purchase 2,690,079 shares of Class A common stock under the 2021 Plan at an exercise price of $10.23 per share, with 50% fully-vested as of the grant date and 50% is subject to time-based vesting over a four-year period from the Closing Date, with 25% of this tranche vesting on the one-year anniversary of the Closing Date, and the remainder vesting monthly thereafter so that vested in full on the four-year anniversary of the Closing Date, and subject to Dr. Hariri&#8217;s continuous service on each vesting date. Dr. Hariri&#8217;s employment agreement provides that he is eligible to participate in our standard benefit plans maintained for the benefit of our similarly-situated employees.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Hariri&#8217;s employment agreement, if he resigns for &#8220;good reason&#8221; or we terminate Dr. Hariri&#8217;s employment without &#8220;cause&#8221; (each as defined in the employment agreement, and excluding a termination on account of Dr. Hariri&#8217;s death or disability), and if such termination or resignation is not in connection with a &#8220;change in control&#8221; (as defined in the 2021 Plan), then Dr. Hariri will be eligible to receive (i) continued payment of his base salary for 24 months following the termination (less applicable tax withholdings), (ii) COBRA premium coverage for up to 18 months, (iii) a prorated bonus for the year of termination paid in a lump sum, and (iv) 24 months&#8217; of accelerated vesting of Dr. Hariri&#8217;s unvested time-based equity awards. As a condition to receiving the foregoing severance benefits, Dr. Hariri must sign and not revoke a general release contained in a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Hariri&#8217;s employment agreement, if he resigns for &#8220;good reason&#8221; or we terminate Dr. Hariri&#8217;s employment without &#8220;cause&#8221;, and excluding a termination on account of Dr. Hariri&#8217;s death or disability), and if such termination or resignation occurs within three months prior to or within 12 months following the effective date of a &#8220;change in control&#8221;, then Dr. Hariri will be eligible to receive (i) continued payment of his base salary for 36 months following the termination (less applicable tax withholdings), (ii) COBRA premium coverage for up to 18 months, (iii)&#160;100% of his target bonus for the calendar year of termination paid in a lump sum, and (iv) full acceleration of the vesting of Dr. Hariri&#8217;s unvested equity awards. As a condition to receiving the foregoing severance benefits, Dr. Hariri must sign and not revoke a general release contained in a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Hariri&#8217;s employment agreement, if payments and benefits payable to Dr. Hariri in connection with a change in control are subject to Section 4999 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), then such payments and benefits will equal an amount determined by us in good faith to be the maximum amount that may be provided to Dr. Hariri so that the Section 4999 excise tax does not apply, or the largest portion of the payments after taking into account all applicable taxes, whichever results in Dr. Hariri receiving the greater economic benefit on an after-tax basis notwithstanding that some or all of the payment or benefit may be subject to excise tax.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Hariri&#8217;s employment agreement, if Dr. Hariri is terminated on account of his death or &#8220;disability&#8221; (as&#160;defined in the employment agreement), then Dr. Hariri (or his legal representatives, in the event of his death) will be eligible to receive a prorated bonus for the year of termination paid in a lump sum. As a condition to receiving the foregoing payment, Dr. Hariri (or his legal representatives, in the event of his death) must sign and not revoke a general release contained in a separation agreement in the form presented by us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Andrew Pecora, M.D., F.A.C.P.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into an employment agreement, dated as of September 15, 2021, <span style="color:#000000;">setting forth the terms of Dr. Pecora&#8217;s employment as our President</span>, on an at-will basis, as a full-time employee, subject to a limited exception to continue his clinical practice no more than &#189; day a week, and other reasonable exceptions that do not interfere with the performance of his duties under the employment agreement. <span style="color:#000000;">The employment agreement incorporates our Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, which Dr. Pecora signed in connection with the employment agreement.</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of his employment agreement, Dr. Pecora is entitled to an initial annual base salary of $900,000 per year, a short-term discretionary performance bonus beginning with calendar year 2022 with a target bonus percentage equal to 60% of his then current base salary. Receipt of a short-term discretionary performance bonus is subject to achievement of individual and company-wide annual performance goals, as set by us and confirmed by our board of directors. Dr. Pecora was also granted a one-time front-loaded </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity award under the 2021 Plan to purchase 2,469,282 shares of our Class A common stock, which award will vest in up to five installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date, subject to Dr. Pecora&#8217;s continued employment with us. Dr. Pecora was also granted a signing bonus equal to $1,200,000 payable in four annual installments of $300,000, with the first payment advanced on the effective date of his employment and deemed earned on the one-year anniversary thereof, with subsequent payments advanced and deemed earned on a similar basis, in each case subject to Dr. Pecora&#8217;s continued employment through such date. If Dr. Pecora&#8217;s employment terminates other than for death or disability, or Dr. Pecora is terminated without cause or resigns for good reason prior to such sign-on bonus being deemed earned, then such payment is subject to repayment to us, with pro rata forgiveness by us for each full month of service in the applicable year prior to termination of employment.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Pecora&#8217;s employment agreement, if he resigns for &#8220;good reason&#8221; or we terminate his employment without &#8220;cause&#8221; (each as defined in the employment agreement, and excluding a termination on account of Dr. Pecora&#8217;s death or disability), and if such termination or resignation is not in connection with a &#8220;change in control&#8221; (as defined in the 2021 Plan), then Dr. Pecora will be eligible to receive (i) continued payment of his base salary for nine months following the termination (less applicable tax withholdings), (ii) COBRA premium coverage for up to nine months, (iii) a prorated bonus for the year of termination paid in a lump sum, and (iv) accelerated vesting of unvested time-based equity awards that would have vested over the nine-month period following termination had he remained continuously employed (provided that his front-loaded equity grant will not accelerate if the four-year anniversary as not been achieved as of the date of termination). As a condition to receiving the foregoing severance benefits, Dr. Pecora must sign and not revoke a general release contained in a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Pecora&#8217;s employment agreement, if he resigns for &#8220;good reason&#8221; or if we terminate Dr. Pecora&#8217;s employment without &#8220;cause&#8221;, and excluding a termination on account of Dr. Pecora&#8217;s death or disability, and if such termination or resignation occurs within three months prior to or within 12&#160;months following the effective date of a &#8220;change in control&#8221;, then Dr. Pecora will be eligible to receive (i) continued payment of his base salary for 12&#160;months following the termination (less applicable tax withholdings), (ii) COBRA premium coverage for up to 12&#160;months, (iii)&#160;100% of his short-term bonus for the calendar year of termination paid in a lump sum, and (iv) full acceleration of the vesting of Dr. Pecora&#8217;s unvested equity awards, provided, however, that the front-loaded equity grant remains subject to achievement of the price targets specified in the award agreement if the change in control is after the one year anniversary of the grant but prior to the four year anniversary and vest pro rata such that they reflect the annualized rate of return implied over the four-year period adjusted to reflect the number of days between the grant day and date of the change in control. As a condition to receiving the foregoing severance benefits, Dr. Pecora must sign and not revoke a general release contained in a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination&#160;obligations, and resign from any positions held with us.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Pecora&#8217;s employment agreement, if payments and benefits payable to Dr. Pecora in connection with a change in control are subject to Section 4999 of the Code, then such payments and benefits will equal an amount determined by us in good faith to be the maximum amount that may be provided to Dr. Pecora so that the Section 4999 excise tax does not apply, or the largest portion of the payments after taking into account all applicable taxes, whichever results in Dr. Pecora receiving the greater economic benefit on an after-tax&#160;basis notwithstanding that some or all of the payment or benefit may be subject to excise tax.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Dr. Pecora&#8217;s employment agreement, if Dr. Pecora is terminated on account of his death or &#8220;disability&#8221; (as&#160;defined in the employment agreement), then Dr. Pecora (or his legal representatives, in the event of his death) will be eligible to receive a prorated bonus for the year of termination paid in a lump sum. As a condition to receiving the foregoing payment, Dr. Pecora (or his legal representatives, in the event of his death) must sign and not revoke a general release contained in a separation agreement in the form presented by us.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">John Haines</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into an employment agreement dated as of the Closing Date, setting forth the terms of Mr. Haines&#8217;s employment as our Chief Operating Officer. The employment agreement incorporates our Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement, which Mr. Haines signed in connection with the employment agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the employment agreement, Mr. Haines is entitled to an initial annual base salary of $445,000. Mr. Haines&#8217;s employment agreement also provides for an annual target bonus of up to 40% of his base salary. Receipt of an annual bonus is subject to achievement of individual and company-wide annual performance goals, as set by us and confirmed by its board of directors. On September 9, 2021, as contemplated by such agreement, Mr. Haines was granted an option to purchase 384,297 shares of Class A common stock under the 2021 Plan at an exercise price of $10.23 per share, with 50% fully-vested as of the grant date and 50% is subject to time-based vesting over a four-year period from the Closing Date, with 25% of this tranche vesting on the one-year anniversary of the Closing Date, and the remainder vesting monthly thereafter so that vested in full on the four-year anniversary of the Closing Date, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and subject to Mr. Haines&#8217; continuous service on each vesting date.&#160;&#160;Mr. Haines&#8217; employment agreement provides that he is eligible to participate in our standard benefit plans maintained for the benefit of our </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similarly-situated</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> employees.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Mr. Haines&#8217;s employment agreement, if he resigns for &#8220;good reason&#8221; or we terminate Mr. Haines&#8217;s employment without &#8220;cause&#8221; (each as defined in the employment agreement, and excluding a termination on account of Mr. Haines&#8217;s death or disability), and if such termination or resignation is not in connection with a &#8220;change in control&#8221; (as defined in the 2021 Plan), then Mr. Haines will be eligible to receive (i) continued payment of his base salary for nine months following the termination (less applicable tax withholdings), (ii) COBRA premium coverage for up to nine months, (iii) a prorated bonus for the year of termination paid in a lump sum, and (iv) nine months&#8217; of accelerated vesting of Mr. Haines&#8217;s unvested time-based equity awards. As a condition to receiving the foregoing severance benefits, Mr. Haines must sign and not revoke a general release contained in a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Mr. Haines&#8217;s employment agreement, if he resigns for &#8220;good reason&#8221; or we terminate Mr. Haines&#8217;s employment without &#8220;cause&#8221;, and if such termination or resignation occurs within three months prior to or within 12 months following the effective date of a &#8220;change in control&#8221;, then Mr. Haines will be eligible to receive (i) continued payment of his base salary for 12 months following the termination (less applicable tax withholdings), (ii) COBRA premium coverage for up to 12 months, (iii)&#160;100% of his target bonus for the calendar year of termination paid in a lump sum, and (iv) full acceleration of the vesting of Mr. Haines&#8217;s unvested equity awards. As a condition to receiving the foregoing severance benefits, Mr. Haines must sign and not revoke a general release contained in a separation agreement in the form presented by us, return all company property and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with us.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Mr. Haines&#8217;s employment agreement, if payments and benefits payable to Mr. Haines in connection with a change in control are subject to Section 4999 of the Code, then such payments and benefits will equal an amount determined by us in good faith to be the maximum amount that may be provided to Mr. Haines so that the Section 4999 excise tax does not apply, or the largest portion of the payments after taking into account all applicable taxes, whichever results in Mr. Haines receiving the greater economic benefit on an after-tax basis notwithstanding that some or all of the payment or benefit may be subject to excise tax.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Mr. Haines&#8217;s employment agreement, if Mr. Haines is terminated on account of his death or &#8220;disability&#8221; (as&#160;defined in the employment agreement), then Mr. Haines (or his legal representatives, in the event of his death) will be eligible to receive a prorated bonus for the year of termination paid in a lump sum. As a condition to receiving the foregoing payment, Mr. Haines (or his legal representatives, in the event of his death) must sign and not revoke a general release contained in a separation agreement in the form presented by us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Equity Awards at Fiscal Year-End</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information with respect to outstanding common stock option awards for each of us named executive officers as of December&#160;31, 2021. The table reflects both vested and unvested option awards. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td colspan="18" valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option Awards</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Named Executive Officer</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercised</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options (#)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unexercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/20/18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">334,816</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(1)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,554</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.87</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/20/28</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/03/18</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174,679</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.88</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/03/28</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/06/20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,119</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(1)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,177</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.70</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/06/30</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/06/21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,921,485</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/06/31</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/09/21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,345,039</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(2)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,345,040</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/09/31</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Pecora, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/02/17</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,297</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/02/27</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/07/20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,718</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.70</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">05/07/31</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/24/21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269,007</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.83</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/24/31</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/06/21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,718</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/06/31</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/09/21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,859</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(2)</sub></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,859</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/09/21</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/15/21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,469,282</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(2)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.32</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/15/31</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Haines</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/02/17</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,607</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.28</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">06/02/27</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/20/18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322,015</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(1)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,089</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.87</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/20/28</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/03/18</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,138</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.88</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/03/28</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/06/20</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,589</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(1)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.70</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/06/30</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/06/21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,296</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">04/06/31</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/09/21</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,148</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(2)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,149</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">09/09/31</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">25% vest at one year after grant, and monthly thereafter for three years.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">50% is fully-vested as of the grant date&#59; 50% is subject to time-based vesting over a four-year period from July 16, 2021, with 25% of this tranche vesting on the one-year anniversary of July 16, 2021, and the remainder vesting monthly thereafter so that vested in full on the four-year anniversary of July 16, 2021.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;">Up to five installments in respect of achieving certain share price targets between third and fourth anniversary of the effective date, subject to continuous service on each vesting date.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Perquisites, Health, Welfare and Retirement Benefits</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers, during their employment with it, are eligible to participate in its employee benefit plans, including its medical, dental, group term life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as all of its other employees. In addition, We provide a 401(k) plan to our employees, including its executive officers, as discussed in the section below entitled &#8220;&#8212; 401(k) Plan.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally do not provide perquisites or personal benefits to its named executive officer, except in limited circumstances. We do, however, pay the premiums for medical, dental, group term life, disability and accidental death and dismemberment insurance for all of our employees, including its named executive officers. The board of directors may elect to adopt qualified or nonqualified benefit plans in the future if we determine that doing so is in its best interests.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">401(k) Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our executive officers are eligible to participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a tax-qualified plan under Section 401(k) of the Code. The 401(k) plan provides that each participant may contribute up to the lesser of 100% of his or her compensation or the statutory limit, which is $19,500 for each of calendar years 2020 and 2021. Participants that are 50 years or older can also make &#8220;catch-up&#8221; contributions, which in each of calendar years 2020 and 2021 may be up to an additional $6,500 above the statutory limit. We currently make matching contributions into the 401(k) plan on behalf of participants. Participant contributions are held and invested, pursuant to the participant&#8217;s instructions, by the plan&#8217;s trustee.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nonqualified Deferred Compensation</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. The board of directors may elect to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if we determines that doing so is in our best interests.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Benefit Plans</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2021 Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021 our board of directors adopted the 2021 Plan and our stockholders approved the 2021 Plan in July 2021. The 2021 Plan became effective immediately upon the closing of the Business Combination.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Eligibility.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Our employees, consultants and directors, and employees and consultants of its affiliates, may be eligible to receive awards under the 2021 Plan. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Award Types.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The 2021 Plan provides for the grant of incentive stock options, or ISOs, to employees and for the grant of nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors, and consultants.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Reserve.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The number of shares of Class A common stock initially reserved for issuance under the 2021 Plan is 20,915,283 shares of Class A common stock (9.78% of the total number of issued and outstanding shares of Class A common stock immediately after the Closing), or the Share Reserve. The number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1 of each year, for a period of ten years, from January 1, 2022 continuing through January 1, 2031, by 4% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by our board of directors. The maximum number of shares that may be issued pursuant to the exercise of ISOs under the 2021 Plan is (300% of the number of shares of Class A common stock initially reserved under the 2021 Plan). Shares issued under the 2021 Plan may be authorized but unissued or reacquired shares. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021 Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021 Plan.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Administration.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Our board of directors, or a duly authorized committee thereof, will have the authority to administer the 2021 Plan. Our board of directors, or a duly authorized committee thereof, may also delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of our stockholders.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options.<span style="font-style:normal;">&#160;&#160;&#160;&#160;ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2021 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of a share of the Class A common stock on the date of grant (however, a stock option may be granted with an exercise or strike price lower than 100% of the fair market value on the date of grant of such award if such award is granted pursuant to an assumption of or substitution for another option pursuant to a Corporate Transaction (as such term is defined in the 2021 Plan) and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code ). Options granted under the 2021 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator. However, no stock option granted to an employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will generally be first exercisable until at least six months following the date of grant. The plan administrator determines the term of stock options granted under the 2021 Plan, up to a maximum of ten years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that the exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#8217;s service relationship ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. Options generally terminate immediately upon the termination of an optionholder&#8217;s service for cause. In no event may an option be exercised beyond the expiration of its term. Acceptable consideration for the purchase of GX common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (i) cash, check, bank draft, or money order, (ii) a broker-assisted cashless exercise, (iii) the tender of shares of Class A common stock previously owned by the optionholder, (iv) a net exercise of the option if it is an NSO and (v) other legal consideration approved by the plan administrator.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Limitations on ISOs.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The aggregate fair market value, determined at the time of grant, of Class A common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all stock plans maintained by us may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2) the option is not exercisable after the expiration of five years from the date of grant.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Restricted stock awards are granted under restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services, or any other form of legal consideration that may be acceptable to the plan administrator and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Except as provided otherwise in the applicable award agreement, if a participant&#8217;s service relationship ends for any reason, we may receive through a forfeiture condition or a repurchase right any or all of the shares held by the participant under his or her restricted stock award that have not vested as of the date the participant terminates service.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Restricted stock units are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted stock units may be granted in consideration for any form of legal consideration that may be acceptable to the plan administrator and permissible under applicable law. A restricted stock unit may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Stock appreciation rights are granted under stock appreciation grant agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of Class A common stock on the date of grant (however, a stock appreciation right may be granted with an exercise or strike price lower than 100% of the fair market value on the date of grant of such award if such award is granted pursuant to an assumption of or substitution for another option pursuant to a Corporate Transaction (as such term is defined in the 2021 Plan) and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of Code ). A stock appreciation right granted under the 2021 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator. However, no stock-settled stock appreciation right granted to an employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will generally be first exercisable until at least six months following the date of grant.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The 2021 Plan permits the grant of performance-based stock and cash awards. The plan administrator may structure awards so that the shares of Class A common stock, cash, or other property will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period. The performance criteria that will be used to establish such performance goals may be based on any measure of performance selected by the plan administrator. The performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i) in the award agreement at the time the award is granted or (ii) in such other document setting forth the performance goals at the time the goals are established, the plan administrator will appropriately make adjustments in the method of calculating the attainment of performance goals as follows: (1) to exclude restructuring and/or other nonrecurring charges&#59; (2) to exclude exchange rate effects&#59; (3) to exclude the effects of changes to generally accepted accounting principles&#59; (4) to exclude the effects of any statutory adjustments to corporate tax rates&#59; (5) to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles&#59; (6) to exclude the dilutive effects of acquisitions or joint ventures&#59; (7) to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture&#59; (8) to exclude the effect of any change in the outstanding shares of Class A common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to stockholders other than regular cash dividends&#59; (9) to exclude the effects of stock-based compensation and the award of bonuses under our bonus plans&#59; (10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to expense under generally accepted accounting principles&#59; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be recorded </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:normal;">under generally accepted accounting principles. In addition, the plan administrator retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the performance goals. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the applicable award agreement or the written terms of a performance cash award. The performance goals may differ from participant to participant and from award to award.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Stock Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The plan administrator may grant other awards based in whole or in part by reference to Class A common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Employee Director Compensation Limit.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The aggregate value of all compensation granted or paid by us to any individual for service as a non-employee director with respect to any calendar year, or such period, the annual period, including stock awards and cash fees paid by us to such non-employee director, will not exceed (i) $750,000 in total value or (ii) in the event such non-employee director is first appointed or elected to the board during such annual period, $1,000,000 in total value. For purposes of these limitations, the value of any such stock awards is calculated based on the grant date fair value of such stock awards for financial reporting purposes.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure.<span style="font-style:normal;">&#160;&#160;&#160;&#160;In the event there is a specified type of change in our capital structure, such as a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, appropriate adjustments will be made to (i) the class(es) and maximum number of shares of Class A common stock subject to the 2021 Plan and the maximum number of shares by which the share reserve may annually increase&#59; (ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of ISOs&#59; and (iii) the class(es) and number of securities and exercise price, strike price or purchase price of common stock subject to outstanding awards.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The following applies to stock awards under the 2021 Plan in the event of a corporate transaction, as defined in the 2021 Plan, unless otherwise provided in a participant&#8217;s stock award agreement or other written agreement with us or unless otherwise expressly provided by the plan administrator at the time of grant. In the event of a corporate transaction, any stock awards outstanding under the 2021 Plan may be assumed, continued or substituted by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute such stock awards, then with respect to any such stock awards that are held by participants whose continuous service has not terminated prior to the effective time of the transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full to a date prior to the effective time of the transaction (contingent upon the effectiveness of the transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards will lapse (contingent upon the effectiveness of the transaction). With respect to performance awards with multiple vesting levels depending on performance level, unless otherwise provided by an award agreement or by the plan administrator, the award will accelerate at 100% of target. If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute such stock awards, then with respect to any such stock awards that are held by persons other than current participants, such awards will terminate if not exercised (if applicable) prior to the effective time of the transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the transaction. The plan administrator is not obligated to treat all stock awards or portions of stock awards in the same manner and is not obligated to take the same actions with respect to all participants. In the event a stock award will terminate if not exercised prior to the effective time of a transaction, the plan administrator may provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value, at the effective time, to the excess (if any) of (1) the value of the property the participant would have received upon the exercise of the stock award over (2) any exercise price payable by such holder in connection with such exercise.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Control.<span style="font-style:normal;">&#160;&#160;&#160;&#160;In the event of a change in control, as defined under the 2021 Plan, awards will generally be treated as described above in connection with a corporate transaction. Notwithstanding the foregoing, in the event of a change in control, vested awards that are subject to Section 409A of the Code will be settled in connection with the change in control (to the extent the change in control constitutes a Section 409A change in control).</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Amendment or Termination.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Our board of directors will have the authority to amend, suspend, or terminate the 2021 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. No ISOs may be granted after the tenth anniversary of the date the our board of directors adopted the 2021 Plan.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021 our board of directors adopted the ESPP and our stockholders approved the ESPP in July 2021. The ESPP Plan became effective immediately upon the Closing of the Business Combination.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Purpose of the ESPP</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of the ESPP is to provide eligible employees with an opportunity to increase their proprietary interest in our success by purchasing Class A common stock from us on favorable terms and to pay for such purchases through payroll deductions. We believe by providing eligible employees with an opportunity to increase their proprietary interest in our success, the ESPP will motivate recipients to offer their maximum effort to us and help focus them on the creation of long-term value consistent with the interests of our stockholders.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Summary of the ESPP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This section summarizes certain principal features of the ESPP. The summary is qualified in its entirety by reference to the complete text of the ESPP.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Eligibility.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Our employees and employees its designated affiliates may be eligible to participate in the ESPP. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Share Reserve.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The ESPP authorizes the issuance of 2,139,220 shares of Class A common stock under purchase rights granted to our employees or to employees of any of our designated affiliates. The number of shares of Class A common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2022 through January 1, 2031, by the lesser of (i) 1% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year, and (ii) 2,139,220 shares (100% of the initial share reserve)&#59; provided, that prior to the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). The shares purchasable under the ESPP will be shares of authorized but unissued or reacquired shares of Class A common stock, including shares repurchased by us on the open market. If purchase rights granted under the ESPP terminate without having been exercised, the shares of Class A common stock not purchased under such purchase rights will again become available for issuance under the ESPP.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Administration.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Our board of directors, or a duly authorized committee thereof, have the authority to administer the ESPP. The ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of Class A common stock on specified dates during such offerings. Under the ESPP, the plan administrator may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of Class A common stock will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Payroll Deductions.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, will be eligible to participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings (as defined in the ESPP) for the purchase of Class A common stock under the ESPP. Unless otherwise determined by the plan administrator, Class A common stock will be purchased for the accounts of employees participating in the ESPP at a price per share equal to not less than the lesser of (i) 85% of the fair market value of a share of Class A common stock on the first trading date of an offering or (ii) 85% of the fair market value of a share of Class A common stock on the date of purchase.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Limitations.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as determined by the plan administrator, including: (i) being customarily employed for more than 20 hours per week&#59; (ii) being customarily employed for more than five months per calendar year&#59; or (iii) continuous employment for a period of time (not to exceed two years). No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of Class A common stock based on the fair market value per share of Class A common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our capital stock measured by vote or value pursuant to Section 424(d) of the Code.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure.<span style="font-style:normal;">&#160;&#160;&#160;&#160;In the event that there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transactions, the plan administrator will make appropriate adjustments to (i) the class(es) and maximum number of shares reserved under the ESPP, (ii) the class(es) and maximum number of shares by which the share reserve may increase automatically each year, (iii) the class(es) and maximum number of shares and purchase price applicable to all outstanding offerings and purchase rights and (iv) the class(es) and number of shares that are subject to purchase limits under ongoing offerings.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Transactions.<span style="font-style:normal;">&#160;&#160;&#160;&#160;In the event of a corporate transaction, as defined in the ESPP, any then-outstanding rights to purchase shares under the ESPP may be assumed, continued or substituted by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of Class A common stock within ten business days prior to such corporate transaction, and such purchase rights will terminate immediately.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ESPP Amendment or Termination.</span><span style="font-style:normal;">&#160;&#160;&#160;&#160;Our board of directors will have the authority to amend or terminate the ESPP, provided that except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We must obtain stockholder approval of any amendment to the ESPP to the extent required by applicable law or listing rules.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amended and Restated 2017 Equity Incentive Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary description of the material features of Legacy Celularity&#8217;s Amended and Restated 2017 Equity Incentive Plan, or the 2017 Plan, is set forth below. The following summary does not purport to be a complete description of all the provisions of the 2017 Plan and is qualified by reference to the 2017 Plan.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Legacy Celularity Board originally adopted and its stockholders approved the 2017 Plan on June 2, 2017. The 2017 Plan was subsequently amended and restated on December 3, 2018 and October 22, 2020 by the Legacy Celularity Board and on January 26, 2021 by Legacy Celularity&#8217;s stockholders. The 2017 Plan terminated in connection with the Closing, and no further grants will be made under the 2017 Plan. Any outstanding awards granted under the 2017 Plan remain subject to the terms of the 2017 Plan and the applicable award agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The 2017 Plan provides for the grant of options to purchase shares of Celularity&#8217;s common stock intended to qualify as ISOs under Section 422 of the Code, options that do not so qualify, stock appreciation rights, restricted stock awards, restricted stock unit awards and other awards, collectively, stock awards. ISOs may be granted only to Celularity&#8217;s employees and the employees of Celularity&#8217;s parent corporation or subsidiary corporation. All other awards may be granted to Celularity&#8217;s employees, directors, and consultants and the employees, directors, and consultants of Celularity&#8217;s affiliates. Celularity has granted stock options under the 2017 Plan. Subject to adjustments for changes to the capital structure, the aggregate number of shares of common stock that may be issued pursuant to awards will not exceed 42,079,496 shares. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a stock award or any portion thereof granted under the 2017 Plan, (i) expires or otherwise terminates without all shares subject to such award being issued, (ii) is settled in cash, (iii) is forfeited to or repurchased by Celularity because of the failure to meet a contingency or condition required to vest such shares, or (iv) is reacquired by Celularity in satisfaction of tax withholding obligations or as consideration for the exercise or purchase price of a stock award, then such shares subject to the stock award will once again become available for issuance under the 2017 Plan.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Administration.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The board of directors, or a duly authorized committee thereof, has the authority to administer the 2017 Plan. The board of directors may also delegate to one or more officers the authority to (1) designate employees (other than other officers) to be recipients of certain stock awards, and (2) determine the number of shares of common stock to be subject to such stock awards. Subject to the terms of the 2017 Plan, the plan administrator determines the award recipients, dates of grant, the numbers and types of stock awards to be granted and the applicable fair market value and the provisions of the stock awards, including the period of their exercisability, the vesting schedule applicable to a stock award and any repurchase rights that may apply.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator has the authority to modify outstanding awards, including reducing the exercise, purchase or strike price of any outstanding stock award, canceling any outstanding stock award in exchange for new stock awards, cash or other consideration or taking any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options.<span style="font-style:normal;">&#160;&#160;&#160;&#160;ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2017 Plan vest at the rate specified by the plan administrator.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the term of stock options granted under the 2017 Plan, up to a maximum of ten years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service with Celularity, or any of Celularity&#8217;s affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that the exercise of the option following such a termination of service is prohibited by applicable securities laws. If an optionholder&#8217;s service with Celularity or any of Celularity&#8217;s affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual&#8217;s service for cause. In no event may an option be exercised beyond the expiration of its term.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1) cash, check, bank draft, electronic funds transfer or money order, (2) a broker-assisted cashless exercise, (3) the tender of cash proceeds from a sale to a third party investor of some of the shares to be exercised, (4) delivery </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our common shares, (5) a net exercise of the option if it is an NSO, or (6) deferred payment or a similar arrangement with the optionholder, and (7) other legal consideration approved by the plan administrator.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Limitations on Incentive Stock Options.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The aggregate fair market value, determined at the time of grant, of common stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all Celularity&#8217;s stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of Celularity&#8217;s total combined voting power or that of any of Celularity&#8217;s affiliates unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (2) the term of the ISO does not exceed five years from the date of grant.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Incentive Stock Option Limit.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The maximum number of shares of common stock that may be issued upon the exercise of ISOs under the 2017 Plan is 53,655,600 shares.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. Restricted stock awards may be granted in consideration for (1) cash, check, bank draft, electronic funds, wire transfer, or money order, (2) past services rendered to Celularity or Celularity&#8217;s affiliates, or (3) any other form of legal consideration. Common stock acquired under a restricted stock award may be subject to a share repurchase option in Celularity&#8217;s favor in accordance with a vesting schedule to be determined by the plan administrator. A restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator. Except as otherwise provided in the applicable award agreement, restricted stock awards that have not vested may be forfeited or repurchased by Celularity upon the participant&#8217;s cessation of continuous service for any reason.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to the board of directors and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the administrator or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Awards.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The plan administrator may grant other awards based in whole or in part by reference to Celularity&#8217;s common stock. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure<span style="font-style:normal;">.&#160;&#160;&#160;&#160;In the event that there is a specified type of change in Celularity&#8217;s capital structure, such as a stock split or recapitalization, appropriate adjustments will be made to (1) the class(es) and maximum number of shares reserved for issuance under the 2017 Plan, (2) the class(es) and maximum number of shares that may be issued upon the exercise of ISOs and (3) the class(es) and number of shares and price per share of stock subject to outstanding stock awards.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Change in Control.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The 2017 Plan provides that in the event of a change in control, unless otherwise provided in an award agreement or other written agreement between Celularity and the award holder, the plan administrator may take one or more of the following actions with respect to each stock award, contingent upon the closing or completion of the transaction: (1) arrange for the assumption, continuation or substitution of the stock award by a successor corporation, (2) arrange for the assignment of any reacquisition or repurchase rights held by Celularity in respect of our common stock issued pursuant to the stock award to a successor corporation, (3) accelerate the vesting, in whole or in part, of the stock award and provide for its termination if not exercised immediately prior to the effective time of the transaction, (4) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by Celularity with respect to the stock award, (5) cancel or arrange for the cancellation of the stock award, to the extent not vested or not exercised prior to the effective time of the transaction, in exchange for a cash payment, or no payment, as determined by the plan administrator or (6) make a payment, in the form determined by the plan administrator, equal to the excess, if any, of the value of the property the holder would have received upon exercise of the stock award immediately prior to the effective time of the transaction over any exercise price payable by the holder. The plan administrator is not obligated to treat all stock awards or portions thereof in the same manner, and the plan administrator may take different actions with respect to the vested and unvested portions of a stock award.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) refuses to assume, continue, replace with new awards or otherwise substitute a new award for, an outstanding stock award (including unvested outstanding shares), such stock award will become fully vested as of immediately prior to the closing of the change in control.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2017 Plan, a change in control is generally the consummation of one or more of the following events: (1) any person becomes the owner, directly or indirectly, of our securities representing more than 50% of the combined voting power of our then outstanding securities other than by virtue of a merger, consolidation or similar transaction&#59; (2) a consummated a merger, consolidation or similar transaction involving (directly or indirectly) us and, immediately after such transaction, our stockholders immediately prior thereto do not own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving entity in such transaction, or (B) more than 50% of the combined outstanding voting power </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the parent of the surviving entity in such transaction, or (3) a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of Celularity and its subsidiaries.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transferability.<span style="font-style:normal;">&#160;&#160;&#160;&#160;A participant generally may not transfer stock awards under the 2017 Plan other than by will, the laws of descent and distribution or as otherwise provided under the 2017 Plan.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:6.67%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amendment and Termination.<span style="font-style:normal;">&#160;&#160;&#160;&#160;The board of directors has the authority to amend, suspend or terminate the 2017 Plan, provided that, with certain exceptions, such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Unless terminated sooner by the board of directors, the 2017 Plan will automatically terminate on June 2, 2027. No stock awards may be granted under the 2017 Plan while it is suspended or terminated. The 2017 Plan terminated in connection with the Closing, and no further grants will be made under the 2017 Plan.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Director Compensation</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we adopted a&#160;non-employee&#160;director compensation policy, which sets forth the terms upon which&#160;non-employee&#160;directors will be compensated for their service on the Board. <span style="color:#000000;">Under this policy, non-employee directors ae compensated in cash for their board service and service on committees, receive equity and reimbursement for reasonable and necessary out-of-pocket expenses incurred in connection with attending board and committee meetings or performing other services in their capacities as directors. </span>Under the terms of the policy in effect in 2021, each&#160;non-employee&#160;director received an annual cash retainer of $45,000. Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee will each receive additional annual cash retainers of $10,000, $8,000 and $5,000, respectively, while the chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee received additional annual cash retainers of $20,000, $16,000 and $10,000, respectively.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the policy, each non-employee&#160;member of the Board will automatically receive an annual option grant equal to $250,000 as of the date of grant, at an exercise price based on the grant-date fair value of the award, which will vest on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the director&#8217;s continued service as a director through such date. In 2022, our directors modified the equity component of our non-employee director compensation program to increase the value of the annual grant to $300,000 and provide for the issuance of 50% options and 50% restricted stock units, and also provided for an initial equity grant equal to $300,000 of options, which options will vest ratably over three years from the grant date. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any&#160;non-employee&#160;director&#160;in a calendar year will not exceed $1,000,000 in the first calendar year such individual becomes a&#160;non-employee&#160;director&#160;and $750,000 in any other calendar year.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Hariri does not receive additional compensation for his services as a director.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides the compensation paid to our non-employee&#160;directors in 2021:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fees</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">earned or</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid in</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">cash</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Option</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">awards</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">All other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">compensation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Bloom</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,996</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">276,996</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peter H. Diamandis, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,990,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,996</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,496</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lim Kok Thay</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,002,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc Mazur</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,550</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">249,996</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">285,546</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sculley</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,250</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,994,746</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robin L. Smith, M.D., M.B.A.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,000</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,496</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,989,496</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew C. von Eschenbach, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,000</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,947,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,984,496</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:-4.44%;font-family:Times New Roman;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:-4.44%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)&#160;&#160;&#160;&#160;&#160;&#160;Amounts reported represent the aggregate grant date fair value of the stock options and a deferred compensation award granted to the non</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee directors during 2021, computed in accordance with the FASB&#8217;s ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 11 to Celularity&#8217;s audited consolidated financial statements included elsewhere in this annual report. This amount does not reflect the actual economic value that may be realized by the non-employee director, which will depend on factors including the continued service of the executive and the future value of our stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;margin-left:4.44%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below shows the aggregate numbers of option awards (exercisable and unexercisable) held as of December 31, 2021 by each non-employee director who was serving as a member of our board of directors as of December 31, 2021 and who is currently serving as a member of the board of directors.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Bloom</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,053</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peter H. Diamandis, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,056,196</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,053</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lim Kok Thay</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,060</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc Mazur</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,053</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sculley</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,093,654</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robin L. Smith, M.D., M.B.A.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709,357</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew C. von Eschenbach, M.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">532,498</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred Compensation &#8211; Director Awards</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, our board of directors authorized the grant to each of our non-employee&#160;directors an option to purchase 350,000&#160;shares of common stock at an exercise price of the then-current&#160;fair market value of common stock, which our board of directors had anticipated to be similar to the fair market value of common stock at June&#160;30, 2020. This grant of the options was subject to the completion of a 409A valuation. Due to Celularity&#8217;s inability to timely obtain the required 409A valuation prior to initial discussions regarding a potential business combination, the option awards that had been previously authorized in August 2020 were not granted to the non-employee&#160;directors. In March 2021, in lieu of granting the previously authorized stock options, our Board separately approved the grant of deferred compensation awards under the 2017 Plan to each of its current non-employee&#160;directors (but not including any non-employee&#160;directors who became our director upon completion of the Business Combination). These awards were structured to be non-qualified&#160;deferred compensation compliant with, and not be exempt from, Section 409A of the Code (the &#8220;Director Awards&#8221;). The Director Awards are not stock options for purposes of the 2017 Plan and are classified as &#8220;other awards&#8221; thereunder. Each Director Award, as assumed in the Merger, provides the non-employee&#160;director with the right to purchase 269,007&#160;shares of Class A common stock for a price of $3.83 per share. The Director Awards are fully vested at grant, but in order to comply with Section 409A of the Code, are only exercisable upon the earlier of (i) the 90-day&#160;period following the second anniversary of the grant date and (ii) a change in control of our Company (as defined in the 2017 Plan, but specifically excluding the Business Combination and requiring that event also constitutes a change in control event for purposes of Section 409A). The Director Awards will expire to the extent not exercised at the earlier of such times. The Director Awards will remain outstanding if the director leaves the&#160;&#160;board of directors&#160;&#160;through the earlier of such events, and will expire if not exercised in connection with the first to occur of the events described above. The non-employee&#160;director would not have discretion as to when to exercise the Director Awards.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Director Awards are not intended to be stock options that are exempt from the application of Section&#160;409A, the Director Awards could have been authorized for grant at any exercise price (including for no exercise price, similar to a restricted stock unit award). However, in order to honor the original intent for such awards, our board of directors used the fair market value of its common stock as of June&#160;30, 2020, $2.94 per share, as determined by our independent third-party&#160;409A valuation provider. This value corresponds to the fair market value of its common stock as of the date our Board authorized the grant of options to the non-employee&#160;directors in August 2020 but ultimately did not grant due to the inability to timely obtain this valuation.&#160;&#160;Our board of directors received this 409A valuation at the March 2021 board meeting in connection with the granting of the Director Awards. While no valuation is required to make these grants for Section 409A compliance purposes, our Board used the valuation solely for purposes of determining the exercise price for the Director Awards. Given the structure of the Director Awards, we expect to recognize the expense for the grant of Director Awards in the amount of approximately $10&#160;million in the second quarter of 2021.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information regarding the beneficial ownership of shares of Class A common stock as of March 1, 2022 by: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman PS Std;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman PS Std;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">each person known by us to be the beneficial owner of more than 5% of our Class A common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman PS Std;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman PS Std;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">each of our named executive officers and directors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.03%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman PS Std;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman PS Std;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">all of our executive officers and directors as a group.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options,&#160;&#160;warrants </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and restricted stock units that are currently exercisable or vested or that will become exercisable or vest within 60 days. This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G or 13D filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that all persons named in the table have sole voting and investment power with respect to all shares of Class A </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock beneficially owned by them.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The beneficial ownership percentages set forth in the table below are based on 137,589,270 shares of Class A common stock issued and outstanding as of March 1, 2022 and other than as noted below, do not take into account the issuances of any shares of Class&#160;A common stock upon the exercise of warrants or options.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name and Address of Beneficial Owner<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Class A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Five Percent or Greater Stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dragasac Limited<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,592,597</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,422,124</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.8</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starr International Investments Ltd.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">4)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,281,389</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celgene Corporation<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">5)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,953,274</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.7</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung Biotechnology PBC<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">6)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,968,848</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human Longevity, Inc.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">7)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,012,573</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Directors and Named Executive Officers</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">8)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,749,397</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John R. Haines<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">9)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,974</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Pecora, M.D., F.A.C.P.<sup style="font-size:85%;line-height:120%;vertical-align:top"> (10)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,037,599</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Sculley<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">11)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,037,601</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Bloom<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">12)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,336,617</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peter Diamandis, M.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">13)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000,143</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">14)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,343,779</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lim Kok Thay<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">15)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,861,604</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.5</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marc Mazur<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">16)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,927</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robin L. Smith, M.D., M.B.A.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">17)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">653,304</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew C. Von Eschenbach, M.D.<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">18)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,445</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">All Directors and Executive Officers of as a Group (16 Individuals)<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">19)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,785,389</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.8</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Less than one percent.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Unless otherwise noted, the business address of each of the executive officers and directors is c/o Celularity Inc., 170 Park Ave, Florham Park, NJ 07932.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of (i) 30,062,779 shares of Class A common stock and (ii) 6,529,818 shares of Class A common stock issuable upon exercise of a Converted Legacy Warrant at an exercise price of $6.77 per share. These securities are directly held by Dragasac, which is an indirect wholly-owned subsidiary of Genting Berhad, a public company listed on the Malaysian stock exchange. Lim Kok Thay is an indirect beneficial owner of the largest shareholder of Genting Berhad, where he serves as Chief Executive and Chairman of the Board, and in such capacity may be deemed to beneficially own shares held by Dragasac Limited. The address for Dragasac Limited is c/o 24<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Floor, Wisma Genting, 28&#160;Jalan Sultan Ismail, 50250 Kuala Lumpur, Malaysia.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">The address for Sorrento Therapeutics, Inc. is 4955 Directors Place, San Diego, California 92121.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">The address for Starr International Investments Ltd. is Bermuda Commercial Bank Building, 19 Par-La-Ville Road, Hamilton, HM 11, BM Bermuda. Starr International Investments Ltd. is a wholly owned subsidiary of Starr International Company, Inc., a Swiss corporation, which, accordingly, may be deemed to beneficially own these securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(5)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">The address for Celgene Corporation is 86 Morris Avenue, Summit, New Jersey 07901.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(6)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">The address for Lung Biotechnology Investments, Ltd. is 1040 Spring Street, Silver Spring, Maryland 20910.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(7)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">The address for Human Longevity, Inc. is 4570 Executive Drive, San Diego, California 92121.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(8)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of 7,734,689 shares held directly by Dr. Hariri and 4,014,708 shares issuable to Dr. Hariri pursuant to options exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(9)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Reflects 1,102,974 shares issuable to Mr. Haines pursuant to options exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(10)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Reflects 1,037,599 shares issuable to Dr. Pecora pursuant to options exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(11)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Reflects 1,037,601 shares issuable to Mr. Sculley pursuant to options and a deferred compensation awards exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(12)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of: (i) 1,661,253 shares of common stock received in a pro rata distribution-in-kind from Sponsor, (ii) 100,000 shares retained by Sponsor, (iii) 1,730,000 shares issuable upon exercise of warrants received in a pro rata distribution-in-kind from Sponsor and (iv) 845,364 shares issuable upon exercise of warrants of GX, which were acquired from GX upon completion of the Business Combination as the repayment of $845,364 in promissory notes in connection with certain working capital loans. Cooper Road, LLC is the record holder of the securities in clauses (i), (iii) and (iv) of the preceding sentence. Cooper Road, LLC is an entity controlled by Jay R. Bloom. Mr. Bloom disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Sponsor </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="font-size:9pt;color:#000000;">is the record holder of the shares described in clause (ii) of the first sentence. Cooper Road, LLC (an entity controlled by Jay R. Bloom) and Dean C. Kehler are the managing members of Sponsor, and as such Messrs. Bloom and Kehler have voting and investment discretion with respect to the securities held of record by Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by Sponsor. Each such entity or person disclaims any beneficial ownership of the reported securities other than to the extent of any pecuniary interest they may have therein, </span><span style="font-size:9pt;color:#000000;">directly</span><span style="font-size:9pt;color:#000000;"> or indirectly.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(13)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Reflects 4,000,143 shares issuable to Dr. Diamandis pursuant to options and a deferred compensation awards exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(14)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of: (i) 1,414,768 shares of common stock received in a pro rata distribution-in-kind from Sponsor, (ii) 394,376 shares of common stock received in a pro rata distribution-in-kind from Sponsor to Elizabeth Kehler 2012 Trust, of which Dean Kehler&#8217;s spouse serves as a trustee, (iii) 100,000 shares retained by Sponsor, (iv) 1,880,000 shares issuable upon exercise of warrants received in a pro rata distribution-in-kind from Sponsor and (iv) 554,635 shares issuable upon exercise of warrants of GX, which were acquired from GX upon completion of the Business Combination as the repayment of $554,635 in promissory notes in connection with certain working capital loans. Sponsor is the record holder of the shares described in clause (iii) of the previous sentence. Cooper Road, LLC (an entity controlled by Jay R. Bloom) and Dean C. Kehler are the managing members of Sponsor, and as such Messrs. Bloom and Kehler have voting and investment discretion with respect to the securities held of record by Sponsor and may be deemed to have shared beneficial ownership of the securities held directly by Sponsor. Each such entity or person disclaims any beneficial ownership of the reported securities other than to the extent of any pecuniary interest they may have therein, directly or indirectly. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(15)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of (i) 36,592,596 shares held by Dragasac Limited and (ii) 269,007 shares issuable to Mr. Lim pursuant to a deferred compensation award exercisable within 60 days of December&#160;31, 2021. See footnote 2. Mr. Lim may be deemed to beneficially own shares held by Dragasac Limited.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(16)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of (i) 48,927 shares of common stock received in a pro rata distribution-in-kind from Sponsor and (ii) 25,000 shares issuable upon exercise of warrants received in a pro rata distribution-in-kind from Sponsor.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(17)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Reflects 653,304 shares issuable to Dr. Smith pursuant to options and a deferred compensation award exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(18)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Consists of (i) 100,000 shares and (ii) 476,445 shares issuable to Dr. Von Eschenbach pursuant to options and a deferred compensation award exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(19)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Reflects (i) 41,516,792 shares, (ii) 11,664,817 shares issuable upon exercise of warrants and (iii) 13,603,780 shares issuable upon exercise of options and deferred compensation awards exercisable within 60 days of March 1, 2022.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation Plan Information (Information as of December 31, 2021)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:1pt;">
<td valign="bottom" style="width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:20.18%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:19.02%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="width:18.42%;white-space:nowrap;">
</td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Securities</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Remaining Available for</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Future Issuance Under</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Securities </p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average </p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Equity Compensation</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">to be Issued Upon Exercise</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Plans (Excluding</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">of Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options and</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Reflected in</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:40.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Plan Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:20.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options and Rights(A)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#FFFFFF;width:19.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rights</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:0.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:18.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Column(A))</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CCEEFF;width:40.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity compensation plans approved by security holders.</p></td>
<td valign="bottom" style="background-color:#CCEEFF;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#CCEEFF;width:20.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,533,868 </p></td>
<td valign="bottom" style="background-color:#CCEEFF;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#CCEEFF;width:0.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CCEEFF;width:19.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.43 </p></td>
<td valign="bottom" style="background-color:#CCEEFF;width:0.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
</td>
<td valign="bottom" style="background-color:#CCEEFF;width:18.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.56%;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,152,282 </p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following includes a summary of transactions since January 1, 2019 to which we&#160;&#160;have been a party, in which the amount involved in the transaction exceeded the lesser of $120,000 or one percent of the average of its total assets at year-end for the last two completed fiscal years, and in which any of its directors, executive officers or, to its knowledge, beneficial owners of more than 5% of its capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under Item 10 &#8220;Executive Compensation.&#8221; Upon the Closing, agreements of Legacy Celularity were assumed by Celularity LLC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subscription Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the Closing Date, certain significant stockholders or their affiliates (including Sorrento), Starr International Investments Ltd., or Starr International, and Dragasac Limited, an indirect wholly owned subsidiary of&#160;Genting Berhad, collectively, the &#8220;Subscribers&#8221;) purchased from us an aggregate of 8,340,000 shares of Class A common stock, for a purchase price of $10.00 per share and an aggregate purchase price of $83.4 million, pursuant to separate subscription agreements dated January 8, 2021. Pursuant to the Subscription Agreements, we agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lock-Up Agreements</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Closing, certain of our stockholders, including the directors and officers, agreed, subject to certain exceptions, not to, without the prior written consent of our board of directors, transfer (i) any shares of our Class A common stock held by such parties immediately after the Business Combination, (ii) any securities convertible into or exercisable or exchangeable for our Class A common stock, including the Private Placement Warrants, held by such parties immediately after the Business Combination and (iii) any shares of our Class A common stock issued upon conversion, exercise or exchange of any of the securities described in clause (ii). The lock-up period commenced upon the Closing and continues through the earliest to occur of: (i) 365 days after the date of the Closing&#59; (ii) the first day after the date on which the closing price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing&#59; or (iii) the date on which we complete a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their Class A common stock for cash, securities or other property. The lock-up restrictions contain customary exceptions, including for estate planning transfers, affiliates transfers, and transfers upon death or by will.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sponsor Vesting Agreement<span style="font-weight:normal;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Closing, GX Sponsor LLC the sponsor of GX prior to consummation of the Business Combination, distributed to its members 7,087,500 shares of Class A common stock, and 7,000,000 Private Placement Warrants.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the distribution, the Sponsor and each member of Sponsor that received such shares in the distribution entered into vesting agreements pursuant to which 25% of the shares received by each such holder became subject to a restriction on transfer, with such shares being released from this transfer restriction on the first day that the volume weighted average price of the Class A common stock on Nasdaq is at or above $12.00 for 20 trading days over a 30 consecutive trading day period. Any such shares that do not vest by July 15, 2031 will be forfeited.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each member of Sponsor that received shares in the distribution also entered into a lock-up agreement on substantially the same terms as described above under &#8220;&#8212;<span style="font-style:italic;">Lock-up Agreements</span>&#8221;.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing description of the vesting agreements is qualified in its entirety by the full text of the form of the vesting agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Our Transactions</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Related Party Financings</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Series B Preferred Stock Financing</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, Dragasac Limited, or Dragasac, a significant stockholder, exercised its right to purchase 8,640,055 shares of Series B Preferred Stock, at an exercise price of $5.787 per share, for gross proceeds of approximately $50 million pursuant to a warrant initially issued in May 2018. Dragasac is an indirect subsidiary of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia. Lim Kok Thay, a current member of the board of directors, is the Chairman and Chief Executive of Genting Berhad.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2019, we amended and restated the Dragasac warrant to reduce the exercise price for the remaining warrant shares in exchange for Dragasac agreeing to purchase 4,464,286 shares of Series B Preferred Stock on or before May 31, 2019. In May 2019, Dragasac exercised its right to purchase 4,464,286 shares of Series B Preferred Stock at a price per share of $5.60, for gross proceeds of approximately $25 million. In November 2019, we again amended the initial Dragasac warrant to reduce the exercise price to $5.20 for the remaining warrant shares in exchange for Dragasac agreeing to purchase 8,495,796 shares of Series B Preferred Stock on or before November 4, 2019. On November 4, 2019, Dragasac exercised its right to purchase the remaining 8,495,796 shares of Series B Preferred Stock, at a price per share of $5.20, for gross proceeds of approximately $44.2 million. Following such exercise, the initial Dragasac warrant is no longer outstanding and was exercised in full.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we issued to Dragasac a new warrant to purchase 8,495,796 shares of Series B Preferred Stock, or the New Dragasac Warrant. at an exercise price per share equal to the lesser of (a) $5.20 per share or (b) 80% of either (i) the value attributed to one share of Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction pursuant to which our stockholders exchange their existing shares of capital stock in our company for shares in a company whose shares are listed on a national stock exchange or (ii) the price at which one share of common stock is sold to the public market in an initial public offering. The warrant originally expired upon the earlier to occur of the 12-month anniversary of issuance, the consummation of a change in control, the closing of a strategic transaction or an initial public offering, which 12-months was extended to March 2025 by an amendment in March 2020. In January 2021, we and Dragasac further amended the New Dragasac Warrant to add a cashless exercise provision and eliminate the provision that would have provided for expiration of the New Dragasac Warrant upon consummation of the Business Combination. Any portion of the New Dragasac Warrant that was unexercised prior to consummation of the Business </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combination converted into warrants to purchase shares of our Class A </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock, with the exercise price and number of shares adjusted as per the Exchange Ratio and the terms of the Merger Agreement.&#160;&#160;Accordingly, the New Dragasac Warrant is now exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,529,818 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares of our Class A </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommon </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tock at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we issued to Starr International, a significant stockholder, 8,640,055 shares of Series B Preferred Stock at a purchase price of $5.787 per share for an aggregate purchase price of approximately $50 million. Additionally, we issued to Starr International warrants to purchase an aggregate of 8,640,055 shares of Series B Preferred Stock, or the Starr Warrant. The Starr Warrant expired upon the earlier to occur of the 60-month anniversary of issuance, the consummation of an initial public offering or the consummation of a change in control. In January 2021, we and Starr International amended the Starr Warrant to add cashless exercise provisions following the consummation of the Business Combination. Any portion of the Starr Warrant that was unexercised prior to the consummation of the Business Combination converted into warrants to purchase shares of our Class A common stock, with the expiration date, exercise price and number of shares adjusted as per the Exchange Ratio and the terms of the Merger Agreement. Accordingly, the Starr Warrant became exercisable for 6,640,694 shares of our Class A common stock at an exercise price of $7.53 per share.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 1, 2022, in order to induce Starr International to cash exercise such warrants in full, we amended and restated the Starr Warrant to, among other things, (i) reduce the exercise price per share to $3.50 per share, subject to adjustment as set forth therein, (ii) remove the transfer restrictions set forth therein, and (iii) make other changes reflecting the Business Combination. Immediately following the amendment and restatement of the Starr Warrant, Starr International exercised such warrants in full, for cash, for approximately $23.2 million, and we issued shares of our Class A common stock in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act to Starr International. Accordingly, the Starr Warrant is no longer issued and outstanding.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes purchases of Series B Preferred Stock and Series B Preferred Stock warrants by our directors and by holders of more than 5% of its capital stock and their affiliated entities.&#160;&#160;All shares of Series B Preferred Stock were exchanged in the Business Combination for shares of our Class A common stock, and the warrants are now exercisable for shares of our Class A common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Greater than 5% Stockholders(1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="4" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.64%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dragasac Limited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,960,082</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,999,994.54</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,095,933</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(2)</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,178,133.09</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">&#8203;(3)</sub></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starr International Investments, Ltd.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,640,055</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,999,998.29</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,640,055</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,999,998.29</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:89.26%;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Dragasac exercised in full the initial Dragasac warrant for 21,600,137 shares of Series B Preferred Stock and immediately prior to the closing of the Business Combination held the New Dragasac Warrant for 8,495,796 shares of Series B Preferred Stock, or 6,529,818 shares of our Class A common stock.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Includes the aggregate exercise price for the initial Dragasac warrant, which has been exercised by Dragasac. The table above does not include the exercise price of the New Dragasac Warrant. The exercise price of New Dragasac Warrant is the lesser of (a) $5.20 per share or (b) 80% of either (i) the value attributed to one share of Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction pursuant to which our stockholders exchange their existing shares of capital stock in our Company for shares in a company whose shares are listed on a national stock exchange or (ii) the price at which one share of common stock is sold to the public market in an IPO. </span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License and Other Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">TNK License and Transfer Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, we entered into a Contribution Agreement with TNK Therapeutics, Inc., or TNK, and Sorrento. In order to effectuate the contribution under the TNK Contribution Agreement, in August 2017, we entered into a license and transfer agreement with TNK and Sorrento. Henry Ji, Ph.D., a former member of our Board, currently serves as President and Chief Executive Officer and Chairman of the Board of Sorrento and as Chief Executive Officer of TNK, a majority owned subsidiary of Sorrento. Sorrento is a holder of more than 5% of our capital stock. The license and transfer agreement with TNK and Sorrento contemplated certain payments by us as a proportion of sublicensing revenues received for certain products. The license and transfer agreement with TNK and Sorrento was subsequently amended in March 2018 and December 2019 and terminated for mutual convenience in January 2020.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sorrento License and Transfer Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we entered into a license and transfer agreement, as amended effective November 13, 2020, with Sorrento. Henry Ji, Ph.D., a former member of our Board, currently serves as President and Chief Executive Officer and Chairman of the Board of Sorrento. Dr. Robin L. Smith and Jaisim Shah, both former members of our Board and Dr. Smith is a current member of the board of directors, are also affiliated with Sorrento.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sorrento Agreement, we are obligated to pay Sorrento a low single-digit royalty on net sales of licensed products containing the CD19 CAR-T construct licensed from Sorrento in perpetuity. Additionally, we are obligated to pay Sorrento a low double-digit percentage of non-royalty sublicensing received by it in connection with a grant of any sublicense of the intellectual property licensed from Sorrento. In November 2020, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amended the Sorrento Agreement to add a patent application to the licensed intellectual property included in the Sorrento Agreement.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently negotiating a supply agreement with Sorrento to obtain the continued supply of CAR constructs and licensed products under the Sorrento Agreement, which we expect to be based on the cost plus a percentage, with no guaranteed minimums.<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Celgene License, Investment Rights Contingent Value Rights Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, in connection with the Anthrogenesis Corporation acquisition, we entered into a license agreement with Celgene and we issued shares of our Series X Preferred Stock to Celgene as merger consideration and also entered into the CVR Agreement and investment rights agreement with Celgene. Celgene is a holder of more than 5% of our capital stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Celgene license agreement,&#160;&#160;we granted Celgene (i) a worldwide, royalty-free, fully-paid up, non-exclusive license, without the right to grant sublicenses (other than to its affiliates), to certain of Anthrogenesis&#8217; intellectual property for preclinical research purposes in all fields and (ii) a worldwide, royalty-free, fully-paid up, non-exclusive, sublicensable license to certain of Anthrogenesis&#8217; intellectual property to develop, manufacture, commercialize and otherwise fully exploit products and services in connection with the construction of any CAR, the modification of any T-cells or NK cells to express such a CAR, and/or the use of such CARs or T-cells or NK cells for any purpose.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Celgene investment rights agreement entitled Celgene to board observation rights and certain information rights that terminate upon the consummation of the Business Combination. In addition, pursuant to the investment rights agreement, Celgene had certain rights regarding any acquisition proposals received by us, such as the right to receive notice of any proposed acquisitions, and a period of time in which we would not take any further action with respect such proposal. On March 4, 2021, the parties amended the investment rights agreement. As amended, upon the consummation of the Business Combination, the acquisition proposal rights will terminate along with the board observation and information rights noted above. The only rights that continue after consummation of the Business Combination are Celgene&#8217;s rights to participate in any process in connection with a sale of our company. In addition, if at any time&#160;&#160;we ceases to be subject to the reporting requirements of the Exchange Act (other than as a result of a change of control or other liquidation event), Celgene&#8217;s information rights and board observer rights will be reinstated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the CVR Agreement, we issued one CVR in respect of each share of Series X Preferred Stock issued to Celgene in connection with the Anthrogenesis acquisition. Such CVRs are not separable from the shares of Series X Preferred Stock other than in an initial public offering or a sale of our Company. Celgene has agreed that the CVRs will become separable from the shares of Series X Preferred Stock upon the consummation of the Business Combination, such that the CVRs may be sold, assigned and transferred apart from the shares of Series X Preferred Stock, which converted into Class A <span style="color:#000000;">common stock at the Closing. On March&#160;4, 2021, the parties entered into Amendment No. 1 to the CVR Agreement reflecting the parties&#8217; agreement to separate the CVRs from the shares of Series X Preferred Stock. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CVR Agreement entitles the holders of the CVRs to an aggregate amount, on a per program basis, of $50 million in regulatory milestones and an aggregate $125 million in commercial milestone payments with respect to certain of our investigational therapeutic programs, which would include the current CYNK-001, CYNK-101, and PDA-002 pipeline candidates and the legacy PDA-001 program (certain placenta-derived adherent cells, proprietary to Anthrogenesis, that are formulated for intravenous delivery, with respect to PDA-001 that is no longer in development. Such payments under the CVR Agreement also expressly cover PNK-007 (which includes certain NK cells proprietary to Anthrogenesis, produced by a process proprietary to Anthrogenesis as of the closing of the Anthrogenesis transaction) and certain PNK-007 cells with a genetic modification (but not including NK cells with a chimeric receptor, including a CAR), along with any derivatives, parts, subparts, or progeny of any of the foregoing, or any therapeutic based or derived (in whole or in part) on certain related development programs as they existed as of the closing of the Anthrogenesis transaction. Accordingly, as we expand our NK cell type franchise into new indications and, as a general matter, because these payments are not payable until a later stage of development, we expect to continue to evaluate its present and future therapeutic candidates as they develop and evolve in light of the specific terms in the CVR Agreement to determine the specific products on which such amounts will be payable. In addition, with respect to each such program and calendar year, the CVR holders will be entitled to receive a royalty equal to a mid-teen percentage of the annual net sales for such program&#8217;s therapeutics from the date of the first commercial sale of such program&#8217;s therapeutic in a particular country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program therapeutic in such country, the expiration of marketing exclusivity with respect to such therapeutic in such country, and August 2027 (i.e., the tenth anniversary of the closing of the acquisition of Anthrogenesis).<span style="color:#000000;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lung Biotechnology License Agreement</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, we entered into a license agreement with Lung Biotechnology PBC, or Lung Biotechnology, a holder of more than 5% of our shares of common stock. Under the license agreement, we granted Lung Biotechnology an exclusive license to placental-derived stem cells in the field of pulmonary diseases and organ transplantation. In April 2020, we agreed to amend the license agreement<span style="color:#000000;"> </span>with Lung Biotechnology to collaborate on the development of CYNK-001 in COVID-19 and Acute Respiratory Distress Syndrome. On April 11, 2021, such license agreement was voluntarily terminated without cause by Lung Biotechnology. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Genting Distribution Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, in connection with our Series B Preferred Stock Financing, we entered into a distribution agreement with Genting Innovation Pte Ltd., or Genting, an affiliate of Dragasac. Genting and Dragasac are both subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia. Lim Kok Thay, a current member of the board of directors, is the Chairman and Chief Executive of Genting Berhad.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Genting distribution agreement, we granted to Genting sole and exclusive rights to import, market, promote, sell, offer for sale and distribute in certain Asian markets our then-current portfolio of degenerative disease products, Biovance and Interfyl, that are approved for sale in the United States. The Genting distribution agreement also provides that future products developed by or on behalf of (or acquired or in-licensed by) us or our affiliates, for which no approval in the United States is required, or otherwise once approved in the United States, other than those in any of the CAR, organ or pulmonary fields, will be added to the Genting distribution agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consulting Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2017, we entered into a scientific and clinical advisor agreement, or the SAB Agreement, with Dr. Andrew Pecora, our current President and a former member of the Legacy Celularity Board, which was superseded by a new SAB Agreement in February 1, 2019, and then further amended in April 2020 and October 2020. Under the SAB Agreement, as amended by the second amended and restated second amendment, Dr. Pecora provided consulting and advisory services to Celularity LLC until his appointment as our President and execution of his employment agreement effective September 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The April 2020 amendment had a term of six months and provided for the payment of $20,000 per month and the issuance of a stock option to purchase 200,000 shares of our common stock (or 153,718 shares of Class A common stock as adjusted). Under the October 2020 amendment, Dr. Pecora was entitled to: (i) cash consideration of $20,000 per month, (ii) a one-time cash bonus of $50,000 upon consummation of the Business Combination and (iii) a non-qualified stock option to purchase 200,000 shares of our common stock (or 153,718 shares of Class A common stock as adjusted), which vests based on certain defined performance objectives.&#160;&#160;The option awards were assumed in the Business Combination and are now exercisable for shares of Class A common stock as adjusted by the Exchange Ratio.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COTA, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, our Company and COTA, Inc., or COTA, entered into an Order Schedule, to the Master Data License Agreement between us and COTA, dated October 29, 2018, pursuant to which COTA will provide to us the licensed data in connection with AML patients. The COTA Order Schedule will terminate on the one-year anniversary following the final licensed data deliverable described therein. Andrew Pecora, M.D., our current President and <span style="color:#000000;">a former member of the Legacy Celularity Board</span>, is the Founder and Chairman of the Board of COTA, and Dr. Robin L. Smith, a member of the board of directors, is an investor in COTA.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cryoport Systems, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, we entered into a master services agreement with Cryoport Systems, Inc., or Cryoport, pursuant to which Cryoport will provide cold-chain logistic services to us to support its preclinical and clinical studies. Robert J. Hariri, M.D., Ph.D., our Chairman and Chief Executive Officer, is a member of the board of directors of Cryoport.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Purchase Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, 2020, we entered into a stock purchase agreement with Andrew von Eschenbach, M.D., a member of the board of directors, pursuant to which we agreed to purchase from Dr. von Eschenbach 100,000 option shares at a price of $2.56 per share for an aggregate purchase price of $256,000, less the exercise price of the option shares of $21,000, for a net purchase price of $235,000.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURA Foundation Charitable Grants</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During each of the years ended December 31, 2019, 2020 and 2021, we made a grant of $125,000, $375,000 and $500,000, respectively, to the CURA Foundation in support of the International Vatican.&#160;&#160;Dr. Robin L. Smith, a member of the board of directors, is the president and chairperson of the board of the CURA Foundation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employment of an Immediate Family Member</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., our Chairman and Chief Executive Officer, is employed by us as an Executive Director, Corporate Strategy &#38; Business Development. For each of the years ended December 31, 2019 and 2020, Ms. Hariri&#8217;s base salary (as a part-time employee) was $37,520 per year. In 2021, Ms. Hariri transitioned back to full-time and her base salary is $210,000. Ms. Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and conditions as applicable to unrelated employees in similar positions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Pecora, the son of Andrew Pecora, M.D., our President and a member of our Scientific Advisory Board, a former member of the Legacy Celularity Board, our President of Medical Affairs and former member of our Scientific and Clinical Advisory Board, is employed by us as Manager, Clinical Supply Chain. For the years ended December 31, 2019, 2020 and 2021, Mr. Pecora earned $90,000.00, $103,534.39, and $121,275.12, respectively, in base salary and bonus and he earned equity awards which were in line with similar roles at our company before the Business Combination. Mr. Pecora terminated his employment with us in April 2021. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employment Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into amended and restated employment agreements with each of our executive officers upon the closing of the Business Combination. These agreements superseded the prior change in control severance agreements. See Item 10 &#8220;<span style="font-style:italic;">Executive Compensation &#8212; Agreements with Named Executive Officers and Potential Payments Upon Termination of Employment or Change in Control</span>&#8221; for a description of the terms of the employment agreements with our named executive officers.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Options Granted to Executive Officers and Directors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have granted stock options to its executive officers and directors, each as more fully described in Item 10 &#8220;<span style="font-style:italic;">Executive Compensation &#8212; Outstanding Equity Awards at Fiscal Year-End</span>&#8221; and &#8220;<span style="font-style:italic;">Executive Compensation &#8212; Agreements with Named Executive Officers and Potential Payments Upon Termination of Employment or Change in Control</span>&#8221; respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into indemnification agreements with each of our directors and executive officers in addition to the indemnification provided for in our bylaws. These agreements, among other things, require us to indemnify each director and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Policies and Procedures for Transactions with Related Parties</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a written related-person&#160;transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related-party&#160;transactions.&#8221; A &#8220;related-party&#160;transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related party&#8221; are participants involving an amount that exceeds the lesser of $120,000 and 1% of the average of our total assets at year-end&#160;for the last two completed fiscal years. Transactions involving compensation for services provided to us as an employee, consultant or director will be considered pre-approved&#160;related-party&#160;transactions by the audit committee under this policy. A related person is any executive officer, director, nominee to become a director or a holder of more than 5% of our common stock, including any of their immediate family members and affiliates, including entities owned or controlled by such persons.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the policy, where a transaction has been identified as a related-party&#160;transaction, management must present information regarding the proposed related-party&#160;transaction to the audit committee (or, where review by the audit committee would be inappropriate, to another independent body of the board of directors) for review. The presentation must include a description of, among other things, all of the parties thereto, the direct and indirect interests of the related parties, the purpose of the transaction, the material facts, the benefits of the transaction to&#160;&#160;us and whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from unrelated third parties and management&#8217;s recommendation. To identify related-party&#160;transactions in advance, we will rely on information supplied by its executive officers, directors and certain significant stockholders. In considering </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related-party&#160;transactions, its audit </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">committee</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or another independent body of its board of directors will take into account the relevant available facts and circumstances including, but not limited to:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the risks, costs and benefits to us&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the impact on a director&#8217;s independence in the event the related party is a director, immediate family member of a director or an entity with which a director is affiliated&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the terms of the transaction&#59;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the availability of other sources for comparable services or products&#59; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:8.89%;text-indent:-4.44%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the terms available to or from, as the case may be, unrelated third parties.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Item 14. Principal Accounting Fees and Services. </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our independent public accounting firm is Deloitte &#38; Touche, LLP, Parsippany, NJ PCAOB Auditor ID 34.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows information about fees billed to the Company by Deloitte &#38; Touche,&#160;LLP for the fiscal years ended December&#160;31, 2021 and 2020:</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,798,747</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,885,054</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit Related Fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All Other Fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,895</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,879,392</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,963,804</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:88.89%;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:9pt;color:#000000;">Includes fees </span><span style="color:#000000;font-size:9pt;">associated with the annual audit of our financial statements, the reviews of our interim financial statements and the issuance of consent and comfort letters in connection with registration statements.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;font-size:9pt;">Includes fees billed for professional services relating to tax compliance, tax planning and tax advice.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="color:#000000;font-size:9pt;">Includes annual license fee for access to an accounting research software application.</span></p></td></tr></table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee&#160;Pre-Approval&#160;Policies</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Audit Committee is directly responsible for the appointment, retention and termination, and for determining the compensation, of our independent registered public accounting firm. The Audit Committee pre-approves&#160;all auditing services and the terms thereof and&#160;non-audit&#160;services (other than&#160;non-audit&#160;services prohibited under Section&#160;10A(g) of the Exchange Act or the applicable rules of the SEC or the Public Company Accounting Oversight Board), except that&#160;pre-approval&#160;is not required for the provision of&#160;non-audit&#160;services if the &#8220;de minimis&#8221; provisions of Section&#160;10A(i)(1)(B) of the Exchange Act are satisfied. The Audit Committee may delegate to the chairperson of the Audit Committee the authority to grant&#160;pre-approvals&#160;for audit and&#160;non-audit&#160;services, provided such approvals are presented to the Audit Committee at its next scheduled meeting. All services provided by Deloitte &#38; Touche LLP during fiscal year 2021 were&#160;pre-approved&#160;by the Audit Committee in accordance with the&#160;pre-approval&#160;policy described above.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Item 15. Exhibits, Financial Statement Schedules. </p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:8.89%;text-indent:-4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are filed as part of this report</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Financial Statements &#8211; See Index to Consolidated Financial Statements in Item 8.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Financial Statement Schedules</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;margin-left:13.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.8%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.58%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:italic;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:italic;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="font-style:normal;color:#000000;"></span><span style="color:#000000;">Exhibits</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;2.1+</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021001040/ea132952ex2-1_gxacquisit.htm"><span style="text-decoration:underline;">Merger Agreement and Plan of Reorganization by and among GX Acquisition Corp., Alpha First Merger Sub, Inc., Alpha Second Merger Sub, LLC, and Celularity Inc.</span><span style="text-decoration:underline;"> </span><span style="text-decoration:underline;">(incorporated by reference to Exhibit 2.1 to the current report on Form 8-K, filed with the Commission on January 8, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex3-1_celularity.htm"><span style="text-decoration:underline;">Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex3-2_celularity.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex4-1_celularity.htm"><span style="text-decoration:underline;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex4-2_celularity.htm"><span style="text-decoration:underline;">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.2 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3*</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex43_892.htm"><span style="text-decoration:underline;">Description of Securities</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1_gxacquisition.htm#T608"><span style="text-decoration:underline;">Form of Subscription Agreement (incorporated by reference to Exhibit 10.5 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span><span style="text-decoration:underline;">&#160;</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.2</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1_gxacquisition.htm#T610"><span style="text-decoration:underline;">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.8 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span><span style="text-decoration:underline;">&#160;</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.3</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex10-3_celularity.htm"><span style="text-decoration:underline;">Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.4</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex10-4_celularity.htm"><span style="text-decoration:underline;">Vesting Agreement dated as of July 16, 2021 by and among GX Sponsor LLC, Celularity Inc. (f/k/a GX Acquisition Corp.), and each of the other Persons set forth on the signature pages thereto (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.5</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390019009582/f8k052019ex4-1_gxacq.htm"><span style="text-decoration:underline;">Warrant Agreement, dated May 20, 2019, by and between GX Acquisition Corp. and Continental Stock Transfer &#38; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the Commission on May 24, 2019).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.6#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-9_gxacq.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.9 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7#</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-10_gxacquisition.htm"><span style="text-decoration:underline;">Celularity Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.8#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-11_gxacquisition.htm"><span style="text-decoration:underline;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.9#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-3_celularity.htm"><span style="text-decoration:underline;">Celularity Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.10#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-4_celularity.htm"><span style="text-decoration:underline;">Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, RSU Award Grant Notice and Award Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.11#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-5_celularity.htm"><span style="text-decoration:underline;">Celularity 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.5 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.12#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-14_gxacquisition.htm"><span style="text-decoration:underline;">Celularity Inc. 2018 Annual Incentive Plan (incorporated by reference to Exhibit 10.14 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.13#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-15_gxacquisition.htm"><span style="text-decoration:underline;">Amended and Restated Employment Agreement by and between Celularity and Robert J. Hariri, dated as of January 7, 2021 (incorporated by reference to Exhibit 10.15 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.14#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-16_gxacquisition.htm"><span style="text-decoration:underline;">Amended and Restated Employment Agreement by and between Celularity and David C. Beers, dated as of January 7, 2021 (incorporated by reference to Exhibit 10.16 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.15#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-18_gxacquisition.htm"><span style="text-decoration:underline;">Amended and Restated Employment Agreement by and between Celularity and Stephen A. Brigido, dated as of January 7, 2021 (incorporated by reference to Exhibit 10.18 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.16#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021022750/fs42021a2ex10-19_gxacquisit.htm"><span style="text-decoration:underline;">Second Amended and Restated Employment Agreement by and between Celularity and Keary Dunn, dated as of April 22, 2021 (incorporated by reference to Exhibit 10.19 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.17#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-20_gxacquisition.htm"><span style="text-decoration:underline;">Amended and Restated Employment Agreement by and between Celularity and John R. Haines, dated as of January 7, 2021 (incorporated by reference to Exhibit 10.20 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.18#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021022750/fs42021a2ex10-22_gxacquisit.htm"><span style="text-decoration:underline;">Amended and Restated Employment Agreement by and between Celularity and Brad Glover, dated as of April 22, 2021 (incorporated by reference to Exhibit 10.22 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.19#</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/ea147489ex10-1_celularityinc.htm"><span style="text-decoration:underline;">Employment Agreement by and between Celularity and Andrew Pecora, dated as of September 15, 2021 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on September 9, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.20#*</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex1020_128.htm"><span style="text-decoration:underline;">Employment Agreement by and between Celularity and Anne Jones, dated as of January 7, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:26.85pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.21</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-34_gxacq.htm"><span style="text-decoration:underline;">Lease Agreement, dated March 13, 2019, by and between LSREF4 Turtle, LLC and Celularity Inc (incorporated by reference to Exhibit 10.34 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.22</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex10-15_celularity.htm"><span style="text-decoration:underline;">Form of Deferred Compensation Award Grant (incorporated by reference to Exhibit 10.15 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</span><span style="color:#000000;font-size:9pt;">&#165;</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-23_gxacq.htm"><span style="text-decoration:underline;">License Agreement, dated August 15, 2017, by and between Celgene Corporation and Anthrogenesis Corp. (incorporated by reference to Exhibit 10.23 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.24</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-24_gxacq.htm"><span style="text-decoration:underline;">Agreement and Plan of Merger, dated July 1, 2017, by and among Celularity Inc., Clarity Acquisition Corp, Clarity Acquisition II LLC, Anthrogenesis Corporation and Celgene Corporation (incorporated by reference to Exhibit 10.24 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.25<span style="color:#000000;font-size:9pt;">&#165;</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-25_gxacq.htm"><span style="text-decoration:underline;">Contingent Value Rights Agreement, dated August 15, 2017, by and between Celularity Inc. and the Holders named therein, as amended by Amendment No. 1 to the Contingent Value Rights Agreement, dated March 4, 2021 (incorporated by reference to Exhibit 10.25 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.26</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-26_gxacq.htm"><span style="text-decoration:underline;">Investment Rights Agreement, dated August 15, 2017, by and between Celularity Inc. and Celgene Corporation as amended by Amendment No. 1 to the Investment Rights Agreement, dated March 4, 2021 (incorporated by reference to Exhibit 10.26 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.27<span style="color:#000000;font-size:9pt;">&#165;</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-27_gxacquisition.htm"><span style="text-decoration:underline;">License and Transfer Agreement, dated September 30, 2020, by and between Celularity Inc. and Sorrento Therapeutics, Inc., as amended (incorporated by reference to Exhibit 10.27 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.28<span style="color:#000000;font-size:9pt;">&#165;</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-28_gxacquisition.htm"><span style="text-decoration:underline;">Agreement and Plan of Merger, dated August 22, 2018, by and among Celularity Inc., CariCord Inc, CC Subsidiary, Inc. and Gregory L. Andrews, as amended by the First Amendment to the Agreement and Plan of Merger, dated September 30, 2018 and the Second Amendment to the Agreement and Plan of Merger, dated June 24, 2020 (incorporated by reference to Exhibit 10.28 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.29</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-31_gxacquisition.htm"><span style="text-decoration:underline;">Warrant to Purchase Series B Preferred Stock of Celularity Inc., by and between Celularity Inc. and Dragasac Limited, dated January 9, 2020 (incorporated by reference to Exhibit 10.29 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.30</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-30_gxacquisition.htm"><span style="text-decoration:underline;">Amendment No.1 to Warrant to Purchase Series B Preferred Stock of Celularity Inc., dated as of March 16, 2020 by and between Celularity Inc. and Dragasac Limited (incorporated by reference to Exhibit 10.30 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:28.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.31</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-31_gxacquisition.htm"><span style="text-decoration:underline;">Amendment No.2 to Warrant to Purchase Series B Preferred Stock of Celularity Inc., dated as of January 8, 2021 by and between Celularity Inc. and Dragasac Limited (incorporated by reference to Exhibit 10.31 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.32</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000156459021056724/celu-ex1025_196.htm"><span style="text-decoration:underline;">Warrant to Purchase Series B Preferred Stock of Celularity Inc., by and between Celularity Inc. and Starr International Investments Ltd. dated March 16, 2020 (incorporated by reference to Exhibit 10.25 to the quarterly report on Form 10-Q filed with the Commission on November 12, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.33</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-29_gxacquisition.htm"><span style="text-decoration:underline;">Amendment No.1 to Warrant to Purchase Series &#160;B Preferred Stock of Celularity Inc., dated as of January 8, 2021 by and between Celularity Inc. and Starr International Investments Ltd (incorporated by reference to Exhibit 10.33 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.34</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-34_gxacq.htm"><span style="text-decoration:underline;">Stock Purchase Agreement, by and between Celularity Inc. and Dr. Andrew C. von Eschenbach, dated as of September 18, 2020 (incorporated by reference to Exhibit 10.35 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;10.35</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021033441/fs42021a4ex10-36_gxacq.htm"><span style="text-decoration:underline;">Loan Agreement, dated as of June 8, 2021 by and between Celularity Inc. and C.V. Starr Co., Inc. as the Initial Lender (incorporated by reference to Exhibit 10.36 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.36</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex10-4_celularity.htm"><span style="text-decoration:underline;">Vesting Agreement dated as of July 16, 2021 by and among GX Sponsor LLC, Celularity Inc. (f/k/a GX Acquisition Corp.), and each of the other Persons set forth on the signature pages thereto (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;16.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex16-1_celularity.htm"><span style="text-decoration:underline;">Letter from Marcum LLP, dated July 21, 2021 (incorporated by reference to Exhibit 16.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;21.1</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex21-1_celularity.htm"><span style="text-decoration:underline;">List of Subsidiaries (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;23.1*</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex231_1187.htm"><span style="text-decoration:underline;">Consent of Deloitte &#38; Touche LLP</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman PS Std;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;24.1*</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PURSUANT_TO_REQUIREMENTS__SECURITIES_EXC"><span style="text-decoration:underline;">Power of Attorney (included on the signature page).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;31.1*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex311_9.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;31.2*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex312_7.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;32.1</span><span style="font-size:9pt;font-family:Times New Roman PS Std;">&#8224;&#8224;&#8224;</span><span style="Background-color:#FFFFFF;">*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex321_6.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;32.2</span><span style="font-size:9pt;font-family:Times New Roman PS Std;">&#8224;&#8224;&#8224;</span><span style="Background-color:#FFFFFF;">*</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="celu-ex322_8.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="color:#000000;">I</span><span style="color:#000000;font-size:10pt;">ndicates a management contract or any compensatory plan, contract or arrangement</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="font-size:10pt;">Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#165;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Certain portions of this exhibit are omitted because they are not material and are the type that the registrant treats as private or confidential.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#8224;&#8224;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="font-size:10pt;">These certifications will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent specifically incorporated by reference into such filing.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:8.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized<span style="font-weight:bold;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity Inc.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert J. Hariri</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, MD., Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert J. Hariri, M.D., Ph.D., David C. Beers and Keary Dunn, Esq., and each of them, his or her true and lawful attorneys-in-fact&#160;and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective&#160;amendments, to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact&#160;and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact&#160;and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="PURSUANT_TO_REQUIREMENTS__SECURITIES_EXC">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert J. Hariri</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David C. Beers</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal Financial and Accounting Officer)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">David C. Beers</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jay R. Bloom</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jay R. Bloom</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter Diamandis</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Peter Diamandis, M.D</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Dean C. Kehler</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dean C. Kehler</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Lim Kok Thay</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lim Kok Thay</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:4pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Marc Mazur</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marc Mazur</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;John Sculley</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">John Sculley</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robin L. Smith</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robin L. Smith, M.D., MBA</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Andrew C. von Eschenbach</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:22.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Andrew C. von Eschenbach, M.D</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>celu-ex43_892.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex43_892.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:4.27%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="tx166297_15"></a><a name="_Hlk95854904"></a>DESCRIPTION OF SECURITIES</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following is a summary of the material terms of our securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not intended to be a complete summary of the rights and preferences of such securities. The full text of our second amended and restated certificate of incorporation and amended and restated bylaws, as well as the warrant agreement governing the public warrants, are included as exhibits to the Form 10-K of which this exhibit is a part. You are encouraged to read the applicable provisions of Delaware law, our certificate of incorporation and bylaws and the warrant agreement in their entirety for a complete description of the rights and preferences of our securities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized Capital</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized share capital consists of 730,000,000&#160;shares of Class A common stock, $0.0001 par value per share and 10,000,000&#160;shares of preferred stock, $0.0001 par value, all of which shares of preferred stock are undesignated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Class A Common Stock</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of Class A common stock possess all voting power for the election of our directors and all other matters requiring stockholder action. Holders of Class A common stock are entitled to one vote per share on matters to be voted on by stockholders.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of Class A common stock will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on Class A common stock unless the shares of Class A common stock at the time outstanding are treated equally and identically.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation, Dissolution and Winding Up</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the Class A common stock will be entitled to receive an equal amount per share of all of our assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preemptive or Other Rights</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to Class A common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Election of Directors</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class serving a three-year&#160;term, except with respect to the election of directors at the special meeting held in connection with our initial business combination, Class I directors were elected to an initial one-year&#160;term (and three-year&#160;terms subsequently), the Class II directors were elected to an initial two-year&#160;term (and three-year&#160;terms subsequently) and the Class III directors were elected to an initial three-year&#160;term (and three-year&#160;terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors.</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Stock</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that shares of preferred stock may be issued from time to time in one or more series. Our board of directors is authorized to fix the voting rights, if any, designations, powers and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of Class A common stock and could have anti-takeover&#160;effects. The ability of our board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control or the removal of existing management. There are no shares of &nbsp;&nbsp;preferred stock outstanding.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Public Warrants</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our public warrants are issued under&#160;that certain warrant agreement dated May 20, 2019, by and between us and Continental Stock Transfer &amp; Trust Company, as warrant agent. Pursuant to the warrant agreement, each whole public warrant entitles the registered holder to purchase one whole share of our Class A common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing after August 15, 2021, which is the later of (a) 30 days after the consummation of our business combination or (b) 12 months from the effective date of the registration statement relating to our initial public offering. The public warrants will expire on July 15, 2026, which is five years after completion of our initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a public warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No public warrant will be exercisable and we will not be obligated to issue shares of Class A common stock upon exercise of a public warrant unless Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the public warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a public warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will we be required to net cash settle any public warrant.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We filed a registration statement covering the shares of Class A common stock issuable upon exercise of the public warrants, and such registration statement was declared effective on August 12, 2021.&nbsp;&nbsp;As specified in the warrant agreement, we are obligated to maintain a current prospectus relating to those shares of Class A common stock until the warrants expire or are redeemed.&nbsp;&nbsp;During any period when we will have failed to maintain an effective registration statement, warrantholders may exercise public warrants on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not be able to exercise their public warrants on a cashless basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the public warrants become exercisable, we may call the warrants for redemption:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in whole and not in part;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;at a price of $0.01 per warrant;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;upon not less than 30 days&#8217; prior written notice of redemption (the &#8220;30-day&#160;redemption period&#8221;) to each warrantholder; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if, and only if, the reported last sale price of Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption to the warrantholders.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If and when the public warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares of Class A common stock upon exercise of the public warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established the last of the redemption criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public warrants</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, each </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrantholder</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will be entitled to exercise its </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public warrants</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior to the scheduled redemption date. However, the price of </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class A common stock</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may fall below the $18.00 redemption trigger price (as adjusted for stock splits, stock dividends, reorganizations, </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recapitalizations</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the like) as well as the $11.50 warrant exercise price after the redemption notice is issued.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we call the public warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise its warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their public warrants on a &#8220;cashless basis,&#8221; our management will consider, among other factors, our cash position, the number of public warrants that are outstanding and the dilutive effect on our stockholders of issuing the maximum number of shares of Class A common stock issuable upon the exercise of our public warrants. If our management takes advantage of this option, all holders of public warrants would pay the exercise price by surrendering their public warrants for that number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the public warrants, multiplied by the difference between the exercise price of the public warrants and the &#8220;fair market value&#8221; (defined below) by (y) the fair market value. The &#8220;fair market value&#8221; shall mean the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. If our management takes advantage of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Class A common stock to be received upon exercise of the public warrants, including the &#8220;fair market value&#8221; in such case. Requiring a cashless exercise in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to us if we do not need the cash from the exercise of the public warrants. If we call our warrants for redemption and our management does not take advantage of this option, our former sponsor, GX Sponsor LLC, and its permitted transferees would still be entitled to exercise their private placement warrants for cash or on a cashless basis using the same formula described above that other warrantholders would have been required to use had all warrantholders been required to exercise their warrants on a cashless basis, as described in more detail below.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A holder of a public warrants may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such public warrants, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (or such other amount as a holder may specify) of the shares of Class A common stock outstanding immediately after giving effect to such exercise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the number of outstanding shares of Class A common stock is increased by a stock dividend payable in shares of Class A common stock, or by a split-up&#160;of shares of Class A common stock or other similar event, then, on the effective date of such stock dividend, split-up&#160;or similar event, the number of shares of Class A common stock issuable on exercise of each public warrant will be increased in proportion to such increase in the outstanding shares of Class A common stock. A rights offering to holders of Class A common stock entitling holders to purchase shares&#160;of Class A common stock at a price less than the fair market value will be deemed a stock dividend of a number&#160;of shares of Class A common stock equal to the product of (i) the number of shares of Class A common stock actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A common stock) and (ii) one (1) minus the quotient of (x) the price per share of Class A common stock paid in such rights offering divided by (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for Class A common stock, in determining the price payable for Class A common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the volume weighted-average&#160;price of Class A common stock as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the shares of Class A common stock trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if we, at any time while the public warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Class A common stock on account of such shares of Class A common stock (or other shares of our capital stock into which the public warrants are convertible), other than in certain circumstances as described in the warrant agreement, then the warrant exercise price will be decreased, </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class A common stock</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in respect of such event.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the number of outstanding shares of our Class A common stock is decreased by a consolidation, combination, reverse stock split or reclassification of shares of Class A common stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Class A common stock issuable on exercise of each public warrant will be decreased in proportion to such decrease in outstanding shares of Class A common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the number of shares of Class A common stock purchasable upon the exercise of the public warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares of Class A common stock purchasable upon the exercise of the public warrants immediately prior to such adjustment, and (y) the denominator of which will be the number of shares of Class A common stock so purchasable immediately thereafter.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In case of any reclassification or reorganization of the outstanding shares of Class A common stock (other than those described above or that solely affects the par value of such shares of Class A common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding shares of Class A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the public warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the public warrants and in lieu of the shares of our Class A common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the public warrants would have received if such holder had exercised their public warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Class A common stock in such a transaction is payable in the form of Class A common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter&#160;market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the public warrant properly exercises the public warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes&#160;value (as defined in the warrant agreement) of the public warrant. The purpose of such exercise price reduction is to provide additional value to holders of the public warrants when an extraordinary transaction occurs during the exercise period of the public warrants pursuant to which the holders of the public warrants otherwise do not receive the full potential value of the public warrants in order to determine and realize the option value component of the public warrant. This formula is to compensate the public warrant holder for the loss of the option value portion of the public warrant due to the requirement that the public warrant holder exercise the public warrant within 30 days of the event. The Black-Scholes&#160;model is an accepted pricing model for estimating fair market value where no quoted market price for an instrument is available.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The public warrants have been issued in registered form under the warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and us. You should review a copy of the warrant agreement, which is an exhibit to this registration statement, for a complete description of the terms and conditions applicable to the public warrants. The warrant agreement provides that the terms of the public warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 65% of the then outstanding public warrants to make any change that adversely affects the interests of the registered holders of public warrants.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The public warrants may be exercised upon surrender of the public warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of public warrants being exercised. The warrantholders do not have the rights or privileges of holders of Class A common stock and any voting rights until they exercise their public warrants and receive shares of Class A common stock. After the issuance of shares of Class </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A common stock</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon exercise of the </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public warrants</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No fractional shares will be issued upon exercise of the public warrants. If, upon exercise of the public warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number the number of shares of Class A common stock to be issued to the warrantholder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Provisions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Special Meetings of Stockholders</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide that special meetings of our stockholders may be called only by a majority vote of the board of directors, by the Chairperson of the board of directors, or by the chief executive officer.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our bylaws provide that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely under our current bylaws and the bylaws, a stockholder&#8217;s notice will need to be received by the company secretary at our principal executive offices not later than the close of business on the 90<font style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font>&#160;day nor earlier than the open of business on the 120<font style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font>&#160;day prior to the first anniversary of the preceding year&#8217;s annual meeting. Pursuant to Rule 14a-8&#160;of the Exchange Act, proposals seeking inclusion in our annual proxy statement must comply with the notice periods contained therein. Our bylaws also specify certain requirements as to the form and content of a stockholders&#8217; meeting. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized but Unissued Shares</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized but unissued Class A common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Class A common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Forum Selection</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (subject to certain limited exceptions) shall be the sole and exclusive forum for any of the following claims (i) any derivative claim or cause of action brought on our behalf, (ii) any claim or cause of action asserting a claim of breach of a fiduciary duty owed by any of our director, officer or other employee or our stockholders, (iii) any claim or cause of action against us, our directors, officers or employees arising pursuant to any provision of the Delaware General Corporate Law, or DGCL, our certificate of incorporation or the bylaws, (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the certificate of incorporation or the bylaws, (v) any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any claim or cause of action against us or any of our current or former director, officer or other employee governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named as defendants. Any person or entity holding, owning or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and to have consented to such provisions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law in the types of lawsuits to which they apply, a court may determine that these provisions are unenforceable, and to the extent they are enforceable, the provisions may have the effect of discouraging lawsuits against our directors and officers, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Additionally, we cannot be certain that a court will decide that these provisions are either applicable or enforceable, and if a court were to find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating </font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and financial condition.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable law. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, the Proposed Charter provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to provisions of Section 203 of the DGCL regulating corporate takeovers under our certificate of incorporation. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#8220;business combination&#8221; with:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;);</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an affiliate of an interested stockholder; or</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A &#8220;business combination&#8221; includes a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;our board of directors approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;margin-left:10.26%;text-indent:-5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on or subsequent to the date of the transaction, our initial business combination is approved by our board of directors and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least two-thirds&#160;of the outstanding voting stock not owned by the interested stockholder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:5.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances, this provision will make it more difficult for a person who would be an &#8220;interested stockholder&#8221; to effect various business combinations with us for a three-year&#160;period. This provision may encourage companies interested in acquiring us to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if our board of directors approves either the business combination or the transaction which results in the stockholder becoming an interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>3
<FILENAME>celu-ex1020_128.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex1020_128.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.20</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Employee Confidential Information, Inventions, Non-Solicitation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>and Non-Competition Agreement</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of my continued employment by Celularity Inc. and its subsidiaries, parents, affiliates, successors and assigns (together, &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) and the compensation now and later paid to me, I hereby enter into this Employee Confidential Information, Inventions, Non-Solicitation and Non-Competition Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) and agree as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>1.<font style="font-weight:normal;margin-left:28pt;"></font><font style="font-variant: small-caps;">Confidential Information Protections.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Recognition of Company&#8217;s Rights; Nondisclosure.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein.&nbsp;&nbsp;At all times during and after my employment, I will hold in strict confidence and will not disclose, use, lecture upon or publish any of Company&#8217;s Confidential Information, except as such disclosure, use, lecture or publication may be required in connection with my work for Company and solely for the benefit of Company, or unless an officer of Company has expressly authorized such disclosure, use, lecture or publication in writing.&nbsp;&nbsp;I will obtain Company&#8217;s written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that discloses and/or incorporates any Confidential Information.&nbsp;&nbsp;I hereby assign to Company any rights, title or interest I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Company and its assigns. I will take all reasonable precautions to prevent the unauthorized disclosure of Confidential Information, and will promptly notify Company if I learn of any unauthorized use or disclosure of any Confidential Information and cooperate with Company in connection with the foregoing.&nbsp;&nbsp;Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&nbsp;&nbsp;In addition, if I file a lawsuit for retaliation by Company for reporting a suspected violation of law, I may disclose Company&#8217;s trade secrets to my attorney and use the trade secret information in the court proceeding if I: (A) file any document containing the trade secret under seal; and (B) do not disclose the trade secret, except pursuant to court order. Notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or regulation with the Equal Employment Opportunity Commission, United States Department of Labor, the National Labor Relations Board, the Securities and Exchange Commission, or other federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under the applicable provisions of law or regulation, including but not limited to &#8220;whistleblower&#8221; statutes or other similar provisions that protect such disclosure.</font></p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="Background-color:#auto;text-decoration:none;">1.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Confidential Information. </font><font style="font-weight:normal;color:#000000;">The term &#8220;Confidential Information&#8221; shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, &#8220;</font><font style="font-style:italic;color:#000000;">Confidential Information</font><font style="font-weight:normal;color:#000000;">&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">includes (a)&#160;trade secrets, inventions, mask works, ideas, processes, formulas, compositions of matter, models, methods, software in source or object code versions, data and databases, programs, drawings, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques and any other proprietary technology, whether or not patentable or protectable by copyright, and all Intellectual Property Rights therein (collectively, &#8220;</font><font style="font-style:italic;color:#000000;">Inventions</font><font style="font-weight:normal;color:#000000;">&#8221;); (b)&#160;information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals,  methods of conducting Company business, suppliers and supplier information, and purchasing; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential customers; (d) information regarding any of Company&#8217;s business partners and their services, including names; representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and </font><font style="font-family:Open Sans;font-weight:normal;color:#000000;">other</font><font style="font-weight:normal;color:#000000;"> non-public information relating to business partners; (e) information </font></p></div></div>
<p style="margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="Background-color:#auto;text-decoration:none;">1.3</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">regarding personnel, employee lists, compensation, and&nbsp;&nbsp;employee skills; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company.&nbsp;&nbsp;Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which was known to me prior to employment with Company, provided I have no knowledge that the source of such information was bound by a confidentiality agreement or other obligation of secrecy to Company or third party or which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me.&nbsp;&nbsp;This Section 1.2 will not be construed to prohibit disclosure of Confidential Information to the extent that such disclosure is required by law or valid order of a court or other governmental authority; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided, however</font><font style="font-weight:normal;color:#000000;">, that, prior to disclosure, I shall first have given reasonable notice to Company so that Company can elect to seek a protective order or other available protections.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.4</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Third Party Information.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I understand, in addition, that Company has received and in the future will receive from third parties their confidential and/or proprietary knowledge, data or information (&#8220;</font><font style="font-style:italic;color:#000000;">Third Party Information</font><font style="font-weight:normal;color:#000000;">&#8221;) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes.&nbsp;&nbsp;During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, disclose, lecture upon or publish, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.5</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Term of Nondisclosure Restrictions.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I understand that Confidential Information and Third Party Information is never to be used or disclosed by me, as provided in this Section 1.&nbsp;&nbsp;If a temporal limitation on my obligation not to use or disclose such information is required under applicable law, and the Agreement or its restriction(s) cannot otherwise be enforced, I agree and Company agrees that the two (2) year period after the date my employment ends will be the temporal limitation relevant to the contested restriction, provided, however, that this sentence will not apply to trade secrets protected without temporal limitation under applicable law.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="Background-color:#auto;text-decoration:none;">1.6</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">No Improper Use of Information of Prior Employers and Others.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;During my employment by Company, I will not improperly use or disclose confidential information, trade secrets or any other Intellectual Property Rights of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company or use any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.&nbsp;&nbsp;<a name="_AEIOULastRenderedPageBreakAEIOU7"></a>I represent that my performance of all the terms of this Agreement and my duties as employee of Company will not breach any invention assignment, proprietary information, confidentiality, non-compete, non-solicitation or similar agreement with any former employer or other party. </font></p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;text-transform:none;font-variant: normal;margin-left:28pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Assignments of Inventions. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Definitions.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">As used in this Agreement, the term &#8220;</font><font style="font-style:italic;color:#000000;">Intellectual Property Rights</font><font style="font-weight:normal;color:#000000;">&#8221; means all trade secrets, Copyrights, trademarks, mask work rights, patents, patent applications and invention disclosures, and other intellectual property rights recognized by the laws of any jurisdiction or country; the term &#8220;</font><font style="font-style:italic;color:#000000;">Copyright</font><font style="font-weight:normal;color:#000000;">&#8221; means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country;&nbsp;&nbsp;and&nbsp;&nbsp;the term &#8220;</font><font style="font-style:italic;color:#000000;">Moral Rights</font><font style="font-weight:normal;color:#000000;">&#8221; means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk53866617"></a><font style="Background-color:#auto;text-decoration:none;">2.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Excluded Inventions.</font><font style="font-weight:normal;color:#000000;"><a name="_Hlk53866617"></a>&nbsp;&nbsp;Attached hereto as </font><font style="color:#000000;">Exhibit&#160;A</font><font style="font-weight:normal;color:#000000;"> is a list describing all Inventions, if any, in which I have an existing interest or may have a future interest as of the commencement of my employment, that reasonably relate to Company&#8217;s business or actual or demonstrably anticipated research, development, manufacture or sale of products or services and that were made, conceived, developed or reduced to practice by me or acquired by me, alone or jointly with others, prior to the commencement of my employment with, and which are not to be assigned to, Company (&#8220;</font><font style="font-style:italic;color:#000000;">Excluded Inventions</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;If no such list is attached, I represent and warrant that it is because I have no rights in any existing Inventions that reasonably relate to Company&#8217;s business or actual or demonstrably anticipated research or development.&nbsp;&nbsp;If disclosure of any such Excluded Inventions would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Excluded Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such Inventions has not been made for that reason.  I acknowledge and agree that I shall not use any Excluded Inventions in the scope of my employment, or include any Excluded Inventions in any product or service of Company, in each case without informing Company in writing in advance and obtaining Company&#8217;s prior written consent to do so.&nbsp;&nbsp;In the event that I do so use or include any Excluded Inventions, or if my rights in any Excluded Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights </font></p></div></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="Background-color:#auto;text-decoration:none;">2.3</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">assigned to Company under this Agreement, unless Company and I agree otherwise in writing as to particular Excluded Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above and whether not consent is sought or obtained), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.4</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Assignment of Company Inventions.</font><font style="font-weight:normal;color:#000000;"> Inventions assigned to Company, or to a third party as directed by Company pursuant to Section 2.6, are referred to in this Agreement as &#8220;</font><font style="font-style:italic;color:#000000;">Company Inventions</font><font style="font-weight:normal;color:#000000;">&#8221; and will be the sole and exclusive property of Company.&nbsp;&nbsp;Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded Inventions set forth in </font><font style="color:#000000;">Exhibit A</font><font style="font-weight:normal;color:#000000;">, I hereby assign to Company all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, developed or reduced to practice by me, or acquired by me, either alone or jointly with others, during the period of my employment by Company.&nbsp;&nbsp;To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first fixed in a tangible medium of expression) my Copyright rights in and to such Inventions.&nbsp;&nbsp;Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights.&nbsp;&nbsp;To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights, even after termination of my work on behalf of Company.&nbsp;&nbsp;I further acknowledge and agree that neither my successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.5</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Unassigned or Nonassignable Inventions.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I recognize that this Agreement will not be deemed to require assignment of any Invention that I developed entirely on my own time without using Company&#8217;s equipment, supplies, facilities, trade secrets or Confidential Information, except for those Inventions that either (i) relate to Company&#8217;s actual or anticipated business, research or development, or (ii) result from or are connected with work performed by me for Company.&nbsp;&nbsp;In addition, this Agreement does not apply to any Invention which qualifies fully for protection from assignment to Company under New Jersey Statutes Annotated &#167; </font><font style="color:#252525;font-weight:normal;">34:1B-265</font><font style="font-weight:normal;color:#000000;"> (&#8220;</font><font style="font-style:italic;color:#000000;">New Jersey Inventions Law</font><font style="font-weight:normal;color:#000000;">&#8221;).&nbsp;&nbsp;</font></p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="Background-color:#auto;text-decoration:none;">2.6</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Obligation to Keep Company Informed.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, developed or reduced to practice by me, either alone or jointly with others.&nbsp;&nbsp;In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf or in which I am named as an inventor within one (1) year after termination of employment.&nbsp;&nbsp;At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the New Jersey Inventions Law; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief.&nbsp;&nbsp;Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any Confidential Information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the provisions of the New Jersey Inventions Law.&nbsp;&nbsp;I will preserve the confidentiality of any Invention that does not fully qualify for protection under the New Jersey Inventions Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.7</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Government or Third Party. </font><font style="font-weight:normal;color:#000000;"> I agree that, as directed by Company, I will assign to a third party, including without limitation the United States government or its agencies, all my right, title, and interest in and to any particular Company Invention.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.8</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Ownership of Work Product.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:8.93%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">I acknowledge and agree that all original works of authorship and other work product  which are created, prepared, produced, authored, edited, amended, conceived or otherwise made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright (&#8220;</font><font style="font-style:italic;color:#000000;">Work Product</font><font style="font-weight:normal;color:#000000;">&#8221;) are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101) and that Company will be considered the author and owner of such Work Product.  </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:8.93%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">I agree that Company will exclusively own all Work Product, and I hereby irrevocably and unconditionally assign to Company all right, title, and interest worldwide in and to such Work Product. I understand and agree that I have no right to publish on, submit for publishing, or use for any publication any Work Product, except as necessary to perform services for Company.&nbsp;&nbsp;</font></p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a></div></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="text-decoration:none;Background-color:#auto;">2.9</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Protection and </font><font style="color:#000000;">Enforcement of Intellectual Property Rights and Assistance.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I will assist Company in every proper way to obtain, </font><font style="font-weight:normal;color:#000000;">maintain, </font><font style="font-weight:normal;color:#000000;">and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in </font><font style="font-weight:normal;color:#000000;">any and all</font><font style="font-weight:normal;color:#000000;"> countries.&nbsp;&nbsp;To that end I will execute, </font><font style="font-weight:normal;color:#000000;">verify</font><font style="font-weight:normal;color:#000000;"> and deliver such documents</font><font style="font-weight:normal;color:#000000;"> (</font><font style="font-weight:normal;color:#000000;">including copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney</font><font style="font-weight:normal;color:#000000;">)</font><font style="font-weight:normal;color:#000000;"> and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof.&nbsp;&nbsp;In addition, I will execute, </font><font style="font-weight:normal;color:#000000;">verify</font><font style="font-weight:normal;color:#000000;"> and deliver assignments of such Intellectual Property Rights to </font><font style="font-weight:normal;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;"> or its designee, including the United States </font><font style="font-weight:normal;color:#000000;">government or its agencies </font><font style="font-weight:normal;color:#000000;">or any third party designated by</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;">.</font><font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;color:#000000;">My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in </font><font style="font-weight:normal;color:#000000;">any and all</font><font style="font-weight:normal;color:#000000;"> countries will continue beyond the termination of my employment</font><font style="font-weight:normal;color:#000000;"> with Company</font><font style="font-weight:normal;color:#000000;">, but Company will compensate me at a reasonable rate after my termination for the time </font><font style="font-weight:normal;color:#000000;">actually spent by me at Company&#8217;</font><font style="font-weight:normal;color:#000000;">s request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in </font><font style="font-weight:normal;color:#000000;">this</font><font style="font-weight:normal;color:#000000;"> paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by me.&nbsp;&nbsp;I hereby waive and quitclaim to Company </font><font style="font-weight:normal;color:#000000;">any and all</font><font style="font-weight:normal;color:#000000;"> claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to </font><font style="font-weight:normal;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.10</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Incorporation of Software Code.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I agree that I will not incorporate into or link with any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company except in strict compliance with any policies of Company regarding the use of such software.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Records.</font><font style="text-transform:none;color:#000000;">&nbsp;&nbsp;</font><font style="font-weight:normal;text-transform:none;color:#000000;">I agree to keep and maintain adequate and current records (in the form of notebooks, files, letters, notes, memoranda, reports, records, data, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Duty of Loyalty During Employment.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;I agree that during the period of my employment by Company I will not, without Company&#8217;s express written consent, directly or indirectly engage in any employment, engagement, or business activity which is directly or indirectly competitive with, or would otherwise conflict with, my employment by Company.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">No Solicitation of Employees, Consultants, Contractors, or Customers or Potential Customers.&nbsp;&nbsp;</font><font style="font-variant: small-caps;font-weight:normal;text-transform:none;color:#000000;">I</font><font style="font-variant: small-caps;text-transform:none;color:#000000;"> </font><font style="font-weight:normal;text-transform:none;color:#000000;">acknowledge that, because of the nature of my work for Company, my solicitation, serving or retention of certain customers, consultants or partners with whom Company does business from time to time related to my work for Company would necessarily involve the use or disclosure of Confidential Information, and the relationships and goodwill of Company and would otherwise impair the legitimate business interests of Company. Accordingly, I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">solicit, induce, encourage, or participate in soliciting, inducing or encouraging any person known to me to be an employee, consultant, or independent contractor of Company to terminate his or her relationship with Company, even if I did not initiate the discussion or seek out the contact;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">solicit, induce, encourage, or participate in soliciting, inducing, or encouraging any employee,&nbsp;&nbsp;consultant, or independent contractor of Company with whom I came into contact during the them immediately preceding 24 month period, but ending on the last day of my employment with Company, to terminate his or her relationship with Company to render services to me or any other person or entity that researches, develops, markets, sells, performs or provides or is preparing to develop, market, sell, perform or provide Conflicting Services (as defined in Section 6 below);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.3</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">hire, employ, or engage in a business venture with as partners or owners or other joint capacity, or attempt to hire, employ, or engage in a business venture as partners or owners or other joint capacity, with any person then employed by Company or who has left the employment of Company, for any reason, within the </font></p></div></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">preceding </font><font style="font-weight:normal;color:#000000;">three</font><font style="font-weight:normal;color:#000000;"> (</font><font style="font-weight:normal;color:#000000;">3</font><font style="font-weight:normal;color:#000000;">) months to research, develop, market, sell, perform or provide Conflicting </font><font style="font-weight:normal;color:#000000;">Services;</font></p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="Background-color:#auto;text-decoration:none;">5.4</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">solicit, induce or attempt to induce any Customer or Potential Customer (as defined below), to terminate, diminish, or materially alter its relationship with Company;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.5</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">solicit or assist in the solicitation of any Customer or Potential Customer to induce or attempt to induce such Customer or Potential Customer to  purchase or contract for any Conflicting Services; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.6</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">perform, provide or attempt to perform or provide any Conflicting Services for a Customer or Potential Customer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties agree that for purposes of this Agreement, a &#8220;<font style="font-weight:bold;font-style:italic;">Customer or Potential Customer</font>&#8221; is any person or entity who or which, at any time during the one (1) year period prior to my contact with such person or entity as described in Sections 5.4-5.6 above if such contact occurs during my employment or, if such contact occurs following the termination of my employment, during the one (1) year period prior to the date my employment with Company ends: (i) contracted for, was billed for, or received from Company any product, service or process with which I worked directly or indirectly during my employment by Company or about which I acquired Confidential Information; or (ii) was in contact with me or in contact with any other employee, owner, or agent of Company, of which contact I was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which I worked directly or indirectly during my employment with Company or about which I acquired Confidential Information; or (iii) was solicited by Company in an effort in which I was involved or of which I was aware.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Non-Compete Provision.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;I agree that for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit, perform, or provide, or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory (as defined below), nor will I assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>The parties agree that for purposes of this Agreement, <font style="font-style:italic;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Conflicting Services</font>&#8221; means any product, service, or process or the research, development or commercialization thereof, to, for or of, as applicable, any person or organization other than Company that directly competes with a product, service, or process, including the research, development or commercialization thereof, of Company with which I worked directly or indirectly during my employment by Company or about which I acquired or accessed Confidential Information during my employment by Company<a name="_AEIOULastRenderedPageBreakAEIOU13"></a>.</p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties agree that for purposes of this Agreement, &#8220;<font style="font-weight:bold;font-style:italic;">Restricted Territory</font>&#8221; means the (1) United States, and (2) the twenty-five (25) mile radius of any of the following locations to the extent outside of the United States: (i) any Company business location at which I have worked on a regular or occasional basis during the preceding year; (ii) any potential business location of Company under active consideration by Company to which I have traveled in connection with the consideration of that location; (iii) the primary business location of a Customer or Potential Customer; or (iv) any business location of a Customer or Potential Customer where representatives of the Customer or Potential Customer with whom I have been in contact in the preceding year are based. <font style="font-weight:bold;font-style:italic;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">REASONABLENESS OF RESTRICTIONS.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">I agree that I have read this entire Agreement and understand it.&nbsp;&nbsp;I agree that this Agreement does not prevent me from earning a living or pursuing my career.&nbsp;&nbsp;I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests.&nbsp;&nbsp;I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, I and Company agree that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.3</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the court declines to enforce this Agreement in the manner provided in subsection 7.2, I and Company agree that this Agreement will be automatically modified to provide Company with the maximum protection of its business interests allowed by law and I agree to be bound by this Agreement as modified.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.4</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Furthermore, the parties agree that the market for Company&#8217;s products is worldwide.&nbsp;&nbsp;If, however, after applying the provisions of subsections 7.2 and 7.3, a court still decides that this Agreement or any of its restrictions is unenforceable for lack of reasonable geographic limitation and the Agreement or restriction(s) cannot otherwise be enforced, the parties hereby agree that the fifty (50) mile radius from any location at which I worked for Company on either a regular or occasional basis </font></p></div></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">during the one (1) year immediately preceding termination of my employment with </font><font style="font-weight:normal;color:#000000;">Company</font><font style="font-weight:normal;color:#000000;"> shall be the geographic limitation relevant to the contested restriction</font><font style="font-weight:normal;color:#000000;">.</font></p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">No Conflicting Agreement or Obligation.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;I represent that my performance of all the terms of this Agreement and as an employee of Company does not and will not breach any agreement to keep in confidence information acquired by me in confidence or in trust prior to my employment by Company.&nbsp;&nbsp;I have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Return of Company Property.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;When I leave the employ of Company, or at such earlier time requested by Company, I will promptly deliver to Company any and all drawings, notes, memoranda, specifications, devices, formulas and other documents and materials of any nature pertaining to my work with Company or containing or disclosing any Company Inventions, Third Party Information or Confidential Information of Company, together with all copies thereof.&nbsp;&nbsp;I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company.&nbsp;&nbsp;</font><font style="color:#000000;font-weight:normal;text-transform:none;">In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any </font><font style="font-weight:normal;text-transform:none;color:#000000;">Company</font><font style="color:#000000;font-weight:normal;text-transform:none;"> information, including but not limited to, Confidential Information, I agree to provide Company with a computer-useable copy of all such </font><font style="font-weight:normal;text-transform:none;color:#000000;">Confidential</font><font style="color:#000000;font-weight:normal;text-transform:none;"> Information and then permanently delete and expunge such </font><font style="font-weight:normal;text-transform:none;color:#000000;">Confidential</font><font style="color:#000000;font-weight:normal;text-transform:none;"> Information from those systems; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and/or deletion is completed.&nbsp;&nbsp;</font><font style="font-weight:normal;text-transform:none;color:#000000;">I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice.&nbsp;&nbsp;Prior to leaving, I will cooperate with Company in attending an exit interview and completing and signing Company&#8217;s termination statement if required to do so by Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Legal and Equitable Remedies.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms.&nbsp;&nbsp;I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="Background-color:#auto;text-decoration:none;">10.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I agree that if Company is successful in whole or in part in any legal or equitable action against me under this Agreement, Company will be entitled to payment of all costs, including reasonable attorneys&#8217;<a name="_AEIOULastRenderedPageBreakAEIOU15"></a> fees, from me.</font></p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.3</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;In the event Company enforces this Agreement through a court order, I agree that the restrictions of Sections 5 and 6 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-weight:normal;text-transform:none;margin-left:28pt;color:#000000;"></font><font style="font-variant: small-caps;text-transform:none;color:#000000;">Notices.</font><font style="font-weight:normal;text-transform:none;color:#000000;">&nbsp;&nbsp;Any notices required or permitted under this Agreement will be given to </font><font style="color:#000000;font-weight:normal;text-transform:none;">Company at its headquarters location at the time notice is given, labeled &#8220;Attention Chief Executive Officer,&#8221; and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other</font><font style="font-weight:normal;text-transform:none;color:#000000;">.&nbsp;&nbsp;Notice will be effective upon receipt or refusal of delivery.&nbsp;&nbsp;If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark.&nbsp;&nbsp;If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-weight:normal;text-transform:none;font-variant: normal;margin-left:28pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">Publication of This Agreement to Subsequent Employer or Business Associates of Employee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If I am offered employment or the opportunity to enter into any business venture as owner, partner, consultant or other capacity while the restrictions described in Sections 5 and 6 of this Agreement are in effect, I agree to inform my potential employer, partner, co-owner and/or others involved in managing the business with which I have an opportunity to be associated of my obligations under this Agreement and also agree to provide such person or persons with a copy of this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK3"></a><a name="OLE_LINK4"></a><font style="Background-color:#auto;text-decoration:none;">12.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">I agree to inform Company of all employment and business ventures which I enter into while the restrictions described in Sections 5 and 6 of this Agreement are in effect and I also authorize Company<a name="OLE_LINK3"></a><a name="OLE_LINK4"></a> to provide copies of this Agreement to my employer, partner, co-owner and/or others involved in managing the business with which I am employed or associated and to make such persons aware of my obligations under this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-variant: small-caps;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-weight:normal;text-transform:none;font-variant: normal;margin-left:28pt;color:#000000;"></font><font style="text-transform:none;color:#000000;">General Provisions. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.1</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Governing Law; Consent to Personal Jurisdiction.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;This Agreement will be governed by and construed according to the laws of the State of New Jersey as such laws are applied to agreements entered into and to be performed entirely within New Jersey between New Jersey residents.&nbsp;&nbsp;I hereby expressly consent to the personal jurisdiction and venue of the state and federal courts for the county in which Company&#8217;s principal place of business is located for any lawsuit filed there against me by Company arising from or related to this Agreement.&nbsp;&nbsp;</font></p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a></div></div>
<p style="text-align:center;margin-top:12pt; clear:both;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div style="width:100%;">
<div style="float:left;width:48%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><font style="text-decoration:none;Background-color:#auto;">13.2</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Severability.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;In case any one or more of the provisions, subsections, or sentences contained in this Agreement </font><font style="font-weight:normal;color:#000000;">will</font><font style="font-weight:normal;color:#000000;">, for any r</font><font style="font-weight:normal;color:#000000;">eason, be held to be invalid, </font><font style="font-weight:normal;color:#000000;">illegal</font><font style="font-weight:normal;color:#000000;"> or unenforceable in any respect, such invalidity, illegality or unenforceability </font><font style="font-weight:normal;color:#000000;">will</font><font style="font-weight:normal;color:#000000;"> not affect the other provisions of this Agreement, and this Agreement </font><font style="font-weight:normal;color:#000000;">will</font><font style="font-weight:normal;color:#000000;"> be construed as if such invalid, illegal or unenforceable provision had never been contained </font><font style="font-weight:normal;color:#000000;">in this Agreement</font><font style="font-weight:normal;color:#000000;">.&nbsp;&nbsp;If moreover, any one or more of the provisions contained in this Agreement </font><font style="font-weight:normal;color:#000000;">will</font><font style="font-weight:normal;color:#000000;"> for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it </font><font style="font-weight:normal;color:#000000;">will</font><font style="font-weight:normal;color:#000000;"> be construed by limiting and reducing it, </font><font style="font-weight:normal;color:#000000;">so as to</font><font style="font-weight:normal;color:#000000;"> be enforceable to the extent compatible with the applicable law as it </font><font style="font-weight:normal;color:#000000;">will</font><font style="font-weight:normal;color:#000000;"> then appear.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.3</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Successors and Assigns.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.4</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Survival.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;The provisions of this Agreement will survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.5</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Employment At-Will.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;I agree and understand that nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company&#8217;s right to terminate my employment at any time, with or without cause or advance notice.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.6</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Waiver.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.&nbsp;&nbsp;No waiver by Company of any right under this Agreement will be construed as a waiver of any other right.&nbsp;&nbsp;Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.7</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Export.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:7.14%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref25264694"></a><a name="_Ref25264695"></a><a name="_Ref25264696"></a><font style="Background-color:#auto;text-decoration:none;">13.8</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Interpretation</font><font style="font-weight:normal;color:#000000;"><a name="_Ref25264694"></a>.&nbsp;&nbsp;The parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting party will not be applied in the construction or interpretation of this Agreement.<a name="_Ref25264695"></a>&nbsp;&nbsp;As used in this Agreement, (i) unless otherwise specified, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words &#8220;without limitation,&#8221;<a name="_Ref25264696"></a> (ii) the word &#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; will mean the degree to which a subject or other thing extends, and such phrase will not mean simply &#8220;if,&#8221; (iii) the word &#8220;will&#8221; shall be deemed to have the same meaning and effect as the word &#8220;shall,&#8221; (iv) the terms &#8220;or,&#8221; &#8220;any&#8221; or &#8220;either&#8221; are not exclusive, and (v) the headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement and will not be referred to in connection with the construction or interpretation of this Agreement.&nbsp;&nbsp;</font></p></div>
<div style="float:right;width:48%;padding-left:4%">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="Background-color:#auto;text-decoration:none;">13.9</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Advice of Counsel.&nbsp;&nbsp;I ACKNOWLEDGE THAT, IN EXECUTING THIS AGREEMENT, I HAVE HAD THE OPPORTUNITY TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND I HAVE READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT.&nbsp;&nbsp;THIS AGREEMENT WILL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION OF THIS AGREEMENT.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:5.36%;font-weight:bold;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.10</font><font style="font-weight:normal;margin-left:28pt;color:#000000;"></font><font style="color:#000000;">Entire Agreement.</font><font style="font-weight:normal;color:#000000;">&nbsp;&nbsp;The obligations pursuant to Sections 1 and 2 of this Agreement will apply to any time during which I was previously engaged, or am in the future engaged, by Company if no other agreement governs nondisclosure and assignment of Inventions during such period.&nbsp;&nbsp;This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between us; provided, however, prior to the execution of this Agreement, if Company and I were parties to any agreement regarding the subject matter hereof, that agreement will be superseded by this Agreement prospectively only.&nbsp;&nbsp;No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the party to be charged.&nbsp;&nbsp;Any subsequent change or changes in my duties, salary or compensation will not affect the validity or scope of this Agreement. </font></p></div></div>
<p style="text-align:justify;margin-bottom:12pt; clear:both;margin-top:0pt;text-indent:7.14%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>[Remainder of page intentionally left blank.]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[Signature Page to Employee Confidential Information, Inventions,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Non-Solicitation and Non-Competition Agreement]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.71%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Agreement will be effective as of <font style="font-weight:bold;">_</font><font style="text-decoration:underline;">April 26, 2021</font><font style="font-weight:bold;">______________</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.14%;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">I have read this agreement carefully and understand its terms.&nbsp;&nbsp;I have completely filled out Exhibit&#160;A to this Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Anne Jones</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anne Jones</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Printed Name)</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Accepted and Agreed To:</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Celularity Inc.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:45%;">
<tr>
<td valign="top"  style="width:8.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style="width:91.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Robert J. Hariri</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.4%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:78.56%; border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, MD, PhD</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.06%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:13.4%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:78.56%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;">Exhibit A</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;">List of Excluded Inventions</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk53866605"></a>1.<font style="font-size:12pt;font-weight:normal;margin-left:28pt;"><a name="_Hlk53866605"></a></font><font style="font-weight:normal;">Except as listed in Section 2 below, the following is a complete list of all Inventions that reasonably relate to Company&#8217;s business or actual or demonstrably anticipated research, development, manufacture or sale of products or services  and that were made, conceived, developed or reduced to practice by me or acquired by me, alone or jointly with others, prior to the commencement of my employment with Company:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.71%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check1"></a><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check1"></a>&#9746;</font><font style="margin-left:28pt;">No </font>Inventions.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:5.71%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="Check2"></a><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check2"></a>&#9744;</font><font style="margin-left:28pt;">See below:</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:26.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="top"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date</font></p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Identifying Number or Brief Description</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:26.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:26.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:26.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:26.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:26.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.71%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check3"></a>&#9744;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="Check3"></a><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-family:Times New Roman;">Additional sheets attached.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:28pt;"></font><font style="font-weight:normal;">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to Inventions generally listed below:</font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:5.96%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.78%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Invention or Improvement</p></td>
<td valign="top"  style="width:1.2%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.8%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Party(ies)</p></td>
<td valign="top"  style="width:1.2%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.06%;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Relationship</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:29.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.8%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.06%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5.96%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:29.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:29.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.71%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><a name="Check4"></a>&#9744;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="Check4"></a><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-family:Times New Roman;">Additional sheets attached.</font><font style="font-size:13pt;font-family:Times New Roman;"> </font></p></td></tr></table></div>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;color:#auto;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">235784396 </strike></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>celu-ex231_1187.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex231_1187.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:inherit;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk34763402"></a>Exhibit 23.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:inherit;font-style:normal;text-transform:none;font-variant: normal;">CONSENT <font style="Background-color:#FFFFFF;font-family:Arial;font-size:11pt;">OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:inherit;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk3236476"></a>We consent to the incorporation by reference in <a name="_Hlk3236476"></a>Registration Statement No. 333-260025 on Form S-8 of our report dated March 31, 2022, relating to the financial statements of Celularity, Inc. appearing in this Annual Report on Form 10-K of Celularity, Inc., for the year ended&#160;December&#160;31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:inherit;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">/s/ DELOITTE &amp; TOUCHE LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:inherit;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parsippany, New Jersey</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:inherit;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>celu-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Robert J. Hariri, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">I have reviewed this annual report on Form 10-K of Celularity Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert J. Hariri</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>celu-ex312_7.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex312_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David C. Beers, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this annual report on Form 10-K of Celularity Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David C. Beers</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">David C. Beers</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>celu-ex321_6.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex321_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Celularity Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk90081173"></a>Date: <font style="Background-color:#FFFFFF;color:#000000;">March 31, 2022</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Robert J. Hariri</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Robert J. Hariri</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>celu-ex322_8.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
celu-ex322_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of Celularity Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.1%;">
<tr>
<td valign="top"  style="width:45.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk90081173"></a>Date: <font style="Background-color:#FFFFFF;color:#000000;">March 31, 2022</font></p></td>
<td valign="top"  style="width:5.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:46.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;David C. Beers</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:46.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">David C. Beers</p></td>
</tr>
<tr>
<td valign="top"  style="width:45.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:5.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="width:46.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gizttcucplmb000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000017.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M)+ZEXQ^($E[\.[LS1^!/"^L1^)KOSBQ)N A2*R /W5,P6X./XK<\?.37Z/\
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M.[&T\5[5^R)X.UWP!^S+\-O#WB5YFUNQT:%)TG #PY&Y(6QQF-"L??[G4]:
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M[\>/AKK?@;Q5!)<:+JT027R9"DD;*P>.1&[,KJK#.1Q@@@D4 <A^RC\)]/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG[3/[.>C^)M8=7\2V,TFE:NZ*%$EQ%M(D   &^-XV.!@%F':@#Z-HIAD4=7
M_&E5U;H0?H<T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXFMQNAN;RZB,0LT?&&V YR">K_4_;Z]* %HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC=/)#)%NNG!/";U=5WO\RCA2,D ^M:6BB@ HHHH **** "OF3X5_\GJ?$_\
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M8'^Z:[+%4-4T6PUNW%OJ-E;W\ 8,(KF)9%##H<$=>M5#E4O?6@XVO[VQX/\
M\-X?";_H(ZC_ ."^2O5?AA\5-!^+_AU];\.3336"SM;EIX3&V]<$\'ZBOG%/
M"NB_\-XR:;_9%C_9W]A;_LGV9/*W;!\VW&,_A7UEI>C6&AV_D:=96]C 3N,5
MM$L:Y]< =:]#%4Z%.,?9IW:3W_X!TUHTXI<O4OT445YIRA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&7_!+VST#P[<FSU[4_#^LV=A.&V%)Y);I(SN_A^8CD=.M<S^P/\ \HV?%_\
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ML:^GOVI?COJ'[-_PKNO'5KX1G\7Z?8S(NH06MT()+:%OE\[E6W*&*@XZ;L]
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M,XZJ<'#=QZ'('KYE3Q4:<'46EE?U.W%1K**YMOU/2:***^>/,"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"-
M\E3CKVKY;\5?L9ZAXR\1:AK6H^,UDO;V5I9"+$X&>BCY^@' ^@KZFQTSUHV\
MUC5HPK*T]3R\?EF&S**ABH\R7FU^1\B_\,&R?]#<O_@"?_BZ/^&#7_Z&Y?\
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+P;X^NI[?PSXMT/Q%<0*'FBTG4H;EHU/ 9A&Q('UK\"J^P_^"77_ "<)J/\
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M%% !1110 5\)_M5?MT^,/!WQ>?X._ CP2/&/CV-?M&I3?9FFBMF90VT(A&6
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M&Y]U$$>/3:*ZW_@C+KU]JG[+NLV%S,TMMIGB2XBM5;_EG&\,,C(/;>[M]7-
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MDB#^WF =:^D=5^$/@;7/$2Z_J/@[0;_7$9774;G387G#+C:V\KG(P,'/&*[
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M$X96![@BK'K7S7<_LLZ_X+9[KX=>.+[2),[ELKQ]T1/7!(&,9]4/XU&OQO\
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ME<0O=Q0/&PD+AOWC*""&QP?X:];!XJ7M4JKT\_\ ,\[$X=>S;@M3\PZ^HO\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+_X8>%_
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M$QOB?^\P&6!ZX5L]J]+'9=5IT8S3NHK7[SKQ&%G&FI;V1]C4445\P>0%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "5^?OQT^"'[6
MW[0GQ<\5Z+I_CH?#OX3QWIBL)X+E89KJWVID[8#YCC.[AV7.*ZO_ (*5?M+>
M-/A#X?\ !G@3X:RM;>-_'%XUK!=Q &:&(%4Q$>BR,\B -V ;'."/?OV6? OC
M/X9_ GPOX:^(&L1Z]XJL8I%N[])Y)R^Z1F4-))\SLH8*6[D<4 > _!?_ ().
M_!GX;PV=WXIAN_B-KL>UY;C5V\NT9Q@Y6V4XVY'W79^N"33-!_8<N?AC^WQX
M9^)OPZTC2O"_PSBTB:+5[&UF\HR74D-S&5C@ (";C:M@8&5.*\:_:3^(7QV_
M8B_:8D^)FH^(O^$@^$OB[6O+DT@2R26]M",8B\MO]5*(@2'3ABISGI7Z<6=U
M'?6L%S"P>*9!(C#NI&0?RQ0!.*XGXT?%?1O@?\+?$?CK7RW]EZ+:FXDCC(#R
MMD*D2_[3NRJ,]V%=O5+5-)LM;LI+/4;.WO[.3[\%U$LD;8.>58$&@#\R[']M
MC]KOX@?#/6/C)X2^'OA6+X96+S3);SJTUPUM"S"5_P#7*\@3:P9E5>5; X-?
M7/P"_;*\,?&;]FG4/B]?6TGA^QT2&Y;6[1B93;/;IOD"$#+AD*LN!D[@.M>(
M_MZ_M8:#\'?!-U\"_A7I<-[X^\102:<NE:#;+Y>FQW!8/B.,?Z^3>VU%&<ON
M/;=R7BW]GO4_V6?^"4OCCPYJ5R?^$CU")+_51"WRQ237$"F%3W"HJJ2.IW=C
M0!RZ_P#!03]IKQUX.\4?&#P5X \.+\)-!O3%)#>JSW1A7:7+-YRLQ4,-S(N%
MW=" :^^_V;/CMI/[2'P<\/\ CW2(3:1ZC&RW%DS[FM;A&*21$X&<$'!P,@J>
M]?'W[+]M"W_!'?Q3E1\WA;Q3(WNP:\P?_'5_*KG_  19FD;]FOQ5&S$QIXHF
M*J>@S:VV?Y"@#]!:^9/A7_R>I\3_ /L&1_\ MO7;^-/VL/A]X \47_A_6+V]
MBU*Q<),L=F[J"5####@\,*\K_9U\::9\0OVK/B#X@T>2233KS2E:%I4*,0'@
M4Y4].0:: ^N****0"5@>.=2UC1_"NH7F@Z>NJZQ$@:WLV.!(V0,=1VSWK?I/
M2I>UB)Q<HN*=KGQU=M\8KKXK6GCMOAX%O;:T-HML)5\L@AN2=^<_-^E?3?PU
MUKQ!K_A.VO?$VDKHFKN\@DLU;<% 8A3G)ZC!_&NJXI *PI4?9MOF;N>/@<L>
M!J2FJTI<VK3MN^NB0^BBBND]L**** "BBB@ HHHH ^;D_P"3UG_[ W_LHKZ0
M/2OF]/\ D]9_^P-_[**^D#TKEH?:]6?.Y-_S$?\ 7R7Z"T445U'T04444 %%
M%% ">]'O1FN1^*WQ B^%?P^UGQ5-IUUJT6F1+*UG9#,TN75<*/7YL_@:$FW9
M";LKGAMY_P GR67_ %X'_P!)GKZ?[5^=,W[5EG-\9(?BH/!^NBUAA^SG1S&/
MM9_=F/<!TVY;/TS7W!\&_B=#\8?A[IOBJ#2KW18KTR 66H*!-'L<I\P'KMS^
M-94J<XJ;:TYF?,Y+4C*6)2?_ "\E^AW%%%%:GTX4444 %%%% !1110!\M:Q_
MR?/H?_7FW_I++7U+7RUK'_)]&A_]>;?^DLM?4M<M'>?J?.9/OB?^ODOR0444
M5U'T8AJK>:=;ZA;O!<V\5S#(,/'*@96'H0>M6@:6@F45)69XQXN_90^'_BC?
M)#IKZ'<MTFTM_* /LF"OZ5QL?PD^,?PQ4_\ "(^,H_$=A']RPU0$' Z*-Q('
M''#**^F*2N:6'@W=:>AXE7)<).7/33IR[Q?*_P -']Q\UV7[5&O>#I!9_$3P
M-?Z3/&=KWUFA:)O<!CC'T=J]4\+_ !X\">,+)Y].\16F8U+/#<MY$B@#))5\
M''N./>NZN+2&[A:*:))8V&&6100?PKXJ_;#T'P/X3O\ 3K'0]&M;#Q!<'[1<
MM:$HB0\@?NP=H+'OC/RGUK&I*IAXN7-=>9X^/Q&.R3#RQ$JJJ0722L_DUO\
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MM=E_-M8@R!HR&)P/N\*V..@KTLO=*.(C.F[/L_\ ,%BJN#_>-7L<5_;FG?\
M/_;?]_5_QKZ$_83TM/%'[0FE7=I>V[1Z/;W%Y,JRJ696C:(!1GKND!Z= ?:O
MB.OI_P#X)O\ _)U&A^]C>_\ HDU])C,1)X>=NQI'/*E=^R<59G[ T4E+7Y\:
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ ?\%4
M?AWXIL?^%:?&KPGIIU6;X?:@9[ZW1=Q6$R1.LC* 24#1[6(^Z'STR1T_@K_@
MKA\!/$6@P7>M:EJGA?4C&#-I]UITLY5\ E5>)65AG(R<=.U?:4T$=Q"\4J++
M$Z[6C=<@C&""/2OGKQ]_P3V_9[^)&M-JNL_#33X[YV+2/I=Q<:>LA)R2R6\B
M*3GN1F@#X9_:X_:<M/\ @HAXJ\#_  7^$.CZGJ%@VK+>WNKW5N8@-H9-X3JL
M:(SN6?'8 5^LFCZ;'HVDV.GQ$F*U@C@0G^ZJA1G\!7'?"GX$?#_X&Z0--\">
M$M,\-6^T([VD.9Y@  #),V9)#P.78GBN^H *\@_:N^(7B_X9_ GQ+K7@+PYJ
M7BCQB8UM=,L-+LI;N599&"><8XU8D1J6?ICY0"1FO7Z2@#\*?V=;[]HK]G?Q
MQK?C2W_9U\1>,/%^J,6;6O$GA;5)YX2S%I&C*A0&<GYF//&,@9S^D7PUNOB#
M^VI^R?X\T#XM^#7^'.NZO]HTNWM9],N;38HC1X;CR[@ECB4@Y!P=G%?6M% '
MXW>'?$O[1?P._9]\6?LPR? _7=<NM5>ZL++Q#912R6T5O='$@4I$8Y%.Z1A(
M95"[SN'RU^@W[!?[.5U^S'^SMI/AC5@G_"27L\NJZN(VW*EQ+M41@@D'9&D:
M\<$JQ'6OHHC-+0!BWG@W0-1NI+F[T/3;JXD.7FFM(W=N,<DC)Z5\[?!^PMM-
M_;*^)=M9V\5I;QZ8FV&% B+S;DX4#US^=?4=?,GPK_Y/4^)__8,C_P#;>FNH
M'TW1112 **** "BBB@ HHHH **** "BBB@!O.>.E<U\1-:UKP_X/O[_P]I7]
MMZO#Y?D6.['F9D56Y]E+'\*Z:F]JEJZLC.I%S@XIV;Z]CXW6?XMCXN-X]_X5
MU)]L-I]E^R>8-F, ;LYSGCI7U'\/-:UOQ!X1LK_Q#I7]B:M+O\ZQ#9\O#D+S
M[@ _C72TH%8TZ/LV_>O<\?+\L> G*2JRES7;3MN^NB'4445T'N!1110 4444
M %%%% 'SE<?\GJVO'_,%/\FKZ,KYSN?^3UK3_L"G^35]&5RT/M^K/G\HWQ'_
M %\E^@M%%%=1] %%%% !1110 4444 ?+6L?\GT:'_P!>;?\ I++7U+7RUK'_
M "?1H?\ UYM_Z2RU]2URT=Y^I\YD^^)_Z^2_)!11174?1A1110 4444 -YZ"
MOE7XG?L@:]X\\>:QKZ>)K817TOF(EQ"Y:-< !<@] !C\J^JJ/K6%6E"LK31Y
M6899ALTIJEBE=)WW:_(_.K4OV=]2T[XPZ9\/WU:V>]OH#.MXL;"- $D;!'7_
M )9GIZBO4="_8<U:QUNQN+WQ%836<4ZR31BV9MZ Y*X/'(&*ZCQ/_P GQ>%/
M^P>__HBYKZ<K@HX2E)RNMF?$97PUEM:I7<Z=^2HTM7LDO/S/GSQ-^R'HZW#:
MCX+UB_\ "&JJ=R-;RNT0/IC(89]FP,]#TK';QQ\:_@_L_P"$DT2+QMHT?#7M
MA_K0H[G:N>/5D^I%?3=(R@CG\J['0BM8/E?]=#ZN>2T8OGPDG2E_=V^<=CR+
MP+^U!X%\;S1VIU Z+J#<?9=4 B.[T#9VDY[9S[5ZU',DR!D=74C(92"#7!^/
MO@7X,^(T;'5M&A%WVO+4>5,/^!+]X>S9'M7DTOP'^(WPKN#=?#GQ?)?6/).D
M:JV5QZ+D%2?<!3QU-+FK4_B5UY?Y$?6,QP?\>G[6/>&C_P# 7^C/IDMQ1^%?
M-^E_M4:GX1OETOXE^$[SP_<YVB^M8RT+\\D ]AQRI;\*]L\'_$3PWX\L_M.@
MZO:ZC&/O+&_SIGLR'YE/U K6%:$]$]3OPN:87%OEIS][L]']S.D-?FQ_P5F!
M_P"$N^'AQQ]ANQG_ +:1\5^DX^;O6+XB\%Z!XP2%->T/3=;6$DQ+J-I'<!">
MI4.#CCTKOP];ZO54[7.VM3]M!P/Y^LBOJ#_@F^I;]JC0R!P+&])^GDD?U%?2
MOQG^&_A>Q_;R^#>E6GA?2+?1KK3IFNK*'3XEMY6Q<X+H%VD_*.2.P]*^R/#_
M ,._"OA.Z:[T/PUH^C73+Y;3:?810.5/.TLB@X]J]C$9@ITN51^)'F4,+:HY
M<WPLZ2BDI:^>/;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OF3X5_P#)ZGQ/_P"P9'_[;U]-
MU\R?"O\ Y/4^)_\ V#(__;>FNH'TW1112 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** &_2N?\=+K[>$]0'AAH%UW8/LIN?\ 5[MP
MSNX],UT-)S4M75B)QYXN-[7/DEOA7\<I/B GC,RZ'_;B6_V82;_DV<_P[>O)
MKZ1^':^)5\*6@\7-;/KV6\]K7_5_>.W' _AQ724O%8TZ*IMM-ZGDX'*Z>!G*
M<)R?-O=W5^_J.HHHKH/9"BBB@ HHHH 0UF>(O$6F>$]%NM7UB^@TS3+1/,N+
MNY<)'&N0,LQZ#)%:9K'\6>$])\=>';_0=<LDU'2;Z/RKFUD)"R+D'!((/4#H
M:%:^HG?H?(6I?&/P/<?M8Z5XPB\5:4_A:&V,4NL"Z4VRO]GD7!?.,[F4=>I
MKZY\(^--!\?:+'K'AS5K36M+D9D2\LI1+&S*<, P[@U\CZA^SM\.K;]I'3/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!ELZ^(YJ7P3LM7HK)]Q5&U0/2EHHKTC]#"BBB@ HHHH **** "BBB@ HHHH
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M^*Y"N%;Q1, WKBUML_S'YT ?H-7S)\*_^3U/B?\ ]@R/_P!MZWOB%^V5X/\
MAOXRU/PWJ.EZU/>Z>ZI+);11&,DHK?*3(#T8=17S[X,_:B\,^'?V@_&'CNXT
M[5'TK6;-;>""..,S*P,62PWA?^6;=&[BFD!]_P!%?,'_  \#\!?] 7Q#_P!^
M8/\ X[1_P\#\!?\ 0%\0_P#?F#_X[19@?3]%?,'_  \#\!?] 7Q#_P!^8/\
MX[1_P\#\!?\ 0%\0_P#?F#_X[19@?3]%?,'_  \$\!?] 7Q!_P!^8/\ X[1_
MP\#\!?\ 0%\0_P#?F#_X[19@?3]%?,'_  \#\!?] 7Q#_P!^8/\ X[1_P\#\
M!?\ 0%\0_P#?F#_X[19@?3]%?,'_  \#\!?] 7Q#_P!^8/\ X[1_P\#\!?\
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MP?\ #P/P%_T!?$/_ 'Y@_P#CM'_#P/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\
M#P/P%_T!?$/_ 'Y@_P#CM'_#P/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P/P
M%_T!?$'_ 'Y@_P#CM'_#P3P%_P! 7Q#_ -^(/_CM%F!]/T5\P?\ #P/P%_T!
M?$/_ 'Y@_P#CM'_#P/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P/P%_T!?$/_
M 'Y@_P#CM'_#P/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P/P%_T!?$/_ 'Y@
M_P#CM'_#P/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P/P%_T!?$/_ 'Y@_P#C
MM'_#P/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P3P%_T!?$/_ 'XA_P#CM'_#
MP/P%_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P/P%_T!?$/_ 'Y@_P#CM'_#P/P%
M_P! 7Q#_ -^8/_CM%F!]/T5\P?\ #P/P%_T!?$/_ 'Y@_P#CM'_#P/P%_P!
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M#O'WA^7X3ZW<.TTET^R;RI"H<$&)G7*J-RHV#STR:^_/V8_@+IO[-?P7\/\
M@+39OMAL$:2[O=NTW-R[%I),=@6. ,\!5%>JT4 %%%% !1110 4444 ?,-O_
M ,GZ7'_8!_\ :8KZ>KD%^%GA]/B0WCD6\O\ PD36WV4S^<VSR\ 8V9V]NM=?
M0 4444 %%%% !1110 4E+24 ?,2?\G[2?]@'_P!IBOIZN/'PK\/CXC'QU]FE
M_P"$B-M]E\_SFV>7C&-G3..]=A0 4444 %%%% !1110 4444 ?,=S_R?I:?]
M@$_^BVKZ<KD'^%OA^3XCIXY-O+_PD26WV03^<VSR\$8V9VYP>M=<* %HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -$F@#]+Z*** "N(^,7Q>\-_ OX>ZMXR\57R66D:=$9""P$DS]%BC!/S.QP
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M^L,@Y3M0![WXJ\4Z3X)\.ZCKNNZA;Z7I&GP-<75Y=2!(XT4$DDGZ5Y3^R_\
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M_P#CM?6_P;^*^C?''X:Z%XY\/)<QZ-K$32VZWD824*LC1G<H)P<H>]?D_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>F17X_77Q(\3>+O^":OQ_P##6O:O<^)-.\'^*+/2=)UJ[D\R2>W&H6Q$;/\
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M4J-<NDDC2$ET1%W*S94A1C:.]>-3?\$Q? .I^ [/PEK'CWXB:SIFF2QR:/\
M:]9B/]E!#D+!'Y'E<@8RZ,0.%VU]BT4 >->(/V6_"_B7X^>!OB[>ZIK;>*/"
M&FMIEE"D\(M9XV29"\R>5N+XN'^ZZC(7CL? O^"B7A:SUS6O!MWKGPE\6>+=
M&L@TD?C#X?WFS6]'DW995BV$,I 1EW'&0W0]?N*B@#\R_P!D?X1S^,/VT-/^
M(_ACX?\ C+P9\/-"\/R6TFH>.XMFI:E?N&1GD9G9I&8.3G)"B(#Y05%?0GC'
M_@G+\/\ Q+KOB&ZTKQ/XT\%Z+XDE\[6_#?AW5E@T[4&))<O&T;8WY((4@8Z
M5]844 >*_$G]DGX??$C]G^W^#LUI<Z-X0M$A6R73)0LUJT3;E=&<."Q);.X'
M.YL]:Z_X+?"N+X+_  \TWPE!XAUSQ1%9-(RZEXBNA<WC[W9L-(%7*KNPO'
M':N[HH ^3OB!X+U/X4_MV>"OB?I&DW5]X?\ '&EOX3\1/9P/(+:X3$EK=2!%
M. ?+2(LW "\D4?%#_@G)X%^*7Q7\0?$*7QQ\0/#6O:V4^U+X<U:"UAPB*@4
MV[-C"@X+'GFOK&B@#YU^!'[%.@? /QR?%&G?$'XA^)[DVDEI]A\3ZU'=VNUR
MI+[%A0[AM&#GC)KJ_P!F7]F7PO\ LJ>!]2\*^$[_ %?4-/U#59-7EDUJ:*64
M2O%%$RJ8XHQMVPKP1G)//IZ_10!XZO[+_A5/VEG^. U#6/\ A+'TW^RC9^=%
M]A\K:%W;/*W[L#_GICVKS+]NCP3K'QQE^&7PBTJRO&LM>UY-3UK5(XG\BQT^
MT&]]TF-HD<L%13U(/'%?5]% $-O#':PQPQ*$CC4(JCH !@#]*\F^#/[,GA?X
M&_$#XF^,-!O]7N]2^(&HKJ>J1:C-$\,,JR7$@6 )$C*N;E_OEC@+SUSZ_10!
M\V>,/V%?!WB?XO:Q\0]-\4^,?!FIZ]&L6MV?AC5A9V^I@ <R?(7!( R493U(
M()))X7_8)^''A'X1?$'X:65YKTGA+QI=->7-K/=Q,UC(=N#;.(@1MV(1YF_[
M@SGG/TG10!\K/_P3V\&7W[/UU\(=7\:^.=:\.S:I#J:7E]J4$MW;&.-8T@B9
MH"J0@*/DVG!)(QFNU_: _8]\#?M$-H=_K%QK&@>)]"01Z9XE\/7OV74+9 <[
M0^TJ0>>J\;FQ@FO=** /!_@;^QOX"^!TVOZC"^J^,/$FOQ/;ZKXA\5W7VV]N
MX6ZPL<!=F !@+D@#).*\]NO^";/@6.TU/0](\<_$#P[X#U.X-Q=^"]+UE4TQ
M]Q!>,*T3.$;'*[^F>:^NJ* ,3P;X/T?X?^%M*\.>'K"+2]%TNW2VM+.'.V*-
M1@ 9YS[GDDDFMNBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gizttcucplmb000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000021.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M)[ U=^'7Q&\-_%KP;IGBOPEJL.M^']20R6M["&4. Q4@JP#*00058 @@Y%?
MG[7]GKUA_P $G/"MOXG\P:[%:Z*MT)L[PV],!L_Q!=N??-=M^S>[_LC_ +4&
MM_!C49?(\">/5;Q'X-;!$-O<$?Z19C^Z<*2%Z?*O=Z /K7P_\8O!_BGXC^)/
M >EZP+KQ9X<BAFU33OLTR&W24!HSO9 CY!'W&..^*BT/XU>#O$GQ3\0?#K3M
M5:;QAH-M%=ZA8?9I5$4<@4H?,*[&^\O"L2,_6OF?]GW_ )22?M(?]@K2?_12
M5XQXX_:(TO\ 9G_;H_:#\47ELVHZI<:)IFGZ1ID?!O+R181&A;HJC!9F)Z*<
M<X! /OK7/CIX)\/?%30OAM=ZSGQKK4+W-KI-M;2SN(4!)DE9%*PI\IPTA4''
M&:[B\NX;"UFNKB0100HTDDC<!5 ))/L *^>OV2_V<]2^&EOJOC[X@W4>N_&#
MQ<1<ZUJ60RVL9P4LX,<+'& !\O!('8"JO_!0+XG:AX _9[OM&T G_A*O&MW#
MX5TI%.&\RZ;RW8<]1&7P1T)6@#.^'/[9.H>(OV8?'?QOUCPQ''X?TF\OGT>R
MLYBLU[8PR"-)'9BP#LP8' Q\O%?17@?Q1%XV\%Z!XCA@:UAU?3[>_2&1@6C6
M6-9 I(X) ;%?.'[37P[L/A+_ ,$Z?%_@W3(UCL]$\)K9+M_C9 @9S[LVYC[L
M:R=2_:8U/P#\+?@_\./AII%KXP^+NN^'-->UTJX+?9=.MOLT8:\O&4@K$,]-
MP+<X]P#["S17SK\=/V@/&/PXU?X;_#KPSHVDZ]\5O&B2B.:[,L.D60@C4SW$
MBAC*8PS?*@.2 06!QGS/6/CU^TI\/_C9X-^&7B#2OAGJE[XJCFN-/UJ!K^UM
MV6$!I82N9&$BJ<@D;3D<T >_:Y\>(?#'[17AWX7:KIAMH?$>D37^E:SYN4GN
M(7_>VI3;PPC^<'/.".O7UA>E?''_  4BE3P)X=^%'Q8C*P7'@?QG9SW$^&+?
M89MR7" #KN*Q_KBOL=>E "T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &=XBT:'Q%H&IZ5<C-O?6
MTEK)_NNA4_H:^&O^"=OQ4TOX+>'/$7P!^(>I6_ACQKX0U>Y%O'J=P(HK^UDD
M+));NY 9=VXX'9D(ZG'WM7F'Q?\ V:/AC\>OLK^//!NF^(+FU&(;R56CN(US
M]T2H5?;WVYQ[4 )XA^,O@CQ!JTOP_P!*\7:9>^,=8LKM;33[&Y$TJ[(F+,Y3
M/E@?[1'/ YKYW_X)>^/M$TW]G,>!-2O[;3/%WA35+^UU;3;V98[A&-P[^8R,
M0V,-MR1U4@U]%_"/]FOX9? C[0W@3P;IGA^YN%VS7D,9>YD7.=K2N2Y7/\.<
M>U8?Q1_8W^#?QF\2'Q!XM\":?J.MNNV6_C:2WEF'0>88F7>0 .6R: /"OA)=
M6WQ:_P""E'Q \=>%;F/5/"?A[PI!X>N]6M6#6\M\TBN8D?&'*A6SM/!0<]*Z
M3]CW_DYS]J__ +&>Q_\ 2>2OI/X?_#;PO\*?#-OX>\(:%8^'M&@)*6=A"(TR
M>K'NS'NQR3W-,\*_#'PQX)\1>)M=T32(M/U;Q+<I=ZM<QNY-W*B[5=@20" 3
M]T#K0!\O3?\ *6>#_LEN?_)]JQ?V:_$UC\*_VX/VB?"/B^\CTK6/$VH6VN:+
M-?OY:W]JRMA8F;[Q0.JX!_A8#[IKZX;X5^%6^)@^(1T>'_A,5TW^R!JV]_,^
MR>9YGE;<[<;N<XS[UA_%[]G7X<_'JVM(O'GA.P\0M9D_9KB962>')R0DJ$.
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MG\#_ /A.6?\ \;H [K_A)-)_Z"EE_P"!"?XT?\))I/\ T%++_P "$_QKA?\
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M^&8_@[_T2?P/_P"$Y9__ !NC_AF/X._]$G\#_P#A.6?_ ,;H [K_ (232?\
MH*67_@0G^-'_  DFD_\ 04LO_ A/\:X7_AF/X._]$G\#_P#A.6?_ ,;H_P"&
M8_@[_P!$G\#_ /A.6?\ \;H [K_A)-)_Z"EE_P"!"?XTG_"1Z3_T%++_ ,"$
M_P :X;_AF/X._P#1)_ __A.6?_QNC_AF/X._]$G\#_\ A.6?_P ;H [G_A(M
M)_Z"EE_X$)_C2_\ "2:3_P!!2R_\"$_QKA?^&8_@[_T2?P/_ .$Y9_\ QNC_
M (9C^#O_ $2?P/\ ^$Y9_P#QN@#NO^$DTG_H*67_ ($)_C1_PDFD_P#04LO_
M  (3_&N%_P"&8_@[_P!$G\#_ /A.6?\ \;H_X9C^#O\ T2?P/_X3EG_\;H [
MK_A)-)_Z"EE_X$)_C1_PDFD_]!2R_P# A/\ &N%_X9C^#O\ T2?P/_X3EG_\
M;H_X9C^#O_1)_ __ (3EG_\ &Z .Z_X232?^@I9?^!"?XT?\))I/_04LO_ A
M/\:X7_AF/X._]$G\#_\ A.6?_P ;H_X9C^#O_1)_ _\ X3EG_P#&Z .Z_P"$
MDTG_ *"EE_X$)_C1_P ))I/_ $%++_P(3_&N%_X9C^#O_1)_ _\ X3EG_P#&
MZ/\ AF/X._\ 1)_ _P#X3EG_ /&Z .Z_X232?^@I9?\ @0G^-'_"2:3_ -!2
MR_\  A/\:X7_ (9C^#O_ $2?P/\ ^$Y9_P#QNC_AF/X._P#1)_ __A.6?_QN
M@#NO^$DTG_H*67_@0G^-'_"2:3_T%++_ ,"$_P :X7_AF/X._P#1)_ __A.6
M?_QNC_AF/X._]$G\#_\ A.6?_P ;H [K_A)-)_Z"EE_X$)_C1_PDFD_]!2R_
M\"$_QKA?^&8_@[_T2?P/_P"$Y9__ !NC_AF/X._]$G\#_P#A.6?_ ,;H [G_
M (2/2?\ H*67_@0G^-'_  D>D_\ 04LO_ A/\:X;_AF/X._]$G\#_P#A.6?_
M ,;H_P"&8_@[_P!$G\#_ /A.6?\ \;H [K_A)-)_Z"EE_P"!"?XT?\))I/\
MT%++_P "$_QKA?\ AF/X._\ 1)_ _P#X3EG_ /&Z/^&8_@[_ -$G\#_^$Y9_
M_&Z .Y_X2/2?^@I9?^!"?XT?\)%I'_04LO\ P(3_ !KAO^&8_@[_ -$G\#_^
M$Y9__&Z/^&8_@[_T2?P/_P"$Y9__ !N@#N?^$BTG_H*6?_@0G^-'_"1Z3_T%
M+/\ \"$_QKAO^&8_@[_T2?P/_P"$Y9__ !NC_AF/X._]$G\#_P#A.6?_ ,;H
M [K_ (232?\ H*67_@0G^-'_  DFD_\ 04LO_ A/\:X7_AF/X._]$G\#_P#A
M.6?_ ,;H_P"&8_@[_P!$G\#_ /A.6?\ \;H [K_A)-)_Z"EE_P"!"?XT?\))
MI/\ T%++_P "$_QKA?\ AF/X._\ 1)_ _P#X3EG_ /&Z/^&8_@[_ -$G\#_^
M$Y9__&Z .Z_X232?^@I9?^!"?XT?\))I/_04LO\ P(3_ !KA?^&8_@[_ -$G
M\#_^$Y9__&Z/^&8_@[_T2?P/_P"$Y9__ !N@#NO^$DTG_H*67_@0G^-'_"2:
M3_T%++_P(3_&N%_X9C^#O_1)_ __ (3EG_\ &Z/^&8_@[_T2?P/_ .$Y9_\
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MCM_B!\;/VDOB3J,0FUU_&,WAVWEDRQM[*U&V.-"?NY!7..I454^-=I#\._\
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M/^"ITVM>$H56T\&^%FM/%.H6R;8YKN;<L5L[# 9PK(W.<>41U7C[@H ****
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MK<CLY%5_V[]/A\'?'S]F3XC62B#5(_&4/AZYDC^5YK:Y*@AB!DA0),#/\9H
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M6/!7P\\--I+:W:2*]M/J$[-F)&'WP$>3E3C*=>1GZ=^)'[/'PT^,5Y!>>-?
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MI47@?Q=HW[//_!1KXNZ9XNO[?0--^)&GZ;J6C:CJ,RP0330KY30AW(&YG>3
MSU '<5]<?#?X-^!_@_83V?@KPII/ABWN&#3+IMLL1E(SC<P&6QD]3W-/^)'P
M?\$_&#38=/\ &OA?2_$UI"V^*/4K99?+8]2I(RN<#H: /DG]HSQ?H_[1/[7W
MP'^&GA+4+7Q GA'66\7^(KC3YDF2R%L8S!&[#(RS95EZ_.G3-=C^V+^V%#\+
M];T_X6>$=<T31OB+KT8+:QXAO8K33M"M6!!N9I)2%+XR4C&<XSZ _0'PU^"_
M@7X.V=Q:>"?"FE>&(+A@TPTVV6)I2.F]@,MC)ZGO63X\_9K^%?Q1U\ZYXN\
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ML?\ P3M/$@U^+X7>%TU82>:+C^S8SA_[P7&T'\*]>,*-&4*@H1MVXXQCI]*
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MEH/_ ("R_P#Q5+]B^(G_ $$M!_\  67_ .*H [S</6C-<%]B^(G_ $$M!_\
M 67_ .*H^Q?$3_H):#_X"R__ !5 '?45P/V+XB?]!+0?_ 67_P"*H^Q?$3_H
M):#_ . LO_Q5 '?4E<%]B^(G_02T'_P%E_\ BJ1[+XB;?^0EH/\ X#2__%4
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M+;?_ .)H_P"$"\<_]%%NO_!;;?\ Q->D9/M^E+SZB@#S;_A _''_ $46Z_\
M!9;_ /Q-!\!^./\ HHMU_P""VV_^)KTCGU%'/J* /$_B1IGCWP3X!\0Z_;_$
M":XN--L9KN.*73;?:S(A8 X7H<=JU/#?BF^\<?LVVGB#4_+_ +0U+PV;JX\I
M<+O> DD#TYK9^/W_ "1/QSD#_D"W7_HIJY#X5_\ )HOA[/3_ (1-"?\ P'-
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M8X+.0*-R;<#).,[FQWJ;]G^SN?#/BSQ;;ZIK=OX6\2^+H_L&B>(;4BX1;@R
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M,'T'Y&@!_'M1Q[4S\J/RH ?Q[4<>U,_*C\J '-C:?I7F_@K_ )*U\0?II_\
MZ*:O1&^E>=^#/^2L_$/Z:?\ ^BFH ](P/04O'M3%4XXHV'VH DHHHH ****
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M-Q]* ,/_ (07P]_T!-/_ / 9/\*/^$%\/=]$T_\ \!D_PK<W'THW'TH P_\
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M _O'\Z\G_9KLVTWX;_96@N(##J=\ACN;DW$BXN'&&D/WC[DUZOYF/X30!7U
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M_.DX]6_,TA8>A_.EW?[)H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8:)JL2P:EI_AK[/<Q*P8+(L!# 'V(KUS"^AKG/B&H7P'XBQQ_P 2^X_]%M0
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M3GG'85YQ<,-'N+3PO+>6"3+<R7=UJ-PA>!KAN0I.. , $X[U^I\!Y/4P^/\
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MYKZ)^&OQ&T#XM^!=&\7^&+T:AH6K0"XM9]I4[3P593RK @J0>00: .IHHHH
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M*** /./COI>IZI\,-<33-2?3I$M9))=EH+@RQA#NC"EAU]<]JO?!-2OPE\)
MY!_LNWZC!_U8ZBL+]H+QYX8\)_#W5[+Q%K>D:0^I6<\5JNLRF.&9@A)!(/;(
MZ'N*W/@CM_X5+X1V%"O]EV^#'G:?W8Z9[>E '<X]Z,>]+10 F/>C'O2T4 )C
MWHQ[TM% "8]Z,>]+10 F/>C'O2T4 )CWHQ[TM% "8]Z,>]+10 F/>C'O2T4
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M:_MFDL)])T^'3MMW8V)C)VS2[<AV#1GYCD\],U[?^SA\%_$/B/P7\+O&=O\
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M^F[<6>(SAWY'!R>A[5U'P1+?\*E\([P5?^R[?<K=0=@R#[T =U1110 4444
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M9/J: /$K[]I^#3/%GASPW=^#O$%MJOB%IUT])DB59&A+!P27X^Z3]"#7;_\
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M_P"_J_XURO\ PI?P7_T+]I^3?XT?\*9\%_\ 0O6OY-_C0!U7]M:?_P _UO\
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M&>XU.RCTZ\D;.9K=&D9(SST!FE/'/SFMO'U_.C'U_.@#F+CX;^';CQ<OB9K
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MS0 ?A^M'X?K1C_.:,?YS0 ?A^M'X?K1C_.:,?YS0 F/K^=>/_M??\FM_%?\
M[%C4/_1#5[#M]S7CW[8 _P",7/BOS_S+.H?^B&H U/V>/^2=0_\ 7W<_^C37
MIFWZ_G7F?[//_).X?^ONY_\ 1IKTWGTH ,?YS1C_ #FCGTHY]* #'^<T8_SF
MCGTHY]* #'^<T8_SFCGTHY]* #'^<T8_SFCGTHY]* #'^<T8_P YHY]*.?2@
M Q_G-&/\YHY]*.?2@ Q_G-&/\YHY]*.?2@ Q_G-&/\YHY]*.?2@ Q_G-&/\
M.:.?2CGTH ,?YS1C_.:.?2CGTH ,?YS1C_.:.?2CGTH ,?YS1C_.:.?2CGTH
M ,?YS1C_ #FCGTHY]* #'^<T8_SFCGTHY]* #'^<T8_SFCGTHY]* #'^<T8_
MSFCGTHY]* #'^<T8_P YHY]*.?2@ Q_G-&/\YHY]*.?2@ Q_G-&/\YHY]*.?
M2@ Q_G-&/\YHY]*.?2@ Q_G-&/\ .:.?2CGTH ,?YS1C_.:.?2CGTH 6BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@# \;*DGA'7%<*X-C/E6 (_U;=JR?@S_R2SPK_P!@V#_T 5R7[1W@?4/$
MW@6_OK#Q7K7AR33;.XE\K29(U2ZRA 60./NCV8=374?!(,OPE\(;F+M_9=OD
MGJ3Y8Y- '=44F?:C- "<YKS7XW_%:/X:>%KDV4$6K>)[F&1M-T)9MEQ?;"OF
MF->K;$8L<#H*Z+XA?$;0/A?X;EU[Q)?_ -G:7&RHTQ1GPS'"C"@GK7Q]^W%X
M^\1-'IFH:3X7MG\.O8*VG>,EW?:83< %XXR&'E[T 4[EY#&O3R_"O$5XJ2T_
MK^M-3"M45.#9Y1^SW\1F\$>/M#3Q7X0DUV&"Z:6UU*..6:YT]KCYM@P<8+')
M#=,FOT[ADWHK#(##/(YK\@/ _COQCX/\,ZMIO@W4-0$ >'5I]1TJ-D*.B[3&
M^X\QC<<X!S@9K[D_96^-7Q(\86>A:7XQ\+:C>17UO/>#Q9,$AC*!OW<9B5 ,
MD=\@\@XKV<VH_6%]8IJR7>ZOYV8J<)8=JG-W;[-.WS1]0=>]&WW--0<=*=@>
ME?)G0&,=S7+_ !/_ .2=^)^<_P#$LN?_ $4U=1@>E87C;29]>\):SIML56XO
M+*:"(R9"[G0J,GTR10 G@//_  AFAX_Y\H?_ $6M;_->3>']:^(^BZ'I]@W@
M32Y7M;>.%I%\1%0VU0"0/L_MTS6A_P )=\1O^A!TW_PI/_N:@#TGFCFO-O\
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M_N_K1@_W?UHT 7_@5'_ J3!_N_K1@_W?UHT 7_@5'_ J3!_N_K1@_P!W]:-
M%_X%1_P*DP?[OZT8/]W]:- %_P"!4?\  J3!_N_K1@_W?UHT 7_@5'_ J3!_
MN_K1@_W?UHT 7_@5'_ J3!_N_K1@_P!W]:- %_X%1_P*DP?[OZT8/]W]:- %
M_P"!4?\  J3!_N_K1@_W?UHT 7_@5'_ J3!_N_K1@_W?UHT 7_@5'_ J3!_N
M_K1@_P!W]:- %_X%1_P*DP?[OZT8/]W]:- %_P"!4?\  J3!_N_K1@_W?UHT
M 7_@5'_ J3!_N_K1@_W?UHT 7_@5'_ J3!_N_K1@_P!W]:- %_X%1_P*DP?[
MOZT8/]W]:- %_P"!4?\  J3!_N_K1@_W?UHT 7_@5'_ J3!_N_K1@_W?UHT
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MD:MX6USPUI][.L#:O=S0R0V^Y@ \H!R$YY(SBOT#CD66-71MZ,,AE.00>^:
M'X/K_.C!]?YU\J_ ']O[PS\?OCYXA^%NG>%]6TO4='6\=K^ZEB:&7[/,L3#
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M':73*9(\.RD$KP>5/3VKN+RZBL+2>ZN)%@MX4:221SA551DL3Z8S0!/@^O\
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MM<2N%4?(&; 5$50,GH3W-,#:_:DL?&NK?L^^.=-^'FF?VOXPU#3GLK&V-Q'
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M.:7;_O4;?]Z@!.:.:7;_ +U&W_>H 3FCFEV_[U&W_>H 3FCFEV_[U&W_ 'J
M$YHYI=O^]1M_WJ $YHYI=O\ O4;?]Z@!.:.:7;_O4;?]Z@!.:.:7;_O4;?\
M>H 3FCFEV_[U&W_>H 3FCFEV_P"]1M_WJ $YHYI=O^]1M_WJ $YHYI=O^]1M
M_P!Z@!.:.:7;_O4;?]Z@!.:.:7;_ +U&W_>H 3FCFEV_[U&W_>H 3FCFEV_[
MU&W_ 'J $YHYI=O^]1M_WJ $YHYI=O\ O4;?]Z@!.:.?2EV_[U&W_>H ?111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJEW#U_E1N'K_ "H 3C_/_P"JCC_/_P"JEW#U_E1N'K_*@!./\_\ ZJ./\_\
MZJ7</7^5&X>O\J $X_S_ /JHX_S_ /JI=P]?Y4;AZ_RH 3C_ #_^JCC_ #_^
MJEW#U_E1N'K_ "H 3C_/_P"JCC_/_P"JEW#U_E1N'K_*@!./\_\ ZJ./\_\
MZJ7</7^5&X>O\J $X_S_ /JHX_S_ /JI=P]?Y4;AZ_RH 3C_ #_^JCC_ #_^
MJEW#U_E1N'K_ "H 3C_/_P"JCC_/_P"JEW#U_E1N'K_*@!./\_\ ZJ./\_\
MZJ7</7^5&X>O\J $X_S_ /JHX_S_ /JI=P]?Y4;AZ_RH 3C_ #_^JCC_ #_^
MJEW#U_E1N'K_ "H 3C_/_P"JCC_/_P"JEW#U_E1N'K_*@!./\_\ ZJ./\_\
MZJ7</7^5&X>O\J $X_S_ /JHX_S_ /JI=P]?Y4;AZ_RH 3C_ #_^JCC_ #_^
MJEW#U_E1N'K_ "H 3C_/_P"JCC_/_P"JEW#U_E1N'K_*@!./\_\ ZJ./\_\
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MMK$44:A$CC,"A0!C &/2OT%\L8Z#-)Y?M2_LV/\ /+[Q_P"NM3_H"H?^ ?\
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M']I__H+7W_@;'_A7UA_PK?Q;_P!%(U'_ ,%UO_A2?\*U\7_]%(U'_P %MO\
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M?^$+T0C_ )\H?_0!6\,]Z /-/^%?>-A_S4.Z_P# "&F_\*_\;?\ 10[K_P
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M Z?_ -BO;_\ H"UY>(_@S]&>[DO_ ",\-_CC_P"E(9_P3W_Y)+K'_89E[?\
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MSV/ZT ._/\J7\3^5,\SV/ZT;_K0!+1110 4444 %%%% !1110 4444 %%%%
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MZ*.?0_G1SZ'\Z #Y?[HH^7^Z*.?0_G1SZ'\Z #Y?[HH^7^Z*.?0_G1SZ'\Z
M#Y?[HH^7^Z*.?0_G1SZ'\Z 'T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?F]^TKJEMHO[7E]?7DRP6ENUK)+
M*W15%LO)K[J^"\BS?"OPHZG<C:; RGU!05\&_M1QQ2_M8:JD^WR6^S!MQ4#'
MV9.N[Y?SK[P^">/^%3^$L'(_LRWQ_P!\"O&R_P".M_B9^D\7?[IEG_7F)W-%
M%%>R?FQP'Q<^%/ASXK:+:6_B*W:6+3;E;^"19/+*2)R"6_N^OK7YQZ;:ZEIO
MQ$\47VH331ZP][+<^5"PGLS"9"ZX<'&3A@,'M7Z*?'RT\4WOPKU^+PA+9Q:L
MUL^?MJ%E:+:?,50 ?F*Y ]R*_)[POJFG^&;[2+J\M+XR"9_M$CL^P1A6&Q8_
MXMI(;\Z[JN$Q&-RJO3I2NK?"M7WZ]&?-9SS\L5376[/8(=;\+VT,>IV$<TNK
M-=-J"V,QW0I/G'DLW7')/2F_$*U\9:_X;M-9TZUFL+:ZF>2^\J:.)PI)X7)S
M@\\BNNT/7O R:Q%J=G9O*]]HX:)#; 0M( !N"]0YS]XUP7P3\"VOQ"^.%IX8
M\9:U>V=HUK+_ &?^\99"[#=&@;&,KD]3SC'-?CO!N6SQ.9SJ/W'2U:G%RNNJ
M236Q^G\89M@LZPN%I48WTNFWK%]K=8_+IN>^_L__ !\\0?$K2=(\!>!]&M-$
ML+6"XM;F\FOE:[MK?RP(KM$)!=P[DM@=2*^J?A;X5USP;X.LM*\0>(I_%.IP
M[O,U*X7#R9)(!Y.< @?A7FWP._9%\+? WQ9+XATK4+_4+Y['["OVS;M4,RLS
M# ZDJOY5[RJ_+S7[5CZU"<W'#+W?36Y\;1C*,$I[ASZUR_Q/S_PKKQ/_ -@R
MY_\ 1356^+'Q'@^%'@N\\1W.F:AK$-LR*;73(?-F.Y@H(&>@)YK546WCCPDH
MGMYX;/5;+]Y;S@QR*DL?*,/X6 ;!]#7E\DE%3Z&]U>PSP)\O@W0P3C_0H>W^
MP*W]P_O?I7F-O\ ])L[>."#7O%$,,:A$1-9E 4#@ 5+_ ,*+T_\ Z&+Q5_X.
MI:D9Z3O'][]*-P_O?I7FO_"B]/\ ^AB\5?\ @ZEH_P"%%Z?_ -#%XJ_\'4M
M'I.1ZC\J-P_O#\J\W_X47I__ $,7BK_P=2T?\*+T_P#Z&+Q5_P"#J6@#TCS!
MZ_I7@W[;3!OV=?$.&S^^M.W_ $\1UV'_  HO3_\ H8O%7_@ZEKQW]K7X7V?A
M;X%ZY?P:QKUXZ2VP\F_U*2:(YG09*'@XKEQ7\"?HSZ/AO_D<X3_KY#_TI&[^
MR/XJTKP;^S'H>I:S>+8V8O)H?-96;+R73(B@ $DEF'0>IZ UV/B;Q_KOB;Q]
MH6E^!I);FRTG4U'B-5A2%C"2T> 9U7S(L^83)!N.^';G*L*XC]E/PG;>-_V5
M]+T:\N+BVMI[F=G>U*!_DNV< %E8=5':O;?"OP]T[P?J6H7]I-=3SWN5;[0R
ME8U\Z68JH51P7GD.3D\@9P *C!?[O#T'Q)_R.L7_ -?)?^E,^)_VF':3]L/P
MV"C(%?3P"QSN'G,<_P#Z_0U]^1*?+7GM7P/^T]_R>!X6XQSI_P#Z.>OOF//E
MKVXKFP?\6MZGTG%/_(NRO_KU^J'^6?[U'EG^]2?C1^->KJ?FX;6[-7 ZUX'\
M1ZA\4M%\1VOBZ[LO#]E;/%<^'T4F*Z<YP['/49';M7?<^M&X^H_.KA-PU0-#
M0I*C!_2G;&QUH+8&>?YTF[/?]*@ *\=>_P#6O+_AWX>T[Q5X,\1:5J]E#J&G
M7.M7ZRVUPH9' N6(!!]P/TKT\GY1]:X+X-_\@76?^PWJ'_I0]4F[W0':V-A!
MIUK%:VT:V]O"@CCBC7"JH&  /2LSQ1X7T+Q39Q6^OV%IJ-M',LL:7B*RK(#\
MI&>]8'Q0^'FK>/?^$?\ [+\47OAG^S=1CO9_L8)^UQKUA;##Y3_D4_XJ?"/1
MOC!H]CINN/>QP6=TEY&;&Y:%BZYQDCJ,$UM!13C)SM??NA.YVZ1 * IP!P!7
M-?$3Q5/X'\'ZEKEOI-WKD]G%O6PLES+*<XPOYUTD,?DQJHSA0 ,G/04_D]JQ
MBTI)O5#U/)U\"V7QDN/ ?CW4AKOA[4=-3[7%I(N3$NYB"4G3'S8*C\#7JZH>
M?FI5R.U!SZ?J?\*N=24].BV\A)6#RS_>I=I_O4WYO0_F:/F]#^9K,9P7Q^S_
M ,*3\<]_^)+=?^BFKQS4O^4?^G?]BO;_ /H"U['\??\ DB7CG/\ T!;KU_YY
M-7C>I?\ )@&G#_J5[?\ ] 6N?$?P9^C/9R3_ )&F&_QP_P#2D-_X)\*/^%2:
MMD_\QF;_ -%0U]39/J*^6O\ @GSG_A4FL?\ 89F[_P#3*&OJ/GT_6LL'_NU/
MT1Z?%G_(\Q7^)CL^XHS[BF8;_)HPW^37:?)C\^XHS[BF8;_)HPW^30 _/N*,
M^XIF&_R:,-_DT /S[BC/N*9AO\FC#?Y- #\^XHS[BF8;_)HPW^30 _/N*,^X
MIO/I^M)AO\F@!^?<49]Q3,-_DT8;_)H ?GW%&?<4S#?Y-&&_R: 'Y]Q1GW%,
MPW^31AO\F@!^?<49]Q3,-_DT8;_)H ?GW%&?<4S#?Y-+AJ )**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S:
M_:>D>+]K;4G2=;5P;8K,\1E"?Z,O)3^+Z5]V_!5BWPI\)G<'/]F6_P P7:#\
M@YQVKX;_ &C#.O[8ET;58WN ]KY:RDA=WV9<9('3Z"ON;X-;C\+O"Q?&_P#L
MV G'(^Z.E>-E_P =;_$S]*XN_P!TRS_KS'\CMJ***]D_-2*0#K7P/^U'\ O$
MN@^+O%'Q._M4ZB[W%NNB:7:*3*&<I&RLO]Q5W<+UW#-??$PW#&>M?$'QUT_P
MAX#\ ^.[6;QUK7B'59M;C\R2V<3S:'),&=4V[AM5T5E!)["O5R]U.9PII/FL
MFFM&F]3CQ<(SI--7/"=1U+5['Q9)HMY?:7;-9VWV6]AL3YCVMV00-F5#$JW!
M4# YZXKG=-DTR\^)%O9_$+^U[-K*U^QEM%^:]EN"W[J5 <8P&!-:7AWX9^+?
MBEXH\+6EY)IVAW5Y;B"*65XX+ZX@ ),[1;M\KL,_-C+5Z[^SGX";P;XH\#P:
MEJ47AOQEJ&K33W>E:[8L;J[LXR501%D^3< W)(S^&*]NCD^"RJI+$4K<W+HE
MNM[N^OX^1\YA<OC"M[1;>9]X^#=!B\*^%=)TB&XN+N*QMHX$GNF+2N%4 %CZ
MFMOBHU7CVI^T5\@WS.[ZGUY6O+B&TMY)[B1(8(QN>21@%4#N23C INFZA::K
M9QW5C<PWEI*-T<]O(KHX]0P)!%5/%'ARQ\7:!J&C:E$9["^A:">-6*DJ1@C(
MYZ52\ ^!])^&_A/3_#FAP-;Z78H4AC=RQP6+')/J2:KW>3?46MSI.E)CW_6D
MQ[?RHV^U0,=Q28]_UI-OM1M]J '<4<4W;[4;?:@!U>"_MNC/[.WB ?\ 3:T_
M]*(Z]XV^U>#?MN#_ (QV\0?]=K3_ -*8ZY<5_ GZ,^CX;_Y'.$_Z^0_]*0?L
M0?\ )N^A?]?%U_Z4/7O:UX)^P_\ \F[Z%_UWN_\ TH>O>UJ,%_N\/1#XD_Y'
M6+_Z^2_-GP%^T_\ \G@^%_\ N'_^CGK[YA_U*_2O@7]J#_D\'PM_W#__ $<U
M??,/$:].@KGP?\6MZGT?%/\ R+<K_P"O7ZHDQ[_K1CW_ %I/R_2C\OTKU3\X
M%Q[_ *T8'K^M)^7Z4G^>U &%XZTG5M<\*:I8:%J_]A:O<0LEMJ(B$OD,>C;3
MU_\ KTSP#H^L:#X1TO3]>U<Z_K%O#LNM2\L1_:'R3NVCIQC\JZ#\!2CV6JYW
MR\@NHC?=[]?ZUP/P;_Y VL_]AO4/_2AZ[USP/3->0>%]7\2^!_[8T]O!&J:B
MCZI=7,5U:S0;)$DE9U(!<'HPZCL:D9[$ #SUI=H]*\Y/Q(\1G_FGFN#_ +;6
M_P#\71_PLCQ)_P!$\US_ +_0?_%T >B[0*.*\Z_X61XC/_-/-<_[_0?_ !='
M_"R/$?\ T3W7/^_UO_\ %T >C<&CBO.1\2/$G_1/-<_[_P!O_P#%T?\ "R/$
M?_1/-=_[_6__ ,70!Z-M%' KSG_A9'B3_HGFN?\ ?ZW_ /BZ/^%D>)/^B=ZY
M_P!_K?\ ^.4 2_M 8_X4GXY_[ MU_P"BFKQO4O\ DP#3O^Q6M_\ T!:[?XH>
M(O%GC+X=^)="L_A]K"7>HZ?-:PM+/;A0SH5!)#].:YKQQX;U#P?^Q&VA:K$L
M.IZ=X>AMKB-6#!9%500#W (-<^(_@S]&>UDG_(SPW^.'_I2,O_@GNN[X2ZOG
M_H,R_P#HJ&OJ3;Z=*^6_^"?# ?"/6.G_ "&9O_14-?4GF#V_.LL'_NU/T1Z7
M%?\ R/,5_B8FVC;3O,'J/SH\P>H_.NS4^3&[:-M.\P>H_.CS!ZC\Z-0$VFOC
M/Q-_P5A^!/A/Q;J6@7DWB*2XT^[DLY[F'3 T.]&*L1\X8C(/\.>.E?9OF#U'
MYU_.QI?P7U#XZ_';XO:'H\<D^M6*ZQJ]E;18S/)!<[C$!CDLA< #'S%:8']"
M7AGQ%IOC#P[INNZ/=I?Z5J-NEU:W,>=LL;@,K#/L1UKPKQ)^W5\-/"W[1$7P
M7O?[9_X3&2[M[(-'9!K423QI(@,F_.-KKR%ZDU\I_P#!'O\ :F.N:#>_!CQ#
M?!KW3%:]\/F8\R6Y.Z:W![E&)<#^ZS=EX\;^-;?\;D+0_P#4R:-_Z1VU '[,
M;:^>?V]/V@)/V<?V;O$7B+3KK[+XDO2NF:,P )6ZE)_><\?(@D?G^X!WKZ(\
MSZ?G7Y"_\%:OB9?_ !@_:!\%?!;PX%N'TTQ>8H8XDU"[8*B' Z)'L.1G_6MZ
M4 ?4G_!*[5OB3XX^!^K>-?B'XOUCQ,NLZFZ:5#JLQE\F"+(>168;L/(SC;DJ
M!&N *]*_:?\ V[/AK^R;K&FZ/XO76-1UC4+;[7%8:);132I#O*AW\R6-5!(;
M&3SL:O6?A#\.M,^#/PK\,^"]+(&GZ%I\5FLK8!D**-\C=LLVYB?5C7Y#S^'+
M;_@HQ_P44\1V\MU*W@NR%Q&MQ W6RM4,<15@>!+*5;C'$AZ&@#]3?V;?VGO!
M7[5/@^]\1^"GODMK*Y^R7-MJ4(AGBDV*XRJLP((8<AN<'TKUS;7XQ?\ !+7X
M@7WP(_:\\2?"S6Y?LT>M-<:1<0R-@+J%H\A3\<+,GN6'7BOV>\SZ?G0 FVC;
M3O,'J/SH\P>H_.EJ W;1MIWF#U'YT>8/4?G1J W;1MIWF#U'YT>8/4?G1J W
M;1MIWF#U'YT>8/4?G1J ^BJ=]JMEI:HU[>6]FLC;5-Q*J!CZ#)Y-> > /B1X
MDUC]MKXI>#+O5I)O"^D^'=+O+'3BJ!(9I2?,<,!N);W)]J8'T715"^US3M*D
MC2]O[6S>3[BW$RH6^F3S5F2XBA\O?(B>8P5-S ;B>@'J: )J*CFFC@C:25UC
M11DLY  ^II4=9%#*0RL,@@YSF@!]%?/?CQ?VH_\ A+]4/@U?A2?#'G?Z!_;=
MSJ*WGEX'^M$<)3=G/W217)?LX_'KXO>-OVC/''PW\>6?@R>S\*:;%-?:CX3:
M[=([R9D,4&Z8+D^7YA8;>"!R>: /K&BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /SE_:*663]L:Z6"18IS):A)&7< ?LR\D9K[D^#.?^%6
M^%@QRW]G09(&!G8.@KX?_:"8#]LR8DX'FVG/_;LM?<7P;X^%_A?/_0.A_P#0
M!7C9?\=;_$S]+XN_W/+/^O,3M**3(HR*]D_-!KKN%>5_$SX ^#_'WA/Q7I<E
MG'H\WB)H9]0U&QC43R/"VY')(Y(&X<C^(UZH>:X#_A4.GCXP2?$,ZC?MJ#Z;
M_9IL#(/LVS<#OVX^]QZXK>A-PES<UO\ ,B2YE8^#&\7> E\4:Y'JUW>:IH36
M2:78?$.&":2^TQE&Q1+'@;2=K!2!G XKZ-_97\%Z_K%]!XNU'QOI?CGPG!;&
MRT*3[ 5NHU1L!G9T5D? ((R<YZUPO[1'P['[,<,WB[P5J%G!HVK7:I=>$]4B
M-U!?7+,?G"L>-H.<#IBO:_V>/'6O?9%\/>/(]!T#Q-/NN].T+2L(PM-H.XH"
M>^:^EQ#7U+FPWPON[OSW5_6SL<%"G[.?(^A[HJD4-G::\_\ B9\3KWP#JOA:
MSM?#.HZ^FM7RVDMQ9#Y+)25'F2<=.2?^ FO0$;*Y-?+.G**4GLST;G Z/XC\
M9W7Q4UC1[[PQ#:>#[>U62SUL7(9[B;Y<H4SQP6_[YKO>?84NU?7]:7@=Z4Y*
M3NE8!,^XHS[BG9'K1N'K4C&Y]Q1GW%.W#UHW#UH ;GW%&?<4[</6C</6@!OX
MBO!_VW%_XQV\0#_IM:?^E$=>];AZUX+^V]_R;OX@_P"NUH?_ "8CKEQ7\"?H
MSZ3AO_D<X3_KY#_TI"?L/_\ )O&A?]?%W_Z425[VM>"?L/\ _)O&A_\ 7Q=?
M^E#UWGQ&^(\W@;Q%X.L8H[.>/6]22QECFE*S*K8&]%&2<$C^$CD9*@EA&"_W
M>'H@XD_Y'.+_ .ODOS9\@?M.G/[8'A?C_H'_ /H]Z^^8<^4N/2O@/]IJ5)?V
MPO#01@WEMIZMCL?.8X_6OOR$J(EY'2N;!_Q:WJ?2<4?\BW*_^O7ZHDYH^:D\
MP>HH\P>HKUC\W%^:CFD\P>HH\P>HH 1L]^!7!Z?J/CJ3XM:G9W>DV*> 4LD>
MTU%9@;A[@XW*R;LXSGMVZUWVY2.H_.F?)US51ERWTO< 7&*-H]/TIR[<4A91
MW'Y5("87^Z/UI&4=A2[U]1^5&]?4?E0 NT8^[S3=H]/TI=Z^H_*C>OJ/RH -
MJ^E+M7TYI-Z^H_*C>OJ/RH 3:.XI=J^E&]?4?E1O7U'Y4 )L'H/R_P#K5Y5^
MU0/^+ ^,\<?Z$?YBO5MZ^H_*O*?VJL?\*!\98Q_QY'^8KGQ'\&?HSVLD_P"1
MIA?\<?\ TI'F/_!/?_DD>K_]AF;_ -%0U]2;O8?E7RY_P3WQ_P *CU;.!_Q.
M9O\ T5#7U+YB^M98/_=J?HCTN+/^1YB_\3$W>PHW>PI?,7UH\Q?6NT^3$W>P
MHW>PI?,7UH\Q?6@!N[V%?C1_P3B_Y2/>,_\ =US_ -*!7[,^8OK7Y8_L+_LV
M_$WX=?MX>+_%7B3P9J>C^')5U;R]3N$ @D\V<-'M;)SN'(Q0!XU^W1\)]9_8
MD_:VT7XH>"5^S:-JM]_;6GA4*Q07*MFYM&QU1@2?]V4CMFLF]^)VE?&3_@J'
MX1\:Z(^=-UK6-#NHU)R8V-E;!XVQ_$K!E/NIK]7OVOOV=]/_ &GO@;KG@Z80
M1ZMM^UZ1>3@XM[Q,[&SV# LA]G/%?E!^RK^Q#\<?!O[3G@#4M<^'>J:7I>DZ
MU#<7E_.8Q!''&V68.&(88'&W.: /VP\9>+-/\#>$]9\1:K*(-,TJTEO;F3&2
M(XU+-CWP#7Y#?\$Z_"][^U5^VYXI^,/B2$O#H\\VN&#AHUNIV=+:+./NQKN9
M>AS"I]:^J/\ @KM\<7^'/[.D7@_3Y@FJ>,[K[')S\RV<6))B./XF\N/Z.U=5
M_P $L_@S#\)_V5M&U.> 1ZQXND.MW,C#YC$P"VZY_NB-0WUD:@#O_P!NWXW)
M\!?V8_&.OQ2^7J]W;_V7IB@X8W,_R!AS_ I>3C^X:_*S_@GK^V!\-_V1?^$P
MU7Q9H7B+6O$6M&&WAFTJ&W>.&V3+,-TDJ-N=VY&,8C3WKZV_X*R?#_XM?&S5
MO O@[P)X&UC7_#UFDFHW5]9*K0O=2,8TC)W<%$5FRW'[T8Z&OJGX(_LE?#GX
M;?"/PEX9U/P1X9U?5--TZ&&]O[S2;>:6XN-H,SL[(2<N6QDGC [4 ?BU^TU^
MT5X=^(G[4P^+WPVL=4\/N;BSU(QZE'%'*M[ 5S( CNN&V(>O4G(]?WR^&/CR
MQ^)WP[\->+=-=9++6].@OXBO82(&*^Q!..>X-?(G_!1;]C/3/B-\ ?,^&7@+
M2X/%NDZA#=Q6VA:=#;SW439CD3Y%7=@,'P?[AK<_X);>'_B#X!_9[N_!_P 0
M/#6H^&Y-'U28Z:FHQ[#);S8D8*/02M)_WU0!]C[O84;O84OF+ZT>8OK0 F[V
M%&[V%+YB^M'F+ZT )N]A1N]A2^8OK1YB^M ";O84;O84OF+ZT>8OK0!\*?!/
MX6^%?VNOCU\>?&'Q.TB/Q7!X:\33^#M#T?4R9+73[>V&V21$X >5@&)(R.U7
M?V6?AA8_"']NSXT>&]*O]0O=(@\-Z5)91ZC<M<26L+,2MNKL2QC3HN>@P,G%
M=E-\!OBY\'?C9XY\8?!^\\)ZCX=\<W$=_JGA_P 4RW%NMG?!</<PM"C;M^2S
M X))]AC2_9]_9K\>_#;X^>//B-XW\86/BR?Q5I5K;R26\;PM!<)(S-%'%MVI
M BE%3+LQP2W- 'GWC#0_V9/$'C+QK;R?#K6/B_XE%[.=:U'3](N]9:TN&<EH
M%N2=D13) CC8;0M>+_#O0_$/QP_X)K^)5TV6^D\2?#CQ1=W_ (:FN6:2]@^P
MNL\: D%O,6.62-1[**^@?A1^S]\=/V>8_%?A'P)J'@?4O"6M:Q=:M:Z]KSW0
MU&Q:?&X/;QILG9=JX_>*#SG%>A?L7_LZZ[^S;\+]>\+^)=6LM?O-0\17NK+>
M688"2*98U4NI5=KG8254%1NP": /'OVDOBC%^TQ\#?@KX$T6X:"Y^,=W:&]>
MU.6M=/A"S7S+E>JE0G(]?2OMG3--M=%TVTT^RA2VL[6%(((8QA8XT 55 ]
M!7Y[?L _!46O[2'Q1U4:JVL>#OAUJ%]X<\)0^6!#:-<W#3W03Y0=R9V<''[Q
M^Q%?HI0!POQN^*5C\%?A+XI\<:D%:UT2QDNO+9MHED Q''G'!9RJ]/XJ\H_8
M-^&.I>"?@A'XE\3(_P#PG'CN[D\4:Y-*I63S;C#1QD$Y4)'M&T]"6]36A^U1
M\ _$?[1%Y\/O#\=]IEM\/K'6X]5\3VEU+*+B_CBYBMT14*LI8DL'9<84C.*]
M^C01J%50H48  Q0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /S1_:PLX-0_:FUFWNMPMY%ME?9($;'V9>C9&#^-?>OP055^$GA)5Z#2[
M<#G/'ECO7PE^U S+^UGJ90QAA]EP99?*7_CV7JP!P/?!K[M^"N?^%4^$SD<Z
M9;GY3D?<'0XZ?A7C9?\ '6_Q,_2>+O\ =,L_Z\Q_([FBF<^I_*CGU/Y5[)^;
M#C7%_%:S\9W_ (2GA\!WVG:=XA,L92?5$9H0@8;\@ \XSCBNRY]3^5!7CO50
MERR4A/4^//"?Q1U/XP?$8>!?'O@>S\5S:+K,D<FHZ6LGV?2Y(L@-(2.22I[]
M.M?3C_#KP[)XTM_%ITN$^(8+8VD=_P [UA/51SC'X5K:?X=TW2+B\N+'3[6S
MGO9?.NI;>%4:>3^^Y ^9O<UH+T[UUU\3[1KV2Y5;O]Y$8V6HFWBGA>*/S_6B
MN(T%VCTHVCTI** %VCTHVCTI** %VCTHVCTI** %VCTHVCTI** #:/2O!OVW
MO^3=_$/_ %VM/_2F.O>:\%_;>_Y-V\0_]=K3_P!*(ZY<5_ GZ,^CX;_Y'.$_
MZ^0_]*1R'[.O@N?X@?LB:7HMM+!!/)?23))<!BBM%>F0'"]\IQ^%>P?!/X4W
M/PITG5+2XOH;U[VY6<O!&4#LL2(TKCO+(REW('+,>O4\=^P__P F\Z%_U\7?
M_I0]>]?PU&"_W>'HA\2?\CG%_P#7R7YL^ ?VG4"_MA>&,#OIY/\ W^>OOF&,
M&-#[5\#_ +3W_)X'A;_N'_\ H]J^^83^[7_"N?!_Q:WJ?2<4_P#(MRO_ *]?
MJA_E+Z4>4OI2[O\ .#1N_P X->J?FXGE+Z4>4OI2[O\ .#1N_P X- ">4OI1
MY2^E+N_S@T;O\X- "","CRUI=W^<&C=_G!H 3RE]*/*7TI=W^<&C=_G!H 3R
ME]*/*7TI=W^<&C=_G!H 3RE]*/*7TI=W^<&C=_G!H 3RE]*/*7TI=W^<&C=_
MG!H 3RU]*\G_ &J%"_ +QE_UY'^8KUG=_G!KR?\ :J/_ !8'QEG_ )\C_,5S
MXC^#/T9[62?\C3#?XX_^E(\Q_P""?"C_ (5+J^>G]LS?^BH:^I=B>E?+G_!/
M?_DDNK_]AF;_ -%0U]29]FK+!_[M3]$>EQ7_ ,CS%?XV)L3THV)Z4N?9J,^S
M5VGR8FQ/2C8GI2Y]FHS[-0 FQ/2C8GI2Y]FHS[-0 FQ/2C8GI2Y]FHS[-0!\
M1_MA_P#!/C7/VLOC;X>\47OCBUTWPEI=K#:'16LW:38)&>8JX<#=)G&[MM7K
MBOM'3=-M-(T^VL;.".VL[:)8(88QA8XU 55 ] ./PJWGV:C/LU ";$]*-B>E
M+GV:C/LU ";$]*-B>E+GV:C/LU ";$]*-B>E+GV:C/LU ";$]*-B>E+GV:C/
MLU ";$]*-B>E+GV:C/LU ";$]*-B>E+GV:C/LU #J*** "D;D8I:* .,^%?P
MC\*?!?P[/H?@_2ETG3I[N6_F3S9)GEN)""\CN[,S,<#J>@ KLZ** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\W?VEA)_PUUJ'
ME%Q)FUVF,J&S]F7&">,_6ONSX,@_\*K\*;MV[^S8,[L9^X.M?FQ_P40FG@^*
M_CZ2V>2.=;* HT3$,#]F3D$5^C7[/K%O@GX'+$D_V+:9)ZY\I:\;+_CK?XF?
MI/%W^Z99_P!>8_D>AT445[)^;!1110 4444 %%%% !1110 4444 %%%% !11
M10 E>"_MO?\ )N_B'_KM:?\ I1'7O1KP7]M[_DW;Q#_UVM/_ $HCKEQ7\"?H
MSZ/AO_D<X3_KY#_TI"?L0_\ )N^A_P#7Q=_^E#U[V>E>"?L0_P#)O.A_]?%W
M_P"E#UVGP7A\<PZ3J9\<B5+QKA&A6:2%\?ND\WRS$3B(R[]@<[@.H' J,'_N
M\/1#XD_Y'6+_ .ODOS9\B_M-3)-^V%X9"L"4;3U;&>#YS'^1%??L./*7'I7Y
MZ_M$6\D'[8VD&2XN)A)<V#J)@ (UWXVIP/ESD\]R:_0B%OW:_2N?!_Q:WJ?2
M<5*V797_ ->OU1/13=]&^O5/S<=13=]&^@!U%-WT;Z '44W?1OH =13=]&^@
M!U%-WT;Z '44W?1OH =13=]&^@!U>2?M5,/^% ^,AG_ER/\ ,5ZSO]J\F_:H
MQ_PH'QD.G^A'^8KGQ'\&?HSVLD_Y&F&_QQ_]*1YE_P $]R/^%2ZQG_H,S?\
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M_(9EZ_\ 7*&OJ7;[C\ZTP?\ NU/T1R<6?\CS%?XF&T>BT;1Z+2;??]:-OO\
MK7:?)B[1Z+1M'HM)M]_UHV^_ZT +M'HM&T>BTFWW_6C;[_K0 NT>BT;1Z+2;
M??\ 6C;[_K0 NT>BT;1Z+2;??]:-OO\ K0 NT>BT;1Z+2;??]:-OO^M "[1Z
M+1M'HM)M]_UHV^_ZT +M'HM&T>BTFWW_ %HV^_ZT +M'HM&T>BTFWW_6C;[_
M *T +M'HM&T>BTFWW_6C;[_K0 NT>BT;1_LTFWW_ %HV^_ZT 2T444 %%%%
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M^1!_K/G7_07/_P "9Y]_PPM\*_\ H'7W_@?+_C2_\,+?"O\ Z!M]_P"!\O\
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M'#?R(/\ 6;.O^@N?_@3/GK_AA7X5_P#0.OO_  /E_P :/^&%?A7_ - V^_\
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MW\(?]_KK_P"(H'_"RO\ GW\(?]_KK_XBCZG7_P"?S%_K-E?_ $*Z?WL^4/\
MAJSXZ_\ 0GK_ ."R;_XJE_X:L^.O_0GK_P""R;_XJOJ['Q+_ .??P?\ ]_;K
M_P"(HV_$K_GW\(?]_;K_ .)H^IU_^?S'_K-E?_0KI_>SY0_X:L^.G_0GK_X+
M9O\ XJC_ (:L^.G_ $)Z_P#@LF_^*KZNV_$K_GW\'_\ ?VZ_^)I=OQ*_Y]_!
M_P#W]NO_ (FCZI7_ .?S)_UERO\ Z%=/[V?*'_#5GQT_Z$]?_!9-_P#%4?\
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M4OJE;_G\P_UERO\ Z%=/[V?"/_#5GQT_Z$]?_!9-_P#%4?\ #5GQT_Z$]?\
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M^!2__$T?\*?G_P"AR\2?^!2__$UZ/G_.*,_YQ0!YQ_PJ"8?\SEXC_P# I?\
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M_@F__P >WCK_ '[/^4M?6_CB[N+#PGJL]K9M?SI;2%;9'"ESM/ )X%>;E_\
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MOSF_;8_Y.(A'_3O;?R%?HTP^4_2OSE_;:_Y.&B_Z][;^0KR<T_W67R_,_0N
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MVS_R<-"?^F%K_(5^C;;>>G3TK\Y?VV?^3AX?^N%L?Y5Y6:?[K+Y?F?H7 ?\
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MSGM+J-9[:>-HI8GZ,K @@_@: ,3P+=PKX,T3]ZO_ !Y0_P 0_N#WK=^V0_\
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M7GT=_O.J%.A#W:%3F4>MK;]D^QV7PX^+7B?QI\=O'?ANXT=K/PGH<4:6MY+
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MZYK>G?;+_0G9[%C(RHA8@G<@.U@2HZCM776-E;:;;);VL*6]O&,)#$@55'H
M!5@%AV-+N/H?SK)U)R2C)Z(++<X#X^8/P2\<_P#8&NO_ $4U<-X#'_&&6B_]
MB@O_ *3FNZ^/F?\ A2/CG_L#77_HIJX;P&?^,,=&_P"Q07_TG-93^%G;@_\
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MJ_*>5<'(/T-?)/\ P3?_ ./7QU_O6?\ *6OL3Q!\VBWV#@^2_P#Z":\S+_\
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M(/\ R;3\/,_] J/_ -":O8-H]6_6H -I_NG\Q1M/]T_F*-H]6_6FL!CJ?UH
M=M/H?S%-8'T/Z&O/V^+<2_&)/ ']C:EYS6)O?[4\L_9@,?=W>O\ 6O0/O=2?
MUJI0E3MS==17N>&-\"/'#>/GU[_A;FN#36UD:B-'V#R1!_S[?>^YSCTXSC/-
M>Y\^A_2N&^+?C;6O /AF+4="\+WGBV\:ZC@:QLSAU1CRYXZ #T[UH6_Q+\.R
M>,(?"4FJ0Q>)Y+479TMF/FB/ .<8]ZZ:GM:T5-K;M;IZ?J)6B=5^!_,4GX'\
MQ2\9ZG]:7:/5OUKD*&_@?S%'X'\Q3MH]6_6C:/5OUH ;Z\'I7YS?MLC_ (R'
MBX_Y=[7^0K]&648/)_6OSG_;8X_:&B_Z][7^0KRLT_W67R_,_0> _P#D>TO\
M,_\ TEGZ*V[ 0I_NCN!VI^X>GZBH[?/DQX_NC^53<XKTX['Y_+=BLP7J0/K7
MA'@CXO\ B+7OVPOB3\.[N6W/AK0M!TZ_LXUA E$TV=Y9^X..!7AWP\^'NG?M
MK?';XSZ]X\U36[KPOX-U^7PEH7A^QU6XL((&@ 6>Y;R)%+.[X(R>G4= +'[*
MOP_O?AA^W-\9?#MUXFU+Q5#:^&=)%G>ZNP>Z2W)/EPNX \S8,C<>2,9YJA'W
M 6"GD@?C2[J^&/BUX;_9I/Q \66GCWQYXH\6^-WGEN)H+#6=2FDT=78E($AL
MF$<2H" %=2>!G->7>$O%'C?XO?\ !.'6/$6F:[JE_P"+/ACXEGO=)U265_M5
MS;V+K*OF]"^()64JV<^6,\T ?IQGU.*6OC/]J+XP/\9?@/\ "KPMX-U*73]:
M^,5[8V]O<6<G[RSLL+-=S @Y_=J O'=J^P-)TN#1-*L].M0PMK2%+>(,Q8[$
M4*H)/7@4 > _M-?M:-\%;/7=,\)^$M1\<^,-*TPZM>6\*&*PTVVPQ$MU<'A<
MA25C7+MC@ <UZG\$O'EU\4/A!X,\7WMM%9W>NZ3;:C-;P$F.-I8U<JN>< GO
M7,?M;QHO[,7Q5<* S>'+W+ <G$+8S4/[*5[;Z9^R;\+KRZF2WM;?PI8S2S2,
M J(MLA9B>P !/X4 4OVK_P!HR7]GOP/9SZ+HR>)O&FL3FWT?1&D*+-L4R3RN
MPY$<<2NQ(] ,C.1L_LL?&:]_:"^ OA/Q]J&G0:5>ZQ#(\UI:N7C1DE>/Y2W.
M#LSSTSWKYS\'Z]IOQRA^*WQVUC5K06,VB:EH'@C3[B=5>WTU(Y!)=;"<K)<2
M ]L[%4'T'H/_  31U"UN/V,OAW;Q7,,D\-M/YL*."Z9NIL;AGC/O0!]24444
M %%%% !1110 4444 %%%% !1110 4444 %%%% '-?$2UDO/ VOPQ7,EG(]A.
M!/$ 67]VW(R,5G?!A2OPK\* OO(TR ;CW^05-\2/$VE:'X7U./4M2M+"2XL[
MA8%N9UC,A$;9"@GDC-0_!@@_"WPL000=-@Y'^X* .TY]?THY]?TIU% #>?7]
M*.?7]*=10 WGU_2CGU_2G44 -Y]?THY]?TIU% #>?7]*.?7]*=10 WGU_2CG
MU_2G44 -Y]?THY]?TIU% #>?7]*.?7]*=10 WGU_2FR9V]:DIDOW?QH X7X.
M_P#(!UG_ +#NH_\ I2]=[7EG@?Q1IO@WP9KFIZM,UO9+XAO86D2)Y2&>[*+D
M*"<;F'.,#O6=K'BVY^)FL>&+SP#<ZC=V^FZO$-3FBE-K;BV8*SATD=?-5XV#
M*RQ2 @_*48AP ?/?_!1[/]K>!O\ KA>_^A0U]K:#G^Q;+D?ZE/\ T$5\0_\
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M0UP/[(BEOV:?AW_V"H__ $)J]$L_!>@Z;XFO?$-OI5K!K=ZBQW%^D8$LBK@
M%NN  /R%?*+E=^?Y'I:FZ6..E?-OQ9^,'Q4\,^ _B7J$'@^.P72+M8-,U 29
M+V91_,NMN>2F%/3^+V->U_$#Q1%X7\+ZA=C4].TR]%O*UI)JDFR$R!"1N'WB
MHQD[<G .*_.KXI?%S7=0T.(:U\3M.\82S7T6J7N@:?'<PVC6Y&!;Q2-& \;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ*XN#;L')7Y,2J5.[&,9Z8-6?B1J<.L?!_7K^V$HM[K2)IH_/B>)]K0DC<C
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M%']FX7^3\6/_ %XS_P#Z"/\ R6/^1\8_\.Y;'_H<KG_P#7_&AO\ @G+8]?\
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ME<_^ :__ !5+_P .Y+'OXRN?_ 1?_BJ],_X;E^%'_05O?_!?-_\ $UQ?Q/\
MVV/ UYI^CGP]J^N?:H=6LIIDLK4Q*]NMQ&9UD+[<J8A)\JGDD<4>RRSNOO\
M^"/^T>.?Y*G_ (+7_P B>>ZU^Q/HFA>._#WA6X\3ZL;O7$G:UO$LX/LZM$C.
MR/F4.&*J<80CIR,UU/\ P[DL?^ARN<_]>B__ !59_P (?VI? <4DVJ>.[V^O
M]:M;M9M/GOK:2Y:W<VXCFD@(W>7&[O/M4G*K(1A0=H]<_P"&YOA1_P!!6^_\
M%\W_ ,33]CEO=??_ ,$/[1XZ_DJ?^"U_\B>:?\.Y+'_H<[G_ , U_P :/^'<
MMC_T.5S_ . :_P"->F?\-S?"G_H*7O\ X+IO_B:/^&YOA3_T%+W_ ,%TW_Q-
M'LLL[K[_ /@A_:''7\E3_P %K_Y$\R_X=QV/_0Y7'_@&O_Q5<S\1/V)_#_PS
MT!-6U+Q9J=S$T\=ND%C8(\K,[8+ %P,*NYR2>%5OI7K'C/\ ;;^&M[X3U>WT
MW6=6AU"6UD2W>SLF282%2%V,XV@Y[DC'J*\DT7]IKP-XP\36:^//MFL>'TTV
M-;BSUBT^UVS7"P6H1EB^<"991>DR*%RLBC+<;3V.6]U]_P#P0_M'CG^2I_X+
M7_R)U/\ P[EL<_\ (YW'_@(O^-'_  [EL/\ H<[C_P  U_QKTQ?VXOA0BA5U
M2\  X TZ;'_H-+_PW+\*>^JWO_@OF_\ B:7L<M[K[Q?VCQU_)4_\%K_Y$\R_
MX=QV/_0Y7'_@(O\ C1_P[EL5_P"9RN!_VYK_ (UZ:?VYOA1_T%;S_P %\W_Q
M->&_&;]L"PU;Q5(WA/7O$0T>2P5)$MA]F F'F;#$<JRL':)F+ @HCKSD*7['
M+7U7W_\ !#^T>.?Y*G_@M?\ R)%X1_8IT3QCK7B#2H?$NK:=>:+<"&6'4+2!
M7F1BX2=$65F$3E'VLZKNVG&<5UUM_P $Z[*WN(I1XQN28V#@?9%['/\ >KKM
M _:^^#NBM)>B[F75KN.-;V\CTV;=.R[B,G;T#.Y Z#>?6MV']N#X5W$R1KJE
MX7=@J_\ $OEZD\?PT>RRSNOO_P""*69<<<KYH5+?X%_\B>\Q1F*-03G: .E+
MY@]3^0I5D$B @\$9%&.^?Y5] ?D)+1110(**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y?XA^*V\%^$-3UA(XYY[6/
M=%#++Y:R.2 %W=N3Z5CQ7WQ&=0W]G>'2#SS<S>G^[3/CM8VNI?"W75N(5N$C
MC650PR RR*01[@BN\L_^/=#_ +(_E0!Q7VSXC_\ 0.\.?^!,W_Q-+]N^(W_0
M.\.?^!4W_P 37=T4 <%]N^(__0-\.?\ @3-_\32B\^(__0.\._\ @3-_\37>
M44 <']L^(_\ T#O#O_@5-_\ $T?;OB/_ - [PY_X%3?_ !-=Y10!P7VSXC?]
M [P[_P"!4W_Q-+]L^(__ $#O#G_@3-_\37>44 <']L^(_P#T#O#G_@3-_P#$
MT?;OB/\ ] [PY_X$S?\ Q-=V!BFO)MH X;[;\1_^@?X<_P# F;_XFD^V?$;_
M *!_AS_P*F_^)KN1,A_B%+YR?WA0!PPO/B/_ - [PY_X$S?_ !-'VSXC_P#0
M/\._^!4W_P 37<^<G]X?G2><OJ* .'^V?$?_ *!WAW_P*F_^)H^V?$;_ *!W
MAS_P)F_^)KN/.7U'YT><OJ/SH X?[9\1_P#H'>'/_ F;_P")IK7GQ&Z'3_#N
M/:YF_P#B:[KSE]1^=-:5"1SWH Y[X<^*)?&G@G1]<GMELY;^V2=K=7\P(Q'(
M#<9_*NFVCTKR_P"$?B+3/#/P1\)WNK7T&GVAM((A-<.%7>[;54$]RQ Q[U!\
M1_&-_JEQ80>"M<N)+[2=4C.JZ9I=O'+-<PG<ODL\D,JQ(6!)?Y<^6RAU.< '
MHVM:@NDZ7=7C+-(D,;2%;=-[G Z*O<UY/\)_#.K^,?ASX>UF^\;^)'O+ZSCG
ME82Q)\S#/W1'QU[5Z?K?B#3M%@SJ%_;V'F%EC:XE6/<0#P,GG\*Y?X!_-\'?
M")'.=/B(.>#QUH G_P"%9WG_ $.WB3_P)B_^-T?\*SO/^AV\2?\ @1%_\;KN
M-S?W:-S?W: .&_X5G>?]#MXD_P# B+_XW1_PK2\_Z';Q)_X$1?\ QNNYW-_=
MHW-_=H X?_A6=Y_T.WB3_P "(O\ XW1_PK.\_P"AV\2?^!$7_P ;KN-S?W:-
MS?W: .%_X5G>?]#MXD_\"8O_ (W3C\,[P#/_  FWB3_P(B_^-UW&YO[M#Y*G
M(Q0!PO\ PK:\_P"AU\2G_MO%_P#&Z7_A6MYW\:>)?_ B+_XW7)>'_ ^F^.O&
MGC>?66O;J2VU(00A;R6-8XQ&I"A58#J3V[UTW_"C?"G_ #[7O_@QN/\ XN@"
M;_A6MYC_ )'7Q+_X$1?_ !NC_A6EY_T.OB7_ ,"(O_C=0_\ "C?"G_/M>?\
M@QN/_BZ/^%&^%/\ GVO/_!C<?_%T 3_\*UO?^AU\2_\ @1%_\;H_X5K>_P#0
MZ^)?_ B+_P"-U!_PHWPI_P ^U[_X,;C_ .+H_P"%&^%/^?:]_P#!C<?_ !=
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M<MKY?$6CP;WU!W!CDU"".1"#U#(S*<^IKZ'S[UXW^U1_R3C3/^QGT+_TYV]
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MUW]KN))=N<B-(T08 ^5410,^_K6QD]C7JGYT-VCT/ZT;1Z']:=\WJ*/F]10
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MR?\ ZU9_B/\ Y%_4?^O:3_T UH9/K^E9WB(_\2#4?^O>3MC^ T >7_L@@_\
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M3$K(A^;)SV[&OJC;]:^7OV]M/UO7/AWH>E:+H&H:U)+JD=Q(]C&7\E8U)&X
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M "2#PI_UX1_R-;_A/P/HG@>UNK?1+$6,5S+YTH\QW+,%5!RS'"JJJJJ/E4
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M\44R,2TOF1ASN],$XXKS/2].U3X]_$3QDUWXDUG1-!\/W?\ 9MC9Z/=M:EY
MN9)9&4Y;G&,\"K'[.NFZAI'Q6^*UEJFH'5;V&[M%:\9 K2J(1L) '7;M!QW!
MI>VE*<$EHV_R9LLLI4<-B'5FG4C"+MKIS2CUV>CL_4]3^+WC&Z^'_P -]?\
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MQ]1^?_UJ-Q]1^?\ ]:O-[>'XF2:I>0S7/A^*PC2,P7(@E)E)!W@KNXQQW[U
MQ^*BV.K2!_#IN(6?[##Y<N+D 94L=WR9/Y8H ].W'/4?G_\ 6I<GV_/_ .M7
MDEQ>_%O[5J$,-OX?E\B.!H9&CE59F=L2*#N_@&?KP*X7XI?%+XT?##PB=>F\
M/>']0@2ZM[>2&W\YY%$L_EE@H/(52K?B: /I3<?4?G_]:C<?4?G_ /6KA([3
MQ_(H;^U-!&1G_CSE].GWZS+;_A:DNGW\LS^'(KN*65;:#RY2)D5B$8MN^4L
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M *[Z9_Z5PU\6_M(:M>_L\? GXR_LSZ]<2S:=8W]CKO@F\NV^>XTV2\B+VX)
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MAMXN\$ZK\,_B'86HOUT;5)4F6[MB<>9#*H ;'?C'7!.#CS?]F>\T^/\ ;_\
MVFK>22W&JR+IC0QL5\YHEA ?;W*@E,X]5]J3]H!H]2_X*1?LW0:01)K-CINL
M7&J"'!>*S:!UC,F!PI;S0,]SQ[@'I;>,_ G_  W3'X4;P1&?B'_PA_\ :8\7
M;QN%IYYC^S;<9ZY.[\*E^*_[6$_A?XD3?#KX>^ ]5^*/CBSMUO-3LM.GBM;;
M386Y3S[B7Y0[C[J ?7%>:-_REJB_[)?_ .WIKSK]G/P]\3]:_:1_:=M_#'CW
M1?"FNIXQ>2[MM2T);ZXFLF,ALG#^8N(Q$<!>>23GF@#ZC^!'[4%M\6_$^M^"
M_$/A;4OA[\1=%C6XO/#>JNDI>W8X6>&5/EECS@$C&"?3!/*_$3]LZZL?B5K'
M@/X7_#76_BSK^@[!K4NF7$5M96#L#B)IWR#+QRN/7G((H\ _LN^.=/\ VD[#
MXO\ C;XAV/B+4;319-%%GINC?84DB9BZEOWK9*LQ[<X%<%_P2]FB7P;\7+:]
M*CQ9#X[U$ZRCD><)2PP7Q[JX^H:@#UJU_:<U37O@WJGBNP^%7C%O$>GWG]FW
MWA![=([^"3 )D4E@KQ!65@X/([=J^?O^":G[1'CCQ)\(_!WAS6? OC/Q+;W5
MY>B;Q[=SI-9 >=*WS/(_F$*<1XQU&!7WC>7,,UI?QQRI))$C+(BL"4)7.".Q
MP0>:^3_^"49 _8G\)+T9+W458=P?M<O!_.@#Z^I:** "BBB@ HHHH HZII-E
MK5E)::A:0WUK(,/#<1AT;Z@\55T+PSI'A>W>#2=-M=-A8[FCM85C!/J=H&:U
M))%C0N[!57DDUXS\=/BQ!8_"W6K_ ,(^(K1]4LYK=2]G-'*T0:95.1SU&1TK
M&I*%-.;Z'HX/#U\94CAJ3TDTNMKON>G/X+T&;61J[:/8MJ@Z7AMT\WIC[V,]
M*F/AG23IL>GG3+0V$;^8EMY"^6K;MVX+C .[G/K4T>H16VDQW=W.D$:Q!Y)9
M&"JHQDDD]JJ:#XNT3Q.LO]DZO9ZD(CA_LLZR;?KM-5[MS!^W:O=M1]="]?:7
M9ZI'&EY:PW212+*BS1APKJ<JPST(/0TFH:39:DUNUY9P71MY!-#YT8?RW P'
M7/0\]1ZUY]:?'CPY-\0M6\,S:AI]O%96T4RW\E[&$E=F8-&!GJNWGGO7=ZUX
MDTOPW9BYU74+;3K<G:);J98U)],DU,9PDFTS2IAL30E&,XM-JZ^:Z'!^*?AU
M?:[\9_#'B3R[>71;'3KJTN8Y#EF,FW;\N,$<<Y-=QH/A71_#,,D6DZ9::;'(
MVYUM85C#'U(459TO6+'7+..\T^[AO;6092:"0.C?0BLZY\<^'K/6%TJ?6["+
M4F("VCW*"4D]!M)SFA1A%N7<NI6Q->,:+3M!6LK[7;U^;-*UTFRL;BYFMK2&
MWEN7\R=XXPIE;&,L0.3CN:R+OX=^&+[4_P"T;G0--GORV\W,EI&TA8=]Q&<U
MS.O?'#0/#_Q&T_PK<WEG&+BVFFGO)+Q$6V="N$8'H3NSSZ5V>H>*M'TG2XM2
MO=4L[73Y0K1W4TZK&X/0AB<'.1BA2IRNNPI4<70Y)--<ZNO-;?H2:QX>TSQ!
M8_8]2L+>_M<@^3<Q+(N1T.".M.T70=-\.V8M-+L;?3[8'(BMHEC7/T IND^(
M--\06/VO2[^WU"VY FMI!(N1VR*\C^#/Q.,ECXTNO%>O11PVGB6]LK:2^E6-
M4C1\)&I.. *3G",EY]2J>'Q%2E.U[1MIKU\CVR2,2*RLNX,,$'I5#3_#^F:3
MI[6-E86UG9'.;>WA5$.>OR@8YKE?BSXGDL?@]XFUS1+Y1+%I<]Q:WENP8 B,
ME64\@]JO?#S7FNOAIH&K:K=KYDFG0SW%S,P49,8+,3TZYJN9<UO(R]A5C0]J
MGIS6MYI7-_2]&L=#L4L].LX+*T0DK!;QB-!DDGY1@<DT[3]*L])A>&RM(;2%
MG:1D@C"!F;EB0!U)YS5/0O%^B>*/-_LC5K/4_*.'^RSK)MSZ[36NQ.TMZ"J5
MK:'//VD9-5+W>]S(T_PCHFDZE=7]GI5G:WMUD3W,,"I)("<D,0,GGUJWI^DV
M6DV*6=E:0V=G&,+!!&$C4'GA1P.M?/W@WXC?%?XD7?BRZT&;PU;VFC:O<:;'
M9WUK/NE$>,$R+)P2".W^%=!IOQ^NM<^"?BKQ5'IJ:?XA\/BXMKO3YF+QQW40
MR1N'WEY'2N:->FU>UM_^">Y5RK&<W*Y*3O%/79R^&_\ GLCV/3=+M-'L8[2P
MM8K.UC^Y! @1%YSPHX'-6Z\9_9S^-MY\5M$N;?78+>R\1V:1S2P6X*I)!*@>
M*102>"#@\GD>XKH?AOX^U'Q=X@\=V5ZD"PZ)JALK8PJ0QC$2-ELDY.6/3'TK
M2G6A-1<=F<F*RW$X>I5IUEK"S?S:LUWO<]%H[UX+\/OVBFNO@O>>,O$Z0)=Q
MWDUK;VEBC!KAPV(HD4DDNQP.OOP*]+^&%YXIU3PG;7WBZ"UL]6NB9OL=FI M
MXSRD;$DY<#J1QGIZTX5H5+<O57)Q66U\'S^V5N67+ZM;V[VZG8T445N>6%%%
M% !1110 4444 %%%<YXX^(7AKX:Z1'JOBO7;#P]ILDZ6RW6HSK#&97^ZFXGJ
M<?I0!T=%-5MR@@Y!Y!KGO"GQ"\,^.KC6(?#VNV.LS:/=M8:BEE,LAM;A?O12
M8^ZP]#0!T=>5_"#]G?P[\%?%WQ \0Z)>ZI=7GC74_P"U;^._EC:.&3YOEBVH
MI"Y=OO%CTY]>P\%?$3PS\2+&\O?"VO6'B"TL[J2QN)M/G698ITQOB8@\,,CC
MW%=)0 5Y9\*OV=_#GPA^('Q$\7Z/?:I<ZEXYOH[_ %&*^EC:&&1 ^!"%C5@O
MSM]YFZ#\>A7XQ>!Y/B(W@)?%FD'QHL?FG01=I]K"[-^?+SG[GS?3GI794 >$
M_M._L:_#S]K*WT-?&B:E;W.CR,]K>Z3.D,^Q\%XF+(X*,5'&,C'!%=5\?O@+
MH'[1GPGU'X?>([O4;'1[YH'>?2Y$CN%,4JR+M+HZ\E!G*G@GIUKTNO+_ !1^
MU!\(?!.O7FB>(/B9X5T;6+-]ES8WVK0130M@':R%L@X(Z^M '2^*_AGX>\<?
M#J\\#Z_8KJGAZ\LA836]P 2T84 -G'## 8,.A (Z5E_ [X/V/P&^&^F>"M+U
MO6==TK3=R6<VNS1S3PPDY6$,D:#8@X4$9 XSC%=%X0\<>'?B!I0U/PSKNG^(
M-.)V_:M,NDGCSC.-RDCH17.?$CX_?#CX0R11>-/&^B>&YY1E(-0O$25AZA,[
ML>^* /0:*YOP-\1/#'Q,T--9\)Z_IWB/2W.T7>F7*S)GT)4G!]CS7'>(?VJ/
M@YX1UR]T;6OBAX3TO5;&5H+JRN]7@CFAD!^9'4MD$'L: /5:*\R\(_M,?";Q
M]KUMH?AKXD>%]>UFYW>18:?JL,TTFT%CM16). ">/2O3: "BBB@ HHHH ***
M2@!:*\,_9G_:0E_:$O\ XF6\N@IH8\'>)KGP\K)=>>;I8B0)3\B["<?=Y^M6
MOVA_V@IO@7K7PKL(M$361XV\6V?AEW>Z,/V19VV^</D;>1_=XSZT >TTUE#=
M1FO%/VE/VB9?V?[KX:PQZ$NM_P#"8>*K/PVQ:Z,'V59R<S#Y&WD8^Z<9]:]L
MH 6D90PP1D5Y9^TM\<K?]G?X.ZWXVEL/[8N[4Q6]CI:R&-KVYED5(XE(5CDE
ML\*> ?2LK]E']HI/VEOA?)XCGT?_ (1O7;#4;C2=7T-I_.:QNH6P4+%5/*E&
MY'\1':@#VBC'&*6O"/VO/VEKC]F'P'HFNV7AE?%=[JVLP:/!8O??8U#RJY#&
M3RW[KC[O?K0![J% R0,$G)-&WOWKY#\=_MG?$WX&6]OKGQ8^ \WAWP2TT4%Q
MXAT+Q+;ZHMHTC[09(A&C@9QST^8 '/%>\?%CXNR?#WX=6_B;0_#.J^.[F^D@
MBT_2M#0-+<M,,HQ8\)'CDN> .: /1J*^+?%W[;'Q6^!]QH^L?&+X&?\ "*^!
M-2N([9]9TC7XM1?3W<\+/&B]1SD@@=@2>*^C/B]XX\;>&? ]GK'PU\"1_$S5
M;B>,#2SK,.F 6[(S&82R@J<$(-O4[\]J /1J*^+_ !U^UY^T3\,_!^K>*?$W
M[+MOI>@Z5;M=7EY)\0M/<1QKR2%5"S'_ &5!)/ %?2?P*^(]W\7OA#X4\:7V
MBMX=N=<L4OCI;S&8P!^5&\JN<K@YVCK0!WM%%% !1110 4444 %%%<YXX^(7
MAKX9Z*-8\6:[8>'M+:9+<7FHSK#%YC'"IN8XR2* .-^-/[/NE?&BZT34G\1>
M)/!_B+11-'8:WX7U VMS''*8S+&P*LCHQBCRK*?NBLCX/_LJ^'?A/XTOO&EU
MK_B/QUXVNK7["?$/BJ]6YN(;;(/D1!$1$3*@\+DDGGM7M2L&4$'(/0USOA7X
MA>&O'-YK-KX?UVQUBXT:Z-CJ,5G.LC6DXZQR ?=8<\&@#QSXK?L6>%_B-\4/
M^%C:3XH\5?#GQG-;BUOM4\'WR6K:A$ % G5HW#$!5 /^RN<X7&I\+?V._A]\
M'?B-9^-O#<>I0ZY%I$^D7$US<B=M0\Z=9I+FYD9?,EG+(!N+XP<;>F/3O!7Q
M$\,?$BSOKOPOKUAX@M;&[>QN9=/G658;A,%XF(/##<./<5TM 'S7XQ_8+^'O
MC'XB>*/'S:GXCTGQOK5U#>6^O:5?I;W.DR1Q>5_HK"/A74D.LF\'VK?^"_[*
MOA#X ^(/$'C:36=<\6>,=4@V:CXH\47@N;HP* =B[5550!5X"YPHYX%>ACXP
M^"&^(A\!#Q7I!\:>7YO]@_:T^U[=F_/EYS]SYNG3GI77LHD4JP!4C!!% 'PM
M\)_&VA_'3_@I7K'C;P+J$?B'PIHW@)-(NM6M58P?:7NO,$:N1@G:>WH?2O=O
MBQ^R'X7^)GCM?'6FZ]XC^'_CGR!:S:_X2OEMIKJ$  1SJR.D@&!U7/ YX%>U
M:?I=EI,)BLK2"SB9MQ2WB"*3ZX KSKQ5^T]\(O ^O7FA^(/B7X6T76+-@EQ8
M7VK0130L0#AD+9!P1UH H?"']G&S^%7B"Z\077C?QGXYUZ>W-H;SQ3JYN$CB
M+*Q6.%%2->57YMN>#SS7)_$C]B/PMXT^(VH>._#WBSQ=\-/%.J*J:I>>#M26
MU74 !@&9&1E9@/XACGGDU[;X/\=>'?B!I(U/PSKVG>(-/)V_:M-NDGCSCIN4
MGGVKGOB/\?/AS\()(H_&OC;1/#4\HS'!J%XB2N/4)G<1^% #/@O\#_#GP+\*
MW.BZ!)J-Z;VY:]O]1UB[>ZN[VX90K2RR-U8A1T ''2O-_AA^Q-X:^#OQ%G\1
M^$_&7C32]%FU"75'\'QZHHT=KB1-K,8A'O*]#M+GE5[ "O9O OQ%\,?$[0UU
MCPEX@T[Q'I;':+O3;E)D!_NDJ3@^QYKD/$7[4_P>\(ZY>Z-K?Q/\)Z3JUC*8
M;JQN]7@CFA<=5=2V01Z&@#U2BO,?"/[37PE\>^(+70_#?Q)\+Z[K-T6$%AI^
MJPS32[06.U%8DX )X["O3J "BBB@ HHHH \1_:TU:YL?A:MC!<-:1ZMJ-MI]
MS,K8*PR/A^?0@$'V)KB?VD?@OX-\*_!U]1T?1[?2[ZRDMDCGLU$;2JTJ*1)C
M[XZ'G/(!KWKXB^ --^)GA.\T#5?,%O< %983MDB=3E74^H(!KRK7?V;_ !%X
MT\-2:1XG^(MWJL<7E_8]EBD4<;*P.^15;,K8!') &XG!.,>7B*,IN?NWNM/+
M<^VRC,*&'A0YJWL_9S;DM?>3Y>RUM9IWZ;&;^T1JE[=Z_P##+PM'I,FOZ=J;
MSW-UI,5PD!O#!&A2,L[!=H+[B">=HJIIO@77_P#A:'A#6]"^%K>!;>TFDAU.
MX@O;(1S6SKRK)$^6(8*1Q7KWQ%^%MMX_TC3(A?7&DZOI4JW&GZI:@>9;R 8S
M@]5(X*G@BJ/A#P'XXTW6K>[\0_$&36[.#[ME;Z9%:K(2",NP))'.<#'(INC)
MU&Y7Z=NGKK]P4\SHPP<84G%2BIII\]Y<S>J2]UZ-+WMK>AYOHOPK\'ZA^T9X
MNL+KPWIDUE%I-I<+;O;(4$C22;WQCJ<#)K)\17=[XP_:$\7VMUX%;Q[:>'X+
M:VL[%[FW2*U$L8D:0I,P#,Q.,@' 45ZEXT^#NL:MX]_X2OPSXNE\,7UQ:K97
MRBS2X6:-6+*0&.%89///6I_&_P '[[5O%B^*O"OB.7PKXA:!;:YF6W6XANHP
M<@/&Q&2.S9XJ9496M%6UOTU6OY>9K3S.@YQG5J*5Z:BN;G]R2Y;WM9ZV:O%O
M?4\U\'Z/XI^',WQ)UZW\(2>#- FTO[7:Z:UU;S1K=QHP9E2)R%!4*3TZ5J_!
M+X*^#/%WPAT;4];T>VUC5=6@^UWFI7"[KEY7.XMYGWE(/H>,5Z9X-\%:[I]I
MJ,?BKQ/)XK>\3RC&UFEO!&G.0J+D\AN22>@KA-+_ &??$GAN%]&T+XC:AI?@
M\R,T>FQVB-<0(QR8X[@G*C)X.,CZ\U4:+A9\MUKH[=7]QG4S"%>-6/ME3G>+
MYH\]FHQM:^LK[/7<Q_&GPU\+:A^TGX5M[G0;&X@OM+O)[I)8%83R*T85WR/F
M8 GD^M;WQ/;P+I_B+P]X=?P6OB_7X+-AI^C6\$;+:VPP-Q$A$:+\@49],#I7
M0?$GX2W_ (NUO0=>T#Q')X:U_28Y8([HVXN4DBD W*R$CN <YK/\3?!/5]2U
M[1O$VC^+9=)\6V>GKIUUJ4EFDT=Y&.26B) 4[MS<'^+Z4W3E'GY8;ORVT_'U
M,H8RC6^KNM7?NP<;>]H[NU[+X7=;:GGOP'NIM+^/GC328_#+>#K.XTR"[;1_
M,C9(Y%;;O41DH-P;G'H*;\ _A5X8\9:E\0=4UW3(=8G7Q+J$$4=Z/-BA7S,D
MHAX4D]3C)P/05Z9X#^"=SX1^(&H>+[[Q+<Z[J-_8+9S_ &B%4RP<,67:<*O
M 0#C&<DFN<T_]G/7?"M]K>H>%?'MSHM_K&H7%Y=;K)9H&61RRKY;-]]<XW@C
M(ZCIC.-&<5'FC>S?;K^!VULQPU:=54:_LW*--7]ZUXK7765O/5LX/1[1/#OP
MI^/?ABSG\W1M(EO%L4!RL"R0%VB7V5B1CUS2>/M6OKKPS\$O"L6DR:]IVJ6@
MN+G28KA(3>>1!&4C+.P7:"VX@GG:*]@TCX"V.B_"O7_",&I3/>:['<&^U>=
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MZ/KUM\)?A3;IKGQ>UR$E.AM]"MSPU[=-T7:,E4/)..#D!@#R3]DWPCIG@?\
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MYX+NI3;^'OBGIR^)=&!)"&_BW"XB'.-Y"ROP.@7VKS'X#_LF^'?VU?%7Q/\
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M<*%3[4"J\*<K@  #ZG\0?LX?";Q9K5WJ^N?"_P &:SJUX_F7%]J'A^TGGF;
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M_:U_:?:!</OV>1&"RKN &X\YP1Q5.MRWOY?B8PRV5:,%!I7YFW=M6CULE?\
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M20J4&W/3+>IKTNB@!*6BB@ HHHH **** "BBB@!,44M% !1110 E!&>M+10
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MJ)HA)CYB)RHC*D_Q$XYKN_&GAV]D^.WPLO+32YQIEC:ZBDTD,),-MNCC"*S
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>\_S'+]T4ZBBNH\0**** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gizttcucplmb000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000024.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M[P_;ZM8"SN_#\-RS:<7$BNLZHV2)  5ZXPQP!DY\#_8P_P"3\?VM/^O^S_\
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M\:OC%J""]T/0 /!7AX.H,:QJ/W[*?5L,WM]H8=,4 ?3_ /PU!\(/^BG>$O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S3_P %(?\ DRGXG_\
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M(.2=H'8#T'I7T[^S_P#''XKV/@!-/T;P9-XRTZSG:&*_>1@T8X/E9[A<\9/
M(':O+PV<PK5'"4&OQ/?QO"]3"T(U85$WUO9+[VS[EHYKYD_X7Q\;/^B/R?\
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MXM?'SXP)\/\ 5UO? ,WA2TE18I=621BT"NP7CT)SM![9SZ5,\PI0BY6?W/\
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ME?#NEJ6.X[;2,9/J<#FO'OCI\,YO"WE^,O"MN;=;/#WMK9@*44<^?& .H_B
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M\YZ^]<E^S_K7@_XV>"8]12UNK;6+0B#4K'^T;D&&7!Y \S[K<D?B.H->G_\
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MX=_Y][S_ ,&-S_\ '* .NHKD?^%6>'?^?>\_\&-S_P#'*/\ A5GAW_GWO/\
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M[S_P8W/_ ,<H_P"%6>'?^?>\_P#!C<__ !R@#KJ*Y'_A5GAW_GWO/_!C<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#\:Y7_A,/%'_ $(5_P#^#&T_^.5V=+0!Q?\ PF'BC_H0K_\ \&-I_P#'*/\
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M+;6Z[(Q+JUM*V.O+-*6/U)S7S$_BK5VGTV?^TK@3:;&T5G*'P\*-C< W7D
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M/^A"O_\ P8VG_P <KM** .+_ .$P\4?]"%?_ /@QM/\ XY1_PF'BC_H0K_\
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M ,&-I_\ '*[2B@#B_P#A,/%'_0A7_P#X,;3_ ..4?\)AXH_Z$*__ /!C:?\
MQRNTHH XO_A,/%'_ $(5_P#^#&T_^.4?\)AXH_Z$*_\ _!C:?_'*[2B@#B_^
M$P\4?]"%?_\ @QM/_CE'_"8>*/\ H0K_ /\ !C:?_'*[2B@#B_\ A,/%'_0A
M7_\ X,;3_P".4?\ "8>*/^A"O_\ P8VG_P <KM** .+_ .$P\4?]"%?_ /@Q
MM/\ XY1_PF'BC_H0K_\ \&-I_P#'*[2B@#B_^$P\4?\ 0A7_ /X,;3_XY1_P
MF'BC_H0K_P#\&-I_\<KM** .+_X3#Q1_T(5__P"#&T_^.4?\)AXH_P"A"O\
M_P &-I_\<KM** .+_P"$P\4?]"%?_P#@QM/_ (Y1_P )AXH_Z$*__P#!C:?_
M !RNTHH XO\ X3#Q1_T(5_\ ^#&T_P#CE'_"8>*/^A"O_P#P8VG_ ,<KM**
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M3[G^$_F#[5Z1X7\=:'XOMQ+I>H13MCYH2=LB?5#S_2MR:".ZC:.6-9488*N
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M@RXMGCM[":QD)R)HKJ5V!]<.S#]*\M76/CU\(X]M_I]M\0=)AZ36^3<%!TZ
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MDM8EACNMI9751M!/Y=5W5XV49Y7JRDL=HNCM97[,PP^)E+^*=E_PI'P=_P!
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M  977_QVNZHH X7_ (4CX._Z!US_ .#*Z_\ CM'_  I'P=_T#KG_ ,&5U_\
M':[JB@#A?^%(^#O^@=<_^#*Z_P#CM'_"D?!W_0.N?_!E=?\ QVNZHH X7_A2
M/@[_ *!US_X,KK_X[1_PI'P=_P! ZY_\&5U_\=KNJ* .%_X4CX._Z!US_P"#
M*Z_^.T?\*1\'?] ZY_\ !E=?_':[JB@#A?\ A2/@[_H'7/\ X,KK_P".T?\
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MU'4DW=^G^1]EA>*,7A:,:$(QM%6Z_P"9^8__  R;\6/^A0F_\"[?_P".4?\
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M $(MS_X,8/\ &N@L[>BN(_X3+Q5_T(MS_P"#&#_&C_A,O%7_ $(MS_X,8/\
M&F!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )
MEXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!
MC!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_
M *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_
MC0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )
MEXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!
MC!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_
M *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_
MC0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )
MEXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!
MC!_C1_PF7BK_ *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_
M *$6Y_\ !C!_C0!V]%<1_P )EXJ_Z$6Y_P#!C!_C1_PF7BK_ *$6Y_\ !C!_
MC0!V]%<1_P )EXJ_Z$6Y_P#!C!_C6QX;UK5M6DG&IZ!+HHC *-)<QS>9G.1\
MIXQQU]:0&_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!%<?ZF0[/,^4_)_>XZ5\^M\?/$L'P=TCQG+\!_$TNM7U_):3>%+5(7
MO;6-2X6=]VT;&"+^+CZU]#UX+^UM\5O%_P /?#OA'0O ?V*V\6^-==A\/6.J
M:DNZWTYI%=VG9#]\JJ':IZG'!Z$ X3_AKOQA_P!&L?$/_OQ:_P#Q=?1?PS\4
MW?C3P-I.MWWAN_\ "%W=QLSZ+J847%KAV4*X4D9( ;CL17S%??LW_M(>$[.[
M\0:1^TM=ZUKD*"?^R]9T* :?<,GS&(@']VK 8R@!YZU[O^S1\8)/CY\#?"7C
MN>P72[K5K4O<VB-N1)D=HY-AZ[2R,1GG!&: /4**** .%^*WPGTWXM:186UW
M?ZEHFHZ7=K?Z9K.CS"&[L;A590\;,K*05=E*LI4AB"*Y>U_9>\(MX"\4>&M:
MN=7\3R^)Y$GU?7-5O"=0N9D"B*42(%6(Q[5V"-55=O ZY]BHH \M^&?P&L?A
M]XDN?$FH>)O$'CCQ-+:#3H]8\2SQ236]H&#^1&L,4:*K,H9FV[F(&2< #U*B
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^</VU/ MUJ?@?3O&FCIC
M6O"=TM\DB#Y_)R"YSZ*55O8*U>Q?"OQU:?$OP#HOB6S($=_;K(\><^7(.)$/
MNK!A^%=#JFFP:QIUW8W<8FMKJ)H98ST96!!'Y&OES]E/4KSX6_$CQE\']6DW
M+9SM?Z3*W_+2(XR/Q0HV!T(>O5C_ +1A'#[5/7Y/?[F>-/\ V7&*?V:FGS6W
MWGU?24 YI:\H]D^??CUHMYX#\6:/\3-&BW-:R+!J42\>9&> 3^&5]OEXXKW#
M0=:M?$6CVFI6;B6UNHEFC8>A (I/$&AVGB31KS3+Z(3V=U$T<B'T(Z^Q_P *
M\1^ .MW7@7Q/K'PUUF1A+:RM/ISOP)(R<D#ZYW8]V]*]3_>L/_>A_P"D_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)?\ 0*_\F)?_ (J@#M**XO\ X4[X2_Z!7_DQ+_\ %4?\*=\)?] K_P F)?\
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M[U_D7#-*D7[.M2<7YK3[]4?0O[/>FQZIH^FZI?\ BW6M3\06XE-S876IM)$
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MQ+_\50!VE%<7_P *=\)?] K_ ,F)?_BJ/^%.^$O^@5_Y,2__ !5 ':45Q?\
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MHH **** "BBB@ HHHH **2EH ***2@!:*** "BBB@ HHHH *2EHH 2EI*6@
MHHHH **** "BBB@ I-HI:* $VBEHHH 2BEHH 2EHHH 3%&.,4M% ";112T4
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M^A0@_P#!LG_QNNOHH Y#_A(O%W_0H0?^#9/_ (W1_P )%XN_Z%"#_P &R?\
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MPD#SQ),_W8V<!F^@H YC_A(O%W_0H0?^#9/_ (W1_P )%XN_Z%"#_P &R?\
MQNNN)Q4%O?6]YN\B>*?8<-Y;AMI]#@T <Q_PD7B[_H4(/_!LG_QNC_A(O%W_
M $*$'_@V3_XW73+?6[W!MUN(FG R8@X+#ZBK- '(?\)%XN_Z%"#_ ,&R?_&Z
M/^$B\7?]"A!_X-D_^-UU]% '(?\ "1>+O^A0@_\ !LG_ ,;H_P"$B\7?]"A!
M_P"#9/\ XW77T4 <A_PD7B[_ *%"#_P;)_\ &Z/^$B\7?]"A!_X-D_\ C==?
M10!R'_"0^+O^A0@_\&R?_&Z\7^/6O:G?216=W\--?N]36W+VVH:)')>Q(22
MLACBP>1G;G//&,U]+45A6HT\1!TZJNF3*,9KED?+OP/BNY+RXV_#77%U&.W&
M^X\0QO90\D!EB$D0!/MDG&>>M>@ZKX &L9:7X;6$+G^*UU98OQ^5 "?K7L-%
M<T<!A(4_9*FN7T,U1IJ/+;0^;=9^ -WJ$;"U\.26K$8 DU6.9/R,8/ZUR?\
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ME=?YF=*OF&'AR\GM%T;=G\]#ZM_X23Q;_P!"C;_^#=/_ (W1_P )%XN_Z%"
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M ,71_P ,#ZK_ -#=9_\ @$W_ ,73O X/8<3?WOO7^9S/_#;_ (^_Y]-'_P#
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MDJKCO7T!X-^'>KZ7^U=\2O&=UI:Q:)JWA_1K&QU#?&3++"]T9TP&W# >+.0
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MO!OA:Z\*V,]O<ZY>ZZTDF\2WL4*,@P!M B1!CCN":Z.F[U_O#\Z-Z_WA^=4
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MNN3QD)7K8&7M8SPLOM;>JV^_8\?'ITI0Q<?L[^CW^[<^@_\ A5/A3_H#Q_\
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M=0L9X[NRNO&%O/!<1,&26-M+LV5U(Z@@@Y]ZV?V<?^2J_M$?]CK#_P"FBPH
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M0>.OBMX1_98\-_'R[^)>H7NIVL.FW$OAJ.SMDTR[MI)XXG24>7YAE=7+&17
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M_P &@_\ B* .R[UR/Q6\ VWQ.^'^M^&KIA&M];LD<I&?*D'*/C_98 _A4?\
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MWQK_ -"M9?\ @T'_ ,11_;OC7_H5K+_P:#_XB@#LZ0C-<;_;OC7_ *%:R_\
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MDL+T I'IB?\ 7:]DC_\ 0H:X98'$QW@SVZ><Y?5^&M'[[?F>\TE>1VGQT>]
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M]!$5Q?Q$^#G@_P"*5J(O$FB6VH2(I2.Z*[9XP>RR#YAZXSBNCZU1KZ8F&O\
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MIJ\$USI']LR6DT5^L0#2(K6\TFR15(8QO@XSC.#CS;XUW7B;]J+X+:_9^&O
MOB?0)=)OM-U6P77O^)7<:J]O<K-+!$HD$D1"IA9&*@LR[3QD6OA#IOA/Q9\2
MO#VI1^!?BK;:SHJ7%Q#J'CFZOWM=,E>$PNB_:;AU>1TD= 8@PQDY QD WM:_
M:T2"^\46OAWX;^+_ !A_PB]]<V6LSZ7#;I%:>21EE::5/-+*2PCCW-@<@9&>
M8^*G[5.N6/BOX)W/@'PQK7BKPIXOFDN7FTU;/_B9PFPN94MH_/E5HY49$E;.
MT81AN)^6N<\$_&37?AU<?&73[;X:>)O%HO/&>J+I=SX?A2YBFN&\M3#."RF
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MOP7_ -"_;?F_^-,#K_M,7_/5/^^A1]IB_P">J?\ ?0KD/^%-^"_^A?MOS?\
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M?\]4_P"^A1]IB_YZI_WT*Y#_ (4WX+_Z%^V_-_\ &C_A3?@O_H7[;\W_ ,:
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M_-_\:/\ A3?@O_H7[;\W_P : .O^T1?\]4_[Z%'VF+_GJG_?0KD/^%-^"_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\3_:V\2:IH?PKM=.
MTC4+C2+OQ+K^D^&FU&SE,4]K%>WD<$LD;]5<1NV&'()!'2O;*X/XU?"R#XQ_
M#^\\./J4VBW9F@O+'5+:-9);*[@E6:"95;ABKHIP>O3WH \<\.^$;'X"?M4>
M$?"_A*6_MO#/B[P]J$M_IEW?SW<?VJS> QW*F9V*NR2NK%2-WRD\@&OI^O(_
M!GP=\01_$Z#Q]XY\2V7B+7;'2Y-(TV'2]-:QMK6*61'FD*M-*S2.8T&=P "X
M Y)/KE %6_DN(K.=[2%;BY5"8HI'V*S=@6P<<]\5R7]O>//^A4TS_P &Y_\
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M//\ H5-,_P#!N?\ XU1_;WCS_H5-,_\ !N?_ (U7;T4 <1_;WCS_ *%33/\
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M]65V1A\+1PL.2E&R.'_MOQW_ -"EI?\ X-S_ /&J/[;\=_\ 0I:7_P"#<_\
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M'WC&L(..P7UK5_99M[>QO?C#;:>JII47CS4/L\<7^K1FCA:<*.@_?-+D>N:
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M^JW"7>I6*:A<QV%_,@4+)<6JR"&5@$7.Y#G:,YP*]548& ,#H!3J* "BBB@
MHHHH *KWEK'>VLUO+N\J9"C['9&P1@X8$$''<'-6** ///!_P)\'^"?$B>(;
M.UO[_7(X7M8-0UG5+K4)K>%RI:.)IY'\M257.W&=HSFO0Z** "BBB@ HHHH
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M$W3PPRJCDJH4DC) P<BO1M)TFRT'2[/3=.M8K+3[.%8+>V@4*D4:@*JJ!T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!WH BN;J&QMY+BXF2W@C&YY)6"JH]23T%<YX=^*G@OQAJ$MAH/B_0=;OHO\
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MZ/K43V82^GMO+,DDX?F)USD1KUST]^0#]-[37M-OYA#;:A:W$I&1'%,K-Q[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5+64>;1[Y(@6D:"0*!U)*G
M%7:* /@#_@C!<6W_  S3XKM4C$5]!XNN?M"DDL<VEKM8C' X88_V2>]??U?G
MMKOPD^+W[$OQ\\8?$7X3^$#\2/AGXQN#>:QX7LIBMY9S;F;?$N"3AG<@JK\-
MM('#5M>)OVPOCY\7-$N?#/PP_9Y\3^%_$5^OD#7O%7[BTT]6P'D^94!< DC+
M<'G:V-I ,7_@GJ\6K_MB?M;:OID#0Z.VO^4& RDDOVN\RX;_ &BKMC_;^E><
M?#SX/>.OBY^W%^TO%X'^*NH_"^6QU.!KJ;3[,7!O%<R!5;+KC:58]_O=J^TO
MV+?V88OV5O@^GAVXO8]5\2:A<MJ.LZA$I"37#@#:N>=J* HSU.3@9P/E/P_X
MF^)_[,?[8/QZ\36WP,\:>/-'\6WT+65YHMHYAV1[VWAPC!@=_0=,4 ?6?[._
MP+^(WPEUC5[OQM\9=4^)]K>0)%;VFH6*VZVKAB2ZD2-DD<8XKWBOF+X,_M:>
M.?BA\0=/\.ZQ^S[XX\#:?<K(TFN:S R6T&U"P#$QCEB .O4BNS_:&^/GB+X)
MS:&N@_"?Q5\3%U%9C,WAJ R"SV%,"3"G!;><?[AH ^:/^"??_)XG[77_ &'H
M/_2B]KWO]M7]EVX_:B^&-AIFCZNN@>+="U&/5M%U*0'9'.H(*L0-P5@1R.A5
M3@XQ7Q9^S?\ $SXK? _XV?&?QS>_LX?$?4[;Q[J,=[;VEOI<JO:A99WVN2F"
M2)@./[OO7WK\3?C1XO\ !?P>T+QMH/PKUKQ7J-VUO)J/A>WF$6H6$,D3,[;-
MK>8Z.$0Q@ _.3_#B@#R#1M;_ &TYO#]IH%UX9^'%AJD:"";Q==:C+,CXX,PM
MD .\CG!PN?X0.*XC_@D;I]^/ OQ>U.^O8]4:[\:7$9U*%-L5W(D:%Y4 _A8R
M C'K6AXN_:B^.GQ\\/7O@OX:? KQ3X(U?5$-I/XG\6$6EMIL3?*\JDJ-S@'@
M#)[@$U]*?LQ_ ?3OV;?@MX>\!Z?,+QK",O=W@39]IN7.Z63';+'@=@ * /5J
M_*CX4_!SQY\7/VTOVG8_ _Q6U'X726&MQM=2:?9BX-Z'DGV!@77&PJWK]\U^
MJU?F?X/\4?%']F#]K/\ : \00_ KQKXZTGQ=JT<ME>:-9R>28XWE8.'",K!A
M*.G3!!H ^O/V=/@?\1/A)J6M7'C?XQZI\4+>]BCCM;?4+%;<6C*S%G4B1LE@
M0.W2O)_^"G7C"_F^%'ACX4:!,P\2_$K7+?1H886(<VXD1I6.#G9N,2MVPY!X
MS7;_  1_:L\;_%;X@6?A[6O@'XV\ Z?-#+(^N:Y"R6T15"P4DQKRQ 4<]Z\L
M\$-_PT9_P4L\4>)%;[9X6^$FE#2+1\[HAJ4^Y9"O4;AF=21R/*7/:@#[)\ ^
M#['X>^"- \,:9&L6GZ/8P6$"*H V1H$' [X6OB7_ (+/_P#)LO@__L=K/_TB
MOJ^^J^*O^"L'PT\6?%+]GGPSIGA#P[J/B74;7Q;:7<MII=NT\JPBUNXR^U03
M@-(@/^\* /LS3_\ CQMO^N2_R%6:KV2M'9P*PPRQJ"/3@58H RO$WB;2O!V@
MW^MZWJ$&E:380M/=7MTX2*&->2S$U\-?"'3=3_;K_:<LOC9JMG>:=\(O KO;
M^#;6XC\LZM=9^>[96&[:#AN@Y2-?X9!7(_M^ZM\7OB1\<M+\$R_";QEXG^"6
MBS6]]>P>&;>1O[?D\L. \J*0J(Y">6>1L9NNPKZ/H7[;'CWPSHUEI&D?LA?$
M73=,L85M[6TMK%DBAC4 *BJ(>   * /JKXP_"#PO\=O .H>#/&-B^H:!?M&T
MT,<SPMN1PZ,'4@@AE'0^U:W@/P3I'PU\&Z+X5\/VIL]$T>TCLK. NSE(D7"@
MLQR3@=2<FO/?VG/'WQ#\"_ /6/$OPS\,_P#"0>-H5MGMM(FMWN"%:5!*?*1E
M9V1&?@'J,\@8KK/A+XA\3^(OA)X7UKQAHZZ/XMN]+AN=3TN%&007+1@O&%8D
MK\V?E))'0DXH ^1_^"R?_)J-A_V,=K_Z*FK[<\,_\B[I7_7I%_Z *_,7]N3X
MJ?%3]JSX10^"M*_9P^(^AW$&JQ7WVRZTR25&6-)%V@+'WWC\J^P_V;_VC/%G
MQ2UH>'->^"OC+X=V]EIPD&K>(+8Q6\S(47RURH^8@D]>BF@#Z*HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!-HHQ2T4 )2T44 )BEHHH *3%+10 4E+10 4E+1
M0!#<QO-;RHCF)V4JL@&2I]?PKR']F3]FO2?V9_".L:/I^K7FOWNL:K-J^H:M
M?JJSW$TF.6QU  [GJ3ZU[)10 4444 %%%% ";12T44 )2T44 %%%% !1110
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MOP!_;,MO%*WFG^/[JPT>[@420ZAN\J&<="I!/##@\'D$\#'/LO\ PT3\-?\
MH=='_P# I:JCC:%:"G&1&)RO&86JZ4Z;;7971Z/17G/_  T3\-?^AVT?_P "
M5H_X:)^&O_0[:/\ ^!*UM]8I?S+[SF^IXG_GW+[F>C45YS_PT3\-?^AVT?\
M\"5H_P"&B?AK_P!#MH__ ($K1]8I?S+[P^IXG_GW+[F>BTGX5YU_PT1\-?\
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M_M-S:PW!7[OFQAL?3(J'_A']+_Z!EG_WX3_"M"B@#-_X1_2_^@;9_P#?A?\
M"O*/VD?@B?BE\.YK'0H+6VU>UE6YMU"",38R&0L.A()P>F0,X'->T=Z:>>:F
M24HN+V9492A)3@[-.Z]4?DOXI^$WC/P5;7=UK?AC5-/M+4@374EJ_DKDA1\^
M-N"Q R#W%?3W[.?ACX-_$'P[INEZGX>MF\1+%@RW$L@^UXR2R_-C=CJO7@]J
M^O=:T>SU_2;S3;^!;FRNHF@FA<95T88(/X&OSB\;_#Z\^ OQ-N/"]U-(-)O'
M^TZ-J397J>%+>H.%/H<'C-:Y9E&6QHU%.+Y][[Z=;+R./B3B?/%.E7IS7)'1
MI:7OW=]^W0^U/^&6?A7V\(6G_?V3_P"*H_X99^%G_0H6F/\ KI+_ /%5YE\%
M_P!J!H98]!\9R$&,^4FI2#YE(Z"4?^S_ $SW-?3]O<1W,*2PR+)$ZAE=3D,#
MT(-9ULOIT;7@FGLTE9^A67\13S*GST:TKK=-NZ?GJ>7?\,K_  K_ .A/M/\
MOY+_ /%4?\,K_"O_ *%"T_[^2_\ Q5>K\45S_5J/\B^Y'K?7\7_S]E][/)_^
M&5_A9_T*%I_W]D_^*KB_BU^QOX2\1>#[B'PCI=OH.O1,);><.Y27 .8WR3A3
MGJ.00#['Z+H-9SP="I%Q<%KY&M+,L91FJD:LKKS9^>O@?]B7QWJGB:UAU^VM
M])T=) ;FX^TJ[,@/(0+GDCUQU_ _62_LK_"SI_PA]I_W\E_^*KU?;BG<_6N?
M#Y;A\,FDK^NIVXW/,=C9*4I\MOY;H\H_X97^%?\ T*%I_P!_)?\ XJC_ (98
M^%?_ $*%I_W\E_\ BJ]7XHXKK^K4?Y%]R/-^OXO_ )^R^]GE'_#+'PK_ .A0
MM/\ OY+_ /%4?\,L?"O_ *%"T_[^2_\ Q5>K\44_JU'^1?<@^OXO_G[+[V>3
M_P##*_PLQ_R*%I_W\E_^*KS'XZ?L9:1KN@03_#_3[;2=8M6)>U:1O+ND/;))
MVL#T[<G/J/J6BL:N"P]6#@X(Z*&:XS#U%4C4;:[MM'P;\'_V*?$UUXNM+GQM
M9P66@VS^9+;^>)'N<=$&P\+ZDG_ZWTU_PRO\+/\ H3[3_O[)_P#%5ZO@4N:S
MP^7X?#QY5&_KJ;XS.L;C:GM)3Y?)72/*?^&5_A7_ -"A:?\ ?R7_ .*H_P"&
M6/A7_P!"A:?]_)?_ (JO5^*.*ZOJU'^1?<C@^OXO_G[+[V>4?\,L?"O_ *%"
MT_[^2_\ Q5'_  RQ\*_^A0M/^_DO_P 57J_%%'U:C_(ON0?7\7_S]E][/*/^
M&6/A8?\ F3[3_OY+_P#%5XM^T!^Q>NHFSU+X<6%O:,B^7<Z6TI4/W#HS$\]B
M#V_7Z_\ PHQ6%; X>M#D<4O0Z<-FV-PM158U&[=&VT?$_P !?V+=1CU]]3^(
M=E;C38498M+$V]IG/&YRAP /0'D^F.?H'_AECX6?]"?:?]_)?_BJ]7(YHXI4
M,!AZ$.2,;^I>+SC&XNK[251KR3:1Y3_PRQ\*_P#H3[3_ +^2_P#Q5'_#+'PK
M_P"A0M/^_DO_ ,57J_%'%='U:C_(ON1Q_7\7_P _9?>SRC_AECX5_P#0H6G_
M '\E_P#BJ/\ AECX5_\ 0H6G_?R7_P"*KU?BCBCZM1_D7W(/K^+_ .?LOO9Y
M1_PRQ\+/^A/M/^_DO_Q5?/7QX_8KU-O$0U+X>V5NVES*HDTPS;&@<#DJ7."I
MZ]<@YZ]OMOBBN>O@,/7AR2C;TT.S"9QC<'5]I&HWY-MH^0_V?_V+X]-CO-1^
M(]A;7LLBA+;2UE+"+U=V4C+'I@9&._/'LO\ PRQ\+/\ H3[3_O[+_P#%5ZO1
MSQ3HX'#T8*"BOF1B<VQN*JNK*HTWV;2/*?\ AE?X5_\ 0H6G_?R7_P"*H_X9
M8^%?_0H6G_?R7_XJO5^*.*W^K4?Y%]R.;Z_B_P#G[+[V>4?\,L?"O_H4+3_O
MY+_\51_PRO\ "O\ Z%"T_P"_DO\ \57J_%'%'U:C_(ON0?7\7_S]E][/)_\
MAEGX6<_\4?:8_P"NDO\ \57S#\7/V*/%%IXPO)_!=G!?Z#<OYD,/GA'M\\E"
M'/(!Z$'I7WK1Q^-<N(R[#XB/+*-O30[\'G6-P4^>,^;RE=H^7O@;^QGHN@^&
MY9O'VGV^L:S=,&%N)&\NU49PH92-Q/<_0>Y]*_X97^%G_0H6G_?R7_XJO5Z*
MUIX*A2@H*".>OFF,Q%1U95&F^S:1Y3_PRO\ "O\ Z%"T_P"_DO\ \51_PRQ\
M*_\ H4+3_OY+_P#%5ZO1Q6OU:C_(ON1A]?Q?_/V7WL\H_P"&6/A7_P!"A:?]
M_)?_ (JC_AE?X5_]"A:?]_)?_BJ]7XHH^K4?Y%]R#Z_B_P#G[+[V>3/^RO\
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MO\+/^A0M/^_DO_Q5>JTHZUUQPM"*24%]QYTLPQDY.3JRN_-GE/\ PRQ\*_\
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MG_WX3_"KL,20QJD:+&BC"JH  'H!4E%4(**** "BBB@ HHHH **** "BBB@
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M_F+^'_\ P63_ /R11]C\=?\ 07\/_P#@LG_^2*\X^K.NHKD?L?CK_H+^'_\
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M "11]C\=?]!?P_\ ^"R?_P"2* .NHKD?L?CK_H+^'_\ P63_ /R11]C\=?\
M07\/_P#@LG_^2* .NHKD?L?CK_H+^'__  63_P#R11]C\=?]!?P__P""R?\
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MLXZV\N_R/B^#JBP.(G[5>[.R3Z7[?,]A_P"%F>$_^ACTS_P*3_&C_A9GA/\
MZ&/3/_ I/\:W/[-L_P#GT@_[]K_A2_V;9_\ /I!_W[7_  KY4_;#"_X69X3_
M .ACTS_P*3_&C_A9GA/_ *&/3/\ P*3_ !K=_LVS_P"?2#_OVO\ A1_9MG_S
MZ0?]^U_PI@87_"S/"?\ T,>F?^!2?XT?\+,\)_\ 0QZ9_P"!2?XUN_V;9_\
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M4GCFL:M6G1@ZE1V2)E)15WL=5_PLOPG_ -#)IG_@4G^-'_"R_"?_ $,>F?\
M@4G^->/?"GXM>(_&OBVTT[5K'PO96K;BZ00S>=(-I("$G;G..O;->^?V?9?\
M^L'_ '[7_"LL/BJ&*A[2C*Z)A.-17BS$_P"%F>$_^ACTS_P*3_&C_A9GA/\
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M?=CM7]<*AJ7^S['_ )]K?_OVM:<T7LQF)_PLSPI_T,>F?^!2?XTG_"RO"?\
MT,>F?^!*?XUN?V?9_P#/K;_]^U_PKR?XG?&:W^&^OIIH\'2:Q&\0E^TVMS:J
M <G*E&;>,8')7'/!ZUG4K4J,>>I*R\Q2DHJ[9WO_  LSPG_T,>F?^!2?XTG_
M  LOPG_T,>F?^!2?XU@_#'QI)\1+6XN[CP>V@V:A3#-/=6MP)B<Y&(G8J5XS
MNQ]X5W7]G67_ #[0?]^UJXSA.*E%Z,:::NC$_P"%F>$_^ACTS_P*3_&C_A9G
MA/\ Z&/3/_ I/\:V_P"S[+_GVM_^_:U&UOIT?WHK5?JJBGS16[&9'_"S/"?_
M $,FF?\ @4G^-'_"S/"?_0R:9_X%)_C5^2?18<[WL4QUW%!5=]8\.1YW7>F+
MCGEXZS=:FMY(GF7<K_\ "S/"G_0QZ9_X%)_C2_\ "S/"9_YF/3/_  *3_&FR
M>)_"<7WM1TA?^VL?^-?.OQA\76VH>)+P>&];UBTRR!IK.]5;88"@B*,)C! .
M6SU)(]:X<3F6$PD.>K/]3*=:%-7DSZ,_X67X3_Z&33/_  *3_&D_X67X3_Z&
M/3/_  *3_&O-?A%XW\+0:)<?VCJUPEXT@+IKEVLY&!_RS8J/E/TZUZ!'XZ\$
MR+D:OHX'^U+&*TI9AA*T5.%16?F.-6$DFF6_^%F>$_\ H9-,_P# I/\ &C_A
M9GA/_H9-,_\  I/\:K_\)KX*_P"@QHO_ '_B_P :<GC+P9(<)JNC,1SQ-%_C
M6WUK#O\ Y>+[T7[2/<E_X67X3_Z&/3/_  *3_&C_ (67X3_Z&/3/_ I/\:3_
M (2KPA_T$]'_ ._L7^- \5>$"<#4]'S_ -=HO\:KZS0_G7WASQ[B_P#"S/"?
M_0QZ9_X%)_C1_P +,\*?]#'IG_@4G^-/_P"$A\*_\_\ I7_?V/\ QKYG^)&O
M&Q\3RPZ!XK\0201S,TS_ &F PMG/R1@0\!21SD]*Y,3F6%PD.>K/]2)UH4U>
M3/I7_A9GA3MXCTS_ ,"D_P :7_A9?A/_ *&/3/\ P*3_ !KC_@GK]AXF\*RV
MR--=:I:$^:VILDLAW9*DLJ+E>".F1C\:P_$7B'XC>%=<\,6-U8^"[Y]:U)+)
M+>S@N!,(@"\L@+-@!(U9B<>@[@5V4*]+$TU5I.Z9<9*:4HGIG_"S/"?_ $,>
MF?\ @2G^-;UI=PZA:Q7-M*L]O*H>.2-@592,@CVQ7B7Q)\2?$;P%8B]CT_P7
M?I=7\5C8V*6]P)YWED"HF=VW<!DGL,$U[-=33Z=H\T\=HUW<00%UM+7:#*RK
MD1IN( )/ R0.1S6Y9?HKS;X6_$+7O%WB3QMI>OZ99Z3+H=W;PQ06LK3,$EMT
ME^=^C,-P'R@#MSC-<GI7QF\6W&@Z-XYN;'1AX$U:\AMX[6'SOM]O#-,(8YW<
MG8WS,I*!!@-UXH ]UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HKQ+Q[^UAX9^&^H:S!K/A;Q\MMI!<W6IVO@
M^_FL51!EI!<+&8S&!D[PV.#S5GQ3^U/X1\-264<.F^)O$-Q/I<6M7$&@Z)/>
M/864HRDUP%'[O(#83ESM;"D T >R45D^%_$VF>,O#FF:]HMVE_I.I6T=W:W4
M>=LL3J&5@#SR".#SZUK4 %%%% !1110 4444 %%%% #:Y3XG?#O3/BEX)U+P
MYJJ?Z/=IA95&6AD'*2+[@X_E75T8JH3E3DIQT:(G"-2+A+5,^2_V>_%$]K<Z
MU\"/B(0VHZ=N33)G^7SX  RA&[D##KWQD?PUZ)X-UJY^&/B"3P7XE;SM'N"?
ML%W*H,>TD\'T!Y&.Q]CFL[]J[X.WOBS1[+QMX6:2W\9^&B+FW>!<O/$I+&/'
M=@<D#O\ ,,?-7'ZU\7K3XV?!?0=;BBC75+:\%OJ<2C#6\PC.0,_P/U'TQU!K
MCS^DO8_VQAM)Q^)?G?R>Z[,^>A)X63H5-X_"^\>WR/1?%_P2^&7Q'T.^TK1K
M;1-.U;EX;K25B26*0 X+!.2OJ#^AP:\)O+_6[JZA\">,V-EX[T5MVA:TS'%Z
M@Y6)I#U)QE')Y. <-G-73=0N-)OX+RUE:&Y@<.C*<8(.1^%>P_%36OAW\:O#
M LM0O9-*UB%2UC?26S[H)/<J#\I(&0?3MC->)DO$T*\G*LU"2[O<\O&X.GC*
M<I44HRZK92_X*Z,[_P"!_P 5%^(_AWR[PB+7[#]S?0$;6W#@.!Z'!^A!%>F?
M2OSX\*^//$OP[\<1ZE<JUQJ%JWE7-W$=\&H0C RS8Y8@#YB<DX)&0<_=GA/Q
M9I_C+0;/5M-F$MK<IN'8J>ZL.Q!R/PK['$1I5$L1AVG"7X/M_D=>0YH\5!X;
M$:58=^J[_P"9NT4W=3JXSZT***0MB@!:*:'#="#]#2TMP 44;A6?J7B#3='C
M+WU_;6B#^*>94'ZFHE.,%>3L)M+<OT'VKS;5OV@/">G,8[>YGU*4'&VUA)&?
M3+8!_"L)OBYXO\3.(_#7@^9$;[MS>;MI'X[5!_X$:\R>:86+Y8RYGVCK^1BZ
M\%HG<]FR/6O)OCUXQUKPCI^D3Z'KD>FS-,PFMVLTG:X3 /#,?W>WUP<[ATJH
MWA#XG^)U"ZGXB@T:!NL=F/G'XJ ?_'JXWXH?"$^%=%MY;./Q!XIUBXD.7M+7
MSD4 #.\ Y7.>"2>E<&+QF-K4)?5:+3MN[)_)&-2I4E%\D2/PM^T%KJ^(;)M;
MNE?2MVV=8H%4X(QNSC/&<X'H:]4N/C]X+A^YJ,L__7.UD'\P*\&\ _#35_$'
MBW3[+5-#U?3M/8F2:XN+&2*,*HSL+,!@MC&?>OJ&T\"^';$YM]#TZ)O[RVJ
M_GBO-RC^V)TFJKM_B3O^9CA_K#C[S^\X:3]H[PXQVP6>HW#>BPC_ .*JO_PT
M ]P<6/A+5;D]LKC^0->KPZ?;6XQ%;11CT5 *G$8'0 ?A7O?5L=+XJZ7I%?JS
MKY*KWE^!X]_PMOQMJ#;;'P%=0D]&N"Y'ZJO\Z5=>^+U]RN@:;9J>C,RY'U!D
M/\J]AVBC%'U"M+^)B)?*R_0/92>\V>0+IOQ>O,[]2TVS!_NA2?\ T$_SKSKX
MN^#?%]C:V>I^(-235HU)C#0C ASSTVCJ>,X["OJ3%8/BSP-H'CJUAMM?TFVU
M>WA?S(X[I-P5L$9 ^AKEQ.2T\32=.525WW;?X$3PRG&UV?)OP^\)W_B[Q+:V
M=A.UDX.\WBY'D@<Y&"#GCC%>W?\ "A=3F_X^_&^IW!/#8##(].9#76:#\%O
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M-SW\GKNG'/UXJ=/V>?""=;>Y?O\ -<-_2O3*3BM%EF"7_+I?<5[&G_*>>Q_
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M^Q_'7_0R:3_X*F_^.T?V/XZ_Z&32?_!4W_QVNSHH XS^Q_'7_0R:3_X*F_\
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M7QU_T,FD_P#@J;_X[2_V/XZ_Z&32?_!4W_QVNSHH XS^Q_'7_0R:3_X*F_\
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MTLT\KV<JI&B*"S,S$ *!DD@"O./BOJ'C3PO\+?A/;::OB33-!(MK?Q3<^&+
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MN0_X6YX,_P"AGTS_ ,"%KIK&]@U*S@NK65+BVF021RQG*LI&00?0T 6:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3:*6B@!.?6N3^)GP
MTT/XM>$Y_#OB&*=[&26*XCEM+A[>>WFBD62*:*1"&1T=58,#P176T4 >0^$/
MV;=&\.^,--\4ZQXC\3>.=<TM)(]+N/$^HBX6P\Q0KM%&B(F]EX,A4MC(R,FO
M7<4M% "4M%% "4M%% "8HVBEHH *3;2T4 )BEHHH 3%&*6B@ I,4M% !1110
M 4444 %%%% 'SG^T]\//"/CCQ?X*MO$?Q;\6_#G4]3D?3-*L/#FK"T74920^
M&4QMEQD#)(ZXKP+Q)\+?@EX/UV]T76_VO?'NEZM8RF"ZL[KQG"DD,@ZJRF'@
MBON_6O!^A^([[3+W5=(L=1O-+E-Q8W%U;I(]K(<?/&S#*MP.1Z5\D?&CXO?"
MRW^)?B'P[X6_9^?XT^-=/?=K4^DZ%;-#;3,,A)[ET/[P]<!6Z'O0!'^SSX<^
M#UA\8- G\+?M,^*/B#KR_:/LWAS4?%,5[!=YMY ^Z)8P6V(6D&#P4![5]JU\
MF_L[?%#X3^)/B=#X>;X,-\'OB9#;R75C9:QH-O:37$6PK*]K/&/GPK,& P<$
M\$9KZRH **** /G'Q-\(/B9HNL?$K3_!$OA>;PWX]F>ZENM;FG6XTF>2V2"=
MEACB*W"L$#@%TP203BJ^A_ _X@_!'Q!JLGPR_P"$:U?3-=TW3K6\/B.ZGMI;
M2ZL[5;5;E1%$XF5XDCRA*'*<,=QQ]*XI: .+^#GPZ3X3?#'P[X26[.H-I=J(
MY;LKM\^8DO))MSQN=F;&>,UVE%% $$UG!<X\Z&.7'3S%!Q4?]DV7_/G;_P#?
MI?\ "K=% %3^R;+_ )\[?_OTO^%']DV7_/G;_P#?I?\ "K=% %3^R;+_ )\[
M?_OTO^%']DV7_/G;_P#?I?\ "K=% %3^R;+_ )\[?_OTO^%']DV7_/G;_P#?
MI?\ "K=% %3^R;+_ )\[?_OTO^%']DV7_/G;_P#?I?\ "K=% %3^R;+_ )\[
M?_OTO^%']DV7_/G;_P#?I?\ "K=% %/^RK+_ )\[?_OTO^%<]XZ^'.B?$#PE
MJ>@:C8P_9KV(QEUB7<C?PNI]5."/I75FC^55&4H24HO5$2A&<7&2NF?*/[+O
MB6Y\"^*M5^#/C&"W.J:6[R:5=.H/VF'[VU<]L?.OL6!QMKZD&E67_/G!_P!^
ME_PKP+]K;X1WGB+1[+QWX73R?&/AEA<QR0\230*=Q3W*GYA_P(?Q5Z)\#/BU
M9?&7X>V&O6^V&[_U-[:@Y,,Z@;E^AR"/9A7J8J*KP6+AU^+R?_!/)P<I8>H\
M'4>VL?-?YH[G^RK+_GSM_P#OTO\ A5/5/#&EZOI]Q976GV\MM.ACDC,8P0>*
MUNU&VO*3:=TSUY14XN,EHSX3^('P;_X17QB?#MQ<KI\LS&XT'6W8HH;J(I".
MBEL#."5."."17M_P'^+T/B2XD\&^,;"#3/&VG?NGCFB5?M8 SN'&-V,$@=<Y
M''3T?XL?#:T^)OA6?3IML5XG[RUN2N3%(.GX'H1Z5\@_$F^34/!<TFK+-IOQ
M(\)SQ01WD#%);BWWA06(ZE,@ALYQ@YY->O42QE+VT?B7Q?Y_YGYM4ISX=Q4I
M4O@>J[-=8^J^R_D?<,<>D2W+VZ)8O.G+0J$+#W(JR-+LO^?.W_[]+_A7Y/:?
MK%_I.J1:G9WDUMJ$3^:ES&Y#ALYW;L]:^V_!_P"VIX+N-#L$UUM0L]46%%NG
M^R;HVD  8KM).,Y(X'TKRG%H]?+.)\/CG)5E[-KN]SZ'_LFR_P"?.W_[]+_A
M1_9-E_SYV_\ WZ7_  KRRQ_:L^&%^ 4\3+%ZK/;31G]4'K6[8_'WX>ZA_J?%
M^E_]M)PG_H6*GE9]+',,)/X:L7\T=K_95E_SYV__ 'Z7_"C^RK(?\N=O_P!^
ME_PK'T_XB>%]6?;9>(]*NV_NPWL;'OZ'V-;T=Q'*NY)$=3T*D$&@ZHU(35XR
M3(?[+LO^?.W_ ._2_P"%']DV7_/G;_\ ?I?\*L;AZBL7Q9XTT3P-IO\ :&NZ
ME;Z99[@@DG?&YCT '<X!X'I0.52$(N4G9(TO[+LO^?.W_P"_2_X4O]DV7_/G
M;_\ ?I?\*P/!OQ,\,?$)9F\/:S;:F8?]8D3?.F>Y4\@>^*ZCI2"G4A5CSTW=
M>16_LFR_Y\[?_OTO^%']DV7_ #YV_P#WZ7_"K=%!H5/[)LO^?.W_ ._2_P"%
M']DV7_/G;_\ ?I?\*MT4 4_[*LC_ ,N=O_WZ7_"D_LJR_P"?.WQ_UR7_  JW
M7)_$+XH>'?A=I4=_XAOQ9Q2L5AC52\DK#LJ@9/\ (9%!E4J0HQ<ZCLEW.B_L
MFR_Y\[?_ +]+_A1_9-E_SYV__?I?\*X3X:_'KP=\59WM=$U!Q?HI=K*ZC,4N
MT=2 >".1T)Q7HW:G:Q-&O2Q$/:4I*2\BK_9-E_SYV_\ WZ7_  H_LFR_Y\[?
M_OTO^%6Z*1N5/[)LO^?.W_[]+_A1_9-E_P ^=O\ ]^E_PJW24 5/[+LO^?.W
M/_;)?\*/[*LO^?2W_P"_2_X5:W5SOB_Q_P"'O -DEUX@U:VTN&0[4,S<N1U"
MJ.3U'04&<ZD:<>:;LD;']E67_/G;_P#?I?\ "E_LJR_Y\[?_ +]+_A6+X/\
MB%X=\?6LMQX?U>VU2.(@2>2WS)G.-RGD9P>H[&NC_'- 0J0J1YH.Z*W]DV7_
M #YV_P#WZ7_"C^R;+_GSM_\ OTO^%6Z*#0J?V39?\^=O_P!^E_PH_LFR_P"?
M.W_[]+_A5NB@"G_9=C_SYV__ 'Z7_"E_LFR_Y\[?_OTO^%6CBN,\7_%[P?X!
MO([77M>M-/NI!N6!V+/CUVC) XZF@RJ5:=&/-4DDO,ZC^RK+_GSM_P#OTO\
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M &+XZ_Z&;3/_  5G_P".4?V+XZ_Z&;3/_!6?_CE ':45Q?\ 8OCK_H9M,_\
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M\<_]#-IG_@K/_P <KRK]HKP;XVUCP3;[[I-?C@O%E>WT^R\MD41R9=OG)('
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MZC_^1Z]B_L7QS_T,VF?^"L__ !RC^Q?'/_0S:9_X*S_\<I<QZW]DQ_Y_5/\
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MM2,8P& ZY;:/S/:OIH?"/XXKP/BA;D#@$PG/X_)UH^!D=Q/:-'X/LV\.V5S
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M/UYK]$O[&\<_]#-IG_@K/_QRO+?B+^RY>?%+7O[6U[Q,DMSL$:"&U9$50.@
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M%17EGQH^+&J^ ]0\(>'/#&CV^N>+_%=]):6%O>S-#;0QQ1-+/<3.JLVQ$4<
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ML<U[C"S-&C.OEL0,J2./;B@"6BBB@ HHHH **** "BBB@ KP*U_9QOKCPO\
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MR*O_  T-\/E8@^)("0>T<A_]EJ.3]HOX>0H6;Q)$0/[L$K'\@O-:B?!?P,H
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MR"X<Q>9C=LW -MSC(!ZT ?"/[/OBS6IOVT/"?@#Q7Y[^+O 'A#5]#N[R8?\
M'_;BYM'M+M3W$D!3/.=RO7-?#6QU+X8_$CXK?'2TMVUO1_#/Q(US3=?TIHS*
M]OILT%BTE]:C^&:,A2^!\\08=A7Z'GPGHK>)D\1G1[ ^(5M38C5OLL?VL6Y8
M.81+C=Y98!MN<9 .,T:7X6T;0X=0BT[2+&PBU&XDN[U+6V2);F9P \L@ &]V
M  +').!F@#S^:;XD^+/$6GZ_X.\8>#9?A[>BWN((IM'N+BZFMV52Y6X6Z5,M
M\Q4^7QD @XY\F_;B\:^'K2Z^#-A/KVF0WUE\3-&N;JVDO(UE@B$=P2[J3E5
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MY-+^+_\ V*VH?^B&KV>L_6M%T_Q)I-YI6KV%MJFEWD307-E>0K-#/&PPR.C
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MT?"7_0QZ=_W_ %H_X6CX2_Z&/3O^_P"M=']CM_\ GA'_ -\"C[';_P#/"/\
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M#G/^%H^$O^ACT[_O^M'_  M'PE_T,>G?]_UKH_L=O_SPC_[X%'V.W_YX1_\
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MQ\3_  BO3Q%IP_[;K716=W#J%K#<V\J36\R"2.2,Y5E(R"/PIWV.W_YX1_\
M? J15"+A0 !P .* %VBD50O3BG44 %%%% !1110 4444 %%%(: "D_6OGOXS
M?M8'X1^.)O#P\+_VKY<,<WVG[?Y.=P)QM\INGUKAO^&_F_Z$4?\ @V_^T5:B
MV?/5L_R[#U)4JM6TEOH_\CZ^YHKY!_X;^;_H11_X-O\ [12?\-_-_P!"*/\
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MQ_?BCN$9E^H!R*T^M?BS9WDVGW<5U;OY<\3B1&QGY@002"/4=Z_4'X6?M1^
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M?^?73O\ P,'^%?H$:6K4FCY'$\,X'%5I5ZE[RUW_ . ?GY_PQC\2?^?73_\
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ME1Q)7W91M% 'DVB_!G0=>\6V/Q%BU?QS:7EVR:BNE7NOZA!:QEE!$<E@\@1
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M;X9.#\]5]ZU_ .?'4?BBIKRT?W/0]X_L/Q?_ -#79_\ @H'_ ,=I?[#\7_\
M0UV?_@H'_P =KY]C\=?M&_"M?+U_PO9^/["+K>::/WS#UP@!Z?\ 3/\ QJ2X
M_P""@'A6U\/W<D_A[5K7Q';GR_[(N%"J7S@@R]@.<Y4'CI1_9M>3_=6GZ.X?
MVIAXI^VO#U5O^'/??["\7_\ 0U6?_@I'_P =H_L/QA_T-=G_ ."D?_':\$^#
M'[<VG?$3QC:>'M=T0:#-?R"&TNH[GS8VD)PJ-E1@L> ><DBOJ<,.N>*Y<1A:
MV$GR5HV9U8;&4,9#GHRNCE/[!\8?]#79_P#@I'_QVC^P?&'_ $-=G_X*1_\
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M:C_A<O@C_H9;#_OY_P#6H [.BN,_X7+X(_Z&6P_[^?\ UJ/^%R^"/^AEL/\
MOY_]:@#LZ*XS_A<O@C_H9;#_ +^?_6H_X7+X(_Z&6P_[^?\ UJ .SHKC/^%R
M^"/^AEL/^_G_ -:C_A<O@C_H9;#_ +^?_6H [.BN,_X7+X(_Z&6P_P"_G_UJ
M/^%R^"/^AEL/^_G_ -:@#LZ*XS_A<O@C_H9;#_OY_P#6H_X7+X(_Z&6P_P"_
MG_UJ .SHKC/^%R^"/^AEL/\ OY_]:C_A<O@C_H9;#_OY_P#6H [':*^5?VXO
M@?K7Q#TO1/$'ANP;4+[3/,ANK2!,S21/M(91_%M*GCKAN.E>\?\ "Y/!/_0R
MV'_?S_ZU(?C)X)_Z&6P_[^?_ %JZ\+B:F#K1K4]T<>,PM/&471J;,_.GX._L
MQ^,OB-XPLK2]T;4]!T>.0->:A=6SP&- <D)O'+GM@'&<]J^I/^&0/%V@J?\
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MS2T_,^W,45\31_M9?&'25/\ :/ACPS?A?^?2Y&[_ ,=G;^57+3]N_P 3V_\
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M]_PMKQI_T,^I_P#@4W^-'_"VO&G_ $,^I_\ @4W^-?47_#)/@C^]J7_@2/\
MXFC_ (9)\$?WM2_\"1_\371_:N7?\^_P1YO^K&?_ //[_P F9\N_\+:\:?\
M0SZG_P"!3?XUL^"_BEXNO/&&AV\_B/4I8);V%'C:X8AE+@$$>A%?1/\ PR5X
M']=2_P# D?\ Q-6-+_9;\&Z/J=I?0'4//MI5FCW7 (W*<C(V^HJ)YIE\H-*G
MKZ(WH<-9["K&4ZVB?\S/8E^Z/I2T*,+BEKXH_95L?,?[0-G;_$']J+X*?#[7
MH8[[PE+;:MX@NM,G&Z&\N;985MQ(O1E0RN^T@C.T]J]SNOACX2O;Y[V7PWI9
MO'LI-.:X6T19#;2##PE@.48 94\5R/QR^"=Q\49O#.NZ#KS>$_''A:Z>ZT?6
MEMA<*HD79/;RQDC?#*H 9<@_*I!!%/\ A[X8^+*>)(M3\?>-= O;&""2%-&\
M,:+):032,5VS2R332R%E"L J%5^<D@X% SYC\ ^#O$^M?$?2_P!FS6XI=1\%
M?#O5!XCN=6G*E;[2<[](L7&26(E:16! XLE'()RWXT>%]:F_:@^*?COPE9F_
M\8_#[2/#NN:?:1@A[ZWQJ"WEGD#)$L0X']]$X]?JGPW\*9M!^.OC7X@MJ*30
M^(=)TW34L!$0T)M6N&+E\\AO/'&!C;[T[PS\*9?#_P </'/CYM02:+Q)IFEZ
M>EB(B&@^R&X)<MGYMWV@<8&-OO0!Y+\)_&VD_$K]K_4O%6AW NM(U?X7Z->6
MLH[H^H7Q /N.A]"#7A/[,HC^+%UX,^&OBZ672/!FG7VO:_8Z7(0(O%=TFN7V
M48]XK8[7,)(+,0Q!50:^D?@;^RC_ ,*0^-?CCQA9>(GOO#^MVJ6FF:')!C^R
MHS<S7,D2.#S'YL\I48&-Y'-55_9#"? ?2_!L>OK;>+]!U>^UW0?%5O;D/I]W
M/?3W2L$W?,NV<Q.I.'&?; !Z;_POGP-'X['@O^V&7Q%Y_P!E%E]CG \S&=H?
MR]G3ONQ7QCX:NK_X3?$[XH?&NP19-+T7XF:AX?\ %<04@MHTUO8NMP<#DV\[
M^9D@_)))VZ?H)I*WR:79KJ4D$NHB)!<R6J%(FDV_,44DD*3G ).!WKS/X<_
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M=24K<>"M$(/]RQC3_P!! KX[_:A_9*U?0O%G]L^ ] DO/#]XBAK'3TW-:2*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !'>^*M0N+F\\2+J>NW5^MSI*6\BM-<QRR,B?OS"L91%^<G' ;'U50 4444
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M6T]S-#9:W<Z;:[1M<S3&"1&8H(SC<V &;CFO/_V>_#_CCQE^RWHECK'BK7M
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M* "BBB@ KF/'$'C">SM_^$/O=%M+I7/G?VU:33HZ8_A\N1"I!YYSGVZUT]%
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M_P ;:[H5Q'X)>:;3H= TR2V>XDD@,!,C22OM3:Q/EH.H4DX&*]THHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,^YP* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gizttcucplmb000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000004.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^,-%'U"/\P?ZRU?^?:/V>_X:&^%__11/"O\ X.;?_P"+H_X:&^%__11/"O\
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M;J^E/\5Q,S_@,G@>PJA17;&$8[(^<J5ZM36<KA1115F 4444 %%%% !1110
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MFND_:/\ AKK(^+7P AT'1-4U32M!OK6*XN[6TDFCMXX[BW&Z5U4A!M4G+$<
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M?^DUS71A_P"-$\O-/]SJ>A^:]%%%?4'Y %%%% !1110 4444 %%%% !1110
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M:^N*^1_^"EW_ "0_0?\ L8X/_2:YKHP_\:)Y>:?[G4]#\UZ***^H/R ****
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M'XC/XF%%%%,@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHQDE!=>MNQ\9_!__ (32V_:4^+MKH6M^&M%\1R7TCR#Q';R222PB5R/*PPP
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M !1110 4444 %%%% !1110 4444 %?(__!2[_DA^@_\ 8QP?^DUS7UQ7R/\
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M)M+5E8 AA_HX(QZ$>M>L?MD?'J'X7^(]=\ :!X4T>,:QI2_;=1, $P:12@*
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MT5OQ(I94IQCS3M*5[*W;S/SVI:62,PRO&>2K%3CID'%)7<>!LPHHHH$%%%%
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M3^-EY^G3) !KPL91C!\T>I^B9%CJV(C[*HKI=?T9Z]1117F'UP4444 ?#/\
MP5 _Y!?P^_Z[7O\ Z##7P+7WU_P5 _Y!?P^_Z[7O_H,-? M?1X/^"C\KSS_?
MI_+\D%%%%=IX 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !11105'='VE1117F'VA]P_%>UDU#X7^+[:)=TLVD7<:+ZL87
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MY:R@)$@T&SD!D9?[LL@^Z#Z)SS]X'IWTL4O9\U0^;QF3S^M*CAHWC;=GR?\
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M<\PK5*/LI6[7MK;U.I^%?BJT\#?$KPUXAOHII;+3+^&ZFCME#2%48$A02!G
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBA5+D*
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M'B#XC?"'XKZ+'YFE:Y=:?!<2J.0QD22!FYQ\R%A[;!ZBM3]KC]H[Q?\  _\
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M?"S\,;S_ (_)_P#KHW\ZAJ6\_P"/R?\ ZZ-_,U%7URV/Q&?Q,****9 4444
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MLGP?_P!#=KG_ 'Q#_P#$T?7:(?V#C>R^\_.NBOT4_P"'9/@__H;M<_[XA_\
MB:/^'9/@_P#Z&[7/^^(?_B:/KM$/[!QO9?>?G717Z*?\.R?!_P#T-VN?]\0_
M_$T?\.R?!_\ T-VN?]\0_P#Q-'UVB']@XWLOO/SKHK]%/^'9/@__ *&[7/\
MOB'_ .)H_P"'9/@__H;M<_[XA_\ B:/KM$/[!QO9?>?G717Z*?\ #LGP?_T-
MVN?]\0__ !-'_#LGP?\ ]#=KG_?$/_Q-'UVB']@XWLOO/SKHK]%/^'9/@_\
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M_B4_#W_KO??^@PU\"U]'@_X*/RO//]^G\OR0M%%%=IX 4444 %%%% !1110
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M4N9<?;5 P(W8_P#+7C@D_-TZ]?M#.:\&I3E3ERR/TO"XJGBZ:J4V.HHHK([
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO6O!O$W[6&CV6Z/1-,N-3DZ"6=O)C^O<G\0*\QUK]ICQKJF\6]Q;:6C< 6T
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M?^1L_I6+PU5?9/0CFF#EM4/L'\:7K[U\<S?\%//ATJMY7AOQ/(V>-T-NH/\
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MRCQ-_P!"=I/_ ($2U\=44?V3@_Y/S#ZI1_E/L7_AY1XF_P"A.TG_ ,"):/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\\8?D3\0.OXFL*BBNE145:*+M;1'V+1117SQY1^@=%%%? 'A!1110 4444
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M HHHH **** "BBB@ HHHH **** $KY2_X*/?\D5T+_L88?\ TFN:^K:^4O\
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M\"\<G);MZ6#P%7&2]Q67<Z:.'G6>FQ]5?&[]N#P?\,?/TW0BOBOQ I*-%:R
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M(]9U;:'31U.;6W/7]Y_ST8=,?=Z_>X-?7EI:Q6-O';V\2001*$CBC4*JJ!@
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M:E1YG)7/7FZ-&,;QO<^"?^'A_P 3_P#GR\._^ <O_P >H_X>'_$__GR\._\
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M8@'@KZX"$XR.E><_ /\ 9=_X6!XU\6VWBV]DTG0?"4CQZI+;L [2*S HI((
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MG83[-6)KW[,7@'4/B-KWCSQ/\0]'D\"ZA+/?)#:W:K<-))EMH8$Y"DD_+DG
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M? /P18_!^_\ BC\4+C4'T:*=H+;2]/.UY2'\O)(.2S/D  J!C)/INZO^S_\
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M#Z***^?/."BBB@ HHHH J7]A%J5E<6=PGF6]Q&T4B9(RI!!''L:SO"?@W1/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBFY]: %KZ _9D_92U7XX:@FJZGYNE^#H'_ 'EV!A[L
M@D&.+(]1@L1@=LGIU7[*O['-W\2I+;Q3XQAEL?"ZL'M[(Y26_P =S_=B]3U/
M..QK]$],TVUT?3[:QLK>.TL[:-8H8(5"I&BC"JH'0  5\IF>;*E>CAWKW['D
MXG%\ON4]RAX3\):3X'T&TT;0["'3=,M5VQ6\"@ #N3ZDGDD\DDD\UM445\.V
MY.[W/#;OJQ:***!!1110!\2_\%,/^07X!_Z[WG_H,-?"-?=W_!3#_D%^ ?\
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MU9_:TLYYOVLO@\41F5I++;COMO=S?D"*\[ZQ6J*%)S:2YM>KML8<\Y)1OW_
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M  4>_P"2*Z%_V,,/_I-<UZ&7_P"]T_4Z</\ Q8GYRT445^IGU04444 %%%%
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M\R;0KV2!0<Y$4G[Q<_BSCZ "OJ&OAL51]A6E3[,\*K#V<W$6BBBN8R"BBB@
MHHHH *2EI* /RTUS_D]BX_['+_VY%?J2OW17Y;:Y_P GL7'_ &.7_MR*_4E?
MNBOH,V^"A_A/1Q>T/0?1117SYYP4444 %%%% !1110 E?*7_  4>_P"2*Z%_
MV,,/_I-<U]6U\I?\%'O^2*Z%_P!C##_Z37->AE_^]T_4Z</_ !8GYRT445^I
MGU04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1170>!? >N?$CQ+9Z#X>L9+[4+EL!5'RHO
M=W;^%0.YJ92C!.4G9(EM13;=DC-T'0=1\3ZQ::5I-G+J&HW3B.&V@4L[L>P'
M^/H?2OTE_9=_9%T[X.VT&O>(%AU/QE(O#CYH;$$8*Q\<MR07]\# Z]+^SA^S
M'HGP'T43OY>I>*KF/;>:GM.%!P3'$#T0$#W.,GL![>:^#S+-I8B]*CI'\_\
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M7_S[_'_@!_:#_E/Q+_L'4_\ H'W7_?E_\*/[!U/_ *!]U_WY?_"OVT^R0_\
M/&/_ +Y%'V2'_GC'_P!\BC_6%_\ /O\ '_@!_:#_ )3\2_[!U/\ Z!]U_P!^
M7_PH_L'4_P#H'W7_ 'Y?_"OVT^R0_P#/&/\ [Y%'V2'_ )XQ_P#?(H_UA?\
MS[_'_@!_:#_E/Q+_ +!U/_H'W7_?E_\ "C^P=3_Z!]U_WY?_  K]M/LD/_/&
M/_OD4?9(?^>,?_?(H_UA?_/O\?\ @!_:#_E/Q+_L'4_^@?=?]^7_ ,*/[!U/
M_H'W7_?E_P#"OVT^R0_\\8_^^11]DA_YXQ_]\BC_ %A?_/O\?^ ']H/^4_$O
M^P=3_P"@?=?]^7_PH_L'4_\ H'W7_?E_\*_;3[)#_P \8_\ OD4?9(?^>,?_
M 'R*/]87_P ^_P ?^ ']H/\ E/Q+_L'4_P#H'W7_ 'Y?_"C^P=3_ .@?=?\
M?E_\*_;3[)#_ ,\8_P#OD4?9(?\ GC'_ -\BC_6%_P#/O\?^ ']H/^4_$O\
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MVT^R0_\ /&/_ +Y%'V2'_GC'_P!\BC_6%_\ /O\ '_@!_:#_ )3\2_[!U/\
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M$C8N77(. SL<'@**^C/&'[*7PL\>^)+[7]=\+_;M7OF#W%Q]ON8][!0H.U)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKDEGN*>R2,7CZKV1\'^'?^":FH2>6^N^-K> =7AT^Q:3/T=W7'_?)KT_P_\
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MZ)_WT*+,"2BH_M$?_/1/^^A1]HC_ .>B?]]"BS DHJ/[1'_ST3_OH4?:(_\
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M !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7O_\ '*/[(Q/D'*S]7**_*/\
MX>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7O_\ '*/[(Q/D'*S]7**_
M*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7O_\ '*/[(Q/D'*S]
M7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7O_\ '*/[(Q/D
M'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7O_\ '*/[
M(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7O_\
M'*/[(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7AW_P7
MO_\ '*/[(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\ ^>7A
MW_P7O_\ '*/[(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_Q?\
M^>7AW_P7O_\ '*/[(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/^'E_
MQ?\ ^>7AW_P7O_\ '*/[(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\ _'*/
M^'E_Q?\ ^>7AW_P7O_\ '*/[(Q/D'*S]7**_*/\ X>7_ !?_ .>7AW_P7O\
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MET]&AIV/C"Z\9?&+]I;XA>&H=$T#7_A=X4TRX\V\U"9GBEF4D;OO*H?Y00$
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MO0;8RH)_X$P_2OU5K\/?AKHWQ9\^?5_ .F>+Y9$!MI;[P_:7+[0<,8V>)?\
M=.">P->@>=^U1_S[_%;_ ,!=0_\ B:Z,RP_UJMS>T2LNIEB)^VG<_83-&:_'
MO[1^U1_S[_%;_P !=0_^)H^T?M4?\^_Q6_\  74/_B:\K^S?^GL3EY3]A,T9
MK\>_M'[5'_/O\5O_  %U#_XFC[1^U1_S[_%;_P !=0_^)H_LW_I[$.4_83-&
M:_'O[1^U1_S[_%;_ ,!=0_\ B:/M'[5'_/O\5O\ P%U#_P")H_LW_I[$.4_8
M3-&:_'O[1^U1_P ^_P 5O_ 74/\ XFC[1^U/_P ^_P 5O_ 74/\ XFC^S?\
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MQZ_]NA7Z]U[69;4?\)<A:***\4@**** "BBB@ HHHH *^.?^"I'_ "0'P_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *GLKVXTV\@N[2>2UNH'66*:)BKHRD$,I'0@@=/2
MH**-]&!^I_[%/[9D7QBL[?P=XNF6#QM;1?N;D@*FIQJN2P Z2@ EE P1R.X'
MUWV]:_G\T_4;K1]0MKZQN)+2\MI%EAGA8J\;J0593V(('2OU0_8Q_;,M?C5I
M\'A/Q5-':>.;:/$<F J:FBKDNOI( "648'<<9"_'YCE_LVZM):?D9RCV/K2B
MBBOGS,**** "BBB@ HHHH ^!?^"KG_(%^&__ %\7_P#Z#!7YW5^B/_!5S_D"
M_#?_ *^+_P#]!@K\[J^ZRO\ W6/S_,VCL"L5;(."#D$?SK>TOQYXBT;'V36+
ME .BNV]?R8$?I6#17J.*>C11Z;I_Q^UZWP+JVL[P#^+:4;\<''Z5T5A^T1:L
M<7VCS1#^];RJ_P"A _G7B%%9.A3?05CZ0L_CEX6NL;YKFU)_AF@/ZE2?YUKV
M_P 4?"MS]W6;=#_TTRO\Q7RQ1BLGA8] L?7=KXMT2^;;;ZQ8S'^ZERA/Y9K2
MBF29=R.KCU4@C\Z^,=HIR,T;;D8J?520:AX1=&%C[/I,U\=QZQ?Q?<OKE/\
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M%?8.17Q%>A/#S<)HY6N5V%HHHK$D**** "BBB@ HHHH **** "BBB@ HHHH
M**** $I&8*"2< <FAF"J23@#DU\$_MF?MF+=1WO@/P#?;XV!BU/6[9P0P((:
M&)A_X\X]P.YKJPN&GBJBA!&M.FZDK(Y/]N3]J9/B#J$O@+PO=++X;LI0;^\B
M;*WLRD$(I_YYHPSGNP!'"@GY&MK:6\N(H+>-IIY6$<<: EF8G 4#UY'3UJ$-
MMK[V_84_96>S-I\2?%MD4E(WZ-I]PG*@\BY8'H3_  \?[7H:^YE*CE>&LO\
MAV>O>.'AH>W_ +'_ .STGP-^'RS:E%&?%6KA9[^11DPKC*0 _P"R#SC@L3U
M%>^T@XI>U? UJLJTW4GNSQ92<Y<S%HHHK(D**** "BBB@ HHHH *2EI* /R$
M\0?\G^W7_8]?^W0K]>Z_(/Q#_P G_77_ &/0_P#2H5^OF:]K,MJ/^$N0M%)F
MC->*0+129HS0 M%)FC- $4\T=O&\DKK'&BEF=S@*!R23Z4L4RW$:O&RO&PRK
M*<@CL0?2L3X@'_B@_$?/_,-N?_135^1WP!_;,\?? F:VLHKL^(/"\?R-HNH.
M2J+G_ED_)C(_[YY/R]Z[\/@YXJ,G#H-*Y^R'6OCO_@J1_P D!\/_ /8SV_\
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MIDTFW\?>)_#.N7NAZ/#JAC19KB Y,K&0[59V9/F)XPW-=!\5?AMK7QE_9O\
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MSXYLVCT-#YFGZ5,I5KLC!65QVC!Z#^+O\O7]$TC$:A5 4 8 %"HJJ H  &
M*?\ C7Q.*Q53%3<YL\NI4=1W8M%%%<AD%%%% !1110 4444 %%%% !2&EHH
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MNSXS^'45/^$L_M-!CY=1M8ICQV+;=W/UKRJF2U%_#DFB?9/H?K_2U^8.D_\
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M]XY\,^+=9U.WGUGPX_F:<Z6B(D;;@V2@&"20.H[5\V\MJ-I^OZV_,SY3[?\
MA3'I;_\ !13XG-=B+^T4TQ39;\;@2D DV^^T]NQ->-_LT7GQ?D_;8N!KSZJ9
MWNKM-?67S!:>2JR;0 3MV!]OEXXY&.,U\Q:S\:O%^M?%$_$-]5:T\6&99A?6
M:+#AE0(,*.,%1@C'()S7K6M?\%!_C'K7A]]+_M:PLGDC\M]0L[%8[EAC!.[.
M%/NJBM'@JL59).\4O0=F?7O@%=-M]<_:I/@4PIXI^TNT7V4#>)OLCD%=O/\
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MIZ>IK-JL'A7AN9MWO]PTK!1117HC"BBB@ HHHH **** "BBB@ HHHH ****
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MJUJ<U6C:^R#5[GVI_P %+_B/=Z9K&A?#/2[:'3/#\<']L7$=NH43S2228!4
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MTV/PHZ HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?'/_!4C_D@/A__ +&>W_\ 26[K[&KXY_X*D?\
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M?X5^E=%']J8K^;\$',S\U/\ AU;XO_Z';1?_  'F_P */^'5OB__ *';1?\
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M/-,-/1RMZE\R/B:BO=_%'[#?QJ\+J[R>#)]2B49+Z9/'<'\%5MQ_[YKR/7O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^A2UW_ON#_XNBP'V/17QQ_P\R\&_P#0I:[_ -]P?_%T?\/,O!O_ $*6N_\
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M +[@_P#BZ/\ AYEX-_Z%+7?^^X/_ (NBP'V/17QQ_P /,O!O_0I:[_WW!_\
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M=KKQE''\2,.H-?K!^SW^T-H7Q^\)K?6+)9ZU;J!J&E,^9(&_O#^\A[-^'6I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,FH*** "BBB@ HHHH ^RZ***@#]$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ODS_@I5_R0O0O^QD@_
M]);JOK.ODS_@I5_R0O0O^QD@_P#26ZH _->BBBK **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY37/BIX-\,ZE+I^K^*M'TR^B +VUW>QQR+D C*DYY!JC_P +T^'7_0\^'_\
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MI^J^)?$&K?\ ",^"=))%UJ1"[I65=SJA)P JXRQX&X#!YQX]XQ'_ !5VN?\
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MMGI@D>QZ&OT4\.?LQ^#M'_;(U*XCL;=])AT2/7+;22BF&"ZDF:+(7'W08V<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2W5%P/S7HHHJ@"BBD.: /TF;QD_@FW_99NO,,=M=VBZ?<#LR36D2#/T<HW_
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M7_)"]"_[&2#_ -);JOK.ODS_ (*5?\D+T+_L9(/_ $ENJ /S7HHHJP"BBB@
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M3<>/,,#[N_7B/\:^0QTI@+1110 4444 ?9=%%%0!^B%%%% !1110 444UC0
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M]](<,MDIZQ1GU_O,.O3IU^CZ2EJ0"BBB@ HHHH **** "BBB@ HHHH ^'?\
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MS7(O@S^Q;I?AB-XO^$A\?7;:C=(K M#9@IM/_ ECC&"/XW]*^5Q2T4 %%%%
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M10!PW_"C?AU_T(WA_P#\%L7_ ,31_P *-^'7_0C>'_\ P6Q?_$UW-% '#?\
M"C?AU_T(WA__ ,%L7_Q-'_"C?AU_T(WA_P#\%L7_ ,37<T4 <-_PHWX=?]"-
MX?\ _!;%_P#$T?\ "C?AU_T(WA__ ,%L7_Q-=S10!PW_  HWX=?]"-X?_P#!
M;%_\31_PHWX=?]"-X?\ _!;%_P#$UW-% '#?\*-^'7_0C>'_ /P6Q?\ Q-'_
M  HWX=?]"-X?_P#!;%_\37<T4 <-_P *-^'7_0C>'_\ P6Q?_$T?\*-^'7_0
MC>'_ /P6Q?\ Q-=S10!PW_"C?AU_T(WA_P#\%L7_ ,31_P *-^'7_0C>'_\
MP6Q?_$UW-% '#?\ "C?AU_T(WA__ ,%L7_Q-'_"C?AU_T(WA_P#\%L7_ ,37
M<T4 <-_PHWX=?]"-X?\ _!;%_P#$T?\ "C?AU_T(WA__ ,%L7_Q-=S10!PW_
M  HWX=?]"-X?_P#!;%_\31_PHWX=?]"-X?\ _!;%_P#$UW-% '#?\*-^'7_0
MC>'_ /P6Q?\ Q-'_  HWX=?]"-X?_P#!;%_\37<T4 <-_P *-^'7_0C>'_\
MP6Q?_$T?\*-^'7_0C>'_ /P6Q?\ Q-=S10!PW_"C?AU_T(WA_P#\%L7_ ,31
M_P *-^'7_0C>'_\ P6Q?_$UW-% '#?\ "C?AU_T(WA__ ,%L7_Q-'_"C?AU_
MT(WA_P#\%L7_ ,37<T4 <-_PHWX=?]"-X?\ _!;%_P#$T?\ "C?AU_T(WA__
M ,%L7_Q-=S10!PW_  HWX=?]"-X?_P#!;%_\31_PHWX=_P#0C>'_ /P6P_\
MQ-=S10!7L[.#3[6*VMH8[>WA01QPQ*%5% P  .@'I5BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[%I&DV>@Z7:Z=I]M'9V-K$L,%O"H5(T4850/0"KM%%2 4444 %%%% !1110
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M-H_Q0\4Z&R?9]8N'13_JYR)5/M\P/Z5R]% 'N/A_]I%BRQZWI@ S@SV)/'_
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M\1SF]=R,$0K\D2?3 9O^VAKZ;H8!1112 **** "BBB@ HHHH **** "BBB@
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M0K!E&&>AQ_+'->,>"_CSX>\31K%?2C1K_@&.X8>6WNK^F?7%>G_\%/O^0/\
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M5!/?@"M.BBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _+__ (*$>#1X<^/+ZK''LBURQBNB0.#(@\IOT1>GK7D/
MP#\;'X=_&;PCKS2>7!;:C$MPQ) \ESY<A/T1F_*OM#_@IAX46]\!>$_$2*QF
MT_4)+-B.GES1[LGZ-"O_ 'T:_/-&,;!U.&4Y!^G0U2 _=A6W<CI3JY;X7Z\/
M%'PW\+:P'W_;M+MKDMZEXE)_4UU-2 4444 %%%% !1110 4444 ?E'^W7_R<
MOXE_ZY6O_HA*_5B#_4Q_[H_E7Y3_ +=?_)R_B7_KE:_^B$K]6(/]3'_NC^5,
M"2BBBD 4444 %%%% !1110 5\F?\%*O^2%Z%_P!C)!_Z2W5?6=?)G_!2K_DA
M>A?]C)!_Z2W5 'YKT4458!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!H^'/$
M>I^$=<L=9T>]ET_4[.02P7,#%61AZ'T()&#U!-?J'^RK^U9I_P =M)&E:J8=
M/\9VD>9[5?E2Z4#_ %L0)_[Z7/'TK\JZN:/K%[X?U:TU/3;J6RU"TE6:"XA8
MJ\;J00P/J"*0'[GT5\U_LH?M;:?\:].@T#79([#QM;Q?,F-L=\JCF2/_ &L#
M)7ZD<=/I/ZU("T444 %%%% !1110!\._\%/O^0/\/?\ KO??^@P5\#5]\_\
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M^WEI U3]FOQ!*3@V4]K<C_O\J?\ L]?E37[ ?M8:6NK?LY^/8&"D)IK7'S9
MS$RR#\<I_*OQ_IH#]:_V+=<DU[]FGP7+*=TEO#-:'GH(IY$4?]\JM>X5\G_L
M$^/-"TW]G^VLM1UJQL+BVU&Z40W=U'&VTE7! )!Q\Q_'-?1G_"R?"?\ T,^C
M_P#@?%_\52 Z2BN;_P"%D^$_^AGT?_P/B_\ BJ/^%D^$_P#H9]'_ / ^+_XJ
M@#I**YO_ (63X3_Z&?1__ ^+_P"*H_X63X3_ .AGT?\ \#XO_BJ .DHKF_\
MA9/A/_H9]'_\#XO_ (JC_A9/A/\ Z&?1_P#P/B_^*H Z2BN;_P"%D^$_^AGT
M?_P/B_\ BJ/^%D^$_P#H9]'_ / ^+_XJ@#\Q_P!NO_DY?Q+_ -<K7_T0E?JQ
M!_J8_P#='\J_)W]MK5+/6/VC/$5U874-[;/%;!9K>170X@0'!![&OT_A^)'A
M/R4'_"3Z/]T?\OT7I_O4V!T]%<W_ ,+)\)_]#/H__@?%_P#%4?\ "R?"?_0S
MZ/\ ^!\7_P 52 Z2BN;_ .%D^$_^AGT?_P #XO\ XJC_ (63X3_Z&?1__ ^+
M_P"*H Z2BN;_ .%D^$_^AGT?_P #XO\ XJC_ (63X3_Z&?1__ ^+_P"*H R_
MBU\6M$^#'ANWU[Q +@:9)>1VCR6Z;S%OW?.5[@8YQSSP*W?"?C+1/'.CQ:KH
M&J6NK:?* 5GM9 XY['N#['!%?,?[?GC#0=<^ WV;3M:T^_N/[5MV\FVNDD;
M#Y. 3QS7P1\-OBQXK^$>M#5/"VL3Z9.>)8E.Z&90<[9$/RL/J*8'[75\F?\
M!2K_ )(7H7_8R0?^DMU3?@3^W]X:\<FSTCQM%'X6UQP(_MNX_89F]=QYB)]&
MR/\ :IG_  4@NHKSX">'IH)$GAD\16[))&0RL#:W1R#Z8H _-RBBBJ ****
M$S[49%?>EO\ L6^ M8_9XMO$=A#J'_"67/AM-4B_TIF5I_)60XCQT).,9[BO
M,?V+_P!FOPU\:M.\2ZMXOBNCIEG-!9VK6]P80TSY+ D#J 8_^^Q2 ^6J*]/_
M &AOAS8?#_XW:]X3\.6UQ)96LT<=M"S&:5MT:MC(&222:Y76/AEXP\.V!OM5
M\+:SIUD.3<75C+$@YZEBN!^=,#FJ*T;'PWJ^I:;<:C::7>7-A;MMFNH8'>*,
MX!PS 8!P1U/<5<UKP'XF\-V$5]JWA[5-,LI<>7<7EG)$C9Z89EQS]: ,*BM&
M7PYJT.BQZO)I=XFE2-M2^:!Q"S9(P'QMSD'H>QIT?A76KC38-0CTB^>PGE$,
M5TMNYBDD)VA%;&"Q((P#0!F45]K:A^SS\-?A/\ O#GB'Q;X6\1^(M?UBP%W<
MR6)D7[ QA$I$B@CRU0$*=P)RISZ5\F:'\-_%GBBQ^VZ/X8U?5+/G_2+.QEE3
MCJ-P7'!]Z .<HJ:]LKG3;J6UN[>6UN8FVR0S(5=#Z%2.OU%;_P#PK/Q?_8XU
M7_A%M9_LPKO^V?8)?*VXSNW;<8Q[T <U17N7[*_[-;_M!>)+T7]Y<:7H.G*L
MEQ/!#EYR3CRXW/RAL<DG.!V->97/P[\2'7M1TRU\/:K/<6C9>W6SD:1$).QF
M&W@$#N.: .:HK1T/PWJ_B::2+2-+O-4EC7<Z6<#RE03@$A1TSZT_3?"FMZU8
MM>6&CWU[:)((FGM[9W0.<84L!]X[AQGN* ,NBO</@?\ #/P['XLU73OBIX8\
M5QHMFLUK;:=83B<,7 W,H7.TC/)'6O(+/PWJ^I:;/J-II=Y<V$+^7+=0V[M$
MC'&%9@, G<O!/<4 9U%;FN>!/$OA>SBN]8\/ZGI5K-_JYKRTDB1\],,R_P C
M5?P_X5UOQ9<O;Z)I%]J\Z+N:.QMGF91G'(4=,T 9=%;-SX*\0V=K>W-QH6HP
M6UE)Y5U-):2*L#@*=KG'RG#+U/\ $*Q=U "T5[A\7OAIX>^'_P "?A9J"6C)
MXL\20S:A=3F1B/L_RF,;<X&1(G;L:H?LH_#'0_B]\8K+PYXBCGDTR:UN)76W
ME,;;E3<N&'^30!X]FBOLC7_"/[+/AGQ]?^$=3@\5VFHV5V;*:<R,T(D#!200
M2V,G^[VKRW]IC]FR7X0_$ZTT+PO]MU_3]4M/MUE"J>;<HH8JRL$'(!&=P7H?
M:D!X315N71[^'5?[,DLKA-1\T0?8VB83>82 $V8SN)(X]2*TF\!^)EN+NW/A
M[5!/:QK+<1?8Y-T2$$AG&W@$ X)]#3 PJ*W;[P%XFTO1H]7O/#VJ6FDR8*7T
MUG(D+9Z'>5Q@_6J>F^&M8UBRGO+#2KV]M+<XFGMX'=(\\@,P& <>IH SJ*U]
M;\(:[X:NK>VU;1=0TRXN5#0Q7EL\32 ]"H8<@Y'3UJYJGPW\6Z'I8U+4?#&K
MV&GD9^U7-C*D7/0[BN.?K0!SE%7-(T;4/$%\EEIEC<:C>2?=M[6)I7..N% S
M^E?2/[.O[-.G>,O#OQ'E\<Z-JNG:IH=BMQ9PS;[5@QCE;+*1R,HOZT ?,5%:
M(\,:Q_8?]L_V5>_V1G!O_L[^1][;C?C;G=QUZT+X;U=]%?6%TN\;2$;:U^('
M,"G<%P7QC.2!U[B@#.HK8\.^#=>\722QZ'HNH:S)$,R+86KS%<]"0H./QK7\
M*?"W7_$_Q TSP@^GWFG:G>3)$ZW-K(&@5F ,C)C=M&?3M0!R%%>O?M*? >3X
M%^-;?1;0WVHV'V2 MJDT&R.>X927"8R ,CA<D@=S7$S?"WQG;:8VHS>$M;BT
M\+O-T^GS",+@');;C&"._>@#EZ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"SI>J7>BZE:ZA87,EG>VLJS0W$+%7C=2"K*?4$#%?IC^R1^UU
M;?&.SB\->)Y8;/QI;I\C@;(M00?Q)SQ(!C*]^HXR%_,6I;.\N-.O(+NUFDMK
MF!UDBFB8JR,""&!'<$#I0!^ZU%?*'[(W[8=M\4[>T\)>+ITMO&$:[8+H@+'J
M"CI])<=1T."1Z5]79J %HHHH **** /AW_@I]_R!_A[_ -=[[_T&"O@:OOG_
M (*??\@?X>_]=[[_ -!@KX&JD 4444P"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /LNBBBH ^-*^\_P#@F))_H?C]
M,<^99MG\)ABOB/QAIG]B^+M;T_:$^R7T\&T #&R1EP!GIQV-?8?_  3'OROB
M+QS99.&M;:;&[CAW'3_@76J8'Z T445(!1110 E?!'Q*A\=3?MVZNOP[FT^#
MQ)_9:%7U( P^7Y";P>#SC':OO<UX]:_L]_9?VC[GXK?V_N\ZQ^Q_V1]CQM_=
MJF[SO,_V<XV4P/(M'_9C^*'Q.^*GAWQ9\7_$6FW%EH,BS6^G:5G#,KAU7 0*
M 652QY)"@>XJM_RDD3_L$?\ MK7V37S-\7OV/]6^(WQ:N?'NB?$F\\&:A+!'
M HT^R<RQA4"'$JW"'YA[>U(#Z9K\_?VJOBKHVM_M4^%]+U6&[U7PSX-99KRU
ML(O.:2<[967;D C(B5LG^\.M>Y?#G]F'Q_X*\::7K>I_'3Q%XFL;.0O+I-ZE
MQY-P"C* VZZ88!(/*GI71_ ?]FN+X.>(O%OB#4-<'BC7/$5QYTMV]C]G\I2[
M.R >8^=S-G.1]T<<4 ?*WPW^-N@Z)^V8?$.BV^H:+X8\8L+2[@U*+R0+B0KE
M\9(QYP4[B>/,;H*]%^)4L>B_\%#O!5YJQ$=G<Z?'':22'Y0Y29  ?7>3_P!]
M"O;?VD/V<K#]H+PWI=@=17P_J.FW7VBVU)+03LJE</'MWIPQ"'KU04[XN?LV
MZ+\;/!>CZ9XDO9CK^EQ*L'B"TC$<PD"@,VPDC:Q4,5)X['O3 [KXB?$+P_\
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M^*-G<_L@_$;QA:6T);X=>/M*O(H8HP<6EPT+A5 [%78#_<?_ &:]Q_X)^?\
M)M^F_P#80N__ $97I_QR^#>E?'3X?WGAG5'%L[L);2_$0D>TF7I(HR,\$@C(
MR&(S5?\ 9^^#G_"BOAQ;>%/[7_MSR;B6?[7]F^SYWMG&S>_3_>H ^<]'_P"4
MENI_]>+?^D*5J_\ !1?XCOI/@?1/!%E*PN]>N!-<QQ LQMXF! ('9I"N/78:
M]5L_V;?LO[2UU\6O^$BW^= 8?['^PXQF 19\[S/;/W/:FWW[-8US]HRV^*>L
M^(O[2BL81#8:(;':MOA"JDR>8=V"SM]P<L/2@#XL^*WQ;\)V>H?"[7? >C:W
MIFH>"XX;22?4+40B>WC8%0S!OO%C)G)Y\UJ_2SPMXCL?&'AO2]<TR;S]/U&V
MCNH).F4=0PR.QP>1VQ6-\3OAQI_Q0\ ZYX6O0D$&IVYA\\1!C$^04D R,E6"
MMU'2LKX$?"V\^#/PWLO"=UKW_"1+922>1=?9/LQ6-FW"/;O?."6YSW''% 'H
ME%%% !1110!YI^TOC_AG_P"(.?\ H"W7_HLU^-]?K?\ MF:@VG?LT>-I%*[I
M+>*$;O\ ;GC4X]\$U^1_:F@/:?A%^R3XZ^-GA,^(O#ITL:>MP]J?MERT3[T"
MD\;#QAAWKM_^'=GQ8_O:#_X'M_\ &Z^L?V!;(VO[-6ARD$?:;N\E_*=D_P#9
M*^BZ+@?F'_P[L^+'][0?_ ]O_C='_#NSXL?WM!_\#V_^-U^GE%%V!^8?_#NS
MXL?WM!_\#V_^-T?\.[/BQ_>T'_P/;_XW7Z>4478'YA_\.[/BQ_>T'_P/;_XW
M1_P[L^+'][0?_ ]O_C=?IY11=@?F'_P[L^+'][0?_ ]O_C='_#NSXL?WM!_\
M#V_^-U^GE%%V!^)OQ/\ AKK'PD\:7GAC7?LYU.T6-I/LLA=/G0,,-@'H1VKW
M-/\ @G=\5V4$-H.",_\ '^W_ ,;K"_;K_P"3E_$O_7*U_P#1"5^K$'^IC_W1
M_*BX'YC_ /#NSXL?WM!_\#V_^-T?\.[/BQ_>T'_P/;_XW7Z>4478'YA_\.[/
MBQ_>T'_P/;_XW1_P[L^+'][0?_ ]O_C=?IY11=@?F'_P[L^+'][0?_ ]O_C=
M'_#NSXL?WM!_\#V_^-U^GE%%V!^1OQ<_9(\=_!7PG_PD7B(Z6=.^T);_ .AW
M32/N8$CC8./E/>O%J_4K]O;0]1\2_ ^#3M)L+G4]0GUBU6*UM(FDD<X?HH!K
MQ7X%_P#!.RXNFAU;XEW7V:# =="L9 9&SSB64'  _NI^8H ^3_AI\(O%?Q>U
MM-,\+:1-J,N<23XVP0C^])(?E48]3]*^B?VAO@'K7P*_9AT>QUGQ9=:Y+<>(
M[=AIZD_8K,_9;K(B#?-DG.2" ?[O>OT(\*^#]%\"Z+;Z1H&F6VD:= ,);VL8
M1?<GN2>Y.2>2:^9O^"E7_)"]"_[&2#_TENJ+@?FO1115 %%%% 'ZC>$?&W_"
M)6O[.=G*0+/7=%;3)@Q&W)M(70X]WC5?^!&LY_#%O^SOH/P_\"Z<53_A(O'J
MSN!U-NMP9$!QZ*ELO/H:^0O%W[5%QXDT3X5V5KX>_LZX\"-"R7/V[S?M9C6-
M?N^6OE@[/5OO5N?%#]L^X^)/Q/\  7BL^%O[.M/"MQ]J73/[2\S[2Y=6),GE
M#;PH'W3WJ; >D:EIOC.[_;P\6W'@;2]'U#5[6-7:?7$9K>UC,42F3Y6!#\[1
MCGYCVYKVGX/:WJ'B1O'6A^)_BII/Q'N6T^1Y]*TNQ'V:Q!W*P$X&U@?N[3SQ
MFOD7PW^V-?>&_P!H#7OB-;^'8OL6N1K!>:/)=%FV*J@%)=@^8%0>4[D>]=/X
M7_;2\(?#75M6'@WX16>EZ3JD;"\0:DR7$KD\$/Y;A$4%L1J,9;/'2BP'>?L;
MZY+X5_91^*VLVT44]QIEU=WL*3J&3S(K2-T)&.@90?PK0^"OQ$\0_'W]E?XN
MQ^-KU-;GL[>Y^SSS0("F+8R(<* #L=0PXS7SC\-/VED^&_P<\<^ 8O#37T?B
M8W.V_;4 AM1+ (0"GE'>5 R?F7.>U,^"_P"TK_PJ'X8^-/"'_".?VM_PDD<D
M?VS[=Y/V??"8L[/+;=C.?O#I3 ]<\:?\HW_!_P#V%A_Z/N*=>:E=:#_P3U\)
MZE9MY%W:>(4N8)-H.'6YE93C'."!^5<!\(OVK-*\)?"6X^'7C;P3#XQ\.J[2
MVR?:/)926W[6^4\!N0RD$9/!JM\4OVLU^)7P;C^'\/@NR\/6=O>)-:R:?=$0
MPPH6V1"+R^3AN6W\G)QS0!] ?M3_ !@\7:?^S-\-+FTU'%UXOTF*#5R(4/VI
M9[)#( ,?+N+M]W'6K":]\2? ^C^"X_&/Q)\*?"K3[>"%;;P_I>GM=7-U&"H"
MO%DD\ +\AQR>]?+WQ6_:1?XF?##X?>$8_#_]E2>$H((5OOMOG?:3' D0;9Y:
M[,E-WWCUKT+Q%^VAX<\8V>A:SK_PNL-7\>Z-"L=IJEQ=M]E5@01(8@OS ,-P
M1B<$G!I6 ]B^+W@'1/%7[>7@6VU*SBGMY=-6[GA905GDB\UDWCN,JO7KM'TK
MB_B1^UU\3/!_[2GB#0M+LO[8T>PN)+&W\-); B9508?*J7R<%^#T.*\;^+?[
M5FH_$/XI>&/'VC:/_P (QKFB0K$I^UBZ24AF.2/+3 (9E(.<@UZ>W[=WADZA
M_P ):/A/I_\ PL7R/(_M?[2-GW=N[.S=TP,9SCC=3 [K]@;QQK.N>._B1IUW
M8PZ'9._]J?V/! 8DMIY'PP4-E@, ?*35C]A?QUK7Q&^+7Q1UK7[O[;J+P6<1
ME\M4^5'E51A0!P />OF[X*?M6:O\,?BYX@\:ZQ9'Q ?$"NNH0+-Y1R7#JR'!
M^[@J%(Z'%;7A3]K73_AW\;M1\8>$_!5OH_AW4;5+2[T*.<+OP=QF5PF%?.3C
M!')^H-0._P#^"9*G_A.O&C8.!IL()QP,RG_ _E6G^RGXSNOA[^QK\2/$5@D;
MW^GZG-+;>:H95D\BW"L1_LD@\^E<UX5_;H\.?#?Q'JEQX1^$UEIFDZ@#)<0Q
MZ@8IYIRP(=G\I@$ + 1J,?,3GM7D7@G]H/\ X0WX!^+/AI_8'VO^WKEKC^U/
MMFSR,K$N/*\L[O\ 5_WQ][VY-0/I?]AGXK>)/C#\9O%NN>*;X7VH1Z%#:HRQ
MA%6-9L@!0 !RS'ZFLO\ 9*\37/@O]COXGZ]9)$][I^H3W$'G('42+;0%6(/4
MAL$9]!7@'[,W[1'_  SIXBUC5/\ A'_^$A_M"U6U\K[;]F\O#AMV?+?/3IBE
M^'G[17_"!? GQC\./^$>^W?\)#+))_:?VWR_L^^.-,>7Y9W8\O/WAU]J /H_
MX9_$7Q#\=OV//BP_C._76;JQ\X07,L"*RA8DE7A0!E7&0>M4?#OB34/@5^P;
MIOB;P7"EIKNL7RB\U-8T=XMTKKO.X8.!&D8!!QOSBO OA3^T=_PK'X/>-/ G
M_"._VE_PD?F?\3#[=Y7V??$(_P#5^6=V,9^\.M>^?LFR>/8_@#J*V6AZ!\3/
M",DLP;PM=7?E7<,F_P"9/FC9"K?ZP*WKD=:-0-Q?B%KGQ._X)_\ C'7/$12;
M56<P2WBQ+&;H)/"JR,%&"V,+G ^Y7PCX7T&7Q1XFTK1X 3+?W45LNWKEW"@_
MAFOT$^,'B#5=#_8O\31>+O#VG^"+[4;A+72O#ECY:K!#YT11 %."P"R.>/7I
M7PW\&_&FG?#GXG>'O$VJZ?)JMCI=Q]I-I"X5G=5;RR"1V?:W([&D@/4OVZ-:
MBO/C@="M"$T_PWIEKI4$*ME4"H7( ]07 _X"*M?\$_\ _DY#2O\ KQN__19K
MQ'XB>,)OB!X\\0>)9T,<FJWTUWY9.=BNY*IGT52!^%=-\ /C!_PHOXD6OBO^
MR/[;\B":#[']I^SYWKMSOV-T_P!VJ ^I_B-^T3\'/"'QDUZTUKX0P:AK&GZI
M(MQJX6&1Y95?F7:PY.1G!-,_:KNM3^%?QR^'/QEL]8GO-,OBB+9W"A6MX54&
M2)0 /D>.5^H)!)Y/%<E>?MQ>!;_6)=6N/V?_  [<:M))Y[WTUQ;O.TF<[RYL
M\EL]R<UY5\6/B[XR_:Z^(.C6$&F11RKNM]*T6UE 52P#.2[D LP0<G'W12U
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MI((P.*U(_P!LSP'9^)9/'%G\'K:#XA.C#^T/[28PB1EV&3;LZD$]%S_M=Z+
M?-OQ,T/5O#?Q"\0Z;KUG;6&KP7L@N;>S4+ CEB2(P. F",8[$5S5;?C;QAJ7
MQ \6:KXCU>19=2U*=KB9D7:N3T51V  Q^ K$J@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHJ6TM)]0NHK:VADN+F9A''#$A9G8G 4 #)))[4
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M(V_LN.X=,8P\V96_'<Y_6O4ZH:'I::)HNGZ=%_J[2WC@7Z(H4?RJ_4@%%%%
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MI:**0!1110 4444 ?#O_  4^_P"0/\/?^N]]_P"@P5\#5]\_\%/O^0/\/?\
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M:_Q/:XL?$/@&[FR8#_:EBK'D*VU)5&>P;8V!_>8U]S4@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6O,/VCOBA'\(_
M@[XAU_=_IHA-M8K_ 'KB3*H?HI.X^RF@#\T?VL/B*GQ-^/'B?4[=MUC:S?V=
M:G((,<(V%@?1F#-_P(5K?L4>"1XT_:(\.>9%YMMI1;5)>!@>4!L)^DA3]*\-
MDD:61Y)&+NQ+,S<DDG))]\U^@_\ P39^'(TWPAXA\:W$/^D:G.+&UD9>1#$<
MN0?1G(S_ -<Q5= /M*BBBI **** "BBB@ HHHH **** /RC_ &Z_^3E_$O\
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MG_@GC\>1?64WPSUBY7[1;A[G1WD;EX^6D@'J5Y<#T+=A0P/N*BDI:0!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E?G%_P %$/C)
M_P )3XZLO NG7(?3M"_>W@C8$/=LH^4^Z(<?5V_#[,_:,^,UG\#?ACJ.OR_O
M=1D!MM-M^/WMPP.W(_NKC<?93W(K\?M2U"YU;4;J_O)FN+NZE:>:5SEG=F+,
MQ/J23^=- 6/#N@WOBKQ!INC:=$T]_J%Q':P1*,EG=@JC\R*_:/X:^![/X;^
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MDGCEF)Y9CW8\FM#1=$L/#FEVVFZ79PZ?I]L@CAMK= D<:CH !T%7ZD HHHI
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M]IFRQ]R:Z:BBI **** "BBB@ HHHH **** "BBB@#\H_VZ_^3E_$O_7*U_\
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M=D>)?^AVTK_P$E_QK]"J* /SU_X=D>)?^AVTK_P$E_QH_P"'9'B7_H=M*_\
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MVTK_ ,!)?\:/^'9'B7_H=M*_\!)?\:_0JB@#\]?^'9'B7_H=M*_\!)?\:/\
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M$E_QK]"J* /SU_X=D>)?^AVTK_P$E_QH_P"'9'B7_H=M*_\  27_ !K]"J*
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M5O#WY3__ !RC_AYAXZ_Z%;P]^4__ ,<HLP/T:HK\Y?\ AYAXZ_Z%;P]^4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-AY;7[4]OE#-_(4 =C17GTWQZ\$1YVZNTI]$M9OZKBLZY_:.\(Q'$?VZ?W2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_#W_KO??^@P5\#5]\_\%/O^0/\ #W_KO??^@P5\#52 ****8!1110 4444
M%)CG-+10 F*-HI:* "DVBEHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /ONBBB@#[@HHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?PDTSX@?&'7=0TV#6"IT_2M- \PJR[E+?*6+%06P,!01DYKGOV@/V:]$\'^
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MUE_9X*A_.5BK(23C@@\DX&#7W'^P9XFC\&_LZ>,-8F($-KKX:0GH%,=LK'\
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M+WC+8DMP2!U[>E?(D-Q-;AQ%*\0<88(Q&1Z'GI46.,4P/N[Q#X7L/VS/V?\
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MY!_*OD*DQBEJ@"BBB@ HHHH **** /ONBBB@#[@HHHJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ODS_@I5
M_P D+T+_ +&2#_TENJ^LZ^3/^"E7_)"]"_[&2#_TENJ /S7HHHJP"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HI8T::18XU:1V.U54$DDG  'J37WO^R7^Q
M"NF-:>,?B+9![T,);#09ER(L8VRSCNV>0AX&.>>  <;^R7^Q//XR:S\8>/[2
M2VT'Y9K'29 4DO.X>0?PQ$8('\0/8=?T-M+6&QMHK>VA2"WB4)'%&H544#
M Z#':IE4(  , = *=4 %%%% !1110 4444 ?#O\ P4^_Y _P]_Z[WW_H,%?
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R9_P4J_Y(7H7_8R0?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *^3/^"E7_ "0O0O\ L9(/_26ZKZSKY6_X*+:/?ZW\$]%@TZRN
M;^=?$,#M':Q-(P46UR"< =.1S[B@#\S:*W_^%?\ BC_H6]7_ / &7_XFC_A7
M_BC_ *%O5_\ P!E_^)JP,"BM_P#X5_XH_P"A;U?_ , 9?_B:/^%?^*/^A;U?
M_P  9?\ XF@# HK?_P"%?^*/^A;U?_P!E_\ B:/^%?\ BC_H6]7_ / &7_XF
M@# HK?\ ^%?^*/\ H6]7_P# &7_XFC_A7_BC_H6]7_\  &7_ .)H P**W_\
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M?_B:/^%?^*/^A;U?_P  9?\ XF@# HK?_P"%?^*/^A;U?_P!E_\ B:/^%?\
MBC_H6]7_ / &7_XF@# HK?\ ^%?^*/\ H6]7_P# &7_XFC_A7_BC_H6]7_\
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M;U?_ , 9?_B:/^%?^*/^A;U?_P  9?\ XF@# HK?_P"%?^*/^A;U?_P!E_\
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M( HHHI@%%%% !1110 5T?PY\%W/Q%\>:!X9M,^?JEY';;EQ\BEAN?_@*[F_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?BOQU>&-K2UG1Y;2S0!290&)4L%; (_Y:CT-?-5)CBEH **** "BBB@ HHI
M: %HJ_HGA_5/$UZ+/2--N]4NVY$%G"TK]<9PHZ?A7M7@7]B+XL^-YHR^@+X>
MLVY-WK,PA _X ,R9_P" T ?05%>N_P##-VL?]!:Q_P"^7_PHI ?0=%%%2 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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/ K2VBEHH 3:**6B@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gizttcucplmb000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000018.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBDH R[CQ1HUG,\,^K6,$R'#1R7**RGT()IG_  F.
M@_\ 0;T[_P "X_\ &OC[_@K1X-T.^_9#U_6YM*LVU?3M0LI+:^\A/.C,EPD;
M@/C(#*QSSS@9Z5\@?\$7O"FC>(/C1XWOM3TNUU"[T_1$-I)<Q!_(+S*&90>
M2 !G&<9]3D _86Z\1:58LBW.IV=N74.HEN$7*GHPR>A]:B_X3+0/^@WIW_@7
M'_C7E7[8WA/1==_9:^+)U'2K.]-IX3U.YMVG@5C%)%:2O&ZG'!5E# CIBOQO
M_P""97@W0O'G[7?AK1_$>D66N:5+97S266H0+-$S+;.5)5A@D$9% '[R_P#"
M9:!_T&]._P# N/\ ^*J5/$>DR6LERFJ6;VT9"O,MPA12>@)S@$UX[XP_8V^
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ME &?O  _2ZEIO*TGF+G&X;O3- #Z*;DTM "T4UG"]2!]:4'- "T444 %%%%
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M#XST'X_ZI\=/BW!:Z/KDU]=ZGI_AVSN5G:&YN6D+O,Z$KA!(P559LDY.-H!
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MN/VOO^46,_\ V+FB?^C;6O /^"&__(6^,G_7'2?_ $*\H _5^BDI: "BBB@
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MY/4\,_\ 8.U#_P!)GH ^ZO\ @K]8OH/P&T;Q?I%_J&C>(+?6X+(7FG7DL#/
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MB^82T:AU0\\A3ZU^@O\ P1K_ .32;[_L9[S_ -$VU? OQL_Y2G7/_90]/_\
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M3\M?MI?\$\?BO^UI\9&\7KXD\)Z)IEK9)IMA9//=R.(4=W#N?)QO8R$G;P
M.<9/Z,T4 ?(OQ:_9T^+GQ0_9!T[X-O<^#;34_LUMI]]K'VRZ,30VQA:-XX_L
M^0[F,A@3A<#&[=\O&_L#_L0_$S]COQAXAGU/6O"NO>'_ !###%>BSFN4NH&A
M,AC>,-%M8?O&!4D=00?EP?NRB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH AN&E6&0PHLDP4E%D<JK-C@%L' SWP<>E?GC^
MV7^P/\9?VP?B'IGB.\UWP7X:L]-L!86NFQ7EY<[1O9V=G-NH+,6'11PJ^E?H
MI10!\R?L7_!/XH_LU?#?2?AYXCD\*:[H%C//)%J>G7US%<Q)(S2;/*:WVR'>
MQYWKPW?'/TT:6B@#X]_;^_9/^(?[7>D^'_#OA_5/#>A:#I5R;YKC4IIVN)YB
MC)MV)$555#'^(YSVQ70?L)_L[_$+]EGX>W'@7Q/>^&]9T07<U];:AI4]P+A)
M)-@,;1O$%*_*QW!@1P,'J/J*B@#C_BM8^*M4\!:O8>#%TD:]>0/;PRZW+*EM
M#O4J9&$:,S$9&%XS_>%?GO\ LL?\$S_BW^S#\:M'\?V_B+P9KWV&.:&33Y+B
M[@$J2QLC8?[.VTC.<[3TK].** /E+]O/]FGXA_M8>!])\&>&M1\-Z%HL%XFH
MW5UJDT[3R2JCJL:JD14( Y.[.3@<#O0_8?\ V9?BA^R5\.?$?A'4;SPGXBMK
MF>74=/GM[JYA9+ID11'*# ?W9* EER1SP:^O** /RMT+_@EG\8]&^/EG\53X
MM\$3ZM!XC7Q(UD&NUB:;[3YYC!\DD+NR,\\5[[^W7^R/\4OVPM*\)Z197_A'
MPUINCL;R8SW=U/++<O$JNJD0 >6AWA2>6!!(3[M?:M% 'S-^P[^SWX[_ &:?
MA3/\/O%]]X?UG2H;B:XLKS2)9_._>MEXY$D11@$L0RGOC'>OD?0_^"/_ (W\
M#_&Z+7O!WQ3@\,^';2\,]CJ=LLIU:VB(/R!0 A;!*DE\$<D<[:_5&B@#\T_V
MIO\ @DOJ?Q2\4:9X@\$^.))M2>U6#6+CQC=SW5Q>3*3_ *3YH#8)!"^6%50$
M&T#I7UI<_"7XE:7^S/>^!+3Q;8^*?&M]IC:9+K>N*;:U@5X/)+1QQ1LQV@ @
M.<L2Q9NU>\44 ?FU^Q__ ,$Z?BY^R?\ %Z/QK!KW@SQ#$]G+87%B]S=P%HW*
MDE7^SMA@4'53GD=Z_2-<[>>#3J* (!<0R3/!YB/*!EHMP+ 'H2/>OAO]D#]D
MG2?AG^V)\<_&VFPQ-H-G=#3-&$8PL$MPJ7-U$H[>6'CC'LQ'K7G^G_LZ_M*?
M!_\ ;P\3_$KP[HT/C[P]X@FO?*O;S78[2VA@G+&*.="3)BW/E_*D9#!!M*Y.
MW[W^$?@*;X;^!K/2;V__ +7UF1Y+W5=3\OR_MM[,YDN)@F3M5G9MJY.U0H[4
M =I1110!\A?M&? ?X^_&+XL^"]>T7Q%X*T?PIX.U>/6-.T6[DNI#>3QM\LER
M1#UVY4*IPNYN2>1]0>$KCQ%<:2K>*+'3+#4PY!CTB\DNH"O&&W211L#G/R[3
MC Y.>-VB@#Y/_;J_9J^('[6/@N+P9HP\*:-I-K?Q7\.K:E>W$ETQ6-E91$EO
MMCY=AD2-D 'C.!XY^QO^P?\ '+]D'Q]=ZQIOBSP;K6AZI$L&JZ1+-=QB=5)*
M.C"$[70LV"000S#OD?HG10!\K_M4?!?XV_'#6?":^%-0\%>&M(\+Z[#KUJ^H
MSW5S/=SPY\HR*L 5%&Y\JI;.X?-Q7T1X+N/$UQHN?%ECI-CJJOM*Z->RW,#K
MM'SYDAC926W#;AL  [CD@=!10!X7^S]^RSH7P#\>?%+Q-I9C:7QEK'V^.../
M;]E@V!C"./\ GL\[<<8*>E<W^V9\&?BI^T=\-=7^'OAF7PIX?T+4)H6FU34;
MZYEN9HD99"@A2WVQDNH&=[Y Z GCZ8HH _-W]CO_ ()Z?&+]D7XL3^,['7?!
M/B..ZTV72[K3YKF\MR\3R129206[;6#PIR5(QGCGCZU_:.\&_$WXK?";7_!7
MA>W\+:4WB'29-.OM1U/4KE_LXE4I,D<:6WSC:Q =F7KRE>VT4 ?E7\"?^"7?
MQT_9Y^)VD^.O"WCKP.VKZ<)%6*]CNY(9$D1D=&41 X*L>0017US?Z7^U]=6<
ML4.N?""SE9<+/'9ZDS)QU 8D9^HKZ;HH ^-?V2?V1OBA\)OCQXT^)_Q2\:Z5
MXRUCQ#I_V3SK$R[T;S%; 5HU54 4*%7@<<5]DTM% 'D_[1?A3QY\1/AKXC\'
M^#(?#\ U_2[C3;C4];O9T-NLR&-RD,<#[_D8\EUP>QKX#^ O_!+#XR? 'XN>
M&O'ND^,/!=]>:-<^;]DN'NU2="I1T)$.1E6;D9P>>>E?JI10!Q?BK3_$'B3X
M:W^GS:)H%WK=_:O;7&F7M[*^G,'&UU:7R-[+M/3RQGIQUK\J;;_@C!\6-/U.
M&_L?'WA.RN8)1-!) ]V&A92"I4^5D$'&#G/ K]BJ* /!_ .D_M Z+\,[K1/%
M5QX%\2^)X[4P6FMQ7EW;I*W #7$0MSDA23E&&2 ,#.1\9_L[_P#!,/XO_L]_
M'/P]\2K3Q/X*UBZTF:>0V$LUW$DRS0R0R+O$!VG;*V#@X..#TK]1** /B;]O
M3]CWXG_MAR>&]/TS4_"GAW0M#>2=#=7-S+<3RR(@8L%AVJJ[2!@DG.>.@[K]
MD7X'_%/]F?X$O\/[Z3PEKT^FM/+I%W#?7,*,TLQD9)P;<D*"[D,N2>!@?>KZ
M?HH _+?X;_\ !,'XR_#[X_:9\5_^$L\$ZCJEKK#ZQ+9M)>1QS.[LSIN\DE0=
M[#/)'O7OO[=O[*7Q1_:_\/\ AGP]IE_X2\-Z/I<PU"9[JZNIYY;HQ%"JE8 !
M&H9P">6X.%Z5]ET4 ?*/["_[-_Q%_90^&^J^"=:N?#&NV$MU/J5I>6-W<1R"
MX=(U$3HT&-A\O[X8D?W6[?+FO_\ !+?XT:]\?KSXKR>,_!HUB;Q%_P )$ML\
MMY)''(+CSTB!,.=BX51[ 5^J-% 'Q;^W1^R;\4OVPO#OA#1+2^\(^&K'26^W
M73S7=U.\ETT>QE3$  C7+8)&6R"0N,5W'["O[/?CO]E_X8S> O%-YX>U?3(;
MJ:]M+_2)I_.W2%2T;QR1*, ACN#=P,=Z^FJ@NX#=6LT*R/"9$9!)&<,N01D'
MU% 'X:^.?BU\??V2_P!KCXLS:)<&^U_6[V2>ZE6T6_BN+5IG:WD"C=LPORA3
M@KRO:MF+_@J3^U#X?;[;J=A82V49S(M[X>:*(CW92I'X$5]?_LR_ WXT_L17
M7C+3AX,M/C-HFN7ZWR:UI.IP66J;PFUC,EVZAE( .T2$ABWWMQQ[CXG\:?%C
MXE>%]:T#2O@G_P (^]_;-:IJ'C+6;%K1-ZE2[06SS/(%R3M(7=@#(SP 3_L3
M?M40_M;?!M?%3Z9_8^LV-VVFZI:1DF$7"HC[XB3G8RR*0#R#D<XR?H&O$OV0
M_P!F32_V4/@[:>#K&Z_M._EG:^U34MA075TRJI95).U0J(H'HN3R37MM !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 FT44M
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% "8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJ&XN(K2%YII4AB09:21@JCZDT 345E?\)5HI.!K%AG_
M *^4_P :THY%EC5T8.K#(93D$&@!]%%% !1110 4444 %%)6;<>)-)M9GAGU
M2SAE0X:.2X16'L030!IT5ER>)-(BCC=M4LE23E&-PF&&<$CGGG(_"I;/7--U
M"3R[74+6YDQG;#,KG\@: +]%%% !1110 4444 %%%% !136.*Y_0_'WASQ-K
MVL:)I&N6&J:KHYC74+2SN%E>T9\E5D"D[&(4G!Y]J .BHKD?&/Q6\)?#ZZM[
M;Q#KUIIMU/#)<1VSL6E,,>/,EV*"PC3(W.1M7/)%=!I6K66O:7::EIMY!?:=
M=1+/!=VT@DBEC895U8'!4@@@@T 7J*X?1/C7X%\1^(8]$TSQ3IM[J<TDT,,4
M4P*SR0G$T<3_ '9&CP=ZH25P<@5M^+O&NA> =)_M/Q#JUKH]AYJ0K-=R!0\C
MD*D:CJSLQ "J"23@ T ;M%8/A/QOH7CO3Y;W0-4M]3MX)VM9S"QW0S+C=%(I
MPR.N1E6 (R,BL7Q)\:? WA'6I='UCQ3IUAJ,"Q27$,LO_'JLK;8FG8<0AV!5
M3(5#'@9H [BBFJ<C/6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**XKXN?$^U^$/@V7Q%>:)K?B"&.:.$V7AZP>]NB7. PC7DJ.Y[5\^:Q_P4B\
M%^'X[:35?AU\4-,CN;A+2!KSPK+")9G.$C4L1EV/11R>U 'UQ17S9X3_ &XM
M#\6>*M'T.'X:?%"PFU.]ALDNM0\*3PVT+2.$#RR$X1%+9+'@ $U])T %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ANHVFMY8T;:SHRAO0D
M=:FHH _F*^,7P_U[X6_$[Q)X9\2V,NGZQ87TJ2QRJ0&&XE9%)'S(PPP8=00:
M^LO^"0OPZ\1^(?VI[7Q5IZ3P>'O#]A='4KD*?*E,T+11VY/]XLXDQ_TQK]?_
M (G?L^?#?XT/;R>-_!>C^)9[<;8;B^M5:9%Z[1(,-MSVSBNB\"_#[PU\,_#\
M.A^%-"L/#VD1,76STZW6&/<>K$#JQXR3R: .BHHHH *^&O&GP_\ &GPC_P""
MC2?%]?#FM^*? ?B;01I%S<:3;_:FTR18XUVM&OS!"T"-NQC]ZW/&*^Y:\\^+
M7@KQ5\1M#N_#FE>(T\):3?QF"\U.RC,NH^4V-Z0%L)$S LN\AR,Y ST /S/_
M &:/"GA3Q?\ LJ_M5WOCW59_"7P[U;Q#OMM1VF1K>:.1I$*J!F4[VMUV@?-T
M')XROAMXO\6>"?B1^S_\-?VDK:]E\!V-S;ZOX+U2,8=YF6-;);EPQS'"753&
M,,A<;BR"OT,^(W['?@OQ=^S#>?!+1(V\*>'FA06DUFH=XIDD$JROG_6%G'S9
M.3N;D'!K \:?LGZE\98_A%8>/]1TM](\ 3Q7SQZ5%)OU2XB1$C#;^(HCLW,@
MW$],CK0!X):>#/%O[-O[1/[3&L>(_#&N:_X&^(&E76I6>O6,/GPQ,JRR>1,R
M_P"I51-(F6 P$4\YS7>?\$E]#U'3/V.=/N;NW!:ZU:_N=.$XVXA)5.&P<*71
MSD#O7T!\:/@_K'QSTU_"VKZZ-$\"7$BG4K+2@?MFJ0@DFW>9N(HFPN[8I8C(
M##O5^)?PM\<VOAWP7IOP:\3:5X"M?#LZ!](O--$]E>6JIM6W;'S(!CJISSG.
M1F@#Y0^"?C;5/!'_  4S\;:7\3/ \&D>,_'=EY>A:OIMRT]L+*"$.$4E5W!U
MM<LY (>, J,U[+^WEX#_ .%P?"S1/@GX:LH6U_Q+J5JT)6(&/2;&WE62>\<?
MPHJ@1C&"QE"CJ<>LZ1\'YM6^*FE_$GQ?_9USXITG2I=*TZ'3D?[/:K*X::4,
M_P S.X"KT&U=PYW$U\W^-?V/?VC_ !+\2/$GBW3/VB(?#;ZQ(%%GI^E.$M[=
M"?*@4E\[4#'ZLS-U8T ?9'@?PK:>!?!NA^'+!G>RTBQAL(6D.6*1($!/N0M;
MM<M\,?"=YX%^'OA_0-0U.36]1L+..&ZU*7.ZZF S)*<DG+,6;GUKJ: "L_7-
M>T[PSI-WJNL:A:Z5I=G&9;F]OIUAAA0=6=V(50/4FM"N!^.WPX_X6_\ "+Q3
MX*:\&G1:[9M82W> 3#&Y =P.Y"Y('0D#I0!X7^TEXY^$_P ;/"=C#X<_:0\'
M^ ?%NDSO<:9K]AXDLF:$O$T4D;+YPRCJYS@@@JI'2O%?V2_A#\$/V76\0>)S
M^T#\-O%OQ.U)&CM];U'6K7[/9JQ)?$8N=S%R?F;<"< #&3E\?_!&'X1"-0_C
MSQ,SXPS"6V&3]/+XIW_#F'X/_P#0]^)O^_UM_P#&Z /K/]E]K*X\!:G=VWC?
M3?B/=W>LW5Q?^)-)0+;7-PQ4E4VNZE8T*1C:Q 6,#.0:]DKPO]C[X(Z/^SS\
M,=0\#:%X@_X233M/UFY9+IMOF(76-C%)MXWJ3V]NAXKW2@ HHHH **** "BB
MB@ HHHH *\K^/&D^+[SP3XGFT/Q%IFEZ6NB7(GM+S26N9)&$4A8K()TV@J5&
M-IP03SG ]4KE?BI_R2_QA_V![S_T2] &%^SA_P F^_#0?]2UIW_I-'7H]><_
MLX?\F^_#3_L6]._])HZ]&H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY7^(W
M_(\:U_U\M7U17RO\1O\ D>-:_P"OEJJ.XF<Y1115DA1110!] ? /_D3;K_K\
M?_T!*]+KS3X!_P#(FW7_ %^/_P"@)7I=9O<L*YOXA:YKOAWP9JNI>&M _P"$
MHUVWBW6ND?:5MOM+Y V>8PVKQDY/I7244@/B_P"(W[97QQ^%'@O5/%GBC]G)
MM-T'3(Q+=W1\56TGEJ6"@[50D\L.@[UOZ;^TE^T1JEK:74/[-#&VN$65)/\
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M*'_7A'_Z415[KX$_Y$?P]_V#K?\ ]%+0!NT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !117RG^T?_P40\!?LZ^.G\'W&AZ_
MXMU^WC22]@T*W1TLPZ[E5W9@-Q4JVT9X89ZT ?5E%>>? OXY>&/VAOA]:>+_
M  I/.]A,[0RV]W$8KBUF7&Z*1,\,,@]P0002#7H= !1110 4444 %>/? _\
MY*5\<?\ L:X/_338U[#7CWP/_P"2E?''_L:X/_338T >PT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1124 4]4U2ST/3;K4-0NH;&PM8VFGN;APD<2*,LS,3@
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MB_#OPS\'M-T2\\&W=OJ>K:M;SOXVM-%^T?8%\W,\DMQE3)(ZE@(BXW;ATP*
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M_P""=7[3&L?M.?L_Q:QXF*2^*-'OI-*U"ZC146Z955TF"CA2R.H/ !96( !
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MV;_^3??AI_V+>G?^DT=>C4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!NJ^(Z^W/^":G_ #4;_N&_^W5)C1]N445#-=16[ 2/M)Z9J2B:O,?VH?\
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M'*D$'D&O2=)TJST/3+33M/MH[*QM(E@@MH5"I%&H 55 Z    #TJ[0 4444
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M"N$8<?=V]: /&#^S_P"%_P#@HE^S#\(]>O+[5?A[IUC9226>B^'Q&EK!.K&
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M -@^U_\ 037SO3)84444Q!7VY_P34_YJ-_W#?_;JOB.OMS_@FI_S4;_N&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW]+110 5\K_$;_D>-:_Z^6KZHKY7^(W_ "/&M?\ 7RU5'<3.<HHHJR0HHHH
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$9I:* /P3_X*;?LW_\
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M\,WOB#Q-J=OH^AV84W-]='$409@H+''0E@/QK?J&XMX[J%XIHUEB<%61URK
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M4J+QA*'>1!W5=@7=T)8@=#C]4J %HHHH **** "BBB@ HHHH **** "BBB@
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M?]BWIW_I-'7HU><_LW_\F^_#3_L6]._])HZ]&H **** "BBB@ HHHH ****
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MJBOE?XC?\CQK7_7RU..X,YRBBBK)"BBB@#Z ^ ?_ ")MU_U^/_Z E>EUYI\
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MU3_P2G_8O\3_  KMW^*_BV]O]%NM9M/)L/#2LT0:W;!6>Z7NQYV(1\H^8\G
M /TBHI*6@ KY>_X*%?&GQ_\  ']GW5/%_@6\TNQN8YX;1Y[RU:>>+SFV"2(%
MM@925/SJPZY%?4-?&G_!6M@O[%_B$$@$ZGIX'U\]>/T- 'I/Q*_:"N/@O^QH
MGQ0U!?[5UF#P]9W"+,,"XO)XXU0OC&%,D@)QCC.*\*;]J;Q9\']9_93U;Q'K
M]YXCTKXO:6O]NVMQ'"J6EU,ED\,UOM53&J/>;67)!1,X+\GH?VM/!>J^//\
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M%% !1110!4U#3+35[*2SO[6&]M9>'@N(Q(C<Y&5((/('Y5: V\"EHH ****
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M /V$+C_T:U8M;7CC_D=-?_["%Q_Z-:L6K("BBB@ K]3_ -C?_DW+PC_N3_\
MH^2ORPK]3_V-_P#DW+PC_N3_ /H^2I92/::^5_B-_P CQK7_ %\M7U17RO\
M$;_D>-:_Z^6IQW!G.44459(4444 ?0'P#_Y$VZ_Z_'_] 2O2Z\T^ ?\ R)MU
M_P!?C_\ H"5Z76;W+/S/_;R_Y.$O?^P?:_\ H)KYWKZ(_;R_Y.$O?^P?:_\
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M_MY?\G"7O_8/M?\ T$U\[U]$?MY?\G"7O_8/M?\ T$U\[TR6%%%%,05]N?\
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MC=Z<?T%Q1K#&J(H5% "J!@ #L* )**** "BBB@ HHHH **** "BBB@ HHHH
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M% %#1-%L?#FCV6E:9:Q6.G64*6]M:P+M2*-%"JBCL  *OT44 %%%% !1110
M5X]\#_\ DI7QQ_[&N#_TTV->PUX]\#_^2E?''_L:X/\ TTV- 'L-%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'Y!_\%O?^2F_#+_L$77_ */6OBC]D[_DZ;X-_P#8YZ-_Z70U^Z_[1W[%
M/PW_ &J-8T74_',>JR76DP/;6_\ 9][Y"[&8,<C:<G(KSGP/_P $L/@=\/?&
MWA_Q5I$'B%=5T/4;?4[,S:GOC\Z&59$W+LY&Y1D=Z /L*BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX@_X*U?M Z;KVI6D.I:#Y5O<R1)NTA"=JN0,\^@H _<.OE2/_E)I-_V31?\
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M\0__ !VL3QI^U#X5\1>#=>TFVT_6$N;^PN+6)I88@@9XV4%B)3P"1G@^U.S
M=^Q3X0T*\_9+^$T]QHFG3S2>'K5GDDM(V9B4Y))')KZ#M[:*SMXX((DAAC&U
M(XU"JH'0 =A7R=^SE\=M ^$/P)\#>"]8M-2N=4T+28+&YFL8HV@>1% )0LZL
M1GU45Z/_ ,->>#O^@;KG_?B'_P".T68'N%%>:_#OX\:!\2]>DTK2[/4H+E(&
MN"UW%&J;05! *NQSEAVKTJD!4U#4(M-MS--NV9Q\HR>:S/\ A,+#TF_[Y'^-
M/\7?\@<_[ZUP],1ROB+]G'X#>+M>U#6M:^&&@:GJU_,US=7ESIR-+-(Q)9V/
M<DD]?6O&O@1^Q#\,O"<GCT^._A_X8UM=1\37E]HFVU$WV7378&"#YE&TJ,_*
M,@>IKZ/HIV"[+OP[\.^ _A)HDFC^#?#MKX:TN28W#VFG6XBC,A !<@'KA1^5
M=9!XJLKB:.)!+O=@HROJ<>M<-5O2?^0G:?\ 75?YBE8+GI%%%%(9^,/CC_D=
M-?\ ^PA<?^C6K%K:\<?\CIK_ /V$+C_T:U8M60%%%% !7ZG_ +&__)N7A'_<
MG_\ 1\E?EA7ZG_L;_P#)N7A'_<G_ /1\E2RD>TU\K_$;_D>-:_Z^6KZHKY7^
M(W_(\:U_U\M3CN#.<HHHJR0HHHH ^@/@'_R)MU_U^/\ ^@)7I=>:? /_ )$V
MZ_Z_'_\ 0$KTNLWN6?F?^WE_R<)>_P#8/M?_ $$U\[U]$?MY?\G"7O\ V#[7
M_P!!-?.],EA1113$%?;G_!-3_FHW_<-_]NJ^(Z^W/^":G_-1O^X;_P"W5)C1
M]N5C:Y_KH_\ =_K6S6-KG^NC_P!W^M249M%%% !1110!?T;_ (^C_N_U%;E8
M>C?\?1_W?ZBMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\>^!_\ R4KXX_\ 8UP?^FFQKV&O'O@?_P E*^./_8UP?^FFQH ]
MAHHHH **** "BN)\4?&SX>>!]6?2O$GCWPSX?U-%5VLM5UBVMI@K<JQ1W#8(
MZ'%1>'?CM\-O&&L0:3H/Q"\*ZWJD^?*L=.UJVN)Y,#)VHCEC@ G@=J .[HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "JMYJ%KID:RW=S#:Q,ZQJ\T@0
M%V.%7GN20 .YJU7YH?MU^'!X=_;A_9MGAU35[E-5UB&:XM;S4)9[=9([J$*\
M<3';&2KD$( .!QUR ?I?7+?%3_DF'C#_ + UY_Z(>NHKE_BI_P DO\8?]@>\
M_P#1#T 8/[./_)O7PU_[%K3_ /TFCK^;7QA_R-NM_P#7]/\ ^C&K^DK]G,_\
M8]_#7_L6M._])HZ_FU\8?\C;K?\ U_3_ /HQJ ,BBBB@ HHHH _H<_X)W_\
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MRK#&L2R3.7=@H RS'DD]R>M6J** "BBB@ HHHH **** "BBB@ HHHH ****
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MGNSTG]H+X<^$[?X@?$I=&UO1M<O;R)O&NH%FEM7T\0D-YN0 +F7ZY'I7IO\
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MHG[5FD>%?C1\?(-<L]8U?Q'H>HZ?IVD>']+@:YN[RT%J75;:$'_GI]ID=C@
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M^.5]X>_X1C]E+X(V&F?#?1)GMUU/Q+&J7.HS+A7EFD>:)#*2OS*NXC@9&
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M@'1(M(U&ZN8,GQ#=&WBCN% &%(\Q R[>(]HSDG:/TAH *6BB@ HHHH ****
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MSX?^'6CZ3]I%MI14?:]0DE<98N&7*1HO52?GXQDUE?L:_#G6/@SH7Q9^"WQ
MND\6>$_"\T-SI<NI1":*XTJYA=]C(Y*[ T4BE",!@^.,4 ?'GB*3X>_ _P"+
M-E\2O@3J'_"6_ _Q*8])\?>&H][V=G!=-Y8AD1\9+J\K(AR4*$'"NH/U3\+?
MV%_B1^SC\0=0N/A!\5;.S^'.J3&:?POXHTZ2^BC#<-M".@9@. P*$@ -NZU[
M+XW^"?@OXH? O2O!_@K2M+TOP7X@O[#47?1;9((&M4GCNGD 0#F1(P@;KEQZ
M5[TJA5  P .* .7^&/P[TGX3^ ]&\)Z% (-+TR'RHP%"[F+%G<@#&6=F8X[L
M:ZJBB@ HHHH **** "BBN<^(CZO'X!\2MH 8ZZNF7)L HR?M'E-Y>/??MH V
M4OK::ZDMDN(GN(QEX5<%U]R.H'(K\^_VPO@3XITWXY>+?C7\+=9E\/\ Q!\)
MZ18:U.MS*%L]5L66>&6 Y.-R"SRRM@,)%Z'!KBO%G[ _B7]EW3M"^.WA+Q_K
MNN^/=&N[?4?$T>H, MY;NZ"[VG[Q4*S%ED9MRJ3U %?6G[2/P'T+]HKQUX2\
M,ZKXTO\ 1+5;=K[5O#-DP4:]81R)A'8$,%25DSCM(>,X( .-_9)_;XG_ &JO
M"/C2XTWP.;?Q/X;T^.YCTF+4XB=2F:-B4C#89%,B[0S CYER<\5Z[\$X?'/C
MB]A\>_$CPEIW@G7192Z=I^B6MW]KN+6VDD220SS !=SM#$=J@@!!DY) L>"/
MV5?A;\-_B9)X]\+^$++0O$3Z>NF>98@Q0K",#Y8@=H8A5!;&2%&:];H 6BBB
M@ HHHH **** "HY)$AC:1V"(@RS,< #U-25\[_MD?!GQ%^T%H/@WP!I^LZAH
M/A36-89?$UYI8'G?8TM9I%C)/ 1Y$1>>,E,@YP0#E?V^OB+K/PY\!>"?'FE^
M'K7QYX+T77?-\2:.RI-'-:M!+&)#D$8C=LY((#%"1@9'Q)\0]:^'?PQ\9Z%^
MT/\ LK:OMCLTCG\7^#+.&1(K*RD9%<RIC$:,Y5#'DC=ATX0D?3?[,/[/>J?L
M;_M-7GPNM=;N/$WPM\<>'[K5+2#5$5GBO+9X$E1@,(<QS?,0HW IG[O/N>L?
M#OP'XZ^ _CGP?\+M&T33+/Q!+=>';\:/9QVZ6]QO:WN'E5 /FB&]L=\+C[PH
M R_VO/#_ (_^+'P3\+WGPCF:R\73ZE:W%E>;@C6MO<V\L$TI8@A=L-PY)'(Y
M*_-BM_\ 9+_9/\,?LH_#_P#L?2/^)CX@O]LNM:[,F)KZ89Q](U+-M7)QN)))
M)->S:+I<&AZ18Z;:@K;6<"6\0ST5%"J/R J]0 4444 %%%% !1110 5E^)/$
MFF>#]!O]:UF]BT[2K"%KBYNYVVI%&HR68]@*OW$Z6L,DTC!(XU+LQZ #DFOG
M?X,MX8_:^\ S^//%&G1>(]#U'4;J+2]#U-1-:6=O!*T*%H?N-*^PR%F!(W@
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M9%9<Y6O7?V4OV9]'_99^%T7A?3;ZYU?4+F=K[5=4NG):[NF #.%)PJ\  #G
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M =!NM;\2:O9:%H]J-TU]J$ZPPH/=F(&?:OCC]I'X2^$/V]?"MAXE\*?$B_\
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M=9V]A9Q#$=O;1+'&H] H&!5RBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KY:_;,^-7QH^',/AZS^$'@J#5I[R
M[\NXU75600%UP5M(T+K\\GS8=BH)7:I9V45Z7\;/VG? ?[.^J>&[;Q]J%QH=
MEK\DD%KJC6SR6J2H5^21D!*9#@[B,8!)(Q786>K>$/C!X3G6RO=)\7^'+^(Q
MR_99X[JWF1AG&5)!XQ^E 'Y_V/\ P5$TW6-(O_!?QK\%:S\*_&EN5DM]12UE
MDMX+N(K)#*\3 3(!(%;: X*\9PV*9^TU^S+/XXL?!_[3W[.=VVD>-M0-E?-I
M^ED1KJ#3,BB1%.!ORV)488=0^X9!#?4?CSPWX8L;>S\"_%SP_'X[\+ZI*+'P
M]JUYIQOKDR%"RV<Q4-()@J.RSC 95.Y@PR_I?P7^"_AWX$^"(?"7A1+N#P_;
MSRW%I9WEP9S:^8Q9HT=OFV[BQ^8D_,>: '_#_P /^(M2\,>&[_XCKI5YXQM$
M\^6/2XF%I:SL@4^7N9B6 W+OS_$V  :[NBEH **** "BBB@ HHI* (II?)BD
MD*LX0%MJ*68X[ >M?G[\=/VQOVDOAC\7O$4^C?":WU?P%HWEK+I',VH^0>1>
ML86++'(-P#JKQJ48$[E85]*^ ?VS_A-X]\9ZWX.7Q-#H'C#1KR6QO-$U[_0Y
M_-C=D81E_DEY0_ZMFXP2!D5Z'XZ\"IXPALK^PO6TCQ'IK-+IFK0C<8F9<,DB
MY EA<<-&W!P",,JLH!\8^"_V_?@S^TQXO\.^&]8T>ZTK4?$2OX;U;PYKML72
M9)ANCVR("K!9E"C<$($S'C&*Q/A#^R;\7OV3/VLI-'^$FKVMY\(_$,)O=1CU
MDF5-/B#!0K(&#-.#D1LI^<9W<*:]UUKX0_"?]I;Q-+I7B_P1'HOQ4\,R17%[
M?Z*DD,UE+A7BFCO%1%FC?(9 X)X.4!1L?3\4?EJ,G<^ "Y !;'^?UH S=!\-
MV/AV*Y^R0(D]W,;B[N @$ES,< R.>[8  ST  '  K7HHH **** "BBB@ I*6
MO+OCQ^T5X/\ V;=$TG7/'4M[8:#J%[]@.IVUH]Q';2E&=?,6,%PK!&P54\CW
MH X7]LKXM?%+X9^ H&^%/A:'5-:N+N.";5M3DCCM+$,,J"'9=Q=ML88D(I<9
M8=OF'2_^"G#V=KJ?@#]I+X9ZSX$U"[B:UDU&PMI!$0P8"3RW(=<$ AXV?D9&
M,"OOWPKXZ\'?%SP\]SX?UO1_%FC74160V=Q'=1.C#!5P"1@C(*L/8UY5XYT/
MPW\/M)3PY\0M'@\7?"Z]D2STY]0L?[0ETV9R52T>/8SR1L<+%(H+*<*Q^ZU
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M;IF,[B#@Q?*0LAR7'/3#'ZWAACMX4BB18HT4*J(N H'   Z"G(BQJ%50H48
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M8X3:"0%  4 <%F .8_9C\,?$^W^'NEZE\:=8L]<\;.OF)#;6D42Z<C*,QED
M#RD?>8<#H.,EO:Z** "BBB@ HHHH **** "DI:* /AC]I[]BWX4_%3XN:W<>
M)-%U6W\4^*+>.\T;4O#\[)/<7,2K!-"ZE6B"HOV>3<PZ/(<X2N&^%/[*'[5?
M[/7CSPWX7\*?&"VU7P+>9DO9-0B:XCTV) FX)!-NP23M0(P!()('./MWXO\
MA/Q-XDM_#UWX.O;+2_$6FZI',E]J$/G0QVS*R7"L@(9]T;$!0P^<(2< UW=K
M"]O;Q1/,\[H@5II -SD#&XX &3[#% $.F:7#ID;B,;II2&GN&50\[A0N]R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gizttcucplmb000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000015.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MO*OV9OCU8_M+_!W2/B!IVE7&BVFHRW$2V=U(LDB>5,T1)9<#DIG\:\;\0?\
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M#X9^$]0\3^)]3AT?0M/02W5[."5C4L%!( )/) P 35;P%\3O"7Q4T4ZKX/\
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MAOBK_P $Z_%'B?X?>+/AKJ6OZ/<71F:TB$D+K.!L$UO+Y;+)&ZJ.W. <CD$
M;_P6(^&GA_P/^T%H.KZ'80:=<>(=*-UJ$=NH19)TE9/-*@?>9<9/?;GK7VI_
MP5(_Y,+N_P#KYTK_ -&)7YE?MU>,OBE\4/B1H_CGXF^'F\(KKNG^9H6A2,=]
MI8)(RJ&4@-N9BS%F"ENNT+M%?KK^VU\&];^.G[&VL^&?#<!N]=%K9W]I:KC,
M[0LCF,<_>90P'N10!SW_  2C=6_8C\' $$K=ZB&'I_IDI_D1^=?#WQ(/_&Y#
M3/\ L;=,_P#14-3_ +%O[;7C[]F'X?WGPKO?@]X@\6ZA'?2RZ5;V\4MO/%+(
M1N@DC\EF(WAFR!GYB,=,<GX0\"?%)?\ @I)X0UOQ_P"&Y[37K[Q-8:IJ7V&W
M=[6U,RQRB+S!E?W:LJGYB 5/- $G_!33QI-X@_;R33]=L[K6M"T!--M(M(M2
M=\T+*LTL:#GYY&D89QS\H[5Z]^T/^V3HOQR^ NK?#A?V;?%NFQ?8_+T63^S\
M1:9.BXADC58_E"G@A<94L.AKIO\ @I_^R?XVD^)NB?'GX::;=:K?V*VPU2TT
M^)I;F*:!\PW2HOS.NW8C;<D! 3QDCF?'G_!5#XJ_$#X9VOACP5\+M9\/_$B[
M,,,VK6L+W*1N&4L;> Q$YDP1M?.T,?O'F@#U[_@D=<>*-/\ V=/&OAOQ'IFH
MZ;'I>JR26*:C;/"?*F@4LJA@,J'5C]7-?)7_  2A^'>A^.OVMM:N];TV#4_[
M"T^XU&SCN461([@3QHLFTC[RAR0>QP>HK]1OV7[3XLI\"8[GXS7\=[XUOEDN
M&MHX8D-G"4 2%Q&H!<8);KRV.U?GO_P2&\(Z[H/[37CJYU/1=0TZWDT.=4EN
M[22)6;[7"0 64<X![]J .Q_X+=>%-)CT?X8^)([&&/6I+B[L)+Q% >2 )&ZH
MQZL%;)&>FYO4U?\ VOO&&I6/_!)OX4QI/,[:Q8:#974G4O&+7S/F/H6B3GUQ
M6S_P6D\.ZMXB\ ?#./2M+O-3>+4[MI%L[=YB@,2 $A0<"O3=4_9MO?VC/^":
MW@/P'&W]F>(HO#.EW=B+Q60)=PP(1'(.J[@60YZ;LX.* (?^"2OP[\/Z'^R-
MH_B*UTVW&L^(KJ]?4+QHP995CN9(4C+$9V!8Q\O3+,>]>G^ OV"OA%\-/C--
M\3O#^E7UCXE:ZFNHECO&2U@:4,'5(5 780S?*<@9K\Z?V;_VQOB[^PAX=U+X
M7^+/A'J6O6MI=R2V5O<22V3VKNQ+[7$,BRQLV6&WN20Q!KU?]A7P[^T#\>OV
ME=0^,'C'4O$GA+P(UQ)>R:6UW<6MG?R%-D5O';E@'B0;27*D'8.I)P <3_P5
M"\&WG[//[6G@;XV>&X/*;4Y(;V3&0C7UHR!@3V#Q>4" .S'O71?\%;_CU%\2
M/!OP@\&^%I9+RV\2PQ^)OLT )DF61?*M4*CDDEY?EQU ]*^N?^"DWP6B^,W[
M*/BE([8S:MX<7^WK!E^\&A5O, ]=T32#'KCN!7YC?\$X?A[K'[0O[5W@ZYUJ
M:74=&\#6*WK-,"4AAMSMM85XP/WKJP'HKGM0!^R7[-?PFC^!OP+\%^"%5!/I
M.G1QW1CY5KAOGF8'N#(SUZ;110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 )CG-+110 4UE#J0R@CT(S3J* (TA2+.Q
M53/7:,5)110 E+110 F!0!BEHH *8L**Q(503U(%/HH JWD3M;RM;K']KV$1
M-(.-V.,GKC-?%_[$/[#/BKX _%KQY\2/B#KFEZ]XDU_>MO)IID;9YLQEN)'+
MHN"S;,8'9J^VJ* "OSZU[]C_ .)=_P#\%/HOC1#IEHW@$75O.;TWT8E 32TM
MF'E9WY\Q2.G3FOT%HH C6)(V)5 ">I J2BB@ HHHH *2EHH 2EHHH 3%&*6B
M@!I4'@\TV.".+)2-4)Z[0!4E% "8IDD$<A!=%8CH6&:DHH _+K_@K%^SC\3?
MC5\6/!NH>!O!>J>)K*ST9H)Y[&(,L<AG9@I)/7!%?IIX?B>'0M-CD4QR);1J
MRL,$$* 0?>M&B@"/R(_,W[%W_P![ S4E%% !42V\2-O6-0W]X*,U+10 FT44
MM% !28I:* (I+>.7&^-7QTW+FGJNW@=/2G44 ?EW^V[^T)^T]KGB[X@?!SPQ
M\,[J[\)7LOV"VU[1_#U])-=6LJ*2HFW-$<ARC,%'1NE>\_\ !,_]D75_V8?A
M;JE]XNACMO&?B69)KFT0JQLK= 1'"S D%LL['!Q\P';-?9=% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.Z?>50L561&P,KD%2"H*L,>A(!]*T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX9_Z=+2@#Z;\/_\ (!TW_KVB_P#0!6A6?X?_ .0#IO\ U[1?^@"M"@ HHHH
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M5X<MM.N@\1%U*/N.Y^:- )5@0<$<@]ZGU#3KK2+R6TOK6:RNX6*R07$;)(C
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M\(_^AVLO^_,W_P 11_PUO\(_^AVLO^_4W_Q%>O;1Z4;1Z5Q\U#^1_P#@2_\
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M3RS' Y)).*Z$4GM1UKCE)R?-)W;-4DE9#J***0PHHHH **** "BBB@ HHHH
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M,]Z]-HZTM14JSK2YZDKLJ,8Q5HH6BBBLR@HHHH **** "BBB@ HHHH ****
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MFH:'IUU-CSI[:.5]HP-S*"<?B:T*R?"?_(JZ-_UY0_\ HM:UJ "OE3_@J/\
M\F*?$S_N&?\ ITM*ZKQM^WK\!OAOXLU3PQXC^(5MIFNZ7.;>\LWL+MS%(.JE
MEA*GKV.*^8?V^_VX/@A\8/V2O'?A'P?X\M]:\1:C]@^RV,=C=1F3R[^WE?YG
MB51A$=N2.E 'Z'^'_P#D Z;_ ->T7_H K0K/\/\ _(!TW_KVB_\ 0!6A0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)0T\C1#<43.(R@^Z.G>O5*** "OE3_@J/_R8I\3/^X9_Z=+2OJNOE3_@J/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFFSM-;Q29/".0"PQCD@4 =#1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!XW^T1^S7\+OCYI^GWOQ.T];JQT)99(KB6^>UC@5PI=F96 Q\HY->)
M^#?^"=/[*GQ$\.VVO>&O#ZZYHMT6$%_9ZQ<20R[6*L58/@C<IYJM^W1;W/QB
M^.GP-^ D]_<Z?X6\6W5YJ>N"UDV-=0VD1E$!((.#L;\=IP<"OK/X=_#GPU\)
MO!^G>%O"6D6^B:#IZ;+>SM@=JY.68DG+,Q))8DDDDDY- 'QA)^Q=^QC!\5)_
MAM<6MO:>-XH(KC^Q[C6+F*61) 2FPL^UVP,[5)8 @D $5]F?#/X<:!\(_ ^D
M^$/"]HUAH.EQM%:V[2-(44NSD;F))^9CU/>O"OVU/V3? _QG^'/B/Q1)I<.D
M>/M&T^6_T[Q/IZ^3>1RP(9$#NN#(HVXPQXS\I!YKL/V,/BIJOQH_9C\ ^+=<
M;S=:O+'RKR;C]]+$[1-(>G+[-Q X!8T >W4444 %%%% !1110 445\X_'+]O
M_P""O[/OB27P[XE\2R7/B" *9]-TBV:ZEM\C($A'RHV#G:6W8(..10!]'45Y
MA\#?VD?AW^TAH=QJG@'Q'#K,=JX2ZMBC0W%NQZ;XG 8 X.&Q@X."<&O3Z "O
ME3_@J/\ \F*?$S_N&?\ ITM*^JZ^5/\ @J/_ ,F*?$S_ +AG_ITM* /IOP__
M ,@'3?\ KVB_] %:%9_A_P#Y .F_]>T7_H K0H **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\%1_^3%/B9_W#/\ TZ6E 'TWX?\ ^0#IO_7M%_Z *T*S_#__ " =-_Z]HO\
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MCJ'V'RI]5\.W%K;+LO[>5M\K#:N0A SU) [U^D]?*G_!4?\ Y,4^)G_<,_\
M3I:4 ?3?A_\ Y .F_P#7M%_Z *T*S_#_ /R =-_Z]HO_ $ 5H4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4UE#=1FG44 )M].**6B@ KY4_X
M*C_\F*?$S_N&?^G2TKZKKY4_X*C_ /)BGQ,_[AG_ *=+2@#Z;\/_ /(!TW_K
MVB_] %:%9_A__D Z;_U[1?\ H K0H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ J&:>.WA>65UBB12S.YP% Y))/05-7PI_P %#OCKK^N:EH?[
M.'PQ=+CQ[XW*PZC+&Y_T"Q;.0Q7)0NJLS'!Q&K''S T ?3WP?_:0^&_Q^N-<
MA^'_ (H@\2MHLBQ7S6]O,B1LQ8+M9T57!V-AD)''7FO3:_+#_@AW_P >OQ8_
MW]/_ )3U^I] !7RI_P %1_\ DQ3XF?\ <,_].EI7U77RI_P5'_Y,4^)G_<,_
M].EI0!]-^'_^0#IO_7M%_P"@"M"L_P /_P#(!TW_ *]HO_0!6A0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ''_%SQI-\-_A9XP\5VUHM_<:'I
M%UJ,=J[%5E:*%I A(S@$KCIWK\2OV9_V[7^!OQ*\;?$?Q/\ #F3X@^/O$\S,
M^L2:K]B%K$Q#/'&GV>3&XA>0P^55&..?WD[T4 ?AY_P2S_:>?X+?%)O!"^%V
MUL>.M2L;$Z@+[R/L&TNN_9Y3>9G?TW+TZU^XE?*7[#'[#TO[&L7BU)?&*>+?
M[>:W(*::;/R?*\S_ *:R;L[_ &QCO7U;0!\]^-_V>/BAXF\7:KJFD?M"^)?#
M.FW<[2P:1::39RQ6BGI&K.I8@>YKYA_;Y^ OQ)\%?LE^.]9U_P"//B+QII-M
M]A\_0[[2K2&&YW7]NB[GC4,-K,KC!Y* =*_2*OE3_@J/_P F*?$S_N&?^G2T
MH ^F_#__ " =-_Z]HO\ T 5H5G^'_P#D Z;_ ->T7_H K0H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_?\ 'S?/GD?4%%^#NCI-XXD&H:YGQ>N+Y?[6GQ;_ +KR\VWS?N#@Y^3'/Y4
M=Y^%)NK@H_@WH\</@6(:CKQ7P?C["3J\^;C$1B_TH[OW_!S\^>?;(J=/A+HZ
MWGC2Y^V:R9/%B+'? ZK.5A B,8^S+NQ <$G*8.<'L, ';BDW5P4/P:T>'3O
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M?7<ZZW<"X@>0@E;>7=NB0%1A%.,9'(.*U;CX7Z7<^,/#7B1[W6!>Z!:2V5K
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MD&O#_B)XJ^#O[%'P_P!;\6_V%H/@VUF )L=#L8+2;4IE!V1(B!=[<GGH,DG
MS0!X%^Q7^W5XW^(7QDU;X*?&C0;30?B#8QRM;SVJB,3R1 -)"Z!F7?L+2!D.
MTJC>V?O"OR[_ .">_P .O$_[1'[4WBO]J#Q1H[Z/H\CW(T2-P0)9I8_(RAXW
M)' 60MC!9^.0<?J)0 5\J?\ !4?_ ),4^)G_ '#/_3I:5O>//^"AG[/_ ,,O
M&6K^%?$OC_\ LW7=)G:VO+3^QM0E\J08RN^.W93UZ@D5\Q?MY_MZ? KXT?LG
M^.?!O@WQS_;/B34OL/V6R_LB_@\SR[^WE?YY8%082-SRPSC YP* /T:\/_\
M(!TW_KVB_P#0!6A6?X?_ .0#IO\ U[1?^@"M"@ HHHH **** "BBB@ HHHH
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MA)H1T;P9X<T[PUIC/YC6^GP+$';&-S$#+''<YZ45UM% !1110 4444 %%%%
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MZ;\/_P#(!TW_ *]HO_0!6A6?X?\ ^0#IO_7M%_Z *T* "BBB@ HHHH ****
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MX_:(^$.O?#W6])^%VGZ7K'V?SKFRU*\\Y/*N(YUV[HB.6B4<CH30!]P^'_\
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M^A=^$G_@ROO_ (W0!]645\I_VQ^V;_T+OPD_\&5]_P#&Z/[8_;-_Z%WX2?\
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M,K[_ .-T?VQ^V;_T+OPD_P#!E??_ !N@#ZLHKY3_ +8_;-_Z%WX2?^#*^_\
MC=']L?MF_P#0N_"3_P &5]_\;H ^K**^4_[8_;-_Z%WX2?\ @ROO_C=']L?M
MF_\ 0N_"3_P97W_QN@#ZLHKY3_MC]LW_ *%WX2?^#*^_^-T?VQ^V;_T+OPD_
M\&5]_P#&Z /JRBOE/^V/VS?^A=^$G_@ROO\ XW1_;'[9O_0N_"3_ ,&5]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_\ :2^#MW\>
M/@WXA\%6'B2^\*W6I0[$O[%MIR#GRY.[1-]U@""0:]$M]6LKNZDMX+RWFN(_
MOPQRJS+CU .15L]* /YSH?A+XW_9^^.S>!/%/BRZ^$>KLX5-;2686KY)\F4O
M"=WDL?XP#MR<@8;'V'KGPY_;P^'NAS6$M]:_%[P9>6Q-Q:--;:O:7T+C[A69
M4N",88;,=L&O=/VB/%WP&_;H^*-_\ Y+R0>-M-MI)=%\7V,2RPQ7BY:6U#CE
ME"J"P^Z<-A@R@GR;]CO]H7XE?LA_&NR_9N^+NF7VI:5<W2VNA7L"/<O;JQ(C
M>(C)DM7QGIF/G( !4 'R]^S?J'[0?[,7[0%BWAOX>ZY8:AK-W]FF\+W5E<0V
M5^C$D1;G[("2LFXE<$DD;L_O3IDUS<:=:RWENMI>/$K36ZOO$;D LH; S@\9
MQSBK8Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !15:^O(--LYKNZF2WM8(VEEFD8*J*H)
M9B3T  //M7YP_%;_ (*X7\WC34M#^"WPYG\>66G,5EU>9)W24 X+I%$NX1D[
M@&8C. <4 ?I-7YS?M]?\$^+W6M4?XQ?!6"32/'&GN+R]TG2\0M=NAW?:;?!&
MV<=2H^_CCYOO?7?[*OQ>\3?';X*:'XW\4>%D\(WNJAI8;!)FDWP!L)-\R@J'
M W '/!!SS7KQH _";]B>U\/_ +3W[9U^OQKL['6I]=TVX6:WOV:W-Q?(L2*0
M RD2D(YPI'.[ '0?:OQ(_P"",GPF\23RW/A/Q!K_ (/D?&VU:1+ZU7UP) ).
M?>0TS]O+_@G ?B9J$WQ.^$,7]D_$2*9;FYTRUD6V34) X/GQOD"*X!^;=D!L
M9X/)^TO@UH?BWPS\+O#6E^.]:@\1>+;6S2+4=3MHC&D\@[XSR0, MQN()P,X
M !YK^R!^Q[X6_9&\$3Z7I$KZOKVH-YFIZW.@5[@@_*BKG"1J.B^N22:^@***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!J?"3R=2\-ZA)+9ZYXGTFX$\EA$"8RJ;#\H+!D:3/RD8X)R/./^";?Q ^
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !117CW[4G[2GA_]E?X6S^,M?M+K40TZ6=I8
MV:_-<3ODA2Q^5% 5B2>P.,G (!\ _L _V3\2/^"A'QGU_P :F._\8VES?2Z5
M%>*&,3+=&)R@(X:.((B]PI/IQ^KO'XU^3?[7/P'\5Z)XRT3]K7]GBXN+NRU>
M*/6;V'2D+S6[NF7F,8SOBD!(D7'!W9')QW/@?_@M7X//@V,^,/!&M0^*XHML
ML6DF)[2:0#[P9W#1@GL5;'J: /8-#_;FUW4/V\I_@-J_A2UT+28X[BWBNI)F
MFN+J80K<02J1A5C:$,=N"?G&3Q@N_9[_ &"9_@7^UMX]^*&G^(VM?"VJ"4:=
MH5L!EQ<%9)4FXP(XY =@49("DG@AO$OV&OAGXY_:6_:HUW]J+QYI3:#I)+KH
M5E*K R$P^1'Y88?ZN.$$%^-SMD#[U?IQ0 4444 %%%% !1110 4444 %%%%
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MSQA+:S>?9V&N20O;QRY!$CA(U,K*1D;CCG)!K[7%+10 4444 %%%% !1110
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MA_\ %+XB^$?AYI>R\3PO?.VL^(+-5D\H/M5[:(C[Q0*2PR!N"CJ#CZ8\'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTM4DUC[(@^T7,MNX:W,9(P&8$H[-GY8UP,U]?KZTZB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gizttcucplmb000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000013.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M@/XO>/O"NE6WP@\>V?@/6(+LR7EQ=VPE%Q"4(" E'VD-@_=Y]1W /:Z*_/\
M_P"&;OVXO^CBM%_\ D_^1J/^&;OVXO\ HXK1?_ )/_D:@#] **_/_P#X9N_;
MB_Z.*T7_ , D_P#D:C_AF[]N+_HXK1?_  "3_P"1J /T HK\_P#_ (9N_;B_
MZ.*T7_P"3_Y&H_X9N_;B_P"CBM%_\ D_^1J /T HK\__ /AF[]N+_HXK1?\
MP"3_ .1J^V?AKI'B+0? .@:=XMUB+Q#XEMK..+4=4AA$274P7#.$QQD_3\*
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MF^8!U89^M+U&*\$\4?L@^'O%GB34M9N=?UV.XOIVG=%GC*J6.2JY0G:.@R>
M *RJ2G%>[&YR8BI7II.A#F?K8]Z\Q/[R_G1YB?WE_.OG'_AB'PQ_T,>N_P#?
MV+_XW1_PQ#X8_P"ACUW_ +^Q?_&ZP]I7_P"??X_\ \_ZUC_^@=?^!_\  /H[
MS$_O+^='F)_>7\Z^<?\ AB'PQ_T,>N_]_8O_ (W1_P ,0^&/^ACUW_O[%_\
M&Z/:5_\ GW^/_ #ZUC_^@=?^!_\  /H[S$_O+^='F)_>7\Z^<?\ AB'PQ_T,
M>N_]_8O_ (W1_P ,0^&/^ACUW_O[%_\ &Z/:5_\ GW^/_ #ZUC_^@=?^!_\
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M44 -V^M.HHH 2DVTZB@ HHHH 2C%+10 F*6BB@ HHHH **** "BBB@ HHHH
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M/_\ PE['_P"-5ZM10!3TO2[/0]-M=/TZTAL-/M8U@M[2UB$<4,:@!415 "J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% "<T45Y9\>O&7Q'\&Z'IUQ\.?
M!]MXOOI;@I=0W$_E^3'M)# ;ESD\=>/3TJG!U)*"Z_(3=CU/'M1CVKX__P"%
M[?M1_P#1$]/_ / K_P"VT?\ "]OVH_\ HB>G_P#@5_\ ;:]'^SZG\T?_  )?
MYD<Z/L#'M1CVKX__ .%[?M1_]$3T_P#\"O\ [;1_PO;]J/\ Z(GI_P#X%?\
MVVC^SZG\T?\ P)?YASH^P,>U'X5\?_\ "]OVH_\ HB>G_P#@5_\ ;:/^%[?M
M1_\ 1$]._P# K_[;1_9]7^:/_@2_S#G1]@?A25\?_P#"]OVHO^B):=_X%?\
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M!G7R5C9A\JHJ$'_:]J /7OB%\+_"/Q7TJ#2_&7AK3/%&G03"XBM=5M4GC20
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MC_AN+X.?]#1-_P""RZ_^-UO]3Q'_ #[?W&WU6O\ R/[CWFBO!O\ AN+X.?\
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M^#W@'4#8>(+F%)-<UBWFVRV44@#);H1]UW4AF;J%9<?>R*O[$_Q"_92_9/\
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M25]<U\C?\$__ /D._M,_]E=UW_T)*^N: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^1O^"?\ _P AW]IG_LKNN_\ H25]
M<U\C?\$__P#D._M,_P#97==_]"2OKF@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG?*41BH[@D]L@'[!K2U!9JRVD*O]]44-]<<U/0 4444 %%%% !1110 4444
M%%%% 'R-_P $_P#_ )#O[3/_ &5W7?\ T)*^N:^1O^"?_P#R'?VF?^RNZ[_Z
M$E?7- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2Z'P)I7@'PW=W_A2TCDG*;E=,$M@'N![U\8^(OBY\19M<OEN7GMG\YL*H;
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MQPGA_6[*%#.<+)"&'3ZM7R[\*/AO>?%;7GTR&YAMF2-6S.Q .2>!^7ZU]3?
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MZ[_Z$E?7-?(W_!/_ /Y#O[3/_97==_\ 0DKZYH ****0!143.=Q &/?M7/\
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M1> [2WN[P,OVCD,&(QNZ5X%9Z,MKJ4%S,HE@CD#&(YP0#G!YZ&OM?Q=^R?\
M#J&PU._T_7MDX5I8H0Z;>F<8KY#5HXY7#?O(D?;QWP:_4LNQE&I"2PSNC[E8
M7 XU*I2MH?1WPY_:M\)^%-9T\1>"[:P+;87NX0=W7KTK[HT/7;77M'M-2MG
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M#;0,D<X_.O3QD<(HI8MOY%YI4J2IQ<-CT1/^"A/PWV_+(S>N&_\ K5TG@/\
M;6^&OCJ^EM!K-MIDBC(^U3*N[!'3./6OF/Q/^R[\$O"?VBW'B:[N;J(D%%9>
MQP1TKQ77O@WX3UB2-?"-SJ"W@?##'.W/)Z?2OF\5B,CI0:C-W/SW$9Q2PLG"
M;YGY'ZCP_''P'=MY</B?3Y92,!5N$_QKSWXU?'KPY%X;O]+M[^&>6X@9 8Y
M>HKY,^'O[*WB;4KRW4"Z@3;\LTF?3J>>M=KXT_8_\4>']-?5VU3S8+9/,9'
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MFNID!\LG.#_]>O@9+EDTNA\S-*#:/'_VGKCQ!#\,-2'A:6&+5G7"O(%8C@]
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MW0US4=0BU;6Y%WI,Y&(]P! '';^M>H?&K4_AZWAF>'Q?>VWV3RV;;N4L<#G
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MKZ T7]K;QIX2U07%QK[7R%@AMY')Z]^O6OGN&WC\(?&;XLZ%$Q6SM/&.JV<
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MQ/'F1IOE4,  <DGCDGK7ITZ:I148GU5"E&A!4X;(^T,!5#8P#2, W(8BO/\
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M<E,XSM;/L/SK])59UC3 &<9.0<U\3FM6M1KJ,I)I:HVJ8ZIC8J,E:Q^7\/\
MP3[^(>D7$\,,D,T88[9-ZY8=B>:DN/V#?B-<1E,0_BZ_XU^GYW!L\8/4TOTQ
M^1K5<1XQ)6M]QY;PM-N[6I\C?L=?LEZU\$=4O];UC46-Q<1^6+6-\H,LISCU
MXKZZ12H]OKDTPY9L!,D<YSQ3DW?Q'GZ<5\_B<34Q=1U:F[.J,5!61(I^<5-4
M,?WA4U<RW&PHHHJQ!1110 4444 %%%% !1110 4444 %(WW32TE)@0,IS36B
MW=35@8'7K2\5/D!2^R^E.^SGN<_B:M$#TJ)F+'.*'H!$L(]Z>D/7!YI5'7CK
M4D9JM!^@+&5;/%/%+11804444P"BBB@ HHHH **** "BBB@ HHHH *HQ:Q83
MZC+81WUM)?QC>]JLJF5!QR5SD#D=NXKR#]K74OB_X?\ A3-K/P76SO?%-A.L
MDNDW=F+DWL!^5EC^88=20WN%8=<5^1W@3XJ_M-:?^V!XR\2:#X/^T_&.[TQH
MM8TC^RP_DVV;?+^3N^7E(.<_Q>] '[K7=Y!I]O)<7,\=O;QC<\LSA54>I)X%
M-L-0M=4M8[JRN8;NUE&Z.>!PZ./4,#@_A7Y(?$;XD?MW_%_P/K7@K6_A?+_9
M.N6[65UY6B+$WEOP0':3"_[QZ5^A/[%OPK\0?!7]F?P/X/\ %"QQZ[I]M(;F
M&*7S%A9Y7D$>X<$J& ..,@XH ]PHHHH I:MIT>KZ7>6,K,D5U"\#,F-P5E*D
MC/&<&O%?V4_V0?"G[(NA:]I7A35=9U6#6;F.ZG?69(G9612H"^7&G&#W!KW>
MB@#P7]J3]C/X?_M9:;81^+(KRQU?359;'6=,D"7$*L060@@JZDC.&!QSC&37
M ?LW_P#!-7X:_L[>.H?&<>H:QXN\36N?L=WK,J;+4E2I9$10"VTD98G'8 \U
M]<T4 >1?M(?LP^!OVI?!D7AWQK9S,MM(9K+4+*017-G(5*ED;!&".JL"IP,C
M@8\&^"/_  2I^%WPA\>Z=XMO-8U[QCJ&ERK-80:O+&(()$.4<JBC<5." 3C(
MZ5]K44 -6G444 ,()8'M2X[=J=10!^-'CKP3]JM?C/XSC #Z1\9?$-I*WJDK
MPL/P!1OSK/\ "6K1V,V'8*DWS*<@=>WZUZE?:0^M?!?]J&W1_+(^->L/GZ$<
M5X]:Z;#);01^8#)"!@]^!BOJ<'A8X_ 3H5-GL=TL LUP-3!R6^QZ1K*"[TMD
M$NPM_%Q7%P^(=)\%D'[8U_<EMJI&P+9SQQ^'I3;S4=0N[)[;S/*'3>.3Z57^
M&_A?1/"_C73-6U:/^T;.&</+&PX/.23S7A8+A+DC+ZU/3HEU/S*CX?XI3<:L
M]/(ZCP;X^A\6:[(-6@N,1+E8I%*D8'';N!7=?%CXG:'K7P_M-%L-)-O=Q.!Y
MQZGYE_P-=7\?_B]\-9/#"2>%='AMM5FAV&9< *< #/'I7@A\-ZW'HUMK-_&S
M6-Q\T<I4A3ST!_$5649%/#8SZS)\L5LC[#)>%ZV78SVK?NKON<AXF\,WFL>1
M/9W\FGW<7W)$.#US7,ZYHOC/Q%9?V?K/BR:_L\Y\@X]Q_(FM7XH^,KOPC8)-
M9H/./"[CQR?3'2ONW]B[]FG1_$'@.+Q/XLACU"[O1E8V4;5Q@YZU]=C,5AZ$
MU[6-Y'W>,EA*<[5%=GQC#)9Z)X'TS1-3M8H8%4%+@J0[\=SGWJA:^-M*\%W$
M4]AJ?V"Y8[5*R =>.A-?K=K'[.?P_P!?M;6"[T2W,5O_ *M=HZ8Q_2O$_BQ_
MP3:^&WQ*O/MD<DVCNJDJ+= 1D\Y//8UQ?V['E<5$\J6(PZ:G3AJCX;U[QY'J
M$MN=6UB/4YW4,C;U) QG!Y],U8MI8[RW$B-\G;!S5/XA?L1CX=>)K^V3QQ X
MB9FAC9 6V\X4_.><54\+V=SINFBVER[QN5\SL1GK7NX/$+$45)QL=N'=:K4=
M1QL<U\0?$EW&OG2KBTA!'F*,#IT)KZI_X)G_  GMO'+:OX[U)4N+>"98((I
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M %,\OWI]% #/+]Z55VTZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0]*^ OVM/^"C_AC]FGXR7OA;PG\.;?Q;XR@A4:KJAD6U\LNJLL6]8V>0@;"V
M< <#D]/J;XY?M0?#G]G%=)_X3_73HHU7S/LA%M+-YFS;N^XIQC<.M?G?X1_:
MT^!?PI_;N\8?$R'7/^$B\*>-=,4?VA#I\IGT>\#1[U9'4$QN$SN3D9P1@9H
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M]?(^9\ML]#T']KCP-!\*OB-+<2&\U![YO-,S+\HW%L+U[8KQI/&5OY 86\H
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MX4N/!L]RS:A$S,JRN>[$X''?/K7HG_!4KXUV?@?X,W'A6.X:#6-:A<0^4Y#
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MY06;.#\V\*?3U)K]*_\ @FG^Q[=?"O1&\8^(HH9K^\"2V@PP,:X;GD>];?\
MP4P_9U;XA>!3XPT>-?[8TM#,SJI)^0 @CGV]*C_X)G_M*#XB>"9/!NLW,G]N
M:.PA59F&6&&. /PI@?<YPJL1DG=@Y_I4\'S+FJI5=V<]>?\ ZU685"]#2Z@3
M4444P"BBB@ HHHH *J3+N9!GOT_K5NHV_P!9C';K0!^>O_!5#X"Q>(O!MO\
M$#37CM=0TIE:23!W/MR!^6!^5=M_P31^/-S\5/A/%I%ZC&XTM%C:5B,$ G^E
M?3WQ<^'EE\3/ .K>'[V)9!=6SQJ&'&XJ<'\#BOR:^ /B[4_V-?VL+GPIK,KI
MH6H7RQ +E5VL<9Y[<C\J /V81 K9[=<U-6=H^K6VMZ=:WEJZRV\\8D1AR.15
MZ+.WGUI("2BBBF 4444 %-;I3J:YVJ30!3G1'9UD(V,NT@^]?D/^WU\'=0^
M'QNT[XEZ%&T=E),TDIB4YRY).>/ZU^O&-\F6KR?]ISX,Z?\ &SX7ZMHUW'NN
M%3S(6 SR#P,9]Z2 D_9H^,FG?'#X6Z3KUM,'GDB59D# E6 Q@\UZG'M1W'7O
M7Y$?\$^/C1J'[/?QJU'X6^)F\K3KAVBC>1MO[S<-HP1W&>]?KNLR^4DB\Y&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4J+_ &9X=\12VEG'M4+E(U&!G&3ZDFN1_P"& $_Z+Q\9?_"OFKZPHH ^,/\
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MW6L;1=;M/%.DVFI6$RRVERHDB>,@AAC-;42[5I=0)**13FEI@%%%% !1110
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MZ5\:?\$N]4^V?LY6,3WRSW$94%7D#,%PV!C/TK[*AZT,"5?NBG444P"BBB@
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M73[K.@)'T-3T4 %%%% !1110!\C?\$__ /D._M,_]E=UW_T)*^N:^1O^"?\
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M/6IZI$A1113 **** "BBB@ HHHH **** (>.YQ0Q7INYI&J"1MK9')X'-+H
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M% !1110 4444 ?(W_!/_ /Y#O[3/_97==_\ 0DKZYKY&_P""?_\ R'?VF?\
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M]3LW;O5>3YL#&1G/)K)X.B_LGI1XCS.+3=9Z'Y=']E/QS<>*Y+6VTLP:9YI
MD.2=N2!7<S?\$\]<AFN=3?59)8!"3':[USNQP,;?ZU^A1VJI(5?3Y<9I!(VT
MCD]LXXKGCEU&-W8]W$\;9I74(\UE$_//X!_#GXL_"7QXC+I^=*>3:X8$C:2!
MGKZ"OT*TZ:22SBDF79(RY;@CGOQ3HX\@L45O0]*GAC.WE<#V.<UUT*"HJT3Y
MG-,TJ9M4]M57O K L/K5I/NU"(PO-31_=KJT/$'4444 %%%% !1110 4444
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M&1R*Y;Q-\4_!G@O5++3/$'B_0="U.^;;:V>I:E#;S7!]$1V!8\]A7P_^PO\
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MCRWS(V#AAP:^GO\ ALKX%?\ 17?!O_@Y@_\ BJ /9**\;_X;*^!7_17?!O\
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M7?!O_@Y@_P#BJ/\ ALKX%?\ 17?!O_@Y@_\ BJ /9**\;_X;*^!7_17?!O\
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M7?!O_@Y@_P#BJ/\ ALKX%?\ 17?!O_@Y@_\ BJ /9**\;_X;*^!7_17?!O\
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M,_"G_@G@_P#B:YS]FKX$ZK\$=0^+-QJ>HV>H+XQ\;ZCXHM5M-X,$%P5*QON
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MUQW[%?P[\0_"_P""\NB>)]-?2M4.O:K=BW>17/E37DDD;Y4D?,C ]>_->^4
M>:?\,R_"3_HF?A3_ ,$\'_Q-'_#,OPD_Z)GX4_\ !/!_\37I=% 'FG_#,OPD
M_P"B9^%/_!/!_P#$T?\ #,OPD_Z)GX4_\$\'_P 37I=% 'FG_#,OPD_Z)GX4
M_P#!/!_\31_PS+\)/^B9^%/_  3P?_$UZ710!YI_PS+\)/\ HF?A3_P3P?\
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M!Z9J-L]GJ%GH5C;7%O*,-%(ENBLC#U!!'X4 9?\ PS+\)/\ HF?A3_P3P?\
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M_P!$S\*?^">#_P")H_X9E^$G_1,_"G_@G@_^)KTNB@#S3_AF7X2?]$S\*?\
M@G@_^)H_X9E^$G_1,_"G_@G@_P#B:]+HH \T_P"&9?A)_P!$S\*?^">#_P")
MH_X9E^$G_1,_"G_@G@_^)KTNB@#YU_: _9V^%NE_ ?XCWME\._#%K>6WAK4I
MH;B'2H$>*1;60JRL%R"" 01Z5<_8'_Y,Y^$W_8$C_P#0FKTSXQ>&;[QI\(O'
M'A_3%1]1U;0[ZPMED8*IEEMW1 6[#<PYKF?V5?AWK/PD_9W\!>#O$,<,.MZ/
MIJ6MVD$@D0."Q(5AP1S0!ZQ1110 4444 %%%% !1110 4444 %%%% !1110
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MI&#/!(K%)(V(X)5U89]J /0:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BOFG]NK]KD_LD_#.QU+3M+BUKQ5K=RUEI-E<%A%O"Y>5PO+*N5^4$$E@,CK
M7R)KO[:O[6_[--QX:\8?&;P;I-UX#UZ90;2"*&*:W!4MY2M%(6BDVC>!*&SR
M,@YV@'ZH9HKQ/XX?M2>'?@W^S@WQ<,3:IIUU8VUUI=HKA6NWN%5H5SG@$,&)
M&<*K$9X%? I_;D_:]\/^ ]-^.6K^%=!F^%%Y<K&-/%JD8\HR;0Z_.9U#$%5D
M8LN<':01D _6>BN&^"?Q8T?XY_"OPWXZT(L--UJU6X2)V!>%\E9(F(XW(ZLI
M]U-=S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%?F1^V!_P %*/$_
MAC]I#1?AS\+-1M;;3=-U"&QUO49+:*Y^U3O(JO#'O!VK&,@L.2Q(Z*,_:G[5
M?[1FE?LN_!C5O'&I6W]H7$3):V&GAPINKJ0X1,]@ &9B.BHV.: /8Z*_)A_V
MYOVNO!/@?0_C9XG\,:!<_"O5[F-%L4M4B B9L!E(D,R;P&".Y9<X.,$9_37X
M0_%#1_C5\,_#?C?078Z5K=FEW$DF-\1(^>)\9&]&#*<'&5- '94444 %%%%
M!1110 4444 %%%% !1110 4444 )17RG_P %%/VJ_$'[*/PBT36_"<.GW'B#
M5=82QCCU.)I8A"(I'D?:K*2050=?XJ^<K;]I/]OZ\M8KB'X.Z.\,J*Z-_9I&
M5(R#S=9Y% 'Z=45\P_MK?M@?\,E?!G3-:_L^+4O&>M$6NFZ?<9$2RB/=)+*
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MX4T36;1K+7M0,NKZA;R1['BEG;*HXZAEC$:G/(*D4 ?2M%%% !1110 4444
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MG4/V0OL\\A>*Q\0WMO;J?X(RL4A _P"!R.?^!5]Q5\\?L#_!/4/@'^RYX/\
M#6L1>1KLRR:GJ$6S:8YIW+^6P_O(A1#[H:^AZ "BBB@ HHHH **** "BBB@
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MT9KXD_X)D?MC^*?VH/"/B?1_&Z17/B7PRUN6U:")8A>0S"0*710%$BF)LE0
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MC3_%-X=2UWPKI\NG_;I6+37%LZ*\+2'NX^=,]PBD\Y)P/^"=O[$WA/\ :8^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 FT4M%% #=M?%/[;/PI_:A^,>
MKZGX0^&^M:#I_P ,=:LDM[S[5*D-R<JRS1.^QG\MQCA>3D@\$BOMBB@#P7]C
M#]E^U_9/^#-KX2^V1:IK=Q.][JNHP(52:X; PH/.Q%"J,X)P3@9Q7O.*6B@
MI*6B@#P7]MSX(>(/VBOV<?$G@3PO-8P:UJ,UH\,FI2M% !%<QRMN958CA#C"
MGG%;7[)?PGUKX'_L\^#? _B"2TFUC1[5H;A[&1I(2QE=AM9E4D88=5%>P44
M%)CC%+10 FT4;12T4 )BEHHH **** "BBB@ HHHH **** $HQ2T4 %)BEHH
M**** $Q2T44 )CWI:** $I:** $Q1MI:* "DQ2T4 )BC:*6B@!-HHVBEHH 3
M%&*6B@ I,>]+10 F*6BB@!,48I:* $Q2T44 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gizttcucplmb000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )>!3H# 2(  A$! Q$!_\0
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M.6 YP1ZUC.C*$U![L+&Q17B7_"X/$/\ SZ:9_P!^G_\ BZ/^%P>(?^?33/\
MOT__ ,76WU*J%F>VT5XE_P +@\0_\^FF?]^G_P#BZ/\ A<'B'_GTTS_OT_\
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MZ:9_WZ?_ .+H_P"%P>(?^?33/^_3_P#Q='U*J%F>VT5XE_PN#Q#_ ,^FF?\
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MTS_OT_\ \71_PN#Q#_SZ:9_WZ?\ ^+K;ZE5"S/;:*\2_X7!XA_Y]-,_[]/\
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M_>:U%'<7[HT%G+9&0.VX JV&Z<C.<4NO>#)9[N[N;&:!YQJ2V4EM!:^3'$6
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M^@"OFBOI?PM_R*.C?]>,/_H KS\?\*)D>'_$/_D?-5_WT_\ 0%KF*Z?XA_\
M(^:K_OI_Z M<Q791_AQ]$-!1116@PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH *?#_KX_P#>'\Z93X?]?'_O#^=(#ZKKY>UC_D.:A_U\R?\ H1KZAKY>
MUC_D.:A_U\R?^A&O,R_>1,2E1117J%!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ;O@S_D<]'_Z^D_G7T+J_P#R!;[_ *]Y/_037SUX,_Y'/1_^
MOI/YU]"ZO_R!;[_KWD_]!->7COXD26?+M%%%>H4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5VWPJ_Y'>+_KA)_*N)KMOA5_R.\7_7"3^58U_X
M4O03V/>****\$@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,KQ/_ ,BEK/\ UXS_ /HMJ^9J^F?$_P#R*6L_]>,__HMJ^9J]3 ?"
MRHA6W;>(/L_A"\T'[+N^TW"S^?YF-N,<;<<]/6L2BNYQ4MQFQX>UW^P9;^3[
M-Y_VNRDM,;]NS?CYNASC'2NEB^(UM&T,Q\/1?:TLOL+S)=,H\K'14QM7GGOZ
M5P5%1*C"3NT%CL3XWM;BSMVO_#MI>ZI;VWV:.[FD++M'0M$00Q&>N>OI5A_B
M/-/I,<%Q97#7T<'DBYBU*:%#CHQB0@$^O//TXKC;*U>^O[>TC(#SRK$I/0%B
M /YUW5Y#X&TO6)] O-.NP(5*2:I]H8N),9XC''7CI^'>LYPIQ=K-_P!>OX 9
MD/C?RM4\/WO]G9_LBU^S[//_ -;\I7.=OR]>G-6+3X@1V]E:PR:+'/-:7CW4
M$KSG";G+$;<<G!(![<''%4--\#ZAJME'=P75E"MPSBTBNIA'+<A>NQ>?IU_3
MFNBT+PEI5Q;>%Q?6!,]W<745V#(ZEO+#X& >,%1TQTJ9^Q2U_K=_YAH9\WQ
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M$7F-MV /F^]\PXZ>]2W5O?\ KJ+4S[GP!J.FH+F6XTZ\BANHX+B*"Y):,LP
M#<?+G(''/(XJ74/!%S<Z_JJ0+I^E6-D45Y)[QC"C,JD*'9=Q)SGD>WIE+;Q;
M80Q^(%:&Y)U'4(KJ'"K\JK-O(;G@X],\U>O/&VB:M/K5IJ-KJ TN_FCN(W@V
M"9'547!!)7!V^O\ /BKUK_UY?\$-3$7P1?+J=U87FH:582P, #=W003 ]&3@
MDC'? ZXZY OR^$X]+\+^)#J,"-J>G3P)'*DC;0'*]!P""#W&>>U3:?XH\+67
MVU8-(O;']\KVD]I*#.5 P5=V)*!B.=O9B.V2NO>-=,U2Q\0Q00W:R:H]N\>]
M% 3RP@8$AC_=X^M'-5<DK::?F@U.#HHHKK*"BBB@ KZ7\+?\BCHW_7C#_P"@
M"OFBOI?PM_R*.C?]>,/_ * *\_'_  HF1X?\0_\ D?-5_P!]/_0%KF*Z?XA_
M\CYJO^^G_H"US%=E'^''T0T%>A>'_#.D7NA^'+FXM-\UYJ#PSMYCC>@#X'!X
MZ#I7GM=OHOC'3]-T?0K2:&Z:33[YKB4HJD,I##"Y;K\PZXJ*ZDX^[_6@,V8_
M VE1^,[B(PBXT>:TFFM@)6^22-@K+D')*GU]?6J-[#X3T+3] ^W>'6NFOK.*
M>>=;V1"N0-Q"YP3U..*-!^(=MIMQK$=Y#<RV=U-+/:[54O$7)R#DX ((S@]?
MK4,WB#PAJ=CHJZK;ZRT^G6L<!2 1".3:!G.3G!(]N*P2J\WO7MY"U.>\6:&O
MAWQ'<Z=%(\D*;6B=\;BK $9QW'3MTKL)_#6@VGA.VO%T>[O[>:R\Q]6M)R[Q
MS<DAHL@!5P03VQ@\\UQ'B+6Y?$.NW.IRQB+S2 L0;<$4  #/X?GFNNT7QEX<
MT*/[58V6K071A*R6*SAK223IN.XEO3MQZ5I453DCW_K^NPSGT\&:C)<Z+ )K
M7=J\9D@)9L*,9^;Y>#],UT \"07/A2R,<UA::E]MEMY;BYN61)2K,H51SDG'
M&!GBG:7XU\/1PZ!/J%IJ1OM(B,2"#88F!&W)R02<<XXY]:8WBSPOJ&F0V>J6
MVJD0WTUVAMQ&,[G9@IRW3#<].G!J92K-[?UK_P  6IF6_P .M7F^U>=<Z?:"
MUN?LLAN9BHW$ J0<'(.Y<=^>E,U#X?ZOINGWMU-/8LUGS-;QS[I0A. ^,< ]
M1D@X[=JT=5\=V>J65\C6UPDUQJD=V@ 4J(T1% )S][">F/>B\\:Z;<7WBJ9(
M+L+J]O'% "BY4JFT[OFX&?3--2K]?ZV_X(:C=5\#3W&N74-I%IVE6MK;12S/
M->NT2E\@?.RYR<'M@8Z]*RK3P5>7E[?0Q:EI/V>R17EO3=@P?-]T;@"<G!Z@
M=/IG>D\<Z7-XLDU03:Y:0FWCC7[(T0)9<@AT;*L.>.>,=.>&?\)KI#>*Y]3C
M&KV$+0JH>R,*O/(,Y:6,C8Q.X_3'OPE*LE:W0-3,M/#:16'B'S$T_46LH$D2
MZ@O6*IG=R@4$.>.C8QCWHD^'>LQVC/YMBUXL/GMIZW'^DA/7;C'Z^W7BM.]\
M<Z5,VO&VLIX6O[:**)_+0%Y%+$R2 $ $[ATSTJ1_'6AKJ,WB*#3[X>();?RB
MCNOV8/@+NZ[N@''&?;K1S5MTOZL@U,NS^'.J7EM92K?Z7&U[")K>&6X*R2#&
M2 NWD@8SVYZUR4L3PS/%(NV1&*L/0CK7;0^,].CU3PM<F&ZV:3:^3. BY8[,
M?+\W(^N*X_4;A+S5+NYC#!)IGD4-U +$C-;4W4O[PRM3X?\ 7Q_[P_G3*?#_
M *^/_>'\ZU&?5=?+VL?\AS4/^OF3_P!"-?4-?+VL?\AS4/\ KYD_]"->9E^\
MB8E*BBBO4*"BBB@ J2!0]Q$C#*LX!'XU'3X7$<\;G.%8$X^M(#UV7PCH4OB:
MXT1?"-Y!:",[=66YEV*=@;(W?+P3CJ>1TK$NO $.H:5H+:5/86US<V[-(;FY
M8&Y88^XO/09)P,<UA>*_&%WK6M7LMC?:A#ILX55MGF*KC8 P*ABN"03^-7X_
M&.GI<^$Y##=;=(C*7'RK\Q( ^7YN>G?%<2A6BD[_ -6)U,W2?!5YJS-$-2TF
MVNA*T(M;B[ E9EX.%4'OG\O3FGVG@74)K$WEW?:9IL8F>!?MUSY99D.&Q@$<
M$$=>WI6_8>.M LYENULM1ANUO)97^S;$6Y1Y"1YISN;:I.%SC(Z^D>C>-])T
M^[OIYKC7E2>[DE^S1^2\#QLY8 HX^4D'!VG\?2W.MK9!J8.E^"-1U.T6Y^UZ
M=:I+*88!<W(!N'!P1'C(;GCW[5%X8T>.Y\;6FDZI;DKYSQ3PEB.5!R,J?4=C
M75Z1\2+"VTLV;QZAIJI/+)$NG)"Z['<L%/F#C!;' _PKE=)\1);>-X]>OEFD
M03M*X4*7.01V"J3SZ#Z52=5J5UZ#U,O5X([76[^WA7;%%<R(BY)PH8@#FJ56
M]4N4O=6O+N,,(YYWD4,.0&8D9]^:J5O&]E< HHHJAA1110!N^#/^1ST?_KZ3
M^=?0NK_\@6^_Z]Y/_037SUX,_P"1ST?_ *^D_G7T+J__ "!;[_KWD_\ 037E
MX[^)$EGR[1117J%!1110 4444 =CX$T?3]4CUF6^TQ]1:TMO-AMTD=&=N>!M
MYR<8Z&NEMO"6B7\FA7,V@7&E&YNY()K&:>0EU$;L&R<,.5'IU^E<;X6\1Q:!
M9ZRC?:5N+RU,5O)!@%'YP2<@CKU%)H'BB>T\4V&JZQ=7M[':E_O2&1P"I'&X
M^I'>N2I"HY2:?]6$3ZWX)O-.AEOH;C3Y;3[6;<I#<AC Q/"R$\*1P#SQWI+K
MP)J,-DEU9WVF:E&TZ6_^@W._:[G"@D@ 9) Z]ZN:=XMTJVTJ^L[JRFN5N=46
M\\ME78T8925;GKQTP15W4_&^C2Z->:=8QZN(Y+B*>'?(B>5M<$QQ[>(U 4;2
M W)Y'')S5DTK"U,'5/!=YIDL<"ZEI5Y=/.L'V6UN@TH<G !5@#UX]J36/!FH
M:/827C75A=QP2>5<"TGWM W3#C P<\?6NEO/B%ID=E:):1ZEJ-U;3QR13:H(
MMT2J06"N@R2P&"3ZYSVJMXM\=VNN:1/9VESJS?:'!:&YCMUB10V[ *KO." !
MR/<GN1G7NKH-2KX:T'3-0\)R7MU;>9<#5(+</YC#]VS(", X[GGK6-XPT^UT
MOQ9J%E91>5;PN B;BV!M!ZDD]ZT- \3V6E^&GTV>*X:9M1AN@R*I78C(2.2#
MGY3VK*\4:K!K?B6]U*V21(9W#*L@ 8?*!S@D=O6K@I^T=]O^&'U,BBBBN@84
M444 %=M\*O\ D=XO^N$G\JXFNV^%7_([Q?\ 7"3^58U_X4O03V/>****\$@*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KQ/_P B
MEK/_ %XS_P#HMJ^9J^F?$_\ R*6L_P#7C/\ ^BVKYFKU,!\+*B%%%%>@4%%%
M% $MM<26EW#<PG;+"ZR(<9PP.17<3>)_"%YJ,FN7FBWTNIR1G?:LR-;,^,9R
M?FZ>W'IWK@J*SG34M6(](T7XCVUKH%M8W#ZE92VH9$_L](721>JY\T,1CIQ]
M>>T&G^/;"!M#DNH;QY+*ZNI[@A4.[S=^,<@$_,,\*.N*\^HJ/J]/73<+$UW*
ML]Y/,H(621F /7!.:Z+5M<76+'PW9:9#=?;=/B\KA!EG^7&S!)/(]!7+T5HX
M)V?8#UGQ5JPE\4^%]-6-89S=P7E["""4F<J #CN!G\Q577/$^D^&]8U\:9:W
M9U>ZEV3&=E,"X.25Q\QSZ'UZ\<^845C'#12286/2/$'Q'MM6T:YAMYM6BGN8
MMCVS+;^0F1A@&VER.OH?I7F]%%:TZ<::M$ HHHK084444 =M\*?^1WC_ .N$
MG\J]2^(7_(AZK_US7_T-:\M^%/\ R.\?_7"3^5>I?$+_ )$/5?\ KFO_ *&M
M>7B?]YC\OS)>Y\[T445ZA04444 %%%% !1110 4444 %%%% !1110 5],>%_
M^11T7_KQ@_\ 1:U\SU],>%_^11T7_KQ@_P#1:UY^/^%$R/#?B%_R/FJ_]=%_
M] 6N9KIOB%_R/FJ_]=%_] 6N9KLI?PX^B&@HHHK084444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >_?##_ )$.R_WY?_0S7 _&#_D;
MK;_KQ3_T-Z[[X8?\B'9?[\O_ *&:X'XP?\C=;?\ 7BG_ *&]>70_WJ7S)6YY
M_1117J%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?2_A;_D4=
M&_Z\8?\ T 5\T5]+^%O^11T;_KQA_P#0!7GX_P"%$R/#_B'_ ,CYJO\ OI_Z
M M<Q73_$/_D?-5_WT_\ 0%KF*[*/\./HAH****T&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !3X?]?'_O#^=,I\/^OC_P!X?SI ?5=?+VL?\AS4/^OF
M3_T(U]0U\O:Q_P AS4/^OF3_ -"->9E^\B8E*BBBO4*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH W?!G_(YZ/_ -?2?SKZ%U?_ ) M]_U[R?\
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MJC_A9.B?\\KW_OVO_P 51[*?8/KN'_G1V-%<=_PLG1/^>5[_ -^U_P#BJ/\
MA9.B?\\KW_OVO_Q5'LI]@^NX?^='8T5QW_"R=$_YY7O_ '[7_P"*H_X63HG_
M #RO?^_:_P#Q5'LI]@^NX?\ G1V-%<=_PLG1/^>5[_W[7_XJC_A9.B?\\KW_
M +]K_P#%4>RGV#Z[A_YT=C17'?\ "R=$_P">5[_W[7_XJC_A9.B?\\KW_OVO
M_P 51[*?8/KN'_G1V-%<=_PLG1/^>5[_ -^U_P#BJ/\ A9.B?\\KW_OVO_Q5
M'LI]@^NX?^='8T5QW_"R=$_YY7O_ '[7_P"*JWIOCG2M5U&&RMX[H2RDA2Z
M#IGU]J3IS70:QE"3LI(VM6LVU'1KZQ5PC7-O)"&(R%+*1G]:\K_X4S??]!>W
M_P"_3?XUZ^[!$9ST49-5/[3@]'_*KI5JE-6@=2N>5_\ "F;[_H+V_P#WZ;_&
MC_A3-]_T%[?_ +]-_C7JG]IP>C_E1_:<'H_Y5K]:K]QZGE?_  IF^_Z"]O\
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MIO\ &C_A3-]_T%[?_OTW^->J?VG!Z/\ E1_:<'H_Y4?6J_<-3RO_ (4S??\
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MC_CVE_W#_*L"M^X_X]I?]P_RK K@IGVD0HHHK0H**** "BBB@ HHHH ****
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MLA<^;$FV-9)E\P'RLKN^8]N/6GRRM<=F7**JOJ5A%-%#)>VR2S &)&E4,X/
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M0:U_T%]0_P# E_\ &GCQ/X@  &NZF .@%W)_C4RP$GU$\.WU/?[W_C\D^O\
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M?^$@UK_H+ZA_X$O_ (T?\)!K7_07O_\ P)?_ !H^IR[A8]ZHKP7_ (2#6O\
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M!6_<?\>TO^X?Y5@5P4S[2(4445H4%%%% !1110 4444 %%%% !1110 4444
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MBBB@#9T__CS7ZG^=>-_&'_D;K7_KQ3_T9)7LFG_\>:_4_P Z\;^,/_(W6O\
MUXI_Z,DK;!?Q_O+H?Q#SZBBBO:.T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!!1110(*
M***0@I:2EH$)1110(*.U%':D(*6DI:!"4M)2T$B4M)2T@$I:2EH)$-+2&EH$
M%%%%(!*6DI:!!1110(*[+X:Z?J%WXH2YLW:*"V0M<R <%2#\GX_TSVKD[2UG
MOKN&UMHS)-,X1$'4DU]%^&?#L'AGP\MC'AI2I>>0#[[D<GZ=A["N3%UE"'+U
M9#9#1117G#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *MZ=_Q]
MCZ&JE6]._P"/L?0TI;">QL4445@0>=_%/II/_;;_ -DKSJO1?BGTTG_MM_[)
M7G5>A0_AH^5S+_>I?+\D%%%%:G"%%%% !1110 4444 %%%% !1110 4444 %
M%%% !6]X,_Y&_3O]]O\ T$U@UO>#/^1OT[_?;_T$U,_A9MA_XT/5?F>SW'_'
MM+_N'^58%;]Q_P >TO\ N'^58%<%,^TB%%%%:%!1110 44SSHO/\CS$\X+O,
M>X;MN<9QZ9H6:)Y9(DD1I(\;U# E<\C([46 ?1110 444R66.")I99%CC099
MW. H]2: 'T56?4+*.*65[RW6.(@2.90 A.,9.>,Y'YU);W,%W'YEM/'-'G&Z
M-PPSZ9%.S"Q+113(YHIBXBD1]C;'VL#M;T/H>:0#Z*** "BBB@"WIW_'V/H:
MT+W_ (\Y/I_6L_3O^/L?0UH7O_'G)]/ZUG+XB7N8E%%%:%!1110 4444 %%%
M% !1110 4444 %%%% !6_;_\>T7^X/Y5@5OV_P#Q[1?[@_E6=0F1D7O_ !^2
M?7^E5ZL7O_'Y)]?Z57JUL-!1113&%%%% !1110 55U.X>TTJ\N8\;X8'D7/J
M%)%6J;)&DT3Q2*&1U*L#W!ZTUOJ".4OFB@T31=)'FLMSL>?RHVD8QJ [G"@G
MYFP.G\1K.EGB?P_>:05?R[6_A$:2QLA,+R KD, >.1T["NKTK2A9+$\X62YA
MB^S),&)+1 Y7(Z ],_3K4EUHVGWMS]HN+??*552P=AD*VY>A[$5NJD4[&G,D
M<AKER]WX<ETUVW2:?%(;DG^(H=B?]]9W?A72:5_R,.O_ /7:'_T2M7)M'L+C
M[;YMN#]M55N"&(,@48'0\8'I39=%LI;N:Y_TE)IB#(8;J6,,0 !D*P'0"DZD
M7&W]=!.2:L5Y6^S^+;<)C%W:.) #WC9=I_)R/_U5L5GV^GNFK27DK JD*V]N
M-Y8A.K%B>Y./7[HYK0K*36A+"BBBI$%%%% !1110 4444 ;.G_\ 'FOU/\Z\
M;^,/_(W6O_7BG_HR2O9-/_X\U^I_G7GGQ$\':AXA\007=I-:I&EJL1$K,#D,
MY[*>.16F$E&-:\BJ+2G=GCM%=I_PK'6O^?K3_P#OX_\ \11_PK'6O^?K3_\
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MZI_]TUX]>;G/F9$CGJ***904444 %%%% !1110 4444 %%%% !1110 4444
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M4WF6RCDGD=[VYC\R%(O,$<9& -^%SSU.>AKH!HNGABPM^3,DY^=OOH %/7L
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M\\D_[Y%'D0_\\D_[Y%'.',0Z?_QYK]3_ #JGJ?\ Q\K_ +@_F:U555&%  ]
M*:T<;G+(K'U(S4J5G<5]3GZ*W_(A_P">2?\ ?(H\B'_GDG_?(JN<?,8%%;_D
M0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\\D_[Y%'.',8%
M%;_D0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\\D_[Y%'.
M',8%%;_D0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\\D_[
MY%'.',8%%;_D0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\
M\D_[Y%'.',8%;UO_ ,>T7^X/Y4OD0_\ /)/^^13P !@# '0"IE*XF[F+>_\
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MC>'/[#,D_P!EV!-^X;\ YZXQ^E:U%/GE>]Q\S,:_\,V&HRZ?+,95DL2#$Z$
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M/^_:?_%T?5JG\H>SEV.[^V7'_/4T?;+C_GJ:X3_A9VB_\^NH?]^T_P#BZ/\
MA9VB_P#/KJ'_ '[3_P"+H^K5/Y0]G+L=W]LN/^>IH^V7'_/4UPG_  L[1?\
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M5MR?ZI_]TUB6O_'U%_O"MN3_ %3_ .Z:SGN2SGJ***T*"BBB@ HHHH ****
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M[_C['T-5*MZ=_P ?8^AI2V$]C8HHHK @\[^*?32?^VW_ +)7G5>B_%/II/\
MVV_]DKSJO0H?PT?*YE_O4OE^2"BBBM3A"BBNI7PE:0?9H-3UR&SOKA0RV_DE
M]N>@9@<#\:3DEN:4Z4ZGP_Y?F<M174P^!KZ2TU-C*!=V+[?(5<B3@-D-GN#D
M#'ITJI;^%Y[S3=,N;:8/-?S-$L3+@)MSDEL], GI2]I'N7]5K+[/]7M^9@T5
MTMSX8LA:7LECKL%U/9#=/$T1C  .#M8G#<\#'7(]12Q^%[.""U.KZW%87%TH
M>.#R6<A3C!<Y&W\?3KUPO:1']5JWM;\5;[[V.9HKH)O"ES:P:NUU,J2:<L3;
M57<LH<G!!XXX]*H:+H\NM7I@26.&.-#+--(<+&@ZDT^=6N0Z%1246M7_ ,,9
MU%=%<^&K9],GO](U:/4$MN9T\EHF0>H!ZCK^568_"%I%);6NI:Y#9ZA< %;8
M0F3;GH&8$ '_ #S2]I$M86JW:WXJWWWL<I16^?##_8=3=+M)+S37Q-;HN04_
MOJV>>AR,9&.:J:OH_P#8\=HD]QNO)8_,E@"?ZD'[H)SR2.V.*:FF[$2H5(KF
M:T_I&71115&05O>#/^1OT[_?;_T$U@UO^"E+>,-/ _O,?_'&J9_"S;#?QH>J
M_,]FN/\ CVE_W#_*L"N@E4O"ZCJRD"LO^S9_]C\ZX(-(^T13HJY_9L_^Q^='
M]FS_ .Q^=7S(=T4Z*N?V;/\ ['YT?V;/_L?G1S(+HIT5<_LV?_8_.C^S9_\
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M=%7/[-G_ -C\Z/[-G_V/SHYD%T4Z*N?V;/\ ['YT?V;/_L?G1S(+HIUOV_\
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M$#>8ZX4$G'!'<FNEM(FAMU1\9&>E5[VTEGF#IMP%QR:B$W&5T["3L[HXC_A
M_#7_ $#?_(\G_P 51_P@?AK_ *!O_D>3_P"*KK_[-G_V/SH_LV?_ &/SK?V\
M_P"9_>7[27<Y#_A _#7_ $#?_(\G_P 51_P@?AK_ *!O_D>3_P"*KK_[-G_V
M/SH_LV?_ &/SH]O/^9_>'M)=SD/^$#\-?] W_P CR?\ Q5'_  @?AK_H&_\
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M:_Z!O_D>3_XJNO\ [-G_ -C\Z/[-G_V/SH]O/^9_>'.^YR'_  @?AK_H&_\
MD>3_ .*H_P"$#\-?] W_ ,CR?_%5U_\ 9L_^Q^=']FS_ .Q^='MY_P S^\7.
M^YR'_"!^&O\ H&_^1Y/_ (JC_A _#7_0-_\ (\G_ ,577_V;/_L?G1_9L_\
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M:7S=\[D/G.1GC'MC&*I452@D[F,Z\IQY7W;^\****HQ"N@\$$+XQT\GU<?\
MCC5S];W@S_D;]._WV_\ 034S^%FV&_C0]5^9[4S!%+,< #)-5_[0M?\ GK_X
MZ:DN?^/6;_</\JYVO.2N?9&]_:%K_P ]?_'31_:%K_SU_P#'36#13Y4!O?VA
M:_\ /7_QTT?VA:_\]?\ QTU@T4<J WO[0M?^>O\ XZ:/[0M?^>O_ (Z:P:*.
M5 ;W]H6O_/7_ ,=-']H6O_/7_P =-8-%'*@-[^T+7_GK_P".FC^T+7_GK_XZ
M:P:*.5 ;W]H6O_/7_P =-']H6O\ SU_\=-8-%'*@-[^T+7_GK_XZ:/[0M?\
MGK_XZ:P:*.5 ;W]H6O\ SU_\=-']H6O_ #U_\=-8-%'*@-[^T+7_ )Z_^.FC
M^T+7_GK_ ..FL&BCE0'017<$S[(Y,MZ8-2NZQH7<X4=36-IG_'X/]TUI7_\
MQY2_3^M)K6P!_:%K_P ]?_'31_:%K_SU_P#'36#13Y4!O?VA:_\ /7_QTT?V
MA:_\]?\ QTU@T4<J WO[0M?^>O\ XZ:/[0M?^>O_ (Z:P:*.5 ;W]H6O_/7_
M ,=-']H6O_/7_P =-8-%'*@-[^T+7_GK_P".FC^T+7_GK_XZ:P:*.5 ;W]H6
MO_/7_P =-']H6O\ SU_\=-8-%'*@-[^T+7_GK_XZ:/[0M?\ GK_XZ:P:*.5
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M8@R\@X/RFK-<W+_KI/\ >-)*X&W_ &A:_P#/7_QTT?VA:_\ /7_QTU@T4^5
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M .)H_P"$Z\2?]!'_ ,@1_P#Q-<[17J^RI_RK[BK'1?\ "=>)/^@C_P"0(_\
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M]3_.O'?C#_R-UK_UXI_Z,DK?!_QAK<\^HHHKV"PHHHH **** "BBB@ HHHH
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MGO=2N+-K*X$<>RX,:0QA596*YVMN)/+ @CCM6Z-/LA;R6XL[<0R'+QB(;6.
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M 'A6]+_J7_W342W YNBBBK **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JYIG_'X/\ =-4ZN:9_Q^#_ '32>P&W11168'G?Q3Z:3_VV_P#9*\ZK
MT7XI]-)_[;?^R5YU7H4/X:/E<R_WJ7R_)!1116IPA1110 4444 %%%% !111
M0 4444 %%%% !1110 5O>#/^1OT[_?;_ -!-8-;W@S_D;]._WV_]!-3/X6;8
M?^-#U7YGLUS_ ,>LW^X?Y5SM=%<_\>LW^X?Y5SM>?$^R"F31+/!)$Q(5U*DC
MK@C%/HJ@,>]\-6&H>'H=%N/-:WA1$C<$;UV# .<8SCV[FH[GPO;7(O(Q>7D4
M%X!Y\,3(%<A0N<E=PX Z'!QTZUN457,P,1O#%HZ7"&XNO+N((X9%#*,E!A'S
MMR&'L<>U-E\+6]S)/+=7U[/+-&D;.[(#M1]XP H Y'I^O-;M%',P,N[T2.YO
MI+M+RZMI)HA#,("H$BC. <J2#R>5(--TOP_::1)$]O),QCMA;*)&!^0,6'0#
MG+?E6M11S.U@*D6G0Q7]Y> LSW:HLBM@KA00,#'N<UF0^$[*#:J7%UY2)/'%
M$67;$LN-RK\N<#'&2<5O44<S Q1X8L?*FC+SGS(H(@^\!HS#G8ZD#A@3G/MT
MITOA]+F-DN]1O[DL\;@NZ@+L8, %50O4<G&?>MBBCF8#9(TFB>*10\;J592.
M"#U%8_\ PC<#1QVTM]>S6,3!ELY'4QX'W5)V[V XX+'H,YK:HI)M; 9+:#'Y
M\[PW]];0W$GFRP02*JLW<YQN7/?:PH7P_:+>+="2;>MV]X!N&-[)L(Z=,?\
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M\CQ__%4G_"">)/\ H&_^1X__ (JO:**7URIV0<S/%_\ A!/$O_0-_P#(\?\
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M+7_GD/S-'V"U_P">0_,U0_M&X]5_*C^T;CU7\J+,.=%_[!:_\\A^9H^P6O\
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M:[D9=2LR">HG7T^M0?VQIG_01M/^_P"O^->34E'U==R?[5G_ "H]:_MC2_\
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MG?[[?^@FL&M[P9_R-^G?[[?^@FIG\+-L/_&AZK\SV>X_X]I?]P_RK K?N/\
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MZB_WA6U+_JG_ -TU+-(;'/T4451F%%%% !1110 4444 %%%% !1110 4444
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MIKT;_A M+_Y^+S_OM?\ XFD_X0'2O^?B\_[[7_XFE[: _P"SJYYP:;7I/_"
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MA?B+_H&2?]]K_C7K?]O:/_T%;'_P(3_&C^WM'_Z"MC_X$)_C1]9EV#^QZ/\
M,_P_R/)/^$+\1?\ 0,D_[[7_ !H_X0OQ%_T#)/\ OM?\:];_ +>T?_H*V/\
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M8KG_ )Y'\Q6QYT7_ #T3_OH4>=%_ST3_ +Z%','(C'^Q7/\ SR/YBC[%<_\
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MHH **** "BBB@ HHHH *W/!__(V:?_OG_P!!-8=;G@__ )&S3_\ ?/\ Z":
M/89O]1)_NG^59-:TW^HD_P!T_P JR: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** +%G_Q\?@:N7/_ ![/]*IV?_'Q^!JY<_\ 'L_TH RZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "M:'_41_[H_E636M#_J(_P#=
M'\J ,^Y_X^7^M0U-<_\ 'R_UJ&@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** -*T_X]E_&JU]_KQ_NU9M/^/9?QKCO&7B2\
MT?5XK>WC@9&@#DR*2<[F'8CTH WZ*\__ .$YU/\ YX6G_?#?_%4?\)SJ?_/"
MT_[X;_XJ@#T"BO/_ /A.=3_YX6G_ 'PW_P 51_PG.I_\\+3_ +X;_P"*H ]
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MZ_X^7J&IKK_CY>H: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4FU8G[R#JGU'4>V?2O7H?]1'_NB@#/NO^/EZAJ:Z_P"/EZAH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H'444#J* -FLA_\ 6-]36O60_P#K
M&^IH ;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $D'^O3Z
MUIO_ *MOH:S(/]>GUK3?_5M]#0!D4444 %%%% !1110 4444 %%%% !1110
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MQ6__ %Z+_P"AO7I-I_Q[+^->;?$?_D8K?_KT7_T-Z ./HHHH **** "BBB@
MHHHH *1J6D:@"!JA:IFJ%J (6J%JF:H6H @:H6J9JA:@"!JA:IFJ%J $@N9K
M.ZBN;>0QS1,'1QU!'2OJ+PY?S:IX<T^^N+=K>::%6:-NQ]?H>H]B*\(\ ^%O
M[?U?[3<IG3[4@R ])&[+_4^WUKZ'A_U$?^Z* ,^Z_P"/EZAJ:Z_X^7J&@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@=110.HH V:R'_UC?4U
MKUD/_K&^IH ;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $
MD'^O3ZUIO_JV^AK,@_UZ?6M-_P#5M]#0!D4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 58L_\ CX'T-5ZL6?\ Q\#Z&@#1HHHH \_^)O32
M_P#MK_[)7G]>@?$WII?_ &U_]DKS^@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "MSP?\ \C9I_P#OG_T$UAUN>#_^1LT__?/_ *": /89O]1)
M_NG^59-:TW^HD_W3_*LF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"Q9_P#'Q^!JY<_\>S_2J=G_ ,?'X&KES_Q[/]* ,NBBB@ HHHH
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M[3!;W,#V[2K= "9IYGE=@.GSL2PQU&#P>1@U-9:39Z?+)+ DAFD #RS3/*Y
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MHHH D@_UZ?6M-_\ 5M]#69!_KT^M:;_ZMOH: ,BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "K%G_Q\#Z&J]6+/_CX'T- &C1110!Y_P#$
MWII?_;7_ -DKS^O0/B;TTO\ [:_^R5Y_0 5VM]?VNBZ9HA71M,N!/:J\IFMP
M7;IGGU/J0:XJNG'B;39;2PAO=!%T]G$L:.UTR@XQU4#';H<T =%'HECILFLB
M"#3=J>0\!U$;HXPW4%CSZX_"J":?;:GK$$=XFBO!!!+.ZZ22-^-O#D<_3\:R
MHO%HE_M'^U-/6\6^9"Z+,8@NSH!@$^G?M4"^(+:QO8+O1M*6RECW!P\[2K(I
M'0@XH V4277-#O+C_A&+-(2K-;36FR-D89SNR<D#Z<XZ<\:5W;06T=FL$/A>
M)6MD=A?H%D+'J>.W_P!>N;/B>SMHKDZ7HD-G<7"&-Y3,TF%/4*I  _EQTIUS
MXETJ_$#7WA_SY8H5B#_;67('L!]: -B#1['5O"P0PVL6H7%Q+Y$L* *7!8[0
M>NW ('X5:L-+LUDL!)8V8D_LAI'%Q"-OF I\S\=N<GKUKD;CQ &TNWLK2U-L
M+:[:YB<2[MO)*KR.V1S[5JR>.5GOEN9],#J;5[:2,3XW;BI)SMXZ=/?K0!>1
M(IM5TV":'PS+')< ,NGJ&?[IZY_A_P#K59NK'8NIC5M$TNRTU8Y/(N8419"V
M?DQ@DY([8']*YJ'7](M+NWNK+P_Y$T,@?=]L=LCGCD5%:^(_*DU*.XM/M%E?
MNSM;F3&QB<A@<'D>N.P]* -KPOHUO)HRR75@;C^T96A641;S @4C?G'R_-QG
MC]*Q=&D;2]=_LZYL+*Y,EPD$GVB+?LPV#MSTZ_RIMYXFO91:QV,MQ8V]O"L2
MQQSGYB/XCC&2:9?ZXE[XAAU9;01.K1O)&),AV7'.<<9P* .KN?L<]SXBLO[*
MTZ-+*U=HI([<!\XZY_PQ5(:/:ZIK&CZC#!'%8W,/FW*1J B-']\8Z '@?G60
M?$V;W6+C[)_R$86BV^9_J\C&>G/Z5'9>(Y[+P[=Z2L6X3D[92WW <;@!COC]
M: .LA^QW.@Q:A;V6@6[37$@']H1*B[ QP!CO@#]:XO7I-^JNNS3EV*JYTX8A
M;C.1ZGG!^E7K3Q#8IH=OI=_H_P!L2%V=6^TM'R2>P'OZUDZC<6=S<A[*Q^QQ
M;0/*\TR<^N30!4K<\'_\C9I_^^?_ $$UAUN>#_\ D;-/_P!\_P#H)H ]AF_U
M$G^Z?Y5Y58SQ7.DWKRRZ_+J'G7"QM;M=E<AV" %?W?' YX]>]>JS?ZB3_=/\
MJYG1M,_LFQ:V\[S<S22[MNW[[EL8R>F<4 8>F7^K17FI+<1FYNXX;,-$9@D<
M;F,^8V>0JYR3@'IP#3K?QDDXNXU@MI[F*6&&(6EX)8IFDSM^?:,8VG/'&.]6
M-2\+#4+B]F-RF;B6"41RP>9'^Z!&'7(WJ<].,<5%_P (G.]S=7<VIJ;J9H9(
MVCMMJPO%NVX7<<KAL$$YZ\^@!-?>))]*B1-1L[:WN991'"6O (&&,EC(5!4#
M!R-N<XQG-5D\9":.)+:U@N;IKU;-EANP\0+(S*XD"\KA>?E!'/!P,WIM&U"Y
M>*ZFU5/MUO+YENR6NV)!MVLI3<68,"<_-Z8QCETFC7ET]G+>ZDLLEM>+<@);
MA$ ",NU1DD?>SDEJ ,K4?$&J-)!;0VT,%U%J<5M<)]I)5@R[U ;9G:0>3@$8
MQ@YJWJ7BF32[R..ZM+6.*2=8T1KT"X9&;:)!%M^[G_:SCKCI4EYX:DGO;F[A
MO5CFEO(;N/?#O5#'&$P0&&0<9ZBJ<W@Z9[>:UCU&&."2[^U,PM,RR,'W@2/O
M^<#)[ \#GC! -+PU/-/;:@9I7D*:C<HI=B<*)" !GL!VK$\-Z[<6VA737\TE
MQ)'&US 9&W,ZEV79GJ?F7'/]\"NFTK3?[,BN4\WS//NI;C.W&W>Q;'7MGK65
M%X2C2#2HFNV;[!*SMA,"92^\*1G@!@A[_=]Z ,O3?$<VDZ>T.H7,<]]+J%Q$
M)+NY$,8"$;B6(.T#/  /4 #%7/\ A.+=H8Q&MF)3.\#R27H6V4JH;(E"G.01
MCY1WSC%6QX:DAE^TVM^([M+N:YC=H=R;93\R,NX9' Y!'2K,FFZK+:A'U:&2
M1F?S4ELE:!T88V;-P; XZN>^<@@  J7OBG[$+*">&TM[RXC,KI=WRQ11J#C/
MF '=D] !TR3CI4=OXN?4);&#3K&*::Y6;<6N0(XVC(#?,JMN4YX('/' R</L
M_"TFEBWETZ^CANH_,60M;9A=7;<5$88;0&Y7#<<@YS5R'1K@:I9:A=:@;B:W
MBEC;]R$#;RIXQT V\ Y/J: *MMXFFOQ;06=BC7\GFF6&6XVI"(WV,2X4DY;&
M,+SU.,55_M/66\4+'#8$R-IRO):S7>R.-A(X)! ;).!@X&1UQTJS;>&)K"9;
MJROT2\$DY+RP%T:.5]^TJ&!R#C!!'?CFKMEI$]OJO]HW-^;F8VHMWS$$R0Y;
M(QT'. .3QR30!0M_&$$MK-<RVQAB33Q?1DR EUY#+TX(8 =\Y%)/XFOX_MH3
M1T)L;6.YN0]UMV[E+%5^0Y(P>N <=JH77AH9\/:0IFF-H^ZXG$!6-H,[BI;D
M9+*@VYSWZ5NW&A>?+K3_ &G;_:=NL&-F?+PK+GKS][IQTH @B\073W(A;3/G
MFM#=VB1W +2*"!M;( 5OF7H6'7DXK(U?Q3--8:S8*UK'=P6#SK-87WF["&VD
M$[5*L"16GJ7A0:C'"AO3'Y5@UGQ'G))0ACST^3E>X)Y%5KCP?<79G,NHV\8D
ML7L4BM[/RXXD8J057>>05]><]L4 =AIA),1)R2@R3]*T+G_CV?Z5C:7I&G0:
MB+M+&U6["G-PL*B0\8/S8S6XZ"1"K=#0!D45H_8HO]K\Z/L47^U^= &=16C]
MBB_VOSH^Q1?[7YT 9U%:/V*+_:_.C[%%_M?G0!G45H_8HO\ :_.C[%%_M?G0
M!G45H_8HO]K\Z/L47^U^= &=16C]BB_VOSH^Q1?[7YT 9U%:/V*+_:_.C[%%
M_M?G0!G5K0_ZB/\ W1_*HOL47^U^=3JH50HZ 8H S;G_ (^7^M0UI/:QR.6;
M.3[TGV*+_:_.@#.HK1^Q1?[7YT?8HO\ :_.@#.HK1^Q1?[7YT?8HO]K\Z ,Z
MBM'[%%_M?G1]BB_VOSH SJ*T?L47^U^='V*+_:_.@#.HK1^Q1?[7YT?8HO\
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M_<6C[<_]Q:J44 6_MS_W%H^W/_<6JE% %O[<_P#<6C[<_P#<6JE% %O[<_\
M<6C[<_\ <6JE% %O[<_]Q:/MS_W%JI10!;^W/_<6KB-NC5O4 UD5K0_ZB/\
MW1_*@"O+=M'*R!0<4S[<_P#<6HKG_CY?ZU#0!;^W/_<6C[<_]Q:J44 6_MS_
M -Q:/MS_ -Q:J44 6_MS_P!Q:/MS_P!Q:J44 6_MS_W%H^W/_<6JE% %O[<_
M]Q:/MS_W%JI10!;^W/\ W%H^W/\ W%JI10!;^W/_ '%H^W/_ '%JI10!;^W/
M_<6C[<_]Q:J44 6_MS_W%H^W/_<6JE% %O[<_P#<6C[<_P#<6JE% %O[<_\
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MM?\ V2O/Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W/!_\
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M5VX!Y/.X]!P,Y"V/A[4M+FM[RV:UEN8VN4DBDD94>.63S!A@I(8$+V(//UH
M=/XG>35=)%E#=2QW"W*36BQJ)1(FSAMQ 4KEOX@#[\5I6?B*TO9[.!(ITEN?
M. 5U ,;1$!U;GKD]LBJ.G^';NVU:SU">6!I US+<JA. \NS 3(Y "8R<?3TC
MB\/ZC97L5];_ &2::.\NY/*DE9%,<S;A\P4X8;5XP1UYH N'Q3;-<QVT%E>S
MSR33PI'&J<F%@'Y+  <Y!)'3UP"6?BFVO/LCBSO8X+J4P)/(BA1*,Y0C=NSE
M2,XVY'6J>D^'=0M-3M;RZEMF,<MY))Y9;GSF5EP"/]DY_K3XO#ETNCZ;9O)
M6MM1:ZD(8X*&21L#CKAQ^O- %V#Q);3FW<6MTEG<R^5!=LJ^7(Q) P VX D<
M$J >.>1EEIXF2^L1>6^EZB\3L$APB9E;)!Q\_ &#DM@<=>E9VE>%GTUK2#^R
M]#=;:0$7S0YG=0<CY=HP_3YMY]<=JD_X1[4$\+V&F)-&SP2DW$:SO$DZ'=E-
MZC<!\P/3MB@!]UXBDEFM8;>.>SG34H;:YAG5"VUU+=06&",<@YXKIJXRT\)W
ML-^]P(].MHGO[>Z$%MD+&J*RE1\HR>0<\9YZ5V= !1110!I6G_'LOXUYM\1_
M^1BM_P#KT7_T-Z])M/\ CV7\:\V^(_\ R,5O_P!>B_\ H;T <?1110 4444
M%%%% !1110 4C4M(U $#5"U3-4+4 0M4+5,U0M0! U0M4S5"U $#5Z7\-/$^
M]?[!O)/F7+6K,>H[I^'4?CZ"O-&IL4\MM/'/ [1RQL'1UZJ1R#0!]+UK0_ZB
M/_=%<;X4\11>)-&2Z7:MPGR7$8_A?U^AZC\NU=E#_J(_]T4 9]U_Q\O4-377
M_'R]0T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#J**!U% &
MS60_^L;ZFM>LA_\ 6-]30 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ>7#!)(Q9/O855)(!(!/3/&:IOXJM/[6L[:(-):W%J]S]H6)V  QCHON<^F
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MT/\ J(_]T?RK)K6A_P!1'_NC^5 &?<_\?+_6H:FN?^/E_K4- !1110 4444
M%%%% !5.[U*&TN(K=EDDED5Y-L8!VHHY8Y/ S@?4CWQ<KG),_P#"4ZN)<Y_L
MR/R?3;NDW?KM_3VH M6&O2ZC!;W$&BZC]GN K)*S0 ;3W(\W./PS39/$L")/
M/'8WLUC;NR2WD:H8UVG#G!;>0O.2%/0XS53PA8W \.Z1.=5O&C^S1G[.5AV8
MV],[-V/^!9K*GETZT^W7.EZW=:1J)+YTR9E8-+G/$+9)+\8*'G(QZ4 ==::I
M;WM[=6L.XM;K&S/@;6#C(QSZ"LN]US3998UDTR6\FBU VL*>7&2)E7?N4NP
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MY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\
M/-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFW
MY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\
M/-ORH\J3_GFWY4 +!_KT^M:;_P"K;Z&LZ&-Q.A*,!GTK2?[C?2@#'HI_E2?\
M\V_*CRI/^>;?E0 RBG^5)_SS;\J/*D_YYM^5 #**?Y4G_/-ORH\J3_GFWY4
M,HI_E2?\\V_*CRI/^>;?E0 RBG^5)_SS;\J/*D_YYM^5 #**?Y4G_/-ORH\J
M3_GFWY4 ,HI_E2?\\V_*CRI/^>;?E0 RBG^5)_SS;\J/*D_YYM^5 #**?Y4G
M_/-ORH\J3_GFWY4 ,JQ9_P#'P/H:B\J3_GFWY5/:(ZS@E6 QW% %^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF5F;E#T&3D?*.<:1\?V44)^U:3JMM=F2W1;*6./SG$Y(C8;7*[2RLOWL@@Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD!EE(4*#\PR2!SL:MH_]J7>D3^?Y7]G7OVO;LW>9^ZDCV]1C_69SST]ZU**
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gizttcucplmb000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000007.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M  40^#O[0FN0Z!I>IWWAOQ1-(8HM$\1VXMIY6&<JC*SQL>#\H?=[5[)\#/\
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M98IHF#*ZL 592."".<BDO+VWT^TGNKJ:.VMH$:26:5PJ(H&2S$] !_*OAO\
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M_>R?]]F@#ZG^(WC:W^&W@/Q#XKO+2\U"TT6QFOY;33XP]Q*L:%BD:D@%B!@
MD<]Z^.)?^"NGP^@C>23X8?$V.-!N9WTBW 4#J2?M' K[K[UQ7QQ_Y(OX\_[
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MPU]I5\P?\%%O@WXP^/'[,^H>%/ VC_VYK\NHVEPEG]IAM\HCDN=\KHO ]\T
M>S_ S_DBO@+_ + -C_Z3I7F7[?WBFR\(_L?_ !/NKV14%SI3V$2LP7?+,1&@
M'OEOTKYP\*_$+]O_ ,'^%](T*S^!G@:6TTNTALH7GU" R,D:! 6(U0#.%'0
M>U3:A^RC^T1^U]XKT!OVBM5T+PWX!TBY6\;PMX;D+&ZD (P2&?!(9AN+M@,V
MT<YH V?@M??#[X)?\$OO!-Q\8]+MM9\,BTDNSI-]:K*UW+<7DUQ!$D;'E\2
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MY,9'!KW[]D[]G/2_V7?@SI7@JPD6[O59KS5-05=OVN[< /)ZX 557/\ "BT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_\ C5+_ ,.U;#_HOGQG_P#"G7_XU7V710!\:?\ #M6P_P"B^?&?_P *=?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@.SW#!E4A0JG RZC)XY]J /0Z*BEF2&-Y)'6.-%+,[' 4#DD^@KQ*/\ ;@^
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M\ &\*_M6_"?P,GCG5OBC\4-6N[>?7]<U#<>7N$2WC6/<_EK''&[$%CPP/ P
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MQ_;63]KRS\5W<7@RZ\,V.@RI&VH2W:S6]QO+E0IV*0P10S @XW#DYH ^??\
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MOPG<>";_ %$S!M'NI6>2(1RM'N)9$8!BA(RHX(K\_?\ @N5CS/@CNZ9UK/\
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MN0NN&'4'#&OU7\8> ?A]^V-\ ]/TVYDFO/ NO06U];MILP@;:C*Z*" =NTJ
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MX1>.Y? MF_BQ]%TO6&U+SIMYN_)CE\W&_;G?\W3'M7V=7D/['O\ R:C\'O\
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MI8?V?O\ L%:;_P"E]_1^UA_REO\ @1_V#-/_ /2J^H_;'_Y2Q?L_?]@O3?\
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M?Q%H'A'3?"NI>/?'FNIYEEH>G-Y?REMJ;F"NV68$ *A/RD\<9^4/^"B3!O\
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M]X&OT%HH \L_9_\ V;_ G[,_A&3P_P"!M*:R@N)!-=W4\AEN+J0#:'D<^PX
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M7\4^"O$WB>.'54>*YT*[N('L&0N60;1"'S&20K%\@$C)R<^@_M+_ +./A_\
M:E^&O_"%>)M0U/3=,^VQ7WGZ2\:3;XPP49D1UQ\YSQVKUJB@#C_A)\,].^#G
MPU\.>"=(N+J[TS0K-+*WGO65IG1>A<JJC/T KL*** "O OV;_P!C?PE^S%XF
M\9ZYX:U;6M1NO%,RS7<>J2PLD9#NX$8CC0@9D/WB>!7OM% 'SE^U5^PS\/\
M]K"?3-2\027VB>)=.B\BWUO2&1)_*W%A&X92'4,6(S@@LV",FLG]F7_@GK\.
M/V9?$TGBBPN-3\3^+#&T4>K:U(CM K##"-%4!21P6.3CN,U]1T4 (!BN&^,7
MP7\'_'KP/=>$_&VD1ZOHT["0*S%)(9%/RR1N/F1ASR.H)!R"0>ZHH _/?_AR
M]\*O[4W_ /":>,?['\SS/[-\^WQUSMW^5T[=,^^>:^K?#/[,W@WP!\#]5^%O
M@R.[\(:'J-I/:RWVES8O@TR%))Q*X;][@\,1Q@8P ,>MT4 >'?LK_LC^#_V1
M_"^KZ+X2N]3U%=4NQ=W-YJ\D;S,50*J QHB[1R>F<L>:[;XV?"'0_CU\+]=\
M"^(S<1Z3J\(BEEM2HFB(8,KH6! 964$9!'%=W10!\Q:7^P1X1T[]E_6/@0_B
MKQ1>>$=0O%NTN;B>V-W:8GCG\N)A"%"&2,L=RD_O'YZ8]?\ @?\ ![2?@+\*
M]"\!Z'=WE[I6CQO'!<:@R-.P:1G.XHJKU8]%'2N^HH ^7OC-_P $^_ /Q@^-
M.G_%,:QX@\(^+[-H9?M7A^:"-9I8CF.5UDA?+@ *2,9"@'-?3BH?*".WF'&&
M+ ?-]:EHH K6MC;V*%+:"*W1CDK$@4$^N!5FBB@#Y]_:B_8M\'_M7ZOX1U#Q
M1J^N:7+X9:9K5=(EA19/-:)F\SS(GSCR5QC'4UF?M2_L%^ OVM-;\/:MXIU+
M6M*OM%MGM(Y-'EAC,\3,&"R&2)R0I#8QC[[5]*T4 ?-_[2G["O@;]I[2O NG
M:_JNN:-:>#H9K?3TT:6%-R2+ I$GF1/G MTQC'5L]L;G[37['_@;]JCP3I>@
M>*A>6EQI#;M.U:P9%N;?*A7 +*5*L%7*D?PJ>,5[I10!\0C_ ()0?#G6/"=S
MI'BOQIXV\67GEI;V&IZCJ:L^F1*ZMLMD9&100NTY4\$X KTGXG?L)^#OBQ^S
M_P""_A'K7B'Q(-#\*3136>H0SP?;)?+BEB19&:$J0%E/1!]U?Q^E:* .=\'^
M#+/P5X#T3PG9RSS6&DZ;!I<,TY4RM'%$L2LQ  W%5&< #/:O'?V4?V*_!W[(
M</B6+PIJVMZNNO& W(UJ6%]GE"0*$\N).OF-G.>@KZ$HH ^>?@A^Q1X-_9\^
M+?BGQUX.U;6[%/$?F?:_#S2PG34W/O41H(@Z["6V_.<!B.E<-\9/^":7P^^)
MWQ'O?'>B>(/$?P[\3:A(TU[<^&[H1)<.WWWVD95F/)VD DDD<U]?T4 ?/G[+
MO[$OP^_92&HW?AL7VK^(=27R[S7-7E66Y=-V[8NU0J*3R<#)(&2<"D^"?[%O
M@_X%_&[QO\4-%UC7+W6_%C71O+6_EA:VB\^Y6X?RPD2L,.H W,>,]3S7T)10
M 5\\_M9_L4^#OVPO^$5_X2W6-<TG_A'?M7V;^Q984\S[1Y._?YD3YQY"XQCJ
M>M?0U% 'Y^_\.8/A-_T//C[_ ,#K3_Y&KVCX&_L(^&?V>_!7CCP[X3\9^+H3
MXK@2"?4YKFW:ZM H==UNP@"JV';DJ<<$8(KZ:HH ^>OV<?V(?AS^S5X3\3Z!
MH\=[XCA\2Y35+CQ 8YY+B$H5\@A8U7R\,_&WG><YXQF_L\_L0^$_V4=4\6:I
MX-\1^));#6K=Q/HNHSP2VB8)*,F(E<,@)4$N<@G.>M?2],91(I5@"",$$9%
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MC/(CA452OSD8V]*^7_%7_!'3X3ZMKD]UH7B?Q5X5TVX.9-*LKJ.6(>H5I$+
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M_P#X)&_"SXB?$+Q/XPO?%OC.TU+Q!J=UJMS'9W5JL223RM*ZH#;DA0SG&2>
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MUKNG:GX:11%:BYBDAO)!YF9K@M&9'=O,()#CA5  Q7UK10!\U_M)?L%_#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >)_M/^*OBWHOAW1](^#OAJTUCQ%K
M=P]I+JFH2;+;1XMG_'R_K@G@>HZ-TKYH_P""1MGJ.GZ!\;;76+XZGJT'C&2*
M\OF))N)@A$DA)_O,"W/K7Z!U\(?\$L_^/C]H3_L?;K^;4 >1^"_AO!_P42_:
M>_: N/'6N:S;:%X'NDTKP_8:7>F.*U?S+F*.X P06S:M)TZR'G  JW\"/VL/
M&GAG_@G9\6;R[UN;4?%W@:\ET'3M6N&W3(LK(D+DMG<T9=RN[/W%'(%0?L_?
M%#PY^Q!^U)^TUH7Q1N_^$;A\17:ZUHURT+M%>0+-=R1K&0.69+I>.F4<9R*Y
MOX#_  %\4>.O^";?QLU&RT>X.H>,-4?6]*L7C/FW$%N\;Y1>Y;;*%X^; [$&
M@#F?&WP3O?V??V2?AI^TSX5\8:_'\3[NXL=1U2ZO+UIH;R.Y#.L;IW"Y088G
M(+Y&<8_77P5XDB\9>#]"U^!=D.J6,%ZBGLLD:N!^ :OR0^+?[1'A;XR?L _"
M7X*>$99M9^)UQ<:;H\OAZ&!Q/ ]L&C+,2,89E3'/1^V#C]!?BE\&/BQ??"7P
M%X7^%7Q%M_ &J:%;0VM]?3V:W(NHXX%CVA65L?,N[- 'T-17YK^(M5_:7_9X
M_:$^"V@>-OC7'XRT3Q?K8M)[2UTN" >6C)N5CY0.&#C[I[&OTHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK]L7]NWQE\(8_'WB'P1X*\$Z.L_E^'YS!)<7!\C<[D'G#S@<]!'QC<37H_\
MP32^,WBOQIHOQ+^'?C;6YO$6O_#W7#IHU*Y8O--;L\R+N<\MAX) "><;0:\I
M^'7B30/V>?\ @J9\9KKQOJMGX7TOQ#HINK"^U.<0P3>8UK*<.QQG,<JXSU0@
M5O?\$J]+;Q!XX_:+^)-MN;0O$OB@IILI! E59KF9FR>O%Q%^M 'Z&T5^7?[;
M7@#]H#]G/PKK/Q*M_P!HG7KS1[G7%AMM!MUE@%O'/(Y1 _FD80 #[O:OTVT6
M5YM'L))&+R/!&S,>I)4$F@"]1110 VC]*YOXB^)I_!O@77=;MXHY[C3[22X2
M.7.UBJDX..<<5\;_ /#P/Q7_ -"UH_\ WU+_ (UV8?!UL2FZ:V.JCA:N(3<$
M?=U%?"'_  \"\5_]"UI'_?<O^-'_  \"\5_]"UI'_?<O^-=7]EXG^7\3I_L[
M$=C[OHKX0_X>!>*_^A:TC_ON7_&C_AX%XK_Z%K2/^^Y?\:/[+Q/\OXA_9V([
M'W?17PA_P\"\5_\ 0M:1_P!]R_XT?\/ O%?_ $+6D?\ ?<O^-']EXG^7\0_L
M[$=C[LIWX5\E_!']L+Q#\4/B5I7AN]T33K.UO/,W30,Y==J%AC)(YQBOK.N&
MOAZF'ERU%9G'6HSH2Y9K4=1117.8#<4N:\O_ &B/BI?_  =^'I\0:=9V]]<"
MZBM_*N"0N&SD\'.>*^81_P % O%>/^1:T?\ [[E_QKNH8*MB(\]-:'91PE6O
M'F@C[OHKX0_X>!>*_P#H6M(_[[E_QH_X>!>*_P#H6M(_[[E_QKH_LO$_R_B;
M_P!G8CL?=]%?"'_#P+Q7_P!"UI'_ 'W+_C1_P\"\5_\ 0M:1_P!]R_XT?V7B
M?Y?Q#^SL1V/N^BOA#_AX%XK_ .A:TC_ON7_&C_AX%XK_ .A:TC_ON7_&C^R\
M3_+^(?V=B.Q]VT=*^<?V:?VF-9^-OBK4]*U+2;'3XK2S^TJ]JSEBV]5P<GIA
MC7T=7GU:,Z$W":U.&I3E1ER3W'4445B9#<<T<BO#_P!ISX[:K\#=/T*XTS3;
M34#J$LL;K=,PV[0I!&T^YZUX'_P\"\5_]"UH_P#WW+_C7H4<!7KPYZ:T.ZE@
MZU://!:'W=17PA_P\"\5_P#0M:1_WW+_ (T?\/ O%?\ T+6D?]]R_P"-;?V7
MB?Y?Q-?[.Q'8^[Z*^$/^'@7BO_H6M(_[[E_QH_X>!>*_^A:TC_ON7_&C^R\3
M_+^(?V=B.Q]WT5\(?\/ O%?_ $+6D?\ ?<O^-'_#P+Q7_P!"UI'_ 'W+_C1_
M9>)_E_$/[.Q'8^[>*4UXM^S/\;M3^-^@:O?ZE86NGR65TL"):EB&!0-D[N_/
M:O:/:O-J4Y49N$]T<%2G*G)PENAU%%%9F8VBOF;]H[]J77/@OX\M="T[1[&^
MMY;".[,MTSA@S22+C@XQA,_C7E?_  \"\5_]"UI'_?<O^->C3R_$58J<5HSO
MIX&M4BIQ6C/N^BOA#_AX%XK_ .A:TC_ON7_&C_AX%XK_ .A:TC_ON7_&M?[+
MQ/\ +^)I_9V(['W?17PA_P / O%?_0M:1_WW+_C1_P / O%?_0M:1_WW+_C1
M_9>)_E_$/[.Q'8^[Z*^$/^'@7BO_ *%K2/\ ON7_ !H_X>!>*_\ H6M(_P"^
MY?\ &C^R\3_+^(?V=B.Q]VXI17GWP*^(=W\5/A?I'B:^M8;.YO&F#0VY)1=D
MSH,9YZ+7H'I7ES@Z<G&6Z/.E%PDXO=#J***DD**** "BBB@ HHHH **2EH *
M*** "BDI: "BDS1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M!",UC>'_  =H/A$WIT+1-.T7[;,;BZ_L^TC@^T2GK(^P#<Q_O')K:HH Y3QE
M\+?!WQ#FM)?%/A71?$<MIG[/)JEA%<M%D@D*74X!('3T%=);VT5G;QP01)!!
M$H2.*-0JJH&   ,  <8J>B@#D=*^$O@C0?$\_B33?"&A6'B"<LTNJ6VG0QW+
MECEB9 H;+'KSSWKK0*6B@#X:_;P_Y.F_90_[&.;_ -"@K[EKX:_;P_Y.F_90
M_P"QCF_]"@K[EH **** $JCJ6M6&BQH^H7UM8QN=JM<RK&"?0$D<U=%<SXX^
M&OAGXE6=M:>)]&MM9M[:3S8H[D$A&QC(P>N*J/+S>_L)WZ%K_A//#7_0PZ5_
MX&Q__%4@\>>&_P#H8=*_\#8__BJX7_AE7X2_]"+I?_?+?XUY+\#_ -GWX=^(
MO$WQ1M]2\)V%Y#IGB66TLTD5L0PB-"$7GIDG\Z[HTL-*,I<TM/)?YF#E432L
MCZ5_X3SPWG_D8-+_ / V+_XJMM6#*&4@@\@BO*A^RK\)0<CP-I>1_LM_\57J
M<,*0QI%&-J( JJ.@ KDJ*DOX;?S7_!9K'F^T2T445D6%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7)^,?A7X2^(6J:#J7B/0++6;[0;G[7IEQ=)N:TFRIWIZ'*K
M^0KK** ,GQ-X7TGQEH-[HNNZ=;:OI%[&8KFRO(A)%*I[,IX/_P!:N*^%O[-_
MPR^"=Y=W?@;P5I/AN\NEV37-G!^]=<@E=Y)(7(' ..!7I=% 'G?Q4_9]^'/Q
MO^Q?\)UX0TOQ*]EG[/+>19DC!.2H<$,%..F<5T_@WP3H/P[\.VF@^&='L]"T
M:U!$-C8PK%$F222%'<DDD]23S6[10!\4_P#!7;_DT23_ +&#3_YO7V-X?_Y
M.F_]>T?_ * *^.?^"NW_ ":))_V,&G_S>OL;P_\ \@'3?^O:/_T 4 :%%%%
M'!?';_DCOC+_ +!<_P#Z :_*:OU9^.W_ "1WQE_V"Y__ $ U^4U?6Y+_  Y^
MI]-E7P2"BBBOHSW0HHHH **** /9?V0O^2_^&O\ MO\ ^B7K],:_,[]D+_DO
M_AK_ +;_ /HEZ_3&OC,X_CKT/E,T_C+T"BBBO"/'/GG]N?\ Y(<__82M_P#V
M:OSOK]$/VY_^2'O_ -A*W_\ 9J_.^OL\G_W=^I]9E?\  ?J%%%%>Z>N%%%%
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MVX/#K%5?9MV.S"T%B*G(V?9O_"Z/ ?\ T.&B_P#@='_C1_PNCP'_ -#AHO\
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M[.?_ "-_QD_[&Z?_ -%1UUTOX53T7YHRG\43W"BBBN0U"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^*?\ @KM_R:))_P!C!I_\WK[&
M\/\ _(!TW_KVC_\ 0!7QS_P5V_Y-$D_[&#3_ .;U]C>'_P#D Z;_ ->T?_H
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MSPG_ #[E^'^9G_Q$7+_^?4_P_P S@J*[W[#:_P#/K;_]^5_PH^PVO_/K;_\
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ME)5'L<U?%5,0DIBUPGQR^'US\6/@UXV\&6=W%8W7B#1[K38KJ=2R1-+$R!F
MY(!/;TKNZ*XCD/$[7]FK2]=_91T?X+>+I5U*TMO#]GH]Q>6@*_OH(T"3Q9Y!
M62-77/<"O,+OX#_M,ZOX+_X5]??&+PU'X7>'[#-XEM=%F77I;;&"-WF^4'*_
M*7 SR3G-?7=% 'SQ^T=^RU/\7/V?]!^&OA_6%TU=)OM/N$O=6:2X>2.V.3O;
M.YG;J6/4DUN?%SX#ZA\1OC]\%?B!:ZI;6EGX"FU62ZLYD8R77VNWCB781P-I
MC).?6O:Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MO@W7OVH/CQ\;OCM\3/!GP*L/#%AHWPZN!::E>>)5<RWEP&D1HT Z*SPRJ,#H
MF2WS 5WGP5_;HB\7?LC^*/B[XPT-=*U'PF]Q9ZI86<@,=S<Q!0JPDDX$C.B@
M,3@D\D#) /K:BOS1B_;J_:$^'O@_P;\9_B%X4\.2?!WQ1?10?8M(5S?V4$F\
MI+DMC)5&(W<$@#Y2PQ^DUC>0ZA9P75O();>>-98Y%Z,K#((_ T ?$7[>'_)T
MW[*'_8QS?^A05]RU\-?MX?\ )TW[*'_8QS?^A05]RT %%%0W%S%:PO-/(D,2
M#+22,%50.Y/:@":BL;_A,-!_Z#6G?^!<?^-'_"8:#_T&M._\"X_\:OV<^PN9
M=S8KQ#]G/_D;_C)_V-TW_HJ.O6/^$PT'_H-Z=_X%Q_XUXI^SWXETBU\6?%]I
MM4LHEE\6321L]PB[U\J,9!SR..M==&G/V533HOS1C.2YHZGT'16-_P )AH/_
M $&M._\  N/_ !H_X3#0?^@UIW_@7'_C7)[.?8VYEW-C=2UEVOB;2+ZX6"VU
M2RN)F^['%<(S'Z &M.I::W0Q:***0#>/QK"\:>,-.\!>&[O7-7>:.PM=GF-!
M"\SC<X08102>6'0>];M-95D7:RAAZ&I=[:%TW%33FKKKTT]=3Q<?M>?#G_G[
MU7_P3W7_ ,;J/_AL;X:?:/(_M#4O.V[O+_LBZW8SC./+Z9KVD6L/_/&/_OD5
MX9#!'_PV%.OEKM_X14';@?\ /R*XY^WA;WEJ^W_!/J,*LJQ'M+T)KEBY?Q%T
M_P"W"]_PU]\.O^?S5/\ P3W7_P ;KU+PKXHL/&GAZRUG3&D>QO$WQ--$T;$9
M(Y5@".AZBM,VD/\ SQC_ .^13T41KM4!1V KHC&I]II_+_@GBXJK@YQ2PU*4
M7YR4O_;424445L><%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 0W%S%:0O-/*D,2#+22,%4#U)-0Z=JUEK%OY]
MA>6][#G'F6\JR+^8.*^%O^"K4&I-H?PEEU6XU"V^$B>(E7QI)IK.'6!GA6,L
M%Y*[?M _WBG<BO./V,8?!MC^VEKUS^SY>ZK<?!2V\-;M:\][@6GVP[C&JB<!
M\@@$$C(S)_#0!^EUWK%A87$-O=7UM;3S'$44TRJSGT4$Y/X5>K\A_@S\#[+]
MN3P+\?\ XP^.M6U27Q=9:A>PZ!-#>,L.F&&W\Z(*@P"B[HUQZ*>YS7VC_P $
MUOC%K/QG_91\.:CXAO)-1UG2YY](GO)N7F6)AY3,>[>4R L>25)/)S0!R'_!
M7;_DT23_ +&#3_YO7V-X?_Y .F_]>T?_ * *^-/^"N5U%)^R/(B2H[CQ!8?*
MK GJ_:OLOP__ ,@'3?\ KVC_ /0!0!H4444 <%\=O^2.^,O^P7/_ .@&ORFK
M]6?CM_R1WQE_V"Y__0#7Y35];DO\.?J?395\$@HHHKZ,]T**** "BBB@#V7]
MD+_DO_AK_MO_ .B7K],:_,[]D+_DO_AK_MO_ .B7K],:^+SC^.O0^4S3^,O0
M****\,\<^>?VY_\ DA[_ /82M_\ V:OSOK]$/VY_^2'O_P!A*W_]FK\[Z^SR
M?_=WZGUF5_P'ZA1117NGKA1110 4444 ?4G_  3]_P"2D>(O^P5_[62OO'N*
M^#O^"?O_ "4CQ%_V"O\ VLE?>/<5\+FG^]2^1\?F/^\,6BBBO)/,/F#]M_\
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M!]M-I7A33=8NM=;0+5KTSB"-A(LGE[VF:0C!SN+$<Y-;$O[7'Q-T?PK_ ,+
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M_P!3'_NC^5?79'\-3Y'\V^+?\?">DO\ VTDHHHKZ<_G\**** "BBB@ HHHH
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M]C'-_P"A05]RT (>]>9_M,?\D!\>_P#8(G_]!KTP]Z\S_:8_Y(#X]_[!$_\
MZ#73A?\ >*?JOS,ZGP,_(2BBBOVY;'QP4444P"BBB@#VW]B__DY#PE_O3_\
MHB2OU:[BORE_8O\ ^3D/"7^]/_Z(DK]6NXK\TXE_WN/H?0Y?_"?J+4=Q_J)/
M]T_RJ2H[C_42?[I_E7R1ZL=T?BG1117Y7+=G^AM/X(^@4444C4**** -7PG_
M ,C1HW_7[#_Z&M?LO'_J8_\ ='\J_&CPG_R-&C?]?L/_ *&M?LO'_J8_]T?R
MKZ[(_AJ?(_FSQ;_CX3TE_P"VDE%%%?3G\_A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXR?\DM\4_P#8/F_] -?F_7R&=?Q(>A^5<8_QZ7I^H4445\V?G@4444 %%%%
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MK>H4445P'AA1110 4444 ??'[*__ "0_P_\ []S_ .E$E>M>E>2_LK_\D/\
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M_AJ?(_FSQ;_CX3TE_P"VDE%%%?3G\_A4-QYGV>7R-OG[3LWYV[L<9QVS4U%
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MZ%>05_Q+]Q-_S^I??+_Y$[VBN"_X3C4_6'_OT*/^$XU/UA_[]"@/^)?N)O\
MG]2^^7_R)WM%<%_PG&I^L/\ WZ%'_"<:GZP_]^A0+_B7[B;_ )_4OOE_\B??
MO[$O_(I>(?\ K^7_ -%K7TC7RG_P3]UBXUCP3XGDN-I9=14#8H7_ )9+_C7U
M;7Z'E_\ NL#%Y+B.'7_9>*:<Z>CMMWTV[BT445Z 'Q'^V7_R5>T_[!4/_HV:
MO"*]W_;,_P"2L6G_ &"H?_1LU>$5^=X__>9^I^!YY_R,:WJ%%%%<!X84444
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M\"\6>&_C3\.O%UWX@\$:S;?$3PO=W#7%UX-\0LEM=VP8DE;&] "A03Q',I
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MK\[Z_1#]N?\ Y(>__82M_P#V:OSOK[/)_P#=WZGUF5_P'ZA1117NGKA1110
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MMCXX****8!1110![;^Q?_P G(>$O]Z?_ -$25^K7<5^4O[%__)R'A+_>G_\
M1$E?JUW%?FG$O^]Q]#Z'+_X3]1:CN/\ 42?[I_E4E1W'^HD_W3_*ODCU8[H_
M%.BBBORN6[/]#:?P1] HHHI&H4444 :OA/\ Y&C1O^OV'_T-:_9>/_4Q_P"Z
M/Y5^-'A/_D:-&_Z_8?\ T-:_9>/_ %,?^Z/Y5]=D?PU/D?S9XM_Q\)Z2_P#;
M22BBD/2OIS^?Q.]%>.^+/VHO"/@WQ)?Z+?0:DUU92>7(T,"LI.,\'?[UD_\
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M52U%;?\ 'O'_ +H_E4M=T/A1P2W844459(4444 %%%% !1110 4444 %%%%
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M**^9/WH**** "BBB@#VK]C;_ ).&\,_]M_\ T4]?J+7Y=?L;?\G#>&?^V_\
MZ*>OU%K[;)O]W?K_ )'\H>*?_(ZI_P#7M?G(6BBBO?/QL^>?VY_^2'O_ -A*
MW_\ 9J_.^OT0_;G_ .2'O_V$K?\ ]FK\[Z^SR?\ W=^I]9E?\!^H4445[IZX
M4444 %%%% 'U)_P3]_Y*1XB_[!7_ +62OO'N*^#O^"?O_)2?$7_8*_\ :R5]
MX]Q7PN:?[U+Y'Q^8_P"\,6BBBO)/,/BK_@I9_P @'P1_U]7/_H"5\&5]Y_\
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MW1^*=%%%?E<MV?Z&T_@CZ!1112-0HHHH U?"?_(T:-_U^P_^AK7[+Q_ZF/\
MW1_*OQH\)_\ (T:-_P!?L/\ Z&M?LO'_ *F/_='\J^NR/X:GR/YL\6_X^$])
M?^VDE(WW32TC?=-?3G\_GYV?'W_DL?BK_KZ_]E6N KT#X^_\EB\4_P#7W_[*
MM>?U^:XG^//U9_.^8?[Y5_Q/\PHHHKF//"BBB@ K])_A3_R3;PO_ -@ZW_\
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M?QV%%%%?0G"%%%% !1110!^@?_!-G_DG_B[_ +"D?_HH5]B5\=_\$V?^2?\
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M[8TQG=S]!7ZMT (>]>9_M,?\D!\>_P#8(G_]!KTP]Z\S_:8_Y(#X]_[!$_\
MZ#73A?\ >*?JOS,ZGP,_(2BBBOVY;'QP4444P"BBB@#VW]B__DY#PE_O3_\
MHB2OU:[BORE_8O\ ^3D/"7^]/_Z(DK]6NXK\TXE_WN/H?0Y?_"?J+4=Q_J)/
M]T_RJ2H[C_42?[I_E7R1ZL=T?BG1117Y7+=G^AM/X(^@4444C4**** -7PG_
M ,C1HW_7[#_Z&M?LO'_J8_\ ='\J_&CPG_R-&C?]?L/_ *&M?LO'_J8_]T?R
MKZ[(_AJ?(_FSQ;_CX3TE_P"VDE(WW32TC?=-?3G\_GYV_'W_ )+%XI_Z^_\
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ML;P__P @'3?^O:/_ - % &A1110!Y[^T VWX)^-F(SMTFX./^ &OR%_M ?\
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M*6?\@'P1_P!?5S_Z E?!E?J^0_[A#U?YGS&._CL****^A.$**** "BBB@#]
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MU/8Z***_=S\*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /BG_ (*[?\FB2?\ 8P:?_-Z^QO#_
M /R =-_Z]H__ $ 5\<_\%=O^31)/^Q@T_P#F]?8WA_\ Y .F_P#7M'_Z * -
M"BBB@#SS]H3_ )(AXY_[!%Q_Z :_'JOV%_:$_P"2(>.?^P1<?^@&OQZK]#X8
M_@U/7]#P<R^*(4445]J>0%%%% !1110![E^Q3_R<AX6^EQ_Z)>OU5K\JOV*?
M^3D/"WTN/_1+U^JM?F?$G^]Q]/U/H<O_ (3]1:***^3/4/FO_@H%_P F^R_]
MA2V_]FK\RZ_33_@H%_R;[+_V%+;_ -FK\RZ_3>&_]S?J_P!#YS,/XWR"BBBO
MJSS0HHHH **** /KG_@F[_R5#Q/_ -@?_P!KQU^AU?GC_P $W?\ DJ'B?_L#
M_P#M>.OT.K\GS[_?Y_+\D?38'^ A:***^?.\^*O^"EG_ " ?!'_7U<_^@)7P
M97WG_P %+/\ D ^"/^OJY_\ 0$KX,K]7R'_<(>K_ #/F,=_'84445]"<(444
M4 %%%% 'Z!_\$V?^2?\ B[_L*1_^BA7V)7QW_P $V?\ DG_B[_L*1_\ HH5]
MB5^/YQ_O]7Y?DCZO"_P8BT445XYU'Q'^V7_R5>T_[!4/_HV:O"*]W_;,_P"2
ML6G_ &"H?_1LU>$5^=X__>9^I^!YY_R,:WJ%%%%<!X84444 %%%% 'WQ^RO_
M ,D/\/\ ^_<_^E$E>M>E>2_LK_\ )#_#_P#OW/\ Z425ZUZ5^D87^!#T7Y']
M"97_ +C1_P *_(6BBBNL]0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^&
MOV\/^3IOV4/^QCF_]"@K[EKX:_;P_P"3IOV4/^QCF_\ 0H*^Y: $/>O,_P!I
MC_D@/CW_ +!$_P#Z#7IA[UYG^TQ_R0'Q[_V")_\ T&NG"_[Q3]5^9G4^!GY"
M4445^W+8^."BBBF 4444 >V_L7_\G(>$O]Z?_P!$25^K7<5^4O[%_P#R<AX2
M_P!Z?_T1)7ZM=Q7YIQ+_ +W'T/H<O_A/U%J.X_U$G^Z?Y5)4=Q_J)/\ =/\
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M^2/Z,X:_Y%-'T_4****^9/IPHHHH *^L_P!EW_DG,W_7[)_):^3*^L_V7?\
MDG,W_7[)_):^\X,_Y&7_ &Z_T/@>-/\ D6K_ !+]3V.BBBOW<_"@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M 2C-?,7[97[1WCGX0WO@7P=\,O#":_XW\97WV2VN;V&1[*R0,B[Y"N.27[G
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M45XYU'Q'^V7_ ,E7M/\ L%0_^C9J\(KW?]LS_DK%I_V"H?\ T;-7A%?G>/\
M]YGZGX'GG_(QK>H4445P'AA1110 4444 ??'[*__ "0_P_\ []S_ .E$E>M>
ME>2_LK_\D/\ #_\ OW/_ *425ZUZ5^D87^!#T7Y']"97_N-'_"OR%HHHKK/4
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HKX:\2^+OVL_C=\7O'FF?#YK;X.^#/"\P@
ML;WQ-HH>77&!8!XVEB=3&Y0G<F-H9.I)POP)_;ZU?6_V2?B3\1/'&EVC^*/
M4\VGW$=EF*WU"X"J( .#LW2.JMC..N.U 'W)17Y>W/[5W[3_ ,*/A?X(^/\
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M%%%<QYX4444 %?I/\*?^2:^%_P#L&V__ *+6OS8K])_A3_R37PO_ -@VW_\
M1:U]+DO\2?H?HG!W\:KZ(ZRBBBOKC]4/E7]JW_D=M,_Z\1_Z,:O$Z]L_:M_Y
M';3/^O$?^C&KQ.OYRXD_Y&M;U7Y(_HSAK_D4T?3]0HHHKYD^G"BBB@ KZS_9
M=_Y)S-_U^R?R6ODROK/]EW_DG,W_ %^R?R6OO.#/^1E_VZ_T/@>-/^1:O\2_
M4]CHHHK]W/PH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCH<]CXAB!UO5+%8["7R)'7*2!N0_5>.17ZF>'_\ D Z;_P!>T?\ Z *^.?\
M@KM_R:))_P!C!I_\WK[&\/\ _(!TW_KVC_\ 0!0!H4444 >>?M"?\D0\<_\
M8(N/_0#7X]5^PO[0G_)$/'/_ &"+C_T U^/5?H?#'\&IZ_H>#F7Q1"BBBOM3
MR HHHH **** /<OV*?\ DY#PM]+C_P!$O7ZJU^57[%/_ "<AX6^EQ_Z)>OU5
MK\SXD_WN/I^I]#E_\)^HM%%%?)GJ'S7_ ,% O^3?9?\ L*6W_LU?F77Z:?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_KQ'_HQJ\3K^<N)/^1K6]5^2/Z,X:_Y%-'T_4****^9/IPHHHH *^L_V7?\
MDG,W_7[)_):^3*^L_P!EW_DG,W_7[)_):^\X,_Y&7_;K_0^!XT_Y%J_Q+]3V
M.BBBOW<_"@I*6D;I0 M%>)?%;]FV_P#BAXNDURW^+GQ"\&1M"D/]E^&]1@@M
M05S\^UX7.XYYY[5Y;\1?V2]=\(?#_P 2Z[:?M!_%R6ZTS3;F\BCFUBV*,\<3
M.H;%N#C*CH<^] 'U_17Q!^S[^S7XD^+7P1\"^,]4_: ^+%KJ.O:/;:A<0V>L
M6XA222,,RH&@)VY/<GZU[1\-?V7]0^'7C;3O$,_QE^)'BR.S\S.CZ_J=O-93
M[XF3]XBP*3M+;AAA\RKUZ4 >[T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\4_\%=O^31)/^Q@T_\ F]?8WA__ ) .
MF_\ 7M'_ .@"OCG_ (*[?\FB2?\ 8P:?_-Z^QO#_ /R =-_Z]H__ $ 4 :%%
M%% 'GG[0G_)$/'/_ &"+C_T U^/5?L+^T)_R1#QS_P!@BX_] -?CU7Z'PQ_!
MJ>OZ'@YE\40HHHK[4\@**** "BBB@#W+]BG_ ).0\+?2X_\ 1+U^JM?E5^Q3
M_P G(>%OI<?^B7K]5:_,^)/][CZ?J?0Y?_"?J+1117R9ZA\U_P#!0+_DWV7_
M +"EM_[-7YEU^FG_  4"_P"3?9?^PI;?^S5^9=?IO#?^YOU?Z'SF8?QOD%%%
M%?5GFA1110 4444 ?7/_  3=_P"2H>)_^P/_ .UXZ_0ZOSQ_X)N?\E0\3_\
M8'_]KQU^AU?D^??[_/Y?DCZ; _P$+1117SYWGQ5_P4L_Y /@C_KZN?\ T!*^
M#*^\_P#@I9_R ?!'_7U<_P#H"5\&5^KY#_N$/5_F?,8[^.PHHHKZ$X0HHHH
M**** /T#_P"";/\ R3_Q=_V%(_\ T4*^Q*^._P#@FS_R3_Q=_P!A2/\ ]%"O
ML2OQ_./]_J_+\D?5X7^#$6BBBO'.H_.3_@H!_P EPL_^P-#_ .CIZ^:J^E?^
M"@'_ "7"S_[ T/\ Z.GKYJK\[S#_ 'J?J?VYP5_R3^%_P_JPHHHKSC[<****
M "BBB@#].OV)_P#DW'PU_P!=+O\ ]*I:]UKPK]B?_DW'PU_UTN__ $JEKW6O
MTO"_P(>B_(_@WB+_ )'.+_Z^3_\ 2F+11174?/!1110 4444 %%%% !1110
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MO^'Y&H_]$>M?_"B;_P"1J] _X+<?\D9^'?\ V'Y/_2=Z_'B@#]1_^'Y&H_\
M1'K7_P *)O\ Y&K$\;?\%HM0\9>#==T!OA-;6@U2QGLC.-?9S'YD;)NV_9QG
M&[.,C/M7YIT4 ?HI\&O^"P%_\(?A1X1\$Q_"VWU1/#^FP:<+UM<:(SB- N\I
M]G.W..F379?\/R-1_P"B.VO_ (43?_(U?ES10!^H_P#P_(U'_HCUK_X43?\
MR-7U?^P?^W'<_MG?\)Q]H\'1>$_^$;^P[?+U$W?VC[1]HZYB3;M\CWSN[8Y_
M FOU4_X(8_\ -;/^X)_[?T ?JI1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !4<CK'&78X51DFI*J:E UUI]S"I(>2)D4@X()! YH _,ZS^
M-/[1/[5,?Q=^)?PT\>V_@OPEX%N;B+2/#J622MJ8@C,A$CLN-[H%/S$@,X'
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M+,^YJ*^&?^&AOVUO^C:M#_\ !_;_ /R31_PT-^VM_P!&U:'_ .#^W_\ DFO
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M@Z=-1ENC[FHKX9_X:&_;6_Z-JT/_ ,']O_\ )-'_  T-^VM_T;3H?_@_M_\
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M8I?V;BOY"_\ 7KA[_H)7W/\ R.^HKF?[4\?_ /1&_'?_ ();G_XU1_:GC_\
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MB?&S7]9OK"\M?''B)M8L4LV<O%&9)VVR;E W8E7IGH:^D*** "BBB@ HHHH
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M %%%% !1110 E%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBL_5-4^PPR)"J76H&&26WL?-5'G*@?*N3ZE03T&X9H
MY'XR_&_P7\ O!TWB?QQK<.C:6K>7'O!:2>0C(CC0?,[$9X Z#)X%<C\ _P!K
M+X7?M46.J0>"]8.H3VB8O-+OH&@N%B;Y=Y1NJ'.,C([&O@WX1^.M _:/_;"\
M6:A^T[<CPYJWA".1]!\ ZT FF6Z(K/*[,QQ*Z(HD(*X<?-RJ[1YYX/\ VR/@
M[\*_VXO%WQ8TGP]J^G^!I+(Z/IMEX;L8D2^DQ&);AD=XU5<*&"CGYD) R< &
MU?Z]XS_9!^*_Q3_9O\-^"K?X@6GC2\COO!UGJEN)X+<S@DR&-@0ZI'E23@!K
M?<>":]A^'O\ P2!'ACP]X>UBV^*FN>%/B)&Z3:E?:(JI;J"P9X80I5AM&5#%
ML$C.W'%;'BJ^^'W_  4:^)GPW\7?"#Q5=Z!XS\!ZE%>:E>7>ES))#8EA(J$X
M\MG\Q,*I?!#R]0#7Z&+[\GUH IZ/IYTG2;*Q-U<7IMH4A-S=OOFEVJ!O=L#+
M'&2?4U>HHH **** "BBB@ KSCXJ?M$?#7X(W&GV_CKQII/AJYOS_ *-!>3XD
MD&<%M@!8(#U8C;[UZ-FOSX^!?[)Z_&SXS?M#:Y\>? =UJUW>:W)8:'JNJD?9
MTLE:4(+100P*H8?W@XP  0=^0#L_#/[&,OQN^/6M_%_XL^*M+^(OA\EE\%Z7
MIXWZ=%9NN8Y67)4L-W0$@L-Y)X"U_P#@FAXHD\'Z/\0O@3KD@M_$GP_UZZ6&
MU?Y3+8RR%TE08Y0N6;J<"1/[P%9O_!+/Q,_A'X _$;1?$&JQ)HG@?Q5J%E'>
MW+[8X+9(TD<DD\*&+M_P(UWOQ _9KO/B'^T1\./V@/A+XPT_2Y)8XXM;GQY]
MMJVF%"59 GWW9<)RP&-C#!3! /K&EIJ]:=0 4444 %%%)0 5Y+\6/BWHJQ:U
MX!\-?$3POH'Q8O;*1-'L-2O8FF2X9"8R82VXYQD<'UP>E>)?\%"/VQ]1_9ZT
MG1/!OA6);3QGXL!AM=<U(&*PTR(ML:9I"-I=21Q_"/F;L#\C?MD?LA?#']FO
M]FW3]>U?Q9J&M_'?5;^"XM=>.H2$ZC,9$:<A"Q B2-F82'YMP3+?-B@#U+X@
M?\$Z9/ /['_CK7KZ]/BKXYRK%XDOO$4S-.XFMW$TD$#/SC8)!N(!<XR,!57[
M=_9E^,UA\??@;X1\:V+KYFH6,8O(5;/D72@+/'V^ZX;G R,''->=? 3]KCX4
M>)OAWX4\/:Q\7/"^M^+8]+M+'5)+B\6W%Y>"%$E*B4+OWON^Z.<].<50_9;_
M &6==_9Q^+7Q!GT'Q+;W'P>\0,FH:3H/,DMM=.Q+[6P%6-5PHP6+ KGE<D ^
MIJ*** "BBB@ HHI* %KY>_:"_P""BWP?_9Q\9+X4\076JZQKJ,HN[70K5)_L
M08 @S,\B <$':I9N>E>S>(?CI\.O"?BB+PUK7COPYI'B"4J%TN]U2"*X^;[H
MV,V03VSUKP?]D[]EO6_AKXB^.-WX\M-'UFR\:^(;BYM;AAYUS<V3LY"S$\!"
M'&$!R"&)ZB@#R[XC>!?$^O>*K_\ :U_9R^(.C?8=4T*3^V-/U^UD>*:&",AO
M+ 4MY@\I?W;;<,OW\'%?/_AGX$WWB#]C/6/VD-'^-FOZ=\0Q->^)M26VOA%9
M->B4^9"T:!<3.%0#/!+(-NW%>L_\$X_B]X+^"?[(OQ2U;Q5KJGP1I'C"]MK-
MKDAVN8FMK?9%&A WM(,G:.[,< 9KOOAO_P $Y?V?/B9-I'Q,\/-XDD\%Z\8]
M:M_"DURT&G2;AN0/"R"38"<A=^.@!*\$ ^EOV6?B/K7Q<_9W\ >,?$5K]CUK
M5]*BN+I=H42/ROFJ >%D $@'8.*]7JO9V<&G6<%K;1);VT"+%%#&H5450 JJ
M.P  &!5B@ HHHH **** "DS7B/[57[5/AG]ESP+_ &KJI.H^(;[,.C:!;DF?
M4)^   .0@)&YL<9 &20*^3Y/V</VQ/BUH4GQ*O?C++X'\77*F[L/ ULLD-K;
M+UC@D(;:K8ZAD?J-QZX /T<8;E(R1QC(ZU\CVO["/P>\??L^Z]\/;#4SK^GW
M&NZAJ,'B%;A+F[L-0:39)^]!^=D,:QL&.6V?-S7DWPI_:"^)W[57PW\>_L_^
M(M6;X9?'K2;7RI-4, 47T"LJRG:N/*=@0&:,8Q(&0#H/J_\ 97_9E\/?LJ_"
MNV\(:%-+?3O)]JU#49LAKNX( 9]N2$4  !1T '4Y- '@W[#WB3XT?"WX@:S\
M OB?HMYKVF^'[/[7H_C2(,T+6I<K%&\C?>#;6"?Q+M92" "/MT<4FT4Z@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .?\ 'GCK0OAGX1U3Q/XEU*'2=#TV(SW5W.<*BC 'U))  '))
M ')KX0U;_@K->V,S^)K?X$^+KKX1K<>2OC)E>-)%W; ZYB\G)8@!#-GD#(/%
M:W_!4OX,_$3QMH/AKQGX>!\5^#?"LHO-8\#N&6.Y"L6,YV$-( HVLN<J#E?X
MJ][_ &6_CW\./VK/@O ?#MA8VMI!:I8:KX2D1"-/RNWR3'C!B(!V,% 8#L00
M #\_OBYJ6G>";[2?VS-!^(VE_$/5KWQ1Y%OH5Y9K;K]A,106?ED,R7$2$9;L
M,,,G&ZW^R1\/]6\-_M#?#;XS>(?!.F:QX0^)EQ>RZ/;>&1)=0^%[Z5F;<8LE
M8_DC(+?P#?\ =,>*]#_9C^&6A?#'_@H;\6?A+H5A;ZS\-I-.35VTNZ07%OI]
MT/)>, -G#(9I(P3SC'I7V[\ /V??#_[.?AO6- \-75]+H]]J]QJL%G>2ATL!
M*1^X@&/EC4#COR<DF@#U,4M%% !1110 4444 %%%(>E &!XY\;Z'\-_">I^)
MO$NI0Z1H>F0F>ZO+AL*BC _$DX  Y)(%?"&L?\%:+RQGD\2V?P*\77GPC2X\
MA?&3K)$DB[]F]<P^3DL0 AE!Y )!X&U_P5*^"_Q%\>>&?#GBWPVQ\4^$/"\H
MO-7\#L&5+I4;<9SL(:0!1M*YR!DKWKW3]E+]H#X<_M4_!> >'+"PLK>VM4L-
M5\(NJ$:?E=ODF/ !A(!VM@!@.@(( !\/_M+:'I?Q*T:__;%T+XI:;KL>A:AI
MP\-:!>V(BCACBD5I+&=3N)G+N[ 8Z9.<$;>)^'6EZGX[^,'A#]J?6OA_I6M>
M O$OB_[#<^%-!:6Y?3+H[88+V2,##R^:Q;E1DA3@&1<>U_LT_#O2/A#_ ,%%
M/BK\)?#5O'J?PUU#25U2ZT><">VLIP8I8T*MD91G95)YP1SQ7VG\&_V;_#/P
M-\4>.]6\-2WEO9^+-0349-&+@6-E*%PQ@C PN]B6/T4<!10!I^'_ (!>!O#G
MQ;\0_$VRT*!/&FO110W>I.,N$C0)A ?N%@%W$<MM&>@KT:BB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ9X-U>'6M"O5S%<1 @AAC<CJ0&1QT*L 17Q[^V/^Q1XEC\;0_'#]G^XD\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIC.%
MZL!SCDXH \E_:._:<\%_LP^#1KOBRZDDNKEO*T_1[(![N_E_N1IG\V. /7)
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ME>M_&+X)^"_CWX/D\,^.-!MM=TIG\V-905D@DP0)(G'S1O@D;E(X)'0U\Z>
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M!H>EQ>5!$6W,<G+.['[S,Q))/<FNOI*6@ HHHH **** "BBB@ HHHH ****
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M[$O[:T7Q]M[GP%X]LQX;^+V@ Q:CI=THB^VF,X::)".&! +(.AY&5Z9/P?\
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M  H Z_O2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E>(/#&C^+-/-
MCKFDV.LV1.3;:A;)/&3_ +K@BM6B@#"\*^"/#O@:P^P^&] TOP]9?\^VE6<=
MM'[?*B@5NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHI,T +7Y^_\ !4[5!J'B;X!>"=<N9+/X?^(/$I_MZ19"B,L<
MENJJY[#;+*?JN>V1^@/![U\!>(KN']O+Q9\;/V??B;I,'A+Q'X4U(7_A;4+,
MF26.W&$6;D#>&&UFZ96XQA2@- 'V7X,^$/@?X?/;S>%_"6BZ%)#;_98IM.L8
MH7$/'R;E&2/E4]>U?'7Q*\8+_P %!]"^/_P0D\*R>&?$W@6>.719[JY61KBZ
MC:559B!B-7:/;P6^2;/45R7@&\_;E_9ZT-_AU:^#-&^(]A9@V^D^)+F\#^5'
MC"[G:5&95XP)%!&,9(Q7T7^Q3^RKJ7[/^C^)O$OC35$\0?%#QI=_VAK^HQL6
MB5MS,L*< 85I')8 9+>BK@ ]3_9X\)^*? ?P/\$^'/&NHV^K>)]+TJ"TO;JV
M#;2R(%"[B<N54*I<XW$%L#.*]&I:* "BBB@ HHHH **2C(H 6OS^_P""K&K&
M\U'X"^#-9N9;/P#XB\4;?$,R2;%\N-[955CZ;99F^J ]A7Z 9KX%\1ZC%^W9
MXT^-7[._Q/T>'PAK_AB^74/"VH6;&658!\BS<C#@@HQZ;EN",*4!H ^QO!?P
M?\"_#YK6;POX1T70Y;>V%K#/I]C'$XA.WY-ZC)!VKU/85\@?$CQHO_!0#1_V
M@?@9)X5?PWXD\$R))HL]W<JYN+J-Y KL0,1J[(%X+?)-G.1BN-^'\W[<7[.>
MB/\ #NT\&Z-\2],LP;?2/$5S>!O*CP=NYFE1BJ\86101C&2,5]%?L4?LKZK\
M ]+\4>*?&^J1Z_\ %#QK=_;]>OHF+11G<SK"G08#2.20!DD <*M 'J?[.7A'
MQ5X"^!G@CPYXVU"WU3Q/I>EP6EY<VH8(2B[57))+LJ!5+G&XJ6P,XKTFBB@
MHHHH **** "BBDR* %K\_O\ @K!K4DTGP*\&:M<2V?@'Q'XI"^(KE'V*(HY+
M<*K''39+,X]X@<<5]_D^]?!'QUU&/]JS]H;QY^S#\1M,A\.6+:9;ZQX*URU^
M>X^T1JSO-R,,KJSJ4&,"%QG)W  ^P_!/P<\!?#_[%/X6\):)HDMO;?98+G3[
M***00D#Y=ZKD@[5SSSBOG&'XL:9^V]J?[0'P!U[PK-X<;0(OL4%Q<3K+)*^Y
MU6YP!A"LJ1NH!;*D<]17COP]?]N#]FW19/AW9>#]'^)VE6>8-'\0W5X&\J+!
MV@LTJ,47C"R*",$ D8KZ(_8G_97U?X#:?XJ\6>.=4CUSXH>-[L7^N7D))BA^
M9G$*'H0&D<D@ '( X44 =%^Q!\*?&_P3_9O\,^#O'U_;7NM:=YPC2U=I!;6[
M2%HX3(?OE0QY   (49"Y/O=+10 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M->R_MO?#7Q;\8OV>=<\$^#]$TW6M2UN>VM9/[3N/*6SB,R%KE,CYFCQNQD'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.C#C'4=>: /L6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI>)-0N)-6U[4^IO-0G.^9\]=H.%7/\*CW->MT4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gizttcucplmb000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,A!T<# 2(  A$! Q$!_\0
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MC\2_\^&E_P#?N3_XNC_A<?B7_GPTO_OW)_\ %UP>:,T?5:78+'>?\+C\2_\
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M7_W[D_\ BZX/-&:/JM+L%CO/^%Q^)?\ GPTO_OW)_P#%T?\ "X_$O_/AI?\
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M/_BZX,]31FK^K4NP6.\_X7'XE_Y\-+_[]R?_ !='_"X_$O\ SX:7_P!^Y/\
MXNN#S1FCZK2[!8[S_A<?B7_GPTO_ +]R?_%T?\+C\2_\^&E_]^Y/_BZX/-%'
MU:EV"QWG_"X_$O\ SX:7_P!^Y/\ XNC_ (7'XE_Y\-+_ ._<G_Q=<'FBCZK2
M[!8[S_A<?B7_ )\-+_[]R?\ Q='_  N/Q+_SX:7_ -^Y/_BZX/-&:/JM+L%C
MO/\ A<?B7_GPTO\ []R?_%T?\+C\2_\ /AI?_?N3_P"+K@J6CZK2[!8[S_A<
M?B7_ )\-+_[]R?\ Q='_  N/Q+_SX:7_ -^Y/_BZX.C-'U6EV"QWG_"X_$O_
M #X:7_W[D_\ BZ/^%Q^)?^?#2_\ OW)_\77!YHH^JTNP6.\_X7'XE_Y\-+_[
M]2?_ !="_&+Q,S!1I^F$DX \J3_XNN#J2#_CXB_WQ_.D\-2ML%D>@7_Q4\8:
M9=M:7NDZ;#.@!9&BDR,\C_EI5?\ X7)XE_Y\-+_[]2?_ !=9_P 2/^1XO/\
M<C_] %<G4TZ%*4%)QW"R.\_X7'XE_P"?#2_^_<G_ ,71_P +C\2_\^&E_P#?
MN3_XNN#S1FK^JTNP6.\_X7'XE_Y\-+_[]R?_ !='_"X_$O\ SX:7_P!^Y/\
MXNN#S1FCZK2[!8[S_A<?B7_GPTO_ +]R?_%T?\+C\2_\^&E_]^Y/_BZX/-&:
M/JM+L%CO/^%Q^)?^?#2_^_<G_P 71_PN/Q+_ ,^&E_\ ?N3_ .+K@\T9H^JT
MNP6.\_X7'XE_Y\-+_P"_<G_Q='_"X_$O_/AI?_?N3_XNN#S1FCZK2[!8[S_A
M<?B7_GPTO_OW)_\ %T?\+C\2_P#/AI?_ '[D_P#BZX/-&:/JM+L%CO/^%Q^)
M?^?#2_\ OW)_\71_PN/Q+_SX:7_W[D_^+K@\T9H^JTNP6.\_X7'XE_Y\-+_[
M]R?_ !='_"X_$O\ SX:7_P!^Y/\ XNN#S1FCZK2[!8[S_A<?B7_GPTO_ +]R
M?_%T?\+C\2_\^&E_]^Y/_BZX/-&:/JM+L%CO/^%Q^)?^?#2_^_<G_P 71_PN
M/Q+_ ,^&E_\ ?N3_ .+K@\T9H^JTNP6.\_X7'XE_Y\-+_P"_<G_Q='_"X_$O
M_/AI?_?N3_XNN#S1FCZK2[!8[S_A<?B7_GPTO_OW)_\ %T?\+C\2_P#/AI?_
M '[D_P#BZX/-&:/JM+L%CO/^%Q^)?^?#2_\ OW)_\71_PN3Q+_SX:7_WZD_^
M+K@\T4?5:78+'HL?Q3\82Z?-?II.FM:PN(Y)1%)A6/0??JM_PN/Q+_SX:7_W
M[D_^+JCIG_)+=;_Z_P"+^0KD<UG3H4Y7O'9A8[S_ (7'XE_Y\-+_ ._<G_Q=
M'_"X_$O_ #X:7_W[D_\ BZX/-&:T^JTNP6.\_P"%Q^)?^?#2_P#OW)_\71_P
MN/Q+_P ^&E_]^Y/_ (NN#S1FCZK2[!8[S_A<?B7_ )\-+_[]R?\ Q='_  N/
MQ+_SX:7_ -^Y/_BZX/-&:/JM+L%CO/\ A<?B7_GPTO\ []R?_%T?\+C\2_\
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M_OW)_P#%UP>:,T?5:78+'>?\+C\2_P#/AI?_ '[D_P#BZ/\ A<?B7_GPTO\
M[]R?_%UP>:,T?5:78+'>?\+C\2_\^&E_]^Y/_BZ/^%Q^)?\ GPTO_OW)_P#%
MUP>:,T?5:78+'>?\+C\2_P#/AI?_ '[D_P#BZ/\ A<?B7_GPTO\ []R?_%UP
M>:,T?5:78+'>?\+C\2_\^&E_]^Y/_BZ/^%Q^)?\ GPTO_OW)_P#%UP>:,T?5
M:78+'>?\+C\2_P#/AI?_ '[D_P#BZ/\ A<?B7_GPTO\ []R?_%UP>:,T?5:7
M8+'>?\+C\2_\^&E_]^Y/_BZ/^%Q^)?\ GPTO_OW)_P#%UP>:,T?5:78+'>?\
M+C\2_P#/AI?_ '[D_P#BZ/\ A<?B7_GPTO\ []R?_%UP>:,T?5:78+'>?\+C
M\2_\^&E_]^Y/_BZ/^%Q^)?\ GPTO_OW)_P#%UP>:,T?5:78+'>?\+C\2_P#/
MAI?_ '[D_P#BZ/\ A<?B7_GPTO\ []R?_%UP>:,T?5:78+'>?\+C\2_\^&E_
M]^Y/_BZ/^%Q^)?\ GPTO_OW)_P#%UP>:,T?5:78+'>?\+C\2_P#/AI?_ '[D
M_P#BZ/\ A<?B7_GPTO\ []R?_%UP>:,T?5:78+'>?\+C\2_\^&E_]^Y/_BZ/
M^%Q^)?\ GPTO_OW)_P#%UP>:,T?5:78+'>?\+C\2_P#/AI?_ '[D_P#BZ/\
MA<?B7_GPTO\ []R?_%UP>:,T?5:78+'>?\+C\2_\^&E_]^I/_BZLW'Q3\86M
MK;7,^DZ:D-RI:%S%)AP.#CYZ\ZKKO%'_ "*'A3_KVD_]"K.="DI17+N%D7O^
M%R>)?^?#2_\ OU)_\71_PN/Q+_SX:7_W[D_^+K@Z,UI]5I=@LCO/^%Q^)?\
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M^&E_]^Y/_BZX/-&:/JM+L%CO/^%Q^)?^?#2_^_<G_P 71_PN/Q+_ ,^&E_\
M?N3_ .+K@\T9H^JTNP6.\_X7'XE_Y\-+_P"_<G_Q='_"X_$O_/AI?_?N3_XN
MN#S1FCZK2[!8[S_A<?B7_GPTO_OU)_\ %TA^,OB11DV&E_\ ?J3_ .+KA*BG
M_P!7^-#PU*VP61]2Z->2ZAH>GWLRJLMQ;1RNJ#@,R@D#VYHJ#PS_ ,BIH_\
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MQCTHJXJ%.5MP;/G<D#DD4M>G>$]-_L=_%FIZE! \MDK(%*AD#\MQD?05YI
MUQ&"."XR/QK6%12;MT"Y'N'J/SHSGI7NGBS5-"\)I:>;X?M[G[0#C8BKC&/;
MWK/U'3M!\6> [K6+72EL)XD=D;8%8%>O3J#6$<7=*3CHPN>-Y&<9%+7?7L;?
M\*HMI#HB("5_T[>F6^<]OO>U9UE\-O$U]:)<K9I&CKN42RA6(^G;\:V5>-KR
MT"YR5&:Z_P +Z)<:?\0K#3M7L]K[B6CD 96&#@^A%7O%7A:]UCX@:E9Z+8KL
MA2)F"X1$RB^O'-#K14N7I:]PN<%15K4M.N-*OY;*ZV">(X<(X< ^F1QFO0/
M/A;2QH<_B;7462WBW&)'&5"KU8CN<\ >U.I54(<VX'F>Y?4?G3J]=L/'7A/6
M+[^S;S18+6UDR$FF5-O_  +CY<_4UQ>I^&[?4/%TNG>%IHKV&1?-C"RC">J[
MCZ5$*]WRS5@N<M172W_@'Q#IFF37]W:)'!$?G_?*3C.,XSSS4]I\-_$]Y9K<
MI8JBL,JDLJJQ'T/3\:OVU.U^9#N<G16FGAW5'UU=%-HR:@Q($3D+G )ZGC&
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MLOK+LK1U87/%:*] ^*VAVNFZM:7UG$L4=XC;U08!9<<X]P17G];TZBJ14EU
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M/79+K7Y%6.)/W"O&SJ7SU( /0>M80Q*DI-+85SERC* 65@#T)&*0 DX ))[
M5[IX=UNS\=C5+*XTB);"$[(WQ]X'..W![\5@^";#3]"\+ZOXCE@2YDADD2$L
MN?E7@8],D_I4_6FDU*.JM^(7/*2"IPP(/H1BBO6?$T=GXL^&R^(ULX[>\ARS
M;!V#;6&>X[UY-6]*K[17M9H+A1116HPHHHH **** "BBB@ KKO%'_(G^%/\
MKVD_]"KD:Z[Q1_R)_A3_ *]I/_0JQJ?'#U_01R-%%%;#  D@ 9)Z 4_R9?\
MGD__ 'R:W/! #>-M)! (,_0_0UZ9XO\ 'A\,>(%T\:5!<0F%9&8G#<DC'3VK
MGJ591GR15Q7/%**]4\?:3INK^$[7Q5ID"PN0ID"KC>K<8..X/]:Q=/\ A5K5
MY917,]Q:VAE *Q2L2W/K@<41Q,''FEIT"YPM%=:GP\U@^(GT626UBN!#YT;N
MYV2KG'RD#.?J.U9MOX5U"Y\4OX>7RUO$=D9F)V# SG.,XQ[5:K0?7S Q**T=
M<T:;0-6ETZXFAEFB W&$DJ,C..0*[/X?^&]'D@M]=U>\3_7^7;VK8 9P>">[
M?2B=6,8<X7//&5D.'5E/H1BA49@2JLP'7 S7?_%Q4'BRT! 53:KDC_>:N_.[
M1;/0[70=$BN[.Y(6>55^XF!\Q/ODG)]*QEB;0C*VX7/ *7:P7<5.T]\<5ZKK
M7AK2K[XL65E#&BPR1>?=1(,+E<G&/? S]:Z2#6--U3Q9?^$I-+M_LL,'!VCD
M\9&.W!_2D\7HFH]+A<\%HK1U_3QI/B"_T]22L$S*N3VZC]"*SJZDTU=#"NP\
M/_\ )/?%?_;'_P!"%<?78>'_ /DGOBO_ +8_^A"LZ_P_-?F(X^BBBMAA3A%*
M1D1OC_=--/2O<M4\0'PMX%T>^BLH9VDBBC*OQU3.:PK573:25[B;/#64J<,"
MI]"**]IL9]+^)GAN]B:PCM;^#@%0"58CY6!QT.#Q7GWAWP'JWB.&6XA:&WMH
MG,9EF) 9AUP .:F&(C9\^C07.7HKKM;^'FJZ&MO--/:RVLTJQ>>C'"%C@;N.
MGN,UG^)?"6H^%Y[:*\:&7[0"8VA)()!P1R!SR/SK2-:$FDGN!@T5T/B'P=?^
M&K*TN;V>V;[2<)'&S%AQDYR!TR/SJ;P/J.@Z5JTEYKD;2!$_<#RMZANY/]/K
M0ZB<.>.HSF2K+C<K+GID8S2 $G !)/8"O<I)8?$W@O4KK6]'2PAC5VMG<8;8
M%RKCN/ZUA>#8+/PY\/;OQ/+:QW%VV2F\=!N"J >PSS6"Q5XMVUO85SRH@@X(
M(/H:4*S9VJ3CK@=*]5\96MGXC\ V?B:&TCM[H%-^P?PLVT@^O.,5L7U]I_P_
MT_1-.BT^*8W3!)W(&<<;F]SDT_K-TK+7MZ!<\1HKO/BIH=MI6O07-G$L4=W&
M6=$& '!Y(^M<'6].:J14EU *BF_U?XU+44W^K_&K>PSZ>\,_\BIH_P#UXP_^
M@"BCPS_R*FC_ /7C#_Z **^=ENS,^>/%'_([:Y_U^S?^AFLVM+Q1_P CMKG_
M %^S?^AFLVO?I? C0****T **** "BBB@ HHHH **** "BBB@!51G=412S,<
M  =36IJGAO6-$@2;4;"2WC=MJLQ!!/IP:V?AMHW]K>+H)'7=!9CSW^H^Z/SY
M_"O3M<-IXU\.ZWIUI\T]E,47G)\Q!D8^O*UR5L0X5%%+3J)L\#HKHO!WA27Q
M5JSVQE,%O"NZ:0#)'8 >YKLK7X<>&-4U"6VT_7YI'MLBXB7:6!Z9!QZ_6M*F
M(A!V871Y717=:-\/DU37]7@DO'@TW39VB:8@;FP3^ X&2:L:IX"TJXT"XU?P
MSJCWJ6V?,C89S@<X.!@]Z'B*:ERA='GM:$.AZE/HTVKQVQ-A"VUYBR@9XX )
MR>HZ5053(ZHG+,0%^IKU/QW%;:'X;\.^'0S1VDC[[ADZD+C)_-L_A3JU'%QB
MNOY V>5T5V?C/P0GAZ33FT^>6Y@O3L5I ,A^,=.Q!_0ULW/PVTJUUO1]*?4+
MHW%ZLC2@;?D"(3QQW/'YU/UFGRI]_P! NCS.BO3]2^'&@V2M9IKCG5)&400N
MZ G<<+E>N/4U+-\.O"]C<Q:=>ZU=1WTJ95F3:I^AQM_#-3];I^?W!='G>E:%
MJ6N/,FFVWGM F^10Z@@>O)&?PK/((.",$<$5V_AM1X7^)MM9P7L5W!))]G,L
M3 AU?IG'<'''M5+XB:4FE>,KI85VQ3@3J!V+=?US5QJMU.7HU=!<Y6BBBMAC
MD=XVW([(WJIP:1F+L68EF/4DY)I** "BBBF 4444 %%%% !1110 5V'B;_D1
M?"7_ %SF_FM<?78>)O\ D1?"7_7.;^:UC4^*/K^@CCZ***V&%%%% !1110 4
M444 %(>0:6BD![-XNLI_%_P_TR\TI?M#Q%93''R3\I5@!Z@]O:N4\/\ PUNM
M2TN[O=5EFTL1C,7FQ\D 98LIYQ7/Z%XMUGPYN73[K;$YRT4B[DSZX[&K>L^/
M=?UVT:TN;E([=_O1PIMW>Q/I7'&E6A[D&K=^HK,Z[X;W,6K^'M8\+S.'7:S0
MD]U;@_@#@_C2_$.=?#G@_2?#=K+AR TC*<$JG?\ %N?P-1?#30(+00^)Y]6B
MCCV2(8#A<<E3N)/3C-<AXWUQ?$/B>ZNHFW6R8BA]T'?\3D_C41@IXAVV6OS%
MU/0?B)%<RZ-X?EC29[>-@URR D!,+DMCMUZTGQ3MM7NH=+;2TN9+0;LBVSPW
M&TG';'2N&?X@:_+H;:3++"]NT7DLS1Y8IC&,T[2?B'XAT>R6TAN8Y84&$$Z;
MBH] ?2B&'J1L]-+A9G:?$!9E^'NCV]_E]3:6( ?QEMIS_,?CBNUT!;^W\/6-
MKJ5PG]I&#OUX]1W(R,UX1/XOUF[UR#5[F=)KFWYA62,&-/HO3WJ2Z\::[>:W
M;:O+= 75L,1;$P@'<;??O2EA)N"CIU86.E\)^'=7N?'>I17^HW-K<6_SW$D+
M8:;<>,'^Z>M=WX4&FIJ6K0Z?I]_&T;[9[N[)/G.">F3^/XUY*_C[7WU>/5/.
M@2Z2,Q%DA #IG.&'>KK_ !1\4-.)5N+=  1L$(*GW^M.KAZM3L%F=?H,\MK\
M-/$4T+F.1+BZVLO!4Y[54\$323?"_P 0+*[.$CGV[CG&8S7#KXRUA-+O=.5X
M!;7KO),HB&27^]@]JATWQ3JFDZ1=:7:O$+6Z#"56CR3N&#@]N*IX>3B^[=PL
M=7XC_P")/\*]#TT?+)>O]HD]<?>'\Q^5>=UKZ[XCOO$)M?M@B46L?E1+&NT
M?Y%9%=-&#C'7?<:"BBBM1A1110 4444 %%%% !78?\TC_P"XL/\ T!JX^NP_
MYI'_ -Q8?^@-653IZB9Q]%%%:C"BBB@ HHHH ***0]#4SDHQ<GT+IP<YJ*ZA
MD&C('>D0?+2/U%>?4Q=2&$5=K5V_%GKT<NHU,PEA4_=5_P %_F.R,XI:C/\
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M2NJ_X6IXI_Y[VO\ X#C_ !KFJ0J>T4X6V$=?X@M9-#^%EAHL[JM[.T<(7/\
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MJ7-QK%SJ:2/!<33-+NB8J5+$G@BDO-6U'4%5;V_N;A5Z++*S ?@:U^J-R3]
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M]_7_ /BJ/^%<>$_^@2O_ ']?_P"*H^OP[,+H^?**^@_^%<>$_P#H$K_W]?\
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MY4GCW.*N^//"O_"5_8HK:^A@NH-S;)#]Y#P3CKQBKG_"N?"G_0)7_O\ /_\
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M*_\ ?U__ (JC_A7'A/\ Z!*_]_7_ /BJ/K\.S"Z/GRBOH/\ X5QX3_Z!*_\
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M_P! E?\ OZ__ ,51_P *X\)_] E?^_K_ /Q5'U^'9AS'SY17T'_PKCPG_P!
ME?\ OZ__ ,51_P *X\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P! E?\
MOZ__ ,51_P *X\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P! E?\ OZ__
M ,51_P *X\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P! E?\ OZ__ ,51
M_P *X\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P! E?\ OZ__ ,51_P *
MX\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P! E?\ OZ__ ,51_P *X\)_
M] E?^_K_ /Q5'U^'9A='SY78?#+_ )'6'_KA+_*O4_\ A7'A/_H$K_W]?_XJ
MK>F^#- TB]%W8:>L,X4J'$C' /7J:BIC82@XI;BNCYQ/4T5]!_\ "N/"G_0)
M7_OZ_P#C1_PKCPG_ - E?^_K_P#Q57]?AV8[H^?**^@_^%<>$_\ H$K_ -_7
M_P#BJ/\ A7'A/_H$K_W]?_XJCZ_#LPNCY\HKZ#_X5QX3_P"@2O\ W]?_ .*H
M_P"%<>$_^@2O_?U__BJ/K\.S"Z/GRBOH/_A7'A/_ *!*_P#?U_\ XJC_ (5Q
MX3_Z!*_]_7_^*H^OP[,+H^?**^@_^%<>$_\ H$K_ -_7_P#BJ/\ A7'A/_H$
MK_W]?_XJCZ_#LPNCY\HKZ#_X5QX3_P"@2O\ W]?_ .*H_P"%<>$_^@2O_?U_
M_BJ/K\.S"Z/GRBOH/_A7'A/_ *!*_P#?U_\ XJC_ (5QX3_Z!*_]_7_^*H^O
MP[,+H^?**^@_^%<>$_\ H$K_ -_7_P#BJ/\ A7'A/_H$K_W]?_XJCZ_#LPNC
MY\J2#_CXB_WU_G7O_P#PKCPG_P! E?\ OZ__ ,52K\.O"BL&72ER#D'S7X_6
MAX^#5K"NCR?XD?\ (\7O^Y%_Z *Y.OHW4?!7A_5KU[V^T]9;AP S^8XS@8'0
MU5_X5QX3_P"@2O\ W]?_ .*J*>-A&"BT%T?/E%?0?_"N/"?_ $"5_P"_K_\
MQ5'_  KCPG_T"5_[^O\ _%5?U^'9CNCY\HKZ#_X5QX3_ .@2O_?U_P#XJC_A
M7'A/_H$K_P!_7_\ BJ/K\.S"Z/GRBOH/_A7'A/\ Z!*_]_7_ /BJ/^%<>$_^
M@2O_ ']?_P"*H^OP[,+H^?**^@_^%<>$_P#H$K_W]?\ ^*H_X5QX3_Z!*_\
M?U__ (JCZ_#LPNCY\HKZ#_X5QX3_ .@2O_?U_P#XJC_A7'A/_H$K_P!_7_\
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M_P! E?\ OZ__ ,51_P *X\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P!
ME?\ OZ__ ,51_P *X\)_] E?^_K_ /Q5'U^'9A='SY17T'_PKCPG_P! E?\
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MQX3_ .@2O_?U_P#XJC_A7'A/_H$K_P!_7_\ BJ/K\.S"Z/GRBOH/_A7'A/\
MZ!*_]_7_ /BJ/^%<>$_^@2O_ ']?_P"*H^OP[,+H^?**^@_^%<>$_P#H$K_W
M]?\ ^*H_X5QX3_Z!*_\ ?U__ (JCZ_#LPNCY\HKZ#_X5QX3_ .@2O_?U_P#X
MJC_A7'A/_H$K_P!_7_\ BJ/K\.S"Z/GRBOH/_A7'A/\ Z!*_]_7_ /BJ/^%<
M>$_^@2O_ ']?_P"*H^OP[,+H^?*Z[Q1_R*'A3_KVD_\ 0J]5_P"%<>%/^@2O
M_?U__BJMW/@OP_>6=K:W&GJ\%HI6%?,8; 3D]^?QJ)8V#E%VV%<^<:*^@_\
MA7'A/_H$K_W]?_XJC_A7'A/_ *!*_P#?U_\ XJK^OP[,=T?/E%?0?_"N/"?_
M $"5_P"_K_\ Q5'_  KCPG_T"5_[^O\ _%4?7X=F%T?/E%?0?_"N/"?_ $"5
M_P"_K_\ Q5'_  KCPG_T"5_[^O\ _%4?7X=F%T?/E%?0?_"N/"?_ $"5_P"_
MK_\ Q5'_  KCPG_T"5_[^O\ _%4?7X=F%T?/E%?0?_"N/"?_ $"5_P"_K_\
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M_P#KQA_] %%>3+=D'GW@LD?$KQ?@D?OG_P#1IKT7>W]X_G7G/@S_ )*5XO\
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M&1D!Z;L=*- .KW-_>/YT;F_O'\ZS-$U[2_$>G+?Z3=I<V['!9>JGT(Z@UI4
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MCI1H!U^YO[Q_.C<W]X_G63H'B/2?$^G_ &[1[Q+F$':V.&0^C \@UJD@ DD
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MJ%E&M[<:BN^SC)PI7 .]N^.>GK7GWQ9^(FA^,/#=EHV@F:\NI[E)B/*(*8!
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M VD$8X]C7F>L_P#"%36.G1_\))XEUA[@@FU0J3"V,=&XSDX&*VOBG9+:^)O
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M;4Z3G>$F[WN1C:=!K$4XTTN11::WU:3OZW.ZHHHKM/FPJ6#_ %H^AJ*I8/\
M6CZ&A@14444 %%%% 'DGQ8DAT7QAX4\2W\:7>GVLC)):EANR2#N53][_ .L*
MS4U[3?'GQB\.W&A0FU_LU6DN9YU$4DR]0@7J<<_]]&KWBV:TTGXY:-J?B,#^
MR'LO+MII5S''*-W7MD$@Y]QZ5#\0M0TG7?&/A.#PU-#=:Y'>J[36A!V0\$AF
M'Y^W-2([V/P1:'X@3^+;FX:YN'@$,-O)&"L& !N4YZX![?Q&N)NY+37?C[I;
M: B,=,@;^T[F$?*>HVDCJ>0N??':CXF>/W;Q /!FE:I!I8<8O]2F8@0J>=BX
M[X_GBM[P)>^ - MH-#T#6[.XO+AAN?<3+<2>I./R':F,] R0<UR?AGP9IW@]
MM7U"6Z%S/>S-<37=P@4HG7;G/W1R:V+;Q'I-WKMUHD-XK:C:)YD\.#E%XYST
M[BO&O$7C*S\?^)Y]$N_$$&B^%;-\3,S$27I!Z#CID?0=>3BFP-;P% NN>,/'
M&JZ'%]GT:[C-O RKM627^\!V[G_@5<^/M.I> M%\!0:/>Q:];:BIFWVY6.(*
MS9DW],<UZ]X3UCPC+:IHWA>_LY8[6/<(+<DE5SC<<CGD]?>H?B%XBE\/>&G%
MB-^K7[BSL4'WFD?C/X#G\O6D(P89X?&'Q,N-7N)HUT+PR3# \C!4DNF^\^3Q
M\O\ /%>C0S17$2RP2I+&WW7C8,I^A%>-:[X9M-$N/ 'A;47!TB2>1[YF?:D]
MQC/S'N"V!]#6Y\-HX+'QIXRTK2VSHEO-$UNB-NC1R#N"FA#/3****8!2BDI1
M3 DG_P!<:BJ6?_7&HJ2V **** "BBB@ HHHH X;Q-HOC>+79=:\+:W"\3HH?
M2KQ?W9*C'RGMGKQBJ.G?%5;;58=%\6Z+<Z+J<I"H<;XI"3@$$= :N^)[7Q]K
M&N2Z=HEW::1HRHF;\C=,Y(RP4<XQTZ#IUI=!^%6@:1=KJ%\;C6=4#;S=W[ER
M&]0O0?CD^](#N:\8\0ZK8^"_C=)K&L1?;+:^LPD!BQ));L /X.HZ'\_K7M'>
MO&]#OM,T'XT>)SXG>*"ZNMK6%S<CY3'W"D\#(Q^1H8#OA_>VOBGXLZYXETF)
M;33UM1 T+$+)*Y(^<H/I7:^&/!VG>#(M5O9KM;F:[F:YN+RX15*KU()R>!R:
MXN&ZT_5_CY9WGAIDD@M[-_[4N(/]6_RL!DC@G.W\O:L37?&5A\1/$LVEWWB"
M#1O"EI)\^7(DOB#VXZ?RZ\F@1T7PK$6H>-_%^N:3 8-!N)5CMP%VJ[CDD#\S
M_P "KTO6M-.L:)>Z:+E[;[5"T1F099 >#@?2LKPIK'A.>T32?#%]9RPVD?\
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M[O=O,I@7);U/J?>M[:W]T_E1M;^Z?RHT :55D*,H*D8*D<$>E8EGX,\,Z?J
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M Y. .!TJKKO@_P /^)98I=8TR&ZDB&$=LA@/3((R/:MS:W]T_E1M;^Z?RHT
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M 2N+^*G_ "(\O_7Q%_,UVNUO0_E7%?%0$>!Y<@C_ $B/M]:TH_Q$".R\-?\
M(JZ/_P!>,/\ Z **/#7_ "*NC_\ 7C#_ .@"BL);B/.O"$CQ?$GQ<4;!,S_^
MC37H/VN?_GH?RKSOPG_R4CQ;_P!=G_\ 1IKO:ZJB5UZ+\BB;[7/_ ,]#1]KG
M_P">AJ&E*D=016?*@)?M<_\ ST-'VN?_ )Z&H:*?*@)OM<__ #T-'VN?_GH:
MAI=I(R ?RHY4!+]KG_YZ&C[7/_ST-1$$=01^%)1RH";[7/\ \]#1]KG_ .>A
MJ&BCE0$WVN?_ )Z&C[7/_P ]#4-%'*@)OM<__/0T?:Y_^>AJ&BERH";[7/\
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M;[7/_P ]#1]KG_YZ&H0">@H^M'*@)OM<_P#ST-'VN?\ YZ&H:*?*@)OM<_\
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M_P">A_*N,^*$\LG@J56<D>?'_6NLKC_B;_R)DO\ UWC_ )FKI17.@.[\-?\
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M;\X[U%Y%MZR5+;_ZW\*BI 'D6W_32CR+;_II113U /(MO^FE'D6W_32BBC4
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M/@0HH/S$=\D$5T%>>>&O^)Y\6?$VM'YH--B33+<]1G[SX_$#\Z&!Z&2%4DD
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M(^<\9X&33N!Z;17C&K:C\0?!_BC3-&_MZ#67UM&C@>> ((9,@%L =!G.*O\
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M4HGU&XM-*L'\M([=MI<\CG\OY5-I$VH>&?&J>';B^EO+"[A,D#S-ED.">O\
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M1Z]2?\:]*\/^(M+\3Z8-0TJX\Z#<48%=K(PZJP/0TT!J4444 %%%% !1110
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M:M\5UT71-#T:?[8DGF2,V#AB,$#'1>Y)]J^D^V*CC@AA+&**-"QRQ50,FL;
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M*;;YL2/M.1N4''YT^E8#P[X:_P#$_P#C7XIUJ8AVMC*(R1V+[%_\=6O<:0*
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M%UN47,%Y#&75'RQVG_OMA^ JKHGB/_A*?C_8ZA%:7%O:+ILD=MYZ;&DC"O\
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M66ULM6U(SVD4J;&*#=\V.V=P_*O0^M%%@"BBB@ HHHH **** "BBB@ HHHH
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MK7L/UHHL!Q/PDL[JP^&NF6UY;36TZ&7=%,A1AF1L9!YKMJ**8!1110 4444
M%%%% !1110 4444 %2R?ZJ+Z5%4LG^JB^E# BHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "I8_]3)^%15+'_J9/PH>P$5%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Q?Q4_Y$>7_KXB_K7:5Q?Q4_Y$>7_KXB_K6E
M'^)'U!'9>&O^15T?_KQA_P#0!11X:_Y%71_^O&'_ - %%82W$>?>"E9OB7XO
MVC/[Y_\ T::]'\F3^Z:\R\)$K\2/%Q!(_?2=/^NIKOO,?^^WYUTU4V_DOR*+
M_DR?W#1Y,G]PU0\Q_P"^WYT>8_\ ?;\ZSY6*Q?\ )D_NFCR9/[IJAYC_ -]O
MSH\Q_P"^WYT686+_ ),G]PT>3)_<-4/,?^^WYT>8_P#?;\Z.5A8O^3)_<-'D
MR?W#5#S'_OM^='F/_?;\Z7*PL7_)D_NFCR)/[IJAYC_WV_.CS'_OM^=/E86+
M_DR?W#1Y,G]PU0\Q_P"^WYT>8_\ ?;\Z7*PL7_)D_N&CR9/[AJAYC_WV_.CS
M'_OM^=/E86+_ ),G]PT>3)_<-4/,?^^WYT>8_P#?;\Z7*PL7_)D_N&CR9/[A
MJAYC_P!]OSH\Q_[[?G3Y6%B_Y$G]TT>1)_=-4/,?^^WYT>8_]]OSHY6%B_Y$
MG]TT>1)_=-4/,?\ OM^='F/_ 'V_.CE86+_D2?W31Y$G]TU0\Q_[[?G1YC_W
MV_.CE86+_DR?W#1Y,G]PU0\Q_P"^WYT>8_\ ?;\Z.5A8O^3)_<-'DR?W#5#S
M'_OM^='F/_?;\Z.5A8O^3)_<-'DR?W#5#S'_ +[?G1YC_P!]OSHY6%B_Y,G]
MPT>3)_<-4/,?^^WYT>8_]]OSHY6%B_Y,G]PT>3)_<-4/,?\ OM^='F/_ 'V_
M.CE86+_DR?W#1Y,G]PU0\Q_[[?G1YC_WV_.CE86+_DR?W#1Y,G]PU0\Q_P"^
MWYT>8_\ ?;\Z.5A8O^3)_<-/>-S%& O(ZUF^8_\ ?;\ZL3,PM;<ACT.>:3BP
M)_)D_N&CR9/[AJAO?^^WYT>8_P#?;\Z.5@7_ "9/[AH\F3^X:H>8_P#?;\Z/
M,?\ OM^=/E86+_DR?W#1Y,G]PU0\Q_[[?G1YC_WV_.CE86+_ ),G]PT>3)_<
M-4/,?^^WYT>8_P#?;\Z.5A8O^3)_<-'DR?W#5#S'_OM^='F/_?;\Z.5A8O\
MDR?W#1Y,G]PU0\Q_[[?G1YC_ -]OSI<K"Q?\F3^X:/)D_N&J'F/_ 'V_.CS'
M_OM^='*PL7_)D_N&CR9/[E4/,?\ OM^='F/_ 'V_.G9A8O\ DR?W#1Y,G]PU
M0\Q_[[?G1YC_ -]OSHY6%B_Y,G]PT>3)_<-4/,?^^WYT>8_]]OSHY6%B_P"3
M)_<-'DR?W35#S'_OM^='F/\ WV_.CE86+_DR?W#1Y,G]PU0\Q_[[?G1YC_WV
M_.ERL+%_R9/[IH\F3^X:H>8_]]OSH\Q_[[?G3Y6%B_Y,G]PT>3)_<-4/,?\
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M\Z+,+%_R9/[IH\F3^Z:H>8_]]OSH\Q_[[?G1RL+%_P F3^Z:/)D_N&J'F/\
MWV_.CS'_ +[?G19A8O\ DR?W31Y,G]TU0\Q_[[?G1YC_ -]OSHY6%B_Y,G]P
MT>3)_<-4/,?^^WYT>8_]]OSHY6%B_P"3)_<-'DR?W#5#S'_OM^='F/\ WV_.
MERL+%_R)/[AI\,;K)DK@8K-\Q_[[?G5BR9C<@%B>#U-#3L!/Y,G]TT>3)_<-
M4-[_ -]OSH\Q_P"^WYT^5A8O^3)_<-'DR?W#5#S'_OM^='F/_?;\Z.5A8O\
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M,G]PT>3)_<-4/,?^^WYT>8_]]OSHY6%B_P"3)_<-'DR?W#5#S'_OM^='F/\
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M5#=7=M8V[3W=Q%!"I ,DKA5&>G)J<_>/UKRSXU7#W&G:)X?A)\W4KX94=U7
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M?H:'=(T9Y&5$499F;  ]S7E_PH80:]XGT_2[F6Y\.6\R_8Y'8L Q^\%)[?X
MU4^*VO7FL0ZAX;T1AY%C;FYU6<'A0/NQ?4G&1_A2YM+B/6XY(Y8UDB=7C895
MT(((]B*C-Y:BY^S&Z@$__/(R+O\ ^^<YKSZTUJ7P_P# :VU.W.+B+3U$1]'9
MMH/X9S^%96F_"O2K_P  1ZA<M<MX@NK7[8+[SVWK(R[P,9QCH#WZT7 ]<[U!
M'>6LTS1174$DJ_>1)5+#Z@'->-W?C?5+_P"#&G^7<.NJWMW_ &8\^?F..ISZ
ME2N3[FKWBKX;:7X8\&/K.AO<VNL:6BS_ &L3,6E((W;AG'?/ %'-V ]=HK,\
M.ZK_ &WX;TW5"NUKJW25@.Q(Y'YUD^*O'FE>$+ZRM=2BN";M'9'B4,!MQQC.
M<G( Q575KC.IHKSV'XO:,MT\&JZ=J>DL8C+%]KAQYH[!0.<FK.D?$_3]2\06
M^CW6E:EID]W_ ,>S7D042^@Z]32YD([FBN1\1_$+3] U>/1X;*\U/5&7>;:S
M0,4'JQJOH?Q.TG7?$5OH45CJ%O?2H[.EQ&%\DJ"2K<YS@9X]11=; =M4,MU;
M0310S7$4<LQ(B1W +D=<#O4U< 1_;GQJ7C=;Z!8?@)I?Z[2?RH8SOZ@FO;.V
MD$=Q=V\,AZ))*JD_@32W9G%G.;55:X$;>4&. 6QQD_6O-M!^%%C<:5-=^,T>
M\UJY=WFF-RV(AVVE3CWH;8'I_! (Z'D&H?MEJ;@VXNH//'6+S5W_ /?.<UY3
M\/9=<U'P-XETG2-1WM;73VVF7D[' 0]P0#VY'H35+Q'X&\+^%O <L]]>!/$L
M<(E6Y6Z;S7G/("KG[N>.GO2N]Q'M-017EK/*T4-U!)(OWD2568?4 YKRSQ1K
M^N1_"70+>222'6-9,=K)(<A\'J3W!(VY^IIGB[X<Z9X4\(-K?A][BUU?2PDQ
MNA,Q,W(#;@3COGBCF[!<]=HK.T#4QK7A[3M3VA3=6Z2E1_"2H)'YUC>*?'VE
M>$=0M+/48KEFNHV=&A0,..-N,YR2>*JZM<9U5%>>P_%[14N9+?5=.U/2I!$9
M8ENH>9AV"@=S5K1OB;8:IXAAT6YTK4M,N;D9MC>1A1+[=>M+F0CN**X_Q#\0
M]/T+65T:WL;W5-3V[WM[- QC'7YB?;^E1:!\3=)\0>(H="@LK^"^>)WD2XC"
M^45R2K<YS@9X]11= =K1115#"K'_ ##_ /MI_2J]6/\ F'_]M/Z5+$5Z***8
MPJN]_9Q3>3)=P++G&QI #^51:LMZ^DW2:<0+QHRL1)Q@GOGVKDH? >E6_AR2
M75PWVX1M)-<^:28SR>.<''ZUC4G-.T5<[L+AZ$X\U:=M;))7?KNM#NJCFGA@
M4--+'&I.T%V !/IS7+_#Z\N+CPBCW<A(BD=$D<_P#'?VYKC_ !3JMSX@OX;Z
M$$:3;W2P0$\>8_4M6<\2HTU.VKZ'50RB=3%3P[E91W?Y?-]CURH(;RUN'9(+
MF&5EZJD@8C\JY;Q_=W L+#2[:0QMJ%PL3LO7;Q_C69XE\*V?AO1H]6T<207=
MFZEG\PGS!G!S_P#6ISKR3=E=+<C#Y?3G"'M)VE4;45:ZTTUU5KO3J>AU#->6
MMNZI/<PQ.WW5>0*3],TVPNA>Z?;78&!/$LF/3(!KS?XEVLEWK]C'$,R?9F8?
M@2?Z55:M[.GSQ5S/+\"L5B?J\Y<N]WZ'J%0_:[87'V?[1#Y__/+>-WKTZUF^
M'=6CU+PS:W[OP(OWI]"O#?R-><Z#/-?_ !$M-3E'%Y+(\?\ NC('\L?A4U,2
MH\EM>8UPV52JNMSNWLT_FU?3\&>LBYMRTBB>(M%_K '&4^OI33>V@@6<W4 B
M8X63S!M)] >]<A%)IC:EXL6U@G2\6)OM#NP*MU^Z.U<W,!_PJS1!C_E^_J]3
M+$N-].C?W.QI1RE5&KR:NXK5?S1;O^!ZL;B$3B S1B9AE8]PW$>H'6I*Y:9]
M-_X3_3T>"<ZB;0F.4,/+"X;@CKGK2:AXWMK;4)+&PL+K49H?];]G'">V:U]M
M%)\W<X_J%6;2I1;NKZ_\/L=516'H_BFQUFRN)X5DCEME)FMY!AUZ_P"%8J?$
M>VN+=9;/2+^YP,RA%'[OZFAUZ:2=]Q1RW%2DXJ#NM_T^\[:BLW1-;M-?TY;V
MS+!<[61ARI]#6E6L9*2O'8Y:E.=.;A-6:"K-C_Q]#Z&JU6;'_CZ'T-$MB"M1
M115 %%%% !1FBLGQ/?C2_"NK7I./)M)&!]]N!^II 7OMUG_S^6W_ ']7_&ID
M=95#1LKJ>A4Y!KY\\*Z9\-)M"T\>(-4;^UIE+S8N'55))P#C@'&*]/UWP[?1
M_#Q="\%R!%DPJRFXY$3'+$.>N?ZU*=Q7.N2^LY)_(CO+9YLX\M95+?EG-2S3
M16\+33RQQ1*,L\C!5'U)KR;Q;\-O#'ASP'=:A!YUKJ=G")([W[0V^27L.N.3
MQP*@\0WL^K^&_AT=><BQO;E#J!<[5<X&W?\ 4;C1=A<]>MKJWO(1-:W$4\1Z
M/$X9?S%(+NV:[:T%Q$;E5WM"'&\+ZD=<>]>8^&KS3/#GC?QFU@\<?A^SMXYW
M6%LQ)+CD+CCGD<>U;OPZTZXFM;SQ5J2$:CK4GFA6ZQ0#_5I[<<T)@=O1115C
M"BBB@ I5^\*2E7[PI 3WO_'RWX57JQ>_\?+?A5>E'9 %%%%4 4444 %%%% !
M116/XFN=;L]':XT"RAO;U'4F"5L!T_BQR.?2DP-BBN"TOXK:3)<BQU^UN=!U
M#H8[Q#L)]GQT^H%=S#/#<1++!*DL3#*O&P8'\10FF YF5%+.RJH'+,< 5#]N
ML_\ G\MO^_J_XUQOQ@U V'PWOU5MKW+QVZG/JV3^BFN+T?P]\*+QK6P?56DU
M HBN?M3JKR8&<'IUS4MZV$>V%T5"Y=0@&2Q/&/7-1V]Y:W>[[-=03[>OE2J^
M/K@UQ7C#PAJ?B*]T+2()6B\-VX_TT)-MD?:,*/4CC'XYKD_''AS2O >H^']2
M\+B2RU&6\6'[.DS,)TXSD,3]/QH;: ]?NKZSL45[R[@MU8X4S2*@)]LFIU97
M171@RL,JRG((]17E^LVNE:I\89+7Q,('L8M*#VL=RV(\DG<>>,]?RK+\+^)K
MG0OA#.UNTDUS-J$MEHZD_,^X@*1GL"6/UHY@/7[>[MKL2&VN(IA&Y1_+<-M8
M=0<=#4U87@_P['X7\,VNFJ0TRCS+B3O)*W+-^?'T K=JD,****8!1110 444
M4 %%%% %A/\ CPE_WQ5>K"?\>$O^^*KU,1!1115#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@"S8_P#'S_P$U6JS8_\ 'S_P$U6J5\0!1115 %%%% !1
M110 4444 %%%% !37=8T:21E1%&69C@ >Y[4ZL/QG_R(^O?]@^?_ - -)@7_
M .V-*_Z"=C_X$I_C5M'21%>-E=&Y#*<@_0BO(/ 'PS\)Z[X'T[4=0TUY+N=6
M+R"XD7.&(Z!L41VEQ\+_ (BZ3865Y<2^'M:?R?L\S[O*D)P,?0D<^AYJ;L1Z
MZMQ \SP+-$TR#+QJX++]1U%25Q>BRZ&?B=XA2U@NUU988_M4LC@Q,O&-HZBJ
MMU\5M.%Y<PZ7H^JZM#:G$]S9P@QKCK@D\T[H#OJ1F5%+,0%49))P *Q-*\7Z
M-K'AM]>M[H+8Q*3,T@VF(CJ&'K_.N*U+XL:=?:#J#+HNKIITT$L$=^T'[HL5
M(&><@$XH;0'IT4T5Q&)8)8Y8VZ/&P8'\13ZX;X/_ /),=*^LO_HQJ[FFMAA1
M113 **** "BBB@ HHHH **** "K$_P#Q[6_T-5ZL3_\ 'M;_ $-2]T(KT444
MT,****8!1110 4444 %%%% !1110 4444 %%%% !5F+_ (\[C\*K59B_X\[C
M\*F6PBM1115#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC_B9_R)DG
M_7>/^M=A7'_$S_D3)/\ KO'_ %JZ?QH#N_#/_(J:/_UXP_\ H HH\,_\BIH_
M_7C#_P"@"BN26Y)YOX3_ .2C^+?^NTG_ *--=[7!>$_^2C^+?^NTG_HTUWM=
M=3=>B*/&?C>^MWMWINE6=E=7&FA?/F6!&.]LX ) [#^=>?:YXDOY_%FA7?\
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M@#@ 5AZIX6LM6\1Z3KD\UPMSI98PI&1L;=C[V1D].Q%4UI8#C?B-!%<?$;P
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M\S\EHQC!)[]",^U>H_$Z^@M_AGK$K2+MGA6.(YX<LPQCUXR:VIO#.CW'AO\
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M/6NC&XN/(MI?-1\KN)R3@\8QS2>&FTUY/\7<J&:X=2BW?24'MVBT_P 3(O\
M=_PM#3MF=WV!L?7:]2?#4Q?V?J*\?:Q='SO[WM_7]:Z&30;:3Q%;ZT991/!$
M8E0$;2.1D\9SS69J7@>QO=0DOK:ZNK">7_6FW? ?WQ6GLIQGSI7U?XG.\;AZ
MM#ZO-N-XQ5[7U3;M;MJ8BF,_$;73:X\O[ _G;>F["Y_'-:GPVC1?!D3!0"\K
M[CCKSBM72/"^GZ-8SV]N)&>X4B6=SEWJSH>C0:#I2:?;R2/$C,P:0C=R?8"B
ME0E&:D_/\18S'T:E!T:;?V$F^JBFK_CL<W\. %M-84#"B_8 #M7:UEZ)H5OH
M4=TEM+*XN9C,WF$<$]A@=*U*WH0<*:BSS\PKPQ&)E5AL[?D@JS8_\?0^AJM5
MFQ_X^A]#6DMCC*U%%%4 4444 %87C&;1H/"MZVOK*VEE0LXB#;B"1C[O/7%;
MM5[VRMM1LIK*\A6:WG0I)&PX8&D]@.5/AGP?+X!D6WT^T727LVE24J-P&W(;
M>>=WOG-8?PQUV/1_A*-2U>X9+*TDE$3MR2@;@ ?7( JQ_P *>TH1FT&MZU_9
M1?=]@^T#R^N<=,X_7WK>\0^ ])\0^';30G>XLM/M7#1QVC*O0$ '(.1SGZU-
MF(X^QTC6?BMJ4&KZY#)8^%X'WV=AR&N?]IO;W_ =S7IFH:1I^IZ>=.O[*&>T
MP!Y,B J,=,#MBN!7X+Z2JA5\0>(54#  NT  _P"^*[O1=+CT32+;389IYX[=
M=JR7#;G;ZD 4*X'GNNZ-IU[K^F_#_0[2*TT_>+_5_(&/W:GY4)[ECCK[>]9<
MVI^)=4TSQ+XEL=>FT^#1;AX;73HD'DE(L9##OD5Z-X<\,)H5[JNH2W;7E_J5
MQYLL[(%(4?=0#)X%8&H_"^"]O;_[-K=]9:9J4HFO=/A V2MWP>V>_6E9A8Z[
M0]0.K:!I^HLFQKFW25E'8D<_K6A45M;Q6EK#;0($AA18XU'90, 5+5H84444
MP"E7[PI*5?O"D!/>_P#'RWX57JQ>?\?+?A5>E'9 %%%%4 4444 %%%% !61X
ME\00^&=';49[:XN0'6-8;==SNQZ "M>C XR!P<CVI,#R?4=.\;?$FW\B]TZQ
MT#1W_P"?F,37##VST_#;]:[WPGX9MO"/A^'2+6>:>-&9S)+C)9NO3H/:MNBD
MHVU$<A\0'\*G3;&W\6)*UK-<@0[-X DQ_$5/ P>]9'Q0\.>'K;X<7LHL+2V:
MU13:/$@4AMP  (ZY';\:[/7] T[Q-I,FF:I!YMNY!X.&5AT8'L:Y&V^$FE":
MW_M'5M6U2TMF!AM+N<&(?4 <_I2:8Q5\;+X7^&NAWVII)<ZG=6L:6]LO,D[X
MXS^&,GWJ/PEX,U;4-;7QAXQ)?5",VED!\EHO;CU]NW?)K1\6?#;2O%^I6U]>
MWVHV[VT8CB2UD150 YR,J2#_ (5EI\&]*1U<>(O$1*D'!NU_^(I6=]1'9ZSX
M:T;Q"L2ZMIT%WY1_=F1>5^AKSHW$-]KNJ:Y96L8T/PC;20Z?"BXC>YQ\S #L
MO^>M>GZA;37>F7-K;7)MII8C&DX7<8R1C<!D<_C6;HGA:PT7PI'X?4>=;>4R
M3,PP9BWWF/N<_A3: \YM-5\3:)9>%O$MYX@GOX];N8XKFQD4>6BR<KL]"*]B
M/!(K@M+^&,-C>V!NM;OK_3M-D,MC8S ;(F[9/\6/PKO:<4^H!1115#"BBB@
MHHHH **** +"?\>$O^^*KU83_CPE_P!\57J8B"BBBJ&%%%% !1110 4444 %
M%%% !1110 4444 %%%% %FQ_X^?^ FJU6;'_ (^?^ FJU2OB ****H HHHH
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M@OYT?N?^>"_G1SBN9]%:'[G_ )X+^='[G_G@OYT<X7,^BM#]S_SP7\Z/W/\
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MN?\ G@M'[G_G@OYT<X7,^BM#]S_SP7\Z/W/_ #P6CG"YGT5H?N?^>"T?N?\
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M@OYT?N?^>"_G1SCN9]%:'[G_ )X+^='[G_G@OYT<X7,^BM#]S_SP7\Z/W/\
MSP7\Z.<+F?16A^Y_YX+^='[G_G@OYT<X7,^BM#]S_P \%_.C]S_SP7\Z.<+F
M?16A^Y_YX+^='[G_ )X+^='.*YGT5H?N?^>"_G1^Y_YX+^='.%S/HK0_<_\
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MPS_R*FC_ /7C#_Z **/#7_(JZ/\ ]>,/_H HKFEN2>>^#/\ DI7B_P#ZZO\
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MA@4---'&"< NX7)_&N-A\4ZC+\8+CPUOB.F)IHND 0;MYV\[O3DT =M1110
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M_86R226UFI)GD90PW8[<@?A[UGZ?KN@Z+X_T2Y\$1ZG;V=U,(-1M)XF$3*2
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M\H?\](_^^J/+'_/2/_OJBX$=%2>4/^>D?_?5'E#_ )Z1_P#?5%P(Z*D\H?\
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M CHJ3RQ_SUC_ .^J/+'_ #TC_P"^J+H+D=%2>6/^>L?_ 'U1Y8_YZ1_]]47
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MC_[ZH\H?\](_^^J+@1T5)Y0_YZ1_]]4>4/\ GI'_ -]47 CHJ3RA_P ](_\
MOJCRA_STC_[ZHN MO_K?PJ*K$*!9,[T/'8U'Y8_YZ1_]]4K@1T5)Y0_YZQ_]
M]4>4/^>D?_?5.X$=%2>4/^>D?_?5'E#_ )Z1_P#?5%P(Z*D\H?\ /2/_ +ZH
M\H?\](_^^J+@1T5)Y0_YZ1_]]4>4/^>D?_?5%P(Z*D\H?\](_P#OJCRA_P ]
M(_\ OJBX$=%2>4/^>D?_ 'U1Y0_YZ1_]]47 CHJ3RA_STC_[ZH\H?\](_P#O
MJBX$=%2>4/\ GI'_ -]4>4/^>D?_ 'U1<".BI/*'_/2/_OJCRA_STC_[ZHN!
M'14GE#_GI'_WU1Y0_P">D?\ WU1<".BI/*'_ #TC_P"^J/*'_/2/_OJBX$=%
M2>4/^>D?_?5'E#_GI'_WU1<".BI/*'_/2/\ [ZH\H?\ /2/_ +ZHN!'14GE#
M_GI'_P!]4>4/^>D?_?5%P(Z*D\H?\](_^^J/*'_/2/\ [ZHN!'4LG^JC^E)Y
M8_YZQ_\ ?5/D3,<8WH,#J3UI7 @HJ3RA_P ]8_\ OJCRA_STC_[ZIW CHJ3R
MA_STC_[ZH\H?\](_^^J+@1T5)Y0_YZ1_]]4>4/\ GI'_ -]47 CHJ3RA_P ]
M(_\ OJCRA_STC_[ZHN!'14GE#_GI'_WU1Y0_YZ1_]]47 CHJ3RQ_STC_ .^J
M/*'_ #TC_P"^J+H".BI/*'_/2/\ [ZH\H?\ /2/_ +ZHN!'14GE#_GI'_P!]
M4>4/^>D?_?5%P(ZEC_U,GX4GEC_GI'_WU4BH!%(-Z<]\]*38%>BI/+'_ #TC
M_P"^J/*'_/2/_OJG<".BI/*'_/2/_OJCRA_STC_[ZHN!'14GE#_GI'_WU1Y0
M_P">D?\ WU1<".BI/*'_ #TC_P"^J/*'_/2/_OJBX$=%2>4/^>D?_?5'E#_G
MI'_WU1<".BI/*'_/2/\ [ZH\H?\ /2/_ +ZHN!'14GE#_GI'_P!]4>4/^>D?
M_?5%P(Z*D\H?\](_^^J/*'_/2/\ [ZHN!'7%_%3_ )$>7_KXB_K7<>6/^>D?
M_?5<3\5DQX&E^=3_ *1%T/N:THO]X@1V'AK_ )%71_\ KQA_] %%'AK_ )%7
M1_\ KQA_] %%82W$>;^$_P#DI'BW_KM)_P"C37>UP7A/_DH_BW_KM)_Z--=[
M774W7HB@HILDB0Q-+*ZI&@+,S'  '<FL*R\;^%]1U 6%IKME+=,<+&K_ 'CZ
M G@GZ&L]$!OT45GZSK6G>']-?4-4N1;VJ,%+E2>2<#@<T: :%%1V\\5U;17$
M+;HI4#HV,9!Y!K!U'QWX6TB_EL=0UJWM[J(X>)PV5_(4: =%16!IWCCPOJ]T
MEK8:Y9S3N<)'N*ECZ#(&3[5OT*S **** "BBB@ HHK+M?$6E7NN7>C6UV)-0
MM%S/$%;Y!QWQCO1H!J4444P"BJ]]>VVFV,U[>S+#;0+OED;HH]3BH=)UG3M=
MLA>Z7=QW5L6*>8F<9'4<TM +U%%% !1113 **** "BBB@ HHJEJVK6.AZ;+J
M.I7 @M(L;Y""<9.!P.>II: 7:*KV5Y;ZC8P7MK)YEO.@DC?!&Y3T/-1:IK&F
MZ+:_:=3O8+2'. \K8R?0>OX4: 7:*R]'\1Z-XA1WTC4K>\$?WQ&WS+]0>146
MH^+?#^D7AM-1UBTMK@*&,<CX(!Z&BZ V:*RM*\2Z)KDTD.EZG;7<D:[W6)LE
M1G&36K1H 4444P"BBB@ JS/_ ,>EO]#5:K,W_'I;_0U+Z 5J***H HHK'UCQ
M5H/A]TCU;5;:TD<95';+$>N!DXI: ;%%5=.U.QU:S6[TZ[ANK=NDD3 CZ>Q]
MJ=?7UKIME->WLZ06T*[I)7. HHT L45!97MMJ5E#>6<RS6\R[XY%Z,/49K&?
MQQX6BU(Z?)KUBMT&VE#)P#Z;NF?QHN@.@HIKR)'&TCNJHHW,S'  ]2?2L.Q\
M;>&-2OQ8V>N6<UT3M$:ORQ] 3P?PHT WJ*** "BBBF 4444 %%%4+O6=/L=2
MLM.N+@)=WQ86\6"2^T9/3IQZT@+]%%8&H>./"^E7IL[[7+.&Y4X:,L25/H<
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M4;<RM<****9(4444P"K-C_Q\CZ&JU6;'_CZ'T-3+8"M1113L 4444P"BBB@
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M>S;1D?G7'>+E!^,G@G(SA9C5/8"*;XH:SHFII8>(_"LEM<749:R2VE\PROG
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MH->??$6R?4/$=A;1_?:V<K[XR?Z5Z!I%L]GHUC:O]Z&W2,_4*!7*Z\ ?B3H
M(X,;?UK7$1YJ*3ZV./*JGLL=.I3Z*;7R3-;PQK4=WX/@OYF_X]XBLV?5.OYX
MS^-<!X<\ZX\=:=J4Y):_>2<9],L!_*GW\MSHESK7A:W1MM_<(;?C@*YY_3 _
M"MZYLX]/^(/AVSB7"0V@0?ANKFE)U.6_V6OON>M2I1P_M7':K&37^'EO^;_
MLI?6]QJ/BRVBT^*"2&)A).K'=+UZBN;F_P"26Z)_U^_U>M6Q_P"1A\;?]<V_
MK65-_P DMT3_ *_OZO2FVT[]G^95""A*"C_-3_\ 2&=C/?6R>/=/LVT^)KA[
M0LMV6.]!AN .F./UJN_B[4=0U.YM/#^E"[CMCMDGD?:I(["JU^I?XH::JGEK
M!@/^^7IOP]O+:SM=1TZYE2&\BN69UD.TL.F>?I6ZG)SY+VNW^2//EAZ4:'MW
M#F:C'1MVU;N]_P#@&MHOBS^TX[Z"XLVM-1LE+26[-P0.X-9%AXVUW6+)KC3?
M#ZR+'_K&,G!/HOKQ5:WGCU+Q]KEY9-OMH[!HWD7[K-@#K]1^E;'PX&/!5O[R
MR?SHA4J5)*/-WU[V'7P^&P]*5;V=V^31MZ<R;:W\C3\,^($\1Z6;H0F&6-S'
M+&3G:U;5<5\.?^/76?\ K_>NUKJP\W.DI,\C,J,*&*G3IJR6WS2859L?^/H?
M0U6JS8_\?0^AK26QPE:BBBJ **** "H[@RBVF-NJM.$8QANA;' /MG%244 >
M#ZYH/B"Q\9>%-7\2ZHMUJ%Y?A!!$/W=N@*G:OY__ *Z](^*FH?V=\.=8D!PT
ML8@'/]]@O]:Q?B=_R-'@C_L(G_V6NC\?ZMINB^&VN]7T<:I8^<JR1,BLJ9Z,
M0WH?YUG;<1YCHFM_#:STC38-2\-R,OE)&^HS6/R2/CDY[UT_Q$2QM%\%WXC0
M^'+.^5IO+7=$J$#8Q _AP&_/WK7\:ZMX>D^&5]*\]H]G/:;;:-&7YF(^0*!T
M(..G3%6OAS9S1_#?1[;4(\L8,[)%S\A)*@@^U"70#D='\0:=8^*_&OBRQ*G0
MX[>)1(B[4N)QV7IDDG_QZNL^'>BW-CH<NJZD,ZMK$GVNZ)'*@_=3Z ?SK(UJ
M"+Q7X\L/"EM&BZ/I!6]U%8U 5I/^6<>!^9_'TKD;BU?7=&\8^*[S4[R'5=+O
M)$L_+G*+ L9&U0OOT_&C8#W2BLWP[>SZCX:TR]N1B>>UCDDXQDE1D_CUK2JT
M,****8!2K]X4E*/O"D!/>_\ 'RWX57JQ>_\ 'RWX57I1V0!1115 %%%% !11
M10 5C^)K?6[G1V7P]>0VNH*ZNC3*"K =5/!ZUL5C^)=3U'2=':XTK2WU*\:1
M8X[=6VYSW)]!28''Q_$?5O#TBV_C;P]/9@''V^S7S(&]SZ?G7=Z5JUAKFGQW
M^F74=S:N2%D3ID=1]:X!O!OC'Q>N?%NN"PL'ZZ;IO&1Z,W^.:[K0=!T[PUI,
M>F:7"8K5"6 9RQ+'J234QN(-?_M;^P[H:$(3J94"#SON D@$GZ#)_"O)_#FA
M:AH7QJM$U74VU'4+BP>>>9AQN/8>PQ7M5>;7O_)P%A_V"F_K1(&4?C5J-I$/
M#=A>EC:27PFN55=Q:-< X'?J:30]8^&UYKUM9?\ "-+I=\[JUJUW9^7O8'Y<
M'L<]*Z;Q3K^@Z5XLT*UUK2HI'N"?LVHS(A6W;/3)&1SC\\US?QIFLKW2=)T^
MT>*;6I;Q#:+$P+J.YXZ G%)[W FUF^TW0?C!)J'B,K'83Z7Y=M/-&60$$[EZ
M'DC/YUA:%J=_H_PK%A8QR1W^O:C+#I439!2)\ O[ #=^>:]FDMH+B!4NX8I0
MH!/F*" 1WYKR^*\GUR^\1^.(%S::1:RVFC#;P6 ^>4#^7_UJ&K >B>'M#M_#
MGA^STFV'[NWC"EL??;JS'W))-:=>&VMJ_A[2O!?BBQU*]FU/5KN-+WS)RZSA
M_O K_L]/PKW,\$CWJHNX(2BBBJ&%%%% !1110 4444 6$_X\)?\ ?%5ZL)_Q
MX2_[XJO4Q$%%%%4,**** /*_B;;07?Q!\#V]S#'-!)-(KQR*&5AE>"#UKK=2
M^'7A+4[.6V?0K&#>"!+;0+&Z'U!4#I7*?$F6.#XB>!I9I$CC6:0L[L%4#*]2
M:[;4_&7AS2;*6[N-9L62-2VR*X5W8^@ ).34:78CS?P3K$VG^"/%^B:K&NH1
MZ"SHL4K'$D?S#83Z97]:Z9/'&F^'_AQH^J+IOE&[C6.STZW;.6/103SCWKC_
M  O9W4WPV\<^([J(Q?VQYDL2MU*#<<_0EC^59?B"WD_X0OX<7KW4MG9Q I+=
M1KDPLVW:W_CIJ;@=W-\0O$6AM;77BGPK]ATN=PAN()]Y@)Z;Q6MXM\='0[S3
M]+TFP.JZOJ*[[>!&VKL_O$^G7\C7$>,-!MK/P\7UOXD:E>V-PRA8$C20S9.0
M0H?D=ZL(\7A_XO>'IM0G9;*?1UM[6XN5V?-M(P>P.>H[;A3NP*'B?7]9U'QQ
MX/L-=T3^S;NWU!9%*2^9'*K,@R#Z@@YKV\]37E7Q'U.PN/'G@FQAFCENX;\2
M2!&!V*S(!G'KC]*]5[TX[L HHHJQA1110!9L?^/G_@)JM5FQ_P"/G_@)JM4K
MX@"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JQ/\ \>UO]#5>K$__ ![6_P!#4O="*]%%%-#"
MBBBF 4444 %%%% !1110 4444 %%%% !1110 59B_P"/.X_"JU68O^/.X_"I
MEL)E:BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%% !7'_$S_D3)/\
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MX"T0W_Q D\0V.A2:/H=I:FVM(Y8]CRL>K$'D]6.?I7KN>,9XHS[U/*(**/\
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M/!*I62.1=RL#V(J;\:/QHT XVU^%?@VSOENXM'5G1MR)),[HI_W2<?GFNR'
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M>?;-.TT+= 86:61I&4>VXG'X5TWXT?C19 5M0LDU+3KFREDECCN(S&[1-M8
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M"N/^)O\ R)DO_7>/^M73^- =WX9_Y%31_P#KQA_] %%'AK_D5='_ .O&'_T
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M_NK^5'G-_=7\JBHHL!+YS?W5_*CSF_NK^51446 E\YO[J_E1YS?W5_*HJ*+
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MNF=IW=L@X_.O4*\%^#^9/BUXHEBYBQ.21TP9>*]ZJEL,**** "BBB@ J5_\
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MIDGM7IE>8^+-"\1:-X_C\9>%[6+47EMQ!>V#.%=U P"/P ^A'>DP&V>J>(_
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M60L]4TVY-K=P(VY0PS@J?0X/Y4(#J****8!1110 4444 %%%% !1110!*O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 5+'_J9/PJ*I8_]3)^%#V
MBHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N+^*G_(CR_\ 7Q%_
M6NTKB_BI_P B/+_U\1?UK2C_ !(^H([+PU_R*NC_ /7C#_Z **/#7_(JZ/\
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MM;=]ZPQKZMW)KMJ** "BBB@ I124HH DG_UQJ*I9_P#6FHJ%L 4444 %%%%
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M/Z4,"*BBC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC% !11BC%
M!4L?^ID_"HZD3_42?A0]@(J**,4 %%&*,4 %%&*,4 %%&*,4 %%&*,4 %%&*
M,4 %%&*,4 %%&*,4 %<7\5/^1'E_Z^(OZUVE<7\5/^1'E_Z^(_ZUI1_B+U!'
M9>&O^15T?_KQA_\ 0!11X:_Y%71_^O&'_P! %%82W$>>^"R@^)7B_P QMH\Y
M^<?]-37HV^V_Y['_ +Y->9^$_P#DH_BW_KM)_P"C37>UTU8WDO1?D47]]M_S
MW/\ WR:-]M_SW/\ WR:H45GRBL7]]M_SW/\ WR:-]M_SW/\ WR:H44<H%_?;
M?\]S_P!\FC?;?\]S_P!\FJ%%'*!?WVW_ #W/_?)HWVW_ #W/_?)JA11R@7]]
MM_SW/_?)HWVW_/<_]\FJ%%'*@L7]]M_SW/\ WR:-]M_SW/\ WR:H44<H6+^^
MV_Y[G_ODT;[;_GN?^^35"BCE O[[;_GN?^^31OMO^>Y_[Y-4**.5!8O[[;_G
MN?\ ODT;[;_GN?\ ODU0HHY4%B_OMO\ GN?^^31OMO\ GN?^^35"BCE06+^^
MV_Y[G_ODT;[;_GN?^^35"BCE06+^^V_Y[G_ODT;[;_GN?^^35"BCE06+^^V_
MY[G_ +Y-&^V_Y[G_ +Y-4**.4+%_?;?\]S_WR:-]M_SW/_?)JA11RA8O[[;_
M )[G_ODT;[;_ )[G_ODU0HHY0L7]]M_SW/\ WR:-]M_SW/\ WR:H44<J"Q?W
MVW_/<_\ ?)HWVW_/<_\ ?)JA11RA8O[[;_GN?^^31OMO^>Y_[Y-4**.5!8O[
M[;_GN?\ ODT;[;_GN?\ ODU0HHY4%B_OMO\ GN?^^34CM#Y4>9,+S@X/-9E6
M9_\ CUM_H:3B!-OMO^>Q_P"^31OMO^>Y_P"^35"BGRA8O[[;_GN?^^31OMO^
M>Y_[Y-4**.5!8O[[;_GN?^^31OMO^>Y_[Y-4**.4"_OMO^>Y_P"^31OMO^>Y
M_P"^35"BCE O[[;_ )[G_ODT;[;_ )[G_ODU0HHY0L7]]M_SW/\ WR:-]M_S
MW/\ WR:H44<H6+^^V_Y[G_ODT;[;_GN?^^35"BCE06+^^V_Y[G_ODT;[;_GN
M?^^35"BCE06+^^V_Y[G_ +Y-&^V_Y[G_ +Y-4**.4"_OMO\ GN?^^31OMO\
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ML?\ ODT;K?\ Y['_ +Y-4:7%'^N&/_EC]S_^2'[")=W6_P#SV/\ WR:-UO\
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M]]/F)S:?D=W8^)QJ7B[4-#M;4O%I\:FXN]_RB1ND8&.3C/?M705YYX8U'0/
MVEPZ9K>LVT.MWC?:KT2$[O-?GYB!\N.!SBO058.H96#*PR"#P17E9AAU2J?N
MXM1V3U]ZV[^;-(.ZU'4445YY84444 % ^\/K10/O#ZUI2_B1]4)[$MS_ *\_
M2HJEN?\ 7GZ5%75F7^]U/4F'PH****X2PHHHH *RO$'B#3_#6DS:CJ4ZQQ1K
M\JY^:1NRJ.Y-:M>>^.? NG:E_:_B+49KBZDAL7^S6SN1%"0G4#U)YKMP%*A5
MKJ-=M1\MWKMY>I,VTM#K/#.N+XD\.V>KI T"W*;A&S;BO..M<E=?%.*WGN[F
M+0KR?0[*Y%M<:FCJ%5L@$A#R0">M:7PN&?AKHP/>$_\ H1KB9M \56GAW5_!
M5OH33Q7UXTD.I"51$L3.&)8'G(Q7JX7!X5XJK3J)6C*R3=K1N[O?5I&<I2Y4
MT>D^)?%-KX<\._VL4-SYA1+:)#@SN_W0/PY^@K9MGEEM89)X?)F= SQ[L["1
MR,]\5Y>L]EJ/BR*6_NXX_#O@^%(O.E;"2W>T#/OMP/QQZUZ!HOB+1_$4+RZ1
MJ$-VL9P^P\J?<'D5QXS!*A2CR1;ZM]K_  KM>VK]2HRNS5KGW\3H_C*/PY:6
MQN)$@,]W,'PMNO\ "#QR3Z5NR.(XWD8_*BEC^%><?"$G4].UGQ+/EKK4[]R2
MW4*O1?H,_I66&H0="K7J*ZC9+U?^2NQR>J2-KQ3\0].\-W\>EPVMSJ>KRC*6
M5JN6 /3)[?J:RH?BLMIJ,%KXE\.ZAH4=P=L5Q/\ ,F?<X&/UQ69\(434]8\5
M:_<@/?2WIB#M]Y$Y./8=!^%>AZ_X?T[Q-I,FF:G"9+=V#?*<,I!X(/:O0K4\
M!A*RPM:FW:W-*[O=J^BVT\]R$YR7,F8_C/QO'X033L:=/J$E](8XD@< D\8
MX.<YK%D^)VK0(TEQX UZ.)1EG,9X'_?-8_Q9$.A/X+$4<LD%C>)M0'<[*FW
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M**H HHHH LV/_'S_ ,!-5JLV/_'S_P !-5JE?$ 44450!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M6)_^/:W^AJO5B?\ X]K?Z&I>Z$5Z***:&%%%%, HHHH **** "BBB@ HHHH
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M&O!>:AJJI##;1 F122"=P['C'XUZF0""" 0>#[UF6GAO0K"]^V6>CV%O<_\
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MFR?WS1S,"GY,O_/-_P#OFCR9?^>;_P#?-7/-D_OFCS9/[YHYF!3\F7_GF_\
MWS1Y,O\ SS?_ +YJYYLG]\T>;)_?-',P*7DR_P#/-_\ OFE\F7_GF_\ WR:N
M>;)_?-'FR?WS1S,"GY,O_/-_^^:/)E_YY/\ ]\FKGFR?WS1YLG]\T<S I^3+
M_P \W_[YI/)E_P">;_\ ?-7?-D_OFCS9/[YHYF!2\F7_ )YO_P!\T>3+_P \
MW_[YJ[YLG]\T>;)_?-',P*7DR_\ /-_^^:/)E_YYO_WS5WS9/[YH\V3^^:.9
M@4_)E_YYO_WS1Y,O_/-_^^:N>;)_?-'FR?WS1S,"GY,O_/-_^^:3R9?^>;_]
M\U=\V3^^:/-D_OFCF8%/R9?^>;_]\FD\F7_GF_\ WS5WS9/[YH\V3^^:.9@4
MO)E_YYO_ -\TODR_\\W_ .^:N>;)_?-'FR?WS1S,"GY,O_/-_P#OFI_*D^P;
M=C9\S.,<U+YLG]\U)YC_ &?.XYW=:')@9_DR_P#/)_\ OFCR9?\ GF_Y5<\V
M3^^:/-D_OFCF87*?DR_\\W_[YH\F7_GF_P#WS5SS9/[YH\V3^^:.9@4O)E_Y
MYO\ ]\FCR9?^>;_]\FKOFR?WS1YLG]\T<S I^3+_ ,\W_P"^:/)E_P">;_\
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MU<\V3^^:/-D_OFCF8%/R9?\ GF__ 'S1Y,O_ #S?_OFKGFR?WS1YLG]\T<S
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MFCS9/[YHYF!3\F7_ )YO_P!\T>3+_P \W_[YJYYLG]\T>;)_?-',P*?DR_\
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MT>;)_?-',P*?DR_\\W_[YH\F7_GF_P#WS5SS9/[YH\V3^^:.9@4_)E_YYO\
M]\T>3+_SS?\ [YJYYLG]\T>;)_?-',P*?DR_\\W_ .^:XWXG1NG@N0LC ?:(
M^2/<UWWFR?WS7$_%5V;P-*"Q/^D1]?J:TI2?M$-'8^&?^15T?_KQA_\ 0!11
MX9_Y%71_^O&'_P! %%<\MR3SWP9_R4KQ?_UU?_T::]$KSOP9_P E*\7_ /75
M_P#T::]$KHJ_%\E^0PI<$=0:\E^-GB?5=,ATG0M(N'MI=3=A),C;6V@J H/8
M$MSCTKBM?T_Q#\&]9TC4;;7IK^VN\F>)\A6(QO4J20<@\-UK%L#Z.I"0HRQ
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M#JZ***8!4O\ R[?\"J*I?^78_P"]4L"*BBBJ *7!]#5'5M/75=+GL7FDA68
M&2(X8<@\?E7FOBOPI8^&](-U_;&I2W$AV01&3[[?X"L:M25-72NO4[\#A*6)
MDH2GRR;LERW_ %1ZN>*7GTKSR(7W@GX<37$T[MJ%P05#G/E,W0<]P,_C523P
M3<6OAG^VX]5O1K,</VIV,G!P-Q7UZ5#KRZ1UM=G0LLI7;E5]WFY8NSU???1:
M[ZGIM+@XZ5YOJ_BR]O\ P1H_V.3R[[4Y!;R2+P5(.&(],G^=0ZYX9E\%Z=%K
MFE:E=O<6[KYZRME90>O'_P"ND\1UBKI;A#*=5"K/EE)M15KW:TU?17T6YZ;2
MX/I5>RNDOK"WNHQ\DT2R+]",UY?\4EN'\06"VS,)!;LXVGT)-76K>SI\]KF&
M7X!XO$_5W+EWU]/N/5Z7!ZUE:!JB:KX=L]0+ !X09#V! PWY$&O,-#U"XU3X
MGP:A(6$5S-(8@3P44%1_*E/$*/+;7F-,+E<ZSK<SY?9IW\VNGX,]DP:,'.,'
M-<*BZ:NI>+FM+RYDO#"WVB-TPD9Y^Z>]<Q/(_P#PJG0CO;<;[DY_VGJ98FU]
M.C_!V-*64^T:]ZUW%;?S)N^_E\]SV#G&<45RDZZ:?B#I[R7=P-0^R'9 $_=L
MN&Y)]>OY"I]4\<:+I5\]B\DL]RGWT@C+[?J:U]K%)N1Q_4JDI1C23DVK[?U=
M>9TE%9.E^)-+UG3Y;RRN/,CA!,BE<,N/45C-\2O#HA62.6XER-Q583E!ZGTI
MNK32NV3# XF<G&,'=;Z;'7T52TK5K+6K!+VPF\V!B1G&"".H([&KM6FFKHYY
MPE"3C)6:"I;?_6CZ5%4L'^M'T-#)(J*** "BBBF 445E^)&U9/#M\="B234S
M$1;AV  8]^>.*0&K@XSBDKQ36/ ,WAWP-/XFOO$^JP>)88O/>=KOY&EZ^6!W
M].OZ<5OZ]XXU2R^#5AK8'EZQJ$442-C&)'ZN!VX!(I7 ]-P<9Q2?A7C.L?#R
M^\,>$G\3Z=XCU4^(+.$7=P\LY:.;'+*5_/J3G\:M>+=<?Q7HO@.!II+73M>N
ME%_Y;["<;?DR.Q)/Y#TIW ]<[9I,C.,C/IFO+O"$MOX1\<>+=%ANI!H&GV\=
MV%FE+BV8C+*">?7\JU/AS;7&K3:EXUU!66?5WVVL;?\ +*V7A0/KU_*BX'?4
M444P"BBB@ I1UI*44 23_P"N-15+/_KC45); %%%%, I0">@_2DKQ;Q=H<?B
MGXZVNBW=Y>06LFF^8?LTNQLJ'(Z@CMZ4F![401U%)R>E>1ZO\*KSP[ITVJ^$
MO$FKQ:A:H95BGF#K* ,E> .WJ"*GNO$VF>,O@PNIZ[>W&G1F1([J6T3<RR*X
M' ]#Q^=%P/5:*Q-0\0Z/X9\.6]_J5\(;,1(L;N/GD^48PO4DCM65HGQ.\,:[
MJ<>FV]S/!=S?ZF.Z@,7F^FTGKF@#L*7!]*YWQ/XVT+PCY*ZK<L)Y_P#500H7
MD?WP.U>=W?C#3?%'Q>\&R:1=3&.-9DGAD5HV1MKG#*:+@>RTNUO0T=Z\)TSP
MA:^-OB=XQ@U'4-2@CLYE:(6L^SKP<Y!]*+@>[8(ZBDKQ;Q+X3UCX9:?_ ,))
MX7U_4+BVMG7[797K^8KH3C/IU..F>>#7H\GC;1+3PE9^)-0NEM;.ZB61 >6)
M89V@#J1S^5%P.BHKA[#XL^%+[4X+ SW=K-<,%A-U;-&KD].3ZFM^#Q3I5SXI
MN?#:2R+J=O&)7C>,J&4@'*GOU%%P-FBLC4?$^EZ5K>FZ/<RR?;M1)%O''&6S
MCJ2>PK7H 7DTE>)?%7Q1XHU'3-9L=,TR:RT.PE\F[OI3M:X(;&U/]DGTZUZ;
M!=W%E\/H[RV3S;B'31(BGG+"/(HN!T.#C..*2O!M#\,VOB7P!<^,=2\6Z@NL
M[993.MUM2W92<(5Z]AW'48KTSX9ZUJ&O_#_3=0U,EKMPR-(1@R!6(#'W(%"8
M'6T444P"BBBD!*O_ ![O]:BJ5?\ CV?_ 'JBH0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 2V_^M_"HJEM_P#6_A45 !1113 ****0!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5+)_JH_I452R?ZJ+Z4,"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4?:(/^>;?]]4?V_EO_/U![.?86EIOVB#_GFW_?5'VB#_ )YM_P!]4?V_EO\
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M7LR6FG9A11]IMO\ GG)^='VFV_YYR?G6VH@HH^TVW_/.3\Z/M-M_SSD_.C4
MHH^TVW_/.3\Z/M-M_P \Y/SHU **/M-M_P \Y/SH^TVW_/.3\Z-0"BC[3;?\
M\Y/SH^TVW_/.3\Z-0"BC[3;?\\Y/SH^TVW_/.3\Z-0"BC[3;?\\Y/SH^TVW_
M #SD_.C4 HH^TVW_ #SD_.C[3;?\\Y/SHU EM_\ 6_A452V\T+2X1'!P>M1?
M:+?^Y)2UN 44?:+;_GG)^='VFV_YYR?G1J 44?:;;_GG)^='VFV_YYR?G3U
M**/M-M_SSD_.C[3;?\\Y/SHU **/M-M_SSD_.C[3;?\ /.3\Z-0"BC[3;?\
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M!QFF,**.<5RD?BJY?XGW'A4VT(MHK$70FYWEOEX],?-Z4-V ZNBBBF 4444
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MBN ADE1BI<L,\D<X"\X%9U]IWB[XL^(M/.I:-+H^D6GWFD1EX)^;&[EF.,#
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M([/8;B=+<^;<.!CY01N([D#-='XK\&ZUK'P_\*:CIUC<+JFD6J12VCQE9?E
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M;_CTM_H:E] *U%%%4 =Z\4LKS71\2/$5QX!M$O+61@MZ+P!(1,.NPY!ZY_\
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M >#\:U\0?%7B#AHX773;=O\ 93EOUQ^5=EJ]X]AHM]>1Q/+)# [JB EF(!P
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M-):72UMZSE^"!JST.S\/>(]-\3Z=]MTZ1V57,<D<B[7C<=58=C5/Q[J4FD>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5B?\
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M7HHHK484444 %68O^/.X_"JU68O^/.X_"IEL)E:BBBJ&%%%% !1110 4444
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MS^E6/"W@:;2-=NO$.LZJVJ:S<)Y?F[-B1IQPH_ 5W?V*?^X/^^J/L4_]P?\
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M_P"Y^HH^R3_W/U%9?V7CO^?,ON8^>/<@HJ?[)/\ W/U%'V2?^Y^HH_LO&_\
M/F7_ ("PYX]Q$_X\Y?\ >%5ZO+;2BV="OS,01S4/V*?^Z/\ OH5^I9%&5++Z
M<*BLTMGZG'4:<G8KT58^Q3_W1_WT*/L4_P#='_?0KU^>/<DKT58^Q3_W1_WT
M*/L4_P#='_?0HYX]P*]%6/L4_P#='_?0H^Q3_P!T?]]"CGCW KT58^Q3_P!T
M?]]"C[%/_='_ 'T*.>/<"O15C[%/_='_ 'T*/L4_]T?]]"CGCW KT58^Q3_W
M1_WT*/L4_P#='_?0HYX]P*]%6/L4_P#='_?0H^Q3_P!T?]]"CGCW KT58^Q3
M_P!T?]]"C[%/_='_ 'T*.>/<!;'_ (^?^ FJU7K6VEBFW,H P1UJ'[%/_='Y
MTN97W KT58^Q3_W1^8H^Q3_W1_WT*?/'N!7HJQ]BG_NC_OH4?8I_[H_[Z%'/
M'N!7HJQ]BG_NC_OH4?8I_P"Z/^^A1SQ[@5Z*L?8I_P"Z/^^A1]BG_NC_ +Z%
M'/'N!7HJQ]BG_NC_ +Z%'V*?^Z/^^A1SQ[@5Z*L?8I_[H_[Z%'V*?^Z/^^A1
MSQ[@5Z*L?8I_[H_[Z%'V*?\ NC_OH4<\>X%>BK'V*?\ NC_OH4?8I_[H_P"^
MA1SQ[@5Z*L?8I_[H_P"^A1]BG_NC_OH4<\>X%>BK'V*?^Z/^^A1]BG_NC_OH
M4<\>X%>BK'V*?^Z/^^A1]BG_ +H_[Z%'/'N!7HJQ]BG_ +H_[Z%'V*?^Z/\
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M '!_WT*/L4_]P?\ ?0HYD!7HJQ]BG_N#_OH4?8I_[@_[Z%',NX%>BK'V*?\
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M_&KP\NA/'+?++ )W@(8;@^1DCKA>OM4NHVD5[^T_!%/&LD8D1RK#()6'(_4
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MX310JWFM!1T NU&/_'*]-HHL@,;PQX9L?">C_P!F:?)<R0>8TF;B0.V3C/(
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M%(#A(/A-X?M_#M]H:76JFTO94EF+7*E\IT .WI^%9@^!/A-5"K>:T%'0"[7
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M=<CH<'N*G*J5*%05(P01QBEHI<\K)7T06*]K86=C:_9;2T@@M^?W,485.>O
MXYS6=%X3\.P7GVN+0M-2XSD2+:H"#ZCC@ULT5I'$5HW:FU??5Z^HN5#719$9
M'575A@AAD$5DVWA3P]9W@N[;0].AN <B6.V0,#ZCCC\*V**F%>I334)-)[V>
MX-)[B5!:6%I81M'9VL%LCN7988P@+'J2!W/K5BBH4Y)-)Z,84444@"KH_P"/
M>+Z52JZ/^/>+Z5]=P=_O<_\ #^IA7V0VBBBOT8Y0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *EC_P!3)^%15*G^HD_"A[ 14444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7%_%3_D1Y?^OB+^M=I7%_%3_D1Y?^OB+^M:4O
MXD?4$=EX:_Y%71_^O&'_ - %%'AK_D5='_Z\8?\ T 45A+<1YYX-E\GXE>+F
MV!LS/U_ZZFO0_MO_ $P2O-_"?_)1_%O_ %VD_P#1IKO:ZJD4VO1?D46_MO\
MTQ2C[;_TQ2JE%9\J M_;?^F*4?;?^F*54HHY4!;^VC_GBE'VT?\ /%*J44<J
M M_;1_SQ2C[:/^>*54HHY4!;^V_],4H^V_\ 3%*J44<J M_;?^F*4?;?^F*5
M4HHY4!;^V_\ 3%*/MO\ TQ2JE%'*@+?VW_IBE'VT?\\4JI11RH"W]M_Z8I1]
MM_Z8I52BCE0%O[;_ -,4H^V_],4JI11RH"W]M_Z8I1]M_P"F*54HHY4!;^V_
M],4H^V_],4JI11RH"W]M_P"F*4?;?^F*54HHY4!;^V_],4H^V_\ 3%*J44<J
M M_;?^F*4?;1_P \4JI11RH"W]M_Z8I1]M_Z8I52BCE0%O[;_P!,4H^V_P#3
M%*J44<J M_;?^F*4?;?^F*54HHY4!;^V_P#3%*/MO_3%*J44<J M_;?^F"5-
M)<[8(F\I3N!X]*SJLS?\>EO]#2<4(=]M_P"F*4?;?^F*54HI\J&6_MO_ $Q2
MC[;_ -,4JI11RH"W]M_Z8I1]M_Z8I52BCE0%O[;_ -,4H^V_],4JI11RH"W]
MM_Z8I1]M_P"F*54HHY4!;^V_],4H^V_],4JI11RH"W]M_P"F*4?;1_SP2JE%
M'*@+?VT?\\$_.C[:/^>"54HHY4!;^VC_ )X)1]M'_/%*J44<J M_;1_SQ2C[
M;_TQ2JE%'*@+?VW_ *8I1]M_Z8I52BCE0%O[;_TQ2C[;_P!,4JI11RH"W]M_
MZ8I1]M_Z8I52BCE0%O[;_P!,4H^VC_GBE5**.5 6_MH_YX)1]M'_ #P2JE%'
M*@+?VW_IBE'VW_IBE5**.5 6_MO_ $P2I?M7^B^9Y2_>QBL^K'_,/_[:?TI.
M*$/^VC_G@E'VW_IBE5**?*AEO[;_ -,4H^V_],4JI11RH"W]M_Z8I1]M_P"F
M*54HHY4!;^V_],4H^V_],4JI11RH"W]M_P"F*4?;?^F*54HHY4!;^V_],4H^
MV_\ 3%*J44<J M_;?^F*4?;?^F*54HHY4!;^V_\ 3%*/MO\ TQ2JE%'*@+?V
MW_IBE'VW_IBE5**.5 6_MO\ TQ2C[:/^>*54HHY4!;^V_P#3%*EMKGS9MOEJ
MO'45GU9L?^/H?0TI15A"?:$_Y]T_.C[1'_S[I^=5Z*P^HX;_ )]K[D5=EC[1
M'_S[I^='VB/_ )]T_.J]%'U'#?\ /M?<@N^Y8^T1_P#/NGYT?:(_^?=/SJO1
M1]1PW_/M?<@N^Y8^T1_\^Z?G1]HC_P"?=/SJO11]1PW_ #[7W(+LL?:(_P#G
MW3\Z/M,?_/NGYU7HH^HX;_GVON07?<L?:8_^?=/SH^TQ_P#/NGYU7HH^HX;_
M )]K[D%WW+'VB/\ Y]T_.C[1'_S[I^=5Z*/J.&_Y]K[D%WW+'VB/_GW3\Z/M
M$?\ S[I^=5Z*/J.&_P"?:^Y!=EC[0G_/NGYT"X3</]'3\ZKTJ_>%'U+#+_EV
MON079<N9428J85;&.347VE/^?=/SHO?^/EOPJO2^IX>6K@ON0KLL?:4_Y]T_
M.C[1'_S[I^=5Z*?U'#?\^U]R'=]RQ]HC_P"?=/SH^T1_\^Z?G5>BCZCAO^?:
M^Y!=EC[1'_S[I^='VB/_ )]T_.J]%'U'#?\ /M?<@NRQ]HC_ .?=/SH^T1_\
M^Z?G5>BCZCAO^?:^Y!=]RQ]HC_Y]T_.C[1'_ ,^Z?G5>BCZCAO\ GVON07?<
ML?:$_P"?=/SH^T1_\^Z?F:KT4?4<-_S[7W(+LL?:(_\ GW3\Z/M$?_/NGYU7
MHH^HX;_GVON0798^T1_\^Z?G1]HC_P"?=/SJO11]1PW_ #[7W(+ON6/M$?\
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M/SH^T1_\^Z?G5>BCZCAO^?:^Y!=]RQ]HC_Y]T_.C[1'_ ,^Z?G5>BCZCAO\
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M *--=[774W7HBC,UWQ!IGAK36O\ 5;I8( =JY&2[>@'<UY=X)^)NK^+OB?\
M8@ZPZ-(DK16QC7< J$@EL9SD9ZUZ;K_AK2O$\%M;ZM;F>&WF\Y8]Q +8(YQU
M'/2O(_#4$-K^T=>P6\210QB941%P% BZ 5C*]Q'4?$CX@ZIH.KV/A[P];)+J
MMVH;<Z[MH8D* .F3@]>U86F_$+QEX;\8V>A^-8(&CNRH#HBAE#' 8%.",\$5
MZCX@U31_#^FR:QJPA2.#E7* N6[*O?->/>';75/BK\0HO$U];FWT6P<")3T(
M4Y5 >YSR3_\ 6I.]P/>,8.*\\\?^)-7L_%GAC0-%NS;S7\V;@A%8^7N '4'
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M%:0+?ZA%]G2TB;<L,/=2>G( K*TK2?'?@%+K2=$TRTUG27E:2TDDG$;0ENS
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MJU2OB ****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "K$_\ Q[6_T-5ZL3_\>UO]#4O="*]%%%-#
M"BBBF 4444 %%%% !1110 4444 %%%% !1110 59B_X\[C\*K59B_P"/.X_"
MIEL(K44450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_XF?\ (F2?
M]=X_ZUV%<?\ $S_D3)/^N\?]:NG\: [OPS_R*FC_ /7C#_Z **/#/_(JZ/\
M]>,/_H HKDEN2>>>#8O-^)/BX;E7$S]?^NIKT+[%_P!-HZ\^\%_\E*\7_P#7
M9_\ T::]$KHJWYODOR&,^Q?]-HZ/L7_3:.GT5G=]P&?8O^FT='V+_IM'3Z*+
MON S[%_TVCH^Q?\ 3:.GT47?<!GV+_IM'1]B_P"FT=/HHN^X#/L7_3:.C[%_
MTVCI]%%WW 9]B_Z;1T?8O^FT=/HHN^X#/L7_ $VCH^Q?]-HZ?11=]P&?8O\
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MZ#2XOM4J]@W+\_4!!38'KQ&#BL+1O&.@>(-1NK#2]06XNK7/G1B-UVX.#R0
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M*+[G&,\CC.>:R_'7BP>%=#WV\?GZI=MY%A; 9,DAX!QZ#K^5><_#K0[OP_\
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M:S8^'/#^EKJ>N7<8D\IGVQPICJQ^F3U'3WJGI_C_ %O3?%%EH'C+1K>P>_\
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M\>_2HIY<WCGA)NUF[OR5V_P0.?N<QU.D^//#&N7WV+3M8MYKDG"QX92W^[N
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M]K%TKPCH&AWUS>Z9ID5M<W0(FD5F)?)R>I/>A[@>3?L_@?V]XK; R#%@_P#
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M-3ZQI%EKVE3Z9J,1EM)\"1 Q7=@@CD<]0*$,X;X(:6;#X=0W3C]Y?SO.6/<
M[1_(UL_$_2YM7^'.L6MLA><1"5$'4[&#$#\ :Z73["VTO3K>PLHQ%;6Z".)
M<X JS3MH!\W>$O$WA.S^#6N:1J/DKJDADVQ-'EY6('ED''8^_&/>MOP/XJD\
M _!.34[J(O-<WL@TZ%^CDJHS_N@AC^%>EWGPS\&W^HM?W&@6S3LV]RI958^I
M4'%:.K>$M UVTMK34]*@N+>U_P!1%ED6/C' 4BE9B/GGP9JWAG4/$<WBCQ[K
M337PEW0VI@=P2.C-@$8'9?:OI73-2M-7TRWU&QD\RUN$#Q/M(W*?8\BN9_X5
M3X%_Z%NV_P"_DG_Q5=186%KI=A!8V,*P6L"!(HU)(51VYYH0RS1113 ****
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M#I]A>0W5WJLD<=M'"X8N-P)/';'ZFF>++3PTQ\,^&/$<$\$S0 6VHHX00NH
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M>*Q6'K2ND[145%:;+>_KY"C%HY_P9XR\.ZIX8:\MUL](CA9_M%F65/)(/4C
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M***^J,0HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +_C_P")I?NN[^X>ATG]K:;_ -!"T_[_ *_XT?VMIO\ T$+3_O\ K_C7-_\
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M_P""&ATG]K:;_P!!&T_[_K_C1_:VF_\ 00M/^_Z_XUS?_"G/#/\ SUU#_O\
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M^"&ATG]K:;_T$;3_ +_K_C1_:VF_]!&T_P"_Z_XUS?\ PISPS_SUU#_O^/\
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M^)H_X4YX9_YZZA_W_'_Q-'[KN_N#0Z3^UM-_Z"%I_P!_U_QH_M;3?^@A:?\
M?]?\:YO_ (4YX9_YZZA_W_'_ ,31_P *<\,_\]=0_P"_X_\ B:/W7=_<&ATG
M]K:;_P!!"T_[_K_C1_:VF_\ 00M/^_Z_XUS?_"G/#/\ SUU#_O\ C_XFC_A3
MGAG_ )ZZA_W_ !_\31^Z[O[@T.D_M;3?^@A:?]_U_P :/[6TW_H(6G_?]?\
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MYZZA_P!_Q_\ $T?\*<\,_P#/74/^_P"/_B:/W7=_<&ATG]K:;_T$;3_O^O\
MC4D.KZ8).=1M.G_/=?\ &N7_ .%.>&?^>NH?]_Q_\31_PISPS_SUU#_O^/\
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M_/\ VO\ W^7_ !H_M33O^?\ M?\ O\O^-8O_  ISPS_SUU#_ +_C_P")I?\
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M !K%_P"%.>&?^>NH?]_Q_P#$T?\ "G/#/_/74/\ O^/_ (FC_4S"_P#/]_\
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M\C:_M33O^?\ M?\ O\O^-']J:=_S_P!K_P!_E_QK%_X4YX9_YZZA_P!_Q_\
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M^X-#I/[6TW_H(6G_ '_7_&C^UM-_Z"%I_P!_U_QKF_\ A3GAG_GKJ'_?\?\
MQ-'_  ISPS_SUU#_ +_C_P")H_==W]P]#I/[6TW_ *"%I_W_ %_QH_M;3?\
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M=0_[_C_XFG^Z[O[O^"&ATG]K:;_T$+3_ +_K_C1_:VF_]!"T_P"_Z_XUS?\
MPISPS_SUU#_O^/\ XFC_ (4YX9_YZZA_W_'_ ,31^Z[O[@T.D_M;3?\ H(6G
M_?\ 7_&C^UM-_P"@A:?]_P!?\:YO_A3GAG_GKJ'_ '_'_P 31_PISPS_ ,]=
M0_[_ (_^)H_==W]P:'2?VMIO_00M/^_Z_P"-']K:;_T$+3_O^O\ C7-_\*<\
M,_\ /74/^_X_^)H_X4YX9_YZZA_W_'_Q-'[KN_N#0Z3^UM-_Z"%I_P!_U_QH
M_M;3?^@A:?\ ?]?\:YO_ (4YX9_YZZA_W_'_ ,31_P *<\,_\]=0_P"_X_\
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MS'C/([G]*W+'QGX:U+5#IMEKEC/> X$*3 D_3U_"@#=HK U#QOX8TJ>X@O\
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MX-6U>TM)I!E8Y9 &(]<>GO5B_P#$&CZ9I2ZI>ZE;0V+ %;AI!L;/3![_ (4
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M"/QS4WBCQ??^,_@UXEU&XTDV%B)D2R=V.Z=-X^8@CCM]>:]JE@AG $T22 =
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M<2Z%JWA?P?HWA33S'XN@ND,S10%)8R/O%VQD_-@Y)X KZA2-(D"1HJ*.@48
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MVC!I(K>&W7;#%'&#U"*!_*@#Y3TB]BT>\T>#2IK'78EO]L6EW>G;+R Y.6)
MS_X\1TXXKL;RTU"^\2?%FVTH.UX]O$%5!\S#)W >Y&17O2VMNLQF6"(2'JX0
M9/XT\1H&+!5#'J0.30!\Q3S:%K.C>"M*\(:>8_%-M<H;AHH-DD6/OF1L<_-@
MY/3!KM-&T33-7^,7CXZC9077E6ZA!,@8+N7D@'H>.M>S);PQR-(D4:NW5E4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gizttcucplmb000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M!^C-X+\-:_XF\?V/A1_$(F>RL[K3KF=F2.4QEBT:D*"<$;L#!K&K6A15YO\
M7\@O;<\CHKVX?LQRZ/>>-O\ A*?%FG^'-+\+W%I;R:DUM-<QW)N$WQE%C!;[
MA0D;?XZPO$7P(NXX_#-QX/UFV\=6/B"ZDL+.;3X)(&%S'M+1NDH4KPX.3QC)
MZ<USQQM"3LI?Y;7WVV%='EU%>U_\,U1WEU>Z-H_CW0-<\8VD+ROX?LQ-OD9
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M?4?_ *(CK];>]?DU^V78SZ?^TEXS$\31^=-#-&6! =&@3!!_ CCN#7SG#O\
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MGUHY]:?]HXO_ )^/[Q\S/F/_ (=X_"S^_K?_ (&K_P#$4?\ #O'X6?W];_\
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M_P#B*^G.?6CGUH_M'%_\_']X<S/F/_AWC\+/[^M_^!J__$4?\.\?A9_?UO\
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M:/[1Q?\ S\?WAS,^8_\ AWC\+/[^M_\ @:O_ ,11_P .\?A9_?UO_P #5_\
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MZ\=+:VMM*LX;[RI6&^>*0;E9!GH$!8Y.<<>U2\HP,5=U']Z$\'02NY'Z"_\
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M&XJ?N@YZTH95@*D.>-1V]5_D$<)AY*ZD?H]_PVI\'?\ H;U_\ ;G_P"-T?\
M#:GP<_Z&Y?\ P!N?_C=?G7??!758O!_@W5+'[3J&K^(KN[LTT5+0B:&2"381
MG=DD\DY48P:LZ?\  'Q);ZYJFE^);*_\.W%IH]QJ\6ZT\\3K%C*@AP,'/+ G
M'IS1_96!M?VC_ 7U2A_,?H7_ ,-J?!S_ *&]?_ &Y_\ C=(?VT_@[_T-R_\
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M_P :W_L/%>7WFGU&L?IYD49%?F'_ ,-^?%K_ )_M+_\  !?\:/\ AOSXM?\
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MD8XJG[2'Q(_4FBFJVX9'3K3J^./&"BBB@ HHHH **** "BBB@ HHHH ****
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MC]/:LROM*,>2E&/9&RVL%?I]_P $_P#_ )-WLO\ L(77_H0K\P:_3[_@G_\
M\F[V7_80NO\ T(5\YQ!_NJ]5^IE4V/I'M7)_%;7+KPS\,?%>KV3>7>6.E75S
M Y&0LB1,RDCZ@5UE<'\>/^2)^//^P'>?^B'K\^I*\XKS,H?$C\;I+A[B5Y97
M,DKDLSL2223DDGU)INZH?,H\ROUE;'U?,3;J-U0^91YE.X^8FW4;JA\RCS*+
MAS$VZC=4/F4>91<.8FW4;JA\RCS*+AS$VZC=4/F4>91<.8FW4;JA\RCS*+AS
M$VZC=4/F4>91<.8FW4;JA\RCS*+AS$VZC=4/F4>91<.8FW4;JA\RCS*+AS$V
MZC=4/F4>91<.8FW4;JA\RCS*+AS$VZC=4/F4>91<.8FWU':VMQJ5]!:VT+W%
MS<2+%%%&I+.S$!5 ]22,?6H99/EQ7TO^P%\+6\=?&0:[<P>9I?AN(719AD?:
M6)$(^H(=O^ "N3$UU0I2J/H85:G)%R/NO]FKX+VOP1^%^G:.L8.K7"BYU*XX
MW23L,D9'91A1CLN>I->KBD]J7M7Y?4J2JS<Y;L^9E)R=V+1114$A1110 444
M4 %%%% !1110 4444 0S0I-&\<B+(C@JRL,@@CD$5^5'[6WP5/P:^*5S'8V_
ME>'=6W7FG;<[4&?GA&>Z$_\ ?++7ZN5\_P#[:OPK'Q(^"NH7-NF[5=!)U*VP
M.650?-3IW3)&.I5:]C*L4\-B%?:6C.W"5O95-=F4_P!B'XQ?\+*^%$>E7UR9
MM<\/%;.;S#EY(,?N9#Z\ KZY0D]>?HP5^5W[%?Q,_P"%>_'#2X)Y"FFZX/[,
MG'8,Q!B;_OX%&>P8FOU0#<49KAOJ^)?+L]18NE[.IILQU%%%>.<84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% #37GGQ1^/7@GX-R6D?BK6/L5Q=
M@O#;Q0O-(RC@MM4' SW->AU^<7_!1K_DN&C?]B_!_P"E-S7HY?AHXJNJ4WH=
M.'I*M4Y9;'TY_P -V?"#_H.7G_@MG_\ B:/^&[?A!_T'+S_P6S__ !->%_#?
M_@G_ *9XZ\ ^'?$4GC&[M)-4T^"]:!+)6$9DC#%<[^<9Q72#_@FII)_YGF]_
M\ $_^+KU)4,JC)Q=25U_78ZG3PB=G)GJ'_#=WP@_Z#EY_P""Z?\ ^)H_X;N^
M$'_0<O/_  73_P#Q->8?\.T])_Z'F]_\ $_^+H_X=IZ3_P!#S>_^ "?_ !=3
M[+*?^?DOZ^0N7"?S,]/_ .&[OA!_T'+S_P %T_\ \31_PW=\(/\ H.7G_@NG
M_P#B:\P_X=IZ3_T/-[_X )_\71_P[3TG_H>;W_P 3_XNCV64_P#/R7]?(.7"
M?S,]/_X;N^$'_0<O/_!=/_\ $T?\-W?"#_H.7G_@NG_^)KS#_AVGI/\ T/-[
M_P" "?\ Q='_  [3TG_H>;W_ , $_P#BZ/993_S\E_7R#EPG\S/3_P#AN[X0
M?]!R\_\ !=/_ /$T?\-W?"#_ *#EY_X+I_\ XFO,/^':>D_]#S>_^ "?_%T?
M\.T])_Z'F]_\ $_^+H]EE/\ S\E_7R#EPG\S/3_^&[OA!_T'+S_P73__ !-'
M_#=WP@_Z#EY_X+I__B:\P_X=IZ3_ -#S>_\ @ G_ ,71_P .T])_Z'F]_P#
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MM&>,DTP1B)KA))EBQM\YHD,G3N6+$^Y->-U]+A9*=&$DK:(T6UPK]/O^"?\
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MP]((=3UGQ!)(+?SB#^ZC6,AB00?F.1\I]C7T/ZU\>_#OX@:-^S)\6OB?I/Q
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M_ R3_P")KZG_ .&5OA-_T(VE_P#?#?XT?\,K?";_ *$;2_\ OAO\:/K66?\
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M^1GRQ_P\H\0?]"7IO_@9)_\ $T?\/*/$'_0EZ;_X&2?_ !-?4_\ PRM\)O\
MH1M+_P"^&_QH_P"&5OA-_P!"-I?_ 'PW^-'UK+/^?+_KYA[3"_R,^6/^'E'B
M#_H2]-_\#)/_ (FC_AY1X@_Z$O3?_ R3_P")KZG_ .&5OA-_T(VE_P#?#?XT
M?\,K?";_ *$;2_\ OAO\:/K66?\ /E_U\P]IA?Y&?+'_  \H\0?]"7IO_@9)
M_P#$T?\ #RCQ!_T)>F_^!DG_ ,37U/\ \,K?";_H1M+_ .^&_P :/^&5OA-_
MT(VE_P#?#?XT?6LL_P"?+_KYA[3"_P A\L?\/*/$'_0EZ;_X&2?_ !-?/_Q\
M^-MY\>O&-IX@O=+ATF6WL4L1#!(74A9)'W9('7S/T]Z_2?\ X97^$W_0BZ5_
MWPW^-+#^R[\*;>9)4\"Z3N1@PWQ%AP>X)P?H:VHYA@,/+GI4FG_7F7#$4*;Y
MHP-3]G]&C^!O@%'4HXT.RRK#!_U*5Z >U110I;QK&BA$4!551@ >E2]:^:J2
MYYN7<\R3YFV+1114$A1110 4444 %%%% !1110 4444 %%%% ">E>4_M-?#/
M5_B]\(-3\,Z&]M'J-S-!(C7CE(P$E5CDA6.< ]J]5ZT&KIU)4IJ<=T5&3BU)
M'YK?\.\_BC_S]^'_ /P-E_\ C5'_  [S^*/_ #]^'_\ P-E_^-5^E5&:]S^W
M,7Y?<=_UZL?FK_P[S^*/_/WX?_\  V7_ .-4?\.\_BC_ ,_?A_\ \#9?_C5?
MI5FC-']N8OR^X/KU8_-7_AWG\4?^?OP__P"!LO\ \:H_X=Y_%'_G[\/_ /@;
M+_\ &J_2K-&:/[<Q?E]P?7JQ^:O_  [S^*/_ #]^'_\ P-E_^-4?\.\_BC_S
M]^'_ /P-E_\ C5?I5FC-']N8OR^X/KU8_-7_ (=Y_%'_ )^_#_\ X&R__&J/
M^'>?Q1_Y^_#_ /X&R_\ QJOTJS1FC^W,7Y?<'UZL?FK_ ,.\_BC_ ,_?A_\
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MOS@HH_L'!^?WA[-'Z/\ _#QWX>?] C7O^_$7_P <H_X>._#S_H$:]_WXB_\
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MY1_P\=^'G_0(U[_OQ%_\<K\X**/[!P?G]X>S1^C_ /P\=^'G_0(U[_OQ%_\
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M:]_WXB_^.4?\/'?AY_T"->_[\1?_ !ROS@HH_L'!^?WA[-'Z/_\ #QWX>?\
M0(U[_OQ%_P#'*/\ AX[\//\ H$:]_P!^(O\ XY7YP44?V#@_/[P]FC]'_P#A
MX[\//^@1KW_?B+_XY1_P\=^'G_0(U[_OQ%_\<K\X**/[!P?G]X>S1^C_ /P\
M=^'G_0(U[_OQ%_\ '*/^'COP\_Z!&O?]^(O_ (Y7YP44?V#@_/[P]FC]'_\
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M(7_0O^&O^_-Q_P#'J^2Z*]G^R,#_ ,^U^)?(NQ]:?\/)/B%_T+_AK_OS<?\
MQZC_ (>2?$+_ *%_PU_WYN/_ (]7R711_9&!_P"?:_$.1=CZT_X>2?$+_H7_
M  U_WYN/_CU'_#R3XA?]"_X:_P"_-Q_\>KY+HH_LC _\^U^(<B['UI_P\D^(
M7_0O^&O^_-Q_\>H_X>2?$+_H7_#7_?FX_P#CU?)=%']D8'_GVOQ#D78^M/\
MAY)\0O\ H7_#7_?FX_\ CU'_  \D^(7_ $+_ (:_[\W'_P >KY+HH_LC _\
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MK_T(5\[Q!_NJ]5^IE4V/I*O/OV@_^2%_$'_L WW_ *(>O0*Y[XA>%_\ A-O
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M@]J^?/V\O^3;->_Z^;3_ -'I7T&>U?/G[>7_ ";9KW_7S:?^CTKS<!_O5/\
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M.>1\&_\ #JO2_P#HH%Y_X+D_^+H_X=5Z7_T4"\_\%R?_ !=?>5%']I8K^?\
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M3JU.5+;;YG,ZGM9.5K!7UMXRU:^\(?"3X&:=X<\2W/@KPEJ]H\VJZYIRN?\
M325,AE*89BIW@+NYP>RC'R37HGP[_:"\<_"[37TS0]74:2TGFG3[VVCN8 Y_
MB42*=IS_ '2*];&8>==1</L]'Z?/\B6KGT_XE^#$7C[Q]IVO>-O$MEXSTNT\
M&R:S#)]G;1_M<<;*L8GDW,P4ARS2$@CCCK7/:;\#?A3XD\8:6]O';K977AS4
M+V_T?1]8>[6SGA*[)8IB<L&!) ;(R#P:\"E_:)^(ESXXB\73>)KB;78HFMUE
MDCC,7DL<M%Y6W9L..5V\D9Z\U+J'[1GC_4M<756UI+>>.QETR&&WLH$@AMI,
M>9&D6S:N[ ^;&>.O%>5' XV.BJ:6Z.UOE;\2>5GK>G_!GP'\5]%^%&K:'HD_
MA!/$&M7&E:A;1W\ET&2)2V]6DSAR%QP,<]*O^._AO\+-!\K4=.L=)T^^T;Q)
M!9MI-KX@DO#J5L90C"0,<Q2J<,57@ ,.>WSI:?%#Q1I^@Z+HUKJTEMI^BWK:
MAI\<4<:M!<'K('"[B3Z%L5L^._C]XW^(^FP:?K6J1FSCG%V\=G:16PGG[32>
M6HWOCN>/:MG@\7SKW_=UZO:_XZ:>0^5GU9\2M-T/Q!\:/C-;V^GW.E76E^%)
M))KBSU&:-;N01QE"Z*P7:JX79C!Q7F/Q+^&WP\^'NM:I\/$\":]KVO6.C)>?
M\)+I-Q++,TQ56,C6^?+6 9P6P2/KS7ENN_M+?$+Q%=W5S>:U#]HO--;2KN:/
M3[=6N+=L;@YV=3@?,.>.,42?M*?$2;P<?#3Z]FP-M]A:?[-%]J-MC A\[;OV
M?\"[]:RHX'%4^7WM-/M/[_\ @>8*+1U_[#MPUK\>+>=/]9%I=\ZY]1"2/U%?
M9/P_TC3M#^(TWCVV\HK\2#:);*",JJ:?-/*0/5FC7(_V:_-?P3XZUSX=:X-8
M\/7W]GZCY4D'G>5')\CC#KM<%>1GM73:7^T)\0=&M_#,-IXB>.+PV9CI2M;0
M.+?S49'^]&=_R.R_/G&>,56.RVMB:KG"22:2_7\[!*+;NCU:U\$_#[P3X+\%
MZUXG\)7GC/4?&FJ7D6^WOY;=;&..X\H",1GYY"6#;6ZD$<5IZ[\!?!'P;L/B
M?K>N:9-XWM= U:VTRPL3>O;*JS11R[Y'B(.Y1*%ZXRIXY&/&O!/[1?C[X?Z5
M)IVD:S&+,S-<1175G#.+>9CDRQ;U.QLD]..3Q53PE\=O&W@N^URZL=8^T/K;
M;]1CU"!+J.Y?)(=DD4KN!/4"K>$Q?O6G^+UUO\M---PLSZZ\9Z+I_B#XDZ-'
M&E]864?POGN((8;R2*1 %!5'=""P (!!X..16K>W6D>(O'7P%\-VUA?Z1:7F
MBB[0V&KW$/E0BW?$.$9<G=M/F9#8!'0U\<WW[0_Q"U37/[8N_$)FU/\ LR31
MC<-:09^R/]^,C9CG^]][WJO!\=_'-KKGAS6(]<V:CX=M/L.ES?9(#]GAVE=F
MW9M;@XR^3S7+_95>RO):)]7O9BY6>K:7X%\!^!_A[X3\2>)O".H>.KWQ=K%Y
M:I#:WLT+V<<4[1!8UC8&65R,@,>3Q[F7X5?"OPB_]M7OB+P5-_9+:\NEVD_B
MS6)-+,"D9,/EQ?/)<#/3!7Z8->6^!OVB/'?PYT^YL-%UA$LYIVNEAN;2*=89
MVZRQAU.QN3TXYZ4GA_\ :&\>>&[#4K2VUH3QW]X=1D:]MHKATNB,&:-G4['Q
MW7\*[)87%M2BI;_WGW_"WXCLSZ8\?^&?!OPM^!GQ>\/V7APW5MI_B&"W#2WL
M@D9I$1X7+=<1[P O1MISU-9?BKX/>%]0^)GB/5==BU+6M)\,^#K35SI;7\KR
MW<AC/R&5F+J@P>%/&1]#\_S?M%>/;E?%2W6KPW@\3*HU-9K& K(RIL5PNS:C
M!1C*@>O4 U5MOC]X]M/&,?BF/7W&LI:)8&86\022W486)XPNQEQ_>6L(9?BX
M7?/KZOLO\GJ+E9[AX=^"?@#Q]J7PC\2V.@7&B:+XIU"YT^_\/O>RRIF)'(DB
ME)\S!*_WNX'UY?QQX#\ :G\$_%FN^'/#MSH>J>%]?32?M<NH27!OXB=N^16^
M5&/7Y *\[U3]H/QWJWBW1O$4FM"&_P!%R-,CM[6)+>S!!!$<.W9R#C)7T]L8
M!^(_B)O#6LZ =1_XE.L7BW][;^3'^]G!R'W;=RX/92!73#"8I2C*4]K=7W?W
MZ::CLSFJ***]TL*]>_96N/'T'Q>TU/A^OF:@_-W%.6%JUN& <SXZ(,CD#.2,
M<UQ/PW^&VO?%CQ=9^'?#MK]IOKCYF9N(X8P0&D=L<*N1V)Y '-?JW\!_@7H7
MP)\'0Z3IB"XU"8![_4F7$ES)ZGT49("CH/4DD_/9OF%+#4G2:O)]/\R)R25C
MTE<[5W?>QSCI7S]^WE_R;9KW_7S:?^CTKZ#-?/G[>7_)MFO?]?-I_P"CTKX'
M _[U3_Q+\SGCNC\S/!O_ "-VA?\ 7]!_Z,6OHS]K'X/^/=4^.GBGQ/I?A;4;
MO2(S%<I?1V^^';'"A9O3 *G\C7R['(T,B.C,CJ=RLI(*D'((/J#70R_$CQ9/
M&\4WB?69X7&UXI-0F*NI&"I&_H1G\Z_3ZU&I*JJM-I636OG;_(ZFG>Y]8>+-
M/\,:5X"UWXVQ:3IL5OXD\-VNGZ?I8A0I!JDC-'<;$Q@!!&&SU/S?2O0[M])A
M^*WB#PD?"WAZ30[?P4NL&%M,BWRW*J,,SXSC  P/2OCOXI_&Z#QUX/T#PCH/
MANW\)>%]'EDN([&"ZDN#),Y)+,\G)QENO]X_AP3>+=<:[>Z.M:@;J2'[.\YN
MI"[18_U9;=G;_LDXKR(9;4JQO.5GK\EI;\OQ(Y7U/L;0;/3O'U]^SCXIU/1=
M+74M8OM0MK];6RCAAN$0D('C P=N/3N:I?$3P_J$WPH^(Q\8^"]-\,#0M=M(
M?"US;V"6K2HUP5=$8?ZU?*VG=SG<>Z\?,?PY^*6J?#SQ?X=UM6DU.'0YVGM=
M/N9W\D%@0P49^7)/8=16=XK\>ZWXPNI6OM2O);3[1)<064ER[Q6^]B<(I/ &
M<<#M5K+:JJI<WNK_ #;LOEH/E=S[C\?ZW!XL^,GQ&\$ZIHVDW.CV_@QK\3-9
MH;G[0MM&4D\W&[*@X&#QM%&B^#_L_BSP1X8TSP)I.H?"*_\ #J7&HZU-IZ.&
M9HF9I7N<?*^=O&<_,2.G'P<WBC67OI[UM7OS>3Q>1+<&Z<R21D %&;.2N ."
M>PJ2#QAKMKH<FC0ZSJ$6D2??L4N7$+9ZY3.,'Z5/]DS22C/2WX]_4.5]SZR\
M!Z#J6@_"WP?<_"OP?I?C234M<O[?6Y[VT2Z(1)REO&[M_J4:+#;N ,@]^8/A
M'\-=+^-VF^(? ^IZ5IFC:UX:\4QZB\5B5(%DTA6YMED&2R+\V.>I7H*^4]$\
M7Z[X:@N(=(UF_P!+BN!B:.TN7B63C'S!3SQZUW/PX^-D?PR\&>)+'2_#T'_"
M4:U;RV+^)&NI/-BMI NZ-8\[<Y4G<,'IZ5=7 UXQE[-W;>CZ[]=>BT!Q9](Z
M[\2;CQW^SS\7)_"NAZ?)IUMK_P!GMX+/3D*K8E #,0HZA06W]1Q5V?P9I4/Q
M>\<7&B^'=.U+Q/IG@NRN]$TM[5'C:=HP))%BQAW&1VS\WO7Q'IGB35M&L[VT
ML-3N[*VO5\NYAMYF1)EYX< \C!/7U-/3Q3K,>K0ZJNK7PU.$!8[S[2_G( ,
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M7XG^'_\ A/'\"?VFNF:D;1=)^S^7]ISFU%V5/V?&#^[R<]-_-;_7K-OV??\
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MFH^)-<F2?5-0</,\<81?E4(H"@< *H'X<FL&N_\ CTH3XM^(0/"R^"_GB/\
M8*",+:9AC) V#;\V=W']ZN KZVBTZ46E;0U6P5^GW_!/_P#Y-WLO^PA=?^A"
MOS!K]/O^"?\ _P F[V7_ &$+K_T(5\YQ!_NJ]5^IE4V/I*BBBOSHYPHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *2EHH CDB292KJ&4C!5AD&O*?&'[*OPG\;S23:IX&
MTG[1(2SSVD/V9V)ZDF,KD^YKUJD-7&I.F[Q=AWL?)^N?\$T_A)JDF^SF\0Z,
M,Y\NSOT=?I^]C<_K6-_PZ[^''_0R^*?^_P!;?_&*^R1FEKJ6.Q,59397-(^.
M[/\ X)A_#&WE1YM>\57(4Y,9NK=5;V.(,_D:]%\,_L,_!KPRR,OA1=2D4@[]
M2N99\X]5+;?TKWVEJ98S$3WFPYY=S'\-^$=#\':>MAH.CV.C60.?L]A;I"F?
M4A0.?<UL4M%<C;;NWJ0%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!0UG34UG2;ZPD=HX[J!X&9>JAE*DCWYKY,_X=J^#?\ H:M=_*'_ .(K[!HK
MJH8NOA;^QE:XTVCX^_X=J^#?^AJUW\H?_B*/^':O@W_H:M=_*'_XBOL*BNS^
MU<;_ ,_&5SL^/?\ AVKX-_Z&K7?RA_\ B*/^':O@W_H:M=_*'_XBOL*BC^U<
M;_S\8<[/CW_AVKX-_P"AJUW\H?\ XBC_ (=J^#?^AJUW\H?_ (BOL*BC^U<;
M_P _&'.SX]_X=J^#?^AJUW\H?_B*/^':O@W_ *&K7?RA_P#B*^PJ*/[5QO\
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M $-6N_E#_P#$4?\ #M7P;_T-6N_E#_\ $5]A44?VKC?^?C#G9\>_\.U?!O\
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M_$4?\.U?!O\ T-6N_E#_ /$5]A44?VKC?^?C#G9\>_\ #M7P;_T-6N_E#_\
M$5N>!_\ @GSX#\(^)[/5[O4-2U^.U;>MC?>5Y#N/NEPJ@D#KC."1SZ'ZEZ45
M$LTQDERNHPYV(BA5  P!Q3J**\P@**** "BBB@ HHHH K7UA;:I:RVMY;Q7=
MM*NV2&9 Z.OH5/!_&O&_%W[''PF\8>8TOA6'3)VY\W2G:VV_15.W\UKVVDK:
MG6JT7>G)KT&FT?$GBC_@FCIDC._ASQG>6R_PPZI;),?Q="O_ *#7EOB/_@G=
M\3-)5WTR[T77$ )58KEH93[8=0HS_O5^EHHYKUJ>=8VG]J_JB^>1^0^L?LI?
M%O0?^/KP+J;XZFUV7(_\A,U<AJ'PK\::2[+>>$]:MR.?GL)<?GM]J_:?BDX_
MR*]&'$==?%!,?M&?AW>:3?:=DW=E<6W./WT3)U&0.1Z55K]S?+'H*KR:7:2N
M7>UA=SU9HU)-=$>)7UI?C_P"O:'X=58L]-O-0XM+6:Y.<8AC9_Y#K7[>+I-D
MK!EM( 0<@B)01^E62@]!3?$CZ4OQ_P" 'M#\6--^%OC+6&Q9>%-:N>_[NPE(
M_/;[BNPT7]E+XMZ_C[)X&U- 3@&[\NV'3_IJRU^O&VEXKGGQ'7?PP2%[0_-C
MPY_P3I^(VIA7U34M%T9#R4,SSR#ZA5V_^/5ZYX0_X)L^&[)TE\2^*=1U7!SY
M&GQ);(?4%CO8CZ;37V6**\VKG6-JZ<]O0GGD>5>"_P!F'X8^ VAETOPA8/<Q
MX*W%\IN9 1SN!DS@^XQ7JBJ%4 # '0"EI:\>I5J57S3E<B]PHHHK,04444 8
MWBOPEI'C?0;K1M=T^'5-,N1B6VG7*G!R#[$''(KYPU3_ ()T_#"_OI)X+_Q'
MIL;G(MK6\B*)[ R0LWYL:^I_QH[5TT<57PZM2FT-2:/E#_AVW\-O^@[XJ_\
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M-CZ2HHHK\Z.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXAZ'XJTNRU*"[8*0CF-)%8A2C.K' ]0#^->:?!O]I3PAX-\"VGA'QC\,]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYF/4UYK7I87E5"')M96&MD%?I]_P3_\ ^3=[+_L(77_H0K\P:_3[_@G_ /\
M)N]E_P!A"Z_]"%>!Q!_NJ]5^IG4V/I*BBD)Q7YT<XG/TI<UXI\>/VMO '[/\
MBV>O7DU]KDD8E32--59)]IZ%\D*@/^T>>P-?-=Q_P5@M1<2+;?#.:2 'Y'EU
MH(Q'J5$! /T)K6-&<U=(X*V.PU"7+.>I]_[O:C=[5^?W_#V"/_HF#?\ @^_^
MYJ/^'KR?]$P;_P 'W_W-5_5ZG8P_M7!_S_@_\C] =WM1N]J^ /\ AZ\G_1,&
M_P#!]_\ <U+_ ,/7$_Z)BW_@^_\ N:G]6J]@_M7!_P _X/\ R/O[%&*^ ?\
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MG(?^::-_X//_ +GI_5:O8/[8P7_/S\'_ )'WI^-'XU\&?\/34_Z)HW_@\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFU_*OR+6R"OT^_X)_P#_ ";O9?\ 80NO_0A7Y@U^GW_!/_\ Y-WLO^PA=?\
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M*I4Y]$=6$PCH.\W=V2^[_,_'+]M#X!_\*)^+ES#I]JT'A?6-U[I1Y*(,_O(
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M^N_^!;4?4)]P_P!9*'\C_ _9#</6C</6OQO_ .&G?BO_ -#_ *[_ .!;4?\
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M7_Z'_7?_  +:C_AIWXK_ /0_Z[_X%M1]0GW#_62A_(_P/V0W#UHW#UK\;_\
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MBIX?VM_#K?ZW1]43G^ 1MQ_WV.:^5Z*/J\ _M+$=SZXMOVJO!TWWX-4M^?\
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MJ_#VO9R_[1\)Q-\5+Y_H%%%%>N?#A1110 4444 %%%% !1110 4444 %%%%
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MRN>K3BW]SL?/GA7X8>+_ !I:/<Z!X9U;6+=#AIK*SDE0$=1N /(^M=K^S_\
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M/_\ &Z/^&RO@S_T/-G_X#S__ !NOFS_AV!J'_10+;_P5M_\ ':/^'7^H?]%
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MI+Z7S0OG2PHS,,KE0'Z$*3WQ7G^VGRMWU['TKP5)S@N6T.]]U:[/$_$?[/\
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M#FXN3O;3IIN?,^17K_P[_9A\3_$+PO;^(6U+0_#6E7DC0V,VOWOV<WKJ<$1
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MQIJ64]FDL,MI,X>6*92#YBE@#\U/EK]R'4R^^D'_ %;S]3N_#_P1T?Q'X/\
M$EMX8U:Q\12R:EH]K9:G<6,UO/ ;EF#1L"VU2.-V X.!@UH:I^Q[!9^(].TU
M/&"Q1S:C<Z7<-J-FMK)YT,3.# KR[9$DVE59F09ZXKSC5?VB/&^K?:P=1AM(
MYY;.5(K.UCA2V^R$FW2( ?NT0D_*/4U<U#]I;QCJ&J6]^T>BPRI+-<3QPZ3
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MDYE\>?M%'4--\-Z#X"T)? ?AKP_?#5;2WBN6N+B6]&0+B64@;F X QP"1DC
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MF@:B"8+E1G!!Q\C<XW8/;(.!7F-*M:RBI*SV."-6=.?M(O4^D]/_ &FOA_\
M#V:35_AU\)+?0_%3HRPZGJ>I27J6>X88QQD#)QGG(_$9!X>Q^/\ >6?PE\9>
M$CIK3ZQXLU!;W4M>DNLNZ*0WE^5L]=QW;_XCQ7DM/J%2BCHGC:TEH[>B2WW+
M^AZQ>>'=8L-5T^9K:_L9X[FWF7JDB,&5A]"!7OVM?M:V6H^-O'/B6V\$"QNO
M%WAUM$O8UU3<JS$;?M(_<_W0HV<9VD[LFOG6BK=.,FFT8T\35HQY8/0M:3JE
MWH>I6NHV$\EK>VLJS0SQDAD=3E6!]00*]*^.OQHM/CAJVEZY+X9CT7Q)':I;
MZG>V]T'BU!E4 2>7Y8V'K_$W&T?PY/EBT]:IQBVI6U1@JTXP=-/1BUZ'X9^+
M1\._!OQEX"_LK[1_PD5S:7']H?:=OV?R9 ^/+V_-NQ_>&,]^E>>4X=ZN45+=
M$0JSI.\7OI]XM+_%24O\56<K)?X:_7O]DOQ$GBC]G7P-=HVXPV LFSU#0L83
MG_OC/XU^0:\J:_1;_@FSXR75/AIX@\.O)NETF_$Z(3R(YEXQ[;HW_.O/QT;T
MT^Q]1PW64,4X/[2/L6BDI:^?/TX*2EHH BDC61&1AE6&"*^.OB7XL^)?[*&F
MFU\)>&/!5EX"N-6%IID3M=RW):7)#29F')*G./;BOLBOF3]OK_DF/A;_ +&:
MS_\ 09*WH/WU%GFX^+]BZD79H]9^$=W\2KJQU!OB1:>'K2Y\Q/L8\/M*59"#
MNW^8Q.<XQBN+^*GQP\40?$6/X;_#;1+'6/%WV47UW=ZM*R6=E"2,;@I#,QR.
MAXW#KT'N</\ J4_W17R7XF\1V?P#_; UGQ?XN%Q9>%?$^CQVMMJRP/)#%,AC
M!1RH./\ 5_\ CP[9HIVE)Z"Q$I4:4%S:-V;\CU+X-_%#QWK'BC5?"'Q#\)+I
M.M6$0N$UC25D?3+J,D8"NV=K@$?*6).&Z8Q7<Z5\5/!NN>(9=!T[Q3H][K46
M0]A;WL;S#'4;0<Y'?TKQV']H"]^.FG_$G2/A[H]Q=:59:'.+#Q0Q>)9KUHF"
MQ)&Z YSSNSQCD<C/S7\/8],UGP?\,-%L_$^@Z7XEM-8A>"QT_P /3-K,%TCD
MN+B02Y\MB?F8@ C'9?ET]DI7;T.;ZXZ?+&F^=:ZOKK:WF?3>J?M">(;/Q-\=
M=.CLM-,/@32XK[36:*3=,[6S2D3'?RNX8&T*<=Z]2^#'C2]^(OPK\+^)M2B@
MAOM4L8[F:.U4K$K,.0H8DX^I-?+^O?+X\_:\_P"Q>M__ $A>OH']ED_\8\>
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MKY_^&-]XDF^)_CWX<3ZYXTLM N?##7T \1WJ2:G;R%D7S8Y%9C&""V%SGID
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M_5E?\_?P_P""?AE_9MY_SZ3_ /?MO\*/[-O/^?2?_OVW^%?N;_9=G_SZ0?\
M?I:/[+L_^?2#_OTM']H?W0_U97_/W\/^"?AE_9MY_P ^D_\ W[;_  H_LV\_
MY])_^_;?X5^YO]EV?_/I!_WZ6C^R[/\ Y](/^_2T?VA_=#_5E?\ /W\/^"?A
ME_9MY_SZ3_\ ?MO\*/[-O/\ GTG_ ._;?X5^YO\ 9=G_ ,^D'_?I:/[+L_\
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M_/I/_P!^V_PK]S?[+L_^?2#_ +]+1_9=G_SZ0?\ ?I:/[0_NA_JRO^?OX?\
M!/PR_LV\_P"?2?\ []M_A1_9MY_SZ3_]^V_PK]S?[+L_^?2#_OTM']EV?_/I
M!_WZ6C^T/[H?ZLK_ )^_A_P3\,O[-O/^?2?_ +]M_A1_9MY_SZ3_ /?MO\*_
M<W^R[/\ Y](/^_2T?V79_P#/I!_WZ6C^T/[H?ZLK_G[^'_!/PR_LV\_Y])_^
M_;?X4?V;>?\ /I/_ -^V_P *_<W^R[/_ )](/^_2T?V79_\ /I!_WZ6C^T/[
MH?ZLK_G[^'_!/PR_LV\_Y])_^_;?X4?V;>?\^D__ '[;_"OW-_LNS_Y](/\
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MH2_E/._U:I_\_']Q^'W_  K_ ,4_]"UJ_P#X R__ !-'_"O_ !3_ -"UJ_\
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M,_\ ( M?_!A#_P#%5^K.11D4_KU3LB?]7,)W?WGY4#]@WXQC_F7[7_P80_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFQ])4445^='.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\+Z***_;3M/I?]G']I
M3QWX5\.Q^!]%\#6WCK1H3)*UE';2O/AW+-N9=R[22>J5[1XS^,7@R[UO2O$O
MQ2^"OB7PYJ6FM"MKJIA++%L<LB[@4!56)XP>IXK@?A[XLU[X-_L:V7B'P5:+
M'X@US6Y([J^2V\Z1(D+J#@@@8V #/ W-T)S6=\%_VS/%^O>,[#PMX]6U\4^'
M=;G73KB&XMDC>/S6" Y  *Y(RK#IZ5\97H>VJ5*U*FK)N]I-2??R,FM3QG]I
M#QQI/Q(^-7B;Q)H4SW&E7[PM#))&T;';!&A&TC(PRG\J\UKOOCWX#M?AG\8O
M%7ANQ+&QLKO_ $<,>5B=5D13[JK@?A7 U]7A>7V,.3:RL:+96"OT^_X)_P#_
M ";O9?\ 80NO_0A7Y@U^GW_!/_\ Y-WLO^PA=?\ H0KY_B#_ '5>J_4SJ;'T
ME1117YT<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 +136=47+$ >I.*J
MR:O8QD![RW4GH&E4?UH N45%#=0S_P"KE23_ '6!J6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML)\)<VS>CIGIZ,,@\X/% 'HE%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK'_@=+_\57.KUIZ]: .B7X@>*?\ H9-7_P# Z7_XJG+\0/%'_0R:O_X'2_\
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M_AN_X.?]#!=_^"VX_P#B*3_AO#X.?]#!=_\ @MN/_B* /H.BOGH_MY_!L?\
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MKX5_X>=K_P!$^/\ X-O_ +533_P4^0?\T];_ ,&W_P!JH ^[**^$/^'H2?\
M1/&_\&W_ -JIC?\ !451_P T\/\ X-O_ +30!]Y45\%G_@J0H_YIVW_@V_\
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M].YKR.OI\//VE&$^Z1:V3"OT^_X)_P#_ ";O9?\ 80NO_0A7Y@U^GW_!/_\
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MOAG\2+6^\ >&_#6H^'M).IZ;?Z#;/ Z;3]Q\N=^<8))[GBK:_$06?["^GO\
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M_P"K$NYR&R2 < <YZ4S7/VHO$_\ PGGB71K;4?"7AN;1[]K2WT?Q)'<137R
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M:-K_ &L8?M L//7S_+SC?LSNVYXSC%>7_M7?"V'XM? WQ)I7E[]1M8?[0L&
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M3 ^U_P!B?]L;[/\ 8/AWXZO5$0 BTG6+ASD<@+!*Q[?W6/L#VK[Z!K\%F_\
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MM/\ KC I_#YLT ?2O/I4-U>064)FN)HX(E^])(P51]2:^4K[XG>*KW/F:W=
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M+VH ^T8/VA? ES\?OBU>P>(YM&T_Q=I=K8Z5XOM[27?8R1VT:.2A42*&=<9
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M0#CW JI75_%+QAJ_C?QYJ^I:W>-?WPF: 3,BJ=B,55<* . !VKE* "GTRGT
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M"-;M)IG61\Y(VRJ.A/;O6Q%^UQXL'B:+4I=*T,Z5'I4FBKH$%J\5DMHY4NB
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M'PGK_P"SM\,].TBTN[+Q3X@UPV2W+I%AKHR"*03-C<8D!;9@]LGO6#KG[/\
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M"%JAD^[4K&OL?]C/]C%O'LEGXY\<VA3PVI\RPTR4$-?$8Q(X_P">61P/XO\
M=Z@$G[%G[& \:-9^/?'5GG0%/F:=I,RD&[8'B60?\\P1P/XOIU_1R.-845$4
M(JC"JHP /04D,*01I'&JI&@"JJC  '0 5+0 4444 %%%% 'D/[6W_)NGC?\
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M_P#R =-_Z]HO_0!0!H4444 %%%% 'Y\?\%'/^2G>&?\ L$G_ -'/7R17UO\
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MBDK[M_X=A_\ 52O_ "@__=--;_@F#N_YJ5_Y0?\ [IH ^$&J)J^\6_X)>_\
M52__ "@__=--/_!+G/\ S4S_ ,H/_P!TT ?#.A^']2\5:U9Z1I%E-J&I7DBQ
M06T"%G=B<  ?X_C7ZE_LF_LGZ?\  71AJVJK%?\ C6]BVW%R!E+1#@^3%^0W
M-WQZ=;O[-O[(F@?L]R7FH->CQ)XBN/W:ZI-:"#R(O[D:;GVD]SNR<#I7OU !
M1110!\3?\%)O^//P-_UTNOY1U\-5^J'[2?[-I_:&AT./_A(O^$?_ +,:5L_8
M?M/F;PH_YZ)C&WWZUX=_P[1_ZJ/_ .4/_P"Z: /B"BOM_P#X=H_]5'_\H?\
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MRS=9)I#]Z1V[LQ_H!@ "NMI:* "OR)_:0_Y+UX]_[#%Q_P"AFOUVKY"^)'[
M/_"P/'VO^)?^$[^P?VI>27?V7^Q_,\O>Q.W=YXSC/7 H _/ZBOM__AVC_P!5
M'_\ *'_]TT?\.T?^JC_^4/\ ^Z: /A]J2ON$_P#!-#_JH_\ Y0__ +II/^'9
M_P#U4?\ \H7_ -TT ?#K=:CK[D/_  3-_P"JD?\ E"_^Z:3_ (=E_P#52/\
MRA__ '30!\-M4;=Z^Z#_ ,$R\_\ -2/_ "A?_=-,/_!,?_JI/_E"_P#NF@#X
M7IC5]U?\.Q?^JD_^4+_[III_X)A_]5*_\H/_ -TT ?"4E1M7W>W_  3 W?\
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MX&R)F_I75Z'\!_B-XHE1-,\#>(+E6Z2?V=*D7XNRA?UH \^DJO)WKZ4\._L
M_&'7MAN='LM$C;JU_?1Y'N1&6->O^"_^"7LK[)?%WC55_O6NC6I/?_GK(?\
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M?_QVE_X8+^"?_0J3?^#6[_\ CM 'Y.KUIZ]:_6#_ (8,^"G_ $*DW_@TN_\
MX[2_\,&_!3_H5)O_  :7?_QV@#\H5IRU^KO_  P?\%?^A5F_\&EW_P#'*/\
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M_4?_ (8=^#G_ $+$W_@SNO\ XY1_PP]\'/\ H6)O_!G=?_'* /RXI5K]1O\
MAA[X.?\ 0L3?^#.Z_P#CE+_PP_\ !S_H6)O_  9W7_QR@#\N:*_4;_AA_P"#
MO_0L3?\ @SNO_CE'_##_ ,'?^A8F_P#!G=?_ !R@#\N:*_4;_AA_X._]"Q-_
MX,[K_P".4R3]A_X/,C*OAJ="1@,NI7.1[\R?S% '@_[!_P"T FCWO_"N==N6
M%K=2&32)I&^6.4\M"<G@-]Y>V<_WJ^\Z_(OXY_!G6O@/X^DTRY:0VC/]HTS4
M$)'G1@_*P(Z.IQGT(^E?:?[)/[5EM\3M/MO"OB>X6W\6VR!(9I&P-111]X?]
M-!CD=\9'<  ^H:*** "BBB@ HHHH **** "BBB@ HHKD/BA\4?#_ ,'_  A=
M>(_$EZMI8P_*D8(,L\A'RQ1J3\SG'3T!)P 30!RW[2'QUTWX"?#F\UJX=)-7
MG#0:79-R9YR."1_<7[S'\.I%?E#X)\)>)/V@OBU;:9'+-J.MZY>--=WD@SM!
M):69^. HR>GH!Z5K?''XT>(OVB/B$VK7R2[786VFZ3"2ZV\9;"QJ,?,[$C+
M9)/T%?H9^QC^S(OP-\(MJ^M0#_A,=8C4W0.#]DBZK I]>A8^H [4 >Y^ O!.
MF?#GP;I'AK1XO*T[3;=;>('&YL#EV/=F.6)]2:Z&DI: "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#A?BO\ #?PQ
M\2?#,]IXET:VU:&!3)"9@0\38ZHZD,OX&OR-^(FCVF@^-]6T^QB\BTMY-L<>
MXMM&!QDDD_B:**^UX?G*[C?0WI['-T445]P;!1110!^F7['?PA\':/X1T[Q3
M:Z#;KX@D3!OY&>1USP=NXD+D$CY0.M?3@HHK\AS"4I8F7,[G++<=1117 0%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gizttcucplmb000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000009.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M* "BBB@""YN(K.WDGGD6&&-2[R.P554#)))X  [U\R+_ ,%+/V=V\7?\(_\
M\)]&)/-\C^T6LYUL=^[;CSRFW'?=G;CG.*^@?B!X+L/B-X)UWPKJDES'IFM6
M4MA=-9RF*7RI$*.%;L2I(Z=Z_/+]MK0/A?\ !C]G72_V9_AWX?B\3>/=>NH8
M],T^,)/?VI-PL[7$L@ 8,P!1<D95N<HIR ?I1#-'<0QRQ.LD3J&1T;*L",@@
MCJ"*\U\+_M(> O&?QF\0?"[1M7-_XNT&W^T:A!%"QAA * KYOW2X+@%0<@Y!
MZ&O$_B_\6-<_97_9G^'GP]T3R]=^,>KZ=:>'=#TV%C(S7*Q*DMSCO'%UW' R
M5SQG'@'["WP<D^ _[?WCWPA<ZG-K.IV_A""YU&_F.3/=S&VEG8?[)D=L=\=<
MT ?IU7FWPQ_:&\"_&+Q5XO\ #GA75VU#5_"=R+35X&MI(OL\A>1-H9E ;YH9
M!\I/W?<5'9_M,_";4O%Z>%;7XB^&KCQ*UV;!=)CU*(W)N Q4Q"/=NWA@1C'4
M5^:7[,/[0&M_ G]IS]IB31_AAXE^))U3Q+(LJ^'8BYL_+O+T@R84_?WG'^XU
M 'Z8ZY^T-X&\._&?1?A5?ZL\/CC6+7[99:<+:1A)%B4[O,"[1_J9."<_+[UZ
M3FOR@T;XOZI\;/\ @JI\(]?U?P)KGP]N8M&DM!I6OH4G=5@OV$H&T?*=Y4?[
MAKV?XS_M$?'?4/VV-8^"'PPU#0[&"?1H;NUN]7M0RV+>6DDDS,%8OD!D"D$9
MD![4 ??&:\G^/'[47PU_9LTVUN_'OB2'29+S<;2QC1IKJX"]2D2 MM'3<<+G
M SS75_"G3_%NE_#O0K;QYJ=IK/B]+<?VG>V$(B@>;))V+@?*,A<XYQG S7P-
M\ _#5E^T+_P4P^-7B'QO%#K<?@F/[#HVFWR"6&#$@B1U1LCY520]/O3%NN*
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M0I?A+\(?&7C6*R74I/#^E7.I+9N^Q9C%&S["V#C.,9P<9KEOV3?CM/\ M*?
M?P]\0[G2(]"EU9[I3813&98_*N)(>'*KG/E[NG?':OF/Q-^V_I/[4O[.OQXT
M33_!'B+PM)IO@G4+UI]:C14E4QE-J[3URV:\L_88\&?M3:O^S'X3NOAKX_\
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MNBO*B$@LLF&)#;6#$\<T ?H?]HC\WR_,7S,9V;AG\JDR*_$#P?H\7C#X#?\
M":QZ9\;=5^/-Z\NIV?BW3+.>;36F$Q,:*XDYC**H9@N0V<<+@_2G[4WQT^)G
MB[]G']GGPIJ%S?\ @;Q'\2M1ATCQ+<^4;2Z3;)'#(-O!C5V?S"!C( '0F@#]
M)XKB*;/ER+)C@[2#2M/'&"6=5"]<D<5\=^#?^"?EO\$_B]X.\5?##XEZUX:M
MK,L-:T?67;4DUJ'*[DQYD80E=_S8;:65@,K@_.G@#X!Q_M1?MM?M'^&?$WB7
MQ!8^$M+U$71L])OS"7N2[I"3D'Y54S< 8R1Z"@#]3Y)HX8][R*B?WF8 5'<W
M45K:R7#MB*-#(S#^Z!DG\J_)3XO^)M.^(G[9GB'X<^,],\?:_P#"OX=Z7#IF
MD^&? T$TLQD2.!1+<8=202TG[SJ<1@<9)]1_8_TGQ+XDM?C5\']=TSQ_:?!^
M\L)+OPY>^*K62TO[6-B!);B4YY^92 #_ ,LV.!N- 'UA^SK^U3H?[47@WQ=X
MF\&:;>+INC:G+IEI]NPDM\R6\4H?8/N*QE"@$YXR<9P.E_9]\?>-_B-X#?5O
MB!X&;X>:Z+R2!=(:[6Y)B54*R[U&/F+,,?[-?GU_P2)^%NCM\&OB-\2//OQX
M@AFO]#2);DBU\@VMM-N,?3S-W\6>G%<-\+/C]XO^$/\ P2OUS6]!U2ZBU_4_
M&,VD)JC2,\UK')#$SLC'.&VJP##[I;(Y H _89;B)I#&LBEQU4,"1^%/9PN,
MD#TS7YA_&O\ 8CM_V<?V:Q\8/"/Q"\3P_%#PU;6FK7.L3:DS6]](SHLJ^60<
M*3(Q4$G/ ;()JE^WA\9?$?C;]FW]F'Q[:WD^A:]J]_!?2R6A*!9S"C%@N>5W
MC<%.1B@#]1UFC:0HKJ77JH(R/PIY..3P*_+;]JCX'V?['/Q9^!GC7P+XH\4/
MKFM>)ELM9FU359+G^T SQ%V<$]6#R KT.X<<<_J'=6T=[;2V\R"2&5&C=3T9
M2,$'\* )58,,@Y'M0KJV<$''7!K\Q/@K\<KO]B.']I?X8^++V:2;PF)-?\+S
MW4K2FYBGVQ0)N;DY:2T[]6D_NDUI?#_X(_%+0_\ @F%K4_A&YU:[^)?C()KU
MUMN'-]):2.A\J)L[MS6Z[MH.29''5L4 ?I-'<12L52178=0IS4M?C7\*/&/P
M4\(?$;P(FMVOQ8^ 'CBQO(A<7]U>27-K?2 *K)-YJDB-FP&Q'MPQW<<C]D8W
M61 RD,I&0PZ&@!)G\N)WQG:I/Z5\@?L<_P#!0G3?VGOB%XG\$ZIH,7A;Q!IN
MZ6QC2\\Y;Z)&*R$95<.ORMM /!)[&OKV\_X]9O\ <;^5?AS\(/@QKZ? WQ+\
M?_A]YJ>/?AWX^NYYDA9@;K3EAMW=" >0A=V([H\@.>!0!^GGAW]K"ZUS]MKQ
M1\!CX=AAM-%TA-3&MBZ)>4M#;R;#'MP!FXQG=_#[U]%R7$4+!7E1">@9@*_+
MG]D3XQZ5\?O^"GGB?Q]HR-!9:QX+AE-N[;F@E6WL$EB)[E'5UR.NVL;XQ^'?
MA-X\\;?%&_BU7XK_ !U\8K-/MOO#<,D>G:!(BG;"9 5C*(0>0"H53WYH ^^?
MVO?V@KC]F+X'ZI\0+71HM?EL;BW@%C+.85<2RK'G>%.,;L].U>C_  _\5'QK
MX#\,^(I(%LWUC3;;4#;A]PC,L2N5!QR!NQG':ORFUCQIK?CC_@C7<W6O:G<Z
MM=VFO16<=S=RF67RDO4**6)R0H; SV %=%^W5?:S;^&/V([71-;N]!O+JS2)
M+NU<@QN4TD(^WHQ4MG!'K0!^JZS1N[(KJSKU4$9'UHCF27.QU;:<':0<?6OR
MF_:$_9[7]GG]K3X,>'?A]XX\7:)%\0VDTO6[I]6>:>56E2.60.P.'=93S_"R
MJ5P:[+P;\.(OV4_^"F/A+P%X)UG65\)^)_"DE]?:?J-_)<J[_P"E#)W=P]LK
M G)&Y@.#B@#U'XA?M]>+]6^)7C/PO\$OA8_Q+L_! /\ PD&KR7WV:))%9Q)%
M$NW+D&-P""=Q1L*0 3]"_LT_'G3_ -I+X0:-XXL-.N-&>ZW0W>FW)+/:W"'$
MD>[ W+T(; R"#@=*_-;]A/X=_&7XC:'\8E^'WQ0A^&ME8^();B1ETJ.]N-0O
M2&(21G/[N(*HZ Y+MP<8K[>_X)X_M*:O^T]\ 5UWQ%%$OB+2=1ETB_F@B$<=
MPZI'(LJJ.!E)5! [@^U 'U!1110 4444 %%%% !1110 4444 %%%% !1110
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MFG17?Q5^*:27;:'8.C&WP\C1P[\[=Q,KDX. -O).:_12DH ^'/"/P-\=Z?\
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MK'PXU:*Z:+0WTQ4F%U*D<:3R29SE40*0IVGK@5:^%_\ P3NT7P[^R7KGP/\
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M^7Y<\U\??LS?MU>+/VD?VSM0\-VEE<Z#\,V\.RZAIFFZA9HES<;7B"73/MW
M.'8A0Q7&.M?7?A'X+^!_"?PMT[X?:9H=K<>"[%-D&F7I-W%M$IE 8REB^)#N
M^8GD#TKY#\*PQV__  6!\30Q(L<2>!8U5$ "J ML  !T% 'L&H?'7Q%\-?VV
M;/X<>*M1BO/!GCG21=^&'\E4>QO8<K-;,P +APNX%CP64"OID5\'?\%%+B;2
M_C_^R;?V+%=0'C-85VC)9&GM R_0AB/QK[Q'2@!:*** "BBB@ HHHH ****
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MT1YFC54>*1UDR KAE)&&P<,&4 'LU%%% !1110 4444 %%%% !1110 4444
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M/M)T#6X8TE>QNW82*K#*DX7N*F\*?M1?"GQQX8\1>(M!\<:7JFB>'81/JM]
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M^_#G6X8KOP=J^H:EJVH6$ZAHKV:RMU>WCD!X9 TA8J>I"^E>R?EAV&D?MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,-8\9_'WXX6K65Y9:3XE^'MAHMKJS12) TS-?HZI*!RZ"5&(4Y&Y3Z5],44
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M#=.^&NG^._#EIX2L%CL8/&$<,_\ ;Z:?& $C$1S#YX50GFEL8^;;FO5/V@/
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M44 >%_LT_P#(Z?'O_L?I?_3;85[I7A?[-/\ R.GQ[_['Z7_TVV%>Z4 %%%%
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M\<>))M?/AVRN?M,>FJT:($:0*%>1MA9F48Y%?0&/>B@!:*** "BBB@ HHHH
M*8\BQKEV"CU8@4^OD;]I[]G'P[XN\;ZU\3/B_P#$*]M_A=H^AF&S\.6]U-81
MV=R,9N#(DH$LC$L NW))0<XP0#ZXW#;GM2)(LB[E(8>H.:_**'QQ\3A^P?\
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M^*/'GAKP.VG#Q%XBTK0#J5PMI9#5+V*V^U3M]V*/>PWN>RKD^U?/'[07AO\
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M^ ?B-X \'?%SX]VGBSX2^(/']_)X]NY8M0TGPA_:\<49M[<"(RX.U@0S;/\
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH :#NI:^:_VJ/VAO$WP8\0:'9Z%#82
M17MM)-+]KB9SD, ,88=J\/\ ^&[OB'_SZZ+_ . S_P#Q=>G1RVO7@JD%HST*
M>!K58J<=F?H'1^%?GW_PW=\0_P#GUT7_ ,!G_P#BZ]>_9A_:6\5_&+X@7FBZ
MW!I\=I#I\ETIM(65MZR1KR2QXPYIU<MQ%&#G-:(*F!K4XN<MD?5%<A\4OBGX
M8^#/@R\\4^+M4CTC1K4JKS,&9G=CA(T106=V/ 503775\O?M*;K[]J3]FK2]
M4^;PS)J>JW9BE'[A]1BM5-J6/3>NZ4H#WW$=./+//-F;]LS3]&C;4O$_PP^(
MW@_PF"N[Q-K.BQK9Q(Q 6298YGEB0Y!W/&,?Q;:Z+]H;]JSP9^S3H7AG6O%,
M.J7VE:_>BS@NM'@CG2$%#(9I,R+^Z" L2FXX' -7/C?XN\5:/9WNGZ=\+!\0
M/#-QILC:C-)K5M:)M(<20M%*,L-@!R.#NQU%?/7Q&@\+?M >"_V6K2+P^NA^
M#O%37=JFB0L%%I9S:-<QB%2@ &U" -N,8&* /LG7O$=AX9\,ZCKU].$TO3[2
M2^GG7D"&-"[-U_N@UQWP!^.FA_M&_#2R\<>'++5--TNZGGMUM]8ACBN5:*1H
MWW*CNH^93CYORKYMTSQ;K'Q8_9N^'_PEDN!%XKO]?_X0KQ(&(#K:Z9(6U!SU
MXEMK=1R<?Z4HSS6Q^SI\8-#^"_P1O9]6TW7;V"[\;^)8(8]!T>XU!DVZG.?F
M6%6V+C&"<4 ?27Q1^*GAKX.^$IO$?BF_-CIR2I!&L<32S7$SG$<,,:@M)(QX
M"J"37E]K^V%I%EJUC!XO\ ^.OAYI.H74=G9:]XFTN.*QDF<XC1WBED:$N<8\
MU5&3@X/%<%\2/%EK\2OVG/V7-5:#48/"MXNO7MM::M:R6O\ I\=O&L+20R $
M2JOFE-PR 6(QS7TK\2K?PG<>!]87QTFEOX26'S-1_MO9]C$:D-NEW_*%! .3
MZ"@#D_BU^T%HOPIUK2_#PT?7?%WBW5()+FS\.^&K,7-Y)"A >9MS*D<8) W.
MP&3@9/%0?"O]H[0OB;XHN_"ESHNO^"O&=K:B^D\.^*+,6]TUN6*B:,H[QR)N
MXRCG&0"!7)?%?X=ZYXF^*FG^./A'X[T'2_'^E:$-.NM$U9/M5E>Z=++YT1D6
M-Q)#F1"5E4'(W#UK+^'_ ,3O$T'QS\+^&?C-\-M#T;QWJ%C>Q^'/&&@W*W5K
M=QQ*LES;H742P,457V$D,%/I0!J7G[9%HWB[Q7H&A?"?XD^,'\-:G)I%]J&@
MZ;9RVOVA%1V56>[1ONNAY4=>E>J_"_XA3_$K09M3N?!_B3P4\<[0BP\46T,%
MRX"J?,58I9%V'.,[LY!XKY&^#]Q\<H?BE\?Q\,+7P'/HI^(%T;AO%+WBW'VC
M[+;9">3\NS;LZ\YW5]B_#A_%\G@S3F\>1Z/%XK/F?;4T RFR'[QO+\LR_/\
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M]NS<4 >YWG[4WP<'[+L7Q)DD@E^'-Q;?8(M(-BI>23!C_L\6Q&TR94IY?W<
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M_1*5V]<1\#_^2.^"?^P+9_\ HE*[>O9I_ C\KQO^]5?\3_,6BBBM#C"BBB@
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M"Y]?FZUZ=\+/'?BS]FW]JKQ1\)/$_CG6OB+X:G\%MXML+S7G#W=O+$S+)$'
M^ZRQR'T&%XR22 ?<M%?E)I/QF^+NA_ GP3^U->_$O6+V77O%AM+SP7+L_L@:
M>;J6 Q1IC*L/).'SGG/4$G]5H91-$DB]'4,/Q&: /$/V:?\ D=/CW_V/TO\
MZ;;"O=*\+_9I_P"1T^/?_8_2_P#IML*]TH **** "BBB@ HHHH **** "D/0
MTM(WW30!^4.K?$3Q6OQ]O;1?$VLBT'B9XA +^8)L^UD;=N[&W'&,5L_MI?\
M)Q7B7_=M_P#T2E<-K7_)Q-]_V-4G_I8:[G]M'_DXKQ+_ +MO_P"B4KT.-HQC
MA\/RJUS]-\(6WG->_P#S[E^<3]#O@?\ \D=\$_\ 8%L__1*5V]<1\#_^2.^"
M?^P+9_\ HE*[>O+I_ C\^QO^]5?\3_,6BBBM#C"BBB@ HHHH **** "BBB@
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M=DK\V,9QSTJU\0/BMX,^%-C;7GC/Q7H_A6UNI/*@EU>^CMEE<#)5=Y&2!Z4
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M$_\ 8%L__1*5V]>13^!'Y]C?]ZJ_XG^8M%%%:'&%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\X_M.>&]6US7M&DT_3;J]2.W=6:WA9PIW#N!7B_P#PK_Q-_P!
M#4O_  %?_"OO3:.XI,#T%?!YAPG0S#%3Q,JC3D?=Y?Q9B,NPT,-"FFHGP9_P
MK_Q-_P! #4O_  %?_"O5?V;_  KK&B^/;BXO]*N[. V,BB2>%D7.],#D=< U
M]/8'H*7:.RU&!X1H8'$PQ$:C;B[]"L=Q=B,?AIX:5-)25A17$_$/X4Z5\2M6
M\%:CJ5S>6\WA/6DURR6U= LLRPRPA9-RG*;9F.%(.0.:[>BOOSX(\(\3?LJI
MJ_Q4\4>/="^)?C7P3JWB2*SBU*WT&6R$$HM8VCAXFM9&X#O_ !?Q'VKT;X:>
M [_X?Z-<V&H>,_$'C>::X,ZWWB)[=IXUVJOEKY$,2[,J3RI.6/., =C10!XO
M\:OV9[7XT^-O"GBB;QOXI\+ZAX96;^SH]#>T\J.64;7F*SV\O[S;\H;L,XQD
MD[WPS^$>K?#[5KJ]U#XF^,/'$<T'DK9^(I+-H8CN!\Q?(MHCNXQR2,$\5Z51
M0 4444 %%%% !1110 4444 %%%% 'C/[8=[J=A^S7X[FTJ\;3Y?L2I<74>PR
MQVK2HMR8PW!D\DR;1U+%0.<5XAX3^"O[.'_",Z8-,^-6LSV @3R9%^)4\>5Q
MD?(LZJOT"C'H*]T^+7@7X@^)KO48=.?P7XO\'7T*+<>#?&>EN879 #Q<H7&"
MZJV)(7P1QVKQZT\+_";P[--;_$7]E'1?!ZPY)U?3_"5CK.F.N?O"6UB:5!W_
M 'D28SSWH ^PJ^"/^"KWPIUKQ#\!?%OC6[\::A%X;T"VT_[%X3M8UCMY;N2_
MBADN+A_O28CEPJ'A2N>]?><,J7$*2(=T;J&4^H/2O)/VL?@?=?M'? #Q3\.K
M+58=$N=9^R[;ZXA,J1^3=PSG*@@G(B*]>] 'BG[4GPY\=_%[]A/PCX)\ :$^
MOZCK=KHD-[&EY#:^3:(D<KR%Y6 QOCC4A0QPQ." :Y_]G/7-)^$OQ[U#X>^*
M/@GX/^&/Q%NM!FU+2-8\'JLL%[9J27A=]H8,#&">S%#PO&?>OBE\ _$/C3X*
M^&/"GAKQ]JG@CQ1X;2SDLM:TN1TAEF@C";;B$,/-A;!)1B>QYQ@\O\'OV7_%
MEA\:+GXL?%KQE9^-/&4>F?V-I<.E6'V.RL;9CF0A"26D8D\D\;FZY& #X#_X
M0_2;K_@F7XI^+$MG%)\2(/&G]IQ^)V4-?K,+^*$$S'Y\;68[2<9.>M?2-CI^
MG?'[_@HX-.\=:59ZYI6E_"N&^M=*U&(301S32VYD?RV&W<1<R#=CHJ^@QI7?
M_!./Q/-877PZ@^)<<?P(N_$7]OS^'#IV=0.7#FV%QG_5[E'/7OC/7U/XZ?LK
M^+?$?QATOXI?"?QK9^!?&$.AOX<O/M^G_:[:XLRQ9"%SPZ-@C((.U?3! /@6
MVUR_OOV%/#_@N2ZG7P^WQ=_L%H#*VUK'>9/)//*;V)VD]A7TG?Q6?[/_ /P4
M*\4Z=X$TJUT#2=4^%<VJW.G6$*Q6OVJ!Y?*E\M1M! A5> /OGUY])F_X)[Z.
M/V4[/X36_B>[BU^TU,>(8_%!B!;^U=Q8S&,'_5\E-N<[0#DGFNB^!G[*_B?P
M[\6O$OQ1^*_B^S\=>--5TI=!@^P6'V2TM;$$,Z!,\L[#)Z8RWKP ? T/A'2?
M#O\ P3A^$WQ6L;&$?$1_''V]_$2H#?R2_P!H7,>'FY8@K$G!.#@'&:_5SQG\
M9O GPSCTY?&GC/P_X3FOXS);QZUJ<-H9@,;B@D8;@"PSCID5\C:#_P $Y?%%
MG;^'O &I_$R.^^!V@:^VO6?AU-."W[MO,BP27!)^0.SYQUWMWQM^ZGMHI  \
M:-MZ;E!Q0!\__LC^)M(\9:M\;=9T'5+/6M(O/'<SVU_I]PL\$RC3[$$HZDAA
MD'D'L:^AJ\*_9G18_%_QX55"@>/9L #'_,.L*]UH **** "BBB@ HHHH ***
M* "DI:2@#\B_%'_)S&H_]C4W_I57;?MM?\G#:[_UQM__ $4M<3XH_P"3F-1_
M[&IO_2JNV_;:_P"3AM=_ZXV__HI:]+C;_=</_71'Z7X1?\CNO_@E^:/T(^"?
M_)(/!?\ V!K3_P!$I7;?Q5Q/P3_Y)!X*_P"P-:?^B4KMOXJ\FG\"/@,9_O57
M_$_S%HHHK0XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,KQ5_R
M+&L?]><W_H#5^5_[(_\ R<7X,_Z^9/\ T3)7ZH>*O^18UC_KSF_] :ORO_9'
M_P"3B_!G_7S)_P"B9*^PR3_=,5Z?HSRL7_%I>O\ D4OB+_R7S7O^QAD_]'U^
MMEK_ ,>\7^Z/Y5^2?Q%_Y+YKW_8PR?\ H^OULM?^/>+_ '1_*OR[*_CK>O\
MF?T%XB_[IE?_ %[?Y1)J***^A/Q(**** "BBB@ HHHH **** "BBB@ HHI*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)2TE 'Y%^*/^3F-1_P"QJ;_TJKMOVVO^3AM=_P"N-O\ ^BEKB?%'_)S&H_\
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M/QY_['Z;_P!-UA7N=>&?LU?\CC\>?^Q^F_\ 3=85[G0 4444 %%%% !1110
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M24 )S1^%>8_%K]H3PS\&]1L++78=0DFO(FFC^QPJXV@X.<L.]<)_PW5\._\
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M!Q7QC^'/_"W/ACXA\''4WT=-8M_LSWT=M%<-$I8%L1R@H<@$<CC.1@@$?/\
MKO[%?C_Q1X4B\-ZM^TCXRO\ 18Q&#:S:99'S50C:LK;-TJ\#*N6#=P:^M:*
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M!'Y]C?\ >JO^)_F+1116AQA1110 4444 %%%% !1110 4444 %%%% !1110
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MMZ\BG\"/S[&_[U5_Q/\ ,6BBBM#C"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH P/'G_ "(WB+_L'7'_ *+:ORW_ &1_^3B_!7_7S)_Z*>OU(\>?
M\B-XB_[!UQ_Z+:ORW_9'_P"3B_!7_7S)_P"BGK[#)?\ <\3Z?HSRL7_&I>I4
M^)7_ "7SQ!_V,$G_ */K];+7_CVC_P!P?RK\DOB5_P E\\0_]C!+_P"CZ_6V
MU_X]H_\ <7^5?E^5_'6]?\S^@O$3_<\K_P"O;_*)-1117T!^)!1110 4444
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M^E5=M^VU_P G#:[_ -<;?_T4M>EQM_NN'_KHC]+\(O\ D=U_\$OS1Z5\<O\
MD2_A+_V+%O\ ^@+7TS^RRP'P/T#)Q\]S_P"E$E?,_P <O^1,^$O_ &+%O_Z
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M$2+XEQVI^(NJ:+:W.GW6BL?[*ET6&9HT6-6 D699I&WA]WWUVMB@#ZIHHHH
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MU\D_\-N?'#_HH-]_X#V__P ;KNIX.=2*DCVL/E5;$4U4BU9G[09_"CBOQ?\
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M:^C_ !%XBT7]DO\ ;\@\4_$#4!HWA/5_AC'I%KJ\L3M$US;R0%H<J#\Y6V)
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M_P#Z M5/BU_R:1\/?^PQ<_\ H5Q7S&1_\CCY?Y'XA@O^2RQ7S_0]._X)\_\
M(G^*_P#K_B_]%U]8=A7R?_P3Y_Y$_P 5_P#7_%_Z+KZP["OI<P_WJ9]CC/\
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MHK.1@-,4*Z_;)(U.98T5F!7!'S\CN/EWP+X=\)?&/]J;Q7J/[.NEV^F_#E_
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MO_@E^:/2OCE_R)?PE_[%BW_] 6JGQ:_Y-(^'O_88N?\ T*XJW\<O^1+^$O\
MV+%O_P"@+53XM?\ )I'P]_[#%S_Z%<5\QD?_ "./E_D?B&"_Y++%?/\ 0]._
MX)\Y_P"$0\5_]?\ %_Z+KZP]J^,_V+/%5MX)^%OC;6+R.::WMKZ$LD !<Y4
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MPUW/[:7_ "<5XE_W;?\ ]$I7I\<?[MAS]-\(/^1S7_P2_.)ZC\;O^1'^$?\
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MQJ7J4_B5_P E\\0_]C!+_P"CZ_6VU_X]H_\ <7^5?DG\2O\ DOGB#_L8)/\
MT?7ZV6O_ ![1?[B_RK\OROXZWK_F?T%XB?[GE?\ U[?Y1)J***^@/Q(****
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MJ?[>O_)!YO\ K_M__0C7EG_!-O\ X_O'W_7.Q_G/7S]7_D90]/T9^VY>O^,
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M78^1?$W[&_Q*\6:7X?L+[XO: L&AV*:?:F'P3(K&-0 "Y.HG+<#I@>U1Z_\
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M&+A3E9/<B4(R:<EL?#.M_P#!.WQIKOBR\\0W/Q@TE=0NKMKUUC\'.(_,+;B
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MO^$>G^RY\S?Y?E_VC_J_X=N>G&:^TJ*TA4G3^%BM<\9_X0?X\?\ 16_!O_A
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M=W6AV$FC77PVU><Q+H5VQ=9;@HH5FD92 LAZ%>,,N%X?P7XP\7?\$V?B)9^
M_&]S>^)O@#KET8_#_B5D:2;1)';BWFQT49Y'?ED_C4 'Z)45'#*DT22(VY'
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M&?B!#X8^)WPI\*V'AA(\CQ+H>K>7#%&J@!5A+RO(V2 %81]#SW/U/0 M%%%
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M?C5%/\:-6\"_&OPUI/A[X_VUG]AC\0);I''XDT\.S(T#X&>I.P=<'T*KS_Q
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MHFHPM!<VERNY74]QZ,."&'((!!S0!^6GQDB_:7\.?%+1_C)X?^"!T'QO;_\
M(4U7P3>'4M-U^TPIQ/;1EG8-A?F!SMP>J@C]*OA[J?\ PNCX4>&M9\8>#&T:
MZOX;?4)M UJ))6M9T<.C%3G!5U5U)PP^7(4C XG]E;X">)OV=='\0^$KWQ@W
MB?P/!> ^%K6[B)N]/M2H+0R2]& <D*H' 7.1NVK[L!B@!:*** "BBB@ HHHH
M *Y"3XK>$8_B5#\/VUZS_P"$SEL6U%='5\S?9PP!<CMR> >2 2. :Y3X]?$;
MQ5H?@^^T_P"%FG:?XJ^(<DT-I#I\M[$@L!*VW[7.A8-Y<8^8C'/';)KXK^$O
MB#Q)_P $_?V@-5M?C@MOXBTCXC3I+%\4XX6WI=87=;3L23'$I)PO '##*Y"@
M'U=^T5^SQX1^/WQ&^&T7C'5K2?3=*_M*0^%+LC_B:B6W$9D0;@VZ([6R <;B
M1@UY%\&O#_Q&_9&^*NG_  ;U33M5^(_P2\2/)#X>UI(3<3Z)E69K2Z'_ #Q"
M@\GC'([J/9])_9?\/ZC^T7<_&S5?$&H>*]1:T2+0;.ZE5K/2(RF':W"\$.#D
M$_WF.23D>Z[10!P/PO\ @3\/_@HNHKX&\(Z9X8_M!Q)=-80[6E(S@$YSM&3A
M>@R<"N_HHH **** "BBB@ HHHH 2BO(?VG_VA+3]F_X:CQ"VER^(-:U"]BTG
M1=%MWVO?WTN?*B![ [220"<#@$X%8O[.NJ_M!ZIK&L2_&32/"6C:4;>-]/AT
M"622;S&8[D=BY&%4#/J6&#P: /D#QU^T'^UE\#_VH;CP5K&M^#[_ $GQ%<R2
M^&?^$DM?LNFWR;QLMH)XL/'+\ZIMF?&0.3N4MP_V[]HG]G7X_CXA^&_V?]5\
M.Z?K4BQ^)_#?AZ4ZCI.HN6.)HQ$&\A_F)W9P&/HQ!_2GXV?!/P?^T=\.+WPI
MXJM$O],NAO@NH&'G6LPSMFA?^%U/X$9!!!(JE^S;X \;_"_X5V7AGQYXLC\9
MZIITTT%IJBQ%)&LE8K;B5CR\@0+ECSS@EB-S '<1Z;8^)X=#U;4]$2/4+3%Y
M;1W\4;W%A,\15@&!8*X5V0E&(Y(!(K;% &*6@ HHHH **** "BBB@ KR7]JK
MPCXG\>?L[^/=#\&ZE=Z5XFN=,D-E-8OME=UPYA4XX\Q5:/(Y^?J#S7EO[:OQ
M4\76?B;X7?!WP)K7_")^(OB/?SV\OB3:"UA9P*C3^5G_ );.' 7'(QU4D,.E
M^&GPOT/]BSX?^,O$WB?XE>+O%FCHJWMY?^)KR6^-I$@P1'&@/)9B20N3E1VH
M ^"_AC^TU\6_@3\&OAWXY\/_ !/T_P"+&D^))1I)^'WB3S)=:COD94>*V9-T
MC@$KRQP!)'\K%UKWG1?#L/[9_P 3++QOH_AWQ=^S]\;O!-W!'K-]=Z<QAN[8
MD!H"YPLI,>[;N4'!P0RX(3]E_P#9]TW0_P!MKQ/\1M&\)KK?P]\5Z!'XG\-^
M)I!L32IKIP9(%B/ E<^8<@;D55'1FK] 0O>@ 48&#S3J** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\I_:,^*
M'B?X7^ DN/!GA"^\9>*]4NH],TRTMXR8(9Y,A9KE_P""%<9+'CH,C.: .^;Q
M9HH\4#PV=5LQX@:U^W#2_.7[0;?=L,NS.=F[C.,9K\ZO^"@7[&NN:7\2G^/W
M@O4/%%S$A5_$FG>']0>'4[:!$VM<6<I#8554%H\8 '&!G$_[,/C+4OV9?VI/
M%7AW]HFRA7XB>.IDN-*^(3OOL[R(@#['&Y 6&,,,!0%YPI&-E?I$RK*I# ,K
M#!!Y!H _+76OV,O'?[5'P[\*^-?AU^T;)XZL+&4WFB7'BBV:&^LIU(S&;N,/
M+&ZD#*D8W*#CH:_1SX0Z3XMT+X9^&]/\=ZM;:YXNM[*./4M0LXS''-,!RP!Z
MGIDX&2"<#.!C?"G]GGP3\$]?\8:MX/TQ])D\47BWU]:13,+5)%7'[J'[D8)+
M,=HY+>@ 'I= !1110 4444 %%%0SSQV\+RRNL44:EF=VPJ@<DDGM0!+D>M>(
M^ ?VGM.^*WQNUWP1X.T:ZU[P_P"'X&35_&%O(OV""^W#;:(?^6K[0Q8J3@X^
MM>+_ !,_:U^'/[3>L3_ _P "?%2Z\'Z[JE\EE)KT%BWDW\ 8BXMK2X) $K@%
M5?H3PN=U>>^-?@UXJ_X)N>*S\2?A)!?^)?@Y=")/%?A&:5YY[3;A3>1,3R<<
M[L?+R&^3[H!]4^+OC)\+)/VD_!?P_OK=-:^)<,5S=V$MK:^>^D*T)#^;(O,(
MD0G@\<*3CY37,W/[(+^$_P!I;3_BO\,_$,?@F+4G*^+]!6V\RTUA/F;>$! 2
M8LV2WJ=W7<&[WX'W'PM^)4,_Q=^'UCIDMYXJ@B%]J]M"JW,OEC CF[JZ\!@>
M>%SG"UZS0 4444 %%%% !1110 4444 )FD:OFS]NKXU>)?A+\.?#6E>"[N+2
M_%OC;Q%:>&+#5KB,/%I[3EMTY!&,J!QG/)SVJQ\%OV>X?V68?%'C#Q'\5O&7
MC6V.G>=>OXDOI+B"U$>Z2:9(ESR0!V) 4@$[C0!\2?M0?LCZA^S'\<;CXJZ?
MXM\;Z7\,/$%XTFL:UX7OW74M"GDDR))LY-Q;[V)Y(/."<@;^O\1?L&_&CQMX
MG\&_%CX>_M :;XPU&UBBFTOQ%J5L;:Y>U89YFA63SUVL1LDXPS#CD']!/!'C
M/PG\?/AE8Z_I'E:]X0\06S[!=VY"7$)9D97C<9QE6!##M5'X(_ WPM^SWX,D
M\+>#X+FVT9KVXOEAN+AIO+:5RQ1,_=1>  /3)R220#M]+CO(=-M8[^>*YOEA
M5;B:"(Q1R2 #<RH6)4$Y(4L<9ZGK5RBB@ HHHH **** "BBB@#'\4>+-%\#Z
M#=ZUXAU:ST31[1/,N+[4)UAAB7U9V( KRCQJ/A[^VI\!_&GA?PUXGTGQ-I.H
MV[V+7FGSK<+:W2@21,P!X97"..G3BO _VQ3HWB_]LOX%^!OB9*!\*[RWNKV.
MSN9#'97VJJ2(HYST8#]V K<'S".CD5[;\</%&A_L4_LW^*/%?@/P+H\%EI3Q
MW)T6Q\O3K=I)I8XC(=J8R-RG:!D@8'- 'Y>_#?PJ=>D\%^#?@]I/B?P+^T]I
M=U<:/XFGTF]-MI<5M;R!'O+SA@005&$ !8/D,3&&_0SX?_L__$?XK:?)X9_:
M=T[PCXYTWPY?0WGA_P 0:9YD5Y=2*P;?(JA%1<*%90!NS@AL;CO?"'X"R:;^
MTCK/QR\.ZE_9/A;Q[X:M)M1\.2VY$LE\VUUF)./+VQ@9&,EI),XKZ5H
M.*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-!^&?A+3/#/AG3(=(T/38A!;6=N#M11W/.22>2Q)))).370T %%%% !1110
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M^.,'QO\ @)KFH^"_#=[<O:^.?".JZ7+##=2A"P:)<^7YN_&[8QV[L]RK?>-
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MA8CAAR"K#'!!%>,Z#_P3\\3:Y<Z-I7Q7^-OB#XF^ =&F2>V\+W=L(8KEH_\
M5"YDWLTJJ.JGKQSU!A_X)KV-E9S?&.7P2;YO@O<Z_#-X/DOXI8BV8F-WY:R
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M1CN9B!CGL.*]!HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*,*JJ.   .!0 MM;16=O'!!$D$$2A(XXU"JBC@  = !VJ>BB@ HHHH ****
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M/B-?6\5S#<VCA5BB<N2PE"L<,I)V@Y)!5C]=^#? WAWX=:#!H?A;0M/\.Z/
M28['3+9((5+$EB%4 9)))/4DYH WJ*** "BBB@ HHHH **** "BBB@ HHHH
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M<B@,2,$" # )4$X?+)X@\66O[<?QJ\?^$/B/XSU#X2> _ *R,?!R70L=1O\
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M'L3G8?0?WMU?6)&:R=%\*Z-X;FU&72=*LM,DU&X-W>-9VZ1&XF( ,C[0-S$
M98\G% &DD:QLY"J"YRQ QDX R?? 'Y"I:** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /DW]NG]A?1_VJ/"YUC1Q!I'Q(TV$K8ZBPVQWJ#)%
MK<X'*$]&ZJ?49!]*_9(\9>*?&'P3TG_A,? DGP]US27DTB72A&(X&^SGRA+
MG\,3;3@=.#M++@GVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M O\ :UUSX?\ [ GPUU-;*3Q9X\U75#X,\/VMR_RW-TL\D4)F<'(C2./D]3M
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M7L-O?>)GT^WN(YVWV>ZT7:T1S\NUOFP,<B@#[&HKX?\ AO\ M4W_ ($_8/\
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M!\U?\$[O#VJ^%_V1_!>F:SIMYI&HPM>>99W\#P3)FZE(W(P!&00>1SD5\^>
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gizttcucplmb000026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000026.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
M   !          #_VP!#  ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,
M# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$
M!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!3_P  1" /:!% # 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!M''>C=U-?,G[3W[4C_#^
M:7PMX5>-]?*C[5>D!EM 1PH'0N1@\\#(ZUO1HSQ$^2!YF8YCA\KP[Q&(=DOQ
M\D?0/B#QEH7A.%9-9U>RTQ6!V_:IUCW8] 3S^%<S9_'SX=WTPAA\8Z0TAZ W
M2C^=?GQX:^'?C_XYZQ<7]C:7NN3NX$^I74N$!]#(YQP#]T<^@KMM4_8M^)>F
MV+7$5II^H.HR;>UNQYGX;@HX^M>S_9^'I^[4J^\?GJXJS7%7JX/!-T_GK]Q^
MA&GZA:ZI:QW-E<Q7=O(-R30N'1AZ@BK7UK\M_"OC[QW\!_$306\M[HT\;A[C
M2[Q2(I!_M1GU'\0Y]#7Z+?"?Q[+\2O FF^()M+N-)DNDRUO/_P"A*>ZGJ#Q7
M!BL%+#)23NF?39'Q%3SARHR@X5([I_YG9T4@;-+7G'UXAJM?7D&FV<UU=2I;
MVT"-)+-*P544 DL2>@ !JQNKB/C<3_PIWQO_ -@2]_\ 1#U4%S22,*]3V-*5
M3LFS2TCXC>%M>U".QTWQ#IM]>29V0V]TCNV!DX .>@KI<U^;O[(/_)?/#W^[
M<?\ HAZ_2&NW&8986HH)W/G>'LXGG6%E7G'E:E;\A]%-)VTGF#U'YUP'U%T.
M-5[V\AT^SGNKB016\*-))(W15 R2?8 5/NKGOB)_R(?B'_L'W'_HMJ<8WDD9
MU9^SIRFNB,7P]\<? GBK6+;2M)\2V-]J-R2(;>)R6<A2QP,>@/Y5W8ZU^:'[
M*8_XR \(_P#76;_TGEK]+Z[\=AHX6:C%WNCYCAS.*N=8:=>K%)J5M/1"^V*Y
MSQMX^\/_  ZTG^T_$6I1:;9[M@>0%B[<G"JH)8\'@"NB!]Z^:OVS/A#XC^(V
MDZ%J?A^!]1;2C,LUA&?WC+)L^=!W(V=!SSQ7/AZ<*E10F[(]7-<37PF#J5\-
M#GFMD>X>!_B)X=^)&F-J'AS5(M3M5;8[1AE9&QT96 (/U%=+Q7S%^Q?\)?$O
MP_L_$&J>(+673!J/E1064W#D(6/F,N>/O8&>>OMGZ=HQ-.%.JX4W=(64XJOC
M,'"OBH<DWNAU%-W8Z\4;P>AS7.>O=#J**0F@8M%,\P#J0*7=GIS0*Z'4444#
M"BBD9MM "T4WS >AS^-.H **3--\P>H_.@5Q]%-5LTZ@844E)O ZG% #J*;Y
M@['-+0 M%-W4>8!U.*!7'44W=06QUXH&.HIGF ]"*<3B@"CK&L6.@6$M]J5W
M#8V46/,N+B0(B9( R3QR2!^-9^@^./#WBBXD@TC6K#4YXUWNEI<)(57.,D*3
MQ7F_[8'_ ";WXI_WK3_TJBKY]_8'/_%?^(O?3E_]&"O1I855,-*O?5?\ ^1Q
MF=SPV;T<M4+J:O?[_P#(^P_''Q$\._#?2UU#Q'JD6F6KML1I S,[8SA54%F.
M/04_P3X_\/\ Q%TG^T_#NIQ:G9;MC/&"I5N#AE8!E/(X(KP7]L_X1^)/B'8Z
M!J?AZVDU/^S?.CFL82-^'VD2*I/)^7! YZ8'6I/V,?A%XC^'>EZ]J?B""333
MJAA2&PE^^%CW'>P[$E\ 'GCFCV%'ZM[7F][L/^T\?_;'U'V'[FWQ:]K[[;Z6
M/IFBD[4WS .I _&O./K1]%-W9]Z4F@!:*3=2%ORH =13!(&Z$4X'- "T44A.
M* %HINZC>!UXH$.HIH<'IS2YXH&+13=U&\=":!7'44E)O Z\4#'44W>#T.:4
M]* ,W7M?T[PSI<^I:K>0Z?8P#=)<7#A44$X&2?PKSK3OVH_A?JFHBQM_%</V
MAF"KYMO-&A).  [(%/YUY9^WWJ$\/@WPU:)*RV\]Z[R1@_>*I\OY;C^=>0?L
MY_LTK\7]%G\0OKQTO[#J'V=+=;;S-Y18Y,D[AC[X'X5[%'!T7A_;U96N?GN8
M9]CX9K_9N!I*32N[_IJC[*\:?'3P+\/=6ATW7_$,%E?2A2(/+DD8 ]"VQ3M'
MNV*["WUJQO-)35(+J.73VB\];F-@R&/&=P/<8KX:_:4_9]\<7_Q6U+5M*TBY
MUS3]4='AFML,8SM"E'&?EQMZGC!%?3?PS\#ZC\.?@!%H.JRJ]_;V%PTH1MPC
M+[WV ]\;L?AQ65;#T84X3A*[9Z& S7,,1C,10Q%#EA!.SUU_SOY&YH7QT\!^
M)]6MM+TOQ/8WNH7#%8;>)\LY )P./0'\JT?'GQ1\+_#&RANO$NKPZ9',VV)6
M5G=\==J("QQD9P..*_/3]F$?\7Y\(?\ 7R__ **>OH3]LSX,^*?&VKZ1X@T"
MRDU>"VMS:S6D'S2QG<6#A>X.<<<C [<UT5,%2I8B-*4K)H\G!\1X[&956QM*
MBG.,K)*_EKW/I7PCXUT/Q[H\>JZ#J,.IV#DJ)82>".H8'D'V/-;M?/O['GPM
M\0?#?P7J<GB"!K&?4KA98[*1@7B51C+8. 6]/8?0?01/O7EUX1IU)1@[I'VN
M6XBMBL)3K8B')-K5#J*;N Z\4!\].:P/2NAU%%(6Q0,6BF>8/4?G2[J!70ZB
MD!S2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3AX23P&7XC,W-M1NN7ILG?U/ _C)^V%XE\8:M-I_@^XFT315;RXYH01<W/.
MV<90'L%Y]3V'GK3?%_28/[:>;QC;0@>8;R22Y"XZY+'@CZ\5ZI^PS\/]-\0>
M*=9\0:A EU-I*QK:)(N521RQ+X_O +@>F2:^Y#&&4@JI!XQCBHKXFE@Y>QIT
M[V.G+<HQW$5#^T<5B91YK\J6RZ=SXM^ '[8FJ)K%IH'CF=;RSN'6*'5BH62%
MB< 2=F7IS@$<YSV^LOB"V[P%XA(Y_P")?/\ ^BVKX"_:V\":=X#^,%Q#I<*6
MUIJ%I'?BWC7"QLS.K!1T )C)Q[XKZU^&OB*[\3_LMP7U](9KHZ-<0O*Q)+[$
M= 23U)"C)]<UABZ-.U/$4E9,]/(<PQ2GB<IQDN:5-.TO+;_*Q\>?LJG_ (R
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MLOIVN[W$B9P=K-E@/0J<?4<'O=._;POM)L8;.T\$Z?;VT"+''%'=LJHH&
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M9!QP#D_G530;WXN?'CQIINKB\U^RT&\U!8OM6GR20V]I'N^8IM('RJ"-QZD
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M9)Y <'RST50<C(Y/;CK[!\.=5GTC]D&WOX'9+BWT.X>-QU4@/C'N*^1?V:/
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MJH3J.[:ZCJ***XCZ,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&AN[2>)666,@J6 ;@Y4[E_"ON[PSXA^#WBK2(=0L!X7\EU!*30P1R1GKAT8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_1+SX=Z"L<^HZ*EF+F75[<./M<T=TLF(S%%N**JG+1L&R",6O 7[-WA;Q/\
M /X2>'/BCX&T?7=:\+^&;'3VM=6MXKO[%.MK!'<(C?,OWHE!*D@[!R1@UWFI
M^#?"_@'X0:SX?TRPL_#/A6STN[7[-81"&"UB9)&D95487[SMQW)H X+PGX_\
M9>.?VJ/%NC:?>Q0_#3PGI5K;W48@C9KO5;A?."B3&X".%D)4'JZ>M>[UY7^S
M7X/C\*_"'1+AM0_M?4]=C77-0U(J5^U7%PHD+ 'D(JE44')"HH.37JE !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0!\X_LQ_\
MER_:6_[&ZT_]-MM7BOQV^"-K\>OVYO%&@&[?2M;M?AO!J6AZO#GS-.U&'48V
MMYUQ_=;&0",@L,CK7U)\)/A)J'P]^(?Q7\07=[;75OXPUN'5+6*$-O@1+2*
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MGX9TC0[0L;33+.&RA+=2D:!%S^"BM:BB@ HHHH **** "BBB@ HHHH ****
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M(*M)8I%@*P8YD' ]>*_5GPI?3:IX7T>]N&WW%S9PS2,  "S(I) ^I[5^:/\
MP50TGQY_PC?C6]?X4^$XO _G6 'CM5C_ +7+;XP%)W;L%_W?3[OM7Z4> _\
MD1_#O_8.M_\ T4M &[1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M;I2TC4 ?F=_P5*_9)\-:3\./'/QHB\2>*I-?NKVQ#:/+?Q'2EW/% =L/E;ON
MC=]_[QS[5^CGA/\ Y%71O^O*'_T6M?G/_P %2_@GX[LOAGXY\?3_ !7U2Z\&
M37MB(_ S08M8\R11C#[^S@R?=ZG\:_1CPG_R*NC?]>4/_HM: -:BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J
M6D(S0!\%?\%5O"_P[7]F_P ::Q'I_AW_ (3W[3IX-VJ0_P!I;?M$2D9_UF/+
MX^GM7VSX#_Y$?P[_ -@ZW_\ 12U\&?\ !57]F/X<V_P5\:?%^/077X@M<:?&
M=4^VW!4J9HH2/*W^7]SC[OOUYK[S\!_\B/X=_P"P=;_^BEH W:*** "BBB@
MHHHH **** "BBB@ HHHH **** "F[J&J&\NH;"UEN;B58+>%#)))(<*B@9))
M/0 "D+;<GI"0*Y7_ (6KX/\ ^AGTG_P,C_QK&\6_$K1KSP[?0Z%XRT6QU=X\
M6UQ-<QLB-ZD'.1^%8NM32OS'++%T(IOG3MYH]$XHKY>_X23XB]?^%O>$_P X
M?_C586O?$WXD:'JFD68^)&@WXOY3$9[5(&CM^GS2'R^!S^E<4L?"*NXO\/\
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M"ZT_^-5XW11]4P_\B^Y!]6H?R+[CV3_AL#XN?]#:?_!=:?\ QJD_X:^^+O\
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M&=+Y_DSZLHHHK[T_;PHHHH **** "BBB@ HHHH **** "BBB@#Y5_P""@?\
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M?_(JZ-_UY0_^BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S
M;_;+_P"2^:U_UPM__12UXA7M_P"V7_R7S6O^N%O_ .BEKQ"OT7"?[O#T1]YA
M?X$/0****ZSI"BBB@ KJ?A3_ ,E0\)?]A:T_]'+7+5U/PI_Y*AX2_P"PM:?^
MCEK*K_#D9U?@D?K2OW1]*6D7[H^E+7YH?GP4444 %%%% !1110 4444 %%%%
M !1110 445\;?M@_M@:K^SGK>O6>GMJ&H^)[VRM;?PMX9&F[K:[FD9EDNVN!
M&6;86"^2&!+1CL^0 ?9&:6OE/]DG4?BUHNNVOA[XK_$&U\8^)=1T:36]2T5;
M&&*70&,T2P1&6/&[>KR90K\IC.#C!/U90 4444 %97B3Q/H_@W1;K6->U2ST
M72;5=\]]J%PD$,0]6=B !]36K7P9_P %'8?^$[^,7[-_PTU!VD\+Z[XE-QJ=
MCNPET(VB55;OC:\@_P"!T ?9/@/XG^$/BEILFH>#O$^D>*+*)_+DGTB]CN51
MO[K%&.#]:ZC=7YZ>&]*T7]G?_@JYIG@_P5I-OH/AOQSX1,EWI.G1K#:13QI/
M()$B VKQ98^4#F1_4Y^[O',6OS^#M:B\+36MOXD>TE73IKT$P)<%2(RX /RA
ML9X/% $%U\1_"]GXZL_!D^O6,?BR\MFO(-':=?M,D*[LR!.NT;6Y]JZ:OS!^
M$'PO\0_"O_@J9X>L_%WC"Y\<^*-3\)W&J:EJ\\0B0S2"9?+B0$[(D6-0J\=^
M!T'Z=22+$I9F"*.K$X H ^1?^"KO_)DGC+_K[T[_ -+(J^H? ?\ R(_AW_L'
M6_\ Z*6OE?\ X*K7UO<?L3^,4CN(I'-WIV%5P3_Q^1=A7U1X#_Y$?P[_ -@Z
MW_\ 12T ;M%%% !1110!Y?\ &K]H#PW\!X-)F\117LJZDTJ0?8X@Y!0*6SDC
M'WQ7EW_#PSX:?\^NN?\ @*G_ ,77#_\ !2X?\2OP!_UVO?\ T&&OA*ONLKR;
M"XS"QK5+W=_S/&Q&+J4JKC'8^TOC-^UKH'Q'NM+E\->//%7@1+1)%FCL],$H
MN2Q7:21<)@K@XZ_>-><?\+LN,?\ )>O''_@D_P#NROG2BOHJ>44*4>6/Y1?Y
MHX98F<G=_J>[Z7\=M?N-2U&._P#C1XNL[&-@+.XAL#,\Z\Y+I]H7RR,#C<W4
MUJ_\+LG_ .B\^./_  2?_=E?.=%;/+:+=U^4?\B%B)K?]?\ ,^_OAS^W)X(\
M&^#M/TG6=6\1>*-2MPXEU6XL522?+E@2IE;H"!U/2NG_ .'AGPS_ .?77/\
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M_P!W04445[!ZH4444 %%%% 'ZE_LY_\ )#?!?_8-B_E7I%>;_LY_\D-\%_\
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MOJ:K!E# @@C((Z4Z@ HHHH **** "FM3J1J /SY_X*I6OPF7X ^-9;5?!_\
MPLW[;8>:T1M?[8_UT0;=C][_ *O'7^'':OO'PG_R*NC?]>4/_HM:^!?^"J'[
M-7PXTWX%^-OBM;^'(X_'MQ>V EU?SY=S9FBA/R;MO^K 7[O:OOKPG_R*NC?]
M>4/_ *+6@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _-O]LO\
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MI_NV?_M>O6RO_>H?/\CZ;AO_ )&=+Y_DSZLHHHK[T_;PHHHH **** "BBB@
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M97)_%K_DF/BS_L%77_HEJY:GP,RQ'\&?HS\W****_,GN?SG+=A1112$%%%%
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MO"?_ "*NC?\ 7E#_ .BUKY5_X*P?\F2^+O\ K]T[_P!*XZ^JO"?_ "*NC?\
M7E#_ .BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** $K-\0ZU;^&]"
MU'5;O?\ 9;*WDN9?+&6V(I8X'<X!K2-<?\7_ /DE?B__ +!-U_Z):HFW&+:,
M:TW3IRFNB9YW_P -B>!?^>>I_P#@,/\ XJL+QI^TK\.?'/AN[T745UE;2YV[
MS#"%;Y6##!W<=!7R#17Q<LVKM--(_(:G%&.FG"2C9^1[9]J^"/\ ?\48_P!X
M?XUSFO77PW_X230_[)DUW^QMS_VEY[?O<<;=GOUS7FU%<4L7*2MRI?(\BIFD
MZD;>SBO1'MHN_@C_ '_%/_?0_P :[+X:_&#X5?"V:_ETC^WG:\5%D^TH''R[
ML8YX^\?TKY@HK6.83@^:,8W]#IIYY5HS4Z=.*:\C[;_X;$\"]TU3_P !A_\
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M*NC?]>4/_HM: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*Y#XP?\
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MG_DJ'A+_ +"UI_Z.6LJO\.1G5^"1^M*_='TI:1?NCZ4M?FA^?!1110 4444
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MH ^5?^"@?_(@>&?^PF?_ $4U?"U?=/\ P4#_ .1 \,_]A,_^BFKX6K[C*?\
M=E\S[#+?]W04445[!ZH4444 %%%% 'ZE_LY_\D-\%_\ 8-B_E7I%>;_LY_\
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M*6OS!_X*G7?AKRO&T"_ ;7(?$?FV)_X6F;"3[ 1NB.SS]NW)7]UC/4XK]/O
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M/[2Q7\X?ZC</?] J^]_YGU9_P\,\8_\ 0OZ3_P!]2?XT?\/#/&/_ $+^D_\
M?4G^-?*=%']I8K^</]1N'O\ H%7WO_,^UOA7^W!XI\=?$70/#]UHFF0VVHW:
M6\DD1?>H/<9/\Z^U@>*_)K]G/_DN?@G_ +"47\Z_65/NC-?4Y37J5Z4I5'=W
M/P#Q#RC!9/CZ5' TU"+A=V[W8ZBBBO</RH^5?^"@?_(@>&?^PF?_ $4U?"U?
M=/\ P4#_ .1 \,_]A,_^BFKX6K[C*?\ =E\S[#+?]W04445[!ZH4444 %%%%
M 'ZE_LY_\D-\%_\ 8-B_E7I%>;_LY_\ )#?!?_8-B_E7I%?FM?\ BR]6?G];
M^)+U"BBBL3(**** "BBB@ HHHH **** "BBB@ IK4ZD:@#\J_P#@J)X^\'7&
MB^/?#4/P6UFS\5QWMEO^(KZ*BV4V#$YQ=?>.4Q']1BOT_P#"?_(JZ-_UY0_^
MBUK\Z/\ @J9\;_'-Y\,_'/P_G^%&K6O@Z&]L3'XY:;_1),212#"[.[DQ_>ZC
M\*_1?PG_ ,BKHW_7E#_Z+6@#6HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 2N0^,'_)*_%W_8)N__ $2U=?7(?&#_ ))7XN_[!-W_ .B6K&I\$O0YL3_
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M %(<]J6FM0!^<'_!51_CC_PJKQJLT?A/_A2_GZ?M9?-_M??YT6.^S'G8_P"
MU^@G@/\ Y$?P[_V#K?\ ]%+7Y[?\%4O ?QAC^&/C3Q)+\1K)_A,9[!1X/_LZ
M/SPYEB4-Y_E[O];A_O\ 3CIQ7Z$^ _\ D1_#O_8.M_\ T4M &[1110 4444
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MFKX6K[I_X*!_\B!X9_["9_\ 135\+5]QE/\ NR^9]AEO^[H****]@]4****
M"BBB@#]2_P!G/_DAO@O_ +!L7\J](KS?]G/_ )(;X+_[!L7\J](K\UK_ ,67
MJS\_K?Q)>H4445B9!1110 4444 %%%% !1110 4444 %(U+2-0!^9W_!4O\
M:V\-:M\./'/P6C\-^*8_$%K>V)?5Y+&(:6VV2*?Y9O-+?=.W[GW@1[U^CGA/
M_D5=&_Z\H?\ T6M?*G_!6#_DR;Q=_P!?NG?^E<=?5?A/_D5=&_Z\H?\ T6M
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M5>$_^15T;_KRA_\ 1:T :U%%% !1110 4444 %%)2T %%%% !124M !1110
ME<A\8/\ DE?B[_L$W?\ Z):NOKD/C!_R2OQ=_P!@F[_]$M6-3X)>AS8G^!/T
M?Y'YOT445^9O<_G1[A1112$%%%% !7U=^P__ ,>/BS_KI;_RDKY1KZO_ &'S
M_H/BS_KI;_RDKU\J_P!ZC\_R/J.&O^1G3^?Y,^H:***^\/VT**** "BBB@ H
MHHH **** "BBB@ HHHH _-O]LO\ Y+YK7_7"W_\ 12UXA7M_[9?_ "7S6O\
MKA;_ /HI:\0K]%PG^[P]$?>87^!#T"BBBNLZ0HHHH *ZGX4_\E0\)?\ 86M/
M_1RURU=3\*?^2H>$O^PM:?\ HY:RJ_PY&=7X)'ZTK]T?2EI%^Z/I2U^:'Y\%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E
M+24 ? /_  56_9_^'T/[/OC3XFIX8M5\>-<Z?&=;W2>=M-Q%$1C=M^Y\O2ON
M+P'_ ,B/X=_[!UO_ .BEKY5_X*M:I9-^QCXSLQ=P&\^UZ<?LXE7S/^/N(_=S
MGI7U5X#_ .1'\._]@ZW_ /12T ;M%%% !1110!\3?\%+O^07X _Z[7O_ *##
M7PE7W;_P4N_Y!?@#_KM>_P#H,-?"5?J^0?[A#U?YL^:QG\9A1117T)PA1110
M 4444GL,_8OX#_\ )#_A[_V+VG_^DT==SW%<-\!_^2'_  ]_[%[3_P#TFCKN
M>XK\-K?Q)>K/KX?"A:Y/XM?\DQ\6?]@JZ_\ 1+5UE<G\6O\ DF/BS_L%77_H
MEJY:GP,RQ'\&?HS\W****_,GN?SG+=A1112$%%%% !7U)^P[_K?&G^[9_P#M
M>OENOJ3]AW_6^-/]VS_]KUZV5_[U#Y_D?3<-_P#(SI?/\F?5E%%%?>G[>%?E
MG^U]_P G&>,?^NMO_P"DT5?J97Y9_M??\G&>,?\ KK;_ /I-%7SN=_[O'U_1
MG[-X5_\ (YJ_]>W_ .E1/':***^)/ZJ"BBB@ HHHH ]&_9S_ .2Y>"?^PE%_
M.OUF7[@^E?DS^SG_ ,ER\$_]A*+^=?K,OW!]*^UR/^!+U/Y<\5O^1I0_P?JQ
MU%%%?1GXD?*O_!0/_D0/#/\ V$S_ .BFKX6K[I_X*!_\B!X9_P"PF?\ T4U?
M"U?<93_NR^9]AEO^[H****]@]4**** "BBB@#]2_V<_^2&^"_P#L&Q?RKTBO
M-_V<_P#DAO@O_L&Q?RKTBOS6O_%EZL_/ZW\27J%%%%8F04444 %%%% !1110
M 4444 %%%% !2&EHH _-/_@J9\*OBI:_#'QSXQNOBNUU\-Y;VQ\GP-_9B 1Y
MDB1?](SN.) 9.G?%?HMX3_Y%71O^O*'_ -%K7RK_ ,%8/^3)?%W_ %^Z=_Z5
MQU]5>$_^15T;_KRA_P#1:T :U%%% !1110 S(I=WO7R#_P %#/%VO>$M'\%/
MH>MZCHSSW%T)6T^[> R +&0&*$9QGOZU\5?\+E\?_P#0\^)/_!O<?_%U]+@<
MCJ8V@J\9I)GGUL9&E-P:/TU^,%C\8[G7K1OAUJ6A6>E"WQ.FJ1[I#+N/(^4\
M;=M<)_9/[4G7^W?"'_?G_P"PKX$_X7)X_P#^AY\2?^#>X_\ BZ/^%R>/_P#H
M>?$G_@WN/_BZ]VGD=>G%1]QV[Q.*6,A)WU^\^Q?AY\0_VB_B7J7B6RTO6/#,
M<N@7IL+HW%L%!D!.=N%.1P:[?^R?VI/^@YX0_P"_/_V%?GGI?Q#\5:'-=RZ;
MXFUC3Y;R3S;E[6_FB:9SG+.5;YFY/)S6C_PN3Q__ -#SXD_\&]Q_\7714R>H
MY/V:@E_A)CBHI:W^\_73P-'KT/A/3$\4S6T_B!80+V2S&(FD[E1@<5O5^-G_
M  N3Q_\ ]#SXD_\ !O<?_%T?\+D\?_\ 0\>)?_!O<?\ Q=>5+AFM)M\Z^XZ5
MCX:*Q^RHQVI:X?X*7UQJ7P?\%7=W/)=74^CVDDL\SEWD8PJ2S$DDDGN?6NWK
MXR<?9R<>QZL7=7"N0^,'_)*_%W_8)N__ $2U=?7(?&#_ ))7XN_[!-W_ .B6
MKGJ?!+T.?$_P)^C_ "/S?HHHK\S>Y_.CW"BBBD(**** "OJ_]A__ (\?%G_7
M2W_E)7RA7U=^P_G[#XL_ZZ6_\I*]?*O]ZC\_R/J.&O\ D9T_G^3/J*BBBOO#
M]M$HI/Y5Y1XG_:B^&7@WQ!>Z+J_B06FI6;^7/#]CG;:V,XW*A!Z]C6<ZD*:O
M-V.S"X/$XV3AA:<IM=(IO\CUC-&:\6_X;*^$'_0VC_P N?\ XW1_PV5\(/\
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MO_!9<_\ Q%'_  ])_9R_Z'>;_P %ES_\17VA^O'U@?N_A7Y2?M/?\E\\:?\
M7]_[(M?51_X*D?LXG_F=YO\ P67/_P 17P!\=/VGOAWXT^+GB?6])UMKG3;R
MZ\R"4VTB[EVJ.A /4'J*\'.*4ZM&*@KNY^N^&N.PV S*K4Q=10BX6]YI=5W)
M**X#_A>W@S_H*'_OR_\ A1_PO;P9_P!!0_\ ?E_\*^1^IXC^1_<?T?\ ZRY-
M_P!!5/\ \"7^9W]%<!_PO;P9_P!!0_\ ?E_\*/\ A>W@S_H*'_OR_P#A1]3Q
M'\C^X/\ 67)O^@JG_P"!+_,[^BN _P"%[>#/^@H?^_+_ .%'_"]O!G_04/\
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MU>6_\-#>!?\ H*O_ . \G_Q-?=X7$T8T()S6RZGVF&Q%*-&*<E=(](HKS?\
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MO[66V:5?$,)*!T*Y W<D9_2L)IN+2,ZT7.E*,=VF>0T5S'_"!?M1?]$#G_\
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M *(9<?\ @TMO_CE?4Y?CJ%"@H3>I]'@<91HT>2;U'T4S_A2W[4'_ $0NX_\
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MX=_\%,'_ ,11_P *A\"?]"3X=_\ !5!_\17744 <C_PJ'P)_T)/AW_P56_\
M\11_PJ'P)_T)/AW_ ,%5O_\ $5UU% '(_P#"H? G_0D^'?\ P56__P 11_PJ
M'P)_T)/AW_P56_\ \17744 <C_PJ'P)_T)/AW_P56_\ \11_PJ'P)_T)/AW_
M ,%5O_\ $5UU% '(_P#"H? G_0D^'?\ P56__P 11_PJ'P)_T)/AW_P56_\
M\17744 <C_PJ'P)_T)/AW_P56_\ \11_PJ'P)_T)7AW_ ,%4'_Q%==10!R/_
M  J'P)_T)/AW_P %5O\ _$4?\*A\"?\ 0D^'?_!5;_\ Q%==10!R/_"H? G_
M $)/AW_P56__ ,11_P *A\"?]"3X=_\ !5;_ /Q%==10!R/_  J'P)_T)/AW
M_P %5O\ _$4?\*A\"?\ 0D^'?_!5;_\ Q%==10!R/_"H? G_ $)/AW_P56__
M ,11_P *A\"?]"3X=_\ !5!_\17744 <C_PJ'P)_T)/AW_P56_\ \11_PJ'P
M)_T)/AW_ ,%5O_\ $5UU% '(_P#"H? G_0D^'?\ P56__P 11_PJ'P)_T)/A
MW_P56_\ \17744 <C_PJ'P)_T)/AW_P56_\ \10OPC\#(P9?!?AY64Y##2H
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\N_LD? OQ?\
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MTKSG]GGX2Q_ OX*^$/ :7G]H-HEBEO+=8*B64DM(P'4*69L ]L5Z-0 M%%%
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M!?[//@;]G+PK+H'@;2/[.M)YOM%U/-*TT]S)@#?)(W)( QCH.PKTN@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .2^*GPWT?XP?#OQ!X+\01&;1]:M'M9PN-R@\JZ\<,K!6!]5%?G=X-^*FO?L
M-_VE\"?VC=+G\6?!F]@:VT/Q7'8R3P?9G# V\B\Y7'_+,?/&<XW*5Q^GU5;_
M $VTU2W,%[:PWD)Y,=Q&'7\B,4 ?#?\ P2_\-R-\/_BM9VEI=77P;U'Q#-_P
MB4>L0%9+BS<,)=R-G,94PC)^\=^0.E?<EA86^E6-O96=O%:6EO&L,$$*!4C1
M1A551P  !P*D@@CMXDBBC6.)!M5$   '85-0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45QGQ;^+'AWX)^
M]2\7>*;MK72K%5&V-"\L\C,%2*-!R[NQ"A1Z^@)KR&/X_?&N^TV/7K+]GBX/
MAUHC<""[\56T.KM'C((M?+*A\?\ +,RAN0.#Q0!](T5X7-^UIX9OOV9-9^-&
MAV=UJFE:5:337&E3?Z-=130OLEMY 0=CJP(Z$' (R"#6_P#LU_'RP_:0^%EI
MXQL=-FT.5KJXLKS2;J59)K.>&1D:-R!U*A6Z='% 'JM%?/@_; T:?]KB+X$V
MFB75U??9'GGUQ9@+>&98//:#;M^9A&T9.&X,@STKZ"H 6BO ?%'[3NIZE\1-
M>\"?"SP)<?$77_#X1=9O)=033=+L)G4,L+7+JYDDVD$K&C8Z$@YQ=^&?[2-Y
MKWQ,/PV\?>#+GX=^.Y+%M2LK62^COK+4K=2 [6URBJ'9"?FC958#)Q@9H ]Q
MHKYTU3]IKQ?XJ\:^*/#OPE^%[>.X_"]\--U;6-3UN/2;-;H*&>WB+1R-*ZJR
M[CM &X<G(STOP?\ VCH/B9?>,/#^K>&[[P=XY\)!6U7P]?3),5C=2T4L4Z?+
M+&X!PPQCC(&: /9J*^7?A7^UA\1_C-X#TSQAX5^!=Q>:%J(=K:>;Q59PLX5V
M0DHRY'*FO>_A_KWB'Q%X>6\\3>&#X0U0R.K::;^.](4'Y6\R/Y>?3MB@#IZ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ^4OVX#:MXO_9VCUK</##?$*S^V
M]=GG!'^RA_\ 9\[;G/'7/%>V_%KQ9X[\)Z983>!/ 5MX]O)92MS;76NII:P(
M%R'#M%)O)/& !ZU;^+OPD\.?&_P'J'A+Q3:-<Z9=[762&0QS6\J,&CFB<<HZ
M, 01Z8.02*\A@^!OQ[TBQCT;3/VA8FT:)!#%>:GX0M[G5$C P 9_-6-W _C:
M,^I#=P#R3XA?&'_A;O[#/[132^!++X>ZCH%SJ>BZAI=A>I=1O=Q.HFE\Q(8P
M2SELG:<XSGFND^"_BS2_V?/BEXOTG595TWPWXD\&V?CZUFD.V&.6VMDAU$9/
MR@D+!+QZN3VKOT_8ST72_P!G'QS\*])\1ZD+KQ@;BXU/Q+J^;VYGO)R#)<.F
MY 22/N@K]<]7?'O]CS3?COX4^'^CW/B&?1KCPN\=O<7]K;9DU#3VC6.[LB1(
MIC6=43+ MC;T89H ^=?A+X1N/#_[4G[/.O:I&X\1>,M-\3>*=5,A)837<:R)
M'R3@1P^5'@''R'WKZ=^&?[6^A_%+QE9>'+/P/\0-&N+H.5O-=\-3V=HFU2Q#
MROP,XP,]3@5N>)_@.GB'X^?#OXDQ:PMC%X0TZ_T]=(6TW"Y6Y0(&$F\;-F.F
MQL^U>M4 ?*W_  3Q%I_PK'QX6S_PD?\ PG>M?VX9,^;]J\_Y=V>?]3Y./:O?
M]=USPAIOC+P[9:Q=Z1;^*+[SDT:.\:,74VU=TJP%OF)"\D+V'->2^)OV9->T
M7XC>(/'/PF\>GX?ZMXC9)-;TV]TI-3TV^F0!1/Y1D1HI=H +(P!YR,G-7/AC
M^S7J.B_$[_A9GQ&\:2_$3QU#9-IVG3"P2PL-*@8Y<6ULK/AWX#2,Q8C(X!Q0
M!P3?!GQMI/B;Q9XU_9S^*6@'3/$.K37NK>'-:MUOM-DU)2(IVCN(3NA8F,*R
M@'E!TQ6S\(/C-XDUKQSXS^'WQ.\%:3X7^*%AH8U,ZEHDHFM-6T]F:))4<CS%
MVNK+Y;DXQGVJS<_LO^-? ?C#Q#K'P@^*"^"-+\0WKZEJ'AW5]$35+%;N3_63
M6X\R-H2YY902"?2ND^%/[.=]X1\2>(_&?C#QC<>./B!KU@FESZN]DEG;6MJA
M8K!;VZ$[$#,6.6)8\D\F@#Y8_8;L_P!I63]E_P %MX%OOAG%X7,<_P!C378[
M\W@'VB3=YGEC;G=NQCMCO7WWX.77H_"NE+XH>PD\1BV3^T'TL.+4S[?G\K?\
MVS.<;N<5Q7[-7P5_X9X^"_AWP!_;/_"0?V0LJ_VC]E^S>;OE=\^7O?;C=C[Q
MZ5ZA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !17AW[4'Q'^)W@W1-+TGX4^"CXH\
M2ZTTT7]I7$OEV>CHJ@F>8XY^]PN1G!Z]*^?O^"1/C;5O$G[+_C+6_$FL7VLW
M<7BZ]>2[U"Y>>3:+*S<C<Y)QDL<9QDF@#[RHK\DO#B_$_P#:7^!/Q>_:6E^*
M7B;PIK&@7M[/H&@Z3>E+&"VM(DF:-D!YRK%.G)0E@VZOT-_9+^,5S\?/V=_!
M/CB_C6+4M2LL7JH,*;B-VBD90#P&="P'8,* /8**@GNX;5=TTT<2DX#2,%&?
M3)J8'/2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DI:* "BBB@ HHHH 2EHHH *2EHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHQN)/&)3]UN/3]XM+_Y!EI_UQ3_T$5^2W_!2JP,?BO4;G_A>W_"1!O$MJ/\
MA6OF@_V;\H^?;O/W>OW1]^OUITO_ )!MI_UQ3_T$4 6J*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %)2TE 'YK?\ !4K]I/X<>*O"$/PNTOQ%]J\=:1XGLI+W2?L5
MRGE*H8L?-:,1MPZ_=<]:_2#2_P#D&VG_ %Q3_P!!%? W_!5KX7^#=(^$.F^+
M+'PEH5EXIO/%-BMUKEOIL*7TX(<$/.%WL"%7JW\(]*^^=+_Y!MI_UQ3_ -!%
M %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME(]"":YG6/AEH^M?$KP_XXN#<?VWH=G=6-ILD B\NX*>9N7')_=K@YXYKL*
M/SVL_B!?_"G]GOXB_L_V5RT'C;2O$:^"/#&YRTDUGJ1\VTFS_P!,[=Y\\_\
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MWKZ \!?#_P .?"_PK8^'/"FCVNA:)9KM@L[--J+ZD]V8]2QR2>IH Z.BBB@
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M+_%#3[^]\*ZS;:U;:??2Z9=M;DY@NHL>9$X(!#+N7@CN#4OCSXA>'?AEH/\
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MZ"* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M?&7]IKQ7X
M^(VK:#IMKI<EG:&,1M<0R-(=T:L<D2 =6/;IBN+_ .&RO'/_ #Y:)_X#S?\
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MKY='TA]/@QY\JSJPQ%E@-^X*!N..>:]__:Q_Y-9^,G_8F:S_ .D,U?).I?\
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M%'@3X4^'O#SVGA#RK?7?$OB>XG6V^V.F_P"S6\4*[G*@C+,PQD^@W8?[,/\
MR>#^U+_V$-&_])7K \!_%#0/V3_CI\9](^)]V/"FC>+=>'B70O$%ZK_8[U9(
M426 2!2%DC:,?*3R"<#'4 ZS4/VOO$7P]^%OB&]\?> +G3_B!IFM1^';#1[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!>\?\ Z"*T*S_#_P#R M/_ .O>/_T$5H5^GQ^%']'T_@7H+1115F@4444
M%%%% !1110 4444 %%%% "#M7QW_ ,%"O^/7P9_OW/\ *.OL0=J^._\ @H5_
MQZ^#/]^Y_E'7IY9_O4?ZZ'HY?_O,3XQHHHK[T^T"BBB@ HHHH *_1S]BG_D@
M>D_]?-U_Z-:OSCK]'/V*?^2!Z3_U\W7_ *-:O"SC_=UZGC9K_!7J>[T445\8
M?)A1110!A>(/!>A>*I(9-8TFSU)H01&;J%9"@.,@9''05E_\*?\ !/\ T*ND
M_P#@)'_A78?6BLG3A)W<3GEAZ,WS2@F_0X__ (4_X)_Z%;2?_ -/\*/^%/\
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M@-@9&>N#4F/>EHH 3%%+10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!\M_M2?$;QQ^S3XUM?BIH7AFY\<>![NP72_$NCV)Q<VC1.
M[V]Y'P<@"21&!XY4GU'B=]_P62\&ZU##8^"OAQXI\2>)KK]W;::XCC#R$'"Y
M0NQ&<=%K]#6"N"I (/!!YK$TWP9X:T+4Y+VPT+2M/U"?[]S;6<<<LGKE@H)H
M XG]F?PCX@\(?"'3%\6JD?BO5;BZUO5H8_N0W5Y<27#Q+[)Y@3_@)->J444
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M*7$;L-\C*@PJD\L.E4[;XY?&."WBC/[-7B)BBA<_\)5HO88_Y^:^A:*W/,/
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M -!%?%W_  5M_P"3<- _[&NP_P#:E?:.E_\ (,M/^N*?^@B@"U1110 4444
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M9_/F9_[]6_Q/\PHHHKE/-"BBB@ I4_UB_4?SI*5/]8OU'\Z:W*A\2/T^\/\
M_("T[_KWC_\ 016A6?X?_P"0%I__ %[Q_P#H(K0K]/C\*/Z/I_ O06BBBK-
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M =135D5QE2"/4&L3QIXVT'X=^';G7_$NJVVBZ-:E1-?7;[8X]S!5R?<D#\:
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M\%;?^3<- _[&NP_]J5]HZ7_R#+3_ *XI_P"@BOB[_@K;_P FX:#_ -C78?\
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M[]#_ !K[?+ZU*.&BI25_^"?7X&K3C0BI-7/.-HHP*]'_ .&<_B7_ -"9JO\
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M>8Z1H$#-BW R0!T%<IRGJFE_#OQQ\5O@SXC\)_&E]!M]4U1Y8(YO ]S<B.&
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M)_'"^,/$?@W0?#$.M:O9^!=,O9)M9OG<Q!KA+3,D=NNW<%#8W-C)KT!?A/\
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MI7@G4]8U2T\)7'@)M1U+3-/NGMA?^3?A4B=T(=4+2 L$9=VP Y%3_"OP19?
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M>[T445\8?)A1110 E%+10 E%+10 E+110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (1FN;\*_#OP[X)U/Q#J&B:7'I]YX@O?[1
MU.9'=C<W!4*9&R3@[5 XP.*Z6B@ HHHH **** "BBB@ HHHH **** "BBB@
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M -AG_P!H25^>E?J?#_\ N*]6?.X[^,%%%%?2GG!1110 4444 ?HU_P $Z?\
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MZ!7"?'3*_!_Q@0>?[+N/_19KNZX7XZ_\D=\8_P#8+N/_ $6U14^"7H>GE_\
MOE'_ !1_,_(_SI/[[?\ ?1H\Z3^^W_?1IE%?E[D[[G]]1I4^5>ZA_G2?WV_[
MZ-'G2?WV_P"^C3**7,^Y7LJ?\J'^=)_?;_OHT>=)_?;_ +Z-,HHYGW#V5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:7K.IPW1,&G^;.D2K&R@B20;G)&<#"CN<?8] 'Q+_P %;?\ DW#0/^QKL/\
MVI7VCI?_ "#+3_KBG_H(KXN_X*V_\FX:!_V-=A_[4K[1TO\ Y!EI_P!<4_\
M010!:HHHH **** /D3_@I'_R3#PO_P!AG_VA)7YZ5^A?_!2/_DE_AC_L,_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,_\ #KM_^C@_BE_X-?\ Z]'_  Z[?_HX3XI?^#7_ .O7W/15G*?#'_#KM_\
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MO=G^=N^-V![ 5WM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKXO_ .%@Z5XDTR;4-!\4")8[J)D5B=ZG/&$?*L6P=N"1D5],?LX_"'Q%\%_
MMUH?B7Q]JGQ"OIM1N;Q=1U10&BCDD++&O)..<G)QEFVA1@4 9G[+/[,]G^RU
MX*U3PMI?B;5_$&D7&I37EE;ZE(&33XF;*P1#L,<L>C,6; R:]JI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gizttcucplmb000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M&8;^7[4C#(X(D!X(]#FOM']G?]N;2?B9?6WA_P 76\'A_7YB$@N8V_T2Z<G
M4;CF-CQ@$D'USQ7YN4!BC!E)4@Y!''3N/>O-Q>5X?%1UC9]T2XI]#]S^.U%?
M,G[#WQ\G^*W@6;P_K5RT_B3055&FD.6N;8\)(3W92"I_X"3R:^FNU?F6(H3P
MM65*>Z.5JS'4445SB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110!]!_L)^)9M"_:+T2S0GR-6M[FSE&>,")I5./\
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M_P!]468^:/<LT4U9%;HP/T-&ZD4.HHHH **** "BBB@ HHHH **** "BBB@
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M -":O2*^]JYU6IU'!16C.^Q^:/\ PH7XE^3Y/_"):QY6[=Y?E';GUQGK4?\
MPS[\1_\ H3=5_P"_/_UZ_3*BL?[<K?RH+'YLK\%?BLJA5\.:\ .  &'X=:B_
MX47\4/M!G_X1?6O/(P9-C;NF,9S7Z5T4O[:J?R(+'YF_\,^_$?.?^$/U7/7/
MDG_&K$?P.^*4=T+E/#&MI<K]V958.,=,-G/'UK]*J*/[;JO>""Q^:^H_!/XJ
M:Q-YU]X:UV]EZ>9<*SM],DTD'P/^*=K&(X?#.N11CD*BLHY]LU^E-%']M5+6
MY%8+'YJW'P-^*-W'LG\+ZW,F<[9%+#ZXSUYJ.;X!_$NY??-X2UB5\8+/$2>/
M?-?I=11_;=5;006/S1F^ OQ,N-GF^$]8EVC:N^,G:/0<]*)?@+\3)@@D\)ZQ
M($&U=T1.!Z#GI]*_2ZBC^W*O\B"Q^:+? 7XF-"L+>$]8,2G*QF(E1[@9Z\G\
MZ(O@)\2X5<1^$M8C#KM8+$0"/0\]/K7Z744?VY5_D06/S9C^"GQ5A0(GAO75
M11A54, !V &>E5[CX#?$V[DWS^$]8E?&-TD98_3.>E?I=11_;51:J""Q^:T'
MP.^*5K'Y</AC6XDZ[8U91SWQFH[CX$?$Z[(,_A769B.ADC+'^=?I;11_;52]
M^1!8_-&3X"_$R9463PGK$@C&U0T1(4>@YZ?2A?@)\2UA>(>$]8$3'+1B(A3C
MH2,]J_2ZBC^W*O\ (@L?F[9_!WXMZ=:O;6F@>(+:WDX>*$NBM]0#[^E4XO@+
M\3()O.C\)ZQ'+UWK&0W/7G.:_2ZBC^VJJV@M0L?FU_PI?XKY_P"1=U[_ ,>_
MQJ*'X&_%&WW^5X8UN+<<ML5AD^IYZU^E5%+^VJG_ #[0K'YI7'P'^)UVP:?P
MIK,Q'0R1EOZU#_PS[\1_^A.U7_OS_P#7K],Z*K^W*NW(AV/S<L_@W\6M/M9+
M6UT#Q!;6T@^>&$NJ-[%0W/4]1WJDOP!^)4<@D7PCJRR Y#"$@@^H.>M?IA12
M6=55=J"U"Q^;7_"E_BO_ -"[KW_C_P#C42? WXHQS/*GAC6TE?[SJK!F_'-?
MI512_MJI_P ^T%C\UYO@C\4[B,I)X9UR2-N"KJQ!^HS2I\%/BK&@1?#>NJBC
M 4!@ !T &>E?I/13_MJI_(@L?FE)\"/B=-,)I/"FL/*.DC1DMQTYS5F_^#?Q
M:U2&.*]T#Q!>11C"1W!=U7V +>P_*OTDHH_MJKH^1:!8_,[_ (9]^(W_ $)V
MJ_\ ?G_Z]'_#/OQ&_P"A.U7_ +\?_7K],:*K^W*W\J"Q^9W_  S[\1O^A.U7
M_OQ_]>C_ (9]^(W_ $)VJ_\ ?C_Z]?IC11_;E;^5!8_,[_AGWXC?]"=JO_?C
M_P"O1_PS[\1O^A.U7_OQ_P#7K],:*/[<K?RH+'YG?\,^_$;_ *$[5?\ OQ_]
M>C_AGWXC?]"=JO\ WX_^O7Z8T4?VY6_E06*G['4$EK^SGX/@F0QRQI<(Z,.0
MPN)01^8KVCUKRK]E_P#Y(OHO_7>]_P#2N:O5:^0Q3YJ\WYO\SBEN+1117,2%
M%%% !1110 4444 9GB?_ )%O5?\ KTE_] -?B%7[>^)_^1;U7_KTE_\ 0#7X
MA5]OPUM5^1O3"BBBOMC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /7_ -D3_DY#P-_U^/\ ^B9*_7#^&OR/
M_9$_Y.0\#?\ 7X__ *)DK]</X:_/.(O]YC_A_4YZFXM%%%?*F04444 %%%%
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M2_\ H!K\0J^WX:VJ_(WIA1117VQL%%%% !1110 4444 %%%% !1110 4444
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MI(,:G/+@JPVCGY33LWL@-&BBBA;@6/V7_P#DBVB_]=[W_P!+)J]6KRG]E_\
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M25KRXDC$A*H&PD85E_B)Y/-0W/[0$]QX5\*.T]GH6HZQ<W4$]]<6\DT$26Q
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ME_\ 0#7XA5]OPUM5^1O3"BBBOMC8**** "BBB@ HHHH **** "BBB@ HHHH
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MI6M13]I.UFP*>CZ39Z#I=MIVGP+;65LGEQ0KDA5'0=?YFKE%%0VWJP"BBB@
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M_P BWJO_ %Z2_P#H!K\0Z^WX:VJ_(WIA1117VQL%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'K_[(G_)R'@;
M_K\?_P!$R5^N'\-?D?\ LB?\G(>!O^OQ_P#T3)7ZX?PU^><1?[S'_#^ISU-Q
M:*S+77K.ZUB]TI)?]/LTCDEB/!V/G:P]B58?4&M.OE3(**** "BBB@ HHHH
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M,?O_ "R?X9 1^O\ ]>H<9+H9NG)=#4HID<J2J&1@Z^JD&GU!F%%%% !1110
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M_(WIA1117VQL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-9Q_>7Y6_P *Z&Q\066H;0DVR0_\LY.#]/\ ]5>>45E<Z3U6EKSS3_$5[IY
M\SSHNGER9(_ ]JZG2_$UIJ&%9OL\QXV.>#]#0!M44F12TP"BBB@ HHHH ***
M* "BBB@ HHHH ^6?V<_^2(>$?^O(?^A-7I%>;_LY_P#)$/"/_7D/_0FKTBO;
MQ/\ &GZL] ***RIO$5G%K46DJS3W[KYC10KN\I/[[G^$$^O6N5R2W,YU(T[<
MS-6BA>E%4:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11136X%C]E_\
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MOV]\3_\ (MZK_P!>DO\ Z :_$*OM^&MJOR-Z84445]L;!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z_^R)_
MR<AX&_Z_'_\ 1,E?KA_#7Y'_ +(G_)R'@;_K\?\ ]$R5^N'\-?GG$7^\Q_P_
MJ<]3<^'/VQ?^2P#_ +!T'_H3UYC\.?&UU\._&FF:[:EB;:3][&IQYL9X=#]0
M3U]J]._;%_Y+ /\ L'0?^A/7AM?*F1^HNAZU:>(M(L]3L)1/97<2S0R#NK#(
M_&M&OEK]CCXH&XM[GP5J$X\R+-QIV\\E>LD8]<'YOQ;TKZEH **** "BBB@
MHHHH **** "BBB@ HHHH **** $[9J.69(8R[L$11DLQP!5'6-<MM'CS(VZ4
MCY8U^\:X'5M<NM8ES*Q6(=(E^Z/_ *_UK6%-S]#2,'+4Z#6/&P&8K%<GH9F'
M'X"N3N+B6ZD,DTC2.>I8\TRBNV,(QV1TQBH[!1115EA1110!B7B[;F0>^?S&
M:BJYJ:[9D;U&/R-4ZT6QY\U9A1115$!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )M%7=/UBYTUAY3YC[QMRO\ GZ52K&U+7A'F.W^=^A?L/I4N
MW4&D]STJ#QE8-$!*_E7&.(>I;Z>WUK)U'7[G4,J#Y,7]U3R?J:\NDE>1M[L2
M_7)-;&F>(7AQ'<DO'T#]Q]?:N>4.J.:5&VL3IL4M,AD2:,.C!T/((YI]8F 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!+:J&N(P?[V?RY
MK=7I61ID>ZXW?W1_/BM>N>H];'917NA1116)N%%%% &OI?B:ZTXA&/GP_P!Q
MCR/H:[#3=7M]4CW0298?>1N&'X5YQ3X9I+>0/$Y1UY#*<&F!ZG17,Z+XL2XQ
M#>$1R=!)T5OKZ&NE!J@%HHHH **** "BBB@ HHHH ^6?V<_^2(>$?^O(?^A-
M7=:WK$&@:5<ZA<K*\%NAD<0H7; ZX4"N%_9S_P"2(>$?^O(?^A-7H[?3VKVL
M5?VL[;W9V24G!\F_0\TUWXP6VH:#I@\*D7^M:RQBLH'&#$0<,\@[!>O/\JZO
MP5X1B\):68C*UW?W#>;>7LA)>>4]6)]!V'M7.> _@WI_@GQ-J>M)+Y\MQ(XM
MHMN%MXV8$@?[7&,^E>B5YM&-1OGJ[GAY?0Q527UC'I<ZT26R7?U?Y: !BO-[
M3Q\]G\8O$FB:IJ]O::3;:;9SVL%PT<0$CM('(8@,<A5X)_"O2*\LLO"$>I?'
M/Q3>ZIHJW>GOI5C';W-Y:!XF<-+O5&9<;@",X/<5Z='EM+F[?Y'OB2_$26Z^
M*6MZ9::W')H5KX:_M#-HL4WE3B9E,@.,DA0/E)QTXKH+CXD:=H>D^'ED:^UN
M_P!4M5FMX;*T+W$ZA%9IFC7A%^89SQE@*XO5O!\FG_%+Q1-IFAM;:=/X/>W2
M2TM"L,DYF<[ 5&TN1CY1STJ'3[34/ OB#POXEGTG4=3MG\+6VDW-G8VYENK2
M1&#AC%G=M8L5.!P4YKK=.G*UNWZ!J6_%'QVL)+71-0T>[NH+*+Q!'IFIQR6+
M"8Y@=VB$;+NW;M@^49R,>M=UX3^(FF^+M0OM.AM[[3]3LE62:RU*U:"41OG:
MX!ZJ2#R#VKQK1[>^\4>*+B\_L.ZMUC\?0W$UN8@[0(M@F'DVY52"5)R>"PKT
MV#2[Q?CY>Z@;286#>&K> 77EL(C(+J9B@;&-P4@XSG!%*K2I1CRK>P:G0^+/
M'&F^#ELDO/M%Q=WTODVEE9PM-/.P!)"J!V .6) %9:_%K0O^$=U;5Y%O8$TB
M01ZC:R6KK<VO0[GCQG;M(;<,C&:YGXP^'KN3Q9X:\0JNM/I=E#<6MTWA]C]J
MA\PH5D" %G7*%2%&?F%9?AMKC0=,\6Z_8>&O$6JRWPAL[,:V[RSZ@0"JEX2F
MZ&)6<Y9S]T$X%3&C3=-/^M]@/38?'FD76O-I%K,UY<I9#4))+==\4<3?<+/G
M +#.%ZD FL#1?C?X=UP:9-!%J46G:E*L%KJ=Q9.EJ\K=(]Y&,D_+R,$@C/%<
MA\)?!NI?"-M5\-W]HUY%J=M_:$>K6ELYB201!9+:1OX0N!LR>5)'6L+0]1O/
M'7P=\*>#++0=5L]1DAL3)=R6K+:00QLCF99\;&RJ\*#G)QBJ]A3N[:I6U"[/
M6->^+&E:'J&H6:V.JZH^FJK7TFFV+SI;94, S#^+:0VT9(!J'4/C-X?M+JPM
M;9+_ %>ZO[%-1M8=-M'G::!B<. !P,#G..HK@M=N->U#Q%XGT[5HO%$<KW#K
MI=EX?@,%K<VY4;'DNE7AB0=VYQC&!4_P4\-:CI>O>')[[2[NT-KX.M[%I+BW
M= DJSDO&21][Y0<>F#1[&E&'-(5SNU^,'AMO!Z>(UGN#:/<?8EMQ;N;DW(8H
M8!%C=YFX'Y<5S^@_%.37/BUJ.FL]UIVCV.@?;+FQU"U$+PSB<@N21NP8]O1M
MM<EI?AO6M)2[UO\ L2^N4TKQSJ.IM8K"1+/:R>;&)HE.-^!('&WKMX[5HKJ6
MM>(_B9XC\0:)X>U"!/\ A$6MM/EU2Q>!+BY69V5"' ZD@;6P<#/3%6J--7L%
MSM-/^,^A7]YI43VVJ6-MJT@AL+^\L7BM[ER,JJL1U8=-P&>U8VG_ !F@TG5/
M%UKJJ:CJ TK4Y%>2QL6E2SM?+C*F0HO3)<]VP#VKSO5['5?%!\&W,4/C35+R
MPUFQGU :E9/;6UL ^'VPA%5L$_>4,% /(SFNRM/$E[X3N_'=A/X4UJ[EU/59
MI-/DM;%WBNM\,2 %\80 C[S87&<'@T_8TTM%O_F.[.[NO%,%SJT'V#5FECN-
M&FO[>&*)'AE4,FV828SD;A\H.#N-<W\./'EWJWAWPW>:GJ%U?ZC<^'CJ$]E;
MV:'SV#H#("H'SY;;L48.XUF>#_!.J^%6\,:==023O8^$;BRFGB1FB$QDA/EA
ML=>&P.^T]J3X.:#J>ES>"C>:==V@M_";6TWGP.GER^?$?+;(X; )VGGBL^2F
MHM?UU$:7PM^-$?BKPSX6EUFVN;+5-<:2.)_LK);R2*I<A&ST*@XYYVFN^L?$
MUCJ'B#4M&MW:2\TY(GN<+\J>8"54G^]M&<=@17A^@Z;J$/[.\%K)I=WIOB+P
M85NT&H0-"K36[&0F-B,.C(67</[U=A\,=471=*T[4[^SO'U+QMJ$M\\JQEE@
MW(3"CMGY0(40#KSFE5HP]Z4>[7Z_=89WOBWQ7I_@GP_<ZUJLC16%MM,KHI8C
M<P4''IR*Q]!^*.D:[K4&E>3?Z=>7,#75HNH6KP"ZB4C<T9(YP"#M//(XQ6/^
MT.S#X2:R4A%P^ZWVPL0 Y\^/"D^A/KZUG7%]>?$KQKX8DLM$U/2[316N)[V[
MU*U:WVR/"T2P(&'[PDL6++\OR#GFLZ=*,J?,_/\ (#<'QJ\.M,6"W_\ 98N?
ML1UG[&XLA-NV;3)CIN^7=C;GO5O6?BOHNB^)O[ :+4+S4E:(2QV5H\PA5\;9
M)& ^1,D?,??TKQ+3_"-S9>#X/!U]IOC:_P!9CQ:/IT=T\6F3('YE%QL,:QE1
MNY.[)QC->O\ AG1;BR\?>-[IM/?9<6FGQ0R3 A)]D<@*!\<@%N<#O6LZ-*&O
M]= U)])^,.B:Q>Z=%%;:G!:ZE(8K'4+BR=+:Y8 D!7(_B .-P&>U+)\1-/T%
M=3:[N[W5)?[6.GV]G!9[I?,\I'\F-5'S@ EMS'N>>*\M\+V>JZ/JFC6?A73_
M !1HEW]MC.I:#JL;SZ5;0ALRF.>1=N ,E3&W/'%;'B;P^TMIK[:GX<U>]LCX
MG>Z%UI3RQ7MJGV:)5N8%0;I!NRIVGN>N*;HTE)+_ (<5SIO%?QAAM/AWXIUK
M2K.\35='C99+&\M'62&39N1G3_GF>#N!Q@''>M>7XI6%CI^C&>RU274]2C9X
M=,BLF-T0N-[%/X5!(^9B!R*\ZAT_Q1XB^'?Q%T^/^U]4TBXTYH-'DUNU$-_-
M(8V#J1M5F7.W!=<G)IFOVT^I^)-#\9RVWB[3]'FT9=-ECTN"6*\M94E9@9(0
MI?8P8\A?X%H]C3^%_P!:+0>IZ7+\6_#MOX3E\0S3SPV,%RMG<1R6[B>WF9U7
MRWCQN# LO&.XZU+X9^)FE^)M6N-+%MJ.EZA%;_:Q;ZK:/;-)#D*95##E02 ?
M3(KS.R\)3S^$KRZM]%UI?[1\1Z?=?\3:9I[N>..>(&>2/:#$ JGY6[*"<5T_
MCOPM?^(OB7;QV\=Q!;7/A?4K$Z@D;;(9)7A" OC ;JP&?X34>RI7Y;]Q7-?2
M_C-H&K7MC'#%J*65_/\ 9;/5);-UM+B3) 5),?Q$'!(P<'%(WQH\/)<2$K?_
M -EQ7/V.36/L;_84ESM(,N/NAOEW8VY[USW@KQ5J5IH/AKPFGA/4!K%CY%K>
MM>6;I901Q;0\RSXV.2!E0IR21TYKSRQ\'7.F^#1X,O\ 3_&VIZPN;1K"&X>+
M3;E"Y_>?:-AC2,J=QR<@D\5<:%)MW_/IW'=GT]+,D,+RR.J1HI9G8X  &22?
M3%<)8_&C0KRZTQ6M=5M++4YEM['4KJQDBM;B1CA%5R/XS]W(&<C%=+J\=_9^
M$;V/2H8Y]3AL76TAF;<C3",A%8^A8#KZGI7SUK%GJ_BC3_"TH@\::GJ=CJVG
MSZA#>V;VUI;;9D,FR)457"D'&T,% )S6-"C&=^9@>P:Q\:-#T?4M5L!9ZO?S
MZ2VV^-AI\DR6ZE%?>S 8QM;L<\'BM#6OB=HVE6^CM#]JU:;6(O/L;;3(&GEF
MBVAC(%'1 &7YB>XK*\/Z1<V\WQ)9K*:,WM\SPEHV'GK]CA7*\?,-P*\9Y!K@
MO!NF:E\/SX&\3:CI&IW-F/"L.C7=O;6<DMQ93*RN"T0&_!R5.%X(&:M4J3^7
MXZ"N>B_"OQL_CEO%=T+B2>RM=8-K:I+#Y+PQBVMV:-EVAMPD>3.X9Y(KNJ\]
M^$/VRXF\:7]WI-WHRW^NM<007D1C=HC:6RA\>Y4]#P0PZ@UZ%7-745.T1H**
M**Q6XRQ^R_\ \D6T7_KO>_\ I9-4O[2__)%/$G^Y'_Z,6HOV7_\ DBVB_P#7
M>]_]+)JZ/XN>#KOQ]X!U/0;*6*"XO/+59)L[5Q(I)/![ UQXC^-+U9PRW9^=
M6AZ%J'B;5(--TNTEO;VX;;'#"N6)/?V ]3^E?9OP/_9AT_P+]GUGQ$L>I^(
M-R1?>@M2?0=&8?WCT/3UKO?A7\'=!^$^E^1IT7VC4)0/M&H3*/,D/H/[J_[(
M_6N^KG)$I:** "BBB@ HHHH S/$__(MZK_UZ2_\ H!K\0J_;WQ/_ ,BWJO\
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M/&KQL&1AD,.E25Y]H6O2:3)L8EK9C\R=Q[BN\M[B.YA66-@Z,,AA5@2T444
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MH1>I_P YK>AB$,811P!BLIRLC>E&[NQU%%%<QV!1110 4444 %%%% !1110
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MX4276Y50<?PGS\8_N#UKS+_@HM\1FUSXC:5X1MYLVFB6WGSQJ>/M$H##//9
MN,C^,U^@.M:M8>'=%U'7+QXX;6UM6N+BX_Z91J6))] ,_G7XQ>.O%MUX\\::
MWXAO69KG4KN2Y.XDD!F)"CGHHPOX#M491SXW$^WJ?8200U=V8=%%%?<FQZ_^
MR)_R<AX&_P"OQ_\ T3)7ZX?PU^1_[(G_ "<AX&_Z_'_]$R5^N'\-?GG$7^\Q
M_P /ZG/4W/AS]L7_ )+ /^P=!_Z$]>&U[E^V+_R6 ?\ 8.@_]">O#:^5,@HH
MHH 7.WD<'K7Z#?L^_$U?B9X M;B=\ZK8XM;T$Y)8#Y9/^! 9^N:_/BO3_P!G
MGXG'X:?$"VEN9FCT?4"MK>C/RJI/RR$?[!)/T+4 ?H-2TR-UD0,I!5AD$<@T
M^@ HHHH **** $JO?7D=C:R3RG"(,G_"K-<%XRU?[5="SC/[N$Y?W;T_"KA'
MF=BXQYG8Q=1OY-3O)+B4Y+' 7J /056HHKT4K*R.U*RL@HHHI@%%%% !1110
M 4444 %%%% !1110!5OK7SH\C[Z]/\*R>F:WZH7]F>94'^\!_.KB^C.>K"_O
M(SZ*2EJSD"BBB@ HHHH ***3- !GBO)/BE\?+7PCJ">'O#EH_B7Q?<'RX;&U
M!=8F/ WXY)S_  CG@YQ6)X]^*FO?$#Q:GP[^%L?V[69SMN]5B;]U:+G#D-C@
M+D9?MT&37T7^SW^S#X?^!NGB[8+K'BNX4F[UB=<MD\LD>?NKG\3W/8=<O9X2
M/M*VKZ1_5]D:**6K/(_AC^QOK'CS4K?Q;\9]1DU*[90\'AZ&0B. 'D+(R\#_
M '$X]6/2OKC1=#T_PYI=MINEV4&G6%N@2&VMHPD:*.P4=!5_%''XUXF(Q57$
MN\WIVZ(&[BT445R""BBB@ HHHH **** "BBB@ HHHH *3&:6B@#YX^-W[''A
MCXE32ZYX><^$/%ZOYZ:A8C9'+)G.9$'?_:7!SSSTKP[1_BYXL^#7B2/P?\7K
M%[=F;;:>((ES#,HP S-C##I\P&1GD5][?C7,?$+X;^'OBEX<GT/Q+IT6HV$G
MS*'&'B;! =&ZJPR>1ZGWKU*.-]WV6(7-'\5Z/] =I*TCRJTNX+ZUBN+:9)X)
M5#I+&P964C((/H14U?.VNZ#XN_8S\11P7CW/B?X77DN(;H M)9$M]UAC"MUX
MX5L\8/%>\Z'KUAXFTJVU+2[J.]L+A=T4\1RK#./S!!Z^AJJV']FE.#O%[/\
MKJ<52FX>AH4445R&(4444 %%%% !115[3K,MB5QQU4?UJ6^579<8N3+&GVOD
MQ[V^^WZ>U7*!17*W=W.^*458****D84444 %%%% !1110 4444 %%%% !7<^
M&=8.I6OE2M_I$0P<]6'8UPU6=/OGTV\CG3^$\CU'<?E30'IM%16\Z7,$<L9R
MCC(-2U0!1110!\L_LY_\D0\(_P#7D/\ T)J](KS?]G/_ )(AX1_Z\A_Z$U>D
M5[>)_C3]6>@%%%%<X!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 9=]9;<R1CCNO]15.N@K.O+#J\8]RO\
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M.K+C%R>@VQL?,Q)(/D[#U_\ K5K 8HZ45S2DY,[8Q44%%%%06%%%% !1110
M4444 %%%% !1110 4444 %%%% '6>#=2W+)9.>1\Z?U'Y_SKJJ\PL+MK&\BN
M$ZHV3]/_ *XKTR-Q+&CJ<JPR#5(!]%%%,#Y9_9S_ .2(>$?^O(?^A-7I%>;_
M +.?_)$/"/\ UY#_ -":O2*]O$_QI^K/0"BBBN< HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX5HO0;8M%%%<0@HHHH ***0T 'XT&O OC;^V1X(^#MQ<Z8CR>(_$4(P=.L&
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M_P! C4/_  =WO_QZC_ACWX6_] C4/_!W>_\ QZCVF'_F?W+_ ##VJ+E%4_\
MACWX6_\ 0(U#_P '=[_\>H_X8]^%O_0(U#_P=WO_ ,>H]IA_YG]R_P P]JBY
M15/_ (8]^%O_ $"-0_\ !W>__'J/^&/?A;_T"-0_\'=[_P#'J/:8?^9_<O\
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MA\1K_P"#%C+X+GL8]5EDTWQ(KWB6;*',JPM$ Q"?-MW#(%=;\6/VJO\ A'/
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M#H!3JT2LK&B5DD%%%%, HHHH **** .!^/6H-IGP<\7SH<-_9\B#/3YAM_\
M9J[7]CS2TTG]G#P5$B[?,MGN#[F25W)_\>KS?]IQC'\"O%A4X/D1C\YHQC\C
M7LO[-D:Q_ 7P($4(O]DP'"CC[N:VQ&F"2_O?H85=CTRBBBO$.8**** "BBB@
M!&K\>?VD5*_'SQ^",'^V;D\^[D@_E7[#U^<'[?GP7O/"WC\^.K2/S-%UPJEP
MRC_472J!AO9U4$'U#>V?I<@JQIXEQD[71I#<]E_X)Q^+;*^^%NM>'Q*%U+3]
M2:X:+N8I43:W_?2./P'K7UQU-?C+\)OBOKWP9\86_B+P_,J7" QS02@F*XB)
M!:-QGID#H>" :^[/!W_!13P#J]BG_"0:=J7AZ\Q\ZI&+J+/LRX8_BHK7-<KK
M^WE6I1O%CE%W/J_ZTT@-QC.*^1_'W_!1;P;I>FSKX3TR_P!<U(J1"]W%]GMU
M;'!;)WD ]@!Z9'6O;?@'\<M(^._@>+6M/'V:]A/DW]@QRUO+CIGNI'(;N/<$
M#PJN!Q%&G[6I"R(Y6C7^)'Q:\-?"O3?M6N7ZQ3.,PV<7SSS?[J=<>YX'<UYC
M\'?VJK3XF>.[W1;ZR71XIP#I>Y]S2$9W*[=-QZ@ 8X(R>,Z/[4'P2;XH>&TU
M32HB_B'2T8PQK_R\1=6C^O<>^1WKX*5I["[#*9+:Y@?((RKHRG]",?I7=A,+
M1Q%)N_O?D?FF>9UC\KQT-/W7Y]]3]9E/Y4[WKY$^%_[:T=M8Q6/C6QEDFC 5
M=2L5!W@#'SH3U]U_(5Z!J_[:'P^L;0O9R:AJ4^.(H[1D.?J^*X98*M&7+RGT
MU'B#+:U)5?:I>3T?W';?M >)K3PK\(?$US=/@SV4EG$G=Y)5**,?5LGV!-?F
MMGBO3/C1\=M:^,FHQBZC73](MG+6NGQDL%R,;G;^)L#\,G'4DU_@3\+KOXJ>
M/[.PC3&G6K+<7\Q'"1!L[?JQ&T?4GM7O86E]4HN531GY?G6._M[,(4L*KI:+
MS[OT/O?X.Z9-H_PJ\)65PI2XATNW613U#>6N1^!S79>E)&@C55'0#%.KY:4N
M:3EW/VVC3]C2C371)"T445)L%%%% !39%#(P/((YIU(>E 'PW^R6PTGQ9\6?
M#G0:;KC%<X[R31G\O*'YBOH^OFS]G=BO[1'QTC'"?VU.=HQCB[N/Z$_G7TG7
MI9EKB.;NE^2+EN%?-W_!03Q(^D_LWZGHMM<+;W_BJ_L] MW92P_?3*9./3RT
MDY)[U](UQ?Q2^#?@[XU:/:Z5XTT5-<T^UG^TPP232Q!9 I4-^[=<D GKZUY1
M!YI^T/\ $SP?\(?V=]7T*VOK6:YGT=M"T71;%UEN+F1X3!%''$IR<9'0< &O
MFC3_ (3ZI=>/?V>OA+?^)[CP?JG@SPC<^)-1OK+RO.M9II/+2-&D!3<')7D'
M@'U!'V)\/OV7?A3\*]434_#'@?2]/U.,DQWTBM<3Q9 !V22LS)D#^$CJ?6H?
MB-^RK\*_BWXH?Q%XM\)Q:QK+PI;FZDN[B,^6F=J@)(%P,^G<U5P.27X6^*?#
MNDZ[J&D_&?Q+XTU>+2;T6.CZA-9F"6X-NZQ,PAB5OE<J>#V'TKE/V4[Q[[]B
MGPCI_@3Q1HWA?Q!;6Y6YN[ZW6Y6UG%P[7 EAWI\['=RQ'W@:]?\ AG^S#\,?
M@YX@EUSP=X5AT;59+=K1KE;J>4^4S*S*!)(P&2B\@9XQ61XL_8U^#?C;Q)<Z
M]JW@:QEU.Z?S;B2"6:!9W))+.D;A68G.21SWJ0/.OV??C[XIU#P/\:?$_C;7
M-,\0Z5X+N[FWM=5TNQ6W2Z2V@:21PJLV0<KC#'K7"_LI? W5IO@5X;U@?&WQ
M%X4NM>236+G3=,>R2%))W+YQ)$S9*[,Y;KG@=*^N6^$O@[_A7]UX'B\.V-GX
M3NH&MIM*L8_LT+QL,,I\L@\CJ0<FO+E_8)^ RJ /A];@#@8U"\_^/55P.*_:
MQT.[M_@+X&^''_"1W_BJ^\6^*M.T9M5OO+DN+F-[@S.[>6H7:BH.0H "BO(?
MVN-6O?V<];^)GA+1[00>'_B[ID/]FJB$QPZCYD5M>* O>2"0ODX!;;C/-?;T
M7P;\'0P>#H4T2)8O!_.AIYLF+,^7Y>0-WS'9D OGUZ\U:\=?"WPK\3/[&/B?
M1H-7;1KZ/4K!I693!<(<K("I'3T/!P.M(#Y \5>"W\8?M<>#/ ^G^,+SP1:?
M#OP+&(;_ $P0K+#-*5A9%,JLN&B"#IV[5[_X/\'W?PTDU7Q'J7Q?\0^.+.QT
M^:9].U.6T:%0HW>9B&-6R I'7N>,U=\??LE_";XH^*KOQ+XH\'PZKK=TJ+-=
MO>7*%E10JC"2*N  .@J3P9^RG\*OAY'K*^'O"4.FC6+)].OMMW<.9K=OO1Y:
M0XSZK@T@/D_X%>!OC(?V4=0^('@?XA2:;JVN7-_XC?1/[%MW^U.TK[RDKAF$
MCJ@P2K#H,=Z]Q_9HN/AYX+^!NK_&2TU;4]1/B"V.KZ_KFO3++>-)$K!H6V*%
M&QMRA44#D>U?0?A;PMI?@KPWIN@:+9I8:/IMNEK:VJ%F6.-!A5!)). .YKCO
M^&=_AW_P@M_X,'AJ$>%;^^.I7.DB>8023EUD)*[_ +I=5;8/DX'%,#XL@M?B
M9X\^&GQA\<ZS\'-8U>Z^(FFR-9:DNK6*+8:2D6ZVB6!IO-)&-[ *"QQA<]>E
MU[Q0_P 6_AS^Q]X4WS7/]L:A9ZG?*9?FDCT^ A]_/S MEN_W?6ON]K.&2U-L
M8U^SE/+,> %VD8VX^GZ5P7AW]G[X?^$[[PI>:5X<AM+GPK;SVNBR>=-(;..;
M=YJJ&<YW;FY8$\\4[@<)^W=XJ;PE^RGX]EC8BXOK1=,B55)+&XD6(J .Y5FK
MR[XVZ'9_L^ZA^S#XJO[R+3M(\*W'_".:G<21[46.>SP78Y^4 P/U_O=:^KO&
MWP_T#XC:?9V'B/3EU.SL[V'4(87D=56>)MT;G:PSM/.#QTJK\2OA;X6^+_AE
MO#_C#2(M:T=IDG-K*[H/,0DJV48-GD]#WYJ0/'?V5- U'QI?>)/C;XHM&M]9
M\8,(]'MIP-^GZ+&3]GC _A,F/,;!YRM>,_L]^#K_ .,7BSXN_$*W^*^M>!VU
MCQ7<6B0Z2;5!<6]N!' 6\Z-C\JM@8QWK[KM[&"SLH[2")(;6*,1)$@PJJ!@*
M!Z #M7A4G[!WP(FEDE?P!;M)(Q=F^WW@RQ.23^^ZDDT >B_"GPG=>$=$N;>[
M\<ZKX]DEG\P7VK/ SQC:!Y:^2BKM!!/()Y-=O7*?#7X5^%OA#X=.A>$-)31M
M*,S7!MXY9)!YC !FW.Q;D =^U=70!T_VQO>BJU% '<45\7W'_!2[PVL\@A\%
MZI)"&(1WNHU9ESP2N#@D=@3BF_\ #S'P_P#]"1J7_@9'_A7L?V3C?^?;_ OD
MD?:5%?%O_#S#P_\ ]"3J7_@9'_\ $T?\/,/#_P#T).I?^!D?_P 33_LG&_\
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M_P"'F'A__H2=2_\  R/_ .)H_LG&_P#/M_@')(^TJ*^+?^'F'A__ *$G4O\
MP,C_ /B:/^'F'A__ *$G4O\ P,C_ /B:/[)QO_/M_@')(^TJ*^+?^'F'A_\
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MX@=S],==_P /,/#_ /T).I?^!D?_ ,31_9.-_P"??Y!R2/M*BOBW_AYAX?\
M^A)U+_P,C_\ B:/^'F'A_P#Z$G4O_ R/_P")H_LG&_\ /M_@')(^TJ*^+?\
MAYAX?_Z$G4O_  ,C_P#B:/\ AYAX?_Z$G4O_  ,C_P#B:/[)QO\ S[?X!R2/
MM*BOBW_AYAX?_P"A)U+_ ,#(_P#XFC_AYAX?_P"A)U+_ ,#(_P#XFC^R<;_S
M[?X!R2/M*BOBW_AYAX?_ .A)U+_P,C_^)H_X>8>'_P#H2=2_\#(__B:/[)QO
M_/M_@')(^TJ*^+?^'F'A_P#Z$G4O_ R/_P")H_X>8>'_ /H2=2_\#(__ (FC
M^R<;_P ^W^ <DC[2HKXM_P"'F'A__H2=2_\  R/_ .)H_P"'F'A__H2=2_\
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M/A_H_BRQM9K*WU&-G6WG(+H5=D(.#@\J?TZ5V%>5*+A)QENB!:***0!1110
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M*ZAHZ2M!J.HV^J V^FLJY(F<CMD#"Y.6'8USOBK]G'Q+X7\>>%?#)O-,O_\
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MZ\<TFE9Q/A:G!.&E.\*K2]+GPAX%_8W\:>)DM[G5WM_#ME(062X;?<A?78O
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M1PK"XA9UW /D8R,J"!T+5[[J'AVV^)R_#7XN^*E!\/Z/H-S?ZLW7SY(+IS%
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MQ<0_?BLH@L)"G^$-\Q./7VX\C_9M^%WA+QQ>6DNF^/=>\/\ C:SL[B^G^Q6
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MK(Y R5#*2,@=LTU7HMJ*DKCNCC=M&!7OWP=_91\7Z]XP\*S^*?"6I0^$-0G
MN)@=C+&48JQ .Y 3CD@=17C?C;2[?0_&6OZ=:*RVMGJ%Q;PJS$D(DC*H)]<
M5-/$TJM1TZ;NT*ZZ':?#GXZ7/PO\':QIFB:!IL6OZ@LD/_"2.&-W! ZJ&C3L
M/N\'WZ=*\QI:*TA2A"4I16K'Z!1116P'K_[(G_)R'@;_ *_'_P#1,E?KA_#7
MY'_LB?\ )R'@;_K\?_T3)7ZX?PU^><1?[S'_  _J<]3<^'/VQ?\ DL _[!T'
M_H3UX;7N7[8O_)8!_P!@Z#_T)Z\-KY4R"BBB@ HHHH *Z;X;^![SXC>,M.T*
MT&#<29FD[1Q#EW/X _CBN9K[3_9%^%__  C'A-_$U]!LU+5U'D;QREL#E2/]
M_P"]] M 'NFB:3:Z!I-GIMC$L%I:1+#%&H^ZJC _E5^BB@ KC?']OS:3CW0G
M]?\ &NRK#\76?VO192!EXB)!^'7]":TINTDRX.TCSNBBBO1.T**** "O-OC]
M\&T^/'P\E\(SZQ-HMI/=V]S/-!"LK2)$X?R\$CAB!S[5Z310]=!>3,S6/#VG
MZ_X=O="O[9;G2KVUDLKBW;[KPNA1D/L5)'XU\X6_[&_B6U\/KX+C^-?B:/X;
M+&;4:"MK;BY^RXQY'VH#=MQQPOW>,5]144G%/<&D]SRKXH? #2/B#\';3X;6
M%Q_PCOAZWDL@L5O )!Y%O*DBQ;2PX)C7DGUX-9'B+]EO0O%7[1FB_%C4;V2X
METG3X[6#1C$/),\;2&.X9MW+()#A=O! .>*]LHHY4Q63/%[+]E[PY=>"/B)X
M9\23R>(K3QOK5SK-],\8B>)Y"GEK&03CRO+3:WM^%<>/V1?$VO6,?A[QA\:/
M%'BCP+'A6T-H8;:6ZC4\17%RG[R1"!@]"?45],44N5=@Y4>5_%_X Z1\5/A;
M9?#^&9= \.6]S9N]K:VX9)+>!PXMP-PV@E5Y!R,>M;7QJ^$FF?&WX6ZYX*U.
M3[-:ZG $2X2,.;>16#)(JYZJR@XSSBNZHIV78=D>">-OV8M0\277A'Q#I'Q"
MU7PU\0/#VEC2#XBM;6.47\'&X3P/D'YEW#YNI/7C&G\+_P!G67PIXZ/CKQCX
MOU#X@^-5M#86NI7T$=M%9VY;<R10QC:&8]6))/;&3GVBBERJ]Q<JO<****HH
M**** "BBB@!K5XE^RIJD?P[_ &DOB3X"G(@BU0_VE8H<@,0=^U?4[)2?^ -Z
M5ZSK'B*ST=2)7WS=HDY;\?0?6OF?XU>*KOP?\4/!OQ1M;3 TFX6WND@^\\))
M."<]2K2+SZBO0PU*56$Z3^TOQW1R5*U/F5.^I^AU%4-&U:UU[2;/4K&9;BSN
MX5GAE7HR, 5(^H(J_7S;33LS(****0#6'%?*'PQ\ K^T%H_B7QAXH\6:_8Z\
MFK7=I:_V;J<EJFBI$Y"HD8(7.W&XN#GCOS7UA7BOCS]DKP+X_P#$]WKET-4T
MZ74"&U&TTJ]:WM[]@>LR <GW!!-=N&JQIJ2D[7ZVO\OF4F:'Q<\3ZG\.OV<]
M:U?0M2FUS4=/TE?L^JR%)7FR%3[02HVL0"9,@8XKYI^'.F_%2"Y\#^(]'\,:
MY%=W5S;RZGKU[XICNX-7MY!E]UNS[0-I+)L&5 [FOMC3_"FD:7X;C\/6FFV\
M.B1P?95L%C'E>41@IM/!!!.<]<G->7^'?V3_  -X9\56FLVQU>6WL;@W=AHM
MQJ#R:?93$YWQ1'H02<9) S],=.'Q5*E3E&2U?EOY;K]1IHK?M=<_#C0S_P!3
M+I?_ *4+6E^UI?7NE_L[^,[O3[B>TNX;:-TGMI#'(F)H\D,,$<9Z=J[?Q]\/
M]+^)&CVVFZP)OLUO>07R?9Y-C>9$X=,G'3(Y%;&LZ/9>(=)N]+U*VCO;"[B:
M&>WE7*2(005-<D*T8JG?[+O^7^1-SQO]HKQ#+;Z7\*Y-.U&2 7WC#2U+6TY7
MSX660LI(/S*>.#P>*3]M?/\ PS?XG_W[7_THCJ'0?V+_  %X?UK3M2CN==NI
M=+NXKO3X[O4FECL_+?>(XU(^X2!D').T<UZE\2/A[I7Q2\'WOAK6_/\ [.O"
MAD^SR;'^5PPP<>JBM_:4:=2FX.Z3N]/,JZZ'*?M,^,]7\ ?!#Q1K>AR-!J<$
M"I%<*,F'>ZH9!QU4,3R*\,^-'PEL/AG\*]'\3Z#XP\22:M-?6"W-ZVMS/'J?
MF2KN9T+%>02PVXX'<5]=ZMI%EKNEW.G:A;1WEC=1M#/;S*&21",%2#V(KP:'
M]A_X=Q7"L]SK]Q;P2K+9VD^IL\-D0P;$2D<=,?-G@GZU6%Q%.DDI.VM]M_($
MT=5^U7J%WI?[/?C*[LKJ:RNXK5#'/;R,CH?-09# Y!P3T]:V?@Q\.;+P'X5A
MDBU#4]5O]3BAN+V^U2]DN)9I-G4;B0H&>B@#IUKH/'W@?3?B1X/U+PWJ_G?V
M;J$8CF^SOL? 8,,'''*CM6U86::=8P6L.?*AC6--QR=H  _05R>VM1]FN_\
MD3T/'_@7J5Y??$;XR0W%W<7$-MX@CC@CEE9EB7[-&=J GY1DYP*\Q\0_!?0-
M4_:^_LR>[UI+>^\-2:I*T6LW,<@E:[<%4</E8_2-2%'I7T?X4^'^E^#]:\2:
MII_G?:M?O!?7GFR;E\P(J#:,<#"CBN>^+'P'\._%ZXTR[U*?4M*U33MRV^I:
M-=?9[D(WWHRV#E3UP1ZXZG/33Q"A5<DVDU;\"KZDWQI\ 7OCKX6ZGHNC:C=Z
M7K$42S:=>6UPT<BS1X* L#DAL;3GLQ->*_"SXH:G^T1\1O \9GNK"#PKI9U'
MQ#!;L\*R:FS&%;=UR/E4HTFWD<@'O7TMKVL6WA/PW>ZG>,YM-/MGGE8#<Y5%
MR< #DG'YUY1^RMX9FM?!.I^,-2LELM<\::C-KEU"%VF%)&)BBYYP%YYYR['O
M4TJBC0FY+T^>_P" +9GMU%%%>>0%%%% #>]>!?MP>-#X/^ &LP0R^7>:U)'I
M<6WJ0YS(,>\:N/QKWWBOA?\ :<\3Q_%C]I;PYX.AD%WHGA4?:[^)6RCS$J[H
MWKP(T]MS#BO2RZE[2NI/:.K^0<R@G*6R/7_@OX03P+\+?#6C!=DL-FLDPY_U
MTG[R3_Q]F_(5VM8^B^);/6 $1O*GQ_J7X/'IZBMC(KAKN4JDI26K(C4C47-%
MA1116!84444 5=4L!JFF7=F9I;87$+P^= 0)(]RD;E)!&X9[@C@5\V^%?V"?
M#/A+0K?P_:_$CXE2>&85=!H7]O1P6C*[,S*1# C8+,S':PR37TY10!Y7XH_9
MI\%>(?@C<_"FRMI_#'A*=50Q:*R1R@+(LA.Z17R691EF!)R:I_$S]F+PQ\1;
MS0-3@U+6O"'B'0;7[#I^N>&[L6US';D &$Y5D9" ."O'.,5[!10!Y/\ #']G
M'0?AQKEWXAFUC7O%OBVZM39-X@\1WHN;J.W)W>5'A51$R ?E7GOFO.O#?[!N
MC>#;.:RT#XL_%'1+*6>2Y:UT_6K:&(R.<LVT6O4G^E?3M% 'C&K?LNZ3XD^%
ML?@+7_&7C'Q#HYU&/4+JXU/48I;J]5'5Q;2OY/,!*CY5"GCK7I_B'PK8>)/"
M>H^'+A&ATR^LI+"1;?"E8G0H0O& 0I[CL*V** / -2_8R\*2Z7X232/$?BGP
MUKOAG2X]%M/$>CW\<-_-9H/EAG/E>7(H_P!P8P,5V/PG_9^T#X4ZM?ZXNI:U
MXH\4ZA"MO=>(/$5X;F[DA4Y6($!51 ?X54>^:].HH ^:-*_85TCP_<ZM+HOQ
M7^)^AIJE_-J=U!INLVT,4EQ*07D*BU^\<#D]E%=O#^S%X>O?A;K'@/Q1K_B;
MQYI6IW(NGN_$FHB:[@8!-@BDC1-@5D## ZLW7I7L%% '@6A?L>Z+;ZGIMQXG
M\<^-_B!8Z;-'=6>D^)M52:T29#F.1DCC3S&7'&\D>U>^T44 %%%% !6CX?MO
MM6L6R=E;>?\ @//\Q6=72^";4O=3W!'"+M'U//\ +^=- =C1115 ?A91117[
M2SK.RM/BKK%E\*K[X?PQ6B:+>Z@NHS3>6WVAG4*%7=NV[1M!QMZ]ZX^.0Q2(
MX )5@0#TX.<&O1_AK^SOXZ^+>CRZKX9TJ.]LHIS;,[W,<1WA0Q&&8=F'05?\
M<_LM_$7X<^&[S7=>TB&STVTV^;(+R%R-S!0 H;/)(Z"N%5L-3FX*2NWKZDW6
MQR_Q6^*6L?&'Q8?$&MQ6D%W]GCM5AL49(41!A0 S,1W[]S6QXA^/_BSQ%/X,
MO&EMK#6/"ELMI8:M9(Z7+H H'FL6(<@ ]% ^=L@Y-=#HO['?Q4U[1K'5+30(
MFL[Z".Y@:2]A0LCJ&4E2V0<$=1D5YY\0OAGXF^%>M)I7BC2I=*O)(_-C5RK+
M(F2 RLI(/(/0]JSA]4J-4XM-K9#TZ'K%]^V=XNF2>ZLM \+Z/XDN$9)?$5CI
M@6];<,,VXL0&([X/>O-_!/Q?U_P)>>)KRS:WO+[Q#936-Y=7RO)+ME.7=6##
MY\]VS3/A]\'?%OQ2L]8NO#>E-?VVDQ"6\E+JBQJ0Q !)Y8A6X'I57X<_##Q)
M\5]9N-*\,:>=1O8+=KJ2/>J8C4@$Y)QG+#@4*EA*:E%6TW_X(:&W>_';Q-?_
M  HTGX=R?9!X;TZY^TA$C<27!WLX25M^"NYCP .0*VX_VHO%T7Q8OOB&+32?
M[>NK'^SUC,$GD6\>U5#1KYF5;"]V(^9N.:X#P3X!UWXB>++;PUH5D;K6+@R!
M+=F"?<1G;))P,!3U-=9\//V<?'WQ2T^?4/#^CK/IL4I@^VSW$<,,CJ>0C,WS
MX_V:52GA(7Y[*_Z_YV%[I-\,/VB/$'PS\.W/AW^SM(\2>&YYOM!TO7+7SXHY
M>A=/F!4G ]NO3--\<_M#>(O'5_H)GL=)TW1M#NEN[+0=.M?)L1(&W;F0-N8M
MR#ENA.,9S7*?$+X;>)?A9KG]D^)M+ETN\*>:@<ADD0D@.C [6&0>A[&CQU\.
M=?\ AO=Z;:^(+065QJ%E'J$$7F*S&%RP4D \$E6X/I35'"RFII*['H=C#^TG
MXKM_BGXA^("0Z;_PD&M6;V4I,+F.!61$WQ#?D,%C7!8D<GBL+X._&3Q#\#_%
M3Z]X=-L]S);M:RPWB,\,D9(/S*K*<@J",'^M<-7J+?LR_$2/4/#-E)H7E7/B
M.&2?3HY)XU,B(BNQ;YOE(#KPWKBKG3PU-<D[)-6^2_R%HMRA\.OCIXH^&?B3
M5=6TR2VN8]7+?VCIM]$9K2[#$DATSV+'!!SR?4UUGB#]K/Q/?Z%?Z3H&A^'?
M!5M?Q-#>2:!IPBFGC((*ER3@$$] #UYJP?V)?BZJACX>@ /0_;X,<?\  Z\Y
MTGX1^)]<U#Q39V=BDLGAB":XU5O.0) D3$.=V<'!4]#S@FN>V!JRY]'86C.3
MM9C:74,ZJKF)U<*X)4X(.",]./6OH+5OVUO$VNW0NM1\%>!;^["J@N+G1WE?
M:OW1N:7.!7%?#[]F?XB_$S0UUC1=")TN1BL5W=S1VZ2X.#LWD%AD'D#'!KC_
M !Y\/O$/PR\02:+XETR72]050XCEP0Z$D!U8$AEX/(/4$5M-87%3Y9--HK2Y
MW=O^U'XXC^(%SXSN)+"^UU[)]/M)+BW.S3XFR/\ 1T5@$8 GD@]3G/->=>&_
M%%_X7\6:=XBM7674;&Z2\C:X!8-(K!@6P<D$^_<UJ^(/A7XG\+^"]#\5ZEIK
M6^A:UD65UO4[\9/(!R,@$C(YQ574/A[KNE^!]-\77-J(M"U*XDMK6X,BYD=,
M[@%SNQP>2*J$</%6@EKI]W06AZ9I/[6_BRRO]?:_TG0-=TG6[UM1N-&U*R:6
MUBN"!N>(%\J20.K'G)P.:Y7XI_'+7_BM9V.FW5MINBZ!8,TEKHVC6WD6T<C<
M&0KDDN03R3@9/')SF^!OA!XL^(VC:YJN@:6UYI^BP^=>SEU18U"EB!D\G"DX
M'/YU1\$?#O7OB&^K+H=HMR-*LI-1NV>146*!" S$L<9&>GL:SC1PE.3DDDX_
M@.R.MU[]H[QEK7Q,T?QU%-::3K6DVL=G:+80LL"0IN_=E'9LJ0[ Y/\ %73Z
MW^V)XKOM/OX](T/PWX5U/44:.\U?1=/,-W*K'+8<L2NX\YZYP<@BO!A72_#W
MX=Z_\4O$D>@^&[+[?J<D;RB(NL8VJ,L2Q./3KW(JIX7#12E**2061S>26W$Y
M.<G//YUVGQ.^+&L_%:\TJ758K.SMM*LDL+*QT^-HX((E' 569CD\9.>PKMM6
M_8W^+6DZ?/>/X8-S'"I=H[2ZAFDV@9.$5MQ/L!7.?#?]GGQU\6M)NM3\-:2M
MY96LWV>622XCAP^ 2,,PZ CIZU7M\-*U3F3Y>M]KA==S6\!?M.^*OAWH/AW2
MM.L='N(M FN9K&:\MY&E0SAA("1(!CYB>G85R_PO^+FO_"3QVOBS1&MY-2"R
M*\=VC-#*L@(8,H8'J0W!Z@5N>/OV9_B#\,_#[ZUK^DPVE@LJ0[X[N*5B[G"J
M%5B22?05L0?L<_%JXT=-07PS@-'YJVC742W&W&1^[W9R1V(S[5CS8*TFVK2\
M]_ZN+0S_  !^TIXE^'OB#QEK%KIFB:I<^+)&DU%-4M7FC.YY&=%42#Y6,AR&
MSP *L>+OVIO&/B;P]=:'8VNB>$=+O!B[@\-V M#<#&,.VXMC'H>G'2N,\ ?"
M?Q3\3/$USX?T#36N=5MHWDFMY76(QJC!6W%B,') P:[_ %#]C7XJZ78W%Y<Z
M';Q6]O&TLC_VA <* 23]_L*4XX*-1.=N;^K!H>)45/I^GW.K:A;6-G"UQ>7$
MJPPPQC+.[$!5 ]22*Z7XF?"WQ+\(=>@T;Q18BPU":W6[2-95D!C9F4'*G'5&
M_*O1=2"DH7U97D<G17MFF_L:_%?5=-L[Z'P_$(+J%)XO,O84;:R@KE2V0<$=
M17&ZA\"_'FF^/+?P;/X9O1XBN%$D5FJAO,C.?WBL#MV#!^;.!@UBL50D])K[
MR;HX6BO5O'?[+?Q)^'7A^76]8T'_ (ED',\UK<1S^1GNX1B0,]R,"N-T_P"'
M>O:EX%U+QA#:*?#^G7"6MQ=-(JXD;&U0N<D_,.@[U<<12FN:,E8=T<W172^&
M_ASKWBKPQXB\0:=:+)I.@)')?W#R*@C#DA  3\Q)7H/;/6N:K13C)M)WL,**
M**L HHHH **** /UG_8Q_P"3:?!?_7&?_P!*):]K]:\4_8Q_Y-I\%_\ 7&?_
M -*):]K]:_(L9_O-3U?YG++<6BBBN004444 %%%% !1110!F>)_^1;U7_KTE
M_P#0#7XA5^WOB?\ Y%O5?^O27_T U^(5?;\-;5?D;TPHHHK[8V"BBB@#Z8_9
M0U2/X9_#?XK_ !(GLX;MK"Q@TNTAN 6BFDF?#(P!'RY\K/L3S7+:M^UEXADT
M*^TSPWX<\->"?MT1@N;S0K#RKAXSU0.6.T8ST&>>"*\9CU2]BT^6P2\N$L)6
M$DEJLK")V'1BN<$C ZCL*K5YGU"G.I.K4U;_ $)Y5>[/N'QIX/NO&W[;"VUI
MKU]H$]MX?AN_M.F%1=R!8 &BB+<;F#8Y[9XJ&/PV=*_9E^,*Q^!/$'A&":.W
MD67Q)>R375^RS M*8F550@;265<'=U.T8^-&\1:J^J1ZFVIWC:C'C9>-<.9E
MP,##YSP/0U9U#QIX@U66XDO-=U*[DN(_)F::[D8R)_<;+<K[5P2RVH^1<^B2
M_!^OY["Y3Z\^,'@?X@>._C)X%\0_"X74?A9],LQHFJ6H)L]/0 Y$@Y"X[@CD
M8&#C%6&M1XB_9\GTN31;SXF:Y9>*KO\ X2&/PI?&!IK@LY6X(2(M*A7:!\@&
M1[5\<Z?XRU_2M+ETVRUO4;33Y1A[6"ZD2)L]?E!QS]*AT/Q)JWAFY:XTC5+S
M2YV&UI+.=XF(]"5/3ZT?V94Y8P<E[NVGYN]PY3[PL/$6LZ/XMU$7.BCPSK6B
M_"S47MM^IB^O%020-#YQV+M=2&X(/4\UX+X'U.\U']C?XK)=W4URL>L:?(@F
M<OM9I4+'D]20,UX0WB+56O+N\.IWAN[Q&BN9_/??,C8W*[9RRG X)["J\.I7
MD-C/91W<\=G.RM+;K*PCD*G(++G!(/J*TI99[.^NMXO[G<%$^Q]-\!^(/B7\
M+_V<ETC4+W3K*&:\2\UJT.X63BY'ED\\-N0JN>XKM/ ?@V72M<^+"_\ "%^*
MK8R:)J%O/XH\3W[,VJ2;> D.Q8V#88AEW8"@9&XU\(6OBK6K/2CIEOJ]]!IW
MF"7[)'<NL6\'.[;G&00#TSQ5J[\?>)[Z>*>Y\1:K//"ACCDDO92R*1@J#NZ$
M>E8SRNK.ZYU;7IW=^X<K._C\2_!Q?!-G:IX3UR/Q<MO"LNI27H-L9QM\R3R]
MWW"0WRXZ$5])^,O!?CS7/VPO"?B_PU#=OX,<:?+!JL)(LTL!&GGQ[^5&X;\+
MWWC'K7P=BMF'QEKUMI<6F1:WJ,6GQ.)8[5+J18D8'<&"YP"" >!756R^4M:<
MNZUUWM_D-Q/LOP_]@U;P_P#M$:-::'?>)->?QE<S76D:3=?9KRYL_M!"[6"L
M656$A*@=#C^+GH?AG/J&E^//@7HE_P"#YO"L$,^JSZ?#JFJFZU!(C93AXWC,
M:-&F=I&?0=*^"[+Q#JFFZJVJ6FI7EMJ+,SM>0SNLQ8G))<'))/J:EN/%FMW6
MLKJ\VL7\NJJ,+?-=.9@""" ^=V,$]#W-<DLIDTUS;KS[6[V%RGT+^S+XLU?Q
MA\4OB)?ZO?SWUQ+X6U:7]]*S*A=XRP4$\#..GH/2K?[,>AVGQ]^&^I?"_5KE
M4ET?4[?7M/=C@BW,BI=1CG.W:Q(Q_$^>PKYCL=4O-+DDDL[N>TDD0Q.\$K(6
M1NJD@\@X'!]*-/U2\TF<S6-W/93,I0R6\K(Q4]5)!Z'%=M3+^92Y)6O:WE8;
MCV/MGX9_$[3?B5\</C#-9HU_-/H;Z;X>M+6X%O+/;0_*8K=\'87 #C [DXXK
M"EGC\#_".UM=>^'5[X4\)S^*;"9E\2ZLTURK1S(\KPV[PJ2K1+(IY[DXZU\?
M6MU-8W$=Q;326\\9W)+$Q5E/8@@_R-:&O>*M9\421R:QJU[JLD8PC7EP\I7/
M4#<>,^U8/*[37++33OT^=A<I]PV?@7XAR_MO)XKB@OI?"<\PECU9&)LWLF@&
MV-7R5ZD#:._/O7Q=\3/^2D>+/^PO=_\ HYZJQ^./$4-A;64>O:G'9VK;H+=;
MR0)$1T*KNX(]A6/-,]Q*\LKM)([%F=V)9F)R23ZD^O6NK"8.>'ES2:>B6B[#
M2[C:***]4H**** /7_V1/^3D/ W_ %^/_P"B9*_7#^&OR/\ V1/^3D/ W_7X
M_P#Z)DK]</X:_/.(O]YC_A_4YZFY\.?MB_\ )8!_V#H/_0GKPVO<OVQ?^2P#
M_L'0?^A/7AM?*F04444 %%%% '??!'X;O\4/B!8Z6P8:?%_I%[(HZ0J1D9]6
M)"_\"[U^B5O;QVL,<,*".*-0B*HP% & !^%>2?LS_# _#WP#%<WD036-6VW5
MQQRB8_=QY]E.3[L?K7L- !1110 5%-"LT;HPRC J1]:EI* /)KZU:QNY;=NL
M;%<^N#P?Q%0UT_CC3A#=17BCY9/D?ZCI^G\JYBO2A+FBF=T7=(****LH****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBJ.J:O;Z/;^=.^!T51R6/H!32
M;>A,I**O)EN:9+>-Y)6"1J,LS' %</KWCAY=\&GY1.AG/4_0?XUB:YXBN=<E
M_>'RX ?EA4\#W)[FLRN^G02UD>!B,=*?NT]ASLTDA=V+NW)9CDGW)K&\6>&X
M/%WAV_TBYXCNHBF[&2K=58#N00#^%;%%=D6XM-=#RE)IWOJ:O["OQ6N+G1=3
M^&.OS*NN>&W;[(K'YI;7=R!GKL9O^^77TKZQK\X_B=8:KX#\4:3\3O"X5-6T
M>16NX]IQ-$.#N ZC:2K>Q]J^Z_A3\3-)^+W@?3?$NC3*T%TF)8=P+6\H'SQL
M.Q!_,$'N*\K,\.E)8B'PRW\G_P '<^BIU%5@IH[.BBBO#- HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 2BEHH **** "BBHI9$AC:1V"(H+,S'  ]: .
M$^./Q4L_@W\-=7\378$DL$?EVEN3_K[A@1&GTSR?8&OB_P"!/AB]M=)O_$^L
MY?7/$,[7DTDGWMK,6&?=BQ;\14WQ8\<2?M4_&9+.S:0_#SPS)\K;L)=R_P 3
MX_VB"HY^X">-V*]*CC6.-550JJ,!0, 8Z #TKZ:G3^J4/9OXI:OR71'D9A7Y
M8^QB]>HX95@P."#D$=:ZK0?&\MJ4@O\ ,L7038RP^OJ*Y6BN6<(U%9GB4JTZ
M+O%GL=M=17D*2PNLD;#(93D5+7D^C:]=:)-NA;=$?O1-]T_X'Z5Z1H^M6^M6
M_F0-@C[T;8W+]?:O)JT73]#Z/#XN-96>YH4445S'>%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5W_AFR-GI,08?/)^\;\>GZ8KC-(L3J&H10C[
MI.6/^R.3_GWKTA5"J . .*I .HHHI@?A91117[2SK/:_V.='FU_]H3PI;^9(
M+:UF>_D0,=O[N-F!(_W@O7VKCO&FL7WQ.^,&K&&:6=M:UN18(C(2I\R;" <]
M.15GX*_%X_!K5M?U2WTK^T=1U#2)],M9OM/DBS>3;^^QM.\KM' *]3R*POAC
MXQ@^'OQ T'Q-<:;_ &Q'I5VEV++SO)\QEY7Y]K8PVUONGI7ERI3]O4JJ-]++
MSW8NK/L_XQ?"+PS\8_C=;^%K3XHKH6JZ/ID-@N@Q:;+(X6./>=K^8J,Q5ONC
MG\C7S_\ M'^/M.^(>L>#/!7A:WU*[M_#%M_8\5SJ2$7=W<,RHP9>HP44 '')
M/&*\[U7XH:G??%JY\?P%[34Y-5;58E\TL8V\W>L>[ RH&%Z<@=*] 7]HS1(?
MCW>?$^+P%"MS)$9(=,;4,PQ7I0(;DGR?F[MMP/F.=V<5P4L'6P[C*W-RQTVT
MD39H^M/A?\/_ !/\'=:^'7@/3/#]U<>'&BN+SQ1K:(/*ENIK=U6,'.=L;;1G
MTQZ&O"_@'/=?L_>'?C5XV>!9;K0[N'0;7=QOF-R5E4#/8;#7@6B_%[Q'IOCZ
MR\576IWM_<0:DFIRPM=.JS,)!(RGT!(/;O\ A7;?%3]HZ'XA>#-8\/6/A<:$
MFK>(I/$-S,+_ ,_=(Z;2FWRE[\Y)_"L/J.(4N66JG;F?H[]Q<K/H>Q\(V/@O
MXF?$7XMZ-'GPUJ/A"77-+NE7:JS7(^9<=G#*W';>*\I\,^(O!?CSX4Z#\+OB
M1=ZI\/=8T26233M2>W8VTJRDL&FC.".IY.!CG<,G'%V_[36IQ_LY7?PHDTSS
M$EE'EZLMR5:. 2I*8?+V\Y*D9WCAL8]=K5/VC/!/Q$M=-N_B-\-6\2>);"T2
MT_M2RUB2S%XJYQYJ*O7GJ,]3T&!0L)7C?GBWKHTU>R6CUTZNX6?4=\1O!/C=
MOB=\/?A5XMU.UUK3('@CTF\M%4K-93RA2XDQN/"-U/&WCL3C?MD>)CXD_:'\
M4['S:Z>T>GP(!PBQ1J"H]M^\_C33^TQ=7_QTT#XA:GH%O<6FAQ+;6&@VTY@B
M@@1'6)%?8WW2^[.WG&!@8Q=\3_&SX5>*-1U34[OX+2/JVH223R73>+;HCS7)
M8MM$8&-QZ# XQ793A7IU(2G3O:/2V[>O5#UN)^R+\&S\3OB(VJ7]C)?>'/#J
MB_O(4CWFY=<M' J_Q%ROW3U /K7KG[1$/C;Q/^SC<^(O&.E76@ZW8^+GFMX9
M@%9+*:/:J @] Q5?^ U\]R_&V;3_ (.V'@+P[ILF@J;QK[5=3BO"TVHR@808
M"KY:* /E!/W1[YE\+_'2XTGX7^*/!>L6%QK]OK5Q;7"W4M^RM;&)PQ 4HV=V
M .HQ[U%;#8BM65=K9JR\NO6VH--ZGH7[5EY<>%_!OP?\(17$T;Z=X>%Y<;9"
MI:6<J6+#URAZ_P!X^];O[-6@PQ_ 7Q3+<R&%_&7B32_#)FSSY+3()?S6:0&O
M#_CG\6I/C5\0;CQ*VFC1X&MX;:WL!/YXACC0# ?:N<MN;A1][O5RY^-UROP;
M\->!--T]M-ET?5GUB358[HEKB;+>6=FT;-@8?Q'.T'BG+"57A84HJTF[ORUO
M^86=K'4?MA^.=1UKXS:MH*M)9:%X=9-.T[3HR5BA1$4%E4<98Y.<9QM'05TO
MQVCOM5_9M^")UYGN/%ETUTMO)<',[69<>7N;J1@Q8SZUFZO^TEX&\<7EOXB\
M:?"FWUSQG"D:R7UOJDEM;7C)@*\L(4@D <CG. .G X#Q;\<M6^('Q3TKQEXB
MM8;N/3IX&ATFV8Q0)!$X;R$.&V@X/.#U)HIT*O+3CR6Y.NFKM;3U\P5SZW^(
MEK9>-HM<^ :H@GT'PK8W6B,H^;[;;QEI%![[T95^@8UX?^T%IMY8^"?@C\,[
M.UD;5DTE=0FM0,L;B[<;4X_B!5A^(KS_ %+X]ZI=?'YOBE;6OV.\_M!;Q;'S
MBP$84(82^T9!C!7.WN>*Z^]_:J@U'XZWGQ.N?!ZW%\ED+?2K";4"T5A*(]@E
M)\K]YC+';A1ECSGFN>G@\10<7%725[?WK6$DT?4WP[^'OB;X5^(OA_\ #O3O
M#UU/X1CM+F7Q-K4<>(+F\GMW'!SDJAVKG'0@=J^>/A3HLOPQ^!/QZU6[.R[B
M=/#,<@X+2>84D4#/8.IKQOPG\8_$7AWXA:;XKN]1OM5GMK];^>"6\=!<-OW,
MI/(&[G^'OTKUF\_:J\(:[X9UC0=<^%CZGIVIZ[/K\T4?B*2VS<2$XW&.$%@H
M..3C@''3&;P>*I.UN92Y6[:;._5A8^;!TKZ?_8STNRTOP_\ %3Q?J&JKH$%I
MHO\ 9<6K/"TPM6N"?W@1>25*)Q[UXO\ $CQ5X,\3?8!X2\"-X,\G=]H+:S-?
M^?G&T?O%&W&#TZY]JT-#^,+:#\#_ !#\/;?2L2ZUJ,5Y/JPN<'RX]F(O+V],
MJ3G?W/%>SB85,10Y%&UVNVU]?(MZK0^A?A_X:\(_LXZ/9_%X>/-2\?6+":RL
M;72[%X(#<%"-EPSN2F>>&4=,\]Y%M_!UA^RWX4TSQKXGN_!EQXLU6Z\1;M.M
M&N&D"N55"!]U=KQ-^'UKYZ\ _&0>$/AEXS\$ZAHW]M:7X@1'B8W7DFRN%!VS
M*-C;N=OR\?='-=]KG[2?@'QEX?\ #&F^)OA))K!\/Z?'IUK(OB>:W4(J@$[(
MX@,L0/7H!VKR*F#K\_O)O7=6O9+3LMV19G+>*-.\,:#XC\-7'PX\0ZS\0+RW
MN?MEQ:76GR1A/)9'0!>2P;YLX' 7WKVBZTWP]^T;\0%\=_#+Q=<>'_BA&8K\
M^'=:!VO)$J[A#)SD +]W!!YR%'3QC2_CIHG@/XD:)XJ^'_@2+PLMC')%=6%S
MJLU^MZK\$%G *?+TQWYKIM/_ &CO ?@?59O$O@7X7?V'XPE201WUYK$MS;VC
M2*0YCBP 3AF Z8S^%:U:-:5G"+NEO[OW2Z6]!V9V_P"SCJB3:+\;?B-X[U-M
M'-[$-'GU2UM@6CGN&*R,D2 #<K&(].Y]S7E'CSP_\+-+\*W]SX;^)6N:[K2A
M1;Z?<:>\*2Y=0VYR< !2Q_"KG@+]HCP]H/PKO? _B?P#)XLL[[4VU6YG36Y+
M$RRG:%R$C)P-HZMV'M7+^//'7PYU[P\]IX9^%[>%=4:16&I/XAN+W:H.641N
MH7)X&3[U=/#U8UY3E%I-K;EM9?B%F>J?L=_"K4GM=>^*":%-K<F@Q/%H=@B;
MOM5^PP& SRL>X')/&<]5KI?C[X!\1>---^ G_"5VUQ#XDU)WT?4UN0%E+&="
M&8CN0SMQZUX7X^^.EWXD\*^%/#'AZRF\*Z!H%L46W@O6EEN9V.9)I'"IDM_=
MQ@9/K@=/X#_:D?PKX?\ !.G:MX=D\13>%]9FU:&ZFU(HTH>)U$1S&VW:[A]V
M3]W&.<U%7#8J53ZPE=]NJ5FEK>P6>Y[Q\6?A-X<^//Q^UNUM?BI_9VIZ? L)
M\.6FF2M-''"@W)$Q=5=L[FPH/7H0*L_$#XU:?'^S9KWB#P1%?6]UIL]OX+MM
M9OQMOO*5$DED)QE"V\KU!R W'0?'VG_%;4]-^,(^(42G^TO[6;5#"9#@[I"S
M1[L?=*DKTZ&O3+/]J;2WUOQO;:GX%AO_  /XMN5O+OP^U^P>WN %W2Q3!!R6
M7=C:#G'/'///+ZT?9IKF4;=OFO,7*SSOX;^.?&_A.U\47GAZ&ZU#3[RQ>UUG
MS+9[FW$,G5Y1]U20K ,W8L*^@=-TCP-X9_9#\':'XYUS4?#W_"4:E/K8;2[4
M7#RK&?+56'92IC;ZCZUY-XR^/NE?\(#?>"?A]X03P9X?U&59=1EDO7N[N\Q@
MA6D8#:F0/E&>AY&XYY_XN_&'_A:.F^#=/ATC^Q[/PWI::;%%]I\X2D8W2?<7
M:6P.,'IUKOG0J8B47R<BO?I?1:?B59L]T\8:;X/^'7['.K3>"]6U#5K'Q9KD
M-K]HU*W6&1O*RS!5'\(,1Y/<U\BUZ)XZ^+Q\7?#'P+X*MM*.EV/AE+@O(+GS
M?MDTK!FD*[!L(.[C)^^>:\[KMP5&=&,O:/5MO_+\ 04445Z!04444 %%%% '
MZS_L8_\ )M/@O_KC/_Z42U[7ZUXI^QC_ ,FT^"_^N,__ *42U[7ZU^18S_>:
MGJ_S.66XM%%%<@@HHHH **** "BBB@#,\3_\BWJO_7I+_P"@&OQ"K]O?$_\
MR+>J_P#7I+_Z :_$*OM^&MJOR-Z84445]L;!1110 445W7P3^%]U\7OB+IGA
M^$^39LWGW]TS;5M[9.9'SZXX'N1T'-9U*D:4'4EL@]3T;X;_ +*<GC+X*ZSX
MYO\ 6'TZ\6UNKO2=,6($WD<"9=R<\*6(7@>_>G^"?V7[#Q9=?!Z&37;FW'CJ
M#4Y9RD"M]D^RQEEV\_-NQSGI7T+X+\3> _'/QVM[;0/B%:76DRZ#-X<TOPO%
MIUW$L<(BW,1(ZB/<3&3GC("CG JA\*;233_$7[*UK,ACE@@\21NC=0RQ."/P
MP:^/GC\3[VMMW:UK>[)VU\T9<S/@RQL+G4KA+>SMY;NX<X6*!"['VP!_(47U
MC<Z;</;WEO-:3K]Z*="C#Z@C^E?1GP>OM0\%_LL^.O%7A+=#XM;6H-/NKZV&
M;BSL2B$,G==SLR[ACUX*\=YIJCXE> /@=K7Q%C6[UJ?Q7_9ZW5^@$UY8C<1Y
MF1\Z^8J+D^O?=S[,\Q=.3O&Z3MY[7V+YCX_DT#5(8;>:33+Q(KC_ %,C6[A9
M,#)VG'/'I4>FZ1?ZU,8=/L;F^E R8[:%I&QZX K[N^$OCSXC:E^V=KVA:DU]
M/X9AFO(S8S(3:V<$:L()(AC:A/[M<CKO/6N)\ 7FA^!_V1?#VI6_B?6O"%SK
M&LW U35/#UKY]RTB,ZQPN^]3&NQ$; /.?<YQEF<XZ."OIL[[W\O(7,SY"-G<
M+-+$;>42Q F1-ARF.I/' 'O4]_HVH:7'#)>V%U9I,NZ)KB%D#CU4D<CZ5]X6
MOBNVM?B%K_BJRTN]&KP?"V^O+B[UG3DMAJ<D3P-'.T8)!W #/X#M7C\OCK7?
MB5^QOXQN_%&I3:W>Z?XBMOLMS>$/)$'VE@K=A\S8 X .!Q54\RG4=^31-)Z]
M_D"D?.-GH6IZC:RW-IIUW<VT/,DT,#NB?[S <?B:V[7P_H$WPVOM9FUB>+Q'
M#?K;PZ4+9C') 5!:0RXV@Y)&TGMTYK[0\6>(M*^'-U\*=(T;Q9XB\.VHTNTF
MM-'T'2UN+74W?&XRGS%\UGZ$,#USG)KE?BC9Z*WPC^)<.GZ7=:'I,WCZS9[&
M]B\F2 O;0-*"N3M&]G(P>A%9+-)5&ERVN_UMV_(.8^/HM!U.;37U"/3;R2P3
MAKI8',0]BV,?F:H9XK[;^*?C[XE^$_VF+3PAX"M/MNA16$5KIOAQD TZYA>W
M!8NORKP=QW$\;<9QD5\CVL*6OQ&ABU2WALHX]65;JWC8-%$!, Z Y.54 CJ>
MG>O1P^+G7BY-+:^_YE)W/6-+_9Z\+^#?"6E:Y\5O%\_A:?6(Q/8:)I]H9[PP
MG&))!_ ,$<$>O.<BN0^,WP;C^&LFAZEHVLQ^)?"WB" W&EZE'&4=@,;HY(\_
M*ZY'Z]#D#O\ ]M;P_K^I?M$:B5T^\NX;J&U73O*A9UDC\M0!'@<_-NZ=\UV'
M[._P9?X<_M#6&C>,;VSOM6LO#\VKV>GP.;@VMR0H6-D("F0(TC!03T##L:\^
M.*G3IK$2J7;5^7_+T[DWTN?*&I:'J.D")K_3[JR$HW1FXA:,,/49'(^E>ZZM
M^S'8:;\7?B3X-&N7+V_A/PW+KD5T8%W7#K#!((V7. ,S$9!_A%=]K7C;3/&'
MP3^)%M=ZYXN^(BJ$N8[O6-(5$TFZW95E?>?+5NFU0 !G@9KKO%7_ "=3^T+_
M -D^N?\ TDLZYZN85I?#[MD_SCW7F+F9\)T445]6MC0**** "BBB@#U_]D3_
M ).0\#?]?C_^B9*_7#^&OR/_ &1/^3D/ W_7X_\ Z)DK]</X:_/.(O\ >8_X
M?U.>IN?#G[8O_)8!_P!@Z#_T)Z\-KW+]L7_DL _[!T'_ *$]>&U\J9!1110
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M^H]C7DUZ'L_>CL?1X3%^V7)/<U****XSTPHHHH **** "BBB@ HHHH ****
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M_P"?;4?_  -;_"O=:*/KN(_G86/"_P#AC'X;?\^VI?\ @:?\*/\ AC'X;?\
M/MJ7_@:?\*]THH^NXC^=A8\*_P"&,?AM_P ^NH_^!I_PI?\ AC'X;?\ /MJ7
M_@:?\*]THH^NXC^=A8\*_P"&,/AM_P ^VH_^!K?X4?\ #&'PV_Y]M1_\#6_P
MKW6BCZ[B/YV%CPO_ (8Q^&W_ #[:E_X&G_"C_AC'X;?\^VI?^!I_PKW2BCZ[
MB/YV%CPO_AC'X;?\^VI?^!I_PH_X8Q^&W_/MJ7_@:?\ "O=**/KN(_G86/"_
M^&,?AM_S[:E_X&G_  H_X8Q^&W3[-J7_ (&G_"O=**/KN(_G86/"_P#AC'X;
M?\^VI?\ @:?\*/\ AC'X;?\ /MJ7_@:?\*]THH^NXC^=A8\+_P"&,?AM_P ^
MVI?^!I_PH_X8Q^&W_/MJ7_@:?\*]THH^NXC^=A8\*_X8Q^&W_/MJ6?\ K]/^
M%+_PQC\-O^?;4O\ P-/^%>Z44?7<1_.PL>%?\,8_#;_GUU'_ ,#3_A2_\,8_
M#;_GVU+_ ,#3_A7NE%'UW$?SL+'A7_#&/PV_Y]=1_P# T_X4O_#&/PV_Y]M2
M_P# T_X5[I11]=Q'\["QX7_PQC\-O^?;4O\ P-/^%'_#&/PW_P"?;4O_  -/
M^%>Z44?7<1_.PL>%_P##&/PW_P"?;4O_  -/^%'_  QC\-_^?;4O_ T_X5[I
M11]=Q'\["QX7_P ,8_#?_GVU+_P-/^%'_#&/PW_Y]M2_\#3_ (5[I11]=Q'\
M["QX7_PQC\-_^?;4O_ T_P"%'_#&/PW_ .?;4O\ P-/^%>Z44UC<1?XV%AW[
M*-G'IOP)\.VD((A@>\B0,<G:MU,!D_05Z[7E7[+_ /R1;1?^N][_ .EDU>J;
MJ\/$W=:;?=G%+<=124M<Y(4444 %%%% !1110!F>)_\ D6]5_P"O27_T U^(
M5?M[XG_Y%O5?^O27_P! -?B%7V_#6U7Y&],****^V-@HHHH *Z'PK\0O$/@>
MRUFTT+46TZ+6+;[)>F.*,O)#S\@<KN0')SM(SQ7/45$HQFN62T U/"WBC5/!
M/B"QUS1+MK#5;*3S;>Y558HV",X8$'@GJ.AKKQ^T%\0%UG0=67Q RZAH;W<N
MG3"U@_T=KHG[1A?+VG?N/# @9XQ7GE%3*C3F[RBF%CJ?AY\4_%/PKU26_P##
M&K2Z9/,GES($5XIESD*Z,"K 'IQGD^M:/B'XN:U\2?&6D:MX[U"\UNSM)$5K
M>V98#'"&!81!0%1B.^.PS7+^&M%/B3Q!I^E"[MM/^V3+#]JO) D,6XXW.W91
M7O7_  Q;J/\ 8?\ ;7_"P_!?]D^=]F^W?VB?)\W&[R]^W;NQSC.:XL1+"T97
MJV4GUMK]XG9;GI-C^TQX9\)ZL?$,?Q0\0^+;73[:0:1X5O-+:&59FB**;FZZ
M3!=S<MD\@\D<_,/PZ^-7C+X4QW4/AO6&L[2Z8--:30I/ [ 8#;'!&X#'S 9X
M'I6CXX^"-]X+\(WWB1=;TK6M*M=<70?/TV5I5DF-L+@NC8P5 .WZ@UYMGVK+
M"X7#<LN3WD][VZ?)=Q**.WO?C9XWU'7]=UJYU^>XU'6M.DTF^EE2-A):2 !X
M54KM13M'W ,<X[UC6?CK7=/\&ZAX4@OVC\/WUPEU<V?EH1)*H&UMVW<.@Z'\
M*P=U&ZO05&E%:12*/3/!O[2?Q&\ ^'X]%T;Q%)%I\.?L\<\$4[6V<Y$3.I*=
M>@.!VKF;CXE>)KKPSJ7A^XU::XTK4K_^T[R&94=IKG 'FLY&[) '\5<SFDW4
ME0HIMJ*^X5EV/5=-_:B^)^D^%T\/VWBJY2PCB^SQR-%&UQ'%C&Q9BN\ >S9'
M;H*\K9F9BS$DDY)/)^I-)NHW54*-.E=P5KA:QZWX;_:K^*/A3P]!HNG^*9A9
M6Z>7!]H@BFDA7& $=T+  =.>,<5Y_!XUU^W\5)XF36+T>(%F^T#4FF8S^9_>
M+=3D>O'\JT/'_P /KWP#-I#3SQ7UAJUA%J-C?6X8131..1R,AE.5*GH17*UE
M2I4&G.G%:^0*QZ-X\_:%\?\ Q+T0:1KVO-/IF\226UO!%;K,XZ-((U&_!YPW
M<#BJ%S\;/&M[XHU_Q%/K;OK.O:>VEZE=?9X0;BV9$1H]NS:H*QH,J ?EZUQ-
M%4L-1BN507W!9=@HHHKI&%%%% !1110!Z_\ LB?\G(>!O^OQ_P#T3)7ZX?PU
M^1_[(G_)R'@;_K\?_P!$R5^N'\-?GG$7^\Q_P_J<]3<^'/VQ?^2P#_L'0?\
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M8?WOJ:ZBJ0"T444P"BBB@#Y7_9S_ .2(^$?^O,?^A-7I%>;_ +.?_)$?"/\
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M%O4+GO%59-2M8M0BL7N(Q>31M+' 6 =D4@,P'H"R_F*\HO-0\<:]>^-YM/\
M$D.CV6A7CQVD0L$F:;;;QRE78G[F6(X&<D\]*NZ/\1KG5+CPEJL\4<-M?^&;
MC5KB%(P2'40,0K8W8&]N ?2E]7??^K7"YZI25Y1X,N/'WBC1=#\61ZW8F+4C
M'=/H4ML%@CM7((590#)YH0YR>">, 5ROCCXG:SH-GKNLVOC.UN;S39I&30].
MTQKFT\M&(\J6<)N#E1RVX &B.'E*7*G^87/=H]6LYM2GT^.ZB>]@C666W5@7
M16)"L1Z$J?R-7*\W\+R^?\:_%,H& ^C:>V/JTQQ4GB?5->\0?$#_ (1;0]77
M0(;/3DU&[O5MDGE<R2/''&H?Y0!Y;,3CTJ71][E7:X'<:=K%EJS78L[J*Z-I
M,UM.(F#>5*H!9&]& 8'!]15MJ\"\"ZMJ_A[P?\09KC6=*TK4AXNGBGU.Z1A"
MF8X SI'GYG(SA">IJ_X6\;:QJ7C:]\*0^)Y]7MKO1Y+ZVU6XTD6TMM*CHA"@
MHJRJ0^>G&.M:O"N[Y7L%SVJWN(KN%989%EB895XV!!]P:EKP'P'J6J>&?@1X
M++>++/28[U(0+N\ME:6"$QDB&",+^]?('+=B>M=7\)O&VH:SXH\2Z%=ZI)KM
MMI\5M<VNH7%@UG,RRF0,C(57(!CX<+SFHGAW%2:>W_#!<]3HHHKD&%%%% !1
M1136X%K]E_\ Y(MHO_7>]_\ 2R:MWXT>+-0\#_#C5M;TQHQ>VGEO'YJ[E.9%
M!!&>A!/0BL+]E_\ Y(MHO_7>]_\ 2R:I?VE_^2*>)/\ <C_]&+7#B/XTO5G#
M+=D/P>_:"T+XJ6Z6K,NEZ^H&^PE88DXY:,_Q#VZC]:]7K\K;>XFL[B*>"5X)
MXF#QRQL59&!R&!SP01VKZC^"O[694V^B^.)<@G9%K..GH)0!_P"/#VSZUSDG
MU?15>TNH;ZUBN+>5)X)5#I+&P96!&00>XJQ0 4444 %%%% &9XG_ .1;U7_K
MTE_] -?B%7[>^)_^1;U7_KTE_P#0#7XA5]OPUM5^1O3"BBBOMC8**** "BBB
M@ HHHH 2OHSXQ >%?V4?A#X='R2:I/<ZY,IZDY(1L>FV7'Y5\Z5V7Q(^*FK?
M$\>'TU*WLK.WT+3(M*LX+!'5!$G1FW,Q+$8R<X^4<5PXBE*K4IZ:)W?W:":U
M/8_ ?C-/ G[&MWJ2Z1I^KWO_  G?EV?]IVXGAMI38(?-\MOE9@BN!NZ%L]JZ
M+QIX!\._$WXD? >ZFT:RT8>,;%+C6(-+C%O%,RD%L*!P6Y7/7D?6OG$_$;4_
M^%6_\(%Y%K_8W]L_VYYVQOM'G^1Y.W=NV[-O.-N<]^U:>M?&KQ'K$7@<(;;3
M;CP= MOIEU9(RR?*P8,^YB"<J.@ //%>9]1JJ<IPT;<ON:T_$5M3ZPU?1?!6
MK>)/%/A3Q%JOPWL/"D4=Q;V%KI-MY>IZ7*O$<AD"9+ _?RQ!/MP?.OBWXJTG
MX9_"/X;Z5H?@KPVVI>*/"L3:EJ=QID;W#;D559&&,2;BS;B"<A#VKAKS]JW7
M'AU2[TWPSX;T/Q3JT#6]_P")-.M'2\E5C\Y7YRJ.V 25')YXXQP/CCXIZOX^
ML/"EI?P6<">&].CTRS:U1E9XT^ZTFYCEOH /:L,/@*W-'VB]WKKY>7F2HOJ?
M9OP_\)VMOXP\,^$M?T+X?>&M)O;-([CP?<QI?ZQ<.82WFO+Y8*OD!N3P >_3
MR_4)M'^$/P!DUW2?"NAWVO1^,K[2K;4=3T^.Y>&%=Y RP^8@( -W3)KC9/VQ
M/$1\2V7BF/PKX63QA"J1S:ZUG(T]PBJ%VD>9A=R#:2N"03@K74Q?'C3]-_9T
MMY+C3?#NO:GJ7BZZO;[P[?QF2-8I%=]RINWH ^ K9Z=<\US/"XFG).<=&UI?
MU_K7YAJ5/BL?#OA_5/@O\33X<TFW7Q#;?:=;T5;.-K*4QNBRN(2"H\P2-CW4
M'J"3U&N?"/P]\(_$_P 8/&=_HUC?^%[6QC/AVWNK=);=[B]PT0C1@5(C]AP*
M^??&GQ UKX[>--&BU.;3=%A'DZ786\8-OI^G0E@JC'S%4&<EN3@>@ KU7]IK
MXB0V?PO^'_PMM?$-IXGN-"M_-U/4M/</;LX!2&)&_BV(2,X_N]#D#KE0JQ=*
ME?5[_P"&]_PV^869D^,(QK7[&O@74;G!N=*U^\T^%L#/E.ID(Z=F _*O :]D
M^+_BBTT?X6^ ?ASIUQ#>'386U;5)[>4.GVNX^819!P3&IP2#U;V->-UZV!BX
MTVWU;?RN6@HHHKT!A1110 4444 %%%% 'K_[(G_)R'@;_K\?_P!$R5^N'\-?
MD?\ LB?\G(>!O^OQ_P#T3)7ZX?PU^><1?[S'_#^ISU-SX<_;%_Y+ /\ L'0?
M^A/7AM>Y?MB_\E@'_8.@_P#0GKPVOE3(*^G/V./AC]LOKGQI?PMY5L6M]/##
MAI",/(/]T';^)]*^??!OA6\\<>*-.T*P ^TWLPC5B"0@ZLY]E4$_A7Z2>%/#
M=GX/\-Z=HM@NVTLH5B3/!..K'W)R3]: -BBBB@ HHHH **** "BBB@ HHHH
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MM8BSTFQAL;<<E8EP6/JQZD_4UIT5<Z\ZBLWIVZ'EU<35K?$PHHHKG.4****
M"BBB@ HHHH **** "BBB@ KTCP;K']IZ:(I#F>#Y6YY(['\OY5YO6IX;U3^R
M=6BE9L1.=DGIM)ZGZ''Y5SUZ?M(';A*WL:BOL>J44B^M+7B'U84444 %%%%
M!1110 4444 %=#X9\/F[87=RG[@?<1OXO<CTI/#WAIKPBXNE*P=53N_N?;^=
M=HJA5"@8 X %4 N,4M%%, HHHH **** /E?]G/\ Y(CX1_Z\Q_Z$U>D5YO\
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M.NH-<?V#I<FEH#$%\U6,6'//! B'3U-=#X7\16WBOPWIVMVBO'9WUNMS$)@
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M** "BBB@ HHHH **** "BBB@ HHHH *3%+10 4FT4M% !1110 4444 %%%%
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MPD:[5%/50J@ 8'I2USRDV<<YN7H%%%%29A1110 4444 %%%% !1110 4444
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MCO\ RQ5ZOSF^%OQF\0?"?4/,TZ;[3I\A_?:=.Q,3^X_NM_M"OM_X7_&'P_\
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MI\M/^>:GYC]3766]K%9Q".%%C0=E%344P"BBB@ HHHH **** "BBB@ HHHH
M^5_V<_\ DB/A'_KS'_H35Z17F_[.?_)$?"/_ %YC_P!":O2*]W$_QI^K/0"B
MBBN< KD?$'Q+TW0M6GTQ;/4]5O;:%9[B+3+-Y_(1L[2Y P"0#A<Y.#VKKJ\9
M\77FK2>.M;L;]O$]MITBPC3(_#=D0MV#&-YDN%0E6#EE^9U 4 \5T48*<K,3
M.TN/BMX=C\-Z5K<%S-?6VJOY5C#9P/+/<2<Y18P-VY=K9XXP<UR7C;X[1Z9I
MVEOI%G>&\?7+?3+ZSN+)Q<0*WS,-F?O,N-F,AN<=*Y/X>Z#K'@KPI\/M7O\
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MY8&-8F*;V\LNB_*KE-I*COFNLKAG'EDTB@HHHJ "BBBFMP+7[+__ "1;1?\
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M>J_]>DO_ * :_$*OM^&MJOR-Z84445]L;!1110 4444 %%%% !1110 4444
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M_C2]6<,MV?GU1117.2%%6;#3[G5;R&TLK>2[NIF"QPPJ69F/0 8ZU]=? _\
M95MO#WD:WXQBCO=3!62'3>&AM^X+_P!]AQQT&#UZT >:? _]F+4/'?V?6?$2
MRZ9H!^9(N5GN@.F!CY4/]XCGMZU]F:%H.G^&M+M]-TNSBLK&!0L<,*X QW/J
M?<\GO6@JA5  P!T IU !1110!F>)_P#D6]5_Z])?_0#7XA5^WOB?_D6]5_Z]
M)?\ T U^(5?;\-;5?D;TPHHHK[8V"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#U_]D3_ ).0\#?]?C_^B9*_
M7#^&OR/_ &1/^3D/ W_7X_\ Z)DK]</X:_/.(O\ >8_X?U.>IN+1117RID%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+
M24 >$>(H?L^O:A'TQ.WZDG^M9]=-\1+/[+XGGD'W9T60?E@_R_6N9KZ2E+F@
MF?$UX\E62\PI*6BM# **** &[1W /X4TPQMUC4_\!%244!=D?V>'_GDG_?-*
M(47HB_@!3Z*!W8FT>E+110(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MI6SR7%D4C"8C(/S(<;MI(^8FO3**TA4E3=T!Y!H/P=UCPIX9\,1Z;JMF^O\
MA^XNFAN+F%C#<0W#EI(W .Y21LY!X*"M.3X>^(M:OM.U/6M9@ENX-9AU'[)
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M" /?BO0:*/;3"QXJOP>\2S^'= T5KK0-.L='N[6Z_P")?:.K7A@D5@7)/R9
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M_P /ZG/4W%HHHKY4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:7JSAEN5[6UAL;>*WMXD@@B4(D4:A550,  =A5BBBN<D**** "BBB@ HHHH
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M]_\ 2R:O5JX<1_&EZLX9;A1117.2%%%% !1110 4444 9GB?_D6]5_Z])?\
MT U^(5?M[XG_ .1;U7_KTE_] -?B%7V_#6U7Y&],****^V-@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]?_
M &1/^3D/ W_7X_\ Z)DK]</X:_(_]D3_ ).0\#?]?C_^B9*_7#^&OSSB+_>8
M_P"']3GJ;BT445\J9!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /E?\ 9S_Y(CX1_P"O,?\
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M8[@BTBMXC-%Y!AQM)9%/S$;LL#FLH4.9Z[7"Y]$V=REY:Q7$7,<J+(I(P=I
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MAAN$RA^Y* =KC_'_ #Z5[F'Q"J*SW/EL7@Y4'S1V,ZBDI:[#S0HHHH ****
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MW.B^.H[K5C9V$F^;3KI \L\,*MPV,-MRP4;LD@9K&\=:AX!^)GCSPOK/[/\
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MKEH++4+B>Z:26=06(8L>C88CC@#'%+\/OBMHWBS1=#%UJVF1Z_?6L<LEA#,
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M_EH78C.X_P A7<5Y]X^\>:CX5M?$-U9SZ3<)8:9%>06KLS7&]I&4NZAA^Z(
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MPZT+PT(7\017>FRQV<"@3VS(R-/*Z]5 &_+'KN[YS7T?Q35AC60R*BAV&"P
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MG(>!O^OQ_P#T3)7ZX?PU^><1?[S'_#^ISU-Q:***^5,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I*6B@#*UCP[8Z[#Y=W"&8?=D'#+]#7G.O?#F_P!,W26?^FVXYPHPX'N.
M_P"'Y5ZUUHK>G7G3V>AQUL+3KZM:GSPRM&Q5E*L."I!!'L117M^L>%M.UP$W
M-N/-Q@2I\K_G_C7!ZO\ #"^M=SV,JWD?7RVPK_KP:]6GBH3T>C/!K9?5IZQU
M1QE%2W5G<6,GEW$,D,G]V12*BKL335T>:XN.C5@HHHH$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45);VL]Y*(X(GFD/\,:DFNLT?X9ZA?!7O
M'6RC/.W&Y_YUE.I"GK)FU.C4JNT$<> 68*HR3P .3]*ZG0?A[J&J[9+D?8K<
M]W'SGZ+7H>B^$=,T/#06^Z8#'G2?,W_UOPK:VUYU3&-Z0/;HY:EK59DZ+X9L
M-!CVVL(#D8:5N7/XUK#I1^E+S7G-N3NSV8QC!<L586BBBD6%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\K_LY_\D1\(_\
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M]'_#9'PT_P"?^_\ _ %Z**/[+P_F%V'_  V1\-/^?^__ / %Z/\ ALCX:?\
M/_?_ /@"]%%']EX?S"[#_ALCX:?\_P#?_P#@"]'_  V1\-/^?^__ / %Z**/
M[+P_F%V'_#9'PT_Y_P"__P# %Z/^&R/AI_S_ -__ . +T44?V7A_,+L/^&R/
MAI_S_P!__P" +T?\-D?#3_G_ +__ , 7HHH_LO#^878?\-D?#3_G_O\ _P
M7H_X;(^&G_/_ '__ ( O111_9>'\PNP_X;(^&G_/_?\ _@"]'_#9'PT_Y_[_
M /\  %Z**/[+P_F%V'_#9'PT_P"?^_\ _ %Z/^&R/AI_S_W_ /X O111_9>'
M\PNP_P"&R/AI_P _]_\ ^ +T?\-D?#3_ )_[_P#\ 7HHH_LO#^878?\ #9'P
MT_Y_[_\ \ 7H_P"&R/AI_P _]_\ ^ +T44?V7A_,+L/^&R/AI_S_ -__ . +
MT?\ #9'PT_Y_[_\ \ 7HHH_LO#^878?\-D?#3_G_ +__ , 7H_X;(^&G_/\
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M3*O%]<1A8[?/7RH\G!_VB2?IS117R^89IB:S=)NT?(F4F?0=+117SQB%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gizttcucplmb000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )>!3H# 2(  A$! Q$!_\0
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M.6 YP1ZUC.C*$U![L+&Q17B7_"X/$/\ SZ:9_P!^G_\ BZ/^%P>(?^?33/\
MOT__ ,76WU*J%F>VT5XE_P +@\0_\^FF?]^G_P#BZ/\ A<'B'_GTTS_OT_\
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MZ:9_WZ?_ .+H_P"%P>(?^?33/^_3_P#Q='U*J%F>VT5XE_PN#Q#_ ,^FF?\
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MTS_OT_\ \71_PN#Q#_SZ:9_WZ?\ ^+K;ZE5"S/;:*\2_X7!XA_Y]-,_[]/\
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M_>:U%'<7[HT%G+9&0.VX JV&Z<C.<4NO>#)9[N[N;&:!YQJ2V4EM!:^3'$6
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M^@"OFBOI?PM_R*.C?]>,/_H KS\?\*)D>'_$/_D?-5_WT_\ 0%KF*Z?XA_\
M(^:K_OI_Z M<Q791_AQ]$-!1116@PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH *?#_KX_P#>'\Z93X?]?'_O#^=(#ZKKY>UC_D.:A_U\R?\ H1KZAKY>
MUC_D.:A_U\R?^A&O,R_>1,2E1117J%!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ;O@S_D<]'_Z^D_G7T+J_P#R!;[_ *]Y/_037SUX,_Y'/1_^
MOI/YU]"ZO_R!;[_KWD_]!->7COXD26?+M%%%>H4%%%% !1110 4444 %%%%
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MFNBT+PEI5Q;>%Q?6!,]W<745V#(ZEO+#X& >,%1TQTJ9^Q2U_K=_YAH9\WQ
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M$7F-MV /F^]\PXZ>]2W5O?\ KJ+4S[GP!J.FH+F6XTZ\BANHX+B*"Y):,LP
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MBBB@ HHHH **** "BBB@ HHHH W?!G_(YZ/_ -?2?SKZ%U?_ ) M]_U[R?\
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MJC_A9.B?\\KW_OVO_P 51[*?8/KN'_G1V-%<=_PLG1/^>5[_ -^U_P#BJ/\
MA9.B?\\KW_OVO_Q5'LI]@^NX?^='8T5QW_"R=$_YY7O_ '[7_P"*H_X63HG_
M #RO?^_:_P#Q5'LI]@^NX?\ G1V-%<=_PLG1/^>5[_W[7_XJC_A9.B?\\KW_
M +]K_P#%4>RGV#Z[A_YT=C17'?\ "R=$_P">5[_W[7_XJC_A9.B?\\KW_OVO
M_P 51[*?8/KN'_G1V-%<=_PLG1/^>5[_ -^U_P#BJ/\ A9.B?\\KW_OVO_Q5
M'LI]@^NX?^='8T5QW_"R=$_YY7O_ '[7_P"*JWIOCG2M5U&&RMX[H2RDA2Z
M#IGU]J3IS70:QE"3LI(VM6LVU'1KZQ5PC7-O)"&(R%+*1G]:\K_X4S??]!>W
M_P"_3?XUZ^[!$9ST49-5/[3@]'_*KI5JE-6@=2N>5_\ "F;[_H+V_P#WZ;_&
MC_A3-]_T%[?_ +]-_C7JG]IP>C_E1_:<'H_Y5K]:K]QZGE?_  IF^_Z"]O\
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MIO\ &C_A3-]_T%[?_OTW^->J?VG!Z/\ E1_:<'H_Y4?6J_<-3RO_ (4S??\
M07M_^_3?XT?\*9OO^@O;_P#?IO\ &O5/[3@]'_*C^TX/1_RH^M5^X:GE?_"F
M;[_H+V__ 'Z;_&C_ (4S??\ 07M_^_3?XUZI_:<'H_Y4?VG!Z/\ E1]:K]PU
M/*_^%,WW_07M_P#OTW^-'_"F;[_H+V__ 'Z;_&O5/[3@]'_*C^TX/1_RH^M5
M^X:GE?\ PIF^_P"@O;_]^F_QH_X4S??]!>W_ ._3?XUZI_:<'H_Y4?VG!Z/^
M5'UJOW#4H>$]#D\.>'H-,EF69XF<EU& <L3_ %KG?&OP_N?%6M17T-_%;JEN
ML.UT))(9CGC_ 'J[J&59HPZYP?6HI[R.W<(X;)&>!6,:LXSYUN+6YY/_ ,*9
MOO\ H+V__?IO\:/^%,WW_07M_P#OTW^->J?VG!Z/^5']IP>C_E6WUJOW'J>5
M_P#"F;[_ *"]O_WZ;_&C_A3-]_T%[?\ []-_C7JG]IP>C_E1_:<'H_Y4?6J_
M<-3RO_A3-]_T%[?_ +]-_C1_PIF^_P"@O;_]^F_QKU3^TX/1_P J/[3@]'_*
MCZU7[AJ>5_\ "F;[_H+V_P#WZ;_&C_A3-]_T%[?_ +]-_C7JG]IP>C_E1_:<
M'H_Y4?6J_<-3RO\ X4S??]!>W_[]-_C1_P *9OO^@O;_ /?IO\:]4_M.#T?\
MJ/[3@]'_ "H^M5^X:GE?_"F;[_H+V_\ WZ;_ !H_X4S??]!>W_[]-_C7JG]I
MP>C_ )4?VG!Z/^5'UJOW#4\K_P"%,WW_ $%[?_OTW^-'_"F;[_H+V_\ WZ;_
M !KU3^TX/1_RH_M.#T?\J/K5?N&IY7_PIF^_Z"]O_P!^F_QH_P"%,WW_ $%[
M?_OTW^->J?VG!Z/^5']IP>C_ )4?6J_<-3RO_A3-]_T%[?\ []-_C1_PIF^_
MZ"]O_P!^F_QKU3^TX/1_RH_M.#T?\J/K5?N&IY7_ ,*9OO\ H+V__?IO\:]3
MTBR;3=%L;%G#M;6\<)8# 8JH&?TI?[3@]'_*K2,'17'1AD5E5K5*BM,3N>;>
M)?AA=Z[XAO-3CU*&))V!"-&21A0/Z5E?\*9OO^@O;_\ ?IO\:]6EOXHI&1@^
M1UP*;_:<'H_Y5I'$UDDDPU/*_P#A3-]_T%[?_OTW^-'_  IF^_Z"]O\ ]^F_
MQKU3^TX/1_RH_M.#T?\ *G]:K]QZGE?_  IF^_Z"]O\ ]^F_QH_X4S??]!>W
M_P"_3?XUZI_:<'H_Y4?VG!Z/^5'UJOW#4\K_ .%,WW_07M_^_3?XT?\ "F;[
M_H+V_P#WZ;_&O5/[3@]'_*C^TX/1_P J/K5?N&IY7_PIF^_Z"]O_ -^F_P :
M/^%,WW_07M_^_3?XUZI_:<'H_P"5']IP>C_E1]:K]PU/*_\ A3-]_P!!>W_[
M]-_C1_PIF^_Z"]O_ -^F_P :]4_M.#T?\J/[3@]'_*CZU7[AJ>5_\*9OO^@O
M;_\ ?IO\:/\ A3-]_P!!>W_[]-_C7JG]IP>C_E1_:<'H_P"5'UJOW#4\K_X4
MS??]!>W_ ._3?XT?\*9OO^@O;_\ ?IO\:]4_M.#T?\J/[3@]'_*CZU7[AJ>5
M_P#"F;[_ *"]O_WZ;_&C_A3-]_T%[?\ []-_C7JG]IP>C_E1_:<'H_Y4?6J_
M<-3RO_A3-]_T%[?_ +]-_C2I\&[Y9%;^U[?@@_ZIO\:]3_M.#T?\J/[2@]'_
M "H^M5^X:ERO)KWX0WMW?W-R-6MU$TK2 &(\9)/K7K-5&U&%6*D/D''2L:56
M=._()7/*O^%,WW_07M_^_3?XT?\ "F;[_H+V_P#WZ;_&O5/[3@]'_*C^TX/1
M_P JV^M5^X]3RO\ X4S??]!>W_[]-_C1_P *9OO^@O;_ /?IO\:]4_M.#T?\
MJ/[3@]'_ "H^M5^X:GE?_"F;[_H+V_\ WZ;_ !H_X4S??]!>W_[]-_C7JG]I
MP>C_ )4?VG!Z/^5'UJOW#4\K_P"%,WW_ $%[?_OTW^-'_"F;[_H+V_\ WZ;_
M !KU3^TX/1_RH_M.#T?\J/K5?N&IY7_PIF^_Z"]O_P!^F_QH_P"%,WW_ $%[
M?_OTW^->J?VG!Z/^5']IP>C_ )4?6J_<-3RO_A3-]_T%[?\ []-_C1_PIF^_
MZ"]O_P!^F_QKU3^TX/1_RH_M.#T?\J/K5?N&IY7_ ,*9OO\ H+V__?IO\:/^
M%,WW_07M_P#OTW^->J?VG!Z/^5']IP>C_E1]:K]PU/*_^%,WW_07M_\ OTW^
M-'_"F;[_ *"]O_WZ;_&O5/[3@]'_ "H_M.#T?\J/K5?N&IY7_P *9OO^@O;_
M /?IO\:/^%,WW_07M_\ OTW^->J?VG!Z/^5']IP>C_E1]:K]PU/.M#^%5YI.
MN66H/JD$BV\RR%!&03CMUKTJ\@-U8W%N&"F6)D!/;(Q3(]0ADD5%#Y8X&15D
MG:I)[#-8U*LYM.0G<\@_X4S??]!>W_[]-_C1_P *9OO^@O;_ /?IO\:]4_M.
M#T?\J/[3@]'_ "K;ZU7[CU/*_P#A3-]_T%[?_OTW^-'_  IF^_Z"]O\ ]^F_
MQKU3^TX/1_RH_M.#T?\ *CZU7[AJ>5_\*9OO^@O;_P#?IO\ &C_A3-]_T%[?
M_OTW^->J?VG!Z/\ E1_:<'H_Y4?6J_<-3RO_ (4S??\ 07M_^_3?XT?\*9OO
M^@O;_P#?IO\ &O5/[3@]'_*C^TX/1_RH^M5^X:GE?_"F;[_H+V__ 'Z;_&C_
M (4S??\ 07M_^_3?XUZI_:<'H_Y4?VG!Z/\ E1]:K]PU/*_^%,WW_07M_P#O
MTW^-'_"F;[_H+V__ 'Z;_&O5/[3@]'_*C^TX/1_RH^M5^X:GE?\ PIF^_P"@
MO;_]^F_QH_X4S??]!>W_ ._3?XUZI_:<'H_Y4?VG!Z/^5'UJOW#4\K_X4S??
M]!>W_P"_3?XT?\*9OO\ H+V__?IO\:]4_M.#T?\ *C^TX/1_RH^M5^X:GE?_
M  IF^_Z"]O\ ]^F_QH_X4S??]!>W_P"_3?XUZI_:<'H_Y4?VG!Z/^5'UJOW#
M4\K_ .%,WW_07M_^_3?XUO>$/AS=>&M>349=0AG58V38L9!YKMO[3@]'_*GP
MWL4\FQ V<9Y%3+$UI1:>PM2S1117,(\[^*?32?\ MM_[)7G5>B_%/II/_;;_
M -DKSJO0H?PT?*YE_O4OE^2"BBBM3A"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K>\&?\C?IW^^W_H)K!K>\&?\C?IW^^W_ *":F?PLVP_\:'JOS/9[
MC_CVE_W#_*L"M^X_X]I?]P_RK K@IGVD0HHHK0H**** "BBB@ HHHH ****
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MLA<^;$FV-9)E\P'RLKN^8]N/6GRRM<=F7**JOJ5A%-%#)>VR2S &)&E4,X/
MVC/.?:H8M6B-WJ44^R"*Q9%:5Y  =R!LG/3KBCE8K,T**I_VC;RQ0RVMS:31
MR2B/?YXP3Z*1G+>U5K[7K2UN(;>.6">X>X2%X5F&^,,<;B.3QD?G0HR;L.S-
M6BBBI$%%%% !1110!LZ?_P >:_4_SJGJ?_'RO^X/YFKFG_\ 'FOU/\Z\F^+&
MJ:A9>*;:*TO[JWC-DC%8IF0$[WYP#UX%%"FZE3E00CS2L>@45X+_ ,)!K7_0
M7U#_ ,"7_P :/^$@UK_H+ZA_X$O_ (UW?49=S?V#[GO5%>"_\)!K7_07U#_P
M)?\ QH_X2#6O^@OJ'_@2_P#C1]1EW#V#[GO5%>"_\)!K7_07U#_P)?\ QH_X
M2#6O^@OJ'_@2_P#C1]1EW#V#[GO5%>"_\)!K7_07U#_P)?\ QH_X2#6O^@OJ
M'_@2_P#C1]1EW#V#[GO5%>"_\)!K7_07U#_P)?\ QH_X2#6O^@OJ'_@2_P#C
M1]1EW#V#[GO5%>"_\)!K7_07U#_P)?\ QH_X2#6O^@OJ'_@2_P#C1]1EW#V#
M[GO5%>"_\)!K7_07U#_P)?\ QH_X2#6O^@OJ'_@2_P#C1]1EW#V#[GO5%>"_
M\)!K7_07U#_P)?\ QH_X2#6O^@OJ'_@2_P#C1]1EW#V#[GO5%>"_\)!K7_07
MU#_P)?\ QH_X2#6O^@OJ'_@2_P#C1]1EW#V#[GO5;UO_ ,>T7^X/Y5\S_P#"
M0:U_T%]0_P# E_\ &GCQ/X@  &NZF .@%W)_C4RP$GU$\.WU/?[W_C\D^O\
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M?^$@UK_H+ZA_X$O_ (T?\)!K7_07O_\ P)?_ !H^IR[A8]ZHKP7_ (2#6O\
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M!6_<?\>TO^X?Y5@5P4S[2(4445H4%%%% !1110 4444 %%%% !1110 4444
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MBBB@#9T__CS7ZG^=>-_&'_D;K7_KQ3_T9)7LFG_\>:_4_P Z\;^,/_(W6O\
MUXI_Z,DK;!?Q_O+H?Q#SZBBBO:.T**** "BBB@ HHHH **** "BBB@ HHHH
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MY[*>.16F$E&-:\BJ+2G=GCM%=I_PK'6O^?K3_P#OX_\ \11_PK'6O^?K3_\
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MZI_]TUX]>;G/F9$CGJ***904444 %%%% !1110 4444 %%%% !1110 4444
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M4WF6RCDGD=[VYC\R%(O,$<9& -^%SSU.>AKH!HNGABPM^3,DY^=OOH %/7L
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M\\D_[Y%'D0_\\D_[Y%'.',0Z?_QYK]3_ #JGJ?\ Q\K_ +@_F:U555&%  ]
M*:T<;G+(K'U(S4J5G<5]3GZ*W_(A_P">2?\ ?(H\B'_GDG_?(JN<?,8%%;_D
M0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\\D_[Y%'.',8%
M%;_D0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\\D_[Y%'.
M',8%%;_D0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\\D_[
MY%'.',8%%;_D0_\ /)/^^11Y$/\ SR3_ +Y%'.',8%%;_D0_\\D_[Y%'D0_\
M\D_[Y%'.',8%;UO_ ,>T7^X/Y4OD0_\ /)/^^13P !@# '0"IE*XF[F+>_\
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MC>'/[#,D_P!EV!-^X;\ YZXQ^E:U%/GE>]Q\S,:_\,V&HRZ?+,95DL2#$Z$
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M/^_:?_%T?5JG\H>SEV.[^V7'_/4T?;+C_GJ:X3_A9VB_\^NH?]^T_P#BZ/\
MA9VB_P#/KJ'_ '[3_P"+H^K5/Y0]G+L=W]LN/^>IH^V7'_/4UPG_  L[1?\
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M5MR?ZI_]TUB6O_'U%_O"MN3_ %3_ .Z:SGN2SGJ***T*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *MZ=_Q]CZ&JE6]._X^Q]#2EL)[&Q1116!
M!YW\4^FD_P#;;_V2O.J]%^*?32?^VW_LE>=5Z%#^&CY7,O\ >I?+\D%%%%:G
M"%%%% !1110 4444 %%%% !1110 4444 %%%% !6]X,_Y&_3O]]O_036#6]X
M,_Y&_3O]]O\ T$U,_A9MA_XT/5?F>SW'_'M+_N'^58%;]Q_Q[2_[A_E6!7!3
M/M(A1116A04444 %%%% !1110 4444 %%%% !1110 4444 %%%% %O3O^/L?
M0UH7O_'G)]/ZUGZ=_P ?8^AK0O?^/.3Z?UK.7Q$O<Q****T*"BBB@ HHHH *
M*** "BBB@ HHHH **** "M^W_P"/:+_<'\JP*W[?_CVB_P!P?RK.H3(R+W_C
M\D^O]*KU8O?^/R3Z_P!*KU:V&@HHHIC"BBB@ HHHH Y[1M8N)=0U."^D!CBF
ME:!RH&$1]K#CKC*'/^U4&D>(II9+AK[<5EO(X;=$0?NPZ!E!Z?B?6BX\,W,]
MO(@GCC=[Z65F!/,$G#+TZX_4=:EFT&[-Q=7$30;C?17<*,Q (10I5B!QWZ ]
MJZ?W;N:>Z2ZGK31WL5I:^8LD=[#%-E5PZNI; S]/:J^F>()[M;<W,%RLTL]P
MD<48BVR; WRG)R",8ZCGOBC^P]2GU)[VX:U0O>07&R-V.U44J1DJ,GD>GX4Z
MPT*]MKRR:1K<PVMS<2AE=MSK(&QQMP",^II?NU&W];?YA[MAFAZ[<2Z;;/<Q
MWEW>W6Z18$6(;4'5A@@!<D#YCDFKH\26TDEK%;VMU/-<*Y$2*JLA0@,K;F !
M!_E],U=/T._TN+3YH#;37,%NUM-&\C*C*6W JP4D$'U'.>V*?I^@W-IJEM>R
MRQ,V)WN N0/,E93A1_=&,<G-$O9MM@^6Y(/%%NRK(+&^\EYVMUDV+@R D;0-
MV>2, XQSR1SB<>(("KJ;:Y6Z680?9"JF1G*[N,-MQMYSG&*J1:#=1Z=:6YDA
MWPZB;MB"<%-[-@<=<&HK[PU+=:G<WQ6TFS<QS1P3C*.HC",K<'![@@'H*5J=
MQ6B;5CJ$=\9D\J6&>%@LL,H&Y<\CH2"".X)JY6;I-@UD)B;+3[3S&&([-.P'
M\38&XYS_  C'O6E64K7T(=KZ!1114@%%%% !1110!LZ?_P >:_4_SKQOXP_\
MC=:_]>*?^C)*]DT__CS7ZG^=>-_&'_D;K7_KQ3_T9)6V"_C_ 'ET/XAY]111
M7M':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !11102%%%%(3"CM11VH$%%%%(0=J*.U% A:2EI*"0-+2&EH
M$)2TE+2)$[TM)WI:!!2=Z6D[TA"T444""NI\$>(SHNJ?9YWQ97)"OGHC=F_H
M?;Z5RU=IX!\-_P!HWW]IW4>;6W;Y%8<2/_@.OUQ[UE6<>1\Q+/5Z***\@ HH
MHH **** "BBB@":U_P"/J+_>%;<G^J?_ '36):_\?47^\*VY/]4_^Z:SGN2S
MGJ***T*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *MZ=_Q]CZ&
MJE6]._X^Q]#2EL)[&Q1116!!YW\4^FD_]MO_ &2O.J]%^*?32?\ MM_[)7G5
M>A0_AH^5S+_>I?+\D%%%%:G"%%%% !1110 4444 %%%% !1110 4444 %%%%
M !6]X,_Y&_3O]]O_ $$U@UO>#/\ D;]._P!]O_034S^%FV'_ (T/5?F>SW'_
M ![2_P"X?Y5@5OW'_'M+_N'^58%<%,^TB%%%%:%!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 6]._X^Q]#6A>_\><GT_K6?IW_'V/H:T+W_ (\Y
M/I_6LY?$2]S$HHHK0H**** "BBB@ HHHH **** "BBB@ HHHH *W[?\ X]HO
M]P?RK K?M_\ CVB_W!_*LZA,C(O?^/R3Z_TJO5B]_P"/R3Z_TJO5K8:"BBBF
M,**** "BBB@ JO?WB6%C+=2 L(QPJ]6)X"CW)('XU8K'\1@K96LQ_P!5!>P2
M2GT4..?PR#^%5!7DDQI79)+J=S]J2RMK-);P1K).&FVQP@YP"VTDDD' V\@9
MXJO=:Y=6=E-)/II2XBECB"F4^4^]L J^WD<\_+D4LJOIVM7=S)#/+:7L:*7M
MT9VB90PP0N6P0>"!P:P;^TNI[:^DAAU0V#26PBCF>5Y#MDR[*I)=1C'H>*VA
M"+:OY%I)G0OJ]U:W#07UE%&YMY)XC#.9%?9C<IRJD'D=C3[#78+S0?[5>-HE
M5"TD6=Q4@9P/7/&/7(K&DMA)?F73(]2*&SFCN#=+,=P(^15\WG.[^[26>GWB
MR:7:FWE%I<06\UR67A'B3!5AV)(B'/\ =-#A"P<JL:]AKINX-.GEMO)CO=RJ
M?,W;'&<*>!U"G!]>*V*Y"""6/PWH-K)$Z7!OHR(V4A@%=G;C_=!KKZSJ12>G
MF3));!11169(4444 %%%% !1110!LZ?_ ,>:_4_SKQOXP_\ (W6O_7BG_HR2
MO9-/_P"/-?J?YUXW\8?^1NM?^O%/_1DE;8+^/]Y=#^(>?4445[1VA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444$A1112$PH[44=J!!1112$':BCM10(6DI:2@D#2TAI:!"4M)2TB1.]+
M2=Z6@04G>EI.](0M%% !)P!DF@1?T;29]:U2&QMQ@N<LV.$4=2:]TL+*#3;&
M&SMDVPQ+M4?U^M8'@KPX-#TOS9T_TVX :3_8'9?\??Z5T]>9B:O/*RV1(444
M5S %%%% !1110 4444 36O\ Q]1?[PK;D_U3_P"Z:Q+7_CZB_P!X5MR?ZI_]
MTUG/<EG/4445H4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;T
M[_C['T-5*MZ=_P ?8^AI2V$]C8HHHK @\[^*?32?^VW_ +)7G5>B_%/II/\
MVV_]DKSJO0H?PT?*YE_O4OE^2"BBBM3A"BBNI7PE:0?9H-3UR&SOKA0RV_DE
M]N>@9@<#\:3DEN:4Z4ZGP_Y?F<M174P^!KZ2TU-C*!=V+[?(5<B3@-D-GN#D
M#'ITJI;^%Y[S3=,N;:8/-?S-$L3+@)MSDEL], GI2]I'N7]5K+[/]7M^9@T5
MTMSX8LA:7LECKL%U/9#=/$T1C  .#M8G#<\#'7(]12Q^%[.""U.KZW%87%TH
M>.#R6<A3C!<Y&W\?3KUPO:1']5JWM;\5;[[V.9HKH)O"ES:P:NUU,J2:<L3;
M57<LH<G!!XXX]*H:+H\NM7I@26.&.-#+--(<+&@ZDT^=6N0Z%1246M7_ ,,9
MU%=%<^&K9],GO](U:/4$MN9T\EHF0>H!ZCK^568_"%I%);6NI:Y#9ZA< %;8
M0F3;GH&8$ '_ #S2]I$M86JW:WXJWWWL<I16^?##_8=3=+M)+S37Q-;HN04_
MOJV>>AR,9&.:J:OH_P#8\=HD]QNO)8_,E@"?ZD'[H)SR2.V.*:FF[$2H5(KF
M:T_I&71115&05O>#/^1OT[_?;_T$U@UO^"E+>,-/ _O,?_'&J9_"S;#?QH>J
M_,]FN/\ CVE_W#_*L"N@E4O"ZCJRD"LO^S9_]C\ZX(-(^T13HJY_9L_^Q^='
M]FS_ .Q^=7S(=T4Z*N?V;/\ ['YT?V;/_L?G1S(+HIT5<_LV?_8_.C^S9_\
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M=%7/[-G_ -C\Z/[-G_V/SHYD%T4Z*N?V;/\ ['YT?V;/_L?G1S(+HIUOV_\
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M$#>8ZX4$G'!'<FNEM(FAMU1\9&>E5[VTEGF#IMP%QR:B$W&5T["3L[HXC_A
M_#7_ $#?_(\G_P 51_P@?AK_ *!O_D>3_P"*KK_[-G_V/SH_LV?_ &/SK?V\
M_P"9_>7[27<Y#_A _#7_ $#?_(\G_P 51_P@?AK_ *!O_D>3_P"*KK_[-G_V
M/SH_LV?_ &/SH]O/^9_>'M)=SD/^$#\-?] W_P CR?\ Q5'_  @?AK_H&_\
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M:_Z!O_D>3_XJNO\ [-G_ -C\Z/[-G_V/SH]O/^9_>'.^YR'_  @?AK_H&_\
MD>3_ .*H_P"$#\-?] W_ ,CR?_%5U_\ 9L_^Q^=']FS_ .Q^='MY_P S^\7.
M^YR'_"!^&O\ H&_^1Y/_ (JC_A _#7_0-_\ (\G_ ,577_V;/_L?G1_9L_\
ML?G2]O/^9_>'.^YR'_"!^&O^@;_Y'D_^*H_X0/PU_P! W_R/)_\ %5U_]FS_
M .Q^=']FS_['YT>WG_,_O#G?<Y#_ (03PU_T#?\ R/)_\52CP'X:S_R#?_(\
MG_Q5==_9L_\ L?G0--GS_!^='MY_S/[PYGW,K_A6OA'_ *!/_DS+_P#%5CR>
M O#2R,!IO ) _?R?_%5Z)64^G3M(S#;@DGK41KU.LG]XE)]SCO\ A _#7_0-
M_P#(\G_Q5'_"">&O^@;_ .1Y/_BJZ_\ LV?_ &/SH_LV?_8_.K]O/^9_>/F.
M0_X0/PU_T#?_ "/)_P#%4?\ "">&O^@;_P"1Y/\ XJNO_LV?_8_.C^S9_P#8
M_.CV\OYG]X<QR'_"">&O^@;_ .1Y/_BJ/^$#\-?] W_R/)_\577_ -FS_P"Q
M^=']FS_['YT>WE_,_O%<Y#_A!/#7_0-_\CR?_%5+;>#/#]I<QW$.G 2QL&4F
M5V (]B<5U7]FS_['YT?V;/\ ['YT>VE_-^(7*=%7/[-G_P!C\Z/[-G_V/SJ.
M9!=%.BKG]FS_ .Q^=']FS_['YT<R"Z*=%7/[-G_V/SH_LV?_ &/SHYD%T4Z*
MN?V;/_L?G1_9L_\ L?G1S(+HIT5<_LV?_8_.C^S9_P#8_.CF071#:_\ 'U%_
MO"MN3_5/_NFLZ"PFCG1VVX4Y/-:+@LC =2,5G)ILEG/45<_LV?\ V/SH_LV?
M_8_.M.9%713HJY_9L_\ L?G1_9L_^Q^=',@NBG15S^S9_P#8_.C^S9_]C\Z.
M9!=%.BKG]FS_ .Q^=']FS_['YT<R"Z*=%7/[-G_V/SH_LV?_ &/SHYD%T4Z*
MN?V;/_L?G1_9L_\ L?G1S(+HIT5<_LV?_8_.C^S9_P#8_.CF0713HJY_9L_^
MQ^=']FS_ .Q^=',@NBG15S^S9_\ 8_.C^S9_]C\Z.9!=%.K>G?\ 'V/H:7^S
M9_\ 8_.I[2SE@G#OMQ@C@TFU839H4445B2>=_%/II/\ VV_]DKSJO1?BGTTG
M_MM_[)7G5>A0_AH^5S+_ 'J7R_)!1116IPA7<:M9:9XFU*/5X];LK:*95^T0
MW$NV6,@ $*IZ\#_]=</14RC=W1M3JJ"<9*Z?Z'H][XL@DT[5;VQN8TF2[A-N
MCMAY%7:"=N<D'G\*L3>(M%LTT6[MY4$#3R230JX9X?,5MV0.1AF_PKS"BL_8
MQ.G^T*E[V_J]SI+GP]I=E:WMQ+KUI, I^R1VT@=W;/&\?P\=?<]>,'2U2VL?
M%<UIJ46LV-F?*2*XANI-K1D==N?O#GV''7KCB:*OD>]S%5XI./)H_4]&EU33
M]>77K:"_M;=)(+:"WDNI/+$FPL2>>>_IZ5EZ3!::)+=:?>ZM8/%J=NT(N+67
MS1"W8MP, Y_3M7&T4E3LK7+>,<FI..J_5O\ S.RM$L_"VDZD\FJ65Y=WD)@B
MBM)/, '<L>W7]*T&.FZGKHUV"_T9HKF-5N+;5#\T1 4':O<X'!Z=:\]HH=/K
M?4%B[)1Y=%_7ZG96&J:?%\1Q=6$T5MIKG;D 1)M\OG@XP-P_.N:UBX:ZUJ]G
M:7S=\[D/G.1GC'MC&*I452@D[F,Z\IQY7W;^\****HQ"N@\$$+XQT\GU<?\
MCC5S];W@S_D;]._WV_\ 034S^%FV&_C0]5^9[4S!%+,< #)-5_[0M?\ GK_X
MZ:DN?^/6;_</\JYVO.2N?9&]_:%K_P ]?_'31_:%K_SU_P#'36#13Y4!O?VA
M:_\ /7_QTT?VA:_\]?\ QTU@T4<J WO[0M?^>O\ XZ:/[0M?^>O_ (Z:P:*.
M5 ;W]H6O_/7_ ,=-']H6O_/7_P =-8-%'*@-[^T+7_GK_P".FC^T+7_GK_XZ
M:P:*.5 ;W]H6O_/7_P =-']H6O\ SU_\=-8-%'*@-[^T+7_GK_XZ:/[0M?\
MGK_XZ:P:*.5 ;W]H6O\ SU_\=-']H6O_ #U_\=-8-%'*@-[^T+7_ )Z_^.FC
M^T+7_GK_ ..FL&BCE0'017<$S[(Y,MZ8-2NZQH7<X4=36-IG_'X/]TUI7_\
MQY2_3^M)K6P!_:%K_P ]?_'31_:%K_SU_P#'36#13Y4!O?VA:_\ /7_QTT?V
MA:_\]?\ QTU@T4<J WO[0M?^>O\ XZ:/[0M?^>O_ (Z:P:*.5 ;W]H6O_/7_
M ,=-']H6O_/7_P =-8-%'*@-[^T+7_GK_P".FC^T+7_GK_XZ:P:*.5 ;W]H6
MO_/7_P =-']H6O\ SU_\=-8-%'*@-[^T+7_GK_XZ:/[0M?\ GK_XZ:P:*.5
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M8@R\@X/RFK-<W+_KI/\ >-)*X&W_ &A:_P#/7_QTT?VA:_\ /7_QTU@T4^5
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M .)H_P"$Z\2?]!'_ ,@1_P#Q-<[17J^RI_RK[BK'1?\ "=>)/^@C_P"0(_\
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M]3_.O'?C#_R-UK_UXI_Z,DK?!_QAK<\^HHHKV"PHHHH **** "BBB@ HHHH
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MGO=2N+-K*X$<>RX,:0QA596*YVMN)/+ @CCM6Z-/LA;R6XL[<0R'+QB(;6.
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M 'A6]+_J7_W342W YNBBBK **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\[PW]];0W$GFRP02*JLW<YQN7/?:PH7P_:+>+="2;>MV]X!N&-[)L(Z=,?\
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M\CQ__%4G_"">)/\ H&_^1X__ (JO:**7URIV0<S/%_\ A!/$O_0-_P#(\?\
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M+7_GD/S-'V"U_P">0_,U0_M&X]5_*C^T;CU7\J+,.=%_[!:_\\A^9H^P6O\
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M:[D9=2LR">HG7T^M0?VQIG_01M/^_P"O^->34E'U==R?[5G_ "H]:_MC2_\
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MG?[[?^@FL&M[P9_R-^G?[[?^@FIG\+-L/_&AZK\SV>X_X]I?]P_RK K?N/\
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MZB_WA6U+_JG_ -TU+-(;'/T4451F%%%% !1110 4444 %%%% !1110 4444
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MIKT;_A M+_Y^+S_OM?\ XFD_X0'2O^?B\_[[7_XFE[: _P"SJYYP:;7I/_"
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MA?B+_H&2?]]K_C7K?]O:/_T%;'_P(3_&C^WM'_Z"MC_X$)_C1]9EV#^QZ/\
M,_P_R/)/^$+\1?\ 0,D_[[7_ !H_X0OQ%_T#)/\ OM?\:];_ +>T?_H*V/\
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M8KG_ )Y'\Q6QYT7_ #T3_OH4>=%_ST3_ +Z%','(C'^Q7/\ SR/YBC[%<_\
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MHH **** "BBB@ HHHH *W/!__(V:?_OG_P!!-8=;G@__ )&S3_\ ?/\ Z":
M/89O]1)_NG^59-:TW^HD_P!T_P JR: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** +%G_Q\?@:N7/_ ![/]*IV?_'Q^!JY<_\ 'L_TH RZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "M:'_41_[H_E636M#_J(_P#=
M'\J ,^Y_X^7^M0U-<_\ 'R_UJ&@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** -*T_X]E_&JU]_KQ_NU9M/^/9?QKCO&7B2\
MT?5XK>WC@9&@#DR*2<[F'8CTH WZ*\__ .$YU/\ YX6G_?#?_%4?\)SJ?_/"
MT_[X;_XJ@#T"BO/_ /A.=3_YX6G_ 'PW_P 51_PG.I_\\+3_ +X;_P"*H ]
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MZ_X^7J&IKK_CY>H: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4FU8G[R#JGU'4>V?2O7H?]1'_NB@#/NO^/EZAJ:Z_P"/EZAH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H'444#J* -FLA_\ 6-]36O60_P#K
M&^IH ;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $D'^O3Z
MUIO_ *MOH:S(/]>GUK3?_5M]#0!D4444 %%%% !1110 4444 %%%% !1110
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MQ6__ %Z+_P"AO7I-I_Q[+^->;?$?_D8K?_KT7_T-Z ./HHHH **** "BBB@
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MD'^O3ZUIO_JV^AK,@_UZ?6M-_P#5M]#0!D4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 58L_\ CX'T-5ZL6?\ Q\#Z&@#1HHHH \_^)O32
M_P#MK_[)7G]>@?$WII?_ &U_]DKS^@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "MSP?\ \C9I_P#OG_T$UAUN>#_^1LT__?/_ *": /89O]1)
M_NG^59-:TW^HD_W3_*LF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"Q9_P#'Q^!JY<_\>S_2J=G_ ,?'X&KES_Q[/]* ,NBBB@ HHHH
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M[3!;W,#V[2K= "9IYGE=@.GSL2PQU&#P>1@U-9:39Z?+)+ DAFD #RS3/*Y
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MHHH D@_UZ?6M-_\ 5M]#69!_KT^M:;_ZMOH: ,BBBB@ HHHH **** "BBB@
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MBM'[%%_M?G1]BB_VOSH SJ*T?L47^U^='V*+_:_.@#.HK1^Q1?[7YT?8HO\
M:_.@#.HK1^Q1?[7YT?8HO]K\Z ,ZBM'[%%_M?G1]BB_VOSH SJ*T?L47^U^=
M'V*+_:_.@#.HK1^Q1?[7YT?8HO\ :_.@#.HK1^Q1?[7YT?8HO]K\Z ,ZBM'[
M%%_M?G1]BB_VOSH 6T_X]E_&JU]_KQ_NU>C01H%7.!ZTR6W25MS9SC'!H RZ
M*T?L47^U^='V*+_:_.@#.HK1^Q1?[7YT?8HO]K\Z ,ZBM'[%%_M?G1]BB_VO
MSH SJ*T?L47^U^='V*+_ &OSH SJ*T?L47^U^='V*+_:_.@#.HK1^Q1?[7YT
M?8HO]K\Z ,ZBM'[%%_M?G1]BB_VOSH SJ*T?L47^U^='V*+_ &OSH SJ*T?L
M47^U^='V*+_:_.@#.K6A_P!1'_NBHOL47^U^=3JH50HZ 8H S;K_ (^7J&M)
M[6.1RS9R?>D^Q1?[7YT 9U%:/V*+_:_.C[%%_M?G0!G45H_8HO\ :_.C[%%_
MM?G0!G45H_8HO]K\Z/L47^U^= &=16C]BB_VOSH^Q1?[7YT 9U%:/V*+_:_.
MC[%%_M?G0!G45H_8HO\ :_.C[%%_M?G0!G45H_8HO]K\Z/L47^U^= &=16C]
MBB_VOSH^Q1?[7YT 9U ZBM'[%%_M?G1]BB_VOSH L5D/_K&^IK7JN;.(DD[N
M?>@#.HK1^Q1?[7YT?8HO]K\Z ,ZBM'[%%_M?G1]BB_VOSH SJ*T?L47^U^='
MV*+_ &OSH SJ*T?L47^U^='V*+_:_.@#.HK1^Q1?[7YT?8HO]K\Z ,ZBM'[%
M%_M?G1]BB_VOSH SJ*T?L47^U^='V*+_ &OSH SJ*T?L47^U^='V*+_:_.@#
M.HK1^Q1?[7YT?8HO]K\Z *4'^O3ZUIO_ *MOH:B6TC1@PW9!SUJ8C((/>@#'
MHK1^Q1?[7YT?8HO]K\Z ,ZBM'[%%_M?G1]BB_P!K\Z ,ZBM'[%%_M?G1]BB_
MVOSH SJ*T?L47^U^='V*+_:_.@#.HK1^Q1?[7YT?8HO]K\Z ,ZBM'[%%_M?G
M1]BB_P!K\Z ,ZBM'[%%_M?G1]BB_VOSH SJ*T?L47^U^='V*+_:_.@#.HK1^
MQ1?[7YT?8HO]K\Z ,ZK%G_Q\#Z&K/V*+_:_.G1VT<3[ESGW- $U%%% 'G_Q-
MZ:7_ -M?_9*\_KT#XF]-+_[:_P#LE>?T %%%% !6WX3L+;4_$,%K>1>9"RN2
MNXC.%)'(YK$K6\-:I!H^MPWMPDC1HK B, GD$=R* -.*WT77-,U!K+3GT^ZL
MX3<*1.TH=1U!W=/\_2KS^']('C&SL&3RK:2U63R_,;]X_/&2<C/MZ5F?VMHN
MFZ=>PZ/#?-/>1^2\EV4PB=\;>Y_S[NU#7-(U+78;F[LKB:S%LL++NV.K#/S#
M!Y^A- %]=%TZ7Q-IMG/HUS8^9Y@GMWE+QOA204D!R3TSCC]<MUS2(['3;F7_
M (17[*B_*MS_ &AOVY. =N>:D3QAI\$^F1QKJ$]O:2/(\MRRM*<JR@#G&/F]
M>U9-Q)X4E=Y5&L^8[[B&$6WD\^_K0!=B\/V+^&@FS.LR6QO4PS']V#TQTR5]
MNM1^%](L[_3;VX>R_M"\B90EI]H,7RGJV?S_ "J9O'EX-:$D3,-*#@"V,:9\
MO&#SUSWZU0LK_0(+BZ9X=1A/G%[:YM9 LJ(?X""<<>O).: -71]$TV]O-:\O
M2+F;R/+,%I<R&%U+9RI(/Y9[54U72[6&_P!.MKO1_P"QHIY</+]L\[*\9]EQ
MGJ?6K4GBW2[ZXU07EO>);W<4<*&':7PI8Y.3@$Y]ZPYI?#D,]O):6^H7"*_[
MZ*Z=5#+CL4Y!H U/%>E6.FP,D>CW%E()<13K*98I4]R3\K<9Q[5R5=3J'B#3
M/^$?N-+TY=0=)W4@7;J5A4$'"8)..,8KEJ "BBB@ K<\'_\ (V:?_OG_ -!-
M8=;G@_\ Y&S3_P#?/_H)H ]AF_U$G^Z?Y5DUK3?ZB3_=/\JR: "J^H2O!IMU
M+&=KI"[*<=" 2*L5!>PM<V%Q A :6)D!/3)!% ')3^(KE=#62.ZG^WBQLIW)
MCC\O]XX#$<9R><CH.,5M?\)/9M%)-#!<S0^<(()8U4K<R?W8^><8/S'"\'GB
ML6?PA>SV,ELTEL0^GV=J06;!:)]S]NA'3^E37/A2Y:![*$64NGP72W=G!<@L
MJG!#1,,$;/F8@\D9Z'% '06&J1WTL\!@FMKFWV^;!,%W*&SM.5)4@X/0GH:Y
MV\UMUUJ]L[_6WT61"19HT2"*5 H/F%W4@Y)P0&7ICKDULZ+IAL&N)&T[2['S
M"H6.Q3G [L^U=W)X&T8]3GAL\6N*UU"L>GW]K,3L^TR&(HIZHRJC!U'KD$C@
M^M %%O$5[::HL%[:AH8M,:[GDM2K(6')*EF!V\$ 8SD^G-7$\2)(EMLTV^::
MZ7S((/W>]XP 2_W\*O('S$')QBLQO"MY;0);VDL$L9TF33V>5V0ACDA@ &XS
MQC/ [FM!])OK:YTV^LC;R7-M:FTEBF=D1T.TY#!200RCMR/2@!1XJM9&M(H+
M.]GN+GS0($10\;1[=ZON8!2-WK@XX/(R6?BFVO/LCBSO8X+J4P)/(BA1*,Y0
MC=NSE2,XVY'6J^G^';NVU:SU">6!I US+<JA. \NS 3(Y "8R<?3T2'P[=QZ
M1IEH98?,M=1:Z=@QP4,DC8''7#CKQUH NCQ%&+FVCETZ_@ANIC##<2HH1FP2
M.-V\9VG&5%-T'5)9_"<.I7TAD<1O)(P4 D*6[# Z"L2'PGJ7VC39ITL&N+6Z
M2>>]:9Y)[@#C&67Y!CG:"1G'3OT.B:4]AX=ATR[,<A5&2383M())]CT- %*U
M37-0TF'4X]2$-U/&LT=H8T-NH(!",=I<\=6#=>0,<5:G\0)!).@L;J?[*H-T
M]N%98"1G!RP+$#G"@G&/6JJ:?K]MI(TBWGL_*2,017[2.)43 &?+"X+@< [Q
MD@'VJI+X4:&\NY(M/TK4EN K++J0S)$X4*<G8Q<':#C*\Y]<T ,GU^\;4YEM
MKH&V_M"RBBPB_P"JD12PZ9YSUZUM66O1W\T8AL;TVTKND=UL4QL5)!SABRC(
M/+*/U%9;^&;O[8\B/:K&;RSG54!0!(5 8!<''3@9/'>G1^'[S^VXKX06%G(L
MQ>>YLY9$:Y3).UXL!<G(R2S=#Z\ '44444 6++_CX_ U>E<QQ,X&<51L_P#C
MX_ U<N?^/9_I0!6^W/\ W%H^W/\ W%JI10!;^W/_ '%H^W/_ '%JI10!;^W/
M_<6C[<_]Q:J44 6_MS_W%H^W/_<6JE% %O[<_P#<6C[<_P#<6JE% %O[<_\
M<6C[<_\ <6JE% %O[<_]Q:/MS_W%JI10!;^W/_<6KB-NC5O4 UD5K0_ZB/\
MW1_*@"O+=M'*R!0<4S[<_P#<6HKG_CY?ZU#0!;^W/_<6C[<_]Q:J44 6_MS_
M -Q:/MS_ -Q:J44 6_MS_P!Q:/MS_P!Q:J44 6_MS_W%H^W/_<6JE% %O[<_
M]Q:/MS_W%JI10!;^W/\ W%H^W/\ W%JI10!;^W/_ '%H^W/_ '%JI10!;^W/
M_<6C[<_]Q:J44 6_MS_W%H^W/_<6JE% %O[<_P#<6C[<_P#<6JE% %O[<_\
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MM?\ V2O/Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W/!_\
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M5VX!Y/.X]!P,Y"V/A[4M+FM[RV:UEN8VN4DBDD94>.63S!A@I(8$+V(//UH
M=/XG>35=)%E#=2QW"W*36BQJ)1(FSAMQ 4KEOX@#[\5I6?B*TO9[.!(ITEN?
M. 5U ,;1$!U;GKD]LBJ.G^';NVU:SU">6!I US+<JA. \NS 3(Y "8R<?3TC
MB\/ZC97L5];_ &2::.\NY/*DE9%,<S;A\P4X8;5XP1UYH N'Q3;-<QVT%E>S
MSR33PI'&J<F%@'Y+  <Y!)'3UP"6?BFVO/LCBSO8X+J4P)/(BA1*,Y0C=NSE
M2,XVY'6J>D^'=0M-3M;RZEMF,<MY))Y9;GSF5EP"/]DY_K3XO#ETNCZ;9O)
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M^1BM_P#KT7_T-Z])M/\ CV7\:\V^(_\ R,5O_P!>B_\ H;T <?1110 4444
M%%%% !1110 4C4M(U $#5"U3-4+4 0M4+5,U0M0! U0M4S5"U $#5Z7\-/$^
M]?[!O)/F7+6K,>H[I^'4?CZ"O-&IL4\MM/'/ [1RQL'1UZJ1R#0!]+UK0_ZB
M/_=%<;X4\11>)-&2Z7:MPGR7$8_A?U^AZC\NU=E#_J(_]T4 9]U_Q\O4-377
M_'R]0T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#J**!U% &
MS60_^L;ZFM>LA_\ 6-]30 VBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ>7#!)(Q9/O855)(!(!/3/&:IOXJM/[6L[:(-):W%J]S]H6)V  QCHON<^F
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MT/\ J(_]T?RK)K6A_P!1'_NC^5 &?<_\?+_6H:FN?^/E_K4- !1110 4444
M%%%% !5.[U*&TN(K=EDDED5Y-L8!VHHY8Y/ S@?4CWQ<KG),_P#"4ZN)<Y_L
MR/R?3;NDW?KM_3VH M6&O2ZC!;W$&BZC]GN K)*S0 ;3W(\W./PS39/$L")/
M/'8WLUC;NR2WD:H8UVG#G!;>0O.2%/0XS53PA8W \.Z1.=5O&C^S1G[.5AV8
MV],[-V/^!9K*GETZT^W7.EZW=:1J)+YTR9E8-+G/$+9)+\8*'G(QZ4 ==::I
M;WM[=6L.XM;K&S/@;6#C(QSZ"LN]US3998UDTR6\FBU VL*>7&2)E7?N4NP
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MY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\
M/-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFW
MY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\ /-ORH\J3_GFWY4 ,HI_E2?\
M/-ORH\J3_GFWY4 +!_KT^M:;_P"K;Z&LZ&-Q.A*,!GTK2?[C?2@#'HI_E2?\
M\V_*CRI/^>;?E0 RBG^5)_SS;\J/*D_YYM^5 #**?Y4G_/-ORH\J3_GFWY4
M,HI_E2?\\V_*CRI/^>;?E0 RBG^5)_SS;\J/*D_YYM^5 #**?Y4G_/-ORH\J
M3_GFWY4 ,HI_E2?\\V_*CRI/^>;?E0 RBG^5)_SS;\J/*D_YYM^5 #**?Y4G
M_/-ORH\J3_GFWY4 ,JQ9_P#'P/H:B\J3_GFWY5/:(ZS@E6 QW% %^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF5F;E#T&3D?*.<:1\?V44)^U:3JMM=F2W1;*6./SG$Y(C8;7*[2RLOWL@@Y
MH ZVBN6TKQS9ZIJ5O9?V;J5J\T\UH'N$C"+<1!B\1*N<D*I.0"I'1LY%4O$W
MBV]TG79;$7VDZ5$EJ)[>75HW$=Z^3NC27>B(1\N<[F^;.W Y .VHKF)O&D%G
M,D-YIM]&\:0&_=-CQV+S<*DC;LL<]2@8 $$X!S5=?B!;2W$<,&B:M,TU[-8P
M%%A FEBW^9MS*, ",G+8ZCWP =?17)S_ ! TVVBN9YK+4%M(X;F6&Y,:;+KR
M 3(L?S;LX5L;@H;:2"1S5#5?B'+#8,]AHE\+Q+FR#6]RL0+07$FU9%Q*!SAE
M )!#$;@!D@ [NBN>M_&%C<ZRM@MK>+#)<26D%^RIY$T\8)>-3NW9&UQDJ 2C
M $]ZOB6_\1:?JNE1:=>Z6EMJ-X+15N+"21XCY4DA8LLRAO\ 5XQ@=>O'(!U=
M%<39>-KFWUV_TO5K-Y([>_M[!;ZTA"0B26*,C>&D+#<[D#:&P"N3W-J7X@:;
M!!<7,MEJ"6B6]S<07!C39=K "9!'\V0< D;PNX D9'- '645RUUXW2RL%OI]
M UI+41">:4QQ;8(R2 S'S/FX&[:FY@,9 ) I\?C>Q?57LC8W\<*7QT]KUT00
MB?&0OWMW/&#MQD@$@\4 =-17'M\1M+BL9KV:QU&&V%JU[:R/&@%[ &"EXAOS
M_$AP^TX<''7#];\8R6&M6NF6.GS7$GV^"VN6(3:JRHS#;EP<_+Z=C[4 =;17
M)67CB&>UMC'97U_,\7G7'V2W5?L\1D9 [H9"<$JW"%V.TG':M+2?$D>L7;1P
M:=?I;$RB*\=$,,IC?8P!5BRG.<!PN<'&<&@#;HK(U_59]+_LOR$C;[5J$5J^
M\$X5LY(P1SQ638?$'2[PK)-:7]E9O!<7$=Y=(@CD6 @2XVN6&W)ZJ,@'&: .
MMHK+T;6CJZR%M,O[!D".JW:*/,1@=K*49AV.02&'<#(SJ4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD!EE(4*#\PR2!SL:MH_]J7>D3^?Y7]G7OVO;LW>9^ZDCV]1C_69SST]ZU**
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gizttcucplmb000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000020.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M6_\ '0\.Z]H.C_8I]';5+#Q!H]\\UI>,)$3RPK(&0@.K$Y8$,I!Z@?._PO\
MV_\ QM\5OCQXY^$>C_"VQD\2^'9[VT2^_MQA8F2VG,+RSL8 Z1$CC:KL2RC;
MC+* ?;Y-?/?BO]N#X=>!?C=I?PGU^#7=,\8ZG?6UC:0R6(:&5KB01PN)%<C8
MQ8<]1SD @BN2_9U_;:U#XC?'CQ5\%_B%X4M_!WQ!T5I&A6PO3=6E[&@#-L8J
M&!V,)!D<J?X2"*^2?VVO^4KGP3_["'AO_P!.- 'ZTT5\Y^,/VLX$_:6@^!GA
M:TLI/&+:>U_)>:S+)':*=GF"%!&C,\ACRW)4  \D\5S/[+G[<$OQP^-'C_X4
M>(_#4.@>+O"EQ=Q&?3[AI[2Z6WN/(D(+*&4AMIYSD'L1B@#ZRHKXND_;R\4Z
M#^V%8? CQ1\/]+T.:^NEBM=<&M22Q7$3H7A=$^SCYGQLVD@!\C)QFOHO4/'G
MB:/XV:=X.L- LKO07TI]3OM9>]=9;3$BQQQ>5Y9#-(=Y7Y@,1/0!Z+2U\X:5
M^U+J/Q4^.GC/X;_#'2=.U$^#;7=K&NZQ<2);?:V)6.VB6-2S'<'#.< >6V W
M%5_A9^W-X1\<?L_^+?B3K%I-H-QX->:V\0Z,&$LEO<Q]$C;@2"0D!&XY.#C!
MH ]C^+'Q0T_X.^"M0\5ZS8:E>:-IT9GO)--A69[>(#)D9"P)4?[()]L5@?L\
M_M&^#?VG?!=[XI\$37D^E6FH/IDK7UL8'$R1Q2-A23D;9DY^M?+GB;]I'XB_
M'S]BKXB?$%_A_IVF>"-3TK4+>SMX=3>34Q H:(W+(8Q&5#!LJ&!PI(SP#6_X
M(J_\FL^*?^QSNO\ TAL: /O^DR*H:YK5EX<T>^U74KA+33[&![BXN)#A8XT4
MLS'V !KXSUK]OSQ+=?L]Z_\ '+POX&L;[X?Z;JZZ?#:7UW(FH74 E6)[DA4*
M1C>Z@*2>A)/:@#[<HKXN^/G_  4 UGX4_ [P!\7/#WP]B\1^#/%4,9;[9J;6
MEU8SNI94=!"ZLIVL-P;JOH0:]>N?VA-3O/V9]"^*7A_1M-UO4-8M;&>UTA=0
M=(Y9;J2.-(%E\K.\22A,%!R#G% 'M5]?6^FV=Q=W4R6UK;QM++-*P58T4$LS
M$]  "<^U.L[J'4+2"ZMI5FMYD62.1#E75@""#Z$$5^<G_!7+XR?$WP+\*/#_
M (;MTTO1O#GBG?:ZI<6-W)+=3NJ*SVX!156$AL%LDOTPHSGZA\+_ !EU7X0?
MLXR^-?BOINC^'](T72K66V_L/4I;][J/R5"*PD@AVRLQ50HW#+?>H ^@:*^,
M9OVWO&NF_LV:?\>[_P !Z8/ ]U>?-I$.H.=3CLFG,*3[BGEEBPW;.."/FK<_
M:Y_:2\2Z3^QW<?%'X2RZ?)8ZC813C5[R9EGM(9F5 \,00JTH+D?,P"E<_-TH
M ^I-+U>RURU-UI]W%>6PEE@,L+AE\R.1HY%R.ZNC*?0J15W-?%7_  3%\3>.
M)OV6O!UQKFG:(G@H1:K=#7WUB9]0EE_M*Y:1I;=K<(J[C+\WG-PJG') V?AY
M^VIXB^/6E_%'Q'\,?"NF7WA3P6&CM[C5KN2.;6941I&6)50B)2B\%LG+KP.<
M 'UY2UX7^SW^T]8_M0_!&;QKX$L8CK4+/;3:)J=R8Q;W:@-Y3R*K?*RLK!@I
MX8=.<>(_ /\ X*,:G\6/%OQ!\+>)O MEX%\1^$[&:X.FW6JR3S7,T;[&A4+
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M"![K^U?^U?I/[,?P5L_'4EC_ &O-JES!9Z7:.[1I)++&T@:1E5BJ*B,QP">
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M>RJ .?I0!XW^W=H>G:_^R#\5H=2M8KN*#0KB[B64<)-$OF1./=752/I7R_\
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ME![L 5_&OD#_ ()'_'3P9JG[/^J?#/7-2L+36-'OKB=K'4G54NK.;#[EW\,
MWF*R\X^4G@BOT>KP#7/V#?@/XB\<S>+K[X<:7+K,UQ]KF*M(D$LN=Q=X581D
MD\D%<$DY!R: -[XS_#7PQ^T]^SMXA\)V,EO>:/JUB\>FW5KQ$DT1)@EC.,%5
MD1<%?E('&0:^*/\ @E/XE\3^*-)O/A;KNFS1Z=\-]:GU"6:<$!)I \<5J5)S
MN6;[3+R.-B]^:^K/V@?VN-%_9C^)'PR\':KX8N/[ \53?8VUV&18;32P'2-
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M:Z@C!4&1%W#NK#^&O,/^"@WA>7X5_M&:%^T?X)T6.;1-/UNWL]1G<1M!=:G
M=SNJ\X4JOE%R/]9$^.Q/ZJVOP_T#3O!<?A/3=.71O#T4 MHK+2)'LA%'_=1H
M65D^JD'D^]<#??LE?"K4OAM;?#Z[\,R7'@NVG^T1:+)JMZ;=7R6SCSN@8E@.
M@)SC- &;\1OB=H/Q2_8U\7^-]$O%DT+5?!][>Q3.0/+5K5RROZ,IRI'8J:_.
M_P"!_A#5O'O_  2 ^*6F:#$;N]@UY[V6VC.6>*"6SGD&!W$:%P.^T5^E.C?L
MJ_#'P_\ #?4?A_IOAZ>R\&Z@Q:YT:'5KU8),_>7'G<*W\2@@-W!K2^$?[._P
M^^!-CJ%EX$\/_P#"/V%^_F7-G%>W$L$CX"[_ "Y)&4,0 "P )  )P!0!\H?\
M$N_C=X$\4_LEV7@C7-4TB&^\,27,=]IVJRQJ#;O.\Z3%9."GSL,\X*&JW_!7
M[6M.U3]D+P]>65Q')9WVOV<EHP!42H8)V!4$="HSTZ5[_9_L$_ 2Q\;#Q5#\
M-=)751/]H"?.;82$YR+?=Y6 >0-N >U=O\7/V=?A[\>+?3[;QYX>_P"$AL]/
M8M;6DU[<1P1L01O$<<BKNP2-Q&0"1TH ^(?^"@?[_P#X)E?"^2+]Y'MT%MZ\
MC'V)N<^AR/SKZ\_8SU*SN?V6OA':Q7,,EQ'X2TQGB5P64>0JY('3E6'X&NK7
MX"^ _P#A5O\ PKB?P]%?^"1"(%T?4)Y;J)(U(*HAE=F4+@;0I&W QC%>?>,+
M7P7^PA^SWXFU_P  _#X3V&F!;E](TZ5EENG9U3<\S!VPN[.XAL ' H ^$8?#
M/C3]CW_@HIKOA#P,GEZ7\3K>2/2V:/?%;BY+,DY7(!^RS!R1GE 1QOS7ZN^&
M]!M/"N@:;HU@K)9:?;QVL(=BS;44*,GN<#D]^:\"^$^M>%?VJO&7@#XPZ?8*
M$T#0I?(9CN:"\O5C+PE\ ,88T8''&9^Q&*^D: /G7]O#XU>$O@9^SUJ>K^+_
M  O9^-+74;J+3+/0=1A$MM=W3!I4$H*D!56%WSC^  <D5^9?[;_BFV\9_LN?
M!'6IO%VFZSK5\TDTN@Z&\<.GZ'"84$=K#:H?W00#82Y+$J><  ?LG\2OACX7
M^+_A&\\+^,=$MM>T*[VF6TN@<;E.592#E6!'# @UP.H?L;_!;4OAO;^ Y?AW
MHX\+6]P+N.SBC:-A.!M\TRJPD+[?E+%B2.#Q0!X'^WY\*?!7QJ_97\(WFK^+
M[7P[?Z=):C1+T@3QWES-&L8M=JGDOP=P/R[<GY0:D^./[+7CW]L/0_A7X<\;
MIHOA'2O#++<ZU/I^HF^FO9/*1&2W0(H13M;YF;C<.#CFO_P40^$_A1?@7\//
MAQ9>%IM$\+OKMO:P:[I:E;/PPN"IN9XU4^8A#ME25R<G>#R?F?QQ_P $V_!7
M@_PO/XA\&_M'K=Z]I4)GBM+6W2XN+NY !BC@$%QYB.SC  5SDCTH ^K?^"D7
MQV\*? 7X=>"]'O\ P7H7BW7-5NG705\1VBW%GIIMQ&KW+ C)*":/"@C.3S@5
M\:?M:WUB?VU/V>[G_A.T\=W CT674=;6YC:#SO[3=G"+'\D,8&"$'0')R22?
MT.^'_P"SY%\;OV9_AOHO[0WA^#Q3XJT^SCN+G[<[^?#,<@;Y$8,9/+V*_."P
M.<UUOB[]C_X,^.-+\.:=K'PZT2>P\.Y&F6\,'D);J2&9,1E=RDC)5L@G)/4T
M ?&/_!:;4K23P=\'D6YA<SZK=SQ;7!WQK'%N=?51O3D?WAZT_P#X+&2*_P"S
M3\*2K!@VK1D$'((^QOS7VC\4_P!D_P"%/QLN-+F\:^$8==_LN#[-8PRWES'#
M:Q\ K'&DBHF0JYPHSM7/04SQY^R7\*_BAHV@Z1XL\,2>(--T.+R-.MK[5;V1
M;=< <?ON3@ ;FR< #.!0!\!?\%464?LE_L]+GDI$<?\ ;C'S_GUKZP^,'PO\
M!_&S]E3X6> /'5[)I7_"10Z;9:)J4*J6M=2&G22Q,-W&"D4JXXW;]N1G(]%\
M;?L=_"'XD:/X>TKQ1X2.NZ?X>MFM-+M[W4[QUM(B1E5_??[*C)R<*HZ* .JU
MCX%^"/$7@/2?!FK:%'JWAG2F1[.POYY;@1,BLL9#NQ?*!SMRWRX&,8% 'YT?
ML>V'QC_8S_;"T?X ^(+_ /MWP5KUO<7MJD;%[=8MLCBZ@!YA.^)E=#P2Q/)*
MM63X7D6S_P""W%T\["!?MEX=TA"C!T23'YY'YBOTI\#_  '\&?#WQ-=^(]+T
MZYN/$-U;+9/JVK:A<:A=+;J<K DL\CLL8/.U2!G\*R_B)^RU\*OBQXTT[Q;X
ML\$:9K?B&Q"K%?3JP9E4Y59 I D R<!P1S0!Z=8WD&I6D-U:S)<6TR+)%-$P
M974C(8$=01WKX*_:N_:0\-6'[8W@7X;Z3I_ASPYXRC:*+4/B3KEC#)<:-;RQ
MM)Y-K)(,+(R-@.V5!FQC);'WU'&L,:HBA$4855& !VQ7EWQ'_9=^%/Q<\9:;
MXK\8^!]*U_7]/01PW=W&3E 256100LH!)P'# 9/K0!^>7[..H:-9_P#!6SQI
M)9:Z-5TQK&Y2#5+J]%P;G_18,L92?G)(;D'''' K]8!BO*M0_9;^%.J?%"T^
M(=WX&TJ?QA:+&(=1:,_(8QB-O+SL+J ,,5R,#!X%>J[: /RV^)EO;W__  6E
M\%13*LB)# ^UNSII\SJ?J&"G\J_2GX@>*=-\"^ _$GB36E+Z/H^FW.HWJB/>
M3!%$TD@VXY^53QWKSW5/V1?A1K7Q''Q O/#$T_C19UN$US^UKU;E' PI5Q,-
MH X"C  XQCBO6KRPM]0L9[*[@2YM)XVAEAF7>LB,"&5@>H(SG/J: /R USXQ
M>'_C+^Q7\;=7T^XT#X<Z+%>10Z)\./#GDVA<FXMV>ZN@H#W$C*>@ 0;#P2 1
M]4?\$V;ZWD_X)[VD$=Q&\\$6L&6)7!9,SSD;AGC(]:]\\&_L=_!?P!I6O:=H
M7PZT2TM-=A>VU!7A,S3PO]Z+>Y+!#_=4@< BM+P5^S+\,_ASX!U;P9X9\+0Z
M)X>U?<+^WLKB:.2Y##!#S!_,(VDC&[H2* /ST_X).L%_9G_:!9C@")B2>G_'
ME+6C_P $>?"^E^-O@3\;/#^MIYFCZI<0V5XH?8?)DMI%?YNW!//:ON3P?^QU
M\(OA_P"'O$>A>'/"1T?1_$5M]DU6RM=3O%BNXO[KCSNX)7(Y(9AT)%0:'^SS
M\.?V<? OC2[^'_@.=!=:9,UUH>F7MPYU+;&Q$2I)(R^8PRH8#/S$ \XH ^2_
MV3O@UXE\,_LZ?%GP%\/-0T'QKX*\6WU];:-XLN;_ .R8+1_8YW> (S%5\K@J
M?F(R/E()])C_ &/9?V>?^">?Q)^'&AW3Z_XDU+3+S4+ZYA4J+FZ:)0RQKR0H
MCB50.^"3C.*^0_A+_P $\OAK\4O B:_<_&C_ (5[K&HR2-'X5OUB:?1GW'_1
MIQ))$\S*,?-MCR"..Y^K_P#@G#\+?'7PC\1?$WPU>>+;SQI\+]/FM[?0=7N8
MI(H+F?:6G:V1W;$:[@I*,4++D$\X /,/^":.H?#7XQ?LIZI\-O%NMSQSZ;<7
M4>I:)<:N]M#/9ROYPE"!@"F696(Z%"3U%??WP7\*>$O!/PVT?1? MN;7PI:K
M(M@F]W4H9&)96<Y96))5LX(((R"*\XU#]@WX#:EXZ?Q=/\.-,.L/<?:W\LR)
M \N=Q9H PC.3R1MP>XY->^1QK"BHBA$48"J, #VH _,[_@LCX5U-M6^"WBTJ
MS^']-O[BSNI-I*V\DCV[JS'H RQ/U_N"E_X+(6TWBCPW\$-!TE?M>KZIJ5RM
ME:P@M+*6C@52H'.-SJ./45^BWC3P3H/Q&\,W_A[Q-I-IKFB7R>7<6-]$)(Y!
MP1D'N#@@CD$ CD5P_A']F3X>>"_%&F>(K/1KB^UO2K8V>F7FLZE<Z@^GPD8\
MNW\^1Q",<?)CCCH: /ST_P""Q6FW6EZ'^SC:7;;[FU@U&"9\YS(JZ<"<]^5-
M?J=X9_Y%S2O^O2+_ - %><_%S]EGX7_'C5+/4/'WA<>)KFS1H[;[5?W0C@5M
MN[9&LH52VU<D $[1G.*]%\-^';+PEHEGI&FK,EA:1K#"EQ<RW#*@  7?(S,0
M !U)Z4 ?-'_!23]GW5OVAOV:+_3O#ULU[XAT.\CUNQM(_OW!C21)(E'=FCD?
M [E0*X;_ ()(_$JSUK]FD> IR;/Q%X.U&[MKK3YSMF6.69YU?8>0-TKH<]"A
M]:^Y*\K\7?LQ_#?QEXR3Q?=>'1IWBU1M.NZ'=SZ;>N.!\\MNZ,_  RQ/ H ^
M(?\ @K'\9OB/\!_%'@.Y\!^.M:\-VVKVUT+JTM;EBC/&Z%6 ;..'Q@>E?0O[
M5EO);?\ !/3QHUQ?7>H7$WA>&6:ZOYVFEDD98BS%CW)],#DX%>E?\,E_"Z\U
MZUUO6_#LGC#5;7_CVNO%FHW.LM!@@@H+J20*<J#D#M76_$OX.^$_C!X=_P"$
M?\6:;-J>AD /IR7UQ;02 $%0Z0R*K@$ @," 0"* /B7_ ((YKI<W[(?CF+6!
M:OIG_"5WGVQ+S:8?)-A9;O,#<;<;LYXX-?-W_!.5M7L_^"@'B2U^&4D[?#'[
M;JHOA$Q:U;35:8618DD%M_D[3G/+=MU?H]I?[!/P(T73KK3['P%'::==LK75
ME'JEZ(+@KROF1^=M?'/# ]37K/@'X7>$?A7HITCP=X:TOPSII.YK?2K5(%=L
M8W-M +-_M'F@#@?#'ES?M:?$F)MK?\4?X?#(>>/M6K9!'T(_,5^=O@G]E_Q-
M\,_^"E.O_#OPG<R:-X*URTDU*_(CW*VA2N))+9>F-SH;=6Z@$GDBOTPT7]GG
MP)X=^(5[XYL-,O8/%EZJQW6J-K-Z\DZ*0520-,59!@84@@8QBNW;P_IK:]'K
M9L8#JZ6S6:WNP>:(6<.8]W7:653CU% 'Y>?\%R(UCC^"*( JJ-:  [?\>'%?
MHY\!S_Q8_P"'G_8NZ=_Z31US/Q5_9-^%7QPU>'5/'?A9O$]Y;JRP&^U*[*0*
MQRPC02A4!('"@=!Z5W7@#X>Z'\+_  Y;:#X<M[BRT>TC6*VM)KV>Y6"-1A43
MS78JH' 4< 8% 'EO[=4;2?L?_%H(I8_V!<'"CL "3^ !->!?\$==2M(/V4Y[
M:2YACN)O%%ZL<+. SGR(&P!W.%)_ U]V7UC;ZE9SV=W!'=6EQ&8I89E#)(C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ***3/.* %HI,TM !1129H 6BF[J=0 44W=3J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-+0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#_"W3?#VD3)J-S/F_P!3UH@&35+R7YI;EV_B+$\9SA0H[5X/^VU_R<M^R?\
M]C=+_P"@Q4 >J?MG_&_4?@/\#[W5M ,/_"6ZO>6^A:$LXRGVRX?:KD=PBAWY
M'\ !KQ7XF?LU_$7X(_"J_P#B3X:^-7C;7OB+X>M3JVHV^KWPGTK5A&H>: 6I
M7$:E0X3:<\\YX(UO^"FUO-_P@?PCO]K&RL?B-I$MRX!(C4^: S'L,D#ZD5]$
M?M#7D%C\!_B)<7+JD$?AZ_9V<X 'V=^2: /ESXF?$:\^,&N?"7QAX@L?&:?
M[7O"?]HM;^##??:4UB0JPCNOL)\[RUC(";3M+!\\8->F_P#!/_X@:]\0/@GJ
MC:_/JEQ-I'B74])M9-<;=?"VBE_=I<-DYD0-L8GNAZ]:X[]D7]GVQ\9?LC?!
M>\U#5M?\.:Y9Z,[P7_AS4Y+.5K>XF>8(_P#"P*LIY7(YP:^G/A?\+_#WP?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYF^*?[,_C.U
M^-UQ\7?@[XLTWPQXKU.RCL-=TK7;-[C3M62,*L4C^6RLLB*H4$<X P1SGZ9H
MH ^:_A7^S5XMN/C!%\6/C%XJL/%?C+3[5K+1-.T2U>VTS28G!$C1J[%GD?/+
M,>!GKQBWX5_9337/'7Q%\8?%:YL?&FK>*89-&M+1(W%MIFCGI:Q;N0S'YG<8
M)(!%?1-)0!Y+^S;\+O%/P8\ OX-\0^(;?Q/IFEW+Q:#>!'6YCT_.88;@L2'>
M,?+N7&0%&..<;X]_L^ZC\7OBI\&_%=EJMK86W@;6GU2YMYT9GN5(0;$(X!^4
M]?6O<Z* .$^-WPAT7X[_  OUWP/X@#KIVJ1!//AQYD$BL'CE3_:1U5A]*^<=
M:_9G_:$^)7A.#X<^/OBWH-Y\/CL@U/4-+TJ6+6M6M58$Q2NSE$+@8++SUSNY
MS]DTM &;X?T'3_"NA:=HVE6D5AI>G6T=I:VD"[8X88U"(B@= J@ #VK2HHH
M3%?!_P#P55_X]_@)_P!CY:_R%?>-?!W_  56_P"/?X"?]CY:_P A0!]XT444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "O@[_@JM_Q[_ 3_L?+7^0K[QKX._X*K?\ 'O\
M 3_L?+7^0H ^\:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7P=_P56_X]_@)_V/EK_(5]XU\'?\%5O^/?X"?]CY:_R% 'WC11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!YV<_A6QX7_X*,?\(MJ-MIGQU^%_B7X/2W+K'!J]W;O<Z9(Y[&4("ISGH&
MR2* /M&BLKPWXDTKQ?HEGK&B:E:ZOI5Y&);>]LYEEBE4]&5@2"/I6K0 4444
M %%<1\/_ (S>#OBEJWB33O"VMPZS=>'+S[!J8@5ML$_/R;B &.5/*DCBNWH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX9$)_>;05#;\D'/)ZUZ?^QK^T#XB^+FD^,/"GC^&SMOB7X#U9]'UL:>I6"Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]I/Q[)\*_P!G[X@>*H7V7.E:)=36[9 _?>65CP?7>5IGPG_9C^%WP-U"YOO
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MO>*OC=^P7K/BFW-IXDOX[BYU&%EVE9W@LV?Y>QW$\=LXKN_C>?\ C9Y\!/\
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MX)@\3WUY)%%IFAZ)XIO9KO46=U3,2B[Y4!BQ;IQCDD _H#XR\#^'_B)X=N]
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MM/MM*TNTC$5O9V<2Q0Q(.BJH& /I0!;O+?[5:S0YQYB,F?J,5\:_\$K=VC_
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M'6M'XE?%W]KK]FOPXWCOQKIW@+QWX+TYU;6+308IX+R"!F"F5&8XP"PR=K8
MR1C) !]WT5\G_M6_M9ZEX'_8WL/C)\-9+9WU,V$]F=3M_,40W##<KIN'S '!
MYX(-=S^QW^TM:?M._""TUZ6*/3_%&GO]@U[2A\K6MX@PWR'YE1OO+GIR.JF@
M#W:EKYL_:1^/7BGX7?M!_L^>#=$-F-'\<:E?VNK?:(-\NR$6Q3RVS\I_>OG@
M]O2LOXJ?M'>+O!_[=WPE^$EA]A_X1/Q-I%Q>W_FVY:X\Q$NV78^[@9@3C'K0
M!]3TE>._M-?M->%_V8? ;:[KC-?ZK=-]GTG0;5@;K4;@\*B+UVYQEL'&1U)
M-3]EN^^,?B3P:WB/XPMI6F:AJF)[+P[I=H8VT^%LD+.Y9BTA!7Y1C;WR>@![
M=117R!XZ^/\ \5_C)\;O$_PP^ W]A:3;>$46/Q#XP\0PM/$ET^"MO;(IP67Y
M@VY3RK#C + 'U]2U\L_ W]H+XA:/\:Y_@M\;K+1X/%T]@=4T'7]#W)9ZS;J2
M'4(QRLJX8D#'"MP."U[]I;]HSQ=X7^)'A+X0_"?2M/U?XF>)(6OVNM6W-9:1
M8H2&N)U0ACN*NJ\@9'<D*0#Z7I:^,;3X\?&O]F_XD^#]"^.LOAOQ/X0\77@T
MRS\4>'8'MFL+UB2D<Z,-I1AP" #P3SBO2_V@&_:67QE9?\*:7P"?#'V!/M/_
M  E7VG[3]K\R7?M\L[?+V>5C/.=WM0!]!T5^<7QQ_:(_;&_9_P!.T.;Q#'\*
MK^_UR_33=+TC2(;R>]O)F(&(XRZY R,DGC([FOOOX?R>(IO WA]_%R6D?BEK
M"!M52P!%NMT4!E$8))VA]P&2>W- '144AHW4 +13=U&Z@!U%-W4;J '44W=1
MNH =13=U&Z@!U%>-?$;X_-X'_:'^$OPOBTD73^-QJ4TNHM+@6L=I:O-A5Q\S
M,P4<G@9[U[)D4 +129I: "DKSK]HCQUJ?PS^!/C_ ,6Z,81JVB:)=ZA:_:$W
MQ^;%$SKN7(R,@<9JI^S#\1-6^+7[/O@/QCKOD?VQK6EQ7EU]ECV1^8V<[5R<
M#\: /4:*2DW>U "TM?-_[%?QX\4?'C1OB9<^)S9M+X=\9WV@V?V.#RA]FA6,
MH7Y.6^<Y/'TKZ.W4 .HHINZ@!U%-W4;J '44W=3J "BO!/CW\8=;TWXE_#[X
M4^")1!XM\47/VV]OS&LHTS28"&N)BI!&]\>4FX8RQ)Y !]YY% #J*;D^E+0
MM)17G'[0GQNT;]G;X0^(/'VNQR3V>EQ+LMH?OW$SN$CC''&YV7)[#)/2@#T?
M(HS7Q(OB;]LQO!9^)A;X?06@LO[3_P"$!EMIO.%O_K/+-QG_ %WE\?>VY[5]
M _!#XS6O[3GP#TWQKX9DFT&?6;.:-/,597L+I2T;#D;7V.N1D88 <<XH ];H
MKQ+]ECXUZC\6_!VK:;XHMTLO'_A'49-!\16T:[4:YB.!<(IZ1RJ Z]N3C(%%
M 'ME?(7[7'PY^(G@?XO>%?V@OA3H@\4ZWH>FOHOB#PVK8EU+3#(9<1>KJS,?
ME!;(7 ;&#]>U\W_M-?M1:]\*O'_@CX<?#_PB?&_Q \3L;A;-I=D5G9(V))Y#
MD<<,!DJ/D))XP0#X;\$_MN77A7]L#XB_$V7X0^-9Y?$FE6FE6N@+:$7,=Q$L
M:D.=O0E.RD\CBOK+]C#X7?$/Q!\3/''Q^^*NEKX:\1>,+:&STOPUM82:=IZ8
M*B7)R'("#:P##:Q(!;:L/[7/[37Q'T/XS^$_@I\$-,T^^^(FL6C:G>7VIQ[H
M+&V&XKDGY02(W)+=,H "7&.K_9+_ &BO&OCCQ7XN^%OQ;T:RT;XH^$TAN)WT
MUP;74+24#9.G)P<D9QQ\R].0 #Z>HHHH **** "BBB@ HHHH **** "BBB@
MKX._X*K?\>_P$_['RU_D*^\:^#O^"JW_ ![_  $_['RU_D* /O&BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M</RS^ ?[2]G^S[^TS^TO%=>"O%GBTZIXHW*WAG36O!!LDG!$F#\I.[CUP:]
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M1_CEI_[7GP=\1_##XIZ>/^$WT2-M%\4Z+<R-#)=Q@E/. 4JPW;<-M(PWLPH
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MB+P_>0QZ786TIEM(&A87$UR-F(1'&7;#D$E>/6O<_P!A+_DSWX2?]@&#^1H
M?^VQ\<;_ /9X_9M\6^,](V?VW!'':Z>TD>]5GFD6-7(Z$*&+8/'RBO'?!/\
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M?Q T)M;32FD:T"W<T'EF0*&/[MESD*O7TH ^;?\ AD&W_P"CS/BA_P"%J/\
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MC/".J>']5T.TE\,7FFWFC; +=])EC>WV8XV&,[<8]* -RBBB@ HHHH ****
M"BBB@ HHHH **** "O@[_@JM_P >_P !/^Q\M?Y"OO&O@[_@JM_Q[_ 3_L?+
M7^0H ^\:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E3XU?\
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M7UK_ ,(-X;Z#P]I7_@%%_P#$U;TWP[I6C2-)8:99V,CC:S6T"1DCK@D#D9H
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M@[_@JM_Q[_ 3_L?+7^0K[QKX._X*K?\ 'O\  3_L?+7^0H ^\:*** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9\  < 5]%? '5/'VI?"_2D^)NAC1/&EF#:7QCN89X;TI@"ZC,3$!9!\VU@K
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M2BJ-):36_E?_ (!PX:C:3D^A+2T45\,>F%%%% !1110 4444 %%%% !1110
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MB#/04 9D7[87[57V/^WI/V5IQX>*"?[*-5Q?",C/W"N_=CMY6<\8KZ&_9?\
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MTCXY7NI?M4>(?A,VEP)8Z9X;M]=74ED8RNTLQC,97& !C.<U\EZ'X0U?X,_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'B?[4?A7XX>*O"VCP?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME>)K^T^*.LV\%QJ$.]HX_.+;!STRQ/XU^A5?'G_!/O\ Y&_]J#_LJ^L_^C*
M.$_:W_9FT/\ 98\'#XY_ VQD\#^(_"D\$^I:=ILK_8]5L6F1)(Y8F8KA0Y.0
M!QN[A2/:/C5\+=7_ &P?"OPE:QUB"R^%>HM%KGB:QCNI8;G4[5X$DMX(RB$&
M-F8[P67@Y!R*R?\ @I9\1K;P?^RSXC\/0M'<>)/&#0Z%I.F@YEN7EE02;5Q_
M#'N_$J,\BNMUCXF:!^QI^S'X)@\3-<7MYI.C:?H%AI=FOF7>IWD=ND20Q*.K
M,R]>@'/M0!X)^W9\%_AU\ ?A3H7C?X<Z)9> ?B+IFLV-KX?NM C$$]W(T@5K
M8HO^N4Q[B0P/W?0D'ZF^,^O_ !0TWP#I:_#3P[IFL>,-2N([61]8N##9Z8C0
MNSW,H'S.J.JKL7DEQZ5Y!\&_@#XQ^+'Q'TWXU?'01Q:Y:+YGACP- V^T\/*V
M/WDA_CN2%4DYPI)] $^LA0!\)_L#^$_$/@?]J/\ :=T3Q7XEF\8>(;=O#SWN
MLS)L,\DEO<2L%7^%5,FU1Z*.!7W;7R)^S+_R?9^UQ_UT\,_^D,M?7= !1110
M 4444 %%%% !1110 4444 %%%% !1110 5\Y?M[?\F^WG_80M?\ T(U]&U\Y
M?M[?\F^WG_80M?\ T(UWX#_>J?JC&M_#D>X>!_\ D2?#_P#V#[?_ -%K6[6%
MX'_Y$GP__P!@^W_]%K6[7%4^)FL=D)7D_P"TA\:K?X)?#NZU-?+EUJ[S;:;:
ML>9)2/OD=U0'<?P'<5Z;J6I6VCZ?=7UY,EO:6T;3332'"HB@EF)] !7R%\+]
M.NOVK_CK=_$35X<>!_#,OV;1[*8$B:13D,1TZX=O<H.<5W8.C&3=:K\$=_/L
MOF959/X8[L],_9+^"]Q\-_",_B#Q!F?QCXC;[9?S2C,D2L=RQYZYR=S?[1QV
M!KWSMQ2?A2_2N6O6EB*CJ2ZEPBH*R%HHHK$L**** /E3XU?\GJ?"#_KUD_G-
M7U5Z5\J_&K_D]3X0?]>LG\YJ^JO2O2Q?\*A_A_5F%/XI>OZ"T445YIN%%%%
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MU_\ 0C7?@/\ >J?JC&M_#D>X>!_^1)\/_P#8/M__ $6M;F:Q/ W_ ")/A_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_!5;_CW^ G_8^6O\A7WC7P=_P56_X]_@)_V/EK_(4 ?>-%%% !1110 4444
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M44 )44TR0PO)(ZQQH-S,QP !R3FN4^)7Q5\-_"709-6\2ZE'90 'RH1\TT[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\'?\%5O^/?X"?\ 8^6O\A7WC7P=_P %5O\ CW^
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M_L(6O_H1KOP'^]4_5&-;^'(]P\#_ /(D^'_^P?;_ /HM:W:PO W_ ")/A_\
M[!]O_P"BUK=KBJ?&S6.R"BBBI&%%%% !1110 444E '"?&33;5_AQXDN#;Q&
M<64A\PH-WW?6LWX"Z79R?"OP_.UM"TVQSYAC!;(D;OBL#XM?&CPG=>&/$OAZ
M+4)&U3RYK0P_9Y,>8,J1NQCKWZ50^#/QF\*:)X(T'0;N_DCU1283$+>1AN:0
M[1N QW'?O5'V4<%CGE#2IR^-/9[<KU]#WRBD4[E!I:D^-"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O@[_@JM_Q[_ 3_ +'RU_D*^\:^#O\
M@JM_Q[_ 3_L?+7^0H ^\:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI,BC<* #
MK17)^+OBMX/\!6\DOB'Q+INEA.L<]POF'V5!\S'V )KPS7OV\_"373V?A#0-
M;\8WO1%MH&A1SVZ@OU_V*ZZ6#KUO@@W^7WF<JD(_$SZ?S7F7[0GQ@B^"?PWO
M=?\ )6ZOW=;6QMWSM>=LD;L?P@!F/3[N.I%>+P^*/VFOBQF32]$TWX=:3)_J
MY+Y1]H"GU#[FR/\ KFM<E\4OV,_'6K>"=1U[5_'=]XU\5VP$T6G,',.T??2,
MLQRV.1A5SC&.:]'#X*C"K%8FK&U]EK^6B^\QE5E)/DB?,.O?&[QKXB^(-GXS
MO-<F/B*T7R[:[C15\A,M\BJ!@+\[\8/WC7O_ ,"=%U#]LCQ?>7GQ'\3W.H6'
MA](F318 (8Y=^1N^7  RGS8&XY'(KY,NK6:TO#;S0R0SH=K12*58'T(Q_2OO
MG]@/X1ZSX1T76O%FKV\EDFL)%#96TJE7,2$EI"#T#$C&?0GH0:^QS7V.&PO/
M3M&6T>_R//H*4YVEL?5.@^'].\+Z3:Z9I-E!IVGVZ;(K>W0(B#T '^3FM("@
M"BOS)MMW9[0M%%% !1110 4444 1NXC4LQ 4#))KY<_;B\9:#K7P'N[73]:T
M^^N3?VS>3;W2.^ QR< FOJ&YA6ZMY87Y212C?0C!KY]_X8/^$N23IFH_^#"3
M_&O1P,Z%*JJM9M6:>B,:JG*-HGJ?PW\7:'JGAG0;*RUBQNKQ=/AS;P7*.XQ&
MN?E!SQ79_6O(_AK^RWX"^$WBA=?\/65W#J*PO 'FNWD7:V,_*>.PKUS;^=<V
M(]E[1NDVUYEPYK>\.HI**YRPZTF?:DW@=<"L37?&V@^&8R^IZM:V8':24!C]
M!G)H-(4YU7RP3;-RCWKQC5/VGO#ZS&#1+"_UV?\ A6&$HK'\>?TK-C\4?%[Q
MUE],T:W\,6+?=DNQ^\Q_P+G_ ,<%,]F.38JW-7M37]YV_#?\#W2XN8K>-I)9
M4B11DL[8 KA?$WQQ\&^&8Y%GUF*YG&0(;/\ ?-GT.W@?B17$V_[.^K^)IA<^
M,O%][J;'YC;6Y*HI]B3@#Z**[?P[\#_!OAO:\&C0SSKR);L><V1W&[(!^E!?
ML,LP_P#%JNH^T59?>_\ (^,O%6J1:YXHUC4(%98;R\FN$#  A7<L,C\:=X3'
M_%4:-_U^0_\ H:U[%\3OV=[_ $__ (27Q/\ VK;FV$D]\+<0D$*6+!<YQWJE
M\+_V?=0\1Z?H?B:/5;>*!I5G$#1,6PDG(SG_ &?UHZG[#'/,N_L[F52T;<O7
M>VVQ]:1_ZM?I3J11M4#T%+2/Y^"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHKS']H7X[Z+^SO\.+CQ5J\$^HRM/'9:=I5ICS]0NY3MC@CSW)R2>P5CSC%
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M?X;E&_D:X[,^?CA<1+X:;?R9V/2DXKA)OCAX'MP=WB.T.T9/EDOQ^ ZU3?\
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M +[G_P#CE '0?\-K? 7_ **]X/\ _!O#_P#%4?\ #:WP%_Z*]X/_ /!O#_\
M%5S_ /P[R_9T_P"B4Z/_ -]S_P#QRC_AWE^SI_T2G1_^^Y__ (Y0!T'_  VM
M\!?^BO>#_P#P;P__ !5(?VU?@*01_P +>\'_ /@WA_\ BJP/^'>7[.G_ $2G
M1_\ ON?_ ..4A_X)Y_LZ=OA5HX_[:3__ !R@#YW^(WB73]?\2:SJ^D7L.H:=
MJ%U)/:7ENX>.:-CE75AU!'(/TK"\/ZY%IMS:23AR()E<[!GY0P.!SUZ_I79_
M%KX%ZI\,]/\ $6KVNBQZ1X"\/Q32PE9E9;>RB!((7<6X5?K63\(?A?KWQ4\.
MZ)XMT'3UU7PMJ9RMP)EC\V(.4?@D,.58=.U?*5ZN*EB^>$6EMMT/)QW$N:RS
MZG6PB<*4(JFFXW7+I=VZZZ_<?1$W[:7A:%@L&D:G)& /FE\M#^08U0D_;;TO
MYMGAN9O[NZ\49]/X#BM[_AA?X%S?-)\/K-W[EKNY)_\ 1M+_ ,,(_ C_ *)Y
M9?\ @7<__':]KV>*_P"?B^X/9X^]_:1?_;K_ ,SF?^&X+3_H5#_X,1_\:JO/
M^VX&;,/AJ-%QT>]+?^TQ77?\,(_ C_HGME_X%7/_ ,=H_P"&$?@1_P!$\L__
M  +N?_CM'L\5_P _%]W_  39?7EUA_X#+_Y(X63]M:^);9HEF@_AW2L:@_X;
M2U;_ *!6G_F__P 57H'_  PG\"/^B>67_@7<_P#QVC_AA'X$_P#1/;+_ ,"[
MG_X[1[/%_P#/Q?<:*>.6SA_X"_\ Y(\YF_;,UN0CR[#3XQWX<_\ LU59/VQ/
M$I8[8M/4=AY+'_V:O4?^&$?@1_T3RS_\"[G_ ..T?\,)_ C_ *)Y9?\ @7<_
M_':.3%_\_%]QJJ^/7_/O_P  ?_R1Y1_PV!XJ_O:?_P" [?\ Q=<#X\^*EY\0
MM474]2\HW<< @3R(RJ[0S,.Y[L:^E/\ AA+X$?\ 1/+/_P "[G_X[61K'[$?
MA""1(?"+)X1TO&Z2QMXGG$DIX,A9Y,Y*A1CI\OO6-:.-4'R23?I8J>9YQA:<
MYX5P4[65H6>NF[>A\GV-U]EN-[Y*MPW<_7\Z](\/_M >)_"^E0:7INNM9V5N
M"L<7V6)MN3GJR$\DUR?[%?A*/]KKX>Z[XG>X;PP=,UA]*^S*OVGS-L,4F_=\
MN/\ 68QCM7U)9_L-_".\MDE\1>%;;Q#K3#_2-3EDGB:<C@$JLF 0,#CTKBP.
M'QU%.#?*OO\ U/%R#%9Y@,++!5.7DYN9*45/5[]=/^"SQ2;]I+QC>8$GBR2/
M;R-EO&G7_=2J,WQR\37$A=_&-Z">R2.H_(#^0KZ!_P"&$?@1_P!$\L__  +N
M?_CM)_PPE\"/^B>6?_@7<_\ QVO4]GB_^?B^[_@GTO\ :>;+X727_<)'S]'\
M6M3>0>;XZUM5/WBDLK$?0;Q_.K<?Q*M[HXO?B%XE5%Y4I TAS]#<#^=>[_\
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M9U1B!_RT=V'Y&;%>C_\ #"/P(_Z)Y9?^!=S_ /':7_AA'X$?]$\LO_ JY_\
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M / NY_\ CM'_  PC\"/^B>6?_@7<_P#QVO3]GBOYU]W_  3U?8YC_P _H_\
M@/\ P1?^&RO _P#S[ZI_WX3_ .+H_P"&RO __/OJG_?A/_BZ3_AA'X$?]$\L
M_P#P+N?_ ([1_P ,(_ C_HGEG_X%W/\ \=H]GBOYU]W_  0]CF/_ #^C_P"
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M\$_ [0;G1? GAZV\-Z7=7)O)K:U9RKS%50N=S$YVHH_X#7;T %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXQ_P""1_\
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M^+.I:7J/CR]LQI>FZ9H@<V&C6.=QCC9P&DD8_><@=6QUX /I 4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gizttcucplmb000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000010.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
M   !          #_VP!#  ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,
M# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$
M!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!3_P  1" 4 !/8# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M?_B0]CXRUV^\9Z18WCV>K:+K3B29=CE)!'*1N1U(.,G!(Y%?N#X)\7:=X_\
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M^@KX*_#O5_@_^SWX0\&V\EM?Z[H6AP66ZXD98)+A(P&RR@D)OR. 3C%?B_\
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M[)?[9WCC]D/Q1.=)"ZEX;NYU;5?#MX2J3%?E+(V,QR@#&['8 @T ?L#^SO\
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ME_\ %/X>^"O!6D^$;=[AK+1M?ENKC4=4B@)#F.2-HXXV)5U *L-P[XY^.O\
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M/_8O\.75K9P075_J%_-=311JKSNMR\:LY ^8A$103V4#M7Y)_MQ*%_:Z^+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\0_M'?$[4O'/B?XT6L6J7J1Q&&R\(%(HXXU"HJ@WQ/ '<U[]\!_V:?'WP%^
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M",E7'\+J<@J>00:SYM<T#XS^$O&6AZ+J2W]NJW&AW5U I,*S-" ZI)C:Y7S
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M+[4;K5--U?0;TM<R0R2EB)!&=RG#!61Q@\_>%9__  V!^U"G)\>^-ACU5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2<=<,#^-=I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=ZO_ +37['?@C]K)=!3QK>:W##HIF:VATJZCA5FDV[F?=&Q)&P =.IH P?\
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M'_)UQ1MCUS2Y/LUX .S, 5D'LZMCMB@!6_;L_9_&CG4S\6O#(MQ$9=@O 9\
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MO^W=_P %'(/VD/#\?PK^$NF:C<:/JLT27M]-;D7-^P?Y+:&$9;:6"')^8GC
M'7[>_P""<_[*]Y^S#\#?(UY?+\7^(9EU'5(001;87;%!D'DJN23_ 'F8=LUZ
M+\%?V/?A!^S].UUX)\%V6GZBQR=2NF>ZNAVPLLK,R#V4@5[10 5^2'_!2[_E
M(Y\$O^O#0_\ T[W5?K?7S_\ &C]B?X??'?XQ>&?B7XDGUJ/Q#X?BM8;-+&[2
M.W*P7$EQ'O0QDD[Y&SAAQCIUH ^@**** /CS_@HI^V<G[,_P]3P]X:N$G^)'
MB*(QZ?"OSM90$[6N64=^JH#U;)Y"D&M_P3=_9!E_9_\ A]/XP\6V\C_$GQ8@
MN+][H[I;. G<L!)YWDG?(>[$ _=%7IO^"=VAZU^UL_QK\3>*[_Q5$)3=P:#J
M4"%(;@<0@.#@Q1CE4VCE5))Y!^O10!!>6J7UG/;29\N9&C;!P<$$&OB>?_@C
M[\ [B:25W\5;W8L<:JF,DY/_ "RK[@HH \A_9N_9?\&?LK^%]3\/^"3J)L-1
MO?MTW]I7(F?S-BIP0JX&$'%>O444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 450U?7-/T"S^UZG?VNG6
MVX+Y]W,L29/0;F(&34NGZE:ZM9Q7=C=0WEI*,QSV\@=''3(8<'\* +5%%% !
M1110 445%+,EO&\DCK'&@+,['  '))/I0!+163HGBG1O$OG?V1K%AJOD;?-^
MPW*3>7NSMW;2<9P<9]#6M0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'4.I4YP1C@D?K3Z*
M/R2\._M&_$O]EC_@H1)X#\?^-=<\2> [K4380IJUT9%6UNB#:W&6(Y1F0,WH
MLG'2OUK7IG.17YI_\%F/@4-4\%^&?BYI5L8]1T.8:9J=Q$,,;>1@8'8_[$I*
M@^LU?5G["?QU;]H+]F?PGXCO)_M&N6L/]EZL_P#$UU  K.1C +C;)@#'S\4
M<)_P4V_:/U#]GO\ 9[9/#VIOI?B[Q'=+8:?<PMB:&-<//*A[$* N>QD'>KW_
M  37@^(&I_LY67BWXB^(]7\0:OXFG:^M1JTQD:"S'R1!0>@< R>X=:^$OVMM
M0OOVY/\ @H5H_P -- NOM&@Z'<KHWG+DQ0I&WF7\_!Z@JR]L^4@]#7ZN?$#X
MC>"_V<?A>VM>(]0AT'POHMM';Q9!)(50L<,:#EG(4 */3TH ] HK\S-0_P""
MR5SK&H7$G@OX+ZQKFC6\G[ZZFNB'6/&=S+%$ZJ?8M^->_P#[)/\ P4:\ _M4
M:L_AQ;.X\)>, IDATJ_D61;M0"6,,H #%1R58 ^@(!( ,+_@KI_R9GJ__87L
M/_1AKT_]@'_DS7X3_P#8'7_T-Z\O_P""NG_)F>K_ /87L/\ T::\?^%/_!0O
MPC^SE^R]\(/!NEZ->^/_ !U+HJO)HVD,/]$4L[*)6 )W$'(15)P,G (R ?IE
M7%_&;3O%&K?"GQ;9>";M;'Q=<:9<1Z5<,P CN"AV')Z'..>W!KX,^'__  67
MT>Z\;6^A?$/X=7O@RWDN!!->QW1F-H&(P\L31HVT Y..0.@-?H%XV\:6W@_X
M?ZYXL$?]H6FF:;-J0CA<#SDCB,F%;I\P'!]Z /D+_@FCX(_: \'V/CC_ (71
M/K(L9IXAIEOKUZ+F?S@TGG.GS,5C.5[X. 1ZU]Q5\T?L8?MKZ7^V1:^+9],\
M+WGAH>'GM4<7=TLYF\\2D$;5&,>4?^^J[#]IC]K#P%^RIX3AU?QC>RO>7>Y=
M/T>Q4/=7C#&0BD@!1D99B ,^I (![/7-?$S_ ))OXK_[!-W_ .B7K\WI/^"U
M5T\AO[;X-W;^'D.R2\?4SE6R,#<(=F>1W[BOMCP'\;-/_:(_97NO'^EZ?=:5
M9ZOHU^5L[ME:2-HQ+&P)4X(W(<>V.!TH ^&?^"&/_-;/^X)_[?U^JE?E7_P0
MQ_YK9_W!/_;^OO+]I7]J?P-^ROX-77?&%Z[W%P62PTBSVM=WK@<A%)&%'&68
M@#([D @'L5%?F#)_P68U216U:V^"6HR>%%R#J+7[\$''+B'9U_VNM?8?[*?[
M97@7]K;P[<W?AIKC3M;L #J&A7^!<6X)P'!!VO&>S#Z$ \4 >]T4E+0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% "5\3_MY?\ !173_P!EV4>#_"EG!K_Q#N(?-=;@DVNFHRY1I0""
MSMD$("..21P#]A^*M<B\+^&=8UF89ATZSFNY!_LQH7/Z+7XL_P#!/#X;M^UQ
M^V/KWCGQO;_VU8:8)O$%ZMYB1);N24+;Q,I/*C+L!C;B$#TH WO"_P &/VW_
M -K.V'B*^\4ZQX?TB\ N+>;5M5;2H)%(^7R[> ;@N,<F, YSDFM.^^!?[=/[
M+K1:YHOB/4O%UA:MYTT.FZLVJQ8&,J]O. [ @?P(?J#7[$JH4  8'I3J /)/
MV4_BMKGQO_9_\'^-O$FGV^E:YJT$K75I9AA$C)/)%D!B67(0$J2<$D9.*]:(
MJ&UM8;./RX(4@CW,VR-0HW,2S' [DDGW)KYO_P""@W[0L?[/'[-OB#4;6Z^S
M^)-97^R='53A_.E!#2#T\N,.^?4*.] 'S=X+_P""A2ZQ_P %'-4\,RZAYGPZ
MOT'A6P99?W"743LRW/7!\R4O'D=F3L*_2BOY_;[]DG7O"W[$V@_':V@GBU1M
M?\YFB)#VVG86."?KQ_I"GD#.)$/0<?LK^QS\>5_:/_9]\*^,I9(3K$D'V35H
MX.%2\B^67 S\H;AP#T#CKUH YS_@HCXVU[X=?L=_$#Q%X9U:ZT/7+/\ L_[/
M?V4ACEBWZA;(VUATRKLI]B:_,KX'R?MH_M$>!;_Q=\/_ !YK^MZ?8Z@VG2Q-
MK\=O,)5CCD)"RLH("R)W[GBOT:_X*C_\F*?$S_N&?^G2TKYE_P""3/Q\^'/P
MC_9R\66GC/QIHOAJZ?Q1-<);ZC=I%(T1M;1 X4G)7<K#..QH X;]GO\ X*"?
M&CX"?'2T^&_Q_:\U#39KJ*QNFU6"-;W33(0J3K(H'FQ\@L26RN2ISP?U\5@R
M@@@@\@CI7X:?MQ?$31/VMOVUO#EK\+V_X2!&CLM'AO;2-@MW,)&=G7(!VH'P
M6QC"$]!7[BV-N;2QMX"V\QQJA;UP ,T 6**** "BBB@ HHHH **** "BBB@
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M88_+E00#]#%Z4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,D+?ZRUF'$D,@[.C9'H>",@@D ] HHHH **** "BBB@ HHHH **** "BBB@
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M ]$_X+'?! ^-/@GH_P 0K&T\S4?"5UY=U)&I+&RG94;/LLGEGV#,?6MOPO\
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ME28Y%*Y!Z''%6/#GAK2/!^BVFC:#I5EHFD6BE+?3].MTM[>%<DD)&@"J,DG
M'4FM2B@#E?''PM\&_$Z&TA\8^$="\60VC,]LFN:;!>+"S !B@E5MI( SCK@5
MJ0^%]&M_#:^'HM)L(] 6V^Q+I26J"U%OMV^3Y6-NS;\NW&,<8K6HH Y/P/\
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M5_O)_P!]B@":BH?M2?WD_P"^Q2?:D_OH?^!B@">BH/M*]F3_ +[%'VI?5/\
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M>C_^!\7_ ,51_P +,\*_]#'I'_@?%_\ %4 =/17,_P#"RO"O_0R:/_X'Q?\
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M)-'_ / ^+_XJ@#J**YC_ (69X4_Z&31__ ^+_P"*H/Q,\*=O$NC_ /@?%_\
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M>N?SD_\ B*%_X*H^$B7!T"[]L"0]O]R@#[JHKX8C_P""IWA)DYT&\S_NR?\
MQ%+_ ,/2O"G_ $ KS_OF3_XB@#[FHKX8;_@J7X3'_,!O/^^9/_B*<O\ P5*\
M)_\ 0!O#_P !D_\ B* /N6BOAK_AZ1X3_P"@#>?]\R?_ !%'_#TCPH/^8#=D
M^XD _P#0* /N6BOAC_AZ5X7#'_B07./K)_\ $4R3_@J=X5CZ^'[HY_NB0_\
MLE 'W517PI#_ ,%4O"K'GP]>?]\R?_$5-_P](\*?] &\_P"^9/\ XB@#[EHK
MX9/_  5)\*+_ ,P&Z_$.!_Z!3A_P5*\*;?\ D 7.?^VG_P 10!]R45\-C_@J
M1X4;KH-V/H)#_P"R4?\ #TCPIG/]@W>/]V3_ .(H ^Y**^&&_P""I?A8G"Z!
M<Y^LG_Q%*?\ @J9X5CX;P_=?AYA_]DH ^YJ*^&E_X*G>$L9/A^\_[YD_^(H/
M_!4OPF<8T"\'X2?_ !% 'W+17PPW_!4OPH&P-"N_^^9/_B*4_P#!4OPL!_R
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M5\N&ZA655)]?PHH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;KS_ +Z?_P"+KS--3MN?WR_B:E74+5O^6R_F* /2/^&B/B4HR?%UZ!ZYD_\
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MX_TUQV^M4;K^TY,.NL:JB$YS]KDQ_.E72T>,%^P!'3TH\575Q;6-JD6=@/\
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M1_\  I_\:Y<^,DW<6W!X_P \4_\ X3 ?\^W\_P#"@#IH]4U3I_;.HG_MZ?\
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M_H:E\-$[I/\ >_K0!6UCPN;6#(GS@9Z5BO9JVCB?<P.[:1G]>E=YX@&;5_\
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M$;_A*)B&QM;/Z"NWO+4R?#6XNV.3N8?HW^%8%' Z/\VGL'4'+?U-;$<,<?E
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M(S]!7*W'[S6<X( ''OS7IOBZT:XL)997:?+[L,<XR1P*\PW/)J"EN-IQ58_
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MYAG\DKV3_@H<H_X4KI7'34%Q_P!^)J\:_P"":LA?PWXD]F _1*]G_P""A_\
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M6;BWOX##Y1V@L.3U-?IE\'_#,?[-_@IY=4T237-;O+C:LNG@L8XF4'#;BO\
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M8@CBG,NQB<FEC9I6VA=OO0 Y@H4 &LW5%( ...M:30%226Z=JJ:IS;YQUXH
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MS6W8A-JXR!Z?2OS(^&%B=0^(EI!<'='YL;#/^\*_7;X.Z!;RZ+86[C$85?F
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ME6O.#6DX_P"F;?RK*C; 3Z?TJ]'(#;R@=T(_2@#F[1OE'^__ %KN]).;5/\
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ME22!V[^YKU)XS'("GS9&3WKEO$D=Q<W !^1,_P"->;.M6J)*<V[%-MGY5_\
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M>H1^)K]9_&1_XL_K9_V;;_T?'0![-\,/^29^&O\ KRC_ )44?"GGX:>&^_\
MH4?\J*E@=C1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<Q\1FSX'UT#J+63/_?-=/7,?$7_D2=?_ .O23_T$T ?@YXN?/C37P?\
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M)_K7O>O0C3?E8X.[AOQJ9;!V,'QA\7KGP/XLM(+[2G/AQXV,VH1DLRL$8KA
MN>6"CKQDURGPC_:6O_B=\4;W0#H<EOI$8=K>[92"<$X)&SN!W]:]CTW2+;7M
M/07D-O>1  E9XPX[8R#[U?T/0+'2;YVM-*L;(@8,EM B$_B!7:JM!4W>GK;O
MMYFO.C1<G"R.?FZ8J#6(3=Z3+$!F1^1G\13-4NA; R.-H)XY!K0L;B.XA1\
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MPV5Q^F:_9'XE:3%K'@N[@0;B!GIGL?\ &OR/^/'AVY\+ZU]H: XE)'"\=_\
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M4HRA)QD@:MHSS;6))UD\J)3N8G/:N*\=LUOI5Q&^1(83D<D#BO6[RWAEN#N
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M;=\T3,2 "203QD<9_06@ HHHH **** "BBB@ HHHH *YCXC<>!]?/_3K)_Z
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M07%JMO>26Q5VD*L248$\#O7KG_!<#_DH'PM_[!E[_P"C8ZA_X(@_\E,^)O\
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M_!)=6'[%OAO<" =1U KGN/M#?US0!]D4444 %%%% !1110 4444 %<O\2/\
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MJXADL""6!+9QGC'R]>1U-<[\&K7[)\7/#:Y!!FSQ[JPH _<7P9_R!X/^NO\
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MJ\X3]H/5->^%(\1V$ADO+@*XAR?EW!3Z]L^O:OBSXJ:U=>)-1U>2ZF,B"YD
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M< '_ -F-:'[,^@[=:N=4E3]U&K%B<]BE>>_$35!K/C/4[H'HVT-Q_=7_  H
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M:W/CC2?$=Y=KME#;>W<(?2NR_P""D:G_ (4GI'_7^O\ Z)FKRC_@FNN=#\4
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MR9_1_>N0\56Z1WQ 7 S_ %KJ/@G&&^+WAL=O-Q_XZ] '[C>"UV:+ N<XE_\
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M3L22)2Q]?E/^-?,SQO#&BHF><ECGWKZ"_:6D1H]/(Z^4O?V-?/DDV&VD<=:
M,FXU0^%O%%CJ\4,C+&RAE3WQSU]C7HGQB6W\6^ K377MV27RU*@CG@ >OM7%
MWT9N+:1%0'Y21GGH*X_6_B!K$VGG0YMQMXSA1@  9^E &[\*H\?$KPIQC_28
MC@_45^K7C+CX0ZR/]BV_]'QU^3?P;EDD^)GA@,>!>1C'XBOUG\9KGX1:R/\
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M<RP@\*V/ZU#5S71MUR\!_O#^0JG0 Y<K3FER,'I48D)XIV5_B[\4 ,FD'DE
M,9. W;DU[_\ "W1T\$^ [S5YF4?:%^4G@GY1R#G_ &J\)MK7^T;^WLU_Y:,
M/S%>R?%V^E\.^ =&TF-L9B 90<= @_I0!XSJUS]NU2XNT)!=R1N]SGC\ZJ;V
MX^8?I2[ANP_)3C^E!5-W2@!R[EY;I3JDWQ^6!4+D_P )H 7=L;CFFR2%V&?6
MA%;J339'&X#'.<4 3V.1J%J3Q^]7^8KVWXN-_P 6PT[![#^25XE;MFXMC_=D
M7^8KV3XHLUQ\+].*G@#!'X)0!X6[;H$ .< =*5HT&3BF1R*L87&#@<T]F[4
M1,XY&W\:Q_$6/[-./2MC;EJR-=7_ $ _2@#Z=_X)K_\ (#\4?[V/T2O8/^"B
MB;O@GHPQTU!?_1,U>/\ _!-W_D!^*#_MC^25['_P4,W-\%=+[_Z>I_\ (,U
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M?3^G]]JSK5$*YV\].F:]$\3>&(XO$>M%H\NUY,>@QR[54L_!MUY)D2%2IY'
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MJ7<: )G<J#W&,;:]T^!<G]F_#+7[@M_JQCT)RT8Z_C7@OF;>OTKWCPOM\/\
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MBL'=CG-=#\2B?^$TU+C!,SD_B[5S);;G- $JR<\58\[Y<=ZJ@!>IQ0S!><T
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M2+?H3*#_ ..L?Z5^K>H2&U\$:LRGE5AR?^VJC^M?DM^RK\WQLT1E/!E )_X
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M@*Z+X50JOQ(T+'_/P?\ T$USK3;>@K=^%DA_X69X?'8W!_\ 06H _9_P1_R
M[;_KI_05V=YAHY03QY9KC_!?&CV__73_ -E%=A??ZF7_ *YF@#\#M=LXFUV]
M.[/S?X53:UBAFW;MPZ?_ %ZOZXPCUJ\.W^+W]!4-M&UU?);QQAY)?E4'/4D
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MJ(L-12XQF2/YE^H(Q^HINN-_Q.+_ #S\Q_D*I*PW$T :&H:M-JMU)>3D^:>
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MEY9Q@*[!7!4,H()R#T8\$5I6_P#P37^(EO*7COH;63I^ZN4''3)^;D]:0_\
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MXN))Y=(OY7>5IFWQL06+%CVZ$FOU['Q ^!W7^U=-_P# 9_\ XBAOB!\#N/\
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MKS_ORW^%-;POKKG/]C7G_?IO\*_7;_A8'P2.?^)KIO\ X"M_\12_\)]\$_\
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M *"NG?\ @*__ ,11_P +"^!W;5=-_P# 5_\ XB@#\@6\-:X/^8+>_P#?IO\
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M>';Z\N9K;XL:;%'<G(.^7=Z8)"^U5C^P7X?B8!?BSI<<L9W%E:8':.3SLZT
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MY%_^+KYLU"_O-.,8DA8[UW#;CW]ZIQ>))903Y3*1Q@@9_G0!]0#]O3XS$_\
M(<A_\B__ !=0R?M\_&:&-G;6X<_]M/\ XNOF63Q)-%@^6V3[#_&FV^N2ZCJ$
M<?ED(W!!QZ_6@#Z>M_V^OC++&'&NPY/7_6__ !=3?\-\?&;_ *#L/YR__%U\
MQW&L26-U+#Y384\8''3ZTS_A(Y#_ ,LF_(?XT ?3)_;X^-/4:Y#_ .1?_BZ1
MOV]OC5VUN$_]_?\ XNOF!_$TRL1Y+D]< "K46L7DJJRPMSV.,^_>BP=;'THW
M[>WQIC^]K</_ )%_^+H_X;S^-+C(UV%?^_O_ ,77S3_;5S/=)&8F !PS=A^M
M=A:QZ1+"GVJ_1)<?=7./_0>M=V'P=3$0YX-+UT-%&ZN>QM^WK\:L_P#(?@_\
MB_\ Q513?M^?&JWN(A+K</3_ *:^_P#MUX_?6NA6L>_^T03C( S_ /$UP?\
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M.<UGW:P32D@8&WT/J:[KPWI<4VAI)+$DCDX^;/H*L?V/;"1P;2/[N>A]3[T
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MO'\J0%ME<_\ +Q)_WU3-C_\ /Q)_WU33H%T.#,<_7_ZU-_X1V[[S'\__ *U
M#;AF5=OVN0'!XW'T^E7/!?F+XNT1O/E)%U&?O'^\/:H(=!DAD0RR9;GO[?2N
M@\+6K1^*]#1"/^/E.OUH _;;X,75Q=Z1:>9<DD6,?<T4SX&C_B6P848^PQ_S
MHI7 ]<HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M-YIU% 'Y5_\ !4@!OB]HY/\ SS/'_;.&OCDQ(8Q\F:^QO^"H7S?&/2,]/+_]
MIPU\@K]T#MG^M $2PQ=XZE6VAD88C4__ *J?C=VJ41[<'&3^- &?):1K(_[M
M:R3;Q#[3(PP@...O45M20EYL#C-4[JT:U63C=N.5!^HH ]>L_ %['X)LKZY2
M)+.9<(RD[CRW7CV/>O&=9M1#')E,H'QN_ U]I:;X1T&'X!Z')J!NWUJ]A:2$
M0C*X$DBC(W=/E/05\>:KMDM[BV.X;)O09/7@_G0!#IMC%)E5C!&W/.?2IK>S
M1;F,^4ORM[^M)I.68_/@A<8X]*M6L:_:$W<Y;GD^M &-K-O%)JK'';^E;?AW
M38)+??L!8?6LG6(5CU9\# (]3Z5O>'8@MN3SM[XY- %'5+-(X;C;$OZ^M8^G
MJ$2+=&,%L<?2NHETU]2O!;P[R\QQL_,_TKU;X2_LWCQ%)]JU2>2WMX6) ['@
M=./ZUZN'R^K5A[>348+=L\_&XZA@8WJO7L>6OX?GOK(BWTV:<-R-B@^GO61J
M6ASZ3Y#W=D]M(?X7&/7W]J_0'PYH&D>$[58+*V1]HP6=0<].>OL.E>:?M#>"
M[?Q9IMM?1P+%/'A7\I<# W'./Q%1AZN3YAB'A,+4;J-:/I='S4.(*DJL5.C:
M+=M]5YGR/-8QO$"T*[B<YY]*IK8I',,1J.??UK5NH"N^-N3&<;OPS_6J440,
M@W#/XFN"<7&;C+='VB:DDXZH2\MX_,W-"#P/7T^M6M/LXI(F(@&0/?T^M17&
M=F!5W2\B!QG!*D?H:@94N+56MSF%<Y]_7ZUT'@G1Q=WQ7RU'RJ._H:HQV>ZV
M<LV[G^M>N_LR_#N/XB>)M3MGN3;BUB1QC'.5<^G^S0!P_P 1M!_LVZTY2H :
M$>OO7'Q6")<RJ8EQNQWKZ$_:R\'VO@S6O#=M$Q<262LSY/)RV3U]NU>#-&)9
MGE0X5FR.: *^N6,4-J/W2CCW]:R-*BC34H#M')_K6WKR9A3<V>/ZFL;2OFU"
M$L<\\?G0!J:E BWTY$0;)![^@IC0HMON\E>GO_C5C4E5KR7<<=#^@J/R9[FW
M\N%"[MPH&2>>!^M5&+G)1CJV&K9C+#OU)V$63MZ=.U=5INDNVFM)*BQOGY<X
M'&37NWP>^"MG=>&K>^O]TDMRY W#'1B,?AFO4M7^!VCO9+Y400J!G823V[9K
M#&9CDV755AL;7:J=4EHOF?.5,W_>\M*DY);O1?=K<^$[F,QW<R@ #/)_$UIZ
M>B?9DX7.<?-UZ"OH/Q_^S3%<6,M_I]W)]H3K!@9;D< 8],UX[JW@^_\ #KQ0
MW4#1(RY!8$'CJ3QT/'ZUZRPOUJ@\1@JBJ4_+?[NAWX?,L-BI*%-V?9[F'KT<
M:6@;"]/>N1L&#7\7R#'X^]=IXA4RVI(^0*-H0]\'_/Y51^'^CP:OJ$RR@,8T
MW+^>/ZUSX>A4Q594>K_0]1;V)/)C8GY #FH;^W6./(4=*M7&0Q&, 'K5+4+I
M5C"MPQ[FL9Q=.;@^@&1:P^9/(6"X%=FD8M_#B%(,[FQN Z=>:YZQTE)"<2C?
M(P 7/KV%?2FD_!767^"]_JMQID-O#!$THN)7<,5"N3@8QG J /ENZ1BW('WO
MZULPQKM3<%Z#^55+RT1)MH<OSFKD,9*ID8_.@"UY"!<X6H?)7<20,=:M-&/+
MZ57DC+#&<4 1RHI7@ "J=Y"OEDU=^SMM/-5K[*QF@#]?O@.N?!.B #_ER_\
M:AKSW]@^/;X=^*/_ &$X/_13UZ%\!SM\$Z(5X_T,C_Q\UP7["?\ R+OQ/_["
M<'_HIZ /E7_@H0F?CM%_UP/_ *!%7S=''M[XKZ7_ ."@6W_A>T61_P L&_\
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MBD5PQ &,?P\_XT 4X6_? >9_*M"^PL:#?A2.M9\2_O"2.<XJ]J:LT<8SA._
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M0W6E2W1!68JP[E15Z'9@\8JQ&IQS0!T_A7XP_$#P/9"QT/Q UC; 8*QQQ'/
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M*9.1M;/7_P"O0!^L7P-&/!^D?]>G_L]>??L,\>'_ (G?]A2$?^0GKT'X'_\
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MN?H)\,?@/X6^'GCR+6?#/B&.ZB,>TV_GJ[?>!)( Z9 [=Z\4_:$^"_B?QO\
M'.[_ +-TMCIURL9^T(45<!$5B<MU!S^5>0_!'XQ3_"_Q8-7:!KY"GEF%N>K
M\<]>*_1+PWXO_P"$G\.Z?J4+-Y-XK$1!@<$,5_F#UKJQ7UG*<1[>3Y[JUV5[
M2.(IIIZ'R]^SK\'=9T"Z\0)KFFF.T\MHU$C(PD)4XXS_ )S7LNBZ78XGM8HQ
M L8^X!@="?2O4->M3;VJ,&;RE&X*#U.,X/XUPUTT5O(UQ;P$!P0^<9X&,_SK
MYW%XN>+J^TGUZ&[T]V+T/B;]KCPSY=U)>1\  \\<\J*^)/$'_'^,^E?HQ^U3
MHLE]X5N;A4X"L>H[$&OSE\2MMU3;G!'!%<?J0=5X D$=O.?6NEFNMMO(<XKD
M_!;B.UD#'!)K>F.;>3F@#]!_^"=K>=X-W,<G[8>3S_RSCKN/^"E@V_!JW Z?
M:#_Z U<)_P $Y^/!/_;V?_1<==]_P4J7=\&K;'_/P?\ T!J /RZM_N(,U8VJ
MI+]ZBA4@1_Y[U+)\S8[YS0!6OMNSYC@GBOH;]E?0YWO)9W#)&=H!_P"^J\-T
M/09O%6M0VD$9D&X XP.I K[]^$/PU@\.^%K=C&(IRJY&0>@_^O0!Z#I-JUO
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M?:>AYS^-,#J[>&2/GJ"<UM7BS-9KM'&*P7O)))O+  QQQ70V0GN( B\GWZ4
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M.G46Y^D'A?Q[H/COPK%'J-H\3E=@EC^\,8./O=![CO78^&;S2?#FFI!I\1N
M.?,D )S@#'7T'ZU\C_"?PMXNECMM7@MXETZ,X*L[9;C&,8]QWKZ8\)^*X=.M
MS%>V(0L2PP6.,@=R?:OP;CK@6CEKEB<'+FA4=^2^JOY=C@P_%>-PLO[)EB/<
MCU]-+,]'T_Q5YC99<'L-HK"\079U'Y>H[?K7FFO?$:QT_5"3>01G=@0[QG\1
MFNY\$N/$]Q((V0D#(PW';D?G7YMB^%<5D-*.88BBX1:[!#.O[2E]54KO\S-O
M/#S16YN5DQMYQGV^E8,FH26\C+OZCVKOO&&A7UO;"4.HA4\G\#QTKQ?Q+XNL
M?#FJ6=E>2$SW1PNT @9..>>M?0<.8/$9^^3#+G>^G8\#-E]1GRI-'FGQJ^(E
MI]C-A#YS72N ^T#!SR,<^AKYRF=9+IR0=^_+9]R3_*OM'QA\&]+\9:=YZQ>5
M=E=[2[V ; R,C.!QCH*^.?%%D-!\0WM@O)ADV[NN>3Q^5?TW.-"AEU"AAH\L
M5NGNI6UN:</5J$H2IQ=ZCU?^:\C<TEH_LXVU=9L'ZUFZ*Y>W&1[5H']W7EGV
M(FTIR:EZ[:C\WV%/7YL4 4-8(\DD_P!VN5\,WUQ:ZU9740Q.C_*<>AKIM=D\
MN-CVQW^M<C8V\MQ?6]O VS!R6/U]:Z,/_&AUU1,HTYP<:FSW/O#X-?$QM6T^
M6/6H([HK)@[EP2,#T/\ *OIC39++4-'BCMT2.!P2JL3QR1ZU\6_L_P"B/IMG
M+?S3>:S@QA3C')'/3KQ7T%I?BI=-T/[(8CL9L"0$DC.>G/O7X+XH\-TL9FDJ
M^5MNJM9QZ1T5_(\W(LZCA)SP6(J?[/>T?+Y'4^(M:CTMOL=H@0L.6 ![?_7K
MA-0O;VS\RYFN7\O&,8 '-<?XN^)T>B>(41G\T, ?FP.PXK4MM<MOB1&L-H19
M01#,KR,0#QD@$]^#^=?E%'*JV&4958W3W9_36#P=#!X*GBTDJ+5^;R9Z]X"6
MUU#PO+.\8E#?>)_'WKE-7L?">GW#32V'FR;C\NYL=?K[U;M[/^S_  0\>F3*
M88S\_P V22<#^AKY[^+_ (PN_#L-M#9RD/,"7=@#W'3(^M?5<&<&U.(LPG2C
M5Y%=WUZ>A^'\1<88C!XMPRR3M/;S.P^)7Q&TO2=J>1]G?R\00)TVY(!Z_7\J
M^=K?Q%=->75PS_/,/F/'KFL34=>>:X\V^E:1F&=S=!DG^M9MGK]G>7L]O%)@
MQ]6)&&Y['-?W%P[DF X;PJP>'?O=7U;/SR6"Q&(G+%XA\TIF9JC!KB<CKYF?
MT%5K5MS 4^Z\F<;U^4,V0,G/2H+<B*0!:^,S*:J8RI./<^KBN6*1KJ-JXI3R
M*15#(I/6D8$=.E>>-C6&T9-0R2[B,5*3\M1#Y&/'!H&*K9R:BFD'([]*?YGM
M4$J]_4T 1F+>/FZ55OMD4+CBK6TLN*IZE;EX6H _6CX'L&\%:,1VM,?^/FO/
MOV$6#>'OB?\ ]A2#_P!%/7H?P/4+X(T3'_/I_P"SFO-_V"VW>%?B?W_XF4/_
M *+>@#YC_;X;_C(*+G_E@W_H,->#K\RD>]>Z?M\-_P 9"0#_ *=V_P#08:\*
MH >JYXI<[6(%()"*-VXT 2*V:=(=K4BMWQ2\L: )U.5!J1346W('YU(ORT"U
M&W7$.>M<_<KDDKU'(K>NI"8B!7._-YC#O1Y#+<T+W.@WK@8E,9$:^IQC^=?1
M'[ /C_P=\%6N=2\1073ZO=MY?^CA2%^=P"06'8CH*^<;J]-KI%Y(I'RKQ]<&
MOHW]CKP;X3^-OANZTHS_ &3Q5"\<D;,Y P&D+ C=W 7M7=@Y89S<<5L%F]C]
M0DU+2?%?AW3]5$$4]O>6ZW%OYZ@L%9 P_0CO7G6O:/I?CIFT#5K 2Z<&W*(V
M=!P<@@JP]!77Z;X5DT'P+H^F2OYLFGV:6NY>A*(JY_2LSP[C[68IU =>!Z\9
MKC<G&34):)Z#>C(H_P!GSP#<:3%ILVA^9:Q,'7=-*3QC!SOSV'>N]M])L=/T
MJ"SMU6.SME\N- Q. !P,Y_K4>GZIYGF12#9LX#'COBIFF5K4(NV09SP>:)U*
MDU:4FQ\S>Y^?W[5'QX\17WCJ_P! L9CI^G61^SM'&HQ)@D[B3SDY'0U\VWUU
M=R*&\^9U9LDECCO7VM^UI\%O$?C[QCID_AS1VN(/*5)FAC9B&RY+-A>F".I[
MBO0O^%%^#_"?P/TZT\86D$LVG1[I+@RM%ABSD9*L.S=Z^YH9GA<%AJ<E%-]4
MMS&K2=5/6Q^6^KZ;''JD-XX8F1@K],?YP*W[.2-(N!A,?+ZUF?&;Q9:^+/'T
ML>BHJZ3&<*Z]. !US]>];OA_1;[7O(M[2(RR[>B D_RKT<GQ,,95JUH0Y=OR
M/(S!K#T4JDB,L-GN:B\MY.AYJYK.CW6AWQMKR)H)UP6# @\@$<?0BH>>&'4#
M-?42E:UCS</&-6/,M4;W@7^R]-\4:;/KULUQI:2!IXE)!9<<@<C^=?2NF_&#
MX8^%?'FG:YX3MM2T.S@5EFMPJ/YF49>"[L>2W8U\G3:E--(GFG=M4*H"@< 8
M]/2M:QT+4-4TV[O[6WDDM+4+YKJI(7+!02<>I'6O'Q>#C7?-4E96MOH?08.O
M&,7&FCZ%^.7[8MWXSAFTWP_;_P!GV?F;A.T8,K8.<')([#H*^==6O]4\2>9>
M74PDF*X+;0N>?0#U-4[729]2O8[:!2]Q*V%49R3]*]+U+]FWQSH.C3ZEJ]H-
M+LH8]Q:ZW1YY  &5Z\]*FE3P66PY;I'-5^M5G^[T1XKX5T0PW!ANHT3+Y616
M;=C &?YUT3ZA=:7=*MO>RCR^1AC4>EZEIFHZ?./,5K[?Y<3JWWN!VSZY[5ZE
MX9_9C\8^(/"M_P"('L_L5E;1M(6NMR,X 'W05P?P/8USX3%X!4G.'NQ<GOU8
MJF'Q$JJ<9'I?PQ_;<U3PSX;TC1;^RBO$M699+G:?,96D9O[P' ;'3L*^@[S4
MK_\ :8\%VE_X+U6;0GMY )EF5!N(8C/1O[M?FO\ /IUYL3B6)\ ]1D'K^?K7
MV=^Q5XJ\>:_XAEN+J99?#<,?ERE;:., XPHRJ#G@]Z\W-,NHX>#Q5!)-:_TC
MLPN*G4?+):H^O_!>C7&BZ)9V5_.U[?P1!9;C ^8@>V/Y5S/Q,:^^QW!T\_O8
M5+I%C)8\''3VKL+[4G^Q3_9G4W)1@BX&>AQVKF);>YFL97O&S<LN!&%P3D8P
M!BOSZ+YGS,[KIRO(^,/CAX\_X6EX:31;>UD&N:-+(UU%MX;!4G SVV-V[5\U
MZOK5M)I+B2P0=!O7).<CWK]$_%_P TVVT#4[W0-#;_A(=74AKF6:7$98C<2N
MXK@AF[=Z^#?VD-/B^"'A=O!U_+;76MW#>=O@<-Y>67@G_@!ZCO7W.%S:AA<(
MU1CZ+\SBQ."AB*D:C=K')_9;@6%M<M$T=O*,IN&/\\4^/4I[6$JA..I_3_"K
M_P %_B-I5YHMMH&OQ1S1N<J[,5YP.X(XXKZ^@^!/PVOOA3K>LC3MNJ6L9,3B
M[F(ZI@X\S'\1ZBNG"<0TI1C3J0:D]-%H<E7 1K/F<CXMO+Y[ILL.:;'<&-05
M8@^U:VBZ7;:K?B"XNX[)"V/,D8 #GU->NWW[)GB"V\.P:M:WVGWT$ZEHEAN-
MSO@D< +TR#T-?2UL;0H659VN<M+ U=Z1Y]\,;CQ3=Z^FG^&IY8[RY(4>6H/4
M@<\'CD=J^G/#VF>// NG6[C3X]3UTR;W5PY+X.5& !V(Z"N6_9M^"?B?PWXW
MM]5U#;IUE&<R>8OS, P) W+W /0U]-:]>:7I=O<ZQ=?Z/8V"F221W(Z L2#G
MJ0I[U\+G.,A6K1IT4I+^M#W**G"FE/5GSI\6/V>?B%\9;Z+Q'-IUO8W\B+')
M;9=2  H! VGL#WKPSX_? 2[^%/@$RZQ>0M<L%9K=')(PR<$;0<Y/Z5^@/@GX
ML>&?&>B7FH:9J*O;VO$@D< KC//WNG!ZGM7YL_M[?&Z7Q5XV_L33KE9;!!AF
M7:?X@>N/5?6N"IFF*C3^K-<J72Q;C'VCJ\NK/&IG#:38$#&X9 ]L"H)EVJ3_
M +-5;&8R:;8HT@=U&,<=,#%6KOY8VKPDE8#]#_\ @F[_ ,B/_P!OA_\ 1<=>
MA_\ !23_ )(W;D]/M!_] :O//^";W_(DO_U^'_T7'7H?_!2C_DC-O_U\'_T!
MJ /S$C5-A(]*^DOV'X[>3Q5=NZ*64J 6[<@U\U1[O)0+_*O6_P!E_P >CP1X
M]C@N"J1WDL:Y; 'WU']: /TWV)!9^8TR@A20!CT^E>*^.FU'4KP)IFI-IDF[
MYI%52#R/53VSV[U[,(TU#P\DMN!+$R[R4)/O_C7EEQ8I-?7$+YC)^[N_&KA-
MTY<Z&FTTSNO!]C<)X=M4:Y:\GQ^\F8 $\#L!_2NCTK2G6ZS$,GJW7WKG? -O
M)INDSK*<N6 0'TY!Q^&*]"L(YH;.)[:,L2?F.,]JF4G)W#5N[.9\074VDWT6
MQ>&Y;CW->A:3X@L%LX^0)MO//_UZXOQQ<BULS*\6;@KU[=?3ZDUYEI?B#4/M
M!D9B!G@8'^%(1@?M[?#:V^*?PY$UN";JV!.T,1_>[?C7YL_")IWFNK&Y3&R/
M81C'4J?ZU^JGQ 8WOA'4)KM_+"+]YN!VK\G_  OKT-KXPUB3S08]G5<>JU<(
M2J/E@KL#[Z_88\,Z9X>DU-[-!]I=1DDD_P 0_P#K=J^@_BA=/F-+?ARWS'\*
M^,/V&_BQ#?>))[.25$964*K8!.67C]:^[O&?A];^QCNU4G'( SZ?_6J&FG9[
M@1^"S!J&CQPM)_I"#<>?K6[X?TE;JZGDD.XH<#\S_A7$>&]/*:@LH)C.,8)(
MS^%>FZ.JJLJHS*[+C.!Z&E=;!Y&+XLCU*&$)81_)_&<9],=OK5?P[X@?2X0D
M[9E[@_3FN@NK:^T[3[@32K*AR1D#C\A_.O*].22XUJ; RA8\Y..M&^P'IL^N
M#4O,MY=LD<@RT?X_Y[U^4/[<7PNTKP'XJEU?2[<Q"X<F3#$@9+'U]A7ZD>2+
M&VW^8&.,8&./;-?FK_P4"\=6.L7QTBU=9W4X<+@G@L/7Z4P-/]F6QTSQ)XAL
M-4D4,T=O@<X_C!]:_2O0<#PR/+7Y0,C\C7Y4_L4ZPFDZ\]G*WEB5< /@]U_P
MK]4M!06_A0; 7^7&>3UR: ,W1=8_M#4'M&'0X_4#^M=5?Z:([  CYV/'ZUR]
MKY6D31W&W>S-R .>O_UJ[2ZO%9;:16YD ^4XXX% !I]F++3<RMM.W=^7-<S<
M>+[2ZNC9QN"ZMCMV./7VKHKN\6\62VSD@=!]*X6ZTCR]0S:C,F[+=^__ .NE
MJ!Z!;6Z_V>[2\HT>/TK\I/VJ/A[)H_QNN=8@!$3SR'J2.7<_UK]3XUNH]*7S
M!\X7GCV^E?G3^U?JA;6]0C)7S/.8CIGAS_A3 ]>^#5U'>Z;8&!<?+_[+7NEG
M>3Z>LDL>'=>HQGTKXA_9U^-UC]HM-,E=1?PK@@D=EP>,_7M7V58^--)U!DF@
ME#!5RR @\^IY]Z /5-!U9=6TM)67$@[_ .36;X@\1 7'V4KD,<9'T^M><Z7\
M==$75?[/215F+;=O'M[UZ]96ME>!+Q521F7/+'/Y9H \_NM.TO0Y3?W)82GY
ME&X]0,^OM71Z-XP^V6RLA_<@<<#-9'BOP9=Z],7D_=VZMN')';Z?UJ]I>@I8
MVD<2,I$:\G/I0!G?$C7&NO"]^WRF)87W*P_V37XM_%A$U7XU:O;V4(\R:[D4
MHN?[[>_UK]'_ -L#X[6G@?P;J>FV5U"M](&CV94G@ 8Q^/I7Y@^ ]4EUSXK6
MFH73;I[B=G;IW)/]?2@#[?\ V=OA[_PC.C6)GC*.VTD$GC('%?:,^I1Z3I-M
M*_\ J8T4'\>!_,5\TZ+<M81:<L/!**3WYQ7NMEJ4-UI]K;W1SY@Q^0S_ #%
M'>>'+Z#5H?-C'&/\/>JWCJ36M!\/3WWAFS^WZP,".#:6SUYQ^%9NDW$WA<I(
M%\R!^F!GK_\ JKL/[55HX[A6 W#.WC_/:G%J+3:N5%V=VC#-UJ#^#[>]O[7R
M]3,9>:#:<[P2 ,?3%<OX5U:34-6E>Y7 [C&.F.*Z?Q%XCFDD2UC@,@;J0O\
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MINI-&!/9W 7,;H^-P&X $9P1D$8-?SD:;J%WX>UFVOK.9K>]L9UFAF3@I(C
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M&W@:$K(@)(Q56WTM;:]$J#"#/'U%-.S30>I[)IOQ[N]%\&II4<"B:- JR*H
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M=V9LK)?/O)5ZHH=0<X//X'M7YE^)-<N_&'B*[U?4IOWDKDD,0 ,G/\R:^B=
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M7U%\1KEY/@?9"1LGRXR.?]H5\LS-NDC_ -]?_0A7TQ\4)O+^$.G1_P!Z&/\
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MQ-#=07D,:O/"0RDJ"<@@C^50_$KXJ:UXHTBWTF^"^7&N%"H%[K[>PK15BJ#
MR>W^-<-XXRUPGS;7]>G<5R^0&3HS,+Z.,C&/\#707*97_>'/Y5S^B@?VE%\Q
M8]_3H:Z^>$>6/I_2@#[^_P"";JX\$?\ ;X?_ $7'7HO_  4KX^#=M_U\'_T!
MZX#_ ()RKM\$#'>\/_HN.N__ ."E1_XLY;?]?!_] >@#\O(X4D"%A_G-7U^7
MIV[=JJ1G"IBIXFRSYH EVACG #>W%/=#(B%>!GFFK4BL1\G0'O\ 6@#Z(_9.
MTK/]I7;#B/!'ITD_PKR?XN:DVI>/-4DW;S'*R*>P&]OZ5[U^SO9?V+X$UB\9
M@FZ(D$D ?<?W]Z^:_$4WVGQ!JEQG>))F(.<C[Q/]: ,WRED4C'S9QD_RJM-I
M-NHW/$I/J  :M*^V'..2<U(6+1?/S0!;\,ZY=^&[EW@F:2+LI8D=NWX5K)\3
MY&UXZG<Z9ON%39&X7 SD$9&WVK \N.&$!3R>M#+Y84 [N<\B@!MTTNK7SW5V
MV-QSM89'3L*MQL&QM.1T!Z5#N$C D9]JE9UR"H"#ICB@!]PK2+UQQU[U[C\/
M=(TK6OA_?37-C]INX8L+(O485NO'L*\,:8M$ZX[8KZ"_9MU!+CP3XEMYE0[(
M>-^,])/\*TIU)TI<U-V#9W1\_7*[;RX"911(P"9/')JC=1,_J3[UHZHP_MG4
M"!QY[@>GWC44?S=:AMR;<F&N[*=F9+;YER'!R#WKM?#'Q.U'19/.N"T\B_=\
MS)';MCZUS3QJZ_)C(X-(N?XU&.YXI 5];U*X\3ZU+=2*R"0Y8'./RJ6*%+7.
MTABW!P,4\*58E,&FR(WRDJ%.[V]* )K>0F2VP<%9 !C@]:^W?#/B">U^"MS(
MTV;A;4A&]/E;']/RKXBM(P=0M4SG,@Z'WKZ_\07%OX4^"H$CC?-#CD^JL<?K
M0!\D7EY<7EY<7-Y,9[AIY,,QS@;CP.?3'Y51N[-+B-W.XL>V[C\J<\B322D=
M6D+#\234C2>6H'6@##M+B?2KM&@EDB=6S^[8J<>A]J]2G^*$UWX?6REMEG&T
M!MPR> .>GM7"F*)Y\LO)%3*JQGB0@'M@T 9T=P)F51N '  )Q4YMEMV$N>^?
MFYJ9(8HEW ?RI+B5&MBK#J>/6@#ZP\8S07G[-Z88,XQPIQV?M7R9&VZW3"A2
M">WN:^DC;W%Y\ Y0C[U7G&<]F]_>OFN/*H%?KDC]30!/$H;+-S_+\JK26XMY
M&DBBP3U;BK"EE4[1SV]*D5"R_O6V'T% $/AXVEKJINKMRR*<LNX@=^*UM:\8
M275XRZ2GV2)>%D&<_7-8LD$6XJ$PK=6IT:)'PO(7M76\75]E&E'1+MU+YVDD
M1R7>H7]UYMW>3RN!C=YAP?PS3S&&8*V6YS\QSVJ7>O4+@]<4T$%LYKD?F1IT
M*^2K'< 4*YYY[U]"_LKW,JPWK$L8E5C[=4KY[?YHQV./ZU]*? >S&B^ ;RZ!
M =]PRV!UQ_A0!XY\9O$$NN^-)U#EX(6R%!.,@?\ US7"[E9=K#C\JTM?FEEU
M^_D8ABTN.OL/\*R0NYCZT 9>H6 ?>0,]QWQQU%=3\-_B)-X3#Q2HUPO0 DG'
M7V]ZRWPH(*Y]:KI;P!BR,5[MP: -KQMXH'B>\^U+&(LC&T#ICOTK*\,_-XLT
M0N.?/3^=1M%&[@H^5YZ\=N:L>'5_XK#1L=/M"_3K0!^R'P5_Y!\'_7C'12?!
M7_CQA_Z\8OYT4 >MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %(U+10!^7__  4VDV_%32AZ+_[3AKY$D<!B?;-?77_!3=<_%32N
M>=O_ +3BKXZN RN10!;63S,5/TJG;_NU#$YJQN\P CB@!ZL=W(XJ3/!4>M,W
M#;QUIT2'<&/;K[T 2*V%5<\CFI-Q]:A!+.[#I3=Y9L4 6E;%2!@:K[67G&:5
M2!R3B@"RK8HW!6R>E1ABRC%() S!"* )S)G[M-7/>D4;>E*6).,4 /QQ3X5=
MHPOE*1G/:F,<"J\<DJM\A9!G/S'/X4;Z,/,]3^%6K:=;^&]7GO+=1+%N$1Q_
M%M!';ZUSOCZ[BNKB.\A_B3#-Z <?TJMX=:2XM9-/MOWTLS[BHX[ ?G6_?>"9
M[C0[DSN+<PQL&1N3R"?Y5]]D].GB\OE0J/J>#CK8?%4\9+T.#9MK#8,)C^G-
M.W#'/6D^;[IZ#C\N*7Y2.AS7PDXNG)P?1GO+9" ;N3UI NX_2@KZ4J_>J $V
MD4X_,H_*CS%5MIYI?XCZ9H 9DKG'6I!G:%/>HY(VY"GFG1L9+A01C"Y_7I2\
MD&VK/4_V>]%TCQ%K=Y#J,7F^2I=1QCC;UXKU?XL>(3I>@W<4$BV\8@954'!Y
M0XXS_2O/?V8="G_M"]OO*;R74QDY'&<<GVX-1?'SPS?S74NK+=L=.=EVHK#(
MVK@@_4@U]U1BZ-'WY)4U#\6?F>)H+'YTH0EL[_<>-LWS.2>6.?SI(F"M\W2H
MW4[@0V13N"*^&/TPG;#8VFH]IWX/6HSD?=.*$5R>3DT /DC_ !IC?NS@4]LT
MUOWG44 *J_Q4&G=%I#CKF@!A7OWIC,12NVWWIF[<I^4YH 9)-M]Z@,Q=E]JD
M:/CDTWY5Y/% #I/WBXZ5"H1#[T>>&;BB0=#MQ[T )(S,/:JE\K^0^*MC/3<!
M^=5KQOW+C=_.@#]8O@6K#P;I&[K]B/\ Z'7F7[ /_(N_%3_L)P?^BGKU'X'Y
M_P"$,T8Y!S98X_WS7EG_  3_ 'W>'?BIQ_S%+<?^0GH ^6_^"A3[?VB;?_KB
M?_08:\4M2#&,]*]F_P""AREOVBK<C_GB?_0(:\-6X,=NHQSF@"_QNX-./R_6
MJMJQ;!-6).7XZ4 /\PBE?K3 N1FI$4S<]* )HV*KG\*D7)YJ!FVMMQGG.:EW
M_+Z4 2<$\]*<)-C #UJKN)XJ=%_O'F@"=V^:D#;6 J-FYI=XXH FD(500>:-
MIDVY/&*C'-$C-N0#Z4 6([=)KNWBSC<Z\_0BOH3X[WZZ7X!\/VH7):).?P/^
M%>%>%[-;[Q/IULW/F/U'L"?Z5ZS^TKJL:W&D:2I&;6-0WJ<!AQ0!XLJI@$'/
M<T\R8X'--:%5D;RP0/>@#';=0 ^D/2A3NI2P7KS0!!O.ZO5/V:F,WQ+6,\8
M/_CI->9"('YJ]0_9I^7XH(0/X?Y(U %+]HBZ,WQ6NTZB-V'Y C^E><O*6;%=
M]\?"&^*6HG'+2L?R)-<&S*S<#% #E;:N3WIPYJ-E)QCM2K)\V* %\O.2:38O
M2B23;CWJ*16'>@"1HPJ<5WGP%NOLGQ$T]B,DR*!^8KS\;@O7-=#\,=1>Q^(.
MC;1@-,@)/3[ZT >J?M-3,VIV9V=\_P#H)KPUE&2?QKW+]IF22-M/E^4[D7 ^
MH6O"HV9^HQ0 OF'.,4+(4S3_ )0WO3)7#, !0 BJ3V[U)D*,4*P;&..U,D&W
MGK0!#DFHIF$<3G&3M(QZ\=*F*^],CC+7UF,C;YR]>G7I51?+)/L!HZI 6TZW
M+J\05E(RIQQ^%8_VAF;)^E?0GQXM['3_  3ID<%C#%<20Y,JK@]#7STD0;VX
M_I7JYECECZD915N5"Y>70ECD^8$>M<)XXR]Y_GUKMED59 .O/:N+\:8^T9]?
M\:\@9E^'0HOH\_YZUW$BB57';%<+X=Q_:"%N1GC\C7J46GHRD="RYH ^Y?\
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M?WBC<>U $JA?O9YJ)C\U+M.\ =*" G7F@ :3"X_&D5R.M-90\@(X&,8ITBD
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MVLZ= O\ RQR/_'4_PKC_ ($X_P"%G6 '' /_ (^E7_VB-6^W>/YX>J1G@?\
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M )T4 >MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)UI:* /R\_X*;3&/XL:7G@;?_:<-?(@F_>'TQ_2OK?_ (*>Y_X6QI?IM_\
M:<-?(BXY)[#- #]QZCFI/,9L<&HEF#+QUJ&3>K9SQ0!?&)!@<FDRRG&/TJK#
M=AOE'!J?>1U.: )=Y].*L1G<E5?,J6-_ES0!(IVYI\; GYCBH=QI-WO0!.OW
MB>U2JP5<U K\"E5NU :[(&VL^<YI^TMSWJ%V*-T]_P#Z]2+*64]JJ2<'RR6H
M6:W'L^W@C-/4YZ57:3\Z:LI#5(%F0-Y;8';O7I,>H#6?A:UWY6;NUW!<9)P"
MYZ?@*\R2;<P!Z5WGPONGO+'4](*Y1U8J.^2/_KUM1JSP\XU(/J!S4:C4-K^5
M(F!D2;>,]_UK/;+?,W!W$?7G%/FFN]/N9;=B8I Y!7 '?@XQZ8JK*7;#9SM.
M?S.:^BS3&T<?04Z:]^.^G0SA2=.[@_=98Y7.>*3S"W;-0"4MQFC<.YQFOES0
MG,G^S^E&[<*@V(.?,_44@;!X.: )6SNP<X]JMVRC[4HAB;S!R20?6J/F!LAN
MG>M72M.BLXQ-/\DNWYW+G'7ZU]'DN!>)K>VO90_'R,:M105K7N=Q\*_#\/BC
M7YWO586]NN[R^AX*G)_,]ZXSQ5?M?ZY+(H(C7,>WOCC_  KN?">H)X?T#5-2
MB;:9,QJV>#E?\17EMQ(\TAE)Y9^?Q-<N;5YUL5.$I7BMC1)15HK04J6QC]*#
M]W!/-1M.R\"A6+<GK7C%$B[EZ<T_;NY(P:;&V:<S#/6@!U)YGJ:;N'K3E=7[
M4 .+#KUH7$L9Y -(TJC;QFD8<?+UH C6$Y*M\NWN:5L,N-W3FGC)C&>M5V!8
MX% $HD9!DKQ3)+P8 "<=":-Q9=G6FM& A]J $:/S!N4TS@+C'(IRMMC.*;'\
MR$T ,!.<YJO=R%2>/\YJ?'RL:@O^03[4 ?K)\#VSX/T?_KTS_P"/FO+/^"?N
M?^$=^*?_ &%;<_\ D)Z]3^!N#X1TC/ ^QX_\?KSG]@V 6_AWXI ?Q:G!_P"B
MGH ^2/\ @HFVS]HA,\9@8#_OB&O%--;%FG<U[G_P4*TQYOVAH&8_\L2?_'(:
M\+MX]D8C!QB@"UY@/7BE$B]C42X7J<TXS(O3^E $M/&Q>K!3[U75_,S@^]/7
M$J\T 66F&!Z9ZU*9,(#5+V[=:E5ST(XH DW;N:%'(%1^9MX I1+STH DDC&Z
MG+"2,^E"G>V>M.:0KVXH ;N*\#FG,Z@!0/G/)]: PZCZTAD3<Q[XQ^0H ]F_
M9O4:;J6KZDPS (6&_MR".OXUY-XBD5O$.IW$?(EG8ANQR<\5ZE\/[Q=#^%.J
M79.QY=JKGCJR?T->/>87FW/TSF@">.3+N=P//:IFD,G6JRE&4,O0\T[<5Z4
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M_P"/5X!8VYNKJWMI#_KIE7'U;']:]I^,&L0:-X5T?P[;LIS$'< @\D(?7W-
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M44<BLQ4#!%2<4 "2?.1CCK4I<JW'2H>-Q]:;+(5H E;CI03N&*B,O6F>9N9
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MCNAS.9&!8YVC _"D5MW;%1&3YL4[=MXK2I4G5ESS=V#;>Y)2_+C.<U%YGO3
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M?!]*/,"L/K36\L?.3SUJ%FWG*=!0!)(=LFX#BCAE)W8SVJ/S?EYZU S$$^]
M%F/:P*'\Z.(\J#G-54R#3I'*D4 .GRORCOWJK>3?NVRO2K$D@X8U2OFW0OB@
M#]:_@?\ \B;HV.<V?_L]>??L,#'A_P")O_84@_\ 13UW_P "5/\ PA^B _\
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M/X@7GV7X>:18I)NWLK$]^CC&/QKR[S!PI'-=Y\3+J$:?I4 /*J.,_P"]_C7
MP;9U/]^@"02LN-J[AWYJ1I-XXX-5H"P9U[8J0>F: )(Y.>>,4HW;]P&:0QJN
M"3TI_G#HO- #E;;DGG/:H9)MC%NU2,Q_&JKM[;L\8^IH ];^&4_]E>%]2U=,
M95=@4G&<E><_C7E=Y(VH7DDO3<V37?ZC"_AWX96\0DV-<,&*].H_^M7GD,C9
MCPN,C)_/K0 _?M'EL,>]-E^9LE>G%+*Z>9SQ37D'X4 1R2%E 'R4_:%CRW/_
M .JH]P9OUI[':,=: *S;WD&!@ '^56_#ZM_PE6C,2?\ CX3C\151F*R8'H?Y
M5:\/LY\4:,<?\O"?SH _8_X*M_H$/'_+C'_.BD^"?_'G#_UXQ_SHH ]>HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D+UH _+
M;_@I\2/BYI'IM_\ :<-?'X*GS/K_ %KZ^_X*@$?\+8TK!^ZG.?>.&OCJ-CE_
M?I^= %K(I?,/K4*L6) ZCD\XI&DV_>X[T 658=Z=YA],BJZMD9S3UE.X*!DX
MH F\P],8%*&]\U 9C@<=>*%<[@/49% %D-BG;L]>14 D^0,>A_IQ2^:/6@"R
MK#H%P:5^F<U"O.!GD].U)O)8)GG)'Y4 /W"C=3"P_7'^?:ACMZT *S4Z.;BH
M#(*6(C)4]CB@";<&;'XTY7"\56W[T+IR*?&VY03QG\Z )>"V<5+YF1UJNS!0
M<<XZTC-M&3Z9H G\R@,/2JXF!4D'A1D\4JS!E#9X/- #W;WJ12NT9)JO(V%#
M8X-.7YFV[L'&>3B@"?Y>N<_C3Q+N7 /%5/E!.3TI6?;CWZ4 6FDQ@9IDCCM5
M=F))%"L1UH G$G:E9P.>]5B^WDFG*P89SQ0!85MW>G[2JY!XS5;S-M/64LN.
MU $T4VX8%#.<\$BHE(7IUI5S0!.6.P<\YIF[WIC-4;/[T 3CG.>:1?ES@8%0
M^=\H&>:>T@*C'6@!)#S3&8, ">E#'UJ!NO)H F\PKTYIK.6QFH]Q7!'-#28&
M6XH ?N[57NY L34OG#=DGBJEXQVOZ4 ?KS\#.?!FB'_IS_\ 9S7 ?L-Y/A_X
MF]_^)I!_Z*>N]^! /_"$Z(?^G/\ ]G-<%^PSD^'_ (FX_P"@I!_Z*>@#YB_X
M* ?+\=(@>GD-_P"@15\V;?F.!7T?_P %!6Q\=8O^N!_]!BKYQC8KR.: '*F[
M[W%.7"\#FHC(7H5MO&>>E %D$4H7'>HMV,#O2^83TY/U% $V:3=4"R%<[N!4
MJG=TH L1M\HIVZJK2;,9H:3;C/&: +&<T[=4<<@]:56!+<T *?FJ[X=MS>Z[
M;VRJ#\VX[O8$_P!*H;BQ(6I;74)+&Z%Q$-LR+C@^V#0!M^.;QKC7I(&;/D#:
M.<C@D8K"5?>H[F]EO+B6>9<R2'+'//6HEF/KGMZT 6NC4N:@$A..*D7VH D5
MN?6G*X7D#%5=Y7&>]/>0JI4]2N10!O>"XS_PE%@V,['W,?Q!Y_"I_'EU]K\7
M7C[MZ @*,Y P,8%6/AVB2WMY/(0H2$[2<#Y@#Q^8KF;Z[-QJ%V[GY_-8?DQ
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M/_"F;?\ Z[G_ - :N&_X)TNK>"1@_P#+X?\ T7'7<_\ !3 _\69M_P#KN?\
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MAM;V^MK:V(,$*@,B_=&-W;'N*XF1EZHV1V_PJ&:4R>;(1O>1LG)Z4V-P5XX
MH >3SEN?K3)''9J9,Q/2HV([')H ECW9]J3S"&Y-(LV>*B9OFS0!9W@L/7!Q
M4V@LW_"4Z-@G_CX3^8J@K_,.>Q_E5_PZP_X2C1O^OA/YB@#]D_@E_P >4/'_
M "XQ_P Z*/@@"UC 1T^PQ_SHH ]=HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *:?<<4ZF,W:@#\LO^"H;)_PMW1QA0WED9<$CF.'
MFOE_P#\-/$OQ.NKB+PWIXO)K%7DFD3"KM ))Y8= IZ5]-?\ !4K?)\7M%MHL
MF6Z7RE_WFCA Q^)JQIG@FT^&OP9\'6:^,=/\)>(;IX;R]DVRB26W+([HQ53U
M0M_WT: /E72/!^LZ]XFO_#VGV7VC5;/<;B,@!HRH8MSGML;H>U&F^#-:UB?4
M6M+-I/[-/EW#3$;=P;:0.1W/&#Z5]G:3X"L=$^/FD>---O(;SPMJNFL9Y+/*
MM/\ Z*Y9CN'<OGD=S7B/Q^GU+5)-3E\&;3X+CO6$D%MD/YF\ &3G!.=G0=10
M!YSH/P=\8>)+,WECIT,=OT5IY8U/0<<N,\'L*R[#P#XCOM<DT"&PD-W&2TCY
M"X[<DG'4BO1M)^'6O:;H.F>*/&BZAJ=DBAK#1X'3+$C"EMP(P,D\$?=KT7P?
M\0-:^(?@7XBRZQ9K9:LL/EV5DF0VT2P$8RQYP6[]J / /&'PQ\2^!+*";5+%
M4LMVPW$3*PSR>2&/855D\#:ZOA1/$4ME)%HYE\M;EB-O\6>^>JGMVKUKP)#>
M:3^R9XXCUY9(+F2^8PQWC R%=B8QCW!_(UKZ9_PD>M?L+RVEZMS+;1:B3$CL
M"-F)R3CZD_G0!XGX2^'OB+QLLLVD69N+.,86:1U5=WH"6'<'\J76OASXAT7Q
M)!I%QI]P;^8+Y0B=2C9 /4''!8=Z[KP#XVL?&'PKM/AUJ<%[916MP9%O=(94
MF)+R-M8N&7GS#T7L*^D/#NH>&?#A\'>$=.UB6XO+:RNI)O[08-,"S!U#%5"\
M!AT]J /DO7O@SXN\.Z6-0N[!3$B^8S)*CD#&<$!LYQZBKFB? KQ=XDLX+NPL
M8C;W2*R SQAB2 3@%^O/<5Z-\#+74M,^)'Q)GU420Z:UOJ3)/<$%/]5,5*\]
MSCMZ5R_P?\,)'J&N_$+Q!<S#0])N9FM4D8&*>0E@BXQG!8ICD=: .3U#X0^+
M=-\3#09M,==4=<\NFU4 )!)W=2 >]4_%7PS\0^"+>.\U:T9("/\ 61R*ZY)Q
M@[2><D?G79:)=>.?CUXPUF^TN[NK+2B["[6!L?9X@68!<D\=N<\5NV7B>Y\+
MWFG^!](TRYG\-S7F=1U._*GSB #@E2.,HG5>] 'EVE_#GQ!K6ARZO!:^780\
MNSRHN[IT!;/<=!ZTSP;\/]>\=-(=(M6EMD.WS)'55+  GDD#H17TK\6SX=\4
M_%J/P9!X2DCTE8!%:ZK;^6(HL-(=P!.<X!SQW]:Q/B=X8/A7]FFY\,:!=/JM
MU9ZHQ\V!AO9#$IY.!W- '@VO>!?$7AOQ!::1<6 %Y.5,*1KN5N2!\P..H/>M
MC7?@[XLT/2WU&XL1)&@S*D,J%UX)Y 8]AZ5]*_#47T?PW\!64FH'2=061C-%
M(V'=?.E^4^Y!'X8KGO NJVU_XF\7V]IH,OA>]6!C)JDY7$K"-<!2I[C';J*
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MAZ/V9_B3_P!"]-_WPW^-+_PS/\2<8_X1V;_OAO\ &OW!HH _$'_AF?XD[?\
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M5[X8^+LVH:W-<Q^'_$OVHBZ+'$5TN\Y=>"V3\QY/\0KW#_AWMI6?^2@VF/\
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MW.JQJX!A =@<^9U+'T[U\_\ Q0CT:U^(6M'PY,IT1I#- Z^A.,=/3%?2?_#
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M>7_OL_XU$);T_P#+NWY'_"D+7^XXMS^1_P * '&.7_GO-_WV?\:;MDWI^^F
M[_.?\:1CJ!4CR,?@?\*LV-E/)\\PQ^!H O11[9()5GF!61?XCW;ZU^U?[)EY
M<3?"O1TE;?LLXSGJ>BU^*P<%HT52-LB<_P# A7[3?LBX_P"%8Z7G_GTC_DM
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M(J$_\%&/C-S_ ,3&'_OE/_B*^8SJUJW3=4;:E;?[7^?QH ^G_P#AXU\9L_\
M(2A'U5/_ (BD;_@HU\9_/13JD!R>RI_\17RZVI6^>%8]L?Y-36ZFYE5U1AS[
MT ?7WAS_ (* ?%V_\5:);7.HPO;W%S'',H5/NLP''R>]?IQX"\9'Q18V1G5C
M</;I*['IDKDXY]1Z5^&_A'_D<_#P;K]LA'_CZU^T?P47]W8?]>41_P#'#0!Z
M\L9YR>]%2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI';9S\HQCTK)T'_CT'IFMR.;G ';% ',:G&/M"<X^;&W%=+X7M8[[6%C9/D
MZYQ6,U@VH:S;V\/,\KX&?H>?T-?0O[.GP7C\5?%ZU\,:O+Y7G8(>-0>"<>OL
M>] 'COQ*TZ&PO;.V@._Y-V<GU;WKD]-0?:K@*N O8\]A7U5^VU\)=,^&_CK1
M](TQ][FW4L^T#DN_!YZ\#O7S$EFVGZE<1N<MU/Y"@"W;E64Y7GZ"EV MR/F^
ME.MH\ MW]*7&3TH JR?*<#'7TIK+FI9A\PI,9H @==QC!'_+1>@Q_$*_9?\
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MN,//U-2:1Q8Q]^*T]W[D@<GT[T <1J&DP)>A53:I;!SS71Z3I5HES&B!6]L
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M5^T8+R(9-K ''WFP.:]T7X82S2-,TS(=WW<9!YKNO!_@>2UM[F"<'9*A&Y,
M8P>"* /R3FMIK'6+J*X3RY8Y65A[@\U;F (W5Z7^T]X/'@/XE31[<17;-(I
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M;K5QP#VJK)\K4 ,J.1?2I=U-H JNFXI_UT3_ -"%?L;^R2,?#G31_P!.D?\
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M2U.R &R1V*J.@^=AZ>U '/:P8_[//F\)N^7\JWH+^UM[BRM[7 W#YFZ'&?\
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M;1E2*DM=-E\%ZA;W4\K&VE8*R9XZCV^M 'G?QC^(Q\.>99SQ>=YFZ/:V2.0
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MZQ;V49P)278]N5Z\_6OM^'29+..2=X\L74 X/<FOC+]LS0?M'VR91_&2?S%
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M:>'W>[E'E[> W7H?_KU^=7Q,E>^\=7\A!,>[(/;[JU]R?$)9[RQ-L_RQCO\
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M:_"GXF?\E&\0_P#7V/\ T&@#GF&#2KR,8I&Y:IDC^2@!%&33@Q4]*<JT[:*
M -Q0":1N.E*!B@"&ZR82*PMNUB1S71R+NC;Z5SS';(1[T )(O^A.<]>:S[-B
M)E;T./UK4VYLW!K*C4JWIS0!WM@P^Q*WM_4U*OS#@9JIIF3IZ]^/\:MQ_*O-
M "*A4DU(J\Y-&X4;C0+4)A^Y<>U<<P_TYQ[UV$C;8S]*X^5MUZ_U_K2>PXG8
M_#O33J&M[%^?"YQCGJ*^W])NH;#P_9V>,!8_RR2?ZU\B_L\VR7'CK9*?E\IN
M#]5KZJN8PLQ0'Y1P/RJN(,RJX')*,:2^.33/S+-ZCKYG*D]H+\[%E5B6^1@=
M\9/(KUC1-:TVWT-(@5MW[L2!QDY[]:\EM52&0.QR!1JFK*MI+/(QCM(1EB#[
M9Q_/O7\XX[**G$5:.&I1=V]D>QEN9O)[UTDWYG?:U%;:@28]81(VZ_,"?H!F
MD\,W&E>&8;J9KXWDQ5@ VW'.1V/O7A5M\8-(FU:&Q2TF='?9YI;U(&<?CZUW
M5]9K##%.C';(H8 ^X!'?WKU<P\-,=E&%53%/W/)K\3ZBKQ_CZM+ZNX))KL:E
MYXF)U">>),%F)7IW/'\ZX[XA^/(_"FB2:OJN_P A3P> "2P YSZD5MPZ7)-
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M&> %)(.17Y>6'CW]I;X[7=]K>D:M\3?&C02[IY]%:^N(;9\9 VP_)%@=  *
M/Z+:*_ GX$_\%$/C9^S[XLAM-=U[5O%6BVUSLU#0?$LSS3  X=$DES)$XYXS
M@$<KUK]S/AC\0])^+/P_T#QAH,K2Z1K5I'>6YD #JK#E6 /WE.5/N#0!U5%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 5M0(%G+_NU^%7Q+<?\ "QO$/'_+V/\ T$5^ZM]_
MQZ2\?PU^%7Q*VM\1O$)_Z>Q_Z"* ,!:>W^K_ !IJT[^''>@!8QQUI^.>#0J[
M<4^@ I<^U)2[30 9^1A[?UKFY/\ 7&NDV_*_T_K7-R?ZXCO0 \?\>[UF1'YA
M_O5K+&WV=QCFLF,?.!W!S0!VVC_\>H';_P#75_'M5#1?FMACT_QK0'- F)M'
MI2>V*=2A<<T!J1S+^[:N088OGX[UV4IQ$WTKCY&!OGQZT#.G\$ZTVAZQ]H21
MHCMP6#;>,CO7V'X3UJV\0Z397D,WFJR8D[\@D<G\J^&9H9IK.>.W;$[KM'Y@
M]?PKWK]GGQO=:79VF@7ELD<=PVW[1+,HYSUY'L>]=V)R]Y]ELL!&-I1]Y2Z7
M\_4^0SS!J+CC::NUOZ'U)#X)GU2W%Q:S*R'C;W[U6U;P/J4&F7%M-;>9;RKA
MMJ$GD'GI[U7T7QQ#X;O(XEOH)4)_U:S*3_.O1/\ A/[#48!<2O)&Z#)C"G:V
M.W3V':OYDQ-7B/AK'*K0I-\KWM_5S;!X7*,SI<M>I[.5CY<N?@K=1>(()K:Z
M6*)90[+(FPC!S_>KVAK.&72[>U$RM+#$JENH)"@$]?:G>+?$$7B&Z#P6BV^.
M-R@#/ &3Q[5QGBS68_#&AW%P;A?/="J*C#.2,#\LU^XY9Q!F_%=*G@\9AE9_
M$UT7Y'Q^.IQI5;4ZO/;X?,UKJ[M]'1S-J4 "@YC,HS^ SUKY"_:$^+B>*+B\
M\.0-(8HYL*I^[\L@.>G?;6AXXURZTNSFU"\O) 9U9H]KER21QQGW%>"6]])J
M%])>70\R5V)+$9//O^-?6K+,NX?<X8!<TIJTFW>R[=CZO+<J:<:^+]ZVR[/N
M>T?#SQ++X4UKPI+D21[-K  =T8=<>]?9?AR2&[FBFF)6"==RD^__ .JOBOPM
M'"^EVE[+&"EO&#D\G.,<<>]>T_#GXSP:DL5M?2[+6,;8G5<GC& >/>N//,CJ
MY[DT8PE^\@WRKRMMZF>;4:M+%QQ4(75E?KZ'N>M:6-+F,L%QO1N1M//\_:LZ
M&X7<#,2_/.3FLO6/%.G:?8"YNM0A, &?E<,>_;-<]8_%SPIJ4HMK:[9[ECA0
MR%03VR:_*,'PKGE:BZ<J;27=\OYGASJ1J5.:A!OT39WT5Q<7$NVWDDC0<@*Q
M K3_ .$HU#2+>59KH(FTC<TW3CK]?QKQ+Q;\<O\ A&X98([)0Q&%D28,>1[+
M[^M>4WWQ0U34[:Y5;F8BXY D<G'!&!7U='@?+%A>;,9WGVCK^)W86CFE6JU!
M>SCW?^5SJOC=\3IM2U%+73KZ=9(V(DDC<G=DC(//3&>]?.7BZ%KB\$SDEV;)
M8]>2,D_6NR59&N3)*6DD<Y8[B*PO&<2QK&P&/_UU]7&4:6'AA*,>6G#9?\'J
M?88+!QPE/EWD]WW,;PZXCNROMC]#6\W+<5SF@G_B8<GKGW[&NF9?ER/\*S/0
M+EC'EO7\*M%?WF.U5M-;Y3G/7'Z"KK?>S0!#)VJ-N<4]F!%,5@S8% #77Y>.
M*B'%3-(NW'4U#0 W'.*:0/2I*8WRKD]* ('_ (/^NB?^A"OV"_9+_P"2=:</
M^G2/^0K\?I&PJ$CCS$_]"%?L%^R3\WPYT[_KTC_D* .W^/R_\6A\38_Y]?\
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M37XA_$21T^(FL>9CBX96 QGL*_>+Q)=6^L:7):O@HXP<C/!!%?C%^U]\+_\
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MQ#?0V=E86DC()G"F>7:1'$@S\S,V% 'K7\T$<,VIWZQP1-)/<2[8XU&2S,>
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MC9R<_P#+!2.3_&05Z9K]HXXUC4*BA548  P!0 ^BBB@ HHHH **** "BBB@
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MT-;.H:_<:O#:0K";*>,Y\ZW8+Z\\?7UJU#9Q_>=5<XQ\P!J*2S$6/+ 3'3'
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M(Z]*C90PH B*]Z3;3VRHQVJ/=B@ -1LV[Y:?NJ&3[V>] #9"/D![2)_Z%7[
M?LFY_P"%;Z=CK]D3^0K\>W^9D]Y$_P#0A7["_LF_N_AWIV#_ ,ND?7Z"@#M_
MCP<_!_Q*3VM<?^/+7XB1*)K4;N@;)_*OV[^/2[?A!XJR<_Z+D?\ ?:U^)OAF
MQO-6"):VK3?-D\C% 'T3^Q#\2(/!?BR33;J7RHIV"Y)('+**_0K7+5-4T=Y+
M282;E.T X!X//YU^4WAKX.^*;^\CO?.CT@HP^;=@\$>C?YQ7TQKG[1R^!_AV
MVC6VJ/<:S#&VV5&?[VUB,GTR1WH ]PATMFFDM79E=C@J#_+\Z],\*VUOHVEB
MT>3S)&(.2><<\?K7Q7\)_P!IB7Q/=6L>JS-#?F0+Y@+8Y; SS].]>H:]XVUN
MTURV%K<%XYCE7W-CJ,]_4T ?4VIV6H:DMLEM/LM@/WB*2,],=_8]JY[Q9"VB
MM$L2$[A\S >XJQ\-_':Q^'3)J[QAT4%GVGL#FN8\0?M"^&=0UPZ7:*E[@X,@
M7&W!/&2/:@#?\-V=U?,;@L<?="L>.G_UZ\ _X*!>)K3P;\)Q!YJRW\PSL4\]
M0/Z&NN^)W[3%M\.[4P:=I[7MU)'YBJA  R2 #QUX/>O@WXS:G\2/C1K0U?4M
M/V629"0/,K+@DGE=W^UZ=J /#O#MN]OH\KL/G/)'X"NQ_9E^*-U\$_B=9:UO
M?[)*RI*BL0-N]23C_@/I6'H\=_>:I+IS69CF88VX&.HKO]'_ &=Y;F-+K4]4
MCL8DZJ<GWQ@=Z /U_P# ?Q@\,_$;2;>YLKV-S(N6B)YZXZ8_I4VL^$[>ZOHK
MB$H) <\8!ZC_  K\O? OBKP]\$M874[37]0U!UX6V6:01<$'ICU'ZFO1;']N
MK5;KQ=;$1216#,H8.[$XROOZ9[4 ?>5Q'I^D W$[+%-_>X'3OFK7A^^TKQ(L
MB?:UD(;H#[G_  KYQ\4>-#\4_"WVW2[J8.J$E5=AR5Z?F#65\-M0O?A[I\^I
MZK=O&GW@'<GID^OTH ^K]9T)=L<5N%B"\DGC/3_#]:X#XX>)M,\)^$42YFC6
M20>W;;7RU\1/VZK^'7HK;3X_,LXRRR,"P)Y !!S['L:\Z^*?Q+L?CSI]O#'K
MEQI]U&N/*:23'.#Z>QH \I^*GQ@DU#Q7*EL<VUO(P# G'WB ?Y5^F_[*WBK3
M_$G@'3Y Z-,\:Y'![#KQ7Y-:_P#!OQ!I-O<1Q)]O20<2JX+'G@YSWQ7T]^R!
MX@\2_#_08KC7I3:6D( 4%R>,+C.&^O:@#[^O/#LD&L--D>0QSCC%3:/I<]OK
MGG&XVP;?NCIU'O[5X;X#_:\\/>-M2FTM;@AX^ T@8YY'3CWKT#Q-\3/[&T0S
M6D2SR%=P;\#Q_*@#U22ZECAFDB02.!QT]*R;N:?^SS<7RYFS\J]?7_ 5YW\-
M_BM<:U(_VR$Q1!<G:WOCU]*[BZ\?Z#=31V;W*RW(.2G)QTZ\>XH BTS3;W4+
MA;ED*1CD*./IW]J^=/VX]8A\)^&(KR9]DLI*@9Y_A_QKV/XC?M0>#?A;9N=1
MNS&\:D)&B-RP _V?<?G7YI_M*_M+7W[3'B8V%E:$Z9;2MY1C!4D9&"<GT4=N
M] 'H_P"S!XTBU2[AA,N9WD9\<]""1_*OT0_LI]0\,VX'!"J?T%?CKX$U36O@
M[XGLM=;397MUVQM'N!&!D9P#U.?3M7ZF?"W]H;2_'G@ZSN[8^01$I>%XV!!V
M@D9Q[_I0!ZAIMK=MHL!C&QQC/8]!6W*TRVOF$@N%^7!YS^?UKR/QW^T!9^&/
M#<<]F%-P<;@5.!]./ZUR7PG_ &A+SQAK @NH<0-G#9X[>_N: /76MY;J*XN;
MX$.O*CKZ?_7KE?#]Y/JNJSJJ%4!P/PP*[W4O$&E&-Q<7<<"8YW G^E<YI_C#
MPQHWVB\@FS$#RY7Y3QVX]C0!M7VB&WL1-++L &3^7UK\@OVY?%G_  D?Q,N;
M.']Y#;3%=P.>BI_45]\?M3_M56'AWPF-/\/.+O5;K,2A<@#*D#]2.]?G+J/@
M7Q-XPU&YO[N.))[IS(?.8,?H#NH Z7]CO_D8IX@"9&7!]>C5^FGP]TUK?PB"
MZ\D'M["OS0^$-MK?PC\;6U]<6$=S8,=LAC*@C@CU]_2OT0\'_&2PNO"]I*Z+
M!;R*I92,D9 )[?TH ZYM!1K/[5!%FY'S=!^/:NH\.W]Q=:0QOHO*DC&%!P>X
M']34WAK7]*U+24GM+A)$==RG!Z8! /%<1XQ^+&FZ'?/;3/C!P&53CJ1Z4 ;O
MB'Q1);^791H2&/WOS_PKA?$4ZV=T&3'F-R?7O78Z7JUGKVC"ZBV>H:1<GM[>
M]9BZ#:ZI,)I9555?#,Q'IG ]L4 ;/ARXNGTV,R*Q5AQS[FO&OVGKF#3_ (>Z
MK<7K*XD1E1&P?X6'3\*](^*WQ3TKX8^'XW$R$J  J@YZ,?3VKX/_ &D_C+J'
MQ$T4*LZ06P;(C7<">".><=_3O0!\YM,\NH2,!B,LQ 'UJYN^7K6?:J3AP#C'
M)SQ5QLA: +WA=2WB[1#_ -/D7_H:U^P'P7^Y9?\ 7G'_ .@FOR \*L?^$LT3
M_K\B_P#0UK]@/@Q]VR_Z\X__ $$T >PT444 ?D3_ ,%P/^2@?"S_ +!E[_Z-
MCKX'^%?QP\=_!&^O[SP)XGOO#%U?1K#<RV3*#*BG*J<@\ Y-?TI:]X+\/^*I
M(9-:T+3=8DA!6-[^SCG* ]0NX'%9A^$'@3_H2?#O_@I@_P#B* /YR]>\8?%3
M]H#7+>UU75/%7Q U5W9K>TEDN+^0,>2(X_FP/91Q7Z#_ + '_!,/Q!I'C'3O
MB-\8--73(=,D2YTKPU*X::6=22LMR!PBH0K!,DD_>  PWZGV.CV&E@BSLK>T
M!Z^1$J9_(5<Q0!X]^UE\!8?VE/@+XG\"/.+.\O(EGL+IE!$5U$PDB)_V2R[&
MQSM=J_"CP7XQ^*G["7QRFNHK*7PYXKTT-:W5AJ4):"ZA;&589P\;85@RGL"#
M7]'%<SXT^&?A+XC68M?%7AG2?$=N%*B/5+*.X !&"!O4XS0!^&/[1W_!2;XI
M?M)^ Y/!NIV^DZ#H-RZ->0:3"X>ZVL&569V)"@@':.I S7TK_P $E_V./$FE
M^,%^,WB_3KC1M.AM)(-!L[N-HYKII 5:X*D B,)D*3][?D<#)_0[PS^RY\(/
M!M\+W0_AEX4TN\#;Q/;Z1 KJ0<@@[>,'ICI7J"J%  & .!B@#\[?^"FW[?"_
M"S2;WX5?#_4\>,[V+R]7U.TEPVE0LH_=JPZ3NI]B@.>I&/QNDD::1G=BSL<L
MS'))]37]/=Y\+/!FH7<MU=>$=!N;F9C)+--ID#N[$Y)9BN22>YJ/_A4'@/\
MZ$GP[_X*K?\ ^(H _!K2_P#@HY^T5HFFVNGZ?\1I+*QM8EA@MH-(T]$C10 J
MJHM\   =*_:;]B_Q]KWQ0_9A\ >*?%&H-JVO:G8M-=WC1I&96\UUSM154< =
M!VKO_P#A4'@/_H2?#O\ X*K?_P"(KH]-TNST6RBLM/M(+&SA&V.WMHUCC0>B
MJ  !]* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 5[[_ (])?]VOPL^)2_\ %QO$.?\
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M 8;,DJ8,.0O"R#'7N3^E<[JGA]EF-T&^?J"O!_SS70*S1.0/[Q/ZU3U$22S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#0Q7Z]_!G.VRY_Y=(O_037Y">&2#XPT3'_ #]Q?^AK7Z]_!G[MG_UZ1_\
MH)I,#V.BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!7U#_ (\Y?]VOPL^)3$?$;Q!C_GZ'_H(K]TK_ /X\Y?I7X6?$IO\
MBXWB''_/T/\ T$4 8,GM3XV/0TQ5W=:.5;B@![,=V*5E!'-1+RW-2MPM !&H
M4\5,9@>M5T;MGFG\>M #R0W04TY['%)G;[THD'KM^M #DSWYJ0N.E0&3/3FG
M*"P^G- $N['2E#,S9S@5%DTJR%: +.5QSUI5 /W?E-0(Q)YXJ7_5\]<T 2J^
MU@#R:4]:AW;OF[T_/RT 2A5;GOTIQ4=Z@C8X.:&D- %CHJ^S9/ZU[7\ 9&LO
M"OB2]89*PL%;TR#_ (5X@S'RY?\ 9Y_2O>_A6BV/P4\0WC+CS(V56/?[_3\J
M /$KN1[N\O96?<SSL2?^!'^E0?=)'O4#LWVAF!X+,Q]LDU(K;AF@!V:<K$=Z
MCHH D;:5)S@UI^'6$>N67[SI)QT]#6/UR""?I]:OZ;)'%JMFV#CS,9[=* /3
M_P!HR%;?Q!I4D7 :W3G\7KR=U9I!@\ 9KU;]HB3S+_1& ./LJ?\ H3UY.LQ\
MP8Z;<9H 5D+<F@ K\H.,TOF&DP9"#G&* '^25&2PH52W>DD#,N,^U-C<H<'M
MQTH /++/@]*:5VMR>*E\SY@14;Y[T /\M<AEX[4UBQ[_ *4BR%1Q2;BW YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ]>:!DS3"HI)B<;>#46[=TXJ-9L,1GM0!/N#?>IDLBJ< \5$TG/)J.1@3Q0
M/(>N?>F;O,II/Y4F0O\ LT (S%=@_P"FB?\ H0K]B/V2U_XMSIP_Z=(_Y"OQ
MRDS(T7/21/\ T(5^Q_[)8V_#O3LG_ETC_D* .V^/I'_"H/%/K]D_]G6OP_T]
ML0*?;^M?M[\?CCX0^*O^O//_ (^*_#S3V_<ISVH T/,Y_P#KTW=G\>*B+>E&
M[:I]<YH [3X5K_Q<+2(_29#_ ./K6Y\?-1^V>/Y%SG:@7\E _I6-\'%\SQQ;
M3$[O*7?GN,,IS^E9GQ U7^V/%M[<;V?:S+N.<\$C^E &,"=[?2EJ"-]T:-GD
M<'^E*TGO0!*S\TX.>QJNO/)/M2^:%XZF@"?<:=YE0>8#WI589ZT 3^8:UO"J
MI)XFTC?T^TQY_P"^Q6+NK;\$0F;Q9IBXWYG0X[<.* .^_:&G#>*K",'Y!!D#
MM]R.O+_,VD"NT^-.HB^\9&//^I10/;Y5&!^5<+N]Z +#%3@DXH79ZYJOG=C)
MR*<VW;QUH F\[YB,\#BI5;I5.,_G4ZN.] $F[]TOUKW;4)EC_9OL5;O-G_QV
M6O VE^_C@!<C\Z]D\4Z@L/P,T>W X>7./PE']: /)/-/EH5IX8M596!4 ' !
MZ4;BC=2: +>>*-QJ-7RN:;N.[KQ0!-NHR*9N'6DW[NE 'MW[,MZEKXCU,!L;
MH&!_-:\L\32HOB"_P<YE)KT7]G&,"\UFX(&8H6RW?[RC^M>27UT+K4KV4\DR
MGD]>E $GG+2^<*JM**53N7- %@,68$4^23L*JK)A@,^U$A/K0!/RM)YQ%0^8
M6&,FFC.[DY% C8T%OM&M6$>?^6P->F?M&7V=6TV G[D"#_T*O+_"C;O%&G*O
M_/3M["NY_:&N@_BBVYSY<*@_FPH&>:,V:AD?"U&DV[//O3/M Y#<_6@6I/NW
M0U%)+MJ+S?WG7Y?3M4<TFX]>*!CI'++QUJ/DTH8;:B=O0T :7A5L>+M$'_3Y
M$?\ Q]:_83X*_<LS_P!.<?\ Z#7X[^$R6\8:'GG_ $R+_P!#%?L3\%_]79?]
M><7_ *": /8/XJ*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBH6D.XTGF-0!8X]:56VGBJ_F'UI5D.>30!:9CMXI4=2O+<_C4#3;1UJ-9MM
M%AS\W!IN3Z5&9>,TWSA0!-N(I#[U'YU,::@!TA8?<Y%0E^G/-#3$4S<.N>:
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M_H!H ]BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH KWY_T27_ ':_!#XF-_Q<OQ)_U]C_ -!%?O=J'_'G+]*_ SXG-_Q<
MKQ)S_P O0_\ 010!A<TN['6H?.]Z1IQWZ4 3^8I[FE5O3I5?SXZ>LPV_+TH
ML*>YIT<RLQ!XQ57[136D2, ^M %Q9@P-.\P#I55YDCQ3DN(VH M"08S09!58
MW,8.*3[0C=.M %I6_.G[B>F/QJHLE.\Q5^\V/2@"UN/JM)D^HJOYT7]_]:/.
MB_O_ *T 62Q QQ0KGO5;[1&IR&R:?Y^Z@"PS\TN[TJON)IP8T 3;C0'*Y]*A
MW4%J +(DS3E.1556S4L<F%H L*VWWH#8J#S#2^8:!:DM.1]M5FD)Q2K(?6@9
M::3VI/.]A4'G&C[P- %A9]W84-)WZ574^709@>E $S-NZFD].:B\WVH\WVH
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M]?L7_H:U^SGP6YCL/^O*+_T$T >QT444 %%%% !1110 4444 %%%% !1110
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M>49G\A@J$$;54C:HPQZ#TH \V^&_A7PYJ*ZQ +2WU'7X]2GMFL[NY>$11J^
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M?'A+6.#,9*C:+C]R)0HZ OC<1UZD]2:GU+X ?';6([:*]M;&>*V41QAK:VW
M D@AMN<\GO0!P^G^#/"VNKIVFZQH<GAR\O)MMNJO*TK*5/+HS#;R#T]!6SH/
MPM\,>/-0UNQCT<Z8=!G"ETFE8S+M#'@OTRP_*M[6OV?_ ([^( %O(+5YU.4O
M4CMTD3Z$+GUZ'O4=]^SQ\=[R2#88[/:V99;80HTIYY?:!NXQU/84 4H/ASX
MFD^WWEJ9+"TD6-X[621ADC.68.,< ]37->*?"VC3K97^C>&!J>E-(5#6<TKN
M6S@!@#P!@\YKK+S]G/XYWZQ"2.WB$;B0K"D"*^,XW*HP>#W%7+;X#?'RRO8+
MBTBM;0HI7RHHK<1<D'.S;MSQZ>M ' ZUX#\)>)-7TRPMFA\,ZF@\R[$T[>48
M_E.P%V^\1GH.]=OKGPG\ >!_%B1ZC"D^ERZ;'+;"*>1@TAB#,Q;?P"2IZU2\
M2_LK_&3Q=Y9U&RMU>-M_F0"&)R<@\LH!QQW-2-^S/\<I;ZWN)EBG^RQ+%$L_
MDR#8% "D$=, =10!E:7\%QXJ\96EU_8R0>$X+?[0[V\CLLRE2RJS9RIX'1N]
M<A\=OAW%X%UC3=3TZR:RT+5HS/!%EW$>1NV%F).0&4<FO4KC]GOX^7-O<P-=
MM!:7*JKV]L\<*J!DA1MQ@#/;TK'U3]E/XU:WH=MI5^&O;2U;]RL]PC%.%&0Q
M.>0H[]J /G=&PHVL<8XR!3@[?WO_ !T5[F/V)?B<J\V$?_?U/\:/^&)?B=U^
MP)_W]2@#PXLQ_C/_ 'R*-[#HW/\ NBO<?^&*/B=_SX1_]_4_QI1^Q-\3FY^P
M1_\ ?U/\: /"U=E;[Q_[Y%39]F_*O;G_ &)_B;VT] ?^NR_XT?\ #$_Q1_Y\
MD_[^I0!XBI/HQ_"G;C_=;\J]L_X8H^*(Y^Q1_P#?U/\ &G?\,4_%#_GS3_OZ
MG^- 'AY)/<CVVBCG^^?^^17N'_#%/Q/_ .?&,_\ ;5/\:/\ ABGXGD'_ $"/
M_OZE 'AK,Q;(;_QT4[S&VXWG_OD5[BO[%/Q-Q_R#X_\ OZO^-(?V*?B=G_CP
MC_[^I_C0!X>LA_O'_OD4I9LGYC^0KW!?V*?B=_SX)_W]3_&FM^Q5\3MW_'@F
M/^NJ_P"- 'B0+==Q_(4UI&S]X_D*]P'[%OQ._P"?!/\ OZO^-+_PQ5\3<?\
M(/3_ +^+_C0!X<LC<_,?^^13&D;^^?R%>Y_\,4_$W_H'I_W]7_&D_P"&*?B;
M_P ^$?\ W]7_ !H \*WG^^>?]D4FYB?O'T^Z*]T;]B?XF_\ 0/3_ +^K2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P *&UZSR@\[W/7_  H ^\/^'GS_ /0F)_WV/_C=(W_!4"3/_(EQ_P#?0_\
MC5?"D&J07,:,A;!.">??VJ&37K6.;89?KP?\* /N_P#X>A2#KX*C_P"^A_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'5N=-N_^N3_^@U^
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M\"S^GG-_(4 ?H'IO_(/MO^N8HHTW_D'6W^X** +U%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML/'.$ /?US6-;^(K&X6%-4(M8D.-PX/?W^M>CZ'XQ\)PV_E6&H"X;;AE8@T
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M%/P2 3_C0'F/\,O-XHTB2&^<PR;5.WI[X_ BOE3]ISP[<6<L^)#B+=M) /\
M$1Z5]R3>#X;155#LD4<\D9_7ZU\X_M0>#VU+1;AHXV5T4Y;GGF@#\S/^$DO)
M;R6-L.5<C.T#H?I3O$"F6W65HP >_-8EU;M9^)KR&0LFV1AR,="16QK=B\^@
MI\Y!/^%-6N!/\,;-M5O+FXV'9$,X49[C_&OL_P#9WU*Z\0ZC]BGE(@A3 4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR@X^BD_TK[H_;E\-E;ATSL$DF[=QS\P-?*?PN\!WVN^-XRD)>*!2-_'8$>M
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MI8U%_&,XP!T49/UX'>OE>-E5'!8^8H(V#ITJ!$#'=&_TQ^E?>'[ /_(FS?\
M79OY"OA!DS"QZ$C/Z5]X?L KM\&S=_WS?^@B@#[WTW_D'VW_ %S%%&F_\@ZV
M_P!P44 7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"KJ7_(/N_^N+_^@FOPC\7''C766'/^D?\ LBU^[FI?\@^[_P"N+_\
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M>9_DMCT7!_Q]JZTW<T,8,K;8!R2?3- 'Y8?M]?!ZS\/^/KSQ%9N7:ZN&9AD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *.J,5TV\)_YYL!_P!\FOPG\9+_
M ,5OK:CIY_\ %T^ZM?NOK&PZ?<[FQB)^/^ FOPUO/#-]XP^)&M6]N"(S.!D
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MMQ^I%>C?$KP'XLFOGU35YS?N6);Y> 223C"CN:XC1;?4KR8VMG9F>8]5"DT
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M^%]2BUW37R)'P48$CGOC/OZUUW[5W[25S\;/$<MO;H+?3H9&"!5 )PW7.3U
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MS7YQ<0R)IS-A3Y> ?E '.*\B59+.,12)AU.3]>M "S6_EPNH&1M/7Z5]X?\
M!/M=O@J=, #SV/OT%?"$ET&C8?[/]*^\_P!@#'_"&3'_ *;M_P"@B@#[VTW_
M )!]M_US%%&F_P#(/MO^N8HJ +U%%%6 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M &8_B]I/BK2+I_[.:5(-7T\L?*O+0M\ZL,?>7)96Z@@>X(!_2$3BOB3]I/\
MX*F^"?V=_BMJ7@0^%]1\4WNFI&+RZL+J*..*5EW&+G)+*"N?0G':OLNWNTUW
M0X[K3[G;'>6XEM[E &P'7*N >#P0:_)S]L[_ ()E^&_@W\%?'GQ87QYK_B#7
M[2:*\ECU"*+;<RW%Y''(SL!NSF9FSGDT ?0WP%_X*O>%_CU\7O#7@&P\!:OI
M5WK<[01WEQ>Q.D6V-WR0!D\(:^[J_GG_ ."<_P#R>M\*_P#L(3?^DLU?T,4
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M&0IG_9K]K_V$?'UWK/[$_@#Q)XBFFWV>DS+/<7!!<PV\DL:N3GG]W&#_ #H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ9_XEUW
MZ>2_\J_"+Q@=WC+6_P#KO_[*M?NYJF/[-NR?^>+?R-?A!XPD'_"9:SCKY_\
M[*M &<IVU(DF>IJ .O\ $:<I#*<=: +0S)@#FO5OV=+ 7OC!Y",^0R'^9_I7
MD\+B-,CK7N?[*MCYNI:M=R_NT6/=N;@<*Y'\J *7[27B9=8\;16G&($(_P#0
M?\*\C;Y6XZ5TGQ/U*/5/'6HS!A(4<KN4\?>(Q^E<RK!J )(^?SJ=6P*K*QW8
M[5/0 N32;"YYX'6E;VZT+O\ XNE $F[:N*=&S,KX'0<TW-"R>7O ZL,&@#H?
MA[<-:^.M(E3_ )[(3^#+7?\ [34\MWXGL)BA"&,GIQ]U*\O\.:D-'UBTNI,9
M212,^F0?Z"O<OCII*ZAX+TC7V!9YHOE&W ^ZG],4[,#Y]122Q[$<5,LFW*U#
M!N\E"W7TIQ^]FD!.H )QUZ4UF_>#/3-,\P=>]-W%FH L?)3) &^[R13-P7J,
MTBS!>5&&Z<\\4 ?27[*FJ1V.AW]S(%W)CK]6/]*\-^(6O2>(/'&JSD[@LC8_
ME_2O9?@38QZ?\+-?U%LH\:[E)/' <_TKY[O)&EUF\E!_USL6/XG&/SH =N(P
MW;&/TI^[S.M1#/*GIVI0P7D4 /''R$<>M./[GIS3-Q;ZFD*LN>_UH 7S,7''
M0C%>K_LTWD-OXV2&8C$B,!^:UY.H3*%>M=Y\#Y/+^)=C&AP.2: *OQDM8K7X
MA:GLSC=_05QRA2HKT#X[VYM_B%>!"H#')R >PKSQF\MCNY^E $WRJI-)O#J>
MU-7,@..!WS3'5NF.* !5 )P<T[?N[U#M*GY>_6I  H]Z !J:S<<=:5<L>>E-
MDV\XX- 'I7[/UM]K\;*WEY\M6.?IC_&K/[1UZ;KQ) Q_A"CZ?>K0_9AC,VO7
M\@7,D:-SCW7_ !KBOC+J[:AXPN(6((A; Q]/_KT <-<'.W_>_I2K]T5!,77K
MTZ_I3H9"W6@!K$"0Y&1_]:H6F.[ '%22<R'TIN: &R+NCD./X?Z5]W?\$_OE
M\#S?]=V_D*^$9&/ER#_9_I7W?_P3_&[P-.?^F[#]!0!][Z;_ ,@^V_ZYBBC3
M?^0?;?\ 7,44 ?DQ_P %P/\ DH'PM_[!E[_Z-CJ'_@B#_P E,^)O_8(M?_1S
M5-_P7 _Y*!\+?^P9>_\ HV.OGK_@G_\ MA:%^R!XL\6:MKF@ZCKT6LV4-K''
MISQJT;)(6);>1Q@T ?O/XB:UCT'4VO2@LUM93-YGW?+V'=GVQFOY<+K'VJ;;
M]W><8^O%??O[4'_!6WQ+\9_ NJ>#_!GAD>"]-U1&M[S4)KK[1=R0'AHTPJK'
MN'!(R<$@$=:^</V/OV8]?_:D^+^F>']-M7_L*TFCN-<U)E_=6EKN)()_ON%9
M57N?8$@ _>']EF._A_9I^%":GY@U!?"NEB?S?O[OLL?WO?UKR_\ X*=?\F,_
M$[_KGI__ *<;6OIJQLX=-LX+2W01001K%&B\!548 'X 5\R_\%.O^3&?B=_U
MST__ -.-K0!^17_!.?\ Y/6^%?\ V$)O_26:OZ&*_GG_ ."<_P#R>M\*_P#L
M(3?^DLU?T,4 --?-/[;W[9NA_LE_#UY(V@U#QSJ<;+HVD.2<GH9Y0.1$I]QN
M(P.Y'9_M3_M.>&OV5_A?>>*]>9;J]?,.F:2D@66^N,<(OHHR"S8^4>^ ?Y]_
MC5\9O$_Q[^(NJ^,O%=\]YJ=](2J;CY=O$#\D4:_PHHZ >Y/))H [#X,?!WQ[
M^VA\=);&T,VH:IJMVU_K>M2H3':1N^9)Y#T'4[5XR< 5^YOQ ^'>F?"7]CGQ
M9X-T%'32]%\'7MG!NQO8+:2 LV /F8Y8X'4FO@+]EO\ X*&?LY?LK_#:V\->
M'? _C:>_E"RZKJ\EI9^=?3CJ[?Z5PHSA5' 'ODG]*/A?\0M#_:1^"VG>)K*Q
MNH/#_BBQD L]05!,(GW1LKA69<G![GK0!_.E\#\?\+I\ ;L;?^$@T_.>G_'S
M'7]*GCA4;P5X@64*8SI]P&#XQCRFSG-?S>_%;X>ZY^S;\<=8\-79QJWAC5 U
MO.Z8$JHP>&8#T==C?C7ZF_%[_@JM\+?$G[+NJRZ/<7!\?ZYI,EA_PCOV>3-G
M<2QE'9Y2H4QH68A@<L .!S@ _(GP42OCS02O!&I6^/\ OZM?U!VO_'O%_NBO
MYU_V'_@KJ'QV_:6\&:):V[2Z=9WL>J:I,5)2*U@82/NY_B("#W<5_18N!P.E
M #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH J:H/\ B5W8_P"F+?R-?@]XRCV^,M:;/_+?/7_96OW@
MU3_D'W?_ %Q;^1K\(/&(#>,M;!_Y[_\ LBT 8#/NDQFK]O&..1SQUJN;4,V5
MXIZ6[KLYZ,#0!8(_>8SWKZ@^"MG;:#\,=;U.X_=2-"P&[Y?X7Z'\J^7;>,R7
M<*J"SR2*/U KZ1^)6H-X/^#^E60XEOTPR]#C"@?^A=Z /G[4)A<:K?S(2PFE
M8Y//\1/]:K%RE,W/'$.PW'^E/5MZY[T /AD,F:DDD.VHH_E_.I<^E $@D(ZB
MG),9&V@$GT%5=S8^_4NG*([M7D<D*0:Z<+25>M&DW9,"?S.W?TIPYY]*BO)8
MX]6\N'D,N21T'(&*>A*Y!.3ZU>+P[PM>5&3O846I*X[)GD0@X\M@WY'_ .M7
MLFM?$*\\;?"H:7-;)&NFJH65.N",<\>B>M>+!L1RG_9/\C7LG@WPN6^$.KZM
M)-N$BJ@11Z!QG]:WH/#/"5?:_']D+NZ1Y!$_[E%ZX7.[UXJ13Q4$.&^ZQ( V
MX/M3]^*\SI<-2QY8VYSG\:3;MJ%6YJ4MA30,4,JGYAFAG1ER%YZ=*8JYI))&
M53Z4 ?3/AVS;2_@;JL:93SH6.<8_A?\ QKYEC;*NQZAB/U-?4NO7)T_X"V;$
M_P"M1A^CU\N)_&?4Y_6@!QDZ4;O:F*W45)NXH 16^;-233;>/PIGWH\4TO\
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M3^$/AJ+P_P"#- LO#NCQMO%M91[0S="S'JS' Y8D\#FNLHH *\R_:0^"=O\
MM%?!?Q)\/+O59=$M]:6!6OX81,\7E7$<PPA(SDQXZ]Z]-HH ^!_V?_\ @D]H
MGP#^,?ACQ_:_$34-8GT.=ITL9M,CB67=$Z8+"0X^^3T[5][BEHH ^(OVG/\
M@FS=?M3_ !(G\5>)_BWJ5O"B^3IVDV^DH;>PAX^1,RY))&68\L3G@8 \C_X<
M>>'/^BKZI_X)X_\ X[7Z<T4 ?F-_PX\\.?\ 15]4_P#!/'_\=K[W^ ?PC@^
M_P (?#7@.VU&35X-$MS;I>RQ")I069LE03C[WK7H5% 'SA^UI^PUX"_:VL+:
M?6O/T/Q391^5::_IZJ9@G)\N52,21Y)(&002<$9.?BVV_P""'^H_VM_I'Q5M
M?[+SUBTAO.Q]#+C-?K#10!XE^R_^R/X$_91\*RZ7X3MI;G4;O!U#6KXJUU=D
M$E0Q  5%R<*HP/<Y->VT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVTBFK\Q%-\LF;B@9,WR]%S36&^/@[6/&#]:))"I( R>E-A7=/$Q^]N''KR*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGT%?"$VV-9#D?=Z?A7WA_P $_F\[P-/CC]^W\A0!]\Z;_P @^V_ZYBBC3/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M *FI_+IMW_UR;_T$U^"7C&0KXWUH]<3_ /LBU^]VJ?\ (,N_^N3_ /H)K\"_
M&DFSQOK1() GSQ_N+0!2AF(:.XQC:V<?2KFI:I<:S<IYQRJKA?TS6=N_<X#
MA.=H(R:2*0HN1P&!5BQR1GI@4 6%9.1W6G1,,U6+?Z0$4  KC)/)Z=J59-OR
M)PV>6/)_*@"W(2>!0F>,U#(Q&TF13V.<+^.,TBS!<[C@?PGJ&_&@"PR%FS3E
M^456$@VR*[;"1D8.<<]/K2FX/F("I*!<;>A/XT 6PU.)JBLCR2DL ,]7W #\
MO_KU,KHS91RZ(<GC&: )\TA-5^69L'#M]T;ABGF8Q@LI60]"I( 7WS0 YB=I
MQP:FN]4N+B*"-\E$& ?P_P#K52DDW*0S@D\Y P/I0TS2(BK\@'\7WOTH F;*
M'V/(IZMFH&D4\/N XPPR<_AVITC'Y$4_/C/'3\30!823M^%-8G=FHE9(VV$%
M"W((;=3V61LJ74;N-W'R^^,T 2;JU/"_E_V_:O-_J58$Y^HK$;"S-M<E,8QC
M(_.E61U0>4WEG.#SDX]10!L^*+P7&O7C1G,!.%Y]A64A-0FY#2%?O=]^[/Z?
M_7IS.ACW,V/]H' _*@"<S?+BDW=Z@6;S8U*C&&&>^:>'7SG#=^@!H <9":>L
MAJ'D=1VH- $KMYC8/;K36V,?E;"#G%1JWYT?+MP,8H D7(;=_P LZ=O&[CI4
M8;Y<=J. W% %A6)4TU2?6H@YI=W% %A6*CFG;JKAO>A9"IYH ZGP[;VEC&=4
MN9AOB&44XZD8QU]_2L;5=5EUS4)+^X/SL<*/;)(_G6;)(S J6.PG.W)Q^51M
M,-N,\#CK0!:;.=PZ4>=NJ!9MRTF[N* 'NVVFLY?&*"V:BED Z<4 3;_EV]ZC
M9MM0[OE%)NXH ?<3?Z/)_N_TK[\_X)ZR[_ ,_P#UW8_HM?G[-@PR#_9_I7W[
M_P $\!GP+/\ ]=F_D* /T!TW_D'VW_7,44:;_P @^V_ZYBB@"]1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%F&1E?X>U 'D4?PI\,>#O!^BZYX\U:ZM!K2![&*T4D$%4)+$!NTB]<=ZV/\
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M%%&FC_B7VW_7,44 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@""XM5N89(V) =2IQ[@C^M?&VK?\$M?AQK&I7-[+XE\31R
M7#[F5);?'0#'^JZ<5]H44 ?$S_\ !*7X:/LSXF\3?*VX?O;?_P"-4#_@E/\
M#82!O^$G\3D#^#S;?'T_U5?;-% 'Q(W_  2B^&;9!\2^)BN<A3);X'_D*D;_
M ()1_#;"[?%7BI &!.V:W&<= ?W72OMRB@#XHD_X)3_#-V5AXC\3(RYY66WR
M?_(5!_X)4?#,MG_A)/$PXP<26_/N?W5?:]% 'Q1'_P $I_AE'T\0^)<=?]9;
M_P#QJE;_ ()5?#=YC(WBCQ.2?^FMO_\ &J^UJ* /BB3_ ()3_#638I\3^)S&
MIR(_-M]OY>52K_P2I^&JR*[>)O$[NOW2TMN<?^0J^UJ* /BK_AU9\-E8NOB;
MQ,CGJRRV^?\ T52-_P $J?AJS$_\)-XG!)RQ$MOSCIG]U7VM10!\4_\ #JOX
M;[GSXG\4.&Q\IEM\#'I^ZH_X=5_#?;M/BCQ04Z[#+;X_]%5]K44 ?%/_  ZK
M^&V[(\3>)P<8.);?GT_Y94Y?^"5OPU&\-XE\3/N&!NEM_E]Q^ZK[4HH ^*D_
MX)5_#570MXD\2R!>@:2W(_\ 15.;_@E=\-6C,?\ PD?B54SD*)+?'3_KE7VG
M10!\6M_P2O\ AMNW#Q+XF!Z#$EO_ /&JC3_@E7\-5SGQ+XF=SR6:2WS_ .BJ
M^UJ* /BUO^"67PX(VCQ-XG"?W1+;X_\ 15))_P $K_AL^W'B3Q,A'=9(,GZ_
MNJ^TZ* /BP_\$K_ALP?/B3Q,68 ;C+!GI_URIW_#K'X:^6D;>(?$C(!R#)!S
M[_ZKKFOM&B@#XN_X=8_#55"KXC\2J/\ 9DM__C5.;_@EK\.'7;_PDOB8#_KK
M;Y_]%5]GT4 ?%X_X)9?#<?\ ,S>)O^_L'_QJC_AUC\-]V?\ A)O$W_?VW_\
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..;PI$"2$& 314U% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gizttcucplmb000028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000028.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
M   !          #_VP!#  ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,
M# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$
M!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!3_P  1" /9!5\# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MS.@6?DZ?I.H30(TKS3Y(2-@"[' SC)PH["@#]C\T5^8O_!)7]L#6O&6H:O\
M"3QUK5]K&JHKZAHE]J=PTTS*O^OMBSDL=O#KDGC>.,"O2/\ @L1XJUKPK^SG
MX<ET76+_ $>2X\1Q03/873P-+&;:X;8Q4C*Y4'!XX% 'WE1FOF+_ ()J:YJ/
MB/\ 8F^&VH:M?W6J7\BZ@CW5Y,TTK*FHW*("S$G 554#/ 4#H*_./X4_$CQ=
M<_\ !4=+&;Q3K4MDWCJ^M&MGU"8Q&$33*(MN[&P* -N,8 H _;G-+7Q#_P %
M./VQS^SW\-5\'>&+T1^/?$\+1I+#*5ETVSY5[@$<AV/R)R.2S?P8/$_\$GO@
M;X]T_0[_ .+GCCQ#KD\/B"W,&D:5?:A+*DD!<,UU(C,?F8KA">=I8]&% 'Z*
M445@^.O%]G\/_!6O^)]12673]&L9]0N$@ ,C1Q1L[!02,DA3CD4 ;N11FOP\
M_:G_ &U/CI^TIX/U/Q%HVE:KX'^#MC>1PK)8LT/GR,2(UFN>#,V024C^5<C(
M) :OMO\ X(_Z]J7B']F/5;C5-1N]3N%\17"++>3O*P40PG +$\9)_,T ?=-,
M>14^\P'U.*\>_:S_ &@+7]F?X$^(_',RPSZA;H+?3+2<G;<WDAVQ(0""0#EF
M YVHU?DM\'_@I^T5_P %$KSQ%XX?QZUM9VMW]G:YU34)X;?SBH8PV\,08(JJ
M4SA0/F'4DT ?N6K!AD'(I:_#WX-_M ?%[]@']IH_#_Q[K-UJGA];R"VU;3;N
M]>YM?L\F"MU;,_W"%D#\8S@JPR./UO\ VE/CUI_[-OP7UWXA:AIT^L6^FB)4
MLK9PC322R+&@+'[J[G&6P<#. >E 'J>:6OY_/VJ_VF?C_P#%JXT+Q3XT;6/!
MGAK4S.=!TRS,MC;.B;"[JN0TI E0>:V<Y(4\$#]B_P!A?4+O5OV1/A7=WUU-
M>W<NC1F2>XD+NQW,!EB<G@ =: />***\@_:ZUS4?#7[+WQ4U32KV?3M2M?#E
M[);W=K(4EA?R6PZ,.589X8'(/(H ]?HK\"OV5_A_\??VN-4\0V/A/XKZO83Z
M)!%/.=5\07J!Q(S*H4J6[H<YQVKJ_&7Q&_:K_P"">?Q(TZW\2>,+[5K2^C\Z
M"'4M0?5-,OXE;#*HE.Z-@>NW8XR.<$4 ?M=XP\9Z%\/?#=]XA\2ZO::'H=BJ
MO<ZA?2B*&(%@JY8\<LRJ/4D <FN=^$_QW\ ?'33KR]\!>*M/\3V]DZI=?8W.
MZ!FW;0Z, R[MK8R.<'%?+'[6WQ@T_P"/G_!+GQ+X^TR,06^M:?82O;A]_D3+
MJ5NDL1..=DB.N?:O#O\ @ALXC3XVLQ"J!HA))Q_S_P! 'ZK45E:5XETG7I)D
MTW5++47A8I*MI<)*8V'4,%)P>G6M2@!:*H:IK5AH=L;G4;ZVT^W'66ZF6-!^
M+$4[3-8L=:MA<:?>V]_;MTEM95D4_B#0!=HJ*69((S)(ZQH.K,< ?6F->0):
MFY:>-;<#<9BX" >N<XQ0!8HK.T?Q#I?B&W,^E:E::G #@R6<ZRKZ8RI/H:T*
M %HK/U77=-T&W\_4]0M=.@_YZW4RQ+^;$4NEZUI^N6XN--OK;4(#TEM9EE7\
MU)% %^DJAKVH_P!DZ+?7@*!X('D4.< E5) _2OSR_8!_X*$?$7]ICX\ZMX0\
M86N@VVCQZ3<:A"]A;/%)&\<L**NXR,"")&//?% 'Z.T57DOK>&,227$:1DX#
MLX /XU+'(LJ!D8,K#((.0: 'T57GO(+5E$TT<1;A0[!2?IFEN+J&U0--*D*D
MX!D8** )Z*IW^J6FE6CW5[=06=J@RTUQ(J(/JQ.*-,U:RUJU2ZT^\@OK9_NS
M6TJR(?HP)% %RBBL>_\ %VAZ5?1V=[K.GV=Y(?DM[BZ1)&^BDY- &Q13(Y%E
M0.A#*PR&4Y!I] "4%@.3TKB?C-\6M"^!OPQU_P <^(YO*TK1[<S.JL TKDA8
MXDS_ !NY51[FOQAU#XV_M*?\%&/BA/H/A6^O=/TU%>5='TJ[:STZP@W<&XE7
M!D/0;GR2?NJ.@ /W2617^ZP/T-8GC7QQH'PX\,WWB/Q1J]IH.A6(4W.H7THC
MABW.$7<Q[EF50.Y8#J:_'_6?V"?VMOV?H!XO\(^+)M7O+ ?:)(?#FM3FXPI#
M$&&0*)@<<H-VX#&TYQ7UC^V#XHU_QM_P2CU#Q!XJ@:W\2:EHNA76HQM;^01.
MU_9ER8_X<GG'&,T ?67PH^.'@3XY:1<:IX#\3V/B:RMI!%.]FQW0L1D*ZL R
MDC.,CM7=U^8/_!$*18O!?Q9=V"(M]IY+,< ?NI^37Z5Z3XDTGQ!YO]EZI9:E
MY3;9/LEPDNP^AVDX- &G116/K'B[0O#I U76M/TPL<*+RZCBSQGC<10!L45!
M:W4-Y"LUO-'/$WW7C8,I_$4MQ=16J;YI$B7^](P4?K0!-16?J6N:=HMLMQJ%
M_:V-NQ 66YF6-23T )..:N1R+)&'1E9&&0RG((/>@"2BL.;QOX=@U%=/DU[2
MX[]ONVK7D8E/7HN[/8]NU;2L& (.0>XH =13))%C0LQ"JHR23P*S--\5Z+K%
MY-:V&KV%]=0_ZR"VNDD=/]Y0<C\: -6BO#_VS/C9K'[/O[//BCQMX?BLKC6M
M.$'V>&_4M$=\R1DE0P)P&)X/:O,_^"<_[6'BO]J;X9>)-9\:II5MJ.EZJ+*)
MM/B:%9(S"CY92[<Y8]* /KVBDK(U'Q=H>CWD5I?ZSI]E=2G$<%Q=)&[GC@*3
MD]>WK0!L45''*DR*\;!U89#*<@CU%,GNH;7'G2QQ;CA=[!<^PS0!/6+KWC+0
M/"K0#6]<TW1S/D1#4+N. R$8R%W,,]1TJUJ.NZ;H[0KJ&H6MD9FV1"YF6,NW
M]U<GD^PKX+_X*%?L ^+OVI/BAH'BSPWXJT/2[>WTM=-EL]9DDCVLLKN'1E5M
MVX28(P,;1USP ?H!'*LT:R1L'1P&5E.01V(J2N(^#/@23X3?"'P;X/NM0&HR
MZ!I%KILM]C8LS11*A< DX!(R 2>HKL/MUM_S\1?]]B@">BHHYTF!,;K( >2I
MS5?4M8L=&MVN-0O;>PMU&6EN95C4?4DT 7:*S=(\0Z7X@@\[2]2L]2A_YZ6<
MZ2KUQU4GWKG/C-XTN?AW\)_&'B:R6![[2-)NKZWCN,['DCB9U# $'&0.AH [
M6JUY?6^FVDMU=SQ6MM"I>2:9PB(HZLS'@ >IKX2_X)P_MR>._P!JGQ1XUTSQ
MO!HMO#I-K#<VSZ? T+$O(RE6W.00 !CO7TC^UO\ !>__ &B/V>_%7@72-6M]
M'O\ 5(HFAO+G<808YDEVOMYVMLVD@'&<X/2@#T_P_P"*M%\5VSW&B:O8ZQ;H
MVQYK"Y2=5;'0E2<&M:OBG_@G'^Q9XE_9,@\;W?B/Q'I.M3:^UK%#;Z.[O%$L
M'FDLSL%RS&7& . O4YP/M.218D+,P55&2Q. * 'T5B6OC3P_?:@]A;:[IEQ?
MK]ZUBO(VE'3JH;(Z^G>MG=0 ZBH/M</G^1YT?GXSY>X;OKBJ&H>*-'TF]@L[
MW5K&SNY_]5;W%RB228_NJ3D_A0!K44BG=SVI: "BBB@ HHHH **** "BBB@
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M3_\ !0/]FK_AI;]GG5M-T^-3XHT7.JZ.VT$O+&IWP#_KHFY1S][83P*_#_\
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M_P#CE?HA^R;\";K]FWX%Z!X O-;'B"XTUYW:^6(QHWF2O)M5220!NQU[4 >
M_P#!6C3+31_V*Y[*PM8;&R@UBPCAM[>,1QQJ&8!54#  ]!67_P $9?\ DUG6
M/^QEN?\ T3!6[_P5[_Y,XOO^PW8_^A/6!_P1E_Y-:UC_ +&2Y_\ 1,% '&?\
M%N-:FA^%?PWT=<?9[G6I[M^.=T4&U<<^DS_I7M?_  2CT^WL_P!B7P=+#$L<
MEU>:C-,RC!=Q>2QACZG:BC\!7D7_  6P\+SWWP3\!Z_%&[Q:;KKVLQ5<[1/
MQ#,>PS"!]6%>C?\ !(OQA8^(OV/-+TJW?-WH&J7MG=)T(9Y3<*?H5F'/^R:
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M(K8)"HNT\%OF^S/^"DW@&#X5_P#!.W0/!EI=27MMX?N-(TR*YF 5Y5A0QAV
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M+^,_[5W[52>(/$5[I&G_  UMIXK*T\F_9IX=/1@SE8MG^M<ESSW(&2%%>_\
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M/]C7X,:S^SW^S7X+\ Z_<6USK.DQW+7,EFQ:+=-=33[5) )VB4+G')4U\7^
MO^"=?Q5\-_MV#XJ7<FA_\(BGBFZUP21WK&=H9))'51'L^_AP,9Q[U^GE% 'C
M7[6'[.FD?M/?!?6O!NH1PQZBR?:=)OY5YL[Q ?+<$#(4Y*MC^%F]J^5O^"=G
M[(OQW_93^(FMV_B:;0I/ .K6Y^U6]K?M,_VE/]5-&NP8."RMDC((SDJ!7Z'4
M4 (O2N8^)NCZSXA^'/BG2_#M[_9NOWNEW5OI]YO*>1</$RQON )&UB#D#(Q7
M444 ?C7XG_X)L_M=^-M+.F>(O'EOKVG%UD-GJGBN[N82P^ZVQT(R.QQ3/"O_
M  33_:W\":>VG^&O'%KX=L6D,IM=*\57=M$SD %BL: 9P!SC/ K]EZ* /+OB
M)\$K'XS_  %N/ASXWG>]%_ID-K>7T>#(+E%4BX0D?>$BAAGTK\N4_P"":/[5
M'P5UO48/ACXR:/3KIU#WWA_Q#+I+7"@G:98]Z\@'IEL;C@FOV7HH _-']CO_
M ()<^(?!?Q2M?B7\9]8M=9UBQN/MMKI4%P]T9;O.Y9[B9L;BI^8*,Y;!)XP?
MLC]KCX?^//BA\ _$7AOX;:V?#_B^[:W-K?+>26A54GC>11*@W+N16''7..]>
MS44 ?B[XN_X)>?M4?$%[5O%/BO3?$CVH80'5_$MS=&$-C<$\Q#MSM7..N!Z5
MZ'\"_P!@G]K#X9^/?!,MS\0%M/"&CZE:S7&F6?BB[, MDE5GC6#:$(*[OEQ@
MYYZU^K]% "5YQ^T9X!U+XJ? CQ[X/T9H%U;7-&N;"U:Y8I'YDB%5W, <#)]*
M](HH ^"/^":/[%GQ$_95U[QSJ/C@Z4B:S;6MO:QZ==F=LQO(S%OE  ^88YS7
MWO110!XK^V3\(-;^/7[-?C7P)X<DM8M:U:&W%LU[(4A+17,4Q#, <9$9 XZD
M9KP?_@F5^QWX\_91M?B))XY;2UE\0OIZVL.G71G*K;BYW,YV@#/GKC!/W3[5
M]Q44 ?!'_!2_]BWXB?M5:_X%U#P,-*>/1[:ZM[I-1NS P,CHRE?E((^0Y[]*
M^K? _P *88_V>]"^'/BRVM[^!?#L.B:G AWQ2 6XBD"G XZX.,]*]*HH _(_
M5_\ @F)\??V?_B-<>(/@/XWCDM"S"WE^W?8;L1'GRIT8>5*![G!P#M';<U#]
MD?\ ;A^.5Q;V/Q ^*2:'HV<3+'JH1"I(!W06B*LAP. Y_$9)K]5** /F?]N[
M]GGQ1^T/^S;+X'\)RV;ZVE[:7*'4)3#'(L1(8;L'!.<C/YUF?\$X_P!FWQ=^
MRY\"]7\+>-#8?VO?>()]55-/G,R)$]O;Q*"Q ^;,#'CL1[U]5T4 ?G)_P4:_
M8-^)W[4'QP\/>+/!?]C-I=IH$&ES#4+TP.LJ7-S*3C8<KMF7IZ'BOMOQ[\']
M$^*_P=O?A[XKMEO-*O\ 3DLK@+R4=57;*A(X9'574XX*BO0** /Q\C_X)I_M
M-?L]^.+W4/@WXSAEM'.V.]L=4.GS3QY.U)X7^1L YP2PSR.:V_A__P $K?B[
M\8?B1#XG_: \9>;9[P]TD>HM?7]RH((B5R-D2\D9!..R]Q^M%% &=I6AV.BZ
M'::/8VT=MIEI;K:06T8PL<2J$50/0* /PK\B/B)_P2G^-OP]^+E_KOP<UV"/
M2_M$DVEZA;ZP^GZA9QN2/+9Q@Y56*EE;YAV&<5^Q%% 'B'['/PU\>_"CX$Z1
MH/Q,UZ;Q'XP%Q<7%W>3WSWC 22LRH9G&Y\ CJ3U(!QBOR_\ ^"Q_PWTWPG^T
M;I/B:QN+877B?2UFO;*,XE22$B(2L,?==0H!SDF)_2OVN;I7YF?M7?\ !.WX
MP?M0?M37GC"]U7PU9^"7EMK6W5[Z<SPV$84, @A_UC?O&P&QE_O8YH ]X_X)
M;_")?A7^R7X>O)K?R=3\52/K]PS?>9) JP=^GDI&P_WR>]?-O_!<S_CS^#'_
M %TUC^5E7ZA:7IMOH^FVMA:1+!:6L*00Q(,!$5=JJ/8 "OC/_@I5^QOXW_:T
MTWP"?!-YI$-QX?EOOM,.JW$D/F+.(-I0JC#Y3 <@X^\,4 ?"WP%_8?\ CEXG
M^ GA3XF?!7QU=Z8WB6&[34M)M-8ETN56ANYX  Z,%E5EB4X8@@D]17T+^Q3_
M ,$L_$OP^^*>G_$3XN7UG+=:3/\ ;;#1[&X-PTET#E9IY,8PI^8*I.6QD\$'
M[1_8V^"^L_L\_LV>#? 'B"ZL[S6=)2Z-S+I[,T&Z:[FG 5F52<"4#) Y!KVN
M@#YV_;2_8]T/]KSX=V^DW-TNC>)=+=I](UCRO,\EF&'B<9R8WPN0#D%5/;!^
M&/ ?[(7[<?[/]G+X>^'WC"SCT R$I';ZK!+;+GJR1W,>8\Y).U1S7ZX44 ?#
M/[&W[+_[0'@GXRW?Q&^-7Q"/B!I--GLXM(.I37>QY'C;<%PL4:@1GA!WK[FH
MHH Q/&7A'2?'WA75?#FO64>HZ-JEM):7=K*,K)&XP0?0\\$<@X(K\F_BY_P1
MY^(?A'QE)JOP@\3VFH:6)?-LX[^[:RU"TZ\>8J[6V\88%2<]!U/Z_P!% 'XX
MVW_!-/\ :L^)TD6E^._'WE:)D%SJ_B2XU%5YY*Q L"<9ZD?6ONKXW?LGZEK'
M[!]S\"_!=[#=:E;:;I]E:7>IN8DG:WNH)G9B VTOY3X&" 6 Z<U]244 ?%O_
M  31_9*\<_LJ>%?&UMXX;35N];O+:6WBTZY,^U(D<$L=H )+C&,]#7$?\%)_
MV'?B3^U-\0O"6O>!_P"R'M-.TMK&X34+PP.',K."/D.1AO7M7Z$T4 ?,O[0'
M[(*_M!?LIZ#\--1U!-,\0Z)8V36.H)EX8[R" 1G<."T; NO3/S ]1BOC'X6?
MLA?MP_!G0[OP'X,\9:9H'A&ZF=FFCOX)8XMYPSQ%XFFA)'S?NPO.3U-?K110
M!^3_ (/_ ."4OQ+^'G[3/P]\5VFOZ=XA\/Z3K&F:WJVK7]TR7,TT4Z37(6/:
M6.65@I9B3D$D<U]-_P#!2?\ 97\:_M4?#OPGI?@@Z<U_I.IO=3QZC<F -&T1
M7*MM(R#V/:OL6B@#PO\ 8F^#>O\ P _9E\&^!/$[6IUS2_M;7/V*4RQ S7<T
MZ@,0,X610>.H->)_\%$OV ]1_:JFT?Q7X/U*VL?&&E6S63VNH,5M[RWW%U <
M ['5F;M@AN<8%?<%% 'Y:^'_ -D7]L[XG^'-.^&_Q%^)46@_#6!8[:X\FZ@G
MN9K9 !Y>^)!+*"O&)9,<<YZ5W'_!/?\ 8'^(/[+/Q_\ %GBGQ+-I<GAZXT:X
MTFP:UNS+/+ONK>1'9=@ &R Y]V'%?HE10!^>?[>W_!,_4?C_ ..I/B-\.M3L
M=.\474:+J6F7^8HKMXU"I*DB@[7VJJD,,' .1SGP#3_^"=O[7GQ$BA\,^-/B
M#=V?A,,(Y(M4\57%_;B,8Y2W#L#QT!V_A7[%T4 >->.OV;=-\<?LNR_!BYU&
M468T&#1X=3*?.DD,:"*8J#SAXU8KGGD9K\PO#/\ P3/_ &K_ (8ZMJ%IX,\4
MPZ#8WKB*XOM$\2S6*7,:DA3(B;6( 8G!!QD_C^T5% 'SC^TY^QWI?[4/P-T?
MP=KVIO:^)=&AB>PU\+YC1W*Q!'+CC>DF#N QV/4"OAOP%^QQ^V[^SO'<:'\.
M?%]FFAR2;@EMJL,EL#W=8KF/Y,Y.=JY..]?KE10!\'_LB_LN_M%^&?CC'\1_
MC5\1/[:AALY[>/1O[3ENAOD55!5 %AB  )^0=?J32_\ !3+]C7X@_M67O@"Z
M\##2W_L..]BNH]1NS ?WIA*E?E((_=MG\*^[Z* /-?V;_A[J?PG^ O@/P;K+
MP2:KHFD6]E<M:L6B,B* VTD#(SZBOC7_ (*1?L)?$O\ :B^+/AKQ1X(.CR6-
MGHBZ9/'J%X8)%D6>:3<!M(*D2COG(/%?HI10!\A?M!?LL^.OB#^PCX5^#GAV
M_P!/3Q-I>F:-87;S7#Q6MP+6*-)%#["=I9 PRO\ ",U\/>$?^"8?[5OP_BN8
M_"_B^P\-QW)5ITTCQ-<VHE*@[2PC09(!/7IDU^SU% 'P]^Q7^RS\:/ >G_$G
M1_CCXNF\4Z'XDTZ+3[:V;7;C4"@(F68@RC]V2KJ/EZ\>E?-NA_\ !/']J#]E
MWXF:EJWP.\6:?-97*M;)?M/#&\EN6RHN+>=&C++@<C=@YQC.*_7.B@#\B?B]
M_P $OOV@?BUI-OXQ\5>-K#Q?\2KZZVWEK=WGEV]I:A#M6-O+VYW?P(JJ > <
MU^E/PX^%+:3^S?X6^&OB0I.]KX4M/#VHFU<E&*6B02E&P#CAL''IQ7IM% 'X
MQR?\$M?VD_A'XZOKGX9>*(8;8EH+?7-)UR32[F2W)R!(JD,N<+E0S#..37W;
M\0/V;?B!XW_X)^R_"&^UBWU7XA3:5:PSZCJ%V\D<UQ'=1SL&F*ECD(5W$9Z9
M]:^KZ* /AW_@F5^QWX\_90M?B))XY;2UE\0/IZVL.G71G*K;BYW,YV@#/GKC
M&?NGIQ7$_MR_\$P=1^,WQ N?B/\ "_5+/2_$E\RRZEI=^[0Q33  ">*10=CG
M W C!(SD'.?T8HH _'S6OV(?VV?BIHMMX0\8^-&G\,0E5*:GXD,T+@=&=4W/
M+C QO!//UK[T_8K_ &,]!_9!\#W=E;7?]M^*=69)-6UEHMGF;0=D4:Y.V-"S
M8R<DL2>P'T?10!^9'C#_ ()X_%36_P!OJV^+5L^A_P#"')XOL?$!D>]83B"*
M:*5U\O9]_$9 &<<CGT^_OCCX-OOB/\%/B!X3TMXDU/7O#^H:7:M<,5C66>VD
MB0L<'"[G&3BNYHH ^"_^"9_[&/Q$_95UKQY>^.1I21ZS;VD-JNG79G;,;2EB
MWRC ^=<?C7WI110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 44AKQOXX?&_7OAIXF\)>'O#7@Y_%^L>(3<F* 7:VZHL*!F
M)9AZ$4 >RT5\[_\ "ZOC?_T0L_\ @_@_PI?^%T_&_P#Z(6?_  ?P?X4 ?0]%
M?/'_  NGXW_]$+/_ (4$'^%!^-7QO_Z(6?\ P?P?X4 ?0]%?._\ PNKXW_\
M1"S_ .#^#_"E_P"%U?&__HA?_EP0?X4 ?0]%?.__  NKXW_]$+/_ (/X/\*/
M^%T_'#_HAA_\'\'^% 'T117SQ_PNKXW_ /1#/_*_!_A2_P#"Z/C?_P!$,_\
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M/'_"Z/CA_P!$+/\ X/X/\*3_ (73\;_^B%G_ ,'\'^% 'T117SQ_PNGXW_\
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M .B&?^5^#_"@#Z'HKYVD^-GQMC4LWP."*.2S>(( ![DXJG_PT-\7/^B/6?\
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M0?X4?\+J^-__ $0S_P K\'^% 'T/17SQ_P +J^-__1#/_*_!_A1_PNKXW?\
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M?/'_  NGXW_]$,_\K\'^%'_"ZOC?_P!$,_\ *_!_A0!]#T5\[_\ "ZOC>/\
MFA9_\'\'^%:O@GXU_$'4O'NDZ!XO^&3>$[34HIV@O5U2.YR\:!MNU1GD9YH
M]SHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/#*@(8QR0R2*=K @E6YQ@\/XS^#_ ,3?B-H^MRZWXJT6WU&273VTG2+&"?\
MLVV^S7<=RTDQ9M\LDC1A=P"A5  &<D^]75U%9V\D]Q*D$$2EY))&"JBCDDD]
M!CUK%;X@>%X])BU5O$FD+I<TGE1WQOHA [X)VA]VTMP> >QH \YTOX6^.O%'
MCS3O%'CKQ%I,<FBV=U;Z1IWAJSECCAGN$$;W4CS.Q=U0%54*  [9W9XY3QA^
MS7XK^,FDVVF?$+Q%I,XTO1;S3+&_TFS=9+BXG1(_M<\;G8-JH#Y*Y4LQ.0
M/?=$\3Z/XFADFT?5K+58HVVO)97"3*K8!P2I//-376L6=C=1VTMP@NY$:5+?
M</,=%*AG"]2H+KD@<;AGK1Y ><^"_AOXBF\<WWBSQQ<:+>7[Z1%HL-II$,@M
MVC64RO+()2?F9RN%QA IY;.:Z+X:_"O0OA3I-Y8:+$[)=:A>ZB\TZH9=]U<R
M7#H&55^16D(4'HJKDD\GLE;=@TM 'SOXD_9OU?6OC*GC*UNM$TN?^U;>].O:
M?%/::L;2/RR]C+Y3"*Y1_+*[Y<X1R-I*@U7\$_LZ^,O#NJ?#>SOO$&CR^&?
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M/VMOAPVI:IXVU:TE;4X(;CQ1J4=U"^V ?-$J.Q4D'/S#TH _1.BBB@ HHHH
M**** "BBB@ HHHH ***3- "T457NKJ*SMYIYY%BAB0N[N<*J@9))] * +%%4
MM+U2UUJQ@O;*XCN[290\4\+!D=2."#5S- "T444 %%%% !7DOB[P7XKT/XKG
MQ[X.L])U>2^T>+1]4TO5+R2S9UAFDE@EBE6*0;E,\JLK*,AE.1MP?6J* /F[
M6? /Q7D\=^ _%-U/X=U_7M-N]6N9=*DO);.UM;>XA2.*"&46[M+LVY+NBEBQ
MZ# '?_"WX;ZUH_CCQEX[\5-8Q^)/$B6=F;+2YWGMK2TM5D\J-9'1&=B\\S,Q
M1?O* /ER>SN'_P"*NM5W#BW8@<9Z_2M^@#YRM?V>/$L/[%6C_")KK3#XFM-(
ML["2X$TGV0R12QNQ#[-VW"'!V9Z=*9^T#\%?B%\3+SQM9Z/?VPTC7=!.F66[
M6[C3DM)C',CM/%!"6N03(I :3& PQ@G=](44 >%>//V1O ?Q2UWP9KWB3PYH
MMUJVCRQR:@\^GI<'4HULY;=;=W;!V*TBR#(/,2\#J/3/"&H7\FH:]I4VB1Z3
MI.D7,5GI<T4C%;J#[/&Y;:47;M=F3"EA\@^;.0.IHH ^?O#7P[^*GPQ\*ZIX
M'\)'PY-H\EY>S:1XBOKN9+C38;F>2;:]J(669XFE8)B10X5=VWFK>F^#_BIX
M)\6?$"?P]8>&-5MO$FH0WUOJ6K:M/!+"RV-O;$R01VK!OF@+85P#N XKU_Q!
MXJTCPG!:3:SJ5MID5W=PV%NUS($$MQ*X2*)<]79F"@#N:77/$^D^&?L']K:C
M;:=]ONH[&U%Q($,]PYPD29ZL>< 4 >,:+\&?$GPO\/\ @_3?#^D^&/&PTO0I
M=(O+G7LV=W)+(ZN\J3B&4^2[;]\..ZG)QBN'L_V3O$'A/0-9TC3K'PQXD;Q%
MX3L?#=WJ.JO)#)ISP131F2)1$^^'$JE8]R$&)>><K],>,?&_A_X>Z#-K?B;6
M;+0=(A94DOM0G6&%&8A5!9B "3@5S_@3X[?#OXH:M<:9X0\;:%XEU&WA^T36
MNEW\<\B19"[RJDD+N8#/O0!QVL?LB_#GQ%X^T+Q;JWAG1M3U2QMI(KR:[TV.
M26_F*PB.>20\[T$)P2#]\],<^E>'-;U?5M:\36M_I*Z?9Z?>I;V%T)&?[;$8
M(Y&D*LB[=KNZ84L/D^]G('1TM 'RC'^S3XZN=)\2Z!%=Z;X;T75-'U;3IK>S
MU>ZO+":6ZB=8I(+2:,FS568.RQRD=0 >M2^.?@;\4/B-XBU/Q!>VWA73KA]-
MT&RM-+;4)[F'S+#6DOY7DD^SJ<.BE5 4D%5SU-?5-% 'S-XJ^!OC?QEK&K^*
M-1TS08]4O=2LYXM,L=:N[6>TBMK:>)9H-0BC1EN&:=LYC*F/*'UK"T_]FWXF
M:3J\/B"]U>S\4:O=:-+HUS VN76F_9XQ>7$]MF>"+_25$=P(Y-T:%C&&'WC7
MUM10!X%\"_@[JWPI^)>IY72VT-O">B:0OV%YE\F>S$RE4CDWGRF$I*EI2PV
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M1FLS8V=S=VT\TT$EQL*" Q[@2RMAL%E(R!W%?%/B7X[>(/"_BN\U_3=9T?\
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MQ@>81D\9S4&D_$GP;8Z#X6_MKP[<:1J%M+J$VG:W<0,S6R*3%Y]VN,L9';+
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MOG_@H_\ &;_L4K'^25[!^QC_ ,F^^'O^NU[_ .E4M(#W&BBB@ HHHH ****
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MI67A2_N-"U*QM;K[<H7]V)CD@\_P#EOJ*[";QMI,GA$^(CJ"6>CB(W!O)U*
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M?#:6UM:R:1)I#XM)&E!-[*IP90IZ@#/7UKL&D@L_$>G7,WE2!H984N<+YT*
M!M@;/())YQ6?KFI:9-=ZA:-),\:X+,S$EY-P)"GL!7"JF(Q52,;-K?NM[?EH
M?=8_BRE1PRLFXZ/5WUUW^6FNY>U75K19+26(K=QLACN1'E760L77!['..GH:
MY.97FU"*&>)8E5R""/?DGD<_C5RXOHH;.%DC\HR+(5&0V_+$ ,/4 ]:HPPES
M$Y=#'D%F;.1SR!SZU]QD. FYN%-/S]$[Z]#^=,UQ:JM2DUW^\K7FL&Q(<RP_
M8))/)5'.%$F?E!;L,CO[5YB/"W@[Q!I^O74FH)8>(K>Z46L4:EH;R9WP(PI/
M"AA@MGOFO0_&6FVOV&[6\E>+3'4-<QM$90JA25*@'@D[<XKQ+6?$VCWV+_3_
M  ]$EY<0_8ECEN&<Q7 ('G+&,8#*1@$G!4U_7?#E%TL#&,6[[-Z;I_TCYC+:
M+GBI5-=/7[CW?P3<ZAX@O+?03X*L[SP?9 ^=!X7OU#0W7W99@"VZ64#HA' S
MC-?5G@'X;6GA?QI>ZG:76DOX;U"S@M;2P6V4SAH0H7=*6.X*JG@?7M7R]\,O
M .H:E\6-*TF[\(Q%M-CMM4N-:CO3;W9$@;=/*-V&W'@H!QMZ\U]1?"WX"^$O
M ,=M!INHWVL1V-R;RRCOKU9A9R.C*S1A0,!E8]?6N#-*D(MQC*VFV]_QT/U'
M"Q?*>N1[5&!3NXI%7;3J^2/0/CSX+Y_X>-?';_L :7_):^PZ^//@M_RD:^.W
M_8!TO_T%:^PZ "BBB@ KPOXW?\ET^!7_ &%M0_\ 2"6O=*\,^-W_ "73X%?]
MA;4/_2&6@#W%?ZTZFCI^/]:=0 4444 %%<QKWQ,\(>%X],?6O%6B:0NIS?9K
M%K[4881=2YQY<19AO;/&U<G-=,I##(H 6BBB@ HI*\KUKXH:SX8^+.K:1JD.
MGCPK:^&;C7XI+=9&O/W,D2N')(7!WOA0N?E4[N<  ] \1^(;#PIH5[J^I3BW
MLK2,R2.>O'  '=B< *.22 .37,_!OXDW'Q4\&2:W>:(_AVZBU*_TV;3Y+@3M
M$]K=2V[9<*HR3$3@=,XR<9KS7P_XB/QJU33/!GQ'T?3;NVUC0K/QII4>FM/!
MY/ES1YC=A)N:2&22W<2*4!+C"@KFNV\!^ ]%_9Q^'GB0PW%W=:8M_J7B"=G,
MLTBK-,\YC4,S,=BD)D'+;<GEC0!W^N?\@>__ .O>3_T$U\C?LD^%O#6O? .P
MUXZQ;CQ)%IDMG)J>CJ8+FUA1M_E,O1V7C+%<G-,U3_@J%\'+G3;F(1>) 9(F
M49T>4#D8ZX]ZYG]C/1+'3?#OA'Q%X@%KX5TJ3338V5G+G;JCW9)\UI"W+L(P
MNW'&!7H87X9ZV_K8SENB/2/'T7A^PU"T^)&HV6K_  ZNME_I]G;Z25DU>2<^
M8TB$'Y6C8_,">":[Z^AU#6H_!?B>UFL_%VF:;--?1RZ4JV^H6%F8P(D$>XF0
MH#\RD<X%6IM&8K<:5X#M=+M_^$?O99(-/O=.:2[T9?+??(L1;=,9CC:>F&'M
M7$_!GP_J_A+XK^)?$YN] \3^*=36Y2"P6X^RSQR*J/L,7\!;.&4\KMZU]%S0
MJ1=2.C73^K6\W<XG%QT>M_Z^9QVB?"'Q-K7AN3Q]H1OI_$']HO<(NHHELFI,
M'+072K(,,Q4L#'W+5SNO:';7W]KZ?>:'=:*;0W.K7%OK,)A>246JN?+52"3Y
MN[CILQ70_%OQMXUUKQO'H5_9R/ID&KV-\KF;?;Z==- '-LDBC:P#MPN<\ =\
MUL^+K^;3?#_CZ;7_ !')-XLEM526*>RWO;19$@AE<#"0S%@H48P6 S7K4ZE6
M/*YM:[6Z;?D<UHMM'%>$M-?P3JUGK&O)/X.TB72$M[. :DK2W#3D[&E(!/D_
M+(VTCC@5YCXFUCP[J7B"X6"PAT(V2B&%K$N\-S(KA6D*DY0,H) 'K70VOV_Q
M!\.]*L=7TN76;(W'D:)K%A-OET]R0SVKKW!R"%;IDD>E:'C#PSIWAD65RJ6W
MBW3H]0WKJMK+Y-W<R2)DP(^3YAC?!+!>"/>O4I6C/FE\3T/+Q"57W?G^!YAX
MFL9=)O[R*80Q!I4\J/80"I!;(/\ =P1U]17=>$;SPSJVH2PWEI:Z5),WRWUM
M<R-*$5"60Q9Y#8&,8QQ6!-K%EXJU*Y4Z!<7=S*8Y+R:2<Y@*N1+("!A <KDL
M#T/K7;-H>@:98ZA?7TO]KQ66H?9!J@(47:L"9/) _NX'/O7H3DKV>A\[BX/V
M"O=R7;S);RZTO3]%D@&HH/#&XRHH4K+=2(1(R!BW4#@^XKL;J:S_ +-:]\N3
M,<27%O/%&65&()# 9YP",C%<?<>"=/3Q%I5U9"WU71=S,=/D5FAC!BR&?G(+
M9'.?3BNKT5;>]T^XA2S#W=GYCI:Q29\D[?E5#C[I ')KYG-<&J\55O\ \"_7
MU\SXJHJ<5%0DW+S7W7-2WDN=0L;9Y9A.9(<L4PH?OGZD=O:J]O<1[4\I53RS
MG.!U!.,__7]*K>%YK?6+#ST#110Y5XV<DQRCAE?CKGVK6NK.!;SSG<.&"J^P
MXQ@$@'W!S7\^<186K&<Y)NVVNC=GO;SL?0X%Z)/?^NI)I^HRV.9?+:5]VS<6
MR, < ?A4ZM>-.'A#22%_,C6,Y9& R01[ '\JH/.$PD)D23&)"3C.>2,5=M]<
MEMXPMLWV=XVWQ3#[W3!'XU^85*,U)VAKYGTU.K&UI3T)-L_V-;B.Z:24NX\M
M4*L"1R<_A6;;[C) PDP"V,L 1D]3_+K5I-6N8@^9\^:Q+X (.1@\^N/2LN^G
M33[>XO%M'G2--QCBRS[ >P]:]W*,)6J8E02U=K6_)^1Q8RK#D3B_6_YG(>,W
MT&^NG36=1<V2@FUN[>%REHQP'!P?F)('Y5H_ ?7(O <=M=V&A76H>)+AWM]-
M72[MD?4&8C]W/S\B*!N!V\^O%9OCW7+F?P_;?VC9^5:2RQ[M+DD"O-#NSN+8
M^0Y]JET>R$'Q.T);'5KO7M"TJ>VFAUC269[JUCVL3:1L!ARHR>F<(WO7]=T:
M$*&!]@E9);>G32Q&0>T=YWZ_U8]8\5S:YJ7P1^-LU[Y.CZK;6<PUK31 9&<"
MU*QJ+C=AV. VY0.I%?3'[/FL6FI_!OP5Y4#6,G]CVI-G,H26,>6 "4'0$@GW
MS7BGQD^(OBCQI\!?BHEYX/32])_L^[":NDV4NK7[.[0SQ\?/NP@..FZMSX*_
MV]:_#WP-XCNM$TSPWX@U,Z?IES)-<F4W5BD/R[><"0@< >AKX?$1=2<G*R>G
M5'Z3%V22/?F\(:4_BJ/Q']D!U=+<VBW)9LB(MG;C..OM6TT:R<$9&,41_=%2
M5YC;>[-2M;V,%IQ#!'#P%_=H%X'0<=A4[\J:6EI <LO@_;-(_P#:NIX>_%]M
M\\8&!CRAQ_JSUV_K6CIOB;3=4U;4-+M;M)K_ $XHMW H.Z(NNY<_45K^U01V
ML44TDJ(J22'+L  6P,#)^E5S7^(18HHHJ1F3IVC_ &#4]0N_M5S.;QU?RIGW
M)%A<808X!ZFM1I O!/-+6%XDL]9O)-._LB_@LA'=+)=B:'S/-@ .Y%Y^5B<?
M-VQ1\3U8&]1110 4444 %%%% !1124 ?&'P]_P"4C_QG_P"Q2L?Y+7K_ .QC
M_P F^>'O^NU[_P"E<M>/_#P_\;(/C-_V*5C_ "2O8/V,O^3?/#W_ %VO/_2N
M6@#W&BBB@ HJM->06LD,<T\44DS%8D=P#(P!)"CN< GCT-8WA?X@>&/'$FH1
M^'/$FDZ_)ITQMKU-+OHKDVTH)!20(QV,,'Y6YH Z*BBB@ HHKE?BAK6L>&?A
M[XAUC019-JEA92W<(U%7:#Y%+'<J$,> > PSQR.M '55YMJ'QD@M?C+HO@*T
MTJ:]%W%.;S5A)LAM)DB$J0 ;?WDC)\S $; R$YW@5P>H_'OQ=<>'I]2T>PT9
MCH?@NR\7ZU'=++_I/VB.9Q;6V''E'%K.?,<O@E 5/)KIH_V>_"&I^//#WC[3
MX[JPO(+JXU:2..\N"EU-<("79?-VK@D' 7!X&,#% 'KHKY-_;,\/^&O$_P 4
M/@[IGBJ\DL]-GN-25&CF\DO-Y">6F_:<;FP*](^/G[67@G]F_4=)LO%JZH9=
M3C>:#^S[%[@;58 [BO3DU\Z7G[27PO\ VLOVCOA%I.G6U]/#ILU_=2)J]J]J
MF_RE\LJ2?F8,HX^GK6U&7)44M=.VY,ES*QZ-X\^&-QX#T?Q!>>)_%FFW6CZE
MIZ:581ZOI[7%P64[H8Y)%/SD#>-P .2#GBO$O$FJ:=96L\.E^$+>VOYM",N^
M.Z>>XBEA"JUNJCF%H7_>$M\Q6,\D&OHCXBRKXV\?:CHVC?$'4$O6>W@BTG2K
M<3?V9,A;=-,".(SD \]2M>.^*/ACXKT?Q5XOO[71=6EO9[J^N-,G@MO+@O-\
M4J2/,<_*X+$ICAAGCFOL,%6]VU66KU[=O3]=CSZT;ZQW1YKXO\4:EX5TW1;^
MSU!]7O+JT74-7N+$LLSRN0(II9,'&"=H3 ^[G^*NIN)-7\2^ ]8U;7_#[0>'
M?$(:X&N:A;K+<VB0( @,F!D.2=F!QSU%>K^+/#,WPG^#K>-=-TZQ@\27VE65
MGJ$5S'\YD941W=,X8KD811UY->-Z/X7\0KX%MK#Q9XLD\.6/AG5&AAT3[*;J
M9Y)4WAPF>5*ERF<CAJ]*->&(@FM$GYW^5NSMY'C3I<K<9WNT1?"76/ G@N\U
M:\M])DU'7+Y4M-&TNVGD:1!)"!)+-+G:N2Q'/2B]\-^);636-<UF.+PMJEY<
MJML][=*MQ ZX^SB$9_>*PW?,!SMJ?PQK]M\(M-OM/TW4O$$@U22WGAGCT<0S
MO D@>24;LY4Q9 8'UJE\<M'-II=C9:Q9S_VI]H8:=J=U>"6T-I+\Y!.?W3J0
MN%/JW7MJXRE5]QVYNN[MY7_X)YM2C&JE3[+?L_7^MC@_#*S^(/$=Q_;3'4KR
MYD87%Y>2X82(2K+'S\QVLW'^%>IZ3K=I-;VUK87ITK5+.%H-/LVMO,<QH,QR
M"7'S)DD\UQ.FZ-KWA#54O_$5LS*EO&MI9V\*^;.LJ_)*R@_>(QG)SS4^D:SK
MVH:I;Z/KUC+I.B7$L[+;VC^5)/(%&0K$G! )Z=\UQ9GAU6<JC5XQ2>[L^]E;
M70^3E!^UG)66EGZK^M3J]+D$5SID5S?&]U^=,K!&P5;E@1EBN.V>WJ:VK.^O
M!=7=M/(+BV1I$B\E (XI <-$7_B;<#U[5REC-:S^*$>.^BE\J)H[>':1/;E2
M%<$XZY(_*M5_$"0ZTUFEB=AF*R37%RL71-Q91CYAD]O2OP_-,IE42DZ<G4E%
MN]DDM=%TZ:=+:G1@\9!)W>B???N[=KZG77&M7-];P));0P0S!;>:9(0 ,,<L
M#[ #]?6H;&^-J;\30QO)%B59;GY&1U8 'KTP?NXK-TW7+?R6AAN%DCD81<N.
MI/(+=L<5>OY+B*ZM9Y?,O$5T*K/\RM$3U[9&0._<5^85LLGS3IPC9=NKTOI?
M[CZ2GCDXQJ.5W^70U[QIH[8F"6'4)3,)!'P70L =V,<@G/4=Q4^I>(5M[K1_
M*%S>WWEXDV1@0VY&%8-Q\K'=QS6#XCNK6ZTV\N[=3>:AYK(+>-PAE8<K\W8#
MIT[5L1V2W L8K:8Z5J$UJKS0^:6+O@,%=NQX[BOGL3@7AU'ZPFFFTT]'MUZV
M]$?1T<7S3DZ5FK*UG^7GZLG_ +2>XEU+2=OVQ_*8B293O?:PS&!Z]1QZ54N+
MVT$=C"J31RK$(I4CFZ YPJ\<MSZU2:]O-8L+F5;5X)+5F4/=1YD:97P6#9^8
M'&[Z8KG?#>N-KOA^WEFOK5KE[MUNQ"Q9(F4## 8ZD'MZ5W4<I;INO"RC%I2U
M>[6_X??H<U;'\RY)7;:TOII?;U_0Z.W9=+^^RF)XS$T<A*@L>0"<]1S]>*RY
M+VQTN&WN;N4):2W"PK#N(+\XQG'4D^M:5M,+>-(C$J([AHI9I 4Q@D#'=L9X
MS6'JFK6NEV]Y>I;-+$C>8MN4,I R0"!UW$_RKTJ%*MB*KAR.7-;;1OHO0\>M
M4IT8Q:E:W?\ 'U1K>(K W=U.=0TU;>!U'V."4D-$Q.6;.>@QW]:YS4-'B\3+
M&)=1S9F%X(I(6!A922'^K9W#.?6K&K>*=+%FD7B"]>)[D%X4F) D+8!7V_\
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M$\&ZKI<VBR6VGV^F.Q:"/4#&$5G&.#&0N 3AL#/6N>G_ !.:FO=>ZTWO;O\
MD>I4O32Y]K_G^G<YGX@?#F]:^UCQ1>:DZH=1:"./5AB>"#"NLK8(VL<@; .
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MQMKZ*.5)XX[J)9%21#E' (X93R".1CBKU07=U#86LUQ<2I;V\*-))+(P544
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M/""(I"2?]>^2=H/.#Z5@^)OAA>W*DV6JV/B6"^9KW3-9F?9<R0Q0@R,PST4
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MQ&Q RX7<"1SW !K*\8>(+:ZL](UC2]-FL-7NYL3V,*>9;2Q1R AAZ@-C##T
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M2N@NO#/C;P:M]-JL4USJ$]PE]!<6L\5]+8PY(>9Q'E@" .GH?2NKGA2]U/\
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M/#=U<>+]5T:"34-;TJVNFU%;5L))>0I&SI,[L-H7:,\GG=Q5NZ\26EKXPO\
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MM9%$;L2-D;R?=C9B#G..,8KO9+6]^(GB+P])H7PWAL_$EK&-0>'3IC';76G
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M6\N;?8)%=FVX95"$\=!Z"NFS7SM2<Y:2=SL5N@ZBBBLAGQY\%O\ E(U\=O\
ML :7_P"@K7V'7QY\%_\ E(U\=L?] '2__05K[#H **** "O"_C=_R73X%?\
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M2:K?#_\ 9M^%WPIUXZWX/\":)X<U8PM;F\T^U6*0QL067/H2H_*@#TRBBB@
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M@M] ?39;;2=>N)TG%I+XFU4[%MV=F65$10$WG<?WC@AO4T4L4W4<'):]>_\
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M&+?*U=^T:]<<TZCZUQ3GS:V-#F?#>@W6E^(/$E[/Y7DZA<QRP^6SE@JQ*AW
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M^M9_@2QAT/P+J7Q)TN[L=1U'PO;?8K*U9<7$#L-@DE5\ J"S2)CG!QVKG/\
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MM):-IS?!OXH:KHNIZ?)IUKX9O;*73[*&-C',279F=3D'(.5(ZFO7O@S;Q_\
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MD>@QWK;X?=O;\=1&KJEKI)N;._U**U26VDQ;7%QM#1NPVX4GH3TX]:R/%?C
M> [/6=;UN2VM_#EC;)*DB%C,7RP8,,8P<H!CU-<W\2O$$?AWQ5H<-Y#/K\&J
MM':VN@16@8"=9=[71D/W=BG//]VM;QY\.?"_Q O(;37W:666SFMELQ<E/,B9
MD+MLSR5*K\V.*N,$N5U;V?\ 6@7['-_#_5[BX\>ZQJMSX7U31+35-,M[Z74[
M^]#VX8*H\I4S\A4,<G_9-8_B3_A"=;\,^--*MO$NH:4VOZM'IUQ?J7?;=R*N
MU82>-K ?PG')K;^,WPWM/$>FV5HK6BP7$*Z=<I?:A);*;0$2-Y>WK(/+!Y[
M]JSO"?POO8_B)HVNVGV8^";?18]-@TNZD,K1/%)F*=/X22 /FSG!KMBZ;7M;
MV_X&VYDV[\HW6].U?P/X/TW4M%MM+O/^$7O/)DCTZ,//+IJG;)$"1\LN/F91
M_=KQSXU>+X_BOJ^A>-M#TZ/2])\)SI>KK>IGR'O5#+NB6,@.41LY]?FQGO\
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M=7EP;RX:X874[2A"0!M3)^51_=%;->2]]#46FGJ#3J* /CSX+_\ *1KXZ_\
M8!TO_P!!6OL.OCSX+'_C8U\=O^P!I?\ ):^PZ "BBB@ KPSXW?\ )=/@4?\
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MR.M9WA73+_1] L[/5-1.KW\2;9KUHQ&93DG)4<#@BM9<XYI>U97=K +1110
M4444 %%%% 'R#^R[_P GE?M,_P#7[8_^BC7N_CO_ )*M\._KJ'_HBO"/V7O^
M3ROVF/\ K^L/_11KW?QU_P E6^'?UU#_ -)Z /1Z*** "BBB@ HHHH ****
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MO_T$5]AU\>?!?_E(U\=3W.@:7].B\U]A"@!:*** "O"_C=_R73X%?]A;4/\
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M*,'K4U%.[ Q-(\'Z+H,<J:?IEM:K+*TSB.,#<[')8^^:>OA?2X]<FU@6<?\
M:<T"VKW.,L8E8D+],L?SK7HIN<F[W%9)6,C2_"NDZ+'<QV5A!;1W,S7$JQH
M'D8Y9C[DU<&F6OE^7]GB\O.=FP;?KC%6Z/QI.4KW;"R(6M8V5E9%*-]Y2!@_
M6H_[/M]JKY,>%Y4;1@>N*MT478R%K>-TV,H*XQ@@4S[#!N!\I,@[@=HZ^M6:
M* /)/VKK2>^_9P^(]O;0O<3R:)<JD4:EF8E#P !_*N#^%_[7/PET/X;^%M/O
MO%RV]Y::9;030OI]WN1UB4,I_<]00:^DY(Q*I5@"",$-R#57^Q;#_GRM_P#O
MTO\ A2 \?_X;1^#?_0YQ_P#@ON__ (S2_P##:/P:_P"ASC_\%]W_ /&:]?\
M[%L/^?*W_P"_2_X4?V+8?\^=O_WZ'^% 'D'_  VE\&O^ASC_ /!?=_\ QFC_
M (;1^#7_ $.<?_@ON_\ XS7K_P#8MA_SY6__ 'Z7_"C^Q+#_ )\K?_OVO^%
M'C__  VA\&O^ASC_ /!?=_\ QFC_ (;1^#7_ $.<?_@ON_\ XS7L']BV&/\
MCRM_^_2_X4?V+8?\^5O_ -^E_P * /(/^&TO@U_T.<?_ (+[O_XS1_PVA\&O
M^ASC_P#!?=__ !FO8/[%L/\ GRM_^_:_X4G]BV'_ #YV_P#WZ% 'D'_#:'P:
M_P"ASC_\%]W_ /&J/^&T?@U_T.<?_@ON_P#XS7L']BV'_/E;_P#?I?\ "D_L
M6P_Y\[?_ +]B@#R#_AM'X-?]#G'_ ."^[_\ C-'_  VC\&O^ASC_ /!?=_\
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M_P#&/?AW_KM>_P#I7+7L4UC!:VLY@ACA^1L[% [>U>.?L7\?L^>'A_TVO/\
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MW$??*/@X-?*TGPTT;P#^T]\(3IGC+7?%$TKZI'+#K.LB]\@K;+R !E23_(4
M?8E%%% ",,C%1QPI'G:H7<<G ZGUJ6B@""&TAMRQBB2,L<MM4#)]32R6\<S
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MN/\ XFOI6B@#YJ_X8J_ZJ_\ $;_P;C_XFD_X8I'_ $5_XC?^#<?_ !-?2U%
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MM=^=!;9@#8B7 V]0/H!0!]=T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'C'Q=_9GT_XL>,+7Q*/%?B7PMJ<-E]@:30;WR!+
M$'+@.,')#$UR'_#%(_Z*_P#$;_P<?_8U]+44 ?-7_#%7_57_ (C?^#<?_$TG
M_#%/_57_ (C?^#C_ .QKZ6HH ^:O^&*O^JO_ !&_\&X_^)H_X8J_ZJ_\1O\
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M !1110 444F: $9L5\I>)/BQ9>/_ -JSX2Z9;:'X@TN33)]75[C5M/-O!-B
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MZ^'.FW,ND0:5>6FM^*?[.ELH-18M"+>W#2(IN'C*2-NP1&.,_,10!](4444
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M_)=/@5_V%M0_](): /<5_P _G3J04M !1110 W:,YQS3J** "BBB@ I,4M%
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MIXFF_:W^&5X?BZGQ"M+B;5G@TN,P%;!3 & 'EG.,';\WH* /MNBBB@ HHHH
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MT^E 'URO2G4U>E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(P:_*3]FNV;]DW_@J7XE^$^@7DL?A#6I&M38NS,NR2T6\MA_O1[]@8]BWJ:
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M2O"_C=_R73X%?]A;4/\ T@EKW2O"_C=_R73X%?\ 86U#_P!(): /<UI::O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\O_\
M!3#4+C2_V'_B?-;<R-!90'()^22_MXW/_?+-6?\ \$L[>.']AGX=.@PTSZD[
M^[?VC<K_ "45Z+^VAX/G\=_LJ_%#1K6-I;F;1)YHD4$EFB E  '<E*\!_P""
M/7Q"MO%'[*K^'00EYX8UBYM73<"3',PN$?'8%I)%_P" &@#[IK\H/A_J-QHW
M_!;'7K6S4>1J,UY!<\$_)_9)F[?]-(TZ^M?JZS!5))P!U)-?EI^Q'/#\:/\
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M/"6IRW-X8SID]NDR>>H"GSH]MW.<*0=T2#HY9/HO3[-=/L;:U0DI!&L2D]<
M #^56:* .#^(?P3\!?%:YM+GQAX1TGQ)-9HT=O)J5JLQC5B"0N1P"0*^&OA+
MH/A#P_\ MJ>"[7POJOA&Y,,^K1O8>'=%:QFME6+ 65\?O,=/J*_1Z3[M?!?A
M?7I=4_;0\"V[^/?"WBE8;K5\:?HFEK:W%G^YZ3.!\Y[<]Q0!][T444 %%%%
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M?M;_ /!1\^+/&_@GQ'H_PU\,S^9I[Z]I-Q:6LMM:L!!&AE0!S+,?-*\DAF[
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M>"O^A>\9_P#A.W'_ ,32-^V_X+7_ )E[QG_X3MQ_\37T)%]Q?7']*<R[QC-
M'S;:?MZ?#Z^O+RSM]*\63W=FRI<P1Z#<%X689 88X)'(INJ?M\?#S1OLPOM+
M\669NI5MX//T&=?,D/1%R.6//%>O^#_A?9>#?&_C/Q-;74\]SXGGMY[B&0@I
M$88O+4)[$5%\4OA-8_%*3PL][>7%J?#^L0ZS +<X\R2,, K>QW&@#R>\_;T^
M'VGW%G;W6D>+;>>\D,5O')H%P&E<+N*J-O)"@FH_^&^OAV-4ETTZ9XJ_M"*$
M7#VO]@S^8L9. Y7'"Y'6O8_&WPQLO&WBCP9K=S<SP3^&+^2_MXXB-LK/"T15
M_;:Y_*N;'P>O6^/FL^.WU&+^SM0\.IH@LU1O-1UD+F3=G&"#CIVH \[MO^"A
M'PRO+6QNH;/Q/+;7TODVLR:'.5GDR1M3CEN#P/0UGS_\%)OA%:17$L[:_#%;
M*6G9]'F B <H2QQP P*_48KTGP[^S7H_AWP7X \.0ZG?26W@_5/[5M9'(W32
M9D.U^/N_O&_(5\[_ +67[+*^#?@-\0]2\,/JNOZQJD'V;["BF0E9=0-RY51W
M#.WX"@#V&']N+P1<1++'H/C&2-U#*R^'K@@@\@CY?2I/^&WO!?\ T+OC/_PG
M;C_XFO:? L<D/@O08Y49)4L8%=6&""(UR#]*W&H ^;+']O?X>:I=7EO::5XL
MN9[.017,46@SLT+D [7&.#@@\U+=_MV> K%H%GT;Q= ]Q((H1)X?N 9'()"+
MQ]XX/'M7JGP_^%-CX!\4^-==M+RXN)_%.HKJ5S'*1MB<1+&%7VPHK7\7>";?
MQ=>^';B>XF@.BZDFIQ+$>)'5'0*WMAS0!XGJ'[>'@#2;<3WFC^+K2 NJ>9-H
M%PJ[F("KG;U)( ^M17'[?'P]M=4M-.FTKQ9#?W2L\%L^@W DD"\L57;R #S7
MM7Q)^']K\2O#D>CWMQ-;1)>VUZ)(#\VZ&59%'T)45RWB_P"$M]XC^.G@7QS#
MJ,4%EX>M+ZWFM&1B\QG5 I5N@ VGKUS0!YE'_P %$?A;<211Q6_B61Y;EK-%
M719\M,HRT0X^^!VJEJ7_  4J^#^CZ3;:I?2:]:Z;<RM!#=S:1*L4DBYW(K$<
ML,<BNZT7]D_0]%U32[Z/6-0DDT_Q->>)T5F&&GN%*M&?]D G%?,?[>_[*;Z)
M^R3X?T'PLFK>(;K0?$#7T$$,7FRR?:'<R;@.R[CTH ^A;?\ ;D\#74$<T6@^
M,98I%#I(GAZX*LI&00=O0BI?^&WO!?\ T+WC/_PG;C_XFO8/AG#+:_#KPO%/
M&T4T>F6RO&X(*L(E!!%=(T@7@GWH ^;HOV]/A[-JDVFKI/BQ]1AB6>2U70+C
MS4C;(5BNWH2#CZ&EU+]O+X?Z-9O=W^D>+;.V0JK2SZ!<*H)( &=O<D"O6],^
M%UCI?Q;UOQ]'=3OJ&JZ9;:7);,1Y2I"\CJP]R9#GZ5/\5/AS:?%;P7>>&[ZY
MFM+6YDAD:6W.''ERI( ,^I2@#QK5OV^/AYH-O'/J.E>++""298%DN-!G0&1C
MA5!(ZD\5-)^W9X"BOH;-]%\7I=S*TD<)T"X#,JD;F QT!8 _45ZA\8/A%8?&
M+P_INDZC>7%G%8ZI:ZHKVY +202"15/L2*MZMX(NM0^*7AWQ1'=1QVNEZ=>6
M;VS*VYVF:$A@>G B/YT >+S?\%!OAG;V)O);+Q1':"?[*9VT.?9YV[9Y><?>
MW?+CUXJK?_\ !1KX3Z6]PEXGB*V>W,@E$NC3*8S&H:0-QQM4@GV->DZQ^SGI
M.L>!9/#$FIWJ6K^(?^$B\Y6&\3&Z-SLZ?=W''TKQW]J;]F*V3X7_ !)\4:1/
MJ>I:[-:ZM?0:=" XDFN[=8615QD@*HQCO0!UFD?MY_#_ %[3;?4-/TGQ9?V5
MPN^*XM] G9)%]00,$?2KO_#;W@K_ *%WQG_X3UQ_\36S^Q;I=_H?[+GPXT_4
M[.;3[^WTF..:WN$*21L,\$'I7MM 'S9%^WI\/YM2GTY-)\6/?V\:RRVJZ!<&
M1$8D*Q7' )'?TI-5_;V^'NA6HN=1TKQ98V[.L8EN-!N%7<QPJYVXR2<"O7M)
M^&-EI?Q5UWQU'=7#W^KZ=;:=+;N1Y:)"TC*RC'4[S^51_%WX4V7Q@\*PZ%?W
MEQ96\=];7PDMCAM\,HD4?0E10!Y1JG[>7P_T/3Y[[4-'\765G N^6XGT"X5$
M' R6V\#)'6F7'[>WP]LULO/TOQ9!]N=4M?,T&<><S#<H3CDD<\5[#\6OAG9_
M%SX=ZWX0U"ZGM+/58?(EGM\>8HRIR/?Y:PO'WPCN?%$_PU^Q:BEM#X3U>#4)
M!,I9KB..%X]@QT)W#K[T >;2_P#!0#X;P-.LFG^*D,,Z6L@;0IP4F< HAXX9
M@1@=\BLW5?\ @I)\(]"L[NZU#_A(+*WM+C[)<2SZ/,BQ3$9\MB1PV.QKUW4_
M@7INK76MW$VH78?5==L=>E"D#;+:B((@X^ZPA7/U-?/G[87[(]CK'[/7Q6.F
MW.JZAJ>J:K_PE*6ENH=FNDC"+$JXY7% 'H5A^W7X$U.SAN[71?%]S;3()(IH
M= G974C(8$#H:L_\-O>"_P#H7?&?_A.W'_Q->A?L]6-SIWP,\ VM[!);7<&B
M6D4L,R[71A$H*D>HQ7H4GW3V[4 ?-DW[?'P[M]6@TN72O%D>HW"-)#:-H-P)
M75<;F5=O(&1FN>O_ (TZ=\:OCS\($T'0/$D*:5?WMQ=SZCI$UM%&C64JJ2S#
M&2Q QFO>-9^$UCK7Q>\/?$![NXCU#1=/N=/AME(\ITF*EF(]05_6N^% "+_7
M^M.HHH **** "BBB@ HHHH **** "BBB@#SGXR>,/%/A/1T/AKP3+XR,\<JW
M"QZC':?9U"_>)=3G.3^5?-7[-/[7_A+P7\ _"6FW^B>*6FL;$I/+;:)/-""&
M8MM<#! ]1Z&OM'4+,:A9W%NQVK-&T98=1D$'^=<;\/\ X467P\^%-AX$L[RX
MN+"TLY+)+B8CS-K;LD^XW4 >/W'_  4$^&EGI-MJ<UCXHBT^Y*"&Z?0IQ')O
M^X%;&"3QCZU/=_M[?#ZQO(;2XTGQ9#<S(\D4,F@SAW5.78#'11U]JZ;XD?L_
M3>(O@QX3\!:/JR6R:#=Z;(EW>J6,D5JRG:0#]Y@HKM?%GPML_%WC+1/$D]Y<
M076DVE[9Q1Q$!66Y149C[@*"* /%T_X*)?"N1(66#Q(PFM6O8BNBSG? OWI1
MQ]T8/-+X8_X*'_"[QM9R7F@6OB;6;2-_+>:QT2>50W!VD@=<'I73V?[)>@Z?
M;Z-$FKZBXTSPK=^%(\L/F@G'S2'_ &QVKR[_ ()E_#34?A-\./B!X=OK"^LX
MK;Q;=+:/?Q%'GA"1JL@SU!"]10!Z)_PV]X+Q_P B[XT_\)VX_P#B:HZM^WM\
M/-!M1<ZCI7BRPMRZQB6XT&=%W,<*N<=22!7TI7"?&+X3V/QE\(IX?U&[GLK9
M;ZVOO,MB VZ&19%'T)44 >9_\-O>"]N?^$>\9XZ_\B[<>G^[5/3_ -O+P!JR
MRM9:/XMO!#,UO(8= G8)(IPR$X^\#U%?2"IM3;GMC-<?\-_AK:?#6QUFVLKF
M:Y34]5NM6D,Y!VR3R%V4>P)H \6C_P""@OPTDTFXU5;+Q.^F6Y<37BZ'/Y<9
M1BKAFQP5((/H:D/[?OPY_M"SLAIOBK[7=QF:W@_L&??-&,9=1CE>1S[UV%]^
MSO'8_ 7QC\.]$U1Q)KQU"5+V]7=Y4EU,TK9 _A4O^0K<M/@K:_\ ";>"O%EQ
MJ$[:IX:TB324BCXAE5U4,Q'7.5% 'DR_\%&/A4T:-Y?B/#RR0 _V+/AI(P3(
M@X^\H'(J;2?^"AGPPUS4[O3M/M/$U[?6B))<6UOHD[R1*XRI8 < ]JWO^&/=
M %O:0_VUJ6+?5=3U93N'^LO4*2*>.@!)%>6?LI^!-9\(_MI?'>:ZTR^@T9K#
M3;.QO[F$K'<B)2N5;H3@#I0!Z=_PV]X*_P"A=\9_^$]<?_$U4U']O#P!I,*3
M7FC^+K2)I%B5YM N%!9CA5^[U)P!7TB>E<E\1O %K\2M%L]-N[F:TCMM1M=1
M5X",EX)5D53[$K0!Y+_PV]X+_P"A=\9Y_P"Q=N/_ (FJ>F?MZ?#[6(9);+2/
M%MY''(T+O!H-PP5UX93\O4'K7TBJ\8-<A\,OAO:?#'2=3L+*ZGO$O]4NM5=[
M@@D23OO91[ F@#QNS_;X^'FH37T5MI?BN>6Q?R[J./0;@M V,X<8X.,'FJ\?
M_!0CX92P:;,EGXF,6I-Y=D_]ASXN6P3A#CYCCT]*];\*_".S\%ZMX^U.SO9Y
M[GQ=>?;9UG/RPN(1$ N.V%%<CX7_ &;8K/P7\*-,U?5GFU#P'<"[BFLP5CN)
M-CIA@W.W#F@#E+7_ (*"?#2\%L8+'Q1.+J22*#R]"G/FNF=ZKQR5VMG'H:K>
M'?\ @HQ\*?%MU>6VB0^)-6N+-MMS'9Z+-(T)R1A@!P>#7I?A3]GK2O":^$A!
MJ5Y+_P (YJ=_J<'F$'S'NA*'5N.@\UB/H*^;_P!A/X/ZC\(/VE/V@;!['48]
M$EU")K&_O8BJW09F=BK=&P6/2@#V/_AM[P5_T+WC/_PG;C_XFJ^H?MV^ M*L
M9[R\T7Q?:6D"&26:;0+A411U8G' %?1S8 YZ5S/Q&\$VWQ)\":]X7O)Y+:TU
M>SDLI982-ZJZX)'O@T >.)^W#X)DC5X_#_C)U8 JP\/7&"#W^[5.S_;X^'FH
M7UY9VVE>+)[NS8+<01Z!.7A)&0&&.#CUKZ,L;,6-C;VRDNL,:QAFZD  9^N!
M7&>"_A-8^"?'GC3Q3;7=Q<7?BB>&>YAE(V1&./8H3ZCUH \CM?V_/AWJ OVM
MM,\53BQ=HKK9H-P?(=1EE?C@@'-%K^W_ /#B\ATZ6#3O%,D6H\6;KH4Y6X^4
ML0AQ\W )X]#7J/ACX/VO@RT\>II]]-)+XLO[C49?M'*PRRQA"% _A&!65\._
M@6?"_@GX8:5J6IFYU#P4I99;8;8[AVADA.0W.-LAQ]* //[K_@H-\-+$3FXL
MO$\ @G6VE\S0YQLE8 K&>/O$$8%0:;_P43^%>L:A#8V,'B6[O)H/M,=O#HD[
M.\62/, QRN01GVKTKQ9^SWI?BZVUR&YU*]B35=>MM?D\H@%984C147_9(B7-
M> _##X/W_P +OVW]$TZRM-1NO#>E^ 18Q:M/'E'D-R[E&?&-WS'@>U 'J"_M
MO>"\#/AWQG_X3MQ_\3575OV\?A_HFGSW^H:1XMLK* ;I;BXT"=8T!XR21ZD5
M](+P *Y#XM?#NS^+7P[USPA?W$]I9ZM!Y$D]L1O0;E;(]\J* /)8?VXO!%Q'
M')'H'C%XW4,K+X=N""#T(^7T_G5>R_;S^'^I37<5II'BVYFM)/)N$BT"X9HG
MP#M8;>#@@_C7T)I.F+I.E6EBC&1+:%859NI"@ $_@*YKP-\,[/P+KGB_4[:Z
MGN)/$FI?VG.DQ!6-_*2/:OMA!U]: /(8?V\?A_<:A<6$.C^+I+VW17FMUT"X
MWQJV=K,-O&<=ZH+_ ,%#OA@^GF_6U\3-9K<?9&N!HD^P3;MOEYQ][=QCUKV_
M1?AO::)\2?$GC&.YFDO=<MK6UF@8CRT6 .%*^YWG->7>%?V73#\,=2\):YK1
MG6Y\5-XDCN+%2FT"Z6=(CGTV@&@# D_X*(?"R&1XW@\2I(EV+%E.B3Y6=AE8
MCQ]\_P!WK4>C_P#!1CX4^(-;O-&TV/Q'?:O9;OM-E!HLSS0X.T[E R,$@5V.
MH?LHZ'J&JWE^^KZ@)+GQ9!XN9588%Q&@41CC[I KPG]GGX)WWPM_X*+?%W48
M+/4I-!UC1&OEU*YB/DM//=12/$K].#GCV- 'LG_#;G@O'/A[QG_X3MQ_\345
MS^W-X%L[>6>?0O&,,,2EWDD\/W 55')).WH!7T6.E9/BC0XO%/AO5=&FDDBA
MU"UEM))(S\RB12I(]QF@#P"U_;L\!Z]I"7>G:/XMO;2ZBW0W$.@7#)(I!P0<
M=.GYUT_[&MO<V_[/?AH7EG<Z?.[W4GV>\B,4JJUS(R[E/(.".M>B_"_P#:_"
MWX?:!X2L;B:ZM-'LX[.*:<CS'5!@%O>NJH **** "BBB@ HHHH **** "BBB
M@!DC;0*^+?C1\<M;\*_M#?"W4?&/P_U/0]'T^YU2*UNK&X74);W= %!6&-0R
MC #<D]:^U:X7Q;\*K'Q=\1?!GB^XNKB&\\,&Z-O#&?DD\^,(P;Z 4 >4R?MV
M> X;V"S?1?%Z7<ZLT4+:!<!W5<;B!MYQD9QZBH+/]OGX>ZA?7ME:Z5XLN+RS
M*K<6\>@W!>$L,J'&."1SS7M^J>!X-4\<:'XFDN)DN=*MKFWCA4C8ZS;-Q/N/
M+'YFN1^'?PDO_!OQ<^)?BNXU&&YM/%4UI+!:HC![?R83&0Q/!)//% 'F\/\
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M1P_:&M3H,XD$62-Y7;]W(ZU['X^^&]IX^O/"MU=W,UL_A[5H]7@6$X$DD:L
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M-Z"G5Y=^TTMXGP!\>W>GZOJ6AWUCHUW>07FE7)MYU>.%W7$@^91N ^Z0>.M
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MC&5['(%=?61X6\,V'@S0;71]+%R+&VW>6+N\FNY?F<L=TLSL[<L?O,<# &
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MA]X;\&WE_=Z)HMGI=S?-NN)+:(*7^9GQ[#<[M@8&68]2:Z+-+0 44F:-P]:
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M#MA>Z5I40M[*UGB#)!$$$?EJ/[A0!2IX( !!KJXXUC0*JA548"J,  4_-&:
M%HI,TF[GK0 ZBBB@ HHHH **** "BBB@ HHHH ***3<* %HI,T9H 6BDS1F@
M#F;_ .&_AG4M _L2YT6UFTO[7)?"W9>%N))7E>53U#%Y';(.?G/K6YIVGVNC
MZ?;V-E;QVEG;1K##;PJ%2-% "JH'0 #&/:K=)0 M%)FC- "T44F: %HI,TM
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M_:W-OX=T:TTB&XD$LRVR;=[!0JY]E4!0.@  & ,5T.:,T %+24;A0 M%%)0
MM%)FC- &8WAW37U[^VFLXCJOV4V7VHCY_(+AS'G^[N .*H^$? /A[P'%<Q>'
M]'M=*2Z<23"W3&\@84$_W5'"KT4<  5T5)F@!:*3-)N'J* '4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A^,]=;P
MOX3UC6$A%PVGV<UTL3' <HA;;GMG%;E>0_M&77CJU\ ZP/">GZ'>6;:9=?;F
MU:YEA9%\IO\ 5A$.3C/4CM0!C_#WXA?%SXB>!]#\3V6@^#[>TU:TCO(HIM1N
M2R*ZA@K8BZ@'M71?;OC/_P! ;P5_X'W7_P :H_9;)_X9U^'.>O\ 8=KG_OVM
M>J4 >5B^^,__ $!O!7_@PNO_ (U1]N^,W?1O!?\ X,+K_P"-5ZI10!Y7]N^,
MW_0&\%_^#"Z_^-4GV[XS_P#0&\%?^#"Z_P#C5>JT4 >5_;OC/_T!O!?_ (,+
MK_XU1]N^,W_0&\%_^#"Z_P#C5>J44 >5_;_C-_T!O!7_ (,+K_XU1]N^,W_0
M&\%_^#"Z_P#C5>J44 >5_;OC/_T!_!?_ (,+K_XU1]N^,W_0&\%_^#"Z_P#C
M5>J44 >5_;OC-_T!O!?_ (,+K_XU1]N^,W_0'\%?^#"Z_P#C5>J44 >5_;OC
M/_T!O!?_ (,+K_XU1]N^,_\ T!O!?_@PNO\ XU7JE% 'E?V[XS_] ;P7_P"#
M"Z_^-4?;_C-_T!O!?_@PNO\ XU7J,CB-<L0 .I)Q4!U*V'_+>/\ [['^- 'F
MIOOC/_T!O!?_ ('W7_QJC[=\9O\ H#>"O_!A=?\ QJO2O[2MO^>\?_?8_P :
M/[2M?^>\?_?8_P : /-?MWQG_P"@-X*_\&%U_P#&J/MWQGS_ ,@;P7_X,+K_
M .-5Z5_:5K_SWC_[[7_&C^TK7_GO'_WV/\: /-?MWQG_ .@/X*_\&%U_\:H^
MW?&;_H#>"_\ P877_P :KTK^TK;_ )[Q_P#?0_QIW]H6W_/>/_OJ@#S/[=\9
ML?\ (&\%?^#"Z_\ C5)_:'QF_P"@-X*_\&%U_P#&J]+.I6O_ #WC_P"^A2_V
MC:_\]X_^^A0!YI]N^,W_ $!O!?\ X,+K_P"-4?;OC-_T!O!?_@PNO_C5>E_V
MC;?\]X_^^A2?VE:_\]X_^^Q_C0!YK]N^,_\ T!O!7_@PNO\ XU1]N^,W?1O!
M7_@PNO\ XU7I?]I6O_/>/_OL?XTG]I6O_/>/_OL?XT >:_;_ (S?] ;P5_X,
M+K_XU1]N^,__ $!_!7_@PNO_ (U7I7]I6O\ SWC_ .^Q_C1_:5K_ ,]X_P#O
ML?XT >:_;OC-_P! 7P7_ .#"Z_\ C5'V_P",W_0&\%_^#"Z_^-5Z5_:5K_SW
MC_[['^-9M_XTT#2[CR+W6M/LYMH;RY[J-&P>AP3WH X?[=\9O^@-X*_\&%U_
M\:H^W?&;_H#>"_\ P877_P :KM;;QUX<OIUAMM?TRXF<A5CCO(V8D]  &K>5
MMPH \L^W?&;_ * O@K_P877_ ,:I/MWQF_Z W@L?]Q"Z_P#C5>JT4 >5_;OC
M-C_D#>"__!A=?_&JYWXA?$+XM_#OP/KGB>^T'PA<6>DVDEY-%!J-R'94!)"Y
MBQG [U[M7EG[4O\ R;G\1O\ L"77_H!H ] \.:HVM^']-U%T6-KNVCG**<A=
MRAL9_&M.L#P#_P B/X>_[!]O_P"BUK?H **** "BBB@ HHHH **** "BBB@!
M#TKQV[^(OCS6OB5XJ\-^%='T"6UT!;3S;C5KV:-Y6FC,@PJ(> !CDUZ9XFFU
M2'1;Q]%BM9M56)C:Q7TC)"TG8.P!(7Z#->+?L]W'B>Z^+WQ=D\6VFF6>L;M)
M#1Z1.\T&W[,^T[G53G\* .L^W?&;;_R!O!?_ (,+K_XU0+[XS9_Y W@O_P &
M%U_\:KU2B@#RO[=\9O\ H#^"_P#P877_ ,:H^W?&?_H#>"__  877_QJO5**
M /*_M_QF_P"@-X+_ /!A=?\ QJC[=\9O^@-X*_\ !A=?_&J]4HH \J^W_&;_
M * W@K_P877_ ,:I?M_QG_Z W@H?]Q"Z_P#C5>J44 >5_;_C/_T!O!7I_P A
M"Z_^-4?;OC-_T!O!7_@PNO\ XU7JE% 'E7V[XS_] ;P5_P"#"Z_^-4OV[XS=
M/[&\%_\ @PNO_C5>J44 >5_;OC-_T!O!?_@PNO\ XU1_:'QG_P"@-X+_ / ^
MZ_\ C5>J44 >5_;_ (S?] ;P5_X'W7_QJ@7WQG_Z W@K_P &%U_\:KU2B@#R
MO[=\9_\ H#>"_P#P877_ ,:H^W?&?_H#>"O_  877_QJO5** /*VO_C,J_\
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M_P")H Y'_A:GCG_H(?#/_P 'TW_Q%'_"U/'/_/\ _#/_ ,'TO_Q%==_PS?\
M"S_HGOAO_P %D7_Q-'_#-_PL_P"B>^&O_!9%_P#$T <C_P +5\<_]!#X9_\
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M\&%U_P#&J/MWQF'_ #!O!?\ X,+K_P"-5ZI10!Y7]N^,P_Y@W@O_ ,&%U_\
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M ,2;P5_X,+K_ .-5Z7_:5K_SWC_[[%)_:5K_ ,]X_P#OL?XT >:_;_C-_P!
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M);B**W6VW6LQD'D.]NB1,620816 5LD^M_\ " Z*OBK2?$0MB-4TO3YM+M9
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MG96&]=S $'!QC&5KWQU\9^"O#?Q7\/ZG);ZMXR\(IITUCJVFZ5(Z7EO?R>7
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MP313L&+F%?+N%+J"Y!C;;G*BN;U#]G/Q3H_CSPEK/A'XB_8=;TK0[[3KJ_\
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M(^X\F/E4^M> ?L5^&V\+^-/BQ9MX3TKP81-I;?V7HVH_;H!FW?YA)ZG'3VH
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MM3^)7AG6= N]3\02ZEJ2Z@NF7(> 6S1-C_1O-WSC[.I50(@0HVT ?5U%%+0
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MS6OLX=Z %HHHH *\L_:F_P"3<_B+_P!@2Z_]%FO4Z\L_:F_Y-S^(O_8$NO\
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MFQN(Q+%/&V5=2,A@?2FXRCN@//OVFF#? GQ?T_X]D_\ 1J5Z9:D&VA/^PO\
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MGX\LOB-\6OB[K%A9ZG80.^E1^1JUF]K,"MLX)V-SCWKZ"89&,9^M>1_#//\
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MBBB@#Y#_ &75_P",QOVES_T_V/\ Z*->W^/C_P 7?^&_TU'_ -)Q7B/[+O\
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M!]*53#SBUS:1W[]-?ZV"$U)7/9U/2G4R,!551T I]>6:A1110 4444 %%%%
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M!%3[UO("Y1112 **** /@GX_?\I/?@-_V!IO_:]>[_LU_P#)2?CK_P!C8O\
MZ20UX1\?O^4GGP&_[ TW\IZ]V_9J_P"2E?'7_L;%_P#22&@#Z HHHH ****
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M^''TU'_TG%>(?LN_\GB?M+_]?UC_ .BJ]N\??\E?^''TU'_TG% '(ZI^Q/\
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MH<'J*R? 7@/1?AGX+T?PIX=L_L.@Z1;+:6EL79RD:C !9B2Q/<DY.3FNCHH
M\P^$/[./P]^ MAXBLO N@1^'[;7KHW=\D$TAW.5*@(23L503M5<!<G %:WAG
MX,>#_"/PEB^&NG:-&O@I+&73?[+F=I5>WE#"1&9B6;=O;))SR:[FB@#FOA[X
M!T?X7>"M(\*>'XIX-$TF 6MG#<7,EPT<0)VIOD8L0 < $\  #@"NEHHH ***
M* "BBB@#PKQC\>M9^'_Q ^*%EJ]AI]SX?\*^#+?Q79K:>8MU,7EO4>.1V.T<
MV@QM7C<>3T%FUT.W^*WB*^\%?%[PAX/\67>F6-IK5H7TL7%O$+AIXF0)<>9B
M1&MV!D!&X.ORKR!T_B+X)Z)XL\8>*];U:2>Y@\2>&H?"][I_"I]FCENI-RL/
MF#-]K<>VU:N_#_X;/X-O[W4M0\0:AXFUBZMK:Q:^U!(XV6W@W^6@6-57.Z21
MV;&69ST   !B66@Z'^R_\$+^#P[H\ESHOAG3I+BWTRQ@C2:?RXMS#$:*IDD9
M68MMY9R:^-?&O_!4J/Q!X/US3/\ A3/C*U^V6,]OYTJ*$3?&5RWR]!GGZ&OT
M:D174A@"#V/(KYI_;+TOQC)X/)\(7.OV5L+&[-ZNAV5K,CKY9P)3*ZD#K]T'
MO0!Z'^RRP?\ 9S^'# 8!T*T/_D):]6KRO]EK(_9S^'&[.?[#M>O7_5BO5* $
M]Z8SA5)/ ')IQ8 UC>(M+O=8LXH;/4'TYEN(Y'=4#^9&K M&0>S 8/UH5F[,
M"_INJ6FK6:75E<17=L^=LT+AE;!P<$>A!%9?C#4-7TW3;>71=.74[IKN"-X6
M?8%A:0"1\^JJ2WO@50L;RR\'P:G8V^B2:3HNEP?:1-;QH() 0SN$13NW Y)R
MHR6[UA^"/B)>^+]%TN]^PQZG::I<S)'>:3+F*WA&=C2[RK*^, JH.#FMU3?Q
M):(7D=A;:C=/KUU9/ISQVD<,<J7Q<%9'8L&C ZY4 <_[0I\WB*TA\00Z,Q<7
MLUNUR@V';L5E4G=C&06'!K&N/!ESI_@.YT+0-5NM.NO*=;;4+AS/+$Y);<2Q
MYP3W/3TKE]3M?%.H:'<P^)M(%W$J69B7P[>NET\P;,Q9B5Q&"%/!Y&:<81D[
MW_KN%_(9XD^-1^'E_JU_XQT\:%X7BN4L=/NANFGOIFRVY44'"84]>>#76ZW)
MJ>K6XDLKJSL-#N+&5IKJ96\^%V7*. ?EV@$D[O2O)?%7@'Q)XX\2:]HOC+Q+
MI=IX3-[%JFEB-D%['"G#)\P'E@9'[P$D$GUK.^-'Q@N=-UBW\#^';BWN85LC
M+?>1(MU?2P1@%XX4)VLVT-N$A!()QFN^.'51Q5+?KVMI^)BZG+=RV,WXIR0:
M?X!T[3["+[?I6@W%M<7OB72+=(I+&0;)GN57[KHZ-SL/\1ZUS/C#XF6GB:/P
M.VF^'8?#FO:B]S:Z'?W$J2PP-A2LBQ)\HED+#&1\N[-.\<>/O">K6=C9:E)K
M?AFSGLTBN+#38_\ 1I[#'FF$QDC8XA(9F5>,%1GI7(ZEXN\):7JFDO9^#-/M
M/#;:B;>*ZDFD6\M%B",LJ)_#(VX'(.#A=QKWL/0=DI0=]?Z[,\RMB84VE>U_
MZ^1SGQD_:"O_ !+X(ET;6YKQ?%*0KINH6-J#%;?+*KO(Q_O?*4.WCYC]*BB^
M*JQG1)[S2=)UG4;RSETJ;7XYF@)MG10J3(HW*T8^7>>H Q7-:[XTUGQ3<:OH
MKZMI>M6^L71DDUF>$03?9HOG,1#*-A8@':.21WK<_P"$?A^)&GZA8FPA\(B&
M!#9KI\?G_P!J/_#ND?YRB@#.!U->QRX>BHQFK6NWZ;>NY\_B<;+X5))_Y&9I
M5UH=K<:Y-<8\86.BV\ D-K<O&D=J&"BV@5OF8ARK>9_=1_7GU7P7HWAN[@O?
M%/BNQEN=5VQZP9;Z,K;6D(PB6R+&<2/Y03C';'8UY;I=W9Z7XN@UI;:UT:_\
M/VTEIJ=NL+"(L5,850BG>Y)(Y]>M-T_Q%%;^&M0AL];N$FA+W5BVH73M%M\L
M%D$:EMA4DXR!G ^E16:K3<*<K6M?Y]+_ '/T.*.9\G+[NJOH_(A\7^+]=L?A
MO+X?U[3+74-&N"K37$\:-Y*WDORRB3G#*B#!4\9P>0*]BU'7_!/@'7/$VG:'
MIOAB?5AID&GV5W!J#I"MK+((RKDG_6A6WLR=CSBO"/%&K2>&O D5[XQO-1>#
M6M+:W@MHK>'R85\T!F:-6Z8).XKGDULZHNCPZ'JEQI.G:7XQM+[5DC+&U:"2
MWM5C C&0-T>3R2#VK+V4*M5WT6FVSNSU:.9<JM)+E;T>AJ_#_P"-B>"?#O@O
M0?!UMI6G>)8[_P C4M<N[4%95>X8^5YO78%V[CG.",5ZK\2_BCX:^(W@GPYX
MGO\ PQINHVU_JO\ 9=Y("(6EGCQL8RE=PM\\G)ST]Z\(UL6OA_P3I&E)9R7&
MC7$;7CL6=5*ERL<LN/NRHY90!PRXS6]?^*M5\(_"_P /^'[+289-5>=[2&]N
MH8FMC&S!W0H259BRKM9AD@&M)X>E4JQE!>]=]>FM_P"NAH\TI)NE*5G^'?\
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MVIO^3<_B+_V!+K_T6: .U\ _\B/X>_[!]O\ ^BUK>K!\ _\ (C^'O^P?;_\
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MR22,69VT> DDG))^6O5/#_A_3/">B66C:-86^EZ58Q+!:V=I&(XH8U&%55'
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M%J>DVL7D[1##@A70,#YAYR6! X'I3?$UK::M>V<;R3+92S>9?2W;>43@D+M
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MNVZA%YKE;@W2 -]Y&:9&Z[F!KTF;POH_@?X=^,/$=W?:MX@\0Z'I,MA!?:F
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M\:5=337J:M=M//9QEB7N()OO.WEDKLQV%>_Z]JFK6,NZSMK22V%O(S2W4_E
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MGQ3OX;K4=1L](T62"YM(8+<PPSLT;!T>3)\T9(.W'&!67\0/B5H_@.&[TFR
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M,Q8>3@CYL*VX$#C%0Q>&-07XE7'B%KK33I<FEQV*VHTP"^$JRLY<W6_)B*L
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M5U./[/D21<.P4C/F-G:!_=Q6MX(>Q&E:?HD2K+%H?E7&I:I"JHLC8<QA3UD
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M.UY;Q C8S8&2Z[6/'7-6/'7BCQ!I+ZI;MX:NKOP\;41K?:1<![[S'(7Y8L#
M7<6W%OX:JW+6FM?$!]9T";^W=5TR1-,O=-EOO*BT]&^:294Q_K-N%]QD>M>B
MZI?1Z5I<]Y*KNL,9D*1C+M@9P!GDGZUM*;BXIJ_EZA;J>>_#?X=ZWX&O+BQ&
MJ6MQX+%N$M-.:VQ<K(0#))+)GYF=R['(ZM3[_P *>)?#]]I>D>!TTG0_"Z6T
M_G"2,LT<[,&0HHZJ<MGGO5OP[XFB^*_A'5+-Y9]!U$AH+B"VGQ=V(<;HRQ'W
M)#&5;;VR1FMBU@L_A[H^H7FH:O=3V7F>?)<:A*7\H%40*#Z9 /U)HE4FIOG^
M+M;\?4$E;0@\*Z?J4,VNZCJ@-M<74V$@-QY\*1HNU77@;=P^8KZU0\#+;_$;
MX;^3K.I6'BVTNVEAFN+: I!,H<C;M/0KC;]171ZIXLTK2+[2[&]O(X;G5)#%
M:1/G,S ;B!^%-T\W&EZI/90Z;:V6@QP"2.YCD5<RECN0QXX &#NSSDUBY2:;
M:L]/P[#L&O>&K*\M;&?^S+>^N]*)FTZ.4[1'*$*K@\XX..E8WPQ\/^(_#^GW
MW_"0:HNH)<3FYM8.7>T5_F:$R?QA6) .!P!77:EJ-MI>GSWES*L5K C2R2,>
M%4 DL?;&:RH->N-6;0[K2((M0T2^4R2WOG!=D93<C*N/FW' J5*?)R] MJ8O
MQ'U%Q:O:W/AS_A(M",8:[A@D#7&\2+Y86+^(9^8DL,;3UJ#PK8SZ7XTUF"QM
MUTOPW OS6K6NS[1>2L)'G23=\RD-M(Q][-=?;^'].L]7O-4BM4CU"[1(YY\G
M<ZIG:#SCC)_.N(O)?"^L3:AXPNM=EN-$T^)K:XMGF(LXI()2YE*_\]%88SGL
M*UA)./(E_P /_F!9\5^&=/\ &7B'[)%K^HZ7?VEBZRVNG3;/DG(596&/O QM
M@]N:NQ^%X-0\7B]U'0;-FTJ)4TW52X>=MX_> C'R\JO.><_6K0T&WU[Q%HWB
M>UU"Y1(K9PL-N^(;I'"E6D&/FVC.WGC<>]=1M&.E2ZKBDD^GW=PLGN?.K>/-
M6N?!>M^(?A]X6M;?Q9:ZSN\0Z')GSY50LK ''^L9 C# Z$U1\1:+/IO@>3Q7
M\0/%UQX?EOI+Q[?2GN6-I%]IBVQVTN%._803P!@YQ7LWCOPCJ>KZ6+;P[?PZ
M!/=W<;:A=I%^]D@ (<*PY$A&,,>F*X7XK-%\*_#.D:A,UF_P]T52-3TR:R%W
M<3EB%C,98]=[#))[FO0I5E)I06K?SMVO^1C)-;GS)X5M-8@^&>F^&+W2K_QE
MHES;RFUU_0X3>+9,TK1RQ1LVW8#""O(X+#K46D_$:]L?">J:7XAUM/A_XAU"
M[M=/CO+33BLZ01#;ME=6'S*NW/ID8ZX'M5GXNO=<\&:%XA;PQJ%[X"62ZFDB
MTI!:32PR,\:1-9K_ *U0&5MP;GEJ[WPSX9\-^/-)UG5-3\/:#>QZA(8; ,J%
MY[98U"))D95PVY3W&!Z5[,\8H7=2'7I;>_W>IR>QC\*9\(?$36[FT_:*TO7=
M4L-0O])TC2/LU^MW&$OFM]Z1HUP,E3N+#!SR,5VL/B35_B-<66B+XDL8(]%@
M>]T8>'@2VXD[A(V 5"KC@BK_ (RL?"/P[^*XL+RR6*WU7PS="*VDOC<I->"=
M"86;'"PM@)D=Q7*>,=8\'^"_#.C>)? FO7$FJZC'-IVJ07T(%X<@>8Q;I&<<
M;AV/%>SA*OME91ZZ::;?.W4^=QN%BVVOBM:_X_F4]'\#Z;:^((K&^MKSQ3XI
MU#6)HUNEE @GV'<LBG[VXD'.?45Z'KNHB>_O]3U5([*>#:ETK3!C".,ACC[P
M^G-<1XA\;>'8;ZVN]-MH?"\FI+&TUY%>&^EM "I*B/:-JG'8]ZGMVTKQ1J5_
MJ&A7<EI>SJZK#>)B&Z)'$KIGKSW]!7!G.71QM*]6]EK_ )[::]K,^.QWM(M5
M9O?MMMI;JCM;M7DT6 QR-/;7&YO++80@ ;2!ZD'\:9#I=M<O9V-[<FVM6P5>
M)RN6"$B-CC[N.H K/T32Y[.XO/M.\N%5VE>XW+NQC:J?P*.?^^JLV=["]S<6
MNU7>%HS)&_!5F&1@^X]*_FO&</5?:3Y$^75WLFUZVVMM^A[^#S9X>4)P=FNS
MZV-F.UM],LDD2-+2.>%H(8X5V< ?>W=QD\\?TKE?%6JPV^A:=IK/&VK2-&DD
M4<)<7.6"N!'G[I#>M:]QY5X);5YUB8"1;=1( 5) !*_CC]*YKQ-XHU323<Z<
M=.GU#R]/60:I&P;RL+M+D8X"DC//!Q7V7"?#E6&+I8NI'FNV[.ZT6BWW7WG'
MC<RGCFZ6_P";?4Z&PT;5_$&N2>"[#PS8RBW:,3:A<0B[@AA+JJJL>1RK$;CG
MY<'M7H_P9\=6WCRZ\0>!;";1_"]A%=QK':^'KEH9R8G#3W*N5PR.ZHNWK@G\
M?,?"NDV&L>"]$,%UXJMO$%T;C4)39#R5U.:*# $$Y;A<<G(.26KZ'^&/PO\
M"\?A#2;O6-'N] _L6TFM[S3K]E(G*E96E=U&90I (;ZU^MXWV-&#BE;MZ]_/
M8^QRG#NA0C%6/H>-<*!UQQ4E97A[7K#Q+I-KJ6EW4=[87";XIHF!5E/3!K4S
M7Q;NGJ?0BT444 %%%% 'R)^R[_R>)^TO_P!?]C_Z*->W^/O^2P?#?Z:C_P"D
MXKQ#]EW_ )/$_:7_ .OZQ_\ 11KV_P ??\E?^''TU'_T0* /3**** "BBB@
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M3@N(]I46ZQ@#*<\\]@:WK.\\+Z 5U'Q%)?6FM_;()+>VG)E2&,KN,B*/X1D
M?0UTA^"=U\/_ !-X3A\1Z5)-X/B3[?=K(5, NFBYC\Y1P#($4*QR>?K4=O\
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M444 ?&'_  4+_P"1V_9R_P"Q]M/YBOL^OC#_ (*%_P#([?LY?]C[:?S%?9]
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MH5E"].0OO7/Z=\)K.7XG:7X?\':LVL77A^1FGTW7+Q89A=*=Y,",,&,Y7/\
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M$K2(D1A7&=@W-ENOS&O5-2^$-KXAM;B.]\1:[<P3H?+5KS AD,OFI*F!PZ'
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M!8K'I]OX(N+N&ZBO[I0ID@"!(WBFSE#C:=N.<FO5_&G@_5?$VARZ ++4M/\
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M.M>L+H.N:AXA@O)]9:TTNUD62WL[) #,ICPRSD@Y^8Y&W%8'[3:_\6)\7?\
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M .)IW_#?'PV_Y\/%7_@AN/\ XFLG4U]U67WCL?25+7S9_P -\?#?_GP\5?\
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MK'&H55 Z "IJXISYNAJ-6/:2<G\33Z**S&%%%% !1110!\B?LN_\GB?M,?\
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M/ Z5Y0/V.?AY_>\0_AX@O!_[4H ]N\Y/[Z_G1YR?WU_.O$/^&.OAYTW>(?\
MPH+S_P".4O\ PQW\/?[WB'_PH+S_ ..4 >W><G]]?S%'G)_?7\Z\0_X8Z^'G
M][Q#_P"%!>?_ !RE_P"&._AY_>\1?^%!>?\ QR@#V[SD_OK^='G)_?7\Z\0_
MX8Z^'G][Q#_X4%Y_\<I?^&.?AYC[WB'_ ,*"\_\ CE 'MWG1_P!]?SH\Y/[Z
M_G7B'_#'/P]_O>(?_"@O/_CE+_PQW\//[WB'_P *"\_^.4 >W><G]]?SH\Y/
M[Z_G7B7_  QU\//7Q#_X4%Y_\<I#^QW\//[WB'_PH+S_ ..4 >W>='_?7\Z3
MSD_OK^=>)?\ #'7P\_O>(?\ PH+S_P".4?\ #'?P\_O>(?\ PH+S_P".4 >W
M><G]]?SH\Y/[Z_G7B'_#'7P\_O>(?_"@O/\ XY1_PQU\//[WB'_PH+S_ ..T
M >W^<G]]?SH\Y/[Z_G7B'_#'7P\[MXA_\*"\_P#CE'_#'?P[_O>(?_"@O/\
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MLNM:LH]6\&^"+;2&G5+NXL?$UU/-''G#LB&R4,P&?E+#..HJS\<-(\3W%_\
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MF:UZI7E?[+7/[.OPYXQ_Q([4X_[9K7JE !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?QGIC)XDF5/L4N')"J<[LDG'([&@#ZW3^+Z_TI],7J?K_A3Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O,_'W_ "6#X;_34?\ TG%>F5YGX^_Y*_\
M#CZ:C_Z3B@#TRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWPZ_[ =K_P"BUKU2O+/V6_\ DW7X=?\ 8#M?_1:UZG0 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7@'[-?_)2OCK_ -C8O_I)#7O]> ?LUG_BY7QU_P"QL7_TDAH
M]_HHHH RO$]I=7_AO5K6RDD@NYK26.&2(@.DA0A67) R"1U(%?(7P#\"^'M!
MU3PIHK_!B[L?%&D?9_MUY'XTL[XVLR%=\[Q_;C(RALMCR\\XQVKZU\;3QP>#
M]::358=##6<J+J5Q((X[9F0A9"Q(P%)!_"OD7P?X#GF\5?#OP59_!S3_ (;^
M+?#%W!JEQXL34-/9I[6&3;<R0>3(;F<78W(WFHH_?$O\P (!]KT444 %%%4-
M:UFT\/Z9-J%](T=K" 798VD;D@ !5!8DD@8 )H OUAR>-?#T/B*/0)-=TV/7
M9!E-,:[C%RV!NXCSN/'/3IS7/7WQQ\%:=X=T'7)M99M/UVS.H:>8;.>66:U"
MH[3>2L9D6-5D0LS* FX;B,UYWXP\1'XA?&/PUH\OAG7D\+:)?6NL0:[::9)+
M;ZI=F-O)VSJI5((Q(&=RPW$!<;0VX ]_8;N.E> _M=+MTOX;8X'_  FVE_\
MHPU[M=:A;:>H:YN(K=6. TKA03Z<FOG_ /:RU:QO--^&R07MO.W_  FNEG;'
M,K-_K". * /HA>I^M.IB=6^O]!3Z "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KRS]J;_DW/XB_]@2Z_]%FO4Z\L_:F_Y-S^(O\
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MD?PS_P"2^?&'_N$?^DTE 'KU%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7@'[-?_ "4GXZ_]C8O_ *20U[_7@'[-7_)2OCM_V-B_^DD5 'O]%%%
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M_P FY_$7_L"77_HLUXC\$_\ @J5\$_C)X@M="DOM0\':K=%5@3Q!"L4$KG^
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MVE7<8EM[RSE66&53T96!P1]*\3_9J_Y*5\=O^QL7_P!)(: /?Z*** "BBB@
MHHHH **** "BBN,O?'5[8_%32?";Z,IT_4M-NKZ/5OM8SYD#P*T7D[>F)U.X
ML.F,'J #L)%+#BOC[]J#X7ZQIGC_ ,"^+9O'FMWFF7/C+3$3PS,$^Q19;&Y3
MC=D$$\GN:^Q*\ _:\_Y!?PU_[';2_P#T8: /?5[_ %_I3J9'W^O]!3Z "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_&O_  5C^.WAO1/#'A^_T'X2>';DFZOKL?+$K8,DLS*=OG,BA4C4DC=UP6-
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M<^;M^X0W6@#ZDHKQX?M!:@?^:5>.O_ .W_\ CU(W[05^JDGX5^.@/^O.W_\
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M;C\0?%37M7\/:CX<@U[Q"M[96^IJBS-%]FB3<55CCYE/?M0![U1110 4444
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M)/M0![K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gizttcucplmb000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000011.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_5E>>SAO.)GM][".5EQ\N]0'"]0&&>: .VHHHH ***CFF2WB>5SA$!9CZ 4
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MRSX1;X5>'?AGIOQ4T33]\'AWQ9_;,5H(+=F)C2XBD8,3'GH".  "0,U]]44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'^)FC>!/CI\*[_X2ZGKKK%I.J/=K=:?<REMHC:0* K%L#AFZC.W()M?\$O?
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M$C) 1T /'"^V*^J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGKI\LCM%;S2,RI-OC7$@##(4L/0F@#RO_@E'JR6?[/\ KO@:X(BUCP=XEO\
M3;RU;B6/,A<;A_O%QQ_=/I7TQ\<_C!I/P%^%/B/QWK2--8:/;>=]FC8*\[DA
M4C4GNS$#GUKY\^-_[(/CO3_C!>?&#X ^+K'P=XUU%%CUG1M5B)TS5@HQOD"J
MV'QZJ<GG*G)/'S?L@_'C]I3Q1I+_ +1GCG0AX&TFXCNAX2\'I(L5_(ISF9F1
M< ].K'!.W:3F@#[*^&OCB'XE?#_P]XKMK"\TNVUJQAOXK/4%59XDD4,JN%8@
M'!'0FODG_@I5&/!>I_ 7XKW".^E>"_&<)U)E4D16T[(7D('/'D #W<<<U]JV
M=G#I]K!:VT206T"+%%%&NU44# 4#L  *YGXK?#'0?C)\/M<\&>)K4W>BZO;M
M;SJIPZ9Y5T..'5@&![$"@#I[6YBO+>*>"1)H)4#QR1L&5E(R"#W!!KR77/VE
M]!T?]I3P_P#!>+3-0U+Q#JNE2:K+=V01H-/C7?C[1E@5#;#@C)RR<?,#7S7H
M/P!_;$^!>DOX-^&_Q'\'^)_!=N#'I5UXJBD%]8Q9XCXC8$+VRSCL !@#U[]D
MW]D.Y^!.K^(_&_C3Q/)X[^*?B<*-5UV2/:D:#!\F$8SMRJ\X&0B850,4 >;_
M +'7_)[W[5W_ &$K+_T%Z^F/VB?'%K\-_@7X\\27EPEM%8:-=2*\F,>88V6-
M<=R790!W) KX_P#%G[(O[4OAG]H+XF>//@]\1O!GA/3/&%\MP\6H*T\[1HN$
M#K)8RJI!+?<;O5^V_87^.7QROM+C_:/^--OXF\,V-RMR_AKPW:K#;W;*<J)'
M6& 8X[QD\G!!YH ]5_X)I>#KCP;^QGX BNHWBFU&*;5-LF,[9YGD0CV*%2/J
M*Y_]K+_D]C]D#_K^\0_^DMM7UU8V<&F6=O:6L*6]K!&L44,:A51% "JH'0
M#CTKPWXX? ;Q!\2OVAO@1X\TN[TV#2/ =SJLVIPW<LBW$PNH84C\E5C96(,;
M9W,N,C&: .U_: \/^ ?%WPEU[0?B7?:=IWA#4XQ:7-SJETEM&CLP\IED<@"0
M.%*<YW 8KY7M/V%?%WACP?=:!XQ_:"U[Q#\$=*MVNF\,_9%MY)[6-2YMYKKS
M"_DA5P54X(Z!*^JOCY\%]'_:"^$OB'P'KCR066JPA4N83^\MYD8/%*N#R5=5
M;!X."#P:^5-4_9T_:M^)7@V'X4>-?B!X.L?AUY:V-_X@T6&=M8U&Q3 $;*RA
M SJ,/R.IR6&0P!A_LA^&?BKIG[ NA7GP5ATG2O%&M^(;W4U3Q I%N+)IY8P0
MI!P2L46,#D<]Z]1\!^ _VE/B!X)^)OA7XWWOA>32=>\-7>EZ<?#H D6XFC:,
ML_RCC:W';-?3_@SPCIG@'PCHWAO1K<6FDZ3:16-K"O\ #%&H51]< 5MT ?)?
M_!+_ ,:0^)OV1?#6CL!#K'A:YN]%U*U.0T,J3NZ@@]S'(GMG=Z<>S_M%?'C1
M/V;?A1JOCO7X9;JRL7BC6TMV437#R2*@1,\%N2?HIZ5\^?$O]CWXF?#WXN:S
M\3?V<?&6G>&=0U]_,USPKKR,=,O)#UE4*K;6)RWW0<EL, Q%9.C_ +'/QA^/
M?Q$T+Q+^TKXRT/5- \/72W6G^#/#,+?8991G#S%T7//8[R1D94$B@"#_ (*,
M_$#6?B5\#?AQ\-_"5K+IWB'XLZA:Q)8ZH1#-#;*JSE)=I8(WF&%6P3P''-<]
MXT^&?[:_CGX7ZC\/]1TOX4#PU?:=_9CVUNTZ%(-@50AR<%0!@XX(%?07B']G
M7Q%XT_;2\,?%;6;K2CX*\):#-9Z+I\,TIO/[0E)5YI$,80)L=P,.3F-#CDX^
MBN: /AK]C#XD7/C3_@G[XH\/ZJ)(/$/@G3=5\-W]K-Q)"88',8(QV1E7ZH1V
MKB/V%_V)_@M\;/V0_"NL^+_ UKJ6MZA]I$^IQW$\%P2MPZJ0\;KR ![<8(->
MS>#_ -DOQCX%^,W[0.LZ9J.AKX)^)6G2FULS/,+F#4'C8%Y$$.T(7EF)*NQY
M''IZ5^QO\$]<_9Y_9[\->!/$=U87NKZ89_.GTN21[=M\SN-K.B,>&'51S0!\
MM?LJ6.E?L7_M8:O\!];TC2Q8^(HVU'PCXNDM(X[ZYC;<?LD\P4;R-CJ,G[R
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M1'^&W%>=:E\ ?VO/B)X1A^&'C'X@^"[3P+(/L6I>)=*2=M9OK)1@*59 H=P
M&.5ZG);^+ZRTO1_#7[.OP76RTV'[#X8\):0Q1"=S>5#&6)8]V;:23W)- 'SU
M_P $_?F\9?M.M <V!^*>K>7GKOW_ #D=L?=QC\:^PZ^6O^";_A/4-&_9IL_$
MFLQ+%K?CC5+SQ9>%4V[VNG!1L9Z&-4(]B*^I: "BBB@ HHHH **** "BBB@
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M4 *J@=    /:K-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/]F:AK]G:"XN=0U$$AXU)(^5"K J&&,9.[<, 'W717RA^SO\6OB!X)^.&L_
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M#2DP0O<$-:7BJ?E5DD5E8]U?V% 'T7135QVIU !1110 4444 %%%% !1110
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M *]K?_TIBKU;]G=@G[//PQ9B J^%M+))/3_1(J\I_P""E!_XPI^)?_7M;_\
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MHW_H9KT?]H/]DN#]H#Q-IVLR_$GQWX*:SM/L@M/"FJBTAE^=FWNNPY?YL9]
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
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M$\3VOB3Q#9:AIWB*&'[.VJZ'>-:3S1<@)(0,,!D]1G'&<5[]10!YO\#?V?\
MP1^SKX2?P[X'TC^S;.:7[1<SR2-+<74I !DED/+' 'L.P%>D444 ?)?Q5\/R
M?"3]N;X;_%%<1Z#XSTZ7P/JTQR%BNB1-9ECG'[QH]@XZH!U88]QU;X&^%M:^
M,VA?%&Z@N3XMT6PETZTF6=A$(9-P8-'T)^=N?I6[\0/AWX>^*7AF;P_XGT\:
MGI,LL<S0^=)"RR1N)$=9(V5U964$%6!KHT4*H S@#'))- '"?%+X*>&/C#=>
M$+CQ'#<2R>%=;M_$&F_9YS$%NX3E&;'WER?NFN^HHH 2N)^+WP;\(?';P3=^
M%/&ND1:QH\[!PC_+)#(!\LD3CE'&3\P/<CH2*[>B@#YC^$O_  3O^#WP@\;6
M/BRPL-4UO6=/YL9->OVNTM&Q@/&A &X=B0<=1@UG?M]6=Y\3/#?@7X*Z5\][
M\0-?@CO57DQ:;:,MQ<RGD8"E(^>^<=2*^K:YG_A7?A]OB"/&[Z>9/$ZZ?_92
M7SSR,([;>9#&D9;8N6.2RJ"<#)(   -VPLX=-L;>TMT$=O;QK%&B]%50  /H
M!5FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<*">22?FKQ9\4;WP1_P3/^ WAFPU[_A%Y/&]W:Z!=ZT)?*^PV3RRM<2[LC
M"@^S-0!^A^C_ !F\ >(/%]QX5TOQOX=U+Q/;[O-T:TU6"6[CV_>W0JQ<$9&>
M..]=G7YD_%GX<_L=Z=\#=1MOAWXT\*Z)\0=$L&O-$\0V6LE=0DOH4+QEY V6
M,CC!XXW9 R!7VI^R'\5KKXW?LU^ /&E_*L^HZEIP6\E48#W$3M#*V,#DO&U
M'/\ [=7Q0G^%O[,/CW4-+UR'1?$3Z:R:>_V@17!9G5&,0SN+!6/*]#@UQO\
MP3]^!'A7X<?#VS\7:+XSU7Q;K?B;1[&?5EOM32ZBM9FB$K(JJ,QME\$,2?E%
M'_!33X;^&?%?[*OC'Q#J^C6U_K6@67FZ7>S E[1GEB5V3GJ0!^5>,_$_3[7X
M)_L4_"?PE\+=.B\)^(/BY/H>E7^I:>664-<6J-/<=>78+M.".')[4 ?<VG_&
MCP!JWC&;PE8^./#MYXIA)$FBP:K ]XI'4&$-NR >>.]=-JFL6&AVOVG4KZWT
M^VWJGG74RQ)N)P%W,0,D_G7R)X\_X)J_"&R^!]UHWA3PZND>,-*L#-IGBF.=
MTO\ [9&I9)9)%/.YQR,8&?E P,>)_&'XX:U\7/\ @DGIWC;4+XS^)8+K3X+F
M]*C<]Q;:@B"5AC&X[%8\8))XH _1/3?B!X7UCQ3J/AFP\1Z5>^(M.19+S2;>
M\C>ZME;[K21!MR@\=1Z5QO[5%[<:=^S'\7+NUGEM;J#PEJTL4\+E'C=;.4JR
ML#D$$9R/2N$_9K_8J\#_  +U"P\:+'>ZO\3+NP:/6?$FH7LLTE[-,5DG<HS%
M5RX(!4 XX))R:[;]K;_DU;XQ_P#8G:Q_Z12T ?%W[-?[ =I\9O@1X)\;ZM\7
M?B-::CKFG)>3P6FLD1(Q)R%R"<<=S6E=>%/''[ /[0GPIBL_B'XA\=_"_P >
M:LOAZ\TW7KCSY;.YE=5CD7)]7W;E X1@<Y%<I^SQ^TE^TK\.OV9_!4?AOX P
M^*/"6GZ6HL]5AORTMS""Q\SRE);L> .U=3^S_:?$'_@H1\2O WQ?\>/H.A?#
M[P-?//IOAG2KEIIY=11E(>=2?D*LJ-\^#A1A<,20#]$KJZAL;>6XN9H[>")2
M\DLKA511R22>  *YGP/\6O!'Q,:[7PAXPT+Q2UFP%RNC:E#=&'/3?Y;''XU\
M8?M[>/-"\7?M#?"_X->./%*>$?A?<6TNO>(YGN_LPO\ 866&V>3(PA*-P#SO
M[%01Y=^TMJW[.OP9T#0_B=^SSXH\+Z'\1/"U_!(NG:#J *ZM:-(%FMYH\G>"
MO.>N >>A !^IU-9@BDD@ =2>E>6ZA^U!\*M CL$U[Q_X=T"]N[."^6RU+4HH
M)A'+&KHVUF!P58<XKYY_;D^)7_"UM)^#GPS\$^)]FA_%/7?LMYKVC3"3?I\1
M'FI$X./F9AR./D(/!(H ^J/"_P 9/ 7C;7KS0_#OC;P]KNLV>?M&GZ;JD%Q/
M%@X.Y$8L,'KQQ7S9\<?$&HV'_!1[]G'38M2NH-+NM)UM[JT2=E@E*V=P5+H#
MM;! //3%-^*W_!.+P1'X*T>7X,Z=8_#OXC>'[JWNM)\1"64%F1@'%PPW-(&3
M=U!YQT!(KS?]M#X8GXQ?MQ?LY>#M6O9K*+5-(U)-2DTV5HFDA2&22XB1P0P6
M1$>,]]KF@#[@\(?%WP-\0-4U#3?#'C+0?$>HZ><7EII.I0W,MO@[3O5&)7D$
M<CJ*Z'5M8L=!TVYU'4[VWT[3[9#)/=W<JQ11*.K,['"@>I-?GI^UM^SYX#_9
M5\:_!#XC_"_0T\'ZI'XOL]'NX=-FD5+RWFSN5P6/964GN'.<XKZ$_:F_9YMO
MC=XT\$:CXZ\3V&G?!_PUYU[K.AW<YMEO[@C]TTLN0OEH0O!(X+^M 'L'@7XT
M?#_XHW5S;>#O''AWQ5<VRAIX=&U6"ZDC4GAF6-B0"<\GKBO!YM:U'_AY=!I?
MV^Y_LS_A7?G_ &+SF\GS/MC#?LSC=CC.*^4?VFM0_9P^%GC[X4>)O@7K&A:=
MXXT[Q/9K=V_@^[+I<V+R8E638QCQQMZY(8@\5]13?\I1(/\ LFW_ +>M0!N?
MLP:Q?ZA^T9^TW:W5[<75M9^(=.CMH9I69(5-D"0BD_*,^G%>W>.?B[X'^&+6
MB^,/&6@^%6NSBW&LZE#:&8CKM$C#.,CI7SI^SWK2>&_CI^U[J\PS%8:S973
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M<X^178%N<=*^$/V&3>?L]W7[7;:E?S>(KGPA>1.+N\D)ENEMX+HQ>8W]XJJ
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MF8X3& 70EF4-E?E!)/2OI[]GEH9/@IX1N+?P=;^ (KNR%VOANU "6/FLTA3
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M5/"]SX<\7:-:Z]H=PR/+8WBEHW9&#*2/4, ?PH Z"T'^BP_[B_R%>6?M;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCBT^(J/]V>(C^5?%7[$/B";1_P#@E[^T',-T@M[O4@B[B -^GVJG!Q[]/\:
M/'/@)\$?%'_!4#X]>.O%/BSQ--H6GVJBYGEBC^TF'S&*V]K"K,H5%53SZ)TR
MV1Z=_P $^/%_B;]E?]M7Q!\ =>U9[_1M0N+BP"(S?9Q=Q1F6&X1"?D\R-2I
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ML_\ Q[_"CZS1_G7WD_7<-_S\C]Z/0J*\]_X7]X _Z&>S_P#'O\*/^%_> /\
MH9[/_P >_P */K-'^=?>'UW#?\_(_>CT*BO/?^%_> /^AGL__'O\*/\ A?W@
M#_H9[/\ \>_PH^LT?YU]X?7<-_S\C]Z/0J*\]_X7]X _Z&>S_P#'O\*/^%_>
M /\ H9[/_P >_P */K-'^=?>'UW#?\_(_>CT*BO/?^%_> /^AGL__'O\*/\
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MUC_P1C^%=W96\[>+/$RF6-7(#P\9 /\ <J?_ (<M_"K_ *&WQ-_WW#_\17Z
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MF(W$9Q@#U6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*'P(^"Q?^\5/5_F.HHHK0Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M VZ*^%?VG?\ @J]X)^ ?C>_\(:#X:NO'NN:;+Y-^T=ZME:P2#[T8EV2%G7N
MF 01G->Q_LE_ML>!OVNM)OSX?2YT?Q!IJJ]]H=^1YT:,<"1&'$B9XR.0<9 R
M,@'T/7R+_P %3/\ DTC4O^PUI?\ Z5)7UU7R+_P5,_Y-(U+_ +#6E_\ I4E
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M]8=)T+0OO9K3O>]CZNM;A+RWBGB8212*'1EZ,",@BI:\G^)'CV7X%_!W3YA
MNH:O'%;Z;9V^3MEN"FT>Y VLWJ<=NM</>:#\>]'T%_%!\8V&H:C%']HD\,BP
MC$)4?,8UD');''OZUYT:'-K=)'B0PCJ+FYDDW97ZGTA1ZUR'PG^(EK\4? >E
M>)+5/)6[0B2$G)BD4E77\&!^HP>]=/?WT.FV-Q>7,@BM[>-I9'8\*J@DD^P
MKG<7&3B]SCE3E";A):HLUA^--:G\.>$=9U6W5))[*SEN(UE!VEE0L,X/3BO
M?"VM?%GX^6]WXET#Q-;^!_#'GNFF0&R2XEN@C%=[EN@R"#SU!X/4Z_AOX@>)
MO$WPQ^).@^,+-8O$.@VMQ;2WD"%8;M3$VUUXQGCH/4>N*Z_J_*]6G;='H?4G
M!ZR3::NNJ_KR/3/@SXUO?B)\-=#\1:A##!>7T1DDCMP1&I#,, $D]NYKMJ^/
MO@?I/Q<\;?";1QX<\167@[1+&-X;3=;"::\978LS%E.U=V0,>AZUZC\#_B_K
MNO>#_%L/BJW^T>)?"=S-;WB6<?S7 125*J.[%7 P.< ]\4ZV'Y7)Q:T9>*P7
M).;@T[/9=-=#W#UYJ.XD,4$CCDJI8 ].E?-WA?3_ (V?%C0QXE'C.#P1!<,[
M6FCKI:NRJ"0/,9QN!./?C!]JZWX _$CQ#XTTGQ7HWBQ8GU_P[>/8W%Q FU)A
M@X;&,9RK= .,<<U$L/RJZ:=MS&6#<(N7,G:UTNG]>1G^#_CQKOB'X$^*O&UQ
M9V":II+W2PPQHXA81@%=P+YYSS@BO4/AGXFN?&GP^\/Z[>1Q17>HV45S+'""
M$5G4$A023CGN:^9?AC_R9_\ $3_KK?\ _H*UZ!:_%$_"7]EOP?JT%L+W4I]/
MM+2QM><23O&-H/<C@G ZXQ[UT5:*U4%K>QVXC"Q?-"E'7GLON/H(45\WWOA_
MX]Z/H#^*#XRL=0U"./[1)X9%@@A*CYC&L@Y+8_\ UUT7B3XW7&N?LU7GC_PY
M(+'4/LH8!E$GD2K($=2",'G/;D8-<SP[NN5IZV.)X*5UR24KNVG1GMW\Z6OF
M/2H?CG\2/"-GXKT_Q18^'A);)/::/]E1VN %'S2.5X+\G & &'3MVWPO^.O_
M  D'P)G\;:]%Y5WIB3)?QQC:&DC_ +H[;@5^A;%$L/**NFGK8*F"G!74E*SL
M[=&>R^U'%?,WA=?CA\2O#R>-+3Q58>'HKE3<:?X?-DDD<D1Y422$;AN'?GMT
MSQL_LY_&/Q)X\OOB!)XN,=D-#EA3[(J*HM2!*)5W 9(S'W)Q52PSC%R4D[;E
M3P,XPE-23Y=[>MCZ I.>:^:?#>O?%/X__;/$'ASQ)!X$\*+.\>G(UDEQ/=!3
MC>^[H"?0^HP>I[+X+_$[Q#J/B;7? ?C9(/\ A*M'59A>6H BO(&QAP.Q&1V'
M4>]3+#N*;OJMT14P4Z<9/F3<=UU1XWX9_P"3NI/^PK=?^BY*^RA7QKX8_P"3
MNI/^PK=?^BY*^RA7S>6?#5_Q,^)R/X:_^-BT445[9],%%%% 'R/+^W%J$?[>
MW_#/ \)VIL?E_P")]]M;S>=-%[_JMF.IV?>Z<^U?6]8)\!^&6\3?\)&?#NDG
MQ#_T%OL47VO[FP?O=N_[GR]>G'2M^@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OR>_X+?6NK_P!L_"VX*N="%O>QJ<':+C=&2">QV!?R-?K#7YY?\%>?CUI7
MA?X<Z1\+!X;M/$>O^)R;F.2[C+_8(T;8DL(4@^<SDA<'& V0<XH I_MW^ _@
M7H?[ ]I=:#8>';22.&Q_X1B\L%B6YN)2R!MKCYI-T7F%\D]"3R,UV?[#_BC7
M/AE_P3,C\2WBLEUI>EZQJ.G"YS_JUDF>'WVENGMCM7Y__%;_ ()T?%[X!_"/
M3?B5KZZ)K>E::8[K4= %Q+(]BC."!(A559<D!PC9!;N,D??=C\?M/_:4_P""
M9GC[6_#FF0^'K[3M N])O-(L?W<-G-#"I*1?],S&R,/0-CL: /F3_@C[\&O#
M/Q7\9?$?Q?XQT>U\4WFF106\ UB!;I!)<F5I)2'!!<B/&XC.&;GDUD?#.&T_
M97_X*R-X;T!1IOAK4-8;2A919*+;WL0:.+GHJ2O&1SQL%>L?\$.?^1?^,'_7
MSI?_ *!=5Y-^T40W_!7K0=A7/_"2:&#]=L&<^] '[/5\B_\ !4S_ )-(U+_L
M-Z7_ .E25[E\=/ 'C/XD>#HM+\#?$.;X9ZPETDS:Q!ID=^S1 ,&B\MW4?,2I
MW9_A]Z^ _P!N/X _&7P!\!KG6/&?[0U[\0]"BU73TDT&?PS!8K*S7"A7\U)F
M(VGG&.: /TXT;_D#V/\ UPC_ /015RJ>C?\ ('L?^N$?_H(JY0 4444 %%%%
M !29I:\:_;"\<ZY\,_V9/B%XH\-7[:7KVEZ:9[.\6-)#$X=0&VNI4\$]0: /
MC3_@EG_R<M^TQ_V%F_\ 2VYK],*_G3_9M_;#\<_L\_%F\\86$[ZO%K-V;K7M
M+ BA_M7YG?:9/*8Q?.[-\@'ITK]=?V&/V[I_VRM2\86LO@I/"/\ PC\5M(&7
M4S=F?SFE&/\ 51[=OE^_WNU 'UO1110 4444 )7P5_P46_Y';PG_ ->,W_HP
M5]ZU\%?\%%O^1V\)_P#7C-_Z,%>3FG^ZR^7YGZ1X>_\ )04?27_I+/LKX4_\
MDQ\+?]@NV_\ 12UU1[UROPI_Y)CX6_[!=M_Z*6NK]:]*'P(^"Q?^\5/5_F+1
M116AR"8JCKG_ "![[_KA)_Z":O=ZK7]O]LLY[<-M\V-DW8SC((S3CN5'22;/
MFS]DOX?>&?%'P=$VL>'],U29[^X5I+RSCE8J&&!EE/2LF[MT_9-^,5D]O%M^
M'7B9]CAEW_89NG#GD#)!P3RI/797N?P5^%I^$'@E?#YU/^UL7,L_VCR/)^^<
MXV[FZ?6I_B]\+['XN>![WP]>2FU:4K)!=*F]H)5/RN!D9[@C(R">17H?6%[6
M7,_<9[7UV+Q,U.5Z<GKZ=_D>2?MGPFYT'P'<"];3[,:_ )-0C^;[/N5L2_\
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M_ >R\&^ O$.AQZG/?:MKT<O]H:U=)NDFD="N\KGH,DXSW//-:2]ES.IS;O\
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M$K7CZ=:I<V*R7R<FVS%Q)CU4 G\/>O;/"_[/K>'?@]XB\"_V]]H.KM<-]O\
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M?G3IOV<_$G@_6]1N_AKXYD\*:?J$AEFTF:S6Y@C8]3&&R%_ =AS@8KJOA?\
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MDKZZKY%_X*F?\FD:E_V&M+_]*DH ^KM&_P"0/8_]<(__ $$5<JGHW_('L?\
MKA'_ .@BKE !1110 4444 %<[\0/ .A?%+P;JWA3Q/8_VGH.JPFWO+3SI(O-
M0D';OC96'('0@UT5% 'SK\/O^"?/P"^%?C/2O%GA;P%_9GB#2I?/L[S^V=0F
M\I\%<[)+AE/!/!!'-?)__!)#_DN'[1__ &$(/_2J\K].J_,7_@DA_P EP_:/
M_P"PA!_Z57E 'Z=4444 %%%% #?QKX*_X**_\CIX3S_SXS?^C!7WK^E?GW_P
M4&U[3M4^(6@V=G>0W-U8VDD=U%$X8Q,S!@K<\$CG%>1FC2PKOY?F?I7AY&4L
M_I-*]E+_ -)9]M?"?_DF?A7_ +!=M_Z*6NJK@_@CK^G>(/A9X9GTR\AO8H["
M"%VA<-MD6-0RGT((Z5WGO7ITVG!-'P6.C*&*JQDK-2?YCJ***T.(**** "BB
MB@ HHHH ***0MB@!*45A^'O&&D^*;C5(=,NOM3Z;<FSNF5&VI, "R;B,$@$9
MP3C(K;+;:;36C&XN+LQ:*QO#/B[1_&-A+>:+?Q:C:Q3-;O)"3A9%QN4^XR*D
M\2>)=,\(Z+<ZMK%Y'8:=;C=+<3'"KS@?J0,>]+E=[6U'RRYN6VIJTGZ5';W"
M74,<T;;XY%#*P[@C(KCO%_QD\%> [U;/7O$=EI]X1N^SN^Z0#KDJ,D ^_6JC
M&4G9(J-.=1\L5=G:CFEK(\.^*M(\7:7'J.BZC;ZG8R<">VD#KGTXZ'VZUD^,
MOBIX2^'K1)XAUVSTN64;DBF?]XPZ9"CG'OC%"A)OE2U!4YRER):]CK?2DK!\
M)>.M \=:>;[0-5MM4M5.UGMWW;3Z,.H/UJ3PWXNTKQ=#=R:5=BY%G</:7"E6
M5HI4.&1E(R"/IWH<9+<3ISC>ZV-NJVHZ?;ZI8W%G=PI<6MQ&T4L,@RKJPP01
MZ$9JSVHJ=MB4[:H^?I/V0M-M_-L]+\8^)M)T"4L6TFWO#Y04DY49SQ]<^]>P
M>"?!&D?#SPW:Z'H=J+2PMQ\JY+,S'EF8]R3704&M9UIU%:3.FIBJU:/+.5T%
M<S\0O!I\>^%KK0SJ$VFQ76%EFMP"Q0')7GL>A]LBNFHKGE%33C+9G#4A&I%P
MELSYR_X8OT3'_(PW_P#WZ3_"O1_!?P+\,^%=!ATZYL+/6GC9B+J\LXS(03G!
M..<9_+%>C45QT\#AZ3YHP/.HY7@Z$N:G35SE_P#A5OA#_H6=)_\  ./_ .)H
M_P"%6^$/^A9TG_P#C_\ B:ZFC\:Z?8T_Y5]QV_5J/\B^XY;_ (5;X0_Z%G2?
M_ ./_P")H_X5;X0_Z%G2?_ ./_XFNI_&C\:/8T_Y5]P?5J/\B^Y'YZS_ !TO
MX_\ @I=_PHA?"WA/_A!\I\W]DK]LYTD79_>9Q_K3_=Z<>]?</_"K?"'_ $+.
MD_\ @''_ /$UU I11[&G_*A?5J/\B^XY;_A5OA#_ *%G2?\ P#C_ /B:/^%6
M^$/^A9TG_P  X_\ XFNI_&C\:/8T_P"5?</ZM1_D7W(Y;_A5OA#_ *%G2?\
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M/@U!KO\ PI+Y>1H:&PYTE93_ *7Y.[_CYS_RT^]\OM7W$M%% "T444 %%%%
M!1110 4444 %?)'[:'_(S>'?^O23_P!#%?6]?)'[:'_(S>'?^O23_P!#%>/F
MO^ZR^7YGSG$'^X2]5^9]/>#/^11T7_KRA_\ 0!6P*Q_!G_(HZ+_UY0_^@"M@
M5ZE/X5Z'O4OX<?06BBBM#4**** "BBB@ HHHH **** "BBB@ HHHH **9)(L
M2EG8(HZLQP*B_M"U_P"?F+_OL4 6**K_ -H6O_/S%_WV*/[0M?\ GYB_[[%
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MT"S\5:#J.CW\?FV=] T$JCKM8$'!]:TI2Y)J1TX>K[&M&H^C.)^+W@Q/C/\
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MXH_X4;\GS"!O[+_Y!()^?;C_ (^<]_O5]PBEHH **** "BBB@ HHHH ****
M"ODC]M#_ )&;P[_UZ2?^ABOK>ODC]M#_ )&;P[_UZ2?^ABO'S7_=9?+\SYSB
M#_<)>J_,^GO!G_(HZ+_UY0_^@"M@5C^#/^11T7_KRA_] %; KU*?PKT/>I?P
MX^@M%%%:&H4444 %%%% !1110 4444 %%%% !1110!X-^W%\*?$OQO\ V6_&
MO@KP?!'<^(]4^Q?98IIU@5O+O;>5\NQ 'R1OU],5^3W_  ZD_:6_Z >G_P#@
M]@_^+K]VJPO&GC#2_A_X2UCQ+K=P+32=)M9+RZF/\,:*68@=S@<>] 'XA?\
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M(/\ TJO* /TZHHHH **** "BBB@"IJW_ ""[O_KD_P#Z":^!/^">/_)4-?\
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MQ [%A;3)$X;"%BHW#:0,]S0![W_P2X\?2> OCA\8/@+%/'J?A_0]1OI](O\
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MZJ]PBL &<CD$]J /T0T;_D#V/_7"/_T$5<JGHW_('L?^N$?_ *"*N4 %%%%
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M_P"N3_\ H)KX$_X)X_\ )4-?_P"P5_[52O'Q7^]4/G^1^F\._P#)/9MZ4_\
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M":^!/^">/_)4-?\ ^P5_[52OOO5O^07=_P#7)_\ T$U\"?\ !/'_ )*AK_\
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M])>%?C+X)\;:L-,T+Q-IVJWY0R"WM9U=]HQDX!Z#(_.NU_G7YO\ [#]N+/\
M:(, ;<L5E=1AO7#*/Z5^D&*Z<%B)8FESR5M3PN*LDHY!CUA*$W.+BI7?G<=1
M117H'QH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJXDCWJK%50,,,#M&,5]1+_P7,(4;O@H">^/%6!_Z15]/?\.T_P!EK_H2;?\
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M_N&?^G2TIW_!+_\ Y,?^'/TO_P#TNN* /JFBBB@ HHHH 3;3?+7.<#/TI]%
M" 8I:** "HYO]3)_NG^524R;_4R?[I_E0-;GYS?L5_\ )REQ_P!>UY_Z&M?H
MUZ5^<O[%?_)REQ_U[7G_ *&M?HT.U>+E/\!^K/U+Q&_Y'$/^O</U'4445[1^
M6!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=]HR<#<QK^?/XT>&_&?B_P +VOQR\8LPE\>ZW?+:^8,&980F^11VC5G\M?\
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MI/K.AM:VX"7"L09"QP2!QZU^GV*^1O\ @J9_R:1J7_8:TO\ ]*DH ^KM&_Y
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M?_DY3]FC_L(G_P!++2OTWK\R/^"J_P#R<I^S1_V$3_Z66E 'Z;T444 %%%%
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M$M7@/[%/_(0\6?\ 7.U_G+7OWQ:_Y)?XL_[!-U_Z):O ?V*?^0AXL_ZYVO\
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M+>-I9IYG"I&BC+,S'@  $YK+\*^-O#WCNQEO?#>NZ=X@LXI?)DN-,NH[B-'
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MKX7?&+P7\:M%NM7\#^(K/Q+IEM<&TFNK%B424*K%#D#G:ZG\16KX^\)Q>/?
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M/_$6L>!OA_X=T[5IO#%Q']KO9+2WD^S3W4DOE0QR2 ;?EP2%)ZN">U?J#24
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M4'T.YA]2*\#%S4,;0<GIJ?(YC4C2S3#2GHM?QT/M>EIJL&Z'-.KWSZX****
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M -<(_P#T$5<JGHW_ "!['_KA'_Z"*N4 %%%% !1110 4444 %%%% !7YD?\
M!5?_ ).4_9H_[")_]++2OTWK\R/^"J__ "<I^S1_V$3_ .EEI0!^F]%%% !1
M110 4444 %%%% !3)O\ 4R?[I_E3Z9-_J9/]T_RH&MS\YOV*_P#DY2X_Z]KS
M_P!#6OT:':OSE_8K_P"3E+C_ *]KS_T-:_1H=J\7*?X#]6?J7B-_R.(?]>X?
MJ.HHHKVC\L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,;Q=XGLO!7A36O$.HF0:?I-E/J%SY*[G\J*-I'VCN=JG K
MS_\ 9R_:6\'?M2>$-0\2^"3J#:98W[:=-_:-N('\U8XY#A0QR-LB\_6O0_%'
MANQ\9>&=6T#4XVETW5;.:QNHT8HS12H4< CD':QY%<-\ _V=/!/[-/A6_P##
MG@.PN-.TN]O6U":.YNGN&,S1HA8,Y) VQH,>U 'I]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <%\;;F]A^&>N6^G:?<:G>WL#6:06T;.W
M[P%2Q '0 D_@*^'YOAOXOTJ%KV7P[JMI';KYK3M;.HC Y+;L<8QG\*_1OKP:
MY/XK*%^&7BGC_F&7'_HMJ\7'X&.)_>2E;E1\SFV50QW[Z<VN5'B'[&^K7VI3
M>)OMEY<7>P0;?/E9\9+],FOIROEK]BG_ %WBGZ0?^SU]2BM,K;>%BWY_F;Y$
MW+ 4VWW_ #%HHHKUCWPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "OD7_@J9_R:1J7_ &&M+_\ 2I*^NJ^1?^"IG_)I&I?]AK2__2I* /J[1O\
MD#V/_7"/_P!!%7*IZ-_R!['_ *X1_P#H(JY0 4444 %%%% !1110 4444 %?
MF1_P57_Y.4_9H_[")_\ 2RTK]-Z_,C_@JO\ \G*?LT?]A$_^EEI0!^F]%%%
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M&'P_I=U=&]FMX7=@TQ1$+_,Q.2J*/PH [VBBB@ HHHH **** "BBB@ HHHH
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MEXC?\CB'_7N'ZCJ***]H_+ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOEK]BG_7>*/I!_-Z^I:\_*_]TC\_S/(R'_D7T_G^8M%%%>L?0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?(O_!4S_DTC4O\ L-:7_P"E25]=
M5\B_\%3/^32-2_[#6E_^E24 ?5VC?\@>Q_ZX1_\ H(JY5/1O^0/8_P#7"/\
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MAE93P002"#UK.\-^$="\&V<EIH&BZ?H=I))YKP:;:QVZ,^ -Q5  3@ 9] *
M-FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $-<G\6/^29^
M*?\ L&W'_HMJZPUR?Q8_Y)GXI_[!MQ_Z+:L:W\.7H<V)_@3]'^1X-^Q3_KO%
M'T@_F]?4M?+7[%/^N\4?2#^;U]2UY^5_[I'Y_F>1D/\ R+Z?S_,6BBBO6/H
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MBY3_  'ZL_4O$;_D<0_Z]P_46BBBO:/RP**** "BBB@ HHHH **** "BBB@
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MBL;_ (33P_\ ]!W3?_ R/_&C_A-/#_\ T'=-_P# R/\ QH V:*QO^$T\/_\
M0=TW_P #(_\ &C_A-/#_ /T'=-_\#(_\: -FBL;_ (33P_\ ]!W3?_ R/_&C
M_A-/#_\ T'=-_P# R/\ QH V:*QO^$T\/_\ 0=TW_P #(_\ &C_A-/#_ /T'
M=-_\#(_\: -FBL;_ (33P_\ ]!W3?_ R/_&C_A-/#_\ T'=-_P# R/\ QH V
M:*QO^$T\/_\ 0=TW_P #(_\ &C_A-/#_ /T'=-_\#(_\: -FBL;_ (33P_\
M]!W3?_ R/_&C_A-/#_\ T'=-_P# R/\ QH V:*QO^$T\/_\ 0=TW_P #(_\
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M:>'_ /H.Z;_X&1_XT ;-%8W_  FGA_\ Z#NF_P#@9'_C1_PFGA__ *#NF_\
M@9'_ (T ;-%8W_":>'_^@[IO_@9'_C1_PFGA_P#Z#NF_^!D?^- &S16-_P )
MIX?_ .@[IO\ X&1_XT?\)IX?_P"@[IO_ (&1_P"- &S16-_PFGA__H.Z;_X&
M1_XT?\)IX?\ ^@[IO_@9'_C0!LT5C?\ ":>'_P#H.Z;_ .!D?^-'_":>'_\
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M\$O_ -F:XTZUED^&FZ22)68_V]J8R2 3Q]I]:L_\.N?V8O\ HF?_ )7]4_\
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M[^(?[._PX\3^(/A__:&N:MH5I>7MU_;6H1>;,\2L[;4N HR3T4 >U5_VC?\
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MKU"@ HHHH **** "BBH9IDMX7EE=8XD&YG8X"@<DD^E $U%?'OCK_@JM\ /
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MT?6YY#'9VVNVHMA>$=!$X9ER>RL0Q]* /J*BBB@ HHHH **** "BOECXV?\
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MP[HFM7FC:]<MMM=/UZU%L]RW]V-PS1EC_=W9/85],SSQVT,DTTBQ11J7>1V
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M-#D-&XZQR(<,CC/*L >10!VE%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8OC3Q%'X1\'ZYKLJ[X],L9[QE_O".,OC\<5^,?_!/CX :-^V[
M\<OB/XM^*37.OVUFBWUS";AXVN+JZDDVEF7G:JQR84$?P]ABOUA_:JN;BS_9
ME^*\]HI>ZC\+:DT2A=Q+"UDQQWK\_P#_ ((9#_DM9_[ G_M_0!YU\"-)3]BW
M_@J0_@&PO91X8U*]_L>,W+@&2WNXEEM48_Q,LK0IGN5/3-?LS7XT?MD((?\
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MWI+E067Q%;[3Z9BFS0!]3?LQ_$YOC)^S[X \9RR))=:KI$$EVT; K]I5?+G
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ML'GPKU/&0.M '%?\$_\ _@GKX$_: _9NUWQCXQ2YN-:UBYN;+1YH;AHUL%B
M42[1C<YEW9#9&U5[DU>_X(P_$+5O#_Q(^(?POU&9X[9K;^TTL)6YANH9%AF*
MCU*L@;_KFM?5O_!*-1_PQ'X,XZW>HY_\#)A7QC_P3OB6U_X*6?$6&%0D2?V\
M@5> JB\7 ^G H _8NEI%Z4M %#6M4CT31[_49E9XK."2X=4ZD(I8@?@*_"S]
ML3]KOXB_MJ6NJ7VD:#?Z+\)O#)CGEM$;=&LC,(TEN9,!6D9GPL8Z G&<%J_=
MC4M/AU;3[JQN4\RWN8FAE7)&Y6!!&?H37Q7_ ,%"/ACX5^$?[ /BGPYX.T*S
M\/Z+;366RULH@H)-S'EF/5F)Y+,23WH I?\ !&W_ )-'O/\ L9[S_P!$V]?.
MO_!5Z&\\??MA?";P+JEY)I_AF[M+.!;D, L37-ZT4\@SQE46/KZ"OHK_ ((V
M_P#)H]Y_V,UY_P"B;>O+?^"R'B?X>WT/A'PI)HM[JOQ5<>=IEQI\NTVMN\@7
M;(N#YOF,I"H #E201G# '(_\%+OV(?A+\ ?@+H/BKP18-X?UB#58=-=);MYC
MJ$;QR$DAV_UBE V5 & V1TQ[AXN^-^O^#_\ @DOIGBRXO;E/$E]X<M=+ANPQ
M$V99!;A]QYR(LMGKQQ7Y^_&OX=_''X=-\.M7_:1TSQ5XB\ Q.D<%I-K2RM''
M@%H/,!D\F4H!]\9(4@'@[?M+_@I%X]T#QE_P3N^'^L?#R'R_!FIZSI\,,*P[
M?L]JEO<XC8?P%)(D0^XQSF@#S+]@7_@GCX&^/W[,NM^,/%Z7$NN:W<7-IHUQ
M#<,BV"Q#8LNT8#,90^0V1M50,$FM/_@B[\0M4T7QU\1OACJ$K1V_D#5H[&1N
M8;B*18)B![AHP?\ <6OJ_P#X)7J!^PYX ('6;4L_^#"X%?%7_!-V-;7_ (*.
M_$F&%-D2P:X@5> JB^CP/T% '[%T444 87CBZU6R\%^(+C0[9KS6H=/N)+&W
M0KNEN!$QC09(&2P4<D#FORJ_8C_X)P7_ ,1/&GCC7_VA_"VLVTL$L?V:ROI7
MA^W7$Q=YIS(A_>!<+]UL9<YZ5^N5>8_M"_'[PQ^S;\,]3\9^*;C9;6Z[+6TC
M(\Z\G(.R&,9Y)/7L!DG@4 ?DQK7P_M_V+/\ @IUX+T#P#>3G1[K5M+B2WNG+
MNEK>LD4T#,/O8#N5)Y^YG)&3^@7[?G[:\O[(GA71K72-".L>*_$T=TFER3-_
MHULT7EAI)%'S/@RIA!C//(KXG_8-\$>+OVR?VR-4^//B^$MH^B7GVUIF&(OM
M03;:VT0/41(JGCIL7/+"OU5\7_!SP;X^\7^&_$_B/0+36=9\.";^RIKQ3(MJ
MTIC+NJ'Y=W[M,,02,<8H _!OX;V_CIOVX/A1JOQ&BOH_%.M^+M#U:=M1P)Y$
MFO(6C9ES\@*XPIQ@8& *_;W]K3XF7GP?_9O^(/BW39&AU/3]*E^QRJ 3'.X$
M<;X/]UG#?A7YI_M?#;_P5T^'(_ZCWA?_ -*(*^VO^"HUU<6O[$OC\VREF=K&
M-\+N^1KR$,?RS0!\-_\ !-']B?P-^U!X'\>>,/B+%>ZLXOSI5IY=V\;QRF)9
M99R1]Y_WJ8W$C[V0<UK?\$N?$%W\#?VR?B'\&K^]WVEX+RSB60A?.N[*4E'5
M?5H1.V!V ]*]]_X(JX_X9:\4GO\ \)G=#_R1L:^8O@ZH@_X+*7"QKM'_  DV
ML<#CK97.3^IH _9VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** .5^*7AV3QA\,_%FA0KOFU/2;JS122 6DB91^IK\J?^",GQ"TCP+\2?B;X
M3US48-*O]5M+2:!;N01*[6KSB1 6(^8"?..N WI7Z_U^?'[5G_!)?1/C9\0-
M1\:>"?$T7@W4]5F-QJ.G7%F9K669CEYD*L"C,<DC!!))XR: /FZ\NM/_ &GO
M^"O%A=:#<+J>@Z9KEM<+>6Q)C=-.A1W;/=#+"5R."&&.N:_9BOE/]BK]@/PS
M^R'#?:J^IGQ3XSU"+R)]7DMQ"D,6<^5#'N8J"0,L6);:.G2OJV@ HHHH ***
M* "O#_VQ/V@-8_9D^"E[X^TCPQ%XJ%C=P0W5K-=M;K#%(Q02Y"-G#F-=N!]_
M.>*]PK"\:^#=(^(7A/5O#.OV2:CHNJVSVEW:R9Q)&XP1GL?0CD'!'2@#P?\
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M8[TCQ?X>N(=5TC3M5L]5%Y;/OCDM)D>)94(X*EIHN?0YKR7_ (<8_P#5;/\
MRU/_ +MK]#/"OP3TC2_@#HWPIU\Q^)-&M- @T"[>2$PB[C2!8F?8&;9NV[L!
MC@]^,T ?)7[&?[17@_PS_P $XC>WGB"PM+SPMINH6=S:W$ZK*D^Z1XD"9W$O
MYB;<#G=Q7C'_  1)\#W=UXF^)OC:6W=+..VM])@G/W'D=VEE4>ZA(O\ OX/6
MM/Q-_P $1%N/&$DF@?$Y;/PO)+N$%]IAENX$S]P,L@5SC/S$+]*_0C]G_P"
MWAG]F_X9:=X)\*12+86I:66YG(,UU,V-\LA ^\<#IT  [4 >DT444 %?#?\
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M#V*BBB@ KY)_X*H?\F5>-/\ KO9?^E,=?6U>1_M3_ 3_ (:8^"NM?#_^W?\
MA&_[2>!_[1^Q_:O+\N19,>7YB9SMQ]X=: /G#_@C=_R:/>_]C->?^B;>OF']
MLCQ!#\,_^"K'A3Q5XRE7_A&8+C1KV*21#M@M5149SZA)EEDXK]$OV-_V8/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9[U]U?\ !.74?CHOPOU#1/C9H.K6DMA)&VCZQK4Z/=74#J=T4J[S)NC*@AG
M)$F/X: /KNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28YS2T4
M%%%% !2;12T4 %?D=^WQ^UQ\==7\=_$+X&:1X9B/AV:Z%E#=Z1I5S)?7=LZ(
MXCW;BIW!L'8@SSBOUQIGEKNW;1N'0XH ^2O^":G[,.H_LV_ 4CQ)9&Q\8>)+
MG^T=1MW"[[9 H2&!B.ZKEB#G#2,*^N*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gizttcucplmb000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000006.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MW$JDAQD=%'\5 'OE8/C;QMH7PY\+ZCXD\3:I;Z-H>GQ>==7MRQ"1KZ^I.>
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M'J41T.&&53&\DJ!<-(K;@86)P.A%?5-?G%\>O^4Q7P3_ .Q>3_T'4J .J/\
MP5V\#QJ7E^%7Q(CB4$NYTR#Y1W/,P'ZU[]^S=^V=\+_VIK>:/P9JTT>L6\7G
M7.AZG#Y%Y"G W%02K@$@91F XR:]S]#7YE_%?3;'PE_P5_\ AH/ D,5K>ZEI
MT<GB"'3P%#.ZW0F,BCC)@2)SGT!ZT ?IM7D_[1_[0>F_LV> X?%6JZ#K/B*V
MEO8[+[)H<*RSAF5V#;691M&PYY[UZN*6@#X$U#_@L-\/])MS<7WPR^(5E;@X
M,MQ86Z+GL,F:IH?^"O'@>XA26+X5_$B6-UW*Z:; 58'D$'SNE=%_P5V_Y,TU
M7_L,6'_HPU])_L^#_BQ/P\_[%^Q_])TH T_A7\0K;XK_  ZT#QA9V%YI=MK-
MJMW'9ZB@2XA5OX74$@-QV-=;16)XR\8:/\/_  MJOB/Q!?1Z9HNF6[W-W=RY
MVQ1J,DXQDGT Y)( H VJ6OAC1OV^OBM\6(9M=^$G[.>L^*_!4+L%U?4M2CLG
MNE#$9B0@[CP>%+8X%>V_LM_M<>'_ -IJQURTATJ^\*>,/#\_V?6/#>JC%Q:G
M) 8''S+D$= 0000.,@'O5%?(/Q/_ &]+Z/XK:I\-?@S\-]0^+GBS2<KJ<UK<
MK;6-E("04:8@C((8$G:,C ).<.^&O[=VHQ?$W2?AW\:OAMJ'PA\2ZRWEZ7<W
M-TMUI]Y)T$:SJ  Q. ,$C) )!QD ]>_:5_:1T+]F#P7IWB7Q!IFHZI9WVI1:
M8D6FB,R+)(&*L0[*-ORGOWIG[2'[2N@_LR_#FP\8:_IFHZG87E]#IZP::L9E
M5Y59E8AV48&T]\\U\]_\%=O^3>_"G_8VV7_H$M0?\%:O^34O#/\ V,FG_P#H
MJ6@#[FM+@75K#, 0)$#@'MD9J:O%_P!H+]I#P_\ LP_"&T\5:[;7.IS3O#8:
M=I5E@SWUTZ$K&GIPK$GL!T)P#X!K_P"W%\=_ VAW/B[Q3^S!J6G>![>,W$]Y
M%KD4EU!"!GS)(@FY<#DY V\Y/% 'W/17#_!?XO>'OCQ\,]#\<^%YGFT?5HC)
M&LH"R1.K%'C<9X965E/TXXYKN* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _.
M'X1?\IF_BY_V+R_^DNG5^CU?E;\2KOXN_ ?_ (*-?$KXI^%?@GXI^(FD:A8P
MZ?;O96-RMM*&M+/<ZS)#(&VM"RX ZYY&*]0A_;E_:>\51SZ?H'[)FM:9JKQG
MR;K6IKB.V1N "WF00J1DCCS >OUH Q?^"C-R/&7[7?[,O@C3V634X]534947
MYFCC-S#M)7T(@E.?]DU[E^VI\4?@S\(]:\!Z_P"/O"LOC+Q_;71D\*:9I\;2
M7OFAT)91N"A=X3[P.2!@'%<=^R;^R'X\A^,FI_'KX\W5IJ'Q)O8_+T[2[5ED
MBTA60H<$$KN"$HJJ2 &8Y).:POVY/@[\0O#_ .TM\,OVB/ WA>?Q]%X7MTL=
M2\/VPWSB)7F;S(T^\25N''R@[656P1F@#H_^&HOVD_B982Q>$/V:I/#UG<1.
MHU7QKK*VR1?*<L]OM20KT^Z><_C7)?\ !&JW%U^S-XX@N8TD$GC*[26/&5.;
M*S##Z'FNNOOVI_C%\?M!U#PK\-?@=XG\&ZQ?1&WE\2^-U%E8Z8C@AI5!&Z9P
M,[57N02,9%9__!*OX<^+O@SX#^)/@?QCX?U?1[ZS\4274-U?:?+!;7T;1)#Y
MMO(Z@2J3;D_*3PR'^(4 8'["MQ-^SC^TQ\:?V?=3GQHT=P?$WAYY&X%LX!=<
MD_\ /-X>@ZQ2'O5O]AB&3]H3]IOXT?M":A&38B\_X1GPV"#M6UBP&<9'4HD/
M3O)(*Y?_ (*L^'=<^%^O^"/C9X+F2UUYH+OPC?!AN,L5S!(L3!<C++OFQUY,
M9Z+S]=?L@_!>+X _LZ^"O!P7;?6]DMSJ#=VNYOWDW/H'8J/95H ]FKX _;@C
M31?V[OV4M:N)BEM<:D]BH9L*',\2@CW)F4?@*^_Z^:OV[OV9]4_:.^%FG_\
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M:MYH+PQG&6*]#RIYKVJB@#XM_P""NW_)F>J_]ABP_P#1AKZ2_9]_Y(3\//\
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M^VQXV\+Z-X2\)>+/@-\/M*O5N]8\0:G<RZ?J%V!P8XPNUB-I;Y5RI)&X@#!
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MM?\ &OLZB@#XQ_X9C_:N_P"CK4_\)"U_QI/^&8_VKO\ HZU/_"0M?\:^SZ*
M/C'_ (9C_:N_Z.M3_P )"U_QH_X9C_:N_P"CK5_\)"U_QK[.HH ^,/\ AF/]
MJ[_HZU/_  D+7_&C_AF/]J[_ *.M3_PD+7_&OL^B@#XP_P"&8_VKO^CK4_\
M"0M?\:/^&8_VKO\ HZU/_"0M?\:^SZ* /"OV>OA3\8?AWK&KW'Q,^,*_$RRN
M8$CL[4:+#8?99 Q+/N0Y;(XP:]UHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<D\D_2OSX_8,_8H\)?M5>-OB/HWB36M9TNW\->2+9]+>%6DWRS(=^^-NT8Z
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MV6)9'5G>:0Y(2-%!9V.#P >AKYQT'_@K-^SUK>M0:>^N:OIBS2"-;R^TN18
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M_P#@+P7_ ,$[/$.C6'AC3(TT7PY'>VUP+5/.6Z5$)GWXW>8QSELY(8CI4_\
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MY5>BJ3CENM?I!10!Y3^S+\ ]+_9J^#.@^ ],G:_^PJTEU?.NTW-P[;I)-O.
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0AD12660O<;0IY.UO:@#]+/@7XNO/'WP7\!^)=0*G4-6T.RO;DH"%,LD",Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#]!Z6O+?A7^TY\+OC;K%SI/@7QGI_B34;6'[3-;V>_<D>0NXY4#&2!^->I4
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M^=OVD=>TS7/V\OV4#INHVFH".77 YM9UEVYMDQG:3C.#]>:]YUC]F+P;XX^
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M_MH^#OA#^S9IGQ?C635[#7(8/[$L PCDNYID+JA/.W:JN6/. AZG%?,^A_\
M!3;XE>!]8\&:C\9/A)!X1\ >+"K6&MV<TA9(VVD2D,3N 5@Q'RG:<@&O&O\
M@J/X!N/@O^S_ /LZ?#D7CW-OHUI=0S.OW)ITC@!?'L7?&>S&O;_^"Q^GV]O^
MR;X!,:K&;?Q-:0Q* .$-A=Y ]AL6@#]$(9DN(4EC<21N RLIR"#T(KXW_:F_
MY/U_9+_ZZZ]_Z31U[-\!_'NE>&_V6_ACKOBO7+/2+5_#NFK)?ZI=+"C.;=
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MQ;^R7I%Y)9?LS:YXE\77SR?:_$UY'=1W#QLP(B0?96*)PI(#'<PR>P'[<T4
M?GG^V[\(_%O[:G['G@7Q]I?A.XTOQQI8.J/X:8.UR()1LGA4,JL7&R-P"H)V
MD 9(KY_^.'Q2^*G_  4"\/\ PS^$.F_"W6_#NH:;>13ZUJVHVTJVZS)$83,2
M5'EQJ'E8AB2<@#IS^QE)MH \WU;]GWP1XH^$>A_#CQ'HL6O^%M)MK6WBL[MF
MP?LZ!(V)!!R /6OCGXD?L_\ P]^ _P"W=^S!%X"\+VGAJ/4YM9:\%J7/G&.U
M4(3N8]-[=/6OT/KXR_:F_P"3]?V2_P#KKKW_ *31T ?9M%%% !1110 4444
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MX:QW$658A<\9RIPC*T'>VBT7W['B?[)?P"\0>)OB5I^M:KHUQ9>'=-+/.][
M46X8HRB-0P^;KSQC ]Z^LK7]C;X5VNO+JB^'MS*^\6SW#M "#G[F<8]NE-7]
MKSP(O2WUT?\ <&N!_P"RUWGPW^*^B_%.WO9M&2^2.T=4D^W6DEN26!(P& ST
M[5KA<-A*<5334F>?Q#GG$.,KRQM2,Z$+*-DVE;S>EW=G90PI!&J( J*,!0,
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M2H^TO]A6]VWVO.]M]3L****^A/Q0**** &FFLP09)P.Y-.KYX_; ^(5WX?\
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MU% 'QS_PO[]K?_HW#1?_  J(_P#"C_A?W[6__1N&B_\ A41_X5]C44 ?'/\
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M?M;_ /1N&B_^%1'_ (4?\+^_:W_Z-PT7_P *B/\ PK[&HH ^.?\ A?W[6_\
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M&?B[X/\ @5I>E?&*\M[KQ!;-Y5K&C"6YAM5 ")<2@E7<<\CMC))H ^@****
M"BBB@ HHHH **** ,;Q=>:Q8>%=6N?#^GP:KKT-K+)8V-S/Y$4\X4E(VDVG:
M"V 6P<9K\P%_X)O_ !5_:G\)^+OB5\8/$4VD_%35@&T/1YF'V:RC1CB*91N\
MM&'"JA^7.YMQ)K]6*2@#\S_V'?VXM>^''B\? 'X]^=I/B#39AI^EZOJ!VD%>
M$@G<]01CRY>A! )Z&OTO#!L$'(KY9_;D_8=T']K#PB;RR$.D_$+383_9FK8V
MK*,Y\B? R4)S@]5)R.,@[W[#'A'XO^!_@;8Z-\8[RUN-8M)#!80H_FW,-HO"
M+/*"5=L@XQG"[<DGH ?15%%% !1110 4444 %%%% !7G?B+X ^ ?%GQ4T/XC
MZKX;L[WQCHL#6]EJ4B99%))!(Z,5RVTG.W>V,9KT2B@#YD_;9_8G\._M:>"R
MZB/2?'>FQ-_9.LA??/D38&6C)S[J3D=P?F']A_\ ;-\4_!OQ]'^SM\=X;BPU
M6RG73=&U6ZR[(V=L<$C\[XV^7RY1Q@@$X((_3BN.UKX0^#?$7C_1?&VI^'-/
MO?%6BQ20V&J30AIK=7QN"GUZX)Y&YL8R<@'94444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !115/5K[^R]+N[T6UQ>?9XFF^S
MVJ;YI=HSM1>['& /4T 7*PO&WB;_ (0SP=KFO_8;C5/[+LIKTV5H 9IA&A?8
M@/\ $<8_&O$_V8_VK+_]H;P!XA\13^ =6\+7-CJ5S8:=8ZDZ1'4S&&94C9RO
M[P;2KC&%96&3@X^;H_\ @IE\0?@KX^O=!_:%^#U_X6T>XGD%IJ6DHTBI&6&U
M07_=W"A3R\;@\?=R<  P?C#XHUK_ (*6_L&7/B3PSIT<7C'POKTES=^';5BQ
M98U8B-"2-S>1,C X^8HP !X'F'P/_:Z^'_Q>\:V_CG]ISQ>L5[X-BCA\.^"H
M=*N&L3.B?/>.JJRO.6'"O@*5!Z8 VOV//C/X$^#G[>GB#0?!?B*UO?A?\2P)
M=-,1V+:73.SP0.AP8V5S+"%8 D/&>00:_1/Q1^R?\'/&GBH>)=<^&OAO4];W
M^8]Y-8(6D;KND&,2'/=@: /F3_@GYX/\1_'7X=?%KQ1\5C?^)O"/Q U96TS3
M?$*AMUK%O E5< *IW1J @ !@!7%?=MG9P:?9P6MK"EO;0(L<4,2A415 "JH'
M0 8&!1:VL-C;Q6]O#';V\2A(XHE"HBC@* .@'I5B@ HHHH **** "BBB@ HH
MHH **** "DP*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***YCXD_$+1?A1X%UOQ?XBFEM]$T>V:ZNI(86E<(H[*HR3G
M']: .GK@?BY\=/ ?P'T.'5O'GB:Q\.6<[^7!]I<F2=NXCC4%GQD9P..^!6%^
MS?\ M->"OVH_ B^)O!UX^(V$5]IMT MU8R'HDB@GJ.0P)!YP>#CX"N_ ^C?$
M[QY\?_CE^TSH6LW7A+PG<3:1X=TB\FEMK254=X52W(92S%@@&T[=\K,<L. #
MVS]LSX.ZE^UM\-/"?Q7^!'CB:]U7PRSWVEV6F7)6WO&W9=HP/N7*G(^8<\J0
M,UH?L8_ME^'?VNO#5Q\./BCI-A'\1=/1HK[1]4M4\G4ECX>1(G'$BD'?'C*X
M)''3XC^$?BSXK_\ !,_6/"'B_7=):?X=_$"U^U7'AL7!\R#D$## ;+E(RAR1
MA@VUN?N_>UU^R)\*?VH?B)\/OVA= EU?PW++Y>J2K9Q/8R:J -T3R#AHVSC+
MK]]3UZ-0!:A_X)@_ [3_ (P:/X^TO1KW2FTZY%X-"MKH_P!GO.IW(^P@LH5L
M-L5@IV@8QD'ZWH6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ5_JMEI;6R
MWEY!:&ZF6W@$\BIYLI!(1<]6.#@#GB@#FOBS\6/#'P3\!ZGXO\7ZFFEZ)8)N
MDE89=V/"QHHY9V/ 45\\>!/^"G7[.WQ/L5MKSQ._AV2Z01S:?XEL6A&&X*,X
MWQ$=C\Y&#7TUXX\#Z%\2?"NH^&_$VEV^L:)J$1AN;.Y7<DBG^1!P01R" 1BO
MQ6_:._8YLOV*?B_;:YXE\*S_ !&^"FJ2-"LB3207%H&.1&9(V7;.@'R,WRN,
M@CDX /7/B]\,KS]E'Q\W[1'[,'B#3_$W@)Y#)K^@Z5>I<VUM$6^='6-CFW)S
MSUB.,<8QZ]^T1?)_P4Y_8[L+WX2WL9\2:-J4.HZAX6N)UCF$HBD1H&)(&<2%
MT8_*VWL>G ^'?^"6OPO^,7@^V\<_!#XN:YINF:I#)Y7VM4N1'N&&@<Q^4Z[?
MNLK9/J3WZ_\ 8S_X)J_$K]FGX\?\)5?_ !&LH_#4$&UK?0C)YFJ@_P#+&XCE
M3:B _-D%SP-I4\@ ZC]G[X-?'#]H+XH:!X^_:5TG3=-TCPE9W%KHWAE((]MY
M<3Q^7)<3QAG!&PD8)&3M(4 '/WC'&L**B*%11A548 'H*<!3J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF#%(SJ0T;A@-S+RP]#S7U(O2EHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124
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MA_L<GP_MFU3R]WE_:1-;"$OVW^6/ESSMW8[T ?:M%%% !1110 4444 %%%%
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..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gizttcucplmb000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" --!TH# 2(  A$! Q$!_\0
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M *%P_P#@;_\ :Z\NHH^IT>WYA9'J/_"[F_Z%P_\ @;_]KH_X7<W_ $+A_P#
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M?_ W_P"UUY=11]3H]OS"R/4?^%W-_P!"X?\ P-_^UT?\+N;_ *%P_P#@;_\
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MNYO^A</_ (&__:Z\NHH^IT>WYA9'J/\ PNYO^A</_@;_ /:Z/^%W-_T+A_\
M W_[77EU%'U.CV_,+(]1_P"%W-_T+A_\#?\ [71_PNYO^A</_@;_ /:Z\NHH
M^IT>WYA9'J/_  NYO^A</_@;_P#:Z/\ A=S?]"X?_ W_ .UUY=11]3H]OS"R
M/4?^%W-_T+A_\#?_ +71_P +N;_H7#_X&_\ VNO+J*/J='M^861ZC_PNYO\
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M_0N'_P #?_M=>744?4Z/;\PLCU'_ (7<W_0N'_P-_P#M='_"[F_Z%P_^!O\
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M^(W_ "&-/_[!\/\ *N.J*>%I2BFU^8)(]1_X7<W_ $+A_P# W_[71_PNYO\
MH7#_ .!O_P!KKRZBK^IT>WYA9'J/_"[F_P"A</\ X&__ &NC_A=S?]"X?_ W
M_P"UUY=11]3H]OS"R/4?^%W-_P!"X?\ P-_^UT?\+N;_ *%P_P#@;_\ :Z\N
MHH^IT>WYA9'J/_"[F_Z%P_\ @;_]KH_X7<W_ $+A_P# W_[77EU%'U.CV_,+
M(]1_X7<W_0N'_P #?_M='_"[F_Z%P_\ @;_]KKRZBCZG1[?F%D>H_P#"[F_Z
M%P_^!O\ ]KH_X7<W_0N'_P #?_M=>744?4Z/;\PLCU'_ (7<W_0N'_P-_P#M
M='_"[F_Z%P_^!O\ ]KKRZBCZG1[?F%D>H_\ "[F_Z%P_^!O_ -KH_P"%W-_T
M+A_\#?\ [77EU%'U.CV_,+(]1_X7<W_0N'_P-_\ M='_  NYO^A</_@;_P#:
MZ\NHH^IT>WYA9'J/_"[F_P"A</\ X&__ &NIY_C'=6JQ-/X5EB$J[XR]T1O7
MU'[OD5Y/79>.^+#PO_V"T_DM9RPU)24;;^H61O\ _"[F_P"A</\ X&__ &NC
M_A=S?]"X?_ W_P"UUY=16GU.CV"R/4?^%W-_T+A_\#?_ +71_P +N;_H7#_X
M&_\ VNO+J*/J='M^861ZC_PNYO\ H7#_ .!O_P!KH_X7<W_0N'_P-_\ M=>7
M44?4Z/;\PLCU'_A=S?\ 0N'_ ,#?_M='_"[F_P"A</\ X&__ &NO+J*/J='M
M^861ZC_PNYO^A</_ (&__:Z/^%W-_P!"X?\ P-_^UUY=11]3H]OS"R/4?^%W
M-_T+A_\  W_[71_PNYO^A</_ (&__:Z\NHH^IT>WYA9'J/\ PNYO^A</_@;_
M /:Z/^%W-_T+A_\  W_[77EU%'U.CV_,+(]1_P"%W-_T+A_\#?\ [71_PNYO
M^A</_@;_ /:Z\NHH^IT>WYA9'J/_  NYO^A</_@;_P#:Z/\ A=S?]"X?_ W_
M .UUY=11]3H]OS"R/4?^%W-_T+A_\#?_ +72_P#"[F_Z%P_^!G_VNO+:*/J=
M'L%D>_\ @?QQ_P )G]O_ .)=]C^R>7_RV\S=NW?[(QC;^M==7D?P1^]K_P!8
M/_:E>N5Y=>"A4<42]SR/XW?>T#ZS_P#M.O+J]1^-WWM ^L__ +3KRZO4P?\
M"12V"BBBNH84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =A\.?^0Q
MJ'_8/F_E7'UV'PY_Y#.H?]@^;^5<?64?XDOD+J%%%%:C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ I&^Z?I2TC?</TH [3XC?\ ']H__8-B_E7&5V?Q&_X_M'_[!L7\
MJXRL:'\-"6P4445L,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *[+PW_R3[Q9_NQ?SKC:[+PW_P D^\6?[L7\ZQK_  KU7YB9QM%%%;#"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3\.?\C-
MIG_7U'_Z$*N>-_\ D>-8_P"O@_R%4_#G_(S:9_U]1_\ H0JYXX_Y'C6/^O@_
MR%8?\OOE^HNI@4445N,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JUI?\ R%K+_KNG_H0JK5K2_P#D+V7_ %W3_P!"%3+9@;WQ%_Y'[5?]Z/\
M]%I7+UU'Q%_Y'[5?]Z/_ -%I7+U%'^''T0EL%%%%:C"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH$.B_UJ?[P_G76_$K_D<)/^O>+_T 5R<7^M3_
M 'A_.NL^)7_(X2?]>\7_ * *PE_&CZ,.IR'>BBBMQA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% CL/B-_R&-/_ .P?#_*N/KL?B+_R&-/_
M .P?#_*N.K*C_#0+8****U&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M;1116PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MT_#G_(S:9_U]1_\ H0JYXX_Y'C6/^O@_R%4_#G_(S:9_U]1_^A"KGCC_ )'C
M6/\ KX/\A6'_ "^^7ZBZF!1116XPHHHH **** "BBB@ HHHH **** "BBB@
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M%% !1113 **** "BBB@#3\.?\C-IG_7U'_Z$*N>./^1XUC_KX/\ (53\.?\
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MD)@<#/K[5R0DW44:<FT]Q&OI.A_#O7+A[?3;:&>5$WLH>08&<9Y/J:AO]/\
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MMGNDU;P]'=V."8S9-YI(_P!I6]O3-=$L6XRY4@N>5?#G1]/UOQ(]KJ-N)X1
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M,'C08 =<<^V<_I7GU;TJBJ04EU&%=EX;_P"2?>+/]V+^=<;79>&_^2?>+/\
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M@ HHHH **** "BBB@ HHHH **** "K6E_P#(7LO^NZ?^A"JM6M+_ .0O9?\
M7=/_ $(5,MF!O?$7_D?M5_WH_P#T6E<O74?$7_D?M5_WH_\ T6E<O44?X<?1
M"6P4445J,**** "BBB@ HHHH **** "BBBD 4444P"BBB@ HHHH$/B_UJ?[P
M_G76?$K_ )'"3_KWB_\ 0!7)Q?ZU/]X?SKK/B5_R.$G_ %[Q?^@"L)?QH^C
MY"BBBMQA1112 ****8!1110 4444 %%%% !1112 ****8!1110 4444".Q^(
MO_(8T_\ [!\/\JXZNQ^(O_(8T_\ [!\/\JXZLJ'\- M@HHHK484444 %%%%
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MW?>O&M?UNX\1:M)J-U'$DKJJE8@0N!QW)JM<:E?7=M';7%Y/+!%C9&[DA<#
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M\UB_CL;&$RSR'A1Q^)/85J>,M,TW1O$DVGZ89&B@50YD?<=YY//XC]:?X/\
M% \*7\]W]B%RTL8C&6VE1G)_I^54YR=/F@M1G0_\*?UOR-_VVQ\S&=FYOY[:
MXJ\T>_L-6.F7%LZW@<((QR6)Z8QUS7H'A+6=>\4>/VU"*6>/3T),L1;,:)C
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M ^+_ %J?[P_G76?$K_D<)/\ KWB_] %<G%_K4_WA_.NL^)7_ ".$G_7O%_Z
M*PE_&CZ,#D**.]%;C-KPQX;N/%&HO96TT4+I&9"TF<?IFNM/P<U?'&I6.?\
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M)[U]I Z[!R?Z"O$JTP47RN<NOZ!$[3X6W26_C2)'8#SX71<^O4#]*Z7QZGB
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MA6E.,ZE;VDE9(.I2HHHKM*"BBB@#3\.?\C-IG_7U'_Z$*N>./^1XUC_KX/\
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M%% !79>/?^/'PO\ ]@M/Y"N-KLO'O_'CX7_[!:?R%8S_ (D/G^0=3C:***V
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M9U#_ +!\W\JX^NP^'/\ R&=0_P"P?-_*N/K*/\27R%U"BBBM1A1110 4444
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MQ17DNQ78X <8QGZUIZC\/;!?%+^(KG4EAL/.^T2Q..K9S][/0FG)1Y_WFUM
M*_Q?:-+?1&F0O"+EBZ*<%EP,C\JTX-?U^]L+-?#GAEK:$ !C?81 G&-H##/^
M>*@^),MM#?\ AF6]Q]F2^+29Z8P.OM6OXITK4]>MK1M)UP6-H,F9DZ.IQ@AA
MZ#/YUFFO9P37??81B_%FU27P;#=31(+J.9!N'\.X'< ?2MW4];C\.>"X-4>
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M]JO^]'_Z+2N7KJ/B+_R/VJ_[T?\ Z+2N7J*/\./HA+8****U&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110(?%_K4_WA_.NL^)7_ ".$G_7O%_Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!I^'/^1FTS_KZC_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '8?#G_D,ZA_V#YOY5Q]=A\.?^0SJ'_8/F_E7'UE'^)+Y"ZA1116HPHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *1ON'Z4M(WW#]* .T^(W_ !_:/_V#8OY5QE=G
M\1O^/[1_^P;%_*N,K&A_#0EL%%%%;#"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "NR\-_\D^\6?[L7\ZXVNR\-_\ )/O%G^[%_.L:_P *
M]5^8F<;1116PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH T_#G_(S:9_U]1_^A"KGCC_ )'C6/\ KX/\A5/PY_R,VF?]?4?_ *$*
MN>./^1XUC_KX/\A6'_+[Y?J+J8%%%%;C"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *M:7_ ,A>R_Z[I_Z$*JU:TO\ Y"]E_P!=T_\ 0A4RV8&]
M\1?^1^U7_>C_ /1:5R]=1\1?^1^U7_>C_P#1:5R]11_AQ]$);!1116HPHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ****!#XO]:G^\/YUUGQ*_Y'"3_K
MWB_] %<G%_K4_P!X?SKK/B5_R.$G_7O%_P"@"L)?QH^C Y"BBBMQA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% CL?B+_R&-/\ ^P?#_*N.
MKL?B+_R&-/\ ^P?#_*N.K*A_#0+8****U&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5V7CW_CQ\+_ /8+3^0KC:[+Q[_QX^%_^P6G\A6,_P")
M#Y_D'4XVBBBM@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.]%
M'>D!ZC\$?O:_]8/_ &I7KE>1_!'[VO\ U@_]J5ZY7B8K^,R'N>3_ !GADN;G
MPY!$I>21YU11W),6!7&_\(#XH_Z!$WYBN_\ B@<>(_!Y/:ZD_P#0HJ]%^TQY
M[_E6T,1*E3BHKO\ F.]D?/G_  @/BC_H$3?F*/\ A ?%'_0(F_,5]!_:4]_R
MH^TI[_E3^O5.P79\^?\ " ^*/^@1-^8H_P"$!\4?] B;\Q7T']I3W_*C[2GO
M^5'UZIV"[/GS_A ?%'_0(F_,4?\ " ^*/^@1-^8KZ#^TI[_E1]I3W_*CZ]4[
M!=GSY_P@/BC_ *!$WYBC_A ?%'_0(F_,5]!_:4]_RH^TI[_E1]>J=@NSY\_X
M0'Q1_P! B;\Q1_P@/BC_ *!$WYBOH/[2GO\ E1]I3W_*CZ]4[!=GSY_P@/BC
M_H$3?F*/^$!\4?\ 0(F_,5]!_:4]_P J/M*>_P"5'UZIV"[/GS_A ?%'_0(F
M_,4?\(#XH_Z!$WYBOH/[2GO^5'VE/?\ *CZ]4[!=GSY_P@/BC_H$3?F*/^$!
M\4?] B;\Q7T']I3W_*C[2GO^5'UZIV"[/GS_ (0'Q1_T")OS%'_" ^*/^@1-
M^8KZ#^TI[_E1]I3W_*CZ]4[!=GSY_P (#XH_Z!$WYBC_ (0'Q1_T")OS%?0?
MVE/?\J/M*>_Y4?7JG8+L^?/^$!\4?] B;\Q1_P (#XH_Z!$WYBOH/[2GO^5'
MVE/?\J/KU3L%V?/G_" ^*/\ H$3?F*/^$!\4?] B;\Q7T']I3W_*C[2GO^5'
MUZIV"[/GS_A ?%'_ $")OS%'_" ^*/\ H$3?F*^@_M*>_P"5'VE/?\J/KU3L
M%V?/G_" ^*/^@1-^8H_X0'Q1_P! B;\Q7T']I3W_ "H^TI[_ )4?7JG8+L^?
M/^$!\4?] B;\Q1_P@/BC_H$3?F*^@_M*>_Y4?:4]_P J/KU3L%V?/G_" ^*/
M^@1-^8H_X0'Q1_T")OS%?0?VE/?\J/M*>_Y4?7JG8+L^?/\ A ?%'_0(F_,4
M?\(#XH_Z!$WYBOH/[2GO^5'VE/?\J/KU3L%V?/G_  @/BC_H$3?F*/\ A ?%
M'_0(F_,5]!_:4]_RH^TI[_E1]>J=@NSY\_X0'Q1_T")OS%'_  @/BC_H$3?F
M*^@_M*>_Y4?:4]_RH^O5.P79\^?\(#XH_P"@1-^8H_X0'Q1_T")OTKZ#^TI[
M_E1]IC]_RH^O5.P79Y%X(\)ZYIFIWLMYI\L2264L:DXY8C@5S/\ P@/BC_H$
M3?F*^A%F1SQGBD^TQ^_Y5*QDU)NPKGSY_P (#XH_Z!$WYBC_ (0'Q1_T")OS
M%?0?VE/?\J/M*>_Y57UZIV'=GSY_P@/BC_H$3?F*/^$!\4?] B;\Q7T']I3W
M_*C[2GO^5'UZIV"[/GS_ (0'Q1_T")OS%'_" ^*/^@1-^8KZ#^TI[_E1]I3W
M_*CZ]4[!=GSY_P (#XH_Z!$WYBC_ (0'Q1_T")OS%?0?VE/?\J/M*>_Y4?7J
MG8+L^?/^$!\4?] B;\Q1_P (#XH_Z!$WYBOH/[2GO^5'VE/?\J/KU3L%V?/G
M_" ^*/\ H$3?F*/^$!\4?] B;\Q7T']I3W_*C[2GO^5'UZIV"[/GS_A ?%'_
M $")OS%'_" ^*/\ H$3?F*^@_M*>_P"5'VE/?\J/KU3L%V?/G_" ^*/^@1-^
M8H_X0'Q1_P! B;\Q7T']I3W_ "H^TI[_ )4?7JG8+L^?/^$!\4?] B;\Q1_P
M@/BC_H$3?F*^@_M*>_Y4?:4]_P J/KU3L%V?/G_" ^*/^@1-^8H_X0'Q1_T"
M)OS%?0?VE/?\J/M*>_Y4?7JG8+L^?/\ A ?%'_0(F_,4?\(#XH_Z!$WYBOH/
M[2GO^5'VE/?\J/KU3L%V?/G_  @/BC_H$3?F*/\ A ?%'_0(F_,5]!_:4]_R
MH^TI[_E1]>J=@NSY\_X0'Q1_T")OS%'_  @/BC_H$3?F*^@_M*>_Y4?:4]_R
MH^O5.P79\^?\(#XH_P"@1-^8H_X0'Q1_T")OS%?0?VE/?\J/M*>_Y4?7JG8+
ML^?/^$!\4?\ 0(F_,4?\(#XH_P"@1-^8KZ#^TI[_ )4?:4]_RH^O5.P79\^?
M\(#XH_Z!$WYBC_A ?%'_ $")OS%?0?VE/?\ *C[2GO\ E1]>J=@NSY\_X0'Q
M1_T")OS%'_" ^*/^@1-^8KZ#^TI[_E1]I3W_ "H^O5.P79\^?\(#XH_Z!$WY
MBD;P#XHVG&D3=/45]"?:4]_RH^TQ^_Y4?7JG8+L\D\;^%-<U.[TQ[/3Y)EBL
M8XG*X^5@.17+_P#" ^*/^@1-^8KZ$:94QG/(S2?:4]_RJ(8R<8I)!<^?/^$!
M\4?] B;\Q1_P@/BC_H$3?F*^@_M*>_Y4?:4]_P JOZ]4[!=GSY_P@/BC_H$3
M?F*/^$!\4?\ 0(F_,5]!_:4]_P J/M*>_P"5'UZIV"[/GS_A ?%'_0(F_,4?
M\(#XH_Z!$WYBOH/[2GO^5'VE/?\ *CZ]4[!=GSY_P@/BC_H$3?F*/^$!\4?]
M B;\Q7T']I3W_*C[2GO^5'UZIV"[/GS_ (0'Q1_T")OS%'_" ^*/^@1-^8KZ
M#^TI[_E1]I3W_*CZ]4[!=GSY_P (#XH_Z!$WYBC_ (0'Q1_T")OS%?0?VE/?
M\J/M*>_Y4?7JG8+L^?/^$!\4?] B;\Q1_P (#XH_Z!$WYBOH/[2GO^5'VE/?
M\J/KU3L%V?/G_" ^*/\ H$3?F*/^$!\4?] B;\Q7T']I3W_*C[2GO^5'UZIV
M"[/GS_A ?%'_ $")OS%'_" ^*/\ H$3?F*^@_M*>_P"5'VE/?\J/KU3L%V?/
MG_" ^*/^@1-^8H_X0'Q1_P! B;\Q7T']I3W_ "H^TI[_ )4?7JG8+L^?/^$!
M\4?] B;\Q74:'X4URU\%^([*;3Y4N+D1^2AQE\'FO6_M*>_Y4&X3RV?G"]:R
MK8^2@Y3LDM?N"[9\^?\ "!>*/^@1-^8H_P"$!\4?] B;]/\ &O??M\0[&E^W
MQ>C5P_ZSX/\ Y^1^\OEGV/ ?^$!\4?\ 0(F_2C_A ?%'_0(F_2O?OM\7HU'V
M^+T:C_6?!_\ /V/WAR3['@/_  @/BC_H$3?I1_P@/BC_ *!$WZ5[]]OB]&H^
MWQ>C4?ZSX/\ Y^Q^\.2?8\!_X0'Q1_T")OTH_P"$!\4?] B;]*]^^WQ>C4?;
MXO1J/]9\'_S]C]X<D^QX#_P@/BC_ *!$WZ4?\(#XH_Z!$WZ5[]]OB]&H^WQ>
MC4?ZSX/_ )^Q^\.2?8\!_P"$!\4?] B;]*/^$!\4?] B;]*]^^WQ>C4?;XO1
MJ/\ 6?!_\_8_>')/L> _\(#XH_Z!$WZ4?\(#XH_Z!$WZ5[]]OB]&H^WQ>C4?
MZSX/_G['[PY)]CP'_A ?%'_0(F_2C_A ?%'_ $")OTKW[[?%Z-1]OB]&H_UG
MP?\ S]C]X<D^QX#_ ,(#XH_Z!$WZ4?\ " ^*/^@1-^E>_?;XO1J/M\7HU'^L
M^#_Y^Q^\.2?8\!_X0'Q1_P! B;]*/^$!\4?] B;]*]^^WQ>C4?;XO1J/]9\'
M_P _8_>')/L> _\ " ^*/^@1-^E'_" ^*/\ H$3?I7OWV^+T:C[?%Z-1_K/@
M_P#G['[PY)]CQ#1/!'B.VUZPGFTN9(H[A&=B1P :L^+/!OB"_P#%FIW=KIDL
MD$LQ9'&,,,"O9UO8V8+@\\4/>QHY4@Y'6C_6'"_QO:1MMO\ ,7+*^QX!_P (
M#XH_Z!$WZ4?\(#XH_P"@1-^E>_?;XO1J/M\7HU'^L^#_ .?L?O'R3['@/_"
M^*/^@1-^E'_" ^*/^@1-^E>_?;XO1J/M\7HU'^L^#_Y^Q^\.2?8\!_X0'Q1_
MT")OTH_X0'Q1_P! B;]*]^^WQ>C4?;XO1J/]9\'_ ,_8_>')/L> _P#" ^*/
M^@1-^E'_  @/BC_H$3?I7OWV^+T:C[?%Z-1_K/@_^?L?O#DGV/ ?^$!\4?\
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MOS%'_" ^*/\ H$3?I7OWVZ+T:C[?%Z-3_P!9\'_S\C]X^6?8\!_X0'Q1_P!
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MV?/G_" ^*/\ H$3?F*/^$!\4?] B;\Q7T']I3W_*C[2GO^5'UZIV"[/GS_A
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M):O<RM;I8*5B+DHI^3D#H*V?AQ%8PZ-?BR\02:U&;QR\TBLOEG RGS>GY47
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MBWMR\8(R ?4^PZ_A7;B,HK4/91FUS5':W9W2U?S^1*J)W\C=HKQ2V\+ZI>>
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M8]6\9:!\)-9GU^-DU>R5DM[G>KF1#@!S@GD9/7VI7 ]/P1U%)7B*65QX.NO
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M*]32(6KP^59;9-S8PJ\CMP"?QKT*A 8?C#71X:\(ZEJV1YD$)\H'NYX7]37
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MD_IFNQJKJ-A!JFFW-A=)OM[F)HI%]588-=.#K*AB(57]EI_B3)731D>!W1_
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MYCM5C5OX0X0#/TS6'X?TC7;GPI=Z9XTN+:]N;EI$9H#\OE%0 .@YSN/3THZ
M>?>$OA5IWBOP58:IKNHW\][=0 P-'+A;9!PJJN,<8K7^%ES<:]X<\0>%=?D-
M^FFW#632.22\9W#&?8J<?45!I_ACXD^$K&71/#]_I=WIA9OLLUT2)( ?;'^-
M==X \&+X+T%[62X^U7US*9[NXQ]YSV'L/ZDTDA',WO@W0OA_I[>);W4=2U"+
M1XV_LZTNY]T<3MPJJ/7./IUQQ63HU[KOA:WTVPLK."Z\8>*9'O[J2[)"0KU
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M_NFHJ.H!1110 4444 %%%% !1110 4444 %%%% !1110 5Q?B7X8Z%XDU?\
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MJ6;I'_NTGN!%1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"T4GVJ#_ )XG\Z/M4'_/$_G1J M%)]J@_P">)_.C[5!_SQ/YT:@+12?:H/\
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M3?G1_J?COYD'MXD-%3>;;_\ /)OSH\VW_P">3?G1_J?COYD'MXD-%3>;;_\
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M56K5[]^/_<%5:F.P@HHHJAA1110 4444 %%%% !1110 4444 %%%% !1110
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MI6GVLM]KDL6^.%(R5C&"=S>O )P/3G%2_"G5K_6_ MO>ZG=27-TTTH:20Y.
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M-TBQQ + G]YC].:'*P'N5%>=>(;O6=;^(EGX2LM7N-,M8['[7<W%M@22MG
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M>F0#BO'H[+XJ>)M:LQ>HNA6L'RS2P,BAQQDX!.XGMVKV5%V(JY+;0!D]3BG
M$>3_ !)_XGOQ*\)^&U)**XN)@/0G@_DK?G7K7?I@>GI7F^D>']5NOC/JOB'4
M+.2&Q@@\JSD<C#\!>/\ QX_C7I%.('F?Q*^'>L^--;TZZM+ZVM[6W3R_WA8,
MI+9+# Y[5P7B*SU_X1>(]-O+37;B_MKG+.DI($F"-RLI)'((P>M=Q\3?!?B'
M4]6L_$'AJX<W5N%#VWF[,E3D,N3@]>0>M<])X-\<_$/Q%97/B^"/3]/M1@JI
M4%AG+!54DY/J?Z8J6M0/4K[PYHFJ78\07%BEQ>K:;89)>0BX)! Z9YZUYC\
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M1G QU/4DTD@.^F_X]Y/]P_RKQ7X0>!]#U_P_>:EK%H+R1KE[:)9&.V)  25
M/4EC^5>V2J6A=1U*D#\JXGX3Z!J?AKPI)9:O:FVN#>R2A-ZM\I"X.5)'8U36
MH'$_"[P9I&L7&N_VK ;VWT^\>UM8)W8I$,DD@9ZFE\+73^$H_B7;Z:66#3F+
MVJ$D^6?G _3'/L*[/X;>']4T'_A(O[3M3!]KU)IX/G5MZ'//RDX_&J&B>%;F
MWUSQY-KL"V^DZJQV3/*F&CR^6.#E< @\XI): 5/ /P\\.ZIX%MK[5K);V\U-
M#--<2,=XR3]TYX/O4/P6L?[,U#QAI_F&3[+?+#O/5MID&?TIOAV/X@^'M(&C
MZ';Z5K.F;F^Q:E]H7:BD]P&YQZ8-+\$(IXI/%1N)A<2?;D5YE.1(PWY8'WSG
M\:%N@/6Z***T&%%%% %J]^_'_N"JM6KW[\?^X*JU,=A!1115#$R!C) SP*\2
M\=Z-XET6\LO$_B&^BU_2[.Y#&S&8EBR?E. !GMS7:_$#PUK6I7.EZYX=F U3
M3'R+=WVI,N<X],]>O8GFN?URW\>?$&VBT2\T*'0]-:16NYWG#EMISA0#G]/Q
MJ)=A'J5E>1ZA8V]["28KB-95SUP1FO'O'D6K7'QKTBVTFY6UN;BP$23L,^4"
M9 S#W KO]<_X2+1X-$LO"VGPW5LC"&[,K*#'$-H!&6'.-W3/2LWQ]X3U34K[
M3/$/AUHAK6F-E(Y#@3+UVY/&>O7U-$M4!ROBC3-?^&26GB*Q\2ZAJEJ)UBO+
M:]D+!P><C).,X(]1Q7L,$JSP1S)]R10Z_0C->4:QIWC;XBR66DZOHD>AZ3%,
MLMW)YX=I2.RX)[$X[<]:]91%CC5$4*B@*H'8"B((\>^),&I7/Q>\+PZ/=1VN
MH-9GR9Y%RJ'=)G(P>V>U,\6>%OB;<:!<B]U^VU"S1=\]K;@1-(@Y(SM&>!TK
M7\?:)XHD^(&A^(?#VDI?BPM2I$DR(NXL_!RP/1L\5'>ZC\6=8LIK!?#>FZ<)
MU,;7'VA6*J>#_&W;VI/<#-UW6K#7/V>YIM.M?LD,'DP&WW;O+*R+QGOZY]Z?
MX@_Y#'PL_P"N4?\ Z!'6EJ'P^OM.^#<_AG34%[J4CI*^U@@=O,4M@L0, #OZ
M5-K'A;6KK4O $L-D732HT%Z?,0>40J ]^>AZ9HU CT3_ )+YXD_Z\%_]IUR_
MA?5[C1/@]XJO;1F2X%^\:.O5"V!FN[TOP_JEO\7M<UR6U*Z;<V:QPS[U^9AL
MXQG(Z'J*S/"'@2__ .$"U[0=<@-H]]<R/&=ZO@$#:WRDCJ.E&H$OA+X9>&9_
M!5F=0T]+JZO8!+-<NQW[F&?E.>,?_KKC].NKF'X8>._#L\[3Q:/.88';KMWD
M8^F5SCW-='I=W\2O#.C)H">&X-1>W7RK6^6X4+L'0L"0>/?%.M?A[JVG?#'7
M[)RM[K^KGSI@C@ MG(&XX'<DGWI>@#?#?PV\.7OPVM[B]LA/?WEGY[W;N2ZL
M5R,'/ '_ .NM7X+W4UU\-[832%_)N)8DSV48('ZFND\/:?=6/@?3].N8O+NX
MK%8GCW X<+C&0<=:QOA7H.I^'/!*Z?JUM]FNA<R.8RZM\IVX.5)'8U25F@.V
MHHHJQA5F'_CSN/PJM5F'_CSN/PJ9; 5J***H HHHH *\P^(&/^%H^!M_^J\Q
M\YZ9R,5Z?7&?$3PI>>(].L[K294CU;39_/MBYP'_ -G/X"IEL ?%C9_PK/6M
M_38F,^OF+C]:UO!>X>"-#WYW?8HO_0>*X'6;;Q]X_M[;0M2T.+1K#S%:^N3,
MK^9M.<* 3WYQZ@<UVOB)O$.E6&E6_A33H;E(Y%AG65E'EPJ  1N8<\4KZW$<
MIXG_ .2\^$M_W/LC[<_WOWO_ -:M#XT[/^%:W>[_ )^(L?7)J?X@^%=3UEM*
MUO061=:TF3S(D<@+*#@E<].H[\<FL#4]/\:?$.YL--UK1(]%T>"82W9,P<S$
M=EP?KCZ]:3ZH"&RW?\+N\/"?[W]AKLSZ^6^?ZUJ?'''_  @UN!_K/MT>SZX-
M7?'7A75I]6TCQ-X9$3:KI8\O[/(0!-%_=R>.[#G&0361<:5XN\?Z[I?]O:.F
MC:/I\HG>,RAWF<=N#TX__70^P'H]WJ$6E:%+J%P<1VUMYKGV5<FO/_A'ILU]
M#J/C/41NO]5F;RR>=D8/0>V>/H*Z3XC:;J>K>!=0T_1K<S7EP$18PZKE=PW<
ML0.F:U/#&FMHWA72].==DEO;(CKD'#8RPX]R:=M0,?Q-X,N-6UNTU[2-7?2M
M7MXC!YPC$BR1G/!!^I_SBN+U'PXEK/9^ ;.\DN9M1G.HZY>-\I,8.><= ?\
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MQ+8Z)<:O9WUH('2V/SQNO3(]#@<UI_#3P_?Z#X<N#J<8BO+^[DNY(00?*W8
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M1]E@_P">Q_*GSH"G15S[+!_SV/Y4?98/^>Q_*CG0%.BKGV6#_GL?RH^RP?\
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M\J/LL'_/8_E1SH"G15S[+!_SV/Y4?98/^>Q_*CG0%.BKGV6#_GL?RH^RP?\
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M.M2Y*X&;15S[+!_SV/Y4?98/^>Q_*JYT!3HJY]E@_P">Q_*C[+!_SV/Y4<Z
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M-<)\4O\ D8?"'_7S)_Z%%7=GJ:I_PX_/\P$HHHJ+@%%%%%P"BBBBX!1111<
MHHHHN 44447 ****+@%%%%%P"BBBBX!1111< HHHHN 44447 ****+@%%%%%
MP"BBBBX!1111< HHHHN 44447 ****+@%%%% $L'WS_NFHJE@^\W^Z:BI+<
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M HHHH EG^^O^Z*BJ6?[R_P"Z*BI( HHHIW ****+@%%%%%P"BBBBX!1111<
MHHHHN 44447 ****+@%%%%%P"I9ND?\ NU%4LW2/_=I/<"*BBBF 44447 **
M**+@%%%%%P"BBBBX!1111< HHHHN 44447 ****+@%*.HI*4=10!PGPM_P"1
MA\7_ /7U'_Z%+7IE>9_"W_D8?&'_ %]1_P#H4M>F4Z_\1_+\@9YG\4O^1A\(
M?]?,G_H45=T>IKA?BE_R,/A#_KYD_P#0HJ[H]35/^''Y_F 4445F 445R7Q
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M@!**** "BBB@ HHHH **Y3QKXGO-!ET2STV**6]U2]6 "4$A8_XFP".@KJZ
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MCC:?SKKOCDK-\-4"@D_:8N /8U@:_87-Y^S1I"V\+R-"L4SJHR0H9P3CVR*
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M!Z>A[YKURO$_$OB&+XJZYH6B>&[:YDM;6Z6ZN[N2(HL:C''/MG\:]L "@ =
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M]HC#&(C@# ],@T(9Z-1113 **** "I;C_6GZ5%4MQ_K3]*.H$5%%%, HHHI
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MY)_OI^='DG^^GYT7 BHJ7R3_ 'T_.CR3_?3\Z+@145+Y)_OI^='DG^^GYT7
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M%%%@"BBBBP!11118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHIV
MDA_U\?\ O"G77_'U)]:;#_KX_P#>%.NO^/J3ZU/41#1113L,****+ %%%%%@
M"BBBBP!11118 HHHHL 44446 ****+ %%%%%@"G1_P"L7ZBFTZ/_ %B_446
MEO/^/N3\/Y5!4]Y_Q]R?A_*H*2V0@HHHIV&%%%%%@"BBBBP!11118 HHHHL
M44446 ****+ %%%%%@"BBBBP"CK4][_Q\'_=%0#K4][_ ,?!_P!T?RI/X@*]
M%%%, HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 ****=@
M+%Y_K$_W!5>K-Y_K$_W!5:ICL(****=AA11118 HHHHL 44446 ****+ %%%
M%%@"BBBBP!11118 HHHHL 59N_N0?[@JM5J[^[!_USI/="*M%%%.PPHHHHL
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M+\(6$-[JKRB*641((DW,6P3T],"BZ$;E%>?VWQC\*W=U#;1&_P#,ED6-<VQ
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MGR>!6W1< HHHI@%%%% "CK4][_Q\'_='\J@'6I[W_CX/^Z/Y5+^) 5Z***H
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M:0GJ25')^O6G%] 1JT4458PHHHH **** )(?]?'_ +PIUU_Q]2?6FP_Z^/\
MWA3KK_CZD^M3U AHHHJ@"BBB@ JO?)<2Z==1V<HBNGA=89",A'((4_@<&K%%
M(#P77O!9\+^*?"EY>:G/J6J7VH W-Q(>#@K@*#SCFO>S]X_6O,/BE_R,_@G_
M +"']5KT;4=0M-+LIKV^G2"UAYDE<X"@G'/XD5,4)$SQI*NV1%=<YPR@BO*_
MB)*WB3Q/IW@+2ECB\\B?49D092,<X_+GZD5Z=:7UK?6,=];3K+:R)YB2H<AE
M]17F?PH3^V?$/BGQ1-AI9[LV\9/91SQ_X[^5#UT N_$;PV;;P1I<&BV+/;:1
M=Q3FVB&6:-<@\=SSDU0AUR#7OB+_ ,)=#;W5KHNDZ8XN+BXA,>]CD[0#U(S^
ME>K5YWX\D?Q)K^F>!;-BL<S"[U-DXV0*<A?J3_2AH ^'Z"07WC37)HK:\UN3
M_1EGD"^7;C[BC/K@'\ >]>B9! (Y!&1BO))-%TOQ#\6-=TS7(U:QTW38UL8&
M;:D:[5RR@>F3_D5O_"*ZGN/!'ERRO+%;W4L-N['),8/'-$7J!WE%%%6,****
M "G1_P"L7ZBFTZ/_ %B_44@);S_C[D_#^505/>?\?<GX?RJ"B.R$%%%%,84'
M.#CKVHHH \!\=>![G1+*PUS6=7FU/6+G4(XW<\1HO7"C_P#57LWB+04\2^&9
M]'EN9;:.Y1%>2( L "#CGUQBN-^-'_(O:1_V$XZ[77==M/#?AVXU:]8^3;Q
M[1U=NRCW)XJ%:[$96J'0_ _P]>TN_+^P06OD"-E&;A]N.G=F/)K*^#FGW=AX
M!A-TC1K<3//#&W58ST_/K7%Z'<:;XYU=/$OC;7]-AMHV/V+2&NU 0 ]7!/\
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M!Z%1115C"BBB@!1UJ>]_X^#_ +H_E4 ZU/>_\?!_W1_*I?Q("O1115 %%%%
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MJ%4 *HP !P!2T4)) %%%%, HHHH **** )(?]?'_ +PIUU_Q]2?6FP_Z^/\
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MO?\ CX/^Z/Y5+^) 5Z***H HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"S>?ZQ/]P56JS>?ZQ/]P56J8[ %%%%4 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5J[^[!_USJK5J[^[!_USJ7NA%6BBBJ&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4#[P^M% ^\/K0!R'PK_Y#
M_B[_ *^8_P#T*6O3J\Q^%?\ R'_%W_7S'_Z%+7IU1B/XC_KH)[GF/Q4_Y#WA
M'_KYD_\ 0HJZ\]3]:Y'XI@G7_"( R3<R?^A15V9MIL_ZIORK2Z]G'^NH^A%1
M4OV>;_GD_P"5'V>;_GD_Y5-T!%14OV>;_GD_Y4?9YO\ GD_Y470$5%2_9YO^
M>3_E1]GF_P">3_E1= 145+]GF_YY/^5'V>;_ )Y/^5%T!%14OV>;_GD_Y4?9
MYO\ GD_Y470$5%2_9YO^>3_E1]GF_P">3_E1= 145+]GF_YY/^5'V>;_ )Y/
M^5%T!%14OV>;_GD_Y4?9YO\ GD_Y470$5%2_9YO^>3_E1]GF_P">3_E1= 14
M5+]GF_YY/^5'V>;_ )Y/^5%T!%14OV>;_GD_Y4?9YO\ GD_Y470$5%2_9YO^
M>3_E1]GF_P">3_E1= 145+]GF_YY/^5'V>;_ )Y/^5%T!%14OV>;_GD_Y4?9
MYO\ GD_Y470$5%2_9YO^>3_E1]GF_P">3_E1= 145+]GF_YY/^5'V>;_ )Y/
M^5%T!%14OV>;_GD_Y4?9YO\ GD_Y470$5%2_9YO^>3_E1]GF_P">3_E1= 14
M5+]GF_YY/^5'V>;_ )Y/^5%T!%14OV>;_GD_Y4?9IO\ GD_Y470$EG_K'_W#
M5:KEK#*KN61A\A'(J#[--_SR?\J2:N(BHJ7[/-_SR?\ *C[/-_SR?\J=T,BH
MJ7[/-_SR?\J/L\W_ #R?\J+H"*BI?L\W_/)_RH^SS?\ /)_RHN@(J*E^SS?\
M\G_*C[/-_P \G_*BZ BHJ7[/-_SR?\J/L\W_ #R?\J+H"*BI?L\W_/)_RH^S
MS?\ /)_RHN@(J*E^SS?\\G_*C[/-_P \G_*BZ BHJ7[/-_SR?\J/L\W_ #R?
M\J+H"*BI?L\W_/)_RH^SS?\ /)_RHN@(J*E^SS?\\G_*C[/-_P \G_*BZ BH
MJ7[/-_SR?\J/L\W_ #R?\J+H"*BI?L\W_/)_RH^SS?\ /)_RHN@(J*E^SS?\
M\G_*C[/-_P \G_*BZ BHJ7[/-_SR?\J/L\W_ #R?\J+H"*BI?L\W_/)_RH^S
MS?\ /)_RHN@(J*E^SS?\\G_*C[/-_P \G_*BZ BHJ7[/-_SR?\J/L\W_ #R?
M\J+H"*BI?L\W_/)_RH^S3?\ /)_RHN@);W[\?^X*JU=NX9':/:C'" ' JO\
M9YO^>3_E4Q:L(BHJ7[/-_P \G_*C[/-_SR?\JJZ&145+]GF_YY/^5'V>;_GD
M_P"5%T!%14OV>;_GD_Y4?9YO^>3_ )470$5%2_9YO^>3_E1]GF_YY/\ E1=
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MHL [S'_O'\Z/,?\ O'\Z;118!WF/_>/YTOF/_>/YTRB@">%V+'+$\&HO,?\
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MQ2$L>,5!4L?^HD_"DP&^8_\ >/YT>8_]X_G3**8#O,?^\?SH\Q_[Q_.FT46
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M_P"\?SIE%,!WF/\ WC^='F/_ 'C^=-HHL [S'_O'\Z/,?^\?SIM%%@'>8_\
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MI*5?OCZT /G_ -<U1U)/_KFJ.A; %%%% !1110 4444 %%%% !1110 4444
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M16SMJ5P >@7[N?Q _.O1J\Y\%XUWXD^+/$)PT5NZZ;;L>P7[WZBO1J$!YO\
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M<5('8^'=0;5_#6EZBX^:ZM8Y2!ZE0:\T^.FI6T$/ARPNRWV>2^$UPJC<3&N
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M0!Y)IGP%T>WOX9M1U:\U"W@/[NV<!5(]"<]/85ZS&B11K'&JJB*%55& H'
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M .N:HZDG_P!<U1T+8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHI:0"5+<?ZT_2H^]23Y\S\*3W BHI:2J ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHP:0$L_WQ_NBHJEGSN7_
M '145"V **6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B
M@!*EFZ1_[M1_A4DWW8_]VCJ!%112T )12T4 )12T4 )12T4 )12T4 )12T4
M)12T4 )12T4 )12T4 )2CJ** .:8'"?"W_D8?&'_ %]1_P#H4M>F5YG\+?\
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MNF_V/^^:/MTW^Q_WS5:BCE0%G[=-_L?]\T?;IO\ 8_[YJM11RH"S]NF_V/\
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MZ;T7\J/MTWHOY57HH_MC'_\ /Z7WL/9Q[%C[=-Z+^5'VZ;T7\JKT4?VQC_\
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M_?-5J*.5 6?MTW^Q_P!\T"^FS_#_ -\U6H'4?6CE0CD?A:2WB'Q>3U-S&?\
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MLP?\>L_X56JS!_QZS_A7!FG^Y5?\+_(J/Q(@HHHK\4.\**** "BBB@ HHHH
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MS1R;3@[&!Q^5+)/#"4$LJ(7.U0S ;CZ#UH=.2ERVU"Y)1114#"BBB@ HHHH
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M+5FN UW GEF*,,.  <DD8KSG]H#_ )"'ASZ3?SCJM\=!_HOAC_KU/\EJ;V;
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MOO%FD6/A<^(S<&XTP*&$MN-Q8$XX''>N9C^,WA&:ZM+>![Z62Y(50MO]TDX
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MBO&-0HHHH **** 'P_ZY/]X4L_\ Q\2?6DA_UR?[PI9_^/B3ZUZ2_P"1<_\
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M>XM\_P"H'YUP7Q2_Y&'PA_U]2?\ H45=V>IJI?PX_/\ ,!V+?_G@/SHQ;_\
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MSIE%%@'XM_\ G@/SHQ;_ // ?G3**+ /Q;_\\!^=&+?_ )X#\Z9118!^+?\
MYX#\Z,6__/ ?G3**+ /Q;_\ / ?G28M_^> _.FT46 GA$6YMD04[?6HL6_\
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MO_SP'YTRBBP#\6__ #P'YT8M_P#G@/SIE%%@'XM_^> _.C%O_P \!^=,HHL
M_%O_ ,\!^=2((O)DQ& .XSUJ"IH_]1)4SBI1Y9:I@,_<?\\1^='[C_GB/SIE
M%<G]FX/_ )]1^Y%<TNX_]Q_SQ'YT?N/^>(_.F44?V;@_^?4?N0<TNX_]Q_SQ
M'YT?N/\ GB/SIE%']FX/_GU'[D'-+N/_ ''_ #Q'YT?N/^>(_.F44?V;@_\
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MBW_YX#\Z,6__ #P'YTRBBP#\6_\ SP'YT8M_^> _.F446 ?BW_YX#\Z,6_\
MSP'YTRBBP#\6_P#SP'YT8M_^> _.F446 ?BW_P"> _.C%O\ \\!^=,HHL _%
MO_SP'YT8M_\ G@/SIE%%@'XM_P#G@/SHQ;_\\!^=,HHL _%O_P \!^=&+?\
MYX#\Z9118!^+?_G@/SJ241;8]T0/R\<]*@J6;I'_ +M+J W%O_SP'YT8M_\
MG@/SIE%.P#\6_P#SP'YT8M_^> _.F446 ?BW_P"> _.C%O\ \\!^=,HHL _%
MO_SP'YT8M_\ G@/SIE%%@'XM_P#G@/SHQ;_\\!^=,HHL _%O_P \!^=&+?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!+/U7_=%15+/U7_=%14+8 HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *EC_U$GX5%4L?^
MHD_"A@14444 %%%% !1110 4444 %%%% !1110 4444 %%';-% !1110 444
M4 %%%% #D_UB_6EF_P!<_P!:2/\ UB_6EF_US_6CJ RBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "E7[X^M)2K]\?6@!\W^N:HZDG_ -<U
M1T+8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J6?_6_A
M452W'^M/TI=0(J***H HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!+/]Y?]T5%4L_WQ_NBHJ%L 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5+-TC_W:BJ6;I'_ +M)[@14444P"BBB@ HHHH ****
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MA <)X^^)%OX3+:786TM]KTL1>*WCC)$8P2';U& 3@>G.*D^$NLZCK_@.WO\
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M%-U!>2[UE!.,XZ?@<_6DP/:8@ZQ()&#.% 8CN<<FDGFBMK>2>>18X8U+N['
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MT34IU"S^4F])<8ZC(]!QR.,TF@.(C;Q)>?'7PY<^(XK:WN6C9X[.!]XMXPK
M9/J3S7NCL4C9U4LRJ2%'<UQ?A3X=QZ#K<^O:GJUQK&LS+L^TS+M"+Z*,G_/:
MNVII <1\,=&O].T74+[5K9[?4=3OI+F6)SEE7/RC\J[>BB@"KJ<3W&D7L,2[
MI)+>1$&>I*D#]:Y3X5:'J/A[P+;Z?JUJ;:Z6:5FB+JV 6R.5)%=K10!Y/;V/
MC7X?^(-5.F:4WB#1;^4S1K]H DA8]N3TYQWX%6_"GA77]4\;77C/Q9!%9SM
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M8_\ 42?A452Q_P"HD_"A@14444 %%%% !1110 5B:GX.\-ZU>M>:GHEG=7+
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M@ HHHH **** "BBB@ J6X_UI^E15+<?ZT_2CJ!%1113 ****0!1110 4444
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M 5+'_J)/PJ*I8_\ 42?A28$5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 Z/_6+]:6;_ %S_ %I(_P#6+]:6;_7-]:740RBB
MBF,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I5^^/K24J_>'UH
M ?/_ *YJCJ2?_7-4="V ****8!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %2W'^M/TJ*I9_P#6GZ"EU BHHHI@%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444@)9_OC_=%15+/]\?[HJ*A; %%%%, HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "I9ND?^[452S?=C_W:3W BHHHI
M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4HZBDH'6@#A?A;_R
M,/C#_KZC_P#0I:],KS/X6_\ (P^+_P#KZC_]"EKTRG7_ (C^7Y SS/XHX_X2
M'P>3T^U29_[ZBKO#+;9^^_Y5P7Q4_P"0]X1_Z^9/_0HJZX]35M7IQ_KJ/H7O
M-MO[[_E1YMM_??\ *J-%1R(5B]YMM_??\J/-MO[[_E5&BCD06+WFVW]]_P J
M/-MO[[_E5&BCD06+WFVW]]_RH\VV_OO^54:*.1!8O>;;?WW_ "H\VV_OO^54
M:*.1!8O>;;?WW_*CS;;^^_Y51HHY$%B]YMM_??\ *CS;;^^_Y51HHY$%B]YM
MM_??\J/-MO[[_E5&BCD06+WFVW]]_P J/-MO[[_E5&BCD06+WFVW]]_RH\VV
M_OO^54:*.1!8O>;;?WW_ "H\VV_OO^54:*.1!8O>;;?WW_*CS;;^^_Y51HHY
M$%B]YMM_??\ *CS;;^^_Y51HHY$%B]YMM_??\J/-MO[[_E5&BCD06+WFVW]]
M_P J/-MO[[_E5&BCD06+WFVW]]_RH\VV_OO^54:*.1!8O>;;?WW_ "H\VV_O
MO^54:*.1!8O>;;?WW_*CS;;^^_Y51HHY$%B]YMM_??\ *CS;;^^_Y51HHY$%
MB]YMM_??\J/-MO[[_E5&BCD"QIPR0,S;&8G;SD5%YMM_??\ *HK/_6/_ +AJ
MM24=0L7O-MO[[_E1YMM_??\ *J-%/D06+WFVW]]_RH\VV_OO^54:*.1!8O>;
M;?WW_*CS;;^^_P"54:*.1!8O>;;?WW_*CS;;^^_Y51HHY$%B]YMM_??\J/-M
MO[[_ )51HHY$%B]YMM_??\J/-MO[[_E5&BCD06+WFVW]]_RH\VV_OO\ E5&B
MCD06+WFVW]]_RH\VV_OO^54:*.1!8O>;;?WW_*CS;;^^_P"54:*.1!8O>;;?
MWW_*CS;;^^_Y51HHY$%B]YMM_??\J/-MO[[_ )51HHY$%B]YMM_??\J/-MO[
M[_E5&BCD06+WFVW]]_RH\VV_OO\ E5&BCD06+WFVW]]_RH\VV_OO^54:*.1!
M8O>;;?WW_*CS;;^^_P"54:*.1!8O>;;?WW_*CS;;^^_Y51HHY$%B]YMM_??\
MJ/-MO[[_ )51HHY$%B]YMM_??\J/-MO[[_E5&BCD"QISO"I7>S#Y>,"HO-MO
M[[_E4=[]^/\ W!56DHW06+WFVW]]_P J/-MO[[_E5&BGR(+%[S;;^^_Y4>;;
M?WW_ "JC11R(+%[S;;^^_P"5'FVW]]_RJC11R(+%[S;;^^_Y4>;;?WW_ "JC
M11R(+%[S;;^^_P"5'FVW]]_RJC11R(+%[S;;^^_Y4>;;?WW_ "JC11R(+%[S
M;;^^_P"5'FVW]]_RJC11R(+%[S;;^^_Y4>;;?WW_ "JC11R(+%[S;;^^_P"5
M'FVW]]_RJC11R(+%[S;;^^_Y4>;;?WW_ "JC11R(+%[S;;^^_P"52I)"89"K
M-M'7(K,JS!_QZS_A7-C9NCAIU8[Q3?W(:5W8E\R#^\U'F6_]YZIT5^=?ZW8_
MM'[G_F=?L(ESS+?^\]'F6_\ >>J=%+_6[']H_=_P0]A$N>9;_P!YZ/,M_P"\
M]4Z*/];L?VC]W_!#V$2YYEO_ 'GH\RW_ +SU3HH_UNQ_:/W?\$/81+GF6_\
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M_#^H^)/!WQ>M_#%[K=QJ=M<R)&WGR,X8.,A@&)((-)XG\5:MXM^(5QX?M/$
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MN]-78'%I\1-?T75;*U\8^'(].MKUQ'%=6\V]58]FY/\ ,5Z.655+%@% R6[
M>M>1>,M3'Q$\3V'A/0L3VMI<">_O5Y1,=0#^?XUL^.M4O-8U&V\!: Y^UW2@
MW]PO/V:W[Y]R/TX[T)V G\+_ !(3Q5XWU#1K*WB.G6T9:*YR=TA!P3Z8]*[Z
MO)?".CVNA?&C4=,L83';V^FHBC')X&2?<GDUZU1'5 @HKR'Q WB+5_C#-X>T
MS7;K3[66R1Y6C<GRU')*#. QXY&#[UGW-IXJ\/?$"W\':;XIO)K?5K<2"XNR
M9)(%RV\KD\-A&_/UYIN07/;J*\B2VUCP+\3-"T\>(=0U/3]6#++'>2%RI'<9
M)P<XY%23/K/Q$\?ZQI5OK-UI>B:,PB?[&Y1Y9,D<D>I5O8 #BES#/6:*\:AA
M\1^&OBWX?T.Z\0W]_I<H=X?-E.77:V0XS\Q!'?->RTT[@<OXQ\2W6A2:-::?
M#%->:E>K JR D!/XFX(Z UU%>>S?\3WXUP1_>M]"L2YP>DLG3]*]"H0' :QX
M_P!3D\37'A_PGH:ZI>6@S<RRR;(HSZ=OYU/X7\>W6I>(Y?#6OZ0=*UE4,D:*
M^Y)5 S\I^F3U(X/I6_'IV@^%UU'5UBAL5G/FW=PSG#$=SD_H*\^\+R7'CSXH
MMXPC@>#1M-A:UM'=<&<_,,_^/L?;@4M;B-:^^(6L:AX@O-(\'Z FIM8MMN;F
M>79&&[@<CZ=?PK0\(^.Y=<UB[T'6-+;2];M5WO 6W*Z\<J?Q'KD<YK86U\/^
M"]/O[]4BT^VE?S[F0NQWOZ\D\GT%<+X%6\\7_$'4/',EL]MIJP_9;)7&&D&,
M9_+.?<@=J-;@=9XV\=Z9X,TQY)I8Y=09?]'LPWS.>Q;'(7W_ "K3\+ZO+KWA
M?3M5FC2*2Z@61DCSM4GL,\UQOCSP1H=OH?BCQ&]N9]3N("XDF.X1?='R#MTZ
M]:Z+X=?\D[T'_KT2B[N!T]%,F)$$A!P0I(_*O$/ .C>)?'NASSWWB[5+6TMY
MWA@6&5M[O@,2S9R0,K@?7I5-V8SW*BO$_!UGXI\;P7VF:EXHO;:RTB9K?S;8
MD33OD_?;.2 !6GX*\3:GH5CXTL=8OI=2_P"$?<M#-*27<?.,$GG!*C\S4J0K
MGK-%>0^&_"OB3QCH:^);_P 7:E9WEYNDM8K:0K%&N<#*@]#CIZ>M7_A#J6MW
MUUXHAUR^GNKJVO$C(D<E4;+A@HZ 9'0<<4U(#T^BBBJ&%%%% %J]^_'_ +@J
MK5J]^_'_ +@JK4QV$%%%%4,YCQYXL/@SPY_::6RW,K3I"D3-C).3_(5SB^-?
M'Y8 ^ 2 3R?/Z?K2?%O3-=U<^'[?1=,DO%BNS-+Q^[!&W:&/8?>_"J6K>(_B
M'X)2'5==CTV_TII%6X2V!5H<^A_KS4-ZB/5HV9HD9UVL5!9?0XZ4ZH;2ZBOK
M."[@;,,Z"1#Z@C-<7\0/$%X&MO"F@$MK>J_+E?\ EWA/WG/IQG]:INR&1Z=\
M2HM7^)+>&=/@BDLHT?==[CN9U'.WMC/%=]7CFC>';7PO\:-'TFS0[8M+)=R.
M9'(.YC]37L=*+N)' >-O'.MZ!XJTS0=%TBVU"XOH/-197*DG<PP#D#HO>LN[
M^(/CC0H?MNO>"4BT]"/-DMYMQ0>O#-^M9_Q)OKO3?B[X8O+"P>_NHK-C':H<
M&0[I 1^1S^%5_&GCGQ==^&+RRNO!D^F6MRGE3W4I:0(A//  _.H; ](U#Q)<
MS>"QKWAJR_M*65$>" @Y8%@#D#G(&?RK.UGQG?Z1JOA2Q>PA$FLX%RKDYA;"
MY Y[$GKZ5SFKW=MI7P#2;PWJ<I2&.)4NH6,;[O,4-TY4YR"*K^)99)M=^%\L
MKL\DB(SNQR6)5"23W-5<+G9V'BVYO/B/JOAAK6%8+*V69)@3O8G;P>W\57O"
MFJZSJ]C<2ZWI0TV:.=HXX\'YT'1N37'Z)_R7SQ)_UX+_ .TZS_!WB^^TWX:^
M(];OKJ:]GM;R1(/M$A?DX"KD]LGI0F!Z]17DNC>"?$GB708M<U#QEJMMJ=XG
MG0QP2%8H@>@*@CVSC]:KV_C#6M0^%GBB"_N'BUO17^SR7,+;&;YL9!'0_*1D
M4<P7/8N]%>.Z;X2\3^(O!D&OW/C+4X+^2V\ZVAAD98U4#Y0V#R2!R>O/>NP^
M%_B"\\2>!;6]U!_,NDD>!Y,8+[<8)]\']*:>H'944450PJS!_P >L_X56JS!
M_P >L_X5P9I_N57_  O\BH_$B"BBBOQ0[PHHHH **** "N4\:>-(_"<%K%%9
MO?:E>R>7:VJ'&\^I/IR*ZNJ5QI6GWE];7MQ9PRW5J28)F0%X\^A[5TX6=&%5
M2K1YHKIW[?*^Y,KVT.'@^(.MZ5K%A9>,/#RZ;#?OY<-U!,)$5NP;DXZ^M>BU
MX5XTUG5M5U[1(?%^D2Z)H$5WYGF+F7S&'3)XQQ^62>:]S1U=0ZL&5AD$'@BO
M3S;#1I0I5%!1E)._+K'1Z6=WKW5R*<KW0IK@M%^)$6O?$:X\-V$$;V,$3DW6
MX[G=<9QVV\TGQ UZ]GN+;P=H!)UC4QB61?\ EV@_B<^A(S^'X5SOA_0;3PW\
M;K72K&/$4&BX+8Y=N['W)K; 9?2^K3J5U>3C)Q7DNOW[?,4INZ2.Q\5^+-0T
MS7-+\/:%8P76KZ@K2#[2Y6.*-<_,<<]C^53>#?%5SX@_M&RU*R2SU339O)N(
MHVW(<]&4GG%9WC#1-:3Q;H_BO0K2*^N+*)[>:T>39O1LX(/J-Q_2N5O(]<T#
M3M6GN8XXO$OBR[$%O:Q/N\A,8))]@>M71PF&Q&%C3AR\S2UO[W-S:W5_A4==
MA.34KG=>%O$]UXGUC6)(88ET6SF^S6TP!WSR#[YSTV_AW%=77 :3XJ\'^#+>
MU\*_VDJRV@$4K["4$A^\68# ))-=ZK!E#*05(R"#P:\O,:3A5YHP<8/X;JUT
MNOSW^9I!Z#J***\XL**** "BBB@!\/\ KD_WA2S_ /'Q)]:2'_7)_O"EG_X^
M)/K7I+_D7/\ Q_H1]LCHHHKS2PHHHIH"EJVJ6NBZ5<ZE>R;+>WC+N>^!V'O7
MG ^)GBHZ8=?7P;G0/OB3S_WNS/WL>GX5H_&F5E^'=Q&I($MQ$C8]-V?Z5UMM
M:0MX4ALBH\EK%8BN.-I3!KV\+&A1PL:U6"FYR:UOHDE>UNNNYD[N5DRQH^K6
MFN:1:ZG8N7MKE Z$C!^A]P<C\*CU_55T/0+_ %1U#BU@:0(3C<0.!^)P*X?X
M'S/)X!D1R2L-]+&GL,*?YDUK_%*UU+4/ 5[8Z79RW=Q<.B&.(9(4-N)_0?G6
M4L%"&9_5G\/-;7M?_(?,^2Y@6/Q"\;ZE8PWMGX%,MO,N^.07'#+Z\UTNJ^-/
M^$=\$PZ[KE@]O=R +]A5LL9#G"Y^@SFN-C/Q/\->&+:\$6E-:6-NBMIZH=ZQ
MHH')_O8'.#Z\5W&B7ND>/_#%CJEQI\,T;'>(YE#>5(IP<'V/>O0QU'#P<:GL
MXNDI:N#;?DG=Z7\B(MO2^IS$OQ&\3Z-;P:EXC\)"TT>9U4S0S;GA#="RY/Y<
M5T7B_P 8G0-*T^73K9;V]U29(;*)B55RV.2?3D?G7#_%76?$5S9SZ9=:+)9>
M'?M*I-J*?O&:,$<A?X:Z'Q%H$FN^&/#>H^%I(KF72GBN+19&VK,@ R,]CP/U
MJY87#7H5JT%%2;O9OEM;W;N[L[[Z[=@O+5(T/#?BS5;GQ+=^&O$5A;6NI0PB
MXC>U<M'*AXXSSG/\C5BV\3W6I^/[G0["*)M/T^$&]N""6$IZ(O./K]*Y"YGU
MG2-2U3Q]XAL8K&=;-;+3[&.7S&9R>,D>Y/\ D5<\/:WH/P\TB&RUV^(UJ^_T
MR]V1L[*S\_-CH ..:FO@J;4JM&"E)I)*.JYK>\UOHE\KL%)[,].HJ&TN[>^M
M(KJUF2:WF4/'(AR&![BIJ^9DG%V>YL%%%%2,*5/OK]124J??7ZBM*7QQ]1,D
MO/\ C[D_#^505/>?\?<GX?RJ"OW2.R//"BBBJ **** *]]?6^F:?<7UW(([:
MW0R2.>P%>;#XC^*]1LI=8T7P=YVB1%F$LTV)9%'5E7/\@?QK4^,MQ);_  TO
MC&2/,EBC;_=+<US^FZO\0G\+6U]H.BZ;#H]O;J+>UGRTTT:CK@$=>2!_.H;U
ML(]$\+>)+3Q7X?M]7LE9(Y<JT;'F-QU4^OU]ZLZYK%KX?T6[U6])%O;)O8*,
MD]@![DD#\:QOA[K>F>(/"D-[IFGP:<AD9)K6! BI(,9Z 9R,<T?$9-,E\ ZK
M%JUS]FM7C $@7<0X8%,#O\P'%.^@SE/^%D^+ETD>(7\&H-!/S[Q/^]$>?O8]
M/?;73:[X]LM,\"1^)[2)KE+D(MK$?E+.W0'TQ@Y^E>7OXF\<M\+5LG\/%=--
MN(/[2V'/D#@'9].,UUTGA:W\2_!S3-/\.7B3M;[)[>5QM$DJD[@?[IY;\:E-
MB-?1?%^NIXJM_#_BG3+2UN+R SVLMHY93CJC9[CVJ]>^*+MO']EX:TN&&4)"
M;C4II 3Y*<;5&#]X^_\ >%<O.VN_VZGC;Q7IT&EV>B6;B*!)A(T\K>GH"<4G
MAC6]*\'Z<^L>*+LIKGB!S>/&L9>18^=@P.@ S^9]*+L#U2BJFF:G9:SI\-_I
MUPEQ:RC*2(>/I[$5;K084444 %%%% "CK4][_P ?!_W1_*H!UJ>]_P"/@_[H
M_E4OXD!7HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M +-Y_K$_W!5:K-Y_K$_W!5:ICL 44450!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %6KO[L'_7.JM6KO[L'_7.I>Z$5:***H84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !0/O#ZT4#[P^M '(?"O_D/^+O\ KYC_
M /0I:].KS'X5_P#(?\7?]?,?_H4M>G5&(_B/^N@GN>8_%3_D/>$?^OF3_P!"
MBKKSU/UKD/BI_P A[PC_ -?,G_H45=>>I^M:K^''^NH^@4445(!7CWQTT#4+
MR+2];L[=[B&R#).BJ6V@G(8CT[$U[#12:N!\Y>-/'4OQ+L-)T'2=%G%TDHD<
M??.[:5PN/X><DGT%>^Z#8/I7A_3M/E<-);6Z1.0<Y('/ZU=2&*(L8XT0L<L5
M4#/UI])*SN)'DFM_\5#\?](L/O0:1 )I!V#@&3]<H*];J,01+,TRQ()6&"X4
M;C^-24)6 \-_: !_M#PY@?PS?SCJO\<P3:^%\ G_ $7^BU[U12<=PL>9_&P9
M^'*=_P#2(OY&L+7;.XN_V;])$$32&%8I7"C)"!G!/ZBO::*.4+'@OAZ^/CGX
M47?@ZQLY%U#3K99E=F&V4B7(4>A(/>N3TW5O#6D>'I].U?PD\WB"%BJ/+E5)
MS_&,@@CT'6OJ1(TB7;&BH,YPHQ2-%&SJ[1H77[K%1D?2ER!8\4NK&2#X&:Q=
M2Z#!H\EW)&X@AWY=0R@,P8D@GGCTKK_@P,?#2QX_Y;R_^A5W]%4HV&>%?"@'
M_A;OB7C^"X[?]-EI='!_X:4U$X_Y:R_^@5[I12Y16/"_$6?^&D-)..DUM_*L
M/Q+HMOX.^)=U>^(-%DU#0KQW>-EX!#<Y!Z;@>QKZ0I&574JRAE/!!&11RA8\
M*\!2:?K_ (\CET3P;;6^EVL@E6\D+^9%M&1SG:6)Z#%9\EU>?"?XIWU_=V$M
MQIUZ9-C)QO1FW94],@]J^A$18T"HJJHZ!1@4.B2+M=59<YPPR*.4+'S1K^OW
M7BOXEZ)K,FGS6=K+)%':+*.7C5S\WOR3_D5TOQ'!_P"%Z^'3@X\ZT[?]-17N
ME%'*%CYY^)[-:_%B*X\2VMU<Z"!&8HXV(#1[1N"GIG=G(^GK6'=ZAIDOQ%T#
M5-.T1]'T87-NT.^/;YBK(-TA['OTSTKZ@>..5=LB*Z]<,,BG=J.4+'@7Q/N9
M/#_Q@TO79[:22UC2&5=O ?:3D ],_P"(J'XE6L^N2:)X]MM,DGTR>&,W,#<[
M-K?=<CL1QFOH%XTE&)$5P#D!AG%.H<0L?-HU+P[KNM6-AX4\"13M+Q,MT7.T
MG'(*MPHYY-?1UO$(+:&$*%6-%0*O08&,#VI4BCCR8XT3<<G:,9-/IQC8#R6R
M_P"*A_:$N[CAX-&M=BGMN Q_Z$Y_*O6JC6&&.1I$BC5W^\RJ 3]3WJ2A*PSQ
M/XR:!J-IXBT[QA86[3PVZHLX49V%&R"?8YQGVKG_ !-K]Y\8=?T?3])TJ: 0
M ^:['<$W$;F) X48KZ,IJ1QQ B-%0$Y(48YI.(K'D?Q(\4ZIX<\16=MJ.C6N
MH^&6"D>9"&9N,,N\YPW?Z5S&@6,OQ$^)=GJUAI T_0=/>-L!0%4)\P7(&"S'
MJ!T!KZ#=$D0I(BNIZJPR#2JJHH50%4#  X H<=0L+1115C"BBB@"S9_ZQ_\
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M7X=TJZAGN#<!;2-HL8#*%!)SVRU4_$'PKTSQ!XBGUR35=3M;J954BVD50 %
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MH*,8M:W=W?6R6G9"A#E84445Y!H%%%% !1110 ^'_7)_O"EG_P"/B3ZTD/\
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MB@ HHHH **** "BBB@"S>?ZQ/]P56JS>?ZQ/]P56J8[ %%%%4 4444 %%%%
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M !1110 4444 %%%% !0/O#ZT4#K0!R'PK_Y#_B[_ *^8_P#T*6O3J\Q^%?\
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M_P#"9:]_T(NL?]\/_P#&Z/\ A,M>_P"A%UC_ +X?_P"-UZE11[:/\H7/+?\
MA,M>_P"A%UC_ +X?_P"-T?\ "9:]_P!"+K'_ 'P__P ;KU*BCVT?Y0N>6_\
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M_P#"9:]_T(NL?]\/_P#&Z/\ A,M>_P"A%UC_ +X?_P"-UZE11[:/\H7/+?\
MA,M>_P"A%UC_ +X?_P"-T?\ "9:]_P!"+K'_ 'P__P ;KU*BCVT?Y0N>6_\
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MA%UC_OA__C='_"9:]_T(NL?]\/\ _&Z]2HH]M'^4+GEO_"9:]_T(NL?]\/\
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M?]"+K'_?#_\ QNC_ (3+7O\ H1=8_P"^'_\ C=>I44>VC_*%SRW_ (3+7O\
MH1=8_P"^'_\ C='_  F6O?\ 0BZQ_P!\/_\ &Z]2HH]M'^4+GEO_  F6O?\
M0BZQ_P!\/_\ &Z/^$RU[_H1=8_[X?_XW7J5%'MH_RA<\M_X3+7O^A%UC_OE_
M_C=2R^.->E$8_P"$#U@;5Q]U_P#XW7IM%'M8_P H7/+?^$RU[_H1=8_[X?\
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7&MQ$R9YD) ) SC(KTFBBLZD^>7,(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gizttcucplmb000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000008.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MHHKQO]I_]J+PO^RCX)TWQ/XLL]2O+"_U!=-B33(T=Q(T4D@)#,ORXB;H>XH
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M0&G6'[6'A/4/VF[[X'166J#Q79VGVR2Z:)!:%/)27 ;?NSAQ_#ZT >W4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSZQ\*]6>33O%/AX#3;:ZNHV +1$363MD?=('E,1SA"?:@#Z'_P""=_PG\/\
MPU_9+\!2:79P?;-?TV+6=1O-JF2XFG4/AVQR$5E0#L$^IKKOAW^R#\-/A3\9
M-?\ B;X9TJXTSQ-K:RQW(AN66U"R,C2*L"X4!G16Y!YY%?#'P)_;U\2?L8^
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M/$7P;TOXQZ3XKT35'U%(=2MO EOI<1EEM)7!3'RCJC!MOF;MN?FW\5QGP-^
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M +67[2'Q4^'/[$&B?$!](_X0#XB2WMI;:CIUU##<K"Q9U?:I+KM?:'7)) 8
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MMC<K_P %F/%%R;>46YT' FV'9_QXP#&<8ZT ?HU1110 4444 %%%% !1110
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MT266RFM[AV57&Y3E(RO(.>M<M_P\>_9O_P"BI:=_X"77_P :KX0_:N\8> _
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M0/+_ /@IA\8M5^#?[)_B&[T.>2TU?6IX=%ANH_O0K,6,K Y&#Y:.H(Z%@?H
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MC3\3?$7B'_@E;I>M>"/ ^DZ#HFM6DL&KV&ERF"WTFR-Q(K/"I;+;I%52O/\
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MM?'.N?MR?'KX$^/O ^G_ !J^%>@:7X?\57ZV,-UHNH%YHLNBLQ^>0$J) =I
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M]J+]KRVT+X5V _X4YIMN#J^HZIIYWN &)D5L@QLY*HBL2< L1U ^Q_B!\&_
M?Q7%L/&?@W0?%1M<^0VKZ=%<M"#U",ZDJ#@9P>U:O@_P/X=^'NBQ:/X6T'3/
M#FDQ%BECI-I';0JS'+$(@ R223QR30!^5G[1GQ"\&_"W_@K98>*/B"8QX1L-
M.7[:9K-KM?GTN:./,05BW[QT[''7C%?1T/\ P4+_ &/+6XCF@N+"&:-@Z21^
M$IE96'((/D<'..E?4GBSX!_#'Q]K4FL>)_AQX3\1ZM*JI)J&K:':W4[JHPJF
M22,L0!TYK(/[)_P0[?!OX?\ _A+V/_QJ@#X9_P""G'Q&U']H#QC\'O@1X#F2
MY?Q2\&M3LR,,+,-MLSCJJ+&9I7!&<!3VJ#XA?L!_M5>+/A-+X*U?XQ>'==\*
MV=K&+?0%MV12+=088T(MP5(V*!R/?C-?HI:_"/P-8^*K;Q/;>"_#]OXEM85M
MX-9BTJ!;R*)8_+6-)@F]5"?)M!QMXZ5UU 'PQ_P24^-T_C_X 77@75@T6O>!
M;LV)CDR'-I(6>(L,<%6$D>/2-?6NW_X*F?\ )C?Q#_W]-_\ 3A;U]#>&?A9X
M,\$ZUJ6K^'/"&@Z#JNJ,6O[_ $O38;:>[)8L3*Z*&<EB3\Q/))K2\5>$=#\<
MZ'<:+XDT;3O$.C7.TS:=JMHES;R[6#+NC<%3AE##(X(!H _/3]D/]BOP!\8?
M^">?V-M)M[?Q/XRBFNI->E7?/#=03R);,C8RL:[!E5ZAWS]ZI/\ @F#^T=JW
MAO5M9_9O^)$ILO$_AF::+1EN>&:.-CYMJ&_B*'+IZH3CA17Z%>&?"VC>"]$M
MM&\/Z18:#H]J"(-/TRV2WMX@6+$)&@"KDDG@=236#-\%_A_<^-AXQE\"^&IO
M%PE68:^^D6YOQ(JA%?[1L\S<% 4'=P !0!\!?L!_\GH?M;?]?]Y_Z7W%:'_!
M%B-/^%>_%1PH#G7X06QR0(3@$^V3^9K[X\/_  P\'>$]:U;6-$\):'HVK:PS
M-J5_I^FPP7%Z68LQFD10TA+$GYB<DDT_P5\-?"/PUM[JW\(^%=$\+6]W)YUQ
M%HNG0V:S.!C<XC50S8[GF@#\^/V+M ?Q%^TI^V?HEHRV\NH336D; 8"M)->*
M#^;5\]_L@Q_#?P7X-\9>&OBI\8/B#\(/%GA[4)FFT+2==FTV"X4( 3'&JG=-
MN4J1U(V8XK]C/#OPY\)^$=:U;6-"\+Z-HNKZN_F:C?Z?I\,$]ZV2=TTB*&D.
M68Y8GDD]ZPO'/[/_ ,,_B=K$>K>+? 'AKQ+JB((UO=4TJ"XFV#HI=E)*C)X/
M'- 'QE^R=X$^'\G[(/QR\2_"O3/&\=IXFT:^M7C\5M'+)=W$5G-AK?RQ\X+3
ME2W.6! Y!K#_ ."-/Q7\*6_PAUWX=2:O&GC.XUR\U>+2_+<NUJ+:T0R[L;<;
ME(P3GCI7Z06&GVNDV,%G96T-G9P((XK>WC"1QJ!@*J@8 'H*X_PS\"_AUX+\
M577B;0/ WAW1O$-T'$VJ6.F0PW#ASEP9%4-\QZ\\]Z /S7_8=\$ZC\2/V<?V
MN_#&D!FU75+FXMK5%."\IBGVI]&.%_&NE_8;_;J^&/P#_93F\(>.+Z30?&/A
M.6]5M#FLY%FO6:5Y$5,+C>6;8P8@@J2<"OT9\'_#?PG\/?MX\*^%]%\-"_E\
M^[_L?3XK3[1(,_/)Y:C>W)Y.3R:P/%'[/'PO\<>)!XA\0_#OPQK>N@J?[1O]
M)@FG8J?E+.RDG';/2@#F_P!DWX^:K^TG\(K3QQJ?@FX\#QW<SQVEI<78N?M,
M2X'GHVQ#L+;@,KSM)Y&">7_X* ? 74?VB/V9?$/AS1$$OB"RDCU;383_ ,MI
M8228A[O&TBCMN*U]%PPQV\*11(L4: *J*N%4#H /2I* /S<_9+_X*6?#'X8_
M G0/ WQ.EU7PIXL\)6:Z5):2:7/)YZQ K&%V*2KA%4,)-O/K7I/[$/[4OQ6_
M:J^+'CK7IM,MM.^"]J[)I+75J$NS+N 2-9 </A0S/P=I*@'FOICQM^SW\,/B
M1K2ZOXK^'GACQ'JJH$^W:II,%Q,5!X4NR$D#)P"<<GUKL]+T>R\.Z3!IVDV-
MKIUA:Q"*WL[2%8H8D X144 *H]!0!^4?[:7B#5_V)?VNO%WC?0+%X]%^)WA6
M\MP\!"+'?M'L:08YW+*L,AZ$^<QSGBOLO_@F_P#!E?@U^R?X2@GM#:ZQKR?V
M]?[TVN7G"F,-W!6$1+@],&OG'XL?!G]H3]N/XU>"=-^(OP]LOA[\,O#-])<7
M$IO8IS=KO7?C#%F:1$55 7:NYB2:_2N.-8D5$ 55& H& /:@#\H?^"3'C?P]
M:_#[XE_"C4=672_''B&\FCL=+GCD65\6;J[=,#84;.2#P/45?_X)W_M.>"OV
M1_"OCCX2_&&>3P'XDTO69KX27EG*5N%,<:,F45B7!BRO9E9=N:_1C3?@;\/-
M'\<2^,K'P-X=L_%LC,[ZW!ID*799P5=O-"[MS D$YR03GK2^/O@?\//BI=6U
MUXR\#^'_ !3=6R[89]7TV&YDC4D':K.I(!P.,XXH ^#/V"[:Y^.7[<?QB^/&
MBV5U9> KJ&;3K&YF@,0O9'D@QQZA8"[#G!=<\U@?\$V_BMX6^&W[3G[0'A/Q
M-JBZ1XA\3^)8;?2;&>)]UU)'<W^]!A<*1YJ?>QG-?IUH7A_3/"VCVFDZ-I]K
MI&EV<8BMK&Q@6&"% .%1% 50/0#%<O=? WX=WWCJ+QI<>!O#L_BV)UE37)-,
MA:[61>%<2E=VX#HV<CB@#\W_ ()_$+2/V'/V]/C-9?%AFT'1_&5S->:7KTEM
M)+$T<ET\\9W*I(5ED*L0,!DYQC-:;>,K/]M'_@IMX$\4_#6";4?!W@.QB74?
M$(MVBBD\N2>3.YL$JS2K&H(R<.P&W)K]'O'GPO\ "'Q1TV+3_&/A?1_%-E$_
MF10:O91W*QOC&Y0ZG:<=QBI_!?P_\,_#?14TCPGX?TSPWI2L6%GI5I';Q;CR
M6VH ,GUZF@#\U?V_-:O/VW/V@-"^ /PRL--U/4?# N+_ %7Q!,.+:41X: 2@
M'$:Y16 SF1D!QLKU_P#X);_M 6FN?#NX^"VN:6OAKQWX$WV\NGFW6W-S )"#
M)MX/FJ^1)D9)*L<ECC[!\(?"KP5\/]0U"^\+>#]!\-7NHG-[<Z1ID%K)<D$L
M#(T:@ORS'YL\DGO38/A)X&M?&TGC&'P9X?B\7R$E_$$>E0+?L2FPDW&SS#E/
ME^]TXZ4 ?F_^R%X'O_B8_P"W)X2TITCU/6[O4-/M6D;:OFRO?(@8]E+$9]C3
MO^"?'[97PY_9M_9_\1^ _B5J+>%/%?AW4[N<Z;<64OG708*=@VH09 ZLF"1@
M;>P)K])_"_PX\*>"+_5+WP[X7T70+W59?/U"YTO3X;:2\DRS;Y6109&RS'+9
M/S'UK!\9?L^_#'XB:\FM^*/A]X9\0ZP@"B^U+2H)YL+]T%F4D@=@: /E?Q?^
MT9J7[47_  3I^+?C6]\%3>"K233+JVLXIKP7(NXU"YF0^6F$R2O(ZJV#@9/&
MZ/;377_!%F5(8GE<>'II"J*2=JZ@S,V!V"@D^PK]!]4\*Z-K?AZ;0=1TBQO]
M"GB^SRZ9=6R2VTD6,>6T3 J5P/ND8XJ/0_"&A>&?#L7A_1M%T[2="AC:*/2[
M&TCAM41B2RK$JA0I+,2 ,<F@#XK_ ."9'C;P/\4?V,],^$YU.*_UNQT_4H-<
MTD1ON@M[J]NBI)(VG<D@Z$]>:^"&A\=>9'^Q9<F=!'\0@ZWL3$;K8@J1M'6/
M&+D;B>HSC:*_77QA\/+#]GGP'XB\2?!'X0>';WQG+Y*_V7IEO!ISWR&90ZM*
M .$5F?:3_#QS7SG^R+^S5\3_ !-^U)XL_:%^-GAVS\-:U/&]OHNBQS1RM 61
M8_-&TM@+"#&"S;F+N2!Q0!]T>&?#FG^#_#FEZ%I5NMKIFF6T=G:P*.(XHU"J
MH^@ KSW]J+X,6?[0'P%\8>"+J/?+J%DSV3YP8[N,B2!\^TBKGU!([UZM2$9H
M _%G]CX>*_VMOCE\&? WB6V9/#?P;T^6:]AN,Y9XIR(E9<8W9%K'M(X6%Z^M
M/^"DC_ W5O$O@'P_\9-#\2:?]N\R+3_&^CX2#3E=L2)(QW!\%4;:8VP#D?Q5
M]F>&_AKX1\&ZQJNJ^'_"NB:'JFK2&;4;[3=.AMY[URS,6F=%!D8LS'+$\L3W
MJYXL\&Z#X\T2?1?$NBZ?X@TB?!EL=4M4N('P<@E'!!(/3CB@#\??!.J:K^SO
M^U1\-O#'P&^.=_\ %[0=?OHTU#1( \]O;6S2QJXE 9XBVSS&\Q K1A,G QG]
M.K/]J;P9>?M'77P3C74_^$SMK3[:[-;+]E\OREEXDW9SM8?P^M=3\/\ X'?#
MSX4W%Q<^#? _A_PO<W*A)KC2=,AMY)%!R%9D4$CD\=*U(_AKX1A\:R>,$\*Z
M*GBZ2/R7U]=.A%^T>T+M-QM\PC: ,;L8 % '35^=/P9MXKK_ (*Z?'*">-)H
M9-!1'CD7*LIM[$$$'J"*_1:N:L?ASX3TOQA>^+++POHMIXJOD\J[UR#3XDO;
MA % 62<+O881!AC_  KZ"@#\._\ @H-\ M9_9;^(&K^%=($D7PL\6:A'XATJ
M$'=%'<1)+&8<]FC%PX'JCIU(X^OOVPOVA_'OP9_9_P#V<=#\+Z[/X+T#Q/H]
MG;ZUXHM;4RSVD:V]L,1M_"VQY'^7YSY?RD8.?T%\;?#7PC\3+&WLO%_A;1/%
M5G;R>=#;ZWIT-Y'')@C>JRJP#8)&1S@FCQ%\-_"GBWPFGA;6O#6DZKX:1(XD
MTB\LHY+5$0 (JQ$;0% &,#C'&* /QE_:LL/A)H?CSX42> OB7XB^*FKKJT$F
MM>(=9U9]1AB7?'Y:>80%5SMD8J#D!1G%?6'[>W_)\W[*'_82_P#;J"OLW_AG
MKX7#PG;^%V^''A.3PU!/]JBTB71;9[5)B"#*(BFT.03\V,\UNZW\-?"/B;6M
M(U?6/"NBZKJVC'=IE_?:=#-/8D$$&"1E+1G*@_*1T% 'P-JG_*:2P_[%\?\
MI U4?&D:S?\ !;'P(KJ&']CN<$=QI5X0?SQ7Z#M\-?",GC1?&#>%=$;Q<L?E
M+KQT^$WX3;MV"XV^9MVDC&[&.*;/\,O!]QXVM_&4OA/0Y?&%NGE0^('TV$W\
M:E&3:MP5\P#8S+@-T8CH: /@#XV?\ICOA-_V!(O_ $7>UPFFZKHG[%/_  5
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M44 %%%% !1110 4444 %%%% !1110 E? '[;6J3_ !F_;-^ 'P*WF/0OM?\
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M/--^(GQ*UGP_=7/BZ73+B^:[749T3SHK;$9V!MO C7C'..:^2/\ @F;^Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7RE^WM^S_ *_\4M!\#>./ FE?VK\1/ &N
M6VJZ9:+(L;740FC:6+<Q"C!1'Y/\! Y-?5M)0!QWB3X=>$?BYHNE-XU\$Z/K
MXC03Q67B+38+PVDCJ-P D5@K#H2OIUKG/^&4/@C_ -$<\ ?^$O8__&J]5HH
MY32?A7X+T'PC=^%-,\'Z#IWA>[$BW.B6FF0Q64X<8</ JA&W#@Y'-:?ACPGH
MG@G1;?1O#NCZ?H&D6^[R=/TNUCMH(LL6.V- %&22>!U-;%% ',7WPS\(:IXR
ML_%UWX4T.[\66:>5;:]/IT+WT" ,-J3E=ZC#N, _Q-ZFI/&'PY\*?$2WLX/%
M7AC1_$\-G+]HMH]8T^&[6&3^^@D4A6QW'-='10 G2N'\:? _X<_$?5DU3Q;\
M/_"_BC4XXEMTO=:T:VNYEC!+! \B%MH+,<9QECZUW-% 'F6F_LQ_!W1=1M;_
M $_X3>![&^M95F@NK;PY9QRQ2*<JZ,(LJ00""#D5T^H?#7PCJWC"R\67OA71
M;SQ58Q^5:ZY<:="]] GS?*DY7>H^=^ W\3>IKIJ* .;\<?#OPO\ $S1QI7B[
MP[I?B;3 XD%IJUG'<Q*XX#!7! 89ZCFE\$_#SPO\-=&_LCPEX=TOPSI>\RFS
MTFT2VB+G&7*H "QP.371T4 <S!\-/"-MXTF\81>%=$B\6S1^5+KR:="+]TVA
M=K3[?,(VJHP6Q@ =JUM;T/3O$NDWFE:QI]KJNEWD30W-C>PK-!/&PPR.C JR
MD=01BM"B@##\+^$] \!:#%I'AO0M/\/Z/;[GBT[2+-+:!"26;;'& H)))X')
M-?-7['7P/\5:1\3/BQ\9?B#H[:#XI\:ZDT5CI4\J33V.FQM^[1V1BH9MJ?*I
M(Q&O/.!]8T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *2EHH ;MIU%% !1110 4444 %%%% !1110
M4444 %%%% !2=\TM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*:&'K2[AZT +12;AZTF[TH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?,?_  4M_P"3'_BC_P!>UG_Z76]?3E?,?_!2W_DQ_P"*
M/_7M9_\ I=;T >[?#'_DFWA/_L$VG_HE*Z:N9^&/_)-O"?\ V";3_P!$I734
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "OGO3_ -ENYLOVS]3^.A\11/;7FA#1AHGV0AU(6,>9YN_I\G3;WZU]"44
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M7PEJ^J7#7>HWNG0SW$[*%+NR@DX  '/H*[?-?*5(NG-P>Z/3B^970M<-\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)2T4 )2TE+0 4E+10 4444 )2TE% "T4FX4M !129I: "BDI: "BBB@ HHH
MH **** "BBB@ HHI,^U "T4E&10 M%)NI: /C_\ ;-_Y.9_9-_[&F]_]$Q5]
M@5\?_MF_\G,_LF_]C3>_^B8J^P* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ;WH^[17B7QUUOX@>"VAU;0_$6F0:7=7]I816-QI;221F5UC+F
M02C(!);&T>GO652?LX\S1VX/"O&5E1C)1;VO?[M$SVVEQ7->!].\1Z?I4B>)
M]8M-;OFE+QSV=D;5%CVKA2I=\G.XYSW'''/2?C5IW5SFJ15.;BG>W5;?C87&
M:\N\#*/^%W?$D8XVZ?\ ^B37J5>7>!_^2W?$G_<T_P#]$FL*WQ0]?T9Y>*_B
M4?\ %_[:SU&BBBND] **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ;368#J0/8T^O&OVDO!5O>^ _$?B>/5-9L-4TO2)Y+?^S]3GMXMR([J
MS1HP5CGN1T&*SG)Q3DCJPM&->M&E.7*F[7M<]C5EQP?RI:\_^$?@&S\(Z'#>
M6^H:M>S:A;0O+_:6HS70!VYRHD8A<DG.,=J] [546VKLBO3A3J.$)72ZVL-?
M.UMN-V.,UXM<>)/BQ;^,;/P\9O"9N;JTEO%D^SW.T*CHI!_>9R3(/R->UD5Y
MUJG_ "7G0?\ L!7G_H^"L:R=DT^IY&,BVHM2:U2T\V=UIGVM;"V%^86O?+7S
MS;@B,OCYMH)SC/3-7::U*:Z#O2LK"T444#"BBB@ HHHH **** /CC_@HGX5U
MOQ/I_@9=&T>_U=H9KLRBQM9)C'E8L%MH.,X/7T-?%'_"I_''_0F^(/\ P5S_
M /Q%?LYQ1BOIL#GD\%05",+I'G5L%&M-S;/QC_X5/XX_Z$WQ!_X*Y_\ XBC_
M (5/XX_Z$WQ!_P""N?\ ^(K]G:2N_P#UGJ_\^E]YA_9T?YCS[X V-SIOP5\%
M6EW;RVMS#I<"20SH4=&"C*LI&0?8BO0,4X8[4#UKXVI-U)RF^IZT5RI(^??&
M_P"QSIOB[XKZ[\0K#XE_$+P;KNLV]O:W2>&]3MH(3'"N$10]L[ 9RV-V,L37
MD'[)_P"SOK?A3]I3XT:CJ?C#X@SZ?8:O:I;MJUR@@\0(]G@RW+"!?/*$X#1E
M0-H!S7W%14%'@?@#]AWX,_"_QAIGBCPWX3DT_7--D,EK<G4;J41L5*GY7D*G
MAB.0>M<I^P/X<U7PWI?QS75M+O=+:\^*VNWELM[;O"9X'6WV2IN W(V#AAP<
M&OJ>B@#Y._:J\-:QK'[5W[*^H6&E7U]I^FZMJ[WMU;6SR16JM! %:5P,("0<
M;B,X-:^F^'=47_@HGK&M-IEXNCM\/8K5=1,#_9VF%Z&,?F8V[]O.W.:^FJ*
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M_@D2/ATVN6:>-X]0?3CH+2#[9O.K-=9\K[V/+;[V,9XZ\5^AGA'PW\5/A_\
MLA?#K0?A_:^''^(&F:%I=I+!XI,XL4VP()E;R2'W @@=.G- '!?MF_\ )S/[
M)O\ V--[_P"B8J^P*_-SXH77Q[N/VI?V9O\ A<UIX!MK0>);C^S3X,-V7+^4
MGF>;Y['C&S&WGK7Z1T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 G<5Y#^TU_R)NB<9_XJ'3/_ $I2O7NXKR']IK_D3-$_[&'3/_2E*PK_ ,-G
MJY5_OU+U1ZY%_JT^@I],B_U:?04^MSRWN%>7>!O^2W?$G_=T_P#]$FO4:\N\
M#?\ );OB3_NZ?_Z)-<U7XH>OZ,\[%?Q*/^+_ -M9ZC11172>@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )7GO[07_)#O'?\ V!KO_P!$
MM7H5>>_M!?\ )#?'?_8&N_\ T2U9S^%G9@O]YI_XE^9U/@W_ )%/1O\ KSB_
M] %;-8W@W_D4]&_Z\XO_ $ 5LU4=D8UOXDO5A7G6J?\ )>M!_P"P%>?^CX*]
M%KSK5/\ DO.@_P#8"O/_ $?!6579>J_,\W%?#'_$OS/1J***W.P**** "BBB
M@ HHHH **** $XHKF/&GQ*\,?#Q+63Q)K5IHZW180&Z<+O*XSCUQD?G7+_\
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MV9_^2#^"/^P;%_*NZ\1?\B_J7_7M)_Z":X3]F<_\6'\$?]@V+^58?\O5Z/\
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MEU.U68*"R;6 Z$5]8? _P'X]\!Z/J=OX_P#B1+\2+^YN1-;W4FDP:?\ 94V
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MV;_R<S^R;_V--[_Z)BK[ H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!.XKR#]IK_D3=$_[&'3/_2E*]?[BO(?VFO^1,T3_L8=,_\ 2E*PK_PV
M>KE7^_4O5'KD7^K3Z"GTR+_5I]!3JW/+>XE>7^!S_P 7M^)/^YI__HDU\_\
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MK#(;C@FO+Q>.I8;]W/=H^_X;X3S'/$L9A.7DA))W=GI9]C](O!O_ "*>C_\
M7G%_Z *V?UK\S[#]N+XFZ;9P6L,VEB&%%C0&S)PH& /O5]]_!OQ1?>-OA=X9
MUW4BC7^H6,<\QC7:NYE!.!V&:K"XVEBFXPZ&'$/"F89!%5\9R\LVTK._GV/E
MO]LABOQ2M "1_P 2V/O_ --)*\'W-_>/YFO=_P!LG_DJEK_V#8__ $9)7@]?
M'X]OZS/U/Y-SN3_M"MKU/7/V5V8_&K1LL2/+G[_],VK[WKX'_97_ .2U:+_U
MSG_]%M7WQ7TF3_P'Z_Y'Z)PFV\#*_P#,_P D%%%%>\?;!1110 4444 %%%%
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M&6Z#XR=D=Y&4N#@# ^60\9.Z@#ZH\.^#M!\'VIMM!T33=#MSR8=.M([=/R0
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M!^>/C[X=^*KOQSX@G@\.:K+#)?SNDB6<A5E+L00=O0BL#_A6?B[_ *%?6/\
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MVBOC)K'PCM]#?2;6SN3?-,)/MBNV-H7&-K#^\:\3_P"&T/&7_0+T;_OW+_\
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MTN^T>\\&VZ6=U;V0L]JVL[R"02_?5BP R8UZ4 >S?MA-_P 8H_&'_L4M4_\
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M\J>O2OT];'](Q^%"T444R@HHHH **** "BBB@!*6BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OGGQ'XY_:"^'?B[599O &A?$KP0]W+)9R
M>&]1-EJ]M;%F*))!/^[FD52J_)(H;;GC.*^@9;B.!<RR+&#T+-BOE>Q\#>*?
MVB]7\676M?'._LO ]KKFH:5;^'_!5O\ V3,GV:YDB,<]XX,TA&P ^7M4D$@E
M2* .S\'?MK_"SQ1XC7PWJFK7G@/Q2W T/QI9/I5R3DC"F7]VYR.-KG/:O=HI
MDFC62-U=&&593D$>U?-N@_"']G'X8>+-+^&,?A;1;_Q+XJM+F5(]5M&U2YO8
M8@3*9;F8.0HS]UF .>!Q7H7[./P7N/@'\/9/"4GB"7Q!9QZC=75@9(F065K+
M(7CM5R[$K&#@$GOT% 'JE%%% !1110 4444 ?'_[9O\ R<S^R;_V--[_ .B8
MJ^P*^/\ ]LW_ ).9_9-_[&F]_P#1,5?8% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 ?*W_!1#_DD>@_\ 8<B_])[BOSXK]!_^"B'_ "2/0?\
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M?!32?'-M9+IEW))):7^GK)Y@MKF,C>H;'((*L,C.&%<5_P %+?\ DR#XH?\
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M!XE^)WBSXB^-]=\57$]G;Z]J'AJP\(1HB6VE16ER8P[X^9YY F\LQX$@ XH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^5O^"B'_ "2/0?\
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MB4KIJ "BBB@ HHHH **** "BBB@ HHHH **** /R_P#V]/\ DXO5/^O*U_\
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M?^N2_P#H(K\6J_:73/\ D&VO_7)?_017=D?_ "\^7ZGR/BY_S!?]O_\ MI\
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MJYKU[M75BFY35^T?_2494]$[=W^9XQ^V'_R;QXL_W(?_ $<E?EO7ZD?MA_\
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M3Z4 25\Q_P#!2W_DQ_XH_P#7M9_^EUO7TW7S)_P4M_Y,?^*/_7M9_P#I=;T
M>[?#'_DFWA/_ +!-I_Z)2NFKF?AC_P DV\)_]@FT_P#1*5TU !1110 4444
M%%%% !1110 4444 %%%% 'Y?_MZ?\G%ZI_UY6O\ Z+%?.]?1'[>G_)Q>J?\
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M_P"/ZY_ZZ-_.H*_&)?$S_12A_"CZ(^]_^"=/_(@^*/\ L)C_ -%)79?MK?\
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MH_E3UZ5^GK8_I&/PH6BBBF4%%%% !1110 4444 %%%% !1110 4444 %%%%
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M)^S7_P D(\$?]@N'_P! %:9'_%GZ'-XL?[AAO\;_ "/G#]LG_DJEK_V#8_\
MT9)7@]>\?MD_\E4M?^P;'_Z,DKP>O,Q_^\S]3_.;//\ D8UO4];_ &5_^2U:
M+_USG_\ 1;5][=A7P3^RO_R6K1?^N<__ *+:OO;L*^ER?^ _7_(_1N$O]PE_
MB?Y(=1117O'VP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 1RHDD;JX#(P(8-TQCFO@3QU9_ 3X3:Q>6WP>^)'B?PKXW9F=/#?PRF
MEUJ&:4$C$E@?,@"AL#EHL8 W+7T1\?OVB+_P#XIT3X>^"?"$_C[XC:];27<.
MDK,+>VM;-24>YN9CPB;OE'J>,CC/6V_P]LO@[\--7M_A3X(T'3M92T9[+2X4
M2T@N+@+\BS2*,D9QECS0!\Y_"WXZ?M/>%_!NJ^(?B#\*T\2^%]/3SH[E)8-*
MU^6W50SS-9"66,E5W'9OC;C@&OK#X;^/](^*?@/0?%^@RR3:-K-I'>6KR+M?
M8XSAAV8'@CU!KS?X _'^/XX1^)_"WB?PQ-X0\>>'G%KKWAB^83*J2@^7)')C
M$L,BYPP'Z8)]?T71-/\ #>E6FEZ386VFZ;:1B*WL[.)8H84'1510  /0"@"_
M2&EHH KK9P+=-<+#&+AAAI0@#$>A/X#\J@U#0].U=HFOK"UO6A;=$;B%7V'U
M7(X/TJ_10 U5VC & .!7S+_P4M_Y,?\ BC_U[6?_ *76]?3E?,?_  4M_P"3
M'_BC_P!>UG_Z76] 'NWPQ_Y)MX3_ .P3:?\ HE*Z:N9^&/\ R3;PG_V";3_T
M2E=-0 4444 %%%% !1110 4444 %%%% !1110!^7_P"WI_R<7JG_ %Y6O_HL
M5\[U]$?MZ?\ )Q>J?]>5K_Z+%?.]?LF6?[E2_P */DL1_%EZGT?^P'_R<):_
M]@VZ_DM?H-\8O^24>+O^P3=?^BFK\^?V _\ DX2U_P"P;=?R6OT&^,7_ "2C
MQ=_V";K_ -%-7Y_Q-_O3_P *_4^HR/XZ7^)?FC\@J***_!GN?Z*P^%'Z=_L3
M_P#)N/AK_KI=_P#I5+7!_MQ?\?WA#_KG=?SBKO/V)_\ DW'PU_UTN_\ TJEK
M@_VXO^/[PA_USNOYQ5]KB/\ D6+T7Z'^=/B/_&S#_KY+_P!+/EVNL^$O_)4/
M"7_85MO_ $:M<G76?"7_ )*AX2_["MM_Z-6OE*'\:/J?SU@?]YI>J_,_29?N
MCZ4M(OW1]*6OTL_HI;!1110,**** "BBB@ HHHH **** "BBB@ HHHH _/\
M_P""E7_([>#/^P?-_P"C!7QO7V1_P4J_Y';P9_V#YO\ T8*^-Z_7,D_W"G\_
MS/EL9_'D>G_LP_\ )P7@/_L*1?UK]=)O]0_^Z?Y5^1?[,/\ R<%X#_["D7]:
M_72;_4/_ +I_E7R7$W^\Q]/U/5RWX'ZGXMZA_P ?US_UT;^=05/J'_']<_\
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M "52U_[!L?\ Z,DKP>O,Q_\ O,_4_P YL\_Y&-;U/6_V5_\ DM6B_P#7.?\
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M#FEH **** /S_P#^"E7_ ".W@S_L'S?^C!7QO7V1_P %*O\ D=O!G_8/F_\
M1@KXWK]<R3_<*?S_ #/EL9_'D>G_ +,/_)P7@/\ ["D7]:_72;_4/_NG^5?D
M7^S#_P G!> _^PI%_6OUTF_U#_[I_E7R7$W^\Q]/U/5RWX'ZGXMZA_Q_7/\
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MB@ HHHH **** /C_ /;-_P"3F?V3?^QIO?\ T3%7V!7Q_P#MF_\ )S/[)O\
MV--[_P"B8J^P* "BBB@ HHHH **** "BBB@ HHHH **** &=C]*_$GQ!_P A
M[4O^OF3_ -#-?MMZ_2OQ)\0?\A[4O^OF3_T,U]OPQ\57T7ZGC9CM'YE"OT)_
MX)L_\DU\5_\ 87'_ *)2OSVK]"O^";/_ "37Q7_V%Q_Z)2O;X@2^HR]4<>!_
MC(U?^"B'_)(]!_[#D7_I/<5^?%?H/_P40_Y)'H/_ &'(O_2>XK\^*_G3.?\
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MBS_<A_\ 1R5^6]?J1^V'_P F\>+/]R'_ -')7Y;U_-^=_P >/I^K/[/\*?\
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M82JZ-2W,M[-/\4!KPOQYX+U.S\?>&K2#QIXCAM]>OKD311W:A85$3RA8_DX
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M^9/_ $,U^VWK]*_$GQ!_R'M2_P"OF3_T,U]OPO\ %5]%^IXV9;1^90K]"O\
M@FS_ ,DU\5_]A<?^B4K\]:_0K_@FS_R37Q7_ -A<?^B4KW.(/]QEZHX\#_&1
MJ_\ !1#_ ))'H/\ V'(O_2>XK\^*_0?_ (*(?\DCT'_L.1?^D]Q7Y\5_.><_
M[S\D?VWX8?\ (B_[?E^@5^TNF?\ (-M?^N2_^@BOQ:K]I=,_Y!MK_P!<E_\
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M:+_USG_]%M7WMV%?2Y/_  'Z_P"1^C<)?[A+_$_R0ZBBBO>/M@HHHH ****
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M!7Z3>#;^?5O">C7MRWF7%Q9PRR-@#+,BDG ]S7XUU^QOPZ_Y$/P]G_H'V_\
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M^EGR[76?"7_DJ'A+_L*VW_HU:Y.NL^$O_)4/"7_85MO_ $:M?*4/XT?4_GK
M_P"\TO5?F?I,OW1]*6D7[H^E+7Z6?T4MAO2OG#XP?MK>'O@[X_U#PI?^'M3O
M[FS6)FN+9XPC;XU<8#'/ :OI"ORS_;F_Y.4\3?\ 7&S_ /2:.O=R;"4L;B73
MK;6O^1Q8NK*C3YH'IQ_;B\-GXX1^.O\ A'M5^R+H#Z/]DW1[R[7"2[\[L8PA
M'XU[U\$OVQ]!^.'C8>&M.T'4=.N#;27/G73QE,(5R.">?F%?EY7TI_P3\_Y.
M!7_L%7/\TKZO,<GPE+#3JQ6L5IJ>9A\55E447U/OKXW:A<Z7\(?&5Y9W$MI=
MPZ3=217$+E'C81,0RL.00>X]*_+>3XP>/9HVCD\;^(W1A@JVK7!!!Z\;^]?J
M#\?B?^%*>./^P/=_^B6K\D*_#,ZJ3A*'*[:']5^%N#PV*P^)E7IQDU)6ND[:
M=+G3Z?\ %/QKI-C!96/C#7[.SA4)%;V^ISQQQJ!C"J&P!7Z/_L?ZYJ/B+X!>
M'K[5;^ZU2^DDN@]U>3--(V+B0#+,23@ #V K\N:_3K]B?_DW'PU_UTN__2F6
ML<GJ3G7:E)M6_P CU/$_ X;#Y33JT:48R=17:23?NR//_P!N#_D+>$_^N-Q_
MZ%'7S%7T[^W!_P A;PG_ -<;C_T*.OF*N+,O]ZG_ %T/\[N(O^1G5^7Y([?X
M(_\ )6_"G_7_ !_SK]&D^Z*_.7X(_P#)6_"G_7_'_.OT:3[HKW<E_@R]3[7@
M_P#W2I_B_1#J***^A/OC\_\ _@I5_P CMX,_[!\W_HP5\;U]D?\ !2K_ )';
MP9_V#YO_ $8*^-Z_7,D_W"G\_P SY;&?QY'I_P"S#_R<%X#_ .PI%_6OUTF_
MU#_[I_E7Y%_LP_\ )P7@/_L*1?UK]=)O]0_^Z?Y5\EQ-_O,?3]3U<M^!^I^+
M>H?\?US_ -=&_G4%3ZA_Q_7/_71OYU!7\^R^)G^D%#^%'T1][_\ !.G_ )$'
MQ1_V$Q_Z*2NR_;6_Y)WI'_853_T3+7&_\$Z?^1!\4?\ 83'_ **2NR_;6_Y)
MWI'_ &%4_P#1,M?:+_D6?+]3^#/$_P#W_,/7]$?&=6-/_P"/ZV_ZZ+_.J]6-
M/_X_K;_KHO\ .OCH_$C^4Z7QQ]4?J/!_J8_]T?RIZ]*9!_J8_P#='\J>O2OT
M];'](Q^%"T444R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#\L_\ @IY^VA+;_$9?@=9ZAJ.A
M^%8EA;Q;J>BHDM]/'*BR?9HE9T4#RV4MN8;MX!X!#>H?LW?%#X1?M+?LY_$;
MX&?!'PUKWA6&T\-W$"/XAMX$66:YC>-97>.>0NY?!9B![>@^_** /Q<A^-#0
M_L*G]E)_#FNCXRIK1TP>'Q8ON\MK\WGF;@,8^;;^(;[O-?IMI/P$U/\ X9G\
M$_#2'QEK?@[4M%TG3K*;6_#LHANM\$*(X5B" K,#D8/%>S?98?M'G^3'YV-O
MF;1NQZ9]*FH _.;XN_ W5OA#^U)^S)-J?Q0\8_$);[Q+<(D7BB[29;79%&2T
M>U%P6W#/^Z*_1JOC_P#;-_Y.9_9-_P"QIO?_ $3%7V!0 4444 %%%% !1110
M WBL;Q-XHL_">GK>WJ74D1D$>+2UDN'R<_PHI..#SBMGZ4DF-K9':I=[:$2Y
MN5\NYP_A;XQ^'?&6J1V&EG4997=X]\FG3QQJZ EE9V0*IXZ$]>*[D-D9KR_X
M"_\ (+\4_P#8Q7__ *,%>H5E0E*4%*9RX.=2I14ZCU?;3]6.HHHK<[1GK]*_
M$GQ!_P A[4O^OF3_ -#-?MMZ_2OQ)\0?\A[4O^OF3_T,U]OPO\57T7ZGC9EM
M'YE"OT*_X)L_\DU\5_\ 87'_ *)2OSUK]"O^";/_ "37Q7_V%Q_Z)2O<X@_W
M&7JCCP/\9&K_ ,%$/^21Z#_V'(O_ $GN*_/BOT'_ ."B'_)(]!_[#D7_ *3W
M%?GQ7\YYS_O/R1_;?AA_R(O^WY?H%?M+IG_(-M?^N2_^@BOQ:K]I=,_Y!MK_
M -<E_P#017=D?_+SY?J?(^+G_,%_V_\ ^VGP#^T=_P EK\4_]=H__1*5YK7I
M7[1W_):_%/\ UVC_ /1*5YK7@XK^//U?YG^>.9?[[6_Q/\SZ+_8I_P"1VUW_
M *\%_P#1@K['/2OCC]BG_D=M=_Z\%_\ 1@K[';I7V65?[K'YGZWPQ_R+8>K_
M #%HHHKUSZL**** "BBB@ HHHH **** "BBB@ HHHH 2OR%_::_Y. \>_P#8
M5F_G7Z]5^0O[37_)P'CW_L*S?SK[#AG_ 'F?I^J/)S'X$>95]B?\$U_^1]\7
M_P#8-C_]&U\=U]B?\$U_^1]\7_\ 8-C_ /1M?69U_N%3Y?F>9@_XT3Z<_;#_
M .3>/%G^Y#_Z.2ORWK]2/VP_^3>/%G^Y#_Z.2ORWK^;\[_CQ]/U9_9_A3_R*
M:W_7Q_\ I,0K]9/V:_\ DA'@C_L%P_\ H K\FZ_63]FO_DA'@C_L%P_^@"M,
MC_BS]#F\6/\ <,-_C?Y'SA^V3_R52U_[!L?_ *,DKP>O>/VR?^2J6O\ V#8_
M_1DE>#UYF/\ ]YGZG^<V>?\ (QK>IZW^RO\ \EJT7_KG/_Z+:OO;L*^"?V5_
M^2U:+_USG_\ 1;5][=A7TN3_ ,!^O^1^C<)?[A+_ !/\D.HHHKWC[8**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBOA?XB?ME_%_P ;?&CXA>#/@)X3\-:[I_P\B\S7-2UZ65C<S+NWV\"Q
MR+AMR2(,YR8VY'&0#[HKYC_X*6_\F/\ Q1_Z]K/_ -+K>NW_ &2_VB[+]J/X
M*:3XYM;(:7=2R26E_IXD\P6US&0'4-CD$%6&0#AQ7$?\%+?^3'_BC_U[6?\
MZ76] 'NWPS_Y)KX3_P"P3:?^B4K\E/CI_P EN^(/_8PZC_Z4R5^M?PS_ .2:
M^$_^P3:?^B4K\E/CI_R6[X@_]C#J/_I3)7V/#/\ O$_3]3R,Q^&)Q%?<?_!,
MG[WQ(_[AO_MU7PY7W'_P3)^]\2/^X;_[=5]/GW_(OG\OS1YV"_CQ_KH>S_MQ
M?\F]:U_U\6O_ */2OS-K],OVXO\ DWK6O^OBU_\ 1Z5^9M?SCG7^\+T_S/[7
M\+/^1+/_ *^/\D%?L;\.O^1#\._]@^W_ /1:U^.5?L;\.O\ D0_#O_8/M_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&U]9G7^X5/E^9YF#_C1/IS]L/_DWCQ9_N0_^CDK\MZ_4C]L/_DWGQ9_N0_\
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MP!3L2ZU/>Q&>!\R_F*_2&OECXW?\$]_!'QD^(FI>-+7Q-XJ\"ZSK,'V76O\
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MQQ7WA.991LB5#D*6&,KZU^P.*3\:[,)C*N"J>TH[[&52E&JN61^&7]F^/O\
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M!ZZW]J;]I3X6>+OB):WNB^/-#U.T73XXVFM;M73<'<D9'?D?G7CO_"[/ ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q=X5T[QQX5U
MGP[J\/VG2M7LYK&[AS@O#*A1USV^5CR*V:* /S4_X=\_'J/X=M\"8_'OA?\
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M]0T'5YKS2H=#MDM;F1(I"CR1"/:[*1D%@<8KZI_X93^"G_1'_ /_ (3%C_\
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MFR/+/^&5/@I_T1[P#_X3%E_\:H_X94^"G_1'O /_ (3%E_\ &J]3HH&>6?\
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M9,C:ZY^8J<E<*J@'TM^RO\3O'?QB^%L?BSQYX1A\%W.HW4LVF:>DS/*;!FS
M\JLH*/M./]K ;"YVCV2OSH_9A_:>\7?LL_$6#]GK]H68PI&1#X8\83L?L]S!
MG9&CR-C,9QA7/*GY6QV_18,&Y'2@!:*** "BBB@ HHHH **** "BBD)H ,U\
M??M+_MF>)=)\?1_"+X">'8/B!\6'3SKP.RFRTJ)<%A,Q=%WD<89U"EESDD*?
MJWQ#I+^(/#^HZ=%J%UI;WEM) E_8L%GMRRE1)&2" RYR"0>1TK\EM'^(WCW_
M ()4^+O'GA?7/"-CXPB\7.UWH'C*0^2UW,#@"YF(RRIO+/&3E6)(;:^X 'V/
M^Q)^UEXT^-'B'QK\._BGX9@\-?$KP>ZM>I9 B"6)C@?+N8!E..5<JP92*^MZ
M_+?PA^R?^V;\/;W6?B1X0^(/A"]\5^, FH:S%B*6:X8 M'$LDML8]N&QA'51
MQ@D#-?;O[+.J?&_6/ ]Q<_''3?#VCZ[YYCM+31 QD\I1@O.1(\>YCD@(<8QG
M!X ![71110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 133);Q/+*ZQQ(I9G<X"@<DG/05Y;\%_VEO WQ_UCQ?8^"[ZXU1/#
M-ZME=7HMG6UG8KG=!+C;(,AEX.?ESC:RD_.G[8"_'#]I#QUJ_P $/ASI5UX-
M\)6^G_:=;\9:@KQ0:AOC)CM877JC,-K@<\-G"C#\W_P3G_:&T[X?PC]F_P >
M^'K?X??$+0)7BMHF411ZN3EB^<_-.1@YR1(,%?2@#]!J*04M !1110 4444
M%%%% !1110 4F12U\G?M(?M)_$FQ^-FC_!;X):%HNJ^.;G2CK>I:AXA=EM-/
MM=^Q>%8$L3CUQN7@YX /K#-+7PK\"?\ @H!XETWXR'X-_M#^&K3P+XX>18K'
M5+/*6%ZSMB,?,[8W]%=6*L01\IXK[IH 6BBB@ HHHH **** "BBB@ HHI#0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQPUO0]8UHW>VQ_L2 *JP!>6=P%W%F/ V @+SG/ !^9W[*-U\=?!_P.O/B/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*^*WPW^ (M]6\6ZKI?A:3Q%J$-F+B1%26\G8!$9]HW$*N,NW"*.2!0!\^_\
M!,'X@?"G7O@+:>'O -E_8?B+2PK>(],O) ]])=GY6N7; +JY7@@ *!MP,8K[
M*KX%_:X_9!\3>"O'"?M!?L\EM-\<6+?:M6T&Q4>3JL6,NR1CAV8?>C_CSD?.
M.?M'X7Z]X@\3_#SP]JWBO0?^$8\1WEG'-?Z/YPF^RRE<LFX=?Z=#R* .4\ ?
MLT?#[X8_%3Q1\0?#>AC2_$7B2)8[YH)66 X;<S+%G:&=L%CCDJ,8R<^JT44
M%%%% !1110 4444 %)2UY_X=^/'PY\8>,-7\)Z1XTT34/$>ES?9[S2X[Q//1
M]H) 4GY\ X.W(!!!P010!\T?M%_M/>,/BE\2G^ _[/4ZS>+<X\2>+D :VT"
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M?Q9JFK^%=4O_ +7I>A7@4PZ4A!W*C8W,S$\G(!"KD9R3[[110 4444 %%%%
M!1110 44QV"J68@ #))X%?#'Q2_:X^*7QN^)VI_#S]ENPT[4SX?#-KGC'4T#
M6*2AMHMX68;"<Y^;!W8.WA2Q (/VT?VI/'WBS6_$7P3_ &?=&U#7/&=E9//X
MCUBP0@Z7#@'RH6)'[YP<9Z_-A<MRM_\ X)6^.OA;J7P5;PQX2L#H7CS3CO\
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M]FWQS;^(-9_9W^-?@M?B9\)K&V>[\.^-YCL;3XC\J1))D.K'!&Q6W(0>L>*
M+W[+GP/\4_#'XO>'O&WP&URSU?\ 9V\>P'4-3T;4;PG^RGV<K&!D^:K_ "#
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M,D/ASQKJO@O3M3O6MXKNQN=<TA!>VZL Z*PD7<C*3G:>AS0!P'[ MCXLT_\
M9#^&MOXT$R:VFGMM2X_UBVIFD-JK>X@\KKR.,\YKZ#I!T'&*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%51P  !P*?96<.GVD%M;0QV]O BQQ0Q*%1% PJJ!P !@<58H **** "BBB@
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MN4Y';=BO!?B/_P $_O WQ;^-4GQ \6^(O%.N6TTT5Q-X5N;]3I4C1)MC4QA
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M&I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD\2P_'SQ+X:\3:7<PI'8VFDVJG)<'S=[>7&-H'R[2I!R<''7Y>^,7P:\8_\
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M=A[]\'?V5_@_\([7P_J'@WP1HEK?V%MMM==2W22]D61 &=K@@LY8'J3P&(&
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MTH 6&%+>)(HT6.- %1$  51T '8"IJ** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDS0 9%?%7_!3
M[X_?%'X%_#'P^_P\MO[/M]8OOLM[XF21"]BPPT<(5N!YN&^<\ (PX)!KI_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BDS7BOCS]L;X+_#OQJ_@WQ)\1=)T?Q"&6*6W>1C]G9N@DD"E(R.#\Y&,C-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH73+[15U:SCNQI^I1&.X@W '8Z]B/UXKIZ (XXUBC5$4(BC"J   /05)110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %,9 P((R#P0:?10 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHI#0!\;?#'53\=/^"A7Q&UB]87.C_"O2X="TBW8 I#>7))N)P/[Y"21Y
M]!BN$_X*.?#C2?B]^T?^S5X,UY96TC6KG5+2X\F0HZAD@PRD=P0"/IZ5T/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gizttcucplmb000025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000025.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MWU%?'_PK_P""@ ^,O[5&K?"'PQX(DO=.TNXNDN_$RZ@OE1PP95I?+V<AI-J
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M32+* 7%SXB^UY"J;4S@+"$RS$@1@!N2PH ^SJ2OS1\7_ /!7_7?"FJ65_=?
MO6M/\&7K'[+J.J7+VTUPF3AD!AV9P,[0Y^M?>_P7^+GA_P".WPST'QQX9F:;
M1]6@\R,2##Q.K%9(W'9D=64]LKQQ0!W%%8_BW4M1T?POJ]_I&FC6-4M;66:U
MTXR^5]JE5"RQ;\':6(QG'>OFK]BW]O'3/VO-5\4:1_PC<GA/6=#2.8V4]UYS
M31LS*S#Y%QM8*"/]H4 ?5M>!?M4?MF>"OV1+?P_/XPTO7M236WF2W&AV\$I4
MQA2V_P V:/&=XQC/0UQW[:G[>.F_L@:IX7TH^&9/%6JZW'+/]EANQ T,:LJJ
MWW&SN8L/^ FO-_\ @H%\;_!/@;P+\+M4^*_P9M?&E_J\,LRZ5=Z@4.E2F.)I
M(]ZKASE@I(X^6@#[/\*?$#2?%GPZT7QNDC:9H>J:7!JZ/J)2)H()8EE!E.XJ
MI"L,_,0,'D]:3X?_ !(\,_%30FUOPGJ\&NZ0MS+:"]M23$TD;;7"MCY@&!&1
MP<<5^=W_  44^/T=C^QGX!\':%X)N+#0/&OAS3=0AN;:5C!HT,36LD=LWR_-
ME2$!)'3H:K_\$E?VEK_^P?#WP:_X0J^%ANU"^_X2C>WV<MEI/+QLQG/R_>H
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M#J2:_.5O^"L/BCX=ZU80_%OX$:WX*TN^?]U=I-(7V9^8JDL2!RH[!A^%=O\
M\%)?VDH-)_9<@M_#FCW'B?1/B#ILJ1:U9NRQ6<.(G65P$/#!L8)7H: /KCX=
M_%GPC\68=7G\'Z]:>(;72KTZ==W-BV^%;@(DA17QM?"R(<J2.<9R#785^/\
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M.<C<ZAO]@#M6MX=_91_:R_8=\<:S)\%1;>-?"FJ2'=&983&ZKGRVFMY9$*R
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M5[+1]+\<7&O:#)-:Z&<V\*&>'RU!W-E@N,_,>>]?67_!;K_DDOPW_P"PY/\
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M4 %)MI:* $VBC:*6B@ I*6B@!**6B@!**6B@ I,<YI:* $VTM%% !2;12T4
M)M%&*6B@!NVE(I:* $Q[T8I:* "DI:* $Q1M%+10 AYHI:* "BBB@!-M&*C6
M>-IGB5U:1 "R!LL <X)'X&I: "DQ7+>./BEX+^&,5K+XQ\7Z#X3CNV9;=]<U
M."R$Q4 L$,K#<0".GK7*?\-8_!#_ *+)\/\ _P *BQ_^.T >J;12UYSX?_:/
M^$WBS6K32-#^*'@O6=6NW\NVL-/\06D\\S8)VI&DA9C@'@"O1J "BN;\;?$;
MPG\-=/@O_%_BC1?"MC/+Y$-UK>H0V<4DF"VQ6E906PK' .< UQW_  UC\$/^
MBR?#_P#\*BQ_^.T >JT5Y5_PUC\$/^BR?#__ ,*BQ_\ CM>FV=Y#J%I#=6L\
M=S;3HLL4T+!DD0C*LK#@@@@@CK0!/M]Z3;3J* "D(S2T4 )BEHJ&.XCEDD1)
M$=HSAU5@2N1D9';C% $U)7%ZI\:/A]H?B^#PGJ7COPSI_BF>6.&+0[K6+>*^
MDDE($:+ S[RSEAM &3D8KM: $VTFVG44 %)CBEHH 2EHHH 3:*6O//B%^T)\
M-/A/J$-AXQ\=Z!X;OIEWI:ZCJ$<4Q7^]L)SCWQBNE\%^.?#WQ'\/6^O>%=;L
M/$.C7!817^FW"3PN5)# ,I(R""".H(H W<4M)7GVK?M!_"_0O$B^'M2^(WA6
MPUUFV#3;G6K:.XW=,;"^03Z$9H ]"I-HJ.&9+B%)(G62-P&5U.0PZ@BI: "D
MK)U[Q9H?A?R/[9UG3](\_=Y7V^ZC@\S;C=MW$9QD9QZBLK_A;7@;_H<_#_\
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M3J* $HQQ2T4 %-VTZB@!NVC;[TZB@!-M&/>EHH **** "BBB@ HHHH ****
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MGOG/H*_<;2]/AT?3;2QM@1;VL201ACD[5 49/T%?EM_P7._YHG_W&_\ VPH
MW_@5_P $F_A+\2_@IX!\7:GK'B:+4=>T&QU.Y2WNHA&LDUNDC!08B0N6..3]
M:_2+P[HD'AGP_IFD6S.]MI]K%:1-(<L410BDG'7 %>;_ +(?_)J?P=_[%#2?
M_22*O6Z . ^-7QP\(_L^>"_^$K\;7\FFZ+]ICM//B@>8^8X8J-J@G^$UXMXT
M_P""EWP%\#Q^'7OO$]U<_P!N6D=_"ME8R2M! Y(1YEQE"<9VXW8P<8(SP_\
MP6%_Y,_?_L8+'^4M>>_\$]_V#_A3XV_9E\,^-?''AF/Q'XDUZ9[X7%U/(/LL
M45PR0QQA6 VE8E9LCG>5.0,4 ?9_Q:_:8^'7P.\%Z=XH\:^(H]&TW4E5K*.2
M%S<7.Y0P"P@;\@'G(&,\XKP[PS_P5>_9Y\1:Q%8/XAU+2/,8(MUJ6F21P<D
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ME\5_^N-A_P"A34 ?J]1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7XV?M[:3K/P1_X*!:=\6/&?A:;Q=\/KBZL;BUCGBWV
MTT<5NB26P+ H)%9'D"'KD'N:_9.H+FUAO(_+GACFCZ[9%##\C0!^.7[=W[4F
MH_M@? JRD\ ?#;7M'^%GAK4XK[4->U:VCA!NRCP1PQK&[+M7SWSACU7(7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%=2>#5W]DR]L_C]_P4S^+7Q7\..U]X.TW3OLEOJ:HPCGF,<%NFTXY#+%,WT
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MB3C\@2:TC3G/5(TC3G+9'K]<]XL^('AWP+9M<Z]K5GI<0&0)Y0';V5!\S'V
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MKP5XB\'Z]^T))K^@ZIH<>J?$;4KZP;4K.2W%W;NQVS1;U&^-NS+D'UH X/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SW\._V>_$/
MA']L#XH?%>[OM-D\/^*=,LK*SM8))#=1O"D:L9%,84#*'&USVR!7T)10 444
M4 %%%% !1110!\D_\% OV=OBI^T)X=\'6?PN\0P^'[K3+NXEO7FU.>Q\U'1
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MGK]MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHG_*8>3_ +'NX_\ 9Z_;>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV=O'#"BQPQJ$1%& JC@"IOPI!2C",/A5C.G1ITK^SBE?L.HHHJS8*\H_:?\
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M ,,>*] N/M>A^)]'8)=V$I()P2/F1MJY4XSCJ*]EHH ^0IOV&_%?Q+UG1O\
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M_P#!/?\ ;ON?VGK74_"'C.QCTWXB:'%YLS0Q^7%?0A@C.$/*2*Q 9>G(([@
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M#2_!-_$2VEK:W2ZG_8>O+IJ[V>/R]X,T>\X#X/..?6OC+_AF7]O;_GM\0/\
MPN$_^3*_<"B@#^?[]D_1?%/AW_@H1X&TSQN;MO%MKXE,6J&^N?M,_P!H"N'W
MR;FWMGJ=QS7] -?B1HG_ "F'D_['NX_]GK]MZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 9V->2_%/Q[JNI:Y'X \%2@>
M*;R,27E_MW1Z5;'@R,?^>C?P+^)[9TOBQ\2[GPQ]C\/>&[==3\:ZOF.PL\_+
M"O1KB7^[&G7GJ1@=\:7PL^&EM\-]$EC:=]2UJ_?[3J>J3<RW4YZL2>BC.%7L
M/Q-=$(JFE.7R_KL=$4J:YY?(T?A_X!TOX;^&[?1=)C*PQDO+-(=TD\AY:1V[
MLQY/Y=!73^M)[9IU82DY.[,&W)W84444A!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117 _&[Q-XT\(_#;5=
M5^'GA>+QGXM@:$6FBS7*VZSAI460EV8 ;4+MR?X<4 =[2U0T:XN[K2+&:_MQ
M:WLD"//;J=PCD*C<@/?!R,Y[5>W4 +124M !24;J\W^)7BSQ_P"'_&?@:Q\)
M>#X?$6@ZE>M#K^I2W:Q-I=N-NV55+#>3EN #]V@#TFBO,O$'QSTK0?CQX6^%
M36-U/K>NZ9<ZLMTI40PP0Y!!/4LS#& .G.>U>F;J %HI,T;J %HHKYJ_;L_:
MNU/]D7X;^'_$^F:!:^(9-2UE-,DMKJ9XPJ&&60LI4<M^[ _&@#Z4HS7%?!WX
MLZ!\</AMH7C7PS=+=Z5JUNLR@,"T+]'B?T=&#*1ZJ:\^3]H;47_;+?X+?V1:
MC3%\)_\ "1_VIYC><9//$7E;?N[<'.: /=Z3(KP/P!^T=J7C']KKXH?!^;1[
M6VT[PAIUE>P:DDC&:X:>""0AE^Z #,1QUP*=^U)^U5IO[/.EZ;IFFZ9+XN^(
MNO/Y&@^%;++374A.-[X!*1 ]6[\@="0 >]T5ROPVNO%FH>#=.NO&]CIVE^))
MH_,NK#2W:2&V)Z1AV/SD=V&!GITR=MM<TY=8723?VHU5H?M*V)F7SS%G;YFS
M.[;D$;L8S0!>I:YKXD>)I?!'P]\2^(H($N9])TVYODAD)"N8HF<*2.Q*XXKB
MOV6/C->_M ? CPOX^U#3H-)N]7CDD>SMG9XX]LKH,$\G(7]: /6J*3-&: %I
M*^3O''[9GB+Q1\3M:^&_P'\!K\2?$6B,8M7UN\O1:Z/IL@R-C2_\M'#?*44@
MY5@,[6QS>L?M0?M&? 32W\2_&CX2^']1\%12*+W5/ E^[S:=&>/-D@E=RZCU
M!4#N: /M:BL;PAXKTOQWX7TGQ%HETE]I&JVL=Y:7$9R)(G4,K?D16S0 4444
M %%%% !1110 4444 %%%% !7Y4_\%.IO^%=_MJ_!#XB>)+>6]\$6UM:I+$$+
MJ&M[V26<!<8)*2Q'U.T^@K]5J^??VJ=)^"/Q5L]*^%?Q7U6PMM4UR1)=&MGE
M,5\)2Y19+=@.&+97'0Y(((H ZS3OVJ/@]JGA-?$MO\3?"W]C&/S3<2:K#&4&
M.C(S!E;_ &2,YXQFOS[_ &/?%FD_&[_@J)X^\?>![-T\)'3KJ5[DH8Q+N2*(
M2E2,@R."P!&>YYS6W<?\$/=#;7C-!\6M0CT7=_QYR:'&USMQT\[SPN<]_+_#
MO7TW^RKX7^ W[.?BC5?@OX UF*Y\?Q)]MUB.Z1VOI]H4 R2; N%#@B-3P')Q
M\Q) /J->E+110 4444 %%%% !1110 4444 ?B1HG_*8>3_L>[C_V>OVWK\2-
M$_Y3#R?]CW<?^SU^V] !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 G2N'^*GQ+MOASH<4BPMJ.LWTHM=,TN#F6ZG;A5'HH."S=A^
M K1^(/C[2_AOX9N-8U64B-,)#"G,D\IX6)%_B8GM]3T!KB_A9X!U2^UN;X@>
M-(P/%-[&8[2PW;H]*MCTB3_;/\3=^GKG>G%)<\]OS-X127//;\S1^$WPUN?"
M_P!L\0^([A=4\:ZQA[^\ ^6%1]VWB'\,:#CCKC)KTFC%%92DYOF9E*3F[L=1
M114DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,0
MH)/ I:BFA2XADB==R.I5E]01@T 5_P"U[(_\OEO_ -_5_P :Y?XF?%30_AAX
M*U3Q+J-PL]M8H&\FWD4O*Q(5449ZDD#GUKFO^&5_A7_T)]K_ -_YO_BZY7XH
M?L;^!O%'@75=/\.:);:)KLD>ZSO?-E*I("" P+'Y6Q@\' .:[Z,,(ZD54D[7
M[+_,PDZEG9'D?A'_ (*0"^\40V_B'PI%IVASR;#=6MTTDMNI/#,I4;P.^,'O
MST/VC'K-A(JLM];E6&0PE4Y_6OS5\&?L(_$O6/%EO8ZYIL>BZ.LRBYU W44@
M\L'+&-58L6/09 YK[=B_93^%44:I_P (A;$*  3/,>G'/SU[&:4<MIRC]7E]
MVOZG+AY5Y)^T1ZC'JEI(ZI'=0N[' 59 2?;%6OK7FWA_]G;X=>%]:M-6TKPQ
M;V>H6DGF03I-*2C8ZX+8_.O2/:OG*G(G[C^__ASOCS?:'5\V_P#!1'Q]XB^&
M/[(OC7Q)X5UBZT+7;-[$07]FVV6/?>P(P!]U9A]":^DJ^3O^"IW_ "8W\0?^
MNFF_^G"WK,HYW]L?XO?$+P!\/?V?;OP/K'V7Q%XA\0Z?ITHN6;R+MI[8@"<
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M$*0BD]UZ _>%;&CW4.H?\%6)KJ!UEAF^%"RQR#NIOT((^H/ZT 8WQ0U/XD_
MFW^%/[//@CXA:KXC\<>.-0O6;QGXD NKO3]/B422%=Q.YU3=@D_\LST)&)?C
M'\$?B?\ LO\ P[U3XH^ ?C/XT\6ZIX>A;4M9T3QGJ'V^QU*UC!:?8A7]PP3<
M1L[+@'I6G^VM9WGPI_: ^"/Q_P#[+O-5\-^$I;W3/$'V&%I9+6UN87B6X*C^
M%/-D)X_NU!^U-^VK\./&OP,U[P=\,_$$/Q \;>-=/DT72M'T M-.K7*>69)
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M,B$,7\U@3%&A()9><D #)H ^&/\ A(O^"D/_ #R\0_\ @OTG_P"(KTO]@?\
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MHHHK$R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYW5/_;8^'VL_!;X@Z+^U%\/[0SZKX>06GBW28EV_VII1(#.6]8U4 G'0(?\
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M?AM_SUUG_P #!_\ $5[IX#\&VGP]\)Z?X?L)[FYLK%/+A:Z</(%R< G R!G
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MHP%2.,!54#@ #L*F6EK&=24]S&524]Q:***S,PHI*CFF2",R2.L:*,EF( %
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M#9)%FU&WO-:GZF34K^:8GZ@M@CZBNMT7X?\ AOP]_P @S0=.L#_>M[5%)^I
MS7T5ZTNB7X_Y'WZEBYKX8Q^;?^1Q\G[0WA^X.W1].UW7S_TX:5,1_P"/**F3
MXA>-=57.E_#NYCC;I-JVH16P'N57>WZ5Z0L:+P%4#V%/P.W%/DJ/XI_<O\[@
MJ->7QU?N27YW/*S9?%S6&(?4?#F@PMT^SP2W,B^WS$*?R%3Q_"KQ'J2_\3SX
MAZS<$]5TN..Q7Z<!F_)J]-I?H:7L([MM_,:P<+WE)OU;_+8\QC_9Y\'23+-J
M-K>:U<?\]=2OIIF/?G+8/Y5YU\</V;;+6)["]T&71O"^GVT)CE61!$)')R"2
M!R<#O7TE]:^>?VT?BU9_#+X>6,1MM/U'5M1N_P#1;+4K47,3JG+L5)&-NY?F
M]2*J.6QQK6'A%79Q8W+\)4P\H2@OR_$\_P#V;_@Y<WGB+0/%L>M:<\5O+*\E
M@K$SA5+Q9P.V>?H17V-Z 5\*_L?_ +15IX@^)D^F:YIOAWPZ]U9.EK+IVG+:
MF5PRN5:3/3:K':1@X'/%?7>J_%WP1H()U'QCH-ECM/J4*'\BV<UTQRFKE?[B
M4==]+LSR?"TL'AN2&G?U.PHKQ[4/VL_A9I\ACC\4+J$G9=-L[BZ!^C1H5_6J
M7_#5&C7W_('\'^-M;4_=>S\/S%&^A8#\S70L+7M?D=CV_:0[GMU(17D$?QB\
M<:H,Z3\'M>=>SZIJ%I9#ZD%V;'_ :@G\3_''5019>"O"VA9'#:CK$EWC\(XU
M_G1]6GU:7S7^8>T73\CV?I29KQ5/#WQXU7_C[\6^$=#'KI^E2W)_\B.M6HOA
M#X_OD"ZQ\8M7<?Q+I&E6MF#^)61OUI^Q@MZB_'_(7.^D3COVQ/VA[WX,:5HU
MEX>U2.U\27CF;R'M5G!@4$98,1M!;H<'.UO0US7[(_[4]_\ $S5-9T[QMK]J
M-06%)[2$VB6T8521(?,W?,3N3@@8QW[>7_MK?L]W/A.UT?Q9%XFU3Q%))FRN
M/[=NQ-/QET\L[0-H^?*@=\CJ:Q/V(O@+IOQ&\5:EJ_B6"SU#2M-@"_V7/EF>
M20X1V7H% 5N"<^U?50PN!_LIU&_>[VUO<\UU*WUCE2T/NW6/C5X!T%3_ &AX
MST&T(_ADU&(-^"[L_I7(7?[6WPTBD\NSU>\UF7H%TO2KF<'T 98]IS[&NVT3
MX2^"?#>/[*\(Z)I[==UMI\2-]20N:Z>&S@MUQ%#'$/\ 94"ODT\/'HW\TOT9
MZ7OOJ>-P_M)RZJ^S1/AGXYU(D?*\FE?9HS[[Y& _,U:_X6-\5]23_B7_  FC
ML-P^676/$,"8]"4B60_AD5[#MHQ3]K36U-?-O_-!RRZR/$Y(_C]JTGRS^!=
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MX=W7RT"Y_*IZ*=WL 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%CX@\3:/Y-DS,?E\QE<F+/\ MCISP,UZO\:_VC?!OP!L_"]_XNO6M-+U^_\
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M5:"#:*-HI:*XC82EHHH **** $HVBEHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N+^+GPC\,?&_P'JGA#Q=IR:EHU^A5
MU/#Q-_#)&W\+J>0P_EQ7:44 ?E]\&_\ @DGJ6F_&JX7XBZ^VO_"OPY/YV@Z?
MYQ8ZAO;>4DCSB% 0/,"_?/3BOTWL;&WTVS@M+2WCM;6!!'%#"@5(U  "JHX
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M0-6\<_!;XE:M\'?$&K.9M0L[2U2^TN[E)R9&M9"%!/)[C)) &3GZCT/0]/\
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MI)R23U))K:[>E=4L1*G'V5!N,.W?U-J="$8I-;?AZ"TM%%<9TA1110 4444
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M[OO_ )&.&H*C'7<6EHHK [ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHJ&XD>."5XX_-D525CR!N..!GMF@":O(?VCOVHO 7[+?A$:YXTU!TEGW
M+8Z59J)+R]<=5C0D# R,LQ"CUKAO^%]_M!?]&OW_ /X6FD?_ !ZOSU^+_BKQ
MO\;O^"CVC:?X]^$<NJ7^E6\45E\.;G6+0)(BVIN &N6?R) SLTAY^8 1\D4
M?0FB_P#!:+P?)JEHVO?#3Q'HV@73[8M4CFCF)4-@ML(4-COM8]#UK[Y^'_Q
M\/?%+PAIOBCPMJD.LZ#J,?FVUY;YVN,X(((!!!!!4@$$'(KYD\>>,/BS\1/
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MYU#PC>^%;R/Q'9>(4\36%P;!H,L[F-&W./+W<#/(4XXH ]I_X*P_\F3^+?\
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M9I*K[&^MKGM1R+'3R^69*F^124=M?7TZ>K/H['M1CVKE/^%J>#C_ ,S/I/\
MX&Q_XT?\+4\'?]#/I/\ X&Q__%5T<\>YY'U6O_(_N9U=%<K_ ,+4\'?]#/I/
M_@;'_P#%5!+\8O \+;7\6:.K>AOHA_[-1SQ[A]5K_P C^YG945Q?_"Z/ O\
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M.<<=J]+HH XWX-^")_AG\(? _@^ZN8[VZ\/Z%8Z3+<PJ0DKP6Z1,Z@\@$H2
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MJ7Q4_9AT/XT?L\V'PP\37,B&RL;6.WU.SX>VNH(@B3H#U (/RGJ"1WS7ME%
M'QCK7[/O[5'B_P $S> -8^-/AF'PY<1&SN?$%EHTJZQ/;'*D$[P@9E(!((/7
MYLY)^FO@]\*=!^"'PVT'P/X9@,&C:/!Y,._&^1B2SR.0!EW=F8G')8UVE% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'XDZ+_P IAI/^Q[N/_9Z_;-CM%?B7HO\ RF%D/_4]W'_L]?JQ^TA\7O\
MA5O@WRK&6/\ X2'5=UO9*Q_U0Q\\Q'H@.?J5%5&/,[#TW>QYA^T!\6-/U7Q!
M-#=&.[\)^%Y0TT&["ZEJ8&Y(3ZQQ<,^.,D*>HJ[^SK\&=2\2:X/BEX]AD?5[
MIC<:587."8%8?Z]U[.5QM7^!<#KTY3]G/X%'X@7EAXI\16W_ !2VG,3I>GW
M+&]F#EFN)<]5WY;_ &CZ* #]D+\HP.!6SJ<NWHO)=?F_P6AYD+XRJJ\_@7PK
M_P!N?FQU%4-6US3]!LY+O4KZWL;:,9>:XD5$4>I).*\INOVD++7;R2P\!:!J
M7CF]&5\ZTC,-BK?[5RXV@>Z[O8&N*52,/B9[^'P6(Q2;I0NEN]DO5O1?,]D8
M@#K@5R7C7XK>%/A];>;KVN6MB?X(-^^:0^B1KEV/L 37 Q^!_BG\0O,/BGQ3
M!X1TN3@Z7X:0FX*GLUT_*_\  %![@BNK\$? KP9X F:[TW2$EU-^9-2OF-Q<
MN>Y,CDD9/.!@5GSU)?#&WK_E_P ,=GU?!X?^/5YGVA^LGI]RDCQ?XS?M9:SH
M_@6YU'P_X4O=.LKIOLMKK&M?Z,7=@<-# ?G? RVX[5&.O:OAWP-XVU3P3XNL
M]=T_4KK3[R.0^9=6^UI-C</PP(;@G[P/.*_1?]I;]G;0?C39Z?J7B'QEJWA'
M3-#AFDD>PDMHX-IP6DD,T3@;0O48&":_.']G^Q^$/QN_:%\5^ 5^*7B:QTC?
M''X5U"6&SA;4V53YZLS6^-Q;F-=JDKGOQ7BXO XK$55*,M%L?JO#?%6091@*
MF'JT'S5/BLKW6R3;>OW)>1^E&A^#/''B/0[/5=+^+]Q<VEY"L]O,-'MV1E8
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MEY7+G=[OKMO?4[U?@-\-W4,/ GAS!&?^05!_\12_\*$^&_\ T(GAS_P50?\
MQ%=[MHQ7M>SCV1^6_6\1_P _'][."'P%^&__ $(GAS_P50?_ !%7;3X/^!]/
MB$5MX1T2"/.=D>GPJ,_0+78?2BGR1[">*KO>H_O9RW_"K?!__0KZ1_X Q?\
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MGQ:^)7P47PWX6O?A-X8\:?#GQQX>2-;76998B-1PY8S2LL@9)1N)#H&X 3&
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MZ\5\J_\ #WS]H?\ Y\?#/_@GE_\ CM,D_P""P/[0<*[I+7PO&,XRVD2#\/\
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M>*DMH]>U9;LW*V<)AB'EWD\2[5))'R1KWZYH ]NHHHH **** "BBB@ HHHH
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M9<<8I: *']@Z;_T#[7_OPO\ A1_8.F_] ^U_[\+_ (5?HH H?V#IO_0/M?\
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M\+_A1_8.F_\ 0/M?^_"_X5?HH H?V#IO_0/M?^_"_P"%']@Z;_T#[7_OPO\
MA5^B@"A_8.F_] ^U_P"_"_X4?V#IO_0/M?\ OPO^%7Z* /RV_P""IG[$O@OP
MWX*\1?&_PY//H>KFXMUU'28(U-I>/+,D9D X,;98,<9!(Z G->;?\$O_ -AW
MP;^T!H5Q\2O&=Y<ZC9Z#KSV,'AP +;321PP3"25LY9295&P 9V#)(.*_07_@
MH!\(O%/QT_9@\1^#_!M@NIZ_>7-G)#;/,D(98[A'<[G(7A5)ZUQG_!,?X >-
M_P!G/X%^(?#OCS2DTC5[OQ'-J$4,=S'.&A:UMHPVZ-B!\T;C'7B@#ZO3P_ID
M:A5TVT55& ! N!^E._L'3?\ H'VO_?A?\*OT4 4/[!TW_H'VO_?A?\*/[!TW
M_H'VO_?A?\*OT4 4/[!TW_H'VO\ WX7_  H_L'3?^@?:_P#?A?\ "K]% %#^
MP=-_Z!]K_P!^%_PH_L'3?^@?:_\ ?A?\*OT4 4/[!TW_ *!]K_WX7_"C^P=-
M_P"@?:_]^%_PJ_10!0_L'3?^@?:_]^%_PH_L'3?^@?:_]^%_PJ_10!0_L'3?
M^@?:_P#?A?\ "O@+_@M%IMI9?LR^$WM[6&!SXOMP6CC53C[%>'''X5^AE?'_
M /P4Y^ /C?\ :,^!?A_PYX#TI-7U:T\1PZA-#)<QP!85M;F,MND8 _-*@P#G
MF@"K_P $J=*LKO\ 8K\(R36<$TAO-0!>2)6/%W+W-?7?]@Z;_P! ^U_[\+_A
M7@'_  3^^$/BGX%_LP^'/!_C*P73-?L[F\DFMDF28*LEP[H=R$CE6!X-?1U
M%#^P=-_Z!]K_ -^%_P */[!TW_H'VO\ WX7_  J_10!0_L'3?^@?:_\ ?A?\
M*/[!TW_H'VO_ 'X7_"K]% %#^P=-_P"@?:_]^%_PH_L'3?\ H'VO_?A?\*OT
M4 4/[!TW_H'VO_?A?\*LPP16T0BBC6*->B(H 'X5-10 4444 %%%% !1110
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MCHI%Z4M !1110 4444 %%%% !1110 5#<7$=K!)--(L44:EWDD8*JJ!DDD]
M/6IJ\)_:H_9RU;]I31M!\.P^.=2\'^&H[EWUNWTLD2ZE 0 (<Y  R">01ST-
M "? 3]L/P-^T?\0/&_A?P<E]=?\ "*,BS:K(D?V2\#,RAH&5RS+E#RRC/!&:
MN_M)?M;> /V5+/0;CQS/?QC6Y)H[./3[;SW;R@A<D;A@#S$Y_P!H5\<?\$O_
M  IIO@/]JG]IWPSHT#6VCZ+JSZ=90L[.4@AOKJ.-2S$EB%5>2<UI?M\>"_BK
MXZ_;#^$]]X0^&,_C[0_"MD+Z"&X7R;&6]:9W9)IW(0*!%;G:2,X(SS0!]"_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+]LKX+7?[0'
M[-?C;P3IO_(6O;9)[ ;@NZXAE2:-"3P QC"DGLQZ5[;10!^-OB3XE_%'XJ?L
MF^%?V7;3X1^*K?QM:W-MI][?7EB\=HMK!+OB.\_=((C!9OE 0\G/'ZN_!?X>
MQ_";X1^#O!:3?:/[!TFUTYIL8\QHXE5GQ_M,"?QKM:* "BBB@ HHHH ****
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M?'"?P1K?@CP%X3TTVUG)KEOY$]Y)Y<J*N,\DM.[';D ( 3SS^D=%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%KPCXJ^)7_!3#QUX)\)ZY)X?U'Q)K-QI<NH+D^3:R0 W!P"/^60?@$9Z9&:
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M/'/VA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?PU_Y3/Z_P#]A:^_](S7Z1?!_P#9;^%_P%U[6=9\">%UT'4]84)?3K>W,_G
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MV\R5;92TDS= TDC$O(<=V8X[5WE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>gizttcucplmb000027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000027.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MXZ D9^YO^"-FL7^M?LX^)I=1OKF_E3Q-*BO<3-(546UN< L>F30!]]4E+24
M+17\_/[07B3Q[\0?VUO%WA.P\8:M;W.J^,7T:R\W4IEA@WW0AB7"M\J+N48
MX X%>H_%K]BW]J3]F;P?>^/+;Q]>:C9:6GG7DOAW7KL7%O%D9D*L$+*.IQG
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M\;>%_L3:_8O:QVZWT9DC'FW,<3$H&&<*YQSU% 'ONZEKXV_X)N_M9>,?VI/
M/BW5/'3:6E[I.I1VT#:? 8 T;1[SN!8Y(/<5]@S7UO;E1+/'&6^[O<#/TYH
ML44BG-0O>00S")YHUE;[J,P#'Z"@">BH)KN&VV^;*D6XX7>P&?I46I:K9:/:
MO=7]W!96R#YIKF58T'U8F@"Y15/3=4L]8M4NK"[@O;5^5FMY%D1OHP./2K>:
M %HK'U+Q9HFBW$=OJ&LZ?87$AVI%=721LQ] "02:U(I5F0/&P=&&0RD$'\:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /SL_X+9_\F_^!O\
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M\8YB3/% 'M'[+OQ8C^+O[-O@7QO<W0FFO-(1KZ=B/^/B(&.<G!X/F1O7Y&?
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MA:VEO%:VT/C"TCBAA0(B*+&^PJJ. !Z"G?\ !%?_ )-K\5?]C1-_Z2V]2_\
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MFFM;JY$@-M&) K(-[-P3SQZ5]Z_MA13R?\$G=-,/W$T+PZTO'\/FVH_]"*T
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M>+Y><!Y-PR"/E'UK\Z?^"B'P)^)7P1OO D?Q&^*-U\2Y-2BO6LGN?-_T,1F
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M<*XD1BH(SVR17[YU^%'[<RA?^"F6L #'_$[T0\?]>]H<U^[% !1110 4444
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M!P:_4GXL:?XE7X0>*[+X?^7:>+!H]Q%H>-BK'=")A !N^48;;C=P.,\5V]%
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MPO\ "*'7_P!F/1OAKXSL<1W'A>#1=4M5=6,;?9EC<*ZDC<I!PRG@@$&O6**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $Q2T44 )2T44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 44E+0 44E+0 444F: %HHI* %HI,TM !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117+_$SXB:-\)_ .N^,/$,[6^C:-:O=W+HNYMJCA5'=F)"@>I% '3YHK\?]
M!_: _:S_ ."@GC+65^%FHKX"\(Z<P5_LMR+6&#))19;D*99)& Z(,8'W1W^A
M_P!EO2?VO?@[\=/#WA/XJWO_  G/PZU>.Y2;6XYA>"PD2WDEC;SBJRKN=5CQ
M(-IW<<XH ^^J*_(#XK?'[]I#X@_MV>+/A!\.?B3+H?F:M<6NF6USY45K#'#
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M"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI\;/B1XB\,?#C1/#NNWFFO/,UJEE'&8K=)=@;=+,H."RCKFNQ?\ X*5?'_\
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M+_P4(_;BTKX7:>UU-\*?AW(]SKEQ"6$-S.K 2C<.,LW[E>^!*R\4 97[)?\
MP4,^.7Q2_:F\&?#OQU::-9:;K2O+/;QZ8T$XB:Q>Z@=27. RB-AD'*M[U^J%
M?DLUG!I__!;RVM;:)(+>":&***-0%1%\.J H'8 "OUIH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^CJ['_OUHW_QJD_X3:Q_Z.LL/^_>C?\ QJ@#Z>HKYA_X3:Q_Z.LL?^_6C?\
MQJC_ (3:Q_Z.LL?^_6C?_&J /IZBOF+_ (3>Q_Z.LL/^_6C?_&J3_A-K'_HZ
MRQ_[]:-_\:H ^GJ*^8?^$VL?^CK+'_OUHW_QJC_A-K'_ *.LL?\ OUHW_P :
MH ^GJ*^8?^$VL?\ HZRQ_P"_6C?_ !JC_A-K'_HZRQ_[]:-_\:H ^GJ*^8?^
M$VL?^CK+'_OUHW_QJE_X3>Q_Z.LL/^_6C?\ QJ@#Z=HKYA_X3:Q_Z.LL?^_6
MC?\ QJE_X3>Q_P"CK+#_ +]:-_\ &J /IVBOF'_A-K'_ *.LL?\ OUHW_P :
MH_X3:Q_Z.LL?^_6C?_&J /IZBOF'_A-K'_HZRQ_[]:-_\:H_X3:Q_P"CK+#G
M_IGHW_QJ@#Z>HKYS\'^*/%>E_'CPCH<GQ'?QUX6U[0+S4ED>QLT0M&\81XY(
M(URN&/?TKZ+H 6BBB@ HHHH **** "BBB@ HHHH ***\(\8?M&:_I/Q,USP=
MX8^&6L^,9]&AMYKN[LKNWAC3SE+(N)&!)X/2@#W>BOG_ /X:!^)__1 ?$?\
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M_P#!G9?_ !R@#Z HKY__ .&@OB=_T0'Q'_X,[/\ ^.4?\- _$_\ Z(#XC_\
M!G9?_'* /H"BOG__ (:!^)__ $0'Q'_X,[+_ ..4?\-!?$[_ *(#XC_\&=E_
M\<H ^@**^?\ _AH'XG_]$!\1_P#@SLO_ (Y1_P - _$__H@/B/\ \&=E_P#'
M* /H"BOG[_AH'XG?]$!\1_\ @SLO_CE+_P - _$__H@/B/\ \&=E_P#'* /H
M"BOG_P#X:!^)_P#T0'Q'_P"#.R_^.4?\- _$_P#Z(#XC_P#!G9?_ !R@#Z H
MKY__ .&@/B=_T0+Q'_X,[+_XY1_PT#\3_P#H@/B/_P &=E_\<H ^@**^?_\
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M?_'* /H"BOG_ /X:!^)__1 ?$?\ X,[+_P".4?\ #0/Q/_Z(#XC_ /!G9?\
MQR@#Z HKY_\ ^&@?B?\ ]$!\1_\ @SLO_CE'_#0/Q._Z(#XC_P#!G9?_ !R@
M#Z HKY__ .&@?B?_ -$!\1_^#.R_^.4?\- _$_\ Z(#XC_\ !G9?_'* /H"B
MOG__ (:!^)__ $0'Q'_X,[+_ ..4?\- _$__ *(#XC_\&=E_\<H ^@**^?\
M_AH'XG_]$!\1_P#@SLO_ (Y1_P - _$__H@/B/\ \&=E_P#'* /H"BOG_P#X
M: ^)W_1 O$?_ (,[+_XY1_PT#\3L_P#) ?$G_@SLO_CE 'T!17S_ /\ #0/Q
M/_Z(#XC_ /!G9?\ QRD/[07Q.Q_R0'Q'_P"#.R_^.4 ?0-%>>? OXN1_&SX?
MP^)H])N=#9KJXM);"[96DBDAE:-P2IP>5/2O0Z "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHKE?'WQ*T#X8Z?87FOW-U%'?W8
ML;6*QL+B^GGG,;R;$B@C>0G9%(W"X 0YH ZJO#?VK/ACJ'CKX=ZU?6GC37?"
M\6FZ3>226NDNBQW?[ICMD!4Y&!CCU->SZ7J,.L:?;7UN)5M[B-98Q/ \,FUA
MD;D<!E//1@".A%<O\:/^20>-_P#L"WG_ *)>@#)_9M_Y(#\/?^P%9_\ HE:]
M)KS?]F__ )(#\//^P%:?^BEKTB@ HHHH **** "BBB@ HHHH **** "BBB@!
M*^9?V4/">AZR_P 6Y[_1["]G_P"$[U(>;<6R.V,1\9(KZ;KYZ_8^_P!7\6O^
MQ\U+^4= 'LG_  KSPM_T+>D_^ 4?_P 31_PKSPM_T+>D_P#@%'_\370T4 <]
M_P *\\+?]"WI/_@%'_\ $T?\*\\+?]"WI/\ X!1__$USGQD\>ZOX-T[0-.\.
M6]G<>*/$VJ+HVEMJ <VL$IAFG>>94PS)'%!(VT%=Q"KN7=FN+U[Q=\6OA9X"
M^(&I^*'\.>)%TC0;C5M,US3+.2Q3[1'&[&VGM7GE8@;0PD63D$@@'!(!ZO\
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M^5,NUTR <,.Q&>10!C_\*\\+?]"WI/\ X!1__$T?\*\\+?\ 0MZ3_P" 4?\
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M 'SI_P ,F^(_^B[?$#_P(@_^-T?\,G>(_P#HNWQ _P# B#_XW7T710!\Z_\
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M_P#I;+7OU> _L2?\D6N?^QAU?_TMEKWZ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I#2T4 </IOQE\):KX?\2:Y#J3QZ7X>N7M-1N+B
MUFA\J18HY<*KH&<%)HR"@(;>,9KA_'NO>%?BQI-K<V=AXLU;4/#VI3>4OAX2
M6.H:9??9B@$B2-&R,\-R=OF*4*R G@@FKXN^%WB'7?#'Q=M;>T9+K5/%-AK>
MF1^<B_;8[:WTQRF<_*'DLY8OFQW/0YKHO@]X4UFV\<?$GQEJ^FRZ(OB>_LVL
M]+N)(VFCAM[..'S)?+9D$CN'^ZQ^1(\\Y  -FS\0>(_!/P7L]6\2:?<:_P"*
M=.TB*;4++3%5Y;FY6,>8L8 "EBV>@QZ5\P?$K]N#6=8^'?B>PE^ _P 1-/2Z
MTRYA-Q=62(D0:)AO8[N@SDX':OMVOEO]N;P7>^*/![7%MX/L_$L=GIMXSW%U
MXBDTUK3]WG<L:@B8\9P?2@#UW]F__D@/P\_[ 5G_ .BEKTBO-OV;?^2 _#W_
M + 5G_Z*6O2: "BBB@ HHHH **** "BDI: "BHI9XX5!DD6,$X!8@<^E1WU]
M#IMG<7=S(L-O!&TLDC=%51DD_0 T 6*6L_0];LO$6DVNIZ=<)=V-T@EAGC^Z
MZGH15_UHZV8"U\]?L?\ ^K^+?_8^:E_*.O<88=476KB22YMWTHQ*(K=82)5D
M!^9F?=@@CMM%>'?L?G]W\6_^Q\U+^4=%K ?0M%%% '!_%KX=WOC[2]&FT?5(
M]%\1:#J<>KZ5?3V_GPK,J21,DD>Y2T;Q2RH=K*?GR#D5Q>O?"+Q_\0M#\<6W
MBSQ?81?VYX?FT*PTG1[:5;"T:16#W,F]RTLA+*/X0JK@9))KW"DX'UH \5B^
M%'CCQ=X@\)3>./$&AMH7AJ[34K?3- L9HFN[J.-DB:>265OD0N7"*HRP7)P,
M5K>+_@?!XXU7XF'4KW_B5^-/#=IX>>&)/WEOY1OMT@).#D7BX&.L?.<UZID=
MC2T >1^"?A5XAC\<0>)/&6IZ1J,EAHAT&SM-*LWCC>-Y$>667S&;+,8HP$'"
MX;EMW&K+X%D^&/@/Q;+X#L+>Y\2W'V_4K*.]A1U>[F9I5B(4Q9C\P@!=Z\8^
M;O7HW%% 'GGQ.^'NJ>/M#\/75AJ<&A>+M!OHM5L+Q[?[1;K<")XI(W3<&:-X
MYI8SA@<,"#D5R'B/X/\ C_XC>'?'EIXK\86$7]O:!+H5AI.D6LBV%DTBOONI
M-[EY96+*/X0JI@<L2?;8+B*XW^6P;8VUL=C7">//BYHOP\U@:?)8ZKK>KRV<
MFIS66BVOVB6"TB(5IW7(PN3@ ?,Y#!5;:<'J!RT?PI\<>,/$'A:;QOXBT3^P
M_#=TNHVNF^'[&:)[F[2)HXGFEED;Y$WLX15&6"DD@8K%\2_L[^*/BKIMMHWQ
M"\3Z?J>EZ?IE_I]O=Z?9-'=W<ES;M;?:9R6V*RQNQV(N"YSD !:ZK6?VF/!V
ME,98?[2U;3H+&UU._P!2TVR::WTZVN1F&2<\,-R_-M5695^9E .:]'USQ!IO
MAG1[G5M5O[?3=,MD\R:[NI D4:^I8G [?F* /.O!?PO\1#QP/$WC+4=(U":U
MT7^PK2TTNS>*)XVD62667S&;+,8XP$'"@-R=W'7^!_AWHWP]M;V'2H,?:[VY
MOGDD1-X:>9IG0%5'R!F.!V ')ZU#\+?B=H7QB\#:9XM\-32SZ+J7FFVDGC,3
MN(Y7B8[3R!N1NO;%=?0!X5\?/V?;WXN>(;'4[=]#::SLGM[*YU&UD2\TF=B?
M]*M+J!DE!((S&S;3L4_+SG&U;]F_Q<T'B71M,\5Z<NA>(M;TWQ!?W=]922W[
MSVJV*2(&#A-LJV"'<1D&1L=B/HWBCB@#PS2?@EXMCNM+TO5/$.E7'A73?$]S
MXFB6WLI$O79[J>XBMV8N4VH\P)<+DA ,#J>+;]C6?4KSQ+#=:CI&CV>O66H6
MNIW?A^SDM9M7>X1DCFN[</\ 9S)&6#EE3+,H/ )!^J*3 H ^8+']DO4(=)U\
MP_\ "(Z#J=U86UI:_P!BZ5(D320W45R99W=S)M9HD7RT( &3ECC'TKI_VK[#
M;?;C"U[Y:^>;<$1^9@;MN>=N<XSVJW10 4444 %>-?MD_P#)J_Q1_P"P#<_^
M@U[+7C/[97_)J_Q1_P"P#<_^@T ?/O[(O^L_9D_[)Q=?^C(:^Z*^%_V1?]9^
MS)_V3BZ_]&0U]T4 %%%% !1110 4444 %%%>3?&3Q1XA\+^.OA(FE:N+32M:
M\3_V3J5C]E1S<QG3[V<?O&!*8:W0_( ??'% 'HOB0WZ^'M4.E)YFI_993:ID
M#=-L.P9/ ^;'7BO+?V=/$4UU9ZOH&MOXEM_&FDQVCZOIOB>\AN9H_-C;RYHF
M@=X_*D:.7&UNL; @8KA['XG>*O$%CI'BF_U9Y/#OB#QE=^#Y/"\-LD:PVJW=
MS9+,)U'GB;=")"V_;M) 52-U>]>#O .A^ H;J+1K22)[MUDN;FZNIKJXN&"A
M5,DTS-(^%  W,<#B@#E?$O[37PI\&Z[=Z+KOQ!\/Z5JMF_EW%G=7T:2Q-@'#
M*3QP1UKSO]G_ ,=^'OB)^T5\7]9\,:S9:]I4EKI,:WEA,)8BRQ2!EW ]<TWX
MX?L<_!+Q)_PE'CSQ-X8TJ/69HVN[O6=2,SPHRKCS)$5UR  ,@$=*\\_8%\/^
M$?#?Q*^+%GX*OM%U#0PFFLDV@P20VV_9)N 61V;<#U^8B@#[7HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***2@!:2BN>L]6DUK7Y#INI6DNG6#R6E_;
M>4QE6X 4@!\X& PR,'.1S0DV!T5%8^LZ\NCW>EP&SN[K[=<?9Q);1%UA^5FW
M2'^%?EQGU(K7S19K4#Q/]FS_ )#GQA_['>]_]%Q5[;7B/[-O_(<^,/\ V.U[
M_P"BXJ]NH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\Z[_\
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MM:L]*L?'NA72SC2;C[=?VL$\+S7;6HC\X1K\R@LN2(\X VYVOV/?^0A\9/\
ML>+[^25]&4 ?)7QDTL?'KQ)?ZUIGA_Q7'H>A^%+^SDOHM%DM;ZXNIKFTFBCM
M8;I8S-Y9M?-(QM)"J-Q)%8T?@GXL_%/Q1XIUK2];L]5M;_3]+T>[DU#3[SPS
M!=VL<MS+<PPAHYY@[!XT:0C&)I FPKFOLZEH ^5O@-\-?'FH?!#Q7X?O)YOA
MEJ'_  EVN3VAT#9*TD+WMPWEXN[7:(69_D=5^9%1LKN*UV'[-WAK5?@+\(?A
MUX5\;:]JVHZU?6=GI<-A<6T,L.FW$=IN>V66VB"^6HB<"25CDJ!N)89]YJK<
M:?:W5Q:S3V\<TUJYD@=T!,3%2I93V.UF&1V)'>@#QKXV:=>Z'\6OA?\ $%[3
M4-3\/: NJ6.HVNFVLMU+;F[BB$=WY48+,J&!HR54D"<GIN->>?&?QI<>/[>R
MUK2O NM)H.D>+/#TYUS^R+@7FH1Q7+23E;;R?.,,*D?.1@EWP,#)^LJ3B@#Y
M%^-&DQ_'KQ!K6L6GA7Q;=>%=/\%ZEH>H-:Z;)IVHZC]LGMF:"U6ZC4OL2W=R
M=I&64#)/&#\3?"7BCXA^"_B#IO@6?Q;J'@^&+0;^T36DNFN_MEMJ"SW2V8NU
M\QB((HSL/R&0*%&2PK[8VBB@#Y;\+>&/%WCC5/'VE^&/&'C31?!!MK&73-4U
M6$/>RWQ2Y6[MD.H1,Y@V_9F.5X<L$8#<*]&_9;^&OB3X4_!?PMH/BC7=0U75
M+;2K.&2SO1;%=-9($1K>)X$4.BL" S%R<?>->OT4 ?!$O@WQ2UK\0=(T33-8
MU/7-;\/^(K8:C<:=J.G:I:S2V\Q@6[D\QK6\)DV)$T9! *E!C..F^*FHZK\5
M+/X@1:1X?\57>DO\+9+ -)I5S;_:;YIVW01)*@+3*N/X?X^^#7VC10!\7^+/
M"MO?1^)(/!-AXJT7P5+9Z<-0%QI%].DU^MV6D:>UE9)IXS$ MPT1+,&7DX..
M9.E>*[ZU\*6U_H'V+X=6=UJRW"OI.KWNFW-P5M6MIEL3(MS##S=+&K%HU="1
M]Z-J^]J* /D3X#^!Y]#^+W@C6_$6EZW<ZI=^&;VTM=7U739TE0I>.T44Q+R>
M41;'"^<^\K@'Y\BIOCO_ ,G[?L]_]@O6O_1:5]:U\C?'296_;\_9^B_C72=9
M8\=C&H_H: .[_8E_Y(M<?]C#J_\ Z6RU[]7@7[$O_)%KC_L8=7_]+9:]]H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY
ME_;8\ ZIXQ\&W%WI_@CP[XKBL-,O&FNM:O9()+,>63NB5>&. 3SW KZ:KY$_
M:I^$7P@T/1_%FN>*O%>H:)K^KV=Y=6UM/XAF@CGE\MCM2+=@KNQ\H&.: /<O
MV;_^2!?#W_L!6?\ Z*6NK\5Z9K&J6=M'HVKKH]PEU'++,UN)A)$&R\>">-PX
MSVK@/V3_ !!;^(_V=? -S;0W,,<>DV\!6ZA,;%DC"D@'JI(X/>O3-<U:+0=(
MO-1GCFFBMHVE:.WC,DC #)"J.I]A5)2C.W46YH<BJ%UK>GV-P\%S>V\$T<!N
M7CDE566('!<@G[H/>N?L_B%$B7"ZM9R:3> 3RVMB\BRSW<$0!,J(O/.1\O45
MF:#<MXVUQ]0N_#,#Z-J&F*+;4;B,)<>4Q^>VGC8;ADDM@<8]ZT]DU=R W[7Q
M@EWXBDT^.PNC8K9+>KK& ;216/W5?NV.?3%;&G:I::Q9QWEC=0WEK(,I- X=
M&QQD,.#7-WVBZU-\/;W2K66STG5?LTD-H]A'NAA R(P%<=-H4$=.M>">"?BO
MK.E^']9NIM5\/^%[#25_LV[T,PLO]GW$199Y(@@_> O)"?3D]^3T4\-[:+<'
MJB)24=SZ#6:Y\,WFO:KKVOVYT5WC>UBFC2%;- H#*TA/S;FYYZ9J;PKXL_X2
M;PRFL-IUWIJMYA6VO%"R%5) ;@XPP&0<]"*^=;WP'K]OJ=U;>,M9T[QG::YI
M]O*_ANUNS#<:G=1%#YZ"0!44*I^53@XYYKH_$'Q+T[QY9>&QH$^BW.AKJEM:
M+8R:@]G<Q7$;?/'@?*P5!PG\7N*Z'A>:UM?/H0JJO8Z_4/B7IOB+0?!NL&T\
M06T>I:LD$,.G-RK;F4?:-A(\KY3G/'2DT_QE/:ZK=:9X7OK;7K<M=(S:E>R/
M<Q:@2S);E=OR185N3T &/?Q:'XP6/P=N==CTGPO'X;\2W^M?9WT._N'-JMN%
M!64,I\N$R%F(/W3M-=IJ'Q>;PQXYD\1W&C/I>CW%CYTPLY[6;^TT\Q$2[)4^
M9L1&SD]!6[P;7PQTZ:B]HKV;.EOO%%W<>%[F[^)&E:"8](1;J:TL-0#LEZKE
MHXP&(&2FTC)ZFO0E\=:'-H4M[=W,<21V27EU9MB6:&)UR-\:Y/0XX!SS7R3\
M1-!TR/XD6LFM^*X?&&C75TE[KJR0!(5A*@V@/E<,4W,Q8_P%<\5G>%_&EM\/
M=6U'1['PC=:A'H<,FLWNI^>WVIY(@S0!Y$.QH&!7" X SQ71++E4IJ4=]]-%
M^/\ 6QE]8C%V;/J?PC\3M-C\*W^J:I=:39:;:7&R$Z;(76.W)Q&TBX!C8\Y!
M Q^=7K'XE07D]ZUH]GK=N98_L*Z/<I/-)"VU7E=0>%63<,CLOK7S/%\>H_&5
MOK5_X=O-/\)V<>E>?J4LUDJ+JMYYB%DA5_F<;0\?S=Y!Q5?2QHW@KPJT&MZ=
M=>&-8\33-/X<\.Z&F[4+- XD3S),Y"M)ERK':-Q'8XAY=:[DK/M_7]>A*Q'-
M9)GUQXK\>:#X'MX9M;U&*Q6=]D2L"S.>^% )P!U/0#KBOG7]D+XBZ''JWQ-T
MMKQ/.U#QS?R6$B,'2\5E0EHRN<JN.6Z<@5Y[\+OBMX9N/BM<>.]9T_Q$G]IB
M2/38]8F3[*-PVW!A.<,>%&T#N>M8G[/.HW^J>%/B)J?@RQN_#VH6?C:Z\BPT
M[3HVODM75)'MWW_+&IV[OE/45G4RUTFHROZ]+_\  *CB82=KZGZ#YKD_&GB#
M0%L[[2=6U]M!+Q)NN5N?LKH&)V[)3@;CM/ .>#7C>G_$>+1?BM:>(?%5YJ6F
MBZTV2QB@:)HM/9E4W(8[SGS!%@,<8#9%9NO_ +1VB_%#3=.TV+P1'KM[)+%*
M-#U2,2R2,2^Y(P 0LBJJMN;@*X]:Y8X&JI)VNNYT>TC8]^T7Q-'-JE[I3VM[
M!#9"&.#4+H Q7N],YC?/S$="?6MKSK6ZN @=))8^<*<E>U?.'PCU*]TFTU;Q
M!<W%J!?WS7NJZ7/<NUYI!9L6T C/RH N<YQU&,BO4==\2:;H5U!!-<1:5J5\
MRI:V4\P1II">"#GEASP*BKA7&?+'^NY,:L6DVSL[K4(K"WO9H83YJ-@@@C>V
M!CGTQ3H[I+F3?)-Y>%VE8Y,X9ASD>M>:^*OB)I&BV\NC>*?$EIH=Y*GVA%O9
MEBD\H'&0O<%@W2C0_&GA^\\/B?2_$.GSW:2@7$JRAD(0@$,1TX(Z^HJ?J\E'
MFL#K4XNTI6/4TF$*I\ZFVV_ZYWR2>WUK.FO;^'5K<J4ETR0MF1!D@XP%..V:
M\ZOOB-X+L$U0MXDT^5;5%-TGVH%87+97(_AX!QFK7A_XR^'VT635&\1:;+I5
ML/\ 2+D2J$AW$[&8CN<@>U3]7G%*5MR5B*3?Q(]'L+B 6LDVYHE+%G$W!4^A
MS7RO\?OAC%=_'#5?&6KV'B_6?#^K>%+?2M._X0FZO$FAU*WGN9$$HM75@&%R
M-CN?+!5]V/ESZ[>_M(?#ZVC5-2\2Z4L<L0F4>;D.A/# 8Z?SJ,_%?PUI=C%)
MI_B*Q-C>72I:F&127>10PC ]P0?7FG]3K/>+']8IO:1\L77P?^(?A]?%UYK\
M/BO4?BYK]EI-]X=U7PY=W2Z;!J\>GV]M/]K$+"!=LT 9S.I1HB N?F6ON.SO
MH=>NK[1-2TR69K!;9Y;BZMA]EN9&&\-$3G<491G@;3MKD-8^*/A73-#CG?Q%
M!:6URK@R),C$,AS*2V>J@'..E5;?XQ>$+R"ZN['Q%;ZI#<0[T:)PH2.+_6.6
M_NJ6&<>M3]5J[\K^XOVD-[F%^RMHNK^"_@KX?L=4TFYM]1BOM16:UN(3%+;Q
MR:A<R*Q!'1E96'L1ZUZZGBF*YL[B:WB?,4OD_O?E4MZY]*X[4?BIH>@Z?IVI
M:EXDM=.T>[0&VU%W!M[MF7<"K_3/Y50M?C=X0U#PW<:FFN:/+HMO=);3W<TZ
M^2DC E1P.IZ\_A3^KU&K\H_:+8]+MM3,EW/%(JI'$BL9,\9/49I(9HI-8G42
M3"5$'R,?D(/=17'^$_&WA[5K&^UBUUO3[_2;B?R//AG!A\U5&44GJ<8Z>E5+
M?XGZ!)/!/9ZYIOV:8+&$DN5\\22@M&%!/.X D#O@U/L)W:41\\>YVM]-<_;T
MA*$1OQ&T<FWMR6%7=/OH;R(>4^2O#*Q^8=N16%>^)])TF2Y;4=1M8;NRL?MK
M&X8J8[?)!E<=AE6_*K6@W+S017D4"7"7I$@N82 IC(!5AW((/ZUBXOEU11OT
M56FO/)N(8C&["3(#J,@$=CZ5235+YO$C6!TJ0:<+?S1J?FKL,F['E;,[LXYS
MC%9J+8S7HHHI %>-?ME?\FL?%'_L W/_ *#7LM>,_ME?\FK_ !1_[ -S_P"@
MT ?/O[(O^L_9D_[)Q=?^C(:^Z*^%OV1?]9^S)_V3FZ_]&0U]TT %%%% !111
M0 4444 %<]XH\#Z7XOU#PW>:BDCS^']2_M:Q,<A4+<"":#+#N/+N)./4@]JZ
M&B@#SW3_ (&>%=+\7?V_;Q7B2"_DU:/3OMDAL8KV1622Y2#.T2,'?)QC+LV-
MQ)/H5%% ',?$L,? .O;=2CT=OLDF+^:T%TD'R_?,6#O _NXYKYH_8RWCXP?%
MKS/$MMXK?R=+SJ%KI(TQ#^[D^7R0HY']['-?17Q!/Q _T/\ X0=?#;?>^T_V
M^]POIMV>4I]\YKR+X MXH;]HCXN_\)>-(&L"TTD,-%:4P;?*DVX,@#9Q0!](
MT444 )116-)XBCNM#O-0T95UMX/,5(+:51YDJ$AHPQX#;@1SWH2; VJ*RX]>
MMDFT^UNY([/4;V-GCLI)!YAV@%P .NW(R1ZUI[AZT[ +25EZEKT&EZEI=E)%
M<22:A*T4;Q1%D0JA<EV_A&%(&>Y K4S2LT M%%)0 >M)7G&K?& :7XQG\+G0
M[I]9W(]G"TR(M[;D#?+$Q/)3YLIUXR.M;7PU\?P_$?P[_:L6EZCI!69X'M=4
MA,4JLIP2!W4^M;2HU(QYVM">97L=#=ZO9:=<6MO=7<-O<73E((Y9 K2L!DA0
M3R<>E374S1VTKIMW*C,N\X&0.,GTKRGQ]XX\,^&_&L6I>)+MU@TM8X+2QFL
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M_P#^1V_;A_Z]K+_TD% 'Z">'_P#D Z;_ ->T7_H K0K/\/\ _(!TS_KVC_\
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MFR1X%:DL'BXM62[=.VYC^ ?%UCXO'Q'\/21CQ'9^)?%#76E6\02S>!EQNFN
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M3_:;IHV>66YEQS)+([,[M[LQZFO'?V#XDC\(?%9E159_B;XB+$#!8_:0,G\
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M:);6[175K;F%(IE6:U:W.]D1ONX_AR<]NF*/$WC-=%EG%MI>H74.T'*J/*&
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MYBNM4;%NBBBD 5XS^V5_R:O\4?\ L W/_H->S5XU^V5_R:O\4?\ L W/_H-
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M_P#7M9_^DHH _03P_P#\@'3?^O:+_P! %:%9_A__ ) .F_\ 7M%_Z *OGI0
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M).[29T)D]GX6TJQ\07VN064<>JWT:0W%T,[I%3.T'Z9K7H]J6L;MZLH****
M"BBB@ KY ^.7_*0KX"?]@75O_0#7U_7R!\<L_P##PKX"?]@75O\ T"@#T']B
M7_DBUQ_V,.K_ /I;+7OU>!?L2_\ )%;C_L8=7_\ 2V6O?: "BBN$^-'Q$G^%
MO@&XUVUL8K^[-W9V%O'<RF&W26YN8[=))G .R)&E#,P!.%- '=T5X)=?&SQI
M#>ZOK*:3X?\ ^$1TGQ#'X>GM3=3'4Y7,\<#3(-NP$O*&6,C+)M.X;@![U0 M
M%%% 'R+_ ,%'=)O]7\&_!D6-C<7QM_BAHD\PMX6?RHPER"[8'"@LHR>,D>M;
M?B_3[I_^"B'P_O%MIFLX_ FI1M<"-C&K&YCPI;& <>]?3]% 'RY=:==_\/)+
M.]%M-]B'PV,7VGRV\O?_ &@QV[L8SCMFI/@/I]U;_MF?M(7$MM-';SKH/DS.
MA"2;;5P=K$8.#UP:^GZ* /A?X9_&'3_V5?C'\;_#/CK1O$"7WB/Q1)XB\/G2
M=(N;Y=7AGC4+'"8D(#AEVD,0,D\C%;?['>L7'A?X-?'+7O&'A/5;9)/'>NW]
M[H LFNKDQR,C/&L8'[[ 8CY<AL'&:^R]H)!(&1T.*=0!^?'PAU?PU#^TIX(A
M_9HN?$O_  AEZ]S)XTT&\L[V#1+"WV I)$EU&HBF,AP%B...F,UU?P=^&NJ?
M$#X=_M?^$HXY+"\\2>*==LK*:XC959IK4(C#.,KN8<CWK[:50O0 9ZX%.H ^
M(_AO^VQH?@3X':)X'\0>%?%-I\6-#T>/0V\(1^'[MGNKN&(0J8I%C,?E2%0P
M;=PI_/DV^"WB'X/_ +/_ .R#X0U>RD.M:7\0]/NM1AM\S"V:1;R1@S#(PGF!
M21QD'''-?H-M7=NP,^N*=0!\W?M<6-U?>-_V=VM[::X6#XB6LLK11EA&@M+D
M%F(' 'J?6OI"EHH **** $HI:* "OF+]MW1_!VI>#9I/$W@?Q!XKO(M,O#9W
M>C02/'9MY9.Z4JZ@#(!Y!Z&OIVOG[X\>#?B;<>#O'5[9?$2SM-%;3KR1-,;0
MDD98O*8^7YF_)..-V.] '1_LO^)M+U3X.^$='M;R*?4M+T.P6\MD.6A+P*5#
M?45W>N1ZY_;5A+:75G;Z$D4W]H"1&,Y.WY#&>@P>N:\4^ ?P[OX?!/@CQ%X>
MF@T:74O#&GKJ-X093<2($(#19VY,88;\Y&>E>T_\(Q=W/B--3N]8NWBMW?[/
M8P$10;&15VRK_P M""&8'C&ZNBT(M2B^G]?\ 6O4\ZT_PO"OPGMM0LM6;X@7
M,%R=2TK4/$-QY:I(V45F8@?*H9N",\D>E/M;W49KSPAH^O\ @72M=2XC:&ZU
M73?+EM[)@"RG8RY6-@/7O5S]I&73;/X2WFFW%QIFF1:A<06D/]I1.;7)E5BK
M"/D?*K8/&" :@\*ZIX/T'P'J^H);3>%M,>9=)-Y!)YC2! (HI(F4MQR,$_C7
M=%N5+G:O=NW]*WY&=M=#SC1/B%X>N%\:WM_J"Z5>0ZK'9W]EJLKSK:V'G"/R
MHUB7";L' YP3R:ZF31KKP+?>,/$FJ^(4\4:O<V\TVAZ0TXB-G8X&53(."<ID
MXYVK6!\1O"K_  _F\-P>%/$#:;H^JW5K8?:;B**:T@=9M[RSN1NDDE)V\GJ3
MTKN9_#L7B+Q!XG\3^&6T_5O$EO:IHBBYA> 0NK R@R<Y!!!&%XP.377*4%:2
M?NO_ ("MY?>8N/1;GSA'\3-6T?P#X8NM+\/2+X7DN?M4.O7$OV>YL660BXCF
MDVE=SRAL8&-K#CTYOXR>*KOQ?=7WB>"UDL='M[?^P)I->MS]JB,A\XRQ(HZD
M':N#VSQ7U-\7/ NJ7?AOP5X3TK2(]7A>]07.J:E&+D6&P;A.Z J)#N]>/:LR
M^T'4_&WB2&;PO<Q7UUI&L+'JEYJ^'MQ&80LGV5 ",D=B3M-=]'&4H_O5%=;_
M 'Z7]?Z1S2HKF=WJSY]\/_M#VUU&=!\9:7'9Z)J?A^&SMM-CW+'<L2R++*P_
MU2_+DX!(K(TOX2ZM<?#;5_LKLEOH[?8GU7704CLHRK&[^R,#AE+ _-CG</6O
M4_B5\&-#N?$D$GB;4M=B?P[I4DDOC*."+[,7,I9(W 'WD#;=N.A%>7?\+)L/
M$6AZ?X3\9W%UHFEZ;<R6-J9"S0VL"J3%]NMAS+(0!AE(')/U].G44X\V&5N_
M_ [_ )G#5PKY7!LR;R/PGI<>E'P790N6MI+*36XY)(%N) H-PS-*2$01.OS!
M?O%@.E6?$OA'0K?1]!-K%=7>MZ'#-8W%U9S?:88V*AK<R.H"JI+-SCN<UW^F
M_#*#Q1X;FM=-T^"VT?2UAU&/3]2F=I+JR8MYKO$OW Q!>)0V>3G->.?#1?&%
MU_:MUX?NEMO#S:A"=4>^"XACC9CN/.[RT0C=]0*Z**A).2D[Q[OO_6QYM;#<
ML[MZM:[V\OO$T_X1ZY\3+RWG\.8TB[N(W232)92OE20!0X()^X=X"\9^8CUJ
MUX.^'&NW^N7.G:)KNFZ1;VI;^T8KZ\ DMP%Q*"-H]&SMY &,]ZM7NC,WQD;^
MS[F[\0O<K'%9:AI;Y2<- SJT8S\C*57Y"> IJEXZT+4H_&(/C82:GXLN!';+
M'I*(B7""!3YCR='D(8*3V*]Z[$G+W5)6:O:VWR..6&C"3275::?=I]YT6K6.
MFZEXKC:P\2K<:WKMI!#<BS@*I>,2QEF4R#^(*JC<!GG\?.OA%'<KX,\;V^HZ
M'IUM=Q>-':&WU!?*&]8@K0QL!]_H>?E&/>M^W^'FK:*+F\\5:PVD:)J&G_:Y
M9[6X$LFH*C#=$@Z>:A*_+D=*Q?@#>7%CX+\01^&+U+V_U;Q7<V,1UR$*(4*I
MM7);;YC#YL _PCVKBJ4:7/&UGT_SU^0JV%4H3J17Q6^Y_GT^1Z5X/TV+5M5N
M--L=,71O[,/VF]L-1N!+-<1L !)$V '<LP7'OBL_4-;L+3PI.1%>6E[-(T[0
M6 22>WC.%61N."2I^4YZ5'X"NO%7B;XM6?AO4;>TN()5FMX[V2$B,K:LY61#
MGY5+Q@'/4DU<UFUU?0=+G@M;*Z1[-4$7V>)9K^9G9R8I3DB-006W '@K7FYC
M@Z6*JQI5(7=E]WW]_+U/!G@I4?>BEOO?KUM_P2OJ'BBV\;6FGZ<NL26]_*,M
M/'^YENE"_,"/[I [>AJ_$T=EKNG6<UO;VWDL)+589B7*;,$NN>%/W>3R37)Q
M6#^*-/M_$.HZ?%'K=NL<D,PG+3O&H(>><#K$A Z#/2LR6<ZQXHU&[TJS,BQ6
MD<EU>W:,\4,<:C,T9W MDC*J1Z?AXV'X8IQJ2=-N%T]'9V;:=T_.QA)SJ.TD
MVEL_\[7O;\SKO$:R^.-0FFDEGLI["<,EZL+1?*,AE4YVLN %SCM6=JOCZTN-
M*GTV^NA:6UR#%%>0QNIV='*''+$X_/VJ_J^O:[=^ 8+&VECUVXU&^MUTV21$
MA#P@%V2==W4NPZ-W-6+'1->OM%N+O5VFO%6X:UGN(TB6TA<LH)5<[GV-M''K
M6%+(E5J1G7<9\KLEI>-NM[:MO>_GH9N-2%G3DWWM^O9(Y^P\9S:#HCZ=?:M&
M/#Y@DM[.2RA.XA2"1\PSY@ 7GH.:P;K4?#]G)YEQ=>?YMKY+O=J[:E""A964
M9"[6#+WSR:;K6H0^'EU"[O(H;S6(KB6Q>2<"YMBO)!C4XV,!V(KIO"7@.YD\
M.:+':V_]H+XIL;B^FN%M5GDC2+<'B1B1ME"IPQ[D#%?;4\-3PT8S4==%NOFU
M9;V]+G9A\%[1IR5WMZ:'-6_B&\L?%UAK4^H0WOGAK6%+:8F$/E5P<KG;@]AU
MQ7LMGIEII/Q3;0[75O/@O=+,FHK?P,/)+1F,13END:N1@ 9Y!S7#:;XCLO#]
MSI$>B^$;G7!96L=S:MK=D/-O8U)/F+M. J#=@@YZ5UNI>.-(:QUGQ$WC;3KW
M6=7MXS&-6T4FYMTF.)(]R$C8D>[&>,@5E.+^"UDE96]=-$GMW/7HX6%&?/:S
M6B[VW*?A3P[!\'=<UK3M<6SU'Q+<6I2SGGN5(L2$/S*C)M=#C[X/ [5@ZQ\0
M-8NO"OAC5='@C3XA7^K2L;K2Q()SPH,8B88=F(4EEZ J.YKT9;KX>_$3P+J?
MAK4]9U6PTS35,EMXGU)//5PBA%$!*ATC& 2I'.2,]ZU? NLZ%I.O:9KWC6XT
M]8]&M-VGZRMW(T)-TNVW\J/9D'$$A.?N\?A@JCC%RJIREZ;]O^"CZ*E1YJG.
MG_7^=CR#4_$47B;0?%>E:W9^([WQ++?/J%[):6?DB&'.Z='5R<(L@]."!]*]
M8\"V?@CXCZ+HMYJ5S<64R:$T_B"ZLCY2-IT#F)(I5.6).U0=H&=N>G%7M#\+
MP:I<:MYNO:MJ_P 4-*M)FD\/7\IDAGB68.CJ=H\Y,%64%OF.W(K;^'^DSZEX
M-\6_$>PT"*SO[V9/[*L+<BTNKTPDJ\%PI)7#R*3L7J *PQ&(AR6A[K7ZZ?=U
M3\CJH8?EDTUIJ_UO^)9\"ZY\.OASI\&A>$(-3\77FI1FZTA)H5(E=RZM*DCC
MY"H4*<] J\&N_P#AS#XOU#Q9ISNTUGI6EV5O$T.JZ>$FDBDB)<>:.#(LBIPN
M !GO7+^(O!FD^*?'FC>*M:T"?0=*T2QM[_4-3L[LI"UPN"D*QHIWB-MP;&.M
M>JZ[\0M576M=T2P\-:NOV737N[;64A5X)I-HVQH"?F?)Z'T->%7GS+W%=M:M
MVT_K[STXP2.AU?2?[0\0:;J:Z]/8P:5YGVBRAD40S;E&/-S_ '>H^M=!'(LJ
MAD8,K#((.0:XGPOX/T_6/"-S)JNFN+OQ%;1OJ\=PAB>9S$$.]03M.T8PIKL-
M.L8=+L;>SMHQ%;6\:Q1(/X54  ?@!7C5+;7V-T5+K16N]:BO'NY3;+;26[V!
MP89-S*=[#N0 1]&-7[6UALK>.&")((8U"K'&H55 [ "IZ*RNQA1110 5XS^V
M5_R:O\4?^P#<_P#H->S5XS^V5_R:O\4?^P#<_P#H- 'S[^R+]_\ 9D_[)S=?
M^C(:^Z*^%_V1/O\ [,O_ &3FZ_\ 0X:^Z* "D(S2TUA0!\4_$70?"_QCUZ*7
M0? DO_">7?BG4[%%@\77VD63-8%HI+V=K7'[UTVJ-L9<AR-Y52:^AOV>9K&+
MP'+H]KX;A\)W>B7TVG:AIMO=F\C%TNUWD6X8;I@XD5][@.=QW -FO%?^%;Z[
M\5OB?K/CWX>>'OAWX-?1=7O=.@UC5M#FNM2U*ZB+P7,[O!- $1FWH-WF,0,D
MC@5[%^S3>67_  KF;2K;PU;>%+O0]4O-*U#3[.5IH6NHI3YDZ2-\[K+D2[G^
M;$F&)(- 'K5%%% !7->+/ FF^,]0\+WNH&<3>'=5&L67DN%!G%O/;X?@Y79<
M2<<<XYXQ72T4 >;Z=\!O#.E^,?[?@DU$1KJ$FKQ:,;MCI\-](K+)=)#CB1@[
MDC.T,S,%#$D^D444 8'CNWO;KP?K$.FR:?#?O;.L#ZLF^U#XX,J]T]:^8_V;
MO^$A\+?%7XSS:RF@:SJ]K8:;,L'A&#R;>;$,K+&JY^^<8Y/4BO8/V@/&S:!H
M*Z+-\.]>^(&F:S#)!=V^C(A"1X *N2R_>!/3TKQ?]BK3](TWXN?%F'1/ VH_
M#VQ\G3"-%U/B96,<F7^\W#'GK36C ]PD\!S^/+'1=?M[_6? U_<S1ZEJ%C;2
MC=,^Q5\J;/& % P/QKK_ !)K<<-]::";.>:;589T294S!'M0G$ASD9SV%3:Q
MXAGTO7-&T^/2;R]BU!Y$DO(%!BM=J[@9#GHQX&*H:]8V,_C?PU<SZ+<7EY"M
MQY&I1G]W9Y0;M_/\0X'!KIYG)KFVUL2[(\/^&?BJ#P1+J][J,E[=OX;M6L;Z
M/P_:2?V:ZK)\J@RD%I8EW9QV8]:ZG7=3NOC=I4IT/PY;ZEX3U&#:NN0Z@L$]
MPJ$DP%&CW*K,I0G/ )(KH/B9X-\3^,H;C0;&ST.#P_=74$DMQ=(SN4'SR,8P
M0"VY4 R>A.:FTF3Q+X@\Q]!U+2='T*PU!HXA;VA<W4,8VRQN"1Y3"16&Y>U=
M[J0G:JOB]=ONZF:BUH4KC0K";QYX=TBPT31HWTW293>V\BDR6L4@41*@ VNA
M=&!SZ9KS&XTNY\2_VSI.KZAI7C#Q%J GMW\+Z=,+"U18F"FX1F0MYR<98?TK
MJ_#?Q-U7PWH>N:S>^&]3U[6GU<6<MOIMW'=1'*Y!MCD$18 ^4\AB:E\7> =7
MT#4-:^(5GJ$EUXCF6-;"SBTZ.2:WMNLEM&A<!G<DDL3GBKIMTY6D_3U_RU\B
M9)21Y'I>N1:O\/\ 4M>\'27NDZ[#$FD:Q8ZM=AH+;R ";MY&7 E$:$*P&,GI
MFN"\&ZEJOP3\9:7Y.A6\GFH-2UC4Q&\L5G:S$(9XI5;YXVC56R1PX;UKW/XA
MCPU:^%YK?Q)HOBA]*L;PQW=[Y\8;;=0L'DDV_>2,-MP1D'&,US6N> /#=WJ6
MI/H=]=Z]>IIDVG6-SJ&1I^G6XMH]EM.G!D4AMX('5N:]>C6C9Q<='_6YSRCU
MOL?/VK7=Y\1-&T[2K^_U*_D@B:/1K;28?*M'A4GS)IY7ZONV[OE_G5+X:V=Q
MX%$UM)J]E9W.N2/I5_=1Q,]WI+ %L,[#:NXKR!SA3@Y%=?XYUZ^O]8\"6HU!
MTNM*M+C1;ZQBM@I=HBJRE60982'#+N4?=IWAOX;ZOJFM76GWUUX9UW29=+;6
M-2OK)W=C&K8\X@<_:!OR"1T+ ]:^@C6C&G:6B_X/]/U/)K45K*/4\VO+RUOH
M[;1K>4C1ECE%UJ$*J;FZEC9V#'(RJDD$+GH1FNBTGQ%JU]OB@EM=*U/;'=(]
MY:^5$UN0%,K'^+<2N,#M5/Q1INGZY!>:MHVBZUJ/@+2H6M3D)%<0WS1\2R[>
MJL0AR1]W"]JB^(=AJJ^"?"?B#7K/2;G3]2A;R+G2)2)XT0+MB;G"$$],'H1U
MKN]I&?+'O_PY\OB\O]HKM72Z=O\ ._R.J!N;K69[9Y[75[NT59;Q5D,!EE (
M01*1SU!)-:.J>([BQTJYU2UDEG^QJOVFSCE5MO #CIU7^E<-X7OH;GQEI5PT
M"ZGJ\FF1BQEDN"X-PRDL)>F2%)X)XXZUW]FV@JEE'A;#4_LI2Z%M*+BV>-7+
M. &/#GGENF>*\[%8?FBX->[I:RU\_O\ 0^4Q.$5"<=;/KOJ26^H+J%O;26WF
M2PW.TC:IXW#.XC^[P>>U2+I-M;ZA_:$D0%R8_)CE#$C9D$@CZCKBH[#6)(=-
M$URUF;V*',=O;2;CY1) 8>Q&.@[55TWQA$M]=Q:B\=O9[E^QS*O,J$C('L&.
M.E?D>(X2]M6E+"0<8JZN]>JV770Z*6,DE:HTVM2U);_:8P-KP74B^63"W*Y)
MPV:YO7-4_L<I%HFH16=W<732?:;V4&%L*!)DXZY ^4>U=!IGB:UNM<DT_4-1
MMH]5,PMXK2.(@JS$A03WSQ^=<RO@S4O%5]J>D?8K/6;I(9KK['93;(H&C/W
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MOF;?[),^G_"3X3>.[+Q-IIM=1LO$E_(U]#%OAMYXT7RXY'!Y)+[57G))KL?
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M*\#Z+I&E2:;%9+/927+W;171,P\UGWEANS_$>/2N@KDJ24AH6BBBLAA1110
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M>#D8%7_B9HOBKQ#I=K8>%M9A\//+-FZU1H_-FAC49'EH?E)9@%.[H">]>?\
MQ/\ #GB;XE>%[W2_#OB[6--N=&C-GJ$=K9)&^IR&-&!21V4 <_>5@.2*TIOG
MY6Y)?>[+SZ$O0Y;4)[_QA!::%JWB6SU#5=(W>(O]"E(O;)H\26\2PD SJ4R"
MS8.2.]94&H>!ETG0-1\1>%IC-K&N)-#X?MKH/#I\DJL8YIXB5$3.I+,I')KI
M=-U#3[.\T_PUXH\+:A=>-H=+MX]4\3VL"PIY(0&20W61PF.0#D\X%8OQ$\*Z
M9\2/!9U+Q#9R>&M9\2WJV%MJ/A^-K])[=)5D@F?;P"0H^<XP#[UZ47'F47HO
M+]+=#*2TNCI9O";?%"R\3:?8+'X4UJUO)$L(=0TV(-#:,B)(RQJWSI*5;#L,
M]1VKY?\ &/PS^-'P;N;+4YVD.FVHDBM+JSQ>"QA9@IC8D;E4A@<'/*CVKZ"^
M%XN]8\::_K&C3ZCJK_V';Z'9:S'$JJXBD9))I#(1F59%<E1D%0O4FO+_ !SX
M?\;W&FVVO>-/'XU;PY8ZE)I.M662L0'F+RIMP>I .7"E2 #Z5Z&#J3HU73YE
MRZ:-:[=/^"<U9*<;VU[G':7\(;'Q-J4BW7Q3TG5;1+PM<7-Q#+%<19!=OWK#
M]RSL#D,>?4GBN?\ %VB^,+3P+)J>G^'8="MWN+LWFI1WF6U*-!\LL:L<LB+T
M=.IR>];4NO>$=+\5:S8Z1X7LI)(99;EO[:UV8VNI1@YAE"YQ,74G"\G+#WJ[
M-\0;CQ%\+M2\,MI%MI6O7&H-NN-28XT^T< R! V?*"J-NU>0@!(KVXRJJ2:5
MUIO;]&><X1V;/,=?UF_\-VOAF]_L^.U:+1EMX[[R02TK,Q4OD?+(N3SUQ@]Z
MA\'_  XO/%D.EWFGW.HW&M7%Q)+(OV4301JJLP=I QY8C^(#K^?0ZWXP\*_$
MS2;];;08M/\ &,Q+2S7.H[;$*@4&5 [#]ZP7&T#G-6OASXQOO!M[K7B73-2E
MCT+4K7[#);7ELEI#>W'E_P"I81G:GR;F$BD=O6O0=2I&E>*M)'![&,I-7W_R
MU.5AT:]MYK,V>O:8A@/VVV$!4%+Q6!,<AQ]\+G&?EX KJ_AGI=Q-\:=/@.HS
M1:7?DWE_+';PQ(I3+.Q57*QJ#C]YUY/%/\1W?ACQ=JGVS1?#=GX>T_5M).FV
MD<UW]G_TA K&Y#M\A0%=IR<GZU.WP]TC0=>TCPOK.APZ+K,=G]JN]4:YF^R7
MC+DJI8?*('7;N<#((-95*JG!J6C?I_GT##12>FO2_P#7<]5\!>-=8\+ZM>BY
MMG/B[6-0U*PBU6\O&DLM'NW8O!"F3L\M\9X.>!D=J^A-$MKJXB30OB'H>FQQ
MP16MS%J\)5+>YN<\J>F'$F2%'4&OF"/3? 6M>*=4NWN_$VAZ'K+_ +U+FS#:
M783R%7EG2X+;,94JKCO(".*]MTWX>W7C#QI;7&F?$:>RL-/AM<>&;A(+P?94
M8&.0MN/^L(W"0_-\W6OD<9"$GS?#\G^']6/I:<FE8I_ 'P;H]]=?$>^\7?9=
M5OM#\<WUQ%J<X\E8GVQ$/C( P-O7TS7TVK KD=*^<O@AIO\ PE=]\>?#MYI\
MB:;=^*;Z+[>Q1HW+Q1@J%Z[EX/(QS7K7PF\#ZC\._!EMH>H>(KCQ,]L2(KVY
MC"N(^-J'!.<>I-?-2]Z%Y2U[>IU]3:U>YUR'6M(CTZSM;C3)'<7\TTI62)0O
MRE%Q\Q)K;YI-M+6#=T4+1110 4444 %%%% #68+UI:RM<\/6VOOI[7+SJ;&Z
M2[B\F5DRZ9P&Q]Y>>AK6H **** "BBB@ HHHH *_.O4/^1V_;A_Z]K/_ -)1
M7Z*5^==^/^*V_;A_Z]K+_P!)10!^@GA__D Z;_U[1?\ H J_5#P__P @'3?^
MO:+_ - %:% 'B'Q$^!_CSQE\1+'Q/I7Q6;PY'IC2'3;)/#MM<_9UDB6.5#([
M9<,5#<]PN.E>@_#GP[XH\-Z3<0>*O%__  F5Z\WF17G]F16/E1[0/+V1D@\@
MG)Y^;%5O$6M7MG\3O"&G1:I=VUE>07K3Z?%I#SPW)18]K270&VW*$DA21YF2
M.U.\/ZQ>W7Q.\6Z=+J=W<65I:V+PV$NDM#!;,XEW-'=$;9R^T94$^7M&<;J
M.UHHHH **** "BBB@ KY?\8?$3P_XQ_:V^$=EI-\US=V":NES&T$D>P^0!P6
M4 \@]#7U!7@GQ8_Y.F^"8S_RRU?_ -)UH ]YW 8'>EK%OO"UIJ'B+3-;E>X%
MYIZ21PJDS+&0X ;<G1CQQGI4^OZE=:5IS7%GILVJSAE46UNR*Y!."06(' Y_
M"GRIV2 O30)<Q/%+&LL3KM9'&0P/;'<5S_AOP[=Z;>:Q/J=Y;ZFUU.WV?;:I
M$T%M@;86(^\!SU]:Z122H)&/:L6V\*6=KXJN_$"/<F^NK=+:16F)AVJ200G0
M'GK51E9- 4;CQ58^'?%&F^&S8-9074!>VN@$CMBX; @7D9<C+;0.@KJ<\5B^
M)K;1XK,:OJ]M#-'I :]CFEC#M 54EG7C@@9Z53\&ZYJ7B*&ZU*=;/^Q;KRY]
M)EMV?S98&0-NE4@;6R>@[53BI14D(POBGJ_C#S=,T'P=8F.]U(L9M;G4-;Z?
M&I&YB#]YSGY5^M;EUI>G^'_"MY!<7$ME'<AA<W=GN24S2D*TJX!*L6.<CI3]
M7N1XPT;6]-\/Z\EAJD#FU>\M@LSV<P ."IXW8(X/K5[P_<7D]B4OK::">!V@
MWS%,SA3@2C:2 &ZX.#STJW+W$MK?>%M;G$>(&\6:;H&J6,<-L-*@,$$.IW&I
MM%<&TV8GG>3'RR+R0>^,T:EH?@GQM#X8MI+]M0D\Z.[LKZTG+/<M;]#),O#@
M$G(8\FMKQ5!%X^MKS0=*\00VEU9W$0U*%(DG)B(RT,B-T#K^AKG_ !EJGA[P
M3#H7@,>']2M]&UP/:QS:';E8;0EAPQ3E-Q8\@>I-;Q=[6^+R]-R6;&N>";A[
M.#3[2[O[F&ZU+[5<W4VH,MQ:)@D^0V#@;@J[1_"S5YCXBC@\6:EK.CZ'X\U#
MPKJ6HZBT.E"2WVV\K) HN42,X\T?>8L>C$D9KN_BAXL\/?#>[M?$M^;V]U2Q
MM&CBTZRFR[V[.BR2F(D!@G!+'IS7E/BSQ)XB^(&N6OCW3/%%MX9^'NBW/E)-
M<6*O-=H$!>2 ,N[+L3$ ",@ C-=.&C-KF>W?S_&Y$FEH.^*%[K=OX \&W2>%
M;3Q-KC126-SXAT^Z?;9*!Y9E\Z-2?F ].#FN(^ _AC4+/Q)K&H^)-$L;W4;7
M5I+5HWU%IG6*2)C*^U>&E<*J[Y,;@#Z5] ^&_&NHW<T%OX8\'/9^'K&^DM+Q
M+M1:R%&0.DUNN0K(6;YLX/7CBOG7XCZEX<A^(GB6P\3^'-;\)1^(((;IX8+A
M(&>:/>@F65&\KR]LC%_,/4+P<UZ6&G*494&K>F^_:^AC.*OS&8ND-??%"#Q!
MH,=QX?\ !VI64,MU%)?BT?38H9%M]H,9;*@QAMI&.1DC%<[)X?MOA+KFLZA>
M:=I_C&*>\6_T/4S<-#:/)R'B$"]9F!7Y2.0*W/"?A+6/AAX@TFXTVYM/&'PS
MAMKA8M8NXP8?*.Y[I08-S$ >9\LGRE@:Y[_A!O"FD_&;4(CJUU9^&+;4;74;
M34VD*)"S)N6!Y)" I4$-\N6( %>U3DKM7O&WX)]>MSBJ1=DWN1Z)X73Q?X9T
M*[M/"UOJ]XUY/=:[HVGAOM-GF0A!#&1B($ ,5SV%<[I>N:]'XEL+2^CNM7U.
MSBD./$4@M8X48F("+><%%=EEW8!^3I7I.F^$_&]Y9^/6LM6_LOQ5KC6\VGWV
MEW/^A:V#OWB.1CM5V&.ASP?>O%M2\,^(;QK>*_\ $&F:U TN;NSUG4HXIX98
MGVO"SN=R@MG[C<C!KOH2]HY)M67Z_IT^1Y4U&+M):O\ X'XF+?V*^&\VMA?W
M=YJ7G2S:A'+Y:VQ,>"A1@Y\SDL??(XK;TVX\9:]XDCL5TK4[>?SEEU!=/C 8
MDJ2BY _=$J=N,]ZMZWX8U?QQXL7P;<>%8[;6M.LS#;OIC1CA TP) .V3*R#D
M'=@ ]:QM/\:V-@UU<WMUJ5I]LLI;4VVEW"QCS(PJQLXW9))4Y9ADYR*]&,W*
M-EN<\J*YE)[^?ZG0Z>=3;Q%)IEI<ZWX>N],MWFCT6ULC#<0R[@QMHY-P(5ES
M(TC8SL)P:^@OV9M$\-W\L_B#QGX(7PIJ^BRF=->NG*6MVLN-N]W.V1P&SNY!
MR#UKD_ /A*/QY\,6\>^--5N],M+,M('MYH9AJ)2-H[6+[V[?&"5VL/F+#/>N
M>TV^TCXJ:#H?PSDUS7I+BTU-+AX[Z.*-5@8J&MPD;DDC!/ .S)S@"OG\1+ZQ
M&5-.UMVNG?U_X)[<?W5I-&S^SCXNUSX?:C\4O#L=U=^/+K4/$FH%K:UMU>6.
M-5&^X9L_,S[E"H3@[3BO5;/X?7MYJG@A=5T.+2]+N+6&.75%N'M+]FC1F\J2
M !D"CN"<=>>U?._@'4]/\-^,O%4=Y/JWA[Q*GBC4K$W>A6S260S&BP^=(3N=
M44'@ D98\5]&R:]H?C#X-:)87T.KIJUB9ETV'2[Y@=1DB&&D@D=AYRD$L%8Y
M.#P:\2,)0A&<5\6[MZZ]$=OM(W<;G7V]UX7\!:;XHU'2VL/%J:AJRW5IHNAB
M/SO/4*2@P_SNI&[CD#M70Z5I?C3RK[Q<=/TR/Q1>Z=#;KHSN0D;+(S?-/U(V
MMTQP0:\;\&R6-]X7U#2%\+:I=ZU>+&Z&^T=; :?--$L?F-+%SF1CEF3)7<>F
M*^B8]/TGP3'+XDU:]^P.EC!:74D]VQMHU0\$!L#.6(W=3QFO.Q$?9.V[?X['
M13U10^)7B77=%L=#@L_"\GB*#4IC;ZI%;MG[/"8R78>O.5[5U7A?R$\-Z7]G
ML9-+M_LT?EV4R[7@7:,1L,]0./PINI:Q<6K:<UEITVIP74H62:!T"P1D9\P[
MB"5_W<GFN.\/Z3_PL*UU'4KK6-3NM*FU".XL;&:!K)[1H&P5SPS*S+GYNH]C
M7!92@DU:QJ=5XF^T:SIFIZ/H^LQ:7KIM\I.%65[?<2%D*9Z$@XSZ5>T'2WT?
M1;*QDNY[^2WA6-KJY?=)*0!EF/J:SO"=C?\ DG4-=L=.M?$,P,4TFGEF5HE9
MC&NY@&. <GW)KHJQD[+E 6BBBH&%%%% !1110 4444 %?('QS_Y2$? 3_L"Z
MM_Z :^OZ^0/CE_RD*^ ?_8%U;_T"@#T']B7_ )(O<_\ 8PZO_P"ELM>_5X#^
MQ)_R16X_[&'5_P#TMEKWZ@ K%\6:#<>)M#GTZVUO4O#TTI4C4-*,0N(\,#\O
MFQR)SC!RIX)Q@UM4R3_5MU''\/6@#Q[P7^SO/X$CLK;3/BAXY;3;6Y-PNG3S
M6#0-NE,C1D?8PP0EF^56& <+MXQ['7CMJ=<_X9PN2;[QX=;^Q38NI+*T'B+=
MYC8*Q8\CS,8VCIC'>O6K/=]CA#&1WV+DR@!R<=6 XS].* +-%%% !1110 44
M44 %%%% !1110 4444 %%%% !24M)0!6BO[:X^T>7<Q2?9V,<VUP?*8 $AO0
MX(.#V(KAOBEX@T=O!L4W_"06>DBZF\FRUAM/&HPQ2E6&=N"O*AURQ R<<DX/
MBNM>%(- ^&GQ]TGPWID-EIR^,;.2[L[.' >S:STA[_Y5ZL\)N"3U)8YSS7;_
M +./V.Z\9?%;4/#(A_X5]>ZO:2Z,]F +2:46,(NI+;;\IC+A1E1@R+*>: .C
M^">HP^#_ -GGPG<:]&/#EII>CQ1S?;081%%&NQ9'#<QAE57VMRN[!Y%<=\6O
MVH/A)J/PM\7VEK\1O#DUS/I%U'%$FH1EG8PL  ,\DDBO<]>\/Z=XHT6\TG5[
M*'4=-O(S#<6EP@>.5#U5@>HKX<_;'_9]^%O@+PONT2P\&^!Y)+"Z<Q3>%6O9
M+IE3Y0DB*?*(Z9/KF@#ZB_9WTZVN_@3\-9YK:*6>WT2U:&21 6C)A4$J<<$C
MN*[W2]<CU6\U*W2WN(383_9V::(HLA*JVY"?O+AL9'<'TKB_V;_^2 _#S_L!
M6?\ Z)6NZU>_;2]-N;M+6:]>%"XM[8 RR8&=J@D9)]Z:UT O&L+3_!^E:;XD
MU+7H;?.JZ@$2>X<ECM08"KG[J^H'4\TOB>UUC5O#LD6AWZ:/J<GEM'<3P"41
MC<"P*YY)7(]LU/INAC3]2U"]-W=7$E\8V:*:4M%$47;^[7HH/4X[U2]V.X&1
MX\;39K'3AJ%O>W:+J=KY:Z?N+)*)049]IX0'!;/&.M0:MI-YHOBV#6=$THZC
M<:I)%::E)->&-+>W0,1(B'@MEN@'.:VK/2='\,RWEQ!#!8-J%SYL[YV^=,V
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MR;B"5%:.J7BQ_!?1=(5)-1O(RLLEYIFH-&]Y&)"+I)'*[F(!.8SRV.G%8?\
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MBBB@ HHHH *\9_;*_P"35_BC_P!@&Y_]!KV:O&OVR?\ DU?XI?\ 8!N?_0:
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M9NQIZ-;3336DVI7PT_4;O2(;V&[NK:Y@M5NI+DR1*P:3KO8 Q=>V<<5=\/\
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M110 4444 %%%% !7R!\<O^4A7P#_ .P+JW_H%?7]?('QR_Y2%? 3_L"ZM_Z
M: /0OV)?^2*W'_8PZO\ ^ELM>^UX%^Q+_P D6N/^QAU?_P!+9:]]H *YWQYX
M^\/?#'PM>^)/%&J0Z/HMF%,UU/D@%F"HJJ 69F8A0J@DD@ $UT54-8T73_$6
MF7&G:K86VI:?<IY<]I>0K+%(O]UE8$$?6@#PW3?VA?%OQ$\=:7X>\&?#^ZTN
MQFMDU2XUKQH[6!:Q\X1LT%HH:8NP#;1,(NQY%?0"]*^;M*^"/A;P7\<X].\
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M7UBK?XB52@G>QX?XY_92\-^,;810ZAJ.FR/%;64\R2EW>SAS_HZD_=5L\^I
M/-/U[]DWP?JUKI*6EQJFEW6BO))I5S!=$M:,Q! 4$<JK*"%/OZU[=1FMOKN(
M22YWH"IP70\7\5?LUV7CB+3;?6?$6J)9V]HT-U:Z6PM(KV=R"\TBJ,9;GCWK
MM+[X2^&=4\$:7X2O; 76A:>(1#;3$L,18V!CWZ#ZUV>/SHQ6<L36E:\MA^SC
MV.7T?X?V6B^8(+O4'5]0.H[9;EF"L1CRQZ1@?PU4\8_"O2_'-Q=2:A=:BD5S
M:K9RV]O=-'$T8DW_ '1W)X)[CBNTZ4<=JR56=^:^I7*CG=.\%6&EZ^FJ6KW$
M/EV26$=DLI^S)&ARI6/H&[9]*T-)\/Z;H<E])864-F][,;BY:% IED. 7;U/
M K3I*ARD]V4<+-\+;+5/$&G:]JUU->:WIUW)-:WL($#K S$K;OM^_&H/?K@$
MUTVH:??W.K:;<V^I-:V=N9#<V@B#"YRH"@L>5VGGCK6I15.I*5K@+1114 %%
M%% !1110 4444 %>,_ME?\FK_%'_ + -S_Z#7LU>-?ME?\FL?%'_ + -S_Z#
M0!\^?LB_ZS]F3_LG%U_Z'#7W17PO^R+_ *S]F3_LG%U_Z,AK[HH *:U.I,4
M>0_"K7-9^*5G\0;O5-:C2!M8O=#L]*MK>/.DK:RR0!V+ EY9,+-\_P H!0!<
M9S=_9[\7:SXH\)ZO;:[JMMX@O]!UJ\T0ZW:1+$FH+ X42E%^59!G8X7"[XWP
M!]T?-FJ^*?A-\1/$FOW_ (_\#^,[OQ/I^N:CIDM_X.T/7$MKRW@NGBA6:2Q
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M4;?4- O]4UI=6O=,AN(I+B2RC1Y_-92""/N !<8'7OTK8_X3;P[_ -!_3/\
MP,C_ /BJ/^$V\._]!_3/_ R/_P"*J/:2_I#L;6.*RM1T&'4]4TN^>:XCDT^1
MY(TBE*H^Y"I#K_$ "3]0*B_X3;P[_P!!_3/_  ,C_P#BJ/\ A-O#O_0>TS_P
M,C_^*K--K5#-I>E+6)_PFWAW_H/Z9_X&1_\ Q5'_  FWAW_H/Z9_X&1__%4
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MM;P7_P!#;HO_ ('Q?_%5Q7_#(/P8_P"B;>'_ /P%'^-'_#(7P7_Z)KX?_P#
M44 =K_PM;P7_ -#;HO\ X'Q?_%4?\+6\%_\ 0VZ+_P"!\7_Q5<5_PR#\%_\
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M1_PR%\%_^B;>'_\ P%% ':?\+6\%_P#0VZ+_ .!\7_Q5'_"UO!?_ $-NB_\
M@?%_\57%?\,@_!C_ *)MX?\ _ 44O_#(/P7_ .B;>'__  %% ':?\+6\%_\
M0VZ+_P"!\7_Q5'_"UO!?_0VZ+_X'Q?\ Q5<5_P ,@_!?_HFWA_\ \!1_C1_P
MR%\%_P#HFOA__P !10!VO_"UO!?_ $-NB_\ @?%_\51_PM;P7_T-NB_^!\7_
M ,57%?\ #(7P7_Z)KX?_ / 44?\ #(/P7_Z)KX?_ / 04 =K_P +6\%_]#;H
MO_@?%_\ %5X_^UY\2?"6I?LQ_$RUM?$^D7%Q+H=PL<4=]$S.2O  #9)KJ_\
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M3?\ H'VO_?A?\*/[#TW_ *!]K_WX7_"KU% %#^P]-_Z!UK_WY7_"E_L/3?\
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M]6\>^)/%G[8/PNL]9\"ZCX6M+%=82UO[R>-TO1Y(&Y IR. #SZT ?7%%)2T
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MMR1:\;N[<\8KZ36@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<:QJ%10BCHJC H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH *0TM(:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !7DG[6G_)MWQ$_P"P1-_*O6Z\D_:S_P"3;OB)_P!@B;^5 'I?A_\
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M\6Y9?B!!\2G\C2Q_;EO'&BM^[D_=XC.W*^U 'UK1110 4444 %%%% !1110
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MZT\7+72^4?E5L_)P".G>@#JOV;?^2 _#S_L!6?\ Z)6O2*\V_9M_Y(#\/?\
ML!6?_HE:])H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"O%O\
MR>+X _[%C4O_ $;#7NM>%>+?^3Q? '_8L:E_Z-AKW6@ HHHH **** "BBB@
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M0I'#<_N ,QD,<CC/('6@#ZGHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 44E)NH =129%+0 4444 %%%)F@!:*0&EH **3-&: %KR3]K/_
M )-N^(G_ &")OY5ZW7DG[6?_ ";;\0_^P1-_*@#TOP__ ,@'3?\ KVB_] %:
M%9_A_P#Y .F_]>T7_H K0H **** "BBB@ HHHH **** "O!/BQS^U-\$SU'E
M:N/_ "76O>Z^5_$_PN\/> _VNOA/J.CV]U%>:FFL/<M<7\]PI/D!OE61R$&2
M>% H ^J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(W^$_P ";9O%7Q$O)C82ZE:1&=+.;)4Q0IC][,"#D_=7'.>0/DC]C/P-XO\
MAS_P5$\)Z#X]NS>^,87OKC4YFN&N&,TVC3SD-(1\S 2 $\C(."1@U^O7ASX
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MA-\<O"2^ O',LHMK>ZABDB@FG;'EQ21.6:-G!^5@Q5B1TR*^^G^XWTK\FO\
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M_P!@B;^5 'I?A_\ Y .F_P#7M%_Z *T*S_#_ /R =-_Z]HO_ $ 5H4 %%%%
M!1110 5PGQB\-ZEXJ\(V=EI=O]JN8]<T>\9-ZIB*#4;>:5LL0/ECC=L9R<8
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M_0U6O/\ @H#X$T^WGGNO#/C6"&"].G2N^A2 )<@9,).?O@=J /IZBOEW0?\
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MK67_ #^6_P#W]6C^UK'_ )_+?_OZO^- %NBJG]K6/_/Y;_\ ?U?\:/[6L?\
MG\M_^_J_XT 6Z*J?VM8_\_EO_P!_5_QH_M:Q_P"?RW_[^K_C0!;HJI_:UE_S
M^6__ ']6C^UK'_G\M_\ OZO^- %NBJG]K6/_ #^6_P#W]7_&C^UK'_G\M_\
MOZO^- %NBJG]K6/_ #^6_P#W]7_&C^UK+_G\M_\ OZM %NBJG]K6/_/Y;_\
M?U?\:/[6L?\ G\M_^_J_XT 6Z*J?VM9?\_EO_P!_5H_M:R_Y_+?_ +^K0!;H
MJI_:UC_S^6__ ']7_&C^UK'_ )_+?_OZO^- %NBJG]K6/_/Y;_\ ?U?\:/[6
ML?\ G\M_^_J_XT ?,?\ P4:^ WC;]HSX VOA+P)##<ZJ-<M[R:&XNUMT>!(I
M@06;@X=HSCU /:OB3X8?LA_MR?!?PW_8/@G5;'PWI)E:9K>SU*R&^1NKLQ4E
MCTY).  .@Q7Z[_VM9?\ /Y;_ /?U:/[6LO\ G\M_^_JT ?EO_P *?_X*+?\
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MMQ_V,.K_ /I;+7OU> ?L1L&^"EP001_PD.K\@@C_ (_9:]_H **** "BBB@
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MG'\']=^"OP]\<^']9T6^T6W7Q1=OIR:@N'FM<A8Y >X( Y[U]=4E(PR",XH
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MJK0R:M*TMW@9!65V+%G!!!.XY(ZGJ0#K@*=110 4444 %%%% !1110 4444
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MGPE\477CVQF\0:SINO2V N);^?*JB+\HPXXSD_C7V)_PQ3\'?^A4/_@?<?\
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MM]-T^W79#:VL2QQQKZ*H& *@\2:U/H.FFZMM'O\ 79MP46>F^5YIX)SF61$
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M(<C?V 8=>]<#??\ !/?49/AGIEE!#;)XK2;4S<W9U.YVLCI*+09W_P #&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6^<G.WGCBOI6N.OOA1X8U)_%K7>F^>?%7E?VMNFDQ-Y42QQD?-\A557!3!R
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MY&ZG!5M(D!!]"//H ^D:*^;?+^/'_14_AW_X*G_^/T>7\>/^BI_#O_P5/_\
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M%3^'?_@J?_X_0!])45\V^7\>/^BI_#O_ ,%3_P#Q^CR_CQ_T5/X=_P#@J?\
M^/T ?25%?-OE_'C_ **G\.__  5/_P#'Z/+^/'_14_AW_P""I_\ X_0!])45
M\V^7\>/^BI_#O_P5/_\ 'Z/+^/'_ $5/X=_^"I__ (_0!])45\V^7\>/^BI_
M#O\ \%3_ /Q^CR_CQ_T5/X=_^"I__C] 'TE17S;Y?QX_Z*G\._\ P5/_ /'Z
M/+^/'_14_AW_ ."I_P#X_0!])45\V^7\>/\ HJ?P[_\ !4__ ,?H\OX\?]%3
M^'?_ (*G_P#C] 'TE17S;Y?QX_Z*G\.__!4__P ?H\OX\?\ 14_AW_X*G_\
MC] 'TE17S;Y?QX_Z*G\._P#P5/\ _'Z/*^/#<?\ "T_AV3[:2_\ \?H ^DJ*
M^=?!'C+XK>'_ (Z^'_"'C;7O#FO:5K.D7E_')H^GR6[QO"T0&2SMD'>>GI7T
M50 4444 %%%% !1110 4444 %%%-:@!U%?+G@SQ'\>?BM/XGU/0?%/A'1M(L
M=>O]*MK6\TB6:4);S-&I9Q* 20!VKI/^$3_:0_Z'[P3_ ."&;_X]0![_ $5X
M!_PB?[2'_0_>"?\ P0S?_'J/^$3_ &D/^A^\$_\ @AF_^/4 >_T5X!_PB?[2
M'_0_>"?_  0S?_'J/^$3_:0_Z'[P3_X(9O\ X]0![_17@'_")_M(?]#]X)_\
M$,W_ ,>H_P"$3_:0_P"A^\$_^"&;_P"/4 >_T5X!_P (G^TA_P!#]X)_\$,W
M_P >H_X1/]I#_H?O!/\ X(9O_CU 'O\ 17@'_")_M(?]#]X)_P#!#-_\>H_X
M1/\ :0_Z'[P3_P""&;_X]0![_17@'_")_M(?]#]X)_\ !#-_\>H_X1/]I#_H
M?O!/_@AF_P#CU 'O]%> ?\(G^TA_T/W@G_P0S?\ QZC_ (1/]I#_ *'[P3_X
M(9O_ (]0![_17@'_  B?[2'_ $/O@G_P0S?_ !ZC_A$_VD/^A^\$_P#@AF_^
M/4 >_P!%> ?\(G^TA_T/W@G_ ,$,W_QZC_A$_P!I#_H?O!/_ ((9O_CU 'O]
M%> ?\(G^TA_T/W@G_P $,W_QZC_A$_VD/^A^\$_^"&;_ ./4 >_T5\]7'A[]
MHJSB,MQ\0_ L$2]9)-#F51]3YU4O+^/'_14_AW_X*G_^/T ?25%?-OE_'C_H
MJ?P[_P#!4_\ \?H\OX\?]%3^'?\ X*G_ /C] 'TE17S;Y?QX_P"BI_#O_P %
M3_\ Q^CR_CQ_T5/X=_\ @J?_ ./T ?25%?-OE_'C_HJ?P[_\%3__ !^CR_CQ
M_P!%3^'?_@J?_P"/T ?25%?-WE?'?_HJGP[_ /!2_P#\?I/+^/'_ $5/X=_^
M"I__ (_0!])45\V^7\>/^BI_#O\ \%3_ /Q^CR_CQ_T5/X=_^"I__C] 'TE1
M7S=Y7QW_ .BJ?#O_ ,%+_P#Q^D\OX\?]%3^'?_@J?_X_0!])45\V^7\>/^BI
M_#O_ ,%3_P#Q^CR_CQ_T5/X=_P#@J?\ ^/T ?25%?-OE_'C_ **G\.__  5/
M_P#'Z/*^/';XI_#O_P %+_\ Q^@#Z1I:^:_#OC3XM>%?C1X'\.>+O$?A?Q%H
M?B.*^);1]/>"2-H(MX.XNP().*^E* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHK#\5>-/#_@73H]0\2Z[IGAZQDE$*W6JWD=
MM$TA!(0,Y +$*QQUP#Z4 ;E> ?M=>'_B#JOPU\27/A3Q5IVB:+;Z)>'4;.\T
M_P ^2Y41,2$?/R?+D=.]>ZZ?J%MJUC;WMC<PWEG<1K+#<6\@>.5&&596'!!!
M!!'6N+^/_P#R0WX@?]@&]_\ 1#T 6_@S_P DE\&_]@>T_P#12UV=<;\&?^21
M^#/^P/:_^BEKLJ "BBB@ HHHH **** "BBB@ HHHH **** $-?%W[*/[,_PN
M^)/PONM>\3^"]-UO6;C7-2$U[=JSR/BZ<#)SV&*^TJ^>_P!A@?\ %C7_ .P[
MJG_I5)0!K_\ #%7P/_Z)MHG_ 'Y/^-'_  Q5\#_^B;:)_P!^3_C7MM% 'B7_
M  Q5\#_^B;:)_P!^3_C1_P ,5? __HFVB?\ ?D_XUVGQ7^(\GP[T;3?L.EG7
M?$&M7ZZ5H^E^>MNMS=.DD@#RD'RT6.*1W8*Q"HV%8X!\Y\2?'+XC?#WP;XGO
M?%GPZT^'5].M[>XL)M*UF2XTJ\\VX2'RGN&MTDBE5G#%?*8%<$$\@ &E_P ,
M5? __HFVB?\ ?D_XT?\ #%7P/_Z)MHG_ 'Y/^-3^&_C)XMTGQ]H7A+XD^$=-
M\-W?B+SUT6_T+5Y-2M9YH8_-D@E+V\+1/Y89UR"&",,@C!+#]I+3IM4^)OV[
M0=4TC0_!&D6^KO?W\)AEOHY#>!S% P#!5-F0K-@N6X&-I8 @_P"&*O@?_P!$
MVT3_ +\G_&C_ (8J^!__ $3;1/\ OR?\:T?@Y\8-=^(6HZI;ZWH.BZ9;V\,=
MQ%>:'XBBU..,NQ'V:Y 1&AG4 $J Z<G#Y'/?^#?&6F>.M#CU;29FEM)))8@7
M7:VZ.5XVX_WD;\,4 >7_ /#%7P/_ .B;:)_WY/\ C1_PQ5\#_P#HFVB?]^3_
M (UV?Q8^(\OP[TO2UT_2CKWB+6[Y=+T?2_M MUN+IHY),/*0?+C6.*1V8*Q"
MH<*QXKAM1^-'CWP+X,\<:GXW\ V=C>^'M&FUJUN-%U5[O3;Y45B8#,\$<D4P
M*\J8R,$$$\@ $W_#%7P/_P"B;:)_WY/^-'_#%7P/_P"B;:)_WY/^-1Z/\:/'
M7A_Q!X:LOB-X'TO0]+\27:Z?I^J^'M:DU)([IHWD2.X1[:$QJX1@'&X;L XW
M UG_  E_:1UCXD7=[J%WI'A33_"=M:W%\T]EXI^V:G' A;8\MD+=?+W*NX_O
M#C('- &I_P ,5? __HFVB?\ ?D_XT?\ #%7P/_Z)MHG_ 'Y/^-2_!OXZ:S\4
M-:=;OP]I.G:-<60OK66Q\017M[:*2I2._MPB^1(Z.& 1I -K@L"!GTOPKXPT
MSQE:75SIDQFCM;RXL9-PVGS()6BDP/3<IP>_% 'E_P#PQ5\#_P#HFVB?]^3_
M (T?\,5? _\ Z)MHG_?D_P"-=QJ'QB\&:3XRC\*WGB&TMM>DEC@%K)N $TB[
MHX6DQL61Q@K&6#,", Y%9VJ?'7PE'X#M?$VE:U9ZK;:G!>/H_ER$+J$MM#-+
M)&C8ZA;>7/'&QJ .8_X8J^!__1-M$_[\G_&C_ABKX'_]$VT3_OR?\:U?A#^T
MAX-^+'@?3]<AUBQL+MM%@UK4+*68@6<;Q!Y&WNJAXXV+(9 -H*G.#Q6K8_M
M?#W4?#^J:U'XJL8].TSROM<EP6A:+S>(?D=0Q\SHF =YX7- '*_\,5? _P#Z
M)MHG_?D_XT?\,5? _P#Z)MHG_?D_XU=UK]I[P7I^L> ;&QNVU8>+M8FT:&6W
M1Q]DEBMY)G$R%=RL"J+L8 _O >@)KV"@#Q+_ (8J^!__ $3;1/\ OR?\:/\
MABKX'_\ 1-M$_P"_)_QKVVB@#Q+_ (8J^!__ $3;1/\ OR?\:^3O^"EO[.OP
MW^%7[.::YX2\(Z?H&KC6K.$7EFK)($9B&7.>AK]'J^*/^"N'_)J:?]AZQ_\
M0S0!WO[./_)>OB1W_P")'H'.>?\ CU:OIJOF7]G'_DO7Q(_[ >@?^DK5]-4
M%%%% !1110 4444 %%%% !1163XD\4:-X-T>;5M?U>QT/2H2BRWVI7*6\"%W
M"(&=R%!9F51D\E@!R: -:N$^+FA^-M<\/PP^!?$=CX:U%)M\US?V7VI'BVG*
MA<C!SCGVKJM#U[3?$VEP:GH^HVFJZ=<+NAO+&=9H91DC*NI*D9!'![5<N?\
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MXE_PQ5\#_P#HFVB?]^3_ (T?\,5? _\ Z)MHG_?D_P"->VT4 >)?\,5? _\
MZ)MHG_?D_P"-'_#%7P/_ .B;:)_WY/\ C7MM% 'B7_#%7P/_ .B;:)_WY/\
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M&FBZAX@\*:=HNEZ5H7ABV\1ZG:>())#/.THF9K6-T8+$$%O(IF8."Q7Y< T
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MX=L]-O)GN=>L+O4K*&:VDB<PVTL,5P'5U!C='N(U*, <D\<&@#BO^&*_@?\
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M@#YV\)_ !O$'BXWOB_P1X8T?0(_#L6@S:18.+F/4W2=)4ED'E( D1C_=JP+
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MW[6K?:#D2[>-_KCC.:^E* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#_5=/U[3-=\3^'[#5=+G;79[J2);:]N()E5)<M)*8/LT48,G,B@DE":^B:*
M/E_PC^S]\4/ASH-II^B^(/#.H7$OA6+P[>W>H6TR[9UN;N7[9&B?> %T?W)(
MR1]]<<U]0_9'UFW\9>'KO0]0T[28]);384\36DUQ:ZH;&V2%)K.>&+$-VLJP
MLHDE.8UEP%.T9^J** /EKX/_ +(<_P -/$OA%9(O#\VD>%)YY;35E$\NI7H9
M'CA5T8^5 R+(=[Q[M^W@(&85UO\ PA>M?#K]ECQWX<UF6QN#8Z3K"V=Q8E\2
MV[12R(TBL/EDR[ JI(X&#SQ[Q7$?''_DBOQ _P"Q>U#_ -)I* /@[]@?_D4/
MV9_]_P 1_P C7Z45^;'[ _\ R)_[,_\ O^(OY&OTGH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BDI: "BBB@ HHHH 3K2T44 %?+?[;RW/_"&ZF8?
M"?C'74&C7>Z]\/ZJ]K:6WR-S/&' <#KT/ (KZDKY6_:/^#WB<^#/B!K/_"Y]
M?L;"73[VY30MEN(?+\MSY()7=MQ\O7/- 'NWP9_Y)+X,_P"P1:_^B5KLZXWX
M-?\ ))/!G_8'M?\ T4M=E0 4444 %%%% !1110 4444 %%%% !1110 5\]_L
M,9_X4:__ &'=4_\ 2N2OH2OGO]AC_DAK_P#8=U3_ -*Y* /H2BBB@ HHHH *
M*** "BBB@ KP7Q]H^C_$[]HKPWX-N+*&6R\.6*^+]63R1BYF:5H-/CD;'S*K
MQ7$NW/WH(CTKWJH!:PK<-<+$@G=0C2A1N91DA<]<#)_,T ?(VMWEOX'^(WCC
MQ-X<\:6NK^*+_P ;:?!=>#;_ $B&.>1FBL[;RHV?]\0(5$JS1D)PQP0#7I_[
M3ND>%OBG^SG\0IGN8-=LM*TC59%2SO2T NX+:9"DJQMM<QR _(^=KH#@%1CV
M)]%T^;4DU%["U?4(UV)=M"IE5?0/C(%2K86R6\L"VT0@E+>9&$&U]WWB1WSD
MYH J^&?^1<TK_KTA_P#0!6I354*H & .@%.H **** "BBB@ HHHH **** "O
MBC_@KA_R:HG_ &'K'_T,U]KU\4?\%</^35$_[#UC_P"AF@#O?V<?^2]?$C_L
M!Z!_Z2FOIJOF7]G'_DO7Q(_[ >@?^DIKZ:H **** "BBB@ HHHH **** $ Q
M1MI:* "O)/VCA.?!]GY'AOQ1XF?[5DVWA34FL9T^1OG=PZY3VSU(KUNO%/B?
M\(?$_B+Q!=ZO9_&'7O"%A*H5--M$M_)0A<'!=<Y/UH POV#-W_#.&D;H+BT;
M^T-0S!=R&2:/_2I/E=LG+#H3W(KZ(KY\_85MWL_V>=-@ENWOI8M2U%&NI,;I
M2+N0%SCC)Z\>M?0= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C?[4W_ "(>@?\
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M &HOVAX+**6Z\3>,M(T&Z\,Z0@+&^U,QRVB[%_WBA;'\,9)Z4OQD^$R?!?\
M9Q^ WPEUO4TDTOQ'XXTZU\9ZC(YV:@\K2W-PKR-_#+,JKN8Y( S0![M;?MT?
M"Z6;3);IO$>DZ!J=PEK8^)]4\.WMKH]S(YPFR[DC$>&P<,2!P3G%?0@.1D5\
MC_\ !02^L/$'PBT'X1Z +6[\6^,M9T^QTG2;=AOBABG266XV*/EBC1.6P -P
MKZQLK?[+:00YW>6BIN]<#&: +%%%% !1110 5X1^UI\%O!OQ$^&/BC7?$&C+
MJ.JZ1HEX]E.TTB&(B)F! 5@#R!U':O=Z\"_:W^#.B?$+X:>)==U*]UBWN])T
M2\>"/3]1EMXFQ$S?O$4X<9 Z]N* /2_@S_R2/P9_V![3_P!$K795QGP9_P"2
M2>#/^P1:?^B5KLZ "BBB@ HHHH **** "BBB@ HHHH ***@O(Y)K6:.&4P3.
MC*DH&=C$8#8[XH GKY[_ &&?^2&/_P!AW5/_ $JDKW/0;.[T_1[.VOKUM2O(
M8E26\9 AF8#!<J.!D]A7AG[#)_XL:_\ V'=4_P#2N2C8#Z$HHHH **** "BB
MB@ HHHH **** "BBB@!**R[CQ#:6NNVFD2-+]MNHWEB"P.4VKC=EP-JGGH3D
MUJ4-=P%HJK?7]OI=G-=W<\=M:PJ7DFF8(B*.I)/0"IHI5FC#HP=&&593D'Z4
MP'T9JE!JEI=W5W:P744US:D+/#&X+1%AE0PZC(YYK+\"MJ+^'8#JK73WOF2[
MC>1JDFWS&VY"DC&,8]L=Z.5VNP.BHHHI %%%% !7Q1_P5P_Y-33_ +#UC_Z&
M:^UZ^*/^"N'_ ":HG_8>L?\ T,T =[^SA_R7KXD_]@/0/_24U]-5\R_LX_\
M)>OB1_V ] _])6KZ:H **** "BBB@ HHHH **** "BBB@ KBOBE\*?"OQ=T&
M/3/%FE+JUC;R?:(H6EDCVR!2 <HP/0GJ:[6N&^+/PKTGXM>'XM-UBZU2T@MY
M?M"MI5]):2%@I&"R$$C!/!]J /-OV&=/M])_9\T^QM8O(MK;4]2BBCR3M5;N
M4 <G/ '>OH*OGS]A?3X]+_9ZTVRA:1X;?4M1B1I7+N56[E W-U)XZGK7T'0
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MQMXD\,>(-:T>&]UOPS<27.D7Q9TEM'==K[2K#*L ,JV5.!QP*ZOM2;ORI0:
M.(\(_!7P3X%\;^)O&&A>'K;3_$WB5UDU74D9VEN2O(SN)"C/90 3UK0D^&OA
MN3XC1>/'TM&\6Q::VD)J1D?<MHT@D:,)NV8+J#G;GCKBNG-)GW% '#:I\$?
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MFOM>OBC_ (*X?\FII_V'K'_T,T =[^SC_P EZ^)/_8#T#_TF-?35?,O[./\
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M7L0MS$EQ.0OG8).T[\EBS-\N3R:\?^-'Q&O/%%OX:'A6PUS5+*[NDDU'PW<
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ME1C.,C(!\L>#_C5;_LK?$W]I7P_XEDN[S3+.^M_%WA^P9G>>[-^H0VMON)W
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M'_$#]JKX^>)/^$ITN6\U35+#P_H-JU[%YEQ;65NP=H%#9='D=WW#.?T'VC0
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M;@+9W4EG+Y\+1_O$.&VY'(]QQ6W4<+*R!E& PSTQ4E>-+?0Z1:***0!1110
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M9/-:M% &7KWAG2/%5K#;:UI5CJ]O#.ES%#?VR3HDR'*2*&! 93R&'(K4HHH
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MKJ37#-+_ ,)%;*(EM9=H\J.<.V=I(.64XY Q7IEC'/:W%Y]JUVWN9]0=I-/
M@1'BBVC"C!S+M^]GWKD?#&HVOC.+7/!'C#4M%\2ZG8RCSX;4;?.AR"C21]%<
M$<JI(&%]:[55O&RC[J6OGY]";>9G:-\/]+U[PAX8U#Q!9R^';VQG%S?6B.(4
MNKK=N96;.6C:8EU ;!^6LS6M5\'?%3Q1'82>$;C6;W<UKJJ7&89].,8+P&5-
MP.QB6PRDCFJMGK]_\3M1\=:7)>+!9Z1&\2:7JEC$D&F7<?S02M,#EU.T2=.
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MOVA/%&I>!_@;X^U_1I?(U73=$O+FTEV[O+E6)BK8[X/.#QQ7RWXP;]GWP?\
M"_4]9\'_ !$LX_B'I=C+J-AJ\7BR>>_NKY$:0"7,Q\X22<-$P*D-@ <8 /N"
MS:9K2 W"JEP44R*ARH;'(!],U8J"RE-Q:02L,-(BL1Z9&:GH **** "BBB@
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MHHHH *^+/^"L]Q-:_LKB2&5XG_MVQ&Z-BI^^>]?:=?%/_!6__DU,?]AVQ_\
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MXO)("<1S*H^Z6?).X?K7J:?=&:YOP=X970;!M^JW&MRRR/*M[=LKOL=BPC#
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M.UM;&!K:9KNYN"VY\@A#D@';GIP>U>)_%:3[1X=M&$DEP%UK3V9, _\ +>,
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M 1!+8Q2QB1%N8FQE_FX"CC&>N:<:C46WHTOZWV>Q@Z;<_4Y#XR_#OP5\4/\
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M[HH\G*]VV@8Y-;VEZAX?\>:;<&V>SUFTBN#!,-JRHLJ$$J1C&5./I70*@48
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M:W4$\?V>(%[6,,?L\6X$&,@?,&;'S9(!VU%%% !1110 4444 %%%% !1110
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M:L\R&6::)4P$C.[Y #CH,<?C7*:I)K=Y\0=.OO#.L7J:!9W2:5?Z):Z0@4%
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MW7:QX.(RWGDFW;]%N2S>&XY(='U/S-1N+35KJ6S5)X(PHB4@&>9\?O#\P*H
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M)/XG\0Q+"EDT-S+=22R!4\DDQL0#V+'MSGO777&J6MG=6UK/<Q17%R2L,3N
MTA49(4=\#)X]*R=2T+4M0\26=R=14:(D,D=SI<D"LL['&QRW4;>>.]*G>+O>
MPS%L-<UN/Q98:=<.+VPNK>>Z6ZM[!EB5=P\I&DW\-M/3;SC/%<%X!\"W7B[X
MB>)?$WCS2YO[6TV[\K24N,O:VMOLR&@;[KEC\Q)&5.?2N\^(UOJL<OAV]TO3
MI]12QU%)+FWM;HPOY;*4+;<XD"EL[6XP">U=FTD>TAV4<<]*Z/;.$/<7Q*WG
MO^I%KO4^6?B)XN\ :W8V%IJ#3>+F\/303MK&HW#HK1SR-S'Y?RRR*5VA2N/E
M%=YJ6DZ)X5^$XUC3=%ATR]U*YBN7FUL+%<Q3S,$,K,5;;*NXXXQVK4F^$&B-
M-I]YI>L26?A>VOI-2FTVT8-%/,&#*H8=(U<,?+48)8TGQ>DL?&7A_3;5/$NI
M^'K67;>,]A92M+*N0L8)V_+B1HV(/) /;)KO=6,N2$&[)Z[_ '6_R,K*[;W/
MG^[T>R^"GQ&T=-3US6+AH=;D31;FX@2[DO'N(HA<S2E=OR9<*,<[E;KT"ZSX
MT\4VWBZ]^%.I0ZA=QPK)<2>)X;5+:Z^RJI+"./:5>,9*\$$C..:]]U'P7:Z;
MJ'AK1'AT5Y]0M9K:]U/<MK?M@%B]LJC.XNS.=IXSFD^'LS:3XUU31-U_XLMY
M)YI1KTK12P6/0?8RV[<&&.01WKL^N1Y>=QYFE^N_YZ&<J3>BT/D+5GM?";Q:
M/X4O6U70M<DBG;Q,L9BBLIH SF.U!)SMBW#8^3DCG-;>H>%QXV\%Z=:6[:GK
M1\E(-8U6\F86VF03W)D2=E&/-N5C=2PR0!VKZ4\?_#VXUZUU#0?#5IX<ALK:
MZCN+S1VC0"Z65<.TA49A<8W*R\DJ*YJRAETW7-'MM#>ZLO#,>J/!XEB\1?.5
M*1*MN(S+P0Y4$%,YW"NV.8>T@G'26^_Y^JVZ7.7ZO&*;M?Y'S#XT\'WNGZS<
M^$='TBUUWP?I-PB0:QI<(N)X9!\[2.<X=\9W(1MZ8Q4.BMIOQ$CUF_\ '.B:
M['=74RZAIUYI=F6MHK?'E!&3/$:L0=H/8<U]5P^)/A_JD=OJ?A^.PT[0;B9=
M-CU'3+8VUW(X;+QIE58IG:<ID\GWJ*;Q_!X5\:Z[J"Z#XIT_PY%=K%?:@]BL
MFGHD*%69$^^$8D,65>>#73_:$Y0Y90?-WV?3\6><\*G4=DK)GR!\6O!^L:7I
MMV;O2; 6^DZQIRZL)9BAO#YJQ1NG!^0C:S>Y-:_AWX=^%?$WB[5+T7VK>(X[
M64 0:'9B,7:E1Y@B!'"Q97=D@G>.E=_XZ\9>'?\ A";_ ,3V6A36]W<:_INH
MZCI]J)I5FQ?H(FB++Y9WQX8JIR"QXJK'X9G\83:QXM\1ZAJOP\_MBY5-&M;7
M292EU"@_>&XAA7^(L@W,>=IZBNJ.,J7GS>[HE\_3[_D<E/+:<5R-;WZ?Y_UH
M:&NZ/JFE> _$WA;2K9[C1H+=K2Y^S,#+OD/F)->+C,?EA1\P8\ ^M'PCN=+U
MBQ%HUWI-MJ^D6<=CI_CH6Y:6.>60*(##P-^-VQVYPN>]>N_#OPVNOZ5<>%-4
MUC6](\96]G+:7#+%*(?LK2+\RR$;)6V859&;>-WL:[SP;X TBX\1:?XA\.3P
MP:1#"UE>V\VEA;B^FC;:DDDKJ'RI7KCGKFO'K8Z,82IR6N]^_P#G<]VAA?9*
M*3O96+/PXLT\>>#=3M-=\-7&E1F9M/=KN$6\]]$@'[Y@H&T.Q8XS@5ZG'&(X
MPB] ,"J=MK.GW6I3Z?#>02W]NBR36RR R1JV=I9>H!QQ5^OE:LW.3>QZBV.?
MU;4-;M_$&D066GV\^DR^9]NNI)BKP84%-BX^;+9SSQ70+]T?2AE!ZTO\JR;O
M9#%HHHH **** "BBB@ HHHH *\__ &@?^2&^/O\ L"7?_HEJ] KS_P#:"_Y(
M;X^_[ EY_P"B6H ^%OV!O^1-_9I_WO$?_H)K]*:_-;]@7_D3/V:?][Q'_P"@
MFOTIH **** /G;XP?M@67@?3_'"^$/"NH>.]5\'12R:TL4\5G:V/EQB1EDEE
M.YCM(($2/]17KOPY3QB_AWS?'%QHLFLSR>8(=!BE6WMHRBXCWRL6E8'<=^U,
M[@-@QSYY^U5\+?"7B[X0^,-5U7X?VGC36+32IWM[:*)TO;AE0D0I-"!,-QXP
MIYSC!Z5Z%\-_!EQX"\.?V7+XCUCQ)$LF^WFUV9)KB"/:H$)E"JT@!!.Z0L_S
M'+'C !UM%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G+H.FJNHJN
MGVJKJ+F2] A7_2F\M8RTG'SGRT1,MGY44= *9X>\-:3X1TF#2M#TJRT;3+<8
MALM/MT@AC'7"H@"@?05J44 %?*'[<FH:':^%[Z+4[OP)!=/H]WY$?BB$O>N2
MAQ]F(/!SCKWQ7U<QPIKX\_:AO/B7K?ASQPMQ\&O#6L:)9V5Y':ZY>:G&;A+<
M(Q$RH8\JV!NV@]J /I#X+KM^$?@X 8_XE%K_ .B5KM*XSX,X_P"%3>#L=/[(
MM?\ T2M=G0 4444 %9DN@VTFN1ZL3+]KCMVM5Q(=FPL&/R],Y YK3HH 8L>T
MYR>G>E?[IIU)0!QGB#P OC"UU_3=:U*ZN-)U+R@EK;N8&MPH&X*ZG=\S#//O
M72:?I<.EZ?:V<!?R;>)8H_,;<V%  R3R>!5_%%4YRDN7H*QS_AO1-0TV35&O
M]7DU1;B[::W62)4^S1D "(8Z@$'D^M/T?PA8:'K>K:K;>?\ :M4='N/,G9TR
MJ[1M4G"\>E;O2EI<SU&8:Z7>CQ3)?_VD[:>UJL(T[8NT2!]QEW=<[<+BMNCB
MEI7N!0N])M+VYMKB>WCEGMG,D$CH"T3$%2R^AP2/H37@_P"PY&LOP-<G_H.Z
MH/\ R;DKZ&;I7SY^PO\ \D,?_L/:I_Z5R4 >S^+?"=CXT\-W^AZEYWV"\3RY
M?(E:)]N0>&'(Z#I69>^"Y[7PG8:%H6K7.CI9>2D=S@32&-",H2QY+ 8)/K77
MT52G**LA6,N;0;"\OK2^N+2&>^LPP@N'C!>+<!NVG'&<#I5?Q1X3LO&&ARZ3
MJ!N!9RE2WV>9HG^5@PPRG(Y K<VT4N9W3N,S+KP]I]_<65Q=6D5Q/9,7MY94
M#-$Q4J64D<$@D<54C\&:?'XLG\1 W!U&:V%HVZ9O*\L-N&$SMSGOBMZBCFDN
MH%>2TCEB>)U#QN"K(V""#U!KG-1^&?AW4+6*W&GQV8A1(HI+(>3(D:N'$:LO
M(7<!\O0UUE%.,Y1^%@8/AKPC8>$]&32[$3-:*SOBXF:5OG8LV2Q]2:SM2\#6
M']GV-C80VNGVUG*9HHTM4948AN5&.#EB<BNMHQ3522ES)DRBI*S/$H_V<H)H
MKTWWB.^NKO\ LYK#3IT58AIN]"LDD2C@.Q).<<=!Q7):;^R;JOA_P2="L?'M
M_=W$NK6]]+=W@?'DQY!A50QX;/<X.!7TS2^]=D<?B(W][\$9.C3DN5H\"\._
MLL6NB^+KZ]F\1WESX:N%D1/#4<?DVT>]@Q^ZW)#*#G&>E>G>'_A?X;\,:+<:
M99:9&;&>\>_DAG_>J9F;<7^;/.0#QTKKR*7%95<56K.]215.E"DN6"LCD]#\
M(PR7T6MZSIVER^)(_,B34+:WPZPEFVH&;YA\I&><9)Z5U:J%%+17-*3D[LU%
MHHHI %%%% !1110 5\4_\%;_ /DU,?\ 8>L?_1AK[6KXI_X*W_\ )J8_[#UC
M_P"C#0!W?[./_)>/B1_V O#_ /Z3-7TU7S+^SC_R7KXD?]@+P_\ ^DS5]-"@
M!:*** .%^.'AO6O&'P?\::)X=G-OKFH:3<VUDZR>4?-:-@J[_P"'.<;ATSGM
M7A/Q \<>#OB!\%9_ASX>^'OB!?$36:VFE^'9O"UU:II%W@"*;[0T0@B$+D/Y
MJ2?P$J2>*];_ &J+2ZO_ -F_XEVUC"]Q>3:!>)#%&C.SL8F  4<D^PJI9V7Q
MQ%G!C5_  &Q<;M,OL]!U_P!(ZT >LVB216L*3/YLJH \F,;FP,G';)J>FKD*
M,\GOBG4 %)2T4 4H])LH;^YOH[.WCO;I$CGN5B42RJF[8KMC+!=[X!/&YL=3
M57P[X4T7PC:S6VA:/I^B6TTS7$L.G6J6Z/*QRTC*@ +,>I/)K7HH 0UXW^TM
M>Z18^"[)]9N?!UI#]KPC^-83):EO+?A #]_&?PS7LE?/OQHU#XF:EK5QI>F_
M"+P_XU\-PA9+>[U;4T1BY4Y/ELAP1DB@"']@QHI/V<=&:![1X#?:AL:P4K;E
M?M4F#&#_  8Z9[8KZ)KYW_8026/]G725GLXM/G&H:B'LX""D#?:Y,HI'& >!
MQVKZ(H 2LCQ)8W>J:3>6EE?MIEW-$5BNT4.T3'/S!3P3]:V*2DM'<"&WC\N-
M06+D#!8]\5-12TP(FA#$$\_7FJJZ7;6]Y->10(EU,JB255 9PN=H8]P,G\ZO
MT4 8NGIJK:AJ'V]K1[0R*;,0*P=4V\B3)P3NZ;<5R/B#X20>.K74['Q+K%_J
M.G3WRWMK!;R&V:TVC 0.ARRYYYKT?%)M!JXU)0?-'0&DSC])^%NBZ'X@&M6S
M7OVU5E7]Y=R,F)-N[Y2<?PBIO&7@F+QA':6\]R\-FGFK/'&H#RJ\31D!_O(1
MNSE3V]#75^]%/VL[\U]161P'PU^%UM\-;>]M;6\N+VU=\6AN\/-;0C)\GS/O
M,N\NPR?XS7*:U^SC:>)M=O-6U?Q%JMY->7>^YA:4K!):*VY;7R\X"@JIW#DX
M->U<45:Q%6,G-2U8N56L<-K_ ,.8-;\8:'KXO[FW.GQ2VTUFK9@NXG&-KJ>.
M",Y'TK(NO@/X:BN(;W1H3HFJ6;3RV%Q;Y*6<DR!79(_NX('3&.2>]>H4E"KU
M59*0N2-[V//?!/PYO_#/BSQ'KNH^()-:DU;RQ'%);)$;=$!PFX'YL9[UF?#_
M . /A[P'8>)(HVDN[O7KBXENKYL),$E8DQHPY51SCGJ<UZJ%]J*'B*KO=[V_
M#8(TXQV1Y3I_[/NBMI5I!JU]J6I:C"CQ-J0NGAFE1AM"L5/(50H'N,]:WO#_
M ,-K2QT_6=/U9K?7+'4KM[@P7%I&%52!\C ##D;?O'FNX^E)_.G+$59:2D$8
M1BK)'@OQ_P#AS'IO@OX@^)[?4KB*V3P;=Z8FCH0+95$;L'"_WL<<#H*[3P_X
M)TKQM\*?#]GJD#.KZ3!$)HF*2HK11EMCCYESM'0CI5GX\Z;>:S\%/'FGZ?:R
MWM_=:)>0P6T*[GED:%PJ*.Y)XKR?P?\ M2IHOA31]/G^%_Q)^T6MG#!(%\.R
M,-RH%.#GU!K/VDVU*^Q5DEH>Z:_X?NKSPX^EZ3JDVCW(1%BOE02N@7'9NN0,
M<^I[UNVX*QA2V\@8+=,UX+_PUO;=_A?\2_\ PFY?\:/^&N+;M\+_ (E_^$W+
M_C6=V]!GO[+N7'2HQ  <\\]:\%_X:WML?\DO^)?_ (3<O^-'_#7%M_T2_P")
M?_A-R?XT >QW/@K0[RXN)I])LYI;B6.>9Y($)D>/[C-QR5['M6U&NP8%> _\
M-<6W_1+_ (E_^$W+_C1_PUQ;'_FE_P 2_P#PFY?\:')O=@?0-%?/W_#7%O\
M]$O^)?\ X3<O^-'_  UQ;?\ 1+_B7_X3<O\ C0!] T5\_P#_  UO;_\ 1+_B
M5_X3<O\ C2?\-;VW_1+_ (E_^$W+_C0!] T5\_\ _#6]M_T2_P")?_A-R_XT
M?\-<6V/^27_$O_PFY?\ &@#Z HKY_P#^&N+;_HE_Q+_\)N7_ !H_X:XMO^B7
M_$O_ ,)N3_&@#Z HKY^_X:XMO^B7_$O_ ,)N7_&E_P"&N+;_ *)?\2__  FY
M/\: /H"O&?VQO^37?BA_V ;K_P!%FL4_M;VW_1+_ (E?^$W+_C7GO[07[0$_
MQ+^"?C7PKI/PO^(QU35M+GL[;SO#LBIYC(0-QSP,GGB@!OP(_P"1P_9O_P"R
M<W'_ *#:5]B5\C?!_1[[P_\ $3]GO2]2M);'4+/X?74-Q;3KM>*11:AE8'N"
M#7US0!PWQP\-ZUXP^#OC70_#EP;;7=1TBZM;*193$?->)@HWCE<DXW#D9SVK
MPGQ[XY\&^/O@G/\ #?0/AYXA'B%K);/2_#<OA:ZMETJ[V@12_:&B%O$(7*OY
MR28&TE237K'[55I=:A^S;\3;:RADN+N;P_>QPQ1H79V,+  *.3G/056L;'XX
M_8[?&K>  /+7&[3+[/0?]/'6@#U>QCEALH(YY/.G2-5DDQC<P')_$U9ID>=H
MW$%L<XZ4^@ HHHH I1Z59PZA<WZ6=NE_<Q1P3W2Q*)98XRYC1FQDJIDD(!.!
MO;'4U4\/>$]$\(VL]OH6CZ?HMO/,]Q+#IUJD"R2L<M(P0 %F/)8\FMBB@ KR
MO]H:[TRS^'KRZQ<>%K:S^TQ@OXOC+V.3G (!^]Z?C7JE>(_'#4/B'-JD6E>'
MOA?H?COP\\2RR2:QJ*PA9MS J(V0]!@[O<T <Y^PC);S?!_5Y+2339;9O%.K
M&.31TVV;*9S@PC^YZ5](U\Y_L.QW4?PGUQ;W2[?0[P>+-7$NFVC!HK9OM#9C
M0C&57IG':OHR@ HHHH **** $K#'A&Q'BP^(LS_VBUM]C(\YO*\L-N^YG&<]
M\5NT4)N.P#&C#4U8@N,"I:* *5UI=K>75O<S6\<L]LQ:&1U!:,D8)4]L@D?C
M5P4M% &%K6EWVH:AI<MIJDFGQ6MSYMQ"B!A<Q[2/+.>@R0<CT%4?$GPYTGQ3
M>1W5\;OS4,1'DW+QC]W(9%R ?[Q.?7I74\4&JC.4=A;G*>*OAIHGC#0;?1[V
M*:&Q@N$N8TLYF@(=6+#E<<9/2NE6W55"@GCCGFI^E)0Y2:2;!)(Y?0?"(MUM
MY=9N4UW5+:::6WO[B!5EA61B=JX' "D+]!S4MUX#T:5HFCM?L9CO1J)^RGRO
M,G&?G?;][/?/6NDQ1BG[25[W"R/,-:^$3WUYXSN]/\076D7?B<6L<T\"@M"D
M*%"$)[LI//;-:_A7X?C0[.XT^_U!]<TL2Q/8VU[$K&T2-5"J&ZL<@-N/-=QM
MHQ5NO.2Y6PLC@_&OPIT3Q5I>EV8A73I=*NDO=.FM45?LTRDD,%Z8//&*V[#P
MC8Z?I^H6:F:>*_FDFG6:4N&9QA@,]%QV''I708%&!Z5+JS:46]B>57OW/C?X
MO?L^Q?#O_A'=1M]3GN=#T_Q!I<6D:?),X-AYEXGF)C.UU.YCEAD9'/%?2>J?
M"G1-8U30;^>2_%QHLKS6OEWCJNYR"0X!^<<#@^]</^UMJ%OI/PSTN_O)/(L[
M7Q'I,\\Q4E8HUNX]S-@<*!U/:M)?VL/A'U_X3O2?3_6'M^%:RQ-6<N:4M1*G
M%=!DWP)D;X@P>)D\6ZQ&EKJ#7MOIOF$VZK)DRQ$9Y5F.>>F.*Z36O#OBK6KZ
M[\GQ%%HUFHD6U%G;;W;=& &D+=T8%AM]:P/^&L/A%_T/>D_]_#_A2?\ #6'P
MB'_,^:3_ -_#_A4O$5)6;Z>1:BE=G9^$_ ^G^%[B\OHT\_6-0*/?:C(/WMPR
MJ%&3V QPHX&:ZC%>2?\ #6'PB'_,^:3_ -_#_A2_\-9?"+_H>])_[^'_  K&
M4G)W8SUNBO)/^&LOA%_T/>D_]_#_ (4?\-9?"+_H?-)_[^'_  I >MT5Y)_P
MUE\(O^A\TG_OZ?\ "C_AK+X1?]#YI/\ W]/^% 'K=%>2?\-9?"+_ *'S2?\
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M+E[>QUZYAB$CL68A ^!EB3Q0!] ^8G]Y?SI/,7^^/SKP+_AB7P#_ -!3Q?\
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M^&)? /\ T%/%_P#X4MW_ /%T >_>8G]Y?SI/,7^^/SKP+_AB7P#_ -!3Q?\
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M1110 4444 ,*^U.50O2EHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I-H]*6DH \-\7<?MA?#[_L6=4_]&P5[G7AGB[G]L+X>_\ 8LZI_P"C
M8*]SH X3XY:YI_AGX.^--6U:"\NM,L]*N)[F'3KI[6Y>-8R66.5"&C<@<,I!
M'45XYHG[/GPQU[QUK?A."_\ B"NIZ1I]CJ-PS^.-8\HQW33K&%/VO)(-O)G(
M[CK7OOC[P5IWQ'\%ZYX6U?SO[+UBSEL;G[.^R3RY%*MM;'!P>#7A=U\ [/PS
M\6-+CL_%WQ";4/$MA)%>ZS'K2CRX[+#01/\ N",'[3+CD?Q=>P!](QH(XU49
MPH &23^M24R-=J@9+8&,GK3Z "BBB@ HHHH *XWXE:'XIU_PV;7PCXDB\+:O
MYRL-0FLUNEV#[R["1R?KQBNRKC_B);^+[KP\4\#WND6&N><K>=K<$DT&S/S#
M;&RG)!&.: /*_P!BVUU&S^&WB.WU:_74]3B\7:NES>I"(5FD%PP9P@X4$YXK
MZ$KY[_8MCU.'X;>(TUF:UGU9?%VL"ZELE98&E^T-O*!CD+G/!-?0E !1110
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M_P")/:?^B5KM*XSX+KM^$?@P?]0>U_\ 12UV= !1110 4444 %%%% !1110
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M9;8&!_:VJ8 &!_Q^2\5[W0 4444 %%%% !1110 4444 %%%% !1110 4444
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M5M-G^U:=?>+]8N+>8*5WQM<LRM@C/((ZBOH.O"OV255?"'C$* JCQIK0"J
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MM_X)]V-OIO[,/AZTM#<&U@N[Z.(W8 FVK=2 %QD_-@#.#7TE0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >&>+O^3POA[_V+6J_^C(*]SKPSQ=_
MR>%\/?\ L6=4_P#1L%>YT %? /Q?^&'A7QIXL^)OQ!OK'X=V_P#PC>HSPWN@
MZ]I\L^H:B841@9)Q<H8FF!'E!8R-KQ_>R0/L;XV>-K[X;_"+QEXJTVU2\U#1
MM)N;Z"&4$H6CC9@6 .=HQDX(X!KR'XR_#6QT_P"$=M\1)]2T;5O'7A2R&L+X
MJU+1K*5M3,*-(L+_ +OY$<D!3$593L(.1@@'T;8.)+*!Q$T :-2(FX*<#@_2
MK-5K&X:ZLK>:2)H'DC5VC;JI(!*GZ59H **** "N8^(SZ1;^#]0N=>U:[T72
M+=?-N;RRO)+655!Z"2,AP22!A#DD@#KBO*=6\3^(O /C'XZZ@-:U'Q%'I7A2
MRU[3-+NA'Y5I+C4R88515X;[/%DL2Q(Y;H!SW@G0E\9?$;5/AQXTNYOB'X<_
MX1G1?%L<VM%93#?RS743E2H&$;R$D1 ,(=VW (  /6O@:FO0_#VV?Q ^H&XF
MN+BXM(=68M>P6;R,UM%<,3DRK$4#%B3D'))YKNGOK?:09X\]_F%9OA[PGI?A
M'21I>C6@L+'<S"*-F(#'J1G-?"WQ;_X)S?#KPM%J'BB_\5?$:_%U=,SVFD7<
M<KAI&+?*K$84<]30!](_LEG/A'QB001_PFNM'(_Z^7KW2OE[_@GGI%EX?^ E
MSIFFM?/86GB/5(8&U/'VHHLY ,N#C?CKCWKZAH **** "BBB@ HHHH ****
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MB@#SS]AN2YF^ &GR7L"VUVVIZDTT"OO$;F[D+*&[@'(!P,U]!5\]_L+M>/\
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M>2@  = *]_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /#/%W_)
MX7P^_P"Q:U7_ -&05[G7AGB[_D\+X>_]BSJG_HR"O<Z "BBB@ HHHH ****
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M.R,?\2BU_P#12UVE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!PWQ2^"?@;XVZ?96'CKPS8^)[.RE,]M#?*
M66.0C:6&".2.*\X_X8#_ &>?^B3^'_\ OT__ ,57T!36;&3^- 'Y;?\ !3SX
M4_ S]G?X,V.F^%/A[H.E^./$MT(;*>",F:WMXR&FE4%N^43./^6A]./J[_@G
M1\"+GX _LN^']+U*%[?7-<D;7M1@=B3%+.D85/8K%'$"!W#?6OAEO^-B'_!2
M@ B1_A_X/?&5Y5[.TDXR?2><_P#?+^HK]@54*H & . * /SX_P""ULC#]FOP
M?&#\C>+86(]Q9W8'\S^==]^S1^Q-\"_%W[.OPPUS6?AGH>H:MJ7AG3;N\NYH
MV+SS26L;.[8;J6)/XUR/_!8#P?XA\?\ P;\ >'_#.CWNNZK=>*5:.RT^!II7
MVVEQSM4= "<GH*\HT?Q-^W]X6\!>&-*\,?#G3_#_ (>\/Z=;65M9PQ64T\L,
M$2QJLBS3M)N(7G:%//% 'VA_PP+^SQ_T2?P__P!^G_\ BJ]\AB6&-(T&$0!0
M/8#%?GK^S+_P4ZU77/B=#\+_ (Z^%H_ WBZ6<6D-_'#);PF<G"130R$M&6R,
M.&*DD<*#FOT,#4 .ICDJI(!8@=!U-/HH _)[XM^+OCS_ ,%%OC%K'PK\.:-J
M'PX^&V@WK6VM-?+M*LAP3=,I_>.1RL",1R&)(^8</_P32\&P?#K_ (*)>-O"
MEK<27=KH5OK6EQ7$P >5(+I(U=@.,D*"<>M?LE#:PP/,T421M*_F2,B@%VP!
MN/J<*!SZ"OR._85_Y2J?%W_K\\2?^EXH ^]?A+_R=9\:/^O/2/\ T5)7T$O2
MOGWX2_\ )UGQH_Z\](_]%25]!+0 M%%% !1110 4444 %%%(: "N=^(&K:MH
M/@K6]2T*VL[O5;2U>:"+4)7C@)49)<JI;  )P!SC&1G(X2[^+VK>%]8^++^(
M;;3_ .Q_!^C0ZW;?8?,\V2!DNW=968XW8MAC:H W$?-UK/\ !/Q"\1>-/%?B
M7X<>+H=-MM4E\,VFN6]WI$<@B6WO&N(&B97=BSQ/ WS@@.&'RKB@#N_@WXRN
M_B)\(? WBS48H+>_UW0K'5+B*V#")))[=)65 23M!<XR2<8YKK+IA]FEP<_*
M?Y&N3\$^!9_A[\(?#_@S3=1$]SH>AV^D6VH30X#O#;K$DK)DX!*AMN3Z9KY*
M^)5M^TI\*=$CU/Q!\:=$-K-+]G1;#PI+<R;BI/*H"0,#K[B@#V[]BG_DAEM_
MV%M4_P#2R6O>J^;_ /@G_<W%Y^S-H,]W<"[NI;R^>6<1&,2,;J0EMF,KGK@]
M,XKZ0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC;_Q*+7C&,?N5KM* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KY6_X*1?M"+\ _P!FC7#8WQM/$WB16T;2
M_*8B53(I\Z52#D;(]WS#HQ3UKZHK\>_VH-4N?V\O^"AF@?"K3I6'A#PU<G3I
MIH'W QQGS+^?T5B5,0_W$/\ %B@#ZB_X),_L^M\)_P!GO_A+M3M%AU[QJZWV
M64;TLE!%NN?1@S28_P"F@K[BJGI>EVNB:;::=8P);65I"D$$,8PL<: !5 ]
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MH%W( Y;N3US[U]#4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7P'_P6B_Y-=\/?]C5;?\ I-<U]^5\!_\
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M\*]=L[74IM8MH/%FKQQZA/,)GN%%PP#LX^\2._O7T50 4444 %%%% !1110
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M/0CY: /;J*\1'[9GP9,QA_X3_3?.V[O+^?=C.,XV^M*O[9GP:>1HQX^TTR*
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M2+(UQ)YDI\MG*#<_/ XZ# IG_#8_P=_Z'O3_ /OE_P#XFHU_;,^#,S.J>/\
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M\=[;^F?NX]*L_P##8WP>_P"A[T__ +YD_P#B: /:J*\5_P"&Q?@Z/^9[T_\
M[YD_^)J.']LSX,W"[HO'^FRIG&Y-Y&1P1]WJ* /;J*\1;]L[X,K*D9\?Z8)&
M^ZAWY..I QVXH/[9WP9698CX_P!-$K E8_GW$#J0-O2@#VZBO$/^&TO@LOF[
MOB#I>Z+F0;F^3Z\<<4O_  VE\%<QC_A/]+S(NY!E\L ,DCY>1B@#VZOD/_@I
MI\!?'/[1'P(T?PYX!T9=<UBWU^&^DMVNX;;$*P3H6W2NJGEU& <\].M>DO\
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MBK'_  V-\'?^A[T__OE_\* /:J*\4?\ ;(^#D:EF\=Z>% R25?H!G/W:2/\
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MR'#A0Y*G&<'Y>#WH Y;]I+_@G_\ ";]IS4)=8U[3KK1/%#JJMKNB2+#<2A<
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M:D_[+>ASZEX&N_M*+_PB^CSZ4J?9(O\ 21+$L9D?C[PVYX[DU[IM&<XYHP*
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M,9;6QMK:0C:6AA53^8%7Z6B@ HHHH **** "BBB@ HHHH *C9>_4U)2$ ]:
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MXDD25T=9(DCC6-T960J$7!0YYS0!NVN@Z;9R^;;6%M;28(WPPJIY]P*T:**
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M,\T ;^@^!=.\/>+/$_B&U>X-_P"(9+>2\61P8P881$FP8X^4<Y)Y]*Z:BB@
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G1M*MK;ES%"HC1%P#+(Q.W<Q;YB<#'>4 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>gizttcucplmb000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000014.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %126\4A!>-7(Z%E!J6B@!*6BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHI* %HI*6@ HHHH **3-+0 4444 %%%(3B@!:*2EH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **2C/.* %HHI"<4 +1129YH 6
MBBB@ HHHH ***3- "T444 %%%(30 M%)2T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117/>.O'GA_X9^%[[Q)XIU:WT71+)0UQ?73;8X\G ]\DD
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MRRR-D$=8&_'Z\_:\^*%Q\&?V:_B!XOLKK[%J5AIKK97&1E+B1EBB(W<9#NN
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M-S#Y$Z_W1Z4 ?#?Q2\ _M7?LM^$;GXCZ/\:!\4[#2/\ 3=:\.:SIJ(LUN/\
M6&(\L H^;:C(< D9(VG[#_9[^,^G?M!?!WPSX^TR$VL&KVWF26I<.8)E8I)&
M6 YVNK#..< UX%_P44_:9T[X;?"^^^&NAQOKWQ)\;6[:5I^BV0$LL4<P*-,Z
MCD @E4&,LQ'8$CUC]C7X*WO[/O[-_@SP3JA0ZM96[S7RQMN5)YI&FD0'N%9R
M/PH ]LHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /)?VD/B1K'PP\$6VJ:*T(NI+Q(&^T)O7:5<GC/\ LBOFK_AL/XA?\]--
M_P# 4_\ Q5>V_MI?\DNLO^PE'_Z!)7Q'7RN8XFK3K<L)61^0\3YGC,)C_9T*
MCC&RV/</^&P_B#_STTW_ ,!3_P#%4?\ #8?Q!_YZ:;_X"G_XJO#Z*\OZYB/Y
MV?)?VYF7_/\ E]Y[A_PV'\0?^>FF_P#@*?\ XJC_ (;#^(/_ #TTW_P%/_Q5
M>'T4?7,1_.P_MS,O^?\ +[SW#_AL/X@_\]--_P# 4_\ Q5>V_LP_&CQ'\5K[
MQ!%KK6I6RCA:+[/%L.7+@YY/]T5\15]1_L,?\A7Q=_UQM?YR5WX'%5JF(C&4
MKH^AX?S;&XC,:5*M5;B[Z7\CZ[HHHKZ\_:A*^*O^"EGQ>\?_  %TGX9>-?"/
MB&[T?18M=^Q:Y:PK&T5U"X610X92PXBE7Y2/OG/:OM:OG;_@H!\+O^%M?LD?
M$'28T+WUE9?VO:;0"WFVS";:,]V5'3_@9H ^@-/O(M2L;>[@<20W$:RQLIR&
M5AD'\B*_*GXW?MH_%S1OVFO$OBKPUXBN4^#/@_QCIWAK4-.CCC,5R3O^TJ&9
M<Y)@E&0W&^,U]:?LU_'R*3_@GSH?Q$U&XS+X?\+3+=2RON9I;*-XLD@<LYB4
M^N7[U\V_";]FZY\??\$J_&<EW;.WB;Q0]YXRB:1?WLDT,F^+ENOF) 0&STE]
MZ /TW@N([F".:-@\4BAU8="",@_E7Q5^QQ\9/'WQ^_:D^.>L7?B6YE^&7AN]
M;1]'T4+&;=I3(5$JL%W$A(&;!)_X^!Z5TWP"_:8M]6_X)Y6GQ-O96>\\.^&+
MB"]&5WR75G$T0XSC=(R(P!Q_K!TK!_X)@^#_ /A5_P"QXGB_7S]FN/$5S>>(
M[R:50&$ RJ.Q'4%(O,^CT ?:=%?FM\'_  O\1?\ @I->>(?B#XE^(OB3X>_#
M"'4'L-#\/>%;C[++,(P,N[D$$_,,E@V6+ ;0HJQ\05\<?\$T?'O@G7E^(OB#
MQ[\%O$&I+I6JZ?XHG^U7.G.REO-CDP.0BNX"@9\M@0<@T ?I#17QI^W-^T%X
MVTGQ5\/O@M\*;N+3?&OC]^=<;YC86>[!D3&>3ASNP<!&QR01A77_  38U[3]
M'?5=$_:%^)"?$%$\U-2N]4S8O/U^:$#>$)XQO.!V/2@#[HKXS_X)P_&7QI\8
M+?XO-XQ\07.O'1_%#V-@;A4'D0 -A!M R..]=)^P'^TMKWQZ\!>(-"\<(D7Q
M%\$ZBVCZT8P%%P5+*LV -H8LDBL!QF,G@, /EC]B+]H3PK^S3\*?VA_&'BBY
M 2'QA,MGIZ.!/?3[6VPQ@GJ>YZ 9)Z4 ?J?17Q1^RS\*_BQ\8O'7_"]/C#X@
MUK08+S]YH/P[L;Z>VM+2 ?ZI[B,. YP2=K@DD[F[*/M>@!*^+O\ @HU^V%J'
MP'\$GPEX!N)&^).J6[WAEMHA(VE6$?,ERP(*@G!5<C^\>PS]#_M"_'3P_P#L
MZ_"K6?&OB!V>*T39:V<8S+>7+9$4"#U9L<]ADG@5\2ZQ\#?$&D_L;_'+XR?$
MY?M/Q5\=:%+<3+*23I5@2K0V:#^ !=I8#T4'E30!]C_LD^+M8\>_LT_#?Q%K
M]])J>M:GHT%U=WDV TTC+EF(  &?85Z]7A?[#)_XQ!^$?_8O6O\ Z#7NE !1
M110 4444 %%%% !1110 4444 %%%% !1110 5QOQ8^%'AOXU>";OPEXMM'U#
M0;N2)[BU25HO-\MU=5+*<@949P:[*B@#\D_^"@7@7P_\-?VLOV;?#OA;2+/0
MM$LY+-8+&QB$<:9U($G '4DDDGDDD\DU]7_\%6KB>W_8F\8B%F027>GI*5S]
MPW<?!]LXKP3_ (*2>#]>U[]LKX!WVF:)J6I65K+9F>YM+226.+&H*QWLH(7
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M9)M^1^5M%?8W_#N75/\ H=+7_P  6_\ BZ/^'<NJ?]#I:_\ @"W_ ,77Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R[\$?\ D^S]I+_L
M&^&?_2>XKZBKY=^"/_)]G[27_8-\,_\ I/<5]14 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 %%%% !1110 4444 ?+OP1_Y/L_:2_[!OAG_ -)[BOJ*OEWX(_\
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M_M[>(K#]H&QO)?CKJY*Z5K<KQO8G= % C"J,,\2LBN#C *84YS5^!D<6I_\
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M% 'QC^R'\-]/^$_[7?[0_AO2KW5-0LK:P\.NMQK-])>7+;H;EB&E<Y(R>,]
M,5]G5\N_!'_D^S]I+_L&^&?_ $GN*^HJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;I7Q5^W1^Q
MG\*/CWXDT+4]7\:6_P .OB3J;QZ9IEX71CJ; X2)K<LK2,,D!D8$9&<@ 5]K
M5^8F@^$=-^/W_!5[QJOC?6+NTD\$QP7'AW3A/Y9E:$PE0F[J@+O(54<[B<XS
M0!QUC_P2H\!_"OQKX:M?B[\;[6'3=6NG2QTN.U^P'4)5*YC$\DC*I(8<;<G=
M@'/-?JKX6\-Z7X-\-Z7H6B64.G:/IMM':6=I ,1Q1(H"JOT KY+_ ."HOP1\
M'?$;]G?5?%_B+4)],UKP?9SW.C3)<A(WFD,>860\.7**HQR,\=\^A?\ !/SQ
MAJ_CG]D#X;ZIKES+>ZA]A>U-S.2SR)%*\2%B>2=J*,GKC- 'T31110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKX1^&?'FDPR6UIK-J)C;2_>@D!*R1D]]KJRY[X![T >@4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORU\-^&/AYK'_
M  5$^+OAGXNZ/8ZO/XB@2+P[#K%H+F%G>.)EV!E*J_EJ=K'IM8 YK[Q^-7[3
MG@/]G_5O"^F>,;ZZM+SQ)<&VTU;:T>822!D7#%1\O+KU]:\$^/G[57[+_@/]
MH2QNO'D=Q%\3/!;&.WU&WTN=Y(5DB/R&1!B1=LK8#9 +$C!H ^/_  %#^S_X
M-_9?^+7PV^*5AH&G?%GP7J.I6%EJ1T](-6O'5S]FEAE5=[XD4KMW, H&[Y6%
M?HQ^PIX^UGXF_LG_  \U_7RKZK+8F"694V><(I&B60CU94!)'!))X!Q7PS\8
MOBI^P1\<OB%/XT\13>(H]:NF5[QM/L[JWCNV4 ;I%"XR0 "5P3]>:_2'X"^*
M/!GC+X/>%-5^'D(MO!,EF(M*A$!@"0Q,8@NP\C!0CGKUH ]!HHHH **** $K
M\1OV2?V??"WQ7_X*#?$#PC\0[!=0L-,GU>^&FR2%$N9TNE55;!!*A9&?:#SM
MYR,U^W5?#'[4G_!//6O'7QBM_B_\'/&*^ /'Y<27AE+K%/(%"><CKDHQ7AE*
ME6'ISD ^??'W@?3/V0O^"H7PTTGX6K-H6B>)[:S>_P!(MYF:';<7$\$D.TG[
MF(DD /0X(Q@4?!^Y/@S_ (+-^)K'486CDU:[U**%L@ >99FX1CST94 '?YA7
MT-^S3_P3^\2>%OC4_P 8?C7XW'Q \>0X^P"'?Y-NP0H)&9@,E5.%55"KDGDX
MQI_MD?L"WWQR^(6C?%+X<>*$\$_$K2_*!NI580W/EG]V^Y0621!P#@@@ ''6
M@#YA_P""CUFWB;_@I'\&=,LF62Z^PZ+"R_W6.IW+X/\ P%@?QK];J^%/V9O^
M"?/BGPK\=I?C)\:O&L/COQM <V*VZL8DD\L1K,[,JY*KE515 7@YS@#[KH R
MM=\,Z1XHM5M=9TJRU>V5MZPW]LDZ!O[VU@1G!/-8?_"F_ '_ $(WAO\ \%%O
M_P#$5V-% 'R=^SSH>G>'?VW/VCK'2=/M=,LH].\-E+:RA6&-28+@DA5 ')-?
M6-?+OP1_Y/L_:2_[!OAG_P!)[BOJ*@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ;2 CM2_6O'_'_AOXM:AXJN[CPOXET_3M%94$-O/$&=3M ;)V'^('
MN>M95)N"NE?T.3$UW0AS1@Y>2/8#1GM7R9HNO?&C6_B#K'A"'Q98KJ&F1+++
M*]NGEL#MP%_=Y_B'45[;\*]%^(&DW&HGQMK=GJ\;JGV9;6,+L(+;B<(O7Y?R
MKGI8GVSLH-'GX3-/K<N6-*25VKNUDU\STBBBBNT]L**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH6CY7.01UK]/?@+\7=/^/'PA\+>.]-B:VM]:LUG:W8Y,$H)62,GOM=6&>^*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>!_MC?M66?[(OP]TKQ5?>'Y_$45_J2Z<+>WN%A928I)-Q)!_
MYYX_&O6_B!!KEUX%\0Q>&)4@\1R6$ZZ;+(0%2Y,;>43D$8#[>HK\8_V\/"_[
M4^B_"_1IOCEKVEZKX8;5T6TBL9(&877DRD,=D:G&P/U- '[)_"[QQ'\3/AGX
M1\8PVKV,/B'2+/5DM7?>T*SP)*$+ <D!\9QVKJJ_-_\ 8L\)_M<PP_"'4-6\
M1:3+\'#IMC*EC')!Y_\ 9IME\A,>7NW!#'GYL\'K7Z04 %%%% !1110 5D^*
M?$VE^#/#NI:]K=]%IFD:= ]U=W<[82*-%)9C] /QK6K\Z_VS?B-K/[67QTTC
M]E[X=7\L6EQS+<^-M7MHV*01IM<Q%^A"#&1T,C(F<AA0!ZU^QM^WU!^U]\1/
M&>@V'A%M!TO0X!<VM_+?>;+=1M*44O'Y8$9( ;&YNN/>M']KS]O;0/V6_$&C
M>%+3P]>>-_'&JQB:#1;"788T9BL9=MK'+L" JJ2<$^F?E3_@D]X<L_!_[5'Q
M]T#3E==/TKS+&V$C;F$45](B GN=JCFL?X<6[_$?_@L_KM[J!C==%O;V58W0
MD,MO8F"+'/524;/^S^0!]3_LN_\ !1;2/CM\2I_AQXK\(7WPV\=!"UOINHRE
MUN652S1J61&#A!NVLHR 2.E?8M?DE_P4(O%\"?\ !3#X/:YID?D7DUGHUU,\
M9"&1_P"T+B$DD#O&BKSV&*_6V@ HKS;XZ?%C4_@[X2@UK2O ?B'XA7$ETMN=
M+\-6YFN$4JQ,I7'W1M _X$*\&_X;T\:?]&L_%S_P4G_"@#H/@C_R?9^TE_V#
M?#/_ *3W%?45?$W[&'Q$O_BG^U=^T)XBU'PCK7@B[N+#P\C:+X@A,5W#LBN5
M!9<=&QD>Q%?;- !1110 4444 %%%% !1110 4444 %%%% !39/\ 5M]#3J;)
M_JV^AH%+9GY;^*O^1HUC_K\F_P#0VK+K4\5?\C1K'_7Y-_Z&U9=?F\OB9_+^
M(_BS]6%%%%08'JO[+G_)=_"_^]<?^DTM?H37Y[?LN?\ )=_"_P#O7'_I-+7Z
M$U]?E'\!^OZ(_:N"_P#D7S_Q/\D%%%%>X??!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!3U35;+1
M=/GOM1NX+"R@7?+<W,@CCC4=V8G 'UKYU_:$^&'PF_;F^%\>E3?$6UET#0K[
M^TY]1\,ZI:3"%DCD0B5R'55 9B<X^[]:^>/^"N6MZEK&I?!OX=S:W+X<\'^)
M=68:M?!RL(VR0HID ^\$$CO@_+D GH"/,?CY_P $W]>^"RZ&_P #-7\5Z]X9
M\51#1?%<5N8[F06;21L9L1J-R'!.%4XV^AQ0!]@? _\ ;,_9TT>U\+_"3PY\
M3[6]N-"L+;0[*XU"&6&*Z%O&D*8N&C6%W8*/NMAB?EKZI#9K\S?VQ_\ @G7\
M!_@[^S/XA\2:,UUX<\1:):":SO[O4FD:_G#*!"Z.=I9^@V!2"0>@Q7U;^P#X
MPUKQU^R'\.-6\07,U[J1L6MFNK@DR2I%*\4;,QY8[$7+'DXSUH ^AZ*** "B
MBB@""]65K.=8#MG*,(V/9L<?K7Y*?"_]A7]LOX+ZIKNI^#/&'AO1=1UR3S=2
MO%O(YIKE@6;+/);,WWF8X!QDYK]<J* /PY_8>\(_'C5/VI/&L/@SQ-9:?K6G
MZLK>-)IGC"WL2WQ%PJ9B;.YA(1M"]>U>G^.=4C_9-_X*V1^+O%$\FD>#_$$T
METVH2J/*:"ZM6B+$XX5+C&['(">G7]*?AM^SA\.?A%XP\1>*O"/AJ/1]?\1.
MTFJ7BW,\AN6:0R-E7=E7YR3\H'6K7QD^ /P__: T&/2/'OAFS\06D+[X'FW)
M- W&3'*A#IG'(# 'H<T ?F)\?/$>B_MA_P#!3CX:VG@&[C\2Z-HL.GV]SJ-B
MV^W:.VN)KN>17'!11)MW="PP.HK]?Z\H^"7[+OPP_9W2]_X0'PG:Z'<7I_TB
M[W//<2 8PGFR,S!> =H(&><9KU>@ HHHH ^7?@C_ ,GV_M(_]@WPS_Z3W%?4
M5?+OP1_Y/L_:2_[!OAG_ -)[BOJ*@ HHHH **** "BBB@ HHHH **** "BBB
M@ ILG^K;Z&G4V3_5M]#0*6S/RW\5?\C1K'_7Y-_Z&U9=:GBK_D:-8_Z_)O\
MT-JRZ_-Y?$S^7\1_%GZL****@P/5?V7/^2[^%_\ >N/_ $FEK]":_/;]ES_D
MN_A?_>N/_2:6OT)KZ_*/X#]?T1^U<%_\B^?^)_D@HHHKW#[X**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /'?VFOV7?!G[57@2/PUXNBGB:UF^TV&I6;!;BSEVE2R\$,I!(*L"#P>
MH!&M\$?ASI7[//PE\-^!/[>6^@T:$P+?7S+"\V79\E2QP?FQP>U>"_\ !2O]
MJSQ'^S?\,M$TWP2NWQAXJNGL[2[$8D:UB51O>-,'=(2R*N01R3U KY2\-_\
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MU_1'[5P7_P B^?\ B?Y(****]P^^"BBB@ HHHH **** "BBB@ HHHH ****
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M]<?^DTM?H37U^4?P'Z_HC]JX+_Y%\_\ $_R04445[A]\%%%% !1110 4444
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M3\'?"?@.PF-S#HEDEN]R5V^?*<M+)C/&YV8X[9QVH ]!HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCSQK\0OAM;ZA\0O!S>!O%L%Q+9WVE^89(RT9 \V-N<H_489A_M&@#TZBBB@
MHHHH *_,C4/V'_BI^UM^U1XJUWX]C6-!^'-DTQT&UL]2MI/,A\T+%%$$:01
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7YQ+XF?R]B/XL_5A1114&!ZK^RY_R7?PO_O7'_I-+7Z$U^>W[+G_ "7?PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[@@T ?0?C[XF>%/A7H\>J^,?$>F^&=,DF$"7>J7*P1-(02%#,<9(!./:O/\
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M+XOT?5=.FCA$=U9WB21MB, @,"1Q7Z<_\*/^'./^2?\ A?\ \$UM_P#$4?\
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MW)'_ $&8/_BJ[+_A1_PY_P"B?^%__!-;?_$4?\*/^'/_ $3_ ,+_ /@FMO\
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ML%O;6Z!(XHT 5451P    !Z5=HH **** "BBB@ HHHH **** "BBB@ HHHH
M*\C^)WP$_P"%C?''X1?$3^W?[/\ ^%?R:H_]F_9/-^W_ &R!(<>9O'E;-F[[
MK;LXXZUZY10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4HI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7DG[1GP'_X7_P"'?#.E?VY_8/\ 8OB*QU_S?LGVCSOL[EO*QO3;NS][)QZ&
MO6Z* "BHHKB*9BJ2HY7J%8$BI: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*:U '@G[7?[8?A+]D;P3%J>LQMJWB#4 ZZ3H-O($ENW4#+,QSY<2DKN?!QD
M GBOEOX!_M\_M%?%SXP>$]!OO@Y:Z7X<U^XRM]=VEY:1I;!2\DJ3N"KE4!8
M+\V .,Y'$_&)O#WBS_@L)X:TSXAO#-H%K#:V^G6]^P-NTYM6>WC(/'S7#\+W
M8J.<U^JBQA5    &  ,8H <*6OB7]L+]O#Q%^S'^T!\/_![^&K'_ (1'6'M[
MB_UJXE=Y7MVE\N98T  1HQ\W5L_+P,U]LKTH 6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!*,UYK\0OVA/ /PS\>^$_!/B'Q%!IO
MB7Q5-Y&F6C=68Y"LQZ*&<!%W?>8@#/./SZM?VP/B;^PC\:/'_P //B5INJ_$
M_P#MR_&J^&KJ*8"6?SI0H"C;PK("-B@[9(PH7#9 !Y!\=OC7\3?V?_V_/BUX
MT\$7NIZ[IVAW=NVL6]Q(\UJ;1XX@(9@/NHKR%$/\)Q[Y_4[]F;]J#P9^U)X#
MC\0^%;P"[A")J6DS-_I%A,1G8X[KUPXX;![@@<9\$_V1O#7@SXA?$WX@3B[U
M&'XEPPSW>A:_;HSV8<O)/!(,D,"SC(/3;CG&3\0_M&?LT^.O^"=WQ1B^-7P3
MENKGP(9/^)EI;%I$LT9N8)U!^>W;(VN>4.,G(!(!^N5%>4_LS?'S3OVE?@]H
MOCK3=.N]*2]5HY[2ZC8>7,AVR!'( D0-G#KP?8@@>K4 %%%% !1110 4444
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M(].T;3?"M[;6EG#DK%&MNP"C)ST]30!S?_!/_P"-FL?'S]EWPOXD\0SM>:]
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MUK_@G]^T?\;?VL/C1I=WJ'BO3],\)>"M%2TU;2U4/+K#2 JLS(3GS"R!C("
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M^)S\Y4#"EFP3V^BZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAV*[8;.V7"C/)8G.68GDL22370I"D;.515+G+%0!DX Y_ 5+0 4444 %%%%
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M)>.ATJ'AWCE7<#<0[D!1>3G:&Z;Z ,S7K=O^"A?_  40TKQ#\/;)[;P7X/\
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MB0-PQCKSV^D/^"AW[3'BW]G7X36Z^"O#VH7_ (A\03?V?:ZQ#!YMOISL0,L
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M!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *2BB@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>gizttcucplmb000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000016.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M.#_%5_P[_P %7_V==>U**TE\3:EH_F.$6?4=)G6+)..60-M'3DX ]>M>2?\
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MU6OSBC;0K[_@K7HMQ\*UAEB70IAXRGT?!M?,*R;O-*_+OR+?=ZL$_BS7Z.T
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MKM!/;72;)[6=0-T4BY/S#(Y!((((/- 'IE%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^T]\>
M+#]F[X*>(O'M];M>'3XUCM;0 _O[F1@D2$@<*6(R?0'VKU>N=\<> ?#GQ*\/
MRZ'XKT2Q\0Z-*ZR26&HP+-"S*<J2IR#@X(S0!\'?L3_&KX*_#?P]JWQ!^('Q
M<\.7WQ;\=2#4=<N)KD!K1&YCLT&/E5!C*^O'117-_L5_M'?#+PO^U'^T=J6J
M^-=)L+#Q/K\+Z-/--A;]3+/@QG'.=Z_]]"OL\_L6_ ;_ *)!X-_\$\'_ ,37
MR-^QK^S/X(U']IS]HF#7_AQI<NDZ/KT/_"/K?:6ODVJ"6<C[-N7  VI]WT%
M'KWQ_P#^"AH^!/Q2U7P8?A/XJ\3_ &!8F_M/3%S!+OC5\+\IZ;L=>U=K^RW^
MUX/VI(_%T8\!:[X)_L2&!MVM+C[3YOFCY/E'W?*Y_P!X5]%[!W4'\!45TH6T
MGP/X&Z?2@#\]O^",O_)-?BI_V-'_ +16OT1K\:/V(_VM+O\ 9$\/^-M"UGX6
M^+_$$NKZTU]'-I]H45%"!,'<O7(S^-?1FJ_\%-/'GCK1[C3OA?\ L\^,;WQ+
M<?N+:XU*W=K:WD;@.X1.0,@D%D'4E@* ,VRND\5_\%FKTZ8YF30_#WE7SQY*
MHPLUR#]#,B^QXKT?XZ?&?]GW]FG]I6?Q=<:/J_BGXV:G8BTFL=!62\GCMV2,
M*61G$<9*Q( %^;#$XPQ-:O[ _P"R)K?P+B\4?$#XBR6]_P#%7QC.UQJ$T;"0
MVD;R&5X0_=GD(9]O&50#.W-?/<.N:E^PY^W9\3_&_P 0_!FM^*_#'C4RSZ3X
MITNS-U+:H\HD$"Y.!M $;+N!Q$A VG% %_\ :Z_:Q\>?&K]FOQYI-O\ L]>+
M- \--:QO>^(/$LBVB6D8E1ED1&3]ZVX*-JMD;J^D_P!F?X=Z=\6O^">W@GP=
MJZ[M/UOPFME*V,E-RL%<>ZG##W45X#^U+^TOXG_:Z_9_\9>&OA'\-_$XT&&R
M:^USQ#X@LOLD26\(\UH+=,L997*+PO09XYR/IS]@&[-U^Q[\,8Y8I[>XM---
MG-#<PM%)')%*Z,K*P!_AX]1@]#0!XM_P36^,$GA/X&^._A]XXN$L]1^$U_=6
M]W(Y/RV(+R!^>RLLP'^R$H_X)E^']2^(5Y\4OV@M>@,%]X^UF2/3HI.6CLHG
M/0YZ;B$_[89[C'@?_!0[PGXI^"O[1&O/X%MVFM?CEHL>AW$"OM OEN(%<J .
MK(JCD]9Y#VQ7Z9?!/X86?P8^$WA3P38,)(-$T^*T,H&/-D"CS),?[3EF_&@#
MN*^2/VNO''P!^"WQ1\%?$;XBVEWK/Q)TY/+\/Z9IADN+IERZAA;[Q& &E8AG
MP2P&W)4 ?6]?FU^U)INO?L[_ +?OA_X]ZYX.U+QS\/;C3DL1-I\'VB3291"T
M1*I_"P)+C. ?-?!W"@#L_&G[<7CGXJ>!_$FE>$?V:O&M_8WVF7$;7^OE=/M%
M@:-@\C.ZE>%)(7=SCWJ?_@D]_P F0W/_ &$]2_\ 05J;QE^VUJ?[1_@[7/ _
MP.^&_BO4O$FKV<MG)JNOV L=/TR.1&5YI)"QRP7=M7J3CKTJ'_@E7:WFD_LD
M>(-#U"SNK+4M/UF^CEM[JW>)OFC1@5# 9!R>1W!% &)_P1S\):98_!_QWXAB
MMD_M?4?$<MK/=%1O,,4:F./.,[0TCG'JQJG_ ,%++.*V_:A_9"OXD$=Y)XH,
M33*,,52]TYD&>O!=_P#OHUV/_!)31=0T+]G_ ,30:E8W6GS-XHNG6.ZA:)BI
MCBPP##H>:PO^"D6A:EK'[1'[)$]AI]U>P6GBF5[B2W@:185^UZ8<N0"%&%;K
MZ&@#)_X*G?\ )<OV3?\ L9KC_P!*=,KV_P#X*;?\F4_$+_<M?_2F*O*?^"K7
M@GQ"\7P9^)FB:->>(+7P+K[W%_86,1>0QR/;R*Y(R57-KMSM(S(,X[V/VE?C
ME;_M4?\ !/OXCZYX=\,Z]I<D=U!8_P!FZE9D7+.LL#EE1<[E^?&?530!V,/[
M28_9C_8W^#&OGP?J_C+[?I=C8_9-'&9(LVI?S&^4_+\F.G4BL/X5?\%,A\3_
M (C>'?"?_"F_&&B_VQ>1VG]H7J?N;?<?OO\ (.!7T5^RW:2V?[-_PSM[F%X9
MXO#UDKQ2J59"(5!!!Z&O4?+7LH'X4 ?F]H$H\"_\%G-<CU<&V'B?0MNF.1\L
MV;.)OPYM9EYQRON*_2,5\??M[?LK^*/BQ<>$OB?\,)(;?XH^"9A/9QR;5-["
MK[Q$&/&Y7R5#'!WN.,UPWA/_ (*IP:/I$=C\3OA'XV\->+K= MU;6>F,T+R8
MY*B0JZ _W6!QGJ>M 'VMX[^(_A?X8Z3#JOBW7]/\.:;-<+:I=ZE.L,1E8$JF
MYC@$X/4]J^+_ /@L%>0:E^R'I5W:SQW5K<:_92Q31,&21&BF*LI'!!!!_&O,
M_$UO\3_^"HGQ&\-6EQX/U/X=? G0;I+RYEU9&2XU&3D-MX =BN54*"$RQ+'(
M%>L_\%;/"]S=_LEZ5I>A:9<70MM=LTBM;&!I"D:12J %4= ,#\J /L'X7_\
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M3?$O4%M9[/4((FOK6</'%N\Y5#.$,J,,\89QC/)_3D9K\VHK3Q=_P46_::\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O(_VCO"_P 6
M_%7A73;?X/>+-)\(:['>^9=W6L6YFCDM_+<;%'EO\V\H>G0'FO7** /A_P#X
M4W^W'_T6[P-_X+#_ /(M'_"F_P!N/_HMO@;_ ,%A_P#D6ON"B@#X@_X4W^W'
M_P!%N\#_ /@L/_R-0?@W^W'_ -%N\#?^"P__ "+7V_10!\0?\*;_ &X_^BW>
M!_\ P6'_ .1J3_A3?[<?_1;O W_@K/\ \C5]P44 ?#__  IO]N/_ *+=X&_\
M%9_^1J:_P7_;AD7:WQL\"L/0Z6?_ )%K[BHH ^'E^#/[<*+A?C;X% ]!I9 _
M]):YKXE>$?VYOASX#UKQ)%\4?#?B:338//&DZ)HIGO+G! *Q)]F^9L'./8U^
M@U% 'Y!_#;X._M?_ +7GB_0OB)XGU&W\(W_@Z4G1)_%VE&T#2L<LR6PARV,+
M\[KC(&"<5]._\*;_ &X_^BW>!_\ P6'_ .1J^WZ* /B#_A3?[<?_ $6[P/\
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M^"LW@^X\3? OX7_%FYUV_P#/U$Z?I\FA*V++?+:7%P;C;G_6 J5!_NDBM_\
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M\OD_[1H _3&BOQ7^$>L>%?VHM/\ $?CWXY_M,:IX'\67%Y)'I&BZ?J8M8K)
M 5D,94_N\G 5-I^0DL2>/H?]A[]M#Q)<?LT?&L^*-5D\7ZW\+[66\LM6G<R?
M;X&CG,*LY.7Q);M\QYVNO)Q0!^D-?*7[)_[77B']H#XW?&+P5JVBZ9IECX(O
MVM+6XLO,,MP!<31;I-S$ XB!X'4FOE;]CG]FKQC^V!X)U+XS^,_C'XYT;Q+>
M:C-'I+:-?^5%"T1 W%6!S'OR B;0 IYYK4_X)*V^KV?[0'[1%OK]U]NUZ*YB
MCO[K:%\ZX%U<B1\ <98$_C0!^FVJ736.FW=P@#/#"\BANF0I-?F9\(?^"CG[
M3'QZL=0O/ /P3\/^)+;3Y%ANI+>>51&[ E0=\R]0.U?I?X@_Y .I?]>TO_H!
MK\2_^"=G[57B?]GO0?%FE>'/A1K?Q&;5KR&9Y=)\S;;E(V 5BL3C)!)Y(Z4
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MD\-W][]LT77-.LH[DGY=HW-Y3E0RA<JP4@JQ (.:_62B@#XT_9W\$_&OQM\
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M#]C7Q3\ _P!D?XL+XA274_B1XVTJZEN=/MV-Q)$?L\@BM]P)\R4O(Y9E)!+
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MI6^0F2*)[>0*X5]WWCUSP#FOMQE#*01D$8(-?*$?['/CSX>:EK%E\(/C-=>
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M ,:[;X:_&SP'\8EU%O _BW2?%2Z<8Q=G2[I9O(\S=LW8Z;MCX_W30!W%%%%
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MZLO$>CWCW,&E^*H;F/9:1S[A)(N7 QEF<"1<J2>#TK]5Z* /C+X)_L\_$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@#!^-?P=\4_%&\TJ;P[\5?$/PXCLXY$FAT2&&1;HL5(9_,4X*X(&/[QKP?\
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MOPY>WOB#561[J>+5;B%7*1K&N$5P!\J*.!VKZ7HH ^/O^'3O[-W_ $*6H_\
M@[N__CE'_#IW]F[_ *%+4?\ P=W?_P <K[!HH ^/O^'3O[-W_0I:C_X.[O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH)/S _-@BMS]FWX/O\"O@UX?\'W%\-5U.V$USJ.H*"!<W<\KS3R >A>1L9[
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ME6/!KS/_ (*7>.[SP#^QMX[N;"1H;K4%@TL.K%2$GE5),$>J%Q^->(_\$O\
MQ!%\!?V)/$'CGQ]/-HGA)M9FOX+B2&23_1RL,)E5$!8AI%(X7^$GI@UZ)^WE
M?Z;^TA_P3^\0^)_ T\FM:3(EOK%I,MO(C2PP7(\QMC*&&%63J!TSTYH ^9M?
M_9-^'$/_  2ILO&T7ARS@\:QZ7#KQU]5_P!+>1YP"C/U,?EMMV=!@'&1FON#
M]@'QY>?$C]D'X;:SJ%R]Y>"P:QEGER7<V\SP9)/4XC'/?%?%_B+]IKX?2?\
M!)>P\,1^)M.F\5RZ5#H']A)<+]L69)UW%HL[@@1=^[&"".Y KZ:_9-^$_CO1
M?V#_ (;^'?"GB6/P%XGEM_[2:_OM,6_"1SS23E#"74?,)5YW9'IVH ^O:^5?
MV:O^3ROVJ?\ KOX=_P#26YK0_P"%,?M,?]'$Z+_X0D7_ ,DUQ/[$NB^)= _:
M8_:9L?%WB&'Q5X@BF\/BYU6WL19)-FWNBN(@S!<*0/O=LT ?:%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?CO^V]_R>U\1O^O#2?\ TF%>0UZ]^V]_R>U\1O\ KPTG
M_P!)A7D-2?C7$7_(RJ?+\D%%%%(^9/JG_@EG_P G#_$G_L7;3_T>U?IY7YA_
M\$L_^3A_B3_V+MI_Z/:OT\JS]VRK_<:/^%?D+1110>J%%%% "?Q5^='P@_Y2
MV?'S_L78?_0-,K]%Z^$OBQ_P3_\ B7XD_:3\:?%CP#\8H_ =UXB2*!HH-.>2
M58EAA0HS[P""T"MT]*35U8TIRY9*1]=T5\<?\,1_M/?]'4W7_@L;_P"+I?\
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M^6C'HO&<>I-=!\9OA?9?&GX6^)? ^I7=Q86.NVC6<US:A3)&I(.5W#&>.XH
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MC;6-FA>64S#RFVJ.20KL?PH ^3!_P6R^&';P'XO/X6O_ ,=K[:^!_P 6-/\
MCG\*_#WCO2K*ZT[3]:@,\-M>;?-0!V7#;21GY3T/>OS)^"_CS]J#]CW]F_2K
MD_!/2#X"T9I[W4I]7!74I%DE9B[1B4-$%#*.8SPH-?I-^SI\:]&_:&^#WAWQ
MWH4'V.TU*)O,LRP)MIT8I)$3@9VL#S@9&#@9H ],KY6_9K_Y/*_:I_Z[^'?_
M $EN:^J:^5?V:_\ D\G]JG_KOX=_]);F@#ZJHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?=\H(YP:D\;?MA2P?$37/!7PW^&VO_%35_#SK'K=SI4L-O96$ASF$S2'#3
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M9S7UM_9MK]K^U_9H?M6-OG^6-^/3=C.*LX[T ?./_#O'X#?]"GJO_A6:Q_\
M)=<#^Q7\/=#^%O[3G[37AKPU:RV.C64WA\0037<UTR[K>Z8YDF=G/)/5CUQT
MK[-KY5_9J_Y/*_:I_P"N_AW_ -);F@#ZJHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH _'?]M[_D]KXC?]>&D_^DPKR&O7
MOVWO^3VOB-_UX:3_ .DPKR&I/QKB+_D95/E^2"BBBD?,GU3_ ,$L_P#DX?XD
M_P#8NVG_ */:OT\K\P_^"6?_ "</\2?^Q=M/_1[5^GE6?NV5?[C1_P *_(6B
MBB@]4**** &XK\*/VW_"-EXQ_;X^+-K>O,D<9LY1Y) )/V.U'4@\<U^[';UK
M\-?VR=;L-"_;_P#BW-?W,=K&XM$5I#P3]CM#C]#^5)GG9A*K#"U)4?B2TL>0
M?\*+\/\ _/QJ'_?U/_B*/^%%^'_^?C4/^_J?_$5T7_"P_#G_ $%[;\__ *U'
M_"P_#G_07MOS_P#K5)^9?7,[_O?=_P  YW_A17A__GXU#_OZG_Q%?77_  2#
MT6#P[^TM\3=.M6=H8?#\85I""W,\1.2/K7S/_P +#\-_]!>V_/\ ^M7U!_P2
M1U"WU3]J#XHW5I,L\$GA^,K(G0XGA!_E31])D.(S"M7DL7?EMU5M;H_6>O%?
MBY^R]X1^,7C^P\7^-&OO$%GHU@(K#PS<W!_LJ.X5I&-V\(P))2) GS9&$'%>
MU57U+_D'W?\ UR;_ -!-4?='R-_P2=_Y,G\)_P#7]J/_ *525[7^U!\;K;]G
MGX(^)?&DJB>]M81!IMI@DW-Y*0D$8 Z@NP)]@QKQ3_@D[_R9/X3_ .O[4?\
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MOVJ?^N_AW_TEN: /JJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#\=_VWO^3VOB-_UX:3_P"DPKR&O7OVWO\ D]KXC?\
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MMQ:RVSMMM[E3F.559>0>H%?97V.#_GA'_P!\"OEK]FA%C_;'_:H"J% G\.\
M?].MS0!]5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?CO^V]_P GM?$;_KPTG_TF%>0UZ]^V]_R>U\1O^O#2?_285Y#4
MGXUQ%_R,JGR_)!1112/F3ZI_X)9_\G#_ !)_[%VT_P#1[5^GE?F'_P $L_\
MDX?XD_\ 8NVG_H]J_3RK/W;*O]QH_P"%?D+1110>J%%%% #:^._C5_P4W^'O
MP-^+'B#X?ZKX;\2ZCJ^BM$L\NG01/$V^))05RX/ D'45]B^E?C_\4$5O^"D_
MQHW $?8;;J,_\NUC7-B*WL*4JMKV./&8CZKAYU[7Y4?17_#X?X9?]"5XT_\
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M_L7L_P !/C5X_P#V<]12UU2\L+9?%-CXFAA*7.J6\SJLAO26):=6=!NS@C/
M  /:?\%)D6/]B?XF!0%!M[<G [FZA- 'K?ANQU/QM\ ]'M(M>O-*UC5/#<"+
MKD1\RY@FDME'V@%OO.&.[YNI'-?,WQ<^"OC7X*_#C7O&GB3]JOQ]!I&D6S3R
M[+.T+R$<+&@[NS84#U(Z5]6?!W_DD?@C_L!V/_I.E?,7[3L<GQ[_ &M_A/\
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MX7?#/P)#<:MXB\#^+8M=\1ZHMLZ0:3;P(P>-I&'+2%U "Y!(7GT /M:BDI:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/E?]H35+KX/_ +4'PX^*EWH>I:UX2ET6\\+:G<:7:F=],DFN(9()W4<^6S*R
MDCI[\"O--7_:,\+?L>_&KXW^'/B?#?67A_QE=IXF\/316,MQ%J+2VJ0W-N-J
ME0V^) =V!\_.."?;_P!I7]I;Q#\)_%'A?P/X \"S?$3XA>(H9[NVTM;I;6&"
MVAVAII9&X"EFP,D=#DCC/EUW\8_VOM0\K[5^R]X;N3$V]/.\66+;&]1F;@T
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MXA\,:M;:YHEY-X?,%]9ONBDVVURIP?8@C\* /LBBBB@ HHHH **** "OE?\
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MHH **** "BBB@#\=_P!M[_D]KXC?]>&D_P#I,*\AKU[]M[_D]KXC?]>&D_\
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MZ\#_ &$[[7M2_9-^'%SXBCD2_?3SY33+MDEMA(XMY']6>'RV)/)+9/)->^4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&N(O^1E4^7Y(****1\R?5/\ P2S_ .3A_B3_ -B[:?\ H]J_3ROS#_X)9_\
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M/_I,*\AJ3\:XB_Y&53Y?D@HHHI'S)]4_\$L_^3A_B3_V+MI_Z/:OT\K\P_\
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M.CCH01D$?A4U !1110 4444 %%%% !1110 4444 ?CO^V]_R>U\1O^O#2?\
MTF%>0UZ]^V]_R>U\1O\ KPTG_P!)A7D-2?C7$7_(RJ?+\D%%%%(^9/JG_@EG
M_P G#_$G_L7;3_T>U?IY7YA_\$L_^3A_B3_V+MI_Z/:OT\JS]VRK_<:/^%?D
M+1110>J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5.^U2RTOROMEY!:"5MD9GE5-['L
M,GD_2L?XC>,H_AU\/?$_BR:TGU"#0=+NM4>TML>;.L$+RE$S_$P3 ]R*_&+]
MJCXG_&'XP?&;X,^+/B3X9D\$>'-1U93X9\/3$B6*%;BW\R:16 ;<^^/YF49"
M\*!U /W!I*6O-_VCO'3_  S^ OQ!\4Q2)%<Z7H=W<6[2'"^<(F$>>?[Y4?RH
M [_^TK3_ )^H?^_@_P :ECD650R,'0]&4Y%?AA^S;\%?@9\2/A_X<N_B+^T%
MJ7@[QGK-Q.B:-#=+Y<")*R(97966)G"[AYC+D,N.HK]EO@;\-+'X/?"CPYX.
MTS5;G7;#2[?RX=1NW5I9U9F<,Q7@_>ZB@#$^-/[,/P]_:"O-*N?&^DW&IS:9
M')';-!J%Q;!%<J6!$3KG)4=>F*\%_8C^&^@_"7]I;]ICPMX:M9++1;&;P_Y$
M$D\DS+NM[ICEW)8\D]37VE7RK^S5_P GE?M4_P#7?P[_ .DMS0!]5445#/-'
M;QO)*ZQQH"S.YP% [DT 345\_>,OV^?V?O 6IO8:O\4M%-VK-&\>G^;?A&7
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MQ/I]_JWAO5;+2M4?0]3N;66&UU..%)6M)60A)@C@JQ1B&VL"#CGBOSV^'_\
MPU3XD^-WBOX5^)/VCD\*>*=*A74-.SX,T^Y@U;3V.T7$+[$P0W#1D'![G!P
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MU 'SK_P4-_Y,Q^*?_8,'_HU*_GAK^A[_ (*&_P#)F/Q3_P"P8/\ T:E?SPT
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MM?*FA_L#>"OAW^U!>V$_PJL?&'PK\6VKWD%W<0&0^'+Z/K#NW9\B0$[<@D'
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M?BE&61& *L#Y/(((Y]Z]+^!/[&]A\"?&S^)+;XF?$+Q;(UI):?V?XHUI;NU
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M[6%Q_8ED+V'1H-=2[6!1*+MKA6:3?C.XJQ0G/W3CI7TY_P $XO%5QXP_8O\
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M^T#X9_X2#Q"\1T[06_M)M3<WX^21\"?[V.,8]#BO?]2^'<6IP^'8VUW7K?\
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M!]U6^3J/[S>M9>E?"6#2?"&I^'U\3^*;F.^?>VH76KR27L/"\13'E!\O;U-
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MUK_Z):OR'K]>/^"(7_)-_B;_ -A:U_\ 1+4 ?4W_  4-_P"3,?BG_P!@P?\
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M_7)O_037QW_P3=_Y,Y\!_P"[=?\ I1)7V)J7_(/N_P#KDW_H)KX[_P"";O\
MR9SX#_W;K_THDK2>QR87XSZ:HHHK ]0*^;?^"6/_ ";CK7_8WZK_ .AI7TE7
MS;_P2Q_Y-QUK_L;]5_\ 0TK:F<&*V1]BT445J><%%%% 'P7_ ,%=O^25_#'_
M +'"'_TEGKX-K[R_X*[?\DK^&/\ V.$/_I+/7P;4L_,N+/XU+T?YA1112/@2
MO#_R/GP[_P"QJTS_ -*%K][>YK\$H?\ D?/AW_V-6F?^E"U^]O<TT?L'#/\
MN"]6?CQ^V]_R>U\1O^O#2?\ TF%>0UZ]^V]_R>U\1O\ KPTG_P!)A7D-!\+Q
M%_R,JGR_)!1112/F3ZI_X)9_\G#_ !)_[%VT_P#1[5^GE?F'_P $L_\ DX?X
MD_\ 8NVG_H]J_3RK/W;*O]QH_P"%?D+1110>J%%%% 'Y0WO_ "<+\>/^QOF_
M]%I6Q6/>?\G"_'C_ +&^;_T6E;%?G69?[U,_$\\_Y&-7Y?D@HHHKS#P3U?\
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M_AC^V5^Q_P#LXVVKZ5KOAG2_#'A>.?4+KPH(8;FZ>-Y6DE:5_+(8C<3\DH.
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M!?\ Y2!?$?\ [$;3?_2J2OL&OC[X+_\ *0+XC_\ 8C:;_P"E4E?8- !1110
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M@P?^C4K^>&@ HHHH *_IU^"W_)&_ ?\ V ;#_P!)XZ_F*K^G7X+?\D;\!_\
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M_&?35%%%8'J!7S;_ ,$L?^3<=:_[&_5?_0TKZ2KYM_X)8_\ )N.M?]C?JO\
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MP_\ H"UJ5^:U/C?J?A-;^)+U"N2^+W_)*_%__8)NO_135UM<E\7O^25^+_\
ML$W7_HIJTP_\:/JC;!_[S2_Q+\S]'OV4/^36_@[_ -B;HW_I##7JM>5?LH?\
MFM_!W_L3=&_](8:]5K]0/W\**** "BBB@ HHHH **** "BBB@ HHHH ****
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M .SHHHH **** /E#]O;_ (_OV?O^REZ?_P"D]S7J->7?M[?\?W[/W_92]/\
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M_P"2V?!W_L&ZE_Z%'7U=?^#+T/YTR?\ Y&5#_$OS/DRBBBOCS^F0KT;]D/\
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M_P"3VOB-_P!>&D_^DPKR&@^%XB_Y&53Y?D@HHHI'S)]4_P#!+/\ Y.'^)/\
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MOV4/^36_@Y_V)NC?^D,->JU^H'[^%%%% !1110 4444 %%%% !1110 4444
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M951=6^R5T&\*2/F"AQ@]'%=9110 4444 %%%% !1110 4444 %%%% !1110
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MYGDS*5*36TH )CE0\JP!!YZ@@@D'- 'H5+110 4444 %%%% !1124 +7G_\
MPIW2O^%ZI\5/M=[_ &XOAU_#8M-R?9OL[7*7!?&W=OW1J/O8P3Q7?;J7/.*
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M)? \VVRN+EA+B$2&)XP6Y9,A&7=G&_'3 H \"USXBS_'G]L7P]\1/V4OA/\
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M-^I_LP?L_:?X7UVYCN/$%W<R:EJ"0'=%!)(% B5N^U54$]VW8XQ0!]'4444
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M">?[,.J_LM? 4:)XAF5_$NL7SZMJ-O&X>.U=D2-858<,56-<GD;BV. *^H*
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M?V:OAU9>$?"%EY5O'^\NKV4 SWLW\4LK=R>PZ*, 8 H ],7.T9.3T.!3Z**
M"BBB@ I"<5YG\.?VC?A[\5_''BOPAX7\26NJ:_X9F\G4+6,]".&9#T=5;*,5
MZ,,'M7S?_P %-OCEXH\"^'_ /PX\'ZO_ ,(YJWQ#U)M/FUE6*/;6RM$C[6R-
MI8SIE@0< XZY !]%_'C1=8^)OPL\5>$O WC2'POXPN[1XK:]MY$>2)NZ$ [D
M##*[U^9=V1R!7P;^P#^T;??!OXQ>.O@]\=HVT?QWX@U6.Y36]4V+]LN! D"P
MR28"L'6-#&^<.7;^)AE/CG_P2K_X51\.;KQ[\+/'>OMX^\/PG49YK^X"&]$8
MWR&-T :-P%+*"6!Q@GO73^&/A+8?\%1/V1?#WBOQ"]OH'Q6TF2;3XO$MO;@"
M62(C E53S&X*GC[K%BOH0#5^.G[ _C/P+\?]!^+G[-M[:^&]7N[\#5])E81V
M<:R$>9*%Z-"P+;X@.."G/3] +-9UM8!=-&]R$42M$I52^/F*@DX!.<9-<S\)
M_!-[\-_AMX=\,:CXAOO%5[I5G';2ZQJ6WS[DJ,;F(';@#.3@#)8Y)Z^@!*\R
M^/\ ^T/X+_9I\!R^*_&NH&VM-XAMK2 ![F\E(R(XD)&XXR>H  )) KTQL[>.
MO:OQJ^)_BV^L?^"A.GW'[6^FL_A6V9AHMM;YDTB"$O\ N)0I'[V'(/F9^8M]
MX87;0![3H/\ P6ET"Z\3&#Q-\*M7T;PG<,4BU2&^6YF*D\%X#$BX*Y)"R'&,
M#=7V'^REX$^$/A/X8QZC\&K>R'AG79GOVO+5R[32,Q^5R?F&S[@0XV[<8'-=
M9X\^%?@;XY?#:3PWKFEV&M^%M0M0(/)5=L:,OR20.OW" 059:_.[]BR/7_V.
MOV\O$W[/=U>3:GX3U^.2XTYV((!6 W$,Y&?E8Q*\; #E@.P!H \Z_9[_ &M?
M#/[)?B[]IO5M1B;4?%>H>(Y8-%T=0V;F07%UDN>BQJ2I)Z\@#FOT)_8@UCXU
M^*/A7-X@^-+V<6H:O=->Z581VOD75K:N-P28=!R?E4C< /F))P.#\"_\$W_!
M^A?M4>+OB_K\D6N07>HG4M$T5XSY5K<2*&EFE'1V$A?8,8'#'G&/L>@!:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC_93^$K:;J$\>H>,M;E6_P!=OH^09MN%A5NK)'EL$]2SG W8KZ1HHH ****
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M!K&F:[>:-8:AKVCK*=+O+R .UJ[@;BA(RN=J\CGBOQ_^$'Q@^*'@O2OB_P#
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MQT;1[*'3M*L85M[6TMD"1PQJ,*J@=@!6G14%U*8;>614:0HA8(@RQP,X'N:
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MJ_\ !3#P7^T_\3Y? UMX;U3PSJ<D4L^G27DJ31W21\LK;?N/M^;'(X;YLXR
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M9A]Y%5L+VQSU))]DH \H_9K_ &<_"W[+_P -+3P=X6CDDC5S/>:A<8\^]G8
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MF?'?X@2_$WQ7I.UM.L]\DUK;NIRKEY0&?:V650JC."<U]THHC4*  H& !3Z
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M.,'J/5?V8OA;XM^/'[2%M^T+XN\'CX;>'-&TO^Q_"GA>2$)<F+8R>=(-HVJ
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M4A&6F?<0,*"H )QEUSQFO@'XI7GQ[_88^,F@:_\ \+3U+XI>)[W3GUKQ/X?
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M@!I,@9:O)?!5WX9_X*1:A\+O &E?#?5/"WPL\!6,S:MJ+A(OWAMA##;V\B9
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M$W6?2?#^EJ!#-< C][<$1HIQM7L2>1D#(/WC0 M%-8[>3P.I-?-GBC_@HM\
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M_L1_M _"JRO)_@%\7M+M/AUXN@CO[>348MMPD,J QNR^5(!*J,!O0C/7 X
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MMM"TQ1GDWR1O!'\S)NRR2H,IO8'C);5\'^%?BY^WU^T!\/O'_P 0/AY)\+?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGPM\3#P[XJ^(V@Z/KF\))8RW(:2 D @2A0?*R"#\^W@YK\]?VE?@GXJ_9/\
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M)+>.1-:\9ZI^]UKQ!(G[RXD/)C0GD1*<X!/)))Y- 'T,*6BB@ HHHH ****
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MBB5"WXE37$_!O]E7X4_ "66?P)X*L-#O)$\MKW=)/<E3U7SI69P#Z!NU>LT
M%+110 4444 %%%% !1110 444E "T5X1^UII/Q?\6?"[3XO@=KFGZ7KLFIVL
MD]Y.ZC-KO&YD<Y7:#M9A@ED5@,DX-OX%_M3^ _C/KVM>$-'\4V>L>+O#@6#4
MEMXS!'=2*JB6:V5B2T0D++D'@CT*D@'S/_P4\_9]\:7FJ>$?CU\-?,?Q3X)
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M5<G!VJ2%VC'):OJ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ&C\"Z_XYM[?76D6"X-O!+-!9R,<!9I44I&>><GY>K;:[;]IR_\ &&F?L_\
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MG3Q!<B06MY<,T-K"N2D2IG#%26_>-EL''KGZ"H **** "BBB@ HHHH ****
M"BBB@ JCK&L6/A_2KO4M4O(-/T^TC::>ZN9!''$@&2S,3@ #UJ]7Q[_P4,^%
MWQ"^.-O\+? 7A73KR]\)ZMKWF>*FM)Q"$M(O+8;W/R[<&4C)Y9$ !- %G5OV
MEO@M^VWH?BWX->$?B5>Z9KNJ6<L$%U:136;3XZ^4[JHE3(^:,$%D+8XR1\J_
MLE_&KQ#^P'\=/$'P>^.(DBTGQ#=PSV?BJ:1I8]XC6&*4R'.8&C2-<D_NM@!P
M,XYSXQ?LQZ?\=OB-XWUW]GO2M(\">'/A!9"S&K60,)U?5+<F60)(K??C1?\
M6D<D+DD,"/8/@7K$?_!3SX$W7@GXL^#]3T_Q-X?A26V\=VUHL4)=U_=.A;DN
MZX+QJ"K !OERN #TS]I[_@GVGQ8^*'AKXK_";Q)#\/O'"7T5Q?:E:J?)N(SC
M-R@3K*%ZC[L@.&(Y)^T+"&6UL;>&>X:[FCC5)+AU"M*P&"Q & 2>>..:YGX2
M_#/3?@W\-] \%Z/<7UUINC6JVL,VH7#SS,H[EF)XR3A1PHP   !784 %%%%
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M0OBKX\^.WA+XR_!;Q-9Z+XQTFQ_LUTU!U C7,H\R/>CH04GD5E8>A&<U[/\
MLE_LZ:E\#/#&LW_B_7O^$M^(WBB]_M/7];*@!Y@NQ(H^!\B+G' ^\W &!7O=
M% "4M%% !1110 4444 %%%% !1110 4444 %131":)XVR%=2IP<'GBI:* /S
M#T/_ ()X_M!>!?$_BSP%X1^*%KHOP5\3WTEUJ,T>/MDD,F%="AC+"0Q@(2DB
MJV!GT'Z0^"_".G> _">C>'-(A%OIFDV4-A;1@ 8BBC6- ?\ @*BMNB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\Y?B!^P_P#M!>#_ -H;QQXH^"?Q%LO#
MWAOQ[/Y^K3W3 7%MEF9EVM&^[:SN49"K -CC&3^C5% 'GWP)^$&F? CX4^'?
M ^ES/=P:3;F-[R50)+F5W:265O=Y'=O^!5Z#110 4444 %%%% !1110 4444
M %%%% !1110!\L_M]?LJ^(?VG/ ?AUO!VLP:/XM\,:B-2T\7C%89FP 5+ ':
MP(5E;!'&#UR,_P#9._9E^)GASQO??%#X[>,(O&'Q!FT\:18VUNB?9]/M-X=@
M"B(N]FQG:H'')8GCZVHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>gizttcucplmb000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000019.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M-3?M??\ !5#PEI6J7)U/P%H.KWT6C:<S;K8_8[6>5;@*#@F26!7W'MM'08H
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MLM<T\6LTT*7D"2FWF$,BK-$6!\N10[8=<$;CZFO0JQ_&'_(I:W_UXS_^BVH
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MON.OG[]NCX 77[2/[-_B3PII95=?B\O4M+\SHUQ"V[R^O_+1-\>3P"X/.,4
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MS/MWW5LTC+&,GJR2RX'7*U^RE[JEGIAMQ=W4-M]HE6"'SI OF2-]U%SU8X.
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MXF>=U!VLV2J<Y/?FOLZB@#%\'^$=(\ ^%]+\.Z!80Z7HVF6Z6MI9P#"11J,
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M\5-.NK:[6:/3]6E\+NLU@L[,9QM%]B0G<VTY7:22=W KR7]FO_@EWXA_9?\
MBI9>./#?QCM+V[AADM9[.]\),8KB!\;T)%\"#\H((Z$ X(XK] J* $7I2T44
M ?,7[2O_  3]^&_[1VL#Q++]L\(>.(]IC\1:(P25G0@HTB'Y7*X&&&UN!\W
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M%Z* ,[1(=1M])LXM6NK:_P!32)1<W-G;-;PRR ?,R1M)(44GHI=B/4UH4M%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYGXQ?LA_";X_^(+76O'_ (4/B/4;6 6L$DVI7<2Q1ABV%2.94&2220,GC)H
M_&7P5^Q7\2OCY\ ?'7QUN+J:XNX;B2]M[>Z3=/K**6:[F5L\;2>.#N*.!T%?
M<W_!)_\ ;(/Q%\)K\(O%E\A\1Z%!G1;B5P&O+%0!Y/)^:2+V_@Q_<)/W_P"%
M?">D>!_#&F>'="L8M-T73;=+2ULX\E8HE7:J\Y)X'4DD]3S7C.A_L'_ KPQX
M]@\::/X"BTOQ+;WIU"&^M-2O(_+F+%BRH)@@&2?E"[<'&,<4 ?F7_P %GO\
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MYX^\0_%;4K-C8Z+ =,TJ61?E:ZE \UU)'5(OEX/_ "V-?KY0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH XKXO\
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M7YI7)_WJ\>_8;\::II?[&G[7FFVNZWM]/T_[5;3*3Q)<6]S%)M]"%@C_ #%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,%.?V>/%7BZW\/VOC9[>>XF^SP7=[I]Q!:NQX&9&0!03W; ]Z^CO%_C;0?
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M.1C!VU]#_P#!-NQUS3_V,_AVFO>:)VMYI+99E*LMJTSF$8/;81CV(QQ7Q)\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***3(H 6BDS2T %%)FEH **2EH **2EH **** "BBB@ HHHH **** /
M/?CE\=/"7[._P]OO&7C/4/L6EVY$<44>#/=S$$K!"A(W2,%8XST5B2 ":^ ]
M8_X+0?#[Q+<7&CZQ\(M3U+PK<YCG^U7EO,\D>/XK=DV$Y[&3WS7LW_!5?X6^
M)?B#\#_#>J^'=";Q0GA?Q!#JNH:.BL[7%L(W1OD7YF +*"%Y"LQ[&OE^3_@J
MG\+KCPJVA0_LWZ4T<D'D)9>9;&V)/ 78+?.,_C[T >GR_L'?#3]H;P[I_P 8
M_P!F+QE??#;5+E6:WAMVDCM5F1CNC90?,@;.%8*67 &$]8=!_;A^.W[(.H67
MAW]I3P+=:[X?$S6T/C/2$4O(/X3N7$4O'8^6^,D@D&O7O^"4/PE\4?"C]F"0
M>*;.YTRYUS69M5M=/NT*20V[0PQH64\J6,3-C'0BOL'6]#T[Q)I5UIFK6%MJ
M>G72&.>TNXEEBE4]596&"/K0!A?"WXH>'/C+X%TOQAX2U#^TM U-"]O<&-XR
M<,58%6 ((8$$$=JZVN:\ _#WP[\+?"]MX<\*:5#HNAVS2/!8VY;9$7<NP4$G
M +,3CH,\5TM !1110 4444 %%%% !115>]6:2SG6!MD[1L(V/9B#@_G0!^.?
MA'QE\*OV6?C5^T!X>^/WAB#QKXEU2\ENM.U6**/4?/CD:5O*.6_<2/O1B3@C
M!!(VKGVS]C&/7_@A_P $S_B;XP%]%(U[!JFM:+#;7(E^QJ;98T#%6^5A(A8K
MG([X.:\T_87^,GPV_9SG^,WAK]H"U71/B)<ZF]Q?W&N69N9+^$H=\ 8!MS;R
M[^C^<""<<=#^P#\*?$_Q(_9+_:/L;.WN-/\ !_C!;FW\*:;,6*QS"&<.R$XR
MI+6T9;/)A;T- &%\#_V</ OBK_@EAXZ\8:IH5I=>*I+;4]8CUIXA]JBDM2QC
M59/O!3Y9!'0[VXKZY_X)C?$:\\:?L8^%KK6;Z2\GT5[K3)+B?)80PR$QKG'(
M6)D4>RBOB3X5_M<>#OAO_P $Y_'GPBUR6:S^(R?VCH4.@O;R"9S<N5,A.,+L
MWR;@2#F/&.1G[Q_X)U_!_4?A3^R#X4T/Q#8FSU34UN-2N[20$,BSR%D5QP0W
ME>7D=CD=J +O_#QO]G/_ **=IO\ WXG_ /C=?+?_  1[U*VUCXE?M'ZA9RB>
MSNM1L)X95SAT:;4&5N?4$5]7?\.]?V=O^B5:+_WU-_\ %U\I?\$>]/MM(^)G
M[2%A9Q+!:6NI6$$,2]$19M055'T 'Y4 ?IM1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5E>)/#&C^,-)GTO7=)LM:TV8;9;34+=)XG!]48$'\JU:^0O^"DG_"X=0^&
M/A?1/@R=>&O:OJ_V:[_X1\F.7[/Y+L=\PQY*;@N7+*.0,\XH \Q_:I_8>_9&
MT/3[W5=?UZT^$=\09!_9>H*"S=<)9MO+=/NQJ.,XQ7Y;P_$#4O@)\1KB7X/?
M$S6;JSB8"'6+.WETW[5U^5[9G;*\]'SG/2OMKX0_\$<?'7C+5$U?XN^,HM&@
M=O,FL]/<WU],3DD-,QV(<D'=^\[\#K7WQ\$/V%/@Q\ MEQX>\'VU[K"_\QC6
M0+RZ'NC.,1_\ "T ? 'P!_X*_>//"/B&TT7XR:+%K>DR%4EU.UMOLE_; G_6
M-'PDBXYP%4]>3TK]==-U&VUC3;6_LY5N+2ZB6>&5#D.C ,K#V((KXU_X*4?L
MB:M^TEX"\.'P+X:T^\\9V.HC-Z\D5LRVC1L'5G;&Y=P0[><$9%?3'P'\'ZE\
M/?@C\/O"VLLK:OHOA_3]-O#&VY?.AMXXW"MCD!E.#W S0!WM%%% !1110 44
M44 %%%% !1110 4444 %?FE_P2-_Y*[^TW_V%[/_ -*-1K]+:_-+_@D;_P E
M=_:;_P"PO9_^E&HT ?I;1110 4444 8_B#POI'BJU2WUC3;74[='WK%=Q+(H
M;!&0"#S@FOEJ^\%: G[75AH2Z/8KHSQ$M8"W3R"?LDC9*8QG< >G85];3W4-
MJH,TJ1 G +L%%?+VH7D'_#:FFS>='Y/E']YN&W_CS?OFO+QU-/V;:^TCY?.J
M5.3H2DE?VD3Z-\/^#]$\)QS)HNE6>EI,09%LX5B#D=,[0,UL]*AM[R"Y!,$T
M<N.OEL&Q^53FO34>71*Q]+",8148JR%HHHIEA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 WFBL/QEXPTWP+H-QK.KRO%
M8P%0[1H7/) ' ]S7F_\ PUI\//\ H(77_@(_^%<\Z]*F^6<DF<5;&X;#RY:U
M11?FSV3-"G=WKPS6_P!KCP1;Z3>2:=<7%UJ"Q,;>%K9U5Y,':"3T&<5Y_P#
MW]I^ST/1+ZQ\9WL[RBY:>VG6$N2'8LZG'HQ)&>QXZ5S2Q]",U#FW/-GGF!A6
MC1]HM;ZWT7KZGUG17C?_  UG\._^@A=?^ C_ .%=%X$^.GA3XCZT^E:)=33W
MB0M<%9(&0; RJ>2/5A71'$T9M1C-79WT\PPE22A"JFWYGHE%%%=)Z!XK^U]^
MT!=?LQ_ _5?']IHT.ORV-Q;P"QFG,*OYL@3.\*V,9ST[5:_9/^.ES^TE\!_#
MGQ"NM(BT*;5FN0UA#.9EC\JXDA&'*KG/EYZ=\5XY_P %9/\ DROQ1_U_Z?\
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M+4[.\3J&@G1Q^AJ_YBLN58'Z&N?E:W1I=#Z3UKX0_P"'EVHG_F0K7_P:-_\
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M\)Z)X4@NW62XBT73XK19F (#.(U&X@'J: /PB_;J_9_US]E7XH:UX+LYYO\
MA7?B"[CUW28\YC?RQ*BJW'#Q>?*GNKJ3UX_62;]G/1?VI/V*OAQX(U_4]0TG
M3VTC2KW[1INSS=T=N,#YU(P=Q[5[QXZ^%?@OXI06L/C+PCH?BN*T9GMX]:TZ
M&[6%F #%!(IVD@#.*Z#3-+L]#TZUT_3K2&PL+6)8;>UMHPD44:C"JJC
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MEM\P^&O[2VH?#3QQXK\36_AW3=0E\02&22VN-WEP9=GPGMEN_H*_1O\ 9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%>A9]*]*%2-2/-!W1]#1KT\1!5*4KIGE/[4W_)#/$?\ O6W_ *4Q5I_L]_\
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M:G=CJ*2EKQ#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*0G%(U !VHYKYO\ C]^T_K_P/\91Z6WA:UO].NH%GM+QKMD+CHZL-APP/H>A
M4]Z\[TW]OK7M8U"VL;/P/:SW=S(L4,*7S$NS' 'W/4BO0IX"O4A[2*T]4=T<
M'6G'GBM#[6HJI8/<-9V[7:QQW31J9DB8L@?'(4D D9S@D"K6X5YYPBT4E+0!
MQ7Q8^,/A'X'>$SXF\;:PFAZ()TMC=21NX$CYVKA%)YP>W:KGPW^)/ASXO>"=
M-\6^$]275O#^H^8;6\1&02;)&C? 8 \.C#D=J^2_^"P7_)GL_P#V'['^4E=M
M_P $O_\ DQ?X9?[NH_\ IRNJ /5M:_:7^'/AWXO6'PPU#Q)';^.+[R_L^E&"
M0M)YBED^8+MY /4]J]1K\K/CI_RF7^'OTT__ -)Y*_5+- &3XH\5:/X(T"]U
MSQ!J=KHVCV2>9<7U[*L442YQEF)QU(^I.*\.\/\ _!0+]G[Q-K]OH]C\3-+-
M[/*(8O/66&)F)P!YCH%Y/J:\D_X*[^#O%_B[]F*S_P"$8MKJ_L=/UJ&\UBUL
MPS,UL(I0'*@99$D9"?3@]LCX_P#VB;K]F'Q+^Q_X.T;X7:=87OQ9D_L^.WM=
M+M)FU+SB!]I$Y"_/GYQ@YRQ7:/0 _6OXJ_&CP5\$-!M-;\<^(;7P[I5U<K:0
MW5UNVO*59PHV@\E48_@:\M_X>&?L[?\ 14]&_*7_ .(JIX-_9BTCXR?LJ_#'
MP5\<=%D\07^D6-K<SV\E]<0/%=)"T:[GA=&++'(RD$XSGVKXE_X* _LT? KX
M*V?A3P!\,OALDWQ3\8W20V+-K-_,;.$N$\P(]P5+.^$7>"O#G^$4 ?H_X9_:
M6^&?C+X<^(/'FA^++35/"6@>9_:6I6ZR,EOY:+(X(V[B0K*> >M8?PE_;(^$
M'QR\6?\ "->"?&4&MZWY#W0M$MYHR8T(#,"Z '&X<9S7C&O_ +->D_LL?\$Y
M/B7X.TYUNK]O#=]>:M?KD"[O&M]KR 'HH"JJCT4=\FOS/_956[^ 7Q1^ 7Q9
M2X?^R?$&L7>E78;(6/;(+>8$CJ/*N48 _P 2$^E '[@_&/X\>!?@%H=GK'CW
M7X?#^GWEQ]E@EEC=_,EVEMH"*3T!/2H_@U\?_ G[0&D:AJ?@'7X]?L+"<6UQ
M-'#)&$D*A@N'4=B#QZU^>G_!5G6+OXR?M#?"OX,:7YCQVUK+JU\8BHQYNXLV
M3WC@MI'Z=).]=5_P17O(M/\ @7\2KJ9ML,&N+*['LJVJ$G\J /N;XN?'KP!\
M"-)AU'QWXIL/#D%P2L"W3DRS$=0D:@LV.^!QFO%O#W_!3K]G+Q)JPT^'Q^+.
M1FVK-J&G75O"><??>,*.3W(KX7_9C^'X_P""DG[7_CCQQ\2I9-2\)Z!B5-)C
MG9(S&\KK:6H(.1$%1V;:06*\_>-?;7QL_P""9_P8^(WPWU31O#'A#2_!GB(P
MDZ=K.GHR&&8#Y/, /SH3PP(S@G&#S0!]6Z;J-KK&GVU]97$5W9W,:S0W$#AT
ME1AE65AP000015NO /V+_P!G?Q+^S%\(_P#A"?$/C"/Q='#=/-9-' \2VD;
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M0TM%8&A\S?%[]L*^^%?Q UCPY'X U'6+?3_+/]H0R,L<@:))"1^[(&-^.O\
M":XBP_X*'76J0F6R^&FHWD0.TO;W!D7/ID1]:^K_ (@ ?\('XCX_YAMS_P"B
MFKYV_P""=@_XLOJ?_87E_P#1<=?0T981X6565&[C9;O6_4X9^U]HHJ6C\CZ;
MT/4#JVCV-ZT1@-S DQB;JFY0=IXZC-7Z**^>>^AW!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&VEAC(8\A"*O?L;_ !XUF_\ V%X?B?X\U>XUW4-.L]2U"]O+EE#R1V[RL%R
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M@#\-=5\<>)([R;1]-\L3)8QK)+\[J@PI8 \L.]?)W_#Y7X&?] [Q9_X+XO\
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M.1FO'_V1_P!D7XS^-OVHV^/_ ,=XH]*U*W9YK337D4S-,8S#&HCC)6.*./.
M3DG;D$Y-?H?JG@GP]KEXUWJ.@Z9?W3 !I[JSCD<@< ;B">!0!Y=\%?B+X-_;
M2^"^A^,KOPFDVBRW\DUMIFNQ1W!CFMY'C$A7E<@AB/3([U\._M+1)#_P5Z^$
M<<:A$6#3 JJ, #=/P*_4/3-)LM%LTM-/L[>PM5)*P6T2Q("3DD*HQW-? WQX
M_9S^(_BS_@I5\.OB1I/A>XO?!.F16*WFKK/"J1&-IBX*EP_&Y>B]^] 'W+XF
M\ ^'/&EUI5QK^AV&M2Z5.;FQ:_MUF%O-@KYB!@0'P2-W49K\O-H7_@M]; #
M^TN./^P&]?K)7YTG]FCXF?\ #UR'XJ_\(K<?\*_6=F.M^?#Y>#I+09V;]_\
MK"%^[U_.@#T[_@J5\8O#/PR_9MN-&U[PW:^*KKQ1/]AL;&\++%"ZC>;@LI#
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M\Y^*7[#_ ,:/V8?CM??%3]FN6/5-.OVDDN/#\LBAXQ(Q9X&C<A9H<X9<,&7
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M>&_@7X+T;5OAYJ?A;X@ZE>7_ -FN+&+5%D,,7ELWF?NF)^\ .?6@#X"^%O\
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ML;!"I&IK%W'4445B:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#*P[%30!UU?FE_P2-_Y*[^TW_P!A>S_]*-1K]+:_-+_@D;_R5W]IO_L+V?\
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M;SRD\XC'W\#=T]\U=-%)U[5[2T/KTK)(=1113*"BBB@ HHHH **** "BBB@
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M3-/;R2%U\N19!C)QU7OV->M@<NJ^WA5PL^:%U?6WWHYJV(CR.-569]>_LO\
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M])_:T\!Z;X4UG6[S0[&SU%-0::QB1Y7*HR[06X7ASS@]*],^'/@>Q^&7P_\
M#7A'2WDDT[0=-M],MY)R#(\<,2QJS8 &XA03@=2: .DHHHH **** "BBB@ J
M.2-9HVC=0R,-K*PR"#V-253U.XGM=-NY[6U:]N8XF>*U5E4RN =J!F( R>,D
M@#/- 'RI^TG\?/AC^P7X#N=,\%>%M&L?&GB!R^F^%_#]G%;>?.R[%N)HXE&$
M! &<98C:/4>#?!?]G'7_ -G#_@G/\;M=\06[Z9XT\8:'=7MW;8Q);6P@=8HG
M]&Q+,Q';S,<$&O)-'_9[_;0T_P#:"U'XR7WPDT/Q+XPN9&D@.N:KI\]O9$\)
MY$8O5V[%^5,DX'OS7W%\"[3X^?&KP'\3?"G[1_@_1O"NGZKIR:=IG]CS0R&>
M.>.XCN2WEW,V"H,)&=OWCC/8 \#_ &;;&W'_  1[\;8A0>9H7B"5_E^\X$N&
M/N-J_D*],_X)/WNIW?[$EA$J[9;?4M1BL2RX!!?>#D]?WCO7SMI_P"_:W^&/
MP4\2?LYZ%X)TG6O">LWDB1^,$U&)5BLY6'G+M>0%0P!)!3<-SX#$@C]#/V7?
M@=;_ +.?P+\*> 8;G[;-IEN6N[H @37,CF29E!_AWNP7/8"@#XP_LO\ X*-_
M]!#PY_WUIW_Q-8G_  1G&I+XX_:%&LE3JXO--%X4QM\_S-0\S&./O9Z5^H%?
MFE_P2-_Y*[^TW_V%[/\ ]*-1H _2VBBB@ HHHH *Y6?XH>$[;Q_;^!Y?$.GI
MXON+5KV+1C./M#0J1E]OI]>2 2.AKS7]LOXZ>(/V=O@/KGC#PWX:N?$FJ0@0
MH8E#0V._(%S. =QC0XS@=2 2HR1_/YJGQ>\9:U\3'^(5YXAO9?&37@O_ .U_
M,(F68'*E2.@' "C@  8Q0!_3O17R5^P#^V='^U%\,Q%XCET^P\<Z6XM;NWCN
MHE:^PN1<)#O\Q01URNW<#M)Y ^M: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@!M<?\ %7X=V7Q0\#:IX>O50?:(CY$S+DPS 91Q[@^G;([UV':CWJHR
M<)*4=T5&3C)21^6GPS^"OB_QMXVU32=$BM(]7T!S+-]L8>4)(Y0H3[K*26!X
M(P0IR:^B_P#A;7[1?PYE1?$/@N+7[-2=\L%L)"5'H\#$+V^\M:'[*_\ R7_X
MO?\ 7RW_ */DKZOX/!_*O>QF,?M.6<%)61[.*Q7O\LXIH^5]+_;TTFWF$'B7
MPAJVBS@?,L3++C\&V']*]0\+_M4?#'Q7M2W\46]E.<9AU%&MB,]MS@*3]":]
M&UKPUI'B2U:UU;2[/4[9NL5W LJG\&!KR[Q%^R/\+_$)=CX<73I&Y+:?,\/Y
M*#M'Y5P<^$GO%Q]'?\SBYL-/>+CZ:GJNEZ]INN0^;I]_;7T77?;3+(/S!J_Q
MBODW6OV#+>QNA>>$/&FI:-.AW(MTF\@]L21E"OY&J_\ PKO]I3P"I_LCQ5!X
MH@0<17%PLCM^,X'_ *%1]6HS_AU5\] ]A2E\%3[]#ZZ%!KY!M_VHOBYX#F:+
MQM\-I+N!#M-Q:PRV_P"._$B-^&!74:!^WAX%U!A'JMAJVB29PQ>%9E7UY4[O
M_':B6!KK6*NO+4EX2JM4K^A]+>U?+7[=N!H/A7C_ )>IO_0!7K%M\>_!_BS0
M;N3PKXJT:YU;R6:UMK^8P%I /E#(Q5P">"<<9KX=^-/[26O?%R.RL=6T>RTY
M].F=L6Y<L6(P0<GMBN2KEN(Q=*=.G'7ST/H>&V\)F=/$55:,;W^YH_2?3U_T
M&W';RU_E5'Q!X7TGQ5ILEAJ^GV^HVC\F*XC#KGL>>_O7@O[,_P"T!XO^->M7
MD%UHFFV&AZ;"//NH3(7,C<(BY;&>"2<<;?<5](4ZU!T6Z=1:GSE15,/5=G9K
ML?-GC;]CC39+Q=4\$:M<>&]2C;>D9=FC#?[+ [T_,_2N;C^*WQ?^!]TMOXST
M=O$FBIQ]NCY.!W\U1^C@$^M?6_M3)(DF4JZ*ZD8(8 YKRY8.*?-1?*_+;[CZ
M.EQ%5J05',::KP_O?$O22U_,\"TSXB_"'X_1QP:M;VL&JXVK#J"^3.,]DD!^
M8>P/U%8^L_LH7>AW_P#:OP^\4W.DW&/EAFD([YP)$[=.&!]Z[/X@?LK>"/'
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M&UMP^;C'( [\>OZJZOI-IKVEW6G7\"W-E=1M%-"W1T(P5/U%?%G[;'PP\+^
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MQ( 4 'DDFNN4YYHC*,]8NXZ=6G55Z<DQ]%%%6:A1110 4444 %%%% !1110
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M7YI?\$C?^2N_M-_]A>S_ /2C4:_2VOS2_P""1O\ R5W]IO\ ["]G_P"E&HT
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M?#97^VOAQ)=(OWWM[>;'YKN KYP\>>/)?'WBS4=<OI DUU)N6(9(C0<*@X[
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M +3/_1KFH_\ ?N\_^-T ?H[17YQ?\/!_VF?^C7-1_P"_=Y_\;H_X>#_M,_\
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M^TS^S-X1_:C^'=SX8\3VPCN5!?3M6B0&>QFQPZ$]CW4\$?@:^0?^'@_[3/\
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M (>#_M,_]&N:C_W[O/\ XW1_P\'_ &F?^C7-1_[]WG_QN@#]':*_.+_AX/\
MM,_]&N:C_P!^[S_XW1_P\'_:9_Z-<U'_ +]WG_QN@#]':*_.+_AX/^TS_P!&
MN:C_ -^[S_XW1_P\'_:9_P"C7-1_[]WG_P ;H _1VD-?G'_P\'_:9_Z-<U'_
M +]WG_QNC_AX-^TS_P!&N:C_ -^[S_XW0![_ /M9?M#?!*V\#_$+X<>,_%FA
MC7?[)FB?0K_+2"9[?S(.,8#9:-E(.1D&OD'_ ()5_M!?!WX)_!OQ''XR\5Z+
MX8\2WVKLS?;,K/+;K&FSD*?E#%\#/7-4OB%X<T[XW-K/Q*^)W[.$^D^)[^W:
M;5+^YO=6@6V2"+REE8+(D:A8HD;E0.,GN:XCX6? +X;:]X<>\LO@R?B!;F=D
M&J6NI:H8U( S'FWF"9&0>>>:]"&"JRASIK[SNCA*DH\UU]Y^R5K=66O:7!<P
MM'>6%Y$LL;8RDD; %3@CH01^=>?>+OV8_A)X\:5M>^&_AG49)3NDDDTR(2,?
M4L%!S^-?%=G^W9^T7X;M8=)TS]EW43IU@@M;7Y;T_NHP%3DH2> .I-3?\/!_
MVF?^C7-1_P"_=Y_\;K@:MH<.SL>N^//^"4_[._C2.8VGA>^\*7<O_+SH>IS*
M5XQE8Y3)&.G9/6O'[S_@CC8>'+B:Y^'_ ,8?$WAF=E^4RQJS9&<%GA:+(Z=O
M6G_\/!_VF?\ HUS4?^_=Y_\ &Z/^'A'[3/\ T:YJ/_?N\_\ C=(#,N/V0_VV
M/ABWF^"OCS;^(X(UPL&HWLN\], 1W$4D?XEZ=8?M ?M[_"V.*+Q1\)=.\;0Q
MKA[B"UC>9\?Q%K2;8"?:.M'_ (>$?M,_]&N:C_W[O/\ XW1_P\(_:9_Z-<U'
M_OW>?_&Z *2_\%=?$G@&:W@^)_P&U[PV6<I),DDD'(&?D2>)=WTWUZ=X2_X*
M^? #Q%9M)J5UX@\,3@'_ $?4M*,A8^BM TB\^Y'X5YQ=?M^?M)7T#PW'[*U[
M<0L,-'+!=LI^H,7-?/OQ\\7>.?C-X1U#3+[]C*/P]J%XV]-<T;2;F*\AER6W
MADB&XDYR'R"">_( .5\2_P#!2K6M0_:^L/BWI^A)'X<T]C:Q:#-)\\UL8VB+
MNXZ3%7+#&0#@<C.?TXT;_@HO^SUJN@V.IO\ $C3;!KJ!9FL[I9%G@)&2CJ%.
M&!X_#C-?@Y-\*/&MOXP@\*2>$]:C\3S)YD6BM82B\==I?*Q;=Q&U6;@= 3VK
MZ;^%GP_U7PCX3M;;4_V.]2\::LK%;C4M4;5(I)".0?+7$:CYB,*HX49+5<G*
M5N;H4W*5KGZ>ZG_P4O\ V<-+C9Y/B1;S!<<6MA=3'GT"Q'-<U>?\%9OV<;7_
M %?B?5+OD_ZG1;@=.GWD'6OB>WNM3M<;/V!;%O\ KK;W[_S6NCL?B3XLTV-$
MM_V"=%554(N[1IVX[#F$U!)]#:S_ ,%F/@9I\@2TT;QIJN5SYEOIULB ^A\R
MX5L_0&N;OO\ @ME\,$_X]/ 7BR?G_EM]ECX]>)6YKSO3_P!H+XD:3<1SV7["
MNB6T\;;DEBT!U=3CJ&\C(/XUU=E^VY\?M-4"T_9$:U"C \FQN4 'MB&@"G_P
M]\M?'7FQ:;^S_J/B! =A7[:+GK]T,%MCC/I6)K'[:GB;Q1"PT[]C*[NV<_*7
MTVY<'U_U=J.:[M?^"@O[3"J /V7-0 '0>7>?_&Z=_P /!OVF?^C7-1_[]WG_
M ,;JXSG'9EJI*.S/(+[QY\6/%40DM/V-7M-XW*P_M* @'IE0R<^Q%?$W[0EC
M\0M)\:K9?$+0+[POJ'DB:VTN[B:-4B).&0$G()!RP/4'TQ7Z<?\ #P;]IC_H
MUW4?^_=Y_P#&Z^*?B+^REXQL]*35?'/B7Q#%I]NWEI>>(;:80Q,Y' >5L M@
M<9YKKI_6,0G%2NO-_P"9U0=>O%Q3NO4N?\$S_#?CSQ;\?M'M?#=@]]X9L;J&
M^UJ29RD%K&K;E?=@_O"5P% ^;IQC(_>1!QBOPW^$/[.OQ)^%NH:#XU\(3>)M
M9TZRN;?6[?3K"SN5M-4$;"1$)C)5DD"A=W.0W>OJ[_AX-^TQ_P!&NZC_ -^[
MS_XW7-4P\J,KRW8J[K*,:=5Z+;R/T=HK\XO^'@_[3/\ T:YJ/_?N\_\ C='_
M  \'_:9_Z-<U'_OW>?\ QNLCC/T=HK\XO^'@_P"TS_T:YJ/_ '[O/_C='_#P
M?]IG_HUS4?\ OW>?_&Z /T=HKY[_ &1?CO\ $7XYZ/XANOB'\-KCX<7.GW$4
M5I!<+*/M*,K%F'F*.A ''K7T)0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5P7QZ^'\GQ6^"GCKP?"XCN=<T
M6[L(';HLKQ,J$^P8K7>T4 ?B]X&_:PM_@[^Q-XT_9U\0^&M;MOBE<2WFB6>E
MM9,H=+MB"Y)YW*7<!0,L=F.N1^BW[ /P9U3X$_LL>$/#FNVXM-=F674KZWQA
MHI)Y#(L;?[2H44^ZD=J^@7TVTDO$NWM86NT&U9VC4NH] V,XJS0 M)CWI:*
M"BBB@ HHHH *_.73])OQ_P %EKN_-E<?83HC*+KRF\K/]GJ,;L8ZU^C5% ""
MEHHH **** "BBB@ HHHH ^3O^"HUC<ZE^Q3XXM[2WENKAY].VQ0H79L7T!.
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MO"$UU8?'+PU/<ZIK-G',9GNH_.D*[.2'D6/;N7HX9AR<9^ZOV+?VO-$_:O\
MAK'?H8K#QCIBK!KNCC*F&;&/-C4DDQ.0<<G'*DY&2 ?1-%%% !1110 444E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBOG_\ :H_;&\*_LMVFE6E]87WB?Q=K)*Z5X:TE=US<
MX.-Q.#M4L0H."2>@.#@ ]"^.?Q@T?X"?"CQ'X]UU))=-T6W$K0Q$!YG9UCCC
M4G@%G=5_&O@V;_@H=^T/\/\ 2?#OQ+\??!W3D^#^OE98)]*D9KJW@<_NV>3S
M&"L5((\R- ^1C;GCKM)_:>T#_@HA\//B'\"-<\,7OPQ^(MWISR6^DZO*94,L
M+I+&=YB1@RNL;,K1@XR1G!QS/["?[05K>:/JW[*7QWL(+/7=+232+*WU3[E]
M;@<VK,3@NHY1@0&3;MY ) /H3P7\,?!/[27Q>\%?M*>%/'FNW%E!IK6T.DP7
M;"WWGAD="28\ L)(@,,=K<8R?I2UUS3KW4KS3[>_M;B_LPAN;6*96EAW@E2Z
M@Y7< <9'-?FI^R_HNJ?L2_\ !0+4/@5:W]UJG@/QK9/J.F122!VMRL4LD<C^
MC 02Q,0/F^0FOL[X9_LE^#_A9\;O&WQ1TJZU:77_ !2Q-Q!<7KM;Q!BK.%3/
MS9<$C?G:#A<#J 9'B3]B;P!XB_:4T3XU1MJ6D>)]/&^>#3+DP0WLP 5))=N&
MR%W*R@X<$!LC(/T)110 4444 %(339'\N-GP3M&<"OG']E']M[P?^U5=^)-+
MT^UF\/>(M%NI$;2+^5#--:ARJ3J!^ =1]QB!D@@D \2^)'[<'QK\>_$;QQHG
M[/'PYT[Q5H7@1V@UC4M4;?)<SJS!D@C$T9/W'PJ[F.T\#(!Z3X4_M(^&/^"B
MGP;\8_#'4YK_ .''CY[-K?4=-AG:.9"",RP\JSQA@ \;8(!*G@YKPCQ5X@U_
M_@FK^VAK7B.^@EO?@O\ $B[:YN)(49_L[LQ=L#H)8G=S@9WQMZ_=T/\ @H#\
M+]/\ W'A;]KKX,:I9VUY%>6TVHR64@^SWPD.V.X !YWY$<BC[P;) (8D ^^_
MA3X'TG]GOX1^&_"5QXAFN[#1X([%-3UJX57E9FPJ[B<#+'"KV&T#-'QY^!?A
M?]HGX:ZIX+\66@GL;Q=T5P@'G6DR\I-$W9E/X$$@Y!->??%#X&^$/VZO@OX"
MOO$AU72;.X2S\06\=C<^7(GF1*[1..0?E8KG&0>0?7WC1M*@T'2++3;5IFMK
M.!+>(W,[SR;% 5=\CDL[8 RS$DGDDT <9\!O@SI7[/\ \*]"\":+>WVH:?I4
M11+G49C+*[$EF;T4%B2%7 &<"O0J** "BBB@ KYQ_;._;.\._LC>$;1[FTEU
MGQ?K*2C1='C1@DS)M#/)(!A44NF1]XYPHZD?1U?/?[<7[-,?[3WP)U30+5(4
M\4:>?[1T.ZD !2Z0']WN_A61<J>P)4\[: .%_9#UKXD^!?#VM^+?VB_B)I6D
M7_B^XCU#3?#>JW45L=-38 57>PV94(/*7[NTDG<S5Z)X&_9ET?1?VC/$/QLT
M[QIK>J-XAL8[==,-]YUBJ]RIR=R<*47HAW8X.!\E?LY_L!W_ .TAX3OO''[3
M4?B*3Q?>QQZ?I5G<7Q@DM+.*%$27RQG:Y(8[6')RQ4ELUT'_  3:7Q%\)_C5
M\:_@'?ZW+XB\->%)4N=/N6<L(=[;2JX.$W*RDJ.C(_?- 'W]INN:=K37:V%_
M;7QM)C;W MIED\F4 $QO@G:P!'!YY'%>&>"OV)_ /P]_:0UCXQ:"^HZ9J^I0
M/'+I-K<F*Q\Z0GS92BXW!QM.QLJ&&X#."NQ^SK^R?X0_9GO/%EUX8NM6NIO$
ME\UY<_VC>O*B#<Q1%7./E#$;R"Q[GM7ME !1110 44E&: *6L:M;:#I-[J=[
M+Y%E9P/<3R[2=D:*69L#DX /2OSLT_\ :9^+7[<7QIMD^#>I3?#KX0>$+V.Z
MU/Q7?P@&\9<G8ZL0&5ES^YR.#N?&5 _1V2-9HV1U#(P(96&01Z5^6'C']A/X
M@Z3^T]K'PQ\(SZQI_P  /'EU#KVM2V)VPVD43L7M]Y. V]MJKC)5D)#",D '
MVE\?/ASX-_;,^%]WX%TSXC0PR)<PW4ESX=U*.=EV-DK+&CX92,\-T(4]J]>T
M6#3/ .@Z!H$^L,YCCCT^SEU2Z4W%VR)@#<<>9(54DX&3@U^8/[8W[*>E?L'R
M^"?C3\%=8N_#\UCJD-A=Z7=W33BZWAF!!)RRL$=7C.00P(VXY^Y_C%^RIX/_
M &EM?^'GC#Q-/K-AJ'AUEO((=-OY+8/N ?8Q4AD97"G>A5AM(SSP :7[4/[*
M_@[]J[P)'X=\4I):7%K,+BPU>S"_:;1^C;21@JRY!4\'@]5!'I'@3P;8_#WP
M;HOAG3)+J73])M([.W>]G:>8HBA5+.W).!_D5O*,*!3J "BBB@ HHHH ^=_V
M\/CUXD_9O_9UU?QGX5@L)M:CNK>TB;4 S)&)7VEP@QO8#H"0.<G.,&_^R;^U
M'X<_:Y^$J:WIKC3M:BC%MK.DQS_OK*<K@E2.=C<E'XZ>H.*O[97[-VI_M->"
M_"OA^QUB+3;/3_$5GJ6H03)E;FV1BLB@X.'5&9E&,$C!ZYKY'_:F^!/BC]AG
MXN+^T1\%K8+X4EDV^)O#42GR41V&]BH_Y8N2#Q_JW (XX !]C_LR_LSV'[+>
MA^++>+Q9JWB&'6-4FU6676)\K;J22.2?O;2-\A/S$9P*]<NK;1?'GAF6"9+/
M7-!U2V*.IVSV]U"ZX([JRL#^M>3>&?%O@#]NC]G2[;3;ZXD\.>(K1K*]BMYC
M#=V,N!OC;'1T.#SPPP>5;GJ_@'\#]!_9W^&.E^!_#<]_<Z;8[F$NHW+32.['
M+L,_*@)YV( HR3C)- ''?LO_ +(?A+]E&W\50>$[[5+FWUZ^^UM!?7!>*V1=
MPCBC3I\H8@N?F; R>!7N]%% !1124 +7(?%KXD:9\'_AKXC\:ZP)'TW0[*2]
MFCB^_)M'"+[L< ?6NOKS_P"/GPOC^-7P9\8^!Y9OL_\ ;>G26L<Q&1'(1F-C
M[!PI_"@#Y$^ _P </VK/B[X@\-?$75++P9X4^#&M2M</'J#+OM;$,</N+K(7
M8#"L2%).[:!@5[U\5?V<_#W[17Q(^'7Q"M/'6K6\?A&Z:>.'0=1#6UR>JXPQ
M5&W8#,HRR$J>Q'YH_!6]OOB5\3O /[+'Q_O+OPWX;\'3ZA;I91W36XU*Y(4V
MT$LG0JH$OELK ,)$"]1GV_PW\/+W]@C]OKP!X0\":S>:I\/?B*IAF\.S7!ED
MM.2ID9<]$8*ZR'G:)%YP<@'Z8+K>G'6#I'V^V.J"'[0;+SE\_P K.WS-F=VW
M/&<8S7A?QP_8E^'_ ,>/BIX2^(.K'4-)\1Z!/'(UUH]P;=[U(R6C21Q\P*O@
MAU(;&1G&,:UI^R;X1L_VFKOXWI>:M_PDTUB+06@O'%JIVE&<H#\P*E?D;* K
MN W8(]NH :JX4"G444 %%%% #2:^(OCE^VA\4M8^,FN_"[]G?P%:>,]=\+0F
MXU_4=4D @B./]3&#+&"V2!DL22" O!-?;U>,_#+]EOPS\*?BI\1?B!HU]J(U
M[QM+YMWYLBM#;]P(TV]=Y9LMG[V.E 'G7[)O[0%U^V[\ _%=CXFTV\\'>);.
M:;P_K*Z7));O'(8P?,A)^:)OF(*L2593U!KT?]G+X*Z9^R?\$[3PI<^*KC5=
M/TYI+FXU76)5BCC+'+;03B.,'HNX\DGO7P]\:O\ @G]XC^ 7P&\6?$?0OC3X
MG3QQI%S<^)+]K>Y:UL;QR^798T(VRE<?,2<D;<8QCZ.^'/AN/_@H!^PWX6A^
M(]Q=6U[K,"R7-[I;^0[30S,@EV_=(8+DJ05R3@#C !]'?$3X>^'?B]X%U7PM
MXDL8=6T#5K<PSPL 05;[KHW9APRL.00".E<5^S#^S;H7[+7PU7P;X?U+4M5M
M3=27DEQJ4NYB[X!"J/E1< <*.3DG))-=S\.O .F?"_P/HGA/1C=-I6D6R6EL
M;VY>XEV*.-SN23].@'    '34 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?*'C?]E7Q3XF_;[\'?&JVU/3T\+Z+HGV2:VO$:68S8G0I$F<#*S!]
MY/!'0U]7T4 ?G7\>+>T_X>]?!!--M8[?4&T SWMS&<&;Y=0&&&.2(T^]W! _
MAKT#X]_ _P" 7[<7Q.UGPK:>)%TWXL>%(8VNM4T(*+B-,_ZN0D;9@AP" <H6
M R.17AO[>OP%^,7C[]NCPGJ/PL@NK6^O_# MX]>C)C@L%#7$-QYDP4^7^[F'
M(&[]X-HS7V/^R7^QWX0_92\)M;Z8/[8\5WZAM6\1W*?O[I^I502=D>>B@^YR
M>: .>_9G_81\._L]^-;SQOJ/BG6OB%XWGM_L::WK\A9[> X!6,$L02 !N+$X
MR!@$@_4%)2T %%%% !1110!A^-6UI/!^NMX;AM[CQ +&<Z=#=R&.%[CRSY8=
ML'"EMN3BOR:D_8)^*/[/?P/\%?&WP9+=V?QB\///J7B'21(T[30&5V7"\[V6
M+:)(QPP9L9(Y_8&D;I0!\J_!CXI?#3_@H]^SS<:=XBTNVNK@(L&N:)+Q+870
M!Q-$WWE!P620'U!Y#"O+_#O_  2)\&Z7JUO:ZI\1?%FN>!+>\^V)X1GE$=LS
MCH'*M@\<%E56([U[=\./V'? _P */VC-=^+7AJ\U33+C5H65] M9S%8++(29
M7*C[ZL<,(VRJMDC^';]&4 06=K#I]K#;6T26]M"BQQ11J%5%4 !5'8  <"K%
M%% !1110 4444 %%%% 'S3^UI^R5XE_:2U+P[?>'_B_K_P -IM&WB.+3(F>%
MF?AI2(Y8GW[?ER7( R !N.>I_9A_93\*_LN>&]2L]$NKW6M:U>87.K:]JC[[
MJ]D&<%CV RQQZL2237MM% !1110 4444 <9\8OB-:_"'X6>*O&M["US;:#IT
MU^UNAP9=B$A,]MQP,^]?F3-<_M:?%[X+W'[3ND?%1M(MK,7.HV?@K2I)$MOL
M,#.LC-%_JY678YVR*Q(4'=G K]2?'G@O2_B-X,UOPMK<!N-(UBSEL;J,'!,<
MBE6P>QYSGUQ7B/QJ\ ^'/V>_V'?B3X;\%Z?_ &-H^F^$]2AMHXW9G#R6[J9"
MY.XN6;=NSG- '5?LC?'&7]HO]GWPEXZNK9;34;^!HKZ&,807$3M'(5&3A692
MP'8,!6[XW\=>&O$&N7_PIMO&Z^'O'>K:3//;I8NC7MM%PAF0,I4,-X*AN3@D
M#Y21^;7[.?[<$'P-_9%^&WPZ^&^D?\)S\8-8NKH)HT2/)':;[N7!E"G.XH%(
M0$<-N.!C/Z%>'_V?_"6N_$O0OC/KWA*'3OB?_9$5M<D3"1;>0H _3AI%!:,2
M?W>* /GKX4_\$O;'PWXSTC6_B/\ %#Q!\5;#0KG[3I&B:JKQVENP8%2ZO-)O
MP0,JNT''((XK[F Q2T4 %%%% !1110 4444 %5-2TVTUC3[JPOK:*\LKF)H9
M[>9 \<B,"&5E/4$<$>]6Z* .#^#WP1\%_ 7PE_PC?@;1(=#THSR7+QQLSO)(
M[9+.[$LQZ 9/   P *[RBB@ HHHH *\C_:L^-DO[._[/_C#X@6]FNH7>DV\8
MMK>3.QII9DAC+8YVAY%)]@:]<KB_C)\+=+^-?PO\2>!]:+QZ=K=FUK)+&/FB
M8\I(H]58*PSW6@#\Y;CXD?MH_#_X5Z'\>SXNT?QWX2U"T35;_P -06<6+2U?
M#+E5B5@ I&6C?*\YR 37W9^R]^TUX6_:H^&=MXJ\./\ 9[E"(-2TF1PTUA<;
M02C>JG^%L ,/0Y ^$_V3OVB=6_8G^(.J?LY?'N86WAJ-V.AZ[=)_HD<4C$C+
M,.;:3YB&.=C;E.!G;:^!^BZ3\!?^"I,OA'X3:A9ZOX"\6Z3+>ZI8Z9*LMOI@
M,4LRH&4E1LDCC*^B7 4#H: /HW]HC]G'X&?MF>/-1\,W&M0V'Q0\,0127-_H
M3HM];Q.6V)+D%90I7[IR4W#[N_FY^S-_P3W\$_LY>-G\8OKFL>-O%BQ-;VNI
M:XZM]DC8881J.C$9&XDG#$#&:]=\(_LX^ / _P 6O$_Q*T?08K7Q?XB14OKT
M$D<?>*+T4N0"Q'WBH)]_3J "BBB@ HHHH *_._XD?&[X\_M,?M.>/?A5\%/%
MFE?#K3/ D9%U=WZ*T^HS*0K<F)RJ^82O Q@;B26"U^B%?FI^W=\)_&7[-'QV
ML?VIOA;;O/$-D?BG3U),;#"QEW4?\LI$5%8C[K*'X)S0!UO[+?[='C/0_B]<
M? W]HJVATKQTDRV^GZVD*Q17KL,HK[<)\X(V.@ ;." :^U/B)\3?"OPI\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME"1Q1J%5% P  .@ '2IZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH **2@&
M@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*'_@J]^TE
M\4/@[^T1X=T7P5XWU;PUI4_A:WO);2PFV(TS7=XK.1C[Q5$'_ 17$6OP^_X*
M)7EM%<07?BJ2&9 Z-_PD&GC*D9!YG],5E?\ !:K_ ).G\+?]B9:_^EU]7M>C
M_P#!:_PMINDV5FWPSUB0V\*1%AJ,6#M4#/W?:@#COA[\._\ @H!;^/O#4VOW
M'B<Z%'J=JVH"77K!E-N)5,NY1,21LW< 9K]<*^"?@-_P5B\._'7XO>&/ 5IX
M U32KG7+DVZ7D]]&Z181GR5"Y/W>WK7TW^U=:^-+W]GGQO!\/#?KXU>S4:8=
M,D\NX\WS4SL;(P=N[OTS0!Z9K:W#Z/?K9EOM9@D$.TX._:=N,].<5^/]Y\.O
M^"B43SR"Z\5+ I9L_P#"0:?]W).<>?Z5]L?\$Y])^-6D?#?Q1'\;FUY]?;5@
MUD=>N?/D^S>2GW#N.!OW\9KZLU3_ )!EW_UQ?_T$T ?@?\+_ -H;]K+XS^-Q
MX0\&^/O$VM>(BDDGV%=1AA.V/[YW2,J\?6OMS]C'P5^V/HOQZTBZ^,$^O/X&
M6WN!<K?:O:7$7F&,^7E(I68G=CH*^5O^"5?_ "?0G_7CJ?\ *OW(H ***^$O
M^"MWQ6\8_"3X-^#-2\&>)=2\,7USK_V>:XTRY:%Y(_L\K;6(ZC*@_A0!]VT5
M^+?@N;]L3]M/X=6>O>"_$VJ:=X?\,6L>GPM#KTFGW&K7<: RR&0,/-E9F^\[
M*BY49R&)^D_VR/&W[2WPY^''PV^'WPWL/$NLZN^E0OXA\8V%FUQ-)<XV&$3;
M<(=VYF;@X*<@9H _1&BOQ^^+/[*/[6?P/^&.J_$Z^^.FJWD^D6ZWU_8VWB._
M:5%R-X!8['VY&0>" <>E?0__  3]_:8^('[57[./Q%T#5=2$GC_0K=K.PUW=
MY+2^?!)]GD=E'#I(C98#IM.,YH L_'K_ (*%:SX7_:R\-?!#PKH4-J7UW3[+
M5]:OB)&:*9HV9($'"DJ^"[9/7 '!KZK_ &AH?%5Q\#O'4?@8W/\ PF#Z1<#2
M?L;!9OM.P^7L)X#9QUK\&OB!\.?BSH_[6\'A+7_$HO?BPVJV=NFM_;I) +EQ
M&8'\\KN^7*<[>,5^L5OHOQ@^!O[ 7Q(/Q!\73ZE\1=/TW4KV'6[74'N)(E\O
M,165@K K@]N* ,[_ ()RZ9^T3I]YX^_X7P=>,;QV/]C_ -M3QRC.;CS]FQCC
MK%G/M7VU7YK_ /!'_P"-GC[XP:A\55\;>+M7\4KI\6F&T&J733" NUUOVY/&
M=BY_W17,?MU_M\?$35OC8?@I\#[F6TO;>[33;K4=-4/>7=\2 8(FQB-4.58C
MG(;D <@'ZGT5^.OC[]G;]M3]GKP1/\23\4]6UHV41N]4T^S\175[);1CYBSQ
M3#RY%49W8SCG&1DU]C_\$\_VW)/VJO NJ6'B2.WM?'7AU(VOA;C8E["V0MPB
M=CE=K*. 2#P& H ^PZ*_&-?CY\:_V\OVDO$'@OPY\4_^%5:% MQ)8VL5_+91
MM#%(L:INC(>69]X8C..&XPN*[#Q%\'/VU_V5_''AO_A$/&NN_%BTOG:3R1-/
M?6BE"NZ.X2=L1*P;[P=<_-@@B@#];**QO".J:CK?A;2=0U?2I-#U2YM8Y;K3
M99%D:UE*@O&64E3M.1D'M6S0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XJ_\%JO^
M3I_"W_8F6O\ Z77U?ISX:_9%^!]QX=TN67X0^"))9+6)F=M M26)0$DG97RM
M_P %&/V"/B=^U-\;M%\5^"Y=#32[/P]!I<HU.]:&3SDN;F0X41M\NV9.<^M>
M*1_\$\OVRXHU2/XG>7&HVJJ^,;X #L -O2@#]./#?[,_PC\&ZY9:UH/PR\):
M-K%F_F6U_8:+;PSPM@C<CJ@(."1P>]>DR2+&I9V"*.K,<"OR-T+_ ()__MBV
M>N:=/>?$QI;2*YCDFC/C"^8,@8%AC;@Y /6OT;_:N^&.N?&3]GGQOX+\./;Q
MZWK%D(+5KJ4QQ!A*C?,P!(X4]J /5HYHY@2CK(!P=K9J+5/^09=_]<7_ /03
M7RC_ ,$Y?V8_''[+OPS\3Z%XZGT^?4-1U?[; =.NFG41^1&F"65<'*G]*^L+
MV)I[*>),;GC91GU(Q0!^'_\ P2K_ .3Z$_Z\=3_E7[D5^:/[#_\ P3U^*?[/
M?[3*^//%4F@MH8M;R+%A?/+-NE&$^4QCCUYK]+: %K\Z/^"VG_)!_ ?_ &,O
M_MK-7Z+U\C?\%(/V7?&?[5'PO\,:!X*;34O].UC[=/\ VG<-"GE^1(G!"MDY
M<?K0!L_\$T-%70_V(_AE$K!VF@O+IW"XR9+V=P/P#!<_[->$_M^?\% /&_PN
M^+VG_!WX20V7_"52BV2]U"XC661+BXV^3;QJY"*Q5XV+/G_6+TY-?7'[)?PN
MUKX*_LZ>!_!'B$VQUK1K-H+DV<ADBW&5V&UB!D88=J^2_P#@H!_P3F\4?';X
MH6WQ.^&.H65GXDDAACU"SNIVMFEEAPL5Q'* <.$"*<X_U:X- 'FW[1G[)7[0
MTOP!\8>,_BW\>[F_MM)TZ2^D\,:<9#:SM@?NG(,:8W$#[C>U:'_!#K_D&_%S
M_KMIO_H-Q6Y/^R)^UQ^T9X1E\,?&/XF6>A^&(;=BMA8M'+-J$RKF(3F)0I4.
M%)+,>F<9Y'HO_!-?]D/XE_LG7WC>W\:KHLFG:Y';202Z7>M,XDB+@JRF->")
M#SGMTH ^.OV@?^4N.G_]C5H__H,%?J'^VQ_R:+\7?^Q9O?\ T4:^,?VW?^">
M'Q7^(7[14_Q6^%5_92W%VUM<^5)>BTNK.ZB55#HQ&TCY%8'<"#GCI7OO@?X)
M_&_Q!^Q5\0O /Q.UFVUKXCZ]#?VUG=SWYFC$4L*+$KN$&P!M_"@C&#WP #Y>
M_P""&O\ R$OC+_UQTC_T*\KQC]E'4K+P/_P5*N%\5.MG/_PDNM6:RW7RA+J3
M[0D9);N[,%![[QZU]N?\$T?V-/B!^R;>?$*7QQ)I#KKL=@MI_9=VT_,)N"^[
M*+C_ %JXZ]ZS_P!N7_@F?_PT'XP/Q!^'VKVOA[QG*%^WVUX&6WO60 )*KH"T
M<H"@$X(.!T(Y /L[XH:YIGAOX;^*=4UJXAM=)M-,N9;J6=@J+&(VW9R<=/YU
M^/\ _P $9--NI/VE/$VI")QIEGX6N%NKD@B.,O<6^P,W0$A'(![(Q[5VOB#]
MB3]M?XOZ/:>#/''CJ*;PG$T8;[=K@FB8+]TNL:[Y=N!]_/.#[U]\?LD?L@^&
M/V4_AC/X9T^0ZSJFJ!9-;U2XC"_;) I7:$_AB4,P523@,<DDF@#X6^/'_!,'
MPS\6/B-KNJ_ _P")GAN>[NBU_/X6NKQ93;,S?.R2Q%F$9=APR?+G&X\"O%/%
M6M?M>_\ !/V;2WUK7M7M/#CS"WL?M&H+JFE3,J;O*5&9O+^4'Y2$)VG'3-?0
MGC#_ ()F_&#X%_&*Y\<?LX^+K6SMI7<P6=Y.(+BVC<@O;L64QS1Y QN X"\$
MKNJAXV_8B_:[_:OU+2++XQ>,](TK0+&0RHBS1S+"QX,BV\ "N^TG!9QP2 1D
MT ?H-^RW\:#^T-\ ?!OQ!DM8[.YUBU<W,$08(D\4KPRA0>=OF1OC.>,<GK7J
M]<?\)?ACH_P9^&_A[P5H"R+I.BVJVL+3$%WQDL[$8&YF+,<=V-=A0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>gizttcucplmb000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gizttcucplmb000012.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  8*8  (
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MS0 M%)GVHH 6BBB@ K\^?^"TW_)N/A?_ +&*/_T1+7Z#5^?/_!:;_DW'PO\
M]C%'_P"B): /EK_@E+^T'X"_9ZF^*^K>/=>&AV=Q9Z?Y!^S33-*4>?<JB-&.
M<NO7'WA7WM^PG^T(G[36O?&3QM:6TMGI$FNVUIIMO.?WBVT5JBJS@' 9CN;
MZ;L<XS7R/_P1'L[?4-;^,,%S!'<P26>FH\<R!E92USD$$="*^\?V;?@/IGP%
M\=?%NQ\/Z?\ V7X<UG5K;5;&VC7$41>W42I&,<*)%;"C@!@/2@#V^STNTT^.
MX6SMHK07$K3R^2@3?(QRSG'5B>I[U^-O[>W[2?QC_9]_::\1^#_"?Q4\2PZ#
M##:W5O!<3I*T7FPJ[)N*9(#$XSS@]^M?K[:^-=-N_'5[X4A9I-5LM/AU&Y '
MRQ12R21Q@G^\QADX]%]Z_#__ (*T?\GJ>)?^P=I__I.E 'U7^U!8_M)ZA^R^
MOQAN_BQ<>![:RTZSN%\)^'&D@F:&3RU\V>]1U9IF+ABH7:,D#W[#_@DY^U9X
MT^.VA^,/"OCK5IO$&H>'Q;W-GJ=U@W#PREU9)&_C*L@(8\_-@GI7H?[9/_*-
M76O^Q:TO_P!"MZ^3?^"'_P#R4+XI?]@NS_\ 1TE 'U'_ ,%)?VU]1_9<\&Z5
MH7A'R?\ A./$*N\%S.@=;&V0@--M)Y<D[5SQPQ/3%<;^R?\ !#XT_$#X)Z5\
M5[WX^^,4\=:[&=0T_2=0N?M.AK#DB.*>U<'(?;DM$4P'X!(R?DG_ (+)75W-
M^UE80SNYMX?#-I]G5C\JJ9IR2![MN_*OU9_8_D23]EOX5LC!E/AVR&5.1Q$M
M 'XC_!>XU*Z_;^\.S:S;166KR>/=][;0/OCBG-XQD16[J&R ?05_0U7\^OPY
M_P"4CUE_V4>;_P!+WK^@J@ K\N?VF/VY?&WQ9_:JT/X%?"?7KCPMH_\ ;T.A
MZCX@TL![R>8RA)VC;G9'$-_(ZE6).,5^G6K-*NEWAAW><(7*;>N[:<?K7\_O
M_!/U6O/VZ/AN;L--*=6N)',N2V\6\[9.>^X9_"@#[Y_;>D^(/[#_ (8\)?$#
MX<?$KQ;JUFVI"PU32/&&K2:Q;W.Y"RO^^)9,[&4A&'W@1@C)^J/V=?CM9?M:
M?L^V_BO1)9O#NH:A;36-TL1#R:=>!2K%/4*2'4GJ"N>]?/G_  628?\ #*NG
MC/)\0VN/^_<M<A_P1)DN/^%,?$)&W?9%U^,Q]<;S;)OQQC. G?T_$ ^#/^"A
M'@S6/AS^U+KND:SXOU+QOJ4%I92-K6K(BW$FZ!&52$ &%S@8["OVN_9?\ ^(
M? WPYLI?$/C_ %CQY+JEM;7D,FL1QJ;)6A4F)-@&5R>_-?C_ /\ !63_ )/6
M\4_]>&G_ /I*E?M[\+_^29^$?^P1:?\ HE* .GK\WO\ @KU^RWXE^)NC:#\3
M/"UG)JTGAZUDL]4T^W3=-]F+;UF10,L%8L& Y 8'H#7Z0UQL/Q(TZ;XKWO@)
MU$>JPZ/#K,9:0?OH7FDB8!<?P,BY.?\ EH* /PD_9C_X*#?%/]F-+32M.OD\
M2>#X6Y\/:LQ:-%)RP@D'S0GDGC*Y))4U^MG[-'[;GPK_ &Q-/BTN(+I7B>WD
MCNG\-ZP5,OF1.)$E@;I*%9 V5^8;>0.^'^TQ_P $S?A1^T NHZMI]G_P@_C&
MYW2#5M)C AEE)SNGM^%?/<J58GG/K^/_ ,7O@[\0_P!B7XW6-EJ4HT_7M,DB
MU/2=7L6+0W"ALK+&2.1N4J589X((P>0#]H?^"AGA77O$'[,7C:]TGQCJ/A>T
MTK2;F\N[73XTSJ2JF1#)(?F5#SD*1G.#GI7Y??\ !+WX;Z]\3OC)XDT_P_X^
MUGX>W4.BM.^H:+'&\LJB:,>6PD!&W)!Z=A7ZF?M.>)G\:_L#>-_$,MM)92ZM
MX):_:VE4JT1EMED*,#T(W8K\]/\ @BI_R<+XP_[%QO\ THBH ^T/VRK'QQ\
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M?C)XALH+B6P\ 6QT3P@L;L%O=0@99]0E5>C;L"V'^X><YQ]>_M1?%'4?A/\
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M$] "*X?_ (*8?L!ZS\;M8?XH?#I([[Q+:68@U?0PP$EXL8S')%_TU"'!4_>
M3'(PWQ'^R'^W%X\_9%\70>'=9%UJ/@7[5Y>J>&]1#*]IDX>2 ,,Q.IPQ3&&P
M1@$[@ ?J9_P4@U[Q-\//V;->\>^$/%FL^%]=T22T6(Z=<!8IEENHXF$B%2#Q
M(2#P1@=J\&_X))_M#_$CXY>(?B3!X\\7:AXGATZUL7M%O2I$+.\X<C '4*OY
M"O:O^"G5_!JW[!?CB]M7\RVN1I<\3C^)6OK9E/Y$5\H_\$.?^1I^+G_7EIO_
M *'<4 =;^UE^V-J>H?MMZ/\ !VX\=:G\-/AII=S!:Z[K.BW7V6YFDE@64DW
M&Z) 72/(QCYV/;'N/Q"\$?$CX/\ C?X4ZSX.^*GB+Q)\*]1\3:98ZQIVLWG]
MH7"+/*L44B794R/ [,BLK,<%P<E2<>%_\%-?V ?$7Q)\6:G\7OAU NL7QM8Q
MKF@VXS=2-%&JK-"!]]O+" Q@;CM!&XG ^8?V(_V^?%W[,OBO3?"'BJYN=3^'
M#78M[S3KP.\VE;FPTL ^\NQLLT>,'#8 8YH _=VBHHI5FC21'5D8!E([@]**
M ):*** "OS8_X*E:]K_QX^'WA_P9\/\ X<?$'Q)=V6KM=WMW'X-U2*")4C=
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M6$=VF!YO3C,'/_;%CZU^H_A#PKIO@;PKI'AW1[=;32M*M(K*T@7HD4:A5'Y
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MDD GY1FOULHH AMX4M8(X8QB.-0BC/8# HJ:B@ HHHH **** "BBB@ HHHH
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ME6Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]*^5O"O_  1[^#>@Z[I]WJFM^+O%&EV+EXM'U2_B%LV3G:WE1(V">3M9<]Z
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M#;X\?#71/!WBW3[F[CT.S2STS6(IA'J%J%C5 RR8VDD*"592A('RUXO\./\
M@DO\'? _BS3]<U;4/$GC@:>JBUTW7[N)K1"I!4E(XU+!3T4G;R<@T >T:#IN
MG?"W]C&*SN]:3Q%H^A>"'5]6,1A2[MXK(GS=A)*AD&<$DU\J_P#!$O3+F#X+
M^/[Y_P#CUN->CCBY_B2!2W_H:U[;_P %+?B9%\,_V1_$NG6Q":EXG\OPY86L
M0RTAFSYBJHZ_NED_,>HKM?V(/@3_ ,,\?LV>$_"MS#Y6M21-J.JD@!C=3'>R
MG_<79'](Q0![W1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC(96!P0?44 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSS^P",?LZQ@=/^$CUX?^56YH ^CJ*** "BBB@ HHHH *_+W_ (+1?&.?^S?
MWPFTQLR:A,=9U!$SN(4F*VCQCD,S2L1ZHE?J S!5))P .:_ CX[?M'/\0/V\
MK[XE'P\_B[2O#FM1C3]&BD9!/;V3[8LL$8A6=1(05/WR* /4?@'X>NOV$?\
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M1V-T@U76'M;772HMYKY;G$2.K_*RB/>54\':O7BM#_@J-X1^%_A+]H;X>IX
MM-'TW6;A/,UVST142)6$Z"!W2,;5D8>;G !("D]B0#]2?CQ^T_\ #K]FW1](
MU+Q_KATB'593%9QQV\D\LI4 NP2-2=JAER<?Q#U%>D:!KVG^*-#T_6-*NX[_
M $O4+>.ZM;J$Y26)U#(ZGT((/XU\R_MO?"/X%?$SPSX.G^-GB:/PG%8SR)I=
M[]N6UDD:14,D0)4[E(1">.,#D9KZ*\ Z'H?ACP/X?TCPR(1X<L=/@MM-\B3S
M(_LZ1JL15L_,-@'/?K0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!\"_\%AOC3_P@O[/VG^![.79J7B^^5)@,C;9P8>0].[F)?H6KX/T'PC=?
ML+_'O]GWQ[>S31Z?K>DV6MWK,<^4D^^*ZC QG B<-S_?XK6_X*5_&=?B[^V-
M<:7'82:WH'@YHM(2QMG97O"C"2Z (4E27+QY .!&#65^VQ^U[?\ [6'AOPQ#
M=_">X\$R>'))#%?+>/.AA=0IB*FW3: 50@Y['CF@#]B?VB/VHO!_[,?A/2O$
MOB^'5)]%U&Y%I%=:3;+<*LA0NH;YQ@,JM@\_=-:7A;]H;P9XP^!G_"V["\E'
M@];";47FF0)*D<6[>K+GA@4(QGK7S/\  .*R_;D_X)NQ^%+VXAO-;BTY]#D>
M=@S6]]:X-L['D@[1 V>N'/K7YG:;^TAXO^'_ .R[XV_9XN8;BVOKSQ%&I@VM
MYT$2LWVJV!!_BGBA^4==THYW< '[.? ']M#X>?M'Z-XFUGPR=5L=&\.(LFH:
MEK5HMK;Q@JS$!]Y&552S>@(]17D\/_!7#X 7'BU-'74M:2S>80C6I--9;09_
MC()\P)[E/PKR[XM? S5_V9_^"3.M^&;.*2V\0W,5G?>(&ME^??/=P>>C$<D(
MFV,G^ZA[5E_\$O/AE\"O$W[-&JW_ (KTCPGK'B62]N8=9?7E@EF@MQM\L 2\
MQQ[<-E<9.><C@ ^M_@O^VY\-?CU\4]<\ ^$YM2N-:TA9WFFFM56VD6*41LT<
M@<[@201QR#FMO2?VNOA5KWQRN?A%8>*([CQS;F2-[)()/*\Q%+21"7;L,B@'
M*YR,$=017YN_\$M;;0[/]NCXDV_A>02^&HK34DTN16+!K47B"$Y/)R@6OL3P
M=\!?V;=%_;4U3Q/HOB6U?XO^?<7\OAM=21EAN)8SYTBPXSO*N[E=W&XG % '
MV)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>7NYSYH4C#5].U5O]/MM5LYK2]MXKNTG0QRP3H'1U(Y5E/!'L: /PNTOP_\
ML?>'/A'XE\36/BWQ3X@\9RZ;<0Z1X5\160C:"Z96CCD?R4,3%=VX$R8&,XS7
MVA_P1C\#:MH/[/\ XKUG4K.6TL-=UK?8M*-OGQ1PJC2+WVEBR@^J&OJV/]D7
MX(Q:H-13X2^#4O!)YHE&B6_W^N[&S&>_3K7JECI]MI=G#:65O%:6D"B.*"!
MD:*.@51P!["@#Y7_ &;?^"=?@O\ 9F^,FM>/]"U[5M1EO()K:TT^\V[+2.1U
M9@7'S2'Y0 6[=<GFOK*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_X)M_#;Q3^TH/C%=7^JIJ)U*+59-%C\K[#+/&%^9@4W89UWGYN23VKZUHH
MX?XV7&D6?PA\8SZ_H-UXGT./2KAK[1[%%>>[@V'S$12R@L5SCYA[5^-/PN\,
M_L2:YXDOM9UKQ;X_\-:993!T\-^(+2-A>*/F\L26RR$C(P0S*>G/>OW-(W#!
MKRKQ!^RG\&O%>K2ZIJ_PM\(ZCJ,S;Y;J?1X&>1NY8[.3]: /S7_X)#^';KQ#
M^TU\1/&>DZ/)8^$8[*XBB<1[8H3-<*\4"GIN"*>!T"]LBOLWPG_P3M\%^#OV
MKKKXXVFNZK)J$UY<ZDFC2[3"EU<*ZR/YGWBO[QR%[9'88KZ:\,^$]$\%Z7'I
MGA_2+'1-.C^[::=;)!$.W"H /3M6O0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4AI:* /GKXD?LHZQ\0/&NJ>(+
M?XW_ !+\+PWSJRZ1H>LF"SMP$5<1IC@$KN/N365_P3ML6TO]F+3K)[F:]>WU
MW6X3<W#;I92NIW*[W/=CC)/J:^FJ^<?V ?\ DW9/^QDU[_TZW- 'T=1110 4
M444 %075U%96TMQ/*L,$2&1Y'8!54#)))[ 5/7Y\?\%9?VIKGX:^"=.^%.@7
M4FGZ[XNA\V_OP2BVVG%RC+N]9&5E..BJ^>HH \2^.W_!6+XH0^-/$>H_##3-
M)'PUT_45TFTU34[!IFNIMC,7#B0##B-V51R%VYP37ZB_"/Q->^-/A7X.\0:C
MY?\ :&JZ/:7UQY*[4\R2%7;:,G RQK\7OVK]>^"OAW]DGX9_#?X7>++7Q/K&
MFZNVHZU<0PR(\\SV[*\IW*!MW$*HSPJK]:_6#]CCXI>&/BA^S[X/?PQJT>JI
MH^EV>EWQC5E\FYCMH]\9R!R..G% 'HWQ0^(VC_"/X>^(/&7B"5H='T2TDO+@
MQ@%V51PB@D99CA5&>2P%?E_H'[>7[6_[15QK_B#X2>![$>%M(D/F6\%BMRP&
M-PC9Y&!DD*\[8P#[>OZF>-?!.A?$;PO?>'?$NF0:SH=\H2YL;D$QR@,& (SZ
M@'\*^4/VG/C1\-O^"=7P7OM(^'^B:9H?BG7FDETG0[-#M,Y54:[E7/"(%7J1
MN( '?  ?\$\_V[[S]K;3]=T3Q+I5KI?B_1(H[B22PW>1=P,VWS I)*,K8!&3
M]X$>E=3^WI^U\?V6_A]80>'K>+5?B)XAG%KHNF,AEQ\PWS/&"&91D( O)9U[
M9KYN_P""6'P)U+X*> _&_P >_'\4VF0:EI4DEH)EW3G3X_\ 2)[DJ/FPYC7:
M#R?+ST(KQOX)_M%?#?XZ?M?:U\;?C?XLAT'3=#=5\*^';Q7E" ;A$2$4C$8R
MY]9'SVH ^EO^"?/[:7Q5_:(^-'C+P9\1(-'MAH6G22M#I]FT,B7"7"1,K-O;
M(&6Z>E>_7GQLUWQY^U1J/PA\+W,>BZ;X9T>/5=?U<P++</+,5\FW@5P44;6#
ML[!O0#J:_.[_ ()P?&CP;X3_ &SOB5?ZKK<5I:>*9;FTT>1D<B[EFOU>-0 N
M067GG%?H_JWP.U?PG^T5?_%[P8MC?7.N:5%I&NZ)?SM;"<1.#'<0RA'Q(JC:
M49<, /F4]0#RCQS\?_C_ .%_VAM<^%7@SP_X5\>SV6C0Z]:3:M<-87,UM))Y
M15MI$1='#?W05 (YXKTK]FCQ9\5?B9JVN>)/'-[H-CH-E))I5AI/AI6EMI[A
M'Q<3M<2#?((W4Q+MVJ2LI^8;6/ >*_AWXDL?C9K7BG4=2L[/QYXWTP:+;6^G
M3-);^&_#]LP>ZNVE*HTDI+_*=H DE4#(!-==\#?BQKOQ&^$MWXB^&7AG2-,\
M!Z49+'PUIVH&59]4@MCL+Y7Y;=7*E4R'/&6')% 'TI2UP7P0^+VB_'?X9:+X
MVT%9HK+48VW6UP );>96*21/@XW*ZL,@X.,CK7>T %%%% !1110 4444 %%%
M% !1110 444UE#*0>] 'YC?&#_@HO\7/B7\?-2^%_P"SIX=L]2;3YY;<ZA/
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M:^-UTD1:);V<EK_9EHT!W2M,&W9=L\1K7V+\6!_Q:WQE_P!@6\_]$/7YA_\
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MTSX!_&ZR^.7A._U".QDTC6='U*YT76=*E<.;.]@<I(@<?>0X#*V 2&&0#D
M].HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW*:Y7XN_"+5M*_:2^'GQH\.Z3)KJZ/IL_AS6=*M'5;@64I9HYX%8A6,3NQ9
M=Q4_+N( KZ-HH ^;-1^'>M_&?]JSX?\ Q$GTBZT/PAX!T^_6REU-#!=:A>WB
M")]L!^9(HT7K(%)+# (YKZ3HHH **** "BBB@ HHHH **** "BBB@ HHHH \
M>_:D^(WCOX<_"N]N?AKX/OO&7C2[/V:PMK6#S([9B#F>7D#:O&%SR2!TR1^/
MOP^^ _[6'P[^+3?$FV^%FK:QXP,LEQ]OUJP2ZQ.YRTP5FQOZ@'MDX[5^\=%
M'R'^S_X^_:5\3?LZ?$C4_'GAQ=.^)MJLX\.64UC';+*1;AHSMSM8^83]XXR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK+_X)VZ7;Z'^S%I^G6BE;2SUW6[>%6)8A$U.X502>IP!R: /IJBBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRK7/\
MDZ#P9_V*.M?^EFF5ZK7E6N?\G0>#/^Q1UK_TLTR@#U6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OG']@'_DW9/\ L9->_P#3K<U]'5\X_L _\F[)_P!C)KW_ *=;F@#Z
M.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O*M<_P"3H/!G_8HZU_Z6:97JM>5:
MY_R=!X,_[%'6O_2S3* /5:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@#P'XB?MS?![X5^,
M]3\*^)/$-W9ZYIKJES!'I-U*JED5P Z1E3\K*>#WK$_X)VZI;ZU^S'I^HVC&
M2TN]=UNXA<J061]3N64D'D'!'!KZ3:UA9BS1(Q/4E037SM^P",?LZQ\8_P"*
MCU[_ -.MS0!]'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E6N?\G0>#/^Q1UK
M_P!+-,KU6O*M<_Y.@\&?]BCK7_I9IE 'JM%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?./[ /_)NR?]C)KW_IUN:^CJ^<?V O^3=H_P#L
M9->_].MS0!]'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%(: /Y=O'W_(]^(_^PE<_
M^C6K!K]X=1_X)/\ [/NK:C=7MSH^M/<7,KSR,-7E +,V3Q]2:\\U+_@E[\"+
M7XX>'?#$>D:P-)OO#^I:C,AU64L9H;BQCC(;L-MQ)D=\B@#\A/AO_P E$\+?
M]A6U_P#1R5_4&OW1]*^.]+_X)1?L^Z+JEGJ%KH^M)=6LR3Q,VKRD!T8,O'?D
M"OL4<"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=;J@#Z.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVY74ZI<D,#W!!H ^E**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#%U7P;H&NW7VG4M#TW4+C;M\ZZM(Y
M7QV&6!.*J_\ "M/"'_0JZ)_X+H?_ (FNDHH YO\ X5IX0_Z%71/_  70_P#Q
M-'_"M/"'_0JZ)_X+H?\ XFNDHH YO_A6GA#_ *%71/\ P70__$T?\*T\(?\
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M9T^*Z$!?;O*>8IV[MJYQUVCTKK NWH *=0!Y+_PR-\#_ /HD'@?_ ,)^U_\
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M +"5S_Z-:L&OW$U3_@D#\#]8U2\OY[WQ5Y]U,\\FS4(P-S,6./W7O7G^I?\
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MLTR@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&5SV!'(K\G/''_!*']H?PKKC6>E^&++Q999Q'J&EZI;1QL,\96>2-E/X8]Z
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MN?\ )T'@S_L4=:_]+-,H ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M':PSD'!YH OT5Y!_PSO+_P!%3^(__@[3_P",T?\ #.\O_14_B/\ ^#M/_C-
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MY8R0#AE9@1P0>?6O'O\ @GW<17?[-]M/!*LT$OB'7I$DC.593JER00>X(]*
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M?>*1H$!/N<9/N30!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M444C4 +17X4^+/\ @J1^T1I7BK6;*V\6V26]M>S0QJ=)MCA5=@!G9Z"LG_AZ
MU^T?_P!#?8_^"BV_^(H _>RBOPM\%_\ !4;]H?6?&.A:?=>++)[:ZO[>"51I
M-L,HTBJP^YD<$]*_=%?NB@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0OF,8_'?P["9X#>$KTD#MD_VCSQ[4G_  C?[1'_ $/OPY_\)&]_^6->VT4
M?$O[8'QH^-_[,GP6U+Q3JOCCP%=3W#KI]E:67AB[AGEFD!Y1VOV4%%#/DJ1\
MO0U\U?\ !+O]H3XG>---U+X3:'XR\-:5<Z:)M7L(_$FB7%_+<1R2[KA4DCNH
M0-LCA]I!)\UB. <>0?\ !5?]I!?C-\?'\*Z1??:?#'@O?8IY;?NY;TD?:9!Z
ME2HCS_TS..O/S)\!_C#JWP%^+GAGQUHV6NM(NUEDM]VU;B$_++"Q]'0LN<<9
M![4 ?OY_PC?[1'_0^_#G_P )&]_^6-'_  C?[1'_ $/OPY_\)&]_^6->G^"/
M&&F?$#P?HOB;1IUN=)U>SBO;652#NCD0,.G?G\Q6]0!XE_PC?[1'_0^_#G_P
MD;W_ .6->;>'M ^.Q_:!\:)%XU\!)JBZ!I)GG?PM>&%XS-?>6JI]OR&!#Y8L
M<[EP!CGZVKX[\/?M2^%8?^"BWBOX:_:E,^H>'['3HKH*=G]HVS7%P]ONZ<Q7
M'4_Q1E>I H ]7_X1O]HC_H??AS_X2-[_ /+&C_A&_P!HC_H??AS_ .$C>_\
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MFZAM?"UY%-)"&!=4<W[!6*YPQ4@$@X(XKV2BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 0Y[5^3O[2VN:[^VE_P %!+7X&0>*
M-0T/P'H3O;W*:?,5WR1P>9<R%?NM('S&NX$+M)[G/ZQ&OQ\_98LIM$_X*\^.
MK?4$9)WUGQ"Z>9C+"1I9$;G^\C!OQH OZ7I^M?\ !.#]NSPAX-TGQ7JFL?#;
MQ>;6*:TU%]^(YY3#EE&%WQR ,'4 [21ZY_7-:_)3_@JE;S:I^V=\&K"Q?;?R
MP64414!F5WOR$.T\=?7K7Z2?&+P_\3]>CTH?#7Q?HGA22)I?MS:SI#7XG!"^
M7L D39MP^>N=P]* /2:^<?V O^3=X_\ L9->_P#3K=5#_P *[_:D_P"BP>!_
M_"0D_P#DFHO^"=\=W#^S+81W\T=S?+KVN+<31)L1Y!J=SN95YP"<D#/% 'TS
M1110 4444 %%%% !1110 4444 ?B[_P4]_;<\1^.OB=K/PM\*:K<Z1X,T&7[
M)J'V60QOJ5TO^LWL#GRD8[0G0E2QS\N/SYKTK]I30+_PQ^T%\1]-U-&2]A\0
M7V_=U.Z=V5OH0P/XUYK0!]M_\$X_VVO$?P4^*&B>!]?U2?4OA]KUVMFUM=S%
MQITTA"I-"3]U2Y 91P0Q/45^K_[2G_(>^"'_ &4&T_\ 2"^K^>GX;Z'?^*/B
M#X:TC2S(NI7VI6]O;-"FYUD:10K >H)S^%?T+?M*?\A[X(?]E!M/_2"^H ^*
M?^"X5KJ+>'?A+<QD_P!E1W6I1SCMYS);F+M_=6;\Z_)NOZ2_VHOV<]!_:B^$
MNH^"M;D:SDD87-AJ,:AGL[E =D@'<<E67N&(XZU^'7Q>_8'^./P;UB>TOO >
MJ:_9*Y6+5?#MM)?VTH'\68U+(/\ ?530!\\U^T7_  1;M-1A_9O\3S7.[[!-
MXDD-INZ8$$(<CVW?UK\__@/_ ,$Z/C3\;->M(I_"=_X,T!I%%SK'B*W>T$<>
MX;C'$X#R-C. !@GJPZU^Y?P3^#WA_P" GPQT+P-X9A:+2M*AV"20YDGD8EI)
M7/\ >=RS'L,X& !0!W=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\OWW_!,_P#9LU2^N;RZ^&J2W-Q(TTK_ -M:B-S,26.!<8ZD]!BH?^'7_P"S
M)_T3%/\ P=ZE_P#)-?4U% 'S!IW_  31_9MTG4+6^M/ALD5U:RK/#)_;6HG:
MZG*G!N"."!UKZ>Z4M% !1110 4444 %%%% !1110 4444 %%%% !7F7[1_B;
MQAX5^#/B>[\ >'[KQ+XRDMC;:796FW*S2?*)6)(&V,$N<GG;CO7IM% '\\=U
M^P#^T?>7,MQ/\+=<EGE<R/([0DLQ.22?,ZDYJ+_AWO\ M%?]$IUK_OJ'_P"+
MK^B&LGQ)IVH:KHMS:Z5JS:)?R >5?K;I.8OF!)V.-IR 1SZT ?'/_!+W0?BQ
M\,_A?JOP\^)OA'5- MM)G^U:)<WH0HT,I+2P!E8X*R98 ]?,..G'VY7EO_"N
M?B/G_DKES_X3]E_A1_PKOXC_ /16[G_PG[/_ .)H 3]IKXW6/[._P2\4^.KS
MRY)=.M2+.WD.!<73_+#'^+D9QV!-?SK6OQ/\26?Q,C\?IJ<O_"5IJ?\ :XOV
M.6-SYGF;B.X+=NF..E?87_!4_P".&OZU\2+?X5S>-YO%NF>&RMS?'[##:HM^
MZ'Y/W0^?9&PZ]"[#M7PC0!_3!^SS\9-/^/WP9\+>.].5(TU>T62>W1]P@N%.
MV:+/^S(&'/8 UZ17XI_\$J/C;X@L_'5Y\(X?'4WA.PUPO?:8O]GPW:27JH-\
M>9!\A>)"1S@F/'4C/ZM_\*Z^(W_17+G_ ,)^R_PH ^=_^"JG[0UU\(?@$?"F
MANR^(_&9>P#1$[X+, ?:) !SE@RQY_Z:$]J_#G^S;S_GTG_[]M_A7](-Y\(_
M'&H,K77Q.^TNHPK3>&K%B/896O0['PGIMO8V\5Q865U.D:I).;2-?,8  MM
MP,G)P.F: /YC_#&HZWX/\2:7KNE)<VNIZ9=17EK,D;926-@ZL..Q K^C_P#9
MS^,VG_'_ .#/AGQO8*T+:C:K]JMF!#6]RORS1D>SAL'N,'O7<_\ ",Z/_P!
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MG_A)OC[_ -$_\!?^%?=__*^N_P# E]XLOM&:3QCI.E:-JOFL%M]'U"2]A\O
MPWF/#$=V<\;>PYH Z>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EHH
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M=1110 4444 %%%% !1110 4444 )2T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?./[ /_)NR?]C)KW_IUN:^CJ^<?V ?^3=D_P"QDU[_ -.MS0!]'4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% 'AWCW]F
M[7/&WB[4=:M?C;\1O"]O=LK+I.BWMJEI;X55(C5[=F&2"QRQY)]JYC_@GC9O
MIO[,MA:O<S7CP:]KD37-P09)2-3N078@ %CC)P.I-?3%?./[ /\ R;LG_8R:
M]_Z=;F@#Z.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYQ_8!_P"3=D_[&37O_3K<UL^/_P!IC6_!'C#4M#M/@E\2/%%O
M9LJKJ^BV%L]I<90,3&SSJQ )VG*CE3]:YS_@G?>/J/[,EA=O;363W&NZY*UM
M< "6(MJ=R2C@9&X9P<'J* /IBBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUN: /HZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTJ/Q;!J4ZZ8TC6W]G:O=6!'F; V[R)$W_<7[V<<XQDT >D5\X_L!?\F[Q_\
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M_P#)- 'TA17S?_P[Z^#?_/AXF_\ "OU7_P"2:/\ AWU\&_\ GP\3?^%?JO\
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M !"LZD#N ?N#144,J31))&PDC<!E93D$'H0:EH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M QQW.,_C0!Q_P!_9H\ ?LT>%Y-$\#:.MBD["2ZOIF,MU=-C&9)#R<=E& ,\
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M'L8+*QM8;*RMT$<-O;QK''$HZ*J@8 'H!5NBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-+110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2UY;^TW\6+KX'_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW3[==D-K9Q+%%&O]U54  ?2K]%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5XG\<_V/\ X8?M$>)O#6O>,] 6]U+0[A94EB8QFZC'
M/D3X^_%NP=I]",X9@?;** *UG9PZ?:PVMK#';VT*".*&)0JHH& J@= !@8]J
MLT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>37
<FILENAME>celu-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T15:44:19.6352960+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ccfc69a50e5a44e89f9a89b5c642c0de -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:celu="http://celularity.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://celularity.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://celularity.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="celu-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="celu-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="celu-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="celu-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" id="Role_StatementConsolidatedBalanceSheetsParentheticals">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100060 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals" id="Role_DisclosureBusinessCombinationsAndDisposals">
        <link:definition>100080 - Disclosure - Business Combinations and Disposals</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilities">
        <link:definition>100090 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventory" id="Role_DisclosureInventory">
        <link:definition>100100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses" id="Role_DisclosurePrepaidExpenses">
        <link:definition>100110 - Disclosure - Prepaid Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet" id="Role_DisclosureGoodwillAndIntangibleAssetsNet">
        <link:definition>100130 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedParty" id="Role_DisclosureShortTermBorrowingsRelatedParty">
        <link:definition>100150 - Disclosure - Short-Term Borrowings - Related Party</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>100170 - Disclosure - Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100180 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition" id="Role_DisclosureRevenueRecognition">
        <link:definition>100190 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreements" id="Role_DisclosureLicenseAndDistributionAgreements">
        <link:definition>100200 - Disclosure - License and Distribution Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlans" id="Role_DisclosureBenefitPlans">
        <link:definition>100210 - Disclosure - Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation" id="Role_DisclosureSegmentInformation">
        <link:definition>100230 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100240 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100250 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsTables" id="Role_DisclosureBusinessCombinationsAndDisposalsTables">
        <link:definition>100280 - Disclosure - Business Combinations and Disposals (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
        <link:definition>100290 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryTables" id="Role_DisclosureInventoryTables">
        <link:definition>100300 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesTables" id="Role_DisclosurePrepaidExpensesTables">
        <link:definition>100310 - Disclosure - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100320 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" id="Role_DisclosureGoodwillAndIntangibleAssetsNetTables">
        <link:definition>100330 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100350 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquityTables" id="Role_DisclosureEquityTables">
        <link:definition>100360 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100370 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables" id="Role_DisclosureRevenueRecognitionTables">
        <link:definition>100380 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100390 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationTables" id="Role_DisclosureSegmentInformationTables">
        <link:definition>100400 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails">
        <link:definition>100430 - Disclosure - Property and Equipment - Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails">
        <link:definition>100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Business Combinations and Disposals - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails" id="Role_DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails">
        <link:definition>100460 - Disclosure - Business Combinations and Disposals - Schedule of assets and liabilities were divested/written off (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100470 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails">
        <link:definition>100490 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails">
        <link:definition>100500 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Aggregate Fair Values of the Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails">
        <link:definition>100510 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails">
        <link:definition>100520 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails" id="Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails">
        <link:definition>100530 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Convertible Note Valuation Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails" id="Role_DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails">
        <link:definition>100540 - Disclosure - Inventory - Schedule of Major Classes of Inventories (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2" id="Role_DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2">
        <link:definition>100550 - Disclosure - Inventory - Schedule of Major Classes of Inventories (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails" id="Role_DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails">
        <link:definition>100560 - Disclosure - Prepaid Expenses - Schedule of Prepaid Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100570 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails">
        <link:definition>100580 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails">
        <link:definition>100600 - Disclosure - Goodwill and Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails">
        <link:definition>100610 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails">
        <link:definition>100630 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails">
        <link:definition>100640 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails" id="Role_DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Short-Term Borrowings - Related Party - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails">
        <link:definition>100670 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Non-cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails" id="Role_DisclosureEquitySummaryOfWarrantsDetails">
        <link:definition>100690 - Disclosure - Equity - Summary of the Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails" id="Role_DisclosureEquitySummaryOfWarrantsParentheticalDetails">
        <link:definition>100700 - Disclosure - Equity - Summary of the Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100720 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>100730 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails" id="Role_DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails">
        <link:definition>100740 - Disclosure - Stock-Based Compensation - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
        <link:definition>100750 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails" id="Role_DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails">
        <link:definition>100760 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Product And Services (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" id="Role_DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails">
        <link:definition>100770 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails" id="Role_DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails">
        <link:definition>100780 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails" id="Role_DisclosureRevenueRecognitionAdditionalInforrmationDetails">
        <link:definition>100790 - Disclosure - Revenue Recognition - Additional Inforrmation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails">
        <link:definition>100800 - Disclosure - License and Distribution Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails" id="Role_DisclosureBenefitPlansAdditionalInformationDetails">
        <link:definition>100810 - Disclosure - Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails" id="Role_DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails">
        <link:definition>100820 - Disclosure - Income Taxes - Schedule of Current and Deferred Tax Provision (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails">
        <link:definition>100830 - Disclosure - Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails">
        <link:definition>100840 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100850 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100860 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" id="Role_DisclosureSegmentInformationAdditionalInformationDetails">
        <link:definition>100870 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails" id="Role_DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails">
        <link:definition>100880 - Disclosure - Segment Information - Schedule of Financial Information by Segment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100890 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100900 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="celu_ConvertibleNoteReceivable" name="ConvertibleNoteReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_PreferredStockWarrants" name="PreferredStockWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_WarrantLiabilitySponsorWarrants" name="WarrantLiabilitySponsorWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_WarrantLiabilityPublicWarrants" name="WarrantLiabilityPublicWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_InventoryGrossCurrentAndNoncurrent" name="InventoryGrossCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_InventoryReserveCurrentAndNoncurrent" name="InventoryReserveCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_PromissoryNotesReceivable" name="PromissoryNotesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_FinancingObligationsCurrent" name="FinancingObligationsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_FinancingObligationsNoncurrent" name="FinancingObligationsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_WarrantLiability" name="WarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesXRedeemableConvertiblePreferredStockMember" name="SeriesXRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ChangeInFairValueOfContingentConsiderationLiability" name="ChangeInFairValueOfContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_OperatingIncomeCostsAndExpenses" name="OperatingIncomeCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_IncomeExpenseRelatedToWarrantLiabilities" name="IncomeExpenseRelatedToWarrantLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_OtherNonoperatingIncomeExpenses" name="OtherNonoperatingIncomeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_LicenseRoyaltyAndOtherMember" name="LicenseRoyaltyAndOtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_TemporaryEquityShareIssuanceCosts" name="TemporaryEquityShareIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" name="RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" name="RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" name="RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" name="RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" name="ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_CTHBiosourcingLLCMember" name="CTHBiosourcingLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_PublicEquityFinancingMember" name="PublicEquityFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CariCordIncorporatedMember" name="CariCordIncorporatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_PalantirTechnologiesIncMember" name="PalantirTechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AmortizationOfInventoryStepUp" name="AmortizationOfInventoryStepUp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" name="SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ProceedsFromPromissoryNote" name="ProceedsFromPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" name="ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_CashReceivedOnRecapitalization" name="CashReceivedOnRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ProceedsFromInvestment" name="ProceedsFromInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_RecapitalizationFromMerger" name="RecapitalizationFromMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_CancellationOfTreasuryStock" name="CancellationOfTreasuryStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_NonCashAssetsAcquiredFromMerger" name="NonCashAssetsAcquiredFromMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_WarrantLiabilityAssumedFromMerger" name="WarrantLiabilityAssumedFromMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" name="IssuanceOfCommonStockAsPaymentForRelatedCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ReclassificationOfWarrantLiabilitiesToEquity" name="ReclassificationOfWarrantLiabilitiesToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ReclassOfOfferingCostsPaidInPriorYear" name="ReclassOfOfferingCostsPaidInPriorYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" name="ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" name="RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" name="UltraMISTSystemsReclassFromInventoryToFixedAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" name="FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_IssuanceOfWarrantsAtEstimatedFairValue" name="IssuanceOfWarrantsAtEstimatedFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" name="IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_GXAcquisitionCorpMember" name="GXAcquisitionCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" name="BusinessCombinationsAndDisposalsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_BusinessCombinationsAndDisposalsAbstract" name="BusinessCombinationsAndDisposalsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_PrepaidExpensesDisclosureTextBlock" name="PrepaidExpensesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfStockBasedCompensationExpenseAbstract" name="ScheduleOfStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LicenseAndDistributionAgreementsTextBlock" name="LicenseAndDistributionAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_LicenseAndDistributionAgreementsAbstract" name="LicenseAndDistributionAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_RestrictedCashPolicyTextBlock" name="RestrictedCashPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_AssetAcquisitionsPolicyTextBlock" name="AssetAcquisitionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" name="PreferredStockWarrantsLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_GovernmentGrantsPolicyTextBlock" name="GovernmentGrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_EmergingGrowthCompanyPolicyTextBlock" name="EmergingGrowthCompanyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" name="ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" name="FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" name="FairValueOfFinancialAssetsAndLiabilitiesTablesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_GXSponsorWarrantsMember" name="GXSponsorWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_DragasacWarrantMember" name="DragasacWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" name="ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" name="ScheduleOfConvertibleNoteValuationModelTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" name="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfPrepaidExpensesTableTextBlock" name="ScheduleOfPrepaidExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfIntangibleAssetsNetTableTextBlock" name="ScheduleOfIntangibleAssetsNetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" name="DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" name="DescriptionOfOrganizationAndBusinessOperationsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LegacyCelularitysMember" name="LegacyCelularitysMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_HLICellularTherapeuticsLLCMember" name="HLICellularTherapeuticsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AnthrogenesisMember" name="AnthrogenesisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AlliquaAPAMember" name="AlliquaAPAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CaricordMember" name="CaricordMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_BusinessCombinationSharesExchangeRatioDescription" name="BusinessCombinationSharesExchangeRatioDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_BusinessCombinationSharesExchangeRatio" name="BusinessCombinationSharesExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_NumberOfClinicalTrials" name="NumberOfClinicalTrials" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_AreaOfBuilding" name="AreaOfBuilding" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_ContingentValueRightIssuedForEachShare" name="ContingentValueRightIssuedForEachShare" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RegulatoryMilestones" name="RegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_OneCustomerMember" name="OneCustomerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CustomerTwoMember" name="CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_EquipmentEvaluationPeriod" name="EquipmentEvaluationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" name="ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" name="MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" name="ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_NumberOfBusinessSegments" name="NumberOfBusinessSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_BusinessCombinationsAndDisposalsLineItems" name="BusinessCombinationsAndDisposalsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" name="ScheduleOfBusinessCombinationsAndDisposalsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AlphaFirstMergerSubIncorporationMember" name="AlphaFirstMergerSubIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SurvivingCorporationMember" name="SurvivingCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CelularityMember" name="CelularityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_GXTrustAccountMember" name="GXTrustAccountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_GXWarrantsMember" name="GXWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_MISTUltraMISTBusinessMember" name="MISTUltraMISTBusinessMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_UltraMISTBusinessMember" name="UltraMISTBusinessMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_BusinessCombinationExchangeRatioOfCommonStock" name="BusinessCombinationExchangeRatioOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_BusinessAcquisitionTransactionCostsProceedsNet" name="BusinessAcquisitionTransactionCostsProceedsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" name="BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_OptionToPurchaseSharesOfCommonStock" name="OptionToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_SubscriptionAgreementsDescription" name="SubscriptionAgreementsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_LicenseArrangementTerm" name="LicenseArrangementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_FairValueOfConvertiblePromissoryNote" name="FairValueOfConvertiblePromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_AssetPurchaseAgreementDescription" name="AssetPurchaseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_AssetsDivestedAbstract" name="AssetsDivestedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ConsiderationDescription" name="ConsiderationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" name="DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" name="DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" name="DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" name="DisposalGroupIncludingDiscontinuedOperationProfessionalFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_PublicWarrantsMember" name="PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SponsorsWarrantsMember" name="SponsorsWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ContingentConsiderationObligation" name="ContingentConsiderationObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_FairValueNetAssetsLiability" name="FairValueNetAssetsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" name="StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ProceedsFromIssuanceOfWarrant" name="ProceedsFromIssuanceOfWarrant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_GainLossRecognizedInEarningsFromChangeInFairValues" name="GainLossRecognizedInEarningsFromChangeInFairValues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_WarrantLiabilityAssumedAtClosingDate" name="WarrantLiabilityAssumedAtClosingDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" name="ReclassificationOfLegacyCelularityWarrantsToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_FairValuesOfCommonStock" name="FairValuesOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PercentageOfExercisePrice" name="PercentageOfExercisePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_ClassOfWarrantExercisePriceDescription" name="ClassOfWarrantExercisePriceDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_FaceValueOfNotesReceivable" name="FaceValueOfNotesReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_PercentageOfCouponRate" name="PercentageOfCouponRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ValuationModelThatRelateToSanuwaveCommonStock" name="ValuationModelThatRelateToSanuwaveCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_ValuationInputForConvertiblePromissoryNoteTerm" name="ValuationInputForConvertiblePromissoryNoteTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ValuationInputForConvertiblePromissoryNote" name="ValuationInputForConvertiblePromissoryNote" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_InventoryRawMaterialsCurrentAndNoncurrent" name="InventoryRawMaterialsCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_InventoryWorkInProgressCurrentAndNoncurrent" name="InventoryWorkInProgressCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_InventoryFinishedGoodsCurrentAndNoncurrent" name="InventoryFinishedGoodsCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_InventoryNetCurrentAndNoncurrent" name="InventoryNetCurrentAndNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_PrepaidClinicalExpense" name="PrepaidClinicalExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_LaboratoryAndProductionEquipmentMember" name="LaboratoryAndProductionEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_MachineryEquipmentAndFixturesMember" name="MachineryEquipmentAndFixturesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" name="GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_CellTherapyMember" name="CellTherapyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_DegenerativeDiseaseMember" name="DegenerativeDiseaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_BiobankingMember" name="BiobankingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AcquiredProductRights" name="AcquiredProductRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_AmortizableIntangibleAssetsAbstract" name="AmortizableIntangibleAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LessAccumulatedAmortizationAbstract" name="LessAccumulatedAmortizationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_NonAmortizedIntangibleAssetsAbstract" name="NonAmortizedIntangibleAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ReacquiredRightsMember" name="ReacquiredRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" name="IndefiniteLivedIntangibleAssetsAmortizationMethod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_AccruedClinicalTrialExpense" name="AccruedClinicalTrialExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_AccrualsForConstructionInProgress" name="AccrualsForConstructionInProgress" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" name="ShortTermBorrowingAmountEqualToExitFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_LoanAgreementMember" name="LoanAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CVStarrCoIncMember" name="CVStarrCoIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" name="RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_OperatingLeaseExpiryYear" name="OperatingLeaseExpiryYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_CommitmentsandContingenciesDetailsLineItems" name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CommitmentsandContingenciesDetailsTable" name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_WarrenNewJerseyMember" name="WarrenNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CedarKnollsNewJerseyMember" name="CedarKnollsNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_OfficeManufacturingAndLaboratorySpaceMember" name="OfficeManufacturingAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_FlorhamParkNewJerseyMember" name="FlorhamParkNewJerseyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_HLICellularTherapeuticsMember" name="HLICellularTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LLCAndAnthrogenesisMember" name="LLCAndAnthrogenesisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_MasterSubscriptionAgreementMember" name="MasterSubscriptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CariCordParticipatingShareholdersMember" name="CariCordParticipatingShareholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_PercentageIncreaseInBaseAnnualRent" name="PercentageIncreaseInBaseAnnualRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_AreaOfBuildings" name="AreaOfBuildings" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_OptionToRenewLeaseTermPeriod" name="OptionToRenewLeaseTermPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_InitialMonthlyBaseRent" name="InitialMonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" name="ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AnnualFeePaid" name="AnnualFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_PaymentsForMasterSubscriptionAgreement" name="PaymentsForMasterSubscriptionAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_PaymentSubscriptionPeriod" name="PaymentSubscriptionPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_UpfrontFee" name="UpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_AnnualMaintenanceFee" name="AnnualMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ClinicalAndRegulatoryMilestones" name="ClinicalAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_LicenseAgreementNoticePeriod" name="LicenseAgreementNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_NumberOfSharesIssuedInLegalSettlementAgreement" name="NumberOfSharesIssuedInLegalSettlementAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" name="NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" name="EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_StockholdersEquityDetailsLineItems" name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_StockholdersEquityDetailsTable" name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesBPreferredStocksPurchaseAgreementsMember" name="SeriesBPreferredStocksPurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesBRedeemableConvertiblePreferredStocksMember" name="SeriesBRedeemableConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesBPreferredStockPurchaseAgreementsMember" name="SeriesBPreferredStockPurchaseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesARedeemableConvertiblePreferredStocksMember" name="SeriesARedeemableConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesXRedeemableConvertiblePreferredStocksMember" name="SeriesXRedeemableConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" name="SeriesBRedeemablesConvertiblePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_DragasacWarrantsMember" name="DragasacWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AmendedAndRestatedDragasacWarrantsMember" name="AmendedAndRestatedDragasacWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AmendedDragasacWarrantsMember" name="AmendedDragasacWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LegacyGXWarrantMember" name="LegacyGXWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SponsorsMember" name="SponsorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_PercentageOfSharesRequiredForVoting" name="PercentageOfSharesRequiredForVoting" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_NumberOfSharesRequiredToBeOutstandingForVoting" name="NumberOfSharesRequiredToBeOutstandingForVoting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_ConversionPricePerShareOfCommonStock" name="ConversionPricePerShareOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_WarrantsPerSharePercentage" name="WarrantsPerSharePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_NumberOfWarrantsIssued" name="NumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_DescriptionOfExercisableTerms" name="DescriptionOfExercisableTerms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" name="WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" name="WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" name="ClassOfWarrantOrRightWarrantsExercisableForCash" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_WarrantExpirationTerm" name="WarrantExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PublicWarrantsCallPrice" name="PublicWarrantsCallPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_MinimumWrittenNoticePeriodForRedemption" name="MinimumWrittenNoticePeriodForRedemption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DescriptionOfWarrantCallProvision" name="DescriptionOfWarrantCallProvision" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" name="AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_March2020SeriesBWarrantsMember" name="March2020SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SponsorWarrantsMember" name="SponsorWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" name="DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_StockBasedCompensationDetailsLineItems" name="StockBasedCompensationDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_StockBasedCompensationDetailsTable" name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AwardsWithServiceConditionsMember" name="AwardsWithServiceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_AwardsWithMarketConditionsMember" name="AwardsWithMarketConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ScheduleOfStockOptionsActivityAbstract" name="ScheduleOfStockOptionsActivityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ExpenseRelatedToPerformanceAwards" name="ExpenseRelatedToPerformanceAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_UnrecognizedExpenseRelatedToPerformanceAwards" name="UnrecognizedExpenseRelatedToPerformanceAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_AwardModificationExpense" name="AwardModificationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" name="ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ContractedStoragePeriods" name="ContractedStoragePeriods" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PaymentPlansForCustomerToPayOverTimePeriod" name="PaymentPlansForCustomerToPayOverTimePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_IncentivePayment" name="IncentivePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_LicenseAndDistributionAgreementsLineItems" name="LicenseAndDistributionAgreementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_LicenseAndDistributionAgreementsTable" name="LicenseAndDistributionAgreementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_SanuwaveLicenseAgreementMember" name="SanuwaveLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ArthrexAgreementMember" name="ArthrexAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_EvolutionAgreementMember" name="EvolutionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ReimbursementOfCostUnderLicenseAgreement" name="ReimbursementOfCostUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_LicensingArrangementTerm" name="LicensingArrangementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_AnnualSales" name="AnnualSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_AnnualSalesNotExceed" name="AnnualSalesNotExceed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_LicenseAgreementDescription" name="LicenseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_SupplyAndDistributionAgreementPeriod" name="SupplyAndDistributionAgreementPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_SupplyAndDistributionAgreementRenewalTerm" name="SupplyAndDistributionAgreementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" name="DiscountPercentagePaymentForInvoicesWithinTenDays" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PaymentTermNet" name="PaymentTermNet" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_MaterialBreachContractTerminatedTerm" name="MaterialBreachContractTerminatedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" name="SupplyAndDistributionAgreementNonRenewalNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" name="PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RemainingDuePercentageNetFortyFivePaymentTerm" name="RemainingDuePercentageNetFortyFivePaymentTerm" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_SupplyAndDistributionAgreementForecastDescription" name="SupplyAndDistributionAgreementForecastDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleOfIncomeTaxProvisionAbstract" name="ScheduleOfIncomeTaxProvisionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" name="EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" name="EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" name="ScheduleReconciliationOfTheFederalIncomeTaxAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_DeferredTaxAssetsStartupCosts" name="DeferredTaxAssetsStartupCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_DeferredTaxAssetsUnicap" name="DeferredTaxAssetsUnicap" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" name="DeferredTaxAssetsImputedInterestOnContingentPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" name="DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" name="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_ScheduleOfNetDeferredTaxAssetsAbstract" name="ScheduleOfNetDeferredTaxAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_TaxCreditCarryforwardsExpirationYear" name="TaxCreditCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_UnitedStatesFederalAndStateMember" name="UnitedStatesFederalAndStateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" name="NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_SegmentContribution" name="SegmentContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_IndirectExpenses" name="IndirectExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_ScheduleOfFinancialInformationBySegmentAbstract" name="ScheduleOfFinancialInformationBySegmentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_OtherMember" name="OtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_PaymentForMonth" name="PaymentForMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_StockOptionsVested" name="StockOptionsVested" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_RelatedPartyTransactionsDetailsLineItems" name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_RelatedPartyTransactionsDetailsTable" name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" name="ConsultingAgreementWithDoctorAndrewPecoraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CURAFoundationMember" name="CURAFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_COTAIncMember" name="COTAIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CryoportSystemsIncMember" name="CryoportSystemsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CVStarLoanMember" name="CVStarLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_StockPurchaseAgreementWithDirectorMember" name="StockPurchaseAgreementWithDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_EmploymentOfImmediateFamilyMemberMember" name="EmploymentOfImmediateFamilyMemberMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_MsHariniMember" name="MsHariniMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_MrPecoraMember" name="MrPecoraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="celu_CashConsiderationPerMonth" name="CashConsiderationPerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_RelatedPartyCashBonus" name="RelatedPartyCashBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" name="NonqualifiedStockOptionToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="celu_PaymentsToRelatedParty" name="PaymentsToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_LoanAgreement" name="LoanAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="celu_NumberOfSharesHolding" name="NumberOfSharesHolding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="celu_RelatedPartyFullTimeBaseSalary" name="RelatedPartyFullTimeBaseSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="celu_RelatedPartyPartTimeBaseSalary" name="RelatedPartyPartTimeBaseSalary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>38
<FILENAME>celu-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T15:44:19.6352960+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ccfc69a50e5a44e89f9a89b5c642c0de -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="celu-20211231.xsd#TemplateLink" roleURI="http://celularity.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PromissoryNotesReceivable" xlink:type="locator" xlink:label="celu_PromissoryNotesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsCurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiability" xlink:type="locator" xlink:label="celu_WarrantLiability" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsNoncurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_PreferredStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_CommonStockValue" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_TreasuryStockValue" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_AdditionalPaidInCapital" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="celu_FinancingObligationsNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="celu_WarrantLiability" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="celu_FinancingObligationsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_InventoryNoncurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="celu_PromissoryNotesReceivable" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10340.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10350.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:type="locator" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingIncomeCostsAndExpenses" xlink:type="locator" xlink:label="celu_OperatingIncomeCostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherNonoperatingIncomeExpenses" xlink:type="locator" xlink:label="celu_OtherNonoperatingIncomeExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeExpenseRelatedToWarrantLiabilities" xlink:type="locator" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="celu_IncomeExpenseRelatedToWarrantLiabilities" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="celu_OtherNonoperatingIncomeExpenses" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="celu_OperatingIncomeCostsAndExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="celu_ChangeInFairValueOfContingentConsiderationLiability" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10190.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:type="locator" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizationOfInventoryStepUp" xlink:type="locator" xlink:label="celu_AmortizationOfInventoryStepUp" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromPromissoryNote" xlink:type="locator" xlink:label="celu_ProceedsFromPromissoryNote" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromInvestment" xlink:type="locator" xlink:label="celu_ProceedsFromInvestment" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CashReceivedOnRecapitalization" xlink:type="locator" xlink:label="celu_CashReceivedOnRecapitalization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="celu_CashReceivedOnRecapitalization" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="celu_ProceedsFromInvestment" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="celu_ProceedsFromPromissoryNote" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="celu_AmortizationOfInventoryStepUp" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="10250.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="10270.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10280.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10290.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10300.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10320.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10330.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10340.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails" xlink:href="celu-20211231.xsd#Role_DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ConvertibleNoteReceivable" xlink:type="locator" xlink:label="celu_ConvertibleNoteReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityPublicWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilityPublicWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilitySponsorWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilitySponsorWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PreferredStockWarrants" xlink:type="locator" xlink:label="celu_PreferredStockWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="celu_PreferredStockWarrants" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="celu_WarrantLiabilitySponsorWarrants" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="celu_WarrantLiabilityPublicWarrants" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="celu_ConvertibleNoteReceivable" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryFinishedGoodsCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryWorkInProgressCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryWorkInProgressCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryRawMaterialsCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryRawMaterialsCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryReserveCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryReserveCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryGrossCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryGrossCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryNetCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryNetCurrentAndNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryNetCurrentAndNoncurrent" xlink:to="celu_InventoryGrossCurrentAndNoncurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryNetCurrentAndNoncurrent" xlink:to="celu_InventoryReserveCurrentAndNoncurrent" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryGrossCurrentAndNoncurrent" xlink:to="celu_InventoryRawMaterialsCurrentAndNoncurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryGrossCurrentAndNoncurrent" xlink:to="celu_InventoryWorkInProgressCurrentAndNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryGrossCurrentAndNoncurrent" xlink:to="celu_InventoryFinishedGoodsCurrentAndNoncurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2" xlink:href="celu-20211231.xsd#Role_DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryNetCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryNetCurrentAndNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryNetCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="celu_InventoryNetCurrentAndNoncurrent" xlink:to="us-gaap_InventoryNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PrepaidClinicalExpense" xlink:type="locator" xlink:label="celu_PrepaidClinicalExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="celu_PrepaidClinicalExpense" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AccrualsForConstructionInProgress" xlink:type="locator" xlink:label="celu_AccrualsForConstructionInProgress" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AccruedClinicalTrialExpense" xlink:type="locator" xlink:label="celu_AccruedClinicalTrialExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="celu_AccruedClinicalTrialExpense" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="celu_AccrualsForConstructionInProgress" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:type="locator" xlink:label="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:type="locator" xlink:label="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsUnicap" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsUnicap" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsStartupCosts" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsStartupCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="celu_DeferredTaxAssetsStartupCosts" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="celu_DeferredTaxAssetsUnicap" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>39
<FILENAME>celu-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T15:44:19.6352960+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ccfc69a50e5a44e89f9a89b5c642c0de -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="celu-20211231.xsd#TemplateLink" roleURI="http://celularity.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="celu-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiability" xlink:type="locator" xlink:label="celu_WarrantLiability" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsNoncurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsCurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PromissoryNotesReceivable" xlink:type="locator" xlink:label="celu_PromissoryNotesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10360.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="celu_PromissoryNotesReceivable" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNoncurrent" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="celu_FinancingObligationsCurrent" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_FinancingObligationsNoncurrent" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_WarrantLiability" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAbstract" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="11180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherNonoperatingIncomeExpenses" xlink:type="locator" xlink:label="celu_OtherNonoperatingIncomeExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeExpenseRelatedToWarrantLiabilities" xlink:type="locator" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingIncomeCostsAndExpenses" xlink:type="locator" xlink:label="celu_OperatingIncomeCostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:type="locator" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_CostOfRevenueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseRoyaltyAndOtherMember" xlink:type="locator" xlink:label="celu_LicenseRoyaltyAndOtherMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10200.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="celu_LicenseRoyaltyAndOtherMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenueAbstract" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="celu_ChangeInFairValueOfContingentConsiderationLiability" order="11010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="celu_OperatingIncomeCostsAndExpenses" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="celu_IncomeExpenseRelatedToWarrantLiabilities" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="celu_OtherNonoperatingIncomeExpenses" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TemporaryEquityShareIssuanceCosts" xlink:type="locator" xlink:label="celu_TemporaryEquityShareIssuanceCosts" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CariCordIncorporatedMember" xlink:type="locator" xlink:label="celu_CariCordIncorporatedMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicEquityFinancingMember" xlink:type="locator" xlink:label="celu_PublicEquityFinancingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CTHBiosourcingLLCMember" xlink:type="locator" xlink:label="celu_CTHBiosourcingLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_CTHBiosourcingLLCMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PublicEquityFinancingMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_CariCordIncorporatedMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PalantirTechnologiesIncMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_TemporaryEquityShareIssuanceCosts" order="13120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="13960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" xlink:type="locator" xlink:label="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfWarrantsAtEstimatedFairValue" xlink:type="locator" xlink:label="celu_IssuanceOfWarrantsAtEstimatedFairValue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" xlink:type="locator" xlink:label="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" xlink:type="locator" xlink:label="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" xlink:type="locator" xlink:label="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassOfOfferingCostsPaidInPriorYear" xlink:type="locator" xlink:label="celu_ReclassOfOfferingCostsPaidInPriorYear" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassificationOfWarrantLiabilitiesToEquity" xlink:type="locator" xlink:label="celu_ReclassificationOfWarrantLiabilitiesToEquity" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" xlink:type="locator" xlink:label="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityAssumedFromMerger" xlink:type="locator" xlink:label="celu_WarrantLiabilityAssumedFromMerger" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonCashAssetsAcquiredFromMerger" xlink:type="locator" xlink:label="celu_NonCashAssetsAcquiredFromMerger" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CancellationOfTreasuryStock" xlink:type="locator" xlink:label="celu_CancellationOfTreasuryStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationFromMerger" xlink:type="locator" xlink:label="celu_RecapitalizationFromMerger" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromInvestment" xlink:type="locator" xlink:label="celu_ProceedsFromInvestment" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CashReceivedOnRecapitalization" xlink:type="locator" xlink:label="celu_CashReceivedOnRecapitalization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromPromissoryNote" xlink:type="locator" xlink:label="celu_ProceedsFromPromissoryNote" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:type="locator" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizationOfInventoryStepUp" xlink:type="locator" xlink:label="celu_AmortizationOfInventoryStepUp" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXAcquisitionCorpMember" xlink:type="locator" xlink:label="celu_GXAcquisitionCorpMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10350.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="celu_GXAcquisitionCorpMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="celu_AmortizationOfInventoryStepUp" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="celu_ProceedsFromPromissoryNote" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="celu_CashReceivedOnRecapitalization" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="celu_ProceedsFromInvestment" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_RecapitalizationFromMerger" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_CancellationOfTreasuryStock" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_NonCashAssetsAcquiredFromMerger" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_WarrantLiabilityAssumedFromMerger" order="12800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_ReclassificationOfWarrantLiabilitiesToEquity" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_ReclassOfOfferingCostsPaidInPriorYear" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="13040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" order="13120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_IssuanceOfWarrantsAtEstimatedFairValue" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" order="13200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXSponsorWarrantsMember" xlink:type="locator" xlink:label="celu_GXSponsorWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:type="locator" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:type="locator" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_GXSponsorWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" order="10810.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommercialMilestonePayments" xlink:type="locator" xlink:label="celu_CommercialMilestonePayments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RegulatoryMilestones" xlink:type="locator" xlink:label="celu_RegulatoryMilestones" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ContingentValueRightIssuedForEachShare" xlink:type="locator" xlink:label="celu_ContingentValueRightIssuedForEachShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AreaOfBuilding" xlink:type="locator" xlink:label="celu_AreaOfBuilding" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfClinicalTrials" xlink:type="locator" xlink:label="celu_NumberOfClinicalTrials" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationSharesExchangeRatio" xlink:type="locator" xlink:label="celu_BusinessCombinationSharesExchangeRatio" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationSharesExchangeRatioDescription" xlink:type="locator" xlink:label="celu_BusinessCombinationSharesExchangeRatioDescription" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CaricordMember" xlink:type="locator" xlink:label="celu_CaricordMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AlliquaAPAMember" xlink:type="locator" xlink:label="celu_AlliquaAPAMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnthrogenesisMember" xlink:type="locator" xlink:label="celu_AnthrogenesisMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_HLICellularTherapeuticsLLCMember" xlink:type="locator" xlink:label="celu_HLICellularTherapeuticsLLCMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:type="locator" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:type="locator" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_HLICellularTherapeuticsLLCMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_AnthrogenesisMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_AlliquaAPAMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_CaricordMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_BusinessCombinationSharesExchangeRatioDescription" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_BusinessCombinationSharesExchangeRatio" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_NumberOfClinicalTrials" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_AreaOfBuilding" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_ContingentValueRightIssuedForEachShare" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_RegulatoryMilestones" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_CommercialMilestonePayments" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfBusinessSegments" xlink:type="locator" xlink:label="celu_NumberOfBusinessSegments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" xlink:type="locator" xlink:label="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:type="locator" xlink:label="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EquipmentEvaluationPeriod" xlink:type="locator" xlink:label="celu_EquipmentEvaluationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentExpense" xlink:type="locator" xlink:label="us-gaap_EquipmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CustomerTwoMember" xlink:type="locator" xlink:label="celu_CustomerTwoMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OneCustomerMember" xlink:type="locator" xlink:label="celu_OneCustomerMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="celu_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="celu_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="celu_OneCustomerMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="celu_CustomerTwoMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportingUnits" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquipmentExpense" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_EquipmentEvaluationPeriod" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_NumberOfBusinessSegments" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LineOfCredit" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10700.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="locator" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConsiderationDescription" xlink:type="locator" xlink:label="celu_ConsiderationDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfConvertiblePromissoryNote" xlink:type="locator" xlink:label="celu_FairValueOfConvertiblePromissoryNote" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseArrangementTerm" xlink:type="locator" xlink:label="celu_LicenseArrangementTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetPurchaseAgreementDescription" xlink:type="locator" xlink:label="celu_AssetPurchaseAgreementDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SubscriptionAgreementsDescription" xlink:type="locator" xlink:label="celu_SubscriptionAgreementsDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OptionToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="celu_OptionToPurchaseSharesOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrants" xlink:type="locator" xlink:label="celu_FairValueOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessAcquisitionTransactionCostsProceedsNet" xlink:type="locator" xlink:label="celu_BusinessAcquisitionTransactionCostsProceedsNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationExchangeRatioOfCommonStock" xlink:type="locator" xlink:label="celu_BusinessCombinationExchangeRatioOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_CommonStockConversionBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UltraMISTBusinessMember" xlink:type="locator" xlink:label="celu_UltraMISTBusinessMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MISTUltraMISTBusinessMember" xlink:type="locator" xlink:label="celu_MISTUltraMISTBusinessMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXWarrantsMember" xlink:type="locator" xlink:label="celu_GXWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicEquityFinancingMember" xlink:type="locator" xlink:label="celu_PublicEquityFinancingMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXTrustAccountMember" xlink:type="locator" xlink:label="celu_GXTrustAccountMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CelularityMember" xlink:type="locator" xlink:label="celu_CelularityMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SurvivingCorporationMember" xlink:type="locator" xlink:label="celu_SurvivingCorporationMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AlphaFirstMergerSubIncorporationMember" xlink:type="locator" xlink:label="celu_AlphaFirstMergerSubIncorporationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:type="locator" xlink:label="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsLineItems" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_AlphaFirstMergerSubIncorporationMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_SurvivingCorporationMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_CelularityMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_GXTrustAccountMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PublicEquityFinancingMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PalantirTechnologiesIncMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_GXWarrantsMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_MISTUltraMISTBusinessMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="celu_UltraMISTBusinessMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_Goodwill" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessCombinationExchangeRatioOfCommonStock" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessAcquisitionTransactionCostsProceedsNet" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_Liabilities" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_FairValueOfWarrants" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_OptionToPurchaseSharesOfCommonStock" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_SubscriptionAgreementsDescription" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_SharePrice" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_AssetPurchaseAgreementDescription" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_LicenseArrangementTerm" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses" order="12700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_FairValueOfConvertiblePromissoryNote" order="12780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_ConsiderationDescription" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="12900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" order="12940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" order="13000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" order="13020.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityPublicWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilityPublicWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilitySponsorWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilitySponsorWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PreferredStockWarrants" xlink:type="locator" xlink:label="celu_PreferredStockWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConvertibleNoteReceivable" xlink:type="locator" xlink:label="celu_ConvertibleNoteReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="celu_ConvertibleNoteReceivable" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="celu_PreferredStockWarrants" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="celu_WarrantLiabilitySponsorWarrants" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="celu_WarrantLiabilityPublicWarrants" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrants" xlink:type="locator" xlink:label="celu_FairValueOfWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueNetAssetsLiability" xlink:type="locator" xlink:label="celu_FairValueNetAssetsLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_PublicWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_SponsorsWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueNetAssetsLiability" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueOfWarrants" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassificationOfLegacyCelularityWarrantsToEquity" xlink:type="locator" xlink:label="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityAssumedAtClosingDate" xlink:type="locator" xlink:label="celu_WarrantLiabilityAssumedAtClosingDate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:type="locator" xlink:label="celu_GainLossRecognizedInEarningsFromChangeInFairValues" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfWarrant" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfWarrant" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator" xlink:label="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueNetAssetsLiability" xlink:type="locator" xlink:label="celu_FairValueNetAssetsLiability" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_SponsorsWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_PublicWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueNetAssetsLiability" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ProceedsFromIssuanceOfWarrant" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_GainLossRecognizedInEarningsFromChangeInFairValues" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_WarrantLiabilityAssumedAtClosingDate" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" order="10420.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValuesOfCommonStock" xlink:type="locator" xlink:label="celu_FairValuesOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_SponsorsWarrantsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValuesOfCommonStock" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="11200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ClassOfWarrantExercisePriceDescription" xlink:type="locator" xlink:label="celu_ClassOfWarrantExercisePriceDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfExercisePrice" xlink:type="locator" xlink:label="celu_PercentageOfExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_PercentageOfExercisePrice" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ClassOfWarrantExercisePriceDescription" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationInputForConvertiblePromissoryNote" xlink:type="locator" xlink:label="celu_ValuationInputForConvertiblePromissoryNote" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationInputForConvertiblePromissoryNoteTerm" xlink:type="locator" xlink:label="celu_ValuationInputForConvertiblePromissoryNoteTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationModelThatRelateToSanuwaveCommonStock" xlink:type="locator" xlink:label="celu_ValuationModelThatRelateToSanuwaveCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfCouponRate" xlink:type="locator" xlink:label="celu_PercentageOfCouponRate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FaceValueOfNotesReceivable" xlink:type="locator" xlink:label="celu_FaceValueOfNotesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FaceValueOfNotesReceivable" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_PercentageOfCouponRate" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ValuationModelThatRelateToSanuwaveCommonStock" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ValuationInputForConvertiblePromissoryNoteTerm" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ValuationInputForConvertiblePromissoryNote" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MachineryEquipmentAndFixturesMember" xlink:type="locator" xlink:label="celu_MachineryEquipmentAndFixturesMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LaboratoryAndProductionEquipmentMember" xlink:type="locator" xlink:label="celu_LaboratoryAndProductionEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_LaboratoryAndProductionEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_MachineryEquipmentAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionHistoricalCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleLeasebackTransactionHistoricalCost" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" xlink:type="locator" xlink:label="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BiobankingMember" xlink:type="locator" xlink:label="celu_BiobankingMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DegenerativeDiseaseMember" xlink:type="locator" xlink:label="celu_DegenerativeDiseaseMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CellTherapyMember" xlink:type="locator" xlink:label="celu_CellTherapyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_CellTherapyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_DegenerativeDiseaseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_BiobankingMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:type="locator" xlink:label="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AcquiredProductRights" xlink:type="locator" xlink:label="celu_AcquiredProductRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonAmortizedIntangibleAssetsAbstract" xlink:type="locator" xlink:label="celu_NonAmortizedIntangibleAssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LessAccumulatedAmortizationAbstract" xlink:type="locator" xlink:label="celu_LessAccumulatedAmortizationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizableIntangibleAssetsAbstract" xlink:type="locator" xlink:label="celu_AmortizableIntangibleAssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReacquiredRightsMember" xlink:type="locator" xlink:label="celu_ReacquiredRightsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:type="locator" xlink:label="us-gaap_TrademarksAndTradeNamesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksAndTradeNamesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="celu_ReacquiredRightsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_AmortizableIntangibleAssetsAbstract" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_AmortizableIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_LessAccumulatedAmortizationAbstract" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LessAccumulatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LessAccumulatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_NonAmortizedIntangibleAssetsAbstract" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_NonAmortizedIntangibleAssetsAbstract" xlink:to="celu_AcquiredProductRights" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" order="11910.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" xlink:type="locator" xlink:label="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShortTermBorrowingAmountEqualToExitFeePercentage" xlink:type="locator" xlink:label="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CVStarrCoIncMember" xlink:type="locator" xlink:label="celu_CVStarrCoIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LoanAgreementMember" xlink:type="locator" xlink:label="celu_LoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="celu_LoanAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="celu_CVStarrCoIncMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" order="11240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" xlink:type="locator" xlink:label="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" xlink:type="locator" xlink:label="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesIssuedInLegalSettlementAgreement" xlink:type="locator" xlink:label="celu_NumberOfSharesIssuedInLegalSettlementAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementNoticePeriod" xlink:type="locator" xlink:label="celu_LicenseAgreementNoticePeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="locator" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClinicalAndRegulatoryMilestones" xlink:type="locator" xlink:label="celu_ClinicalAndRegulatoryMilestones" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualMaintenanceFee" xlink:type="locator" xlink:label="celu_AnnualMaintenanceFee" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UpfrontFee" xlink:type="locator" xlink:label="celu_UpfrontFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualFeePaid" xlink:type="locator" xlink:label="celu_AnnualFeePaid" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentSubscriptionPeriod" xlink:type="locator" xlink:label="celu_PaymentSubscriptionPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentsForMasterSubscriptionAgreement" xlink:type="locator" xlink:label="celu_PaymentsForMasterSubscriptionAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsCurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsNoncurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InitialMonthlyBaseRent" xlink:type="locator" xlink:label="celu_InitialMonthlyBaseRent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="celu_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OptionToRenewLeaseTermPeriod" xlink:type="locator" xlink:label="celu_OptionToRenewLeaseTermPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AreaOfBuildings" xlink:type="locator" xlink:label="celu_AreaOfBuildings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageIncreaseInBaseAnnualRent" xlink:type="locator" xlink:label="celu_PercentageIncreaseInBaseAnnualRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLeaseExpiryYear" xlink:type="locator" xlink:label="celu_OperatingLeaseExpiryYear" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CariCordParticipatingShareholdersMember" xlink:type="locator" xlink:label="celu_CariCordParticipatingShareholdersMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementMember" xlink:type="locator" xlink:label="celu_LicenseAgreementMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MasterSubscriptionAgreementMember" xlink:type="locator" xlink:label="celu_MasterSubscriptionAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LLCAndAnthrogenesisMember" xlink:type="locator" xlink:label="celu_LLCAndAnthrogenesisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_HLICellularTherapeuticsMember" xlink:type="locator" xlink:label="celu_HLICellularTherapeuticsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FlorhamParkNewJerseyMember" xlink:type="locator" xlink:label="celu_FlorhamParkNewJerseyMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeManufacturingAndLaboratorySpaceMember" xlink:type="locator" xlink:label="celu_OfficeManufacturingAndLaboratorySpaceMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CedarKnollsNewJerseyMember" xlink:type="locator" xlink:label="celu_CedarKnollsNewJerseyMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="celu_OfficeAndLaboratorySpaceMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrenNewJerseyMember" xlink:type="locator" xlink:label="celu_WarrenNewJerseyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeSpaceMember" xlink:type="locator" xlink:label="celu_OfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommitmentsandContingenciesDetailsTable" xlink:type="locator" xlink:label="celu_CommitmentsandContingenciesDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommitmentsandContingenciesDetailsLineItems" xlink:type="locator" xlink:label="celu_CommitmentsandContingenciesDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_CommitmentsandContingenciesDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_OfficeSpaceMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="celu_WarrenNewJerseyMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_OfficeAndLaboratorySpaceMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="celu_CedarKnollsNewJerseyMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_OfficeManufacturingAndLaboratorySpaceMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="celu_FlorhamParkNewJerseyMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="11390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_HLICellularTherapeuticsMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_LLCAndAnthrogenesisMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_PalantirTechnologiesIncMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_MasterSubscriptionAgreementMember" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_LicenseAgreementMember" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_CariCordParticipatingShareholdersMember" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_OperatingLeaseExpiryYear" order="12100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" order="12140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_PercentageIncreaseInBaseAnnualRent" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_AreaOfBuildings" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_OptionToRenewLeaseTermPeriod" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_OperatingLeaseCommencementDate" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_InitialMonthlyBaseRent" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_TenantImprovements" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" order="12730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_FinancingObligationsNoncurrent" order="12770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_FinancingObligationsCurrent" order="12810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="13020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_PaymentsForMasterSubscriptionAgreement" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_PaymentSubscriptionPeriod" order="13150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_AnnualFeePaid" order="13210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="13270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_UpfrontFee" order="13360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_AnnualMaintenanceFee" order="13380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_ClinicalAndRegulatoryMilestones" order="13400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="13420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_LicenseAgreementNoticePeriod" order="13440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_NumberOfSharesIssuedInLegalSettlementAgreement" order="13490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" order="13510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" order="13530.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" xlink:type="locator" xlink:label="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfWarrantCallProvision" xlink:type="locator" xlink:label="celu_DescriptionOfWarrantCallProvision" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MinimumWrittenNoticePeriodForRedemption" xlink:type="locator" xlink:label="celu_MinimumWrittenNoticePeriodForRedemption" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsCallPrice" xlink:type="locator" xlink:label="celu_PublicWarrantsCallPrice" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantExpirationTerm" xlink:type="locator" xlink:label="celu_WarrantExpirationTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClassOfWarrantOrRightWarrantsExercisableForCash" xlink:type="locator" xlink:label="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" xlink:type="locator" xlink:label="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" xlink:type="locator" xlink:label="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfExercisableTerms" xlink:type="locator" xlink:label="celu_DescriptionOfExercisableTerms" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfWarrantsIssued" xlink:type="locator" xlink:label="celu_NumberOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsPerSharePercentage" xlink:type="locator" xlink:label="celu_WarrantsPerSharePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendPaymentTerms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConversionPricePerShareOfCommonStock" xlink:type="locator" xlink:label="celu_ConversionPricePerShareOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesRequiredToBeOutstandingForVoting" xlink:type="locator" xlink:label="celu_NumberOfSharesRequiredToBeOutstandingForVoting" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfSharesRequiredForVoting" xlink:type="locator" xlink:label="celu_PercentageOfSharesRequiredForVoting" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsMember" xlink:type="locator" xlink:label="celu_SponsorsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyGXWarrantMember" xlink:type="locator" xlink:label="celu_LegacyGXWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmendedDragasacWarrantsMember" xlink:type="locator" xlink:label="celu_AmendedDragasacWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmendedAndRestatedDragasacWarrantsMember" xlink:type="locator" xlink:label="celu_AmendedAndRestatedDragasacWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantsMember" xlink:type="locator" xlink:label="celu_DragasacWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemablesConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBPreferredStockPurchaseAgreementsMember" xlink:type="locator" xlink:label="celu_SeriesBPreferredStockPurchaseAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBPreferredStocksPurchaseAgreementsMember" xlink:type="locator" xlink:label="celu_SeriesBPreferredStocksPurchaseAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_StockholdersEquityDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_SeriesBPreferredStocksPurchaseAgreementsMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStocksMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBPreferredStockPurchaseAgreementsMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStocksMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStocksMember" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_DragasacWarrantsMember" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_AmendedAndRestatedDragasacWarrantsMember" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_AmendedDragasacWarrantsMember" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="12600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="12630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="celu_LegacyGXWarrantMember" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_SponsorsMember" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="13040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="13060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="13110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_PercentageOfSharesRequiredForVoting" order="13160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TreasuryStockShares" order="13330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="13400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="13420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="13470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="13490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesSubscribedButUnissued" order="13510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="13560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="13690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_NumberOfSharesRequiredToBeOutstandingForVoting" order="13740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="13790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_ConversionPricePerShareOfCommonStock" order="13810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="13860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="13980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="14020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="14090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="14110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendPaymentTerms" order="14130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="14340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="14810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsPerSharePercentage" order="14850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="14870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="14920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_NumberOfWarrantsIssued" order="14940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_DescriptionOfExercisableTerms" order="15030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="15050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" order="15070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" order="15090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" order="15110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantExpirationTerm" order="15130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_PublicWarrantsCallPrice" order="15180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_MinimumWrittenNoticePeriodForRedemption" order="15230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_DescriptionOfWarrantCallProvision" order="15250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" order="15300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15350.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureEquitySummaryOfWarrantsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_March2020SeriesBWarrantsMember" xlink:type="locator" xlink:label="celu_March2020SeriesBWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_StockholdersEquityDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_DragasacWarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_March2020SeriesBWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_PublicWarrantsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_SponsorWarrantsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10420.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosureEquitySummaryOfWarrantsParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" xlink:type="locator" xlink:label="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsPerSharePercentage" xlink:type="locator" xlink:label="celu_WarrantsPerSharePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_StockholdersEquityDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_DragasacWarrantMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsPerSharePercentage" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UnrecognizedExpenseRelatedToPerformanceAwards" xlink:type="locator" xlink:label="celu_UnrecognizedExpenseRelatedToPerformanceAwards" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardModificationExpense" xlink:type="locator" xlink:label="celu_AwardModificationExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ExpenseRelatedToPerformanceAwards" xlink:type="locator" xlink:label="celu_ExpenseRelatedToPerformanceAwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardsWithMarketConditionsMember" xlink:type="locator" xlink:label="celu_AwardsWithMarketConditionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesTotalMember" xlink:type="locator" xlink:label="us-gaap_LiabilitiesTotalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardsWithServiceConditionsMember" xlink:type="locator" xlink:label="celu_AwardsWithServiceConditionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_StockBasedCompensationDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="celu_AwardsWithServiceConditionsMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_LiabilitiesTotalMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="celu_AwardsWithMarketConditionsMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ExpenseRelatedToPerformanceAwards" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_AwardModificationExpense" order="12510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_UnrecognizedExpenseRelatedToPerformanceAwards" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_StockBasedCompensationDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="13390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13490.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_StockBasedCompensationDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10330.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseRoyaltyAndOtherMember" xlink:type="locator" xlink:label="celu_LicenseRoyaltyAndOtherMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="celu_LicenseRoyaltyAndOtherMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionAdditionalInforrmationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:type="locator" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentPlansForCustomerToPayOverTimePeriod" xlink:type="locator" xlink:label="celu_PaymentPlansForCustomerToPayOverTimePeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ContractedStoragePeriods" xlink:type="locator" xlink:label="celu_ContractedStoragePeriods" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="celu_ContractedStoragePeriods" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="celu_PaymentPlansForCustomerToPayOverTimePeriod" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenuePracticalExpedientFinancingComponent" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DeferredRevenue" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementForecastDescription" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementForecastDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RemainingDuePercentageNetFortyFivePaymentTerm" xlink:type="locator" xlink:label="celu_RemainingDuePercentageNetFortyFivePaymentTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" xlink:type="locator" xlink:label="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MaterialBreachContractTerminatedTerm" xlink:type="locator" xlink:label="celu_MaterialBreachContractTerminatedTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentTermNet" xlink:type="locator" xlink:label="celu_PaymentTermNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DiscountPercentagePaymentForInvoicesWithinTenDays" xlink:type="locator" xlink:label="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementRenewalTerm" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementRenewalTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementPeriod" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualSalesNotExceed" xlink:type="locator" xlink:label="celu_AnnualSalesNotExceed" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualSales" xlink:type="locator" xlink:label="celu_AnnualSales" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementDescription" xlink:type="locator" xlink:label="celu_LicenseAgreementDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicensingArrangementTerm" xlink:type="locator" xlink:label="celu_LicensingArrangementTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReimbursementOfCostUnderLicenseAgreement" xlink:type="locator" xlink:label="celu_ReimbursementOfCostUnderLicenseAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncentivePayment" xlink:type="locator" xlink:label="celu_IncentivePayment" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EvolutionAgreementMember" xlink:type="locator" xlink:label="celu_EvolutionAgreementMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ArthrexAgreementMember" xlink:type="locator" xlink:label="celu_ArthrexAgreementMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SanuwaveLicenseAgreementMember" xlink:type="locator" xlink:label="celu_SanuwaveLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsTable" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsLineItems" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_LicenseAndDistributionAgreementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_LicenseAndDistributionAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_SanuwaveLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_ArthrexAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_EvolutionAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_IncentivePayment" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_ReimbursementOfCostUnderLicenseAgreement" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_LicensingArrangementTerm" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_LicenseAgreementDescription" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_AnnualSales" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_AnnualSalesNotExceed" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementPeriod" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementRenewalTerm" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_PaymentTermNet" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_MaterialBreachContractTerminatedTerm" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_RemainingDuePercentageNetFortyFivePaymentTerm" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementForecastDescription" order="10740.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" xlink:type="locator" xlink:label="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="celu_TaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="celu_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UnitedStatesFederalAndStateMember" xlink:type="locator" xlink:label="celu_UnitedStatesFederalAndStateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="celu_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="celu_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="celu_UnitedStatesFederalAndStateMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_OperatingLossCarryforwardsExpirationYear" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_TaxCreditCarryforwardsExpirationYear" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" order="10630.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:type="locator" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IndirectExpenses" xlink:type="locator" xlink:label="celu_IndirectExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SegmentContribution" xlink:type="locator" xlink:label="celu_SegmentContribution" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:type="locator" xlink:label="us-gaap_DirectOperatingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherMember" xlink:type="locator" xlink:label="celu_OtherMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DegenerativeDiseaseMember" xlink:type="locator" xlink:label="celu_DegenerativeDiseaseMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BiobankingMember" xlink:type="locator" xlink:label="celu_BiobankingMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CellTherapyMember" xlink:type="locator" xlink:label="celu_CellTherapyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_CellTherapyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_BiobankingMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_DegenerativeDiseaseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_OtherMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DirectOperatingCosts" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="celu_SegmentContribution" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="celu_IndirectExpenses" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="celu_ChangeInFairValueOfContingentConsiderationLiability" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AdjustmentForAmortization" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11620.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyFullTimeBaseSalary" xlink:type="locator" xlink:label="celu_RelatedPartyFullTimeBaseSalary" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyPartTimeBaseSalary" xlink:type="locator" xlink:label="celu_RelatedPartyPartTimeBaseSalary" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesHolding" xlink:type="locator" xlink:label="celu_NumberOfSharesHolding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LoanAgreement" xlink:type="locator" xlink:label="celu_LoanAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentsToRelatedParty" xlink:type="locator" xlink:label="celu_PaymentsToRelatedParty" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyCashBonus" xlink:type="locator" xlink:label="celu_RelatedPartyCashBonus" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CashConsiderationPerMonth" xlink:type="locator" xlink:label="celu_CashConsiderationPerMonth" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockOptionsVested" xlink:type="locator" xlink:label="celu_StockOptionsVested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentForMonth" xlink:type="locator" xlink:label="celu_PaymentForMonth" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MrPecoraMember" xlink:type="locator" xlink:label="celu_MrPecoraMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MsHariniMember" xlink:type="locator" xlink:label="celu_MsHariniMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EmploymentOfImmediateFamilyMemberMember" xlink:type="locator" xlink:label="celu_EmploymentOfImmediateFamilyMemberMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockPurchaseAgreementWithDirectorMember" xlink:type="locator" xlink:label="celu_StockPurchaseAgreementWithDirectorMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CVStarLoanMember" xlink:type="locator" xlink:label="celu_CVStarLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CryoportSystemsIncMember" xlink:type="locator" xlink:label="celu_CryoportSystemsIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_COTAIncMember" xlink:type="locator" xlink:label="celu_COTAIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CURAFoundationMember" xlink:type="locator" xlink:label="celu_CURAFoundationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConsultingAgreementWithDoctorAndrewPecoraMember" xlink:type="locator" xlink:label="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyTransactionsDetailsTable" xlink:type="locator" xlink:label="celu_RelatedPartyTransactionsDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyTransactionsDetailsLineItems" xlink:type="locator" xlink:label="celu_RelatedPartyTransactionsDetailsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyTransactionsDetailsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_CURAFoundationMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_COTAIncMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_CryoportSystemsIncMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_CVStarLoanMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_StockPurchaseAgreementWithDirectorMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_EmploymentOfImmediateFamilyMemberMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_MsHariniMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_MrPecoraMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_PaymentForMonth" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_StockOptionsVested" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_CashConsiderationPerMonth" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyCashBonus" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_PaymentsToRelatedParty" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_LoanAgreement" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_NumberOfSharesHolding" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyPartTimeBaseSalary" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyFullTimeBaseSalary" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="12130.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssued" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>40
<FILENAME>celu-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T15:44:19.6372793+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ccfc69a50e5a44e89f9a89b5c642c0de -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConvertibleNoteReceivable" xlink:type="locator" xlink:label="celu_ConvertibleNoteReceivable" />
    <link:label xml:lang="en-US" xlink:label="celu_ConvertibleNoteReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ConvertibleNoteReceivable" xlink:to="celu_ConvertibleNoteReceivable_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PreferredStockWarrants" xlink:type="locator" xlink:label="celu_PreferredStockWarrants" />
    <link:label xml:lang="en-US" xlink:label="celu_PreferredStockWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PreferredStockWarrants" xlink:to="celu_PreferredStockWarrants_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilitySponsorWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilitySponsorWarrants" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilitySponsorWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability Sponsor Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantLiabilitySponsorWarrants" xlink:to="celu_WarrantLiabilitySponsorWarrants_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityPublicWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilityPublicWarrants" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityPublicWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability Public Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantLiabilityPublicWarrants" xlink:to="celu_WarrantLiabilityPublicWarrants_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryGrossCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryGrossCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryGrossCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory, gross current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InventoryGrossCurrentAndNoncurrent" xlink:to="celu_InventoryGrossCurrentAndNoncurrent_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryReserveCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryReserveCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryReserveCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory reserve current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InventoryReserveCurrentAndNoncurrent" xlink:to="celu_InventoryReserveCurrentAndNoncurrent_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class A Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PromissoryNotesReceivable" xlink:type="locator" xlink:label="celu_PromissoryNotesReceivable" />
    <link:label xml:lang="en-US" xlink:label="celu_PromissoryNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">It represents of promissory notes receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PromissoryNotesReceivable" xlink:to="celu_PromissoryNotesReceivable_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsCurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsCurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_FinancingObligationsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing obligations current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FinancingObligationsCurrent" xlink:to="celu_FinancingObligationsCurrent_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsNoncurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_FinancingObligationsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing obligations noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FinancingObligationsNoncurrent" xlink:to="celu_FinancingObligationsNoncurrent_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiability" xlink:type="locator" xlink:label="celu_WarrantLiability" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">This represents the fair value of our warrants at the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantLiability" xlink:to="celu_WarrantLiability_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series X Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net of allowance of $283 and $272 as of December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts And Other Receivables Net Current</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PromissoryNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PromissoryNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Notes Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FinancingObligationsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of financing obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FinancingObligationsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Obligations Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition-related contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FinancingObligationsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FinancingObligationsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financing Obligations Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2021; none authorized, issued and outstanding as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, $0.0001 par value, 730,000,000 shares authorized, 124,307,884 issued and outstanding as of December 31, 2021; 155,640,290 shares authorized, 18,529,453 shares issued and outstanding as of December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Treasury stock, at cost, 0 and 90,834 shares as of December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net of allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allowance For Doubtful Accounts Receivable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, par value (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Shares</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:type="locator" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability" />
    <link:label xml:lang="en-US" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of contingent consideration liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:to="celu_ChangeInFairValueOfContingentConsiderationLiability_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingIncomeCostsAndExpenses" xlink:type="locator" xlink:label="celu_OperatingIncomeCostsAndExpenses" />
    <link:label xml:lang="en-US" xlink:label="celu_OperatingIncomeCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating income costs and expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OperatingIncomeCostsAndExpenses" xlink:to="celu_OperatingIncomeCostsAndExpenses_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeExpenseRelatedToWarrantLiabilities" xlink:type="locator" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities" />
    <link:label xml:lang="en-US" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income expense related to warrant liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IncomeExpenseRelatedToWarrantLiabilities" xlink:to="celu_IncomeExpenseRelatedToWarrantLiabilities_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherNonoperatingIncomeExpenses" xlink:type="locator" xlink:label="celu_OtherNonoperatingIncomeExpenses" />
    <link:label xml:lang="en-US" xlink:label="celu_OtherNonoperatingIncomeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other nonoperating income expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OtherNonoperatingIncomeExpenses" xlink:to="celu_OtherNonoperatingIncomeExpenses_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Sales and Rentals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProductMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseRoyaltyAndOtherMember" xlink:type="locator" xlink:label="celu_LicenseRoyaltyAndOtherMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseRoyaltyAndOtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License, Royalty And Other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseRoyaltyAndOtherMember" xlink:to="celu_LicenseRoyaltyAndOtherMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseRoyaltyAndOtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Royalty and Other</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseRoyaltyAndOtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Royalty And Other [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenues:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_CostOfRevenueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of goods sold (excluding amortization of acquired intangible assets)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Revenue [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Contingent Consideration Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of acquired intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of acquired intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Indefinitelived Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingIncomeCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingIncomeCostsAndExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Costs And Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on the sale of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfBusiness" xlink:to="us-gaap_GainLossOnSaleOfBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Business</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income (expense) related to warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Expense Related To Warrant Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OtherNonoperatingIncomeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income, net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OtherNonoperatingIncomeExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share &#8211; basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding &#8211; basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_TemporaryEquityShareIssuanceCosts" xlink:type="locator" xlink:label="celu_TemporaryEquityShareIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="celu_TemporaryEquityShareIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, share issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_TemporaryEquityShareIssuanceCosts" xlink:to="celu_TemporaryEquityShareIssuanceCosts_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period value new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" />
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" />
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization net of redemptions, equity issuance costs and merger costs shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization net of redemptions, equity issuance costs and merger costs additional paid in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassified from warrant liability to additional paid-in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" xlink:to="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CTHBiosourcingLLCMember" xlink:type="locator" xlink:label="celu_CTHBiosourcingLLCMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CTHBiosourcingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CTH Biosourcing LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CTHBiosourcingLLCMember" xlink:to="celu_CTHBiosourcingLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CTHBiosourcingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CTH</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CTHBiosourcingLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C T H Biosourcing L L C [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicEquityFinancingMember" xlink:type="locator" xlink:label="celu_PublicEquityFinancingMember" />
    <link:label xml:lang="en-US" xlink:label="celu_PublicEquityFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public equity financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PublicEquityFinancingMember" xlink:to="celu_PublicEquityFinancingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PublicEquityFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Investors</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PublicEquityFinancingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Equity Financing [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CariCordIncorporatedMember" xlink:type="locator" xlink:label="celu_CariCordIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CariCordIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CariCord incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CariCordIncorporatedMember" xlink:to="celu_CariCordIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CariCordIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CariCord</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CariCordIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cari Cord Incorporated [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:label xml:lang="en-US" xlink:label="celu_PalantirTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Palantir Technologies, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PalantirTechnologiesIncMember" xlink:to="celu_PalantirTechnologiesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PalantirTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Palantir</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PalantirTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Palantir Technologies Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity, Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Value Acquired Cost Method</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Shares Acquired</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Redeemable Convertible Preferred Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Redeemable Convertible Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of liability classified legacy warrants to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassified From Warrant Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TemporaryEquityShareIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TemporaryEquityShareIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Share Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity, Balance (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in Shares)</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizationOfInventoryStepUp" xlink:type="locator" xlink:label="celu_AmortizationOfInventoryStepUp" />
    <link:label xml:lang="en-US" xlink:label="celu_AmortizationOfInventoryStepUp_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of inventory step-up.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AmortizationOfInventoryStepUp" xlink:to="celu_AmortizationOfInventoryStepUp_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:type="locator" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of net operating losses and research and development tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:to="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromPromissoryNote" xlink:type="locator" xlink:label="celu_ProceedsFromPromissoryNote" />
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromPromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ProceedsFromPromissoryNote" xlink:to="celu_ProceedsFromPromissoryNote_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" xlink:to="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CashReceivedOnRecapitalization" xlink:type="locator" xlink:label="celu_CashReceivedOnRecapitalization" />
    <link:label xml:lang="en-US" xlink:label="celu_CashReceivedOnRecapitalization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received on recapitalization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CashReceivedOnRecapitalization" xlink:to="celu_CashReceivedOnRecapitalization_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromInvestment" xlink:type="locator" xlink:label="celu_ProceedsFromInvestment" />
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from investment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ProceedsFromInvestment" xlink:to="celu_ProceedsFromInvestment_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationFromMerger" xlink:type="locator" xlink:label="celu_RecapitalizationFromMerger" />
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recapitalization from merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecapitalizationFromMerger" xlink:to="celu_RecapitalizationFromMerger_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CancellationOfTreasuryStock" xlink:type="locator" xlink:label="celu_CancellationOfTreasuryStock" />
    <link:label xml:lang="en-US" xlink:label="celu_CancellationOfTreasuryStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cancellation of treasury stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CancellationOfTreasuryStock" xlink:to="celu_CancellationOfTreasuryStock_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonCashAssetsAcquiredFromMerger" xlink:type="locator" xlink:label="celu_NonCashAssetsAcquiredFromMerger" />
    <link:label xml:lang="en-US" xlink:label="celu_NonCashAssetsAcquiredFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash assets acquired from merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NonCashAssetsAcquiredFromMerger" xlink:to="celu_NonCashAssetsAcquiredFromMerger_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityAssumedFromMerger" xlink:type="locator" xlink:label="celu_WarrantLiabilityAssumedFromMerger" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityAssumedFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability assumed from merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantLiabilityAssumedFromMerger" xlink:to="celu_WarrantLiabilityAssumedFromMerger_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" xlink:type="locator" xlink:label="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" />
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock as payment for related costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" xlink:to="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassificationOfWarrantLiabilitiesToEquity" xlink:type="locator" xlink:label="celu_ReclassificationOfWarrantLiabilitiesToEquity" />
    <link:label xml:lang="en-US" xlink:label="celu_ReclassificationOfWarrantLiabilitiesToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liabilities to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReclassificationOfWarrantLiabilitiesToEquity" xlink:to="celu_ReclassificationOfWarrantLiabilitiesToEquity_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassOfOfferingCostsPaidInPriorYear" xlink:type="locator" xlink:label="celu_ReclassOfOfferingCostsPaidInPriorYear" />
    <link:label xml:lang="en-US" xlink:label="celu_ReclassOfOfferingCostsPaidInPriorYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclass of offering costs paid in prior year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReclassOfOfferingCostsPaidInPriorYear" xlink:to="celu_ReclassOfOfferingCostsPaidInPriorYear_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs captured in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" xlink:to="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" xlink:type="locator" xlink:label="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" />
    <link:label xml:lang="en-US" xlink:label="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of asset and financing obligation related to facility build out.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" xlink:to="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" xlink:type="locator" xlink:label="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" />
    <link:label xml:lang="en-US" xlink:label="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">It represents of ultra MIST systems reclass from inventory to fixed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" xlink:to="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" xlink:type="locator" xlink:label="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of Fair value of warrants issued in connection with Series B preferred stock sale.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" xlink:to="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfWarrantsAtEstimatedFairValue" xlink:type="locator" xlink:label="celu_IssuanceOfWarrantsAtEstimatedFairValue" />
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfWarrantsAtEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of warrants at estimated fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IssuanceOfWarrantsAtEstimatedFairValue" xlink:to="celu_IssuanceOfWarrantsAtEstimatedFairValue_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" xlink:type="locator" xlink:label="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" />
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series B convertible preferred stock in connection with CariCord acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" xlink:to="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_GXAcquisitionCorpMember" xlink:type="locator" xlink:label="celu_GXAcquisitionCorpMember" />
    <link:label xml:lang="en-US" xlink:label="celu_GXAcquisitionCorpMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GX Acquisition Corp [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GXAcquisitionCorpMember" xlink:to="celu_GXAcquisitionCorpMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_GXAcquisitionCorpMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gx Acquisition Corp.</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GXAcquisitionCorpMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G X Acquisition Corp [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operations:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Taxes And Tax Credits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Doubtful Accounts</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefits And Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AmortizationOfInventoryStepUp_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of inventory step-up</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AmortizationOfInventoryStepUp_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Inventory Step Up</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle liability with CTH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on sale of business</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Capital Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of net operating losses and research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Net Operating Losses And Research And Development Tax Credits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the sale of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Divestiture Of Businesses Net Of Cash Divested</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromPromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from promissory note</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromPromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Promissory Note</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Series B Redeemable Convertible Preferred Stock And Warrants Net Of Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from short term borrowings - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Related Party Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of short term borrowings - related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Related Party Debt</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CashReceivedOnRecapitalization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received on recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CashReceivedOnRecapitalization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received On Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Palantir investment</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Investment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from PIPE financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Private Placement</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of PIPE/SPAC related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Issuance Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment included in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recapitalization from merger</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecapitalizationFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recapitalization From Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CancellationOfTreasuryStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancellation of treasury stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CancellationOfTreasuryStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cancellation Of Treasury Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NonCashAssetsAcquiredFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash assets acquired from the merger</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NonCashAssetsAcquiredFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Assets Acquired From Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityAssumedFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability assumed from the merger</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityAssumedFromMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Assumed From Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock as payment for PIPE/merger related costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Common Stock As Payment For Related Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassificationOfWarrantLiabilitiesToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liabilities to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassificationOfWarrantLiabilitiesToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liabilities To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassOfOfferingCostsPaidInPriorYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclass of offering costs paid in prior year</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassOfOfferingCostsPaidInPriorYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclass Of Offering Costs Paid In Prior Year</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in PIPE/SPAC related costs in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In P I P E S P A C Related Costs Captured In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of asset and financing obligation related to facility build out</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Asset And Financing Obligation Related To Facility Build Out</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receipt of convertible note in connection with the Sanuwave Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UltraMIST systems reclass from inventory to fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ultra M I S T Systems Reclass From Inventory To Fixed Asset</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued in connection with Series B preferred stock sale</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants Issued In Connection With Serie B Preferred Stock Sale</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfWarrantsAtEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants at estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfWarrantsAtEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Warrants At Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock in connection with CariCord acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Series B Convertible Preferred Stock In Connection With Caricord Acquisition</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated By Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Business and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combinations and disposals disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:to="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsAbstract" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations And Disposals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessCombinationsAndDisposalsAbstract" xlink:to="celu_BusinessCombinationsAndDisposalsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations and Disposals</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations And Disposals Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PrepaidExpensesDisclosureTextBlock" xlink:type="locator" xlink:label="celu_PrepaidExpensesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PrepaidExpensesDisclosureTextBlock" xlink:to="celu_PrepaidExpensesDisclosureTextBlock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Borrowings - Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock Based Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="celu_ScheduleOfStockBasedCompensationExpenseAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsTextBlock" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and Distribution Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAndDistributionAgreementsTextBlock" xlink:to="celu_LicenseAndDistributionAgreementsTextBlock_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsAbstract" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License And Distribution Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAndDistributionAgreementsAbstract" xlink:to="celu_LicenseAndDistributionAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Distribution Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Distribution Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Distribution Agreements [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_RestrictedCashPolicyTextBlock" xlink:type="locator" xlink:label="celu_RestrictedCashPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_RestrictedCashPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RestrictedCashPolicyTextBlock" xlink:to="celu_RestrictedCashPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_RestrictedCashPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RestrictedCashPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Tangible Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetAcquisitionsPolicyTextBlock" xlink:type="locator" xlink:label="celu_AssetAcquisitionsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_AssetAcquisitionsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AssetAcquisitionsPolicyTextBlock" xlink:to="celu_AssetAcquisitionsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AssetAcquisitionsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AssetAcquisitionsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisitions Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Process Research and Development Policy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" xlink:type="locator" xlink:label="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" xlink:to="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Liabilities Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising and Marketing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advertising Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_GovernmentGrantsPolicyTextBlock" xlink:type="locator" xlink:label="celu_GovernmentGrantsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_GovernmentGrantsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Government grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GovernmentGrantsPolicyTextBlock" xlink:to="celu_GovernmentGrantsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_GovernmentGrantsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GovernmentGrantsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Government Grants Policy [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="celu_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PatentCostsPolicyTextBlock" xlink:to="celu_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Significant Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_EmergingGrowthCompanyPolicyTextBlock" xlink:type="locator" xlink:label="celu_EmergingGrowthCompanyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for its emerging growth company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EmergingGrowthCompanyPolicyTextBlock" xlink:to="celu_EmergingGrowthCompanyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EmergingGrowthCompanyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Emerging Growth Company Policy [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="locator" xlink:label="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of assets and liabilities written off of this transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" xlink:to="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combinations and disposals.</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of assets and liabilities were divested/written off</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Assets And Liabilities Written Off Table [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:type="locator" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Financial Assets and Liabilities (Tables) [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:type="locator" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Financial Assets and Liabilities (Tables) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:to="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Of Financial Assets And Liabilities Tables [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Assets And Liabilities Tables [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_GXSponsorWarrantsMember" xlink:type="locator" xlink:label="celu_GXSponsorWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_GXSponsorWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GX sponsor warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GXSponsorWarrantsMember" xlink:to="celu_GXSponsorWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_GXSponsorWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">G X Sponsor Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GXSponsorWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G X Sponsor Warrants [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:label xml:lang="en-US" xlink:label="celu_DragasacWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dragasac warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DragasacWarrantMember" xlink:to="celu_DragasacWarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_DragasacWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dragasac Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DragasacWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dragasac Warrant [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Of Financial Assets And Liabilities Tables [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Assets And Liabilities Tables [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Fair Values of the Warrant Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of Fair value significant inputs for warrants issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:to="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Warrants Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Significant Inputs For Warrants Issued Table [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of convertible note valuation model.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:to="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Convertible Note Valuation Model</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Convertible Note Valuation Model Table [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of inventory current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Major Classes of Inventories</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Inventory Current And Noncurrent Table [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfPrepaidExpensesTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfPrepaidExpensesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of prepaid expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfPrepaidExpensesTableTextBlock" xlink:to="celu_ScheduleOfPrepaidExpensesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfPrepaidExpensesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfIntangibleAssetsNetTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfIntangibleAssetsNetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of intangible assets net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:to="celu_ScheduleOfIntangibleAssetsNetTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfIntangibleAssetsNetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfIntangibleAssetsNetTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets Net Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Aggregate Amortization Expense Related to Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Payments under Non-Cancelable Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of the Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Activity Related to RSU Stock-Based Payment Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Disaggregated Revenue by Product And Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Deferred Revenue from Contract Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue By Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Current and Deferred Tax Provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of the U.S. Federal Statutory Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Deferred Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Information by Segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Segment Reporting Information By Segment [Text Block]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:type="locator" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of Organization and Business Operations (Details) [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:type="locator" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of Organization and Business Operations (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:to="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Organization And Business Operations Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Organization And Business Operations Details [Table]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LegacyCelularitysMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy Celularity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LegacyCelularitysMember" xlink:to="celu_LegacyCelularitysMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LegacyCelularitysMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy Celularity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LegacyCelularitysMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legacy Celularitys [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_HLICellularTherapeuticsLLCMember" xlink:type="locator" xlink:label="celu_HLICellularTherapeuticsLLCMember" />
    <link:label xml:lang="en-US" xlink:label="celu_HLICellularTherapeuticsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">HLI Cellular Therapeutics,LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_HLICellularTherapeuticsLLCMember" xlink:to="celu_HLICellularTherapeuticsLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_HLICellularTherapeuticsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HLI Cellular Therapeutics,LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_HLICellularTherapeuticsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">H L I Cellular Therapeutics L L C [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AnthrogenesisMember" xlink:type="locator" xlink:label="celu_AnthrogenesisMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AnthrogenesisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Anthrogenesis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AnthrogenesisMember" xlink:to="celu_AnthrogenesisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AnthrogenesisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anthrogenesis</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnthrogenesisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Anthrogenesis [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AlliquaAPAMember" xlink:type="locator" xlink:label="celu_AlliquaAPAMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AlliquaAPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Alliqua APA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AlliquaAPAMember" xlink:to="celu_AlliquaAPAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AlliquaAPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alliqua APA</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AlliquaAPAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Alliqua A P A [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CaricordMember" xlink:type="locator" xlink:label="celu_CaricordMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CaricordMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Caricord.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CaricordMember" xlink:to="celu_CaricordMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CaricordMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Caricord</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CaricordMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Caricord [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description Of Organization And Business Operations Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Organization And Business Operations Details [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationSharesExchangeRatioDescription" xlink:type="locator" xlink:label="celu_BusinessCombinationSharesExchangeRatioDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationSharesExchangeRatioDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination shares exchange ratio description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessCombinationSharesExchangeRatioDescription" xlink:to="celu_BusinessCombinationSharesExchangeRatioDescription_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationSharesExchangeRatio" xlink:type="locator" xlink:label="celu_BusinessCombinationSharesExchangeRatio" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationSharesExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination shares exchange ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessCombinationSharesExchangeRatio" xlink:to="celu_BusinessCombinationSharesExchangeRatio_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationSharesExchangeRatioDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, shares exchange ratio description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationSharesExchangeRatioDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Shares Exchange Ratio Description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationSharesExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, shares exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationSharesExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Shares Exchange Ratio</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfClinicalTrials" xlink:type="locator" xlink:label="celu_NumberOfClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfClinicalTrials" xlink:to="celu_NumberOfClinicalTrials_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AreaOfBuilding" xlink:type="locator" xlink:label="celu_AreaOfBuilding" />
    <link:label xml:lang="en-US" xlink:label="celu_AreaOfBuilding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of building.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AreaOfBuilding" xlink:to="celu_AreaOfBuilding_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AreaOfBuilding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of building</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AreaOfBuilding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Building</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of consideration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred1</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ContingentValueRightIssuedForEachShare" xlink:type="locator" xlink:label="celu_ContingentValueRightIssuedForEachShare" />
    <link:label xml:lang="en-US" xlink:label="celu_ContingentValueRightIssuedForEachShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value right issued for each share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ContingentValueRightIssuedForEachShare" xlink:to="celu_ContingentValueRightIssuedForEachShare_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RegulatoryMilestones" xlink:type="locator" xlink:label="celu_RegulatoryMilestones" />
    <link:label xml:lang="en-US" xlink:label="celu_RegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RegulatoryMilestones" xlink:to="celu_RegulatoryMilestones_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommercialMilestonePayments" xlink:type="locator" xlink:label="celu_CommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="celu_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CommercialMilestonePayments" xlink:to="celu_CommercialMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ContingentValueRightIssuedForEachShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value right issued for each share</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ContingentValueRightIssuedForEachShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Right Issued For Each Share</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Substantial doubt about going concern, within one year [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Substantial Doubt About Going Concern Within One Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="celu_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="celu_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="celu_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="celu_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OneCustomerMember" xlink:type="locator" xlink:label="celu_OneCustomerMember" />
    <link:label xml:lang="en-US" xlink:label="celu_OneCustomerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One customer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OneCustomerMember" xlink:to="celu_OneCustomerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_OneCustomerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One Customer</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OneCustomerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Customer [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CustomerTwoMember" xlink:type="locator" xlink:label="celu_CustomerTwoMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CustomerTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CustomerTwoMember" xlink:to="celu_CustomerTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CustomerTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Another customer</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CustomerTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Two [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Building</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software Development [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Estimated Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Estimated Useful Lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reporting units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Reporting Units</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill, impairment loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment Loss</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_EquipmentEvaluationPeriod" xlink:type="locator" xlink:label="celu_EquipmentEvaluationPeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_EquipmentEvaluationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment evaluation period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EquipmentEvaluationPeriod" xlink:to="celu_EquipmentEvaluationPeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentExpense" xlink:type="locator" xlink:label="us-gaap_EquipmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentExpense" xlink:to="us-gaap_EquipmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EquipmentEvaluationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment evaluation period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EquipmentEvaluationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Evaluation Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advertising and Marketing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketing And Advertising Expense</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:type="locator" xlink:label="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" />
    <link:label xml:lang="en-US" xlink:label="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction of research and development expense resulting from grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:to="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of research and development expense resulting from grant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduction Of Research And Development Expense Resulting From Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" xlink:type="locator" xlink:label="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" />
    <link:label xml:lang="en-US" xlink:label="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with the tax authority.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" xlink:to="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with the tax authority</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Recognized Tax Benefit Likelihood Of Being Realized Upon Ultimate Settlement With Tax Authority</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of basic and diluted net income (loss) per ordinary share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:to="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Basic And Diluted Net Income Loss Per Ordinary Share [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfBusinessSegments" xlink:type="locator" xlink:label="celu_NumberOfBusinessSegments" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfBusinessSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of business segments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfBusinessSegments" xlink:to="celu_NumberOfBusinessSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfBusinessSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of business segments</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfBusinessSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Business Segments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCredit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsLineItems" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combinations and disposals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessCombinationsAndDisposalsLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:type="locator" xlink:label="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfBusinessCombinationsAndDisposalsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of business combinations and disposals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="celu_ScheduleOfBusinessCombinationsAndDisposalsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfBusinessCombinationsAndDisposalsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Combinations And Disposals [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfBusinessCombinationsAndDisposalsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Combinations And Disposals [Table]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AlphaFirstMergerSubIncorporationMember" xlink:type="locator" xlink:label="celu_AlphaFirstMergerSubIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AlphaFirstMergerSubIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Alpha First Merger Sub, Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AlphaFirstMergerSubIncorporationMember" xlink:to="celu_AlphaFirstMergerSubIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AlphaFirstMergerSubIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Merger Sub</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AlphaFirstMergerSubIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Alpha First Merger Sub Incorporation [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SurvivingCorporationMember" xlink:type="locator" xlink:label="celu_SurvivingCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SurvivingCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Surviving corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SurvivingCorporationMember" xlink:to="celu_SurvivingCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SurvivingCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Surviving Corporation</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SurvivingCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Surviving Corporation [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CelularityMember" xlink:type="locator" xlink:label="celu_CelularityMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CelularityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Celularity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CelularityMember" xlink:to="celu_CelularityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CelularityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Celularity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CelularityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Celularity [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_GXTrustAccountMember" xlink:type="locator" xlink:label="celu_GXTrustAccountMember" />
    <link:label xml:lang="en-US" xlink:label="celu_GXTrustAccountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GX Trust Account.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GXTrustAccountMember" xlink:to="celu_GXTrustAccountMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_GXTrustAccountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GX Trust Account</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GXTrustAccountMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G X Trust Account [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_GXWarrantsMember" xlink:type="locator" xlink:label="celu_GXWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_GXWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GX Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GXWarrantsMember" xlink:to="celu_GXWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_GXWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GX Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GXWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G X Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MISTUltraMISTBusinessMember" xlink:type="locator" xlink:label="celu_MISTUltraMISTBusinessMember" />
    <link:label xml:lang="en-US" xlink:label="celu_MISTUltraMISTBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MIST Ultra MIST business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MISTUltraMISTBusinessMember" xlink:to="celu_MISTUltraMISTBusinessMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MISTUltraMISTBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">M I S T Ultra M I S T Business</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MISTUltraMISTBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M I S T Ultra M I S T Business [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disposal Group Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Groups Including Discontinued Operations Name [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_UltraMISTBusinessMember" xlink:type="locator" xlink:label="celu_UltraMISTBusinessMember" />
    <link:label xml:lang="en-US" xlink:label="celu_UltraMISTBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">UltraMIST business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_UltraMISTBusinessMember" xlink:to="celu_UltraMISTBusinessMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_UltraMISTBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UltraMIST Business</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UltraMISTBusinessMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ultra M I S T Business [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations and Disposals [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationsAndDisposalsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations And Disposals [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_CommonStockConversionBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of common stock term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Conversion Basis</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationExchangeRatioOfCommonStock" xlink:type="locator" xlink:label="celu_BusinessCombinationExchangeRatioOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationExchangeRatioOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination, exchange ratio of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessCombinationExchangeRatioOfCommonStock" xlink:to="celu_BusinessCombinationExchangeRatioOfCommonStock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIntangibleAssetsNet" xlink:to="us-gaap_OtherIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Intangible Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationExchangeRatioOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Each one Shares reflecting as exchange ratio in business combination</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessCombinationExchangeRatioOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Exchange Ratio Of Common Stock</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessAcquisitionTransactionCostsProceedsNet" xlink:type="locator" xlink:label="celu_BusinessAcquisitionTransactionCostsProceedsNet" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessAcquisitionTransactionCostsProceedsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition transaction costs proceeds, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessAcquisitionTransactionCostsProceedsNet" xlink:to="celu_BusinessAcquisitionTransactionCostsProceedsNet_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" xlink:to="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_BusinessAcquisitionTransactionCostsProceedsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition transaction costs proceeds, net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessAcquisitionTransactionCostsProceedsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Transaction Costs Proceeds Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, transaction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Cost Of Acquired Entity Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Transaction Costs Relating To Merger By Issuance Of Common Stock Offset Against Additional Paid In Capital</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrants" xlink:type="locator" xlink:label="celu_FairValueOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValueOfWarrants" xlink:to="celu_FairValueOfWarrants_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant or Right, Reason for Issuance, Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Reason For Issuing To Nonemployees</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Warrants</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OptionToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="celu_OptionToPurchaseSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_OptionToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to purchase shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OptionToPurchaseSharesOfCommonStock" xlink:to="celu_OptionToPurchaseSharesOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_OptionToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OptionToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option To Purchase Shares Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding to purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SubscriptionAgreementsDescription" xlink:type="locator" xlink:label="celu_SubscriptionAgreementsDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_SubscriptionAgreementsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subscription Agreements, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SubscriptionAgreementsDescription" xlink:to="celu_SubscriptionAgreementsDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SubscriptionAgreementsDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreements Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Number Of Shares Issued In Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate purchase price</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseArrangementTerm" xlink:type="locator" xlink:label="celu_LicenseArrangementTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseArrangementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License arrangement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseArrangementTerm" xlink:to="celu_LicenseArrangementTerm_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfConvertiblePromissoryNote" xlink:type="locator" xlink:label="celu_FairValueOfConvertiblePromissoryNote" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfConvertiblePromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of the convertible promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValueOfConvertiblePromissoryNote" xlink:to="celu_FairValueOfConvertiblePromissoryNote_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetPurchaseAgreementDescription" xlink:type="locator" xlink:label="celu_AssetPurchaseAgreementDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_AssetPurchaseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of asset purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AssetPurchaseAgreementDescription" xlink:to="celu_AssetPurchaseAgreementDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AssetPurchaseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset purchase agreement, description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AssetPurchaseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Purchase Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseArrangementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License arrangement term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseArrangementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Arrangement Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Divestiture Of Businesses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration financed through convertible promissory note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred Liabilities Incurred</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory note due date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible promissory note conversion date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionDate" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Date</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfConvertiblePromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of convertible promissory note</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfConvertiblePromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Convertible Promissory Note</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetsDivestedAbstract" xlink:type="locator" xlink:label="celu_AssetsDivestedAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_AssetsDivestedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets Divested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AssetsDivestedAbstract" xlink:to="celu_AssetsDivestedAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AssetsDivestedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets Divested</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AssetsDivestedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Divested [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Inventory1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Goodwill1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets divested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Of Disposal Group Including Discontinued Operation</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ConsiderationDescription" xlink:type="locator" xlink:label="celu_ConsiderationDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_ConsiderationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ConsiderationDescription" xlink:to="celu_ConsiderationDescription_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" />
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation discount rate of discounted cash flow.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" />
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation tax rate of discounted cash flow.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" />
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation long term growth rate of discounted cash flow.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" />
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disposal group including discontinued operation professional fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ConsiderationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration, description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ConsiderationDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consideration Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount rate of discounted cash flow</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Discount Rate Of Discounted Cash Flow</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax rate of discounted cash flow</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Tax Rate Of Discounted Cash Flow</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term growth rate of discounted cash flow</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Long Term Growth Rate Of Discounted Cash Flow</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="locator" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on sale of business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Not Discontinued Operation Gain Loss On Disposal</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disposal Group Including Discontinued Operation Professional Fees</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents - money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ConvertibleNoteReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible note receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ConvertibleNoteReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Contingent consideration obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PreferredStockWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PreferredStockWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilitySponsorWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability - Sponsor Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilitySponsorWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Sponsor Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityPublicWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability - Public Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityPublicWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Public Warrants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_PublicWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PublicWarrantsMember" xlink:to="celu_PublicWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PublicWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PublicWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SponsorsWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsors warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SponsorsWarrantsMember" xlink:to="celu_SponsorsWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SponsorsWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsors Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SponsorsWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sponsors Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 1 to level 2 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, level 2 to level 1 transfers, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers into level 3, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value, assets, transfers out of level 3, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ContingentConsiderationObligation" xlink:type="locator" xlink:label="celu_ContingentConsiderationObligation" />
    <link:label xml:lang="en-US" xlink:label="celu_ContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liability exceeding amount recognized Fair Value Measurements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ContingentConsiderationObligation" xlink:to="celu_ContingentConsiderationObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Obligation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net transfers into (out of) Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases, settlements and other net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueNetAssetsLiability" xlink:type="locator" xlink:label="celu_FairValueNetAssetsLiability" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueNetAssetsLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of asset after deduction of liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValueNetAssetsLiability" xlink:to="celu_FairValueNetAssetsLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueNetAssetsLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of the warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueNetAssetsLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Net Assets Liability</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator" xlink:label="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <link:label xml:lang="en-US" xlink:label="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of preferred stock and warrants for common stock issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfWarrant" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfWarrant" />
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromIssuanceOfWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ProceedsFromIssuanceOfWarrant" xlink:to="celu_ProceedsFromIssuanceOfWarrant_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:type="locator" xlink:label="celu_GainLossRecognizedInEarningsFromChangeInFairValues" />
    <link:label xml:lang="en-US" xlink:label="celu_GainLossRecognizedInEarningsFromChangeInFairValues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) recognized in earnings from change in fair values.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:to="celu_GainLossRecognizedInEarningsFromChangeInFairValues_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityAssumedAtClosingDate" xlink:type="locator" xlink:label="celu_WarrantLiabilityAssumedAtClosingDate" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityAssumedAtClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability assumed at closing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantLiabilityAssumedAtClosingDate" xlink:to="celu_WarrantLiabilityAssumedAtClosingDate_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassificationOfLegacyCelularityWarrantsToEquity" xlink:type="locator" xlink:label="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" />
    <link:label xml:lang="en-US" xlink:label="celu_ReclassificationOfLegacyCelularityWarrantsToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of Legacy Celularity Warrants to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" xlink:to="celu_ReclassificationOfLegacyCelularityWarrantsToEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValueNetAssetsLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants issued in connection with Series B preferred stock sale</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issued During Period Value Preferred Stock And Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromIssuanceOfWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrant at fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ProceedsFromIssuanceOfWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GainLossRecognizedInEarningsFromChangeInFairValues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (Loss) recognized in earnings from change in fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GainLossRecognizedInEarningsFromChangeInFairValues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss Recognized In Earnings From Change In Fair Values</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityAssumedAtClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability assumed at Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantLiabilityAssumedAtClosingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Assumed At Closing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassificationOfLegacyCelularityWarrantsToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of Legacy Celularity Warrants to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReclassificationOfLegacyCelularityWarrantsToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Legacy Celularity Warrants To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueNetAssetsLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValueOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Fair value of warrants</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValuesOfCommonStock" xlink:type="locator" xlink:label="celu_FairValuesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_FairValuesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FairValuesOfCommonStock" xlink:to="celu_FairValuesOfCommonStock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValuesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FairValuesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Values Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Measurement Input</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Term</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfExercisePrice" xlink:type="locator" xlink:label="celu_PercentageOfExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PercentageOfExercisePrice" xlink:to="celu_PercentageOfExercisePrice_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClassOfWarrantExercisePriceDescription" xlink:type="locator" xlink:label="celu_ClassOfWarrantExercisePriceDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_ClassOfWarrantExercisePriceDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant exercise price, description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ClassOfWarrantExercisePriceDescription" xlink:to="celu_ClassOfWarrantExercisePriceDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of exercise price</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ClassOfWarrantExercisePriceDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price, description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ClassOfWarrantExercisePriceDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Exercise Price Description</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_FaceValueOfNotesReceivable" xlink:type="locator" xlink:label="celu_FaceValueOfNotesReceivable" />
    <link:label xml:lang="en-US" xlink:label="celu_FaceValueOfNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of face value of notes receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FaceValueOfNotesReceivable" xlink:to="celu_FaceValueOfNotesReceivable_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfCouponRate" xlink:type="locator" xlink:label="celu_PercentageOfCouponRate" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfCouponRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Coupon rate is the rate of interest paid by bond issuers on the bond&#8217;s face value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PercentageOfCouponRate" xlink:to="celu_PercentageOfCouponRate_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationModelThatRelateToSanuwaveCommonStock" xlink:type="locator" xlink:label="celu_ValuationModelThatRelateToSanuwaveCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_ValuationModelThatRelateToSanuwaveCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation model that relate to sanuwave common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ValuationModelThatRelateToSanuwaveCommonStock" xlink:to="celu_ValuationModelThatRelateToSanuwaveCommonStock_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationInputForConvertiblePromissoryNoteTerm" xlink:type="locator" xlink:label="celu_ValuationInputForConvertiblePromissoryNoteTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_ValuationInputForConvertiblePromissoryNoteTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation input for a convertible promissory note term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ValuationInputForConvertiblePromissoryNoteTerm" xlink:to="celu_ValuationInputForConvertiblePromissoryNoteTerm_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationInputForConvertiblePromissoryNote" xlink:type="locator" xlink:label="celu_ValuationInputForConvertiblePromissoryNote" />
    <link:label xml:lang="en-US" xlink:label="celu_ValuationInputForConvertiblePromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Valuation input for a convertible promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ValuationInputForConvertiblePromissoryNote" xlink:to="celu_ValuationInputForConvertiblePromissoryNote_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_FaceValueOfNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Face value</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FaceValueOfNotesReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Face Value Of Notes Receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfCouponRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Coupon rate</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfCouponRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Coupon Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ValuationModelThatRelateToSanuwaveCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ValuationModelThatRelateToSanuwaveCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Model That Relate To Sanuwave Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ValuationInputForConvertiblePromissoryNoteTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term (years)</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ValuationInputForConvertiblePromissoryNoteTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Input For Convertible Promissory Note Term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ValuationInputForConvertiblePromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation input for convertible note</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ValuationInputForConvertiblePromissoryNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Input For Convertible Promissory Note</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryRawMaterialsCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryRawMaterialsCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryRawMaterialsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory raw materials current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InventoryRawMaterialsCurrentAndNoncurrent" xlink:to="celu_InventoryRawMaterialsCurrentAndNoncurrent_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryWorkInProgressCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryWorkInProgressCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryWorkInProgressCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory work in progress current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InventoryWorkInProgressCurrentAndNoncurrent" xlink:to="celu_InventoryWorkInProgressCurrentAndNoncurrent_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryFinishedGoodsCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryFinishedGoodsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory finished goods current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:to="celu_InventoryFinishedGoodsCurrentAndNoncurrent_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryNetCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryNetCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryNetCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory, net current and noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InventoryNetCurrentAndNoncurrent" xlink:to="celu_InventoryNetCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_InventoryRawMaterialsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryRawMaterialsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Raw Materials Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryWorkInProgressCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work in progress</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryWorkInProgressCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Work In Progress Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryFinishedGoodsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryFinishedGoodsCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Finished Goods Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryGrossCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, gross</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryGrossCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Gross Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryReserveCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: inventory reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryReserveCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Reserve Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryNetCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InventoryNetCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net Current And Noncurrent</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PrepaidClinicalExpense" xlink:type="locator" xlink:label="celu_PrepaidClinicalExpense" />
    <link:label xml:lang="en-US" xlink:label="celu_PrepaidClinicalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid clinical expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PrepaidClinicalExpense" xlink:to="celu_PrepaidClinicalExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PrepaidClinicalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid clinical expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PrepaidClinicalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Clinical Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LaboratoryAndProductionEquipmentMember" xlink:type="locator" xlink:label="celu_LaboratoryAndProductionEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LaboratoryAndProductionEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory and production equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LaboratoryAndProductionEquipmentMember" xlink:to="celu_LaboratoryAndProductionEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LaboratoryAndProductionEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and Production Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LaboratoryAndProductionEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory And Production Equipment [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MachineryEquipmentAndFixturesMember" xlink:type="locator" xlink:label="celu_MachineryEquipmentAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="celu_MachineryEquipmentAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Machinery, equipment and fixtures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MachineryEquipmentAndFixturesMember" xlink:to="celu_MachineryEquipmentAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MachineryEquipmentAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery, Equipment and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MachineryEquipmentAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery Equipment And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionHistoricalCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleLeasebackTransactionHistoricalCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale leaseback transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:to="us-gaap_SaleLeasebackTransactionHistoricalCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleLeasebackTransactionHistoricalCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Leaseback Transaction Historical Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale leaseback transaction, accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:to="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Leaseback Transaction Accumulated Depreciation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" xlink:type="locator" xlink:label="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" />
    <link:label xml:lang="en-US" xlink:label="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill derecognition of goodwill related to sale of UltraMIST business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" xlink:to="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Business Segments [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CellTherapyMember" xlink:type="locator" xlink:label="celu_CellTherapyMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CellTherapyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cell Therapy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CellTherapyMember" xlink:to="celu_CellTherapyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CellTherapyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cell Therapy [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DegenerativeDiseaseMember" xlink:type="locator" xlink:label="celu_DegenerativeDiseaseMember" />
    <link:label xml:lang="en-US" xlink:label="celu_DegenerativeDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Degenerative Disease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DegenerativeDiseaseMember" xlink:to="celu_DegenerativeDiseaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_DegenerativeDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Degenerative Disease [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_BiobankingMember" xlink:type="locator" xlink:label="celu_BiobankingMember" />
    <link:label xml:lang="en-US" xlink:label="celu_BiobankingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biobanking</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_BiobankingMember" xlink:to="celu_BiobankingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_BiobankingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biobanking [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Derecognition of goodwill related to sale of UltraMIST business</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Derecognition Of Goodwill Related To Sale Of Ultra M I S T Business</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AcquiredProductRights" xlink:type="locator" xlink:label="celu_AcquiredProductRights" />
    <link:label xml:lang="en-US" xlink:label="celu_AcquiredProductRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of acquired IPR&amp;D product rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AcquiredProductRights" xlink:to="celu_AcquiredProductRights_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizableIntangibleAssetsAbstract" xlink:type="locator" xlink:label="celu_AmortizableIntangibleAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_AmortizableIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortizable intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AmortizableIntangibleAssetsAbstract" xlink:to="celu_AmortizableIntangibleAssetsAbstract_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LessAccumulatedAmortizationAbstract" xlink:type="locator" xlink:label="celu_LessAccumulatedAmortizationAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_LessAccumulatedAmortizationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Less accumulated amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LessAccumulatedAmortizationAbstract" xlink:to="celu_LessAccumulatedAmortizationAbstract_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonAmortizedIntangibleAssetsAbstract" xlink:type="locator" xlink:label="celu_NonAmortizedIntangibleAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_NonAmortizedIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Amortized intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NonAmortizedIntangibleAssetsAbstract" xlink:to="celu_NonAmortizedIntangibleAssetsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed Technology</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Relationships</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Relationships [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:type="locator" xlink:label="us-gaap_TrademarksAndTradeNamesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade Names &amp; Trademarks</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksAndTradeNamesMember" xlink:to="us-gaap_TrademarksAndTradeNamesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trademarks And Trade Names [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ReacquiredRightsMember" xlink:type="locator" xlink:label="celu_ReacquiredRightsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_ReacquiredRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reacquired rights.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReacquiredRightsMember" xlink:to="celu_ReacquiredRightsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ReacquiredRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reacquired Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReacquiredRightsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reacquired Rights [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AmortizableIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortizable intangible assets:</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AmortizableIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortizable Intangible Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortizable intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LessAccumulatedAmortizationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LessAccumulatedAmortizationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Less Accumulated Amortization [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortizable intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NonAmortizedIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-amortized intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NonAmortizedIntangibleAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Amortized Intangible Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AcquiredProductRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired IPR&amp;D product rights</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AcquiredProductRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Product Rights</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:type="locator" xlink:label="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" />
    <link:label xml:lang="en-US" xlink:label="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite lived intangible assets amortization method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Amortization Method</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Impairment of acquired intangibles</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AccruedClinicalTrialExpense" xlink:type="locator" xlink:label="celu_AccruedClinicalTrialExpense" />
    <link:label xml:lang="en-US" xlink:label="celu_AccruedClinicalTrialExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AccruedClinicalTrialExpense" xlink:to="celu_AccruedClinicalTrialExpense_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AccrualsForConstructionInProgress" xlink:type="locator" xlink:label="celu_AccrualsForConstructionInProgress" />
    <link:label xml:lang="en-US" xlink:label="celu_AccrualsForConstructionInProgress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accruals for construction in progress.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AccrualsForConstructionInProgress" xlink:to="celu_AccrualsForConstructionInProgress_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AccruedClinicalTrialExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expense</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AccruedClinicalTrialExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued wages, bonuses, commissions and vacation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AccrualsForConstructionInProgress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals for construction in progress</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AccrualsForConstructionInProgress_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accruals For Construction In Progress</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ShortTermBorrowingAmountEqualToExitFeePercentage" xlink:type="locator" xlink:label="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" />
    <link:label xml:lang="en-US" xlink:label="celu_ShortTermBorrowingAmountEqualToExitFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term borrowing amount equal to exit fee percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" xlink:to="celu_ShortTermBorrowingAmountEqualToExitFeePercentage_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LoanAgreementMember" xlink:type="locator" xlink:label="celu_LoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LoanAgreementMember" xlink:to="celu_LoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lender Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of Credit Facility, Lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Lender [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CVStarrCoIncMember" xlink:type="locator" xlink:label="celu_CVStarrCoIncMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CVStarrCoIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">C.V. Starr &amp; Co., Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CVStarrCoIncMember" xlink:to="celu_CVStarrCoIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CVStarrCoIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CV Starr</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CVStarrCoIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C V Starr Co Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan outstanding principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShortTermBorrowingAmountEqualToExitFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term borrowings exit fee</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShortTermBorrowingAmountEqualToExitFeePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Borrowing Amount Equal To Exit Fee Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of consecutive business days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Threshold Trading Days</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional borrowings under the loan agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" xlink:type="locator" xlink:label="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" />
    <link:label xml:lang="en-US" xlink:label="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayments of short term debt including accrued interest and exit fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" xlink:to="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of short term debt including accrued interest and exit fee</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Short Term Debt Including Accrued Interest And Exit Fee</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLeaseExpiryYear" xlink:type="locator" xlink:label="celu_OperatingLeaseExpiryYear" />
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLeaseExpiryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiry year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OperatingLeaseExpiryYear" xlink:to="celu_OperatingLeaseExpiryYear_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommitmentsandContingenciesDetailsTable" xlink:type="locator" xlink:label="celu_CommitmentsandContingenciesDetailsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_CommitmentsandContingenciesDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitmentsand Contingencies Details [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="celu_CommitmentsandContingenciesDetailsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CommitmentsandContingenciesDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitmentsand Contingencies Details [Table]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeSpaceMember" xlink:type="locator" xlink:label="celu_OfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="celu_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OfficeSpaceMember" xlink:to="celu_OfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrenNewJerseyMember" xlink:type="locator" xlink:label="celu_WarrenNewJerseyMember" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrenNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warren New Jersey.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrenNewJerseyMember" xlink:to="celu_WarrenNewJerseyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrenNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warren, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrenNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warren New Jersey [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="celu_OfficeAndLaboratorySpaceMember" />
    <link:label xml:lang="en-US" xlink:label="celu_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OfficeAndLaboratorySpaceMember" xlink:to="celu_OfficeAndLaboratorySpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CedarKnollsNewJerseyMember" xlink:type="locator" xlink:label="celu_CedarKnollsNewJerseyMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CedarKnollsNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cedar Knolls New Jersey.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CedarKnollsNewJerseyMember" xlink:to="celu_CedarKnollsNewJerseyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CedarKnollsNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cedar Knolls, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CedarKnollsNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cedar Knolls New Jersey [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeManufacturingAndLaboratorySpaceMember" xlink:type="locator" xlink:label="celu_OfficeManufacturingAndLaboratorySpaceMember" />
    <link:label xml:lang="en-US" xlink:label="celu_OfficeManufacturingAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office manufacturing and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OfficeManufacturingAndLaboratorySpaceMember" xlink:to="celu_OfficeManufacturingAndLaboratorySpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_OfficeManufacturingAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office, Manufacturing and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OfficeManufacturingAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Manufacturing And Laboratory Space [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_FlorhamParkNewJerseyMember" xlink:type="locator" xlink:label="celu_FlorhamParkNewJerseyMember" />
    <link:label xml:lang="en-US" xlink:label="celu_FlorhamParkNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Florham Park New Jersey.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_FlorhamParkNewJerseyMember" xlink:to="celu_FlorhamParkNewJerseyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_FlorhamParkNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Florham Park, New Jersey</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_FlorhamParkNewJerseyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Florham Park New Jersey [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_HLICellularTherapeuticsMember" xlink:type="locator" xlink:label="celu_HLICellularTherapeuticsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_HLICellularTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">HLICellularTherapeuticsMember</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_HLICellularTherapeuticsMember" xlink:to="celu_HLICellularTherapeuticsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_HLICellularTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HLI Cellular Therapeutics, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_HLICellularTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">H L I Cellular Therapeutics [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LLCAndAnthrogenesisMember" xlink:type="locator" xlink:label="celu_LLCAndAnthrogenesisMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LLCAndAnthrogenesisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">LLCAndAnthrogenesisMember</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LLCAndAnthrogenesisMember" xlink:to="celu_LLCAndAnthrogenesisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LLCAndAnthrogenesisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anthrogenesis</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LLCAndAnthrogenesisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">L L C And Anthrogenesis [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PalantirTechnologiesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Palantir Technologies Inc</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MasterSubscriptionAgreementMember" xlink:type="locator" xlink:label="celu_MasterSubscriptionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="celu_MasterSubscriptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master subscription agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MasterSubscriptionAgreementMember" xlink:to="celu_MasterSubscriptionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MasterSubscriptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Subscription Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MasterSubscriptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Subscription Agreement [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementMember" xlink:type="locator" xlink:label="celu_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAgreementMember" xlink:to="celu_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sirion License</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CariCordParticipatingShareholdersMember" xlink:type="locator" xlink:label="celu_CariCordParticipatingShareholdersMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CariCordParticipatingShareholdersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CariCord participating shareholders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CariCordParticipatingShareholdersMember" xlink:to="celu_CariCordParticipatingShareholdersMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CariCordParticipatingShareholdersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CariCord Participating Shareholders</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CariCordParticipatingShareholdersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cari Cord Participating Shareholders [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CommitmentsandContingenciesDetailsLineItems" xlink:type="locator" xlink:label="celu_CommitmentsandContingenciesDetailsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_CommitmentsandContingenciesDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Details [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_CommitmentsandContingenciesDetailsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CommitmentsandContingenciesDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitmentsand Contingencies Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLeaseExpiryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiry year</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLeaseExpiryYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiry Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents Current</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageIncreaseInBaseAnnualRent" xlink:type="locator" xlink:label="celu_PercentageIncreaseInBaseAnnualRent" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageIncreaseInBaseAnnualRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage increase in base annual rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PercentageIncreaseInBaseAnnualRent" xlink:to="celu_PercentageIncreaseInBaseAnnualRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageIncreaseInBaseAnnualRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage increase in base annual rent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PercentageIncreaseInBaseAnnualRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Increase In Base Annual Rent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Monthly lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AreaOfBuildings" xlink:type="locator" xlink:label="celu_AreaOfBuildings" />
    <link:label xml:lang="en-US" xlink:label="celu_AreaOfBuildings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of building.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AreaOfBuildings" xlink:to="celu_AreaOfBuildings_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OptionToRenewLeaseTermPeriod" xlink:type="locator" xlink:label="celu_OptionToRenewLeaseTermPeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_OptionToRenewLeaseTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to renew lease term period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OptionToRenewLeaseTermPeriod" xlink:to="celu_OptionToRenewLeaseTermPeriod_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="celu_OperatingLeaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OperatingLeaseCommencementDate" xlink:to="celu_OperatingLeaseCommencementDate_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InitialMonthlyBaseRent" xlink:type="locator" xlink:label="celu_InitialMonthlyBaseRent" />
    <link:label xml:lang="en-US" xlink:label="celu_InitialMonthlyBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial monthly base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_InitialMonthlyBaseRent" xlink:to="celu_InitialMonthlyBaseRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AreaOfBuildings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of building</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AreaOfBuildings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Buildings</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OptionToRenewLeaseTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to renew lease term period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OptionToRenewLeaseTermPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option To Renew Lease Term Period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InitialMonthlyBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial monthly base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_InitialMonthlyBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Monthly Base Rent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction-in-progress property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of future minimum payments under non-cancelable operating leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Payments Under Non Cancelable Operating Leases [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent consideration</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualFeePaid" xlink:type="locator" xlink:label="celu_AnnualFeePaid" />
    <link:label xml:lang="en-US" xlink:label="celu_AnnualFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual fee paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AnnualFeePaid" xlink:to="celu_AnnualFeePaid_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentsForMasterSubscriptionAgreement" xlink:type="locator" xlink:label="celu_PaymentsForMasterSubscriptionAgreement" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentsForMasterSubscriptionAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for master subscription agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PaymentsForMasterSubscriptionAgreement" xlink:to="celu_PaymentsForMasterSubscriptionAgreement_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentSubscriptionPeriod" xlink:type="locator" xlink:label="celu_PaymentSubscriptionPeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentSubscriptionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment subscription period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PaymentSubscriptionPeriod" xlink:to="celu_PaymentSubscriptionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentsForMasterSubscriptionAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for master subscription agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentsForMasterSubscriptionAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Master Subscription Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentSubscriptionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment subscription period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentSubscriptionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Subscription Period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnnualFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual fee paid</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnnualFeePaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Fee Paid</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs related to straight line basis agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses Related Party</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_UpfrontFee" xlink:type="locator" xlink:label="celu_UpfrontFee" />
    <link:label xml:lang="en-US" xlink:label="celu_UpfrontFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_UpfrontFee" xlink:to="celu_UpfrontFee_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualMaintenanceFee" xlink:type="locator" xlink:label="celu_AnnualMaintenanceFee" />
    <link:label xml:lang="en-US" xlink:label="celu_AnnualMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual maintenance fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AnnualMaintenanceFee" xlink:to="celu_AnnualMaintenanceFee_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClinicalAndRegulatoryMilestones" xlink:type="locator" xlink:label="celu_ClinicalAndRegulatoryMilestones" />
    <link:label xml:lang="en-US" xlink:label="celu_ClinicalAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ClinicalAndRegulatoryMilestones" xlink:to="celu_ClinicalAndRegulatoryMilestones_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementNoticePeriod" xlink:type="locator" xlink:label="celu_LicenseAgreementNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAgreementNoticePeriod" xlink:to="celu_LicenseAgreementNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_UpfrontFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UpfrontFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnnualMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual maintenance fee</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnnualMaintenanceFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Maintenance Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ClinicalAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and regulatory milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ClinicalAndRegulatoryMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="locator" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Purchase Commitment Period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Notice Period</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesIssuedInLegalSettlementAgreement" xlink:type="locator" xlink:label="celu_NumberOfSharesIssuedInLegalSettlementAgreement" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesIssuedInLegalSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued in legal settlement agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfSharesIssuedInLegalSettlementAgreement" xlink:to="celu_NumberOfSharesIssuedInLegalSettlementAgreement_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" xlink:type="locator" xlink:label="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional shares to be issued if certain targets are met under settlement agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" xlink:to="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" xlink:type="locator" xlink:label="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" />
    <link:label xml:lang="en-US" xlink:label="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of shares issued under legal settlement agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" xlink:to="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesIssuedInLegalSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued in legal settlement agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesIssuedInLegalSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Issued In Legal Settlement Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of shares issued in settlement agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of Shares Issued Under Legal Settlement Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares to be issued if certain targets are met under settlement agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Shares To Be Issued If Certain Targets Are Met Under Settlement Agreement</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_StockholdersEquityDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders&#8217; Equity (Details) [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_StockholdersEquityDetailsLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_StockholdersEquityDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders&#8217; Equity (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="celu_StockholdersEquityDetailsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_StockholdersEquityDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockholdersEquityDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Details [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBPreferredStocksPurchaseAgreementsMember" xlink:type="locator" xlink:label="celu_SeriesBPreferredStocksPurchaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBPreferredStocksPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B preferred stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesBPreferredStocksPurchaseAgreementsMember" xlink:to="celu_SeriesBPreferredStocksPurchaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBPreferredStocksPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBPreferredStocksPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stocks Purchase Agreements [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStocksMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesBRedeemableConvertiblePreferredStocksMember" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStocksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBPreferredStockPurchaseAgreementsMember" xlink:type="locator" xlink:label="celu_SeriesBPreferredStockPurchaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBPreferredStockPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B preferred stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesBPreferredStockPurchaseAgreementsMember" xlink:to="celu_SeriesBPreferredStockPurchaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBPreferredStockPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBPreferredStockPurchaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock Purchase Agreements [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStocksMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesARedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesARedeemableConvertiblePreferredStocksMember" xlink:to="celu_SeriesARedeemableConvertiblePreferredStocksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesARedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stocks</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesARedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStocksMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series X redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesXRedeemableConvertiblePreferredStocksMember" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStocksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series X Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series X Redeemable Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemablesConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemablesConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" xlink:to="celu_SeriesBRedeemablesConvertiblePreferredStocksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemablesConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SeriesBRedeemablesConvertiblePreferredStocksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemables Convertible Preferred Stocks [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantsMember" xlink:type="locator" xlink:label="celu_DragasacWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_DragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dragasac warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DragasacWarrantsMember" xlink:to="celu_DragasacWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_DragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dragasac Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dragasac Warrants [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AmendedAndRestatedDragasacWarrantsMember" xlink:type="locator" xlink:label="celu_AmendedAndRestatedDragasacWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AmendedAndRestatedDragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated Dragasac warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AmendedAndRestatedDragasacWarrantsMember" xlink:to="celu_AmendedAndRestatedDragasacWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AmendedAndRestatedDragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated Dragasac Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AmendedAndRestatedDragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Dragasac Warrants [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AmendedDragasacWarrantsMember" xlink:type="locator" xlink:label="celu_AmendedDragasacWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AmendedDragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Dragasac warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AmendedDragasacWarrantsMember" xlink:to="celu_AmendedDragasacWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AmendedDragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Dragasac Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AmendedDragasacWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended Dragasac Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investor [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyGXWarrantMember" xlink:type="locator" xlink:label="celu_LegacyGXWarrantMember" />
    <link:label xml:lang="en-US" xlink:label="celu_LegacyGXWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Legacy GX warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LegacyGXWarrantMember" xlink:to="celu_LegacyGXWarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LegacyGXWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legacy GX Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LegacyGXWarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legacy G X Warrant [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsMember" xlink:type="locator" xlink:label="celu_SponsorsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SponsorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information related to sponsors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SponsorsMember" xlink:to="celu_SponsorsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SponsorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SponsorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sponsors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockholdersEquityDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockholdersEquityDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Details [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfSharesRequiredForVoting" xlink:type="locator" xlink:label="celu_PercentageOfSharesRequiredForVoting" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfSharesRequiredForVoting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares required for voting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PercentageOfSharesRequiredForVoting" xlink:to="celu_PercentageOfSharesRequiredForVoting_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfSharesRequiredForVoting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares required for voting</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfSharesRequiredForVoting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Shares Required For Voting</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase redeemable convertible preferred stock, shares authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares undesignated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:to="us-gaap_TemporaryEquitySharesSubscribedButUnissued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Subscribed But Unissued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of equity and warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, voting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockVotingRights" xlink:to="us-gaap_PreferredStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Voting Rights</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesRequiredToBeOutstandingForVoting" xlink:type="locator" xlink:label="celu_NumberOfSharesRequiredToBeOutstandingForVoting" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesRequiredToBeOutstandingForVoting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares required to be outstanding for voting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfSharesRequiredToBeOutstandingForVoting" xlink:to="celu_NumberOfSharesRequiredToBeOutstandingForVoting_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesRequiredToBeOutstandingForVoting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares required to be outstanding for voting</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesRequiredToBeOutstandingForVoting_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Required To Be Outstanding For Voting</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ConversionPricePerShareOfCommonStock" xlink:type="locator" xlink:label="celu_ConversionPricePerShareOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_ConversionPricePerShareOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion price per share of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ConversionPricePerShareOfCommonStock" xlink:to="celu_ConversionPricePerShareOfCommonStock_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ConversionPricePerShareOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ConversionPricePerShareOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Per Share Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Terms Of Conversion</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion ratio of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Conversion Ratio</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend accrued on preferred stock, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash dividends declared or paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Preferred Stock Cash</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock dividend payment description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendPaymentTerms" xlink:to="us-gaap_PreferredStockDividendPaymentTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Payment Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Exercise price of warrant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from warrants exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsPerSharePercentage" xlink:type="locator" xlink:label="celu_WarrantsPerSharePercentage" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsPerSharePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants per share, percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantsPerSharePercentage" xlink:to="celu_WarrantsPerSharePercentage_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsPerSharePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants per share, percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsPerSharePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Per Share Percentage</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfWarrantsIssued" xlink:type="locator" xlink:label="celu_NumberOfWarrantsIssued" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfWarrantsIssued" xlink:to="celu_NumberOfWarrantsIssued_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued to the investors</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfWarrantsIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Warrants Issued</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfExercisableTerms" xlink:type="locator" xlink:label="celu_DescriptionOfExercisableTerms" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfExercisableTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of various exercisable terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DescriptionOfExercisableTerms" xlink:to="celu_DescriptionOfExercisableTerms_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" xlink:type="locator" xlink:label="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercisable period after completion of business combination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" xlink:to="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" xlink:type="locator" xlink:label="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants exercisable period from effective date of initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" xlink:to="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClassOfWarrantOrRightWarrantsExercisableForCash" xlink:type="locator" xlink:label="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" />
    <link:label xml:lang="en-US" xlink:label="celu_ClassOfWarrantOrRightWarrantsExercisableForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right warrants exercisable for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" xlink:to="celu_ClassOfWarrantOrRightWarrantsExercisableForCash_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantExpirationTerm" xlink:type="locator" xlink:label="celu_WarrantExpirationTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_WarrantExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Represent information warrant expiration term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_WarrantExpirationTerm" xlink:to="celu_WarrantExpirationTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfExercisableTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of exercisable terms</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfExercisableTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Exercisable Terms</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable period after consummation of business combination</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercisable Period After Completion Of Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercisable period from effective date of registration statement of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Exercisable Period From Effective Date Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ClassOfWarrantOrRightWarrantsExercisableForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public warrants exercisable for cash</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ClassOfWarrantOrRightWarrantsExercisableForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Warrants Exercisable For Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_WarrantExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Expiration Term</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsCallPrice" xlink:type="locator" xlink:label="celu_PublicWarrantsCallPrice" />
    <link:label xml:lang="en-US" xlink:label="celu_PublicWarrantsCallPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public warrants call price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PublicWarrantsCallPrice" xlink:to="celu_PublicWarrantsCallPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PublicWarrantsCallPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Call price of public warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PublicWarrantsCallPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Warrants Call Price</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MinimumWrittenNoticePeriodForRedemption" xlink:type="locator" xlink:label="celu_MinimumWrittenNoticePeriodForRedemption" />
    <link:label xml:lang="en-US" xlink:label="celu_MinimumWrittenNoticePeriodForRedemption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum written notice period for redemption.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MinimumWrittenNoticePeriodForRedemption" xlink:to="celu_MinimumWrittenNoticePeriodForRedemption_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfWarrantCallProvision" xlink:type="locator" xlink:label="celu_DescriptionOfWarrantCallProvision" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfWarrantCallProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of warrant call provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DescriptionOfWarrantCallProvision" xlink:to="celu_DescriptionOfWarrantCallProvision_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MinimumWrittenNoticePeriodForRedemption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum prior written notice period for redemption</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MinimumWrittenNoticePeriodForRedemption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Written Notice Period For Redemption</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfWarrantCallProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of call provision</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfWarrantCallProvision_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Warrant Call Provision</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" xlink:type="locator" xlink:label="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" />
    <link:label xml:lang="en-US" xlink:label="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate number of warrants issued as repayment for working capital loans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" xlink:to="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of warrants issued to sponsor as repayment for working capital loans</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Number Of Warrants Issued As Repayment For Working Capital Loans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_March2020SeriesBWarrantsMember" xlink:type="locator" xlink:label="celu_March2020SeriesBWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_March2020SeriesBWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2020 Series B Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_March2020SeriesBWarrantsMember" xlink:to="celu_March2020SeriesBWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_March2020SeriesBWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">March2020 Series B Warrants [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SponsorWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsor warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SponsorWarrantsMember" xlink:to="celu_SponsorWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SponsorWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sponsor Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SponsorWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sponsor Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Maturity Date</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" xlink:type="locator" xlink:label="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The description about exercise price and number of shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" xlink:to="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of exercise price</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Exercise Price And Number Of Shares Of Common Stock</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, number of shares issued for future issuance automatic increase period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_StockBasedCompensationDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Details [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="celu_StockBasedCompensationDetailsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_StockBasedCompensationDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation Details [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="celu_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and seventeen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="celu_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardsWithServiceConditionsMember" xlink:type="locator" xlink:label="celu_AwardsWithServiceConditionsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AwardsWithServiceConditionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Awards with service conditions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AwardsWithServiceConditionsMember" xlink:to="celu_AwardsWithServiceConditionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AwardsWithServiceConditionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards with Service Conditions</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AwardsWithServiceConditionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Awards With Service Conditions [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesTotalMember" xlink:type="locator" xlink:label="us-gaap_LiabilitiesTotalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesTotalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesTotalMember" xlink:to="us-gaap_LiabilitiesTotalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesTotalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Total [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardsWithMarketConditionsMember" xlink:type="locator" xlink:label="celu_AwardsWithMarketConditionsMember" />
    <link:label xml:lang="en-US" xlink:label="celu_AwardsWithMarketConditionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Awards with market conditions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AwardsWithMarketConditionsMember" xlink:to="celu_AwardsWithMarketConditionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AwardsWithMarketConditionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Awards with Market Conditions</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AwardsWithMarketConditionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Awards With Market Conditions [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After 1 Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After 2 Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_StockBasedCompensationDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Details [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_StockBasedCompensationDetailsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_StockBasedCompensationDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Based Compensation Details [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares remaining available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares issued from outstanding capital stock, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued for future issuance automatic increase period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued For Future Issuance Automatic Increase Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option, expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant-date fair value of stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockOptionsActivityAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockOptionsActivityAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfStockOptionsActivityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of stock options activity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfStockOptionsActivityAbstract" xlink:to="celu_ScheduleOfStockOptionsActivityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfStockOptionsActivityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock Options Activity [Abstract]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one and two thousand and seventeen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan and 2017 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One And Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options opening balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contract life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contract life, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average contract life, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested options to acquire shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested options to acquire per share (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" />
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, award vesting rights on closing date, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" />
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, award vesting rights over four year, percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage on closing date</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights On Closing Date Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage over four years</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights Over Four Year Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment awards accelerated the recognition of expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, stock option exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercised, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercised, value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost for options issued (in Dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted-average amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ExpenseRelatedToPerformanceAwards" xlink:type="locator" xlink:label="celu_ExpenseRelatedToPerformanceAwards" />
    <link:label xml:lang="en-US" xlink:label="celu_ExpenseRelatedToPerformanceAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expense related to the performance awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ExpenseRelatedToPerformanceAwards" xlink:to="celu_ExpenseRelatedToPerformanceAwards_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UnrecognizedExpenseRelatedToPerformanceAwards" xlink:type="locator" xlink:label="celu_UnrecognizedExpenseRelatedToPerformanceAwards" />
    <link:label xml:lang="en-US" xlink:label="celu_UnrecognizedExpenseRelatedToPerformanceAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized expense related to performance awards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_UnrecognizedExpenseRelatedToPerformanceAwards" xlink:to="celu_UnrecognizedExpenseRelatedToPerformanceAwards_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardModificationExpense" xlink:type="locator" xlink:label="celu_AwardModificationExpense" />
    <link:label xml:lang="en-US" xlink:label="celu_AwardModificationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Award modification expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AwardModificationExpense" xlink:to="celu_AwardModificationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ExpenseRelatedToPerformanceAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to performance awards</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ExpenseRelatedToPerformanceAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expense Related To Performance Awards</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AwardModificationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award modification expense</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AwardModificationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Modification Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UnrecognizedExpenseRelatedToPerformanceAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized expense related to performance awards</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UnrecognizedExpenseRelatedToPerformanceAwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Expense Related To Performance Awards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Closing price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Outstanding opening balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Outstanding ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, ending balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrecognized expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Goods Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:type="locator" xlink:label="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability increase decrease for contract from business combination and deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:to="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferral of revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Recognition of unearned revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferral of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining deferred revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ContractedStoragePeriods" xlink:type="locator" xlink:label="celu_ContractedStoragePeriods" />
    <link:label xml:lang="en-US" xlink:label="celu_ContractedStoragePeriods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contracted storage periods.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ContractedStoragePeriods" xlink:to="celu_ContractedStoragePeriods_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ContractedStoragePeriods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contracted storage periods</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ContractedStoragePeriods_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contracted Storage Periods</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentPlansForCustomerToPayOverTimePeriod" xlink:type="locator" xlink:label="celu_PaymentPlansForCustomerToPayOverTimePeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentPlansForCustomerToPayOverTimePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment plans for customer to pay over time period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PaymentPlansForCustomerToPayOverTimePeriod" xlink:to="celu_PaymentPlansForCustomerToPayOverTimePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentPlansForCustomerToPayOverTimePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment plans for customer to pay over time period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentPlansForCustomerToPayOverTimePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Plans For Customer To Pay Over Time Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:type="locator" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, practical expedient, financing component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:to="us-gaap_RevenuePracticalExpedientFinancingComponent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Practical Expedient Financing Component</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_IncentivePayment" xlink:type="locator" xlink:label="celu_IncentivePayment" />
    <link:label xml:lang="en-US" xlink:label="celu_IncentivePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IncentivePayment" xlink:to="celu_IncentivePayment_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsLineItems" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and distribution agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_LicenseAndDistributionAgreementsLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsTable" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and distribution agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAndDistributionAgreementsTable" xlink:to="celu_LicenseAndDistributionAgreementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License And Distribution Agreements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Distribution Agreements [Table]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SanuwaveLicenseAgreementMember" xlink:type="locator" xlink:label="celu_SanuwaveLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="celu_SanuwaveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sanuwave license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SanuwaveLicenseAgreementMember" xlink:to="celu_SanuwaveLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SanuwaveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sanuwave License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SanuwaveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sanuwave License Agreement [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ArthrexAgreementMember" xlink:type="locator" xlink:label="celu_ArthrexAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="celu_ArthrexAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Arthrex agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ArthrexAgreementMember" xlink:to="celu_ArthrexAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ArthrexAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arthrex Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ArthrexAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arthrex Agreement [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_EvolutionAgreementMember" xlink:type="locator" xlink:label="celu_EvolutionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="celu_EvolutionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Evolution agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EvolutionAgreementMember" xlink:to="celu_EvolutionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_EvolutionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Evolution Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EvolutionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Evolution Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License And Distribution Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAndDistributionAgreementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Distribution Agreements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncentivePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive payment</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncentivePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Payment</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ReimbursementOfCostUnderLicenseAgreement" xlink:type="locator" xlink:label="celu_ReimbursementOfCostUnderLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="celu_ReimbursementOfCostUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement of cost under license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ReimbursementOfCostUnderLicenseAgreement" xlink:to="celu_ReimbursementOfCostUnderLicenseAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ReimbursementOfCostUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement for enrolled patients in related clinical studies</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ReimbursementOfCostUnderLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Of Cost Under License Agreement</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LicensingArrangementTerm" xlink:type="locator" xlink:label="celu_LicensingArrangementTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_LicensingArrangementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing arrangement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicensingArrangementTerm" xlink:to="celu_LicensingArrangementTerm_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualSales" xlink:type="locator" xlink:label="celu_AnnualSales" />
    <link:label xml:lang="en-US" xlink:label="celu_AnnualSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of annual sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AnnualSales" xlink:to="celu_AnnualSales_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LicensingArrangementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing arrangement term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LicensingArrangementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Arrangement Term</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementDescription" xlink:type="locator" xlink:label="celu_LicenseAgreementDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LicenseAgreementDescription" xlink:to="celu_LicenseAgreementDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LicenseAgreementDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnnualSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual sales</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_AnnualSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Sales</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualSalesNotExceed" xlink:type="locator" xlink:label="celu_AnnualSalesNotExceed" />
    <link:label xml:lang="en-US" xlink:label="celu_AnnualSalesNotExceed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual sales not exceed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_AnnualSalesNotExceed" xlink:to="celu_AnnualSalesNotExceed_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_AnnualSalesNotExceed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Sales Not Exceed</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementPeriod" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementPeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply and distribution agreement period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SupplyAndDistributionAgreementPeriod" xlink:to="celu_SupplyAndDistributionAgreementPeriod_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementRenewalTerm" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply and distribution agreement renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SupplyAndDistributionAgreementRenewalTerm" xlink:to="celu_SupplyAndDistributionAgreementRenewalTerm_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DiscountPercentagePaymentForInvoicesWithinTenDays" xlink:type="locator" xlink:label="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" />
    <link:label xml:lang="en-US" xlink:label="celu_DiscountPercentagePaymentForInvoicesWithinTenDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Discount percentage, payment for Invoices within ten days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" xlink:to="celu_DiscountPercentagePaymentForInvoicesWithinTenDays_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentTermNet" xlink:type="locator" xlink:label="celu_PaymentTermNet" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentTermNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment term, net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PaymentTermNet" xlink:to="celu_PaymentTermNet_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MaterialBreachContractTerminatedTerm" xlink:type="locator" xlink:label="celu_MaterialBreachContractTerminatedTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_MaterialBreachContractTerminatedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Material breach, contract terminated term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MaterialBreachContractTerminatedTerm" xlink:to="celu_MaterialBreachContractTerminatedTerm_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply and distribution agreement non-renewal notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" xlink:to="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply and distribution agreement period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply And Distribution Agreement Period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply and distribution agreement renewal term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply And Distribution Agreement Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply and distribution agreement non-renewal notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply And Distribution Agreement Non Renewal Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DiscountPercentagePaymentForInvoicesWithinTenDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount percentage, payment for invoices within ten days</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DiscountPercentagePaymentForInvoicesWithinTenDays_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discount Percentage Payment For Invoices Within Ten Days</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentTermNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment term, net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentTermNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Term Net</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MaterialBreachContractTerminatedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material breach, contract terminated term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MaterialBreachContractTerminatedTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Material Breach Contract Terminated Term</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" xlink:type="locator" xlink:label="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payment upon receipt and acceptance of purchase order.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" xlink:to="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RemainingDuePercentageNetFortyFivePaymentTerm" xlink:type="locator" xlink:label="celu_RemainingDuePercentageNetFortyFivePaymentTerm" />
    <link:label xml:lang="en-US" xlink:label="celu_RemainingDuePercentageNetFortyFivePaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining due percentage, net forty-five payment term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RemainingDuePercentageNetFortyFivePaymentTerm" xlink:to="celu_RemainingDuePercentageNetFortyFivePaymentTerm_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementForecastDescription" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementForecastDescription" />
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementForecastDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply and distribution agreement, forecast description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SupplyAndDistributionAgreementForecastDescription" xlink:to="celu_SupplyAndDistributionAgreementForecastDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of payment upon receipt and acceptance of purchase order</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payment Upon Receipt And Acceptance Of Purchase Order</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RemainingDuePercentageNetFortyFivePaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining due percentage, net forty five payment term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RemainingDuePercentageNetFortyFivePaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Due Percentage Net Forty Five Payment Term</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementForecastDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply and distribution agreement, forecast description</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SupplyAndDistributionAgreementForecastDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supply And Distribution Agreement Forecast Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributions made to the plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfIncomeTaxProvisionAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfIncomeTaxProvisionAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfIncomeTaxProvisionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of income tax provision [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="celu_ScheduleOfIncomeTaxProvisionAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfIncomeTaxProvisionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Tax Provision [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current income tax expense (benefit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax expense (benefit):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total (benefit) from income taxes</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:type="locator" xlink:label="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" />
    <link:label xml:lang="en-US" xlink:label="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation interest accretion expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:to="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:type="locator" xlink:label="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" />
    <link:label xml:lang="en-US" xlink:label="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation mark to market warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:to="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:type="locator" xlink:label="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule reconciliation of the federal income tax [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Reconciliation Of The Federal Income Tax [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest accretion expense</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Interest Accretion Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mark to market warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Mark To Market Warrant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Reconciling Items Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsStartupCosts" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsStartupCosts" />
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsStartupCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets startup costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DeferredTaxAssetsStartupCosts" xlink:to="celu_DeferredTaxAssetsStartupCosts_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsUnicap" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsUnicap" />
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsUnicap_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets unicap.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DeferredTaxAssetsUnicap" xlink:to="celu_DeferredTaxAssetsUnicap_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" />
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsImputedInterestOnContingentPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets imputed interest on contingent payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:to="celu_DeferredTaxAssetsImputedInterestOnContingentPayments_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets legal fee capitalization and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:to="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities in-process research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfNetDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfNetDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of net deferred tax assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="celu_ScheduleOfNetDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfNetDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Net Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research And Development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsStartupCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Startup costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsStartupCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Startup Costs</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsUnicap_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unicap</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsUnicap_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Unicap</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsImputedInterestOnContingentPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Imputed interest on contingent payments</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsImputedInterestOnContingentPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Imputed Interest On Contingent Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fee capitalization and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Legal Fee Capitalization And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">In-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities In Process Research And Development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Uncertainties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase related to current year tax provisions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2020</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="celu_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OperatingLossCarryforwardsExpirationYear" xlink:to="celu_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="celu_TaxCreditCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="celu_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_TaxCreditCarryforwardsExpirationYear" xlink:to="celu_TaxCreditCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="celu_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="celu_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="celu_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IncomeTaxDisclosureTable" xlink:to="celu_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_UnitedStatesFederalAndStateMember" xlink:type="locator" xlink:label="celu_UnitedStatesFederalAndStateMember" />
    <link:label xml:lang="en-US" xlink:label="celu_UnitedStatesFederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">United States federal and state.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_UnitedStatesFederalAndStateMember" xlink:to="celu_UnitedStatesFederalAndStateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_UnitedStatesFederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Federal and State</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_UnitedStatesFederalAndStateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">United States Federal And State [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration Year</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" xlink:type="locator" xlink:label="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" />
    <link:label xml:lang="en-US" xlink:label="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating losses and unused research and development tax credits sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" xlink:to="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses and unused R&amp;D tax credits sold</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Losses And Unused Research And Development Tax Credits Sold</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_SegmentContribution" xlink:type="locator" xlink:label="celu_SegmentContribution" />
    <link:label xml:lang="en-US" xlink:label="celu_SegmentContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Segment contribution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_SegmentContribution" xlink:to="celu_SegmentContribution_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IndirectExpenses" xlink:type="locator" xlink:label="celu_IndirectExpenses" />
    <link:label xml:lang="en-US" xlink:label="celu_IndirectExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of indirect expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_IndirectExpenses" xlink:to="celu_IndirectExpenses_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFinancialInformationBySegmentAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfFinancialInformationBySegmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFinancialInformationBySegmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financial information by segment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ScheduleOfFinancialInformationBySegmentAbstract" xlink:to="celu_ScheduleOfFinancialInformationBySegmentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ScheduleOfFinancialInformationBySegmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financial Information By Segment [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Segment Reporting Information By Segment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CellTherapyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cell Therapy</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_BiobankingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biobanking</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_DegenerativeDiseaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Degenerative Disease</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherMember" xlink:type="locator" xlink:label="celu_OtherMember" />
    <link:label xml:lang="en-US" xlink:label="celu_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_OtherMember" xlink:to="celu_OtherMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_OtherMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:type="locator" xlink:label="us-gaap_DirectOperatingCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DirectOperatingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCosts" xlink:to="us-gaap_DirectOperatingCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DirectOperatingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Direct Operating Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SegmentContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment contribution</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_SegmentContribution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Contribution</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IndirectExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indirect expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_IndirectExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indirect Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Components of other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of acquired intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Finitelived</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment For Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentForMonth" xlink:type="locator" xlink:label="celu_PaymentForMonth" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentForMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for month.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PaymentForMonth" xlink:to="celu_PaymentForMonth_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockOptionsVested" xlink:type="locator" xlink:label="celu_StockOptionsVested" />
    <link:label xml:lang="en-US" xlink:label="celu_StockOptionsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options vested.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockOptionsVested" xlink:to="celu_StockOptionsVested_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyTransactionsDetailsLineItems" xlink:type="locator" xlink:label="celu_RelatedPartyTransactionsDetailsLineItems" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyTransactionsDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transactions (Details) [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyTransactionsDetailsLineItems_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyTransactionsDetailsTable" xlink:type="locator" xlink:label="celu_RelatedPartyTransactionsDetailsTable" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyTransactionsDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transactions (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="celu_RelatedPartyTransactionsDetailsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyTransactionsDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyTransactionsDetailsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Details [Table]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_ConsultingAgreementWithDoctorAndrewPecoraMember" xlink:type="locator" xlink:label="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" />
    <link:label xml:lang="en-US" xlink:label="celu_ConsultingAgreementWithDoctorAndrewPecoraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consulting agreement with doctor Andrew Pecora.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" xlink:to="celu_ConsultingAgreementWithDoctorAndrewPecoraMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_ConsultingAgreementWithDoctorAndrewPecoraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting Agreement with Dr. Andrew Pecora</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_ConsultingAgreementWithDoctorAndrewPecoraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consulting Agreement With Doctor Andrew Pecora [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CURAFoundationMember" xlink:type="locator" xlink:label="celu_CURAFoundationMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CURAFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CURA Foundation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CURAFoundationMember" xlink:to="celu_CURAFoundationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CURAFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURA Foundation</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CURAFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C U R A Foundation [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_COTAIncMember" xlink:type="locator" xlink:label="celu_COTAIncMember" />
    <link:label xml:lang="en-US" xlink:label="celu_COTAIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COTA, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_COTAIncMember" xlink:to="celu_COTAIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_COTAIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COTA, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_COTAIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O T A Inc [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CryoportSystemsIncMember" xlink:type="locator" xlink:label="celu_CryoportSystemsIncMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CryoportSystemsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cryoport Systems, Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CryoportSystemsIncMember" xlink:to="celu_CryoportSystemsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CryoportSystemsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cryoport Systems, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CryoportSystemsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cryoport Systems Inc [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CVStarLoanMember" xlink:type="locator" xlink:label="celu_CVStarLoanMember" />
    <link:label xml:lang="en-US" xlink:label="celu_CVStarLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CV star loan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CVStarLoanMember" xlink:to="celu_CVStarLoanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CVStarLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CV Star Loan</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CVStarLoanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C V Star Loan [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_StockPurchaseAgreementWithDirectorMember" xlink:type="locator" xlink:label="celu_StockPurchaseAgreementWithDirectorMember" />
    <link:label xml:lang="en-US" xlink:label="celu_StockPurchaseAgreementWithDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock purchase agreement with a director.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_StockPurchaseAgreementWithDirectorMember" xlink:to="celu_StockPurchaseAgreementWithDirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_StockPurchaseAgreementWithDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement with a Director</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockPurchaseAgreementWithDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement With Director [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_EmploymentOfImmediateFamilyMemberMember" xlink:type="locator" xlink:label="celu_EmploymentOfImmediateFamilyMemberMember" />
    <link:label xml:lang="en-US" xlink:label="celu_EmploymentOfImmediateFamilyMemberMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employment of an immediate family member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_EmploymentOfImmediateFamilyMemberMember" xlink:to="celu_EmploymentOfImmediateFamilyMemberMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_EmploymentOfImmediateFamilyMemberMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employment of an Immediate Family Member</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_EmploymentOfImmediateFamilyMemberMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employment Of Immediate Family Member [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MsHariniMember" xlink:type="locator" xlink:label="celu_MsHariniMember" />
    <link:label xml:lang="en-US" xlink:label="celu_MsHariniMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ms.Harini.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MsHariniMember" xlink:to="celu_MsHariniMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MsHariniMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ms. Harini</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MsHariniMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ms Harini [Member]</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_MrPecoraMember" xlink:type="locator" xlink:label="celu_MrPecoraMember" />
    <link:label xml:lang="en-US" xlink:label="celu_MrPecoraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Mr.Pecora.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_MrPecoraMember" xlink:to="celu_MrPecoraMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_MrPecoraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mr. Pecora</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_MrPecoraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mr Pecora [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyTransactionsDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyTransactionsDetailsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentForMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for month</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentForMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Month</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockOptionsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Options vested</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_StockOptionsVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Vested</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_CashConsiderationPerMonth" xlink:type="locator" xlink:label="celu_CashConsiderationPerMonth" />
    <link:label xml:lang="en-US" xlink:label="celu_CashConsiderationPerMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash consideration per month.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_CashConsiderationPerMonth" xlink:to="celu_CashConsiderationPerMonth_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyCashBonus" xlink:type="locator" xlink:label="celu_RelatedPartyCashBonus" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyCashBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Cash Bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RelatedPartyCashBonus" xlink:to="celu_RelatedPartyCashBonus_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonqualified stock option to purchase shares of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" xlink:to="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_CashConsiderationPerMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash consideration per month</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_CashConsiderationPerMonth_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Consideration Per Month</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyCashBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyCashBonus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Cash Bonus</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonqualified stock option to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonqualified Stock Option To Purchase Shares Of Common Stock</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentsToRelatedParty" xlink:type="locator" xlink:label="celu_PaymentsToRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentsToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_PaymentsToRelatedParty" xlink:to="celu_PaymentsToRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_PaymentsToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount paid</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_PaymentsToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Related Party</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contribution made</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Amounts Of Transaction</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_LoanAgreement" xlink:type="locator" xlink:label="celu_LoanAgreement" />
    <link:label xml:lang="en-US" xlink:label="celu_LoanAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_LoanAgreement" xlink:to="celu_LoanAgreement_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesHolding" xlink:type="locator" xlink:label="celu_NumberOfSharesHolding" />
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesHolding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares holding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_NumberOfSharesHolding" xlink:to="celu_NumberOfSharesHolding_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_LoanAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_LoanAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to purchase Class A common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesHolding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares holding</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_NumberOfSharesHolding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Holding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Exercise price of options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock repurchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair market value per share</link:label>
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyFullTimeBaseSalary" xlink:type="locator" xlink:label="celu_RelatedPartyFullTimeBaseSalary" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyFullTimeBaseSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party full time base salary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RelatedPartyFullTimeBaseSalary" xlink:to="celu_RelatedPartyFullTimeBaseSalary_lbl" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyPartTimeBaseSalary" xlink:type="locator" xlink:label="celu_RelatedPartyPartTimeBaseSalary" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyPartTimeBaseSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party part time base salary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="celu_RelatedPartyPartTimeBaseSalary" xlink:to="celu_RelatedPartyPartTimeBaseSalary_lbl" />
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyPartTimeBaseSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Part time base salary</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyPartTimeBaseSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Part Time Base Salary</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyFullTimeBaseSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Full time base salary</link:label>
    <link:label xml:lang="en-US" xlink:label="celu_RelatedPartyFullTimeBaseSalary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Full Time Base Salary</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base salary and bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Salaries Wages And Officers Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Number of shares issued</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>41
<FILENAME>celu-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T15:44:19.6372793+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ccfc69a50e5a44e89f9a89b5c642c0de -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://celularity.com/20211231/role/TemplateLink" xlink:href="celu-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="celu-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:type="locator" xlink:label="dei_DocumentInformationTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiability" xlink:type="locator" xlink:label="celu_WarrantLiability" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsNoncurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsCurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PromissoryNotesReceivable" xlink:type="locator" xlink:label="celu_PromissoryNotesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="celu_PromissoryNotesReceivable" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNoncurrent" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="celu_FinancingObligationsCurrent" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_FinancingObligationsNoncurrent" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_WarrantLiability" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAbstract" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherNonoperatingIncomeExpenses" xlink:type="locator" xlink:label="celu_OtherNonoperatingIncomeExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeExpenseRelatedToWarrantLiabilities" xlink:type="locator" xlink:label="celu_IncomeExpenseRelatedToWarrantLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingIncomeCostsAndExpenses" xlink:type="locator" xlink:label="celu_OperatingIncomeCostsAndExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:type="locator" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenueAbstract" xlink:type="locator" xlink:label="us-gaap_CostOfRevenueAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseRoyaltyAndOtherMember" xlink:type="locator" xlink:label="celu_LicenseRoyaltyAndOtherMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="celu_LicenseRoyaltyAndOtherMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenueAbstract" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenue" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="celu_ChangeInFairValueOfContingentConsiderationLiability" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="celu_OperatingIncomeCostsAndExpenses" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="celu_IncomeExpenseRelatedToWarrantLiabilities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="celu_OtherNonoperatingIncomeExpenses" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TemporaryEquityShareIssuanceCosts" xlink:type="locator" xlink:label="celu_TemporaryEquityShareIssuanceCosts" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CariCordIncorporatedMember" xlink:type="locator" xlink:label="celu_CariCordIncorporatedMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicEquityFinancingMember" xlink:type="locator" xlink:label="celu_PublicEquityFinancingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CTHBiosourcingLLCMember" xlink:type="locator" xlink:label="celu_CTHBiosourcingLLCMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_CTHBiosourcingLLCMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PublicEquityFinancingMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_CariCordIncorporatedMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PalantirTechnologiesIncMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_TemporaryEquityShareIssuanceCosts" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="13390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="13950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="14230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="14250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="14270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="14370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="celu-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" xlink:type="locator" xlink:label="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfWarrantsAtEstimatedFairValue" xlink:type="locator" xlink:label="celu_IssuanceOfWarrantsAtEstimatedFairValue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" xlink:type="locator" xlink:label="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" xlink:type="locator" xlink:label="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" xlink:type="locator" xlink:label="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassOfOfferingCostsPaidInPriorYear" xlink:type="locator" xlink:label="celu_ReclassOfOfferingCostsPaidInPriorYear" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassificationOfWarrantLiabilitiesToEquity" xlink:type="locator" xlink:label="celu_ReclassificationOfWarrantLiabilitiesToEquity" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" xlink:type="locator" xlink:label="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityAssumedFromMerger" xlink:type="locator" xlink:label="celu_WarrantLiabilityAssumedFromMerger" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonCashAssetsAcquiredFromMerger" xlink:type="locator" xlink:label="celu_NonCashAssetsAcquiredFromMerger" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CancellationOfTreasuryStock" xlink:type="locator" xlink:label="celu_CancellationOfTreasuryStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecapitalizationFromMerger" xlink:type="locator" xlink:label="celu_RecapitalizationFromMerger" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromInvestment" xlink:type="locator" xlink:label="celu_ProceedsFromInvestment" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CashReceivedOnRecapitalization" xlink:type="locator" xlink:label="celu_CashReceivedOnRecapitalization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromPromissoryNote" xlink:type="locator" xlink:label="celu_ProceedsFromPromissoryNote" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" xlink:type="locator" xlink:label="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizationOfInventoryStepUp" xlink:type="locator" xlink:label="celu_AmortizationOfInventoryStepUp" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:type="locator" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXAcquisitionCorpMember" xlink:type="locator" xlink:label="celu_GXAcquisitionCorpMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="celu_GXAcquisitionCorpMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="celu_AmortizationOfInventoryStepUp" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfBusiness" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="celu_ProceedsFromPromissoryNote" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="celu_CashReceivedOnRecapitalization" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="celu_ProceedsFromInvestment" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_RecapitalizationFromMerger" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_CancellationOfTreasuryStock" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_NonCashAssetsAcquiredFromMerger" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_WarrantLiabilityAssumedFromMerger" order="12790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_IssuanceOfCommonStockAsPaymentForRelatedCosts" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_ReclassificationOfWarrantLiabilitiesToEquity" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_ReclassOfOfferingCostsPaidInPriorYear" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="13030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_UltraMISTSystemsReclassFromInventoryToFixedAsset" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_IssuanceOfWarrantsAtEstimatedFairValue" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition" order="13190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="celu-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals" xlink:href="celu-20211231.xsd#Role_DisclosureBusinessCombinationsAndDisposals" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals">
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsAbstract" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsAbstract" xlink:to="celu_BusinessCombinationsAndDisposalsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventory" xlink:href="celu-20211231.xsd#Role_DisclosureInventory" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureInventory">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses" xlink:href="celu-20211231.xsd#Role_DisclosurePrepaidExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses">
    <link:loc xlink:href="celu-20211231.xsd#celu_PrepaidExpensesDisclosureTextBlock" xlink:type="locator" xlink:label="celu_PrepaidExpensesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="celu_PrepaidExpensesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:href="celu-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedParty" xlink:href="celu-20211231.xsd#Role_DisclosureShortTermBorrowingsRelatedParty" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedParty">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="celu-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquity" xlink:href="celu-20211231.xsd#Role_DisclosureEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognition" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreements" xlink:href="celu-20211231.xsd#Role_DisclosureLicenseAndDistributionAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreements">
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsTextBlock" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsAbstract" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsAbstract" xlink:to="celu_LicenseAndDistributionAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlans" xlink:href="celu-20211231.xsd#Role_DisclosureBenefitPlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlans">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedBenefitPlanTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation" xlink:href="celu-20211231.xsd#Role_DisclosureSegmentInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="celu-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="celu-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="locator" xlink:label="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EmergingGrowthCompanyPolicyTextBlock" xlink:type="locator" xlink:label="celu_EmergingGrowthCompanyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="celu_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GovernmentGrantsPolicyTextBlock" xlink:type="locator" xlink:label="celu_GovernmentGrantsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" xlink:type="locator" xlink:label="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetAcquisitionsPolicyTextBlock" xlink:type="locator" xlink:label="celu_AssetAcquisitionsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RestrictedCashPolicyTextBlock" xlink:type="locator" xlink:label="celu_RestrictedCashPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_RestrictedCashPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_AssetAcquisitionsPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_GovernmentGrantsPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_PatentCostsPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_EmergingGrowthCompanyPolicyTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsTables" xlink:href="celu-20211231.xsd#Role_DisclosureBusinessCombinationsAndDisposalsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsTables">
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsAbstract" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsAbstract" xlink:to="celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables">
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:type="locator" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXSponsorWarrantsMember" xlink:type="locator" xlink:label="celu_GXSponsorWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:type="locator" xlink:label="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_GXSponsorWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable" xlink:to="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems" xlink:to="celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryTables" xlink:href="celu-20211231.xsd#Role_DisclosureInventoryTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryTables">
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesTables" xlink:href="celu-20211231.xsd#Role_DisclosurePrepaidExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesTables">
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfPrepaidExpensesTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfPrepaidExpensesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="celu_ScheduleOfPrepaidExpensesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:type="locator" xlink:label="celu_ScheduleOfIntangibleAssetsNetTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="celu_ScheduleOfIntangibleAssetsNetTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="celu-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="celu-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquityTables" xlink:href="celu-20211231.xsd#Role_DisclosureEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquityTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationTables" xlink:href="celu-20211231.xsd#Role_DisclosureSegmentInformationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommercialMilestonePayments" xlink:type="locator" xlink:label="celu_CommercialMilestonePayments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RegulatoryMilestones" xlink:type="locator" xlink:label="celu_RegulatoryMilestones" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ContingentValueRightIssuedForEachShare" xlink:type="locator" xlink:label="celu_ContingentValueRightIssuedForEachShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AreaOfBuilding" xlink:type="locator" xlink:label="celu_AreaOfBuilding" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfClinicalTrials" xlink:type="locator" xlink:label="celu_NumberOfClinicalTrials" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationSharesExchangeRatio" xlink:type="locator" xlink:label="celu_BusinessCombinationSharesExchangeRatio" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationSharesExchangeRatioDescription" xlink:type="locator" xlink:label="celu_BusinessCombinationSharesExchangeRatioDescription" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:type="locator" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CaricordMember" xlink:type="locator" xlink:label="celu_CaricordMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AlliquaAPAMember" xlink:type="locator" xlink:label="celu_AlliquaAPAMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnthrogenesisMember" xlink:type="locator" xlink:label="celu_AnthrogenesisMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_HLICellularTherapeuticsLLCMember" xlink:type="locator" xlink:label="celu_HLICellularTherapeuticsLLCMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:type="locator" xlink:label="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_HLICellularTherapeuticsLLCMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_AnthrogenesisMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_AlliquaAPAMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_CaricordMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable" xlink:to="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_BusinessCombinationSharesExchangeRatioDescription" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_BusinessCombinationSharesExchangeRatio" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_NumberOfClinicalTrials" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_AreaOfBuilding" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_ContingentValueRightIssuedForEachShare" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_RegulatoryMilestones" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="celu_CommercialMilestonePayments" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:type="locator" xlink:label="us-gaap_LineOfCredit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfBusinessSegments" xlink:type="locator" xlink:label="celu_NumberOfBusinessSegments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" xlink:type="locator" xlink:label="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:type="locator" xlink:label="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:type="locator" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EquipmentEvaluationPeriod" xlink:type="locator" xlink:label="celu_EquipmentEvaluationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentExpense" xlink:type="locator" xlink:label="us-gaap_EquipmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:type="locator" xlink:label="us-gaap_NumberOfReportingUnits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="celu_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CustomerTwoMember" xlink:type="locator" xlink:label="celu_CustomerTwoMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OneCustomerMember" xlink:type="locator" xlink:label="celu_OneCustomerMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="celu_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="celu_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="celu_OneCustomerMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="celu_CustomerTwoMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesTable" xlink:to="celu_SummaryOfSignificantAccountingPoliciesLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportingUnits" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquipmentExpense" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_EquipmentEvaluationPeriod" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketingAndAdvertisingExpense" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="celu_NumberOfBusinessSegments" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LineOfCredit" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_SoftwareDevelopmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="locator" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" xlink:type="locator" xlink:label="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConsiderationDescription" xlink:type="locator" xlink:label="celu_ConsiderationDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfConvertiblePromissoryNote" xlink:type="locator" xlink:label="celu_FairValueOfConvertiblePromissoryNote" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="locator" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinesses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseArrangementTerm" xlink:type="locator" xlink:label="celu_LicenseArrangementTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetPurchaseAgreementDescription" xlink:type="locator" xlink:label="celu_AssetPurchaseAgreementDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SubscriptionAgreementsDescription" xlink:type="locator" xlink:label="celu_SubscriptionAgreementsDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OptionToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="celu_OptionToPurchaseSharesOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrants" xlink:type="locator" xlink:label="celu_FairValueOfWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" xlink:type="locator" xlink:label="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessAcquisitionTransactionCostsProceedsNet" xlink:type="locator" xlink:label="celu_BusinessAcquisitionTransactionCostsProceedsNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationExchangeRatioOfCommonStock" xlink:type="locator" xlink:label="celu_BusinessCombinationExchangeRatioOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_OtherIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:type="locator" xlink:label="us-gaap_CommonStockConversionBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsLineItems" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UltraMISTBusinessMember" xlink:type="locator" xlink:label="celu_UltraMISTBusinessMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="locator" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MISTUltraMISTBusinessMember" xlink:type="locator" xlink:label="celu_MISTUltraMISTBusinessMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXWarrantsMember" xlink:type="locator" xlink:label="celu_GXWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicEquityFinancingMember" xlink:type="locator" xlink:label="celu_PublicEquityFinancingMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GXTrustAccountMember" xlink:type="locator" xlink:label="celu_GXTrustAccountMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CelularityMember" xlink:type="locator" xlink:label="celu_CelularityMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SurvivingCorporationMember" xlink:type="locator" xlink:label="celu_SurvivingCorporationMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AlphaFirstMergerSubIncorporationMember" xlink:type="locator" xlink:label="celu_AlphaFirstMergerSubIncorporationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:type="locator" xlink:label="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsAbstract" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsAbstract" xlink:to="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_AlphaFirstMergerSubIncorporationMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_SurvivingCorporationMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_CelularityMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_GXTrustAccountMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PublicEquityFinancingMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_PalantirTechnologiesIncMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_GXWarrantsMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_MISTUltraMISTBusinessMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="celu_UltraMISTBusinessMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfBusinessCombinationsAndDisposalsTable" xlink:to="celu_BusinessCombinationsAndDisposalsLineItems" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_Goodwill" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_OtherIntangibleAssetsNet" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessCombinationExchangeRatioOfCommonStock" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessAcquisitionTransactionCostsProceedsNet" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_Liabilities" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_FairValueOfWarrants" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_OptionToPurchaseSharesOfCommonStock" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_SubscriptionAgreementsDescription" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_SharePrice" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_AssetPurchaseAgreementDescription" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_LicenseArrangementTerm" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinesses" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_FairValueOfConvertiblePromissoryNote" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_ConsiderationDescription" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" order="12890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow" order="12930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsLineItems" xlink:to="celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails" xlink:href="celu-20211231.xsd#Role_DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="locator" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="locator" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AssetsDivestedAbstract" xlink:type="locator" xlink:label="celu_AssetsDivestedAbstract" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BusinessCombinationsAndDisposalsAbstract" xlink:type="locator" xlink:label="celu_BusinessCombinationsAndDisposalsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_BusinessCombinationsAndDisposalsAbstract" xlink:to="celu_AssetsDivestedAbstract" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_AssetsDivestedAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_AssetsDivestedAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_AssetsDivestedAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_AssetsDivestedAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_AssetsDivestedAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityPublicWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilityPublicWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilitySponsorWarrants" xlink:type="locator" xlink:label="celu_WarrantLiabilitySponsorWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PreferredStockWarrants" xlink:type="locator" xlink:label="celu_PreferredStockWarrants" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConvertibleNoteReceivable" xlink:type="locator" xlink:label="celu_ConvertibleNoteReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10090.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="celu_ConvertibleNoteReceivable" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="celu_PreferredStockWarrants" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="celu_WarrantLiabilitySponsorWarrants" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="celu_WarrantLiabilityPublicWarrants" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueOfWarrants" xlink:type="locator" xlink:label="celu_FairValueOfWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueNetAssetsLiability" xlink:type="locator" xlink:label="celu_FairValueNetAssetsLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_PublicWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_SponsorsWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueNetAssetsLiability" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueOfWarrants" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ContingentConsiderationObligation" xlink:type="locator" xlink:label="celu_ContingentConsiderationObligation_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ContingentConsiderationObligation" xlink:type="locator" xlink:label="celu_ContingentConsiderationObligation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="celu_ContingentConsiderationObligation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="celu_ContingentConsiderationObligation_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueNetAssetsLiability" xlink:type="locator" xlink:label="celu_FairValueNetAssetsLiability_li0l2" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReclassificationOfLegacyCelularityWarrantsToEquity" xlink:type="locator" xlink:label="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantLiabilityAssumedAtClosingDate" xlink:type="locator" xlink:label="celu_WarrantLiabilityAssumedAtClosingDate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:type="locator" xlink:label="celu_GainLossRecognizedInEarningsFromChangeInFairValues" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ProceedsFromIssuanceOfWarrant" xlink:type="locator" xlink:label="celu_ProceedsFromIssuanceOfWarrant" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="locator" xlink:label="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValueNetAssetsLiability" xlink:type="locator" xlink:label="celu_FairValueNetAssetsLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_SponsorsWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_PublicWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueNetAssetsLiability" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ProceedsFromIssuanceOfWarrant" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_GainLossRecognizedInEarningsFromChangeInFairValues" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_WarrantLiabilityAssumedAtClosingDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ReclassificationOfLegacyCelularityWarrantsToEquity" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValueNetAssetsLiability_li0l2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FairValuesOfCommonStock" xlink:type="locator" xlink:label="celu_FairValuesOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorsWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_SponsorsWarrantsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FairValuesOfCommonStock" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ClassOfWarrantExercisePriceDescription" xlink:type="locator" xlink:label="celu_ClassOfWarrantExercisePriceDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfExercisePrice" xlink:type="locator" xlink:label="celu_PercentageOfExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_DragasacWarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_PercentageOfExercisePrice" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ClassOfWarrantExercisePriceDescription" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails" xlink:href="celu-20211231.xsd#Role_DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationInputForConvertiblePromissoryNote" xlink:type="locator" xlink:label="celu_ValuationInputForConvertiblePromissoryNote" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationInputForConvertiblePromissoryNoteTerm" xlink:type="locator" xlink:label="celu_ValuationInputForConvertiblePromissoryNoteTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ValuationModelThatRelateToSanuwaveCommonStock" xlink:type="locator" xlink:label="celu_ValuationModelThatRelateToSanuwaveCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfCouponRate" xlink:type="locator" xlink:label="celu_PercentageOfCouponRate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FaceValueOfNotesReceivable" xlink:type="locator" xlink:label="celu_FaceValueOfNotesReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_FaceValueOfNotesReceivable" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_PercentageOfCouponRate" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ValuationModelThatRelateToSanuwaveCommonStock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ValuationInputForConvertiblePromissoryNoteTerm" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="celu_ValuationInputForConvertiblePromissoryNote" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:type="locator" xlink:label="us-gaap_InventoryNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryNetCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryNetCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryReserveCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryReserveCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryGrossCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryGrossCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryFinishedGoodsCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryWorkInProgressCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryWorkInProgressCurrentAndNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InventoryRawMaterialsCurrentAndNoncurrent" xlink:type="locator" xlink:label="celu_InventoryRawMaterialsCurrentAndNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_InventoryRawMaterialsCurrentAndNoncurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_InventoryWorkInProgressCurrentAndNoncurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_InventoryFinishedGoodsCurrentAndNoncurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_InventoryGrossCurrentAndNoncurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_InventoryReserveCurrentAndNoncurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="celu_InventoryNetCurrentAndNoncurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNoncurrent" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PrepaidClinicalExpense" xlink:type="locator" xlink:label="celu_PrepaidClinicalExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="celu_PrepaidClinicalExpense" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MachineryEquipmentAndFixturesMember" xlink:type="locator" xlink:label="celu_MachineryEquipmentAndFixturesMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LaboratoryAndProductionEquipmentMember" xlink:type="locator" xlink:label="celu_LaboratoryAndProductionEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_LaboratoryAndProductionEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_MachineryEquipmentAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleLeasebackTransactionHistoricalCost" xlink:type="locator" xlink:label="us-gaap_SaleLeasebackTransactionHistoricalCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleLeasebackTransactionHistoricalCost" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_SaleLeasebackTransactionAccumulatedDepreciation" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="celu-20211231.xsd#celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" xlink:type="locator" xlink:label="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems" xlink:type="locator" xlink:label="us-gaap_GoodwillLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BiobankingMember" xlink:type="locator" xlink:label="celu_BiobankingMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DegenerativeDiseaseMember" xlink:type="locator" xlink:label="celu_DegenerativeDiseaseMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CellTherapyMember" xlink:type="locator" xlink:label="celu_CellTherapyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfGoodwillTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_CellTherapyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_DegenerativeDiseaseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_BiobankingMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill_li0l2" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:type="locator" xlink:label="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AcquiredProductRights" xlink:type="locator" xlink:label="celu_AcquiredProductRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonAmortizedIntangibleAssetsAbstract" xlink:type="locator" xlink:label="celu_NonAmortizedIntangibleAssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LessAccumulatedAmortizationAbstract" xlink:type="locator" xlink:label="celu_LessAccumulatedAmortizationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmortizableIntangibleAssetsAbstract" xlink:type="locator" xlink:label="celu_AmortizableIntangibleAssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReacquiredRightsMember" xlink:type="locator" xlink:label="celu_ReacquiredRightsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:type="locator" xlink:label="us-gaap_TrademarksAndTradeNamesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksAndTradeNamesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="celu_ReacquiredRightsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_AmortizableIntangibleAssetsAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_AmortizableIntangibleAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_LessAccumulatedAmortizationAbstract" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LessAccumulatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LessAccumulatedAmortizationAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_NonAmortizedIntangibleAssetsAbstract" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_NonAmortizedIntangibleAssetsAbstract" xlink:to="celu_AcquiredProductRights" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="celu_IndefiniteLivedIntangibleAssetsAmortizationMethod" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AccrualsForConstructionInProgress" xlink:type="locator" xlink:label="celu_AccrualsForConstructionInProgress" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AccruedClinicalTrialExpense" xlink:type="locator" xlink:label="celu_AccruedClinicalTrialExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="celu_AccruedClinicalTrialExpense" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="celu_AccrualsForConstructionInProgress" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" xlink:type="locator" xlink:label="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShortTermBorrowingAmountEqualToExitFeePercentage" xlink:type="locator" xlink:label="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CVStarrCoIncMember" xlink:type="locator" xlink:label="celu_CVStarrCoIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LoanAgreementMember" xlink:type="locator" xlink:label="celu_LoanAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="celu_LoanAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="celu_CVStarrCoIncMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="celu_ShortTermBorrowingAmountEqualToExitFeePercentage" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" xlink:type="locator" xlink:label="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" xlink:type="locator" xlink:label="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesIssuedInLegalSettlementAgreement" xlink:type="locator" xlink:label="celu_NumberOfSharesIssuedInLegalSettlementAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementNoticePeriod" xlink:type="locator" xlink:label="celu_LicenseAgreementNoticePeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="locator" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClinicalAndRegulatoryMilestones" xlink:type="locator" xlink:label="celu_ClinicalAndRegulatoryMilestones" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualMaintenanceFee" xlink:type="locator" xlink:label="celu_AnnualMaintenanceFee" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UpfrontFee" xlink:type="locator" xlink:label="celu_UpfrontFee" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualFeePaid" xlink:type="locator" xlink:label="celu_AnnualFeePaid" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentSubscriptionPeriod" xlink:type="locator" xlink:label="celu_PaymentSubscriptionPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentsForMasterSubscriptionAgreement" xlink:type="locator" xlink:label="celu_PaymentsForMasterSubscriptionAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsCurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FinancingObligationsNoncurrent" xlink:type="locator" xlink:label="celu_FinancingObligationsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_InitialMonthlyBaseRent" xlink:type="locator" xlink:label="celu_InitialMonthlyBaseRent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLeaseCommencementDate" xlink:type="locator" xlink:label="celu_OperatingLeaseCommencementDate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OptionToRenewLeaseTermPeriod" xlink:type="locator" xlink:label="celu_OptionToRenewLeaseTermPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AreaOfBuildings" xlink:type="locator" xlink:label="celu_AreaOfBuildings" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageIncreaseInBaseAnnualRent" xlink:type="locator" xlink:label="celu_PercentageIncreaseInBaseAnnualRent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashEquivalentsCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLeaseExpiryYear" xlink:type="locator" xlink:label="celu_OperatingLeaseExpiryYear" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommitmentsandContingenciesDetailsLineItems" xlink:type="locator" xlink:label="celu_CommitmentsandContingenciesDetailsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CariCordParticipatingShareholdersMember" xlink:type="locator" xlink:label="celu_CariCordParticipatingShareholdersMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementMember" xlink:type="locator" xlink:label="celu_LicenseAgreementMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MasterSubscriptionAgreementMember" xlink:type="locator" xlink:label="celu_MasterSubscriptionAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PalantirTechnologiesIncMember" xlink:type="locator" xlink:label="celu_PalantirTechnologiesIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LLCAndAnthrogenesisMember" xlink:type="locator" xlink:label="celu_LLCAndAnthrogenesisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_HLICellularTherapeuticsMember" xlink:type="locator" xlink:label="celu_HLICellularTherapeuticsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_FlorhamParkNewJerseyMember" xlink:type="locator" xlink:label="celu_FlorhamParkNewJerseyMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeManufacturingAndLaboratorySpaceMember" xlink:type="locator" xlink:label="celu_OfficeManufacturingAndLaboratorySpaceMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CedarKnollsNewJerseyMember" xlink:type="locator" xlink:label="celu_CedarKnollsNewJerseyMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="celu_OfficeAndLaboratorySpaceMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrenNewJerseyMember" xlink:type="locator" xlink:label="celu_WarrenNewJerseyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OfficeSpaceMember" xlink:type="locator" xlink:label="celu_OfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CommitmentsandContingenciesDetailsTable" xlink:type="locator" xlink:label="celu_CommitmentsandContingenciesDetailsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="celu_CommitmentsandContingenciesDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_OfficeSpaceMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="celu_WarrenNewJerseyMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_OfficeAndLaboratorySpaceMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="celu_CedarKnollsNewJerseyMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="celu_OfficeManufacturingAndLaboratorySpaceMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="celu_FlorhamParkNewJerseyMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_HLICellularTherapeuticsMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_LLCAndAnthrogenesisMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_PalantirTechnologiesIncMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_MasterSubscriptionAgreementMember" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_LicenseAgreementMember" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_CariCordParticipatingShareholdersMember" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsTable" xlink:to="celu_CommitmentsandContingenciesDetailsLineItems" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_OperatingLeaseExpiryYear" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashEquivalentsCurrent" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_PercentageIncreaseInBaseAnnualRent" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_AreaOfBuildings" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_OptionToRenewLeaseTermPeriod" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_OperatingLeaseCommencementDate" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_InitialMonthlyBaseRent" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_TenantImprovements" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_FinancingObligationsNoncurrent" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_FinancingObligationsCurrent" order="12800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="13010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_PaymentsForMasterSubscriptionAgreement" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_PaymentSubscriptionPeriod" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_AnnualFeePaid" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_UpfrontFee" order="13350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_AnnualMaintenanceFee" order="13370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_ClinicalAndRegulatoryMilestones" order="13390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_LicenseAgreementNoticePeriod" order="13430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_NumberOfSharesIssuedInLegalSettlementAgreement" order="13480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_CommitmentsandContingenciesDetailsLineItems" xlink:to="celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" xlink:type="locator" xlink:label="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfWarrantCallProvision" xlink:type="locator" xlink:label="celu_DescriptionOfWarrantCallProvision" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MinimumWrittenNoticePeriodForRedemption" xlink:type="locator" xlink:label="celu_MinimumWrittenNoticePeriodForRedemption" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsCallPrice" xlink:type="locator" xlink:label="celu_PublicWarrantsCallPrice" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantExpirationTerm" xlink:type="locator" xlink:label="celu_WarrantExpirationTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ClassOfWarrantOrRightWarrantsExercisableForCash" xlink:type="locator" xlink:label="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" xlink:type="locator" xlink:label="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" xlink:type="locator" xlink:label="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfExercisableTerms" xlink:type="locator" xlink:label="celu_DescriptionOfExercisableTerms" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfWarrantsIssued" xlink:type="locator" xlink:label="celu_NumberOfWarrantsIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsPerSharePercentage" xlink:type="locator" xlink:label="celu_WarrantsPerSharePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendPaymentTerms" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockCash" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConversionPricePerShareOfCommonStock" xlink:type="locator" xlink:label="celu_ConversionPricePerShareOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesRequiredToBeOutstandingForVoting" xlink:type="locator" xlink:label="celu_NumberOfSharesRequiredToBeOutstandingForVoting" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockVotingRights" xlink:type="locator" xlink:label="us-gaap_PreferredStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesSubscribedButUnissued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesSubscribedButUnissued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfSharesRequiredForVoting" xlink:type="locator" xlink:label="celu_PercentageOfSharesRequiredForVoting" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorsMember" xlink:type="locator" xlink:label="celu_SponsorsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyGXWarrantMember" xlink:type="locator" xlink:label="celu_LegacyGXWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:type="locator" xlink:label="us-gaap_InvestorMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmendedDragasacWarrantsMember" xlink:type="locator" xlink:label="celu_AmendedDragasacWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AmendedAndRestatedDragasacWarrantsMember" xlink:type="locator" xlink:label="celu_AmendedAndRestatedDragasacWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantsMember" xlink:type="locator" xlink:label="celu_DragasacWarrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemablesConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesXRedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesXRedeemableConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesARedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesARedeemableConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBPreferredStockPurchaseAgreementsMember" xlink:type="locator" xlink:label="celu_SeriesBPreferredStockPurchaseAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBRedeemableConvertiblePreferredStocksMember" xlink:type="locator" xlink:label="celu_SeriesBRedeemableConvertiblePreferredStocksMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SeriesBPreferredStocksPurchaseAgreementsMember" xlink:type="locator" xlink:label="celu_SeriesBPreferredStocksPurchaseAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="celu_StockholdersEquityDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_SeriesBPreferredStocksPurchaseAgreementsMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemableConvertiblePreferredStocksMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBPreferredStockPurchaseAgreementsMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesARedeemableConvertiblePreferredStocksMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesXRedeemableConvertiblePreferredStocksMember" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="celu_SeriesBRedeemablesConvertiblePreferredStocksMember" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_DragasacWarrantsMember" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_AmendedAndRestatedDragasacWarrantsMember" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="celu_AmendedDragasacWarrantsMember" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_InvestorMember" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="celu_LegacyGXWarrantMember" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_SponsorsMember" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="celu_StockholdersEquityDetailsLineItems" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="13030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="13100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_PercentageOfSharesRequiredForVoting" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TreasuryStockShares" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="13390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="13480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesSubscribedButUnissued" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="13550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockVotingRights" order="13680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_NumberOfSharesRequiredToBeOutstandingForVoting" order="13730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="13780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_ConversionPricePerShareOfCommonStock" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="13850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="13970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="14010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="14080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPreferredStockCash" order="14100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendPaymentTerms" order="14120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="14210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="14330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="14800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsPerSharePercentage" order="14840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="14860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="14910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_NumberOfWarrantsIssued" order="14930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_DescriptionOfExercisableTerms" order="15020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="15040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination" order="15060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering" order="15080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_ClassOfWarrantOrRightWarrantsExercisableForCash" order="15100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantExpirationTerm" order="15120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_PublicWarrantsCallPrice" order="15170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_MinimumWrittenNoticePeriodForRedemption" order="15220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_DescriptionOfWarrantCallProvision" order="15240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans" order="15290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="15340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureEquitySummaryOfWarrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SponsorWarrantsMember" xlink:type="locator" xlink:label="celu_SponsorWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PublicWarrantsMember" xlink:type="locator" xlink:label="celu_PublicWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_March2020SeriesBWarrantsMember" xlink:type="locator" xlink:label="celu_March2020SeriesBWarrantsMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="celu_StockholdersEquityDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_DragasacWarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_March2020SeriesBWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_PublicWarrantsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_SponsorWarrantsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="celu_StockholdersEquityDetailsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosureEquitySummaryOfWarrantsParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" xlink:type="locator" xlink:label="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_WarrantsPerSharePercentage" xlink:type="locator" xlink:label="celu_WarrantsPerSharePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsLineItems" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DragasacWarrantMember" xlink:type="locator" xlink:label="celu_DragasacWarrantMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockholdersEquityDetailsTable" xlink:type="locator" xlink:label="celu_StockholdersEquityDetailsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="celu_StockholdersEquityDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="celu_DragasacWarrantMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsTable" xlink:to="celu_StockholdersEquityDetailsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_WarrantsPerSharePercentage" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockholdersEquityDetailsLineItems" xlink:to="celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UnrecognizedExpenseRelatedToPerformanceAwards" xlink:type="locator" xlink:label="celu_UnrecognizedExpenseRelatedToPerformanceAwards" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardModificationExpense" xlink:type="locator" xlink:label="celu_AwardModificationExpense" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ExpenseRelatedToPerformanceAwards" xlink:type="locator" xlink:label="celu_ExpenseRelatedToPerformanceAwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:type="locator" xlink:label="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardsWithMarketConditionsMember" xlink:type="locator" xlink:label="celu_AwardsWithMarketConditionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesTotalMember" xlink:type="locator" xlink:label="us-gaap_LiabilitiesTotalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AwardsWithServiceConditionsMember" xlink:type="locator" xlink:label="celu_AwardsWithServiceConditionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="celu_StockBasedCompensationDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="celu_TwoThousandAndSeventeenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="celu_AwardsWithServiceConditionsMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_LiabilitiesTotalMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="celu_AwardsWithMarketConditionsMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="celu_StockBasedCompensationDetailsLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_ExpenseRelatedToPerformanceAwards" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_AwardModificationExpense" order="12500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="celu_UnrecognizedExpenseRelatedToPerformanceAwards" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharePrice" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockOptionsActivityAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockOptionsActivityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockOptionsActivityAbstract" xlink:to="celu_StockBasedCompensationDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="celu_StockBasedCompensationDetailsLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsLineItems" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockBasedCompensationDetailsTable" xlink:type="locator" xlink:label="celu_StockBasedCompensationDetailsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="celu_StockBasedCompensationDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsTable" xlink:to="celu_StockBasedCompensationDetailsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_StockBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:href="celu-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfStockBasedCompensationExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseRoyaltyAndOtherMember" xlink:type="locator" xlink:label="celu_LicenseRoyaltyAndOtherMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:type="locator" xlink:label="us-gaap_ServiceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:type="locator" xlink:label="us-gaap_ProductMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="celu_LicenseRoyaltyAndOtherMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:type="locator" xlink:label="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:type="locator" xlink:label="us-gaap_LicenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRevenueRecognitionAdditionalInforrmationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePracticalExpedientFinancingComponent" xlink:type="locator" xlink:label="us-gaap_RevenuePracticalExpedientFinancingComponent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentPlansForCustomerToPayOverTimePeriod" xlink:type="locator" xlink:label="celu_PaymentPlansForCustomerToPayOverTimePeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ContractedStoragePeriods" xlink:type="locator" xlink:label="celu_ContractedStoragePeriods" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="celu_ContractedStoragePeriods" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="celu_PaymentPlansForCustomerToPayOverTimePeriod" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenuePracticalExpedientFinancingComponent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DeferredRevenue" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementForecastDescription" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementForecastDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RemainingDuePercentageNetFortyFivePaymentTerm" xlink:type="locator" xlink:label="celu_RemainingDuePercentageNetFortyFivePaymentTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" xlink:type="locator" xlink:label="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MaterialBreachContractTerminatedTerm" xlink:type="locator" xlink:label="celu_MaterialBreachContractTerminatedTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentTermNet" xlink:type="locator" xlink:label="celu_PaymentTermNet" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DiscountPercentagePaymentForInvoicesWithinTenDays" xlink:type="locator" xlink:label="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementRenewalTerm" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementRenewalTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SupplyAndDistributionAgreementPeriod" xlink:type="locator" xlink:label="celu_SupplyAndDistributionAgreementPeriod" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualSalesNotExceed" xlink:type="locator" xlink:label="celu_AnnualSalesNotExceed" />
    <link:loc xlink:href="celu-20211231.xsd#celu_AnnualSales" xlink:type="locator" xlink:label="celu_AnnualSales" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAgreementDescription" xlink:type="locator" xlink:label="celu_LicenseAgreementDescription" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicensingArrangementTerm" xlink:type="locator" xlink:label="celu_LicensingArrangementTerm" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ReimbursementOfCostUnderLicenseAgreement" xlink:type="locator" xlink:label="celu_ReimbursementOfCostUnderLicenseAgreement" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncentivePayment" xlink:type="locator" xlink:label="celu_IncentivePayment" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsLineItems" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EvolutionAgreementMember" xlink:type="locator" xlink:label="celu_EvolutionAgreementMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ArthrexAgreementMember" xlink:type="locator" xlink:label="celu_ArthrexAgreementMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SanuwaveLicenseAgreementMember" xlink:type="locator" xlink:label="celu_SanuwaveLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsTable" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LicenseAndDistributionAgreementsAbstract" xlink:type="locator" xlink:label="celu_LicenseAndDistributionAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsAbstract" xlink:to="celu_LicenseAndDistributionAgreementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_SanuwaveLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_ArthrexAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="celu_EvolutionAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsTable" xlink:to="celu_LicenseAndDistributionAgreementsLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_IncentivePayment" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_ReimbursementOfCostUnderLicenseAgreement" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_LicensingArrangementTerm" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_LicenseAgreementDescription" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_AnnualSales" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_AnnualSalesNotExceed" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementPeriod" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementRenewalTerm" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_DiscountPercentagePaymentForInvoicesWithinTenDays" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_PaymentTermNet" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_MaterialBreachContractTerminatedTerm" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_RemainingDuePercentageNetFortyFivePaymentTerm" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_LicenseAndDistributionAgreementsLineItems" xlink:to="celu_SupplyAndDistributionAgreementForecastDescription" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureBenefitPlansAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfIncomeTaxProvisionAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfIncomeTaxProvisionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfIncomeTaxProvisionAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:type="locator" xlink:label="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:type="locator" xlink:label="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:type="locator" xlink:label="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsUnicap" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsUnicap" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsStartupCosts" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsStartupCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="locator" xlink:label="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfNetDeferredTaxAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="celu_DeferredTaxAssetsStartupCosts" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="celu_DeferredTaxAssetsUnicap" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="celu_DeferredTaxAssetsImputedInterestOnContingentPayments" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfNetDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="celu-20211231.xsd#celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" xlink:type="locator" xlink:label="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="celu-20211231.xsd#celu_TaxCreditCarryforwardsExpirationYear" xlink:type="locator" xlink:label="celu_TaxCreditCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="celu_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="celu_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_UnitedStatesFederalAndStateMember" xlink:type="locator" xlink:label="celu_UnitedStatesFederalAndStateMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="celu_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="celu_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="celu_UnitedStatesFederalAndStateMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureTable" xlink:to="celu_IncomeTaxDisclosureLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_OperatingLossCarryforwardsExpirationYear" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_TaxCreditCarryforwardsExpirationYear" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_IncomeTaxDisclosureLineItems" xlink:to="celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSegmentInformationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_Assets" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:type="locator" xlink:label="us-gaap_AdjustmentForAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ChangeInFairValueOfContingentConsiderationLiability" xlink:type="locator" xlink:label="celu_ChangeInFairValueOfContingentConsiderationLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:loc xlink:href="celu-20211231.xsd#celu_IndirectExpenses" xlink:type="locator" xlink:label="celu_IndirectExpenses" />
    <link:loc xlink:href="celu-20211231.xsd#celu_SegmentContribution" xlink:type="locator" xlink:label="celu_SegmentContribution" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DirectOperatingCosts" xlink:type="locator" xlink:label="us-gaap_DirectOperatingCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_OtherMember" xlink:type="locator" xlink:label="celu_OtherMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_DegenerativeDiseaseMember" xlink:type="locator" xlink:label="celu_DegenerativeDiseaseMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_BiobankingMember" xlink:type="locator" xlink:label="celu_BiobankingMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CellTherapyMember" xlink:type="locator" xlink:label="celu_CellTherapyMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain" xlink:type="locator" xlink:label="us-gaap_SegmentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ScheduleOfFinancialInformationBySegmentAbstract" xlink:type="locator" xlink:label="celu_ScheduleOfFinancialInformationBySegmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_ScheduleOfFinancialInformationBySegmentAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_CellTherapyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_BiobankingMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_DegenerativeDiseaseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="celu_OtherMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_DirectOperatingCosts" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="celu_SegmentContribution" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="celu_IndirectExpenses" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="celu_ChangeInFairValueOfContingentConsiderationLiability" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_AdjustmentForAmortization" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyFullTimeBaseSalary" xlink:type="locator" xlink:label="celu_RelatedPartyFullTimeBaseSalary" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyPartTimeBaseSalary" xlink:type="locator" xlink:label="celu_RelatedPartyPartTimeBaseSalary" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NumberOfSharesHolding" xlink:type="locator" xlink:label="celu_NumberOfSharesHolding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LoanAgreement" xlink:type="locator" xlink:label="celu_LoanAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentsToRelatedParty" xlink:type="locator" xlink:label="celu_PaymentsToRelatedParty" />
    <link:loc xlink:href="celu-20211231.xsd#celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" xlink:type="locator" xlink:label="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyCashBonus" xlink:type="locator" xlink:label="celu_RelatedPartyCashBonus" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CashConsiderationPerMonth" xlink:type="locator" xlink:label="celu_CashConsiderationPerMonth" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockOptionsVested" xlink:type="locator" xlink:label="celu_StockOptionsVested" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="celu-20211231.xsd#celu_PaymentForMonth" xlink:type="locator" xlink:label="celu_PaymentForMonth" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyTransactionsDetailsLineItems" xlink:type="locator" xlink:label="celu_RelatedPartyTransactionsDetailsLineItems" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MrPecoraMember" xlink:type="locator" xlink:label="celu_MrPecoraMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_MsHariniMember" xlink:type="locator" xlink:label="celu_MsHariniMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_EmploymentOfImmediateFamilyMemberMember" xlink:type="locator" xlink:label="celu_EmploymentOfImmediateFamilyMemberMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_StockPurchaseAgreementWithDirectorMember" xlink:type="locator" xlink:label="celu_StockPurchaseAgreementWithDirectorMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CVStarLoanMember" xlink:type="locator" xlink:label="celu_CVStarLoanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CryoportSystemsIncMember" xlink:type="locator" xlink:label="celu_CryoportSystemsIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_COTAIncMember" xlink:type="locator" xlink:label="celu_COTAIncMember" />
    <link:loc xlink:href="celu-20211231.xsd#celu_CURAFoundationMember" xlink:type="locator" xlink:label="celu_CURAFoundationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_ConsultingAgreementWithDoctorAndrewPecoraMember" xlink:type="locator" xlink:label="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_RelatedPartyTransactionsDetailsTable" xlink:type="locator" xlink:label="celu_RelatedPartyTransactionsDetailsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="celu_RelatedPartyTransactionsDetailsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_ConsultingAgreementWithDoctorAndrewPecoraMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_CURAFoundationMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_COTAIncMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_CryoportSystemsIncMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="celu_CVStarLoanMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_StockPurchaseAgreementWithDirectorMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="celu_EmploymentOfImmediateFamilyMemberMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_MsHariniMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="celu_MrPecoraMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsTable" xlink:to="celu_RelatedPartyTransactionsDetailsLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_PaymentForMonth" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_StockOptionsVested" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_CashConsiderationPerMonth" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyCashBonus" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_PaymentsToRelatedParty" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_LoanAgreement" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_NumberOfSharesHolding" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyPartTimeBaseSalary" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="celu_RelatedPartyFullTimeBaseSalary" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="celu_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="celu-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="celu-20211231.xsd#celu_LegacyCelularitysMember" xlink:type="locator" xlink:label="celu_LegacyCelularitysMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="celu_LegacyCelularitysMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssued" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786212568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celularity Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,720,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001752828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1702591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">170 Park Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Florham Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-2170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Parsippany, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated By Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">None.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELUW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786445832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,240<span></span>
</td>
<td class="nump">$ 54,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net of allowance of $283 and $272 as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">2,745<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PromissoryNotesReceivable', window );">Notes receivable</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">5,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">9,549<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">7,076<span></span>
</td>
<td class="nump">6,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">59,100<span></span>
</td>
<td class="nump">72,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">90,625<span></span>
</td>
<td class="nump">90,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">123,304<span></span>
</td>
<td class="nump">123,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">123,187<span></span>
</td>
<td class="nump">125,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">14,836<span></span>
</td>
<td class="nump">15,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, net of current portion</a></td>
<td class="nump">2,721<span></span>
</td>
<td class="nump">1,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">414,128<span></span>
</td>
<td class="nump">431,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,317<span></span>
</td>
<td class="nump">5,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,661<span></span>
</td>
<td class="nump">13,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FinancingObligationsCurrent', window );">Current portion of financing obligation</a></td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">3,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">2,196<span></span>
</td>
<td class="nump">4,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">26,225<span></span>
</td>
<td class="nump">26,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">7,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">232,222<span></span>
</td>
<td class="nump">273,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FinancingObligationsNoncurrent', window );">Financing obligations</a></td>
<td class="nump">28,085<span></span>
</td>
<td class="nump">27,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">25,962<span></span>
</td>
<td class="nump">76,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">335<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">314,710<span></span>
</td>
<td class="nump">412,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2021; none authorized, issued and outstanding as of December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value, 730,000,000 shares authorized, 124,307,884 issued and outstanding as of December 31, 2021; 155,640,290 shares authorized, 18,529,453 shares issued and outstanding as of December 31, 2020</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 0 and 90,834 shares as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">763,087<span></span>
</td>
<td class="nump">32,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(663,681)<span></span>
</td>
<td class="num">(563,563)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">99,418<span></span>
</td>
<td class="num">(531,400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 414,128<span></span>
</td>
<td class="nump">431,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Redeemable convertible preferred stock:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FinancingObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing obligations current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FinancingObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FinancingObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing obligations noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FinancingObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PromissoryNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of promissory notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PromissoryNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents the fair value of our warrants at the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786508152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, net of allowance</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">730,000,000<span></span>
</td>
<td class="nump">155,640,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">124,307,884<span></span>
</td>
<td class="nump">18,529,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">124,307,884<span></span>
</td>
<td class="nump">18,529,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,484,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,484,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,484,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,088,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,205,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,205,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStockMember', window );">Series X Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,953,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,953,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,953,274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786695544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21,335,000<span></span>
</td>
<td class="nump">$ 14,278,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of goods sold (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">88,353,000<span></span>
</td>
<td class="nump">52,707,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">71,341,000<span></span>
</td>
<td class="nump">31,336,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ChangeInFairValueOfContingentConsiderationLiability', window );">Change in fair value of contingent consideration liability</a></td>
<td class="num">(41,145,000)<span></span>
</td>
<td class="num">(55,566,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">2,192,000<span></span>
</td>
<td class="nump">3,394,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of acquired intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">129,400,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OperatingIncomeCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">130,394,000<span></span>
</td>
<td class="nump">166,203,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(109,059,000)<span></span>
</td>
<td class="num">(151,925,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Interest expense</a></td>
<td class="num">(3,171,000)<span></span>
</td>
<td class="num">(2,354,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on the sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,434,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IncomeExpenseRelatedToWarrantLiabilities', window );">Income (expense) related to warrant liabilities</a></td>
<td class="nump">13,482,000<span></span>
</td>
<td class="num">(58,686,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OtherNonoperatingIncomeExpenses', window );">Other (expense) income, net</a></td>
<td class="num">(1,682,000)<span></span>
</td>
<td class="nump">4,096,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">8,961,000<span></span>
</td>
<td class="num">(61,008,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(100,098,000)<span></span>
</td>
<td class="num">(212,933,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="num">(4,700,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (100,118,000)<span></span>
</td>
<td class="num">$ (208,233,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share &#8211; basic and diluted</a></td>
<td class="num">$ (1.49)<span></span>
</td>
<td class="num">$ (11.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding &#8211; basic and diluted</a></td>
<td class="nump">67,057,278<span></span>
</td>
<td class="nump">18,417,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales and Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,801,000<span></span>
</td>
<td class="nump">$ 6,854,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of goods sold (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">3,528,000<span></span>
</td>
<td class="nump">2,247,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,522,000<span></span>
</td>
<td class="nump">5,556,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of goods sold (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">3,649,000<span></span>
</td>
<td class="nump">2,294,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=celu_LicenseRoyaltyAndOtherMember', window );">License, Royalty and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Net revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,012,000<span></span>
</td>
<td class="nump">1,868,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of goods sold (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">$ 2,476,000<span></span>
</td>
<td class="nump">$ 391,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ChangeInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ChangeInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IncomeExpenseRelatedToWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income expense related to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IncomeExpenseRelatedToWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OperatingIncomeCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating income costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OperatingIncomeCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OtherNonoperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OtherNonoperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=celu_LicenseRoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=celu_LicenseRoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779943496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>PIPE Investors</div></th>
<th class="th"><div>Palantir</div></th>
<th class="th"><div>CTH</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th">
<div>Series B Redeemable Convertible Preferred Stock </div>
<div>CariCord</div>
</th>
<th class="th"><div>Series X Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>PIPE Investors</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Palantir</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>CTH</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>PIPE Investors</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Palantir</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>CTH</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (327,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (355,330)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,484,740<span></span>
</td>
<td class="nump">27,552,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,953,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,247<span></span>
</td>
<td class="nump">$ 206,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,421,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_TemporaryEquityShareIssuanceCosts', window );">Share issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,596<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible preferred stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,620,063<span></span>
</td>
<td class="nump">33,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(208,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,233)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(531,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (256)<span></span>
</td>
<td class="nump">32,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(563,563)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,484,740<span></span>
</td>
<td class="nump">41,205,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,953,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity, Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 184,247<span></span>
</td>
<td class="nump">$ 290,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,529,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="nump">131,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 40,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital', window );">Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs</a></td>
<td class="nump">485,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">485,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares', window );">Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,484,740)<span></span>
</td>
<td class="num">(41,205,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,953,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue', window );">Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (184,247)<span></span>
</td>
<td class="num">$ (290,866)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares', window );">Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,122,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,400<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,399<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,340,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">743,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of liability classified legacy warrants to equity</a></td>
<td class="nump">96,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(100,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,118)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 99,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 763,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (663,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,307,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization net of redemptions, equity issuance costs and merger costs additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization net of redemptions, equity issuance costs and merger costs shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassified from warrant liability to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_TemporaryEquityShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_TemporaryEquityShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period value new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787583672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (100,118)<span></span>
</td>
<td class="num">$ (208,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,817<span></span>
</td>
<td class="nump">8,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(1,353)<span></span>
</td>
<td class="num">(8,482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">40,010<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(13,482)<span></span>
</td>
<td class="nump">58,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AmortizationOfInventoryStepUp', window );">Amortization of inventory step-up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock to settle liability with CTH</a></td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(41,145)<span></span>
</td>
<td class="num">(55,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="nump">2,627<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,909)<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6,422)<span></span>
</td>
<td class="num">(643)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,068<span></span>
</td>
<td class="num">(5,761)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits', window );">Sale of net operating losses and research and development tax credits</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">3,007<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,801)<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(8,382)<span></span>
</td>
<td class="nump">4,093<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(110,096)<span></span>
</td>
<td class="num">(63,193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(6,203)<span></span>
</td>
<td class="num">(27,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from the sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ProceedsFromPromissoryNote', window );">Proceeds from promissory note</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,903)<span></span>
</td>
<td class="num">(12,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts', window );">Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from short term borrowings - related party</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment of short term borrowings - related party</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ProceedsFromInvestment', window );">Proceeds from Palantir investment</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE financing</a></td>
<td class="nump">83,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of PIPE/SPAC related costs</a></td>
<td class="num">(10,862)<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">98,562<span></span>
</td>
<td class="nump">102,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(17,437)<span></span>
</td>
<td class="nump">26,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">69,513<span></span>
</td>
<td class="nump">43,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">52,076<span></span>
</td>
<td class="nump">69,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable and accrued expenses</a></td>
<td class="num">(970)<span></span>
</td>
<td class="num">(806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CancellationOfTreasuryStock', window );">Cancellation of treasury stock</a></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IssuanceOfCommonStockAsPaymentForRelatedCosts', window );">Issuance of common stock as payment for PIPE/merger related costs</a></td>
<td class="nump">10,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReclassificationOfWarrantLiabilitiesToEquity', window );">Reclassification of warrant liabilities to equity</a></td>
<td class="nump">96,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReclassOfOfferingCostsPaidInPriorYear', window );">Reclass of offering costs paid in prior year</a></td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses', window );">Changes in PIPE/SPAC related costs in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut', window );">Recognition of asset and financing obligation related to facility build out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Receipt of convertible note in connection with the Sanuwave Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_UltraMISTSystemsReclassFromInventoryToFixedAsset', window );">UltraMIST systems reclass from inventory to fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale', window );">Fair value of warrants issued in connection with Series B preferred stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IssuanceOfWarrantsAtEstimatedFairValue', window );">Issuance of warrants at estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition', window );">Issuance of Series B convertible preferred stock in connection with CariCord acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=celu_GXAcquisitionCorpMember', window );">Gx Acquisition Corp.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CashReceivedOnRecapitalization', window );">Cash received on recapitalization</a></td>
<td class="nump">5,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecapitalizationFromMerger', window );">Recapitalization from merger</a></td>
<td class="nump">550,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonCashAssetsAcquiredFromMerger', window );">Non-cash assets acquired from the merger</a></td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilityAssumedFromMerger', window );">Warrant liability assumed from the merger</a></td>
<td class="nump">$ 59,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AmortizationOfInventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of inventory step-up.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AmortizationOfInventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_CancellationOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_CancellationOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_CashReceivedOnRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_CashReceivedOnRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs captured in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Fair value of warrants issued in connection with Series B preferred stock sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IssuanceOfCommonStockAsPaymentForRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as payment for related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IssuanceOfCommonStockAsPaymentForRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B convertible preferred stock in connection with CariCord acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IssuanceOfWarrantsAtEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants at estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IssuanceOfWarrantsAtEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NonCashAssetsAcquiredFromMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash assets acquired from merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NonCashAssetsAcquiredFromMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ProceedsFromInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ProceedsFromInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ProceedsFromPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ProceedsFromPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecapitalizationFromMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recapitalization from merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecapitalizationFromMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReclassOfOfferingCostsPaidInPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclass of offering costs paid in prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReclassOfOfferingCostsPaidInPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReclassificationOfWarrantLiabilitiesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liabilities to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReclassificationOfWarrantLiabilitiesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recognition of asset and financing obligation related to facility build out.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of net operating losses and research and development tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_UltraMISTSystemsReclassFromInventoryToFixedAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of ultra MIST systems reclass from inventory to fixed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_UltraMISTSystemsReclassFromInventoryToFixedAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantLiabilityAssumedFromMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability assumed from merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantLiabilityAssumedFromMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=celu_GXAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=celu_GXAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783022136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Business and Basis of Presentation</p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Celularity Inc., (&#8220;Celularity&#8221; or the &#8220;Company&#8221;), formerly known as GX Acquisition Corp. (&#8220;GX&#8221;), was a blank check company incorporated in Delaware on&#160;August 24, 2018. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses</span>.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On July 16, 2021 (the &#8220;Closing Date&#8221;), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated January 8, 2021 (the &#8220;Merger Agreement&#8221;), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of GX (&#8220;First Merger Sub&#8221;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (&#8220;Second Merger Sub&#8221;), and the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (&#8220;Legacy Celularity&#8221;). Upon completion of the merger transaction, GX changed its name to Celularity Inc.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The business combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States (see Note 3). Reported shares and earnings per share available to holders of the Company&#8217;s common stock, prior to the business combination, have been retroactively restated as shares reflecting the exchange ratio established in the business combination (1.00&#160;share of Legacy Celularity for approximately&#160;0.7686&#160;shares of Celularity)</span>.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Description of Business</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Celularity is a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic T cells engineered with chimeric antigen receptor (&#8220;CAR&#8221;) T cells, natural killer (&#8220;NK&#8221;) cells and mesenchymal-like adherent stromal cells (&#8220;ASCs&#8221;), targeting indications across cancer, infectious and degenerative diseases. Celularity is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (&#8220;Anthrogenesis&#8221;) in August&#160;2017 from Celgene Corporation (&#8220;Celgene&#8221;), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously, Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene&#8217;s cell therapy division. Celularity currently has&#160;three</span><span style="color:#000000;">&#160;</span><span style="Background-color:#FFFFFF;">&#160;active clinical trials and plans to submit two additional investigational new drug (&#8220;IND&#8221;) applications in 2022. The Celularity IMPACT platform capitalizes on the benefits of placenta-derived cells to target multiple diseases, and provides seamless integration, from bio sourcing through manufacturing cryopreserved and packaged allogeneic cells at its purpose-built U.S.-based&#160;150,000&#160;square foot facility. Celularity&#8217;s placental-derived cells are allogeneic, meaning they are intended for use in any patient, as compared to autologous cells, which are derived from an individual patient for that patient&#8217;s use. From a single source material, the postpartum human placenta, Celularity derives four allogeneic cell types: T cells, unmodified NK cells, genetically-modified NK cells and ASCs, which have resulted in five key cell therapeutic programs: CYCART-19, CYNK-001, CYNK-101, APPL-001 and PDA-002, focused on six initial indications. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is a placental-derived unmodified NK cell in development for the treatment of acute myeloid leukemia (&#8220;AML&#8221;), a blood cancer, and for glioblastoma multiforme (&#8220;GBM&#8221;), a solid tumor cancer. CYNK-101 is a placental-derived genetically modified NK cell in development, to be evaluated in combination with a monoclonal antibody to target HER2+ cancers, such as gastric cancer. APPL-001 is a placenta-derived ASC being developed for the treatment of Crohn&#8217;s disease</span>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to early-stage&#160;companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting&#160;capabilities. Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Acquisitions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shortly after Legacy Celularity&#8217;s incorporation in 2016, it completed four business combinations. Legacy Celularity did not have any significant activities prior to its acquisitions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;31, 2017, Legacy Celularity acquired HLI Cellular Therapeutics, LLC (&#8220;HLI CT&#8221;) from Human Longevity Inc. (&#8220;Human Longevity&#8221;). HLI CT operated LifebankUSA, a private umbilical cord blood stem cell and cord tissue bank that offers parents the option to collect, process and cryogenically preserve newborn umbilical cord blood stem cells and cord tissue units. The HLI CT acquisition also provided Legacy Celularity with rights to a portfolio of biomaterial assets, including Biovance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Interfyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;as well as PSC-100, a development-stage&#160;placental stem cell program. Prior to the acquisition, Human Longevity entered into to a Supply Agreement and a License, Marketing and Development Agreement (collectively, &#8220;the HLI Agreements&#8221;) with Alliqua Biomedical Inc. (&#8220;Alliqua&#8221;). The HLI Agreements gave Alliqua exclusive rights to market and distribute Biovance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Interfyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>. Rights, title and interest into the HLI Agreements transferred to the Company as a result of the HLI CT acquisition. In aggregate, the fair value of the consideration to acquire HLI CT was $28,876. The acquisition led to goodwill and intangible assets including in-process&#160;research and development (&#8220;IPR&amp;D&#8221;) and a licensing agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;15, 2017, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">executed a Merger Agreement with Celgene whereupon it acquired </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wholly-owned</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;subsidiary of Celgene (the &#8220;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Merger Agreement&#8221;). The </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisition included a portfolio of pre-clinical&#160;and clinical stage assets, including key cellular therapeutic assets in immuno-oncology, inflammatory and age-related&#160;diseases, that </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continues to develop. The </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisition gives </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access to </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; proprietary technologies and processes for the recovery of large quantities of high-potential&#160;stem cells and cellular therapeutic products derived from postpartum human placentas (each an &#8220;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Product&#8221;). As part of the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> acquisition, some of the inventors of the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Products and other key members of the </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Product development team joined </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legacy </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Celularity</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In aggregate, the fair value of the consideration to acquire </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthrogenesis</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346,430</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The acquisition led to goodwill and intangible assets including IPR&amp;D and a licensing agreement and contingent value rights (&#8220;CVR&#8221;) agreement</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, Legacy Celularity issued shares of its Series X Preferred Stock to Celgene as merger consideration and entered into a contingent value rights agreement (the &#8220;CVR Agreement&#8221;) with Celgene pursuant to which it issued one CVR in respect of each share of Series X Preferred Stock issued to Celgene in connection with the Anthrogenesis acquisition. The CVR Agreement entitles the holders of the CVRs to an aggregate amount, on a per program basis, of $50,000 in regulatory milestones and an aggregate $125,000 in commercial milestone payments with respect to certain programs. In addition, with respect to each such program and calendar year, the CVR holders will be entitled, with respect to a given calendar year and program, to receive a royalty equal to a mid-teen&#160;percentage of the annual net sales for such program, from the date of the first commercial sale of such program&#8217;s product in a particular country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program product in such country, the expiration of marketing exclusivity with respect to such product in such country, and August 2027 (i.e., the tenth anniversary of the closing of the acquisition of Anthrogenesis). Celularity estimates the liability associated with the CVR quarterly. Changes to that liability include but are not limited to changes in Celularity clinical programs, assumptions about the commercial value of those programs and the time value of money.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;7, 2018, the Company completed an Asset Purchase Agreement with Alliqua, a regenerative technologies company that commercializes regenerative medical products (the &#8220;Alliqua APA&#8221;). The Alliqua APA included the acquisition of Alliqua&#8217;s biologic wound care business, including the marketing and distribution rights to Biovance<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and Interfyl<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup>as well as a Class II medical device, the MIST<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;and UltraMIST<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;Therapy Systems. In connection with the Alliqua APA, the Company paid cash consideration of $29,000. The Alliqua acquisition led to goodwill and intangible assets. No debt or significant liabilities were assumed by the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;5, 2018, the Company acquired CariCord Inc. (&#8220;CariCord&#8221;), a family cord blood bank established by ClinImmune Labs University of Colorado Cord Blood Bank (&#8220;ClinImmune Labs&#8221;) and the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado School of Medicine (the &#8220;University of Colorado&#8221;). In the aggregate, the fair value of the consideration to acquire CariCord was $9,326. The acquisition led to goodwill and intangible assets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company&#8217;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While management has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company&#8217;s continuity plans will be successful.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Although the Company was able to operate continuously throughout 2020 and 2021, the Company implemented work-from-home policies as needed following local health recommendations for non-essential employees and employees whose roles are able to be performed remotely. Because certain elements of the Company&#8217;s operations (such as processing placental tissue, certain biological assays, translational research and storage of cord blood) cannot be performed remotely, the Company instituted controls and protocols including mandatory temperature checking, symptom assessment forms, incremental cleaning and sanitization of common surfaces to mitigate risks to employees.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Due to a broad decline in economic activity and restrictions on physical access to certain medical facilities, the Company did experience a decrease in the net revenues of its degenerative disease business due to the pandemic in 2021. As for clinical trials, the Company did not cancel or postpone enrollment solely due to the risks of COVID-19. However, enrollment in the clinical trial evaluating </span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">CYNK-001 for AML experienced some delays in the first half of 2020 as sites assessed their safety protocols and experienced high volumes of COVID-19 patients. Enrollment has continued in the AML trial and remains ongoing. As a result, during 2020 the Company had a year-over-year increase in research and development expenses notwithstanding the enrollment delays. The Company also initiated a clinical trial evaluating CYNK-001 in patients with COVID-19, which necessitated additional research and development and project management resources. The Company believes that it would have deployed its human and capital resources to other efforts, such as its C</span><span style="Background-color:#FFFFFF;">Y</span><span style="Background-color:#FFFFFF;">CART-19 clinical development program, had the COVID-19 pandemic not struck.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">COVID-19 did not have a material negative impact on oncology clinical trial patient accrual rates during 2021. However, screenings and enrollments in the COVID-19 trial were lower once vaccines became more widely available. During 2021, Celularity continued to utilize mandatory temperature checking and symptom assessment forms and, commencing with the third quarter of 2021, instituted additional safety protocols for unvaccinated employees. Celularity also utilized a liaison to help schedule vaccination appointments for employees.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The extent to which COVID-19 or any other health epidemic may impact the Company&#8217;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on the Company&#8217;s business, results of operations, financial condition, and prospects.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Going Concern</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No.&#160;2014-15,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic 205-40)</span><span style="Background-color:#FFFFFF;">, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Since its inception, Legacy Celularity funded its operations primarily with proceeds from the sales of preferred stock as well as revenues generated through its biobanking and degenerative disease commercial operations. The Company has incurred recurring losses since its inception, including net losses of </span>$100,118<span style="Background-color:#FFFFFF;"> and $208,233&#160;for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of $663,681. The Company expects to continue to generate operating losses for the foreseeable future. As of the date these financial statements are issued, the Company expects that its cash and cash equivalents will not be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company is seeking additional funding through public or private equity and/or debt financings. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783164696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United&#160;States (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use&#160;of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to the Company&#8217;s goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and common </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock warrants. The Company based its estimates on historical experience, known trends and other market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facts</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December&#160;31, 2021 and 2020, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company maintained letters of credit of $14,836 and $15,202, respectively, for the benefit of the landlord of leased properties, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inventory</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out&#160;basis. Prior to initial approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial material as research and development expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)&#160;expected to expire prior to being sold, (ii)&#160;has a cost basis in excess of its net realizable value, (iii)&#160;is in excess of expected sales requirements as determined by internal sales forecasts, or (iv)&#160;fails to meet commercial sale specifications, the inventory is written-down&#160;through a charge to cost of goods sold. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged,<span style="font-style:italic;">&#160;Biovance</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;currently has a shelf-life&#160;of five years in the United&#160;States and between two and three years outside of the United&#160;States, and Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;has a shelf-life&#160;of five years. If actual market conditions are less favorable than those projected by management, inventory write-downs&#160;may be required. Inventory, net of current portion on the Company&#8217;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:68.57%;"/>
<td style="width:1.45%;"/>
<td style="width:29.97%;"/>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 7 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shorter of the estimated useful life and the lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress&#160;and depreciated once placed into service.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Tangible Long-Lived Assets</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible long-lived&#160;assets consist of property, plant and equipment. Tangible long-lived&#160;assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived&#160;asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived&#160;asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on tangible long-lived&#160;assets during the years ended December&#160;31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under Accounting Standards Codification 805,&#160;<span style="font-style:italic;">Business Combinations</span>, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business. If the single asset or group of similar assets does not meet the threshold, an entity must next evaluate whether both an input and substantive process are present.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i)&#160;identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii)&#160;the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is tested for impairment at least annually. Acquired IPR&amp;D is recognized at fair value and initially characterized as an indefinite-lived&#160;intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. Transaction costs related to business combinations are expensed as incurred.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, the selection of valuation methodologies, estimates of future revenue and cash flows, expected long-term&#160;market growth, future expected operating expenses, costs of capital and appropriate discount rates. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and, as a result, actual results may differ materially from estimates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition-related&#160;contingent consideration, which consists of potential milestone and royalty obligations (see Note 11), was recorded in the consolidated balance sheets at its acquisition-date&#160;estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related&#160;contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The fair value measurement is based on significant inputs not observable by market participants and thus represents a Level 3 input in the fair value hierarchy (see Note 4).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Asset Acquisitions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Process Research and Development</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived&#160;intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived&#160;asset and amortized over its estimated useful life.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of an IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indefinite-lived&#160;IPR&amp;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived&#160;IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived&#160;IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived&#160;IPR&amp;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived&#160;IPR&amp;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived&#160;IPR&amp;D. Under either approach, if the fair value of the indefinite-lived&#160;IPR&amp;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the year ended December&#160;31, 2020, the Company recognized an impairment charge related to its indefinite-lived&#160;IPR&amp;D of $129,400. No such charge was recognized during the year ended December 31, 2021 (see Note 8).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the third quarter of 2020, the Company managed its operations as one reporting unit. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the change in reporting units, goodwill was required to be allocated across the operating segments under the new reporting structure. Goodwill was attributed to each reporting unit based on the acquired value, which is reflective of the relative fair value.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company&#8217;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, not to exceed the total amount of goodwill allocated to the reporting unit.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock Warrants Liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the business combination with GX (see Notes 1 and 3), the Company classified warrants for the purchase of shares of its convertible preferred stock (see Note 12) as liabilities on its consolidated balance sheets as these warrants were freestanding financial instruments that may have required the Company to transfer assets upon exercise. The warrant liabilities, which consisted of warrants for the purchase of Series B convertible preferred stock, were initially recorded at fair value upon the date of issuance of each warrant and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liabilities were recognized as a component of other (expense) income in the consolidated statement of operations. Fair value of the preferred stock warrant liabilities were remeasured through the July 16, 2021 closing date on the consolidated statement of operations until the liability was reclassified to equity on the closing date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into lease agreements for its laboratory and office facilities. The Company determines if a lease arrangement is an operating lease or capital lease at inception. Rent expense is recognized on a straight-line&#160;basis over the term of the lease. Incentives granted under the Company&#8217;s facilities leases, including allowances to fund leasehold improvements and rent holidays, are recorded as a deferred rent liability and are recognized as reductions to rental expense on a straight-line&#160;basis over the remaining term of the lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the nature of the renovations and the Company&#8217;s involvement during the construction period of newly leased office space to determine if it is considered to be the owner of the construction project during the construction period. If the Company determines that it is the owner of the construction project, it is required to capitalize the fair value of the asset, including potentially the building, construction costs incurred, and capitalized interest, on its consolidated balance sheet along with a corresponding financing liability (&#8220;build-to-suit&#160;accounting&#8221;). Upon occupancy for build-to-suit&#160;leases, the Company assesses whether the circumstances qualify for sales recognition under the sale-leaseback&#160;accounting guidance. If the lease meets the sale-leaseback&#160;criteria, the Company will remove the asset and related financial obligation from the balance sheet and evaluate the lease for treatment as a capital or operating lease. If upon completion of construction, the project does not meet the sale-leaseback&#160;criteria, the leased property will be treated as a capital lease for financial reporting purposes.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>, Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;and MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;and UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term&#160;pregnancies), and license, royalty and other operations (i.e., license agreement with Sanuwave Health Inc.).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Product sales and rentals</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biovance<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is a low frequency ultrasound system used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates and bacteria. The MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System consists of a generator and treatment wand (collectively, the &#8220;MIST Equipment&#8221;) along with single-use&#160;applicators (the &#8220;MIST Applicators&#8221;) and optional accessories (e.g., roll stand and carts).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has the ability to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns. The Company offers product warranties which provide assurance that the product will function as expected and in accordance with specification. Customers can purchase warranties separately and these warranties give rise to a separate performance obligation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System had both software and non-software&#160;(e.g., hardware) components that function together to deliver the product&#8217;s essential functionality. In addition, the hardware sold could not be used apart from the embedded software. The MIST Equipment was obtained by the customer in three ways: (a)&#160;the purchase of the MIST Equipment outright; (b)&#160;the lease of the MIST Equipment for a monthly rental fee; or (c)&#160;pay-per-use&#160;arrangement whereupon the Company provided the MIST Equipment for a single pay per use fee, subject to a minimum purchase requirement of MIST Applicators. MIST Applicators were separately ordered and purchased by customers who opted to purchase or directly lease the equipment. In addition, the Company offered the MIST Equipment for a standard 90&#160;day evaluation period at no charge to the customer for the MIST Equipment; however, MIST Applicators were required to be purchased during the evaluation term. When the Company leased or entered into a pay-per-use&#160;arrangement, it retained title to the equipment at all times.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For multiple-element&#160;arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. When the Company&#8217;s customer arrangements are multiple-element&#160;arrangements that contains a lease or pay-per-use&#160;arrangement, the Company allocates the arrangement consideration between the lease deliverable (i.e., the MIST Equipment) and non-lease&#160;deliverable (i.e., the MIST Applicators). The consideration related to the pay-per-use&#160;arrangements was allocated to the lease deliverable based on the &#8220;Minimum Volume Method&#8221;, which used the contractual minimum volume in the relative fair value calculation because the ultimate level of MIST Applicator purchases was unknown. The consideration allocated related to the lease arrangement was established in the lease arrangement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides inventory to certain customers through pre-arranged&#160;agreements on a consignment basis. Customers consigned inventory is maintained and stored by certain customers; however, ownership remains with the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Services</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">License, royalty and&#160;other</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement with Sanuwave Health Inc. (&#8220;Sanuwave&#8221;) which acquired certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business (see Note 14), the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognized the quarterly license fee over each quarterly term based on the actual sales occurring over the period. The license agreement with Sanuwave was terminated during the third quarter of 2021 due to an uncured material breach.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up&#160;basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ee Note </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for further discussion of the Company&#8217;s license agreements.</span></p>
<p id="DA_RN_3767174097100001138" style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the<span style="font-size:12pt;color:#000000;"> </span><span style="color:#000000;">consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order). </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related&#160;expenses, depreciation and amortization, stock-based&#160;compensation, third-party&#160;license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising and Marketing Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $252 and $764 for the years ended December&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Grants</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company recorded a reduction of $290 to research and development expense resulting from grant awards for the year ended December&#160;31, 2020. The Company did not receive grant monies during 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related&#160;costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures all stock-based&#160;awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based&#160;awards with only service-based&#160;vesting conditions and records the expense for these awards using a straight-line&#160;method.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company&#8217;s Board of Directors approved the award of performance-based&#160;stock options to a non-employee&#160;consultant who also serves as a director for the Company (see Note 13). The performance-based&#160;stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based&#160;awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based&#160;awards and adjusts expense accordingly on a cumulative basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes&#160;option-pricing&#160;model. The Company historically has been a private company and lacks company-specific&#160;historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted to employees is determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employee&#160;consultants is equal to the contractual term of the option award. The risk-free&#160;interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future (see Note 13).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company awarded options to its President which have market-based vesting conditions. <span style="Background-color:#FFFFFF;font-family:Calibri;">The Company uses the Monte-Carlo model in order to calculate the fair value of the market-based awards. Also in 2021, the Company granted restricted stock units (&#8220;RSU&#8221;), the fair value of which is determined based on the stock price on the date of grant. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies stock-based&#160;compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is reversed in the period of the forfeiture.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step&#160;process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not&#160;to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per&#160;Share</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average&#160;number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, stock options and warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average&#160;number of shares of common </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,643,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,533,868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,167,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,811,204</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,694,763</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,621,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making&#160;group, in deciding how to allocate resources in assessing performance. Prior to the third quarter of 2020, the Company managed its operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December&#160;31, 2021 and 2020 in Note 18.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Customers</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United&#160;States. During the year ended December 31, 2021, the Company had one customer (Customer A) provide for 38% of revenue and another customer provide for 11% of total revenue. In the year ended December&#160;31, 2020, the Company had one customer provide for 13% of the revenue earned. As of December&#160;31, 2021, Customer A comprised approximately 47% of the Company&#8217;s outstanding accounts receivable. As of December&#160;31, 2020, one of the Company&#8217;s customers comprised approximately 24% of the Company&#8217;s outstanding accounts receivables.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging&#160;growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2019-12, <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span> (Topic 740) (&#8220;ASU 2019-12&#8221;). The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification 740 and clarifying existing guidance to facilitate consistent application. The standard was effective for the Company beginning on January 1, 2021. The adoption of ASU 2019-12 as of January 1, 2021 did not have a material impact on the consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2020, the FASB issued ASU 2020-06, (Subtopic 470-20):&#160;<span style="font-style:italic;">Debt &#8212; Debt with Conversion and Other Options</span>&#160;(&#8220;ASU 2020-06&#8221;) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06&#160;includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity&#8217;s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06&#160;will require entities to use the &#8220;if-converted&#8221; method when calculating diluted earnings per share for convertible instruments. ASU 2020-06&#160;is effective for fiscal years beginning after December&#160;15, 2021 (fiscal year 2022 for the Company), including interim periods within those fiscal years. As no debt is currently outstanding, the Company does not expect the impact of ASU 2020-06&#160;to have an impact on its financial position, results of operations or cash flows.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, <span style="font-style:italic;">Financial Instruments &#8212; Credit Losses</span> (&#8220;ASU 2016-13&#8221;), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02<span style="font-style:italic;">, Leases (Topic&#160;842)&#160;</span>(&#8220;ASU 2016-02&#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line&#160;basis over the term of the lease. A lessee is also required to record a right-of-use&#160;asset and a lease liability for all leases with a term of greater than 12&#160;months regardless of their classification. Leases with a term of 12&#160;months or less may be accounted for similar to existing guidance for operating leases today. The guidance is effective for the Company for annual reporting periods beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022, with early adoption permitted. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC 842 as of January 1, 2022 using the modified retrospective method, which did not require it to restate prior periods and did not have an impact on retained earnings. The Company has elected the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its Consolidated Balance Sheets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company will determine whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the Consolidated Balance Sheets as right-of-use assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets will be recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the right-of-use asset. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not yet finalized the impact of this new standard, however, the Company is expecting its adoption will have a material effect on the Company&#8217;s consolidated financial statements.&#160;&#160;Upon adoption, the most significant impact relates to an equity adjustment and the recognition of a new right-of-use asset and lease liability arising from the derecognition of existing assets and liabilities from the failed sale-leaseback transaction of the Company&#8217;s Florham Park, New Jersey facility.&#160;&#160;Upon adoption, the Company will derecognize the portion of the existing build-to-suit facility financing obligation and the corresponding existing asset that was recorded solely as a result of the transaction&#8217;s build-to-suit designation in accordance with Topic 840.&#160;&#160;The difference associated with this derecognition will be recorded as an adjustment to equity as of January 1, 2022.&#160;&#160;The Company will then follow the general lessee transition requirements discussed above to record the new right-of-use asset and lease liability in accordance with Topic 842.&#160;&#160;Certain Company-paid costs associated with this transaction that were capitalized will not be derecognized and thus will be carried over and </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">retained at their currently recognized balances as they would have been recognized in the absence of the build-to-suit designation.&#160;&#160;Further information regarding this transaction is discussed within Note 11.&#160;&#160;&#160;&#160; </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783130840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Disposals<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsAbstract', window );"><strong>Business Combinations And Disposals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsDisclosureTextBlock', window );">Business Combinations and Disposals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.&#160;&#160;&#160;&#160;&#160;Business Combinations and Disposals</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Fiscal 2021</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 16, 2021, the Company consummated the previously announced merger pursuant to the Merger Agreement, by and among GX, First Merger Sub, Second Merger Sub and Legacy Celularity (see Note 1).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, a business combination between GX and Legacy Celularity was effected through the (a) merger of First Merger Sub with and into Legacy Celularity with Legacy Celularity surviving as a wholly-owned subsidiary of GX (Legacy Celularity, in its capacity as the surviving corporation of the merger, the &#8220;Surviving Corporation&#8221;) (the &#8220;First Merger&#8221;) and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the merger of the Surviving Corporation with and into Second Merger Sub, with Second Merger Sub as the surviving entity of the Second Merger, which ultimately resulted in Legacy Celularity becoming a wholly-owned direct subsidiary of GX (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Mergers&#8221; and, collectively with the other transactions described in the Merger Agreement, the &#8220;Business Combination&#8221;). On the Closing Date, the Company changed its name from GX Acquisition Corp. to Celularity Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the effective time of the Mergers (the &#8220;Effective Time&#8221;), each share of preferred stock of Legacy Celularity (the &#8220;Legacy Celularity Preferred Stock&#8221;) that was issued and outstanding was automatically converted into a number of shares of common stock of Legacy Celularity, par value $0.0001 per share (the &#8220;Legacy Celularity Common Stock&#8221;) at the then-effective conversion rate as calculated pursuant to the Amended and Restated Certificate of Incorporation of Legacy Celularity, dated March 16, 2020, as amended (the &#8220;Legacy Celularity Charter&#8221;), such that each converted share of Legacy Celularity Preferred Stock was no longer outstanding and ceased to exist, and each holder of Legacy Celularity Preferred Stock thereafter ceased to have any rights with respect to such securities (the &#8220;Legacy Celularity Preferred Stock Conversion&#8221;).</p><p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (&#8220;Company Class A Common Stock&#8221;) equal to the Exchange Ratio (as defined below) (the &#8220;Per Share Merger Consideration&#8221;);</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, &#8220;Legacy Celularity Capital Stock&#8221;) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Company Class A Common Stock (and not Celularity Capital Stock) (each, a &#8220;Converted Warrant&#8221;) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Company Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the &#8220;Celularity Warrant Shares&#8221;) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Company Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">e)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;"/><span style="color:#000000;"/><span style="font-size:10pt;">each option to purchase Legacy </span><span style="font-size:10pt;">Celularity</span><span style="font-size:10pt;"> Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a &#8220;Legacy </span><span style="font-size:10pt;">Celularity</span><span style="font-size:10pt;"> Option&#8221;) was assumed by GX and converted into an option to purchase shares of Company Class A Common Stock (each, a &#8220;Converted Option&#8221;).</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Business Combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States. Under this method of accounting, GX was treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on existing Legacy Celularity stockholders comprising a relative majority of the voting power of the combined company, Legacy Celularity&#8217;s operations prior to the acquisition comprising the only ongoing operations of Celularity, the majority of Celularity&#8217;s board of directors appointment by Legacy Celularity, and Legacy Celularity&#8217;s senior management comprising a majority of the senior management of Celularity. Accordingly, for accounting purposes, the financial statements of the combined entity represented a continuation of the financial statements of Legacy Celularity with the business combination being treated as the equivalent of Legacy Celularity issuing stock for the net assets of GX, accompanied by a recapitalization. The Company recorded net assets of GX at historical costs, with no goodwill or other intangible assets recorded. Operations prior to the business combination are those of Legacy Celularity. Reported shares and earnings per share available to holders of the Company&#8217;s Class A common stock, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio established in the business combination (1.00 share of Legacy Celularity for approximately 0.7686 shares of Celularity Class A common stock).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net proceeds from this transaction totaled $108,786. These proceeds were comprised of $5,386 held in GX&#8217;s trust account, $83,400 received from the completion of a concurrent private investment in public equity financing (&#8220;PIPE Financing&#8221;) and $20,000 received from an investment by Palantir Technologies, Inc. The Company incurred $21,657 in transaction costs relating to the merger with GX of which $10,795 were satisfied by the issuance of Class A common stock, which has been offset against additional paid-in capital in the Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the Merger Agreement, the existing stockholders of Legacy Celularity exchanged their interests for shares of Class A common stock of Celularity. In addition, GX had previously issued public warrants and private placement warrants (collectively, the &#8220;GX Warrants&#8221;) as part of the Units in its initial public offering in May 2019. None of the terms of the GX Warrants were modified as a result of the Business Combination. On the date of the Business Combination, the Company recorded a liability related to the GX Warrants of $59,202, with an offsetting entry to additional paid-in capital. During the period from July 17, 2021 to December 31, 2021, the fair value of the GX Warrants <span style="Background-color:#FFFFFF;">decreased to $25,962, resulting in an expense reduction of $33,240</span> in the consolidated statement of operations for the year ended December 31, 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon consummation of the Business Combination, Legacy Celularity warrants qualified for equity classification. As a result, the transaction date fair value of the Legacy Celularity warrants of $96,398 was reclassified from warrant liability to additional paid-in capital (see Note 12).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately following the Business Combination, there were 122,487,174 shares of Class A common stock with a par value of $0.0001 issued and outstanding, options to purchase an aggregate of 21,723,273 shares of Class A common stock and 42,686,195 warrants outstanding to purchase shares of Class A common stock.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">PIPE Financing (Private Placement)</p><p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the &#8220;Subscribers&#8221;) purchased from Celularity an aggregate of 8,340,000 shares of Class A common stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the &#8220;Subscription Agreements&#8221;). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Arrangement with Palantir Technologies Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the subscription agreement entered into by GX with Palantir Technologies Inc. (&#8220;Palantir&#8221;) on May 5, 2021, Palantir purchased 2,000,000 shares of Class A common stock at a price of $10.00 per share and an aggregate purchase price of $20,000, upon closing of the Business Combination and closing of the PIPE financing.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Fiscal 2020</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August&#160;6, 2020, the Company executed (i)&#160;an asset purchase agreement to sell certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business to Sanuwave and (ii)&#160;a <span style="-sec-ix-hidden:F_000527">five-year</span>&#160;licensing agreement with Sanuwave for total consideration of $24,524 (the &#8220;Sanuwave Transaction&#8221;), of which $20,000 was paid at or prior to closing. The remaining $4,524 of the purchase price was financed through a convertible promissory note due on or before August&#160;6, 2021. The convertible promissory note can be converted into shares of Sanuwave stock at the election of the Company any time on or after January&#160;1, 2021. As of December 31, 2021 the fair value of the convertible promissory note related to Sanuwave was $2,488 which is included in other current assets on the consolidated balance sheet. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="-sec-ix-hidden:F_000534">five-year</span>&#160;licensing arrangement with Sanuwave includes: (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market and (ii)&#160;a non-exclusive&#160;license for the distribution and commercialization of Interfyl in the wound care market. Under the licensing agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following assets and liabilities were divested/written off in this transaction:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets Divested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,901</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,296</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,764</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets divested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total upfront consideration was allocated between both components of the Sanuwave Transaction to (i)&#160;calculate the goodwill attributed to the UltraMIST business, (ii)&#160;determine the allocation of arrangement consideration to the three performance obligations and (iii)&#160;determine the loss on sale of the UltraMIST business. The Company utilized a discounted cash flow model to value the UltraMIST business, which determined the fair value of the UltraMIST business was $15,019. Significant inputs of this discounted cash flow model included (i)&#160;a discount rate of 11%, (ii)&#160;tax rate of 26% and (iii)&#160;a long-term&#160;growth rate of 2%. The remaining proceeds of $9,505 were allocated to the license agreement on a residual basis. During the third quarter of 2020, the Company recognized a loss on sale of UltraMIST of $4,434, which included approximately $40 in related professional fees. Due to the Company&#8217;s tax position as of the closing date, there was no tax impact resulting from the sale of the UltraMIST business.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationsAndDisposalsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations and disposals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationsAndDisposalsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationsAndDisposalsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations and disposals disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationsAndDisposalsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529782990152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.&#160;&#160;&#160;&#160;&#160;<span style="font-weight:bold;">Fair Value of Financial Assets and&#160;Liabilities</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,488</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,488</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,188</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,222</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,222</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability - Sponsor Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability - Public Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,362</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,362</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258,184</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents &#8211; money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2021 and 2020, there were no transfers between Level&#160;1, Level 2 and Level 3.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash equivalents consisted of a money market fund. The money market fund was valued using inputs observable in active markets for similar securities, which represents a Level 1 measurement in the fair value hierarchy. The carrying values of accounts receivable, accounts payable, deferred revenue and other current liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term&#160;nature of those instruments.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation&#160;of Contingent Consideration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted&#160;income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December&#160;31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in to (out of)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">settlements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,145</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in to (out of)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">settlements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328,933</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,566</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the liability to make potential future milestone and earn-out&#160;payments was estimated by the Company at each reporting date based, in part, on the results of a third-party&#160;valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving specified events, discount rates, and the period of time until earn-out&#160;payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company&#8217;s consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has classified all of the contingent consideration as a long-term&#160;liability in the consolidated balance sheet as of December&#160;31, 2021 and 2020. See Note&#160;11, &#8220;Commitment and Contingencies&#8221;, for more information on contingent consideration.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation of&#160;Stock Warrant Liabilities</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The warrant liability at December 31, 2021 is composed of the fair value of warrants to purchase shares of common stock. The private placement warrants assumed upon the Business Combination (the &#8220;Sponsor Warrants&#8221;) were recorded at the Closing Date fair value based on a Black-Scholes option pricing model that utilizes inputs for: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset and (vi) maturity. The Black-Scholes option pricing model&#8217;s primary unobservable input utilized in determining the fair value of the Sponsor Warrants is the expected volatility of the Class A common stock. Inputs to the Black-Sholes option pricing model for the Sponsor Warrants are updated each reporting period to reflect fair value. The public warrants assumed upon the Business Combination (the &#8220;Public Warrants&#8221;) were recorded at the Closing Date fair value based on the close price of such warrants. Each subsequent reporting period, the Public Warrants are marked-to-market based on the period-end close price.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The preferred stock warrant liability at December&#160;31, 2020 is composed of the fair value of warrants to purchase shares of Legacy Celularity Series B convertible preferred stock that were issued in 2020 and became exercisable for Class A common stock upon consummation of the Business Combination in accordance with their terms. Warrants were issued by Legacy Celularity to Dragasac Limited (&#8220;Dragasac&#8221;) in January&#160;2020 for no consideration and were recorded at fair value at the date of issuance (see Note 12). The liability associated with the warrants was recorded at fair value on the dates the warrants were issued and exercisable and was subsequently remeasured to fair value at each reporting date through the Business Combination date. The aggregate fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company used a lattice model to value the Legacy </span><span style="Background-color:#FFFFFF;">Celularity</span><span style="Background-color:#FFFFFF;"> warrants issued as the exercise price was a function of the stock price. In the application of each model, estimates and assumptions impacting the fair value measurement included the fair value per share of the underlying shares of Legacy </span><span style="Background-color:#FFFFFF;">Celularity&#8217;s</span><span style="Background-color:#FFFFFF;"> Series B convertible preferred stock, risk-free interest rate, and exercise date with considerations of the earlier of when the investor was required to exercise and the anticipated exit date. The most significant assumption in the forward contract model impacting the fair value of the preferred stock warrants was the fair value of Legacy </span><span style="Background-color:#FFFFFF;">Celularity&#8217;s</span><span style="Background-color:#FFFFFF;"> convertible preferred stock as of each remeasurement date. The Company determined the fair value per share of the underlying preferred stock by taking into consideration the most recent sales of Legacy </span><span style="Background-color:#FFFFFF;">Celularity&#8217;s</span><span style="Background-color:#FFFFFF;"> convertible preferred stock, results obtained from third-party valuations and additional factors that are deemed relevant.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2021 and December&#160;31, 2020, the fair value of the warrant liabilities was $25,962&#160;and $76,640, respectively. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated remaining term of the warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s warrant liabilities for which fair values are determined using Level 3 inputs:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of warrants issued in connection with Series B</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred stock sale</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,954</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrant at fair value*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,988</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss recognized in earnings from change in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,698</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain recognized in earnings from change in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed at Closing Date (Sponsor Warrants)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,764</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed at Closing Date (Public Warrants)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,438</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Legacy Celularity Warrants to equity</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,398</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="Background-color:#FFFFFF;">The warrants issued at fair value were immediately charged to expense see Note 12.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the Public Warrants was $12,362&#160;and $24,438&#160;as of December 31, 2021 and July 16, 2021, respectively, based on the publicly stated closing price. The fair value of the Sponsor Warrants was $13,600 and $34,764&#160;as of December 31, 2021 and July 16, 2021, respectively.&#160;Significant inputs for the Sponsor Warrants are as follows:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common share price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000613">4.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000614">5.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the warrants issued to Dragasac was $33,435&#160;as of July 16, 2021. On the Closing Date, the Dragasac warrants qualified for equity classification and were reclassified accordingly.&#160;Significant inputs for the warrants issued to Dragasac are as follows:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.66 - 10.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17 - 6.95</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price <sup style="font-size:85%;line-height:120%;vertical-align:top">a</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000626">3.67</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33 - 1.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09% - 0.10%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;">The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the warrants issued in connection with the Legacy Celularity Series B Preferred Stock was $62,963&#160;as of July 16, 2021. On the Closing Date, these warrants qualified for equity classification and were reclassified accordingly.&#160;Significant inputs for the warrants issued in connection with the Legacy Celularity Series B Preferred Stock are as follows:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.66 - 10.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17 - 6.95</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price <sup style="font-size:85%;line-height:120%;vertical-align:top">b</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">3.67</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33 - 1.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09% - 0.10%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;"/><span style="Background-color:#FFFFFF;">The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation of the Convertible Note Receivable</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The convertible note receivable was received in connection with the disposition of the UltraMIST/MIST business. At any time on or after January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted into Sanuwave common stock at a defined rate. The convertible promissory note was to be paid on or before August 6, 2021, however, remains outstanding in full at December 31, 2021. The fair value of this note was determined using Level 3 inputs and is based on a bond valuation which employs a credit default model as of December 31, 2020. As of December 31, 2021, the Company utilized Level 3 inputs on a probability weighted model based on outcomes of a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant inputs for the convertible note valuation model are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coupon rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12% - 17%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.7 - 3.19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000662">0.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783496184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.&#160;&#160;&#160;&#160;&#160;Inventory</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s major classes of inventories were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,902</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,016</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, gross</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,318</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,852</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: inventory reserves</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Classification:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,549</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,850</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net of current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,721</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,998</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783169032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PrepaidExpensesDisclosureTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.&#160;&#160;&#160;&#160;&#160;Prepaid Expenses</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,269</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,408</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,076</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,576</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PrepaidExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PrepaidExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783214648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.&#160;&#160;&#160;&#160;&#160;Property and Equipment, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvement<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,289</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and production equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,884</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery, equipment and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,054</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,404</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,163</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,077</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:88.89%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes $12,513 at December 31, 2021 and 2020 under financing lease resulting from a failed sale leaseback (see Note 11).</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes $70,959 and $55,273 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Includes $5,971 $2,624 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense was $6,625 and $4,780 for the years ended December&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Construction in progress</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress of $2,054 and $19,773 as of December&#160;31, 2021 and 2020 primarily relates to the leasehold improvements made at the Company&#8217;s leased facilities in Florham Park, NJ.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783049528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.&#160;&#160;&#160;&#160;&#160;Goodwill and Intangible Assets, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs its annual goodwill impairment test in the fourth quarter of every year, unless a triggering event occurs prior to the impairment test. Based on the Company&#8217;s annual assessment performed during the fourth quarter of 2021, it was determined that goodwill was not impaired. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of goodwill assigned to the Company&#8217;s operating segments are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell Therapy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Biobanking</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,374</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,068</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of goodwill related to sale of UltraMIST business</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,764</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,764</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,610</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,610</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:88.89%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets, Net</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lives</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangible assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 &#8211; 16 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names &amp; trademarks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 &#8211; 13 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquired rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,170</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names &amp; trademarks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquired rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,540</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,306</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangible assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,687</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,879</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-amortized intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired IPR&amp;D product rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000760">indefinite</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,187</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization expense for intangible assets was $2,192 and $3,394 for the years ended December&#160;31, 2021 and 2020, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December&#160;31, 2021 is estimated as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,193</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,356</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2020, the Company experienced a triggering event as it discontinued development of PDA-001&#160;for an indefinite period of time and opted to pursue an alternative clinical program. As of September&#160;30, 2020, the Company determined PDA-001&#160;did not have future cash flows as the Company did not intend to further develop and commercialize the asset. The triggering event required the Company to perform a quantitative impairment test as of September&#160;30, 2020. As a result of this impairment test, the Company recorded a $129,400 impairment charge to write-off&#160;the entire IPR&amp;D intangible asset related to PDA-001.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783167912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.&#160;&#160;&#160;&#160;&#160;Accrued expenses and&#160;other current liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued wages, bonuses, commissions and vacation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,991</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals for construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,321</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,661</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,451</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783044744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Borrowings - Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Borrowings - Related Party</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.&#160;&#160;&#160;&#160;&#160;Short-term borrowings &#8211; related party</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On June 8, 2021, Legacy Celularity entered into a $5,000&#160;loan agreement with C.V. Starr &amp; Co., Inc. (&#8220;CV Starr&#8221;), a stockholder of the Company. The loan accrued interest on outstanding principal at a rate equal to (a)&#160;8.0% per year until, and including, July 31, </span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2021</span><span style="Background-color:#FFFFFF;"> and (b)&#160;</span><span style="Background-color:#FFFFFF;">10.0</span><span style="Background-color:#FFFFFF;">% per </span><span style="Background-color:#FFFFFF;">year</span><span style="Background-color:#FFFFFF;"> commencing on, and including August 1, 2021. Accrued and unpaid interest was payable on July 31, 2021, the last day of each month thereafter, on the date of any prepayment of the loan, on the maturity date and, after the maturity date, on demand. The loan&#160;was required to be&#160;paid in full on the earlier of (</span><span style="Background-color:#FFFFFF;">i</span><span style="Background-color:#FFFFFF;">)&#160;</span><span style="Background-color:#FFFFFF;">June 8, 2022</span><span style="Background-color:#FFFFFF;">, (ii) the date of the consummation of the&#160;Business Combination&#160;and (iii) the date the outstanding principal&#160;was&#160;declared due and payable by CV Starr as remedy to an event of default (the &#8220;Maturity Date&#8221;). On the earlier of (</span><span style="Background-color:#FFFFFF;">i</span><span style="Background-color:#FFFFFF;">) the Maturity Date or (ii) the date on which the loan&#160;was&#160;repaid in&#160;full&#160;and the commitments of CV Starr&#160;were&#160;terminated,&#160;Legacy&#160;</span><span style="Background-color:#FFFFFF;">Celularity</span><span style="Background-color:#FFFFFF;">&#160;was required to&#160;pay CV Starr an exit fee in an amount equal to&#160;</span><span style="Background-color:#FFFFFF;">2.0</span><span style="Background-color:#FFFFFF;">% of the aggregate principal amount of the loan advanced.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the terms of the loan, Legacy Celularity could not permit the aggregate amount of cash and cash equivalents to be less than $5,000&#160;for more than&#160;five&#160;consecutive business days. Legacy Celularity could not borrow an additional $5,000&#160;under the loan agreement should it project that the aggregate amount of its cash and cash equivalents would be less than $5,000&#160;prior to the consummation of the Business Combination.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the year ended December 31, 2021, the Company repaid amounts outstanding under the short term borrowing arrangement with CV Starr and the arrangement was cancelled. Total amount paid to CV Starr was $5,146, which included principal, accrued interest and the exit fee.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783216312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;&#160;&#160;&#160;&#160;Commitments and&#160;contingencies</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2017, Legacy Celularity entered into an operating lease for office space in Warren, New Jersey, which expires in 2022. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $481, which is classified as restricted cash (non-current) on the consolidated balance sheets as of December 31, 2020. During the second quarter of 2021, the full $481 was drawn by the landlord. During the third quarter of 2021, the lease for office space in Warren, New Jersey was terminated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 10, 2019, Legacy Celularity extended the operating lease for the office and laboratory space in Cedar Knolls, New Jersey on a month-to-month basis. Beginning November 1, 2019, Legacy Celularity began paying the landlord the base annual rent and all additional rent at a 2% increase, pro-rated monthly for each month it remains in possession of the premises. Monthly lease payments of $15 due under the lease include base rent and ancillary charges.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 13, 2019, Legacy Celularity entered into a lease agreement for a 147,215 square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in 2036. The Company has the option to renew the term of the lease for two additional <span style="-sec-ix-hidden:F_000809">five-year</span> terms so long as the lease is then in full force and effect. The lease term commenced on March 1, 2020 subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly base rent is approximately $230 and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $14,722 which is classified as restricted cash (non-current) on the consolidated balance sheet as of December 31, 2021 and December 31, 2020. The lease agreement allows for a landlord provided tenant improvement allowance of $14,722 to be applied to the costs of the construction of the leasehold improvements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not the legal owner of the leased space. However, in accordance with Accounting Standards Codification 840, Leases, the Company is deemed to be the owner of the leased space, including the building shell, during the construction period because of the Company&#8217;s level of direct financial and operational involvement in the substantial tenant improvement. The lease arrangement did not meet all the criteria for sale-leaseback accounting due to the continuing involvement of the Company in the property and therefore was accounted for as a failed sale-leaseback financing obligation. As a result, as of December 31, 2019, Legacy Celularity capitalized the fair value of the building shell, the tenant improvement allowance, and ground rent expense, approximately $28,062, as construction-in-progress within property and equipment, net and recorded a corresponding build-to-suit facility lease financing obligation. As of December 31, 2021, $28,085 related to the lease financing obligation was classified as a long-term capital lease liability on its consolidated balance sheet, while $3,051 was classified as a current liability.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, construction costs incurred as part of the build-out and tenant improvements were capitalized as construction-in-progress within property and equipment, net. Legacy Celularity began to occupy completed portions of the facility in the first quarter of 2020. As the building was occupied, costs were moved out of construction-in-process and were placed in service. As of December 31, 2021 and 2020, there were $0 and $15,415 of costs related the facility included in construction-in-progress, respectively. Remaining construction was completed during January 2021 and remaining construction-in-progress costs were placed in service.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes rent expense on a straight-line basis over the respective lease period and has recorded deferred rent for rent expense incurred but not yet paid. Rent expense was $668 and $1,612 for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments inclusive of the amended lease, by year and in aggregate, under non-cancelable&#160;leases consist of the following as of December&#160;31, 2021:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,895</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,531</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,414</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Related to Business Combinations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s acquisition of HLI CT, Anthrogenesis and CariCord, the Company has agreed to pay future consideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $232,222 and $273,367 as contingent consideration as of December&#160;31, 2021 and 2020, respectively. Due to the contingent nature of these milestone and royalty payments, there is a high degree of management estimates that determine the fair value of the contingent consideration. See note 4 for further discussion. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2021 or 2020.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Palantir Technologies Inc.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 5, 2021, Legacy Celularity executed a Master Subscription Agreement with Palantir under which it will pay $40,000&#160;over&#160;five years&#160;for access to Palantir&#8217;s Foundry platform along with certain professional services. The Company will utilize Palantir&#8217;s Foundry platform to secure deeper insights into data obtained from the Company&#8217;s discovery and process development, as well as manufacturing and biorepository operations. During the third quarter of 2021, the Company paid its first annual fee of $6,000. For the year ended December 31, 2021, the Company has recorded costs of $5,333&#160;on a straight-line basis related to this agreement, which was included as a component of selling, general and administrative expense in the consolidated statement of operations.</p>
<p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sirion License Agreement </p>
<p style="text-align:justify;margin-top:7pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December&#160;2021, the Company entered into a license agreement (&#8220;Sirion License&#8221;) with Sirion Biotech GmbH (&#8220;Sirion&#8221;). Under the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (&#8220;Licensed Product&#8221;). As part of the Sirion License, the Company will pay Sirion $136 as an upfront fee, a $113 annual maintenance fee and may owe up to $5,099 million related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration of the last to expire valid claim of the patents covering such Licensed Product, and (ii) 10 years after first Commercial Sale of a Licensed Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company for convenience upon 30 days written notice. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Legal Proceedings</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 24, 2021, CTH Biosourcing LLC (&#8220;CTH&#8221;) filed a petition and request for disclosure in the District Court of Travis County, Texas seeking declaratory relief challenging Legacy Celularity&#8217;s for-cause termination of a Tissue Procurement Agreement (&#8220;TPA&#8221;). During the year ended December 31, 2021, the Company entered into a tri-party settlement with CTH and the CariCord </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">participating shareholders, as interested parties, in which the Company agreed to amend the TPA in exchange for a full release of all claims underlying the aforementioned litigation. In addition, the Company issued</span><span style="font-size:12pt;"> </span>743,771<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Celularity </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Class A Common Stock to the CariCord participating shareholders</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with an estimated fair value of </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span>5,333<span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in exchange for a full release</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This amount was recorded as a legal settlement expense within selling, general and administrative in the statement of operations for the year ended December 31, 2021. Pursuant to the settlement agreement, the CariCord participating shareholders are entitled to receive up to an additional </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">371,885</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of Celularity Class A Common Stock if certain procurement targets are met by CTH under the TPA during a specified period, which was not probable of being achieved at December 31, 2021.</span><span style="font-size:12pt;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783044744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.&#160;&#160;&#160;&#160;&#160;Equity</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Subsequent to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue&#160;730,000,000&#160;shares of $0.0001&#160;par value Class A common stock.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Voting Power</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company&#8217;s directors and all other matters requiring stockholder action. Holders of&#160;common stock are entitled to one vote per share&#160;on matters to be voted on by stockholders.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Dividends</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Holders of Class A Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#8217;s board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Liquidation, Dissolution and Winding Up</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the event of the Company&#8217;s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company&#8217;s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Preemptive or Other Rights</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Election of Directors</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class serving a three-year&#160;term, except with respect to the election of directors at the special meeting held in connection with the merger with GX. Class I directors are elected to an initial one-year&#160;term (and three-year&#160;terms subsequently), the Class II directors are elected to an initial two-year&#160;term (and three-year&#160;terms subsequently) and the Class III directors are elected to an initial three-year&#160;term (and three-year&#160;terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than&#160;50% of the shares voted for the election of directors can elect all of the directors.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Prior to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of&#160;December&#160;31, 2020, Legacy Celularity&#8217;s certificate of incorporation, as amended and restated, authorized Legacy Celularity to issue&#160;155,640,290&#160;shares of $0.0001&#160;par value common stock. The voting, dividend and liquidation rights of the holders of Legacy Celularity&#8217;s common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock (as set forth below).</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Each share of&#160;common stock entitled the holder to one vote&#160;on all matters submitted to a vote of Legacy Celularity stockholders. The holders of common stock, voting exclusively and as a separate class, were entitled to elect one director of the Legacy Celularity. Common stockholders were entitled to receive dividends, as was declared by the board of directors, if any, subject to the preferential dividend rights of Preferred Stock. Through the Closing Date, no cash dividends were declared or paid.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December&#160;31, 2020, Legacy Celularity had&#160;90,834&#160;of repurchased shares recorded as treasury stock. On the Closing Date, previously existing Legacy Celularity shares held in treasury were cancelled without any conversion.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Subsequent to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company&#8217;s Certificate of Incorporation authorized&#160;10,000,000&#160;shares of preferred stock and provides that shares of preferred stock may be issued from time to time in one or more series. The Company&#8217;s board of directors is authorized to fix the voting rights, if any, designations, powers and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The Company&#8217;s board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and could have anti-takeover effects. The ability of the Company&#8217;s board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management. As of December 31, 2021, the Company does&#160;not have any outstanding preferred stock.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Prior to Business Combination</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Legacy Celularity issued Series A convertible redeemable preferred stock (the &#8220;Series A Preferred Stock&#8221;), Series B convertible redeemable preferred stock (the &#8220;Series B Preferred Stock&#8221;), and Series X convertible redeemable preferred stock (the &#8220;Series X Preferred Stock&#8221;). The Series A Preferred Stock, Series B Preferred Stock, and Series X Preferred Stock are collectively referred to as the &#8220;Preferred Stock&#8221;. Immediately prior to closing of the Business Combination on July 16, 2021, the outstanding shares of Preferred Stock were converted into shares of Legacy Celularity common stock and then exchanged for the Company&#8217;s Class A common stock at the Effective Time. As of December&#160;31, 2020, Legacy Celularity certificate of incorporation, as amended and restated, authorized Legacy&#160;Celularity&#160;to issue a total of&#160;116,526,341&#160;shares&#160;of Preferred Stock, with a par value of $0.0001&#160;per share. As of&#160;December&#160;31, 2020,&#160;no&#160;shares of Preferred Stock remained undesignated.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of Preferred Stock had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of Legacy Celularity. Therefore, the Preferred Stock was classified outside of stockholders&#8217; deficit on the consolidated balance sheet.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 16, 2020, Legacy Celularity entered into a Series B Preferred Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors and certain individual investors (collectively &#8220;Investors&#8221;). Pursuant to the terms of the Purchase Agreement, Legacy Celularity sold and issued to the Investors an aggregate of&#160;13,620,063&#160;shares of Series B Preferred Stock and warrants to purchase up to an aggregate of&#160;13,281,386&#160;shares of Series B Preferred Stock for an aggregate purchase price of approximately $102,550. Legacy Celularity utilized a probability-weighted option pricing model to determine the fair value of the warrants at the issuance date with the residual proceeds allocated to the Series B Preferred Stock. Based on this valuation, Legacy Celularity determined the purchase price allocated to the Series B Preferred Stock was $84,596&#160;and the purchase price allocated to the warrants was $17,954.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Legacy Celularity&#8217;s classified Preferred Stock in accordance with Accounting Standards Codification 480,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">Distinguishing Liabilities from Equity</span><span style="Background-color:#FFFFFF;">, which required that contingently redeemable securities be classified outside of permanent stockholders&#8217; equity. Accordingly, Legacy Celularity classified all shares and classes of Preferred Stock as mezzanine equity on the accompanying consolidated balance sheets at December 31, 2021.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rights, Preferences and Privileges of the Preferred Stock</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of the Preferred Stock had the following rights and preferences except where noted:</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Voting</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of&#160;Preferred Stock were entitled to vote, together with the holders of common stock as a single class, on all matters submitted to stockholders for a vote and had the right to vote the number of shares equal to the number of shares of common stock into which each share of Preferred Stock could convert on the record date for determination of stockholders entitled to vote.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As long as there were at least&#160;5,000,000&#160;shares of Series B Preferred Stock outstanding, the holders of Series B Preferred Stock, voting as a separate class, could elect one director of Legacy Celularity. The remaining directors were elected by holders of common stock and Preferred Stock, voting together as a single class on an as converted basis.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Conversion</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Each share of Preferred Stock was convertible, at the option of the holder, at any time after the date of issuance. In addition, each share of Preferred Stock could automatically converted into shares of common stock at the applicable conversion ratio then in effect (i)&#160;upon the closing of a firm-commitment public offering resulting in at least $50,000&#160;of gross proceeds to Legacy Celularity at a price of at least $9.41&#160;per share of common stock, subject to appropriate adjustment of any recapitalization (&#8220;Qualified IPO&#8221;), or (ii)&#160;upon the written consent of the holders of a majority of the then-outstanding shares of Preferred Stock, voting together as a single class.</span></p><p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The conversion ratio of each series of Preferred Stock was determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price per share was $6.27&#160;for Series A and X Preferred Stock (the &#8220;Series A and X Original Issue Price&#8221;) and $7.53&#160;for Series B Preferred Stock (the &#8220;Series B Original Issue Price&#8221;), each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in Legacy Celularity&#8217;s certificate of incorporation, as amended and restated. As of December&#160;31, 2020 and the Closing Date, the Conversion Price was equal to the Original Issue Price for each series of Preferred Stock. Accordingly, as of December&#160;31, 2020 and the Closing Date, each share of each series of Preferred Stock was convertible into shares of Legacy Celularity common stock on a&#160;one-for-one basis.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Dividends</span></p><p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of&#160;6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date,&#160;no&#160;cash dividends were declared or paid.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Liquidation</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of Legacy Celularity or Deemed Liquidation Event (as defined below), each holder of the then-outstanding Preferred Stock was entitled to receive the greater of (i)&#160;an amount equal to the Original Issue Price for each series of Preferred Stock plus any dividends declared but unpaid thereon or (ii)&#160;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event at the conversion price. In the event that the assets available for distribution to stockholders&#160;were&#160;insufficient to pay Preferred&#160;Stock holders&#160;the full amounts to which they&#160;were&#160;entitled, the assets available for distribution&#160;were to&#160;be distributed on a pro rata basis among the holders of the Preferred Stock in proportion to the respective amounts that would otherwise be payable in respect of such shares.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">After the payment of all preferential amounts to the holders of Preferred Stock, then, to the extent available, the remaining assets of Legacy Celularity were to be distributed among the holders of common stock, pro rata based on the number of shares held by each such holder.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Unless (i)&#160;the holders of Series B Preferred Stock received an amount less the Original Issue Price or (ii)&#160;the holders of majority of the then-outstanding Preferred Stock, voting together as a single class, elect otherwise, a Deemed Liquidation Event included a merger or consolidation (other than one in which stockholders of Legacy Celularity own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of Legacy Celularity.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Redemption</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Legacy Celularity&#8217;s certificate of incorporation, as amended and restated, did not provide redemption rights to the holders of Preferred Stock.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Warrants</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Legacy Celularity Warrants</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On May 7, 2018, Legacy Celularity granted Dragasac a warrant for the purchase of an aggregate of&#160;16,601,736&#160;shares of Series B Preferred Stock (the &#8220;Dragasac Warrant&#8221;) at an exercise price of $7.53&#160;per share. On February 15, 2019, Dragasac exercised its rights under the Dragasac Warrant to purchase&#160;6,640,695&#160;shares of Series B Preferred Stock, at an exercise price of $7.53&#160;per share, for gross proceeds of approximately $50,000. On May 29, 2019, Legacy Celularity amended and restated the Dragasac Warrant to provide for a reduced exercise price of $7.29&#160;for the remaining warrant shares in exchange for Dragasac agreeing to purchase&#160;3,431,223&#160;shares of Series B Preferred Stock on or before May 31, 2019. On May 31, 2019, Dragasac exercised its rights under the Dragasac Warrant to purchase&#160;3,431,223&#160;shares of Series B Preferred Stock at a price per share of $7.29, for gross proceeds of approximately $25,000. On November 1, 2019, Legacy Celularity again amended the Dragasac Warrant to provide for a reduced exercise price of $6.77&#160;for the remaining warrant shares in exchange for Dragasac agreeing to purchase&#160;6,529,818&#160;shares of Series B Preferred Stock on or before </span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">November 4, 2019. On November 4, 2019, </span><span style="Background-color:#FFFFFF;">Dragasac</span><span style="Background-color:#FFFFFF;"> exercised its right to purchase&#160;</span><span style="Background-color:#FFFFFF;">6,529,818&#160;</span><span style="Background-color:#FFFFFF;">shares of Series B Preferred Stock, at a price per share of $</span><span style="Background-color:#FFFFFF;">6.77</span><span style="Background-color:#FFFFFF;">, for gross proceeds of approximately $</span><span style="Background-color:#FFFFFF;">44,178</span><span style="Background-color:#FFFFFF;">.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 9, 2020, Legacy Celularity issued a warrant for the purchase of an aggregate of&#160;6,529,818&#160;shares of Series B Preferred Stock to Dragasac. The exercise price per share at which the warrant will be exercised shall be the lesser of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of the common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange. The estimated fair value of the warrant of $11,988&#160;at the issuance date was immediately charged to expense and recorded in expense related to warrant liabilities in the accompanying consolidated statements of operations. The incremental change in fair value resulting from the amendment was also immediately charged to expense and recorded in the same line item.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On January 8, 2021, Legacy Celularity entered into a warrant amendment agreement (&#8220;Amendment No.&#160;2&#8221;) to amend the warrant issued to Dragasac on January 9, 2020, as amended on March 16, 2020. Amendment No.&#160;2 added a cashless exercise provision and eliminated the provision that would have provided for expiration of the warrant upon consummation of the Business Combination. Any portion of the warrant that was unexercised prior to consummation of the Business Combination converted into warrants to purchase shares of the Company&#8217;s Class&#160;A common stock, with the exercise price and number of shares adjusted as per the exchange ratio and the terms of the Merger Agreement (see Note 3). This amendment did not result in any changes to the accounting for these warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March 16, 2020, Legacy Celularity entered into the Purchase Agreement with the Investors. Pursuant to the terms of the Purchase Agreement, Legacy Celularity sold and issued to the Investors an aggregate of&#160;13,620,063&#160;shares of Series B Preferred Stock and warrants to purchase up to an aggregate of&#160;13,281,386&#160;shares of Series B Preferred Stock for an aggregate purchase price of approximately $102,550. The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering and (c)&#160;the consummation of a change of control. On January 8, 2021, Legacy Celularity entered into a warrant amendment agreement to amend the warrant issued the Investors on March 16, 2020. The warrant was amended to add cashless exercise provisions following the consummation of the Business Combination. Any portion of warrant held by the Investors that was unexercised prior to the consummation of the Business Combination converted into a warrant to purchase shares of the Company&#8217;s Class&#160;A common stock, with the exercise price and number of shares adjusted as per the exchange ratio and the terms of the&#160;Merger&#160;Agreement&#160;(see Note 3). This amendment did not result in any changes to the accounting for these warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Prior to the Business Combination, Legacy Celularity classified the warrants as liabilities on its consolidated balance sheets because the warrants were freestanding financial instruments that might have required Legacy Celularity to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and was subsequently remeasured to fair value at each reporting date with the final remeasurement occurring on the Closing Date. Changes in the fair value of the warrant liability were recognized as a component of other income (expense), net in the consolidated statement of operations. On the Closing Date, the warrants held by Dragasac and the Investors were converted into warrants to purchase shares of the Company&#8217;s Class A common stock. The aforementioned warrants qualified for equity classification on the Closing Date and were reclassified accordingly.&#160;&#160;</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Legacy GX Warrants</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Upon consummation of the Business Combination, the Public Warrants and Sponsor Warrants remain outstanding.&#160;The Public Warrants became exercisable on August 15, 2021, which is the later of (a)&#160;30&#160;days after the consummation of a Business Combination or (b)&#160;12&#160;months from the effective date of the registration statement relating to GX&#8217;s initial public offering.&#160;No&#160;Public Warrants would have been exercisable for cash unless the Company has an effective and current registration statement covering the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to such common shares. Notwithstanding the foregoing, if a registration statement covering the common shares issuable upon the exercise of the Public Warrants were not effective within 90 days from the consummation of the Business Combination, the holders could have, until such time as there was an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration were not available, holders would not have been able to exercise their Public Warrants on a cashless basis. The Company filed its registration statement on August 12, 2021. The Public Warrants will expire&#160;five years&#160;from the consummation of the Business Combination or earlier upon redemption or liquidation.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company may call the Public Warrants for redemption (excluding the Sponsor Warrants), in whole and not in part, at a price of $0.01&#160;per warrant:</span></p><div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">at any time while the Public Warrants are exercisable,</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">upon not less than&#160;30&#160;days&#8217; prior written notice of redemption to each Public Warrant holder, and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">if, and only if, there is a current registration statement in effect with respect to the issuance of the common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Sponsor Warrants are identical to the Public Warrants underlying the units sold in GX&#8217;s initial public offering, except that the Sponsor Warrants and the common shares issuable upon the exercise of the Sponsor Warrants were not transferable, assignable or salable until after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Sponsor Warrants are held by someone other than the initial purchasers or their permitted transferees, the Sponsor Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The exercise price and number of shares of Class A common stock issuable upon exercise of the Public Warrants and Sponsor Warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. The exercise price and number of Class A common shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In order to finance transaction costs in connection with the Business Combination, members of GX&#8217;s sponsor, GX Sponsor LLC (the &#8220;Sponsor&#8221;), entered into promissory notes with GX to provide working capital funds. In connection with the Business Combination,&#160;1,499,999&#160;Sponsor Warrants were issued to members of the Sponsor as repayment for the working capital loans made to GX.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">As of December 31, 2021, the Company had&#160;42,686,195&#160;outstanding warrants to purchase Class A common stock.&#160;A summary of the warrants is as follows:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dragasac Warrant</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,529,818</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;16,&#160;2025</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2020 Series B Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,281,386</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;16,&#160;2025</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,374,992</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July&#160;16,&#160;2026</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsor Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,499,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July&#160;16,&#160;2026</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="Background-color:#FFFFFF;">The exercise price is the lessor of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783192952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfStockBasedCompensationExpenseAbstract', window );"><strong>Schedule Of Stock Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2021 Equity Incentive Plan</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2021, the Company&#8217;s board of directors adopted and the Company&#8217;s stockholders approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) to employees and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The number of shares of Class A common stock initially reserved for issuance under the 2021 Plan is&#160;20,915,283. As of December&#160;31, 2021,&#160;15,152,282&#160;shares remain available for future grant under the 2021 Plan. The number of shares reserved for issuance will automatically increase on January 1 of each year, for a period of&#160;10&#160;years, from January 1, 2022 through January 1, 2031, by&#160;4% of the total number of shares of Celularity capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021 Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021 Plan.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The 2021 Plan is administered by the Company&#8217;s board of directors. The Company&#8217;s board of directors, or a duly authorized committee thereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan </span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of the Company&#8217;s stockholders.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">2017 Equity Incentive Plan</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The 2017 Equity Incentive Plan (the &#8220;2017 Plan&#8221;) adopted by Legacy Celularity&#8217;s board of directors and approved by Legacy Celularity&#8217;s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with the closing of the Business Combination and effectiveness of the 2021 Plan, no further grants will be made under the 2017 Plan.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The total number of stock options that could have been issued under the 2017 Plan was&#160;32,342,049. Shares that expired, forfeited, canceled or otherwise terminated without having been fully exercised were available for future grant under the 2017 Plan.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The 2017 Plan is administered by the Company&#8217;s board of directors or, at the discretion of the Company&#8217;s board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy Celularity&#8217;s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could not be less than&#160;100% of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than&#160;ten years. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over a three or&#160;four year&#160;period.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Stock Option Valuation</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;text-decoration:underline;">Awards with Service Conditions</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally required judgment to determine.</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the respective expected term or contractual term.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">The expected dividend yield is&#160;0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes&#160;option-pricing&#160;model to determine the grant-date&#160;fair value of stock options granted during the years ended December&#160;31, 2021 and 2020:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000936">4.65</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000937">6.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant-date&#160;fair value per share of stock options granted during the years ended December&#160;31, 2021 and 2020 was $4.13 and $2.24, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity under the 2021 Plan and the 2017 Plan:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contract life</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,954,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000964">7.6</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,572</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,662,072</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.88</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,340,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,167,165</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000965">7.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,633</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,681,736</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(703,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,080,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.04</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,064,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000966">7.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,525</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,064,586</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000967">7.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,840,068</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000968">6.9</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In March 2021, Legacy Celularity&#8217;s board of directors approved the issuance of fully vested options to acquire&#160;269,007&#160;shares at $3.83&#160;per share to each of its non-employee directors. During the second quarter of 2021, the grant notice was provided to the non-employee directors. Accordingly, the grant date was established in the second quarter of 2021 under ASC 718,&#160;</span><span style="font-style:italic;Background-color:#FFFFFF;">Compensation &#8211; Stock Compensation</span><span style="Background-color:#FFFFFF;">&#160;and the Company recognized the commensurate expense.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">During the second quarter of 2021, Legacy Celularity&#8217;s board of directors approved the issuance of fully vested options to acquire a total of&#160;2,613,217&#160;shares at $10.21&#160;per share to certain members of senior management. Accordingly, the Company recognized the full expense of $13,723&#160;during the second quarter of 2021, of which $6,861&#160;was recorded to research and development expense and $6,862&#160;was recorded to selling, general and administrative expense on the consolidated statement of operations.</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In September 2021, the Company&#8217;s board of directors approved the issuance of options to acquire a total of&#160;3,766,107&#160;shares of common stock at $10.23&#160;per share to certain members of senior management as a result of the Business Combination (the &#8220;Transaction Awards&#8221; or &#8220;Performance Awards&#8221;). The Transaction Awards vested&#160;50% on the Closing Date, with the remaining&#160;50% vesting over&#160;four years. Accordingly, the Company recognized expense of $7,186&#160;during the third quarter of 2021 for the shares that vested on the grant date, of which $3,388&#160;was recorded to research and development expense and $3,798&#160;was recorded to selling, general and administrative expense on the consolidated statement of operations. Additional expense was recognized in 2021 for the portion of the awards that vest over time. </span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In July 2021, the Company amended two non-employee stock option awards such that any unvested awards at the time of the Business Combination would become fully vested. The Company </span><span style="color:#000000;">accelerated the recognition of $567 of expense related to the modification of these awards</span><span style="Background-color:#FFFFFF;">. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2021 and 2020, the aggregate intrinsic value was $2,959 and $671 for the stock options exercised, respectively. 131,256 options exercised with a value of $441 were classified as liabilities at December 31, 2021 until the shares are issued to the holder.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, unrecognized compensation cost for options issued was $12,408, and will be recognized over an estimated weighted-average&#160;amortization period of 3.3&#160;years.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Awards with Performance Conditions</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had certain performance-based stock options, which were earned based on the attainment of specified goals achieved over the performance period. During the years ended December 31, 2021 and 2020, the Company recognized $31 and $21 expense related to the performance awards in which the performance condition was probable until those awards were amended such that the entire unvested portion of the award vested upon closing of the Business Combination.&#160;&#160;The Company <span style="color:#000000;">accelerated the recognition of </span>$121 of expense related to the modification of this award and as of December 31, 2021, the there was no amount of unrecognized expense related to these performance awards </p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Awards with Market Conditions</span></p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company awarded options to acquire a total of&#160;2,469,282&#160;shares with an exercise price of $6.32&#160;to the Company&#8217;s President in connection with the commencement of his employment. The grant was comprised of four equal tranches, which award will&#160;vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date, subject to his continued employment with the Company. The fair value of the President&#8217;s award was determined based upon a Monte Carlo simulation valuation model. The Company&#8217;s assumptions for expected volatility and closing price were&#160;75.0% and $6.32, respectively. The aggregate estimated fair value of the President&#8217;s award was $7,013, which is expected to be recognized over a weighted-average period of&#160;four years. The Company recognized $514&#160;in share-based expense related to the President&#8217;s award for the year ended December 31, 2021. As of December 31, 2021, there was $6,499&#160;of unrecognized compensation costs that the Company plans to recognize over the weighted average period of&#160;3.7&#160;years.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Restricted Stock Units</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issues restricted stock units (&#8220;RSUs&#8221;) to employees that generally vest over a <span style="-sec-ix-hidden:F_001010">two-year</span> period with 50% of awards vesting after 1 year and then the remaining 50% vesting after 2 years. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity related to RSU stock-based payment awards:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,900</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded stock-based compensation expense of $222&#160;for the year ended December&#160;31, 2021, related to RSUs. As of December&#160;31, 2021, the total unrecognized expense related to all RSUs was $3,296, which the Company expects to recognize over a weighted-average period of 1.92&#160;years</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company recorded stock-based&#160;compensation expense in the following expense categories of its consolidated statements of operations:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,010</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,371</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfStockBasedCompensationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfStockBasedCompensationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783215480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.&#160;&#160;&#160;&#160;&#160;Revenue Recognition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information about disaggregated revenue by product and services:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,012</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,868</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,335</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,278</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides changes in deferred revenue from contract liabilities:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,449</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferral of revenue*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,532</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of unearned revenue**</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,310</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,067</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">2020 includes $9,505&#160;received in advance of performing services under a license agreement (see Note 15).&#160;&#160;The remainder of the 2020 and all of the 2021 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">During the third quarter of 2021, the Company terminated the license agreement with Sanuwave due to an uncured material breach (See Note 15). As a result, the Company recognized the remaining deferred revenue of $6,754&#160;that was to be recognized on a straight-line basis over the non-cancelable term of the license agreement.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying Accounting Standards Codification 606,&#160;<span style="font-style:italic;">Revenue from Contracts with Customers</span>&#160;(&#8220;ASC 606&#8221;): (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2)&#160;the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3)&#160;the Company expenses costs to obtain a contract as they are incurred in the expected period of benefit and therefore, the amortization period is one year or less; (4)&#160;the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are recorded as selling, general and administrative expenses; (5)&#160;the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; and (6)&#160;the Company does not disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product sales&#160;and rentals</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. For each contract, the Company considers the obligation to transfer products and services to the customer, each of which are distinct, to be performance obligations.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its degenerative disease products. The goods and services listed below may not all be included in every contract. Some contracts may include all of the Company&#8217;s products and services while others may only include one product or service type.</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Supply of Biovance</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;products;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Supply of Interfyl</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;products;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Supply of Biovance 3L</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;products;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Supply of MIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;and UltraMIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;product;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Supply of MIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;and UltraMIST</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-size:10pt;">&#160;rental product.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Degenerative disease commercial operations revenue is generally recognized when the customer obtains control of the Company&#8217;s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Sales and other taxes collected on behalf of third parties are excluded from revenue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Variable Consideration</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, the Company is required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, discounts, and other deductions), and recognize the estimated amount as revenue, when the Company transfers control </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the product to customers. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled. An expected value method may be an appropriate estimate of the amount of variable consideration if an entity has a large number of contracts with similar characteristics whereas the most likely amount method may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes. Variable consideration is included in the transaction price if, in the Company&#8217;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company&#8217;s anticipated performance and all information (historical, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and forecasted) that is reasonably available.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales Incentives and Other Promotional Programs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers volume-based&#160;discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer&#160;basis to estimate what levels of incentives will be earned.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Product Returns</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with industry practice, the Company maintains a returns policy that generally offers customers a right of return for products that have been purchased from the Company. To date, the Company has had minimal product returns and currently does not have an accrual for product returns. The Company will continue to assess the estimate for product returns as it gains additional historical experience.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Services</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Obligations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its biobanking services:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Collection and processing services; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Storage services.</span></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contracted storage periods are 18&#160;years and 25&#160;years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the 18- and the 25-year&#160;storage fees that are being recognized over the contractual storage period. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12&#160;months from the balance sheet date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Significant Financing</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans (annual, 18&#160;years and 25&#160;years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans for customers to pay over time for a period of <span style="-sec-ix-hidden:F_001052">one to 24&#160;months</span> (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When considered over a 24-month&#160;period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, the total aggregate transaction price allocated to the unsatisfied performance obligations for services was recorded as deferred revenue amounting to $4,067, which will be recognized as revenue ratably on a straight-line&#160;basis over the contractual period of which $2,196 will be recognized as revenue over the next 12&#160;months.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales Incentives and Other Promotional Programs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer&#160;basis to estimate what levels of incentives will be earned.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allocation of Transaction Price</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the Company&#8217;s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License, royalty and other</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement with Sanuwave which acquired certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business, the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognize the quarterly license fee over each quarterly term based on the actual sales occurring over the period. If quarterly revenues were lower than the quarterly license fee, the Company recognized the difference during the third month of the quarterly period. Any royalties earned in excess of the quarterly license fee were recognized at the end of each quarterly period, as that is when it is probable that a significant future reversal of revenue under the arrangement will not occur. During the third quarter of 2021, the license agreement with Sanuwave was terminated due to an uncured material breach.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783136488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Distribution Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAndDistributionAgreementsAbstract', window );"><strong>License And Distribution Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAndDistributionAgreementsTextBlock', window );">License and Distribution Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License and Distribution Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. License and Transfer Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 15, 2017, Legacy Celularity entered into a License and Transfer Agreement with TNK Therapeutics, Inc. and Sorrento Therapeutics, Inc. (collectively &#8220;Sorrento&#8221;), pursuant to which Legacy Celularity was granted an exclusive license to certain materials, patents and intellectual property related to Sorrento to develop and commercialize products for the treatment of any disease or disorder (the &#8220;2017 License Agreement&#8221;). During the first quarter of 2020, the 2017 License Agreement was mutually terminated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 26, 2020, Legacy Celularity and Sorrento entered into a binding term sheet for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells for the treatment of any disease or disorder (the &#8220;2020 Sorrento Term Sheet&#8221;). The 2020 Sorrento Term Sheet outlined various provisions to be incorporated and further negotiated in contemplation of a final license and supply agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 30, 2020, Legacy Celularity and Sorrento entered into a new License and Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder (the &#8220;2020 Sorrento License Agreement&#8221;). Celularity retains the right to sublicense the rights granted under the agreement with Sorrento&#8217;s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until terminated by either the Company or Sorrento for uncured material breach upon 90&#160;days written notice or, after the first anniversary of the effective date of the Sorrento Agreement, by the Company for convenience upon six months&#8217; written notice to Sorrento.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and Sorrento are actively negotiating a new supply agreement related to the 2020 Sorrento License Agreement. The 2020 Sorrento Term Sheet details certain aspects of this supply agreement, including pricing terms on material and/or licensed product supplied under the 2020 Sorrento License Agreement. The Company did&#160;not incur incentive payments related to the 2020 Sorrento Term Sheet.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lung&#160;Biotechnology PBC License Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 30, 2017, Legacy Celularity entered into a license agreement with Lung Biotechnology PBC (&#8220;LB&#8221;), a wholly owned subsidiary of United Therapeutics Corporation (the &#8220;LB Agreement&#8221;), whereupon Legacy Celularity granted to LB an exclusive, worldwide sublicensable license of certain intellectual property to develop and commercialize products in the fields of thoracic and abdominal organ transplantation and pulmonary diseases (the &#8220;LB Licensed IP&#8221;). Pursuant to the LB Agreement, Legacy Celularity agreed to supply LB with placental-derived stem cells for use in the development and commercialization of products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 3, 2020, Legacy Celularity and LB agreed to expand their strategic collaborative license agreement to include treatment of COVID-19 and Acute Respiratory Distress Syndrome (&#8220;ARDS&#8221;). Under the amended collaborative agreement, the Company will seek regulatory approval for CYNK-001 in the treatment of COVID-19, and LB will seek regulatory approval for CYNK-001 in the treatment of ARDS. LB has global rights under the amended collaborative agreement to commercialize CYNK-001 in the treatment of COVID-19 and ARDS. The collaboration will be governed by a joint steering committee to oversee development and commercialization activities. LB will provide financial support as needed and requested by Legacy Celularity, subject to a maximum of $75&#160;per enrolled patient in the related clinical studies, which will be recorded as an offset to research and development expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2021, the license agreement with LB was terminated in its entirety effective April 11, 2021. The termination applies to the April 3, 2020 amendment for the treatment of CYNK-001 in COVID-19 and ARDS.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Genting&#160;Innovation PTE LTD Distribution Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;4, 2018, concurrently with Dragasac&#8217;s equity investment in the Series B Preferred Stock, the Company entered into a distribution agreement with Genting Innovation PTE LTD (&#8220;Genting&#8221;) pursuant to which Genting was granted supply and distribution rights to certain Company products in select Asia markets (the &#8220;Genting Agreement&#8221;). The Genting Agreement grants Genting limited distribution rights to the Company&#8217;s then-current&#160;portfolio of degenerative disease products and provides for the automatic rights to future products developed by or on behalf of the Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Genting Agreement was renewed on January&#160;31, 2021, and automatically renews for successive twelve month terms unless: Genting provides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party for cause.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genting and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Celgene Corporation License&#160;Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Anthrogenesis acquisition, on August&#160;20, 2017, the Company entered into a license agreement with Celgene (the &#8220;Celgene Agreement&#8221;) pursuant to which the Company granted Celgene two separate licenses to certain intellectual property owned or controlled by Anthrogenesis as of the date of the Company&#8217;s acquisition of Anthrogenesis (the &#8220;Anthrogenesis IP&#8221;). The Celgene Agreement grants Celgene a royalty-free, fully-paid&#160;up, worldwide, non-exclusive&#160;license to the Anthrogenesis IP for pre-clinical&#160;research purposes in all fields and a royalty-free, fully-paid&#160;up, worldwide license, with the right to grant sublicenses, to the Anthrogenesis IP for the development, manufacture, commercialization and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte&#160;or NK cell to express such a CAR, and/or the use of such CARs or T-lymphocytes&#160;or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic uses thereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Celgene Agreement will remain in effect until its termination by either party for cause.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sanuwave Licensing Agreement</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 6, 2020, in conjunction with the sale of the UltraMIST business, Legacy Celularity entered into a&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_001060">five-year</span></span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;licensing arrangement with Sanuwave that includes (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market worldwide, except for certain Asian jurisdictions and (ii)&#160;a non-exclusive license for the distribution and commercialization of Interfyl in the wound care market worldwide, except for certain Asian jurisdictions (the &#8220;Sanuwave Licensing Agreement&#8221;). Sanuwave has the right to grant sublicenses of the exclusive Biovance license and non-exclusive Interfyl license to&#160;</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;its affiliates without the consent of the Company and (ii)&#160;any third party for the sole purpose of providing services directly to Sanuwave upon prior written consent by the Company. The Sanuwave License Agreement will automatically renew for additional one-year periods unless either party </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gives written notice of termination at least 180&#160;days prior to the expiration of the then-current term. Under the Sanuwave License Agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Company may terminate the Sanuwave Licensing Agreement following the second year if annual sales of that year are less than $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,000</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Following the third year of the agreement, either party may terminate the Sanuwave Licensing Agreement upon 90&#160;days written notice should annual sales not exceed $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;in that third year or any year thereafter.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Sanuwave Licensing Agreement, the Company will serve on a joint steering committee where it will oversee Sanuwave&#8217;s marketing efforts with respect to the licensed products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2021, Legacy Celularity sent a notice of deficiency to Sanuwave under the existing license agreement, where Sanuwave had until July 19, 2021 to cure a material breach. This material breach was not cured by Sanuwave and, as a result, the agreement with Sanuwave was terminated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusive Supply and Distribution Agreements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 7, 2021, the Company entered into a&#160;<span style="-sec-ix-hidden:F_001064">six-year</span>&#160;supply and distribution agreement with Arthrex, Inc. (Arthrex) that includes (i) an exclusive Biovance, Interfyl, and Centaflex license for distribution and commercialization within the United States for the orthopedic surgery and (ii) an exclusive Interfly and Centaflex license for commercialization and distribution within the United States for the acute and chronic non-healing wound market (the &#8220;Arthrex Supply and Distribution Agreement&#8221;). The Arthrex Supply and Distribution Agreement will automatically renew for terms of  <span style="-sec-ix-hidden:F_001065">two-year</span> periods unless either party gives notice of non-renewal at least twelve months advance of the end of the then current term. At least ninety days prior to the start of each calendar quarter, the Company and Arthrex will agree in good faith to a minimum binding forecast based upon projected sales volume by Arthrex for said upcoming calendar quarter for each of the products. Upon agreement, Arthrex shall submit to the Company a purchase order to purchase products for the minimum forecasted quantities. The Company shall invoice Arthrex after the product has been issued and payments for such invoices will be 2%, ten net forty-five days from the date of the invoice. Upon material breach of the Arthrex Supply and Distribution Agreement either party may deliver such breach to the other party and the notified party will have thirty days to cure such breach. If the notified party fails to cure the material breach of the Arthrex Supply and Distribution Agreement the non-breaching party may terminate the respective agreement.&#160;&#160;&#160;&#160;<span style="color:#000000;"> </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Arthrex Supply and Distribution Agreement, the Company and Arthrex will establish a joint steering committee to oversee commercialization activities of the products. Membership of the joint steering committee will be comprised of an equal number of employees of each respective party. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2021, the Company entered into a&#160;<span style="-sec-ix-hidden:F_001070">three-year</span>&#160;supply and distribution agreement with Evolution Biologyx, LLC (&#8220;Evolution&#8221;) that includes an exclusive Interfyl license for the distribution and commercialization within the United States within any medical specialty where Interfyl is administered in an in-office or in-patient setting and is reimbursed through Medicare Part B or any successor, equivalent or similar category established by the Center for Medicare Services or other Government Authority, except in the medical specialty of orthopedic surgery excluding trauma or spine applications in the medical specialty or orthopedic or neurologic surgery (the &#8220;Evolution Supply and Distribution Agreement&#8221;). The Evolution Supply and Distribution Agreement will automatically renew for terms of <span style="-sec-ix-hidden:F_001071">two-year</span> periods unless either party gives notice of non-renewal at least twelve months in advance of the current term. Evolution will provide a non-binding twelve month rolling forecast to the Company. The next forecast is due October 31, 2022, and each October 31 thereafter. At least forty-five days prior to the start of each calendar quarter, the Company and Evolution will agree in good faith to a minimum binding forecast based upon projected sales volume by Evolution for said upcoming calendar quarter for each of the products. The forecast may not deviate to less than 70% for the immediate following quarter, 50% two quarters out, 40% three quarters out, and 25% for full quarters from the original forecasted amount for that specific quarter set forth in the respective agreed upon binding forecast. Upon agreement, Evolution shall submit to the Company a purchase order to purchase products for the minimum binding forecasted quantities. The Company shall invoice Evolution after the product has been issued and payments for such invoices will be 50% upon receipt and acceptance of purchase order and 50% 2%, ten net forty-five days from the date of invoice. The Evolution Supply and Distribution Agreement may be terminated by (i) material breach of the Evolution Supply and Distribution Agreement and subsequent failure to cure the material breach within thirty days of notice of material breach and (ii) otherwise mutually agreed in writing by the Company and Evolution. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicenseAndDistributionAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License And Distribution Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicenseAndDistributionAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicenseAndDistributionAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and Distribution Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicenseAndDistributionAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783111304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Benefit Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.&#160;&#160;&#160;&#160;&#160;Benefit Plans</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax&#160;basis. Matching contributions to the plan may be made at the discretion of the Company&#8217;s board of directors. During the years ended December&#160;31, 2021 and 2020, the Company made contributions of $989 and $835, respectively, to the plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 715<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472162&amp;loc=d3e58407-109430<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235042<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783192952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.&#160;&#160;&#160;&#160;&#160;Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax expense (benefit):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current income tax expense (benefit)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax expense (benefit):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,366</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,351</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax expense (benefit)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,717</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total (benefit) from income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest accretion expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark to market warrant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities as of years ended December&#160;31, 2021 and 2020 consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,495</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,748</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Startup costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,544</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unicap</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imputed interest on contingent payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fee capitalization and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,550</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,535</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,158</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,519</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,062</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,232</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,232</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,297</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Benefits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase related to current year tax provisions</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase related to current year tax provisions</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, and 2020, the Company had U.S. federal and state net operating loss carryforwards of $88,327<span style="font-size:12pt;color:#000000;"><span style="-sec-ix-hidden:F_001144">&#160;</span></span>and $53,495, respectively, which may be available to offset future taxable income and begin to expire in 2040. As of December&#160;31, 2021, and 2020, the Company also had U.S. federal and state research and development tax credit carryforwards of $7,672<span style="-sec-ix-hidden:F_001148"> </span>and $5,673, respectively, which may be available to offset future tax liabilities and begin to expire in 2032.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year&#160;period. A corporation that experiences an ownership change is subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term&#160;tax-exempt&#160;rate subject to additional adjustments, as required. The Company experienced an ownership change on August&#160;15, 2017. The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development credits before utilization.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of deferred tax assets is dependent upon the Company&#8217;s ability to generate taxable income in future years. Accounting Standards Codification 740-10,&#160;<span style="font-style:italic;">Income Taxes,</span>&#160;requires a valuation allowance to be applied against deferred tax assets when it is considered &#8220;more likely than not&#8221; that some or all of the gross deferred tax asset will not be realized. The Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded valuation allowance against its federal and state gross deferred tax assets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company had gross unrecognized tax benefits of $1,270 and $1,028, respectively. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next 12&#160;months. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company&#8217;s consolidated statements of operations. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2016 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sold $1,356 and $4,005 of its net operating losses and unused R&amp;D tax credits through the New Jersey Economic Development Authority&#8217;s Technology Business Tax Certificate Transfer Program during 2021 and 2020, respectively. The income resulting from the sale of net operating losses and unused R&amp;D tax credits is recorded as a component of other income (expense) on the consolidated statement of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783146056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.&#160;&#160;&#160;&#160;&#160;Segment Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. Prior to the third quarter of 2020, the Company managed operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This change was prompted by certain organizational and personnel changes. The chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were approximately $414,128 and $431,008 as of December&#160;31, 2021 and 2020, respectively.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information by segment is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative Disease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,522</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,335</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,682</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment contribution</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,017</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,058</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a) Components of other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,145</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,192</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,722</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,262</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,084</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,346</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,470</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,653</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,348</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment contribution</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,470</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,697</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a) Components of other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,566</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of acquired intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,394</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783037976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">19.&#160;&#160;&#160;&#160;&#160;Related Party Transactions</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The related party transactions described below do not have any associated balances on the consolidated balance sheet as of December 31, 2021. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Consulting Agreement with Dr.&#160;Andrew Pecora</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2017, Legacy Celularity entered into a scientific and clinical advisor agreement (the &#8220;SAB Agreement&#8221;) with Dr.&#160;Andrew Pecora, a member of Legacy Celularity&#8217;s board of directors, for the provision of consulting and advisory services. The SAB Agreement was superseded by a new SAB Agreement executed by Legacy Celularity on February 1, 2019.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 13, 2020, Legacy Celularity executed the First Amendment of the SAB Agreement with Dr.&#160;Pecora. The term of the First Amendment was six months. It provided for the payment of $20&#160;per month and the issuance of a stock option to purchase&#160;153,718&#160;shares of Legacy Celularity&#8217;s common stock. This consideration was in addition to consideration defined in prior agreements. Upon the execution of the agreement,&#160;76,859&#160;of the options were vested. The remaining&#160;76,859&#160;options were vested upon Dr.&#160;Pecora&#8217;s achievement of a performance objective.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 15, 2020, Legacy Celularity executed the Second Amendment to the SAB Agreement with Dr.&#160;Pecora. Under the Second Amendment, Dr.&#160;Pecora agreed to provide Legacy Celularity with strategic advice on clinical development operations and strategy and assist in establishing a long-range clinical development plan. Compensation under the arrangement includes: (i)&#160;cash consideration of $20&#160;per month, (ii)&#160;a one-time cash bonus of $50&#160;upon consummation of a merger, combination, consolidation or similar transaction involving Legacy Celularity in relation to a transaction with GX, (iii)&#160;a non-qualified stock option to purchase&#160;153,718&#160;shares of Legacy Celularity&#8217;s common stock. This non-qualified stock option was granted during the second quarter of 2021. The original expiration of the Second Amendment was January 31, 2021. On January 31, 2021, the Company executed the amended and restated second amendment to the SAB Agreement which extended the term of the Second Amendment to September 30, 2021, unless earlier terminated by the Company for cause.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the SAB Agreements, the Company paid Dr.&#160;Pecora $390&#160;and $460&#160;for the years ended December 31, 2021 and 2020, respectively. On September 15, 2021, the Company hired Dr. Pecora to serve as President. Upon hiring Dr. Pecora, the SAB Agreement was terminated.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CURA Foundation</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December&#160;31, 2021 and 2020, the Company made a contribution of $500 and $375, respectively to the CURA Foundation in support of the International Vatican. <span style="Background-color:#FFFFFF;">Dr.&#160;Robin L. Smith serves on the Company&#8217;s Board of Directors, previously served on the board of directors of Legacy Celularity, and is the president and chairperson of the board of the CURA Foundation.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">COTA, Inc</span></p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November&#160;2020, Legacy Celularity and COTA, Inc. (&#8220;COTA&#8221;) entered into an Order Schedule (the &#8220;Order Schedule No.&#160;2&#8221;), to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide the licensed data in connection with AML patients. The COTA Order Schedule No.&#160;2 will terminate on the one-year anniversary following the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity&#8217;s President, is the Founder and Chairman of the Board of COTA and Dr.&#160;Robin L. Smith, a member of the&#160;Company&#8217;s&#160;Board, is an investor in COTA. The Company paid COTA $149&#160;during the year ended December 31, 2021.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cryoport Systems, Inc</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company made payments totaling $104 and $158 to the Cryoport Systems, Inc (&#8220;Cryoport&#8221;) for transportation of cryopreserved materials during the years ended December&#160;31, 2021 and 2020, respectively. The Company&#8217;s Chief Executive Officer and director, Dr.&#160;Robert Hariri, M.D, Ph.D., has served on Cryoport&#8217;s board of directors since September&#160;2015.</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CV Starr Loan</p>
<p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 8, 2021, Legacy Celularity entered into a $5,000&#160;loan agreement with CV Starr.&#160;CV Starr is an investor in the Company, holding&#160;3,320,346&#160;warrants to purchase Class A common stock and&#160;4,320,347&#160;shares of Class A common stock as of December 31, 2021. During the third quarter of 2021, the Company repaid amounts outstanding under the short-term borrowing arrangement with CV Starr.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Purchase Agreement with a Director</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;18, 2020, a Director of the Company exercised options to purchase 100,000&#160;shares of common stock at a price of $0.21 per share. Subsequent to the aforementioned exercise, the Company and the Director entered into a stock purchase agreement on September&#160;18, 2020 whereby the 100,000&#160;shares of common stock were repurchased by the Company at the then current fair market value of $2.56 per share.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employment of an Immediate Family&#160;Member</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity&#8217;s Chairman and Executive Officer, is employed by Celularity as an Executive Director, Corporate Strategy&#160;&amp; Business Development. Ms.&#160;Hariri transitioned to part-time&#160;in late 2018, and her base salary for each of the years ended December&#160;31, 2019 and 2020 was $38 per year. In 2021, Ms.&#160;Hariri transitioned back to full-time&#160;and her base salary is $210. Ms.&#160;Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and conditions as applicable to unrelated employees in similar positions.</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew Pecora, the son of Andrew Pecora, M.D., the Company&#8217;s President, was employed by Celularity as Manager, Clinical Supply Chain. For the year ended December&#160;31, 2020, Mr.&#160;Pecora earned $104 in base salary and bonus and he earned equity awards which were in line with similar roles at Celularity. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783176648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20.&#160;&#160;&#160;&#160;&#160;Subsequent Events</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated subsequent events and there are no items requiring disclosure except the following:</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Warrant Amendment and Exercise</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March&#160;1, 2022, Celularity and certain of the investors amended and restated the investors&#8217; respective Legacy Celularity Warrants (the &#8220;A&amp;R Warrants&#8221;) to (i)&#160;reduce the exercise price per share from $7.53 per share to $3.50 per share, subject to adjustment as set forth in the A&amp;R Warrants, (ii)&#160;remove the transfer restrictions set forth in the A&amp;R Warrants, and (iii)&#160;make other changes reflecting the impact of the business combination.&#160;</span>In conjunction with the amendment, those investors exercised&#160;13,281,386 of the A&amp;R Warrants in exchange for 13,281,386 shares of the Company&#8217;s Class A common stock for gross proceeds of $46,485.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787532520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United&#160;States (&#8220;GAAP&#8221;). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use&#160;of Estimates</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related to the Company&#8217;s goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and common </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock warrants. The Company based its estimates on historical experience, known trends and other market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facts</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.44%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:10pt;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December&#160;31, 2021 and 2020, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RestrictedCashPolicyTextBlock', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021 and 2020, the Company maintained letters of credit of $14,836 and $15,202, respectively, for the benefit of the landlord of leased properties, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inventory</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out&#160;basis. Prior to initial approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial material as research and development expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)&#160;expected to expire prior to being sold, (ii)&#160;has a cost basis in excess of its net realizable value, (iii)&#160;is in excess of expected sales requirements as determined by internal sales forecasts, or (iv)&#160;fails to meet commercial sale specifications, the inventory is written-down&#160;through a charge to cost of goods sold. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged,<span style="font-style:italic;">&#160;Biovance</span><span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;currently has a shelf-life&#160;of five years in the United&#160;States and between two and three years outside of the United&#160;States, and Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;has a shelf-life&#160;of five years. If actual market conditions are less favorable than those projected by management, inventory write-downs&#160;may be required. Inventory, net of current portion on the Company&#8217;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:68.57%;"/>
<td style="width:1.45%;"/>
<td style="width:29.97%;"/>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 7 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shorter of the estimated useful life and the lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress&#160;and depreciated once placed into service.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Tangible Long-Lived Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Impairment of Tangible Long-Lived Assets</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible long-lived&#160;assets consist of property, plant and equipment. Tangible long-lived&#160;assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived&#160;asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived&#160;asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on tangible long-lived&#160;assets during the years ended December&#160;31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under Accounting Standards Codification 805,&#160;<span style="font-style:italic;">Business Combinations</span>, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business. If the single asset or group of similar assets does not meet the threshold, an entity must next evaluate whether both an input and substantive process are present.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i)&#160;identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii)&#160;the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is tested for impairment at least annually. Acquired IPR&amp;D is recognized at fair value and initially characterized as an indefinite-lived&#160;intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. Transaction costs related to business combinations are expensed as incurred.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, the selection of valuation methodologies, estimates of future revenue and cash flows, expected long-term&#160;market growth, future expected operating expenses, costs of capital and appropriate discount rates. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and, as a result, actual results may differ materially from estimates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition-related&#160;contingent consideration, which consists of potential milestone and royalty obligations (see Note 11), was recorded in the consolidated balance sheets at its acquisition-date&#160;estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related&#160;contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The fair value measurement is based on significant inputs not observable by market participants and thus represents a Level 3 input in the fair value hierarchy (see Note 4).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AssetAcquisitionsPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Asset Acquisitions</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research and development expense at the acquisition date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In Process Research and Development Policy</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Process Research and Development</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived&#160;intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived&#160;asset and amortized over its estimated useful life.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of an IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indefinite-lived&#160;IPR&amp;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived&#160;IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived&#160;IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived&#160;IPR&amp;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived&#160;IPR&amp;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived&#160;IPR&amp;D. Under either approach, if the fair value of the indefinite-lived&#160;IPR&amp;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the year ended December&#160;31, 2020, the Company recognized an impairment charge related to its indefinite-lived&#160;IPR&amp;D of $129,400. No such charge was recognized during the year ended December 31, 2021 (see Note 8).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the third quarter of 2020, the Company managed its operations as one reporting unit. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the change in reporting units, goodwill was required to be allocated across the operating segments under the new reporting structure. Goodwill was attributed to each reporting unit based on the acquired value, which is reflective of the relative fair value.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company&#8217;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, not to exceed the total amount of goodwill allocated to the reporting unit.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock', window );">Preferred Stock Warrants Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock Warrants Liabilities</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the business combination with GX (see Notes 1 and 3), the Company classified warrants for the purchase of shares of its convertible preferred stock (see Note 12) as liabilities on its consolidated balance sheets as these warrants were freestanding financial instruments that may have required the Company to transfer assets upon exercise. The warrant liabilities, which consisted of warrants for the purchase of Series B convertible preferred stock, were initially recorded at fair value upon the date of issuance of each warrant and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liabilities were recognized as a component of other (expense) income in the consolidated statement of operations. Fair value of the preferred stock warrant liabilities were remeasured through the July 16, 2021 closing date on the consolidated statement of operations until the liability was reclassified to equity on the closing date. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leases</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into lease agreements for its laboratory and office facilities. The Company determines if a lease arrangement is an operating lease or capital lease at inception. Rent expense is recognized on a straight-line&#160;basis over the term of the lease. Incentives granted under the Company&#8217;s facilities leases, including allowances to fund leasehold improvements and rent holidays, are recorded as a deferred rent liability and are recognized as reductions to rental expense on a straight-line&#160;basis over the remaining term of the lease.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers the nature of the renovations and the Company&#8217;s involvement during the construction period of newly leased office space to determine if it is considered to be the owner of the construction project during the construction period. If the Company determines that it is the owner of the construction project, it is required to capitalize the fair value of the asset, including potentially the building, construction costs incurred, and capitalized interest, on its consolidated balance sheet along with a corresponding financing liability (&#8220;build-to-suit&#160;accounting&#8221;). Upon occupancy for build-to-suit&#160;leases, the Company assesses whether the circumstances qualify for sales recognition under the sale-leaseback&#160;accounting guidance. If the lease meets the sale-leaseback&#160;criteria, the Company will remove the asset and related financial obligation from the balance sheet and evaluate the lease for treatment as a capital or operating lease. If upon completion of construction, the project does not meet the sale-leaseback&#160;criteria, the leased property will be treated as a capital lease for financial reporting purposes.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>, Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;and MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;and UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term&#160;pregnancies), and license, royalty and other operations (i.e., license agreement with Sanuwave Health Inc.).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Product sales and rentals</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biovance<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;is a low frequency ultrasound system used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates and bacteria. The MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System consists of a generator and treatment wand (collectively, the &#8220;MIST Equipment&#8221;) along with single-use&#160;applicators (the &#8220;MIST Applicators&#8221;) and optional accessories (e.g., roll stand and carts).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has the ability to</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns. The Company offers product warranties which provide assurance that the product will function as expected and in accordance with specification. Customers can purchase warranties separately and these warranties give rise to a separate performance obligation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;Therapy System had both software and non-software&#160;(e.g., hardware) components that function together to deliver the product&#8217;s essential functionality. In addition, the hardware sold could not be used apart from the embedded software. The MIST Equipment was obtained by the customer in three ways: (a)&#160;the purchase of the MIST Equipment outright; (b)&#160;the lease of the MIST Equipment for a monthly rental fee; or (c)&#160;pay-per-use&#160;arrangement whereupon the Company provided the MIST Equipment for a single pay per use fee, subject to a minimum purchase requirement of MIST Applicators. MIST Applicators were separately ordered and purchased by customers who opted to purchase or directly lease the equipment. In addition, the Company offered the MIST Equipment for a standard 90&#160;day evaluation period at no charge to the customer for the MIST Equipment; however, MIST Applicators were required to be purchased during the evaluation term. When the Company leased or entered into a pay-per-use&#160;arrangement, it retained title to the equipment at all times.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For multiple-element&#160;arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. When the Company&#8217;s customer arrangements are multiple-element&#160;arrangements that contains a lease or pay-per-use&#160;arrangement, the Company allocates the arrangement consideration between the lease deliverable (i.e., the MIST Equipment) and non-lease&#160;deliverable (i.e., the MIST Applicators). The consideration related to the pay-per-use&#160;arrangements was allocated to the lease deliverable based on the &#8220;Minimum Volume Method&#8221;, which used the contractual minimum volume in the relative fair value calculation because the ultimate level of MIST Applicator purchases was unknown. The consideration allocated related to the lease arrangement was established in the lease arrangement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company provides inventory to certain customers through pre-arranged&#160;agreements on a consignment basis. Customers consigned inventory is maintained and stored by certain customers; however, ownership remains with the Company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Services</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">License, royalty and&#160;other</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the license agreement with Sanuwave Health Inc. (&#8220;Sanuwave&#8221;) which acquired certain assets comprising its MIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>/UltraMIST<span style="font-size:6pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>&#160;business (see Note 14), the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognized the quarterly license fee over each quarterly term based on the actual sales occurring over the period. The license agreement with Sanuwave was terminated during the third quarter of 2021 due to an uncured material breach.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up&#160;basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ee Note </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for further discussion of the Company&#8217;s license agreements.</span></p>
<p id="DA_RN_3767174097100001138" style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the<span style="font-size:12pt;color:#000000;"> </span><span style="color:#000000;">consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order). </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying Accounting Standards Codification 606,&#160;<span style="font-style:italic;">Revenue from Contracts with Customers</span>&#160;(&#8220;ASC 606&#8221;): (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2)&#160;the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3)&#160;the Company expenses costs to obtain a contract as they are incurred in the expected period of benefit and therefore, the amortization period is one year or less; (4)&#160;the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are recorded as selling, general and administrative expenses; (5)&#160;the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; and (6)&#160;the Company does not disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related&#160;expenses, depreciation and amortization, stock-based&#160;compensation, third-party&#160;license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#8217;s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising and Marketing Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $252 and $764 for the years ended December&#160;31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Grants</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company recorded a reduction of $290 to research and development expense resulting from grant awards for the year ended December&#160;31, 2020. The Company did not receive grant monies during 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All patent-related&#160;costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures all stock-based&#160;awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based&#160;awards with only service-based&#160;vesting conditions and records the expense for these awards using a straight-line&#160;method.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2020, the Company&#8217;s Board of Directors approved the award of performance-based&#160;stock options to a non-employee&#160;consultant who also serves as a director for the Company (see Note 13). The performance-based&#160;stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based&#160;awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based&#160;awards and adjusts expense accordingly on a cumulative basis.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes&#160;option-pricing&#160;model. The Company historically has been a private company and lacks company-specific&#160;historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#8217;s stock options granted to employees is determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock options granted to non-employee&#160;consultants is equal to the contractual term of the option award. The risk-free&#160;interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future (see Note 13).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, the Company awarded options to its President which have market-based vesting conditions. <span style="Background-color:#FFFFFF;font-family:Calibri;">The Company uses the Monte-Carlo model in order to calculate the fair value of the market-based awards. Also in 2021, the Company granted restricted stock units (&#8220;RSU&#8221;), the fair value of which is determined based on the stock price on the date of grant. </span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies stock-based&#160;compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is reversed in the period of the forfeiture.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step&#160;process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not&#160;to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss per&#160;Share</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average&#160;number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, stock options and warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average&#160;number of shares of common </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,643,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,533,868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,167,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,811,204</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,694,763</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,621,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making&#160;group, in deciding how to allocate resources in assessing performance. Prior to the third quarter of 2020, the Company managed its operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December&#160;31, 2021 and 2020 in Note 18.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Significant Customers</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Significant Customers</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United&#160;States. During the year ended December 31, 2021, the Company had one customer (Customer A) provide for 38% of revenue and another customer provide for 11% of total revenue. In the year ended December&#160;31, 2020, the Company had one customer provide for 13% of the revenue earned. As of December&#160;31, 2021, Customer A comprised approximately 47% of the Company&#8217;s outstanding accounts receivable. As of December&#160;31, 2020, one of the Company&#8217;s customers comprised approximately 24% of the Company&#8217;s outstanding accounts receivables.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Emerging Growth Company</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging&#160;growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2019-12, <span style="font-style:italic;">Simplifying the Accounting for Income Taxes</span> (Topic 740) (&#8220;ASU 2019-12&#8221;). The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification 740 and clarifying existing guidance to facilitate consistent application. The standard was effective for the Company beginning on January 1, 2021. The adoption of ASU 2019-12 as of January 1, 2021 did not have a material impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently Issued Accounting Pronouncements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2020, the FASB issued ASU 2020-06, (Subtopic 470-20):&#160;<span style="font-style:italic;">Debt &#8212; Debt with Conversion and Other Options</span>&#160;(&#8220;ASU 2020-06&#8221;) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06&#160;includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity&#8217;s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06&#160;will require entities to use the &#8220;if-converted&#8221; method when calculating diluted earnings per share for convertible instruments. ASU 2020-06&#160;is effective for fiscal years beginning after December&#160;15, 2021 (fiscal year 2022 for the Company), including interim periods within those fiscal years. As no debt is currently outstanding, the Company does not expect the impact of ASU 2020-06&#160;to have an impact on its financial position, results of operations or cash flows.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13, <span style="font-style:italic;">Financial Instruments &#8212; Credit Losses</span> (&#8220;ASU 2016-13&#8221;), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2016, the FASB issued ASU No.&#160;2016-02<span style="font-style:italic;">, Leases (Topic&#160;842)&#160;</span>(&#8220;ASU 2016-02&#8221;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line&#160;basis over the term of the lease. A lessee is also required to record a right-of-use&#160;asset and a lease liability for all leases with a term of greater than 12&#160;months regardless of their classification. Leases with a term of 12&#160;months or less may be accounted for similar to existing guidance for operating leases today. The guidance is effective for the Company for annual reporting periods beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022, with early adoption permitted. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted ASC 842 as of January 1, 2022 using the modified retrospective method, which did not require it to restate prior periods and did not have an impact on retained earnings. The Company has elected the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its Consolidated Balance Sheets. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company will determine whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the Consolidated Balance Sheets as right-of-use assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets will be recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the right-of-use asset. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not yet finalized the impact of this new standard, however, the Company is expecting its adoption will have a material effect on the Company&#8217;s consolidated financial statements.&#160;&#160;Upon adoption, the most significant impact relates to an equity adjustment and the recognition of a new right-of-use asset and lease liability arising from the derecognition of existing assets and liabilities from the failed sale-leaseback transaction of the Company&#8217;s Florham Park, New Jersey facility.&#160;&#160;Upon adoption, the Company will derecognize the portion of the existing build-to-suit facility financing obligation and the corresponding existing asset that was recorded solely as a result of the transaction&#8217;s build-to-suit designation in accordance with Topic 840.&#160;&#160;The difference associated with this derecognition will be recorded as an adjustment to equity as of January 1, 2022.&#160;&#160;The Company will then follow the general lessee transition requirements discussed above to record the new right-of-use asset and lease liability in accordance with Topic 842.&#160;&#160;Certain Company-paid costs associated with this transaction that were capitalized will not be derecognized and thus will be carried over and </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">retained at their currently recognized balances as they would have been recognized in the absence of the build-to-suit designation.&#160;&#160;Further information regarding this transaction is discussed within Note 11.&#160;&#160;&#160;&#160; </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AssetAcquisitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AssetAcquisitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its emerging growth company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Government grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RestrictedCashPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RestrictedCashPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784659400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense</a></td>
<td class="text">Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:68.57%;"/>
<td style="width:1.45%;"/>
<td style="width:29.97%;"/>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 7 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shorter of the estimated useful life and the lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvement<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,289</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and production equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,884</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery, equipment and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,054</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,404</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,163</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,077</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redeemable convertible preferred stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,643,496</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,533,868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,167,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,811,204</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,694,763</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119,621,865</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783040856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Disposals (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsAbstract', window );"><strong>Business Combinations And Disposals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock', window );">Schedule of assets and liabilities were divested/written off</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following assets and liabilities were divested/written off in this transaction:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets Divested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,901</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,296</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,764</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets divested</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,413</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationsAndDisposalsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations and disposals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationsAndDisposalsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities written off of this transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784686744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems', window );"><strong>Fair Value Of Financial Assets And Liabilities Tables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents - money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,488</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,488</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,488</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,188</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,222</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,222</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability - Sponsor Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability - Public Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,362</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,362</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">245,822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">258,184</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents &#8211; money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,715</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350,007</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December&#160;31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in to (out of)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">settlements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,145</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232,222</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfers</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">in to (out of)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchases,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">settlements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">adjustments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328,933</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,566</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">273,367</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Aggregate Fair Values of the Warrant Liability</a></td>
<td class="text">
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The following table provides a roll-forward of the aggregate fair values of the Company&#8217;s warrant liabilities for which fair values are determined using Level 3 inputs:</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of warrants issued in connection with Series B</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; preferred stock sale</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,954</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrant at fair value*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,988</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss recognized in earnings from change in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,698</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76,640</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain recognized in earnings from change in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,482</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed at Closing Date (Sponsor Warrants)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,764</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability assumed at Closing Date (Public Warrants)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,438</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of Legacy Celularity Warrants to equity</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(96,398</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock', window );">Schedule of Convertible Note Valuation Model</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant inputs for the convertible note valuation model are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Face value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Coupon rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12% - 17%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.7 - 3.19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000662">0.6</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.29</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n/a</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember', window );">Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems', window );"><strong>Fair Value Of Financial Assets And Liabilities Tables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Fair Value of Warrants Issued</a></td>
<td class="text">Significant inputs for the warrants issued to Dragasac are as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.66 - 10.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17 - 6.95</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price <sup style="font-size:85%;line-height:120%;vertical-align:top">a</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000626">3.67</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33 - 1.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09% - 0.10%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">&#160;</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;">The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems', window );"><strong>Fair Value Of Financial Assets And Liabilities Tables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Fair Value of Warrants Issued</a></td>
<td class="text">Significant inputs for the warrants issued in connection with the Legacy Celularity Series B Preferred Stock are as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.66 - 10.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.17 - 6.95</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price <sup style="font-size:85%;line-height:120%;vertical-align:top">b</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">3.67</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33 - 1.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.60</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.09% - 0.10%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;"/><span style="Background-color:#FFFFFF;">The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_GXSponsorWarrantsMember', window );">G X Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems', window );"><strong>Fair Value Of Financial Assets And Liabilities Tables [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Fair Value of Warrants Issued</a></td>
<td class="text">Significant inputs for the Sponsor Warrants are as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 16,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common share price</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000613">4.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000614">5.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.79</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Financial Assets and Liabilities (Tables) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of convertible note valuation model.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair value significant inputs for warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_GXSponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_GXSponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783037256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock', window );">Schedule of Major Classes of Inventories</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s major classes of inventories were as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,359</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,902</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished goods</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,057</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,016</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, gross</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,318</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,852</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: inventory reserves</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Classification:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,549</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,850</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory, net of current portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,721</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,998</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of inventory current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783490856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfPrepaidExpensesTableTextBlock', window );">Schedule of Prepaid Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid clinical expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,269</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,151</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,399</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,408</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,219</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,076</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,576</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783462120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense</a></td>
<td class="text">Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:68.57%;"/>
<td style="width:1.45%;"/>
<td style="width:29.97%;"/>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful Life</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 - 7 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lab equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr style="height:12pt;">
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shorter of the estimated useful life and the lease term</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,513</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvement<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,468</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,289</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory and production equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,395</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,884</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery, equipment and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,974</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,054</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,404</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,163</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">3)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,086</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,625</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,077</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786069496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of goodwill assigned to the Company&#8217;s operating segments are as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell Therapy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Biobanking</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,374</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127,068</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition of goodwill related to sale of UltraMIST business</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,764</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,764</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,610</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,610</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfIntangibleAssetsNetTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated Useful</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lives</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangible assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11 &#8211; 16 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,413</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names &amp; trademarks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 &#8211; 13 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquired rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developed technology</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,170</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade names &amp; trademarks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(220</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reacquired rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,540</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,840</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,306</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,114</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortizable intangible assets, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,687</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,879</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-amortized intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquired IPR&amp;D product rights</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000760">indefinite</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123,187</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Aggregate Amortization Expense Related to Intangible Assets</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December&#160;31, 2021 is estimated as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,193</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,784</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,356</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfIntangibleAssetsNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfIntangibleAssetsNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783194072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical trial expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,644</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,653</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,866</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued wages, bonuses, commissions and vacation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,824</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,991</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals for construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,321</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,661</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,451</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783043016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Payments under Non-Cancelable Operating Leases</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum payments inclusive of the amended lease, by year and in aggregate, under non-cancelable&#160;leases consist of the following as of December&#160;31, 2021:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,895</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,969</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,116</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,531</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,414</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783042296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the Warrants</a></td>
<td class="text">A summary of the warrants is as follows:
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">date</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dragasac Warrant</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,529,818</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;16,&#160;2025</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2020 Series B Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,281,386</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March&#160;16,&#160;2025</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Public Warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,374,992</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July&#160;16,&#160;2026</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsor Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,499,999</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.50</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July&#160;16,&#160;2026</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,686,195</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><span style="Background-color:#FFFFFF;">The exercise price is the lessor of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786161544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfStockBasedCompensationExpenseAbstract', window );"><strong>Schedule Of Stock Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes&#160;option-pricing&#160;model to determine the grant-date&#160;fair value of stock options granted during the years ended December&#160;31, 2021 and 2020:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000936">4.65</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000937">6.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes option activity under the 2021 Plan and the 2017 Plan:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contract life</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31,2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,954,174</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000964">7.6</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,572</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,662,072</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108,369</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.88</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,340,712</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,167,165</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000965">7.3</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,633</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,681,736</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(703,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,080,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.04</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,064,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000966">7.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,525</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,064,586</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.23</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000967">7.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,525</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,840,068</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000968">6.9</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,898</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Activity Related to RSU Stock-Based Payment Awards</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes activity related to RSU stock-based payment awards:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">grant date fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">488,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,900</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">474,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company recorded stock-based&#160;compensation expense in the following expense categories of its consolidated statements of operations:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of goods sold</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,105</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,010</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,371</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfStockBasedCompensationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfStockBasedCompensationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784648856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Product And Services</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information about disaggregated revenue by product and services:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product sales and rentals</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,801</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,854</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License, royalty and other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,012</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,868</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,335</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,278</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Changes in Deferred Revenue from Contract Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides changes in deferred revenue from contract liabilities:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at January 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,449</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferral of revenue*</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,928</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,532</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of unearned revenue**</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,310</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,916</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,067</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,449</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">2020 includes $9,505&#160;received in advance of performing services under a license agreement (see Note 15).&#160;&#160;The remainder of the 2020 and all of the 2021 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">During the third quarter of 2021, the Company terminated the license agreement with Sanuwave due to an uncured material breach (See Note 15). As a result, the Company recognized the remaining deferred revenue of $6,754&#160;that was to be recognized on a straight-line basis over the non-cancelable term of the license agreement.</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779851880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Current and Deferred Tax Provision</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s current and deferred tax provision is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax expense (benefit):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current income tax expense (benefit)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax expense (benefit):</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,366</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,351</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax expense (benefit)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,717</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total (benefit) from income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the U.S. Federal Statutory Income Tax</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal statutory income tax rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes, net of federal benefits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest accretion expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46.1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark to market warrant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other permanent items</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Liabilities</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities as of years ended December&#160;31, 2021 and 2020 consisted of the following:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,327</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,495</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,672</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,673</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,748</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Startup costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">729</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,544</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unicap</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imputed interest on contingent payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,340</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fee capitalization and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,550</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,587</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,535</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,158</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,519</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,062</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,232</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,930</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(29,232</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(92,297</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrecognized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Benefits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">786</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase related to current year tax provisions</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase related to current year tax provisions</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td>
<td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,270</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783192952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Financial Information by Segment</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial information by segment is as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative Disease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,522</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,335</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,682</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,107</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,119</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,450</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64,017</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,693</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment contribution</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(85,107</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(246</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,017</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(148,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,953</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,058</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a) Components of other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,145</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,192</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,953</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cell</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Therapy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioBanking</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Degenerative</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,556</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,722</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,262</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,084</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,346</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,470</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,653</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,348</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,573</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,043</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Segment contribution</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,470</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,609</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,264</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,573</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,697</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indirect expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151,925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(a) Components of other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,566</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment of acquired intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,394</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,228</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787660248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th">
<div>Oct. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 07, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>ClinicalTrial</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems', window );"><strong>Description Of Organization And Business Operations Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 24,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationSharesExchangeRatioDescription', window );">Business combination, shares exchange ratio description</a></td>
<td class="text">1.00&#160;share of Legacy Celularity for approximately&#160;0.7686&#160;shares of Celularity<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationSharesExchangeRatio', window );">Business combination, shares exchange ratio</a></td>
<td class="nump">0.7686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfClinicalTrials', window );">Number of clinical trials | ClinicalTrial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AreaOfBuilding', window );">Area of building | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Debt assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear', window );">Substantial doubt about going concern, within one year [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,118,000<span></span>
</td>
<td class="nump">$ 208,233,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,681,000<span></span>
</td>
<td class="nump">$ 563,563,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems', window );"><strong>Description Of Organization And Business Operations Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationSharesExchangeRatio', window );">Business combination, shares exchange ratio</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_HLICellularTherapeuticsLLCMember', window );">HLI Cellular Therapeutics,LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems', window );"><strong>Description Of Organization And Business Operations Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,876,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_AnthrogenesisMember', window );">Anthrogenesis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems', window );"><strong>Description Of Organization And Business Operations Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ContingentValueRightIssuedForEachShare', window );">Contingent value right issued for each share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RegulatoryMilestones', window );">Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_AlliquaAPAMember', window );">Alliqua APA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems', window );"><strong>Description Of Organization And Business Operations Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_CaricordMember', window );">Caricord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems', window );"><strong>Description Of Organization And Business Operations Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AreaOfBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AreaOfBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationSharesExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination shares exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationSharesExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationSharesExchangeRatioDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination shares exchange ratio description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationSharesExchangeRatioDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ContingentValueRightIssuedForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value right issued for each share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ContingentValueRightIssuedForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of Organization and Business Operations (Details) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846462&amp;loc=SL51888449-203568<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_HLICellularTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_HLICellularTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_AnthrogenesisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_AnthrogenesisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_AlliquaAPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_AlliquaAPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_CaricordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_CaricordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779611624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,836,000<span></span>
</td>
<td class="nump">$ 15,202,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of acquired intangible assets</a></td>
<td class="nump">$ 129,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">129,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquipmentExpense', window );">Equipment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_EquipmentEvaluationPeriod', window );">Equipment evaluation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and Marketing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="nump">764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant', window );">Reduction of research and development expense resulting from grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 290,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority', window );">Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with the tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfBusinessSegments', window );">Number of business segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Another customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Accounts Receivable | One Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_EquipmentEvaluationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment evaluation period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_EquipmentEvaluationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with the tax authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfBusinessSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of business segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfBusinessSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of research and development expense resulting from grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquipmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquipmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=celu_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=celu_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=celu_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=celu_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786186776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Estimated Useful Life</a></td>
<td class="text">26 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Estimated Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and Equipment, Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and Equipment, Estimated Useful Lives</a></td>
<td class="text">shorter of the estimated useful life and the lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786478648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">69,694,763<span></span>
</td>
<td class="nump">119,621,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,643,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">26,533,868<span></span>
</td>
<td class="nump">17,167,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">474,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding</a></td>
<td class="nump">42,686,195<span></span>
</td>
<td class="nump">19,811,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780198280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Disposals - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Conversion of common stock term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:




&#160;

a)

each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (&#8220;Company Class A Common Stock&#8221;) equal to the Exchange Ratio (as defined below) (the &#8220;Per Share Merger Consideration&#8221;);




&#160;

b)

each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, &#8220;Legacy Celularity Capital Stock&#8221;) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;




&#160;

c)

each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;




&#160;

d)

each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Company Class A Common Stock (and not Celularity Capital Stock) (each, a &#8220;Converted Warrant&#8221;) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Company Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the &#8220;Celularity Warrant Shares&#8221;) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Company Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); and




&#160;

e)

each option to purchase Legacy Celularity Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a &#8220;Legacy Celularity Option&#8221;) was assumed by GX and converted into an option to purchase shares of Company Class A Common Stock (each, a &#8220;Converted Option&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,304,000<span></span>
</td>
<td class="nump">$ 123,304,000<span></span>
</td>
<td class="nump">$ 127,068,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessAcquisitionTransactionCostsProceedsNet', window );">Business acquisition transaction costs proceeds, net</a></td>
<td class="nump">$ 108,786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Business acquisition, transaction costs</a></td>
<td class="nump">$ 21,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,710,000<span></span>
</td>
<td class="nump">412,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,482,000)<span></span>
</td>
<td class="nump">$ 58,686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of liability classified legacy warrants to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,307,884<span></span>
</td>
<td class="nump">18,529,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,307,884<span></span>
</td>
<td class="nump">18,529,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SubscriptionAgreementsDescription', window );">Subscription Agreements, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the &#8220;Subscribers&#8221;) purchased from Celularity an aggregate of 8,340,000 shares of Class A common stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the &#8220;Subscription Agreements&#8221;). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AssetPurchaseAgreementDescription', window );">Asset purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August&#160;6, 2020, the Company executed (i)&#160;an asset purchase agreement to sell certain assets comprising its MIST&#174;/UltraMIST&#174;&#160;business to Sanuwave and (ii)&#160;a five-year&#160;licensing agreement with Sanuwave for total consideration of $24,524 (the &#8220;Sanuwave Transaction&#8221;), of which $20,000 was paid at or prior to closing. The remaining $4,524 of the purchase price was financed through a convertible promissory note due on or before August&#160;6, 2021. The convertible promissory note can be converted into shares of Sanuwave stock at the election of the Company any time on or after January&#160;1, 2021. As of December 31, 2021 the fair value of the convertible promissory note related to Sanuwave was $2,488 which is included in other current assets on the consolidated balance sheet.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseArrangementTerm', window );">License arrangement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ConsiderationDescription', window );">Total consideration, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;calculate the goodwill attributed to the UltraMIST business, (ii)&#160;determine the allocation of arrangement consideration to the three performance obligations and (iii)&#160;determine the loss on sale of the UltraMIST business. The Company utilized a discounted cash flow model to value the UltraMIST business, which determined the fair value of the UltraMIST business was $15,019. Significant inputs of this discounted cash flow model included (i)&#160;a discount rate of 11%, (ii)&#160;tax rate of 26% and (iii)&#160;a long-term&#160;growth rate of 2%. The remaining proceeds of $9,505 were allocated to the license agreement on a residual basis. During the third quarter of 2020, the Company recognized a loss on sale of UltraMIST of $4,434, which included approximately $40 in related professional fees. Due to the Company&#8217;s tax position as of the closing date, there was no tax impact resulting from the sale of the UltraMIST business.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=celu_UltraMISTBusinessMember', window );">UltraMIST Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Fair value of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,019,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow', window );">Discount rate of discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow', window );">Tax rate of discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow', window );">Long term growth rate of discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Loss on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees', window );">Professional fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_GXWarrantsMember', window );">GX Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant or Right, Reason for Issuance, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, GX had previously issued public warrants and private placement warrants (collectively, the &#8220;GX Warrants&#8221;) as part of the Units in its initial public offering in May 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfWarrants', window );">Fair Value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_AlphaFirstMergerSubIncorporationMember', window );">First Merger Sub</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_SurvivingCorporationMember', window );">Surviving Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_GXTrustAccountMember', window );">GX Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessAcquisitionTransactionCostsProceedsNet', window );">Business acquisition transaction costs proceeds, net</a></td>
<td class="nump">$ 5,386,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_PublicEquityFinancingMember', window );">PIPE Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessAcquisitionTransactionCostsProceedsNet', window );">Business acquisition transaction costs proceeds, net</a></td>
<td class="nump">$ 83,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_PublicEquityFinancingMember', window );">PIPE Investors | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_PalantirTechnologiesIncMember', window );">Palantir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessAcquisitionTransactionCostsProceedsNet', window );">Business acquisition transaction costs proceeds, net</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate number of shares purchased</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of liability classified legacy warrants to equity</a></td>
<td class="nump">$ 96,398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_MISTUltraMISTBusinessMember', window );">M I S T Ultra M I S T Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Fair value of consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,524,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Consideration financed through convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,524,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible promissory note due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  06,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionDate', window );">Convertible promissory note conversion date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_MISTUltraMISTBusinessMember', window );">M I S T Ultra M I S T Business | Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfConvertiblePromissoryNote', window );">Fair value of convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Other intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital', window );">Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital</a></td>
<td class="nump">$ 10,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationExchangeRatioOfCommonStock', window );">Each one Shares reflecting as exchange ratio in business combination</a></td>
<td class="nump">$ 0.7686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">122,487,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">122,487,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OptionToPurchaseSharesOfCommonStock', window );">Option to purchase shares of common stock</a></td>
<td class="nump">21,723,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase shares of common stock</a></td>
<td class="nump">42,686,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | PIPE Investors | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_BusinessCombinationsAndDisposalsLineItems', window );"><strong>Business Combinations and Disposals [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate number of shares purchased</a></td>
<td class="nump">8,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price</a></td>
<td class="nump">$ 83,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AssetPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of asset purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AssetPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessAcquisitionTransactionCostsProceedsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition transaction costs proceeds, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessAcquisitionTransactionCostsProceedsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationExchangeRatioOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination, exchange ratio of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationExchangeRatioOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_BusinessCombinationsAndDisposalsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations and disposals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_BusinessCombinationsAndDisposalsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation discount rate of discounted cash flow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation long term growth rate of discounted cash flow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation tax rate of discounted cash flow.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueOfConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueOfConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicenseArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License arrangement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicenseArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OptionToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OptionToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassified from warrant liability to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SubscriptionAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SubscriptionAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of basis for conversion of convertible common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date debt instrument can be converted into equity, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=celu_UltraMISTBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=celu_UltraMISTBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_GXWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_GXWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_AlphaFirstMergerSubIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_AlphaFirstMergerSubIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_SurvivingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_SurvivingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_GXTrustAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_GXTrustAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_PublicEquityFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_PublicEquityFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_PalantirTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_PalantirTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_MISTUltraMISTBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_MISTUltraMISTBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_CelularityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_CelularityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529781522376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations and Disposals - Schedule of assets and liabilities were divested/written off (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 06, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AssetsDivestedAbstract', window );"><strong>Assets Divested</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="nump">$ 1,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="nump">13,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, and equipment, net</a></td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">3,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets divested</a></td>
<td class="nump">$ 19,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AssetsDivestedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets Divested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AssetsDivestedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786537112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ConvertibleNoteReceivable', window );">Convertible note receivable</a></td>
<td class="nump">$ 2,488<span></span>
</td>
<td class="nump">$ 4,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">39,188<span></span>
</td>
<td class="nump">49,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">232,222<span></span>
</td>
<td class="nump">273,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PreferredStockWarrants', window );">Preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilitySponsorWarrants', window );">Warrant liability - Sponsor Warrants</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilityPublicWarrants', window );">Warrant liability - Public Warrants</a></td>
<td class="nump">12,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">258,184<span></span>
</td>
<td class="nump">350,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money market funds</a></td>
<td class="nump">36,700<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">36,700<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilityPublicWarrants', window );">Warrant liability - Public Warrants</a></td>
<td class="nump">12,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">12,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents - money market funds</a></td>
<td class="nump">36,700<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ConvertibleNoteReceivable', window );">Convertible note receivable</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">4,715<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,488<span></span>
</td>
<td class="nump">4,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">232,222<span></span>
</td>
<td class="nump">273,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PreferredStockWarrants', window );">Preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilitySponsorWarrants', window );">Warrant liability - Sponsor Warrants</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 245,822<span></span>
</td>
<td class="nump">$ 350,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ConvertibleNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible note receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ConvertibleNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PreferredStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PreferredStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantLiabilityPublicWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability Public Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantLiabilityPublicWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantLiabilitySponsorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability Sponsor Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantLiabilitySponsorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787648312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value, assets, level 1 to level 2 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value, assets, level 2 to level 1 transfers, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value, assets, transfers into level 3, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value, assets, transfers out of level 3, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueNetAssetsLiability', window );">Fair value of the warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,962,000<span></span>
</td>
<td class="nump">$ 76,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember', window );">Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 33,435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">62,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">24,438,000<span></span>
</td>
<td class="nump">12,362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember', window );">Sponsors Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 34,764,000<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueNetAssetsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueNetAssetsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779371384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ContingentConsiderationObligation', window );">Beginning balance</a></td>
<td class="nump">$ 273,367<span></span>
</td>
<td class="nump">$ 328,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Fair value adjustments</a></td>
<td class="num">(41,145)<span></span>
</td>
<td class="num">(55,566)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ContingentConsiderationObligation', window );">Ending balance</a></td>
<td class="nump">$ 232,222<span></span>
</td>
<td class="nump">$ 273,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ContingentConsiderationObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration liability exceeding amount recognized Fair Value Measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ContingentConsiderationObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787636568">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Aggregate Fair Values of the Warrant Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueNetAssetsLiability', window );">Fair value, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Fair value of warrants issued in connection with Series B preferred stock sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ProceedsFromIssuanceOfWarrant', window );">Issuance of warrant at fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_GainLossRecognizedInEarningsFromChangeInFairValues', window );">Gain (Loss) recognized in earnings from change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,482)<span></span>
</td>
<td class="nump">46,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReclassificationOfLegacyCelularityWarrantsToEquity', window );">Reclassification of Legacy Celularity Warrants to equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(96,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValueNetAssetsLiability', window );">Fair value, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,962<span></span>
</td>
<td class="nump">$ 76,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember', window );">Sponsors Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilityAssumedAtClosingDate', window );">Warrant liability assumed at Closing Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantLiabilityAssumedAtClosingDate', window );">Warrant liability assumed at Closing Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 24,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The warrants issued at fair value were immediately charged to expense see Note 12.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValueNetAssetsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValueNetAssetsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_GainLossRecognizedInEarningsFromChangeInFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) recognized in earnings from change in fair values.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_GainLossRecognizedInEarningsFromChangeInFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ProceedsFromIssuanceOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ProceedsFromIssuanceOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReclassificationOfLegacyCelularityWarrantsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of Legacy Celularity Warrants to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReclassificationOfLegacyCelularityWarrantsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantLiabilityAssumedAtClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability assumed at closing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantLiabilityAssumedAtClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529776751096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Jul. 16, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember', window );">Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValuesOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">$ 9.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValuesOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">9.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">3 months 29 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValuesOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">10.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FairValuesOfCommonStock', window );">Fair value of common stock</a></td>
<td class="nump">10.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6.95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember', window );">Sponsors Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price</a></td>
<td class="nump">10.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend Yield | Sponsors Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">0.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">0.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Minimum | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Minimum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Maximum | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Maximum | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate | Sponsors Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">0.79<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">54<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">90<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility | Sponsors Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants input</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63.0<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FairValuesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FairValuesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_SponsorsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779523592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Parenthetical) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Jul. 16, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember', window );">Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageOfExercisePrice', window );">Percentage of exercise price</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ClassOfWarrantExercisePriceDescription', window );">Exercise price, description</a></td>
<td class="text">(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#8217;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#8217;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ClassOfWarrantExercisePriceDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant exercise price, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ClassOfWarrantExercisePriceDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PercentageOfExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PercentageOfExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780154456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of Convertible Note Valuation Model (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FaceValueOfNotesReceivable', window );">Face value | $</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageOfCouponRate', window );">Coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ValuationModelThatRelateToSanuwaveCommonStock', window );">Stock price | $ / shares</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ValuationInputForConvertiblePromissoryNoteTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageOfCouponRate', window );">Coupon rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ValuationInputForConvertiblePromissoryNoteTerm', window );">Term (years)</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageOfCouponRate', window );">Coupon rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ValuationInputForConvertiblePromissoryNoteTerm', window );">Term (years)</a></td>
<td class="text">3 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ValuationInputForConvertiblePromissoryNote', window );">Valuation input for convertible note</a></td>
<td class="nump">0.29<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ValuationInputForConvertiblePromissoryNote', window );">Valuation input for convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FaceValueOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of face value of notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FaceValueOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PercentageOfCouponRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coupon rate is the rate of interest paid by bond issuers on the bond&#8217;s face value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PercentageOfCouponRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ValuationInputForConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation input for a convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ValuationInputForConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ValuationInputForConvertiblePromissoryNoteTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation input for a convertible promissory note term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ValuationInputForConvertiblePromissoryNoteTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ValuationModelThatRelateToSanuwaveCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation model that relate to sanuwave common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ValuationModelThatRelateToSanuwaveCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786308168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Major Classes of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InventoryRawMaterialsCurrentAndNoncurrent', window );">Raw materials</a></td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="nump">$ 376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InventoryWorkInProgressCurrentAndNoncurrent', window );">Work in progress</a></td>
<td class="nump">5,902<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InventoryFinishedGoodsCurrentAndNoncurrent', window );">Finished goods</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">5,016<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InventoryGrossCurrentAndNoncurrent', window );">Inventory, gross</a></td>
<td class="nump">12,318<span></span>
</td>
<td class="nump">5,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InventoryReserveCurrentAndNoncurrent', window );">Less: inventory reserves</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InventoryNetCurrentAndNoncurrent', window );">Inventory, net</a></td>
<td class="nump">12,270<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">9,549<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, net of current portion</a></td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">$ 1,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InventoryFinishedGoodsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory finished goods current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InventoryFinishedGoodsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InventoryGrossCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, gross current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InventoryGrossCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InventoryRawMaterialsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InventoryRawMaterialsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InventoryReserveCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InventoryReserveCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InventoryWorkInProgressCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory work in progress current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InventoryWorkInProgressCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787506040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses - Schedule of Prepaid Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PrepaidClinicalExpense', window );">Prepaid clinical expenses</a></td>
<td class="nump">$ 3,269<span></span>
</td>
<td class="nump">$ 5,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expense</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">2,408<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 7,076<span></span>
</td>
<td class="nump">$ 6,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PrepaidClinicalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PrepaidClinicalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779365832">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 105,404<span></span>
</td>
<td class="nump">$ 97,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(14,779)<span></span>
</td>
<td class="num">(7,086)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,625<span></span>
</td>
<td class="nump">90,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">12,513<span></span>
</td>
<td class="nump">12,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">71,468<span></span>
</td>
<td class="nump">55,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_LaboratoryAndProductionEquipmentMember', window );">Laboratory and Production Equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,395<span></span>
</td>
<td class="nump">5,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_MachineryEquipmentAndFixturesMember', window );">Machinery, Equipment and Fixtures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,974<span></span>
</td>
<td class="nump">3,704<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,054<span></span>
</td>
<td class="nump">$ 19,773<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $5,971 $2,624 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes $12,513 at December 31, 2021 and 2020 under financing lease resulting from a failed sale leaseback (see Note 11).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes $70,959 and $55,273 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_LaboratoryAndProductionEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_LaboratoryAndProductionEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_MachineryEquipmentAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_MachineryEquipmentAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529785153416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation', window );">Sale leaseback transaction, accumulated depreciation</a></td>
<td class="nump">$ 5,971<span></span>
</td>
<td class="nump">$ 2,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionHistoricalCost', window );">Sale leaseback transaction</a></td>
<td class="nump">12,513<span></span>
</td>
<td class="nump">12,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleLeasebackTransactionHistoricalCost', window );">Sale leaseback transaction</a></td>
<td class="nump">$ 70,959<span></span>
</td>
<td class="nump">$ 55,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=123386837&amp;loc=d3e51840-112757<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=123386837&amp;loc=d3e51843-112757<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 55<br> -Paragraph 50<br> -URI http://asc.fasb.org/extlink&amp;oid=123386837&amp;loc=d3e51831-112757<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123417830&amp;loc=SL77919786-209982<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406127&amp;loc=d3e45014-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleLeasebackTransactionHistoricalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The historical cost of the asset(s) sold in connection with the sale of the property to another party and the lease of the property back to the seller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=123386837&amp;loc=d3e51840-112757<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 55<br> -Paragraph 50<br> -URI http://asc.fasb.org/extlink&amp;oid=123386837&amp;loc=d3e51831-112757<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123417830&amp;loc=SL77919786-209982<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=123386837&amp;loc=d3e51843-112757<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleLeasebackTransactionHistoricalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784319464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 6,625<span></span>
</td>
<td class="nump">$ 4,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">105,404<span></span>
</td>
<td class="nump">97,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 2,054<span></span>
</td>
<td class="nump">$ 19,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786189096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at beginning of year</a></td>
<td class="nump">$ 123,304,000<span></span>
</td>
<td class="nump">$ 127,068,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness', window );">Derecognition of goodwill related to sale of UltraMIST business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,764,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of year</a></td>
<td class="nump">123,304,000<span></span>
</td>
<td class="nump">123,304,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyMember', window );">Cell Therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at beginning of year</a></td>
<td class="nump">112,347,000<span></span>
</td>
<td class="nump">112,347,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of year</a></td>
<td class="nump">112,347,000<span></span>
</td>
<td class="nump">112,347,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_DegenerativeDiseaseMember', window );">Degenerative Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at beginning of year</a></td>
<td class="nump">3,610,000<span></span>
</td>
<td class="nump">7,374,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness', window );">Derecognition of goodwill related to sale of UltraMIST business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,764,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of year</a></td>
<td class="nump">3,610,000<span></span>
</td>
<td class="nump">3,610,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_BiobankingMember', window );">Biobanking</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at beginning of year</a></td>
<td class="nump">7,347,000<span></span>
</td>
<td class="nump">7,347,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at end of year</a></td>
<td class="nump">$ 7,347,000<span></span>
</td>
<td class="nump">$ 7,347,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill derecognition of goodwill related to sale of UltraMIST business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_DegenerativeDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_DegenerativeDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_BiobankingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_BiobankingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780095432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AmortizableIntangibleAssetsAbstract', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 23,993<span></span>
</td>
<td class="nump">$ 23,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LessAccumulatedAmortizationAbstract', window );"><strong>Less: Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(9,306)<span></span>
</td>
<td class="num">(7,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortizable intangible assets, net</a></td>
<td class="nump">14,687<span></span>
</td>
<td class="nump">16,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AcquiredProductRights', window );">Acquired IPR&amp;D product rights</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="nump">108,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 123,187<span></span>
</td>
<td class="nump">$ 125,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IndefiniteLivedIntangibleAssetsAmortizationMethod', window );">Estimated Useful Lives</a></td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AmortizableIntangibleAssetsAbstract', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 16,810<span></span>
</td>
<td class="nump">$ 16,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LessAccumulatedAmortizationAbstract', window );"><strong>Less: Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (5,376)<span></span>
</td>
<td class="num">$ (4,203)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AmortizableIntangibleAssetsAbstract', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 2,413<span></span>
</td>
<td class="nump">$ 2,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LessAccumulatedAmortizationAbstract', window );"><strong>Less: Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (1,170)<span></span>
</td>
<td class="num">$ (906)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade Names &amp; Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AmortizableIntangibleAssetsAbstract', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LessAccumulatedAmortizationAbstract', window );"><strong>Less: Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (220)<span></span>
</td>
<td class="num">$ (165)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade Names &amp; Trademarks | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade Names &amp; Trademarks | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=celu_ReacquiredRightsMember', window );">Reacquired Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AmortizableIntangibleAssetsAbstract', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LessAccumulatedAmortizationAbstract', window );"><strong>Less: Accumulated amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (2,540)<span></span>
</td>
<td class="num">$ (1,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonAmortizedIntangibleAssetsAbstract', window );"><strong>Non-amortized intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AcquiredProductRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of acquired IPR&amp;D product rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AcquiredProductRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AmortizableIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortizable intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AmortizableIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IndefiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets amortization method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IndefiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LessAccumulatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Less accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LessAccumulatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NonAmortizedIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Amortized intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NonAmortizedIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=celu_ReacquiredRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=celu_ReacquiredRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784958520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,192,000<span></span>
</td>
<td class="nump">$ 3,394,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of acquired intangibles</a></td>
<td class="nump">$ 129,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 129,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783612120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">2,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">$ 1,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784486680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AccruedClinicalTrialExpense', window );">Accrued clinical trial expense</a></td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="nump">$ 2,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">2,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued wages, bonuses, commissions and vacation</a></td>
<td class="nump">3,824<span></span>
</td>
<td class="nump">4,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AccrualsForConstructionInProgress', window );">Accruals for construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,321<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 11,661<span></span>
</td>
<td class="nump">$ 13,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AccrualsForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accruals for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AccrualsForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780155864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Borrowings - Related Party - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2021 </div>
<div>USD ($) </div>
<div>Day</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,311,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=celu_LoanAgreementMember', window );">Loan Agreement | CV Starr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan outstanding principal amount</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Convertible promissory note due date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  08,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ShortTermBorrowingAmountEqualToExitFeePercentage', window );">Short term borrowings exit fee</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Number of consecutive business days | Day</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Additional borrowings under the loan agreement</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee', window );">Repayments of short term debt including accrued interest and exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments of short term debt including accrued interest and exit fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ShortTermBorrowingAmountEqualToExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short term borrowing amount equal to exit fee percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ShortTermBorrowingAmountEqualToExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=celu_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=celu_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=celu_CVStarrCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=celu_CVStarrCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780408024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 24, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 13, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,836<span></span>
</td>
<td class="nump">$ 15,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FinancingObligationsNoncurrent', window );">Financing obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,085<span></span>
</td>
<td class="nump">27,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FinancingObligationsCurrent', window );">Current portion of financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
<td class="nump">3,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,222<span></span>
</td>
<td class="nump">273,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=celu_LicenseAgreementMember', window );">Sirion License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_UpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ClinicalAndRegulatoryMilestones', window );">Clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">License agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAgreementNoticePeriod', window );">Notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=celu_CariCordParticipatingShareholdersMember', window );">CariCord Participating Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfSharesIssuedInLegalSettlementAgreement', window );">Number of shares issued in legal settlement agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement', window );">Estimated fair value of shares issued in settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement', window );">Number of additional shares to be issued if certain targets are met under settlement agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FinancingObligationsNoncurrent', window );">Financing obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_FinancingObligationsCurrent', window );">Current portion of financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity | Palantir Technologies Inc | Master Subscription Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentsForMasterSubscriptionAgreement', window );">Payments for master subscription agreement</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentSubscriptionPeriod', window );">Payment subscription period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AnnualFeePaid', window );">Annual fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Costs related to straight line basis agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity | HLI Cellular Therapeutics, LLC | Anthrogenesis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,222<span></span>
</td>
<td class="nump">273,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeSpaceMember', window );">Office Space | Warren, New Jersey | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OperatingLeaseExpiryYear', window );">Operating lease expiry year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space | Cedar Knolls, New Jersey | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageIncreaseInBaseAnnualRent', window );">Percentage increase in base annual rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Monthly lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeManufacturingAndLaboratorySpaceMember', window );">Office, Manufacturing and Laboratory Space | Florham Park, New Jersey | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OperatingLeaseExpiryYear', window );">Operating lease expiry year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AreaOfBuildings', window );">Area of building | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OptionToRenewLeaseTermPeriod', window );">Option to renew lease term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_InitialMonthlyBaseRent', window );">Initial monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="nump">14,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments And Contingencies Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation', window );">Construction-in-progress property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,415<span></span>
</td>
<td class="nump">$ 28,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AnnualFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AnnualFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AreaOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AreaOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ClinicalAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ClinicalAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of shares issued under legal settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FinancingObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing obligations current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FinancingObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_FinancingObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing obligations noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_FinancingObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_InitialMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_InitialMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicenseAgreementNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicenseAgreementNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares to be issued if certain targets are met under settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfSharesIssuedInLegalSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in legal settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfSharesIssuedInLegalSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OperatingLeaseExpiryYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiry year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OperatingLeaseExpiryYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OptionToRenewLeaseTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option to renew lease term period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OptionToRenewLeaseTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PaymentSubscriptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment subscription period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PaymentSubscriptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PaymentsForMasterSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for master subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PaymentsForMasterSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PercentageIncreaseInBaseAnnualRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in base annual rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PercentageIncreaseInBaseAnnualRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919398-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=celu_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=celu_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=celu_CariCordParticipatingShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=celu_CariCordParticipatingShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=celu_PalantirTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=celu_PalantirTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=celu_MasterSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=celu_MasterSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_HLICellularTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_HLICellularTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=celu_LLCAndAnthrogenesisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=celu_LLCAndAnthrogenesisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=celu_WarrenNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=celu_WarrenNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=celu_CedarKnollsNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=celu_CedarKnollsNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeManufacturingAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=celu_OfficeManufacturingAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=celu_FlorhamParkNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=celu_FlorhamParkNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784694568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Payments under Non-cancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract', window );"><strong>Schedule Of Future Minimum Payments Under Non Cancelable Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 2,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">2,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">3,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">3,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">73,531<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 88,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum payments under non-cancelable operating leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529772210376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 04, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Jul. 16, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 29, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 07, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
<td class="nump">155,640,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">common stock are entitled to one vote per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockVotingRights', window );">Preferred stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Preferred Stock were entitled to vote<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend accrued on preferred stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Cash dividends declared or paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentTerms', window );">Preferred stock dividend payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of&#160;6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date,&#160;no&#160;cash dividends were declared or paid.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13,482,000)<span></span>
</td>
<td class="nump">$ 58,686,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,686,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=celu_LegacyGXWarrantMember', window );">Legacy GX Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfExercisableTerms', window );">Description of exercisable terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Public Warrants became exercisable on August 15, 2021, which is the later of (a)&#160;30&#160;days after the consummation of a Business Combination or (b)&#160;12&#160;months from the effective date of the registration statement relating to GX&#8217;s initial public offering.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination', window );">Warrants exercisable period after consummation of business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering', window );">Warrants exercisable period from effective date of registration statement of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ClassOfWarrantOrRightWarrantsExercisableForCash', window );">Public warrants exercisable for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantExpirationTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PublicWarrantsCallPrice', window );">Call price of public warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_MinimumWrittenNoticePeriodForRedemption', window );">Minimum prior written notice period for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfWarrantCallProvision', window );">Description of call provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">



&#160;

&#8226;

at any time while the Public Warrants are exercisable,
&#160;




&#160;

&#8226;

upon not less than&#160;30&#160;days&#8217; prior written notice of redemption to each Public Warrant holder, and




&#160;

&#8226;

if, and only if, there is a current registration statement in effect with respect to the issuance of the common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=celu_SponsorsMember', window );">Sponsors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans', window );">Aggregate number of warrants issued to sponsor as repayment for working capital loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,640,290<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">common stock entitled the holder to one vote<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,834<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Conversion of preferred stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The conversion ratio of each series of Preferred Stock was determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price per share was $6.27&#160;for Series A and X Preferred Stock (the &#8220;Series A and X Original Issue Price&#8221;) and $7.53&#160;for Series B Preferred Stock (the &#8220;Series B Original Issue Price&#8221;), each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in Legacy Celularity&#8217;s certificate of incorporation, as amended and restated. As of December&#160;31, 2020 and the Closing Date, the Conversion Price was equal to the Original Issue Price for each series of Preferred Stock. Accordingly, as of December&#160;31, 2020 and the Closing Date, each share of each series of Preferred Stock was convertible into shares of Legacy Celularity common stock on a&#160;one-for-one basis.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity | Warrants | Series B Preferred Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the issuance of equity and warrants | $</a></td>
<td class="nump">$ 17,954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Legacy Celularity | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageOfSharesRequiredForVoting', window );">Percentage of shares required for voting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ConversionPricePerShareOfCommonStock', window );">Conversion price per share of common stock | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,686,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued', window );">Temporary equity, shares undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Warrants to purchase redeemable convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,526,341<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember', window );">Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,529,818<span></span>
</td>
<td class="nump">3,431,223<span></span>
</td>
<td class="nump">6,640,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,601,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from warrants exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,178,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember', window );">Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Amended and Restated Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,431,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember', window );">Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Amended Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,529,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember', window );">Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Series B Preferred Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Warrants to purchase redeemable convertible preferred stock, shares authorized</a></td>
<td class="nump">13,281,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued</a></td>
<td class="nump">13,620,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the issuance of equity and warrants | $</a></td>
<td class="nump">$ 84,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember', window );">Series B Redeemable Convertible Preferred Stock | Legacy Celularity | Warrants | Series B Preferred Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the issuance of equity and warrants | $</a></td>
<td class="nump">$ 102,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBPreferredStockPurchaseAgreementsMember', window );">Series B Preferred Stock Purchase Agreement [Member] | Minimum | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfSharesRequiredToBeOutstandingForVoting', window );">Number of shares required to be outstanding for voting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStocksMember', window );">Series A Redeemable Convertible Preferred Stocks | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStocksMember', window );">Series X Redeemable Convertible Preferred Stock | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemablesConvertiblePreferredStocksMember', window );">Series B Redeemable Convertible Preferred Stock | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Legacy Celularity | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="nump">$ 7.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Aggregate of shares</a></td>
<td class="nump">13,620,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfWarrantsIssued', window );">Number of warrants issued to the investors</a></td>
<td class="nump">13,281,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Legacy Celularity | Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregate number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,529,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantsPerSharePercentage', window );">Warrants per share, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Legacy Celularity | Warrants | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from the issuance of equity and warrants | $</a></td>
<td class="nump">$ 102,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of warrants issued as repayment for working capital loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ClassOfWarrantOrRightWarrantsExercisableForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercisable for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ClassOfWarrantOrRightWarrantsExercisableForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ConversionPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ConversionPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DescriptionOfExercisableTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of various exercisable terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DescriptionOfExercisableTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DescriptionOfWarrantCallProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of warrant call provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DescriptionOfWarrantCallProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_MinimumWrittenNoticePeriodForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum written notice period for redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_MinimumWrittenNoticePeriodForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfSharesRequiredToBeOutstandingForVoting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares required to be outstanding for voting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfSharesRequiredToBeOutstandingForVoting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PercentageOfSharesRequiredForVoting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares required for voting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PercentageOfSharesRequiredForVoting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PublicWarrantsCallPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public warrants call price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PublicWarrantsCallPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders&#8217; Equity (Details) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent information warrant expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable period after completion of business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable period from effective date of initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantsPerSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants per share, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantsPerSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a new issue of securities classified as temporary equity that are allocated to investors for them to buy.  When securities are sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the securities to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=celu_LegacyGXWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=celu_LegacyGXWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=celu_SponsorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=celu_SponsorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=celu_SeriesBPreferredStocksPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=celu_SeriesBPreferredStocksPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemableConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_DragasacWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_DragasacWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_AmendedAndRestatedDragasacWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_AmendedAndRestatedDragasacWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=celu_AmendedDragasacWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=celu_AmendedDragasacWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBPreferredStockPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesBPreferredStockPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesARedeemableConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesXRedeemableConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemablesConvertiblePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=celu_SeriesBRedeemablesConvertiblePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784358136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity - Summary of the Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="nump">42,686,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=celu_DragasacWarrantMember', window );">Dragasac Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="nump">6,529,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Mar. 16,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=celu_March2020SeriesBWarrantsMember', window );">March 2020 Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="nump">13,281,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 7.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Mar. 16,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=celu_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="nump">14,374,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Jul. 16,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=celu_SponsorWarrantsMember', window );">Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="nump">8,499,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="text">Jul. 16,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders&#8217; Equity (Details) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=celu_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=celu_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=celu_March2020SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=celu_March2020SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=celu_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=celu_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=celu_SponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=celu_SponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529785258872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of the Warrants (Parenthetical) (Details) - Dragasac Warrant<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=celu_DragasacWarrantMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders Equity Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 6.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_WarrantsPerSharePercentage', window );">Warrants per share, percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock', window );">Description of exercise price</a></td>
<td class="text">The exercise price is the lessor of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description about exercise price and number of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders&#8217; Equity (Details) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_WarrantsPerSharePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants per share, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_WarrantsPerSharePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=celu_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=celu_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780776968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested options to acquire per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,723<span></span>
</td>
<td class="nump">$ 40,010<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment awards accelerated the recognition of expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,959<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost for options issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ExpenseRelatedToPerformanceAwards', window );">Expense related to performance awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AwardModificationExpense', window );">Award modification expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_UnrecognizedExpenseRelatedToPerformanceAwards', window );">Unrecognized expense related to performance awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.40%<span></span>
</td>
<td class="nump">67.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LiabilitiesTotalMember', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=celu_AwardsWithServiceConditionsMember', window );">Awards with Service Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="nump">3,766,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested options to acquire per share (in Dollars per share)</a></td>
<td class="nump">$ 10.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage', window );">Vesting percentage on closing date</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage', window );">Vesting percentage over four years</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=celu_AwardsWithMarketConditionsMember', window );">Awards with Market Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="nump">2,469,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested options to acquire per share (in Dollars per share)</a></td>
<td class="nump">$ 6.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost for options issued (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted-average amortization period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price</a></td>
<td class="nump">$ 6.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Estimated fair value</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | After 1 Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units | After 2 Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,861<span></span>
</td>
<td class="nump">$ 11,105<span></span>
</td>
<td class="nump">$ 1,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense | Awards with Service Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,862<span></span>
</td>
<td class="nump">$ 28,833<span></span>
</td>
<td class="nump">$ 2,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense | Awards with Service Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celu_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,342,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of shares issued from outstanding capital stock, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod', window );">Number of shares issued for future issuance automatic increase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celu_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celu_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celu_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Plan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,915,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,152,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AwardModificationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Award modification expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AwardModificationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ExpenseRelatedToPerformanceAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to the performance awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ExpenseRelatedToPerformanceAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, award vesting rights on closing date, percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, award vesting rights over four year, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, number of shares issued for future issuance automatic increase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_UnrecognizedExpenseRelatedToPerformanceAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized expense related to performance awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_UnrecognizedExpenseRelatedToPerformanceAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LiabilitiesTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LiabilitiesTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=celu_AwardsWithServiceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=celu_AwardsWithServiceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=celu_AwardsWithMarketConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=celu_AwardsWithMarketConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=celu_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=celu_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786432856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 7 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.40%<span></span>
</td>
<td class="nump">67.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787759912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(131,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember', window );">2021 Plan and 2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options opening balance</a></td>
<td class="nump">17,167,165<span></span>
</td>
<td class="nump">13,954,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">9,681,736<span></span>
</td>
<td class="nump">4,662,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(703,512)<span></span>
</td>
<td class="num">(108,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(2,080,803)<span></span>
</td>
<td class="num">(1,340,712)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options ending balance</a></td>
<td class="nump">24,064,586<span></span>
</td>
<td class="nump">17,167,165<span></span>
</td>
<td class="nump">13,954,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested and expected to vest</a></td>
<td class="nump">24,064,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable</a></td>
<td class="nump">17,840,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">8.57<span></span>
</td>
<td class="nump">3.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">0.91<span></span>
</td>
<td class="nump">3.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">4.04<span></span>
</td>
<td class="nump">2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance</a></td>
<td class="nump">4.23<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest</a></td>
<td class="nump">4.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable</a></td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average contract life</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average contract life, Vested and expected to vest</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average contract life, Exercisable</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value ending balance</a></td>
<td class="nump">$ 56,525<span></span>
</td>
<td class="nump">$ 100,633<span></span>
</td>
<td class="nump">$ 40,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">56,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 51,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786577592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockBasedCompensationDetailsLineItems', window );"><strong>Stock Based Compensation Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options Granted | shares</a></td>
<td class="nump">488,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Options Forfeited | shares</a></td>
<td class="num">(13,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Options Outstanding ending balance | shares</a></td>
<td class="nump">474,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited | $ / shares</a></td>
<td class="nump">7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, ending balance | $ / shares</a></td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787636456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 13,723<span></span>
</td>
<td class="nump">$ 40,010<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Goods Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">6,861<span></span>
</td>
<td class="nump">11,105<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,862<span></span>
</td>
<td class="nump">$ 28,833<span></span>
</td>
<td class="nump">$ 2,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529772125688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Disaggregated Revenue by Product And Services (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21,335<span></span>
</td>
<td class="nump">$ 14,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales and Rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,801<span></span>
</td>
<td class="nump">6,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">5,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=celu_LicenseRoyaltyAndOtherMember', window );">License, Royalty and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 12,012<span></span>
</td>
<td class="nump">$ 1,868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=celu_LicenseRoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=celu_LicenseRoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786491384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at January 1</a></td>
<td class="nump">$ 12,449<span></span>
</td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue', window );">Deferral of revenue</a></td>
<td class="nump">4,928<span></span>
</td>
<td class="nump">14,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Recognition of unearned revenue</a></td>
<td class="num">(13,310)<span></span>
</td>
<td class="num">(5,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at December 31</a></td>
<td class="nump">$ 4,067<span></span>
</td>
<td class="nump">$ 12,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability increase decrease for contract from business combination and deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786342008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Remaining deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination', window );">Deferral of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Remaining deferred revenue recognized</a></td>
<td class="nump">$ 6,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779252056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Inforrmation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentPlansForCustomerToPayOverTimePeriod', window );">Payment plans for customer to pay over time period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePracticalExpedientFinancingComponent', window );">Revenue, practical expedient, financing component</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 4,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 2,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ContractedStoragePeriods', window );">Contracted storage periods</a></td>
<td class="text">18 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentPlansForCustomerToPayOverTimePeriod', window );">Payment plans for customer to pay over time period</a></td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ContractedStoragePeriods', window );">Contracted storage periods</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentPlansForCustomerToPayOverTimePeriod', window );">Payment plans for customer to pay over time period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ContractedStoragePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contracted storage periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ContractedStoragePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PaymentPlansForCustomerToPayOverTimePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment plans for customer to pay over time period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PaymentPlansForCustomerToPayOverTimePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePracticalExpedientFinancingComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130569-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePracticalExpedientFinancingComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786538120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Distribution Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2021</div></th>
<th class="th"><div>May 07, 2021</div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAndDistributionAgreementsLineItems', window );"><strong>License And Distribution Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IncentivePayment', window );">Incentive payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ReimbursementOfCostUnderLicenseAgreement', window );">Reimbursement for enrolled patients in related clinical studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=celu_SanuwaveLicenseAgreementMember', window );">Sanuwave License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAndDistributionAgreementsLineItems', window );"><strong>License And Distribution Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicensingArrangementTerm', window );">Licensing arrangement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAgreementDescription', window );">License agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;its affiliates without the consent of the Company and (ii)&#160;any third party for the sole purpose of providing services directly to Sanuwave upon prior written consent by the Company. The Sanuwave License Agreement will automatically renew for additional one-year periods unless either party gives written notice of termination at least 180&#160;days prior to the expiration of the then-current term. Under the Sanuwave License Agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AnnualSales', window );">Annual sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_AnnualSalesNotExceed', window );">Annual sales not exceed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=celu_ArthrexAgreementMember', window );">Arthrex Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAndDistributionAgreementsLineItems', window );"><strong>License And Distribution Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementPeriod', window );">Supply and distribution agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementRenewalTerm', window );">Supply and distribution agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod', window );">Supply and distribution agreement non-renewal notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DiscountPercentagePaymentForInvoicesWithinTenDays', window );">Discount percentage, payment for invoices within ten days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentTermNet', window );">Payment term, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_MaterialBreachContractTerminatedTerm', window );">Material breach, contract terminated term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=celu_EvolutionAgreementMember', window );">Evolution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LicenseAndDistributionAgreementsLineItems', window );"><strong>License And Distribution Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementPeriod', window );">Supply and distribution agreement period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementRenewalTerm', window );">Supply and distribution agreement renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod', window );">Supply and distribution agreement non-renewal notice period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DiscountPercentagePaymentForInvoicesWithinTenDays', window );">Discount percentage, payment for invoices within ten days</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentTermNet', window );">Payment term, net</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_MaterialBreachContractTerminatedTerm', window );">Material breach, contract terminated term</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder', window );">Percentage of payment upon receipt and acceptance of purchase order</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RemainingDuePercentageNetFortyFivePaymentTerm', window );">Remaining due percentage, net forty five payment term</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SupplyAndDistributionAgreementForecastDescription', window );">Supply and distribution agreement, forecast description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The forecast may not deviate to less than 70% for the immediate following quarter, 50% two quarters out, 40% three quarters out, and 25% for full quarters from the original forecasted amount for that specific quarter set forth in the respective agreed upon binding forecast. Upon agreement, Evolution shall submit to the Company a purchase order to purchase products for the minimum binding forecasted quantities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AnnualSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of annual sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AnnualSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_AnnualSalesNotExceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_AnnualSalesNotExceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DiscountPercentagePaymentForInvoicesWithinTenDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount percentage, payment for Invoices within ten days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DiscountPercentagePaymentForInvoicesWithinTenDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IncentivePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IncentivePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicenseAndDistributionAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and distribution agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicenseAndDistributionAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LicensingArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing arrangement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LicensingArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_MaterialBreachContractTerminatedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Material breach, contract terminated term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_MaterialBreachContractTerminatedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PaymentTermNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment term, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PaymentTermNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payment upon receipt and acceptance of purchase order.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ReimbursementOfCostUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of cost under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ReimbursementOfCostUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RemainingDuePercentageNetFortyFivePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining due percentage, net forty-five payment term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RemainingDuePercentageNetFortyFivePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SupplyAndDistributionAgreementForecastDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply and distribution agreement, forecast description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SupplyAndDistributionAgreementForecastDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply and distribution agreement non-renewal notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SupplyAndDistributionAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply and distribution agreement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SupplyAndDistributionAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SupplyAndDistributionAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supply and distribution agreement renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SupplyAndDistributionAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=celu_SanuwaveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=celu_SanuwaveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=celu_ArthrexAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=celu_ArthrexAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=celu_EvolutionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=celu_EvolutionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529783209688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions made to the plan</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="nump">$ 835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529879361624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Current and Deferred Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense (benefit)</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(2,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(2,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(4,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total (benefit) from income taxes</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="num">$ (4,700)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529785179032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract', window );"><strong>Schedule Reconciliation Of The Federal Income Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefits</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense', window );">Interest accretion expense</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(46.10%)<span></span>
</td>
<td class="num">(21.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant', window );">Mark to market warrant</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="num">(5.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other permanent items</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation interest accretion expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation mark to market warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule reconciliation of the federal income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529784530152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 88,327<span></span>
</td>
<td class="nump">$ 53,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">11,748<span></span>
</td>
<td class="nump">1,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DeferredTaxAssetsStartupCosts', window );">Startup costs</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">4,471<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">3,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DeferredTaxAssetsUnicap', window );">Unicap</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DeferredTaxAssetsImputedInterestOnContingentPayments', window );">Imputed interest on contingent payments</a></td>
<td class="nump">4,410<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization', window );">Legal fee capitalization and amortization</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">121,519<span></span>
</td>
<td class="nump">74,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment', window );">In-process research and development</a></td>
<td class="num">(29,232)<span></span>
</td>
<td class="num">(27,930)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(29,232)<span></span>
</td>
<td class="num">(27,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(92,297)<span></span>
</td>
<td class="num">(46,139)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DeferredTaxAssetsImputedInterestOnContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets imputed interest on contingent payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DeferredTaxAssetsImputedInterestOnContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets legal fee capitalization and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DeferredTaxAssetsStartupCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets startup costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DeferredTaxAssetsStartupCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DeferredTaxAssetsUnicap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unicap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DeferredTaxAssetsUnicap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities in-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529786210696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income Tax Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31, 2019</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax provisions</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 1,270<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529787663880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,270,000<span></span>
</td>
<td class="nump">$ 1,028,000<span></span>
</td>
<td class="nump">$ 786,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold', window );">Net operating losses and unused R&amp;D tax credits sold</a></td>
<td class="nump">1,356,000<span></span>
</td>
<td class="nump">4,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=celu_UnitedStatesFederalAndStateMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 88,221,000<span></span>
</td>
<td class="nump">53,495,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=celu_UnitedStatesFederalAndStateMember', window );">U.S. Federal and State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 7,856,000<span></span>
</td>
<td class="nump">$ 5,673,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_TaxCreditCarryforwardsExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating losses and unused research and development tax credits sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_TaxCreditCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_TaxCreditCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=celu_UnitedStatesFederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=celu_UnitedStatesFederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529779851880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,128<span></span>
</td>
<td class="nump">$ 431,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529781537368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Financial Information by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21,335<span></span>
</td>
<td class="nump">$ 14,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">11,682<span></span>
</td>
<td class="nump">9,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="nump">159,693<span></span>
</td>
<td class="nump">84,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SegmentContribution', window );">Segment contribution</a></td>
<td class="num">(148,011)<span></span>
</td>
<td class="num">(74,697)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IndirectExpenses', window );">Indirect expenses</a></td>
<td class="num">(38,953)<span></span>
</td>
<td class="nump">77,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from operations</a></td>
<td class="num">(109,058)<span></span>
</td>
<td class="num">(151,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Components of other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ChangeInFairValueOfContingentConsiderationLiability', window );">Change in fair value of contingent consideration liability</a></td>
<td class="num">(41,145)<span></span>
</td>
<td class="num">(55,566)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyMember', window );">Cell Therapy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="nump">85,107<span></span>
</td>
<td class="nump">51,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SegmentContribution', window );">Segment contribution</a></td>
<td class="num">(85,107)<span></span>
</td>
<td class="num">(51,470)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_BiobankingMember', window );">Biobanking</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">5,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">3,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SegmentContribution', window );">Segment contribution</a></td>
<td class="num">(246)<span></span>
</td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_DegenerativeDiseaseMember', window );">Degenerative Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">15,813<span></span>
</td>
<td class="nump">8,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,809<span></span>
</td>
<td class="nump">6,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="nump">8,450<span></span>
</td>
<td class="nump">10,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SegmentContribution', window );">Segment contribution</a></td>
<td class="nump">1,359<span></span>
</td>
<td class="num">(4,264)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=celu_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="nump">64,017<span></span>
</td>
<td class="nump">20,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_SegmentContribution', window );">Segment contribution</a></td>
<td class="num">(64,017)<span></span>
</td>
<td class="num">(20,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_IndirectExpenses', window );">Indirect expenses</a></td>
<td class="num">(38,953)<span></span>
</td>
<td class="nump">77,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Components of other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_ChangeInFairValueOfContingentConsiderationLiability', window );">Change in fair value of contingent consideration liability</a></td>
<td class="num">(41,145)<span></span>
</td>
<td class="num">(55,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2,192<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other</a></td>
<td class="num">$ (38,953)<span></span>
</td>
<td class="nump">$ 77,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_ChangeInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_ChangeInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_IndirectExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of indirect expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_IndirectExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_SegmentContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_SegmentContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_CellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_BiobankingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_BiobankingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_DegenerativeDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_DegenerativeDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=celu_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=celu_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529780504088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2020</div></th>
<th class="th"><div>Sep. 18, 2020</div></th>
<th class="th"><div>Apr. 13, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="nump">$ 2.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CURAFoundationMember', window );">CURA Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Contribution made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_COTAIncMember', window );">COTA, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Contribution made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CryoportSystemsIncMember', window );">Cryoport Systems, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Contribution made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity | CV Star Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_LoanAgreement', window );">Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember', window );">Legacy Celularity | CV Star Loan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase Class A common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,320,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NumberOfSharesHolding', window );">Number of shares holding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,320,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=celu_ConsultingAgreementWithDoctorAndrewPecoraMember', window );">Consulting Agreement with Dr. Andrew Pecora</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentsToRelatedParty', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=celu_ConsultingAgreementWithDoctorAndrewPecoraMember', window );">Consulting Agreement with Dr. Andrew Pecora | Legacy Celularity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_PaymentForMonth', window );">Payment for month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_StockOptionsVested', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_CashConsiderationPerMonth', window );">Cash consideration per month</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyCashBonus', window );">Cash bonus</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock', window );">Nonqualified stock option to purchase shares of common stock</a></td>
<td class="nump">153,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=celu_StockPurchaseAgreementWithDirectorMember', window );">Stock Purchase Agreement with a Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair market value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=celu_EmploymentOfImmediateFamilyMemberMember', window );">Employment of an Immediate Family Member | Ms. Harini</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyPartTimeBaseSalary', window );">Part time base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyFullTimeBaseSalary', window );">Full time base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=celu_EmploymentOfImmediateFamilyMemberMember', window );">Employment of an Immediate Family Member | Mr. Pecora</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_celu_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions Details [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Base salary and bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_CashConsiderationPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash consideration per month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_CashConsiderationPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_LoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_LoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonqualified stock option to purchase shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_NumberOfSharesHolding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares holding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_NumberOfSharesHolding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PaymentForMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PaymentForMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_PaymentsToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_PaymentsToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RelatedPartyCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Cash Bonus</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RelatedPartyCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RelatedPartyFullTimeBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party full time base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RelatedPartyFullTimeBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RelatedPartyPartTimeBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party part time base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RelatedPartyPartTimeBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions (Details) [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_celu_StockOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">celu_StockOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>celu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CURAFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CURAFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_COTAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_COTAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CryoportSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CryoportSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CVStarLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celu_CVStarLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=celu_ConsultingAgreementWithDoctorAndrewPecoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=celu_ConsultingAgreementWithDoctorAndrewPecoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=celu_StockPurchaseAgreementWithDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=celu_StockPurchaseAgreementWithDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=celu_EmploymentOfImmediateFamilyMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=celu_EmploymentOfImmediateFamilyMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=celu_MsHariniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=celu_MsHariniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=celu_MrPecoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=celu_MrPecoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140529781405032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Legacy Celularity - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase shares of common stock</a></td>
<td class="nump">13,281,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares issued</a></td>
<td class="nump">13,281,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from warrants exercised</a></td>
<td class="nump">$ 46,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=celu_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>celu-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:celu="http://celularity.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="celu-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001752828_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20220325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001752828_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">celu:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">celu:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCariCordIncorporatedMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:CariCordIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CTHBiosourcingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CTHBiosourcingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CTHBiosourcingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">celu:GXAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXSponsorWarrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:GXSponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuHLICellularTherapeuticsLLCMember_20170531_20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:HLICellularTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170815_20170815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AnthrogenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-15</startDate>
            <endDate>2017-08-15</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AnthrogenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlliquaAPAMember_20180507_20180507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AlliquaAPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-07</startDate>
            <endDate>2018-05-07</endDate>
        </period>
    </context>
    <context id="C_0001752828_20180507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCaricordMember_20181005_20181005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:CaricordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-05</startDate>
            <endDate>2018-10-05</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareDevelopmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20200101_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_20200701_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtMajorCustomersAxis_celuCustomerTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">celu:OneCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlphaFirstMergerSubIncorporationMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:AlphaFirstMergerSubIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuSurvivingCorporationMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:SurvivingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:CelularityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuGXTrustAccountMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:GXTrustAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:GXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:GXWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PublicEquityFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_20200806_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:MISTUltraMISTBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:MISTUltraMISTBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:MISTUltraMISTBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_0001752828_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">celu:UltraMISTBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">celu:UltraMISTBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-16</startDate>
            <endDate>2021-07-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-16</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">celu:ReacquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210607_20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">celu:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">celu:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtStatementGeographicalAxis_celuWarrenNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeSpaceMember_20170901_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:WarrenNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtStatementGeographicalAxis_celuCedarKnollsNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeAndLaboratorySpaceMember_20191101_20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:CedarKnollsNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">celu:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">celu:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:LLCAndAnthrogenesisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:HLICellularTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:LLCAndAnthrogenesisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:HLICellularTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210505_20210505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210324_20210324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CariCordParticipatingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-24</startDate>
            <endDate>2021-03-24</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:CariCordParticipatingShareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SeriesBPreferredStocksPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBPreferredStockPurchaseAgreementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBPreferredStockPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStocksMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesARedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStocksMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesXRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemablesConvertiblePreferredStocksMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemablesConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20180507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-07</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215_20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedAndRestatedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:AmendedAndRestatedDragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-29</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:AmendedDragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104_20191104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">celu:SeriesBRedeemableConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-04</startDate>
            <endDate>2019-11-04</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-09</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109_20200109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">celu:DragasacWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-09</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20200316_20200316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_celuLegacyGXWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">celu:LegacyGXWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:SponsorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:March2020SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">celu:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">celu:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20210301_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithServiceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_20210701_20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapLiabilitiesTotalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">celu:AwardsWithMarketConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20210701_20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_0001752828_20200403_20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2020-04-03</startDate>
            <endDate>2020-04-03</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SanuwaveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-06</startDate>
            <endDate>2020-08-06</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:SanuwaveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:ArthrexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-07</startDate>
            <endDate>2021-05-07</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:EvolutionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-01</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">celu:EvolutionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">celu:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">celu:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-13</startDate>
            <endDate>2020-04-13</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-13</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-15</startDate>
            <endDate>2020-10-15</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:ConsultingAgreementWithDoctorAndrewPecoraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CURAFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CURAFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCOTAIncMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:COTAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CryoportSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CryoportSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CVStarLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">celu:CVStarLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:StockPurchaseAgreementWithDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-18</startDate>
            <endDate>2020-09-18</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MsHariniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MsHariniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MsHariniMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_srtCounterpartyNameAxis_celuMrPecoraMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">celu:MrPecoraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">celu:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">celu:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_celuClinicalTrial">
        <measure>celu:ClinicalTrial</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_celuSegment">
        <measure>celu:Segment</measure>
    </unit>
    <unit id="U_celuDay">
        <measure>celu:Day</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001752828_20210101_20211231" id="F_000002">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="C_0001752828_20210101_20211231" id="F_000004">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001752828_20210101_20211231" id="F_000005">0001752828</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001752828_20210101_20211231" id="F_000012">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear contextRef="C_0001752828_20210101_20211231" id="F_000450">true</us-gaap:SubstantialDoubtAboutGoingConcernWithinOneYear>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000493">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000494">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000931">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RevenuePracticalExpedientFinancingComponent contextRef="C_0001752828_20210101_20211231" id="F_001055">true</us-gaap:RevenuePracticalExpedientFinancingComponent>
    <celu:LicenseArrangementTerm contextRef="C_0001752828_20200806_20200806" id="F_000527">P5Y</celu:LicenseArrangementTerm>
    <celu:LicenseArrangementTerm contextRef="C_0001752828_20210101_20211231" id="F_000534">P5Y</celu:LicenseArrangementTerm>
    <celu:OptionToRenewLeaseTermPeriod
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313"
      id="F_000809">P5Y</celu:OptionToRenewLeaseTermPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      id="F_001010">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <celu:PaymentPlansForCustomerToPayOverTimePeriod
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_001053">P24M</celu:PaymentPlansForCustomerToPayOverTimePeriod>
    <celu:PaymentPlansForCustomerToPayOverTimePeriod
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_001052">P1M</celu:PaymentPlansForCustomerToPayOverTimePeriod>
    <celu:LicensingArrangementTerm
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806"
      id="F_001060">P5Y</celu:LicensingArrangementTerm>
    <celu:SupplyAndDistributionAgreementPeriod
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507"
      id="F_001064">P6Y</celu:SupplyAndDistributionAgreementPeriod>
    <celu:SupplyAndDistributionAgreementRenewalTerm
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507"
      id="F_001065">P2Y</celu:SupplyAndDistributionAgreementRenewalTerm>
    <celu:SupplyAndDistributionAgreementPeriod
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      id="F_001070">P3Y</celu:SupplyAndDistributionAgreementPeriod>
    <celu:SupplyAndDistributionAgreementRenewalTerm
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      id="F_001071">P2Y</celu:SupplyAndDistributionAgreementRenewalTerm>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20211231"
      decimals="-3"
      id="F_001144"
      unitRef="U_iso4217USD">88221000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-3"
      id="F_001148"
      unitRef="U_iso4217USD">7856000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001752828_20211231"
      id="F_000091"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001752828_20201231"
      id="F_000092"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001752828_20211231"
      id="F_000096"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001752828_20201231"
      id="F_000097"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231"
      id="F_000613">P4Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716"
      id="F_000614">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716"
      id="F_000626">P3Y8M1D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716"
      decimals="2"
      id="F_000620"
      unitRef="U_iso4217USD_xbrlishares">9.66</celu:FairValuesOfCommonStock>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716"
      decimals="2"
      id="F_000621"
      unitRef="U_iso4217USD_xbrlishares">10.20</celu:FairValuesOfCommonStock>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231"
      decimals="2"
      id="F_000622"
      unitRef="U_iso4217USD_xbrlishares">4.17</celu:FairValuesOfCommonStock>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20200101_20201231"
      decimals="2"
      id="F_000623"
      unitRef="U_iso4217USD_xbrlishares">6.95</celu:FairValuesOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231"
      id="F_000627">P3M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231"
      id="F_000628">P1Y3M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231"
      decimals="2"
      id="F_000632"
      unitRef="U_xbrlipure">0.09</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231"
      decimals="2"
      id="F_000633"
      unitRef="U_xbrlipure">0.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716"
      id="F_000644">P3Y8M1D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716"
      decimals="2"
      id="F_000638"
      unitRef="U_iso4217USD_xbrlishares">9.66</celu:FairValuesOfCommonStock>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716"
      decimals="2"
      id="F_000639"
      unitRef="U_iso4217USD_xbrlishares">10.20</celu:FairValuesOfCommonStock>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231"
      decimals="2"
      id="F_000640"
      unitRef="U_iso4217USD_xbrlishares">4.17</celu:FairValuesOfCommonStock>
    <celu:FairValuesOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231"
      decimals="2"
      id="F_000641"
      unitRef="U_iso4217USD_xbrlishares">6.95</celu:FairValuesOfCommonStock>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      id="F_000645">P3M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      id="F_000646">P1Y3M29D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      decimals="2"
      id="F_000650"
      unitRef="U_xbrlipure">0.09</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      decimals="2"
      id="F_000651"
      unitRef="U_xbrlipure">0.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <celu:ValuationInputForConvertiblePromissoryNoteTerm contextRef="C_0001752828_20200101_20201231" id="F_000662">P7M6D</celu:ValuationInputForConvertiblePromissoryNoteTerm>
    <celu:PercentageOfCouponRate
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231"
      decimals="2"
      id="F_000655"
      unitRef="U_xbrlipure">0.12</celu:PercentageOfCouponRate>
    <celu:PercentageOfCouponRate
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231"
      decimals="2"
      id="F_000656"
      unitRef="U_xbrlipure">0.17</celu:PercentageOfCouponRate>
    <celu:ValuationInputForConvertiblePromissoryNoteTerm
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000660">P8M12D</celu:ValuationInputForConvertiblePromissoryNoteTerm>
    <celu:ValuationInputForConvertiblePromissoryNoteTerm
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000661">P3Y2M8D</celu:ValuationInputForConvertiblePromissoryNoteTerm>
    <celu:IndefiniteLivedIntangibleAssetsAmortizationMethod contextRef="C_0001752828_20210101_20211231" id="F_000760">Indefinite</celu:IndefiniteLivedIntangibleAssetsAmortizationMethod>
    <celu:IndefiniteLivedIntangibleAssetsAmortizationMethod contextRef="C_0001752828_20200101_20201231" id="F_000767">Indefinite</celu:IndefiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231"
      id="F_000761">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231"
      id="F_000762">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20210101_20211231"
      id="F_000763">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20210101_20211231"
      id="F_000764">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231"
      id="F_000768">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231"
      id="F_000769">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20200101_20201231"
      id="F_000770">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20200101_20201231"
      id="F_000771">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001752828_20210101_20211231" id="F_000936">P4Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001752828_20200101_20201231" id="F_000937">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20190101_20191231"
      id="F_000964">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      id="F_000965">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000966">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000967">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000968">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <dei:DocumentType contextRef="C_0001752828_20210101_20211231" id="F_000001">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001752828_20210101_20211231" id="F_000017">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001752828_20210101_20211231" id="F_000010">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001752828_20210101_20211231" id="F_000011">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001752828_20210101_20211231" id="F_000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001752828_20210101_20211231" id="F_000019">001-38914</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001752828_20210101_20211231" id="F_000000">Celularity Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001752828_20210101_20211231" id="F_000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001752828_20210101_20211231" id="F_000021">83-1702591</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001752828_20210101_20211231" id="F_000022">170 Park Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001752828_20210101_20211231" id="F_000023">Florham Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001752828_20210101_20211231" id="F_000024">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001752828_20210101_20211231" id="F_000025">07932</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001752828_20210101_20211231" id="F_000026">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001752828_20210101_20211231" id="F_000027">768-2170</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231"
      id="F_000028">Class A common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231"
      id="F_000029">CELU</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210101_20211231"
      id="F_000030">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000032">Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000033">CELUW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001752828_20210101_20211231" id="F_000008">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001752828_20210101_20211231" id="F_000007">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001752828_20210101_20211231" id="F_000006">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001752828_20210101_20211231" id="F_000031">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001752828_20210101_20211231" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001752828_20210101_20211231" id="F_000013">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001752828_20210101_20211231" id="F_000014">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001752828_20210101_20211231" id="F_000016">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="C_0001752828_20210101_20211231" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001752828_20210630"
      decimals="-5"
      id="F_000035"
      unitRef="U_iso4217USD">128100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001752828_20220325"
      decimals="INF"
      id="F_000003"
      unitRef="U_xbrlishares">137720526</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000356">
&lt;p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;None.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001752828_20210101_20211231" id="F_000036">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001752828_20210101_20211231" id="F_000037">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001752828_20210101_20211231" id="F_000038">Parsippany, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">37240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">54311000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">283000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">272000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">2745000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">1134000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <celu:PromissoryNotesReceivable
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">2488000</celu:PromissoryNotesReceivable>
    <celu:PromissoryNotesReceivable
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">5416000</celu:PromissoryNotesReceivable>
    <us-gaap:InventoryNet
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">9549000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">3850000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">7076000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">6576000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">2000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">873000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">59100000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">72160000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">90625000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">90077000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">123304000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">123304000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">123187000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">125379000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">14836000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">15202000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">2721000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">1998000</us-gaap:InventoryNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">355000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">2888000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">414128000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">431008000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">9317000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">5390000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">11661000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">13451000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <celu:FinancingObligationsCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">3051000</celu:FinancingObligationsCurrent>
    <celu:FinancingObligationsCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">3008000</celu:FinancingObligationsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">2196000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">4828000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">26225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">26677000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">1871000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">7621000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">232222000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">273367000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <celu:FinancingObligationsNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">28085000</celu:FinancingObligationsNoncurrent>
    <celu:FinancingObligationsNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">27634000</celu:FinancingObligationsNoncurrent>
    <celu:WarrantLiability
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">25962000</celu:WarrantLiability>
    <celu:WarrantLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">76640000</celu:WarrantLiability>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">10000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">7000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">335000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">349000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">314710000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">412295000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000111"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000112"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000113"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000115"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000117"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000114"
      unitRef="U_xbrlishares">29484740</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000116"
      unitRef="U_xbrlishares">29484740</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000118"
      unitRef="U_xbrlishares">29484740</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">184247000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000119"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000120"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000121"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000123"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000125"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000122"
      unitRef="U_xbrlishares">75088327</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000124"
      unitRef="U_xbrlishares">41205482</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000126"
      unitRef="U_xbrlishares">41205482</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">290866000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000127"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000128"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000129"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000131"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20211231"
      decimals="INF"
      id="F_000133"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000130"
      unitRef="U_xbrlishares">11953274</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000132"
      unitRef="U_xbrlishares">11953274</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000134"
      unitRef="U_xbrlishares">11953274</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">75000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000143"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000144"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000145"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000147"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000149"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000146"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000148"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000135"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000136"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000137"
      unitRef="U_xbrlishares">730000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000139"
      unitRef="U_xbrlishares">124307884</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">124307884</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">155640290</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000140"
      unitRef="U_xbrlishares">18529453</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000142"
      unitRef="U_xbrlishares">18529453</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000098"
      unitRef="U_iso4217USD">12000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000151"
      unitRef="U_xbrlishares">0</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000152"
      unitRef="U_xbrlishares">90834</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">256000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">763087000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">32418000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">-663681000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">-563563000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">99418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">-531400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">414128000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">431008000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">3801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">6854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">5522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">5556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">12012000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">1868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">21335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">14278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">3528000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">2247000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">3649000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">2294000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">2476000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">391000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">88353000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">52707000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">71341000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">31336000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <celu:ChangeInFairValueOfContingentConsiderationLiability
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-41145000</celu:ChangeInFairValueOfContingentConsiderationLiability>
    <celu:ChangeInFairValueOfContingentConsiderationLiability
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-55566000</celu:ChangeInFairValueOfContingentConsiderationLiability>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">2192000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">3394000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">129400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <celu:OperatingIncomeCostsAndExpenses
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">130394000</celu:OperatingIncomeCostsAndExpenses>
    <celu:OperatingIncomeCostsAndExpenses
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">166203000</celu:OperatingIncomeCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-109059000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-151925000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">332000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">370000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">3171000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">2354000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">-4434000</us-gaap:GainLossOnSaleOfBusiness>
    <celu:IncomeExpenseRelatedToWarrantLiabilities
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">-13482000</celu:IncomeExpenseRelatedToWarrantLiabilities>
    <celu:IncomeExpenseRelatedToWarrantLiabilities
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">58686000</celu:IncomeExpenseRelatedToWarrantLiabilities>
    <celu:OtherNonoperatingIncomeExpenses
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-1682000</celu:OtherNonoperatingIncomeExpenses>
    <celu:OtherNonoperatingIncomeExpenses
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">4096000</celu:OtherNonoperatingIncomeExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">8961000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">-61008000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">-100098000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-212933000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">20000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">-4700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">-100118000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-208233000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001752828_20210101_20211231"
      decimals="2"
      id="F_000197"
      unitRef="U_iso4217USD_xbrlishares">-1.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001752828_20200101_20201231"
      decimals="2"
      id="F_000198"
      unitRef="U_iso4217USD_xbrlishares">-11.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001752828_20210101_20211231"
      decimals="0"
      id="F_000199"
      unitRef="U_xbrlishares">67057278</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001752828_20200101_20201231"
      decimals="0"
      id="F_000200"
      unitRef="U_xbrlishares">18417910</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000201"
      unitRef="U_xbrlishares">29484740</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">184247000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000203"
      unitRef="U_xbrlishares">27552236</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">206035000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000205"
      unitRef="U_xbrlishares">11953274</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20191231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">75000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000207"
      unitRef="U_xbrlishares">18421084</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20191231"
      decimals="INF"
      id="F_000209"
      unitRef="U_xbrlishares">-13975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">27909000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">-355330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_20191231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">-327420000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000213"
      unitRef="U_xbrlishares">108369</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20200101_20201231"
      decimals="INF"
      id="F_000216"
      unitRef="U_xbrlishares">76859</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20200101_20201231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">256000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">256000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">4371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">4371000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <celu:TemporaryEquityShareIssuanceCosts
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">-15000</celu:TemporaryEquityShareIssuanceCosts>
    <celu:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231"
      decimals="INF"
      id="F_000222"
      unitRef="U_xbrlishares">13620063</celu:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">84596000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <celu:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCariCordIncorporatedMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231"
      decimals="INF"
      id="F_000224"
      unitRef="U_xbrlishares">33183</celu:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCariCordIncorporatedMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20200101_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">250000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">-208233000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">-208233000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000228"
      unitRef="U_xbrlishares">29484740</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20201231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">184247000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000230"
      unitRef="U_xbrlishares">41205482</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">290866000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000232"
      unitRef="U_xbrlishares">11953274</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">75000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000234"
      unitRef="U_xbrlishares">18529453</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20201231"
      decimals="INF"
      id="F_000236"
      unitRef="U_xbrlishares">-90834</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20201231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">-256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">32418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">-563563000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">-531400000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000241"
      unitRef="U_xbrlishares">572252</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">197000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">197000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">40010000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">40010000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20210101_20211231"
      decimals="INF"
      id="F_000246"
      unitRef="U_xbrlishares">29484740</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStockMember_20210101_20211231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">-184247000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20210101_20211231"
      decimals="INF"
      id="F_000248"
      unitRef="U_xbrlishares">41205482</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStockMember_20210101_20211231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">-290866000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20210101_20211231"
      decimals="INF"
      id="F_000250"
      unitRef="U_xbrlishares">11953274</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStockMember_20210101_20211231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">-75000000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000252"
      unitRef="U_xbrlishares">94122408</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">10000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20210101_20211231"
      decimals="INF"
      id="F_000254"
      unitRef="U_xbrlishares">90834</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapTreasuryStockMember_20210101_20211231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">256000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">485332000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital>
    <celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">485598000</celu:RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000258"
      unitRef="U_xbrlishares">8340000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">83399000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210101_20211231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">83400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">96398000</celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital>
    <celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">96398000</celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000264"
      unitRef="U_xbrlishares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210101_20211231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000267"
      unitRef="U_xbrlishares">743771</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">5333000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuCTHBiosourcingLLCMember_20210101_20211231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">5333000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProfitLoss
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">-100118000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">-100118000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000272"
      unitRef="U_xbrlishares">124307884</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">763087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">-663681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">99418000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">-100118000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">-208233000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">8817000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">8174000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">-1353000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">-8482000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">129400000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">298000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">292000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">40010000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">4371000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">-13482000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">58686000</us-gaap:FairValueAdjustmentOfWarrants>
    <celu:AmortizationOfInventoryStepUp
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">57000</celu:AmortizationOfInventoryStepUp>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">5333000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">-4434000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">-41145000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">-55566000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">-2627000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">-70000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">1909000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">-1652000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">6422000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">643000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">-3068000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">5761000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <celu:SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">1356000</celu:SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
    <celu:SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">3765000</celu:SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">3007000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">314000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">-1801000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">184000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">-8382000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">4093000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">-110096000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">-63193000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">6203000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">27834000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">15019000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <celu:ProceedsFromPromissoryNote
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">300000</celu:ProceedsFromPromissoryNote>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">-5903000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">-12815000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <celu:ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">102535000</celu:ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">256000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">5000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">5000000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <celu:CashReceivedOnRecapitalization
      contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">5386000</celu:CashReceivedOnRecapitalization>
    <celu:ProceedsFromInvestment
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">20000000</celu:ProceedsFromInvestment>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">83400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">638000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">138000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">10862000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">403000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">98562000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">102014000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">-17437000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">26006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">69513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001752828_20191231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">43507000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">52076000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">69513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">146000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">13000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">970000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">806000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <celu:RecapitalizationFromMerger
      contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">550113000</celu:RecapitalizationFromMerger>
    <celu:CancellationOfTreasuryStock
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">256000</celu:CancellationOfTreasuryStock>
    <celu:NonCashAssetsAcquiredFromMerger
      contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">163000</celu:NonCashAssetsAcquiredFromMerger>
    <celu:WarrantLiabilityAssumedFromMerger
      contextRef="C_0001752828_srtConsolidatedEntitiesAxis_celuGXAcquisitionCorpMember_20210101_20211231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">59202000</celu:WarrantLiabilityAssumedFromMerger>
    <celu:IssuanceOfCommonStockAsPaymentForRelatedCosts
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">10795000</celu:IssuanceOfCommonStockAsPaymentForRelatedCosts>
    <celu:ReclassificationOfWarrantLiabilitiesToEquity
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">96398000</celu:ReclassificationOfWarrantLiabilitiesToEquity>
    <celu:ReclassOfOfferingCostsPaidInPriorYear
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">153000</celu:ReclassOfOfferingCostsPaidInPriorYear>
    <celu:ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">-2130000</celu:ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses>
    <celu:RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">-216000</celu:RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">4524000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <celu:UltraMISTSystemsReclassFromInventoryToFixedAsset
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">79000</celu:UltraMISTSystemsReclassFromInventoryToFixedAsset>
    <celu:FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">17954000</celu:FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale>
    <celu:IssuanceOfWarrantsAtEstimatedFairValue
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">11988000</celu:IssuanceOfWarrantsAtEstimatedFairValue>
    <celu:IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">250000</celu:IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000357">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Nature of Business and Basis of Presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity Inc., (&#x201c;Celularity&#x201d; or the &#x201c;Company&#x201d;), formerly known as GX Acquisition Corp. (&#x201c;GX&#x201d;), was a blank check company incorporated in Delaware on&#160;August 24, 2018. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses&lt;/span&gt;.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On July 16, 2021 (the &#x201c;Closing Date&#x201d;), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated January 8, 2021 (the &#x201c;Merger Agreement&#x201d;), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of GX (&#x201c;First Merger Sub&#x201d;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary of GX (&#x201c;Second Merger Sub&#x201d;), and the entity formerly known as Celularity Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (&#x201c;Legacy Celularity&#x201d;). Upon completion of the merger transaction, GX changed its name to Celularity Inc.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The business combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States (see Note 3). Reported shares and earnings per share available to holders of the Company&#x2019;s common stock, prior to the business combination, have been retroactively restated as shares reflecting the exchange ratio established in the business combination (1.00&#160;share of Legacy Celularity for approximately&#160;0.7686&#160;shares of Celularity)&lt;/span&gt;.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity is a clinical-stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic T cells engineered with chimeric antigen receptor (&#x201c;CAR&#x201d;) T cells, natural killer (&#x201c;NK&#x201d;) cells and mesenchymal-like adherent stromal cells (&#x201c;ASCs&#x201d;), targeting indications across cancer, infectious and degenerative diseases. Celularity is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (&#x201c;Anthrogenesis&#x201d;) in August&#160;2017 from Celgene Corporation (&#x201c;Celgene&#x201d;), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously, Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene&#x2019;s cell therapy division. Celularity currently has&#160;three&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;active clinical trials and plans to submit two additional investigational new drug (&#x201c;IND&#x201d;) applications in 2022. The Celularity IMPACT platform capitalizes on the benefits of placenta-derived cells to target multiple diseases, and provides seamless integration, from bio sourcing through manufacturing cryopreserved and packaged allogeneic cells at its purpose-built U.S.-based&#160;150,000&#160;square foot facility. Celularity&#x2019;s placental-derived cells are allogeneic, meaning they are intended for use in any patient, as compared to autologous cells, which are derived from an individual patient for that patient&#x2019;s use. From a single source material, the postpartum human placenta, Celularity derives four allogeneic cell types: T cells, unmodified NK cells, genetically-modified NK cells and ASCs, which have resulted in five key cell therapeutic programs: CYCART-19, CYNK-001, CYNK-101, APPL-001 and PDA-002, focused on six initial indications. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is a placental-derived unmodified NK cell in development for the treatment of acute myeloid leukemia (&#x201c;AML&#x201d;), a blood cancer, and for glioblastoma multiforme (&#x201c;GBM&#x201d;), a solid tumor cancer. CYNK-101 is a placental-derived genetically modified NK cell in development, to be evaluated in combination with a monoclonal antibody to target HER2+ cancers, such as gastric cancer. APPL-001 is a placenta-derived ASC being developed for the treatment of Crohn&#x2019;s disease&lt;/span&gt;. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to risks and uncertainties common to early-stage&#160;companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting&#160;capabilities. Even if the Company&#x2019;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Acquisitions&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shortly after Legacy Celularity&#x2019;s incorporation in 2016, it completed four business combinations. Legacy Celularity did not have any significant activities prior to its acquisitions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May&#160;31, 2017, Legacy Celularity acquired HLI Cellular Therapeutics, LLC (&#x201c;HLI CT&#x201d;) from Human Longevity Inc. (&#x201c;Human Longevity&#x201d;). HLI CT operated LifebankUSA, a private umbilical cord blood stem cell and cord tissue bank that offers parents the option to collect, process and cryogenically preserve newborn umbilical cord blood stem cells and cord tissue units. The HLI CT acquisition also provided Legacy Celularity with rights to a portfolio of biomaterial assets, including Biovance&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;and Interfyl&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;as well as PSC-100, a development-stage&#160;placental stem cell program. Prior to the acquisition, Human Longevity entered into to a Supply Agreement and a License, Marketing and Development Agreement (collectively, &#x201c;the HLI Agreements&#x201d;) with Alliqua Biomedical Inc. (&#x201c;Alliqua&#x201d;). The HLI Agreements gave Alliqua exclusive rights to market and distribute Biovance&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;and Interfyl&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;. Rights, title and interest into the HLI Agreements transferred to the Company as a result of the HLI CT acquisition. In aggregate, the fair value of the consideration to acquire HLI CT was $28,876. The acquisition led to goodwill and intangible assets including in-process&#160;research and development (&#x201c;IPR&amp;amp;D&#x201d;) and a licensing agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&#160;15, 2017, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legacy &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Celularity&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;executed a Merger Agreement with Celgene whereupon it acquired &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, a &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;wholly-owned&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;subsidiary of Celgene (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Merger Agreement&#x201d;). The &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; acquisition included a portfolio of pre-clinical&#160;and clinical stage assets, including key cellular therapeutic assets in immuno-oncology, inflammatory and age-related&#160;diseases, that &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legacy &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Celularity&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;continues to develop. The &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; acquisition gives &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legacy &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Celularity&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;access to &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2019; proprietary technologies and processes for the recovery of large quantities of high-potential&#160;stem cells and cellular therapeutic products derived from postpartum human placentas (each an &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Product&#x201d;). As part of the &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; acquisition, some of the inventors of the &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Products and other key members of the &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Product development team joined &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legacy &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Celularity&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. In aggregate, the fair value of the consideration to acquire &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Anthrogenesis&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; was $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;346,430&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The acquisition led to goodwill and intangible assets including IPR&amp;amp;D and a licensing agreement and contingent value rights (&#x201c;CVR&#x201d;) agreement&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2017, Legacy Celularity issued shares of its Series X Preferred Stock to Celgene as merger consideration and entered into a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;) with Celgene pursuant to which it issued one CVR in respect of each share of Series X Preferred Stock issued to Celgene in connection with the Anthrogenesis acquisition. The CVR Agreement entitles the holders of the CVRs to an aggregate amount, on a per program basis, of $50,000 in regulatory milestones and an aggregate $125,000 in commercial milestone payments with respect to certain programs. In addition, with respect to each such program and calendar year, the CVR holders will be entitled, with respect to a given calendar year and program, to receive a royalty equal to a mid-teen&#160;percentage of the annual net sales for such program, from the date of the first commercial sale of such program&#x2019;s product in a particular country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program product in such country, the expiration of marketing exclusivity with respect to such product in such country, and August 2027 (i.e., the tenth anniversary of the closing of the acquisition of Anthrogenesis). Celularity estimates the liability associated with the CVR quarterly. Changes to that liability include but are not limited to changes in Celularity clinical programs, assumptions about the commercial value of those programs and the time value of money.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May&#160;7, 2018, the Company completed an Asset Purchase Agreement with Alliqua, a regenerative technologies company that commercializes regenerative medical products (the &#x201c;Alliqua APA&#x201d;). The Alliqua APA included the acquisition of Alliqua&#x2019;s biologic wound care business, including the marketing and distribution rights to Biovance&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;and Interfyl&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#160;&lt;/sup&gt;as well as a Class II medical device, the MIST&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;and UltraMIST&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&#160;Therapy Systems. In connection with the Alliqua APA, the Company paid cash consideration of $29,000. The Alliqua acquisition led to goodwill and intangible assets. No debt or significant liabilities were assumed by the Company.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&#160;5, 2018, the Company acquired CariCord Inc. (&#x201c;CariCord&#x201d;), a family cord blood bank established by ClinImmune Labs University of Colorado Cord Blood Bank (&#x201c;ClinImmune Labs&#x201d;) and the Regents of the University of Colorado, a body corporate, for and on behalf of the University of Colorado School of Medicine (the &#x201c;University of Colorado&#x201d;). In the aggregate, the fair value of the consideration to acquire CariCord was $9,326. The acquisition led to goodwill and intangible assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;COVID-19&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On March 10, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and conducts its business and which the Company&#x2019;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However, the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While management has implemented specific business continuity plans to reduce the potential impact of COVID-19, there is no guarantee that the Company&#x2019;s continuity plans will be successful.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Although the Company was able to operate continuously throughout 2020 and 2021, the Company implemented work-from-home policies as needed following local health recommendations for non-essential employees and employees whose roles are able to be performed remotely. Because certain elements of the Company&#x2019;s operations (such as processing placental tissue, certain biological assays, translational research and storage of cord blood) cannot be performed remotely, the Company instituted controls and protocols including mandatory temperature checking, symptom assessment forms, incremental cleaning and sanitization of common surfaces to mitigate risks to employees.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Due to a broad decline in economic activity and restrictions on physical access to certain medical facilities, the Company did experience a decrease in the net revenues of its degenerative disease business due to the pandemic in 2021. As for clinical trials, the Company did not cancel or postpone enrollment solely due to the risks of COVID-19. However, enrollment in the clinical trial evaluating &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;CYNK-001 for AML experienced some delays in the first half of 2020 as sites assessed their safety protocols and experienced high volumes of COVID-19 patients. Enrollment has continued in the AML trial and remains ongoing. As a result, during 2020 the Company had a year-over-year increase in research and development expenses notwithstanding the enrollment delays. The Company also initiated a clinical trial evaluating CYNK-001 in patients with COVID-19, which necessitated additional research and development and project management resources. The Company believes that it would have deployed its human and capital resources to other efforts, such as its C&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Y&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;CART-19 clinical development program, had the COVID-19 pandemic not struck.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;COVID-19 did not have a material negative impact on oncology clinical trial patient accrual rates during 2021. However, screenings and enrollments in the COVID-19 trial were lower once vaccines became more widely available. During 2021, Celularity continued to utilize mandatory temperature checking and symptom assessment forms and, commencing with the third quarter of 2021, instituted additional safety protocols for unvaccinated employees. Celularity also utilized a liaison to help schedule vaccination appointments for employees.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The extent to which COVID-19 or any other health epidemic may impact the Company&#x2019;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Accordingly, COVID-19 could have a material adverse effect on the Company&#x2019;s business, results of operations, financial condition, and prospects.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No.&#160;2014-15,&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern (Subtopic 205-40)&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Since its inception, Legacy Celularity funded its operations primarily with proceeds from the sales of preferred stock as well as revenues generated through its biobanking and degenerative disease commercial operations. The Company has incurred recurring losses since its inception, including net losses of &lt;/span&gt;$100,118&lt;span style="Background-color:#FFFFFF;"&gt; and $208,233&#160;for the years ended December 31, 2021 and 2020, respectively. In addition, as of December 31, 2021, the Company had an accumulated deficit of $663,681. The Company expects to continue to generate operating losses for the foreseeable future. As of the date these financial statements are issued, the Company expects that its cash and cash equivalents will not be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company is seeking additional funding through public or private equity and/or debt financings. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Based on its recurring losses from operations incurred since inception, expectation of continuing operating losses for the foreseeable future, and need to raise additional capital to finance its future operations, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="C_0001752828_20210101_20211231" id="F_000436">2018-08-24</dei:EntityIncorporationDateOfIncorporation>
    <celu:BusinessCombinationSharesExchangeRatioDescription contextRef="C_0001752828_20210716_20210716" id="F_000437">1.00&#160;share of Legacy Celularity for approximately&#160;0.7686&#160;shares of Celularity</celu:BusinessCombinationSharesExchangeRatioDescription>
    <celu:BusinessCombinationSharesExchangeRatio
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210716_20210716"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlipure">1.00</celu:BusinessCombinationSharesExchangeRatio>
    <celu:BusinessCombinationSharesExchangeRatio
      contextRef="C_0001752828_20210716_20210716"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlipure">0.7686</celu:BusinessCombinationSharesExchangeRatio>
    <celu:NumberOfClinicalTrials
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000440"
      unitRef="U_celuClinicalTrial">3</celu:NumberOfClinicalTrials>
    <celu:AreaOfBuilding
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000441"
      unitRef="U_utrsqft">150000</celu:AreaOfBuilding>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuHLICellularTherapeuticsLLCMember_20170531_20170531"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">28876000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170815_20170815"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">346430000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <celu:ContingentValueRightIssuedForEachShare
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831"
      decimals="INF"
      id="F_000444"
      unitRef="U_xbrlishares">1</celu:ContingentValueRightIssuedForEachShare>
    <celu:RegulatoryMilestones
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831"
      decimals="0"
      id="F_000445"
      unitRef="U_iso4217USD">50000</celu:RegulatoryMilestones>
    <celu:CommercialMilestonePayments
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAnthrogenesisMember_20170801_20170831"
      decimals="0"
      id="F_000446"
      unitRef="U_iso4217USD">125000</celu:CommercialMilestonePayments>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlliquaAPAMember_20180507_20180507"
      decimals="0"
      id="F_000447"
      unitRef="U_iso4217USD">29000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="C_0001752828_20180507"
      decimals="INF"
      id="F_000448"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCaricordMember_20181005_20181005"
      decimals="0"
      id="F_000449"
      unitRef="U_iso4217USD">9326</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">-100118000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">-208233000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">-663681000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000358">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United&#160;States (&#x201c;GAAP&#x201d;). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use&#160;of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;related to the Company&#x2019;s goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and common &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock warrants. The Company based its estimates on historical experience, known trends and other market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;facts&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Level 2 &#x2014; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December&#160;31, 2021 and 2020, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021 and 2020, the Company maintained letters of credit of $14,836 and $15,202, respectively, for the benefit of the landlord of leased properties, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out&#160;basis. Prior to initial approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial material as research and development expense.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)&#160;expected to expire prior to being sold, (ii)&#160;has a cost basis in excess of its net realizable value, (iii)&#160;is in excess of expected sales requirements as determined by internal sales forecasts, or (iv)&#160;fails to meet commercial sale specifications, the inventory is written-down&#160;through a charge to cost of goods sold. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged,&lt;span style="font-style:italic;"&gt;&#160;Biovance&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;currently has a shelf-life&#160;of five years in the United&#160;States and between two and three years outside of the United&#160;States, and Interfyl&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;has a shelf-life&#160;of five years. If actual market conditions are less favorable than those projected by management, inventory write-downs&#160;may be required. Inventory, net of current portion on the Company&#x2019;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:68.57%;"/&gt;
&lt;td style="width:1.45%;"/&gt;
&lt;td style="width:29.97%;"/&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Building&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 - 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;shorter of the estimated useful life and the lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress&#160;and depreciated once placed into service.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Tangible Long-Lived Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tangible long-lived&#160;assets consist of property, plant and equipment. Tangible long-lived&#160;assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived&#160;asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived&#160;asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on tangible long-lived&#160;assets during the years ended December&#160;31, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Business Combinations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under Accounting Standards Codification 805,&#160;&lt;span style="font-style:italic;"&gt;Business Combinations&lt;/span&gt;, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business. If the single asset or group of similar assets does not meet the threshold, an entity must next evaluate whether both an input and substantive process are present.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i)&#160;identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii)&#160;the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is tested for impairment at least annually. Acquired IPR&amp;amp;D is recognized at fair value and initially characterized as an indefinite-lived&#160;intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. Transaction costs related to business combinations are expensed as incurred.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, the selection of valuation methodologies, estimates of future revenue and cash flows, expected long-term&#160;market growth, future expected operating expenses, costs of capital and appropriate discount rates. Management&#x2019;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and, as a result, actual results may differ materially from estimates.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition-related&#160;contingent consideration, which consists of potential milestone and royalty obligations (see Note 11), was recorded in the consolidated balance sheets at its acquisition-date&#160;estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related&#160;contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The fair value measurement is based on significant inputs not observable by market participants and thus represents a Level 3 input in the fair value hierarchy (see Note 4).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Asset Acquisitions&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;amp;D with no alternative future use is charged to research and development expense at the acquisition date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;In-Process Research and Development&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived&#160;intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived&#160;asset and amortized over its estimated useful life.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of an IPR&amp;amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indefinite-lived&#160;IPR&amp;amp;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived&#160;IPR&amp;amp;D annually for impairment during the fourth quarter. In testing indefinite-lived&#160;IPR&amp;amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived&#160;IPR&amp;amp;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived&#160;IPR&amp;amp;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived&#160;IPR&amp;amp;D. Under either approach, if the fair value of the indefinite-lived&#160;IPR&amp;amp;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the year ended December&#160;31, 2020, the Company recognized an impairment charge related to its indefinite-lived&#160;IPR&amp;amp;D of $129,400. No such charge was recognized during the year ended December 31, 2021 (see Note 8).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the third quarter of 2020, the Company managed its operations as one reporting unit. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the change in reporting units, goodwill was required to be allocated across the operating segments under the new reporting structure. Goodwill was attributed to each reporting unit based on the acquired value, which is reflective of the relative fair value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company&#x2019;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;its&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value, not to exceed the total amount of goodwill allocated to the reporting unit.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preferred Stock Warrants Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the business combination with GX (see Notes 1 and 3), the Company classified warrants for the purchase of shares of its convertible preferred stock (see Note 12) as liabilities on its consolidated balance sheets as these warrants were freestanding financial instruments that may have required the Company to transfer assets upon exercise. The warrant liabilities, which consisted of warrants for the purchase of Series B convertible preferred stock, were initially recorded at fair value upon the date of issuance of each warrant and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liabilities were recognized as a component of other (expense) income in the consolidated statement of operations. Fair value of the preferred stock warrant liabilities were remeasured through the July 16, 2021 closing date on the consolidated statement of operations until the liability was reclassified to equity on the closing date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into lease agreements for its laboratory and office facilities. The Company determines if a lease arrangement is an operating lease or capital lease at inception. Rent expense is recognized on a straight-line&#160;basis over the term of the lease. Incentives granted under the Company&#x2019;s facilities leases, including allowances to fund leasehold improvements and rent holidays, are recorded as a deferred rent liability and are recognized as reductions to rental expense on a straight-line&#160;basis over the remaining term of the lease.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers the nature of the renovations and the Company&#x2019;s involvement during the construction period of newly leased office space to determine if it is considered to be the owner of the construction project during the construction period. If the Company determines that it is the owner of the construction project, it is required to capitalize the fair value of the asset, including potentially the building, construction costs incurred, and capitalized interest, on its consolidated balance sheet along with a corresponding financing liability (&#x201c;build-to-suit&#160;accounting&#x201d;). Upon occupancy for build-to-suit&#160;leases, the Company assesses whether the circumstances qualify for sales recognition under the sale-leaseback&#160;accounting guidance. If the lease meets the sale-leaseback&#160;criteria, the Company will remove the asset and related financial obligation from the balance sheet and evaluate the lease for treatment as a capital or operating lease. If upon completion of construction, the project does not meet the sale-leaseback&#160;criteria, the leased property will be treated as a capital lease for financial reporting purposes.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;, Interfyl&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;and MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;and UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Therapy System), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term&#160;pregnancies), and license, royalty and other operations (i.e., license agreement with Sanuwave Health Inc.).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Product sales and rentals&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biovance&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;is a low frequency ultrasound system used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates and bacteria. The MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Therapy System consists of a generator and treatment wand (collectively, the &#x201c;MIST Equipment&#x201d;) along with single-use&#160;applicators (the &#x201c;MIST Applicators&#x201d;) and optional accessories (e.g., roll stand and carts).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;has the ability to&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns. The Company offers product warranties which provide assurance that the product will function as expected and in accordance with specification. Customers can purchase warranties separately and these warranties give rise to a separate performance obligation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Therapy System had both software and non-software&#160;(e.g., hardware) components that function together to deliver the product&#x2019;s essential functionality. In addition, the hardware sold could not be used apart from the embedded software. The MIST Equipment was obtained by the customer in three ways: (a)&#160;the purchase of the MIST Equipment outright; (b)&#160;the lease of the MIST Equipment for a monthly rental fee; or (c)&#160;pay-per-use&#160;arrangement whereupon the Company provided the MIST Equipment for a single pay per use fee, subject to a minimum purchase requirement of MIST Applicators. MIST Applicators were separately ordered and purchased by customers who opted to purchase or directly lease the equipment. In addition, the Company offered the MIST Equipment for a standard 90&#160;day evaluation period at no charge to the customer for the MIST Equipment; however, MIST Applicators were required to be purchased during the evaluation term. When the Company leased or entered into a pay-per-use&#160;arrangement, it retained title to the equipment at all times.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For multiple-element&#160;arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. When the Company&#x2019;s customer arrangements are multiple-element&#160;arrangements that contains a lease or pay-per-use&#160;arrangement, the Company allocates the arrangement consideration between the lease deliverable (i.e., the MIST Equipment) and non-lease&#160;deliverable (i.e., the MIST Applicators). The consideration related to the pay-per-use&#160;arrangements was allocated to the lease deliverable based on the &#x201c;Minimum Volume Method&#x201d;, which used the contractual minimum volume in the relative fair value calculation because the ultimate level of MIST Applicator purchases was unknown. The consideration allocated related to the lease arrangement was established in the lease arrangement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides inventory to certain customers through pre-arranged&#160;agreements on a consignment basis. Customers consigned inventory is maintained and stored by certain customers; however, ownership remains with the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Services&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;License, royalty and&#160;other&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the license agreement with Sanuwave Health Inc. (&#x201c;Sanuwave&#x201d;) which acquired certain assets comprising its MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;business (see Note 14), the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognized the quarterly license fee over each quarterly term based on the actual sales occurring over the period. The license agreement with Sanuwave was terminated during the third quarter of 2021 due to an uncured material breach.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up&#160;basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;S&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ee Note &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for further discussion of the Company&#x2019;s license agreements.&lt;/span&gt;&lt;/p&gt;
&lt;p id="DA_RN_3767174097100001138" style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the&lt;span style="font-size:12pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order). &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related&#160;expenses, depreciation and amortization, stock-based&#160;compensation, third-party&#160;license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#x2019;s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Advertising and Marketing Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $252 and $764 for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Government Grants&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company recorded a reduction of $290 to research and development expense resulting from grant awards for the year ended December&#160;31, 2020. The Company did not receive grant monies during 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related&#160;costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures all stock-based&#160;awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based&#160;awards with only service-based&#160;vesting conditions and records the expense for these awards using a straight-line&#160;method.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company&#x2019;s Board of Directors approved the award of performance-based&#160;stock options to a non-employee&#160;consultant who also serves as a director for the Company (see Note 13). The performance-based&#160;stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based&#160;awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based&#160;awards and adjusts expense accordingly on a cumulative basis.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes&#160;option-pricing&#160;model. The Company historically has been a private company and lacks company-specific&#160;historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options granted to employees is determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected term of stock options granted to non-employee&#160;consultants is equal to the contractual term of the option award. The risk-free&#160;interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future (see Note 13).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2021, the Company awarded options to its President which have market-based vesting conditions. &lt;span style="Background-color:#FFFFFF;font-family:Calibri;"&gt;The Company uses the Monte-Carlo model in order to calculate the fair value of the market-based awards. Also in 2021, the Company granted restricted stock units (&#x201c;RSU&#x201d;), the fair value of which is determined based on the stock price on the date of grant. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies stock-based&#160;compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is reversed in the period of the forfeiture.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step&#160;process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not&#160;to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per&#160;Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average&#160;number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, stock options and warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average&#160;number of shares of common &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,643,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,533,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,167,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,811,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,694,763&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,621,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making&#160;group, in deciding how to allocate resources in assessing performance. Prior to the third quarter of 2020, the Company managed its operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December&#160;31, 2021 and 2020 in Note 18.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk and Significant Customers&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United&#160;States. During the year ended December 31, 2021, the Company had one customer (Customer A) provide for 38% of revenue and another customer provide for 11% of total revenue. In the year ended December&#160;31, 2020, the Company had one customer provide for 13% of the revenue earned. As of December&#160;31, 2021, Customer A comprised approximately 47% of the Company&#x2019;s outstanding accounts receivable. As of December&#160;31, 2020, one of the Company&#x2019;s customers comprised approximately 24% of the Company&#x2019;s outstanding accounts receivables.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Section&#160;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging&#160;growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This may make comparison of the Company&#x2019;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt; (Topic 740) (&#x201c;ASU 2019-12&#x201d;). The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification 740 and clarifying existing guidance to facilitate consistent application. The standard was effective for the Company beginning on January 1, 2021. The adoption of ASU 2019-12 as of January 1, 2021 did not have a material impact on the consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&#160;2020, the FASB issued ASU 2020-06, (Subtopic 470-20):&#160;&lt;span style="font-style:italic;"&gt;Debt &#x2014; Debt with Conversion and Other Options&lt;/span&gt;&#160;(&#x201c;ASU 2020-06&#x201d;) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06&#160;includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity&#x2019;s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06&#160;will require entities to use the &#x201c;if-converted&#x201d; method when calculating diluted earnings per share for convertible instruments. ASU 2020-06&#160;is effective for fiscal years beginning after December&#160;15, 2021 (fiscal year 2022 for the Company), including interim periods within those fiscal years. As no debt is currently outstanding, the Company does not expect the impact of ASU 2020-06&#160;to have an impact on its financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments &#x2014; Credit Losses&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02&lt;span style="font-style:italic;"&gt;, Leases (Topic&#160;842)&#160;&lt;/span&gt;(&#x201c;ASU 2016-02&#x201d;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line&#160;basis over the term of the lease. A lessee is also required to record a right-of-use&#160;asset and a lease liability for all leases with a term of greater than 12&#160;months regardless of their classification. Leases with a term of 12&#160;months or less may be accounted for similar to existing guidance for operating leases today. The guidance is effective for the Company for annual reporting periods beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022, with early adoption permitted. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted ASC 842 as of January 1, 2022 using the modified retrospective method, which did not require it to restate prior periods and did not have an impact on retained earnings. The Company has elected the &#x201c;package of 3&#x201d; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its Consolidated Balance Sheets. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company will determine whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the Consolidated Balance Sheets as right-of-use assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets will be recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the right-of-use asset. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has not yet finalized the impact of this new standard, however, the Company is expecting its adoption will have a material effect on the Company&#x2019;s consolidated financial statements.&#160;&#160;Upon adoption, the most significant impact relates to an equity adjustment and the recognition of a new right-of-use asset and lease liability arising from the derecognition of existing assets and liabilities from the failed sale-leaseback transaction of the Company&#x2019;s Florham Park, New Jersey facility.&#160;&#160;Upon adoption, the Company will derecognize the portion of the existing build-to-suit facility financing obligation and the corresponding existing asset that was recorded solely as a result of the transaction&#x2019;s build-to-suit designation in accordance with Topic 840.&#160;&#160;The difference associated with this derecognition will be recorded as an adjustment to equity as of January 1, 2022.&#160;&#160;The Company will then follow the general lessee transition requirements discussed above to record the new right-of-use asset and lease liability in accordance with Topic 842.&#160;&#160;Certain Company-paid costs associated with this transaction that were capitalized will not be derecognized and thus will be carried over and &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;retained at their currently recognized balances as they would have been recognized in the absence of the build-to-suit designation.&#160;&#160;Further information regarding this transaction is discussed within Note 11.&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000377">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United&#160;States (&#x201c;GAAP&#x201d;). The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management, is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001752828_20210101_20211231" id="F_000378">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use&#160;of Estimates&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;related to the Company&#x2019;s goodwill and intangible impairment assessment, the valuation of inventory and of contingent consideration, accrual of research and development expenses, and the valuations of stock options and preferred &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;and common &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock warrants. The Company based its estimates on historical experience, known trends and other market-specific&#160;or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;facts&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000379">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Level 2 &#x2014; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000380">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having an original maturity of less than three months. The Company considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. At December&#160;31, 2021 and 2020, substantially all cash and cash equivalents were held in either commercial bank accounts or money market funds.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <celu:RestrictedCashPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000381">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021 and 2020, the Company maintained letters of credit of $14,836 and $15,202, respectively, for the benefit of the landlord of leased properties, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.&lt;/p&gt;</celu:RestrictedCashPolicyTextBlock>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">14836000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">15202000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000382">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory is stated at the lower of cost or market (net realizable value), with cost being determined on a first-in, first-out&#160;basis. Prior to initial approval from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred. After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product. The Company continues to expense costs associated with clinical trial material as research and development expense.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company periodically analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)&#160;expected to expire prior to being sold, (ii)&#160;has a cost basis in excess of its net realizable value, (iii)&#160;is in excess of expected sales requirements as determined by internal sales forecasts, or (iv)&#160;fails to meet commercial sale specifications, the inventory is written-down&#160;through a charge to cost of goods sold. The determination of whether inventory costs will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. Once packaged,&lt;span style="font-style:italic;"&gt;&#160;Biovance&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;currently has a shelf-life&#160;of five years in the United&#160;States and between two and three years outside of the United&#160;States, and Interfyl&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;has a shelf-life&#160;of five years. If actual market conditions are less favorable than those projected by management, inventory write-downs&#160;may be required. Inventory, net of current portion on the Company&#x2019;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000383">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:68.57%;"/&gt;
&lt;td style="width:1.45%;"/&gt;
&lt;td style="width:29.97%;"/&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Building&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 - 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;shorter of the estimated useful life and the lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated useful lives are periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations in the period of disposal. Costs for capital assets not yet placed into service are capitalized as construction-in-progress&#160;and depreciated once placed into service.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000406">Depreciation and amortization expense is recognized using the straight-line&#160;method over the estimated useful life of each asset, as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:68.57%;"/&gt;
&lt;td style="width:1.45%;"/&gt;
&lt;td style="width:29.97%;"/&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful Life&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Building&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 - 7 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lab equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12pt;"&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:2.25pt;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;shorter of the estimated useful life and the lease term&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Building&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvement&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,289&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and production equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,884&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery, equipment and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,054&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,404&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,163&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210101_20211231"
      id="F_000456">P26Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231"
      id="F_000461">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231"
      id="F_000462">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210101_20211231"
      id="F_000457">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231"
      id="F_000458">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareDevelopmentMember_20210101_20211231"
      id="F_000459">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231"
      id="F_000460">shorter of the estimated useful life and the lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000384">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Impairment of Tangible Long-Lived Assets&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tangible long-lived&#160;assets consist of property, plant and equipment. Tangible long-lived&#160;assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived&#160;asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived&#160;asset group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on tangible long-lived&#160;assets during the years ended December&#160;31, 2021 and 2020.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="C_0001752828_20210101_20211231" id="F_000385">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Business Combinations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The purchase price allocation for business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values. Under Accounting Standards Codification 805,&#160;&lt;span style="font-style:italic;"&gt;Business Combinations&lt;/span&gt;, the Company first determines whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If this threshold is met, the single asset or group of assets, as applicable, is not a business. If the single asset or group of similar assets does not meet the threshold, an entity must next evaluate whether both an input and substantive process are present.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for business combinations using the acquisition method of accounting. Application of this method of accounting requires that (i)&#160;identifiable assets acquired (including identifiable intangible assets) and liabilities assumed generally be measured and recognized at fair value as of the acquisition date and (ii)&#160;the excess of the purchase price over the net fair value of identifiable assets acquired and liabilities assumed be recognized as goodwill, which is not amortized for accounting purposes but is tested for impairment at least annually. Acquired IPR&amp;amp;D is recognized at fair value and initially characterized as an indefinite-lived&#160;intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. Transaction costs related to business combinations are expensed as incurred.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Determining the fair value of assets acquired and liabilities assumed in a business combination requires management to use significant judgment and estimates, especially with respect to intangible assets. Critical estimates in valuing certain identifiable assets include, but are not limited to, the selection of valuation methodologies, estimates of future revenue and cash flows, expected long-term&#160;market growth, future expected operating expenses, costs of capital and appropriate discount rates. Management&#x2019;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and, as a result, actual results may differ materially from estimates.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the measurement period, which extends no later than one year from the acquisition date, the Company may record certain adjustments to the carrying value of the assets acquired and liabilities assumed with the corresponding offset to goodwill. After the measurement period, all adjustments are recorded in the consolidated statements of operations as operating expenses or income.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquisition-related&#160;contingent consideration, which consists of potential milestone and royalty obligations (see Note 11), was recorded in the consolidated balance sheets at its acquisition-date&#160;estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related&#160;contingent consideration is remeasured each reporting period, with changes in fair value recorded in the consolidated statements of operations. The fair value measurement is based on significant inputs not observable by market participants and thus represents a Level 3 input in the fair value hierarchy (see Note 4).&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <celu:AssetAcquisitionsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000386">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Asset Acquisitions&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;amp;D with no alternative future use is charged to research and development expense at the acquisition date.&lt;/p&gt;</celu:AssetAcquisitionsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="C_0001752828_20210101_20211231" id="F_000387">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;In-Process Research and Development&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived&#160;intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset is reclassified to a definite-lived&#160;asset and amortized over its estimated useful life.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of an IPR&amp;amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indefinite-lived&#160;IPR&amp;amp;D is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company tests its indefinite-lived&#160;IPR&amp;amp;D annually for impairment during the fourth quarter. In testing indefinite-lived&#160;IPR&amp;amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived&#160;IPR&amp;amp;D without performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived&#160;IPR&amp;amp;D is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived&#160;IPR&amp;amp;D. Under either approach, if the fair value of the indefinite-lived&#160;IPR&amp;amp;D is less than its carrying amount, an impairment charge is recognized in the consolidated statements of operations. During the year ended December&#160;31, 2020, the Company recognized an impairment charge related to its indefinite-lived&#160;IPR&amp;amp;D of $129,400. No such charge was recognized during the year ended December 31, 2021 (see Note 8).&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">129400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000463"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000388">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the third quarter of 2020, the Company managed its operations as one reporting unit. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note 18). The Company determined that the operating segments represented the reporting units.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the change in reporting units, goodwill was required to be allocated across the operating segments under the new reporting structure. Goodwill was attributed to each reporting unit based on the acquired value, which is reflective of the relative fair value.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In testing goodwill for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than its carrying amount, or the Company can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances considered in the Company&#x2019;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;qualitative factors and the Company determines that it is more likely than not that the fair value of its reporting unit is less than &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;its&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; carrying amount, the Company would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value, not to exceed the total amount of goodwill allocated to the reporting unit.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="C_0001752828_20200101_20200630"
      decimals="INF"
      id="F_000465"
      unitRef="U_celuSegment">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001752828_20200701_20200930"
      decimals="INF"
      id="F_000466"
      unitRef="U_celuSegment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000467"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <celu:PreferredStockWarrantsLiabilitiesPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000389">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preferred Stock Warrants Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the business combination with GX (see Notes 1 and 3), the Company classified warrants for the purchase of shares of its convertible preferred stock (see Note 12) as liabilities on its consolidated balance sheets as these warrants were freestanding financial instruments that may have required the Company to transfer assets upon exercise. The warrant liabilities, which consisted of warrants for the purchase of Series B convertible preferred stock, were initially recorded at fair value upon the date of issuance of each warrant and was subsequently remeasured to fair value at each reporting date. Changes in the fair value of the warrant liabilities were recognized as a component of other (expense) income in the consolidated statement of operations. Fair value of the preferred stock warrant liabilities were remeasured through the July 16, 2021 closing date on the consolidated statement of operations until the liability was reclassified to equity on the closing date. &lt;/p&gt;</celu:PreferredStockWarrantsLiabilitiesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000390">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into lease agreements for its laboratory and office facilities. The Company determines if a lease arrangement is an operating lease or capital lease at inception. Rent expense is recognized on a straight-line&#160;basis over the term of the lease. Incentives granted under the Company&#x2019;s facilities leases, including allowances to fund leasehold improvements and rent holidays, are recorded as a deferred rent liability and are recognized as reductions to rental expense on a straight-line&#160;basis over the remaining term of the lease.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers the nature of the renovations and the Company&#x2019;s involvement during the construction period of newly leased office space to determine if it is considered to be the owner of the construction project during the construction period. If the Company determines that it is the owner of the construction project, it is required to capitalize the fair value of the asset, including potentially the building, construction costs incurred, and capitalized interest, on its consolidated balance sheet along with a corresponding financing liability (&#x201c;build-to-suit&#160;accounting&#x201d;). Upon occupancy for build-to-suit&#160;leases, the Company assesses whether the circumstances qualify for sales recognition under the sale-leaseback&#160;accounting guidance. If the lease meets the sale-leaseback&#160;criteria, the Company will remove the asset and related financial obligation from the balance sheet and evaluate the lease for treatment as a capital or operating lease. If upon completion of construction, the project does not meet the sale-leaseback&#160;criteria, the leased property will be treated as a capital lease for financial reporting purposes.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000391">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generates revenue from its degenerative disease commercial operations (i.e., the sale of Biovance&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;, Interfyl&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;and MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;and UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Therapy System), biobanking services (i.e., the collection, processing and storage of umbilical cord and placental blood and tissue after full-term&#160;pregnancies), and license, royalty and other operations (i.e., license agreement with Sanuwave Health Inc.).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Product sales and rentals&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biovance&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;is a decellularized, dehydrated human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure with its biochemical components, and is intended for use as a biological membrane covering that provides the extracellular matrix while supporting the repair of damaged tissue. Interfyl&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;is an allogeneic decellularized particulate human placental connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;is a low frequency ultrasound system used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates and bacteria. The MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Therapy System consists of a generator and treatment wand (collectively, the &#x201c;MIST Equipment&#x201d;) along with single-use&#160;applicators (the &#x201c;MIST Applicators&#x201d;) and optional accessories (e.g., roll stand and carts).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;has the ability to&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; use and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers and&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore does not record a provision for returns. The Company offers product warranties which provide assurance that the product will function as expected and in accordance with specification. Customers can purchase warranties separately and these warranties give rise to a separate performance obligation.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;Therapy System had both software and non-software&#160;(e.g., hardware) components that function together to deliver the product&#x2019;s essential functionality. In addition, the hardware sold could not be used apart from the embedded software. The MIST Equipment was obtained by the customer in three ways: (a)&#160;the purchase of the MIST Equipment outright; (b)&#160;the lease of the MIST Equipment for a monthly rental fee; or (c)&#160;pay-per-use&#160;arrangement whereupon the Company provided the MIST Equipment for a single pay per use fee, subject to a minimum purchase requirement of MIST Applicators. MIST Applicators were separately ordered and purchased by customers who opted to purchase or directly lease the equipment. In addition, the Company offered the MIST Equipment for a standard 90&#160;day evaluation period at no charge to the customer for the MIST Equipment; however, MIST Applicators were required to be purchased during the evaluation term. When the Company leased or entered into a pay-per-use&#160;arrangement, it retained title to the equipment at all times.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For multiple-element&#160;arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. When the Company&#x2019;s customer arrangements are multiple-element&#160;arrangements that contains a lease or pay-per-use&#160;arrangement, the Company allocates the arrangement consideration between the lease deliverable (i.e., the MIST Equipment) and non-lease&#160;deliverable (i.e., the MIST Applicators). The consideration related to the pay-per-use&#160;arrangements was allocated to the lease deliverable based on the &#x201c;Minimum Volume Method&#x201d;, which used the contractual minimum volume in the relative fair value calculation because the ultimate level of MIST Applicator purchases was unknown. The consideration allocated related to the lease arrangement was established in the lease arrangement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company provides inventory to certain customers through pre-arranged&#160;agreements on a consignment basis. Customers consigned inventory is maintained and stored by certain customers; however, ownership remains with the Company.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Services&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;License, royalty and&#160;other&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under license agreements, the Company assesses whether the related performance obligation is satisfied at a point in time or over time.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the license agreement with Sanuwave Health Inc. (&#x201c;Sanuwave&#x201d;) which acquired certain assets comprising its MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;business (see Note 14), the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognized the quarterly license fee over each quarterly term based on the actual sales occurring over the period. The license agreement with Sanuwave was terminated during the third quarter of 2021 due to an uncured material breach.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up&#160;basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;S&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ee Note &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for further discussion of the Company&#x2019;s license agreements.&lt;/span&gt;&lt;/p&gt;
&lt;p id="DA_RN_3767174097100001138" style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For certain distribution agreements as described in Note 15, the Company will utilize the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to invoice so long as the&lt;span style="font-size:12pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="color:#000000;"&gt;consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue upon invoicing for these agreements (subsequent to receipt of the related purchase order). &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying Accounting Standards Codification 606,&#160;&lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&#160;(&#x201c;ASC 606&#x201d;): (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2)&#160;the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3)&#160;the Company expenses costs to obtain a contract as they are incurred in the expected period of benefit and therefore, the amortization period is one year or less; (4)&#160;the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are recorded as selling, general and administrative expenses; (5)&#160;the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; and (6)&#160;the Company does not disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <celu:EquipmentEvaluationPeriod contextRef="C_0001752828_20210101_20211231" id="F_000469">P90D</celu:EquipmentEvaluationPeriod>
    <us-gaap:EquipmentExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000468"
      unitRef="U_iso4217USD">0</us-gaap:EquipmentExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001752828_20210101_20211231" id="F_000392">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development and other agreements with commercial firms, researchers, universities and others for provisions of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related&#160;expenses, depreciation and amortization, stock-based&#160;compensation, third-party&#160;license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#x2019;s estimates. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upfront payments, milestone payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000393">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Advertising and Marketing Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Advertising and marketing costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were $252 and $764 for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">252000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">764000</us-gaap:MarketingAndAdvertisingExpense>
    <celu:GovernmentGrantsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000394">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Government Grants&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency. The Company recorded a reduction of $290 to research and development expense resulting from grant awards for the year ended December&#160;31, 2020. The Company did not receive grant monies during 2021.&lt;/p&gt;</celu:GovernmentGrantsPolicyTextBlock>
    <celu:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">290000</celu:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant>
    <celu:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000473"
      unitRef="U_iso4217USD">0</celu:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant>
    <celu:PatentCostsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000395">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All patent-related&#160;costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;</celu:PatentCostsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000396">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures all stock-based&#160;awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company typically issues stock-based&#160;awards with only service-based&#160;vesting conditions and records the expense for these awards using a straight-line&#160;method.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2020, the Company&#x2019;s Board of Directors approved the award of performance-based&#160;stock options to a non-employee&#160;consultant who also serves as a director for the Company (see Note 13). The performance-based&#160;stock options are earned based on the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based&#160;awards over the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability of vesting at each reporting period for performance-based&#160;awards and adjusts expense accordingly on a cumulative basis.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each services and performance-based stock option grant is estimated on the date of grant using the Black-Scholes&#160;option-pricing&#160;model. The Company historically has been a private company and lacks company-specific&#160;historical and implied volatility information for its stock. Therefore, it estimates its expected stock price volatility based on the historical volatility of publicly traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company&#x2019;s stock options granted to employees is determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected term of stock options granted to non-employee&#160;consultants is equal to the contractual term of the option award. The risk-free&#160;interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future (see Note 13).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2021, the Company awarded options to its President which have market-based vesting conditions. &lt;span style="Background-color:#FFFFFF;font-family:Calibri;"&gt;The Company uses the Monte-Carlo model in order to calculate the fair value of the market-based awards. Also in 2021, the Company granted restricted stock units (&#x201c;RSU&#x201d;), the fair value of which is determined based on the stock price on the date of grant. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies stock-based&#160;compensation expense in its consolidated statement of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified. The Company elects to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure to satisfy a service or performance condition is reversed in the period of the forfeiture.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001752828_20210101_20211231"
      decimals="2"
      id="F_000474"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000397">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. There was no difference between net loss and comprehensive loss for each of the periods presented in the accompanying consolidated financial statements.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000398">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step&#160;process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based on the technical merits of the position. If the tax position is deemed more-likely-than-not&#160;to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note 17).&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <celu:MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000475"
      unitRef="U_xbrlipure">0.50</celu:MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000399">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss per&#160;Share&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average&#160;number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, stock options and warrants, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average&#160;number of shares of common &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,643,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,533,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,167,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,811,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,694,763&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,621,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000407">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average&#160;shares of common stock outstanding, prior to the use of the two-class&#160;method, as they would be anti-dilutive:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,643,496&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,533,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,167,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,811,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69,694,763&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;119,621,865&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20200101_20201231"
      decimals="0"
      id="F_000476"
      unitRef="U_xbrlishares">82643496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="0"
      id="F_000477"
      unitRef="U_xbrlishares">26533868</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="0"
      id="F_000478"
      unitRef="U_xbrlishares">17167165</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="0"
      id="F_000479"
      unitRef="U_xbrlishares">474700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="0"
      id="F_000480"
      unitRef="U_xbrlishares">42686195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20201231"
      decimals="0"
      id="F_000481"
      unitRef="U_xbrlishares">19811204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_20210101_20211231"
      decimals="0"
      id="F_000482"
      unitRef="U_xbrlishares">69694763</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001752828_20200101_20201231"
      decimals="0"
      id="F_000483"
      unitRef="U_xbrlishares">119621865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000400">
&lt;p style="margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segment Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making&#160;group, in deciding how to allocate resources in assessing performance. Prior to the third quarter of 2020, the Company managed its operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments are presented for the years ended December&#160;31, 2021 and 2020 in Note 18.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000484"
      unitRef="U_celuSegment">1</us-gaap:NumberOfOperatingSegments>
    <celu:NumberOfBusinessSegments
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000485"
      unitRef="U_celuSegment">3</celu:NumberOfBusinessSegments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001752828_20210101_20211231" id="F_000401">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Concentrations of Credit Risk and Significant Customers&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts receivables are a result from product sales and services performed in the United&#160;States. During the year ended December 31, 2021, the Company had one customer (Customer A) provide for 38% of revenue and another customer provide for 11% of total revenue. In the year ended December&#160;31, 2020, the Company had one customer provide for 13% of the revenue earned. As of December&#160;31, 2021, Customer A comprised approximately 47% of the Company&#x2019;s outstanding accounts receivable. As of December&#160;31, 2020, one of the Company&#x2019;s customers comprised approximately 24% of the Company&#x2019;s outstanding accounts receivables.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="2"
      id="F_000486"
      unitRef="U_xbrlipure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001752828_srtMajorCustomersAxis_celuCustomerTwoMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="2"
      id="F_000488"
      unitRef="U_xbrlipure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000487"
      unitRef="U_xbrlipure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231"
      decimals="2"
      id="F_000489"
      unitRef="U_xbrlipure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0001752828_srtMajorCustomersAxis_celuOneCustomerMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapAccountsReceivableMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20200101_20201231"
      decimals="2"
      id="F_000490"
      unitRef="U_xbrlipure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <celu:EmergingGrowthCompanyPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000402">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Emerging Growth Company&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Section&#160;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act of 1933, as amended, registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging&#160;growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This may make comparison of the Company&#x2019;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/p&gt;</celu:EmergingGrowthCompanyPolicyTextBlock>
    <celu:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000403">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2019-12, &lt;span style="font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt; (Topic 740) (&#x201c;ASU 2019-12&#x201d;). The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by Accounting Standards Codification 740 and clarifying existing guidance to facilitate consistent application. The standard was effective for the Company beginning on January 1, 2021. The adoption of ASU 2019-12 as of January 1, 2021 did not have a material impact on the consolidated financial statements.&lt;/p&gt;</celu:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000404">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August&#160;2020, the FASB issued ASU 2020-06, (Subtopic 470-20):&#160;&lt;span style="font-style:italic;"&gt;Debt &#x2014; Debt with Conversion and Other Options&lt;/span&gt;&#160;(&#x201c;ASU 2020-06&#x201d;) to address the complexity associated with applying GAAP to certain financial instruments with characteristics of liabilities and equity. ASU 2020-06&#160;includes amendments to the guidance on convertible instruments and the derivative scope exception for contracts in an entity&#x2019;s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06&#160;will require entities to use the &#x201c;if-converted&#x201d; method when calculating diluted earnings per share for convertible instruments. ASU 2020-06&#160;is effective for fiscal years beginning after December&#160;15, 2021 (fiscal year 2022 for the Company), including interim periods within those fiscal years. As no debt is currently outstanding, the Company does not expect the impact of ASU 2020-06&#160;to have an impact on its financial position, results of operations or cash flows.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments &#x2014; Credit Losses&lt;/span&gt; (&#x201c;ASU 2016-13&#x201d;), which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on its consolidated financial statements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&#160;2016, the FASB issued ASU No.&#160;2016-02&lt;span style="font-style:italic;"&gt;, Leases (Topic&#160;842)&#160;&lt;/span&gt;(&#x201c;ASU 2016-02&#x201d;), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line&#160;basis over the term of the lease. A lessee is also required to record a right-of-use&#160;asset and a lease liability for all leases with a term of greater than 12&#160;months regardless of their classification. Leases with a term of 12&#160;months or less may be accounted for similar to existing guidance for operating leases today. The guidance is effective for the Company for annual reporting periods beginning after December&#160;15, 2021 and interim periods within fiscal years beginning after December&#160;15, 2022, with early adoption permitted. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted ASC 842 as of January 1, 2022 using the modified retrospective method, which did not require it to restate prior periods and did not have an impact on retained earnings. The Company has elected the &#x201c;package of 3&#x201d; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its Consolidated Balance Sheets. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company will determine whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year will be recognized on the Consolidated Balance Sheets as right-of-use assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets will be recorded based on the present values of lease payments over the terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the right-of-use asset. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has not yet finalized the impact of this new standard, however, the Company is expecting its adoption will have a material effect on the Company&#x2019;s consolidated financial statements.&#160;&#160;Upon adoption, the most significant impact relates to an equity adjustment and the recognition of a new right-of-use asset and lease liability arising from the derecognition of existing assets and liabilities from the failed sale-leaseback transaction of the Company&#x2019;s Florham Park, New Jersey facility.&#160;&#160;Upon adoption, the Company will derecognize the portion of the existing build-to-suit facility financing obligation and the corresponding existing asset that was recorded solely as a result of the transaction&#x2019;s build-to-suit designation in accordance with Topic 840.&#160;&#160;The difference associated with this derecognition will be recorded as an adjustment to equity as of January 1, 2022.&#160;&#160;The Company will then follow the general lessee transition requirements discussed above to record the new right-of-use asset and lease liability in accordance with Topic 842.&#160;&#160;Certain Company-paid costs associated with this transaction that were capitalized will not be derecognized and thus will be carried over and &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;retained at their currently recognized balances as they would have been recognized in the absence of the build-to-suit designation.&#160;&#160;Further information regarding this transaction is discussed within Note 11.&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LineOfCredit
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000491"
      unitRef="U_iso4217USD">0</us-gaap:LineOfCredit>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001752828_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20211231"
      id="F_000492">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <celu:BusinessCombinationsAndDisposalsDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000359">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&#160;&#160;&#160;&#160;&#160;Business Combinations and Disposals&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Fiscal 2021&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 16, 2021, the Company consummated the previously announced merger pursuant to the Merger Agreement, by and among GX, First Merger Sub, Second Merger Sub and Legacy Celularity (see Note 1).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the Merger Agreement, a business combination between GX and Legacy Celularity was effected through the (a) merger of First Merger Sub with and into Legacy Celularity with Legacy Celularity surviving as a wholly-owned subsidiary of GX (Legacy Celularity, in its capacity as the surviving corporation of the merger, the &#x201c;Surviving Corporation&#x201d;) (the &#x201c;First Merger&#x201d;) and (b) immediately following the First Merger and as part of the same overall transaction as the First Merger, the merger of the Surviving Corporation with and into Second Merger Sub, with Second Merger Sub as the surviving entity of the Second Merger, which ultimately resulted in Legacy Celularity becoming a wholly-owned direct subsidiary of GX (the &#x201c;Second Merger&#x201d; and, together with the First Merger, the &#x201c;Mergers&#x201d; and, collectively with the other transactions described in the Merger Agreement, the &#x201c;Business Combination&#x201d;). On the Closing Date, the Company changed its name from GX Acquisition Corp. to Celularity Inc.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Immediately prior to the effective time of the Mergers (the &#x201c;Effective Time&#x201d;), each share of preferred stock of Legacy Celularity (the &#x201c;Legacy Celularity Preferred Stock&#x201d;) that was issued and outstanding was automatically converted into a number of shares of common stock of Legacy Celularity, par value $0.0001 per share (the &#x201c;Legacy Celularity Common Stock&#x201d;) at the then-effective conversion rate as calculated pursuant to the Amended and Restated Certificate of Incorporation of Legacy Celularity, dated March 16, 2020, as amended (the &#x201c;Legacy Celularity Charter&#x201d;), such that each converted share of Legacy Celularity Preferred Stock was no longer outstanding and ceased to exist, and each holder of Legacy Celularity Preferred Stock thereafter ceased to have any rights with respect to such securities (the &#x201c;Legacy Celularity Preferred Stock Conversion&#x201d;).&lt;/p&gt;&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (&#x201c;Company Class A Common Stock&#x201d;) equal to the Exchange Ratio (as defined below) (the &#x201c;Per Share Merger Consideration&#x201d;);&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, &#x201c;Legacy Celularity Capital Stock&#x201d;) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;d)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Company Class A Common Stock (and not Celularity Capital Stock) (each, a &#x201c;Converted Warrant&#x201d;) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Company Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the &#x201c;Celularity Warrant Shares&#x201d;) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Company Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;e)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="text-decoration:none;Background-color:#auto;font-size:10pt;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;each option to purchase Legacy &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Celularity&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a &#x201c;Legacy &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;Celularity&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; Option&#x201d;) was assumed by GX and converted into an option to purchase shares of Company Class A Common Stock (each, a &#x201c;Converted Option&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Business Combination was accounted for as a reverse recapitalization in conformity with accounting principles generally accepted in the United States. Under this method of accounting, GX was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on existing Legacy Celularity stockholders comprising a relative majority of the voting power of the combined company, Legacy Celularity&#x2019;s operations prior to the acquisition comprising the only ongoing operations of Celularity, the majority of Celularity&#x2019;s board of directors appointment by Legacy Celularity, and Legacy Celularity&#x2019;s senior management comprising a majority of the senior management of Celularity. Accordingly, for accounting purposes, the financial statements of the combined entity represented a continuation of the financial statements of Legacy Celularity with the business combination being treated as the equivalent of Legacy Celularity issuing stock for the net assets of GX, accompanied by a recapitalization. The Company recorded net assets of GX at historical costs, with no goodwill or other intangible assets recorded. Operations prior to the business combination are those of Legacy Celularity. Reported shares and earnings per share available to holders of the Company&#x2019;s Class A common stock, prior to the Business Combination, have been retroactively restated as shares reflecting the exchange ratio established in the business combination (1.00 share of Legacy Celularity for approximately 0.7686 shares of Celularity Class A common stock).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net proceeds from this transaction totaled $108,786. These proceeds were comprised of $5,386 held in GX&#x2019;s trust account, $83,400 received from the completion of a concurrent private investment in public equity financing (&#x201c;PIPE Financing&#x201d;) and $20,000 received from an investment by Palantir Technologies, Inc. The Company incurred $21,657 in transaction costs relating to the merger with GX of which $10,795 were satisfied by the issuance of Class A common stock, which has been offset against additional paid-in capital in the Consolidated Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the Merger Agreement, the existing stockholders of Legacy Celularity exchanged their interests for shares of Class A common stock of Celularity. In addition, GX had previously issued public warrants and private placement warrants (collectively, the &#x201c;GX Warrants&#x201d;) as part of the Units in its initial public offering in May 2019. None of the terms of the GX Warrants were modified as a result of the Business Combination. On the date of the Business Combination, the Company recorded a liability related to the GX Warrants of $59,202, with an offsetting entry to additional paid-in capital. During the period from July 17, 2021 to December 31, 2021, the fair value of the GX Warrants &lt;span style="Background-color:#FFFFFF;"&gt;decreased to $25,962, resulting in an expense reduction of $33,240&lt;/span&gt; in the consolidated statement of operations for the year ended December 31, 2021.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon consummation of the Business Combination, Legacy Celularity warrants qualified for equity classification. As a result, the transaction date fair value of the Legacy Celularity warrants of $96,398 was reclassified from warrant liability to additional paid-in capital (see Note 12).&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Immediately following the Business Combination, there were 122,487,174 shares of Class A common stock with a par value of $0.0001 issued and outstanding, options to purchase an aggregate of 21,723,273 shares of Class A common stock and 42,686,195 warrants outstanding to purchase shares of Class A common stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;PIPE Financing (Private Placement)&lt;/p&gt;&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the &#x201c;Subscribers&#x201d;) purchased from Celularity an aggregate of 8,340,000 shares of Class A common stock (the &#x201c;PIPE Shares&#x201d;), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the &#x201c;Subscription Agreements&#x201d;). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Arrangement with Palantir Technologies Inc.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the subscription agreement entered into by GX with Palantir Technologies Inc. (&#x201c;Palantir&#x201d;) on May 5, 2021, Palantir purchased 2,000,000 shares of Class A common stock at a price of $10.00 per share and an aggregate purchase price of $20,000, upon closing of the Business Combination and closing of the PIPE financing.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Fiscal 2020&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August&#160;6, 2020, the Company executed (i)&#160;an asset purchase agreement to sell certain assets comprising its MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;business to Sanuwave and (ii)&#160;a &lt;span style="-sec-ix-hidden:F_000527"&gt;five-year&lt;/span&gt;&#160;licensing agreement with Sanuwave for total consideration of $24,524 (the &#x201c;Sanuwave Transaction&#x201d;), of which $20,000 was paid at or prior to closing. The remaining $4,524 of the purchase price was financed through a convertible promissory note due on or before August&#160;6, 2021. The convertible promissory note can be converted into shares of Sanuwave stock at the election of the Company any time on or after January&#160;1, 2021. As of December 31, 2021 the fair value of the convertible promissory note related to Sanuwave was $2,488 which is included in other current assets on the consolidated balance sheet. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The &lt;span style="-sec-ix-hidden:F_000534"&gt;five-year&lt;/span&gt;&#160;licensing arrangement with Sanuwave includes: (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market and (ii)&#160;a non-exclusive&#160;license for the distribution and commercialization of Interfyl in the wound care market. Under the licensing agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following assets and liabilities were divested/written off in this transaction:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets Divested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,296&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets divested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total upfront consideration was allocated between both components of the Sanuwave Transaction to (i)&#160;calculate the goodwill attributed to the UltraMIST business, (ii)&#160;determine the allocation of arrangement consideration to the three performance obligations and (iii)&#160;determine the loss on sale of the UltraMIST business. The Company utilized a discounted cash flow model to value the UltraMIST business, which determined the fair value of the UltraMIST business was $15,019. Significant inputs of this discounted cash flow model included (i)&#160;a discount rate of 11%, (ii)&#160;tax rate of 26% and (iii)&#160;a long-term&#160;growth rate of 2%. The remaining proceeds of $9,505 were allocated to the license agreement on a residual basis. During the third quarter of 2020, the Company recognized a loss on sale of UltraMIST of $4,434, which included approximately $40 in related professional fees. Due to the Company&#x2019;s tax position as of the closing date, there was no tax impact resulting from the sale of the UltraMIST business.&lt;/p&gt;</celu:BusinessCombinationsAndDisposalsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_20210716"
      decimals="INF"
      id="F_000495"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockConversionBasis contextRef="C_0001752828_20210101_20211231" id="F_000498">At the Effective Time, by virtue of the First Merger and without any action on the part of GX, First Merger Sub, Legacy Celularity or the holders of any of the following securities:




&#160;

a)

each share of Legacy Celularity Common Stock (including shares of Legacy Celularity Common Stock resulting from the conversion of shares of Celularity Preferred Stock described above) that was issued and outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a number of shares of Company Class A common stock, par value $0.0001 per share (&#x201c;Company Class A Common Stock&#x201d;) equal to the Exchange Ratio (as defined below) (the &#x201c;Per Share Merger Consideration&#x201d;);




&#160;

b)

each share of Legacy Celularity Common Stock or Legacy Celularity Preferred Stock (together, &#x201c;Legacy Celularity Capital Stock&#x201d;) held in the treasury of Celularity was cancelled without any conversion thereof and no payment or distribution was made with respect thereto;




&#160;

c)

each share of First Merger Sub common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time was converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, par value $0.0001 per share, of the Surviving Corporation;




&#160;

d)

each Legacy Celularity Warrant (as to which no notice of exercise had been delivered to Legacy Celularity prior to the Closing) that was outstanding immediately prior to the Effective Time (and which would have otherwise been exercisable in accordance with its terms immediately following the Effective Time), became, to the extent consistent with the terms of such Legacy Celularity Warrant, the right to purchase shares of Company Class A Common Stock (and not Celularity Capital Stock) (each, a &#x201c;Converted Warrant&#x201d;) on the same terms and conditions (including exercisability terms) as were applicable to such Legacy Celularity Warrant immediately prior to the Effective Time, except that (A) each Converted Warrant became exercisable for that number of shares of Company Class A Common Stock equal to the product (rounded down to the nearest whole number) of (1) the number of shares of Legacy Celularity Common Stock that would have been issuable upon the exercise of a Legacy Celularity Warrant for cash and assuming the conversion of the Series B Preferred Stock underlying such outstanding Legacy Celularity Warrant into Legacy Celularity Common Stock (the &#x201c;Celularity Warrant Shares&#x201d;) subject to the Legacy Celularity Warrant immediately prior to the Effective Time and (2) the Exchange Ratio (as defined below); and (B) the per share exercise price for each share of Company Class A Common Stock issuable upon exercise of the Converted Warrant is equal to the quotient (rounded up to the nearest whole cent) obtained by dividing (1) the per share exercise price for each share of Series B Preferred Stock issuable upon exercise of such Celularity Warrant immediately prior to the Effective Time by (2) the Exchange Ratio (as defined below); and




&#160;

e)

each option to purchase Legacy Celularity Common Stock, whether or not exercisable and whether or not vested, that was outstanding immediately prior to the Effective Time (each, a &#x201c;Legacy Celularity Option&#x201d;) was assumed by GX and converted into an option to purchase shares of Company Class A Common Stock (each, a &#x201c;Converted Option&#x201d;).</us-gaap:CommonStockConversionBasis>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000496"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuAlphaFirstMergerSubIncorporationMember_20210716"
      decimals="INF"
      id="F_000497"
      unitRef="U_iso4217USD_xbrlishares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuSurvivingCorporationMember_20210716"
      decimals="INF"
      id="F_000499"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000500"
      unitRef="U_iso4217USD">0</us-gaap:Goodwill>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000501"
      unitRef="U_iso4217USD">0</us-gaap:OtherIntangibleAssetsNet>
    <celu:BusinessCombinationExchangeRatioOfCommonStock
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="4"
      id="F_000502"
      unitRef="U_iso4217USD_xbrlishares">0.7686</celu:BusinessCombinationExchangeRatioOfCommonStock>
    <celu:BusinessAcquisitionTransactionCostsProceedsNet
      contextRef="C_0001752828_20210716"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">108786000</celu:BusinessAcquisitionTransactionCostsProceedsNet>
    <celu:BusinessAcquisitionTransactionCostsProceedsNet
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuGXTrustAccountMember_20210716"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">5386000</celu:BusinessAcquisitionTransactionCostsProceedsNet>
    <celu:BusinessAcquisitionTransactionCostsProceedsNet
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_20210716"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">83400000</celu:BusinessAcquisitionTransactionCostsProceedsNet>
    <celu:BusinessAcquisitionTransactionCostsProceedsNet
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">20000000</celu:BusinessAcquisitionTransactionCostsProceedsNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="C_0001752828_20210716"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">21657000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <celu:BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">10795000</celu:BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231"
      id="F_000509">In addition, GX had previously issued public warrants and private placement warrants (collectively, the &#x201c;GX Warrants&#x201d;) as part of the Units in its initial public offering in May 2019</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:Liabilities
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20211231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">59202000</us-gaap:Liabilities>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">25962000</celu:FairValueOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXWarrantsMember_20210101_20211231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">33240000</us-gaap:FairValueAdjustmentOfWarrants>
    <celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210716_20210716"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">96398000</celu:ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000514"
      unitRef="U_xbrlishares">122487174</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000515"
      unitRef="U_xbrlishares">122487174</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000516"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <celu:OptionToPurchaseSharesOfCommonStock
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000517"
      unitRef="U_xbrlishares">21723273</celu:OptionToPurchaseSharesOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuCelularityMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210716"
      decimals="INF"
      id="F_000518"
      unitRef="U_xbrlishares">42686195</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <celu:SubscriptionAgreementsDescription contextRef="C_0001752828_20210101_20211231" id="F_000519">On the Closing Date, certain significant stockholders of Legacy Celularity or their affiliates (including Sorrento Therapeutics, Inc., Starr International Investments Ltd. and Dragasac Limited, an indirect wholly owned subsidiary of Genting Berhad, collectively, the &#x201c;Subscribers&#x201d;) purchased from Celularity an aggregate of 8,340,000 shares of Class A common stock (the &#x201c;PIPE Shares&#x201d;), for a purchase price of $10.00 per share and an aggregate purchase price of $83,400, pursuant to separate subscription agreements dated January 8, 2021 (collectively, the &#x201c;Subscription Agreements&#x201d;). Pursuant to the Subscription Agreements, the Company agreed to provide the Subscribers with certain registration rights with respect to the PIPE Shares.</celu:SubscriptionAgreementsDescription>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716_20210716"
      decimals="INF"
      id="F_000521"
      unitRef="U_xbrlishares">8340000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716"
      decimals="INF"
      id="F_000520"
      unitRef="U_iso4217USD_xbrlishares">10.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPublicEquityFinancingMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapPrivatePlacementMember_20210716_20210716"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">83400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716_20210716"
      decimals="INF"
      id="F_000523"
      unitRef="U_xbrlishares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716"
      decimals="INF"
      id="F_000524"
      unitRef="U_iso4217USD_xbrlishares">10.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuPalantirTechnologiesIncMember_20210716_20210716"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <celu:AssetPurchaseAgreementDescription contextRef="C_0001752828_20210101_20211231" id="F_000526">On August&#160;6, 2020, the Company executed (i)&#160;an asset purchase agreement to sell certain assets comprising its MIST&#xae;/UltraMIST&#xae;&#160;business to Sanuwave and (ii)&#160;a five-year&#160;licensing agreement with Sanuwave for total consideration of $24,524 (the &#x201c;Sanuwave Transaction&#x201d;), of which $20,000 was paid at or prior to closing. The remaining $4,524 of the purchase price was financed through a convertible promissory note due on or before August&#160;6, 2021. The convertible promissory note can be converted into shares of Sanuwave stock at the election of the Company any time on or after January&#160;1, 2021. As of December 31, 2021 the fair value of the convertible promissory note related to Sanuwave was $2,488 which is included in other current assets on the consolidated balance sheet.</celu:AssetPurchaseAgreementDescription>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">24524000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">20000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">4524000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806"
      id="F_000531">2021-08-06</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionDate
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806"
      id="F_000532">2021-01-01</us-gaap:DebtInstrumentConvertibleConversionDate>
    <celu:FairValueOfConvertiblePromissoryNote
      contextRef="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapOtherCurrentAssetsMember_us-gaapBusinessAcquisitionAxis_celuMISTUltraMISTBusinessMember_20200806_20200806"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">2488000</celu:FairValueOfConvertiblePromissoryNote>
    <celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000408">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following assets and liabilities were divested/written off in this transaction:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets Divested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,296&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets divested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="C_0001752828_20200806"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">1901000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="C_0001752828_20200806"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">13296000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="C_0001752828_20200806"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">452000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="C_0001752828_20200806"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">3764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="C_0001752828_20200806"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">19413000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <celu:ConsiderationDescription contextRef="C_0001752828_20210101_20211231" id="F_000540">(i)&#160;calculate the goodwill attributed to the UltraMIST business, (ii)&#160;determine the allocation of arrangement consideration to the three performance obligations and (iii)&#160;determine the loss on sale of the UltraMIST business. The Company utilized a discounted cash flow model to value the UltraMIST business, which determined the fair value of the UltraMIST business was $15,019. Significant inputs of this discounted cash flow model included (i)&#160;a discount rate of 11%, (ii)&#160;tax rate of 26% and (iii)&#160;a long-term&#160;growth rate of 2%. The remaining proceeds of $9,505 were allocated to the license agreement on a residual basis. During the third quarter of 2020, the Company recognized a loss on sale of UltraMIST of $4,434, which included approximately $40 in related professional fees. Due to the Company&#x2019;s tax position as of the closing date, there was no tax impact resulting from the sale of the UltraMIST business.</celu:ConsiderationDescription>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20211231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">15019000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <celu:DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231"
      decimals="2"
      id="F_000542"
      unitRef="U_xbrlipure">0.11</celu:DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow>
    <celu:DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231"
      decimals="2"
      id="F_000543"
      unitRef="U_xbrlipure">0.26</celu:DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow>
    <celu:DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231"
      decimals="2"
      id="F_000544"
      unitRef="U_xbrlipure">0.02</celu:DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">9505000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">-4434000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <celu:DisposalGroupIncludingDiscontinuedOperationProfessionalFees
      contextRef="C_0001752828_us-gaapIncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_celuUltraMISTBusinessMember_20210101_20211231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">40000</celu:DisposalGroupIncludingDiscontinuedOperationProfessionalFees>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000360">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&#160;&#160;&#160;&#160;&#160;&lt;span style="font-weight:bold;"&gt;Fair Value of Financial Assets and&#160;Liabilities&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents - money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability - Sponsor Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability - Public Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;258,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents &#x2013; money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;350,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;350,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2021 and 2020, there were no transfers between Level&#160;1, Level 2 and Level 3.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s cash equivalents consisted of a money market fund. The money market fund was valued using inputs observable in active markets for similar securities, which represents a Level 1 measurement in the fair value hierarchy. The carrying values of accounts receivable, accounts payable, deferred revenue and other current liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term&#160;nature of those instruments.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&#160;of Contingent Consideration&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted&#160;income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#x2019;s own assumptions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December&#160;31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;transfers&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in to (out of)&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;settlements&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;transfers&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in to (out of)&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;settlements&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328,933&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the liability to make potential future milestone and earn-out&#160;payments was estimated by the Company at each reporting date based, in part, on the results of a third-party&#160;valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving specified events, discount rates, and the period of time until earn-out&#160;payments are payable and the conditions triggering the milestone payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence of these specified events.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At each reporting date, the Company revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the Company&#x2019;s consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has classified all of the contingent consideration as a long-term&#160;liability in the consolidated balance sheet as of December&#160;31, 2021 and 2020. See Note&#160;11, &#x201c;Commitment and Contingencies&#x201d;, for more information on contingent consideration.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation of&#160;Stock Warrant Liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The warrant liability at December 31, 2021 is composed of the fair value of warrants to purchase shares of common stock. The private placement warrants assumed upon the Business Combination (the &#x201c;Sponsor Warrants&#x201d;) were recorded at the Closing Date fair value based on a Black-Scholes option pricing model that utilizes inputs for: (i) value of the underlying asset, (ii) the exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset and (vi) maturity. The Black-Scholes option pricing model&#x2019;s primary unobservable input utilized in determining the fair value of the Sponsor Warrants is the expected volatility of the Class A common stock. Inputs to the Black-Sholes option pricing model for the Sponsor Warrants are updated each reporting period to reflect fair value. The public warrants assumed upon the Business Combination (the &#x201c;Public Warrants&#x201d;) were recorded at the Closing Date fair value based on the close price of such warrants. Each subsequent reporting period, the Public Warrants are marked-to-market based on the period-end close price.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The preferred stock warrant liability at December&#160;31, 2020 is composed of the fair value of warrants to purchase shares of Legacy Celularity Series B convertible preferred stock that were issued in 2020 and became exercisable for Class A common stock upon consummation of the Business Combination in accordance with their terms. Warrants were issued by Legacy Celularity to Dragasac Limited (&#x201c;Dragasac&#x201d;) in January&#160;2020 for no consideration and were recorded at fair value at the date of issuance (see Note 12). The liability associated with the warrants was recorded at fair value on the dates the warrants were issued and exercisable and was subsequently remeasured to fair value at each reporting date through the Business Combination date. The aggregate fair value of the warrant liability was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company used a lattice model to value the Legacy &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; warrants issued as the exercise price was a function of the stock price. In the application of each model, estimates and assumptions impacting the fair value measurement included the fair value per share of the underlying shares of Legacy &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity&#x2019;s&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; Series B convertible preferred stock, risk-free interest rate, and exercise date with considerations of the earlier of when the investor was required to exercise and the anticipated exit date. The most significant assumption in the forward contract model impacting the fair value of the preferred stock warrants was the fair value of Legacy &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity&#x2019;s&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; convertible preferred stock as of each remeasurement date. The Company determined the fair value per share of the underlying preferred stock by taking into consideration the most recent sales of Legacy &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity&#x2019;s&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; convertible preferred stock, results obtained from third-party valuations and additional factors that are deemed relevant.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of December 31, 2021 and December&#160;31, 2020, the fair value of the warrant liabilities was $25,962&#160;and $76,640, respectively. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated remaining term of the warrants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s warrant liabilities for which fair values are determined using Level 3 inputs:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of warrants issued in connection with Series B&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; preferred stock sale&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,954&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of warrant at fair value*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,988&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss recognized in earnings from change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,698&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain recognized in earnings from change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability assumed at Closing Date (Sponsor Warrants)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability assumed at Closing Date (Public Warrants)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of Legacy Celularity Warrants to equity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The warrants issued at fair value were immediately charged to expense see Note 12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The fair value of the Public Warrants was $12,362&#160;and $24,438&#160;as of December 31, 2021 and July 16, 2021, respectively, based on the publicly stated closing price. The fair value of the Sponsor Warrants was $13,600 and $34,764&#160;as of December 31, 2021 and July 16, 2021, respectively.&#160;Significant inputs for the Sponsor Warrants are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 16,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common share price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000613"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000614"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The fair value of the warrants issued to Dragasac was $33,435&#160;as of July 16, 2021. On the Closing Date, the Dragasac warrants qualified for equity classification and were reclassified accordingly.&#160;Significant inputs for the warrants issued to Dragasac are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 16,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.66 - 10.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17 - 6.95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;a&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000626"&gt;3.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33 - 1.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.09% - 0.10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#x2019;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#x2019;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The fair value of the warrants issued in connection with the Legacy Celularity Series B Preferred Stock was $62,963&#160;as of July 16, 2021. On the Closing Date, these warrants qualified for equity classification and were reclassified accordingly.&#160;Significant inputs for the warrants issued in connection with the Legacy Celularity Series B Preferred Stock are as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 16,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.66 - 10.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17 - 6.95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;b&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000644"&gt;3.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33 - 1.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.09% - 0.10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(b&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#FFFFFF;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation of the Convertible Note Receivable&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The convertible note receivable was received in connection with the disposition of the UltraMIST/MIST business. At any time on or after January 1, 2021, at the sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted into Sanuwave common stock at a defined rate. The convertible promissory note was to be paid on or before August 6, 2021, however, remains outstanding in full at December 31, 2021. The fair value of this note was determined using Level 3 inputs and is based on a bond valuation which employs a credit default model as of December 31, 2020. As of December 31, 2021, the Company utilized Level 3 inputs on a probability weighted model based on outcomes of a default, repayment and conversion of the note. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#x2019;s own assumptions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant inputs for the convertible note valuation model are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Face value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Coupon rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12% - 17%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.7 - 3.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000662"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000409">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents - money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,188&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability - Sponsor Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability - Public Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;245,822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;258,184&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents &#x2013; money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible note receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preferred stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;350,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;350,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">36700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">36700000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <celu:ConvertibleNoteReceivable
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">2488000</celu:ConvertibleNoteReceivable>
    <celu:ConvertibleNoteReceivable
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">2488000</celu:ConvertibleNoteReceivable>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">36700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">2488000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">39188000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">232222000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">232222000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <celu:WarrantLiabilitySponsorWarrants
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">13600000</celu:WarrantLiabilitySponsorWarrants>
    <celu:WarrantLiabilitySponsorWarrants
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">13600000</celu:WarrantLiabilitySponsorWarrants>
    <celu:WarrantLiabilityPublicWarrants
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">12362000</celu:WarrantLiabilityPublicWarrants>
    <celu:WarrantLiabilityPublicWarrants
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">12362000</celu:WarrantLiabilityPublicWarrants>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">12362000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20211231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">245822000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">258184000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">45000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0001752828_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">45000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <celu:ConvertibleNoteReceivable
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">4715000</celu:ConvertibleNoteReceivable>
    <celu:ConvertibleNoteReceivable
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">4715000</celu:ConvertibleNoteReceivable>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">45000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">4715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">49715000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">273367000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">273367000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <celu:PreferredStockWarrants
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">76640000</celu:PreferredStockWarrants>
    <celu:PreferredStockWarrants
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">76640000</celu:PreferredStockWarrants>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001752828_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_20201231"
      decimals="-3"
      id="F_000575"
      unitRef="U_iso4217USD">350007000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000576"
      unitRef="U_iso4217USD">350007000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000577"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000578"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000579"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000580"
      unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000581"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_0001752828_20200101_20201231"
      decimals="INF"
      id="F_000582"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000583"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_0001752828_20200101_20201231"
      decimals="INF"
      id="F_000584"
      unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000410">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs as of December&#160;31, 2021 and 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;transfers&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in to (out of)&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;settlements&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;232,222&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;transfers&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;in to (out of)&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Purchases,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;settlements&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;and other&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;328,933&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;273,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <celu:ContingentConsiderationObligation
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">273367000</celu:ContingentConsiderationObligation>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">-41145000</us-gaap:LiabilitiesFairValueAdjustment>
    <celu:ContingentConsiderationObligation
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">232222000</celu:ContingentConsiderationObligation>
    <celu:ContingentConsiderationObligation
      contextRef="C_0001752828_20191231"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">328933000</celu:ContingentConsiderationObligation>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">-55566000</us-gaap:LiabilitiesFairValueAdjustment>
    <celu:ContingentConsiderationObligation
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">273367000</celu:ContingentConsiderationObligation>
    <celu:FairValueNetAssetsLiability
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000591"
      unitRef="U_iso4217USD">25962000</celu:FairValueNetAssetsLiability>
    <celu:FairValueNetAssetsLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000592"
      unitRef="U_iso4217USD">76640000</celu:FairValueNetAssetsLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000411">
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The following table provides a roll-forward of the aggregate fair values of the Company&#x2019;s warrant liabilities for which fair values are determined using Level 3 inputs:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of warrants issued in connection with Series B&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; preferred stock sale&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,954&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of warrant at fair value*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,988&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss recognized in earnings from change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,698&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gain recognized in earnings from change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability assumed at Closing Date (Sponsor Warrants)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability assumed at Closing Date (Public Warrants)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification of Legacy Celularity Warrants to equity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(96,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <celu:StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000593"
      unitRef="U_iso4217USD">17954000</celu:StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants>
    <celu:ProceedsFromIssuanceOfWarrant
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000594"
      unitRef="U_iso4217USD">11988000</celu:ProceedsFromIssuanceOfWarrant>
    <celu:GainLossRecognizedInEarningsFromChangeInFairValues
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000595"
      unitRef="U_iso4217USD">46698000</celu:GainLossRecognizedInEarningsFromChangeInFairValues>
    <celu:FairValueNetAssetsLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000596"
      unitRef="U_iso4217USD">76640000</celu:FairValueNetAssetsLiability>
    <celu:FairValueNetAssetsLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000597"
      unitRef="U_iso4217USD">76640000</celu:FairValueNetAssetsLiability>
    <celu:GainLossRecognizedInEarningsFromChangeInFairValues
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000598"
      unitRef="U_iso4217USD">-13482000</celu:GainLossRecognizedInEarningsFromChangeInFairValues>
    <celu:WarrantLiabilityAssumedAtClosingDate
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210101_20211231"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">34764000</celu:WarrantLiabilityAssumedAtClosingDate>
    <celu:WarrantLiabilityAssumedAtClosingDate
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210101_20211231"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">24438000</celu:WarrantLiabilityAssumedAtClosingDate>
    <celu:ReclassificationOfLegacyCelularityWarrantsToEquity
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000601"
      unitRef="U_iso4217USD">-96398000</celu:ReclassificationOfLegacyCelularityWarrantsToEquity>
    <celu:FairValueNetAssetsLiability
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000602"
      unitRef="U_iso4217USD">25962000</celu:FairValueNetAssetsLiability>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210101_20211231"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">12362000</celu:FairValueOfWarrants>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuPublicWarrantsMember_20210716_20210716"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">24438000</celu:FairValueOfWarrants>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210101_20211231"
      decimals="-3"
      id="F_000605"
      unitRef="U_iso4217USD">13600000</celu:FairValueOfWarrants>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716_20210716"
      decimals="-3"
      id="F_000606"
      unitRef="U_iso4217USD">34764000</celu:FairValueOfWarrants>
    <celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuGXSponsorWarrantsMember_20210101_20211231"
      id="F_000412">Significant inputs for the Sponsor Warrants are as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 16,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common share price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000613"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000614"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.79&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231"
      decimals="INF"
      id="F_000607"
      unitRef="U_iso4217USD_xbrlishares">5.12</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716"
      decimals="INF"
      id="F_000608"
      unitRef="U_iso4217USD_xbrlishares">10.20</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20211231"
      decimals="2"
      id="F_000609"
      unitRef="U_iso4217USD_xbrlishares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716"
      decimals="2"
      id="F_000610"
      unitRef="U_iso4217USD_xbrlishares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20211231"
      decimals="0"
      id="F_000611"
      unitRef="U_xbrlipure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_20210716"
      decimals="0"
      id="F_000612"
      unitRef="U_xbrlipure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231"
      decimals="2"
      id="F_000615"
      unitRef="U_xbrlipure">1.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20210716"
      decimals="2"
      id="F_000616"
      unitRef="U_xbrlipure">0.79</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20211231"
      decimals="1"
      id="F_000617"
      unitRef="U_xbrlipure">63.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20210716"
      decimals="1"
      id="F_000618"
      unitRef="U_xbrlipure">50.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716_20210716"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">33435000</celu:FairValueOfWarrants>
    <celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210101_20211231"
      id="F_000413">Significant inputs for the warrants issued to Dragasac are as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 16,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.66 - 10.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17 - 6.95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;a&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000626"&gt;3.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33 - 1.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.86%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.09% - 0.10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#x2019;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#x2019;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716"
      decimals="2"
      id="F_000624"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231"
      decimals="2"
      id="F_000625"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716"
      decimals="0"
      id="F_000629"
      unitRef="U_xbrlipure">54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20201231"
      decimals="0"
      id="F_000630"
      unitRef="U_xbrlipure">90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716"
      decimals="2"
      id="F_000631"
      unitRef="U_xbrlipure">0.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231"
      decimals="2"
      id="F_000634"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <celu:PercentageOfExercisePrice
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231"
      decimals="2"
      id="F_000635"
      unitRef="U_xbrlipure">0.80</celu:PercentageOfExercisePrice>
    <celu:ClassOfWarrantExercisePriceDescription
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210101_20211231"
      id="F_000636">(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#x2019;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#x2019;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</celu:ClassOfWarrantExercisePriceDescription>
    <celu:FairValueOfWarrants
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716_20210716"
      decimals="-3"
      id="F_000637"
      unitRef="U_iso4217USD">62963000</celu:FairValueOfWarrants>
    <celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210101_20211231"
      id="F_000414">Significant inputs for the warrants issued in connection with the Legacy Celularity Series B Preferred Stock are as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;July 16,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value of common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.66 - 10.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.17 - 6.95&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise price &lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;b&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000644"&gt;3.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.33 - 1.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.60&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.09% - 0.10%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(b&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#FFFFFF;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716"
      decimals="2"
      id="F_000642"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      decimals="2"
      id="F_000643"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716"
      decimals="0"
      id="F_000647"
      unitRef="U_xbrlipure">54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20201231"
      decimals="0"
      id="F_000648"
      unitRef="U_xbrlipure">90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20210716"
      decimals="2"
      id="F_000649"
      unitRef="U_xbrlipure">0.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20211231"
      decimals="2"
      id="F_000652"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <celu:ScheduleOfConvertibleNoteValuationModelTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000415">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant inputs for the convertible note valuation model are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Face value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Coupon rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12% - 17%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.7 - 3.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000662"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.29&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.09&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;n/a&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfConvertibleNoteValuationModelTableTextBlock>
    <celu:FaceValueOfNotesReceivable
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000653"
      unitRef="U_iso4217USD">4000000</celu:FaceValueOfNotesReceivable>
    <celu:FaceValueOfNotesReceivable
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000654"
      unitRef="U_iso4217USD">4000000</celu:FaceValueOfNotesReceivable>
    <celu:PercentageOfCouponRate
      contextRef="C_0001752828_20200101_20201231"
      decimals="2"
      id="F_000657"
      unitRef="U_xbrlipure">0.12</celu:PercentageOfCouponRate>
    <celu:ValuationModelThatRelateToSanuwaveCommonStock
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000658"
      unitRef="U_iso4217USD_xbrlishares">0.17</celu:ValuationModelThatRelateToSanuwaveCommonStock>
    <celu:ValuationModelThatRelateToSanuwaveCommonStock
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_000659"
      unitRef="U_iso4217USD_xbrlishares">0.19</celu:ValuationModelThatRelateToSanuwaveCommonStock>
    <celu:ValuationInputForConvertiblePromissoryNote
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20211231"
      decimals="2"
      id="F_000663"
      unitRef="U_xbrlipure">0.29</celu:ValuationInputForConvertiblePromissoryNote>
    <celu:ValuationInputForConvertiblePromissoryNote
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_20201231"
      decimals="2"
      id="F_000664"
      unitRef="U_xbrlipure">0.09</celu:ValuationInputForConvertiblePromissoryNote>
    <celu:ValuationInputForConvertiblePromissoryNote
      contextRef="C_0001752828_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20201231"
      decimals="0"
      id="F_000665"
      unitRef="U_xbrlipure">70</celu:ValuationInputForConvertiblePromissoryNote>
    <us-gaap:InventoryDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000361">
&lt;p style="margin-bottom:0pt;margin-top:4pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&#160;&#160;&#160;&#160;&#160;Inventory&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s major classes of inventories were as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, gross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: inventory reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet Classification:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,549&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,850&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,998&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net of current portion includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000416">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s major classes of inventories were as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;460&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,016&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, gross&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,318&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: inventory reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance Sheet Classification:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,549&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,850&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Inventory, net of current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,998&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock>
    <celu:InventoryRawMaterialsCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">2359000</celu:InventoryRawMaterialsCurrentAndNoncurrent>
    <celu:InventoryRawMaterialsCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">376000</celu:InventoryRawMaterialsCurrentAndNoncurrent>
    <celu:InventoryWorkInProgressCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">5902000</celu:InventoryWorkInProgressCurrentAndNoncurrent>
    <celu:InventoryWorkInProgressCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">460000</celu:InventoryWorkInProgressCurrentAndNoncurrent>
    <celu:InventoryFinishedGoodsCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">4057000</celu:InventoryFinishedGoodsCurrentAndNoncurrent>
    <celu:InventoryFinishedGoodsCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">5016000</celu:InventoryFinishedGoodsCurrentAndNoncurrent>
    <celu:InventoryGrossCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">12318000</celu:InventoryGrossCurrentAndNoncurrent>
    <celu:InventoryGrossCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">5852000</celu:InventoryGrossCurrentAndNoncurrent>
    <celu:InventoryReserveCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">48000</celu:InventoryReserveCurrentAndNoncurrent>
    <celu:InventoryReserveCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">4000</celu:InventoryReserveCurrentAndNoncurrent>
    <celu:InventoryNetCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">12270000</celu:InventoryNetCurrentAndNoncurrent>
    <celu:InventoryNetCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">5848000</celu:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">9549000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">3850000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">2721000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">1998000</us-gaap:InventoryNoncurrent>
    <celu:InventoryNetCurrentAndNoncurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">12270000</celu:InventoryNetCurrentAndNoncurrent>
    <celu:InventoryNetCurrentAndNoncurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">5848000</celu:InventoryNetCurrentAndNoncurrent>
    <celu:PrepaidExpensesDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000362">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&#160;&#160;&#160;&#160;&#160;Prepaid Expenses&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,408&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</celu:PrepaidExpensesDisclosureTextBlock>
    <celu:ScheduleOfPrepaidExpensesTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000417">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid clinical expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,269&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,408&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,219&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,076&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfPrepaidExpensesTableTextBlock>
    <celu:PrepaidClinicalExpense
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000684"
      unitRef="U_iso4217USD">3269000</celu:PrepaidClinicalExpense>
    <celu:PrepaidClinicalExpense
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">5151000</celu:PrepaidClinicalExpense>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">1399000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">206000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">2408000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000689"
      unitRef="U_iso4217USD">1219000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000690"
      unitRef="U_iso4217USD">7076000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">6576000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000363">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&#160;&#160;&#160;&#160;&#160;Property and Equipment, Net&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Building&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,513&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvement&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,289&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory and production equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,395&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,884&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery, equipment and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,974&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,054&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,404&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,163&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,086&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90,077&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-right:88.89%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes $12,513 at December 31, 2021 and 2020 under financing lease resulting from a failed sale leaseback (see Note 11).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes $70,959 and $55,273 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;Includes $5,971 $2,624 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation expense was $6,625 and $4,780 for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress of $2,054 and $19,773 as of December&#160;31, 2021 and 2020 primarily relates to the leasehold improvements made at the Company&#x2019;s leased facilities in Florham Park, NJ.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20211231"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">12513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">12513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">71468000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">55289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20211231"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">11395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuLaboratoryAndProductionEquipmentMember_20201231"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">5884000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20211231"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">7974000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuMachineryEquipmentAndFixturesMember_20201231"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">3704000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">2054000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">19773000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">105404000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">97163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">14779000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">7086000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">90625000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">90077000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:SaleLeasebackTransactionHistoricalCost
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20211231"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">12513000</us-gaap:SaleLeasebackTransactionHistoricalCost>
    <us-gaap:SaleLeasebackTransactionHistoricalCost
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231"
      decimals="-3"
      id="F_000709"
      unitRef="U_iso4217USD">12513000</us-gaap:SaleLeasebackTransactionHistoricalCost>
    <us-gaap:SaleLeasebackTransactionHistoricalCost
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000710"
      unitRef="U_iso4217USD">70959000</us-gaap:SaleLeasebackTransactionHistoricalCost>
    <us-gaap:SaleLeasebackTransactionHistoricalCost
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000711"
      unitRef="U_iso4217USD">55273000</us-gaap:SaleLeasebackTransactionHistoricalCost>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000712"
      unitRef="U_iso4217USD">5971000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:SaleLeasebackTransactionAccumulatedDepreciation
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000713"
      unitRef="U_iso4217USD">2624000</us-gaap:SaleLeasebackTransactionAccumulatedDepreciation>
    <us-gaap:Depreciation
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000714"
      unitRef="U_iso4217USD">6625000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000715"
      unitRef="U_iso4217USD">4780000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000716"
      unitRef="U_iso4217USD">2054000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000717"
      unitRef="U_iso4217USD">19773000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000364">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.&#160;&#160;&#160;&#160;&#160;Goodwill and Intangible Assets, Net&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company performs its annual goodwill impairment test in the fourth quarter of every year, unless a triggering event occurs prior to the impairment test. Based on the Company&#x2019;s annual assessment performed during the fourth quarter of 2021, it was determined that goodwill was not impaired. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of goodwill assigned to the Company&#x2019;s operating segments are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cell Therapy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biobanking&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,374&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition of goodwill related to sale of UltraMIST business&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:88.89%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible Assets, Net&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lives&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortizable intangible assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11 &#x2013; 16 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade names &amp;amp; trademarks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10 &#x2013; 13 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reacquired rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade names &amp;amp; trademarks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reacquired rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortizable intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,687&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,879&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-amortized intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired IPR&amp;amp;D product rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000760"&gt;indefinite&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization expense for intangible assets was $2,192 and $3,394 for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December&#160;31, 2021 is estimated as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,493&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,356&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the third quarter of 2020, the Company experienced a triggering event as it discontinued development of PDA-001&#160;for an indefinite period of time and opted to pursue an alternative clinical program. As of September&#160;30, 2020, the Company determined PDA-001&#160;did not have future cash flows as the Company did not intend to further develop and commercialize the asset. The triggering event required the Company to perform a quantitative impairment test as of September&#160;30, 2020. As a result of this impairment test, the Company recorded a $129,400 impairment charge to write-off&#160;the entire IPR&amp;amp;D intangible asset related to PDA-001.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000419">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of goodwill assigned to the Company&#x2019;s operating segments are as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cell Therapy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biobanking&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,374&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;127,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition of goodwill related to sale of UltraMIST business&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,764&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20191231"
      decimals="-3"
      id="F_000718"
      unitRef="U_iso4217USD">112347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20191231"
      decimals="-3"
      id="F_000719"
      unitRef="U_iso4217USD">7374000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20191231"
      decimals="-3"
      id="F_000720"
      unitRef="U_iso4217USD">7347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_20191231"
      decimals="-3"
      id="F_000721"
      unitRef="U_iso4217USD">127068000</us-gaap:Goodwill>
    <celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231"
      decimals="-3"
      id="F_000722"
      unitRef="U_iso4217USD">3764000</celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness>
    <celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000723"
      unitRef="U_iso4217USD">3764000</celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20201231"
      decimals="-3"
      id="F_000724"
      unitRef="U_iso4217USD">112347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20201231"
      decimals="-3"
      id="F_000725"
      unitRef="U_iso4217USD">3610000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20201231"
      decimals="-3"
      id="F_000726"
      unitRef="U_iso4217USD">7347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000727"
      unitRef="U_iso4217USD">123304000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20211231"
      decimals="-3"
      id="F_000728"
      unitRef="U_iso4217USD">112347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20211231"
      decimals="-3"
      id="F_000729"
      unitRef="U_iso4217USD">3610000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20211231"
      decimals="-3"
      id="F_000730"
      unitRef="U_iso4217USD">7347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000731"
      unitRef="U_iso4217USD">123304000</us-gaap:Goodwill>
    <celu:ScheduleOfIntangibleAssetsNetTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000420">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets, net consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated Useful&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lives&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortizable intangible assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11 &#x2013; 16 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,413&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade names &amp;amp; trademarks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10 &#x2013; 13 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reacquired rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Developed technology&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer relationships&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,170&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trade names &amp;amp; trademarks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(220&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reacquired rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,540&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,840&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,306&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,114&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortizable intangible assets, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,687&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,879&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.28%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-amortized intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.12%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Acquired IPR&amp;amp;D product rights&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;108,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000760"&gt;indefinite&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.28%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;123,187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.12%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</celu:ScheduleOfIntangibleAssetsNetTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20211231"
      decimals="-3"
      id="F_000732"
      unitRef="U_iso4217USD">16810000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231"
      decimals="-3"
      id="F_000733"
      unitRef="U_iso4217USD">16810000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20211231"
      decimals="-3"
      id="F_000734"
      unitRef="U_iso4217USD">2413000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20201231"
      decimals="-3"
      id="F_000735"
      unitRef="U_iso4217USD">2413000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20200101_20201231"
      id="F_000765">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20210101_20211231"
      id="F_000758">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20211231"
      decimals="-3"
      id="F_000736"
      unitRef="U_iso4217USD">570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20201231"
      decimals="-3"
      id="F_000737"
      unitRef="U_iso4217USD">570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20211231"
      decimals="-3"
      id="F_000738"
      unitRef="U_iso4217USD">4200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20201231"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">4200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20200101_20201231"
      id="F_000766">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20210101_20211231"
      id="F_000759">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">23993000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000741"
      unitRef="U_iso4217USD">23993000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20211231"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">5376000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapDevelopedTechnologyRightsMember_20201231"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">4203000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20211231"
      decimals="-3"
      id="F_000744"
      unitRef="U_iso4217USD">1170000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapCustomerRelationshipsMember_20201231"
      decimals="-3"
      id="F_000745"
      unitRef="U_iso4217USD">906000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20211231"
      decimals="-3"
      id="F_000746"
      unitRef="U_iso4217USD">220000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapTrademarksAndTradeNamesMember_20201231"
      decimals="-3"
      id="F_000747"
      unitRef="U_iso4217USD">165000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20211231"
      decimals="-3"
      id="F_000748"
      unitRef="U_iso4217USD">2540000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_celuReacquiredRightsMember_20201231"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">1840000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">9306000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">7114000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">14687000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">16879000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <celu:AcquiredProductRights
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">108500000</celu:AcquiredProductRights>
    <celu:AcquiredProductRights
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">108500000</celu:AcquiredProductRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">123187000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000757"
      unitRef="U_iso4217USD">125379000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000772"
      unitRef="U_iso4217USD">2192000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000773"
      unitRef="U_iso4217USD">3394000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000421">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate amortization expense for each of the five succeeding years related to intangible assets held as of December&#160;31, 2021 is estimated as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,784&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,493&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,356&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000774"
      unitRef="U_iso4217USD">2193000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000775"
      unitRef="U_iso4217USD">2193000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000776"
      unitRef="U_iso4217USD">1784000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000777"
      unitRef="U_iso4217USD">1493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000778"
      unitRef="U_iso4217USD">1356000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001752828_20200701_20200930"
      decimals="-3"
      id="F_000779"
      unitRef="U_iso4217USD">129400000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000365">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&#160;&#160;&#160;&#160;&#160;Accrued expenses and&#160;other current liabilities&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued wages, bonuses, commissions and vacation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,991&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals for construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;292&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,661&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,451&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000422">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical trial expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,866&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued wages, bonuses, commissions and vacation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,991&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals for construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;292&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,661&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,451&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <celu:AccruedClinicalTrialExpense
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000780"
      unitRef="U_iso4217USD">1861000</celu:AccruedClinicalTrialExpense>
    <celu:AccruedClinicalTrialExpense
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000781"
      unitRef="U_iso4217USD">2644000</celu:AccruedClinicalTrialExpense>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000782"
      unitRef="U_iso4217USD">1653000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000783"
      unitRef="U_iso4217USD">2866000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000784"
      unitRef="U_iso4217USD">3824000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000785"
      unitRef="U_iso4217USD">4991000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <celu:AccrualsForConstructionInProgress
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000786"
      unitRef="U_iso4217USD">171000</celu:AccrualsForConstructionInProgress>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000787"
      unitRef="U_iso4217USD">2000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000788"
      unitRef="U_iso4217USD">292000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000789"
      unitRef="U_iso4217USD">4321000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000790"
      unitRef="U_iso4217USD">2487000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000791"
      unitRef="U_iso4217USD">11661000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_000792"
      unitRef="U_iso4217USD">13451000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermDebtTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000366">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&#160;&#160;&#160;&#160;&#160;Short-term borrowings &#x2013; related party&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On June 8, 2021, Legacy Celularity entered into a $5,000&#160;loan agreement with C.V. Starr &amp;amp; Co., Inc. (&#x201c;CV Starr&#x201d;), a stockholder of the Company. The loan accrued interest on outstanding principal at a rate equal to (a)&#160;8.0% per year until, and including, July 31, &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;2021&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; and (b)&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;10.0&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;% per &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;year&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; commencing on, and including August 1, 2021. Accrued and unpaid interest was payable on July 31, 2021, the last day of each month thereafter, on the date of any prepayment of the loan, on the maturity date and, after the maturity date, on demand. The loan&#160;was required to be&#160;paid in full on the earlier of (&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;i&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;)&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;June 8, 2022&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, (ii) the date of the consummation of the&#160;Business Combination&#160;and (iii) the date the outstanding principal&#160;was&#160;declared due and payable by CV Starr as remedy to an event of default (the &#x201c;Maturity Date&#x201d;). On the earlier of (&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;i&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;) the Maturity Date or (ii) the date on which the loan&#160;was&#160;repaid in&#160;full&#160;and the commitments of CV Starr&#160;were&#160;terminated,&#160;Legacy&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Celularity&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;was required to&#160;pay CV Starr an exit fee in an amount equal to&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;2.0&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;% of the aggregate principal amount of the loan advanced.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Under the terms of the loan, Legacy Celularity could not permit the aggregate amount of cash and cash equivalents to be less than $5,000&#160;for more than&#160;five&#160;consecutive business days. Legacy Celularity could not borrow an additional $5,000&#160;under the loan agreement should it project that the aggregate amount of its cash and cash equivalents would be less than $5,000&#160;prior to the consummation of the Business Combination.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the year ended December 31, 2021, the Company repaid amounts outstanding under the short term borrowing arrangement with CV Starr and the arrangement was cancelled. Total amount paid to CV Starr was $5,146, which included principal, accrued interest and the exit fee.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608"
      decimals="INF"
      id="F_000793"
      unitRef="U_iso4217USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210731"
      decimals="INF"
      id="F_000794"
      unitRef="U_xbrlipure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210801"
      decimals="INF"
      id="F_000795"
      unitRef="U_xbrlipure">0.100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210101_20211231"
      id="F_000796">2022-06-08</us-gaap:DebtInstrumentMaturityDate>
    <celu:ShortTermBorrowingAmountEqualToExitFeePercentage
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210607_20210608"
      decimals="3"
      id="F_000797"
      unitRef="U_xbrlipure">0.020</celu:ShortTermBorrowingAmountEqualToExitFeePercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608"
      decimals="-3"
      id="F_000798"
      unitRef="U_iso4217USD">5000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210607_20210608"
      decimals="INF"
      id="F_000799"
      unitRef="U_celuDay">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608"
      decimals="INF"
      id="F_000800"
      unitRef="U_iso4217USD">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608"
      decimals="-3"
      id="F_000801"
      unitRef="U_iso4217USD">5000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <celu:RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee
      contextRef="C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210101_20211231"
      decimals="-3"
      id="F_000802"
      unitRef="U_iso4217USD">5146000</celu:RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000367">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&#160;&#160;&#160;&#160;&#160;Commitments and&#160;contingencies&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Lease Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2017, Legacy Celularity entered into an operating lease for office space in Warren, New Jersey, which expires in 2022. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $481, which is classified as restricted cash (non-current) on the consolidated balance sheets as of December 31, 2020. During the second quarter of 2021, the full $481 was drawn by the landlord. During the third quarter of 2021, the lease for office space in Warren, New Jersey was terminated.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 10, 2019, Legacy Celularity extended the operating lease for the office and laboratory space in Cedar Knolls, New Jersey on a month-to-month basis. Beginning November 1, 2019, Legacy Celularity began paying the landlord the base annual rent and all additional rent at a 2% increase, pro-rated monthly for each month it remains in possession of the premises. Monthly lease payments of $15 due under the lease include base rent and ancillary charges.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 13, 2019, Legacy Celularity entered into a lease agreement for a 147,215 square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in 2036. The Company has the option to renew the term of the lease for two additional &lt;span style="-sec-ix-hidden:F_000809"&gt;five-year&lt;/span&gt; terms so long as the lease is then in full force and effect. The lease term commenced on March 1, 2020 subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly base rent is approximately $230 and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease agreement, Legacy Celularity issued a letter of credit of $14,722 which is classified as restricted cash (non-current) on the consolidated balance sheet as of December 31, 2021 and December 31, 2020. The lease agreement allows for a landlord provided tenant improvement allowance of $14,722 to be applied to the costs of the construction of the leasehold improvements.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is not the legal owner of the leased space. However, in accordance with Accounting Standards Codification 840, Leases, the Company is deemed to be the owner of the leased space, including the building shell, during the construction period because of the Company&#x2019;s level of direct financial and operational involvement in the substantial tenant improvement. The lease arrangement did not meet all the criteria for sale-leaseback accounting due to the continuing involvement of the Company in the property and therefore was accounted for as a failed sale-leaseback financing obligation. As a result, as of December 31, 2019, Legacy Celularity capitalized the fair value of the building shell, the tenant improvement allowance, and ground rent expense, approximately $28,062, as construction-in-progress within property and equipment, net and recorded a corresponding build-to-suit facility lease financing obligation. As of December 31, 2021, $28,085 related to the lease financing obligation was classified as a long-term capital lease liability on its consolidated balance sheet, while $3,051 was classified as a current liability.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, construction costs incurred as part of the build-out and tenant improvements were capitalized as construction-in-progress within property and equipment, net. Legacy Celularity began to occupy completed portions of the facility in the first quarter of 2020. As the building was occupied, costs were moved out of construction-in-process and were placed in service. As of December 31, 2021 and 2020, there were $0 and $15,415 of costs related the facility included in construction-in-progress, respectively. Remaining construction was completed during January 2021 and remaining construction-in-progress costs were placed in service.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes rent expense on a straight-line basis over the respective lease period and has recorded deferred rent for rent expense incurred but not yet paid. Rent expense was $668 and $1,612 for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum payments inclusive of the amended lease, by year and in aggregate, under non-cancelable&#160;leases consist of the following as of December&#160;31, 2021:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,531&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingent Consideration Related to Business Combinations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s acquisition of HLI CT, Anthrogenesis and CariCord, the Company has agreed to pay future consideration to the sellers upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $232,222 and $273,367 as contingent consideration as of December&#160;31, 2021 and 2020, respectively. Due to the contingent nature of these milestone and royalty payments, there is a high degree of management estimates that determine the fair value of the contingent consideration. See note 4 for further discussion. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Indemnification Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December&#160;31, 2021 or 2020.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with Palantir Technologies Inc.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 5, 2021, Legacy Celularity executed a Master Subscription Agreement with Palantir under which it will pay $40,000&#160;over&#160;five years&#160;for access to Palantir&#x2019;s Foundry platform along with certain professional services. The Company will utilize Palantir&#x2019;s Foundry platform to secure deeper insights into data obtained from the Company&#x2019;s discovery and process development, as well as manufacturing and biorepository operations. During the third quarter of 2021, the Company paid its first annual fee of $6,000. For the year ended December 31, 2021, the Company has recorded costs of $5,333&#160;on a straight-line basis related to this agreement, which was included as a component of selling, general and administrative expense in the consolidated statement of operations.&lt;/p&gt;
&lt;p style="margin-top:7pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Sirion License Agreement &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:7pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December&#160;2021, the Company entered into a license agreement (&#x201c;Sirion License&#x201d;) with Sirion Biotech GmbH (&#x201c;Sirion&#x201d;). Under the Sirion License, Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (&#x201c;Licensed Product&#x201d;). As part of the Sirion License, the Company will pay Sirion $136 as an upfront fee, a $113 annual maintenance fee and may owe up to $5,099 million related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration of the last to expire valid claim of the patents covering such Licensed Product, and (ii) 10 years after first Commercial Sale of a Licensed Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company for convenience upon 30 days written notice. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Legal Proceedings&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 24, 2021, CTH Biosourcing LLC (&#x201c;CTH&#x201d;) filed a petition and request for disclosure in the District Court of Travis County, Texas seeking declaratory relief challenging Legacy Celularity&#x2019;s for-cause termination of a Tissue Procurement Agreement (&#x201c;TPA&#x201d;). During the year ended December 31, 2021, the Company entered into a tri-party settlement with CTH and the CariCord &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;participating shareholders, as interested parties, in which the Company agreed to amend the TPA in exchange for a full release of all claims underlying the aforementioned litigation. In addition, the Company issued&lt;/span&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;743,771&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of Celularity &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Class A Common Stock to the CariCord participating shareholders&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; with an estimated fair value of &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;5,333&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; in exchange for a full release&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;This amount was recorded as a legal settlement expense within selling, general and administrative in the statement of operations for the year ended December 31, 2021. Pursuant to the settlement agreement, the CariCord participating shareholders are entitled to receive up to an additional &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;371,885&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of Celularity Class A Common Stock if certain procurement targets are met by CTH under the TPA during a specified period, which was not probable of being achieved at December 31, 2021.&lt;/span&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <celu:OperatingLeaseExpiryYear
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuWarrenNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeSpaceMember_20170901_20170930"
      id="F_000803">2022</celu:OperatingLeaseExpiryYear>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231"
      decimals="-3"
      id="F_000804"
      unitRef="U_iso4217USD">481000</us-gaap:RestrictedCashEquivalentsCurrent>
    <celu:PercentageIncreaseInBaseAnnualRent
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuCedarKnollsNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeAndLaboratorySpaceMember_20191101_20191101"
      decimals="2"
      id="F_000805"
      unitRef="U_xbrlipure">0.02</celu:PercentageIncreaseInBaseAnnualRent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuCedarKnollsNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeAndLaboratorySpaceMember_20191101_20191101"
      decimals="-3"
      id="F_000806"
      unitRef="U_iso4217USD">15000</us-gaap:OperatingLeasePayments>
    <celu:AreaOfBuildings
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313"
      decimals="0"
      id="F_000807"
      unitRef="U_utrsqft">147215</celu:AreaOfBuildings>
    <celu:OperatingLeaseExpiryYear
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313"
      id="F_000808">2036</celu:OperatingLeaseExpiryYear>
    <celu:OperatingLeaseCommencementDate
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313"
      id="F_000810">2020-03-01</celu:OperatingLeaseCommencementDate>
    <celu:InitialMonthlyBaseRent
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313_20190313"
      decimals="-3"
      id="F_000811"
      unitRef="U_iso4217USD">230000</celu:InitialMonthlyBaseRent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20211231"
      decimals="-3"
      id="F_000812"
      unitRef="U_iso4217USD">14722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20201231"
      decimals="-3"
      id="F_000813"
      unitRef="U_iso4217USD">14722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:TenantImprovements
      contextRef="C_0001752828_srtStatementGeographicalAxis_celuFlorhamParkNewJerseyMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_celuOfficeManufacturingAndLaboratorySpaceMember_20190313"
      decimals="-3"
      id="F_000814"
      unitRef="U_iso4217USD">14722000</us-gaap:TenantImprovements>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20191231"
      decimals="-3"
      id="F_000815"
      unitRef="U_iso4217USD">28062000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation>
    <celu:FinancingObligationsNoncurrent
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231"
      decimals="-3"
      id="F_000816"
      unitRef="U_iso4217USD">28085000</celu:FinancingObligationsNoncurrent>
    <celu:FinancingObligationsCurrent
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231"
      decimals="-3"
      id="F_000817"
      unitRef="U_iso4217USD">3051000</celu:FinancingObligationsCurrent>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20211231"
      decimals="-3"
      id="F_000818"
      unitRef="U_iso4217USD">0</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000819"
      unitRef="U_iso4217USD">15415000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000820"
      unitRef="U_iso4217USD">668000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000821"
      unitRef="U_iso4217USD">1612000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000423">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum payments inclusive of the amended lease, by year and in aggregate, under non-cancelable&#160;leases consist of the following as of December&#160;31, 2021:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,895&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,969&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,531&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,414&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000822"
      unitRef="U_iso4217USD">2861000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000823"
      unitRef="U_iso4217USD">2895000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000824"
      unitRef="U_iso4217USD">2969000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000825"
      unitRef="U_iso4217USD">3042000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000826"
      unitRef="U_iso4217USD">3116000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000827"
      unitRef="U_iso4217USD">73531000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000828"
      unitRef="U_iso4217USD">88414000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20211231"
      decimals="-3"
      id="F_000829"
      unitRef="U_iso4217USD">232222000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuLLCAndAnthrogenesisMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuHLICellularTherapeuticsMember_20201231"
      decimals="-3"
      id="F_000830"
      unitRef="U_iso4217USD">273367000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <celu:PaymentsForMasterSubscriptionAgreement
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210505_20210505"
      decimals="-3"
      id="F_000831"
      unitRef="U_iso4217USD">40000000</celu:PaymentsForMasterSubscriptionAgreement>
    <celu:PaymentSubscriptionPeriod
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210505_20210505"
      id="F_000832">P5Y</celu:PaymentSubscriptionPeriod>
    <celu:AnnualFeePaid
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210701_20210930"
      decimals="-3"
      id="F_000833"
      unitRef="U_iso4217USD">6000000</celu:AnnualFeePaid>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuPalantirTechnologiesIncMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapTypeOfArrangementAxis_celuMasterSubscriptionAgreementMember_20210101_20211231"
      decimals="-3"
      id="F_000834"
      unitRef="U_iso4217USD">5333000</us-gaap:CostsAndExpensesRelatedParty>
    <celu:UpfrontFee
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231"
      decimals="-3"
      id="F_000835"
      unitRef="U_iso4217USD">136000</celu:UpfrontFee>
    <celu:AnnualMaintenanceFee
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231"
      decimals="-3"
      id="F_000836"
      unitRef="U_iso4217USD">113000</celu:AnnualMaintenanceFee>
    <celu:ClinicalAndRegulatoryMilestones
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231"
      decimals="-3"
      id="F_000837"
      unitRef="U_iso4217USD">5099000</celu:ClinicalAndRegulatoryMilestones>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231"
      id="F_000838">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <celu:LicenseAgreementNoticePeriod
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuLicenseAgreementMember_20211201_20211231"
      id="F_000839">P30D</celu:LicenseAgreementNoticePeriod>
    <celu:NumberOfSharesIssuedInLegalSettlementAgreement
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210324_20210324"
      decimals="INF"
      id="F_000840"
      unitRef="U_xbrlishares">743771</celu:NumberOfSharesIssuedInLegalSettlementAgreement>
    <celu:EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210101_20211231"
      decimals="-3"
      id="F_000841"
      unitRef="U_iso4217USD">5333000</celu:EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement>
    <celu:NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuCariCordParticipatingShareholdersMember_20210324_20210324"
      decimals="INF"
      id="F_000842"
      unitRef="U_xbrlishares">371885</celu:NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000368">
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&#160;&#160;&#160;&#160;&#160;Equity&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Subsequent to Business Combination&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of December 31, 2021, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue&#160;730,000,000&#160;shares of $0.0001&#160;par value Class A common stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Voting Power&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company&#x2019;s directors and all other matters requiring stockholder action. Holders of&#160;common stock are entitled to one vote per share&#160;on matters to be voted on by stockholders.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Holders of Class A Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#x2019;s board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Liquidation, Dissolution and Winding Up&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In the event of the Company&#x2019;s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company&#x2019;s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Preemptive or Other Rights&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Election of Directors&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s board of directors is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class serving a three-year&#160;term, except with respect to the election of directors at the special meeting held in connection with the merger with GX. Class I directors are elected to an initial one-year&#160;term (and three-year&#160;terms subsequently), the Class II directors are elected to an initial two-year&#160;term (and three-year&#160;terms subsequently) and the Class III directors are elected to an initial three-year&#160;term (and three-year&#160;terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than&#160;50% of the shares voted for the election of directors can elect all of the directors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Prior to Business Combination&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of&#160;December&#160;31, 2020, Legacy Celularity&#x2019;s certificate of incorporation, as amended and restated, authorized Legacy Celularity to issue&#160;155,640,290&#160;shares of $0.0001&#160;par value common stock. The voting, dividend and liquidation rights of the holders of Legacy Celularity&#x2019;s common stock were subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock (as set forth below).&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Each share of&#160;common stock entitled the holder to one vote&#160;on all matters submitted to a vote of Legacy Celularity stockholders. The holders of common stock, voting exclusively and as a separate class, were entitled to elect one director of the Legacy Celularity. Common stockholders were entitled to receive dividends, as was declared by the board of directors, if any, subject to the preferential dividend rights of Preferred Stock. Through the Closing Date, no cash dividends were declared or paid.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of December&#160;31, 2020, Legacy Celularity had&#160;90,834&#160;of repurchased shares recorded as treasury stock. On the Closing Date, previously existing Legacy Celularity shares held in treasury were cancelled without any conversion.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preferred Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Subsequent to Business Combination&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company&#x2019;s Certificate of Incorporation authorized&#160;10,000,000&#160;shares of preferred stock and provides that shares of preferred stock may be issued from time to time in one or more series. The Company&#x2019;s board of directors is authorized to fix the voting rights, if any, designations, powers and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof, applicable to the shares of each series of preferred stock. The Company&#x2019;s board of directors is able to, without stockholder approval, issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common stock and could have anti-takeover effects. The ability of the Company&#x2019;s board of directors to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management. As of December 31, 2021, the Company does&#160;not have any outstanding preferred stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Prior to Business Combination&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Legacy Celularity issued Series A convertible redeemable preferred stock (the &#x201c;Series A Preferred Stock&#x201d;), Series B convertible redeemable preferred stock (the &#x201c;Series B Preferred Stock&#x201d;), and Series X convertible redeemable preferred stock (the &#x201c;Series X Preferred Stock&#x201d;). The Series A Preferred Stock, Series B Preferred Stock, and Series X Preferred Stock are collectively referred to as the &#x201c;Preferred Stock&#x201d;. Immediately prior to closing of the Business Combination on July 16, 2021, the outstanding shares of Preferred Stock were converted into shares of Legacy Celularity common stock and then exchanged for the Company&#x2019;s Class A common stock at the Effective Time. As of December&#160;31, 2020, Legacy Celularity certificate of incorporation, as amended and restated, authorized Legacy&#160;Celularity&#160;to issue a total of&#160;116,526,341&#160;shares&#160;of Preferred Stock, with a par value of $0.0001&#160;per share. As of&#160;December&#160;31, 2020,&#160;no&#160;shares of Preferred Stock remained undesignated.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The holders of Preferred Stock had liquidation rights in the event of a deemed liquidation that, in certain situations, were not solely within the control of Legacy Celularity. Therefore, the Preferred Stock was classified outside of stockholders&#x2019; deficit on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On March 16, 2020, Legacy Celularity entered into a Series B Preferred Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain institutional investors and certain individual investors (collectively &#x201c;Investors&#x201d;). Pursuant to the terms of the Purchase Agreement, Legacy Celularity sold and issued to the Investors an aggregate of&#160;13,620,063&#160;shares of Series B Preferred Stock and warrants to purchase up to an aggregate of&#160;13,281,386&#160;shares of Series B Preferred Stock for an aggregate purchase price of approximately $102,550. Legacy Celularity utilized a probability-weighted option pricing model to determine the fair value of the warrants at the issuance date with the residual proceeds allocated to the Series B Preferred Stock. Based on this valuation, Legacy Celularity determined the purchase price allocated to the Series B Preferred Stock was $84,596&#160;and the purchase price allocated to the warrants was $17,954.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Legacy Celularity&#x2019;s classified Preferred Stock in accordance with Accounting Standards Codification 480,&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, which required that contingently redeemable securities be classified outside of permanent stockholders&#x2019; equity. Accordingly, Legacy Celularity classified all shares and classes of Preferred Stock as mezzanine equity on the accompanying consolidated balance sheets at December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Rights, Preferences and Privileges of the Preferred Stock&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The holders of the Preferred Stock had the following rights and preferences except where noted:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Voting&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The holders of&#160;Preferred Stock were entitled to vote, together with the holders of common stock as a single class, on all matters submitted to stockholders for a vote and had the right to vote the number of shares equal to the number of shares of common stock into which each share of Preferred Stock could convert on the record date for determination of stockholders entitled to vote.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As long as there were at least&#160;5,000,000&#160;shares of Series B Preferred Stock outstanding, the holders of Series B Preferred Stock, voting as a separate class, could elect one director of Legacy Celularity. The remaining directors were elected by holders of common stock and Preferred Stock, voting together as a single class on an as converted basis.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Conversion&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Each share of Preferred Stock was convertible, at the option of the holder, at any time after the date of issuance. In addition, each share of Preferred Stock could automatically converted into shares of common stock at the applicable conversion ratio then in effect (i)&#160;upon the closing of a firm-commitment public offering resulting in at least $50,000&#160;of gross proceeds to Legacy Celularity at a price of at least $9.41&#160;per share of common stock, subject to appropriate adjustment of any recapitalization (&#x201c;Qualified IPO&#x201d;), or (ii)&#160;upon the written consent of the holders of a majority of the then-outstanding shares of Preferred Stock, voting together as a single class.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The conversion ratio of each series of Preferred Stock was determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price per share was $6.27&#160;for Series A and X Preferred Stock (the &#x201c;Series A and X Original Issue Price&#x201d;) and $7.53&#160;for Series B Preferred Stock (the &#x201c;Series B Original Issue Price&#x201d;), each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in Legacy Celularity&#x2019;s certificate of incorporation, as amended and restated. As of December&#160;31, 2020 and the Closing Date, the Conversion Price was equal to the Original Issue Price for each series of Preferred Stock. Accordingly, as of December&#160;31, 2020 and the Closing Date, each share of each series of Preferred Stock was convertible into shares of Legacy Celularity common stock on a&#160;one-for-one basis.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Dividends&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of&#160;6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date,&#160;no&#160;cash dividends were declared or paid.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Liquidation&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In the event of any voluntary or involuntary liquidation, dissolution or winding up of Legacy Celularity or Deemed Liquidation Event (as defined below), each holder of the then-outstanding Preferred Stock was entitled to receive the greater of (i)&#160;an amount equal to the Original Issue Price for each series of Preferred Stock plus any dividends declared but unpaid thereon or (ii)&#160;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event at the conversion price. In the event that the assets available for distribution to stockholders&#160;were&#160;insufficient to pay Preferred&#160;Stock holders&#160;the full amounts to which they&#160;were&#160;entitled, the assets available for distribution&#160;were to&#160;be distributed on a pro rata basis among the holders of the Preferred Stock in proportion to the respective amounts that would otherwise be payable in respect of such shares.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;After the payment of all preferential amounts to the holders of Preferred Stock, then, to the extent available, the remaining assets of Legacy Celularity were to be distributed among the holders of common stock, pro rata based on the number of shares held by each such holder.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Unless (i)&#160;the holders of Series B Preferred Stock received an amount less the Original Issue Price or (ii)&#160;the holders of majority of the then-outstanding Preferred Stock, voting together as a single class, elect otherwise, a Deemed Liquidation Event included a merger or consolidation (other than one in which stockholders of Legacy Celularity own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of Legacy Celularity.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Redemption&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Legacy Celularity&#x2019;s certificate of incorporation, as amended and restated, did not provide redemption rights to the holders of Preferred Stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Legacy Celularity Warrants&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On May 7, 2018, Legacy Celularity granted Dragasac a warrant for the purchase of an aggregate of&#160;16,601,736&#160;shares of Series B Preferred Stock (the &#x201c;Dragasac Warrant&#x201d;) at an exercise price of $7.53&#160;per share. On February 15, 2019, Dragasac exercised its rights under the Dragasac Warrant to purchase&#160;6,640,695&#160;shares of Series B Preferred Stock, at an exercise price of $7.53&#160;per share, for gross proceeds of approximately $50,000. On May 29, 2019, Legacy Celularity amended and restated the Dragasac Warrant to provide for a reduced exercise price of $7.29&#160;for the remaining warrant shares in exchange for Dragasac agreeing to purchase&#160;3,431,223&#160;shares of Series B Preferred Stock on or before May 31, 2019. On May 31, 2019, Dragasac exercised its rights under the Dragasac Warrant to purchase&#160;3,431,223&#160;shares of Series B Preferred Stock at a price per share of $7.29, for gross proceeds of approximately $25,000. On November 1, 2019, Legacy Celularity again amended the Dragasac Warrant to provide for a reduced exercise price of $6.77&#160;for the remaining warrant shares in exchange for Dragasac agreeing to purchase&#160;6,529,818&#160;shares of Series B Preferred Stock on or before &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;November 4, 2019. On November 4, 2019, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Dragasac&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; exercised its right to purchase&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;6,529,818&#160;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;shares of Series B Preferred Stock, at a price per share of $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;6.77&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, for gross proceeds of approximately $&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;44,178&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On January 9, 2020, Legacy Celularity issued a warrant for the purchase of an aggregate of&#160;6,529,818&#160;shares of Series B Preferred Stock to Dragasac. The exercise price per share at which the warrant will be exercised shall be the lesser of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of the common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#x2019;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#x2019;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange. The estimated fair value of the warrant of $11,988&#160;at the issuance date was immediately charged to expense and recorded in expense related to warrant liabilities in the accompanying consolidated statements of operations. The incremental change in fair value resulting from the amendment was also immediately charged to expense and recorded in the same line item.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On January 8, 2021, Legacy Celularity entered into a warrant amendment agreement (&#x201c;Amendment No.&#160;2&#x201d;) to amend the warrant issued to Dragasac on January 9, 2020, as amended on March 16, 2020. Amendment No.&#160;2 added a cashless exercise provision and eliminated the provision that would have provided for expiration of the warrant upon consummation of the Business Combination. Any portion of the warrant that was unexercised prior to consummation of the Business Combination converted into warrants to purchase shares of the Company&#x2019;s Class&#160;A common stock, with the exercise price and number of shares adjusted as per the exchange ratio and the terms of the Merger Agreement (see Note 3). This amendment did not result in any changes to the accounting for these warrants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On March 16, 2020, Legacy Celularity entered into the Purchase Agreement with the Investors. Pursuant to the terms of the Purchase Agreement, Legacy Celularity sold and issued to the Investors an aggregate of&#160;13,620,063&#160;shares of Series B Preferred Stock and warrants to purchase up to an aggregate of&#160;13,281,386&#160;shares of Series B Preferred Stock for an aggregate purchase price of approximately $102,550. The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of Legacy Celularity&#x2019;s initial public offering and (c)&#160;the consummation of a change of control. On January 8, 2021, Legacy Celularity entered into a warrant amendment agreement to amend the warrant issued the Investors on March 16, 2020. The warrant was amended to add cashless exercise provisions following the consummation of the Business Combination. Any portion of warrant held by the Investors that was unexercised prior to the consummation of the Business Combination converted into a warrant to purchase shares of the Company&#x2019;s Class&#160;A common stock, with the exercise price and number of shares adjusted as per the exchange ratio and the terms of the&#160;Merger&#160;Agreement&#160;(see Note 3). This amendment did not result in any changes to the accounting for these warrants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Prior to the Business Combination, Legacy Celularity classified the warrants as liabilities on its consolidated balance sheets because the warrants were freestanding financial instruments that might have required Legacy Celularity to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date of each warrant and was subsequently remeasured to fair value at each reporting date with the final remeasurement occurring on the Closing Date. Changes in the fair value of the warrant liability were recognized as a component of other income (expense), net in the consolidated statement of operations. On the Closing Date, the warrants held by Dragasac and the Investors were converted into warrants to purchase shares of the Company&#x2019;s Class A common stock. The aforementioned warrants qualified for equity classification on the Closing Date and were reclassified accordingly.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Legacy GX Warrants&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Upon consummation of the Business Combination, the Public Warrants and Sponsor Warrants remain outstanding.&#160;The Public Warrants became exercisable on August 15, 2021, which is the later of (a)&#160;30&#160;days after the consummation of a Business Combination or (b)&#160;12&#160;months from the effective date of the registration statement relating to GX&#x2019;s initial public offering.&#160;No&#160;Public Warrants would have been exercisable for cash unless the Company has an effective and current registration statement covering the shares of Class A common stock issuable upon exercise of the Public Warrants and a current prospectus relating to such common shares. Notwithstanding the foregoing, if a registration statement covering the common shares issuable upon the exercise of the Public Warrants were not effective within 90 days from the consummation of the Business Combination, the holders could have, until such time as there was an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise the Public Warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration were not available, holders would not have been able to exercise their Public Warrants on a cashless basis. The Company filed its registration statement on August 12, 2021. The Public Warrants will expire&#160;five years&#160;from the consummation of the Business Combination or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company may call the Public Warrants for redemption (excluding the Sponsor Warrants), in whole and not in part, at a price of $0.01&#160;per warrant:&lt;/span&gt;&lt;/p&gt;&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;at any time while the Public Warrants are exercisable,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;upon not less than&#160;30&#160;days&#x2019; prior written notice of redemption to each Public Warrant holder, and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;if, and only if, there is a current registration statement in effect with respect to the issuance of the common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Sponsor Warrants are identical to the Public Warrants underlying the units sold in GX&#x2019;s initial public offering, except that the Sponsor Warrants and the common shares issuable upon the exercise of the Sponsor Warrants were not transferable, assignable or salable until after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Warrants are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Sponsor Warrants are held by someone other than the initial purchasers or their permitted transferees, the Sponsor Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The exercise price and number of shares of Class A common stock issuable upon exercise of the Public Warrants and Sponsor Warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Additionally, in no event will the Company be required to net cash settle the Public Warrants. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. The exercise price and number of Class A common shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In order to finance transaction costs in connection with the Business Combination, members of GX&#x2019;s sponsor, GX Sponsor LLC (the &#x201c;Sponsor&#x201d;), entered into promissory notes with GX to provide working capital funds. In connection with the Business Combination,&#160;1,499,999&#160;Sponsor Warrants were issued to members of the Sponsor as repayment for the working capital loans made to GX.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;As of December 31, 2021, the Company had&#160;42,686,195&#160;outstanding warrants to purchase Class A common stock.&#160;A summary of the warrants is as follows:&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expiration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;date&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dragasac Warrant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,529,818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;16,&#160;2025&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 2020 Series B Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,281,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;16,&#160;2025&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Public Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,374,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;July&#160;16,&#160;2026&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sponsor Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,499,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;July&#160;16,&#160;2026&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The exercise price is the lessor of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231"
      decimals="INF"
      id="F_000843"
      unitRef="U_xbrlishares">730000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231"
      decimals="INF"
      id="F_000844"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="C_0001752828_20210101_20211231" id="F_000845">common stock are entitled to one vote per share</us-gaap:CommonStockVotingRights>
    <celu:PercentageOfSharesRequiredForVoting
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20211231"
      decimals="INF"
      id="F_000846"
      unitRef="U_xbrlipure">0.50</celu:PercentageOfSharesRequiredForVoting>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231"
      decimals="INF"
      id="F_000847"
      unitRef="U_xbrlishares">155640290</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231"
      decimals="INF"
      id="F_000848"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20200101_20201231"
      id="F_000849">common stock entitled the holder to one vote</us-gaap:CommonStockVotingRights>
    <us-gaap:TreasuryStockShares
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231"
      decimals="INF"
      id="F_000850"
      unitRef="U_xbrlishares">90834</us-gaap:TreasuryStockShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000851"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000852"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000853"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000854"
      unitRef="U_xbrlishares">116526341</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000855"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesSubscribedButUnissued
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapRedeemableConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000856"
      unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesSubscribedButUnissued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316"
      decimals="INF"
      id="F_000857"
      unitRef="U_xbrlishares">13620063</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316"
      decimals="INF"
      id="F_000858"
      unitRef="U_xbrlishares">13281386</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316"
      decimals="-3"
      id="F_000859"
      unitRef="U_iso4217USD">102550000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316"
      decimals="-3"
      id="F_000860"
      unitRef="U_iso4217USD">84596000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_us-gaapTypeOfArrangementAxis_celuSeriesBPreferredStocksPurchaseAgreementsMember_20200316_20200316"
      decimals="-3"
      id="F_000861"
      unitRef="U_iso4217USD">17954000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PreferredStockVotingRights contextRef="C_0001752828_20210101_20211231" id="F_000862">Preferred Stock were entitled to vote</us-gaap:PreferredStockVotingRights>
    <celu:NumberOfSharesRequiredToBeOutstandingForVoting
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBPreferredStockPurchaseAgreementsMember_20211231"
      decimals="INF"
      id="F_000863"
      unitRef="U_xbrlishares">5000000</celu:NumberOfSharesRequiredToBeOutstandingForVoting>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20210101_20211231"
      decimals="INF"
      id="F_000864"
      unitRef="U_iso4217USD">50000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <celu:ConversionPricePerShareOfCommonStock
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20211231"
      decimals="INF"
      id="F_000865"
      unitRef="U_iso4217USD_xbrlishares">9.41</celu:ConversionPricePerShareOfCommonStock>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20210101_20211231"
      id="F_000869">The conversion ratio of each series of Preferred Stock was determined by dividing the Original Issue Price of each series by the Conversion Price of each series. The Original Issue Price per share was $6.27&#160;for Series A and X Preferred Stock (the &#x201c;Series A and X Original Issue Price&#x201d;) and $7.53&#160;for Series B Preferred Stock (the &#x201c;Series B Original Issue Price&#x201d;), each subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization and other adjustments as set forth in Legacy Celularity&#x2019;s certificate of incorporation, as amended and restated. As of December&#160;31, 2020 and the Closing Date, the Conversion Price was equal to the Original Issue Price for each series of Preferred Stock. Accordingly, as of December&#160;31, 2020 and the Closing Date, each share of each series of Preferred Stock was convertible into shares of Legacy Celularity common stock on a&#160;one-for-one basis.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesARedeemableConvertiblePreferredStocksMember_20211231"
      decimals="INF"
      id="F_000866"
      unitRef="U_iso4217USD_xbrlishares">6.27</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesXRedeemableConvertiblePreferredStocksMember_20211231"
      decimals="INF"
      id="F_000867"
      unitRef="U_iso4217USD_xbrlishares">6.27</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemablesConvertiblePreferredStocksMember_20211231"
      decimals="INF"
      id="F_000868"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:SharePrice>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20201231"
      decimals="INF"
      id="F_000870"
      unitRef="U_xbrlipure">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockDividendPaymentTerms contextRef="C_0001752828_20210101_20211231" id="F_000873">The holders of Preferred Stock were entitled to receive noncumulative dividends when, as and if declared by the board of directors. Dividends accrued on the Preferred Stock at a rate of&#160;6% of the Original Issue Price per year; however, such dividends were only payable when, as and if declared by the board of directors. Holders of the Preferred Stock were to be paid dividends prior and in preference to any dividends on common stock. As of the Closing Date,&#160;no&#160;cash dividends were declared or paid.</us-gaap:PreferredStockDividendPaymentTerms>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000871"
      unitRef="U_xbrlipure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStockCash
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000872"
      unitRef="U_iso4217USD">0</us-gaap:DividendsPreferredStockCash>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20180507"
      decimals="INF"
      id="F_000874"
      unitRef="U_xbrlishares">16601736</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20180507"
      decimals="INF"
      id="F_000875"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215"
      decimals="INF"
      id="F_000876"
      unitRef="U_xbrlishares">6640695</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215"
      decimals="INF"
      id="F_000877"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190215_20190215"
      decimals="-3"
      id="F_000878"
      unitRef="U_iso4217USD">50000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedAndRestatedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190529"
      decimals="INF"
      id="F_000879"
      unitRef="U_iso4217USD_xbrlishares">7.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedAndRestatedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190529"
      decimals="INF"
      id="F_000880"
      unitRef="U_xbrlishares">3431223</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531"
      decimals="INF"
      id="F_000881"
      unitRef="U_xbrlishares">3431223</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531"
      decimals="INF"
      id="F_000882"
      unitRef="U_iso4217USD_xbrlishares">7.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20190531_20190531"
      decimals="-3"
      id="F_000883"
      unitRef="U_iso4217USD">25000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191101"
      decimals="INF"
      id="F_000884"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuAmendedDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191101"
      decimals="INF"
      id="F_000885"
      unitRef="U_xbrlishares">6529818</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104"
      decimals="INF"
      id="F_000886"
      unitRef="U_xbrlishares">6529818</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104"
      decimals="INF"
      id="F_000887"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_celuSeriesBRedeemableConvertiblePreferredStocksMember_20191104_20191104"
      decimals="-3"
      id="F_000888"
      unitRef="U_iso4217USD">44178000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SharesIssued
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109"
      decimals="INF"
      id="F_000889"
      unitRef="U_xbrlishares">6529818</us-gaap:SharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109"
      decimals="INF"
      id="F_000890"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <celu:WarrantsPerSharePercentage
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109"
      decimals="2"
      id="F_000891"
      unitRef="U_xbrlipure">0.80</celu:WarrantsPerSharePercentage>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapClassOfWarrantOrRightAxis_celuDragasacWarrantsMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200109_20200109"
      decimals="0"
      id="F_000892"
      unitRef="U_iso4217USD">11988</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316_20200316"
      decimals="INF"
      id="F_000893"
      unitRef="U_xbrlishares">13620063</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <celu:NumberOfWarrantsIssued
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316"
      decimals="INF"
      id="F_000894"
      unitRef="U_xbrlishares">13281386</celu:NumberOfWarrantsIssued>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20200316_20200316"
      decimals="-3"
      id="F_000895"
      unitRef="U_iso4217USD">102550000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapInvestorMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200316"
      decimals="INF"
      id="F_000896"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <celu:DescriptionOfExercisableTerms
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_celuLegacyGXWarrantMember_20210101_20211231"
      id="F_000897">The Public Warrants became exercisable on August 15, 2021, which is the later of (a)&#160;30&#160;days after the consummation of a Business Combination or (b)&#160;12&#160;months from the effective date of the registration statement relating to GX&#x2019;s initial public offering.</celu:DescriptionOfExercisableTerms>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000898">2021-08-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <celu:WarrantsExercisablePeriodAfterCompletionOfBusinessCombination
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000899">P30D</celu:WarrantsExercisablePeriodAfterCompletionOfBusinessCombination>
    <celu:WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000900">P12M</celu:WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering>
    <celu:ClassOfWarrantOrRightWarrantsExercisableForCash
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      decimals="INF"
      id="F_000901"
      unitRef="U_xbrlishares">0</celu:ClassOfWarrantOrRightWarrantsExercisableForCash>
    <celu:WarrantExpirationTerm
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000902">P5Y</celu:WarrantExpirationTerm>
    <celu:PublicWarrantsCallPrice
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20211231"
      decimals="INF"
      id="F_000903"
      unitRef="U_iso4217USD_xbrlishares">0.01</celu:PublicWarrantsCallPrice>
    <celu:DescriptionOfWarrantCallProvision
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000905">



&#160;

&#x2022;

at any time while the Public Warrants are exercisable,
&#160;




&#160;

&#x2022;

upon not less than&#160;30&#160;days&#x2019; prior written notice of redemption to each Public Warrant holder, and




&#160;

&#x2022;

if, and only if, there is a current registration statement in effect with respect to the issuance of the common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing.</celu:DescriptionOfWarrantCallProvision>
    <celu:MinimumWrittenNoticePeriodForRedemption
      contextRef="C_0001752828_us-gaapSubsidiarySaleOfStockAxis_us-gaapWarrantMember_20210101_20211231"
      id="F_000904">P30D</celu:MinimumWrittenNoticePeriodForRedemption>
    <celu:AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorsMember_20210101_20211231"
      decimals="INF"
      id="F_000906"
      unitRef="U_xbrlishares">1499999</celu:AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231"
      decimals="INF"
      id="F_000907"
      unitRef="U_xbrlishares">42686195</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000424">A summary of the warrants is as follows:
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expiration&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;date&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dragasac Warrant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,529,818&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;16,&#160;2025&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 2020 Series B Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,281,386&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;16,&#160;2025&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Public Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,374,992&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;July&#160;16,&#160;2026&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sponsor Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,499,999&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.50&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;July&#160;16,&#160;2026&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.18%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,686,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.14%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-style:italic;color:#000000;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The exercise price is the lessor of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231"
      decimals="INF"
      id="F_000908"
      unitRef="U_xbrlishares">6529818</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231"
      decimals="INF"
      id="F_000913"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231"
      id="F_000917">2025-03-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231"
      decimals="INF"
      id="F_000909"
      unitRef="U_xbrlishares">13281386</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231"
      decimals="INF"
      id="F_000914"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuMarch2020SeriesBWarrantsMember_20211231"
      id="F_000918">2025-03-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231"
      decimals="INF"
      id="F_000910"
      unitRef="U_xbrlishares">14374992</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231"
      decimals="INF"
      id="F_000915"
      unitRef="U_iso4217USD_xbrlishares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuPublicWarrantsMember_20211231"
      id="F_000919">2026-07-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231"
      decimals="INF"
      id="F_000911"
      unitRef="U_xbrlishares">8499999</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231"
      decimals="INF"
      id="F_000916"
      unitRef="U_iso4217USD_xbrlishares">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_0001752828_us-gaapStatementEquityComponentsAxis_celuSponsorWarrantsMember_20211231"
      id="F_000920">2026-07-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_000912"
      unitRef="U_xbrlishares">42686195</us-gaap:ClassOfWarrantOrRightOutstanding>
    <celu:DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20210101_20211231"
      id="F_000923">The exercise price is the lessor of $6.77&#160;per share or&#160;80% of either (i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon consummation of a change in control or the closing of a strategic transaction or (ii)&#160;the price at which one share of common stock is sold to the public market in an initial public offering.</celu:DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231"
      decimals="INF"
      id="F_000921"
      unitRef="U_iso4217USD_xbrlishares">6.77</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <celu:WarrantsPerSharePercentage
      contextRef="C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231"
      decimals="2"
      id="F_000922"
      unitRef="U_xbrlipure">0.80</celu:WarrantsPerSharePercentage>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000369">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In July 2021, the Company&#x2019;s board of directors adopted and the Company&#x2019;s stockholders approved the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provides for the grant of incentive stock options (&#x201c;ISOs&#x201d;) to employees and for the grant of nonstatutory stock options (&#x201c;NSOs&#x201d;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of stock awards to employees, directors and consultants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The number of shares of Class A common stock initially reserved for issuance under the 2021 Plan is&#160;20,915,283. As of December&#160;31, 2021,&#160;15,152,282&#160;shares remain available for future grant under the 2021 Plan. The number of shares reserved for issuance will automatically increase on January 1 of each year, for a period of&#160;10&#160;years, from January 1, 2022 through January 1, 2031, by&#160;4% of the total number of shares of Celularity capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#x2019;s board of directors. Shares subject to stock awards granted under the 2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021 Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The 2021 Plan is administered by the Company&#x2019;s board of directors. The Company&#x2019;s board of directors, or a duly authorized committee thereof, may delegate to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;administrator has the authority to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan. Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of the Company&#x2019;s stockholders.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;2017 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The 2017 Equity Incentive Plan (the &#x201c;2017 Plan&#x201d;) adopted by Legacy Celularity&#x2019;s board of directors and approved by Legacy Celularity&#x2019;s stockholders provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with the closing of the Business Combination and effectiveness of the 2021 Plan, no further grants will be made under the 2017 Plan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The total number of stock options that could have been issued under the 2017 Plan was&#160;32,342,049. Shares that expired, forfeited, canceled or otherwise terminated without having been fully exercised were available for future grant under the 2017 Plan.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The 2017 Plan is administered by the Company&#x2019;s board of directors or, at the discretion of the Company&#x2019;s board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy Celularity&#x2019;s board of directors, or its committee if so delegated, except that the exercise price per share of stock options could not be less than&#160;100% of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than&#160;ten years. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over a three or&#160;four year&#160;period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Stock Option Valuation&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:underline;"&gt;Awards with Service Conditions&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally required judgment to determine.&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;The expected stock price volatility is based on historical volatilities of comparable public entities within the Company&#x2019;s industry.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the respective expected term or contractual term.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="color:#000000;"&gt;The expected dividend yield is&#160;0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock&lt;/span&gt;&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes&#160;option-pricing&#160;model to determine the grant-date&#160;fair value of stock options granted during the years ended December&#160;31, 2021 and 2020:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000936"&gt;4.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000937"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant-date&#160;fair value per share of stock options granted during the years ended December&#160;31, 2021 and 2020 was $4.13 and $2.24, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes option activity under the 2021 Plan and the 2017 Plan:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contract life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31,2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,954,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000964"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,662,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(108,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,340,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,167,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000965"&gt;7.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,633&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,681,736&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(703,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,080,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,064,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000966"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,064,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000967"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,840,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000968"&gt;6.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s common stock for those options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In March 2021, Legacy Celularity&#x2019;s board of directors approved the issuance of fully vested options to acquire&#160;269,007&#160;shares at $3.83&#160;per share to each of its non-employee directors. During the second quarter of 2021, the grant notice was provided to the non-employee directors. Accordingly, the grant date was established in the second quarter of 2021 under ASC 718,&#160;&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;Compensation &#x2013; Stock Compensation&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#160;and the Company recognized the commensurate expense.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;During the second quarter of 2021, Legacy Celularity&#x2019;s board of directors approved the issuance of fully vested options to acquire a total of&#160;2,613,217&#160;shares at $10.21&#160;per share to certain members of senior management. Accordingly, the Company recognized the full expense of $13,723&#160;during the second quarter of 2021, of which $6,861&#160;was recorded to research and development expense and $6,862&#160;was recorded to selling, general and administrative expense on the consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In September 2021, the Company&#x2019;s board of directors approved the issuance of options to acquire a total of&#160;3,766,107&#160;shares of common stock at $10.23&#160;per share to certain members of senior management as a result of the Business Combination (the &#x201c;Transaction Awards&#x201d; or &#x201c;Performance Awards&#x201d;). The Transaction Awards vested&#160;50% on the Closing Date, with the remaining&#160;50% vesting over&#160;four years. Accordingly, the Company recognized expense of $7,186&#160;during the third quarter of 2021 for the shares that vested on the grant date, of which $3,388&#160;was recorded to research and development expense and $3,798&#160;was recorded to selling, general and administrative expense on the consolidated statement of operations. Additional expense was recognized in 2021 for the portion of the awards that vest over time. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In July 2021, the Company amended two non-employee stock option awards such that any unvested awards at the time of the Business Combination would become fully vested. The Company &lt;/span&gt;&lt;span style="color:#000000;"&gt;accelerated the recognition of $567 of expense related to the modification of these awards&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;. &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2021 and 2020, the aggregate intrinsic value was $2,959 and $671 for the stock options exercised, respectively. 131,256 options exercised with a value of $441 were classified as liabilities at December 31, 2021 until the shares are issued to the holder.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021, unrecognized compensation cost for options issued was $12,408, and will be recognized over an estimated weighted-average&#160;amortization period of 3.3&#160;years.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Awards with Performance Conditions&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had certain performance-based stock options, which were earned based on the attainment of specified goals achieved over the performance period. During the years ended December 31, 2021 and 2020, the Company recognized $31 and $21 expense related to the performance awards in which the performance condition was probable until those awards were amended such that the entire unvested portion of the award vested upon closing of the Business Combination.&#160;&#160;The Company &lt;span style="color:#000000;"&gt;accelerated the recognition of &lt;/span&gt;$121 of expense related to the modification of this award and as of December 31, 2021, the there was no amount of unrecognized expense related to these performance awards &lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="text-decoration:underline;"&gt;Awards with Market Conditions&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2021, the Company awarded options to acquire a total of&#160;2,469,282&#160;shares with an exercise price of $6.32&#160;to the Company&#x2019;s President in connection with the commencement of his employment. The grant was comprised of four equal tranches, which award will&#160;vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date, subject to his continued employment with the Company. The fair value of the President&#x2019;s award was determined based upon a Monte Carlo simulation valuation model. The Company&#x2019;s assumptions for expected volatility and closing price were&#160;75.0% and $6.32, respectively. The aggregate estimated fair value of the President&#x2019;s award was $7,013, which is expected to be recognized over a weighted-average period of&#160;four years. The Company recognized $514&#160;in share-based expense related to the President&#x2019;s award for the year ended December 31, 2021. As of December 31, 2021, there was $6,499&#160;of unrecognized compensation costs that the Company plans to recognize over the weighted average period of&#160;3.7&#160;years.&#160;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company issues restricted stock units (&#x201c;RSUs&#x201d;) to employees that generally vest over a &lt;span style="-sec-ix-hidden:F_001010"&gt;two-year&lt;/span&gt; period with 50% of awards vesting after 1 year and then the remaining 50% vesting after 2 years. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity related to RSU stock-based payment awards:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;grant date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;488,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.83%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recorded stock-based compensation expense of $222&#160;for the year ended December&#160;31, 2021, related to RSUs. As of December&#160;31, 2021, the total unrecognized expense related to all RSUs was $3,296, which the Company expects to recognize over a weighted-average period of 1.92&#160;years&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company recorded stock-based&#160;compensation expense in the following expense categories of its consolidated statements of operations:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,384&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20210731"
      decimals="INF"
      id="F_000924"
      unitRef="U_xbrlishares">20915283</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231"
      decimals="INF"
      id="F_000925"
      unitRef="U_xbrlishares">15152282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000927">P10Y</celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000926"
      unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000928"
      unitRef="U_xbrlishares">32342049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000929"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000930">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_celuTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      id="F_000932">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001752828_20210101_20211231"
      decimals="2"
      id="F_000933"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000425">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes&#160;option-pricing&#160;model to determine the grant-date&#160;fair value of stock options granted during the years ended December&#160;31, 2021 and 2020:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000936"&gt;4.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000937"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;67.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_000934"
      unitRef="U_xbrlipure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_000935"
      unitRef="U_xbrlipure">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_000938"
      unitRef="U_xbrlipure">0.804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_000939"
      unitRef="U_xbrlipure">0.678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001752828_20210101_20211231"
      decimals="2"
      id="F_000940"
      unitRef="U_iso4217USD_xbrlishares">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001752828_20200101_20201231"
      decimals="2"
      id="F_000941"
      unitRef="U_iso4217USD_xbrlishares">2.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000426">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes option activity under the 2021 Plan and the 2017 Plan:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercise price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contract life&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31,2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,954,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000964"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,662,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(108,369&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,340,712&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,167,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000965"&gt;7.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,633&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,681,736&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(703,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,080,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,064,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000966"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,064,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000967"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,525&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,840,068&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000968"&gt;6.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,898&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000942"
      unitRef="U_xbrlishares">13954174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231"
      decimals="2"
      id="F_000953"
      unitRef="U_iso4217USD_xbrlishares">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20191231"
      decimals="-3"
      id="F_000969"
      unitRef="U_iso4217USD">40572000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000943"
      unitRef="U_xbrlishares">4662072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000954"
      unitRef="U_iso4217USD_xbrlishares">3.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000944"
      unitRef="U_xbrlishares">108369</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000955"
      unitRef="U_iso4217USD_xbrlishares">3.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000945"
      unitRef="U_xbrlishares">1340712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20200101_20201231"
      decimals="2"
      id="F_000956"
      unitRef="U_iso4217USD_xbrlishares">2.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000946"
      unitRef="U_xbrlishares">17167165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231"
      decimals="2"
      id="F_000957"
      unitRef="U_iso4217USD_xbrlishares">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20201231"
      decimals="-3"
      id="F_000970"
      unitRef="U_iso4217USD">100633000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000947"
      unitRef="U_xbrlishares">9681736</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000958"
      unitRef="U_iso4217USD_xbrlishares">8.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000948"
      unitRef="U_xbrlishares">703512</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000959"
      unitRef="U_iso4217USD_xbrlishares">0.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000949"
      unitRef="U_xbrlishares">2080803</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000960"
      unitRef="U_iso4217USD_xbrlishares">4.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000950"
      unitRef="U_xbrlishares">24064586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="2"
      id="F_000961"
      unitRef="U_iso4217USD_xbrlishares">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="-3"
      id="F_000971"
      unitRef="U_iso4217USD">56525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000951"
      unitRef="U_xbrlishares">24064586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="2"
      id="F_000962"
      unitRef="U_iso4217USD_xbrlishares">4.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="-3"
      id="F_000972"
      unitRef="U_iso4217USD">56525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000952"
      unitRef="U_xbrlishares">17840068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="2"
      id="F_000963"
      unitRef="U_iso4217USD_xbrlishares">3.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20211231"
      decimals="-3"
      id="F_000973"
      unitRef="U_iso4217USD">51898000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001752828_20210301_20210331"
      decimals="INF"
      id="F_000974"
      unitRef="U_xbrlishares">269007</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="C_0001752828_20210301_20210331"
      decimals="2"
      id="F_000975"
      unitRef="U_iso4217USD_xbrlishares">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001752828_20210401_20210630"
      decimals="INF"
      id="F_000976"
      unitRef="U_xbrlishares">2613217</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="C_0001752828_20210401_20210630"
      decimals="2"
      id="F_000977"
      unitRef="U_iso4217USD_xbrlishares">10.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_20210401_20210630"
      decimals="-3"
      id="F_000978"
      unitRef="U_iso4217USD">13723000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210401_20210630"
      decimals="-3"
      id="F_000979"
      unitRef="U_iso4217USD">6861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210401_20210630"
      decimals="-3"
      id="F_000980"
      unitRef="U_iso4217USD">6862000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930"
      decimals="INF"
      id="F_000981"
      unitRef="U_xbrlishares">3766107</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930"
      decimals="2"
      id="F_000982"
      unitRef="U_iso4217USD_xbrlishares">10.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930"
      decimals="2"
      id="F_000983"
      unitRef="U_xbrlipure">0.50</celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage>
    <celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930"
      decimals="2"
      id="F_000984"
      unitRef="U_xbrlipure">0.50</celu:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210901_20210930"
      id="F_000985">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_20210701_20210930"
      decimals="-3"
      id="F_000986"
      unitRef="U_iso4217USD">7186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210701_20210930"
      decimals="-3"
      id="F_000987"
      unitRef="U_iso4217USD">3388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithServiceConditionsMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210701_20210930"
      decimals="-3"
      id="F_000988"
      unitRef="U_iso4217USD">3798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="C_0001752828_20210701_20210731"
      decimals="-3"
      id="F_000989"
      unitRef="U_iso4217USD">567000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000990"
      unitRef="U_iso4217USD">2959000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000991"
      unitRef="U_iso4217USD">671000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_000992"
      unitRef="U_xbrlishares">131256</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001752828_us-gaapBalanceSheetLocationAxis_us-gaapLiabilitiesTotalMember_20210101_20211231"
      decimals="-3"
      id="F_000993"
      unitRef="U_iso4217USD">441000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_000994"
      unitRef="U_iso4217USD">12408000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001752828_20210101_20211231" id="F_000995">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <celu:ExpenseRelatedToPerformanceAwards
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000996"
      unitRef="U_iso4217USD">31000</celu:ExpenseRelatedToPerformanceAwards>
    <celu:ExpenseRelatedToPerformanceAwards
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_000997"
      unitRef="U_iso4217USD">21000</celu:ExpenseRelatedToPerformanceAwards>
    <celu:AwardModificationExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000998"
      unitRef="U_iso4217USD">121000</celu:AwardModificationExpense>
    <celu:UnrecognizedExpenseRelatedToPerformanceAwards
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_000999"
      unitRef="U_iso4217USD">0</celu:UnrecognizedExpenseRelatedToPerformanceAwards>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930"
      decimals="INF"
      id="F_001000"
      unitRef="U_xbrlishares">2469282</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930"
      decimals="2"
      id="F_001001"
      unitRef="U_iso4217USD_xbrlishares">6.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231"
      id="F_001002">vest in up to five equal installments in respect of achieving certain share price targets between the third and fourth anniversary of the effective date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930"
      decimals="3"
      id="F_001003"
      unitRef="U_xbrlipure">0.750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharePrice
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210930"
      decimals="2"
      id="F_001004"
      unitRef="U_iso4217USD_xbrlishares">6.32</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210930"
      decimals="INF"
      id="F_001005"
      unitRef="U_xbrlishares">7013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210901_20210930"
      id="F_001006">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231"
      decimals="-3"
      id="F_001007"
      unitRef="U_iso4217USD">514000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20211231"
      decimals="-3"
      id="F_001008"
      unitRef="U_iso4217USD">6499000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001752828_us-gaapAwardTypeAxis_celuAwardsWithMarketConditionsMember_20210101_20211231"
      id="F_001009">P3Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20210101_20211231"
      decimals="2"
      id="F_001011"
      unitRef="U_xbrlipure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20210101_20211231"
      decimals="2"
      id="F_001012"
      unitRef="U_xbrlipure">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000427">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.82%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes activity related to RSU stock-based payment awards:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;grant date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;488,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,900&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.94%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;474,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_001013"
      unitRef="U_xbrlishares">488600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="2"
      id="F_001016"
      unitRef="U_iso4217USD_xbrlishares">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="INF"
      id="F_001014"
      unitRef="U_xbrlishares">13900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="2"
      id="F_001017"
      unitRef="U_iso4217USD_xbrlishares">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="INF"
      id="F_001015"
      unitRef="U_xbrlishares">474700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="2"
      id="F_001018"
      unitRef="U_iso4217USD_xbrlishares">7.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      decimals="-3"
      id="F_001019"
      unitRef="U_iso4217USD">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20211231"
      decimals="-3"
      id="F_001020"
      unitRef="U_iso4217USD">3296000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231"
      id="F_001021">P1Y11M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000428">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company recorded stock-based&#160;compensation expense in the following expense categories of its consolidated statements of operations:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.94%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,105&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,384&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,010&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,371&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20211231"
      decimals="-3"
      id="F_001022"
      unitRef="U_iso4217USD">72000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20200101_20201231"
      decimals="-3"
      id="F_001023"
      unitRef="U_iso4217USD">70000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_001024"
      unitRef="U_iso4217USD">11105000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_001025"
      unitRef="U_iso4217USD">1384000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20211231"
      decimals="-3"
      id="F_001026"
      unitRef="U_iso4217USD">28833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20201231"
      decimals="-3"
      id="F_001027"
      unitRef="U_iso4217USD">2917000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001028"
      unitRef="U_iso4217USD">40010000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001029"
      unitRef="U_iso4217USD">4371000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000370">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.&#160;&#160;&#160;&#160;&#160;Revenue Recognition&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides information about disaggregated revenue by product and services:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product sales and rentals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License, royalty and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,335&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides changes in deferred revenue from contract liabilities:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferral of revenue*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,928&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of unearned revenue**&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,310&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,067&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;2020 includes $9,505&#160;received in advance of performing services under a license agreement (see Note 15).&#160;&#160;The remainder of the 2020 and all of the 2021 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;During the third quarter of 2021, the Company terminated the license agreement with Sanuwave due to an uncured material breach (See Note 15). As a result, the Company recognized the remaining deferred revenue of $6,754&#160;that was to be recognized on a straight-line basis over the non-cancelable term of the license agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying Accounting Standards Codification 606,&#160;&lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&#160;(&#x201c;ASC 606&#x201d;): (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2)&#160;the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3)&#160;the Company expenses costs to obtain a contract as they are incurred in the expected period of benefit and therefore, the amortization period is one year or less; (4)&#160;the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service and these fulfillment costs are recorded as selling, general and administrative expenses; (5)&#160;the Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer; and (6)&#160;the Company does not disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Product sales&#160;and rentals&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Performance obligations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At contract inception, the Company assesses the goods and services promised in the contracts with customers and identifies a performance obligation for each promise to transfer to the customer a good or service (or bundle of goods or services) that is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. To identify the performance obligations, the Company considers all of the goods or services promised in the contract regardless of whether they are explicitly stated or are implied by customary business practices. For each contract, the Company considers the obligation to transfer products and services to the customer, each of which are distinct, to be performance obligations.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its degenerative disease products. The goods and services listed below may not all be included in every contract. Some contracts may include all of the Company&#x2019;s products and services while others may only include one product or service type.&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Supply of Biovance&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;products;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Supply of Interfyl&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;products;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Supply of Biovance 3L&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;products;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Supply of MIST&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;and UltraMIST&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;product;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Supply of MIST&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;and UltraMIST&lt;/span&gt;&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;rental product.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative disease commercial operations revenue is generally recognized when the customer obtains control of the Company&#x2019;s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract. Sales and other taxes collected on behalf of third parties are excluded from revenue.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Variable Consideration&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, the Company is required to make estimates of the net sales price, including estimates of variable consideration (such as rebates, discounts, and other deductions), and recognize the estimated amount as revenue, when the Company transfers control &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of the product to customers. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to which the Company expects to be entitled. An expected value method may be an appropriate estimate of the amount of variable consideration if an entity has a large number of contracts with similar characteristics whereas the most likely amount method may be an appropriate estimate of the amount of variable consideration if the contract has only two possible outcomes. Variable consideration is included in the transaction price if, in the Company&#x2019;s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company&#x2019;s anticipated performance and all information (historical, &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;current&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and forecasted) that is reasonably available.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales Incentives and Other Promotional Programs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company offers volume-based&#160;discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer&#160;basis to estimate what levels of incentives will be earned.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Product Returns&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consistent with industry practice, the Company maintains a returns policy that generally offers customers a right of return for products that have been purchased from the Company. To date, the Company has had minimal product returns and currently does not have an accrual for product returns. The Company will continue to assess the estimate for product returns as it gains additional historical experience.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Services&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Performance Obligations&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the following distinct goods and services represent separate performance obligations involving the sale of its biobanking services:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Collection and processing services; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:10pt;"&gt;Storage services.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Processing and storage services include the Company providing umbilical cord blood, placental blood and tissue processing and storage for private use. Revenues recognized for the fees for processing and storage represent sales of the biobanking to customers. The Company recognizes revenue from processing fees at the point in time of the successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contracted storage periods are 18&#160;years and 25&#160;years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the 18- and the 25-year&#160;storage fees that are being recognized over the contractual storage period. The Company classifies deferred revenue as current if the Company expects to recognize the related revenue over the next 12&#160;months from the balance sheet date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Significant Financing&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. For all plans (annual, 18&#160;years and 25&#160;years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans for customers to pay over time for a period of &lt;span style="-sec-ix-hidden:F_001052"&gt;one to 24&#160;months&lt;/span&gt; (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms were structured primarily for reasons other than the provision of financing and to maximize profitability.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When considered over a 24-month&#160;period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when considered in the context of all contracts entered into nor significant at the individual contract level.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company elected to apply the practical expedient where the Company does not need to assess whether a significant financing component exists if the period between when it performs its obligations under the contract and when the customer pays is one year or less.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021, the total aggregate transaction price allocated to the unsatisfied performance obligations for services was recorded as deferred revenue amounting to $4,067, which will be recognized as revenue ratably on a straight-line&#160;basis over the contractual period of which $2,196 will be recognized as revenue over the next 12&#160;months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sales Incentives and Other Promotional Programs&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company offers promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer&#160;basis to estimate what levels of incentives will be earned.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Allocation of Transaction Price&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As the Company&#x2019;s processing and storage agreements contain multiple performance obligations, ASC 606 requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone selling prices of the processing services and storage services and concluded that the published list price is the price that a customer in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;License, royalty and other&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the license agreement with Sanuwave which acquired certain assets comprising its MIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;/UltraMIST&lt;span style="font-size:6pt;"&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&#160;business, the Company received a quarterly license fee and a defined royalty on each product sold. A credit was provided to Sanuwave for Biovance royalties up to the quarterly license fee. The Company recognize the quarterly license fee over each quarterly term based on the actual sales occurring over the period. If quarterly revenues were lower than the quarterly license fee, the Company recognized the difference during the third month of the quarterly period. Any royalties earned in excess of the quarterly license fee were recognized at the end of each quarterly period, as that is when it is probable that a significant future reversal of revenue under the arrangement will not occur. During the third quarter of 2021, the license agreement with Sanuwave was terminated due to an uncured material breach.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000429">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides information about disaggregated revenue by product and services:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product sales and rentals&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License, royalty and other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,012&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,335&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20210101_20211231"
      decimals="-3"
      id="F_001030"
      unitRef="U_iso4217USD">3801000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapProductMember_20200101_20201231"
      decimals="-3"
      id="F_001031"
      unitRef="U_iso4217USD">6854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20210101_20211231"
      decimals="-3"
      id="F_001032"
      unitRef="U_iso4217USD">5522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapServiceMember_20200101_20201231"
      decimals="-3"
      id="F_001033"
      unitRef="U_iso4217USD">5556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001034"
      unitRef="U_iso4217USD">12012000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_srtProductOrServiceAxis_celuLicenseRoyaltyAndOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001035"
      unitRef="U_iso4217USD">1868000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001036"
      unitRef="U_iso4217USD">21335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001037"
      unitRef="U_iso4217USD">14278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000430">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides changes in deferred revenue from contract liabilities:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at January 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferral of revenue*&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,928&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of unearned revenue**&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,310&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,916&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,067&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,449&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;2020 includes $9,505&#160;received in advance of performing services under a license agreement (see Note 15).&#160;&#160;The remainder of the 2020 and all of the 2021 deferral of revenue resulted from payments received in advance of performance under the biobanking services storage contracts that are recognized as revenue under the contract as performance is completed.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;**&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"&gt;During the third quarter of 2021, the Company terminated the license agreement with Sanuwave due to an uncured material breach (See Note 15). As a result, the Company recognized the remaining deferred revenue of $6,754&#160;that was to be recognized on a straight-line basis over the non-cancelable term of the license agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001038"
      unitRef="U_iso4217USD">12449000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001752828_20191231"
      decimals="-3"
      id="F_001039"
      unitRef="U_iso4217USD">3833000</us-gaap:ContractWithCustomerLiability>
    <celu:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001040"
      unitRef="U_iso4217USD">4928000</celu:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue>
    <celu:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001041"
      unitRef="U_iso4217USD">14532000</celu:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001042"
      unitRef="U_iso4217USD">13310000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001043"
      unitRef="U_iso4217USD">5916000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001044"
      unitRef="U_iso4217USD">4067000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001045"
      unitRef="U_iso4217USD">12449000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231"
      decimals="-3"
      id="F_001046"
      unitRef="U_iso4217USD">9505000</us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20210701_20210930"
      decimals="-3"
      id="F_001047"
      unitRef="U_iso4217USD">6754000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <celu:ContractedStoragePeriods
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_001048">P18Y</celu:ContractedStoragePeriods>
    <celu:ContractedStoragePeriods
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_001049">P25Y</celu:ContractedStoragePeriods>
    <celu:ContractedStoragePeriods
      contextRef="C_0001752828_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_001050">P18Y</celu:ContractedStoragePeriods>
    <celu:ContractedStoragePeriods
      contextRef="C_0001752828_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_001051">P25Y</celu:ContractedStoragePeriods>
    <celu:PaymentPlansForCustomerToPayOverTimePeriod contextRef="C_0001752828_20210101_20211231" id="F_001054">P24M</celu:PaymentPlansForCustomerToPayOverTimePeriod>
    <us-gaap:DeferredRevenue
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001056"
      unitRef="U_iso4217USD">4067000</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001057"
      unitRef="U_iso4217USD">2196000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <celu:LicenseAndDistributionAgreementsTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000371">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.44%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;License and Distribution Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Sorrento Therapeutics, Inc. License and Transfer Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 15, 2017, Legacy Celularity entered into a License and Transfer Agreement with TNK Therapeutics, Inc. and Sorrento Therapeutics, Inc. (collectively &#x201c;Sorrento&#x201d;), pursuant to which Legacy Celularity was granted an exclusive license to certain materials, patents and intellectual property related to Sorrento to develop and commercialize products for the treatment of any disease or disorder (the &#x201c;2017 License Agreement&#x201d;). During the first quarter of 2020, the 2017 License Agreement was mutually terminated.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 26, 2020, Legacy Celularity and Sorrento entered into a binding term sheet for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells for the treatment of any disease or disorder (the &#x201c;2020 Sorrento Term Sheet&#x201d;). The 2020 Sorrento Term Sheet outlined various provisions to be incorporated and further negotiated in contemplation of a final license and supply agreement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 30, 2020, Legacy Celularity and Sorrento entered into a new License and Transfer Agreement for the exclusive worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any disease or disorder (the &#x201c;2020 Sorrento License Agreement&#x201d;). Celularity retains the right to sublicense the rights granted under the agreement with Sorrento&#x2019;s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until terminated by either the Company or Sorrento for uncured material breach upon 90&#160;days written notice or, after the first anniversary of the effective date of the Sorrento Agreement, by the Company for convenience upon six months&#x2019; written notice to Sorrento.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company and Sorrento are actively negotiating a new supply agreement related to the 2020 Sorrento License Agreement. The 2020 Sorrento Term Sheet details certain aspects of this supply agreement, including pricing terms on material and/or licensed product supplied under the 2020 Sorrento License Agreement. The Company did&#160;not incur incentive payments related to the 2020 Sorrento Term Sheet.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Lung&#160;Biotechnology PBC License Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 30, 2017, Legacy Celularity entered into a license agreement with Lung Biotechnology PBC (&#x201c;LB&#x201d;), a wholly owned subsidiary of United Therapeutics Corporation (the &#x201c;LB Agreement&#x201d;), whereupon Legacy Celularity granted to LB an exclusive, worldwide sublicensable license of certain intellectual property to develop and commercialize products in the fields of thoracic and abdominal organ transplantation and pulmonary diseases (the &#x201c;LB Licensed IP&#x201d;). Pursuant to the LB Agreement, Legacy Celularity agreed to supply LB with placental-derived stem cells for use in the development and commercialization of products.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 3, 2020, Legacy Celularity and LB agreed to expand their strategic collaborative license agreement to include treatment of COVID-19 and Acute Respiratory Distress Syndrome (&#x201c;ARDS&#x201d;). Under the amended collaborative agreement, the Company will seek regulatory approval for CYNK-001 in the treatment of COVID-19, and LB will seek regulatory approval for CYNK-001 in the treatment of ARDS. LB has global rights under the amended collaborative agreement to commercialize CYNK-001 in the treatment of COVID-19 and ARDS. The collaboration will be governed by a joint steering committee to oversee development and commercialization activities. LB will provide financial support as needed and requested by Legacy Celularity, subject to a maximum of $75&#160;per enrolled patient in the related clinical studies, which will be recorded as an offset to research and development expense.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the first quarter of 2021, the license agreement with LB was terminated in its entirety effective April 11, 2021. The termination applies to the April 3, 2020 amendment for the treatment of CYNK-001 in COVID-19 and ARDS.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Genting&#160;Innovation PTE LTD Distribution Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May&#160;4, 2018, concurrently with Dragasac&#x2019;s equity investment in the Series B Preferred Stock, the Company entered into a distribution agreement with Genting Innovation PTE LTD (&#x201c;Genting&#x201d;) pursuant to which Genting was granted supply and distribution rights to certain Company products in select Asia markets (the &#x201c;Genting Agreement&#x201d;). The Genting Agreement grants Genting limited distribution rights to the Company&#x2019;s then-current&#160;portfolio of degenerative disease products and provides for the automatic rights to future products developed by or on behalf of the Company.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The term of the Genting Agreement was renewed on January&#160;31, 2021, and automatically renews for successive twelve month terms unless: Genting provides written notice of its intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party for cause.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Genting and Dragasac are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Celgene Corporation License&#160;Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Anthrogenesis acquisition, on August&#160;20, 2017, the Company entered into a license agreement with Celgene (the &#x201c;Celgene Agreement&#x201d;) pursuant to which the Company granted Celgene two separate licenses to certain intellectual property owned or controlled by Anthrogenesis as of the date of the Company&#x2019;s acquisition of Anthrogenesis (the &#x201c;Anthrogenesis IP&#x201d;). The Celgene Agreement grants Celgene a royalty-free, fully-paid&#160;up, worldwide, non-exclusive&#160;license to the Anthrogenesis IP for pre-clinical&#160;research purposes in all fields and a royalty-free, fully-paid&#160;up, worldwide license, with the right to grant sublicenses, to the Anthrogenesis IP for the development, manufacture, commercialization and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte&#160;or NK cell to express such a CAR, and/or the use of such CARs or T-lymphocytes&#160;or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic uses thereof.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Celgene Agreement will remain in effect until its termination by either party for cause.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Sanuwave Licensing Agreement&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 6, 2020, in conjunction with the sale of the UltraMIST business, Legacy Celularity entered into a&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_001060"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;licensing arrangement with Sanuwave that includes (i)&#160;an exclusive Biovance license for distribution and commercialization in the wound care market worldwide, except for certain Asian jurisdictions and (ii)&#160;a non-exclusive license for the distribution and commercialization of Interfyl in the wound care market worldwide, except for certain Asian jurisdictions (the &#x201c;Sanuwave Licensing Agreement&#x201d;). Sanuwave has the right to grant sublicenses of the exclusive Biovance license and non-exclusive Interfyl license to&#160;&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(i)&#160;its affiliates without the consent of the Company and (ii)&#160;any third party for the sole purpose of providing services directly to Sanuwave upon prior written consent by the Company. The Sanuwave License Agreement will automatically renew for additional one-year periods unless either party &lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;gives written notice of termination at least 180&#160;days prior to the expiration of the then-current term. Under the Sanuwave License Agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;The Company may terminate the Sanuwave Licensing Agreement following the second year if annual sales of that year are less than $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Following the third year of the agreement, either party may terminate the Sanuwave Licensing Agreement upon 90&#160;days written notice should annual sales not exceed $&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,000&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;in that third year or any year thereafter.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Sanuwave Licensing Agreement, the Company will serve on a joint steering committee where it will oversee Sanuwave&#x2019;s marketing efforts with respect to the licensed products.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the second quarter of 2021, Legacy Celularity sent a notice of deficiency to Sanuwave under the existing license agreement, where Sanuwave had until July 19, 2021 to cure a material breach. This material breach was not cured by Sanuwave and, as a result, the agreement with Sanuwave was terminated.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Exclusive Supply and Distribution Agreements&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 7, 2021, the Company entered into a&#160;&lt;span style="-sec-ix-hidden:F_001064"&gt;six-year&lt;/span&gt;&#160;supply and distribution agreement with Arthrex, Inc. (Arthrex) that includes (i) an exclusive Biovance, Interfyl, and Centaflex license for distribution and commercialization within the United States for the orthopedic surgery and (ii) an exclusive Interfly and Centaflex license for commercialization and distribution within the United States for the acute and chronic non-healing wound market (the &#x201c;Arthrex Supply and Distribution Agreement&#x201d;). The Arthrex Supply and Distribution Agreement will automatically renew for terms of  &lt;span style="-sec-ix-hidden:F_001065"&gt;two-year&lt;/span&gt; periods unless either party gives notice of non-renewal at least twelve months advance of the end of the then current term. At least ninety days prior to the start of each calendar quarter, the Company and Arthrex will agree in good faith to a minimum binding forecast based upon projected sales volume by Arthrex for said upcoming calendar quarter for each of the products. Upon agreement, Arthrex shall submit to the Company a purchase order to purchase products for the minimum forecasted quantities. The Company shall invoice Arthrex after the product has been issued and payments for such invoices will be 2%, ten net forty-five days from the date of the invoice. Upon material breach of the Arthrex Supply and Distribution Agreement either party may deliver such breach to the other party and the notified party will have thirty days to cure such breach. If the notified party fails to cure the material breach of the Arthrex Supply and Distribution Agreement the non-breaching party may terminate the respective agreement.&#160;&#160;&#160;&#160;&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Arthrex Supply and Distribution Agreement, the Company and Arthrex will establish a joint steering committee to oversee commercialization activities of the products. Membership of the joint steering committee will be comprised of an equal number of employees of each respective party. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 1, 2021, the Company entered into a&#160;&lt;span style="-sec-ix-hidden:F_001070"&gt;three-year&lt;/span&gt;&#160;supply and distribution agreement with Evolution Biologyx, LLC (&#x201c;Evolution&#x201d;) that includes an exclusive Interfyl license for the distribution and commercialization within the United States within any medical specialty where Interfyl is administered in an in-office or in-patient setting and is reimbursed through Medicare Part B or any successor, equivalent or similar category established by the Center for Medicare Services or other Government Authority, except in the medical specialty of orthopedic surgery excluding trauma or spine applications in the medical specialty or orthopedic or neurologic surgery (the &#x201c;Evolution Supply and Distribution Agreement&#x201d;). The Evolution Supply and Distribution Agreement will automatically renew for terms of &lt;span style="-sec-ix-hidden:F_001071"&gt;two-year&lt;/span&gt; periods unless either party gives notice of non-renewal at least twelve months in advance of the current term. Evolution will provide a non-binding twelve month rolling forecast to the Company. The next forecast is due October 31, 2022, and each October 31 thereafter. At least forty-five days prior to the start of each calendar quarter, the Company and Evolution will agree in good faith to a minimum binding forecast based upon projected sales volume by Evolution for said upcoming calendar quarter for each of the products. The forecast may not deviate to less than 70% for the immediate following quarter, 50% two quarters out, 40% three quarters out, and 25% for full quarters from the original forecasted amount for that specific quarter set forth in the respective agreed upon binding forecast. Upon agreement, Evolution shall submit to the Company a purchase order to purchase products for the minimum binding forecasted quantities. The Company shall invoice Evolution after the product has been issued and payments for such invoices will be 50% upon receipt and acceptance of purchase order and 50% 2%, ten net forty-five days from the date of invoice. The Evolution Supply and Distribution Agreement may be terminated by (i) material breach of the Evolution Supply and Distribution Agreement and subsequent failure to cure the material breach within thirty days of notice of material breach and (ii) otherwise mutually agreed in writing by the Company and Evolution. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</celu:LicenseAndDistributionAgreementsTextBlock>
    <celu:IncentivePayment
      contextRef="C_0001752828_20210101_20211231"
      decimals="INF"
      id="F_001058"
      unitRef="U_iso4217USD">0</celu:IncentivePayment>
    <celu:ReimbursementOfCostUnderLicenseAgreement
      contextRef="C_0001752828_20200403_20200403"
      decimals="-3"
      id="F_001059"
      unitRef="U_iso4217USD">75000</celu:ReimbursementOfCostUnderLicenseAgreement>
    <celu:LicenseAgreementDescription
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20210101_20211231"
      id="F_001061">(i)&#160;its affiliates without the consent of the Company and (ii)&#160;any third party for the sole purpose of providing services directly to Sanuwave upon prior written consent by the Company. The Sanuwave License Agreement will automatically renew for additional one-year periods unless either party gives written notice of termination at least 180&#160;days prior to the expiration of the then-current term. Under the Sanuwave License Agreement, the Company will receive a quarterly license fee and a defined royalty on each product sold. A credit is provided to Sanuwave for Biovance royalties up to the quarterly license fee amount.</celu:LicenseAgreementDescription>
    <celu:AnnualSales
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806"
      decimals="-3"
      id="F_001062"
      unitRef="U_iso4217USD">3000000</celu:AnnualSales>
    <celu:AnnualSalesNotExceed
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuSanuwaveLicenseAgreementMember_20200806_20200806"
      decimals="-3"
      id="F_001063"
      unitRef="U_iso4217USD">5000000</celu:AnnualSalesNotExceed>
    <celu:SupplyAndDistributionAgreementNonRenewalNoticePeriod
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507"
      id="F_001066">P12M</celu:SupplyAndDistributionAgreementNonRenewalNoticePeriod>
    <celu:DiscountPercentagePaymentForInvoicesWithinTenDays
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507"
      decimals="2"
      id="F_001067"
      unitRef="U_xbrlipure">0.02</celu:DiscountPercentagePaymentForInvoicesWithinTenDays>
    <celu:PaymentTermNet
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507"
      id="F_001068">P45D</celu:PaymentTermNet>
    <celu:MaterialBreachContractTerminatedTerm
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuArthrexAgreementMember_20210507_20210507"
      id="F_001069">P30D</celu:MaterialBreachContractTerminatedTerm>
    <celu:SupplyAndDistributionAgreementNonRenewalNoticePeriod
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      id="F_001072">P12M</celu:SupplyAndDistributionAgreementNonRenewalNoticePeriod>
    <celu:SupplyAndDistributionAgreementForecastDescription
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210101_20211231"
      id="F_001077">The forecast may not deviate to less than 70% for the immediate following quarter, 50% two quarters out, 40% three quarters out, and 25% for full quarters from the original forecasted amount for that specific quarter set forth in the respective agreed upon binding forecast. Upon agreement, Evolution shall submit to the Company a purchase order to purchase products for the minimum binding forecasted quantities.</celu:SupplyAndDistributionAgreementForecastDescription>
    <celu:PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      decimals="2"
      id="F_001073"
      unitRef="U_xbrlipure">0.50</celu:PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder>
    <celu:RemainingDuePercentageNetFortyFivePaymentTerm
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      decimals="2"
      id="F_001074"
      unitRef="U_xbrlipure">0.50</celu:RemainingDuePercentageNetFortyFivePaymentTerm>
    <celu:DiscountPercentagePaymentForInvoicesWithinTenDays
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      decimals="2"
      id="F_001075"
      unitRef="U_xbrlipure">0.02</celu:DiscountPercentagePaymentForInvoicesWithinTenDays>
    <celu:PaymentTermNet
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      id="F_001076">P45D</celu:PaymentTermNet>
    <celu:MaterialBreachContractTerminatedTerm
      contextRef="C_0001752828_us-gaapTypeOfArrangementAxis_celuEvolutionAgreementMember_20210901_20210901"
      id="F_001078">P30D</celu:MaterialBreachContractTerminatedTerm>
    <us-gaap:DefinedBenefitPlanTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000372">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.&#160;&#160;&#160;&#160;&#160;Benefit Plans&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company established a defined contribution savings plan under Section&#160;401(k) of the Internal Revenue Code. This plan covers all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax&#160;basis. Matching contributions to the plan may be made at the discretion of the Company&#x2019;s board of directors. During the years ended December&#160;31, 2021 and 2020, the Company made contributions of $989 and $835, respectively, to the plan.&lt;/p&gt;</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001079"
      unitRef="U_iso4217USD">989000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001080"
      unitRef="U_iso4217USD">835000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000373">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;17.&#160;&#160;&#160;&#160;&#160;Income Taxes&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current income tax expense (benefit):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income tax expense (benefit):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,366&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax expense (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total (benefit) from income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest accretion expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mark to market warrant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities as of years ended December&#160;31, 2021 and 2020 consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Startup costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;729&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unicap&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Imputed interest on contingent payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,340&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fee capitalization and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,232&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,232&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,297&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax Benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase related to current year tax provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase related to current year tax provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021, and 2020, the Company had U.S. federal and state net operating loss carryforwards of $88,327&lt;span style="font-size:12pt;color:#000000;"&gt;&lt;span style="-sec-ix-hidden:F_001144"&gt;&#160;&lt;/span&gt;&lt;/span&gt;and $53,495, respectively, which may be available to offset future taxable income and begin to expire in 2040. As of December&#160;31, 2021, and 2020, the Company also had U.S. federal and state research and development tax credit carryforwards of $7,672&lt;span style="-sec-ix-hidden:F_001148"&gt; &lt;/span&gt;and $5,673, respectively, which may be available to offset future tax liabilities and begin to expire in 2032.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year&#160;period. A corporation that experiences an ownership change is subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term&#160;tax-exempt&#160;rate subject to additional adjustments, as required. The Company experienced an ownership change on August&#160;15, 2017. The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development credits before utilization.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The realization of deferred tax assets is dependent upon the Company&#x2019;s ability to generate taxable income in future years. Accounting Standards Codification 740-10,&#160;&lt;span style="font-style:italic;"&gt;Income Taxes,&lt;/span&gt;&#160;requires a valuation allowance to be applied against deferred tax assets when it is considered &#x201c;more likely than not&#x201d; that some or all of the gross deferred tax asset will not be realized. The Company considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&#160;31, 2021, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded valuation allowance against its federal and state gross deferred tax assets.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The impact of an uncertain income tax position is recognized at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2021 and 2020, the Company had gross unrecognized tax benefits of $1,270 and $1,028, respectively. The Company does not expect that there will be a significant change in the unrecognized tax benefits over the next 12&#160;months. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts had been recognized in the Company&#x2019;s consolidated statements of operations. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under statute from 2016 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal, state or local tax authorities if they either have been or will be used in a future period.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sold $1,356 and $4,005 of its net operating losses and unused R&amp;amp;D tax credits through the New Jersey Economic Development Authority&#x2019;s Technology Business Tax Certificate Transfer Program during 2021 and 2020, respectively. The income resulting from the sale of net operating losses and unused R&amp;amp;D tax credits is recorded as a component of other income (expense) on the consolidated statement of operations.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000431">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current income tax expense (benefit):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current income tax expense (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income tax expense (benefit):&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,366&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,351&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax expense (benefit)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,717&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total (benefit) from income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001081"
      unitRef="U_iso4217USD">17000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001082"
      unitRef="U_iso4217USD">17000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001083"
      unitRef="U_iso4217USD">17000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001084"
      unitRef="U_iso4217USD">17000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001085"
      unitRef="U_iso4217USD">1000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001086"
      unitRef="U_iso4217USD">-2366000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001087"
      unitRef="U_iso4217USD">2000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001088"
      unitRef="U_iso4217USD">-2351000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001089"
      unitRef="U_iso4217USD">3000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001090"
      unitRef="U_iso4217USD">-4717000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001091"
      unitRef="U_iso4217USD">20000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001092"
      unitRef="U_iso4217USD">-4700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000432">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes, net of federal benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest accretion expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mark to market warrant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other permanent items&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001093"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001094"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001095"
      unitRef="U_xbrlipure">0.098</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001096"
      unitRef="U_xbrlipure">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001097"
      unitRef="U_xbrlipure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001098"
      unitRef="U_xbrlipure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <celu:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001099"
      unitRef="U_xbrlipure">0.086</celu:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense>
    <celu:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001100"
      unitRef="U_xbrlipure">0.055</celu:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001101"
      unitRef="U_xbrlipure">-0.461</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001102"
      unitRef="U_xbrlipure">-0.216</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <celu:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001103"
      unitRef="U_xbrlipure">0.028</celu:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant>
    <celu:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001104"
      unitRef="U_xbrlipure">-0.057</celu:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001105"
      unitRef="U_xbrlipure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001106"
      unitRef="U_xbrlipure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001752828_20210101_20211231"
      decimals="3"
      id="F_001107"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001752828_20200101_20201231"
      decimals="3"
      id="F_001108"
      unitRef="U_xbrlipure">0.022</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000433">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities as of years ended December&#160;31, 2021 and 2020 consisted of the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,327&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,672&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,673&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,748&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Startup costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;729&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unicap&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Imputed interest on contingent payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,340&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fee capitalization and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,587&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,158&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;121,519&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.62%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,232&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(29,232&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(27,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(92,297&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.62%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001109"
      unitRef="U_iso4217USD">88327000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001110"
      unitRef="U_iso4217USD">53495000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <celu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001111"
      unitRef="U_iso4217USD">7672000</celu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <celu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001112"
      unitRef="U_iso4217USD">5673000</celu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001113"
      unitRef="U_iso4217USD">11748000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001114"
      unitRef="U_iso4217USD">1304000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <celu:DeferredTaxAssetsStartupCosts
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001115"
      unitRef="U_iso4217USD">697000</celu:DeferredTaxAssetsStartupCosts>
    <celu:DeferredTaxAssetsStartupCosts
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001116"
      unitRef="U_iso4217USD">729000</celu:DeferredTaxAssetsStartupCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001117"
      unitRef="U_iso4217USD">4471000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001118"
      unitRef="U_iso4217USD">4544000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001119"
      unitRef="U_iso4217USD">1103000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001120"
      unitRef="U_iso4217USD">3226000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <celu:DeferredTaxAssetsUnicap
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001121"
      unitRef="U_iso4217USD">6000</celu:DeferredTaxAssetsUnicap>
    <celu:DeferredTaxAssetsUnicap
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001122"
      unitRef="U_iso4217USD">6000</celu:DeferredTaxAssetsUnicap>
    <celu:DeferredTaxAssetsImputedInterestOnContingentPayments
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001123"
      unitRef="U_iso4217USD">4410000</celu:DeferredTaxAssetsImputedInterestOnContingentPayments>
    <celu:DeferredTaxAssetsImputedInterestOnContingentPayments
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001124"
      unitRef="U_iso4217USD">2340000</celu:DeferredTaxAssetsImputedInterestOnContingentPayments>
    <celu:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001125"
      unitRef="U_iso4217USD">1550000</celu:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization>
    <celu:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001126"
      unitRef="U_iso4217USD">1587000</celu:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001127"
      unitRef="U_iso4217USD">1535000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001128"
      unitRef="U_iso4217USD">1158000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001129"
      unitRef="U_iso4217USD">121519000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001130"
      unitRef="U_iso4217USD">74062000</us-gaap:DeferredTaxAssetsGross>
    <celu:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001131"
      unitRef="U_iso4217USD">29232000</celu:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <celu:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001132"
      unitRef="U_iso4217USD">27930000</celu:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001133"
      unitRef="U_iso4217USD">29232000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001134"
      unitRef="U_iso4217USD">27930000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001135"
      unitRef="U_iso4217USD">92297000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001136"
      unitRef="U_iso4217USD">46139000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001137"
      unitRef="U_iso4217USD">10000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001138"
      unitRef="U_iso4217USD">7000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000434">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrecognized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax Benefits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase related to current year tax provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,028&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.18%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase related to current year tax provisions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.96%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CCEEFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.18%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.96%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001752828_20191231"
      decimals="-3"
      id="F_001139"
      unitRef="U_iso4217USD">786000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001140"
      unitRef="U_iso4217USD">242000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001141"
      unitRef="U_iso4217USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001142"
      unitRef="U_iso4217USD">242000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001143"
      unitRef="U_iso4217USD">1270000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20201231"
      decimals="-3"
      id="F_001145"
      unitRef="U_iso4217USD">53495000</us-gaap:OperatingLossCarryforwards>
    <celu:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_20210101_20211231"
      id="F_001146">2040</celu:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-3"
      id="F_001147"
      unitRef="U_iso4217USD">5673000</us-gaap:TaxCreditCarryforwardAmount>
    <celu:TaxCreditCarryforwardsExpirationYear
      contextRef="C_0001752828_us-gaapIncomeTaxAuthorityAxis_celuUnitedStatesFederalAndStateMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20210101_20211231"
      id="F_001149">2032</celu:TaxCreditCarryforwardsExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001150"
      unitRef="U_iso4217USD">1270000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001151"
      unitRef="U_iso4217USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001752828_20211231"
      decimals="INF"
      id="F_001152"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001752828_20201231"
      decimals="INF"
      id="F_001153"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <celu:NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001155"
      unitRef="U_iso4217USD">1356000</celu:NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold>
    <celu:NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001154"
      unitRef="U_iso4217USD">4005000</celu:NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000374">
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.&#160;&#160;&#160;&#160;&#160;Segment Information&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. Prior to the third quarter of 2020, the Company managed operations as one segment. In the third quarter of 2020, the Company began to manage its operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioBanking&lt;/span&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. This change was prompted by certain organizational and personnel changes. The chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation among these segments.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were approximately $414,128 and $431,008 as of December&#160;31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial information by segment is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cell&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioBanking&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative Disease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,335&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,682&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment contribution&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(64,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(148,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indirect expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(109,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a) Components of other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cell&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioBanking&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,084&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment contribution&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indirect expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(151,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a) Components of other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of acquired intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001752828_20200101_20200630"
      decimals="INF"
      id="F_001156"
      unitRef="U_celuSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001752828_20200701_20200930"
      decimals="INF"
      id="F_001157"
      unitRef="U_celuSegment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets
      contextRef="C_0001752828_20211231"
      decimals="-3"
      id="F_001158"
      unitRef="U_iso4217USD">414128000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001752828_20201231"
      decimals="-3"
      id="F_001159"
      unitRef="U_iso4217USD">431008000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000435">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial information by segment is as follows:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cell&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioBanking&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative Disease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,335&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,682&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,119&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,450&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;64,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159,693&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment contribution&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(85,107&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(246&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,359&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(64,017&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(148,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indirect expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(109,058&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a) Components of other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(41,145&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,953&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="19" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cell&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therapy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;BioBanking&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Degenerative&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Disease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,722&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,262&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,084&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,346&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Direct expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,653&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,043&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Segment contribution&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,470&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,573&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Indirect expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(151,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(a) Components of other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value of contingent consideration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(55,566&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment of acquired intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77,228&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231"
      decimals="-3"
      id="F_001160"
      unitRef="U_iso4217USD">5522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231"
      decimals="-3"
      id="F_001161"
      unitRef="U_iso4217USD">15813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001162"
      unitRef="U_iso4217USD">21335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231"
      decimals="-3"
      id="F_001163"
      unitRef="U_iso4217USD">1873000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231"
      decimals="-3"
      id="F_001164"
      unitRef="U_iso4217USD">9809000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001165"
      unitRef="U_iso4217USD">11682000</us-gaap:GrossProfit>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20210101_20211231"
      decimals="-3"
      id="F_001166"
      unitRef="U_iso4217USD">85107000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231"
      decimals="-3"
      id="F_001167"
      unitRef="U_iso4217USD">2119000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231"
      decimals="-3"
      id="F_001168"
      unitRef="U_iso4217USD">8450000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001169"
      unitRef="U_iso4217USD">64017000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001170"
      unitRef="U_iso4217USD">159693000</us-gaap:DirectOperatingCosts>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20210101_20211231"
      decimals="-3"
      id="F_001171"
      unitRef="U_iso4217USD">-85107000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20210101_20211231"
      decimals="-3"
      id="F_001172"
      unitRef="U_iso4217USD">-246000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20210101_20211231"
      decimals="-3"
      id="F_001173"
      unitRef="U_iso4217USD">1359000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001174"
      unitRef="U_iso4217USD">-64017000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001175"
      unitRef="U_iso4217USD">-148011000</celu:SegmentContribution>
    <celu:IndirectExpenses
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001176"
      unitRef="U_iso4217USD">-38953000</celu:IndirectExpenses>
    <celu:IndirectExpenses
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001177"
      unitRef="U_iso4217USD">-38953000</celu:IndirectExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_0001752828_20210101_20211231"
      decimals="-3"
      id="F_001178"
      unitRef="U_iso4217USD">-109058000</us-gaap:IncomeLossFromContinuingOperations>
    <celu:ChangeInFairValueOfContingentConsiderationLiability
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001179"
      unitRef="U_iso4217USD">-41145000</celu:ChangeInFairValueOfContingentConsiderationLiability>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001180"
      unitRef="U_iso4217USD">2192000</us-gaap:AdjustmentForAmortization>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20210101_20211231"
      decimals="-3"
      id="F_001181"
      unitRef="U_iso4217USD">-38953000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231"
      decimals="-3"
      id="F_001182"
      unitRef="U_iso4217USD">5556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231"
      decimals="-3"
      id="F_001183"
      unitRef="U_iso4217USD">8722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001184"
      unitRef="U_iso4217USD">14278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231"
      decimals="-3"
      id="F_001185"
      unitRef="U_iso4217USD">3262000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231"
      decimals="-3"
      id="F_001186"
      unitRef="U_iso4217USD">6084000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001187"
      unitRef="U_iso4217USD">9346000</us-gaap:GrossProfit>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20200101_20201231"
      decimals="-3"
      id="F_001188"
      unitRef="U_iso4217USD">51470000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231"
      decimals="-3"
      id="F_001189"
      unitRef="U_iso4217USD">1653000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231"
      decimals="-3"
      id="F_001190"
      unitRef="U_iso4217USD">10348000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001191"
      unitRef="U_iso4217USD">20573000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001192"
      unitRef="U_iso4217USD">84043000</us-gaap:DirectOperatingCosts>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuCellTherapyMember_20200101_20201231"
      decimals="-3"
      id="F_001193"
      unitRef="U_iso4217USD">-51470000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuBiobankingMember_20200101_20201231"
      decimals="-3"
      id="F_001194"
      unitRef="U_iso4217USD">1609000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuDegenerativeDiseaseMember_20200101_20201231"
      decimals="-3"
      id="F_001195"
      unitRef="U_iso4217USD">-4264000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001196"
      unitRef="U_iso4217USD">-20573000</celu:SegmentContribution>
    <celu:SegmentContribution
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001197"
      unitRef="U_iso4217USD">-74697000</celu:SegmentContribution>
    <celu:IndirectExpenses
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001198"
      unitRef="U_iso4217USD">77228000</celu:IndirectExpenses>
    <celu:IndirectExpenses
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001199"
      unitRef="U_iso4217USD">77228000</celu:IndirectExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_0001752828_20200101_20201231"
      decimals="-3"
      id="F_001200"
      unitRef="U_iso4217USD">-151925000</us-gaap:IncomeLossFromContinuingOperations>
    <celu:ChangeInFairValueOfContingentConsiderationLiability
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001201"
      unitRef="U_iso4217USD">-55566000</celu:ChangeInFairValueOfContingentConsiderationLiability>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001202"
      unitRef="U_iso4217USD">129400000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001203"
      unitRef="U_iso4217USD">3394000</us-gaap:AdjustmentForAmortization>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001752828_us-gaapStatementBusinessSegmentsAxis_celuOtherMember_20200101_20201231"
      decimals="-3"
      id="F_001204"
      unitRef="U_iso4217USD">77228000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000375">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.&#160;&#160;&#160;&#160;&#160;Related Party Transactions&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The related party transactions described below do not have any associated balances on the consolidated balance sheet as of December 31, 2021. &lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Consulting Agreement with Dr.&#160;Andrew Pecora&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 1, 2017, Legacy Celularity entered into a scientific and clinical advisor agreement (the &#x201c;SAB Agreement&#x201d;) with Dr.&#160;Andrew Pecora, a member of Legacy Celularity&#x2019;s board of directors, for the provision of consulting and advisory services. The SAB Agreement was superseded by a new SAB Agreement executed by Legacy Celularity on February 1, 2019.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 13, 2020, Legacy Celularity executed the First Amendment of the SAB Agreement with Dr.&#160;Pecora. The term of the First Amendment was six months. It provided for the payment of $20&#160;per month and the issuance of a stock option to purchase&#160;153,718&#160;shares of Legacy Celularity&#x2019;s common stock. This consideration was in addition to consideration defined in prior agreements. Upon the execution of the agreement,&#160;76,859&#160;of the options were vested. The remaining&#160;76,859&#160;options were vested upon Dr.&#160;Pecora&#x2019;s achievement of a performance objective.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 15, 2020, Legacy Celularity executed the Second Amendment to the SAB Agreement with Dr.&#160;Pecora. Under the Second Amendment, Dr.&#160;Pecora agreed to provide Legacy Celularity with strategic advice on clinical development operations and strategy and assist in establishing a long-range clinical development plan. Compensation under the arrangement includes: (i)&#160;cash consideration of $20&#160;per month, (ii)&#160;a one-time cash bonus of $50&#160;upon consummation of a merger, combination, consolidation or similar transaction involving Legacy Celularity in relation to a transaction with GX, (iii)&#160;a non-qualified stock option to purchase&#160;153,718&#160;shares of Legacy Celularity&#x2019;s common stock. This non-qualified stock option was granted during the second quarter of 2021. The original expiration of the Second Amendment was January 31, 2021. On January 31, 2021, the Company executed the amended and restated second amendment to the SAB Agreement which extended the term of the Second Amendment to September 30, 2021, unless earlier terminated by the Company for cause.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the SAB Agreements, the Company paid Dr.&#160;Pecora $390&#160;and $460&#160;for the years ended December 31, 2021 and 2020, respectively. On September 15, 2021, the Company hired Dr. Pecora to serve as President. Upon hiring Dr. Pecora, the SAB Agreement was terminated.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;CURA Foundation&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December&#160;31, 2021 and 2020, the Company made a contribution of $500 and $375, respectively to the CURA Foundation in support of the International Vatican. &lt;span style="Background-color:#FFFFFF;"&gt;Dr.&#160;Robin L. Smith serves on the Company&#x2019;s Board of Directors, previously served on the board of directors of Legacy Celularity, and is the president and chairperson of the board of the CURA Foundation.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;COTA, Inc&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November&#160;2020, Legacy Celularity and COTA, Inc. (&#x201c;COTA&#x201d;) entered into an Order Schedule (the &#x201c;Order Schedule No.&#160;2&#x201d;), to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide the licensed data in connection with AML patients. The COTA Order Schedule No.&#160;2 will terminate on the one-year anniversary following the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity&#x2019;s President, is the Founder and Chairman of the Board of COTA and Dr.&#160;Robin L. Smith, a member of the&#160;Company&#x2019;s&#160;Board, is an investor in COTA. The Company paid COTA $149&#160;during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cryoport Systems, Inc&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company made payments totaling $104 and $158 to the Cryoport Systems, Inc (&#x201c;Cryoport&#x201d;) for transportation of cryopreserved materials during the years ended December&#160;31, 2021 and 2020, respectively. The Company&#x2019;s Chief Executive Officer and director, Dr.&#160;Robert Hariri, M.D, Ph.D., has served on Cryoport&#x2019;s board of directors since September&#160;2015.&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;CV Starr Loan&lt;/p&gt;
&lt;p style="text-align:justify;Background-color:#FFFFFF;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 8, 2021, Legacy Celularity entered into a $5,000&#160;loan agreement with CV Starr.&#160;CV Starr is an investor in the Company, holding&#160;3,320,346&#160;warrants to purchase Class A common stock and&#160;4,320,347&#160;shares of Class A common stock as of December 31, 2021. During the third quarter of 2021, the Company repaid amounts outstanding under the short-term borrowing arrangement with CV Starr.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Purchase Agreement with a Director&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September&#160;18, 2020, a Director of the Company exercised options to purchase 100,000&#160;shares of common stock at a price of $0.21 per share. Subsequent to the aforementioned exercise, the Company and the Director entered into a stock purchase agreement on September&#160;18, 2020 whereby the 100,000&#160;shares of common stock were repurchased by the Company at the then current fair market value of $2.56 per share.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Employment of an Immediate Family&#160;Member&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Alexandra Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity&#x2019;s Chairman and Executive Officer, is employed by Celularity as an Executive Director, Corporate Strategy&#160;&amp;amp; Business Development. Ms.&#160;Hariri transitioned to part-time&#160;in late 2018, and her base salary for each of the years ended December&#160;31, 2019 and 2020 was $38 per year. In 2021, Ms.&#160;Hariri transitioned back to full-time&#160;and her base salary is $210. Ms.&#160;Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and conditions as applicable to unrelated employees in similar positions.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Matthew Pecora, the son of Andrew Pecora, M.D., the Company&#x2019;s President, was employed by Celularity as Manager, Clinical Supply Chain. For the year ended December&#160;31, 2020, Mr.&#160;Pecora earned $104 in base salary and bonus and he earned equity awards which were in line with similar roles at Celularity. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <celu:PaymentForMonth
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413"
      decimals="-3"
      id="F_001205"
      unitRef="U_iso4217USD">20000</celu:PaymentForMonth>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413"
      decimals="INF"
      id="F_001206"
      unitRef="U_xbrlishares">153718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <celu:StockOptionsVested
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413_20200413"
      decimals="INF"
      id="F_001207"
      unitRef="U_xbrlishares">76859</celu:StockOptionsVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200413"
      decimals="INF"
      id="F_001208"
      unitRef="U_xbrlishares">76859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <celu:CashConsiderationPerMonth
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015"
      decimals="-3"
      id="F_001209"
      unitRef="U_iso4217USD">20000</celu:CashConsiderationPerMonth>
    <celu:RelatedPartyCashBonus
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015"
      decimals="-3"
      id="F_001210"
      unitRef="U_iso4217USD">50000</celu:RelatedPartyCashBonus>
    <celu:NonqualifiedStockOptionToPurchaseSharesOfCommonStock
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20201015_20201015"
      decimals="INF"
      id="F_001211"
      unitRef="U_xbrlishares">153718</celu:NonqualifiedStockOptionToPurchaseSharesOfCommonStock>
    <celu:PaymentsToRelatedParty
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20210101_20211231"
      decimals="-3"
      id="F_001212"
      unitRef="U_iso4217USD">390000</celu:PaymentsToRelatedParty>
    <celu:PaymentsToRelatedParty
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuConsultingAgreementWithDoctorAndrewPecoraMember_20200101_20201231"
      decimals="-3"
      id="F_001213"
      unitRef="U_iso4217USD">460000</celu:PaymentsToRelatedParty>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20210101_20211231"
      decimals="-3"
      id="F_001214"
      unitRef="U_iso4217USD">500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20200101_20201231"
      decimals="-3"
      id="F_001215"
      unitRef="U_iso4217USD">375000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCOTAIncMember_20210101_20211231"
      decimals="-3"
      id="F_001216"
      unitRef="U_iso4217USD">149000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20210101_20211231"
      decimals="-3"
      id="F_001217"
      unitRef="U_iso4217USD">104000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCryoportSystemsIncMember_20200101_20201231"
      decimals="-3"
      id="F_001218"
      unitRef="U_iso4217USD">158000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <celu:LoanAgreement
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_20210608"
      decimals="-3"
      id="F_001219"
      unitRef="U_iso4217USD">5000000</celu:LoanAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231"
      decimals="INF"
      id="F_001220"
      unitRef="U_xbrlishares">3320346</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <celu:NumberOfSharesHolding
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCVStarLoanMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_20211231"
      decimals="INF"
      id="F_001221"
      unitRef="U_xbrlishares">4320347</celu:NumberOfSharesHolding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918"
      decimals="INF"
      id="F_001222"
      unitRef="U_xbrlishares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918"
      decimals="2"
      id="F_001223"
      unitRef="U_iso4217USD_xbrlishares">0.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918"
      decimals="INF"
      id="F_001224"
      unitRef="U_xbrlishares">100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001752828_us-gaapRelatedPartyTransactionAxis_celuStockPurchaseAgreementWithDirectorMember_20200918_20200918"
      decimals="2"
      id="F_001225"
      unitRef="U_iso4217USD_xbrlishares">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <celu:RelatedPartyPartTimeBaseSalary
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20190101_20191231"
      decimals="-3"
      id="F_001226"
      unitRef="U_iso4217USD">38000</celu:RelatedPartyPartTimeBaseSalary>
    <celu:RelatedPartyPartTimeBaseSalary
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231"
      decimals="-3"
      id="F_001227"
      unitRef="U_iso4217USD">38000</celu:RelatedPartyPartTimeBaseSalary>
    <celu:RelatedPartyFullTimeBaseSalary
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuMsHariniMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20210101_20211231"
      decimals="-3"
      id="F_001228"
      unitRef="U_iso4217USD">210000</celu:RelatedPartyFullTimeBaseSalary>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="C_0001752828_srtCounterpartyNameAxis_celuMrPecoraMember_us-gaapRelatedPartyTransactionAxis_celuEmploymentOfImmediateFamilyMemberMember_20200101_20201231"
      decimals="-3"
      id="F_001229"
      unitRef="U_iso4217USD">104000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001752828_20210101_20211231" id="F_000376">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:4.44%;text-indent:-4.44%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;20.&#160;&#160;&#160;&#160;&#160;Subsequent Events&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated subsequent events and there are no items requiring disclosure except the following:&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Warrant Amendment and Exercise&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:4.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On March&#160;1, 2022, Celularity and certain of the investors amended and restated the investors&#x2019; respective Legacy Celularity Warrants (the &#x201c;A&amp;amp;R Warrants&#x201d;) to (i)&#160;reduce the exercise price per share from $7.53 per share to $3.50 per share, subject to adjustment as set forth in the A&amp;amp;R Warrants, (ii)&#160;remove the transfer restrictions set forth in the A&amp;amp;R Warrants, and (iii)&#160;make other changes reflecting the impact of the business combination.&#160;&lt;/span&gt;In conjunction with the amendment, those investors exercised&#160;13,281,386 of the A&amp;amp;R Warrants in exchange for 13,281,386 shares of the Company&#x2019;s Class A common stock for gross proceeds of $46,485.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;text-indent:4.44%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:4.44%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231"
      decimals="INF"
      id="F_001230"
      unitRef="U_iso4217USD_xbrlishares">7.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301"
      decimals="INF"
      id="F_001231"
      unitRef="U_iso4217USD_xbrlishares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301"
      decimals="INF"
      id="F_001232"
      unitRef="U_xbrlishares">13281386</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301"
      decimals="INF"
      id="F_001233"
      unitRef="U_xbrlishares">13281386</us-gaap:SharesIssued>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220301"
      decimals="-3"
      id="F_001234"
      unitRef="U_iso4217USD">46485000</us-gaap:ProceedsFromWarrantExercises>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000594"
          xlink:label="F_000594"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The warrants issued at fair value were immediately charged to expense see Note 12.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000594"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000624"
          xlink:label="F_000624"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000625"
          xlink:label="F_000625"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The exercise price is the lower of $6.77&#160;per share or&#160;80% of either&#160;(i)&#160;the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii)&#160;the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a)&#160;March 16, 2025, (b)&#160;the consummation of Legacy Celularity&#x2019;s initial public offering, (c)&#160;the consummation of a change of control and (d)&#160;the closing of a strategic transaction pursuant to which Legacy Celularity&#x2019;s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000624"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000625"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000694"
          xlink:label="F_000694"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000695"
          xlink:label="F_000695"
          xlink:type="locator"/>
        <link:footnote id="FNT_000004" xlink:label="FNT_000004" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $70,959 and $55,273 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000694"
          xlink:to="FNT_000004"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000695"
          xlink:to="FNT_000004"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000705"
          xlink:label="F_000705"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000704"
          xlink:label="F_000704"
          xlink:type="locator"/>
        <link:footnote id="FNT_000005" xlink:label="FNT_000005" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $5,971 $2,624 at December 31, 2021 and 2020, respectively, under financing lease resulting from a failed sale leaseback (see Note 11).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000705"
          xlink:to="FNT_000005"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000704"
          xlink:to="FNT_000005"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000643"
          xlink:label="F_000643"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000642"
          xlink:label="F_000642"
          xlink:type="locator"/>
        <link:footnote id="FNT_000002" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The warrants are exercisable at a price of $7.53&#160;per share on the first to occur of: (a)&#160;the 60-month anniversary of the date of issuance of the warrants, (b)&#160;the consummation of an agreement for a public exit event, and (c)&#160;the consummation of a change of control.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000643"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000642"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000692"
          xlink:label="F_000692"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000693"
          xlink:label="F_000693"
          xlink:type="locator"/>
        <link:footnote id="FNT_000003" xlink:label="FNT_000003" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $12,513 at December 31, 2021 and 2020 under financing lease resulting from a failed sale leaseback (see Note 11).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000692"
          xlink:to="FNT_000003"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000693"
          xlink:to="FNT_000003"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>133
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY-*\ +^OA-#;&S- =9Y\]C]02P,$%     @ #8)_5$$<S0B%!P  !R(  !@
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6RU6FMOVS@6_2N$-UBT@%.+#[TZ
M28 VQ<STP\P&26=GOS(2'1.51 ]%)\W^^B5E1[3%A]UM)DAB2;Z\//>2O.>0
M]L63D%_[%6,*?&N;KK^<K91:OU\L^FK%6MJ_$VO6Z7>60K94Z5OYL.C7DM%Z
M:-0V"Y0DV:*EO)M=70S/;N35A=BHAG?L1H)^T[94/G]DC7BZG,'9RX-;_K!2
MYL'BZF)-']@=4W^L;Z2^6XQ>:MZRKN>B Y(M+V<?X/MKDIL&@\6_.7OJ]ZZ!
M">5>B*_FYG-].4L,(M:P2AD75+\\LFO6-,:3QO'7SNEL[-,TW+]^\?[S$+P.
MYI[V[%HT?_):K2YGQ0S4;$DWC;H53[^R74"I\5>)IA_^@Z>=;3(#U:97HMTU
MU@A:WFU?Z;==(O8:0!)H@'8-T*D-\*X!'@+=(AO"^D05O;J0X@E(8ZV]F8LA
M-T-K'0WOS##>*:G?Y;J=NKH672\:7E/%:O"1-K2K&+@S[GIP#OZX^P3>G+T%
M9X!WX,M*;'K:U?W%0NF>3?M%M>OEX[87%.CE$ZO> 0SG "4(>II?G]X\.6R^
MT/&.0:,Q:#3XPZ&@-U*R3@':]SK.]Q&/>/2(!X\DY)'V*Z!S RISP?[:\$?:
MZ"Z\N=JZR@=79ID]7N$<$1W8XWY*7*N48 A'JP.<9,1)HC@_5)78:%AZ!59,
M8[QOV!QTNEJ():"-7M/#^.N;,U3@(: SE".=*/-,#P-K[YD<1W(PF#Y-YMIY
MOV;#^FR>?0G88DSW0D,Y22?QNT808N(//QW#3Z/A_RX4VX_=!RYUP9&BF(!S
MC5(",S^X; 271<%][A[UC!'2F[+,Z;!,23E!Y1KA(DW\J/(151Y%=2/9FO(:
ML&^:.7KFG="YTV^>Y-D$G&N4I7D@9<4(KHB"^Y=:Z8E7'2QG'\#"'=,).M>B
MR+$?7#F"*Z/@O@A%FQ/ E>Y<*F$R+0>N58Y@%AA<F-CRGQP97JT(I'H>EK*I
M6VO-T6JH"=XRG[CS,,G0=.UZS9(\#Z#=(RL81?N+$/43;QHO-.@6#(1Q0J;8
MCMH=@K.D M&1]:MH]\!U6=D-=CB+R <!%OD4JL\NQ7D9@&K9"L;IZI;U2O+*
M<+XA+"]&[/9-"CQ=U3ZS5+-  *'E*1@GJK$8CO3TLI#60AH!Z,7L(Q8$IY ]
MS%*610"QI188YY9M+6I$]W"NF&PC"QZZ[(%39PEY>*@H0B@MQ\ XR6R+4@2;
MRR$$$HBF!.BSP[IJA0!:NH'Y2=JLX?2>-UQQ%A5HT%(%C'/%*'W6]#G$_="E
M@1)#9UFZ5BDN0Z78T@6,\X4&*#?,,NU0DL4!P^TEQ0O?)0D(L\Q9 !XS3-*
MM$262U"<2ZX/5ZA9M$O>:47)NP<@[AO^0$,K%[F$@9-T"MQK%9IRR+(*BK/*
M)[9D&GFMA:$N.AOOS$ N:R!83JNAQXH4* 1P;[L29Y9#)7%D$B"7-%"&'(KV
MFF4ABD:66E"<6J;)_)[ZC3QD4N3.+'"M\@R%9J]E''1L:Z353\\-MG/)FF%#
M7(E.Z<EK8.O+GM=,AJ>PAWPPTC]3^#Z2PC@+9=X2$(H3T,^>M>:?(3YJ20IG
MAGC,\BRT!4.6@E"<@OZD4M(3YK'+,"@M,R>=KEF>9210C9'E(13?]XSSF'>5
M:!E0]-M1Q.X6!TYEO,<F-/"6V= INZ!CX%S2PM@9<H\1":A-9(D-G;(1.H;/
M)24,2>XFT+73\@25J1\EMNR%C["7:%NNS.YGR[SCVJ\T8O#&'!T "-]Z#W2B
MGLU)[/M^32MV.5M+UC/YR&97P'<,]@J.#J.W'(AA5';=*5%]78E&5[C^G_\H
M$,Q_&K:#>F?XIF9+7G'U-GI09LD,Q\GL1KZLK-[T.0=GR;LD2:#691(\TL90
M!DSF^I'Y _V*2J.%-FHE)/\OJS6AB(X!WO=&+ T:::-ZO?6J3>FCRCVF^FG;
M8M]%J+7WG"OQCGDTRN\9\Q]W=#@2>V>61PXM]8S7,NTN. PYCHX#1&2.DWQ>
M%.3[$JI'!*;I7%?I.2K]KHMYBLHY2?'+NZ\P8AYU,643GTV@L%AA@>/"XHMD
MM-_(YY?Y3HV8Z-4<)$,T93(O,!F3\*HGK=?8%1OG* V<NF$K-7!<:GRHZT$H
MZ;)N#@?/>0<JNN:ZS'L3[PH)K2,2Y[C#8X<1@0'YC*W@P''!H3=6FW:S572[
M6N:%Z2J)\RS#63$5H#[#-,/Z-X#4B@X<%QU;INQ/J,7> %QM49;[^=O!=\W.
M4\VU24 S82M$<%R(.$1O)FC-6&OVVX90'YG6_N9Z?4@"P_3^O\,NG$]*O$<6
MV!4WL2,+;/4-CNN;.R:-1/@ ;FVPUWO!6L8;2FVD=A.K5D@2Y>O;D_(:8VQB
MM0&)[X]/Z\M7?HCGK+4@B 0D+[$B@L1%Q"[E'U\AY98N"?Z[4[[W,5V<,WX@
MY9[M99D46:#F$UOS2;SF[U+^GU=(N:W<)/N[4VYK+XG7WA](>>X4H#Q-G'*Z
MV/N4WGQ%XC<J'WC7@X8M=;OD7:[S+[??.MC>*+$>/KB_%TJ)=KA<,:K+HS'0
M[R^%WI/L;LQW <;O?ES]#U!+ P04    "  -@G]4SC[@.S0$  !U%0  &
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M0@O$9(/WJ7QDQ]_(29"O\T4L%<4W.);8P+5 M!>29:=@Q2"C>?F+OY\FHA$
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M9)+/1?$IS]3F>A)/4,97;%>H>_'P!^\""K2_5!2R^44/K6WD3U"ZDTJ4W6!
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MS>:,"W5?,]<>6!7A@VC1:$HXS3]V*<C%<AQO,XW(#=W E2IRJ0$&GH<0]MO
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M#="L(*^[3;OM2MA-6=V!AV&66L^ T/74][$V#BN1T')IZ,5ZW];9]TNM*GD
MBPE2JWH/%,_Z6:!T&<Z0@,U(.,&+-8N6Q('XB/V)%W&ZX]6#T/MO"RL<//*R
M$YK[G[B4'):[+/BF* UKH> )YI3'_C:@G[=CJV25..!3"Y]ZX=\<[6H-NZ@>
MP4EK^1*H5C2778/YZ=#G"9BE XEE?1+YMXA2':\R8SQ8^CW@4=H;--<IT;9
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MK??F<2=X+J1N +]O:]#/X8,>8+R!>_T_4$L#!!0    (  V"?U0+PH"5:!@
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M>EI M3LYN"VG2X",W(L[Q=E#P3R*K6A$-Y!Q9H5BJ-0VJ%8- B[_#5#_<+)
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MM+-@KI_M)9'Y+8$\YA8\*0-_F-*F3/I($GK68&^EJ)!B"7(U!A8,%EA:P<7
MNH.XXD82#$"%S KZUG?'Z:N9D\G9'8H%EEKB'2:KV3EQ-X2I+<U@**0()NE7
MHG<\HI-6\C1Q[7KK3\(R@/WN%@&Z/9Z(2<"3"S?23_\((RP07JP&$(+X"1:1
ME!]^Q%""*\6D=%JG"><C@<^$?R:PS6"\OX782G"D.EV1R*RJAGAS QJ8I:[@
M2@_CZ43]F/Z'U(?)O- :$G4Q_^%XJ:H[%JE#_\0*Q4&2F<GY,=84H8YJQ; H
MJZ)AT9\:]5;O0OUV\7SVN7S@QS>O[PN/I5(3 %T>^Y""49'?CQ)-O'%(;6]3
M22&],+TY5C'\2F.8_L:NS%(W-Q^O+^@JP-8M-7"HJ3Y4>PBX#&ZHZTWM'8 8
M!F_TMNMPH%S!ATG(+9DP,/RBIE,MG$]ZQ02K2BI%./LBUG 9AL+;!%\3 U*"
MV]*US1]0TAV0,L"[=SXR#[QFIX/0JG,Q?BZ/'(R@7,LFA\3A$ @4<07_Z6BT
M0/$8W/GZ:9=CR$L+'"!4_O4OB^=/OCK^ST\ID5L\O5\_S"?#,('%M8/"I9 8
M4ZL[IL0#*U.VOR_+Y+GZTMS)L=)<7"HO;^ZM<%^UTXMY^FPN;2\;86,B1QSR
MR7&0]>[S4+8Q,A4[R:-3_RA-W];UT+@3!TCPS@NP66F6BP6F6:E<$R,KT?LQ
MHQ*U/3R"PK%Z-AC1@P"0?\3O6F+X8^8NVHZ%IN\&'#ON?FVHM 5;D>3 !S+P
M4/3#<GH5HR?U&TO='IAP;0/]/=G"OS<2:N\;RS$Q!C#NIBG1O;E+IQX:S0"M
MN4=CKOQZHZ)<"";TL1YXKPP1^;G:Q,>8HC<QW#E\[RI23;Y\;X**4IMZ:?[@
MG8G/ZY%'JU^=;8YBPAS0"MV!\J^A.M[5K;1M%>/=1"J;$P"5X(J('=X:][9G
M:?<+]?C)L]F3QV?**U2N0I7/6M= .7&CWO_WNEE;5E:3ND?#>'WU_J^ZWG[U
M*M3B 94,#!BG3%H=7IW7_.G)#B"7"D8_C^6Z\4UA/2L\'<,J@=TRJWK2(UY#
MC?#K%U:*X!!:*2VSN^3+X (XD$0HGD]E)_%-$^MK@L+W43]2.NDD_?S^$*NF
MN)FWAWQ&+/&-<,+F%9>PK&IV6R8 ;*]1WU,Y^%[^PAH9F[XXWX1@6ZCXK 6$
MJE+.@V^(L(#/-_=+ZS^_][XJ4](0:<X8^&LIT8<LGLU]"]##NU^$DHVPF<+9
MVF*;'B+P1C59](O%^=/XRAA-CZ_ PG>UN'WO1H/PZ/A#T!AK"=ZD0@@\.WC<
MRYH98"1;5!B!8E,"N'9(M6:1]R0.,9>EB;(J#Y?5 M#-=*&(L=Q&,EE6 !A8
M:]6ZG:[HC7\;?-:"'-:6)SV[$)"I(.$Z 8!NFD&JB"&D%;C.F0B5.3Y;AI:4
M0(FT[3)Y\FW>S-\=ZV8!OJP<+!#5%@+FTNUIF2WUM@H],&8L)-L5R*;B=N;3
MU@9#"U=82!"I\X[LS+@7=F99$:07@7_6%CZ$7H?0,CF:C"*Y'BB9'=FMUNV-
MK[>83P"PSMZ.,==X3''UXZM*)2LBTOES]=#.S=QO1E+IDQK+/ED(;P2;0VLY
MGE2&M[@TL<1'DX(S4[Y:\E$15.I_ H8=SJJ/U?*HBZ$Q4+'F*4TG7\UEA#&^
M'*(B2?@))].D/W0.):3)PY$8(443D@[^4&]#_KUT6,W[H:1(F7_BC$!\,R7K
MX,V,#]6PX%W*7I[[ 83]!GQ,JH +%S) <!6F!?8#U(NJLI#&3-J665ME$MY,
MN@]Y?BY=O.PM:61YYKW#S^$^;*4NKB[V M/QQAB*'E, _URR,83Y4E!1=VX0
MW,FF&/*@5-J_2:6E@V19K5KZ3MR81OS9S."GHG>(7-338\)/T?TE-.*2&<\D
MXXM7\\+?2@.;=WGB)(E:W@)=PI=#M5XS>#;JC5YV; 73?JAU3 \@BU:73LF6
M+V65EUPE;3Q]?8PB@I:]YT'VR5T=7UUJG2P(IG;^S#=8&ZD<+\U&5ZO/+Z&N
MBXUS%2^]C7W/7$V.OS5JS&M?J?O/ [UT+A+C_7WV^/S9?QC? 3U^^OGU*Q;$
MQ1QA8FIQ)F,H9YZL?[FV*M6/!OYIHW[*IW1* [!N@Z*G98 .R];H&W$:36EJ
M&^8/;FT;NI]^> 'ZJF^,\ 5$LN+W&=#Y:4A?%MGHTN,P#0,(#]P.T!5R)AD
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M/ )OSGRJW,AH5RH_((""&PL%B  *BUGNIC)%/, $&:9J/+.BM9FKR!L9M);
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MP>_(-%JFCM*@"#%E'CW)14A8BB]^OJL.8RY>QUCG-VRG+,Y93^<WH4E]2;U
M7E9'_*QI'122(#VONJ,C)^7YA/=V6%: *^8O89*'9/H<[M1QC [H$39#4#3=
M@DXKR">5*98"8.D-:2C*IT/^"2-9*AUUS[%EOYY<C7VD\54N'[R.C':)WXD-
M30G1XGR#+YS?4R 0FP]-OSF_ /7#Q59F[O9,482?84PRVF"CHWUZ/<K2:5_D
M(<=_7J&]YV/A10I0 M[WS#^*5#Q*A)@D]ZK[3H:P'=L7'IE]Q>H^SR!#:7_*
M$\0*=6C%A#M_@/FE$SV)C2S)H\I?AZZ/UL (B(<8HH;1"$!<D>8[\GE"?B8P
M"5_^G/<9/PN#4_ S_]+REC:W)T3:9*&#-YE0_)Q_'*O!?(H!:^H"^L'&I"EA
M(L/79'K;K72:JHTM/YL*SW5M^TGV(?RR4XD J/7?\:8Z\K'OLD^SC^ EO+R4
MN1X)G_SW\.EJ^K\)7/B/Z,?'_?^*X*UNU\S2*[/"JV?SYT\?>,N+/Q#YR"?U
M2]<C%9$_^?&3:?D [O,CC_B#&Z3_Q\*W_PM02P,$%     @ #8)_5))1Y;P&
M*   ](4  !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6S5/6N3W+:1W_TK
M6(HK)57-CK2KAQ5+5M5*LA-?28FBM9*KNKH/'!(S@XA#C ER1^-??_T"T."0
MNVOG<I7[(.WN# $T&HU^=_/EP76?_=:8OOBR:UK_W;UMW^^_??C05UNS*_W2
M[4T+WZQ=MRM[^+/;//3[SI0U#=HU#R\>/7KV<%?:]MZKE_39A^[52S?TC6W-
MAZ[PPVY7=L?7IG&'[^Z=WPL??+2;;8\?/'SU<E]NS)7I/^T_=/#7PSA+;7>F
M]=:U16?6W]V[//_V]1-\GA[XFS4'KWXO<"<KYS[C'S_6W]U[A "9QE0]SE#"
MCVOSQC0-3@1@_"QSWHM+XD#]>YC]!]H[[&55>O/&-7^W=;_][M[S>T5MUN70
M]!_=X4]&]O,4YZM<X^G_XL#//GE\KZ@&W[N=# 8(=K;EG^47P8,:\/S1S( +
M&7!!</-"!.7;LB]?O>S<H>CP:9@-?Z&MTF@ SK9X*%=]!]]:&->_NN+#*-RZ
MN+*;UJYM5;9]<5E5;FA[VVZ*#ZZQE37^Y<,>UL-1#RN9^S7/?3$S]_E%\=ZU
M_=87W[>UJ?,)'@*@$=J+ .WKBQMG?&NJ9?'X?%%</+HXOV&^QW'WCVF^QS/S
M36RS^*_+E>\[H);_OF&!)W&!)[3 DW\)>F^>^V)9W'WZXG7IK<<'/W3&F[8O
MZ5+\M#7%&[?;E^WQ][][?G'^S0M?5*[U,*HN>U,7:]N6;67+IO PQ,!U['U1
M=J8 %K"'GW5A\6I5KJOA.0/4VV_I;UE_WUD8OF\ @HUI35<VS1&_-_N>Q_8
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MTDT!<E^;#ED@W1NWVP%@_-BA[(!-],(@9.>D/<!6 8_I6&#(UL*@#LZK(2"
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M]659'=FEA#* 'P8V8N"F]ZPDW+?7#U">,L9VZ(U7C!%'%,'B8Y-T,4(W@'8
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MT]&=;16JB(<@OSB=%*1(\BX"B#\%I^,[UV[.WI%?Y9)!BU\U^%5#7PG4P8J
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MUXM$1,Z&)?$,UY*X<.LUZDBP1."3P><ZMW$,-VCHIG(%IHW7D]0G/T%T: #
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M8Y+<<G ?*F+4P;?0)=9N4J+)'OP' * !)/AWC0N#=?0F<V.*E2Y+BK]^F@R
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M%74<*(V/^8#.W]1TI@.N. &4J7M=!(1^IL*P-"6?[^V:,-(LMCU KN/<\#$
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M@L2=2NF&65SJ0VQ:#:STH$;$-$FRN&%<AJO<QW9ZE:NC%5S"3A-S;!JF?VQ
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M]VOXO-;06JFHJXS%"M0:[!9AK22UIV@V5XPDQWJ%VLG.G.SN$;.;3LB*#&
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MS$:GS'*J<0(7*8F7_6^<*.I)_?&1KD:"VG'B-W95[86C#3&)J:6T;ZT]<FT
MW8'XTZ2'\-HV?GV!.OG"[_&>1+_1@?N%,WNIU8)N8R'W1,#M<0-6>=[RI88V
M=/=4Z/1W)K>J;GFS__VW29H4?YC>A?J2ET(**PB+"+Z32F]Y#4NN[^ED^G,(
M+YVNT<D55J/>^(O:T$'5-;:_S8Y?C_\"U_T5^&S>_TC<<;T1C6.S)M=X6.0!
MZ/YR[B=6M?Y"7"E+UZL?;NE_!K4SH/6UHGH?)B[ \0]I\1]02P,$%     @
M#8)_5!G_J*P(!@  E0X  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MK5=+;]LX$+[K5Q#>H,@"JJV77WD!3M/=#= 609+N'A9[H*6Q1$0B59**Z_WU
M.T/)BA,[V1YZL$51G)GOFP>'/%LK_6 * ,N^5Z4TYX/"VOID-#)I 14W0U6#
MQ"\KI2MN\57G(U-KX)D3JLI1% 234<6%'%R<N;D;?7&F&EL*"3>:F::JN-Y<
M0JG6YX-PL)VX%7EA:6)T<5;S'.[ ?JUO-+Z->BV9J$ :H233L#H?+,*3RX36
MNP5_"EB;G3$C)DNE'NCE.CL?! 0(2D@M:>#X>(0/4):D"&%\ZW0.>I,DN#O>
M:O_-<4<N2V[@@RK_$IDMS@>S <M@Q9O2WJKU']#Q&9.^5)7&_;-UNW8<#UC:
M&*NJ3A@15$*V3_Z]\\..P"QX12#J!"*'NS7D4%YQRR_.M%HS3:M1&PT<52>-
MX(2DH-Q9C5\%RMF+WY7*UJ(L&9<9NY:6RUPL2V +8\ :GWT!>S:R:(B6C]).
MZ66K-'I%:1BQSTK:PK"/,H/LN8(1(NQA1EN8E]&;&J\@';(X]%D41.$;^N*>
M=NSTQ?]'>W&(-KL2)BV5:32POQ=+8S4FSS]OF$UZLXDSF_Q<;[^M=#9D/Z"7
MW1? /JBJYG+#:M!4SX8)),NE;'C)\JT.@6N$QL*SS(*Q3$AF47:E&FT+]JWA
MVH)F:L7@$?2&;8!KGS6R!(.ZF-4BST$+F=-WU*'2M-&&U5HHS:QRNEZ8&+)+
M+*R,J=92A_+=+[,HG)[V #F2,<8)=?A1)&N<J<, *5E\Y,C6W&"IXBQ6$ K9
M@MLGOO11*MN!@FSH7)5RK3>D^I&7#1A2UTL@$I$[1>H@8-PR-;<D;" GP,@!
M4PGMK%2)VZ Y\6@?(CN:UQOO"G*03N01*/< O>%="K7D\@&U>/?*\M*[Y"67
M*:JQ#,L!JB62;$LBG'M'7AA&?IQ,<33UXVG2/MU[&$W]8#)#,QI2E4OA]L-=
M0AI*;EL^AF/>X+>O)6;]Y^N[>[9L#'K-&,_QBTZ]X]B?3A+OU_V)ZSZN_;?7
MGJ^SB8)G;&)_$@;/V,1^'"0_R5;X8[8.E]3.-.^F)4ZG"GN6(7^B']O,I*AC
M)$^\??O[[#\:*RH7CZ\&5DW)/F%>&&]1*6W%OYS,B9>62?,CMMB:H@AI(56I
M\@U1F/@SQZD;A"%S;@E/63AQQ6N\#Z[/( 27!Y@<IA"U\2(_">/N/PRZM?>:
M9\ DK[ FWO&J/L6*QQGLZ _&&T\#]\/5O9&X$[P%GGYKJ,"8IE9IO,3'HT/W
MOX6"#I_/X^WC$Z;="5O@#E(U;8;RS@F$\C#EXS&F_P23\9@TQSAXA=YQZ(>(
M%1?. UK_)K/C*')+P\D8'_M<CB-_G+0K_%D[F&/J.!Q3/PRI.MX,H$L=+TS\
MR6SJ8C6=>U^4?-\11DM[(MYB"^+ZYM8AOL)M5F5-:K>PPF#FCX.@?PKLQRN!
M.P!TV1W.VCPGI\U[A&Z#@.]X\C.4O7K?MMLUCR(_G$>NZ1QAH<P3MY8RW@63
M 77__9)S I3I/D;$U. .9N5FR!9YKB''.#\+\S,@Z/BB+RO:+DV3I@ 9;;:M
MT9V];!]U 65&^S!JV(<E$'%?>KN;-7Z-T$O$-J:7^&F8>*$_G24T'.,P:6<G
M.(S'$^_JJ3O90NCL17-"!^RT#\=3"\"=*CO42#FU:Y;AT03/5D(VU/W: G ]
M$57>7"W>!T'H',4E>PHV-4RAVOT(C]0N *KNO%1C>VYHCO$2L<FV#:5XS! I
MMEW,J%SS"J/CW'8'*-?Z+? /D-AILULXF<A<@RTXZETUEHY5*3<%6Y%[B=<S
M!=UJ#![F#P%<45]'@QU;ASY5%59T*GB)M>'D783;WKWG.@U=H>P:(NKM.0*]
MC8%!I]J6^\L3$'^%N?,)IR3&.T";E9A#+Z2?NX<ZL,Y<@(_":.XG0; KD!9<
MYT#0UAKC]EZMVE3';XA_I\Y?IO9NVG=^'QXZL(YVK@KHP-Q=B RZLY&VO37T
ML_V=:]%>-9Z6MQ>VSPA52,-*6*%H,)R.!^VVLWVQJG87CZ6RN/^Z88'W1M"T
M +^OE++;%S+0WT0O_@-02P,$%     @ #8)_5"IYP&NY @  _ 4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,34N>&ULM51-;]LP#+W[5PC>L),1Q[*;CRX)
MD+0;-F#%@A;;#L,.LDW'0F4ID^2F_?>C9,?-T#6W72R)(M_CHTPN#DK?FQK
MDL=&2+,,:VOWEW%LBAH:9D9J#Q)O*J4;9O&H=['9:V"E#VI$3,?C2=PP+L/5
MPMNV>K50K15<PE83TS8-TT\;$.JP#)/P:+CEN]HZ0[Q:[-D.[L!^VV\UGN(!
MI>0-2,.5)!JJ9;A.+C>9\_<.WSD<S,F>."6Y4O?N\+E<AF.7$ @HK$-@N#S
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MFKX*O(_]C.[;'<T[FIPG9U?GP+TIO#"9C"[&1^''42Z/NCP]NG;L'GBAH3;
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MYP4B:LE:9]XK&WIAX6G?N8WPM7,?):#]+5-ND11-EL+EH<JEE+G-; 9(^@_
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MY81\B$$K%R)U"1[F\=@-?Z<DA \/&P43O)P%BUG$ZB;JI3$;RH[8<3@IDXB
MQ8YK(;L<ATF:&Q_-K6268?W UE2Z3NLZS#;/S/79LDGKJR)3J=#)._ZS[7QJ
MW^H3-?;F.[FK-3@^[9;&*1V?5RO$.9L%4>?+AYT4J^;QT]5,\"M(SDW6GEL,
M=CK=+O$GI[6OFQBV*@1M,^:#<T>B-\;<'#FF86U\2ATE4]R8%NQW7-H[E<+6
M],EIK"TAN0_3-E^&@&7 @%V[1=1?S%RS19%5'J.,K07<0U[KGOD!@+DF/@[&
MB\4WFCA,X.9X[O_,Q+MC\W:^7=O(3>5]8>R*TFVOVELO5C9:.50:CDY?</+%
M5F?(]4/1CQ:]+J"AS4TI?<).;9G<J, >PO:+T9-F_< M17,,[D)M[VRZ.R8T
MSFLD8;=\.9W-N>]BA.6<NG.GB([@4&0Z$JI:&?5"R>/J!%,0GLRUN(R(D53?
M&("<.U;;2YW:5OUAF1%1<CZ='0^T!WUM^G,YF42ZF9W0%25]( X&,B66MILQ
ME$Y"9:C77$\BV#(G&$9P^E3HS"6E)G=L,G&#>E)4NOO099U,F643Q<$$-0-+
MQQ[&.(1T1S=W^IJV*+RR=8_8DL&;P\SNYM%X-&[1Q^GNNF!XT.'M.A)I"]C.
M_3+3INMI+3"(PD+'8MRE=+LXHB8RUK&[:PKK@AIR2/F4O+?;9.=UV+,]ZV\T
MR@&(O1Q'IIR-3CG(P(4ZB$'O\O!]>VYND\RE/H\WUE1TGJ5/GPRF='#!905&
ME[)#C2'XLJ#.)_V/. Q\$F*XUO&C/C)Q#.-\BJ'9>T0V.$$)X-S?&S[29A^>
MC<;QJ5;J!\REQDD]=.+?)<A)&TDVU"YEZ-:)Y*<V)#[P[:<MUF5K7>EP;5JK
M&)%L9&O=]A@>WLD1!(LW.^)QQ6&-YRBZ"IIE^K:$RBV&\541MG(^=C!>I?,B
MO>=:E&N).6ZIJ:.]OG-*Y[7XF&.ILJ([@D;O[5FOB>[.-98--S9A5SG!3+?_
M3DY&L$/G$?2ZE7,K>2."@_,(]G0V2L'WN$%8E!FR ;6EDII4<]^>,7$#</B>
ME=M0)*"4QZTT??AE3%]+CIUJ/ATA\=*Q!98SU*/JHM.YTZ%S>T8^%J*4,.9
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M:78Z.1D]'AW.LF>3<WQ(#D],@%//LI/SIST;3YA7")F7+4G]Z%DV.YF!=JZ
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M<M!B =Y-5.KVGDUN:%/8R&&7=2ETWE'57M,*RN86&G:.-H-Q2I^T9,O AS!
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MQ?\!Z,(!WE]:2[M)"+#_5YG_ 5!+ P04    "  -@G]4(6=ZW%T*   <&P
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M1B.+.3%[9KE%+!]%#!A<-#L($LF".7<5]M\'+J3&F"] KC(A.%E+HB&?NES
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M4=@5D#-G'VF-$!MVW?@$(U(G$P-@NSTI>I +#Y*\ !(G[+ULS$:S[YN2RL<
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MX[W)^.=*@2U9$L#SA3&^OJ -F@]I5_\#4$L#!!0    (  V"?U1IAC?_) ,
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M3R5P3&!YKLQXO@J JH'@ZT^N738'M\%-3H!/\ - M[O!/=\"AZQJH?V\3=;
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MQZC<,,;V&/(Q@@&_2-03P*Z*10_= -HMR+[6E<N,_ F[NNJN=[C875I?DY'
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M.CPJ\%%!CP2I:G'" **+@_X.R"C;F .>S W"IAD93O@1>>?(\05G5MR2R-2
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M.@Y'@$"#J=C4H",6.*;]+BC_GUM,!KL)I!2R4^+0]#^Z[)H-)*!#F82#(ST
MQ.9ES_<V)V/#[TLOE*QZRX; R8;1>HQ66UJ!D?/:.)4,<0')?*2HF4DZNH*9
MLK3.$&V9M\&2%Z?/P!:9Q.BK?FK+-"*#'FX]DJJ%6W0"US@<"H6 #@XPS;$W
MP^Z0!$)3.4)F'VF/@LL\>F^ Y\>3^ W91VL?:LM$G?3LK!>_\CS!KIS\L_@=
M&>U#_M&C%6^GH/$>APAFESQ))Q'_34,.@SH1<]8610'6R*C)R.IJU+,;RI^
MEXVB8M,>6C(K4!,J.T0;1K,%M+?O/_PIW1^^>]VSV'K8HW.0B_,93010.D#G
M%;"1;9<4Z<U;)WRLOYV+)*_-03#6O]^4&)X=#YP6Y,[@T\/2IB,_D0G(#KQ8
MX]2?BG.@;!CL8-2\G@W_W'<[,48W.O54LA$R,:OC*--B^:_\;)$0VACWY& 3
M/++3LW=JP/# V 1E?WB.")#A:G!Y&PGYCQ'LG>DX9,'[;%I 3<B@B2);"YN1
MXATS-O4HB,Y%4!E(#)+M*^YB$,VW[6XQ\.R(=H)<WZ?9,!%0E$G,+33[@MGK
M!7=24WX&6,&Z%SZ'*(8ZCGXS4^\.51EE)4DV3#;(AF$L\CEF^Q*]D64+F]B5
MN@L (SDT4M&5,+<HRC-!W5^R3-2/"@.01A5239+705NPF0=LEBHS(>&9(4=)
M\*!(&!I#]JAA!"VMSR#[896CZC5^$=D_.@V0B3@=5[SN>Y"(R-D&)YY1E20N
MJNT6]3680OFD^LJG%HYA,@O=6.[/N)T_2*=L1H@.C1$X,]7>"4=EK"V5$TUG
MD/&.B-%*<QVJUE%T+]GGH VWN"\DT:HCL$!T7Q?YM0#SJ'$N^2M\D)R=8? D
M;>97%<>/$DKC:NP^+TD0!AW?ZL C.<'W4R!^&X^C?P&>6"9Y 4].P'Y^HL:.
M@BUHYORJO1Y ;BD+( KN8\.Z)24!&:9)5%@?1Y.$V-G7X>(D#Q<Y@*8\T% *
M\5BBC-G_IX]G]?Z0^'YV/JNODX/%TO"XTO^E@T3ZJ:"QB16U1JRPU'X6Y:=D
MSNT]?QV7[)$)2+Y&U/J9S1C.X]4JEG--E-5%\N,D>5L&^]3 9-R8:DUD=I*@
MMQ YEM6$XD)92L'%>E<\3..I?9X\N^NA&N%LOHX UOJ^KDCA_6 !>6T H4*(
MT3#QG8,O[QQ\R"("'KV4""&F4=T*$1I[3.^CCB;(I0K9U/VA<-[9O 8@JU*]
MD9P2S6QJ<K,DO0B3P=@_?J^O*%^-IL984\A"9$4\I P@E26]Y0A]ANB+RX('
M8S3",,:/ 5%&_^]C".V)XT&"#,83PD8D(9D29$G'0M9\BPI.')4+WC UFR9<
M17"TV:J3+"Z3E'F/9?4&EEST,(A7\!K,_^2\!-WTA<:\U^K4Q6VG;"Q4HIMN
M@S3LW_H'@\S:)@4[>0N-&BLL'Y_ #)(R3C$(DX$>Z40>/ES2<G/<%.,+2YF=
MJ<K%J!,1(MNZIB2 XBA[-*D ,X_UM2M$L7GSR6=[]X/ZK-5I'EO3@J*[)W;9
MH\S(H$3VW73K?XBQ$@5R8I-53=.^[4K929@9BR84:\_YUJ2$BR^]XNR>\&'L
MD,-).+=\P!@,PYD P;CBME57 RY^[U*,Z)&PP*')ES$]<#Q>K$[O)+F#"P$0
M29SWRH2",P%)BA!11_]$J@-F00,NQ35O A)1\('=IG$((J>=(#P7^2=7'-DT
MP-V3Y]8MBN_.^FLITR#./RE#O '7!+Q7%F7=%)C@@;D2T0+'LS%GL(W4BNE!
M,B&!%>$QG,&3Y#_'\#L72!G&1?Y'HQD16+N*?#_WH1D-+WL/M>*WN1\%?/$N
MW$TC%APF2N)L7[_SZE"5A$<52PMA&/]N^./ DF2_Q$ZT+[,Z7L<N_PF/?R_+
MT;KLQ@ R3K$[V!^E1*Z^63P]/3T!XX+SSV04M3!EINQ>D)X9.^7%O)T2"@W/
MYNL$_RR&_Z@^>K]/$_\78WT-7;]#:HE-4ZU%J9W)7QE^A (\#B?,^KR#UCOI
M3#P)"_C?)&&]IAADK:G(&Y]:;=Q(JOIT'R0MD]Z);[:[O,[LBV-IOZA\<EE<
MSW]3VNK&#@X!"_#[C;L&-E]RA2A.T!_?&RFE!I-]W 33P]F%1^CV7J3&<83J
MVP0;$B VZ_1P7, Y$DT8&?CKO*&,("2=EWGU,BT_X;?& _3B<2_X&#1US[J'
MDP;B=[965#&#^>C!*^E/ -=N4: _>GL1]II9A9INI-@'@SG=U%733($4R@=+
M=VNFX/07,* -Z>,T:=O6.1"YQ/!C[Q#"%?L%_-$2QY8/L8@2+&$);[O%\;I(
MV?.K_?]>M1OG6CTT(K+_6S6^$9T-1YO2VG[ZG.ZI#0'6T:*8FL*(J0<37M.O
M&AZ?XAZ%R9$ZEV8@ 1I[0 I@%U1%%5AX0=8K*0[ZOLW<WJ@'HBL16^@K9$/3
M6Y'_RS3 G+F()92OUOJ45F371ZD%#Q^SNN@-_!FUJEK+<S@59[J2JP=S/V(1
M4K#2WJNVVBM$(-Y.Z0N]>5"]<%DS-MD"_87]_)9(E3Q)_E+=8J+9C#9[[[T0
M_C?<"C_?N"[IBV490^NC*77IH\^N-@;,'ST;9" RJ^0K%LD5Q?#\9@1EPKI?
MA\//ZIFA\/ILOF#ZO:_%OZ("_+]+ 7[R+H2K1G70V6&QO=*WS2'=N!\>DO2M
M;]S#>\T5JT&C?E!N;?%_@FK0))P==/ZXEZH67(O:5R"T!]&$!^2L.TIHDY,.
MK/0&*YQ05PV="K@]@=%&5H]1U8J*R.\L:)("E\8%>*B"#312AYR<#IQMK((*
M@80;D35A2'*7WCBC=UC-U-:-LY)-05SW&:L>M.1$9HZ+.Z,HG:, URS&KK#S
M0).\G$/6@M<6LBE\C*I74G\0M45K"/.FZ33ODG0=!1GW&"4T5@AZ%=Z$S5 Z
MF%!VV]>4N#[]5>Q^&+*7$0SQ4N(4EI3X+^C:DBM-*LPC"6<\5I_Q%^181QT%
M-"^G1X SL 4TB(:.W__< 8K.+L1,Q?IU140((MTC^SO$$$+; #&5(_<]DB7Z
ME65H,]U),L>N0K7OV7R-+E4>C#.D^WP8V0]H$I"K"P#G:H3TNG;BLB!]%_XL
M4JKE#MU2MI@?!;J&%L6/FR0-2J]4A\4]N_9A5<Q%\#8!OV%RY^43TLS<@;6A
M#S90%GM>J&@PKC7A.BQOJE.:B:;3XN"HX&_0-L<BBVLD)TYV=9%F:Z27KI4_
MCVK!44;=L@J*IZ_#/(?1XA")A<(Z=D1M1^P78Y,4Z$1E2NWT9J U"BH,3B"\
MR-4"#4<8RU8ZP2":[D8,')E4,J&&*+*[&MRB9+*EK70UXD'*ZL9THAK#8%[>
M5,6-Z_O8;;V#*:P DQ!+LKG<5NB-1.F@["7OMX)@*Y1,L=LR%.+$$W%DYPY
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MCK2J#;FB[]%K";U1*'02LF9#QLWD4N1V.+XOE>J[S<T<OAF!&)P^_WSL[M:
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M7VT"YZ,M3'ZY8B;M0!K"!DAD9IKUF9L+D!D1KY:+!LT:#(5Q/I5/PS"^.V]
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M:R<V:!H&*_WLK6PVG4%XNZ5H6%K*TFR9XN/$!X[45[(NJ&@V"J2LN2:Z0GZ
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M19O_R*(86&S_RT*/+/*>A78LY(Z%!YD(B28B'3 JZ[4PS%:>Y35:Q]!L7/_
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M@N::X_(%91W0GDII]H(EZ-;YXC=02P,$%     @ #8)_5".R!!MU @  0 4
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MP*VRV,[>K'!^@G8'<+]0RAX<1]!/Y,4?4$L#!!0    (  V"?U3\Y46@4P,
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M$_="%](@-V4AOE\OH/!@KM):+@295I46%1+I'4Q+N$F*+K/(C(.= GAK'S$
M($Q($+%)$K,@B\D+"'B6D,Q+81C[+,E"\K;C'8E9FH;,AYG(RS#6';*2O S\
MG$7IA)S 2IX3N#T60EJWPB+0D@4AK(5>D)$/:VLL. "=]PT6QU429"Q(\9<
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M-$*C *POE+*[%S0P?"-=_@]02P,$%     @ #8)_5/FH_8YC!   \ D  !D
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MN$\PS=&E>7"Z]L>%B79X^/#+!9[VP! !?I]I[58/I* [/Y[^"U!+ P04
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M+J SFKYW]A.GN]"OEMI!]PO#+?S=$,8;P/Y::_<T\0>,?V#F_P%02P,$%
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M,+2"M6)?NZ)C']2 +1F.W;;$N_8,@IXY$:K;^]V]6&'7Q3C87:3:R_<?)6Y
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;+U86V_;-A1^[GX%86Q
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MVR'24O5;H>X8N777[2=I\/+NFAM\7X&R!CB_DM+L._8#[8MM^C]02P,$%
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M@EE'Q8[O:JQN3%5G<ZH5X3,+<)/S!61M>9D%5&Q#+5=^!YL[DLA3BB9J!(A
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M9AR%A8X>"S^2:W)'[F7?DU3O]NA1.@HAG2=#2%<AI*M'R'9?L'40TG<RY?8
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M>;(1ORPT3_(\68N7*T:A0,,!\/TB@<RT?(,_5E3_7M;;_P-02P,$%     @
M#8)_5"5:"R)U @  \@4  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
MA53=;YLP$/]7+-2'5NH"(0FL%4%J$FWKPZ2H:;=G)QS!JK&I?83VOY]M",I6
MDKV /^[W<;;ODD:J5UT ('DON=!SKT"L[GU?[PHHJ1[)"H39R:4J*9JIVONZ
M4D S!RJY'P9!Y)>4"2]-W-I:I8FLD3,!:T5T7994?2R RV;NC;WCPA/;%V@7
M_#2IZ!XV@"_56IF9W[-DK 2AF11$03[W'L;WB]C&NX!?#!I],B8VDZV4KW;R
MF,V]P!H"#CNT#-3\#K $SBV1L?'6<7J]I 6>CH_LWUSN)I<MU;"4_#?+L)A[
M7SV204YKCD^R^0%=/C/+MY-<NR]INMC ([M:HRP[L'%0,M'^Z7MW#B> <'P&
M$': T/ENA9S+%46:)DHV1-EHPV8'+E6'-N:8L)>R065VF<%ANJBU6=&:+&6Y
M98+:H]*$BHRLF*ZDIER3+V1CWD)6<R R)U1KP#:$,[IEG"$#31I00#)SPAHA
M\QO%$$&8^)Q<KP IX_J&7!$FR',A:VW0.O'1)&!M^+O.[*(U&YXQ^U#O1R2(
M;DD8A,'+9D6NKV[^9O%-^OT9A/T9A(YV<HZVS6C5F;_ ..D9)XYQ>H;Q41Q
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MI.7AEA+3>(6!^7XM#"'JD^)%1?-B:O8?4$L#!!0    (  V"?U0R[FS?B ,
M ($.   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;,V748_:.!#'OXH5
MW4,K[6WB) 2H &EWT>KVU-ZA16T?3GTPR0#6.C:U'6B_?6TGF\ "(;WV85_
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M3Z2J2I,ZV5""HZA'41SUSD8=[W5&W HQ!VDC<8MFYE,$I W&7(OTJ6V'36_
MK[$YX*8[X*[MX6(&HJ,7) F'270^ TV-Q^U%?E8L&*V?>]6VL:;PXMYK#'Q3
M7W'7 GLQ\,<5,HSC:'!4F>Y.6.(P.JQAA[A-3<7M176^$5P)4_J[)*FI>'CP
M&I/4E$\\_%U)&A[7I[COVL++)!U;XB@)3O0/?^]SWQ[./A"YHER9MKLTTN"Z
M;Q(MR_-..=%BXTX "Z'-><(-U^:,"-(:F/M+(?3SQ!XJZE/GY =02P,$%
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MCWL4+%,T]L7 Z77>ZMYI1XUS_KFBQQ :OX#F%YI(EP._0?6\&OT+4$L#!!0
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MC5S&W<TZAON6(7B%80[9-0G]=R3P O^$?':^W'LI=[$:?4F"OB2!]0M?]2M
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MCF\?H[[)O+@[9<YY)I6HUCJ4:F#V&@CO9+Q)?C@X.^.D28C$_B#&*T7M2HA
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M+)[^\\<57M! .P-\OU3*[@9N@>K*-_P/4$L#!!0    (  V"?U25]C2O-04
M '(<   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+69:V_B.!2&_XJ%
M1JL9J32Q'6Y=BM3"[&RE:571=O>S2PQ$36+&=DJ[VA^_SJ5Q HD#V?*E)>&<
MU^=B/SCQ>,OXBUA3*L%;X(?BLK.6<G-A66*QI@$1YVQ#0_7-DO& 2'7)5Y;8
M<$K<Q"GP+63;?2L@7MB9C)-[]WPR9I'TO9#><R"B("#\_9KZ;'O9@9V/&W-O
MM9;Q#6LRWI 5?:#R:7//U965J[A>0$/AL1!PNKSL7,&+J3.('1*+OSRZ%87/
M($[EF;&7^.+&O>S8<434IPL92Q#U[Y5.J>_'2BJ.7YEH)Q\S=BQ^_E#_(TE>
M)?-,!)TR_V_/E>O+SK #7+HDD2_G;/LGS1+JQ7H+YHOD+]AFMG8'+"(A69 Y
MJP@"+TS_D[>L$ 4'V*]Q0)D#VG5P:AQPYH"31-/(DK1F1)+)F+,MX+&U4HL_
M)+5)O%4V7ABW\4%R]:VG_.3D!V/NUO-]0$(7W(22A"OOV:?@2@@JQ1FX4S.I
M"Q[4['$C=9LMZXR^SJ@DGB^^*?.GAQGX^N4;^ *\$#RN6224NAA;4@4<#VLM
MLN"NT^!037 0@5L6RK4 WT.7NF4!2V6:IXL^TKU&1L4979P##,\ LA&L"&AZ
MN+MM" ?GU<>)'J[1NPH8E]X_)"ZFI^M*DKI>& 9P\@&<9 "GS0!5#4GE!HE<
MC(#7"<*C$1Y;K\4J-5F58NWEL?:,Q?A)A;@ 5XM%%$0^D=0%)(L^7O"&8O3S
M ?K&8APS0%J-5*]7R+,[PG9_IQH55@,(G>IJ#/)@!^T[=P9"*JL"'NR% IW^
M<+ 3<(65,AI5!SS, QX:VW?'PFY63U79ALE6&F&4CS REV3Q*_*X$K^YG_]&
M@LWO,[#AS(T6$O"8UI43>K2?JSWLV?9.21K-2A%#6^/5-L9\<W#K,J'BHH((
MP[WF5=KU<%W[8.&7 !I#_2ZD%R3+XDG09>2#G^H'MIK:9J$;!>NE%WJ25A&V
MI7,Y*:230D:Y&7U56Y6-2NJ1+M8A\]GJW22LR0U/A&ZHV0T_&=YPG\MJ8</=
MN=YH5HY7\QN>".!0$QQ^-L(SP6*R7;5:=AE>9>8@N^8G#6J*0S/&J^8?^!?<
MJAD>1(&I)IJ[\%3@A9J\T(S>(]A@%H(0O%/"JURGK5S+VT#-963F<EU?R%M#
M7Y#F*8(GZ@O2>$-FO!W>EP8AV*_O2RO7<D(:JP@;Q:;)(P_E8$[]9$V+M;<Q
M2FN<(N<TQ$::@*CWN<3.]$H[:0?N;K>;K,K1:IBB_FEXC33^D!E_Q_,Z$RR!
M&,+![F]8E=FHL#,OQZM9BD[%4J19BCZ+I0U"T#:LV3:NY6=8S5)L9NDC)RX%
M=R2@ B3[<I#<"0A_,0Z@28K-)&V]<K$&*39#[.B5F^D5)V!O;Y8V&)5C+;PT
M,&\]6Z];K%F)S5O/X]<MWM]4=A':*TB%%>SW:BJBN8O-W#7-P(-V6UA#$YNA
MV9X06%,3FZEY."$:A$R$:.5:3DAC%0__5W\:=UU8TQ6/3M0?1P//,0/O\/XT
M"$%<WY]6KN6$-& =\T/WG)*/=ROSBC<I957-5 >=Z.VF1J%CWBX>_WX3[P%(
M/>;M8JK)JAQMX66L>0?:&MR.)J%C)N'QX';V-Y==U'/V2E)A!H=.74TT3YU3
M\=31/'4^BZ<-0H:'I#:>:3I6X?1&/?FLDD,M 18L"F5ZLI'?S0_.KI+CHIW[
MU_!BFAY_:9GT-.Z6\)47"N#3I9*TSP>JF3P]X$HO)-LD9T3/3*K'K^3CFBI"
M\]A ?;]D3'Y<Q /DQXR3_P!02P,$%     @ #8)_5*IIKW*6 @  X08  !D
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M;+U:WW/;-A)^;O\*C-J[:6<<BS]%J6=[QI'MBQ4G\<3)]:'3!XB")$Q(@@5
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M86$S)#%?$77 X@2E1*(B@\3Z!W,_:>_KD3MN$)M=UJJQVK-C]1WD0KQ!4Y(
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M$K;9/Q<9?!M!O^+LY3^[J+A%C]&+Y3)BNX_$Z$U2@@C;BP\O:4&B.'_T;%[
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MT=GUN=?/?[!E^MCR!QB'U[@.,CD-FJ+GX+6+<T]Q1\1RV87O 8SU9"#PQNZ
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M?LU:N]*BI,#7IM432G%&9?[]+5?+=G)LFJC:^E2WF:;U.=#D/>H#X>N8"I3
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M[Z":2=#M[6D\--IMC%JCOS6?L(<7;FQKDLI*F/JRMJ?MRW#O!N+>^0A?C'K
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M?(93JAHJ_VBJ$?=(5<:$)AQ2I RNAU@GJAH;U<;(C6ND:VFP+;MECI,6E#7
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M%#@BI WX_4HINW^@]]+-GT:N_@%02P,$%     @ #8)_5#,FAWQ7 @  . 4
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M .7;D1=ZNX47LLJ56?#'PS5>P0+4VWHN],QW7E)2 ).$,R0@&WD/X?TT# S
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M^PBMH)'ERU1EW"_;M7OC@&5;@ZINP>1!+63SSQ_;0!P DO$10-H"TI> X1'
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MXGGUN*)$%WAIH']?<*X.+V4'S=W]Z%]02P,$%     @ #8)_5.L0?2$"!@
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M<',O87!P+GAM;%!+ 0(4 Q0    (  V"?U3Y=,Z0[@   "L"   1
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M965T,BYX;6Q02P$"% ,4    "  -@G]4SC[@.S0$  !U%0  &
M    @('J%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M#8)_5 [\Y+$?!@  +!H  !@              ("!5!L  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    (  V"?U3V-=,'= <  *@E   8
M          " @:DA  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    "  -@G]4P:R99CT*  "-*P  &               @(%3*0  >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ #8)_5 O"@)5H&   ;T$
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M:&5E=#$Q+GAM;%!+ 0(4 Q0    (  V"?U3IN9+E8P(  #\%   9
M      " @1B9  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ #8)_5&Y*4K/6 P  +0D  !D              ("!LIL  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  -@G]4&?^HK @&  "5#@
M&0              @(&_GP  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    (  V"?U0J><!KN0(  /P%   9              " @?ZE  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ #8)_5(R!W5OF
M!   P0L  !D              ("![J@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    "  -@G]4V@R L0L/  !C)P  &0
M@($+K@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  V"
M?U3]6;V.PQD  #=@   9              " @4V]  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ #8)_5$L8%[RQ$0  -C<  !D
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M=#(S+GAM;%!+ 0(4 Q0    (  V"?U12-GTS208  ,X.   9
M  " @8X3 0!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M#8)_5,H-JRDF"@  5!L  !D              ("!#AH! 'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    "  -@G]4:88W_R0#  #0!@  &0
M            @(%K) $ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    (  V"?U1>2GJS C4  +:[   9              " @<8G 0!X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ #8)_5*/^%R.\!
M7PH  !D              ("!_UP! 'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    "  -@G]4RTIIR84"  !Z!0  &0              @('R
M80$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  V"?U2S
MJ^"^\0@  ,@>   9              " @:YD 0!X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ #8)_5&T\MM+1 @  V@4  !D
M     ("!UFT! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  V"?U1TX^[:KP(  )T%   9              "
M@39_ 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ #8)_
M5/SE1:!3 P  X 8  !D              ("!'((! 'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    "  -@G]4]%\@+EP%   O#0  &0
M        @(&FA0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   (  V"?U3YJ/V.8P0  / )   9              " @3F+ 0!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ #8)_5-9O6,)U!0  2PX
M !D              ("!TX\! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    "  -@G]4\(.N(=4#  #,"   &0              @(%_E0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  V"?U18VB +
M6 4  (<5   9              " @8N9 0!X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ #8)_5/E<USFE!0  "A<  !D
M ("!&I\! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  -
M@G]4$0938T4#   (#@  &0              @('VI $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (  V"?U2P8FM.A ,  +T-   9
M          " @7*H 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#
M%     @ #8)_5.=HM!( $0  .TL  !D              ("!+:P! 'AL+W=O
M<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  -@G]4)5H+(G4"  #R
M!0  &0              @(%DO0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM
M;%!+ 0(4 Q0    (  V"?U1XNXH"1P0  *02   9              " @1#
M 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ #8)_5#+N
M;-^( P  @0X  !D              ("!CL0! 'AL+W=O<FMS:&5E=',O<VAE
M970T.2YX;6Q02P$"% ,4    "  -@G]4J>Y P<L"  #2!@  &0
M    @(%-R $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M  V"?U1V)KA**@0  &H-   9              " @4_+ 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ #8)_5#EP=U$ "   K2T  !D
M             ("!L,\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    "  -@G]4/'H)>20%  #8$P  &0              @('GUP$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    (  V"?U2P@%J P@,
M +@.   9              " @4+= 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ #8)_5(H4U/;N @  VP@  !D              ("!
M.^$! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  -@G]4
M=U"[KGX"  "%!@  &0              @(%@Y $ >&PO=V]R:W-H965T<R]S
M:&5E=#4V+GAM;%!+ 0(4 Q0    (  V"?U1@^EV<9 0  ,T1   9
M      " @17G 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%
M  @ #8)_5+\\)4R@ @  H <  !D              ("!L.L! 'AL+W=O<FMS
M:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  -@G]4LE#'1:D"  !'!P
M&0              @(&'[@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+
M 0(4 Q0    (  V"?U1XM/)XH0,  /X-   9              " @6?Q 0!X
M;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ #8)_5)7V-*\U
M!0  <AP  !D              ("!/_4! 'AL+W=O<FMS:&5E=',O<VAE970V
M,2YX;6Q02P$"% ,4    "  -@G]4JFFO<I8"  #A!@  &0
M@(&K^@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (  V"
M?U1VUY]>6P(  -T%   9              " @7C] 0!X;"]W;W)K<VAE971S
M+W-H965T-C,N>&UL4$L! A0#%     @ #8)_5!##(XGW @  9P@  !D
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M=#8X+GAM;%!+ 0(4 Q0    (  V"?U1LBR\9.P,  $T-   9
M  " @<LA @!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @
M#8)_5&(0^6E- P  :P@  !D              ("!/24" 'AL+W=O<FMS:&5E
M=',O<VAE970W,"YX;6Q02P$"% ,4    "  -@G]4[@SVW.<)  !Q-   &0
M            @('!* ( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4
M Q0    (  V"?U3^:U):XP(  .4'   9              " @=\R @!X;"]W
M;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ #8)_5'\>M([I!
M]A0  !D              ("!^34" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX
M;6Q02P$"% ,4    "  -@G]4X7J=\-$"  #4!P  &0              @($9
M.P( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (  V"?U2A
M4YP<0@,  (@+   9              " @2$^ @!X;"]W;W)K<VAE971S+W-H
M965T-S4N>&UL4$L! A0#%     @ #8)_5,MT!6_V @  : D  !D
M     ("!FD$" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  V"?U0S)H=\5P(  #@%   9              "
M@=M4 @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ #8)_
M5+N-C=O9 @  QP@  !D              ("!:5<" 'AL+W=O<FMS:&5E=',O
M<VAE970X,BYX;6Q02P$"% ,4    "  -@G]4JD^+EU4#   U"P  &0
M        @(%Y6@( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0
M   (  V"?U1) H2X" 0  "H.   9              " @05> @!X;"]W;W)K
M<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ #8)_5#^:V?&D @  F@8
M !D              ("!1&(" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q0
M2P$"% ,4    "  -@G]4'7V-LXT#  "1"P  &0              @($?90(
M>&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    (  V"?U0&J"%$
ME (  % '   9              " @>-H @!X;"]W;W)K<VAE971S+W-H965T
M.#<N>&UL4$L! A0#%     @ #8)_5 +YJ+!&!0  QQ<  !D
M ("!KFL" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4    "  -
M@G]4ZQ!](0(&   T&P  &0              @($K<0( >&PO=V]R:W-H965T
M<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    (  V"?U1D#V#%XP(  #P(   9
M          " @61W @!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#
M%     @ #8)_5'^]M$XH P  %!,   T              ( !?GH" 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  -@G]4EXJ[',     3 @  "P
M    @ '1?0( 7W)E;',O+G)E;'-02P$"% ,4    "  -@G]4U!73?C,&  !I
M.P  #P              @ &Z?@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ #8)_5.;BI-"@ @  !34  !H              ( !&H4" 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #8)_5,* #&LZ @  :#,
M !,              ( !\H<" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ &( 8@#E&@  78H"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>344</ContextCount>
  <ElementCount>573</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>131</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Business Combinations and Disposals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals</Role>
      <ShortName>Business Combinations and Disposals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses</Role>
      <ShortName>Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Short-Term Borrowings - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedParty</Role>
      <ShortName>Short-Term Borrowings - Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - License and Distribution Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreements</Role>
      <ShortName>License and Distribution Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlans</Role>
      <ShortName>Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Business Combinations and Disposals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsTables</Role>
      <ShortName>Business Combinations and Disposals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureInventory</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesTables</Role>
      <ShortName>Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureEquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property and Equipment - Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails</Role>
      <ShortName>Property and Equipment - Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Business Combinations and Disposals - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Disposals - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Business Combinations and Disposals - Schedule of assets and liabilities were divested/written off (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails</Role>
      <ShortName>Business Combinations and Disposals - Schedule of assets and liabilities were divested/written off (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Aggregate Fair Values of the Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Aggregate Fair Values of the Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Convertible Note Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of Convertible Note Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Inventory - Schedule of Major Classes of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails</Role>
      <ShortName>Inventory - Schedule of Major Classes of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Prepaid Expenses - Schedule of Prepaid Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails</Role>
      <ShortName>Prepaid Expenses - Schedule of Prepaid Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Goodwill and Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Short-Term Borrowings - Related Party - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails</Role>
      <ShortName>Short-Term Borrowings - Related Party - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Payments under Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Equity - Summary of the Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails</Role>
      <ShortName>Equity - Summary of the Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Equity - Summary of the Warrants (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails</Role>
      <ShortName>Equity - Summary of the Warrants (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Stock-Based Compensation - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Product And Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Disaggregated Revenue by Product And Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Revenue Recognition - Additional Inforrmation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails</Role>
      <ShortName>Revenue Recognition - Additional Inforrmation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100800 - Disclosure - License and Distribution Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails</Role>
      <ShortName>License and Distribution Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Income Taxes - Schedule of Current and Deferred Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Current and Deferred Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Segment Information - Schedule of Financial Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Financial Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="celu-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>100900 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="celu-10k_20211231.htm">celu-10k_20211231.htm</File>
    <File>celu-20211231.xsd</File>
    <File>celu-20211231_cal.xml</File>
    <File>celu-20211231_def.xml</File>
    <File>celu-20211231_lab.xml</File>
    <File>celu-20211231_pre.xml</File>
    <File>celu-ex1020_128.htm</File>
    <File>celu-ex231_1187.htm</File>
    <File>celu-ex311_9.htm</File>
    <File>celu-ex312_7.htm</File>
    <File>celu-ex321_6.htm</File>
    <File>celu-ex322_8.htm</File>
    <File>celu-ex43_892.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gizttcucplmb000001.jpg</File>
    <File>gizttcucplmb000002.jpg</File>
    <File>gizttcucplmb000003.jpg</File>
    <File>gizttcucplmb000004.jpg</File>
    <File>gizttcucplmb000005.jpg</File>
    <File>gizttcucplmb000006.jpg</File>
    <File>gizttcucplmb000007.jpg</File>
    <File>gizttcucplmb000008.jpg</File>
    <File>gizttcucplmb000009.jpg</File>
    <File>gizttcucplmb000010.jpg</File>
    <File>gizttcucplmb000011.jpg</File>
    <File>gizttcucplmb000012.jpg</File>
    <File>gizttcucplmb000013.jpg</File>
    <File>gizttcucplmb000014.jpg</File>
    <File>gizttcucplmb000015.jpg</File>
    <File>gizttcucplmb000016.jpg</File>
    <File>gizttcucplmb000017.jpg</File>
    <File>gizttcucplmb000018.jpg</File>
    <File>gizttcucplmb000019.jpg</File>
    <File>gizttcucplmb000020.jpg</File>
    <File>gizttcucplmb000021.jpg</File>
    <File>gizttcucplmb000022.jpg</File>
    <File>gizttcucplmb000023.jpg</File>
    <File>gizttcucplmb000024.jpg</File>
    <File>gizttcucplmb000025.jpg</File>
    <File>gizttcucplmb000026.jpg</File>
    <File>gizttcucplmb000027.jpg</File>
    <File>gizttcucplmb000028.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="887">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>139
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "celu-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 344,
   "dts": {
    "calculationLink": {
     "local": [
      "celu-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "celu-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "celu-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "celu-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celu-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "celu-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 874,
   "entityCount": 1,
   "hidden": {
    "http://celularity.com/20211231": 25,
    "http://fasb.org/us-gaap/2021-01-31": 39,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 68
   },
   "keyCustom": 186,
   "keyStandard": 387,
   "memberCustom": 77,
   "memberStandard": 47,
   "nsprefix": "celu",
   "nsuri": "http://celularity.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Inventory",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureInventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:PrepaidExpensesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Prepaid Expenses",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses",
     "shortName": "Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:PrepaidExpensesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment, Net",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Short-Term Borrowings - Related Party",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedParty",
     "shortName": "Short-Term Borrowings - Related Party",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Commitments and Contingencies",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Equity",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Stock-Based Compensation",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Revenue Recognition",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:LicenseAndDistributionAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - License and Distribution Agreements",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreements",
     "shortName": "License and Distribution Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:LicenseAndDistributionAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Benefit Plans",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlans",
     "shortName": "Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Segment Information",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Related Party Transactions",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Subsequent Events",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Business Combinations and Disposals (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsTables",
     "shortName": "Business Combinations and Disposals (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Inventory (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "celu:PrepaidExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:ScheduleOfPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Prepaid Expenses (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesTables",
     "shortName": "Prepaid Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "celu:PrepaidExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:ScheduleOfPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Equity (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureEquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Income Taxes (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Segment Information (Tables)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Nature of Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20200101_20200630",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_celuSegment",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property and Equipment - Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails",
     "shortName": "Property and Equipment - Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "celu:BusinessCombinationsAndDisposalsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210716",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Business Combinations and Disposals - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
     "shortName": "Business Combinations and Disposals - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "celu:BusinessCombinationsAndDisposalsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockConversionBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20200806",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Business Combinations and Disposals - Schedule of assets and liabilities were divested/written off (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails",
     "shortName": "Business Combinations and Disposals - Schedule of assets and liabilities were divested/written off (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20200806",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:ConvertibleNoteReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:ConvertibleNoteReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:ContingentConsiderationObligation",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "celu:ContingentConsiderationObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:FairValueNetAssetsLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Aggregate Fair Values of the Warrant Liability (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Aggregate Fair Values of the Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "celu:StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20210716",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapClassOfWarrantOrRightAxis_celuSponsorsWarrantsMember_20210716",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Parenthetical) (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapStatementClassOfStockAxis_celuDragasacWarrantMember_20211231",
      "decimals": "2",
      "lang": null,
      "name": "celu:PercentageOfExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:FaceValueOfNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of Convertible Note Valuation Model (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of Convertible Note Valuation Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:FaceValueOfNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:InventoryRawMaterialsCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Inventory - Schedule of Major Classes of Inventories (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails",
     "shortName": "Inventory - Schedule of Major Classes of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:InventoryRawMaterialsCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfPrepaidExpensesTableTextBlock",
       "celu:PrepaidExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:PrepaidClinicalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Prepaid Expenses - Schedule of Prepaid Expenses (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails",
     "shortName": "Prepaid Expenses - Schedule of Prepaid Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfPrepaidExpensesTableTextBlock",
       "celu:PrepaidExpensesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:PrepaidClinicalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleLeasebackTransactionAccumulatedDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Parenthetical) (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleLeasebackTransactionAccumulatedDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Goodwill and Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "celu:GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfIntangibleAssetsNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "celu:ScheduleOfIntangibleAssetsNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:AccruedClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "celu:AccruedClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Short-Term Borrowings - Related Party - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails",
     "shortName": "Short-Term Borrowings - Related Party - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ShortTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapDebtInstrumentAxis_celuLoanAgreementMember_us-gaapLineOfCreditFacilityAxis_celuCVStarrCoIncMember_20210608",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Payments under Non-cancelable Operating Leases (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Payments under Non-cancelable Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Equity - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Equity - Summary of the Warrants (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
     "shortName": "Equity - Summary of the Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Equity - Summary of the Warrants (Parenthetical) (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
     "shortName": "Equity - Summary of the Warrants (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "celu:DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapStatementClassOfStockAxis_us-gaapCommonClassAMember_us-gaapStatementEquityComponentsAxis_celuDragasacWarrantMember_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210301_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Stock-Based Compensation - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Stock-Based Compensation - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapPlanNameAxis_celuTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Stock-Based Compensation - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210401_20210630",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Revenue Recognition - Schedule of Disaggregated Revenue by Product And Services (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
     "shortName": "Revenue Recognition - Schedule of Disaggregated Revenue by Product And Services (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails",
     "shortName": "Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Parenthetical) (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails",
     "shortName": "Revenue Recognition - Schedule of Changes in Deferred Revenue from Contract Liabilities (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_srtProductOrServiceAxis_us-gaapLicenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:PaymentPlansForCustomerToPayOverTimePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Revenue Recognition - Additional Inforrmation (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
     "shortName": "Revenue Recognition - Additional Inforrmation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:PaymentPlansForCustomerToPayOverTimePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "celu:IncentivePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - License and Distribution Agreements - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails",
     "shortName": "License and Distribution Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "celu:IncentivePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Benefit Plans - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails",
     "shortName": "Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Income Taxes - Schedule of Current and Deferred Tax Provision (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails",
     "shortName": "Income Taxes - Schedule of Current and Deferred Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Liabilities (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100850 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20200701_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "U_celuSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - Segment Information - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
     "shortName": "Segment Information - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100880 - Disclosure - Segment Information - Schedule of Financial Information by Segment (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails",
     "shortName": "Segment Information - Schedule of Financial Information by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100890 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_celuCURAFoundationMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:BusinessCombinationsAndDisposalsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Business Combinations and Disposals",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals",
     "shortName": "Business Combinations and Disposals",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "celu:BusinessCombinationsAndDisposalsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100900 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "celu-10k_20211231.htm",
      "contextRef": "C_0001752828_us-gaapBusinessAcquisitionAxis_celuLegacyCelularitysMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 131,
   "tag": {
    "celu_AccrualsForConstructionInProgress": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accruals for construction in progress.",
        "label": "Accruals For Construction In Progress",
        "terseLabel": "Accruals for construction in progress"
       }
      }
     },
     "localname": "AccrualsForConstructionInProgress",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expense.",
        "label": "Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expense"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpense",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AcquiredProductRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of acquired IPR&amp;D product rights.",
        "label": "Acquired Product Rights",
        "terseLabel": "Acquired IPR&amp;D product rights"
       }
      }
     },
     "localname": "AcquiredProductRights",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of warrants issued as repayment for working capital loans.",
        "label": "Aggregate Number Of Warrants Issued As Repayment For Working Capital Loans",
        "terseLabel": "Aggregate number of warrants issued to sponsor as repayment for working capital loans"
       }
      }
     },
     "localname": "AggregateNumberOfWarrantsIssuedAsRepaymentForWorkingCapitalLoans",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_AlliquaAPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliqua APA.",
        "label": "Alliqua A P A [Member]",
        "terseLabel": "Alliqua APA"
       }
      }
     },
     "localname": "AlliquaAPAMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AlphaFirstMergerSubIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha First Merger Sub, Incorporation.",
        "label": "Alpha First Merger Sub Incorporation [Member]",
        "terseLabel": "First Merger Sub"
       }
      }
     },
     "localname": "AlphaFirstMergerSubIncorporationMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AmendedAndRestatedDragasacWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated Dragasac warrant.",
        "label": "Amended And Restated Dragasac Warrants [Member]",
        "terseLabel": "Amended and Restated Dragasac Warrant"
       }
      }
     },
     "localname": "AmendedAndRestatedDragasacWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AmendedDragasacWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Dragasac warrant.",
        "label": "Amended Dragasac Warrants [Member]",
        "terseLabel": "Amended Dragasac Warrant"
       }
      }
     },
     "localname": "AmendedDragasacWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AmortizableIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortizable intangible assets.",
        "label": "Amortizable Intangible Assets [Abstract]",
        "terseLabel": "Amortizable intangible assets:"
       }
      }
     },
     "localname": "AmortizableIntangibleAssetsAbstract",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_AmortizationOfInventoryStepUp": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of inventory step-up.",
        "label": "Amortization Of Inventory Step Up",
        "terseLabel": "Amortization of inventory step-up"
       }
      }
     },
     "localname": "AmortizationOfInventoryStepUp",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AnnualFeePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual fee paid.",
        "label": "Annual Fee Paid",
        "terseLabel": "Annual fee paid"
       }
      }
     },
     "localname": "AnnualFeePaid",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AnnualMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual maintenance fee.",
        "label": "Annual Maintenance Fee",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "AnnualMaintenanceFee",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AnnualSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of annual sales.",
        "label": "Annual Sales",
        "terseLabel": "Annual sales"
       }
      }
     },
     "localname": "AnnualSales",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AnnualSalesNotExceed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Sales Not Exceed",
        "terseLabel": "Annual sales not exceed"
       }
      }
     },
     "localname": "AnnualSalesNotExceed",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AnthrogenesisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anthrogenesis.",
        "label": "Anthrogenesis [Member]",
        "terseLabel": "Anthrogenesis"
       }
      }
     },
     "localname": "AnthrogenesisMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AreaOfBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of building.",
        "label": "Area Of Building",
        "terseLabel": "Area of building"
       }
      }
     },
     "localname": "AreaOfBuilding",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "celu_AreaOfBuildings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of building.",
        "label": "Area Of Buildings",
        "terseLabel": "Area of building"
       }
      }
     },
     "localname": "AreaOfBuildings",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "celu_ArthrexAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arthrex agreement.",
        "label": "Arthrex Agreement [Member]",
        "terseLabel": "Arthrex Agreement"
       }
      }
     },
     "localname": "ArthrexAgreementMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AssetAcquisitionsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisitions.",
        "label": "Asset Acquisitions Policy [Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionsPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_AssetPurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of asset purchase agreement.",
        "label": "Asset Purchase Agreement Description",
        "terseLabel": "Asset purchase agreement, description"
       }
      }
     },
     "localname": "AssetPurchaseAgreementDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_AssetsDivestedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Divested",
        "label": "Assets Divested [Abstract]",
        "terseLabel": "Assets Divested"
       }
      }
     },
     "localname": "AssetsDivestedAbstract",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_AwardModificationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award modification expense.",
        "label": "Award Modification Expense",
        "terseLabel": "Award modification expense"
       }
      }
     },
     "localname": "AwardModificationExpense",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_AwardsWithMarketConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Awards with market conditions.",
        "label": "Awards With Market Conditions [Member]",
        "terseLabel": "Awards with Market Conditions"
       }
      }
     },
     "localname": "AwardsWithMarketConditionsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_AwardsWithServiceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Awards with service conditions.",
        "label": "Awards With Service Conditions [Member]",
        "terseLabel": "Awards with Service Conditions"
       }
      }
     },
     "localname": "AwardsWithServiceConditionsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_BiobankingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biobanking",
        "label": "Biobanking [Member]",
        "terseLabel": "Biobanking"
       }
      }
     },
     "localname": "BiobankingMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_BusinessAcquisitionTransactionCostsProceedsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition transaction costs proceeds, net.",
        "label": "Business Acquisition Transaction Costs Proceeds Net",
        "terseLabel": "Business acquisition transaction costs proceeds, net"
       }
      }
     },
     "localname": "BusinessAcquisitionTransactionCostsProceedsNet",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital.",
        "label": "Business Acquisition Transaction Costs Relating To Merger By Issuance Of Common Stock Offset Against Additional Paid In Capital",
        "terseLabel": "Business acquisition, transaction costs relating to merger by issuance of common stock offset against additional paid-in capital"
       }
      }
     },
     "localname": "BusinessAcquisitionTransactionCostsRelatingToMergerByIssuanceOfCommonStockOffsetAgainstAdditionalPaidInCapital",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_BusinessCombinationExchangeRatioOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination, exchange ratio of common stock.",
        "label": "Business Combination Exchange Ratio Of Common Stock",
        "terseLabel": "Each one Shares reflecting as exchange ratio in business combination"
       }
      }
     },
     "localname": "BusinessCombinationExchangeRatioOfCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celu_BusinessCombinationSharesExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination shares exchange ratio.",
        "label": "Business Combination Shares Exchange Ratio",
        "terseLabel": "Business combination, shares exchange ratio"
       }
      }
     },
     "localname": "BusinessCombinationSharesExchangeRatio",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "celu_BusinessCombinationSharesExchangeRatioDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination shares exchange ratio description.",
        "label": "Business Combination Shares Exchange Ratio Description",
        "terseLabel": "Business combination, shares exchange ratio description"
       }
      }
     },
     "localname": "BusinessCombinationSharesExchangeRatioDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_BusinessCombinationsAndDisposalsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations and disposals.",
        "label": "Business Combinations And Disposals [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAndDisposalsAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_BusinessCombinationsAndDisposalsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations and disposals disclosure.",
        "label": "Business Combinations And Disposals Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Disposals"
       }
      }
     },
     "localname": "BusinessCombinationsAndDisposalsDisclosureTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposals"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_BusinessCombinationsAndDisposalsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations and disposals.",
        "label": "Business Combinations And Disposals [Line Items]",
        "terseLabel": "Business Combinations and Disposals [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationsAndDisposalsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_COTAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COTA, Inc [Member]",
        "label": "C O T A Inc [Member]",
        "terseLabel": "COTA, Inc"
       }
      }
     },
     "localname": "COTAIncMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CTHBiosourcingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CTH Biosourcing LLC.",
        "label": "C T H Biosourcing L L C [Member]",
        "terseLabel": "CTH"
       }
      }
     },
     "localname": "CTHBiosourcingLLCMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CURAFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CURA Foundation [Member]",
        "label": "C U R A Foundation [Member]",
        "terseLabel": "CURA Foundation"
       }
      }
     },
     "localname": "CURAFoundationMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CVStarLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CV star loan.",
        "label": "C V Star Loan [Member]",
        "terseLabel": "CV Star Loan"
       }
      }
     },
     "localname": "CVStarLoanMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CVStarrCoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C.V. Starr &amp; Co., Inc.",
        "label": "C V Starr Co Inc [Member]",
        "terseLabel": "CV Starr"
       }
      }
     },
     "localname": "CVStarrCoIncMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CancellationOfTreasuryStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of treasury stock.",
        "label": "Cancellation Of Treasury Stock",
        "terseLabel": "Cancellation of treasury stock"
       }
      }
     },
     "localname": "CancellationOfTreasuryStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_CariCordIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CariCord incorporated.",
        "label": "Cari Cord Incorporated [Member]",
        "terseLabel": "CariCord"
       }
      }
     },
     "localname": "CariCordIncorporatedMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CariCordParticipatingShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CariCord participating shareholders.",
        "label": "Cari Cord Participating Shareholders [Member]",
        "terseLabel": "CariCord Participating Shareholders"
       }
      }
     },
     "localname": "CariCordParticipatingShareholdersMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CaricordMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caricord.",
        "label": "Caricord [Member]",
        "terseLabel": "Caricord"
       }
      }
     },
     "localname": "CaricordMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CashConsiderationPerMonth": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash consideration per month.",
        "label": "Cash Consideration Per Month",
        "terseLabel": "Cash consideration per month"
       }
      }
     },
     "localname": "CashConsiderationPerMonth",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_CashReceivedOnRecapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on recapitalization.",
        "label": "Cash Received On Recapitalization",
        "terseLabel": "Cash received on recapitalization"
       }
      }
     },
     "localname": "CashReceivedOnRecapitalization",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_CedarKnollsNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cedar Knolls New Jersey.",
        "label": "Cedar Knolls New Jersey [Member]",
        "terseLabel": "Cedar Knolls, New Jersey"
       }
      }
     },
     "localname": "CedarKnollsNewJerseyMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CellTherapyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cell Therapy",
        "label": "Cell Therapy [Member]",
        "terseLabel": "Cell Therapy"
       }
      }
     },
     "localname": "CellTherapyMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CelularityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Celularity.",
        "label": "Celularity [Member]",
        "terseLabel": "Celularity"
       }
      }
     },
     "localname": "CelularityMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_ChangeInFairValueOfContingentConsiderationLiability": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10170.0,
       "parentTag": "celu_OperatingIncomeCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of contingent consideration liability.",
        "label": "Change In Fair Value Of Contingent Consideration Liability",
        "terseLabel": "Change in fair value of contingent consideration liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsiderationLiability",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs captured in accounts payable and accrued expenses.",
        "label": "Change In P I P E S P A C Related Costs Captured In Accounts Payable And Accrued Expenses",
        "terseLabel": "Changes in PIPE/SPAC related costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ChangeInPIPESPACRelatedCostsCapturedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ClassOfWarrantExercisePriceDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant exercise price, description.",
        "label": "Class Of Warrant Exercise Price Description",
        "terseLabel": "Exercise price, description"
       }
      }
     },
     "localname": "ClassOfWarrantExercisePriceDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_ClassOfWarrantOrRightWarrantsExercisableForCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right warrants exercisable for cash.",
        "label": "Class Of Warrant Or Right Warrants Exercisable For Cash",
        "terseLabel": "Public warrants exercisable for cash"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsExercisableForCash",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_ClinicalAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones.",
        "label": "Clinical And Regulatory Milestones",
        "terseLabel": "Clinical and regulatory milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestones",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_CommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments.",
        "label": "Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "CommercialMilestonePayments",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitmentsand Contingencies Details [Line Items]",
        "terseLabel": "Commitments And Contingencies Details [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitmentsand Contingencies Details [Table]",
        "terseLabel": "Commitmentsand Contingencies Details [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_ConsiderationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration description.",
        "label": "Consideration Description",
        "terseLabel": "Total consideration, description"
       }
      }
     },
     "localname": "ConsiderationDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_ConsultingAgreementWithDoctorAndrewPecoraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreement with doctor Andrew Pecora.",
        "label": "Consulting Agreement With Doctor Andrew Pecora [Member]",
        "terseLabel": "Consulting Agreement with Dr. Andrew Pecora"
       }
      }
     },
     "localname": "ConsultingAgreementWithDoctorAndrewPecoraMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_ContingentConsiderationObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liability exceeding amount recognized Fair Value Measurements.",
        "label": "Contingent Consideration Obligation",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContingentConsiderationObligation",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ContingentValueRightIssuedForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value right issued for each share.",
        "label": "Contingent Value Right Issued For Each Share",
        "terseLabel": "Contingent value right issued for each share"
       }
      }
     },
     "localname": "ContingentValueRightIssuedForEachShare",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability increase decrease for contract from business combination and deferred revenue.",
        "label": "Contract With Customer Liability Increase Decrease For Contract From Business Combination And Deferred Revenue",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ContractedStoragePeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracted storage periods.",
        "label": "Contracted Storage Periods",
        "terseLabel": "Contracted storage periods"
       }
      }
     },
     "localname": "ContractedStoragePeriods",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_ConversionPricePerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price per share of common stock.",
        "label": "Conversion Price Per Share Of Common Stock",
        "terseLabel": "Conversion price per share of common stock"
       }
      }
     },
     "localname": "ConversionPricePerShareOfCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celu_ConvertibleNoteReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note receivable.",
        "label": "Convertible Note Receivable",
        "terseLabel": "Convertible note receivable"
       }
      }
     },
     "localname": "ConvertibleNoteReceivable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_CryoportSystemsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cryoport Systems, Inc [Member]",
        "label": "Cryoport Systems Inc [Member]",
        "terseLabel": "Cryoport Systems, Inc"
       }
      }
     },
     "localname": "CryoportSystemsIncMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "Another customer"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_DeferredTaxAssetsImputedInterestOnContingentPayments": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets imputed interest on contingent payments.",
        "label": "Deferred Tax Assets Imputed Interest On Contingent Payments",
        "terseLabel": "Imputed interest on contingent payments"
       }
      }
     },
     "localname": "DeferredTaxAssetsImputedInterestOnContingentPayments",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10130.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets legal fee capitalization and amortization.",
        "label": "Deferred Tax Assets Legal Fee Capitalization And Amortization",
        "terseLabel": "Legal fee capitalization and amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsLegalFeeCapitalizationAndAmortization",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DeferredTaxAssetsStartupCosts": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets startup costs.",
        "label": "Deferred Tax Assets Startup Costs",
        "terseLabel": "Startup costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartupCosts",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research and development.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research And Development",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DeferredTaxAssetsUnicap": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unicap.",
        "label": "Deferred Tax Assets Unicap",
        "terseLabel": "Unicap"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnicap",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DeferredTaxLiabilitiesInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities in-process research and development.",
        "label": "Deferred Tax Liabilities In Process Research And Development",
        "negatedLabel": "In-process research and development"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DegenerativeDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Degenerative Disease",
        "label": "Degenerative Disease [Member]",
        "terseLabel": "Degenerative Disease"
       }
      }
     },
     "localname": "DegenerativeDiseaseMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_DescriptionOfExercisableTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of various exercisable terms.",
        "label": "Description Of Exercisable Terms",
        "terseLabel": "Description of exercisable terms"
       }
      }
     },
     "localname": "DescriptionOfExercisableTerms",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description about exercise price and number of shares of common stock.",
        "label": "Description Of Exercise Price And Number Of Shares Of Common Stock",
        "terseLabel": "Description of exercise price"
       }
      }
     },
     "localname": "DescriptionOfExercisePriceAndNumberOfSharesOfCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Organization and Business Operations (Details) [Line Items]",
        "label": "Description Of Organization And Business Operations Details [Line Items]",
        "terseLabel": "Description Of Organization And Business Operations Details [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfOrganizationAndBusinessOperationsDetailsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_DescriptionOfOrganizationAndBusinessOperationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Organization and Business Operations (Details) [Table]",
        "label": "Description Of Organization And Business Operations Details [Table]",
        "terseLabel": "Description Of Organization And Business Operations Details [Table]"
       }
      }
     },
     "localname": "DescriptionOfOrganizationAndBusinessOperationsDetailsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_DescriptionOfWarrantCallProvision": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of warrant call provision.",
        "label": "Description Of Warrant Call Provision",
        "terseLabel": "Description of call provision"
       }
      }
     },
     "localname": "DescriptionOfWarrantCallProvision",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_DiscountPercentagePaymentForInvoicesWithinTenDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount percentage, payment for Invoices within ten days.",
        "label": "Discount Percentage Payment For Invoices Within Ten Days",
        "terseLabel": "Discount percentage, payment for invoices within ten days"
       }
      }
     },
     "localname": "DiscountPercentagePaymentForInvoicesWithinTenDays",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation discount rate of discounted cash flow.",
        "label": "Disposal Group Including Discontinued Operation Discount Rate Of Discounted Cash Flow",
        "terseLabel": "Discount rate of discounted cash flow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDiscountRateOfDiscountedCashFlow",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation long term growth rate of discounted cash flow.",
        "label": "Disposal Group Including Discontinued Operation Long Term Growth Rate Of Discounted Cash Flow",
        "terseLabel": "Long term growth rate of discounted cash flow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermGrowthRateOfDiscountedCashFlow",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_DisposalGroupIncludingDiscontinuedOperationProfessionalFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation professional fees.",
        "label": "Disposal Group Including Discontinued Operation Professional Fees",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationProfessionalFees",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation tax rate of discounted cash flow.",
        "label": "Disposal Group Including Discontinued Operation Tax Rate Of Discounted Cash Flow",
        "terseLabel": "Tax rate of discounted cash flow"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTaxRateOfDiscountedCashFlow",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_DragasacWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragasac warrant.",
        "label": "Dragasac Warrant [Member]",
        "terseLabel": "Dragasac Warrant"
       }
      }
     },
     "localname": "DragasacWarrantMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_DragasacWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dragasac warrant.",
        "label": "Dragasac Warrants [Member]",
        "terseLabel": "Dragasac Warrant"
       }
      }
     },
     "localname": "DragasacWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation interest accretion expense.",
        "label": "Effective Income Tax Rate Reconciliation Interest Accretion Expense",
        "terseLabel": "Interest accretion expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestAccretionExpense",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation mark to market warrant.",
        "label": "Effective Income Tax Rate Reconciliation Mark To Market Warrant",
        "terseLabel": "Mark to market warrant"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_EmergingGrowthCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its emerging growth company.",
        "label": "Emerging Growth Company Policy [Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_EmploymentOfImmediateFamilyMemberMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment of an immediate family member.",
        "label": "Employment Of Immediate Family Member [Member]",
        "terseLabel": "Employment of an Immediate Family Member"
       }
      }
     },
     "localname": "EmploymentOfImmediateFamilyMemberMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_EquipmentEvaluationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment evaluation period.",
        "label": "Equipment Evaluation Period",
        "terseLabel": "Equipment evaluation period"
       }
      }
     },
     "localname": "EquipmentEvaluationPeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of shares issued under legal settlement agreement.",
        "label": "Estimated Fair Value Of Shares Issued Under Legal Settlement Agreement",
        "terseLabel": "Estimated fair value of shares issued in settlement agreement"
       }
      }
     },
     "localname": "EstimatedFairValueOfSharesIssuedUnderLegalSettlementAgreement",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_EvolutionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolution agreement.",
        "label": "Evolution Agreement [Member]",
        "terseLabel": "Evolution Agreement"
       }
      }
     },
     "localname": "EvolutionAgreementMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_ExpenseRelatedToPerformanceAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to the performance awards.",
        "label": "Expense Related To Performance Awards",
        "terseLabel": "Expense related to performance awards"
       }
      }
     },
     "localname": "ExpenseRelatedToPerformanceAwards",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FaceValueOfNotesReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of face value of notes receivable.",
        "label": "Face Value Of Notes Receivable",
        "terseLabel": "Face value"
       }
      }
     },
     "localname": "FaceValueOfNotesReceivable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FairValueNetAssetsLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value Net Assets Liability",
        "periodEndLabel": "Fair value, Ending Balance",
        "periodStartLabel": "Fair value, Beginning Balance",
        "terseLabel": "Fair value of the warrant liability"
       }
      }
     },
     "localname": "FairValueNetAssetsLiability",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FairValueOfConvertiblePromissoryNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the convertible promissory note.",
        "label": "Fair Value Of Convertible Promissory Note",
        "terseLabel": "Fair value of convertible promissory note"
       }
      }
     },
     "localname": "FairValueOfConvertiblePromissoryNote",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Financial Assets and Liabilities (Tables) [Line Items]",
        "label": "Fair Value Of Financial Assets And Liabilities Tables [Line Items]",
        "terseLabel": "Fair Value Of Financial Assets And Liabilities Tables [Line Items]"
       }
      }
     },
     "localname": "FairValueOfFinancialAssetsAndLiabilitiesTablesLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_FairValueOfFinancialAssetsAndLiabilitiesTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Financial Assets and Liabilities (Tables) [Table]",
        "label": "Fair Value Of Financial Assets And Liabilities Tables [Table]",
        "terseLabel": "Fair Value Of Financial Assets And Liabilities Tables [Table]"
       }
      }
     },
     "localname": "FairValueOfFinancialAssetsAndLiabilitiesTablesTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_FairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants.",
        "label": "Fair Value Of Warrants",
        "positiveTerseLabel": "Fair value of warrants",
        "terseLabel": "Fair Value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Fair value of warrants issued in connection with Series B preferred stock sale.",
        "label": "Fair Value Of Warrants Issued In Connection With Serie B Preferred Stock Sale",
        "terseLabel": "Fair value of warrants issued in connection with Series B preferred stock sale"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedInConnectionWithSerieBPreferredStockSale",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FairValuesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock.",
        "label": "Fair Values Of Common Stock",
        "terseLabel": "Fair value of common stock"
       }
      }
     },
     "localname": "FairValuesOfCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celu_FinancingObligationsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing obligations current.",
        "label": "Financing Obligations Current",
        "terseLabel": "Current portion of financing obligation"
       }
      }
     },
     "localname": "FinancingObligationsCurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FinancingObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing obligations noncurrent.",
        "label": "Financing Obligations Noncurrent",
        "terseLabel": "Financing obligations"
       }
      }
     },
     "localname": "FinancingObligationsNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_FlorhamParkNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florham Park New Jersey.",
        "label": "Florham Park New Jersey [Member]",
        "terseLabel": "Florham Park, New Jersey"
       }
      }
     },
     "localname": "FlorhamParkNewJerseyMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_GXAcquisitionCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GX Acquisition Corp [Member]",
        "label": "G X Acquisition Corp [Member]",
        "terseLabel": "Gx Acquisition Corp."
       }
      }
     },
     "localname": "GXAcquisitionCorpMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_GXSponsorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GX sponsor warrants.",
        "label": "G X Sponsor Warrants [Member]",
        "terseLabel": "G X Sponsor Warrants"
       }
      }
     },
     "localname": "GXSponsorWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_GXTrustAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GX Trust Account.",
        "label": "G X Trust Account [Member]",
        "terseLabel": "GX Trust Account"
       }
      }
     },
     "localname": "GXTrustAccountMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_GXWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GX Warrants.",
        "label": "G X Warrants [Member]",
        "terseLabel": "GX Warrants"
       }
      }
     },
     "localname": "GXWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_GainLossRecognizedInEarningsFromChangeInFairValues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) recognized in earnings from change in fair values.",
        "label": "Gain Loss Recognized In Earnings From Change In Fair Values",
        "terseLabel": "Gain (Loss) recognized in earnings from change in fair value"
       }
      }
     },
     "localname": "GainLossRecognizedInEarningsFromChangeInFairValues",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill derecognition of goodwill related to sale of UltraMIST business.",
        "label": "Goodwill Derecognition Of Goodwill Related To Sale Of Ultra M I S T Business",
        "negatedLabel": "Derecognition of goodwill related to sale of UltraMIST business"
       }
      }
     },
     "localname": "GoodwillDerecognitionOfGoodwillRelatedToSaleOfUltraMISTBusiness",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government grants.",
        "label": "Government Grants Policy [Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_HLICellularTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HLI Cellular Therapeutics,LLC.",
        "label": "H L I Cellular Therapeutics L L C [Member]",
        "terseLabel": "HLI Cellular Therapeutics,LLC"
       }
      }
     },
     "localname": "HLICellularTherapeuticsLLCMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_HLICellularTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HLICellularTherapeuticsMember",
        "label": "H L I Cellular Therapeutics [Member]",
        "terseLabel": "HLI Cellular Therapeutics, LLC"
       }
      }
     },
     "localname": "HLICellularTherapeuticsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_IncentivePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive payment.",
        "label": "Incentive Payment",
        "terseLabel": "Incentive payment"
       }
      }
     },
     "localname": "IncentivePayment",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_IncomeExpenseRelatedToWarrantLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income expense related to warrant liabilities.",
        "label": "Income Expense Related To Warrant Liabilities",
        "negatedLabel": "Income (expense) related to warrant liabilities"
       }
      }
     },
     "localname": "IncomeExpenseRelatedToWarrantLiabilities",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_IndefiniteLivedIntangibleAssetsAmortizationMethod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets amortization method.",
        "label": "Indefinite Lived Intangible Assets Amortization Method",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsAmortizationMethod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_IndirectExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of indirect expenses.",
        "label": "Indirect Expenses",
        "terseLabel": "Indirect expenses"
       }
      }
     },
     "localname": "IndirectExpenses",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InitialMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial monthly base rent.",
        "label": "Initial Monthly Base Rent",
        "terseLabel": "Initial monthly base rent"
       }
      }
     },
     "localname": "InitialMonthlyBaseRent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InventoryFinishedGoodsCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails": {
       "order": 10050.0,
       "parentTag": "celu_InventoryGrossCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory finished goods current and noncurrent.",
        "label": "Inventory Finished Goods Current And Noncurrent",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsCurrentAndNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InventoryGrossCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails": {
       "order": 10010.0,
       "parentTag": "celu_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, gross current and noncurrent.",
        "label": "Inventory Gross Current And Noncurrent",
        "totalLabel": "Inventory, gross"
       }
      }
     },
     "localname": "InventoryGrossCurrentAndNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InventoryNetCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent.",
        "label": "Inventory Net Current And Noncurrent",
        "totalLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InventoryRawMaterialsCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails": {
       "order": 10030.0,
       "parentTag": "celu_InventoryGrossCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory raw materials current and noncurrent.",
        "label": "Inventory Raw Materials Current And Noncurrent",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsCurrentAndNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InventoryReserveCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails": {
       "order": 10020.0,
       "parentTag": "celu_InventoryNetCurrentAndNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory reserve current and noncurrent.",
        "label": "Inventory Reserve Current And Noncurrent",
        "negatedLabel": "Less: inventory reserves"
       }
      }
     },
     "localname": "InventoryReserveCurrentAndNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_InventoryWorkInProgressCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails": {
       "order": 10040.0,
       "parentTag": "celu_InventoryGrossCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory work in progress current and noncurrent.",
        "label": "Inventory Work In Progress Current And Noncurrent",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProgressCurrentAndNoncurrent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_IssuanceOfCommonStockAsPaymentForRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock as payment for related costs.",
        "label": "Issuance Of Common Stock As Payment For Related Costs",
        "terseLabel": "Issuance of common stock as payment for PIPE/merger related costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAsPaymentForRelatedCosts",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B convertible preferred stock in connection with CariCord acquisition.",
        "label": "Issuance Of Series B Convertible Preferred Stock In Connection With Caricord Acquisition",
        "terseLabel": "Issuance of Series B convertible preferred stock in connection with CariCord acquisition"
       }
      }
     },
     "localname": "IssuanceOfSeriesBConvertiblePreferredStockInConnectionWithCaricordAcquisition",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_IssuanceOfWarrantsAtEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of warrants at estimated fair value.",
        "label": "Issuance Of Warrants At Estimated Fair Value",
        "terseLabel": "Issuance of warrants at estimated fair value"
       }
      }
     },
     "localname": "IssuanceOfWarrantsAtEstimatedFairValue",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_LLCAndAnthrogenesisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LLCAndAnthrogenesisMember",
        "label": "L L C And Anthrogenesis [Member]",
        "terseLabel": "Anthrogenesis"
       }
      }
     },
     "localname": "LLCAndAnthrogenesisMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_LaboratoryAndProductionEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and production equipment.",
        "label": "Laboratory And Production Equipment [Member]",
        "terseLabel": "Laboratory and Production Equipment"
       }
      }
     },
     "localname": "LaboratoryAndProductionEquipmentMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_LegacyCelularitysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy Celularity.",
        "label": "Legacy Celularitys [Member]",
        "terseLabel": "Legacy Celularity"
       }
      }
     },
     "localname": "LegacyCelularitysMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_LegacyGXWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legacy GX warrants.",
        "label": "Legacy G X Warrant [Member]",
        "terseLabel": "Legacy GX Warrants"
       }
      }
     },
     "localname": "LegacyGXWarrantMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_LessAccumulatedAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less accumulated amortization.",
        "label": "Less Accumulated Amortization [Abstract]",
        "terseLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "LessAccumulatedAmortizationAbstract",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_LicenseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Description",
        "terseLabel": "License agreement, description"
       }
      }
     },
     "localname": "LicenseAgreementDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "Sirion License"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_LicenseAgreementNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement notice period.",
        "label": "License Agreement Notice Period",
        "terseLabel": "Notice period"
       }
      }
     },
     "localname": "LicenseAgreementNoticePeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_LicenseAndDistributionAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Distribution Agreements [Abstract]",
        "label": "License And Distribution Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndDistributionAgreementsAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_LicenseAndDistributionAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and distribution agreements.",
        "label": "License And Distribution Agreements [Line Items]",
        "terseLabel": "License And Distribution Agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndDistributionAgreementsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_LicenseAndDistributionAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and distribution agreements.",
        "label": "License And Distribution Agreements [Table]",
        "terseLabel": "License And Distribution Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndDistributionAgreementsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_LicenseAndDistributionAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Distribution Agreements",
        "label": "License And Distribution Agreements [Text Block]",
        "terseLabel": "License and Distribution Agreements"
       }
      }
     },
     "localname": "LicenseAndDistributionAgreementsTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_LicenseArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License arrangement term.",
        "label": "License Arrangement Term",
        "terseLabel": "License arrangement term"
       }
      }
     },
     "localname": "LicenseArrangementTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_LicenseRoyaltyAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License, Royalty And Other.",
        "label": "License Royalty And Other [Member]",
        "terseLabel": "License, Royalty and Other"
       }
      }
     },
     "localname": "LicenseRoyaltyAndOtherMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_LicensingArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing arrangement term.",
        "label": "Licensing Arrangement Term",
        "terseLabel": "Licensing arrangement term"
       }
      }
     },
     "localname": "LicensingArrangementTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_LoanAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan agreement.",
        "label": "Loan Agreement",
        "terseLabel": "Loan agreement"
       }
      }
     },
     "localname": "LoanAgreement",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan agreement.",
        "label": "Loan Agreement [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_MISTUltraMISTBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MIST Ultra MIST business.",
        "label": "M I S T Ultra M I S T Business [Member]",
        "terseLabel": "M I S T Ultra M I S T Business"
       }
      }
     },
     "localname": "MISTUltraMISTBusinessMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_MachineryEquipmentAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Machinery, equipment and fixtures.",
        "label": "Machinery Equipment And Fixtures [Member]",
        "terseLabel": "Machinery, Equipment and Fixtures"
       }
      }
     },
     "localname": "MachineryEquipmentAndFixturesMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_March2020SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March2020 Series B Warrants [Member]",
        "terseLabel": "March 2020 Series B Warrants"
       }
      }
     },
     "localname": "March2020SeriesBWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_MasterSubscriptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master subscription agreement.",
        "label": "Master Subscription Agreement [Member]",
        "terseLabel": "Master Subscription Agreement"
       }
      }
     },
     "localname": "MasterSubscriptionAgreementMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_MaterialBreachContractTerminatedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Material breach, contract terminated term.",
        "label": "Material Breach Contract Terminated Term",
        "terseLabel": "Material breach, contract terminated term"
       }
      }
     },
     "localname": "MaterialBreachContractTerminatedTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with the tax authority.",
        "label": "Minimum Percentage Of Recognized Tax Benefit Likelihood Of Being Realized Upon Ultimate Settlement With Tax Authority",
        "terseLabel": "Minimum percentage of recognized tax benefit likelihood of being realized upon ultimate settlement with the tax authority"
       }
      }
     },
     "localname": "MinimumPercentageOfRecognizedTaxBenefitLikelihoodOfBeingRealizedUponUltimateSettlementWithTaxAuthority",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_MinimumWrittenNoticePeriodForRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum written notice period for redemption.",
        "label": "Minimum Written Notice Period For Redemption",
        "terseLabel": "Minimum prior written notice period for redemption"
       }
      }
     },
     "localname": "MinimumWrittenNoticePeriodForRedemption",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_MrPecoraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mr.Pecora.",
        "label": "Mr Pecora [Member]",
        "terseLabel": "Mr. Pecora"
       }
      }
     },
     "localname": "MrPecoraMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_MsHariniMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ms.Harini.",
        "label": "Ms Harini [Member]",
        "terseLabel": "Ms. Harini"
       }
      }
     },
     "localname": "MsHariniMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating losses and unused research and development tax credits sold.",
        "label": "Net Operating Losses And Unused Research And Development Tax Credits Sold",
        "terseLabel": "Net operating losses and unused R&amp;D tax credits sold"
       }
      }
     },
     "localname": "NetOperatingLossesAndUnusedResearchAndDevelopmentTaxCreditsSold",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_NonAmortizedIntangibleAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Amortized intangible assets.",
        "label": "Non Amortized Intangible Assets [Abstract]",
        "terseLabel": "Non-amortized intangible assets"
       }
      }
     },
     "localname": "NonAmortizedIntangibleAssetsAbstract",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_NonCashAssetsAcquiredFromMerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash assets acquired from merger.",
        "label": "Non Cash Assets Acquired From Merger",
        "terseLabel": "Non-cash assets acquired from the merger"
       }
      }
     },
     "localname": "NonCashAssetsAcquiredFromMerger",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_NonqualifiedStockOptionToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonqualified stock option to purchase shares of common stock.",
        "label": "Nonqualified Stock Option To Purchase Shares Of Common Stock",
        "terseLabel": "Nonqualified stock option to purchase shares of common stock"
       }
      }
     },
     "localname": "NonqualifiedStockOptionToPurchaseSharesOfCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares to be issued if certain targets are met under settlement agreement.",
        "label": "Number Of Additional Shares To Be Issued If Certain Targets Are Met Under Settlement Agreement",
        "terseLabel": "Number of additional shares to be issued if certain targets are met under settlement agreement"
       }
      }
     },
     "localname": "NumberOfAdditionalSharesToBeIssuedIfCertainTargetsAreMetUnderSettlementAgreement",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_NumberOfBusinessSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business segments.",
        "label": "Number Of Business Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfBusinessSegments",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "celu_NumberOfClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical trials.",
        "label": "Number Of Clinical Trials",
        "terseLabel": "Number of clinical trials"
       }
      }
     },
     "localname": "NumberOfClinicalTrials",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "celu_NumberOfSharesHolding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares holding.",
        "label": "Number Of Shares Holding",
        "terseLabel": "Number of shares holding"
       }
      }
     },
     "localname": "NumberOfSharesHolding",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_NumberOfSharesIssuedInLegalSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in legal settlement agreement.",
        "label": "Number Of Shares Issued In Legal Settlement Agreement",
        "terseLabel": "Number of shares issued in legal settlement agreement"
       }
      }
     },
     "localname": "NumberOfSharesIssuedInLegalSettlementAgreement",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_NumberOfSharesRequiredToBeOutstandingForVoting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares required to be outstanding for voting.",
        "label": "Number Of Shares Required To Be Outstanding For Voting",
        "terseLabel": "Number of shares required to be outstanding for voting"
       }
      }
     },
     "localname": "NumberOfSharesRequiredToBeOutstandingForVoting",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_NumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Number Of Warrants Issued",
        "terseLabel": "Number of warrants issued to the investors"
       }
      }
     },
     "localname": "NumberOfWarrantsIssued",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory space.",
        "label": "Office And Laboratory Space [Member]",
        "terseLabel": "Office and Laboratory Space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_OfficeManufacturingAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office manufacturing and laboratory space.",
        "label": "Office Manufacturing And Laboratory Space [Member]",
        "terseLabel": "Office, Manufacturing and Laboratory Space"
       }
      }
     },
     "localname": "OfficeManufacturingAndLaboratorySpaceMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_OneCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One customer.",
        "label": "One Customer [Member]",
        "terseLabel": "One Customer"
       }
      }
     },
     "localname": "OneCustomerMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_OperatingIncomeCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating income costs and expenses.",
        "label": "Operating Income Costs And Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingIncomeCostsAndExpenses",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_OperatingLeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease commencement date.",
        "label": "Operating Lease Commencement Date",
        "terseLabel": "Operating lease commencement date"
       }
      }
     },
     "localname": "OperatingLeaseCommencementDate",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "celu_OperatingLeaseExpiryYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiry year.",
        "label": "Operating Lease Expiry Year",
        "terseLabel": "Operating lease expiry year"
       }
      }
     },
     "localname": "OperatingLeaseExpiryYear",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "celu_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "celu_OptionToPurchaseSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase shares of common stock.",
        "label": "Option To Purchase Shares Of Common Stock",
        "terseLabel": "Option to purchase shares of common stock"
       }
      }
     },
     "localname": "OptionToPurchaseSharesOfCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_OptionToRenewLeaseTermPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to renew lease term period.",
        "label": "Option To Renew Lease Term Period",
        "terseLabel": "Option to renew lease term period"
       }
      }
     },
     "localname": "OptionToRenewLeaseTermPeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_OtherNonoperatingIncomeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10090.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income expenses.",
        "label": "Other Nonoperating Income Expenses",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenses",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PalantirTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palantir Technologies, Inc.",
        "label": "Palantir Technologies Inc [Member]",
        "terseLabel": "Palantir",
        "verboseLabel": "Palantir Technologies Inc"
       }
      }
     },
     "localname": "PalantirTechnologiesIncMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_PaymentForMonth": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for month.",
        "label": "Payment For Month",
        "terseLabel": "Payment for month"
       }
      }
     },
     "localname": "PaymentForMonth",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PaymentPlansForCustomerToPayOverTimePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment plans for customer to pay over time period.",
        "label": "Payment Plans For Customer To Pay Over Time Period",
        "terseLabel": "Payment plans for customer to pay over time period"
       }
      }
     },
     "localname": "PaymentPlansForCustomerToPayOverTimePeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_PaymentSubscriptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment subscription period.",
        "label": "Payment Subscription Period",
        "terseLabel": "Payment subscription period"
       }
      }
     },
     "localname": "PaymentSubscriptionPeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_PaymentTermNet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment term, net.",
        "label": "Payment Term Net",
        "terseLabel": "Payment term, net"
       }
      }
     },
     "localname": "PaymentTermNet",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_PaymentsForMasterSubscriptionAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for master subscription agreement.",
        "label": "Payments For Master Subscription Agreement",
        "terseLabel": "Payments for master subscription agreement"
       }
      }
     },
     "localname": "PaymentsForMasterSubscriptionAgreement",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PaymentsToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to related party.",
        "label": "Payments To Related Party",
        "terseLabel": "Amount paid"
       }
      }
     },
     "localname": "PaymentsToRelatedParty",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PercentageIncreaseInBaseAnnualRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increase in base annual rent.",
        "label": "Percentage Increase In Base Annual Rent",
        "terseLabel": "Percentage increase in base annual rent"
       }
      }
     },
     "localname": "PercentageIncreaseInBaseAnnualRent",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_PercentageOfCouponRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coupon rate is the rate of interest paid by bond issuers on the bond\u2019s face value.",
        "label": "Percentage Of Coupon Rate",
        "terseLabel": "Coupon rate"
       }
      }
     },
     "localname": "PercentageOfCouponRate",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_PercentageOfExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of exercise price.",
        "label": "Percentage Of Exercise Price",
        "terseLabel": "Percentage of exercise price"
       }
      }
     },
     "localname": "PercentageOfExercisePrice",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payment upon receipt and acceptance of purchase order.",
        "label": "Percentage Of Payment Upon Receipt And Acceptance Of Purchase Order",
        "terseLabel": "Percentage of payment upon receipt and acceptance of purchase order"
       }
      }
     },
     "localname": "PercentageOfPaymentUponReceiptAndAcceptanceOfPurchaseOrder",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_PercentageOfSharesRequiredForVoting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares required for voting.",
        "label": "Percentage Of Shares Required For Voting",
        "terseLabel": "Percentage of shares required for voting"
       }
      }
     },
     "localname": "PercentageOfSharesRequiredForVoting",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_PreferredStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants.",
        "label": "Preferred Stock Warrants",
        "terseLabel": "Preferred stock warrants"
       }
      }
     },
     "localname": "PreferredStockWarrants",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PreferredStockWarrantsLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants liabilities.",
        "label": "Preferred Stock Warrants Liabilities Policy [Text Block]",
        "terseLabel": "Preferred Stock Warrants Liabilities"
       }
      }
     },
     "localname": "PreferredStockWarrantsLiabilitiesPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_PrepaidClinicalExpense": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid clinical expenses.",
        "label": "Prepaid Clinical Expense",
        "terseLabel": "Prepaid clinical expenses"
       }
      }
     },
     "localname": "PrepaidClinicalExpense",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PrepaidExpensesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses.",
        "label": "Prepaid Expenses Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "PrepaidExpensesDisclosureTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ProceedsFromInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from investment.",
        "label": "Proceeds From Investment",
        "terseLabel": "Proceeds from Palantir investment"
       }
      }
     },
     "localname": "ProceedsFromInvestment",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs.",
        "label": "Proceeds From Issuance Of Series B Redeemable Convertible Preferred Stock And Warrants Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of Series B redeemable convertible preferred stock and warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeriesBRedeemableConvertiblePreferredStockAndWarrantsNetOfIssuanceCosts",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ProceedsFromIssuanceOfWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds From Issuance Of Warrant",
        "terseLabel": "Issuance of warrant at fair value"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrant",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ProceedsFromPromissoryNote": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from promissory note.",
        "label": "Proceeds From Promissory Note",
        "terseLabel": "Proceeds from promissory note"
       }
      }
     },
     "localname": "ProceedsFromPromissoryNote",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PromissoryNotesReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10320.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of promissory notes receivable.",
        "label": "Promissory Notes Receivable",
        "terseLabel": "Notes receivable"
       }
      }
     },
     "localname": "PromissoryNotesReceivable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_PublicEquityFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public equity financing.",
        "label": "Public Equity Financing [Member]",
        "terseLabel": "PIPE Investors"
       }
      }
     },
     "localname": "PublicEquityFinancingMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_PublicWarrantsCallPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public warrants call price.",
        "label": "Public Warrants Call Price",
        "terseLabel": "Call price of public warrants"
       }
      }
     },
     "localname": "PublicWarrantsCallPrice",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celu_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public warrants.",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public Warrants"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_ReacquiredRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reacquired rights.",
        "label": "Reacquired Rights [Member]",
        "terseLabel": "Reacquired Rights"
       }
      }
     },
     "localname": "ReacquiredRightsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_RecapitalizationFromMerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization from merger.",
        "label": "Recapitalization From Merger",
        "terseLabel": "Recapitalization from merger"
       }
      }
     },
     "localname": "RecapitalizationFromMerger",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization net of redemptions, equity issuance costs and merger costs additional paid in capital.",
        "label": "Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Additional Paid In Capital",
        "terseLabel": "Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs"
       }
      }
     },
     "localname": "RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsAdditionalPaidInCapital",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock shares.",
        "label": "Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Redeemable Convertible Preferred Stock Shares",
        "negatedLabel": "Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock (in Shares)"
       }
      }
     },
     "localname": "RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockShares",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock value.",
        "label": "Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Redeemable Convertible Preferred Stock Value",
        "terseLabel": "Recapitalization net of redemptions, equity issuance costs and merger costs redeemable convertible preferred stock"
       }
      }
     },
     "localname": "RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsRedeemableConvertiblePreferredStockValue",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recapitalization net of redemptions, equity issuance costs and merger costs shares.",
        "label": "Recapitalization Net Of Redemptions Equity Issuance Costs And Merger Costs Shares",
        "terseLabel": "Recapitalization from GX Acquisition Corp. merger, net of redemptions, equity issuance costs and merger costs (in Shares)"
       }
      }
     },
     "localname": "RecapitalizationNetOfRedemptionsEquityIssuanceCostsAndMergerCostsShares",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ReclassOfOfferingCostsPaidInPriorYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclass of offering costs paid in prior year.",
        "label": "Reclass Of Offering Costs Paid In Prior Year",
        "terseLabel": "Reclass of offering costs paid in prior year"
       }
      }
     },
     "localname": "ReclassOfOfferingCostsPaidInPriorYear",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ReclassificationOfLegacyCelularityWarrantsToEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of Legacy Celularity Warrants to equity.",
        "label": "Reclassification Of Legacy Celularity Warrants To Equity",
        "terseLabel": "Reclassification of Legacy Celularity Warrants to equity"
       }
      }
     },
     "localname": "ReclassificationOfLegacyCelularityWarrantsToEquity",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ReclassificationOfWarrantLiabilitiesToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrant liabilities to equity.",
        "label": "Reclassification Of Warrant Liabilities To Equity",
        "terseLabel": "Reclassification of warrant liabilities to equity"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilitiesToEquity",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassified from warrant liability to additional paid-in capital.",
        "label": "Reclassified From Warrant Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of liability classified legacy warrants to equity"
       }
      }
     },
     "localname": "ReclassifiedFromWarrantLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of asset and financing obligation related to facility build out.",
        "label": "Recognition Of Asset And Financing Obligation Related To Facility Build Out",
        "terseLabel": "Recognition of asset and financing obligation related to facility build out"
       }
      }
     },
     "localname": "RecognitionOfAssetAndFinancingObligationRelatedToFacilityBuildOut",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction of research and development expense resulting from grant.",
        "label": "Reduction Of Research And Development Expense Resulting From Grant",
        "terseLabel": "Reduction of research and development expense resulting from grant"
       }
      }
     },
     "localname": "ReductionOfResearchAndDevelopmentExpenseResultingFromGrant",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones.",
        "label": "Regulatory Milestones",
        "terseLabel": "Regulatory milestones"
       }
      }
     },
     "localname": "RegulatoryMilestones",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ReimbursementOfCostUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of cost under license agreement.",
        "label": "Reimbursement Of Cost Under License Agreement",
        "terseLabel": "Reimbursement for enrolled patients in related clinical studies"
       }
      }
     },
     "localname": "ReimbursementOfCostUnderLicenseAgreement",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RelatedPartyCashBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Cash Bonus",
        "label": "Related Party Cash Bonus",
        "terseLabel": "Cash bonus"
       }
      }
     },
     "localname": "RelatedPartyCashBonus",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RelatedPartyFullTimeBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party full time base salary.",
        "label": "Related Party Full Time Base Salary",
        "terseLabel": "Full time base salary"
       }
      }
     },
     "localname": "RelatedPartyFullTimeBaseSalary",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RelatedPartyPartTimeBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party part time base salary.",
        "label": "Related Party Part Time Base Salary",
        "terseLabel": "Part time base salary"
       }
      }
     },
     "localname": "RelatedPartyPartTimeBaseSalary",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transactions (Details) [Line Items]",
        "label": "Related Party Transactions Details [Line Items]",
        "terseLabel": "Related Party Transactions Details [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transactions (Details) [Table]",
        "label": "Related Party Transactions Details [Table]",
        "terseLabel": "Related Party Transactions Details [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_RemainingDuePercentageNetFortyFivePaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining due percentage, net forty-five payment term.",
        "label": "Remaining Due Percentage Net Forty Five Payment Term",
        "terseLabel": "Remaining due percentage, net forty five payment term"
       }
      }
     },
     "localname": "RemainingDuePercentageNetFortyFivePaymentTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments of short term debt including accrued interest and exit fee.",
        "label": "Repayments Of Short Term Debt Including Accrued Interest And Exit Fee",
        "terseLabel": "Repayments of short term debt including accrued interest and exit fee"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebtIncludingAccruedInterestAndExitFee",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_RestrictedCashPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash.",
        "label": "Restricted Cash Policy [Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashPolicyTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10310.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of net operating losses and research and development tax credits.",
        "label": "Sale Of Net Operating Losses And Research And Development Tax Credits",
        "terseLabel": "Sale of net operating losses and research and development tax credits"
       }
      }
     },
     "localname": "SaleOfNetOperatingLossesAndResearchAndDevelopmentTaxCredits",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_SanuwaveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanuwave license agreement.",
        "label": "Sanuwave License Agreement [Member]",
        "terseLabel": "Sanuwave License Agreement"
       }
      }
     },
     "localname": "SanuwaveLicenseAgreementMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities written off of this transaction.",
        "label": "Schedule Of Assets And Liabilities Written Off Table [Text Block]",
        "terseLabel": "Schedule of assets and liabilities were divested/written off"
       }
      }
     },
     "localname": "ScheduleOfAssetsAndLiabilitiesWrittenOffTableTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of basic and diluted net income (loss) per ordinary share [Abstract]",
        "label": "Schedule Of Basic And Diluted Net Income Loss Per Ordinary Share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfBusinessCombinationsAndDisposalsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of business combinations and disposals.",
        "label": "Schedule Of Business Combinations And Disposals [Table]",
        "terseLabel": "Schedule Of Business Combinations And Disposals [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessCombinationsAndDisposalsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfConvertibleNoteValuationModelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of convertible note valuation model.",
        "label": "Schedule Of Convertible Note Valuation Model Table [Text Block]",
        "terseLabel": "Schedule of Convertible Note Valuation Model"
       }
      }
     },
     "localname": "ScheduleOfConvertibleNoteValuationModelTableTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Fair value significant inputs for warrants issued.",
        "label": "Schedule Of Fair Value Significant Inputs For Warrants Issued Table [Text Block]",
        "terseLabel": "Schedule of Fair Value of Warrants Issued"
       }
      }
     },
     "localname": "ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ScheduleOfFinancialInformationBySegmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of financial information by segment [Abstract]",
        "label": "Schedule Of Financial Information By Segment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFinancialInformationBySegmentAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments under non-cancelable operating leases [Abstract]",
        "label": "Schedule Of Future Minimum Payments Under Non Cancelable Operating Leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfIncomeTaxProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of income tax provision [Abstract]",
        "label": "Schedule Of Income Tax Provision [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfIncomeTaxProvisionAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfIntangibleAssetsNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets net.",
        "label": "Schedule Of Intangible Assets Net Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsNetTableTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of inventory current and noncurrent.",
        "label": "Schedule Of Inventory Current And Noncurrent Table [Text Block]",
        "terseLabel": "Schedule of Major Classes of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ScheduleOfNetDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of net deferred tax assets [Abstract]",
        "label": "Schedule Of Net Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfNetDeferredTaxAssetsAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfPrepaidExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prepaid expenses.",
        "label": "Schedule Of Prepaid Expenses Table [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesTableTextBlock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "celu_ScheduleOfStockBasedCompensationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockBasedCompensationExpenseAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleOfStockOptionsActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of stock options activity [Abstract]",
        "label": "Schedule Of Stock Options Activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsActivityAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_ScheduleReconciliationOfTheFederalIncomeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reconciliation of the federal income tax [Abstract]",
        "label": "Schedule Reconciliation Of The Federal Income Tax [Abstract]"
       }
      }
     },
     "localname": "ScheduleReconciliationOfTheFederalIncomeTaxAbstract",
     "nsuri": "http://celularity.com/20211231",
     "xbrltype": "stringItemType"
    },
    "celu_SegmentContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment contribution.",
        "label": "Segment Contribution",
        "terseLabel": "Segment contribution"
       }
      }
     },
     "localname": "SegmentContribution",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesARedeemableConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stocks [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stocks"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStocksMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesBPreferredStockPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock purchase agreement.",
        "label": "Series B Preferred Stock Purchase Agreements [Member]",
        "terseLabel": "Series B Preferred Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockPurchaseAgreementsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesBPreferredStocksPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock purchase agreement.",
        "label": "Series B Preferred Stocks Purchase Agreements [Member]",
        "terseLabel": "Series B Preferred Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStocksPurchaseAgreementsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesBRedeemableConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stocks [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStocksMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesBRedeemablesConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemables Convertible Preferred Stocks [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemablesConvertiblePreferredStocksMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesXRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X redeemable convertible preferred stock.",
        "label": "Series X Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SeriesXRedeemableConvertiblePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X redeemable convertible preferred stock.",
        "label": "Series X Redeemable Convertible Preferred Stocks [Member]",
        "terseLabel": "Series X Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXRedeemableConvertiblePreferredStocksMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, award vesting rights on closing date, percentage",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights On Closing Date Percentage",
        "terseLabel": "Vesting percentage on closing date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOnClosingDatePercentage",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, award vesting rights over four year, percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights Over Four Year Percentage",
        "terseLabel": "Vesting percentage over four years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsOverFourYearPercentage",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, number of shares issued for future issuance automatic increase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issued For Future Issuance Automatic Increase Period",
        "terseLabel": "Number of shares issued for future issuance automatic increase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_ShortTermBorrowingAmountEqualToExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowing amount equal to exit fee percentage.",
        "label": "Short Term Borrowing Amount Equal To Exit Fee Percentage",
        "terseLabel": "Short term borrowings exit fee"
       }
      }
     },
     "localname": "ShortTermBorrowingAmountEqualToExitFeePercentage",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_SponsorWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor warrants.",
        "label": "Sponsor Warrants [Member]",
        "terseLabel": "Sponsor Warrants"
       }
      }
     },
     "localname": "SponsorWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SponsorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to sponsors.",
        "label": "Sponsors [Member]",
        "terseLabel": "Sponsors [Member]"
       }
      }
     },
     "localname": "SponsorsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_SponsorsWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsors warrants.",
        "label": "Sponsors Warrants [Member]",
        "terseLabel": "Sponsors Warrants"
       }
      }
     },
     "localname": "SponsorsWarrantsMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock And Warrant Issued During Period Value Preferred Stock And Warrants",
        "terseLabel": "Fair value of warrants issued in connection with Series B preferred stock sale"
       }
      }
     },
     "localname": "StockAndWarrantIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_StockBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Details [Line Items]",
        "terseLabel": "Stock Based Compensation Details [Line Items]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_StockBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation Details [Table]",
        "terseLabel": "Stock Based Compensation Details [Table]"
       }
      }
     },
     "localname": "StockBasedCompensationDetailsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_StockOptionsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options vested.",
        "label": "Stock Options Vested",
        "positiveLabel": "Options vested"
       }
      }
     },
     "localname": "StockOptionsVested",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_StockPurchaseAgreementWithDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement with a director.",
        "label": "Stock Purchase Agreement With Director [Member]",
        "terseLabel": "Stock Purchase Agreement with a Director"
       }
      }
     },
     "localname": "StockPurchaseAgreementWithDirectorMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_StockholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders\u2019 Equity (Details) [Line Items]",
        "label": "Stockholders Equity Details [Line Items]",
        "terseLabel": "Stockholders Equity Details [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_StockholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders\u2019 Equity (Details) [Table]",
        "label": "Stockholders Equity Details [Table]",
        "terseLabel": "Stockholders Equity Details [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDetailsTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_SubscriptionAgreementsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreements Description",
        "terseLabel": "Subscription Agreements, description"
       }
      }
     },
     "localname": "SubscriptionAgreementsDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_SupplyAndDistributionAgreementForecastDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and distribution agreement, forecast description.",
        "label": "Supply And Distribution Agreement Forecast Description",
        "terseLabel": "Supply and distribution agreement, forecast description"
       }
      }
     },
     "localname": "SupplyAndDistributionAgreementForecastDescription",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "celu_SupplyAndDistributionAgreementNonRenewalNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and distribution agreement non-renewal notice period.",
        "label": "Supply And Distribution Agreement Non Renewal Notice Period",
        "terseLabel": "Supply and distribution agreement non-renewal notice period"
       }
      }
     },
     "localname": "SupplyAndDistributionAgreementNonRenewalNoticePeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_SupplyAndDistributionAgreementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and distribution agreement period.",
        "label": "Supply And Distribution Agreement Period",
        "terseLabel": "Supply and distribution agreement period"
       }
      }
     },
     "localname": "SupplyAndDistributionAgreementPeriod",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_SupplyAndDistributionAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply and distribution agreement renewal term.",
        "label": "Supply And Distribution Agreement Renewal Term",
        "terseLabel": "Supply and distribution agreement renewal term"
       }
      }
     },
     "localname": "SupplyAndDistributionAgreementRenewalTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_SurvivingCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surviving corporation.",
        "label": "Surviving Corporation [Member]",
        "terseLabel": "Surviving Corporation"
       }
      }
     },
     "localname": "SurvivingCorporationMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_TaxCreditCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards expiration year.",
        "label": "Tax Credit Carryforwards Expiration Year",
        "terseLabel": "Tax credit carryforwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationYear",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "celu_TemporaryEquityShareIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, share issuance costs.",
        "label": "Temporary Equity Share Issuance Costs",
        "terseLabel": "Share issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityShareIssuanceCosts",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period value new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of convertible preferred stock (in Shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "celu_TwoThousandAndSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and seventeen equity incentive plan.",
        "label": "Two Thousand And Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenEquityIncentivePlanMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one and two thousand and seventeen equity incentive plan.",
        "label": "Two Thousand And Twenty One And Two Thousand And Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2021 Plan and 2017 Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_UltraMISTBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UltraMIST business.",
        "label": "Ultra M I S T Business [Member]",
        "terseLabel": "UltraMIST Business"
       }
      }
     },
     "localname": "UltraMISTBusinessMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_UltraMISTSystemsReclassFromInventoryToFixedAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of ultra MIST systems reclass from inventory to fixed assets.",
        "label": "Ultra M I S T Systems Reclass From Inventory To Fixed Asset",
        "terseLabel": "UltraMIST systems reclass from inventory to fixed assets"
       }
      }
     },
     "localname": "UltraMISTSystemsReclassFromInventoryToFixedAsset",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_UnitedStatesFederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States federal and state.",
        "label": "United States Federal And State [Member]",
        "terseLabel": "U.S. Federal and State"
       }
      }
     },
     "localname": "UnitedStatesFederalAndStateMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "celu_UnrecognizedExpenseRelatedToPerformanceAwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized expense related to performance awards.",
        "label": "Unrecognized Expense Related To Performance Awards",
        "terseLabel": "Unrecognized expense related to performance awards"
       }
      }
     },
     "localname": "UnrecognizedExpenseRelatedToPerformanceAwards",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_UpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee.",
        "label": "Upfront Fee",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFee",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_ValuationInputForConvertiblePromissoryNote": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation input for a convertible promissory note.",
        "label": "Valuation Input For Convertible Promissory Note",
        "terseLabel": "Valuation input for convertible note"
       }
      }
     },
     "localname": "ValuationInputForConvertiblePromissoryNote",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "celu_ValuationInputForConvertiblePromissoryNoteTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation input for a convertible promissory note term.",
        "label": "Valuation Input For Convertible Promissory Note Term",
        "terseLabel": "Term (years)"
       }
      }
     },
     "localname": "ValuationInputForConvertiblePromissoryNoteTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_ValuationModelThatRelateToSanuwaveCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation model that relate to sanuwave common stock.",
        "label": "Valuation Model That Relate To Sanuwave Common Stock",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "ValuationModelThatRelateToSanuwaveCommonStock",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "celu_WarrantExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information warrant expiration term.",
        "label": "Warrant Expiration Term",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantExpirationTerm",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_WarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents the fair value of our warrants at the balance sheet date.",
        "label": "Warrant Liability",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "WarrantLiability",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_WarrantLiabilityAssumedAtClosingDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability assumed at closing date.",
        "label": "Warrant Liability Assumed At Closing Date",
        "terseLabel": "Warrant liability assumed at Closing Date"
       }
      }
     },
     "localname": "WarrantLiabilityAssumedAtClosingDate",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_WarrantLiabilityAssumedFromMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability assumed from merger.",
        "label": "Warrant Liability Assumed From Merger",
        "terseLabel": "Warrant liability assumed from the merger"
       }
      }
     },
     "localname": "WarrantLiabilityAssumedFromMerger",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_WarrantLiabilityPublicWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability Public Warrants.",
        "label": "Warrant Liability Public Warrants",
        "terseLabel": "Warrant liability - Public Warrants"
       }
      }
     },
     "localname": "WarrantLiabilityPublicWarrants",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_WarrantLiabilitySponsorWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability Sponsor Warrants.",
        "label": "Warrant Liability Sponsor Warrants",
        "terseLabel": "Warrant liability - Sponsor Warrants"
       }
      }
     },
     "localname": "WarrantLiabilitySponsorWarrants",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "celu_WarrantsExercisablePeriodAfterCompletionOfBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercisable period after completion of business combination.",
        "label": "Warrants Exercisable Period After Completion Of Business Combination",
        "terseLabel": "Warrants exercisable period after consummation of business combination"
       }
      }
     },
     "localname": "WarrantsExercisablePeriodAfterCompletionOfBusinessCombination",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercisable period from effective date of initial public offering.",
        "label": "Warrants Exercisable Period From Effective Date Of Initial Public Offering",
        "terseLabel": "Warrants exercisable period from effective date of registration statement of initial public offering"
       }
      }
     },
     "localname": "WarrantsExercisablePeriodFromEffectiveDateOfInitialPublicOffering",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "celu_WarrantsPerSharePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants per share, percentage.",
        "label": "Warrants Per Share Percentage",
        "terseLabel": "Warrants per share, percentage"
       }
      }
     },
     "localname": "WarrantsPerSharePercentage",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "celu_WarrenNewJerseyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warren New Jersey.",
        "label": "Warren New Jersey [Member]",
        "terseLabel": "Warren, New Jersey"
       }
      }
     },
     "localname": "WarrenNewJerseyMember",
     "nsuri": "http://celularity.com/20211231",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated By Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation Date Of Incorporation",
        "terseLabel": "Date of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r125",
      "r280",
      "r284",
      "r289",
      "r506",
      "r507",
      "r511",
      "r512",
      "r590",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r125",
      "r280",
      "r284",
      "r289",
      "r506",
      "r507",
      "r511",
      "r512",
      "r590",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r71",
      "r73",
      "r123",
      "r124",
      "r295",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r211",
      "r364",
      "r370",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r294",
      "r319",
      "r388",
      "r390",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r655",
      "r659",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r294",
      "r319",
      "r388",
      "r390",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r655",
      "r659",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r211",
      "r364",
      "r370",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r207",
      "r364",
      "r368",
      "r610",
      "r654",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r207",
      "r364",
      "r368",
      "r610",
      "r654",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r294",
      "r319",
      "r376",
      "r388",
      "r390",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r655",
      "r659",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r294",
      "r319",
      "r376",
      "r388",
      "r390",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r655",
      "r659",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r72",
      "r73",
      "r123",
      "r124",
      "r295",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r364",
      "r369",
      "r657",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r364",
      "r369",
      "r657",
      "r688",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10310.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts And Other Receivables Net Current",
        "terseLabel": "Accounts receivable, net of allowance of $283 and $272 as of December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r53",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities And Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r21",
      "r23",
      "r56"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r50",
      "r263"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r40",
      "r432",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r429",
      "r430",
      "r431",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r104",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Adjustment For Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r131",
      "r132",
      "r133",
      "r134",
      "r143",
      "r215",
      "r216",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r279",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r468",
      "r469",
      "r470",
      "r471",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r582",
      "r612",
      "r613",
      "r614",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs Policy [Text Block]",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r392",
      "r421",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense recognized"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r45",
      "r213",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance For Doubtful Accounts Receivable Current",
        "terseLabel": "Accounts receivable, net of allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r104",
      "r245",
      "r252"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10180.0,
       "parentTag": "celu_OperatingIncomeCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of diluted weighted-average shares of common stock outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r104",
      "r259"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r119",
      "r183",
      "r196",
      "r203",
      "r218",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r506",
      "r511",
      "r544",
      "r591",
      "r593",
      "r630",
      "r645"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r17",
      "r19",
      "r70",
      "r119",
      "r218",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r506",
      "r511",
      "r544",
      "r591",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r5",
      "r6",
      "r8",
      "r9",
      "r10",
      "r267"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Assets Of Disposal Group Including Discontinued Operation",
        "totalLabel": "Total assets divested"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r393",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r387",
      "r389",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition Cost Of Acquired Entity Transaction Costs",
        "terseLabel": "Business acquisition, transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r493",
      "r494",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Fair value of consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination Consideration Transferred Liabilities Incurred",
        "terseLabel": "Consideration financed through convertible promissory note"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r103",
      "r500"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r492",
      "r495",
      "r499"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination Contingent Consideration Liability",
        "positiveTerseLabel": "Contingent consideration obligations",
        "terseLabel": "Acquisition-related contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt",
        "terseLabel": "Debt assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r12",
      "r126",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "negatedLabel": "Property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r13",
      "r47",
      "r106"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10300.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Cash equivalents - money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r100",
      "r106",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r100",
      "r554"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r127",
      "r128",
      "r130",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r279",
      "r425",
      "r426",
      "r427",
      "r468",
      "r519",
      "r520",
      "r521",
      "r545",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r575",
      "r582",
      "r612",
      "r613",
      "r660",
      "r661",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r127",
      "r128",
      "r137",
      "r215",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r279",
      "r425",
      "r426",
      "r427",
      "r468",
      "r519",
      "r520",
      "r521",
      "r522",
      "r525",
      "r545",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r575",
      "r582",
      "r612",
      "r613",
      "r660",
      "r661",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r131",
      "r142",
      "r217",
      "r226",
      "r432",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r116",
      "r119",
      "r144",
      "r145",
      "r146",
      "r148",
      "r150",
      "r155",
      "r156",
      "r157",
      "r218",
      "r280",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r316",
      "r317",
      "r322",
      "r326",
      "r544",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails",
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Warrants exercisable date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r340",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "positiveLabel": "Exercise price of warrant",
        "terseLabel": "Exercise price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants outstanding to purchase shares of common stock",
        "verboseLabel": "Warrants to purchase Class A common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Number of shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reason for issuing warrant or right.",
        "label": "Class Of Warrant Or Right Reason For Issuing To Nonemployees",
        "terseLabel": "Warrant or Right, Reason for Issuance, Description"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r62",
      "r277",
      "r635",
      "r649"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r278",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockConversionBasis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of basis for conversion of convertible common stock.",
        "label": "Common Stock Conversion Basis",
        "terseLabel": "Conversion of common stock term"
       }
      }
     },
     "localname": "CommonStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r127",
      "r128",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r39",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r39",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common Stock, $0.0001 par value, 730,000,000 shares authorized, 124,307,884 issued and outstanding as of December 31, 2021; 155,640,290 shares authorized, 18,529,453 shares issued and outstanding as of December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting Rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r211",
      "r542",
      "r543",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r211",
      "r542",
      "r543",
      "r672",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r211",
      "r542",
      "r543",
      "r672",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r160",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk and Significant Customers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r164",
      "r165",
      "r211",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration Risk, Percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r211",
      "r542",
      "r543",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r342",
      "r343",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.",
        "label": "Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized",
        "negatedLabel": "Recognition of unearned revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r342",
      "r343",
      "r365"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.",
        "label": "Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r342",
      "r343",
      "r365"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Remaining deferred revenue recognized",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r37",
      "r38",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Convertible Preferred Stock Terms Of Conversion",
        "terseLabel": "Conversion of preferred stock, description"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r86",
      "r119",
      "r218",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r544"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10120.0,
       "parentTag": "celu_OperatingIncomeCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost Of Revenue",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost Of Revenue [Abstract]",
        "terseLabel": "Cost of goods sold (excluding amortization of acquired intangible assets)"
       }
      }
     },
     "localname": "CostOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of Goods Sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs And Expenses Related Party",
        "terseLabel": "Costs related to straight line basis agreement"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r120",
      "r464",
      "r475"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r120",
      "r464",
      "r475",
      "r477"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense Benefit",
        "totalLabel": "Total current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Current income tax expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r120",
      "r464",
      "r475"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r163",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer Relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r118",
      "r125",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r564",
      "r631",
      "r633",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionDate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date debt instrument can be converted into equity, in YYYY-MM-DD format.",
        "label": "Debt Instrument Convertible Conversion Date",
        "terseLabel": "Convertible promissory note conversion date"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument Convertible Threshold Trading Days",
        "terseLabel": "Number of consecutive business days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r291",
      "r309",
      "r310",
      "r563",
      "r564",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument Face Amount",
        "terseLabel": "Loan outstanding principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r58",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Loan interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r59",
      "r294",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Convertible promissory note due date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r60",
      "r118",
      "r125",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r60",
      "r118",
      "r125",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r333",
      "r334",
      "r335",
      "r336",
      "r562",
      "r563",
      "r564",
      "r565",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "terseLabel": "Receipt of convertible note in connection with the Sanuwave Transaction"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r120",
      "r465",
      "r475"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r120",
      "r465",
      "r475",
      "r476",
      "r477"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "totalLabel": "Total deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Deferred income tax expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r34",
      "r35",
      "r454",
      "r632",
      "r643"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes And Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r32",
      "r567",
      "r579"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.",
        "label": "Deferred Revenue By Arrangement Disclosure [Text Block]",
        "terseLabel": "Schedule of Changes in Deferred Revenue from Contract Liabilities"
       }
      }
     },
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r120",
      "r465",
      "r475"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10140.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r462",
      "r463"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r443",
      "r457"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "auth_ref": [
      "r385",
      "r386",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined benefit plan.",
        "label": "Defined Benefit Plan [Text Block]",
        "terseLabel": "Benefit Plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Contributions made to the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r104",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r104",
      "r178"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DirectOperatingCosts": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate direct operating costs incurred during the reporting period.",
        "label": "Direct Operating Costs",
        "terseLabel": "Direct expenses"
       }
      }
     },
     "localname": "DirectOperatingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r364",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Schedule of Disaggregated Revenue by Product And Services"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group Including Discontinued Operation Consideration",
        "terseLabel": "Fair value of business"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r5",
      "r6",
      "r8",
      "r267"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group Including Discontinued Operation Goodwill1",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r5",
      "r6",
      "r8",
      "r267"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group Including Discontinued Operation Intangible Assets",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r5",
      "r6",
      "r8",
      "r267"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group Including Discontinued Operation Inventory1",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r5",
      "r6",
      "r8",
      "r267"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group Including Discontinued Operation Property Plant And Equipment",
        "terseLabel": "Property, and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsScheduleOfAssetsAndLiabilitiesWereDivestedWrittenOffDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r104",
      "r260",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group Not Discontinued Operation Gain Loss On Disposal",
        "negatedLabel": "Loss on sale of business"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Groups Including Discontinued Operations Name [Domain]",
        "terseLabel": "Disposal Group Name"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r337",
      "r640"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends Preferred Stock Cash",
        "terseLabel": "Cash dividends declared or paid"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share \u2013 basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r121",
      "r445",
      "r478"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r445",
      "r478"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Reconciling Items Percent",
        "terseLabel": "Other permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r445",
      "r478"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r445",
      "r478"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits And Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued wages, bonuses, commissions and vacation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Total unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Estimated weighted-average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation cost for options issued (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.",
        "label": "Equipment Expense",
        "terseLabel": "Equipment charge"
       }
      }
     },
     "localname": "EquipmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r77",
      "r78",
      "r79",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r141",
      "r154",
      "r225",
      "r332",
      "r337",
      "r429",
      "r430",
      "r431",
      "r470",
      "r471",
      "r528",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r662",
      "r663",
      "r664",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r104",
      "r314"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r531",
      "r532",
      "r533",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfAggregateFairValuesOfWarrantLiabilityDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value, assets, level 1 to level 2 transfers, amount"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value, assets, level 2 to level 1 transfers, amount"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r536",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r300",
      "r309",
      "r310",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r532",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r300",
      "r377",
      "r378",
      "r383",
      "r385",
      "r532",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r300",
      "r309",
      "r310",
      "r377",
      "r378",
      "r383",
      "r385",
      "r532",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r300",
      "r309",
      "r310",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r532",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Aggregate Fair Values of the Warrant Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3",
        "terseLabel": "Fair value, assets, transfers into level 3, amount"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3",
        "terseLabel": "Fair value, assets, transfers out of level 3, amount"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements",
        "terseLabel": "Purchases, settlements and other net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r300",
      "r309",
      "r310",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3": {
     "auth_ref": [
      "r538",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset) out of level 3 of the fair value hierarchy.",
        "label": "Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3",
        "terseLabel": "Net transfers into (out of) Level 3"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Estimated Useful Lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r251",
      "r254",
      "r611",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r251",
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "terseLabel": "Amortizable intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r246",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r251",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "terseLabel": "Amortizable intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r104",
      "r510"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain Loss On Sale Of Business",
        "negatedLabel": "Loss on sale of business",
        "terseLabel": "Loss on the sale of business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r237",
      "r239",
      "r593",
      "r629"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r241",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Policy [Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r104",
      "r238",
      "r240",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill Impairment Loss",
        "terseLabel": "Goodwill, impairment loss",
        "verboseLabel": "Impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r84",
      "r119",
      "r183",
      "r195",
      "r199",
      "r202",
      "r205",
      "r218",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r104",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment Of Intangible Assets Finitelived",
        "terseLabel": "Impairment of acquired intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r104",
      "r255"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10190.0,
       "parentTag": "celu_OperatingIncomeCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment Of Intangible Assets Indefinitelived Excluding Goodwill",
        "positiveTerseLabel": "Impairment of acquired intangibles",
        "terseLabel": "Impairment of acquired intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Tangible Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r51",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research And Development Policy",
        "terseLabel": "In Process Research and Development Policy"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r85",
      "r105",
      "r135",
      "r136",
      "r137",
      "r138",
      "r147",
      "r150",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income Loss From Continuing Operations",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r80",
      "r183",
      "r195",
      "r199",
      "r202",
      "r205",
      "r628",
      "r636",
      "r638",
      "r652"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r387",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]",
        "terseLabel": "Disposal Group Name"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r266",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r446",
      "r452",
      "r459",
      "r473",
      "r479",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r140",
      "r141",
      "r181",
      "r444",
      "r474",
      "r480",
      "r653"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Total (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCurrentAndDeferredTaxProvisionDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r440",
      "r441",
      "r452",
      "r453",
      "r458",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10320.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10280.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10340.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10290.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase Decrease In Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10330.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase Decrease In Other Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10270.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase Decrease In Other Operating Capital Net",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10300.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r244",
      "r249"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r98",
      "r101",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r14",
      "r66",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2": {
       "order": 10010.0,
       "parentTag": "celu_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10330.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails2": {
       "order": 10020.0,
       "parentTag": "celu_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory Noncurrent",
        "terseLabel": "Inventory, net of current portion"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureInventoryScheduleOfMajorClassesOfInventoriesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r25",
      "r67",
      "r114",
      "r153",
      "r231",
      "r232",
      "r233",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory Policy [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance Of Stock And Warrants For Services Or Claims",
        "terseLabel": "Issuance of common stock to settle liability with CTH"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease And Rental Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r55",
      "r119",
      "r197",
      "r218",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r507",
      "r511",
      "r512",
      "r544",
      "r591",
      "r592"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r44",
      "r119",
      "r218",
      "r544",
      "r593",
      "r634",
      "r647"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r57",
      "r119",
      "r218",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r507",
      "r511",
      "r512",
      "r544",
      "r591",
      "r592",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities Fair Value Adjustment",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of total liabilities, when it serves as a benchmark in a concentration of risk calculation. Sum of all reported liabilities as of the balance sheet date.",
        "label": "Liabilities Total [Member]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfChangesInDeferredRevenueFromContractLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r33",
      "r633",
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line Of Credit",
        "terseLabel": "Debt outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r54",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Line Of Credit Facility [Axis]",
        "terseLabel": "Lender Name"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r54",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line Of Credit Facility Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line Of Credit Facility Maximum Borrowing Capacity",
        "terseLabel": "Additional borrowings under the loan agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedPartyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Longterm Purchase Commitment Period",
        "terseLabel": "License agreement period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.",
        "label": "Marketing And Advertising Expense",
        "terseLabel": "Advertising and Marketing Costs"
       }
      }
     },
     "localname": "MarketingAndAdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input Expected Dividend Rate [Member]",
        "terseLabel": "Dividend Yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flow from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flow from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r100",
      "r102",
      "r105"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r10",
      "r74",
      "r75",
      "r79",
      "r81",
      "r105",
      "r119",
      "r131",
      "r135",
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r147",
      "r183",
      "r195",
      "r199",
      "r202",
      "r205",
      "r218",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r530",
      "r544",
      "r637",
      "r651"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number Of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r183",
      "r195",
      "r199",
      "r202",
      "r205"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r576",
      "r578"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Monthly lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Current",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r566",
      "r568"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r56"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r69",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10350.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10290.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r516",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets Net",
        "terseLabel": "Other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental non-cash investing and financing activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Total other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):",
        "verboseLabel": "Components of other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r15",
      "r18",
      "r236"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments For Repurchase Of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments Of Debt Issuance Costs",
        "negatedLabel": "Payments of PIPE/SPAC related costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r91",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments To Acquire Businesses Gross",
        "terseLabel": "Cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r393",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock Convertible Conversion Ratio",
        "terseLabel": "Conversion ratio of preferred stock"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockDividendPaymentTerms": {
     "auth_ref": [
      "r37",
      "r38",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.",
        "label": "Preferred Stock Dividend Payment Terms",
        "terseLabel": "Preferred stock dividend payment description"
       }
      }
     },
     "localname": "PreferredStockDividendPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock Dividend Rate Percentage",
        "terseLabel": "Dividend accrued on preferred stock, percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r38",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r38",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r38",
      "r593"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding at December 31, 2021; none authorized, issued and outstanding as of December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockVotingRights": {
     "auth_ref": [
      "r38",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Preferred Stock Voting Rights",
        "terseLabel": "Preferred stock, voting rights"
       }
      }
     },
     "localname": "PreferredStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r15",
      "r18",
      "r235",
      "r236"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10340.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid expenses",
        "totalLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r16",
      "r18",
      "r234",
      "r236"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance expense"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePrepaidExpensesScheduleOfPrepaidExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds From Divestiture Of Businesses",
        "terseLabel": "Proceeds from sale of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds From Divestiture Of Businesses Net Of Cash Divested",
        "terseLabel": "Proceeds from the sale of business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds From Issuance Of Private Placement",
        "terseLabel": "Proceeds from PIPE financing",
        "verboseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from the issuance of equity and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds From Related Party Debt",
        "terseLabel": "Proceeds from short term borrowings - related party"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r93",
      "r424"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds From Warrant Exercises",
        "terseLabel": "Gross proceeds from warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Sales and Rentals"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r10",
      "r74",
      "r75",
      "r79",
      "r99",
      "r119",
      "r131",
      "r140",
      "r141",
      "r183",
      "r195",
      "r199",
      "r202",
      "r205",
      "r218",
      "r280",
      "r281",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r505",
      "r508",
      "r509",
      "r514",
      "r515",
      "r530",
      "r544",
      "r638"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r270",
      "r694",
      "r695",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Property and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation": {
     "auth_ref": [
      "r262",
      "r580"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.",
        "label": "Property Plant And Equipment Excluding Lessor Asset Under Operating Lease Before Accumulated Depreciation",
        "terseLabel": "Construction-in-progress property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r49",
      "r262"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r28",
      "r29",
      "r264",
      "r593",
      "r639",
      "r648"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r48",
      "r264",
      "r694",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r28",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Estimated Useful Life of Assets Based on Depreciation and Amortization Expense"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetTables",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r28",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and Equipment, Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r82",
      "r230"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision For Doubtful Accounts",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r384",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r585",
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction Amounts Of Transaction",
        "terseLabel": "Contribution made"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r384",
      "r585",
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r384",
      "r585",
      "r587",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r583",
      "r584",
      "r586",
      "r588",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments Of Related Party Debt",
        "negatedLabel": "Payment of short term borrowings - related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r437",
      "r609",
      "r709"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10150.0,
       "parentTag": "celu_OperatingIncomeCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r13",
      "r27",
      "r112",
      "r689",
      "r691"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r20",
      "r30",
      "r112",
      "r690"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r41",
      "r337",
      "r432",
      "r593",
      "r646",
      "r666",
      "r671"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r141",
      "r225",
      "r429",
      "r430",
      "r431",
      "r470",
      "r471",
      "r528",
      "r662",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r174",
      "r175",
      "r194",
      "r200",
      "r201",
      "r207",
      "r208",
      "r211",
      "r363",
      "r364",
      "r610"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r367",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuePracticalExpedientFinancingComponent": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.",
        "label": "Revenue Practical Expedient Financing Component",
        "terseLabel": "Revenue, practical expedient, financing component"
       }
      }
     },
     "localname": "RevenuePracticalExpedientFinancingComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInforrmationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Net revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salaries Wages And Officers Compensation",
        "terseLabel": "Base salary and bonus"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleLeasebackTransactionAccumulatedDepreciation": {
     "auth_ref": [
      "r570",
      "r571",
      "r572",
      "r573",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The accumulated depreciation and amortization related to the asset(s) sold in connection with the property sold to another party and leased back to the seller.",
        "label": "Sale Leaseback Transaction Accumulated Depreciation",
        "terseLabel": "Sale leaseback transaction, accumulated depreciation"
       }
      }
     },
     "localname": "SaleLeasebackTransactionAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleLeasebackTransactionHistoricalCost": {
     "auth_ref": [
      "r571",
      "r572",
      "r573",
      "r581"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The historical cost of the asset(s) sold in connection with the sale of the property to another party and the lease of the property back to the seller.",
        "label": "Sale Leaseback Transaction Historical Cost",
        "terseLabel": "Sale leaseback transaction"
       }
      }
     },
     "localname": "SaleLeasebackTransactionHistoricalCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale Of Stock Number Of Shares Issued In Transaction",
        "terseLabel": "Aggregate number of shares purchased"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r164",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Diluted Weighted-average Shares of Common Stock Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Current and Deferred Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Net Deferred Tax Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of the U.S. Federal Statutory Income Tax"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r392",
      "r420",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r246",
      "r250",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Payments under Non-Cancelable Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule Of Goodwill [Table]",
        "terseLabel": "Schedule Of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule Of Goodwill [Text Block]",
        "terseLabel": "Schedule Of Carrying Values Of Goodwill Assigned To Operating Segments"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r183",
      "r186",
      "r198",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule Of Segment Reporting Information By Segment [Table]",
        "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r183",
      "r186",
      "r198",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule Of Segment Reporting Information By Segment [Text Block]",
        "terseLabel": "Schedule of Financial Information by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r393",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Schedule of Activity Related to RSU Stock-Based Payment Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r398",
      "r408",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r340",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of the Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r451",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Aggregate Amortization Expense Related to Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r272",
      "r273",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segment [Domain]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r172",
      "r173",
      "r183",
      "r187",
      "r199",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10160.0,
       "parentTag": "celu_OperatingIncomeCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost",
        "terseLabel": "Share-based payment awards accelerated the recognition of expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Vesting description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Options Outstanding ending balance",
        "periodStartLabel": "Options Outstanding opening balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, ending balance",
        "periodStartLabel": "Weighted average grant date fair value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Intrinsic Value",
        "terseLabel": "Vested options to acquire per share (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares remaining available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, stock option exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value of stock options granted",
        "verboseLabel": "Fair market value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value ending balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r400",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Options ending balance",
        "periodStartLabel": "Options opening balance",
        "terseLabel": "Options outstanding",
        "verboseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of shares issued from outstanding capital stock, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r391",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityRelatedToRSUStockBasedPaymentAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "positiveLabel": "Exercise price of options",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "After 1 Year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "After 2 Years"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Purchase price",
        "verboseLabel": "Closing price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Stock option, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r415",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average contract life, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted average contract life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted average contract life, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Vested options to acquire shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "positiveLabel": "Number of shares issued",
        "terseLabel": "Aggregate number of shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short Term Debt [Text Block]",
        "terseLabel": "Short-Term Borrowings - Related Party"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureShortTermBorrowingsRelatedParty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r113",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfEstimatedUsefulLifeOfAssetsBasedOnDepreciationAndAmortizationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r7",
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r194",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r241",
      "r268",
      "r272",
      "r273",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Statement Business Segments [Axis]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfCarryingValuesOfGoodwillAssignedToOperatingSegmentsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSegmentInformationScheduleOfFinancialInformationBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r116",
      "r119",
      "r144",
      "r145",
      "r146",
      "r148",
      "r150",
      "r155",
      "r156",
      "r157",
      "r218",
      "r280",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r316",
      "r317",
      "r322",
      "r326",
      "r332",
      "r544",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails",
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r65",
      "r77",
      "r78",
      "r79",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r141",
      "r154",
      "r225",
      "r332",
      "r337",
      "r429",
      "r430",
      "r431",
      "r470",
      "r471",
      "r528",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r662",
      "r663",
      "r664",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsParentheticalDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r154",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r38",
      "r39",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period Shares Acquisitions",
        "terseLabel": "Aggregate of shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r38",
      "r39",
      "r332",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r39",
      "r332",
      "r337",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Options Exercised",
        "positiveLabel": "Options exercised",
        "terseLabel": "Exercise of stock options (in Shares)",
        "verboseLabel": "Options exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r38",
      "r39",
      "r332",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r65",
      "r332",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "verboseLabel": "Options exercised, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r38",
      "r39",
      "r332",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period Shares",
        "terseLabel": "Common stock repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r39",
      "r42",
      "r43",
      "r119",
      "r214",
      "r218",
      "r544",
      "r593"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r78",
      "r119",
      "r127",
      "r128",
      "r129",
      "r132",
      "r139",
      "r218",
      "r225",
      "r337",
      "r429",
      "r430",
      "r431",
      "r470",
      "r471",
      "r502",
      "r503",
      "r513",
      "r528",
      "r544",
      "r555",
      "r556",
      "r560",
      "r663",
      "r664",
      "r726"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r317",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r337",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r561",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r561",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r561",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r561",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r594",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureBusinessCombinationsAndDisposalsAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.",
        "label": "Substantial Doubt About Going Concern Within One Year",
        "terseLabel": "Substantial doubt about going concern, within one year [true false]"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Redeemable convertible preferred stock:"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r280",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Temporary Equity, Balance (in Shares)",
        "periodStartLabel": "Temporary Equity, Balance",
        "terseLabel": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Redeemable convertible preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Redeemable convertible preferred stock, shares authorized",
        "verboseLabel": "Warrants to purchase redeemable convertible preferred stock, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Redeemable convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Temporary Equity, Balance (in Shares)",
        "periodStartLabel": "Temporary Equity, Balance (in Shares)",
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesSubscribedButUnissued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of a new issue of securities classified as temporary equity that are allocated to investors for them to buy.  When securities are sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the securities to the investor until it receives the entire proceeds. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Subscribed But Unissued",
        "terseLabel": "Temporary equity, shares undesignated"
       }
      }
     },
     "localname": "TemporaryEquitySharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of convertible preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r650"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks And Trade Names [Member]",
        "terseLabel": "Trade Names &amp; Trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetScheduleOfIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r64",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r64",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock Shares",
        "terseLabel": "Treasury stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r39",
      "r332",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock Shares Acquired",
        "negatedLabel": "Repurchase of common stock (in Shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r64",
      "r338",
      "r339"
     ],
     "calculation": {
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock Value",
        "negatedLabel": "Treasury stock, at cost, 0 and 90,834 shares as of December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r332",
      "r337",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock Value Acquired Cost Method",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r131",
      "r132",
      "r133",
      "r134",
      "r143",
      "r215",
      "r216",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r279",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r468",
      "r469",
      "r470",
      "r471",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r582",
      "r612",
      "r613",
      "r614",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureLicenseAndDistributionAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r439",
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31, 2020",
        "periodStartLabel": "Balance at December 31, 2019",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax provisions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r158",
      "r159",
      "r161",
      "r162",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquityAdditionalInformationDetails",
      "http://celularity.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfDilutedWeightedAverageSharesOfCommonStockOutstandingDetails",
      "http://celularity.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants And Rights Outstanding Maturity Date",
        "verboseLabel": "Expiration date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureEquitySummaryOfWarrantsDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants And Rights Outstanding Measurement Input",
        "terseLabel": "Warrants input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants And Rights Outstanding Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/DisclosureFairValueOfFinancialAssetsAndLiabilitiesScheduleOfFairValueOfWarrantsIssuedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average shares outstanding \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://celularity.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=116846462&loc=SL51888449-203568"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130569-203045"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235042"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406127&loc=d3e45014-112735"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "50",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386837&loc=d3e51831-112757"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386837&loc=d3e51840-112757"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123386837&loc=d3e51843-112757"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123417830&loc=SL77919786-209982"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "715",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472162&loc=d3e58407-109430"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r710": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r711": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r712": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r713": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r714": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r715": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r716": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r717": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r719": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r720": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r721": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>140
<FILENAME>0001564590-22-013004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-013004-xbrl.zip
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MZHDA"::K+R +F'\/^$8Q7/CCACEL& S5D%1G[FWBW$+OQ$.H&!Z?W<>!&WA
MC*9C=>@3?)Q2YQ(TC3\&$Q_^!*\(F\5H,\4Y]P>9&+M>.SJ:IM$#?CB@]YR
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M$1QX'[H)NJCCN^:/;P[SO8?.MP5\W\C*]P<)2*EAX.2@"&^!.'>AR:,+-^[
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M7?Z??8*J7T[V+WO@J8#O:@-$3)CCZ&\UY^+OI 5ANK9-1A[]%/[X;#PSRQ^
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M3] O#PC$>F#-@1_)F?<#Y/8Y!9_*0 5E>#+J%EH:Z$)P7'(03\K8@1M_;8^
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MGM.7,;EYYIKK>0P0.'M=!3QG;G!JL=F1J,ITTY<]2F>ZX0W2"(=;,&=GR@>
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M*+@0W\+@%:^.5?%,%M\,3WZ:7[#S675-FA-"C@)[VVA/(6W4MM-7C2H/S;)
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M$#E3IT^KHW,,6SJX*H#QX@OK6Y@I:(=&97*':!(#6M ^4[ENLM9BKP(M*]Z
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M'7\U[^^OY37\T/U%$_YH5"3 D$\#[N G0:2Z9J#6X3SVH@J>)TZ[J$Z^90C
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MDFP!DRMK,8N".;@4Z/)Q1<0N]E$5@^>A'/X4NWDZS@0:NNU$D0!AO$CWP'7
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M:;*C1SE&#@Y^U=*5CP^3GXO[C2_.JW$&>Y&.A8V>5BQ.&>]TS.&<;?FB]"%
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M@] (<#.5SIC. V ?TH$I>>]R@^8QSPD]^P.3/K&(T=I_^G]W(Y-A?I36C1J
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M8"ML7?2L6CL/ [XIK/WAO$_=^F:P3$/ B,08M_ID$I=\>H#3%^0$8\IH]#Q
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M'Z,09O7G5 $HTN_4TD'%)DS=/:'K 9[CH0G"OQ5 )AKZR *XRW-BTJPBK$I
MX_%Y@;V,&@06YG@W"-AA<-^Z>/U9W=I2ZE+U8B#N+)_:8QONP#8\W5%LPQ^H
MA%Y)RVOV$N/2J1C#ACZX+=2;,-$9C"V2-!X!%R.;!)"T.IB0_!)<)!("&=G3
MRT$_SHKO,72+R5W(90ZJ-A*KH*M<K_B"<P*HI;;BJ(;$@-2][0Z2(7M_OZQ,
MGEH0NY'*-99,#,&4RAC:#N!(<^5FDDDASNJ5M8UVE)6C9@$[G.,X[YRS?LN\
MG%"0-7K8*Z#Y7C9%KJ(^^9X#0E<N70BD0!T%E[S.*DZRV,=L?O8)>J?OGBPP
M:9&,Y R-RFP91Z"-LX_;ZD!!SK(EF=GU+>+$RL;G][T=0XEU<U!R"G'D==ZM
MA(XWI*Z"X5()\&7G+-7S&&&R"<WI-Q];SH]%PJ$#&_36)QES0[XLP0"P/WK2
M@!@>C#C,P=E+,D#)$#VX@@H7&+^Y6=93D?[<PBZ;1>,-&@Y\6@Z@98?BKMH
M,T[%1MUKZ(Z-KH&:%$4.4]P'F1IV5=;&WS9/U^B!5AM,XJL#029[3Y@OT.FE
M_4'AR[P85H'ES?FVL=YK5._>^;R(<+%8++^+IY'-[/3$,95DZ#'F58ZW!+W@
M9X4!W+5^IFH?8K_/.(O\#DF01V'2M8_V*S*Y [%$1<"1WFV7@[V4HB&S&S&/
M?(*82< 364LT?:_=DG!'JD'LW W,+QK@FP- !MBLIG_*N=3263E\?"K%"N?"
MV74OH'O!?,[TJSNN6C^[ #*^9NL+RH_#(0,+#2W2:QHENQ&+%+8%3Z"B!PZ0
M6U&<%,SW 4)#15D#!"7_[4#.^NH<NGX!+M/:JLEQ6L<;XOGTKGF1U3ZKZU\B
MY0>]4N+CI1R/\</DVQ67FY9.U+SW5JK(&^2G@O1$BPU2?[ 8M\964B5U(WI*
M(V"-]HJ-;;JUY_EXOG<"[[H5\37:/<GE)95B&#JFYZ>>=U[GVZQR?9=_'9&I
MQS>)3J#?H[7[0@9?E6F!\^\I##0ML^JBE[ 0AHN43 UW3;YG-J&(J(RB[XY?
MT'<1^3V=B[A[Q]+"3QM5*1_)JI@[(X7*--#G*V2BT-O& IFU[6A5.9G8T:LQ
M[A$(:\(EVC)[IK?20BU]3O(/*$N&Y7@P]+VFJH![).?;RE6V="U/=_V@-7<L
MZ6%RZHOQHB:N!1D>4XDMJ3OL%Y%>3%>E*G+."+C)A!F0.6L@0=ONFKOU(>W>
ML7V@'2AA2/QJK&PU3!1->HE/V$"Z2BC>2%@=$L6?:W9>7'X-4/J*N3X?9NB9
M6OJU7,_6\_ L6.&GT,G;#X)=BB,0QU4.$%>Q^(0$7=;,73V.F!)R?$ OY%%$
M7-KJ\M$O!8>Z01AVE^"N4WZ7I;6V;MU++P^^4Y3+D?=#>Y16&N(8PN0?TBP>
M1PX>F"WJB%G(ZUQMXFEYN<J-F@BMP1D"#CP+JX(SVKEU6P@IYZSRA3C VFM@
M19 >FTYH\ *P/?8.M"SN>86!A/EI/?+T=I:!\D9/5>VYQ%I37F:C:Q"CQ]-5
M!<R,>_?.<TA_*7(Y!;MKK-VK%=>$]C)=Q3<8$&E +NE@%@T$]SB;DKE%@H"-
MIBD?*EQSN[W^CF.'89Z ?,@BCI[ W-?K=F]5JBZLWTOS9/DJWG69'J*1>B:'
M<<[=@4S+)B%L!*$JX<Y+C(B-*Y>N;K):D%X,D.&DT?"N 9CA$=2RA4WN5<W+
MCMKH&@3 30&DES%J"#@J7WPK<&9\<>@"SD8,!4 7YDTEH%O=8 TSY$4R;5(6
M\0!E2'DN%IT7Z"5M+(?:GL357'R!8<]R[#PL/&ULNB %<Y^-L7/7\8=,' #4
MLW..V"?C-BD@+@797'ILAZ;GFQII*<(;NS=$>$#%&4)CB33/Z7*6G%G7YSJF
M&>%\)@:Y\6V#EKSV4OK>Z<'G 60>@'2>*M=D,?GW;9G5)+=Q?A2(_]G$]%8!
M1\YC&^M";:R=._D,=PMI+BU&U)HGD:&<RI.2 ,-@!$?&FS*IX%5]_$FKBF+*
ME18AE58:B4US%UV:AA_H,\RQ?R_*PX>L!QY^.8B:I0>:?:-A9)B:).8V/3.B
M)<G)2IHC@B#F$OYJX,A6.5,T5YG!=5[<'LR*6T%C]ZPY*Z8'++P41K#TAS6H
M,5Q>2(]0]=L0'%T6.)6%/Y>EN^'@B/R6T[#QDSJ4*O(8I7HK2.^ME)\S=A+C
M<V![;VB=^&04F@P>0M8M '37;F,"C!Z J88'408<$G[FH*&""AW\K-B8;%F1
MXG3P1-O@GD'DGV@92.R&^6"/1, B1=X-0GBT8!I/TP.I]K",CX-E/-O#,GX#
M;"!+EA+E+06CJ0#>+J^%X6G,;ES):"0340.+3;$WZ"79B$DG20"F4I%&'YID
M8P'I,1&OQQM:A95>-8V+R.4)H,1-XF.3P)"<P^:WMG'9465K]X$DZ+ ZWA?'
M!;]OL-UGBSM$-GEQ"QX-H!M@A:UQ+J8MUB>)6\ &Q)@<"9%BY: AX%DT<TB<
M:A!J\5LX1'9A*N>N57Y+I:*,O7;3TKB0NPNDLHE466H9];#I3-NO"\_9PMFJ
MDB)\\M[+&&_)-/9&IV6?XE _C"3AE>A^*5[H*(5=&;'3KZV0@@U\Y*P$,5[_
M?!P>;RS^@\2)Y0Z;'6X3&]].&7L5[PE'1^)T8_=/AE.#XW\LS3)C;DY6%:W%
MP==#XF/HV&O&+<E%.8FVEDBPF03B10-P[^IL-QE-?^V$RADYY9UAC1>CYO8
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M%,A,4P+ UD5):%$*S @,Q%$^<N.]6OBBC_5>+>S5PEXM[)):6+H2<^:$'AR
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MD!U5UA#<7.^\Z"E/[2 ][,45P0M'#9=@J8Q;*3&&T5?M[&B/& )H;>O'>OS
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M?<>5'9(FOLMC6<&1!%%@!+(H&V3A \D79RM&<-66=35P9W_Y^KO3RA0SJU0
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M25M)^JG V1P*LL5Q#4PP^R*@[VC55<M%;-@3OI]Z9YA+I,Y6.>3[[ 7RQU(
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M"?RX) Y]BDL<$K_3M13"@=%<L+[\*+/#L)3TS7 +,%PV8N)\8/]8[TR"..,
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M\P(_!;W]V+S:3Q:$H0KB>23O^/!;8W?D_NG*K?EY$_QEL5+VJ,;"210J$]=
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M'BN%[MT6+E#G<&WNCQY-(O^1']9)Y$\B?Q+YIR#R$?7A>6D8N2B/)2HTI<"
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M4.T!M?8<+)FT80+#UNZND20ICM_3[Z]"U4/&",$M<!=;.6T,/.AE"^3U%A]
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MU##J"-@)-=\I^-#AL<DC*]>)O<C4J.'CYV';="E''+_ %#TRYZ4"DKJ>"S:
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M;IG5*I_>@+D\-J[5E<9_;=@(TQ@1NG^= E2'T\+](_&IRY%NJT&DYQ>DF'_
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M9\O@/5GC"'"$I<"9DC! 6<'=(K^//L3^!3-T2I#!/YP>]'OUUOAV972<Z$!
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M* TVX2-*VLLV!@);O4!5"':Q!(C*E_6:A1F7J&ROFXC1UM(!SELV>B#.E1?
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M5-.HG!X$9WLD"O>+-^Z&XJ$V(DW&IN,C9W)U_2F2);9KZQ 7[:Q]L=^30;#
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M_?HBS97<C60?$<]Z[<-WSQ@WR' U8E2>XV3'2I 1'>1G8JP0U1_@7@ZM#P)
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MP@/].\^U:UMPW[?KBE^,G9_8PK_&F$H'I*+%-])MG.VHH#S0_=(_RQ")ND8
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MV$-1-?U!%!'K':YJ]3FDIX3S@JG%*0:^6T5=MVM&_VKE^WHY;[D2]0994 E
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MWP(M#(B,"4E"5+',$\9Q?K[3R4G/TSWD@B]MDIWO.&MDT K=K70*G!<CMDO
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M21^T&8:D3J044O"M*Z;0150GY6M3+!I:2@]QS%:VE-#<QA^F66F;A0<3&3_
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M$STR360TB?1%!:GW4F\RK6<0(*%5T3N,.H;=X;Q7G[$1]JI61'S47S_K<9O
MA45$/EITV,[^0OU=HP)3SO)+O%\9GDKVFHM5UQ:EL>SAP2.7*IN8C.6;%9/"
M'SSSD*#Y&N&1HWTP4![^<7]:8!(U DP&/[/A3;D=)[>,XI71!?OK4!C-T 3_
M(RZFS0LU802XYRC=S[F!RU_LFGHY$.]>0>+N%R^_N79/7Y9Q_/7#&>VV9[JR
MFBN$#/9LI\F@ALG=5(HB8$R6++X9B5WW0E<3[O=C4=7Q1Z9OOEEOSD\>MIT1
M@#&R'Q<=25SI+=?O,X%U]+0_5^&.C^WZ%&Y"BXP(@0+9KKQO;?/0\CB<8$FR
MRLSP)-LLOR\7Y2&.= L&5)#+71VF)6):&I3I65E'E;Y75?W%RH:3!O44,ZJI
MPJC@GH+C3+8?B,,A'_\34E7W3+'G13Z^I!&W7BK4LSPOU>JU3[J?EO6Q6$TA
M//7W^>Q<JNA^\39"N3ZSI(2=B3/<#UT_! U?PO2=@N1,7ZH/N$DO4X!7=I.^
MGMH.KU2JG&;:MEXA<M+N"_:G-&1L?HX01GY*687/B?1!,K7@-JDVX8[637\=
M&KWGL)"]8#YJ1$<A#-R-!ICM"3 1R+P8P57'P?L"[.IP)[V;NW)0I@;8*6H?
M]C-2.\I;L:UOA*M7HSO[X3JK&D;<QD@^D/%/N@!)4"- 9*#A6& 01<_HYP[B
MWJ++'[83#/ ??2[*-3TE+8IUW#NLY9C#%2A#O7J\&\;5R;X/[9MJ9:6\-^3?
ML72Q>VT^[,]X"8!P-+V0EG,+K>T,##5%B/@0EVCAD(GHC7$$I=,G?Y>G#N1D
M="!M)T2@(F#<G,NIH%4['!2(=,LO7=@["LC4QM(Z @(RA7NMGOL*(3'YW)T,
M9LCE9%<\8A>S(PRQ43=4_7>WFUU+*GFWI',B326$]+V*%?V'XJO*\]ONH6B4
MK(G3>R!BVTE "[QH?+FG*RA(B&08;6&\UPS&*ZU5S(K:,MRS=Y'VYHU&NLUI
MYX;T4%0(S#GT\1HFZK/)9$3Q$C4S<L2YIQC9E'AP[;CFGP]R!L\; <#RLI.&
M-8HG=N%@@1R+H2X3&S"5#+YQ _7:>3V<T-%LZSF#/?:ZH(4R>E/O4BF"O_C_
M<*@ ["O^0J@XLX0;]V%>N#&&2F9JVL-/6+U&BLMQ+JN_+DCTJ?R^S,S."Y/T
MNT3NF6=TX\[^Z_6:F9<?:D<H_(1"85V%1QV++GQV_2QN;@8._F'GNG1NMT;Z
MQW;(4^E/QO4"Z/]X8N,4_OWB6:?KO#]JN4W'JVO@QQ)P6+8]08.HJ$F.J-$\
MA? C8/'CY<F<1-+;VFIK.,?)]S9OSQ/Y=FE#$I]SRL_PLS1P(:>L:Y]\:L=]
M< W?*H&C3![5:,UG_'?R@X8^DYLR8?I^J A@+=PG1G%13![\A(P*V_N"OQBZ
ML;$U4M"3_9*>,_$SN,K5J)F%-"5@;F&IL&*-87=_J&*JH SMUCB?UR2&1*.F
MJ)F6#]=,_!,7C*W)2B,7=L_:S8AA+-T&UK.8U!OEQ9#QP)?Z4&]2\M$0T%C+
M34=T$E,DXA4-\&8:Y8]L@_L?<QO<Y]0&]YU1FFE>7-(M9ZC.YPZSOT&'6269
M #_"F-H:4"(7+7S%;W;=C6:)<F<-&[L9ZHS*;Y;S_T(Y9SN>#>M^)AUA'ZQF
M+]=\SRN,AZ'@PE!BAS+Y'_59<BY&6RK/S$@GU\O_%K<)U>+("G$FUT3!^O3L
MO9I:.IQ#(=I:-.%!N*L2W\VH16M<+(M2U8_XLLR7SYI=>E>*SFG;)K=ZZ><]
MSM0NS@ZA[P:P;H%HQ-I0L)1L1G#IE\-IKG;7^J'Z,S&J<0NOVZ$Y=$QF^CK;
M%V'J>41&N]B1NSY:&M? N(0N9&X*,[GCFC*7),L=G:$0X?&_<U B_2:]:U=!
M[E)BQP?.?DF<MM3EG:WR9WUBB>+F95 S2#Z>?$P9T#B0G)8P#2C!X+0_2-!X
M_D2G]!3Z*9G&980U,!QZCN3/O.D9T1+Q6+D(F%.?H=JM$ -Q9+,*&V[\.O!A
MC3_;%[5N,5USOR9>*7>0K%'KL&; :IU40JJ+KBDF>P@Q'V7\0-PI MEU=%!N
M_NBF5;76_.WU=[3_F=:H?7>-X5/$B_C]6:&:EAN]Z1.M,)K(=%=SDZ51-N?L
M ]=*E*!/!8WY%H^)<RN]4%0F(VE/!FMJT"UR8$<&](J31?S3$U_(7D-*KBE;
MY M>;$=(9B/9'C9/?J37':@.^A>21U,2YSTWGA\T1W00.79,'$FRFYCY=<<F
MU*-&YZ3;E=IKSKQ)U0AV5F.5#]E77O$_\GV6%)*CHCXU0+WR3.$BFJA%HZU]
M\P+32)]RY,:D<6NZ(-)0/-3VXZYH<-F-L)^0K,S/OM57''>[IK5+1%T7MVOI
M72FG%:V%Q#VP7=&N%<[4:KM)N3AI /*3)],7PME'Y+^:/GA:X7PM],^%W)CJ
MK#B?$^6V\TG* :VU%3IA82MI?TAT=WU"C)O>HUNW#*^;X[06-+MJTF7F]-+-
M2QRHW6.@OS R8O+7JD-L%F;H5:6%((%8'R^ZAGD.F"U8XF'\_G=_?,<FJ^->
MR>277A1Z%D]K=#I H$Y-DE8B6=VBP$R.\WY[[$E^BH:+P4-C_RPLN/B2D^M:
M'X;6$2F\,QO&T(?4]D"W@U0UNW@E/--J-8AO%\A\E?TRPI8KA;/9#>59K/KW
M"_BT.ZU2TV^U]9ACMLIFO8L73GN;(,!;O;"3)]Y_ZO=;+NH"*7=$!/MB_;YX
MX/_T[[E$4QE%.6$A9JX+Z#?@C_6TFN(AZ"<.52_/L5ABB784^BP:<J5'@1/F
M*)>]#V&O%OXEAL)I&KHSVE# >WRJ [V0L%3V86PZI=\CX7EQ:ZN3>#FY*>I4
M/PHA;X,7X^I)HN]F E<0:'/ $%7PV%E9__Z/;U5-#QT'-;]_\[:/C6WCX(-O
M^IM0HX2(H]? HY=UYO6T\4\Y+R#.$*$ 8^$?_B#;Z/?NM<SWG+,_^F9%1+IQ
M>#9"3LK%/(3*4Z^NX1XJ?ZI_4O,&HN4R6"* QWGD3";=88U@:1%HBY .EUYP
MWM)R8&6Y0\GZ];*Z[5-(!Q_=V';';]YV[W7R0_Q9[>#4;C/L'BG_);1GB H3
MTH[50P9 O@D!<S*:]B,?#\TB]'WR)/%4KG7)N8.4_0Q)M7FXG@LXDG0WLHE,
M%.OR,9[K52Z!S/Y)(X\?_XD3'YE,1*Z(D<'7*J$F%N2XHYY8=$.=U+S>R:4F
M#>0<EJ/:<4D_LB:+V8*8OA]VH9-+F6D?T]9RK1M;@"@]N3 Z0L/&@%Y_@G4B
M=?DA>#=FY-+R"OHD133O4W3,3_W[]TW[U.#N:YM?N]G<L9J5Y=*'M GN'Y8R
M;E#$U9+W04+6'>]8ADGS:V#6<ZL4SUJPA-'/F^,/,,3'*D8K)S8RGD#^V=0>
MI7$+Q1)!5#3/-==L6HMDUY-BC'S!_#A0+@>(R%H"@KIXLI4D+!-:Q+9:57%:
M*<LWG>Z/=J 4L9HMC7IXH4&R!QRB<K<C>8X<7^*!&"D[?=B$O^K]7+J($MK<
M+_[0/H'BVCD1_.6E'GP%>2D#+KVT"$H7U%^&\@'[C2MK)-IU>!!*^]A/GXG?
MQ"K33L>,JNZ@[.LJT#M7_%V_O+BR];9%H@5.FO6+]3E/-C_7[H>?NNJB)&<N
M4V]94-NXR;/*2,(^"XKG_RFS.E7/;2#"7*/6ATY\:.3^OS1TR5.2SM-BHY&'
M0Q@H[91G7;L[UT?N7'<_4G7E'<]0J^K &%W%ZE2=K;.^(#=G2&+]9;';<A0^
M8A=ZL_U9EXVYF=I.R)3@:FR<?1&/L:],,S@7+*>N]\E9QT^N[H9[>.*.4*I4
M]_3,F\_M1F))=W\[\&R]AC/:I'J_^$Z=14M]P#;)R81^TJYIC^W,N?VB>SEC
M[7WP)EU0C3/6WHRU]YEA[8T# LF&6!C9CLWA<ZE8[6Z,99#LDSQ1D7X 3R<O
M>V@.J(?*3Y7:+*AA.$4TY"?.+!:?NJ3/]F*V%[.]N 5[L4'C."GZHN,:M+P2
MAP3;MB[9A,P41+<E=K/RGI7WK+QO07EW83/TF/!.K-6NW(S$[4DK%1K:D")+
ME>"8M,H^MZEJ:=X;]#L]>B)TNJL+CZVA9VT6]"5IE[ R_0=8B'EJZ .GAO[U
M.J:&9LM^C3IIMNRS99\M^R]JV3_DY#_HK']!-\"R:WVH_C..B1QD?'DI]EK\
M!&Y=[-!HS55P;E?2AD3^KPO#6/[W+HU%^<^=22O.[$PW<$EF4S.;FMG4W$(0
M635_&1I'Z*J6(34.K*O'2C"4.H9OJU/_^\^@2+J%UAAM84J=<:D/>G(Z23^8
M.+"8"(/!8[0%+/4F/B0@<]]:ILU== #<HNW@,74P1YOLTJSH!T]@W"]^C. Z
M]%",*DFK6_4^U-6V;<OEHF%\;O$=#HK5-;EB62%WR7=5KRALFX&_7:.+N(Z8
M,:-A2'YV6 _\AT(G8A4(ZB*O<,'P339JA+;&'CB7:(-,,"AEL3_H7![M?B]@
M.@H>.)[7X-:>LMW;A4##S?@S=J2& ZR_S !%$?C[= K8M\;JJ$G=]H+[/S%"
M:_,/<917>EIU;NDI@>@6ZRW#,4GJAG^5'K&I#M;\=\-32'^RX>;]L*H!U[TG
ML=*6W*I9HT$Y'Q'JUQU)6<.M;0K CU:H4'08B5# )D&33'VD^. ",#E65X]H
M_?!!!;:RV &;5I=!GC=&8MVHW)DQ +X*W!F'CDH9T&8*GC229CW.^.L(_H,V
MKK-4W/TSPP>WWL4(58TCN],C$Z5Q".MMPQ0!(0T7H<M3[NYCJ.\7;T^.3W5P
MU6QJ;GSC/.FZ+JJ=/B23C0JM=.C/6]KLN<U'DDG?LU4?BY/=X@>C89)I:L&3
M5'1*E6W13M:;JPVM:.[]MG$@;#+YJ, <TLDNC;V+88^N\=1@RR#WF'?4F=4T
M,2D#00+K:IV_QJAX1I*!JQF[<X4+) Q,"".]Z&;N2*274?TN%<X3<E%AZ>X1
MB9'%YN!S7$<]F=B&?+_ *)E=>OQD1#Y(Y]G;O<_V/[5Y;@* T=P>G;Q]6B!W
MO1QUFI2/!IM-'Y0;ZB#EZ1;3=O%@Z>DSY.2X#3:#EM7AF&>N<CXK\5 ]*B4/
M"W0TW9N)^\#3-!Z?T5^0I;/PHN"8A&0\]C3=3>KGX;J@4\$\VB'(GI:42"W6
MV6_CG4QS-V?TNT'\QM\%#.NT%_42-R(;..:I&7:SSB-H9$AL:"Z.A$X1'S1R
M(L1Q:MJ\HNI.('9UK$D)LFV6[EF[488=HQ6RV5]O_U:Z_HJ-_REOQD=,(#.R
M8+H&YJE'E:S];DXK2\-STA%Q3)+^:]OV>^P _><:'W:7?2$5J-Z/8ZE0GJKT
MS\!"Z^T/#:TY,.9DY#DR/B.YIN)D,0RVP^Z-V\K\*Q@29J2#_%HED)(UL#LX
M6("CY0!+_K;GN'!D%PXN2*:<@@(RDGGJ70MGQ/#&D$3_C-G=2.\ES%#1\_1?
MAMCC\'C/#C@G;\C&WG0;>:A!$!0*N2/]T&U@!G1^+L9[J\"&DH/#QG8LGIL-
MC(+T2OZM'7IWMJ3P^1CW;2_,.9%2X<QZ\9/O*[FS?3C[W&D@  H,Y2[CEQ@N
M1''>_;A*28>])8\BQ>CHHVT[=:BB.YC0@B]X1IV#R*E\FZ[[Q7EFXIIS=W,&
M?,Z SQGP6\B L[MG(99G=4OAYG.J7'NHYM[83UP<9Z4^*_59J=^"4O<QW$LC
MMYB<PU1SA8 325!!WS^3WRP$0DF!4)23,CY]M@>?N"3/]F"V![,]N 5[<,AH
MOEC;HP+$Y%611[1_+L4.DL&BUL* U_3S6-RG+J2SJI]5_:SJ;T;5=V"B%B*P
MQD-)"76XS_'/FOL3E[E9<\^:>];<MZ"Y;9(IXN<Y#LVJZ4-W&#7>9D#2EUNO
M9R7_28OGK.1G)3\K^5M0\AD(=&?00X(=+\,,VA 3K4"$J$A %[,^_\0E<=;G
MLSZ?]?DMZ'-N(L5D*,.):F_T%#78^2IJH@_9[<.ADNY^'929-?TG+J.SII\U
M_:SI;T73@Q\RH]T0)@2;]F[G\NAMRM^LQ6<M/FOQ6]'B.B$M@ + >$%G"\ *
M!(4D_'7 *-J()OMX2K>S+XZM-D^Z4=LY[WX[$COK_5GOSWK_5O3^!32*/0 )
MAL-=N[G;M^O(068()*L^*/S(;"MF6S';BME6S+;B=FV%)'0>D>YI'D-3Q49*
MQE%"$Z4#ZV,FR\3JV2N?NU D3Z>#(F^W9?LCTLJ,#GP#(CP;@MD0S(;@%@P!
M?/\XV&IA X,)%K5RL"><4OI@VQU^#BKPS/UR'B#KG[^X#NZ7G_?8E^W="P[P
M%C#/OKW<&.&019C:'G3E[%,INN\OCT-G7=3GX<N6$11LA%\&-,D.F8">3J?:
MT+<8=)&TQA#N%X;+A]<=0>N=?9NE1S1VOQ2!E!5K;+P)/*5YH*/##P*L.6*N
M B[50[YBAZU3Q="T\7>*0/I(6G55'QE)C@=%Z0/-^,1H.^-7N#B:< "8>H-I
MU,??6;2KOB7[$&X9B_&-3Q3E^2$%B.-64-I7P>8VU%:&/%60.CW=/CPD!-B+
MC,4,UR.(Z+OB/3WKL"BKS08XN ?^]L#9KAXR>"J,2XB,W;EEQ,RN;QY]\9U@
M V^&6BW[,Q"9V38IEK!B%7Y,;4FII*<SABFV3'E#4DG;0+'E=HW+1PMYZ(H=
MK8MA3RD$_2/KK4Y^5/Y0T4IIZV@E%'H6C%[_4#2*K=J/(%<7\MM+U:BB%.\7
M[YQN&QH54GI-!B\6P.-6X$//RWY_* Y#;Y.(%S <198O(IF.L'Y785TPAN9Y
MH](%0V6$9N3GD (.<>'))N#HV$X@NF>5U@ZR365090\E9Z#0K*V5-H"4\0!;
M0+HST-W8*:ZE&\!7PR '__G"DK^U!/S3MEVH)#]6)4FH&=YT'AL!^ZZZA"?<
MJ]6MV4C1__ 5G+Y%#+RL<K@HZMIPIFV("K8+$MRW)/]0RB!_UQ^,B[A??,>R
MB,OX\^]U#TJ1@[QFZRVUL^:W+@$_G-D<BNDPHRPZH.R&![EZ+H5&1W,43VPM
MN!3"5 "--<CUS<[B?O']N$13G#D:A:A. /'%HAEV*_@Q&P,]=2F_)3NGN/=F
MSX'G+MBR4X^/?"E@*>M *9.80A0!N,CT0=7/4*C7G*B8TWUSNF].]]U"NJ\0
M6X)\@R".DY=K\:OXVT!D;^9*_2<N:[/&GC7VK+%O06,+LU3*.7)%1F)'B@>;
M@*Q.T1UGC?V)R]JLL6>-/6OL6]#8G'/==TBR64Y/:/<VH!F4A."LKC]Q09O5
M]:RN9W5]"^H:=9&[Z%_/[:DW(%:S<IZ5\ZR<;T$Y-\KD&W[:AZ[2QI"&V7L?
MT7GPH/R]/Z,E]1:*S&>*]GFM_J3LRL7[P@_K19#5,W5CYEU%Y]T=&'2&74XL
M38:T/J+$SRSD7.Z51BW%=-76+&V!L(84>7(_[,$NC5?HUXB0$"TM$VV;_<!=
MUJPL/\[4X!9I:8%YW)"7.A13OTW<*WRW2$3:]B7N@L(SA4@4:\MWM(MMG!7M
M!IK0L'+7B1F[&[67ZJ031AK6@G9C5AVJ[]I8=>X0>N4VE2U=M_2!HT*P,.4]
MMCW.?6XJE/@3^^EQL26ANU_$OA0L?FCJZCVZ2\!9?KF[B#Z*LXT[!P97[6A9
M3H@<Y,4:1^CAVL>0=9#RJ;>-[U*YW)MVOW@7:$\F>E%4 K+.@D,?Z@WOF+8]
M6*]IHI#_MND/H2BEH\&.#A^W&2CAB8I-M];<&'\=G7&T>QL!,Z;-8!+=O->J
MDWM1#BPL9U@':;MH_\O[Q3=#A[]?:G\-6EUQ6^C_EXLW?WR'[JJJ9Q+?\2;T
M1UKO3IZ3MP1I>6_MNI"R+@]^6&RK>QO?]IL0%N_66UIZ+5KEN^&@\K5XV[7(
M;'!B^JV(X>(=KV":A[<+TH@;?\9DE_O<>O UKZ77;-]5C])5-GT'K!O*&IU$
MBKCK;OSPN">T'=:1DOZQ$YEZLRV:!^F2<_IPH@51])J\2%R^5E&5VMD^R>*F
M//*T6E#!KP_I.WRVS[VGW"G^L:GY[M@(_OS=O?5&JV^E._7/#3J49 _?':29
MM:&](85#GR1!J:OU:=OJJ2:)/>76^LE]HF>.Z7[Q ^UYH.^!?_N%#Z:CX=9E
M$ARG$*%(6##8+,K<?MLYE= V:C//M5DE"SLR<-9\5[:A%ZO4]]!'0KW-=E^E
MCKO.R'Z=>900</##P)=M"GZ\-Z<MX6/ER[SH#?^7^ :Q]9_N!8E\#5+R?I%L
MJZ@T$MK_Q/8N?*JU"X>A:Z 3< ?$/S3\LOCFB2O^UJ_#CSSY@ X_[H8/[V-/
ML>PSM]U?L/2T:_3>VS-WBF6;/D+6E=0_:72(/FW=XB]#5_6D?UD;DU;W_E9<
M ,CI&QZ?D$&,J>\^/PF0N.O[8?476@8+QV!C:]I-S<]B]ZHE]3A>GAH=6\$:
MG94=SPE CC%44'1PC/C+])3?#21O8:DWH%HK*.JJXHF3-?>\NM5D_>S O^Y:
M:>D62^%_3A]&]J(]5+IL[M#-GN'0-%A_'# "86R6<J/@+/"PF&X[GII&^.(9
MG$0#<6_)P<*>B$/F5YDYGN*L[?849:K[%GUU^C!\7PT >%0\^G93_CLO)>WW
M]*K8?QRZ+K"*=!K$1CON%]^Q"OO=GQ>[P,VLO8IJ7;=/LI"F$A._J7Y2?[M]
M4ETC L>5=7(/>FYY)95?'=I.@P\^/7W.44='1/.31GUJGHJN!"V1Z%3:$N]P
M2?/UMNC1PH_=I3,]R@7M:<-?(ZX2-XD],E)Q/9V6NNN+5='1_G?BK:\"CV)V
M<N\TB*)=Z=BJ^7&HT?! 91Y6DKHU^6_]G60<%0YF!U=*G1/:MSO>'+W[(D8P
MB6#J*+)Q"O?B)LL07UQ[_<6+,S;S8.B%P=!75S88>F.F\D*:ZE=<%?2*7#@W
M:_6BB:+GLV^_XFL]A:M>GLV"3@UC\18[G8=!.K:)\$_)WE2;#/@*$W,7DFE]
M'/<]\;'/#]S<7_?A_GCEAXLT,@= $^9ZORWH8VN^5VS0Q(AQVJHAWPE3SC$(
MBT?%\62E+N<S$9"D"R$P:\XV+#"-C M-KYWRDS:6_)(90^37#DJJPOZR\ZJS
M<>19.?RME<-RP9G1B=/+1.2<1% 44\&9QE\GAIS-0#%M\,6-&QTEA[%CEN9U
MK%6XW!MG5G9G\FF($<U"VN!W)>-SST\V?SX#X&?F$)&G#6RE2HH->FP6J0J-
MAY?X[RS^S R@ "-H3@6Z,HM<^G:_K?! 'C;=T8^T92^)-XZDF/G)'3*'2!RR
M/)=W,.R R;P!Q^;TN&WQB%@IY,.-=7BH>H4^<TD"7.1UR@!S(<!%;Y) ]A6M
M"[+WXJEZ)WMF6-+Z$%)W+H>AO[M"[J_O#<M"_A*&BW]V-?2(7>F'-E5#=ZF2
MK(,$@/J^B#%E^G\?I&C+%16)T/L@A"ZHOQUJ^A6NA'_QU=?Z8/[SJR^_6OP^
M^3G?IS7B%]YJJNVUZD5^PJNO- 595OUZZ/M4\.E! _9TDK'1A&HZ1:DN:9U*
MAV+%*F/C5V%YZ6B1)&Q[Y"1HSUBOFGQO O(F4E[D=(&E',M* VSZQJIKR1MK
MK$8RQC]P,FR) DV[T"M3""WE(U_<2M^0]$'4_$7,I>"3^B3)GM*](E.0$%Q.
M]:,8DCU/WF/05F)X21><@+CH?/Y2_8<HC/Q6R_R>(]EZ6D]]!R0&^V43Q$=)
MRY8D';T!2W&9ALYJ7>U9%630 &>"&9;N)_.N#;JB/IJVX9W.,!2XQ'<61T&!
MK.@O9$DP$&R?29#.W15WL>U7/]O*2LHBF7;M1;DFE7]R 4-#3U9[CDP72>_!
M')L)S<[)3OK,7G.GW#)-(G[DZ?CHC^\[4KS(UY$$:E,U)F%.U3Y3@C,2!3(^
MBS_?O[O' 3_ Y>>>$5H+4IGFF4VI O="R%E"&LJ 8HW.P#OP$#C_S0.IWA5?
M=W'!L;U(?S9K$2/W(DLNXM*920U7]=ZVVM/J#T]X 7MC$=UFP& ^J8#.JOLH
MWY"!94BD!) BJH_])1>,ZK^/47K8*!M8$JX3 Q' ")?TMN6 (/=@Y8 SYR:7
M'K4B36UF7D AQ6%H&"S7BXE>LZC\I+\B)>W=3L?LZTF0)L8F[FFJ9DL!J4V[
ME;\Z<N9T/!4C9\$J(479XU#HKZT$T2:<(@]<T8]Q\5A;XR%UR]&D #FXLS?M
MS<?C,K%2Z_8O2A\G5<NM%9R)E7T2%!46LY2-QZ^LAOK]8C]TY+Q@<V]=$_T8
M$6C(S,'C8Z$D8\LEDT<S'!I0%66[/PVF%J]5ET6U8:Z$@SBT=I1TA9;<X]/Q
M;8NUA&<!A[*J:NXK]*%[Y+J#BC>DC%T^+O9+P>#$N_A'-&&18/1!!5POAMA^
MM;NUF;D95>.:^ROG+N6Y2WGN4KZ%+F58BC+L+"9Y)@-P$?!M'@S\Q.5QUNJS
M5I^U^BUH]9/D[H%[**NU=DQ6Z&6L 6W,A;A-4753ZG^F/?K4A7%6Z;-*GU7Z
M#:KT<35$TOX*5\_S0K$;W55'9GW^B4OBK,]G?3[K\UO0YTB\<,&>\_7%3ZYR
M+'5QGE4H=8QJQO:X ;&;E?>LO&?E?2O*^X1+IN#I^\\<SN-U<Y0Z,!?_N5!P
M0KH1I]QC0]AINT<_&K\'\@*]0-'E3Y^>2$_]H3;'/RXO<Z9+JNIYA'32AO#S
MVY)_WME\[$%\7_7O^\7WZ,X1+^([>N-OFP-9=WI_M,>\Q3QH=SC^THT7U].:
MK1QVUA@A\RJ'H+T7,G\=#D7W?]A[$R6WC6Q;]%<0OGWNE>.QV!HL3WUO1Y1*
MDJT^FIY*;I\3+UXX0")9!0L$: Q%L;_^YMI##@#(JI+D-D7S1!RW5&*!B1QV
M[F'MM39)F=)6$.A$'D[32J:)D4X\EY0G#=7:<NE*E\Z7;?)P+"L<R%8""\Y=
MWPS).704S"E-%0%7H-9,P#DV ;.\ZB&D J@*J7HREE+$7PC69<T!FA1(*:CL
M(YJU<YO@3CX9T@I.V"[UZ#)/DY\-4W2(O(P=QDP)"L!;D;:L66A?."/8<6W:
M\,$,]IVC.S9)+VIC1!(GWGS7;C'J PBVV#2!:0V06GA%NVWRQC,)X.MG&^[E
MX:YD5DO#L^95N<@SD;@*MWX.K.,R1&H+K8%J8(M"DXU'YN\ 8^U6!2'C$^(^
MJ@&.ZQT(8CWB7-12)NNR:Q)35X1O(VV[0&![536Y&O3@*& A"*&WR('G3AWV
M2=8 A6<:"6/G,>\(GAQ<]YK?<"WX_/@(:35A(/]VY*!P"/1P;1.HK 7$#M/D
MQVH-+&<H0";PKR/ :9^=S&.H=@S5CJ':(81JZ%O"S7 )6#K?W6SY\Z;IS+$@
M\IEOL:.A/AKJHZ$^!$/-2%0$3-P(1#0#"+C"T&K#9CN+37F* #]#WV!Z8<.\
MI@UCE["S1AN&XPB)GD%THR"BH>"KQ-)G$N20E[_.P2>5U_-N24V*"%1D$+>X
M1([\0;?+%WQ]?S_X@XZ7_SZ:K>/E?[S\CY?_)[W\;[/RMUKK3^@IZ"UNKV8D
MU.AZEEM<DK[J'<R+-%]2(S+U9C>C%$*#YVNEJ:UN]'&AV'3JM)N;?8MU(&[V
M>'T9>$4C>4R&AE3U,8K]?(_@\2([7F3'B^P0HEB]FY3BN312SN-&?Y,4N4J_
MA#H--5-UD-""R9B-PZ,79D852J+'E\S2TY@_.>;$2\AX[A;\;5A2UJLT;V1"
M)TPZ[21AA 8)O![O74EQI)"/FB%?R+6=_WF':B.MMF@:8V7 C<%\>J/UR@"D
M/U'"F;AX#*IF&;#CAJ#T!Z-=&K 8C9="6^)D3IM**[D-Z7@0C@8O;'>278C2
MU-/D&4N=$&%^U30Y$U-["B-E^N3:\4*'1,]5KTI$3VK3F+2V@\);!'SU]A_;
M58?Y WD5FL^  :BJI!!R[,AK"Q(^5 +6V:=2,#'.8..$S"H,YF!E%2+ZL:NC
M:ZGK$U7OXSJPS'>FK$Y!:HA6*>3V=]_/!7U9'?<$(F +?C\25Q")C<";BX81
M[#*WJ;*0C2CC]>.%8^;TAMZ&4!08V8QIBIBOR"V+4JL=.K;$,ZS 7@KY#6UE
MPIL@%&@48@ ("5'M[, %*#>]RS:R?[S9A@EX+<^R*_86V!# &))7D'\PM(]^
M.G_]]A7]:::GR"[1@HA4 DK  $U >A6#\<,NR-*.)4/CD5,>,]Q%^A+@ZFEW
MD2-Y+D4_).9\L]>5*2^ W%EXB\K/L2;7P4 V? !C"[S(#3@(RZNJ0/.IF%HP
M*RE_E9/02G[KP.JH?#30#)A!\4F6EL<RMH!JOD"03U;O1 ZH4L%[J^8!AH.I
M!(,BS[GP%4( :H?J!,MA,7FG(731CIEUV)&1*58VW?;26XNLBKGD:+237AY;
MZ'F+PB!U[G_=4>/19J _N<W@%+N:>;4R.OAQ":3@PFF$G&\.4J$"E)!E6M?5
MVA!%E";/,SSX$@O>E<'V<YR12[*+QK_O1D2]W%MDDS#1OBT$]EIE@K]C+;=6
MZ?+&P58D:,.,@Y)"H N *:V$]S /1&_L=DFOJCS35_?Q/@&::*^0; @=!'O]
M9C@B=7Q<?#%#Q<?4HESWCFLH?-FI[)/-[1)"P6Z$D)<I:6&4=3/#]DFS@ V*
M7YTB]QFYQJ*!(-HV<IE/A"J:']D'W$6LBY.=,FB.C)HY18@Y#->6_:(")1BQ
MTCU9#M$N,75>9035A.N6=357=H1,D=_P>I$8EKT:N!S)6LE*1? K9,X6FE4[
M.J+DDU\NTK6;5_+F^3*VAZ S/1/)79N%,/[-F @XKQ44%TRF;E_:_4X4X\!O
M\,=&[V6[$#9(RQO:^7KE8L[/A :1]X(2'\IEQKO3Z$U++58C#*T"-_?WOY*
M"K>Y7:BN%)@>79=<%J1;A3ZW-NF[X?X7+Y9D3.2Q[#VJ<T]89$ARA=_LCWM
M'4H>KCROSZ=]L$3:9P%"%5,:@&?)%!GK*E0;$Q+61U>?@"N90K84N:%_F2P$
MS<)J!+C=B.EN'!-[Z%YSP)#J9$V#BCM5UOF2<LCGM6%5+O*?6,MP%QAZOGU=
M T,73O^[LEJ?7%;K0!94 /;>$9^H6FND'^).%=B]<SC7\%V",TAA%QQH6G-3
MR$#$GW9B:V#5))VC?BCKOY2'Q8[LZ.@G$;2Z"@#2FR1\I\"1D.%3W$OZ6#;
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M-T_E/K%S0!^3%[B14WR0QOVIV *H_AFQ0BZHEFZJJFE1;^RL]>GLD-PV)9>
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M0?UC<QAFSM8"%B/)F;U^26UTW.M![C\,5UM$]WJ09*5P[OQF5JI&L6.)O24
M>],6-RBA<I7</GQN0M@2;BH$8A3/:E$7VC!C-'.^@,A)2>&%ZO7TFG&#YFSL
M7D^N=S;W>IC:A]T0E920Q="ETRU1$IU3,%AGCO)->O%C:C&?&R8CQT^ID/'4
M!(YG/^+5E5A=.8ZTC"#)GZ"8[TNP#O?I>V+W>FJU5_>G\].]'J<-1NQJ3D&
M/&P7]Y(_0;0TB,$XCH$CLM=O2HS/>SW">]_N]? FCD-;[H<WM"GL.=6BG6+
M;$@/ZA^6B7=II8"<5[@@]OP>]R3&>SU,O;;W>I ]6:\]'NF'(6\_JV3G*:@4
MFEQR>?8R?YP#(LTPY0-/?+X:PHPQ"\KSK0BO.?--A).4T20Q"(5X%R7*)\'$
MAAJTW=4Y34Z]FYM!0[)H8O:5 ,X0?9/4BHFT QX175OWG.U]Z9*/CT+!R$>I
M"%2\9@P"#4+-LD!>KC?+88MKKT\S4<"TM]W7<;P?"E[M1^)K?%Z5%P95X0,_
M'\\ =-]P?E$86(SG7OGQ^;/D["W'"/;/4_V!N/!9$OB]8+2Q?OL57/LXGA#:
M0!=T<#$._\ 184(L-XR06%".'*2K#'X/M<LD?'$<4C&!%$%AE;88Q;Q959?7
MC*09#(6TT+AD(.\:'-?$1C25AD*9#6BXCZ#&:C0,,_!,,_9TVM#&E^F:QK01
MA'>49\JW!PFJEG[-62#6;DC0PV!J1J]2B0-D8!<7L#@"0P&FMDY07'&E"VJJ
MR\0$TFAYF?5%(?CVE_O?3K_3=@B>AO#]"P:V7MA)I'JL<-"DY06SCO-@_2O:
M8Z!KM:V +@IV;_[G_WCP[=\>"S.1I-[(6CKNK ,_B:>M-AJY%1ONP,D6=C(J
M937=[%?!H)-BNEV%1O D >[>P[1Y]Y[:M?ZM2_%@0;1,@!V=TL+(/](&"^W$
MM[&=<%5VW@!D+^17PQTO/W)DCXI*"U.HOG#-]2YW_S!MF[07#/L)_"$<G:$1
MEC6LY$,JK_SOIEL-_^W;A__Q-X"%3BYYD>_=MY?4%=B7(!+!&\_N-%^=L4_Y
MNWB30;(L%6729\\<8LAN?[N_^9R^>';^ED;Z4V'W"?U-"PSG&Q@JIOKKJZCB
M5W7E:-8#94<],;1&I(U-X-7X_(,*X/YWT[OQ87>/O.VA/_33:9> ><KT"$BE
M^T[^)8!4@OK@[2\<8YI(Q9K^U:^N2ZC8.3U/RVX-I_)' L$$!T__A0WBG=Q^
M#15,J?Y -PV8G!FG-&(L>9.XQY.G5[4,]NAO@J]\ ]R$FY=Q[OYR_Z[?'"P&
M2BKKI)2S4CC!O*B:H,:^E&;.OP3/=%!QW9_VE]'D"9)/[I3Q+(K@Q"OIB&%G
MV:MC:6]E8$1+N,5 JN%Y()Y'][(RQWVMC?!O^9;;^@!QMN4C.I4*$W5*PF[:
M&(*OG8="84G0);;2-!:6%?J'_1VTN*O;[+JZ/)!4.KY1P:ND2;'MBQ$M<G13
M'_IA>DN8OY'MV[^;W$K(+=!\CP/'1S"ZXIS-EYH=[?CXWB-'K]]D)CGH00G/
MG3KY+H:8NZ\+OT7!(M=\DUUA=UMO^]9I\I-+=X\<ZHE#Y%.O$+6JVB,C !RB
MYY-A&:$)(.(70%OJ:F,-S 9;EI J81OD%*+9 ,2U?,S5O0WM$U[4S3$_#-5H
M>VU*97QT$)3N=TU/6?!>+OL_AB&ZMU44^[,+)B/RR@,_U8,KLA]-#@A0UY<V
MHMN<5&ML4;1:YED.(PI$94A$&OUBY)LX[[ 7>=DX\,3AD^E ZE]8W&L8C2D;
MYZ!CV 4U+@@+D?H2R5PWS@LDDQ P>AAY]&%QB2/2Z@%QJ",5=78'S3#V*J,9
M*T#FCI-D!T>'T_X,,-@3+[?2CWMW-$@WL:;)5CT+.X=D4.R/)&453\)K?ISD
MI@BU'O2/\4[IS009W##D(<2XW);*G-U<]X37^AZ^"19+O*3TUDU_.T)Z$QWN
MKQ7L*7^H:SXN\-[Z[12)/_CJZ^E7GRX4=R'V]@A;;BYL[@O\E5]" JN='-;)
M<_>T4_V<$XB<V1E<'TQZ\,S^Y*RJL\,WYJ_F;>4(-(8QOTX$##F/,4RQ44K/
M-*@AY\TE8V3/K U^QCJ%S]-98YV=G!0Z!$./5T^M:XR')H_H*4!5.$S]&P!$
M/(7[^&^32DF5T5A6:(FWIY(Y$;(8I+#]$<GY_+*J"#+[0F0<'>3YPY-L.EV<
M9OMN^N CC_:14/D#4;S??E8HWL^JT#A,LOWQ8QJ[F?X<9$MBLJB1"/[DO.IJ
M)@H(<JQ10#9.)^\=*'$%!*>,P$UD.#RRF2HD5=<Z)2R51;_^N9.H<##(>!)S
MQWB1EBO9(%)IYC8,1S@PJR##N+,JBP>.>$';:K(/75'VN<P8E]*#R'_H^T@M
M-K5O)5W1_\Z:+&Z\IW8[)/?NGOSGP7A@*JMV^,?WW*S:@,3,)9U[F> BV(_\
M;!0.@ZP1I=)DUI(?36F-P3]R)QJ2$HZ!2#>4;>HYJP=YE0M?LJGLZ:$.(U+!
M(?E4+^Q&M5?J%P,P(<\TJ-BB0T+)5B>2YT:(;0PS$LL?4S+VTFX[_CT8LX#O
MSU-IOG[V^LDT>8W2:,K=I_BI>_AIE$UC)BW*'ZRKNK#^5N8LXL176LA D4]6
MTU"(^Y![ Z+)==,D\E03P:]J?2QX7_?1<>,X-(FB2J)U+LI%* $*F"$1M#DJ
M4F5:E>\E6<.STS=>S! $$)4KRCJZR0E^$SVCTDDR83&]C5!WDB8H9P88IPWF
MBJ"-NZ< TY=D+;._HF/=10F]?Q\5:D.V71OB.:=K?UTE;*C#\)V9>&2.O "0
M[A-&$SB6NXEP(Y"("OUO5$0T/O7!6JG"04OB@:&$7C"OHA7&>I#!Y$8 ZEO.
MPA\PF1R"H*1R41'ABKH$39!B9Z@#DXV'- A^#N(=BBF(L^;])Z0.Y;#K#,1&
MXJV*=$83GA2CPIO,&,(H<T5,X2\B%BE"D2SQ0Q/F)#8/O0+CZPQ;#",=*)(F
MQH+A**ANGY8\>H2(HQ4/MRQ>/2T *>@.<E+CPP4?[!E=^Y.W/<I)[^H)&0W*
M*I6UTQ=*5TC$.FZ4U) +/2]"N2O9H,_H#E[*#-_F3[]+!G,,!F+WV914O+/*
MWI;F),LO0(AM9].0ICI6&>9!*U/N3F7W?XZ<KWV:MAP(+ZN]WO)V+#I(Y6H6
M(^=O:#[7?M<,%_$&6V?DM5C]65XK**^!W87;II!2VO&]I+9HZI5IP0=YC< K
M4J[/D+V_IT'(&*CZ.G\\X#W8E;AU_^A>^6W$=@F0PO68[B]NH4TXLK]<V@_7
M 0G,-]UJ!=7% !#V[T-N_T')9I'*NU/:':=UDT>U=4NJ(GE!5-[G-B*>S;X\
M<$LT6EL<,0/MKBK<SMBI%R[)S"L*[9+XAU#\GAGP+F@2W-HCMQPF6(]A .*#
M"L.F"DZC+&\0?$S4EIPL[(!$:O>$H#>=]<Y'80@\9/1N71.KW&%OR[JWE)H&
M_TRZ .0$C)!?:K R6I@<]]! HP5";F:Z&H&T^/02<O!-H,KLQ29'S3DP-M@9
MG!'W#/*>?J-'RDT</;6C PQH\Z-:L(.AKKH:9B7FX_?7?\A?;"9)G]P_$PUD
M&TD4%>ZUL-KH1BOLEABG#M.YK*I+;E_47A!<3HC\4?G'MRQ?;U]+]=I!6O<>
M0.=&VLSY 1(0!-$?_2L)U=N?\W.:X$&-(XN6N?#J&V[N@DC ;20X3-/D24Y[
MB=5NP9+DR6W#92>N=[O=.G!,DU2JX*&1;P=WL-"J.+,O 6P5/+U"@&!]T2N[
MS3;Z&\$'#MT-&S5^@Q0-YTP(Q9X%8#8<\G.PH37)?R$K8R-BK,,Y0=O@4*L-
M:O0(Q24LXE,+;2;Q8/SS37!3AP:3,>EI2/L%8D@>%4B$\*OL\[.(QT*H<RY3
M[G/9.E9Y1C#DV]I_B1ZCL0,9T1:&@T3.+CDS9C_9")C:U?V$$I84NU/X;TH5
MPA$F 2C_\M #)V.:=OM3:%.4DC&/'OR7>_<?AK\6G$+W:]XCWA:-2T\F)\6$
M:#*-!+P=MXFCGJ<L4J37+0U3CL>/_G#O+FNBO7Y\>@*YX%6^,D2FZ(GEG=,F
M\N/\T7MNCN[H, =)C31#&AM$\+!,DQ@(4_6A0T[+'&='-,X69";LB;)F F1(
MF1T<L#'R:;L5?.-$7L8,2>>PE&YN?<]YO%?H@(GII6HWY(-?TQ1]D]R)X.J-
M6Q!G;.,W&L%^J 0]7XZIZW*Y]A<%,N/VK8!RK\.XD/%AHKHO!0_$0]97XG%K
M>#66,[DSLTX'P*T^3>G>5WYO?FF-94T,V% SA:2._S!=75]&HAR4HG()1A*U
MJ25O('^J^,P95CD0L8,V3&!-E&$PW/;"[E4[8-,=^ZI H!F^8.B+OL2Y]GD)
M5<_SJ0Y'#)22R=B(_Y,E'S/]/<*_5&% \LMVR]GEX3_;P\U_<-[ 9@7FH+2T
M$TU5/'M:F,DP<^+5*?2>J15!59KL-=PBB3H3PN&6I9[U!'";4>LTIU@SP7K+
MN+T%0A>SC$T&0Q[1HA*R-]-[%2529K>*&A[#A0O-BTQZF*,Q5_ ,^$EVT0IR
M?ZN%3#+8E#A!.1?M <FOQD>;'#\A@DOB7PJ54W#-T#%GQTO8P57Y16:+06&9
M<BKV+35?=QV#<,DJ,C=E 4[KF@I_$S="O9'T*^2ZRF($L*8?S&_PSBFN6>;9
M28M0)<ZXD*_%)4*?J* $>3 @5YJ(WMVQ4X7>/3.W!E>54E==]SPL0QH(>R4D
M1@6-.-IJ=(=@R9G!?0Z!$F6X?[_*ZX Q$!_DC]&_&#4*=J_E+B<]+])\R18;
M1S.:_MZHF-6$1S,9^4;?@Z2!6$Z:Z_$JL[[(KB=CU:6!X?[=^_8"R:=FRE^(
M(<,2,CQ)$+%#TQ*!AG3'1Y;FRVGRLCKR_7T@4NB[SPHI=.3[^X!17>OS41V$
M<C[4]Z_T>[Q /^MM9Q=CZ2-?U9?IR]WITUVOQ#0Y(]W'AK,#:1O\LOKC\+#T
M.@YDD.;RBWG9NTQ=IL.[^6"A7Z[$%9AIGB@PV@&"L6(60?%QQ)NG;B?WH:6=
MS\WMDZ_CI^';T=![;-5W;9!/N"-&,NV[4^PC27603KPU<K.?*1 U^1&)0FO,
M]6,:Q^HG[ +)K-XB<ZX/B4 @_6U\R%3.9]42S/:"#'[E-%W>,._U#M33]8F@
M_:D$O Q$ PX\W16^JIK![[G15NMJ/YZ]_>MK=2O'.!6"/OD'SR>N\TX[![->
M4R[_/.Z[)J$V7]^6>A^"I72U J6$@)^8E(+DUR?:[I*<IRI7^@;.=V$CNH??
M_8W[>-GX%M).ZM@LG(J))]CKD5>$H))"</8L6$34%=R(BKST"2(9Y+TO"&%H
M!L,\EPPUCXK"0SLT.[:@>8^'[WO]7 V6KTIDF91W.K0]<2NDJRGV1_!<2Q=O
M)';![[Z"PSP=71NW(2A-6!;N@N2[E<47[DJ Z'NL ;9GC"@#Q+S#??=@\)!G
M%:.4T"_04#/Z@1N(X0LK6*OA1K@9LDR>>04X8QM(79ITFZ@Q266NJT!=UCM'
M P+$R4WT)Z<P0/HA_M(HPRJOH(?=03>)=Y'.SKM<X,"E6=OMCF<%]9,F*EMI
MFXQ(T6SZ[[N(D&(!\IKH;B@VY8'T>*45*Q:_P/@<PHRQ-%W0&XB$A-UNZJQX
MZQ6M3F !XT^)99-:+4?>J73VP\Y:!UI&)IBDD;$KO:V.GK;'33:%@ \R7ZS#
M3T9OF)B,19NKD1QOIM[4U8&I$X%/^F(E(PND9"@#GX4U3E()&K>M$HV,!XV?
MJU5[<XW@SH';N%?=#MUPMU$\3ZZO,J,.-4\:4J"F#*9[#!TC=[B*C<N$V[]0
MQ@C)5BV_!#7SIK7.%0>IP.!08T% JQ>D;0?!)Q6RM,UX*=UT$_^Y\*VD=*6)
M[2@*#36V,F-'AX/J9%WI+#$@G>MJ!20#<7"&1RKU6L"LZW>]-CM8#%@CV3V.
M49#: ;-)SMZ\<F6IAF##J!]T)4O;]R6Z;(S2H'!9Q ]T8Y'%:ZCNP>J"=J-E
M4,=;XD'BFIF4&R*)E9Y3[61W'*V2AW?+]PS&C0RK7F.4,/6SJLZ=LY+A7(J[
M[==?+QXPP+2&!9#E%Z9$5QB.QKUHK%R,JF557#'8O6Y+4^N+RL<S@X8 ?EG#
MP$VOUAW669MN!N(7?FB3S.N\Y06HMNU<>8[N5TG=;IC1W*[%/%]Q@B=ULE0[
MSB8+N4O:WLF(L;ZT*2]PXP=BIX/]X:NW)E([[(',26@<W47^^ I:!(-RY\C.
M">.@I;V;]HA^]^A!MSO 57RYR/YK5P95=MT:F!ANMG4E&NEFI<H(<X'+R_?T
MN\K.^E=X!B V%$CY724I)TET#T^/M77X5^3%#:A*2&Q[ 0SO_V7OR[O:1K*^
MOXH.DYXW.4>X;7DEF<XYA) >GB<=>(">GODK1Y;*H&E9\FB!,)_^K5M5VI -
MMKSHVKK/D@8C2ZJZR^_67?EUELA*>O:EU"N2#53/Q\?2Q@[W/OB_TKG0!W-$
M^%6%_81RM/G>.:+Q*9A)S8#3US<@.T)DH K5%ZFJSMO (H9D0MX- -+8]V*1
M22;[14'[+TB32C7IF#]\DECS>7T>1N9D(KFO *Q^K@]>KFMM*U=!-4VGTR:C
MW#BL0M:%JZL.'5S_R+'QJDHJ-]@N:2SR)$[3HO-)P8EV]_IN28$":4EA0<ZO
MLOP[3RQ.#&U/8%?HT20H+%&RJ N%EW.>U.8'W7/)GXF\)GF>F5-P (&_= 9/
ME$W-2=3V"RN3]"UJ;)'A =YOJ=:F)E];!(<(Z79)5!0\-3\L<HG]>Z8.U5GC
M3F3US5-ZLMN+R]2H;XCPISF'R@&R\ 24=L;1<V$#=<<4,IGWX 2^)RVQH  [
M@DWEA$1F%\Q 44P3^(]1FLB7LFV^ V*R/>I^&<<\.W&-F4P*F8E40\&4_+L'
MHX5EL$<@?Z%O1*[E2C'W+HT&';AV_I1EH11+O/GF%+/Y1!)"FK+HE3H4JX'E
MEHBRJZ0PSH$I5^;J^&3U>TYAY9Y\G!R\%Y)&R>R8@P"8'^$]8\+F-T4BC_@L
M=2+DP_13QK6FJ.M3+RFZ)\[IJ/-BT_:7XD.JF&]%#@,S>=XH1)&&-E87*9H+
M5ZHHT!&JUA26>:Y95#+/+ F+JF3'_)WR8[V?IT[((.J?W,B[]Y.MNG?8@SQP
MI JK6)^5RY%4E3OIQJ7%.=GG\_8H3Z57R>^ UT;-[[9E2D^0C,< F\'QE4K+
M*=S<XX#K CNK62[T!4B[ 11'MF;!8FF2SW^QW$.R[5?'73$&-P=N06$TM>H9
MOX#=T[U3M+2@8 <* X4MQ%<)S<?$&3;QE\%9*PW&J2&T+>U_(64N-]5>K7[^
M4Z5%4<Z>I8R6:GIVU*:,EJ9DM.@J6CHG=SRO%),/6]!>*Q&T0AZHZKJ;U[S"
MP#;=?"5\FHN:VI:_>R)7Y28J)(:?QU [Q/>-_QFPZGJ>>!>>#Q^(!)0D$P9>
M*&U +,I7T@:'^41$Y="1Y?MIIJQ(.TR3.S,G0"L-1!8>;CZO6$V2)ELJQ+O@
MI>$=Q0$H[8R>YOE+LL"DXQ"R.\-\BA&T@/TM/=EI4XA5@F$$O3$C4Z[QW[&M
M_NQDXY.5U^1Y*[*Y:I4?(U-D$*[#\5/N./E*XM%[[2WJ<3X.ZK=[EW=""9$
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M;:H5JIL,2"6$\(&XO[ED('PX^M@QABV:.EHW%:A6J-[]/[LWO3NF.9XV,9T
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M_$0OKV#!5'K6./2:KJO.:/?J+X 4IO>4^SH\PK0?P'_%#XCF9,*L2%Q_[[M
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MT#@SG^2$W(F8R^I/6!C*\4$A"QX<BR\J8*[8$(X=\#03)FC!=_AE\"E0 +8
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M*A"F5<"T075,JWY>[NJC_N:J\DBN<9V7*?2\!A&N8."V8XMIU5[(J!M [4*
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M_*F7\HHQT(&XGUHRU\'\U-9XEP1(PMR:/]%DE%K[I,V2D'13FAN'$'I'5V-
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M],?MK%I+U/__[+UI<]M(LB[\5Q!]EK#C)=5<M72?.Q&R;,_H7-O2M=2S?.H
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MG..^VZ37QZ39>P/TVEIM(U%AM<=J[PU3%M1>A]6>DW[W_3AUSP>U*OWPG27
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MG> 6V;=#*VZ1?3;':[!5Q^L!/VIC]^GPI#7L;J^QEBM&.ZQ&V/XZ1 RVO[M
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MG3\IU_E)>VN)D]IK=O7T6MT^+VYWCQ-YN^WKEVO3FR32G<<$KTQA[CA*_"3
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M _>\@WQ@&2O;[S(^N\4+*E;#M)M5BJLUCBRR*K63DL^.G\9COBIG,Z!^O>'
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M@JUFR"K7EU%3C%2.*L(5LTCJG:D_UX*S+."4-D[E-"3.- K8N"3&LW1<;;4
M&F "=-:.OM38)GK,T.\OL->I"@,1XSI*9,:<"@:T:@6>3E"#*<H#7$VO0_!R
ME%)=H]!O:L"I=>I2IB#Q">S3("QTL@KRS5MJ[2.=$+#M:8!1+ZXU@+#6?#&H
M;)*E?70B4RXUU8G,Q6.LVA/T@<)C5\%\R\J081)1]9<I(TK-11MR_$YNS?IS
M2MZ+9 A6!/;18'\B<6\%Y7Y:;5&\0C_2S\+<^VU&;7S59JC?3#WR6WI@5B@-
MVMUA:_52G2:;W)='B'+L95.[KG^K(>S+%C"XL%QM;.3FM$*9/].U!&I5J;&
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M:(M8+>Y:.#5PM'7Z%4M>]D =39ZL2!N8P##2J_+0 Y("'>.6DUS$5 2C4.%
M[5IM_D4&G,NV/5MK-O0GBR4!@:7B\,(2<FM99-MD,V,@JTR+=2[T8 \?G[3)
M*+/ =[EIND<PTWMYM=9IJDY=!6J6E:E':"-1W GU#O(VRNS3*5G].'7!?6\\
M#?J2TFGW?-.2:@5V5'\."S23[/0]+YI+;)W%.<WFT]? =73%3)G!OZ8QZ&/O
M*X64JFRFY[UD"=;*@)6T;$=^\59^,;*@Y>LX/.#PQU2'E\<;^*6R;TAWC)WA
M27%K2]/F&M4FW[!,_DC2NV39:54OOW!NS?$,O!(.T8&<Y9,J]&Y\<-<UU])
M-TH0N09'83"Z5?NX*N]%5]MGF6BKH]* _]5<3:HRO A((^OM.(I1BP#E'^GP
M]?T00P+K]=*RZ*XVY3XM/LB"F:2^_7P2S=281UZ!IJLWW--&LRNEE_<C=7.Y
MO"NRJE(K-.UF,$'#[/7.2>J5;-W7/+FB"1,=.S"FMZC8:.VM:IJNS71I[P_"
MDEQ]8^G%#**=ZA54X9;5*FIGH>I)GR45?8HJK5O1[76B)XT43B:02=]([5_
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M:(J\;':IZ>5.U?&9?3<//N^!][5YZ+7=D2@&=L]*U;YITL8UG4^I<21S7D,
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MJ_%K)2].H@-E[<!D)E>*J64F1B[U]XH%,\OP) !:$@$I#=QX)0-YHQC^1WN
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M?-,0&)F^JL55>BY1O9#*40B>*M%TEG2B3G>];2ITAY7'\YO]D\_FBFE&1:E
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MT%,18-XW=-$:U%I]_+\> [-IXL^9!N?FP-?2=IEK#L:9F%!I.^E<-*^\)C*
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M/OS3D>1E<V>EEZ.DFJ7(9J5TL_*$N_*C^]%/(Y1@R(RD]DSO/C)TN4N$]C9
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MK[<+%92'>HL3.\J(U#.'2*>H72VAYTJ,9/LSG0FDT MO"Q-/T(PYUZ;L5[G
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MNRI,>J$Q31]] /1[G'US0^3\)#9-?7GN798,C"E>HMXK[F3;"NI-:2'1@M,
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M]IWTNGQG8TN3VZ4V:]4'MS"43:9_MUWK#_NU5FD<,+&S,@F(:]+U2AATL&5
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MF.OC'2/,>>H(3G@-9O[HU'=V]&")?R\\H#75UU!'J=8;:P9?6EJPF>\BMB9
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M)UC^:)OEM]7R6Z91?]@\W?*?@?K#0L.K9/E_"AL!<09:XE]>_/"7'XPC$?Y
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M5=_K=\Y#,,4-D,+")>,D33AQKIC"D^!Q"[ H@(^HYN8+6#KPYK7UTGN5U]!
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M8)]4'WT.B:<W/[WH;WR)4J215J1_4J3Z:7-G*RNGTZT-^L>KBV:EP5&:*^'
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MIBI8QC66?L8UQK4]<&UT*EPK.,X:UT:,:Z:)$-\+GIL#."O;>KD4=AB],B^
M5$7[@B\&S\N4QL"J6QV""]..0^71P0PV5%$K&4!VEGXCV,"NSS9CY?NR9?6!
M4^7Y,!GF:/#]W+X<V&TF"L<TS805CGQ<.1L8W7=/^^EWRF.9-"WC0Q!F6KY]
M2;H.8D'$L\[F6-.4M=EH<V#4.!$TL'L]XR(+?G79P+BX!RYV+P072W)M:98(
MXZ)I(GB$%%N^*]R7^.E,8?/B656T3OBF\+Q,\7^US3L(%0,$4V])JJB/#" [
M2[\1;&!O:0]OJ6>,MT1CHU)K;X.CU'SQ=G"\?BNL%T[H)A7G2J6#2]:=RN,/
MP2@.M%HW0J73;ZW..OOHX^PM$/OW7N1, Y39;^+P82F66H]P;^+TY7^[CA__
M#1(_Z3CVN-Z9C#OU[JC3K-M.9U+O.I.A.YR,G%&KLX,<=5?D2(Y6R5*O+G^5
ME8@SCN7J-23KUOTWX<CF83C]-<-PDJ^_6X38XOS&=S\%OB-_X&$X6PX+6QU4
M-+/_.P@M!P?WR1E+GB*S!S\^"AZ!\VRMN@^:@I/AQ/&:J%?76CU\XL))&+*U
MHC_C#(:^"?&E3K/1X1D,FV<P\%"",YV6=5<1E<494QG%B&,R:XR\T7BR23!#
M$D\Q,^H8G57#[75,6 6R"KP:OO*(,$.M<:[M.5%MC_UHS6PXPYX]C<S+D>.[
M>)Z"8@"?C&UCQ%-0]KW(+Y^"TL]?=R677* F_]1:LNS"ZU1#P]JU3H]SF8V3
M*U/U-L,EPZ4!?&*XO$R^[0Z7@U/ 9>D,L103.X,^(Z)IHL/M ,_-@7\%X7?+
M\ZUY&-R'(MK;F>?$^HN,Y[,F,IP-G%B_CX$Q+#<P4-E]]+\H5?><'GFO-FKR
M !_C),O44\^8Q])?738PYNV#>:/38-X3;G6WS]5@Q@F/*1?D1\A5O2:V?/!\
M+WH0KG4?!.[9KLT/3U*])IZ8?SFP*<.JXEK-#%;E+PD.8A>;-%F39M L-VFT
M'OT=U>AS>O'=6K-GSK"\K31%5HNSMF"0K2 O&&2O@%4,LJ<"V=9)0+8T;+!E
MJ+S9,N>JGD&VXO?WK4YC8#83DB-;LX"J?(5OP"DP@^R<8'@9?.(LPY,8-NUR
MP^9WU)'/&35HM6N=UI!O24R3*%/5 :,EHR7SB='R>=&R<U2T/,3]'_8X4\XX
M@>*4 B/9\H>(HM=)N\^E%8I(A#\$)Q<8P1U3@^E\[W$QK.)[C^WX]W)WBZ>[
MI@I1JM C10@RR0/'"P'PI<8I1>D5@Z<);#!5(S-X7@RK&#Q/!IZ](X/G4V4&
MC)T7(4FOSI\+L"E"X 8+G$+1;AP11B\J0< 7L4FM8T_(%L,/BJG1]=U;O^:8
M5TGS9^_&16>_)#D**Z_:--K=,EK3"_"3B)\YZ:!MT*"^=5;36LU?*05B7D]W
M!F;3-#H#,P,S _,AP+RFZ^!>P'Q0?L,1;P(8EZN0]'#"\@;#.7!K3VW?$=;=
M@Q"Q]0XGG'H3SZ%!PJ_-"SASZJ8!G939[C&53T7CAPV;BV%>Y1,>S6 #0PQ#
M#/.)(>8:F5=YB.'J^?-=CIL7*V2HY\J>ZK*!NP#O$^1..M\OHOJ];<]S<>Y3
M73:/:KWN\>;-\<F^\I/-N,;27UTV,*[M@VNC_7%M_[O:3FW8,R>'BD^V8=>R
MSUV+?D'.-&6:6\'$4MD4UCP(\?!P:9T);#(W_L>E=1?"*BZM.Y&E,VRNMW2>
M87#\H-WB4KN+D"QN<,^\8$"]&E8QH)X*4%L' ^K^$816;33BOB^7(5G;AQ6>
M*2W_^6K8+XXS7!]735YP?1S7QQV-E6PGY>RD-?WRN7"="^3,! ,&9G-XP<#,
MP,S ?!I@7M.:GPO7+P"7I1QI,=HD<<\1R?@UMH$Z\%O7^_%6\_+38B9"SUEW
M O][$<7>9/GT&<R1XY?,]H?S>&516[W8@0>),/N65GM>I@O*7GR>L_VAWN[@
M#F%'#Z'>TMR^%_5Q*.SO=7L".WIM3Q_M9?3"^G4W^5M+7R)+CL! 7U0"GK^@
M2OE4F73ZK;]=QX__!CTPZ3CVN-Z9C#OU[JC3K-M.9U+O.I.A.YR,G%&KL^/Y
MV)\-V;4?4PJ[C6[WE_6GLOG,Q_+)[!C+\YWIPH5%I!,=Q,^Y<&+A6G%@A6)F
M>[X5^/4'VW>ML5@&\#_P1FLI[-":A,',$K;S8(U5VX2(VB:X=BRL.8Z&@ /E
M-I(CF!41#4OJ3&8E)N\7?@G%W/;<WV!9?B2B]U[D3(-H$8IO0(C;:>!\?\(S
M;,+_S[B( A!FCKP.%V*M%; 5][/:@92T9']6(.KR5UG&CH.I>Z"(["L/_884
M^W7_5:2V-*WUT2YC4[>5;V]SYSP(=S$5GR<K#/N&"'!V7@W-/JF:\D(1#:GT
M_[/WYDUN(T>?\%=!:#W[:#9 #N]#LA71:DFVO!I)K]0^]J\)$"AVPP,2'!S=
MHC_]FYE5N $2!,EFD2P[0M.\@$)E5O[R3M_V\1C"J0T>&*A,CN,^@5+RZM!"
M*RO:2\0C8C=J6TA(H?W\Y44'*,D<!_4;6%3\6FA.]#HCQU\98>"^%KH3[+MC
MK'SV*OKCM2;TJTY'9.H_?PQD6U5BG5!I)9-F=8M]=+[K-?FE2 &I+<HGQY3D
MI82 E<!C R4 0$]_:KK]V@D&SW!JY"#;.V:RQ8QYG'S]KKY!EE_:LR.JR^=E
MDB=A20XJR2/AKVF#E>26G6Q7+KD[2G++3B59BM3JFE&5$9W+C;)%5K[IV$O;
M-)S8W)<O.UB5S$O0]4TESS>.2S]GPS>5-'^ F/.@S.E_*P2E\"4?*P6LK_=&
MAVLGHZ3#M4MQ!9[J>$A )P6>YTFWW<%SN#=X[I.FU1W*4\*MI(-J!GLN%(C<
M ?;2#SU*GQ'^ /F<;4JC47VVKI<,JH->$Z5DE"^#%_+N8R3NCE;1I?>GJCNL
M=!PDZ^E6V*:X_WK)H+"M";:-]\.V4FL[U16M,U+P)1N3R!)??^XFL)*3Y4OP
MP#S5E$X&4L@?%SAUII BE6I*=R*-I3"GA01GME;K]MC-7@<=>7K3*7EQ-O)"
MP:P\M%#'Y@)(I6#V6#!;&!O3%&;W:0';ZYY7-IN2%SO[&)ZI%$MUA)7"?:L:
MS\E#B[TRC%3C.=5X3FE/5=K3M#"*YEG]$V.],SZ/P(N2,^>%&0J_Y:&%.E<*
MOQ5^'P>_"Y-OGM7Q,=*'"K]5@]FDS^NS-9PM=,VK;F[9+QX1=\6\8/W5,:BQ
M\OL_0GNU@%NH3I?-^66\M=,EWW0-VYK&.Z[#[8/-_6P'G=%OV,ZV=^'M*%/;
MPY+MP2ZRI^I,F6_J+$UCRN.61\F1[G6]YH(4L>?:4O6$K<M&,K0NZW?:?=6Z
MK+QUF2:ZEIUT>H+JQW6= "(K3124R$,(J;M@UC75KQMK3MGD5V&,!/*LT3%1
M D\)O#.EZRE[XRJ!)VV3V\L-^+T-;0<?_<]^&#]?BOC#GUX[]I*U'O@=N[W.
M3Z\?F1=@(RHA I R;U[^^1>XP)L]K]+]65Q&NN16U51 -?F2@$ZJ!>!YTFWW
MT'NO=ESQKY[K^QLBB>("E;]_N[Y;K]C-#]N/OAIAPJ_D9]Q['/NPVS^+\H6K
MDB2R2GP%M IH):"3 MKSI-ON0%L_@><Y@':/,D$%M%)RI"QQP^MU<7QBAL\>
M7,?2[,7*<Q\9'D8I_!V]/?T=JHGB609:E&R4G RJB6(336IP0DTJEO$?$Q'O
M'\)_,>[J@]'ANAPIT7'AHD,!I^+^ZR6# LXFP#F4%SCWF",TU'L3U;9?.O94
M*1>GIL G8^9Z1N!ZO!X+CIT5<E$1EV;)Y[53>HUREEXO&91>TT2O*9D8='R]
M!D<F)A(6OO0UEJ_QUP^2V(!CB88JWB(;F\HJ0A2 *NZ_7C(H &T"H"5CB60#
MT'T&#4\F X6?LG&IRE<X-05^-<P'>\F\M9XX!,A3,(?S%'K,E\^'II0;Y;J\
M7C(HY::)<E.88/1<RDTL7^,OP)<_"-EZD)P!?3H^G&:CQ,>%BP\%GHK[KY<,
M"CR;@&=A+I%DX-G<+=#7QQT%GM*QJ"QI W*T/Y.&++?NT@\\D3Y@+S&9X!X.
M8F,7@1KM* _FJE%MBE1JM..15*AQIV0XT;-E7:;%]L?E5R&T#^%[Z.F=H3Q1
ME5KR)HT%2N8HJ+Y"6BBHO@!2*:@^%E27S"&2!JKWZ-@PU<=C>3HV**R^\K2(
M;K\]EIL(Y7-LY/,-JHB.K(/8KEQFR4$GU<GJ*%K2X5I&[E<8T1GJ Q7"D8^C
M9!4'"BT56BHZ*;1\7K0\7-_'O9P T['>'1W.":# 4C)[7^4['+B7H^^_TFY,
M,UR$CH%3:RVV\N!8T5Q?*9HZ]D\\Q$+%=<XA6*#B.F=#*A77J4>_E[LK8866
MD2G)_BXEV.%OA^$?H)?=+%P0NO^E]RMUMJ,Y-P;Z>'RXKE8J9G-,AOQ90; ,
M9)!5KBL(/AM2*0@^&@07FD\^#P0W]YB,]<YDI!#X+/CQY],G3&QRH%AN.'.8
MUFM?#QB7IU#HVI*=+(]B@[9TA022-0RQ^R3I#/&N4IUJ/$7LY-&D@Y#RHE6M
MW36M^NTP/[.C.3"F'7W4.US;RH/-/*\K^*]*?IP6"Q0NRT,+A<L*EQ4N'P>7
MZW?9W(K+>^2!=/3.>*QP>4<>XWP4L=$FCGN.W)!? @-V!]ZU[,<W1$MD%GL9
MDJ>LZ@S^)_0#>[[>?@JSI/B>D@\Q"<5GW>3'=,)?32;MR?2G[);^E-K"T2K(
M/!@L%9XA6BQ?)U*&$Y4>4W#&7UYTX$PPQT':PQ+BUV))]#KB4_X 0$?'6/GL
M5?3':TWP6Z<C,D$W.HGXEP?MP: L*:E2UM7:YQZ\K.*SZ3/SV9_AL9;1@\BR
MJ)==S&^!A57))DJ".0()#O8,]<!I2B<"T63NNL'2#1C'C,]WO]&B0+#_6#BO
M "* Q=FR]8_O+]Y\7)I.:,$%_[0["A7:(7X':*#I3"C=[_"Y^+7^9ON!ZV'6
MT:WK;\*C0\RC;FYH[KX#A9Y64NS $29RY][0C$![QTRZH];OZAKN._EG\?:P
M<2 SM;F]-)8H7S4'=T3SF!\Z ;Z>>^Y",[2Y83O,TGRX._\*;IKVTF=,^XS,
MV^W^W*9;1^R<G%^"KRQX7:W\[RCYOT7^]XXM_RM(()G\'QQ6_G<+[6A.(/V.
M-T6WHT^'Q;0I$G(-]JK0#T"^O=IO<&))6X#-**$C(*P8?/61.6M=@88"#:E
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M!(*L04:AS^XY#!D>0X";NX[C/OFO]CW,G2K]F)H?E*8'[./5XW=^982!^_I
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MM%"0=/ZD4I"D(.D"B*,@2=%"0=)ED$I!DH*D"R".@B1%"P5)ET$J!4D*DBZ
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M)?E]9+>A#\_!/,UC#A7,^@_VRI?/Q:PDE(IK72\9E*+?1-$?2*'H1Q+V6UK
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MG (1; &D:7:,;II!\*9K2Q;(%VI5"= G3D:H5$BO"N%EI9.:,7^,&?/#7<9
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M&_YVMD$*@SA+BA3>_S"=$$GW5]>UGFS'.9J?K]?7NP>L\3M6HX]*!+@J0:(
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M''7ZI0R#.]+MK39(*.(8/F<]O6TM_E::^%4C^W804TUYIMMI<Z)5_4O4: 5
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MC*3W-<W:*[2Q3H8-^-' C_Q\Y!PBNAYOZ5M#:KZM"I&<*X;$F,'/[5?L 1[
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M-J[O9G4!;&%,$,J;W(MQ[7/6<$A7OY\=94R7^\#85[C-I?+[6'1J[4S1,=)
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M8BI9QOK%FWZ12/ ^6*R@B /GHD.71I==</3M$\WY_8JF.T,.J1-TNT@/Z4W
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M9#$:3ZX!;Y=<\(((VM)@)5H*2!V6-%/>;>!I=6?B8@)?W)BXTA#@S:J'T]=
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M'E<B_'U;T@/YM'BP.*/M$84@*]&'(GXDW&/.",F@38)2#MAPG6BDA"M8@W.
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MK@#P"Q18#[-^*0.!;<.N7AEVO8^3%U#I.Q$>Q8)OCMR$"I!?C@L['R.-1BH
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MO61"DZPA(Q&J$'ED3_PI<#^$/R+EY$ '(.:*9-4HX3C4T;%10X%20";E051
MIH!, =E9 YD])QG,9\[C"QX?L_U4E+$B[&)'82V>^!<-O17IG/DL\DS,DV=$
M45DT!>>2)$Y>ITTF>!9'<)%1[QY,<8-%]CM@8JTQMY)\Z"(X%Y>^8%QLYD8!
M6V["\3!Z/8.]CH%^;6&.0EX5>D-PN#8@?S*Q.^\R29$;/\;@A&BV 3RT/?&!
MIH2R56J\=7$9(MMRU^ATX4)QD#/*V.5Q3LQ^O%_RW"H/9YGRRU)X.9T^$R4
M;0Y7^^'L/^*HX&Q)C!%C-75 3:#Q27G6Z0UH++P3A;/6*YZ[V%2D$"BFE %Z
MJF7+BUN?P?YKCDN3D/'2:_I*NH0@(09/2\7Z!T_$<.&H+5#GL^)M8IAC\+%B
M4].7]MT%PT8LJ9&UC>Y6L2%19Z?4@XKGB2)T5+R>VC)<4S*"V8\R8:D3@MA
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M8X,OH!M /*?.9='2#4!462'(IJ!,C&5EX28E X#/LFPD*XHU/;J 36)#@Z.
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M8@=R$(-!(79_DS?Y6&K8.08XNF,5X*BKJ5;M52[J %]+1QWB0 <HM(68],8
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M$W%%S1.A-TG_"=CPDW(<$+A,L%NZ2GS0.R("KY2(?Y!YVZ^8ME4/E_F@G-&
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M]=,-[6-+J' L=.L9V/:XT1M.J'Q+-5%^I1X'"%Y)\&O+!H+70[.5@\JSE1$
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M,),ND&&;;V(/=N^FA$G(V"&>=2J04P#W)7WG497KW]7K+:A56K=_33-<1AQ
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MU>U3>.?7FSO]*H.,/O8?XJ%&-.2Z[:M7ZLRAZGHYH6J%.76%4[XK7'ZV,YT
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MTP?-@3X9L:'>[K">^6+#2@[HKER*4KL)1+F.Y/W\P?KW;,8\CYG2E+][OO%
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MLQLPK3-XU1(7%O]B'TV/+72+_Q8N', ;G(DXH%BW[=1['=E-,W.<"_[7#^T
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M I,JGM+G;E*L,.!3YE5A(.IK$^+0RQX%C)4;AC1)IZYMKK44XUTL1:6,@)7
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MG\%_S'O]1Q5'A-]9[E14%R3GA-O1.>%VZ4;\@\9@,%2F$3^AK^(P0.A+Z*L
MGPA]+Y)M^Z-O3Q'T35?#R!*12F%XW!AUU9F'0S"L.!X0#!,,*\ G@N&+9!N%
M6%7A@YIFCOI G4GZB>:$Z(3HA.@GV%CWC[NQKF97W.DWNJ,Q;8M5$[>+F AW
MU15@OWJN[VM+SYU9@7J-XR@\4:]^?<2&G,-2;W_DP @#J<AUJP@!!$E_?=E
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MQ, /U"E9<9]A:2_,?9[^XKP//HB3>BP=5&3%8BK;?HG/=V'9KKDJ2/[E5-[
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M46B3:KISCF@KC-=+A;:G!L%F:[<1J*!]--0Z$%I:.D)6AC>5$JU+?=8C;/\
M5T_,67"8#U(<+_[<M['EG-==7LFD[UA9M5+RN)9[P-_C\O9%QM%$0X="Z9 ]
MVL#T$8R7-$4L<*'N%E'1\6*4TYEQ6(\^0ZH<U<#).Z!(3#E$6JMUJ%.Y8EI>
MG= GA0 D5(QQ0"YX(H:_Y+*PA&A"I37*@LG.T%T,@)'I)P/IE&T\>;0)Z)B
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MWPCO%O\QXL"W4N*&0E=S'?*)"!^9'WNY5C&ES\A@LU6V"%*3C$?BF76<6GI
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MN*J7>-7TUE43/=O6J%H=XEQN4A1&55$6((TJ:RV].":N,CX:\,CI@/Q*@IO
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MY#7FX"6_R4/,<1G_#)NZ91[\%TQ'3UA89](R!?Q^Y\ Q0T27@_D,H[15[&@
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MOS<&@1/Q?I!I,052(4.2,(HG4<,5V2KH=<=R:I(S*A]GNWP>6:*IZX$2W56
MO.#J7/^/@^ 5 57Z!' NY&) H+[!.-5N7+V'M'83Z_OW G5JOP8#J)FY+6-Q
M&=R8EA4\S\*_LI!CSLA$N=9$AAN%>R?SDM71:O=PC]9TP4=IL ;F"];VJXS6
M7?I0>W]OD^+=<R^&8IL;6\<5Q$K[F^6MBF)DG0DF %, ZXR#X7_1O:)4GCQ2
MY>]N:6V==[LGI"C#6FHAA\T'C3J4K:(66P0)[D4/[N7P].3WH_**VE58N;&S
MK%]Z]2"IE(M4LWZSF5F_4TA95%W?P>[)9QH)8:X['SA'80AW[R0E;1C48UD1
M@X4C<_9FJ%QCV95 N%U%%P*AA"(G4!T5B)3=2@<#N-%9E@2]/.-F-X-J9P60
M03Q*D;PJ[1A AT=U+!A)-1;V%F-Y6-$1XM6['DSKU?:4%;A?06^[;#D'81P/
MG\"31$G*N-93B\V6L;3NHS.9$PPK7B<! )]%1EC9*!P52?)[;JDUDA),QMO.
M<8Y58%1E#Z0#^JG06H7CG?]-%FL_5^9GL5HW7INK*%4HRV:5[^=_.1VC\%28
M7R<GK6)/HF52/P@#2L#$C!NRA0;L5E=WN-IE5SZ*62URVCIM=5MNW7'@ E$[
MQ0P-2Y*46(L%_ CH75\\DE28=$QO..^E:>+)E&'C;U05G.:]-=E"Z(-AW1:(
M*E![5^ #X:WS8?&3$ZI0]^2@:Y2WU.4YXR/:B"OY!VC)HSP!^P_9)@<+!7M9
M',AT]<+25'1TAY^1;F4R&8M^&?@5@G):RKRM'JRZN5AT<:+DV3GW>2IM=U]6
M&Q5&?+%1P0"Y+W,%,+!%W\4BUEB\+G-F#6J3>07B#T79CA-C'JHJ "!="S-L
M8<LNI7%+T9"00T2\K(@*]"J/Z,W(T"UV!+"@M.9<] M2S4!2635JD(G <I5$
M#-V/Y.)-G)(>V8OAFOV=(X_7E398@B"D#X]N"'@D !0DY=%-YX(,JL)61[!7
ML13LLR4_-.GV1@(0K&7;V+K:UOWTC;I"PG_P$)A?$J&3X)0-J2M@D<*NC08X
MB"1W%E7/*5QJIWR =P24!!1IJ<D\B7/*MBIXNQFE+5RP/,0F8L!T+X,^W !?
M*P_":?29)0F@"/CP'T$VD!<^9"E&48'YC,'$3]UZ]C\SH?PH="Z W\3.:>S%
M4C?*@:^%E*-_<G'NO$=283EF6J<?7.?7;N?"*+43.3;]X =AE:K8"HBD/S.J
ME"N27P0I?NM<'7;^[R^TU@<L!4;\GZ*H4TD[ .FU41*CU:)K73]@_FCB):R?
MR63W0"O8[W5#*54:\4$4P"28[71&!624\D-U'>_3$<?=H]KFTP <3";Z0$JE
MUL4DC$<(XVF-(3J>!Q?(+\=;W@\XNQUCPS7O.VDS<53<PF__OCKZQ>ET_\!S
M(U,( Y^$B>S'(RM/WE<!!X\?8MO26'.IB^ __V'J^&4<'2>D-W@L(:<7J&SZ
M.0:8A=_C4]($ZB9Q2KE4IYD/3V0\Y%Y)63<W_OE?'RCA3!BCL)84_+CMU@6\
MCA[1FS$\=-*Y.KDRO6EE$,FJY%26):>X=X_#>V>@1?(H"O(A$.H-52X+].DJ
MH_<>=F#]66X47XGQ;F"W'IG9_P46#8E'BE-[3)1 HYP=26A^N[HHEA1$P?H\
M&Q<$Y"(C&7*PIOX(L"!'*$0&8,1K96#!6U>@8 $[*^Y(Z>0)6)]!B(]EL$N\
MDE<9YZ%$.^('T5:0C:#C:U0FL=Y3K&+Z<.F0TXCN0V'WI8H1E#L_Z;0X$%W(
MLU3' 2!PI0?"WI!+87<XK!WQ')4YG-6UI'/O:1)8TR01TYF](-1F3LTCOZ&H
MT2$XK:%B7Y$$N+4^DUS*59VI4'O$*Y#E:64?U5?,)A&8OEP722QES=7UQRL8
ML-HK]@,;#D%@ D&'#/2":<WUA).:',0RF\XM+,EIFQ+OR'0_E81'DO[^AH&(
M5/G-K^@R5A\M*7133>LC/U R1*!,?@I7O:12HHK)0(WZ:NS-J5WO'!_4")GN
M4YB16H5Q#4'C%GF72G<@'8C^+6A6!8H*,W0.^](FY,Q(R&FO>$).8[WU4_T$
MK[BG"XY2XTL+A#:#E7PJWP&N\B+E!?J;=:M.^$B>[--/[F(IG079[].E&#W9
M2JSJ]I\_EL(>&$TI>FH70%&^)_S<L;&+PL%3C:S\J]I9&<U4(&5E7_2+ELO"
MM&,8_TZ!5<@&6T*TD*V6 ']+/2R?Q@U&]#T:RY$%1<X_.6KU=HX+*_D*=$W5
MI;.<)J64A36TBD-X$*XM[.=W)ORT12\DIYQENJ=JN*D<3+CU[^(D]+65(/VL
M*&5!\I%2&)!__2:)[RB)PE E:X"-*Y:Q)G(FUHQSU3;>IA9@DVV^2)#K[(T!
MO8FM>9$NJY_73GBAF5 (OHB23_0[YF#(X "1TE]$(^>3:^V?UVV;OK#D%@E/
M%1,(Q>A^-_J WZ/-%!VH:Q48K:G(GDR%C5=QD>,Z1L8D2*(<H_1O(KWL$)UM
MW9;S*Q^$/%DDM^QE@M1B?\_C;)=KO[2W_9F=Z5/<S_*P*^A_-DYF'="/<T"7
MB*3. SW%]WL/<;V$\U=NH>R)(6,ZG>V3U4ZJ&E=?V9MZ>MX]_R!^=1$G&>[A
M,L!(D*(4PP_5PJ"1WKN4T^7E+J[/O@GGTQ5'+R<H+<=4'BKN\GMOW*,#R;_I
M3$M#GJ5Q/\.6&A]</)9F4$$EK:92BZ_8U'VC-^1?9B2#%[Z.;WF2$LT2$0(_
MYTDIN0*=W<5V9KG896J*>K7$]$ZB6R!]B2?3J4FYA0G#SE8<.]N $L:UJ_=&
M_N%#B5*FY*&4O,_I -7#JXS?87WK)*&0IU%@M8O?1.T/)TL$24@Y_N(Y)G\T
M_;S=SJE\<4$OL?CQ"PTX..18&484<05;YY4=FF]^.;R2KU[#%X 9>Q4_*KQU
M0NTDN;ARFNLHLKT^..[*)0YB;%39!=7QNW/U/1 !@.+;Z!"FCGKBZ9 '@#"N
MX'5@--:ASYHN=OG,M^[D0P;,Y_"3BP>_\GZ?DJ.*3,\IWF,68:XV2"5UT6=[
MJ-U:%[5XM>RFGG*$:WC] (Y!;?8$X-4.I6L=&WP/B5ZEV[Q@]K\E/>*#C +1
M):*<+B>GT+W4H7KT.W'9KKL3)(]4B7MU2,L<8GUA',UUKQ0#=D$OX0P)P9B'
MI5A-P4CE<#C20CJ71Y@.##PNXNK)BA&&AB,-1!"2D<P>T*91ZW6H06'P'U4/
M;VRU<"'/R"B:S0*KFN0R.F&7WYHY#8;.K_%WYWK [DVOK;5E))"FFC2/MF6N
ML4=F$CBXTR<W9@[N:VQ8_?KD'9U.G]I5M*=C/B*Y<8;9(HI,B#<?\&3 ?#V6
M2[F60&3E&)B:<Y4S%K)Q*CH,P'+NU#6*MTWM4RUS$0+=R-BBN5*]<TN]A6XE
M-HJI8&%(AH..H]4\_=NO\!G@E5,P#FJ/FM=5I./>%?J06D8$T]4DF-V=8K#9
ML<H%%0H<^H$N..Z"BD^,*6134Z#E0UK# \L,5$PFK";MK%,-XD"P$92!"[D:
M$17Y,J@=NE8_KDRU&ZED(YJSIJ8NE!D[5^L8NR^Q>O)FZ>V:Z)B'A,OU4H22
M+S'\SZ_X/Y(.3!=<&*19D0MRAJU*"GA3;Z78^P[KHQ5\PV56:7FY"LW(SB5U
MS4"P#0Q8SUBK4_'$34HK46@I3 #L'*@&_ZG(+MK)1MS5[*.&FY1./,U7I& D
MQ\?N_IQ)L17@W^?6LQFRSSN5!ILC <[_DR?3G7@+2%'4A&C5YW'7B:6GC_V<
MY12;NK4(^)AP^ZI\!9&9D>!A[["FL"MS6TKY0V:3"I_W,IDIJV7E5M%?=4>F
M>V$TP34V,G>MP $(:QS!$&/:NN@_-]D?G<E[+DL<;X11.<1^F4:ZJBJWEO6-
MTBDDN&R@9WWI#;?7BW$4ZW65\MA]O>Y$<P@"A/)QT$MBJC&4C$V9&<K6/.Y>
M=<FZ=UA.TPQHS*7J0DB%]I6))ZWJ?HA*O(HD9, =LF($M81*><^W+,PKH^")
M!>>7L:8):=')[5[!_WV@',VZ,D_=!Q@9HE#J241A*K(<X8(M!L$P6L-9A]RO
M=$%!$5G,PBR5FU3QB<Y?]"4,<H8=I'%-O>7*I)/U[0F(F:%$HQP7.R&&\3 N
M'&\B,4K5KVS)2IC=PL5=OY)4=(XII5$VYC]49:M26I:[]YM^!?6Y74FE6-U2
MG117&MY'4UOE<JH>9E?6VNRC[IS=85&([FJ/M]<MCS\M,YFKC(U)49']@8EX
MJ@\=\M^#L(?IIJK.9A*;$A"XEJA2COS*2$ZP WGHIR:*](@4O+#4@@R6P7RQ
M3 ;9C"X0=>E)@M2_ZBA=76.)<@Z3TCP?9=I*"M7][&0@MBR1=>\W<Y:H*X<2
M4XZC,>Z,G,;JHA7-XEAY8JG8E<U)>JJ<I V;DV1SDM2>+F/0T+#?]!7(QX&:
M+GMVT)D: GY,#+GJ4GF&/"<ZQROX9XIO&SU,A+/SR<X'>S<AK'?_="E0LGM*
MT8BUY92!.E%-7!*K<9)P;#HAEBEIF;!()2R4FC,1#B[/#$^U5,\-4?%D1^P'
M6$9-&WPZL!53T.5,B?5=DR)4JH%P(G!AL%/G#&.6_?NKX]/C#S+Q2N9=F<Z0
MVO&]M>XARD(WQ]UEL[XK<!60)NOQD2#WF3L%F5QM&/MDH.SF"7LZO!B;UL'5
MRD5--1QG +&.>">G"A*8I?*&KQ\S_,K5]?G_+4$O0J;-C<8!-8@U.1:BIJ8P
MR1P$@KNCFVGDM5R- I'2?UT:!T\:N!BYN5?)9*GV5ZK"Q#2(]934.KXG7J5%
MCLZ?E ,^?E;I!(U,=B)XKX/?3_:5;SS&Z_1TN\:-?I@@RQ+.ZEVW3Y?:-8X6
MGY@V<9Z.ZCTE<5 51-O*82\&X\A>1\"<CH9#ENMVQZ7JO/(@)]>(DTP'SV7L
M?2?CH[Q@:1 ]4;\YPFG?-%ZKRS\9C*XX#^,G)/P:OE =!C@I_^7,^RD%+T7B
MB>Q8^>W?OX']&=V@)E29UVH.QRR<;N[$XN6(NO[4E>PI*"WX(AL:B\/7G@Q*
MGGFC5+.K(A5+8IFZJ6&6E:_M[W(?.IH]/5=HI:.ZH5/[&G.XD&[U]KYS>?9A
M4H33 !+A&ZBDG\_S7<JG0\+&T8/425^TQJK[S%Z=/&3.;1S"Q4/*Z<JYQNCE
MC#WL!&#,,)(^$R/C)3;'P0K"N<RS&_)/%=-@*UG()4_:5>'LJ9;R5B-E,TBR
M7Q%O6P2].Y;.YAE78)["(I]E[_DRRQ"CT,BS=LQ[B;I80 ]/1J,@P?[E\? 9
M>ZV:?)@&O$4&N3W9=X%$3O/HYFF%I#B "?I=<T;=GLG@=#(]1I"*+/A_L](<
MJMK9 9-))T^'7FEO/AU<Y(@"?8#* >>,"&JX%1T(48_"F<:>@_YOG(T3^;(5
M!RR8Q!BMF]Y!L1B+,1DP'-,2M;'&-Y$>TXG\!);I I.-G*/4 T4(0"P=-HV=
M:5/>["MY92J;F'#/X+=G-*F;MD3%9"*59$AI#'HT_ G(U("$=SJI6JW7=^O'
ML POVO1ORQC/?B6>0>EUE+I7"/:R1#5"&Z+XJ)AV+T> 8!C2Z+E*@\;,F0L(
M87,0,4*B%I"&%TCI?4I?DUJ$&E7/5:AE6FO?G^7H!P]8Q1#XB%D]41J#^%M"
M!5E>:4K]9.K$-?\!7SL[+,]GK\5JM0&I[%V-_4E3/AJ8E0?5AF9:5(CA7EFE
M[]EDG^WI9"4!>@K?11PS4N)47U7<UC?L85 ,>DQ&LML1>>YEIUX177$D4#WJ
M3YHK@*7% ,E2)O@7V6^"HE&#  QM'HX&V&K<3.87%0E"C1-+3H'\E"SSF1"0
MNR<<&)-#X5,/0S?BHX.0PWSA"N;GE6V"'58V.$?F2VTR:#E(U@OBROANG263
M!2DWVR^_@5ZR0E/';C4RF>YY!/GC#O>$ 3@B0-W66K1+ R,34PC#$.A0>7V!
MPH0)A[0E"%4Z,N.9095:^IY*]UY./GL<SH5E5YC1 '^/T!03XIGV6$JNU9?C
M"YPM":I^5,,?7;</="V/J*YM7!Y-%@@;;8HJ@*%C&GD=WV(S(2H+$]V09. 8
M>,--'O@B^BRK?560N8!>)G)7S5%CU_6&W9!C,V[,T\89OZ+;,TL#.1,7,PZG
MI5F5E,-WGQA<[]@K05 NA-5NHD%7:\5I'C--/=#O"3VBHXHHW4V&PBLYBZ"1
M(CQDC90V2#H;MM'2-JH$K4[I94.1(LEHJ$<J1GKWQB&[ U$Y\TM3;'PL\R95
M#HO"L3T[K*X^2DW6LP'VE/%")DH,&>9&D?3Z1>(57E+?%$@->1^CWO GD?;:
M ]CPY)_OUM]1<A06:0/QZI]'F*<K?Y;KB#?6J!/B*.6_J']\!/#ZV0#P""Q>
M?"&A__4Q'PJ^#<05C_0RXF%!+G># !.9L$ <L'F7L-&[1^=,+F [S$U7H"H
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M<EY:W9>MR%C6*V-%AA495F2LK,B@"-??>9!A1UQLNHJ,GR;*5R9PTN^$?S\
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M&2 ;RREG9@>L*?',(1N;K]'7U0-N$0^E9\5?V8T(4AJ3-3$GOBYP1' U-DT
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M>! ^9!'# M)7K5"S%NL;^,/,DO:WX8?*T<709)&"F05@&WJ')X"PHQ/I=!.
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M%AA9"D@J#4Z.#\F[UGFG/2-_A _I=)&23B0]V\] TDI6-:+[J^X'KVI391P
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M+I[&U2];:Q>H""&9JM<#P#(X#*7URUB0WD#KPESGY+6U'JIB I_4V<T1D,]
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M&54Q):21IB*DV!S0[*5 ELYJA"=_5.($OD65!'I;%A24BK<BP93I5Z@$/U8
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MQZ5GCI8S6*"Y;H*L G;H("?I.4BX_ZBZ9V">6N6N!QP,($EEQVT2A8'Z.%N
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M*%&@8-:2FJ2O]:^WUQLIW?$S>"!-HGN*F4@KVO#U:?&:*]$ZR\,41UT-C8$
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MCUR=V'9BVXEM:\6V3H=R#/-7L_J2*8AK[:<8T4X0Q?B1$\=/E0QO+([[(TM
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M9]4K_(P^C'93 %SI7)Q7LPWK,)B6YDL#=D."SK@:U(,K!9#G=-$!T7:$HW5
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MGU+$QYH-]F"\90"[%\QQT;@-+,H!F)4RB13]!&"0AM$$)8[LZ^:&8V_H^6H
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MJR3I*\)NGSSM\TFB-HCL[KR2:+*)&^3V$Y(2>?X3 %MZJM.VU9-Q*^LJNQH
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MO5MFD:L((=KWB>RD/@ LP6+A>!)O!BMSXJ=DHF2,+]%7$%K7 .MAWASN "O
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M.ZF0^_L USB/3+]I/4I1?6ZQDD5B5^3MBO,#6(-:!&>&0XG\2=/Q&Y2.!2W
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M.NW]O18B.?B[1T>)]@]:7?[]X. AA[9G'6QT9N@AOK2#@_RP]KT K#<+P/8
MK';O V"?ATDX ,#8,1#L!2J/EX$\ZA?Q>M+%(+(7P51/!L6<IL%B6\^HFX6>
M'G 0>QTGF%WA ;.MB_X7Z_"616[I;G*8B:]S)UK16_9PL-:I$ZP9$6Y<4T:^
M&B#T<EU3CF/PD/%-&72U$%UU'\4W)9#.>.*'4\XEVCI/85@L7A7P+-^&XE$
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M$ !=Y%U[;OA8D*YG()V!= ;2&4AG(-VF0#K3KL- .@/I)*1KM?:[S:Q=1TN
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M["Z[ZF,%1A/>N^8*V+%GL*,.6D]3<5>_4M&3+@8[:LE%SXX=#_3:EO6SJ\&
M!@-F&+#M/ @#_HM%5'$' ,IY"J/ JHI]'GE BO?6>:0J]?23</@- =$<XEO"
M&7<<L6L6LZ%UYHT]P$H9G)(5H0]6!E0'!E#IH HTE1WU2V@]Z6( E99<]-R
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M3!/OAEN?K^ *S)]-HSB55;8N4A\FY[39KM-YS78HX];INO(3O4+UBTXC+\%
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M4TSWL7>(T^J([3$(W2GMC%$R]N&/_P]02P,$%     @ #8)_5"3V#M>#*
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MN(&0R+N37F1C$;O/.WQB6VXS8=]Y3MR%4*;<@AA"EX:5-5=WYYCR$[9-UWY
MHYB%ZIWEIC*5"]LC33#,&%9D,$9R#M)@XR*RL@MDGWB]3Y9+(&\R4WPEBF\<
MO>%^@ZNT=S4+]PIF/)0V![VJ6+T;F(1TG(#>+JL99QH*+%W;9&1.GUEE;58O
ML)0%C-(7-SC/GS(_G,SSDA_:M0.HZI518\/,@.\6B\US\UW5/'55E 0X:#!.
M6)PH%_/'YACVR?)>PUILF2Q!G'@P2>;I U;55V6N_.\T\!>,>;#^H<#N'<7[
M;=1[6+'P(9 QLO<TCB5^#/6$RJ,D7C"NW!IYJ]:J VTE&WQ_Q2Q<?Z<D\ET1
M=!0D,?5N:"S3B.$E:^B?"8<E)NB-6'ZU1Z=MAL7":3#;'&2;G_2=B-KFH5Z^
MV^W#&P63UI8R/2I8*#U%(35\E!<R?:M9O9@9!:L%N?!Y%,M;D??)8Y'\ \^V
M*IXG,VA+UPSW"7_RG\1]MQ8&NR L9:KP.U>6<K7OEC+P[8\IAV5GNAFHQA<T
ME5G+2%N0Q)Y$1^!5M/Q.6F;=RKQT@EC*EH:E?6.G8=HI.5E+E[T[INJN2@UK
M49EB]+T=A1D?2MSTM'BB24:AI@D[;FCMVHMIK1UOAE[S,0,#UL0M6YC3IDS.
MVJ?KQKP D]D, ]+G!,G5)+9[ZU;W2" -MU4[+K+NU\9[(LZKINPVX6 [(BJ/
M>!H-CA'H3AWTNS$P^.I7=C!7W*=I..8S +3Q6"^[.83J-Q=E4\J7U7M%U5([
M/6;E=/[%9=ZF=&AFL-8,1I.4%R+\*AM?N0HVJ*H!H(VJ*L/+SGS,N46]JC^I
MK=1"3T/IA8D&^;27VRB6S+\AVH3M?Y#@P3+>L17'L@GU\B O\1$V;K#$A'&7
M_9)7^BX"]IQ'CNT2I;5^U!Y<3LG+#ONL$]N_0G==,5AGPD0E+VCML.=,$?\K
M="+,A3-8THOE]P4MHA*V0F'-A&J2![+T8F-3ON<]\>.D=W*B9E;:2BUEIN6A
MIB*)5#TJJ!70EFVDT<M]V8+U!K;'8JU3>]:J$\067DTB:<HI=.MOMP@F6S/N
MYHJ]+1IKC)7A8YT-*8M39G*SU0UD#<,F28S &.$)<7'V?AF>$QZ"= 5[M3?>
M<KW8I*8U/;/)DY=IKM-1/ Y8A',U*?;!9K#6L+]1)M#JA8QLA.OS@>IK[E//
M% K=Z*)K+7X%[_^NTE$H03CG+QA&&H%!]]U<O3L =K]&WU'LL\S%FJI:B>@F
M7X$AM(V>@POBTM0'U_+ =!>$+0L:H\E94<,Q$,/".\4&MY5:NXNL7'5>D%AF
M;IVR>Q(FS^2)-IB7GI6L/7+,^1 7X2\8;_4?JY[TOK7L]+";<]&?[PK/U/67
M)'AW:>>WVN_(\S5HJ[COTW3#/6.X1P5;+)C1X[HI5[\S_AVS@K,YQ_ !DXXP
MJ;*/77'AAWZTH-XWQCRSGC"HL8\=<4-C(_9;X?:(Z33)0W;_+XV@+_;7S:5[
MQ. 5><1 1Q 7" D&;7J%(+\^4;GK;@AMJ3/QFK@+/Z3RJ6!!L$A,_X+Y_*N1
M;B:@EK*)]N89ZI]1KF;BSS[G:??E<VFU +C<<;(M&FLVRT8O2- @D'D.ZI&T
MU0)+Y7Y&,;,!8GJB9[ M)!&MI+AJ!["4I5.?/9+P>^T!SOIW2QG(7EQ*C:6X
MK)R/L);"/9H^LO<G 6LU,5 M8L,$U,+PC2L1Z.@FRT38._7%S5I>9A-0"UF$
MQ5E**SK'N\5H!FLADW>4I,--CK.R06DKM=2L7(8>G<&J,Z97^ 9C31"*YEW3
M>%'<B]V@HHV^Q/2AI5)>CLKBO!/$%A-K%.B'C$!MZ4T!?'+17>RQ2QQW ^X3
MW_<+T$5TCYTRSMDSZ!UH9Q+&L"('<;+S%S^^H+3PIN8'P;WK6>MYO6*DB"ZN
M;,6:BBRU5N/?[D'10"EK3W,WE5C*Q!WL]66BDLDL5[$S^ACG05&IQ0&;"CNF
M"#>,J:X5D\P6*/9J-U4\P(V;##"[/E^K;Q"VEZMLSO'3^X]"/*CPQ;N_$0F]
M/- (,Y:T98CL5<7"Q9*>_M*M:&/P#5A]P]0NLYGOTOL5<2O[YH8"2XT4'@S3
M\(8^_U_*(UKQ9+046LJ*['3,G)X['5M%TPYE*7-CZA'^_T(6!%&+L+H@+&5*
MRN*:A,D,:HC(.S/Q&5:QE.V+@/$%6=X2_KU%EET0EC+5DOW5*$6LY:Q=78WQ
MJ=[V++$= ):R=$VB6.3CJ-])K!YK: $M93&[F]BR&VHIM9093(([9MP#BP #
MQE^)I;"(=UFPP /[4,^9:P1N*;O%7ALV.AQ7_)<AOD\X"D/8DM\IA\<FD-;N
MULNY5@NW3/5SE0$K<K!F-[:AC^FSV)7AYK2<5*\;1EW;VQ/#5-YIBO2CZ9-5
M:ERT#JK$&WQY?[XN\3R6!->PUUH$:QPCZCAJ*[7&B6!R+Z1XER;!8_<L$U_J
M0GD(P?+=L'","$7;92'63BYVA\_"#;LTD.C7)'X^7BL?K1&^40QM*I8+QCL6
M+?F\80B]CUV@LE*VQQT =AKCA]6,@TE27*+J%VN$8W+P+8;6-<'TC?C4&U5X
M:B[;)^ZR0S/8!G5E+->"[1//U2W$#8.U-BT/N&X8.\=<EH94IN"1UR(O0[SJ
M%!3Y:&L&M6^MTI1H2;+]C(<BKY3D9LI.:<K1;$QY# -U2O@<C[]A54!CL1(P
MZ)O=X;6Q]\XCF;384W+GJ-H@N-&IT99(K+$?1N?5>),EW9#+^X)MIT,FD!:N
M,5O)+F?(U4!9?01T#QAI=%J^)1[5DB=5<RKTK&6IFR9EXXYZ0"\B*5W>*?'6
MR'^?BG9W09GHC<2_I](?;2K]7A6M[H(_-NV"7A6M[@)E*$<;&P&#FI9V0N4I
MZ JC;:66,C."GQ[UQ!XMBG$MULV>.;S=#!MQN6>LR005>4;QIH=(:X66LI+E
MH6K.3F4Y\>H5?KF=N:,R>OR"\=]8K#S 9P1J[9%6V0V048X;W4D2X[$3'FG5
M>.Y;:Z?;WYT]20AS%^:R$\DU;M-T!(V95,Q@&V1L1X:#S/9E=-<CJKL@=J^Z
MN^$JT\&,=NEOJ&IHM=1"32R]JYUF?$%D>/3:_")Y'>C-G0D]U$ZA5CI21[.8
M<A@ZJX!*?AI>+ZAJYH9([/38MC*%Z<K.9S/JB@N<(AUI>M K$U1.H(PK=G@'
MB.SLH7(:I D7=[8:N,6;,"1:%.<5/:O9Z)?-<S^M_#2_KY)WIJ703BF6LZJ.
M21"4DWFU%5L[DZ81!;]S/XYIJ!X.@4;AQGA92N9E#&ZG^$IS3BHF*27VY$<*
MGP: -DY0H_F<PY8JILV+A5&47^<!<6'6&WPX3#Y9@I>SBOBOK?'8:(:N\7W1
MD^.3X]3OT[S-UD%9NK]+MZ&=&93WA)6FE:%,&(A9>4H;M<;-S>;U;1S3@E ,
MA_-P;4C#2%[.+QX\.5T7(&EXS>B9<*_I/!R&JXPDRW+KCI(8A YF/ M>+4</
MO%/C=LX>0DEJG=%Y8FH ;>NI:1OI]9-3#:35IZ?39S9=L 3O ()QN*>8"(S2
M4)X"@UK"3]AOW :D\NYF_WJ6&ELQ6B-\W!GFNR>PD6,6RAB1JOM9#V@]BS"W
M?Z>QGL,V.$L9+,*$Y0MU8NJ+1KA5QH39K4'%W= 6&J;RJ)L^0^%Z$E+Q]R[&
M\788;=6.3>=P\;_?:(0>;YEB9A(J2=>;TEB\?DO6GCOLDODGRB]8PC&7P.OV
M<DM#UG9RF@TG3^0'1,\87XK%I+#>>12?'E"U;[9'^CZ$/'\+PK@/>E;:I_X0
M-%\S+W\)H9I)J;5\G[C$K!2( I<DXR2"S1+E^3L8V9[IC,I_90HE 8^^\H;#
M YC&SM*8ECN<SI*\N]Z@(6OZW2BS9LJ?"/[A8!+EQC2J]E>]W,Z=:SH+X&)%
MI-I*10QF@*QQ#ICZR\K&OT\-.WDNEFB2E>*>8?7[7JEF=I\#AIB/J_)'05@1
MLEGS0_2H8.&*7T=]R1MA"&RU0R)[:J([>8 .RM*MR(C'"TY?6IAJ*[64F?,G
M%I05K,Q.>[FE#-U1?_F8\$A\1L]X).__5)4L8] <WAH+:WRI#K/Z=+TXWE1N
MYSPHKW9BQO/B>$_]M$^R40B_8?'Y"SX5V,"44K9/W%7'3<-C6IT@5IY>):M5
ML&Z;D2N'34:P=HZR;MI%]A$2J&:D1P4[.<Y>E2[\1K=Y2,!E^,1 4X4OW0^G
M-#PC:_5YYKX5K?5'I92CG&YH-;5#_M5. 69O/YW"KMY=9%M:)!JW\=13M=4,
MUDX^NT?:#0O3P=9T>WZSNG;V@QK6GVKH [[DAR\6KC!O[\AUZ2J6+^YF=P$G
MW%/>%-\"@[5#^([BXAM/&A+EH '&+9BC>'U1. K4\="SDK7,=^LW,$-=$C4M
M1#:H:.7R)#\+O0Q=MJ13\I*'^+6?FW;!6NA#R<.F<[KOP&;CX]*AZP>^-$]9
M^F[7Y;3!H;X=#FOUWX0M# :8,AD24'FM?./JUG9(IN1E'B:SZ8)>4##D),A9
M;1L?O:I:.%RRHPND4[PP G^,A6=V#.);SQ@7!V9W-*(8*BH..YYHP%:J;V1+
M)#O>MK[F>THU3O%YA#A9H3LH:NV.,M ^L_N ^:16K8QFQ?O,XN5RE<3%$P^3
M,$^7'V=9[%KY-ZJ[SYTC4@%=4)K&OV>/9X6EM[1:N\>P]GYV4':$[--(O.@#
M&WMSL]FGLBW=8Y1S*5]&PG:AI@_MB\YN: OGT2(7*8NBTJQ7W/5J?F!%!Z\R
M:\F#*\W3>S.C9K 6,IFOW]"%%[ HX;1VW-P-8Z&:-A!<.E1N+[?Z'/D!'\SS
M[C$;2I0NOS&,%7^7CRD- "T]KP2+6+(9- +"'\(DPK"CIHDB'WC1/0N*B_7;
MHMFG,Z9[.L</PH.;>FWRJ::IR!K>3*;6R]#S.6S(4[^#8I.JWZUAJU]2<1]S
M\_JXD1;!F]CDZ3J56T?N<+-J%MKF2;R@O/+\COK)4L-4G&>);/:58Z'BLS5:
M:)PK-+TL@D'DQ<E[4TE)F2RY_YL&/^.3).LI)V%$Q&.CK2_BF<-;.'0TQ)>6
M.&:P5B]W\/78), I/#^$P#/D,^;&C,/TS>GS+749)Y5G:OI6L]3BC!_N1A<L
M"3WI<B[SV%AF*R.3Z:C^Y&KYHZVD\S5;,1[?KR.T"G4N6LMM94B\=(L)'9I>
MP%6_6\I <U9;,<#%>I!5UA;F\)8R?+Y<!6PMPS$OETN8U,&N7Y"E'Z2/]U4B
M5$W!+67W.OH'@7G(KR3PJ'RUE7C>-"%5OUI*/.::PKG3]ZA$=TO+:]T. &M6
MO09[+W5EA"R=LC!I7!\JA?O$WPT+\8EY?^:G>8ZS]](R*]B19F6SNC9N#+*#
M*'PFKA!I9=M6*[5&SD;7AF"VK@7P5S[NTRE*.;_,/YAXJ##7S.;"G:K>;M*O
MJ1IUD00!7JO#>]OWT!=\W61HFJ"LT<2>%A7_I^>X"<I&CG\]0H8C=T&7Y.__
M!5!+ P04    "  -@G]4DUI L)H4  "H/P$ %0   &-E;'4M,C R,3$R,S%?
M8V%L+GAM;.U=ZU/<.!+_?E7W/\RQ7W;K#AC(8P.UV2T8($45"120S=ZG+6%K
MP!N/-2O9P-Q??RV_9\8//3RR19)*)3!CM[I_DEK=K6[IE]^>9_[H$5/FD>#]
MUM[.>&N$ X>X7G#_?BMBVX@YGK?UVZ___,<O_]K>'IV<G7\:'3FA]XA//.;X
MA$44_WCS\:?1'\?7%Z,++_AZAQ@>G1 GFN$@'&V/'L)P?KB[^_3TM.-.O8 1
M/PJA,;;CD-GN:'L[(SVA&/$O1B<HQ*/XS^%H?[R_OSU^M?UJ[W;OS>'KUX=[
M!SMO7[W9/W@[_O=X?#@>EPC\GD@Q*OTY'+W9&>_L[?R\_Z[TX!5ROJ)[/#H_
M*3WH.%/G[0%Z,\9OT.O7^-W!] "].[A[X[Q]O>^,75SFE,P7U+M_"$<_.C_%
M+(*\08!]'R]&9UZ  L=#_N@FD_0_H_/ V1D=^?[HFK_&1M>88?J(W9V4J@^X
M'?H9>- E 8M_?;]50N_YCOH[A-[O[H_'KW:SI[?2QY_7GG]Z%3^]=W!PL!M_
MFS_*O*H'@>S>[A\?+VZ<!SQ#V]!5(4C"&V#>(8L_O"!.W$<"?(UJG^"_;6>/
M;?./MO?VH8=WGIF[!6B,1@D>E/CX&D]',>^'X6*.WV\Q;S;W.4OQ9P\43]]O
M.=B/@,S^WMY^0N2'6PQ/P2BZB(7F=#Y?G^<\\^=]1+UP$0_![,U=_MSN\JN[
M%>R(D@O1,PG(;)'0O0F!*)\1$\*G@.?"K^XQ\CG"-P\8AZQ-J&L@\Z<XF66\
MRH(XR'> 8]Z/7,JEY_%SB ,7NQD5SGOWDL;,9.SXQ%F2G#?&H+5XT$P1NXM'
M#JBB>X3F<:.[V ]9]DD,TO9X+QU /Z0?_WD9/F!ZQ!BT-XDH!7Z6D?'Y4"8T
M^]!'=]B/-5[MV[LFV+ZB>(X\]_1YC@.&%3BO(6"$^?/@$1HC=/$)2_&\_%XS
MJ^L3@W\"8I.9QQBG04+,KK&#O4=T5^B*)C[:*!@![\AQ2!2$["APX]%7,,
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MHA5;N\&9?L'_N8/5_-?_ U!+ P04    "  -@G]4GEP7Z_]I  #\70< %0
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M2C5]^:C)Q_AQCRAGA!6/^O6#H3KS_<CRY- LKQWH0U^]<&[<(>)B83VX?OU
MJ#ZLD>==X,W6\G<P),LKA^+D!I$55<@^$_PC7$OA60-B*'YN+,\[CP(JOH,
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MW-L'1*C"_\][Y""TB4T73(4!"9EZ40Z)B#?SD@3< ?_SH?"' .Z _VPH_"&
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M;!<T,TP$VG&.VX%_/WH*0BI)J>")^Y#/GG 4?L9Q2J9O(Q)G7+C^PD=)2B;
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M2X!4TYR('=?%D@-^6%OT2#WB<S0/ G;&EA=4"M&C_6B1%4MV(>@6A5^9<OJ
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M"'<#%NX[/.^^!="$B%$F!&NP@(K"1C!2Q_X?-W,VCHV%/Y.1;"BB6A3TZ+=
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M"BR6G089BD!30Q;5&5W'I<I( 27H8(X&($J(F%.K/Z#HP0>Y[:\<Y93 XXS
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M;4IW1FY=;\%["NQ/*+#D^P4NT[5R<BNH+?TZ>@GCJJ0,2.F#]TRTPO;]K/5
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M!),(5OO9:1N=C.B!2,G(57X<+BQ"=O3HL];9P=7+UB7Q'?@7/4+"AU$,F)I
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M(Q]^W1:2_CV=4,E7-'F"V:O/MZK$_H'N.]:1PP+O<S;;*NNSK+WW/S@;(/@
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M#4%:%/14*CM0O"^+DGQ!HV%4'K;F_5?^B2:)H4_W]O9]$X:CCMD*5@ Q0+M
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M9X]279"U@M3AARV<9BYSTS:NV<+5(!9X4DW!Z5W&*MZ0L$%^D7GXL,43:]W
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M+F:);@QKQVSAMHSRLE'%5PM_("K!/7Q(LXR:#%D=O< H_PIBHO,0MVC$"B\
M.7D]) "=<-^YR!(CSX&T)\R4S_B)K+?[W0ZQ^FV$J-#O$?YRF6UPON5O%AB<
M-%8F:>X%BBP\=))K, 9)6L0(%_0&#CW[51TW3FM) CE@K(LR-E3UD2"*>L!D
MD8ER!0VVBS;F)G9'0L5UE";:SU1T/FK3Q*5%RM-! =:4DKX?G IV87C-$ 1X
M0C^!J5M8NZ0-*/&%GH+ 6\B>L#<RZL-/6S4GZE#S;]J4(VTH&DKM<@0//*VI
M\'1?V3E3-*._F*VS'F^?" ;$!NJ+;5E2U3PO2[@UNL>E2]D<)SU.GG.M#&>O
M6(;5N'])LN: +W49F@"V ^"XX!8NRSLB"M[-NY@$X7J7@/%?,",3/5$N&BU1
M2*S9TPL\I_OR$R[_#MG$K5=O4J5I4S)0X^&GX;QH/4*=%<JF(W0R1/N$7ZB.
M.KV+V9]&G;:I8;BTM@5@4Q2"1[M;"^+M@II<@60+"%_:\P 0SFQ"MC]BVCU_
M2P_,?(3Y \S=3T-=7OQ(U99Q"W\D:& 0[(C11T>#.*/G+! 2[XK?T1V$/7U6
MW-DMKG9:73.C=9=2L%.Y=1?$8%#/.-8;(#E-W413'0>93EGMDSWH(%I!)3X=
MY9-,T>2#=8)G?0;1E=/,,C14C4I4LOFH)#NW'B2N_58/IA)F^ZU?N 3+QJOM
M$6?J'J^91H?: ZO8 <'/+63U">S&I=55(<ZAL7NM[%B@I_O\EXT;_,UKQP1%
M(&X3L;H#.Z;(@=0YJ!BH!E!G\)W[NP1I(.^]\9N^?, 31P U)FM$G"3=I+&8
M'CJ635:?=YAN+I4O7A*1%G>*_)>.$]-^ R5FF?;4C;XP!XP&QDJ [OHU'>L=
M!A=NQ[K>K#<;F--W0:G1T'R5/M^4XOSO,/*37E*V%$PL&'/_Y*5#LD#:4>8*
M&^J!#;*-) 50\N3NR&MS[%4J.KZ_.QF??%>=1CUZ-KL9@<@BA2Y,DH,'7^IW
M(,1[6!["=>,]WX&#XX[6PD>G)=14$+,'<$G^N0"WY-\K<-8.XD#*U_>.3NL-
MC0MGZB(FC!^RE = E@8VRV+K>Y0^L" E!+W#[Z.8)1ZG^Q0EZ[V'VFA#)!HY
M6,;=*8CB2J[*SLC,L!&B@7LJ&\![!Q<^ ]$/.E0-"3I,GDXEL1:I,BXRD4BI
M !,+K,=4XZ?">'!#0I90SO<T;HH"Z3JG-\/3"(GO[\BL6-#R-\YT2H\.F)E7
MJ:R9>W$IF.Y*GD_739IHRU%V%!AG&62LP9>T?&3KH]LHVW^)GB!H"!9&I=*=
M)6'GH!V]U8A TW/+J*YY<HFJ/8UU#H10U8^4;48E!']&91Y]O+R]NWTIZ#:)
MR+KD%7SVT#*)N^DS3%A =.\^E02@X"+0E@\L\ZL>@F!2L$F(RJ'TXFRX8T>-
M88./)&6Y!7= 2 !DTENU)^!#IY,,&SJ3PW[D[Z,T_UN$]K!:EQ74'FGR=E:%
MJY](M&*=Z$[;'?+H*Z#NS8"*!)ZH3(WE:<': _+MGFX<K9KD==L,T@[F7XV*
M4$,[3)S&@K8 7"*:T=8R@9\J[1#E=%L%WCI13EW D:*LRHNB3+<T):HTY[=V
M59D(/0<K>9,T59K1<8VRISY5H;PJ0<46U);@<H"B/^9@5\RNT9]%>1KC/&%%
M[2+UDU@UT:Z\?:S!:$^4H(*>$4'YI@*7]*M47(\!53H;ZQW:$SNDC&"EHK.Q
M%4T!X^\>\-/K!*9L,?/;#_3+5_Q+MH(AW_[C',=[=@6;GL#*=SBGAG[Z<D,%
MA60L=_"Y/$6*/4,U">KGE%H,/+PD*5F#)F]Z/;;BONQ*P@Q1;*38HT /*0,'
M?J&L >,]^RDE41,CBX]KC-+8L%O\&!7S]=LP5:<0U6R Y*/<^7NN!;H"3%A=
M<:_GL"SYQ,PY+.(\97UI5EER&A5I0;M0P8*>U*0_U0KT-M3-+5&?FX?S$E$I
MK@Y):5@%EPG!&LPTQ C#:"TL -OK_OC0%O&H@K?!GU6D.=3K-M2+SAZWZ4/&
M-EVS\C#F&/FU*D6+JV-*''R<3]]NH_R%+6MJ$4#/[!.&]VIBB\TT?!PX"L^<
MP,W,%>G2DOG7VW?"N]AB4T:!,[R]3S/FZ@4) N=IL<-%A(KSZC:IEI^9T]9'
MRI27&\P2D7DSEHVH&C<$83-H(D5IW-#];ED?M+8 ;*O]\131T&9UEA::!#U9
MIY<%1V6*3:YLAJ_X!K, ,<-5U?QL+R,M&V&:LWL_IE$34_L"Y&(CU3#<6H9%
M,].J4%_+8U39&*=CGKV,T?6UA]1@%4Q\T<(+Z^AOEB)'GQA&ZYX)0FX-S6,<
M;)@;6>B(,U01DM<A:$!L',@-U_9&%S@*.@T:L(G0L&#8K@X_U *91.U1,C:M
M" ;).NY)((^ -&?3P"*V"E180W>SQ.L>*8S"]3@=IQ;F,5A7W(*UJ-$P/*VL
MD($8]76'A:3K'-*K(?)\NTW=2(64X2)NFK27JI!@6UV6"*'NHP$8UM3>+#'V
M7!PUD?=#^#URF @AR7*1-?#@&:'=/&_-RN9PL15KQT>+Q>&>ZLZ+E 9( Z>+
M=-XW163B 6<6K@P(.T8K\-#6?M"'P^[N5M-<HT#] PBEKB0[U%S3E_"(V5S(
M)C4FX4N!F-5C1./$73]&Q#OW,'8LW%0,@PLPZB!B;7W.,L4.RF*YK-&CZ\$V
M9PJ.C2Y3%>N3\<9_0=BGXL)(7[W'!*5*Q EDMOB <?(E18@(=TG6'-D#/8SM
M(O'5)&P.KQ8CI_A*S@S9FO<1Y*]FJ&,KI<\R[2C)933QZ%+V;- >)Y_*K*,^
MLPYH$C($6]>,G4U$2P"K'ZJ67+KPKA>%[,RA>2!'B8S5PX]#9%T__,CXU,T_
M0CINHX,5UE#>+--#MP,,[ZS2V.Z599;&CVK?.*,WX;/2:/IPS=GZSHHC2=Q/
M/]UV-VP:XH5!P3R\_7E/=G5X8<8I:E^7#:'*?#HME(0]-;NLU;7FYD\;LZ"T
MM"5G0]J.PW;SH9^"7<,2[UL%]V7(:Z<)6+":LF:9[FX?<4[<+-]22<PNNPQ0
ML+@4T4O1PV46RN<5901.<9[C+VGV4(!757\LVKTFD%,%$S!A->6%"0EJH $8
M&LR_EXRKM+]J6K(KSV0>.,/LB@S,XM8<91)N-0E;M,378>2VJ6'-F4VB+=XA
M1VTST+&5SF>)\4IR&<5^7<J>[=GC7-&TZJAKU4=DOZ-SAXF2CPM2[1BUY+UD
MVN3F$:.$F"%O^/P)ET:SSA0EB[Q@E++;_*#!2C3 IB^LA#>/*.*&];0XSVJ@
M5Q#+24*#J&M#G&5J4&G&OJSM*89_31T>#5A3 <33F>7;^!$F>T0[K5'.IU%!
MC^YM:<F2'=P5U4OM^\3:= V/_&GR<8N5X,UZP;%F;XP]:/*7Y=]@)@ KU+&-
MUN<Y$EVY"7O\I)*HV4G_]C'*(9-9/$EB=I'0FI5%^=*.M8<J%36#5X?F'\:$
MX\HHL&,$CMP 9*&[GIGXJS]U\&N_$,$$$C%2BK3HXN4&/L%L#VDS:+JXHJ&*
M]1#=%R7>PMQD%:-,TAQ[11:.WVY@/'G?;,E5=#,5?(.9X4S1Q88JGF5>FY#(
M: )3I^G-6#U.2=)D&\^.'(5=CDX[>NH\%MAT@HS#M<]5&K,LE?5U*?/T?L\:
M$#[D$.IGA;H4#=<[RAR\7.(4W&6WG8H_J 4(8'6CCRLVTZY1ZZXI'MI+;76"
MGFS.;<8Q8'*K89,+)O,PPU?5^)Q<D9P72Q'876(88)!L9AW6$3+ \>F@N.QY
MB&KE262\@66:P_;]*,/3$.IDK38:5=FXWF6LU^L4VIISX.<@M,'&%MJ>JY]#
MFL'D%&;DBY+>MC,K3(Z1L>K#,$360Y='SH5=.0SDZ((*.EA#70$C41UA97Q
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M;<;.2Z6'L-BC* =)N^+#4Q::G#2Z<8 O7#+R%QM>;TD+4-9/G(908K$T%.P
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M:"Y*ELLOM+@HRLWD1U("NFU!UMAT#8W!>L<VQ<@?BA;>@>QYJ<#:NT4_H.>
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M?0DBSCZ,.+&,28Z7TWPC^KLRO[&"7N/AAZ;P5;LX(?Y!WS@Q E /H?5K.@A
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M@)FJ!PE^S?8\#0-6TDZ0*A=&3KG0S;^VL>LGZ@,G"M89E#0U6PKW?-)P+_F
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M)TTGZO^P(<Y]Q+PXTX>? >,DRVTAN-0H#'A20\&IO/5Z6$??]D[F3V[A:!]
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M+GP].555!XE2(/X<ENU+A=TT1CQ[U$$SP,-36GV48 7H\<)!=*BIQJ B0?I
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MSH7@5QHR)0:X F@WU*F[WL?9IMARNJ'I)4U><9K'+'S>L\$P[Z;I&X^KIEM
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M1?9&<8$P?W7IG?;IQ:GQ\%H<G#Q1%C#Q5V$\O"LVB[ QW1G#W4_$N35U-]%
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M)&246C?2BYN2):^Q)Z2%\Q?;R79+P4$2CJ>AW22#G(&6%=CE]KV^Q(-P[FD
M$S74W21GG/H+JS9!M?Z=NWOJ= )T\GA^3O$S7TTF[8\:PXB7K2#0/B5!4KB*
M?[77<<>?HH6.++J9](<5^&,AC6%4YW\.FR@#]8(%$_.0T?OYR,*P.KG =7YE
MNB5C!X3I9@"59LE>F[JFF6;X^DERO3KQ0@)FF#'=J5M;VS].<29>0+9*["V(
MCHB7IDQ"SE[EM 5DOK)&DSHK=#'(%=.@V"E0+W=+OD@R+@HJ==;^2D5#1,+V
M4MA&&.2EL.(R3M'["O:82&TXZWW5&&TH<S%L2USMY:WW:O7';X<:[X.:4''M
ME=M'-4ROXHHC-YW7B#G"J=RO$+=F<\X<PEQJAAPUUZ73L^B%.6HD9?A8[9FF
M+NGA2+!D>G'*X@1G&?O9)DZDPFVW ARYC-PM<.(:=D-!M\BC#-<1%XK7!BJI
MN %OE%S\QX5@$&S7C]4T=R9&X.37]OF6VO5^C[=\G_J*943KO7,AMB].OGW
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MJ)!X,3M;?;K_0EG&R]LUO,V:#7:) V2>;A<O:!A\+5D!BH 365^H?+ /QN_
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M?S 3S2D_4[K[&A/"K.<VR9G>X@W!\I]&S16]=#WZ;@^?()=S% >U%@<:S$U
M[0O2@TI=$H ]KECP%K%3 W<U .Y$OEGO&S?*'9ND/ )8)QUP"RQEJ7AR@II
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MW,N($+R[>%._EZE?]+1NKG?^+'C45I-"3K3RO98,Y]>U!7.'4X,> *G)SM_
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M1V+!ZTQX_0=LD+^S'Q8_8O_AVXO_S_\/4$L#!!0    (  V"?U1"F!P%>H@
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M7N]BOM(#D?YWYCM7?D0^NO$7.%@S5)OX?2"$_H 0JI[,)B [T(_8;]/I%SY
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M>;I08X8?'8()%%(PHF,04H(<*ZG)7\>!E& 2I6B$T1#"2'1U-!5 );6GJ(I
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M]W@0"0T=(:(8N2^@CDXU%-1T_;+"%;EDZ'^H$O]B>30QHB7, *+#[AV94R%
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M.'Z=0ZT@V^PH4T/NV3*N4.3:EC=XGD@=-YHEC91.5:K(=D'X%Z3^)0KMP-W
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MB:4TW#*W]Z$:9LE5R/R^J4!([QBH]:V!D&*[6WH>6YC9]D@HE4$E.D.[6H-
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M6G(]:I?+ "VM"*7V]62 Q&LQ"Q_0)CXOUSCXCH,?9*@+:^/2K8TM']#4MO5
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M?CGM,1("?NB$]$IX^W4>#O#7/+R#DPF?F/71*$D3)CL"'2,MHIB=?@9J5#Q
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MM)CULJ]U2\@O#6O&?%K/&6#*^U.>+WH,W2+?U&[7]/!V9Z4[OI+BM.Q>$ &
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MTQZ'R?<Z3(HS^ BR;NLY5G4N[F[M#!3H!!AB<Q*Z_R!:'IBK?O^Q&$X\_GB
MRE[M(&=YJL0(N^49+_4(:25E6K13BTN3<SWK7@>Q8ZU>Q\ 6%<G?)*K;"1NI
MHG:->)]U&.Z;I3Q#._#U@]N!<V7]G9Y<?CX_>?_I]/ST\C+X_)?@XO3RZN+L
MP]79Y_/+38KWPIO\V(#9LYJBHJ Z12P(%760<MMWII%;E#0NVXWV>5-C). K
M5',$&RRACQ*8"U>P HM;)Q90]5_1_KK >50^[3VD])*P)7%'?$S#X*KM1XEM
MZB(F+<E.9&G+Z0-Q&?H>,9.$-17*7QF?8<V3=5O#04!P(VH<F$ZVE<">R5)H
MEEBU3=\ _H[Q69P?U>DPDBM.2ZGLT(&Q(?'I/H3^SDU?JLIF;NKAKW*N'QLT
M[)7WX4+H6#PFQX:@Z/^JZKD:[=H3"( EDI;&N@\Z\?4H&Q78!ET*1?(A8A<8
M$$)$B2MI9.,._C'E 9#W1WB,\EL#AZB82/]=.EIPBB9.^!;6U<-DZ6*D<?C.
M<.A>&HS6>P?AMW@P&FC]U^G4F6S:F"Q!VH\-BSWK.<2$Q261%5.-(Z:"*D,5
M?196#<N[BYN0.![V*Q(K $[L5.*=[-'8H=KQ&7HKNH2@&601UZZB_EC:&>FX
M55QB=)KMR)FK20_S256*DIOZ!CZOKW;9UJ/9$/C"!/[88+"_<$&M089QR++>
M;\&TA!!&-Q'2Z"KB,2PP1&^JS?LZ2J\5](&ZJ! 5QTM,_=')UE3VI!1X5(@4
M@1.TC%0!$H(S :M)V0UUAZ99PG#9.9>'XY02V#6\VJDY=ZTR*B$6=]V>05JS
M\5Y5D1?2W]FF:%JA$?EKK)N>^TO=BWOE.-AZM>?[7KA1)\RJSCLBCA$W3Q4N
MT)WRIOI*?B3T^JL->GV#7I^#*S9!:NISRJ;!<U@:/TXAX*(?LNZ \ZCG9[E*
MU*UI.<B9F\#-5.0RM;44X7LJ2/0G[\:;.]9TN#(6_<WWAO_P NZ>#+;-=>\/
M$&(=+22K!V,-": J=E(X2^/U:B(\[)\IW$QN-])@VWF[74E12'09A!:Z=35K
MNIG&3D33Q#\9.>)?R.B-,H<#Y,$@9Q?.,:V 2G8LD6V#P6G77G"J+=)%YA)W
M"J*;Z"I#%+<&G40&:@KZ5)9P4^MOX4/^]OLZY!>J'.5>!$Z7G+VO@_T;9H>>
M!:#!2@T7/@8^IA.10(S4!3T@B1%3P;5BJ.IU?5M2VV2ZOF:H+IVGR_75%?N3
M*M5.@PL"H! :9  Z?>'T%/2K*NM\&Q.UE>([0ZZ=(XG@NL)-%>TIWEKQD4LY
M&YW./UGKK^5V??6@%621-, NW!4NLVO%'(%P*%0L?1B3?5?3*J*AN"OV"L$U
M@C,D:#/*-&*LJ7VO=46/AMS%6\\(T3"CDN.9!A,-G)21+1V%G6D"E 1$I''I
M;.G,6E ^#<Y)N.1=M6TQJ!P'L> 1 EHL\"=,S-@9NB,H/;4S".,D*,9 I -.
M3R30-EQ4DLV? T&I.]-ODD!*. 1LZ;9 3>MY#MT4=7;)M7%W=3JNLC6E")/C
MYZKUI85F:7=@U<D[@(2F)3YQA;4NDQWH.M?*/7GBQTBIQ'J8JE38E)*"I>K;
M<)1>J^]R;ES1JX\MVYGLB^.J.[.ZS8P0$WXH9R4L:EKH"$:7Z]H;CXWM68AT
M(2UR=I%OXHKBF*B</H@56-]HOJ)QRY2CU=7QW9:TJ>X&AN#<N!Q1Q#%+:[QX
M:A 7TH"+2SF[(LV>+9 %-Z[403Z"E1O(,J;ZM=2U*>P @RV=(@TD9D)<TA8N
M1S'J_"X-2N*4>I7XD!H[,.)OJ4J\Y!YN79N;*I9PVD$N>DO[16NV*-FI,LV9
M[L*!ZX&Q54_J(: 9=5%NLP0Z^K>X9 <Y<DBNX\M[J)L@8>E[_%P=LNL0*##&
MR[&!GJVXRRT/BLS5LS>J[:*J[?[>]Z7;?J+^$T@YI]@_@B3)A<*#H^J+6Z]!
MN]V$9!:FJ2>%DP$>A+TZ.E3I,2N*6->_+@H2691W,@ &#!(F'$G5?9!BMW&6
M..C"*>$1\E8TJ]<,&:>VY*G&4U,KD 7?8/HW ;F5(RP@IIVI'(+/20&E,Q&G
MOX^X ;!;^=+KI-37QIII2=P0D>5^QF8H3J@)6R? B]*NU!H52\MWZFCII<R!
MS<&84SU;/[F32<=D_05(TM]!5':E3+E.D<EM,[Q<SGS@M8NFEBRZ$4NH'3]<
M1E*OOOZRNN /D4_RQ(_\W'[35RO[38%'/#;FIO&XQM9Q0EH6:;:]4<+YE5FB
MO7\8@]0Y7-P7*7.I/)1NN-=@)Q<$H*MK\-.:Z'A/V=*) !-"4T:+[?FB]%)(
MG&BK;DE5Z#9DB^YFT*-JSJ3[#]33*/3_9(_*"K3V8_*6E5C%8V.8*CU6)SOQ
MB>2L O5,^6*-N\CR"+U*TQ&QV,O)E$8@:7>D47C4K"-.==LU%G.VRG1YI["*
M]M;^@2FG)::\DELP!8.2;"7[@ ;DM*+UD!D/F6+Y'&VK_>_+MCHG!\"]F5$G
MZ$#G5U@K/LN=%H6U#?"T6+R.L9AR0SN\)9U>3H<;U&S[*HS^&(%4Q]*8+D;(
M- [E\:-:0,-I!4G8H20E23P[*76)_0]]4'&#4^J(B(?NL^2)ZVPRZ=K(#42Q
MMV044<\0K*,9%[Z'"=6 /,/"=TX017I;V]N<T,,9:<*V_27V790HH<Q P KT
MD#7NM\<QF)ZL7F,8$(4,R(L^%/17;U2$5*=?XCR5D*GYGFTS[%W V$VZ^1K7
M"W]"/WU+SU"_5N>)L4)E4ZB8GCA)[]6VQ7-&X;@0A!T8CE@L Q^+N#/X*.V\
ME4'L@SU9(K!O^GB!]\<<$=&M83BDH/.#%QJR[C(G*\7L')80^TO:@<UXIU[^
MY^PR<]C?VEG[P2I<LE;ZW%L2&'="-&Z&JXG^HI>(%OUCA'])5Q<BF_?Z1)P4
M1=:-J=>YT_AE@U1>G&8>W2W6XXRF#%@Q<A>ODA8+A"%VQANE5#0]<\ G?OJK
M4U6Z6M?$UCRQKA]3V^2NCW#<"8VWH2R8Z+XU*" N#<(2Q8L^<C23@$4FEU:0
M0OX@=VC<.LK$[45LQ23LQQRF7'T?1VLF[A5<(,Z,-6#\1<-4 WUD=/,7VVZ^
MJ%=S&,E09),1MDHQ-?Y4V+CJ<%SCS+JO%-XG?CJUS^/SI]-_?3H[_YL4DYCX
M?G7@'YSFQW9@39*]40'9753I.%0]O84A9.>8W\<)U;%C(F_=:'VB,LB<>^8>
M#<&W3+[>!>/=P\''I%!="Y]KM>K3KM7Z\,8[N%)Q;4YF\*/8W?>IH*W4G_=A
M%333LMH$5GY4]KW2?M^K<C6Q9]FME)O\%-X=4PM$X3M?-)CLKV" %1$ST'6T
M8[]J\(O02-CP8X!%"GQ[A+Q(MZC3UGX2WIFR(U1!!O_ S?LKC%E1@5;B670=
MLBNJD,56J($=%QYL63.\CM)!/U0KJ0Y!,M8=/IQ7=%1YAZ:L\Q7(&<(S50.H
MDMHEUBO5V3*++,WU>*%_=Q::\XE5.C(>3D*/<,<]%=$Y(U=L82H2PI]I.;;%
M,R=A/7&*#9N28)B$C%*WR9_B)Y+$,8H$P>*-XI*Z4$<,O71C0$[%&S@2A <E
M%VV6NUT3YY,'<X=X=,W]YYZ<=K1)3IN1G/94<HB>N"":.W9Z5&-(U(JH!G%&
MDNM>#8G)+B<@+\).G,3SYP/,B(>A:L<PC91BXY@*K=FO18NTW+3D%G<\Q$HH
M& ^85@1FR3&B?%SR5J=5U9)/D#*U(!7[*M$"TE3=6/*A6#K\NA[T.\?=N.!^
MVK9 %T"Z#LF-0K)?!DE-P.2%Z-;P;R;B>82-X=PNMBE-^**2^SY173^-'I^B
MM%=?%+/"%*TW-"%K/;E+9G9!/\2J1Y@%0]$ >V:6I:?J45LV2[42^\#CGW&A
M@ED\X8D=_$J=Z<KYQ=[#11'?HF;;R;.0-A)AR*-<TB!LAC#L9-'-AEA9%F->
M<H0$L=W"R-)C$R%6*<'<#HW$!MG&'76QDO/2_6MX2588H$OZ?B5,1([#.N,/
MICZ++>'+)5>*1UI92@2!P8"6O(F++&ZZWRN^9T(!8D!?EC.2]*3 */G<J(<%
M+/28;<P!6KVIZL6VJIO^V\W>0P!"88;6HG+KUZ@H84X9D7\^E)4350JD-&P-
M59_M8<Z(K42KVU[D\K?V%71B3LW0.7M]%7-3=40I\%LCZC<&=%#J!6(AR]*I
M4L-T@YE=C>[OM731)-WGMS%H&^NA]&K)H3K43D%O5":AO[D!3P[4E4<)E7CO
M2?2!56A]9/@X:#!LY6U^&6'\QYPD*I4H);IL0)*?M@EB+T.T]]HDKWK-J0UA
MG90[OP%5K<5FE<A9I3XJP3&QO047^ZRE:>"KF-6)B"UX8^Q'V=#7."HD^;LG
M:=.<7D$JBYA:@?1<C].1.1"UA2.<_ALZD:XG;3$(,1Y*>NU OZ6FMIC)[K"=
MUOTZ%4Y.8&LB*9 28BC&%=U2.H=D"6[.S<+GYEY;_%6O^2U$<-@ZSLIY!G1&
MM1?<9A%<#Z$IE\:67-3WR@VVXA-90\"C^2]^4'O>]S)-3X6+>M9V=1A..I'W
M3B\5@TK'*"_A% %X#H)2YTMQG!R."#K[4\E:PD(V]45LECT\,]S"S_GLO'Y0
MF?,-X3S+Y)@W(320E)!>Z,&H[>A/NE1$SW:0JFDT!13YM7W9!GKJ]E/R+41A
M&=H"15[S0/%@F)*2HQ),@W_C(2.'$]Z)&435W,-*:PD9JX0,<RE_2,9' _DV
MQ(5J";J.?%^W]P\?K>K>=W2.3&CB0O4.7AT<'1Z]/:P@9IR?7C7_5!>Z6/A@
MOGG(@WFF:TR'*]34F[* [0D39[*2*XF?44*^3)$Q''C6SBKMG<9KJ09WS(_(
M=15@4 (9:Z2CPH3FSL,>N>*&5/['%4 Z""^%D;V7$J=P%Z5.VC23A9>>47!!
MG F]MT5=9D8I6V>F)*LD^^J"K'=9'A4Z#8(3%)6;Z^#]@J4DW!^)\J7[C>YR
MY2Y!A"/1;E@C56T1QA:5JP'BY.I'K %X-W&C'0N/]X:KE5WG@3*Z*>>&V^#H
M9^E'L:_2=-R5WBS]'"-D<HGGU=17TJ"QPY!@^S6PCR$)H:GU82Q8-E+H(9%X
M>1AOQN\RJT?/+&)0]\=F#WIF\6V3''<2>+.^PE3 M,MI$L<+6!IZ@?8A:[A?
M,?%(>HSSVMMMI\R?7)/9[!CY1NP8_ 8FKI>8RMX9\LFEEMXW(*R"RC)1+R9Y
M :;T8&&PF6TF>FRTW:HT5E*+,%<]T>>R%.5P(T6&G I<7ZW0UR7AB:)+3FEK
MM-#Q;L*&/(G6:=^++)T5YG^]#EGY]B%EY4G$W8S1PSQ*"Y54T%4G'_YV_OFW
M3Z<??SD-KGX]N6H%9^?!Z?\]_?#UZNS\%_CJ[#(X^>7B]/3OI^?X8_#KR3].
MX3\?X:?3X/.7+Y\OKKZ>GUW],[CZ'%R>GOZ-OC_Y^(^S#Z?8:.CL_./IEU/X
MS_E5\.GTEY-/P8?/7\\O3S^U@I/SC_IY%Z?P0/S[*UQY<7GU^3/\^>D3/@ ?
M=W5Z\?=+^OW+Q>=_G%UBUR+^S1V=+[:]GX+?SN!IYY^O@O>G,(#SRZN+KZ?P
MBE].SN S//F?P9>3"YC$^W\&W"Q)O_KCQ<E?:"4^7\#+3^&J$VR:5//VC2MD
M<:CFWH/:<Y6V2.MR@+LP;FJ!)%6@#3Q^GP3 09-_A KX:X<UI9=*T6RW4S?V
M7XJS$>(?57H-7"GB+-"!5BYZ(\K$,3^ZS<%[L(?:XVW>S8!1K).;2E%*RN2A
MPKJNC]V6IM3CTH#V.(O:T^->7(0_#9.6*=HF1?%$2COCT:  T;6KCE)2-$3[
M&6!UL;Q!T!8C1(2J2 JP#52.%7U"JB(:2P7.42&%:P2&.BJ.38L1I\&"J>C+
MBAKE\-8)WY9;*X23'.[0/ZOG(GMKY\IQ#M.EWI^6Z51+ML.$1\O,KZZ%"$R"
M*\ 1.@'UE:HSC3N,V#Q (B*0=CI?HCJS5!P)ON=,2O#45S*IR?1EJP&QM7GL
M%7US4FC)XF%-JMN' U^I[W="X1R3HB@.>%37Z!,]?8#];4N*A19A@F4$N87N
M4*5%* J6J&$.?$@CG<@9B6B-&8E4L_&S4UA]#89VAAMD$5='#7#WC94OL\"Z
M)$ZD_>,"(J2&9RX UIU?^WK#VM?_7E#]BXBI$2&VTDJ->G$D6(2G!VIV$J8W
M[?\W[U(MW0UWJ3TYF']/'@5 _7H#H)[7S_BH_41J:7C.,4QJDSZIU:5GS1[\
M+()[\?/_7E(U"E0V\'PCQ]>YY-,J"]L"V<]K.<ZS=.<R X[K-D;"+S]0.WFJ
M5FWET*+\; WTZ"[,PU+HFD>UJ-WU>O^16Y_7!C2M4A62]W-67_A_-:8C.B89
MZ7'8D0\]!J#U)L'!42LXV#N8F4RGW^+]3VZJ"I"5;6%'*7JLXSK1;-<JZ-CR
MMC=*I NLUV^WOC0H/4G;17!;#\'?$;9Z#TZ_]>-.7/[Y3_M'>\<G-:E@:PX:
MS])KT'U(C_^?%ZA=H<SEZH8=JASV/R_V7@1=E23B'3!_BU>1_I:A\AWH(4A@
M4]0[_0&=W^2,?,4RO<SQ/]P5%-\+PWX1^$E+KV#8,@(]SR+#'J)[[=>OAF5@
M;?85E\KU/^#?_MKA%X_(*':+W> D357P5[BH8 .EC&#*N[R$BZTC3OE1%W'6
MR5[I #<LX9;12;:77;^'IS'WA*ZRXS_NR=F<FM5.S9<<#6]05\%^_X$.SE/9
MT_O2<4ZZ737454Q(Y8B"J^S=][1<FRU?;,L_J 3;VL;4<JK;GEBF7=+VEO!Y
MKJAW_N *[IOVWM%T04T[R:E!SUQ8OQ^['*C$"B>X&[!P!R^FK>';_?;;PXVV
MPW;"1=91>1G\M1W\"K_G\3+\D(GR28CMZ0/%S*HGI*(]SJZC;O9N[B5[_:;]
MZNB'7[/J*6D%?__8"K[T/_X Q^5Y[^P5MM18^#@\[S5I*%'^X#K@:H&&S:L?
MXM6;]VS>LWG/6H[N2OB3IE<?+/'J[P*1\F:#2/E^$2E+%R%N='?QD%ZNQ;N-
MF9X4;0U.GMF\/L4%X6I/OU$>5N2@:!ZNCO3]QR$L@O#7Y.;5RS='1T=[DMFV
MWYY$+EA.6<.D)I#F4Q\_)X(<*0Q=ZDY7'UL^/3@(.BK)[CA_CA/4J/!$(>W2
M"36=R%8BCME!9!-&V&NNC;5CG7Z?IOZ#J55KVXY26^T!)1K1S;"J,5:XQ?%A
M>9\P[_9;<,DM#&_(T%[8JU$/;^?^]D7(&9 FRYBJ.5)GF2((3"T- D,/PDA1
M6XBN BLC,@_6[7O@ =+L,,=::5VJD3O@HA,ZPYF^:<$B2#6YW[.8^JUSN0JJ
MX5Y!;<,"#C!W2T/,_9H7;M?J=_/D,S]YU) AU@]]U;W9K\E7JAO<V@;@3O6_
M*W/][Z;A_?E/;U\?'M4FU]<<QW/3^LN>@^F*P7>V:0=/>],.G$T[G'?3+I5B
M+N>?,O8D+!QH$8<-R^2YXRY&-YO#:7=PU-Y;,6@PM\;PA"/\<X,&R:_FI4C,
MXW"<N<;S1+?N<YU7]JF^W&\?S(C@;>C(H:./H'PL3D8'!\^<C [WVH<;,IJ?
MC,XHAZ W1CWZ?#3H2">['!W='ZF%T= M';)$5*<B(!H#90MOV6RGS&,0X JL
M^FE.J,*8G__^+<TCG^:$*ASQ^]^_#>?9<)[GN7\;SO.T]V_#>3:<YWGNWX;S
M/.W]VW">#>=YGONWX3Q/>_\VG&?#>9[G_FTXS]/>O^E8ZO6B :M#6$^:VWKB
MK=XN<P3^KA^7B@I,8G#@+@^'4Y!T=6OSF"'\)QJM?SDS6O^4%^VAQO'$EF56
M '2)4_% Y#?!?&JI\0D=EJ:=;]AJ+*@<Q5QI,"CZ2I5%$)9EV.VKJ%W=-^+U
M<[)ZP]KG;I3QF(C+@_8LP,_<R,B/(^Z3(["]KE,!#K/10UM6]"SHABF6[C2@
M2*J1;VO7<C52@55RZ:3](.QDMVJBFJP#H;Q6J<JY;B1#,VMP2FO?M"5 W$_\
M10OI( \'^GK[MOUV_GI2[;?5;+^GB0<Y>-M^_>8A1OI0#,6<1\1IG VP%K.T
MHI[?\/E>=JZZ<<\,I/,%ZSAOQ:K8?G:;]_)@:B[W<]B]"R7MO?KQ<*EB.<1"
M5W% ?)_KMM]>E'DOZ[%X8F>"SN[3V>\U,>C-YCS)^0@#_FYV9\,V9QN22[+-
MM7N"GQBI/[>CZ_/5S>Y]7[M78;S?__9M./,,SOQRPYE_D+.]X<S?\^X]4\Y<
MB9H\@[CU%*3!4P[!/E+<^G 3M_XAXM:S3L73B%L?_A!QZX;9S:I&].+G8+'(
M-R;I[O1YJ?;W:O=^[LCF7*62UDCCM3'4-4[(:6YK._DVS*VF(^^]<KIJQK54
MF?JI*//X1@674Z\Z>/GJ]9O#EV^/@%CXAI_K0^SK6<QU5%";PIN6+XSG:SR=
M+!IC?;G=?CE(X,/_!U!+ P04    "  -@G]4Z?Y-E>\"   ?"P  $P   &-E
M;'4M97@R,S%?,3$X-RYH=&W55EMOVC 4?J^T_W!*M3XU<2Z]*61(;0@M&PT(
M4E5[JDQBP%IB1XY;RG[]3B!4=%TG50*MRP/!/N=\YSLWQ_Y^NQ_$WP<A7,<W
M/1C<7O:Z 30,0N[<@)!VW%X)CDW+AEA147+-I: 9(6'4@,9,Z\(C9#Z?FW/7
ME&I*XB&9Z3P[)IF4)3-3G39:G_;\:F_Y9C2MWIKKC.&?A&4/!GMR7/O>ML_/
M3-1#*5F+?;(VV#<,B*X@D.*1*<T4/)Z8ENF89S881J4PEND"WWM^ :5>9.Q+
M(Z=JRH4QEEK+W+,*W:QWM"R62\V>M,%%RH3VK,_-B13:F-"<9PLOYCDK(6)S
M&,J<BI6LY#^99]MHV6@=BG%9-'U2M#8\+@%IQJ?"4WPZ>W;X/@IS5MEZ8YFE
MFWXK]4V*7,R8XO7>DH GI,IIM@+55;4FN(&[@JVT'JGB%#U!K=AH^10$S9'Z
M_77VPST^.W6/+0>W"6V%3S,^YAH<U[1_BW/KF=T,>3-FY^U<;S.USBY2&_2C
M41C%X%?R->M+FOR8*OD@4B.1F53>06?YO'!_@5#9ZY;K=Z ;M<-!B#^(.PRO
MNJ,X'(;M]=Q>!$'_-HJ[.">=[O#&)Q5$:X>UVU)IZDQ8R^<OA7C.Q68MZWQO
M<0H<]Q0'834$=PP2*4HD"EJ"GC'@(I&JD(I6!R&,%Z#8A"DFDDH$;R,-V927
MNC8;::I97J%&T@37=0WGU+*<$T!9!UG!R#@'.0'YH! ?O6E(T2*%&ZJ2&;CV
M$3B6XQRA,$-$,5VSFW!!18+M@[6H79054(#G;(9QZ\41=$5B BT*AFNT1-9Z
MQDNX$.(![88K=VLBMF5\^Q/ $6!6ERX7B ,,BYD>'MBG5K/-$I:/F5JM:JJV
M^?';<*.%N,93/-E*8[ZC#4E)H!WV^MTX#N&0YD43XOYM<!U"KS?X^/G[YV,\
MH*KD14$%]F@5W5>F2K;XWZ-Z.?*[_A+OYKN[#8\5_E+M-8/M7.1\4M\A?5)?
M5W\!4$L#!!0    (  V"?U2PE8VL(@D  %)1   0    8V5L=2UE>#,Q,5\Y
M+FAT;>V<6W/BN!* W[?J_ <M6[,GJ0+,+3,3R*2* #/#G@Q)$5)G]^F4L 6H
M(ENL)$,XOWZ[)1,(Y$(VUR7.0\!R2VJUI$_=DLW!S\V31N^/TQ;YWOMQ3$[/
MCX[;#9+)>=Y_RPW/:_::[D8E7RB2GJ*1YH;+B K/:W4R)#,R9ESUO.ETFI^6
M\U(-O5[7&YE05#PAI6;YP 29PW_]=(!I]I/1 #\--X+!%Y^).,<NR\7B__;S
M( 2WO/F] V\N_7,N1SK?2$-&$Z8,4V2RER_D2_E/19++H4!?!C/X_.E@3+29
M"?8E8]BER5'!AU%5\>'(U$*JACS*]:4Q,JP6QE<I1H[MI<W!HX!%IEKX4!O(
MR.2F#/-6^U($+D'S_[-J$<7MY8"&7,RJ/1XR33IL2KHRI%$BBHI4(ZE"*ESA
M!@TX@ 1(C9B3FE#%*=1($L',8>MRQ/O<D'(Q7SSPQH=/WJB[E%YN\&J+,X>_
M1GT]KMVNE _5,%4[HO[%4,DX"G*^%%)5?_EJ__XY?=!H=7OMK^U&O=<^Z<"T
MZ)Z=USL]TCMY!VWOGA^WSDBQ3'/%R@[=)?5.DQ3W@N3JO--L=4GO>XN<M1KG
MW7:O#<*MWQO?ZYUO+5)O],C)5U+<+U>R[\!4]3-2;YZ<]EK-Y3&"EK'CIEPH
MH36LL>K=HWJG=98[^?VX]<?<3J5"H;1BICO;7BS=TO@'M#6Q4]*&1S6_G86"
M^T!D\EN>?(?;BF>)#]=\,"-F1$W5-2[@$V)[_DM&L(')0)*A?<%(7ZJ J2^9
M0@:R":''U.?1\.IZ3(-@?CVWC\N" T;0L6;5^9<:F?+ C, (8!-;@\)_ 9DD
M-8/],O-"G&@EOU?Y4)N.N&$YK!I-,%5TG+EEV*+N=X]-VS\;63D9\#0V\B$]
MN''G"&9@BN42BU8=O@]0=-ZPS0=#P'RI**[[KL+U>6N;\2I-*N8//)0^Q)$&
MKD.PWNDOW)N/:<^RG1J@9E_Q95,6UWOQEKZXL=\@:V*KY1*2; 7[=XO, [IS
MM;@V&=$)(XI-.)NR +# -:%1%%,!B6,)\) 1^0HF(<5"[C]$#D@#?$(!QC(S
MTH[\?&VUA^&?PG^($/@$NJ2,21GS?$TJI8QYVXPYHAK( A@)9^0"YI=@P9!E
M'6H2Q@022HBD(3Z42WD$")J1.#(J9J  -2P$=PKA0TD(5V!%00;4AR1%9 C1
MF)%.;DT@8C[3FJH9BH3T@D&]2V5J2 M &:A28 =C'2C@<^7'(8A%D!TT > 0
MP(0_(CK&?XO\4Z984@@V(.1:0%@,W0DT,B-HH!XSWRJ(Y8Y!-1E ,R%2!J/T
M9\MF2%&:HO1545I.4?H/12DC QX!K)!["SAE@:,@#K?5TGT>H2UM4^"[+^(
MR@0 +I$H"_#D2LS(&/B%Z$4D"[%@:X(UO5(UX#NP6Y!9E(@%" !0)5#/5J>M
M/C[5(S(0<JKGM%5LR#7VLB$4$YW>H&5V"9IZKLR:MBDW4VZ^*C<K*3??-C=[
MUR#S;YTP,=D,0V=-#@8<+G?TKF5/FU#%+.6 6API 78D3",QN!YA#A0+P5=%
M?Q6O ZY](74,^="+55(XW(V5]%D R9KL -T"!KAT"&M=^B,:#1FI@X/8C05(
MV'W=O1WFM+#[NGBU:ZM?125(8/1>W7K\/=$$V7A2W+\C?>.IR\TS__G:^SK;
MRG]W3CZU'CMT]T'4?=.#J,DT* U8L.'E_2C)8N3KTUAOG@5#T#X#_B0UN:!6
MQ@H*  ]KPK7UVT"*1;8</")8>'S+7J-B KX \Y*H=@&E;.)1XDT.WA_HHJ7@
M 356T;[F 0<[80.XB[VM'QMA2;'&>-B26=O@V7IY4C-0R(!7B9G&%(CMX_XC
M.*?0+*O$(JZ&'"Y*7]Y<@&]]AH+@/T)^%M124J:D?$^D[&\1*7=.J:)#& <C
MN_.'7!G'2L?H$0%$SEH-TF6"0:!,.E+G2;F<^UPJ?_;*E5SET_[GCY:*F%C>
M+]G$_7*QO)LB(47"NT*"OT5(:('6L?4PT!5@@P'S#9^PB.D;=I@@^-O 5W*7
M-V\W69\),H*?H]VF5E_&YO:Z-_'FZ)4TPQV[P?V'!:0_WPNT_A]S-@!]:EAX
MBK,49^\)9\$6X:SI>+'.'3P437:,[)T5K'%\;"]RN_!(&8+<6-J<=Z6XB DB
M.^G[L4*N+(51U\H+I3:0@H\#0BG:AR+^C*E]P'=G37@ 4#2C5;E$31^],3R]
MC:X_6[+K-!E1?15G0EA'+4198&-<VWJJ901\FA'!+YA(CG)7Y+./,,B6(S,]
M/7C3IP=[Z>G!EIP>)$<']I&Z8$[Q[,)30\=QF:H+IPWIN#&NLNO[;J 4C0-N
MI'*^)=ZU"5!8:,-D=J,KW)=467\SX*"3S;X#U 7/4Z-G"Y\X N;+ _LSYJ"R
M71#BR+='NKOI\4/J<KY'EW.;CA_J0A \%N" ,=Q(PT-*GS/@3A(+7QT#3!F]
MP."6Z;ESYPX4[)-X\^<\'D2S9,?>G;?>X.G1 #)J=N7HW4"^/A?X.#((*UPO
M +DVMM806.LX!#M#4VTS$D?ZQF=AMMP)?-/C+X58>C+P>(A!>#Q0X/5D 2G,
MNF@ )?M0;D*OK(LW>3218L(PZ(SH,'FV6"5>'0O'0LX8W)V.I'/EZ#4V LL>
M&7_G[Z;,9M9>ND06)9-B^>VSG$O:T(:E\>HKI$Z;!P,N&3KN+<+,HW'G6@_<
M//K6.#D^Z7[)).\A7A6=5.[,@&:9)W3M*"SD/^TM)?;0=BXIH<E>OO+Q0RUI
MXMS:]M2:.$%BARH>'4>FMOE\6.TAO+[^>B F7 \V'C#@GYH%39@D5?*#*EB,
MR\4L*15*I9NI\.Q=LI<O5-(>N7]5?+8.**<=@!UP-*N^^ R8)QTM#)APZN.]
MG%IL6=SY9O<V=9&GO5]_*7XLU%9?=5[J.,^M*2^WL-S>AVZMV=H)<Q>Q7L/>
M;B%YE^8.>1 (]K+F+C^+N9>M9G\_XG'VWY:QO;(>H#U?:3%X(QVT_F,7/_+-
M?):<CN C70[>&)_2Y6#KS9TN!R^_'+P;VC=&G U(ZY+Y,3YP1T[<$>R]/VNU
M31-^YU3QR.=C*M8-L;NVXOWM;<:'_DK=O;])M[IIO*[!TU1YX"6_/'C@);]P
M^!=02P,$%     @ #8)_5#G!LET-"0  O4\  !    !C96QU+65X,S$R7S<N
M:'1M[9Q;<^*X$H#?MVK_@Y:MV9-4 >:6N4 F503(3.ID28J0VMVG4\(6H!K9
M8B49AO/K3[<D @GDMIE<#G$> I9;EVY)G[O;-ON_M$];_;_..N1K__<3<G9Q
M>'+<(KE"$/Q1;05!N]]V)VK%4IGT%4TT-UPF5 1!IYLCN;$QDWH0S&:SXJQ:
ME&H4]'O!V,2B%@@I-2M&)LH=_/S3/I;93T8C_#3<" 9?0B;2 OM>+5?^\Z$(
M0G J6)S;#Q;2OQ0*I/N%M&0R9<HP1:9[Q5*Q4OQ0)H4""@QD-(?/G_8G1)NY
M8)]SAGTW!2KX**DK/AJ;1DS5B">%@31&QO72Y++$R(D]M#5X$K'$U$OO&D.9
MF,*,8=WZ0(K(%6C^7U8OH[@]'-*8BWF]SV.F29?-2$_&-/&B.)!Z(E5,A6O<
MH &'4 "E"7-24ZHXA1Z)%\P==+Z/^8 ;4BT7*_O!Y."'*W7KH*U^9:B9._@M
M&>A)X^8AA- H4XU#&GX;*9DF42&40JKZKT?V[__'XJU.KW]\=-QJ]H]/N[ )
M>N<7S6Z?]$_?@.Z]BY/..2E7::%<VZ&[I-EMD_)>Y(\NNNU.C_2_=LAYIW71
M.^X?@W#GS];79O=+AS1;?7)Z1,J?JK7\&S!5\YPTVZ=G_4Y[=8V@9>RZJ98J
M: UKK&;OL-GMG!=._SSI_+6P4Z54NKZA5S0M5R:;]O,FY1^@J[>3U^%1ZA_G
M29M.>41:17+(F-)Y$@*-^7!.S)B:NE,MXE-BY_US3K"AR4&1H0/!R$"JB*G/
MN5(.J@FA)S3DR>CR>$*C:'&\L(ZK@LM%T(EF]<67!IGQR(S!!& 1VX/"?Q&9
M^I[!GKE%(TZT5MRKO6O,QMRP G:-!I@I.LG=L&AQ[+>O3#M?][*Q7^XT-?(A
M\W?OJ1',P 8K>(O:<>8.]E%TH=C]ET+$0JDH7N-=A^N[UJKQ(BJ5B_L!2A_@
M2@,W(5J?]&>>S<?H<\]+\8;9O&%.-LX?5/4V6VW!5RO9/]S:9$RGC"@VY6S&
M(MC/7!.:)"D54#B1RA"9D"/0A91+A7\3.20M<-P$:&GFY#@)BXWK4P/_%/[#
MO0^?@(4,#AD<GDZE2@:')X+#(=6 !-C_\9Q\@XTA6#1B><<(#X=(P@@3:4@(
M[5"> #OF)$V,2AFT2@V+P7U!:E 2PQ&H+\B0AE"DB(PAUC'2R:T))"QD6E,U
M1Y&8?F/0[TJ;&LHB& QT*7!FL \4"+D*TQC$$J@.(P%2$-C?X9CH%/\MZ\^8
M8KX15"#F6D#0"?, &#%C4%!/6&@'B.U.8&@R C4A#@6C#.:K9L@8F#'P11E8
MS1CXW QD9,@3H P":TF5/  0Q.&T6CG/$S2"[1N^AR*-H$T@UPI"\D ]KL2<
M3  \R$QDJ1!+*'H>Z6M= W<CFYG+HT0J0 !(* %7MCMMQQ-2/29#(6=Z@4G%
M1ESC]!A"L="-&T:97Z&=7@QF;;09\#+@O2CP:AGPG@AX_2MT^)?V,/,)'W2/
MY'#(X7!'[UIH'!.JF,43X(;C]@8#$*9QJW,]QAHH%H-WB!XB'D=<AT+J%.JA
MWZBD<)R:*!FR"(HUV0$L10PXY]C3^1Z.:3)BI DN62\5(&$SEWL[S(W"9B[Q
M:-=V?YUQ((&!;GWKN75W7O''9@<?M'27]Q4V;]FGT_=E$J?KX'V9<>S0W0?A
M\E4OHC;3,&C @@WH[D9)'F/-D*;Z_E4PZ!LPX(_OR861,E70 +A&4ZZMPP52
M++'M8!I\Z:JMNGN*"?@"S/-QY!)*>>\*XDD.;AN,14O!(VKL0 >:1QSLA IP
M%^U:!S3!EE*-$:@EL[;AJG7/I&8P( /N(%::4"!VB*DZ\"I!+3N(920+-5Q<
MO!K.P[<!0T%P_* ^BQH9*3-2OB52#K:(E#MG5-$1K(.QS;4A5R:ITBEZ1 "1
M\TZ+])A@$.&2KM1%4JT6/E:J'X-JK5#[\.GC>TM%+*Q^JMC"3]5R=3=#0H:$
M-X6$<(N0T(%1I];#0%> #8<L-'S*$J8WI(8@^+N'K^0.-^>)K,\$%<'/T2X;
M-9"IN;GO^WAS]%*:8:IM>'=ZG@P623SK_S%G QA/ QO/<);A["WA+-HBG+4=
M+]:Y@[<A?<;(GKF&-8X/IB4N?8Z4(<B-E:RZ:\5%3!#9R3!,%7)E)8RZTEXL
MM8$2?. -6M$A-/%W2NT#JSMKPD. HAE?E_/##-$;P_NER=7',';=2,947\:9
M$-91"U$6V1C7:D^U3(!/<R+X-R;\S=-K\OE'&&3+D9FE_5]UVG\O2_N_=-K?
MY_SM8V/1 K_YI8N%'M\J#I?>%F+MWIS)KR?,8% TC;B1RCF%>-860&.QC6_9
M1A]V(*FRCF+$84RV^@[@$EQ&C2XI?.+4+;C._DXY#-F2/$U">Q-U-[MOD/F*
M;]%7W*;[!DTA".;S.6 ,,V!X=S'D#+CC@]C+_/V,T6\8E3*]\,K<G0#[T-KB
MR8H'T<RGVMV-T@TN&HV@HF:7'MH&\@VXP$=N05@AX &Y-BC6$!'K- 9+@ZI6
M#>\!;WSZ9,N]MU>]_C*(92G]QT,,XMJA J\G#TAAUD4#*-GG5SV]\BY0Y,E4
MBBG#:#&A(_\8KO)>'8LG0LX9G)V-I7/EZ!4V LL>&3@7;Z?,=6O?_ Z8/T06
M^4VQ^F)4P16MV*FR]@:CZ_'!$//+P[W$EGLTTIR&P,;#+ZW3D]/>YYQ_#>ZR
M:=^Y4Q557Q3T[$HK%3_LK13VT3ZNR!-CKUA[_Z[A55Q8U-Y2)DZ0V.6(]W43
MT]BTYN\W"WA\]>TT++@:4#Q@4?_H_=Z&C5 GOU,%%]QJ.4\JI4IE\\Y_\BG9
M*Y9JV8S<?>5[L@FH9A. $W XKS_[#E@4'2X-Z#GU_DY.+=,2M[Y8O$U3%.C@
MMU_+[TN-JV_:KDQ;X*XHSW=9N7D&W95F:[?+;;QZ"7N[R\B;-'?,HTBPYS5W
M]4G,O6HU^^,%C[/_MJSM:U<#M.<+70I>R01E_'_50,KXO_7FSOC__/Q_,WAO
MC3D;DJ/+A-FINZMZYX\H;=.&WSE3'+2?@/I+0^"MBV88RC2Q-TR\77;7+H#_
M.)'XPW\0[9_]A-/#N]P/_(_<[0?^Q_3^!U!+ P04    "  -@G]4I'S8-B,%
M  #N(P  $    &-E;'4M97@S,C%?-BYH=&WMFNEO&CD4P+]7VO_A=:I6B<1<
M'$D*)!(!TK";A@BFVNVGRLP8L.JQ9STFA/WK]WD.0K=G>H1L$A0QV'[C=_CY
M9WLR[:>]83=X>]&'T^#U&5R\.3X;=,&R7??/6M=U>T$O;Z@[G@^!(B)EFDE!
MN.OVSRVPYEHG3===+I?.LN9(-7.#D3O7,:^[7,J4.I&.K*/?GK1-77:E)#)7
MS32G^".D?&'3JUK5?[?GH! VN65;VRVEG]HVG+^"KA275&FJX++A>$[5V??!
MMHW 1$8KO#YI)Y#J%:>'5DS4C E[(K66<=-+=*NHT3+)BII>:9N)B K=])ZW
MIE)H>TIBQE?-@,4TA7.ZA)&,B<C;4O8/;?KF3NOHA9BD2:OM)D<;&K,."6<S
MT51L-E\KO)D)2VKN;4XDCVYB4UXTAC2%5#'A>>?:#-D4*[!6T%SJDBA&4",4
M@M91_VK.)DQ#K>KXO\2IGQ77$#NE:E/C0?(ID^Y*8+O]43 X&70[P6!XCK-K
M-'[3.0\@&'ZKBW<_=_P#>..,G:X#XWXW<].O-;P*=,;0Z0TO@G[O?OI=>OO2
MVX/A"02G?1AW1L>=\_[8'OYUUG\+G6Y@6JJ>5_V/VQLN^=6O)G#=:=1O-(\V
M8U+8^T.N#@2$4@@:&O3#DNDYZ#F%CA +PF%$$ZDTR"ETD>4<[]8K&(C0@1TC
M]>+90;7JM;HR3HA8926_M0O8T0GV#[YG_P%H0=9C0A63$5 1,3&#'@UI/$'8
MU_P*1K'J TEARCB-KFT8TW"!"AF&@X@(^E?AG(@9Q94BCEF:&GOQSTA&1%.8
M4T71T$W#<O-+NRHP@!"7&#9=52!9J'2!H0 MX3K-7SSS]_9;19:C1222B4:;
M-J4+&9,;J"XSE*@)$32UAU><KJ 39A$SN5'!=J*;>8I$[!*R^7!H<3K5%E9I
M,N$4)E)%5!U:GH7V<9XF),08K<L)B:*R7&99?HL=2LY)DM)F^:.%X8OT'',%
MYT^F09FO""X+S9B75ME)+IJGX'+.-+6-:I-%2T42ZV99_7,3\SM7%MQ?1+?I
M[W;F;-O4EY9NT8X=?[?MFK:CS\?^?Y-$ 4[D G?3!><KQ&*<< .?-9 4_7O!
M%(T1W*F9X6E!3;^V0Y!Z"OS&3K2[IL(UOM;H*M#@OZS56P9JZ[CAES)?A@=X
M150\ N,1&/<.&-5[!@PF3(\DHP!NHS1A G<++-^5E#0A3"%.$D53 XZ*:2:<
M ]Z&6R+<9&%#@B1)*]E=4R:("$T]=AAE)_)L^X-2"YYS1^)>*M.9EJPI=F#.
MEWGR[>?GHFBH4Z3_YJ;5WMBUYA&I?G3"RS7>&%=%(N0'!NN'X95[B!0\?M4=
MG@U'A]:SD^RS[KI0GKMJ7"\K1EE.><Y^8Z,R,/')JPHV-)SZWO-6X6(9T51R
M%D$N"%GB)42A2ZU/9?>WC8(I?W@^,A7;9 H!06)TX]TI?__2\PY\?[^&U2XY
MZF%F-^$#Z!R3\/U,R86(S"A*U2S&H564O.R#W;XF*IR7IX+J%VGQRP>WX7CU
M!SFV7UT??UG(:P\UY,>KYJUG>5EU?!VR@FI[7Z7:]8S]L4<^=WI0W-0UIWVO
M-9(3BDOY[PZ<HI!B&T/EYFO.[2T\GQ^U?"VZ1Y/B2QS:1H3S!>&!!#AF4<3I
M[0:X]I "? ?(;F*X3:QOX^'^(\L?9\)#8_DV OS(\MMA^3U&=7?.Z!3Z5S1<
M:'9)83B=LI"JCXC]W<^Y?OK[##?[[^_WJVR[Q5LQ;;=X^^9?4$L#!!0    (
M  V"?U3]XML+ZP0  %$@   0    8V5L=2UE>#,R,E\X+FAT;>V9;6_;-A"
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MV.]'K+:2JVLWH\B@$=34R&U>+E\'XY,$LDF0)'NE-5VV)%$9F_0D;!VD-0.
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M4ZMULX>4EFNQ@?RC?6#&=WU"<Q)M]G,NN.EV)A80K/_&WG*@8ZFN*>_-6D.
MCJ/OZ!$:!SZX47-(9]X ZUR .HM.']VYP^GLFJH]<@!L/SKR1TJTYXRNUEFR
MRU17R@90)4FQO.;/=-#;][?N>=1\/2QQ8NACQ (6NCKF*CW0[1JU,&)$;Y-&
M#NR#X;BBNZ5(+;H*M6(5W^3K/#7H#"LU]>UQ&X42M\?%E:-J5?@K+4<D#D'V
M,VV1_<'<=EQZ?U>ZXG:K^58]7REX+:%O^'-)2%52,MMA%PX(TF1J6OES$[3Y
M*6,W%IOO9:OXO<]OU0A1Z>Q&ZC5N!VZ[D[H&OKIFANZCO^'FXGNI-@Z<!H%N
MCNP;1\DG=[R/"EX8A_!!K;>TV /!E6&L>X?XT*(MD$1=&8?2I;=5O(D9O$.H
M)8/W]ND:2=S.9'.QYVQPFX(/$@?]3US7<.A@7Z_PW?L"VE8D:KW(X>@IH]-[
MW!:8PS ]%?N:71^V2F"'$+H/9UH>KT?EO$(NSM.D0N "U:\7W.Y]4%G3#%KC
M#?V@?4(']Q6J5X"J,]]V0M75N>".5J1ZA$72X*2)5*:J* QI:F*F:$@_./(-
METK/]N'9$KV& A:$8Z4?PDR8$.<)G4K/ 4[3X X>G:O.I#'+L-33(B-1P.WL
MJY38]T_V26RECFKB@E9,AK7L3 C+.#%;U'"98/ W(_7<L3+KSO-5>NS-YWRI
MFE88AC6^W8,3>[;IJ=#A9LB@FN_BE-V<4*@4"#>YNMF']SP9MQ2)5D?;X#[6
M[B*12H(LE*35[U54S[RPW/""^4D2QJ""_).O(O(JM)^Y!DCF7W5P@]$ 34H\
MVY*QQV6C/4R?B]2%<[!1/L1<4,G9Y!AQJ"/(RMN.]N,%CI!L.%$#G;(U>#B2
MA )6H/@.I OC<^@]5E;K_(BO>FJZZG->ZI#:BZD$L<, \)<FWG_:9<!Q\X&.
M!XRKX&W5S?"2)#<-/\,,\:5->YH2P7WG6&6.>&@/\FG7M+K4&5FC.Y+D76[*
MSBFR:LTV2T?<B5B.)J"Y\NLR/'/8ISX>7G.X-#-SPAC0"7[40@/IVM:/\] 5
MZ[)':KH,P; O20.ABYS[_MO9("TY0:WQ/T[=Z"--]8:%W%9\B.K@_V4BH2?I
MEY.,!\*XZCQ@AP2[.$L74!Q@$QAG *_TB@!$9\M6TZ)2-[95>1-TQC%FZ<.4
M6ADPD00';<_0)>[_5!3RZ?$D3S8(1AXOJF5*__A_4$L#!!0    (  V"?U01
M#V888[X  !$R 0 6    9VEZ='1C=6-P;&UB,# P,# Q+FIP9^R\=UQ4R=(_
M?! 0R2HY""@@.4C.(R!91%!R4@$1D"0Y.00)$@4$! F2,TC.C.2<DY*3Y)P9
MAIEW<-U=]>[>]3[/^SSWWN=WX=-_G#/=757?JJZNJC[G(#XBIH&+\M)RT@ *
M"@KP /D/(,8 2>#"^?,8Y]$O8&!@8&)>P,(AQ,7!QL8ANTR 3WB%G)KJ"CDE
M)0T=.P/--59:2DI&?B96SAL\/#S4#(*B EPB[-P\7&>3H&!B8N)@XY#BXI)R
M7:6\RO4/_R$^ )<NG--#%T)%N0:<NX2">@D%T0A0 P *.LJ7/^#K'\HY5#3T
M\Q@7,+&PD1U*+@+G4%!1SZ&AHJ.CH2%_=4/^#J!=0K]\]8;X>0+EAQC7K FY
M/$(3+]!*%-01J?1MT7$_>N:)B45,0DI&3G^=@9&)F8>7CU] 4$CREI2TC*R<
M_+W[JFKJ&II:!H9&CXV?F)C:V-K9.S@Z.7N]\/;Q]7OI'Q;^.B(RZDUT3%)R
M2FI:>D9F5F%1<4EI67E%97U#8U-S2VM;>__ X-#PR,=/HS.S<_.?%Q:7EE>V
M=W;W]@\.CXZA9W*A *@HO_[]H5R7D'*=0T-#1<,XDPOEG,-9ATMHZ%=OG+\L
MKHSQT)K@&I?'!4*)T,2".DQ:;I4MHD?/^K"(Z7AFZ+?/1/LBV<\)YOE?DNPW
MP7Z7:Q3 045!*@_U$@ "#J&,2>Y8/].8(XN<KB<DKI"\]^8:&Y-CQB!#RPKC
M7F]R1  P=OR+"* G+1H!/$]   &YF7?C5!V#6TK[].@1 +97(VAW.0T\E8X
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MC+V.S^@2L$2 8^-516E'Z.*HU[&#'<M&M'31D6JXVYQ$M6P0+]F +]D2.^6
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M(>"+G;W,&YM11UH6^,RP#/2/5/8(/A[Z,R957_Y3\7]H./D$2!M*S3FS(00
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MY(P =#^TOVTIO:&K9RJD[TM;-)07X5'M4AIEL5DM<?&\&RAC-L#2+X38U]Q
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MI1Z*V!D-@I!<&E%[_0M+*D<Q<[?T+TR*/Z$5MC.JB'H4YU'([UI-$)P>VE_
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MMQ]^'5># ,X(]$-CJP)>_S5WZ>PS!M^2_3I\J(:_*:;))Q&W8VI"YQI_%^$
M-TOP'!J\6(0RMSS')3<?YB8%W\JM  V!3M(JNJ@.<,79+-837+EF7B. ^/V^
M-G@F IC@7>R15A!<84PJ_LM3 >;). 1 ;;!DFJH] )E;<\-E>LI04"!%J(9&
MY;"ME(;,\\TA!_*[67OZ_FX\"2?F"*!0/4X]4?+HR;%.Q^F*/D?;V2LFL5?_
MWF&-]N39X3;D#@)P@^P1:/#63/<<4^QM'HZ='6YS'VF64A_U[NM'KQU2;Z]S
MG/@>JZ%;CH-;BB$;U)\UB.ING\AZ_[U]^=?VE?\G9[MQ;(+2JB;4 >86DIB+
M/76T&[Y\:B;H>JNF4_[O8<+R? HNFH0 K,#,'W)/P$<' :=UL&RA%ZVM2.V$
MM(E!^K.' J:.8.&KI\PU6A_/SL4,SD*+&]4R1%WKL4+FA?Q0'0^ZJ(=&P3=V
M;UC(Z!B0+?*&9IF,-CH4'2M2MB@7N3PV<R3GE;XK3]S!QQVILQTX\E#*A#R8
MN365A3(^A4"E-V9T0*Z2Y(:6.[8V*>P]5C@I6^#B%1+:D%3UX>$YM03EL/[F
MK<3^45XN[4)BMYE2]P^7K8\/NNRDH5>SKB>4P!8\TC%0+7KKP"*A:ED1,A1/
MQ,PHO1N?CJ:E6S,-J4P>T.TTU;P"WSAGSEB7_"A=<'K:=2@Q1U-6A( ^]I*.
M[*J%7\%[? ;2Z?7I!!VU4U7^/EQEGM/\11Y< 0$*>Q_LXWE_O;[2G-)3]$Z;
M**C;W,0*L2<F>;= >M4+CU<[LF]&11O(\$"C1&H'[3/T SE]9 9#N8F>GV4_
MXVC0Q>ZU$U-[V^_KK_$M'.E%/(YEDGIL?U6\V2IEVAB5#LNT2/*>H,M;DN!%
M=<^U%1?V^?&7)J9A*7T1 /NLKPDI+9J[ .UP<F3]"INT64CAA)PE^GYQ3BJ_
M<-8'$JN62>:/#&3S+NI&M(1!T<JQ&737YMC6N&["NIC#6E,R5:3E8PU=K"6R
M&F+G/I>65P[C[A$[8)I?3WSZ@8?UQ9HZWF?95LJ,-M14*4JNO(1DDYYT78H.
M[:-)$['N,0!_5PSVP"MVZWD-2VE2R-,3# %E*:*7*'\3E51;SN'#@H8A9P^M
M<LD?*(+@(B,KX#C'J6;J8XI<\-GYIV%$*?81 G"R!?DY[1,JZ_6-_I5%_T4[
MA[0]#^3JDQ57D%.X^0(92%]4'O475KFHTJ_2>Y7)A.D)G;R6O-9->C9Z-C0_
M$Q-<MK,1KS#/>I^=2,HX;8TT>BD-)?5OS#?E-GJU/Q:ABT^0A&UOZLTPG+WG
M;#O2;K<I!FP;P^BT"+1UY>*D^_@ZPCL#/B& Q$/HR-N@Y/QB?6Y!6GE_QCR5
MOSKC/)?[2P">I5KS)?+NCZQWH4!*\4!\$4P(-0$=(+V!8;Y0OM1W204AR"<D
MHA,RF;H#>X5$/K/^[V%"])UC\?K>[=P#>;]]B'3$^*K'\3W62+7U(X!R\%DH
MWP)S48#/P%4]= A[BOV05/[R^!F]YOOD(2$=W/(12MY[YB8$Q1*&BZ(:%<8;
MD_Q9_OSDMPR9W<R-<AQB('.8*626%O($,D[=7I1Q._ W#Z/QN]?)/3NC3N/\
MFB^A)M14EQ1N1U27.7".-=L>$_+D72188" 3/>)-R-'1TC=3ZV]S2RN-,6_U
M5TC9?<>U(>R+ET5!NKKIO\:8JWHK9TTE(IA?,1*7^][ !GL)D9E,88Q WF/I
MEWB&:JH4;7.6$DHTUAJ]4BX.1!GO'^.8L\?+?F#>0>:.A:A#&GOY4OQJLTQ&
MW(VT?J&T4:020O,'3;@.3R,[GAU>8L5#T51P3Q?E=+8)]2_1S#4_-8,;V1Q3
M*L3QK2QKI@V8[Y46ZQ>PK=<>?6C;/0=;0?5I=BZ3U\AY4%E>0V*.S%PYY*3E
M+*XQRW6^,<]M%=AP@JV6Q3S)G3%)C[CV\KSFA*?'_O6(Z_YR=$%TTHZM>(D>
MS+*MK>LM/#5%I9Z+QM@V:&JC%@D\C)>U:ZBFQP5.^A.8M%G!?O/Q)<3I;"G#
M91<[B/P5KP0^U%LB,XJZ$91$V#K*I=2)N9BQJ0M5H/2NE\TQ,,\C7#3Y("#F
MBT;=G""1:]YK\WHO6LN<O%G]T=K!=L$CF[#[-C$54D0!#H9G*^^W _RX/USP
M:S%@F%,^,G82VH8$@G;XD1O]B#]XJ8WE*<DV?&<)?'$7N4?7)!?_[ N:?]+0
MOCJ#5YZ189$>F$@#I4DN(;1/H4E-27TG<>8-9%\7ORYV/_,&F!?[^\FUSD;0
M7#[K??:LB&<5AT_E\T2'V1<51?;^V(9L-C241#2PA)"]'M/Y=3;CVBJ?X5%N
MN@&!6^*#X?I21\8-[QV-&SH,J,A54A=?X=?./WL>Y_L^[[:NT85G^X9\DE*$
MZK&<?R_?/VO9SE^VYZP(2^0"#2G8XTE]']_<1*BL<=%IZMM*0M]SIKU^\'H9
MO$W/3L\;?R;YLPW'8:8KA XI@JF5]]][@=+2D1LN?2I\BC2L7L4'PX=>H'G+
M <B4Y2G:8,_,XX_@.<FAY\9%OX<:D&_<@CHZ]_HU)(DGO[P'>GLW:1<6<D-D
MNJK3Q6>]HMEZ.8;X2;SF-;E+*2$4@YST-D@[E')W^T+Y'GVDP#43HU"#H/.:
MX].,^]?=J:74W"3:!5(C-MF&!?PN"[X&7LR1"<X)4L?)6=J@CS\W*M[NHK*N
MY,?A7@Z]T\FJ($78NN#_:);IT@%?R^B'=4O)):<4U*6O"B_[T=GL;1Z=4$MJ
MD4"V%QD&H,//CEZZO'G]&^=_T'ZO7GAH(['97B<Y\3I6L\,,#45&Q=1A;N!4
M]6SD;,<,(U!5YY+WO<@QO[W&0:1^K]Q%D7EG0<32!R/49H4P5"VS4#K\UK9L
M8NA@-NHX5?$PU%-08<$?ET"J7R:FPZ9@<2?9A+3YG7 L(\/"4[R$1C,AS5DP
M_J0)NGY'">2%=%ASZVT.&I97'Z@$KPACK>SE,FJR*@EHLC\,6&OC?*1P"T^=
M]ITH]]ZJBNZ34;?UGE%VML-VU?OO[<FPQJ(2UZ0LLJ2$R6WHGI%_[I@X>J;+
M.V8;XZI"$0;V2_R8<#CL\)RHWT1_AW,5 >R/4I]>+GEF3E4_MUYK7@XR5]7V
M)/6B4?;HW?985HR2*HS<,$O8>QWS",>'(M, YR9@R(+2BW4G1<?\U)8@S+3)
M27L-SE:&&:@[*O *=9)/-WWG&>A4M4#S .J2EDL_GX.5PF)IP1]Y5:C@D4MX
MB'ZE8"Y6N^(3!:QOBA@_%3(X+38J89A27=U&([$/UTHQ,2VXQ,(IB+-8&"](
ME'99.<BL-8N-:2)>6,H^82O'+O\8BDR4-^>06B0$UQ<,0Q97E1  ) 0!-*KG
M[OOK=]J=R#H(5+(4(P!O@UQPSS"2.I@: ?@EPXF"D7D02 M\"@/#KX7DJ, ?
M'+S:L+95-T$ 6"U(3Y60"X+#00C@D@R,Y8H9_#ERBA-D_ *3HM9(A=6M7QV?
M7<H;^&&6(S6A$=@I<H;#;62VYB]6H'#L-2I9T=2GF_[C)#\P[_8H:A>CV-<F
M(*E*Z8=90#,:J_J[^\B 9*H% <PR0ILX%O!-\!9)_A("Y3,$J/JO=+/[K_\X
MR]\ LDH(>2.:(ARK2S3ZXS1_@\@P$YC3Y8^!S7ZYY=6(3UY>/<#90,O5AARN
MXABCL(Y1XFO3LY0WJ>]=.<]5;&Z7'B8T*X/D@^E'$>#_MS$[_$EC?/C_>]>H
M,P8JYL9GE\V*?NR:2HWS([+6-BT53<IZWD@Y'!I!N\=IX*E/H"/_M"GL_9)'
M::M*K0((0.-,*_0O4PY>G<W[9/UO-,;QPS7(4J'<IG$V\P\X^'ICR/<7N9 =
M*T*;5$;^;#7F@'[AM*9&;'9!ADCASXSE_:_Z6%\^Q#.TOE^"#-Z_UY3*UQLK
M#5\)E*6/OTWVYRGYJM+?[O\-X1G;;]U%-OZ?$B;J^PE)7)S=FOYP0JV!6K+)
MM$3L%1+B7-/<:&*&1YVB@LJ2C?<4K'6&CHQF(-=D2]ZFG*[Y$J_(3.BM(\=P
MY#IW)JPDG YHJ,EG6F-=\U:E 3  M;4O]_1$G2IZHD-IXY/\F5[_59I%]#4Z
MX57YFKZ\+B7X^!$9V9_#_Y<[_;CAWA*D UWN"*F7A%\KY,BS6"\)NONI\UJD
M]A@C?P0.8 1LN079CL38Y>Y*[R8[A1(4RLX_F; 9/*^"AY]FK9P7\JAT&?":
ME_/^0/^QX!6E#^L=C7F\E+W<9(%<37G9#]6#=L(*V4%BPH?VVMFWY.9?8J._
M?B4. -9EHBB+N?03D]E/*Q>Z5-3(35D+B'U$VE[CJ&Z5MV"0 KN#V[HXE8J!
MAVS6=!2IQD$=EA9:7/)4-2]!>GN%R_8VV'5T@B>/O!,60 *HJ!!*YT<QF513
MONFP2[NTETHH3L84[RF75?.U/6J4L?R<S;)V<]&)5F21FHF42.%N3?6P*W_.
M9$!DJ0_=C=P,J:L^'S0*:.WO;'!*<PKMZA*.XKVU9@I3>"9WX<JM0.*;$ =G
M+]^6DYM]+N^6*U^$U73B-!MA,VKJ$M^V'2=T;[1G"/588E2EB?^02A!5$;]R
M:,CA<(V^-MV,4IQ([*[R':=[89@,"2V\EB<&]YPBVP490B</%D!<A &=EYJE
M@2GO'M$[SN1+YP/2?5C9CKGI%A<M:]W115T @93P6P/S0:'O:+G?!G70LF#B
MJ^'@R4R;G&C84W-QT58/Q^^,*%:8Y(HLTQN5&_FU]V5E M[C'H4?NX7P/'..
M= UO#85INGXBN?N*Y^W-B9UT.CSNO>R$CT*6KPK<XGP^X22)L[QTB,]=,+9W
ML5MNTG@_8,[3JL<B4%WLP,6G4<!Z$RU,3G#Z?KNU=2%!6(&I/V..[#]X(*9C
M];YTF]]__XF=[D[= ]I@;,L;$>I6;<\OS,_M0U7KF=4M#7GR['G4R5QFYLQF
M6BU8><]75@_0F>0N/L,CDCO/\0Z5=!_CW;2QOM3UY)DKVHT.[DZ'H5GB5#;S
M]72D=]UZ&)!YD18STQKT8RH:-/ZEE-/KPP$VG_!D?3Z+7%Z*QT&0Q1PZOF$8
MM]>1JNP^A7=Q]<"XHF6J7);0Y$3+( OE4RJOSX(B^ZBUN*S<&^J%QCG*&F&K
MY R^\(XT3+7+?2%%]7Z=I 0>K6C/7,(W=1['48>:SYRZD:L-6N;'"/M,*KU)
M?6- ]085-IO$HQ-QL";OO2\JY+\KRL[!3(UOEDV7?A<">9*G4R'VB-BH611
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M7#5"SL5\AW&/VHTC;\]>N@<H<_/D.Z& TUUND"DZ%. #?D;0-01G*^!KYU!
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M*$'HV\CU(3^2QS,8\34[%G$-#D^Y:!ZVC!7FM)9FI$WN4G+=TKI[GX& Y_Q
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MIA<A4:+GT-%LDL6@@FY6)VSK;=2R*'Z3+BCEW&T\/J&JMCL?3I_3,G"WLKO
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M2P5[1?B$N[REOI-K"A&P,KQ86)-]Z>X\#+W[\:=GJ >.[86HUZSN_#U8WB8
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MO?;0JPAK8:/5D"J.TM15OT\%8 B?3/'>-=^0%I[&S=XR)UMG,G$!.6>+'?,
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M)1!./=J+P-_G[E;:]@UNW-X,YQFV(A4J%??L4:%X#Q_DXS(X1XWK3-+F'43
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MH<NLUX8V,P+V=.X8(4+U-43PY[]Z#OQ/OS<HU*S)EUN<<18W;EI^5%-;V67
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M^\)5D\RFV2Q"_V5/&793.]0_[EKR9(O_W]N0%B<A&-@1YS[X>"^=!-Q4P$>
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MNT/="8%U.ITNOUH%]@-I4P-#,]=_9PL86GVB3 )ZSF$33X-83NE*AZ3ZR)Z
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MPA_\V2X3MCHR0:!O(:#H26%\B@X^-M0+P^#.\*U!/&KP44RH[FBZ<J8$T2(
M)'N3AQA6>2<R[\_K1-I_W"F='8*WC')V@IH<6N;':J3>UF64+QEP%1'M.P+.
M_:C6K2A\S5/AUMF_LB<QD&&=;*K#D?'SW]T/;!C;\O*XWEA<LV[>W'+K$E^0
MZ*^*Z1=/T+!_V2.\7_ZD?WIBXD:]9H?JM7:]#G5M3'GV!_2'2^)#B)"V]=([
M'S%#'#=\LS=8T.]#QBM=5<1R7N]E>2BVL3(5-#S5$9PV4.]1[M'8U[Z)-4Y"
M-YO<0WY!L$ZOL66XO$TVZ.D?7*D?H!RK6^_+NVUZ6*):W=7K';#J4"%O-ZJ(
M?(P<>,8Q#^)!3%/:X HC"0)P\)2UFR%C0\&)77=1><355D$3WXT!$O"T(T3!
M=T8(J[*J(8P31 1Z9T8LP:\_I7M^(9Q[^*EW@C$9GDWW"E(%^SOQ^BZ%LCS=
M:5;JV,9X3>1UG#/PXR!^RIVT6_4S.O_:NJE 6)EB0,\H/OM(84P/P\(! 5EB
M,]</QW@C$NJO5*;-C(V@GBZY3@P[;FD\<GKVX9M@Y"]K'%?K;MF3,+GL<2N5
M@,+HZXC*>H2M1^NEN]^K7W[UY:C=['K8=W^8R+]VR#N6%(B18Y6M=LN[FM8Y
MHWJ1DD>1G>U.:_\!?==6!,_RZLB:6> 1LAGV[HDSK*USE S0#"'I'4)?B2/#
MY$I7RYG^D%.?IG.G(I0]K"9G*NPZ#I30]##/C3<M)]_:M?.WYO6Q2\]2%UXI
M:^_&22@O,!+:ASZ-:M"O'4[*1:DI>V$J7=#QEH;1'47#HX41GWTWPHT(G?S9
MBB]?QAU6S-_$)AX(13<9EIZ6#A!_I?% <^2\4A=1(IV;LXH^V2_+310D/L^[
M'P=3%V;C0S")41H7W5IH$$-A/05/5$9?3::>CB3QI-$^<HI_Y9:4YA(@='7.
MI=P9KW=W?$^(%?JP_FN.8;IM75H7EY6T1SFSC-53>,I._+M'UUJ[*U+T\'(!
MZ!QFO-FLP3B*=SD2G3PCHV5X9=!.1\1I/EEF8E+_7OL"!P<#E*6AI1(7O.8@
M<N)T&.4IO36)?FIA22?3ELJG]&'E-LO;I"X>=7>PFXZ?6/7.+@FX,-*+G>TH
M+=80<Q44 K/=AU3U6L3 %-U5.9_;&O!Z48%]K"R%VM\G2'[H0GD)6!,4ZG$;
MAYD/JJKJDXR3I:<"4'2^#Z6=9G<J*448$JB><9( QH"L 2Z('TIE(.IC??W@
MG3950W75[A=I^M^O4/Z0:;RA&MT%.#8;%1/$B$-XO:"YQ$VPW*;@@Y/ B=VZ
M@-:L+:_-#\@0@F302J%0*@FX2[:/H/(^1XA@J'3PUKGW1+A3V^O \_:UWU3V
M4_B++U0K^V]NVBNAX.=F("$F52&AMG=^?LR<[_TZ$B!/&ZV8$C7_6ZGQ'/6U
MW]FNB=\.:V&L--'2^Q8QDR'<&_"GCQ&,3JP\C$_AC0L7NB?FEL]DS ]0D%=&
M\Y^(>-6[L2:C_L_>??,L;QFD+"LI0:?X[D9P/X LCU7ZOBK1J2MX>6^@9B!N
M\GV#',JI;D0F8!4**BS83\A/,_&L]C(P[HS+UJJ!!1DS&_E[0V([6@1PXJ^X
M[$?\3TZ$SJF],?3P</Z9I7R613XU=#F8$&%\<R.TV*2U<:H+]^HX,HHX'H@Q
M4E2ER^>\R'DF_"8/.VBZ_73(KVNFHM0!"SX8*T8;#M0&@7Y9&?E5?Y]>7J(3
MGCIL 2,;/ZUNV]PNX)OP( &4A/9[W="'&"].R.%<3JR:J5O@0\Y(/_<@?A7S
MM*X@A#TN@[$1.?;0T(,A 3B$!S2-" _Y6V\7#J1X> YKS!B/FG51C@/CF6LY
M5 H&3=?*(%9W<+=7L[E&SG;(P*I1*5-'!1EYUDHO%K<<=U+[Z7BVU'7=;U24
M.0SYL[6*.HO?&WP;=RXTZE)UN8J'F$ %<9-"2&,UIX9CL3.^$/]B?UHQ2-8I
MO@ [HLB6GL#EK5AV=)1OH5K/?4-D?6(::CJR1TXD2 N=)9V::?X::&(LR6.R
M^OH&\O&C^G[Z[OI6(G6I#;@-><Y-Q2,]<@X7]P7OT/=&FY&SQ?XP.8Z^S9/R
M=/"YTMD>?N>:@($(SH9E5+-(!SQ(5*N'(MWD?FO"TF,V6B?'["*QL-^+H5)N
M)LRS^X?4A2(8K]CJ^_C)[79Y2&97>Y=!S?/IF;["YEX[._VL@]PS9SZ:E?<,
M]"4&ZQ-E()$H!RYLZ<KLHTB+$42Q?TAL](-G+^GXRY=SD_G<:,MKLO&'%0.V
M6,ZB;(E&',WK@'?70];QCJ\/5!OE:MI!:;0&P$Q9Q<?Y"EK*F MX=Y5V="+"
MO<XF?BRIJ*5 H0^3[AX)6=2*40K;I,EXDW>!BE)@+6C%]W/ZOM?-D?;A@$0>
M2"PJN"72L<+M8!N-__1ZY]CH1MV4;'Z<P?-LEZUY<ZG!:-',CB&B*'[ #IL8
MP<M::+/>T(D(^FRG_[.Z_0S*4\.[L4J?E3G?9?(SKK;8'0V*LBGO0T;)-HGY
MA+HSIAM=2O:<0](6:&NUYW^_\E6YGVM1P04MU-[X"\HPU^.UE#FT;#PBNZ_-
MA (W)SF[M4GM*%9:6R0*:'*7"PD7_AA:'>XEYY_J?7QYD5N+)!([30)B_:=Y
M0P5GJ+XVA\H:V.Q@]%&O2JC;=#G2\=$+NW=_$W^>_PVQ:DL8GEBQ2:CT"SA[
M.,ZY8W36X.G-($?-UQZ+*4\JB=>R4V?6!:G&'N)D/Y7C71PB]7/,],<.&'I9
M_?AJW"O%3)MO?[5CSN>GA_M@:U?]FYG*U?0@4)V\'NDO[KSAI_G=3MRI G1"
MC9X:%B*>HUW&3L81J>/[7L;HXFX;@AO2@[+KLGNH1\6T:V;@U$: ?KD@[5*W
MUW3#^</4M_YJKP6D/I)'708[&ZLFXE7QA#<LSP7#E493AZB^DJ7,29WZK&6W
MV7BHT%L@$0'.0M>6E[F&B=6.$8QD-K<0'@=W'[W(JZFY24M]0ZU]EW^GH\I;
MA7X"1Q/>WUP.N6=ZXI)T&A$@UI6^Z+E[>!/GT;^=SG?HKPZ2>+OJT.L!DR.;
M",841B-,Z/!:]MH&=6XNUKD)UI;3%1H###=8E-(*_3;-C&GPXTPL<5X$VSD0
MWVEBAXUQO9M@JFC:8=I/;L]/CGSI!A^G=[ W'!,*$Z2&"$[H7CC;ZM76AZ73
MKNE?3 102I8+2?7,6MT9@H]=&E(&./K<<A@\+XTH]!F"1^::1Q2,E&MJ/52Z
M;;KXQ7W$^=Y5+R;^,'GX8BSW[6JGX &ZN ?BCN)%OM9@@U \Q@DFYMO\GKCE
M/((X2S&?V&.6I$->&6:4B0?!9_1+5 ([D>? ;BT7$<-;T@%9TR#+X8VG^YR(
MY!G5J"UK70=Y7\4TM9?]\E(%PT2F]6"CQ->"LZA:OR<M0N&&?&X5_N4_FZO/
M4MB E(1U:#6\I[L[[E?C97P$BTO6E,(NNO<VWR8!)B/BSM7T2E-75,UIT-8W
M3;.MA/X7=^\=U73;K0E'$5"J] XJ("!->B<"T@4$D=Y[0'H+-0H"TIN (+VW
M$.F]=Q60#J&&WB'4 "$,S\R<*<_[SIDY9\Y:W[?FC_N?E+6R]KU_>U_7WM?>
MZ366/!5RNP,,G7]EO4U_XR)P[M(=A&[@1<LYN/M:3>"K$65:RGWI!+)]\V&7
M/5M-W'\'BY5\_<L1E-M?.+NP!*X[408Q3GS52Q"C^VU-T)S^ 3=QF+,)V?_1
MJ46S N6@/U[[?JR6@=2');J@CBP__F<.BVQS2D:V^:?5M+Q"- =FI+7Z#J:<
M2(_ C!V^!XY$+WJXL25E;!X<7L]L,F#;[I<T5#@MM,SH;7H"(VBGNP?\G9UA
M:LX51G9U.O5UWH]?.;8<2N5'6WK.S\P](_[&& J;W\&('U6T+J,\I135)KEJ
M(Y>J%GV$;2CKG9\KW\]9].9@5U :^2D%;EQM#SOW=EB5LGVK"M4:T1I[6IVH
M5OF9IC]AK $\?)@Z&&?N.HEK-(V=MV",&NE;Q(E9ZJ4R>1ZKVN0P^Q6D,,J=
M\UCIXW!_>6^J+B &>GRBRV3+?L*Z6Y2"*+;W+>KEI3%"L74_\BSJI.@K\O%V
M+IK-WWL=Z#'V0,<"&.)F&--0X= ;R(5T[H(2OY_R+"LCA"@'#?!K,#36@0_@
MKZ.97]!4TU$QO5PS.ZL8[S<AJD-.AZV/LZ6I*I(JNF)/B/(^&/WA$8<U_Y*>
MR7?]4)I\AY$[8E_2=(6LE!,NE/]X^[QOC+V>PI+/>+_IU4#4(U$Z7W>C4VME
MUJ$[>/.1-GTIM.VE$:1+$W']J$71<L7N#$38VB-LX%$W9/M4]N=.3\9@?,W!
M9OJU#E'LG6.8AMT"SB46(5N_TLX8V#HSV3#3XQ5"[51"-YF9^KEU/VJ$(786
M!3(-YD\7 4 /@$"P]A[F\4W"2/?Y'<F>NP54>3;69BS9]'_?$(2N6T*H3Z0O
M@-X%COL<G,>W ,.(_KP[,K(!_<D5^.L6<"Q?8WIUZ'<+*$C47JKI1\=KW-&*
M1B9,M$'8WV0 !3<%MX"U"'#BS< MX-1BFI$9-79F^Z#>MJ\=/Y ?%8:0SK8>
M9[M6R&*&Y(/&TWO9&C"[D!H@?<0U! 'IXR5&ZXS[[_- 7IR_).S+XKMO5[W$
M,'V3<Z6[R6T\6EMV"R#:\;H*3?7F3MHC;!)#6)0_E&Z[LP/4: 6HQ>&P:1K4
M7FL=&Q'=%KTR'?EF<F8OYCHD:/F<\*8/&'^^;?J:$^=M1Q#QDPB Y_^K:IE'
M4Y5GOW(!'QE;:NT'N@2YP "K:6[!OA7;N#/+K",*J)"W>UI-HZ7Y5TUY#_I_
M*&+I2W-.Z7:W44V>Z3XHB$Z??D-NA6"V$;WH@-JS8YT\^Z6.U.AD"EJJAD5[
M.)(ZJO9=]5RM:<[UI4="K47@-=DQ7WXYIZ]^G-PSQ0ZD)'X0.,G(>/0[T+$O
M:YD86\T[H/1-T0V;[H0MH:> V,YP2?P6%<4YE$*RL*+@M!+)%-)"A<0_ST:-
MEOK;'VU&/3L2#LNMN2."Y;3M87-O!0QCV%KT,NT^JS&OX71:Y.'2^2 /OQBT
M1[41^DO=0-$,4!-B$OLKZ.)W3\<2?="03;V;/1YSHV>X_OE^-"[>T(#DB6E1
MC>:O#;RB^..E3E/XQ?)Z:.PR+,R$OF4J4]7!08VREV649U1]0B_1O<HUG3@U
M%M8*3HEN(P''G@=EG?>TC7TH=%0_#P#*C.FZZC1<8\D+QC]W>8DQB'7K7VQ_
M;9>7?&5$OG<0?Q3;PPM778;UM6-MB7M'"IHRM$>>#KADDHV5UTJHUC3SE=:H
MK>WK=FI.-M! J4]-R?R);P%!%KO"!FNTL6C6:0,&N+&,V\$%WY"/P!,M-T,.
M^E*^+ 2LK@?4[#6Y=+-'@/'8$?.M=+\SF4C_2&A3>R?QQ_9';<_ []2O=2.E
MJ6;FYC1L'P*W==QE?\SW@/?6C4B+Z QC''AZ)>6/3LY%4!I'WEW/=Y96V'HX
MY<A,L.-CLBBZZ2)W&ZWH2^2_?1H0DPP8-_4:561WW[8\&3\/NLG"L/H3WV3Z
M\SBB(87@[]UM6).GS==2I"-=%C^U1HU>E!=:-\0EIG#-FGYW)U5PF)&F1-F,
MK&SN"R%O 3T&&;$9N1!;/;#XQ&_H]8Q:8P)2X=6E=Q/1HVUX6UENC.:UPF3J
MY>@U!UH$67NQ3['BC MN,,;7" VD:#JJ2"K^^9O2SLF) ;HA\X?LWOOEQ"]_
M:+=O 3:F<(%7-\EMI' T.RH^'Q6L@,P*/>#)CADF?.X77\(\PA+?VMQ78"2]
MG\?B)CZ]2!Y-6WU?FU2<%,=NO>ZWD_]<WBI3C"E)("LX\OPILJ]H)9:H(FR%
MEV(!8KW51*#9-&^H;S0<WU>/RWU]R)%OL^Q!@Y6VTNY@",%&2R*7]B:/;@&]
M:1XI[41H/ENAOH*'U<D'PDJ.R716X$EEES$VB=:3Q789]MQ%BW?U<JN'01B1
MFV1)9:2$[#CZT;*:='=OE<IAT7P_@H.;EDUI8?9SX9/'(3IB([M&]5'2XOX"
MR//@4C#G>>J159V)X#BO;=T7_2V1J.=?E/R_1W*L$NTPN ZX)A!;FGJ^,Q"R
MP&?G$B>]E]NU89@EB>EJ8HJ6E#KBX/:W\&3]O)/B9D=Y-<XW\60L-6QV;"WS
M=9;_OA1%G&L4<2Y[;HE=N9RWXU\:I/])<5(K* $M_R.V^_,6H*GOL;7V<J"B
M57OC:PI_I4L*5Z(X_(4H"YE"A?C+(64CVU+N_TTP8N+"#$..7TLRWP),Y&X!
MLO:G$2>0OS6'%ME0XV>VV>2:\NX?M00C\N^_8ON4&/LSN85MA>KSDBXR)5R(
M;72O!63[X&7?%-)>S1&2GQ3K>MQY*>/$%%24>5;[(G"T9B;6 W2?H!)/W+U7
MO(6N^U$>V@S9W5D>&:TH5_/G T]-&8/, +]/3D]U4_#) %[IP7YBK,%0$!*J
M\,FJ/D$C'Q0HA1FI;$BSN 4T/$XH:<F4;18GR%JF&#TS_K"8X[Y5!1()CB-R
MG6K1Z*>*%.D98>@G;XYBQ,';@5X8#C=\8/+GQUA4\:)YG1' $ QM0ZW#EP-_
M-?>".53P>\,PHM&F]3FQ2RR^1\>K8>1MY>45%_A9,F6A6S+[G2,(V0%H1CX]
M/3W36 OGBDY8KC_7$:9)DM53.+S46*^+9=RQ0D7VJ0B?PH5^Y_'"^UGOX/DC
MI1(/)GPCL%R_"96C>+?248VN@E(%%#&5B:@5[;'^1%(CYQ\QXW@Y+/+VQW9_
M*G ;>T0;613Y],@TS$D(Y%C4>CS+' .?N7\\<$!"XN::\%L\\PRBU-;0/.YX
MP%O^7;4QSGK?*HDA3XP9^VL2&V-8J\_F/@EB7\+HB(488I?"BY-C]XPWO>+Z
MRVCEB"=+H%!L 8I)%NG= Z2P2UL/&BFT>SP[!Q)W&%BA-@-C"98VKD<F&R_4
MW5,ASWGAOP!!?#R/[HKNKF>&^B,*YGZM.A)W^0H7>+I[YRNNE-U(<Z#/E[RM
MZ04^Z[AX/W;1%5OC]@N9;$M9!MY?*'^F!E0:*[=RGB<=(=?,L=!.7_^("Y57
M>4'(N=.Q>$+>:-S-G" PY*J%UJF,?$L9.KS6?KZS95C5</+&_.+LN@%H@#0V
M5+T%?+8!WG> .X>U(Q@;6J;*+3$3C9-1TQ>5/Y=%D]Z[S$TDN,W;%C@M0@8&
MVL\U+6\!8YX5WQ 6]1,\ 3AC+^(> 3(!0P2=;LH=%Z(PXE$T6R[Z56P_[70$
MEG+IS$Y]<KSZ29-PQ@/NZT0F(-O/!]\_;GHYT'4<CR -M8\\PV*>B7AQ(Y(F
MGM1G1!2L#Z;F@?3NB[R,4IA36OW-UE#>5E[K/0=!,71MCLJF5>'0:#W<[ASR
M;W;U% E#BZSL"\@T)6^J9_4E7UF-2^WF1,QF?Q$,A'"5-7#Y->-4['9+TS4>
M06*>U5>/UV01Z!F#IG$VE6LG,Q$57B&S_'V61OQ92=\8Y=RUCTI?7.!GCK<X
MS<6GV])L[BH-4P'B^%T$=K=-!>W:'HVW2!TY=#+RUNF'A8^MJCKO,TN&S+(V
M1 A'TK5/?G5K?M4+JDCT1F+UFT@$Z,I43ZNG0,XY-0/*!NT^F),P<_9%TCER
M*3N_I,=H![P7AB='7MW(;C;-[Y#)E<WJ0S^/=XHK'8*;_1MH7&OU;,4^I)M!
M'I4A0E4VXP<9=C>;,RP-*TVQ3+GGQ3>JG1%0&SV;VF^_4_B?]5D\/1(A"]ED
M<#?&#493(1A$NC&$2+D=*DK?A=6Y 4^[ YK"B>=),G96+ P[FT >T7[JDB1L
MZH4?C7N3Y"F:O00)R3\5"KX[2^%HK)I D'/:C>,M9$YQQK_,G7U*]&=-C+MZ
M:>E -MKQP1#BGTH+A[UN)IQ'3&'^W"LPXJTKH;1.<^B<B5S)=K@ =5&H*$&X
M $_@\4"QB.?EL#UH5$NY?ND(J[ >-<0]'7:ZK\6$MZ-Q _-(OE)KSWCHUVLV
MM,&415*LS7V2I7+Z2(BU>LP$<RQ<IY0M,,1$8'G/^^7 C@*QALIED3S*$N$0
M^P#])-F8=F%MPOFM,=]"JK?A@!ZCWU>3S*#6X-YJ>WA[F+]BP4X@300AU9X(
M7KVID^Y\:=3;2W/W8=Q 3ON:DA-6PO;E&;(#A[M$25)S\PY#(EP7ZAW6$]?:
M6QYU?^]]Y-"OJ".5S,G).S"LO<:X&F\J@C+M%#<I0,""?.VBH7N\W#:-+1&/
M: B[A>)X:#X-TU3&9[YB;A70:VA$^3DCO>6/5@<MB_1N =:MY1P2+^ !V:7#
M6_-[=,H?/O7-CR=3\OO_\+WCKC^,KI2M=(8?BHJ*"NY%'+72=5V8$"'K0PK&
M3O>9NK8]QN3='QC,#</++9Z;"0O*^969UV^*+ABSQ?"@Y5:8'NQ2BD=GP#Y+
MKL>(.O,(/4$J[;\@YH@ _*1G:,1%E3UZJZ+\G$J*QR$_8E&_[4JA(&9,@B#^
MK/P6@(^*8*( >[^9S([.B;F"2WR-D!5YT10</**9.;F&P0X:[PKDFA!4;N'!
MD$\<"J:RZ7'Q]@YGN57&09]58+$$NS#Q1P7Y3O,5HGC5CF!=2V&9+ZK(B$F^
MM[*:O@6M\2!_<;FVO+9EU%?@K"%PX=0HZ]=>;-+C"6 9QKDG.MBQT7BCV"><
M9AIY>@L@;B&E.73DX:6T[NO5B\!Y8"LFT2\S,QU5$>N#Q.K-%&^8; ':EBL7
M[O!:.[(>5+*6Z;WZ J6[>WH^< %]6NC3K[6GSKE73!^#2:=-,Z>-0&B^8JZ3
M3KYDSH^,#.5,6%ZOWJ5[#HDBOIJVW +*L$<,CXBCUI%3B3?%@GX9/%V63<.J
M)<S<[C1LI-@ZK#(=B%9YC[.-I>KAX**MK$<UN)6UJK8M]8:108V_$TB"^I<
M@>^WA0;?LP\5[_W5OQHP_Z>Z[[^QNPG3OPEO>?=Y;P$L[WJR#A1O 7F4_Z((
M;P9*%^=&;+)(;+1V+]?OBY6BI>T\H"Y#Y6!__[+D!:D?^S\2?\8>9&:4=6]E
M$X\OX:/*5)#)L3@E>:;R =8O?P[2K/F680TP_XF:&@H$H:51J3 T_R1F*6>1
MNMY,S?&Y <U7QJC&"\D8!0UH0.-1Y.K4)Z3%A!P9H82!3*K']O<-Z?+HV/0
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MG8J,_7KX7:O6I)Z/&/6X>,Z@TO32-_9(K((R@H>^R/VFU0RXO@YAQI 'F_P
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M?3/IC9O:!U#F4[ KPR OTZN;_FEXXSI1\482G0-982\W/PVI77<>KMP <UJ
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M4=%@+5F A'L'V&+T^Z0=96L:LG2JT7(7@H,&(*BT(I]K/O2+M@?*RPR$,K>
M3.%(*DQPQ!F>P<@N17O&S4JS)+'V35@@T8X*0E* -=QYI;8MG>1TOB<PJ7L7
M\M?.7#Q'D+_ 2JM?=\I')FZX?*:05 Q !YW95EU0\645J0G/0]\"^$X$5AY!
M;+)B@43??B%@U"#,BR"^D"#4U_C^HD.!$311I=5-CJ3ET8%S)?H-RJ\8Q%-$
M"+'ZW.6SPZ^2.5^6=KVZ_=9HMML'O]N55(,L2M"-W9KY3[ Q_LOW@C UH!H3
M O.ZEL9?Z=*]XQ9 +<F,Q!,2YZE]4(\;#.([+F*<HTL<+UX=:^::Y W/JJ3J
MSF((KSC]Q2'YM%S80 +*1-('FZD!>L1:PP-ZP9FUB%M ='MUS*#G0PC"$B7-
M0[NSY&XD^Q%"I6M$?.AL,HM3HUUL ?PD(3URZD>M$G(6*;43L2Q-@W8Z:N_E
MU+Q) 3^9(+=1$]]\Q(^<($!W+ZAY=TPSJ+@7\.B7"23U]L[FV.5&_([[>\.^
M#&Y$]^VG(E;(W0-81.XHF$-5<@L0@VY9/.XC40185*671V\K'.QYDFL:]9O]
M';7JM(>=]8T5'J^QP"LO4Z[;SN+E ;[I;ES%%5$T>E8D8UE&IB&>(]4#7)O.
M"WR7U%E-&LXY%</EV/\>6<M?,STG[31@WIZF_2F8,V%?9*E=6I0]Y8A1+2BP
M#W$_.19WX]W%#[_$(5]6BOSGRP<?CUM%EO</P]#RB%_-A KX&=(C<L;W,71;
M,X-<>+W!"C\#=5@RLZ/N*<0>'?894$::(\IX'\_,;>FXY?8&UD'/D?91>+U1
MEWX_[A_VJT_N?-6!D8@TE+N>9^)FSNDA"Q"-484M\5RJ-1O<<=\&+0_4P>64
M*%6?6\!#Q>X%XOT_EVTT;35-:<;0.G,"IQ!M+S:7W2V'\>*2]X7M,$[L&$:F
ML N2.P#6I-_T91"FX<.EY2CZ1>WQ*VK?( FO\DC34-^ET+GNE"N&FV![W\!8
MHF@_PCUULZ8(8*J^DD1\4N0Y$#Q=-"H+$YK@<L%',%$7A2G? CYG4B*Q3 /J
MG\]1&HHQ6<]F+.H0:_56C]1:Z:%?3#LZM<B4PW=H;<-J%^0=IX3&N)7J;L93
MN%\DIM)<4+!AK??ZUI)/^D#O]Z>C-!"M-UD]C]#&980OQF[*U>+J1\VLE.OY
MFY4Y1;@ZBOOIK<Y@"KD1P^Y)BCX$=_'T]W^,$-*WUD?C'U[Z%[VC2VX$9_K_
MZ,#_)FV.T@('B',_.G:::=;4I YIN[>YW,B]H"=7Q/TY AB"^/WFX54%A'YZ
M72.Z!>B),*5V\)5:XW9VM_3A(J;C>0A?(Y)ZV,]<(1]P[YH6,T&YA.,IAA99
M43!'&*N8LS>]U9M]\PI[@/ZK&4!TS8S)X.H6L"*RMWG4?/Y53U)AG*HI];U"
M=?;"$Y#VO8_]!%&O5I,&^O@Y$=L3R1J1)?L6\VP3_<N^6=^9'DI3[0!I)"%%
M8-TW28Z;S41#[L\2XG*?6NP! :)G%(OHUS<I:,,CWIY,QJR>YUV["BT3.?4Q
MY\/+CW^;LJJ\))!^ZWM?:O<P-NP6@!M(C?GERSU5]F!T^_=VU:K!E)/V[QTB
M+Z<. *GT#OL@5@4G@@D^?AX!I/?W=KR).9%#0,EKO.YAWG&%M($&=D0<C6RS
M&>ZQZ'H2=+4!22>Q[;VFUCG$I(A'(=$ZTH_;4:;_B;WWC&NJ:_.%@Z!(%P6D
M1Z4IO2LU-R)-! 1%I$9$I8/T ($(2.\@("!$I(F42.\@O8OT3@B]DU!"A)23
M^YEYSC/G?N8W\\Z\Y<-[SH?](2M[K;W6WE?Y_U>YKF)3W#)NB\CRX7Z:#YV(
M1M!Z05N]+Z#.\."3)R(=+X5JG=%M(_*-R0W)= 6+J1O4Z7[E012^X'DNO<JZ
M^HKV&!F"9&NZ>?X4"H31[=1>87BS/&CFD&&N?=7H!Q/R 9-A C=S5MZ+XS(3
M%'SW(@H,@/3NS*Y7DP T\ID./#EC"&=FZU7F] KMMY<@/SC:L(C,W('0V(?/
M(_O%/"T?369^8MJ;P"3_ %UKX=JL:>'$,&17%LUN1]^, \PE\;$$Q?,5>#/U
MMT3BUD@ P:QEB?/K)B2 1BE4Y_PU) 25TA,E>@P.-Q-/<7&J5<TIVC+\UB&2
M3:53NW934\=Z_IVBR1R8^R.L0P@73^R:( %&'"V][(4]T=_NY*U-!?Q"ZO)R
MD0!4@R1  BB.!-AI1A!#!*"8<_L[X%G'[A]HZ,"3W[/J\:/-(D2:/8R-)AH<
M(X=D=+R;N+5B%B=4E>U-QZ7'P3<@=(^^#3=LF>?#>DR]1W%^?1/,@;>#FI-?
M 7TV;WT2BR[ANVB1I%IHLD":(Q6%NPZ[\?%&R_.()0^=\=*\5ZT#^/! 4XM\
M<D>V@K6)E$BE(N-D\[I70K@/&K0;1]2'""H<$PD@M/*5!)@V>4H"S%9CPW?Q
MRLQY.'$#!@@CVD%1/T2A,F-7'B76=D&'*U"R,XU#I,=ZM$7B;_76_E&O)QQ>
ME2WN73UV=7)W'[14^% 7*D>9!*OZ#D*S?<4+$8(]/RH#F:)4A1R/[&N&7&K=
M[;$5HG=<WKMTCGY7?J=Y?X4J8,4,C'Y"%^3JCVYW<CU$/@YHJ9,/:PEM,J +
MG(!3[,N>\SQE #VKB9%-':1/3<XQH=W9+LL5]ELZ6R^X%U4E?<8<4F7N$U#-
M\-0X7@PG%'"N@/-9+HC,P8-JB>,8"Z*G]UF$3OZ591I>]77=H'X1\<? YGBS
M]=:E J.+Z(,@F[8!RP5)_%5)V,?2^/>P2I_@UM>MW/;9-S$FL2^:IUSRV3@U
M:I/7B(<O;\U?87NI'=!89TSOL2T,:WOH:;_?1(?B,;IWVF8+$Y56) &8/KZ+
M(3SRDK6\^W$T14%!_'![MPVJ58$S>9RL0TB4-9^VS,U@HIKKC6LV#HU*T/HU
MM5H:B-AR J%B/ _ .+4<$F"4%=%/>U+!CD""I%'C!'-T+3[="8@5))OXO%BP
M)*Q-C@18_0:!$W\@SZT4SWS:!T&HZ#T28%>7#,ET.%M4R1@K$#?:T0[G*A.3
MX_JXQS<I.R.ZY*M/J<\?.^&QSWIV<H]G9R"7PX AVM ,>7(3*KI(KI(,ZS-#
M;Q""TD@ K0&K6++@H'!)<DP,CHO4#76#9U"X:V5DO.JC\*L7>:/.#0A5"#U"
M0>OKYNLKQCUX_MJ&TI/8_;0"/9;'<[LS-Q__S(R^\X->/T!M;[*%DI#1PA\?
M"N)H4B@=NA-M8$_L\YNYX7O5VC*^8O4NGLKD]45Z[^>;ZLO!K8..B['Q9:KL
MQ)\5. _L%$:^Q)EL2]4*V[W\=>11#]+,4QZ[X86&NT%U*HZ#K4M?D,R9%KC8
M?(CFHM.L7>HB%%.TLG?U78<R]H^Z7J(,^+/B9*DU:N&ZX90$[SUG9V>SY>45
M8KIF?J30+WJB%ZYK!<&V #GJSD!&N)IF;!@U)JWN\R=P1-(J;.;2X1@G.+14
M[U[;VPYXGZ!NXFT]HL%Z*MB#^/=69E9A_\X:CF\G^$"*+ _;'N/SY,%TD0!)
M/T"[/-3$]R>HZGUPC00^E8($>+$).A9",/QKRM?K2K[<O-5G#&3FKP>.S 94
MUV4=?9M>GCR^EO2<*=4 =X7C;+U5562,!+"%1_:@"COI[%W>V!T'_%%:NCG<
M_\U@X"9P]ZK!KVI 8(C1&)]7(N6=BV0DUBM[]C_G^!\B GQY8DN2^]]&2,/:
M2Z8NKHB!]TSN_Y0YK],'+S2#:.NTTJ?K>M*GN\9=5\</^.L^K);_L/K,I&;\
M]4LS2TE)W'A)2?#?5L;^>0'HHOD.6%$YOJ49U%[A]Z9V.Y20OOX4>$"!WUX^
MD\DND3C@4XUZ:%:9\(_UAF19@&W4H4$4&"@&Y?LJ%-ZD8$<4P 2T':+*JR].
M"BHSX%8_D3'51LBG9T+Q@<*.R"O*9G!&(EL/=N^-1\V!<62KEUU]1\+TDK@F
MN%8M&:Q!'(95,H43+VTM[P7O\(K4&;F<1$Z))0_P^YX7PSM/5<(MFK.OJH[6
M(/)@)C.<M_.+E>-1\;NN)9 CHUJ,:W> IM[#O0_*O+QA]_G>\=[O'2 C>[=[
M)S:C+74CGBJ@C@S+FLS\&;7"Y^:?M9U+<VDX;^^R>++"6-QP4Y$17<:=C4-;
M<U\N[?^9;3'XWSWP_^A-:A3@]\J*SZX;*C[RB6X9Q'?XO;(58J,@YZ6\EFCZ
MSU=J2$)^V[#R,8)QA"@.J5R:BN1#P[IVKM>^<:[)OA'I0=\O22EC0Z\(_?'*
M-A'L'R@W"+V/<T4=1%EQP]4QXEELN=9"@SG=O()M%",-Q?396D6G"*.XNPO8
MYZ%#P"X_T"^>O%*^_E+QI9;JJ.795]DT3Q5UN2X],Y*^K/K^Z<113>-G7"-6
M!L/RUDIE.))XW4HWPN6=F$"BV.ES&]H%",I<^07&ZBAG9Y)7<+2T6DQ\6VF.
M+G2!!<-=3+]R1,7;$O:M!CB3?T^I:Y<,X0I9'[KPAH62WT;8/Y(ZL/KK5XI%
M6KA-:)T4N:98IK'72W?#'5=[FEO. [,GW(,TW&M]/%KN:#PGBTABZ+^W9=I'
ME6.2,=]Q[2%RBYF>^\1Z>HKAF>?YQI@K7Q;H_:&*EMOO)W_X.;.R-FUY4+EW
MN\=),^@^_?/9U .@2C@^D>DR"?#W]+Q-R/]U[VJ>26TD499@NDE^D,72_Z.Q
M$ PUY.K80/_KV9[BB>)^V#\5Q3/C[?TJP\S_?'&K_^VDG7E# >7?JW-R<='&
MZ-U2\92B1?NDN_18'R9FU<ZBDMTHLS16 7N1()]G4W(25RQH3O3N[QA^HJ<1
M7_<UWTJ5>QAU.^:I<5(%Q:\A@:8^4?T1LI"8:-[\$)+@L<V4[^2@>@_#6VZ+
M52(!KCBDU82'N+KYBT;V&'RHN7?V3(#EGJ;^'J J4T-,4,,XX=*(V1&NPZIA
MU$0WTWS\]1C+17,%\56[/W@ >G-O55.2=8Q6.%S***H,=364;EQCA6E-G1@P
M_CRR-TM93Y=A*!7X=$#'O/DPL<LP+V\YK][L%YU9:I%_B:7*9(ZO6X G">#G
MGVZFY5I\+1F74:HA(,=>^DX^RNQVX1<*J0-='4U[4XK*@!6#*]MFD.]-4]5*
MC5<N1)LB^"'?%1GRRX."P!;0JX0@%(8ED WSIG+93H*,_^DY0^Q_F;/Z&K^#
MW8'[+"BTW;!%Z%=CW(9\,D ]B(ALWM$;HU5(#D<V,Z^FE[>=<^IO\CV69 VX
MI"(RU&V],QXNSO;P[GPJ7'T?-K>R?)(60KQ. K1??^V>:SHEG]O&T18UHF^:
M.>;V^+//@)_)^IKY1'4T ?8XE01XTEPW+O'&>=3"4GM4R3]5"%1JG"O1)LH
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M?&6'GUL+1 8\#>9D3">A#(XKKW!BRZ=HSY& PG.C24>=Z?OL80GW*WQ#-6E
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MU>:567/!5M5Y&- +TW^-,+D$_'$4]3L>JT#X '5& =FF<1O@ALSVD?MY6OF
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MF9/95"1>Y^WH$$LE^VB/0<PUN;$$1NU[M$TN"JLOZX:O!_Z"7Q%7E<-EHDB
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M7+R)@C_PTF[CR> E@_:=UJAL4.7W6*E"LXIY\* 6S16GO;-R+JWQ[(D#:_L
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M9\MI3TG*"JTSI,S5\ES>A)1=6_X?Q+UU5-3?]SXZOD% D5 :)"1$&J1;05I
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MDW;5_[[HXXO<R&M+R\H:;)([6?>A8N>E@:OY[BE(I=A$Z^!-BON+%YNRBL6
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M'D4FYHTON5J_&I[\6P\$YGVQWE>K.ACPCU.'3F'D6MV</*F(\!U CS_U#E!
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MOR(SM^^ZB8#QEX3*,07BC=^T/W+]BTPK)2=AC['9IM,R>C8V%HF#B/#GC3/
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M>A+) =J_U<R#EV3!:>64J.>3WK^Z(U^4_O]::OCP[XMWXQ84W\<ALGL"(N\
M3SAK0@_+>#],'CYKO)^;II;]*/H>,S^T[)IBQ&VQX= :22?"<RC< WN*G@N"
MK3P.VCI5^'52P20\@Y<BK2P\;I-%5$D7][XM2CNE2X#_2;?!$S7[ZE\1\QX6
M35UL>#\/N.M\LM\52265ZAG< 11\](_&&J%VZ]>5#+ E8D>[2I MQ1($QM!1
MNQNBM/SYP[W<\ :&;V*2AUG<M#@QC\J%5-1#^+HV.43Y05Y#@C6&XR#)#%3]
MFUC=PEI?@6#2V)#06Z_6$J6,H2ZYRO=-M_>.^0F/28UQV;+N[.S9EB%3-/ D
MHX<$ZZ<@-4:\=5L2D?+//Z4=*;_DO&3@&[HVQ*]>C$MPWTG$,5=N_VK2KI03
MA# C"6-O7T)H>N6)0Z9AU/XO?]NF%?Q\/J;]BO1-<'SC$='&AP\HJH_E*N$=
M-H-G32+ L8BTS=3(O_:!>!;7G=I/D+9>D]SXC)6/FVJ1<(! I0[J7H0=!DW6
M-GDL\3GKU$YMTOH9\>>KILO"WKF.3>:,X]1*(9\V*T1B=$\U,D-G$T>](\+/
M.+2URYD7DB4M"3F.#HNVCETVY="_,-0U>=@&'1JI%^C1NEP<[[3Y$JQ0H)(*
M/UY$SG6^Q4S5B4A66W2]G7#Z6)1Y?@U9;;:BZ5:U3P\-?^YV;5R@ $^:CA<V
M)U]EG3$Y.4+O>8<>8>AYON,NUUZ*B?/4NPVY2'#^*D'O&<;/CUDS+F,61H<F
ME\K*V.*+!WB;NEBN(B=3C ^.*QJBKC.[WEPS:Z*9P^4X< (W&:FJTP(>^R\^
MM6J,V(\?46OQJZ1HRXAM<#<=\=2BF8.M)^O&HHCO $2@R/+HM.<YSO*1,MJP
MWXOYZ9 'I'TQP1_#K5<"?U@YB:)#*B/K2F5?[*9<M9W1>W_CN&;WYJ]R)I2N
MWZ;#QYN2T2_M8(9D74&*FC#4I3+HG%A)]K:OU5RTW*1'7WP-A(?V1O<S@>:9
M*]=A/-)8G ;:%4IA8Y]%,<>&<5OJKM[3-0]VL&& #LJTK;G$K_%+/0:I88>[
M8#)S\@X"#[ =/>]6.H*?VIUTE72KUFC<H_?!'&\J(SJ(UR#P<BACY$)8O\EY
M?2KU=^J&GWU%O4BC0]T]I0A:QJZ@;4#0O75#?8=VW=F,EG+/U;4-<8J##K*;
M8 /T'>#P<9Z)K?<J^UQVOZ&PF1V]YMQ");_#[;C"X8<R8_TO7WXRDLI'984A
M,JY"4U%CGWW_6G'P%KJ,?*QDK*BGQ+YP_YUJS%<$"O+;=J+0*R'[]60[<36&
MM+APK[S$Q-XP93%*6-I<4;JL+V*0HVN0_2HM!=67MC);W=RZV(=K+HGF.S63
M_/8/$8N<MR7^F>R(FP97DJ:[4^LUL"UDR)_X^B6VQO!OFB00GGK5AKN<>X(%
M&J1>3M9PTT"&[^.CA6.S@B?+;W_[,A;!UT*O4KMO3#9US9CU&N9J+RV#^'Y'
MINK$NC> GPCAM+.ZVRVK9@1$FM@31X_\U-@5*5J?5%,K[^4'#T@\9587N=$]
M5<L8L?26_?J[X%'*2;60WHP:84Z?U_3PGZ]-'.#%50.&.,O#[-  BMJU"-!3
M.<&13S$!(E<,N^U,M76-U"=CCF1#%@U0QI!.4D'II%B>A\8HM'RW--#,#S%S
M'"+#*1_I\-P:PU\V95JJ\E*FDJ2E.[_T3377=I/$/HC99$73TI6QKW82.$:W
MG-C;9ZQM020_,!O:ABRWZ7NB\KRJU'RO6EDPQL?E)'GLG3C3WW K4S%E6CVE
M=2/G1<-U29+]&?9L^-J9,Q(9= 5Z,":8(FM,FRY>;4LP/W-B6(QG>SS6!C7#
M"-^JJT3)'PAXWP'RLDK@J+C'BA\=K9G:BN$V]DL_&H"#_[Q142AM"9(-L1P1
M7E8_&3IDC^W[OA+QR<)-32[_ZKRB[#DIQ,==K2C7A+]'HW'Q16Z;[K^$5V2@
M_XJZ;N"_9+D[#>]8M;QEGMXN;D)O'T;= 3@" ^:ER&X>[/> ESL<0']X\6Z[
MQ@-VM,T90-Q6_S.&>*_A_W7!?63AU%)  GHH:)>F^L7NPX2$; -V 1QQ&RP"
MN 0'/W+I#I+(>Q=>(DAY+Y 08:YV+8P3E">#XE&-;+P6C0$ZSL"?YEI>NFXO
M:&FW,)?[D?SW0P3*\;*)9L$A06Z5V8+\'V3/V^O #$V.2V4.AG*-,LR][T6G
ML"@M\A4E2-YFTD; S]VK .XMGLDO3;G?5V@\_OY^Z8O_([??_W7\W$MK:X]S
MWM;",E*I<,3]H)QTW'F;GUOY')AFU1"SD1RDG,?[V^6^R]5E+),9VN[/FQT;
M6>WQ@!@+<!9KTQS'#>)DG7 S1!MO.6NKAJ<]$[\N8=U":#*[1?OCZ A[R$I4
MBYMQK-KE\ZI68T2CC!EBZ89U._PHEZN%CGM%/_#H->"6JDK)2ZFQ=DYQ2-=N
M]2JMXU=E'S@JDT8/:UGYN[0"XKAT$ G?2IGS9K&IZ'>^WIR;;*^J')6/F*6O
M#,3IY..TT(WO9VI]J"I0BZXBBL&-I'EVW*OPQ?9]K!Y&6 W;MNXOWMLL,C1N
M]IPCS(7/^06SC(,T>8#@ZR.>H=_H736+9^CA ,X[ *'[3O&T_H?"V-'(%Y6/
MQO_OYDR=R_9_,)=S<UFI6MHQ!K$&_?[M CC_04J!BNO3D \.(/$,H##[S/Y+
M97,1F'3;COC\N&A*)OL#&'D'^"Q'VU8WZ8S3+ML\'R,?G4M2XUQ=_&UDLQ)%
MC5/2Q%C"G\!FY.D21T?RY<EDA#F'EGZENMT!*% WN0]C8>N<,?.5ZK&BL:+Z
M[TKR[KWJI-T!G%46%FGO?95-QQ:4GI@]WOA$]<?RP.)\3\+:2%""9>/Q;',Y
M8?_)XM>@.\#+OG'-Z%]75Y&;MA7&W:)4WY&ZY5+\&)NJ)3,EGX<:Q&4)OP:L
M):GX?.1B*LULDYQ"&M[ SC0OM;',!;[*<>7 ?8-;*Y(@N3/'F.'SB\KGY33:
MXU<R<ORBR5E;_VIZPR'_3WRIA@&(=#:;_%Y:Z D,T\&47<@3/<FKE?-3B>@Z
M?S/NFBWIUG]_DDKA)UZ@1,DKJ<@7A80(:TH=4&U-V47'_+9*.N@F1X;+>4N5
MK_R3WQ]RH:7KQH7/;#?K;?ZEL9C"*G^,-(J@[&.:\9+)[(81Z\LG1;_3B0AE
M):ELUBO[4&BPP=RYAC_/M8K.M$C$V;!Q^]1&E'B2\W%5[3%/K<O#<YG(;JPE
MBE:."?=J'*KI6G@'<% I,"N8KSYMS19*3?YS42^X!#S*2MX<^GK3IEXB/CD\
MYL5?=BV/HND6>(2SQ*XX(\#:D3PY]LURWTF"=H3LJ@<0EG$^B[<6>4(&UWG9
M W-C=X#:@+C:XW!?>+ ,%0+LKWZTUD.]-H\QW5-56EGI>9E'8)YWGQ+@.BAC
MT7JLC\TI7H.:-&%P]P]%)44-9BQ (E4QK2O[3 >/?M*:9WR>;+L78#ORA#G.
M.YL"B:;D<6=75O7HGQ9^9%CP#T,B-#N]Q;'S3ZRW#567!B&0%,7C[@;7K$T0
ML[V:0@3T_-U3.,;9=D8(V5OTS0P\C)XG:HP2;!L\E+(']M:/?KKMX%AK,\44
MVBJP_O025',9!A.%+*P;.]5*-WHPF"T[?UM.3GXU]O'7W&?;#II6E4+LU7"?
MH4GFX4TO?:*]6_><5JGP _SHHO$G9$YW@!"O-2IYVQW8,XBP$?H\+J3_2UI#
M>#Z&Y'?W'6!LA:UP,AU:<#RJAN,A^XFD;+(NR6S*SNMP=:O9\6,FFL<*(&UZ
M05&^(C[HV3S$ \\1_EU#^[(YMBU3+Y>A9:]5GB&H,%+@/O84H16,;D$JK1:C
M+XTF.!(UI77]O,0FR_)_V>5)L!5OK%MF]G ^->LX%"V&7TN:X5XDO3U]8JR2
M6LHW:!![CUO]X\G%:6*^#011%6=6KG<1C=;NU3 3.T:*]QA@.",<^)Y,7>L.
M&R7^-N?>9K+G/M_^.:8W_N'=KV04#-)0$2/JQY$WIU6!L)GV[G7&QZZT<T)E
ML?K(%:TYDRD6"-ND,Q^5^HBU3(Y&A% C.F8:TQ#;BX(M,#V78[_)P>E5G8*+
M:GVA1(1$5<H_?EZLM=Z*3%V_-0/A/,;EGMG[WF_K*PQ[LF1D*S;UC34(7\4H
M 63I/WE=TY#QX8,E#50;4X,PC!1EU--KP?*Q[2U^2=3FF(+4[\2)#EHLO?E@
MZ;HC*-'GI1?BZ_F,:ZHM;W*IH?*]K!/G013: :>%#5\LN(E.77V*WHNZ'M"5
MW=J<XWOZL*/7M')%]I5<W7YV[1LY,8S\ <H=*4"[:VA"VF")W$Y;I0LTT.#*
M6_Q))(M'!<*20"\%^A=J_X*O>J9_T$?ISX,*,95U9EH\W5/V+S]_H7W8;O("
M;Q/_9N+X.U0 ,XE2PX*0<??WJ6GH;]KK7!U=&G37JNNJ(GK(*?-LO ![0L<Z
M0)+P<F-#\*>RUN;S^A]3OEDAUP;FIA!05P<A[AE5[T1[)@+AXUJO4%"046S1
M,_?"]PX N9X]/ICYT</<":(<=G\6@K-&:@KT/'<XW:@=X,#-VMVK),-N8^RU
M8T#D3C+JB[83ZV"(8_D!_BTD5&+\$>%BT["3$Z7_T;G;-LIS",> GOLLLB);
MN^#A;WP>(6IT% &.J%XU7JAUF*<->#PZ#BGBY3 ,"7E1JM;2P>?\)R2SS).Y
MGCG6DQ&,$BO_4:IFG0/Q3-*:JMT9-,IYHW0_687.,BG#AD'EM9D W/:X#K30
ML!XQ]_U(QMAC3L.9H^OWX2=3'[_T8EHA2[FZ]-+;27,"3-]F1WBK';IPS123
MP44_Z.]<HN;H"!D,K.1]ILI^;V!; J\(+Q#C#.<#(@G[9'GZS5GK0H]DI2#T
MC,\7HM^Q/Y9P?D;*8"LALW[^/-*#^V0JCJ-):K>TKO;\]+[[?D!X2KVY6)0I
MEN!GD#]A=[VX"=N+/^U+SG1VE$S7$\FPSS&0@,/[A:M&6,[UN!YI:6,& TT.
MSP?EKX89HAH8].*0]XU@K*UW %WL98D9%.8<:3#;8=EZ.P[LJSJ-ND?[+O3)
MM?+K:*K1U>W(_>, ^Y^BS+$-V1054*8&FD$KOK/2!W7_3!BIL\US< [=;+V$
M.U%:QTEN->VN8RB?FNI/&C9<EG]DGS@7[^D(:W^.-40*A-T!2,^.R<RT$;2'
M_-88L;JGD*"M$S_OIT\W2AA+,SQ8O"JSY"AWJG%"6 K,OGZ+-#_2 _W;C918
M;8LRX=78ASUP/XX3$]=KSH@-*<16'.NTS]C4=P#_K*=@QDW%;G[GGQ <!81U
MJ)^GCRV6=M,?AWK&$)IBC:ZR,HOW:_9/E9C#\^M'>K^@7&/)C5Y(;* "7:?H
M6IFXD^J:OC8!Z].ESS]:;G5-MF??1)^U\/TKW4TE _II7_KCM5WN'<"ZKU2&
M3[ .'!0 >>S#H<[)=/X7"CR1T5\?H_ /A&ATQJR/<7HO$H.%07_^]$]<]S&X
M!D]5^)<J*F*[%\DZ[P#D.-F&R2K^NI]]/G)E_"[0Q@L+ 0'GM\62:\L8\]'G
M5$*4DI2.7BV._M HWW*R'!@S%MPM7Q,;9X.!0$YU,>=1#\K*'#U::(+P7-[%
MI#XZ4K?)HE-Y>[JJU(#V##MH0&@*][=SMJ"MX5&BP,K'3E/E](C\AYOZ1,R>
M7JV:6'_P=B4 9\5$CK5&R>/OT8M?S*8B\54B8N82'2HH&6M>S"\U+9U@+E5$
MU\#9M=F!4&O$'>"1W=]U4WO^"RI?!"\R&6CG3%M1X [4&D#B\;XZWR&T/^'^
ML']Z/=CF;="6.%6]DO#);?7%5*O0#VQ<CR$SJ8QB&>Y5:T/3M75?P6PV^T>9
M%)57-(E=[0[K+C2K;;G[FNC+0P;,/:@W>KAOCHD9FT,7B<-ZFQ""!Y]4(!YE
M;  ZO/&9W"@],#$"J,*(=?D(>L[(=F;L$P%BOF@W)<^/[B4CL(82'+EQ)]?)
M&1P&+IRZ ]@>W\,RZZ?WMM_'FMV$H1[HOF8\WZKB&VG+4\V7C.4%:-$%[D;?
M4I6;B!;8$+44=+1<:A2T$7[RN@/4Q/Y,LNU@@+%!CO4<GZ[VBOB<:P _F$@>
MT99%)[#@N56%GQWYC_BHQ,G(HVLTT.4W8Z&W'."TH]H<I?9LUZ)6+GXS12<W
M%X N'%V:]<]-KHSL#QQ/&UH^ H?'&<5[7"<VXV2CZ:1!P5MD:_HE.H,DK]2+
M:688>_IOC>683+8H%$;3$.*IG&!DKXUDB%HI(35^XY3C!J&3._= GUN:ZWTU
MT2QO<K3&AGS?RZY:ZRY7._0\CGR0HUD^^*,78^M%E-X^ ^NY%SC&P[3NIDTW
MIE^1BCH.A"JA-,77.7$<7G/DV"1=[XEST:9[UKPV"G3A1XK2KOOF-*CCV%08
M.[HR1$8(L<_5RO/#EKJ/>I5X-@7X?7Y++=^E.'%MY;_1]I9Q<2Y;WFBS(1 \
M":Y- @%"XQJT PD>@KLEP=U= P&"!P@0G. $:=RA@[M[X^[0C3;0P$OFS)G9
M9\^>N>_<^[L?ZLM3U=6U:JVJ^J^J)5V8BJ58BLM@6 P*="\5&#NPVA!C!/$B
MV93IY(^&%!7FL9#0B3=.5#:P0Z"KXD*7X*"D'C^+NEA9_))MH79NR3ZI5SH"
M8;8B$"(F@O*=.K#Q9?$SL_3TQL6&;^0E@12H[3/G8[A<-*T/K9E%/1^Q#'<0
M1NIX^U6:-J\28DCZV+GD#=LM-]J8HFQ:CN.?R!HS44C,]9UAT0G08'7#_#IM
M%!60;6)/W^1?RU]K5[_&_KI\^+52NA'H7 @:_P%Y6WE36%4[A;*S*4224MT!
MT)$U&W;L*+'I?=K%Y0<+K*H8U GZ,S "AV'JDV&.$J!I\J9RK5WR"1E(Y&@%
M&N5MMR)L2&S@[DE5\EJQJ=Q+WVR@QBO% 2_-0/E"[6LQNL#'MI9/X\[1Z.YF
MYZ_AKB%K:4[*\ O4<\IO5S,V[!-Z(D44QY-:KBIY_%?1)1X"$2UB.X9P_R5W
MII6+ST2MZ< )$VT7"N-FK\;&@?=!%N3XA5_%E--#8NJV,I"-B)!;TJB4Y04Q
M&OIKVN%V3QV+<LGSC)=R4@*R%V06U@2<GBZEER.%7[X9,CUKOC*4S%]53Q$=
M[Z*T"[RE\>T6JEK$G:S&U^GN3%[GAYI/E$Q14/7U<ZH#V_"DX^:G>ZJWTX60
M3=[Z\.Y?+3@U8U&)1BO?ZCCHZD]\9WF+*7) 9=9TAVM,1^E60WNU#Z2<C3C,
MSVR@QRBT!\3*!I_^&08>:P^\;W0'8!Q?AEZM@6^_R1M,[QF\N":_ _16(3EN
MZ^[A<NZ3Z>JKZ76MX8OD=,B)H$E=E;*DX\,_:V,#"# JW!-RXRE_!\BD1$E
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M]O)K!<+DVX#4SHB;>)=S&DN^.X#,Z!$YZ[9#[_UAPD9VDXMR&&LVFH**>-O
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M%RN'_-S<0,-.T>%XAV=RQ+J,4XP2A(MH :6CPX/)#H6\Q0'=5(1M!RK7G>E
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MY+FVH3KI%';A(4*X<EE%?BH]6AP50T4JS_'<.^=C9ZAZ-Q9#NJ@"6W2 ,XV
M;/W8@7.X#.]UEO>URQ>;1'J,NNX!&9J]"JV"9I6]JWE6#]=R>'=[ OA)$X41
M9GJYKL'LHD\+GVGG14(Y-_;ES29%N/?"C=>QVQ*"85Q$/'..Z,.*PUJ1%U7!
MZL=0.S,&+N%,P<O'.2P$A(@,G2LA??8QKSVK7K9LKT83DV!3)1W.7Y@X7G\
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MJ-6+1Q:DZO1]/H(6S3;U4XS>_V'NK:/:[-HU\5 HT!8I+>Y.BY86*0YML:9
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M[UU<W,VZF%4'1HY8!VTW6IKH(\-OO3Y4<2!B%4NQ/E?'ZATRC>L?Y[%G0G<
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MYQ.2;\4I[4ZZ B]G.IR6=E]R,P3G$K(SQ-7^-,-T^I).X+E"FQE2S+6>6AO
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M>O$9/(R.G6\<H_^0::73I:%$UY:>U2&@1(2-865=Q-(2<P#N=T9IRF#USZ\
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M0[#<(^R:; .&*)P!/<JXF9WL' >U&1,<HT)Z%X>6H<YM3[WI"&-%F?QR@&]
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MOR6Q&D*V=>I3"9+ZV4[P0&P+$[PN/E5^T@O(2&$.[)6$2#SU%FA$X<3R9V@
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MDS:8"\LV6.S[[I4$:P$?*T4=M%3.%/&'[*>.VI[^07^M:8ORW*]ME#V++IN
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MPB5JRKF8JIR:-H[&%Z<P]I+M)HK=W5;/PE=]C/6G^:Z,:3:AKS)1*778AIF
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MV=+C<GP8YP59E2X6R:].98O)VS?6:1L<^X1YOL,K2!*3LW+G@XT]V=,YR>R
MDY]_)#CZ&7Y8Z'N.G\B5<J?7AP+]Q3/D\J_OIU(W%K-I\25)</1+RL^*+?\@
MDC$H6S^_%&WR\8M8H-WC"9?&CSV'(=FVSGN42S>JYT2)ZPHM)QJ&R69\H"!,
MJMV"ANE]!AHH6;R'5=H>2$6T725GMLVYD(Y=O/O::>.B1(6)%@&F4@L3.#\D
M\UC+^S+43<3QA#][KXU_T.FSGE-(,)L:B=&SSQ B]ERZ/>GGFQLD6WQ!?)RE
M/DG &P[N/GZK]^&FIR&K_.UJ+C.'O3'Y7)QTSC=EB$","\KP0-_"@J-0,5*I
M&;W8G,\0.<EG;>H\FK1G.D\D^FYF&5VZTA:H:/:FVVLWS_1GK-<8;SN/2G8.
M,_7QQ3"XDPNHWSY6HP/8?AHFWVB6^BI&RCYZ="]"H::&?MSE77V<F^=+'DI
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M""A=$5"JTJ+R!P2$" A(C31ITCN$1$% NHB TD*1+D2ZU- 1 9&.]-Y+(BU
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MJ-?[YU'TS@1A##X^C*^#W[ZBLGZXS/[9@Y5;R>)<;[+2F1K(J<I+3%D,5XD
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M%B5:YG7EK[MT9'6?P!?]I^ZC/YD=NAB-=<>\2K[+TQP]0CA7AXBWE$AK@=-
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MVAGEC+1'>.T48(%@WP$<!1 N,"YK<?3!AP(XV<#DF''/-7P<ULIIJ,WA7^S
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MXZ'- ].@<ZM5&=[1<]&M!SRJ%SOC)R!5BZ\K.*QY*P.RB$\&N/'I+*_5S2@
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MHD V?G"A(\PKR*-=4$/CFR27<U'C^Z"J'>$?.$O&.7.\_>_1%&]>-DV/0@K
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MQ3*PQWCN3G?#&.L'PC.H5IE(Y43XB"1T?Z<]T2#;LB G+>T4(&$/.3+%BS/
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MC(PV/'+S4W!NJ8;L)JP;OQH8@:<9_CC;L]^Y[GZ' GB=8C>>2P%DE,%FP*2
M&'CM]5LL^D(W'>B(9RB :#[4=XODRTCB>>KW1VI*[]AP9&%TT6'UR#X?(TFT
M-B[0NCS <"J\'<RQ^FT'8E @(>-_</KYH8)33/87KSG!X<;](! .@7]M'7M?
M/PQS(7-^6!IW^!!M-T<!3' ;A+Y9-V$HG@PZGZ17<5<>,_$:]!:9+FG@U&/2
MI:UY(.DV@2R*/T6N=Y(,R9.7?D#H:*0 *HR"B<[^S"GFG3DS/]V2#M:_R@;0
M=9KAVCT"C;Z@%\,JL=::I='MB(:=Q: 10 '-Z/+$J-':3)B-4^P%!SW5MO1-
M*ULK#S4^4<]])"_G&S\M8_D/X_;#F7"!GQ>/QWX9P:8@[A<XZQHR88K.L74
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M#2JS_R_VW@.HZ6[K%XXB(A:B B(U""@* BI-:E0$!,30.T0%I8-(KU%1.D1
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MVLDG-7JBN[2E)J[WEC;89BU1^4GQV>I<4!-3=0+*/^Q2R.:#G#ML[.H>_%\
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M6@*4D85"JS<H_3Y%:"G)X5281_1S&D K8N:IW9JXU>7XJ( FB*(?UIV Q]O
M3C=PSFKQ2F!^PIIU2\R[GE*%' L51TIR3M5)PQ7<$X1?-"TM&1LS6-U,*O=V
M7CS8P%I%WG&S[9??:$F!\U)[P1S"A-+0_,Y\<T<:P+;Z3>^C>\5/=1ANGI1_
MQUB]PV,X2N',52'ZMW-P281ZK&FU'-B^62W=UA9;T\7;C]T0BGW:QMNF[D29
MVB'R?9K5-E<K;ZSX,KB^6H(T[JH-F7I^_Y,O[IMB%"MV<&"@5?Z'7X5\T3(6
MH_^6,69K36*!GP' U/."B8<+-JH7/7CY&0UP!CU)BORPC1@3F&Z9=B8,;40V
M7,[ST3>M']C[:I+5)/8]A%]#ZB3,8[2#G)%ZCG*;#X^7X/8!?DL_0N(H)B$P
MR>F-):.+.I/V;3W;YBTI)[\ VR#=P>T.I#V3X4K@V>G.P"*HA8-LW LLAUY%
MC-M/%^&,@P%7:?-)36X[EPUQ\:>5$)$3\PEI3R'K&<*_^)KK?KW>_9+/B0XA
M6[H82[BO1(O.=CF@CP4)40Q@+(O5?$(U1(-[TVO#D2^K.OKNO5;#Q;_M6.N\
M4M?+9&?V]AHA$=.<SM!'49V!GC51=9M5,L-#-"!I@J!*WS@:H$OPXG7#0+6^
M5#?"A%_EMIE3\DNKB2L(P7"KOF=/6&\#CE_[&?NZY_:WXC%8E/2:L&;-P'7/
MDGN]CVIH '-[QH$<U_1:G3L+2Q9#MZH&=!(J*6+/]CPXKNWTO@T0\8"%R ^U
M-Z//V*>+H6%<%DM[>I:F[3Y=^:(WP@"3YY*>3+9/"4\U7B!_"[I83JHDWEON
MU:@,;>%Z#L]-4_[>]4!K]S4O)$W(Z--1M0[=V $J8_ F7;^CQZ"O B3<,QW2
M6:JP3Y-G'HEGHI+;9F+ 7AOGNO*9?BF^=#S53@-P4E3QR'#C*2FMI)\["J]B
M6^J<D!RQYS-459T6+NJFIFLH>I7*)LV*&,0U)@4=(,&77M8C+$GQVH2%4$^)
ML+I?Z+=K@D.?*;R.!5J.1?9NJJ"QEI(J-]?$T=2CQH>I?#LJ&/F@!#PD'%J^
M6U^P:&;2@)5*:1^TKO[Z )<6:R(J]=BY8XXJ3;1LCY!.*=R83S%")9KOC'L+
M3M3*GI1G9@EZK+3$3U0K=]B%L" #64<*S8UB?@U^RR]007P .2S'&.NJ31S0
M(\AJRKE-Q!.50HU9B5%XL[SGT+LRPABI9'O289F;'F'>*V=UOP3;?_Y Y#1B
MS1^K@H>>LK34(CK>)\J^]DACPDU%9FLI!Q=C\H48;;6S@.(PO$1BK](='EM$
MJ!A%NWAL2=;/0CYWSLQSW+6F0F-$5?)TP(_:)B7YX)\&U5,WL)7:?&=$MLP&
MQ;<[P$.FW1YKYZWSV%+=M@NI784P+Z\A="L8G?%RUW9XFE>ZV!PTQMK,QUA&
M<(&[9S%O'][SY]9Z\+0&G?2$\6'4G2:]XP.O-".\UY[A+JZC6"=6O/I4;(\C
M2L*T4<6X7P,2V1,G-C-CC^;TQ=2>'&500)F1-LEF@]):OQH;T'7U#3J9+L*?
MTN]PK+]J68"76& #GB%)61<%AJ4;50PCCH3%;2[]8FZ[?=IOF-AE^\@@ES-
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M_,SM,1K]:Q7ST?GG/YTV[0JN>,RSW?KBT.AS[G$DN[/A1E5SN7(U<6%U'*<
MCTH_.1R@D&V_EF,&';>?$NP3K-8]R2EP7O7:0VM')@ 1R[?3Z<.]Z]Y'%0L
M$Y]%)Z2G9$^:DZ;LS(WLV#0<GX;.1[,H?3N5:H,]DDT=34H&M3NKMR?6"04_
M&/R<4=[0Q[4A !&1OO^"[%9SHV/?3Y)EIW4%6L'@ #VMJ(T3#;SE*.>)/"=3
MXWI^Y:W>2P'1ZE0>]_1OLPV+.+==W7JRC#>9BC-3I0'&3K9-N899XQ:"&TZ,
MF9$"4G2J=I]::ND\SOB4^TSO!V?08_G'P1-'!J@=:)8&#ACQWK0:<3TE$!P^
M92I01=C921PY=_^XRG4<P2]PJ%V/111."B<_L"(-0YA7JF2P9DQPJ4A(F:7C
MKK>/;-D:_TW+6J.YK?@]>*5U@!@)5^ CC!=+:N'U=0F %*C,^U(#>T:%)YG#
MSL_QO8J9;A;M]W [WRSO55X=Z+HR&M/3'DB W2$LA%!!%"-2<)&/*X0HW1NZ
M7K*ZZK&FX6TND?;B;!GDL;K+C4#'JA0<\'>N%NI@8IU7R9EF>[^,+_7]#0JN
M9^,XXEYX"WV>%%0[AJ_A]VKUV:!;YV2ZUX.\2/)NY0.E6!"0X7,Q_BG^YH@K
M/CDQ*@*WJN060.\/] /NDN]HS(+A8ZXMOMM(\7%(;;5CX!4YU-R-5Q=ND)9?
M//+:N?(E$<0J$C^4:XOM- W<.Z60BFT7$QE0(77BE<"0JHCOS5BCF@AN'S81
MM8@Y1AWYTUZ\HF&EH;.RD4QPQ<!9X#FQLJ_:1KOF92X]/.V-X6/F#+=[<]V'
MUG_J15\MW'@ZW 2MMF*E 6*AZG_D?V\Q^]-^:@#\_)K6PL'%P45'755VPOQ?
MBD LR/YYHQ1530.\B8-U6A V#E\;TP#J75 AX^5:=7(T6*54@9%-UZI)=1)D
M,=B@Y+U;(DY=>%3;IKBBD7RE/>_NDO%VM']+DM4EM8%*)8V=E-T+60]<;+;R
MQ.^]%4M-C?^)T,0@C0X3N8:"E'RLU^Y)=O>.4J;K=Q'E6G-!RBX_K%&BZ6@Q
M^9>%75[OT[$WD=>I J3G;8%J6MU6_</+.]O>=3'[$=UN?(990N#N5_+IHJ)6
M\:WTJ=SA#) KM'(P4QI&2"0/"RQ]4!',4 @9_O:T9! T*[V>SD&"XY"G@WI1
M/%^'*Z)!+0<(RF59X!6$OU]?E]T)$&J<^WC;7<XG$3OCAX[?N*9C&IP+1RU\
MO(V'GA//9%LV_FI-4;^27!4;PBS4@DR\>.-YY,)%Y#G\,VV4@YDC22I\?AT>
MC#5"/<@*=W4YYJ:UT/;&:"R.)V#&-F0F //3(+FML= G8LYBN>[=<.Z+(C8M
M;TG-)O4[I_@0N8%0G"M'@-SO"FU&=M4R4UR61ZE[1LZ&\S&<\V\O;Y<\+]>*
M[N([&3C#(%%IT&?\$!I.!=$ ;XD4YL.\NN<YSAP:9'#2;NK\H&4"V+8-N+[I
M/@"31F,_C^\&T@"G:("D.9XI]2X"*=NDJE^H/VO(]6G_G%!CG,7M=^6#'WKD
M.M?,9.K@D>(-DB\(ELN]N$/%$\]&I1#/0W_</N$[)GMNSW\+:CF^9&:4SQ&S
M+B4FBF&>+08#E\;S:QVO.0\3?BQ;OH*6MU_COJN[.7?R!W$Z7.H!BI-B\),B
M 0Z)VPE)\2PP-Z\X>B$54T4LJ09]%&5LPV NM NGHBO8TK(A111GY"Q/^W?4
M]6HB.,0S34L=^PM5-0CJXAC&LI9S-!=?H0$^KG\348/P&-153(D,-BCDK8R]
MVSE<3^#%F)I-='OTASU3-;JJ[!K[YFMZPDYHF.*SF310Z_4#CW36^AARVW 5
MEE6;M^2;I=QG_O/L8N_+-DZ?BGDKRS_?D-1R;NEL@#1IZ SRO8<)Q=RE[M+K
M8)7ZGAI0G5P3WQTEH#9J*%?1'"&&<T;S'M'J(!;W7G0<>]=75SN\<RHR,71U
MWMXEY_E-OK)X1)W;GB._7I_56$3,]U;ZFFEP!%J.8$3/O?<1IGZK^DN9UABT
MK?(I6"<_ 7+XVNDO55K;W(2;($.?#$9Y<]ETH2?=_TCICM"D"![F-#!F4JX.
M-!S!TP!'>V>UQ7MFS1/2.0W#;+V<WEY^<>?I+;Y&_;;DO=45(@W0C&+_2=>>
M&VB"A15WR ,ILFF6S;G/;VX8CJD^'ME,RDFOE=Z"-$-'L]L17!7C:>J89 _P
MZ!?P!U<)X7-J/8#OR)=W!#/:I=M\T+B%L(93LYT-TB7V^F,K;E^1HP"6WOKU
M#R*/9NY>''-<R'_;/%@Z*5\J:;9( ZC9?B\U)67B+"6;E!6&/+2YS2);S"R+
M^8/U@UTZA[*-;S<)OFGU 3<[)A;7#;\K(#D:(+2'G/('*D]X?7(NU<G.,[C1
M(5CW1?$@(M=J#?SZRL:\W7]^X73ZORZ<:D9<1?;$O/B[FO7_73HB2K<@=KVC
MWLW3%6JAOY9/2$V?'<^[OE/ >JM]<-4-D<82M+2#/]Z8G<ONL:SYX4/&:KL_
M*!QZ4?D8:6'7DWA+M=1,VRY2QLFS6,95X&6^2%^'\LIC6WO,:6-T !/=D,)]
MX$U>!'L^<$5\JYF-K<.RSA?S16S?UWM=,:,8SRZN0P$B1X@'DL-NS\RH.M]\
M.=GY^UKR\/*-17S5W8U#QUE$-)3PL%'2I+9F$,6]O)*M=>FZ1Z!NLM9CMWXY
M@/BK@[.3?C$)VSKM3XAN!D1'J_GOFF8/#E)P26M'9H"1?6I3'$2QM,,N<?S3
M[E\62)[Y*QBW5=$^6>-9#KCR48H&Z>Z+YT2F$&FQ:\[C+]#O CKN\H2PJFE2
MT;&ED4WH*F&Z;!@^VUOC'<D%^@R=@\V3A8 %S@2-A9%!R#5]BT%A#PG;D<.4
M;G''+17,-,% @M=,O=J$4!I<&/O-45^ZG$\^M3SJ$$ 1S:^DBZ+0<M]V#03,
M!"*2N@;'09\MW2U<15K%LDF1HQV')W(HHEMY9.K)I%GF3#?;&6T99K?-BKW-
M!]G31SCVL1])&.I))F)PJZ;>N&$98>YTKID27[=!ZM[T-2^FPV%>;8-;J0_3
MDLLTHSX=9,\"6>V5V?M_#7JF:6(UOT1N3$P]+./?G7@D";T:8$M'$N4#:5;V
M0LR8NY*TI&^<(#ME9GV-KF-YQ/70LWD&5KFT3_8L\EG!JX>=<Q$>;K NVBKC
MS*WS/!:U9N7UYLXB8!850J(OL\=6B-/1QXQ18LD2QY=RX!-=X4C>0*]K8PTP
MW_(U2V(78<2P.SR-@B[1-KRM8EJ.H3@3!=NA%4Q1_/$F]0W$X\5NPDFV3US>
MYOC#)R(N\[ P_>HM"8PFWZ!^L\_3>#8+#W^?LZ<5[DQ1>-\16E8#;O%?9>*5
M3%<-E"2X[[H1P-_&C\$QR7IT[64;E2GV#!?/V^G"OPID.]*NN7U8V1O1S9.]
M^J4K42#-V\7$+D252X6K+>(<VY/?J7+>Y&9%$%CN_)M'@N%4.VQ3B!1,;=H#
M'8@5$V^AG2C>-(  ) R\"G*C ;+&T*RBZ[=='1 2@U,?Z:[$;E[3ORC3^T]D
M"<),AR8OM$JPCY+\,</.O@46LGT"=]06O%:SE6#7XVXA@)0C)91'1$-X:,4I
MM?I!\8FKWQ2L+:+[Y5:+6#3 [X**J+WH\O5W!/KB8/WTPH9)C0[V(#L#J #S
M\!-(#R8J)A.V%'LN7GS9;MJ8]/2RN![L%>R(A\0KU#EM26U(I4/\J[V#U C%
MKG F5QO.2\9?5N(TE+/57>Q6H!\'"^4'W%/J;:77+ZU!E?_T2K3787]K=Y-N
MF)RPZ)7YOV2/]YP!3Q72 .%!UC&+E(JL"-&=K=_)5P#_*6F2O7>E#]^K[HU0
M?/$IH D;K=PECFM[)$;;6(CK>N%!^A#3JBN9O[2BRDJ)V)CG=.OR@-2G#W"%
MBZ)2V2!O<O%T(1XY?3)3C0E@W&++B2(%*.S ,J,6^DX6<;RZ<6U0%WK^\1][
MY#[5:PDTP!4L'G:  U(_J$+CV0]Z_QK7C?\MKL/.H52#@C&(]2T:@&,Q)L+_
MIEU6Q %&YU\I"'(<R4P#=""S:0!L*OC@*'96+&C21XNJZ@RB-N#H!IHQP/B\
M,^2?_$P)"ML'>H@X\7=>)78,1M"#GX *AS>(SGJ^FW[DKS8P]?A6H4"]?/"B
MJ6D98CV9]!6MWSF7^R;?)=1"YBX],*W0,3@(RG3/6;Z '797:IRL*):2O(01
M+)SX#"S@#S)D9)-*+C_J?.\@4%^GMK'.[7+WCQ*I4K:KSY]?;SGRK5,XX\!
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M9GJ?U+5@VXXFK$&/TU>4H5*J#@U 9(-A*G^?GU,QJM^G+ULMQB,&NH?%T30
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MQ7K3V$M^!D&M-Y''DNYO_3AJ; AFHJK;DIVHP[TS/N**3#/CDRC^3R>7Y:.
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M//7"THJ_4GHB+":_U>KJL'3OQ:!V*',>D;%[8+)KMH8_8FTB//GL@,AMEUK
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M:3U_MQ).H8[3 --#OVOP5GZ&+>Q.4ZE($A9GR0;[W?K_@\:&_]08^;]IS%U
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M_63!;0!7*@$<B6!Q1X=#\UGDNP_%HVECHCN@RO2Z"=*%5G\ZP,\5<Y3?(KZ
MH*0@N\%'YQP@AVI.9K7Q!N#*P?<M=W0_X3*R9WMW4<MI_H9C*. :ET-!:Z#
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M(]24;99EF<TV.36*I15&,:6-ZR*3> SZMXM8$IGEXU8PJ105*L+_2<X@\>N
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M_]J-$*3C8T>YIR\#5[T:[BT[)/2#FMW&*4UF\%)=2KD(K3]_89 _ RT O.8
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MYJ8VG>G] 6?003DR_T:]QJBP@][8HP/$!G%LAP=5=,#P>V163HS-XV+%0CZ
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MQS2[X<RAIY@$D+S>'M5ZXUBCZ1)9@<!AD!OU1X[=Q<E'ZZD'8Y%UC^0<JFW
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MI8EP&QT $1FE_2@HWZ32?'T=_39#D60W$[(\8<R+8"&5.T'^I:)7IMC+_RM
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M;8*^L$:J^@.PZ8!3GG1 Q#&>_J"[+<^2'5#  N,LR%8QD\ANMMD:_&?6\J)
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M7H<--2?OV0%2-*A/D%VNO^'!3/SM722"QC?G'0^-H*F17=4;\'K2)Y<[6 (
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M'>V1-N?J(&ACWN;X_,"W%Q<ODF+3- X4]28F*\J6N?.V*$W;/8.?I?V$EV[
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MU5O%0)\J=GCHKZ 31SM?G+JTP'% Q/$FLSI[1_>[0?]ZY*A\\\Y6[)*Z[-0
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M8<3PAK7%<='*B^3H!N7TN,M&ZD^.B>ITR6AI_A1\ 9<>0]8;R@X2M#TG#1R
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M<3_5-Y%<"+2:W-+@#-J!DC^#D QP?4KS8_X8U82(CG1Z/3)F=W5 _.[[BRV
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MM8=O;P9[O$C8^,#Y(+WZT!3Y,4Y?TS(R#;4J$XO<T,0DA)):FY.A"RL?2NE
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M5Y>D3N[7"#'0-R%!S*RK!B=!LEU-M"Y@1;=G[ZJ=0BU1J_WYIHEH\R^E^*]
M'_V[Z?4#@DRO,7*E@:5,['W!F_M$CO@:WE[:?,E8!-/J-O@XT%]A+;P_J];.
MP",$>OZ<9*VN';']">(A.'&34(K9B)M)=Z=?LC*Z8*W0XLU2_TW:5A#;*).S
MT&PTJ5=0Y9FAA"\(WR(ISAT,C&\N7:< 8>]8<J[DZ\\WUDM<DO(\/WXKYJ?Z
MD\'3-(05128AY"9&$,6 UWNY$UW;()X+NC\HK4)*G&L<?/A0:E?ZTI2!*<^M
MB=[Z[X]Y=G_Z,]!%?0<7\+ZS^9FS4*&5<?OP^+PUF, VNB)W8&H;6?T@V+&>
MM<GA%D<(Q$Q5@88@XOTAK8G0 '+/1.#UHG=8]%IM96)P@=QMB'$F#^>GGMZ%
M$]]%F(7\?2(-'..2KJQU<>IU9M*C:$M)F@0!H9/XQ8@G_@7+R(!JJXI)U\.C
M]*)-_SSV^V+0]743_[;'+ !*9IC):MH!"C+A,89X[',%::=>O=H4.WS?\$-%
MO>2-*F.8?C>CL'5?U\*9YODE0?0X>&[[S/'O_<4>5YU,?G8^TF<@9)TL17R&
M,V#G$T%Y<O-(YJ$8$C]6O"\^LT]*0-.C?_(-4H"KI8#WSK]+3>,SS4B6\:N?
MA4:R4(#GF-R:VK=T::/=O^_6FAC0##9=>J0G(DYG-<0%K^KJVN):.3M]%7S"
MV/#J@?)>G<[@G C-:Z[Q$[NJ EX%05T40$B#-YND'M<B/V7C9]<I]3LPQ7JH
M9,30-?7M)X; MBSU1]\;Z2'"5B5K0F?!KS-;X0@N16-.-]NGFLF9Q[LB=HVX
M)-KUSADKA*FJ GIMH4.W,Y!S<L,Y%S;EWW_&Y!VN/1P_6C0+R,R LBE0 ';7
M)J61,X2 6WHXR_2>)KM\%O%484BR\-RKYAFA&2MUVR Q JQP3OKQELT()F_(
MVS"?17.HG>OQ:8EE!AW@D?K)[QA,?EJ(T8/_P7.O#11@+X0")' 3F,C-W-.'
M9];Z)'LI@(OLP1GT*>PZ#57F>R&LFFIO^\U"[CS=JK,[60S#1T+]BBQF/2-:
M+>*I9^_6?F%N9M?$NX4A_9S)NM*2Y"8<=9@.(%"98#[3VPP-;;J8V:9&;IS;
M'\J*4K4OR:[P^[C*<SM)8.;0"DH0F6&(\*( Q\&G74UT!,ZI^IE)LR.OE9PA
M838'F^O&DRA4@8HF@X!W#_+/GYQD64@\0TT*;AQ@=R?L3/_N2'4-^[CKH=N/
M4Z9\86?*AUY:O49=!EMF,. 5#6E\VVQC_@<OID![1?Y)8YN?XI_?? 2.FP:K
MPE]E0>#@$9Z*0^&=D%.@H4':YF&7D9V/39E/9>U3O[R['9=YCO<^#+;*U&9.
ME&/K'.#D3W=+#%9+W$ \]OM\$^L:-VXH+(""?181R2;W5!TAN^!W=VPTC D<
MCT/CZ%:=XS,/%GX ?HJE83_FSDY,&*GK3YS2#8M6D@\&UN*NK5KIX-O1S)L>
MSHU#.822@#?/'C"K5!%EF@TKW*G<@%_DX>:DY'03#TF_"30@\G_%2?.I>XU2
M*45/SZH?ESG-T]L]WTYT;D1V)\ C1X(^X]SUNJ#EV!>H*R77:]1**4!L@NOB
M"6XI]Y0LVF! @/5-%N2M^T[T6IR"SGW/\\^=C.+E?D*T?CV"5=U$KLN.A^XE
M$)S;$#'*:=RA!:&7*S_&CB![+XPHJ3W?\C@=MB 6=)LM7BZ^U>HR]B1*LC1H
M($TORFE F,]H*90A5KQO&.VS+WP[_SOT=3DD6%5X+PL2E3<H*[UAAK,SP-4D
M;GXG?+3L%6$0R@BOQS*1H/4$[E8X%[ALK_!H^8F=75Y:JTT9GPVG(7WOR:R,
MX)W#40SJ[%%!PWV".*XI=1;+W>U:!MJU^XH8U_7?JXRY':O*VN?8_"O/@"$A
M(."W?6-F5(,!OF &VMD(T1N9MVX0QYVH;)0Q/_V@WZZQAT< (Y84^^3MO;DJ
M489.+I\GT[=.N&<EX"Q7!*[9Q/71I(G7)(\X,O=KF!6VQ.I<:/OYTEEQ#]$&
M99GTX]][@)_"S!J?]D.T.)PC2'\?F$*F'7TWN=[7N6#)8],R<XJQ>6M34G;N
M=(!S9!,?Z&A.X(XFB>#B(@]]JEBP$PI,H%C::L<;QQ\6G;C2Y0;G7X.T"Q)>
MZ6O/9).</<43Y,]]>;,^!WY4(2%+0'E\Z](<0[NT>AO7*++@Z$/YTX*7M3$W
M#3F"]43/KP;@FI*/LN$NQMPDN:.LI3Z4K"<RSU7.$"G=\<E6MW7;0$1K0Y+S
MEP&=+-VC]W6RS.5XR,9ND4L=_:2\_L@=N^AN%<?+L9V#/U1XOI'QR3/[U"!
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MZQB]P4)D[W4:R'H.47P%#7B)#571<.7,V?TD^/H'6X[=@"0RKJOP>N!$!H%
MELM0#G2+ 7:NMWEZ=V#M0 _!8O4+BS?S '_CE8^\ZLBFHVT6@-6O($;\!S"&
MR.="9GU&,[15ZH%9CZ6?4ZP:4#$E;]?+SB%8K<I _KUW!$3;&N*$W4IU@%W'
M;&9U8$IOE/D2T[,(&T_A+W3'E#:6U?H8^J>KN,.R"7K!9'Z00VL;IY1Q)J(M
MWB#NM=I$$1=\,UF5 GB-QB&AU*T>O-M.R'\Q4XJV^TSP#9U-P(%N\5>E9=FY
M&56?7PC7*D%'OB7L8M1'FN!^F;8#Z]*B7(\,G7&,#88L\Q*X.[XB*:()"S[A
M&IX9#(KU.(_QB%NC7H%N4]UMAY"(7<U K36UIM2'*YX!-%_I4LYH/ZEWF4^\
M++2&KYE->48^33(C.(?M'!G;8@FQZ;-(S 9#7:SLQR\./)//K?E?E^T2V_>+
MID^0U.\H1U, Y_Q1#YE=B<7^S3(%HF64[ 7&X1:31\%)@/QC@U_<] T)'A.T
M[=*!GL40)A!)9I?<4*W\H6V#M$$1:Z_1T>%,.(-I500V;N&!,F?MHYP&@RPW
M(=K&FO*!# 3]A"'R]B>=\S:6US<OX6[H?R7FN=".-8EV%*+NXHTCR1TX:=UM
MIFFA<9?JZL-<$XE?_9%M\F<?TEA_Y(%[,8<@OP>)H63!F[-VI59MMN@7)*T,
M^0&9G,J4C62D8BDQF4G\57G9_ 5C_I]+/%MI<SG@+(X?<7+*Q;)_;$+G"48V
MLN.7/LZO+$5=2W#!)[3W@C%MVGH5?'RMW8H>MV6,7XKP"@PX=)%1E+X[TO]R
M'\,4;M3RIBC$XN&XZEX6:UOG]*?>T!UT>-ITU(/[!)]W1V%BQ9,RU<E?1E\9
MG,UYDPT8, 'MF-2,-_L8@Y$&CEE[D;F>I%P0YJ[=EN()GG.]QX6?>(,*9;HT
M<TF@?F&_?)<'\XZ$()JM3DGTH^SR=68]("NNN+R8*KMHER5YPPL7[YRMN.:S
M#=N4^_K>8QR+((_T5[W&D\,5&^&Z@:R&>[%W1TT4[EZ\Q<CP/4OHS7QF'N#F
M9S5C'*R /0[RFQ 6/Y=-K#8I^?+=LY7RY'$782TO2?0PN\7>W1K?HEA3%-0=
M=!)$SAXH0H20 ?.?VG &"ES1VM9Z;^LYY^)1'>HP2^:QR96M6Q JUW0MM6IM
MXNE70%( EF68N#'DR^!RBFTENT(UN]Q7X>+@;ZRL(X*7=SA?X##C_!T.\OCF
M?F]/9Q]X#13QM#.F?>M1\['<K8F%8/K3LG=Z)&CEYY;:>& 0DN6HAJ3KTW/9
MSD[]E=P<$E9R#6ZK/*R7:&_/E:F=_)V_99_28?S"-K.CEQ\!YEC55%9C&ZR'
MY\JMK,/;+7B8OP=(K 8B8Q[NT##Y8JR.WE( IR/T7CC!Y5,YY$[6^$=W/<M[
MW[1RCSK(.R_EPWH+\\F]V(K>R#^XG$7^NF7%@/NWINQB UXYNVR19T<K)WJX
M->/N($JG68+X7>",)*CC+(;5IC0_TZVVURJI=RI^ GR380";_"A!,\T:)+ ,
M/8D2NS_;R_(S+S;=K>$X+:HD:"=VNOU[0"*I')&,J(P@I6"$*,#/NW,40%OQ
M< ,1#_^/;0HTBW_>AXB8F56) 8:.E=,3$6%EYC_L^_(?SXE<T/RRLXOI4R'=
MP+)Q_3;$ZU;,'NGINY\O[6T3?&I,9,9S1CJ[3B0TAXS1T@HO-0:A)GYU.WMS
MMK,ZIIVSTA/49CZE5RML5:^\\0(36&;DBCH_^YJ0FTP![GMPE.9$OT]72NX\
MJO]&J(>& =ZV*6U0QC4*4%'3IJFN7UG_B6 <J=AVKT8F_D[9RY#S=#]B.D6/
M5]_>^[IEK;:T3@'P%, RNHM//!1UI<S>KZVE>M!^F@*X:9^J;(BE9WQTYV1V
M(I)M_T7OVJWC*5VE3EVS4^]F/3Y:=\ND%*'=5NK:)(^*!AR%?2[XNB]$>&\&
MEI?CXL83;XWN!/I,];:-TS\K\GNFT8BT'I2>E/%X+?#*X"ZWKWIUW)O$R]QD
M*908> ?_'1G$]9D@4Y<!'Y ^FS2?/ F]45?K,J)-=\<\@+T,YO2 F6]W.A9-
MO_,#.>L1 3L#AN"(1!$]?$Q8"9>:OJG&J-0-WK&DD*O*S.7FHQ.9[ 3E#:,R
MOQSMX3.U^*T('(&^]+9"HUY[O&W-Q$/WD+"?!N[9D3>/!R^Y['!:D?G2.YR0
MGIKAB=X%^<$:JK!4!7-^9/&=MPK1BTO?Z8X6[EP6DIITC3$S[&8'@(Q0E4,+
M=\./;(I7AR4MC*Z?L,U.W!PJ0:ZC?_;NR7D(?76>RQ08/XT?S[S4=OWUJ=%V
M1W85"I!A(P#!40#?#W29Y<[KMS5<1H(T"<,97L=A3N]RO^?R5S.\N ?]_9VM
MF2Q;@.C_,F=M:GKZ[(?6HI> YG'1B[ELN9Y%N2['BCXT UZ 1>6_#AS,PZMJ
M2.D%,11@K1^^\]AJ_BCH8]#(]/;##"KXPURE /U?$8D[@!66_#U#"H]M+85T
M.BB/%H1OF1AZ#^P<\?%716U[* 8G]04NW#3#7H1.88!<-^!PU!H,P^_C9(/)
M4,0*!AJVA>+&\5N+#.ZZZ]RO?<J=IN1L^="&LYR\K+MQBP)T98X7M#/-87A=
M81RU?3/]99,;5E8#&R+*W!>3>,_-"%0_]F>HX?RM[95/!8+F./2X%B(">S*(
MPP8T;5 M6O6I,P\LW2S-J:\M3[6Y]D'U^[WY##VW/'Q!A](T)XR#9#/88#YG
M#]4ER+Z07=_D6K)OT*=+9Y2Z3%X&9&EC)1?I/Z0%:]ZO1#"A((2PAK15$(U;
M3/>^+\Q5!ROI[Z!+'V4>N)#Y!IB6@4<UMLUB7Y+8YK9840I-]A[Z>%$AFE$,
M9M/+_=IR,E%JD+?O<KN368/X]278&/BU?NB2"<.O.MEV# /J+H)^C1TL-L1C
M26<R+@PI(HOM'1 7#*,-ROB\$LZ0C$).?UA2W>N-)9T!L]^O0JO?U;ST\#[A
M%0>YY3:Z?Q='-CUMFM-R*4?N+B"=M+:J6;SD?X%^[3*WAJF"KY#(\/T7(_JY
M=4E)0_.<,OK"AVS6GWR+V6_ZJ_?1L5MMP2,HP#PM%;B/5B(. 4S+"\G]S#8*
ML$TSB%X;EST"3.C#_IE^,!.*-^T].#_%2P$^&E 7OQ<A:D7EAO^W1A,&>ZK%
MXT:CFSA_W3*<#7PX=XUX6<C+<\-EOO.1#0];?&*/^E O(:=SV^_35OL63OVS
MXD2Q4T4R8:^"Q_H)#]UM64&@3"8*6"4+D6P('JWUQ:DDV=);KKHK6CWQ&_<2
M><=MK#E%[_V.77P!DP$[JC8<;0.#-HW,K:N1ZFN%)RN,F  ^^?C6&9I@=2LQ
M(RI+4IB.RI#L=V^ 'X^M4&RPI1NXY1I5]-S.0%RF>WL7MFM,YJ  I]YQVPS
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M#[1TM0 4%!2 >?(?@+0"N*X9[.8, .CK \0    M@.+E.\ %\B<*P+\=I#F
M!H#RPH6_7N2#BORBIJ6FIJ*BIJ.AN4C+0,? 0$]'3\]X^>H5QLO,E^GIK[!?
M869A96-C8V#BX&1GY;S*RL;ZUT4H*,F_H:*^1$U]B961GI'U?_D@?0,PTU*)
M4]M14EP'7&"FH&2F('4#@.2Q4E/\[?C[D"DND,=XD8;V$AT]N4/]%< %"DK*
M"U24?XV:?#:<?!Y Q4Q]]=IM]8LLAG8TU_U892)3\VD%[U5WL!F-H(1D[9^]
MO$3'SL')Q7WCIK"(J)B<O(+B'25EC?N:6MHZN@^,34S-S"TLK1P<G9Q=7-W<
M_0,"GP<%AX1&O8J.B8U['9^6_C8C,^O=^^R"PD]%Q26?2\MJ:NOJ&QJ_-C5W
M=G7W]/;U#WP?'1N?F)R:GIE=65U;_[VQN;6]@SX\.C[!G&+/SO_2BP) 2?'W
MX[^K%S-9KPM45)14-'_I17$AZ*\.S%34UVY?O*IN2&/GQW)=)I*6]5YJ?G7'
M)4%9(Q2;_;,1.G8AN94;Z+]4^YMF_S[%7OYO:?9?%/NO>LT"&"@IR,ZC9 :
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MAQM'#IRJ3NYQ(L0"78PM9?=\L<J<INZ&7UHT)5G-M%T--5D!?\E;+]:ZQS3
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MN"]W9S]=?J_V\@39*+SWD"@[[AT!Q)H=<#/FYLBK]$.N'YJ"=]ZF+-]3VF2
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M6'=S%[<IY1B->R.*P#U^LN!EF6#^SL^&-M6O'&I SXI"Z^5SJU@--2U?_'O
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MZ96/5&I'7 >#BTO0Y_L/*V.R6"E5U;JCAZ< EV'<ZR>P>)#0)%OJ"4=C(@E
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MWEL1F8RBPF[I.\35D0T"VU,;G0B*8F>/+R/^_9G("IS:XIQ =G]FH>E"S07
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M%QS#>Z.Y#&:\%QP.!8*DG!J%NT0B%1^G,&1JO_AB?+1(,E^Q= 'H4I3GA,7
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M+=]FG2/_C9+T?!J\0ZZE(W%3[]=_6\O=H?G^[U:U_\<N@X=/WZG) J1_"=^
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M\\%&Q5\M/]0?1>W\]^)J$F>6T:YY1AC<?#=]_B',K<+BX> )KXN.ZWU+24?
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M+S*A4ATYU#W-"I(TLC7$H*/7$E2>E$J2;!M;\F'M$6 V<T5P=)!$@;->M_B
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MK;_KV5^='_'(O/[V6N>8G7P5Q)8RP'T@7]ABDPX538P(.QBM/Q&:I^P,,(\
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M.(;(V-'T7"YC^7SW0*5Q&W;Z@VLWRTII/#K"FR$MRXPGBN,+I]@/"H 3J[#
M?=YNN+ZXOTB6J_@R=2$I_,E5!FS$8'5!1Z?Q0'+5%&+EUG#]#U-U>YXX-N[K
M+&E*35HS7L.3T']WQ[UC<0WR(ABYY'L3A!?<*$9^9#^(SXE6YR+:MVP/+U$
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MIO=IW8V<$UT>W(F[D8691#K\/1SAX5 ^F6EJ;4SK0_&7T%R'[W$OJ\P[@P0
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MR(,#+,:O2]G%O\S2&K0I25KRQ>A0 #X D$N3(3Z6< ]OKX0#-L@AZ@\//<@
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M>/!)HDQAK*9R;$VH]9(-OVJJ<VR4.'W6BJ*+7IJTB$O^/J%Q\,/WU)#6OV=
MG9*XD-?3QO']I=L-A2V0,?$9/F76':O5Z,1HHQD$V2 I>;N>5FD'RK""'I1#
MWJ/&-$N.? E>*T+IY%[VP#XAP8&-_((OR0G^GJ;PBR''KX)RPSP?5A(C=$5C
M<R0/I1%X =%0OCZXD+TQC>3E,7324N"656 =E.B\2!+:LR^!BQ&%\)'9Q"NX
MDHB0N[#-+=%\FL"05?5'LSW9YTO\MI-K[J.^40"S\\@+F!6:60QAU_EW>&31
MW0ZA%[<9,OC3Q)N>9^EDW07U(NHCZC'2D+_=>>+O=WZG (+#?1Y0 -^ 013
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MV>#2(OL=0@^I#+(^XL\7& ?Y-A 1%T$^8O*- A_-@TD[5,QA!"42B(@9X$$
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M^T[W@(N',#K27+*(["$!."V#P'"L)?IZ=7^9QR[<;;3&6L0]>@OPP["U?BZ
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MO_8GESY/3KXN1L4 TVVM74N<DR7^:54MRB_VA>%LSR^AV<""#J&B;\V)6R*
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M4Y7/5;7-'CU(]AH/3DUW \WLPN1#-1;FH=V!>*U?)NBOHON1MD=-Q"LZ)\1
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M_IT/)("O W"BM#!:]N-O#N,67C(2(D.,GL+MA'JSL]_1I\)$%CTH,>P.\H0
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M)BW[>W98<_"2GND3K#I:#LCI<L7S1;"BO=[@E+QUGYIA&P]SO: /KQ9EQ9B
M%)G*]W[.7;DD:J<5H1E_WR[1TE7\/ W_8JBR6L%^^4Y.>$ZRRMB+G$5)UL\E
M@6V0B^,J@EB$-JKG'8_G=F/&\@)5NNJ[#&;=FYL RI.MM@%1;0VYA;9G!C8_
MEF'3Q-&EC;US]JC9;A61VN\U!,1L37<"8_OZ/<%>.LBFH)0VUQ&O>#39"/"R
MM$&99*UI.[/X8[HM9 M35EU05!=5L(FSW-H\MV^AH&\)XB(F;V<, DNB-ZYJ
M"&U;S#W[!^<E_*.+NIKX$UJ-:<+)8TN&PGZ.!=WV;W-1U%RDS*3^Q$7D8O7;
MEU=!PH#T*H).0+9F =ME_<O@?,PG[^9;B:UR@!=QDUAK[57@&CAL?(<,+!+V
M1)?UIR>[8P(+>B<;V?H3]GAYIRCK']]LT$?U4FORA2E=0:%/ [J$#;.2P._H
M[TP12O-D>X.DL85+0[%\C%5H8(3'2LOW3%5O.J4IP38A!0Z0>.QOAB(!_C!K
MZ&]8S <KL$3=+?9_'GM_A0)-3VI@IY0V), D-0GP2T]^GWI1XP0/F8-.:A(=
MOA0?P%<P*\3&.X>R5)#/P'!>\M<; PS MD'T6%TRW6."=,&9E<R+G=C3L@1&
M!Z9JQNP,[6/<#%)FAYX_DC\ \YN9#12#+<UGA7 Q[]A%QKX_-H\"V&70)2FF
MK^='&=O+I'6([ZMI^$"95-C( %6ES*/ OTHC6[.U/G(HFBLZ:5.;.\0P, Q9
MXPXF#H&89,I<.P,TD.'[9<?23"5R:6X'G('OOW$NOEBYI+70[;SG/(.?H3O\
M)CXM@YPZ6.$KX\7-^G,\]JE(S/D<V/7)?BGT/ F@0(UK.##VEIZ^L[SQ3@DD
M5?5LT?J1+F<_Q3IEM.;,2]^>G[S?->5M<G)W6*&9P<N-2JG1NW@@RK6G5674
MY\\)T5C?PR=UPX.S!]<U-\W"PD4>/$=0O[FXW,C ">F'L^(IEJ#8!S7("\BI
MK4M-J_5]"N^"[8R?]RI/T1DKCB6O>9K29IEK!(?@Y/'L*!*@2WJ*!%CVK25R
MQEB@P\M6,6?V'3U#+V/Y0Q(9Z7&9\-LVP)6#Z>1EOTX&^CB_KE;&YM'JA+3@
M">R:61WC!4*LK]U[E:>*T7WRWSPSOLRG^](>*;5&'[1RX:G1)SW7L_1I_!T.
MS>I":K4]FVS#+0%[MQ1HFQ+;E!$U!MA$5&0/B.:8Q@UOO81K83?_4"VI&,93
MW^/;F)07&Q]97]92=D=*0U)K]=61:8D_!\8<6XP6[]PJPP:V3Z8U/@GS-KVE
M]+(T=URIASNRGBTQ!T^!#5MFX';A8ZQ$M:Q@4SM BAMZR6Z>U^PN(V]R 6\=
M*7?KU^;[-J2&-K096$M'0JY@L[L7Y%081V1<8Y#,$I4=,P$ 7@O^'E5M>6[?
M.J.9UG)"%@GPC+O,J[WUSD30JQRD4$/A[-RL\Q7Y3^RBY??U:J83*W5^A-3Q
MVWFE#]:*I= L/)2V7?XY#-:&#((8XM-@>(UA)0-4S@Y"L2#-K4+;G2=1W-DS
MC-_Q^>#M#(9&_7D8/]85Y=<#Y3@HK$9%1NX?-TBVW5;BES#P:7-\SLH2-G8V
M+G%?6GPS!<[8T&-@/=DU%$)4Q"IB.GOX>)J&<QNN/TN_5WE_EUJ,]Z(5SJ'>
M8N96[/CR_@TRS6[[1XQ"+!CTN''XF-9UA_N=I+1DGOFS+'8Q=.-[XP\8_A R
M*HXH+VTC6!%BH&ZZT+A&*QM.]'VTI?_ZH(2XK<NVP;=#L83333*8#5;M43UK
MA&?O"9NT_)+5U=-]U)C:1YS02*>-XBSIV?;D!#[6@)02>Y"U&FD(R5O2E_V3
M'I0V>SD#5>4*<J(54I1YSJ4:["0B*%:J>%I&_@:([:_;;J>+BKJV\?\?'1,.
MXJ4&$H ?'$$"'*.A9%/1#LX</Q,@.QLK$N"]="?T# LG6XRGL,%M7"F,, $"
M_9RY2_9(-A5J_T4K>NZ?%27.G6C\$4.R@R0.:[#]OG\1_"=H794$</!#GT2"
MEIYB/7^"HKRC*HHZ.4_+]TRQ;_:'?P?K;)2SFDY_F#2XEO*41EFM#'6<'UGT
M[7[>J?50F^PQ;!@\!<14)EA55&$=EW>Z$PQKP=*:\/IDHHHMY_GY=T19(M
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M#)M<X!P0/AF&U_#P</8KF(M::9CF;;YY<(DKS;/:/>'S>\1^LHZ,N&?^(\G
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M:1)_$9V-L.&<@+!MVBB/2;I?K<==R'WM=JTZ7DLB/G9[)XF&DR]E0,E'7L?
MLLNJ%]L7?=#*%'01#4-(6E@RT#@=0#%!W#'%O,]# 0$>OO(_-M:XE/C$<[$_
M<$)X;2Q7H58Q-N%!O-[U**.BK<.+2W$)Y\!O^K-?Q0>[YB^+BHHHF%<@OZZ,
MF=;XVV(4L(4KO-2=%A.)7[5>%^R0 +)E'7.(MP^9[=*RYXL OQ>^V I5$&4A
M WQ*V/-N=FB'3#I?TU)#VAV%KE]5BTEO4>J V[UGWC(2&ERZB=I64@F2Y.'T
MY3]>2F7;!%$2J?VS5Q"Q5W\%*;B8JUWV@UY+I,H+GI]%R1O\*,I\,)H@,Y]$
M44A(4C) <W1".66ZL:_<Y7*AWCN\ZUG:[*.S^]S-*[%B(4G HKU-J.-7*5O#
M1?&5]X7\P++7?KLXW%VL+28 ]2' YAU-MN&G)]M7JDMP.PW47H0QGB4MBKG5
MR6^3';;HFUWCZZ&5^)]V^Y*L!C;.5_^Z&FK]EQF&##\*U+5_B5]]<H)$XUZ1
M -;<I^FA<+V$CO@W.=%B;W:5!%!^"#Z54?!C%#)<UMVE6_"F;'=<26](&V5L
MR-AYD.+G+B0%D1][5R?9:%*)JVS+(@@*V=[NN1_G^2II:C'8=0\ZA3GLFH'N
MZJ[T9U_([\H2B2?ZCDZ,7)4HL'Z_*+:XNJ+T=#*?V!=0UZ,,[23*0./9XS@B
MKHRZ@6=-AMNO<KZ2MP- #AP-5T9Y=]I+$HH?&0Y;2"W8(;U^?[QD<09?S-Z%
M+GG$@NB:-59*AKBTES*E'XX[AN0EL3D)5"?8?KHHK#"%X%D)>;P)K$!&$L7Q
MMLUD'M4)O2)7O)@IU\$]H-659B!>RB#T(/Q>"OTJW9$58'K5:_YX1K3ZJ';I
M9T)*$:PJCQ -X0G2&9']"&$(TO=@P>9JQ;;T? Z(9O94I'0O>?/HPL$GKY#$
MB>9^C"LA):''#BU7M>SN060"7L2Z"A@T)=VPI_]F/IK%X1*JK="CQ?>AHMK*
M"O9]/R'[E2[8V=\#(X*U1PMT$D71TB%$$>N==/9D5X$\S7[[GU[7;K.]5X3U
MMFMRBFR_RG"H3PA#5B9$'#.\S5V.[/;@Z%]$TECI/*^,'^$_N2-X\W&;^XM\
M\"7&)-8LJGL(@RIH0<ZZUL\/IB- 3I#=+/ \TI_!'(6,!BT)H1AB#KY6UHS?
MOWH]/,_-W7Y3V[K+>XV3\>Z97PSH&0D0#J5M]BET:I7%EO@4:I52QNC41/\*
M+C"G=9?\(Z9RPOCE^^I&XA/TF.&C$_A[+X'E,FG=YHD:<7<R%$OZC=G6B.;V
M?U+5N_N23<M3FU?L( I_O0P+L@KFMAPI/VHQETNM;'R79%!_'BYUNU>@[I7-
MX8K^] 1N$;1G3J;_%V;\0S4Y)DW\TGW+>,2$HA6$G,8_711OL)##R/-X@?7P
MXEB?PFGB_,)U,#OVFSZY/71'R_)'9Q]7QLI.[+QJZ!F?B6/> \0_<KU2O]GN
MA3!V#1\:&%#7;QR!Y5>UU*:.[+-/2[!<U=+D51?E8=H7:Q7?!<:!J\K2R.1A
MYM  A0Q1NB^KN_=H>1MGD[K,7.&T?]U],\"#8HV"5Y<^I0&XJX[ZW-78?1*J
M)(E^?0 1F!)X/>$U"YM>N ]4?$/-R;_AVF"S.$Z I$E8-9;L?2?7CI(!^#YQ
M*+O2"LFF(N5?UV8C!&] K><OX5Y?T;\F&]17^<U6D##"?3?RL1KLP7="1#,5
MF;*P.F>QH;*[-<;Q:FZ'EZ%V-%LN%4\5[E/R'-BKTO+@$4K/O_EORR#%;=>U
MNL=,)R#7")\@M. ME:MA'7#V<K=FW9PNN]2A;I.(/H6HN?/%B0)*BYYW;.,5
M8,DTLP@2P*8NUX8M9>472[V!!MO(C?\H_A'VE) .=9CWPL2B/WZO0MI^M7A_
MEEIJ>_VJ%:%[U^Y%ITKAEV]_0C]V=V#$81NY!.W1,/--S*I*;LDMYE3T&8/I
MB_YLKS>7(1WXFUC;I8.W*O25J,F(4O;^1[5<R@N.H  MCV7;V"1H*I7_IPCE
M9RN[BX2#WG<Z,]? D<#+1PSA*LR5*&3$KL#H4;]QF_%:GL=RXBPV,T$P?5LD
M'Q;MZ>D7^.F?21KP/ G0;@I:I44AB:W2), 1I_AA(_S^/XJ%]$DA 1H1&Z>?
MM9Z2;?R$R-_(19X"[#N1D3@ HE>B13GT+R-Z^G?J1GWXR_(W?0-3UDQ^W-/)
M'!R\L'C.F"+I]4I6C?\O[7Z3KOF$!"=8K<]!" EPOE4IZ/IDD"DJYPQ*LY/.
MS%$_*ONNK_2CH3'GW>_<'9FE<63:=-2&-<(I^C-@0@F?9>/4.QX/V:*-U![.
M6\K.-EJE4(4P90%2U,_%QQ?6>!$"LJ5OZ[DZKHKGKEJ(;Q],1V*<404U*$1W
M-DNK^,6]9N$"@6[G%\D?^9P9\;LT"B Y >/]KH2'1]D5L-TAU DFYH\>A2PO
M^&%3E=Q,0G)!*4<E0V77IKG:QH8X0G*2]0G",#0Y\'X0HKO:%!XD3LB< ,[,
MZF%-5YH4TJ>LK;H5.T43AN+<UU)%F2(UGA;-!2RW2"_!=OL7]5D@TUD*6)]@
M6V\BQXA[7M($99-/HGE0!O/B*@&#W\Z/S>?%@5<Y5.1R6C.Q0-PU773@"O6[
MG(]Z^4&*J/W"5Y?7O^R?\XXW.4_Y'((VZ/<V^+$:>[JQ)PCA,/.?V@+22DA=
M2'YJ<3?.<'U;.WPN+-1VSE]C(\,K>9;M5?>]?'U'-N@OZ5^_+<2((5^V^<0F
M)62"A29T]W3.[.MJ:V.X\Q*C+N7^?^R]9UB37;8_' 1%I020WH*"H" @(+T$
M]*$H B)B1(0HH#1I(CTD%"G2BX*"$ 6D"@'IB(0.@H!T"+U(+PDE!-+>^)QS
MYLP\,_.>^<^<<[WE.A\V'\*]U[[WNE?[[;WVVHG?)&I1Y95N8YZ&!"NB-*&E
ME2+'Y+/0;>E5&RYEF;NSA[4 Q(94C=J<^B8JB#66MWIJI,8JE[(A ]/5#10E
MBE)Z*0*$CWF^U>V9&E]K*["0L/?RDVU.-^HWV#/"9Q4JS4U.RQL".W()$T0-
MDBJ.L?&"UF68B%IL9J*+<F+^JEIRZG/R;$QIMQSS)XBHQ_%[PG*]S]K-8J%V
M9(T2'BV#K(9"<B(58#-U;8%E*6,>R=UZA0J@4P==NC(A/O2&VRIQ=LN<N;ZL
MXR;SOK "\9HOV)" P)6W:PGUBSB[2!FA?:4_^/%UO:<'E*EJ!J0-\*9Y%J[J
M/^=9B5>G273^H[^3DO ?NG(2HL%_",*_(@>1U'&F6UXS)](13(0L/?D>MIL6
MTW*+*;>T]"0RNE2W3BTUU&1'86*=7IWO,1J/58IO1D12 4PP,VQJ*X<#1:J_
MY$IZFPUGEP+G>P2GJQ;$K./:@^&/BWB>6Y.8GO-?O\M\UKURR;P_F$&^5(--
M>R4 LC43!P?Y^LP;ARK%SKL(CUH,/EYL\>)UR7O_6-,\W/>Q2!0A8$&?=.9\
MFE\E*-R_.><W5TK;\-BB<HXG:P>Q1(T*X)9:*QVO5(M.^5Q.8EDP]=) T1P'
MB?/:O$207?A@:P,TMB*LN7J"M\,[>_@)?3+EJ,IC"#(.8D:XN86!V!G<K9RV
MYXR,T#\G[D.E3VV_#+==)\_G'$%^=K0"7TS+$2SS-5.CZM4165W%%1HXT$7R
M@,X.#> \3UM<]W_K+<!1^^$CD:59?AC4D&9=F;=>%>V5.V.YQMUS\*3RM=TU
M0H@37A?.[&O;GBF"-<?68RFU^2NIOAT9>5,:K'J>(7?BM"HWA07)7[04"%Y<
MX+E+E$&=^%33RBC;#IL)'\]]E&2NH2F"]7I68/(*'#TPNL2:3 4<5R>\=>J4
MW9-E<6*G^V;I-_\LT,>O#8'#;+C0(&%A6DC!&9)*=6)Y4_R]QZ";?A)I"WYW
M+ZH_HX@154$?7D&68P](7-?,4\2)H)9N%9 C7=ZPM3;0-I@#JX5^[7&_FL39
M,D\SB&DI_O;A>T,VWAK>R=?/!1IVW4$26%1^JN3A$6QW<OJ&9*0D6H5E^C4D
M'%PKO][OOEZU>%A=?8H#MW(OBI2 4]XLP,6WR=4_(_2NF\2V#]39F4Z \NVL
M&HFAUIJ?UM.0D:B<AN%*@:_&^&NI-?492XE?N^7$D 4E&+_S^L77[V&N@,SV
MF>;M29P*<WDA&$L7EJUZ6_A;T,IIVVIF=;YWS/'/F377%Q#1,]6,K:BHK+5>
MIGUL5822V8;:]0L;$6"IGH,WB4WM/_1=:P]GO*7Z&WAA]+B#MO7\+&Q?^-;6
MYMANH.2A4KYZLM0C7Z%@"<S7*%]!<79/0\A4>ON[L[7+<U^=^^%LL.,X9#OY
MT:5ZA8\:55UCR-O(B\Z ??L.*!XB@6GH)]#<"L/DC[U3MD,-9YV@V(0'L9_J
MK.)6BN_$N6\?+&[^D(77HLKVP,#5!KX!EXJ><\TS-P>+7XDI525>\L@Z.BX(
M$992>:&).;U=J]!Z/L>$E9R!L$6>AIT*9S&>@]"X.['KE-Q^K-%8A^TL,911
M(.[>[@]!R(]K\<47>+,:;A<[CJ1JZGN[=QD;_RIN]/D?J.#R;\V9>5DCZI;2
M0/^_F&8+S[M'6"4Q\6Q\D'C[$[/F[X.WZJ3L]-B?O!7X(DN!9K^*05$CWB!&
MK_A0RO%^@^I0*]SJ\)-8P&%RG^,-,GTW+Q40= '5B^* ]PLKX^Z^GOU*T^=;
M+R9\-=J?QTN.LW^0>W'Z7OS7H.C1P>D*F#W1C'05=Q '4YB?LC>K1EI@%P[3
M/#]FG=.;"+5[SRN6H!8WO.LFG8^!HXO1"EIFM+F$R:W2'/UQ3L*[41O93<Y!
MSG&W]MD;VF(3VQ7X#2/?F8U^/QS<9,)FUKFO\.WTVJ;B?NIW[LP;G]*U&3;'
M0&ZI<:J\"XJ[W.6XHK:CT;8S.);]NQ6X1V^?\(PXE,Z]/L9\8>&XWLD.D7>C
MQ<Y0["U$C/]HQ(PA9:3TLY_HSLRM\K)[6_=L&;9Z.8F%4?VSA6T68MN<7QF?
M! ;,<@VZ[/=A<@B<S9D7B885T,?TOND;<3I6]51 1Q,R#_>DOIMRJH4*./4<
M+DSXP%U8%^6+V%C#%:^X(YW/02_G;L]+\L!5YQ0PM+C<E/9V,\=A9N+H.1>C
M8ME<JU0F^9>V-;>?W=75]#OH\<\M(B)@-L.*4M&HS72I>T^JG&UMCT?YT=V+
M_<Y5ONMQ\'(AS:QQ^,:MV#3OX4-&*4U//.VC)^N2L]#KS;^6RPW$"C'BM07Z
M-%GO&4;QW*JSK-G_P/_@U!NU_-K(XRSO%@1M%7=Y@BF:OBUSRR$PDSE-;OS)
M*VX<'6+W8VY;BI87M=L\_.3W(%LX_$,H36&E*6R3L"N&-8POEFN(9A/I7O)^
MZ<.[2[8JD]D[Q9FGL].3Q[^!DYA QFO,28@F!9+:*,N;B590_1.)#U]2)7:*
MJ0#"!3OXA7OP,WEAX>^G^>*^:V:MPA]%/D"E_@2EQC8I;?1I5*F/=OJ !#4L
MO+!1,W,YJ>Z@TY:3@072;74O&=+'=^S:/6KC$4Y[P'!P-6.;29@U3S46GUY@
ML:9F57BRV';8I1Y?;=IO6DU?P1J4!* 7O'V4<:\;(Y99/#%TZ4!3WB0"+$QZ
M1#3PI3?!H5ZF:N/$\+=[\IR5-AF2)BS//;DIYNLR(\<+.V;Q=7VJX1@J^ H2
MD]W*?S=5(K;>;&'"8>OL2/WUDIL%+CN;S WWP[I23A>>7@C2%QQMNH_<Y,,Q
MWB-\=,2=7FA5 ''>?ZCSK+ PL9U.^%Z\@#>;,41P,6VOV)!RF@L7?ZN^LC;B
MSN#SI8A42R/-8[W>K[^G5Y\9?2_B+J4VIK;/<=?2TNC8]R,%_+E:-X*C6]Q(
MD6@D]Q;$X-19'>*=MP\;ODHAJ8 0=RK  1F#/(.HU!K&H\LZD%6N,]6]+NB
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MWS'7%R'S.KN6^V;#T\@9OSOG)-MY[3T R9E9#8[8S"]4P,GJJ.>!]M^()OC
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MR%-T5RV*3/-5$1!? 4H$D(T*F+F,P'$B_MB]TGV*"@ LZ2]Y<1W9_C6[_IK
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MFQJ#+)J"Q6M0>2WQK*\S;:#2F7844U%])C/R]DL]P]7D#G?$\;N3B.VT'<V
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MVMP[D,2E>K6H8QWE/4039VE*D4&IR<'XQ%'4]SIRCH:%RCF5O76;@#;Z,U1
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MY5P-8@)%,8:VHO>[1JF W\[#/^E0<L$'^CMY[F 5Q!R&"F #KX#?4P$SSZB
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MC=IZ?<N,<,S0,+&UMR#A$L>'(X!^U 5+-IEG+%O8SE,=F)4]C6,NXWJIL7]
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M!GUL"@9*PI64Q4&]+C)Z\B1/^$S=3!.M>S1AX;7Q86^/O 26T+H*YT*VG7%
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M_6W7[D )%.DPS$Z%%P<\$OWP59Y_#\$_3.JK]"BI^(^&Z;(6I./N2]_[LO1
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MZ> 7JOQ\+&@?$FL[&;'4J/>>96'X:MNZ3'4>!3TC%.(]+%O778,NO#]@R88
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M;%J Y/L;((SJICOM3"X[$^CI+F "TS (S492X[)\-A-XFH8#[PIO(F@\SYA
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M//?<,]?<S%R36U7\L/)76'R O\-KVE1_?_L7YSQ"Q6EF5,*Y-Z]02T8= $_
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MJ8(Z?!UZW7_[^R=W_,;,>VE:OSW-VX0:HL)R(Z\J9_9*NE##V[4C2X-26/"
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MSK0DTRQ8Y(21><=*H*S*6<;95SIZ3^B3+H1$[:I(3?IKXG(3YB2H6S(8GE5
M@$[)?:Q:;O!+;PQ6OP]\NZF+/*-A+5VQ[=E2RJ^J1 &$/^FC *!(XAOS@JP"
M*$$8@39XQ7OW7DY<-O$&50(AQ-H%I[B?5T;PQXT:$P+FMNCRHDEBL UQ=]\Y
MX1MM'%K;[V-;W:^?YDOW8Q!0.2Z]B ]OYH=B*S."GI' N9;=W%_\>3&O>[D6
MX^Z$R8*VN-X\0V-?+\RE9_IAXN!NA>1>Y!=0ZW75,T)^VHO57?+[6:4ZFS_P
MW+PJ0;R135W\;.S?"6[[*?BM./05N'##$$GE7+S'?L3N#BI:$9C?*G;UV\>W
MSR;&>CD_=IVMI@!"P96?DD-PBR  21/G@HJ#2SM-%KV,*Y! TUWTO?_>=C:8
M]G2<MAW)Y+C8"PR"A;3(.$RPYX75JV MWFZ^F!:@F:I+Y)K1H*;2Z6?7H5(=
M*!7 $N_ [5):*(#*\% Y#*LT&F<2+5^2]8SCS//7<L]R-3L6)_1<:I;<V-=3
M>,(:YS%LELX81G69%>4W/BRE4/HUCI_=C+;Y\[0F#M_6PN_Y+D4=ZLZE;*3E
M$5K;TGGP;N'U#&X?87U&'YY6#Y4(F[7A::>9ZIBBS&@1.<'7E(KU*(!G?53C
MA&0(GQE)X&O('%LV< .X(7PMDMN;6V%]55.-$[SAD]4$G\3+:@W7*^(9VI1=
M&^Q='A<V^U^HJ2J_4RJ8+!31-"M,VZ'"8CGL0ICLX$EI W(XH06'%\R\) R\
MJ]\E>)= M.^. :0)]&V?_YVGHR>2/# 0<&-5S-G!MKKFW4N/5E8.^R?NYP$R
M^B*5 (XJ-O-I;?F*>/:V9\5\":S<#_F"@98A<4E'>\1KS@@PGJ8E0&%G[G+J
MQ.I6"/57#M_B_=AX&6#M4KKRKA!U*AXZKK@O6H73J\ CXUULZO#G3"PD)#50
M["G<C//9AH/\*0(-ZNW4[.)G_E+V2(7;^H?"-RC\)+V#-"X <0?D.@QR^9II
MT_#O)M;<_VK5(,WXB[O:&B!UQ "/XCZP$\4_OG[E;+%JIB<%(,%5#=:JVT-9
MG"3+7H14-=[YH:-G7]9YT(EJ]?KCGW3T=>=8KX/-BRF ,[0X7]Q6YXJ\G,FV
M?(\Z;P.F=?'"M2_Q<)V3F]0HT>,/)!-5-GQKLWF-)Y_[ZMU.049D8:(T&%O9
M8ZH!?KJ<\^E?-O7^RRZE12#A"J*Z%KI.=E%<#]!]4!6D>_!U\U4\R7,7]4.9
MZ$^F=YP75*^<Q3#<7&>=X:[D?4D3W'O38VGJ="*9B(I^823IXFD^N#OYPE%2
M2E*P*I:S4+;T#DV-D/$%,!3\].1=QS.0^\C4I;2";NO5F_S2,:KC28W\O4CS
M/>6/'U<<LQQJ$1\XC^H,8;/0K"MW29^/__T%6W+Y6ST2$O\S3( F?6$D^SD@
MS:T=!Y[-O(_=(D#A--_+=0K*MMGGTO=BM0'/"(D=Z1?P;W[VH-9JTVOD;.B$
M/_E>;I7T"[2*7WDX])?'-!N45YGFO%/5.%BR*2Y5/*7/U%.4*VKS^&=2T#?!
ML6&G*]06;>F2HW";%U7FY,K\M90K=28N!JN&X0SO9V7+E(YXHG7QPBCLKVHK
M,6/T(,?LF;=F4ZJ7-&0#)R$7;/?VY#_\;Y6360$#$: U#%O]?4?L"1@:T\]W
M4I0(S%=_..3EXQJ5Z24<*%L/QFX8MOOUY"9FC_7EKRK>H\5^K;JQN0[1D.Y'
M:O7Y'<L<)U$ -L<JLPU%ZA?P]%J?80/&8*7#CV7W2=(+SPFK%, =I;5!<@_X
MRV8HCD:;DU%P6-7,BXLS-5MJ>B_N F+5:REXC'N=IN;!U.E/?V4'<)5_4C1F
MB@'_0W79[_)OT4"3@T 2VV>X+MX[#=O +ICX8(BO\]0/[/G2>VT<&RTC3/XB
MZ_X4@(CH+.2(F$@!W.S2X']\LL41).B)9D0*!1!R^B3(XRD $$D(;]H*XM3&
M-K(ZQN8YW6>_MOGHIT&1.S<?'WO?/2#7)326T$V4FR%@YA4*4>:D1V6X^I3[
M.J80BS"+"&F>@B96E- IOW.5[<AF3<E*AD9.DM)/R1=U9;GFIPI*OIL>*^A*
MTQ@_77YP142I"_'^P10P65T<?@$OT@QE,5]&BX31NFVZ<!S)5[TU0%NH9';Q
M'^A@7I5<13<3UHBRS27D(8%S.& X2BIY\N[/)_6U=4,HH5J8H%F):H?)<\BT
M9FBO(NBYL^L\MG&]VP;/!Y=(G;0ZR9M>]M;ZCJH/D>]-\P%>;D[6>3 <2*>K
MK03A^=GW[%O=QN_KEQ]_WH.$H25D5FMO<LC,6!@QQC(8O+P8&TD33,VLX_'*
MW]0+1P',0IJD(@04\)!6-84^:$J;WXV>1LO4YY'HZZI5+"7KCQ\&[4@IJ1YD
M L,<4%5H?A(-@0W_!,I! +7BG*/GD, F8N5:P7YT^#T;1]9KD]XTU,'9P=<7
MZ_UGX\,1P'&"SX,Z_(+Y:!0<PO\S>++53^[^J6^TO*TE5$(+V_. %W)-.#:K
M<P6S(.9E!,=@O7;^BBF'LGJVF):]I_LG]?[OF64:OE>IB$TVE0$J>.(^G(#$
M(L/460F)'QUJ#\(J)HL-N.3Y:8QGJDZ=M9_RKIDJ4N"#CUT,0MT__B))HCY)
M,XFS/WT>%ZCT/8UG\G6+OUB?OW^(412TPUCO!I*VLM"#(^IGX;P$FI/-PC!&
MNO&S7G,N@W6-6?Q UC'V0M0//M<+8E+T^GR;(J=';#%?%,-558CW"<XMBO>F
M5M,9\6?>CXY\'N!:TG[X_O!9*\CK#=\L'TN"!DC(T0\^@<YS?/SL_)35K5<Z
M7+.NWO37CQ*L[-M1(60A@NB<80!#&Z[Y#&F_T"_:[5H2_*N/AOX?=H'R(U3.
M;@4AZ$<SFM7Y*D8DX<YNQ1,378A15EH;DZ1;$7G>,M';N[W^^ =(9ZG0F?,X
M\ 8#-H!^S72H2%71\]/D%!0Z,V48(*?G*F)R]6%9!_-CC\#;'B-O05(GR[TU
MVQB)ON*0+CA<<<5EH;Q?@CP,'[S%DG2JG#5S3TEG90-J!E<C7,<!Y_(BA7"-
MX23V>6Z7MEOWVXLD67^^NR\B?GM8A(;WE2U^)94"*(>\# _<A4P8MA9*UQA)
M]LX-VSVB\M(K.57&3R7(W7Y!G3<+W460(LK!%""!J3[Q>RCZ-0Q+)?\-T]ZD
MC[=9BK--O+[=6>W5O.VNWWU..16/F9!M13*],/VYB!/GV8S,_Y&!E^Z7[_:]
MNW&;BLN>7_/;!;:)MP+2?Q/Q!4)_UP'A;J6F!-7+SN5?E.&7P1=+<IM>%GSW
MO B2^8)Z=:Y1-83]64CP.4V:/=0$*':&"L2&9B-DM%XT7D27>YQ=M^F%IH/S
M>@M[$-=Z3B>7ZS/^K+C7T2Z@>*^HZ'?_.0MF()5ZWWY6MXT:#\9RAM;K;=-)
MNHF_LI*9/_:#O_:87#0I(:.Y3SR/,PGB' UB)IS=?/86N/\IJFQ!S$7_@7VI
M2VS0\:+\@?R%_VS\Z-^(UD!R?>M^'.$CJ 4<@KXX>H#,C3"JC*( _.9N?09E
M)58313.!/:")UKFK<","?B[@]G35PXF>XP].SVFE6Q0X:'Z^E44VA3HCV@7H
M!.2.LU2O+VHO3CIJ5^K#N 3N\-(=Z=W?13&]UDG6?:TCN6XHJRCT^KG^00\B
MY#?;'((O5K%%X"*^N V\PO-^KF-$Q_JF-%\-S<_W,13 J+1Q/[ B/ROJ'UB7
M_IB?^J\*W$3_];VWK">Q//!O"/)_D[;]]4$[NOP?AP\ _I@$^F\AY/^?DP;3
M?>3Q![@^GMCV9-0HMJC"T.<NLM @O#L4<MF4.,#R4W-3-DB#"TRK?HZ0.&\?
M?:F?I.+<0/"/KI&Y^#7^ J?W+O>RC!'B,XF>0(5%!<YP\WC',E</"5.AO,Q>
MT94\]$O_=KTECF8HT0))CV:#><XNO9SM5[UN)[$QN)CJ ^CQ$/%)*.L"O^([
M)U;Q&YZ*_FTGYW\%DUNCB%?7S)'A2 >ILZO*Q7M?W^5-3JL8^?C*M)Y_U'KA
MS(<X0!?U:^6H[1-<NXF*P5 AN.#6A ^%L$HR&';?P$CS9VJ77>6;W"%ZC<0-
MK8P48L/:A^,"=4F8L!L=29'@A77Q534"A6]*3"P]E!32*,N,U7UWH']=:$,)
M0$^8B3*AWL3$0"M$PE0YB4]@(AT</)4I$:I@8'@BI+%Z0/+>+QN@?._FW8BI
MNH2O>QUJF@52:%J2U)"ZC&+[%L%\@A6FOP?<Z!+7;O%=7(*]ZOQPV)SXH<['
MLXJ[&162G]44T(P;W0_&]<4UNL1".CC-/Y6$8BL';$LKZH9+6,?-[C^BD=0X
MD^;!\'X>% 9<;YY',<&0^]6$Z"*G](L#%=.75JWTFO.MK=O/L[G5,7X2LIN8
M#!>D2>B!^VMS4*]BQC(ZTD&XO(XM/HRSW^:[[''+%9^[K9Y(7SX6@XY%8?JB
M=2JA4S#URF4HE:I^KA6Y-[4C8=:-F^#?C&31R5:M\IDH2N@8N&GWA-LL!)Y[
M*5,F)!AX:Q'-G!5-=4"S 9R' )TP7]0SL&MND3S(.%7=O-6(@RH@HMCK.=DV
M5^>F]PZ/O..I0JK8S]+M$'PWF24^)N/+:+!7@&)'K?P'3.B+7ZDN"H[]?>(M
MI^\#[C6%3WU0V'FEV]AZ_NXCL*$7*&H4PZ\*QL8Z8P\ZU$2:W!@-4A=3"L0%
MGMD&F@WIR1A\:'IA,I\0M>,,BD[GS]AOQ;TOA^LA60A(W<K:V,IBQPV7C:R$
M.?=[U^_:F-R[0>HL4.4AN$:)TQ22-$?EB%L3_L;#+EL;)7*=>,4)CJ/K21\=
MR/WG<(>357R;-.R[/IU2$1E +^2D(7:_"EGLR+,4*E'Q-JNFKK(Z;G5"%#Z9
M%7PC-.6776R<WRF@ <$IZA$B+2^6LY4"$,@<)1GAJUKGFP:XST9F/H1>TO&Y
M^2 @VY7YTJDVE;(S7VUH3M6WG@3_^'J)G+6,BN8Z_.UP'B?\%+^RSM!'!G^T
MZ/>(VQ3 #%N-[G>("#NNX7P1S3BXW+)4$]?+0?#"^X'I8),]P'P']2NI4NN'
M?L$V.EJCOU2&V#K.*14@73"1J301:!Z";NNHWV+D7'P$1Q6#&OGC1T#_S72+
M,(W9]V>?9$@B0Y3X3#OD[C[ZHWOB=\+U]*<V.P 1GIYT:$KT((DD8AL["J=U
M:+^N"%SJS7;]?HWCAH=,@-8'C"[[4:$U._$QG!W$C6"9T75D"4#J"5, D#&9
MWN^-J@]WO?I ,PRW@#\R7H)97,EL)+W^>F/[ZJ\9[CP/AW:$))(2P+-Z#SVG
MHH[?XC8;;.9B@9 1N>ZDND'4K&&:[V!VQRHWI.IL(]/:5@9!)+XS(>"I8JO:
MDU^(GZX"2[J^O"GQR:^I5DU3J/NK'FM1;UX5%?VGI!/_5)(.VT\"-S.ABP*@
M@\05U3/D688/5DC-S-".,1\\R_ZEOAP.,G5K7>^;D)V7SVC"A"G'-4IM>7%3
M?1UT(1QOM%)7"1(+8SO'(<_%\,1[0Y)>+CJKY&V[ZKK:I+Q4T^OVWD]^M!V]
MABP94=FTUC)M1=5KYBY/O# Z>?D>_$4L5[KLO>FS=RXU.I!Y" )]V,; 72G&
ML4N?T&D.KY[J*%9S^ZBOM[\E)D*9D,W*9 ;URCE#3$3J2ZUU9;LU(Z5KQ /&
M1I5X6ZWX0J+I\E/&,W_V=?ZGPK['N9Y'Y,7 K5,Q;3-7HUQ4FK]K:0D8=.?S
M;7/6=C9W^RRC,ZF3C]^!G_*[S8\4I1P$6XDUCVQ%Q]XL8+H.VO[.K"OQ_FFM
M) 0AM@=L5J?[B> GN'9K_IX$Y9KBD&83IOH:]NMMNEF\MVIJ_\\7AL!SCMX3
MKBGVYS+R)B_$\3J_H.-S4@;0:)JN:OQ]+]E_(S7]+\XD^$N;SW*H?,'0R4H!
M-X9Q3&@NDH:ZZ, L';:/V6# )=;]ZX%E>1YU]O/6U=9*^"\LAAE*@%B5CKPH
M3*X8>F9G-OM.N;#@&TD=74G4Q,MB1Q+Q%LW*>6'R^2^3?<HV@('FW#13"<B)
M^WTK XT@A#C\VH@Z$+9V%]?Q-6-%H?AMGO%%R4M"ZTFR)'&:95TG!^ P:APS
M'Y>&G\?N?:UZ9A/R()QYU>3*N,*.3?].9:E!XM84SYXRR9' @J\S([#-%P;X
M&PK[ZQX/[X6PLBZR^MY?;LUW;3LWSGZ$P6W-"83C=5L4! 1QQ_UU@R6C%W8=
MQ@(6/,;?X'1WVP$O=O^>I?>?2=YGI^14X32??,S4Y>*D'"/5G6_N91V9R4\"
M *>'4Q)L[OVXD<\MM,M^V$Y\AACNQI];A5+##-;!8<4Y/7N[DAX!EW:U*8!<
M)^16%M7R=<!VQD3:_%Y?)RKB^8S&@#:V!^R%3G%: @G[)H4?3 4&!-Z=J :%
M(8%>;E'I2@/UTMDW;!O0;R[:'#S1[/[6^>5S,))^T28V)\%&6W+=_7/F:WTE
M /">\Q[#OOAQ&A)[&W9S[6CC,RIZ+V(XQ^17T>QJ:;R.*D>G.XU3IEHW%A-8
MT1B&8!A0E<]N*1U;P149!OV('5YPVW_WI7,J=24_ZY^2&/R;*)#Q)T\^:W6P
M<09'A. VP@K<<@R=/^OFRQVPE!=>;9=[ZGZ]]RD-3G[]Q!*74"05P;;&715'
M*(%.BO";TO4;7NKXW(0I^90A6?Z(7?L:6 V)'1>X3 %\G#2@ )KTD1WQ!&_=
M2.2R]T CCA6*1_5_OD*],TKF3YB#'O%7H$BG4T@.%$"X+2R%'.XB1@%0G?PN
MSS']26[PIZ8_-?VIZ4]-?VKZ/]:D?I5@2 &<7BK'-49?'%:U+YXD1+4,15X:
M=/GH,&"Z<1*'[XXZK&'B&NTG)SN=&=VU>%K/.[$(:D]\I@$ E.E3_Q'H_.>
M9Y "8/WKR3T]_QW(P_V7/@7PS3\.<]HH "?@>">$<#R+$:4W(Z1 3!*-T(\[
M]!8YP5.NZN&G?6@F1:]0XR;;TGF&2* 2Z^6)GC>UB#S[BU'.OBF,,>"/_)V6
M<49^D/4UHO9:8SD%$,4TG+NA=:/VD=1NWG-6S>-=\GH@DD,M-H!(O(_X[N?6
M&2NTFHI,R25T#%RZ4-?$\"([1X9HG^W%O=N#L(9EMTQ4!5>N-7!:EJ;=&I8
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M3ASL#[BQ2RP%UU/#?BX?;F]5ON4JM/)B.F\?H[O:NF4SB.K@HU="55( -A3
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MB*_2+1!T;G>+V6&?PR^VI[>0/T0[H/&13I@C U/1.4^NK:E^FJ]WH>\;<3M
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M\'U(T+F1;YXARE/-UL20 H4-(APITD>I&#JT!TEAK_J5NC$!7#W\Q,;3SJV
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MVI<\/$K3D'.88Z@S\?$J0CGVMZM*42XR%1B$#WZXZE'"XZ:C^4.3_^58;E/
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M7F]R1  P=OR+"* G+1H!/$]   &YF7?C5!V#6TK[].@1 +97(VAW.0T\E8X
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MC+V.S^@2L$2 8^-516E'Z.*HU[&#'<M&M'31D6JXVYQ$M6P0+]F +]D2.^6
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M(>"+G;W,&YM11UH6^,RP#/2/5/8(/A[Z,R957_Y3\7]H./D$2!M*S3FS(00
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MY(P =#^TOVTIO:&K9RJD[TM;-)07X5'M4AIEL5DM<?&\&RAC-L#2+X38U]Q
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MI1Z*V!D-@I!<&E%[_0M+*D<Q<[?T+TR*/Z$5MC.JB'H4YU'([UI-$)P>VE_
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MMQ]^'5># ,X(]$-CJP)>_S5WZ>PS!M^2_3I\J(:_*:;))Q&W8VI"YQI_%^$
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M?6- ]085-IO$HQ-QL";OO2\JY+\KRL[!3(UOEDV7?A<">9*G4R'VB-BH611
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M7#5"SL5\AW&/VHTC;\]>N@<H<_/D.Z& TUUND"DZ%. #?D;0-01G*^!KYU!
M#?A9YFEL44O+B$,D+3!7B_QY6[']ICA4I A&-7K0M7DC;WJC +<H)&$: :Q9
M# 70@I^*KALBU'7PE;2\*Q;J2V$V_DAGR/9Q"/*2]]:#(M#7"M,@G&A0 *'*
M/)$],ZRN9"B]!59F.0+=.84"QL#/5C!DF'^9<0\3MH()0TB:9TG-)8!ZWW7^
M7TBA01GB[K(!K5S'I\2K6#V1X"^& 9%!Z0<TTH<++G.GJJY?29]Y_@8-U>0H
MT:E6[B_^OU!Y^P_D2/!#CJU'.!H$VS)\;ZL/&;Z!!EIZ +3]77$ 9%S=5'&J
M%/R=_?!W1@1C./A$1- A)SZM&[(H(."$ES>2L G$TRSQ716ML#+;$?6=T[ #
MDB?UF38>(F5)^"%;4 &PC3#[ 9,@OZ<7W4I_D&$8&ATS][%G']X@(>P'N)9?
MVX5$>NN<J;EB 5N"VX0@G6'?)0A%GSLG#/DNP6\78N:&06"%2!*8!VR* P7X
M-8-R()9%W%R^3? @KG8,!415H@V'3URBY_;V0\5IR#!D&;*'B0)6,-71_%[!
M)P2Y H$RC.RCC8[J*<_ H6+_Y08H/@V;*#0=[*3[F'F#,E]KD_"K;RD*@6-L
M!!PI47G !@Y6)<T:$0JHM2G="IY(N&Q_S>K6CV9Q!\W:?9Z++%]1.%?+NA3,
MHZ%TZ=552FLR'%^5E L@]D\T8M/!GB4IL5\<#/HB/UCC/[1W6< G-BXR&1YT
M0P$9/.QS?7&5 6VFXB/7^3'6!/&'U6K5')2>^WUZ+R5"_/[GU(O3*9#1%?9-
M5Q,)9 RZZ*>+/@J@\845L=BIK[,CI^,#A\PMI$04__2%O$H;9'0)5F 0]OV+
MOB XEKFS7/TG)R>G_EA3*6#Y$9"E"3'V@$3*[K]<ES/.II"X/!^1_UZ,H6W;
MU!F_?N##%(0\6Z7)G55H,&%JXV-.UJLA.IAE4506$@MK*=%=<N;D?.='0QV&
M(FM"3/L/F%)LIZ\,OEZ=EC=T"=S.+FQ@E]%A3E?KZTN$6=V*B:$)[T !CK*?
MOO7CD9<KD.;B)4"?IXN?#G.GS)=_^[6QQ;5V2'>\T:YCER/,M6.,1()"1?R3
M.'-9*&&0EBNE7;"SD5ICO_ $F<N#>E]1UC&V2CO$1W/OYUH?%U6>OYY7>N(=
MWZ_6:'*IX^.CB_JU-^^4FEZR\LRC @2>V7(K):FIZ/&1$O87]2U6+69=@]#E
M#+Q>V@0P/D?UI$98F]9EEOE%F*9R8GP410@#WE5PE9,!9HD&D54],;:WIM/K
M,68(^K(\*EXYU$277(WR=PK?'MF ,U1]M,D)#D_*O_")(#I'04=>IMA%/-]J
MH9=8N*9*?#3X09ASU9JODLVKN@'M_(#DKVZ\M-@9\T\=>\@^LS1K":W'*0KA
M7E_R"K<VKN,3*N5(F?F@-T<;Z<Z\G^V9'PNK'D)G3@6@ (2MQ!HR.^1O?L$W
MO:H7Z?X)>P26-8]@']G3=-!]SKOCZ"5A#V<-4];[<M_1ECK<I5_!2$16-1<C
MP"IKF<;)A&JM.C/7(O!NE Y.J$Z@2'6:>H*@&"->2BN[RR8?#1?4PMEVW#S0
MM][%S[XK2O;A-^7^#YB$E9?=ZI^=ZN>MHI(=_;B1*),[:!:NFM@#C5*=ZC1+
MM>C[NFN?9XL"Y&C/6VY@F5[\F-UJ$MPEU37_A+/D0Z+X%7F/_%O'3C0*WNUK
M,HHKX9A])V>O:^0\"2&)29J9UH)%\@9;]/@J29F7-LC W^,5F5Z;+-:NCNW5
M'SPW/Y_\6,+"B*-[CC*0[86FG?^" TN\@R[46_&MN'T :6O<>Y_YZW3A6]5:
M5?JS"4J\B3L:(7QNI*$M\P*7S$)'J1QF9(.GL$+T.;=SD!1+*V),[5GS(C$%
M'E5B@>YS%6/+SN=AH0K")^'ZL<_O93O7?;O@,9T\QK1;KWV=?IVQOTM?A$]Z
MV!3LK!=._%B]0L]B^I""CU& &2S@OF-E*1B+]+S8KUT+^O*]('06EG3W;QTT
MR3Z^=WH$DE5S^ZY5U1N/A<F]@(?BB!,,@3'Z\63R Z*K%VG%*7VSC#^0D<D#
MCO:4Y@\:NXY_,[?+(E"QJ;YW-S4VQR2CGX:3UK4@CH;STQY+='PJV^.LMPUY
M 5KW7?NK\Z]AS$A>*[QZ#7KN"T/6SHB$+<]7JDMT$_?/GA68'!V7.X^XT26B
M!=,PT9);UAS@HKR"QY,^ -U]0['"D\V=A,G*\IHYBOXBJ<EG)GHD,8-,6.=G
MV_GBV(B2XYGY[L@%Y:L?"C)$/$A>,YJ*XN11FG?YAHOHSZA=:%L@YC:"2&=F
MNPZK\\Z(R]TQNSK\D&/\#:)PM=)2@>_JH[[BROH$(B;.QDE SE!5LVYE<JZE
M*$'HV\CU(3^2QS,8\34[%G$-#D^Y:!ZVC!7FM)9FI$WN4G+=TKI[GX& Y_Q
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MIA<A4:+GT-%LDL6@@FY6)VSK;=2R*'Z3+BCEW&T\/J&JMCL?3I_3,G"WLKO
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M2P5[1?B$N[REOI-K"A&P,KQ86)-]Z>X\#+W[\:=GJ >.[86HUZSN_#U8WB8
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MO?;0JPAK8:/5D"J.TM15OT\%8 B?3/'>-=^0%I[&S=XR)UMG,G$!.6>+'?,
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M)1!./=J+P-_G[E;:]@UNW-X,YQFV(A4J%??L4:%X#Q_DXS(X1XWK3-+F'43
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MH<NLUX8V,P+V=.X8(4+U-43PY[]Z#OQ/OS<HU*S)EUN<<18W;EI^5%-;V67
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M._-9I;M8OB<O1ECX)9714KB_HOV#9/\YP4+_MR3[%\'^EURS !L=#=5X=%P
M!"#=^Q M _Q_44'AAQ ==7"" C H8_7;(;$Z$J"G_S)* -:X%OMD?W5D)S=-
MC9/M16CN=V' ('>5P^OA*Q36TC1BUO[F\5#GT.L [8+DBTB7^K'R#MH7@8-7
MVJ3ILME?4  FU$\EI !DVPY*DAHK/3#?'10F6+E5Y,:O+3XX+ZDDX^"C?8TQ
M5/LC72@H2[@*9\2_PL[!LNEP[*T-+H*L6JY"5W;>KK-*/J,[K:ZMK[ZB\JOV
M3PR.KGTRY_,4D?<&>K)R^;WS(@.80@[[Y)SXT<AYU8E+\<,*2]XB\WV.2#C:
M1'9'?#807X3MW:Y#"XN:6M<V3_JXF:]L!YA$%GV$96[$*PIH\SHX[(\#S!)F
MC#6C4YT:2SOEA)MPKULI78V1VU\^74.K)YI>#+/6;XX7*YSEBZV7<$B\;]\J
M.Z/%2GCHLL2/<A2%8HY>'LAFF1LKSF*LFB$^,A&>%^F\/^_11.R@%!.O?#\8
M L2OW;$S)5PB!H\A71+" M02E.=4QW3WC7B/ []+PESLDY(2/]-I 9TO.UG6
MR)+D\1%0#?\&1&(]#+'[6[-#4:<#^_OSO'Z>RWQ6F/"VTV7^5D&DH"@OD@\(
M_/D(G.N9%>C,8=W4D<2I?O+(=PY V/E,[/2?3*JL_'1E&5 T!,P/$>Q4VZK6
M-X-1*T,A4(8TIS!=7$(4O[%-_Y,R;*^DP0G]1U7?IP\?Y+*O48#0"H2:%0,!
M+HSAABL/_>3D__H:4OU]7>R1CN-.PT[<TO9Z]#&A/5AYF'P:A!KCQ",.U57B
M>.[$#-:V?'U6\#$PX4:B'M,WB;";V2S#15A_;%F&[OML81AD>[^PYI;;0.M
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M(ST2Z:!6\]E**PYF5SVV9Z>H]XUV0,=$4R!499VP%![48F=(N(]@J2,5Z##
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MS@W!S-#G6[_C<\+MP!0T2<&.JLY;OXX"LC.=/BZX+'&6G:O*WF5(VBG@'ZX
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M<#Q'=X:$+N7[7W-%#&%,09FCB)HEGMKL='3FCHU>O''<1U+>$S_!=N<5B=4
M]Z=#M4':6 K0.POI&F)V(9\9=F<?S(1G)KUU>RJ!3HUTI#\9G HN5(#V#["#
M+9X?-AN#NM,^T6??3TONN1$A#= L:7EO)4&+Q;] .@<\T$/MI^1\IAUK6E M
M:42K>=I*#^&2"Y_N#6=E?B'/# 0VM-J^ZD"C[X9-_-E]CO;D<[WOF3%\M&DM
M4YF@_>@_>O?JOTV?FYU6C#G1ZQ$^G%SP]/M?1VJ,F(ASF7-U<R*NVD&&ZFTB
MR<]EU_;8D>UF$"</7O@';6Y.H7XGR5&F#\WCRAL[.[8)XEN"5^_L$G2!(%M=
MKT5EW%%DJRAH0N@B2TWL> ?1?C]]\>A(X?6(*;#J(RT!*)KHR;:W\E. =KU6
M.J(=KD",;YAH(ZG1,I[](&/37,FZUW<&N*!9H2;V?5JZ%@A2@0H&CR_]#D95
M04D^4ZB## V":JLBZ1-JE81T0!UO52(WE+UI\&[_Y*_L%4H8:+P/A'8#GZX!
M?55K*F"DW&HSMQ'HUZ6:TE#'U:.G?E@Q-IJ(VWEPXL-8<GUV;SBR\R:\B?RZ
M.!;R6P"<M#W:>5JZT;B;^6$!(8F[+511( G3U+_,^/[,;E"^=DA?1>=]4JD.
MKW/K:0VII=AM>Y3%[_F++YH-VI8C4N_G]C99G,59/!S;H0#.>V$938O7E>NW
M:P.+FCC8@LVJ'17J?><&=0-Y-W2_3\C8Z$UUEZ<.7C&<6\A9M4E?F8HZ5Q_O
MKW,"7F&X0DA6?IX&S1OPA;*3+\"RU2?E+]9"(AN/7N7&\UQ8V,Q4U72G>]2^
M-8AD^5/W]PE*BHT-/-J@)H%193=&)%-WH'LFVD5 ?9[G,=W97.G?E:6M_,1;
MH\%RH+0)3B?:@=_/U8LWES%J')WTV3,1J7,>@ZU]?O"F9.2G:?G2G_A4@_'4
M?,WI;2KJPG&T_0^[(-U/3O!\<0<)AJG;SJJT=+YW-5W#9URH[,M#D\0R;)=E
MH\<+7O&WE^AC4^G*@P,0UJ0\,A<Q@/0N6)0H# 9A01?(2?OLP47-IM) &\U
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M_G^*>^^X)K\M;S0(B%)$D"(U2A$0$*4W$Q"I"DB1*D1%I$1Z"P@)J/0F(*"
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M1G;R;!&)+9@&0/GA.Q>OA"UN_K)$-[ZH[^E,M>:)E4V\;P1EW%>?2D?D$),
M5"XBP&3\/L$HJ60(3CN0EC9%4$^Y:GJCA"[9V #P,:,T0B3F$?'U?&[V3'PR
M5U5=O+ WO[@Q_$QSG/=6?=MVZ% (M^73HC_?OKD6../!M,IO9H.^S&82X-9L
M9]?ZI ZU@LSX$;-7'8KC.K<LUAD"[4(Y<:7+RFGYN!=?%-%Z_GP- 8T/DIEL
M%=<WC\GR=^IZ^'["TV\ULJ)2O"&G3$";XVY6WK] HQD2J!.PNJ)HDF2P4"NA
MH09^Z=V2;VW-V#O/1#_OQ9BBY2^@BJZ%!8F%_>H$!6- 0JPWD0: ZQ%^Q2-/
M:!<'*XW;RPF0E4REYFTI'?HB)SKY H2> U-K#(EH'H3Q4EHJUYNE(]"9]7G1
ML<7TX819TT;K))%VNP6V]G9AX1J%W^O' )P=H#@0'@K($.T K:+BZ /2YB=G
M#Z-L+<U'[]]+N!=XI5ZNV,X2*NW?#&4M1RI2L9 S@!9)T26'>]E:X2F+]WEH
MC13MJ95/&8^NE!BK^9<U.PR?$"SFW(-$_ANX3UT(<6C/2.PQ?O$2H=LF*'5Y
MDG<N:Y1+;]:%_6773QJK:V )K#=-->\QO,\'3BXO8+:.0"358!7N1!^/?!L[
M+;GJ;QF^"2"88#>.9ZNG%4-E A?/SE+[T337RGK<R(8NS :@19;P>0TB'U<H
M].;%-U<NZCMXB1R#38F^"_M":*6_35?Z;>%HR$\+$1Y$6\"A"JB^]V%4&M;Y
MT;4?568G)3[L]@4TO!+<*S"BL(?IA451.8!P$H(ZL+.(8E^'"-E:^]5X8NVV
M H2D)TOK%'N4Q> .D,C14,C.?X8'1I JP=*)RPR=(<:=AI[2E[*D7AIU7A2Q
M8"Y(O!T'?@A?V)8A@H&\P"71L9_[LW ^MDLS"EJ^B6=O[P[D[JALG1(X5L=K
MPAGP!SXI,7LUYWF52R7&Y\!N202D4^>^6$2'PJ"TG^6'G_6P^*\_[#DI;\FG
M%ZM9U@^?H/G'_!CJPQX^+2_7P^KKG9?J%3"&OD6,1$FCV?5)-P'C6W6)G1'=
M3ZH?M(:Q@\7O<47IQ,^BSH V)S_)8)\O^T?GDZ4)]JEY0$9_L-EW*4DXR\#O
M >:2VF6&B\^X(/6_"[0#$5MVZNKY1EEFU :HY@*5KV?U5?DR(765:4];+.1>
M>G>UH6^CV4%L%^;#2"A9>W%.RRBV,\@QQ4X#7SG1^DXJ*?DJCYZ K@W@84Z)
MI(K/ -'[)$/9>6KO$#8CV4XGB4-L1[;FF_+&U:?+"@='H*U>PJ7)O84CT NW
M8*TJ;'R0K7<IR\1 ;+0#<X<BUFC)(&P$%?1+]/[<&>T \XX[O3IRKO.1O0M
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M],XY*)C7(N4QVJ[U;=F3&-'->G-?_GT.FG*RPMYMU/OT9_(X;,_(,CHQ)+
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MES+F_@R]\>Z*6"?=<-UX\T*LW-:5[_;RA.OYV0V]B^X15 3J$RGF$X8BG,\
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MSD7AZ@/"/:X_WI=^F7Z3Y8U!(4((>)SM5!31YX$:71@T&"5.=FX(+>1OO6
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M44>><?(;I"8)D_RN)MK^M// U5&C,Z6(FV?#V^?F^6C[UVS])_=K>6=CIAA
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M?%;:>[;,SP=IRB4OV%^EG?]OBO_-?-.85!10/#48%1TF4E#0**'XL:!3WO^
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M1-K_VD98;1&USJ\\L/ZE9N1%$!;R_NL$#[_<D&Q2JWCZHNXZG*I)4P@11AJ
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MY\BC>3AATCTWE:RRZ8WWZ^G7-2&NW9MY:\@<=!EZ]35QEXQ(,T>SZGZY[AG
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M=Z8KKN0]X::\:D]0NJ'4%^SC+']Y8VOGRRWNG:X"">V[TD\/)B^]OI]Z)N-
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M_/?P_5?6(!\?Q@5E^9]=-G,N*LF=<M@=[K<RG;K>U^NJ<2C&=/1QXCOB%;9
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M NFF8^4'+KU27L97A*[>G=T8GS?J>T(ZG_W50>-SF(69HX^3'L1I;;JH(,=
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M^M0^YF$BR/'WP=9:_5GYIY- [J ;8>B%3]Z1C$8D]:'\AB0!!\K;0#\FT&E
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M5'*<$P^-%,O8$YQ[VPBAJ0BL_"J:H>A>F0@ X?=4]>+:G.LK1RJZ43N;L[1
MO_P;1Y%I#9K7@PE4<<T01V:.XA>W[H'JZ_(($Q##WB%B(\YI.<RM*-C==)!L
M(ZFV#%[O+Q&12GQT>,DG8E#E+0A4PDQ@(PZNRUOTDT7_D7S6Q2_D5#24(AL9
MD1_TX4[SG7?(#^_PY"%#4 BW?_BO?E5TS<U=\!-4:?/3Q1/=AE('32X;*A_]
MF/_0Z3C#-_C7MU7U]A17N0[\>S50U<[FFS@:9])DDN]7#RG@^&3#$E$.IU-_
M2#RR"[8^)Q1?Y]<'FSX[&;$5.]H&.33*&#?;Z5W=>_UU$B5021Q><^I]'>!
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M(03QCB\FWT? P;&1.L9&\R6<V?:8.022"C Q!&U/+'PH0A&FGD> MHUZN5^
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M1JAS$VC83Z.?!&KD0?%J)/9VQ.#JQL9=_RB&ZD:2QPS$(G!?@E#?Q52]L=F
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MDE]VK"W+RK6])]STO:7PC(VEO7_U9QBZ?BLP1(7W4NEGJ:-WW 4H(V#Z,NQ
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ML1,D)3S&(>JM$*A2Z1B.@K8KEX],N+$-/X[(/PI,$G_@(U00$A"5? AAZ!W
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M]&R[]N*CRZ3J+:5W"6.?S*QZCB3L"D-Q>/\-+:QFZCM7P8>#(X%Q*80B)RI
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MJ*:V;FT\B C207J+" B*@-)[0*0=1!"E"U$1:0(B4I204*274 04D*B(B)2
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M$U& /&875E\@9.@M^I8D?*=*R2?&!\P![!6_A()W";_<Y>0]KH.>:L7%JUY
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MW]P5^1S5SHE::$!].K #"5Q<:V2(3A,;Z0>@(%S,QJSLVG0"2K+!)1?IT-/
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MM9V&4'HVS:?"AZ&38/T2-R*J'K$L?M:^J2BT-_>@Y[7"PBM8XZ*<191(ZWY
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M\EX\$H@VI%%("PO&AKO &1IVP2OS?:;+B,0YN*:OXMYS<8-?&??S%JD[4XG
MKT:J#S.6<9!N@(JF]QY]N=*F0WE'/JJ? +50SB8*1$HHB/\RPRO>PQM\3E5=
M5OFO6<S]E9E[/T=3 G?GI^6I[5GG@8&?9\C@%,;PB1]/V*-_;;%M]2MZET9S
M#B4GW\Z<7354!GUI_UA,%2'#U[Z25.=%*HI+4;-X_<0S"$%4W&6U;['F-7W'
MMQ8/V*KU!#\.1OSQWYU!;V'7?]_,N42[23=#E:'Z9C;/D)52&)W:JQ&\*@\7
M(6&V JD7! XLJ7RZ87_GLA6 GJ3K8KHP/,PG:-MPTGB)'TN?\GE,?+X'(_?
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M6%?!I^GR_^FPL/_] MG]^&]02P,$%     @ #8)_5( +2^HS.P$ :7P! !8
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M%XG2>>1AP_H1RA-C (^90!%L]K-C9&?(['7(2T7;T?;6@9JF9I'E=OW))II
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MG1;B1&JO&M$$6SO0XMNG._DK<*XDX(2M>^KOKF\2#T1E>,>JH@/AN:BFB=C
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M/SK?/*&:1=E<:ML1EF')['++[VW);(*>-OQ^@H%DJHI,(Q22DBBO<.!@!6B
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MI#603DBYK;P)EGC=6*T)SAW]^E9GWR-'[8]/&7XOFZY9-GFZ233\T.-2S[:
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M.N!7<QO@8ICD"/OO:]W^#PU>#"?80<7]J,8+QJ(Q$WW"[TQJP5;;]-^_N6@
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M-/M0?VP"Y8*LA7-WUOSZTD;0V%1%!*\I@-"FV:%:C>D!9!HE,H[HG4.^JRZ
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MAK =<%L]M4$1)XB4I]97&I^"CD;1VO) SYG#NEJ6<S6)#Q3E/(C-T:7K)J!
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M--&>[9%,?)_]VT3E=UO_D!$,ND0NFU"T]LAHO'6KXPZ6DPQ*F!G6SCEXU7I
MZ?D4#7PU;U+U2^IRK]091[T_YN<3?SP,L+58;NM/">LOTGM8O!;N3M&^T\V]
M480&4\VGI<$\BP\FW9:E:E?Q,37JZI27A=H_N>\_?&MV]*'EC[/X9L[::VYW
M5Q.W"+:%3XX'->#;(09N]W4]DT>3W.'IQ$Y<\CVZH3<IJ[ZAYB79BV;TX^?[
MQ7>@21_%+V %CQ'31R/L''9\X3R[(X@M,-.BJLIST^U*9SV/X9,<H-=J-GV"
MBR,J[JG&[,:@$;6;O9^/:5!WZZ("D[=Z;Q37GJJ,;E96_NO] 6?^!<!PSJ11
M3^;'!.-$EI@';DB;XX;QDI7?WW:-6"8_<O[HYGONAQ#D(D04U59"[F;P8N79
M<<R=!=!-D3\"S)27/NK-DJZ)\;0MR07?$X7:]%:3TYABX%3PH@V9F\G'CO#$
MDRP@QFXF;4\$P;[KJ'H60$UDY+ZK9 ';>6CZ'N11'"4(]6IS/5)'5Q_6"MGO
M>F.L!QHHF+G/4F#1OC\JN>R4)/>OQ"V!J[$&5XR@,W=MAEX7[^75.)VVV-WI
M8@%5/W*(ZXE[ZQW*0@FH0TW2E2LZ% K&DM!LB^>Y_*!26-2H^J-DCV>(1L?H
M4^17%E"-Q1#L\%=GS I+J>U$@;V(6/3=EVME[F^B.W@H<(WQCX\1&T^FM>Z8
MX#EZ(SI-SYL_IG)29*F:)%R7E$^BH2Y!3XL1://T*_1AL'3II7O72G<]+I3$
M*CP-&SU%XZ0&7B=-9I)[@_W5=JRA?8GXM;E/DV--)^"R_A2KG,CQE.A8&1FI
MO;Q$8-> \H$T4E6.')[ZA"VX502!^.W=KRAK7ANNK?XJ]J'FT'X_=P%Y19G[
M"N>TT<74T&L0ZLF\J@J=+'B# <(H<3A8A).16RQ1D(STUED?^S$^C\W^IPY[
M2O.O;.MPA;LUGW05M7LROUJ(D<K^X86J'U#4T^:QVF72X"<@T: UM0@G:Y)$
MPNVAX#LU-AL78?.F\NF@B0GQ@;!]/7EZZ/IY3.)TP7/%IP7?7EYY$%$Z8%9M
M9C^D?Z9=62!Z^XU0;Z\$T2R%YL=N#9>,):DX0LN0-H@;+F'VTM_<.;O+XJC(
MN<Q[+L%<9_T.!8X>?!QI\Q!\$*GJ!_HHQ/81:S_<X9FFP;?DX#Y*=YQ/;?5S
M7_20=;"*17)9I$7#=;VV,N5]<$F&Y6!-CNHQ$;&4W.87E\<2W3K>O]N;%JS)
MW#.*?=\O/:8<WI6 ,?-)<"_8=D\5&H@TUF"WKVMT^5%C6>;74/7RHJZ,<&*%
MPX(C)M7BFS6,_Z+HV3JAP#G) ^$:H[G(<4@U)+5)B*9,W70?QAK#>[JD(E[K
MK.DDE78"F/J)4+[(.:=S^Z,%0NTAA1]TDCDBSXEMJM-%&YF7_[<;4R!2C1I#
MP'$4-5+CW*KZGT]_:ANM+O>X)1N0WF>_.PSFHSN30E-JN3_^-+0NOKO3(YE1
ML?K'P9R'9W\\=[&%Y(Y8&7%,.KQW'WW<K5MG[)'.;KPTZ-1V)3_%ZR,F:3HN
MZH\XSTC(X.V)8^\%X-OE>D5KHF%R-;Z$2;[K$[M#SY?\KT:@?VX'%[TKJNA3
MW(3%HS:N,J51H\-3S/3:,)M'F [P[BD6<!"WLKS. BSQS2?JE^B!VPSASHO4
MC @GYO.HQ).5T37_R+2*]W33<^Z1Q\<P'"_R*V["!UL;8*DUCH/!UW(K0LMQ
MBSM"_/?=9^8O"!$\5&D&B#/]V2O.([G;O.BMYC#*R'#QD$^0<W_=Z1?JM1]+
M/FL_*3G9:ZK:YQ K%7-9:\6VT"'-UFV]#@-YMG5#=)@8!0WL.8MN\BSPRW1P
MN[&BHX,1SL^3K+1W@7_YHC0H%F@]HA+\ZC(^8JYY]6A=ENJ<X)OM+G.$L,=5
M\F9KF$"VBE3A8G;@LJY4Q9.'$[7EWBZB?5)/OYM9*&]LCJ5F+.&%8K?0 K\C
M<BP'_8-ZO&%GWU;'W';X)7E;5!"^LE4)_V9[7]WKP6"9X_4Y6TL7))O]%3P2
M+R>Z+AI$_4O_R>ZMM2RYZL4"'*<NFO1E-YG20N *[6',PG?C?MGMX\[C1DW)
MSXXZ?.LX;(S,$KO(E!.>!N_MAT)VYL%,-3855[&]X&(GCB+&5M7^"O<*Q/7+
M8R*\G\M\4=>GFW2_GCUR-]BG]Y$I.*EA"WP!1R#(<;* -XZU+ #);J/$E0]4
M3]HMN#41DZ+2I%VTM/=. G/KF]%WB_<ZI9ZO]5:-E#?5FMLIJMUT+?,X T0F
M>._XRF5C:'R9XZ&,6I\#H80_-I$] 4<:#,=_)MU=_^ $OG)*LLK:-"*!WH%$
M( >FA(TUH5.B6)Z[8<4OD7((_7PB,JD([[L6)'UUV/*SRGTU1'7=N;JNEHO/
M;4EN;]#E8#\C::)N E:F.(;TXX^JLO,P[$T-=D2 >*IFY8 G)6'ZB]ZKDWAL
M3H+,8X_S-!3JBQ/E+@OXU/H&M>@PBD5X4]L)?8\A0ML@"6K>7,'':@[/*+$)
MH_'>C@>7\CL5,(!0:0O73^XO4S68MG,H3UR<(T04*0L?[*RB-MH.5<A'@%U&
M*H.54<(UGU3\N4@&AURB-3F/N/N?Z^:*F( IV C<7_3TON(B=%WQ(9AO-YR0
MULH"CB""R%TI9-B,$8;BZO<I MV&$NI/2#/OLTZJ?CP_(1QE<"("+HOJJ)"F
MI#:2ZPK5(YLL293V-O\Y1N+4C4&U^2;(A'SZ=_@L7Z#\PS/G]IM7 (_6U_83
ME5- E#U&EFK.U9<]UI]KR,(-3WYX1MG4"5SY_&/@HJ?D>K)3&7)(3FUPFI%M
MK&KM6>%F'I8G/(SGQC38'_M<_:+403#PM:?,/#:848Z56F0!8FP4[/L=VN:A
M_S':=1"]M0:_J_-E73304O;I4['3K5$)PLZ!O[QK4;[H7PK3YM$XGZD$/#-M
M6CK<"&)%PI9$^#S C%Z^G:ULZ:';^B+JXDG#9+DMCM^(4XR")ET2F&) !1'5
M99<E$F#E2]F..92UV!"1'N"8I6U@S?[;;NG;:">J!'G=G,IXNQR6E_*6&F<:
MU3;KI@^/LX$J/7TA*"F6:I5Q9V$2JT7NRH>5(;M0514IX]9&17T)AJ<$^O7G
M;DB>^69>+!3&D+S"?3X1</TWA'IN*BE?N(!J3EIP)_MW9: JNHLO')<*R93(
M"GS0&?7!K%Y2\2/Z"<H;E0J2P!YC6];%6GY0?,)[N&W;3%M:A,\TKDX/\RDF
MV8;WI>&:YMI#EZR+^SIN>G)N(;$\/UG W%D/!39IR**V>$[N@^"5N[!@ZC;-
M>RF_>NH)/;B4KD>:B$UB5)<O-\AY8G/)]?9> CSV#4<C379?Y?X"E%:K:#;P
M:@(SG<R^,NAP;6D3-(+T6*FA;N0X]YH3):"\R-%,:3YP#OV](S^?Z[7W1X0E
MT5]]&DT7RUOOD-/ 8DB4QT0[GOA[VS9FD-._7RO>1+^:.BG?TIX^'I9(,!:$
M(]=GNI/ ]V$B<"/!VG=0BJZK[;, _US,J)Q[IZ..H6R+$@))#I<"Y@K)W=WU
M.&\(%1I-1CE+O1K^"N'A2)'YE51XU_.,C\]4'VF!TP#S$'P5*4Z=9//40<0I
MXHK7;QC:S[$A6VF'JU_E,;(PA.U'67$SH4]$F+R'C65UZKWS=-.N1)Q;5)6G
M>6^6:8\@T,UIJEC*V3Q],J0@3Y@TU6D7Q^ZG$NT5W 0&.@Y$/)!5X!?RO)68
M?J[*YJ-\EMO7HSO[>&3U TUD)-9R6("2)NT$"_@U&,X"WMY&?U3>#"3&C'8W
MIN$S*7^M6.KUFY:&GB>ZI:T.3K>'N.->Y/GD+%3-2)_%Y-7NF?_GCZ*,.SUE
M#D(V3BR^]F&>EM5D 58.S>&?T4<9Q;C9R_W@U5N#X*TB93X6T.Y3EH'".6R;
M5YHR*XRC\B\G,5PC]AMC##&?V0%$^N\!).AO 62('5+8(?UX(]&.UH!B)FCW
M.A'CT(M]!F)T*S"1!8RY+&O9FP;E1?XCH^P9"[@:"?K3=5EV(4BQ+?=2;9C8
M7ZK Q@K=;A3E0"-;[%5=^@@^WOR,^7QJYGRP,?O:S^S,6 #Z'&Z+PTT[97IJ
M5W0+MK>9Q ),Q*JORSY+@1&MAV/^GAY6_CD]-(LWK5QC <\WW[ OQ;?) LQ;
M7:[_#D-_WPR "* Z<)K][]\FCJ_^VT HDJC\BES2@19 &%J[&%I6N/JN!#F;
MW'^MMO'YAU' L]U1=38NG"4UAM)3\78,MOB\^#"85/V\?M&^A_PJ_O2+]]_L
M_[S%T]/LWC9U,Z6@A%"&X-_.$\TG#:+X<8LA ZAU:BEE"Y<5,3_U6S*-P=G'
M C@R=^7R+3OM^VN35,.MZX:":/'K*O<+#[<;FBL?RSO//8 >6=PHDA"?.>X=
M\[9I; ;6C3I(Y_WI#PM&UT&6PY)38.\6P^XTVH67C@,\L:+V/0\U; %)Q=$L
M9AL+D#.\13.!2W?OC::4SPQL&ZEW9>X9ZM\^%NW)=67LX^,LD\DO ^?4PO+;
M'H.L^B%*ODA5*H-V 4)-<R/=KWZ'.$TJSOQ@5^+G&#8?<WR.4CK[6FMP_8[P
MI84C/(T?]4??,GO TMI]R1YB9+&2I)K&&PI=3.&1!=*?>L&\N8KCGV/LFQ9Y
MCS^Y7\ES\$LK6U?77CB]9O9[: P;RR$XJ4G$E,-W,"-:,*&IN^(/OQX)MGS[
M>.)(F< A27.NP*MT#K)WT<SZ8Y"@H5WYM^H5J='8K0DSRK7S4DV;KMV*R:(
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M>@(^\'&T1Q$D/QO<.I86PP+J[%99P =XK/,V*!YY,@DRC+#[<%3E> /4E%_
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MQS@-#BQFI#X_':MG8F1OH\G;46,>Z&!2)(S_KEN"#+4[1*3 :XB[O /.?\5
MI,*99HIT3G&F:L<,7>!IVIWAC[LEM9NKLFG>UD%HF><[/@'%A5/R_EP)RG;C
MI%EGV<FXP][#Y+8,2U=U_-QFX5+LIH@!:]$^<$:JN*E^XGB[U5I-+6HK2XOI
MY,U3E;R/&A<X!N=".>>U>SJF&=Y;NY7J*"V_#X61BK5Y*AF^@#K="6T<L1;3
MIUH_0(NC&[F\OXW8M:*RK17S(<G:RN_^3Z^N;]<W"UE',FY(?-K2WOK4H@?<
MSWZ.VTF?M7II256H(?+3 RR3]D6X&)GF&N;([ZK/E?:2D7VLAZ)O(5B]?:A[
MF5Y%6;)Z21MB)ZJ'PT]6O*P&X;FDU^7$@L+[!1_YKW54?SHF:MS ^SE29],#
MGGF5E&%Z&.TN/3/5^;[[S(FDU<<KUM;66E>_1+<K?FM.?Y(BE_#B(6P\6K$S
MU^@DG)<>-AH?EH-P6/BFH!]9<R(_,><1&;'=YG:OD:-T8O4Q_06[F_7VE\%]
M-:',C-]5[E<"SB]8 GSE([,<F  =CZ)[9@[X?3A*V./,W>+?]>5JK_6#D&3-
M0/,+TMM4Y^UW5GTO^$RQ'S4/>SLK8J>.A-\>WKW2>KI):7/)A^%31YWOY*!:
M@K0\#*(L*1=[F@ZJ>A,L/^<%7RJ(ZY\0_:D\81I]YF"0OEF5.8__ECGT9#D:
MW+I*@9OWBE\NI)SP]F6$R*/X4#;32?>V;-OX!'9\"K:7%T:+%,.>H1!K6H\O
ML$S($BHUO4Y;U6Y;.&^@J-635>_RGP\>':XU5B3??^A9OEMQ-/5HJU!YW<KS
M.**S2>10_:?]]F+M.Y[N=8MJ]2'4#/=%CN!KE&_KH,]1A!ZO?<=,O$_-/!J_
MRLO"']:>&]<U9 3KKOST@.6;&#AQ+R%H_<BM='[:- 7SM$+)J8G*4QF/@T<W
MU]1HO#ST,_NGF<^29&.QZCFC(]]/V3#3TQ&0FNX&JKDI"%HJ/6E$L^@K5KY^
M$?)+N#W1\[=>7O!^^R+3>$.>CVSN2:$GLE)S@LE=8]>IP-P8T]>&Y51&]R3#
MG]CQ]&IK)]IXZ8KGB\2?N!.:(7;61_R>6<FELVD;G^DY@*W 1JP#]3.*G:Z-
MRO1VO[(^%S!46'6ZU#BHQ/4ZWB-D'_L-N>W<8&7R\4-]ZX?:)V>#,+HQ<01"
MA93B >0P=9_QE0(,W7#[4XS7H?3>S]AJ]_#,S_"AX[.H3$1>^],<4!J[";H5
MOY.3EWI8.M<?W'-_U2)7JH:O"R&TU+TDMQ+G_(&;>13WNO8Q]9[PTMEMMQK.
M,Q7M7A(TYR6.E$7A/S^-_D8F&LJP7WD,&M&\*/'5K6<L>_-GC46,/WYR.7.*
MB-9*0WO'JLJ9/!/](+O=\S7_OC_TAN+<L7;0YY&/X 4*<TUN[[QCZDIG9^SD
M2B+TJ(<*Y-8:/LE*U<-_QA1/2MQ57+[U;_F4=+33B$WC3$#/DPUE "V^S!^Y
M>>JS8W@N><?AI"S$Y ^_V38.;.2M&'S+LM)>H'91A:U03&B/B?E.:K\E%MDS
M/K4X!#K.?1>O0@Q<];Z%&XZ/,R]2IBV5LB+[#584,<J(SGU3QX80]=E/7<A$
M04WX KR-Z.SQG0.[-> (^J@L"I$>-?BYOQPLB$PB_X3<[Q5VY$)Y6O[$--IJ
M"%-"X9^7X,#D"'6(E7X$A$ F"J81^5ZL.((@0'+BP)8O>$[T4%\0QMI[0$=J
MC@/(M&8AEW3#V*' ^'T2,%L%+%\CY+:?IX_1#G!@40.V'!AA$^1X_"L:7&-I
MEA;,+)SC['I0>%^?+_&+U?ZWY>XSU?^FI8E?A/T1HA%#VI;@.&+MN.+B$-$4
M<0?!T(P4!DKXP8CSK")"&+1GD7!D#[Y[2) #:WQ?Q,8":Q=.$RT1MX@,:<DM
M$,JQ0:S!"$VE[)OL1&BUQ]XR8-5=#FQJ0WXC!Q:&./.R+G)UNR9]>!P[RKS)
M@35=+H ^<P=84SU/\5V-'%  SZ<2V &05G5$6P20$B 6Y(/_ +H[XA</9\_X
M#L\1H%W+U(/P#L1TIPH)Y9]YZ0HT"PC.]+SEP$C'H:VSMA@:#/0[]!L#^BX'
MCJI0$4U\;T,5AW3[?@_DJ$"_XIA\+B5B^(R??&_;^/#1:F2A8J%&8+W&1Y!*
M$.# @KY2X]D;EC',514.;&].#6T4>GS$5@B,X7](8-^@X"_L%3MKS^^,2\3I
MCS-HZ(CJL<GSX>?>9C-DIOCI+G QX*O*.0Z,>(\#HS8CZ2[\__ '"J]B._BU
M#C@RHK2D1J1:KJ$HJ[4BDDJ4B^%9MK)N-G;][Q9E3S[>]%!V^SBY] 09MPUH
M4J! NP/=Q5>]^P6KEU_&'BLJCQSX^.GYU&G3P52&I")5@.;RB9Y'[:JQ4Z/Z
MS>U9?<PZGF8HF32Z[;,M;39=BT7ZY%#8?-9;[]QIP?#*B;+;</XI')P#\P_U
M]FT?=0@OC-V+VU,*2%I/->9^<Y'==N2HD\:V<+K,0Z;;@+H7K9N=NX]N2Y[?
M-JH?7(9,]4;4KLTAG+JQ5[+<,:^_[3X9:X97]>JO$A$5W3BR$XVD.5 ;*N'\
MTWETD5%,K:U:K>0)DC#Z9;:5I96?_I6RQ6^)$[=D)J5^NI14BG%GW_%X@2J4
M+T]G/>@$I; :E/GYNOC'6+FWMK>3#_?,#6Q&/R[R<?$H'MYX\U-6])K4%02N
MG$C3X<!B3.C0SQMQ\1S8NUS2EQ-I<P/4L1'\W.Q8TIYVLF/ 3P^5N5:S2SW;
MO%W-?-*UHPQ6=VO7VR?8""SM:MA[[<9GX!M^%%Z+> +_Q%-3KF5!3P5&7\"-
M.Q?R'[1O'DA-ZBE_EM=?F%?F?TIEV%P)UA3N>XDG#]=GS(&)IE"#P3IE,P[,
M\"9A-_L5X(IY".YB)U>(.EDUU);+UYAWLE12O]E9-<H-;N_H/QLM7>UI;HK@
MG<8=PLKUX(1 2"4DI'MT]WFGD+GMO"TN><37=NG)6+OD/Q>*; F_*W[\.$^J
M+WPNY:US%ZX%S_/.3[=GL$PB)4_M]+OH.V]D)P6YEB;GB%3%&H0P<>0UL%?;
M>'3'C1U>ITLH0]%1*&O7+7.AH2.N,$IE1%)F+MV(>8.E1Z=\G)'DH1^AM6[H
M7%RXV+.PH*TG4>P_<4!NR\>%)V*/] (3_$<O#/CTU:>SQ N"ND!>,RIY_SX#
M>TFQCD:#;HB66<"OVUJP!!*/1M*L.Q/.;9NUZM(L ;M*Q%@/6>G<G;J:N [=
MC?1MCDY8E\SOSMRFAGHI=?;N)SY+B<=C38K-EOC+9Q/I-2/P^LB^U=.4MD!R
M]KWCA[1]'CCO:'OC17Y@?,:VW'\D_=8I=]E-%WO;6_>DCTE9#/9'43V':]7S
MP,:O/[4W>[SW*D\>;5T=6/VX6):=JAT-48YO33+K0XB""$0G/V[CR%-?07&6
M1'YNQUNC*Q_SJ9N^6A_=MBAM@EF$%5?JY)Z4P%3#^^UKAO,A7J3M/*JR8XJD
M"6[L6GYABMS5M+>7^KU5=_F!0ZA!=WBZ6K$DFP=PH/ \7$8&Z6[O8!T8_:PR
MQ]YF6 0A,S/%1OMPWQUM1@*D:$."-IV+O$[B#H<NKM:?L'@T[R$??A'O,S)H
M9[V2:%Q[[$9'QD.>-]H3Y7'_Y:K^CU1RGH==C!WSQ;"2"HL@3?%+ V/;;37#
M*K2]>2JMNA/UGV#-[%-ONV5\'OA^9+M0T*GI[Q9A?>!7@.\M^YTG:F=16'Y'
MBO'H2[1LV1)?;X*KP_T+]L=YFX$]RW?IOIU/$P-Z[B\?S[@<V%N._)!GX_5[
MPAMR^P-$;2,J-E#!_%(D9#/L,V:4PJ6*BFY8WV:/-4ZI6>A"7JKI -6+[>]*
M7#:R>&GU:KJNWCF;'\DMIV2L@>]')3"X]00M?F#<V9N#JR.[B'UXT+BA!K72
MN0"1[]0<_G^:U2/^EM6#_V-6CVFCSPH3><OF7TJK!<9NP5<646N6?R&=E[J>
MS@-]*SFPLLX55,+:!:*'WP%GD9^1J<JX.$!/>;T]Z_J?95AYJ>UAPXO6.%X.
MK$__$@?6*:;85^<]6;? 4"9N N9DTH'I[;&D0%"A&16C^H'"(DT\D--'K"4@
M!A'-[](G.3 S!68:PT(ZWTN?W/L&>AP28J6#F'3*; 9.94-NT%:<T2W$N%DA
M#[SQ0 3"S_HMK)^W!,$"GCHX30"^=D#Q$[N .)XT#:<)(=D"RFY$RD4\8R?6
M!*+[T.:_C?ZL,F -&@Y%0;__G;WVZX-Z>)5N<#L5P>; #J^P=_T+VGH"HJW/
M_X=IZ_[_.FWY7UZ$9*S^&+Y_V^AP6('E+<KF0*IB%;^74MP];XR)AE5Y0>ZM
M_=&G$#\GHBYGL*+WNY2,'2.\=BB.V/3ED]*U9:4^0NP<=@<9WZ]B077H+:"V
M@2V5M-*)-ZG6=*#*G /[IJ;P+>?FDP:=L8"CC^_ & \N/S.0,WC-UUXU7$BL
M;A?T#L=J9MPF)7-3C>X>1>RQU(V]=]&@.@&X/RD3GN/>7]Y_(-JIUV#05M3!
M\N(IR9XEUP!*,,V-?IW<JC+Z%"?<@6$9D3.-$DQUS#L*C%[VW=C8[%#RXCBO
MVJKEP^,C;G:!S&,LD6(Z#X6&W&I(WHH]Y2B9XNEY[6;(,TNK%FGO>8M#M5G7
M1G8_6!;DFGG^N\Y/+,"\!6G-%[")2#LZ! &A%YESO'0.C-8*><,$=@PPYUP.
MO<@C%GW_MFV$:[&()7@&-)0,@-Y^(W$YF4S455R&@[S2')ALY'K+QSAJ#>F&
MP@M1OK4SVYO@O4.B0&,8.!P_)<0T>@\T:I# $@CMT@M0^:6.K  78#8:NJ%]
MGS\A&#Z+;&04U1V\1ISGP-CY=!Y:! 342&3\VCP<LE9+5LN$?BW0"!4*S.8#
M:W**K>BJ.D 21UA"M.]M8=.*Z/@)/Q'F.M"<SX' G3^T;A7*/CF6VK!^A(Y,
MX6<.S&X;!Y:RR2]B4''N$V'U*JN]EVX/ZGU< 5[DF^CY3O;\NR2[I KS.K23
M9=YY[$9@^9[%CW+<.UP?L(B15.+ [L'9>V,9&)1($@<FJ8O/1'PH6T?;QI@U
M:*^77P3B/N%:@<73VA"ZOU8,+'.A8CS7FICJT'I;*/IL_W68MLD9TBIA7+!F
M&/RG*(9*;&34T)J@35@_:^-:'[3*S=B1E05X(9(5:X1B;FZ GD:6P$-0@X-+
M"#/61#MBW-ZZ>X7X#04:F8=Q8#:0->AP03VX+T1!_A,HO&:#I_.36)$=Q4;L
M:A09B): +&>9W\??O^_X+&^,$:G6WK3+!5/KTW?HNJ7&9([JL3:>'Y9$2O;Z
M YZ>@)#40S<(HJIWX@0+^':YSHLVAQ__W'R >.8E!Q:('D6NB1PELK@C6?O_
M\5?%=^WE8JNI<Z.LMVOE\'&4VZ:D5\+"U(&!T\].B?9'G7MS1?\U]U/(QECI
M3,V:WXG-UU<D8!4I%J$%FMWJA"U.>^K?2/&N>JW=%&BNW ZS?1X-JWP_!6QE
M[1I-.J^LKT_!!"\GG59Z\G/.HU@Z5O7PW9F'3P,B^-UM703K+<KR RX5)/;/
M;/GIDG8NXNJMDXU3-9LLD1MW&E2]GU[SRXFRQ]A?1^^(C2U#"PKW4A]'R)H$
M7C%Y"(-MYXN]'0K+3'>FE98'UH6O9&D66NS*-QNP.2<;>OEZD+G9LU,;GTKF
M7[UJ[6RN03,WIUI9#IS[6(5Q]3]&UH,=S(C8 "UR]XAY^NOM P#?M+EOSU#N
MY@1'ONS[84)UK/M3>5_"'F8L<I4\E.#2OI&4,I7H%3QGWG*^:]YC0/V6&\:1
MMT[TUHTOI].YY4(4NJ/1IT-A;W*V%79@ZI,OHU[("O\HW:J15,)R0XF#]<,B
M( ]6F:XC&9]-SSM# 6H5@QVI!6FAZK(%W?*]7/NF?P@<5MH>2)L?<Q9:D1O*
M'3L&RBL_/L&7#/* 39H[LG5HAR!Y>7&R:%&#W?K(^DN[Z3DM4@NXOU-7PWN1
M==M.BOVB0GBVZ-VA0RL[? ^,2WDP^C>X1?K".M@Q]I087 =>\*<NO^P!2I#Q
MB=H+_9=DSOO=U4YV*^ >Y\!,QA>.4),J>FA"WO@Y1@;6( +=RE^/Y]-6H2P8
MYA=9'IW%\-W^<&]OO%;#\_0W@G?OG8A&#T#FG9O]D7C; .$P'%RX)SPG>DB&
M:E>"3;0+?)OIPC2N\;IQO"]%8K.APU[7QM5FUA1$5(JL9G9#RI.W3+,*<PK$
MGN]HR'A1H_RJ;N3 @?;F^_/* 23GU_S7Z<K4%%IT$;TNU?O,&$^-Q$$= <L\
MS;OTX&I#K0%G0M"^;7&.GH.Q556B2N^$>2+4R"+SL=2 !I08*.VM-J(0J*V6
M,SW,OV\X>^8$*SJW),$+4_3(/NKN0/19L;8++HUCVCV]L61$WRRMGJXU6BY
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M<@ YDKDUDBT8^PW7/[QX<3F2R0OQD+B*#J Q[\<:OBH9$AWBA"3QK:[:[]J
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MX(5PULN&,,1W"''IR^&L23/Z?T!UE./#U+'IM;PU0C6>(0@]. ':$,,G%G\
M; Q-5!8^#\5Z%KD1Z#L$9\/,$^!4QREW[UQP- @BPJS(5XA?JI;MJ']([B\=
MX< 6U%80;7>6P'/JY4CK7XJ6BZZC-H+-D*^RRD>M32+ L-O,@8^$U"8.["$;
M:&2+/R9^EP,5&-+=_[J.^9=+2%W16^4H\^6#U]DN2L9[JR+%MT@'CQMCO4;@
M_& ':BM6),4)P:M2 <>:TIVB""R9_@J"ITYYM]4#[-?ZUET'#IY[O#_*4"F#
MC^?\VK8QE<HDS;'+PHH/R @A^CUK]2A3Y/;9F.DAI[O'GI]SD]KHEIR@6T"5
MPP>!&[![N_(AWG,;(:&KB+:B!:"%XE+A >HN5F@MYYV;I/3O?-*'-2)*MY\?
M$^1:;I]CCB19&].KR N[68947$ 6UK9[N>7JK:\>&UHV1Z:FE 0*V3 B),_=
M5STL)@N9]4C"2^)-!#=V;X2R>P-^&\OD@S=Y]>JN_MLGADH^M#_ OM6.#4)J
M;]TG<[R_F9^[LR+JM\-;TLOHK#&1%Q5.8@>*71MR#MQ,D!XH[]&42'&K1Z;"
M#%'0.ZHR L8;0(CZDPKP8+PUJ<MS2>'7-L;_N?F5.!0XA%]T\TUC^UA!$IR+
MTB)UP(O26*_L/D#LQYRXIF31ML*4MP1_&+'V,Y3TJ0XS?G F%R1/U=#_]VG,
M,I1Q =@;D/LV(2_\O<V0T([_EP@+J!U>0+(45W139.C30 C.B>7_-E21XE@"
MAM:,ZD\/SR$AY1@;):Q->W%@J:8D'J8;T+#Z&#&;1%H*_=S^+U..?CDRH%Y8
M!RZ8T45&4//XUQ@J;"7&_5\!4Q/)DA(/G@]^3)Q3=($8'F1?@ZDI,X#.-6#(
MV9?PA2V_#I[RPU;U.^.(1HBW<56_#-S]A\$\+S,;<(>B.+!M>2,$]N,"?K9T
M=(4/Y!B>>!?94H:?:LM(QF3-[+&YU_>EK=#"]/1>1D"T4)#; DK:F"I09Z&Y
M$ZD94A#B6"3W)FIA0EE,9N.'P2JIY.2"%8:KT8GEL1"S3\Z@IG[LD_K]1M^*
MY^UI\5[E&IB5W4 I>I% P]"#R=E&8T7^RAAMXRS; :,/YSZ=T6'E1)11FJTW
M/MB%RHCAP-)CV%UV\O8/XU F9L\)GNY%.VPM;)H\$<(K?Q: JE\/0 G^-PM
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MZK@O, >1085-(P@FKQX;O=*)6>%?+VMBB# /0UM0Y<T/5D<!5FR/E^PS$%
M8K'Q D!90]>*CDW1""Z-//1G!?,LIDH(?GH3_ZA^!_S!O\[^V6#^9>Z0%O9_
MHEK^KUS'4&%$@5MTL]'GO3<HP4_*G+;/;KM*O]5SZ-"SPXBR_6T))D_W"CR-
M4"2+$\-QO.QW69YH8@C^$^DIUAEPR)K9XYD-QH^^6[I6&/JC=[_LR_D-IU0/
M!D:=<1D2WVLQ12S'CI)1P2@QG.BLK@Q5P;]"P:E_*.2!C^Y;[)&Q@2-"!6D)
M,@9-.^;$;X9?SN7V+>:Z#+>"C1$=42*W=[$N=[".4(9'A#BP:DS0Z;:)650Y
M*?]HUV3B^"9K-P'] WR&L\4"CZI$U6D[L-<IJR"OY:@+TJ(['R5&O[]@5-XY
MICHT*RF8@#V3<D945N3!RVL7[ -68V">ZBOX );#&]9)RF#D$VW-C'ZTK_*B
M3]QJKVG(OJA[IZHDJC;N]-FXTXG[WKJ?:^,/!_?3DXF%XQ5*O;BM]#RR@C]+
M1.0;2\$YM;ZZP]5V9Y.OX6F)18.];@5NJ^@:Q#7$3GJ8'3L<U,5J=6'%,X8L
MAYT3ZU-$GF37N[1^S2T*OW-RX$M6REW8HI;%7+C/9!7J&P=6B<HK"EHXRA]<
MRL^263/^,8!"8F@M84E+@F=52ITE@EOV;.>...'YFO\+$P-W4@"W9"3N[\X&
M"G8SEKN<)P@O)PL_DJ0U5MJ?#U2\(@T2=]R@KP_'.TZ_[CS*O]T2#1[]1/D9
M@SD4E3&\S8 D/"4W*,\GIG.\20@R*E60UW-DZ.Z#[RFJ:3F3I=[0_P7EC)]+
MON].G ,=XTE)G^]/OK+H"'US&7885KGA(>(X> C">1Q8".(V\ELX3H$N<);B
M5V8G5Z*AZKRG8>#IW(U(;XC=PS:MC9.F>M:KLMR8%W!-:>#[?Q?5VR2=0LVQ
M!/=['Q>++;-\D\GMSY?"=VJ9V6,2%M=HG%I2B?L"7^2AKK(C?(E@),&)D(QP
M5)'TQNAWLER+UJ=@)P(BM^-W*=?-N27L<_Z4\_IC\\?QPR.D4J>*?9UEAMMC
MG$\D)7\0=,D=STN2O^):+&=8E9-U63:C*=_!,.<RMN>?Q?#8/.LQ<J!)YBLP
M=UP$C/EN,5F'\_PMT^CSWR+3R)6VG"& [G<H:]U;&IAE>J!&YLOK@*ESZ).D
M<87YHX@Q*6T?".):$I,>B-G9Y>V)P*MGY=R[@6;;'30O68./[$ CPVA!]#RM
M86M9 <NIM\?W./".Z[L7<R>[)>/>EONWFW_J%LTN&!?9GJ*4:Y"E/XZF\@O1
M%%@"*%"_762=L:NPQ>V&'*+8=F&U[D--'O,.W\DU8\<G/BS^]-/Z"\T63QV!
MALBTF?;9!5Y@W,P:K$"PY:5_24!:C _^VGMA=1.HP[]I)3<P@\19F$7=N^Q/
MP'C&WT(("+:8G+?.@X8_A ^_0&"AK+V; SN>U\X0[5W1P?R33F*L %,1NNG;
M'< L)"=KRID+KM45\0H@]PH$1Y==(?I_-YZ.'P\VT1-:@-_YJV=U8M]0 ^K-
M(3X2.6_M0-6JTXC?1F'6#NT)KO$J7;YTM.F=;8VG;*Y8H;^IF/"MEET/+_E:
M9 WA>E";LSS,>W[0/XQ0TQXO:?_HS1Z0^78F&OE13.>(79*GXZ:5LKC5PPUN
M&P/0=0>#S"6J>/P5OZR?,XT:&8K-RLEVI&16%?9'(Q+CCSB9-\\PVGY(']->
M$>0:A^?IYFHV\/=KD17JDQ2-/W^DR U%.HR6"R_2!K.'KRS>]+E9<O7[YBW;
M LVO-Z[MU,U+'PNY'FXBN&]_Y151[FE3" 0+-6 OT0M&( 4;$HFIQ6E2-^&#
MC]YTVUGRV7ZI\93TKI-*<Z=S^U^_XCXI$2Y$!C8A[A "AO,U<G5C1E!BUC.E
M^?MO:@@,(-%:4O6VNV^:CC@FE33X1HXIS*=2T",B(6\HJQ'::$PJ^M[!SU?K
MT#I?HA2W9QI(AQ=N.,[X:'"4ZZ?0$OS7N)G?IE&XB-.0#F4(3^;GOWV_OSXL
M_:Q"07F^'[4YN!C1E2X5@-+]0\KS*\_GOS9/=</]=_-Z=W%'Z<,C[<&E,5?I
M 19@>\EE2U'U_)PW5Y^]^_3&SF E_?GS*^-SF'.!-A?82:+'=9ML01X?/7=)
M7GHXQ'J>W/W>^AJEOGS_2^8!)]DP9QF98!-\=:G[PD554XL0H0-M3U\=U'M?
MJB-J4OJZ[%%.]JU AP=>4;Q;[>O'&^M'H[HMGIP:)>PTI%K-5D\V5$@)7YH^
M,ASB534AXFR[I3WVZ74_K96LF<L>\ZD_?59F2P\=.+?:E3;SH%Q95?U(?8;A
MC<U;=8QU"[7^7RCO?T4HS]2DV/?KA@X#/F>GOQ5J+4%,G_<*9"6* A!S<$WP
MJ1"UW"\*<DL'USE[%9[&_Q)"V;ST(:)-$^+[ 0@?J_W(Q3=$3?\M3/%*Y"'$
M5PZ(K!!(AL1NQ'H'Z#CJGV/A11MC< F.[%ZY-_QH#1_F^R?5<$MS%?+ .\'_
M12VB*@QA+-&,KE;+@:VR:DC+^O6>O\.YF;^OCJ-/L0Q LU1J0P\\G0)\B&1W
ML#[,=B;PK+W@P ;AS<GEBLLKN6P9>. V/4&S_7_E1,C?7V,5!UA7*6E5&)Y!
M>DK]B=H3&I&NIQ-N;DK61]P_UG'*\9[O07]C;UPX\S#V&+WI!\N,&C@96N;G
MD'V@=\X#(61G3%,^(78J5LIZD_3AT.:7-HCO&\>7+N&ZP]Y9@IVHO,*T,?5'
M9;LVT3[P,;_JMO!E4<[>L;M ??6N2G3YQ@DWE-E]T>GYDY)'F!JL.W04%5VS
MV@OG5[;_BC=PXWLS^B&_(\WV:B[L(8UYCHMGX9"^R2M(\H"1X6!PB_<]YAE*
M7XGUMM:+DU<\2IYI?'/T^YD.XS+3$>13K&39RL?Z0<(B28=^;BF*7OL1'^BI
M3KT3=VUW8=8-YCZ;72R[6^>#)F-U%&<3_V%#_FDCJ!"5 _LGIZ3]:4Z+*RFR
MD[A[_>Q=Z7DCL.(F!_:U%3?@RU:D*M3"%R6[B;,32/9VT@"EH<ZB Y<6_F(>
MGG":>!H8>0D92BSD1J^[K3-MHD[FLB*X-0^BMZ0Z@"8"7Y-3'"!OK$A1N>PV
M CP-1]'W![.B=7C FBA@6J<.A[680OPQ$,?H^GOJE8GY[Y)ZW6 QKC(/&34%
MKK%A)F\K:W9EAB@-.!,8Q_@EH==CCIE$7:]!+*@MLTW&)Q ;M)LK(#WS1T-?
MRUR?K?VW1E'T6"E3 -Q*@"S,POJA0.)P,)R0U4;\?A!+5/M2Q8'M4>C"_X5"
M,-;P?_2WYK'^K^]O_4N71336>WV:&?.4X>B#2/$&3W>7T9>C'ZRM4RN-O.Y>
M>9*T1?KKX_Y3H+!K0JOO(!82Q4U[*)$-J!#\CJ/#F[![OK[K5EIQC&'B?DJ<
M[NT\M6'^&TSM?# ZVLB%1_KP15%_KK'DO>6=".=V^@&>(.P52IYQ!&(3ZWAN
M-,F**O?\@%#!^)>8@V<#W<H<J@/:3N?6?]V:QMQ!!Y#T.J8>KB\Q+>S.2&_.
M@!G88E'Q6$O?19;4\:+>%Q9'59%XYFOAPI2\BNO";\5H2XSL,!O1?XP5H?0.
M-M^V2@U*V5CDW5?[90!C^R[JU:&+-:37,'O^JW0XE42SHL]2'Z#H.B,/D$]P
MXO2DTI&C_<\U/DUK/NVLL+WI,!2Z*G"-CW=^H_]QV'=(TC3HR0MF[#C/ <7I
MFGZG(;G2HL*AN_L"7_O?(!HO:@&5F9!9\0^G+]58$>>LJ8<Z&VI/&,]_+Z0]
MDBHJ#]6_8S>0+*B!A"7.(*X#W_PQW])HG@%5_:LQ;CDS\6JW3W1627N739O(
M',GT57*K+[MK(.M)X&>7$>WQD#YMY\!N$I_HRJ_/_U(X1[HC5?# >M;!CRK\
M.5#T:>Y,5@WU*!=M<KW^#!18!IO^EK*TP%IFV4V=V-%#P[^SF2VZ%'@@[=LG
MI4\_'E8>.DU]M:A_YC).#&A2_X]PW^5XQ,XR%4<W]?*&)\OI"B&AAH+QN8HR
MW/[OA!NE JHR_%VF<HP^6>6U:8LS3\Y*JE&W]]L2:VQQWRUGMJ;=%E&UL9K+
M<\_/TY5MXLT2G><92*3AT)45ZP-2[^,.T3-6]X )&Y!DBVCYZ$7UW2I1.[^7
M:#\-Z.HL)^A3-6+(*II,E<MYW66O?/ WBPWO.QX;S'_ER+.H3@I-:T+<%[;R
M4DM3S+9M15((<';6<Z ZB+JULOVE8SN[O,:.F+@([V\!#52> +/9>#"VQLX6
M&#7J2/X)N5X9)01]# (W,CW+XU=R V#\@X1%H1NOUR-1]<-@"?2+QDROEJ0-
M**_BNSB+8AS?<0:L:T0LOS^_(KGRHQ>_>&]/,#OL&3!](3;<=FS&ISA[>GV8
MR865@_O?EO)1_E_[P_]0^T-&4>^"IZ/;=@M^M&S4)R7J0RO54UQ!YU1/+!ZI
MXU:B&BX3$B/"QNKH4\F;(?R;3?![5*8CGTO#YUYE5%PK-BCDP-+KOQ_74>NL
M>%84/NI_U&>/Q1588^6&6J]C*]DS'9?G%Q0 LV/MB6M7$Y]YO",71X;H2E'O
M/T*[N(W:BACWVE^.6M =QO4.7;W$.U_K\AFAX?[TFB])Z=W;G+9208<GZ1_T
M,BOFY5;SBA=ZGY.>LT3IX6/\3]9<X@JRO!]<Z#RJR#SE]O^Q]YYA3;5=VG 0
M$$$@2N]1 1LB2I%.1$1$!!24*D1%1$":B$0(":* U @(* A1BH (D8ZTT*N
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M+V\S&,=)&'Z$/1"'7Q&_QY!@\D&Y"PE$:_\G-V>M/45OVS7BEG7,RR2XAPH
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M4!M43PT"SM3%$RCR]G9O^)QF=ZOIB -!.%Q'"6%11=:)(!D1FO*>#9(:"R8
MDVN)#T[V>D8V0*(>PR@>:-Q<%.(R\V(;(DUN4S7<7FXB/84P9QYU5,5QRLN(
MX]*#!_=HX?172!DX9A+;=%3+*(^V'RCQO9T09_MJG0DFVE>7;YX.7$R7\!OJ
M3]6B5TJ3+8,VQL2&)L$M1]T]%M^7ALV2W/<I-5\3.G3;*U8IT'5)PBS M;WY
M]@>'K"4YCX+A4",NPH]U7RC/QI)YX[APS[*/G1,^%%T<I3B@VAV P@^_#1)L
M%?6]*6B@W:5Q/=>'G#E695Y'BB,H?[T4='$:W2#,G9]Q9]_9*>_1/&0V8R1U
M[V#-(60'=#]"'=^IX69KVZ^,%\R+KU%M9[A(IA^19($&^Z$"[SOU(?;B1XVR
MD\23 \Z,'+OMU:[1^.XE-8@',4$Q$2ZB=@\(AZEO6\RB&;O085 GW.@NU#,4
MES)Z[_P$"^.,W;R0FZ:A2NC3B'K?+\NG[*]KBS@=\$Z:03&-Q?4*4.?USC"=
MQ@5TW#TAY/C216K?0_FJ]V<68RK<M+WZ+>?H\G[\#7TI"K<',5/(ZTF9;]H_
M%OA1#7S=5-QW0*\!*E.LB>%,7QV!8.+0>C,/<AZ.C69*AH1H.;Z;WX2Q,4ZT
MN3GX\WP) S_+5%1,#WH45,M?-QD#^[@N1HBV#HU\&>L'.6T:LKKM;1YI-UA9
M-,74%7:>8A 8</J[ED&-=D!@WF)FN$$ S-#RS(H):C<V,IG!UPP1SSS%_?-4
MP+^<F@H'.BC1Y*%PQBG$C4&MZ^D(?J# -6O<8%>+X.:S&>L+K?&\YQ)$VK>'
M%GF/0<46ZQV.3W[POZ2YZ&CVTB7?&A("&Z[18482);(2\]%<T22L+3V1(0LD
M3R8VL1",O2?13;FY^QU5RA*S !/+1&_!%M[VTZNIC/CM:2/[^/LKPL^SCIN[
M=+?6JUVZ$AMKT(CCP[G+DLL:5O;/":% #+6ZQSG.:R-ZLBU/O<0JFZ\;[3^M
MUB;)HC- &JL'>KO&#6<! [*4B,.Y%9E4D?+K^JPRL1= !)R'*[C%PGO>GI/,
MGOGQKNOK=>KSM"B_2N7[@@;]+^2FR"(:5N]33$+'[KRY^HI$.V*ZJ]?<U]?R
M&^T*:::$H"!RKW2D^2FINR5I,.Z!2%U %ASI^EQVI,GJ8UB\FJ/TTWXQJA'%
MG_[I,&! RKI(JL&2($2[,7IR5Z_1K<G5KREKFI'"\:87),_.5!,I>TA2.%(+
MY1*)(T3+/+,S;6%POUU>9U27:J,-Q?>*I^EU1^AS[-OR[(;)>_@[T\8NG47Y
M)SN5%K4\OPT?$=@JMACL1&;-K"SMIUYV@8DH%!L6HYZ@1.\/-JN;Z6;#=;\6
M/,AP&Y9&^=9H6C(#?KTC ;=]:$(02GJ93'.EL/6&)PT'<*WY'&:Z+[6/H:R1
M'Q<&(QX@G:9V0 W=X>.'2*AH96.7->9:Y;B=<(]UYINH?_!:U&!3[Q0;_2(V
M%XK')V#6/3!24%($A!8#L^ZQ4T-H:RD_=D[_6CN]KCBG ?>YLZ%C_)NK8EXX
M^/]<B*PI3JM 7Z3ETO-U5!8F(%IZ;V%PU*1O$_5H,=7Z8+P/E/-BY)<N\>EO
M*RV2K5BVOX4ZS-]#'7+VJOT,1*/IEO/Q:TM,Q]5?;Y9STEG>M!GZM&(S$BG%
M7+2A,!5($$[P2$&?@AGAWA)"3NE2^V?JN^<_'^+S!(-+T/F0(O.)=6AP4394
M:P(4H <XA]^PY%42MY14T1A-=U%.U[?A(!@WZJB5ER=<![3))W;?;O -SO=N
MZ]:R4 BEZ><#!1ZV>H ',<_QOGMJ^^*/;>Z^"/]GS<"=8RF%)R]<FXP<6@Z1
MFS']YH$O"ZL18U)3$2+Y3)17>DT!6=ABX"-[,[177G;_8^^3G%NVK@XZ\:L[
MH&$U^^X5J!4Z3'3]=EJ6)+0"G8)S]!BQ- / ^!0'XR$D.\VQ)I5"NG%AQ.F9
MY->C^C?X5@]VZ2[9[H"*A9?<O,D>]0D:]C%,Y;N>UU0]_[T2!M?Z(+AG(=#"
M0KV#=[QD>V_S/4(U.+>/HE,__F,KW\O^\;1-24%21?*H'GF3P:\@R$1[0D .
MTQ%D3!#-1N$335>^ZTLCA( /Y]1N<P0?[I;8'EI8/IH/6?RH.-<=>4,I47],
MG[ZX=1P*''5,.VI.U:'YREZ 3ADQE[@:/6G:\KQ&XT=%WJ(].QG[) 2C>.XF
M^?T+Y2VG[YQC?"MN[:>#_"4L<\R&/@58C/QL</R/-M3\=X^TA#LAJK$&5L2S
MUBG/02QM,JG?<EQ;<:X1"U&J%#N@P-M9)N:& 3[J?$9,Z: YQ5?\B>0I3EHV
M:^,H@^L=*8+!)PWJI=DP!)@X?CB/>+U7MZ=Q:A*LBEQTF*%^;E%K4:%(EC3Z
M)I!-N2-.*&8_C.'5.R;*!CDGMQH[9,1TN:$',L9O(+U-9>MNL^C<&Y(ZA:P$
M02XQ<2.Z&<Q+TZ*_0.Z'8UH8LH5?3RPC5#//C43GG J[\SIO7Z#5QEVNEHG=
M@5I_[S)X]:_*B(867=<J*3GT;!T^H(RXN3B<.S>QKYC'Z/+7*CT?[P]VMO9R
M!D[\^B*6+] 5G!S83/^L)O1HZ.04BIMF-BX)E.&+L%%G)K\%)%[14\!,IR1S
MY"_>_G!Z-A;MI>KH/8(\Z7S&!MV X3?T=6+O:,BT*S96OC3-&1Q]+:9%M^^K
M!61Q.OV;-4V89#Q0'5\EK#@W6'.GI_'#RJO^E,8'CV=P\@HX=P_!>0M+H428
M0*J_,_%>9M1,9&[N+BY,XCLV='-:SP[(;8)O3L,N/R4+8>*JN==J4$2>D'"J
M("U: %$-PGZPOEP=D;647KVI-?&12OL>2<=TGLZZR*!^0%6Y3F&&NRE3@!VT
M#@/&1>O(S[$V<2Q![HL%;Y^8(),5$LL?T<>_^-^NDJ-,TK.04O"^1BFAQ'K4
MON(\LSWR6=:CQC7<^R..L91N'I J(7]KTSH4GZAD,@*QC9E>7T/<.35P_,/5
M>/IL82]]Z/WLMPG^_$/08H[Z,WSO6*FF1SR)FWOMF\NN:KKQR4'.UN-X1XF[
MGZ_*H G92>>I']W#Y+ZMI4*YUE'#/T=O!"M#(L>%<(-5'L[.F74/;![G8[D:
M(Z8_=?!Y1<8,5<.O>6U(&FD8'X.NVJ'[O4UXZ_3811M./TLYJJV\6?(2E]PU
M9OJ-$SH I;['G9!;FJ67U;!LW4\GS 9K.##.&3)4MH9^CJ6L1:V?<48!^XXK
M)7DGA1ZJQFY#VK7L0G/MKE*N/BBAV(>ZP1R13=!5TQ(,E4N5$1Y> V+>VO D
M=%ML'4?;([BANHBA6B$D2;Y!/K9V'@2#T(>YKU6$8@Y55%^["SM^NIQU] #C
M>EU\3P[WN0=1,7C2H/!^@U-F.;OC4^>HX>&D%< =$@A=M]1B<OVG ND,\=!)
M,%VPFPLUV22W!![J]M!>($O_Z\3'O#J]7(?%>P<D[%V/ 4Z;DK%MDJX$C^"3
M*KE;TD.+]JKE,?'/:H/V\NVA'*KI#OG0EZE1TVM1C3-O_2)][.AJ^NT_FE]@
MJ\:(Z__(E2BC\(YP6\;34NCFNN4H[A-L29>4_).](0R<";#G-KQA/CKO9</%
M.YJB4A 9XH':A>!I^RY_^_C+_)$RR17S#V[F=*FX]RSN@$A7P5LR?L+TT$,[
MH%[_<!KP$XJ[*XPDXH^@:T1^".E( *%XNLNR_&WU5'&Y_I@!-OZ@1M[AFTKS
M^@AF>-NK4#^Q+L6T>UP)L-OM4N9E?:)X+F182N*NFM9)H\6%P4C'KK%DHX(^
MRZ63R?]2--=JB7\-Q.,]ML'6J(D1NGT!O4QGEYZ#.YKL6O^A0RPHZZK)'M;Q
M2D4;[U"H8LG2-D:.D*K*$[F=-3!_;#25PJ0#"@XS.Z!_W@_#!14]47RD ;8/
M84462G\/#!E4%Z1:?;'<-R8G_82/-4AC=0]-[ND_J0*></2ZS_M^N_SNR3<-
M[.$))W.CCK@[]6SJU/YSI_3"6B[%F/Z^1@!0;:IHZOI,I'-<"G(]%28[0'A[
M=YR71=M$"6;&#*.>B%W,U?F,-Z6)9 8\LA;5XQ&4=>L>4'OPYH<C*5C?R7<K
ME:@/]Z6I@FLAVW*I CN@NG SR.C326&/B#\^Q:*B_++ZI/!&,"G$V1U04"A"
M<' ]QAG/=%[V(OUFGMV(;8G-]E;674^XLJ=>^.[R\Q]*I:G3<;3#240[H(CR
MI"^C+\]C.M*Y![![4E,J(9-ZFW_:?:&,+=+RCF?O2XG1LH0R6F2*D:85G>U=
M[FPU!V4'1,=HZ;(5Z9*-]$JL1IUMM\2&PYH?".FSH;UNX)I6@*/8>@SKO3-#
M-<)DCU"$XV/9VK#%)9_K%N>/-WZN+Q,%/5RYH0(I,NYX-QSZ3NNZ56^6Z\_B
M[TKIKSKJW^%K]4(/%D84(@E%GQ*VNWKE58JSIU:?%;;LA9QZDWJC3'JD6J'.
MS^1SAK.;$ X+WC>NM&(;7&1[,_=)\$C&[ (L90?$!YU\+P9N5.!]'[OM_OJV
MT.K@2J=8#FI#2:;2:SHZ\S3&;WYI!S3YL6+_O9AU;7GA T(:;9.^T/G<+]&'
M$XL]8)\Q/C#I%B-VDY0<[\,KSF8F@Q8#FIL+\\BG#_/U+(#/DTM[S5(;KI"E
M,,[^+*,GE"X+OIR4V+^N,GN%\1W&<B=,E'$"N"J1?0(W8EBW+$> 14T40QK<
M4(2LYR4\FLT5VDN1:R'A</?X^.8F438?48[5O-/Q\[<F,TU4G::L:Y3V!V9D
MA69UK;CCWE&&@ADGX#K=!&Q4B6B589:!H[];5F95,_Y1Z]6[XQQ]#Q@^\U+B
M0!@>*V)GZ)JV8.'WAISUBCS:+O)AO:WEL^"6.M/:L']X/QBP3^X[] [3 ISP
MED]ICKEVKDCHU^+*QR=*91(M79XD^[W9Y?>&:\WSU9?S'XY[9]T979E'S%@F
M.\Q;1G&]5+\].MB=GS77*8B?('V'@E!S^7#S'=#N8P;_I)B6/1BD_Y-_I 8Q
M?Z0&YTQIJARU)U&$Y;]= GN%*>9H5F #(HBPR!)MI28Q-PK&)[OCA/"^[[L-
M]Z6*FGJZS@./,HX1#L]KRB&S$M$1+_G"3\LMF@*'<31TJL+?QGB?J1%B&N9/
MC\#[;0<TT0.[RJB#%ALT0$/'%<G:W6$(K[2YA$VA_2T"B65&(C'/7A_@[W\"
M,W]S^V@WJ]FI6(^A+VN>Q;-B/6X03\;/MG^=$QO#?^09R[$5*!?PR,ID6022
M TB\U(,\#'B8]^?S'10LJ=[60H==><.R")Z&I4)(A57R.R#=!0B5"NM^W70\
M+D]8, "\,,'MS7V87RZ76]^J[G/UB)WT]Q^Y/Y./Q$G3(-2B, <C4(X\4",+
M,'WQ(&R3@C-DL#*^8=@0FB2/>@WW++)!PQE52L7#TYT>*MMRS75GCQO</K[J
MYQULJ'YA1&+\J,.G\BHAR5OSS6Z&BWT_IAZ@_GBO;OJ/]^KY993W]$P=(7@E
M039O.8+8"38OMM-1&W&U+7GX7;)-5'(+D@)?H9WL9MD!?1W*9%K"6:RFY+F/
M!?PN)X>@@45OI [#MPN#S_0%O%X/72SXI>]M88V#XDU/JQ&%.Q&:$[/GQ]5Z
M'E)%>J^L?;<[GA8GRBJS'2NW. &X@P-A_Q+OL&GMMXY><;G4-3OA62+VTM-$
MY5#?C/^V]/?LCR@N>-$%\E#H?945\+S%=G-4 "39-> >GO#ZP87KH5=?H(Y_
MP]ZG[ONOY$G_;SL^>@C#+4W(+<$^&-YY$CWKTL#B3$%EJ)H"=_;5(>T:"ZWP
MX;1 J H4/P&52@<>3>QR(*\$[X#P!I*V2P1Z6C(5UKJFU<=;FZRS ^J,&O/T
M=9C&5K\'H)/5!K4V"D$;J+T_Q'9 (0_A\I-%?3[^(OEOG^M!$D4Y#\5SY]2J
MS1D_2M:7!SUVHBEFU9EN2X\SE:/^=L<.*.KJ#H@[AV3.>+X9B"*]*MP!$:_/
M/[S"D8!J.(Y@&GV:]B2$=O@$#AB D-HQ[- Y-)QC!\09H<!0L<_2U_RD5<00
M-9_,HN]?84(J_&G''5!S-O,VK@%,U3CO7PL%+ENCR!\V-(ZQD"!-'H$X[F)F
M_#A2NP/B':%ID%+*0C=X."R3UBZ%ZI4:V;[F.\:E%;.'4GE,E/U)L]P\!G"$
M!F'6#6BL3-K5Q*3L8MC+KE9WRJU'!)R_[BL4%'\I]5:J1)NU\J_>Q=']TYA?
M'\/@-Y%8YO2<19_X_7HH/EZ'"]4C10(S^(5@-)=JD_#=_]T2_;,ELNS$%*-_
MXC*<'CT==[=:U01PPTM"309\JDTDS_4.G2L)%V\TTFXO.M02)F@[P_*D;J9F
M)ENF.,A9.O:B0^S%KJNO=>66P2X<CQZ_H#,? ;*5_K<?9WJ4J)\@Y9?[\DL1
M8!_]OMH-.)K^E'[5'])/9$H__3<IY_;/O4V6[OA5,NC?+L6:ISU)M?Y-,M=^
M$PKSSUG^XB*9+(+_VBJ=12A0D<AN9K"D29(,+M5\U1&'&^A5HP1^""UYOY^S
M*%TM-GWP8<Y:FBUWE^Z-R>B2]6SZ+S^B2!@4+Z>8<IF\YK@?+N)4,)/U%M']
M^;]9F]C^LC8I_361!_YE\WSR^Z/8ZU%O()FLFQ.A2CV%,!]XB ZNV=M;H@GE
M'>]V\W?$+UQT"M$/"Z_0:.;Z)'W@:=)V<UJ2R/(A^'34G:@048E=>S8%0A\A
M.JB*C$[8GI*5X4K\A:P<FAS))#W''C U+*^HJB0MO2DRE1MN[):NO&"D=%JF
M0%TFUK7O-\EH'#43Z54;,%-AN7[M)H@#=*V8??0OF_SAUK^LR7<]0FF:F7#3
M"R6]RL:*W1=Z\X0[RC[U+?7N.7ACUN40Z(.Z%LMX<?;_;LG">\-#S9DI01\B
M$XZ KK#>?7T@;"JFT>OMB:X6$$N7(78?H$"U@=L29YO HH!Y'44L.C,3<':P
MUC*7>-R7?U<F-$25L4K291PLCP8=:8,ZM]8<0PXDE0:39O$!2S51I(@;A:[5
MK@3YX/KO!M[[[AH413A$&T[F(^^_>?'N"1D]#"7JY%'9:6<]AB>(\BGY<7AJ
M;L[)*DW"W*%A#Z\9J#6DXK3(]\?G'I6)'&!='PF_YU:[[P%8S^3WM%)L0LU=
M)B,)HUTCF]9AAIT:=8Z2'I4J\_B-+[>KN3^3DX[W?V9YC9LKZ%KJ6Y+XT %6
M#@:7.CFW$<>I(P18FI"Z/N^ ]CQCR),%:T)]"&F*RLF^%LZR'$6WO%_HLMP(
MXN5!=)+#)XBF-'YL(T.0C ZI.>H*$:[BP;8?J.Q!&'C)]A>*$)PS[K GN[P:
MO,#W3MQ3E8,5$P <(Y?53I"NH((K5NJQX4EB/Z2T^W0C;I"^3]4I&HF[4>WR
M3:9'&G>!C[;PO-!U9VU$[:J2I++/VPN2C9?03=#HPOHR,?O0S,+D!6V^(\_3
M;^UZ=@[_[!:\]<2YE&(62E;M1.2X)/VMCLA<JAJIJE<G,<<@CKN6\V:,B4Q8
MK9;B)^EH,-N=?:XUV#C<9#)F-\V(Y#MIDEUSI#>#-#;QW(>:]V"BH5>H*]'C
M4'-,O:XZQ_Y9CM0+CSL#''Z?:O88UX)%V_/1WS D)P!<T^:"FQ-HE+U0HOOQ
M:<B)TPJ/H"\DWH",[8!.<GH]#H1@]2="1&&EF+11C?/V:E]BM:(]L\/53YBN
M'LE$/"'L@+Z5KE#&R= P1  1%W;*56=O5<D]&@M'B%U-I^/>#X7?+W[TO-,Z
MLH!YE=-VXW@V1^]$(:YQ19)V&["%1&@]QHL@A+VSQXS.O,[*^+*:O/M^[6KN
MT:-4$^A([?V3C]!WL%WHX5!**MEWL8@L!!Y>H 2_JH^) 8=HW=*$%'VO2XE)
M;_WVQ4G$4BMGRU82I_]T]]3#M^R_0Z5S]T"=B "J$6,X5;87$0"I5PA,E7Q*
MX&@*-=4@:1XK[$V[(<1_^J'=E%>(#Y>U=^PY3"Y"+P/W7 N:_:/'1=C&=MS6
M<!?LVR?KI8YC5V7N!+&>?,#)$=.+DRU&/1_79NKK-:"R)55X2$O:@;BGZL:2
M[UMXN]Y4R??:R;VOGW<<]SA!CHN_?=$-6PX*0%/YD(/VRD / 2)&TP2R\*^T
M5,AR=<MY?@EGG\N&17-T? YT5)N^D;O;3&[!CU9&"EW$4._2M*L'D3)P/0+X
MF0+"D@A*"BD2.I3@&@(J]CH1.RI"P1<\\[G:S,FJ0EE9+/J \!C4 GMYDUN,
M211T_M:,II'QOM-Q[5>#UF*D6SY'7]SC%>G$$<BR]/ O#OOZKQSZRFT>_!UR
M'[T.)3AY![Y]8-BM:V]+@E$22*HM=(<FBL[>FO(!_@;57$<?/_D4-Z?;G\?8
MRD</M#I.SDYWG2F,6\M:"L1)0)W!DBX[(#8=B1^6]CRD^!H,)<6CV2:HZHJ+
M./&PII6=7_JID4GO!B>N4[0)&C^&$M)7 ZF',EV(%. W@=]LE-]E&3YR^*J
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M)?0U/!F?0P@L<7O\,4+WL)CT=1_[6.U[A=_U3W/KLJVT.*Q>>048T%^ED?=
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M"ZZ0A8S<?=D&?@,@^WKR8 W5/042>)913K>$?H?XR):*B,S<-UQE]S51*??
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M]1+-'+;(Z29PF?!%B!>5-ZS6-BRL44#(SZTVW5E2%F"2:A]G&7H4+0]PX/9
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MQ=7S?/R[T[W6'+["<!PH##D/DT5X,J (MBD3%R)6T*9JI7^0:Y9](\W.LM_
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MT_)U,\A.['<EF4E?V33NDCSM:NT;.*)I>-"(&I: HMK.;0@P'<4[3M-NL=0
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M7-1]0<USL3!NI"%<AC*=1/"D*J>L(2Q*>I1S=,P_>/%H"GX4BO<[I<#L#&@
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M#OA  X1XLU=0KQ75IH<O, 'LD!7ZAMJSBHB%1Z6L/H(6_-)Z;9VM9O_>:LM
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M"^I+XEE[<20;W$S#YZIGE5;E:DYKYF/)E_]ZB,JIJMA8C-/4,G^!HN+[H5S
M$L&/_ 8>[AMF&%O]^!0'M93^),O_C$7E0?-6:&K7+5-9NA,QS]1BV:\E<U^B
M52$L8=H_<?)'2X0R .Q%%"7=!X0VH;1 41_G5U_72TZ*GGYW[#)WB$9JO2[O
M>69B!EF.]>)%G_V+#_$3P]8W_I'(%+I=%&(@9-[%B/O(;!?#%I.!O=;2^/3J
M@+,PJ1>0QP\?$B3C";F ^\;(0O&[;C<K9/>?E1N3[]Z4+O$R-S?K^"CJG?A
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MF82V"-8E(-F^XXY0O@R'L+I(,ENNV[T:J<W/\K\?R]*M6W%2F/_@T[LZ^,Y
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M4&Z.DLN#*/$+K^J69&U+SA_HBVY'*L'^].>=@7JK7^:U'W8&\  .#GA=9[,
M7V1(D%+P<4@&VZZD2>LV5TYG?Y!]ARA>!BM$= <<""FXTR[?40?,% SE7$.,
MJ,0MWGPRJRJM';HHJ'4 +A0OPA$/UU%=2'H2*ZYJ/)[$6'H&\OSU9W4H0@'B
MF[.CUF2#;3%U4^6#C1E4;*RE@H_>I+^$$A24CZ9EZ7Z#H_.U\*4OCXG6'"08
M/C2Z"(BM6(403.(2@R\0[9KL0&:B42[SFB3LG<7VX;:U?BISZ#-OCB?FG\</
M)*@?U@,5W5MIZ2&$(;<C2U'4P4QW1R#IAN\DM>D=)QQ1=?ZK<5R_F'4WA$DJ
M[T^?H]6B2=7>=J^55XG8=[27H5NVC\OK-%,0(_U[++%CK==^,2#FP9Q&Q5XX
MJWEESL'!T=:L;*%+U(>%--JHH?''0"Z%90+C(M(#J57Z^.]6KM=G:M8G8OT/
M%F<94I9O=MM.ZM!MNX6_GYL_%>>;; O$55.XL,_!]=Z+GS,;<U_]K:+V71)?
M6U]'-],?L8,<YCK4 <D>))N_X845(*?;FN$J9_[B3'&!#\ICK4YVXF E]R_"
M^0\4C/B^AG)(AOB E_1L<"LEV6,QN-$V/:5/GWU:8O.D1_OG$J2G#%<ZM9]?
M,.;KUYV;0W !RNM(9I+B5 ?8)T^L:B!Z_XZ'\*-=K4 _[K=&[G)NP*N#OXD_
M.6_\Y>S^-A! %:M1>'65BP/<,'Z-NT:T9:Q/0*!@7II]X?@!*!=<@]SXA"(*
MJ[B=]*<K7V?29"T./'0W7&0^J,Y)#<0:S]K$K\]O([^; 65$=IDH79JD0"A#
M*(*"@XVXVCT'[R$/'RR=\H\X27QUF]D-D*-L823+?\F*/]*F-?P9QRH3[4:(
M!GMYFN_SA:V"'_,?/O7PG3HW6H42/%J".,^E(7N^*R%_Y9N<@6*H8J+?=[;H
M]:8*[XRC30O">RO_<K9.T%!!\&GQYNQ_^#K^C?,9:$(_^0S$R'@&2IG[@AB#
M-)#6P/# 4,PIKM8[>K7O$/$#M1VQY'%]"37B'$':,6BQLQ]6J9=K:;C@T3;W
M-TG[B]ICE? "R]LF,$8LI +JDZ\-,/!]P/85A^8;Q*UN262_LA+ZUB8M2O='
MZ:ZHN"IC"6SG_N&Q0S=:?*FS90?;I9F,-QZ8@D&Z:V#"J[\GI/ >+:*<SP,>
MW8F[7\1&5.M_P?D8O3G."5?&A>ZWXU&]8,8.B64@\PC,,<K7MY6;>FD6,;AD
M>8%^7"9SAS[ZBCGC9*3A4F&')_D5Y1(L>DPD_26$JSIV+:U-YQ'[2EK)!8F]
MO.M)^LD-0UM39.<8'38:G94L91(/RG$:;DR4!G3/0';HENG#XIQC@]&?H^I5
MR>5&(RI2.-#.8J3AZ\*VJ8WQ?BP$@RC!K'"(2=[&6R?#310R=EW!D_0(^(@@
MN\+W2=WB0(E'RP>=0: A[4KKN+7Z#[F]G,F.U3W)U<Q[JP+X6UDEERK"SU5^
M$YP0]TRU$Y<3\QADP;S.B.OJ.6=#LS_]OQKS\8S[857+E!](X0YM^)/IGYE.
M3I:YN/BXCXI'C@O&N:_+& _-^R_)B(4^UX^H#N,9]]4/A.3*%UWN>,&MK?$?
MN%>=.:Y>".@7MAMF.MS7MXI@_QXV9'_^6C&XSWK+""R%&$(P H'XY&Y7Z1E#
M><H/BB2.'^5;->KC6UJ:]*F.VXEI\^&EH1B5OPMS$E%'QWO03^B:ZNZUN#,0
M6R7)O0QN"#17D.Q1K?R[L']I*([B1L\+\K+&PJFQO:GO3Q8[LO_N$,_#J@FV
M/_19-YH0^E>+1C;B\?2''B%BEP]V*4-;UP78V9Y\#(N^Q3SN2!8@9QI>0(S^
M6X2]LP)8_CV1]Z]Q??S#9]%OIJQKN0R[8]J:SF;H_(,6".W/YZ7B83QBO.-"
MXZ0_R6Y]]*+5':*NTTC8A89IR<Q5\Y)+FO89UU LSX88FOAPH;V<"P$4+LA2
M:^<:O1]"EG0MM\>1\$J#-7FWH7)5,B/X>1$],^J4=8;3GC#P6[D+F2K."NQB
MPJO".U%GH$5=D_;]'-41PGU%O"J#4JO+W??^KH%)0,6F%^FS)(:1G"Q/:F !
M$<"TOAWLY 2X[WIZM%\Y,-?O6)I>7=)2,Q/R%M/"OT\KJ9#^^D&!DM%=_\\=
M]7P[XEK UCJ4!FZ!2X_6()OMK\KA]51_$="/,JVURWO@F!N?F2D7Y2?F2D (
M6ZH\MT9(P1_C4=%PLP"M..MH0ZY?CM,OD(M?2\Y -_ ,_:=<PS&@A+N7#B(]
MTM\V+?V[6@';&,=4=X6UW2_K,1B-2RYDO[8A8L/V-:-;+#K::-G(P%S\Y&B.
MQ,])N4FQ)G)2A::<_.\=_*W<]?18+B#&^=W^/\.WQ8I;/U>=# =M)<:>ETFM
MTW7RTG0M4"9M8>,$CYB-PTB22 608TD,T+/"+3%8#BV-7\'ZQ79V,32-@0SD
M-ZF+;@L4E2.[K#0LTY/C9I?Z<@TY,K?J6QE7SGV@JV?G^];5;R/^U"DS3":/
MS 5 \3P]:'Y]YF*@KCL4Z8\[^)PJ_6$@$W=HL_]R_X$@?'C%J#HU&/SWID,B
M9-\42CZW&JD+2=+=&MC_0\5]>AQ'G=OW#C&@P8L<7^F8*V*X1L,:\+1(WU!<
M?;/&?[MCJOHE9+UP-F@/*H[T(&L.^D^+]/OJKJ]_D2*DC!8\**;PG3[]GWI'
ME::^?6\3NE2T:9:*X*=R-Z&#?VYG GM069+I$2OIMR\*NK6E\0=,TICK.P/]
M$U=&'GZ'D$PBQ 4N]KK]ZJ^7JB0C!__\=K]PXQ8[N++--H_T]@P4UP*@ST#&
M?8?DO_%GH(3JCVBW@+1\?> MWMUFDF2UH9?JVFUPT>EEM/>FC11W-QW\BTZ/
MUHY=XF"@X&/;*AUY9>@1"^QWB%1AUC0QYUN;\::50'=HGN+7ZG+CAX%5KJEZ
MM])LKS8WR8Y)0@F-104 N[_#V%I#/"F]H*Z:_-H<<KP6#E5_P4C="L(WP 27
MVSM)+39QP\E@=G_!28>:UN?<E[\-9\4>7 Y@04Q#6>"!F'0N6/)5?'_N%^]\
ML9?67]:,]MWK4J*-=9:F6%8,Y'=F\"L#T4B_PS1VQAXD%_P:\58&YL?(QZL^
M<O5+?/UL!=[Y"N>6 U&ARSH#0OM([P!>BTWE^:)-I2*MJ)!TT/<612R:@&AF
MKP_E_M)=*4W+[.'RLOEV#J/L,DVTD6'VCX852)^P8EQU\:I)F4\H3GJT:J7U
M7)KW!V/Y\@,F"8J&<2=%[X>A%,Q_J5=<<,;OI$KX9TM/^&,+,]F^>[010N8D
M^6WPPM@&<B%]P-&ZV\#6IQ@GD*R(;M#G*7/NL)]=_YBY=\-3IN:2>=V,)8=Y
M*;(+TA: 6:.G#(@SO>O5I;S]:&(P]K'&HGS5Y$DM5YC*!<MO0W13LY&&;85M
M=!NA_:.^KD#B.C2^@#7$2JP!S+WHXJME*/W6A%R5\\%_3T0_L*@LQRRC6WF,
MU\_MV61=AP#I)I#%B+7X2E+ EU"2*W9;D+$/9[$:!II]58]:5%W:'GY@2SL?
M6<)2+K&_TH_]2+?[7U,@_\]V_K@ZZ0SD[D)K'041-=0@<<XPQZT> 0"J)]-K
MJ^5;TU]IIL#3PH?"7'NM* U"%2\-+AB),[-^>65([>HF-(%0Z.4C)#'S9")4
MO)1VLKV:X$M.T@<3E59A23L]B(MXU\;%K;;G<ZP;K//^_!K7>@6[K[V1"1M[
MMM@15QBICR*$DPN"J5UKEQ9"$'=04ODXQT'W94N6596UZ!2S%(N0L92W9F0,
M*.5DNU;?BB@'6/=!ZW/C#357'^M.(^1_5)H6^'FQ_4@62.<)^N6FY'1Z./B*
M0R"MF9 G2S=D*(D8716C5E!,)Y+K1/&.8_TL7'1L5C-'BZNDF)AFG9\JHN;>
M..MXTB+[D5..7(SV@K!3<YL#B6'!VQ$J2G>A3Y).QR:VDW1.^P5EOV>T;&[K
M_(W0^5K7#^9\HN^'V[3#N6R-;G6\+=L=_VP9^/@WBEG$[%NMBNTG_(]L28.*
M+X61VNDQ4);@ZB@J:QXKT_U"Y<52<HMZ)ZX^^W(C<[G)1VCH^5T[&:47LIM\
MW^\COE,$I\Y /@;&FT]"_[7"OI[>$-;/\5,W[;U&"^K2KR*>@9ZWO5692SKY
M+4NW<9B8IU]0STCB%>D4-DGS_&'(/=_87+G\X(DE,9J]O<E@C5FTP&AE#\NP
M:_D_ISP02"KG6)R!?L)PH>28SU2IF8T?16R(>R]!G:+'5SE>>H?K+8U3:+9F
M.XGWF_^ XT-.("2>4HJE?]49Z($.^CB8[Y\>ZL?M@4"[Y W&I$^7#8?GJ# =
M::7 6)=7H-E3T8GV&>6\/:L?B.-V8F6M^%4)#V,?G5KJ'&O$)8OTJ9H;Z3D\
MDUU^JFI4'5'88722_L;?$/R?UU^(B,=Y^=48-%81!#= 1>N-+($UY["T%%/9
MK\,.WQ>?H72ZCC6F$#.K]*AD@AU070(X]4Q(8PDQ08E>10LTBCW[%^Y*^>8$
MW%(;#>_CI?E3.F#]\L5I@C[=^J$H[(+]^$9Z%+:H?9+4)T^8AS<(Z 87"<FI
MTGX43^/%SS8IS\^MS]9L6,\?8BA958]758'0\@6K"(7&1:L>GSF9B.\O%;[@
M<SH%):-F.P8+(PWM@:CU*H?U]/Z"."372U<I_$Y<<!6G#6ZV^EG#B:+MW%B.
MSD:K2O^[$I$B[^7" U I8UX?8+QY"-P'4X5'<H-WL)6#Z3=H?*.-HYC;1)5,
M2P)T&'XHW0F;KM.-NEB!.-3N$CJU3@&?\S>\!/5V'$O>%//MS)>=8"L<MY]D
M"ZHPNQPE]<SI>Q7OE^?E(KF7S>@]8IS6ST"=YAU"L!@7O'W=AM^= 5?MN8MQ
MBZ>]PBW&/!'Y"F^PF#C>>QLI:FH/':1JI-ZS@5[T_2_^\X@!/HK36T<F&C(B
M)@OX3 M*JN:ZQT433@#_7CSG/ME2VE_QN\EI[5!3TX-6(SMH]92Z#6.VUGX1
M[H:I%S)FE2;4/<<3UY<A58"\W *A)XGA!'HLE*5Q\5$D'<Q]Y?-F0?\N905X
M3I5)Q3X35EI7?<KQ(F^_[",;F D0Z$%R'B^H'[+"PBUQLP52HT\)>2:O[6OT
M*\_MR E'WEOW.-'F8S_M03(_=KU2AW^T%GOL5,UWO^^GDV^=#Z[]F(NT=O&6
MPXOJ,1)=^MMVJ^#7-HP&E?#_O-S09ESBNU@==YQJ[3)IH?N\/,R==T[3X^3*
M\+"C?L%!A@L[K\TYSA1]5@PZP5%G$FZ'P2KW+CJ\J7TGYC8LWZ25WK(D9=LL
MI*U]\)CPZ>-N2V.J849$Z>+J[IUNO\\U3;$>T>8)B^X>DCZVVHNF*H[4FSG$
MD=2*87HF#1/U[)='C">PO%4=!9^7I-O;+ENX<:O3W/7(ZOQM=2<=<P:*Q>!?
M=RA:L^\R;Y0_("KD;<SW*N>+0YY[+;65#AO:SJ\[&)N X*/E<"Z\<F_UDF?/
MADSB<<,WG'64.K(6\ WIM=7\%&%X<XZ!+_EBX8<W(;8WRL7D=_-D/](F_=>-
M,QWI-QY)T0/:-]+95@#+:Y195%U=IMP:]JEQ37+T.:D0F?2;<Z,%N-XSD##D
MU\TST'!)[AE(O'H&,IO3$<^:[_;T=;;P8TU7:]*XX6>6#_>?#;469"/_;]-?
MD%.07L@$*#-%[K$P.JD-0LXNM2RQ?)P54;OJ/#C9V_5\0%(\:3DC31Z;IU.:
M,%YS+\^V2$,$(D-Y:,UPZ_WKK-!K24<!J6<@EA-DHO@EX':93];]/L98N(-X
M,QQU:WB<=G'YNOT5WJW3FVW<YVAV/E8[%G8$'W."<3+=+EX]D/K0/FNPR[CG
M/ZVD)^KA3K*%&2F_9A-UASULHXPNV2W%R<2\MQ_ "N'V; $43F; E6UBJR'&
M;D[][;[?H_;GYO9FUVB>V[D)S+$@LG=Y;1BSX"X CP\^9OV[*R>ZR5?,<5@D
M/%79OL%-ZMNTA,V#IM2:@NRY?!W;GO:@@MK#?2IUL(P30G'5D92+/AU@O&E%
ML46(I,5/UM:GDV.'K]5,F:3O>6V)L?^W'T8G\.^Z\I"Q':IPA9DVYB_ LQY7
MP_JZ:76L5H]NH4957%TI)%>ZEV7"]&: :+0.;YFVTH+]N&AHEU#;_:^(->CY
M$$Y>YU\HAT97IF_U38TX8MOLHI/!<K58Q0V,HP630U;@_T;<>T8U];WKHD$0
MI!GI38@""HB 2&]!14!$!%2Z$ 6E2F\! A&0WD% Z0J(2(GTGM!1$5! (ITD
M2).24,*"A'#X[;W'&??>L_<]Y]S[O^-^F%\RUEI9:\ZYWN=YWK9N4X#I[<4C
M+1(K#OD*?=4YH00^T)/C&>?W*_5NXU1F[?>/@)C/HI?7G2_+##^)^_\<Q+52
M=;*K3PZ*]IOPE;9Q:1QD:5M@'PK?408):!(EZ3_]YVS\ $QN'Z,IPB]I/B3Q
MZ0![90@-(+1T4E^%;#L1[AGP5_13N5FZ[J!F[3D>WZ_^W'1[?WB(<@EH#80+
M('T,8EC-&"A0);&@^MSME^8IRD'K&[B0V\TYVK(J*4]2@CMKU6;:/;I6;3'K
M@7C4>7A/K_5P4P5M%"H"?,4-08?O5/LE00R:&M(G%FI?9[[E5IXMOR @9*,F
M+$F_KBZ]([I%;@ (OL2*1T<?9-J-RKJ(^T8DU3$AW,*8_?,,8R[QT[1Q_;=+
MV5[P"\^"$0T;VOQH>:H^T$8Q<BEDI''!^^<[L\AH;JCT..+&%,*B=J@CTS[\
MP;U/'\3C$MBXV@]]Z,C^/ >;\TU-R;)(!V&5WL_3+CWXJ.6X8Q".R:T+<J@8
M:!-+>9*"^=K0**(BD@O7VNHZ!B5!SJ'/T7X62 %:),\^(K MV2YS#&(.R,:?
MV04J/W"(O<AA3-:4^B/^=!QGK+D "LW6#7NV@FPH&Q "1Q><.RK>0W*[8+7!
M5'U\9,G@ L^8PZ.&&H6O(+\6O,Z5>MDPAX@[(Q"9L+<#%](5O;\\30-^T*^4
ME/YOF8S_9T,*?!=TEQTNM\%%>2#1*>-F,#;?LU$9BF;*_<YG9SY4E>C@,A0D
M0=6,OWH,^I)X# +D(52/YBL.GW=+<&I6U)':3F)TX-NGA/CN'TNO&@-3RLQ#
MJ_9*4/$8W*+),>A'D@2-3?\8)(0R/"H\!KF]H:G#1PDW8.S*J4_KW#":LT%%
MN)\!A"<TFF_!>#GA\]ZS=\RVF <U><(%SX$@^QK50'Y]\RW(ST*]AP9E%D/'
MH :G^(8AIWX86Q@8'FB#)G9@D[<\"DVQ?I,,@<I3_B6W#$;Y!@:O1OW4H=M^
M.3 &#2<Y_4RXKE#+:.Z_^%%,M( =D4U 38(7G"*N5N?VM";%=)\(QRH/K&#@
MR?HW/8L^<A3?R-$1GWPK,+YU]@PR5Q-K1=(AOYZ @J>IDC\O_.#"(^,UG4[W
MU3]TYI-R]_0-/-T*W9WM,)<23OD.6WQ<F,M-MVO$@U,O&]".5?Z+<^<<Q/%L
M8)/];03\6?\**-U.N3?JH#_9:',,NEKQI;=:+(EY[3Z(8:>*\LRPF*H$-%3
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M,ZM5E&OPP5X1]?11(^ALNR$N]D)3H^<;$':'2["W\GO7ZU2?N\N*.7)=2!X
MW NK64KP+QT*0T <RJW^6DPAY)2JBD_>\?=20<HXL[QSK [B%I.*K^FV]3=D
M&%N\21A#&)\5XA8&T#^*UZW"]/0$6.TI7)R3G?@>]^T@),"W3FT?Q9ZQ@(GS
M.Z$C81,3@G(]<ISPL)Y>];.O-34^/!9OPJK$I]VIU!P:5<S(B/C:D<=[T((:
M_21)OVP\%=D=C(U%"U%E&D9W$S;N+@WVHX7:6Z)')TOA%^-7V6J;Z?_<-C&4
M7P#YQI,PO C;7U0'RJTYUS HH$O2,24&1FQ-:;.L'!J_\O!PK][,D)S*V[Q6
M>\YW\>.WCQHT$JIMI0C\]I]"&_MEO,5Z?R&77RCX$9&,P0F5D@)RRX"<'[_M
M;I&O8W+2]:A%63QO@RB#DEKL01X-Q+:^X('UBWCVN[:R%"O22 KUA.FCR?VC
M?,WYO*%VP\]>29YN[')-*Q?FUIOOEEZ32X0P*(XDI:Y."&ZVX5EE6$YU4VZ/
MHG0[JJL$KB JWGUNNS#]4_BZ0/BPVP]<M ;\@62JOJ"DF1D_B.ZE_ T1.M)8
M=^MP#<4@;'BJ*CHC).2#B\IA;T[4GXZVK^SOOSK4"%K0GQ% FS9OPRLQYQ#7
M)C2=2/N$J HK.RL7Z"4@Y.G[J;4A[CCZ>T-AR>62YUN936,?IK48EX;*ZX+"
M7%VT&1 RGL2=^\1+QZ#U$Z9);P84"[<'FPU5MFXV\,5<3GLD/9/[JVV;=_(U
M[Y3:XH7'"Q:3VD*HO9$H2)UCC>>"[2F*!>ET5II(9K%+ZV,%V]:[7S[KS1K6
MZJ?^>9/Q2DT-95]2!,Z@:A^#&#:)PH7=(9Y,=FYSBN<,RD(+MN<@W'8R)1GJ
M2TX4U8S!BR6./FU>@2+2F*.D34T+)Z**(7$@R6_H5D]O 6<.[.R(UD9[VJ7=
M@*%:H8\GS,@^7>YJS./$: %\1W_\_SG'"5 @MQT5T*!4YZ.B72.D[FC[)11"
MBXC)EDTK@B>89KIO>L0SAB3$.IBV9-WGL8KM/@MUY-G/YZ;;@5:]HXV)2  0
MSZO6(U%4 9+A_5]1HY:K:<R['7>_RB=8B9@YI008?W^C+2D@\.4/@H^B2M4'
M&D@#ID AZ?VT#I&:"O= LJU:,\54B_RY[5O!7)9E3B]Q=D%6.]9O>B<TZF32
M?0 +LACPTQ_W3W(*4[N1=K08\' AA5.YM74OOS<I]*->;7M:SR)/M_SU+\S:
M<Y#9@XX40E-G8;PU9$/*A52WL-$4L^?NN-63#O=\-*I$B0D7"#Q(&ZXL3F?I
M9UGTYJ='06Q&39BZ.9%=T'9]OO7 YPN6B)M/YCG=VV]I.I#[]7AE/GI^C52=
M_?-*(]#AX[!\7P"&$>F$B9V[!ASAD0GS@E5^,@HF;<0%8G5^T8H*V)L[H'+Z
M3]ILC/FE3LA&TSVVHT"#&Y \=;EU#=(G3WK 8N%^51#N-:"%V^)LK-?49QM5
M+O5_<3DH"RP!DLY*VQZX\,PWZ@"]1FKJFF=$W&FNR^V=@S1,B-<E]M$_]OCN
M>D><C6/5MNH2" Y>+_XP#2 ? 4/O+*5O%J]"57*F^D>^.QHZ)T5E'#@S:UB$
MM#T)=+ [!MGQ412/05]625NT@57D[O13N]5_;>#GOZHFNA@V54B/\"8Y]-+.
MMQ(_1$\U=)16UGS'+_$'R'O=Z$UN&=:P&(80^Y'\QZ 5(T\J_Q22-'5T=W5#
M-XBG]IO2FGJZQ];A>EC^:R J9_'W%?AYS0LX]NK\?8R!V#:6QC]"@!PQ5QV#
M(H6,:1IVJQ3AL!&T-F!+NKMC0=*/F38<F[^7/NOHUGSI>_2=6"&'M!1=Z(P_
MJB%.-#L^1\U64,%,=!:[][MRK/?>M'+7>)=%E)) A884[!AT]ZG=4]+?A42(
M8+O&!UW&&E]<"I=S(&FME2_V1;%%KG';C1ON2;UIG^U10EZ="]B/IB<B+6A'
M>#_R&.0*X[8VPFT8]\VS[]J*X@3G0D/NCLDN89QCIZQD_GA*V89K\EXTV(K'
M)I!A&3WH"T>%%CV'>>ZX8U#TM3F;NTJGC(:^^TR=$9-N",CZ\G7X9W+F[B49
M$&*/I+. 2AH9J#".MSOCR;JV'Z-#ZRF\2[+_5N[QWCS3J2GK4H#YI<;:C46Z
M(2_UIO50PC'HG/,QJ/[<+ZK5N[5@3._1Y?X) 4)3UI20U$+2S]2R84210$#C
MDD-D#H4EZZ4FDA#8-?L0'QC1#BZVM)NR'BD",O0FRM(7FZU$Z_+%T_A8PAQ9
M^_6N!_7!UY$,2.<.(0(R@29JN09CV\L],DTJ>*O<[,^;831F%I<\):[+DALM
M>.NZ5=PRB([,PTVWC=W0^FAG$_8E^*BL3SBDYU"_E\Y%AIPW!TGK]7%5W@EJ
MO/7S,M0!_:?I@?S^VYI^J4+BH#JZ@L(WA5!L[&AJ)'F4>S^M6ML_#'>OA>7K
ML5+Z[=\E&XK'MT-PPM(K'6Y=4&'2Y:J2M1QTY ?7G ]I8H9E=G-6 XH3]W^S
M_6B3DL]H\'F4N&#^!Q0DT2?W2KTP&2V/N$ *S?]3P@ME:Q^7E;N0UYSUU-OU
MZ4T1QNO\BYMB*=;QA 5$:U._9ZS=I5^R,LO$K?AV:2=<?UWBYV81F]FW5LW3
M#5F+=!'&3*(=T?&@@T ]0)M$Z:&QCZ$%5VD:Q#]EKRIY-?@UGYY7. 9Y?BCD
MIQ/C.-^S'&52X/+"86DZ9\]XBKX3*@'$$?5["\X2HZL\2]W4&]Z,19=^-+C
MT;TH/M3"W;@CX 6N<.Q0SGJI>L2',X[R,S[S&QZ@Q70_PZB^)L78<FY".T<\
M43]R8%_7!U('[G;W78#UR $W]]SUL(_&%/-OK6FQX)D",OTF4MLYAEKTM\[)
M/ZQ/O872<L.N2M(YGW [:4(A( F)I D"3KB-K80MJ) S5 ;(QDM7P,ZNU+DJ
MOS<0;WL3BW=4%8_]H7":/K_(.R^EIJ('K8:@&X?*(VP -;R4DH9JN\I"Z ."
M1?OHYD6GD,&D6)G\,PO\LX:^1VN@ SGR&X"K#,%P5(!T*HR8X/.!QE4#%*-Z
MTOGX_HOE]:_>MG>>.6 ]=VLY7##P,=9IP>ARST(9E;NX'\I#M'TER!3MGQ*S
M6F'KPLL16Q7VB_L=YU-^?C;N:P34F[F&7;D-&$5=;D.,N#EH4#\AU(.^]%-)
M56F(U9RYPQUU<>9<*Y(S];O\[X6=1)&'Y+"C-P@SG':"W16@AO2PSQPJ1Z+5
M/!5)H7=1_C#U[5O?W0S!=XMUU\O%=[MHI"+PR]RN5J-E*A>L3YO_0T.R<=P/
M^!CEOAPW).?H,A_IEH+404U#[I_AZS?[W58 OPX%<NPQ*"+A<B9AZ KV\<]Z
M5%2-*V_K_7?\66>6"VQ\Q=;%A$A>!-61;^A(OBWMA7SH]0RC-N Y4V^(*NW4
M'#R!$AS*4<D\_BV;4\@4ZEWG@QK"HC4@CX!5B@PP9@T,E5+- %W\D4(76B;A
M%I)]KJ_",C?798/54\]$75U9/>+LK]TN$*",[15,VEH7.S$H#(,A7JWT5)L3
M->O_[GJC8$]0QA<),:F6ND2R2 0ZN;FAYB@?LU T)S6*.%UJO2)XN9S8Z&Z]
M?*\FSKZ!SWQ++ELNB_''C5=R],#T./;]R,D%]\<PN(Q*-/<T\!ZOS67MZM#K
M#>2_8Q"V\7:XF*"]=B#=I :B3W<K!@1.[KE)#VC!>\8C^1!F'X"1?NL/J6A(
M8X)!G9N;H<TY'?4HS:P 2,S0R-!+.N(C*'A44^/D#]8!4U)8_[=+0(9<,G1>
M+HX;668@08[Z?EL3$Q3.(<$4F4A0.BPFT1,<PXG-+@G5UFY83ECOJ/Y14M'<
MVLT PL6A=N//U!ZAF@+O']BO!9"3!?$'OHV.]6#.^L/B> ,QIZC:>$;L^JYE
M_7;K:TR["^><0;+%D\ 7:5]G!A*3,,%7HDQ G<(GG-KS]WX?;Y@B&OA5Y4*:
MTW4*(I07*(Y?_5.?1U?V.U'SP:?6\Y$]DEK2*ZW_+LG *1 R=.A?)<FJ0@-R
M0C/[QENVBY)*0HLE6)B5\-!31[5H$:H>*2P?UW%Q3Z$<UG+GU40NUT7#\WFD
M3J5UJ-0Q*,W!XAB$4L/LTL.RM&LECT&)R42+HU"#8]#[9RBD;.=HGTG5@P]$
MZ]#ON%[S3+5N^;6PFM%1%FOBV87_.B7R+D@*FKFH+8AT9@"T/[F0C=\W?O3
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M))JX7#)[8H&0#JWP?*%GR^NZOOW7I]]"[:\QTRL=EI&XNC$<2J6C,1&:_B6
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MLRH]K8^<P"&?9@?<63)^\/DPAM89$3U3-)5(7/I&-MWH"Z-4P](Z'KY6W<5
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M:4*)R[+Q/:<Y!NF.V$(N9]UV^8;Y4.C1"L_&)LL-U\FS%$('2:U!6H8\!OP
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M'PNM_>2,X@Z^7A$_RN8</[4+^^%T;;*XJUUKMR@%M!T[FG>5Q"*J9Y!V)&R
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M):F]B;_(]9K462KPX>.7[Y;*URPE!+)2ILTB[P#J5*N J6:Q^Z7JL2?5//>
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MJ5^^O+=<KYGUG% !&J?(L[$&5,A%P-0HQ9;DS<B[@"R1AU]RO^0IL#;5;51
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MXU_A]V=[.O5&$L9"*%GKVXO+E]U-2PJGT@L'+PI8\,!-\Y$\B0XJ$HC6L-_
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MQSS+ 'X3DG".;2Y54$(EMU<F>BRIV>G.N%2J[!^2]&5AFY2&C3G BLS3R4-
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M!%JK-22HA\8NZ7^SI$\_,I">VP'%2G$!KE0?&.] HZX3,=C>^7*#@JI85E3
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M4T]Q9FKY/"PA?/6-<L+DIRCQ+[B+_O):WZ9DRP(XLEQ"-=.>-@E AW5MKNQ
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M:-_J:+847B&\8SJT,UY2^6I@W8(?_/2S6S_?&4L:R_;BIPRX8]P=VWK;'CG
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M'Z)YGN(_J/WP^G1[.J4KL6.V==9;R,W#5E@+_.'R=3%DBY#EHJ.E @\H&C*
M34/) A.D&,C0HDAW]!X7\STC.E4!X;!^W^;/C6,2ON:V06MKVQ4,[@F4"3#/
M<*/1:.CT;@AMVV+J55<2;J-3(ZA0JH([5;+L[.3S?CG*U6 >?" XOL>+O+R!
MBX#OJB*F*%[9^@'X5#/Q&@\$^E+S9-@2T<OVN*U\?DF^;> EF5\XN;OJK.M<
M&M\D#LV>4+-+7@6^(+W(W&A!^V#&$HV?P6W>,-E5\'GQSP!4/XO[Z'P'-6?[
MFAK3,*21 CFZ/XX1:0W86#=CI6K"_Y&X%G8=YRQPEW[J,"1]JD/ZLG_J=).$
M8MZK -;U(@TJA !E#-"A W!"85\9[\2=C08S8>G/C>DAW[-5B1M3K8:D,P>@
M:RZWD/(]):$9<[5K&#$S^^K].; \$$C^HIEW=@H),<12HGP2HBFV/X,5;/;%
M_'F6&T=X0='U5V;@686O/#RY8>G$EL')O;(9*P=5%M-+0KKXU^,W_F% +0>@
MP6R"&N,YS;.I=J57BT:,/=5:>GOG0M+?BZ!5X:!@D?KX2Z-25E+5Y]XMNN6/
MRVK,'8"\L5ER*H=#A!%U!V8G1^:'P7QT@ZW$MD#]/NOZ0<:0WJF;)8FF](2O
MPHNQYC#R5K:^5^HBSV3W9?)NXYM D\>>=W1U\V_%.^=,_VRHDW2#*E2SOPS/
M_XE9WXXY '&-,UH!(JWD?/4+(C=<)N!^VN"?RU]99']PV;)N2#NRX,?+.(=B
MW/X7:V%<N<3^&%BC'F64TO/ZB;S=.M[P&MB##'@M3/<CWB__Q?#YJ'46R2B5
M>2GMANV)BU'X(7X"E*)5N.NHW;^5O,C]*6+W  383 W"H^I7)[^H9WS\U,R;
M [931+T%Y^?MGFPMT]JK.@ %8L0\WW]?N+YV'R7==LWI2?#&,^-+4(L/?:1(
MMIU&'0 739?#[W,%-".UIUIY'0;5R*VW[9"V9H_FT]'MAM]Y)1:Z[EZXO_2)
MO09I<1AZSS%5:#/C:4@K&@QW'9_<N@3+M$::4I)S5[DCKHRKV]^TZ+?X\0)S
MQV?N$X8'=3P0(M8K#Z"'3;B[BVS: F6_O<V_WW%-II:'UK<D'^K%S?0%^G?/
MP3Q57P,Z]./RK$R-26043]$=L':;>_$/?S[#]W!.M:"/(_,6A?Z+I&71>=0L
M(7%K';-[FJD+>),T%FZ/:#JYM-!:5@DW-,$O>9^Z1*?>/"===)_KK@A:</A,
M.7^[>N/H>$JAYS%:8]QP-<U[ "/=;4R'V'&'WJKY^J/SPVCUNSK)Y]U"+<JI
MJAP0]6$$->V0")^$"S!#@,Q==<)0-0S#_X+NV[,Q6P_SUR,LS _/7G8P?SNN
MH7"4^E[RBCWI$_M"J\O /Y2M5(-A= !Z*$S!X#0RG<[E\J)&;6?#HPQ,TVLO
M7O](3CN3HWI_[\?PN01V-34SIUYUI,Y;8.4 =/3(C)ET#:+0?<J,KQ?4.AUA
MKFW?&^V-&GVPFJ.G_:'*(23XA7"330P(O/P<>P9L#"OR3\(&0+F9/-/'Z;_G
M^K<X$;X1IJ7: ["HZ.AJ#WL=097IUQC3]\X+'\GO\*'I*$YZ3V,L)& K^2=2
MFE8X)*O=W_E[/K!,G79(8?0]K,/?"?8)>@[.27<7NNQ^OB/*'I?WB'_BO,9V
M!66)@'YX  I IY@4;DB3^:6!PO[(EG-F*K4!P9&&V95?U@FK*\$G_X0)W7,X
M<2=)*4-X19Z[]P0"3H:O)]*APQA>E/(B$CKQRZ<7.WEK%HD+JWCTT-9?NP@Y
MF=(GV'W$QNZ=/@LC1O1/*&T1GE2F!KA7KJ(%].6S#NG(X,+M2=.U+;$O*]>Q
M3V'A:UC#)-WC@L_N: G#0'HY<1[L@_QI&$$F] #$AJ?+;J46>DR8!5; ##NO
MFKRJ#=1,7%BW1\.7;C2?YBW(G'&?KHUX7\X_^>#G5M8!2%;_ !1G".8IV[W8
M.;U$AZ:=,M,,*%BO.5ZTU*OR"$-RSAP'Y=[/^B-_>G^"V(R*H^TPX'3;P6*H
M(-"T?S+@@1>C@PY#Q&]]+"*?7N<!^^<V-;W[W!3+(K%R@[B12B[5HQR !B!?
MH,/[RNU%U$&YXW2OI/"-L[#H^73$XN(JIV_I-?U')W50N>I"VM8WU5E_G2_X
MY[434HDV3][(QHT)#T.$?FNS'WJD4I$@*5,W^DL$[[TKEF=W!,_/0660N3HS
MJ=I3<J(O@/'^,N&]>A3G19H7E#Z>B(10/&PH>+=DMX1+[9-M=A].7G[F\.K/
MTTBA^['L(P\^L7^]CY7[M48DG-TF,4U\YQBEF.3D%+5IC\=63:]<<PUN;&J.
M"CGJQ,V9A<L=I;.G_\8(('KG!U&2V6>G3AGP*UEW9VWXF>0W]"&_7T+?CQ3J
M<B_3\Q)?08.0@E7H?FBWO3\8@YRE(\[+"YUL:'E0N3&&?/'V^)W'2_O+8)==
MV=I>0(^<VJL))# Z:$G/:CQQ\!B*_]3&IE)I^Y?-5H]ZP?'1MMX[//<.,V&0
MQB&33#H M5W\1T_AY@%((*A,<5L52";I01(VZQW$HMKLYM^U*>04\/>*J<EB
M)KOG*+_Q*6!V0)OQ %"L"=H_W=$\1^J>8<*J$)[&#6W1/6G-/=V>KKI1?FY<
M8C<$TGI_L?QUMD9Y UW#1>P#"["!LI, )\DK0PK<?JO:'5_SPX4@5Z^*J0M<
MG_=S>_BM[_&)D?=SYF']\J^:VI_$O;8AE\BULFQ#A[8(5A3^0Y886*I'VHDU
MDWX&)%SJI'70-3QAU^O>V%4SGM[TD3Z.I-[&Q. G7R-ANU#F74 -IHJEBY,R
M2_'QFC9[MJXT5*_VRZ8,P<YK\783:2![9;XC)3G.;8U_SN_''8!\GF)_+9O'
MV%,#[H2823=:5]?(&JQKB2W99_9>SDQ8-G_S/5:6=  2#P2;TQKR*>;'_IK;
MVLQHYFY.;I[:*#"ZY)P4Q>1XMR1%:!SU>H@5ZO8E8SZSDO /N_6J>^.J@*UA
M780G;Z#>LNOGT0CCP%O+J:<[V!AJO;S1>#S\\P$(!V'?9P<*\1#^"*P0$(9?
M%)RLG%.DL\+:(X6(YJW!>O4?[MEYY_AP]&7&\M!T^D&[Y], ;FIA)M*>/F^U
ME]UFKG>]AY:YD]G(5O20<&/8*%.UV>EN5>A<X",-P?Z3-AQLT%T+I.@GK,^X
M%%*(WH@S78BTQLXPHU\!,)<WG7/:VN73]2$/7UF='-=@XD9)#<:W0Q^ILVX%
M:5#ALH&1V%;\1FDC4X?.UUCEQC2@.2;"J@XCN\?Z&W_G[K??S%:.^X9):=VM
MP>7+O6IF>I!;]PY#0&#CPTL UP'(*:$?(_!;\I>'U\#.W+8' :_@'+ 9S)SU
M2TV *#IR2/0=9I" QC@S;9HF)&"<,,5(G4+>HD %T .BSX**O*__,/&K5'D!
MC=#,S=-H%OAL41&4-.R1*M>!%J^[ Y;=_U2FT0%L_1,X:\FNS4UMM&!&LLJW
MC\659W/N=(AKL-6<^S"$\F<KK;.M!Z'2Y\P/RWGI0#1OMW #4'L]OWQ2'W8"
MOEEJXSZ:Z2##MYS%7H_P7[>.)!4W<B *H,E8X=_\*7*B>4Z!IWXMN'V#U1^U
MZV_S-MY^\^V>45R)D%XNM!5Y]9^=_]T>M+5!$_ZT3<56&J/65R5Q?>I#TTG\
MR<>[&WV0T\/1E%AP!,T%#R784OD3[YCYDXB)B[R39B>JSVFUKGD)PZ8:GD6$
M](D4"@Q>9DUX)+'3>':O%!V80.\Z3X_(:B+79A]#[/3O0'SFNHTB=#\$+^07
M&=F+W*+>K4_"FT(OQR,3K #3W<O['Q^H%"30#LF;,%!*RC34UG"<9+H%,2(9
MG]2/G!$*R/HB:D$N3;X .@;:@OACLT?I:C?HA_F4Z492WY=!ND]L3,:$09UD
M:F.X53\W>)=:Z+XRS IKOY=1='B\+S:ST*O5J-^<&Q_YX,9U_;]YCO6^/*^<
MH5K^&;=2)#]^^+7EV>Y50GR=O9Y#]LK -!\^EM^-\L0UPI?<Z,')NHVVKEJ-
M8"V5CAS+K#/*UKIZ(?<^2E?)'K4FR1,T\)!#4[DEG^[R:4UWK4R!!D^'FRD]
M#RJJWO9S10*WL^PE]AB6&H(8:W:%2^P_?HO^],A>9R>;'D8P6L]X"M/%:+!Z
MPQJ'( 'Q-$_NX0M_XMB>0T[I[!:'QJV-(3P:\=K"B%&&UQX&$C!VG;'2ILV!
MR'!%O)CO.ND9^/,"(^_"1#EA[.< H 1JH<1"SJLW?H3,LU/4TF_M5=UAAI4'
M[8CU<@$6?P5FG\6?/=YADC^^9<7?2>S063:KBE"2'(N>-GE\&!T@\!.:]9O+
M<E* %_E;("7IFFOE#/SCU3/L?$(+]_1*]!ZD@?ZF5:_>_K4RI^08(+0["F]I
MFVPYI]P_WWV$\P;UC'%C+-H;\Z7==N\92G3M^M;@@LN@G')[^N"#EV79E:^Z
M(@-Y,T[<G7_"H7SQI[CV:$'?55;0[9ZP?<ZM>AA[_P%(I%NV!F;4N5$9UQU3
M \ N=$^_U/TJ?4;2K"U2[92E'Y//A O$D(^5E\BC&L7[]KYMNZ@]6.2\3K#I
M>5%;L,O+U'QCUZ_T&*)1&^GB^4=TI>VG"T[Z%PW"%'&GS#T,1HXW(=H'BM#I
M/MF9.3?ZCW]Y*U>,TY#985_QNG[I7]2X_J?!\M-_O9UGGVNO%A+HQ4$\CE/9
MK_>G%)]*XM47U]'MBG?DJJWR9&>/!*?R)QGD'#([T[=S'W-B]N)1TIKE,^ /
M!R#?[=Z%KI'MT';4XOWE,XW>]+G^E;;Q=!0WD/XL"/9BC7!\M-*K M]I#KU0
M^#W:7^G1-8O<BOLW$?V-T.N@/^V,3WME$=II*.$F>F7L]V U"C'AQJJG_'1P
M?%VA=%2T/:>\KETYV7YXW3^^[X\1WD%;"#6';E[&9<OVD[AK#Z.WDV?;; 06
MM";&STT\93FY^47IJ0UI=;>PX2JU@-*[\3P68HJ\#.GGA5F\>0UX[Y[23NE5
M6'20X:Z >7(6#!#ZT]5S&AKD%"6NLBU[&YG]^MX))>!<IL$\R*"]?/]/2+6]
M)M6TSL?LN$7IA_R_(EI351Q<OR1_S0ZU5O8/$-V)B%(;Q,9ITX6I1@-$.:W6
M-QJDU,:7AL>FW\'!$QS9TCO9VB%Z.^[@:9;M97RCZ,5=V!BI,=F3C49,O3E!
MFMLP*$4//OB>'?IJWM4RY,,8UY\?K^R?,,O5E<P=31X8)I(7KL@#ZI&IOU]-
M:8M;YY%G7CX/T@RA++P2WQS6434LY IK-QZ*T3H1P$KV(L#(?!@RD3")IQ1F
M@J4@0_Q))OCD0IMI[_9)%R>,35>:!_WKD],^.H^_OB@_,^H/6#;1YLX!<"HT
MJTP4^I#8TEMXBUROW[9?3<V$XW0#(;XY%CHJ1>^E3$>[)%4L),>]O4(O6\@+
M,(-FD-R4[%1/==K.!B_-D1+-[?88\!^6$DN,K(II_A1[UF"HIG7B?'W)LP%:
M3,M'Y#& F^(EA13?>X:4KK"B:/,PM>FGO+QIJD^I\J<]YIOB,J9$T:4*N;<3
MG=_V&8.6,)^DU%FWX>1!>3:F- WK\&E?&?6AO9;N8M_LH#%VDMBW<3_"O6I:
ML4CC247 ^7>X^]_O'H/>$9Y!^@ PBM@!*#YR]?[A%]>O+58@P7GZUYXE4Y$L
M;9OWW@D=8AENF:>>R0IFE\![>\7\UYZ[MP,ZDWIV%9GGI_3GI4NM+G?0?C59
M^0=R.^AG7;WE+"*F]IF+!B=(#_0JOME[A/;;NS*'*WI3"XF/. #QP AO"F_Y
M_?1\V=/64E=NG3G_N(--KI3N=7_"0AX#:95/R:/,#4.3/17IFW'48N(7_.5/
MKQZY!?Z-6 ^&UZ3>8,>VQT:1[ZO/]W][G&4D];TMFP6XA0TX 'TY -T '&BP
M:[2YV%]H 0DXT_&OR&RNYWM]2V^MYJJW.@I63_TNO0T;=_)Z&7Z)?:A,?Z81
MQ7\ ZC^')>O,, THO%8X.15:8F\"K/K'WQN%=X<B&:_OCUQ"QK*4E,4F3'9A
MO]CB" WI=#@CZ^UT^.@H=XS5\&W*1UAM9*:6]ZZ^]X>,G.0;RSDY0S$ZUB#4
M/<0VR2@=BN^))(5@GA,/:X$J.C&MKCLTLLZ65=K!/6!FJ;?9GS4@2BU)MH0F
M<1?V!0N'QW=BLO6]DO;5)I$JXEGK2,%Z[@7H /B\W=_,A'+[*_KP_ 4+-NTY
MF5B-M>N'XXT;;&**TB_V/JU@*NT5!G?;4QW6JIX5S ^"N0LO-$T)O-Z66XTZ
M[BQM::9D&.V/_2&6=[LHI- _4.;T/![.=>[U?(.21<VQ&=G'WME!7=8@I-JN
M)6+U $2J9(JHG042PD@02: =AZ4UV#R:!* VT=_=DZ:UE F.SC:B]VS6F:-X
M@S8J?%YX&"/1K5B#<"&[]/.GO-E7G3T>#):%#A5=";QO*'<[/W#12B-F2"66
MJLSB%7CH#?S(\WLYW58T/,,=L'T)2!G0(6E@,=BU7I7<(<MKL[(.;=.A83B=
MG+2$O(=XY5D,7IL0MZ^/%*/+QZ+DD>;TWDHJ1BRPY4?CJR!/^8ZF[ ON*44G
M?#HZ\J\I".CL-GPYLY$+_O@\%JQ-3^ZO]R)OMN]*(6Y/3FZY)0\89096K8H5
M?/PTU (5;&VP %_72\C$]^IYN&QLD'N\!HN\^F8F]6L7G.MZ3_YP:3\^LO#]
MIX)U!U$OD3U(R\:5IFO<6%U5SI^-#"=LK5-W;\'0(IM,HSI$,IF8J6_J872Y
M^].I%ST=DPT;*1P_K>1N#+Z#?JB)4ILJ:13T"D*_X=\X02N^1AM/,MA0ZI/G
MA_O--C#M&_]+8U?^#?7ZQT=B*LMD'?O<KBPE)$E91I$MH9+F(B8A62?7,M89
MV<:6I:ZZEXQDJ^S9&4;&6B&&AK'.J":R?(9,GZ\9?.?^!_><Y_GU>9_GO-^O
M[9SGG&?Y[93:S]54U9;F]&MO]=YO]EV$( )W:_G]F.0:@GCG<;Y1Q= ]]KA7
M20WU$^&%)^VT"C*P-C7.@>8-5KV>W2;*;>^8K;"L'7)"K"7;KI>HN/L"*3+\
M"HR6><336]*&F[=/*$3^X<.,JLXK3['$,.0.ZL3I<\JD!=CDU<.+<[X]\\?!
M2ITG7LP@J<7)X;5:WK$=5'KOAS^3K.PGZ@=T1W)-,@^)9<V]JRU&FD5B^I&G
M0#-FG#Z#TZF10O+5KHO3O6Y//C6XPA#_JAJ0K&FK!-5HBE;CRZ1NXCX$@UBU
M/Z*MRRRB(! @JO_I@U)4G2L8$3#C-A1/:2+5K=^Z<<DDQW34=73W;YX,$P&/
M#00;V#5X833O',!*:QP,&S:FM"?9B7W=NGR&1CM:>XBE>%/I25L[X#A]\QIT
M& TX;,#\N^"[N3QX>8!1T+?<5STTHD\A#W9PJ."US6RF@/Q!%>L+,ENL>+RO
MHVSLC=U<_'U=8<N*V>_$WR>0OZVXUN2J5 8#VD/I]]4S%.LW;;_FB9]GF5;^
MO)L.^=^Y4<Y\#)IPVM60@E#A0W@\:S)H'\*0XOO1");PJN8-RY%1C:&YK>"%
MPA=LHE8NL+&*K5Y& /:V."E_O5J>>OTR=67Y2!Y>Z_H6?47SDKP\U-OG+R)6
MXG/7(E]E37E"0$L?NM%WM8E-[5<Y#:P7%T=N]&<KM<<53E;ES)F?'525_>V$
M0!OQ B+^C'=P&VN2?*<:UN>A3N6%LA,'Z-JC!!YZJ=!<QBCH"TSTZ>>G.542
MKZV=[\CW5E.+G= N?+3IX]\A8TW?@.A%48[KR#]1I?,(2?_-C)@?V!3S;*RJ
M5M =\<\'C\:DEW'%0 P*6'_-M2A$V752^6K K&F)N8?1GI<("5Y3&2J9%?X9
MJ'0&>!"PXE]6J;WEA_6R#PB;B"V7'0Z3ZWWK]55'.@%U?E#I$_3]PN' N__^
M5R)T".Q;BK$X5@\4$:IBY1J$G:1IDD9S#L(7/OI(B(=\,/18<$,5\*"@<1"
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MC,!S-%P3X.KY=1VA_4XE.0:%ORY0MG!!M:5;I=//:84TIOCDWJP\&KKU!/T
MI<K$)./DV-F9)MK,:O15K@>90<BW5]]8DZR8SK\Y?6*J2N:7YL"(N/&=3]"'
MD96+M7UXND7OO'0+6(UAX$5 $0K]>32);DBH+2>W3JX7#Z7:'L_IK^^12[AY
M8."X=WC-/L0.U*]QP=%V%OHT6NN1RIU F HB2RAW;T)'<JW\GE9#\'!I:,>%
MM?G.MWS DI?@W68*UNPE:Y *U%X;6V+[=#VFRU:_C$S\:&=_:W!0[9I:IFRZ
MI2=%YLX#\MRQ*A#-#R7*)B%L+W.V6=9VH4;WWM&QNSD52:03>(,9?Z>W\0KK
MV/33UQV/R41GD?)W5/A%*-> EH$-0I%DK,LKT)5+V8=(FLC7.NA4-^*E5T*G
M9K^/QBMH>MOXH.(W(]8.>D=+AG1)[PUBJ[W8M=? //6<]M$^'[LXNZM S]L_
MIMRL!2T4>D=>D,C&^C8W@^^(7S#8_C=CH.-)<*X]#P%BO "6)1H"OJ3:-KH;
M6[.#2V+" \[*#A8?VUJ3U9 TTD1$7!2':+PV1&KB/NP9LUM6HPPI(MD*?+IR
M7\JHS'#KJ([IE3*R/)Z&51H_N69U,OV5L_ \Q304?9/OY=RYYCS]29P6;A2G
M#YS+UBY5Z&HH&:J8^1"YFG,JLU5HVCGU]J\CN+PO9'G\/3/Y2 K'%[1C.,+0
M]]F1+,8:)Z-J1O'7LU4X_-;ILS[R>=C5N\.)C;Z"97$HOG[AF=D/R?+WP(7%
M[*Q;KOA$ X2<RW?)[ZX+R3I-(DD-SF<&E[4+QY+_08L6MUA/QVM$^,T;@H+L
M$N9"_T;2/D2"9!W%T%:AOJ-WMZK J>O!ZA(S-J6.NO1\M:UR!L11QZ"GJ,!@
M>UM:8 N:W76(9S>V#PDHT,W8$^#S,^9Z'?D3$UBOK_C1HO_NU+7J[MSRI/Y,
M$2]!T6B:+P!?G&\#*$QXOSWV5FM]_F@_4E6AF?CTL;')@U1G/4W-%^=0+Y_*
M;7A,\Z^1O.0XU8%B(]:<H1EKV]I(L^3HE#*^6F(OW@L)":ERZ3L;L7DRB>YU
ME]V00%$S4OB)H*,68:E(M<@GW1ZF@&R]5W&L)6 ZL>7W=J7>>'KNG0GN-H>Z
M^K^$M]DD =5O>QSKKG^)>B$2Q4D#ZYEH44NFL@5_JD1B-<H]RKZ5$Z4F?3LG
M#*[]TWO .L$@17UCXCD7-?[!@>]Q;$ V8+@4N- 4\81-8)R:%PH-8L@ L\U=
M>D^W%!_-4HU/NE5<-8E4VX=T;OXTL.Y#',$'P![1A4:3>.%+" (2"G25<!\Y
MX 7I"W9X@P916TD#2I#]TDF;5<?QKCY^@6BPC7OL._$T*,(@$_:.MB.ENH P
M3CLAN4E-:*\O"E/XV,8L\QQ+C-B1]N,VH1<C@!LO4NI"N,<:LZ&\WW!BXTTV
MN+YJ\)E-9WLG<67ZH<L-$53:02M+D_7<NL/*F\A&?@TLF[9*#3=+W8?XE@(%
M4]-@ *-P6?]2E'Y:_F3008FJR%NS/-%UU;:1 #M.#8BHY3VH ]'"B2$5,V8I
M)E%E(/$7UQQUD=/<X_G[0)/B&83> W'H[;K:"/[1P6 9H#K@:C8PB#S#T^P:
M^T(+;NP;V]X0!]-M/1LGJL<H5LMGKPQ+5U+5Y)3$G[.,[4 IMBIS8P!Q./8R
MV*%+^!FG^VX^< >6;'+!A.867.KL9-KW,;5@$)+S)CYNP:)CY:2F8!]2C*?X
M>4^%YP_2F&M7F/WN^OWY6478"NL@U<:Q4MF7<,F$^ -NY>.ST6%58C$]9)78
MPVQ4[PXK<>.G6:J*"(W4=A?82#<XL5HVKNY,[YF_G&ZI9WB\V*,T6FE7AC^
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MVYN]#_L0P6U^0O^U#X&S:#IGN4EL;+:!F=147 (*K_-YL?B1SVQ&FC UIX/
MM>JDOUK9\?^AX/XUZ8DC1OFCO<B'@!/ISJ*GKYS_ZD:4^],HZR\^6:Y.W]N'
M2)']=1\5P?/G''*E<R*U+K9O]OLD4+^1PO',6ZV"N0/K0)0'LJH*(0AJ6($8
MAK(&1071X&YF-;[H%N,6KM;\:MWVRV/;XT3^LL=\^J^V"[H__7]02P,$%
M  @ #8)_5(\L!-F$3P,  (,# !8   !G:7IT=&-U8W!L;6(P,# P,3 N:G!G
M[+L'4%-A]"]X:8;>%) :E*HT$02I 9$F(H@BG:@@182(B/1$J=*;@( 2I(B*
M$) F14(/J C2BT!H*CU!"%?2-K[=]W;>OIV=?6_FS=N=^5]R9IBYW[WYSG?.
M[YS?[[LW]"DZ'N"_9&9I!C Q,0$_&'\ ?1$X:1KJZP4 UM; :0  V &FZ.<
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M^T.;VF1'-X;<X=['"LV%/H!R#U2L[Y0G.P8,]M^OZ5:E]HJ(_@E,>831H#;
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M"3;QD;L6 =WWQ6NL:BEK#O^)$)8ENG2?1>9)).]YB'1,AB)+!B.!&"R_'TU
MT[#[?%01-@T:>Q!#$33U#AU21U%[7$D'F%DED@!1;2NARE?E;>2U>L+/F-(=
M/YZS"]WR(3<R;2U&+B%$PN3.=[UA8<D>"-GT)K.#Z22]R7,.H^V*,Z'IW8?=
M9C-I^;#XU+:T[Y5/9W3B9N])-W^[^D3TN*019 !%<*$#?Q717-A-H3 Z4)K5
M_I8Q)XLSB"F<"1"3>H,"12P<I0D-T<:A!&NL$'("SE]"U$Y$GIV9ZO;FJ!_=
MVX!QH%5G>#87K<1_M&;]J.V[?YZ%^9,+R8#ZK,V%K "ZHSA179_KB(@X9]_J
MI;J\[OB14/G[Q3G/W6 #.0-V"5GW30&D*P.H+K"5O39C.G!SD!&]BYQ4_7_-
M'#60'*E)!S!6"U359HP@2&4$]@V1;TN2J&=''$JD:3KWOG,O"SQ^KTW:3G$Y
M]4+)&^T> B3(G4J DGR)!QWPQTTPGH?8)#$W\(FS@?@-=-?[JINRF?-NQ.2O
MUEF_$*?J5UXN/V8"/0ADVA6];CCIW"QJ[?;D3L762\+(SM+.9BM1O.LP7+,E
M9^+9'V=3*6U+3>6Z$EY88BE#MS%OP8_Z,MB?J=*66H_PS'@33D:J'/&P*?.R
MOL+GS]7'M0QGJ7@>Y+/0"]UNHVUZOOY+;LY#;A.EK#8HCYL35ZW_2 APY+I5
M!&C\>9%AT7$>@#[&$FP6TIQ#-@_(MJ$1[I/;//%QC[+6Q%(VSTBGW0.V82W5
M;W##IS"_)1LJV4:NO$%LQ3\_^6=P+3\2K2:Z@#T_FQ;TXG8["_4-#)]9) ZV
M+I%WA$!(CR6^RL8VIZ)M5-6?>\+N,T[YMWV,:?8 <.;7XP8X7H$BB'$B8*;\
MD0J4ZV-M-HM^7DY\T7O-VR='Y6\-.&E__)%/$Q#[U;RNR+*!.(;\?@B);S_R
M(](Q:V*M38G[Z4_+8Y6?7C7S4]\>.R)W"7K.[.QG\\N3@ZA&&.6H2R<=J'^$
M#EY&)PA.@ZB^R4#J^W/-T.G#YIOLWCCV3?5$D1CT<XF?[:^HQ4CNBC[T$Z0,
M&'0GA#?F2*6OY(N@]^)9<T+#B[8"'?8=+)*5/6T*9%4* N1;]&E3)U0LJ^26
M+KXI%7"> G]9D"_/A*K\.>Z=&'^=.R<UVV=MM!CR\Q?EJ)HM$=X]-%MH1/AZ
M8:G+*A<[$CS+U\9IREK=#RZ?4KX4M*[[9\B2P:*?@ YO0LU)+VQ$ZNT,,Y>J
M=$5O?X0]M&%^ZID2SE\ICIJU"8"983U14]X6U(+@052?;F.K6JKAR8TM&?A&
MW:PR>XFE_H"P8J=>2#N78%@'GE=I#.9C,[WP;PEPW6L4N65QK=PQ[$N_L( +
M/YR^'F'-U#I_7I;?F%5"#/@;1.-0)UOZM!N"0MZ$^0/;-#[AT.MM5Z>_3ODE
MRS_X/B!E,UA?=X+E]?AF5_O(A'Y4\6]#^>_Z>F%O3F\4?&F9GC*KDJT6X&K-
ML7U4$K<ZR\EQ]44-9'<= 9Y$)S]$"[^?@?0FB[N=<BO0FZPIT)LR,QL6@OI)
M>"N$[T(DB <.FSBR).A"NIMV<#7!;JP-OFQ@)I=$!WIF5EY;Y?-+_ V,MLG-
M_^4C^X*[MJ,#\C./(FRS^.D@ >4S)]/[&D+[3!3.%#,/3,\;:I*3M7ES([&9
M1@<:HM ,J+ZF%M=C$M%U:3GX@7W%H:1(:;$^/QU7#JFQ5DW!TP>V"5_Z?WO\
M>H,IH0,^B.F%+FC]4/< 16:9RU?J/RW5O5GO^N?<'#*W^<XK1)\Q[L1\VX"#
M,@II%*5E"[4V)6+2I%5=ZG3IV')]T0Q- )UW%R?/@;.3=7]I ,"L(TV("F:,
M/I>B;[#H)*^M2_LX(A[!]4#L>K2FBEQ/C([CLS@W'/C2_!J\$$IPW?E;@CH0
MIP.SG.1DDC<UYR%\>LBZ[6.4GQVQ(J7A' ,9]M7](W/?*K-JWWIY2!BAFS^2
ML_P8FO#>T)1(#ZQ1.TDS8M!F*0>34._&?[G%*Q\2G[(C\G(U[+5EZLR.;,]+
M 2.6X^L6D$Q4IP!J)8MB00=J5J"'5Y06=\!3& H:VL.0CEL,#O*:?)=ZA9J*
MND4'CB)Q'S9NM*!ZR#!!']U6CNI[JOJ:-S,NO_F<EI7<U\&:\O9:ACK.F?CO
MR3_!(C5H&=%3%=%'DP7GN/R<OR[YTH86>3)5QZ_;VY,13/;7@]:,H%<C10CA
M%!-J?*3*HM>SKG,85O.*L-)W88U%[ML)KW=&L.R&4##;F5K8;N S\VGK6>[A
M0FQPN5^E_'G_[Y:)'AL_CKCN_1K!%@]-XQ;-$VF<D>=&*.(8L&NT[T:+:=NC
M@J@?NCJCJQ:V_,(V>XDF&5J/C=Q%VOTZ&,MD \J'Q,)\!\,1PCXSI:%J?76G
MJP9_/*(%5VT/ V?[.#/ COF*FOZ[P&'A8E//$ _%A7 E;VF(Z^[]]7#Y4N8A
M;F+3:?8!!VC7^@/.(N,C=3\G-?E2:(+$W(22=2M40&7@JSDWH[*N.DUIW;+G
M,ZN1';PC1C>-5P3@:!@$A4^CG23,EY\,;5I:'<0FK'BYI"IUE?A8KT1\=,B<
M8F/UD/$(EI;:/]0C_'MS*8;0U-GB$!>I_AI7[N/L>9++S_'#_=)FV=7G699>
M [)9E@P-JPOGBKSZCO855I\;4WGWT:C3NB'_9/1=82RN48<[1("\;;T!3N[Y
MXA?$?+#\^BH5_SIQ3GMEZ5U^N=Y/<ZWQ9F9 6@0_G_0NK_'/]DO46BP^?_XH
MM:+-6"VYWO]6F^BR9<Z-]37_'E)3JQ$P(+5Z@MBW;Q!OC!$#U1C RB8VQ587
M#3%R1JR!"\II><JOBJ\KR-6H:>#%K>F7]B%J\,P6O-0>TZ$(WN;I#*SGT<3*
M<+G?+(\J=>_GF,SIB8.C)S'/3]Y$WDRY)'C^QWN=SNH/-6VB^#GQQ8.XO2'>
MT B;!*OO#Z>$YR=&YAZ]]RG]FSV@D&6I4#!7S![P7S9*?RU]X$MJB-8Y0KH-
MVUEVV"LDNG3!^"EN'D%W\ L2:X8\T3^GB\.VVW0/4[\&/-#O7]BZJM@APY39
M+#ITET* $4S.AL'$->C @PHZ\&@8LH9]@EJQ)!Q08ZKHP)[=Y J<(CQ*L\(\
M9E!55]BAO0JR*%((#"/R+7Y++O<I4B"2LI<EE:P_N)PO@O(:Q,UN<K[949N5
MO1;'RB\CBE\)^8LB,>I*M#>()KT'GT6Z+2%2&B?,N&YYW+KEO:BQ.C/[/FT]
M7QNKYV7VY87W,   6PR1]0R^ZUG$PV <G\P9Q%,.TX^:3:==V5G"41.J8<\Q
M,]!I#Y(;L6GS$Z&=#G204$<?[@CX5OZR*K<,68Q/?.^=&:-QQJ7[)^XESNOZ
M:OK@3/M-,(X1+\1XNT+HLAO1JY78J3!QKK!9+: LO>N$2$2M[&EJTV-=IBTC
M:'!H-\T:QZ!"M78HJLS=?YJ/40[^ZN[$+)"T?5&']I+(W]J=?(G9R*%4PA(B
MJ<"SI=(9=0=]5#O.Y:N6N\TSVT[28+NO*'5[$U5;Y+=,!U@8M$HT&): /#O<
M=JV4@K!H\!<^E+SP?860NRK8LSB<29HWNVX+F84U5.">40N1S*&EN.C1K8/<
MJ\I:-[[>QP0I/5V:H_5[<<\17F-547BTX<EDTAMJG2KE&C'/*;VGY5/\2_G2
M<I?U$<QT[^=+3P05TS^SWOVV_NZ\4NN;0615Y U0IH(2 JJA&+#"-7&]E2]%
MB+G!UVH*;?9B3V_H6[B1;HV=L1O\;<DZV0WC1>&3G(5CEE:Q1'A/X5:0>5QB
M&LYJM+U3LZAP]0^<1;3_:C:#A*SR@:=)V'(PF=0QOCK2(.YFIA2E^GG>2?FG
MD[WL=;F,'/TS_?T'F GLU&W/;)(Q:%D[3@>6BIJ@IX9,.Z%/,!!J!1;_#,D-
M?C>,B<!'.4,3M)W="AP-ZIU#/S9^3+0\_96EE.,L3M4J8&?HW!;J W0SX37R
MLSL?[2M<<+U(==PS_;/?QL&=Z'F#WADE'^VSG>(ZRAV"COBL^V>8=KVW8(2C
MBP@<9F8Z4H.02W-C6<[)5FUXMSZA6ED^K6DM+NKE5M;0X96RE?YR\,^?;/<!
M8@C)!OQ%OA(:T-V)/MHN#[I8$^XT? V:0W6=*KW<5)"?KG?YM:]6WX.@6+:@
MF)@G\'QT_:]N.I"(K>/;<EN2-+>85#LYJ=8@7G7->GQ/?&3RK(EL^=,,LY!3
MW6R>@3%#\T*,1LSSA&Q;H8!KUSJ^[\!8#$66 QD\9).(QTQ7=M2"+IVZ@?7U
M:K]<YZYT;JNN2O.==>@8Z&!A(**#^=\3CNA%5#]TT88:@J4#P[<PVM04%+X<
M+>RPC(AO$R$J,.X8BS:91"R-7LZ;^-X=[*O\7E#KAJEKZNJ#]WS<]_TV%F;(
M)(#HL!6UE&I(=@:;?4M\9AP*6@)R_!8]3L1Y2M=F70OE3M]]TV\O<;_D\7D&
M;4E.![WY1%7-S)/E9*/N;:$Z:/:K6((KYB\'A=&BJW6Q?^HP[U >\*F*7G3M
MWS'-6;6D&TAY0G7Y ]7MO=9T[L*PR$Y1Z^^7U<1OG;^\;<:J8'3%CX7$6+7H
M*#"/U$F,+WR[ 156>:@B8^Y4.K+7BN#*OZQTRFYU53OFJT>MSDSIJ@2O#TLV
M8_QIAA!]#U;0<'H8ZHE:S#<;4!%-*:KHM2&SX^A &=%APWLSA"P:BB%=&-[?
MXNQ>BLI+U)2T,V^SLDKG?B[%U2W6)\^K.JL4:]UOKF<FZM>!5$!U2NUCDA?X
M@W=$0Q.68X/\= ='W5SK#?G9"]/.""%G.P# \.5OEJT%H+O$%3DH=3RYY^U=
MFA2*PYG'%-'XG <[-?KUCT;?7/,W/SQB&D4*ITV!F&J**_49Q1B2H*]P]T!,
MIXGXPB8(\:;]ZK2,!5'VOO<M[BVL=.!$^SOBPN:OY4\F)"6B>9?+ G3&K^7S
M[^]KAP$-4@4/V[J!E/?:H@6V(>^]M+.5=IO[=^!)M"/@$V(%7JJBRJ>=A\CW
ME&)(=-74GFB1&_UR=_04D"6C(GZF0SS^BM[28YB3/H-)LVY-H'S2DR;F#:C%
M^K[>&(/W'/[^BUB.Z4_ESP(KC]9\D=%,*<NR 5Y0%T?:Q[X_=('R_"8YW\CS
M%8HOO,,Y.^O<\<I.<0QX5UH#./SYR[?UBFS[>XM4RBAG(M(IG@UC>J-$WCB4
M.KP42KB,GBWM6:BO;S]!@*??:6HC7LF\VY+:^(I5B:.E<;YVX),(5[/D\JK1
M4/YHFI'A84E6[F-.Q9+_L/\GB]Y5*)KP6<[HEGEEGQG^5B;:H->&H=#=D%]H
M0F ^&1+I2!S']:#CG>E NF:ZX*5R?<1BLM9X@'WFB^C?S9EV1CV-F[=RS >+
M##_2@?@5@NGX&RW#HV#RN[G:J0GA(BYL6$X-\L81?6\9R?""0ZULYL>&W*-T
MP,M& #D";Q1.(&)ZW=FA/)%RBV]NT;Z-[.ACM@S<ETY)+A>LRLA>9 KL%IQ*
M-4?E[>@Z_Y>W_5E^[<P6XB=3D/K(;P6,8D3A>9L*<RNP\'8L\N!T-TO-:_*6
M9.%SY[#E8YU\3.O'2B"P=Q9B6F#=\$0LI,UWT=K!U#NUP4V\>V3!<;ZT_YN"
M;S$W5RHN1.&UN2L?=DV1Y>>6%:EO1-\2H9(>VRY",28.[GT_RM-$D=&8<;:P
MD.905;67,1VRBPH_VAL(K8%N(M[2A@Z09XF3R5OW-.F *-CXZ%;9VGLIR=/#
M_9YDW8^ H&/U(X)^/>:#8C%S[O_4GT'\A_V'_8?]A_V/6UDYI@@5@$FGG:06
MP+S)=$ BU'GR2MMX<7M#HV.#19'%I7ZR8XZY"?J*#\OONY<H]T=A^/?P^L:&
MTI=P&S!L<98JYWFF8;\Q!B4K=1-XIMK$%I06^&*RA?8%1KCQ!94XKS_2)D#4
M[B+-"X_O*\76-8W7K[DZ4U\]M4^S*),K^7*3Y5.-Q5 5@$RUF_R")M@.S03U
MPC^D=T:)],[SUXU@&I2&^$W*+:4PW%D])R/\\BV99$U:'Y[Z%A@=NFT(9;06
M_%MX@^K;DMXJITB5[XCZ$+@ZHICPLX2@&Q-MDDA,2;D?80O9%%)!AM/ZZ0#!
MOA*>@C0<;6,CBG?S@S8]X;'1,Z.V-9F#99,0FI/^@SN+LH2S@UGW ^&OK@-7
MX;JA,%)YPR3LWI $1:39IU3,*],WI,+0R-=[9NA!_A!,N29#-UV%+':H* 8X
M7_K5+ATZ>QGTPT>A>L._;B#*?T]HP%TMOD(&Q(2E(U[<Y"W+8 L;VHPA]L%G
ME$A(PE!:0.:),;4VL'HQ7=S.\>=#&='SK*=K("_.%//YE)04>$9K9YD[+ALY
MO4QC?C*6O09_@:W_11%:MB $-$4LPF,.90W5)VX]GVULBFB;2A1Z>NN897QA
M9O<1>P.SQ22 *M5?CNG[B K@FT7^S7-H))A5RA?@!J\G=P:=:[[PX,A68>-R
MRO80-OQ0AF3 X,+%=[$BR).^4&Z:+"BWASI^]Z@F/]SWJJZ1XZF;<M$7W-5R
MKCAJ\.JJ ,CX__0,V!7>.Y0\+P1*XMW,>^?5QTM&'OK)?=%[T5:-W S$.#PR
M.!8$>F'/T&10G:XTQ4@+HF8!K!/&I*Q5_ &G,OBL(/>5]H&KN>@TU&0W@]I<
MS#=!&9E<?@@CV/+-*BVV\ESK1;*VH"]=X(YQ(>3TOG?L']KAE^=E6BFB*NU!
M2"K4NOKTV:-=X;W4O(2=-IUWO]-9G5/?;\K%1+Y;O7P6CX"VWHLN3JD.3P(.
M+V1AU6!^6/!412_V":H>EXR4 !V,"7VE%;[9SKW>I%GQ_.IR7_];S]Y.Z\;+
MK4@#Q<LL!7^^H$ EA2T9C[,&.]UJ?%\0'T6NE=P5J+5%WJPBI7%(]I_?*^:;
M"E?Z4XA'4(3-N]S/$-FJ$XC0KKI0L;"?_"@_EQ^%A>>G,B %Y?;+HNO(F[HO
M''['I>ZWO_5FFRLC_IBYDJQ\K6LQRU3FQ+,T=AG(R<?*W]T5R$Z4\ F8]T)<
M536(Z J9/T>4&QQ[U*AK_;*M[HB"W$I&7]F[TS%#;Z_.M\L.H_#OL<?$EQ+B
M]$\L(6(?N8NBG;$-C4J1D[9?:ZW/) ]>#Q8%MCM_7RH J.8E24N&9RAPPE '
M)J&E*87B%MDHIO52ZF<?=U;S>8M25\HW',"W9B39:*J"O'(73K!72X<+ZQN'
MT@&((;_*3L)6NUO%I;;QZJ#L^$S\G8O]N,\B:4@/-]SF 1U@NSU>3MS'/FG7
M PWTQ=_^<%5I6<^ML;[7N+W")B+\1["_6495G$6_6J>8;Z3E5%*7*7<9OYFQ
MY*F]_^7O,/RO-(=>1CER4/NKH>)-ZYJ 'FJU#V.2__T,"[[KY3Q$C7L/V_,'
M;M*!3DGY)-BT%,'RI!KE>E/S#Z/ESTV8)"R^BF>1QYQ4\2&YTVODEXNNI_KZ
M1MEB7:AGU)-HU!>W.(V%G$$X]1D*7S O3RUIY_"5TANA*:9S3:]?<S6G%BC?
MR;Z5=.-IUI>S,:U>X2$8#,I+#91=B&MG!_]<(58DZ]O#TAKFM/!NCAV-MR<F
M1!.49-Z&^(K:?#UKU ^!'&-*9X3]J=4;.N"!9I8C#JZ#[SJNV%#V:$.?Y@Y_
M?MJA<0Q_1M?"NG[>9D[F2%1X0@>@UQP2&<[<Q:Y,1*HP+GN)H64L. S"ZS"4
MHWR], E#5M %)X;J.U4O'N4UMYINH?NP.H,M9SAU"<_RLHS:.?%89V$V"7>1
M&$(Y%G/Q ^ASHG7\5\M(%KB&4PR6RQ"63L]3.I[P:#Y6*VP.WIBR(29\6\AH
M0'8/T[UU$BJ%ZCQ%@ZV-@.CN(BGBG?CW[;?]E"#YFA.M75](88Y'XHWXOG[\
M=?^;&0^R*C(<[*SPA7Y )--._IY$!J"UXSVQH]O9 !;-MWW<^Y7\1<IO%B)+
M+ZK>JU)D*Z&*@B!L7+J=T"L(=_[ZYG/5/<];$M9%A7B[,@F4B!"5)5*/.)%-
MU.MHX4O65$IO\#D<?^8P\6&9M?3-3?9U]F_L!NPGL2=@'M"I5:0!K1LELG.1
MAXI]LQZH%;WUA+QQ/#FU?40\\:3.WM!5=T:S8TVDEF^5@KY+"_%(A6:R3*BE
MW(2_0GZ:<'^6MTE1D<MJ[=H)VA;@PBCG_90(,7A,I!XAPOSYEW=^NZ]+WW9#
MY?Q+(XU%#\*,$>0[VQH1-';,,O%MI!QQ,MH[JJF %R.YU&/,:AHH"DV3@@R]
M-G^#03.T6Q3O!HV3B1%PYHEV&;\:B\A3Q7/5U2I#%^,59F\%X(HL3;UHI %=
MKQ;H%&0+QHS"ERX(T"3F1/V+V_VM;))$98]GWBX<:LI(6^DI?[*18/CZL6$<
M8X)MR.$\%)<ANV\1Y_?JE88)?5_-&AM99?O<+NG7MS+.SWNFZNYRD<<1H-S"
MID=QI 'H4$*Y2E3-0;P)G>SA3YX55;V&(@47IO2NQG2$N.K<\^85F30494RS
MO;;%1H*B_.E!WV=KK</C?0O/+#[TP-%VDK#3U%/4%^>255!X2'>J^97,.Q_0
MW1,\XM++4A>X/6I9^<UO*[*,*"4113H7(*&E??-08A0M[BY-<?B.[[US/L.R
MQ&TS,[-;!QGQ,"5/;TC5HS%;)FN/*Z\; *0J([=-VD^ ":37_SI33+C<4$[9
MFEBLKLH+UV?:63E_MB4"7[8V4F7.RP1BQF'39%(P ;XYB[>"<8>:7$Z:\[ -
M:!!)18Y&J *^<LBR%_=UF3HP VB6>=-%&*BTE[5AMVE&K-J[M>)Z\UNV,HM4
M?JXZ^A5F]F:0$7>69CZG;F4EM]"M#&1#?RAT$1K;+NY7)#NNKUXR^SM/ZD21
MWDLS/4V!7N5^T8N%$*:G 8%C*?NRD]X,W2]/&Z8#N\\'E6BX="XZ\%M8B.Q.
M+(OA?9) -CD'OB*;T('/'IH8LI2^&ATH=G38R@$B91A+?)Z:1E$ABN"Q3Y$R
MOUL,J@N7$=RS6J_.K9;=UHCPE7+V?,9[_%W 35QF?<H?1SC!')HFEI".Y 63
M.UH^;>9E@Q=^RGB.ZGB[Z'3GI!RE*!('TCYR0UB8VWNHI><JH;RTH07!!A6K
M(WT+W>$Q7\M8/B&'I&>8\-DO;N[W8P;1X GJ^\%EOJ2#$RZ;:[<J^@;3M$45
MI+TG.<>8#F?A65""W<Y?BU^=:H<$AG=[.\'PJB\C6%D4OGQA-W,H&KZ_^(H.
MK,VO/X:Y;.S2 1I7V!+/!2@WY<QW_G[-UN3*+\WWS7-'^FK?L0S9RD8&_IA<
M9XML9CC-2LVZ0WUOR(OS*+V<.W]FN,)O3NZU?^V52UM9$(.8ZC-S^0Z-/BRU
MU,1(A;)0$](5\!JB=*;77^A7@G*PZ->;R-VE4$$GM_0';K.8D?;3# 3,@FHF
M"29@X%+_9G%"SP.W'[XC;B5QN1'WHTUOP'H$$F4,]/OV,4J@$MD/.;Q0^RW1
MF]#:"^4*V/\2I5.P8-TX5J5ZHCDU)%#B0<F'P>.R6S-\5^/[E 8I3DN(9#3A
M:OI,13>2GWBEZ%"9-/)7I=24JULX]2Y[1**DZ_9"/7?N2D8RCODQ[!;,TS_(
MCJB]B2547I^0L@Q60O,ZMHU>FO:UR2JVL*D$Q(D8^/M/,E8UA(0$Y?J-\R.C
M5J,J=O/'QVYYQ&MR%O,9O5/J@Y)VJ6B/S$R:$ACL9LEV>:M3$A7_V& [:8EV
M/-*3X-"7*K]SG0!+5(ZTKI@9(OEN*TM\P,D/SUKB7,_ 4A\]^U_>CO^_1 /.
M@52"2#>\/J^[,)T5_&#UN]YW^V2SU^AKQ]<+XG?N]SIZ&(XQ+:()EV!_S\*.
MH";G2^E >=;D9,,O-!.-/32"% SZ5H2*= U%R"?>DAVY.!-;J3R=99;YH?-Z
MU$^#RN'?+'_^I;T]'9"O6T20);90>_&'>215:GT[!T6.FH64\$$J@0FO?9T'
M7[ZO=9WRS_4M\="O9I'UZ8DL"U[.A-O11N!U-K'8N^DLCJ!-G]WZ5=]'X2GA
M9=;EWVJ^_)*UZV%23MW=R@=QKD%P;51W(9*9#@SMI, (OGQTX'@Q'X.^E$,;
M;.+I@!_B:1$G8:<[M+JA4%+6DC4D?J[4;_;MW'59BP6M82$S"]9<_4"X^;_J
MVB!ISJ#:1W&+%5WD-0^Q\;WP@!QD9NV=63_V7-N*X<N93%N'40X$&Q('>(K
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M#U^DSR=<?^!;LRCS<A]^THE\_B.R1*OD2E)6!43LQHU5(5KQ6B]D!,K958.
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MB#[3LS_/$9I@S9_S&W41OE !KU2TQQRT;)TEGOSF%?1"P@)U=HJ7 G1]FJ8
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MG<?FOIJYSF/Q>X/<J&&5"JXD/71E>O^+=6\>L3E!S%S92@]AP@#W9AE(<&Y
MH%C'Q% GC)Y!1QZY]8R_(W4>^]_+@$=;0'*80,D;'^F7SUY<8WZI^O_]/&&W
MP*LZ*!AF%').U:"]3O)'AA_-70"&2C]< ((X "1>7!:C7()W#[WJ6= B4:)4
M?69"98C3ETVA),@:6M?#,2L'W!H[NO1X\8;Y0VGQ4VQY](%(8J#I>08VZQ,]
M!1$-GZP*DFXO].;-[D(9X"A %P"&J;@+0&G/OFLCF>7O>RGG!GRO/ DN33$,
MC=ZWN?LR.2ZD!CG02+Z]=;^'S_BLI>DF7O.="2N]I&*PPP@!<F8LB:1QTKO!
M+476I=@T)#@XNA96,[BNWW*O]D'4@.W/@L&=+4)UXV*QZE>%Z]&-CX!YY;['
M3PA:UG8*34U"H,,[U[-6@Q<" D-J\*G?L#VS.A/7NBK5U=C?5WHT*X " D_R
M;I8MGU.:#N_M%C[$B?*]>T-0U@D,X" P'.=@G>L^-+GH]TWG5W\._TQ%90@Y
M?-BJMCJ\,GI/L73QB?7;.!I05P3;D?RQ=(XP%A@5(D304_/FDW.XSYRPPJC)
M?]6= -<;/[6#3BF:DR(F,P<C3:A49]2I0P1= 4C>UPMN[3X5P$09C!5/"T-=
M!YQ-N2Z+KSHQ5F CU$UU:Q.:C=UMZ"VT2@'<C8>SXT&CE ,D-9KG%<SL=U<G
MYM7B>V+?Y5$(HHF&_86OC62WX]PX:P(0'3#J)ROQ9I#:+/7/$OVL@QI7B5XK
MN4E7TMJ!5_O1<);7:B)%Z4Y-XDCJ$O+WYDYT0FP1P:K[]NO73[B;')P*-=%L
MG+&RGOMQQG68G(=81!N04G6!>=SK7,/L\^[[Q*E*6X">/!Z1'*2U(@1GAK(J
MILSNY7BFDDIW*FFO6<)^#3DG!#U[/V+4\D.BEU/L'W0HA-_/Y_V\Z)L9[&"]
MR!"7#='X#:O'TF1/_H/4/TN;U1H?U=PW7,Y,EBB2B;0)\Z5S0^*>B*AF95/?
MBLZH;L^0/<W3!4W;NK&%:33?;WG^_VZ#9[ 668EMN(I[I[Q'*S4@7?;?XW=F
M0DRNWYS/++Q.DC PF^JG=1\L;N,Y+SWD-B+R5%K0:W3-V%8ZOE0LFG.J6P=W
M_!*6TO+D_/'&^;DO7J:B["G60MTS&Y-,-$*%XSO]*I^[/76ZCAD"?;#X"GKP
MW.Z97N[0L&ZW4&^V1J>(LA>+8LW:+^/O7FTQ+S2I'3805E]]=X3&2$!L;Y-A
MH4XQ342=ZIR82NB2^[ZYK>R89=Y-4#V2"U_6K*3?,HH_=*;]>"7$R6M3X5SH
MB+91+-(*DJK4O.BY*A7W%"?QHJ-OZ,^[_;:ZYR@AY_2GRJ^]=G?W+1G0^_06
M+M[&)I;OMH;Z>^1)I9M#-PB-+T:<]D4FQ63XT5E$!BP"C*J>K>=-7/T0J6)=
M#]0V*:1#_][C-BH=1S[JUHLW&?N%WQRBG?Q5+H)/J;0UX9!MM\Y9RL7H$RRI
M8H[;?=EZT]609YWWZTB&$G5;U:$>)IXQ76/[S+K.HG,I*9#5B5/A;P*R/^ U
M#9M[#D'JV+A:LK#67?![-<:_W:WS!@FYIOUC7F>EQV?"@J/F@]LQV0W_*=DR
MW)T"]]+YN[7ZT<5YK2[A,<>MX;)D;BQ#A#UJ;Z#EVZ^>[;?5[S;<1<+4-0#H
M9JAZA/G3\4?J.WK:0NE5I>?9K?;9GIW$I\3R'[R?9/T_UCM?'A=Y]#"*966H
MX@+0H>:3>H:MDN]%@G(T:@+X8UH=]YD(F9V>FZ,FT[-F?8URW:UN+Z=LT05^
M7WP9..\L5:R298CTD!14QR/%!JN*3@-.R/*G*0)8K0HEHR"RMX_^K1L%U<KQ
M WDAN C?EN3&CL(+-.0R+@#!(>F7G*5T>"=DPE_\_?V%/L^>0$^S7";0:Y5[
M#K)&*$5;'\6"^MGC^JJ_[ H*RAX0-?/T26/3TF-\S8%HCFR$QDYRE8I["W9@
M?C(5-,I[W?U#%IYL/BE\*_KA!\U>.A0.H8>2#HP6MH#LWX2G/MOL' ^16?_W
MW/-[ZU59!41DB@)RQ4BIQBR38R/2<GV/IGZVA"O$<F$\PS+9W9?_V(O>+L<A
M58;[PUMUL)29E(;2,\;PSXH4),P4"5CR/H03:W[LX? V6-W%:.O3J9\33[.Z
MALL$*KQM'*F3FC%B2G[<] 8A]VW0#]IVX.>(<]K+9:R=_Z<($PL@/NY?AD6)
M@11<QBRNP],:_9#Z>;G+1X@<4=&@4]KPK-'FU;&[CY&4,><ND=PO\SG<1Y'M
MZ]6":,$2@Y*^Q!J56)<<@6!9]J!96+43PU3Y@=38<("QV)GJ?_4A6NX:?4K9
M?2<BF. FB>1NEC +T(L-+-$NG)'UX RC<ASJCO> W3:9=D ERE1G!.DXC7I=
M15S-"4A2%EKW)+&8XN)-';?E_NPM27A]3[FALP!2076J+ZPH//C\[P+0F>..
M=!$"=_?=?LM]? $PL ")UWR]"?MX0C060HN,LO4=(H]D3F>FB%2_@O]<2H()
M>#]VXY-[SSH[*:DYF7R3*Y_,7)Z"U%5SOP"$/$1P7 #"'/]:=8;P';\!/T78
M7S:C+@"]+*.7-JAV#7E^FO$!F/.[Y$[?#]P'TD_76V8?EF_,<B,/''7,91HV
MPJY)=:=="^(79-@7.W $')Y+G?B^"+STB()[(NM7))#* VZU&N?W45OP-8NC
M#/@#C9?P+57VAIXD[VO7 HZ0:),T4Y95U"WI:*I!"G9\>9G'+PTU/2-O4)T*
MGN+Q-NN'J.D+P.3MR/DL6-9*L](R Q+!3+H_=C<<D@"6RP</)+5$K1]=J5?/
M[LO:54 WRTQG, OG\QVB$JHIQ#YY#UAU6SX<]X;^>)6S>Z)8[C[,8&6]\*<T
M7M9[X:9P8"0-[6H@2I<V/_)N&!1L])6AX0;W)F7HN+3"WM0SMB59G1!EJ./Z
MW-14)X]<@RCG <MW/I^/]TE1/FXAA:6.*,[\MJ6\TZK%#V1FBG\.LG6ZI5J>
MM()Z.TL;BPL-0PP$)B/<G=_OJJNAX:E);\+WW+2 4> 4,ZQHIJ.MG#%MB&N#
M_ 8",MB2@(4GM"Y;$1P-QW;:<HZ!(IE9N[SL("*3V<NBW9_JN;[6)+@*=C*Y
M:*:7V:#QQUN08I8W (]&,3OVNQY_NC.K)/4AM\R;YQHA,!@G94(>'%O])):N
M<S79=R!4JX?Z#9T/!VH'N0*DKP;.I,GZW%^K51]-H\B\NA34["9T%/,Z3I9>
MHK/$I*!B>:(-A;"8</4$+K.&E9/YS!P7N&H!H-1= 7D%>5LVHN>6E6+04X+9
M+S]6D_JZUM#.->Z\WZM',D0[+*Q3@CQ ONGOK<NHZVG65#]3N;54D?#PA=ML
MS 6 ,<"798 \L4B_&_1RB;/9=,)72;!1?1'#M.^FL;;8'.*9:9C RR18?0R+
MA[M(SPNZ/R<UPW7JFUITPK(>G93GK$P75$[G+L\27TEI>!:D11Q<EV_'&)@-
M\"?1B%T]WYL_17#1*HMIU%=DV%D^P9UND*"![99,+1.DEU29SDR]RET_Q242
M(/@!.>^N$_=.1[G(NXQ-Z(+@/V?,)/ZZJB9=3_VYP]]T;"";2*2KNTZOBW(=
MJ&HEK1,Z%(7)-YU+;M'1G((_J=#B5GI77\*]QYO G05?(97NYL[4+0W6H6F*
M9<XE$JO/_,!!2/?;NR\4Y(^5,6@'WC.9]N=1,[,Z8D_"9UH->G$O4QEOQT[P
MAK50L? 53F]F;+2)Z+N&BV-Z+/XNZ266AV"<*>LL@Z&K[X9=1&04Q(Z#,"E"
MY) :X@8V0@2DA@4^KZJO3AVY2L/N$$K1=O,)?0 3J73)=89S>2>' 5<P73<T
M9;X*5O(76>3I:%7L&3248/IRECVY=@+)M!U;37X5F,HF[ \,!8XV3MTU0T16
MF0JN_8L")EZRC;5W?]Y]C<(T$HU=ESFEBOU"]OA6X^J VBN4H978N9G@1KZR
M#R=UL,1]RY0SE2#^<?(#DFI5Y)A;7>2S=U]]VJG'9L=J/#FJ?2V][N@R 14Z
M['F*6(@V9T""$ 0+_K"[_AKG[O'MA\UL*G+S/>57JVL+!)7MZ5WCW32?]E>I
MJUD ":(QA*ZGM-SQA?GVS=H(X_>&?W<3_&4V0R2G"^<X8T&L[^9S0^@\6#/P
M :*SNQ G7&Y6SX^-G,7B?56@%'D,=M6U4"[DKF2_L&9C6)SSZ5<&",R40 32
MFL]JR=-]N-<.7#7>AD2W\&[R2&+/US,=[K>O:U1W\M)BU8Z.SX56K#[E,,0^
M&=_CB[[CH7,?7I+'D&4["JO<XX<K*.N%M)X[MMH5:?Q\+_F4T\8>L20HXF/O
MK&_D>8CG'4ON-A^M7I0=9_G\R&;L(.]&D\2RQ9.7X[QU'VAN=Z3L#UT +)O'
MVL&4=[$6JQS(&&]VD:*AC,_EXFVWD4*+/#68Q<K63F5191!$*JQ-2CI^K!A=
MX)5;0_]QX6[#6 'V_$N=K,]DUY @[<_E3WR',\VT+1'"Z@^92]]G_\UTCY_\
MA07?PE1AC#VNFSYY7W3[UT=W)&&BN.DVKY]1L+[_56L_P[V LT!#9>HG$S*S
MJ[^K.7_8A-:KM$(,+.H^AMPF)'=Q'#47C$K[)/YK<7=3%62SI5?\3!=2(JS'
M2<VCP?<K:,))18KI@4B-2A!.(_+$Q,4F^ZPCAY1;X-Z*C1MP+1P,,UC+T3XF
M&QY#=H%813KP\_!7(XM]=WXG"O-/"? 75>Q;26@56'#+^AZ8_RS7Z@YY8OF]
MS,C PDPE0V)-BT?G/.EE]&(H)_%<:!LRC54[SU]>%4DSP>42J+5/R[6B9OBN
MVKJT$U&-Y"%6&OX8+VEJLB4#^</K+R%]!#&R*M8S=\'[ A :LR-6M=J?T&)2
M+M4./KA6VW8!2,T]$R@?/*U%/N(.JNH6424!)U)::T61JGP]8(INV25G[$+A
MGXU^ZPM  D>RZ=?:*O\<ZO3<84_#=8/SY(#0U4HYR(FN.&BP6W9.O;E2DX1I
M'M/;C(3<A6DOVW3Y)L:AJ:GQY4.Z\!.EJAYP ;?TE<"!!]X"%ESA.9)02GUL
M\=-HF4Z*&\L:>@L+$ZBM8XBW:)ND1*X+E6,\(G*_9HC-U%2#-MQSN?X$0S2V
MGQ#ZJ3*/G-\3*ITMF0E2P.IL6W*.R\@]OB-2S-[\VW-LX9<6<)^>&FWUPG&!
MM@J;UGX6:Y+]IM%O^*=$.Z@89#.%&GB1Y[11%EQ$5\<%.H<]]7AKO<ML7(*Y
M %2UMK\.>:0;A)(;-3$SBXN*"S5IL539VH%I'[;.Q!Y#6PF>)3K%,[\JN\7Z
MJ]%WWV3/*[>:SA,\ES/G TZ9M%MTH-%ZQXQ9 ;1Q# 8++6NHIF>%A$Y565:%
M7"<[LW^\H(W$\+$,G.?&H[=,&ZUI-G7)TQT2&FB%80,#_:!)3@6[ORL-P3:0
M.P$6226BU%PH'9QGQ\93W&0^3Y848]9GJ4TAN:[TAF'\9+S;CB8I06C]J3M1
M+XJEY]?!:8[.[M]N;QXN+%>=*9(HBDE_P.O&UM8+PI](#]%L85Q_/3LNGMVP
M ]11%E_"U_G=\VPR\V;%^]J Z!A9?QLC)Z8A=G)U=KA/XN%Z&39L=GFHXTS9
MNBQMMPX)E1*;;X.X'@_XTYX?4,L<N>Z:X/(U</2I0>S61;W,J4R2O4HVG.$"
M;:>M4\H: :<FWX27 KT1XY(<H@DLGNH#50-(BYG;CRRGE"?2K]]H[^UV8_1S
M9&&<J[([_ /K+ A^@(4\X[F+>_M>TIGRI7YF)EB4PHF<D[*:RQ1$YXLMZII)
MB/<6_R(<86.#!'QF@#B>YMPO7HO1PFM8\H"^Y'/Z@GJ0&@G4J6L_[#U1I)5:
M,6?KQC%DAEPD)O<;.<63?+NQ,5A6)X_&9966X]T'&_=?<M/S74\0"D>48PLM
M]JGF?;+C<^ME7IJDM9KX]$ZN:$+;N3)F$TY%HDSN;&5P 1F6_G/.L8\S[8#%
M1O'759[LFT>UM5+5H+J&*@=!2_4=A_^E2W(0JXZKP[:1'2VT-3FR"?-W+/+K
M>"RE+%/-='*Y]1A'OBEX!"+_R>FL/X<8%2];5-JPL4B/";@HX3(RE)1W$#F2
M-X#Q(37_\CFE.KPLM-,^E:#AD766XH1@JF9FC3MGSF3+Y<<)P5AH^U$N?:>S
M#;/MUZ9!$WG\4%%92/&FK^F3($[L1'Q9PVZP(H.,&H;_2R;<RI1T</Z]FKT:
MS&3)(-#)U-<M1]FV "L(D8MU--P0V/4)G(1Z]GD1NN.[*XO1ON#$\OV5AVG0
MGY:F>FCKUTC>;;]S:.380YK[=S9R4QLQ4#!!\TC@C3WEZM JC'CTEUHDCV#K
M%VM9.^(4R\[OQ&IN2Y^3\\-X"](!"ZW-I0FZYDQ_]<2C\Y"*ZT"+NR7E$+;S
M9TG)60G):*%]QX0YJ"EW_QXYA2A2--WN7G0!^&%MP;K/DRV?/\R0*:K"LUWY
M_/#IP*W>P<6]G/P"5S^KY5_&J953EF:Q'R0O &S45S=R)QO+S(R#5?9>&:QW
M(1V$-J'_U8*.TJ@^,]6>BT/'&#VN5+E[_J/UW1:('V'NJ%VIXR!4)2@JGG=[
M=Q]CI>@7KE5;4ZUQ_67#&W2MT-X%(,Z*]5>06L&"@SXUHZBZW\81(JKEKF9.
M4'%C;2FC%-S4=[O',X?'E9"ATDF2'UJ"%HX$<03IK/#5U,*9M'J%4-_X4%)+
MN_#2BL\[;/MX&3S#3K\R@B2RN?;..$$FF0O7]YM<3;$+I(;90>GNZ 0_T7\)
M6O.0"]4<!$\342-BW]OS'![150O16GM^5L",UHB!3!QL;)C[6.8$*-2(9RBI
M\B"34728_%Y?.IO->V5%W&0H:+''Q[Y+AT\?63GE[6I.298Y%.MNO#8R7;9<
MM^@"643670#,45,9\&CGHUEPY8SSTY" \^#S[2AX"U,W(DCQ3XS H?M:E5#<
M8:>;_$D>P^"W:U^2%-G:TWMT>)I@B>:%W^R9?9.<E@)NXME)4OYV*[/9@BMW
MM!@?Y]\-CTN W1=B19)98Y^D6PU>>:R@=TY= PC0V"EO#](MI+P @$,9SC91
M6R<QK+X=P6YR(+,+P"8!<]!Z[-S@1[++%]AT2;L /$9, )E_7P B(+\DEIPO
MISN"&Z:N((D +B']F)KT!WD!R!O1Z!C+C5+A.:Z*"PF+2:6V^%_'0LGAKN]B
MW]7"MBZ%$)[)XH$G^%:+ZS5,.+?(_\1" ?TFWRZ(3Z)&CUW/V29RN<+9AK0S
MN],HR4S.7F#*W3$&4O1$4EKLQBT]*C]I"L2*P.1&I[#661/Y>[TR7:(K5; X
MF-<BH<2M;'EZ6#8PY'M]\'T)[E'/K P 9MF9T+YO6; \I;N>QNQAIKNFT6OW
M//*$^M)&"_Q?1(39,@+66_+/D[SIY$Q:$I"OGKE]"]N["_--:#4M[D_5-N)8
M:RE"!%TA?%N.SM=E[->K#SN__77@+D4 _+@9N6:97^P7^W2\[L%D$?0:/E<@
M04O5U44*_U.Q-9RD\&,;IY4_+6S0V]E0P7>T*;4CM"X6G<,T+M8BJY(H 67?
M>_C)T$9XJN\A/0/J"/$VDHDAH?2![L$SH9/Q$N>]_(D6\?>*OS+$Q_B;7CI+
M^7_^>>1"?QU=Q%_@!SRF_[.,N.60**D5F7U34N@-J;.(Y^C8* I*T3 F(A-(
M]>>.^T^1]CD ^]7PHQ,\0K=AK(EO1C[)Q&DG>NW:F&!6')Z/.!+QCX>E7F/!
MHO65\D3B:>^9\2^X9T%9G^RA*[NP&K M*@-G15\-LQZGI.VI^"U/Y"!BCB='
MA->P*3T%=N[. 6^-.LW^ MF07 $45NQ^]%O[TK.%-_W5Z1(W&8X0'%KSM64>
MW"=V8K2F,W-^WV=TTF[//'Z]^Y8:6PLV]T6\PYY$VXS+.!@]U'1.E>(X4+JB
M1O+;MU+VBS1P['MUH,?@4L2"3VO+C7SIAVA+8Z61(YH^2G8?5+U9Q#8T6=OY
M Z.F-6T1\M8FB'/Y!/?PQWVEWW_X#K<,@W0++@"VV_IJ*-="7:5.\H/,#I2^
MY-T@T@^F.'**S[Q9U\RG)F\!MJ6$TE.RS)FMEZE3T#4'HX3[!IDGSX,9GOQ!
ME3\W^JOS(4=M*W'7<J*0H-[#0-GO4,SWTB+%2?N?!E\MPW+B;(V;,6J8X*NO
MF^E>1S:IA9GVHD!0E9^1?'_UPM>+6C;2HHL^(?5N)J\ED.T?K2Q2S60N#4G^
MB5ME&U3;A-)TIWTFN'8>#S#;_TLAZR_\H^ .7&^&MH%ICX#<P97K8WU^PB^&
MW->E*&K4T8/*%!C+>SB=%Y!;?JOM+LRF)G#AG[*J=@!&AC_494$JOM'?U+2E
M]8^3YD^!^4O?++-8:WPEA=?#7S7I9"(//GM6?U8R+B4I6:AL$_\5 VU- &\A
MU E_AHX0S)/W#FRNJ1M\F]/$K[<D$FBP R2K92N5!;^EF9^:<Y"7D_4$E^T?
M:S ?9';69#P7KZ=/2Y0WVNI*4:RH<ZY&4XV.UXM?C;T*U"HY7\O$:(,D-#=B
M%DPF7U"QIR6.H0Y^OB0QH(2/KI[)$/W]^V4A!]V^G[<A2UMEPH4T[H\X30[C
MCC:*:H(/BXM8=T[ P*ZW4(,B#FFHIYANX)[C^PL  W[W_K+)C<_AG^E<,(HB
M!<>9((-NX)?^\!QJB&GU(>_CAVOBDNX+5:(R.LH>[,[?DT^BXES82556,NI^
M#1.</_%P@Y@?RVR'SVJG#UJ[$+13F\1A31_-" ]UZ$8KNZ/L"<</]0<WN#1$
MX$Y *T=B(QH<:C?\S[C02Q 3:?26 39VI45ZHLPN^=57.ROVOT\2C[;,YY[U
M;1I\42)'[8"4HU."%/7,)S6*MCDRVY<M5#17']LG&K"S8^"0@"/$QQP6"*/C
MY.?>8622 O)*$\2B0JN)/Z^7*U3:]Z:I.&R66@:S< /WL86]+GX7==+X*A)=
MJ$#VSJ6='RM9P!S(#>8;O;;G4*KZ1DC''A\^F5C1M/G'Z&5W]</?XY/RM [P
M%7#-K[<9ZT<V/B]FC9/_#@6LU4 ^G01,J@S+L6R-S9*$OF,A725!RTZ]<5A.
MWPI$3=!DI7V;$7DT\@ZHL8Q$MFN,E2<S;NNR"?GPK=KC@*-_$)Q^,\@N3>99
M/CTJN4<G*D? [F!MLWA]_G=\3LAMZ*!4PV--_HP12Z01Y952@;=0JQF:0&FC
MXX/!%U\30UP+_$0F"V@</_; ?'GM732X*#!6YGZ.ZZ/ *)Z'#C8& H]9<GEB
M1R_![(G%)V9[AT'H8=PE2=L>)R)$DB8WMOQ,!;^X!M8&&"6OO+3_:69VG33P
MKS1Y3T-F6R0=K2'T$<$Y^I8.8<+]A^>M1\CWYB0=SN(R?77J/I<H:I(0:KE>
M8TJ[R&B0-MB8.:_Z>?GF\]Q'Z(5?G= ZVH$,Y[+,.3<ZBTRU/S%W"6TJ?RX
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M>L/;?H".$U^B]<QUW,K6^%0:<#CB76'%VC7 $*,8 ,WAE"VU]O1Q27N3)/U
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MQ+*A)4E$SH7D-OU_$WVJ4?C6JM*G)7%Q7BHI&W?<ARZQX?8S1?$70WUD7I+
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MB+,F97'8BF$3Z!=4?@+ZW:#F1MOX/4?29;@]+I =?[7'TE5X)V'OKS_KIM2
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MXQDZ KEI&W,OS-E5N>^C$F1J?6+(S>N;B5U]CNY$<62^&<=X9K)9\:(THON
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M*2;A-+4=EX55/'LIS99Z\<9B;A'][8NKQDU6F>"EZ;8$]7&!.K3<]36)LT3
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M(J+ MN[&FDHD=8N9H%M_'PZA)U@ 7W*Y^9XW,W.B6,?3WJ-/,3R]":L9!;(
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M!W+3MQ[ .Y.7@$YZ&!11D'-Q,Y>^ _0 VH]%T5^0<BX!BBR]UHNSE3"FIY>
MT DPZ)@((L7:]\6%KWZUO>;@M3;%NLGA0=Y_3+"?=%1P&R]*4&'YG!+BF/@2
MB<OTUZ),^WQ2GD.S\]>>,>GK=O)Z0V "J1UF?\&[<@D(V\"MEYGNZ,PK%3E?
M+TKZ^))?I+_7_XOT!<MR*QGF[.I6_J&*;%7R.!V('#1^+#H*V$W07<R"$=ZT
M84T;Z\>UMHW,@<\$R<WO]4'!9E.SX;UZG6KI,36/M.+>VG'M)(2S"$7 V18U
M PKLJ;2F5A6CL''YW/?BJ7()NPNM B5OL1Z=HC@/LZ0WM<W\-Q,HXI4/3L3/
MD9@)TU;,?IL+FT<_1@-IO1![]$69$!84.G<"ZP)1%M4)=*59I$1:^GA,R"_6
M,8@P.+P_K>-H&S*R35 #SS:L(+X$ BMF%Q=,-&U< WN3K-4'PKAN]>4=F#TL
MAXQDTR)BS]+I(ZUJ)E9UFZI^ GYO[I<>BU^I]E[-N/3-[EL_5J(WU!QHS 45
M#YK)^B\VVX!T$#XUNEA94(D23T\-H3!>:D!J3/[DKZ9(K^Y9RDM_F-^#0*>*
MK27R.H0I57<U>%&-YBNS):_]OGI!T%_B*K+.]SZ?8"&*+TMCYY6;FYM(\O N
MX<WF"<P-J_^;*-E=7[,SY\'$#5Y<J8F7XFHO]-6K+A@IL/\R)^&38MUE[O;9
M#[V=+O("$1-]6KX(=B@WC<V[KH[_#[>HU]BH:"C;Q41!Y[O1DA &9OSO"HR3
M$"K\-=VN86ZQE@"O,W&EKB5:&UQ8E;$QDCT"=Y3].QDY@V@:N+KQU 36B0]5
M3H]:V^+<_Z[M#ZQR)?;A]%Z8J+_C/R^5849TZ71W3)15_7 PP_9%MGJLU&5/
M*-A68)/=I9>]\8NDE'7H'$)2@-LV\/<+1PB[/2)27M@!_G30H,7NPN85)> 2
M -1>JK,P&!!H#6N=5A 2J+T&&KL&3Y=5T6$DCC>4KFD-N#;ZNH_KR8"I?#7U
MI_.34--_%\5?T(C$1H]@Z<.\Y( CZ:BY5_'*+\94%W .6&,SS-Y!L1&R*N_V
M>:AZYJ&2K \A8-JGFY[%?O')E'7JQ;WB/20^$_I+.BAH=WLU?=R3@Z<VI>5D
MS[<6XQ>!8+-F&)A?/S8%[^G?? (5-%GY &^CGT35M)KFX^+?!JG:OJNG/WKV
M\'A?Z1)@5D7:M]9Y_Z7UBL=DH484NAK"U7LW)LI?=?3O4\'Y5K#,BUSWE&;:
M@/H70#N-.&IWKX= _[X,LS=I<7>Y0S69EVHO ;>NT8%$S+8Q-:?A04"U$.6I
MRFR4@;*R%9-<=4(;>EO'/IMAG,3E*Q]DUCEC:"\<&YD1_JG_-UN.POFT4L0E
MP";GML.<;\ND=8)J@Q93OP\=H!_D \,AXC2*'ZTE:0CE(USZUWO-;2US4PS0
M=;6V9WA0G)X/XP^=KQJM>\FRQV<7"/$J@K/3J\4%RQB;UWY]8-AXZRA>'0,-
M1ZOGVS](:ZZ /DUB>!W!9BEU,N:,:@J=M/IA$SZN<G<D,_7N9V#NEM0Q.]$!
MC9F=ILYZ,9?#1X#;# K>SQ^>7YL[DD-T24]GE?:.N,FZ-<HZCM)KU!Y$GLTY
MQ<=SW/IYE'@& KD4^C5TM0,2@#M]FC\GIP?7V*!%U5J^[!(AN]N&<(F).DW:
MG82")7F>B"_Z+SACKW2'V8DLXI;>W4R>7TU=I/+)^,?B%D)>GCQ_"5ZE F.)
MYB2K:'=+D\V2LRJ%WKG%TG(55VYM9P,G^4_NLTR_-\\GS^ZHK_^H7+/*I"EE
M0N/\$56$I]CPM-61%[8L\UK$6HFI3R]XN8.7YKUAWRJ[G6MYK]\".XCNE5@;
M^(LS:!C7K-ORCS0GI'SEL\J6WA3?(=W%I97@])@>JHU_[2\ ],4KBEQ,IW6/
MS1Z>TK,C9[=]U$YELEUG5_<W04)-E0L*R\YQ*VWRHP=&[7J^4H=_,C/-5[]*
M9^J/F5=/"3_W"&]8@';(.%B4H"P'C!ZH-:4O2K>V9 2&WIW?S/; 30GHOL_0
M<F6%N8SF3=6UW=)I/!3;#?@>6#C']&QY-0^_N%3Y:;L!*2[C*]CU)A9'MR!Q
M^KA=J6/SA>/[?'49E6-Y2)4^FW2*JMH;KPMPN-!!Q;MJX]K(-N4+ZB[CTEK\
M%]&?,(9C=EB4)_TM7\,DVM>WHJB/JH/[ .:(D8;T?/OT;T>]-VAF-]J>X9H-
MC)P+]:T"21^DS^,,.UUK-4TP+KT_Q(R9T)M@\2M2OI10Z7<%DPESTGBM<:N)
M2H'5$)\S=_H%KNP@O+Z0EY\?\*'VJ$ALSD1TTFI/^GWOFQSYM+]3%1IHRFLW
MY<[TAZ='?HKGB'FF!3@&";)&8+[92R<M7@*XOF#&XF$P1@7^(?[JHW"I[1G]
M(CNXD O#[T0358->X;*%%JCJCA@H9+7'WQ9/4>^=V-C?X7C42S^TXY"#!45L
M8&2';,>[^&" ;A7FY8N R?6FA.H-@[(=)8@H%76UCO99HAZ:^N=+M^C)GW^,
M'"SXLDH"$$\:TIZ_XT[4_^1'+K4[J5^9P&['MXQ4<^%[_M_7!=%^MI-36$G7
MZI./R9[6 4#)^.+(SI(GO6<O"A/Y#P!**\:P/XB)=MJ3R'U/I#NWH0@UFQ"^
M-?I<2&NR\K$AC<Y/;\=2ICZS$Y>.2P!#'8S<5&Q:FWNE\=%KMZ5"7]PP\I;=
MG]/4M #;>),^GLJX0NI$L\/IA;%?@=JH&YY0^OD=G=L47++XKZ#*0"EL""H>
MMCHBLMSJ<JS<I-YJ VMO\R0]PHT$K19:35JI*?=QJ+S@:+H$R*=$7(%Z:#GV
MIDWX(%;Y0S_;:LEJ<9N?085LR8I<(4LTT7K!. ^9N%86IZ]_#^CG- OMD.LB
MW<Q@2GB)-=31.*6BVOK2YD*B?M^._7@,=OI?27<'M ,4^-1O&0ED,#0+.@E\
MVM&Q(NTVWD9.HM8>^TUD\K>GAAY2G&"4D#D_=DF5H 52"C?4-\BNK."_(%"A
M"@M[UU'1=0;P\4#[6*5G-E/"V6>$_%^F_0++?A?51<QP_BC3:J86E4N+[?V8
M(W<[I'<);UYQ+7B!:'L-)%.GQA8Z?N.MW'NA^X#Q%JN%W0\G!D:VOKL)V_ID
MS&QLNE7?_:Q@F*.0EVR1=:F<:M0U07R7 ,N]>)#$:]=[B/1Q7ZML1C:/DZJ0
M%5*RG5?EJ]/9U>!'YDM2G!SN 0%:E"Y=T"_RDECV8Z.V<#'E*1_^"N4]5U\J
M0OJ%R]4Z]MG)W^P2@+>@F+VN\N6@K<+:4\ 7RI=;'N?ZB00#7(R?FQB+?)A?
MC/)[1;S;*(#-[:2*\A9GY::4D.CA\(+?#J0U'7"AJ4RLA1GW0NV2%I;_SLZD
M7(0DH$X>M37)OK5>W4+7Q=V53"Q@_NHV?V]WGV\Y_UJM[YZT?CMD@,3?_FM*
MZ+@NI9[_G7X1I0CQ.B  U M+2(.08Z)G9ACC"0SR!G)*LE=;-%-<:"ZYER7U
MNX#>T@B-NX_-$K%L@R2P<S87$0<SVE\OF.MY[Q9K\V+;Q+_&I=^17A60881K
M@HEW;Z@_%[-9^4X^1DXL&T.T:CM5VKDIWW_E%BMKLQ-$+"N<:A&?0)LNA,N'
M5/KGA)"8;/WI(JYHH'Z]I_?YHX:UDQ>C;J,/ZCC>&6=_P"#[YF!=1'?C'+IP
MT7G(7H&IN[OH>?(B'(:[M]+.V(>2D^F3?SPY4I19@7C>)<J.D^*V9-K<-1.M
M)+RMKF[SP4S'L-<OI4I9C?J3)1]Q>)B@#Z+J%M0\%NS3[O+/MPI\SI>+8 =4
M[3 U-]J[A_*?MT:6:LZ)\^U!DKJPY6\#Y'1-)]BK!-!G]^Y:"GSQW5W:_2!+
MA:V"<@C-H?=8QBD=F=9ZH<="_H033$*"$ 'H$'2]=CQ2D,RT/ 3!F7P^\>_T
M=P=C(C<L>7!S%-V]['^A[TTE4!R;)]7DWG@2],4K7V.@?)[X!FO3+<#:Q:*9
M5:(JL H0)7&37658&ZS'Z^1W09_^&@7P@%L;A]SEB#T0+]\TU..F575IUJ#7
MVP7*.(%L(##,8GM1$ L,>Q\GHV5A3\6(CFLBM(7Y_HJ.S=17T"B>@-;JHUW%
MV>F"A+KJDY'\T8R&=)2CFFR213(^L.#]RFFU66<SE_KY860,AZ9&EEQ8D#AF
M#-4*X<X2@]XU4+3ZMCH&;@ZZ*75QS%ZNCYI.6!$B6S(VV]83GA\[A/</\&7[
M[NX]>WEX$-I^YX! [L0</QV0S.<T\_WW$- ?O[K<T+W]Z0^J9>HC7JY^81A<
M)J@B1^1;01Y$21>5E;,79K)XP45Z?0(N\&<5/V1?5:FT64]9^1JJ_J*QS):3
M>T)^XJW);G<Q'6XS[JSWWNS^):!6!O*Q]:QKZ;XX%*>Z5I\5&<447YQ)?H &
MD^$T41HMRZ<U:@Z]#CS?9:K\0!+*VR<'8#-;$O=$$<;(M\B.V1K_PCV?>:%A
M=R?(EGR;UA)UFIB[M0C)XS2)?W7&24<JT/_AFW8:6_,'35?(["< Z+^S*I\-
M1\$I<0U8/GWL:*D;VP-%/IZ/>4PKC5)LEC/Z LO02):^,*$DWD:\:?A!ME3S
M<1]Y@G/19TFH(W".5P_7X.M4(;O[?QA[RZBHWO#O=U,B2(B(-(."@H(@W0P8
ME%(BG4IW2<<@"$@W2$A(@X (0TA+#-TA'4-(SS#$ !-G?O_G>7'6.<]:Y[RX
M7\RL_6*O^[ZNZ_OYWGOOZS:5TKJA+Z=BPXW0_ !^@H2$2F^VWYV+^*[UI=!)
M2.XJ ,NWMQ_$HXPN+AURFQW@F%2P9=H$W+LN:EAGY9GV%DKJY+-M'6J-2<+=
M6T!FJ407D,YO_NS^=%[;88P?=Z8AN= CCCL1O3;IOENZW7B@XG@Q[\01!5F?
M%L*-(8LNLJ8;?X6U'"#7<MW<0\F+7Y<'3YH]R.XIU/X)MJV'>]3='BYD!OQS
M_">:0$5FTDBQB/#BMGEF"Y'%G_*X&9@=A.Y'H.9CC0BA'/<PV-Q"*T]7'@,K
M_%[DN0H3]@>5J(?7D4B76!H<#(+\*9RB\B@+&&!HN#1)VLU)VGLLWQET'Q1]
MNEZ>EJS[0"2%,5@Z8;)U!TY^&+5^3/QW95>5XG7'T]9O?_?'(8R3[=1S\O=]
M0_=[::N,5X5E8PUU9(-H.<X:WR-OJ2 GXR1ZTP<OJDY@;K1OXC%7GQ:^<MQ"
M%FXHE2)E^F@KS$='H[C\M),UA'MV:IJ.%QJ#J?=NX(&-R'""]R5%$^HNRV]0
MU"H1]]3-F?K*+U8_.=-)&]QSA4[.-KW$1C$LT&N>WC'J:L4;3LBC'[PD%XQ=
M>2?D8;C?>."_YRK=#5*:6!$QF"^_I5+C\?48-E7_?1"NPOQJT]Z!'#57W0]I
MJ(:L5- U[#97XAZ8"YJTD*.-Q12Y[C>2O"%&@.J5&S&GE?ZRG2LJ%2K<9;PR
M9^7\$RSK'(II''E&YX*A1GI)1?-[68<'(#O?8*^XR)$^%$R^NPTP0DA\EGT^
M=\\_[3/D0S3U+]&1I$YF\%=R5(TK\N*07U!6T/F]BV?9(F_<XARKXO&!8[>L
M+E)$!UF_^B]4749#:^+2%\BQH#77-#L;JLJ/2XNYEU(I464NK39"#=)!<\$W
MS'U9SAU#U9?;IX4N_A7*!:EB*G^@7R$77_UNKVO,"L@V;F:EOO ^'3C>XX-G
M&QP9VMR+K>7^2MO"53#&QM(A-M.7+2R7LN'F^]Y<)W3(_EWG&-V7J;J3VA'I
ME='6QXM*0:M(DO,NQ,XGRP"/X%7OTBWM!(C[KID0HA1^U(P,@TDT,F[.[VK5
M?*U%77S2W@N@7VG7G^-&;27[??%3'3W(F6L*'OU-_<=>9["R]<W?,5D:*=F/
M&^VJCI72-)KG.>B1,HPBDC^7]=? K\AC6\E-HGW<Q*$9Z%QL\O22U'U#(RZA
MH#I[P[K0OH->X,/GS=HNJTT(M6FD9KR,]D[@]>^K*9)L].L-X^.(%>F&.8NQ
M=*L7C\"_F>A7I\2N4 C-C88TI$1WPY11/\N_OI:,#J[] \<3O\G9Y31BT>QX
M\3+VL;F5%EI2!YP(8@0/+& >4_=MO4^%L=$?!/TC.;/L,6(9SJ_[G"BQ(M4Y
MP#%34)P==X];V"59KOD.321Q^SO7V#FCL2[[0UEM[X]8%Y5.O><2+I0B<^/7
M^L/M=&@4?)6BJO?[OFNY45'IAV;01S:BBR @GW9B+,:\GJ&F6Y-2_H<SQU'0
MXCUY6%+>!INGR<X?T(+'&)RA>&^DI/T;/]L."?D1H5X&0=00'1$0UBIY?OOC
M[XYN-;FK0O%O )H;"CO3+#N!RNYE@=134%UA):[V#Q;WBI(+.4-\B.8U7YB%
M2T2FLZB]OHBQ,9IQ& N>:^>SR^HK\"Q8,!5>>35$'^^F -N3\:Z)@=B-L>[]
M?EV<U3/QRN/OG82C]0AI/*"&<O8TF5EO"K@.R'PUU/!"0&2J@V/FP)PJ$!P4
M]'W)8>5I+K72LGZ@^U8,,:U&V$^YZ[E<112AG'T1$%L,2*#F8IV1M/^:-!TV
M'?#I4O\?I/N_0Q C(^39%GLWVM2#5ZG _.^C!H"<8(.:S*K@1[X!>M/FZC_K
M4E[?;XBTR/?JQ''!Q/HQB@CYXO5KPBR8KXC-%*^.T"QM6I'T=\*3QL?)I]I9
ML-7T?2SFT:?_YG\(6D0K1;SODKSS<:>=W"'F/ A]6;Z?U>.O4<S_2T7XU017
M_L!.GN*N.:C D9FT89,[*6UYVH4C<C_Z6F<]:#L-U/W:^2WKPS"M:TZ!@?%O
M83PUU0'Z02RG[R._2?TY^7?-/*W+G?SYAW]&W]A"H0;Z]7ID4V+V4-*7&?!M
M"2]VS]RVRE'Z\[ 9L>-PKA[O.\R" L1-D3Q;2W>OSL=J'-!U&R50KPUU9?WD
M/<L'MS(!ZK_DDB2[QAUU/O&?1>)N^%'$]=%+=A+Y<P21N;&P@7O!= ZK=\2:
M7<\JDR\HY[NX+\ ;CLG07\[2=D6KW>*L'%_QP#[E1<<"2=?C]7FR4^T'BEQ!
M$]^64A9!LZUDSIC]==9[MBGAM\8]<R%<"B"30#[T''^6:*(R,]T"[-OJ<SGL
M_K\Q .,2]+J+?FEA*&K&V,>LY_J*R%S4/IC6E'$],_FF^(#P^SSR50R9%6[0
MZ#0&WH+EL!$VSJU8EJY!CY/_;2=%]NZK7.46R+_GX9$ZT("D.3EV0,DC1/7$
M?YGA$-_:#6 0V$K["VR^_!--;*-\>.$Q-%0$.M"Y5Z$A)3=00_:[(7DK]J3?
M*H<MXH,=R=D]4/S"O9CO)3_/T?'6*]Q, W#NLU,QE/FAR/6'%QLC-.J,W2V%
M(N5QF[OQ>8=! ?HC*[?0+7[KUUVECF_%^G+A@W&*3&9"JQR%)]5C/>:T3IC_
MCI>RWWWPS,K\&57*-,GNL0+HT;+=!5^-:,:=3&[[P#[(6PW5W94.Q0[KL=OB
M4.?WSDY*SM^[.3S_P*_F^HQZ5\\9SOJ^/:T-F'$N"+GTE8UOAT%=,$_S^F8Y
MN"-0"H](I6A^60F^R%60]2! SMOS/E.U#3Z[S9ONZ?N+\C-[60+?'%WSB]OZ
M674]1M!S7?ZE,-8$*E^SQU[, ].=1*W?:5&PD^J4=="A(4^\2&'+8 :)I+UX
MR#NZ([^!TWS:0H(*R*A.V-R#V)_,:#9VH.>X*O;UYI*P]6,G'(&#2$@42_WK
M0,'J!Y"ZEXJ).5;(7*G3BQHB=#AR2'L&:@V=_-MK[1H6P4D2(HG[2'1AO9-0
M7T.-UG-^;@CQHCSZX#XJ#"D.ML/-@#AH>\:^N GDJOQJS+8'/\^_P -6<S\6
M,%HQ&[ P%U'&Q(4]8A&6PJ2(M=BS*^]C<Y[ EPB-@K4\NEO&7X<HN/N3A)6Y
MV4[D>@&?=O+I%%UTYMIV MH%KH-FN-&A@W'' ]P^QOL7SLHXY?B.1^VW.Y&!
M:HA\E[DO$&&^L^R^PF&T1%79?L-_CWE@"AP#B%0\T%N'&,/Z*F/*BM%O.I!.
M&+%#2R8L;[E%L!FDRPV\F1_X% _\M#[&Q<6W6V,C\8!3.#8>H[X19]@JO/(0
MMU 7/3=(R*M+8[8&3VA=SMP!XZ'F]2TT[?GO65'JUWW2C5_JYT\-'C8VFM)L
MKSST2@H3<N>_8[6E].R5KRU&2G\M 4L-O@U&6%KB@7XOA4#3:PT\T*73_B!X
MG(.N%9&>4KS@"^K.*"AL,WZ<%5!9-H:ILU=AU8HO>$<_)=DO[W=-B^N7OX\M
M#WYLC\3&.T)(=C,HY*&5TL'_E$I]$C_'BB;$-1U0\*R>*?_I0*@)SJ]V2T2Y
M"T:</77/*/*O+N4KW2BO!_7HS\C3(X*CUN1N3+U ;*=8%_P[CVFXQ2Y/%L'4
MY^%6 0S(IJP^"GFZM#3O&Z":'!#UH7;JAX7 27^7932W2;*FQ=W@-#1A[LEN
M8UNJ"6F0P#"T+GA+_6%IM_.#K73!=6<]JP_RD_!?[JDZHS0J YW8<&R!//$N
MH<KZA%@CO.LVS.E\?5XUN\W%K ]]M4@^)'_PF$6E:-"6M*S/?529X23ROXF*
M_+]-U$>BRZYK5MRX/(#-#K25B)757I.I84%'+]6<OWZZ\((L:N=C@1K;P/B-
ML:%1J<W@,EP_!/&66O"\#EWNOM8B2+KBZV\@.@#E\I$[&2[B3GJT7$#./2AU
M7BV!8ZM$O,!%Y'T!H85J\<"F]%G>?!Z.8A&Q>JZ+C@3'!O)4^99J3V__3-&P
M@U:VV+\_69[X^XF]U=;[@_D&C"<:0.?A;HDA!-].R3] 0S:JTHI^_5LH_F[O
M__F?\$^3'LV,CJE 6Q(P:GC6%D,_AZ.46A><AZT+%*]I?KF7U7J>[B-BOLO(
M8D4A_C*$L>&)H=OK(^L/*I>+#]WXSH9@'&3CP0]]]=\BYJ+J*X-L7TP_.'%Q
MJM9__&"':^FV F>\(A"-P:'#"/"JC1!HKE;U61?D<%BY5YL4PRY_,B X*PO_
M'(3\J3VVLN2WKP#*Q .@8!X'</W%(?6&)J.AO<^-BY[?H4_3L^]<ICC?3.RZ
M32(5]"4L_NQZZ_HAYG[>FO+!_AJ$=/G[H\)2@QMM!LAZ$Y41_DX.M,_[7'2-
M )8@$6O9J[? -M\^"-XVKMJ)D36D6*:IJG)Z, TG[;X34@99D,E.0>G/_A].
M@11!4OCX\IF!3G=Y<&&F8IY@.N%VBCD5\,D^#R[4C@3AVJ<V!%>'D(!W_U?#
M(3'J)J0I8RPW!/WF;%P:^QN"97+D>.5U!7( :EBF)U;EO[E31;?,@9]=T?#&
MB\RM,ACKD0D\4+R@Y0Z^$2)-[=A+[]MX,,Y@MQ:)]NSJ%)NU]W64C'6L%8J%
MJ*'B)+9:**7U"W>=JDI+V>"B1'\Q3Q'[^SCAT&?!*MF>-)IO('%>J_4^,<4S
MK<HT,41VAX<?M/1CW8CPP'R<7?#P%<VRP\Z[-+ 72^T'S[_%?L<]ZEJ.\B+3
M1Y_^+;YPQ\[@ 4I@VTP2D]QS(@E.TPW/E2FR@N=^K^9_G^H7Z;>_JW&2^K-S
M=S)$.AP=5[E[9?BK,=7):L'?WW)JI2D@9L#FM]]#2E3SJ'+S#M3A>8&'D,KL
MOY&+5X C^E;/G#QU4T"+=H9%D$PHN,H27:>7UWNUF:$_O.)(1;3(S T164AY
MKYGJ]D37=!]%E9MYK$"W,(]-)S.C?'<PR"%TB!.%T,B\,[CSS$*:+3B5Z-]J
MW?IMC$:C!R,3F_C-ZZ%>B?/0K\N!;YL3#U5".6_F$UW<J<:-_0X8@5NZ3RLU
M8Z)G>?H>X^;AV9F>Z:R*8 1#0?'#,M.J>,GM5Z-+WF68-&OG9:&L9'&7G6B]
MX)"+PF'JO,\L,QF1@;K\OZN&L%$J[YGZI"6:CN//ZI#9&VES,6*\5:(RVV'J
M\_5]XJBI*?E<:,\E7U-B8<GCP%0]JKM6 5IDCHYW#3J3A<TK53Q3]!8M@?>7
MS\]&A)CJ,\?$N +G1SCRG7SY#%C <1_WH39QF''?M8_R9X=Y4++H,>J2GTD"
M?0I,93NA,ZBAVDBK:'G??K[]V?9D9$2@,<)A92OB\@$54Y[S*EPYWW11*7#[
MUP?G(8Q)PE#QBR*3U^M@!L6J+CJ?J+3H^&NUO-VW2BV6/-X>GEC>)?,(69N0
M$QF^C@26M".HZ\=T?C4JSP1M',,GN.!=,]]VW\W?;[F8'WKNAV'YA.1-PH%@
MXJC[ D4I4WF#(?>AC9\]*K?H5C%9DY,8,$\,=$CNF7S_<G,VN\Q50#!4NX26
MA<J"!KH'JHN+-O/]M><W+JNWQVQPRB8/23.5&DR=7CL8_UAKO,'S:7%=ZHE@
MP;3%[X00"O)CNEC+OSXU0E%J01-FF<C]7FW?E)XH4AY_XTTR^/6(F>N.-(*1
M82*Z]UWO4%9E"^XWW<V^O#]?9M47+[Q(N% _VEZK)KR=^<'AI_T@;B93<[9F
MH%TCA\5@_3+LV<!%M>9+PWTS?O2W0HF(C=IQ'T6?.^]+WC;)<N1)3$']2)WE
M, ERRUVY&LUBULZ6B[7ZT>;\CQB9F(LM[O5QG0_9>G[-4B@.+J(\&V,*?/IS
M/!#$T9K!]^LEZ1\/&A7RA+'9UMPNR-3AW=,[Y01/'AY0VIN9C6-P_K*,>0)^
M65TAF?4WH.+MKX"(?9V=2LOM.V$6I,>D>3W>)>WP9&!?Y_ =5(F$W Y4K*^O
M@NZ"1V_O!\16>KEPAW\R:W/7M@^6FPEF*\_J$8DPH4-CY2HP*>Z=73\T;Z-*
M.63\M=LW%ROD>[%A@8Z>\#B>'I\,QP:MQ0"?FT%\O_! :!+A?L)YBB!S5X2B
ME%DY"%[+VO]&VPO@ 5^.]@&S9H(@<@SGD7X,Q@/(9^98>K'[>5D4= L=:LF2
M\0BYO6$[62@<JGY7H5'-PG(U>.\?)$]M&G&YZ"VTGS4V=[]W4YG=?Z:-(G0%
MI."+&0'\E9;'2Z>N=!JR5,:.WG,5\HYM/E%ORK]!I*:_D&:H;.11X.+9"XA9
M0MIRY1ZO<@46L>4^UKR;2L23^LE=/1[\.(\B!YFGIJ!A?\+I%/@W_^;[$^=-
MSY]1K.C?>,#H9U63#F6$R3TFS.,)6%U!?SX9\XC_ZD&W1 :\<AJ,&M@?\/ ,
MEY2JT<%F<]DBST8)99B?K7'3CN0KNND[F-6,:#P'5](,_@V="M3X:HKN0]8U
M%3IC/4U&E[NS *5HZMA[XF0M>"!%C[L]:X^IJBA=E=,L*3?/K'V[0)?2M[1O
MD>+]; C%5P$ZI6EV.Y1EDOQ;%38=8=T8FI*DU+1 -]6Q_1'@(QZ@_EA;Y=LW
M^K=ZC=W8GOF?R!2BQ@Y;4GU8U<I7:G^>ONLJ,".@>Y<^M @/<)E97H/G!R1Z
M60609#(=QXL0HPELH5AFM?Q]N:SF9\;)Q9)<H=U7NN9*G_W>PS*87L!>Z-S#
MKDR*9'T6O^ OK_5YM^+HA0LM_<YLZ,PB\TG^,-O?LLJ@J2E/.Y'9-*?FUN^D
MG)8[_E.8/Q.)09+YI*_]&,N9\(#\S(.7V9V6X5RD4USF&5F.O-:\ >,DO8V9
MW-X5'MQ.)&=@K/\57V_&2#[F!O33[<NXVV\2*FCWS>7L3Y[L&1E9[CA^-A\)
MJ0E"3]R'HG5*GD?:_RW% QQJP.4LDU4FB:4]_VO;7<.K\/C%N/5?<I6J?@I$
MF]4.@G6-R^1A(X#^^!FUVIA6I/-E_=3%UESL#EO>$/O^G*PN_/53B==AU_=.
M!]STMUTSIJ_S'$[*13<S%1)MV862-(R];M*#. \5;JN+_H[(=ZEA+O5X1E3>
M"EVN8VN4+/U5SA8MP0?0KBN794X'"DZXG(W=>91G#<%F\MWVN<<IKCFU^K.R
M@XG_Z&.;_Y1Z6ZM$..,-,YB,9FD;>,T_!A*EEW(JI46+H0C0JSFD=JG:*,JA
M C.!M:"-T+Q?[_RY-)SY_414;TO>RF$O1/7:."Q(FQH-25</%&X9V#:*5=X-
M,$1-U9R5'=5M)4K3C7Q09(P,%E8L1.N_G8"R7] ^J"CQQC1QR:$6".D6SEB[
M%&B%V$DMXAK(F\#N)R)U?RL'*IA0$2)\3YZBCW7C(@+F*@%"[X^3'TF$SMG$
M$.](9N !:X:_JY#*#%QS%KR5+N_ F("RZN#\ZL$+[+N.L^%QD4L4DE\&.H3"
MS9TR9->'\CGV:*?/'N.!%7"_'B09Z..]O1A!9W1T]Q"LUQKW1M5C@!ZA'^MS
M?E$T/?TTBM,R8??=TXY9Y<,P!8[,HH;]FZGRWF<8!0('-#>R.X*[(>*Y!["<
M$-H=(^=PTY%^'@!'")*RWNGDSS[OYQ\$R:EE6I'"7802_$-10XZ5RM%*&;*_
MUM[[RGI=>55A.2 'QGZFIZCROJ4ZJS(3A#2MT9^FDQ4?ZS=*,+>NW=R9L_G4
M/0O$.T3CS+%+B<?GAP*VE4;,69\=N5R>N)NUK)G')J$%NY,78"Y]JC<ZE>2;
M]P_-G$_Z.R2I'L?4YMF;?!H)]"O0&78V-FR>+F7VEK5%$.Z[-@CU1/AT]^T+
MRKX>WKXC*'=29,)0/DW*NF;DQZ$VM8!O:J\HF&@*VA1YYA9JT-T;WI7.97+Q
MGY,6%^_?+S9ABP]KG&MS?[8XXE+$74RT1R;V5)>I\6&"F3KP=.GBJKBKZ7>+
MWY 7.WF;ZN;WZDWGA%T-$._F=95R?9UM&^#D*V@"H4:7C%Z2T.?<:4/+X@A:
M6%_2)EY>89_ 'YF4! (=ZN<$RDTHU<)O28(NOAAF9B#$5H(GM+^CHT>(2#[
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M5C^)D7O/]#=BX=E@*]6AQJH1DI[7W&4:P ._BSA>LVV'6^2'-A<M-[WSD%\
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MX-U"/1'5=@U>XDX9!\5'1])L-I7'U&I$R[G31-*UU%E<2=];PZ=3KF?DOU6
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MC4T52QH-,&HQ^5,&/IEHO*FPOQ B_N!;*I7[:7&2AN]&I;)W8?SIQ>^G<]%
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M;)(],G=YP["1J*M"^JN=JUE8B"N5T<E+?PWO/*<D'(-YKQN[3 ^CD(KXJ6Q
MV7:(R*QS]]/9O)9;A[IA+LR[&BB98$(9_[+H<594EG;NQHM** ;4"6$85=QY
M-^ZQ[E)G@%<^^;!A(:<'Y.IL=Y5.,+#CQK]SO^[#43!CC>S$M'J%X2M./&"
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M&21U$.7M&N !.@'Y";BSXO3F/0LPU?B-ESHN( D@9[*^,VA*5S<R6=A-DRU
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MYP/XO8)]!OV^$\+">\[[#&D&3 U<B%RLR32T(=].T>&[26WU<G<P@,>]7ZY
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MON\ML#E+L]-ELYB$Y]DD< L\Z)K?'[[^VH%5?H",*X4VA:/QRS:4OM(FU>Q
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MZ7G_*].^YB/; K;[ZC[BE956,W>?!$X^3X[X05P%B6+0KL1<C"IT^OQ@/&N
MG(B"7'5);A,)H-X78O?LT,<>)(MD#"[$3$]=!^[=\HWM_R:I9/P8]<M8II7%
MKG6&&G<%)6BK:EAH'AQWX]7W> <CH@[98FS5TBW8G1^7,;AC32-ET9"CFB:V
M]);1!@<BHWOL-^-Q*_F[.-X_]2IP^Y]M;W^4YU'PL(Y4+5QSZ*H4@X^7^,@Q
M&8WX/B]H3*I]UQE0='U3YNJYG7.2-80\\M8%)PX1%<0S_W^R8M,>=H!PBJ.:
M&YCT1BIZF9H-UJT?U"]SRTSJ!7Q;B(@6KEUFE[/1@[UGL<\47TK,L)&4--B,
M\'^+G3+HI.;_?J.ESD[VY^%^!AW7[KG#_J$DLZ=,-[:/B.*K+"HM4)H)PYLX
MGK#;/Y#5\'M4-E)/%PVYG,WL4VB_-["$-LN)-OMS7N<00ND_K4P3DAA<X^W)
MT9W(Y2\8-[GAC]M6X'!@^W4X=SK49]4;3_:5S1L3W=[@T@XY+T9#@>X@W$ER
M"-/;8H(+,M^I]$RR5[VC+BEUTY6]3;+)M'RC403+==Q++!&SZ>?K+1_B?L-5
MQ\QS3Y)6.&BH ? 2MD68=GU6"\"D=X7G<0]MF5?4?IPTFJQ[A)/4U(EY>/A;
MG$H=D9=Q.:]@YO7W'OD*,NE7=V67GEZ[H7<RGH>PWWY"QYQ!$3\=3X'-Y<:,
M?NN;D-UP2@)B)U,\\K[&J?8_08H#@A@-YR?['0V<DM!LUF# 06G^4>7 N_(/
M_ON_C\JBG^$/BH1WEI?ZO/*2&^]FYIW3M:L?!(D[XGG=3 !;[WN-V/:9BE&G
M* T%0YZ)@ ?PX*>&\Z$A#?+C?Q]_N+0C=U3=T@_MX&<'$BAA*ZL(6M@FR.Z_
M#T<\VD.A%/M_K[JZDFT@J1XZA#2R=A".5,!X]T?]['""W'\/)SB]&*;/WM<>
MQIMS\UL8+_#_]U=B,2])^,0R!MD].P[.)J<(PFSUT\:$8[CBQ*5J?NEB!$?*
M%ZFE "@;D6Q\19@ QPDBYV5&RQ$#)<MUD8PQYO=ZT!<IG#-<2Y]B'=H=/J1Q
MX>,PGIF5PT6"!!W$%9B+D^C7;TTQ%Y\O1IQ[L2>>.P_!<^>V"JBWLE1NEF12
M7W9RWGE_$,PF>GUYZ;# %+L!_UB\>UH[*I!A_BB57'J?Q\.TM!@PJL>_1\\&
M(<E-6R02PO/'U/)Z[5&:PDSW\UTUU\:F* ;<2ZG^$"].>H9WC#H]G"_TVI/3
M=ETO,%*O\F6TN+316^<!O(WP'=G D8!?PD3.0 ]3PZ]]L%['T,_2OZ='/X,B
M05L?1UO6O[]-$8.X!+TBZ3T?(.W 3A#!\03O&::*_DI@T8O,;.H^Z#[QJ;XP
M,D8MS?^3[XJJ2<8>] /D2KW(+(?L!31OO;B7A8M$]-7'[D+F4;>+BF]Q>474
MH%&Y^25SX+RB1&[F9IJ7,,=9&^/J/4YWJUM@,?:.H!K:L^.F[OE3I)MZ+0-Q
MNK^JP&$%BJE3CCN,K+^1:8DH%""F4[OO5MOE17 H<PG+.(6PTWD/G?X4.Q)#
MTGO:&/X<MBN9KZK\*!:_4_A -6.WQ2*"([#N(WPN$4I_VXRW ?'^8#'5GL%)
M>CUU=IFQE 2<[\7'<C)(9#I(03U$2Z#TM0'2) # )U;:V$':9V0&]C24J:[K
M$U$UUW>-KT0&:XJ\_:T#.!%N5^Q'?TJ"=CA0XF=;)NY&]>L/IPE;.+@V2W5E
MV:?$4V8X-_A9KX!KLB"H6;8ZP&UQ?&^;>!32,C!P36CJY;_S1I_/PYDH_+1[
M:W6AZQP9!MC> P/B\L2"L*_8:0H$3:STL)=5\G)G?U/U[K- XVO..Y=-R&ES
M1_/667(2L:9H\?30/8=R>+/:/)5;TA*QAW>2GG))1,=MHD_:?G]-&_Y+3/Y6
M3]>[8<[ZN\T5*-ZQ?H>&R6.MQ^#4W3A\9-!TTXZ;T=0M#LRVZ[D V?2#1W_>
MUN$1=OER&Q)Z,1WWRF$B)4OWG]1(RZG=KNX/;V2O+L.7SLM<3YJ9-^P^2)M0
M750V+N9^*)!B >S+?]DS *<CWF[/HOIM5][^IEH3OG<OCLB>@)G7J6RK_RDD
MDU6MZ(_T#I"&3J@TE[=A#9OLV$]3>Y*LO\/87-JWI!V]):OSY&][OFN4]X0U
M#7F:'W>I#*)?V'^O3;QY3T_M:_J,R$&LM[X5": =PD<NJGZVOBSE0BS=5*MP
MW:R;2(80&+3GV>YOA&N&W*^_DD!)-^_AQTN>A$_$F1Q .3SA"MB&*<ELV_A!
MXOC8I3O3G%>SXA#GKZW9Z)O@(]&FP5":2B159\9J+0>B./_EQ4C&5X+[KY@K
M;D9]\-C61X-*M"(\BOY8RC\?YXZYGRB:XD;A8?0F!3Z7!+TRJFRU+;!E7+T;
MV6Q_[+<&[)* #R2 SA<V-ZW^;$1,PT-U6%:8?U7\M*U;F>=%4-!-S1U[:B;W
M^PW!%OB.YF/]-LBGA./0P/V5^(,_W\??Y1'RN7XITR[?R[+7'CXLA842+W_'
ML=S906E]N@ULA<E\H1Q?<*IC)P$&H!X#+0F/(@@)>F50K^MO::)+MJHS: W;
MT^XG-R%I*Y!X=?,R)*[MR^BZC,S-2%NSJ]SD]^*UW*--QDM:T'2;U[[C6YJ)
M,M4H6>'<ES-PBRQ%J."=EWU<?4P.S].'=?3AV*<DX*.DE@H_*GZW+_P$X?.!
M7VI_>B\7C+#G1_$?+IDW?@2$*^TUV6)_0\4!+U1+KTV'_"UL:ALRR&U:A$J\
M]HV8WT,=_I<ZOXRW"@. %6A(G=0>]/RZ"3<VBX.KMKP,9QP@NI80[Q10\LOH
M&G5&H#.=LBR]@1X)P&K /\;O)$0=L[Y\X+^V2,$NXF\/,P"9[/D1?&!ZPX,/
M6DALY\&'?F+P?L9E,>0$!"V8C?NY:Z AJ16RK&VZL?Q9S?"W;J??B6^I]KJI
MN*\)=BL1#?W$4O+EVS3K] -9=>JBDY_N[R-.74S5P&"7T"JP*#]BM1C<CA9Y
MFT("&E",OTG 7-*,_#W=4H%L=_0=KW_2,V4:7!0@G#5N;X 9Z SC^Z^0FN.P
MXS4HGAO>>D>3LZ[2"94X1 +"<N$MY<3;)*"_-_>4!,"(]P+DE98'8]^3Y]BL
MDP"\>V@K].@DB 2<8P [9X!.XW^+[L@G:(@H?];P[6",+KJGQ7Z*;; H@N*I
M_[7]98*,_CREA>L?59BRX5<L% R&B^J@%_S!![9 ;?]S7TG8/U^DVO)S_:?E
ME!9\/SA;B9YB>OW@8+]>_ ?HX@X=X3(H2M(L]NGL1Q$.AYOL2 P:BB]8)E^X
MN-]N+>'K>K&Q%2RM+'R5VB],0?!7T@FZ/ 09Z#P/X702A$(1CM,AP^T@\L3J
MD./B!W1GESBDZA DH DT]OE\T$K3<8Q8P4T2P'K6L *."]WP_Y;)XX"%].B/
MY1(O)^"8B/[%T.UC.,X5Q.E\)SX,OK@V0 (FWX(WY)%C&F8WB-_BG/8@7TO+
MH.@Q$G %132Q^WN#+BO\E[#_S66B_"9\>^>O+&AWXA:<_ODV5*C+?SMOO[1,
MA<  F:?=$BQ6(P$EG22@[3FX^ [\IUCB%TM_TZ.M-.3VP,5< D.'0 ;^XUX+
M=6D50PHJ#_[K<47RILM<3@)M^FNYC?P\/A&%[*C9VZ]\O&./4+ 3'O]._UMX
MGFSK6)MW@F_K'1(ZO]RGZ/ZU/*P_(D&$5)Y(QLI>%GG+'A?0Y!0Q0(%NFPV3
M]7&;2Z:[_%%<QNYV'TQ"QL<S*R+DZ%/G<;E[X0P]KJ,5?G[5X_H#6^^$\5Q7
MCR@T%SQ1_8J*'(+EU!87WX"-^Y745(G:$CNAJB+2E7_VX>CR>VP6_1%"GLRU
M-N%#O:A6!2?>#H#>G6R;O9*%>YIV\WK"*ESLS=UXJ>DW7Q0WR5#X$%'4,$HE
M@V""CT:?2FQK!+4<[%BAM&Z\K4I_2L<QWYIR=^YM^J)I+A6.?,X!BA,?<B(!
M)L4DH%5S]@J1P@PR4>M /(<D ?0*D'B#V2A9IP(-"SE$Z)!R=:5TE!\$=L*W
M ]S\2?N5HV%=[W"^H]4PS[1K #.TE66DYO<Z]ZN@:<KG0:$>->DUGZ13*=A'
M4W*FLTG@V&N@]8?!\"^@Y,@5OAS0J/A( (Z1[,@-VS_/TTKWP<6X/\-RK+KN
M@GG:5FO7UN7S@:VN75&-7WJ..&[%M?86=Z)'/R^F]]QO2+P/UKUE$?KK%@1^
MNO?(O6O_&1R*?N5+ZW 4MHK$4Y( PF/ 7\>SO-5$#.?RD&WBT;%;!?\- ==N
M\ZH/K^@/&<UJ-F=J92!AZ5?X-^;"C,^Q*_JXM4HF3'BD.G'077C[NIJ^ _0%
M_R02T S'RA #053(H2 JH'E14<UYG%YP14\2Y4S!$)E!UW7*U$:$_O%]F+?^
MW,!TRMK@@QWC[E3[CK 6T,0S %#(FEWKZL[ !\[/JRT."BUZ?,FQPY5="+\N
M5WO59G_#5P'/CCK1UP"=R0)T!5X'4-O5).!33C()""@]4PS%DO%A&^SC@]R
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MN0=TV'X8WB#)]'1?Z&\.YR@S^P4IEG2A%6[S^P2.=0,=?7RO]K\N:SB,B;9
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MJ+/9OY:(YY;5"LN^11CE86+3#3X+79&==>?N&(!' GZW0;JI21>9OL<62@+
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MWN+K:PYR]0UH"I)@[-OA5*1FYL8OK_T:QLSF>CP$17/&D(!N;D(H?H!BB.<
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M.T"5#&J 3F=' C(#_T::KW"'[<@&* )-^#< ;&]2Q9. >*%C>"2GJ1$8MYC
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M4ZR18FYWO <<V:\R(V[Z;:\;WF^OTW8T"3K25>]^I%85*M1GO2#\.3\VNB]
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M0F:U'+M<-;?$93BAH:Q,#N9!#1<[>;2G@45K35AHONN@MQ9>2^(X 5X[7-P
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M'KTB5[P!_%I*S@JLO@&0$)DMLZ([;@#)E#> K!Z(9+'%IMA)[-YE^V'0KQM
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M S50T1"CSYQ6EL7#N@]ZM<CQ)/R5JWR*YG$#0>['\+/*R[O-6;CJ-W]KYO^
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M=5[(K_R+19CR@!XR"875V"0&9E+'B,FV)[[5G<*,HMM,DC_0SCU<#-N#EU&
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MPT"I?> R"]^?G=YI?.GU CQ-==[G<J :(JS 7C0J):7C[/B%80)MKS*QY'H
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MBV\X32UV\[NS3IQ0B.'Y/DD ;ECTD$7$6%1OO>2"\R>>.FE4:N'I):?_?!'
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M\);+$4X<J'T-DU5:^</9NZGZOER-ER1-4KTH5I)1YF>FMHOZUBEB=FB5+(Q
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M'P,\ZWT\0=NRFJ[1'S:]M4#[U 7C(2 C7&5I:O C3!H+&AK_@*@YLP_/>_Q
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MY,NR;'.0<0]PV54+,1%^'DN.&>;HK;/XPNT!YDTIL, @:'$'5+O;0UIG(?<
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MFAJ98<OO5,T\\J-!P3,MG]:?!.CR^7O ]WL ?3R.UZ4(-WZ!9U)_DQW6U6R
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M+@,V@?J,#6TG,I3W*5J@I #R8$:,]BR]I7+_*M/304OZ_3@V@8M0N'O\$I?
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MX@_7$5DPU>I[P%.V, R]ET_/35V%YN/V&3?49H9ZZ0I9X+%(E;$F*G'C'K
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MNC9 $&,(Q/W\-J.)>#8[PNVXW'Q2]0J@ K*,69H!L1NFRVDBX_,XSV0<4F[
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MDG@7P*IS&_18=T5U]P!BU.][@ ;48:>I+B=N83&.@J6MQ=SC2 98Y/\6]:,
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M0HJ.F.8:8E:&-TRQ823G7RT$(4OCF:4M4.4$N?0QN!SV[WE.J0SU?_(+O]P
M1'QKRPNU_TH@W(7C[KN5+A&2>S>!KP2D#F^ Y1QE[..-?]_& <2QA(Y\<.CE
MH(5%8I[30F'V.])O!:L./S?A#V<9M@#Q6IH+1?8'YL0^N24JQ<J](VPW@#%P
MQ7&N.?83D^/5^0FIG*<*[L!%K\WLV<0H455Q9\&^GKQRYKDKP^: H7.+F1;"
MJ2>,'YP^1:L"_HB+B[(D]'/Q63^%0M-WT%CK^UL<A_<P-@3B?:]HPOU^=VL=
M%X[;BNV(RZAIY0-,564U+&NQ[CIT_/3#@X )<JC>>Z4Q$?K(EGTOYS-K8P!M
M<?J]=4?HCK>4]76P1DR=*?DZ=4SM;+E,W<I'(IFT*J'+U_+2]</L<&:/L9WI
M84^OF7GWZA!ES8Z2[O:*JG4/DAS%.I6VF'2[^%0W4GA0KD0&R3R?2K,KPOSL
M $SE$<%GC(+YBPY&S3JM?"%C/V,PV$64EY';?OEG-W*F+*/5>D%!0.;>JHE/
M/&4/="G\- [-I^;)I68ZL1#TSL,/X];H+(#_ED:E[9$62U*6YSUP@=Q95N%3
M[.^)6RP^!R1YBZ(T,''CD/EDM]>E>WG65C67B0_:>V1WJY&(7_O*S^.&ZOAE
MOESX#<3,U<A5#\K8[1Y#.()4ZK&B# ?0;")_9YVZ([EJ_HFP'DY)2_>HOIPP
MFNJA,89:$@(:9([1U_;<GHCCV$S-0V<U(&GQF55->_LK@&'YK*S63WCU]GX
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M_^+/[% J_@W0SQ*%]@1WX+XY4 (7CE,M25@(</:?8X'Y(>I<"\5"?;/?!=X
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M<(2/V7I$OKGJ$XW!.#-L%AG*>R6^Z9E&A$M[V.D.^&IR*[KG=Q19>'CZ< D
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M))A11J>X_:L85&:$8 $7,OBJK)+*.%XK0H(T+;[7'+1W^^"^'&M>/[RF=??
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M25G%%:HO'DOW*(@=!:?U/(<%DO4!SKO>GO?9SK2Z+,C1BLM?H(>B]DHJMVZ
M5RQAN[&N055I;LI;9@F?/=?2H\R?3CE7-386\7,WDE4'5IQ# ZWQW+18ZX=I
M&]^NOD\G6[3%DHR)]']'BXMN>K)JH@M./@'+\1SA/SS-3_$V9BTZT^_8&[,T
M--&UF'V4:93);VSP(/HY[\%6-4R,!D\W>8RQLD_FU"C6#L1,ZI4#::H$F;2G
M95T_5Y9HT,91[=%0-973>/AS^\*YRS?<Y6.L;?=2EEF.EJ8JY+B@EBC#<]MZ
M9'>@QU7)9%H^8C PY%SQ;IHFB;L\&T49E/Z7.?,146Z,JR71^L8+'J8#@_7
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M<^]>(W:/XEE0%*! V,#$"!-%#=Y0EG3:9X2?=P@+#4Z.KK=QT!&6OM&(:N@
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M#R- 0(52'+S(((7]V:2BN\B]1Q"]O[-&PWM3-7FA%%^N CBRZ&7="VTWD.$
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MAN=JP YRP3)A3N69[9_%B@BNF_5N>S\L^W3B3?P__+D)XWE\4]="#LJP>O'
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ML)_ZDFYU[H.G3L^0&1R/96\H'9G(S?,'@2ZX, :K1S\/-9TO@=9/-I#6^Y=
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M+YQO$I16?DT8K\PO3K[&G()8 4?P2$?HQS027A%AS2\>;=$XM%!5)-EJ/V7
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MD^M-))]D].VR+-%O%5Z3ST,+D6FXBZY,53G.[J86BN1/K//9.(E^)-L 6E*
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M<H^N+ ($GP;=W_F47R39,X#G(O[30D% I?=T4:P[VWI&:\6V6]1RA@K/> _
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M!BD29%:PAHO:G?D]G2XTU-B ?QUJ*)^TQG*;UXEDU&1Q^SB_AE41/<U.#M&
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M^J?CT=;R==G4SM-[/U5N[>J5].5'*[,J=+LK*Y4Q0CP!C98;ZVJ*.8DYOX:
M_6>R7(+M;)VRV;MJ+<^"^$WI\A4*64PYQS-$E"_0<9>F(83@U<G%%#UJV&[E
MK&.\8RYD;]0*:)F\DA+ZE9[S$Q_"/XO3.]'Z,?[<KV66*?][=1=,5L33K?GH
MO"SD6!K@W=;Z^^!87??L'O\B=DX>\=) *-$1\.TX\17)G-C Y;>4.NW0T4!<
M XHX7=B962>&AD2N/')>O>T\V7<"__[.3:$ :9*V])S<7$?4&?<]*2W-4.^
M*0%J4U'N-:OK[:*3GQS"2$6=\[RA(1GR$=?BAZBL8&:&SEFA\"6PF6'4<HPR
MZ]?(:4'](;@(<EY/<D+5+,)V0IGU$F&2PT4W4\5F7A(E2Z'M0X;2/OB;ED,V
MU0 KV"-:+VX5*2G98B##5+44=&G O[0')2;%V:E]WBX4\'G6KE@]:*9UD#%5
M 6M*P*6>9/_@W40&D'^M84=@9W@/>EE'=GDC&M9G/&]UPY2'#!3\M:*?B-$3
M$*:][:-=V"$#L%4/@1-,R0 +^.AE.TFI#.=DDR*H(]L:N!381P>F\S<D Q8I
M^)LCL[%)P9TTXT&BUX,.,CLZ.TD7#+M>#X3$!*=HZ=&E^7,Z5Y=GBA%V2H]-
M909L\9'S1KW-?I=+IX-)<OV/:MB[DC!.QA?;J=*]"-P\-,2]_HG/M]V#^)3N
MOA.AC;?U40DR5ODJ)B?GWCD/48F2 0W=?'&U=LG-YN$@<,UT4I[OT,OP5E5F
M*K%XIP*<V:+_TS-Y56H&/MAFP0+9<T/&[C-3U:[O/ /N86YHYZS_*B(]T3NI
M&E;&/ZR@GOTH&1D"T0I&C1KIQLLNY98U?+T7CI+_I#MG/Z7,>I<J@?FW;=P/
MH7N?@OBW=4WI-(*A=8R7:>12Z8M!7R-U)@._UXFURUBH-L,8)\"U#466K>W[
M<)%=Z>L_ZFC:X^ZXGL)YI52_IR0#OL!<O0K=4COOH?X2+7X9G&^\>P.!OJ+1
ML^29>IJAY[?.@XS=."Z?GUW\OQLH#H:B(MU(KNRIBJVDWZ^BMK!9PIC.5) M
M3M#[NH+8G%/4J',-5$9CY]00BUA*[0MMWVO->&01CJX%1)RGN,6K/F\-9*+9
M%*SM]E-/W\MU TGQ%(W39>I/.GHORZOH2E(]2UDZV8&4,D%JFQ9ZZ9T@ R\'
MP\YX_BS6\J)F/.V^KLPE%C2_Z__T!Q5RFXTBL'?E2E*/ TK:#LZY=%A ^!TS
MT?63G?!.;^CO"5[IP)^_>W'I9LY.+1<KK)<]HD!SNONI9];#4ZE\F-L::9(=
MSB16#[*7[RHSQ9:W-RZE73=5<>#6GC0X\RZ(.V+7SX"/ L]E*6'1_3@05;E/
M!MXVWUW.7Z"$;V 6_$6TY=88=.2SY1$]O W)4*Y@E_J:#$"*CB=HBRUI8=*0
M_<7_64?7P@.A_5?)P"O$"25^&<(CQ'GHR-_3 0X<P9AEL0$$C=(URGWX>0\R
M(';WS\J<D![1#<]L_VU?E22O5>4+AZ%^"8:N.K&6R,CD$D:$F 90F%65I7JS
MY*QWJR'^OE2&6H-2*96[[1E&^6Z:3$.?3PH&G^:D4T_?N1W>9\UB,MG&)*C4
M%S&8#Y@9$5;Q'U=A;3^O?]X6-]Z65A2@'IY?*_VJ]#WWL!\*W4_O#<.3@7S
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M]-&IXF_;U(-P>:!$XD4JZ(RC.B%W1Q/KBM//\HZ[78D!?7PY/"19=15_26A
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M6VSP.D1H>AAA1P8B29>I7"^7^0PMBCV0?QFM]%8TP)=[G^M@ X.9WE&39MO
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MB^C&ZX[++P_@G'T-A]4][AZ<+I1 F6.TVF#IDD=-LE)9&&-M^09-VFPAXO9
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MK-[;D%EMLQE==%M/F7E78L1[Z[NR^LGS!*<-BAJB'E1CF-*Q@HL\IPRHE(&
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M(NGO<<^NF%9AA5<"_(R+_5EQ'L[SJ+?EK%XCFJ<J*\+SPMZH4*>LFAHCBK[
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MJ(_K@K%Z#:?#/G&&Y8"*S\Y3A_2LAN 1;L$&KES:[RA/*M*-\+2->2HL<VV
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M[X1?=6\@,SG_!I6:V_GEFYWQZF%%G!M;]_&_N(YS&:3!.QTE5[S[4\?+=F:
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M%3[!JSUT6\0Y8M1=S*5%YJARG#6ZV]1NTG;KWG3NB)?Y/:^SB4LL)<;SN 3
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M)&6>%[R5%E9$:<%Z'G./PB^FZUE8<>_X(EG_CE#"WVHLE;"2L1\&!3/U0LG
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M\D=;7O1WZ*Z>HY(U&S6B)4_^7U!+ P04    "  -@G]4@H^/YC,$ 0 I.@$
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MQWNE'4$H)S^!-J\W.N1(<+)P[IL1NZ*AI,\7D81/@91>CL7)]DYR-(BNI-B
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M\Q0W?G5%Y/) Z>EQIVB'[ 'Z:"05/TXSX-ZIZQ3E%SB\]K4SBOR0B"N#V]*
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MB_2TX?3]$3^59Z)U$0*I4\<U>8;.%&OL[98'=F#X-5CP4]M=@^T(A3X-1;\
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M=\-ULW.Z1%,?Z2#_0LKB]>;=/WI.&@=T$(U):F0EHI#X1#,SWOTMKCOFW>?
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M1^.8X4W8NO89#OLJ@NB^+O$JP:_-& VKQ5&32M<N <G[-W]X?8\_OOW2_2L
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MB-(A4UK_K1D9$YE@'E^9J ,#7#S;O;E ZBEGB1$-2;QKJV]<\XX-,:H0/7;
ML-@6I8+7]SF]C&2 WB;+$95G4*'U8AGZ(63%(J)[J\6.>'R';*$Y=:?B\,U<
MX:SG>*-H6X82! QQ-V+@@U,%B3I%-1O='\.XZW^-MIDDZTM(74M?T)#7O@8V
M_Y]Z%?R_,%DHEI(5\9&O]KKM/,SQY5'%:RH8PM:'*9>^'D]V_D,Q1YG& ,&5
M#W_;ZW.Z <WF8E'_*[[B1:'5Q-/]DV+FZ=N_\XW=D]UV>*^<F'CWN?R:Z%6]
M /."OXLH:16@'U&=P&Z E$@ML%JI?,HGZP\;]EWAJ,L.-D^[GNOAQ:/]Y'MK
M/*SLUK_B8$Y94*!'X5BOGY^G<-E[CNHJXZLO;R9IR_SH# 8$Q/#RUWB=RQU:
MP%P:YP@*PXMK+=2+_1I6KL]F+RSV[?%[F$F*GK/*>W+JYA*HQMNKZU/'P,T6
M#CVK-S,,J\[';DE']U&5R9H$O2:)R'S8#E;]<ZW ^)%;?(6'<A=*1[#N 2*O
MX19@+9U&*&J7.PY7C;X MYG=8&GM[VGS*'OZ?%R:!M0_]NEYMER_GSEKI"ZK
M8S DZV-X,L*AOO+MDZA.DLS[,*+)\7!NTVO,_Q])K [AD@4($[K6OO%G3ZZZ
M1PQ9LQ0N1;22J4T[T'(K;$+[NX=UWZW9F#%CN#AZ+FO&X>QC3OW5G?(]Z<'S
MS:>)321N\E5*YI_P;/&"^W%/CFJC]XQXMVWB_,SNN_3;;CK/ H^4>@_\U00D
MN1DZD2T<R/DD\DT:\&D>?'3G8B^95W$_\A>9><:8E:S:Y_&X(KUMRFVX6$G&
M7,=5X+YER'KY_-*XAK?#?<S,*\SV3:H8<M0+3)'DF4'BK8.L-B$N[*=<"IZG
M-?-'.[I-PKLS@_7D.S0J#OM TH1!ZLG?L]"QVGT/_$B'$)3GCL^:;\V77Z4/
M8K\>N=[N7E R*WE<>?5\Q5S:MP[IW:U] \I[]K:MT0,]8OIL(%IAQVBP'/FY
M7&6F.JVA+?D!6^D'< C9[J(<42HUUHC$#;\=QA\OJW4^GS(V*WIHT0ZM8'\E
MT4\?PG1,]1FL=^C4EMF)AE>,"-33(I (!=(1K/%B1K(%3%=5)EJ:L+5V+1F"
MTC@OZFG>HO^CA T)L'ST[_'6TBX>GGL[R]D*8R+9=/]#)""C,([(WQ9M8,!G
MPVIKU^WZ[.S7\XI!67;M FE"+Z\CC!64+UY;JU/,KIF@SR#;H[MY9&@*6.W+
MP(C6;_<[D%O;J(2Z 7JGT.-G/BF*JD95ZXL'D+\?U]/L<&;<]PIU#2.V$!I:
MD P:TGROR#YEER+S#;T^1WGU&5Q6^/3D_F_!BGEIWPU[G4)D"WW*G(P<3$)_
M3L_J?LAX,EZFF3HD'Z]>U:A]SR$K&6@_UI106*7GV@[!U30STH!^&WPZE96N
M<06A1#>/8#K',B>+TX P2TQ'T5L_/J7 G%\9BO;TY<1:A@=3HZ=?8O"N?,3^
M__S[1T/D_V-%!_4'&A_U[G\C2A<;B?F".78U=>< S&C13NA2X:TP"R2NA,J-
M[%N@:W?X=QK0-JS09A9379BRIWGKRI.K',QF<2>[Y#[&N&Y5K+VV2$9B+>"2
M-.!=5S?U,(5.B_.I@@TX"(7-''KP T4VDBOMH_H<Y"/7;7NI(71=$6Q(3K#)
M:TSYQU)@_*_IDS1@V:N2!C0_I@&SSD<][$O0 /;_<355JB#VWW^V_;F+U3OR
MVM9U:L</S+(@DLB$^;;7VY'<N"TWSHA;[\\OBI89.W.<=<=+'G4+29;;HO.7
M7<4Q&C WC=,?=J8!ZJ3>[#1I]I-J72[*BPG:!6A-NHB@S+ ?":S3 ,(6/I_*
M=Q ,67:JH@&=F-:$TG[Z@Z7L3:B2R0E3"=?S&@_^\3H1.@70QR6GEP:(T(!3
M6E7ZAR-38#LLLO<;97GWHG0O$H>$,5(C B'D0++4?VIJ30F9'83[_^'-;^UL
M_:<2D+]O[*@'O 2%!?FQT@"(Z$%^G_J 4]ES,![SYS,[?;U.-" !&>Z%XD2Z
M>+ YV_.E(=F>IM5_+K<SX^>69T2]J1661_VXU\USG</K!=0_^S:6Y<XE][S!
M'I&QHX' D8P53+5<\)8WR7^!P%Q3G:Q7WO>]P8M3X1YA"'FKA@:PD' T@')Z
M'TD\(-ZUS&"U,PI:D/'E>4]YC]@-X.%9PN QC0PT0$<31=6D+Z!6*A[T'Z6/
MVNG=]H?:_L\,X37N)U]LV..HS$/HLM)<@F:8[417XO4XB<EM^5.O%,FWVX"K
MR<#\B,_XY_";0Q8Q]:I%YMF. 5Y&_FQY7PPA\1C6&C"_:K@LXAS,?*E=VE,\
MW_GYFGDO7/*Z3OL\:+KIUF<+ :$[ 19^YD^YS2\ES,F"VOBXM O6 MP+-&3,
M+$LWYU*30A8LI<_\%2@X_J_9=-THN;]* U*TB'2I\8 E85YZLJ0+\A3)X KA
MAC@A7]%URD:]W5I 1XIRP7N%6Q72W[#!5J\85XT ^)^(F;HT(%F?($K%)B)7
MU-!"=+T_YJQ@0WZ,9ZM\=%ZZB77C1@-,EGN]_<4J4_X.N@PS\P99!4G /$%&
M3BD.- 85:A=,K5J_MU#YSCSAQY!O&9KR9G0.9;W+_KMD_WH-I1S!HU\P/H$M
MA-7JIV[NNJYT;AZDCN-O7A/3(]HF*IRZL,1_]LP(F=NP<SR0VF(O.WRNSL!M
M[[<T_X;(^1.9O1F<*CO?1@T]1P7QX%%%7.K&")F+;S;C5=R/'$FW)ZL#P%N9
MXJ>)@*9!H!]%NL4;0Y3TV+A/.+]S#2\9BRY_ULC^_B>O0(VPFWMIJ0,0BK]^
M)MDW&3BE/G=1P76/A)-KG03/3&/EV(E@'3UUO80GGY/>UKG(=U\-2'OT SF5
MR]ZS13RW67&,/<;:-%5W"#4V<EZ&W,ZW<>JF2/ 7<KO_=%Q9;SN8*.,35Q:3
ML@_ALN9[QMB>Q2*6^^#H.C8G>RV?.$D?8!QQ!.\T=[QL%CDV9U(?H_TK-NY,
MP)U"F4OKG'K=-JH_&O) 0C<E@Q6.*P0M44_^(C'"(F?D7BD;1Z&X).,]A%?E
MOS/7)!OO1U0;\"M5?C^KYF(;WS;#]5WF&D#*M\5/I<ZZRKN4NJ0%E'UL)C"O
MLR@%!I\5+CW1*]%\]<]1(;(F'AE!)U79=S:[6^N-7J,_6EX;&!UK]U#Y+GGO
M07E)$A9LN@%U'?DVC;_7B,2*/;6D ;G#Z32@P,!@+3>COF)^&(+7@X3[^9KO
MU,9HW"ZT_/6-G5V CBA>=#\2*4N^2,>6VK;I@PD(61<1[#R]#:J@ >4<=.]S
MOOR>E]S*6Y+RTD'53B_U3"V^A!HQS86<?DY?E]Q(;!J5!]GW>]:#M FFGL?H
M2.4G(8TBJ^R1@1 -&H#K1I["++L15"D'[#2 0Y]\Q0-G06%MEJ![-#INS$KO
M*D1?X=L=#?RO[X["+V#"H;LJQ$SJ$=TQO4+WC4O-0P<?KL_1BQ.0^R!*FC<F
M"L.GI0![N%?2I#6(Y4,YAMZ(LUNX_R7CLHV&$T=89UE0 PU@6^RC/XK'$ 0O
MJ$X $\51Y*S:#3D:\/ )#1CHSJ!<*G_ZY2)/0:_:),HN9#9V3C;WTZCUYF4;
M:;E?8#J(8NN\(4=">^QD4'P"T>\2O2LZB'=T_TL8&;U7D[[OSG<(4<10?&?9
MCTXAO9'?B#M4X6[Z];[I#\@9#6_DWU5OQK[/)ZFRD%%OD.43VC1 VW@SX1 L
M\J>)ZK^5\:,4(AC'R* 1)5<63;,@4X\9_[=+L>?,2H\?UWP!+98]M&B!XDT]
M#H7_< Q[1>1RB[WOPU#L +:N5<5IXKD3U^)AV@MCUICRI>,%/HX#<I6:<E]I
M0*5(4CE147M(R+XIKKSTX=O$&V_,^D.O[2_60G QU<@C?@_DUH!%)5P*0GA&
MII.F!PT>%.Z:7]$;$7;AGA8AQ.-7);\.M=]_7;PZ3SK0HL]/A"R=2BT_;*(!
M& ,ZM&-YE^G<X?(4#9A^3_=01]>CT>L3<ML()[Y]"2@-T,(H+M( XJ-),#5"
M:)JTB\+ID^7=$^A#R;I%.3+&H]]+%5$RPZG&/R 5"C3@<.\0I4H?EG^\*;VG
MWO_>4V1XT#E=\-@7Z#P92^*BSR4*^G8'^0^WS*?RU^K3#3OB@$J1)%H,<)O^
M[P9V7B#:QQ5B:4"K3A -0"0WNQ#28ASSB/EF@[O%3DV?:EZW"[>51"26,XI<
M=0>)C"H?&0YG.-@7Z"_8OHDMC+,L,)Y$(E?]B3^%L1;1<> 7!(IQ"/4467D
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M63O]W/TS*;$6E2N8IS,K@4U[Y-YBF-]>I$%?M5Q3QF#3EL/JFLW+/]^%?&/
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MA0-A .X00;))<\LH.73J8N*E%!/S)SCTL<]AO8<^M5.T7P->2"4R5#EW<E6
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MB1&86MB_([6\OR6&LOZ&G?T2R@#(TB\90+,6%0:JD$R0(Z$(>71A"'Z+QC&
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M<[&T.CPV%)51?_[[:][1$ 9PZL;SF,U$Y'_!,4/_T\>2P.LDTG_RG08K+O$
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M7BN%-.?00I@3E%@$.C!WC7'GV6%:D_6__=1 1E)&()"^7W+@ _[1@[_D:-\
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M$WS3.74'*YP2C6?@BL/H6#C&(F7M"%2&Z C"W>U[!]-X>@R;%2' ^+E4@>[
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M;,]63",4(64FOF-&C6*<:U._EW-]&<CUB%Q>C4\RU1*IUWF,8H6?6T/P-8D
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MK,<\\_EQD9VV9VD?(-&?W;NA\J#&O#QV]?X6?BI&PX $HLY8,VZZ+B %R6I
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MS&ZK@D"G"_^6L'=ED,RW0360;4.0V$V.0'DK*(/"%=2T'U&%%M)WX].C=DT
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M.K'?I04"7<1RM+_D>/ [/V,E95/0.Z'CQU@A6V6#MU39M68=TS2'D%!%0(=
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MMCRV5=$?KCO1P/9%(4[!\<*MEY?8>Z,D5G1-4_I#:%J,H8-2TV!!TJU"87/
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M:)B#$]:=;=VNTOIP+NS%5F':V54V4>;#Q?]<YIG_:E::HZG_#U!+ P04
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M-M&>$R,3"Z5&>$RW;HI'B'1,A^823N-\:WQ5_;G"O:[3_.G*9!U,V$+[,%B
ME'FP?O"K0NPV2.^JZ&65?-4 Z91SRC50AV*>C/E/+(!T";( (J"VUB.)YCX$
M+O^!N0<MCA[G\.1H\;X8D?:XJD]V8Y6'KB/NE(SG]'_A^6DI5OQF'- 6>TXI
M9^^.^LM#:# 2U[*R&PJ69 &-:1"&B#8BT65M@BY1S+3']+, BJXU"R@__E*X
M (U[BFX!Q:/]:WHT-Y;-YY-3_,/]J_=YMJ;MII[&[&D\GLRZMSD/@KDLK[PK
MV^8M:YG[0,X;GBN86E@7#6Z;*PKI7MM+#Q%_J]$<?U<Z:[5WO4N.:+ +H8LH
M?%ZY,L<\W1?!%7W:UO]U!4;OL+/3O F7R)<T&H820A5^#><FSP]U@839K;R
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M&HEZ8HSI0"FP+V&'F(2*(DQ@703MZBRZ]QMJ@8" @*VV$[GP:+.MXNT;'*,
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M-"/&$;K4+GP)IQ?Y/@MH7GML4!^&>9!'3=AT4E">>OE)#]#VOE:$LZF5.V2
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M:0$=A84L\AF6$.Q/Q)FN2ALF?&SR<^KUEYW7N'LW&#]!U3!*BV237BC__1T
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M[O555=\%-+H#8V1,4WF6%$\/X_.RZ$7 &#68N&U$R(Z'0PC;<J.,Y_5NEK%
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M>P,Y+<@VY^JTGCNS=5A_=;W=!']Z_Z>WZ7\?O@4/E;SEZH3&0,4UAJ>5R=U
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M/H8#_FIS/!=PX1A*G)8(7L;$@!(<*K: 9R<GG.:H'S? D^ QX.:33;?E_O
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M$?A)$G F0J.H-\6KE\7$G-<2)#)<,VYVZAJ=<ZYA=CUY^_6:I&0>^2FP278
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M5J\FX2@VL(E<FJU*NKP6^>99GN=:/)^IYPC?T?,G% HV[(@:E"P8T1YDP=$
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M@.RL[Z#320DZHBRP3MM1;WQ "41^G4BBMAOYT8!+-4H,&Q[_=-6=B;L.JVZ
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MLV(J\]9?;QC,KI_513L\XUXV><_UXM'E:V6+0^4TP*D'E-H?MS0W8R/Y7E0
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M.JX,^1&I%LGFN)#3,$P5M,.Q4'C@3$B<K@,-Z*!K=>A3\#0-T+5N@H!7+&D
M 0-L%/W>"=]JL<QTM,!X[A$Q9A$$CN:T]D*WMAOE94/+#IDF#.+'I5-N 9*/
MO@BN_H%</Y8&3+V"[$*XDTXC]GYI@$Z)[*^BW!IK/3#9Y5QSHJF:IR:#=26Y
MU_C3P@EVG_FAQE@"M!V^VUNR/4TO1)D&<(Y\QQ#+68T+,%B#;ZS)9ON:1!I-
MWI=MNV=Z\SA-IT:@-(7P/6T!A_JSK8LIBA?J&FHB'AW^&BOAP<0^NBM0 >J
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M0^MP>Y:KGF_7LCE;/Q4QZD0%54K-O?/N63Z+QW9 W\"6.UU(9T#SIJU).7Q
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MSKRZG[<D1BDQ;Z4!>#/T&+<-B'Q0@!##FY5J)_C[W:O!?-M,=WYRYEN*AGU
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M;2UC*_.?S$6,">?-"W<%:L&HG&B,&#4,&P8%]>FP<*T]#CQ/ QSC=B !PG0
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M:0D+QN%/:O,=8\G?T/C7 6)SU O?>JC<1!A.CRR-IGOV#;,5)#ZK@@9,.S)
M[Z)BAJ 5Z";Y@^#">E>BC?I E(8/^^ZV?G)9!U@KT''#"*D^A.8F&S@0%*"0
M_ )Y\M&[A33 *8IXRLY]UB<]?(75<SY6W7P$AK]& V(%J56$(UC<]4G5]+8Z
MA]"/XUA(6<N]J(#O <83'%FWG=4WY%JJ$&(ZD'Z6I75"DC%(P3LT3VKT)XL9
MV?;>SIR W'^,NS2:TT-28!8F L-YYM-99*[<&7BX#-G#!Q\+$3'":>R__X[X
M%#V*G\A++0I"^,0C0J;/Z*E):'J(08N1^->-8LC>Z[4_*G^ZR%*,<TCP>,'R
M?@]\V!0G/C]TJ5&,\,P/Z.5N9#W!@A$'W%/8RN>H:=P8NDNM@$/G^I D(A8'
MZ]L_UPP5OL=6ZD'06);+W=?O?:\MG"A@M:$!V3M?350A7+>PM+F44&1PJC(&
MT0[L&M-YW]GY?CX-H-J13[Y:#. @2*2^GC=P=RJ<3[UB:_4IH=K$8D2];*9\
M%SJ7?HQ[9E2R"#1@JB<4 ;]1RGI/I9A8?(=)^=U'<L5YO8K0II43?L-T]+7G
M<QP-T$F'D)F-\<6>U2I$3A^S(8)UQ_.ED%UQ'_8!Y7]7H!.@#B/+8:V%4$<7
MQ9G5]^EC_&0[UG/#.Z8S,F<<]%NM!VH^XF:$;"QBG[%(QJ%?97-\-GZ$+D>U
MQT5BJWC"VE<Q@BXJ[7/G3FIGY(XH&#3JAZT$7CMJ%\.?2FJ+"O#846(^YIB]
MZQ?]W!L>OY,4:'-3T-"IYR>H?<,='=I[ZJIZR4AA:9[N=Q_&X$5%T7);$#?3
MZU)N>PX=?WZ#<[L>2N9V(L:$65![:$"(BX^8ZQCQ27W-"7^O[:=M :-.HH?!
M"?92[S388TT>K_R2$MF".H+N@$*#S[;E%XLRLW8%Q@-:?H/&H,&/*IY>*)Z/
MRK.%)*.R.5*1-XQ!"2<$\[!+P"'RA92>*X3GAS)4#:O@*ON5$H+$H RS38=N
MN%Q/9!7FW,#^1^P7^J?8[^.=$F2S$6&+&D$W>F@\JIX.T/P?0+D0&H35:9ZM
MQZ[&00TL]O3'.AQ^>/A,'(\-.NO-7MP:^JNHRES/9Q_2NU/9' 52* $:$)P^
MLTKAI@$,2!S,BP9\W('B)$ 2#3A' ][#0/,).E)I#-1*BR1D@0:-?[6!U_1O
MI$[*-/:F&?//JYO%%&V7\&+U!L3?A76];_&)8]/S=&^?;$D#YK__0;FI8X(_
M;F2'ML+P%^5':4!;'3&W=($J.(#R,#H_;5A<_$RY_EV?_I+E4^IZ=**WL"D'
M^)#.+<9HP)G0%S0@J!Y-/06#]>I CH'FU+VI>-;W5(D^\ND7(/QJ^>!&_=.5
M93F[H95UX5=-R;5)F7IGF^9A9O]<8B42P$/#837F31PAV@H#Y&/36<*G7SIA
MG(IL+-^];'G:=>0M4\EMX>(?W>/RH*1GH4LI]4?WN+U4YL=5FZ&50T_8X#&;
M&BE7HQ_$ZUGMW/F=N8*]AO^F=J8_M@WJ#[]NZ-\]?A3]>7O%(>\LT\^]W(!'
M,2P&S=D@#_?\V)7WO::Z\"X\Q/2(LI_G3;H^EW_-NC<+G<I4@>=3/U7SHMR5
M9YI03@G*W4W,!OH#*Z<]#P$6,Y*,A<H;;?^J?MA_]_@Y23+40_<X=V/@3:(G
M!BHUC!_#N#2OP.]\+"[^7LW;<_?!$[:+SNO%!_9BW'*3H58_6ABVXEY1/Z7P
MP5V4D\:=ZKZ6NMP'4HY@,CJEIFZ["C0U+4@QSD?^O][D[QW'I)O03CV8_A;(
MF[ 6ZW<.)F]KWA&4!R[6R07-/I+].@ZTN>V),-RU/')?^Q8#L%4D/;<Z$D:,
M&T3?@S\^-A/C9%#1BQ(R>?N&)!NEH5>M]13^-"GI[3 +R1;9I%-" QR@@O.V
M !X=#-<^1#X[P",N:)3[IN3X]DC!K?J&F.A@T_E.L>A ?S\#V,& 3UGX*R\(
MUM/CV'U4<9!W%9<59^A<55GK=4SID=?39[=-O<=1G[(?\WO-9U7_N4Y._L\)
MXC]5?GC ]'Y6Y[]=)???:A35U(54IS-DKDP+69QN2G38T[ AH'ROH8"8#K+:
MDRXB1 :ID 7!JO8(IU==<.G)L7-OZGRNR@3N5A-^TC&C(_K(8=I%[/);"UD/
M:Z'B,%+Y6;?H#D9-P,V;B<JS'42Z1VVJ0P92]R/LP:YI-,\];7E"]-;)GGP]
MZ3=C\^7&A<TYREV\;N7ZEQWV,:C9/B6NCJ*I>^UP/:,M,\9A 4<LO%>O#;EN
MP"N=R]^6QRHE?:Y.84QATW__I 9G^^/Z0KHC3N(#TZFS632@0-H*P*&GXK+6
M''J1(P&D;5W826H/9@#-!9TJHQNB*B7+O(I!Y?!#Z\Q_OH!"X/,>_:'&YS3@
M,7V:SLPV&G"3M/J-!X&>CHK1("K2/R^Q]:YHR[R3,;7*>7U\X>2"O<B7HTNW
M/\S%GKGTF5V=3?1I]GX8>*P]6Y.%Y$$6)!@%JF""3UI<[U0"4I''M\M.Y#[8
M=CL9>[JC*J!2-D 'X4M("2/=_Y%LY+N+Y'B-K$%HY5*B;1;NGY]6/'@U/2I4
M %@V/>SU8%V0<@I$XUF::(#(D;Y<@K/@D\5\I1@72D;QA 7GK//^^@\)JI0V
MTFB'6KL1X*O[R_)4.%EC<0I+!KW3Z7R?8DX#$N^5AI&Y45.QJ2P)#KG@X\_[
M/U&OBTH/<GJ=/!J[N\/$0'*8[D8'>=:1O_BE(PT(\T<(T8 L#FXZ."JB(R$C
MP/^P+@)+ ]AW0%4:H"TJ0<?^:-,?P00H#@MCI@%S+:U8T'P!34[2@>A?@=&_
MU-+8N)\&](1%T&':(');(@[T&FY";^,)JE2>'10-$/_"TG?0O)L&X%=10<AU
MW#2<++T)HQKD4D4V\7 J0M.(CCH#BNE/BK[0D'_C0AN$B 64I 8&?,]E\#1?
M&!(G]L;X@/=TR_F!L]ZY5U*[JYZ<\FZ?_]QW(>[9_?/J7UB^&_&L>_]((OVT
M%,A/&\OFR)-"T1?_\SKT?KDQQOE]TK,TX&>)]?[:OH"=,Y';Z%\*#?GSO@*U
MXW,:X;\BL__%"QV.]"X@G@.]\JE#D[OPNF_ !$W5(M#IVH#K,A0G-1"1Z&U?
M8S&&S'H+B <P--'1V=;_&C7XG[#0K/][H2A&T) DY<W8!JURZ(#OO@?#)_3@
M>EACA$@2 W3%OLJ"D3&Q=)OV[ZD=R7KZW(%Q5R#T[/\6/?AG%QHG>;#J/5D,
ME,3!'PMJK3S#Z<.G*ANREA7WG[U:V^A".H-?KR_C9_S&(N+4^.NEU+4T0 CD
MTP&3<7ZK^\%<@ZIA)>GEQ[/-!%5=N0Y+OOM$#[.=1S:[#S)TD35 >QPLN%%$
MD".H4AK*_GW:[+FEA=X;K>68[KBKC[9-Y2.PS&1.0KI>W$4".F0#RS5Z;FPZ
MEGI@5F+E2N-:)LL9=7,G7< 'VXP>W<+U-/'4T8!@H:8=6&CFXBZ?$AQE*5"4
MY_FW\N7GYCF_=5'*^M;R33RV%<FI# ER _V,_'65Y$7N[C3F=!V13W#B]U\3
M^:3 C&O^2C*O]@YKQ1@';]" FD6KC/RDV[=C(96VG\HEMFZ\JG\Z(],*:,Q6
MXJ48[MX]YOA[<!R#= O9<DK$[S(%U0CQ;A^[Y*-Y*A^T,^U?60W*YC16&EH6
MY/D\\U9LC5EM]EU[>G4@;\KOK2?/I!X@*Q,D0VF $RPN4V[@87LU?BN".8J2
M[#=[F$];][&NW$$57-4 ZA/+)478&1.&WTK5_S.$0:H;0-33D1\SY=E#-$9O
MJOBTS[0W6?K5=Y,J:I:/_\/#97<O+(_>Y^@*90JD7'N^MO?JVA:9>XZZC\<C
M=V&(_D/JR07]5&*2T'ZQ5O?QDH^6 :;5F:8RI1^:+PBQ!!I,I2'Q)G!>#MX
M#(RE41"<7%X*X+G5OK,BD?PB]$[:K,6W!*S:]I5=C.1#-5O%HU!G>5"BIQDK
M@#@TN EC 'T[FK2/]<IDKO6YR&G%VY3<LWGQC*'%]7K@S"R+JX$ $^-*>;=L
M@"L-:))&.D,%R09Q5!Z'&*5N8TM_E5:;^4F)VW?&[J&/M[G-H0X%([Y.!?4K
M[YS58?U-VLW32KY#< A'L.)K6NG'-T13G2I-8,ZZO3[ZG= X]-9#1.O2*0T]
MV6AV_6R.DY1"M$M/&/+-=5^$J%3BNLFP,M.Z2Z6++,\*FTZ\O?^G71*G@:3$
MT^_5U$8ISY!.\# :4.40NJ(LSP(S%-E,W]W8NSJ@Y^6456?I=O;PTD?]!;5#
MD2 ?49B ID-R9SC&KP,SU][-HC?8X.Z3;SEVUU>N8E>W8S'3&8U'3%Q?6632
MB3/2[SY0Q4P"AF!OY*-HP"UL^!6R+R4K<[KG3)7+3F:,*VMIY,GMED/0ADHW
M/NE!=@Z=?8$!9;VV5TDGR?>AE>9-2 YPN9*U9W_GJW9$EU";VGC![MQ;S&!Z
M4?4IT<V%@=\.OQB82M3%&DA6/I[E05O4A(^$'GL><N=B4(W86($5,$<]YH2A
M2Y$J[)UJ@6^,3]L*=WZX_=I9J5/X5>VS \EQ8L\3U=D+8A73MDG4O5B2Y77J
M &S/:^O62U$S&<SSRU6.@[OV\D0XYE^#>%Q(?$K=<%F0GHK;0QW,JH(V(3'6
M'74\,\8$QBOE#2GKYOAWO4<E0E3B%+H59X]L6PL@LD=@3PN!(;YF&&:F&;H7
MZO(5C,!=\<GV%FLW\=&6P&]N'%',-Y"^!7LJ\KKP!#<S<*!D06>%@12DJ\M6
MJ&0@[BP>\][>_A23:+!@RK] "5_EOXW%2"1:<DD-)ZZ\9P"_,$-C&NSS$%KX
MV/)IEX!E9R47B2'#KOI0IJ68@Q4'6,2G[@.=:KO0*A[PL71B/KA,*9[N>93%
MF@(-$W0N*;>Y/BK;W8W)][JM%.2CU<=S]$%,Z_ 0NL8K#!YPG-J!YMS [AU_
M_<)WZ)A;\8WIJPIGE=PZ^=O=+#E#U8=#Z'ITDG[D.,)\"]['<. :*TKFJ3P$
MX]"<1-Z:@==<$_)'U@6"RQ7C!<JP"D'QI[6D&#M*$/8OD$UFFF*2@60[!_@4
M1YPV7Z1UC I1;<3:)MN>J]7.N2XV/>G!<9T;^FR5$RQ3QLN+',%8'.."&7&2
M+9'Q-N9;>^Y=A8Y[ 291<D;M$WFO)]++.QAYD"WX[Q!^Z!2*5_0(:"+V[LN&
MA=4B;+!DCY/Y,Y>7D>9F+$XL\@=]1*P?"'P=7J@"?(;?&P>IP][#@ZG\>-NT
MZ572D68- SCF!,KM?85&YMO=$R-REU1OO>/]30M-P,;"JFJ:LT8_6FL@1<$Z
MK'YC_?:+LM!C<JX7UM>?YIC9VW)\>L\8?2?PE/$8G%A=0WG2*&PU,3*_^-J[
MW_99R4.1HT$*G2>$/R[DG3PG\\ST4+D'H\ '<&S:>/DLR3Z@RP6'XD=<K,9_
M?IF]J'KD<';[#4NO$]BOCP36>:J_NMI,<:X[-,Z1#[)>ZT,Z08,F>>C,5:^5
MX)VRB-M<2C5/\=37G:B\9'=30V=!Y")\GXJ CXFQKO(<LL)\61??,AW7*FL^
MX[ L-O/T#B$KC  ):Y G"C2VV1^XOEUVOJA+O.0K_M)IACC\,K"1A>DGJ@YJ
M2WLC]2@OJ >^IX4]TI8H;?"=+,#Y-VL,(^!<.043;X4NF3-^6F'\JCJ85<[7
M+B\0\ 560<PJ)9_#5Z9IO_I$-#%RY]>OLAC^ILK*^<TT]EHH_U&+6.E6Y%1J
M.=C5/HSF"S@.QAJ9V$#:=NI$COC;1*1YWU*X&3A?;MIWXIK+-C][\E9144Y@
M-J .2.T2TM!_2')T*7T1.SEY<*_P2:EK,3KO31FS&:/WE?]F!/ARNGE5K.$K
MKNECKLLYZWG5>LRZ5S/R7GUE#(I[D<TN/SVWS(A?G#J?EMJH10CX_YH[\W\H
M^[:/GXPE>T26,(HBVR!9LF<9<EE2*!)7"(E)"!DS(F3)5BA[4627+4O&.B.2
MK6@F869LR3(CC5.S]+CN/^"YKM?KN>_G>7XX?CI_/%_'Y_B\C^_W_)P%Q#>+
M3A.6H4<#E@"?)T13'U32YJN=^GO=1QD\:,(1DMTN=A[O1R;?0.EZR6[9=GV\
M?-RBAT^*RW$"%\O]2#LZ!G=N$7-MZ[ZQQ#Z:QB%=P'JJ(EFT[:I"9_/;E#G<
MV<!7<NZ7H.^5#ECQ"SL[BYE!E!<7\U?0-QWPFPA0$3Y8PH'T "VC0WR?>5PM
MB)C<K%"7S[&BW4LV*):4%^A]Q^FPWUQ#OP%_!,&<A(VGHGM8ZM2Q^".]GE*&
M4-@C]5>TZXD"5[_RG%R6,_"4#%,[(A;^Z.$;2:9."S./Q8G"NYG$=6NN7>6V
M]3"_D"AC[WP_IO!K8:C89"Q'C_## =^X]#OYN_5B2!-*!$Z("^\.=O:?03\(
MJZXD==K:V7_U_6PM6.Z7"9<Y\X/007>_=#.(U-:::! =^1@N?5[)V5*:TU$/
M$.R+E4$@9,J%^_D#1#4K+=)/\U:5>@'<IMPW\O_-.[6Z:)RL$66WWT3  TP:
M/#/X,N$Y8>-'/<*'1VJ1:!6=;0T(VGE0%9.;,[A7V]RPG5675SOLGD?EB1/N
M?^?05-K\,  8O^P.!:F476($0Q2VP"HCU@N"6W]\4@_##XX6OW@V_V+H=0>A
MUW!UHMO'RUIYWM%,E&WG[8O%,PDUNCI-\) @+1[Y_!/\Z>4^&O)Q!W;J1\8.
M[_MXCWW_H\RL9OA1?L'$/4!;HFXLGI2M=OHW$!5Q[-T2PO=KR]<B'[F&HV)W
M?=-OF?B,$::P)HVP@61C#N3=]&@'0?=WK_M=WEP/G_J4,;2ZB-K^]"O.>,60
M7T,,I1OI1W)=A] =;\Q+&\M^*Z$\1IZB7GEHU-,V2\/JXWTB3_@,I6UQEN5Q
M>*5WQ;&-,?Q!(>HI%D\XV8Z/!.N?/WP53.W)$^<+#$6$\1Z]QJ.S>_Z5TC#Q
M4DTLOVQ/K,/TW1G&H;8%V,9Y[W*D8]/43T\^D^2-HY]\X^'MUL_OY(A]\%8>
MK@F-;X+H&T75%W5KL:;F]O$E[LFW?%B?22)4"+9CI$Q:.S(:[?I)PE:LX>RY
MN+5.E],F.C:S2Z9 :,E'1.(<=S,80-GGR>)##5E+31/:H.JQ;%/(&>P]B'2$
MWAC95!K= \67]4";X F+$X8"9;4I]GVVU=^>C(2'?<;Z9&Z'X*V ,<!GIFKB
M;RB!Y-F"V' @CN%UB8O&BC/KB' ;]<W<#Q^PH_;7,],*VX\X<G+\F)&0K ^J
MLR5%]*/Y&5<I+J^(,/& AAN$$R^$$P.CWACNA 57K=URSN,0SO1GK^CS3&6)
M@\0% 0.LK.#'LD_:J:N[)R\DI3B04BS7ZBKBA+8'47"D,/B,$@Q], \U1-/-
M ZK))M*]K[3O7HVOZ@NV&PKP,><_V/ZE_1RV1&/ GTOCE-NOW()](N0Y21W9
MH*E%D.KC\YG8]SHN*@]PQNX4%Y5*[)TV.%#\E&_-4QKC':-+J^N:Q/B7X,L&
M<EWN,M??H4/_5"BVULW*1 X&6YRJ5II+T\ M#XV]9^N)5.S]1H=$ZOR@I5'1
M]]7#M@Y%5FW:PO@CA1RZLE74=/2S%ODB!S9O'FN5ER/[#_%;C76<8,9C_.8?
MY,^5D*NW$MUNWW!MQ-VE6*J.?S'02MS;F!BX>3MJ>&%W%+FW,/]YA3R_<9*<
M(7@#TP)]4+/9I4A\RC'=+=6X;8UY[*VFE'"64Z]?4R$K!V"W0Z5:I4IQ6O)6
M:0 2[+%R4SM?/&2Q?"I'+MVLJ1V'"[SM"I0.45K=%PJV54[WOSV<[?*C-3"?
M/V?F=0NNR>KE]>]VR_O[IL^IN)LZ0SJ]#%][[85D; F_ZUGS9X<1FFC9S<RG
MK$.!LNH>4NA#\Y<ERE@?FFY&69T]:VL _!'BZS":;@WYM@UEB"Q/CY"A@PZI
M&*E-Y/FJV<#=7^73Z,]YNFQQE\_U74JK"BUZPUM@+VIE^CTE@\530&2JD&?2
MC4\AKTPCX96!NAUS9:$O9R,13N&Y\G^>BFI,GFCS >XH76@YJR$=<C60;H'Z
MT*V_WRVW&6ZI9(?>>+7Y6)]'OJP"3:WCSSN1TS\JETJ]'[X.OQ!K?\N:VXX:
M2M,'B71E)/)C]TG6A_/O:E<)-=FVH<\M6^:.R@='*B0\^''MZW#.7E[ZDW>?
M)E@ :[RD+6( P?,=VBR8C%@H2;HJ\WA6_9Z4A,);[[B1I4T_3HIH4U;"K*C/
MS-P\T*WAAHP&;8AC,I>^11!.=]<CEID9C@EEV3H<U=[R*V?-".1$B=.K,?YL
M6=A&J\H4,=$@9T@LMYG3O_F+0+$1Y#DPBSAV'\7WD7&9-.HD S6?*OOAU_Z$
MC#\/=[FNQP97R%1Y5<=-]NOUY&.-0P5;3+@B.W ;^1YK2Q[V^* E8#U?9WW-
M/D;(/'.?NT8[94Q(B@RQ E)-V\SDFBPOR%;JH1UB>8@Q8W_&"YJSXF6F>KN1
MJ^>=B2YW30"+9_]]W&#-$: T6,I/VWENW$O)\ )5GKHLGQ33UG7Q&^WJC1V;
MD".),8%%5-EVZA2+YS(9(0RZG^NV,^^[>BS1^\75V0&?YIP&]EELQ>85JP/\
M;P6M(H"7W?OT'(=&#15S[A/.'8P4(^K5-Q,1ABO)>HX5Y$2S[&B9FE%;/@GK
M?7S0(JU_2?FB%R23"WR$A0*8A1I9T2Y*759(-+'DP=TKL/#RL1H\3FP'D-9D
MUY>\?C^[LTPHJ[='3G@8W6N$C*"6$14'1R_0;H$/B1[F;A/-0U(D&;-[V6I:
MAXK2%8(56C+CQ OC,[GYRX99;"#: JS>'T]_=%)AO49&-2C9U3RN;=KVL%%N
M@?'HTCE'@+U\ZC#A+799 L)'!QJ>#_L>Z/8&7E#? =ELM$56&)M88I[?BX%K
MKYOC/FC==CKPB7M1^>M_S\WL3C/OYML<-FHP38?SRB-#^Z8U(E-)B <// QL
M%!H3=:ZE&CQGO)<R:Q%_.*!K<K(> .4IG;2U$K)X(M*2#).Q>1&)VF--5.&B
M0SA'NP["U/@NOQ23P0WS>DM^(,:;0F\S@L'?P$)]+ J:Y$A%87S+WMWU275(
MW/1XN>Q[]@N\= AH7 B6-$QAS%#JUZ.I9-H,A6/^2#@BU<D_?_G-]<X)0V/L
M>?:^NA&IJ*PA#KYM1J=W:-KAQ7SZ(5H3LQ EC9HM%NZ<U*X_M/HZ<K>_<S"W
MK&+.,D2M\#Z[UQN+:Q:(' 7AK$SX,[")YL/L,+2A<^]/^EZ'-);0I\V;S9=G
M\3J%PG4; P\Q-VK2JE75+[UN"'DXZW,+,"C!*Y(36ZBG!F2/,;,Q 4'*'G=^
M/L^=GERYJ-\N((78SG?HNJ2X=>R)S&=(\?V[KNL1=!&D,S,''0 342\@#?F!
MIPRYSHOBD&WK\VOC@[\!U:6T%:WX.$W<^[/;&&[6D4@Z[1GS;4VW\8W?@-#/
MC*2K7!-!KNLJ]?VTP,YI:S>EY+1MVZB$9(B_,R1DZ]?YOUV L%]/FQE#MXEO
MG*QDC7A"8$CW<O]3@6[E,SQ_WE@*#?*3CV\-&/.(36/[FI*6MMQM\5<'H'MM
MMY#FU>X,(W#LU6]@ ,MR^@5/KNM)LY_4/\;3P!YK<U0:. -[ <38T:^AON2+
MK[?\^6?YY8!1LM"##NS$"_#:]%F9G *O7+NJ]Z*9O1?5/?(@T@U4!SR&Q6OD
M1RW#$BKZ'-*+!9LI.NV5T$8S!"I#IF7$IK>Y^"1V]>L]C\YDH4YIZ>!OAN<I
MZK\!(FPC@&I >T[M?N$=LE D9 Y[>7FH.VAZJ=7RF.:DH=;K5^\4AJV Y6Y3
ML)&BR!*O6$\E>Q+:L&ZK+=0/C55JK#S^4.$@@90K?!9-O&Q[H('#%6R[O*H_
MI +<HT!P:(H=.G6"X0T:^V+ T!"Y=+I]45KRS;K9+U<$7QZSQBLZZW$7'F;"
M0'VJBB6SO)MOM5O%0X0D !W0B<JSG0X*R=%W/5NCJ>"SR 4)Y!?NK>=EQF5@
M,6(,:#=E%X<6(C@\_]+7>@;YJ^YXU\=2E:$B?7C:46=!U/45?7W%[]&VUC?5
M_FQM35#;(%JFZY4Y5J5PL5>N Y 4P-9@_]'SUG^9=<=]LRYWT1+"=I&M!])0
MK?V?20>215,[%S(23/QA21T9\8P_*VHWG]XIQQU;L M2XE"=T*5T/,KZO'U
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MCQ//)<#3PZ*6VRFZR<5:)?['_RCQR>KLU0K*XKX8 WY8E[4E[J,+1C R">M
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M+6PA@PQ=\'^I"9*!B^'57FCZ8J;"JE]ZAC]V=RVZDR+D(1O$FGHP_ITF2TV
M:-"&,DIC4)7@CA(^Y)&U=.['-"&\17&9\VQ]#;OI'3OW--RKA[6;K<M-/KC@
M#E B$J1O7K ZS]G,Y^6FCJ]T>FR\6;%N-7%PCCWPC[W6K3]%RD>14\0<D!LI
M&H]I@PKO%FI@Q$-\KA*,LEC;L"JN]J,*"?) X8/B(ZSLMU"7?'8*B%@J"B$1
MHD!\3TW?]65IR6!/^+A>_VO ^XV]/7^G\,9M;,\ELQPXC@^7_>.)Q9-Q,H34
MC8U-T#__V15N@Y=&16@Z^E$:S,\;F*I=P6_8+HO8!&5UQ'M6P;_0 38&TTRM
MH[[";-Q"T0&S^XHLZU V6A^8DR9%BIMVP]>THWE7)4:_!L9:#>].Y&:<^6X7
M65]J9/<<TI&XMQ9Q^TT<0%FK(+DO@N,P>#O+%X>P^$;=3R$HB]BVL7'^J=]O
M>O1]9,UO2JGPB;'KDS/VT%,L-,YN?$-W-F\]JJ6>#=6.DIS(<_%RZH]]-;7Y
M[J)RRO&C7&6 IV2L5;B,]F(Z);\&6T"-TZ(#W\>:EYH;7EI69/\.=ER(T7IC
M[!Y1E">/NJE^ :R(;(4BO2S"<=H;N$*WD'+=*IA8B![65\U:I% "N]N1B?.M
M:TU+7UJ@_*C#:>YH)9%ON'K/UQ ;"$)P"5(^4B1U@;2K@%]"Q_[(*(D:,DL]
ME=HBN7]OU27RVK4EG/ HLE5#WWZ.B:1 &,;J#NRA^+W40W)7JK[BJ3GU30UV
M+,?%:GB[]XO"$IEV2WV(#ZAEIRI14^K$"-)3[398G!Z!H)5WUX>W]-GB:$/F
MM<0Q[:3O]3"-4)NORF9WRVK$L1&:-  Q)"JCRW#C:-).YS!<A4"B#7YE_/<7
MO%?0-R#G+FAR&#'_G/]C?'/H@?&UNL-M8B0U0Q,\I=*18?&F#I?E8$KR\?=/
MN-Q6?_&/I-W["F3I>^FVTPU&K>.IK;_@C'AG)9#VP"\8M4PM/IBC%:%Y"X<2
M['W(7J*:FGE:\[:IY+?&]- _^4QI0;P3W\310]X 99NAS=55(D*:H+ IFN\U
MP.T+Z>Y4\O'E*CNND[QE)YIBR07\&E^-1B"0K:>0OQ#43W1@@T$ IVH"#SG^
M];RY;6K:X!M2W41VARO@?]85>DG$OI"/H[4%5]<F/";'<AX_:^_:=H[OB &O
MU[77OQML$_J.70N4SBD-=Q5>F,?/P#B@J_<R&<Z;#J/X)9'\U)ZA=C4L&.KV
MHFG:SE1+?CH F9_QW7.B ]]HN+E[:'8&+<62&--[^<H\Z50]'< ]1K8_A#-0
M6^X'?XJ(*X,B0PJ>,WBI_Q:H:)QFO"^S8QBB3=$6;>T_E#A)!UKOCO^EKC3)
MEPLK5%Y!Y$+Y^E]NNZ=O3"$C'SRQQ_R!UN['#[HXM*N]I F16@M<YT-L;?32
MJHK;Q-_EI @47_!+S-DU\*DJ]3*R@I?;>^I_P&Z,Y15^B$NY%*>8 WJ'6<A!
M57(P\(!'?X0Y=IL]4W@,[%A=QF$5T2>6:/BJIC>Y_QO4:0%^(Y3L30*WXSJ(
M$DGM23(WG)VII3C#RJ]UU8U9P(S-&82]+V;S67;$J"7IU%D6HG%4]K..-PIT
M0"JCA@)C3-@YDM(B.!;A'T,Q:58GZ$U]E$ \^S3]8VC659@K.;4BPEE<]Y Y
M) =T@YK"@"*^<L0BDH$[SD!KG@PAW/4QL+RFZKR1;L9TA_=IG5GY5YW5]EK-
M#8=(C\KWSN7YK49_)KNN:^DH3.N@$S$+61B>+88]H,F@%7O2.Z37HGE3N%VJ
M<T.2?<IYQ0T1PT3%H4N==N*1[--=^BVUW] ?&PT(TXLU+ZM>/E&X1(I>=/6T
MJY6_[%ZP;C_<K\IT6YB_5TI1X>D @\AQ8PN>0WWGHZ!\<$.<A6<''>#T>US"
M]=U\_>U]WVV)X 1VDPL#16\.O\KLV2Y@XC&^28E(GL<@Z7N0DR1+KX_K9]YM
M+H[XH@4"K38^ZGT\E;-D::2YF[393@=.1A,":)W3&"HP!J((%M"N-BPBJ<_F
MZ8!QSP49PJ).8":2>Q5/BL..[73P3[;5)W3&^TH)S$0Q.R18'N/>DI6Y<+SY
M$<,/(VD#" UJ%DV$%.R 5_$:7-?[U,#W%F8;T7?4V-B 26K+;F6H.1\=C5DH
MF?]CC  S>+DG'<CIN2"1ZHB8/30L'!&U)UU&/Q\QI6;ZU23WZ'0%J6B8Y*""
MI'VJ_Z[,_272#CKD60OB+/[7' OIR^(0LE*#.[+S;OQ1GC(!]?BOW[-_?!3A
MT-SM0U'"+M(!E_$#AY7N[J=TX B2(IRWD$][TVS8U?1!0R]FD-9DTI"T?*A\
MC Y$Q '[\],../^X9KY5)&\Q1?RAKT\IJ:;+7@:\XW=3D#7&E_S-ME7W"%0"
MZMV?Z':2Y$D +3A$-2H$^++GXF#"W7?A-2)8FZG'=R%##M# B&3===AIVB2T
MG)B*LYP.7N2+:U8AQ'7C7DYO6MK$G+82&H;T\7CHGKH8?W#*K-ETMD>LV^P7
M30G1T2PQC/$%16%X2BA( A^MWV98+= \R]QJ7,!Y^E(<V;#B0-8X%0Q5\4Q\
MVP<@HA #4RN=KFKM>G<+VJ0Y3$<IYH5S3S+,^X*"S VTI..[0IDI_9'"ETHM
M^P;&>S"2#-3LANC)EDK%7FO")7%1KN*S*AE@R?M>\NJ:)U$CF(OGVO/2WC?<
M=6^36Y5#T>6!IO(D2;ROH.%08+\4-+;X>$W-UT3KAX7SK%S/5"?F?L$[LFLU
M#W;(KHCA;'72Y"(9&@O1PFN5D*$4_3'T<0G42[BIC\%DBL:#7JXCMZ<2?S =
M9(I=WKD= 36!2(1@A[&>#-_C"RGO4I*M&*LDJ6%C7/P,DUDV=;;4D]KJPWXU
M"ZT>@F(1XB1G<WS53#!-NF+8=V%X"_?:I.)"642BV(-@@,_89=SY/Q[DGAPT
M_[]LX;VNM&(RC7/Z;SOJZ%2((IR7@'[.R%\PKF9YKT,H:J$/=*6V$C/2/,IU
M<*Y\A@UVZFN0PH]K=I9N33[K>HK QRFE>SG,S1>I932F$!RV9I.7K!M2T"YQ
MZ;>36E15G6K@.]JPD-'8R8S1_<T@MJX)6#0K7F>YN?E?F#^$B?0.WT^,(OF0
M_4/:L?/M:C$9R,3'"3[&-</NVAFC51]*1UXB[):-9R34KA[U<>Z"@>B 3](4
MJAV]F"2*;%/ 6[:.M_>.'ALJS:8#=K6Q\OK.@U,&\74Z/(U24I&&3P8-@0<8
M=L31D/ %:+N!:"M$N$KKT"B=_XIJ@/R0P(VE@-FL%^[3V3IH46H4@I?4O:@6
M39.;(:V8TGK&&XVQY%D[V\VC/^X^K3[P?_ON]9VMA9W-8:BU]07P6489@=(8
M_'X!T]KD#9+T\C0D0##8\YM^OUMF#*$I\LJ%#5@/&ZTNR4C$_J*K]B8'@1N'
M>A;8I R*!G-5;C_7NS.VL5_C4#\CPNNO>)^56_YE+?]/(Y_9PAS0#] DNA59
MU;TQ74(Q'*ED1/*41R7MW"BFRB-QI5.+_Z7'K,I]EVO!H+GDU%65W?%K*5@?
M;L^&:-^MJ1->N48S_-\.(@Q:=,6_7/]7=\A8'B9_*[6T(=DN]#D=^O1N<Z[6
M! =H'7AFMRD$NX]4"/= ENN'3>W$S50)04JFW==_:M.$T!'05?,!)-Z9L0Z"
MQA0E&( <2,]A\(]J,.UD ^3>\I>I$9H'K JUHQ[/X$0J"Z!#@5TP1801$1V,
MF.1R: 'OGEB%DD['TH$7I?T9NGE_^\N,(7_\5/^?C_Y?._] @T@P4WQ)GM/J
MU-WLM/O]RQI:5J>4G2,<HUG>,QW85YTX[3'MM]%7O<_PLJ=_?1_,QUBP6Z'4
M%%GPWCE'!KD2=!@%@QC57:%-Q%Y["O1LEU=D;S-/+:# ZY7S]WG%W]]RL@MV
MOJ $FH5#+'&B,>,7"-FQ/EAIJ6OIQW_B!;)O>_K@P^)1/^O?NCO*F0Q>,HH3
MOOX8>!@'K#0?@VOC^SO]N5U(_IU3FM68W)ER_6IM[ZM^WUI?OY?YP411Z:<(
MDJ4IHB1_[$L0/\ES<2XI;_T-C]O4X9S6SO';^:8N9=)B25U-&7$ _N^FH 4W
M=H7ZL@9YR'83V:J'_-7;+$H')@SHP"X\;=M-"=^<AH/Q_=;CJW/G*\C[?4:S
M:C:K;5DW[U:,O4R4G3\K2>XRZ>&B+[0]6V+XUI"& 02J//9]_MAQEY0+/7L*
MF#!@'AW%F./2U!,UK?Y,%BK/L4E=(HE;'4"1P"53R'N'V;1NRE62Z<)V? ;7
MO68M_%[Z"XW:9>>HJN9+W\N!"[>^M;9"W^7P@6VH7YLY23Y71&OH@!!<]:NA
MQ-;1W]8_J!Q,1]\HK*HLH29W?\.J_3<K%+I7*WVR&'0@ZK[\$/Q\("(3;)6Y
MG_R._PE3BH?!PS^@IO=/=#_0&#[#!(?":X*07/KG*A)CPL^>VZ.MOP'GAUOD
MOY=X4FD_]M78WY\K*E',2OEX(G.A%,!QZP(X/5N%FE(Y+X)L-3P-YP=W8)YG
M7X5(H&!UH\B:BR/W,TS?GA(9%GLH=2/PX,PUSN4O:\BR$M1SC/\FK 6,KX H
M]'TB!;=Q%B';KM!D[4>/9=^POL*,ZVGKZ)&3?OKH02AZZ"4RNEFXBI00C)NH
M-+]#B!Y]/NPQ.@+6W7RF<J3BO;MR4X-M)3(&(C*@'X@F]5L.GBZ!6Z.->?2R
M"R,.QI4$6.//_CQ35*3#DK.;P^>/5>C>CL6P!/KSWH-H$O0AX-HQ]U>.+M[.
M439OJ]E!JEI?X.O[S_LU<:AJATTEO)_E9#J6#Q6 \^==W_F=H=F7GXAR+[P<
M?*I&3?SHJ^<=">7"]U^=K=%%YR*.PT_A8SO[>.[1U/%SF5A73>>PBY^=BS]H
MRR9\,_E>S2ENP\<;6A.%O#7_%,(V+CNF@8QQDI)(:'AQ+.->!E*IE?7<"_&(
MFQ=:NXQT<GB@) 5D%/SR FIB>W$Y'1ORJ6949"ZTLZGEN,FM%*SI,2/6.[>U
MKIWWE/ZR)J&8PQSW_\O_UX7/ >O9@>:C',-#2K#]PMX/UIQ4LP0M-'9TQ'<-
MI6],+%Y*-)7E(EA.Y!&_)Q&[!N .1>V+6OABO1.[0<\3"JG%,QR76ONW\B9"
MR!AMMZKE^<KQ#>T2Q"!8K/$BEL& 0K!["/$U>T[5M,7S2K^HOWHXML5W_G1P
M/TO)J>!;=V.P(U8&4D[Q(IRGM1$QAR<*6=;4IMJ))#QX(Z_PQKVPK"Q& =*_
M$0[4QAH.$6,<>X4=DB<668Y.  (/0M":)$8%8K/%%W3T/]?SC]3W62AQ7DQZ
MOJ>4,C7JOT(V;#!;X<_333QI<V!U[FTO4W;:IE[!!@Q/!VY0/^:2YI$GOX1C
M5V](G _/?!VN^/W"L4O)K[]OL@3S[K\P6%^ D115F_(18^!JA?:D& SODF@]
M+4WIZTA@B<&CF\GY]G"=W[+7/11T6%_I20!4GK^W GU ;+2>.>[J<;C]OK:#
M]E"E'B+M=M&XZ#5V9^ 5<Z'<J6OLQH^8#G86&'P@H W#3SOFU<Q/0$5J^L>,
MAW5\D4D+??) ]?0*WX7G#6*X>[VI3Z/OKNT$N)UF&"D!Q7^%+N3,,S>"PKYH
M)29[H4\)\GS,1N3*IIG\NOE1L3')Z>_]N"FO("($3++\,FU4?1CED/[*6-_=
MIXCUQ6MFO9OQ268 ]8)051=<G'"W.PD"(DEVC,?)U8]5JD@;V?$V@#3K3=KU
M/=_H8QOT $4T%RES 9F4T1_OKTH!$<ZWNTGAIXNXGT"M\(L-&>>$V$\KO%5_
MT[/6Y9/.0!">9#LZ,.B#]Z3QK]"!)"N.X4J'/E@9M!,C#;<>1B@YAM !V[(Q
MS:0C(6/D=M/0@DENQZ7$67=)(O/#NI<RUXPN;,+,!O[C#Q?]OR?L"HG07^8$
M#NJS+>BNL\.*)X6?@V9:T+%-YIYBX)HWZ"'G=;% %967YE$[IU<2/B2?,UJZ
M%7E.=]4B=+P5-(E9'-_ ??H=AFS',"!1FX'7YQ\5L]W$Z4ST.4.;H@"-1"-V
M8U8N@)1.XTHF!WI#^?SD208+TA<F0B*7A5)=QDXO3Y]^;0/T^$4]&0\\]JX^
M^F[WW+<O9$'*)>IKS!T&):WJF!?2:/+IKO_H/?6IDIC.FBLKR JM_Q:O%?J[
M.W4"5 0YAFR%T)CA]H1/7QBI(82_RO^H=\K!>'I"B3=_:%*E:E!^6R&@*&;%
MSA8PCU]'32;17J!H#E66-+,<4!IFH;!Z!WZ*^A5RA.+\[F2248VSB:I'XID6
M2?.QC(M;?4*ST,EB*$FYI@O%@1BT@<OCD]HMCSJ&C-MG;'FQANGW0L90O8F*
M$\_^-$A1"I(3#1$Y\&LDRT5P/$T0U>ZF->"K?S'O:K!FT]#[O)L1JPLQQ@#J
MG8F<YA*,@P[<1$6"6>!6V7)X]#.Y).>7;]74MCXU^ 2LBZ5-R"$KV9^LLDP@
M)$EF4 !N@.^..7;^P^#C!E=-2?FE6]%R4ON+/A\_+K_Y%^9CQ @J)!WX%DQ\
M1P?*&TH92V<*<QG_-H^WI ,'?+1A*-$A<)[*J;*>\>_:_/S/( >2-,Z_1^6.
MS4]YTKYO-="!W!-/ F!RR%8H'?AUGGR5#DRZCB-WY=&E]_[-Y\7_DPC++W^2
M AV@Q"*]4&25^FU:5-I>'SR!4<_^SM"K[4UU.G WV)4.#*0TU_V_7N;__7)0
M0:RA?FQ\B(_!7<87M*O%ZB4E40*P1SZFC.:]F/K>:1=YD)JV^6;UQ\LN<X=>
MIY6-!O)#>%"R?Z,KP6.XI:QBRU7AZNC=:I.G+)'5/E5E_7-!AP,<:YW"!Z%@
MBB"2F(6W&VU:B<+<:XC-T-[A,O\\/_WY5OS=1[\7<*_:I=4SMN!J!!RQ@OHN
MD-L$HA'"B3@1HO3+\2Y!(::QIJZ*%?<C\#GH=>!YW,7^^<T+X-SKUQ]\/QDM
M#T1\%_.<N?[ZG^U(,_W1I@C2 =IE3&4_-6TVF Y<,CM<;O[G\?Z?OC*Q!"76
MKHCUP;7)3K09&7W\2N<$C1?.B7]!0':(+0K^=A!PKAR<_")[U\XE^IN]S<\-
MH3M\IK@M;TH5J94 ZD#^S7;3>5TP0<TD3M>0S!89:(VAZ%BQ\(>;<J?B?OGR
MQ<?NW_^[C8B-T$L0)6))P[FTKC*X+69@DV*!M5#K"EC+6*H,,I2-;%/$+\;?
M^$,X9KW\B$E.%UU/XZ78#D%TX&KXE83=,[BK8R4B2\?3V;!^E[LF:"=N?D>D
MD986H--?5^E 16P" D2ZW%H?4X'ME_3)>-FN4806LM\O%E+N^EB9ZJY2$\'-
MDAH/'O6?P"Q"T'A+XEV\0I3FGN/>%Q7U$[^4+Q[M.95P+$DNT@$Q9"QN&P<0
MIYS^N;^#DC$+*#KP1YKZ";E1NHXY%' 8U_RG#O._Z;1-X8\6J9L#K*]M5/SR
M'N2P_4O2,0.<E+)OYGQCDP4;:CH_S&>5N'GZ?\<F.^(Q8@*)MVY"+OAW\@:W
M.*%;>Z'\(7[:CIO^>UYW3-2Z.H*42P3E?$\GO7X?[K!:A7!'MAW@T>TPDM)^
MQWET@C9SUYCDD6+X661AQ]WJX8&/U\3##MQN;QVT_':6]XC0_V+,"+*2Z1 .
M*^<L=6( OB9V^Z/U\;[[=, C.:WE9LMSIG9F4.WQIH8%,$5$SH0430"9X;L3
MX7QS C6CGN;.3]Q^DF8,A7ZV6IG%Q]EQROJSXN3B'VE %S[,5P6WH"00/^NK
M$SZ2"DP)P?$>(2<&?B:H96FFM7U/6#GHH7WQCME.?7^[49U82ZJ=TZ=F(SV@
M7*1L733D+.P3JD2CS^\JQCWY8XR2."'KSVLCY?.1EO<C$*TEIR]Z%%>_^D+=
M,^3=Z]8T^*>/6_R/\C_ZG[B3QG_P\9H3P&G-MVJVYK5A(P*JRPKBNSEL[^I]
M-5I/#C[KV;RQ'U95\I(M>_G(6SK ?4881A,HT0PA/\%0*6#<C>\/$C=B=0H\
M^BJ1/[,+4AT_8TO.T(%>ZC^NVCJMBTREGJFN3;Q0P'&+/?_Z,R^%0J7.U7>E
M1PSXO+R+;;3U;UY/4"CQ>M03;GLC6E,L; S\4M-+PY7]#U'CG+[RC>L\V1SY
M2A:75*_:>"OU[&KM6 1$0*H(BM0JS:[&[&.W>Y;*7$M?9BNWT2:==K\YDW4B
M='OL*/7CJ=2"B_X!2P4=DX&Z.F9.:+E-.XTBXQ*XJ>AF4]'EAX(6!75).LJ%
MG.O]PGNP=I1$)P[-X^S]+4'B!PMK8.LOS_Q Z\[ATH/;88Y2X]QOJ[_^:4KL
M?["77WB;7$F=]ADP>-QMS9BK4SC(IX0Y["?<R0\?0(GJU^QGYS5:$/?6+3ZI
M6^T*]Q06POO#PFJ[3[[J'C2M#1NL#1MFNO?QT]"U!4C<35D)\9CAOC-"FJK>
MTB/4D0W6U[;7]_(_,O_M.>+<M,KL;>:QI:OQ<BS_?*[ H*FYQ?EX!HRZ^:\]
ML".\ ]I,P\.((234W5MJ7;Z6IOBQHN/W=JFW]A0W_"-Y4@H=:82+NE/?6P2'
M,P[#,(J-@>33E\DNR%9CF@+)!VO\/-! I/WJ\*W&H=RO=VYLG3XKD1/UO3A7
MJ.%-&^IM]OL!#@L\FNA!C:9)A"1*>ZQC8[)PN@LW\<XAL6XUX?<F'KM+F3RE
M)=4^QC;_+".IX)_A.)(:H82BZ6M?"6YHWSMOZB%?4]^5N,<IR2L/&J/4'C5
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M1K*U(8RBX[=VN271PD[3+\V?.(5<[F>]4#85C]@^-1,OF$&98Z1+2V1//V(
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M*>K(HCHKW[RYW)],!IC^*L3)W_7['7]O#1 C&P9VJ:8E4:<V8D14))1?Y2E
M-[G(L32N%X1I*U( ?EF:PSS9>GOR\KFOI^.UQ79_*EN23FRW9()9**J,.EZ-
MG/\=5K[E\>"RK/Q9,.I/#BB%<I$,I0W-5V0-#.V>MEFQKJD#:WS=>O!Q9]32
M)7MWDYOXGOJ1#GB:)JP\?URG^3(\T<[O^*LD2Y@MK#Q%7:L%=49F4C.K)"3
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M@12G1W:O"P7YS/]YGM]O7V-5S52H#-3_RZH+=LIBHRQHRCX'>?-I*,A^'*.
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M&AED2C0],IBH_4_B9FD(DR/GUS?SV\]HY JQ-.7#[2Y4S&7A2XG']U'T(Q<
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M=S54"LRZD\4W5=RHE=<>Z'IN(RVV*A#H 1$@,A#DX_3K/F\;U!V*TG-H5@8
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M(+TD/QJ#^?T@ZG:U@YO2'-2+5[\]<$A3Y+P9^",Z@ZH5!'U-W74!P)$9;E\
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M(G"&93VL,(JQ? GV6S$M'$HVY90]WM]!XH-;^!B&016RZV-_Q2Q)*?+<OG(
M'B9G6EN'-\5]8X5"Y1MQRHRIMM.O[,NJMD"U*V0&$A=Q#*/[DR\/:_YT=,$M
M$^O8SSO#8[V91J):7FS=IR'?Q:&?.CK2VLUH):S]9S['Y)41,+D8#!>&@KO9
MRK5^.B?+?]5P[WSP)LZUJA#I0$")X787,H1NB!2@Y1(XI:-7;'BFPB(ZK83[
M$Y#U#;=_*_FD17V,.$1TNLU*M]<[;UD QX87^AA_.2;13ZA$^YPGX>FJAI(P
M_TUX?*KPF_6:6AL4V1:_ V]E4X*AL_+Y2HF"O[GG$GL'U79AS1> F^Y@YNIL
M'[\5D\<HXY2[]+6#'A9-M':08+-(_YZ]\Y%^=WJ)C./X8[5T$@3*=H96UGG>
M+M=F]Z5K2M0AVA-Z-M6+DDA;U)]"VE:W&??*K;:TW ;_%IG= ]EGAPW/5N9T
MLZVIZ\RJ#=<-*GDC;TW($'?WQ5S>IPP%<=/</;^W;?&;C<5J=2=]JF[[=;[&
MOS$3Z5'R=:10.^FO<3_O#OOK0$QN4M^!4D!V7_8/^4RL*:<5:-O5=[FI%ZE2
MC1=%)>:VVXC."%T2?\F'C#C=YE$DT0TC^#L;$R-WL,$>RBGU! CQ)U=(+.\X
M=VK/=-8VS*[!Z3+<%^S?2EIT96YZF4L?V[>3#-4K;K+$/=)J(:R5J_C@1=H7
MZ7='73R//V"^61H'\^ WJ(MA9Q> &LB7QT=OZ?Y^2/DL+B8HTOKA/3VJ"ILE
MALON9$"'7!_ B59%\DZ24MYW>61E3>P\BVJ?".%YYBA]I/Q8],6;#O7<020A
MA9)/!F%(T"-5)FL/YV#4^UP?_FB/:7_#$*CN07\'N^B'LY]C3U:TZX+(+84P
M6Y(,-'LY-ME'U.ZZ7/NJE!@XOZ;)BX\.1[<?>UPY6NEP""7'7GXO"]X6*TCU
M^D<1]C9%N/4[JS]:%1M *O)#G'RDV/TR%-[+;.N0MZRH(N-L"=.$;0.5,X3"
MU(8(U21/T/P0:!0%)UJ2A+?@U/A<M?MX>"%]IN-[WZMC+KR:O*K2%DUX;<("
M;O&SB38#PP6@8W*5W:F\Y%B(ZJO7OH6Z61C#+HM[3?:*#=&:ZI;@,Y[N*H?+
M<D[F70KP6C5"M_/=LHLW7%0MPNS/5KS&K4<E] VUFW1XR%:XU%96]X6U\]5R
M@+*=NE#XFBYQM!1QUNBIA^5O,[GGCQ](L&10=KRQDTV(RW+#[FS_6"DLRLV"
M@%&?%]"6MO?@'50%%P=\5WD ?)16K"CFVG.<_"ZXK6VB&-Y#+'HVAAWUQC.5
M=/ <2!+'9)NIU.J<4H#6B=:!,SG/P&,*2#M* 4S$<6DQ@LF1"W:5QF'WVY\X
MS[GL'L/GRVYHZS;@C7.&V9FAW[/;*'X_;K:#9\#W=]]G!:H'0B;_] D7/US\
M?BQYIUVO+4_6VYK\B#A/_;GQD?VR&S,4"MF8+/J2BKGQ"J>H>%2@]I#\C.C[
M=]--*$RF(4H;!]>_S>+IOZY <4X86R+^)+V&EBM44IAX^?^K_PJ4_-#Q(BJK
MH?HL8*I^ ?X/2*O&OJ&W"1?#*ZEC.)DE[=RE6FRBK<?Y)C 8"0X&-ZZDG_Z9
MR?EA.P<#S]]Z)]CW)>^J&&PJ6P\9,#3,\:PU&0P1XO ZQ=_8%F==X[N"GA4Q
M1M.+#+GRA]+4O=>Z5KW]8"*E>@X+2@JX$8RC649$6)8:JW@YL^5[_[E&Y_['
M-TL.R[EM:O==26'KI6Q)PHZ_(NIVJ-271^-_,"E664$D8V)^^UFIGWCZVVBO
MRC)0(?\IH:2>1!AOG/@1+]:H:._''_/+-/Q-WWJI8@D:1!1:2Y?[S"9J=&O.
M52M95\(?V+!I\1Q/0WA$#%[F;CG[#^?$Y?G3DU2N<6N[.\_CO43=.\%>3J>&
M+#MNFM"VAVWI7O /!S=J$["OL\A_0A,@$AK45"C 4?&_YYB:B-P! ZFG^6'F
M,64&<K/')9[+^66.=[_:[;'-U$R$.6WL(&P9(IN9'H\9U5209)AB1D+[</X>
MD6?9<YH+Q0(IJ;O69;(.>A:#2AG-!(&T+W&4O&(9O/Q OV"KRG%/[Y^R[7-&
MW,[G1V(3ZS%!M$\M,\ZPZ*;%Y7TR,Z+3Y#S],8I_X@)0D:_RV*,G\# [9=JP
MBDAS?JL"=P%0'WD%OT?2*/3O%I4:7&@&;T(DHXN?YI-()?W/E_! =&VQD$4O
M8?@T6(=2Z+JSRW\^V&R$J>$V,+)^KZ'Z@C4>ZQ99O][I_%!,K&0%51Y1Z]E!
M&SS4!SY".E-^-=LV*2_[%%>%!<%490>S/UZIMZ[7JQ/@@W_R1M*EMRK%?3DB
MH[(%FY!FGII-]LFKQ!=:5M@'B^FJ//GWLMA^=1EVR!\J3J0IY+*=4+ME2+)?
M.QR$9]9/#2/*P=U1<:'P^[4CL*?^ZR\S,/>U%?2D;BAN1N)%E9_7XY]_WWUL
M8AB7]?1:P#HNI\-$=#'$Q<K%9-#Y/T2=R-4;@>D7 "1$RT"F3)^2.+D^.ZB_
ME>]G#GQR/@RIM(_>1]W3SH>Z'AC)]'2M0JGN3 ME@8JAB$B8,0;(\0I9LJ@C
MVG8DE<  -!DAVN.=UEM]G](ULN-!]TW#V[-RHM/*\#F8Z_D=<7=,S8PWRS;;
M9+C)W]"W /2I2*4,?MWFB<#8")C!\'*>*9U)_H33V]&I9HWGR_OAYS*XP0P7
MF4 ]##<\W6I.TXS =WQ,O1.&/^R$"TT(XM::G#T"N$JO'JCS<U+S"Y#\#0=0
MMR@YU*TD\'T(@_$6SO6&1MK=H1I%!<4CV3,:DA)QK#V;187!!:-#K1FE<UB;
M9'"W]KWBU3HO!6&6M"2!Q)GO&,GO?D+/,CZJFN?RA"P]ZC2K=AFQ1\KJZ$LJ
MF/\X*4K>KA9%'>/#<<=ULBQO7OVO4],#8**(Z!]H,S9[A[(T[W2F+7Y[RS=!
M=):>A;WVLSSL[(N5:HWAQN)G%9I+:1YZSEF..PF5B=)A4*]X\G5FIHN1Y3TM
MJ0S[V!/LZ=R&<(V;N3I+J"%:N^6C(6))F'DVPX:1?9N>\#HS&:DE)D9<LP3G
M]:>M*\!P[Z%H4,WBS@4@9Y9HM]V"SH[:O;SPN([=</NK\$2!SZ>L'T"] ,N:
M^<&0U[ST!WB5? OC-I/?R:<X+D/BE>ZLY_P<(&JE\$XH-<T!*Z%,RTE5=.>*
MT+6K2EQ'^T0A1+BL.--YUR+MWK%Q;EV=-GNUE@"IZ^'O!(5655QX4;9EM@E1
M;WVI>=>7% B-TQ@[%YF=(S*W&(SF=8R8S\2HR5 +?*NY9$*!!BVJ@66OV32*
M,1&Q9,Z_G/+9&W1K0V[19J326>&OBV6O%;_Z[5NJTUB!+"V!DQ_TD?\/9@S_
M[X;3OUYG95:<>\)QLFMV 8A1\<N%@89=90-="2(B#UDJM!^U8'D8!MY,MGA_
MF-;S2(L; ,TC4Q]< #Z'P>[%9(+#7;I&LILRIO*)VH2O1 16YYXLG7*'G!LS
MPO\)*%-"E2=!Z\$WN6%GD?_P&BD8AY645ZC08_;0 R,YI0M 4/$-E\+DW:EJ
MT&T#@)URC/IJQDJT82:T"+L>TOBHH"FF$R/;%[@Z'QVH(4*E1RF" =U^#\EX
M_2W7"/GB1!3XY(&N/:][JIW4K^^N+=$VFO+XC\!05//27T@E6^J#..<EY4?)
M?J7_Y%/N]O2870510:A@#!7U>+I)<=GO,KO"K5\&*Z1"-@+!D.0F("$2YQ:A
M)D;6FU31YOW;-JI!Z:LVLN;5O #\J4;8+$Z/DC#YD;Q5%)U*!@;3^JCL;Y=R
M><FVJ4EY,@O];:+N2QG43'WI=Y5JP%* \P6 1U9Y)&]3GG&#3?%M@8SH*HI>
MBIMCQ9]K^V<U>]K&Z+MR^5._XW4.UN.,K$=$+YQI*W^;&H^ST1LK_;GO=/=>
MLWLH;'E !!T&"K']CE(&XI5NB\>6XU,]6'Y-M$DB2'0(]UT8FN84/+_E;E(3
M(TKFQ[?UM\(%QQ;:VIR_A.TRV[(4WO:\=19[?"9\Z "ZJD8[Y^POC'!TQ,S;
MH<O9:8MK/GF=3_@)[4:0)$W(?L3G+G^)=@H_\+Q?+)S,-3XU[/)*QP]>AR[N
M@$A:1F:.9V&M;A%,%9!GNW9QOD+F=:J28W$6$\<*CU5OB['*:VZF6I@&MSP<
M_Q*HS76RR[MT 6!S5/JLOJ2L'=#0TD^(?7Z#G[O>,,AXH]^Y\*F75,3[V"==
M_!EWZ-W]-IQW$>SPW@L _<_2\?TC2H#-LHG13_IT?WL.Y->)G%A#.E)// &_
M>*-9K[_LF],S;=J]N#HC,WI9X6_%/X]\V[/1-6UPEDEO//OGW;\T+B%[R]2^
M%DTB>S$,YE53E0$Z+V=::FIC;,S7>1CC_\%!"TZ,W87M'M;4>\LN;8J*O=3Y
M+X^GU01A[XF%^;.._JPA7=ETY8#?4^[7G[0 7]T^+)NQ<?+L$YO?ZWY[2YN1
M+-AOO2\>#N15 >(.Y)5"D1^$+%1"4GU]UJ,)LH>+'4.S?9.3<[-$I_E;/MUH
M 47 5[_-[4A\-MUY/X@)Q:_EY8>A3@%[J_3Z]JB12TLT.R$5Q_FAXK85$RI/
MZK_$' @VI7WRY:/&\X76\6N*M#F'_TE7,7,5NI7\=BV[<6"(C6PT 1=V^I\-
M1@4::W59WSK<5J:]8HR&YQ0YTHD2PGP>L\NM*#\6$L#&QY].AD6HW=Z"T,DX
MBVH$<-[]O$0NE_IJ[.E_2!$&41/%3?""G:OG<6ZBO17HT5_>_(F?596F2O#?
M?8*A:9(G[,_'<U+E4P)=NE<^<C'LMF+IU Y&V2=^)O:>FCQZ]ZY<*5;]*78?
M[=4)5YY41X-%,VC:OG^[KG*&^4O<7D*$PM6@9J8;&RAV_%Y6PW\/ <SX\<^:
MBM0_=R%BQ"JU>V3&2%6:+B659 _V 4-/_JOSH0RUU =(9IK(?B]%SSXVE:%=
M6C;;9P>Q*,W2;:6N'(SVJ3@RWSD]U,P5#GZB=,Z:F6^1'^*FMIB?8^ID;N)S
M\C?[.C'$9_>!\J>6DI%#JK3$;CX6_#<U]GK\]:Q$%32/M:@/%].-F[R!TI!W
M*G)\;_3_S";Q==WW7OT<)^.:%/<>!V_&QV'DTLYTOZ*CD\?DECUXU%-*X 35
M)N>&$80UD >:HUTWKO*FX*68%;63F;@*+?XT;1.QE ;DN(?W_72L3?=T]UZV
MCM7/LC":3UK66>VRT_!A4(U0F(ITOL4&G!EZW.02$7RS0]CF?0)@.W$;HE)D
MD&FO2:UC[*,X:=OWS;&MASBX-N&=:;AS E0R?7FM:$SXI@#\'8$]&.2R'[+
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M+4>7/]6VZ2(+8BF]FFNBLW&!94*P7.2@?G U%,0\V3BVM+\;#+P$P.7T3+%
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M3,/O!R]<FR)+XYB-0[O-$TV:LN;3%JVO6BNHN#LO4:S/F6ATG,Y%=<=>!UP
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M<3[G(.EUF5M3\@7@]AG-,GWP'S(ST3D0%)YK>*<F-7Z*HX57M7#9W:M()B_
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M_>Z3X2A7X_&+O^9WDJD>F.O:^2H'Q=Z!DVZ6Y6G!1H+S/O9V*+Y4) /:HEG
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M!]%6\ER%[L?R,CF.\YU)K#1M+0<R-=HFDTUBF(UV<)@]S7]GS@EO\3:_])?
MC&Z!B.+XO)["N;F]! .[))2?1Z(E_O52.-DQQ0>PR]T"]U<R,YV[IS^8,SM-
MQ__7^_G_-)(S^#*28FM!'*N]*Z@6R5RYN'E-QA!]4>W4+\.2_,"B..JRHUC6
M SV]/!N;J2'!. /V^SJ*("-( *P5ES.#WI7ECN*Q65EON)GP!?9J&T)][143
M&+LU] &^RZ/HWZ&<C)OH01^9@>FK%D^*8!M$4!WWP-87SXI_R[AGV;Q6[:ON
M*_H<+2;O&>8\*9;/+%RP5>WV=T",<JJ&'0WRK0U6R6%MG\-F,PQTCO*);5>
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M=:&?AJRN!%0V+2VE@TP@F9DLX*6O1+5AQ+9STX,"R:*\ 07:'Y!39T.^C\V
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M:I%5T^Q.:RYY*TE'):T (-V/.H<0J0UQ^T:AG>=E[26/$9WT9V-MLE\\F0L
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M2;R.:8:_B)YE.90&B/Z=2NC%LXG2^YI_5H>*Q\G3M@?2%_&%H:+BSQ;@>W3
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M.997AYZ2(<MG<=]/\QX<W[+)=Z.AX<U1L!L- #LT=#:#8UW]\ZZ4O^%5CNZ
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M69R:/D2G5\$"I5'AJ++S_P-=Q-OIN9A:C6^S<NI(>:H)'^>]NGCY1\"[N-$
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M=X;.@:NH<@.NX[?<EY2HFIAZY/2VSUG?@">L;?]6_:T\3":O>OVFQ^"<Z89
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M*F3O%I$7T?KU ^P(G8!5V"82Q(CL$PWN^4]@]D_O]S@]SPVC<_V9)7=_Z!G
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MH_/:?6@C=EL- ]''TQ+$\;=;+5I%WLV]4EHE.H(G=!4JBCGD5S*>O3\2<N\
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M>MT6RJ/RHELUZQ=K/W#(@1.O8_GCI2 ["07FL)?.OZ$HW/M]&9AO_^"<[UJ
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MMZ;8K1UH_*/@Q.K@@/.]#=\M]6E7^9(N]CT[J"CW^68Z[LT.*N88(X+YG-W
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MIP0:!+GG,.HX]BV>/"3]XQD75"9V>9#=UGDO$D7=8D%VJ;A>/9&U6UF)OY3
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MF>^?[W^_F?D/6=>5<W+*7GNO=:_[/F<?&*.,*6#_>3-+,X"%A07XP?P#&-/
M(=-0;P\ N' !. H  !? $O44V,?\Q@+\_<*8 ,X"K/OV_?XP%S;FAYV+G9V-
MC9V'DY.#BX^'CX^7AY>77T!X/[^ D  O[W[Q_4(BHF)B8GR"$I+BHI+"HF*B
MOT_"PLH\AHV=FYV=6Y2?EU_T/[PP6@ AKGTEK,FL+(> ?4(LK$(LC'8 PFPK
M.\O?+?_09)9]S#9R<')Q\_ R=ZC=#^QC867=Q\;ZN]7,7R.8OP-L0NS"!S5/
M<XA<=N4\%"!ZXF%Z 9?"F<I6,9L!HJ*6V[TH;AYQ"4FI TJ'E56.'-76T=4[
M>4K_[#E3,W,+R_-7KMK:V3LX.KG?O.7AZ>7M$Q@4?#\D-.Q!]*.8V+CXA,2,
MS"=9V3E/G^6^*BPJ?EWRYNV[JNJ:VKKZ#Q\;VK#M'9U=W3V?!X>&OX_@1L?&
MIPDSLW/S"XM+RZ2-S:UM\@ZXN_?;+Q: E>4?EC_U2XCIUSXV-E8VSM]^L>P+
M^;V#$!O[04T.X=.7.5T#1 Z=>,@E>B:]H+*56T'+ABCF=F^ 1UQ1>UJ)]-NU
MO_/LW^=8U/^69__HV#_Y-0[PL;(P!X]5"( "M"NO$E6 _X^-]3%83 IL90#L
M36IZ\50_]'AHN'G\VN:OIW,35:]4CJW1/T?YSJBYTWFA1'OKD=<U-40&D!QL
MI3+AA:FOJC^7A@R[O&#716F!^.PJD(MPM?@)%)V'W8]8A[7-T!!<&F_*Y<_(
MI#0&18I$W"U-?=:7>82--A6OE4@[-("9RL-4SZ=/B_8+8E-TR9K[4];+>S]-
M5 #^6G=^<'<B;#BL+PZS_*1RTDKHTO3!7,-Z.BM)U.E%]I1T*7=Z06-=3PM>
M! A $:2NC.9VT8J@MR%QJ*JR24AJ5\Z!9/[R8VN>9%ZMD\;6V9#[7%U[PWN;
M,'DJ-P.(\J7^0<N'^KK.6'. A1;U(-(]/+[P4^Z5D+"2;M&>VZ1W?C]>9O%]
MC1HH='\A<);.F\4 #@I&P[9[[>GW@UBV-)FG^$3O@VTR  *$*JK' ,1<AHAZ
MY"_@68JIBTY<%/PZ_WQ9HF--:??-VH86*24;4^F67Y?25+'(6PQ@U'G*_C'&
M@P'$-I _$E<N8$9TK 4=KT^Z&&;$9=O'.+Z8;NE1-K1OAQ(O68_E]Y$/@AU3
MZ -PM>;&@2":Y>2OSL-/N_<B9OEBHC1G"P3B?#U+!<S8 <3XY.3I$J<+P<':
M]T<J%"R/#59<-;V<\<4:8,$99Y$6'B.GRC" H1@A9N#5\#9*F#VG!W5Y0)ND
M5,8FE*VA4!"\DP([26A$"WGO=:V]IXB.F1?X#H#6ETFO4_P4=YJM+"IG2ZWW
M7VI9<RO+"^7S[:1+,8!6*)V=_@W*JC$%?C$T*EO>Y)YK)O%OQ0JGSZXZ^RW<
MR[J.";I9:72/'8@()B)G0J*,C4)MH,*A(K!Z7%#5A*)7M&):LU:5Q2B'&?F&
MD;G83]S, E7(#M?..@-)O7,[>X8N!%D-D!UJ2$L)7BB(%-D)8=M,+>='M(:L
MF B\PN@@7?W'60D:[=832$)7C*$E@6;E0)Q_.OZR:JB\B$/%L+$_H<8=M$^D
M'7G)_C=(K?\C5E3\*A(JQ !N/1^%<S*S]D93'<[=02FSX\!V8F]PS,U<VP:'
MIP'?>X\FNQO[R]Y%^N&*$<Q8:S5#WNB3 ),(PE0_T)0/ASB84O!Q.*A46'S1
M6H#G^L0+ZK=]AR_!QTSL%:?"KJ.I8E?(B0-P^3UV!H!-.D6UY1*?<?@X^&N@
MDV.P[P[7E</A41+0E@>7.)?Y4#50K+-__(X+RT=2>:KWC+1'BN+ KSMV1W8L
MWG6_DV9)$&@ZHIQ+76+FS"P#Z&(V!;TW5\H #/2_T!XBW?#Q&.'F4U@2;H8]
MYOO[3Y]6ED=(O@%BC</^]<*987Z?S5+B;%KNO:UQ3Q]"MOHVJ;T/S:!,<P\&
MA=,NG95[/Q^1.#8_ENF9,G&Z\^Z#O0, )97,S,Y,*_ T W"K0S& 5\+-\LQ+
M3RU?THBCBWA3#OE&![^Q;EKX<HY[WU1@2IGU*5G;N^:G2)A8#/%RZKCY- R+
M%@C5L@!="[^^]GH UP\NVT% AIWN/];F*9N]QJX6J:\BM6:W)3@V1$Y@GCB.
MZC9(O4#R/-](Q,0<<[R1/__KRZBBW41]DVX:YMN7,86P;MG1&3;6K7 R9R7*
MFO:8+HH-E#;5()^PK'W(R??K<\"O,L$9!TR=Q.K9 OHH:O2>K]R1[]I2VA;J
M"E567(0,A6,QB#!6O@II8%PJ?-.) =3FK*Z$DSS)KL,(N5"Y)2KTC:-S*RU5
M]A/VM$B8@L_$1S9XJMSL[H<>MBWT-]A#:+UY9^HHOJ4>P]-D2<S?=&H8G,TP
MTEQO)P^.56L9J!+T1+H^9%\O#E7F,SO.@D>V&M$-0DO($;2B6L&QN'9"UZ6!
M#/I&Y^=?G\<.>943!)6??@'4JUXAY1QD7Q!]FVE%OU%<BJY.O4OR3S8\13K/
M+VCZO=S.][K1^IW^ME?:UXLO^<F\-7R XV4 ;"NT',0AZCG:RW*D%RIA1,+I
M_+-R_S+WQD<3O1$A^E52;.;S#I=O^GV4R?O0S8&QN]_/N?F38DCO;38".T@,
MH-.8A8A/5NAO,B]X7AGV[E-[M[KA\X<BTYGS!D\74)T8>^0-])@507"U@P%P
M]U&5$=JIS&\3*%>*1$Z@(=YS S$P[_EUJ?'K1=2/A5H?.$![M 6+A,E2G4G&
M71UZ>[4,(/[K0&X;85P[4<,X0'.\92'JN-9X\ZN7^Q)5_ML8&ZN85'W*\P!3
MY>''/DY_!RLLFJ9JHL!5&^>.@^PS]@H%MSB8,".<_7\!WOW_]L_M/.!TY(C7
M7U8RM6N RZ:B3#MXDEG?,K(C>51>_>?8$96^WZ=,/!-@PFLJ^FP^4OP?P^>(
MUN]-EUA,11_U[QNPM#)A%[W\;YB]T0Q:+A0YC8I9;[(DY#GA30>./='IV![R
M>VSX0A">80($Y@*+7NANP608T<9?E JCO3%D+8:?^+X-XX=#DYQKAW[V[WHZ
M" 8?Z%$H/WGF TM@FF1FU%WHI69]N%TE""&F=ACK#[OJZ>XI9?Y("O9[[0VT
M!RQP2K]XMR#CJ<TR.0!+.P#I$)Q0F#%O@X@@^G.54_VV('Q+(M<N^+T\*^-3
M[=QN_<(MOOWS$D25,M(S.OF"MDD1H0^G(X9AP%K3K3<=_B4K3O!!!]_CK>FB
M@9WOYH9%TLJ24Y-?W'P\S+*E([9K64 -9W)/?_\D.3T(AZ&WWY0&&^@IZ)$A
MJ+PF7QT/[]P8^Y(1XW%TU)95L@\6P:P9 8C1_&/@&B21#J&>3S!/;5+$-S>-
M5GX:=C-+&3EW2>QFRO 1U=8?)[M/ 90'_T8B<]!\VQB ;VK2.+.JHH"E7$S<
MA8K&#\.# _3O0NGW)8O='Z9_NQ2RC0Y",QGLU"O(AL66!D7 E $4[8AU);TH
M.',OJ;IRJTDKKCCQV_%AU:[<$QD7C-\0-4!_2")T<\B" ;1H,8". 0; /T<Z
M2]DSI[- Z.K-]U\U2Z^ Z%VP;P6_#3W( %Y:1'0-0(F3,%$HI@@YQ:0GA$4F
MO]T "V@T!08 I#( "9C!97,<";9)BMM#I3& ?D7CF444Z*^1",$/0HE<#( 4
MA,2&P2_1Z>D,(-*3 22A\]X4;U/MJ517>LDL=(M;\ --C%D_H:&E,[?PB86D
M@]6JKXNK3Y,=^. ?G^C>ZX+>1=1N]:#CF*X^QV\(D<C(A:S4S?SF:71-[_+Y
MUP=./&_$;4*S0G&<9UGR<=CI&X5<&V-JS:(=KVOU$[=2XXRE07]2*8'S$7*J
M6$X7O$# "U_WF>3_7E,_W'3*]W[E0VY7T<]O/K.,%ZYI4L>4>R%7MA;6)$A0
MNFA?"T8F=.!^1*'Y8$G^]YN4]P$U\4\H4CRIG<VFM,8"_T>_R_LT*81?/.=P
M,0/@(K\-XK)-.6#",;/HGGM_BS:V=%V#*B;MTD@2C$1 J+(#<S='FA5"L\>[
MYMBRZE*&NQ?J6)M.]2Q*]T^Q]OVNMS6>'7GN,[;,CD)HAD:M.SYW(=;6)]1P
M:P@KT2;\W"1\WO8>2TDS=Y F[6V2F\"" *(GV1=\2*"HHBM][ [XOL_J-+,A
MF#F\4@B1$EB)/+T$.TJ?.*"4NKI ,:%_08IL@3G6_36^6<2\N;9'MHG#*6_*
MK%VE?T!NO!^L8W9O:6YL 0'/254'+8OZ%/6:3Y'.[?]:>9J#"\3R;0E;23-+
MM6'#7F0X;M7T72BV'58-B=+!RZ[8.^TDZ#SW&'[=V&!KMS%W;T!=E.6A7-^7
MW)T'NYGD;G!78M6?<FJL9]K/^)3.LUQ!P=#[W69\ 99S:657@Z^>ZY:<79/E
M#]-CCD]>LR9I(78-?I9D-8-NMZ#+P\[5:W44++_BM9)RX-C(TGVQ:@B/X3#?
M%VF\]:I9B9:&T (W6Y&0IEN4D]1+N#@F4 C\\-%73E!BOZ.^9F$V)O_K3$.%
M<K[DK5C-UCZ"8#Q3?/F/*W0AA(D[CW60<2@.*F\ #14<\O)4[/K5C\+Z+RP7
M._44*BY]M'&*A)J6SF- %<]VM A<D99%M28@N7PVO1ZLE9&3^%=9K.3#!AR
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MKF-PS51"W"IRQLOT0S[%-$6GUVR<UXR\EN.:_ZAM$#V0 N\C:G0*4MP0HPR
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M6/Q8" &V^EE=FBYL"SX3B&&[_-8^^YNW7N'1Z.XPM83.!Q:<#VB)1/^H&@;
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MPB*]1TMWQ/69HNG5/^[>L[X&()X-XA;,5W,H5ZG.1/\U[W>(;[ #M2IPVW=
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MO'BLF<:O,3JRC8#0)R</5=!>WO97 E=*,QKLZE4[R<I!+";)1Y.UVLL2IV:
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MB2YV)-6W6_-2=0:1M8;V!'X];.[]M5<+-@T60D_YUMB95U9F'6R6H>5@;C*
M?2"2G(,B(%M@20^N=T7.I/9@B+6/.DG/'+E"\W9F#Q.K#D]9*/3;)U"#4C"W
MT>!1XRQB?;O6CVN@!';CT[.J.@_3JU$#Y>J\0@-%6?"J&9G;L@]?"@[#XAB
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M9D5T@YU[0:'\O*:+U/DLUZ5O)L81I)V'6WUCO+_G^PQ9@D[57D[*"6MEDPS
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M9+*_C*A8P,O2PT)Z<;_\'4:/ ;CU<=-QQ['$N$O?FTR+>HEWE^I.%"??.[W
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M?^-! ^I325;"[MKN1FF2O\4:@V#*%<1*W/35WZ85_3^10T[E_]W0T_S?/?3
MEDD&,"7BCR+O8&V\>T.<Z)#CX(Y]:9/GY(L[AP=4,JT\DN\]+51?_<'"LGI@
M314R@J1CN1P<@BAS>*( "58_/' BK^]N;8;@V>K@PP)#F _"0;%Z3,E&E'7K
MK>5@TF5O&C")BE9CP75/RH:=4* !X6-G2!<K8MY>XAO>=\M@C8LUZV29W'0
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MAS>,L<4MV1SNO\?G9":@X*]ED"!\S#H<<(.HL&5:7KRFFF$^^* ]4:<X6E3
MWN*JIMC+ ,G_\LPBTXK+.HA SX(2GPS2@,5GX)V3+AOK'U&?(2,FU*O<4!I0
M? TQ5XYBH2=)CVU>4\(:Q[=%NZFUZ"]2H71*P[-L/OU])D3O,G*1?P'R0GDE
M^@T-X+")IKS]P\2'(FA3C@9409)4=JM<"CM(+3(^Q>3O5KHP"&Y(ROO_DY6N
MWY:&/ -"PEZC^(B?L*N1=8+X([65@61>5\SYDUF@(_U]3V0.2;HV>&(!N"<>
MW&(8"SWX"!TQ=J*T#!_[WMW%_<T/;3:Y'\HW>NQO\;!M,&Z;GZ0![ QXR4U\
M13D-"(RC*JQ[ECJ;WR\U>/R>],ITLDZ]'^]V?5909JTS;1@E W?H[X'W(P5G
M\+EU7(9A54YXGON4O"78^@?=MBZDO-LYT<4A.+OW(B8NHGRQ$R'JK3C29 E[
M3)K\$'IK>FJ4N2_,;0@2 G>7:C$4T,6P#)HW*RT6J<%-G/>8S)8@O! W[RL3
MBMR)CJ (R(:J"Y0H0 .P-Q^5FO)W*4EM@8V>>_N9<.H/33H9!3M9D[:,%UTM
M*UUR-C_>\(WTA-O".(DCV&47S.R3)7<R].V/H9O.G+IGN:WE)0K4@F0V?O@R
M0K6>M#0)LBC+W"!KA1,?<C9Y3H8U&^A]@NIO51KUOSA^;E;?T=+"VC:"X>Y=
M98 C=Q!"=TVIQAP(WF@>010$$P=M$V*7B$/?0B"Q>J)'&(M@6,SJ\!BV:>QH
M_]E%T/Y3[QU<3[6CLOM/E[(Q?KAS1G4G,RD*O/S^]>5+A@S)P_<?%("I\C<-
MP6%1I2D3W7M@VLE]B4_>.-<@M\'7$2HVON:)9%GB]BLB5CMSR\(*PGI3]UR$
MJQLJ*;4?\+(+F9@B+%M3$S'+W#<_NOBKFI7699Q:%ZUMK'9EVG,?=%5WUOK:
MVP,1RM6CFW.VIXG/"_K2O*@5H\-TCJY0O?!7'XF1WVO</,&A5VQ"Y6L+1LPY
M]D)PBA!\<9PI!'^RBNY.LC0@*XULB9( QWJK6^EL0?0F5KC">/S@OL5BW2GV
M?F/TV (/)%_XIO;P+;'-N 8WV KEF%>1+&8OSTB\V,6U#$1/;+&LHT[@4,V&
MD50IO'GX(T.BE:]I&.%*H/K0H\,WW#P,Y5[48'G7_'G733[?S,U-A!+6(=Z-
MN(NG-X[HF#QYD6#0&_*MJF['"W(5?H#8N-ZD*/0,KD9,R?:.G-'C+;(+FI'D
M%!<)[DMP^5:&$//V:N9'VO4I5+.2BO)JTEV>>=4OW ==)M]'9=. V^!MV<<T
M@,!!]\8AE[[&F>*',6+6Y.X C"SH4$@C1EXIO#K2HR0RLN>Q%3COK)$>U!BA
M'M$WK\L3W:!CJ-GET8TW:<"WMU./]IH^FPCV$V@0K=N\F)M3?>;%#1/B5/PW
M^%FTY31+"X*9'L9[<A$3]Q!D4_?YJJ)7I;:BTR&?S9-+/!(U)GO>/6@0$=/F
MS+ OY9$Q>;V\7VK]5(]>FF7IK;^HP3#(3'43I5/(B4@.Q'=#&N!4Z^\ I<N$
MAHOHJ0RB%[4103)8[/X,^9$_YY_/C&BG ?NILCU(!N,[R9'D.>HX-T\9/:7/
M []#DI^J@G8H=)W0$UH7ALI$W(9LBS^F<YDG#<AA]V>'YMZBZ\_Y'0FB821D
MRBN*!HB@Y>2U67@[Z0EV4C9,KG>B7V$QXN3RJ^=6.;JLE_23[K8"&R;6Q@E!
M,\EMG_H+#A@]?+V48E*014W"2A$^$NF*4U,51=Z30CY."",9>K,T6W8EI]B^
M'CW_8^HMV^6!!.D3;0"7SMY;[\]:E:21ONR;>2ZH?F,@"OYZ,\W2H$FPB[??
M-^C?.4,+,)]%D/GB,'L)@3BI1AN^TLQ+XGCF=W8U^^X?"1T[WZA(6!=3W&F5
MV;B 5H),5-CPU]01=7$D:*AB0M_5@;L5'^R-'_M\G=Z/!>YRG5MI&@B0@SC'
M#2$:=A>.!-G,"16J"_;=4S//<JI2SSZ:Y[Z'->S#Q^1]*UH=S-8W1I68L-,W
M'_%NLI"YW5L';50I,7"PM<VEM6Y;]U,I=5?U]'TL)<$:D3DX% <%!3\Q-T8W
M5]"U>:4$9SZ=K6;+J\$N;*<OGQ[44R@K;<V1G%:+\)"/+YNI3:3NCYB,0K)2
M6\88]9]YCY&6S1=*3O656$4(7A(+N:^YLN\LPP8XKNZHM\FD39S86RR8<[Y.
ML$_RN4:*;UY' _<ES4-:<JV7F+##-32 *JP[H43AI0%T*$[,@*C':_6;;7A[
M8-9WD]-FXF\7#LML![%?&)**5MPWRML@V* V>)X&'(!,=E.XZ81'OR=MA :$
M9X'BX9S4OO']9Y$C$MCQ<%FXI/?=0:UOA6H0T=#L4_E<#8]Z-,]TO*^[/\(J
MK3R?MB/UTW.KGJ/I^54(SMK $]R$V*_[4-GH1&?V<%BB8V.HNZR4H'+WY?=_
M]60.U9^:BB.Z@@/&-\S)PC0@^#F$^&8),:E+IL?ZEXA)!)G;"H'G033&$1_2
M@(LT@"Z%B4<K: !&FC&6!H3V$-GIJA[1@":>H\O[R)R?&J\&$XWH2@ QAR32
M=033P#A9&XS+H8K0W06"0U/W%Z&)D0 6/5D&9T3T0''N5(Y;OY^@^Z>FB]NH
M/(@F)'TH=@\^5:BD 9RZ9&D:$ ;9,"3+[GY@UIUZ.$!YG.@*"J !N[U!DM@:
M=D_%G44OV^)SZN$GB9-%SKZR41O^YE?3E"]ZF7E%2+J&UXN?EGP S8?LOA26
MJD<?T]VCFNA*M-GH+\:O^(09G_)K#[WO.\4BW0NXF9.8N0:]\DY4NN$&1! ]
M><?;@1I< =ZB.$'^Y?<!\-:V"\']IU>'GH#WC+/"!/.I0^,EKUXX38HR#QKV
M'\5+UY2&&00>_CADRRKU// ^24_2C84IPSR>$J&_G;IC2-:&-5%ANG@:(#_1
M3;P!%Z3'D>4X"@VPY,9(A?(VJ&R&RG]:'T#?1?^"!8\5)J>LG[''%-^6''P7
MAWD0#Q^B 0R]DB9XOX:L  :Z7OH,)IMRP8?!#!T'U66]SR9 YN19: "O-?*G
M@8_[R<K^@L2'_>0J/'^K^YX?WF'7T\#\CFLM1_H+BRL=-8VG@CA\.;OH"&Z<
MP.E2V'T-J7OSB8,+J-\;%O?^ U@0_X85G(V10<5VZO8449[UW#F5A,$^<EP'
MBGA3C)Z*9J/HYJLOHP%"D,G[WA+4T%HI&K"GC^RR:?X+V$DA:$-F[&A P0W#
M[6W9)G)<-VAH'#O8A.2 V>((.6^\QR_T+=V6WT[AY^_)=4KW 3Y),B1H@*_)
M+/>0''>_"_L2/3%.%OD-<K9_ 9V<G][!)I,?)'+BW.$5?QN3I+X.1Q6>J6&W
M'3*ZG:Y@_TD.40UR_"<ZU^J?F0+RIZ;?TCDG!(R;I4;\'3_Z_X2'"H0)7XEL
M'1I$],1H/#WN_O96O^);THQK2IC\%L@^9R1WC86//<;ZS,(7K&E5LN!DE9G>
MP8[F,T_O:PI,>3)_1!!O9.ZZ\6;8KAM34G\?P">@/P(G ]$>^/OS>-=[/Q5\
MN7K5T(10J!0I0#ZY[UK,ON%CIVI!K= _- ;] T.0M@APHOE$-0T8820\[UNI
M.93UX\;W'XXN3BZ*J8RZ;L*&9K>%DAJG/RHS2J7M>/T$"*/?.*AOE[Q.T]-5
M3C+B,SF-> 3OT) &;NG>#UT0D^I=*BS:W)>;AL',<RGWB^ESW6?YB.H[0BE3
M9YP $:W&Z#9JV.64Q]#=H9_] ]L:TT?OIV&4^=9X6R(XZHGU"MRK.4//*L*E
MB=/FP*GCP[ZCZQ AZG<DHWN-1)'5"-D2]Z2OT_Z,KHAO\][4R(. \$>%[44Z
MWA -X T%)PB1#XF%OAG_L\$-?\>$QNX?7.E_R##C4'Z5\:(0;IYN]ZC42<=4
M<E#6=NTME6\K"#+GTHO G82TQM$[\@>RH9C](NB+P4N1B,_=2!I@C$.O$Z!A
MV^ D"*ZRAI,&:)G1X16H1U58!I>$+;/C.ANA7"NKGB@Q(N)RF:OBI627V@O*
M7]\G'&;66VQ0)J"J$9.78#^!\,&?1L_YG)UTEX'>G-<MHCDH"'4 5W 4BS)<
M4\:3',G,?TM8NU\FR\$)4R/IGH? /?R-Y.-^@>3]I$8RO,B*<?7N.S+4_VU=
M,&X8PH">0Q&5: #+:03>]/M?F5;Z+P;M&HOHSR^B^^?V'T/^;$?(GSV2H0W1
M]$_J(O!@_$_]N?Y3V[_(]QHB_]2Q8GT-'T+LN?ONXT5B]<3LW9AGT@/BGR3!
MA+=K7E0^J5#$W/G;-  QL/O9^W^'L2ZP_&MSYNG1]6V";@XN8,\F-8OP2:3+
MTK$"/WV;K7GX6#Y6EGS"D(V>?/DV46E $1CW7DV>SH:+(!*U?&<;.QZ$!HGC
ME,+SHNIM!&(O]A5;6#_RNW\]/)U)](5+*PVX)?N$NF\0;0<.K=Q!!L,@K\>[
M;RV?_#:6PE32#IMGMDC=+R56ES1# ^X84^_Z=_^-R%G/H?*!Z3U1M=WM26T3
M08GX T<?.K30H7[/54''JO-!W[^$SA (RCELCR?<[C!?Y5!/VC'Y%VNXA_U'
MT:PBYUE?CK$"3V98:BHQ/J;KM.=]4^F68Z^*4?V[84"=D0XPFW^-:W'$4I([
M3+J7"EZHM.$CHB:%7W@R(>Y&BE[=?R/Q<&BCV[GMAS9-OZ-@G]B?GGN^#OQO
M+N,1=]:R;A9K>FO!Y!EW^<!B-LX*T:!5SFR<CV$.#I*C 2=<.HO55;V/+NC9
M)3:K@\]<:DFMV6213# <VT+UN_\$4*F?NE:3.CW6.[HIK*Y8R5:H75MQV*/2
M"_&57%I)')KP\R: .>>,UU_TWBR ?*GE;T)4.I /JQRI2,SSQFJ6OZM@TN:X
MHZHIN:D^.X#6_!DYZ#_[WK5.4R5O@Y>.]\M.KVRX?)'MZ-Q0OT=!(MQHP-[%
MMX5T%/O@(8T$'7GP$+S/9V_=TLJ/6!T_\_=T)X+]?2?*I2/^T!_#(<HX0U3Y
M=>7#Q7=E8D()><<^6KT=_><)I@J5+_]?*)/_-T2<$E58:P+RM[VI<Z9\1#BY
MAXBIXL3"7";'PS.%!U;N]*NUA;891YJ;KGUW.Z0G[G%N"_7^9VPA?]/Z7W=U
M#M<(7>>$.%^N53+8/'_OK5RF24Q>S*OBB97$/Z99Z-^I:&27BDCG_N(E4<F[
M![U"6&'\660(T?-4ZB0[R]5D=[#CN\N$-#LY^=;>=W9W"CKB^\5 >=[0[\_0
MJ<CB73[\#)EM1H#7U??3!R%L$KG#06?F\<T_\-&OI5G2U.8\\F<(1F8&O(Z!
MQ&TC3U';H.52C6!F,F])G^=XA(U SR93]8?'%37?#D=JL$YQY<XRF7_8]0^6
M?Y$P?[+O0;4_1RN-_XV3K7F3ZUD%Q6'8U-@S%K&GBL\X?W&M]D6*PWO!%:A0
M[E8^""X$9M$+-B )K"-*/94S(?)^GN*9#R+QM?J$^BB+D#MH8I*M/]>+1M7T
MYW;7? 0;1'T@J:A>PY\@>HCX9X28[[W)7Y&>F&ZNSBWXE.)6^$9E76_#4&N=
MF42(Q(WEWE$2D^N17$OW@.'8Q,ZS5/K6NI.,G<P>MJF)J?1,IBFR)>@0%CK\
M#C[>1/6!?GN<'Y'QIPCX-SQ0[)FDK5I0VG53ZK)LJOD+BN&78-(]:T2/61@-
M8,Q!E:E)D1Q@="0\L=53B6L9WQ=% TJT9[>'FQG(7<&/)ZN+']K$JK.0E>E2
M[C]^#EE=]"NZ[@<)J9UB'R?KX5:8CYCQHM_V3_.CXKX15=^_JN]-4:5A<KC5
M5EF&A3$0WCIHP9*O@#_I <,1PVL='4U)]K<$3L]I>SZ[QC)+H,M'IGM$*WN,
ML,\FB(_XUAQ'YCY;D&UXUHF3"?FTZO4]OV)0K?]\[KR9KUB*TZMYPKNA&Q;-
M[ZQ&K+(N86( 4VVC>@  Q)(>_P>KI-NI4C F>E]B\&V3_,V&R^-+]$$P7W..
MHZ03#)66:<"]P$-MJ34^5HINI*)J96R1[_1__BC):3 'G!G1B";VX W;Z+D*
MPIUN0HS5?D1IW:=I2M320".;3WIW:K5PW0)6>;;(M_9")6=9][YXMM?9::?K
MW[$H2SZ>0TB8_*=JKLSNX67(Y65&DSZU<8GEBA(KGVJO>V,A7K82RMU7!CE)
M*F0Q>K=9<+:-5 ;J(/4'M;G2$5*FWD5 J)[J1LKZ+9.^D]KR? WLD=Q.K&\0
M=U^8M3M#UF<)3];1J]$K%&E&XTA-_5]?+.8CM2R( ^^R>!A,/@_AAJ"CZ0XQ
ML@VZ#O]$B%-=6K'J:-T8J8;X28F%UKK1C?/ZY8?(N\<3<I(6> ,/Y_W[6\S^
M4]>Q(@VQ_21KZG<X%R6^AILOO[!UN#)< 5C,G5-<8TI>[F<KE>M.X4JH1K((
M GN\4<GTL1F'E)FW=$>+<7]UK^.PG(>+#*Z<J1Q\G)(<G_?.>.URXH?CT]?X
M -FN .4ONMSXB)KSF&[B":G0LNYP=[;AO86*%3N>M21&M[YT,S_O=C78(*AQ
MZTY.QN#"RU9>#0!@!A@%LE@.6!)3"(V4&C5MDASU*QA$%J,*T3WMB>X-/[\H
MBC/&W,?F1][:S(VO &<.6,FLN[.^R[^D]M\_,^+/UV5Y&Q<\*^$)#M0$$2,:
M-J@?PO,(N4? 3)7B7UDJF=D^+6Q[&7J?T\M_1IQM/:[[+72$$>.^)('/H:,5
MI'[$J0K53 .6._%OB,X+QP*2$2K7LJ1'&DOV*$JKVD5+WU348'D*>TP<Q"L1
M$!2T^DGOO@;^JLSJ?$>OQ\N%5J.7UBW3=6/%#ST'546N\6B1I<2V*5<IJ6AG
M$#.\/Y,QKEF=MV;/RL&( B=YI1WM)\T.MK&+@QS*]\0F EMAW'1#*4QTAT.Y
MX>)73VT*P(\TL6WY\J'=H@FW.S^I<;$]K2^-#NYS.]=JV PI<UCJPZ*(4EXM
M G4*,.[DA=GZ4$-BJM,]RXNE.FZW7FAN+X](N&1>PTJ)<S'L3&O[&"YUX=>O
M4O+@(,<ZE;Y'B[7'9$US,GL7%,5NMC]NYVS?<Y$]0P7G'R[N6_YKZTJ,S;O!
M// 3CN,B17!I,C_1!?MA Q59Y9;07;>'IWXJP @JJGD\UOS9NGDMX('&&<<-
MZUM2TFF 0Y/79+*CFBZ&M:775384\K4A9DQ/EZ1Y[?7&*1!NL!G!"9E(W:D,
M1=Q]3E5P0G!ZLCNT$8;OJ4M4FQYY&7]@/[@] WRZ/=*+Y=RH.=%CWQQ<B/PH
MCE#TE7R(=()LCP.%ER-YG53>6HTO5CUZ._N]*+\C$<WRXM4E>]O6 3:!TEOP
M()@'+C9^ CHDVP87_7I"HJ_,5:FQLF(@^?Y4H5%1-9 C=?Z\ ? 0@3.D 3%I
M;6W=0UZ-5$D\V[(/2J//J;+R2O:5M0LC%Y]P*)U9EAJ7XMUPA4/@GR&5+&$(
M>]!W=58#I?9!=0EGR^F=&W.-!HU\ZN:KL\#TM6,W9<W50)C;.ZPD'A<D/TP7
M)Z/?7R>OR28F_2$^<]1'S*#3\BF;Z_V O18<5@',P,WU-&"KXY=V6KXJ?6+\
M60.P2]1@A>Y%-!BIJWFC&Q$XE#H74>:Z.\<X<6=I9,S%Y=B3!E ZS^5(;!);
M+]?G?8=,1(6J#(>U,+GCY0[T8(!]2%(E:YW$&.Y=D.OV=W^E;"'+=1AZ1_&,
M446I!"A9BU560F%FO-1]>?_$*E$ZKAG$,F^C1C1Y\-H%SM*'+LL=&*J\T09K
MLWV;10.2W=]+:M^!>]X.XI$#<*C(<2:8.3W&C1 G<5$MEH8MJK56.H.>>RO[
MARG1,N_%#GF4M-6$A>0\>]&6)/'^@,M&W"1X.07GA45&'L'-!L-<G-ZX.!<=
MMCCK<6'M#64F^E(.G$7*S3N7.$DZ!3M%;,."6+T[,1SI[C"88H(6C]*Z:TFJ
MI/CQ*T]";HD$,:S<?]@"]T T:%!!1,,)T+(!SI<T45Y;'(AE-UXX![[0N^]B
MD&<F3X5G-/CI%>M!QWIU"VSB4]#WP-[D5#&L$!^@?H[QE5_?W#]X%MXZ.G9<
M1$V.I 93["<[8:J3@PW+A&U#Y5+=[HHOA<K]>![MRZ$W<8W%'L.Z6"M_H=]M
MZ825<6W0F-ZM$O-]#O'7DZ+E)MS$V9"6Y NX+3)/%%8W%.'8?1"F/2">MGC9
M@M_P&^S0H4?EI97F]I>",FV3A+V^Z.AS"0='[GA-(,A\#CIX_HBI=\07D^Y$
M[8WTMZE\W1:]4=V\59ZF'[36N1BN6<OWP[(\E*$C[@T[],PR8IA_61ZW19)M
M'6>K,9?]#C-]-;*<^66JCBFP'KOU9O]44.+A2N/3#'/(\K9ZBC"!2K2>7(U%
M,*+4A["BQWDCK22?:JFU/X$DC))3#KX_XC,EUP Y^0#)A)A "2&;SO,0=;%>
MP9[IJYQSBP3S_K/$7IF/@LS AR S#;! )V/WED\Q,TD73U?F].S25ZFU.SBE
MSQL]H11IK!IQ<NI9F9-(6)1+ *CS,'?YD3:CLO6G"#TX'S%L8FLY?L) OFT@
M4[ 'IB\2W/YT4>6Z\>C09V"<==6D(T%%1&Q?N_A7EOHZ4!_,:O<45,H;-24\
MHS&NO"U,_2#1*-ZTF&/SPXV\=3;A\*9/$A/J/2%&T5-LU(IOKA##\MY[DV4E
M%:%?>GGW\];6W):(T=5XH\SXW?3-K^U60PE17M.#P7YX!UTANZGI8<[5D.:U
M=%\Y'7S'/7X%V+[^V.BI117#:H SG!Z/!-4<\.,3Q2F8<6&B%I53U'CY>1-7
M@D1U<%#B2[E3D?4;]V8%13@UP"KTA!%ZBLP ;A#E&K?BHF<O37Z;B8WHVS=_
MN+.]O!??'N5R"C&\AN^B<\[JI%@*Z2),E-B'9\%(-1M<Z,2:/QD^%Z\P$LPR
MA'T"1 YM1ZD6/ &86UG;NJ"5:?30_,B05^_5IT(G1=_<-/O><0N%4=9#%2\T
M68]SJ9L!F;I%<$WZ\W41#A!A5)L['_EZXF29XCC'/;OW*B\&XF&FY8XWIF?@
M9^*>[2.93*L*STR_9AQ 3R#'RQ"MX\--6)T4K]?>*,,^M2,31;PG%5Q/7E>K
M:KITH/#SD]G/)P*C P*J[S.,U5.?+PBY%K^__<#6WYWW1U*S*\_ >M:C>(';
M2<]PFDQ![# E7 [! M<=52</DZ%DJS,N*L)!./N!I&D7E?,E=C</2QM*BF-]
M).S2X]CWN5F=(]4%R)>=9+F*JXMSR)WG.^V49I^ASUZ>5WC[<.3IT[S7[P-%
M0K\BLV2FNT?\",,]-, >L3^*7>[. %72^5/EI9['98&L7"^=DBZI,LQE!;4%
MC@: 7K]= U$/!&*6)9K Y<SQ;V%'JON7U$\Y5=FU-9M;<IWFU)Q**#H$7OMZ
MX;/%^\9[GR9L-V4G09'E-$"8+(^;J<;$@?0F#> [75(U/=/WEUT/+7SLAG]0
MBYY8.SY6/A$CM$ #C =-FH:MM\*+SP[VQ73U7RYZP'+BY%2BD[OT^ZE;FVI"
M -FF#A<7AK@['C2^=_=#D*'JJM2O^++!PK2NT.P'8;7/@]P.<\8^SI>K,SRL
M?6\#506Y_<($X[Y\'N>'@43527B7?%EO@JOXI9^7O_C>U#;O5&NH01&9<:]&
M3 1$W+93A"PQ@0@:QW6-E[,$;ZX.,TX6"DDU=1]T]HJRS_=_;9 _WW<VY."'
M$R/QIV-"U;+-9MV&*4<H"0@[45T"E)B*/[RJBS]CB.MKYLX;B)^<WMM5G<$U
M'0=(J]]HU3]>8!NO 3X/;X3@]$>0H>K*'_#=+>%%LN7L1PDW'AD([DOF,HHL
M6@K+_J*D$_9*2^P^R[R[L^6OD7,N*JI.@8YBC>FO-, 1>8!\A&@TV4*,*J;K
M%=GF_8RB[W080#QN'#V'[R\MKQ7_R$]X3,E2L:->9R :D9R\NZ_@Z*)1&Z]N
M&#Q<7)KC;6MT:6-5V'K>"%FRO:HX$F*-KK?6F(KY8F?4,(LB1OGD[6Y94A?W
M!K=!&&$.MIA:B1:J8,N7E-<&,WI';85/Y6I+[/NB]1K++HRZ,K@ :4.&F*F$
M-8Q'?/5VJ4\[A<: N&Y<&E3Q;PQG+E"^<BA!6SCJ%(.-9KM(L0?D!,0.%*@N
M2H22+D!A)RDO:PY7"*&BS^ZM^'I*8;]1=H5//SG<X_J5H>]%W^PNL)Q, TC"
M]<A22 S:!?P=>:%'709VK>9CW>"IMG#7U4=QI^P/7H*U%\TJ-S?H\S4^/?B4
MX=!>3T1)-YG;I!Y:ZA4-F3S]\9MLC0OFPZ!KWDR^4*Z9?U2;0/<77>'46)8K
MYJXD3NH7]:.4E#K!A3&.09@).'QC^ENQ5*]$[!FT??E=54TI8@9Y6J,Q^1[W
MR%S5/[@3^*-[!)+K+/@)G&D !L7X=;^;\[W"[)=:D:S<SG"=H[ YA/'CX0!N
MC%+S*BM, E<T&*%VN]C2&W&Q8G)E99SQP=P;9HOGV)!K>ALH$ Z\[$F"P+_'
M%,!4W@_<&K3K%_>>ZE'P.^8:,^5])/J.-D,X4-GAQ>; *(B*5F.T1=$-:J&N
M/N:2*57MSSHQ_N0(5*()?Q.D;OR#)\#;"TA)%& \4+-^TW YZB599K=,> \<
MR@43[+%/AWYUB%VWPE$CSB;<O1AO*?V,W'QY?L;-*// @VYQ01I0%K94^I;:
M**::;B$&CL(HU;]P0YS"&O9[C%WUX#LFPO[U<W9<BHKGG%^!/FH(;(UW:/"W
M;467LD2YPZQQ6]"HC@$8R^N:N]0O5Y@=,^5)'^W"EX_7LVR;/JUDHFCAW*D'
M#"97AZ7:Y.DAH18W2#VXCCGX:*JR+O55J/F#M88S>D)GY#/VWO,<Z0N^7L='
M;43PHNU1PVN=UXG:Q?7(_>4)=M_,31,_K[GVE+C:1]_.1;RH*>#/[_H0ZQ7@
M <'I^9NTJFR%J8N3Q?#HX.)R4-C7MRG^QM\+S1Y^"CR9_A:KV@ J8RM@,QP3
MH$@2?7"S38@#,*G;DW'[G?AVQ,+N5-\NK;@IW7TDXHM%Q-1[R43K Q?B2Y.T
MC6=/7&=(##A'WON+>;D/8ED4OZ5!2:OC7A@[AV?SXN<;2+\3U#O$>KZE*4-7
MX#P/][?T (8=\+5")+<W]!(^,]COI4N5??'[7)NVZ9O?QYI+FHYG?LZ]12"_
M9L0-8LU#$([@8?Z+<80L/$O8X#7<%']V8=FK\"K+&ZT-O9INNMW.5TW3S[GI
M3<R@C>CI/W1$OW&\W"LPYQ+?N!8^,Y7K5=XD7GQ; ]B?!6[9#XG,!-V!QUJK
M#PCO?:?O;?S)=FWO!\WI<'Q,NJ]KF\ \- E18;ZDA8$.A;7:8M'U@L6/.O7W
MQ_P@Q-_*0QJVJT[%^(R[C:Y&X[(RWVYI0,P756V^/EKE<:S<42^RY\C)&]<@
M#)JE[!,[]]+S>'OGZ$$#;_,E?9)I_K(#[IEWI#4?]N*WI2-6)[6%%$EG2_<R
MU8!ZGM$ KS>)P=^1V:\9&>NIS%_KA(CF!KC!T$?M9_U!5Z,^5=#M(NF20=&3
M3-";2M KVOFU>0E0!@UP10V3KE#BJ4+:;X0ARU#NA2^$8<7,CC&3]K?)"3JB
MG&<^ E-3#*-Q'6@^;Q/L5CU4C"A/0!(#)S^0M17S'U7EHH<?I/(-=?+&"O8!
M]2-[GK=/>M3V1U):\5)/SD($->TYJG,M%@\.6;<@7$679*1#,?+/IZ_I<N1G
M+QP;.XXKCL/&<2P(,:/S1Q:&%;-9-3WM'P7F)(&8.*GW=1P9NQ%WNX=-&L&[
MQXU60WF(9LM7GE_O/_M1P/]E(^RA2-3V9!C;.='%@;?X;JQ7/30<C;N"C/H*
MNTZT>/CP#5FU!ME959'X4)='>YV@_TXEF[K?3^31>801PJ$[1A%<QM]HS=)F
M^3C5/]=J(9Y/T?>)MIBBL6F Y.U!\<G!(+EQ<< 5=I%H/@F)\K7.3,6R,W<W
M\REZQ4,;V*=N#YS+.6<.?BV1S13\](&U\>N8"Z\/ /6,>>J_.#%"E"40*24U
M^KN[;T=@>XD0>T]_O#ST>BB&(/!=(=ICSX6FOC,\G?S31AX/D=5;17?03\Z>
M@YF"(I!ZI>Z<6HX#G LQ>RAY)X>"RS3Q3_,"E+LM ?)M(C=F=;=@<0KA2.I2
MQ2!"#M7TE,\-C&$M*[1DRC_ *"\'C-7M659;-:08LQDAI6.<^- 8[#B'TPX-
M"/-4=;75[C_,/6(SK$Z<UOH:3%$)XG )IN1 '"#[X'U0CA7R,4RUQL2*GZC.
M$3'_:&)]LOR"*DI'1(C<3C3!"V/"R%SCV$28&C[FQ6HD7'!12;"<=%C^Q,AS
MAH>.JI>507P^.Q/T1*YCBFR$0S7:G,7KAJGI%L_QJ1173@Y)INC7? Q7'2X-
M$$P9#_"9TY!@,M>S?5P5DL%O5!@ETE,869(C$:"C82]^T&=.1]>W]!_<1&IB
M45&@_.4<)D!.S1Y['C2Y&NH).DB,,ZGLV;#:%SVHE&)8+F%$[LX2E,3)8*!$
M/Y8E$E[XQD?<773>(NMDS+7R)\.Q;VV%+?2$[?62&%.NJU=[R">PN*?"56$^
M'RE5:)>3_)/\D9X1=7PPA;Y-+7<"W:-ETE/[),Y,N5I 9ZZ#0JQ_?)H=0$SD
M0DL-ZT&!Z))1Z/<QD3ZR$E9@Y>3RQK%E!B6OF)ECSZ\,?7X[[7XD/7LD]H.X
MV#G29?@7=55*<(T%#6 -GI -=P<U+=_A0CJ_OWW_A.VS/>^[&BS$I=@2.!M8
M$S/XMA!$27K2 -_]NA0&%.E5)UXY")>JZ>LL'EOXS.=Z7/'(\Z!9Y:?V:??(
M0S*M^U!9]%R@CO_;*?0="*-CW;D2J^;J]Q^BOR]PNH'L)7M]C*I.3_E<J>'\
M&DG$8E/(7%ZM5=#6(V$3*X6/QL/@Q]Q+%XX=P6;W9D^.G3._KW1P1</(Y]RP
M\*L=X/-@T0CU !V:>P_VUFCA")^6:_@G:,#[MM?>4<\'O)>+)5.^, %>[5:=
MT9[#;ZX"RA082I'(B ,U(DOCFEQ5&^JXRM9<3P[ZMXP&^&R5/F7LE@'.+,>.
M H# GMJCOW8$UGIW+%*$+$7/^%7[U6PQI-42IX&<>_?;0M,63+;N1" B(L@L
MDA-[7+XNXG.H!Q24XM142>:.0FVMKL=GF\=9)FO6S\9 ])XWN!PIAGM'W<)@
M Z!J[P28CNW54-Q<)1Y'+K,3<K"U2I/E2<@FQD=<X'(G+UGN9N&5\HE;U=V0
MTP(L(F(T@&YMQ#)G-KQWG*50S2?+RM!=I,Y.R=+E:9_5J.X6IGTB\XG8&4%#
M49EIY/ BX3M1TY8D%@.J[W7:6<I4Z$G7ZRECE?YF\.Q*II'3;48Y@=(08V8+
M'66FP1RZUY^!."PC" A*NFTY7NV,A0O\4#_8*JU1:]U2IH7G06MG+/C>[? E
M*Y8\ #:21=8D4DC.\*%X_<GJF(>3#H$U+*]Y4]T.'W?%*589"@K;9YJ.*IX^
M9%I;,OZZZV""O$C I<+J&Z=%\+':DF;XQMX2G?#>BMGC67SW&!(7[K-,'7<&
MVG'HD$<(IKF*'<7 /(NY*H.ZU:,=K7M#>49;T@_D,)[04Y\:J/V%*H*>_C5K
M'[1#2OMQJ>&+\%NJ7K>PRLO(RP >--Q)J, AE](GY I=?/K+WW;U./D>J0Y4
MZ ]PH,.<S3;FB^Y]9D/>;9(M'6G&E*P:%I23^B%B!&YX +3'V<,MEK>W^(3E
MI:N@E5.2=P2#,LCUP<O]/H/1-09OR+*4NL.#"!=V#@37<)NZJUWE3*.T%B/3
MUY:@(X&J;4\]KBZ]$Z>(TMM5IN36',-;U6>"B2=QF[;XP<@:74\'/Q#AJI2^
M-W5#\_)F? -8>BXW,?HKRU#="4K.V64(P34%0P-"-ERU6E5<YET*AIUVG.\Z
MF8;I@!L/SOH 20=&1<P_H7%7K=SCP +TQ"X1&Q8'TT?D$_5OQK57?,TS'(7N
M[4[^VCJ^\#)*BJWFO53B%SB*\I1Z8)3:C2Z-"Z(;[Z;_6Z,^5^M5 <5I[BZ9
MKN/'J LUT3E#_HN#R\N8BI##H0J1D@RFG!JFC.]X&/2;Q<3ZU"RRQQUWND+J
M"O*@%[[>'+)NE8QT_/Y;$B]6[F#8MUR6+NPG(^-=N+2,O7&[,G"/I",SKZDN
MP%#/V%OT:SR['\H/'Q['77.LV[-X$ 8A>N9)1=<=LW%EO2OA,UGR8TLKUTZ^
MPT]G7ZNF>M@<#8@;H $'3]4=)";+AJQ;6!$GBZQ(*OJX VXK/,AGYVXNGUP+
M;?5&=>Q6&..::< >F!PE2TW_%<RFS^UL=^1.4O_3$>\X:&+X$??-I\KWU0I$
MIK:?O!@::<,#OOE+VW3;72"&Y))MWN'XVU;WMV2QFSEF!5%.V+]+ZYH2E]#G
M>;(2$\%XOU5E?60>1)3V6I;#C \-3BI4$66:AD-H0#A,4XG@7_R>3<RU+F-)
MHQ/@L+]U2;M5OENY@=A)**@KIP%!L?#O-KPXV28K"]FSLFRMA+3*R$.:T_NN
M9+]*@@I\K[Z<#?%YC@V&%KLZL3TM-&XM:<V[9,%,U110VV)BW,P"I2(FD&!6
M^#'86>)1-*Y<31_Q9F&G;/FU9NX"^TSG*\DGU1+M'BT_GI<>4S9^,*BPH5,[
M00&U*%E:M[[/M7!^.&]^@="H_X'/K#QC#U-\@KH90YS$0,5<%E/>/WBJT[%C
MCEF@&(B[(5&*&D>ZZOB0B&PZV)!#OEH:[L.OQ=E2<'PC]"%ER7\() & 4_)G
MW9>&/&WQW(1*W&H8VEGVH,M1;-/K-)L7>8OU NI]W R\Y4URV[9JF<B:(UZ*
MH"Y2-50"/CK^[E0(R7Q>;M'RR@!5C!AU6R!VY+I=L_F#8.11K.,G1BF7Z"2I
M#Y@ ];)096P,WY'K,1H'WIP&-GA/^M" ^KA0)0AS'2?1ML$++EZ#UVZ-<ZSH
M?@-%%#Z+]194UGSQ9K^D-) 8/9CUZ^7,F^XMB! Q >+0A+5AH]BI7LRW1P87
MSB?H8&=BPGXD*+::]D^$BK(_OGZ-9=*A638@;9#,[4)(PZ&CRKO91V :.";S
M+L54/R\^8U.6E7?SHOVW0JV;G(X+/%)%V-<=(#OCD&TT +CAW=20EK:@HCU@
M%&B<,-*!AA\[N%9<]Z*!R>[@U;@64 A5D/AIXH5A(URV]]; V?,7SB=:?3YG
M0CX5\\WZZC[[!B8S1 ,BJ(Z;R("C-C6,L?>%(G,M[2/N_CBQ5CF6;+[P9=3#
M']C]6?W/&'P--.Q"L,?%+>OA%K"-5.F*M1F#WOGAPN/J/;?5]W&$56V,YH>"
M \$)-(#9KHX.?%OJX!YP9!UOL&E?\<GAL7'KRO".GI&/C,N/,R8RV(MSW8#X
M5KC[J.\Z. Y9B@JD 4X0EC@.;^QEDF>N1\1R\6WW4YAAS=:Y*9'H($W1?6J1
MP!(9C&47;J,*]JEI3_[088=>[,^VBK(:<1A-D'ATCK)/+6B?0N6-NH.[Y2-9
MMOE,41SU!7/2R_EW)VN+7I0LQRKWWP+.^W=+)AA:#O]ZK;9.D5('N75>AI#S
M=;PY4TC?7P)C':UZJ^J>I$JT2X;6N38;N(7J([5'I*.1 #F"WO&[U-XZ(4H:
MS!0%$R(F9C5-H ^.+61""3\^:TLJ,>X[6?R<\HUEY70CK(TT$K?XDNJ)17 A
M[!!T/N&#'_-VP;!$P!3VKD:<563G&67Z.$(M<KARY]J3%>L?<O,M?M("67O_
ML3K'WTRKT<UJ^?_ .:3_I;-+:4/_"U!+ P04    "  -@G]4Y[S7R#ZL  #D
MXP  %@   &=I>G1T8W5C<&QM8C P,# Q-2YJ<&?<O =8DU^S+_HB(!VD22<H
M( (BT@1I 94F(D6EBE'I1$!$)-0H2&\" HI*D"(@)=*5%GJD294J): 4(9!0
M0B#MY+_/]^U[=GGN.??>?7=;R21YDI5WS:R9-;^962NA3=$6@1/7C,V, 08&
M!N G_0;0,,!I(YB7.P!86  *  "P @R1KX%C]%<,P-\:;1:X C >._;7G=Z8
MZ'=F5F9F)B9F=A:6XZR<[)R<'.P<'%S<?">XN'FY.3A.G#S!RR\@*"C(R2,D
M?%) F$] 4."OBS PTK_#Q,S&S,PFP,7!)?#_N-': %Y6QAK&6$:&T\ Q7@9&
M7@9:%P"B\\K,\ _M[RPS'*/S>)R%E8V=@]ZA[@1PC(&1\1@3XU]<TS\-IW\.
M,/$R\YU2,3S.;WV?Y;2_@.KSM ^LTI>KV@5M1G R:@\>1[*QGQ02%A&5/2-W
M5EY!7>.BIM8E[2M7C8Q-3,VNW;QUV];.WL'1Q=7-W</3RSO@2>#3(%AP2-2+
MZ)C8N/B$](Q7F5G9K]_DY!<4%GTL+BG]5%U36U??\.5K8T=G5W</^EMOW^C8
M^(^)R:GI&<S2\J_?*ZMKZW_P.[M[^X0#XN'17W(Q (P,?V__JER\=+F.,3$Q
M,K'\)1?#L:"_.O R,9]2.<YG:,URWY__M.IS5H'+:1^JVMFDU6QP@@\>C["?
ME%''R.+_$NT?)/L_$RSR_Y5D_RC8_R77#,#)R$!7'B,O  8H-_,3S@+_%H14
MH>2A//U8(P:HK UX2+);<ZQISI&>GFC?S^]4:$%C9%Z*BEC 'O)&I?(2LGV!
M)<P7]].1)45=$7YB#7^G8LGQ9Q:[[&TWNT/32PQ3@=L&H//PSGF4!_*0!N!Y
MJ.QB-""A@"JY3]*##]& .#C.:H%\&V9"%N0@6!(M<>:$X+&Z;2:8 KISICEG
MOZ7,V4D].LE"8*!_5V6K;+;.#]ZN"78%1=$ 893;G&)7JPI.+Z:ETKQD_O)!
M-I?4@_@S H_:'NF5,&[[1=+[-.O@-S#S;Y8A['H#.2?S7$_H_3PCSY,M;3QM
M SM\-9D:,8S 66U'P6MRB_P+-D0'>UJ63+FGGT!X.L[+Q?WREZXYYVD2Z#&'
M=4#4%2<]04[%$BY-9& FWO/$3IN.J3O!S 7K<Y:,E156=4M43=5Z%IG#W&@
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M1\,TGZ_,I-T&PS9E[+_+D,ZMI[B?,?JR<DMQHK]&^^N3MY&-X=R.1-@2GV4
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MQJQ)D9A)D?@4_!><R$<'M\L_=)!-5+9N(LLR2Q3UK'DH*+KN6V!L->OD,8'
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M&Q0MO<"7%1<FQ<S,@M8"&A#@J]); O*'I^]></344U&62A0?;] ))9H,PAI
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M94<M9TU_!671 B7!5/SF]?E]$>;]8^-_FPB\I=I#_7^]5?3ODN);99,,WXN
MS""53VG_W/?]]R@G _KG:4@B#P:VGU]DUA?9XU"$7?WC0RB$S;+-C+1(H@I,
MUJ<.OQ/_O:.PGP^QQ\@YI,W1=VOCZ\!S+][RG@$F0) &+OC@#<$3?XRQB3SU
M5C%"> F7BNN6@YZ><B)N7:%89QU+6D?[-TD]=I!QR&X'A<[_!"#8P@E"C9\
MWNX?(T[S[G^;L%I.^OY?&*CR/Y&H>D@V^#P4$X43VM'E-Q4;[)6SSF45YU?:
M96$1P_GFDK#*V5)5_[+.LAG$ 3;X50M[DSL>V'D"8'8BA&%V+@P,''=FE/T(
M_WI/6]VK8&:E>YGK3<=/<VX,8M%H[SXM>HW$/GR0'1R*NIC9QHCVF^I)J);@
MNU#(N".\Q6=02LXV#7B/&G^QMPFN2]U-WY(ELA@0>;N6)]*[KRZCL*NU0I\S
MW$@(B8$3P.<*CZ$3@)MC<Y"U%E"#@#J $G*6/;F>-7Q.(MXBI'>HNL]CK_/J
M?$YQOFX1$ZC[=>/AJVW(*G!N;4FZ$T$#[X.K3?F> !(U+^,_I[@? $':R+&2
M2Q%KON0&J;5X;::OWS&TR2$^96/7_J\>-_G'H:;8@VSR)X6RF6)T'%(<69EI
M,>'AX3A>]>$RLPBR*473YC'F)S^[\4>5OE8AP48=F.%R6?P)H#JR[01 :P/3
MQ9>%D&B*")I#HHT350+,QTO/ICB7GMYQ?N[@D)M\L4;FY0L-Q'(MUB"'P'=@
MB\ HQ5-O!@8-(3Q]\ZV6BNHS?B:K" =OQ^]*[6CQ%5VDVC:S[&.%/2>TX, ]
M"$8L4GH>:FJ&6^MDG!AC-V:9-?242BSLS<P)CVVDSWUZ21FMUZ;2%0C"7L*_
M[-0\WX2S#%,_6^,O",+#"],.B@)XTB0,KO1"^OM8Y9*3NK4VY&SA;ZFV+YIY
M13R<D%UL??&CV_ BE>B_Y^/_<QZCQ4S]K_3$2[6V%<OR$&=7B7Y?#6*[X_AE
MP_V+H1=S]?-:V=YQ^KMWI,A]G&8LU_FIDF( >S:_8VXLV.0AF'W6-84>05NP
M&843D@JKX^P3S]C)\;G.YVT_+E3GG0W:E4]LK^]/G#D!=$R#6/9;:#\8=T87
M/)O>?29O*U7O?5"W$G [W#$3OJ*E176S&Z0*V%N8J"]]8!QQ[+:H-J[^T%/1
MI-#U&);A9H&:E2,GY?I92(JHU32%N70H&8/N/3;$<6EEMJJ> %Z#3?%\K@V3
M6^G37,"Y=! D?O'FI8>?40T*9P$<SV41#URHQRKO:*9^-\:M&=;AIY*6:QHF
MN>Z/;3F-HVL-=>V?X>O/5KW9GA..;Y(_HPM_UYF^9!>N' K31WM_@<8]W)P>
M>\:E3&U=3S1[H%:<&NI._*1E!HC1:M/\'*+!E7&CU"XX,L.])T$!P:$Q5*C(
M)-=MJ,GG._&4\VN"65JRP)R35VW$8V/Q'W$WD+0N#PAJ79J\E'$\^R-HS+'M
MK0W?J5+-\?/)<N4/15$-(C2Z;$;G]+9=J$?E=0U?'()8?#;+>%VRQ2 E)IY5
ML5>_/G[ERQ->W",V7_7M+_(&:/[HR%SR"U<.@YFBTR9@V@= -KO!8%\O<K7W
M0:%34FK4'P+K7).)\8J+8S72TN!2"*W7I_"M5T(;.Q8O*P=^:Q[!BE74A/OR
M((<OZUWDS)"<>_*'Q'I]:Y]EI31I?EG:L>#!D7QF>.X*O.A6[:%I:>T+J<<!
M/ ^_LF\OL)_)I2O@%GD<IB68(+_XAG=%"LFU;FDGA1N.ROAM:8!BF>UW=F=X
M9LH8\$#'7 QZZ)X:8A+AEI4R52%.X,F9AX*[5>DGU6]+JIOXB_Y<Z2^QH<<N
M'/QT7UEHN,BGRP%=2;ASD>K7_.@0)+Z.8)EO RUN7Q1ZN?#8#NHW96#P4+=
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MJO*UT^JVQ9*+WSS4C<\_M]/UU2<5F@O+AGEDEE.S!KC@] '['YE;@59JTU3
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MV,HBW;?T65I&4):AQL)$\7F3PAM/1:C $H;?Y8S4$"W+16/%MYZ7I@M;H2#
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M=0FTK7@KA6_<AXFA6T->=_RQ <1 Q;N"^ZV]R8M *JN]_^ZS,?^D?]+_8'*
M=G3S*H? Y(N@D9VJ<;Q&\06WIKDLTZ4XA+7D]#61(2^, )M:G(H[;*YV7..#
ME,HBJW6E6WIH9>7*Z[([_G2Q]5$\3Q_G3KR1T&/M$,Z'JT ;,54G )RI\6RN
M-L'3:QE,N$FY,#>O+YJ?:5@19-S_ZX<PDWK8]M5>+6L>H;7]WQV!- 7A,-!G
MERE!SQ]51!?LX]_YKF"'*^;S6_J.(3?$%:B*_D^<Z;49[I2.6N0GF"R1[W0)
M7I\LV3-D-([KTUCH>$PUH\5?>:'5_&SR<QJ?R2-+XHMGZ>!J6NS1$GCF>.<A
MPA 'SSHX 7A&\-SB$4L#5O6V"C(>B;+),3,JJ6:%!#XM/P'0Y!'N.)9IY*>'
M-YD7N182@ZN$8^@Z$G>NNPNY!3>'8<%6,&IR/A)(&4/RI#S"2=5DA,Y]LV[D
M>=OE^ZSG8[)\+VV63*_Z$LXU#5S1TBX!I.Y!<U,$H+Y59\.V3@#.Z<;Q,^G<
M_7JZNPN'VPO9WAFD<O(GS0L0$.X><-:Z':Y)>%EH:[A48J4+W1++VG:9C)R]
M_A34G<ES5]Z[5\-4A/H@+68 AXJZWO0(O2!M/9[_>X]\=TJBWY46?^<RK3:A
MF&'\O_\@Z/]#UZY^-H N_C&4^F*E&C\-=9'XMX]T.]*7QK'B]?7O);$?=9,?
MY3_^$O,QS<%8"U 6V>+*\KH6@3.)!5';D&X0BIQ. /22.ZMAX*IJ7?: \A1B
M*^AG+H[#''<.AWFN>*"X N<E%"T1-SDS>CKA_)/N*]5UG.-?1XPO%%G8]CZ_
M>79/8W.W8-FR Q0-PAD XVA[6E@R=CJ#::OU0Q=_#&PYZ$B^HNG6W"P-]E?2
MH-JFHRV!_PC&&<1S$MM4_:,UZ6<T8S$LS+,=P /?IDQ059HH0(\OOE;81>T5
M7Z+=<X@SA?[WJ<(P>4;7<J(8X-?ZR>_QS /DA&[*3U@+5NZ]*?]'\EQ2G"/A
MZ!<4!(;1$([0++-JK4JG:9#'I]JT%_92[G/17U=G&;6O'=@C<C;D)%81<RD4
M^F%GHLZS&J023F"A+!Q^J4O!81G=KT.S<0[8]"*DXOL';:HAF8 V -!SU*:E
M \RXH4F/8W[U<>.8/!VCJ*$Y*KFM&#OR"5)@$HI]=0*8QB0;&?K^UWS+ S/O
M>VFXONOQ%2H3E;*_ /S3IY#OS*D=E86W "E7H9&M&31;!PTU"'G16/"5>-^'
M(W#\TAKAH?+W'Z):;KZMM$PX\,' )%(9O@B7(T#L/=S4.="V[!2@E Y8:?=8
MHO'AHK\*VE+N4Z$&=_E*")+K=%7O$I0QP$@01Y,D49] [R2W#G2.?9 FPG*@
MG^,Y/[2YJ&2Q.U?+P+)8)DA0QO>W(RJ&21<S,4HMF/KMO6;>EPL0XT?VE0$/
M%6I'^_DNFC2ZF@WI!B9:D8&X'6P?49VD5YXV!8J&\Q'5\5L9<U;OK"2*0QDJ
MABZR)7RD*%"U489!.%/P:R 7C,_9:SF8?7WQ#/ZV%U7PYTWYJ$N_:2TB+-1L
M64R&T%ELBTAC<H.F_$,X"LP%%X3Q$-0D"!&S8[L&L8-/58QGPKXQC)W1Q?";
M[%R?/_.0*EOBU\D?<W;:3E-FYQ- ;. X-/86X@$.VSPJIT\;X;D,N<&=E:;C
M\T9\E Y\$WP+_K_:^_)PJ!ZW_=$H^[X3HPB%1-8LHY0E21M"&;*ODUV,&;NR
M30BE;"F2D'V?R3HA*4)&S)C18IG,%.-D%J_/^[M^[_O[_?UYW^O[N=[K_>/^
M<\XYUYSGOI_[.><YSS.Q"VK"#J#FBL[EX=YT\<[=>)\8LF5;=-+MIB<[UCK.
M%[BV?U.<XP=2D#I4G80X\C0FVIY?EW5X6,#LBY'R75*VYX5\0D &_E_^_>G_
M8[G'=D'^6LGM* 4S 2"]SU%!&4.MFWDN.(AM#*Y6_#Z6WWV6$)F@>#_PH^96
MH'IWC2:QI[V8!,7RA]7JD#^!<QTGSH/8X16 +1DUQR WQX@-F6ET 5:US:EV
MP4<>NF!L?GEK\2PL-[)/"'YYDIB&^QS[?:!L?F#I9[I>2OL,5JI'YDZ0W5"E
M77 M'G:&_%/BT15BED?:NZB^A@C64Y.;5#GZ#Z 2116T'>'*;IGW/_(1 ?,4
M'>-WRBPL_&3X]<&QI(&?3_2E=9(0C^G&K KD$>1;E.PZUF<CL\N;_OSYC07-
M^M2X?:9C\[6B2C%W1_*F::6/T$\2."YQ_-I>)[Q ?D U2U$X;BW* 7'UUP-D
MQPES5=3>Z8)!?:<?@[F2W]<3\II"CMRV40Z9V+CX2&]\N"10\VL7WLWD_)1K
M[89()Z@I[<U[(1F<8:WG<\V_-^7,(7#MK>Z\4?W/*MNXZTK^WL66O"]>\O@H
M;X+ $ZW(VTS'75!2!VR<;&=K 6A2OZ$4G/W?.=YT\RJ9O"3(]^SR\249XP0?
M)4,N<8X=.]@30OLL4XRT[3(-(4OU75>>- FM[NCIG8SH.3,;DAZ-#Z9:SN&N
M5&Z0T8\WXJ,9QYAN- ,</*D8DLV\O.1%S?[Y4O9ZD*A//H+C=3YBE#<=?)O+
M1#A\/)96+M0/_UPZ.[ +:MFFE""QLNOKD35;"_I+/NU8GW8#J;>-A^^#CXK>
MS[G]++P;% $)8%KO7;<.0H6F_.L+8#\HNU>^+B."6_U%=Z;C;ROONQB_K#LQ
M/\;F>8-4"1!#7 0LI.CV@]95KH]+=&;.M=F=,2?^H6',,XB0QU'F0;[)(PQ;
MXDPZB<#//$Z=*2+W!@B)Q+3-C!_^%&GLE^5ODHPY.0(&M<O=504;@A0"&8I(
M'$:2E=LC8E;T[/P.IO>%P:.:M?!RIPY%YHO:)\H!I[3J;50P"?\ 'OX''Y<F
M@&,H'%R2J07$$S=X *@#7,@-F+@2*%=RRT"-:EX!/H:EAN@<O^Z^9%\7Q)Z#
MM$]/K.?3'K\I5<!0*SXQC]8ZC]RI"5!7$PM>O*3!5]:3<L!]X)M@N7!88!6K
MRFP_ &7S"C!,_?.!0+>V.Q?UM(36<I,^ODKQJ,Q%4AUE'*\F/0-G9>W5U"@9
M++$(>9Q5S%; #FZDH40V6B'",;'SE-G&^?Z@*I%Z%QO-92LCWIX'(16N^?=;
MUR&-#91> THJ=1?D#&B3ZV+7!J B6A%SP>L(F^=- T=6*5_O>_*=RK$&\QN(
M9"RUE"6CVJ^5<G4">K6$%7QT0I;**'DHNFAF\N%Z5*J7L\6?(7TO]_(@?B]>
M$BIH%Y1B=@ 0H_'1P["  TE:J\>?ZW/$'\L2'3O-[W-9//"H?C.PT9%X:4]Y
M 5#\&$,4V6\&8>5MQO6>6?VF)0)L7%J0GVE]_1+'8R3<7_VS =2X:O]Z'Z:P
MA[I8\")07[;W_6/_T)<K:X?Q;B.\+3,D<W!*F$Y%@DS?MY9#&K?.D 6OA2AL
M'?E[%+]VU4Z^1TNCOG$PX=_]5Z?>KUU0VBZ(^!S"T7..INI(]:?%^A?I7V65
MRE_9@6I=[/48N'-UN9Z#K-6BH%\HSF'+YLTD!3OU[X(:X=G/)GWSYC:46UYW
M%BHET^^$B'A=75^-@EQ:OHHB/E20H9:F,R# *<; Y3?;L0\+X]U6Q.\TN?$X
MW_0RG'@+<N "S'%N\;])7$E,;=KO);?FI=H_P5LH 2!II#PPTUGRVJ$TQ[/N
MH07NK[A_/L4>84J1-S()U/-:&>V+<C2%_% 2/.U4P8"-0K\C_H<[AVG/P\-&
M"2!=WWHCMF2YT PL>Q<DHF4FBE"FV6>]TK6BB>](I!1]M\OP$#N?F_W>0ABY
MFA;RA-*@\M?&]X#,#?S$DF0%*=BM?\)V1B,R+E.&$F0K76"8!^FQF2A<??8]
M[QG1%[S<@ >S>6NJF & ;PW3##A'W#O)EYCV(7W*\S]%E\K]E!Y%V7S5N/AN
M4L+G4DR?$25CIWO/$S)T"<AWT&96:6:]]"YH276Z7LYA6BFS(,W*P2$=.GA9
MXK2I00A.NERHZL<_@/__%^== !2]G(75T^)'N%.W^Z%)Q>>P.6Q%VQ?]Q4_N
M:,)Y]_'-PP]RJ6^7&6;YFK (K>M>Q8&&RITIKE]TU&UX,=0LJV-R8$,37_D7
MX-_;]+>LTD@"WI:^#M@O4<('BJXPM=&GNPQ<6H1:0A3"S_,E_WKM&2!AO=QH
MDD5^$U'B2VI@BL+(RK%NM?0&283$S,]'N45R*E<3O+)\A1<4^0I,#*^NCVUK
M#38 :@8##>G0%OUDZH.!^/K5[>9,6\;XL9.G5J8P)AUSXF)*HDCWLMN>1LM"
M84 #M6P (LODJP&LAO!>+O7W7JC,9K]9D!-TM)Y_V55JP0OZUG"$BJ+<H<K^
M- 4/264OP<3G[L#PQ0?9YT:5/,,0HU%0!R_O"641-W6&[IYOTT'*(-^[Z:.'
M5N)K .R@Y*N+9?JO#_]ZU:%XRO+E216AQ5NAZ ='Z_/IFJS,6ZS[FCVN<*XL
M/2T1US6IO31K@RZ"P_?19+0W3]Z__8L?G$J\A2DIYWS^=V[=,U6)/]\9SJ@^
M:Y-SSX%?J#1H\[=$K6RFA]]Z<2JK+J4X:7"4VX^8H?$GJWK#:+\E=]\J"&H>
M::<_ZSP5LLGX?.7;^U65)#\O&2=+3IW<'Z?U@,AGR%$W$!5*Z6U@"@(%K K_
M\K4KNF9RLYHAG"==6SKC+(T3G;Y (\*X">A8!I0NO)=P4X%*LM1@;4,J1++%
M+\+^X+&W]*O/F_&ZXZ(A>8O7(04/CG4O>QZR?C-L)P2HS[YYM-4  N+(4NG!
M6<A#5,2*!&6A!X5AR%GSAUA_%[EP6J$TL,P%]$>.-)N&5-O[V_79:BNE<D D
M+64M;[7N&Z[\>FU+@C8?!*\QCXA[\N0H5VC?L/J*5A**>E7 BG2QTY]:37;J
MZR[Q')1-Z7_75[6R""\=S+T7Y,OH@-Q))J<97E)W8O.$,TQ_+)HU=K*>(CSK
MVK-[XFL(-ZS$%B$G&:?,H[K;8M^]H<;P9E58Z>U 5-,V'[6^T'NDVVTP3<Q^
MFL&J^_#%,CM[M,GS-A=84>&V&O@1%=('22_C#ZGJIJ8GFA@O!=:F[G-N*3G&
MYW]#,.-=!@]8-8N<?W/Z7S\1[3\ $T;UG<8&-D@Q]3Y%P%,@?+K!9WZ3[#.5
M+N_?/'%"DF8LKG!:*?"\-50_5%K&9'..U8(E/EV49ST,P2Y)4K=2D-I ^N&T
M4P%OSTJ:)UE<'"M<^'!WF(=+N>% 1]EG')M7KP(Y!15]U:-.QG*ML.6 Q(-A
MV9!+B?R-XP4+&M8WX*FC]:$=:;QWWH(2$.'E_B@I*+$0=5 7*QG3;M%,D\QN
M&#[<BTD78U7I'_J6K>K1=?13WAW#^,X_Z4ITN274$)07^0$F4&=BMZ1YG?"C
MZQD_)KBGRHCR.4E6O^]=6(WIJ20=8]EVFNN2?1I&+T;J&A6=&?%YRU3N4A9.
M.>C$6\+ 80.'2),TA8(_>B]^H,11Q'R4/+EW<O]$IIE$3,:2AXA( <;\M,AK
ML,A-Q?<S!T\HI"1P;%NM#^V".#>I]NM+-+%!,WU&_&PFPB(N7-V_O;@I/=\^
M\8^BMBH"I\'?(RIX0F=NIZO)1+-^%]1_>:E7ZSI#X%L1?<WO)W+HQ=#7&WV]
M%D&Y)W]UO.>FU\7NZ>_?>-)R_PG_1]A#"/7RGCQ>3MM9(V[TLT+XXAX1UEUV
M0?=$S]0&=E#\E.[[2G-NY(;GF'_7Y5A'4:_ LPG"/48,X[V,B%#^%:DEL"IJ
MZUL?4V;3(3;B(:RB4_.:6?[:R__DK]P<GK>_T8 *85 H <*-\L$*Q\QHNAEK
MB7\^JTSSGJE-C)&#*M^N1_H]?*)XHQ#>.R&Q^7T]D*$'V!/MWQAK@L]_(M-2
MV[I%":NG,NWHF<;?\[3S144OG74"N2,&"D<:WO^EZDRQMC5BR=;V("I=-J(X
M?6#.BV%9\Q374:)1.&+(%=JNO'6PRC[$G$N@@HTO54BFXV>A?L'A?:=**'GW
ME#Y&,(PD-:M'&#ICNNE)BS9AU\"_#3='&)!S>^)4AU  *,\68^0&W01I#O=H
M_)K/6Y_I-\)X>HB>QRKD0J$&VZ;JLRB/71!>;,F>HDU%VW_81 O]B)5LJ,3C
M!/:<X/Z>.,W^!,[[-1 3*_3C%ZH"$ZKSFV5SVTNER61NA--S)I0Z\XAD;<$Y
MK='2X5$2S2_6>2W,2F9M)L$DG<['NO\3ZE66WO6^+)XDEQUX:68#.:L!/AH<
MDMGI.2>SHJ2R\-W47%Y<;$O@'R *_R$..FP"H066"?7!)AJ8*5*1R6;/7]Z\
MJ#%<\S6]?3(9?._KC>4G1"VY,.0M0ZYG0 $C"'$0L*#I"W$ S<.2.Q>QRK;*
MB1_Q?,&?CS5;E]_]G"0=0ADYW.OL124,"7%C1G0)XC&!#@FUXEZ=K5WWTI64
MCHV> R%C]L1>@\E%[?_=7WH8F&X GA(&":*.-E4S#7I1GR/TE+N-CL=V90][
MXA8O)\A!3P%3]%K@*@D&J(U7#[4GK9VGVJ>/KG=.:5I\"?C=GU6K;?] 8)U<
M" W3FU"5@%)HC - ,MVG9P;A3?UF=P:6)MOT)S:[KJ6N^R(_\:X/B$F5G&^]
M:ZAXX#LGJXC!_P/2#*-P4/GL)C>U0#'(0-;Q14.].BVGI@S2EJK2 :?<HHB,
M9=&#\2<ZWH!6F*J[H/W.K!+F9961'KL7?GMQ<SE8QP'RQ .W!KO&'8&6\9<T
MT'&=7RU&5!F/^72DZ"Q[D',M!+F)R3,]2A?WXC26/;&CA=:=D/(G"&FLMP:;
M>9A<'@@U:CW.P>ORI1.=%&;F5N[T\1.HY*C?W_EBY"5DOAA.+Z*CZ*D-]+23
M=)@1XHNGT=P3]@..[Z@67!+"FR9'1&<PC8D"B!CXD--,E;'K5,&$D=]VCN=Q
MG6Z<^I/94;;8WO5:,TW1]+C\?J121R#VKD&.5A7-RTC3/[H97B1,; &K'B/$
M,+_(=R,9#8^14.0B1 #E6W8/(T,UZPPW93>_O*$<75.-UET)-32[T:PVYOVP
M2EA@_GI[N;M0$M07AK<E<3'%T*06+!=&V^7+%T#0>;LOLNB^<Z7H_ND*I>^)
M=_]42O=],1?H,%C+*7CIQS:D+O2R4H>JVBL""ONMJ^X5!L8]O!G&O2KC;+_F
MYLVP8[]S$V:]9!^T6R*(S-\-^72GRZ?Q(&I%4DQDH#ZTP%1&B#,NP8J'L9\]
MMJC%*L3(K9I!:+Y9A$'[T*A)EY6V=9?1_A/O..Z^)CPZ(),.$ILR4MZ'2B*\
M%AJ )$(/ZDW<0\JV=V30MV0T(H8]Z,$GWZF^_V6^_H8(WK8T7X-=F+SRX5].
MZ?^#!Z 6IQ%4FQ-37&H VC2T4)W60M'N\20SI@44LN&'SK8[+LGZ@)XT#G^Z
MW,$(+?6DGV2U8C20'V'B6_;\,=U+%]Q$IX*"D MFY>>&NOOKASRNY&N]OU%+
M3#(C*WSZ]T6-GD1(&EN</2<+N]=CZQ^W"^+]C@MCO=P)/!HU%FPP)C]U=E"D
MDT^C[[IPM,C4LUV0_%Y&N4N@VL?S3I%4^PG9H!C[2\7:\* 01.;CM,C1W! +
MB]O==U1EWG"%J&\JL7DE&&98BA!#+W#'IRR8CA;Q(]",)AV<-'Z?K>LZLAUQ
MO/)+'3*&W0?EU-H%A4 /NJQ")$Q<57J7T&DS,VWZ&)F.\&\C4N-?A\W!(D):
M@G,:GT&EFQP_8/Q08@,^X_I\3!RY86#H4\2XY2>>+0$=@D=GVWUAY4#GG!&1
M])NO.&3>4-QV00S]OWIT>F2(L)S",CD3&9(\_"*U;JNB9[)'6T/'>42H5-#S
M82/_AX33US^#2SJ5!9&=-*[^L@,Q]02;9&=J/?JEQ3-=>#4NTELN\TR*^*\^
MB)KT04%#B1E!-0Z_OU7*8?Q8K="@,=3G;5MJY-9$ZD^FQ8'.%ZT]DV=(NDG2
M;W0\T,[6'JWV7(%AVN;BNR!B)4&NQX*J1'>;B<3RW=#+:4=%'R@0^"54^LFV
MHR>3/?/)7>C6&WI#5O">0=IF'P<@SQ'6U/;!3(H32;^RNJKCGAJ?P+O)PV.-
M*@(]9K9")_+S+$-AB)CN<\ =1AQRO"CJ%/)5.UMNEB@$1\&3]0I&W6N\H5%[
M]5=9Z"+F(!6^OL0(0^QKQP#>1,W8_NT^ R]<8%WKU\ZT87W-HJSS)C]<N0K.
MNO.,+O\VEX022U'4RQ1'>^&571 /4@LV$JX[F:FI.F@0Q%ES/*JN=0PE:3_:
MI!">$/X$7<G^:_N2(?,D]3L]G:8U!!,);"\U_'1<RVXQ4Z&N,&]\?O^S@F;&
MG/C7:T00R/ ]-]!-_P* J>U$W'HV]=O$!5KIXP:$S8<MF6 O3&.GC0_VMW>A
M[7-OQ]%75U@S(9;<)HT-,T))LRY#&_V0_3=BDM^QOQ2=:X[;,/1@_N:5^F*L
MO_Z=H,N!G_SXK]]G\9]P,V5<04Z60E@%;,D)LB9R<NVRP"EG_/6YAO%0X^54
M#>2U2Q+W5%__-0@2 F*_@<Y!1:'$"HC,UBY(]N$&T],_//YX@00I35MG0?I)
MN5):CN+=WO[\%=SJ!B0;:<>>A7(PG9[&C)UEU:%\,S,SNS7=U+8>?XYXIJ77
MW>7]33MK(\/<.C>T;R%W!!=.1 &:L.2)9$^S$U3+5J$,4F90H[^*:DNQN1G5
M]_;'I#B)H-AB$%U B/YM-E)H?A25@,>F:D9HJAC^U"1UY?D4DU8]>+^</I:;
M>ATOC OA^3-L+WV<5;H+<G_$WL^>630%*JJ![#J$YDL>RY(*5XXBJ?U>!2KD
M?8;+7.Z7\_;EQ1SJL:7+ K[D,KPK_<4L*D!+P=^N?$6YZX?CE5KPH1-_1/YX
MI.]T+'%*D</;S!G3.Z%_<Z"PTRBVG8O27<D>8\O(FN74U"/.3W\8>OZ#)C^\
M;R!@XE@6L^(NOO=&EJ"..=>T Y6+*:'5%[LQA!)E<E*/E*5OP#?E88/LF^SG
M(<^>'<D*3=$P6]'NV<C/4:(;[A#H=VA<.<S+5'C_3ME@G0+A#*UD_&GO5DGS
M,IBI,<84'$M3X\';R%!N8"FG&2XQ7'1'*KWL!8")[NSI[3C;,AF4U/LI\[Z"
MPQ5+"?'2BSJW3Q6#F-]F=5$9952;ABP8/O;D3:"9B&D-XV\T/'STVC+WLN&@
MDQHV,@V<8.PE] F2M@L2-SG$N( X>C.\/_9+T2G]Q@"JC>:#;W+=!EX#E1)&
M&=<FB+<M+07\5HNMDE%^]JFW%MDSA$$,/^U(QH4:'>'F_E69@^"D5SK<)L+F
M&S!=)([P^F(C0PWA3LMI]""OU4[L6^46'3A]KJ](]5!]&/>"]!&'_/U--K@%
M10FD\![75=DB3'4@5RKS)WQK0MHVT*#,UZ/>AF\>=_RTJ*'UI]%12TMR3MCI
MAM8AS7]UM\9_HN!]3"W)(!7!^]=<$?1@U\4D'YFL *=&<UB;>93,=WGUB5U0
M(#QGC*'/Y*#9Y\R(=WW2>'H]2'/Y_=SQYZ$'/;!S^]LAWGI_?C.@J+Y3D>AY
MI?XZ6B99"]V:6P-4&SB>^'Q,!M%SO\EZ\NBE#G"07_E^<.D;\":$C*/8$!L2
ML-S?@414-*N[ZB3W*_+'SQ=#OIJ*W$1>,G7..6!Z6^C>+FC@+&)/2)/N(J1I
M0@,_6C^WU 4ZM'EE6LW<;>MN[X(5RU0:J:O,\B+/A'%PAF=LPQ++0$QMABF3
M9](,<J#M4T2=V32V)63#XUK.+T>94E]+#8GKW[\J$]V]R'J_?8>T !7?-RB\
MW+FR091 PQ(U>W-",?DJ]5U-:%7+BR%I:7#P&V\ED2;W9/.##4S1?-+,\Z4R
MX +6%RT]/..F0DU=_NU\3@7IAQAO'C:->AN==.I5)Z68876%58*4"'0[HG 8
M"P0NJ5.BQYVQ+?6ZMO['3?I&.\,>:7!S*O3P,N\ V=1*LA53#$N>34*JQ10Y
MVXOA61VN*JT"\Q?@=1_WC02?0)5$FY_/6A:H]/]S  J/,+TU/RA[O.SE'(9A
MNQ;STP-^+9*_^M?AA./*@;*I#KPO3X"D]Y7]G9BP<>-C.",_NPFR\I@0R<KZ
MD&F]-<I8E9]^/>?V!:Y%S_=O^X:O)\^"Q,PE=D'!:'PBUAN6HA.3,76N<V:K
M^P^FKVHP5SO):.[B[*.$)2MIMU<Q\F^9S4 Z XJ<A JM1PCA'P]JES@-ZBQD
MN_SD>[M_:.8AAX+%.'@?9USHKRQIS(U4)302\-RK9O;.C+TKB8$ 4U2RW213
MJV9A>*9=?^97>A/LA/3S0J-,GJ37CHN)W.KW>_<C*\<%,#6W:-:Y"RXW+!TJ
M(_GSE/B%3Q.3!$ (%D../8>19-69"+8[9DOFDQCB#M,14@^D[KV&QD&B[Z$M
M*1]^S[['_-4-:K1)R(*U5@ 59+C80@RZGP\NAUOJ[K>QN;_DP0_:]R6>4IEG
MPTE6P?BR7D,]A220;\U.H<G8-T;UKW1KC]H-T8L"^+.K0Z!&?,RH5X;>1GBA
M[=M.FT)T.X""8E@AQ#XB E\ /K_[MXMLOX[ (Z#1QFH<50FE%RZ$M^3.'R0K
M@V<I%%)KDJ%']JT,/>[<IPDO*Q- ZR )S7^09.R!XS>4*6Z_)%A#JZ5?HD5E
M/SVS?6JH*+_6U=4RM=@3_#/BTJE&-%*;L*_'B<T3R+@5$X>#\D6@4O"L91>G
M+*813VMSQE)*("K@5=0=KU(O\S,%:PG<&^@/LH 2O7Z/[8X_(%+,RY%D>+KL
M9 S?T*SHX\S,*$M] YU21-_KGXDCRTU)/!-C^<6@;?C\XMJ Y"ZH"3K82G/X
M%#5S9>6*9MO*ONZ%++E(M&JA3@IY#=\3Q^;>]GSES'[[?N>A=TL';?]REY^W
M$@OB=<R:7%'@TW"(ZL04+2+!T7IK*L :#;DVZ"8W]=GDE'?I\^AXY=*7"D0.
MWON@T335TI+ S<I^,[%)$YZE$JT!_/Z44V[95:[/Z^J>=U&LR9= X%_+I38C
MNAR_<)1.QF& 3&^C12=$>-,4BIXCM*?JL[_5<B=B%I5!]<M!!?%OG:T6\-?S
MN[/B/2M^T#'R'R-8QX:A*J/#B\9^2NQUOXIK2! O]F_Y+2.&!7(&(HCRD;NI
M )</V/!7J34H" X,Y"D-J]PX?RE,R4UGD<A?#%HW.Q$SY@A$4[&#&.4/FWQH
MB0"\]X,B??RYFGVVA9?O5WZ.5 PS-^0D.GV%K*O?64+/\]'K9GH":=UNZ&NT
M\;;Y;+&!:/^O>+/^B\)B28?)0:9_/+L/8!W84LP JM9PB:"F:Y^"VA3"RF=5
MFI5WVQMM0LD[F9Z-G7,70&COD9UK[ZY'C9-&?F(T$ JM\=#AJ.6%@%C+TF&Q
MN,1\TXX;P6735H2U;0R5*Q/5=QWJATW?R_>8PX#5TK>B)IJ)%H+R"D@:=[17
M,YN.\[O+&-J7-Z 8PGLJ&5UE(K]W^"B 9WG./UJ==%,!SSVSO[-K*B5#XAK(
M=2PJQ'Q=( ;%%$T?AG*V:FI= ^)(<)Z54(1=5ZF-PK9;DC&:8IC.;,H:%1P^
M_63PU*\O3\@4N"RJSPSEBU6P%]\F\&T&\E0&][5XQQLJA/]6YL\88!']P--(
M*:8#M0@' \\#9?T&WUVH%#I +G6U<1=UIW@T77-4,I(9%HB<H7]TGA_B%-$X
M85FAE*/'^[+<70U<OJ_V1Y=>>KKN8U,MV^9T^ZD@TG5-2G EST'K2MZ_!$'^
M)>L?X.7_RVN#0PQ'Y(R;,"L? 6;UDD1G=^H6@<TZT87^\;AC661E^=RL[$EW
MLA+'/5!"7"0R8$^NO3&@<9+6?B"<]+[(GWZOQ\SR<6WP05:>U;N+BV/J$H:[
MH-+*Q0K@]%X$2++*D6K,:U2?/#,!_.>8\"&I,;AO=&3P'7X[R9G<A>/7@\(:
ME;!\;RT2814P$2;7<^8E*N2NR9%7N&\KL=,/VJYF>:5&*MV>H.T[K4"\Q+6L
MQ=0V*ZAA3[CX4OBHKJ0;BYS7U^V^LDM>!@AQ-Q5""_UN]:"%"FZ/5LQJ%BQ?
M0_VUD^D53-9,X4=;M(+AAR*25*HDK D5,,'3TK%8?E*Q\YQV=ZJWL;.M>U9I
MN)L'M9IHE<5T8)Q&SSD-*>@_'EB4:ID-"?D9+%V0LVI-'LD3Q[W[=4ZVZ8"Q
MI6TDD;T 0(D-20@AZLS &UE8>I!5RCI1<JWZ1G^SE2*X\/X)XP7TD<?*>78@
M!+2:/;)7O&*)Y<C#U&T<B@<MBC!-LJ7NC#]VT6Q>O7(6?.=^%_8M@UJG(RHX
ME2 M!GMZ^TP;%2=:>"Q#7.H6+L=(^5?\N./'35<AP96H8I\B[P,EU2Z6K^?Q
M+L-*&<I@#@?S-^ /#CO_\C?*_RW=*K]JZ6T=4R;.>_%T'? LCZ'B5%."B:\S
M\/B- SRR%DHOO$T\ON.K3:,2856E9K3Z1U3"7@65T=I>;*ITKJF03:G(>DM2
M^]0M7)EW6P!YFQE&M7R\=RP+0,B#!E]Z(NJ/$C51-Z&+^C6??^I\RYGOV9$^
MD-EDDQ(XJ[NA \0ZE2.>IINC>^V<M,/E!*[RABQL"'0>/8AM0@^B0'YMB]*-
M90,N9)SIM\[(D\W<>>[M(LKNH/H7#NV201LK0P@"597-.UZ/D)MT?8,]R(34
M$=:*%1E'/VF*B/YIHTI^.^K,X0[-.O'^P.D1O<?T!JD]@CEB_85X S[&N)$'
M4%PF2D=_A\#-X'K1Z;DRF+4QE4&[S/N9>?8ON&90"ECW#K86<L8,#'0^7Z,L
MI4Q.*\^8O4VF2.G,=P2&RRAQ/!3-&2\KU'LS'H_$M*S^_^O"_F=@8K8U$R[X
M(S:M-F9>8SUXN>M1KXAX,^2M+*B:-"'KIP">=+U&4VFO_G$J[+5%=,V-9R(A
MIE+APCKQZD^: 0I1WK5?%G>O!2WACU'\N'G7)6XDPCEU;;#<]T%FN*]\8S[L
M(80'R0]4LWD[:>J#!!&,(E#\>V 7)+09U_9Z<K,7ZI]WQ%UN]*ZAUQEA2[<S
M/#Y*K\D;#7/J="TJ>CVY&L@C#$07%0\-MX;EF574'(M_[G&6XY!&PE&.K.S[
MM25$SZS[0IJ P5XXV@'JM*<[>Z77HI(_4R!4O;?G,I!Z#;]H.?CBP.F",TXR
MSB>,%"4;RE"^F3A6RBX(;FJUM)QOH34@=$].^<-&WLT/)$O/@-&!)(>Q-_'1
MZA'#R-=  ^,(^SVV%5E#LC5HF41GKLM<O3QMHA5ZT&FF"1/U*"HIZ[L_Z1R\
M&U:*:D4SQ7Q)JNL;Q$<FKN7 %%L4RQD3//[N<@\Z^$Y56F[X8:L\;$R-1I:@
M9=0'KG5H)D8,4"4)##HIJ%+3TDDR)#G/HFM3%1V1"HDE-OO:-TL4!LRG@C<I
M.J.$BU.4V;&TF<DC&6J?(AS.@3C6]\=LKWO2FNSQ8G0X%9X5LBP:,.4J9V=-
M!--?7,<IB4Q]4\?FG"#U8OX!&]W^&S!(JTZ_.L06FHTX"AFSN])/&GDLSYG;
M)+8+0CLNB'/\V;-EG+]9%;-T(Z"!M)&(DLAGBS",Z^SU=PH^:.,"HRI]W]LS
MFPK.>L/*WQ@->"%; F*'"^#E-U:=MML:?]2&3-E%Z[Y4%*:,^-R*HN"0!;]G
M*?$,+D"*WC(U1/D-34?XPX7R?4E\U@-M'T>??5SFN20:\U;)1.0#,_'9GOPH
MFQU?<#V]=!-.3IM(IXT53M5Y=1>:)C;_FC_)/:#0&V/6PL'%%#6P*;3'VY,M
MZY:R1Z@KP<MM*1)_W"Q[%OR3T4NIOBMSN-;XCPP?!(2&PZ$3=\J23(3J_6/E
MAVN50V%MU>".XOG;&G=745$Q7,:NBN[![P/K "XJ5S^D.7I@'L8=H]-7]^IR
MS\I/%?>IA7?F AIUP]<3N Z"0" .MP)SA9L,/2;7)-:'D!S+E=!R#__+U%3F
MI];-J-;Q@<8[RDJO-2X>N @"M\9F'_F;#;/_B__%?Q,D! 9I^#[E*<.</6O2
M?'#_Y1'E3]._=D%,\7"2SW/J+/T:3?&C#\.LF2133F6]PD%5\3"O:L5EB)I-
M\N=<<WG(@#W^#(/T5Z/FW5V0Z*N(ATY].Q8$5+_AY$D-_!/]7.PCXRU>]#&=
MJ@-GLDHO'A!:MV $^D/:A%*V_,=3W" TRUS]^7'Y$'YLIR>C,_<N9TW?51QG
M7!:]ZWM2$%*6_386EQKQV9%/$]+G)'GY:7B_\PE5TQ$CY5(;Y6(F 3 @"H03
MR]9KJ;[T"B N8%86DZA0X4\:/Z;]:]7%^=//9&/(-1 _.4%\%\2E"*F$M6Y0
M>,(9V@C)7MIT6Z9DKV;OU]87S<7AO&7Z=H_;]YN>7''K?KK*Y?AQ7<N9,SB<
M,UR<2S'D4NC.[ "6>MG^GJS4T :@B@<&!IP:"3^Z6NF/0CE?]+5]NRVKW[?T
M,5E=Z]:SJ(9G&"4 1M+*Q CX14'X37R#B5#1]=;[J[.Q"*>:Y;LY +-3HDCC
M_.\<;7,%["6WFP/5^(G(\&-]\'VZ>6]Q'-?X\^(3)&@XIAIJ_B0[)_RO@6AF
MN%U0EM,+IA%PE:9"6(I&(XQI8R3OLAQ*9*U1W?ZMJL<''FK4*7#E!#W\:'E[
MOMW@PB6N0K]=4!M\:.^'9W9!@] #&!XK4EEZ6]&5/GA= '[2V>XE]XB3WV'O
MMW*)8..N*"/P%Y1/ ][X'.NY"5_HJY69:%F%YJJ;9H_K_)QZ)JH650GW.N32
M8O4/W([A%#;38A6B NPEF6* U4N ;P F$-F0C9&GILQ*[D"S$!#.3&]$MM)Y
MI7R$^T^[=9XLJ+D1 S<')3X^9596$W.5!!F\2C(U<*9996]M?XHL@5X0K'EF
MS?>@Q?L^ER#&<[DI:]G3< 1$;T@L.WC<[%!,^O B/^U(':: W,"UJH+?>?^Y
MO<#TU:- UX[V\"9KJK5R@2+Z D, X4_[?747E*K'B$.(T0H:A>> U??D/GQ_
M%NG,*^76L%,AHM:5H6R1#,;Q?WWV_:\$,,'F;:T:4UT?\ZY3&V]+)=W4W_FQ
M"XJ"GL ]0?4>%AK&O*N_2BH:H!B0< -EHC'&3EDVU8%1HI_'<T?3KX#1D8;N
M<<)J8#'2UTV7LO7?9-O/!VT$<*D-WMFS]T=G<DXK?-8CE5$O=,O%7Z7S )&^
MT;PW7+Z<>VFAH:/F'1%\?EWG?FP2#R0[@M"D.5/["B'="\!HO%/C--7DK%+I
MZ<./+HZMZ5UI^UV/_&7+X18^(O"!YC9-M.< XI;0J4$]>DLW50@6'X*B6<7]
M'Z.&)+?](7[;T3X[^>:0'$);62KS'..PGYL6H'GP9 "4E^E=XPHD#TA=D=P%
MW8MH?%=G^L)H&*08.L&-NE>[I4YRZGL 4*B^%M0QH&%00?!283L,;R;3+3D+
MT[@^A^7Z:MPIO:[> !10T7U8Z<VX>/7A1;G7M.-E<,/.-#Z@_>XR*&$T-CGI
M7&34# WO.L2III1QA/MN[[[$!*XE<X@L:J"Y#O4#^]<H]OZ[*%I7-YDP!W4!
M7!E'$)Y4;*J)/QD""72A%T^ :/*[(/SWFQD6%H+BGK$A<G%YIH'KY\^#_J#H
M2L!'ZN)W^G6J=V]:[S,_ A6]HCT?,"/E=+E/,^4']X-WK][4WS#VVAK1^T9H
ME)]NSX$&PO$G<8M"%YA&GT+J@B@-ASA=%]V>)NLVTD.B]:V8FPJM&XMZK$P,
M-\*")C_<2Q)*ZY)G-]P>^MXE_!#OJ'KDR2$.=*>,WBI2BEJ?280)X7]T'2CR
M?^I']V_C4U<K5+MU([\?/5A6!T(D,H+,$78,!^1HJ4S3H2TMP+I>S^>,O;!Y
MXXB2 K0K&[UM%]\(.X80H(YO# OAXW!0N2UK>5UY'?"2%M>KOO3'<+'\R)B7
M<39'O1UQ[\KI?5"'?TK_R?\(<.W._1M02P,$%     @ #8)_5#"7/8!&F@$
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MLZ.7+S?/^+7+>VOYQW[SL7K6T++[[U3W#OR\H_F.P6OUI)T-Y)BR@95'Z(,
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MC)<#$T?#):L#026"8"%EM \GJ#$M;U\%#TE'%M[:?][XP@F>!]Y=>X2$YV\
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MO=!4+HNWD?"]=N)KOCRYXO/^<;+X(7VSP,=1;*!Q<,V[E/7>A,65 9]\VMI
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MH+WKFWN8-3FAU +7%M'!Q3SED?6XWK*%'9R"D>,L&M3$K8X'BBQ0/;X$X]D
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M\;O!>+N^#82$2U.!9\:E\>MG:K3FGJ0;'EJ2.1O.=WA>X9XIU+K?190:39\
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MI%-2;NDV$>5W<[*L'-=CN%V'EY=N0E&;$;B%!O&M*A]=;WS/[\!?OZD(H:R
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MS[ >#-(:9HSE'1FF0:BJ-(O16K[3,Q8CQS3CE>H^UOFGMTU722!<>T+U2FV
M_2PM^YJ$_J736/Y^'[6M%P,P/@;3J_$;!,Z\,)VQ&ZE#0+QZV'.T<]$5+I:^
M4B%^I1(>[KJJ*2<MREUJU*+"59:"MZ<$FU6]=V,P94LN38--[![WNDOFZ]M1
M\7*IFS73R1V-TI0\C!@8O.4&-N& <$E&WV,PFR$(E0;A5F^:^PP4JLNO=A68
MW15N>6U&0QEX?'67SHMZ7!0>3V,#9XA[ $&#>"%MQG>_5?T(XYCEG65)1Y6'
M)\B?."E':5P'-^0>PGPR.M"".!^UI#QU,I-P:5YAY/'IU2BU<=/F44V!\K(E
M[46N'!UWWTWS1]BO8N_@IU:SYMH18]FDV!8<9!+9/3W7J2;I_2 K&TKXW:0V
M4WE^<<3AB5^9JJ08T+[,\C-PV@TIIP8JWF:B,$J DOHH4(R;A(4@NR[6C?@\
MJU$^?^[&N,'C<7.^J1L;6ENBN%*'!3W9PM 096,/'Q^%P<^'VEXKI[?O[F<U
MDE9:GJ-TGZ,7-/.#H5TYYZV\9(N%>!-U(;T^]Y(N7>VMDK@ N6>\:H):^ /]
M_9LLU..?46R/QVX[RPW=7?YF+GC:Z<J)K1])<)XCK"L)3"T,,Z&_,KB1C]*B
M5\(@((:D[HB._5R\*&KKD$R*>?MF1 %9;W7<5.!IE/(GY+6&@[=&?:FFC#X7
M]MJI*)@"0AA9@W\PDHLNL1)VN";VQLD*];7B@%RRI>C-[ZVLD1J=&I?#AS%0
MF"SJZ( FE@_9VS8Z)>!+L_QEYDJ44;-T.O=KXR#[^&?7Y,)[/ZDS+['9-.@,
MDY?R6"C R ;TNP<I"/.ZW#=E <5_RS-78995G2N$(: .6K/!M)J:7,:FMFS(
M=O$>8ABI7)>^U>5:\OF<%Q_3O[5;'FD--(FP<<IE#?#)6,NARV/U0)?[A2CK
M@0#?>#L82R.Y)'Y5U>&'4MQ&;<.(SR&+6Q?W/TJ>+_EU[WTGU'"IGRFQ$Z)6
MWG _@@6$^^T!6:&=JU\>*A4DG ,<E-5JF<K&\#)C5WCS.OY@Y,>X?/8_AT?,
M+2"12;VR!XRB^?> !=6>!^C.U;%1!$@,*;[F#'9U.HOYP'3EKY#KZQ0C>YK*
M#AL5_I+WE5C(<(90(2#'%#%U185Z'KP[;CM<]^G.'!ET7/$G3SA];IQ<2-GA
MZK[^''*='0@K^6>MX&Q&6=_*(0<OK_H6I@HD6UX<WGSF(*-]ME]5\O?62K94
M@NG'&#,EF7L:SN]=#H7WR^J\I3-]RNU5;M152E9V2#"9L=2V!GK5)7J?N=>H
MNM"XWEX%_"A71D4_5)J].*@+9%]F[H04I-P27@#*@_1NSSL,1@26GLKTG19R
M'VDL^,$V>?Y+R\Y%]KFOK3+('4<I)D;=*5\509F^ 4,H<&(5EIS8V5B$@&7X
ME/Y0G7A54,I[LN->:?XG0*%*/_ ;^P-I.$NM5"I!>73&JKQ"KRE/TF>?I6^-
M:X_ML\,6W4*/%U^[4M\K?U=ZJ-+2#$.=&4![0@F6Q& \?-\9OW)D8@M#-=&)
M(EM:_^VQURFR/&=RT8UN<R<CWL?FSF$ ;.2_.N;6('$KAEZX 1V;,QN0I5X8
M:K(@R?C/+3_0CMDP1RVMG+9FN1Y/'V9S2[7"O]_W3BT67K^5784R>T.&M*NQ
M(6.)T$0M^ [[.)@L/'Y;.NQ[E=BL:N>)T,<LO2*]C)&<4=I1'(&5R-FI>M^J
M<<B NZ"CU'.W<KCN_?,%A/]KN<8C,)^BLDL_IOV&8\)<25!\+\ 8@[(=C'%G
M])$9#3XR6YD5QA(II+$4294X2^!32\1"6NN2D5!X'Z96))O)7-[3(5C-D$T_
M$D;( 7G[$%NW1*3EPY_GQCB5/^A!'#:_T%Z"=(IEURDQ''LS+\VN^EU&)T,*
M3"N<^ ZFR?F^7=J]*2'GF-\5<<3#)O#SS[DJ[\T'_Z6K")?9 _XU-XYU_HO3
M+Z)YQ^%^NEV>W3E8D' 4>C+L\G^F5[%?X: BAO8<WHZABOG -T+M%F;MJ?4V
MC!DSFLK:G_YTFZ>9/SA&?ZZN2)#U9_)RJ5XT2PH3G\1<D.5G1P0G)PGSEI)F
M<HG>U[_B= P,3$*VL2/P.7.TWK> F4O'!>W.=]8=L8LJN>BDL<;).#!%B&7$
M\<TQV)7V #&+/8!K=<5D#SC+L;X'[,OXX_B_2ZKT,GK:F!K]%U,G?+</INW2
M7'8PJ5/D%,80?,,("R<?A8.-6VA0"=&*26B&T MA<LA>DEB$KP'4N]*S'\_]
MHK_OT]N.M4CQYRN70K#]"2H%*8(Q,NN7DY^-17??>Z>KVQ>=NRGZLBGNAT./
MX',Q4VO$NPZ$29!L&A%:C6AQ\MWRHF,"$"S(R%W\I>%C=^^^2I\Y[R6Y3_%9
MD37OZP93B9E*M8[5",G5]EZ"QG1#\@"C#<X#2EJ=^[6->/%3J-?/\%T*9_+I
M3'V9*[2O)S02MF\?8:EX^23R)$1<:TTTFZI#<Z/GH8Q)XN'LWI-"[\BP#V&'
M2_Y<B:1#SV6.DT[STO/,S7HDY'_7JS_477)QZ3>"PAG?X#4I=>2Y#N>C8#*%
ML_T$LH&4FI N[KM:051WL'?L!"P=W0SB.L6.&1V[(JCQ>1[N#8\B8+M6Q[8[
M)O?U'U]>UK*Z>:0P9L;:0^"E1>'CWT<J)@0V.'.VF$S%VI(C/"E"AL?6.F:G
M6"9K7VBHR3*/_]XC?>Y1E9'.EVV1G^C]C'W(J#9,':(#EY#SK<0UK 0L&+Q0
MW;_R,MTT[YNX'*^<CAO/RQ=G;HA'6BAE.&^; "*_7&I+\#)F,V8MJ5)(J,7[
MNK=#=3VZR]/O/AX[9*H@<*U4-46?U3G7!&#:*G8#2#!Y='HUTD"^M(>]9RNV
M8&RA0<A15-U"P;KB3O<[UMI,0Z.9.F0#'C'FV\Z,E#W "RN(Q+;DO,J$M.%$
MHP(K0.?9V01+Q]6GSU9L7&^UZGQ21-Z$1WLO2AYA_05)A+Y-C?=I5IY"7065
M2$MH5N3ZQ4=G*J[>MF6$9U8J)QU] ?Q(T:&3H@9+%/(<V^$UJRMB5&-"0RSL
M&,V8/!5-8S_57^J5Q]:0N_(@G35#J/<(AZ9OMLXG^8,)5+D$H)V,?K2! 9!V
M%N3)*#?1%X5>0?T$!X<VX.J,"0"YWZ549I"C<O<?*3FP?*L)["&JC6&V7H&7
M*=#V454_GU/)I9YVITZ<'KCFV+8JG1@LT"FN@LWJ?G]AC$6B562(:4+88?07
MMY(=&4)>E^]]&QGX'2';M1TXQ!B<JHU$28W0U(B5$.+*-O/2R(+1[NGXTV\(
MT=<3.>QO/2Z_<_%#:G8Z1*XY*)O!PT(15.-;(NS0,]7X4U\Z_;BZF.W]NK/;
MPX#S3O=!T1WKV+).8$XG'_(>)DDS[X,=1T(M*<'1JQ=>YB_>7O7VO^E):ZGJ
M;_C2<F!=GM_L]J+W(U">E.S;B>.A&6*14:=KR2-EI4:CJJ^N_JC\>J)S0#WQ
M3N):\_S6*;,@K8D^3AE*^&BGV!ZPGV;F369X2[E((-S[O;+UGB<]/J.":G85
M,8,?47Q(\#?B!'[ACC;#&.UIC%YX3=A<^ZHTS7I8;";]PMN.G[?SNS13_5*5
MY8PR/YU_?]WL(*4C_"WJ+!A/7(V6%<!1$ F;"@.:4L"K7VLF[E?Q)TP^62..
MM02LNDB'CV$XF@490YB:K0^45;-1I<:A#03DA_/\@]D7@UR0L?-5A]0/)-6^
M_N2OO<_LPA.6#>UEOQF(*)*ZY0J&D"#29Q1@2LV#9R8D8F3=^)>$O^K\,L_2
MA<@X-T()*ET^Y*YI>"K-1CA>IC.SP.E'R\"IX?5'5K-1F_Z%J0Z45/#P'M"%
M$40%T)]6U/5*--:7%4]9%;VP&#)5DT]V/7I4G/<#Y$U:ZQ%$*=:&7EP,WD>3
M]=NM48CAF-QIE:&42<::KA.'I T7:[Z"6UL*[ G+C@15&R7#C"$X4X/'KM+"
MJ.>F0+4.PL=V2E5,0TN<C>(MA/I8M438AYBUDQ)^(SA7!B=-,W9ZM0W'#^J-
M7WU/89.TP3W)R21R.#ZTS[TO8-[;L\L#]I+FEM'44^,,?+,\12U*TPEFJ1_&
M;X4X1[FOH?5SX+B]1+&.TOWD:*XNG:YS!/JC<'G41?1W2!LA.P:E)9:",G%#
MPS"N;J6WC]YZ>[7HZ\NFD9EM5+YLO!$TV.X+KL:.EF>WPF0B)YH^DZ8:--%M
M/^FO]X#Y24TUVK'*\DQZ[&:JB/=4;<F*>M@, M)*]!6TU([M&<GT03;XM2:&
MYK_+1-ZI@LC6LFP5_W,W5>- +XZ7OHH?OQ[X87R00#D7D1G[DC/J\NBC\'YH
M;4P)N:1=5I;L&TD3"Z;PDD0_2F?;-FHU+?D*BU:_L3^N]"3R@/'UPA2$A$R+
MX7?7XA!$*LT.B]*GS$4M&RB2^\ 8?#LA+=5YI*+(T>_58>NP5]8".R5L9'.X
MDL/.G#6]H?G(TFXT#J\&0<F%2<VT#ZKGFHT>MUS(RF*Y3W\Y]\K@>_RA$T6H
MEJ2,AQ-J>*9CDIJ!XM$)>9)D[146(@[B,(Y\;5O;;V!#U+UUR@K)XE;_[)9^
MYM-]PI2,[VM&G*/_U6+G,WZ^(C\%SQA8:)[DJY1.D+@JVRY;VZVO$J8WHN)H
M+E=7'WW:;/\1D0-F1J]U6!><]:EFX?U69%,XQ'-7+*:JR6]F2NB:87,B<5R7
MS12M&FQY+%W@M&F"J<5OLSMI),G1E1Z*BE4./';;A>.W)B)%LG+HWOP#F9[%
MGA*G\9/Z'\?>.Q7>.GUJ?_Z<8@CP' CM76$MOZWGU!61@0!MQ-IG&T>O)Y L
MSD&6KV[O\S6='W]R\$"2K-[HF]$N2<@*-V5N&I?2I%I,0Y%QT<7DAOC50<MZ
M"CRJ./?+FP\9<D>J!"\_U^#[$,,IGS'0W/6_3M4!4%3\]R4?S([^4LL2&[4'
MU''B4Q.R'\@65R+/.8FNMQ%>=&;?]@@[:5%U*)U[P@SF>/)MNEXH6:5'"TW0
M:)NJ7NW$)C.D00S?9G8LS2TH[S!YH_]JMY]HP0"A2/O4S.U,OF8%SB#.WF\Z
M2N-,5G4A,.F/FW:1B&8%65MJF+ :33KB\:%^8&3!YT8D0>;EJRS3Z:/N+9]E
M^,UG8$[!E-2MYB$#;%UX]Z34>_53&^M-]C?'I8;<[_(!#W#+\B^1L7C,VU0\
M%2)$^/']MA_A2[=7$%<6;U">:82X1]+9R[.&')SBV/ J?>+Q.M+J 91A_R94
M!O2'<B/?!MX/*W1T*AYP/)$6&:&L;ON%[2Z$XEH7I,F22&*JI7F& ;FYC#B!
M1B1>Z0_4#Z[[4/O4S2TYA@N&N?A)1ZY9X!W38)WU4FZ0Y(MEFDJQ[S2#=XW4
M\WD2ERI>W$\>KQ=BNO&\"7-L7\X1UG:4"_4H>-F!_@P;SCU_C"%*_KJ5Z"4]
M\DDAW<#\K6:LW\Z+IX(6!EE:'JW0&DB,@395ZSM-9(3 =.CN4IR#<^FSJ.P7
MDJ9A4T=W["WW"_CS1#EW_QF<X\@,%;D-4%4,[S&CE@0ESA&:^U :F5Q3I\P5
M3GW%K(:$A71Z_T8#H- 9T'5Z MK6+%7MI']FP&=D9&",VR>.T]_?0DDAW=_B
M<*/R$0";B?Y31HGY]S)*%0),B=$'Y6_F_;&PQ="EQ&030[##/^NL3'UBW$ZS
MBFRVWM@9[8578U-J(?'0.NB*/@FZ__8(X5=\B';L5[$1W\:CI\:OE;5N'4QM
M>PC[]!_J:#/W ,^GJ/ODV)G56(8FB&@=Q0D$N).I(%.0:A9([HJ'#V[%55T_
MLQUW\\N5P$^]1F;]>9J4O'CR-EZ,(4>1+>;/*+BJE!L8>L_<//N@6^HK<ZP4
MM&%N>7.*U!6[!ZPN[0$4398%/YIZ'Q9VU!YUWMM^A78E1\K3L9NYE'6%7]K7
M_,_&<1VD])9AG\,.3R _;.70"PV@TW3]5DE<+ U"7FW_7'5[4F5$7J CS+#Q
M1(K4">YUD:0HU;QG"TG0LWM #(V>AYLO!]$,!FX/$#*C:3/_^QY@XL)$X&WF
M+V .L+WKL+,',*36M_ZTL< RB92ZNP?0K$)?9981EAQ\\EZZGOQA[]26+7 >
M$V0^<48%<I.+-K]O]F_W^K;+HUT ]P#RTO3'GFA<BL&-8O!FZ(:7:N'0X>_N
M-@?57:X)PO6 -0BAL*WY%+FDPS<6+=D$(8ZAO)6BB4V#6F@^PALQ.]'@0^B0
MNURM 6[?.+BG_36<RZ#X5 C*BN*"GTK(2<DH]0I7ZK_C'LIUW#S%T>U#[)WJ
M"U&ZURM,-5I[_''D"1>F^Z.+8/C0TRY[@$,J>!<[QOSR";TQ.++:'E!IM-Q[
MBEZ@M2K.Z',1T9R*9$B39:L]B!_EG0;K$ >0@Y?C3%Q_MO1/' M*?OYIN55@
MF^U$YTG\,@_Y+Y_D&,Y-KV! 4&84D]18 W6*T.F1S7%2&Z%M8";@[8II$(_Z
MF$UJG^2^KYM?CA1$_-W.Z="4/>!?3FQ&L>'_^E3/I7"M=I>UDV5KM,<73813
MG\'*_M-*7+M?T+^<=5?0QY7W +]"AL@.KXFP]8.7_Y7#IFL-[;V2"/)Z"P$7
M5[DA8]D^>-7T[?&,(E/9Q9_9-N.2&9]W:C8X&G-FFM505@.P_31-"C2Y;N1&
ML6=6<N#)KFV,.$\B8U#=1G;Y""L1$P>O;4@)A*3(\H"YQ-2Q&9+14&VB5*78
MI3=#M2MI$U>_?5;Z/<$KG*F8S*5H?O#-AOS(#+V)9C;[$CWV@?0:=O)+XVT!
MB-^+'W0_YPSJ,7"<--J.Y5\,5P&?Y2^$BPQN!B<LX0F*Y?I.!,+)C,0"LZGK
M%]^U_IRU*[Z/KH,GPW1I\B/7P8AI?1EH!YI_(Q0@K$:[V5J97M.O;1#XS&AW
M@UT<NTI\U\)91U.C-.T!@@:<16 Z\R-+HI6:[=P'M$K;@X.HMVZU)W"WZ@=#
MW$5&[%3(.-+Q9,I]XN^(&2BD=^L%U*'6\D.PP8G]NJ8RSQR5S6X6V=D8'?@L
MAY?2?W/E8I:[#O @9X>!9K+45F@=Q9<F[X^Z.,!1AOL"5^C\<<*G2"H"FJZ[
M^6#3-V$*,@-6DF?:81",[9"F?MCM_N57S0-CHK]TIF*Y[*_R=6<:!+@FR7JO
M0[;Z0 LJC,'4I3_07 'T X&]B0[I'8$E2Y>OLJ):JR[<2I\!E%=LDTQ+^E86
M/5DW4PB_5#[)Y7!?\E2T7E"X(V%O_NE@2O[@JV>JI'][5/;2U^5[POP62F^P
M4O1DE! )'@NOX<1C^<$JBN_FN.H)[B(S_@/V8Z2X$PK:V5(*(9R<[MZ1S+A\
MAIQ<;9FJQJ245*<5O!NRY5/SK[[\-B1306+[] PEGS]O<&L#9 F;.43T##_B
MN5JAF7<IZ9SJV&>"\#7A-8O>PM'F<DYK8Z8?C7)Y(GN0G@F39E(>6]%;2E*X
M1'54I]^"]5*)BWDL8=+NN9OD^5LE61U! >*<$A+8>O@TIEFO"8RG0FE:PZM5
MMYJ:',6JTT/NOV?T:K2<#'UNRN')^D,+RS4?KHC$V/4'T&U(;*:C]=5?K67S
M13DE.E"?__1&=U#[TQO=P6OKWE4',WALO>/X67F3GKK/.M;JHSNC(YEKV.5A
MIC;Z#SE<(,SFGP]FO^'(UE,[&M $]-9^Z*Z6R@X1.Q_*X)': PZ[4A",5J;V
M,2U&&VC^HWGYQA+9D6$^]7 /6&:]P302E-%U$9=!;*OOCGPXZQ[PAB^6D=%E
M)//B;T(+'R-P)X+IMN_41F[/:+?.5QU*08Y?&(I/,=E?PB>J(S^"0X#8KRZ@
MBA@MJS<*M\4WA-LXLL2S\OJ2=_723\JEKT=>53W/_H5BLC/7M]0]P"@72N-
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M'V4&_@GT_!!V+@;W<O5?@:?OWU3?7_2:RU<;] 4<.^YG,@AAM)R"[B)D@*"
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MQ*N%D2U_"]F$H!HSP9?RABF#(\VT@H<ZN"C<@=2.WIA=M<24J-?(ZXM>\GO
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ME[<ERZ-,7E<AP05!->,!7,VA?L6A#8S(6TS#9^5T5U5]8.X^D4=;>D8$2^4
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MJS25QE:*&3H*O[W27L'.U)6-I\2Y>LT=NWFA<F<<UKLH#$_1YEDZ^O_?/=P
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M>-2@Z]EW6DYM:9[A#A:3Y;#\H%;3^?ZL@F_OKR0YG$0,F#Y^_$A3)6ZZA]$
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MK[V,O]<]Z1+"$LE@Z=%NQHQX;NBTG>PSRK]W[]V$DO/Q^TD#SZZGCR8=0Q@
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MZN,R%56*9J6B( =GBI7 V=N7:Y:E]7O6)NE.[J*O<M4-$E81SK0TJF[6#72
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MFS-E6H#]P^0ZTD,S6E(M=O/[Q9+@0/ZK 09_.(X>NG[CDN;]DA09VQC9D(/
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M2[J(,RD)+L-=*9#.7]E^_^%U9:/5XQ.'85=#6./MG*TL8_8##O)6M[P:Z%T
MI6Q 1K,W,A)9-.1:X#F:\#@FW,CD]#AL:UY.\V&^8>FU%<8A\#B5\!!?[!(+
MN.(><J0-^3]VYZ=8M&&TJ1[TFE+MQ6R^C4*%8E8?-O@=Z-O8!V/F1N]1A:F(
M+5JP1$V.T5$QZW<;Y'M E6\?.L\>,/7F3[=SG3M_T?UAAVRBI>Y%7Y[(0%IK
M?P;%+]9P'[9#GH_]!T:%8ENYXS48.N X$_A5Z8FM97[A)M'0;8./]#YO&OJ6
MZ\^'4*<1(@S6ZT".L LK^4<D,5>#**T1I.W*]C=#5]_5/*VW?^JW73%N2'?H
MPT#^<?D0>4TJ+@:UA;@'V\2%;>,(@9HCSRFL:_8Q9JJC.//3^+E<2X?/*M^F
MMM;C'R\-:,5E(*W]-1G+8 E-A4*(J.1AGL0<**'="\M[Z*E==<$\Y=M^C5-N
M[6>4$@]7K^K-[OV2>&^!WQ=%L[((Q^_PP8MA-,!66L8I3Y>+-/6N^K)4Q^1W
MB2;Q%Z0TQPA?IT]4[+>TW[9ITMR?4Y[/N@CQ;CI8-\))ODLKG1G!A6+4<N),
MK'\L[U&\JQ:QA5[=*AK@H2 4HKN9_R'O(WAGPY7/FPX+))Q[;209K7V\S5A@
MQ.*?KUNT8@U8M[YS82[D\,")^,H32BG_#V?O&=54%[W[AB9*E=X)2E,!4:1)
M24"4(F(4I4D)@E(-" @$"0G2>P %!)2@"$@S(DUI 4(3%:1(EQ10BB ):MA(
M$@Z>\_[OISO&'?=\R+?LD>RUUYS/[UE[K3EAX\KV6N2!XA"-4];42[CVCUUH
MGU@CJ"*R9WS?7L3]V12#UV)OETU_PAB=UUG/L1P^MYO=M./P"OECD="_!WIP
MG[ !KD)%[:NO V7EY$_H:Y1Z^?L35G>]<W(\O>7PC]?7KO/:&'CFBCL] ^!L
M/HQVNHE-.!F.Q0F<A("1T+[F37\$1JE$6:+Q?<,9&0?;9P*8&&EI\@8YA[Q!
MTQ[ U5OU?^+<=J*IX>D?*(JX2/URRL3X]_S \[EV;4&70FJ>#TLX'1D//'S0
MM(MWQ7<=3F_H+]$$(BF?E!>U%O)NTM4=6G+9Q$N6(@%21O?7>[<E@5[8K]^+
M2ED<!SJ?XN,)MPB);%.@;Q>&C&<\IN^!$DB4/QW?<:S"9\C[BT=_?)BMWQGG
MK)Z9?G'[D5A;8A<W:W'?J3H1X31[_"Q77Z=@,66J!\85\(GR-(RJL#W]2H_6
M)_BTS59<22/K>H-M[H>A:OE0<Q#X\K[N!J<P+]"4J4+%Y+9X<%K0/=NWNHQ$
M&COL?+>#*U2C)"VL6VEJ<2H>;8 Z2B.LGZ5J)RP<!1#W]T"2E25(QS5WK?/8
M*)57D^,R60JRJK.='CH1(J/%BF5T;_(>* M#?@P518.9YVA3V#]@2:2K2Z<=
M]$8#0>V,,4C1>B92XO8]41V#ZQHDPB2)=A4?!]$ .FAPXM]]9#>&-@)XHM$G
M0HIG<U.FP-2)E.GCK.5S0]U1@]P"N?^Z%'*BIT@*!"\H/].0MMVW/TBG_7'\
MB_7)=BT36K=_!2=-N+4--IAX70H*5IW4[^I'V\/6A)+K7 "L9?V7QM7\[SU_
M#_Y$?+^<:[DFXQQC+K'CNKB909"'DI^C^<<A0N:T@.7N!OYIWZEV6-7.#W^.
M9.YL/%_4)=N@K6UCD:Z?@7_XNTK$XO_5[$,9!&K,N_I+GG(>T,1%31[[PB6R
M=H[=R$'X'P=N8POG8T^"]\/L,%,5R*P"U"G)Q!H<. "B8/W3Y,)+Z<K\V3YI
MWBWZP4'C0Q_><<!\ED&R>Z#F@H'-%$$ZCK*]O@>BE5V+)T(TZ?>"(Z.HQGF\
MZQ%=UA']!W=W;^:ERC.K>;5R* 1>E#N=1,9ON$.)<\$9A_=]DD^!Z +0XD@7
MW^*W4]2!/<:&*-LL#95)7P@]9'CB5$@>/7UP/YZR &T+H)MV>6W9#!@G/^Z5
M34Y*I*7]>O_^GI^;Q'LG[?K^K]V%EZ4YW)QBPS=32TQ93V^QBMN/[)H&E"C0
MA=J,\"DHI]H7/[ARCK877-,=%;"^N!T6>RHV%P1B1=)P:8U8!63PY:G?<D"X
MG=S5Q""$MM:PO=_TK5,,O7HW]:Z1I,,H*<"<(LSE>CEH_-RX5T-@_$#1&B1R
MP/.C\^)"6ROHQ%E5:WI'7NA= WF?ZA]&+XP4<V)>S@?I,^[:A"A=4&U^GF^H
M,,R#OH0ZO9_S<< )]Q8L6O7''D@4;W*R"+&[6J)(^_-2&^%WWO_$YA4BG^-Y
M>W*0E_3#1,Y88QAP[$#I'D@0$X1+A!]F*P/W?_3!#];JTE+])5IP F%80\A2
M\*/609IM4C\Y#9K4ODW<]\6NBR.SOP:@DH3;P@DY:Q&.1CJK+:-K&@IY#6[&
M-39GXS]A3WY0Y+XXE^J^Y!O_>X IQK5HE896!:3Z<4*=1^U8+:^08O:N/&WM
M-W6Q0N[G@P8*CM$-!:*4\.7(K#PZ[Z(Z4PR_F-Q;=[I3.@ N@N)=% Q N-KA
M8$*Q'S03:C3K^T[*UYS0O<2ARB&M8 :I927O@1!EN_8N/SK!=/7DN9[]:\XV
M!A1Y.CD_"3KF+L&^=X)<8[FCD?-^XP\"9;[+PQ2D3P/%=+G%Y5YW!91R+4!O
M<0$"!52;'N"B_//>.1ZYPN,IEZ0B0.TD_?]J@_E?0O_8;KQKA3*A^_9MA%'R
M\ZBNM@29E=%#08U_@NXS!S.0D9<-JI=>44H T._918BRYL(Q6@F!@A<&JL&"
MP'/&D+/FIO>MW$ 7&6L7[EO+V'+4XCZ5Z+/*PO= L5"N.W6HXZ&MD2GM#C&L
MO ,5\)L-Z3?];SFN@.6NZR/G85<]I!8W 97S]S'$*),+%$Q*T<9V7[$&IEG!
M<LW-(OIN3;Z#\G9.T))&<-#,)U (M'ZS/R:,<9Y5C7(GPV;YHIY/FE@A*E<G
M%]0Z@_5.!W]7?7=&)#_IPL/@QS >J8A3U@S2[#:#?^J/<,HLK#]XYN\JZBQ=
M5&.ZHJVAN1!!?O<!Y'MMV[R;1<UVO*"5?=DB%,[1KN[[;Q6-A?49AQP=O$;E
M3< OC:TSK^1HE\AX92Y&0ONE]:<\=@WNSD_-X1J">]QAY,ANW+[6.],O+*=O
M_AXT:9G FPZC&D<^?:N(>.EE#8H&<<P#7J8WP(*K-OB1P)!76K7G_@8>FU&*
M8@B?ZG^1*]Y\]]#PZ1N-C5=XA>GIB^!$"!? >Y6.S6A2';\7>.I 2*O-"Q/-
MD$K'"%/0WR<@.Y2(%%.RYCQ,TNL'!=+ &R]K5U5[LK1BI8H-5>H54]D#"1<#
M#/PQ5F.['7Z&/;<@#6[,+S;9 _'6O2K\G:XE::4?>B.>W=00MW7@^'>\8!;O
MAQ9HU3Y,[HMU'S8QHO72#0\L'LE_K=ZAN2E))="IY7;/CJ?P(^]G;B)9_;$F
M/QB6GSOY%H!(=_IF]_3&[>2^@I&8JJ_*8D:7>^L?3/PZ?&Y A :Y\^L)+HX-
M1H^5B+#R,7<(LP5]G>J^^1LOBDB7QKT&\QG>H7)#UZ;OOJ@G@]#)__0G08\P
M+<SF4ZU &8PU'<*S%8"_>KMZ[=B.]A8A95]Y+^MR2W=BM7XT.4:K[M_N3I0,
M=7/VAP- I,H]J/;;AES80B*HBM?6^-K<OT'[%$7 P1$^(US<7($,?OK4 #A=
M48;.FX4^49Z/H[#0E"#FV?(Z0D%(,(?T_F^/B'+FD?)5&FYQ:JS-9AGNJX+(
MN><9/%P@X8NY_X?@+WZD:Z?J$GB1F"M3>C4K][ZJPQ[\#,*?E->\VQO;8*S8
MQ>%&Z"9D>@@#.^1BC 2@[H1U&E.+2'EMGWOA*&LIY^#0Z\6XL]PBW>(<\S8Z
M%G(F&2_3=%RR0'^GWA-:*A/0QU$7 5?_&J8H_4G.FB+XZ::VKNGQLK"JBA[]
M))GY(7[TMS?XM_3LID5HX_>Z5^A)>(L$;GW>Q"F: N5<*;J_9M3C_TJY^$I>
MW5A,(33ZD*8G5[;.1IR5(FSW OH#6WU?-^X$R@KW:\=W'N]LI7TTL/&O7KU?
M^R!K>;=Z[9FC\Q/.2L/;QM;#H:6*>Z!]XMT"*+1M1B+K:5WG0:#@8D.R!XU=
M=*_#BMBR!NIL=JMZ*AX;-DC"%KHMF\1?90]CZI/[M&>L&"\ZX9S(N 7,@]E>
M1%A,8-79W.O*1XY<'X2$YH(>R8L/KV?S(( 1ALSG3F.4-1!&7^RZSYHBF@;\
M6F]MKF$5R":_M<RP5H FWE:IUB<[/%!]L$)"/-^X<DC3*LR,CT=+*Q0N<=+$
M-9BVW&L/""WT_^@_[GMDC#+QN%88 KG2BS8<X5Y4$2@"T3&S(XP-FOHZ3J'Y
MZ4L+:"K*.UJJ.)#R5?^"*&)8XKLW[KCT,J^_.B_?W<#OIE)L/G=:,>/Y*)XM
MA0JBZ2T_^-T1C7A78DL,"X#<]ONZM+6(=#:*DSX.BK456@C9'YU%NF^"$^,)
M_1%<'O$3-A#]@6$KMRF:./OF=ZZX_6GY'?!)0XW$2]Z"V_@-S*X2X,2H!:(C
M*TFS%K>I-<Y%=NJNF9R?!+HO3T3TWU SY(%-A![CP#46)#0*<[&)!-%[VGS.
M<_YL\!M:^.\(QTFS*%OI%J^#IEMG-4,OVWQ"QZ!$6$U_8,F8-S B*9[$JUDQ
MA3[UPTGJJL'#X.^OGJB\RZX!60HD6@=9?I'Q^8T/^5>\&B#9 WTT.2JF:U.V
ML#)8('GLTIOL7<3),62&S/N1?+IMUG2X0LT<P0L^K4V$OW%\&%;E]D$X!16)
MYG,+5-.17)"G"X"V2C,D@_C!GCR@:%*/<;","U./M@X_?+)6&W4KWT_/IG%P
MR&S<^VGIPT&RZ*E#W+$'0.O^Q_^=/QN9"O]DW/-7BX&O@;NNMKIG:(>$1X4K
M91U3OOKNZ?03'I"H3:D@7Y:-HZKFNH3XK09Y#C=P-S:KY!"K%*6&LB*[ARH$
M7K(I6K O?9$]6/ES,/F[O:7TK5!I6> AXRT]J677CCU;(L-Z_'L/)/X5L.IQ
MG"0AIBKJBX=*&!9WIB#VOQ>X+4VTE4]^-)_IXFU%SY<( WET5XJ* 9S').#.
MGXX#FQN_5N_?&72UO\Z[[=H?=>W7P6D$.OF)4S:F6Y=MA)2C#G3= P2IB)/\
M,-$5Q_&9!;\;C\Q.E@7=\AJN_NINF_UC^P&(9>+$>,3*9IKOSX]-]N"^-7/J
M*RKSEPV?N++V%UU^+$@A[LC=_4A[6NQ]7(;G$?;J;W FP5N!B_'Z2Z<D"DV#
MX$-H [VS3QR-ABOUTMA;U@NGU;X-#*G;GPOJE_:-"!D\$-D-G7Y(]5W'[SK'
MM%"2VNY ^ .MQ];R[[^HT^BI1L9:9=^X OOYC3?6-2)*</O/!=E'%WC2LR&_
MO-5)#^P_<\"-T)/@%M[8?TWFC6T1MV!XY"L6_PPRTN[VKZ]AL5NGJ2KJL=8J
M9+*\?+15[_%V*]XXO1D3,$_>2%K^\+4*BRICU38WA#%7]J$YW);&5C+C$#TX
MZ1JCDQ[ _MR\G;R(^+*95[& S*AJ24(]'3UQJC<TAG0,6^#/<;J?+'QI#$-^
M">;? _E] E\'_.GX+J>% Y^9%N 9V5\;N("6"U[Z;2UY<KT.L4=Z7O.8&^)K
MT&>1QD1%+E8B6]G/@[^AZ0WM4V5<^!%OB1Q!F8Q9:XO]K.BJFBX::G.V+GBV
MA@&C838<:']_7)C2\FJ<I-K_]6D3OQBDI0K:V&EMO(4K/-3-4!+9&F"*CO09
M$3(@<DQG0&RQ G&1U-.@7_QM:,$K/1 +D:DC*KZ4->B/M@% PCS_C@@A;''Q
M>Z!Z4@)$DJE97^P!?* *6FX9EL9IZSI'/7QMPU<B>ZXMHHH<^JFKF^4$R 4N
M%FLGL*7CJ79?GVYFB8Y:5NK%(5)?O._ZK2D51"WEG%'B2*,%3[>P#^U2@F=,
MFP2#UJA0,>38QE*FGLL1D,M<D+%W@F*&4Q!C#::@\>,BZ+C?O^4CO"'P9=<<
M*<6('KVWX31P?_V&:L4S9+[C7+=/KJ62J'A8D_G\I\\<OP=YR[XH6#B_'CLG
M]^-'H-(R7Y"J\S;8_*';=J]PBJ/'(> :%2;7.[HFBWY8YA9X['/G4I'A,W]S
M1P4+GC73P%].C$A6MA.;3X:LY;K(VX<'!Q;<'ZY_Z6;N[5TQ%$>RLQ[^_$SZ
M%)=Z @>2ZZRZ+H?41G 5RI55@ G "S =Z$%E470Y"IBIPE\]8U7/K7_)$VF2
M72J1=CYS^AGW(3X-<+'A7QPCEH5CRV*Z+T .^I>HT2;+?<+#@L97/%1;KGA(
M#7P*OLLQ_)48J!R:(!\V]9TT [M,MR)J8Q=.L;+16B:*1C1(Y4W3X9*@AF/.
MC)V4%>>?&4:W\L"A%W9@87_ ZU&[XA]V58"" >%*8/'JI(E6[>6Z2C^=ER*N
MQT [N;?DAW3>O^-+NL+/&=+(]8R5@@+3,5T8[O7?VAE&B>7L^IMG7%?9UW8:
MRHM0+]4+#"/(Y#]S+2'JE9\?EXDW<@A^^N@8L04SJ1(X7169:\E777HK%V:V
M/VQSBV"FI')/IPC=?3B'MMTM11"YL_["[V?3S6B&K8]2SF[NT4>M3\"/$Q4+
MY;^0 (W^*OK] 3+KA<?AE$IB:B=<]*NS:%"_Z\%<D$[S<D;>VETY_NX_(X!Z
M10LMNA?<L% @W%-S3/-Y2Z;79.U/3KVMKWD[GSYXGW1>#O3VEQ?P!G$]8I6@
M3Z%'",W;?0AUJFIS)B,XK42V7I^V.CL\:G(U6%/5[)!+Q)GFR;6V$:ZC[3@V
M7TR=_W[&? GU<?=V?>>JI3AP)?_[VO=+&UDJ[YI\O;%F9]QP3'$, Y'.\*?#
MDPE^N$0E9!!#X8;J1&V=M;5]!/>+P?CG[QRMS+OGA<X&_#5F)+$*?V\"QY)[
M</$>QV7CD3YJMC%>7J.;>7=>E=JH)D)7*\Y[BH9TF] .\BK0K!AO@(9=5_8$
MYS*E_(4LM(L@U&!>Y;$V>>NIU=VUNF[1)YS5=5M<!</GID@2[YFG &\*(;Z3
M=XRI2M'2T5*W&'\N0N2.4OG;5O_M*585JU+TX[\"<6_QZ22I=@W:F:[[R1DF
MMZM/YCUW >U':(F5.K_LL?TOFT&SZW 'D1\LZ<N)OS=%@.@K\0ZCX=*2U,FM
M&:)*"E$)B^X-E^XN%=2RN-XX5OH+'U3:D%Q9&'+T.?O6U'=?IG@+<0\D;2*W
M:&I,K7CXRFX1EF 34CD22?EV/=!5K?FM2[9UM9!WE!0K<F&'<7HN@X(2!^Q)
MM.L$.=1Y.JD7+A,H62(YIB=2Z5<B-^;C/+9PE%_YS6O#G9#W;@V2RUSB!'Z4
M\2)XVHK1/MIY:.UO$3!.$>Z%SM^87>-3O2:7E"$F,VCEQ"$OG#<1/Y4(^DN\
M.L86P73;$7RM*U-SB+_$?S2NR4K0/*XF(95-JG;<K2$)]OOZCV'*[.N15 _[
M*"VX-].+>(WVJO">)XV4_]V%6?OML3[:^;+E]-QWWDCSC 8&FO5 <P_DLP>:
MU>B%G*5ATO\(0KOOYST[3WOD*=W>[W71^M/3T6>S@Y;RMS(6C3O?E7(6MXFO
M[=BR^2SV7=G8'L@7<1F6*"(J;3CU2NN0 6UZ8V=V'AW]&-4=ZC0!NHMI+&!*
M>'>3>%'P*(KV 63 ,O5R1^60%R%W;-W<-VCH[J#J]>RV*G+L6U[E"$L-8XKV
MQFD:%YM/<!'&ZP),]2Q; O&4PH5?ET:;"AVH^?9E'ZV70(=BC]5]:ZU2.Q5!
M\\>0<Q>4 ',,+7#7N$?_]0SS0HO=@HI4VPU&A#KG>12GI^FCNR_(6Z%1F\ )
MJ77,"TR/0B1]I.LS5A@8(.(EAI_?.9@8]$R48YE\KY#_P+Q1;%@N#\A]?Q1'
MUK%D#+$_.%>5[A:-->.=J63'LAUX"!M/Z6!&%K!#P8#8PU?G*N.9)C<+X/23
M57YC-T:D>UI;0A1UQ(\[1<@?YM";64"J+;+Y7'8Y@:.N;=._82)N[P6)<+<+
M[R37)OVU7JG,GB56?^SB8@88+H-MT".8!E("Q@>?[.@A0DLLR L&;Y[$WP:-
M1!O0;34BU5^OE($\^4"_^X9''S[\3+ZV\M\VBG,A'KZT948F$$V'#RAJT)(3
MF3:!U8%LF>+W$UK>I@<IA<)6#G?*)%:(O$THTC^[#GRC8CD!3!=4R 1<LP?J
M.5N#LI@HAA6[.!YC3 Z-*F_<R2S/6,WGEN?*>@<"7V B1\.QJ01^$P>*-A=R
M#,P/]/P<I39WM.0H6A>W'A9:$M!IF_KN/B/_ 'Z W05M1&QW$S(\C !3^JS^
M*#.2*NAH_&CRCUTZX\,#3K/7[]4X7X=G"@0_.1O!5I.!96%H%PF  U@HJ#V:
MUC!P?Q>Y2Z0]M8S"_^24&Y4F'<G\?""SRW[HD&=(7/04C()-: ;3KL-FI(@+
M&G3^N16P1&.AVCB5KM7QEM/EJ#*GP[6/07PED!^2&BMF>F@C=!?[#$U[@,5+
M75Z?BPZD='C\9 K";?(2(D)J$Z)R$U<^O];J5#(D5YI"S30GPYMBW76#0T7.
MUXGFV0,[:7&7.<[VVX5!#S'%HFDD2DLRZO1+(&FWSZG5X4G$V _9?!)DZ67_
M=Z4(LL 262#_K#J^E!NO ^R!=BT ;88_3;Y3@_ZJ%%%GD(*H4^+X&:RJ?-0P
M.^?MHOI+$*<-9\?IAI:LCAIZ#163'ER+(3\SBAG8"*YH !QG'OLU3^X\M(X3
MW0.]?70<W)&LM%.XDQY#29PS4QPOW??#_O?X\6+2)G:T&J?1=O6[?4>_'.ET
M+4Q[V(T4L'ZKD7MN,"1#\ L#O%Y.AB5 Q !OQ3):P,(@TM>]<'-VZ\N'QK$S
MX+SW.TDC;P\O!LU[AKG[8B$2@-QB ='?Q."5?X0L*;&)_XK2ED-$?P9!)=N(
MU</!XQ+XJXVAB86SL@C!VF+HD4BGAP%HL:G%W,7+$4JQCEPA DN^W[Q%V^^
MOL6N<Y0*&_TCJD"X /L]^B2KX@_"4FT"Y?02F>6LZZY@X?/=/"0\=_EY_XLJ
M=;R24.!O=8;2)$0/**.X[8?S&",D0+9CW&/5461V1\JQ^94!]^-[\K@\ZWG0
M3JHZ5SQ-FRF&Z?XKM7&5NIG^EYD3F.V^IFX_JNN4L>/8(GK,W^?1O0A1J>G3
M#XB*(=CZ%0Z__YM=/.0]T%PE0X) KWB-DX$(&OOM3[4DJ=!N3U1#U2.VGBDW
MV1<O=&#R%9'-Q[-/:RV4#<*#3ADD)_(W7IIYOI/],=GM:?,KW*%[EO>@OSX7
M@GA?@K+/9*!,J36$5/!K@PW>F"@R3/X'1K*VT13"/R+?'2Z?- D^.Y2R;$P*
ME*_1P!9&"BS=NL+;XH<1O0<#3ABL[X%>HH[3;]&1QHN8Y*7=6Z?=E"_(3QV.
MRSQ1>:56)M^:_DA=29YOF*;6M!O!-*'!F2>L48=\JU..((P&^EIRRUCY"FT.
M"0L^4WR0U=OJE;S2==@4,&>[^NZ_4N&F=!+C'OT"/KY3W=7-7*TFZ-?!\JQS
M76>&4]MN#?*CNB3RS&5, W\'FC<3&C[_!O1L)R::#$O/M[9G":OZ/CHFJ'3I
MZ;.LR_-/?&)-7!E:K,<4UB,V_RQ@;SO8I!7ZD]*DX,&0.*+Z+MSAB([.U7,G
MXNY>/O/@B5/'Z 50"%RZ4\,/S@V11<;WLY4?$U^L,/JC.%FKKDHJ <8-[QP4
M-^#%LXC-C?I=/W\"K;Y=@:J!25H0]L^8U<\M&/$*NNH<VU5[9YPK0TR#.X@H
M\2>9*=Y F7Q'UV:8TQ.QR92B-79?Z<3LV+SH+Z+ @Q=7C"DZ@/S3)V$N&)I=
M\*PQ$2.#\84+( /&_#295RD*1H)']T"V"P8[=TNSC!,5OGRY_G FG6LZ6QA&
M+UBGW*2W,6+&V6"F4QOD^)=.HG3KE.0QZE/M<[]"A+[PO= /201E2<L7,5=I
M5OVPU/WD!D^938XU":^<!XB4K+)EMY6MN;?NP.X;UP;Y(RHO<Y4_/\$Z_L6R
M^;Y26:[=A :]O(5DZH]- =)\X*G9XD 99L7$$>02243Y>P_9@%?><UEO<^$P
M33*3WD:&$;OIZD0&6OF=; 2NRD:H"A3:<DX% 9C^>I*UH[048@8^@>XG<3/#
M=LV9@= FJ?Z#X,LEULT C+AT^+5KWHE<\M9A#?W/EBY/GS!&5MRMY&T% E*>
MB5A*7/?D6#EQ\;]0R/[,(QAXX35=#1M5'M!\=TWV]I(6SZ>ZH?]Z8/[AEF76
M W4T_ ".9DM*%T7! *\6V>WN#D<'K..H6EXA(M) Q&8U+D1\/OORY(]?SL #
MJK H>F'A.$"H@S.MWP'NM$A*:NX"?[1WZLER^)GM7Z7AP<5#9 .[[FM/OS?L
M@;RA<ZY7: IUR=V$69U9"E.5RL]3<&$*92-WF!&&_SD6L_.5"]NZQ'S7;;A;
MJE Y$)PX.[!A5P/ &!6L J:%//ODFRSCZ W5IUYO2:(YC4G&J#['Z5&"T(O#
ML'-%(['0 .Q<U3UM;J8CK:.@9P^4'.%T]>L/@U.EKND,;.GYD\MGU:4Y+$/#
M8C7&]VD'/^W;BVG ;YB&4W')$-TL<-S?OK+Y>;\Q:U]_=^Q/\M7MBZ\V/NA'
M@O2?SJBP^AZ8B=]3D!PAWC^)>[%*2]'4],R:7%!=R7F>>!4 :9S[5ZPG>*Z8
MT3:!\34%$]ER-(]L$PNZ0=_#F&*KU[=/UF=V7ZJ-+S N='#*R+4Q/- >S\
M8KN^,ZA;M.4TB#+*(0/IL<ID!=JF[03)>%\??(!HQZKROW;0$I'F23G;C]P$
MCF=^?T;S9;P%9.@56\.+5VBO\NM=/LE[?[.Y^3;?E\N$%_E-A6MJB($?#>9
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MY^B2^YK4@QD^_,>LJQ['Q7GN*)0R^QZ!A,?N[Q@P ,"]RFI7!V7?!OA2!O=
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M\,>4OT=GS4 DP&DD)F3?D]Y"#"28E?%Q5GP9E#$.M<'[O?!X]'\FN%,_29R
M$$[^F[S!087.S%'AR7A=;<$U!A?,/<P^F\BS_O"X0)E\[:6##@61"P)"!S1^
M[&Z<F[)M*/JY1=4PMA9_K_GK[?E,*T<?$XZ?@=_@LV<HL&[,W';W=HGBF(DO
M9<.JO\AH\-Y7)^N.N._4(?.X]T=K;C_W MUF6@KK<FPAFJ9ZA0$54A]%H'^W
M'PHRN1#JHG# KLT@9.:DB-EOE^L1T,@I]BDT$=<P,@#; ,]*SMV8_$;[NM$6
MZ,2 2!ZCKYTL;=LPE[-^TW;;W8DW!'IO::J8R0O0P_X7:>\9UF04K(N&WHF
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M7G%=XEAQ"/CP&/A3HT+D"?\/'\)*M*1^:R[@R8[5(8P8-QQK>A=9[$U.^9-
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MONQH]#Y(*C4QZ\5(^Z3/):[,DNT()1#/Y=&R%Z\1\+VWZ,/(L<*""'=CVKF
MW5+2W\>KLQ,V8?=:H#&Y^L:2$^VZ"1F$.0$:IH_%?Z!K$I"?[B\!8)>VF4;%
MD X =2.UZ(1Z&V\<+ONQPK&PMC@0,6X8-,'5N#A'+YW!W!Y/-.#!&M"6 /+
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M>3K^H!0SC)GZP&_&.7]W,%4E T64VZO0H^B?2E_B\TW;5#VL=^X[HD#2F/M
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MVYSGR1P<^KL!U*V^")00DX.(X5L=+,.>FW[S9S0B3SDC=*CIE1EPU4WAWYR
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M9FU9G>:7INXY>TIST;X(HC)N\>3D(Z].8I+SCJB-B=,L1AJI@SBY5]P#KEF
M+^]BSU*WEU +[3<]%M*KFEXG:M=?K%VY?D0N ^3/CMG ,.S@5O170"1/JHGA
MF;Z80PXS?Z)\A$P?#<0,R<_\;J-RL&USD" \/]_=+C_(^YG/D-(;,O;.KK8D
M. 7$,+$OMA([,<RQ,[3T&/KMN>)L,]H,V0\YS.)D.F4/XENXMBDUJ:39((%2
MZ)4GX(TO3^56VL]V]*E#ZGT$47R-K1CO\OE_B:8Y.UZI(^O";(_?:^3.31IG
M*F,T%7Q<3R5'M(0@-J)4=AD4(WC"_W\_]R7:4TZRHCA3TXG@%,4)I@>-Y\+$
M=K(O]U!0[+15]^8S\;/:KUB_"9$-5O0_P#:*<08Y9J9TD(3:PM>3LB]-^R!S
M+FLO?H^YRM&Y?5+70P\YBJ%>*D]"B9KQ_E0P DIV&],1+F0!J?"N$%3K[>2-
M]=!X!X&VI!W<>E=YY.E>]EAMS,''64AW*QS$15*<J+(N(8?6)"@*K\*%GO3_
M=5:\)%#L70!6^'*4+.=MM*FVN@^:KZ7/4G]0@@B/';!5\!^P%%3@S]OF,-<H
MZHY_<?:.3=\&K )Q!>@[<$@8$%[5D;JMAA($'B[K3;<N&I'\_$0J! [[5ZKP
M\[S=\A!!SN*;)%-[%,E"4/+<QJ 27>8+MGKL<W:EZJBT.=2_XWR^SYU,FDA'
MKOF0!>CJ7D/KY5,0X,1<'Y^90LK<L-BR\QA)JKZW-_4V9T_%@]OMOR,C<8=W
MQ'>3/119 ] F:T @.(K<*.\&%D.XT4"_M^7M"7]K1I&VYV7+JG[\N#<' C\)
MVQ[\'\.(_S]V-CQ<O+0G;_SD6<Z+;BLY\:]?KMF8@G8:2Q%>M'4Z<J^Z]4T8
M49*I(2]#)[LE,TP&:];<'7);]B8Y>Y3>E"!>?P*?$[9N+$<17BQKT7@&R[/+
M!3"W2R&N>5@<+ W1/1:X!K(=%1LY]D(D)Y_]A.S=*..PJ??CA'T04ZR04-@'
MD8)'#R(A$XT^-(FTS&_N>(]1HP)+>W30T)5>@ECF:Y"*T0<IT &IRLY '/!\
MSG+@:SAA7!IGUD%-'^A (LZTBMPW9[,8@.^#"M*Z+^0H5/A$J/SY,5CTXP"K
MJ7C.-K=K-S#3VQ[)9QKRE'8,QXX8;/G;%<1\39&C?5!L$O^.DD-<I1K2XVF7
MYS;6213'Z:LT]^><N</>HF*F3T8@3QMR@W%YG,J]F\^;M4*1(M1QIM@X>1V^
MNT,X@%.ZOAHL3OMKIF.PXPE0^[MDE4#+DG*CLJ:\5I&>']\^\/R; B9Y9[L.
MQ<Z\FFOP+J]W*LBN(5MY*E%3IS)UGHUI"6VYVS=D/GS>H^H&O<&%6([U$&8>
MI9KE$2'\ 9.K#Q6>\28)P/^:A$?<K=^X;ZM@HS1W_7\OLM,O#E&)6YJN(T*!
MDX5#V:)P:!^:!P@BNMFTQMB2N%_,ZN(M!]TT\BLMKWM-Z%XJ?AL6:Q5FKK!%
MRL:-$DSI;2\!GNM )1%HDZW*'?K.NPU1/QH\V8/RO]:DQ*,HB^7P*#OSXQ$B
M_.#E/P.H+/4)2C4MI&]+]$/!M.T1!6]+/J_#&3PC9WP_=GR]5QZ*<6-J' 1!
M1R88N(^6Q'1-:S+/DMQD2&K#,YM;50+A.O+8!Z"_2'>"\))?+)]7R2YF.#O=
M@_M*6PU3'LA^%;!S,SGCHC/VN>N0S[*RLO?M([=,WE$<E>3GA]_R_*M-+4Q
M&B/TVVFPY#:!8#^LS!-!)1VV1*F!G$^UF\V_I%W^RC#_'%S?:U4[8!_4MC/<
M")@KE:$>O7WFF72-55W%< \^5U8KDIY9:_)J9"6-;&)Q\%C;P&_J,*GL.15+
M1*7IJYH= CXEO_]R:=&KO<->8#B4Q\SS6ER+@O^14$.V72>&*7)\^?!>$4MF
ME25$+7V5A1/Y[N9NFV"ZL8+X;?UUGBX/ @ES@1X&:_PW2[;N,307\@\L)FZV
M?4[!A):53\RY+[6(C382NW0X=L@HR:U7O>MDK;1T0P)),D,#K0#P#*!/]$BW
M3OP9+;WBQ1K0ULO</='X*7M^F.XR"0VQ9CK1NLF^K$I2=!W%,4C ])C:R)'X
MKU>O-W7Q!K]6NG[='L0?5C+!<X\1B/Q<Y$>)JUI@W@<$2 #B&@D/3B$'F>I0
MK[2DI.1<""I?6CIZM/V0H5_-O7+'O01HB"T89V5S0%W/#[(<4VFVE\[+#Y8\
MS0CD+]%K>C4D%X8VFU>Z-[UHHGC@R4D>39%]SF_N+&L*P%6L=-Q<E]VMI[3]
M$(61I_UNW5"E\_-X>4BRIO'-]'R&#=SOTEXUZG;Q7XV>&_5S21K:-WEFBDY(
MRUQPYW=]9<\[/)[MZL.APN)??;Z:=Q!>C:$)+(\,0T/T]?J(LXB=]$^PEFY&
M:J>]U0Z#?P^:\.F7XN^(O]V6>^]UL^YY'$(.H)J0W2_@:;!,O.QF%0TR^,8-
M,7\$S89I=J"5>/L7ATC9<7KFRZ]O7OR_X(G_K*+HNUK441MEZV6_!9D6D%M[
M <[T"IN1?-R?"K[4EPU'LM:6K7WM:-;5TK!SO'WBOPP'8*GE(A@_5+:[ 9!-
MTQTL"B_O57W0J?'GO<&RHO+8V+3DPF'M[.)QP0:WIY23/Z&/-G;2QS.++"NI
MCK])L(0CY<,/;ZV.H_R"7@1'-=#C$6V<&5I'XFMS$OH4#[/]?58!% ^BJ!<U
M<2XNT_K= F]""'/I=R]-N+I8FA%.6UVB'D\Y^,W$\C Z=RO)/YB'PP@F* X$
M['@>*5U3*O!,V3/]ZO:XP[#O5WX-V2F]'GUTMOO[UWF%6O8>!OT\%3_8N @>
M,-, 4FDU G[ Y<:C\=B^,V\* %^<=590N-?31]Z*8Q"]Q.*WW.ATJ@=3C$%'
M 3$DA[E65!+N86" 9JGL,LQTZ9[1:2[%(DN+OM5$<ALH"L,4+22,IR!%6)^6
M4:G!9?U; P_3UR9N?.3-50N34?(=ONV9V/1SM S>V'KB]7-SD*?PD[7_KB%>
MS_7C;\*)7V_/80V+8C"I%G7I*C/B5?'2"[""J1>/!PT%"0KF>FQ=153\XGEZ
M] %<B_;*$><)HQ%IID$KZ*G;Q8E9F\<NLD?SV-/RYJV#1LTX6)-%M7T0X ):
M CF)/#/=@#ZY/C5FVA3'YN+O3.-TNM8@%EW*X+738B^SO P%5 N'Q]/,N)JI
M>*Q'HKO4S*:)#?G^[.,@^NBO_JBO@AHEZHL.3;=['4:%G]F!Q?92,80*"0S7
M@TFJ+1D'(PJY8*6;6KZ$'+M5)Q,SKX+CLW]M.<<18'?ZIXLLB_\H;;H?VG[]
M![;Q$817!28'SR([,ES6)+2UDQ80[>>Z/V9I#<YG@3)NH]]1=S:N$S$IY;S,
M$]6(Z*D_XREEIZ<W+-KP*2(^\<18I7J4?V:!%:_PUY4,0HE@T9_RA ,!TK^U
ML.=WX.4"?;-G.'\WC-R=Z9D3KH2<*+#T&VZ_9RZ_]>C/>6*CP$_<V6<-5\K]
MA)X_>X<IB#.$A&7,OO_?XQN[F(7/>MZR:\"[ZIK4<#^)GH+Z67S0:)6]EI?8
MA[3S=]1K:W1;26AK ,*P#(*T_#G#@QW'>0SC?/"B"(N72Z/>*ZI>P7>FM%*6
M/CZU<)8S+/R5P?[Z7D(L.&"OP8P-R[!%<- TXS+ZIUBKHC^NO//D35L[#I8V
MB9D]\GRK;5&<.K<!^S<7 FLTM ]B1YJ=#2<&E0NWN 3LMN%TU46R'/G,.2D@
M9JY@?)7PT\8Z3(@'3F4(VK+3[Q*4S0[<^NU*$W[_0*_.%O#Z[37]+8\_ZZ/P
M34MUSJ ,B?6?<'P<M,D&B*-J7FS;J]%;U)0'^NVGATTGO5"U9U4^:;AO&CA%
M.-XV,3C<Q&\-FN")1_59H + 7,@O[A!J9!_^T?WL%+.3,]M/-PO(EU.+U.Q>
MKH$B.+X'K^0:77=4MQ+?M3V SWW D+B59 *]IUH6HV;;WI1K!X](4SZ'3[WF
M"NO#+#@18;U\ON6]9?QO)[:48!J-D3:F(]>^(%:=2SA^RK8]' ,=;OUO"O G
MW448-P.@DDQG:C<LG1#15;OZ<*.HM#YO^<J:;E#/79^P?)SPK%>\LWCLB)$!
MBXLUP^( QAN#W ]-,J_YU<.[L7&>,P7+NIR1]B=?%@3YWK*]H*3>Q1-ORI_+
M]AO*//R;'D.K_OZ*",GV$$(,TV#QY@Q7B<GDX@U:5[[*]>'/BK<8A25U9;US
MOE0>%G\^-8'D%!>\R0QH= '$!B5^2NS ,$Z_2GNEX7(<77SC/()GO)^;1=+$
M2"B* ,,:.>_( @$Q0:\16M3L>,V"&)@#.O9PI_O4QZ[%D]85*43'/L$;.1F-
MDVB]@[2/9(* !!+WG#XF:?=!457V]S&-C.F%JH9[!?[$'(>5C%]@Q$X%.!LI
MLFS%N'5 SJ[(DH;C6ND=5,D$PHW-MMJ40?I?4;ZCED-FC&=&/.6GCEPQ$M_-
M=_T1BY0#_(@A290_8#[_"'?().&;AKH7[S/3&^1<V"NEHE75_UKN_$^K.E[0
M4T=_W/9O=$0<2ZT=L'F)NPDL$/PW:O.3SG,/I,KZ!5XT]W6\*]Y4?A.T?1/
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MASRYEL>]O<#N8X,&>CV'D/[C9G()A+,:+JHD)?U]'W\_>DKFS@[6+( >K72
M:_STY)T 2QAN*>N \MI?O]C0[Z:LX S03L_]'-I*IY"'C#[D.J5&]*Q:M_GT
M!H>PEFP6A(7=H519T5"1R. &4:.HZII*YS5>@>;WQ<$8C44'9;B5DSM)77IV
M-J)27SR*YP9ZTC?6>ZJXX!#-!(JNZ?*K^WC4?2[Z)X(^.G0A\^AGKT!Q)-(6
MT.K_E]L8_X6KGUF0I^@J>Q#&^"OT%H48O8WXCBF^]''!;K7X9MCS?J#HX@<O
M\7R ;:N%YQ[FK8([.1BZA)8\UR+K42O9=\HJG?4H'\TL[I!9M#=47PS;FGL
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ML>X'PWX=..6@8^PD+\U32$XDX3F>H\D6@3)@TX+0S8UKD49SBNY*B#[;8!=
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MZQJBBF$J^)H;U-I=W!G@*RG9)]XI,U?"T7YOP*F''GC>VY$W8ZUQ!4&\C6L
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M]?6R.;!\HFD;CH7&3?I'A(MDE=@@'IL;?,-(*<<F>5DM4.ZZPCN#+<(.[\3
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M2YLA)4&H4B5H_%L']X*UBUULTE>=P-7DD3T53[>0HY&A$BFO3,Z?<>T*5N_
M4ND4*5("XK<%7)0Q,7H,^)JN+X":5,%3, I/-?P6-[M,_T)/LFM\F2)-\MI8
MG"_=YG*U_5SU!3)M2T<QQ"PZK!1E+G_EYGOW*.0P="SKA.5+WD4S.E'T NF-
MM3UYU?AD^82TI.O)T?SBDD^*/?8Q8&HT"4A<[H0&H3JUN0;W;?B?VBO5&:4>
M P*=\*BVTE]@0]M=1TG=F9L$O_@0A07D":=L4_6W%UNM <=H:Y#Y\'0;DY5$
M:PZ9>RVWRY+5F?ZB?HT&U]._:K,3,JX.(&3<K&B5=_(6WX!T%NM?^K?Z[6-J
M)=;MP399@]"LX64*]]'-F5@"0O D =_!G@^N^F^_;N$@ _%T\_LV%DOCG^,$
M+R\OVK#PJX[/M"20@%W; )IY33*2#88U/&'E!UQ3Q=EAF6+X$HHS[P LJCU$
M+N'E1+_=P,:)#A"T93MRRCZW=;[N6HL_>8S&4T04CZ\H:!Z4E:,)%U?*5+EB
M'Q27A;Z>]2VFV.=EKSR<5F5</5K9Q,R%W66M@';.7F@2G;N$A?!0BW1)Q+KN
M5^X3KZP^/PB87+K5=UO=NOLMC8G^69NE"AB+X_E$;HG_^#E]_M:#<&0 O/<W
M !GXSZ%U%Z06F8BX2B7,QZ2+=_2SZQ,AW#8KY$FVQX+RIGQH!9F>H%N+&>DQ
MU_]4Q*LJV;I)EB+ /DEV1D6"=6N(KTB\/DWL&)"7.S=+ TT@R3U3)'2GW%GJ
MX5HHDOT$?\F\'>=%7*NS#073DDR9/NAU1.QC6K\< 1FL 2>\B;7X7V]:)/TR
M;\#8CT<"GN[6E=%"+[\8Z^;O^Z;%2[=I/?TW9 LZ3_1*TKS<^969FT,%7T?W
M&K4L^G1B8G9X4Q%UUZ.V(9FSM:;MQGQ$4,>ZH!RGVX[;H1;E8[I4TO7O+5X9
MU^HL.CX">!+_\AY&.!@<Z2+Z&X((_6QX%]FVH9JL"X./9\],<;\6?$L(>,F^
M\)F)HEWQ)/&PW&F)/H1E>_*[5TT+V"-P"*3PC>7]8F@^84M8*?.H*'.)IJU&
MRL0RI>J9RM8Q1ZR$K;GAGL[&5ZY!7CPQOOU8Q7'3*.0TK-^.NW$/\TF3[43'
MTDG9J,A>3+RGIQS-0)YS(CJQ5V!2*.S[, E/_VR'UEV%/$HB$$5UAY9Q*AZF
M#BW7$J*2_FI7Z+'7G^8*D]S?D:*)4I=)EPP$6QU$4001(4B&?]@3NGL$38J?
M3/@K[(N,P=+XCKQ6(!X"X XM'C.22./E<:GI?S;/PI8U[MWTF_:^K::T<Z&M
MN\)=+CO8ZZ\G+#DJI&T::0_\O I5N$>^E#[OH2V]*6Y6,UQ6*/AN?M#Y+;_(
M7$FGFW7.D,G/Y4D?U[SXT_^]E\W@[1VV_XJQQO]BLL'*&(%@31,UA<G!#$[:
M.=)],@KE"*EVMPS+^!P_GG'/X]PKYW IFZEHP? _RZ" L<4R-'\9^!F8*J'2
M:>\XKX<Z"9UV^86ZM&63,=DKNX%7G])NZBURU NZ?9=J>OKK[-^H8X 7*@ET
M'NZ31W6AY%#=.%%$%%=]M?USC>L7KCJB/K# _IBC,WS/6>:$@ 8_]'P8_JS\
MU(/P(!#3O3V90ND@>6V6$'&L<!&J?I&[B.A8@(<O:\NXSU/2:^52B7/\GC>V
M1;, 9ZQHX$?^PJHKAR+93P<O9XY.J K<&XDOMD-72##?C9<&=N7<&D2 J);6
MY)O-H2+H?+? 0?OIJ1[O$H%3!G\UGW+^B9@)UTR@U-(Q3>)'UV JIJ.:.J<S
M:PM+[((OJ<L6?$_GB09T7YD>X.+]X5@JP9#: T7/7BS3%H5?(VUW &^L3+S
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MIE Y;M?:D)K&F_)^7"_L_EJM%4UQ00L^C5UTEFCLS':KWD*]KYG]3; D&2]
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MPO<[ "<Z@)>(9FX"?Z9:4UJHJ,+52V:KAP$M:9'2KGSN8K93;UB&4R!6_XG
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M/G;@K[%/0\'EUR5U9V16?2RFJ+L.QX!(#ZH%P3S=@AJV .2&G=U/?N11\6!
M3)WIW3='[0HD?AX]J?_OK;!<#$/MUQ[ZM8@\1/"^(GW"\U-0<-[L3Z\TXQ_9
MDU@1FX;DT)/M@O\[%\]$3T-<H?F3BZ+W<6=6O[K_FGBLE-HA%W01*,C*%D-?
MD+@20V"A0D?;Y@LW+;[LG2Q:H:^#.%;ER6:YR]F2=[(F'^B$9\21H:UQR=JE
M!G]+M_1;^J)3/RXTQ;X8/H.2\?9F*0QN'MLH)=\<FB\LPL?Y\X]U_K6*.90&
M8>\\;&>^,/."GM&N<J:J,XSC2.L8T*;2]*B$VD!&2*\0#$B_O_GPC+O[*"[-
MI?ZV_/&BZQ<_#2^4S!'Z(7/87ORRJ7_P0\EA2EPQNB@7#]#YKB4YCHD7I A2
M4TAM#]"L",6U3"<?O[,995NNJD*24I?ECP$O<>=UJ9M'9O KIN(G^\XFV^3G
MS#(SHJEMFB&%FK\FBT<?+N%T('+[ 7+$7G#KW^8J%.$2CF<SR@ B!6-AG-<B
M%75>$-0*VY<[O5:)39=MP;Q\X+X0 Y%72!31]FY6MQYP %*CB>C7EUYLXVT9
M6163F)DP[56QR8U6$6!EF8M>(3A.H*M G%257_ L\XRLDVOPWPZO"&T6:HF7
M%"Q6I[:N_EET<QR\])76Z[?!-$[]8DQ__T0^$8YCKME4:;=%OMXWML2/F2%=
M=9U#KTJS>?GS S9O ((G@&(XLV- -GSZR G1KW(,N*RI]:R4&F9ARK5"'/'X
ML'GT4#;23"0BXO+E]12'T2>)_J5Z2J);V53;/MX+*;]HHY@"\%,<_\P*4NC*
MP#4WCA@L5-'OG]L/%7VJBY=7:V*0DYA+#53(@J"6V>H0S-K&B#0)1WWM>?QQ
M(0+[]OLJY Y-G)Z!N$U3JZREQA*I,AO[1[YMBAJ_V'=:]02OD-B00;ZU&E$1
M$/OD4KV'HBRBP2]#87%#_E-/IN@7EE)JX$12/Z5G(,##G*:VL*GMQ43-N;0S
MH[$H[;FY03@1@Q'L_FU*>P\51#O<;GA^TYN[W? Q4H,K3'IWHEK*/#!3^X7_
MHO'1]YQXB;('[?^;]<7_\0<GQ^"'05IQ/."YS[C+Y8B;;<^^N <66N(S/9L>
MXJ\5WSEU'5[1+EMP$\A.$'J!,V6DDM(W!8^4X"ST!FT9:LJ=0;BI3R[\*:G:
M0 3CXUCT _MC[EK?#=WDYTP 1:\Z;]8KS\,U"8SSY20"T10/8J(:69$\WQ;
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M]0=4H[FP>YWJ'7S6 F%QB0;"F=*&0=\K$\\Z"]L%K:(+'SS_,VPU;] ]+AS
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M*OJFQW?HQX)?KM3YT;7YS@?K?.Q)SHXQ(6\_%/L/C;IW53&C2/^2X;_$LZ&
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M:6&TR5RN:M*8VS)?PCC@O#3;^1?#,P>@GYA1[DUF+#I"$$+=H<IP>M??T!)
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MALDNK+6^:WW6YY/-#F6:L@1PWM(WT@=H:&B 7]0?@+(,7-2#NSD#@(D)<!D
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MW7-64&=\)?SF2(]ODC1QNI<AF5D8'T4L(WT*/K\%K43O>'V9W_KLH'P@:^D
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MV87\9AU6IIRI/G>W)HIU+CET]^K%E^\\145W-,^4T@@(Z^"5"6L>+@P?;FC
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M@Q)/5C*+R3))O4\\='"H.R %VQG&\C9.H?CU.L![$D=M.QY2<O,=@A5"=.0
M=LH])<7N6U+1>YQ;X:V1MA>M]KF6?>S" 4^,^ D=T:LAVI^HH_7M >JLZ[?
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M&"A[#S<8:=X89UR1_F0A9=^P].?5!W_NV0.X1,6$+H0L!6"/(WV&KI? D12
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M1%D,C,N-S(R[;:)<VZQ>VQLUNJM /XP:VB]BB\W)QCQ4LR.=)\42399A[RA
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M.W1Y0'&AQ9UZ]452"@5XB)[E7K+;"N:%\"C!..!,=A^-BE1BN,VHLEFN6V4
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M4R406 =!2X5%Y4U*)W6-Z]S8:]DU"4?^$EM$SE)#\8W1,=NF?8B*ID_!RL=
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M^\%UQP"97003V+/H^,O WVAA*,38]IP8MB8Z=\6.:_3Z/3[\P$^<:B%H$L1
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MB)>:MI:/ 29N0D+GE&*K6!,.G:CRHU%*+5G,Y1@PB KV\GTGZYSF X52TX<
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M7,O7[QBX-UMHN:1D^B.BS#=R23*=>\B<1PL4R>":H!&I#7Q5JPR8!Y[6Y%J
M4.K#/S/H4#S!7HE^E'M<ZZF@W_Z&1%46#8+,%NL-D@%9EL),C$P)#GY%$OA$
M$Z]T1+]_AINN^&A8')'";AL8IK)Y')U<41'9R1(V(1'&UCJ4J/BSL20_$43A
M#]^^#XF;9!IK#70LU)^&[%VK$[.<?5.J0KX(LLZ1S1H3&0[53 !5.#?D)I%J
M; Y)TYH.(HFW%[>KC"%6.IXL<></O6I//=GY(9GMZ(Z@(H7,,.@:/TOLD5PF
M1^4O#VQQ.F4W"4LINM]951,^\?5>1!+U?'#A<L+$<Z2VY^7WK06Q_'S NWT
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M"-BID_0A9U#V0M=5>JXAJ(0N&MM+7#=W\YE)^.0T/S9F\^M=+NK3-XL8.U[
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MQGLZ:G_; EC^3A(HB-H$A>-@G"=N.U%UM#7!WW+TVQQXSO66^=_2/H F53F
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M M8YNV;_:)>X,X("%AS+XQ A!B8/[:W?V=E$!>L:2M+&J?9K0;X," X$6&7
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M#^P_Y(KZ2OZPMK*)87B#WN#W@U!,A[0/< 0<._'D!&A8QKZ_TS2<^.UE/"R
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MI$VN_.B9\YK[X2D0$2T$$9Q^\EE:)B/CX[Y<18=%1B>K2JV4M6N3,E+H]:.
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M0]S; S0D0;0[-2C$5<%]/N@@6*XZGUED?'QC@B>2X;LS4CQ$SRMIA9["@,)
MB,>#Q>O8"X<<(4)3N]VJ\-4.K8LZ07M;$NH+><;=CY0SQQP!K-> 3U.IRC%7
M^AK_RS^JK'H;I\=W5CWP8"-9GUM//C!*1&(FPAG*17B[KOU9T 9'VB]8<QFI
MHY[N?N&7\/:LS'+RNDZJYBU4/Q=Y'-CNOO\',\5,<!^&\<FUNU.N/[185KM4
MC-95EZ#_(,$9,B2!-<BD$,VGTR1&H<\!221+M 64U95P_7C" L]34FNJ[![
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MPMV$C/*7JX-#MJ;-0D)\W<X\M9:/4.ZJR@! (PF:+B(6?_G\^,K_*:"]R7\
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M[2^1OZ]L2\^CT"7@\TIR3)3>$_EQKS3CM,[&>=^))_4TPMS?&J4J$SN%-@=
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M1\Z5)FB<6M1.\L]Y[V(:5!7>7.8TY!JZ0A]EFVO4A0[HRF<=SB-*.?2SQIV
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M=FY@@4FKWY-D_[HG'W%)7'2)3=B.U8)P'8OQ#@[*SR!"=/??5>3K)^$,]TO
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MK%EUC>K'.2,W-.!K3_F5B\L+%CU4Q^(7!#X$U>=>HP)11>5!165N,_WA854
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M-^)*RR+N/TFZ#0\DQ5$ STBV[< J8&*+X,H'/1@:]$Y^7OF3MY""=:\,(EU
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M^;W%?$HML<UUN:'!R>/C H^Y4).]WJ)6\:=17>XY2".6E\C#3+Z/@Q+8IBF
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M%%"M,Z;!7Q8DZ2<^$W_CMFJTJN5^8J;CF!ZZHMK'O.%I?A0 7FHQ O9D J*
M9I9X?NZ9E?.CK9=.IOK+J*9XMMGM9=T5J;3]Q]4CQ).*9PQ3[DIOJ^:< K^.
MF#^[!JH)%0%=5W"X5DR> 5[PIS<7D8N>SRU&R7R]@T_[ ,SS#_'II0"BFY!7
M4?A]Y(@H:7K6-):/2A.LPX=>F3 [ +D$3A5T+=A<0NBWI)61738.WT4(,@^&
ML6K1$7Z^9P*(=6E9\_ S@8TU3S]W/ZWTR3;J=L=D>4B2G:3!1 $J91 H2Z:G
M #IT:MFX@Q!ZH[8=/).#WQQT/5P$TN6-]W@#-,I]80Z_=P?%>O4TA@5\FF[S
MW(H/:,0-<3URX)_^%TR4G(P3+ J"]HZ@T@WQ#&7N.0&?/GD(E"QJ3S&+9VMS
MT<]&-DS6N VWD/*4 O[Z6@ 7G26Y;0]!( B,J=Q%^2L0X3(%U@(#7OS4&)0I
M[,HLT0+#FH7.-;I=*G-\/L#V=03SURFG#> >N7;T73OZYJAIB>#5*S;<PI^'
M.^.DRD6?_"?T4&E5;'[54  <5@:.WV>04%<)E8X7X:,5+V^Q"7OF@LX3&9-/
MN?R@Q'/)1.G:(<G)Z@Q5XX5']SN+F,SM-^@6<[24244:3 =!:>,&&.B;\BLU
M-<FAW>O97Y1GOCRY^6E4ZTGAKV,Q?^YU$7X,,.[(A-W]Y,2!_O>QX#T)R\S)
M%<.,M,<C/[]PB19_VXXC\:(TS\N.CIQK"<FV5\L(+98_"$KB+P2S8X5P!P;6
M0L+)G2":19L[+]K8QE8NZ95SVFMR3(FJ7K>\?-BG5%U U,2,1.T;KR<7;)XY
MSUY)&/)\GEII>D?TLE\?,,/O"9/T9.)UW^I'EEI?^6P44;X130=456O1^PB[
M2.1.)M^'=P./*8!B"F#3T'*8FK<WB%RV2QOMX)GD3BT&K#T.SMKZM7:FP<A>
M:3TA..N58<.3X%-[J WI)C8PH@6$I=7)TL5JQ10'Q=_+SOA2\=O+L3%\(.7Q
M^Q>/4_3TA4O>4'W]+SQ5R/P5V [%&\]0H:D)@&YC(L\#F4'N0ZZVF-[P?27U
M1(L1@US3#)_G G3L)6).T9+I38]7YJ8&%C&Z@H*A)LO0;D^C!M&FVH8)K\^9
MC"FW[B721EN83; _N+,-#L/++9D@H=%G[\^2W[;0+L,N@NVT)ZOMW<Z,6TNK
M[OXL':W6>Y,A_GA7DO_1IHT6'=YR:20*=Q) 9L'DQR[?DYUW:HC7'4?76'\X
M1ZN:J(>FV7*CQ<3CMDBPXY$92W1T[5+S[75J5@M$,S<<STMHK*L<='W[,?<"
M&WQ0W-24/I4\:8!PU>3%?2'%M0D%B8(GCEDD3;Q$#5L)>KG50_/"#>VG$PG"
MO;6O>Y/:N/%RZ/<\%?C!3C5@'+K&Y770<9F:8&W4!T W75Q &F!8NF!<L5F3
M[4'M^-'VO><W9)Y9>>UZ%3)R/?K6^>-;.P  ./=&ZS$I"[KT4>L"*2-,')$(
M :%]V#VF]I_*Q,P<BS)D5.GI2:XF/M#K6&S\ <58F)S>@G)3 %/D/"HK?S0U
M[1^#II(Z/!1-'Z,<CPYE>X 525:0[G_Z U7TDW6@_;O4TO?+;_2%=0%!^L1+
MW=84P#-8]!U!SSQE[;(_D,W;\#>()\D)84*D^#!UB"UFOU?Z^Q$;^X*BK_"S
M=<;R0 .N-,5L?XN7XH?<R!66>LG:L%:\3^<9*-)/W5A0>ZSTR/[JJ*'MM#M&
MC/UNH^2%N'/?^B7#%QK![V  LA#$+H>_Q74IE+FKGCVQ<LY#67[P>K+VJC?M
MK&H!V]#(S%17  50XTKD!C_&IV,.!#\0+Q7/CH@?8Z(^&;U7-O8NFB+G& ZT
MWQSI_^CD>X:TFWI#%L";+8?%*<(N!+VZCYG,85WQ^FKSA6F(M(ZB-VE<;_H?
M>P^GEF0F48(<OAY7CK]3@ =W3(48YQ<^+>_];GC6=:##$>NUD1!U33!M)B.H
MYR:;$AK$A5C*1W"VN!.X(7)X@Z??@[Q!EX)<37/V<,'[$K9Z^@I/]-"<761L
M2,$?*' T[C29S'2>\-@^; !*!ZU3M/H,ZPX9FL)Y9VR\&6U?XU\(,#N)N(X!
MM0SF*V@#\X"8=;8DZ)$P1H5\<0]QRI-%%D)@Q\F1^0Q4<,^8H@"N3BU ,??S
M M'%<6&T6VH;W0;^ZMM#GA9>E@83_OJF)SQF.CQC<6P#N1DS>@!D(D)6>BT9
M15BQW&4AB(=-YL"[[IF>@:)194</K:=-5',?(**NZ#HYTYW>4IY\HFVQ/TQE
M"6.+X63F-KP/QG*9 GA;:W YR^R7!JAXT]+4IM$MQTJF,': DT:ZD941L"+$
MM.?Y$1^\X@5"Z[\A:J);Q>/=<Q9@])^\K9[L9"J]N'!,4Q$6W:3V/ZSX]592
M_>P-;YE!KT-'M\/-%#VH3:4N( P$[9 GRF$(R_O=<HEM'/@.GV4"F'.SA+M4
M/NC=7^SZS'-ERPD#@-ZS3#%_AQ#S_6DJA6Y*3B(SDE$B(IAG(Z^6I#.:P!<[
M:0X6[M;KFE*%_*6_ZMH/YZ7W$8G "NKR09/)EXU?]SBPQ!W:MG-Z\ 0JV!C=
M"G\C)J^VO]+LE/#"<[Q-&"*/J>\T8;3!NW:<"9='?K)U':RN-:N7+)$7JY;?
M^VF@2'.:A0&N%$<JLN'%-I*.A'7LJVJGGM;^5O39Z7=]]$KL1/SM'4="%X?$
M2WHMBR.EHWTB)V&9-!4#>@9EG=UZ..2!.JK/2>J_*=B?,:"'G"G4?9H_E+.M
MH?-/4W_RB8]6,K'V)\A!GUW)#W:#+*US&)O!RUZS.70I5_JWY*,W+J].C69:
MO'"O>V&#ZLS$_;K:S24O9?[7PW,_PG_1O#D/@%RB %@=\/(4@ Y;/ )SG8VL
M8,=&Y*C7C42&:9 ^'<6[!-:/[]=LW\NYR\R=9'M$E[H(L-S<_3?8Y1N0D=O_
MN6$'(\D@NI&>>>8'XUGVN7<\U2-!L(OG3$]-E5/N'9.DNRB Y3=4!? Y%4I5
M+:L4 'I[&R5M->%K417V'30DQ%W!9_=7X]:X,4S^#ZB2-;OH3TA>&040NZ]D
M?S= OZ;-TY>C#L7'C>*+OFAXW'&JQ^+\!\H)\2)H>-QTT[I=G6Z%F:WKD_N5
MS00GL.K_!$U[ZWO+@ZTLO)N72>I=9\]1826N+,<?D6P7!QN 4'AK<.T?M31<
M#>Q&2T;6D R;<IW9!81G1-BP9]U(?_E7UK@%%GQB8?=W:QOWD*'W><)EHWV:
M'71.'/DQ.=^_0YCQP:5L1P@ZMTN$NCP>J&8MVD&"BM[[$6I(?/IR]\1)TPOQ
M<L7ZP;I1HCIT[?.Q$ 29X)KND(>)P47_(DOH9:H(^L'8:6(J,QI2DKXJ:X;E
MZ6M&>WQ;YQ:5<S5O&,2$12)=&$>V\-,'CXG 0A*33?W.*PS4:MV'WK9S/F=L
M/0CTUPN0X:J_"5YRO[-YG7Y!T_$!!>"R0'BQ2SIV1+5ELN08XD23NW4\DO<U
MB_5R"5*G OMDQNYEMIM:,'2>1W]'WPW1ER#V0F).H<K.)?CFHE8B-M"\6GK4
MJ3[]M!1Y:CG#E=#\/NGWN- L7]L\V8B8D,^34:./#L*T4?=$ZQ)T4:ELF86A
M:S+LQFBY8BX#>2+I0*+VD,OK4"<BN[]'Q;$LM!\+PSW%()"(Z#/X.\59DHWG
MH,Z%OYHR)1+V,MA7+W3\Z47@+1 =T)E"I,!)5(L"NCE^U]R??B;@69);E^WO
M*GJ-EI7PA5H*P*::T1S'6<P"G_)*CGFK "PC6?>HU"OO>\[NWS;'UQ),\:&5
M4,S!H+FN4&MK&QJZ/U=\Q"T$JP-W0UFIHO-MY-+O(X]6NSNOSJU,O=)#3GV<
MFOFD?_]138@%U*%0+ID-F#&U%=I;F8-ZCI_5_?M;16ZFOJ5XR<<5HO#IO;05
M"N NQY3K5VB'-IE[44HAS_.!Y+?&2@8@6";W"/X97N/)\LAPP6K6_MJ61*Q=
MV.?&1/VE^C?^SM+!2_.L2RKV* B8: SR>I,^&>^01@$HRAINNX-77YQ!=[,Q
M,0\?)?-T>YMXQKN;G1;YAX!W:3'CEDY&8)&@T-7TO9ZSA'N]T](W;Y<'6I)2
MP]BWKR\$1CQ'2[9^J9I-/3J8]XR?!"W!$,Q*$D,_/ 4>#?MZAC9 5W4=]65M
M-3^NG,@OLC=)A'([EEIYI)S6!=:=^ )7(LS]B1WP;(3'""K^$1ZX(B-M4(79
MRR[M]7?$I<M@O0;N)S3P[48!\YXM0#M4B2I<"]X9*RPNG7=.K%<2^XC:-J=0
MW&>\BC_&MD? (=T?;03C)'T=W.48\2LM$SA-:*:W;CA]+7*\Y=QP@_NY8=SW
MH347Q*5<#IL:]\7,Q9MX3X*1!Y!%PQ>-N&2+#S2>$,?211O(E*L$OW">P>3/
M>),C$'H4@"L%\,X2R*W%^2=,LK&R?MRE[;#>!K4Q:)S6=-&5-$<R@/?B-L&V
M$ Y228LUQG;9.^9I*.9LQ0SST<%UIC:(V)>I/7[[Z3J7DYC\TPD_HN?\<-5O
MFYR,"X03^Q#;G^@.M)#3Q$+,'^B*+F1^B0*8G5V&QG)SDE<>8G8V(IJBZE9'
MJGMLD\NE41JB6)W.,*W[^,"N$.^*=N?"FD;]5'V"01X2RXWA?I'QAP+@9!%9
M]>B$,JO]N-;\_?> QS_IH\,O),]\?#AZ=,F$UI,LZND8HIC+#S=N"(TVD6'V
MFH],6.'O.+/L@V(.I7W.)*NA2]-0;,X>\HDO7\W\A86%:&YILR)L]>YBF=QD
MFS.>A>"A@T6BN;1X31@-"FLR#T9P7R?HVI\#5GPR6U]M@^]/JB9HVMT@Y3F[
MV*NE?H-S3#S2?97S7UU$_^?V10@UH;J0A;86KN,O+<,X-R</[5!!/N8N"*NL
M%W'\Z4\R6@'^NB.$9X@[$DUQOW6,K__U98GW"<-8]?&@/;!+0'@H^D=FX)GY
MD3'=+[O=(%<]/J?+F#O\Z#=:8J2/B*7O,'I_GZ@PD2IL?LT"*U89YLA2MO:Q
M[E;-Q=&"NU@-M\':RI1B.E>A%:5#.2)7"6X'([DKOD1B7EY$^K=..2:;&6TG
MFAKI1_'_=E",%H>H<]JE&8:?^'[\&,J/92,SLF%4NA<N-TP<@=BWM=BB ^;\
M9ID;7.H2TEY5&!9-N-8=,#QAX/X#K)XB7LI:BMDY@=OBH^>+L8'ORKYPHCQ$
M+C<FW?%8NJCXZ.J/<Q?Z7"ZV?XR0HIV%.B_2>@ O4KT<'*/%\SO<WLSH5]F3
MYKNS=<9K$9LPW6>6&.ZMQWVKUAS65K<J^BZO<IC\^R_Y_<=.,=.FXU.Q#$9X
MYV6CH4#S].?LRXZQ)B.*,7N?D\W($FUFZ;@M+"_NG=\OO[6*>9CXEU<2B\:G
M/5"F(_@LM'.*?!EOZ>7KSFS" PN2A+GUZUX?;/[#R(]3.MT)O=!17JKE<,A\
M8+'JN^G31:(5+PPO?HN;_B'RN[^VV:+>2+;59!(8!>12'(G7NA1C,U[-,>?8
M4.=ROB#%W^R,_76$= T\'.H,3L@!=UCM[[3<<?7G_EHQ>K^^LK=!8AXIYB_Z
MT<GU$[IM#@-/4I03M Z%Z_SVJN53XXG6-B1P3  ='4)*C <>+VNYU&AHK$C"
MLR9?X;S,0HJ;IHH(9;43"[.H%D?TR<[B%_SIK/GHO!^(X\I"/7N"O@)M:@OK
MG1$L:_!^N,-(2C!7J_OC(J;1M1PMG4M1A?$QU66"A6O[YXDA6,G.UF=RS) '
MM3"7 &2)XZOSP[3*#/N\I$]]>XSP+S6)ST;LQI?;QO>>M=1D!_8JWN"W"EFO
MUG!>LN?M11EMHN;?!V;NGAA=U' E#"!3/->'C#K(:J0/Q[>53%A-9!'+]([B
MW:61ZO2W91GF+T,%DN827@3=_K%TE-7*2K(\S>?5DKXV5K3U:!]7N#T/M'GD
M\!I3O6(9TW;=_<_D)5*NJ?E/E-\JH]D<-#BT]]LP&_<?ZR.X(;>HJ<:O0/U?
MHW 3CO.F[\NSUT"U*L24$0X*H-6+*OSD+6 [)Q2 F$\G!7"\30%4"_PD?4>L
M1@<ED[9]2-?B:JB^BC@5=>"E .!@TH<I)@H@E *HAYIU@P]N0X]WH9OZGT=U
MN3>!=_^E0*12%BS9O3^3U0$3]!_4M.V*?*@24$?E)\D[65HV.W.VJ36':9Z3
MW=Q%:M6%6B'>/[-UC6WNG9:0A0D8.*%IBLS 1K[:6DV-TE;195C$3HM\8>E(
MT4PLG:??@N-RWL?5)==,4)3_XXQ:._N0[<S260<GO?>7][D=1S3,"2#(;6Q5
M/PF^M"N[O*C^-8Y-PBZ_&/+:%I08E!4'6LH786YK4G$0FE*"LOX4]//=X^7H
MT3\Q0":%6DU-<OF577.L5 QCK'+6^TB6@G';06A(G\E\82<="'8J?;U2E[R'
MFC,Y3-U<&Q96@]::PE#Q*UE(-^P*+%HFU(OM;'!6U2GA":N!WT+D=CN\QOT"
M]V_2EQ_0%M.$-@MHB,(90JY#(CFKA??O@9QX?_2Y5$^+,UATL>K@"!N,WN3)
M:-IB[)U9# YQ@>B!D4L643V2X]ZT>;M_XC6V9N%( 3SO9SDSQ9<LP<,A+\:T
MZI>-KY.MM8Y&GI=<.5D ^$RVF/3 ,";0&(?+J>NCLOZ@BP/Z'+,_)2.UBIS.
M(P#M9E0NM+4X1(6$)2,B\@2[0P'0_AGA"LHUQOC$^!RWVJSLH)P3)%['UO%,
M1WYOIX-UMC&0ZMO4@R31N,AE6Q\F3P;3G.$M=U=P=3]/MU3!RRV%D2)WHA4I
M.TP*(HU_!9^;AMRCTO"RUI+<(;5UZT<Y0@#SAWNFOGMJECUQZE-CJS/V#'*E
M>L4JTIN;DQMY\5W#<TG*C6>SF W<>WP@%FA3C3F)J5VL]QB[:_V$<*._4]9J
MSXDV?-^A$IRY6($K=B\BCPI(+]AUNPMEGLC_'ZR]9U23[[<F' 1%1(B((#TJ
M(DH'07HB^@-$1 2EERA(C8"(0("0" A(;P**0J1+C2 =)'101*3W$D*1GE!"
M(&WB.3.SULS\S_NN,W,^/!^RUI.5._?>S[ZN:S_[WEO\'D['+S;\@?$+V/[E
MQ$"+7\[DJX^]Q7YE;HSL:Q*J,]W]'3_GY6/.;/Z7%VI=X^@4?\ R&0];9@ 2
MYJKH6 *DRV35 P>SH6FL'<\:))9/<,;'E]X040!'9C^<;=HVHC57;SH^J*GX
M2M N/?!7DGG0EO[3\*L(RX'V'<RMK&/?[@3=*=,VF1$1=>O.DKZ]Z2Z5'S:M
MDMEH5^H]H^SN?.==)7OW10- TL?Y1*E1G'U F^RYMU4LG0A+<CL.%#++"[Y"
MK/F2(?9&TM#1][+G_)W#R3I=R8]B,\4K[:@HL CYVWRF:F<S[W"Z.8&>NRQL
MTZ&G<^6[D&K+8R!WK+IHR2+V?SU"S P*;%@&(.4\V8F^E<L %$H7 _8]8*1T
ML@]N+F84=%H%>%;?"Q^S+;]Q9!)Z:S @V@K\N#$ L*]=,@S;^8HOI!9 <=M#
MQDR!&""];ZC,DK*0P.=*/_E;WK?_C+M?PXV$IUE.G?L;)>=,Y+S3'+R'$XK4
M,'\'8%//<9*0Q!M8K]QQZKW!OHV=-PZ[HY8.SI* @/B0 '!!4PK]U/;\]GER
M(\F!*3]?.TRNT;N-1[.;1F6?M5]7^1+]0.2SX%,#08Z]>5(/F?EWHAIH[Q"&
M%!!94X]L5VAI3[5*H8 U@^SD!IV'FQ;8)_]9E.]'?WR\(F/AN@>@P<@EQ-Q6
M*)NRL)%7-_AB-6$KU?=%3>*,G>?D3JK+J1MAWQ\YDH5VYLAPEXU-!D#76(_*
M1-H%J<(PE+.L.%YRHX30W0H5>6FEI8/*LYR<[O>2V.\ \@W>&BA?"1^(D7FA
ME'C_.MJ=G$X_Q4I11IPB2[O@C $()?*S%,1#8MS@;8>^TKF?SW!RO#]/'APW
MU,2=ATNWHW'G6(X@./2D#0X=VRQ"#NO. ,7(JAASN(JYD-+R/2N5; Y=*]7$
M/1=N56:QK%NB.%#/$EZ#1)JL&("38Z$(IQ.U98? E[)G9UV_QYT\W=( \*[S
M_C@6"V,&>OL4B@RJ51TL0=:\[]N ]>*:LW<?6T^4VQ::@_6P_/DD59R@*[H#
MVX60S&RPKZ#GD"P(*\-(^G?BB0K_?+N('DM2C^PR6WSNCWH] ),*\Z[>!-5!
M!.A:\//S_)$NI? #:&3[4?!2]\3C-,L9ZG>_M,ECU[19M*4@85 0E8-RTTTH
MHG!>%*F-;&OS]O!6?OY=P.!4!&>DR7A8=QDR$-5J[AN#C457J;9APX2@[XA3
MUKTE4('HV(#&F!O&\/F:I*.7*=]\H03=H!XF1H6@SI87>'QI+9<I[ZXL*SZ+
MD@)0/BRL=&, B).#3X81_@L?@-PZS^^VU-Z_]Y5G^+([YPW->>\,HA<0U7H?
MZR)_UKW=.+)[X9>>1\F-[$([F[: [CEX6[SQ"VD<:B(!1_ZW*;9C=#5B=T?1
MT^$FR4\.CP8=,Y.O"_]8=W,_J<YS7-]Y4L>AB8:'>B">,6]VH0J0XPASCP::
M%'%<\JU9EQ12"F$:@4H"SJR+NP"(!F_[L>NAWF%]@&";@K4;#5UHCV G;[Z9
MS)\P9=4S:B]3!9RL+)_KL)W1M<$ :#%,#$:=I?^$_BWUX" "8\6)+Y_/:(T:
MB0#/3NJU\)[:<I;P=VI\T1U]</3O^4I#^JEK%$5X(ZF8#/F;KZP5LFO.=?R;
MKYRLVCZM)U&;I<3RZ(7-RY(N#=8^>&0GA"PYU]$O2.\$<3;S6MK# [2,<9EW
M88T3+DVI'E8"?7'QEV2,M\\7QT<2:2*8).Q\#KHJG;DL)RP;&=1)Y[7T9!E#
M]GT>G]%O$"[QX43+)CQ2-XE@.Z./U &06>DB_<0Y>FC6WXD F=T,@/@  \#M
M0MYF '2,CS,!Z1=39B>M[]62GM#JFX610UD":0=&PXX$^C<G7J//?ZSS?J38
M%,=614]T)/G/:J#.6!]:D'J8F_S5"AY<#3R!X+M6[$Z):YJ5]@5Z\8BC*S'4
M*L\[L^V>@2?F?[//H5@1@BC"RGQA^S;'6AGK6B PLHHFM[GYKDKOW_*4BH#4
MZ4BV5]Z3C<6[F(FQ!R.^7A,47"KIF^S/R:6Q".7OVXM-;/?&N&"\=Y[V_-I9
M^IIUB-']KV;EQ[[U-5DD&IPFEG[IR;<3<;(4.WFI^3AQI566U9Y6UA]2&N8Z
M:48UND"1@_A*3HC9?A;/=A(4>P^(YT*^&NNQ1E/SI.\R&9H/ U!P*#W48M!F
M)G&^.$9;B\N@/5-W[]F"BFN3%47].R@2$9S=B4='.M58_^H1T,DBJ@O&?4'B
MO6E#LPTSY^<]8_"&)@O]86"EY+;G2L^<4U/GG[GT.H"=%E\^;L&'Z@;[EKB2
MK$F9WH5K-RKL)^Z'2]1FLHH7K9W4UD5D$X&D)TR*O/G"2Y *PM;5I"E8VYT#
M6Y:_,%/ROL0 ?)DFMDH"GIC&"RO0I9;02 9@,4A 9)U7_ZZONLV,MJ/\H[W#
M-.6Y2<D%4)MZBC$Y"5>_[9%:4YY]QLQQ=5=^:YI^8:R)S(ZW>(T4;Q<<V'?-
M6HTP^MC=^SY8Y^'WH]CH'<QK5/7YR.9KTF2++M(95^3%)XN&,'C8QICLP%LO
M2AX#X/WM.4<)$D)+0*A@?LA3KWM+1JA(@!T"!%TY61/]]DV!M_*"N>#[S\E-
MPDO(G=VY;<WB1S^\=Y8ZAXZ^Z9-R2T&TQJ'%X)/<NBJ)&JD7S@3#%L.)Z"ZO
M5_['M)'?FZ"X/PS TI)!8K@HM47U&I,G&U<']K>C)\-:46?X+L#F-HSN$$E&
M-U]_A\P@-KWZP2,*G0]3%M,;*-=_=A)(<G$0+[T1-Y2R"E2EX3 WBYQ/4>KV
M9W)M#E"(I 8WED,I!OXN[T6M;1'H.0F_1!+)R"=,D5(;!GU5"-B.& OFAC3K
M?+[SP:1?9YD[##(+NK;>&<R?+!,M:*G0S>9CZ]6!"A<#D;,+/GC8_P[XDZ<3
MP,_O:EQ<6UB!G_R:)3B47M7^A_+2985O9_)=8'PSRTYOZ=]>WU=\0%5+'?YH
M%M_#3TE.4?0?O9=NW&;UX6$3&J>A(8MQ9"C]&XKD"+U&?31$A1*\#!H)$EME
M_$6X/B-^F^?W[TK=Q:2:^@C^B%=_F!+ODX"DI=(OK39?( <X9@OF1)H-'MSR
MF&AQN;=DI^\=%K;%Y3W0(?6N/\#:MJ8VLU^<_9U>L^>(V7<);AOP ?;GP=UK
M2E<Q<$J(Z_]'_3 >*0]76E\XWRY_%N[9!2_;VM>4K(FVVJVPBC1O^05.)3"I
M1NAS\C8] @)D .9\_KYWI)W=S\,8<[QW>&[R/&?C?9\%\/[7^ZYDSG8LP6CN
MS/<BOK$FXX)V!X?GEX>HW:E/NWO\&@ 6:OV7:I C1";1>%@G%EC; 3E^2[%1
M5C4M;([V]!^6:24@<NZ%J6-\ZI#,PC<7^N!;_ 2FMR*CK0W4/I#%2P@C=1&
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M-^/(!=YE,!.&#7A2R_;X\:N3F'JL*V9BJ U2M?+OXU%G'SZS-88%N;=ZRJP
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MJ.K4W]9)>:/[7.I:=L1"JS'EH OFFH\J+CVZ/>+H=B7)<?$TSOC^6Q8;^LD
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MC*6%R0:_CK$3P[I10 0?SB5FP;PB9Q4L-E)KV; ^F&,SO65JK00*2V5/<+0
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MXC(?Z@?,3GB5Y=5<US](5$J=UNZ"X8$)D.-#\[2()&]8^:S["9)+;!3R01V
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M9:AWS];QH#/[&+$RH;=7<"96F28?G3'\8F_?>G8BF$(&>))L1>OS83[L%@Q
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MI.L@C/@)F*?.-C\CBYV+> EF7?TAX"&F6Q[;.7+1QUQRZ&)X4#9#ZH;-N/W
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M;Z@'A"G\2G3\\ Z$G=WDT0C]!(P''X?V?"Y\[QQ^A;I? "<HQ!P/TID_A;1
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M[@S$/G)'FX[09MIP+[NPHF!E<@I%'NZ])"Q +=04).4Z>A4E*+J"E])S^=[
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M"*_H"?)PD*]^0Z[.[BT*9UAO$YMM_CCJ)V#G8%2%*J]-7.]=OY3#^L;RII[
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MX]=W<J7Z7EW]4Q[O.AXHTY@TC)':C?NGG#C\3]EP0RS^_RB'Y/RM-II(!W#
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MN*VE2NH[3:XV=:.3PR38N+T*5]&5R:&((73ER- _[O!A7MZF<$KHH$;AKG0
MQM.]02#+Q7D\)E;OLZ,5\Y3GP*.W<C^%--SW8E/2_^U!3\K4,2Q4N/(<(3J
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MN:FR"AT1F0+!=H;L7)TJH%[5'*I31SO_*(T%;R;;]90M\:E+7(F=D;NKNW
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M,C N:G!GG+AW4%-O]#YX,12IH7<(4@2IT@1I09$F(JA(AT@'$1"1'@@@1;J
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M;DH!V<<8%MM7XU2L@G)H(>Q_T/X'V?\W8&'_6\C^+V#_-ZYY@ 9"0DP>A &
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M6+M"1+>+/[^UBX*$:F9/[<#-_&DK,Y_#/#N:/*:4$.AD]KS!:1(F>[<1\X?
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M&0N/7=7[%F<MB4.&,3TZUQ;$I)]2*= T+N= <YPKXQPO&MM<"P@CZ:C!UDN
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M=8L@CD6:1XSDCVR;6LQOO2M+&183NP4X/@5$91E-7^_K([%KE:"(0O0Q;.Y
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M?@Q_P5^AN/'^';0J^-LET%"1@M-!TLX2^%PY7X'W_-S-4DSC?CA&RB5<D_[
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M^W&51[[^T67F%KE,0"33D=;W&I)6F$S2FW0 UY'<87[1C'H1;W*J-(Z4+[,
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ML1[#X/HY^[S,+,/N*21IF=^+L3E[\+,QN.E%' 5_1R=1MQI10VD[*Z?,DY?
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M'I)D+2>/4J;YRJJQYP"^(.-Q0S;A:E1 ]6A<]VI(W-$FK3NCR4Z(_LL5GDO
M,9O>SX- Z8NI?9)BD"DE%Z2E[_6X00SW3>+ E\R'FR&N.RDN?O'X>J=^WD4*
M@76DN'T2M#*?/H'N&8_'+UX"<UJ8H],W=IV[FP^.6H=WQLQ/) SNU\[(+60J
M$6:XAJF+TBGWG-2Q>EQ7.#ATNDGMZ8.<(4<4!"KU3LRGX %$;41!'*I.4M[E
M>+HZ03SU<T=F_=W$5]NJKS2#8Y!"&'.\/*B AE(Y$=0#> H^_S!X0D,5GG+R
MQ/(L'.X(C>*EF'D=;Z#WT][_V' GMQ<5Y.E+_AX6R9JD+R#4H0UK?;J>\-DD
MQR^EU]A:?,)QTAOB?:K[(5FSMBU]^M/]#P+(A^5Q3,LA\)OPU?@C[4N ^LWZ
M5PJK?8E/)BH?V-@X!!:2_L5<&%<R@5XX3CP?J+$F4.DGVR/<F]ZJ91O82OL0
MRWE/D#$1=_!)%T"'<EQIKPB!BZ/<="E"4*M%V60J5I4?&C![79-V>D.C_(D.
M/][^3NFZ:F^L]FG$:P5C$6\[<-"?3?/B64N"16N@\I!#!#NKID^LC5K(GN*Y
MR5;: #0TF!S\A_Y5!^<%7\WV*2%E*5?-#BMI0NQ>*;W[KB/(S1LX>[6SJK,K
M=?+8@C*8:TOA5H"RSFF5)462[U!CX#?JX).WFAPIOE04ZB*0?M1JE6^5!@ZV
MYY]KW(0EBWL9UGL6WV#<<YY9,ICPW15F! I@<*<?+Q(($*0*5JWR(F+-35O=
M(IOF>?6>LKM-8^*/MV'!+[__DS[AE[E#IAGT",MUZ@ Z8>UZTQ6BD$_0>D':
MO>=JM)$I/'VGIPV_;Q@:BV2:7-,%DMZQATY-H3##G32=:.BXBN@RNVX=#YU6
MQOVZK/TU1)5.+]>JS[NV>UYA<;=^KS.38"X!/-.*(=B*4R-,SI_M;JSK%<ZH
MJ-KDZQ:9?_ 2O!7;S'G;QE:&_]WMQYD?C[_)1^'(MWU249@G4O.<RX$?OS2U
M3'GWA=W@%KO?:R08P?,-R%*FNF#$P+H-R)&BT_*9OCI52?*9AC>FO,L?G[LN
M#$W(]T0U92Z=%D$@/N1DP;;!@P$&81W\ET#WG4YG'JD^&=/G2H[%13M,6_NS
M)#3)M$^0KQ:^E[$3::#M!?2E,Z1\_'@.Z4:T5P4M[3\'LUUSQ).WGUQ3METH
MD)-(22C095#+.S>&[=5T=ZZ6=I*I\R45^7FHK6"E+P&J"WY0 Z>,5P,96Y(P
M!I%[QX&9CPUDSL^\1KQ>=24KC C(5@T)DZX+9IV,@;E$3M!8]W@+&>3\$[Y@
MB'TUQO/=E?%YVE>_O+@W7%H]-K4V0)&E6U<_@)S$EIZ&8Z;/]I8*D/(3_)BS
MD/H%94_65BP_88:DZ*U^9Y9XN<,[M[M_O[?^^NRNR.V%[L08+.S)S!*H3+#Y
M7Z92-[^[U'_;D]R71 XTTQ87#!RQ;VK9O$G6O3TF?RZ]-C9G@E9(5+MF[K?>
MIT8V<=+);#Z0E']R*-<:1G/MM;!]7/NG;A4Z/_;TV5,[T,(!:VL0_0X4TT\<
M.!B:_D"WNN#SZ8K3LU>Y7#W[9[]_4@S",29C;Q3<T!Z4R!>8]6'72O#NOG+@
MIQS8S8@\*.G<KMU'* ZWAS F?._@GU&[CE=J!#/6J.&[%WK]#:=G#&9V,*?Z
M!+[J-T.X?<>/ 913WN:'Y!<%<A[SWY"V()<OV@4/K[CC>PE<_7WSN8Q_N2]I
MN:@NLKB*F?YM^L-7LAO(N9=B.^W4FG68Y>C"+24D_W+/P+*RA5_4O7AFT<0N
M$G58"JHJH3T?>?.B3DW.CV)0J?X@4E[_^?D3%]&5]J_Z<B8R+0,_V.U;'IK)
M=G?O:P65GO:!%*LP<L+@"F>Y&M.O%%_YZ83\2OGVQ48Q <W7-6J;C@[+I<US
M=[Z1Z0YH!FECWYS"00WL.N*-);8RK.S$RE&0(:B=5^>Z-\S;*M=!*F&A-F'Z
M;P<+!AJE D53&U#]-5?-RD#OF.JW!;R6AHH-\^V3PMI;A05_$Q.4 XT(IO4[
M4V\A"MZ];9J6B#*X+68S/W_QVDL.2>20>EQ":\:K*IZSF$:B;#[UO 1HFM?R
MORVJ.+S6.1B)3P2#/QR3$QL*?Q6S=%KI6XA4GBS/GT*G+]MT&)M.&!K?84SM
MNU<L]KX;>'>5O)T"C>A"1'62OMALP B'RW72Y&V7JJ0:KIF%;'5HI"'M+]:<
M(9#35LQH\3IT+FHM.#Y78+AXV9GM42^SW>:[?_;O>7=)$ ,=ZO_]:8%_C7$L
MQL&WLVE.1N[W3)J.'U0(N_+H3C_>'GVAMK'2"RS;UAPEOL^Z6CF^C:'U.J4%
MH6M2W"-K.P=1G)8M/V9AKA]+==[I2?JR^3T-MT\9(GNI>YOB>HA"ARQ>'C.X
MIXI3]HOJ\9&Q6'8^KX\=+%@RQS+J,URGM%/L?IK$1A;\F(*#O$.$&,@3,*V/
M(#+AH<:ZT_)B?&N%]J3XA-+Q,SVC"V20I?BQ5[,C[D%;PBVI8-?ML7F*TZ9Q
ME",\&D;3QE,"VJ[C(/U/@N+K?]F;NLE5\0BHF[BSTVZ;DEN5R,A.M%:&!E-6
M_713>;06:R4D%YC-N7WH6JM.G[MGK[/F])C$Q%XSZ?VQ"[?W"(#4)+))6_Q8
M+R)2JN[CK''+XU^K3%3OX-RP;[-?"2OSM'\2X:O9U'1AO889NO43WES?)!(_
M]BP]\I6&5)'"Q[T05D@#4!\-B^=ER>@-EO_IAM3(U=D1GJL(_6?YVON9AAA-
MEM&;H9-\,!!3V(.@:KO&%M%V(V?N;PN-3=2OG >E^^C85,%F@6);W1SHV"40
MS3D21W2_6JKD.A7\T@TI=L\+!<B-VHP<8'ODQK#0DO/"-_6=Y$2^9$M[.(-.
M%=NLP3F'J2]\C71[,$+/EP#WV?9<4*RL*;\$[#S"?8;)6D"3'^//.I0^6\/2
M"1O';_=U!;\W2%P+X4X.WKR]95U;X>>AA]5Z$_CU^7E00W[N<L_,+*N"M%BO
M^(.;C]YCM)1M0]0$+N*.BY'$\B5MK,)$)GF38,G+<_QB)F:FOD%:ZS?60K1>
MD<CP"3=@K3V([Y2V1O5VUB &</HZL=0CLH_:DD^YOE3G/'KV1A(J0*[ ?0F\
MGEU:H;@$G!!1"  ])8!ABWB!5[[(0>];7]D_M/NZ[R,H0OBKN.TYXN"7>_H$
M=%G;<[6>=C^^L2=9#_:9?]]2^C =;OXU;M5RD/1MK;=*TVWR$#4Y8C4)@\H6
M$\&<> TLRZ),]]?G\Q%UK-?5NQY@\K)<BP3([B2QO=PO@T>V]1*H:-'^P2R$
M\72V/=AJ)NOM.GVX16/ME),GUQWOXBY?Y9*C"-&.1Z_@,_? 78/M\LK>"\A#
MC&4PT^3KC?$V5>8K\V(2_-HU#-H74\YF9FHE=W[C9B%!."&DZ%0'EP52K17S
M(XV7NB%[C\&YYGECP1)"J#91.<?6E"[D\[H<20:6:\WG#5;O5!Z+BC_6ZT^Y
M.XV$!08RCZH?3I=;UG3FWOB>]*NX<O02""703[<%$L\T!,PO<);F:OTE_Z<]
M=5XVU2\G==2?G,*3DPW2,8[(5U+8+<4,]EX"M">PJ'./J,(:C'M.?\5K9V_7
MZ; '%QN#F3V-6!$^A9>N>FC8[@$&MZJ?\,5AU0!Z"?3 ;8()#B.?31H9NP56
M)2\!25T.#7I '! $*+N820ZC\(P'Z[ZA*D]P0G-^ I;3<F\]VJ2%?OC.^Y2*
M/Z=M'3W*Z[=?+1SM55G]4K*",=ES?3@-MY>"6IM9:@MEGG8Z">4"1O<C*7^Q
MD+X6E9W,#[S(WF7", X.]/8;XN4G3)XR7>0(C[J%A__A7_']$.(/<2?9L^KL
M'YN;11\,Q@:I+0QF\5X"X9%C!K8S,RG6B]JD+^YP]7E^*VTEC>^SOZ)]'P"C
M"%04N$L O&[2\X__XG?@:];EMKB@Z.:Q+]_P.SMCO\8>US9?I'8PS/=[T:0Q
M@'H/G*(M61_]%OT=.OG!!N3<GEV5"KD$T,;$LVC*[AU'@()W^:Q@AED61<GR
M?"77/LR]ER3_F>?6-2!M';1.C2 C],!J5Z+K+P$ 3]0;EU!WA,YDOD/JUMRT
M@LH/GJK6VJ;(+HHK(6H,4;UJ<A>)J-6OZ0?A*C19UFE8I66=XP;GLWYW23V9
MAR9\L)H?W$E9A@P#^-GM@\AC+J+8<+K'/RM+-0]J\ZF*LAVI9Q89VG]Y6_5?
MY170H-S/Y+0$FQ:B=G/KE(I)_6?^(4?"9MCAB9T4)1(88!\/'>3(KF:OS'.&
M_$$L]*Z;A'>0!X^99U6N$8WV'#@Q^Z@E]D'M3V_V>PVSO@\XC1C#\LB>1JPH
M$@ *09--Q%[G6H8'!V$XF]2[N,VJ8$=I^DA7KH4N$MM;^/?E1T-M5]H2V!(I
MQ$92C['P,T"QF]U7&:G&!G:BN<:HP4'BGG5B[046>CF>S0^?OG_SX9DVS57Y
MKFU8=6>WFQZZO3-D _3-3:2V6*1NVEV+S[51Y$).BE:]ZUAY7VVKLXI5YZ7
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M8'CSJ_F)IV3=/0E=5PQ62>17$1AMJ_L3T+F'@2Z2-@EK'LS692]K0T:1;[D
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M4&AI:E[:ZC\/0-:3S]DM;OV&9SN^\B,I68H-"I[=< ;3?=!]_:A#;T'3-C\
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MK?6DZWBMD^8#-^;WF+[O)HE2\VP_7 IV\L'YWB^IV*XA7B2LA;*?U? ^/.\
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M":X+(Z;(@OAHY]'D1?5'_> ^DK]A&/H%?'UJ.+95:PSG[C<+:<>)0-%D/UX
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ME'>&]7<^^,BA4#Y%ZJ42\>N1!-&.U-HU&\Q<@XKZGY:^/X('('R-*$-Q)6&
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M8!GQ-Q,/9KG0Q[<(W@RM/_1+;7B8-GTP4.)2M.%&5KC+8+6UM(JDBZ?7PV<
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M*%*]%%+&%Y^@W<5=G&9A$(^9MU8\(J?">8](GXENHM\KY0#C#K:%7Y/OCHD
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M\9-=Z![UC>Y("X'1>+8V;6&<XG,O$+=OS49OR^5!C*J JD\!Z[7LN) $ TF
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MDIZX0!C@1CG.VKKM2%_E55D[O26K0?>&;I5WIY(U*Y)/3,HE;9B\X@[:Z_*
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M -.0.**%^W))B^JQ"BD^_*@*!9#E!X/$5Z>51R[^&)'"FZ,H*)\0&B /C_H
M1KZR65D,UOCKN0(>?+'AG%-K#QM&,<(&@N<=;,J3RS_J^^""RN)RXWJ;5[G^
MW8$UKT)(J:N*]][H9)B@^P<K'HGW+0P79-YWY600>.K+-$%4$33F+ UX\_$]
M#0C=!S?7ZV,@;7T<\(?][EZ)['W*;?'UW=;7AYH'0.=.E0AJ?5GM@8_C99O3
M3J/71W S1K'Z7V*-T_44Y=-L3H1/4E1?OIDPZ:K7OP\Q=;6.#&_@(_IO'"R7
M;1Y;YN*1*XYZ<?*Q5W."93 SHQ1@41B3'1EWEB18VPD)V-U16^[R@?<YY!Z,
M]2&$T5!YC2;_5/*I:=92[?/XLK4'AH:7'T;\/ C"H:;=T3*9':<#]C?*\<_F
M!-;-"DTP,Q$JVT2'IJX>L<UHA:L27?4LM[4W]'&HGF^=IFT!R";P^$PS^K!G
M?XU=Y:3RVSMNO26>AS)MMRZ#&W-"MA)U,I+2^%@ME7NB1R'=5,0\Q^W\')5-
MJOYKN#+EM1=,<'7 %XO5SIH^.29Y"_<KKG%R(NR;10<S: J26NQC,6Q.P$^T
MB)YK3](5?GY]P+L@I!'PY@.[JA4+$PO>1-L'R*?J_H*R2,LSI,3(ONG_BX9?
M4IR<I!H1MJG-_.@#+E0V]&\O%).922/@NPXVQ*=:+7]/)E_JCOT]X<3DM?<X
M?*5#(N?^?X'R%3W4/QQR@V ZHA6.U>EY.)[<9CTVXS-:&L2P[/T4+HLCK[NQ
M&97TO7$X\E72G?B9,Q8BK"GEA4GD)OK+7]$;T:PN8@<[)8O?ZTJJ%5R=R;U%
M5,*G-Z=)A5X48]J@7M_5/<-SO#(I8O'%NDAPA\=,O2G!M,DA\]9@GF*\5N84
M"G)U1CKG3K5.;K[VQ?_[6W?\GY7_BYN1Y'S+?I+%6,372:R=JPPC'X%)-IS$
M*Z3G/E\5W6-;!#GJ;)\G &FXG@#"-B[93@OY_.(Q6+MJ/9=;EK-IGWL6&D*0
M+4[AJ(>%'J-"_#(*KH!YM)$]?JGK1_&ABJ&(8YM>] S1'?5S=+3]YW;YTN.D
M6E S\$A+>T,]R5Z1,P;L@HH52C8<N#@3:7T3N3+?8$H(SAO67OQ& XJAMJEM
MBC_Z.JPK0[W$ BSP/^GL;/'X\(#+=]&6LL"=N%+1"C5!L][S"="!EME/S9_-
MSWQV"TQ!I\1NGG]M9:!]'7EN=4:D#CJG&*42I%0W=D;[5!E$86+CHMD6C_R6
M3$@P6@,?MA<?0 ,:WPG<HGS5A/CYX4&M>^KAD9&#9XSX@9,)=OLB#;; !:0*
M$S;I&RI9H>A169W*]E5)I?<3 ]=S+4%7SE-D-Y$_.#'BI1@Q 6O\(Q3L]$OH
M45X5\\%\B_,G3^><V&&_WAYX])<.JJ0G,$&$K<]X(&5@<TOS@/7.N]R27>,P
M#$6C^<"H^&W.N$Z>"V'YJVR )TN4%@":7RP+SF*5W3XSZ>-4)O]70HBK-FJX
M]#@O^TOH0M]D;+LU1SE.?&/,9+2,M)J,>#QM5#^H,7N^L_%,P_OJ</>BA?!]
M ][L0)8F%!*!":-RSR=_= 43SR63H0.-O>$R!46/1M+\)80+GL9_\$>V( 2<
M_?,B/$5DY1^TK^ ]B<]@1[HTXO2J]W7Z^,8IT&]486IW$ /1:"Y\C*SEZ,/Q
MX4O=H<5:/P&H _@L]@O*=G)_3$5B/$!O667L[9/%RCKUF!NR&5]6#9"N1K->
MC9^-?-HG.",<%/-71BON>;^\)4AA>NI\,5QM!/[%J/1IHC\^_@XA$W?P_=Z
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MT0#P+1HPTT15[K3@L4?C)<=SG)^N@QJ_G%7JL: .E:U[T?.CBM"Z,$(L,:3
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M+)R7'YY5317^U/OM57*_$_(><P^8#?$(/;&),8G7M,"R&2:&36S&D@V?#LU
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MO*_7Z_5^[<MU#>4K!0-P7C(P-@!H:&B 6>H?0,$"Q_2#W5T P-04. 4  !-
M\_ Y<(3ZC0;XVT69 2X M$>._/Y0+SKJAYZ)GIZ.CIZ%D9&!B8V%C8V5A965
MG8.;DYV#BX.5E9.?DXN'EX^/CPTB(,C/*\C-R\?[FP@-+16'CIZ9GIZ9EYV5
MG??_^J*T UQ,M)0C<[0TQX C7#2T7#24;@!*Y96>YL_U=Y9ICE!Y9&!D8F9A
MI0+4<@)':&AIC]#1_N::>C>,>A^@XZ+G/GI6CX'GVFW&8WZ\BI&IKY@DSU=V
M\)D/XZ64[MQ[R,S"+R H)"Q]7.;$R5/**JIJZAKG+ES4-S T,KYT_<9-"TLK
M:QM')V<75S=W#_^ P/M!P0]"HAY%Q\0^CHM/2W_Z+"/S>5;VZX+"HC?%;]^5
M5%77U-;5-S0V=79U]_2B^SY^&AD=&Y^8_#HUC<4M+GU;_KZRND;8^;'[D[@'
M_MK_+1<-0$OS]^O_*!<75:XC='2T=(R_Y:(Y$O0;@(N._NA9!FZ]:XRW_7B.
M*48R\9Y/?579P2RI9([GNW-OF(5?2ADK3?@MVA_)_G."/?PO2?8/P?XIUS3
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M>0%3*^/EA)2-KU^@!QU^-=#.UN#.)*'S^:]$[B\F.A93BP/$]+ FG-<0S[*
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M@/Y'VF'42>>0C@K#\$^8#Z1_P(S\@4GX&\S?Z.RG-2C\1SJH.V <!="39Z0
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MA#8<LTV*",P[X%B#[5_]&8I>X/)J@[;%G*Z96?\Y[C/1X53CQJUYYY-9CNR
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MWW<5N>E(UC>/2=<<N#[1.__N&?T5Y&-^>.9\ZSG5N?GRHI/#B%I)UV5I:>F
M+N_QS1<4P :CPYZXTD2-B+?SO\LANT/$' RZ;L?8425@,('<4'N+7+TPX:AY
MF#OF12R:U4;:V'>-7:6]?W"M?OIE0TB\&N2:+OO,IL&"QWWLVHE9;7U S:=6
M).S=3.S;0NJ423M(AOGAS= P(D/3;PO:(3L'?RG#(,BOA:A],_N439H_90A&
MI/_K=M"_W)88.EW\!G&6:A%/+.R ;AJY\K1T7J:M>;1&LS^'5?+M'%K(;?-B
M/[/_BF@BI/M^"8P-MI0-FI$[5//VI65#UF5%GN2Z3_L^PJB)*>D.\H-0[ Q$
ME'14-:2GM,;<8])_,P;,NI/JG?5L)/C2DT^Z1Y^D7-J<P: >";IS40 7H[H0
M$]O6C-SZZ@1U&QK!^F,+R(S+!B>F%(L=3W_K\K>&5N^WA#,V\-@8WI8AUI+7
M@[\J%N]?P#,M[E28SK8MO 2<0/_.;&2TU]:QT8FP2<5?HZ:!_M*?1]J&&MVE
M7!RC;]+*1,C"^X7^%VOO =54T*X+;T1!Z8CT$J6*-*5()R!-0(J@]**"4B(@
MHG0(17H3$%"0)M)["3WT*M)[)P'I):$&",F-W_F^<\]9_UWW_.>LN];,8N]Y
M]V2%R;SO^SS/S"0#K%^.VK+?$9*O/[5PK'!T!S9%DOK #CC8.-CX.]R$ 2:@
M1OUQXO[L_NQWQZ#3"=;0? )XS?]_UD+R]0)]9I2&$<F(A-+XI4!Q$0Y'AMUC
M@6"9P[)KA.EO]J\484 \XI:!!XRS(=Y^5I=>DB*UZVK')_\STK'F=[N-9RK@
M&)-5YVUBVNY;I4;T^G*.S5\-K#F$$<[#T5L%BVJ!=J9%.XDR/KL:@]B;.2T]
M2-N-G$D_'<?>G)LWG1<\M+<TG%.E_2Z7NN AC0,IFRU=LSELIL-HM/(W/JF5
M-6-F5IKTE_6"7([IY-8**(*8<4N+M"A!+W&6W<OY6??HTFP:XVI[[DAW-ELA
M<J*#?-EF]%$I^7)IK"".8<S1<%B19;KU@+:.K0\>+G= @X--$R">JAS'H2G&
MJ)-8#VZO,'9RO9A>63&UTO3)QX56-ML 2U6T6&=R.A7*,NWGG*Z+0TH 5:79
MJ]OH[@"F>"J_-V#,KJ>Y"_\XHM!8YOUIX>#L4<W)D7CO^]F9EIN(\FIQAX/F
MD\J%]%BT_N+RG"4L]0O#B6 Y@_GG9S8!>ZH^ RA;)/U0AW-DBF28X!Y798QL
MCE9&M<*MUIVK$;_5@:B#:]ZV_DV/FV^C8KZ7:_$*]IO*6K!%_Q%K^GX$'FVB
M4QR9ZF1)W62@M9C'U$ 0UY)GEDU*%DS"W#[[(F*NMQ\->.$8VV]5DGW5C%Q.
MT!UKE(NZN&8DC)33X2@NXYZ$#TW#%<Z7GE?4-L(2;6OJHE]'& \^'PE1(ATC
M*5)'P.\)O==^+=ZO,I$3]>BT_TKX#*FJ2'0G]2.'V( /D4.4'I+*H\<"L.:6
MRJJ(1>]@O2+NB  -@(J(:[0!!%>!ST@P9FT*P6[=W>UR!=T"KZ9Y_'O(MP"/
M97370R,H&!%#X7W+E*+K!7@@5UM?=,F_EX!410A\O^PN],AT<A]+TK3?!KZ)
MY7)&L-.#NF0XI:H^T3NJT2A-DUQ?P&Z[XAA"_Y(TR'#L9>?R/T@98?K[C^ !
MHE)K'$/RO]E:4+;4?[DY'B!7;P<=2=A!,6*A_^#XV3AB=2Q)/11C:DF#![**
M'A%FPW<P]KD(5DB$% \,3V5!EP=!!"(OXT.MB<8#<P >Z!;"$E!UQ1L\X5H%
MY@Y"53>!\("R93 >")*"8@H/G&=[D(S!QR(S&<AH6%FXN'=JN(^D3UP')59G
MKYL!N!>RFM"C">SB =N,,UXT=.I/#RY*8C,1"27'OG1>M@ILF6-TJY4T1#N(
MJJ!G@X7E^@.87C'[MPJ*#7I(#6GF(448/&J1ZIVQE+,>,KR5(Q\H#79-.\RW
MK&PDRV^\KN&Y*;5ZF$W)WFT=]T,V_N&:OTQ9+$.5.8:#,>) ZWFHX1C'XY%G
MX5\66QM9N:)NLL;N11SE-^^;HG1CE^CVCNIWFQ[P!<%J*^$3XM6QG>2KEV'2
M3>&_,C+\U(;V3NGW'US. @D*1RW18BXGV/PA..!BQ335Y;A,J=K$"+7-A53L
MQ@D[)W_08BD7M0T:'(8<3FF,-[U&$DC5(@_:**!)G2<I(W]!D-% YY,@'KAW
MEE'_MD#/=?Q(XK1EE\!/;NAB[UFXXV@N'PUI3C9EJNX>%JK?,KE<<;KM[[9^
M-0)#VH:[7TE 6!W;7Z*%J\.$5^UV][BL97JU@@1CI.Z8D5[U(IMB3'W>][[A
M:\JM\;6%I&3-DZ6RO-^(@M"RF*ZGK0B<3$S_GH0$=<#Z$_2?;CB$)N(7_[6!
MYC36Z[]K:0&W(MM@H2#,% SW.Z.&--*/"]/>T68Z%>(WXV%JX%HX]]AH!YW/
MS4SG;!W<*]]#_\<4W-F/!Q@]*M'+Y1'KCZ*M P<5L]\[MO9)#:[U>*6>0*OJ
M44.1<F;.A1 W' -:)#+[@B0<R:HO3.M$X5^MF>F+2-Q2N^=A)=EI>^9H\L9%
MIUC(.2-^=VJX@SGQE13T(6ZP1!^WY;;[T?LM#*SZ_F$,U'39CP(/]#*:X('R
M?Z1V:@O&H*,2=154<V+>UGDJQ#2M^ 9]]P_TCB05"7GBT-4,KW4%2D(/.K._
M/3*A!R^W3#5F. HVK!)9FS/2;J]<5-M>SBH*[^>MJQ&J1L:IW=!%-=!(L/VU
M\T(7LL%[PU?VSOT^.!'J-SS@%GNQYB\%FB7."/23)KRHT!0AMZPT,T#[LC!0
M7!</^$P84H[!@I%]'MMYV(#2%@(-N8,J=KJ,\Y&3]^'-Q@,\ X"750?HC+>9
MCM!?.P\7KKE8IX].I-"+ZZ"P\8XXL)!$3F8L@X@Q5P;W=<:%_XQ7"W@Z:C=T
MT\^3VQER6DQ1#;EPB/68QYG#8V.:?*G#):C#[!';?\] <!F/[AIIC(JG:9BN
M4:>Z> K9J$1SGRVY%I=]SI<E _;]KBCQU 8Y_4CYL_='VQ0K/@HPMXR"XH%N
MOT"XR-\56-Q PSZ6.X.**E^(KYS1-.VHY4W#W%K/MZ4_CC^C8E]!)@Z/,J^+
ML/;7)$XQ/^?V4YF*PY!JH'6CL2+V)>8>*WK523N-7X5*7LPPS2L^_V4+$(U/
ME3B07E)!3UG/6!"X:ZL^(B,M"]!+RGQ"^ CV18J<WY5IP1&;0='T1L]0X/"W
MU7.-7S !18PAC!\I(<Y1P=RV-\8XX5RNWM",]BJL,A[@Q&5GG)TFX %%!P#9
M8FO%Y "E42#SD.ST&J\8*MR2\=)VY8; 3/IN?Y:A0,+Y[,K8+S_C@=59/_;8
M\V!U0I23\";E@P'@6 >IDUR_9S;6&3G_O&'@6$HD/W3+)$7OJG.,_P9IWO<E
M7;4CPGH_[8&)'60?_-,P]"OVES_;]*Q?XAJ.C #D8&C2S7_PRC(5YQS/I2#P
M:C%6^9S Q<[Y\XE'[\M?$^$8[S*(N3OMFW]%\U]'"OX;56HHDI99@063Q< E
M]C#M/FW8[T_8T.CL!#TLG7[+#2SO]5FU;TX/HJ# [G,%28PIF-Y'<G+YL]5C
ME%F?"YL;XY#=WJ_H8.&?/DWIU/2NRU_G4!GMRA!^EM<M%'-A9Z0&B_ZR$1 V
M(9D( ...(Z-<6:M DP9]8!SUZ0Q\6M#E9Q'0ZUA"8_YBU;HEQZ.E:Y?CHM/+
MZ5N^V6SOVO6?24A1'2&N>Z69,3,\>& _Y1R*(V.FRJ!NFV.=J=XHE9 8_Q$R
MB:[S]IUY<_N<IJX'[K'4D<&N*QGT)"4ZL60U>;C8J5*%K++@];T>^0<1AYBN
M9WC */_5NZ/]>ZYS\"-G-$6RC+EDYS,Q?BR_!EBM1HJ:O!A'@[$\E0FN?V!>
M9=$94#Y8G&6T02VQ@&M?H@1U0V])B# 7'YJ8V+U_]8".>+W)'[?;,D.^N2$@
MLL(7)C37YNJ;"ZU\M%%S$M<%$#T*? 2 0SGAR;@;ASF;BR!4=_U;.6WK @B+
M?ZA>JD8U-_R[#;W%:A2#-#-Q'OW..QA9'0=+HE=<]58-3GON0&['S:$N4J%S
MS6U45U>E6N$3I@(U@+MKSZ(=")G"@1[*?)<)S]!]*]YL_/*/)/ACK>L1_;Q*
ML#5Y0FNW+R02DX.V5L:HYFQZQ<!/RJJV9*)DS$&O/_U:_) 5L4H5><#AESC;
M/3=^?Y4V)=SU0  K,W<L?PT2.[?GP%\RBN2-4:6*>EA9WGO[F'0V9][W[KRO
MP)VO5JA #Q_H;SH"WVPE#"69%4;)1Y[@*=I@ B)(P JXNAQENQQE4H#_<_M=
M NCXNTG^Z!H!$J.8P>VUDB!-0@$Z_F%8.KKZS_;8O_V65/YO3]&#V[^)^&-E
M>I]7"TF/HY1@CZ@KF$HN>T93[\AZZ9&F^DBC<*E(\/7M%+>BEX[YTP_AT(;9
M+9YXL9H_$?$_K0-)G2;F-A481\59(PN.%H1'NR$U"RX\3?>B^?O>5A"GF\3*
M3Y]/B:&\<8I>4Y>A'T&7=[WV[Q+WM-AMNZ>VF_)KN67T3QU-O3$VP5:<Y'=K
M@#ZX1F68'D\W[SO!D"W5H<$&>F/5E*]?C?.E]QN-K0@XYS?1=$=[4ED^#I@3
MD6*+.=Z][F=E"B2+/_,\R588)T* :UHB2GPD+A0\(@1R$C.>/2\/_<7.;?U9
MMX:H+$'N0?8&!R>&BS<M=R'GT\&]Q]9/M#D=]4>)!]_I>!F-M]0:ID(+<$.S
MA=.;Z,4SL2ZY VGSN<Z2I#C7>2JI8XF#T]:Y-%X0Q65A^^+ID]'$W\[O'HF7
MMKX.6\_B=DV?6$&_H6KF"CE#_=+12TG0''H]OMZ^1BXP6%Y7+T'/V#@#;=NQ
MQ+CFVW%<1ZU5V>?JKFT]= M!0N;RPVH:XD:^T1P>K #OY7VWAUML0"$/FV]B
M7%W18MTR-1GY=OIW)DI*?JOB@:H_ALZBYG$=V):.2X%?S?<6[&NM*(^U[X%I
M: L[HUUXRKY<?7-__NXKA3?2[-3,$MN@*JI$I*-DNZE;%0'5,-HK@# O/J=*
M-8GYQ!$)HZ,T]TB8*@9O2 ]*%2Q'-7B8Y]:(9KLDV@OM>W(WV$^>?SACEZ[Y
MR'8H61 .L9"T;YPS@S=;4)?(,:YH<R$90]Y*7)+M6&X:9?N(7>-RHZ(FK;L=
MVTY S$%6!]?^1=N?BP1-+=Y)P-VDE'V.2LP(KK9X>-$[<BU2)-GUK1*G=N$[
MZ2/B$G.,&!ZXK0W!=7B%XK[(^UXSOJN=@[/)^^!%(]X86B+Y#H1K(!!2"&T,
M@<[/R]LW!NRJ(385J?YY%YK#&GHF#NQV3":\.R8P_KN$0AR P0,9&'U+&4+.
MEOCWG/_#P_N?.;\,@X4B^S#KN-:IO]IS',84ND(K1_"R5_%X8%,ZDZJE#7>#
M@-TB"$,FNF(\(BBAD3E2DAVAU?\A,=LP0O37SQBB>RV?CTKA'^8L^-2U!%B-
M2][N(@ZR8('W\\.RR0JS,XF)KU0I,$'[)% 9EX&.X"/-YTNW-BH\8I6;QMY
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M>WA=P\T'EE91Q[V4DDX&UN693&XE;X\C(ZF;$<)EF$UXQK2>ZR<KY'!%(_-
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MUJ^CGX\B/OA8]P>RO]PKV.0<ICUKQ7DB-6-7" ZFD*\G#JM5Y_7'6.RT&EF
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MB#_$<WBD2AKE;*KY _&1U,49.@NZJI)V3G!PU'(_[$!359HBN0@*IX%M)I:
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MXKQF8,S>)8_/ITK<'"B6U4$*>H'CS^J*;O!T#RED,*S_A:.D)_T$&6BT4>/
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MDSJ]P*C8ZJ^#&6]A3[N"\4=D%L0DI_R2,C<].;ZO;:AI&!BU*"6W21)S7M8
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MH_\^Y4N#K63Y??>8$#KZ$D180$ Q7F>UH08A=5C;CB.OKP-=FG;7OA0M<Q-
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M]WC)"=)CT_T.:W?65T0ZRC-O8S^E'Z/J +!_?/V-[K_P<GV>V 5&2*6?'39
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MF'(7K/F<B=ZJW>>]7OB[D2"2.&:&[P:)T$H)VB/K CE >[>9]#1@; AL9T2
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M],G)3IP"'=YT+ ]4FIQ59O="85[E$AX=(QGBKY_^C'QIAC?+VF,Z7H*XZ%-
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MI[E]8IZBD0F#NY2C2'1+6OU.VNBMDW26A-HD'1(E\#PQ<U6UWT&U'\"13M
M2"B8<)J*Y$7TK:KWK?[_S<G YSZ%B-[#D5_3@)^-]VB N3@V'1%:L/QC$9J
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MW3W8RGR>((44>4E?R?#7N?;Z>O'8IJ@U*L#B+UI'.Q=F->AOFJR2E+TMZ?X
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MRK.#V;V(XN./#BE=3R,W1KQ%;<',UR D+Z$(!-\H:N\YG(C^VI^Q[_@-*N=
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M[TM2WJ\\'BB:BG%Q$>U[,J8J@[_HN7%T16-.$64^%K$U23)SO:A5E8/SNE]
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M#YG?-#+%>,6_[[L-DL'\9\->KXV8F+:Z(JG !CMAEG*8-E=[ME;_HXSU9)1
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M^)L/19 /< 601_\9D-.)%.[:8=!*LZ!?<O@'O#]%!4H6:B;HR1*"3R<>U^)
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M>RV3]82Q)B!7!W>]@ZL+L<\)5[9)N*MS7.L3ZUD?/J%B4X&5=?BEP![^RZ]
ME 15(.8FX?U66;PC6LR2[64RHYQC23\/:4).?G?NZJVZL'''YZ/7P-+UG.]%
M 1=.*@XB&RL@(9CCGZ#GR;"^TC%EM%A8</#OVO(+:K%_F0;4O0CQWBRB?'U[
MYN;-XV,G4!>KCNX9HQS,SS.>>081@DVG+< WQP_,/EH##:,E[A(; 9W"HD'$
MKAD;X)6_;3B8WGD95A58LA( ,P>4LU*50:LS"YHB^E3E+)3A8"RM^F: 9!O"
M(1HT[>4')AD!FF3KMJZ\Q3]V6KF7"OQ=J_&FG\Q1%;6(,PO/X.,QX;'+B0NA
M/QJB'JE>4(.6V4]S,D WLG&:MTH*-6H?DKCVTFWYI:X0ZSY>]4FU(:=WGR:A
M<.OEXX\3.86#I3Y;K,QZQ9?63]@.7PX-+CVY\I0]5/ET</+FW,J37N?>GS@G
MF>&SG#<[*K1^P>3X9BHFAD@7R0*$2$\0@PQUKSRU$7<Y6[7OW#IAUKLJM9*U
M[I3W,BO^3E0"<P,?D\@^&^A_%.\R4]B\KY@\,+L929?QEZ41TWO;X>B]VUZ(
MMSW5Y)D@7FA_<!51:W4]==T0">>;)/%.5I"UW7,,"RQ*ITUCXY2NIK4+M*N'
MGY_O2[KWX8I#\W!4M;J\\K(V-,E\'*]:X#T3KIDJ<>*B3DSE7<ZX*[O\OQ^1
M2G&.B,@>[^,&QF8MQRWV\Y_2'F\UPZI^*8<.=9YAT1V6O%^EJ@8.?,)5SXV6
MTWN3E$LQVXA=*K#O$)_A06BC:'5%0K9XJ,"PKG7,NO!?Y!B?KB:.'8$Z$<0O
M.!6P/^.K-*;!LKX7:.)/F4B2[=3NU#F\4SVUIC [KH15<\\C+3::9@CW2)=R
ML(W=Z/@TWG%6>(CQ@HDMVGQ#QKXZ )-N*?YM9:"Y^5:S7^ EC.+.B>7LYUDS
M^7QL/_U?RN_WD6.\4Y:<0"WB::(T#F,H;V4D1XJ*M[RZM@W7%/"P+QARG!_'
M'JL#%=A]5I')#F*057*D*69S$P21.1>QNGB9YQ8K=/M-!,280B=9"%R<CF I
M=6C8QD?S:KPAC[W<PFUO>_04_]+NTVWB4)#^SI&KER*BZ2J#^-36HR?[#7%/
M2A O(2;^MK0@JUUD<>$+H$H+&R/F6M$UV\*_T"'_%3:E%?1Z.EZ#*]M\EMGX
M-6C>#O9-$A6H%MU@_[>H<M?*(0[.4\O&5I6QPV9"=W3YMAAK7C5<IJ@3R\.7
M%=Y-O?*3+4U^X%PEZ"Q*%WE$X,<LX"%*0-\ESVW)@BMP%4Q%K8TR1U[\"4(>
M-N+V_HES",(5T(L5^CB<$D9&V.196<HVGQ1Z]W+ZR/.3]4J'I_9=;IZC[RM_
MZYGENFF^CAI:;4W-:S8,H7 0SW[M@1;DV\^K=UCD-LOH'@[K J9R'7N^K.YV
MTU7L%@H@/_:43VQFN6 6-1BG%DJ<H05:$XC!F#I:AA_:E[1K:&E]+M,2 -&^
M!2]RVMZW&_GO!/2-^'_\4I=<3]L:IH5<C:#4+B-R F,4O^>1'==3_L1AC:!4
MF".[S9)2$54=OW=0F00(&6F/"$?LZL,TI3M\)$*1KWU]35"P[?SDV6T)[$HL
M94 FH-/WXQ8,]G_I0C?"[#E>F=9Q=3N3U=TS%[%.'QJCJF+27_KIO,F^0S?=
M]=W-<53J'XO+_1M14G^-@#0QU=A)G;!K$K[^S;UM:K#V9F?$4&)&TXX10Y2$
M(H<Y^ <8-M:\PK]0*<N;"F!O,R6$1Q3Z*Y9'Z>_KWQZXW'[F]9>LKU5:?M/L
M&EWB.;XKVH7NPN>(;>$E;&;ZW:6U-W\.KEJLGRXIJ;H/[2MA6Z!;;&*'#7/7
MLNC);]\!1YYRU=/AQ^0F,B9WN\%<II;0=$58O6]EM>5M2,L/2>>@N*Z06CKA
MI,7!I2Y^^=Q6D>-Y;R%Z7=TUZKG>+H;ZTJ<;L3>^:DF5;<5]LF-1%CM'GVCN
MTW*^.+HDA)9\57)3['U:7<QF9)M9!MDKWH9DFU_\]?W+3^U/1.@H*>RZ"G,"
M"['HK"'O4,/D#J/2\*V?#\HL?+I5E'YJB.P%[Q@=9L5;25S$#'M>0^V0#(EY
MB$8#FBM^JX,*'.*B E&?9$FW*:P@[(.#D+'^<1;E!!4(H:4^!(TY@0_1&*2(
MP)T%G7K)QR#,9/F3-I+E<B*(VO1ER<R&E/.?,3A#DBPE+$"2"M E(_^F9G-
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M?<0^^5-?\LU\05L^I?GA(C*<A(0U05C;"J[@%E>Y+J48CPBHJSWNEQ.IG"1
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M6B:*"[SV =!XTY7N_Z![@/#'&\L?\._R1A!E/)N3:<\3?7]9G9 ". 8385.
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M>N_-EW@$[?K-H6B_<\/3KVK_RU& *ZD)_,#\DO(2W_ O;#)E$_^O!O-GQVN
MB4[FA1:O-AK\]<292BQ2BNGVU>GO2FLSRW3S$'LKB@9Q2)[%71;B$'.KA4_D
M=WO?X*D=7V._G2H,@E!JH'.F%I,=S-/V$W.=E<#@?^Z2Z=> HQ>0%K<;'E6_
MO 8,OS;Q7O=).78=^[\&FJD/LE+*#^FP1)M?Z*2]1#WLKK,;M/<JG>_2^_FQ
M?OKW&\,T7!&0D#//1X>Y]'R\_U)K-S.=V;.=T-WDXB[VQGPCOL$JM-:C]EON
M$CF050TT84ZAMF;)Z$NBCY^/O:AV.)E+%9CS3[+N@^]@P>]0P-"35:!-W:KE
M1,VV]LH"4V\=R[:@-SC&R6W;5E!:/U9:/XC&N3+'N3(7,5UP\R'PO*07O:17
M_7_Y$RVC^_^"W=[_AMWH.M',UG^5ZO\[I?OBA4["_PAK^)>3_%]<0^GL\_ZC
MK6!<X:7"V;.DK0<<;O]>MXOY_G>465I[+S"".I#4#U@(R<#?+2MU>$4==M_9
M[* @RP)1?&^-#VQ+_-=QO[SE_5JI<W<3[^*3LD+.1*EG[0?)1\N1L3YQJE>5
MX/5E/ZW%5),KKLB69KA"E)0B G0/:] A>1C^L/."NAUC'XC<*\YV_5(VHSNM
M[E<V1[LD[VK_IT<G43+VV8GV9+&S&_(HK1H8V?6J5)?3>U#Q6*^@H'>%ZZ+5
M.,EZIO)=PJOXG#LQ4\]-_X:(YW.';;\LOX.]0IQB VE"<*SDE2ZP2R;=%B_]
MTAH5GK^+KZ(:%&HHF:*>+A%T#.Y%(J18$5="W8$/<;R6:^W4>ROL$[5Z&8N:
M%3-R?]I,AI3>005OM40_()? V=N:Y="Y2I_@_*""20K&M;<C8O:G4L87QML.
M+4X\94JM[DF(=$!8X2)CD0&/(8CN2?WN^_1$,V@Y00%>_I^T;LV31(C(8VE^
MU6D9:=P;=((1-D%O7!@$7+X&6,W-;Y\YVAG+-L;KT:D:I)E+W:N\E-QI"HM#
M&\!KDPH+F+0Q#,UR]GVRI5P1\EVR3)Y(8J;./&3>LT[V'.<CJV&>/ 6R" ^K
M]+==? L[(T]/Y[?WK]0TL:T(AO*;,TMV>@UX,-?[Z,S'OUJ%T6T]Y_E.V@.7
M$Y%FV++N'CUY:L!NY:"',^.?(%3>=TJP/@QL>Z-9=7U%)P5N];;_*!>8#J##
M)JA@%9P13UN<2\J_GER)\)N&K:SUFWZ1[6(E7N:NCZ[G+,R7K K5CF]2N@;\
MC*4A?$T1\B5/A$ZB8=7(/:9N.W7Z/%,UXUE1Y]=.4*C?*1P8L7#64VP2>G$G
MSI\SW +MD6JR*Y:42_<Q](F.10R4I=(Q.VA@3PNGEV>76;T:T<)=:&O,-B,2
M ]*>^C5QR@36:_'-_BI(K3M?]3YXL&,-G?$=7U%K:W.C3!K_=AG<@DRF311R
MUS)Y5-L')-O.78 ] Z_<+2CZ18YFH]K8(<EKX$B1<M*?3K4;:#H]/W[ITVZE
MOVJL$0LT5FS[\I:F&4L66U!_K!LLM9T$"U:9]"#3.-1KCQ$S-%YY-]%2)3#,
M6,G&I]@Q1GBK)E_O0T*D@9.;N>#\VG97RWJ:->J\V Y7<A)@?EK^R$[2)$J8
MEV/Q94-[U111N\T4XA-K]5Q6&<K[!920:CR9="K86!K-:CC%$R"#XZNH;V\,
MZ3K@?;-DH,#-HTD5*]T\Q2@JU.=C,<N;8]N4V7_(C.V#'_>DS'S-MA$;R=O!
M^$@C] _BB _9OQ4.4\[U00CWWB-+.:F*6]N)1A.3"L=#;0?EI=)&=E?[X#6'
M'I/*=CZ!P?C'RY#B?F.QO[]K(VG=&7X\COQ@]BX;3J[(W#+KU>)S;"*$>S;-
M'\"X!V*H97)"UQ:WLB,RE$-E8R3SZC8&: GJ0HE7&@S ()LV5E0YCDTRN6>5
M4@^R"Z=NB.46+YOI6] <>E/)8R7ZLD-BU)NSU)11AT='Y@)C(#1=_JUI>N,T
M,/@I=QZGUU-.?U$CH[&:XTGAU,^,%E9M)MA@],/>C"=8353RAXHIR[\>R^:Z
M=2&P29\<@5CUUUFLKA9.<Y U[? H82:WM;'H%HH2/4B]_@R-WK2FRE2IAW*F
M*-V7X-A3M6:ZVZJB0<2JB?4SVKN2MM@,NT'+7.OWS]HLDIK[_3UGLP]\MF)J
MH$#[%+XX?U?3]AEV2 F"9*0U3KF"[3X_81M7>Z249L&VS^_/CN99AGL/=FED
MY'I[FXM*4\Q_@J05L(PZ87X0K&=3?U]F>%6ZKV$M?K;YY[U%DQ9[^ZJEM"[B
MBRJ70297^UQL6$IX\+]DB9+L2?5%*H1V8[=[ZL6<CI8YD_HIZP)<,@]][ADO
MZ*3/C/ /XT;,D]1=NH?2&O/$AU1>+"YO[C:[7N'EQWKXOZYP0N'LF2%2=/D[
MU;NK9OCQIN;I]!Z*WO:/Z@_C>SZ/0DXD$.7U:.TJ*7/;["6(IXL=YLFFH]DS
M@OI8A[4NH4%I?.+:#;P9*6/RIQR@7Z7DG#=M"=6/LZ9R%1_5=@=LJ-F$6VQS
M_W6J1<HO8G)K)]IK^-JK9KM5A/3.1S;HB'J<YR<][XAY]+[A4CW0.#1WD"<%
M#M]SYUFMWO3-][^\6@;:\= 4$J+SEB.QF\-P:'@ F_$>?7X4S@W.=,>C)87L
MA<KX[:GW!EW1KX1HOX5[]BFR(>JX?T_<\"&B9[6ZK-[K][!O8,E./=)"A,'7
MK%Z,.NK)ID4T]#3#@'E9WK;$@KV^?$E.E:EGPD73KPP=U63+R3>R/;%GOG.%
MJ,S7B<+=5KMOHBR3 X,R[.GCK$!<>RK3Y1F>D2K=Y!HO6QDV3.<>J!F3^<IY
M:F9*>4,S>F$KU,6YA_D>UF<@J8#IS ?LDWXO.,.R4)AZ7][9.($I1P=]@[<?
MWOT$<I 0WVD+J>Z?GV3^?*[#B397:9F68=JK\_&H7EX9=HXH1;"Z1].I$D\1
M&LY&MLG87 . CL([(DB0T22BK5&9VW7F170"%1L+01,N/TT[_/'N^2.KEI^!
M-NF4;WL^RZ&IZ>J"W/N(7R"@M&-G>2\G&T]$I-J9:PKTM21I(G2[V7O4-G9Z
M@VS ,]%AR M,%E#S5\M#N +R!KN^2-+.2!G=:<VQ'?E4%R7<9)XV-/[U5A!Y
MP ZQ."+/W(__JBV VL^J>=K1CTZFNG3)UM.YP*B?.65;XS;LAQ.K^ EC"N!"
M([ZE!^<^^:4+O ^D.%R^!W.?\$Y45EAMP!617 -LR)Y8QK[YVR*OH=)L<"E0
MX>74.1HX[SP4)*TCK /=O@;4U(>+'-*(A>Z[EP;X>SC0:(I:JW+)-3MVK]<]
M5R[H\X4WM6-U$Y@SJ-! _"W^?SF/F$IYO3?3T4Z\IF7:D]W&C[\OOON8[!&A
MSN@!2%KWC2Q;9> Q&\^;5@O'R?*P_LRVE8,^[FE[S^!E?7AIWJX$.&E2.J;#
M2^Y@CE2A6=@O+6+R0VK\:KQ?0PZXNWTH!N 5IVH+Q5T^O)M0>]]\2,B"O_$!
M*2E[PKM/[!EF;UP^9Y!2+/TEKATW5,/Q**H1=ZT\O@9TR!%> UZ7N&-W3#F"
M//+^2KUQ[^CU&\]/6Y=X)7JP?-;:NDTX6<@]7.L,E;3Z+-3KGPT)HU9VKLW$
M)B=$U!<Y#4A[":+3CM55+E_9H 8H54A[.G[F!IDKNR7+6YAV[@]UH[+N7>1W
M7_GL(3)2X;2EW_6Z(?7 HO/=$AZYZ J1V*6#C[/\C'.LUH/Q7ER1ISLOW%9:
MFCO!S.Z9$2GW?5;#:]0>V$E:Q"M2CM:]D%\W*WD^,A_,]$([&<=K$ULAW TK
M?Q"URK)T;M5C/GS_4?IB95H%0B*+G+OK+(,G? T8'A[ZT=PGB=I5CKU1X>=8
MFE3/T88)OVFTV$B[U!I!9W$; !48B7,SOSW;$]8<=OQNJO1P/YO4GDZ/4GQY
MVIAM>>/NZX+SSX(6,FO>2)G[.UY-_%TWJL2<G7:YI;^S);V*\^-AUH\;JM+<
MM5G Y]CE7.REWE^-_HZ)[;_>> NO?EWR0/<!EVH;J?6S8E#UD)3);3_:V ]-
M.]^*'7>^Y8@C9IHO?_R):]JBHR4N7-?Y OG:XHT"KJ5O+"?.))3SA[OC.ATQ
M$F_J&=ZJD\^L'<]Y9@']E_X3M_2^X0(Z=@TH-1:P+?*S;*E7# T/^^+J:'&>
MMUP1XBKO<[4"+-6M;\,V\QY^FVDBLFFWY.=FRPYP-W^NF:'T_/UA4Y!TH L&
M=PVXF$J-V.M'_ NX2I7AQZEC)U'M'0K&=2A,<-DNV7HG<ZKSEF49^P_YRH.Q
MY7NOJ:5T$OPHKLH#I/Q4L'&FL#$*/Z$)'/MO0Y-E6]?=$JL?<FZW:"RY,YM\
M!=8V@V3V_VNU&@<RJYG7 /V60&0@G52BJ2TL[K$\3^YP3)=CD5!&F!2X$K$2
M(0*,?KABU%=GS!1+\ML&D629Z-=+'B0...'2:U\3)MB[A!;\9[V-SD>!%]/'
MHXUH!GA[>!LG]F%7<HI3B&.+"F;:7VGEV;(C,TF*W'VA\6F?#$$Y'Y.Y !8/
M_/3?0!2Y,YXOZ$5K_U1 X)6=&.C]^37@M'@$"</^Y"CTOC\K XKL$H[N=&7Y
M_E.1&,+='.VRVBK;#_\UMSM!C-II",W<?W[N"E\G2.3Q\OL)3OH7S,UX"OKW
M6,F<B\<W3ZD3;VB,,[C4SKXOB@<E#\3>"9./U=+[N4CY]$5[D/5>1QD-/+F7
M/P9T7^J)QTZ+-.SJ%5%3?7T\0Z#$^GL>O-['K",JI7JX#>&.RO]<XI?8R?ZC
MI\Y(%2(+:[S4QLG.V9[@(IXZM\D?5PT.?](<J:>] .33X) SHXAR.E<&B/?3
M90%5E_P5_A-&)X6-0U4%,MFG>.Q+UNC[491\,G[-6YXV\299?0G*6U^>U)M%
M&L\0-BKXJTJ$NSQ*V[-"F8C^]N15I.)FC'GRLT^/J+X&.+VF#' V?>]?C>!6
M8.BWAL73O^W4NS_424<HQ.Q3;.F"E'V$>WGY8GEO(?^KAT2+]J%ON0$)GU9I
MA%Q/157$/)N>F=;;5S'QMTI&6!X7C\LP8>5PA&O2H.X)DT ;F4Q ./+%O>1.
MMD^*;$&R2W_^N"29*7(.X8&XE]B?:,'9'@[\HMQ?/G=_?7^!;'O;)>6-M+N/
MDNB(YW0<A<&4"=JUH7PM8/;/_8]3$ /?!9_W39,V?W/UQAS*,GO 6NW[^[OK
MU&#VMNR5;V:SXU\$<KRY5#(R6Y[/4^\\XF"0U_SMMFB@/B&E"&.Z=0WH[9>?
M]C.'-T=L3:JT).@M*&+X):)=E3=^L8K+O1YU::Q##A)/!3!AK1!=,E1UDTX'
M3YJ;]#B2]+*CAK5MV:W%3;#4X'MST]GVZ9*;[)U>7[\#74FHA+!&,3;-'Z+\
MQU'UN(>-X3B.%;[E(]!_%QY''W\/I,1[G#>"]NO1F3!D1G[QSL0UP$+N$5"D
M)TDR/VF$_M9JEW?'&%4RK/P^S@OM%7ZR[*8T[2?G]7OWN9R+H^1NO.F$?,R'
MJT,]8N-4@XDVW[O&9<SQ^5P:8'LX3S[?F-!=<]M-X5^Y23%[O]Y>B5^^"O0+
M,(/6<)[U;W(?6[8Q!?Q5?-+CH>*G.C/B^1@_DQ"85%Z!;B[S]=$4R;RQFT M
MX-S579^PZC+]N;E^X>H1CBKLAZ]BU?X'7PBAFKV>_C[YN/.X8_!N+"D^S#W@
M^"0?27J%/H^4^=N^"OI1WB<-Q'Q#9[3"2?V9@138KA>#5O5!5[\,?DQPI!$"
M?_3 "&^1<!9(4)T\]&._^A4Z'F2G?P#[A+ELKV-;;-3Q=&L^0$1?H!5F\Z\!
M,A:@_^\D]LB[_S5)YK])1A9-PDQJ>#?ZXZA+R^BZY)$@3'=(B*SGP7E3-..5
MG%L;3P5V=<U?9NA2?T9*SM+>VY<\\Q&T<!@JJJ7]#K=T7U30-^2%YL7)-6#K
M3SB^8*U]VUKY$*R.6\=C<;W,KO\(UD9P#0CSN\JY!FR# V?Q8<37 'A16B9A
MN\UV[5.':T"=A\9$SEMV(P]<94UPB)>'!*@\C[_\PS4@4Y#F(C_X&I"=!VJY
M(OV?U!\)(,&/EQ8KFEY5%M^EI/HQY-%_-&#VX:GC<H!F?T/)0 !MP-\$-4=B
M3%L]XQF%"I<"1S6+8^4#!E8O5WEI!6%\*_C\F.4:\*'"Y$0HYRSS9G$V)H?0
M/^^WRL^N >]-4B7SN\L7:!0FG#RXTU_W@*WJ(T8X1O3E/_X2>BR^/,>_%:S=
M D2U(PY[U$AV9-C'_10*5?+LDO8\'-E2]G(>F7Y[RQDITZJ)]QL 3_-0K@K_
MFR+31NW?#)@O_T@3X-./$L/$)*AG_+77S[)YSR8HVH376](%D!^\70@4^#"[
M=@U 4F.>;-NES)G4^&<.2PX?CB*;*YL/MM(NW":@_T4?X*GR[1L51!+L?<&+
M"?TW+N@_CZ&S.=+>G;E ?C0WYEQD/]G3'/RL>,!;9T[VO&FS<)OY(18)YV<T
MQLHS.1O6S_(*8VLE6)JFUZ.]*06T/BJ['3^C9?[N[QEXO/GROW94X1#\[MUP
M#6[X?'9+#%FQBOXV#KHPM<>%FDRU$0>,-SEP<]M+UL!R=3'=92_B&H+NGC=9
MG!;I!%8!^QR]].NG1$*A[]/UW*17"MC]L[;H."O.RAB-?!HB5;_;*AI>R("&
M7/<30(P>[_J^QVN,2Q^D7*F-*WO*O M\#GJ*U^+8Q&,+X#$MM41'=UY,8NK+
MC\MSP ]],[POWT!8/]Q =+@1"A,=-UBP?,ZL,73Y:#^=\7@Q5,0$[MQUCO-"
M6:F1E0V<1C@^L=<3^Y0L -!,^R1V_^&VB@^4]C>RQ%)>T+&MJ#]/X7EY>+[J
M(WQ/XVQQU66-0A1D##86B5/)QM+TU'7- $$01Z_:UIXOBV.MM\8H/DHR6C!^
MDG.&Z)A@HTKLD^+VF,DF6L!Y90&3GT2$/%AC\@FHS V9YG9]K%J%"'<4J+@B
M-395K@$_<ZOI/N3M%VE&U>Z?MFAZ5577EJWL9)!= TA,8MNH<2_1HGEK2([^
M'DE0Q"9-O,&R,8-U34,?[9:]D^9L,'(Q'1JR"FS1A)G001;UT&_JZH7V7 W>
M)>A_"DUB87IU2J V='<7(+TWYSEA]OT3.CJA>5)3Z6>MW?<\I?<QZ]\-ZDJY
M#<KCY^UGMBC0Q5U-X3%MU-BHUQ/3S/B+Z5^A%HY%NA<9TQLI_6$!_';&I#(
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M:F$GG*E/VOK3!KH_!S'0[M]6N)3:S415^2DB3")B'I+ZGH6K5AS3W'X<)M
MM(K[D1GPXM/A?)=H*LPD,NY1=5UU85!.H8RYIA:[QNCERFIH^Y^B'_KBXJ.4
M,1LJDQHZGH['HNF9*FWZ3G*78EA$+YX=ZVQ*79OU1WAC,C<>_$"M@&?$\[*"
M ,H0S%(Y".X^-%3H,(G*>((ZZT R@X$0^N.>I!0+U]3%N@8#]VN [A]MEI>"
M%4R?!!8E!I@.]_L1TO_2OK;%9+TL7%0NTYM3<A(^_>:-ONV:6^4!H":,6](:
MF[<DRJP."R$AHN43.KSL+[$M5)Y?T#]J=3^2OF^X/0X9LPW7QE2>^:^W;VPV
MKYH8^-5(BW48"U=@0V&\8CV2UC]X#G]1/AD 6)YJ,V>MN^P8$?L< >?Y\6]I
M0MOWOF=>"!3/]D^T<@FZY=/)%(*H?KP/8Z#3#@6'"=KZ<$A&/BV%2OW?^2QR
M'R=CU+'$J$.$6/_A@ET@(^2%$OK-C R?15V"1M!;4VU;Y=O25;*XXA.K=L%
M:_[@A:W>U86'F/A416P>O#R\8A[;F),")!ND)RT=>3:<K#D "%(HS (J7OW
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M&@O;W3D@*,[PK<J4Y[7_M]D'Y'CR?P!02P,$%     @ #8)_5,FB+_RQCP(
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M(&@#!0#OH !A_6#3R^-)%.!H*?/:V,4W1RA8.V^>VSOSN.%:!060HC>]^9&
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MX/-+#3GO3U3S ?QHM#_+?+7^$S__PJ'2G=>'QQ68_"9DH']&T\,0KW(SA+:
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M\?4E) 8/I%(")8EH8YYP!$^!,U3J;EF;83CA;(V5WZNZ&JZJ\31W[[4M?XH
M92WL-M7FP=-4*+W?+\[@8%CUBUQ@Z6;.GNUQQFD:/T6CR'&;/[M+E/]V&.)?
MDFBO-'3!=-,HT((9/#SQ[SLDHAI+ 84C9W3Y<V4!#QXRAPOYI@BY,VR&K^^$
M_.PXB;@;@&WB^<4(J_AC78'*:"L37<M4PX3SF!**;<\G/L35TA(-IWFPQ"!K
M!Z%!V(THP+L]8QK%*'[%M@#_&&I!2;= #'!U6+!OGWUG$-HHWG.F^+6%/)9)
M/W$8*QT?*ZEZQ4!?4$.IS%JK7 OGRETET,IW'!,AZU,:7"RR*-?5E%J3U.]O
M1C6,J9/7EF5?'L-GZQEFQQ<,(WBV*K'KHM+,F//,#67/4QL<+[!/+5\N*3Q/
MLP:I\9[O\ O)!S>5SD/?I"A?'-VVI>=]8^-O9>7.N+Q7^$3S6,W%13*BUE?W
M#:\@@:27"BA(3@^LOL35-YIW.AU"(@/5DR7/S9V<UQ5UB_I*K0,X8WOU\98:
M@"VC0[?)Q]NP&C8_PUTF^#ZIBZ+J2?\*KLA!YU&O&>)!M_IXRZ,21(P>^9:B
M9=Q=[L9+W3>QSQ.N7M[8Y4[G%->#:21RWQ80XDF]>P6$9U(HV(#'PH?!0M4Q
M*R<,U:\90QW-,R"MOD+.RN4UNK4I!#_;85&_M&_*8 K7D<@_+2Q]QHD.OE_F
M?07])&BBP/J3* #P63#B_3#43ZS0(:B. @2D+!T_)8(XLI'B"9Q)RYI\ :,
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MW#W85REP:<9>QRR$<W<;(^'$@N*/0SJQCPV#UXO286*U#$:OFI!/OV]ZZ-I
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M'85?\-DCF68E'@E$&)>.)RP;AB(P0Q&3U[+I :)K-^S=7E7K T2L#SLYTU$
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M8=7I;>7T]:MTK 7)SV8F',L#1Z$U)#=8<\DS(UHO6V:=-UK;/P]+I!O2 KP
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M07OHHN:FX,0UUL('YA+Q]$KH&9;*PGPP':]K1T^1MF&Y$42U:(C([!3CV5@
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M805MKZ,!<'5O'_JWCLS+GSA7@ @M!LSTE*J(!LR,H0'0'$ROMI\#'N%"3DY
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M]30,6&A:7V?J9.$\ *PG[@*E;]-5AG)OV?B0N[&U1$[E-Z.6J*['WA#FY'$
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M2Q=7UTMHP(=8-XVOHGVXN\OQ@^,S4\ 8VN_*WV:.9]^ZYI859AK63D]G>O.
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M=;=Q=S2S$QS)O3YMR7P.RE8X-!Y2P*O24%U175M2F>RIR8T;*4N=QI:KYL'
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M(BNM@TJ#?J.85Y/C\&Y*$.K2:#EN<>E(X#A]17OIO8% J39?ZOT">L=V#[R
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M%(H5'X;:@ F-1J7'3\,RP1Z)Y 9U\SBKTWD(8K; CS3X\A?LBN^Y'^B!E_5
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M!S4_B;#A@=MKZ\7V!.F%QO>E*-QB;TO>$M,T#&-1A]EF:?O2,.%)*CQYY/9
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MO:,N+9JRM8ENG.MPS%[0R%A1\V7;ZN#3%MPJD?OQ+<?)'-T^Y,O1-S>Q@)O
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M48X$:&XXUKNT$)1Z8Z:A]06..9U]:W;2D#"]T&UTOJG!B(]5QG8J=5P'!<R
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M^ ;X^(&5_\_5X7]SH^YO7!4=++5,WZ34ST%GBME8/%RO/<2=326H+9Q83>Q
M/T>F6&TH@75DXMR^X1[,S9)$8#:P $9]6MQLE.>R/+(KQ*5 X55"!'EKF)IA
ME2;Q&]]M(@S%J\KB+<H8E%A;MW99N7.L4:\PU#!ZS^M<$T1P]T<#2VE+R+>%
M_/YP37-[.>$BU1 &P1$T0<8<RKQC35GL^=?:F*@7KVX%1GU@F'5G(O,_O$$
MQT\J!AL\GTRFMC-0!A[/Z($F'_==9UH0AG]Q'0H3'5/---H6O=&8"RU17OD^
M0-:9+<>Z,B_JTNDBB4/0B6%!!=DQJW]O_6SPIN#>TCM)]S*&FCN3[R4ID3+?
M-R@8F)0EAV00XV^VE*;69L>*?$J_10G3C3B*04A1F>O*2)*(="MWI.$6S=N<
M[%NWJZ@H]T6Z-XUD/8$A:-4\W;DYU'Z'G)-;<8_I:/&]T%ZV2IF 2OE2=4A7
M(T<[YMXH6C7WAHQBS8_T6;4 HZ)(T4+<X3$IZW]R&2C.S_M@R[& 1C7-0BR
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M6;@B+4,E#W2!J0T.GZ.O^?B$&#55)>VJ4<A>$W'C(5M,%;Y?X",SEA'=+<C
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MD"P."Y2&7N<.:6#EU_=-.8W(5W8]C<:-+)UC3N5)C=_SJD1[&4-]\Q6=Z(N
M?+[D"H4\W71LMY@UI4>TI,A*PN[Q/LV(":;6M2#=5VGQ3&N9H;[=FJA?V2U$
M\VFYOU^>F024:C-22<0_[CI3^. ZZ>QC1-FQJ33&C=-)GMA,.$MWV%63"A>1
M-S(,3!&GA==B@%LTD]!2*XWZ/ADY#6A_+>"-5\&0FE%BBQW1\XJO$V[U/0SS
M7-+C4I'79G&8OS!\1-C <BXCR],RIET1VO=T?JYGVKCM33180,>E8)J$NQ6$
MNE?QAO;21^R8H-UL9JVN^#L#J _)*H;_<F?YK_+;&HXU>SP6,-Z-&OVIX[0
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M!I^?%%XY-LUB0FRBM#_][ODK/GA@%<",!6Q#9=5_)7Y/:/G',TY,@+X^+])
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M2OST-$KTXUD\1]R>]4EX$ZV5'Q7"?%N4=G9ZFT:?$PNPN<UC]93)?>FCQQ!
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M5.D?]DPIER?T[)(GS#C=8;$6-K00]UU2#/)DY/8UT?&2&':*K[!04<EX1>M
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M+ZM!OG@Z7J'K1]@_A\N#EE+$ C:9>"HA5H*+FNGT>S@X.1/&R";%GI %?0,
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MBF0%+ADVG!RMU*7YC7J*#U=YZ70*S8A/P 4GA(;=! 6#"Y60_CXW(9U'A45
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M)R_J/BHY%^A/R_;:%'V 6\ST>1"=5U@"\;'W,N;AT+AJZL<=K1'Z2K52C"0
MP+E@&]8$7P43NGBFL_L@6D4]',PC-?5 V[M&%&OE_'P!THI.4?U67\7$BJI
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M4>0'>6,CE@VX4Z-[T,K*!2!*-QTVN7/@/EYZ 8@,Z)H_Z&\N,E.Z +!4/[L
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M]!>!D(3Z[>L@7<?H-\;!38]K91<G]>.L2_-_Z1]J\95D_QL!\E>A]Z?C^/M
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MQZ'0+%6,U@Q0$<L:NH)])4RE"8('K7WV=O8227]Y:=6[6_UGIM.O%'ZR;*]
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MP=6:8 5Y/S48+;!<:DB)7#?P78T\XJ!G^R7#YIW!!6_^H \,396LCR;IPYO
M;F)"FOI0F:S8QSXM:)IDO,LUP=3K^FU2W_BWUV7A_O[V>?44<M!:LY?^S\,$
M+4O&U225/@T.P;R&T/8"&]CI\A(D7YKR@=]$T1/ YZ#?3YWO_=9)78O7GWB-
MYD;9IL10!. &)&EJ#@/@&*F.8V$:7+9V3^S)%V$<:TI7&#$=W<RUW'D@9)PA
MD^_T9FEFVK&G(H:;ID45O!BW9(R8NHG46NTPM[(WN7/RT%]OOK@T&5WFPL;[
MQG*VV!%&4=R[+*\0DL'^MEI;;:59/V<P,V?8GS-X26-2IY9J)+AXV279G\-N
M]LK;@6;"R&W9CUHRY#O.@@$HOK06:F:?5@TE#9&(2[WV#ETUG*\E+RQSKPSU
M!>0_3_5V^2 P)/1(5=Y!SM;)J*-,H&_IHZ;)S.1Z;GF.L$IV4.>8NIKF1$YG
M,U$;0=^;2BH[8&M''U]O^^Q(M0:+Z<=*:-K$K%>S7VL5-X-\7GEZW;Y9DESA
MZJ$#FJ.J;[-.4UOG[1*M UG'J:-'=)^I-:LHT1YI&NG3\HEZ\:KJ(!82W^?'
M^W);*XXR?!\_6N*E0O>GR\PV)R!):CX8P#6"T H,(,;\U.S>NS.3*^@773\\
MKG7I)DXB6EV?13@R\_>R1BV,MVZCBA<W1VW]:^4>06,^^:>I%?6B+J_Y>15(
MS'5LEX8:,;W1Y>NZE!OODP.2RJQB"1'((WC\2'G?(:/[=L&W$>-K3\:5?&$&
MX*]5YEFNSIM&S@?AR^MQZ*]0N:\U/)+]*9X5C1[8>S0%9B@^4KAR_:E=U-&H
MNH2 DX<TDZXVD.@A?VQY^NK]<=?R44/BX9K#*2B:"@@I_(H!Z&YK9Q"KE.:<
M\-T_X'_X*3Q_--I, P-8?)UW2Q2Q)W*63@9_+ZG_$HC#'_ V-0A%N_?XQQ$"
MO@Q4SG]+2&;.;!U'8MJNVB@06--I6^H:$:'UOIYD#PS77 TUL>/>M3R0V]C%
M,OXV"=XY=<\;9?*[_RW)J'7F"I9^<D^MUCV]EXD,STOY/^IRCDP<K6R5/OI(
MX?AB283J;:P.-9P]/NLL?6#.W[F#OOA-TW(^085U%J&!DE$308?.-]?);74Y
MN!"XIZ%V=?SEQ<TLS6HT)UNO1H#KS\+UPRWKH9.A)]2G!1H[.BB0)<L6>O/&
MD=TSA&#7-(4,,$!%YXX:!E!FD6Y43@2)B58'.A;!1G= "G")VFF0-]=;#A^<
M]#*Q^>,P/FQXZSM90Q-K+EM9LTLED$,J&&[7'F.&6H'U48*UTD?B=UOQHS(9
M75F&0_+^+-?OI];XB)T?1W]QG]]//:_87YJ!>G:<(AQH 1Q-SI!0^'% 6O65
MX[ J*;UY7ER"6/7:][-4M1GV,Q<D>-X1D FX=U.32^5CKJM 1+*Q-;?=69J-
M UR(?UN_WX(!K$@6."VWR,[WXLD*5VW75^A9&M]8*"UH@$V"YK6YGW 7U+9$
M",$EZ%HFTXS%6@FR>Y_L%2;G#R:QC>909&Y;MK7LE%'0M:-4YXOGPR\XV>!$
MFVR:ESTKM'=HVUS\6AD_9!"!#!J$%W2'Y2$<58;L;E*LLF31*\I<WPQ=:J<;
MI >8#6H3/36P4Y4D93[;4K]0<C@H/XAP5AE!B%/;EM!?%[VCO<UKFW*_FY?1
MWG5UF^M@JR!%I%?[<M(=X9JBI,@[BL@0U22W6[8$[]GW*ITJB^ICR&+[,("$
MT715&I/YKDT**$E/058J3VRN!#J>S#R3234M>SO)K[*H3(^56X/(H3:]5G]P
M*;Y806?'F()J&M(43K96,J/6R^NW;^*V5^G%Z\PNS2?ZF72OC=F2$/5<A+D4
MW0CG4@63A_:_&F7V>WAQ.2II5F._YN(#2?'UN'?64C=:K'.QQB59LDX4WF>0
M#V?O*JF,' N^FP"OYPB%&^P)Q4,.8F\]0HF4556ZY@6 H.K&'H7C6LD]U1C
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M !L&4 5D%@*C5U&YRW$8P,PY54ZC;<"<CZ++ZR<1_9NS;Y+/=DS3HM'4FAB
M'5KY7.7;SJ5++CK42;.[?]HN7+VAN#-[DK63U@7<2NX\I]#IG$*8U/'G)VB/
M^DILL'N0Q_?92LZ6IX._"8_\C$LU9X%)\3ZP=_20]F"[6.[[]/#?4*K\#N",
MEE":-4."HV/T O7T =.1Y6GSD?QB_:'<HNKW^6<,0:2=ODC! $1UIWPFZUI%
M_T31^?PS.<]P_:#G@ZOC6-;WZ5*_$:7U'<!WDO8Y_5&G0!L"BQ-B%!@]C\IY
M:EGAYK^3YV&& 9S14W\8R@>W)^V0F1 6OKRY..8]3_GMF0+P>O 9UC2=I?<<
MU)_ABNUEH\ZP,GN.8I"LE5:V)Z__PMS-HO87*Y;\)/[.R;^+U2HJ^SNGSQ7P
M-U'UHS-?80#)H"WQ/TO*ZI](RO]?2LKJUY(Z,Y3_1%2#_UI4%?]25 3?F3+U
M7V'*OU9?FC.F@,ZH^6X*/S%QUSNX\VQV(Q(O-+(9BX3@A]&6DDRVZU<LD(>?
MVV-=V@4_-2$A*X2C_,./E8F=_RQ4;"P9?/Q7L>+_ *?T+_8\O_0Z5_-A$1:<
M[0WFPA+BOV&P4W"5WB'J<B#IN66<[5T$_\GB<O^+F/V_#=[_EPKD?YOLO^TZ
MA@-3/TPV7'Q(2QEB]UN@D8IHL?X H;>5[I@ZBS3_!$V1_Z^I^%\4WH\L8&$X
M(.V#QLOK/"\?/!S).)^80R3YH-V1,NQCO .6X \(,G]:733Q._Y'_T?3]]]1
M3I@'H^3J7"4.W86#@".ZJ5'W\Z>TY%I5C>!<7XI%5PGWC^,&/B:7/I'2GT_^
M4T61/WY2%0+3[\Y> 78\1P!/[;]GL"P]J-^;$ [_;$)8?[O#X\EU+<(A\AW=
MT"3&8;MVNT2<9Q6N)O:\>O3MDYIOF2_ZC!%-P08J"H!R"(+&6N-G0^9EJZ#-
MPAWCP!V2@+9]9FEL6OBTV:V&8X$/'])8Q:C3AQQV,X;S>0E/.^2U/=X;U4!@
MT1NA\Z>,C[W:DY7JE!K6E%TP -BWTID&ET\+1K'89(VY!RIY^GJ61CZ+W@PA
M'E@D\\?NWY8/$N-N<B6IQO-VU&QB *^FL]\1.*963/8&Z1 -ELD^D:T9HJ:(
M![C-P1.(KI(JHJ3HK16<C*&Z?D*:'B,"AE/)IM?5W\1Q^C:LJ8Z.!'\16&-I
MY-8-_H0L?J>K4!'>S,/)V4%L?4.]G#.R.<]M6M 1I#+JYC[?BV\2XW@<C0@3
M'(O1=!K&>;8F1KNYP9\Z9U>JRC8/#/"@0+CU6F;H%%=*3+W^?)V?.DT8>#TG
MUTT%'A.:JVL"'OTJ96^,+A;R%A>RRJI<\"C5OC AK_4 63E/4**F53O]S5I7
MD/[%P<85)4_;E0MT<>;@-IK+VJ9=6?<RU[Z=W#(.R'^* =2XNO;;83M*6$6X
MZ<&5)BH&%17=-]!JGUJ>2GP-KUW='J@2)41F2<(SDSCL@UN][PG*BTT-T$C(
MCP1[%4M8HRF0B?.Z)+K!5")'(YM^"DRP^[JGLXJ;&M1,B$+?N16Z*+7JAZ65
M.]!0F6K].FQ+%W;LQQ<V[C?N<>_&MEI2K>HP6^+W?IG]YI;#<%/*AX+]A5,[
M"K''/>HTP,:&9G0RW-H_B1<LMK1<',^H%N@Z:6MDQ;_R4DKD8R$V2%X+$E1'
MZV3;N /!+W#JLJ:=*GKJ.TN=CN^=A[2$&OL)*5LSE"<Z09?XOOF1I=W_]L4@
M>K\ARPY;5\()#]1V.1[Z55MGS1%G/KNF?7,^[.Z%SGF9^PL)A\(LPR@9!%9S
M$M$S8)GE\RX![##2#]71PM>POASW6PFXL"3 Z\-JA&$7:/NWW3I2R9P,%,*P
M"PGDMUC2OER:^N+Y[-+>I?T,$,/G^!;14J6'5^[-/OTZU34F(N!A03"OD^-H
M2Y7X\5"14@K7G"[9D$PTX_9%JVLKU])!<>]$RSR8IDWCZD#0BCU7-5*&=$[9
M,MZ$:#%>?)\\&[,!%)T9;)-C?B;-TJ9/9TT<^T"KWE3=AH"R_!FM/=FQ0@7U
M9Y\0:&2=$0+;M^;\;#V<>%V$J0(\&MHP:3"*W<U2@6KP.^@!M+%,UV#ES9K5
M71[@%I:V=A;B_P"C@+=<@9R(82$'7^"'_;%Z;4;4Z0O=4 F%^N-/]>0OKF:G
M!GVY_NK:"AZ#TX#),O1V2SVAR0SM\#:;^5X)T4C3#)"%[@1]&OX2&H4U_A;T
M *GN[DP0("0S_S6G(]?$Q2#X0":'PIFL1]'1#?C %-RZ?4OG-&R]6>":OEWY
MTK)\$@]D?(ZF.:FU B52JD6@OA1":7RE9ET6<2F)"GG3I,#X6Q(>_PO7HZZH
M,MOUCMYYK47_YM GBO W3G% PK7FEM%;L^9AR@GOM4+7XEWV&M8AF9=O8XVO
M6EDG4+JS0"P]Z$T=1:_DV[.HCA?J])XF+MW'(L+R;NZ+\-F0E8 2 &:0+$V;
M4'>:%HVT=9X[QE6/9*L$O2(J2/:6*[D*L;_*JQ_?RHU;\LI:*RX<K@9+EQ\;
M7)2:5Q(2A\GB-!TZC$RTCH-=/SJ&!A%5Z%2*AC[@72FDDT.6S9T^-DE%]T<.
MIX5TQ5>\$/]@&]VKFR&;@GH%KP_@_CB0OV4L4RFIIQF ^T;W4#IU!;\M:,E-
M!K9-@%188Y%]#)6J^6BA:>;T+5)_R&L@I=^#'JG?0EY0^#E+1X9AL4DP7Q:'
M2;NR_=V>$/7]"BK#.Z^O7O)*^LQ5MASK6]8;.J(R%V7^98QK2]!Y /YHVR<9
MB0=PH6(_$Z"X(WW?N!Q;C:1)),];&)6VYYS'O9H\":1Q-C)>+DH%D9F7UYC?
MLZ% FC56WBS*CBT:FX%+H)G1V&:M(S.G[=AZ>^8JXEZR,=_0OC;S8@&K18;>
M26,?D9P6;D2RGGI5O:<1_- K$\&- 03NJPG)$.N^=9[87N#<W_'<7AT%E;%X
M;=I5B/C5I+5X\([H(R52=<4_<7>;=8&EY+W3%V[K/A:[Y&*1OTV()-IM\*#
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M1#BJR)*1MGA_7,-)R*8L6K[KS"2Q?+-)\NM'_V8-%L->6LN:F+S,#N@&EK=
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MK4P:SA7$?X-]:@RRC2'S@AQTM5VK;VK7OCW[9;(Y\4D8 2XQ'G9PC"17+!
M])JL1E5LNA4D>-<_7+D$;!@J]OH%4&S3$(=9P%II9I^-Y?S8_6#$HZI$OZ/F
M8EO^:>3*=X[Z=YEOL:%>86%H/D>D5E<3IKER3H5LQBB-@WM7(2)1SDF_.J&W
M$OREM:WE1!UEZTD2SG.41> 5 Y=)/=QK?/.4!2*W-\T>L][.#E7"CA_9K\10
M;R^P(7K2;MLE(?3OG@N2!G.X/ ?,RAGNN^Z(=+M.+C ;"W\2NX">A$$W!5N-
MZ2K=J<NKJ<R]J"5"&"9;8S\OX 1W3.FF)O9D.Q=O4Q9>,)TY!\GG1*63]%:5
MMY/:LG?1TXT+)#787%]A8^:9GW5=I*9&;U31/W1/FKP$6 \,X-=N3Q.GV.-N
M6L7>>+@@*C.G6[9!607N:!VKK*_\/J44\\3UT[5[60.X!:-^PHZ%**G93D_>
MXP&;\NC:J('ZKUKIR(28-FA'UAN?/!U-FZ1,P;:PSH^B;'T=-Z^SLV);%\)B
M[02QA\H_^#J^R:0=9[EN/]85ZF$Q9D7A>EI<Z8!*<"8'$KEOZH=.UG*V'+&\
MYIQ8##HT;,<E(8 V&@N:XP>J?7WC0G4;K;\N==0;^V8F<<<CU:$>?G=01@9J
M^?+CPS<\>(\'&Q! AE<:+^A,.QM,%F%38?"WMQ;-HZO\>\#ESI< T@?E1R20
M!6QH4X1EX$J"S\.^5Q3 T59- 84<!;AZ$83BN1O K<+1$!&T+<7[S?W SUQ,
M2?26MV'+_#3F093;H<"9GC4U4ERYIAD5NX1?4!\=[YO"_-:>@3\TZK5_(S!#
M#Y5"J.&U_^E1+PU+L/K+N=+@^OO=[@'WKN!AV!!['QVC\.125DFO .[.>@W)
M+39O^(PL.^+S1@A&XZD+]\QM4K(Y4T6"TS):K)D=Y[<'&44N ==D*1:[+P%T
MQJ:<K1<M_71MF&>R27B.===(KKP._A^C7Z:.XT=G1I@5K<;RXF'J6 <[;U_&
M:GZ@J5RV1!SG(SEWF:9X6^XO<]ET0#=GF)J?X/(=$")C&H9A^B8WQ[@-X5[)
M*A,.[ODU-9YMXU;V'8IZ%$MG?I^P=FSQ3S0_2UN)J/.K?:B40AD5:H%)O;(1
MJJ5%#1%A7KFGNF=3H-(9-7"NR?>9(>[U3+P8T?"A#FD O(VS/E1 !"T(2R.B
M%R:[J1<D\-K"UYV=_DC-.75B-9,-Z5&ZO*L#QD<Q%$F99)?\8 [TN54X5>=S
MYC.5NS7I:D<CNYK8.F:@(L%-8\2YQT?&UT 8%7=4R3?:1@PRH*LQW#2]Y7Y3
MQ+B>7QI4=7O+F94-SS)WLXFA4PWO ;\1_JM=Q!2E)O%+#Y$YYRVO:U4MCHAS
M>61YU *CBMPJ#U'J@#UG'Z&XMN=]3GF9N<F*A*7(][7<:@I(AG >M+1CP+4$
MIWQEBXNLE,8A8G]9UUR8:EV3YS&-U]:IGU2 :8TWMM>3@#7TX85D$7;4>(N,
M;R5:'*$#+;Z.VVM(JL*A7O*EV6EZ0P2.J-1!Y4HX^?%/9?1AE7?P^,9_(H"Z
M+DD2KW_F@CW"9DLOND8!%&L07<S:MTY=I81)Y?L]V'&_!%"9V/EPI^'&]'57
MM8GAOLK$4\5,YZJ++0(>'R^2U.+GX8A4A[_UM93&0'M0QU\6-5"=2[Z^1?%Z
M:N^_1O'?I8W",.J6<'(RY7 \UPC1^$:P=@3&KRB%JY!TR1UVN57!=Y:Y%QSV
MCVMZ5VRPHU#1!?KS:"T$N9:A7+_ QP?!-J=!B8P,ZD1ZJ A"#3]Y!"&R)^)>
ML_N#7#QJ$Z[2*3\FP78*%-A8N.!V;G-#V)?Y=8=>Y$O[S0T;),,;RBZ:X\"2
MNW"L43;;I^976)Q[7(0.MX-EWS@ODC!!]I<+8QWVM4W50S?D;P0\DVW\W%M'
M@;>JT9J?6+A[W^;5".G:&+U2B'3L H5SO.2S$&"T#I( Y:N)2O3C/MK>OX$*
MG;^FZ.817C&%C>/7*6%1(>:V7--RH\"@OJ>_<$Q0*<.*2YQ=.#6JUS/MT341
MJ?37P'F!UR?/.'+*7OS<B*O^+5?"W^W$54HUJ*$4I3BY6[($"V*I_%LC$> 4
MAD0?(K.-3&IC!KWQ(V8WZ_C3$[/>>K-^D2U7/9W@-(BAJ58[M@DYLZ;]^5Q=
M;.D(AI*_C>/IJ)=@BMQ33_S=PQ6PP4Q;TQL4__+&PX?0X(<.O?=[#\J)GG0L
M:HVM?VQ202@W&[L. 7L:*E&ZNM&OFMPRF1OM60T]OZ/;G#-3AD\/BXJI>QPT
M=)NJ1T)+PS+PM<JE=&\(UWBJSAI69*@:4,V,=0;<:DH.;UOH9:]: '8T+X:/
MEIG@M\T%G,J:NC9? LH-Q I#W2ZT.C=SFZC*X>KW[D_RBY%NZY&BKJTM+T^#
M: Y/CCWRJ':_"X7V%O>77;R#4>)4NK49$T_%=)IS/FE5=&E0;-9O+CW@,E0Z
MG.Q5@VVD,A#9.HO<BQ]E99[CJ%#KJBY;)*NE2K\6>Y.+1-V%R/,# ( -<+K^
M8HN>EA+#/G:4ZZ;^O9A>-SGC$A#CA2[U>3<;!-FT&/R\G$W[=&O<8TWS?,9#
MXIC.1(UHP^0>8I;,01,^ #UBDHD!RJ F4 +0$3]7&.CZ)2!)!\QW9-&0<)JZ
M>03$F=DR>5 W90*W3JQMH3=Y&N)#NQXSWZP]L$A4O@[9<1^&D@L5:?7_.&BN
M]$-.C39.W#C:F&CE=1U/L@SUZ49K)"1EV?8F\FXW]DV#^WKA[6<KBY/5ZU>/
MIFH?+@%3EP#,UZ/%692*V3AT8+@N"3.AF2]1YJT_W"[I7Y*&(C7MJ*-A.(ZX
M-@H6'_H1<,("=]@3.QMUX]3?',%8=O)WWI<]L.>0S%(0./-\!"7;1AHJOSSO
M5#.7:C;)0GQ9N/% D*M>%M3/\]W2G%_>SU]4\)L*#)K079=Z,A,NA*#RR^+=
M=Y+SM%X<_5B!)A(PR._&A)4-%D#[OU9S.CSQC1NF"!ARSA+3G<"P"T\BCFQ\
M\:0,>\2^SVRVTD&W++KBOJ,5D-=;W]_$WMP;S4%D5^4ACX#EMGY\U752!/K*
MI#7#+)DON#(^.3TR\*$,+C\$^<Y/:1HM+!3K5^31II]=/9\;M,+*\;U<96*5
M#8.=2%-:.M)<$S83T!OY<L_L5#Q/C?2^^E-_2^1T:3ZA.)I*%%A<M#\2;0\E
M(.O4BY8CY?W^W(=0UU,O@ :QC/+@&J>4@^_JXKHH^WJLUVMEE3OH'#+!5&0S
M/2Q-*)!:I7ANNZ>,Q697.*5"<_ZX0JUO4/SO)"[N("(2U03U\8H["Y,/'.,"
M/_5_VM2U2RK/U]_V41E* 5.F@%Q"6(R6X.,^I(]I@=$8^@T,_\<&Y#4[X?ON
MQQK<+9$<#V&ZG!YQWTXJ;IM,.;8H(I2>3#A^.N 6?*F?ITU05MHH8^8\%R X
M11(BMKRY.&T++X5]\!^Q7R$Z!S:V2P+5['9B@P5DEA91LK+5-*:)J[MX:T.N
MS<"%8=&C?#-F)'2.#RTV6:$?]F[&-U%TN]$+?:!'3XRHRU@F>6- GU9N<#I"
M]:;_@.*E* M_7)^(8-8E@"!!JZFN?E002+TPCPJ8#S3D9>'BCX$8L@=B'E>J
MUP=Q&7J5+T6Q\'$\E?[&074MD%ZITLM1I6[\00 ]RH4]XDC_^D*ETTM>QGH9
MM++WRB$#7$-Q.>O.8"%H9B%8,CHS#'8:76O@]];A$8L74=*6R"%3<^5-E %<
M<1*:X?B\$;*M-5X @^.]4J^<D\Z:0E2 U%&6I2U-K3&)R_@[AW3F8*F][TOS
MG/$!9M$;-N,DCT>.R"<%#.D4R7/F'\>'L.^M6%-XE$[KRQ1L3DX*?0JW7]9[
M2]^@$:CSNV=\7Y:5^^&?N7FF:"#QT[^]4VPI6<>HZO1B/JM< CZT^I1[7SVW
MMMTUWL;PJ)':8M@;1O;BYQX3WG(P$QT>;'$??D9%%]I<9+AI@)OM[\G4BR.T
M][5WPPEXV^0Z15[=):#&<N='L2G4[B9_D+@W1.1XN7D*)>U>HDB#2NAIZJFT
MBV[>V7VG=5JCJ[6<A6OH%?DYK%-GC"?CE43U7?D[",B;6]=6?'Q&Y^13O=!;
MPB:B"+K$#"CTNR%.ZDU0_2QA/+S]XD>[R74EN#]OK\]12-Q$;3N);<',ZLN@
M7<=$:L.L=WR2%Y*EWR2TEKAXR6W._,OJ'QDL;&ZUOVQ[\P)N!A@2#W[MG#D/
MNA% :4=3D&\+C/33=2\WF!'Q*B=\(F!%=]/%=7_N;,2,8P/2%-L[J*/R3 !4
M:BP$K E=(:9TY5WSIJ]MX_Q84X]"+IV',S]M:(#("(T$3>L"LCIC.YJ =U
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M[IRY[RET*E_'KE$\WHX*U&/9[%"/G\AW;-A/AT54/FN]SZ/W3&4K,5EPWU'
MPX3!"DRT^:KWP60<&7B)J9&!ZCM;+MR8;? 3EV!SH50+_*AB;P8'"@U= #:2
MX9A^H*HPU*]I2E[&#7.E:ZG$L9E=?<ZJ6ZGU35?%2UA1]D0^.5E7HT>UQ&/4
MWG^HFX$(-/ABR1#F--TT.M!9>W0)L#Z"(\HD\53M@=U2M >ZE)2W:G^<K4:"
ME;4'/3N%?Z!&=G>7D\^%->)%*^C4=W#HI24;<3""C<731O5=*C3+7+8&DQP$
MM9 W)7!/'(SVX("P@R6BMIWAAZ2[091HABCO0H]F@,FVHO\N!M<];[2M&:XP
M(_]2+\TNB86X%<^N)PVCZ!!Q"3!MGRC]4#.VKVN,](L&/51ZPW2'PYG=M'D;
MI6/4I/,AX.[&<4X/?)=TP<&K);=1SC!>_/D7?MN?9\E'2Y\]"DE%95\"\AY9
M_8 MH](*BA.[GG35,%H$_ZBW&QH5Z$<[2^X5%IO.];Y*H"J'!7X)P6X%&4\;
M#2"9U1K.!0HF7GV1R";^YM2)<S@LF%:H5H)BVOKQQ9AM^:Q#7[E*R>%1U+&D
M?ZE<ZSX8UHQ.C+'I%Q/Z,%6[$EVWMP\ZFAWJ2I4<W(LML\/<;6B.7Z8J-P#9
MLKSZ&.4V##_3\0SQXV,/1XO5>YZ5'V/S/RZ^WP$OEFJ9+(@LV$H-+2Y!1:I#
M058-]3;VN\,+/>*QGP@F$$3EW<EOS(*V;MQ[I["2!]$.DPJ%N,VMO$NH:T=@
M4T0\YQAZGGJ<'+)KO[/OF%%IWMXY.]N<0;^UL&>54K9G0.$ARD*P71J'H$B<
MR*@KXRE??=/O]S7H*5>#3]1Q15,38NKXV7ITJHN_2\#0Y(_9E_^X!PU21#\X
MZ/O[?!#76@J[1)&+W>)J1-C-\B/)N[JYM?$>6J>!EP!_W5+==#3WJ.!=6[1B
MJ=VDULS\XA9.429_5)\HCG7=E>K97OWXW':BZZ*H5'[2P'2EPEK2(*(>'DLX
M#SJS3+!UZ<3-+C1FG:A,Z2!KL1?9(#FL &K1[(=93T@8EOG'N>\^(Q\]'.#B
M-WY>3;MR!.0!D_@<E2P]R$[N;B<K'-]C=LZWH0X:,3)3= HX#-X0O^#RJZ<$
M6L$UY]ZJG&Y--;5W[:(@SE,J7PS4('Z2B+,.((G*\4!DFCK+>(7]$C^+9ON#
MEZ_.SJQ:F1:6[Y;:5'"OZ-]+E,DMA@6NT"!G!R)C"0?@QG>VKSS3ALD\S^IX
M*J4RV)0-SG$/.,/'-+AV(./NYS/5#,\KR=TR+.E[E$[?@!;37D/9:124%NXK
M[KOO&[/-&#\XI!#:MW"!<%1F"OVVIX^WP&# P>#E#WIFVA5;<GLZ:?W"^^RY
M]N\[X*6E_)< W^(M9:F?^^1.212ZFE:QRLWN(I8A?6>[@G9I3 _B:AWXR_"9
MQVF*Q!6%V+SW/S_70.Q1-QRP-::L2!5Z -]2),(&I21EEDFZC.]%&(*ZM/U;
M(W&I+U3DLQ= [82S&B/6B%U,<6%KIXJ%\\NT0"(TT2;Z[*@B&-867#Q#9]%%
M,\=@/0Y-BQ4L']9[:VTC%;8&S/<WX6[BO0U9,X)R]Y=,+:@Y<E')F^@=/X0C
MDL,G!^2KD10]*91A:$GVF>@NGA[%+K/=/@E>ZN&CO&\MBI:%1D9> X8Q:TH7
M/C)WTJP=*5,XZE33=!>+UT?K6P*F#%;WTI:V[S%%2Z-G3]_1RCL4LEA/A%](
M;L5&,DK1('M#6Y[4W1[(G9[IMUJ>X5\C#*Y=\G=&T;B!_,U3HU\VEMP72$I6
M,O09,@W"+3L4!Y)XQ:H@I3*.Y\7D+77Y^FDCH7#G"3T/0;7>IG>I\J^/TJ;U
MRHI??8DBX31<Q4/,Z[43[3IDFMX"N1JH6#N6F%*79Z=XU'WB:XCY7KY(:^L"
MDL*?%$"%6B9]C[*82%[#/KC6XJV1*\,7)?7EG>/DK#%0)9IGCA",-\V6A@B=
M(7^<?WC*"G;YH@HV^#&,'P?KDZ!;#ODB+?BUCK),S-[J5/',&HB@.0+B+()?
MH=F@-BX_RA-FWYFH'EUW/MH\G>++0TEA+@%+VCW1GA82-$$""9V$U8G^6[.A
M6'MR\G"3-?JF?$YDV6&BJKZ/E"7*X>7$:+WY5&SU,B]U=VY6YIC"6.$X#RZ_
M1,<;1F!V!0AC7XJ9!>\:;$F09&^S=RPP3QPU*XX93#!YH1O-N>X]C[5#3B7H
M Q&QVPR(#\2)%\G>%[EKZSMM2M[O#QZ=.&<F0N]WI+\(U=0I%.'-K%#;-_?T
M.5$^4B.Z!/15YH&GW@'/ !5X\&"%3(:1&99%IBT.;7]5XNML*?!],MLS[8PX
ME'N%:'T@TP.*T-T2W(!UJ#R\<C>+TDOI25-DYTQ(:]]XXFJMS?>5:&EF5Z>'
M0((#A!<-ZE4/14E>SLI91?&QY9=GZA]Y2,C1SV;XEGQ=>]$7)!C.)EX*+]L6
MVZ61POFJCRWNBL]CW\MRK-/#12G&BCI(\G]^LXH6+P&=$7+G#(UL"3V*#'\N
M-7*?H<,W("#QLSRE:@5;%HN%8B&2"R/L2[X\;GPDFCC5QNZE2:&B)ET_6?Z"
MZM&,D%'1?B\PPF K@&$[DV&J-BVRG*#[%</0)4"I;H8B268.7N%+LVZ!2EZ.
MM+FS</))+-?NWN.+;X[<L^-^A=A(P7S$0*=/01Q]=>FV>C[TN-J)#?2RAPG;
M&3OF$L 'KZ?8L"AF#4DO[7B8E+3JHV32WRJV^,3\8B4IGXAH* $YUD7C9V'?
MEFN3S.I+#<#)FK@$B!W"3"QA*YCOJ._+W)I2]K7;+VMT=UZ*]%W</:Q4J7PD
M7%];"(Z,ISRJ/]5K\KU.KF&B^.'GH71^<&]Z^SY!I<[M7VF!+\!AX!5]I;$C
M$3N_5QPYD..^/U\V_D5Y\.=;CIJ?!@*(N*U=HMN%]3-5WW^(Y/(OB_:O=!2M
M?R2HR-][HYL#N9\=\C-L3$NG_"4@X<W4)6"'@0$32.?C[XU;Z%SAY0K'+:\P
M0!D^G["WKHLA!]FDV8K?9GFH28S?_?3-L"S2[9812EP/LH%]H^9M>JQLW\7C
M2CK*DRHT,>)KW-S@;;"=]XNX+_%!\O"819@Q<7T9"MXKYFOC WY346OHF\[:
M/;$=]V:8\27OQHW2 !%$^C&0Y)#NMGQMYL&.;E72K2[C<.JY%>)@=F T>\4G
M*]1!%W+!:X^$<'$[?F.&N_8F]_BW>'IK3BJ>Q_ @H,'0&%JQP,NZ9^:IR5TD
M=T]QWA;9*:5',O'P*MECPILD?AB\R2:2.S8^29'P:3]CR^QHAR^^[D''7^7H
MI@" +_B203_P+#*)>#+\RU#)W0;>HW[L]!&YLT+GI9&S^)T#.XTF)+064VS1
M#M=]?>]61M"+3(7LE7H[YMH^\L]<6!C5HC]>7V/Q?X2"E,.XZ;>?H."^+US!
M@C]Z\[.8;&=Y5^/3I*5R\XTTROQ$D9DUKG<BO$ML?&J#W$$""XAV"5)4W'#]
M:"P!;[B[6F2]">.$&]>@V*B_1"]^(C&%M$IVK$HO#KR<4=+DI\/__]#+H%"$
M'R]O5Q8E#C63]?XE0$7%AV2Z$+-T"6@K+<G5-0G/::6PV-&Z!#B!%Y_$5JM=
M?+YR7@B&4[!,(-7']R\!#<#];/D_.H30]A$<:O_92*H;>()W<<BQ]E@WI\P?
M MXC.=_0^+,/_[6_ BR:[$RQ4<I@GG4>C#DC_]7IZ^M*6;US\DO ',/)M]Q?
MG6)>\O\EB+?_#0C7?3A[?U'_JX_Q7_)&&0[Y:]YR*PW^2A*6/J+_1U2XWOLK
M-IH#_XHVJ2M)_''B*>$G5+< =X&Z46@+)[FE]+ @CX(LS9_PBWZA+_QO$</(
M-:+SB^<_^_R+23#0\.6_/@NPAP5CK]EE(=X9>85UBB''>"K>W7R?%_DUY@G?
M\*:.!/>2;6VTQW:7V%#)3$&-4Z9I6HVY7+I3+H)B_N(W6%N_$&F>//T+!&HI
MA/\-+GF6_I+&O?^22.9_$PG^0:OA)Y^R /8F)%ZHX$&!D0G6<9%EV!4_XN=N
M@P:(PL#\$??205_="8;GDPX) [:05\]513106"A=]Y\8FX!\OTD2W<WK\8N:
MV']@Z,\S33]IR<6<%;<-\$ZC6W,]T'"!]+<0@7\2_OV#/XE=^W/X<K8;]GZQ
M^_47_)*_7CU_/>TH_SL+^S^MRHE_%NS:WTVUW\X-?#NC4?L#Y//)NM%NH6-U
M7!*?%('E3X6R*L>*L?> &DK'5_JP\0R"MCCGI;L$2%F>/&K.E.SC*,;T T^
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MXKNUP;/TSD/,TI+[/3X\7KBM^0:>S'-\(1;(CA.6U'<%M*54:>_B!''=#]9
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M]8:,/A]A0U=65H:W?7UF(B+3S7?M.IA1P!C5O#ID6#[?2JJ&Y"U'G!IUHJ*
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M?-GPI:F9F/SB,'< L(CZ>E/,Y?.F40(Z\\'94()#8Z'C3K2 >\J@3%VGYSE
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M3V/=I%#.4,H-@T?M,=_L]P.F+![;,[0;KHI$R:AJ*39_#%_=-)P38LP(X@Y
M.F^'M\N3.]>M:^O8*N\8@;I>XG-P,3/T=QFZ)0<G=/5?\\%R>.KF.*_)WWV2
MEMHQTD;S8]4P/W'R./\LFR*]>8/BD!??:!DZ"G.4UQ9 O^<H&IJ;&3P'P.Z_
M>JAF-^A[GQI9V#T@V;V\"'5C/_ODC9YC.\,%:@*&QEL94K@%!JBC]2$/I762
MF7=R\<*T62<3YUF@INH8L-P[!_-,@M7-N464@,W9=/W,"VS/G0,_@;0S$3S,
M;0D!5";FKH(XJ+;^92]J<6^BF6IPPSD-)B^OW LS4MJ\B+ =#HBTGX,Z>0K/
M 9TFYX#KHE9GPR? 'U4M7C[^[P=!-$N.9T1H.XTQ/A%JJ[%;/HT9-KZEB3J3
MW0F!X )5;T+R?+I^2OE=K0]J7WR3/JN1^.1&(;>[5(F[:#(/@M\<1WPSMT9)
M=[A]6N\=&;!#FW?"06]J5\N$H>(A!G#WW32!25F\+#K?G/J5?#/^;EA[7?JV
M':8>\^D^SYL*9E.T%F+ 0]-/Q7X@:B.J<:$VX:G[/C->9@%70TY-U_-U1/Z0
M@AJW Z=1FD=(&PT:U'DX [_)<JB'9C(V46I-EG:2(*XT_((JLY^;H5YI(PWB
M<;1A&A5AI2=1O%8XN8#:XAI9$R"S8?Y<512':GR]\WTUP41[E[/MQQPGF /^
M]901E+S$AF-W>]8\JX,>D)\3OFMPH>=/!"_/YRI=GL]]G(E:93OIS*Z48T1J
MG .N8'[<7"/3D/?J"?XWZ?E(?Y_%+:P[!QB#ID1PO$7:)VV\^_=N^SZ^,"Z[
MX9QFJTD290P*V9:.'D0NU9Y=D:>$\@4KWJ:1D4TOTNU>,&Y[D7 Z',>-U[*7
MZ]B&,PPH[1RT93H9F"Y:?*R-/E 9K0MT6'P2KU85R,R^0N#&'-A#V>274>A@
M7[G)U!00^]BEE_Z5!!T#YP!9HD$Q!^M6/<'MH@@:SCO!\E0Z&@$X$N&<O%C&
M)GU!$T_0<6ZE:Q3NR1*/X?IU/_B)4[!+_2#26$O-RER^,JSYN%-B+\;>0'P2
M7[JN2PN.V;_D8:H+]%:\\8QRAUR7CW#%R1;WC(?A$]_UJ>7RIM"A"F?8=!U[
ML<Y: 3RA><;DU"<X3E%SI';J!7F$UL?ZEB@U':NW,M#-C'<GTH)]ZK4G=Q,3
M6^O P*9P_A(76*#N2OYFR:M7+C*F,.@6?=(B#U )NO=^FD>B%PX1L]_Z^+"(
MZCB6DT>QZUBFBN65K:%)^F0<LER*<X'X<1RDMJB@BES[-"=A:=O/'UE=%\Z5
M:V,-$;2IMX7(+8CKDSG$G(1&ZTWDB[NFBQ,6F\B,J&;=^?Y6VTM\?F%^<1Y2
MH:$(+L4,;1_Y/Z@6<L1(Y]J"229M:7021T=.?[ &FH3.*2JWQ>5IE#GGY+!C
MZ2@ L#^2'7-:ZN;EY++"C;R(/E=ZF-L5/;C=4O=ZB>E3O2J5V^<5)Y_PM))$
M=FURYJLDO1S6^4-<=_UNZE?:/;,RMSLP4GG$!%X^%% @%U_OF$\;=S4E16Y0
M9MI%/(!JSHO?XBFY0EPT'V0DK!O7K1L%_Z WHU=9U/@$)A]'3:\S%G+M6:R\
MQ82G5M>XQ^NM"3EH=@/>'?W-6'Z9W&@@_O>< O(U+=4'JFRM&;,0G[ GAOJ&
M^@HC/^"?7D8O_G@6R<3M'8_GLJ[+7J05K\J6>YD ,^ RW6/,SP/=,>C#B%4S
MDT\SVR[G .*U9V86HN'LE2/13_Y=@LE?/P-H:!>?Y:AWAGXD^<\N$M&C1&F=
M/?0"K<_QK9OD.X/(@0N*R6=M=\[J\OGF%$=)?GC:G<F;,)ZU/#L'#..0_>6-
M_ V89#F#,/D+.G%NZ3NM$-#L>,UN^.S"23^^U3+3"=K1P!B= TSR+C-5-L/7
MBLG@>V9Q\NWUYP H6>YF^UX/9SYY)N>5F0G0:KC&P<SQ\T3-</$G%&=PX/+%
M^\@Y0$JS1$/QLH$B!J4L<UFLH\R^*&MTXG@JH"QSB>=W@W_HX6=5S$]$)>\T
MO@: +^O>^=6"AO[R#CY[GZ^=$ZV-\Q>:R%YE\9Q>5C':GP,*.'38<Q.Q'"^K
MV'_B+9:G*R( _:Q2O,3[;TGZ\R#^:S3^>YKNJMX=_'['D4-MUG.O;*U&#.-M
M=$K(1G9[YL_T<.QD)_W/NO^O#%D1@_Q=P+C["2AQ*9?7OYA@?0[(N*[X4UQ_
M:_(_8=L_<2GF:.[ORO'Z#[[>^H\A;N6?Z!WSI2SR3?=RR92!O@'/X"!E-7:Y
M7]!_-/8MLOQ?D_M_7\RY9YY_+BBVK_#]47]DV^)&GJG[$C2_XD?((:__P"\;
MN#QUP?,11LQ)X;+.2IE,;L@Y(--N2]XDZ5>A(ISYHL05L]9*YJ=(> Z0@4V^
MWFXTWR0Y!PPU^;OZY0"/#M4'2T<41YUF=C?]/O.>_#O(C:J#M^> GSBAOW#F
MKMUS/#IH6Z#TZV>TB3GS@^[F;@K\[-S--/PW/?<])O\..?(O(*U_09+\$Z2[
M_LD#T"6I!&\F@2/0W9*]TL-@1LTNOB/W"U#+_A0-5LYGNKWB(I1PK<L^<@[/
M9(R0)7MMA:%)%01;#YJY_?+_RJ7"?3HQS(G9*_J95WV_QKAR\A"TNY69KI<3
M4X1H7X:?Q/Y;!F[\3P=SR88W?\:84K*G\8L<@NK_(37_57&27E+U5WP_.2;\
MAQH)_6D0EC&U;/\AT&\B?XKE+Z(R57H"_SRM/,M/-608^DL+7-DPGBIGZ)(]
M/W6BP]?0+_C_AGF2;8LQM8H7HUH]&OG=J%*>4:,+-%1WR-2\I?^+,;\X_">R
M_E\':%J7PF"?0VY*S#0*M%:_%$I2WYD,:):U5&-?2O+0B[SU9L6%IORL^=W1
MF#?[<33MF5]E(]'_E8;]_Y#_>Y#O_IA^'@W7KRI^U6IPW2OYG6RFZ%D1-!%!
MUGKS@_D?7N>WF=?]ROZ_Z"G^O;/BU-^J<>0Z4A:=CS$<*A4 ]:7W(90UE*Z9
M74)?S?_ERF3^J;O_S9#ASSS@5YX[XS ^:KN>Z%MGMO?VB%'+1-7Y'$ *7'B<
M<-;<=VJ[*N^2)=E^XQSPN?CO7PG^];4QOY'M UK]3!D8 5JOS3P6AOD84UY8
MV85<-/BL6>GR(T&/.IB6VTJXD,C,39L,&JCA.4"G29\)SW;!HMD;:Q*6[,DV
MYU YMQUV#GA.]'$%PE).7A7E 2AZ=+<J;<&JW-NA'5'.U8TT,EH;7_*T7]I-
MDNZ^\ITYS8UNKY(9.7H3?C8"^VC4'2='E:)!XD1VK0E+_^LAR:CO(W10B;5$
M:TQHB_3+^#6P+:U+Q69V&#Y@-2$(5O?,IOUFBR6BG>K'BK_(:]SHC2*BM]GO
M!#J>:KT6^D2^)L,T)@PB7JVVH_D8S!R4^"J@T>%KZZZI-&+"1&NNLIN]1=7/
MP7[/"._*7>EK6HFR/FD[ZN< PX36CL/(IW,MNWUG+&,;& -$%+9\L^BNV<"'
MUR3Z1SX!]/<[$.< SCVIA:66G Y0Y_V3^S/&?BO"1F8\?MCS#D!1<[2.TA[V
MN +!":DIMM6\8Y@,$TJT,']%CU_9WB)VP_JY,9-?;KSXINEQNY]_W2YQB)LZ
MJ8VI%"P?V?N^*1CZ1? +K<)0G=1TPU6/'@Y^*[,"S&-4:&B+F7VNY^ X'Z>'
MS@N2-Q8WG.B5D5TBFUKJA+6J/-TC733[7G3LC&&5-VJ1'E$M+O-&TF8][L][
MQ\=B/UH2[' ,]A@O+!S*U&;P4II*H[]ED#<T)Q&*CM63R:U\^#Y?, ]ER^>J
M#3@D,%J77.2Q\G!TPM,B"T3M?RJV3+IG_O-S:^_FCT]D\F!#&<+#Q)V.MVQH
M*D/Y>*]J)311FXG#%;3GJ36)O2'H,#>O>>*P5+TW\6LJ]N+C@AW.\5TN O2#
MT[@VNQX$&3"[(OT9JPV/>AB.]]M\7>8=X2/>\NPXYM0EJ@500PR3YHRLE\BL
MC S2%W2#5SC=H\L#IB&D;&X9M^/!CO>1&B^;;#M22*ELG>%6!ET/SV:JA$M4
MV<8U3(VBT'V7J>CRPM.,)<]MGD4C;:OWBIQ53W+9[DFY5@@A=)O+T!&R[6-U
M$>VB8DT68!R=A]:Y;+%X=-'J^2[PY3?",R%FQ/LGS;2E815UUYAK9P3H*("B
M_'AXJ6#G;/CJ.0"[=E/F'&!D3X$;=C?#,L9'$CA48\V4H<8OS6$R2:P88P I
MR/P<H54=_]R)Q$I3Z=@JM9$Y[]'0KYLU&#7M%LX!-[L0/GX, QAQHHI#C7N[
M==>A%IITH&M#7UT^G]7!?15@(CPJG6?7(?ZCZZ?Y-F0P;J73^=@ JU&+A'#Q
MSN5LWT>H-\=B01\TD6>Y+P\)G.)J>C6?8 V^$B=O1-@[.V*X<DW6].KG#K;&
MQ8V%2BB?2P0?'^M%8U30-@6>BIWNX&/+GL%S@,CS1@.6K_UQAU7?%[3;A(9-
M06\R;J'(2^:6U>K#6"S7JZJ"T*) (46A!H9=8>1$KT6&/D+6R501'V_.1F;,
M_@!4>YK#6#,OX_A>U/QT*W%VYJ:4 5N4J^/UE28?AX;1*ZI.)2YA0A\Y,'*9
M7TLQZNG<;E,$G\JED"OU%*CK29.W!M6G7X)(^M2+<]-X??;+]]-WDFJ;P0T$
MHUU,OG[.RH?U<=^>^32[)2K,17&&8%,/"F6DP09LBFS:Z% %R45H'C?MNLE2
M%T((G=@]YDF2(YI15&^D[WW4["J!Y(-D5O;IAU)O=GHW_*EST[_S^F#$QCTH
M-IT)IUIB^:;C[FJ6[HMW%&WNVXMN.;).:-2FFFTI2M3XR\*BT.> #@\9"N15
M70:Z$\N!E%:;[>;/'477T[,L%8@=YAH^7,<0>[@4OG8S(S*5[1K($-T=>V^>
M%H]/M]O10Z2*,U3,$G\OU^:N:[0(]0MW?+S1U)#QLZ\GSI<CFSAL2=&YF$B5
M1.@O%:WCX!QK53\!R#<!5:G8R!1P9GM@EV]+X)I=2D,[I$5\SEY(&ZF\]CDN
MEO=Y8]3'>:G(PZMNC(EBT@^6H?O+[;<PBJ4V'M,,$&')&GN?8I.7+ZZ5N5OP
M.?ED0EH)@J#Y7JI#&&W&6O(6,V]Z"J@S?5!<YFF:O_8"7JE>[#KH9HM&!;IS
MN2L#K_Y-7<%BTIR\IG[E#87M=P#/Y7)OY!K7$G'HL4)[I6>I3@VD+DRXP-*J
MJ>'Q%A-0C=]+9B]O1M:J!$W::\HZ7NX6):8/394V_$IIS7KSG9*QA;UT33/]
MO3N-I1<D/OU8D[JU_?@UK>>3EGBI:U<"9\KM, (HM28IK1)/R6[**!^1C O[
MZ6X_\.X>L_0CYKC4F'F%2A<WWH39$[P[?@HZ7E6G4]^?^-4DG .P\B&S-KYL
M**LP7R/RT^GJ.+]PZ>*K83=EAS!R,]CDJSJ9V2L'<-PPFWQ#)GW[W&L"DX=L
MDVFIPZ51FT4X9!J/_\-$,#A>K4-AOA=>@'2-1O$-P^#7(55'WN4GC:HG>6=K
MD0QI!YNFT=YT;CV>BEVGI-T,=_R\IPG=[>]T<AW1N-<QMJ8^5[^ZG'4E1STK
M9<64"$74SII?8IW!42_?]!%K_)CJ:X^@]W*!#^I(]V[H6RF7^5RW(O1S.T(^
MQ7"%Z*F*W.G#JQXK3D!NGS%)5?-N&B-/\*?4WJSCR/KCQX>B>O:'/]P9VM^7
MS82V4:/8WF)([;G]V1LAW @^^CP*NZAN@;N3KX6^7(0@&T1]BJBI/?]K8_MF
M-VTJ'4%Y N'68\IE VD<Q@=L%4+K!J*'[61N] #/>()65BI3OMJ>@O>"AE(6
MOM__#W?O&=;4M_6+!D%1JC1!6E 0D*I4Z2K2A="D-T5JZ#5T!.E-NM)[D8Z$
MWJ0%I'?I)(!T2*@!0KCH_]WON_<^9^]3/MQS[OVPUGKFDS5FQIQSS%&>->;X
M#<E? < '93'!Y]C"DKFM6;90!AY7XH<KO1ZAPRG-_B"$Z&GO5U\A5.2I1EN@
M]R.:IBD>RFZ!V"M "53Z>]\&B11O&?78LBLC(8H/TM1QTEC=N=J[FE>U_L 0
M\NQD3Q+:C8Y O!G#O!H7E\IIO(SE22*<J;U%LGK@G_%Y3\XOG[7)"]@Q'#+K
M'F+#HVJ=W!#%0[^K:2[5G)#1;A'3T>"C8D^P$0?A&5::LME+FCH:]'&*L^!Q
M;/AY[NE%0.>%LP]K>75Z5^8AC&64)?*.I@6@DL%!;-R6EQM*J+.WLZZPNT:7
MF\2?^':+V,.BZ_*I:T6H$<DXH^[#Z-5^^BBZM[5K3OQ[S[[:]5H4Z2_-&'XK
M@ZXU[V1ZRW!4&9<3WSN/BIJOH(+NUHRQ+<I?6Z@MG I:5&: 2PMU3RM5Y4CS
MKA"W;L;4>N^7X-6;..L2G7>M]T,Q_/EH?M@B4>,($YC?V<7DRYN?8=1KVYGF
M(L?Y ]W.4^45MC:FY(8++^P^+@M4X^$?YHCU*^@)AF_A6]U:)>2(ZYQP[MTV
M>E-H=6]1$IV+L!*<!*=RWY^:G1W]_/$^E_!=J04VU-<3H_O?D&VP,IYI$%>M
MLZZ2@.JW>V1F+#=EO=Y3H$?=J"7BZB_E]"98T9EY&_>$&0U+M>(,EXI4W4E"
M&YBC'2#'Y>W:.,L@="KZ6[<OBTU"W(;.7)PHBX_CM>[CL"'9VD*(B2F4FS\+
MI[2BO\")-WJ;9WT%(!,'6_#4Y2YLIABE#75,+4+<F[/\(,LKV]V>7P !M_$8
ML\(1WE8KG[V?4<B.VG:OA_+XZGO):S_D\^3'.5MI&PN^R4V'>!T'8=:=A'H]
M8,S-E3=I". _:/[2#BL X9=S2G(.APL; 1E9HO<5HME"=A\7T(@\77$XJTJ+
MG7-U:2/%,+,%>TNQ>$:4]>3[/6YH,3TD7J]KE? !4_0L\M9/\+ @+3Z:4NN5
M=7PN9XVY-/S*2)?Q!;9VG%\&Q<U%[D?NN,;@PA#@6OUG5*2SPO2A,RJD\#33
M+<[X$2RK(20785B07MB#M+3%^^A1!9C&\V,$,7D"?*$_-QCO5HYBZ.SA?0BE
M)E?04A@U)^>ZX[.C85!6N=8Y^S)Z/Z>;"$QOE5^I^<(??W!$K=S?TTSV]*[<
MM4BB_A+)3Z*?.!0/C,-$U<&9Y!CF_'ZNV$ZG.)8"H4[*7A:+)9J"A6#/J-9L
M,S<#?2/](8W]:V=H[OA[SI)J55/L"K2E-GU\GTN]A.P8,!T%:?HN:A2[LD1D
MU<B67JB_]7UW+^G.9WL9SMBT4_Q;%=L9M&,8.A3S]_&-)W1/W<4Z13GC&&1'
MAWS"!CFK#(XC2N:4:+J2W57ULY_=TKT1>#8&\P!S/H2YXM9$-%"9J>MX1C+*
MM4$]9&-S9Z]% :$=MN=Z#$Y5?J@&!EL.O.3EXH]!XTAI%0E4$,]"C%?6$M,_
M.%KP9+*,OAK0_W'3@.K^[B?0BAP_84:?#.6;2 X8IO,*L%MX]/7X;Z@KZN\X
M1V4H>ZB&T/M&J9U&1!.N^N\"?CU2(T'%-GS&@2% <$,J)RFR9MXB=%LG9_[F
M]#VD\"RY+JU3.Q4 ^834^5S="V=XIJ*[I)_.JZ9EE(PMZOT;2.5S$Q)2!H\*
MA5J*"'F9/@T'9F.!PI<_UQEG!CV$P\29$<#;EGR0B-<HWWQ'K_<Y"HAZ&]C#
M5=R@H_L;SMV>QB&"]KO[Q)NSY>W!6S=C/[EH23S'.&LP')/S#HMK31T8@!["
MB!0-%Z)O%*W&&UDLMX6Z8[G1(3Z6@3]&M18RIH0B;YF0X,9/9T V53&R*.Z,
M0@2G_4VEXNY"G?=*7PU^7/"ED9%?9) B.*5>37L+FJ&B/6P%.=F/OA? ;.TV
M5MXR YA.LUN>GU@?E('T4:W%*#%MY'K(,9A3G@L>;4;]A).(\J7'K(K3Y%8+
MN&MO%Z/@C!KN4H)'S"DI58')8O?BG1(.$,O>A6F(M \I=:V/4$L?*DI94:]2
M? OS#0>8K+@U3&5AA6^/-PU;*UBA5X [/*$"VW//:F#FPI]^_&!)<(SR/_ Z
MJN! 115&UC1%\>J@\FK/>\+,G,J1,\]".=U8;/&N +&Q*9O-ALY4ZUU+(<FJ
M0AL%5BS2T3 K*F$3@W%Q[9)Y= C,+6XHF.&!LWFK7E2:E$:T)PF4,;$<DFN
M-LO;2O*,2A#-FZ9) <?26XX&FSS',Q4G28S/\>N=0RE==F(R&K:'SYB,Z*\
ME7%7@ U[F9^,QRPH_>^_YI7IY;/LW$V^2E&\AK;4M$:VY$]0$XA^SB.-*1?5
M3@;? Z\81Q3#%Q3E;)F5*O7C;4HU%5?9#+SJ,3>U44815LC#;DG&*8QXF075
MY BT"2K[B$4C>NDU]IG 'K6$V;[MPT/O_B:7@ZI?=HFR T<+P\ H;N@"=-7(
MMJR+'Y9F%_Z\\ZB"J0;9$A/6RH_^RJ J7JNUQ@)V6-.26WYLXXK["[.U'U)3
MXD?@;=,T>I2.W)S6<\^8N@A3G:&/Q$JETP^0ZN2$<_10F?^%8/)7@7KI#6NS
M2JJBG/"L/]EE?2BA!NI@C(A7R4"P3&V,4P_IHIV_KVN9\GM=:M.<QHROG4QC
M)AXV[GZ4Y2Y M/Q*TYAI5(XPYQ_E*.5U?TAJMAS6:<13,^U-31JZ)S0KO?;-
MP$Z*2T:!>+B0:@ RW4--&S6008S\Z >>M,,)1UA> 29G"V7[-M-\C8TX2Y!7
M@""N&A"^/MI-1C_5D4RA,_H1E].\)[FRXKP<F05*UN\N1F',I87!B/N>^M:!
MTMW!/L !WS- ]/SYM,+*@I_F./#5F("N::#J% _F8T,L;JBFJ>/WY<S/OM @
M!"?$UI</S4,(B:-1GU6-[<E^(S<X0K"%,89K(,!>C[DK]&!JE6D&>@8?EZI"
MWHD%PM9>UM_/()LZ_H@2^@:/\CW@G"DE8PL_?DB6'!6"8E\FZU9>W@6KH80J
M2JT7/6C)E4[ M]TBY;7W%3*:,](0#=S."A,U5!GC%QH7<MVMG(FVK_N 297M
MDBA54<"S8?0;M+BK+3SU<<TE<^>I=LJ]8*VI/:P(8+:3+M08L;IZ\)AMGA24
MDPUM"#X9HBMQ7R(:+8VM^QH;JZ$5^&>IWEQTQ"7Z(O/P3MM0!TM!VB74?SWS
M&3Y=.YB:.$9O$>E>W8?>KT,Z&1DFRFS)E9X^$[Y;PL[L*+[+!O7T\? 9QJ09
M)E\&S%T!7GA^N1VCUHK.A2O)3MKGCT%3V6]M(H(E(BD::-Z(^THI;O(TO_!"
M\ )D2B%Z>[-C6SY!C+L)7!9N# IV_!/:H"*:GF2(&2R)R6=F,ZI0\/"RT@]M
M8?LJ[4RY^'$H<&_?>#LE.0OXHFN-RS3NURNBJN*DU_X-,#:)IREFM=EFGKJV
MO+;E]WV1X6^<I)B-)%"<V@M><"G2!;K.?"4KAL%5+>O7\40F[+B7XV>_*H]+
M%N[]6%&9:*;(VM:S*P2+[@U^"UV+J7\;G[%DD#;N-,'C@^OH:F]!EK0%R8IT
M;-4FD.(W,((B2GI]'Z*-E<;W'\2_GF!.+#SHJ'?*K@K>'7$I]_SU8PG61LU6
M-?DZSDK/,$X^R2R\1+Z=(G/XZ$;Q(@0$0K;U5!"F<Q-IU2DQAPJ35U7*X=MY
MXDY%F^-_TXYC_;:R?Q>]U$6K%5*JHS>W6>U?XFQ7N"8!>* @(39=-OT9@HM5
M3(YNV\[S&QCWRN)<0F?"6O$@]N(@ANB2W#ZF:(5=:K!,QB7^EL@QU=:3A;EY
M73DO^E[;O$C%ZO@@#MD7PR/3O*CG79*TVQEN!&><D5< +\^5XW*.D\4.XR!)
M,L8'TZDJXZ-4OVI?F7M!=P+QI=P98O2T+4EUZR8%MAM>:\T&Y8W%+$>;F6,^
M%"<A\+_ %1!6G\Q62 AY)URI#BO"][VYR3>G%\E'!1E$MV8W;[<\J7%\,BP=
MWX?A;$$Q70$^ZB-Z0A /#F:M-T\XJT7M>R@S_9JN -ZC ]020@K+8:./4M@7
MI3]J.Q#ZX&RC-1-_.?IU:Z/*%7PO0X*7?Q96I3=BY6+0-SW-!/;X!R0?>FM&
MO S>5AI1R-0*W4UYR[@*7<<76:Z%P!3WC[:G_$CUC>=K?PF5"!06^!JDK/@^
MWDP2DB)Q[2OC?A"L_X5<8?453MZ[Y3A8B\MC"]<BC(02YV-RL9(H0=.HU:')
M1T_CHQT5C!#/0*1@($6S=GZZ_NO&,>9J#\-W%#+!#_09$S>P#,IV$HR"*+S:
M,6NQ5"]](E;^@Q5DA>BX)#G839(QF@QQL<&[K/5$QGI5O\=)18PBSA,UG>_2
M1B2N[(,P)I*?S2;U,W.8^B:/?]Z1=7?) #@6NE3$4$:IIO4D)YS]1H<?[&/;
M?O@? )%'UY/TQO-S*'M.>/:_2UZY9^.WLHZ]80W5_<]RQYP(P._"!O\NN?_?
M71Q=5P#4KOV1X'^5\U4_??G;W1GI"&<O^)<G#+3>73,@%M-1\N9SV\K0"K(X
MJ</,^C=NZ;\[EF#@US5\1L%R!2A'70'T=CC_OCJM-FCEN;OO_6NCK2%W!:B@
M\3O"D6'\QZ:3DA-(^)^@R>MY_QFOHKQ@>Y22:NU<.U"PWS@J.>-1RB2U8O+@
MW),O=\1RV\^<,UHGMRBU; U(&= ER_OWT6W&02YSK^(5:R-O?VB($A99^QS0
MOEX'5[5,T>Z^Y-T1DD^JM*KDXY2-LOW Z+$Y_/IBNF94XT>%HP[-[OR/IJHX
M_#*/TTY>XJV45[/8PC)]&EY7NL'ONA\D=?KP8]RD$CV)J;2><Z0]89MJ+H$O
M!;CNDT*V]2<%.5^%CVW(/W#]0E_[?OX97BRLS#.?4B"U_J8'*+H5"*Z&- *I
M(8J6/5GU?"\'*)-PZ8(A3-&W!;<FU*V>9G!DX*$*H[WE+/Q63(FA0>5/\6P:
M'-,2<11ZO.)\$^M0=/"]DA)P4@8K<F"3L=B&DF8F8&_65TL=,EPD 1[?R/\1
M9-I5+DZU<FW6K6N-D<F?N6KF-.*JJM?:6J":F9_/,V[:8EX@):O*((6=[GHR
M*1+1&63O6=\;AI>3 -C8/LRV*(:+J.H<_CX:#9QL5KL5D?]3KZ8V&*D @?O?
M3B-9'XGO5D"!OM<M<B-;6LH3^DXB%)J[PE(M/]GV\(\ R]P3--:>0V1+X, P
M7Q9D?GF\^]NWMF 32AE[^M 8$5P[A2$^_''!)H1Q"&U=J#@.?"/W5>UTC9=K
MR ^K%R0 7)R0^V<O@(F>DY0-JCK(,O>.3$KOMUG=MB5R-B7FFMV .$&KN8)?
M(C!<R4S%HTM@9_D2";>XV-<N<FD3[D+#[P&U\Z[T]$#%S:)L&1Q$&['D/; H
M::045+ ?,D;XROX;&4?KJ3BNO\J3.^*GW?;>\LA;)65@(486Y$YL>8DE)4V>
M2=-)6LD-2.^1A-SV9H+:CS(3\?C7HZV/P*WLT):I=64Z4. -G5W#YPFX<3<"
M/"0+Z]:T]IKOERNA6H$4W*46B@;FQB)\4B[:>^ONQM;'!.QK+TRCT4%9Z B]
M,;@DW>2OZJ:@,$LM4]JAPBKF^MT,$<%?LVV!ODSHX1TWS_*H?-W;-/:MJN&[
M/7S="MQ'N&5>DY3S&H2,VBM^P<+3M8V/UD/LJ"] \L'/-!5?GF4_>?-!_ ;I
M,_$W^M=AK%L;@E/D.&QEU,86^>B"^>M9%J/#5Q6%8W'2L1;/<)$W'=^-?) 7
MG8UER6'BH/)MH3)[B<L>)BT3A0B6Z)#Q&RVWPKEPC/A+(*3=B]2HLNE0;ZHU
M$-6,.82^:*9^M9C(H5,\TJ7"/"<X'G=0D@Y"H3T*C9+NRF")I7O3,B]>8S+G
M3E_%XAB_(4I@NQ[HVK0?E81E3IDDB;$I7OMA;H IOIQ?WZ>8;1&ZYJ3T-Q 2
MT1\%-;"$VKS63WJE@]?Z*>F/?GK^&P?'GW-@=43\S?(PQ99G3-".[;$RKX:?
MJ+YP@BQ*83[ \P $&FOA"T\JQ\]$RW5X-C?NE2#LJ?((_8ID3EQJPNJXGIRJ
M>SH!2LLX%5!+_NK;"J,"_<H6"AYZ2@HL:;(C23OMGT!MAU1;-6IO&4T+(4K=
MM*0!QPUE>IPQ5&"^LW@^Q:(J.S8QG4]\?'Y/HQ,CX!) A'#@#NT<"%D0?=#;
M7="0LOFZ.NWTH<IBXBZE^O4:)X_7A#4KY,%XHS!2!5< 2QEFO% <CJ_T3B0@
MMHS+DC24<:>^6(O%\WB9$2[R,;KTZ>\WF"S16Z2+^^V#GH:4._[!4V.S/5-B
M^O+DA)#@GRM1#E\E .7278L,$\>\H494D[LFVM7CL]).OV1N\D>:4,2/0]UJ
M-&H#GU500]PU)IO!RY>*0S?CII7KXY0*^3@2U#5H\%8OQ\=BZ*Y_GFJ6@^LW
MT6C)NUQT<O??IW+C[>_%.QPY*I\*UWHIWGBJ/%FS%*I77K8<42:*1<#E3C(2
MQ>=TZ2X6Y'P]4?';.N=\X#%OC^IDX[B?2S[!<A!N%?49H2>:YP>D*X9MH9+T
MF^=3M:XE7A>7O.IF!(>ZO=0#N!?M,=9U</L;FQGW&AI:PO53!V57W^GWURTP
MD]0S!DJ-%0PMVUKONS-&>)\\^5+>1;K:0R(L28*_KBN).[*&W \4N)1<<UNX
MR6= M'X:Z>2Q;\A Y2.K.<EX(L&Z>_13"PRGH(/,! 3' WD4EHFFHR$6UU$]
MN3B_N[L/,+BF:4%VLU_)P]VEC$WB>5?@C9;&<&4#N<SY812=&C*XF*A1)JJ@
M[(%.6>N@4_.#B]VXU1MB+ML&PT$",:'8N^/*!>EPB?OI<R[3Y N/XS2PHX><
M,T7Y/^[Q>8M(-CCG<64\K*[[-B%<:5FVY&2[XQP_O*(CO,@XL8Z&%H)1[84J
MP7W9<<9/G6C6HQJ&_11WV0O!_MI4"""IM6=(5R816&B$4^<G5P!"^F% P^9W
M$:F@ZW6T>IIF'.XM46R=(8%,*K&ZT9*1RA)UO=3J_KLPO-6C7;E(;['B+2P7
M,O\R@>#DW+5?P:E'QC#<;7DY+2,DWRU!O1JWWTY@P50)A:WX"F%<5YEXWP [
MR4@6^*XGC#U56V*K<-[6E00J.X%BGBI5*-B<7@%,W./H3!/JU/,X?+.N .TE
MT.E6>JOSGMK9R?)LOWQKGFRSE!_*K>82+Q@[RM'Z[;,60>8-30'ZJ2TOU\,J
M>#)=(D57?EJ<:\ZIZ6Q>AXTC;_\3E4:[!'A(>@6HS1S+_V 4SOX54 Z"86E:
M4$)AY%;NP=/J-9]!=MT_2L@F5:2&9%P3U-U,/(Q*;%%T/:+J&]2SRDFQMH_?
MM+10A"SF9B:^V(].NY1QU4O/:,G>I&5-AW."/;+KS(+7=XFR2IEP8N-$Q(\&
M7375U\AB?."\)%ON]NY^.3H&\ZW"_5P/OE0^$3G79K! (F:!876T$99:S"\O
M.$(I\3H&GO:^7@5Z'J6P5P,J.":.0/16?A10/S*TEWQU<\ !#4+#V>'K$S*<
M%0C3&GC2LF"R_<#6]"4Z9N7SPS%HOP^O_-A ^&&JAW"3O_/E+XRHU]1)"USI
M#&.U/#<HN:"O,D;(-?!>5<TART$%I#*Y<.U/^!\.\G>D=%_;.W=W[L;;KJ[=
M7\B+ESJ/U]>V1!%5>^*$B#N2Y!NS!#/9$V45K\:ZUPNHW)\.[2PCY:2-ZF3H
MB[@\]L,PUY$ING:Z&TNMP]:J<[-E(6V_YK6_:>!XY?Y/VOPKP.UK@XT!(WQX
M55$24:V)^59Q'J.S<NRQ:[ZBL7,?-F$J#16@G$QV'42S!'P!!$+'(GS,?]W4
MIT,!9U;)'W-'-^/&HL/I.AN_H-O%I5=Y3^Q/W&-_G46D8QSK1"XYH3D1#X)^
MQY/_D9FF52(DA3J2#"[0Q]'[O<B_,U%+26GERD%P_7X_$EF@^N?;(U^HA!Y?
M=)$_'^+T#7\.&0YRR?S;_N*F:4H?FU=R*5  E0#YCRI4D:OG"SV?XB#!0XO#
MJCS?<^I\>JG%Z5=/3LNL'S]Z2Z_2 E]0N4"XAP@V0=Z4<F6[9%QOG[R]Z\UQ
MO&L(I=10['R626*E%W0%B(*"*+>%XO1K+'8\;<@C*3^Z>OO5^%64.=6) L-K
M4H'DZ'<P:?"<C_G:6@!&,>?9%*BEF?$CP0G!8Z?0[)S-I1E:JN#T-@_HAX?<
M6\]7L:Z^?\-D*SD->L1Q3/F98O$* .OWI3(J-?*[?@)_E(Q%MU/^^603$N["
M2R.-X@-2H-U?0YOE=S"1!BI?&QY\6'&0V![?R+N6HQ85&"(S@FM)L;5NS 5\
M'ZN[&JR\US?O,.#'Y0/6Z#:ZE8JE,D'6A< I%,@B+-TU>:0#!A3:^U:GL]24
M$N1P$$OX6Z>YSZ>.[K^+,!I%:.JLV7"5?$@85FDX84HI=,HD]]9VM[!RM0>&
M<#U(4'"4@$YMLL#,O@])-'JF'#6RK^$.8>3@%7>M? 5 ]]!:['9K260W=Q/&
M; \!,*8,#*EW]%GIA@"0#FQ,+@ BW];S*2M++S^Z$-<FZ,&;7?!8C?/R3;RV
MF3]PC.13A&,P4BM^=ZT;&2/>NML7*Q) !SMB$ER8[/%<]Z^%EMB E+T-V1;3
M[,[=4AA.VZDTNO))@>N>?<,:##%_J7++.5!/4A+I6^+J ]_5[IQ*FF:3/9/Y
MV,7!YQAI$?TT_,CZFED8YFV.MS2J)Y%<(5_7:D2OMUKN'4]BAODQ=SO D]ZU
MO!#AF\YP!>C4G[&3KTL9)4<(L7C'/:9_[^/8[7;<BTZ%'X>$0S_S0@DO4'B6
M7T_4>O'X;%D"9"605H)9E*T4E@>;6&+EEX?</B7R]A9N6](^\UCZ:UT8Y>[R
M<_1AE&G4RX?^7[,< !N/)Q5T=2QX410RK2C\ -ZC0:$'W/--0@\<&CIO>(B_
M:3ABF_"^*R 61KNHRY5TR\7.U"'WDYP![4).A"O9FAL0^>W(]B[$D^%ASVZ.
M-'%K@9T_CNB-%R(L;D.2P8U7@!MH58AT9X3)X9V]_$_#SNP;8T+\,28 8)!+
MC;KB'\FZCM6R"*\C(4;R*T K1XL."(U,OD2]V7K']#]"#/RO2-+\/S+3-"M"
M;_QMP_[O7"44U^(/;?L-?2R%\=*_)%9:N%TA0ZDA3<">\_E?1;8W_P/DL.QO
M@66!_NVRO_F __+4^C_ FP3]8\80QI)DOU/J@,/R"G"\0HKU9\_]W=KX6ZM<
MP4YA/8,X8A =CX W:%/\E:?>VGT%4,ZMD$0:8Q(JJ*^C3(O?>>HMY(T<2ZFK
M;0\B+Z@OA:)CJOS&+3>/M-Q]VBU^MFW6N/A$8%/E0+^+MO/O&!_-BDK^Z:5P
M5&;)X?X)[[DM _!Z4 6CXQLY^_5$?]^%FOO\K3_$<G_Z.6=OVL/]BSCW3T<^
ME(:G.)E_B$?_="3YN_C[\&_BC3_]9/ZN$?__)2:4'U59/C1^>FO$0V(SD2OS
M=[5;H?; /^^"_F)'H^G_7R/^7V>BN'40&[%V%G9ZF#'Q(QEKV+:LF6KRXD]G
M;'^]^WCA_^(I<15LJ4L6VG]*%QWP1?T[]AM2(&_!O^3$]0J0@1K]ZS$AH+V^
MM%W C/6I:-XZ(6P0GIG&>L'D_MQ51^7.-T-_IUKNDYHTQ?ND^ZTWN_RYNQ)3
M^I5_CCD[:47^=VC6_S4-Y-_2R$L$["G_$WMJV :$U/KL1>=/GM4E"^.S?0;@
M]7TO\9\X2,9ZY=^8<2==RI=^?M&Y_8:$KTM147(0_(LD8$^_(<C(:=&:Q_%[
M4>M0V^'"8YX_YS#U$)#:%H*QO.(RH*-LN/4IZX7H%6 8LO'78XN6D_1XF.QW
M1O>BU/_T2-1'_[OL[C-(RP"W,_[,\O_T&/\'1 G_P<,)XW=WMG]BG?T*8( "
M'N[ZP'>HG>R_56!.HV/^W+-S8OXVJ&NR?Q[QW\A\'_P36=8_D/VK?_L/,E[,
MJ:+D0-OAHFAPN-2TN!SFPACB=7.^OO*#U4./KT[MZY5%OD._?Z; 2K"<AP<W
M.M+K&H4':DXW5Z"AYQ2TCY?4_Y'EAK;IU[][\3#ZURS_;X[TOR'+RA7XN[65
M^N])J>7_X@H6_&T%#:!!ZMYA;^K%"6)VY+!><C+)&&_2[,+IR?<-"8=$8F6/
M++QH-&.8*Y?^*(*_*0RC[IG_FU3B_QM,%,3-N3SE_1QHV0/R-%-B.R_")J2:
M:/\]?_]'35-Q;NV</8='N+MI[.P7==COHWSQ-@17@']@R-WD_Z#>[_%6KSUH
M)N/T"%_:)$-*T>Z6_%=5(>!QV6/AW;O,U<AI3'BCU"6D\PJ01<#^#RW.C+\K
M(>3ZWY00^D>0.8*ND.YS8EC8*G)5-$"RC.91V21=)#'L5\_\2BU8&($+*=JH
MU(?(X,_9L1VL)>PR:D)$;#+25C*@*TO$ JGIA"LE5G7)-Q!;M]?)?_"Y/XV,
M\]CNV]85PF\#T^XEPR^DH%O3([,OTK/S;>PD_5W9-C5K@/<A7ET[F[G6E8;R
M@=PT/^H9FW1PP]>;W9$'P]TI91D5Q5O.<J:%LJ^3LOE*_9-,,[(^ 3 W/8P_
MCK^>:A6>,83PS.IS<\R7QG&FMS$92-Y2Z'2!25@)%P$5M'C:$"W 3F[SQOS^
M5]/5'JH</4.&]3M9Y^&S%0]1QAA-8T9OX=S+#8'ZUDF.$^+^PV.<FT+X%62!
MX1VCS:99D$"UQLJQXYOUC=#A=)JH:3L24A: QU'98D$SX7*3+3H"47"D0(J5
MR?ZPGZ =;M5&ZRU3.F]D=:X=9-HR8>J\5LHU=^^)@V[#,2S?%@)$E%T!PH8J
M"@TM-TF@IO8LHR\8=Q2U SXROECX@!YUD&#;/?&;!9I0JZ8.\PX^P:?K.!H2
M191J#TCBH4A#E]'I18MSEF4>/N[,CU;Q1(2VWM/%5/2/IQRUD6/>3.2BWF?0
M(J/#&Z%'(A1BY)ID$X#;R^XLQ_D.$BKAAU< '&\%/\HM]Q36LH)T?KV:FRE$
MZ:4XW]O% Z3*'-4P3BB&X\'!Z%0XQ&[?U&VV\@Y+Q^/51/IS+XUZQFT9R*\2
M5+SNJ&N+E'(3<H>7>S!/0X",_RQ X=9+HHMEEV&]<E\A<"//-]9TA#W!989Y
MC,N3=AV%^%.</A&\4_JQ1MS9C0JF<4F>[5KLDV^CXF_@7>-:1T6AQ;;;]7"%
MOE6+0'U?"70J6[!KJCWI1J/%20;T&?X/$8XO%[FX<;!R"9%"!PGR\$,@H;?:
MA%VS5BL-RBA4(%U153PN;]<TTO\%6\4[$@Y2*F^="5MOHT4:9'EX8_J1<K66
M=VRSDR9 3F4UA0??U0MQ2:@RO5O#V70<H]$PM_9BK8&[?MGIE@C,^54&ST@V
MB@_MI/Q"6\OFW5*_S4%3R#.8BN=T@ %X>I$)#8=O1VDH^?"=WUD.\')C"R92
MD?6Z*^-.&UQADEE#3^MLJ54!>:TS013SBZCC]HH8A-[E>M8]PP^B[!$AH;]0
M9HL?X+Q$ERV[3BQ)9C:USUB(_*G9Z(]+& G1Q460% GS'A^J=],N:$;+W166
MTGP5H>4#$@3^BLH&J2SUB6T1'8[KG6:RLP+ <OWK%1:W^R6"A]2=;7<AX4L(
ME5Q7JUS!M875(%YFD]6YXD]V$LXP%?"8MPQ*6^,*\+'6GA@M)6VHM[?TT(HF
MCD]T^<8S!CZ0GC;N)'LY?CN0G#2"MT+ 1T-%U YJ2:AP2X4&-]#? X_^/5#-
M\'3J,\T5 )E@!40F7 $ZA'AHMC*TT]Z15>'X*)D"RVRTX[R?74OS:3<O#3HQ
M> ,1O_-)V 8W6C(;!P.N1">7@'*\Q:=XN=/R80G,4;";2I4&EP[*# #?;!2P
M@]8HQX97<%NS06OVA_ 3C8VN&_@(L ^4D&6\K89Q[V;U 6:XYCY^\K>+N<9W
MK3K(RZ5.=#/SHXP6<)%2B:&\DM%<#]U.268"425>&CUJL<4%?8N4S)MS_$B*
M%)(B-ZZG(3H/8MS='N[SEP78(*U8NUQ.,BF\[_OXUJI" B:&!J'2M]ZPS80"
ML*Y3VD.95-X/X,;X:"6%*J@,+8JS5>:=WAO8P !_^[#B*2G^HU5?PE$--=Z3
M[NI0I;;]6[.B%R.?!QO_%F[_A2IBS9%X!9CH1H^9R%S'U0 MUA;$%8 4;6HR
MY2K/K?<B(:IZ2*Y\$F\%65;]_+[$3>\K /P*0 5QDB+?/L>V60A5E!@8B6LE
M5>F'S;)K^#M C#HE)U)QYXYLO111Q,ES JD;=LOX5I9S>YDO10./2Q? L%9J
MY/'ZSV-E\T7"#/Y[]V><MRCI?05[T+*'':,RB,Q[Z'<(Q+U[P]Q#B5SO!(-B
ME7!K/#]YTCN!/R'EPKT?Y* ]]J ^0BL&4_8S>[QKT:,63XK? =[!",?%/<?J
M&8__0'.2+>DL2#N"F>:K>Y:+&<[*G8S#L 0!Z)D^!-T+=MN\J&Z<*X W<5N9
M,_8><C'F*T9\B@O#7#[_**F,DXJO0/G+LP4:M<#Q:&7#B69^. @?\S1C7./;
M-PA3S6.67?(PML\5;]C2NQN)4#(_&7;465 LE8U]=/X_-IQH&#_2#D]@9/(V
M3J>$M$^+B2</=VI# _2DT23X#>5L\(*L13JTF'TQN%I<:R2,-<9OD8SB "?3
M:$G-R,^#I.(KI+.CE7=*28:UI*BHID:"J4Y=R)=-Y-)KU$$R+"?A& ,.0"W%
M[(L_*+<\]RE(: RT)EA^6$5B<)>2Y"?+88J)>X)V@B%&!04*/K;D$@?!+9.4
M-OJJE>[74<?[WUV-G8@\MV@QA*+VPP66J*T\I2+$I:S,;GV=X\ZO3?6=6@E>
MC;YS__Q:E7.$'^ZZPU(&,GB2.[!D8R9MK5#E4^?Y7BWVEGH)#]SS-X;X"*$F
M#]2-Z0[1H<";07UAL_"DE_-!YNKIM9_P*SQY\/.G;$]:"JW.6S/S#5YKG:IR
M<2,TN9LL^\F?+YLVE'$<#DIAV=KH!,6&6^RS=<KR?,?Z^LG0=L H(E+I<F,-
M= R<F/&RU-YU#K*GNNNB.EQY3I[E[PL=->SF.M$FD^:-YXJMSOL\U"&+ X,Z
MMC(@A4,PU'"QT&/7ZN9V#WO[\K? 9Z<+<4\D-DS<[KF?> 9%NM>ZJX' #_=T
M<QTT8\J<U;U!2$WWGL%F::M?P;/R\ZK 4U3=<3DA?"K(%4$:TOJX<GPO?[QF
M0?9LJD/NY=S#X<$/L=^!CS'@HBF,"%SJMC=O?<V$3>DLC2V1N<9=<N6G1@09
M31%.(BL;CPT_;)#UQO54RVZAZHE*"YD"1P(U'TW7U O^%!#AF;#6Z#&+GK^A
MH#81=PM_9:K>#S 'B9,*F!K5E8^U'F.F8VVX*(I<L9+P"V'QI1JP9*1K0B[U
M7/)(2&O&J[<U5L5Y182)5?6VG]!<6Y6.<,X U' 7X?X==*#"V$Y-T(2Q:M3)
MM3B\Q[N)6\OG,0APK]%.,+@6![D0*,1EB1RBQUMCU*,<H#/8Y/VE_:6"Q# ;
MU*@*M1ZV(VY:L)'!-6++E3O)5SNNK]0$)H'%9^1*Z?'@YXT:>91!#O7J4:ZP
M8.\'>2_\W,V;*GAXWG-2RETTNZ^25MAQD))ZRTX=DX;>18-T1MZ.[VGA>P63
MWSOSYR)PFY5=,CHR(%7\ S;0=K#CMUCT]2^LC<H_8$8<T,O+\F13P>.=[9LU
MA*T*P)SP;T:NJ":U"]).I2+IMQ5LT:2=8C'8P/,Q$[!?QR@2=$FDE8D^16OK
M$HW.OZ!'5D+R5#<ZL_'>TZ*4Q;I; 55UX[M0WEL&>C.?QU@F[&J.9QX B&%M
M$D[\4RU?2=EV1GTR+6(K/;PD]^8=8VQ4_>.J$:A[\5*AK",Y+7(3RS$#23?Q
MV5O7:8:9(]=3^E'3$?A!+A(GJ+/S_#F/>_?:W_<]6*;W)&E+]!CN+"/9O_9/
M:7BY!0D+&B98QL4OBA6&WCO=]Y=<8+<AM2O7UT9'P27P-5.5)XY=ZII#[+^0
MA?TL?_ZV5UWT+KBX@J1Q4EPD#^.)XEID%<H9+7NK@QW'3VG"%#69+*\(/)$0
MDT&=!C5+0[@%6LP7O9+NZX2^-S^_A2L59+FX?6Z47J)CY>[^CG/N0&OV8:1W
MA^C!+7RU:2I$Z]-69'*X:QOI#(26AJ2:]\W R2</@MAH%2=*1ABR0AJE\HTX
MI(OWMM78IENRAI%X>)U3X*_GLO,)N\,MG!]&I1$^M(A]36CXL9X/N_FQD/!>
MXX7SR-&@MA\MVE6 T-85^HC6=B" W>)@Z=<[^9ZGL;T2)<,"O+\!,_Q^XV7(
M*4\QC?KBH3U_^?",JVFW'G1I/T]4-\2^C5ZA-"!UP+M[6P3OO9J!<#C&W34?
M+"1)C\0F-68TN-/$_["8HW\<7>K[14(.Y%E8B+X"Z(][JYEE0?IEZRJ]K@!)
M8P=3+T?%_%S6EW!1#-%6\Z0R.<T_+A#"H<">\[H@%V/2[UX>UOVKO6,)SS^?
MI4AGNN(R0K/A0 ;KV9AP>W%>A.%#;BFMNI!A:=PD!8J8BB()RWJ&74JUUS?R
M R\MX&I_U14S0U;R;^2$8[B. L+9LVY<7P2TK=#"#5KGI:UD)5OKCS=V[JP>
M 4@42L(>]M/VAG L/Y',F@[QUD1.-5VK<P2QNQ8IO3!'DM 3TH6>R)_]?M"8
M*X"A9S34MMP(HK(XUWFJ.KO8&_LXP_C,_#-=Z/)A=.+.9']11]3CGAP[Y0+L
MCVH0]'P+NR(H[%9J)5V^F4R[>LZE;7T>U?Q2]ZVJ4[C\?3::O6=#'E];F5#F
M8?"/05 O.,[G6%H\"W.8 4> X[Z1,_)46I(!W5*Q6>'!O1I6F-OGR+OH;DI'
M<98R@9)8J O!<F^F_*J^[U([GG&[G,AL[+&3RC-\O)AU??'J@&X.53NE^%1E
M^O0*LX+,,/']I/4L*SUH<%VAC%_!?/Y@:9O;J\L7^)]\HF3RMAM]:^VN -]^
M\7/G]=S1?TO8[ J('88;@7+!U)[4_L=6I4PN#=-0*^;19;,'H=[$<"^</DP+
M>$*<._L%O()4=_-)I7D0/^=ZLG/_T_,4&%WR>$>/W>ZVY3GWW-'<U&7(_08Z
M3;5K]SU;AE(=\#^+2/&2_.FP]2\I^#NTW 7H0NK"<WR7KM:4S<Y'>,5^^XTD
MA[6SE3')L4+6NSCYDMLF#K*'@>?F7WD_",B@WPGTC._V7X8,\-LP6J1^<]M=
M\)Q6H28,/B&H?=3F:?!U:K/)_5B/0-V]6FSDQ?U;.8V-==70N%];[X-O)SOW
M,;_5](PW".E(5_?1@"^F/^JD3F$X68MQB'Q^^507>"]#Z2*&".+NH2,HAEKW
M]STH7Y1"[8_E9!@LBL!9=\WW,(ESF+LB%VDPC3ST82?MVNG/FMUWB^ XARIX
M0MU%D_\P7*^Q]ENAI9OLH49S^-0\O7UL5?R&!&BLGC0\@W[<QIOLLK!0]X65
M1[X"9=)8QP>"J/:[\EM/MS=U:0<^0>(1R8'PJ9/:3)XT'N:@X3Z64IJC4Y-;
M8LL$>_E);ZL(!(M%V+VF58:,MD!*5F785PU]EL/R(\UOKQT]\J:"V*_2S@^)
M:DPYECUW34@DMJ:J*C8E@5!J42A&*/9IQQ=2+I\0#;1VBK>:H5BGYW[0L8\0
M#;>K8/-L/\''PX<K8OZ[0U(4NN>U33G ",_N]= XI?HCJ)(^(5[,(.^#K3>B
M]";KDKFSY4G**M51GMZ+@P6[A8+CT&1E^Y:/6X*Y\\?*A-UZP#!UV=%C&KOF
MMM:21+/S8L *\JM>81<ID>5YW8DAMH1>^[G_]EH3'EO!+UQ"=,J:]V-'.(@,
M@MFF!<T>E>DMWHKV$977(N.+C>HBJ>_=W.#\TMA6/2JPS[CAV<7'8*S:&%MV
MMV/ @A1;6@PS'8:K)*F]=%T04Y)A$% VG&F:'7Q4'LH@!\Z8\2F:M9I]/QLU
M\2/I4X^9AV=4E@4S@Q^!H226& 0*.)^HJDO'BTUZF5>\X>!!M78J=)HR(4F#
M)"KM_%$;OJTCLF:J*M3ET]=^!3C6_MK#+#_YD(!9#?KR".!6P4L=&$Q+J-]7
MM]E?[2=Q2<S,6:TXU#HM<"FF7C6^Q_IP[RS\.WGQNY_WV:+]/5-&*X20XK"N
M14D46]BC![DU\1>B WZNE&FQQSU^M,.$P5'RFB52P80HST>GV-LLN^]=8R&P
MYYE=H"RYHNQ)LG!H:P\^T_O(%0:);8=/."S+.''*WDL5C[I#NNSO0E)^5MDR
MJP<KW#B-JI>"HZ<KKU5Q%RX([>?J87ZQUA+U%CHWM,*&"_P@N/GN -+APBQ3
MM\OM=63+BM5R9Q44;I/6D$7Y!B'(7"\3B[B'9VZ9/[CO%NWS?%AZK&RC<2\5
M04CAE;] &.'PBP^NB.DL6L5=;$Z&RR;,LN:N<#^=<YY[555US"3DI[?1>MNO
M-XCMTF\0DY0DQ9D=$J6K85M4KW<%6-3>85=N,CA2B@@MX\ZO3S^1)J=VZW$
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MURV9ZXK%CZC6V\AM!#XO@9#E(;DZK!4E]1H/VQN"N0X69]8SGUM/1S?SWON
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MMB4*C"G"O"^*Y8(%[]QN'?@\XFRZK#I85F,TF-AL0Y)NK)G?2K VWG951J#
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MR8DZ16^.M73*CAP-D^KXA,A_4U(R_ 7BOL/LV -BR>B(DGLY+@A.%4N]$,@
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M:]9UL*6[;EZ[[I.HXT^JE1C%PQ8-K KIM56H-+T"[$PN69ZSIL(OQ76LA,+
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M*-#\?PH%WK\)"FS_^Z#PMT>%OQP*E/]W]WE2&C\L*^%ETS_#?Y,7;\ND_U*
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M,M-7<#];S1GW&V2G+]T(0CYW I3T8);0_^K3*S+J)JU^HC9%9/*=.-HA6'7
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MRY HT):UMMQ-YE@.7CA1R@PJGI'HE&88W><<KCBSZ_N.>?#>_-UUIW&FIB"
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MVL0K G&W02[+,I$4SJRFW.SH==A%TIAYD?2*",#J!SQ"9:/D2%;?T%J/;VB
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MB/EHM)C0.:"\[?M1XPM?Z\.#2)SKG;_XK3S_:O]J_Z@&.9_X/U!+ P04
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M<+]@N3V#G#0TDH?)']AB #J@TQRO-4_7Q0S53K(SR:@5]_DAZ0KL]\0/MT^
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M.WRJZ\=BW&MNRU;<(+-V)^Y OJ<'=62XC7#ZUFXXUOC4*=?S!W\HM6,$I2?
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M..0@8?T\7A./.41ZFP1^EAE_(]2QOJKEED+7OW9Y=^!@B0\528(!&.U=<F
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M1CS<<#1HM: 1TZ8:+8J\RS;Y"5) (TP>^@VH=IGY@S63P&"-X<8DBR).A,O
MP3JN4(W.^;R]!/'JML$+I#8Z@]7!_,:]$(^8J6%*%+D-OG=%==6TW0.UW'VA
MUGGTF\X45'ID5E9Y!C:%/"F%K*OM=F^!_O9HNZT=PA3[[\*^#?P[L&_TS3.-
M+$?N[?I>A;5A++VI@U;;L#:"^QIL!F_=I%U*9SBR.0PQK1QJXV7,(C]#U>9=
M6"#)ZY+HP#F(MT E8V6SBSXY6'5Q)/=R*#>[$VV= BYU2'[ !H:/(4-MRVUI
MS109X\6)-Z5@VH$0*:S0)7#(JB&R1&@ #9Y-NF,M/_>(E.PFU3OZ(3 5?.0$
M6%E7.9R^8OBF+?83Q1S[;,)@]C,9,14%5>GQ=X6>36>G'3&-BQ7 96G;0%+I
MSQR!009\F"R=H>M8S39M5]%2=6+5VWM<SIV?#[<<O3\?9N^(K(@L,^ON-[&G
MSZ=S%$9R:<CSWTX83+,6*T,U7UJNGN)(@:M\FZ\T*]Q_V'4>1BX<#/=?R'2"
MOS7>QY,H/J)SP8;JQ04)L870(9ZNDYQ8]+T?9K@#Z[#6J</JCNQ7;62MU7<,
M R<ZI("KILU0?V7QB$!>4XMQG@0;5SB_S8S4*Q+8O(D%YBV8??4^S+"F]+6#
M,%7B5TE+U_$T8)&XEL- N7UV*:,%O9B D%[MH.W@AE6*KH&JUR[\K/OAB6>'
M'5D)6E/ 8B.U4^$4T-3N $:T@S"O5GIDGIT7>/^@3/#<;'HV+']VJSCP0OH8
M^L:L1#PW9>X$*W0SBY19C3^[;)F@WGI\QFZ= HB,8+-;^KG!SK3M0"KG"I/P
M<RHZ15VRP4QW<1"U?*RL]8@_,-O1Z[M=8BCPL2M^.]@PXT(T7NYZHG7(77NQ
MVFW3?+*;@0\S$-O%HB7A9FC!"#T:\> F>E!*D]G."U7SDZ=I1#CR0-WFB]DW
MP30^3=@8(XL$)+%8*#;4<%N(OP(\/O_2_T#^!(M2GL_XJJ=]'C>M^@W/Z9H]
M6=15$]MIT!-%?Q#!NI!<_BK/W<3HYI*UG?FMH2*\JJ-?WL3DU&?6PG5JJR/O
M,Q=T5HC6S;-$S>FPFGCQLFG&2IXOK\ +PFJOY_R+CA7!R BQ+G_IHM:\=N:>
M\BNS+NB'R"7'?N>&1S,"3Q8$E'4&%\3++$/Z;>8\F$C3]%^G:+^5:,<'9S&@
MG[S\N#Q@/&FV,KARV4U2!;]&S&(MT3(;2\7A51R#W&\FGE#_9IQF^[VF6!J>
M+F9!W^7B9$L,MR6^;"&RJ=)F+;$.=_%=P1MQ8/:_%%!PQ%ZOC9'HW.Q@@FT!
MH[F9MAX^3ZHF[B1HJ1VU/WLZ]A]]04Z?]>XN&_R%Q](3>:SJ,^C2Y'GN;+_K
MS?8S$(J C"-UM6"Y_OJ>[]0N]5$$=])TU_%(DF=LG]8V3,<\M7 51)737SQ;
M6GJOWJ[S94/(S<G:7J.J;Z)).*6Q!$-Y%\6LYK>P5"]M,9#A)\WV@OJSB!N9
MN>I\M1PBV87KYQ>_4M,TIPMKAHR@EQ*KJY.LSJE$7[0,I!_T$#'1P 8V9AD>
M1VH/,5_T3QJEUKJPVD4RHM<[W+[^-5G\H<Q@IUO?>KSV2!9X2I+<.>H3\<_3
M1/VPICC_Y-L#9O9(5>>M/"$N?KJH&%Q>Q=7-"?)NXYUI:!U[\@<C^Y+<T=:G
M VJHK]9, (/T<7OCZ+7 Q\49WE(07QZCB(6SFE(?GRV.&O ^T$5>KKX<?^!]
M4YWDK5=WF/:<@\7:^"E@DJ#=)P,Q*)#;M/ JG'6D^BYO_T.$M8^3U&?9#UB-
M:2])SL?6.Z0I;W=DS7FB2K(M^"UMRDTD (&ZM5D39*(&CS!(S4_#,H0]/](_
M<7?/UBGFEDA<K_*LYH7!CI3HXKB<[F_W.-N\L")GOSIH*VP:'3U>EP0^LGB8
MD/F6W^W>.NN+KJL8O6028+;WU&T7B@PJDVA.33_'$C%OE1$$(U_%G W&IUUR
M:#X^NIH- <K,O2WN2/-U)*%00]Y .#97]J:K=H;&D, C6E-#,T7JI:T[W<UO
MZ/V[CX+UH7KZWF10HY<M )N4<KGDO+&V:S6E=>$B_7-AKP)M'CIQ\/;_S2NZ
M_X.3\/.(6[JOADF$K[\U#SQ#<S]1E4_R]BG@GN_W1D,UC^6'WE%7DS+\. .;
MPZC&E]6Z5=^_BN7K;4,YJJ(%&#:-X?6A\$<SI0X/S5<2\1%"DW25[".[V6.C
M'1#C]>RHPG=9:^8OM@KF:^PU$:O4WI#48Q(KDV MO3'9Y7H*2072!-/7P*=8
M]H%&\:^'.RH[(LKAAB#KL")VE9U5[@4X890[I)UAO[\Z_-^^_C7\^RAF^HT,
MRH68<51GNJX G;EC77!:<!<]RG-IB@W;%Y<-9G9B1CEK#L)Y0^)":BU=^QP3
M&$AYN.I?IM[ 6K0FY1DCE.J4.8/*.H*.5<3ZEDXXZ["@=C;!O?E[#L7Z/*_F
MKJ[+V-;N%Y-X$(]5R0CDCR]-72\;$@Q]S>&&*+79X0S&#8+!=VZY3GVV;L(5
ME*SX>I5;.UK[R7XZ+S,XUVG@RJ\LL;H/,5YY>K4"ALJNTPX<N;WI0)ZL,LIK
M.)=V% ^1VD( <3'PMK'YQOF@UXILI2\;AL;<F&#YN_3E**$7M_69K_2+C1ND
M]^IFWN)Q>46P<8G'IVJSE<R_W#8N:G>BK&^M2PX7%>!UY,$K[XU[6RFGC8?8
MN)TCU=KMP:E_";P\7%&[X7GQ;7QDO@Z@YCP9\59: .\\LHV*PJZ.JTJ.9;#O
MX)8\&!,,P[+&:_JH^V\8-3WAYDK?];#KRI>N?*:RQR9TM[\"]*).UU>T0V6N
MZLV'XR5_5@,!K"4,IZD-VEH'[A9"2%;UT]FQ_%)AZ*ZY3*DXFKFY$%+Z)0/(
MI0;J /&WWCD(F9J. P'=M$"/#[E:'Q/3*BAS83=8D.GHQERTT2D@TMW^%&!F
M^0,VSYV=!PMZ+L9VQL^)6\/.Q2CV0_BD :.E-L<AL=D%7")*^NUM%O55D_Q^
M>C>8,Z,-9:-=P8W>#M,2)7+4"?.8NN=L)'>TJLI=54ZB%A9M"_B9JL";??%@
M: <]1X,^_-EA-?VG:5J\>(YQ3;_'&Y*B?O_LEZK[G)(E@L.5ZD6VNAGW&YP&
M-;Y++)%:RH;9:XGDFXRI&G&L/""([8IW_^D0810!G.U2(V$N7,Q.VPITT;6O
MKE9I":<K?!0?"YO*]T(:(&E,-2;-[R:< E8^#NGF*<HY.A ITNG]X;4O_=^>
MQNH9_^'Q\N-R8C^T$,&9*CDB2(2EBF+S.M@?\?"AH%98)LWH'Z!&C<= +RNC
MS]VX.BB4,GG-J>\,G\WA%H5-_T.>?+Z; @[,;S>*O)Q+-FQJ7D<YNZ=1*2S)
M?BRB>Z@J<.G?@-I^F][=?RI<\_>'"3?)AOKQJ@5+9US6>CJJM\L:GNKWB<2\
M.TSIR<S1>:!O:3I4:7)LM;HN%3:43&M-E+;#'N1!KP6]\2'^TY\]COXGP#'M
METZN#'N<2ZSHJ:J^%00D*ZIGDPI=U7%(Z<@JG(B,5MI0?T/W2#T=L,=&BM*U
MRY^+/BC*(U!!]_^#F?;70ZX(2R'_<^X#_;OKV@HIJAX]6<Y;@L@K])] EQQO
M0S5O\-T46DD9R2[J*W<PB)^0BA*<_7(,F-$CXWG/E1C[]VOP?PM[4\KB(GA<
M!Y,7S^<1XV?$XG[W.MCY#8F'+(AWV5E.V**!7Z B%?R8DV7LP:Q<3<N)YT*%
M/DWK0,)"_)#^/62R^_24IK?[E7B?M/K:#<V[BO2?!G_<=VI09FEATZK2:>HP
MN[WQD^,:YZ-3-'/X#Y^Y(T!OGRYGT!?O--),?9$59(@_WV;UY-7,;*TIQ'A[
MA8_I?B[?I$M>8:1QTGOW @>1:;.F@P6GOE'XC&R$6H$B_4=5OBL_^K]H[#FD
M;YQ8.52%1DO84#X2J)"3MF75SXV4T7-'-ZH*YKQ0H+/_)'%WX^**>W"\XSEH
MC,JVNR>!N7A;_@QV[Y_ $G4 .YXH10N=-#T\0-: O[2V,C1;$Z@=LR)QVV5+
M'#&_*.T=  EO +5:;(G:0W:W,OH:J6:5-1E^!#<5D]\S+5#@MC)?$(H219PU
MM@MT#O:C0S8Y1.>[F:YOMGMZ96S= YXT9!RD8'WW_+0/KM) D 1A(J)H)Z%T
MHWXE."("-!=CZG$*T!'?+10*A6Q='FI>G83L\$[AO,5RRF=N[+C(ZGO2*!.V
M"4WXTNCF2 F.\XO^"4U]7;BFDG3JT7.*,J7)LOS5F$;-1Y)Y'V/]JLYQAWOX
M^9T"H,S'\U\5VM/>1!O:D,J>9.8VX5YAP?T53\I>5NQDK V(V-1*?G;1(!X'
M1C_X)K;JQ(F.J7?QN=I./U=//SI#RM@16)F;AY<MM:!K?E'L>2V\M>_H7IG$
MRG?$%.*.?9=RQGZJB3P?WL)N8/J>?6S#U?G(S+3+IN2P[HH9Y.[1^$4QS&*X
M\=@E@'7 <_DT:SMRD1-PGAQ7CQ/%*2#\<2/\>SRNXLUR%&73< GZ+=]#9%$1
MBRKR;/2[KC<)6?D=YQ\MB1R,V)?8DB #]J@CL4^&KV&>BC^\%[(B&>L,;*UA
M:P&J30[MUN E9VK$E(.T^A4OW>-FL@*LCA=9XQ6KC4Y88)\T!*]4"XNG +WF
M+9(E-^_[*X"P3]<#O@*[7RBGW(S</)&WL6>7,;-HSW!.4*BMK;ET_AUTXB7Y
M74DKD9B&0+U).^^F:XU#W$X&ZM7E@YW7 5Q?&\&376PBRZ;*GWM2N4[ZJVT5
M&[WTY;7Y@[SPC@4#HD[JVEC1ZCKX"[F!ZQ-)2>U5,3Y'C9W$E5+8J"?HQ*(5
M\I;^]2OEN/Y\Y3.\G"8BZSHMW,X.D,MXQ>36].LG?95EX2JSHTBMN7 K>0G&
M'5,W]T/=JE(9$'/QFX[+)A0K <IGDMN:SI1C#5Y$'S?EE$G1QVQQU,?(,QZR
M6I=4 NL7M7)&B$'HIE1[;]2XIA?CE]Y:W5)&_JA;(CL%$/I3P)QJ.6AG&W@2
M-)R!M3 JCU2NPAP7%'1&%5W-1R1]O$FT7T0%/05L<7T_!2#;((?$>@/:^]X;
M'=$JGCP>+N%)*:]&5D'?U^/Z&2% A9U5U9E-:O%H#Y;^/.,[A5%6'O?5;L7%
M?<8["IF#L$^N_M0RKS].DX+F:#\2^M/]857<S6E\E3LR(_1EFFJL_3CKH\P=
M5>L:/_!%@!=ONLJ^7.6@W?X4Q]!F<9%G+QE?@.S0@5.#.'#R4;J;+-]KG OZ
MHHJSI^SEA<=0V_IX%7%6TBY)P.'(<&[8KK1T9$&T2;MWO&&0AHG-5K?[<&JN
MFE[QHJ#3H0ON_!:(T5YX*?U&TZ?G5O0!6)BBLZNA9P':),]%1L%3H'%H_W[X
M6$+?=UOBYH%/!2.Y@8IN!.U3\#-,\<&/5ZW&/Y*,R;/E_L&DKP?] 4+5^B[.
M3MWRMP 1.AV5,W\2Q$;TSP2;_+'\:;_G,OZ0-8D5THG])6E2/L[]1,E)Y*0I
MZP>TJ2D6CH<QPX_]@7-\5 <!6\>*0RV$OW']A] C?X>^HO]'_-0W3UNF?@"/
M<NX5G.Q #@7XDHNS_FCO9,(PLTO/_Q(2Z7G_/S5+$OX4K/N1T*QR?W#G7\)\
M)11E:RS#R5UFR'$HZD0/;O"';_JZH/#@OX3?#_B#V4!PB?X&.;4#TA:!V*+,
M95&DTV_YAW#]WIDQ.T'_=4&U_VSYIX )N-(_9!31/2@]*[C0(<[J^R0>"G!3
MP9;:/-%G(TNC5O!^PF\6R9XK.L;S"3"WY9-;,=#@$,WY24C>A".0KIOPXX_V
M^;D'V^<;WO.G6^R+LP;J$GXF<G.-2O-]X&QU4Q443:=C<R:<]_.K6.4[%%*J
MV8G[79SUON4T]J\(OV\\771%C*0EJ-->5F4SQ*B5_>R4FSLA856!WS<>PLR3
MV7EV8K1C%E;$P>7!%<"3&<E!%;C+::J!?3%EQ$2JR/\,1!8#9=;XP_;ZRWAP
MT3_QX/[V->\_ '7_;;\C6?X@"ZS_!%'K'ZY7+@IQP%2!.#R$_=B=[G#@EHPC
M<!<#B?T82+!\XE(U",(X[Q2P<\5 QI6PISK*"-X1Z0%9ZXF%?[..Y\V_!#?\
M!XQDO;_%Z,\QN2G>],.$/R;(^4;@2:3:_&K>'^5!7A9>XO#*7T*\/P/\\T08
M<W_NQ1BJX_IW+-W^4F(!0J'^AS>X5#]N</\"L#. [V\QDG^(\+^Y62O+P%[9
MQH?F_\2]_G<EZX_"MI35R/%?=AOQ?YR$1N3_1A*:B/]Y26C^IV&>_3$)#>[?
MDM 8_=4D-,2Q?\E4()08.$'[AXN> HY(6_$%,<5__%J8!Z$X\\>CCO^]E?0?
M<-?__<PE?Q7O[!3 A(I?6&R-O9<]%[>HJS.1</FL:S,F")=U$DP;:%5/\*E(
MV3DQ/K+%'PB",+-$\4C#9_- _UN;6J)$7O$IX/6FC?_!*> \%12T1"V^P$-P
M(DG;@3OG4[?I=X!C#Z>WLM9O;!X\/-S5^NSU%RKJ[*Z\#5D[V#ZY!*2#?+OJ
M\E7G]R9\2Z"*W.9YY9^55X>ESW[?7L1SR!%Z>G=O^G76;TT,OD'LM2'=L)^5
MD1^]+I8O(G#R_H2>Y%\V"RO_WJ3DW<E ^BD@$?BS>HGN&H,M(N.WJ<-^;V.A
M<)PM>PK@E?NENGG^J" B X0BPBH?G[F.;P?^UJ8I]$C-[T0WX)?:C0]+S3+D
M(%^(T;!#$LT#Z.\M DCW7NWC\WZI[)MK62_G_SL]Z'YO<4CUDR@_*_^+A/^3
M2#CPZSQR0+\2)@[,^<5WX4W^5(]/;@^-ZF-^!RU)*PGZKZ> WP=+_419QA:J
M70'?/- MM!E*+2W^"\/5(\S_T>3_2#+]B]/^'R:A$H8*>CO-GM9CEWZ'^Y<I
M"Q_]&PUE$CI.Z)!BTHW":SL'UPT+K5]VS\Y;2M+W_&$WY.AVN'?V_FR;%W[+
M%:IZ]B^,H_E?S/'_(W-X,@/#Q'HLSN)BNIWD=&MJJ0]X7),_+S2Z_)C1?6?:
M'MO%BR.?BF#QH:_6XI$;%ZM^$H+A[PGQ(^)J?[JZ39K9HKI]:;CUI'SF%+ X
M%[AU8#N* ?XV&K5?__B8;[IIFB%+9P_7R S;S2 ]!8"L]R.XCMB)?Z/9\N^S
MS?;;'T?O.,C]:/%+SVN!F+D,ZQ;(K]W]S4A* H_\S:.5?S0 C?@#\<>P*=:$
M-3#5[[W]QC:)F],ND?UY/^L?(@AV5T;946M\ (SH]]Y^UQ"-1^M87S'@CP:G
M ",,9'L/!';3+IL!_=K;JU_9Y]"@.:!)2"GK9_U5.:J30/@FI>J>#.EO??V^
M/FK[FP2"#?VL?VQ+\),0H\>H+CEXT&\;Z_!W-EHV/_Y)L!\M((4XT,$1L$&2
M^[^0P&VBVB3@F''STG0G01NH]'-;*V4 <SD:<0X7<@IH3WD[6?R&/U9=V,8U
MZF9+B:W)Z/>0F>UV*C]FR0>4RL:@$58A;.,'IZI3@+!;]Q$[T5_]9^S6_^-D
M_>_%MQFS^@3OYPPN24!M1'G@B:YJW.MX"4 4LIY O;OR32]?,(I""D?%<RM@
M4X)&>S*A'5.7D+L@QA7Q)%^/3^/=G3I(1HEHA6.%0JK?Z75(M#$;<^<Y*]3E
MQWR U"C[P V]JVD>TZ4\?>-_G5C_XH3_1$[X^BO5^GV9?_:+)_1;O@9F!E.U
MH>]QJZ02!<M EQJ\4;+>NEB1B>_V [T7PL6F:CKN!#F.-$U2K]F;;TB,VY..
M)!^VAB5OZJE\M]^/3#(8Q5#]F8;Z,>/,7V;\\!>^VP*!_Z4-_ALQ:R1A;MS8
MYN>[O=H//R4AM)-T8[IY1HLE"&;='YP<\K[(J,6X]%<_?:-&,O#WO ])S_^Q
M_Z('^9>Y]I]CKA$^$2BB!)HCC S449?!@-,V'>+?(:D<G$LLJMB!WA?>*B6&
M[C;_<$,?5'36<,M$#<G83"14$>BP_V<[Z,=P!H'_-K^"__<(]M^3YX07?YUS
M3R#YW6N5B!<S;]1465J*<\O.:4!WH=O:88MRG-A@-HHAR"%=Y;(GXH5WWO1N
M:?KB&_R#4T!<Q!?@[B[W21B]MVW1LPRZYKE'F(AC_ZY3P'M%L_X5^V84?/$@
M2$>1_O4_/-'_#Q2:S_N(HYS,?,NCQ>-!'9VAOW(0_1=*#DGYKL6^ V]28,')
M4EZ^P#\^(?TUIG7Q1/8Q_L:K[5, >SSR\N.310.\T!8OB(:G7Y$>5[OT5^=%
M%7'L!FG@R3B1 Z[> ZTF'*/407A_U=T254AGXRD ML.Y'D?H<2'I']Y#%.PC
M5U75,@("*[.%8N0R_6C-3@'PP1-@][O\3=#L\BF :OZ^@9;MR9$)_@'^^TW<
M?<(2M1G^HWLSRLSLVE. &8[LA2>]&.)P\TLC+VB#7M;Z,/:$ZZXBG4'*/^SA
MQ\U;H/EM2!VO5)+S#RH7[#.#6F'O%THSH7SR__"L/\4Y[A10?W^HW -V/,8^
MH_@7\GT2J4E!U72&'A(_QYF< CBI(D\!/V[\R8QWNK=!8<U;-W&MO]ST9Y=H
MY%K@8/,'Q#((=#(^2N[2*:#D#6B'IZ!.5O-9\]^SMD,&9G8;_R.6ZNL9*-]K
M+")ZS?]BEG* -TDUC<:"Q%48L3M1NO8C>38E2I%0F+':00]J\64EXI*_4U7-
ML&U-=#')VDCV&QW2^''YAZ/DUMLE679:,W0&%[%^A@$LJ(YW6)4'?O%5V$0)
MD/ B$,,Z @_:.?! G%G:&ZQO6/AN$_?V)5=U[_0*#W$6(#TH10U+!:N+W@U_
MC^JW]7%U9GLR<36V>,-Z-;37UW,QTD.;\ONR?>$*GY/ T(UY4F6K16*0!_MB
M(P/Q^\Q:%AB4_6+54/3SNN.:M-M?[M3*!UP,KMXMG(8&$H32<^56UZHWWN>'
M!;M3GW6;,A[TA [&2*7OF%+)9]9HATT)5F(9GJ];)>N*^U8V*&YZAY-_*+>,
M5Y+RU:L]X05?'3LNS$;.;.NN6^6M$>R%!@9@$0-Q:6;YYNZDD$9_JF%]XTO1
M>3WK9[6>GY>4)A8EUPV!F I_^D63>W4[_/N@E2_P*RO/1+;PM7(51,A^TW)_
M98RO[,KM>N<B&Y6W1J9.'.L<CP.MTUM%JX#4_ISYAF86)HX_H)\K 5]M)L*(
MEEL!6@'!F3.>= ;2[\"KK7(\M7Y.0'TH&D5D3:VDQ.%-%(1 /02'=L@!,7FP
M(]N'T.]S3"H8HU%(W;LTOW0>8C<H_)N,P7MP)D."TM#[>NI30*%>]Z< O2#.
MU8$"7"B<G053D4]9]K'=13JJ4%ZD25;E_C/"4+_-Q,52,'+9DM)O+\8T&+$7
M8)5;$^R,>WIR>UB9+F_??. _0G(+&QKU3#G;,_!VN#BN/$L:7.NQ1S,^JWG5
MM/?H,[QG"S\IF3GCVT@?C::ZO"1W.49\I)*G2&9ZUZZEO+I?EQ;FF_T.KX"I
M?EDB!\]VZ._U4+C*H!3]FDJSQ1:3>1@\J&-^!=T,W61H:P1I5@S'LYT;0)U=
MB^MH22*_6^ :?TZ:;#<21K>D7T<BM=Z12V)LT\U\8YI#0O:F<'Q 68K@N4;Z
MKTL6E_SYT-*(LF7?-A'3M/6PQ*PGA\[$((5>CR% H&@ 7V^@^,J@(?BJM+01
MFZ#+1CR=<!E%,&%_D&UX7*3- 7MKECUY8B<0QY0VEQ"<EK"IV#+P698HRWX'
ME.CC$B-#,2OKW?;)PB[]RF5]36;>+T\\/[-I 4H$+IO?3H9'HJ2U:;6]O8I>
MYH2COKI:)W%E;.SOHQ,L Y1#?,E,@7?-!;#-9D/KE='$R@.>%YP>IY5+1G=O
M?:5WCYET$*($,W2LEAA.@:+62YP$G&?]7J :[<5Y2_EKECM)W!5WB<?M,J'O
M?B1H_G--PL?0'LA5C4D/OEW@3H(D8M*Y\MR_;^U99M!MC&N:JZKYC9E>2%L=
MHL/3*9#IZ;T4]RZ*8*O+$HC)[E. WVJO)Y"F0;'@<T 6V*!U\+R8K-6=(M>8
M1R^>J1S[[#Q<56S9N7-^Y?R'S[)G?=C?SUC0@<W6/2W(<*$/AC>SWBC.OQU:
MK5*4]8TE_38\'2D5GKF)<KJHW9#2L:K;1#3%T,H;1#<7T]*\K-BR2Y'[[40W
M<8'9NS4UP8<.@Y<?*GY.PR?CR&/YS#TT="ICULG": 3O^FC&B6RWD!YUI'D\
M 0F@+>Y?[I#+#F,@'E3AS+L:WU ,/(_+^,+.-2C8(%E@L6IL,W#@&\60D#\J
M7<T5 %Z$[IKO7#^C8VB<$2TCF34U8;0B57$;>1G[\K$J,?F-)86."WM,8@::
MN)<H >.!E85!DVIA8^XWDK&BCQDD^AC/*+D.#MTGU59T]Z6"-0BA'1<_#8C9
M;0CJ7M[JOG69N&;B'(0LM4U.!+,?YE]6N.)JHLK3K1S2UXIT"'$E\,M49FVC
M-/R$?KBXL.BIV&ONFL;)N7L?CU+9%!@/(*P&JO)GZ1>;+^6FZF!!S_%B+OQQ
MJ:G-E1-/K4#>0 F)-1_Z)0LUP W"--M]$&U4; YUCR>FV# CR;)3Q4X-RX+"
M1_5VG=Q>OK: W9;#H>9S@L5"<JSCFMXR"6I(6F<?QC*0Y(9=#7L(D2R1:.*\
M[9<3'FSSRTK5W>.[#_HK"NS]ZUD<5<\D Z<[$2.%_N+#NX8R%F@JTA7FR)5G
MRZ_!@M-)@%@RX=VY0([^9[*B9WS/V/-UB*:RJ:,A+_$*U[/1%X_ED)JUM_?V
MO-R>\H7(6Q\$>E9BFHV&PQO10F0K!NOYBA_42!BB>ZRYG+@QQQ2$!;-[%_O1
M<(<U94Y0C@?'.S; ]T8,YU^K>J%*G/_9LT"S6F+97H#GCH&P#Y;JB[Z47E.N
M7*W+GDG: 7_PFPRV9^]LK"?(AK_A%;+!R=I'7C _MLDF='8R1X'OI6<*[RAX
M^>*;<!DSO=(/G>06S8*=J:N:AKSUY,)>41\>.]HJ8]EA)5W>[ D0^G&CFAAW
M1@DE23B7Y8Y,5 P/\8-_,Z$NV*XT;T"AV1D?3P%UO+R7?PGFJI'HDRBD8L!E
M4IU?XGZ0,N*78Z]_WO*Y_X!*RXP?)5613W60&(+&X13 4#+>=D/@0U'NICI-
M&S^/6B*+.Y*T689 O70H0=;P.DH5&D=$-$CG3-].2VE;D-QD"(&>9W$?ESSF
ML?0U(O$D>6  7:UBSOC2ZZU0-^BOD.=P>7__SA2Z>T]S04M)[002W.ZG=R'H
M'>TW6MQ]O0@]3DP)*R[1R;, ;X3IBV#/][-V\7GBWU'U*I]$-$)B&7_U#5H[
M(B7C>05+(T0%FUYH6Z8MD?WUC0$QP;G>':AA[R;B!CR8.6270J9-.?2@(:'W
M5XP[\@Z9:J&W4[:X7%Y%L 8UH%[ V2N3T?7Y1?[JF+&+FDH^3G-C11Q>.L]J
M-$0H#UBW5[5F?$<H16)X.&*RZ!>,K\WWX'VPUPHFND>6+;.M!-5N'$@2ORO*
MB* V;,VRB!2ZI%JDY,+:,, GE/3L5H9X[KQBR]I2L=PV.B/DJ<M87T @E1B+
M(V/_I"Y!UWY4GC?99]Y+='Q?52FP8_']8_JC6HTZI^6X:DD\3PVSJ,$5'ZSZ
M9WU:./GASI6)<T2<WF/G._OH9I=\BG,&-J9.!O@*5+/2I_0F6>.J]"+R1(G$
M?IBI,@1#\D-%MP_!'%5UC+QU"G O.&$XH >^I"/(5+SI)D&J!O\,>*!OP6MB
M+V?GC"\;"T8*)>0[BE^=DJSOJ 7$+;GU($9JFR\M,2-:HV\#J9?3KPX)/:?A
M::JN#^CB30B17S\%K)184R3R#J%NZ.J\VNQ.\1U'Y-0QJ66G#EJ/VCLT1@]Y
MC]S>CTV#RSA>/3[?^\R"KK+HP5>[.KDW'D\AE<[^;YSANN;GB'87:C UDFB^
MCQ>5%P?&$V\8F>X8\W7(J.<Z6) +BD8;:&#/'N]X,ZB[N-KZ7#\%2'-RP;0R
M@J_6N]"!KV^W2>4UA+:EA*>%W$S7K#UP$T&,U"TFZT1P33Y>F_=30W@.C+_4
MW!M:N^'8XBEPT=B"W0AGHHA]DN_M6OVU,4F5LL=S9F\3MG#6BYVC.KD-1%LH
M(^#MYWWYC4MNP/ND"QI.(CM=5ZOS$^Y0WOZ8XNKV??+:"*+YCI[RZ,Z*VK;V
M&1Q4D[/UA#M2KR%^85"A(9ZGF$OR2;2OH%\ZR'@$Y_XXX'JJ.YI-[\.15QGW
M&,G3MA>9)V>)JX$#M8[S?<\=U-P&!*XM!D $+"8>O!U3=B+8YDEVOSH'<L#=
MKA-,-L'+X#H<N'M2"YJB*R<L:EN&\4XR/C(#=PJX(_>=C4['W/Z78!/W=$GL
M1;#)%X;#0@=FNR%^CITI./&NV&?E&0AU%PJ"4P6A;@Q%O&"FJGR!1TQZ3-"Z
M##1J7#=C'FHL4H->:-++\H8(-&I,K*W%K=$9B,T(T8A#&Z[8YG^E,XVUKB&[
M*=,N(7&(@3!;L*_ LL ,ADTONU62YJE?S81;T5%O;AN(#ZWP:P]GM =:O%TS
MN%79%SM@ %N2.S?DJ0G4KJG%CF11S _7:8RLWNS>8")F0MSA&_)P)!WP<'1D
M*N&JMZ-U--4(M-T7:Y(^JTSQ@7=;;:\R!;]__9;;DD5VR7DL*-J3 @(W5MZS
M*5=\-^YP\6D")SW#K1!Q=JD@*3^@[_H)S]34V6^B)H[Y3E>'*\]6I]NE.I)T
MSK!_1RR;"5TK8'Z5WZ<JF7,L,-WW9>_E9''$NP<&*6!7+DQSVQ&"PL1\ I&M
M;EG]2/#Q+48@P9!?AZ_J-PCP3_%CJ[+03^(5LK\_@6O+M_'%[<_!(=H=GPJ2
M_,1N;/M!>57'_=:*IO'AN>[?\CYDE]SXX?!=">,-V#T<>) [;5%DKSX+RTMO
M0V9@=TX!$5MYO'X(W"&D]4"7?O -I&GD%$#7?%M#[D=J:-?+=#I&@5>'!^4Q
M&^\+I#8NEU8$JW8L$ ?CTL@&WDKJICSWMG(>2PF/;X#<PWB_D#%"#6,%%J&>
M+ '&Z\:.AJB ,B7),;)#X)RBYS2%C+8GVH5<9(6$[4ZW5U4MA[6[T%U<"(AY
MI\S(*DOK8:Z.=N*8OJ;Q*2"E*?F*UL:(M!1/"2VN=E9]-2)5^=N'1(%"-LKW
MGA>=6A/"8)R[^X?ZDEX6#]F,'H2_G7[4Y\"[MM>MW5<K1./@VY&*V16L4#<J
MWN4.X8I29HH+MKR%VX3."\JQK>Q-L24801@<"HH5B6J>V+M>LA2GA^<^'1FZ
MM>(.$S/^*.Y?H+3IHAF;-GW/MYU^CN%$=+A2.]1+*N3KR#[2F^^Q6)LU(TNI
MH2\-J,AL\.D<QJ6=#:A8VEQ?4SK,_S87BK:^SJ;WPC7]S?AARN 1LVM4[=RK
MY-MO#[R1N;&-F4T1^8&B9-OCJO-82%M7;HS1.1@*WU;/&)8RMXO(LU@VCS!E
M+!0?GK#F+E"M'#N60Z,W"(O@]F,E ,1Y^<409"#]^15>QXS=Z3!?7<B$@R]\
M]PI>)1S*4R):^C/,+,_1.,WW]DN_?+5;2=\J4MV'@@ERU,<VHH&O&#=]A^"0
MI=['RF790[R,UJ]6!Y2UO8NM-9^%=3>R7C\GEB\U;-M%LNXG[G5HY.-P+]O6
MQH^>OLU?!'MMKS%STGCE*_#AH"#S"*KE"+<4V,"\;A:BU#=)1P,A:Z4-2V>O
MR.OQ@#-=+Y88, C!U</K%E]LB.87\F]4G *H6'#]W-9EQ2;/CH5'73?-&]'K
MYK-W,('9^6,Y1Y%^;MB06T2[<JTE*+.:J,Q*JL=,E;TZ8Y-O!X;Q)_<^OISN
MG,QL>##^Y3![,2BU0WN60L4A9[*$^$*SV^VY-3@*5N2P(G=K>*/IO,FJPP+%
MG:6B^J]9+!#P_9J=3F"1$W_2MDZVCOK4G*^8[?:$^6"=K#YT*U*:288!2]RJ
M?YLY>K*]JL2YQY.^K4/^ZT<M;'K:2(&V4)0<]\&E'HY^O.37=L9@L1X/<ZDP
M^%* XXUYAUMU;U$]O7X^E8[>+HIY0XB[F5 ^N.BO9PRBUW\Q8E)_,6*..WZ$
MX?L4_DAY_=,Y"+H@02QJ$()7QX45.TJ9'3>%/O*TS?S>=Z5VR'#-WO3VY,>
M6](VA^CPEOV/O,5)[15^EZW46>Q><M>.\E) #& *F..3(MX-=15FL^:IEIE
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M>AKO D/>848BT$>RU.\(KLY./8Q"8\.RMN;N0HOT#/T,S-]W\(38Q$<8_'[
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M^[38(2WU$/:L3I#;,H'^TG)UI_3:0(I6F0E!/N.$RU,#2(T@_$W5J(=+!%]
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M"C&-BDEWW5!XRT07]A2=.AW:VQ \<V+?JAUP$5&K:DUZC7(_%EH"7AL=31.
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M;\"1F_6TG^5H=I+A;=&E2)HWCAC5*8U).[_>);N 4^5/)>9CAP)$4MD&8KO
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M[5*ZMX4OQ!P,&8O)U(=[AO'K( 9(/WD441Z=04T7#WS6,=X]EA+NF]M#Z!G
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M1YS;8)8TQZW,UZ&R!5Z9SG.%[9<Q+Z5C*,5-^27CGM>P6[<9?.UVSQKHSV8
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M-?I_>>2EY8+VQW7^*).4.(]5^)<+[K\[<@IS\VCDG@FI_R=?0SGO?W9'>-P
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M7C7W /?/2@8,6P*'+E?O\Z+"3"S'MWM.&H\GJA]F?PE)?;9,9TRH58B=I0T
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M?-['O!EW((D1Z]]KUSSMX&M(0!LM_.KGUI5,B1F6.\6),VP9B"70+ORJ"Z!
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MU:TK0:-OE7&V+?#QEY1#""9<0ETF.,I;=TWT;S/[\@_M0+7@SB6:'4?TEVK
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M@#@7HR4ZR56EV\5<?GK+V+0EP$*42]'I *$CCEO9[/?2$TUB!^89XR%.I/[
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M]6=$9$\K2QTBC#GDA$U4)2QA@?8A3QPC<[*5\"J!\G!BKX3PJ)C2#0"K-:]
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M,@X#W<^+I,/W><R2/*($&DMDQQV[.X9.I-S)(*"ER'Q],;QL6Y>).X'4@]X
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MQ\=+-6M[+$<G96GAH1X;DB69M3ZV:6N%URK=]!ZD4W-A9/K#4BB]0-GS'&#
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MH%HT1N/OZ6#-_(MU]]\(X/GQCQ?"B?V::=?PW>%A1JSTM6(B&;'R[K]'=LF
M8O^!O ?_^^QU#OQX12$S)68T/O9>OLG+VQQ33O]5/M85MJ0?'UMON@@"\Q>9
M&K]D1%HSZ.)]\KWB:(Q@JFQ+;71'H\B2Y@1_7\R$K/FOPB-_)X#TT=9UNW:O
MM/<7!962=WE.T](^_F,^MK](CZM]VL)V>\Y;<4E!4/8<F,Z XER,P/#/4EE_
M%9DHS^QUMO@H@\Z\F):E=?>/N'^:[Y%_ P?\<4ICH@[^[K1,]'>0R[\!_[4B
M_PAR*?,3Y!)(@W#<(6#-+K0IV)JSV,D,I]+<%0DEEUDPQ]3A8$%="\-"^>N
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M-M'SZGV^L441RJ/@<^!-7&#3=/*W+OU=B!B3%N+:P&^0O4Y//W>;CWPV9(P
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M)3.?>Q&QP,+TP8D^)AI>JW@/1;Y5,N5^>WTE5#N[<^_KJFWE/5F9C]GJ4@2
M"@ X=3C.\,/UZ*_ D'%]C=8CR>S#&&/:RA(14.@)<?,(DB==*E=/AKA7I_.5
M_+R"P%#S@(^4^SD0ZB6ZF#<;#+/RL(EYEOU%BY'BKO[G5/)@FG>%,%<;U,.0
MT%4D7;JE#J@S4;0B)##A<6-)U,XJJ/DS_B3"WN#84%1O%BEA&W)4UI.^;M2.
MV?VJ\AIJK<L_2@G5%.:-A?%VLM-4I?3MI5%EC)+/K.)NN^T)8;PCBZ  EC'J
M2R/#_:&=\X*,-!F=TI?=NRQM(RH& C5GKC94C<0I)JM%"DQPQ52.7S/S?Y,.
M2>XZ<G$]!VA%F*RR)8F.2K6+H^[[LK;Q)CEVZ4S#7?U]&-KF0[YE%0]O>55K
MI\<3E]16,W 3'*[2JF$63(V+D2/(7YSL)%*D\]??Q>?B[NGB!HADG+N1>?<Z
M1@K&7Z,HIY@Y,.4II%Z+;3U]]4"F>%WO9'IVQJ>ORM9KEU%N6(CNLUSHHVH&
MO^Z"HJO@;K-YT)E#Q#D@'NY''4^)_,#PNFF+/OE4J0B!VQ%OG'1EK")HA,LI
MY %-CLAR90^QKYA1TFJ&RN YL#2'5#X'GAZ< Q/.G6NQ(U-(8KB'[@YGK?^#
M2W1/K&\G=KH(-%T5L2K0ZLDW]R&&Z*.'X]O(5<[<!WXHAH(7,G#NL7-@'KW]
MA91/6H]H$RF8W3,R6K*3W?XL4:",:1GOW-6V?7.%,%ACAD9*6^PIMHDT%<.C
MI^,1ZS;<2"PX2+62:F2G2%#WP],[,UT1S1&?0X*W*!?,0IWIR#9K9?S5]-GY
M9O84[A+?QNU3EQ&B'7>?9R#5=6MJTYCHS[>^UAOC]FXIW?_EO5FT.'SB10]I
M(G0* *Q1?0:@.?(!+[QS(,H\^?!4<$\'.*AE37O7^@.B2^K'/5<@]I._J]MW
M1+(69K9UVPU(8&4/N))2/1N7)3J7+XF?$?K$@#J*""TT9K"\%92*JTKKAV?N
M<RU7A3*Q$N'P"A]MJJ/82]<-^&%B3:!>,UNWYTE*W81LJ[#I;QI9G:(Z8Y/S
M#5.8QNZV7V_Z72TU[L%E@MJKX1K-3TM4@(DM/$(BXC?&[LO29T@4\2'6<W0E
M2((XN7N]DQ3F^5NSIQY9^=H]..1?H\9L27%3D"YM3&*EYI!-/5L,Z"$0NIX?
M06Z5=+T8[N.?M5DKK^CLH/R5)_/U=<;[Z]4?PNT'7<E$?9>=9BF0 C6C3TMJ
M8:WK87<Q\6TY'S)=3''-!1X,DFN($871"L)WRR-\!XP6.Z^"P(\G1_;R&<(C
M,L^!5IR;"9\$=QT9OD"-?+:0[9[6 ^N:(@J+(1&X"$/)D1M5IX:O;;ENAK/2
M('2?7DJ&;T^=JJ;0[G9R*'+3G .7=<PKW[0MR#1(O]*1OMKN<PJ>F P]H1Z!
MTQUF!34*:FT*(T,NO^=^-]AB?Y.46E[X9!$]AII(PCFG85O#=A\FZ#.HB((#
M[[!(:NPLTTY1H]" C7]XPUE'1L.2CWI_O6/7A^U(+)+N(2N_A1EJ. F2R8 (
M;MI@07BK,2NW=@T6T_6NOS6&/A&T&VT0-Z=,5!6 Y+"U$- Y4C.K?[MG8+I<
MZEWK0]XC4]5I>"VSYC79F@&9M):Z3 _7#*_LUL/% _J*]HR&Y=FVD*;@[0+#
MS,:XC#?YJ[WJEW'CJD:2WN*=T$,*LO3X5]Y;.6Q6K 0PFQPP8VE8_,V)UNGO
MH%U_1_+B3N']&;8-%Q_N_R19 6&;36/&QM5VJ_JI>YL S4$_Q3E XD2!L*(/
M=YI\OON<86"OZ_W*V\]GTX[)RRI(\]+8_?F"S=:,^ G9%4:2>2)>,."HJX&Z
M/1(W#_78G4@[Y?-P>SX9-(,?UJ3?1I4!)3)\>9)_DM66H%[ML&MR;R)05+Z0
M "7AB^2HA/+U$FM<\E<I>[EQR[KEMG@S@X'5 (I@\APP\>(-W]B.Q=NQ,:DF
MOC&!^8%5Y!RH,X@D*AFXUDN8'UG]J?:#/V)D#3?,2W[$Z?VA][T6,;JA_!NC
M_!0D(NN8_MCW#[<_D![0'XY:G0/$-Z$BUS,1N@KU%,+>^;W,W]0>(38_N+*P
M[!WD,P2DN$5W&7# 7\V*F9URY8AL*]LB"%*0BJXH'KA^A+\72"#/.Q;8@I +
M6>@=J*[O>!+(RC#!9>1@A1&PL9WK?)L/7)]<_1*\H X6K,1;.AU_L"!D:RW&
M@'S0-/8\9OL%=YJW.&_L1!"-PF4$@'+;U:&GAG7LAAZZB1@N)@2[1"2UR>_C
M=,=E<]X[F-OS/-$L((>XR1?+/;=_*<0N<YAB%K4>OQ/G#C?2ADN_9Z]\;?+1
MNKY6BCU*S %'^7%84XRMU[V1'=MQ%7A2QG7*B;Z$-+7[D"GO#OKWYP!!^J+Y
MXMCA-L\\*H9:PO8>8;]RMTHJX^,WET65#P[S78<T.Y/XX"89.ZFN%E8I[<46
ML,E'1EIV69=E?)(_OZ'OE;)O(CA,F/:<WTETSY8=GGH)YRL:$\\79SX66A0;
M_:I^<=%T =DEKWZZN"E.DGSF^,29^0*]ZP?NYY\^:E/@ I \)*/Z'-#Q>>N,
MR?[C[%CVSTXR\<U.%R^V&&=PU%IVMNY_&NGOU_.DS"GB; )R<0@Z[/D=]>71
MGYZ8OG4F>YN>G8F+#ZM"23-0@<>A%_$ 8U; A."E9_"@,V^9<R!5P>"]4A.<
MH7</QSWY;V9!O#_,@N+G??[Q-/2GI9"J%/F[2XXH'IA+W*(^LY:EY69)51L?
MV.?V(?W,Z*"J.+U<IM>EH>W=^035T2)^0C>2G>T/E]1$\0>4GQF443.KYMOG
MYMX,4%?U3;$#LE2E?)>,8'Q&"T^2[L9_RXCNWGM6R>;'T$W)> [,RJ NZ3NC
MYSOE8E$0A8%(]<AR'92;B_B-71JSQG1UD1YZ9IU ??@09D:+Y@?06FBAM4\+
M96S2$TO7\/OW3S3MI2BP/L C_+?K3>;AZ5/3O=94D<;[-U6ZEK?[U6M@.(GN
ML",&7#V]1T>#C&B-!2L0^\V7]9G:"=9B>N^Y<^#5"3A@ ?HT625!K:K)=[+7
MEA?PNY=T=Q9IA0/V%;:(E=T6D<C6_?)I,FD2B+!!+LXT^$ X<1EXVA)IW0@,
M\;[65U9&O1G@]1V^]Q+?*.GC'$DFAW(K_77_%A1=D'153=0":^('N9L!1M6K
M*043K%@06%.;%0^A6Y[J^!S4AB4>(4O-=O5AX?%E.YE,UG*$K8D%_-IB)T>V
M'G_?YRWK3]PMU49%.MOF:<WVFFA)D5]!$JS1>,?[X3RW]8R@KK,4JXO3:A&_
M;B<#_D$$^4:Z1OC&HB*T">+IY;7DQ.PBME"WP5I,B^OO0[HN1CJJ5'1KNC,]
MY^EVO'TK*=1OZC0^I!.$YX1>(4&35PWT+,8_2\3, Z_Q4#Q&NP:OI2C$W4V:
MFANNC:L4-X:H-^YO&U^K*\V[_D7 P7%D!#(#QVWSY+F"F&AKW[<4O#)@#!=N
M#L[0[;5N8RGBGQB2\MT?N.[%/%*O65A8=3G5,<N22G_O(2]M$4:#!!86TZ"&
MI1?1<&I3*?3FN/,-;^N;?2/5FKS=!=5W!Q[9&WSWXABH=X1E*<,+BR[G.A.&
M<%0O7KTGG>KO*X?[)30^01VAGK8I1C92KO!UAUY?&,0]@S#JQ[K/&/[*4]/U
M.^$:T3!!^?+1E(91?L]I5>ONO?F$@,44D>B(9P:Y.#A ,QU:%>#$O96.H!>]
MU^51!<EHM H).?A2\K8YV'[P>%Z\L!+"BO4>GNSG%$%K 9_<N+$8?_.1X%UO
MQ#[4TW]=KR@0A;<V<;OD<I8WV#%'SJ8E-5P=@RRB5KE05%@S6U7J#;W1 OCE
M!!A2+^6:/[T95])KU_QN^!:[+P!<W^Y0&4$!%M0^&58>\<O[%?4]K(\)GL8P
M+AX4Z:>%,/ZZ\_R7\/+HAW8.YET,/T;>FK6*VV8P.>7Y>A3V[G! )ZZC\<J(
MB,G',W\U31H:KWO2=G!0-EK,SJ3YBBQ,SC,[6 K$41\'5]"9SO17Z4Y,T=Z6
M49S:UVV\"Z-(6"2KB+7(+&LLOU]97RGD]NVS:">8?2,[K=D=E0"K)1\K.#2\
M8A4WL724)0"?FI-^Y21$I_C"K:NYUC8T:D+A?59Y8[GUV''LZC69S_:[P[40
MUE(LOZ%&RC:KHI8"*X_1G2IWR[LON.U+09+A*W4G\JQ8'R):CH80)\H4(35A
M[;%-I@++TLVBCN-\<8V7*QO@.XD+8W7O;3BMXZ>M6U^&XME'>:P>!^V1#Z/%
MR"I_$YZN5=+M(><>FV6(/FM).+.*QJ.3I+3Z_0Z>>5&S!:[IS QW[WEOFR%Q
M1?G[#PN&YXP.#K?PM@WZM>.K@OCT/6V/"N,LW!X'6"P0::YYH+D @C"2'39!
MC&2!6T'>SGDRSTC[O;/[EI%=C.%-P>2[#FSF[]4KR]B $^JLC+5:T]<V3X</
M3JV$WBW'XKW$$<NBLSS$Q_";VR7,>E7.L#5:8Y5#;Y:D_=7.V/3^[:JU--\;
M=564+IH4?1T:YO&\;=E$> .;6B@26#W]91C20ZJBK^IN%U-UE#I!>\F Y4Q:
M>(J=<%4KPFR\D+\!5Z=A<)<;O#BG^_3CJT.APP(>/#<L15CHN&"(O3TX9QI<
MU%![WX7.3A1TTEK["2W/W#UAN>1CA<[*)%;C)[1Q,DYPW;G.]D-&EX(B7 2I
M(LRM)AX_JQ[*_=F&QT;)V,<QXEG\!EJT,&6[?<4_;0X=!\T5X4TB6*2L><=V
MK#Y:!7ZHSR5;]J5J/M&4E (<DTAAWE6OFBK$!ERYNHX"AFK!=\6_*+E1H<5L
M":R@*:"H7G$!CWX!I:A\K\?\"4;G8H6RUU*X54%:",8<M7YRVYE:ZZI*%5PC
M8WY2^WK\K@PE55<V?<JIV7"MH9\ )A>' =1Z+HJ&L'>0BT*I4<>F:WS72"QE
MW-UY+H+0T(!_>CSH8-V&:L?,T_E61,YB<F?E?""'FQJ5D>R"1,55,B!]D$ .
M./EYN_LO#06ZX92!3LGDZT'*H]N_P?QK\![H"!P^_C+^(,/K-JSS?8ZDSZ8[
MF+^F#_/(\:;,>L!1X0J$$X<R&'GC(R+76EA?U=1L9/F>Q+)<%9'+X6)R+8=K
M!9D*#F<2Q<@MN+'!;9.$4WE6KX";RM&VIXWU8Z/H!8UMH2C(@ &>>$ 9WZK/
M-RBUE!4MT%+%?-"RH_B\!2;9#'M42O.@QN7#=NQ2#$@/PR $+;F,+&?(A_DC
MB 6#LJKN6GQD#RZ8-!W\> 7CQ$]]!TF9/C-E[M@7O3M$QI7TU=X7P')E$)PF
M'T1+VXY*6&&<U4+"P-7V,K#YS&\WW[[G39 6YK&M91,1G1=E::/V'@U/I,V<
MV="(54\\WN&\ R9R*:AEQ1JP\2%R4W)?=@LXRR<56+=.J>$@]2$?[IDG)D>R
ML02FE]^QL$F@%M*UV/RP<RBTJ5NN^I1-:]VEUB4,)\:&5J<%SP]+0-><:NED
MU)#8S4H)EO2&KX'-1%>52>ZUH:>-T  HP&KHQTWT?X( K3)6KOB@75BOUB;G
M115%Z>%C*'T[?;O'.,M')#.L,3JGQ8=B;WL[W'JQ+KE/MN&.:%Y=6HQO"QSD
M?Y",EC(4^=&E$[TK'<MRQ3OK [30F5NPRLB%:="63D=V_)W)R+?;;I.CRI9?
MTL* !3YP@!CU,+^0,X5NW>8[$#3A:U\(0R;&08Z7 JRMS8=S[').;L&B/IG6
M/EWG*(&P/63KNQBL11+!Y*N?4:2_<0 -GP,GHVN/FX>U>JS)!@CY3/EBW(V[
MFYFFG'/069\C=-L$#$@'TX=?]'9#^O84;@O*]SEH-YQZ7W+D1=X<S&AR/35-
MJ;6:\LXXJ(@[H^T9%SHX*A)/"P$@J4_80UFI !>R\K^[!5[^/>*>[._M-7%^
M67\8#W;88[\9H.XA@J@/!4IB0:\:^,Q>JK\Y_N#(D/ QR[L7'3U[5=ZB'(-K
M:<TFEC[T(\ZV)'*I>@\?*[NU&^CAFHY2-=._:\XY2+P]+C5D79YP]^;$I,RR
M]/72%I^F,(,TW[LB//.*'"TG+V*I'Z*W_G??UW\5+'D.;*X'D!MV).$-U5O0
MY7LTUQA7<AI=Z2\V*?D 'Y#0IR/#6)F%I=63G@,B%0Q(0O2V6],YS7S,AV%H
M^R /@[&B2K_D-8VCT?VET1/68BIJE@ N)WTKS5'4$-?H41:CQ:VW1&F7(PM!
MK^R_$7R"D[19"QJ,KD)'5)I&"KG3K^J?A2OFV26%<I2G^;)94"O&!GR<M(CW
M,E OJ'T1YAB](7?(O+0*'9WXN4W^$_3>/WO^G6'^_D,;B,7X+*00\ARX<PVB
MP_']#RL&:T::[__D#TS9'Q=<ZIS7IV9WXB-@Z=GX4EQDP%NU(?'_F1_#*MAE
MSH;'ENSQX/IZ,#%Z$+#38B& /)MYRG_IQR\L3FC).9 3#7F$9YZ!9,W$_+U/
M^7_V_.Z @^6["5)O,G]CA>AWV,PG?ZI[7E@[9^CM,.B(?X^"J0J-!A=:A@<4
M7_I3O9#- HCY8;9S"HU>[4.RB39#(#KR*7_.Z^DX;ZX-''>=IJ7EF'U>_K5R
M_E='] ?K@@/D!*?1BJPP6H-5&\1459 ";I&5J_QG/]3"T7VU\HZ6I77V/S:-
M/?QA&BM\#K2#>;JOKX#)7AM><9,(4G6\#=K-SJL4'#%#@';CYU'LX&[/5M /
M^UCGU9P"SL3O;'SW@/.LUO8(G4-L6O"4X;A?(RT]!J_L:+WIRSG0:'[J-+L%
MGN77@=Q7Z079))Q%G*Y$5"FBNL[VU;/38S#,MD? :!;P&OJ9W[*"S"'EGSX8
M_N12\H]",I.9YX 1ZELN5/63[[^JA,+G1R&&'W7EJ<JP8P[\+)3^L[)12]9E
M<>T?A?B\?]15($6;3?CO0F JY?9.1N07@1FRI$N2OVCX6S1H.2F]?_I0UJ?
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MP(O!G7GI66 MN_NQ NYQ]F=:-SZZ]F[\?0R'9\FN=4UYC:#1=.C7%P];.9R
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MP<8RYLA/L+=:!8D%SW,D[D:%X&^*L8$J1BM5)9^F/AY##/#J1CN("=VX.JC
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MEM5&IHO&&KI9A045V$DT%D\A?!1.(AI++CTAM/3?BO$D;O8^F-!YHJU#H T
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M89?]&Z^ -0Q^O B6$'0\!T@1KZEDE'^FZ&S&H8')#-7G@!3"O1P-.7\_OG/
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M"4L(P_=/@;TM0[R*1Z5&%[-G"WHUU=U\D4]2K3:XOR&H]85G/V%EVQ(CBZY
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M0W0TE>F)KC5;?73M"W-N40=22X'OC4N?/#TPH']\=17RXK8# (<(?H19U*A
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M*CO[DF!;_KIC[G=XZLM052@.7??^!X7_7Z!P@]?-.N]F*V*<!$4I+[-X@)[
M7Y[_]?NTJ'\H]_>CW#\H_*\S__D*F[Q;&H1W(LTF%_@7W'\B&_+E'QK_[6F<
M&MIX9D&. T$@)>O^-A+XE;+R2D# ^S0MRM>3R1T66E+EN-/23K\05ID 3'SY
M#V"0!W#>3:H ;R'X\( $PT"1[2XIY+<;5+[=0 ##=76?+*9Q?_T0#-D 4"\V
M#^?N<5&Z,%20@(=V P(>3A_@P? ['@Z??^Y7SP_]\7@J2\X6/&!<N \Q=Y-
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MGX7XNLR2"C)D7.S(\%_^%U!+ P04    "  -@G]4JE'[<:V+ 0"9\P$ %@
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MN)3:?9VQ([WZN#E<:9 :[77.L32AUKW#?P-ZA0*2V@&,^($%U.8*.$R9*4?
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M)-;Z5.F.91'UVM!'7['>-!#PW2UA/)TW>A7=@*V)<'KI?G.4@?F3<!>2.G/
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M-P5!:^&52$$H"%ZJGD+(JV;T;_%+$J^ Z6"#BBL4CF\,)7K$XPU46<E IOL
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M(-5VB^]>F?V$CU?$K]%XJ:L*&;S.DQANH:U+SG5;^/<9Y_%"&!"KI>S8[Y_
M9;1H!/0?LK>)J$9L?/(5]+\\N*\75B'^=J/^6DX6M!WT@;GF,(9!(&A7.D/Q
MC-BJKM*CBG$)H?KR^K!?4^H_D]3.OWZZ3C^/XL"EMCAB!NC-H\6T5D;18L+W
MSGB_H=Z]"G>!EWJY?ZF-8;GRJ$5WTC^UZ,A=$R;VQOQSST;U2KBM3T&@7KRL
M672?_(-XM8:P*;$'3LL@F@CK78'N)+?3K.]IJN7X0>]1]6I8FY94-N&$"7-E
MIZSDU(?UYX-O0C8<ELP$SI(!_=$PN*.-#"JOVC_]P4[_*[5S"^<4!K(0_EAX
MQPK6HBHC"+,ELG$W<?Q2F%)I7O*8QJ#>TIBG<>P[F^3U'AV![-4MZX ?;:#(
M=\@H#^@_H0OTG_#L]=2UI@)\6)]3Y4:WL\0T'OUD+FA/M;,2SW7(EI9F$%VO
M(C,RQB__OT1%PQ@T[!_AM!+VC_#G4)\=>/.?AP?_DWK;GS-9N?\)3#7_:?"&
MHLO4H?^"I4/_ LIEZU' ?ROUWTK]>TJ9J?)@KT7/'UT#:U>GS!0P"DN9]\IY
MK(#]XQ0SD@>'_O6X2,A@Z!:8/6 ,#!!]<=28I7$$F@R M OM!NR8G[G7AIZ>
M9]7@:5E8LU0C \P?<5:D-T=([+5_^^7%6I>/V,K&\U&Q47?AF;F"([!U*";&
M\FR,[>T;E884JSX<Q?_9)I3ASS;Z__S >*W_<H?524@XR08/2Q@AU5K!$B'Q
M1_#W<]COR+.0U0<?R<"I+4H.N.2$!QU \? <_$+;(2J#,XW)S $ODG+'W<DC
MNSLOCB8]4*5XSS7$D#\>Q'/EBHH*I#L2YR27:\XOA$ <18)G.-<O(W)5^7_!
MI[I(NC8+HB>1:0.DMWWF=/'-HG-$"-X9JWG_BS^W3FJ[GET!G,TKBD,V)3GZ
M[*NE.R+/_9M-3ZU*=65TK6X4FS@[YE771BE%>R?D)/(\DE),""X!T9QQZ3,:
MK120-QFY#X<53,VN+5(=F$48:7U19,FUHM!A)O1RJ6!%8< HB@T/U\.%$[4=
M#?<=KW:;3NM<G)@IIF7<+#.VO;W>]>[\K]R'JB)>-IK8%2*'43_J_HCCI@0$
MS3^\F)Q=/<?IFT&7:#=XQ4Z(IJ*[]E+8CNDQ"75GI"33RW&/8.;U/.;V4->I
MHJ_,@6^H#F^)QKN9>W;JO7GK9X(]Y64OH58)KIA]/#>ERU+?QZ[C**7+VR@<
MFGBQFUI#B\;E%EC1[P+N!X1/]88>Q@-7$(C!W4]'.S3Q:0PV7O$7KS _BN>/
M=[F2=AG^3,9E*_91Z,_V*F]4:SIK6Q?L:W/HO 5L(2QH_B2:*RXKV\(N96C]
M." WJ?#JXVWYDYR!-CJQ%''Z#:C^8R(#3CZB6=A+KV-6%1>07M*+?FP#OU<^
M6 G97/TQW/Y,ZMZ.<O^$QLN+R3S*V]^ZBOKFD:"?#M1&J7=&GH\9)_@=)'SH
M5 'S(4V!(P+!X0X6OK6& 6U-]PJ($J#?ZLU]W*#=;_\'>^\=U>36[0L'$5$4
M(KT)40$1:=*1DB!($Q$!Z24B($U >H! *-)+* (*4J3WB%3I'0'IU5 3.@@D
MU @!+N[W?<_=>]][SKGCCGN^[QO?N'\\#)YDE;E^S_S--6>>N=:*^!IW^E/J
MD7[4UK78);WT#SZ*[G-5=](+UIO*@>W>)G=FL5L[ZG>>3*&M^A.O/_\>%IC:
M=_T-8,MN3 Q(M>;5L)0S=O#!RMOEU=1F7HT_)\QHC"FRX$@W;/'%KAP(8@NA
M.[U!5"! /3+A0A,5_,KM28U,]5+TT9'XRK[:".>,UPJUUX1TT%-/E:3"?YV'
MO[,AF(&P,T#Y2AOHVBSQ#6XK,.]'=S:K/9EKD;>];L\I6N6#O;]=X,WT/OE(
M][@?YOTN4+<U=OHA5]:4E"@1E<\CI0)&KCMH(TYUGNX'+S.L"C:>0"]97RE.
M-7&5%;7-7IR[JD+<\?'8G#D:)/_>1 U9_.([##E0.W<N]]@>9^/=X[/. "^)
MM_!<R/94VG-JM\L"6[^.Z+5?X.$7?+T4#*S@Z-R*BFQ/KX\*O./L+(DJX!S^
MF9.(U2NO]A3@V'GE'J:FRM1/'?T ^J%&QMG'-@V%80-"JZL#M8<J3I2N(O:%
M9M!=]SHF[:]12>YE4'$<V!,^^>#CY].#X=#\U:RVP]JW6IZ)3EL[8:II$/';
M<G=XQ#U#599,-&3M%@71P 6=B7:0WQF@@JQA)52&=SY%5GA;>^@3+G8$?J)[
MDJ5TLA<Y+,#R"OS"(O0M*5?*1>0@#*-R6W]!,8K.7D?3+\/UPI?2>M GTW41
M6T:6.ZE./J)*5QQR*J-RXH3O:[Z/3."(I T'X%284PXR"<+M<1IM)\_BO%;Z
M1C;ZP#3PIP3H_!G@![*KD16_M)5D@RV2GK$%TEI[I7!/;6_EUJ3&%#ON#BQG
M=7+P?HPJ!/;('1L=2TUL7I^^JN\[1,&4F=1K,O2I4T?CQ1M)]H!\4YB"0M,8
M=LRAP@2\\CR$W62O*G_DCI2]L\0UB\,,8.PI$,;XK!RO][,A![;<(E!YPMV,
MCHQ3]&'RJ*[1?%6HPA&B:-\@_"!_KP2B6TNH.[9>/64VX!BU&A$=_U)=*:V!
MSAY>9(VY '9_[2Q+YI-\X+YCHNQ\@&_X;JMYQX)L](8#8.'FC6LG9,*4XN/C
M6]@M5OV7M5^G5K['%M;7*3&ZN$FRB0S[@:D(EED$.ZQ5<_K;([*NSFTJ:[1]
M9+),(ABD+H">TJEHJ(;]L'=VN!;P8O7;B@W?U327Y.,U.W;()>OK&Y1%N2&Y
MN85=+E#^[)?./FH+[@@6]%^6N5TJ)]-2;6;;P&B@I0]LAGRE8/&M3=0RLOC.
M'2"P#VOMX&!,**!]6A'-Y1JSUGY)YZM6/>6TY<8F@HX0J(Y+#ZY4M]-_;[0F
MY5.1).$BG'B%AL>*$Z#:3)Z!"G6 V&A,VFXW,["3UZ2W[1(>MZZA["L\12,2
M WA2W-?HX8U,VPX(= :E&NJ'%:8SRYZK<F53>2$EQ2#)(J9[(9^B-BT#/]Q8
M0E"8GZ. @PF.&3"/%O:'N*I4Q\7)R@JLJ]O%+<?[M T1#%SEW7<:6<\G\@]G
M@(OX\_E7^2T"I^AT!NC<V$3Z2X7XNT'?GK+5$6SHB]DO)7)+&;O?%[W_ED;2
M/E_NIB-P]!DY0I'N'8GA&>!9Y?#KO/J&K\']PV3":DY.-U46-,<^1 , 'F)(
MC$8HF!&_'"]0A$FGL6&_-7++/5IMYMX1[WO-=_">_D@YCAKN<#P0/5/IX](!
MN0SGS[.60H39NZD[>Z=$">K5B8_K_5Y>\*B\)EI>TSA,_*U])]>FJ0O>JM.C
M=LYO?QNP,4LY#+]5@&0B6"GA+WI=._5)_)0[9R*?\S;M^1.=K%T.2]>++PY$
M2?;S D]OPXRP; W3I_1X<216W_[.?6.UK+D.U\_=,S<ZN^R\V>VR4"EBCE1K
MC60G%> ;79@2\)1RA#XNM\2QP&@-SR?42U]?U>=@0D?RSNH%4[0$-51UD$11
MMS'9SNA!3G6UA,MM!A7Z@&VS(6<8<ZGR*:T@/6(PXK?#P@3I])/VX@W]O9='
M!W3O]O3O5XU ?-9?B[QG:Z!O1[1:8E%'U X(G#DYX=RGNI(4WK2J^-NGB@0M
MR/T_5**Z 3:P:8)K)SXA*.3G%*9O1O&>WA%_TN!QD^L=HKXN9()^$M%J_M];
M&#'J..5Q /H+7.ZZN7X?$66GE)T_&J6R%>VU9V[ZKD#ME=EI'Y06V>'XUE"\
MQ.EFO+:_;X=/I-5 ),"(+>)""?*@:$P(2@<7G*AT](-6/&W"0 C*RX%/\;J"
MKIM<6PN:K#0=\HWN"V&T*%S^'BH?@1'&ZYU<KH80A *)=D5LBMI%?<!@0Y3R
MJ=&-&HKA N5$!)TK0G!7^HE>_QF ML22((:W4\?/O..TKLWR27FN$@PP'PME
M^T;2T'-C0>8HG7@'?.\,\(GAMX-[+KW+J934(5*&'Y%I2F# O*Q%7N4^>'NQ
M<R'!:>"9TR]=F&%A@H8WQ@NBP#=RA4\'.+,F>3SD:T<\D)4?7^?=L+8*>AO[
MV'_HW>)UI8?TPA/](%+?.[ 0U<JO.-GQ(/&"HM7B;]2E"V'M<O/ ]\069T#+
MJFZ#U6]-\,#Q=YU>>W$&8!F@5AS,G^_#,=4LO,$75SBZ_=A7=E)T N$^P(I.
MWQJE$YE:3D7_\@S'R3/<]_2H__8DE8EW3/\\,H#[6Z]=X^I(,"-!K^NSJ.%!
MB%4^ ]-NFNP79%;D?2+E\[\I:#;X/O[<D_WPK_HL'Y[G490M?=16CK6%?C'-
MPJ@N-A$<%V05V@YO59>DMD<.EO6_>7RP=IC0Q+)<;XZ?6V!L.:&<Q[_RSYNN
M;UH]0(\BUM%/:*Y0O%$E"346U&AM##COL>M//98"%R2"]\\ $;,4*?(U.+>Q
M=[,O!QQ=!3,0 HK?+I9Z,G&Z;3]/JTV7CNB9N:>=".6^XJZAO.,-1[XC@H[5
M"5-M8-&O>,J^GUX52;UT>C'&C_*_=#$[^]E#8U#O3V0]R>F/KK UA$2*LJH*
MVM^L#5BG>]=Q.T3SZ\,NCME&EB&(^38;I2YHTX?O#&#%NZQ37AO2YS9P2U62
M?!K97]<'P8 Z@2'5-H+^VVYW^6(6;8Y2IVFZD%L+[K-*#RB$!AY_&,D3ZQD>
MQ7VQ6:Z15,>N]3CMUT&YO_ZL[6I._[D1)@8D7S]DX=J>U3>8;/<I'P66^B9H
M@<)G>7!\92T+ZM1+5?USF[SW[_M\ _%PKS<]QN:>Y-?;X'[R0:\W@HR-+LA'
M;-SAI06]#H82O6KGKIP.2R':D7OJO ^#CPPN@;O .1>=/W>J[,Q=Q*^9\GUI
M>C6-BUM$>!TW?3ORDISFMW$>3N>KDP6=(ZTP6B^T4 +LO)XT7'FYU$#)D&\S
MUK?0L]1/;\"7D^""*#(^J5/!F1SXYY-^M:@8_;2SNU']IFM>T60$;H;GP)R$
M5S5D=A>MX2,_>/ ^#I<UD/!]#6$9V*C$H<UYUHA#8_#QU;V3XD]$Q3Q7[P;Z
MA2/@)N"4LY:A"LQF(\"$,8_7#!9WM*2,3+<=Q-N? <*)!AG3-A&8!D=%$7J(
M_;!;!,R!]AHK!4&R_SYL5=VKPFZD73GY7;P2_J,%BG941 UZCZ#0.BM0@U>J
M9K4#0T8OQ?O07-7&2@(T9I2YDWAXPB0<!GJCF2@.(80G]3IG 'G^@7_P:I5O
M<[64XZ]6%_FW,B_^EWCT?\O\WS+_*&/$SCI>:6^HVIF7H989VGQWV+A+XL/'
M17A>I-/$> SKWI]V%/@_>2DZG>8JE'__I=%]LB6E-U""WVW_#&<;EK$2;$;0
MJI5 H=TV$D'\6HP-E5%J0:F']JQ,MT\%P)5[LC#!37N\4<<9  B7QK!=;4:\
MK,([1KE-PF7-"VW5:N>>VM#/Y%E X(6?T'D%7>2? !@(II1H=@90*L,#3XGG
M[A[>;0_:!J&;(8PTHY]6^V#JS@"7368ZOQ\)Y-(9&V)^R-=H*:F0U/Q4A'?X
M'$N<#K/3EM?A+\4>JYEL&"[>Y3[M'7>]>RG]3?<N4RCYH6VS^5V2E1+OII]#
M^  -9#HIG&OAZT]&M=JQ$K5I-(?#HP]L6?%F&Q5?A)A7+K[RDY4_][ZI&+'5
MK3X2V/%8,WL/1(%U<G22>_71J_*L[[?JRFIT+(&LPE]B='X\_I)P*_3V5V_H
M#^]6_GE!.IB=X=<QHH9@V*+JOH^+3CWWLZ\?+H3FT-S4">VJ=+\\IN..DUJ9
MS,\ \A.L<"Q=F,,P ;AJ/BREG5T2+UH5^!2IC^?#JXHU9+PX?61W33.S2#CX
MU=374&9N % K,QQP]S^X?K4=C.+XQ_/F?:0[DZ7,#7&IPW.<H6 $]\VO YD)
MN@<48S^A%$0W&[Q@LY1@V.MOU'-3Q4AVEZ5ODK' VL]F!#V%0IO/=BQN,U'3
M+^WL\I.9S669]:\K+]HM#?S0T*HG&.$Y.J'D^S82_!\W$=D]<SO#')'(#@IQ
M<GGV!OWSJ-/L!GA,UE<#\35-]#P0= I'O,I-%ZN>]8&JRCW(0=T]T$CWE;6N
M3B/%OT+B190B7 R_?;;5%&2WL/+3P"0<_()A&]H>CI? %;/0MKH.7)6U8:^B
M0CX!PC6N6[NG<0ZA1'M7WQYX:(HZW]KC0)6= 2CP(#^IF0E_N$8Q7&S<PHR_
MN 3\<;LY3MA9[FC%779JN$'CL!AR^.D,D'T&:"8BWY\!8AW.5>SIAB_M&6 S
M">M#JDBGE^@C^4<^VC\O+:TA.?K2DEN-09B:(.Z@SO%HQ6O%LI?%%DVE3MX1
MR1;41]KRQ/WS:6M,;-277+;>3TT,DFZ;=BOQS)1$/R88,B7T&E(H?[?'S2U
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M S#9><S+2/APS=*5S>64J_;K4__/C$ZD)S'%D(W8 U2Q6>RK,$YY9B8'7?(
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M,:H<$^YED160#V_3(HDHZR<6KTT^+P\P'L6XC FG/)YD88IQNTPL_JH$/'W
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M*[Z#E+5SMR /,)=B*'Y'-U:OFF&?]K*XO5PA3NI9;_96CKCN1%]KOWHWW*?
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MAVXU=J) G;34-J.K/5!26EEJ\ZH'YMY1O?F08VPIARV*$+4TV9@J\&4LW8G
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ML(2U OER"=SU <=OH[CQM5^O;U#76FA]Q;(X!; F%M?_WBQ18,7HAE_!WGI
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M-P:J<$5Y PD;(3_'9F']Y4EU\L-TS7/N<D8>(X'F:D?(T3AT!%(D$DJ,J7'
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MZOJ0Z[3SB_0OSB>Z/EYCB4Y?E9%N.R+R07ZSD6/?!G>S6QA&G3"\RHA'QM!
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MK9AW$F62'9C%V3-\A;(!KZ:1*\WD.Y0 HGSYYVX^^(8FT653RM;_S:ARQ+W
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MCC>U$5FV]O<T@O<MR;;P%!;CI1\C]*:E'Z5Q#U5;9Q;&38_5G.-/U=,)XSW
M+<4CS6,LC.Y$/4_0O'Q#E&$6"4BB*"DQ$7O1OMA=<2>R5SUT_=PB;&N1F_I
M8H.;- ODT5G=>^ JV\,2])?Z:4B$QZ%\SNVQ<R6M9S1,^ZZ.[F^>@E/R5Z!?
ML*1HHGVCE /<RPJ0F)&.\"69NS]UFCQ5=L&BHT4?4=H6]^*AGE64 \/"N__M
M'UO_C8/=(9.CY.9^@]ZKH+-B#O3/KAOT7CQX1NJWQU >&V_:L&A[/"=B*_YQ
M7T+., ']R]Y+J%V-",F>$%N4N;A;.H<-?.]4[+0;7A#\KGA<]ZSR?1\0ZWP>
MI'3E^=\?MN7"4:)_\8C.U7]XK-S_$\,@F(-O)Z(V(#E6#CD6M59O=9I8,/S8
MNST.A"F46TCG*E/H%]"Z>^OD+W&_[..?>!FKIX0#!:E61J< .Z\:L& Y&B@:
MHM!/\9M&'G$29!DJU66O]PVP)(8WB4G:,-E6E(//]"08V4F<PW$\4-@P0"@,
MR:-'-TR&"]VJK:?=&+_06Y->W6QTV!;#G8) GYRK@<+KS^=L!0-.15UO7C^9
MU^7 L+PKT4X#V<6==)HZCCD$Z%@-V^JD.@7:AY.FY0X7Z[*@F5LXW!5YVN^X
M*YKDTCUNZRQXMD\-<I?O;;[-6]Y+Z]0OGO&N3;(Q#?:E-VF@L$0\>)?/6X_"
M4T\#-=YDU-0JJ^@&S*R.TT 9.?0NH#8:2C'RP')B'?18**H$RV]%CGF+NU^7
MK*56WG^;B4_3P+F.WN#P$:$XV9XY7*%S[_8OXL]N1@TN8.S?]491MON1KMC'
M7+NS?HH?%LO-_5Z^E#38CSKGS[0CHO3-4SU_.4:$E 2XY3GZ)KM-3RCTYD3:
M*FRSAR7(7%0U]17*$!R<PV](0DXOR916+02^Z(CC?_B5]+0RJ%1=.VH#!3B@
MPK&;J@XT$'"B!%G_*^7[(Z/'-&F@SXF%W>\-J+;;:?8#1.C&-YB7.M\_E\]<
MYL"^#,)OJ>E1R,GCW;^^J5ZF\@GAT7NLE5#J02D/)!?6&788KEC'S9UV<O"]
MFF:!ZN&" JDY5L[88/_SGAS[QO(^KZ5$3N?V/WG^-L;1%GC7;SBC.[$C.QG8
M1X3M!\"D)6)83F3!JX8BTZF%C]I<W@_9SEU[BJI^Q)Z@@HOU6(.92Z\>)PR#
MUU46Z.IQE'9'=)P'PN!MDSE6LF>:<%F92E9[I>J"_X75V-^L1OZ+5J</I](%
M$-\%AK\+9*,O ,OD.PL8UAZ7_EI%DN O0ZXO8HBM<U?N9P(HQ@1/$*] MZM7
M7G2&]CG/E(^*&4G31$Y.T5M^0?V:?4AS"3P-%#I51JI1?%)P7\WU/DRCRDT*
M_2:NU=E.G?>#^ZVBQ=B*&<[-*8J<9CUL5Z $26$R;V:+JY\6ZN2U&)CB?3;C
M?FLV[]">O&9FKY47#724G3!,C7 !TT#[C>/^;%;IX%84K .S$;$$1^UL2U>D
MQ5SU[Z;(Z?U^UB/F4/R;X._/'%_-I(%PVKT_I F[:2+4H/9O]F_X)+JP^#>0
M[P++WP4,AI\$]X#+[D%XG745/W,K\-5TY,UUY]EW1AU_?> FFZ1_E]Y)GVZ>
MH::;F8S*UY;J;>$=1E>U.4;=*C]""C?E3)JA^[ N.C4V5M16($0^IJ"DJ/A*
MONBZ$:_'>DO-^7JU:,\+7?!=1BJ?R-\ ILOB"S[.2@]W]MWUUW:LZ.)4A:FD
MW,T B2[DSZK_[(5*2)'.3O*DQYX>.PT$^;HMVYN+5J:!PB,!9QKH2ED<#10B
MH?EG1_PF#[[50 -U5P1U;%X)T<1;T?GTT>-_.VD2)A @DIVM%B&G^?0>G"FJ
M* [;]\K88UXRUG^,9S&,IU5Y=I-G/@VCRA81H9:-O%)\Y/G,A43UUV*ERV\@
MK>DF;5@0\GZ[&T?!'&J&G']4\-O!$U=R7=<S7GN+7U([CR/X'R!<Z/Y( _V.
MQ-^ ]BXS)L.<R2.>YS6:-^S=XHU7+KXF_V74RX?$D#+D+K>\:>3\.&8N0)YS
M'DKHA1Y%+OC2_40XX_!73_R0K_\#)$^T )._X7WL-[R_"#X7/"YX*JYQ.,F*
MB<RA(O\^S=Q*ASME6&FI7F2?5[^ IGS[XV8\@3CW'+W@=V<=X:J >(X;+GQ,
MCDM1&:8W& S8^T>9FZP$4A'VN:9P/_-2]^RL9^U1^&OXI^RU2TRSI/DT=>G?
M2\LH/?+2P-  \;EX([UOMU>_7\X=D4LWOG+]O\KT@M\":?-'ZFJ\J9[_'4_T
MLQXH /_DA]U&Z3D8/.AO()&=*N6<ER)?1<A?%:&RZY[$V3_)1B=4VY)]X&W+
M#<,GX+[\_ )<RH<?2CQ6:Q6^Z%$Q)L2['-(_A3TK=+X>W^>9N">OSB*H$].L
MU72,7IB#MON2JH7P)JN..!J(!ZXRN=V@@D'A)QRUHN:ZIN^D?VCN>CF;QP@9
MC_U2V/QGU'M?X=3(,GR>E"-P'<NIX7KB[;?JEPN;)J__!H[?R]2?+8/]"&('
M-2>2!D)YDE\N#/QS>;!I-J5]C>T/C A(^?L6D7402GV;5>T-1+M7 22B7+Z+
MFWN!<-9^W]QO-\Y+S+Y:&RN>/C"Z;&E1^[8VQ_^EQ:$'Y>UI^Q"A*(_F4H]I
M64D%P?&^&K)3 %PM3B!FSAOO[->SQ\C!M,YVB#J 8J-HX5\=U=YN,.:3GR4>
M2FGZYF/VB[M[VZ7MDX*XT,DR&NA[K4'^46IN>\C=>W;+?"?-^X-2KE:3X5>?
MV7\>3<>]N\D;TM6H?Q7U0)\OFI\XM:J+@S(#M_0'2KJ/.>[.9; @%TA<Q>'^
MMU^+[GHE!(*<OZZ*D%:(6YCJ9!/2KLMDRFWNHFLL]\[ZCW[?NKUN&VW0W: M
MD[@VLG7^)9<J[Q'#1Y+)09"93:ZX H]*<.,:HW.*>FP&.-([UZ8R3,1TKB92
MX K(O<WBU$;/KA$=TG^A& &1><)#S2&BG\JY*U7,)5+^QDQ@OS$3X]7L <6A
MWML6G0*-U>\$E>_>:5OR9SFL=*K_^-W_X6L+!]#)>,">6(-U>D$5T<T&#GJ[
MK<  #:M1=<_-\:#HR<C.S[ B%YE5\%*[2S=Q)F4W/ JT$V<,<!,5Z[91QQ&J
MA-V->JXT5N+7K:X<CSRGA"[IS< GN743)3>%;<\I*MS3[=,,]V2].!<("\$>
MP[  KPQ?X44HI[<#(#4YCB2_(B#)'Y?4--WWQ<6F(OHJ>V3HY<A*A0L;//6(
MAKALAW1663Q;_2<,.T*.L/THHXH>^I4J?8[DZ)"C#5E)"085N.)B!56[*A71
M=*;R )<":K^7\]%:6-5<$S_X>E0$]?B>-#4D";F-A]:5B*:S3 &:F]C=0U]H
MH*DP&HAI/6Y4$Q<)9!.^.0LP,5NX6 T9593??'A!08:7F?710_> >RPX+ZO>
MR13_N;=:VN>D[0QM1;5NL':JH@V#=8 <O&(TA=/%SZ< L#'L7Y6ZQFZIY435
MG@T#0Q1P10RGMCDWMU?F\7&AR&,(U;>+ :@(.D72X6(I/]$"&8Y.:-^P\55!
M6[$Y[6Z;]ZYL[9W=T,6&N-XO?.-P-JS)J#?\,#0$W27-3X%4 \Q$A9FZ[5O7
MY%XUDV_$Y"F8Y.%U D+#(!&,T4,5=OI)33%7E3!!:YC4^]6Q$.%I!/%&8H#7
M[?C>[.RUB:G@";92*#XIF)-$",OYXX6!O/9X^STFKA<T4&$"#40TFH,=I(&<
M#H6;;H)Y6RY%[VCE78/8"J4_1Z[00->WY3?W:AK\SF=]:/GXZQ*OY8TK##VA
M9D/MB[VEN)1 N414AAGRN)Y,3K=&26&Y;E7.?-[7*4(;W;\TT()>"0V$_;Z$
M(;)>@B)!SXK+_52J#AWT)OG$JUY[YG'KTA6"Y<-$Y 8)%JB&HO+"?FB&^O&N
MQT_8)[ B[*/JJSCR8X10]MB"RN;U,^6O59\G@^846Y5NI64^O0AI7J@\:J\F
MP!3OX6Z^P]?74?3<[IW&^\+J+SO+..1(<G, G9M:#Z\6;*8*"!^:FUD57VEA
M^V7_?(*ZQS !:B:]@B84YU!^(:&VUV%4\1J8J]CXGC.*+0E/:,U"+^>-Q71?
M&/DBIHTHHUIDMD'QB51..F/)<*2!D&=^>YMDN"E@0@-=ICN7DDQW+MID.E8"
MO32 C ]JV0C&/J&7\H_D+U_!A';P=X?<_)-#)!%_=0@T7Y]Z=?O4+E6:&MR^
M9D\/%MUKDLV4**[?U*MNGLE9L<URKCS 3H'VKY:DWAV,##2.KZ[*4O^H-?IY
M<[6U.W<W*:JID)G-F)7U\$)&RLSY+<YK RZ%JR4(?@*2)$:4'WY2< [A8G\P
M*?0^]5X9%1[_S:/W4'W=;@)R=TKW>Y0DZ4I!Z$JU_E *9S!77/\50*CY&[HM
MYV%D59IFG *U]));+87:D/]-=^3_Y@[<'W8]_ZOM^C002Q$!30UCUB/O2']_
M72FZD2/H!S@8_\ &';4V>&L:Z"7D#X=]I[)% 4MGNPT #VLWAQ:,95=27R+;
MN(HL>_==-K?A91JH+MJ8\X-20,^LAT[/8KW=R+C456-Y_G*-,4TZ3=R'O#NA
MH1ZT!7WL:SRC&\9[MZ]A;-1>S=4S L1VT1_R8GX!#-C&A:$V14:14ZU(X-V6
MIW)FE.%YGH!CL]%N2U;22DW32V0M0^=6A?BOT-\#K/?/ JS)V;OE!&W!S'KL
M(;EI(*CM=C$=4TF0_X8317=+P;,P3S;T][\CKV!(_IH4F>:Z[EWV5>C:+)9B
MA-@BSI D!L8:KA@ @;:NH[?;WNB>[RQ*=U<6OXW+6QX^-8]V*P/>5"SCSF_A
M6T7'^NGL]K6-NT]0EI/B[)C##AL)N?=DIM^F>B!8:,3"JOWTH[*^(8,Z:1-?
M YGFMX<T5#>:OS-;2<0?\&C_85)O-\<"SGWS3OH;S+V[7O==Q?/SQ6,4OY3$
MB=&M,/G)BA\!A/U([M]2+4JI@%J@N<,]'NOVLU7870ZIWZP"_U%(_I8W1DL4
M_4:P<2;ER;=+6Q0892]YLEN$OI898-9-T2?]K:1ML#5VCV0V<J6=KT;5^KK#
M%A2EYZZPI1U?W6B]?')]W\*E15A ;_/,[4_156R/XR0SW719*8(^,;5Z:;)S
MZXFC$"N G\R[4,D6_O55\V@0INC]Q'EK5V&W<X,:[AG/8QJVH9>^!4G\O5S]
ML,@J:BB-*4Q45%0H#>,8W6#H8ZO_EOP#&W^UXC\ 1V^C\V_8L/[#+-%_ $+F
M]P5_<N$_P$*62E^+F?<:#?0(,AP?*TR?]N0' 3X!;.L0SPQBPES<\AVE?E$8
MACD8ND2D^]R_$]+,2P.Q]8Q>#Y9O?MSN#CQ_9ESNPJ9S,,W&7<8S>@=-&;;O
M!C,A;9"'X7ZUI"&J5-_JUFJ ALSX;=Z3I]G[Y&K!HLT&,C?T>#^O(.E@YO*@
M@3B"Z'O-#^@:-]=(>=<S7GYM:,B5IGGT=CNOL:MGO@16P5_OKZ'^2X7\$6F3
M07HZG";'HWXJ W]W0=SW#$5NBIK_GJ'!HM.HWZ8\#?HCQ9I\T%]D\4F969/F
M8X 3\Y&YL,S8)5YA:>9C%]V9;4YM=&<C$OW))R@ZH;<#1>^ON$JI=>8'GTNT
MD4CC"=U@\RC91O=F:I5]*N*UXS]N-^/LV[-UWHRD>K C$T+G(_)?\)-']YY2
M!1VL>#\4#7I?\RFX00]<G_1;_WV)W<(X!5#K9\$'QO,4&2P]6_\P-J! =-G2
MHZXG2NM24'.J9#VOLK+*QZH-^^<_4NR_*HTG;_T6=:%E +M#EJY)^P<AS>_+
M_=VW 5B.6W\!"EPO%GN/#>0\R3D@6:++-75E</;Z&$QC73$)-WN/:_;D'3+8
M?,=/>R\R6'C2N?>+Y:C9%S/_%PF4"8E3M]?;&#MNJ-[Q[0Q^0M2*PJ,3\44G
M##Q*JQP"/EVG@01"'V7P;HA01L=ZYM5D<0+\=52!?KDG@?S^IXK*8K\(FB:F
M/A2]J=4L/$TG)N"^9DN9;BI%&C .5\I>MGJG+2:,6,F:'<^NDJ6W$^"^%AKH
MJ0MJ#] CY']H>-J4QR?ID,GT#@0*V&>@;WCJS;_I<4G_9##,H[F#A]@=DJTN
M#&S"&";AKSYCCGQ*&FY(.UTV\$M,07;8E=N/I;H[H0E'II*N<]Y1O#.$C<(Z
M!)GK';OM"&.E'/$B'B]9YG?1N54181#>)/I+*G/C2;N+B"\I%ZHUPWB$SLE(
MU$+4'2$"A$@ZIT1%3'&5'H4V0"22YBSBPE/D"[([!R?SO8X9B]X+^QHNIL.8
M6'&3^?R]1C?$6:)>!-86^AAUO,3M\>AJ81BDP#9C<C%A_!N#OD70.69EFP<S
MVX4)8_%%&BO77B,&]FU)UZ,$'5$<:LP90+&F# UDYT3*\V'JJKIWL?ZYSTJ;
M9Y;OJ6%=JZMD$<#O)@&[LH%K%S#HLV">*TOXIJ,U\/ZI_T:K3*:TG?ZI W3!
MPIY]5^\N]SCWRT%'R@."<D$[*-=2_^+%\ON1<4,?J<TSZ%UF $D#':2SF/6K
M()\!$R$25 #9 Z.W/( DB@9*$"6#8[$+TG@:B,*E1P.U<NP;NEM=10H'I)V)
MQ9_9%U'"?#6%KG++'ZN;1<'>J&\?=O1P@29:_\59.+-5$K+EE=3U8YQNHAEO
M.&L$!\#O#KEQ!>5<&3#S1O,LL@YUN<J\N9SCJ 4]7NZKI*1^-""N#APWNE97
M8&[):/'0_WW!5/NG?CMH35GSK>,B.4$YH4T77J>ZC1;CFB-+G+L!\S(OT]N3
MH_=UM:=NE,!_??I ,Z4V"X&SOG$8QS!:T0G5U(L+<'WA(L^L*N#*[[6'"I)1
M?.FIX>$B]*V)\:+VLR85=[^D,W?.%J(CWI&H6CY6)I-0CYUP$2ET1(,RWK;=
M7!49Y+^#<@%,&D=-8N0>ETJ=7E>M,E/-^'I#V5C@\:9\,6P?0H[(^*2:;=IY
MS.(0M8.HFQGVB;!"_&#1R-QJU,5# W'M8YQKFSW)ED7EH1@/8T1&$TN'Y/BE
MC$\A]A1F=%]U7C]Y MIW"/_:4]W='5Z0;VT05_IF#=P80*=76V;&_B=M<Z>Y
MS^C5[OKON ;:<K;LQ35K4N]2P?2&]A[=S_&:(Q0?&N@2DHW>YW]$4J^AE7:+
M"]]4@(N 9>K#_UPLG;4R:C;X+\@ VQ"']PY2H#300SKCW#G]0&5)(OZOR B*
M:X9M<A-H("HS?;.?C0(MYQ9JK@2KT$#IV @:B&!&GRZL_U=D,/R?3O^GT__I
M]/^P3HT_Z^1=)N%>]I2Y/%8G/;03;OB&J_F,8<+%[KMZ0P\D>__G+Y#NXXX'
MI\[M.,_-N%(0(\O1NP;5%UH,/TIP*EO6*\G_!^\*,U_OXE\V6RT4,BN8NW(R
MOD7F?=:=A^H74@#IQLF#STC^P$=O,5>U.,;E]5<Q(OK)XI+SW8<[TT!G+D'"
M^(O0F)U"YAF3NACHC,@#MVKUH#*Q%_YER5<]7>9O^GZBM$#2XRTY]A*OZ1Q]
M;)*C#DZVJ^[]:L=C8L7D355:I<)DF^7=&$<1P7W&1^;XV!I26=B*IQX:98_
MQS5=)JY]U1,*#:U=.#33.'DFB-\("5R!2"[&/'8-69\9/"Q@&IMPO M?OS^
M%(J_45$PH>N')P\[@R.#CT),H^-0^J4W]C$ J=P,>UD2P\^LNJ>[#RP@2^8?
M6F/*;?LH%G?V-WM7L!T(38T9SU"+NY'Y]*H_8 Y$HT\0Y+^N28=MOD86=">C
M0\,A@I,)V[L%:#=(@F4G.!PKD)UL(,A%[*SHH>AP"9WHV-_H.;&O^Z+>???
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MO(!>(R&T8W8\-,6N4%)I;<%#5,[36"N%R^!EUO2NF>F>;7GX03K9/YL8T*X
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M,^L95 @"A(]Q@Q-9L_=-:07GFGQ3H8O(T@&MM#^/),LC#CE0=#WD/Q@3+;^
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M/!GX:5KZ=^4,%6BFD>F:G?"*"A2-69(/R* ]$.1Q/^0D' U7/6#*I@)'.JA
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MYL?TE<_8!_CXG$=+UZWI_A&I56@D[)0W.!S"6D:<CECC[3>H='@L^CHWZ9Y
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M_I(O]M&&K9=OGL #DO?^)VT&1&4(3.Q7O/8-P9EO:(&@OD9Z<EQ1+KIPR<P
MN7VW),50Q:3V,Y?I%WUS!W-1;?DC-SF;FQ[1ASC29QS$7I%;[9RYIKIABK.O
MW-R_5/U*&[6-:/@=@6MO/+@9( =:,O5_E.HB$)_A<-)R'-?T_K;$")"?Z0T
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M'2*[B6_\KZ>&)*=.[#XR(HM''BHK,UB$'F;=RC+C(.NV^"HXQX)N&R1(3A]
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M=(-9)2FA6XX[8^_*V.;)C*V>P3*-+!E-=R>$AN>18FSTP37\SM"]J"DTZ6K
M <9 DQU6>:AB_A@YKB?J_FB%^W6JL>=FZ^;#NOO?Q3G>> (/3:#7QJ9^1\6R
M[)'<,KK[49^A0).>B% OFM?<WKK])33R[4^E3^:MAV*WFTP1A2X\Y,8$LG17
MF.>S"+WRLQ]7PEXHA#L/AGSM+]WED(GAYY:/T3K&'I9X"11>A-!$;6=,P7?E
M2 C!OKN%"21*5>6KG=69J*CZI/TT4"6[7+KN0]-@2_25^X$Q)C!:8?M!D)TE
MADT]^(P<8 D^)+,3B%O=<RC;S\YJWLJ?O05NPC@"^].DM )4 /RV_93B&-PO
M?Z8=^G/9CE3Y8EXPLP<W\WQ8,ZA-C&&?W7_JJ^Y#]$X!I.)8]??AQ'R2W>NW
MXL2PTFB8X+J<.NG6B]_S :(N%LH-+RHD8ES=GV'&SG:?XBH]T)Y+?\X$?*L/
M,Z:BV%NGM)W54J"VXYYBV-2LH$ZLN/ML186^VYTW,NQ9M\W+N%JG4ACC3*!!
M)0[NAN-89=DY)+_"1U=\:KWT@MRS0[9?:R7F+]=D.&!FS<*$'IB+_IDB7F"I
M:#[2SD.[^!F,Q _SS-),R+>*DP)"%%]V<US+W[_]V>R1C)O;\445R>^!VQK$
M7:J/!E&09&I&RGD:P5=!,R)C7E=UEUF4K-E\2?5%U7V+OSB7;GWHJ^97PQB>
M90!:B3L8I>8-E8%)K,@9C51N^06]]6</#. O>)K#^V[Z_EKR5_[K.Z[89NK'
MN(;&; ^.8J];T>O1/ OM$2R$(9G 0#;M.!.H<46M[/OB=E7%SL!6YT\=/W'9
M$4(^)'>,?1DQG4G9(7$1;RU:!73#A$9IEN]QJ[KQE$<Z'YV1A6Y")Y#79+:%
M'G1L<TE6E_C^&6?P#));"/8]6TEYFN.MG"3_80*FW+=$>\HPJ^'/%7]7<<'J
M[.ME';.F4:+SM+LL&5X@'^)11/5'I.X>!C3<2N$K6^##!8V&I>.OK^GS<5^N
M$^*X?7"II@!25Z[VQ[R7E:#MZ:%=N259]*F.-E]KDOLZM';-L&1PQNK^*WVW
M@[*O.KZ/+*\CPFGBX!<"*]9PAW:@,D@/C]?F$P5_%(4.&5^IL+LX&^(6['ZF
MMC701+97-&UASM)FE*;Q$;<JY36I8^GLZ-$PGMQNCRVY?N)30"?6(=E3=OUW
M]<\F"GD<[CMDWRME3E-\@+1V'!DS2'FQY_+02OJTFN:^N+3#,47Z.Q.HW=3C
MJ EHHV<,VLT2!1E>/*SA\B/3^5'&K%<(Z=)UC$@C$]#U(K]=E!@VO1E*+*<B
M5]&U!\L)D<= #VM1G^;9!\,4!_^>PX=\OG[ !=9]28* /-5Z+$,]C@@@63]N
MY2.U7 >K21Y3F)R_K5K?FF_,%UQ=M7VYX*TX_S'!X'9Q*LP)H,*[\@6T\\4B
M#$<C_#-T7[U;R[TIU0PKM#T:PW/7\>R+S>/%:H=H/8?DK)VL$YB D/%I\K5S
M?@%=8:U2F\^;M+!\,[:7K93\&KH:8;<E!-,[^T3WYU@X%@'ILFD;GG@HEY<+
MS^>:$6-?PI#>U?C?6#M-KY&>R5KS>SB-H:PC;$I!*SYHFI ])1O-Z"3M=5:#
MYZKCXHGGJ RA%"+EP;2W<>L]S,-M^AI /UM<'1,EC^JT;S4@]2UR]4 X?.<A
MS2G&)_<TG>?/(F4;^)[.V>EGZ4:T# IGS'*JY#%2J,(,;/,PT:%=*\>)Q(>4
M&^YNMPD?T'!RP'T[U,GM-1+S(>[9:DS;:1.HPYC]<FAO *@VG_0>Q.YUP_F,
MV<LB+N9.8.%-Q4,BI[.^_XX3T@L]2U\0/V,NH5)'?\DJE&7SPN#<X@SJ -C4
MG8/@ISD^8%RH#\W<;QRW?O-(.O&CTI.=0Y_U,0],Y*$!8U)JRQK@,7%,Y#4\
M8J-N 2>P8J_A7G63>V=0NHQ!$[K2>3GQ8??QK=OA H>!A^AZ+II($WYX@PE4
M6KZ[B<,AFWH$+'_=7)V7?794M]@3YI:Z*B&?+&IW0DN+\P&:!X6OS.=H/XK,
M4)>V84R3SM?5.)S<!17$JGI([R\61R;,=2#"2 &@,FK#%8]^BCN\"TE$"=2K
M(41O^8AOSWAG-Q?NCQ0'TFHO]3^0Q)Y;_,TE?7J^;9C2S,+2'21TT3ZA8AD,
M+O%"0R(<_0PW\R9Q_76?FPSX:R](+=XGQ+*]B8'<C(:\8P)>^5BU"_37[;+5
M*0UM7"YD_N@ZI6M#A'[YMY59C*5:GJ-I2RI\GX4'(4X)%&]ZF;$H]08HAQ(&
M=;9NQT_^JCQ93[?57VQI#(S1^V!4)7GQMJG V8VS!Q(ZTZ;74#R,;Q0H-T-^
M;03\/:DFJ3V8%,MG5CMSRDBQ4XF6>.YC<)=&&*T3-*_V19$NHV8>['6%T?X,
MXM7O3&)]O_SX,.O0WS,SSW^J69=0<ZHG=BP:?HT)> =@'W;FUS8]5B!;)^=2
MO$Z>M!O#=ENF&IS<=#-^F[B9%'?5(:,;"'L..8T/F#'MBC*DOXVX0"Z$'$:6
M6I'BDS,ON?[P\\M8(RNPAYLD&:G>S/CBX7*C[33B#4JZ@1C*X+U%]7=$0KOV
M4C2ZYPYZ-"5NR^R?<C+K)NJ53A3?:="7I/_<U?DK2W5"ZIF#X50>VGG2Y&-7
MN;>%JR[BV6-CD\;$5!T38& IW_:1BD$!'Q.HG2(VD+8HGQDS29WK'U:;4S-L
M2L>#^^_&$PK],PI2'44S0[\^ZC]C+I^'HSP!R0510^A#&K30!=\SEZ@7:[,E
MW!(L6,KQ722(Q&6<O^GVYX\]/G]CE2R-0==.);?*DA.L:E^"(0M__0SM."2J
MBZSRO1MO0P[7GG>?PX2DOWV/OL&"?7&>[BA#"=4):X"*>(FGXU:P];GN<Y4]
M;@+]4]QFD9W]BI^XQJ)AB: 1]0(R8#&@4X*AZF5G6%F:L)2X=L>OS%3HEE]3
MJ+VTK=GE3&G7Y<W3B0MH=]1,6D=^P^^2!6D-+F^8PKCRR$*\;V:5\UFAYJ_?
M/]9]S;V<_WQ9?TUM$([/AVZGA%O_)4_!=R*'(ER9 ,<GD$! 36^9@S.+<+%;
M]'SKVO&@/[*M[A'K7T)G[\4K*[G_3.8/G'W.ILWVMX%J&C6:QT=_2>-42:1Y
M/SKNM!\C[2NMXWAR2\EX/U!1*\:$(\,!X#KZ16,ZEH(A;1'=Y4J""1K<8(O5
MZ ;,42?RP=BDM'V.XMY%U\\AGIW#?-%<2D)LM!X2/#XBDI7ZW.@E&KL(@37X
MSRC>T0/UHS/]I53#H=F-& Z#.>W7SEJBBL<M QNL-YJZMQ+^BG=M<7F[B)$P
M^6(YA=[/GZI7WI7@+<JPV.Q9RC;.L-!F&QW3,6R_2F^+4F3E]/98 NH0C7^D
MY,<N*Q5;!G).[+8UO59_X25\J*K'7%"907MS*#"UGJV!;$K9 8-)38N_8TF)
MOP\[.Y)AY>JMD*,Y,M8![DK##4(>WJ*QKH?.?;RMN=4;J3J&9M^$<8.O\2K$
M:=)P-^/TY'B/G&KK1'V;O4VKN3?76V/"*\NFDV=E/K$?10? M)%="%8MX*9Y
M+SC(NKZ^.+I9?=>3^F[QV2L+FDD!A(O^#HXO9@)<<$^$B#6ATG;].EGC:66^
M^^]\ M7M)58/?B)-*;W '[;V23'YL4L^U9A5!/G1WL2#D>8=S:/-N3\T9K0'
M/]->MUC-Z6$L\'_^J+KCHWW_6#)XH"3/KGQ98T^R?<\\?/1$JVOH'=F7%R;?
M.;_0FCO3;:EJSR$.LYXWIO5-?HA0<X9.FS-X!^!/=I0-$7'!ZM=7^3P<GFP'
MR-O'G\KL=YS7_#+,EPC07RC9#S&DZ:TP6;"/\C(?G_>,O[Q\?:3U$ZS2/UW6
MZ%NBHM)3Z+?Y2X3GA%.?!=\\=+&G!H&O*<GDG)Y**$&ETT_75U;Z^KAK\T2$
M):^$%?J5]M/^J1,AF'>*L^<@FLOLQNQDU :<A%G$HVDB7>.=XF$Q/CEA2CF4
M3!>%+,<W3@8>0$9@1MC?JUS$!I%KCC&J'O* ED4!9R':N/4?GNZ&#S^5*HUK
M%Z"=^-&N+ LS2]GE=K^?$=?O>3Y5S^^5Q*$>CV;4="R#-[:8Y@^6>).6>^=Y
MVDCBB5N2[QH=/4^?&S^FOO39S3SEJ8Q[&+E/A&U/1_1//O$9]1[2FG*6Q'A]
MM-(SL I,NJ%..2PU.JGKAF@[D8J\V-FQ8J%T^_[%_<4.',GN8_;XE WXC)3D
M0/)X%AEPHMFE,>U$H[U0Q3TRYOM(%?MS$</-7X\Q6B9<*R6BVWL;YE0_4ZJ;
M$[(+V7J"(2XG%W[]CC+^\Y]6PJGO(2=/_8HR^M@7I<KBS7:*=6!6.:A&4.GV
M90+/]L(B*OEP3M\7)!TM^$<K ENTV#%_HL-#^KE61)$)1$NJ,PBGF),VGU6
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MXP.([/#3J%D7R0F:. M62U,[LBA')O DR6$\:%W:\NUUC*O>O1Q!C9?7,P<
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MXS/B-4#X"%?IS0$1W>T!H^/G$AVG&2M7M2PHO5&>H#WE*XG8UULMY VO+=W
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M"]N_E2V=8#>IC_)A)(!F1!@F;B4T6R>>J";NUI5/LYK+NY8OGN<\^^6H5WB
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M2N@"0M*W,0\ZJOXY_&,3YO<R=R+,\^'T=:%PWG7()1HK_F/B?*42B)(LNG&
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M Q]*LO*=VO&*OZGJHT%9 :M9DG?*UZ<]8XG(L8]KZKF^K?XKKK>KE,)5NC@
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M7,ZBK2[:\C!/]_3\J4E=2-F?X/IJZ,RK@9V$AU\6VHU5ZNWQ$9J#FN78FB-
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M%I>;E\-17:V\8V>*%$Y8_W6:[<"J?.Z(F&,?<NNM1+!0GY-A2\H]7-9=>_/
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MP+^J#M89]?6<5' V\PGRXUG/DEPLM,C!Z/MLHJ8O*#@M@KILQJ][]#.XUX\
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M=-.REI2RAUR'Q6D#+!VL5@;?--6*$_0^.IH[9,I^D#=U$?&DRZ&94</E)4>
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MW"2RX(70/F@):CS3@/[,%./UW8EA/P% %$.60^"<EH"#M[?6"  <(%O'ULF
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M"10R=N_8^LZ#+_VZP])Q_AG?0UQX6NMY]7^/F>KO:._E!+P245"JO_HK;\Y
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MAN[.2'J9RH'3$Y';];;P>_J'U>'MJJFDG(\PKH<>HF=N?WE+]?AOM&-M'!%
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M3?G^G(K;L95'\4S,L'_YD/%NG^*]^#L)Q6!>#>,(/@)C#@"ASC)(?(;/^Y<
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MW:_G:[\2>M9Z'0#)'+>] NW2E6%88!KHM:$$7D&B1 E<%DL\^B3&.?/9'RO
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ME.:<#?]JE0L4V\%0-[8GR?^D==_3Y\CJF89])LS0[ P'"(3G(AU6YH?6NBX
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M*@=G9@]WPT+,K\GZ53NQYI]03H,82JP>,?MO UO!$_ !09^TH,J/6>G5;F
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M;;[FC5(I9.Q$#=-3L9Q8M[<%>@]<812X_Z2(27[J[N?("  /X+AR\]]/U$Z
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MDUF:><F?QU/;]D5TLL-3H#?,T43,M; ZFE #&1X@N>6PQ'H3G('2$G\[=NG
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M/3-4_0SQ=%9+0X8>B']L4I<F0J4DV"M4TM1!RY<RCT#V3L5"SV,(D<AOZ*W
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M$%*,IO3GCC)=F,WLSS.5_.>G!7@8/.8OL([(SVU",3'7;X82J7><],8NF?3
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ME96\16</GH8\"0X_SO& >"&M@6W95'S@:.LGBO_O6IX(-7IYJS4T<4MM#24
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MC];"NFJ!9VMF$L[=3G!_QW;W>B\V4FI+H"\EZHD<L3B8)?FMS;Z\O/CYU^G
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M\JC*7PZ60;?2-S?_OK@%'"SG_FYAFUV=0P$><^*Q.>M2!Y3]7%@H,IILBBW
M(D6\M*^@8JNP;2CO[*C<JO6A%?U6(9:O3GD5J1=B8A_JZEXK,H9KCM3P/2ME
MD7ZQ6FXK%^Z!A+3MJM00*K"H';WNM5YT$4NZ9,HJ)B:E .;J0+E5T:+0OYLH
MRG"X[G-8D6QV?ZKV.*BUO?=UKO"7N<=:3+D1^HSM$QT0YAV)?D$-8X8-(G'T
MZH"0Z4+M9RD^ ,CU<S#N-T9'T7;=_D3,!%^<5T3X7CN_I/_\)_Z2WO:9PCA^
MX? 3I@.<0$;VM0<RV2M0UP=?-;5$(;$#PS-V.S)J\RY_C&-!G"HCB=IL#3,'
MW6-?7@ZHMN;6<R3YZ@U,BC[7J?J.$J5$M=WSAV!WV==;Y[[\\>'8<GO$/=:]
MPMH;OR;\7*MB9U7D<-_FNPR;;=<S6,^;WTK#2L<A"0GC<\<?W3:]ESO0DL2W
M!/W7;7YPS,A%L)/G;<N\'ENIFA<9"P\J&U)6CZKM(^E67&;H=_5$KW,?S9WH
MD:_-H#C(ALV$:TG^-S,"PRD%KF7]'UYR9"_5C#@+EH1%:JP)ASH72U<:P^)C
M^BT5W^)-0]PF(;OVX4*;(4/8I>[$+>_6BEWV#2,9>@$O)V_=ZP?S$A:('M5C
M3GQKK\!2 I2QR MU=0)4JQK^*GC8B\U8;P#_A\^G-"W7>H@*L,"?[8#L[+5D
ML'II$"7Q;QN?>\X=Z)DQM?8-,K#G#9'HP!:DQ+YI&A(V@#CFAH1W\E (N0.S
MN_-9NC9#T>>W[U0JDO?\DC;F_CH^@O%:7.\O#N-K,N,AN;;0*C<2BCDQA$U;
MPWBGJC2O+P^Z&&[YKRYNN@:'&BVJ=^&>_QFX'- ?%N*6_8D,(47Y!H;?)%B2
M95'.#H+-8E8BY5DF^B>?VG#W"%Q!3K*-TX?VJC,W'2@EWO;QZ":6] &_KN4F
MR9109#$G\73*Q:1B>>L:\)@NA*9.GR+M-_=Z[BH6&*E-U6$*<TQ_RDQ6OG<N
M?G0=K9A,//GR_)2)4H02AXK29A813Z<"9O5)47XE6U?:\*BRG7WZI,-OR'9-
M3IRPVL B;_5,_7OHEN"WWE?&%TL+K(1?W6((MUY##+"AF4]Y?5+RLV$"]>.[
MSU9ELT=_./YX>LEE59]A^7#':>OD#"GA-Z[G5&KLZ0OB=$9?X'GQO)([70,3
M?Q\O!TM.?ZV9#91FJDN5;4'<ZPEM*_^M()_L;O46Q3/1XNF$SL\[^0<VQ@,_
M6__5I[(@U83 C:UI:G [<C8=>"]Q:SX_ID/[96J2 NPZU)I45_9=KL'(WP3>
MYA.0O"' ]O?JSF$93-O;6EN5M('UV3:4+T)#=5*9Q"!2=*1R4#(LGJQ""B^&
MJN*3XUX7VQ?YW8T<E#]W5'39-TAK$#0:P(6H'5KO=V@;3P/OM)F_LRH6^)DG
M\ @=>/H%%DH%NCT)WAB?26M>N^S7 <D#JT:ZQ8JW_LVY4T>9;=!<-C&RE318
M_,O.ZS@@Z[@A(?KO\]XEMZ_\_3KKE1/2QEKZ_/2S4!U,NW*?G5'_^XK9'OB3
MYZVNT:X7OX!Z T=,T7D%Z[>#XP*^J5"D^UFT^[GGA=O;GK#K5W/WO.HW[S6O
M*_4,UOX@\\TOU$DR7[U4&OS]D!)PJ,U'6B7T].>SDS:0MG.D1)-$@]KVI,HD
M,\Q-!KVG0L]9C=<L5027$A$BFIXEF]A]<.TH1/5LXHX=-/T>Q%-D]UW)../W
MC\D#Y0#GL%]'/1&.@8;TG**LJ8#N-5@<66G\\9BV",FW?X%'O6!B^4[%Z?(@
M%=B:*79ZWF-2*M7EB!PED>M87OU4?F@I,+52/O$A"'6\WGYQ*1',K=(1X\2<
M;3OIKY%TS]M#E,WONI"4)JY /+_S< /,O+G$CY*%>L]<:QI'JNJQOFCQC46I
M)!N<7LU-^]/?BIB?<,S9PK+&%O% ZM">5,##0DO-0.P,7&I@U:&I:PD=<\JU
M%$L%:@.6+J =A\63Y88/FA[6/NHE=#H!? !]O]:@ G,\,230ZL;O#$G-851#
MCB&]56NQGN#>X@XY:5@'=9,L/E?N-()U5%IX_K#NT7[7I$O(KR%$983.B3)L
M0@S;W1B%/%_99L@0/O[/%3."OEG%7+Q9X:\DUGS#LM.%ORWM2<3@_ L353[N
M]X2J!P-^5!4]CF;R[T*>)_EA0=L*"6A6Y!/VNG^FQ )B'6KNSW5>;_V*[@O=
MLAMAD]6]+CUJFCY7&,^6,_'=KSX?_"K3SBPH/3TL=#/5EU*MJB *[W;%:MQ!
M-Y$OS\L%2[U&#>35(-J3W'\,P!JPHBR[;3XNY0N@:-8RA1Q98TJVH,91>)P:
MP,:/I)%E[Y]P=P1G;G ]%1@O\UZC K-";"3C-EW$,:/":1*W.O2NS77#3,_2
MJOZC1MOK?L+2VFAPVU_DM!I$=[5@%C:*TB:DQL"8R#=;8ZPZQAM:*T*L3A^^
M?;]R<CN+]?S)?!TB;(L*N+ )>J/4\=I-@<C-;(&&WMNIF4+9+%\_']U_SC:9
M09I1/H'#OY5B(,>G&;1$RFDX8?##K_6Z3UB CB5N8]^ZR#)J-71L1K!(3Y43
M0%-Y>LN%#0>DX)I1V#BB?AQZS;3 PU-X[75I:KA*H2+ZRK+RQ;V!VI.GA"1R
M*A6X .]#)O J+:"]1"2F;]ZT\=Q1>/OR6!8NM;5AJRW>_I540$C?-"S_,#RM
MF@8$K?0G2R4SCEE[D,_"/I"L>P0@,0>"<F(/ZE/&^Z=OI T(1&H-'HJO9$RF
M&U2];@D-5+_&/)CO>MY%O8G7[E%=J1[KH'SI&B(6[@%^W7'AL+BI8U+AS[B2
MYH*RX^*1TS+O4?9L#(F]+P*#1V"S,@C^W3>/?V?]^)":[>>UMM;TEM6T0YOM
MN6XH<B=S65BA5_3";L.<W%B@D5#1&X<RND;ES[6<"Z$CD]:O3[M.)=KJ2/%?
M/!X<5;=5J\G':QH(?F2<CW\<$7+PI>)NOO+%K6[-6GVW,RB%*\.8S)G/F^9E
M[?-_.BIL)BE5*-F0GJX.'D[C4?*]B.(Y8>WKT,30&ZV)ZG*'E]F^?[UPJD6V
M)F47VZP+7$07Q?W\)=>;8]?ZZY?:W;W[A9<Y9YWK.WP5CN1,:;DBST9A?7 ,
M(3[ ^\3'P9C79X+P96U3%HN.1JGO9S/J.=<KHE*=PZ?W,F6U>?+T&>9^FQ>F
M#/O_L&+E>WV7Z6_=1D0:02ZU3_0U^")4YW5@I6__*8> H=8#6W[[B8 7(CK<
MQRQX?>Q3. ],> -]VA>]:32Z<!<1=.LM)I*HI5_#O5^Z0P6*Y@<D7P9RO[;:
M()/X!ZQT&B)!=XW7'"';K+UDA1DZ3?BS9I&EKW$U?67.-])ZI>;RCKAJ;KF%
MFLOD6:O;'1]+1&@805I@;S>]*=/'UC\1E5JI/T6%H5 ",9&@W'OC'C;YOLW<
MYE_VXL_#L7OC;G2W SK/%!,8^Y")-#Z]*^^KDE8IGYL<Y?FQJ(++^R>]THL!
MX6"1=D"(5;(?_63Z]*8W^KFZ=\>E7SKY[Y9>#"&F.XPT)3&.RETPX9JQ@P\V
M.[(^+A>$/#Y&&&@-:F;\^HU"<EIE\=Q(CW[ACIG39A;-M^Z]&_)>+]=U8:L=
MI;_&DT: 8X.[??Q<$%93.^Y)\1$@&T]A/E&+C(_:A:+%$:MX?1QW:C_D7%6%
M+\(5%7EDG14ZF/#076SJ_HK "LA[%]A8E"#IEV^.S_>K:@GK]C7TCPK)+PLK
MI[P,.J0?1\$HL8'S'T ) B7O:MD](TKJ!D6="2W;H$AW*H"JR/E4FM1S>RRY
MF'.Z:X2_9ZY7:3/3\8$E3_8&15FL%U&OGPR]1HBW=I]I8!Z6,9Y:HW^D[*R6
M_/2QV,8$P#1/,F>CE2*<2U,-Z363?SG^;DOKR;U? ^+5Z".#_;<FY^GL!2/V
M]+S[M:7E=Q/R9<R7K)MI8KX27!XF_X$UM7#.9OYCBJ '!Y?E.K<% +IBAY.\
MJ"KU0M?I/N;;#5(N3M#6&BG_P*P=V0K9JU4W3A$54!F)1G&?CK: &S;5& 9<
MG07/N=.G&[O2I\-BRKGQ_0T$!#:[;]CM_DZ@EIV52^;$ 4A)17?$J"8W[92@
M.G:*SI= V)%F@DN:(6+ZC7&+JEI*Z]?<R,$T74;'?5BZ/8*G @_QH.X(EDJY
M-$B@H,>N_)\@\EYK<H_DF$ZGR.+*M(D%7CUD^BWDNC#I-4X]]69%5+'E1*%A
M>& XS+TWB IPT"2DQ.25\$IC\ 1?WA"D@E] \E!0'+>5<*)&#*045,)4-I3F
M'?N$4U]MOU$=;@N=D\YE4]+<3R)$OU#?>N/=1LI>%E;#JL4$RG&:-Z58Y$@H
MWO]^(>$.ZXSY;,RIL,P^DAA(X%Z+@RF3K+ _[^9'8-$/FM5#5HYLV$DKX5$6
M[5E/],Q,ZS^YG39W-R<SF7W9-*TH1AAU_-CI>&8XPCE,N'TL;(!,C7=Y"W=[
M/?92L*UA:35=,7=&&4\CNQGNJKE.G#X>'D;E5UI/1U[G"%,!"4HO:^O--<D2
MF<6.Y8^B>W1XVF*5OJ<"!V<K=V?%V4B6M\=V*0T*IZ^B&RTG;S YE!]H;KBF
M(WL/I3Z/&V-;E@J;2N_1R+87)!&EC,_N9[EG-$;6CRBU&8#0R[5Q^%A>HY/D
M.T260;D_.VZ!@8#6DZ/%3>+6'0.W_'M9P1Y*-B?I1M G)ZY48#!H"K2%7J("
M=[B)"CWP(S46QM.^;S1'<JWEI=E3!)+2?_U5<M#U>M^H_?8W.GD;^6F2!"$^
MH0+I!)H$/3Z"4[@.#R [=02VWGR&%GPT"6[;,FZU(?^C>XYX].&AAL&Q+^@]
M,K?#3?1(082-"B"S:;EJ[#1#!<Z>HP*I(_3P&8VEM;/!TPGYMW/26YJ.$(K9
MEN7Z<7Z!UPU*2AKLX-<WP35K28$= F3%=M1,H$:R&4&5_ZIME: LE_A3^0@E
MXS7P#:@=:16W(X@-3GCV#&I=;F]GOZG<QZ4X%*MK?5D*]Y'[0&U;D@J(I]*@
MN/I+Q[&\]!$]SIV<N<L/G[7"48%[JBD"N=<2*WB%V1=R<8HJ>[+<]RV\S!86
M%O)F7FO+D1U),W[^?H7ZE1(9@L]X6@3NBR6%:7P<$B'GDUVB;)S.4 HTP_$#
MO>?=II"[E9ALG^GL\N][UP'RT/Y>\DS:4MFFS($&9O?ELS;.Y791W>K7+DWU
M3?\<W1'\P.^FO?I:<@O,=(JVDVM,)32&^A2R?SCA\RUF'D79*A]=+HU%&K*;
MCA(]K[C?<@-=[^Y1/IXL-MO<*FEO2T5I*F UP#PAD(?3VX,GUPY;'/1;H^FE
MU+5QJH2E'>X3!Z_]D.C]'M2%MI.SL1_JE3>?OWF:?^<YM&[,0B@IQ=CW]@EC
M3YY5A!A1IZDC:DY>[D C/GG \K*VXA^9%?!<86<0^!+JAL=Q4%&B/.)2>#/&
M-_TE/U-$(O=(V?"+Q_@#C'2FM$R9R&)$CHO,>/=C?.UJ7L '6./E,05M!2_3
MJKKB7Z3N/\K[B=]<FP,AT+WSE11_XF=2? 2FU5$ 9_:U>NK9GPOA)%"@;'F3
MB$-BRL?]M*-@T"?\_ "$25?(*^TC^O-' %B7H6W/?$_G;9\O I*)<C[C2R;Y
M_NX!@U%K\N.F[X+%//D/Q*KY%N/DLZ0_E][V#-(D3USI7R%=P#XG-6M #3M*
M2@MA_3"5&:@?_J]UVTR#8;+9IIPIQL!7T%_ZO/,5_48;1._,J+ R6.FTDPKL
M&1Z.G%RD$?%/EY$E'9DAL[-E6(FT8T;6R3R'SR\W-1I;4CXER+PZ_A]]A'^&
M_Y-MH<?"/9DS1>QO=+; [^%"VGQ>((93<4.6K^F+?;]/G#(#BA!O;EKXGNY=
MHF,<%3D\]G=HZF6+O\W6.WS.2+*7YT+HLX$7VHKB1BG"@I^;OAZ_D!GM<D95
MJ@6&M(]D8&73W-4#RELMXFK@!1@0(]Q'@6W+SK$$@3-XE/KE,GO#;I8=VG_T
MIO4?48<DUM!M+7<32@%*<"/+*% AZ>"UF.7/H?#BG'L'_URK(UG_0*E08@+G
M-0:?XE$-WF6VZ0_NP=^5F,X%2TDO.2B,-VM 9A%8BWV&]"6CID=[6K.780#\
MP4%Q?*<EE%#NLN+IEFL4'3^UB8DHM+L.S\M+F<$B=KK@?DA;_>5$OW/9GC?2
M/7?-?[<!>Q_@46Q(ISP-BCF^ WNVJ9>&()Z+5QOJO]:D;(3&K3)E/NGJ&OC1
MO-X3<\QVEF1^PN;I)-H:;TI(WO/.Z+\GC_#]TKB<NLLYE/J,;I,E0A?"$%0]
MP*7XQ4^OP/+28RFAQTS+_88L'MW1\^4'<RQ".+0QY_N?W^WUFXY$54Y_(=BL
M'?#"B 0Y[/#O5"D#6WV)"^<91 M]M.=4"=?ZV\L6U[-NJV1S&#QQETV?G]]O
M<'KH*[95#T,U'+N<W FI,,*G=H,X'#??5/Y00K=_ME>D @Y[9Q(Z'N8B'AM[
MD>!$2Y*7MAC4JE;-I+[%*2/Q)+<<_2!MM6!GR#]F4L:Z,GMZI>>!N9V^"R:D
M0H$X-RQMXVEG:69F.!/\%\:(!M7!>Q3Q'1C?]R[2.Y-5 _,*-DFBBIT:\&4Q
M9I)[.X3L2X-K#1S\Y,PB?#V^:D;0^DSSTBLG443?(CV!-?X9H<^O;.,O3]J@
M1)",YK./C>>>7T#F$5,"(XI:$5\H9NI0YNXQ.ZFYB(%.T+]O&NRRP9O_XTT#
M5#>EO(T>U"L:<US<\/8<SJ0FL*,QV=I?62+XK$@Q<U1*<U\HN'-I3H&V5Q>U
M)3QA5R<#'95^CX\^$-%PSPA=$I3J-V$MLIZ65;OHW*X9)*'4JU<I&6Y#^B,X
MN&7^W?MQ3?6J/^2/IPPB=ZEVK7_+."9?MCW1SI;WWN282_[]T;H[FP;6Z%MB
M60QT^?H.UFAT_,Y9_);QN*@IG,]3J;O\J_[9<0,9OU&]HAK-%,6<O=UD1$WC
M>]SP YP]?OA7F$BEQGN)IDQF^X<#Y;BW6J1OQ#55[.AIC^@E\;:]G"W]%-&C
M;5^AU"$W^(.-\D/-IYFVQIF'FDF2Q%,=QNAB'<OX.?C,9B@5Z$>^,B<_)Y5J
M%Y;./W1Y-^!2.G])LSLR[V.JE9ND<),S:FM4DX<*L,'=LT8EI'U]5#Q?KC[2
MSQFKT]9JXG18HN'.G+$.R3B0!QFA1MQ]]58XFXW/IG*_:V]FINS7HU MF5E-
MTV*#JA"(Q03&U<"WTC6*?[]>^8II;M#O9C^;SX%"GF8DYW!;$8.$'FG2+PCA
M<VFIRWXXT6W"IP&>(B)0TQ8K[R//TFO6<_E[2T/]QVBM&T8!X'K]3KE[R\A7
MN.EZ<XV0%YXQ:,<KUW;$-]E'?&%;X6$I$<'+'=NQV-0X*L!9#V+?%*C*]O-T
MWE-)ZQSG]1F[[?>6OH(>;$9*[$'#$P[L*R4M&U*(W9O*0J/?E?C@*:$CSLJ.
M@?MG+][-5 N9-^_Z3K(K$9,MU^<6=;<T^MJ13N;'4($ZMATQMCX6+17A((OX
MOILU*S=O5JZXD&8H-?W6F_K\]&S$(UK:!F-V3YA2*9S7_++AU50@X0#$TUB(
M 7/,HN?G?UWX4O+5DR.D^@4=NHCCMGN'0Q#2FC2&=^\'\6OSD\+OM[>/5QYN
M"1:H3G[?"^7 ""L5NNEH1/7?N/6;QICG-K N5KGM2]\.+?P=K(S!=(E%E$]6
MQD<-Y)\:1#HJD&;<!SZDB)XF(A$THK5[I*[ "Y^Y_^\A_PD;\2E)LH+,/:;Z
M0<MI[^>>X7SL>X$?S4QG=F[]*LS95T@&U2HD:(N3'\UH&CSYO!%$S-X5U!?N
MN2\<U/O*_Z78YYS%%(FW?IG2:H7@E=#F.-.4BI[99^+7F\R4IH)^'=_#P,D9
M\(OPV9OS-)4O!\T\@5&!;QB:[-^CD2<]IA/FKF--E B^*K7XYY;X=%":?:O>
MHW'+,^E:M3*]'9[(N1DGTE25QPSZ48&+N_!;-N9*G+IX%J.85[Y,#*,5%\%A
M+\@.8=[+)ZNG<"W$2[%M1UA+UAO67QC<*<<'GPA'4H0.":F]<+81?##.==O<
MIHA(M$N=E_N8#UH8H8OXQL8G)JJP'"&SBXCL8(6<<D-5J_%_BOT@@<$0V9_C
M=EFSP=]^ -\8"XI( WBU'IKX4WFW/,5>V<#\'#94=H?Q/6NX_]^WR]#2B08?
M?7XF]?=-^&_[-7,L4)AI7"E;4(-X)8QHK:^U#!: BA!^Q[-0<D6$&MZ4[?LH
M7(Z^CO7%9,8C_;JVO1G[:3-K7PB1M&Z:^#UQD/<H&-3NHV:<$! 95D>7=")O
MW/0 3_$F<A+:\X:J\LHVPI($J].5VQ[J"V5*WSE^.DT%:(S[\;"5SX-;4.O*
M>?O9ZT/V&ZWYMEI--^A@7U6;:KMUFUNJ%E+.XY0WTY+/+SN73AN[;*;&[RX/
M^S^,=\0GH[*($U5=@4_.Z"V\MNID8.^WV)-!<J=BP$P;,*91'Q4?D6'9^A.+
M.2'3U!\9"Z]7,@8U<V:13#ZW-$1+,#@ILX0<@\/&F;USD+?Y4]BPF9U;^*U3
MSL2.<UY-BH.^C!FJ!YM(MZ>:*@_#_'XAW@I%AR"]TA5EGR4I?;FA@WRC?1W6
MHP3V&E\BR9A&3R^ZR:-]"(_%Q-=6GK,-S3/X;3F&W!]]FU,I$Z0IN]?HJO?6
M-7O"?&;1N"EM#=P B4*)A#CM&G;@K0H\FGB__,89U;XSY*BBXRAGV.97GQ]=
M><Q2TMY!5/-.Y89>F%))?EA/9 [T<SWO.Z;I9:L7[CJ_WQ>J'P=ZHL"SY'4I
MV=]BXF">)FG:O8,\B^=/OZ'/&3?OCAZ W$-$N\+<>Y8NVJP+:(KH)G_R,0F5
M-1A2%EG)S3A$ZO.^*BG32W+],6..VQ-"\IHKE;^S*MQ^<LW7B0HH])*G1QU/
MF:%.KP,I-S4.QQ4$!%L-L%:V+I?+'PO&9&IDXY&M;<I8T9A%Z?$KD[*,L>1L
MDP=&%]D'^;?B]8!RXM7WA!XB9!2F?+?)K-73[D!Q.]$T-OAI(/-5FI;<"X]6
MGD8Y3X*>P$7F'1D:V\<A5Q:B%'+7[ZRE,\'%[!Y47GSFO*9M*Y:?PJB,03=<
MQ^ W&ZYK5*T3J< E: !)$+/+*9$F@2AQ3-K).1XQ2K$/,7YL:_V;"D3&I%9Y
MH\FB[IARE<G)-F5(J5SF9ARO0(!'A702+E-H^3?*CA1XPCC(^C';264*FS7%
M"NLJ\:7LUMV_TTFD)W ?+F87HSU:(MICD^N#LH+6Q>+X+*2O1G4" =R_L>U)
M/@)*D.;#(TEBLKOTUV/%$M1W>_+(3PBZL',FGX$T7.%X9,R=7ZXXZ>/+_?S+
MCQ<X+37&P8&O6GT1CG@PL11?FDS6<#_74&&WCKH2=\WP'<3AGE#5.6:]X2Z&
MI)V?^IL1@ECW[@5&;%,\^/Z,3U*-.U2Y/VB(G@J$"@K!Q191^@30MB V46.C
MH_JP$F1:^]/EQ&K=E3[_/%V46,D+Y749E&HUJ46QU':NJO3'U-#^PWA1<][L
M>VCS\HI4E_6.5XAZ6M%ITI<,2DW+';:2G36$;[IFSM4@WI5?87QDO,P"(4N2
MQC =20*&CNO9-BTOV>IGC?9&6,.>!C/6L8*$$HXT>I:JX4D*59\$4,@2SZ !
MBLM=IU#&:@<IT-^9-; M^1KI%JVOQ+0(VGB\41ZYR3)\,*O\2-]H0)A1G3YJ
MI+SJH:ZFG'10J<RWOR^^. 4G]?EC-Z0#*IO,E\'HX%/#@230U@;HP,QZ?2UZ
MA&QV6X$2>H\*?&0Z@N 8M\.QR%=@CH:E2[.;:(N;V?NR:0//Q^--+K$^?QF$
MK&@#E:(R"C:(9MRA<CNXV/?^T99WQ-TW[%R\)\KUWC[^,ZY."I;O>[POY.J%
MKW>7TSQT_R;:5!HM3P7JZT6Y>Y@-7%<%F5]SPZ>JG3=:1X6'C\*GEN;\L<$]
M[>;=0?D"!*.X1)<JV^@TAZ7Y7IY-33RTGV]1.8DS(REI/[6B31>SH-&7([>8
M46&G'UZZ(#'X^,WSGF.1W)0XU!W"VK9@V4"Y >AEX(?09PY9/"U9J^D*=X1U
M6$A1=B:]9A7W-@\1<HWN\NZ9N&K^MW6:J)RR4H+N:7P3::8?S*C)7&00 >>-
ME[P,^S/]<_%"R=MC::D1W&BPRE*LMAK)E/"DYN-&F(5=KK1XN&"RMOK:';9%
M>L@/N@'I1THROQ<D:?@[O-HM1RPLVL#_Z5%/6WVL/"EE<F'@81K8$LI-8OSW
M-9 6:$7I;ON4O(7<SV)UP26A'5.R3/YS$,=S&6E\SWBIA\6+M(6LZ>&:=\72
M))OQHB84#2!(+F+$=BJ0$4[0 [5[4H%BDYF1I6H0.7615N'5+ZC >A?8 NJ/
M9]FE4<]8]$A<_0:FH:WMQG8Z3MMF3NF^?Z3Q/UKM,C] ;HBY'C!)$>MH;3J%
MW%:XVM)PZ>I<71:#^K.\[^K8!-7R@;.WC3:7CMC?K9(^_]*-Z^OF+>7;/(&"
M?_M3@::_Y 08C=HAYT 'MA6(:O61'B0[VW$".Q5XXU*U1,PAR520O48/O+4D
M]G[^-)3)>H_&?V7@[NR?TIRD\1]05[OU<D=L@Y&R56M]:\Z?OSM21-?&V-F*
MF*^L+TH03?&3EC);\$E#^3[X%R0?Y@1E#UZ!&A,JNM#QW:)).=%Z^0^*=XDI
M>5)\YOP982Z4B3W"@O<.DD;9&ABCH! ,2=ZW84B+V=3BS.\AL_>/I;I"T3:1
M0S-I\U5LW.-D6Y+&1ZCSJ+7Q]*>G.;(-#=OJ')V]@>8Q7;C+A,[CF4&1RY27
M9'>7T,OC@5K*%@TC?U;2<OC/XW;ESS,B[WH7SC\AU.,$1K+N[^4SJF)^N3YH
M#@1Y/RAL;RFLHE2"/%D8>T5X$%V+?&U&ME5Y1JL[S0M,5]]T<;?<$F?5!UB;
ML1\I,3"17Q&MMH2\'\^R3JV)$05/>M*[BIX<H&,(D ?&\4O5@;.3+LV$E)H+
M=?<RW$O^R$G28!*M'4G1C0C]N!ZDS3_NH]*NA-;08+;I]=/AP)CJ'Y&];Y,2
M5#PBP*R[$7-S6:ZA<4_>R\ZHI$HJ]' NC\PGGAJ:P?_+6?PN$4)CEZ++N\=X
MXRTG\Y-_8$.HJZ1V EW@CH+9A(]/;&[0HN/8&VW+W(R]<KZC^%4G'+ZT6\V)
M@13\D03;LREMGMC)XA>/U[C O_&&%<0TQ&F7BZ_'\'Z^79O4P1T_HAB24UU_
MK6[WLS8M4:*CX-_4NCH.T6M40.?!$H5&/5;>;740^> 43I9 4/UNY[ [SC4_
MAB<MW-TMX&]FD5H2+@C_T<4+\6<Z>WL"#[<D*2Y3# VF?'<@DBTH[^)PI;Z[
M[W /A3O]WX+>?<X,@YPI!X-)XA-#-8:OBY.?4^93J(!X.+?JZ5;$]<F9D\H#
M)!^%91MF3K[?DCZ G4F0?Z*>(_QB\Q_0CEQ/&CDV8@N/).;B(:EM((C<(M+S
MT^9ZI,/LTL.:2YTO3&KHLG_!U)$O-8-]L^$"FO<8*EJN:^H\3VH6D_:U83\2
M^+O["ER=7TCY-./$,B6W4OW6E\<N1JG-@>VM.N/SK<F+X8?(JK[NV/OFR=;N
M/OPDB7NO?N"_)ED^.POR%(&$:04'><Q1OG1XLK%M+K*WX(/C L\?VB?VZ[:V
M-OB,#O!=::R(B7.^(^27%+-A ZJ&1_YQ)YQKP&Z\*7[+\[O[S-!IK9[T3QTJ
M\%1*%"_M'M7QF.*U9AYGS+TYW9@3MMPF$,Y_+8.2UW<'C%0E2L9I*I2$J.G4
MC]6'JV__5W*&,#,6SS<0S]FOL"ZX&S^UKK$4%.'DF/7[5O[3.H>?F@G,"Z^/
MX 3#TP<="?!M1=IN%N9T6#I3 :L.'7(%CHT?UJ<M3^!-#LQS9G'1-PR?/_)-
M$_<,/AO*#, >?10XN:N*_LSVQ-:->V,Z694Q'-ZIH6Y-ZP7>V-57\=(95OM3
M5. ]OG1G&'^*,R <(A,*(C^PV#'$>6:&\+(G 0,UU^OX3S<.D \I[ZF YPB+
MT7*>1@],8A(S%NAX\\H9XQ#,E:_)(69"&,O(SLOY?FD[!VJ)FM>*0W ]?W-N
MUGDT9?$:UN">K<W&S,9\NXH"$3JV!2OM-Y4&,8YNTUO&_F_C31:$QJA K:W.
M12U\QW1#H5/<U>@"Q[G*]T,I0_ZRI4KYKEGZ^:K:4OE=A#IB"1X10Y:)@!1L
M\: 7._PY^R B".GO:8JX\-H5EG:_25RIW][(-@)/W*+1<][ZUN(D*N#N\5.A
MJGC[_$A6A]DLF=X:@@'/@OK49M*$X=8UX]O[[\]6;10? W?HM9M!]\!.4#62
MRT?R=?SQA@!+:09K\)#RF_$?E+GYYE-+L\KXKK%,:=:=0\7"[-^A1.TL9:7X
MNE)CC\,(.&8DCPK\>Y1.CP^A J6OJ< !=R45F)4\-7C40 6>E,,/_N&>A$T@
MZ ]3DW-\X\_]6VK3R@;B<?BO%_D  %TZ2BNU&7R\!4EAN94B:MG:T/;UZZ3(
MCM-HC4F)^B@]#9/C#ZI"K?X#E?TG2[.QA;UU_>JPG?Z9([$5R+SRJ2&JG HX
MT93%,8"L@0G"![]Z@(CR^E2@"-N6C5O;+L2"$SHX%#3OE6SF^#04C>D*# 2,
M,YZU9M0P2?B;>H%T<U>'9%H2XA3Z*7UOYH$]8X[FD6NOO9+Z3^4=ZU?(1R%A
M)HE3?*[\O@IL.2[>D[&%&G-_)\D4RCOX2EL(Z!0%IHE%K7!W,I?@*4B3C0HX
M[,)SN2'+5& ;CD7&=W#4*["#O="6?24(6M1!.U>"SO(_5XITEW.*.3&!TDV?
MJCF$O# 2.?[^P[/B>6UB]W+3.Y?^A<]AST#OJEK>?5;@?_0IZ[4(JZ#$0$\\
M0=W ##9N9J20^Q Y:WQJ(%)(6V';C@,'RSW&_MTCF44E6A>N'#B-\]Z%S_5@
MY,OQP9TS=O(5@=[!?G);O^+K92UDK@*LR[>^(\;;%+"\V_;8)=Z0+:?IRH:(
MJS(1=XGV[W"9Q;\^_[C/>&&ZE.UU\44CV^]VRM 9J0'K07Q(6,!\KIIC:JTL
M"->_=-J,W$-&=?BF'LE.(XCGXVD*>1@,G=<;G>^-3T_@G8\"JYR.==2QO4+=
M(!%9@@TGZ^<-/;9=&A07^.FSK(-&OA>YK(E6AI*8J@M?K7VHU2Y-N&&3%&15
M]@0W+%/).K$,B\N7HKP+\!'1FVU".S2NUN3ZRC</X,"L(<8.T[ S4)OH/[_G
M,DS'JNP$/YC-<E0QM:R5G+_%*/+2>CVUFPJP='1WQ(9997Y9M'<W:'SB%Y#T
MSYTS-HWWA>AH78?@3WN"$:7A> >.41K;;M/KU(&$NH=S:KX_*=MH7>/7NDT\
MU_)\-E8@4^Q:R'W"?E))\3,)CN+K9=9%F1F>8$B?<N4HW%LA+FPZ!5)$8/*L
M2GPO![D:F&G\T81U__2/]RH8_8$864OJ^>QY[!M7"W^\49SGGLFDVEN:/&^L
M2U]R1Q/AM<6XS8+E+'LF<GU"NXL*@$0>YKM3"!-40*1*C9A(LL>(QH1IQV,H
MTH<-QIP/=OS@@5>.LFY\U:D7NBR>SBB^LY++M-T]T7VW-N!#!CF5_G:_^VQ2
MBU^_>;*ZC..2K7?M5/[^"4U##,K/@+:5)4]?Q:%RD+F@)UHW#15>!L]PN/O\
M+I<M3TLYHX<89HD0D>D=T,!*C(RK^\K?>B0,6A76Y;*^<%"@RV5"]S_#[H>9
MC9LP#H(:]3)Q"%$O-#C^@(W5RQI]+9U28KN#D<UX] (8>5Z!Z$LM#C/>+L3G
MXS"I/0$^CR;GO7.*$)XMR0,C @?);%^=_&9KD-[]GG[3K:X)&1_+KCV%[LAF
M)6OVV[XM6E4K:570F335]1/]A\M4%_B_VS6Y_P%!&<%;]!MNIT>";K59XLT'
MLN&\JA%ZHDQ>Z39#54;/LYGIT&,?HN^YC\;D4'@2M>WH^X%3BYU/"=N]SL6O
M3,WL134RG]:_>#^5=UUM1WB!QG85__4=\?_R_?]I.GX0[M6VZF&!H8N?3<?B
M[EWGNYSZT+H;+ !R2;U$@M@T3VIR>QWWQPW\,+194KMY^ID.I"[T. ;Q&[97
M2(^O:M.6+A%P&-44FI?H<>?*U+Q;9Z_: E+ 01);GGJZ"H:@IU4%>>:,T(#B
MJ((0G:-HSRY-,3'V5EIIY)E]W_JG.FU?Z[2*Z;M>*#IY7W&@C'ZQ0U^SX8"K
M-:)B+,M;(SS- "%I&'V#O('U_N[GR!^[C&#<6*3'-^9]W# ]LN(Q/3\J8MN:
MY?(KW4![97J]D(N)(/@B.!Q1:%XJ8&(277NO[%."7M3_K+3\W_:_[;_?XB)Y
M$M8"J(!H2+#EC"I%8,*FH7DJ@$UVLS%M\+TLN7>?\X=PD^0/K8HA.*89!<#'
M'/!-IXR50'@Q]UH%X00S%.)^A\!&ELA1'ST\*7 IWF1Y\4EP<(B;O7]A7EI_
MV;MN.C!1@75#K:6D.% X"^'*_,O!X<?S-+U"?PV13L 8<X=W_<L.H\,$V;1@
M _TS(YBGH-CKYM@"VK%SOC"?G^OV_=*OKH_UI^L]_D?_'>J_T?8121U\X.73
M[-+%TFBR)<X\5/D>$<[DB?UC\[RUZ7[Q#%.8^W2DED#"D;(!3=/%;+00"S[/
M;BR=TY9=7/14KFPG7PJ!W0RW?<!XX3(G](ME9G7X)>\)>V(9/A YP,9&OC[I
M,JF"X-K*N>M%] [G*'K(QTE\$?STX9FFH21H:0Y ]))Y22HF^-\GZ?/&%DTM
MMWT5N4HXFQHO!_N6T"<OCWCZ[.C)2\9R?NW^MC6L^TY4"52#E%=.XIG!_$UI
M\_SBV9CUMPF"B;@NCXV[%1,:GII3Q%G3DC+ 17? PKT"/]?AP4CJJEB:5>M!
M")%D[>Y(GA@G'!37)SRK=DRK#AKRSPVSKOI?D:9OZ?;TNT6/;J>B<91A42I@
MY-R62KQ%*57I.'?ZXY1NS(TD0^#M?3$W&^IN,:XI1ZRP3UV\M2#T ?5DQ"%(
M]4"_!Q$K(CT* \'&M,4[QLG)@GV))53 >2'BD\2)=>;C*QFKK+8W<*+J#H="
M_HZBVW[X$S#)^D29Q-@-DZH^'2*<RWZRXH@.'1M>[7BW)HAS,^\2#<BOIUN&
M-P7'!W0D.[%0\@["VV]3@3OC;:8X0;[BVAQVGU"/NLXC:^/EM. 7&I?\[="@
M/BTO\!P5P*EU@UZIE:QAP=%0M7"NORGG!?KSI_>8O0\DRP/I'-RO1(TXS)2>
M3B*8R<8$P3XP U)3HP3N,4_R[R>&H<H6H:81^=,WNE9Z:K/Z];^_A^@X+.T,
MG:B'9&!W8[)[.UB*4B:P;IGN_D_.U%UE>=2-87*PU;AUGHXQ+%O](IO1'"#<
ML3V/'6:CT<K:D2[P3IZW\;@F%3CG*6(\7U48\V/>Y=Q.ZZN?:A=QDU;N_6R\
M4(/QM50L8W0#A6,?LQA=,U*V7NXF[SJUTY/:,"P\/OCJAZFOU.=2.<%SW\1X
MVLZ>J(78]U(!X)0CQ!^;&E4?$6R'[XA[%D!LF*K$MIYP;7DS!)]/WE=8?*TC
M?5^#4?SQ3&@Y2:W[E(ZD\X4$?UA=AQ^)?7;0VG"B^O(NGYSST[0B5TL^<-O.
MP L/^F@\(I7LBD.@"_M:;B+"N4 LFI+%=O,+>I>3<W8MOX+5I3($(U-X[EJ(
M5.4W_#E<A=>!8W!X9+<P!Z:!;2?"V#$Y</B>F;3UCC4OD[@LW<K5<@N3%W<_
MQ60XE=\YRV7ZO]C,3!A_@NI$R=D*:/O3_BUCRLUYZP1R$$G,F[!%_$W0B_1=
M>C"] Q/L*O<(:[NUK[*C)ZQWLRG/CS+=?T?L<O6W+; 95)QD4 ;5(L43P+V\
MP8TS5J<WIC%3<LXO;Y+8Y:Y&5JQ$8,<R^D.NEME".2<KX=Y:^M@>+Y[2^\WX
M=%+@LSL0S8?RZ9 ;A":W*;&J%V$FC#\6-4ES@808S%)7J_&EN3Q1+&.<MD((
M1)]P\VVOFTQ]\T!.Q\%W$\U>K1MAN6ZMS,/A6.WX$PC4'L0&E?Q$^FR@J?$Q
MHB8PV;4> XAZSU5_48(L9/WT2RZL\OY,*: "+E:D2L($IJEWB75+<=TN);[*
MLZGE,+>/G&>%'L>XO=HQ_3$8;RG7+Y249%U*,L;(%V"H )IS@ I<<FMOS'Y$
M$,DLGM7QB&I;SYD<:?^0]*1MM9_-Y0Z[AR@7U!H#9@B)Z5WB)6L4D^0'#.>O
M-L; M>M08I$VG^PK5A3IO2H"AT/C^U+G_;NS$74#?6P\4,4IWP9A2(^=\[?*
M\$(G6UFEA_WJ153 ()8>4SO+?U*HY;WI7!!W_MM!E3*.K;M=DE;*5("#)&:M
M9+^!7OV -E3]2H?[]KUEK:51D#%%BGY5--7J5)K$=L+?E-RFA4WVVNIOB<OT
M]JQP<-@,MN98<EB\VEL[3R_YQ\U@5>^>0&J:K=\W&2)CSP[3?O?I6?R?U+)-
M7KO&@B>E\_,.2XL_)HS]I/4^[VED9+E=3C=VF!F!J5!R8)?)YB1_/!7H/+U,
MT$84>RYRV%2Y3P;LB^]O_FVLX:I-RYP\7VA[YN'FP]B$'2K@U;Z/R6M*K"0+
M.VL&!Q8OD(K_:N$\T@R$T],'O/ZI582>G1\2RLC8!FZW2'V*9/K/F,Q[4BR!
MLP?!!!4K"T'TY;2CX@MLJHYVY3\P*3WG8BU^??DLO7@NTU$J48_R5:'#"YXJ
MRA[ K"4<T''.(\O$8</8G_/:]N:/BM\/+G1:\;N:*-%?S+@C^L04?!'ZD%*/
MDB-]P ;WPMF@3'CY9*RC(*;M'V]T2H-LP@QGV0O\_*>6I^4INKM?"\3H^8_!
MQ&>DG>+3<=%S9!!N1V)N^]-DVG3X+4%_>V-!KG1-W!O^1VS/=7;OB!3\9[N3
M Z(/ O00S#&E"5!!_W#M/!_D1I/ TZ:@3OZK!H52/YIQZB[3+=^EZ"6[%T6;
M\(BX@&36T9KZ"5E,[<LFL[2/NB/+GQK*_I,K_?]K7T2%2.__#_;>/1RJM?\?
M7S:EJ"8YA3(=A$@JQR3384N2IE(),94D21(R,695<@@1BB(F(<EADE-RF)Q)
M<C['&(><F7%<8V;6_-:T]WZ>)^W]?)[G=WT^U_/Y7-?WCW5=FZR9M>[[?;_>
MK]?K_;[OG2_9P[&U--:</.NIV6"4T#@S0W6Z><)0I+R@W>^C[*L[6J_)-=3[
MF+7$G5 G++2?UHGQ:XFP$GZ;3Z^I&8_PVE1HZ]_Q->7EYALOO&]/I1B)A#S2
M+A<<7J[]8LG+T,#I?<+_ <ZZ5-5?=W,LU&<D;>OG$F7L>&PZU-G.4ZA&Q.5\
MY9$=11T?16)Z3,O0[[YN=>0"2^0YKS8]D%",2V]L%@&$7ABL OA?*4\*3=4*
MP%^(XG14.2A#P#;*-<F4QFP/4LP2BW&UO[%92+)ZWPOR,IWT%Z@0RH6]%RM*
MB+LY;QVR[/U2T\8(^LYNMVS/+[LCDY*K !UJ^8(?[$[B D4:L[7B[*T(Y0-'
M"Q7K\S>Z]CD<,R9.3!O5.2CL-+HMJT([GR(R1^M[S&F<QZ9Z\C%*X.7S])R^
MG.#M^99ON(##D'MYK%#1&TTO<.Y44\@-(/K6HXHKPB&!@;;: AZU=PFHEP0-
M>E 8#5QEQ[!SEXWXI;.CXV!T^HMYW5!#N; JN; :@*#&X(>%3C#<:,$^US6X
M@!CQTX=67Q>/6[^&<X'CK>T7#ET6>D%*#S+<X#J)(UR9KSC5,$86NGVY5RSJ
MLG/.3:] 6 -B(*.VNQ ZW*T#/7"T[\7)&#+V69DQ.W21G'Y1<8JF<*7BRML2
MSDO[62Y0#$XI7Z'.#J#@.YE\J?]Y,?/;96BD#Q#0O5CF455O<.P@..B,LR$<
MSF3HQ?;L=>\L<FMQMPVPR0A13Z[9;V11<L.@LF%EZA-!*2:V(2MJ?Z/%6<O3
MF:,'WRC=-B*<Q^DJ8!0)URL4 N>3Q_>A0]$(];0/[C"=<RYH5B>M)CA";J^A
M..,=#_+W)@Q-[ZU?X[ AV?!BR'GEI;L?W=B+)S>3A'#&;_ X@X+W#O.2FC=J
M-@/ MLKX1WJ)6<0K2-"<4B?)@L5:?1:MD E-.Q\U>):O+^LL%\BJ=@Q<HG!K
M3))#Q>:-XQ)D^;E "+J$,K<JAPO4&^V3R?PO?)7_L<LG/+*)CQF'!,F1;&A(
M3QKZ9C% =V-OC?.PGG,6JN*D1S,<OCKE<*Y[<+ZZD>O)R[E 97(<V/H8LZ!B
M/QT!"T6P=H\LN)7@UK%/.#XHW)S;D*9Z[0"D:8!IKY\(57PODR?RS67$?L8>
MB2VEH>^Q%6 .M/SGA=_?KWCUS)87J&H4I.3K1=CQP?%AU@#4YZSZ8$7V!O9.
MN-FO=.G08TI[SB0-])CWY(S.-'X$IS9#;G 1S_7?:C_M"PLE:'U$00?9]NN4
MX\#BF>D4K1UFQ,Z!R0 WC)OL,5"((TM'L_W@]5S@K2L%]C<'NOYC[WK]<>;#
M?>AG5/HI<KM"B3FV)'@=^TI :8Q2&.Y#0?K*N&I0I"'"N8RO$_4D;^(A%9Q<
MQS(=&KS/!?I/UU-&/Z$Y$EG,6B1:C""%OCQ5'^)NQ@P7$)\U(B\U]KBXF:ZV
M/^#LM-R)0#WXRPJ26Q+;?L;Z?_'$7S4_H+8/O00L.IVO2A\'+W,!:7N18=X\
MW9\?U\%K77W$!>P<6+\>.02V6%?W#8_CKD$H^%=P%1=HTZ%^[].30L;B-.<I
MO*Z3+<Y(+(-F)'%^*DZ)Y:[8[*_B2I?]U^BFPKBO?1.LV6^%T_].%+R:B'TC
M4_WZFHI-[OLGYW.\5X0:;BQ^>3?4<"_PRZ/LKS&/'BD_X0+>R;P-&5(S)/:*
M8+:]3!EE3:9][2KJP5A\M7YZ<[>NQ3EC9YE-6DF"N]'>%T=-CK KMJ6[;(H:
M/-9]9>:8(CF"0I.# EIAB7EDAK5!J/F"/564*'?%_57(93VY*UJ]L(E(3/.&
M*^,+A :TZMW:X7,G*XJ5)E01<JI6$7/[2.2W)[O!?@H[9'96?H1)P$?U;E?C
M L)@,?@<P[[Z@0OXQ&@WNQ2<',%*$0SHW](OU3OX[#&[>,A,K>E1<N?>T;/6
M&^7#C#VIWUQ.UB2=B@P(,!WYZL %$F0'%NIGTDQ@B40O+C!DVX#E%!K &HFQ
M4(8!8^=3.YWHM+C^\6EBS:ZJC-WE-_!?4/WV2:?N1S].<P\A'W$,WV6\$*5^
M0O_J];^"/0*+=9Y]G*%53!4<<BM<VT1Y-Y'F&+BKJE]_>_]46]\:9;Y*\:D(
M-I)RRR@+,EA8.!4#-7LBV+?D%P2X!4MP<Z*8A:W)-'?6B@S4H5?KC]PP7D"?
MCJA/T!$ZZ7]M#@M=0P609C1);$ESD/$&0WNKMQVLZP#IEG9<H#RY?(AL.O(4
M[,?=W(MY4P?KS\M6<8&5=QG.L$\C0CA&L;"& 5M3L*SV;U^-[Q+S-$&Q R;V
MSUY%5Q;VM2_ZR"0,C5RXG0O4=5"A[9E<H.]TW^,3LT<Q4ZJYPB--F!#/BA%J
M$6[U55EER)3F:7WJ/>M,W.V+85C-,N,) X6K=P1[E'/(VISGR#+WA53AHG10
M:<:?#;\[D2271Q(Y;7[3Z/T)??&01R?TQ8#%EXEY].$K_--&L- SUNDKYHDE
MF'7L]5AA*&;OY8ZYTNRL+?X/5;*KQ"JN=4[7C;,H>.MNRB%=!2ZP*>TA%[ Z
MCLQO%OD)IB=%"IVN&D 9G3_&!1K>CXY0_C'37.$W]U=\\<O_ENM10_T^=!2&
M?EI5FF#GZ&.E06=342[-$&:P;1>4>76G9S(8);ID2A<19Z-$[*SG[GER'8D/
M>9]@&I4E:(&\<@*R]'J2*5.78G9Q 7+!'BY@M(G\FB"(# O&%QQ;CW#=E^%W
MM*Z\] <4_^(Z-EO%-N<"H=:]M:PEEN!0>-J[7$P ;NHHP8P+G$\F<]8T/\'>
M?0X%]]36DZ(>G] G7N[,90_+3Q2'_1+N;RK>]A@A'6V6WIX&+ 3/4AF)#0BN
MV[=6/YE5&-L#YY23)MJYP+C[[#O*_&L"%]@\_-Z!,JX#8JI(9Y!8F/<=+_H+
MPB;XB4(_CF&NUD6@X )RO8PLE"!_ 'M>@%,;\+9PL2T"G!H$%9S38RZ0I_IL
M3LJ1]0'1. 5>S7^H'<Q)+F"+86XL%$:P\AKN4\&F?.J<,_*N,CT4UM(R=G*#
M\C3RZF41R1A,*MO0W5OLQ-EG?^K!;$Q /FTWI2>)FJ558FG24_L01G7:3RJ4
MRGAT\F^/F).Y$W<M_1CH;CU5._&%.)]CI3R#^L>$Q12$A7)HGK+H-E:Y]#L[
MS:UOLB9(40/9^W?7-.T;8.0EKG<W;>T614#!]! RD8K@C'G=TJS_+@=IBXH8
MGRPM+W7/YB;30<JX<Y^CR!7JNBP/2PRN:<PA?*U0B<-MN2MJTJ$'?#Y6D:61
M=/"D=W)!.HO"7FN,#(]I@9'BD[-;DR8\7*9RF^Z1- ='KT^Z:WFT]D>PMY$E
MP;KF5"[04^P(*P5#9E8(?,0F([%9=)_*/FW/"< ,JL-5$=/HU+R"H:Y)7"B.
M_B[?D@L</(-05J_E% B!-1M\'NR3BL3J4E&0<0J\6,NLX(2I?L-8N-VJC.^:
MC&2'_?1(1O2*7K1_6J$<9"Z5;YQBM"(R]8WN3=RG3Y\N']\ODRL@VO+*3+U/
M@ED9?EJ[K-!Z5LE?G_4RO!!/O_?O+-#0<'^ C63&>TGLD] 3A>)@:4@'ZWW3
M@#Z&37S+:)V+MS%:_O(&Q;8S[QG&;;Y@=$;X1TXW, DI#;*?H0,IHY,\/*I,
M'D'_N'Y?K.SX1WF^5;$&4!&+\DV5\4U%_N-QYG=H?/+OKM!+\YCG WG()S[Z
M_KJ%\1Q?L 5JY'1B.&2<2FL3Z>WD E4:S$.64-9HRR<NT!T[S0Y^1:,PI1J8
M\-&%=_Z*Y *,XU^Y"'JG>6UIR'O<I9%8RTD<L69ZEB>2<I;PY A_">;WK':5
M%9C(:2?4OJT&N^J0M3XF^_IWL.=;0.@^%ZA:2<=QO"["IX?%OW&!#!+[$74)
M0HDT50>L0G"1K?"V C,FQ['7J G!J=+*[X"54BMB?P-O7[(00[XUNCZ-Y*#R
M-6T\Z\ FB8O'M-<*1C(QO?/CHV\@P=+NY72T+RQ#$B>8,I0J;G2+YS27J[/<
M!)(BG41.;!0J3=OQ1EBB?!??W'KQ+WC!LE"HL_B6>>:"3?F#VQOQ:9F=B0:A
M+5>ZXD)W51[);CTC\[@G4*3E@\[?4-.X*8MYEW4-K@>ELB@2^)W7U%4L:#DE
MVOEV2T/$^W-6.H!I1]_MRJ =WM3VIG#I#=;CZ7)JXP( <0%8J(@+R!LAT<QI
MI,RDZ2PD_P 4IO_\W_];F2__M.-<-1)8S%2P51CDB&7UBB.I)AO'CJBQA]__
MEE]6D^MOD";H,P;=%\"[J'TO_953AK_'P0A1#)G!X_0(CG<J9N9FJXHEMIC$
M5))=@V!M5B(<9/Z)3.^W->T)66B@N'ANM9.<"$Y0(5XA$OY:1^)DB&V8[*7)
MK-VC[K,Q,1T^<;T>G<H6H##^DEU>:MJWD&>7\NSO2EUN.ZL:NG9-?5#M([ZY
M0W;V YAVA1-0ULO1[$)9B,Q8VEJNMZ7)Q4ZCP$C?8NW%B'W6ZD8"A\XR\MSS
MGQV@; WLZ1/@F/T&C#;XL-(%C)>+1:JU5?.V&4OY9K=:S]?GY%:7[C5KNR/8
MU)+ZG9BO]X5%*8&X#+#$>'\'5GBT<(N6='30V):ZAR]/GYE\2-[ !>[6";;K
M\4,D&LK?_%JDKU<^-A[_\I/"5#_I<$'0P G*A[*U/1S[UUVXF!B9ADQ<.Q46
MRGV%QQ29&Q=ZT2CKH%^KW.*'ZU,T0[#2V TAF_BO,FR"'Z^Z!)J0\O*=)2@8
MKZS7^2H:J90'L@VG&U\5"'R,6'(X\#W CDV/08GQ+6DM!87;H9':HK#1EIW0
MNZEV\H;Z#E?6T4=I8Y6B:?59N7-ID90=Q-4$50:JF (IV?JFL"W[A$GKH#@3
M>G1Y4M+5Z=)-!]7OV4SU[CM6&6)]/+F"*+A_P54N8$WXY65QR:)W%/G[<9#2
M)/N9PE^#&1E1$CUO6EOFT>F8P)-[_.*=W1(OG"[",)B2%W"G\#]*'N!Z_>]@
M,(#H)<H5U$JVH)=A5.D)JT\?PHX\\@S:T"\F9+%[,YI@&@&6E.A)@[5IN5S@
M3A("_ZTH9%:VHQG*=$'.K0*$KUX@WT^>>)<?)1Q87)YEU$6=UKUV:'N"4MK.
M-I91G]:X_0N"P8>& 7IKL.[IGE\S#26NC,T4*>9N,[63.R<OU--'[M881-/S
MMN_D EM&*]"0'!>8^,1L\%]0NJTO=&(@>$"2&>=S]EE5%YR8-PRNSV(]-#H1
MA-!C@X"4,>OSVR8VOE73'?UBE-@A6;V9_V%-4PN9O1WAXD/Y4!\7$"!QVG&[
MZRUTLP/<<(_!2F^_2.HL(GPF)WTQ.0KW=&5ZQC&&+:Z.(OBXDSFKMC1?WW9:
MCK3][)I79X:6K<<>&>8"-!II!1<8;#W'!3XBT-L[.GW5?SJQI&VWEH)'M/#Z
MTW+!'9-">/_.,EBR06-TXZ;VD? ;W1^WK+VPSF_]?MGW%\QGBPG+^GK $BI+
M$F'U'/F@O#C<TZ8C:DZ6M2\"\DTD%J>3%E,%ACUL&!R &1-W19B7>>X(846%
M"%MJ06WZ)I(;/L<,3C_/N: O=G(U#]%-?TPH Q\6PN80>6K1AYV_Q@7F"MS;
M<:PF/3!DYJL60@!U<']PO\1QVO\^[H?6AALQV:N\67J0?W7Q0LX=@EF?R1N[
M;[QY6-_8,"+GEU=^\OB7W7NP:XO$&8,EZ [1'MLBZFK(RXH>,<9D>!UMU7@?
MN3Q+]'(C5N#7_OA5TV&KA^=OX-?1E<=0'0>P'?H$AT1RD0QV^7HT:^^Q6.=>
M_8T=H*;QZ_NR^\[)&L@4C'XB4#OGX=N$;6S>R@ 6,',6C*5/>H/O%*YI5M^K
M?+Q>/<KOLN:<=&:-QM<C"B%.:NG;&M8LOUCZ/"S4O37%E,1>%EQ^@[VUKJ)4
M>SR.D33=><IBQTNT>NW&S_@^NY/Q'B)6=__&#='+P2)3L-\,VL(%K&=)\)W9
MV<$R,@I*+L.@LAQ4BZRVX);A8VCBUV83LRQ"KA7=W69]P>?3O=VSJ1SKD@6<
MG\229O7.O8;G'QD)=5NDO-1:+^7&[R,;%UE7!A"WP5]CU!GSOFR%WF!?*VU.
MPGB^1[+9N8Z 6L$*VJ4,.QF7F\F>L=: PPIRB7.@A^E8Q(_^$((F2PXUP$H&
M-%#6RI*PF^Y**7'VL![ ?Q"1G"M]7BJV$T5YMLMW@%78O&!/PS#%71P7IGR1
MR$@%[/],8?[_O/B8.=\/NR"T4$:]>88+0VB."W2JPD;?LKC .14N,'.RU<]T
MZ#UV'N^^>7('Y:/O"R2Z6UR\>6/LBA$"^U_CC>#B%M+";OOPM$0:EOT$M1QL
M,T<8DX&*C2ET4RV9?IACA_N@]S@S8-Z@(9RBCM'[*^ZE'1S8*JN6!=F2,25M
MXUL8B8\?O%*!/O]R)L1T%_A.+%WAK?B4>H?C^+"SW$TCA>)G5IL_:.+;_=''
M;]&)3V9KRQU],?1L6&HT!@4W?Z@7/?-P@P=+7EE74>[01=\,AY."+86B4!AK
M%5L*TD\:,G<, *^@UE]9B,G5Z;3+WF7/EYA[RV9_EKBPM;/BUT.[U]4)4H@U
M;^%Z9$#$TT":2Q5-[:51W#F-I_1*(*LRAOHM;,/.8HF*Z]C7Y"3[ 7)[XMP!
M^N38-,/V;--,,!KR+5WPG=O_[D,C8?]->?Q)L[C0W6%WO>4%STTM%W ]J3QB
M_IUK*?<'=S;V8!_"&\X1U* '].[B]?9E%-1LR.NT /5J5&=JU2&70[K7NZ0#
MU^Q:GW<'U3)S7+ 4D\$[C/,!58)B'VW0-U^&X3>@3ZW?<U!:WOM%M7N$<_*:
M@Y\L]_79?U;+ EON!NWRG)ZS9K26X?QDA9H<"[?CI5L_ZK!UO/;;)W8<W6+F
M</]$R-9-!OUYAPO ^TY69?H P3>-(,V(IK+%\DJH:R[6O7(4L,#OSQS.<MKF
M(='#A(*OCS.9K2_[(A=PO0IW79!'Z5[22E!(-G26>);286CCM.7YR]U/UIU_
M?&V=)DI0O*%! R"BX:_4C+V^'Y\2C*QI7,"G6R^B9 YU=1.C.[D7C3GF,+#K
M%74L.2PWT'J^X(9G\ES8(@=9&!8B6;^\K:>9BY9U_-9"Z$1#69>'.,]7E&HQ
M/1B/* 6L ON9^1]NNL)_ZW>Q@WI Z4F@3@G_D%*IT%8W]CTVDN8MR>#,6GN:
M$@>'L)T;OLGL]NFSM7T[$#XX=&SU;WQRZUX?8AE;D+<UACX/EXUCN(!A7-K@
M^S29'@S[$1?PI<RIVB%?:KS>;6\94<8""IVU;2VA'6A=E&P^?.J'5<"JG0Q;
MSKTTRHR1J0KV[K.+&"_,(>)U9&$QP[["SN%C2&0<^+XH%B4;0@[N)+&$,DJP
M@\=)<"O90ID+N/O63NE%^2#H8FLTR%0;^:3XLG"&D_]7E@B/A/,L%$$?<$P>
MG#$Q+6Z>Q[+%$/Z"0O)PVU$DL[\B>R=/["+-VTSKE2 (X+9?7\STK?L?M6+!
M$=S8(!>0TRH"YU8&,$WC3:/@+^#408(DDF';*$_<]8GV..C=K.W@+.6!ZG%D
M$$4W\/BX:FF%"6[5U41]D?7GS8]<\ZY8H& N3,V#&7E2Y)K:Y7 K;BD7N$P1
MQ7<;XTJYP)I\FSX5JYJ+S>IH"?.W>48SESG%B@\WWT>&H[@,+^-A^G5AIGL+
M0[#<R%-&G^$VIQGPRLZ)>K5EIUF)>J-ZPY%PVOHZYGGFFO O$P%WU"+'9FN%
MVT<N6KQ.W7:QY1=TQHAH>WRM*!<0=JX"^NX8-!T77,+:.A*SLX5B2_J%BI_J
M'FDL,QD>:77"*:L4LRNJIP\ZYU=D[/&Y>>QVC7NS,P9%. OOHF<5<$IW=N(,
MU.=,WQXHZPL:61ZSO/ELX),UAR"Y%8$N:9'_ &_Q5P%V'*(M8PE[(3M':X0\
MB5H0+)NVPQNJ;MM\@U9FO>[HWO;T>&^KC,_F4I))),> 3F+[?]#ZOMOR90N"
MFSVO%R+&9KI%& .I]\TW0-]4KQ$;A@7NL28/6*@^I(SLI"80(R LK&\I ^?'
M<H%Z^WW23?^-=3"B ]P.3N$TR NT[]9;_H$"RF*)M;!=E-,MZ\?ZK$K?.(3<
MY!J]D1<VB^730'(29(+PT8/%N#D)A+755YN=AM<%CK#78,Q->5IJ$Z=^)H%<
M@ZK]*TM#@!R&N3J)),0UVP@'G7M!7]+*?&6&O.6Q9;%1K+,I[C'/Y'!.X_W.
MP=MZ-)L[3L_+NCF-H3._Q#DDLF6:&YA@G89P\DKYD6O>+%TMM[?F59J]RTRD
MCWY!7<R=3YLLAL4;="5?6MCIB-_7N1Y]/=;ZWI*/ + +>_*&3BA6C&]:8:RL
MAPL$Z6V'NLAL,ZCJ0B)>7T;?DO\PO3 :$_4.HWUTJG+_A>B2>X8*3K0#@1P[
MJPMZ']31'3+&=0[R5$D_=>&:(W.-1,(S%=NLH*T'N #J:<ZNK7M1H84^!7H_
MIL6#1H>;^)B6"%W ,B)*$AO9#B\JZ%YG@BMZ+=80-ZZ7V'GEE/I1DW&/G$L5
MK'R'T3)BY*+R"]&#5W2%M?#%CMZP!H2G"KOBV?(9;1BVPE+'F5W%9^.%<VQ/
M]E6SNNQG-O\__/Q?BY_?5#M"^WH3B]$2;4C(6=(J"4Z_#(_&0V$E*]]CG1S6
MA1HM*5UR>WJSG<U)X%H*R:5/>7J S!8KZ9TO$RZCUY;4ML^;!)1I*5099IEM
ML?>XO%GVDM>G?;\\%\U]?%Z:(V7A%SDP7NI_6=],6I===/;M28-8)6I(FF0I
M&ETH#6'+A&D%MA4QZ(;9.6WX2U[3Q:#SQW8(A??T!!7<5$1"@%\//8(6AL6'
M9&5;7 ^FV;\MGQZ)C-FQG2P?\NK]HQ4KE(TV]]TM5RY\E;ST^,=[RRHW)^C\
M/<;M39*D[V#TP)XW9RC+(WI0#VVR<,@8%]>P''PCZV5PX\&S]4N[@KNY0'(%
MCE9QE57QC[81) D+Q;(T"-J-Q"509V\6Q7=S<$6.9/8OEKC:".?+5V(Q\N.4
MD8^XO(["A1\@]8[&ZW]2._AW+W8GYQT21(7VN-GB[PL/[^T!CD<@*,?38FD2
MWVE,J?+,.056_EZ1^:>XGH-UR'VC.@=XB^P#R1LS=4H742H7[+&<=5G5IB;T
M1/B([WW*F JR+N+"WR6S=TLU0W+$3'(7^HBY/BMNV @7B2;]E3&^5E:'?CV"
M(5JTT.JC\5ZO,7ZD)=3L:]ES49DD$Z^VZ4<>JU<2^,AP#9A=4;*GN:Y0AGTI
MAX&ZO_I^!LDL?*.;@.<OE9>]:S\! V<'ZUS(=5@)?&1KT8+R2$2[1$B-P,GW
M&Y:U&(:JC&'U+5D/QO@T^BF9\^-V-$J[[['ZI0GQ(]T*K5DY3US&40=]:W*C
MK8&JC54TR9LKIH@7[MS^N!0]%LS:B??MJ9BK]8<WXS\XRK*QK2^#A+LNVDDU
M=+0OM\F^\U9 OO?L\^V'K;3%9[SQX%@GZ\P5=*9#UICF@D0> KZKS52C-!_T
M[E%SW//K85D7@_B0>P="=PL$W@TAW?@Q6X0D77F!JJ% 2A'C-CU[R-[=FI!\
MZ%4,_?FVN36/-1/'.G]-/X9]EL?R:DPE>BVN72-HM^1<!7OGOV1SZ\DC^3T"
MK%3]B)[MF.<"^WT*UY#SP)^@<Y;@Q2F6)4_;UEAC HO]%<FQV@=^>]KX.2F6
M)!T-'_Y'/R.F][WC'2XP=1"611ZL()$+#*N[?IT7AQP<>XV:23B4M_ Y4AF9
M*:^W#4FPIUOA!U='E<,@1,#)5921YH0^( E6Y5R6WE(;/W@%1XJ9B^#1-ZPS
M\XO%6P28EWV7(2/8-C>.XT-,5P87Z)B=ZO(T_+WBQ<H&658%U\B<$32F<N&Z
M#!<(B58E]=<F([>Q&N?H?V6_#N @133;3U8*>:1GR ,8XX1-NS _&Q_O/X%=
M$9]9*W(X74C86A6->/^AWI/ 'UUS*\=%OCK".WJKFTFD%EBN !F_E*,\LH 2
M@3BW$7+EJ]5"6<WFCU4-+$M(RFS5W?9N[82JPT')((O+19R9HPV$Q#WAA]8[
MX:(Z4*7D]LG3[YM0@1C;8%E\=>^M]-==5E;">;=UJRZ'N[GN9]7M.VUC)9I%
M).$#2F-VXP)WV)D?[5 AWQMSP<^N/S'A4AU0<^"VE=V)BW?T=WG+6"LX&>P>
M\]B%?A I62YLZ7:0KN _,<,%1-HB<CR&7)Z=/7O.6VY;M;K%KN4"<:L/#QF8
M _70DK@1:50Q>D7;B+MNX?H8Y6L5+VMN72<=NY^^TT(]<3+3Z?$!9[;VH/B0
MZR")3W=_KZ,H0:E^DG!I+A2?(/<ALRFF7&W=2EW)71_+Q)[??<IJC:W[F^5T
MN"GSN. W7[:XJA7$5"C!K1MNA67H\> 2_?'@]EE\_*.1S[^&B'\M=+*Z_ E!
M6!8EFACX XW$*2$,XBRFOXJ T!#<!S?X21GN-/[?)9I';_^R(A2851 #%I14
M,\NXP%Y1>$',\Y4J<X0T7Y?@8J#K$5I_XF\_!UUZ]"@M%1ZND3SX+: ]](2^
MV*=_UOR)T>0"URA,U<A6SHWO_6)6&ZVHBZT-CN1R>!+UJ^<W26CU#'+7AR^/
M>.&ZV+:XV=S$ZVH,C:6ILH3-P:&!E#=<8-4A5^)R=*HRS\,((0XMG&S]YCOX
M5^7=I8Y^F<(H\2LZ00_?6*2V1+^VJ+)WYG?!=QUY1WHM7[B68?N1VD&AH8)3
M9TD^L!Q]LK1+J;C<4^L(%[B?OZ1I6ZI<J-9.W6?[MRZ5DVF?+NJYU-K,!3(-
MGG(!P=GW<2V3NEIS#U14J&<:)SI:/,YVCXBY&9ZZ=U]9Z_.RR7,^28RT"MI$
M+"UX%71K\ !C^Y/;:A9Z24GX-MV6-^D9S^3MP@UN''BTH[\_V!RHY4029!AI
MHV=S&<'EU#5#\^8!%EFOGM$F5Y6^;*A:_[AJ<U5@Y9CU/KV+8DL'O_4-13(K
MBG2P]\:X@/VOS6ST:SN?42OZDYF%@: 'A'>=,G[7QR2VMJ\>7[.K:M.DDK
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M?<C$;L/[$$**%D;Q^.[1P-:XQ5A+88NK]1J4Y05[Q^RFIU*+VU(+UQIX7+S
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MH\W>M;]R:6%QHZNP@S4VB_(N>GO*Q$4S6LSF)R%K;<RP-_8OI2@1Q=N&ZQ%
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MA@$8*,6B2]#"J1OJ39MH;M?GK1&PGT=]"OZ/D9:?KM^:+92X0,_K&#VZ:WE
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M]9ZG_]FF*D.CWU?K'YO4%S.1M,)<5"!ZZ@@;P:7S410DXSS$WK/RU52 1&?
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M-EB*Z5#MM4KHM5!1/4O_?'-(\E7QT%>+)4OW';M%.V:P- \<(W6$P5XQJ[D
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M$)L)]BRIY0(R*7I9!YFMW<%&+'Y$M[PX0H($*)5SS_^%.^-&3V&B/8<P;]7
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M\2&KOPCZ+YW_O*>)_/5Z_T$DR@21AY!9,\H2:U<A&Z#'T&=HZG1HMMG69=1
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MW__>^:ZW[U)L;^T,+8AN#F[ /:K?39%V07N<BG9-69ZXGI]B;7ZAP7^7PVN
MUAJL!:C]T\MW__F67Q":K$9MZJ8]H"L3T4^T*Z#YN<F[@FQ]D_3FLE^X1ILM
MYDS<#Q$<:E_'5-B1Q;?T'1'P-C8@K2=#J$,3 I\D'7'D^.S6KZ-V:>)/SQR]
M2FD.?]K^\!!"01SGHRY C\*KD_<2T*,JW>?!HIK^Y3HG/"H)N=(V6XIJ'W\4
M"8MGJR!F GR[=IPT4-$F&V\ITXU,Z%,?&5=A\IZQ6K7I2I07 _F1HSMG;EU[
M%J)Z_%JGV"/#Z9MVX]78=A\N0XH+-.8*_-1Z.F_,%W^-?".IEV(\XDU<;PF?
M3I'V1YX^4.]9RDSU3QPMN%I)S8LVT)F?U*2?Q$X<JG0GR#B!BPV5;E0:<;^=
MF3XG=GPL107*\RM,O\N6[O >:45_SZ%CN:])=2'G>LHF]'^^;I98Y"VDO!)_
MWJ$?U'SS5$#1Q.,]H47O*BICOD\>5HAWC3PH^NYP@PTW(-*4^T^IVB:BS7R'
MVBN2@.9AN.&M_([F#*YNJ!&JKE]LU1:2.0YNDK,[34ZCV^&[8VN/4/L(##90
M$D@&9QL3T/+TVQKNV5.7;!7O%<=_ZO92%"HXD<G]^<5]$\-;X%P;$JQ,A./)
MNVFO'G6S]H8*D*4CGH[!/XQ<]/I-<)ZY_BRX"!U1<D;)$O0-\FE\\MA K3KU
M->T>53L&>PQ-$$ OUJFWIND]/!0Y>LO?2O8-(=GC%D]230P;V(DM0G$Q5)/Q
MF":P /W M8"5EA*/P=B[_JJDE2\)][*4[QR[5Y <L>N$KTT]+ZO;@(_YIE;U
MV$.\E^*63F]0?8^_7F]9W_B7,.TOBO<O<.^;U=VU6OU?;BW_O39=KX+4[F$=
M1^I208\8AJ*O30<+Y0?O?1[/6"ZJO=?9: ^V$=^8P$_%I*TO:C-S*,JT^-X9
MJGOCZV'I,2.J<\ )*&CDS?%3R^IGG-%=&BMM#^([[<!Y QQ0;E$VH/95LN+3
MY+D@C7$3.?0!C;-@(8X6JC.T%9$0>J&[IZ>_/\7'BBHX18DV_7C6UCQ66_#@
M>/R;MJM-)U#4J:<Z=N,I$A*;-O%U+][6VJ:D4#\>-]S%>Z''1-S&% ! .[(?
M[203+[R+=XOF&SC/Z;AQY9]?)_E_VO^T_VG_T_ZG_9.:+T:"=101B,>$K:E+
M(G+)A7X%XE85FNI'ET_R7L@R[*HIWB46O+D#WN%&9U*+MBP274J8Z<=$HAP5
M[RG44&W*=&I,XQZI(4LRJ6S@Z-?,*N[P5B!4T1CA/%6>%^F#NVWA3C*)<O?_
MX.EHD]WG['D%G77-6%.]Q"F("^16L$-G][V='0J#;&!QB+K<3'M*=_ DR<B=
M\A*VK?Y<4MOKG>-PJ#1=2DI:6\%?1;S:S_>L?($QD@ZY*R2-'B6J/SR5=G!@
M8'U$/FBM]:4 XK:]'BW<>^K58R^IT]Z"X?JJLRJ HVH#TFKK\GQP:HM%2 -&
M0(_?ERH)H]"-!WT.]N^UZ%T\Y"_XJ;RKX)72J*&J]"F=/<*^@00,63$(B[P$
M$:H-Q7=AHE"Z2:WEJJH.ZEGU)?V%_6%DK_LQF2/\&UFW;+F5]TEEB/B^J_<;
M@'AB)>D%;?6'*4M-L @RZ3-#':DYX63?O_9Y];56]2XI,E%--E[U0\EOW;,R
M4<J*^NJ-;&!41R0Z=?(XA55(J%D"(6::#)UL*&NK7S3L)\R-CU[)ZSKJS=4L
MZ!;W, V@W5'].16!+H]J0<=-<O?IW2# '@9*IDF\DRO,>]UJ>Z\T(N#<Q1/3
M]W/KE@BL.B)8%!'DHV=!""<(67;,CWKB$E8C0#]]3D!2,9>',X33_]GEB/^)
M3>0YSIO[SJ0Z\VW68*6(H':+*J1B;62&!UT2Q0;<OX^]H0[IV54P'*GN"0SE
M7'L+/)3+"4%;=K@X/G8-_C[GXT[)_<UEUCY*U#!0H1.]AI+<C)%A@/(1YJVG
MXA_D7B/[)TD)/G#JC),^\\ZW4^<XC^A<^-,+V/WA>)_VN@-M^C*7F)FN7M)*
MNUN#WM//3<Y<O=#0P(?6<@ODIH^>G#<*!):A3V#[T 1O5C.D[(HYWEP]JCKA
MX8/WL]61J3>"4ZWJQB^_\T2V1!XW/W/W;=[I[T%%R7A<K"9N9(68&KOZUM:F
M#ZE-A/*-T#<'/86'W5)&1_;WFT [^05X:H.K] MPT.%NXU[.#P7+,E1[D:;O
M!;#[9&+CH2W5]3[>[K5OP@\VYT[S)!G,JJYUVR%#F(F:4PDL,3HZ:YP>&2I-
M:EJ2JVME%E;<[->DQ;O5E"A=R-5Z:W6BH>+4ZHTT8&.(H/[86P^R98WJUJ&]
METD41719<%B#_Y7]!Q\/^7Z,!BOA345>R'.U=X0NS$U%HLOKHZCF;;8NLJ44
M2(N0-''VC-.WP.8K(Z.'!HX:=3($2=SZEWF]$1B\#B**--.,B]: "[A)/M9<
M8.K[192-'[/]N8-OCX_,*;?<MN[RX $ 6<@&>*@2&,I'),()0GG&!IH""]'>
M4B=_,0NZ-P+=,6L&E_4+IM8F'C1)^\35ZM[Z>&U.@G6X?B79)(&:)7G%ZUKO
M1]YZUW/+YVBR0TGTU[2;0V6P)Y,*U.XF'WE,U&;EDQ&EP=6QB2-:^J<V;W*=
M9UD]DSX2$":@" 1U?/GF3'?;TIK746]9HCM@1&L]U5N@<D8W1P/>'O]D+B"D
MPG?&U^ON1WH@7C.N]4D'7M82Q#/%A_3*IK]N3==BOF$=\0!=H@H7:OTN)'R[
M,^%3-J)U\,"14=TGEV?M7S:5A 49]HF74L))VM%:6%EZ-V&]98G7TT"2GGDC
M,_[2O*/2.[B%$_2V1]+5^WJMH_-=/ZM.MX5^^-:]B"/!N.C-+3KM32(Q OAX
M]19M[/L[\G(#J^<'CMK^AJXE.R6>./6XZN?S/?RK1<D$Z.),* &\!Y'8ACI.
MC6]/,%" #_+G=!?4)3F,.8YFNGYR&LO4W7U2XHRK_3+T4)B!/3-RD0UX.D!N
ML0'>RH<^]5*MA >R;,#-(D!W!0$:59KX%>3F'>C=INM6%[J._SF412EZ7G\X
MA%_/1"UYRW#U$[&_NW)FN9(Q=O*-]XQX*^H;C!=-2#<0H <V@,<@E*?HFT<+
MF%DT6&E0S<_ [M0Z&BG @#KGDOG/#[/\HYHX8:H<U(*.GA3JT:Q3)D ?)<;H
MF1=J]J ]G<U_CLS.?N!/=TM K0L\>R-?ISJS1%>"QI?[[$%UL4X,,LP^PN#:
MOHCJM>F:_F,N0:=B5;45'R3Y)K5+M9EEB-3F8[^H"ZNW<%P-# ]M71IUA,6X
M'*+D%F>X3'9G>.A8S)GO4RL\8)9VZFQ09_'E-\\/AGMC?TR-J)/$N]N[1Z8:
M#4[CXEW[RU6/NGP0//(Y?O2(U%D]/K^CH.M-8?J/8AZ%?/:R\^LSW9,<UGO<
M"G,I[:7L:@;O?S@NG_-72;)3_J[C_P]-91ZV+%+#!HHLV$!&&H/)!AYI#PO9
MT8RHY<].2QH<K8\*S"4;=* =F;MN"6:+/@T.=Y"7HD2&XPOXCR+UWWF."CU/
M>I4^=JDL8?+4TS"!%V>Y7,5-T"/RS[DVE"F)I,0HM/O2,(94V; D>VE3NZ6L
M9D!SX9K$A9ON-=JVU*9$*8%'VCYGNB=VA0P-3^U W^SRD6(#C08,94H449*6
MDI06_R8PE3JLT^SO_2V05I9X+$X\4M1>7'^?+\Q\G@T(ZH&)(J).\-&\"+]K
MYLX5*C?ZBU;I.9\3/3O)SYY_&@V2I<#S,D0:H:-8FA]EJ$%=WMEC4I8>0I7X
MWFTQ6$B^04U\<BS%XMC:!<'S-^YFR43KN5Y9=TJ$3JJILPQ3,&NMD%516-(4
MQ;J &QRS)H.ANTQ1GO%1U?+90 3\5SCS]7(BQGME/9C9L[ZPEF?.!IYZY3%]
MH4P>2]X/_PT6][]3@^Q'X[,GS]!%\Q%]5W[HZ1*&RNA?O(CF5PKF<WN>7WQH
M@E>:"G_J-@NZR/3IQ4W+>+(!YRL;NQ@-G!WY%M63XG+X$332BBX)Z\-J8O8Z
M=$PJ?2X5N/$@0IE?^7Y@XM;TT!SK!1M0Z()N$C&;.S,$_/Z!9>S^KV_/RSCZ
MR,$=O!>9V2Q91$'3;L:Q7H8Q#2OG*:]<DK1NMB7>&70Q,Q:LE25:*8SS[W9D
M*G  V)]6@0T8BE.T&>)P CK<+_&QCD_L4>3!3 =$[DKK*57_(J>Y3SFK^"@>
M/4+@I_UV!>B=J]AZ/]P&WRAZ2(P-_# &'/\K3U+_+VC<RTNL7:$$7+QMA=H'
M.$NYQYNU]QL1KI$S2S&,'78">08.GPS'T6MBF#I_NPA4'X9X*<NB^2P;*"YJ
MWC"#>7JBEP7+.-;[",=ZQP#E_T6<?(<5&78,-8PK<X]A\<Y/2E52B/9EP7$G
MOVB/[3\AFZ6PKUDPE 3390/-30:'T=UJDFR 2X8-Q&(#A9*(Q5=?. :4KIS^
MX#K7EWJT$G)Q8RT+X\CH9P-1CY&6;"#=49VU0YL-2)HR]!2)48R5'C1%"$>O
MGF,#=L7UL""P2S;JA?6670*J$R>NA8W#[$INT:%4.-'JTL9C[3L/#;2=5EKI
M+@P11Z[=L<ZTZDM?,*H^<24F2<X8,44.HL(=Z3);NG1<&TO>W%,K_M!A%][:
MN-KS9=3,\8Q'"+>I(M7:<FI;\HW,V53I7\5Y<X&.\2\_GZ_^? 'YK3CJ:89;
MA^7(Z5F-M(ZL_'=5,%Z&-<6]):+&8 _5.X+XT&/LF'#\>Z/ Z<JLC;L!F,+[
MD')00JT=I1F/CD;>P(_!G2;<#*/]^4IKSWW1K[TK./?T?N'/I?U5C=SAO6'Z
MKC$-%)^XLBDYA+H)]7+JZ62S@;OO^A5>)$#\#X!X-G>+&+S$8E"R#!_J>JL/
MKRG)0MN.DAM!(%]I([N]>POW@WC](*E+:50LI?UR-[FYKVU@/4,DWP,K4LS,
MU2Q8&DVVIIO2X@\=+/E![.<E]%M^TR=][WEMDUCZ+I=8I;8B#"S,VD(D:D7>
MPQT#$CU)$)&)^=$DS0K;W7>>ZJU?>"78DQ'ZG4_X8L)Q#^ZB=Y^[$N.F1,AZ
M5^OW8=H-9*):/@;$RUNX3/CPKRZ;+S%5/P7LBJCA2HX!0L5;D0?IA9G(.Q2U
MO%CDJ2&A[&L6OCRWY]6/6?SX3JFW4XZG5NA_@L?1C:@^3M3N=I'X=-%^VP$_
M' @V5S'ZP$C*0<K[:,O2+]GE0/GC(/DR+K*8G8QR&P1H)[[2.\[2IA 125I'
M-W7O_! HYWZOX3.ID7A9-9&^M'7.D:%*.1;]'A'\75T*$=4J^6/.1:I/[=A5
MT_QK%_FM;TG91-LXC&Q>%PX2XUJ\:M<U)"_)_$CH_5XEF6@ 'H?O@&BS1*&+
M_"E?*R #L3C(U^XJE_KQH1*D*/U9(-6=D!!-##4Z6T>IR M(2$W3WSSQ!:[G
MW=/Q2L'[6N?%3_MN*:QG"-/^62&$I)08@%'-\9SI]"R2S<_8.9WUQV5P]<<4
M>MK7N>#IO;]H 0!9./U&FQD:+\L%RPN&,<*]( LQZ-D#]6J<817H+Y\]P#2M
M8?015?)?8:&S$O_(\H>'WV6E$$_[_KI0/)/[:T<8^)F)L2$STXL-Z!/90'TK
M>%1B:F52?6OQRL]4URJ8*S+FA(H(6<!G8TF223O,^E'!L154])1K@D. L-TP
MYD!<3/C6N3%62"L;"(V!E*GA9FIAZ\-9*=<B.K<D#G]@ SZ<$9@GN*5B:U.5
M"S7/!H8&+AM+W+AM]J>4;EP4.X98*<M$?0<;&"H<8D6)(Z_!BL!2$'<(/\.O
MMO>WWH6AA4-ODDQ%AO-$X\Y8/WAQ9NM=[1)+;HE2R0J&8^C2.(9QZ*336\*G
ME_96^6^'-M)/*?);YY@>+-[(,T:EH)OK#230W18/V "W'1N([^5TH"38P%]Z
MGF"AS)N--+1O]]JN;#9 @;*!#6TZ;E&9\WG)4*];G2^:GR4^B^-C'-+3SY!)
MOEZJ1R+?YP<_<-/#^S:0K[U%!<452-.C^R._C:\?,6[:I9ZY F6(Q;(N51*A
MS) Q]-Q5K1ET6>!C/ZP<$L%,] OU_JYO=.GYG1)S3YW(&*^4@ 31_K@325DJ
MB-.-V/<L#>3A'H/3R#.#>GN))_TTK]F('C-H/9S@?#2&!-_MVYDP8-0"YM$[
M0_39Q]"G:A%J6;T4E?%C28HO>5JH2M!?\3CM+FG2OAFMCCM!PCC\A&0CKM*]
MV7P"9%'> [.AI&.]D&G((SN<E:R=:D,&SH[;O"1IK;9EWO)Y/SSN,-&4*E$I
M6F;=K-!9?7S_\\1S_$7N]O1;60NP/;404FRX+[,R<V3"?O3NTYVU-8_2;_]L
M5UZ'AZ>?*6H*@^A_9"G &$>8Z:P#K&Z:G1HHO@PKBGVDIU'59::5GHT<,RME
M Y?(D\@5-G",]-1)?((U.,G59R#!.,!\@]R?I7KLU3NDT8^CUZ?BOQ8WWZMY
M/1#-FUBEM62@P'R-W$N$)E2+M-:,.641)Z3'%@>WCNT:K9>P,5.*S>J(]3UL
MJ\\M8AB/C9D"K8K$V=;+5 Y]&TYLWIRHQ[G3S,[M?0#X6VR CD3+*.)D?X B
M9G6$7W)PL8O:ZRV=OF\PP-[Y8_JYWWME1AX^E0U=YM/V)]:&T'0I)JD$,%TY
MMY+$%#A;4D5_*/RZ"#9RI]L[/D1V-KE=NOV(S%/>:S57'ZYHO\<6UM[8.D5W
MYVB!E*9Z-,EJJ PF[NEK#%=*,\@Y6"M)HU[LS9;42$RYT%QZT_?IO6!!;Z0\
M79W0_0@B])$A1%BMPAB6KU3D9BJ\&OL:$"@8$&9X-,0O0P1$$6F8BJB<^I3P
M5L!CTSLG%X8X>Z=2^MM7%>^;52$^^K^_MO@XG,_^=*9S-] V;AO5R)0DVK7Y
MC(00A"N]J*:VE$,?)N6CUT"EO8M8&2LUZ9W33\=;MBX/3"R3#&YTW^EY30/1
M Y52)43A\B?**#8M9+UZ4 55KB58,<7U*\8=].2+*[+\>OTP8-<3C,)XY0R/
MC3@:RI6_+8,+'C^?::UIN>/#PQ\ T+":(1(+P;]A T(,7SCE05/:XM3>\AN$
MCG(AIZ^4V#D)<YZ7==7G+K'LWFA#EA"H/.Z?Q'(]\0*XM$BKSQC\"H4!]ASZ
MV-M$@H:S@IUS8QP/,IP/,^"+%S(O[+WI49P_^^'XF2*99AQ_&68'O90H$NMW
M/OU:8)L([[?5P/OAW.8\\I<,STK9J/ %Z<]R_^H&,0[08:'; 3_)H0J=D%$8
MXIS%G:V6/6V1BY/E-18'>U[&3WJDZM/;INZL7)--W$4'TT2I@Q\D(+L\;;MR
M8=<ZT/Z>6A///7T4TV-JGD42[_'+EQNU&/!2VO+P2[L]4] [ZU4\T;NU#GM;
M0Z)4:1NU1^3?'W>MU"U1<^1]&C5N?P@2)LM%:V_FV/11B[S%)4)B9+I:[UW_
M>)TAHXH^]8\'#97VB$7;A&T>/ZT("C,&H-0'1O176--<[6:,E =*W+ZYG#2_
M:71GQSW?TML'+3XW!\\H]E9!AF>(>3$H->2)P7*1?3#/S?3B''JR=8_%[U=>
MTX8Z3A8_"SYXW_5NU(<Z3H^Q^*EXM.J6OAZ<>DA=T-V'H6A&',-^"D*O='D'
MWF4##]TGZ\,HDIPI"B/5*86)47I'LD9G'0^FD1]]_W;JW6;RQ,NUH_?-YCVX
ML_[+,'H![)I:_-O6+M)-C;(H95FN9-A^A@NSKMPGLM)E%V>.S>5#J".(BO,I
M[4T!.K@T+[(LZ[=3-#)G^/>) %X%7E>80 =HN,P.3"EMEX3LKMWK7C OK<F2
M&Q#H\@K-'K]0HE7XU5KSOFD=RLZR\UYSO@*UMV;7GUQB4IA$S$8B280\11")
MA(!K>2G)%AP-1B2V.)9)W\[P\CGOF;51DNUQ<\,IY.WT1M"5B.FXF$V?-(">
MRMHUQ@8.$3+0PT,WV$"Y*EGNKZ(8DNA&)_3TN*;(EO0BA)83FI7#!CI.]+$^
MY[$>'=XQ\+^- 5K+O^'@_G:2BR%Q:50<J4PT)RO0C5SZA;(>;UD4UL].;QAV
M8BZC+[8ET]XGG![!-$PJ7;5*^N85!OR^#']&S&\=Z5K1J_J%N.C5=F7L"QMX
MMJ2)TL)+0,K+T_-VIO<UUBM4/W[#K_!8)TDG+CR&8Z"%+F%6#R!2.=0!O;FF
M*F5(/J#X^OIT\A4&>$-^OC_WP]PZVKNX\O-P3U#/QW0GYL\.$&BR<.C&@K+_
M=AIDC?^G5)H[=>W:T11++'V-XKZU#NG4V=H=@$U@ _A,&'4!W[W^&_W<?^XG
M;LF*52T?"6-1]Y*V4^HM=VR9*W"V1HG G_[%]G0/Y[$NR">S 9@V;%.K8"4!
M9PIQQ6PH!$.9R GT["!6X+3Y_$(_M12&QUZ9F'T70^_[^4> =JGG<_"/'3UF
MGX/_]!_SL[SBKXA04<])40KM?='\NMF-;,^ DLG):V9O/S7OD7SV_4S3A^3V
M'","6,)37H_R_151;L>F/M2D/\/IM7G'@Q*/X5OV-]U!DV&G_E#^HLBN ;(7
MJ4XU@N+J*$6E7H5.GNN]<ZE>WI>O5\?*W[R\D^?$;Y>=OX7,2=U/7.3HMS+8
M@!<]RR;*M)=!+XQH&7MRHH.@>%9LC[D&<-T29&[\0 ?<XB-$3VYUV4\9?%5@
M&%A$1S9IF2M-U ]]L^[YW='^]0.49[6P4/MJZ>#=K-I/U9&T7N>-!V,=<K([
M#/='@9X&!UOR=OXY&*2:$D4,C/AMH-B-W[?V.I#Z6!I-*ZN^(/2K,-,7G(9H
MF_B:513TOC:$RMT\)<!0#27"Q.]\FAT5?W+%-^3>ONP;+U5F@'0S[KQ@8'8V
MWVLF87[GK^CPU@-1MG([%17Z^__V.N_5U*NE2?._!KQ=0UY?=5".<):,=](U
M/SS-75Z<7F-Q"R%"!$75*R/NC+482 [L'_2#1Q^,4>VZ%W#25-$$?Y.[.4ND
M*4Q'Y?]03,S G9F+\WK+3;M/]<=$^$.X$7FM?3#/A>"E#,=V/=^VW]0(Y&>%
MM_%C:?0N0C?Y"$6&8)J@A99"/,";MH;X[+TCNF^O5=43Y[KGYZ^W^_SJ;-(:
MW;&J!  *OK!;K%[8OGIM#C!;J\!0L@A"V!8A@VL&9Y;*I7XCPV4CS<1=O]R:
MB+@V[BY3UX8L8''6H(,-9-WNX^!.#PB=#(2*;('IN(O4]44V0&"BS_>6ZTM>
MJJON3]-5N_U BWAB7G(G^63ZI83.[_<O"X@FQPV5V:6BOKDH4=%Q!L)S.KA$
MI*YDA)Z3?V"^#%E>;+2B!>:L<GAZYK!HI?NOH]#@->D_V#L5@2[?0+CFP9AH
MT:<E:U+[.M[/9HAT@4>OT((ID,6Y+4M41[#RHS)LL>D#(E9GDQ8D6&E7$CL&
MGK38_S-1.0R0.LVMM2E'[<:S7E-G""F%^'C8E0'-$"&SS!,N'GU'M2^XO3HH
M(_4B[,M984-\V@IX%$*[4D>?HV+QN 0RP]@GVXC"!JZR>E(ZG6Q?8$$8GV,#
MUQOV,QNE%)A+=S9/A4% :#B40X=XD;Z^!*9V,T[L8-_JA/?D)%@<D;9JD3VY
M@QNU*'#^VOA3C?U;A; ::;L_$:G]L"08Q3HV]!KRUOMOVNUPCG*[MU0\@D3F
M;Z1>TC7];L*1ZC1S:L,35CC*(5]J?R1?86K_F[OI7,M#;;!1>"L*H,<7>.AX
M%:4>?)L99S*TNZ-7KJ= ]IF"G#UM+H9#GP@EM1S68."HS.+^Q@;:X6G,/,AT
M!3UV <1ZDE!;42\IFM!RKHPD-1> 4GOIOF_3OOI3A-W-J5\A6,8IT_@O7S[]
MX-AHK">:3C9$;UVC=UN6I(^:RXF9:GK)B%<^E]UMREA;QXJ^JT+AHN]\O[MR
MZZW;=)J_2UX^TH#YKM:",M7\;#;M5FZJVD?O9;[J2!-D\9?ITW*A!;EL(+*#
MB@//2H-9W.;;$VORR)$-.""0<N) ND]"#N].&T_%B;^9?A?G6QZP,=5VF>>A
M4>>G22S]GVR 5$X0>\\J1F5M#!8<;YDBW:9^7P$IU15 +%<+(FO[O+QE@>7S
M10U^7P#JQD!U-V>1&6%E2YOKB=MAM,PAK?6>$7#U%:_&4VIB5E?M_RUAAY<C
MMU\HVL4&$F%\:-P#1A:V&'2'OL3:)<X&Y.L%V0!J9L/4)=V!M09>R)SES&E)
MPT#C#X6(ROZBXTQ99@QZ^N$<9&W%GZ-=CKC3"ZL/:-NU3$ <@C?T;8@5?X=2
MFKCN/X\8P5+LWO]>M3)&WEB^82QF"?J**1]*J#4DR#EQ9%E=-_DRV>CDA8I>
ML4FC0_R;-UG^*^N,8U@Y-O!CZ ,:;XB]Q:R$3&L18)N$[41"!Y'?8$(O;0MD
MKSZ_V<L&PE :&-=BL17I9Q$F*:^U1^3RML>B_S@TBR5IEX";A0] * I#DL9!
M./M"QM*2 7KA,VYC2[T.@V!]E3\PH&=%:577@L^5RV#+.]/]R%6?-!YB#%UJ
M$LJ)D!)^-A![ ;.VI;V*]1;?Y!.M/"=$@]SO_'D$[WG1L4:QDPW P1M:F#@,
M[1 <LFFDA0"%H71=4-WH3SX-/KM'9N\CHK&IIKU@:+@\LD#G4XO#=>W?N_A(
M"4%8-/,C>GH0=0(]_.HC&Y@3'%B^S $NAV2V#B=NIB&5.4)=^+@&A5'MVI?B
M82"&$9ZSJ9[4BU*2Z"=;I0>*HB$TH;66RNI+ZTH?#6[X\:O,<+W2^!X:O?DQ
M;2.1QN0L1"!EAM6I'H5;_5"?GB'RK'Z?8UX#>NQU>[U(FG_%CWKE8?68,H\1
M2IYEU'K@TWSE5-6MOH?KIEM:D/;8?2Q=U!!$H%Z:;^]LNH )]3M._D3NV4NG
M-,"TV%172 W&<819I7?2-P]AWH26\/MD4DSI<HQROA=C_BVO>!GKNF\MNFMK
MXV9@-C-F-8!Z"Y>(.CF9J3VU>ZWJV%V'1L$TBZKC#NH,?M'L.3:@!LH!?.L-
MZ)E$D;WSL')(1*TR 2U@/\^2Z3O:4ITS\TI@?K<%_.3%VXB>5^FG!VH_F9PP
MN7=&-K!Q*M%%F_D6C4]G[: F8+,\TG*R+7*&YP+2[O;I]0Y?FH_($?S VW#P
MTX>+E#.%W3OMQ^]@P!"O6-T++L3?)-,^UYA];0X395M//X#>*Z'\2=*XEFXA
M1!>+'XO'"'M*9P?J+$5HP40\1R??V"3!I5C#?%_$PQ22$A]!JCVX%TXQ,PP4
MD4IT)Q+D"5BZ5B-C-LTF3F)YMCHP2OU6=<WGM-LWG1P"#UL=HD4$JG>ENO7
M15IPLF@/:"2'#8P1[6*07 2I6C5/25KD>P)3U>JSETM3%U?ZN<7T2XG2M]Z:
M\(GAT^8AWKC(8#;0"AG)<NRK/7G;7_].TZ\NN\A&8?E9I\M)M?#YG^(5X?UA
MND-<5"?:3WH@R>?AYN\(_%@L;@_#>&CUO5\!A'?,H5/K\.^9)RW6B,Y$-3?W
MKN+33;+N,<#:E#1J&+93CSMG5M+E +4U,J9^?^^[0<W&^^"3HYU5"8;E4-""
MB_:6&&ML4I ZTSPEA AIG1(M+(=&ZZ3DA=Q-"=S5%&3D<DGMN=?9VN:?I#&Y
MA5F11Q !NP8VL(/!3="_,SBX<K4'"7'/[58J5N52NJ?R&93.S6T/+DEL<,(\
MQ/&M8@3HD6H'UIU+ZW'5VL'W7^V].Y0,W6?G9]N9'2/"S2-[\\%9L#9B@:0<
M:; 3W0CU)P>V)D^.S0V!A5Q+XC]J+L3.G"A?O<QUP6I8J+CRJXF.X+*J.HW"
M+*G?A[1DIB#AA,(=;,#IM6W=!1[^0,+8EOWW$1+';498(4#OY5_,I7-LS/-B
M!(;UQ1H]US99#:4?P3!>V;5 -W]ZL8$<#4N^]5:?1!T.D5L3B9H2T>,B;$'W
M,LY1M3"C"E'65? 059G33X-2[81COI5IV.S*4M;S:PPWI*^1<%R,FQ2.Q&+3
M3*/(')-_U"PJJIP-"%J<=++PW1.5-(KX)9,56ON>)[QAWM?ES)8U0MFXM_X,
M4H4>3_JF:_^9[L8&=GY-$W[_P6-H*"4^^Y+#[1BB;9E_<J>WY4IEE>RNQ(9@
M: -$'HFFR((%]+0+D1=3+Z19F"RT>A'K''\U-W^-$;R+W!A1>M;!W<7=IV<)
M"OG ZL7L0]Z@OB8J-^,B48*4R<P@_-9G)-,45ILV.3[V98>.<H=4W/=?EZ[S
M[GJE#\^HI6]0E8G:;2)BB+T$:%2M'BU]]W+AVM0>>CK1OV++C>/O2IU:=_V^
MGQ%7>KP-FC$1M76<#7S!L_IQM-T]N-47"]P-:#%-D1$(*:\M5)$8.DS)C2=.
M(!"IYZB\\[CA)=L+5@?#+HA%))V*0V8O\S>T6PJ76C*QM<:4=8+/$Q]D*%[@
M+83(]ZK0E# F)-_0<==_H>J3UV@GT5CFW8VW+7&YO2*GQ27C# R0M^E"[^;D
MC],+">B=9OCHW_CR 4S3>J5:8!;_](6L%XR?_"= _K9CC_A)^O .B*?Z;GHJ
MK9A^FZ76@Y0,RF><I@3&:3+-+5(ZX;&A1BTZ?G>:?A-Y+$M4XN?=_*Y_U7[V
MB,^7X:^\6$7RXNL^2S%()D+C4(J#QS(J8:!F(AE1@GV9,UWMH'Q /%8F80V?
MO_D#U(.3@WATR]+52:D/ZV40 DW!/M%+2(?L\4FC!V@_BK%'3S6+9FN)]LMW
M2)#TU3T[/8 39""H[1$H74^P .KP[*9XW4ST46]UO3-8!,K3N)#4P&WA3>U:
M.1KS44;AJ7&03_M2M(XR1]/&X/C!PD)#?Y\,(X+0Q<Y?Q$FI8\9QMR\TI%AD
M5*;D7#V)Q\NFGX!?7"%*)&_9L@:F^+U1<M]'E\)1X'@CNP&&A0\W\^EX-^B9
M4+;U&SZDQ&U ?M=*8X9@XLCM&6(2:Q!2=A(>@-HM 1[5"1JR>#'0UU&D2:#=
MN"NM('71:]+Y/4CWOLIZ)!J^D,C/^E+/38_.0XA H[;@K=B,RBC-?2T7C2:=
MFU]>?:K7[O&<T2X5H#>P])AE\*-69,L3]<-%= @;^8(H(CXQ%U@M][;E+FYT
M=WNNJVET<7G%\^M!\R*96%X*E/$2L\CQ9[<><1 \-/ JUVI>-&?1/>E&Q$2N
M:T@32NICN\9ZE<%"OR.PYO7U/9.>VI)*'P]<.<#S+/#Z286V!XO0 9L59?("
M&S@ ;9K:.H+BJ'WOATWO_T.W3DSPGNN06[N\:W./_Y[#@;Q#2V,8XQ0,V9/B
M1O.A:L=BD==((D\,5*FY!7G[RB= K1+6=2V!=QAC9R,U'QU.F&F3?6]IX-8:
M6DI\Z]2^F=IF<?(<I2CSW3#"M?OREG?-L:R\+OT.3Z6;E0D3*5>=/R7<;WTX
M5BXL/+_(,";(",%#\7U^T?[#1%5/=/ZP6GL27==,RE9%Q%(.ZK)=%GHQA)@H
M@1CBD)"V*I*N3+RV?;WVB7:O((R^E]!7W*V5$V83TT'(="C/,GP4_I(>0OQ)
MK8QTZ]_5+CY^9=Q^TDCJH&MUY2O\6Z[5/2;#W7>EYV;_*KYT$6#$LX%'+Q %
M>/&9F'(A<'.P=2/UG<B>43G7E<4'BCJ\,FP @3)J3,S+095YPI:%_G+"R]@N
M@?H&]4-:/5IO*9+&XAKTF[ SIVIE)]'30GC,==_LN&!FJO:6A%VW0&7-_?EL
MF!'Q[Q_!9^=D9XB$X3R[-]0F#VPVLH%WBE@UK/4V8ZA$_)DQX$ZUHN51'UG(
MKVQ@J@ =S>* 5+LCO_X09E%!?X3EL_R>_Q&1]SF]$(D&YTV"V<!3B;=LP(7*
M!F8/E*E"FMG \@[.]ER8A#!Y;"-0&' $N&>5Q3O+ >&V'O_6Q04%,FS[S?QS
M.-)0(V9IG T<7E@T'*W7Y4@A MV.#8=,5;&LAO)2T'6FF[/!9]!;7Z%Q'MME
M,<A_.0K[^ZC,=YV_!^6U1TG,B>#T4W"&^'Q(G9@5;!_RY3;5BB"*\,ZZJ"1)
M:<4?ZK;V,!1]G6][+HRD<-/WARULNR A#P=\%W!P/%X)3;@6-1CSI>_QV_'+
M03=FOZU<Y,<9<;A&! 2/V10OPS"XH90LEAAGVNA9VUXT10C25"/2E-B46IS'
M*/BM//\9O4&KG[X]BP+W(;7=:?K'VH0,QGQ]#DWL. :]\M!1LTRZQT%53?A)
MJ[&CJJ&G1HRC2LQ>,>N>[5H)8L#+?%*$HEJQN+;<MS(WY?ZM_C)++LO"CZH:
M+\\_NKWO!*],(NG*'V-?_&7;V0FTGI]X<>.IR4XMV5,]CNTE^Y*4O@>\BP [
MIL4 %Q/@]D5N(YIF*NZZUXQ$!G/>A<F4"0+'50Z3;T2:/CL0KX2N[<S8NZ8_
M'WR8NPUI0[&[.H2[H\Z#M$C8_*89#SI7WYM7&CJ)3+K<:9,:7V,R>?_!MQ#!
M4]2QMCV'!Y7DQ,6X-JZ66?*8B'E*G(NY:14V+"6U$&[M-ID2 USZS[SL_Q]I
MR,HM:Z0)M7VQC^0$BTF3C/1&^N)#:GA[&>99PV^<1S4O+_D$@4$*_$HFH(2K
M&"MBX!3%09UOP;+9#8^-DC]"58XNP@5ZY7Y..+Z\^U[5N443WQ[XJM:CSRIG
M%2B&OXHUI_@0\'/]TW6??I050BPYVW3,H5VV)/CGHT<>W-',5PQ%HLA.Y/X^
MR=8/S^A8F\_5@VL>;EM/)UR<S>Y1U4N"'D+P2D,?_F[2J/OHQJL&^@CN%HR(
M%TK>L_Y060TU]Q4Q5K*VI\?98E>^:TM2#4*X3L07]D[G7^(']5R<+?:1H4RQ
MC:6D7J9&1$5HPM4E8(C<5N_RST==S;\T"N\,"AMO(+OD?5K%XLIP&WR._Z%;
M.O]C(OY-$R&8*FKT4"E6/MA;X<H?3IR)ZEN+=BT0BI6G"V0WXK!2'&9V'>;W
MC&%EUSX%Q[!"S-A :-K&HNW=3P/7CIF/=;.XMHX9$?JZ3\PCUJ)_SM2_J1PI
MQYU81'6S 0\G='?+]@'V]J$VRG7[1!QU/+0(O4%69M(\MJY.K8Q"MV;90/Q]
MM(_ZQCJ=#308A+/V'\7-GF0#2FR G#AZ^I=9ZOWC_FM7GD')L#.LQM^]2,&X
M&@G(J*1L\;KXZJU0->GTP3=WG!Y0%ONXF:_C"\)__9I.MANEG5F29YREK#>Q
M@5TN]-16QVR=4Q$WQ<9=ON_+#OE+^'5YB>XM\@C$<A^#,;BKV0#)AL/S&R^^
M]EETH_)^NKRG'Q_(!B[&?!AAC1[0/6W'$@.U'1J3CN_"C]Q#R*[-.:4[K"9&
M,*QRZ'W-@]*_8@,J1VT8YT+@+TRL#L@_Y@-(\ZHNM3"2>R+2EX")<(0EUHIF
MU37T?=5)QQ)"%DY4INH$6?89[_ON^ME8-ZSQIX/O&^E?*!Y63UH>68NJ:CU0
MN_=G*^6!<863[<"Q0GOG.YO)'VJ4G)Z,B*DT:"@DC0ON FAH:>0%RE!S:18;
M:#(M,,H6<MW4/]&:9SNFU?]J9/?UXU*??)-T[#B08,L6>01#@C3 )!#>[=.#
MWS[7]=[F_A6Y"=I[MC-$;I;O04_BG94))UI.ZE5FU'5ZGNMKI%F!IZC#Z,AY
M Q]R]$NGHRH[R??:L6>K3HMQ+:1 P/7@^4!IYU/URF5OURQ<2(8EPR6BOJ%\
MR&%+<J-JV71X97BW^*S_LEK\"S:PF)K!^@K;M?JXKXC07VZ4<V?]RIB/^U,G
MO=XNT>Z.;\=^7T:<QIK0+:A-FPMM&$F&(LF3_&X *8JF#1?MC^TT\_,DKGCE
MZ.&K'[^033@1AO?>$:;?&T.?,F+FU2O32PG89NQBX4FSV':8N%;LAM[I5.KQ
MBMXR>\/GSM\_C+Q( >+X"%4Y4&?Y4C/J3"OZ(1L0K]U+P$1/'OS!"")@I9V_
MY-HO! <D^=6\%CI[OC?[A,E!/\1;J_[C^TOX/+CG.CNID.BR;CY$X)6AM8*.
M52;X4D72[^7?EA>;=QUQ?Q#WAI=GJ!5=7DE./I0T*AS_CNY&]([RST7,6$2N
M6%7VN%=4]'L1:\8T=W<6Z?U\=37B<A*?7'RP:>M27 5:&NV&B=^,QT366A&>
MEU(&\[Q_(/(NAO!G'_HV=E]U;U50V^]7?&$&B3_\%T3$/ *DVU+O5Z9Y,?@?
M>-T+BTC1YGH1:7+/4 YN4J_;AU)#U$#I/EL0A@K]/NV4RTDJ+/)Z;;)C/_G;
M5VF+.(F>C>2-_5$O%[]^"/OD/'.&6*:)CH%(&\BQ^F%"*#'ZF#V%#<24J8LZ
MS&M'M9R2=K(?ATX[I8IJ&L _WDW@.IH=*<S')WQ6'T?,(_-35O!93J8D=3''
M.>W4BXY3T/-)OY;]Y2X%4 HN-+A]>"]^A0 EJU&F2+>F:0:B5$V[ZL+JH%)/
M.TL+]R!I=YFO>]^954):)&43X.V0&TQA$=D[8+'Z8PMPB2QB76!KZJ:?]DE@
MV7[8\72DS%7EWXG/7G-+C5=]/P%'U)!2%\>HBB1,F+<W _K>GG&.0BL9U+DT
MN'DH$SXS?D%:HCSI=L4PM5BMC7):^;2R MCEOR@O"Q<!(X_2<$%]3_N)B?</
MU5F_2O?QWS4"/^E)>977JVQ[2#5KW\],_P#3=A7K$SIIC-5:-A")IL\5PF%B
M]8=1_08'2H?<^W\7:9)UC3S57E\J2R ,CI[.@@<F!Z8\X5":]UV!9]PV_;%(
M^[X,^EO)YLR,^;2V'-\<-G#'V5RH6N:P6ES\[I6; 8#$K;O'^!7D3VLU(V)I
MAG0-H=7Z_7TH8821W9 MK$P@2(WT\"!R^FF-M'X+&PBZ]^"+&%</JI.EA&F=
MXD;JOO]2,(]2*$WN3H0.^A>@#]!8WP[Y5:;?A+3U?&"T"#$,) - A4/\%"A1
MO[(U,7+3_0G93[=;J%UIR-8K>^K#T<$2)^<NKP.['Q=Q-PTWSB6\5:WYV_?"
MNK#T(^M1K%..PQ596'KB^6JZA7KT8EMJ]EAS[/#+]Z/7*@3Q42S%?KNYR50V
MH##VQ]O0V%@<OA"W["T-8L8'@+>LZWNV[Y5*_?E>J1C7G7__,EE2F,&.OW7U
M=>;;62F3)HCJ'\&;!W261QECXHR@S=*-%8[S016RE#<X7M\Y+^T/7OJ//K_7
M.F^S=3-QQL+[JH$2"H- L\XZ!C)#VK=YS8^/;$"$#70(0-D %L$&5D4=Q3>1
M*#&T:1]=,J/,RM@AX[]EC+YYBF+)//5[RX7B4%&>AE>K&T3FCQ2OF"8\JC_'
M!AZC;3@_SFN&24=3L",I$4IWJU790&U&'ZH+Q*!"MZ;MNEWOOXC^.+\RRC)=
M#))\DOSEQ":"-])ZNKYV<**R'/. FL429=JQ'E9BU@E_J%9@N@;=Y'-!3VUG
M &:F;BE!5EHA2\],ASF?IEMQ4->!*MRG(0:# <&G;^=0^X!;W8FC0%C]&TLT
MB;+T;CS2MUOPJ1DS\U[ A8C+)W2E-P^]EH7O(8A;HDLTH/.JL[-]-$W2Y2WP
MD]N(F5=N=TBR04'3$S7.%/08FH"-1AU#?4W7H.0]]ILB)^Z&%7ZN*%DA1GT]
MXBOS:4I115 EN4OXQ>4Q4FK;:35B'.N;RP'7&$D(Y85'721DYE=]Q+M*O>8&
M@Y/C2$?Z*TJJ*<=B1M2J!>(+ UNMF8F._<K]A=<8VK?MHV\)R>+J7B4_%G7G
M7;XP9@_A0G'3PVEV]%>0Q[5@MZ"/#(G!PHA1K=95KV,/\]]]Z#C5T9@=>2^3
M=3:@2N_ZK_JW'-(2#I.:Q96"XR&$++[$?,]H<*.^8JNDO$'?,>MY6?-\#H N
M6^9:$7=[._-20^:R+\S=ZJP\_Y81\B15/:%>E<$_Z*>O3:X.C$2:J[$*M3&R
MZ-MA8WHW:#4[-FYS[^2?R;D'J9!<9)*P,@C2Q2&4M..1*JI!&E*&N!!^_^F&
MM/GWI- <(YW??E?N80[91YN"/,37OHEQK4RU^SPV4"P;,-A+[R,4I;KG+X"%
M;Z=-JNT(&ISP\1M[LD?@B>*SA/Y[Q6T=3G$9,W+WRH5 1#!9B!I"*"K (G8M
M$*8>U>[--RNZ6-VZ]K_:^_)XJ-NV[Y&0"B6RFZZ0(DNR1)A*"-588BHQE;(D
M(2HT9HHDB@FA%)-]2Y.LV<:NDEUVQLS8E\Q8QH_9WI_KN:[[OK;G?>_W_3SW
M>]_OYWW^.#^?^:WS.\_S.([O]SC/XSS.PM6!D-7G'<>BTBNBE4P>FSH[WRSF
MA2RL"(AP37(@XH8[^IA7.RL,G#"!WE=D(_#GW3NT2JT=[2\\RI:Z%M@CQR=-
M2;=CI:$4<H!5>B 00\K;VC6_/H(GS3*V*2,/R2TY1P]W[/)YGANWY_H3Z47W
M3M>W0M@[0H_0*E25MCD.A,SB[857@+P]1/\H*R3'SW#!.F@DT*3C[;/3'\S-
M;.2M]]PJ/PO_=I0$S_%;:L)1+=6">T<4J4.RVPNZ*@S>.=B[?B0V^0=D=3Q)
MNI @W5B>=-+6]B[CF4^K\K3G,QR$J4:K$E!8*<B:+JN*.-R6/ELFLQPG&?&T
M;!ZCY/?Y\CMUB0"9W,9C>_&UA'YB'69KA6D.$"<U[UE?I=1-WKTJN1IV1ZRJ
M? ?OT)Z(UT_(PTLWC_%Z3ZESC27<JR.&83YR(/6>$C-((>8!H7K/4$/5;MRE
M3^VCW7OSNPMSIT7MG!]].^ECPA"9/YAVG_*&*.6'(!/G811XJ$4V2B^8Y!)<
MH4BV\!0><I@-2*P<2;ZON6WONT-U-[]E/3+O=T%-\G%#=?K^[RV1YZLG%"'F
MU<BX_DG*^)RC-&"<Q;1[ZDCM28IWNWI]T/6G3U4#TO+"8[ W 136A=G!"=QC
M3%%F.%L$J&LPE.N .1&%%>@E=U5COD73V+55%Y6-N=SEQAM;\WZRK6ZFI#P+
MG 6[F=X V#/4_>+JX+3AD>2,&<FBK"1^C\)^%S,G4^6(F4.Q\K3N6[(I%75L
MV>\,70K;1 7)@6PN@3+/0 +BYTS)S1R(#+I53_%)D<'>,WQ6WXL<;M,I%O%W
M9TUC$!5..X>XOL9$'M/W%5T0G<1QH95=H5)L,;<D'>K'4PF"N=X!/1FNSVZ1
MCWY*<5$Z>]PYXC5NX>ZT8^CO-\F-PU!M"%"42W<T7'"6(#2GV19B5[6OP.-P
MP\XAWJ3IH.B<+Q/1&A8<"(210K#\K?.[L54?CP<'$N/5#IMS_\"!#,32(^-_
MNYSHW"_NIC^R:0&KAZF&"DX/5*5F.-R(<AP.C'(JNFYGU]<6;5_RU;V.0!H;
M$6MBADL26!S(4^:-7J8(EFT6&@(R>1 <"^7Q;>:,BM0#M13UG#S;>WB;QH:K
M-ZRSFW?-P<()5,M$I'U!5V_UW1)9Z=)($QT-I+% ==2IM6.;I2]/5,RRI7 4
M(=9V;2*@4@+JH'*U*SXC\\5H=E.L-;S7IBUNW[O$(2P:Y$930 ,'8B1:PM[F
ML9'&%$8J,SR$:6\ #X(&,>R]%;SA70P='@[$,'5U;V E<L*EC["5,)I\\7VH
M$RI)O^ 3368H.KLXNO&(1X_FX-(FB(3N0LN]4/;6,R3,NH@6AL&!B &]DRNB
M#39[J[OC=10J!5*?Y8G$MO7B'A"EWAGJ^]G-.G0M#R9JB*LF=#?<_OKMO%+Q
M[:.HVDJ-JG/@-_AR(%^DOA/F#BFRPR.K<D77WAL^4P>R.S,_NA!,SOIVORQ\
M41A;>Q/%PSB+^7*+)M8CQ-HIX^\1$#^ORX$HE-<CS\.63]X9+UHK5@:65ER6
M)ES8+'LF? E$]$]PS9_SR=FPKK),E]+2X2M/5Z"M"4-9J%,LPS\$ EQ@_SP"
M@?O[",0RP-S/QF92U8Z[IH07'/N+L1"N/S,,Y%7![S0B4T29;8"28+/:%B,K
M]0M8,[!>HPY0[$>NHIPVMG?&_6W\0G1=E[&Q]P=W)V9V8I8#,2E">_=.3<Z!
M9$Q>R RD0*_Q+,GO)!?HC]_%C]6-U8)\C'<B?*("09.KD^5)&('M<"_6.QF_
MM67KR&FY$5X-DP"*W-([&. *?TQ</NI* ';C*!=-8LV4LXHC1'6_.,BU?]S_
M&6\ "L@C )0%H^*G',C#,+8FINX$2IL#21XTYD"J068KB7="K"&'$/G93/P/
M [X$Q^]8$FZW*UNCRR0Y>49[/3%R,8C<<VRZ](Z$;"R^Y6K7V6]?,@J=LMY+
M44*QM]"[45*TIF?O\E(J*MHU[5O.2MT/0GV2%;]H;+=G<G,6G^A221!;!=TS
MHD^-C""?.0RRESKHW/S%5N5!SZ/GRQ&+8Y:SI1Y'CLB%;PX,,?;'UAC8DZNR
M,V8\:$@C:D](0,R>?+C B(6W5%-PZ:?GV]6/<(M.ASR04-ST0,989\$7OX.5
MA#:X@1-A7J 9U<KNZYSWQ8CX*3JX\S[^\J;)Y^J,Y,"8YY@8UZ*NM-!%R*JD
M,EAAMP6L9&B-@URM=I)LE\H*7LROP+&H0[-\6\K(!=7^.,3 \8$G0F?'?1K=
M"ZCO"RCNA">.ZOF]A6<,ZVIW/W5CA63;#]U*HKT2'^*WN?=Y9Q!7=>L9R#U-
M:Q?7M)%RGR0#5ZYN&SMC[]@]6$OW78U)VNUH&>#N))*FFNN1,M63?K*WU[/X
MR*JZ[9=5>:'&!SJN.0$AD_V@1UU*95]249I,KAU#Q* _8Z2*U 8.T_VHN'H#
M)+RHLTC 91[MD1YS*$P_]]-;A_0P_2</=0W,W@I=3ZEP/P?T9_6Q>R2AM2%=
M\_;F!.J[=091>"2@6:;ZB0FO=V%PDHF/8WVGDI,/%\XF'!(H,ER]/:9!]FK<
M@/BN7HFW?%:GE\3N#M?=R_!//RAR[<U6R!V1AJCSU\^:9NFF::0L?H-,?WG+
MO_\]DHS$OC/<S3Q*4WMVYXC+IZYE&6V*3>GC;NZ#4752I[X^?"+UQ%'CV&3>
M[6CF29IG.%H2V-9@R$]E)3('5AH3O3%N&)\/%_K.)D]&V2N7G>I^)CA9! E(
M!+_FSIY[R=<0E[(WWY=NY\Y*2_^OS[*Q"Q@6>N2)LGW;0O%\7(8//Z@9$DWN
M/5_2$7^N^-'G$/D(BD,GGDMJKX:A51OO6^!^,KL-*9I2ZLGOFK2Y]UKQT5L>
M>;X,)^^;PSWGPQ<B"KX[',=[E+V>HR\V]UZ-:VI'U(_PL;(-^='=R!V%:H)^
M6%)2;B80;!5BUU5_\7'<WJ+HV>;M/?35G&;5A2K1#\G%TG<N/0A\.$K@=07=
M(29,-NQMW_$,-ZLS^K2+%QOE(@]KMAT.L53G71,?#>AAH>(9>NP.FUFH,/,*
ME6%$3<)[C\+XW?/>PL)6(GQ'AO.ZQ ;2Y7F-!%>4^._*W79Y-K_>^F!WN/(7
M@MO"@-QQ5CQ[YXSCD=ZH]SV*]O8JACK\"O-=8VGFIR@ASHIOE XUB7#-:B(^
M(WDY$(\%X5F<N*90*&RWH?@04Z-''WZMMPJ:N,!3C[B\:<2&JFW8'K JON<:
MHO=6C4C^'JXOBND0O7"@C8QABMRKDX3.RU!72?"'"#CM1=E(OF?ZK%Z:CGS-
ME8G6*)Z(^+UFO).*;[;O;U.$.H-4!D>U(Z[I"'"S&\N%6-E(U^G?KG $RG^-
M<>9 _B+(^>_+D]9VL;>:@M:TKA9D+A(@G@LC)M/1( 37G (]WY=^2'8=C''"
MG+F,[P8PK(: @DEO8B,('E4OEH)^E8X./* (9T95@O<*8Z9*9V?*UFS8_%W@
M6ST1',B'>MRZJM[Z>X)T"X:8LXZS?<S>;IR6GH;?/_W?SO)?.LM@UUI&<2"[
M%G@QO45M[! 95$0A8I!8W%L'$P$8YZEI2;+M/U9<Y]^67DCHO[VCX"?(TA#W
M&J(%2FW%"(/H?/H[9J$=A"8&JJIH/RDE70$#*/:.WNB*V)*MY=.J':ZNW,&!
MD-ZP%4!&]RH'=(:3V9K0_C8RDL6?D,E:AU(<0WOV<R :C%90I"W6HNBF<YJ'
MJ(8PQI8AS%S1LJ(Y#=HO5*O7%L3>:9KIGH!:O[XZF!DSM\HM4$CAR[OO@=JM
MDHUX[=#VM$%+J<O]TQBR6(R9@&V$,D2*X"R%Z(IMHWKL'@PU'<7/>H#;(AC*
M"G.A0^>WY9V^M&9H/K>TJ1:!'G)Q:W2?!GM EJ?;<#]3F#89O)R=-[]B<-^H
MLDLEO<+YO+59LE_W)]NK(KLE?C)K<G+DW]AQ 5G45M?&/24K_C%TM*$A ^LD
M\.@P')/K'QGU]EC+4R^-8S(\M]]DYKAA!)G>-/O1MB=,15KZLE2@S3G_RY&>
MW$-#3T@/4OQO*W\+K[T>XS_J4>U8$0X02?BG^G<8QJ@S701GI,@L_4L&2OM3
M-*5!LB4RF1U#MK=WV^EQU3)-;W%Z\O(;T;$Q<M6[^] !FPN /7G8D(T)U3.-
M>-^ALFS/DOVQEI=G^U$^ :X]E!^EL77_)6'=O:4J]G1160'@WNB!*K$9NS)D
M YQW!.-J1%8Y7;:O0+Y>JF_A@FAB])4DKX:[6=+.#PQ+@\3GDT]=-8[<WZVD
M](R'^P$/*I5FK@6(,3Q0,-K8H2>%0F&[\T99'DLA%E,U<8U.30?[#DDG!1OD
MSB0:O!^I[<>G/I;JDGR56A*5%H'D]K)32LO2K5$2^H _Q,I "S33FDFRF:1A
M0W=WM1UUFGIQ89@[I0KI3.&#SS^;!YT8-R_F.NJ0Q=WL:Z78N#"8:]L]<@@6
MPA:>QO3WW/0W>C>B.CTD._?< VYI/U+Q \Y-1%T#2(QKP($[VTHS2CL+?\K0
MO">8T3-EWR8/EQ5J9M2?\.Z=1IYB?R-NN8,,)@K^\- WO7,]RZ_NXG<UK>&[
M])K$MPF+9.OY_$3;<*6YXZ7<CT3CJ9FCCS^-8@9@%$7LPH_"M4)/B::T]SB>
MBFBI)U7-(MF*">F;GKT2N]5S<W12A&NT2IV5JK7P%)HO%'305S%ZD*R#_3'/
MW*FAV*Q2U.XCF+R/Z^M\I*Z]P3F]Z"-:> J67ZU!;2"F%L=U1\#"N@!P(ZGQ
M[LOW29]>C1XHSML?Y4$V&X^(_;J'JSAW^YM)K>],&.MYD><6=(]D6SU_D;N$
M(;3)@)Z?/&55\"I/RV**%+GH;"-^+,UD_&Z^;E2IA%8WRA7816XF/KT(;2 \
MELR(=Z(DPLX&RBZ=[7V$ZU_/B]&F255<KCB+C;.S-7@H+L(U*1D?=)45B[F!
M#=F=M/E313X55B^A5AAA7V=#/./M*?K-DO_MIX?7G/O0=G:0A\^\O[P'C;I4
M-M,_9M2S_FB@S7'J2:1@R-C5;<T.)\:+Y&ZI[?KL_*QQA^Z:#L1+HV_><9 $
M?8C9R0RDE=?A=K'5;TCR%%:)!I&A0H!3G<!!>KN%WES<Q(4,8^?G65M%5'FY
MVJP<^VG*)-QCMIH?R(5KJU2Z,$6%V^9QKH5+8Z'H)@0R2=M._#K?8YG]W"UL
ML1M(R87">3=#Q:DDH<[E]"[Q?C-2[NS3L(NG;\L+ISS07FH*6$/2N3H(KD_Q
M_8K5MP&Q>H(0Z/=L+1ED-WF^=T/$C.Q3^['Y]8BN[=EK@B9\)U((1EK;#GNG
M#0T8A6B<Z-A'J?XZZC)0$4S7 I3?HT&C5> 9S)8%HA?@E3V^F&+_I>G;9@KE
M:R4QK>42'>*DZY:W4Y\'1)[B"P($V\BV6*:(3=U3VM%SU)'<G)*ZV2YWQ<<>
M^XI#KC!N>,TJYZN4W]M#V8QX@]*E*097';V1I$EK:\!N85K3OD\DOW/LF]8>
MD W+'7*[Z/!,XZ652E*W/]KSL\4178&DT+OHVN_HK;/QQ")Z",WN:)Z^7T!=
MK8[DYN(6N:<%W@I?O[[++7!N2=T<WWK_WGL^(T"9%D,/[*FP\J!&3]8:[J4Z
M5N; WQFE L43,ST.^\A7)<\]/F5]C';X>O'S4OGU!,B26FC50=H;S$?BO!"I
MTLF"EH1[ZW>K<XF]TP#9L.[1$K&\CHK[\47"+?;"P#YK'=ECUWE?DY!\@RA1
M%O86!^):;C]O;P=D!XY>KPPT7UR_<-FD-'Q?A%U?R8O<W9;;U8QU9]R';AI"
M@!^44<5ZO"#PNO$IV5/:KU.JT6W2W^9TUXAKN$)EV957>TZO#)BU>@^48;8S
M^2(I=-N.JAW QU.W3OA=)-:M/^O9WB)QK>1\(L79TDOBW@$E/<']W)\+A?I@
M=67XFF%M;[+G#F.:W42GC"E[-_>-$AN']#5CS.$K\4XGI;#[GXFNKN4^9J7J
M>ZN%@<X'?#M*D58+U-6C!=I1AP2+<OL!L=.5T1[.:T/UDB25P_)W9TN\+/N&
M^K[@CR$?<2"%68"_6&T!&<.;^3BZQ1<'G(VVR,\+##NWYXIG03/C^/$2S.MG
MS*&$*7UOAH9?:"W[$/4>MDKX!MW+KZZN;*O?C8FN!NLVK?<%F1E;#RZ^OW;!
MMD3]Q28SS]='W@H=!(Q0(UM8V?H*+E1"#6R7)NQQDGQA90E-%D<^PVU3TN4[
M^S)%R-UGU_ ^.0U1USY>[A^K>S,!.:JB*=!%:Z8_[*[P],]V7]\=3SDP5[@@
M^"50\ZZ7>0]-,^:%B=2;W+WOSXJY[]#P<6RA+E3#)/2/TRXV-Q)WZ1NG30W<
MC7=1R<,&,^5\O%7>=)K577(P4TJ.>L!]8[XV*H&*#"HFBM]DZZ$[!G!U%MAM
M,W?5**8E9>U,RZ7!E*\JE.NEX:Y6@_+:/2:79'*.2X]Q)]":'J5VH7>C>S"\
M6LW#%O6&TE3!*+$PE)JW?U;K+15K<J._-9]73>+>Z,,AM[]^):K/VR?)4PUC
MJ7CZ&5:B3>VL?X9J/L63?X2X"Z/?>&%?_X2/?$21.!>CJ#:R&E'@!Z?#>ZX!
M"%IT6Z.A0E$W^R?4N9)2+*+GH$>X_<7@FSWT]I.9$Z[))M4J0?YM6JUJ<PNT
M^PW$S6PIO\,--GYZ@U94>/CRF1-2B1H_IIKN9)Z/*OW@>EOQ\A&K1;"+"[F,
MR+W!@V3\/"W=3]&F1\L"SG_)C[](QN)TUX^D/N2:#LE:T?>G[]M.;=M\??@#
M=Y0-4YEJ'%\-&\Q9K4X2*JTJH"*>H 37EP<46L9*U ='C .B^$*_.>_?>G33
MIR;#:D3>&:K]I1AZ=0&0HPHR;, TF7JS2M;=21[GSC!R:%+W*M>^.?#(!>T3
M>:C%<&ETI,2;X3!-$.F9J/9##]84 /[SW[#T J_5J&_BJBWEVLD2Q#>4R&6N
MN>7"H+C_^HC!&W;N6=.K=I$-PGX)>YN[>3>[K. C]:$DD-N;Z3NXD3!B0!>I
M7I:'NMS1XIXUT,!.S)*Z:U<<>7YQL]'MGV)<K=5KX'NP^5I% JG$[%?S-4''
M)TU78\9A&@SL-#+<<?MWV!5=_:,WV6JA30GXL-?W!A?&_0M\U*]*7LFOYF(#
M?%'E?%''H%[L9@PW>S\@Y-B[8O%Z@<\] 1:!0AH2WLU(RBQ_3 \^?AB[=\=G
M_48WD>RQFWW5$U7]>&Y6R.N:,PPUX!133_(E%3&@!9O+?^?!0,2RTGT2 0[$
M_>[AUN%/DUH+A1!$-91Z_D0NM8!T+=Z8-ZY*LX2!>!WQ<G$?HW^^$$9"8GI?
ML]NAFU!:#%.4VG=](?++,79;A;(\0GW'OJ)79ZU=O[!_BM:=X9>9XAZ##DX[
M>@Z:TBTBVW^42U:T+0J]]AQ0\3<<TAES7]Y$%JDHB>/7-1-)#=Q2PU(>AS_$
M?, RE7'A>IY8I@\-:@^DDP4$V^8DM\W,CC=E--K&OD+<OW7UG0F<6W[1RS07
M.#H:N!J"UO=K(LM7:7[7.JJVXV*#A]CCR6&ZQ::'MVGCGYL]#$0"*<>@PNQ>
MY!:F#!5)3V%%,F&C.*%^X)Z9[ $-<161"5.=.$CY)X7$)Y!;5^&BJ_@FM4=Q
M1&FTQ$S5MO*>%:3@X(S -NWTE-,_E3UMCE7@$@_B->?1]Y5'\-$6Z#:%P"SM
M'DDM\H>^L6&43AW+@F&B?&3>SK;2T%=XSOG@5DP6]QYHY;SCRL #&#_!'1-2
M=J\6NOL,Z:DN6N5&2_IL'%7 O<'G8)G*9U+!KBV-R#>"][70D]._"[@$'<V@
M.) ,V'(@_#RK@X9:4QO;2()^AD(A U;W69]0[-;DN1U8^Y!I@*E27@G^RQQ@
MAB?!MX"NSQ=U*H'U&$-_%+LVC4S&4*UA:_MDQ4!?LHW='DTP4%XQA'(@WH[O
MUH;NT4 W%)^N/_IKRJ!E]S^[GK\92>5 -H92GT96Y>*;#B-79ZHROU\A!.]T
M.^"F_%4/_M^!6W\(W(*\L.XXQF^L OXH_,>3(&XQ<7]-Q=<1! %%&YI@<HJ;
M]_1JTIY*=D?WA.E='1V>$Z^DY$?G+8]4D\LN_E,7J&_2=;J0ZC=L)+?IG= )
M(:OSQ56\U/&(=W8]Z[RO1':D-$F[N8EO?7N9J^D8CZ?5,8EUU=!,(*!I#N1R
MDH$OH\U"*@NO[-"/UHS6[FB\,/QR/6Y?X>^L;=I;H<]"P '%\*I-CL"2;:>^
M;O*0/=,YM#XN$]'MR+_IU$,3JG15UW.GJ<K<E<'?2#QB@H\ILD!_05T-STL#
M[-U)'K?;+G7JGW%><M?9;1YGP[/Y>?2/+ZVT[KM:ZYB-]>?:?UQ_#MV+^=,(
M33L!. !EQ@AMXT#Z7$!^9X9,BEW'"7$@I7@[U(^C0 THK)U)7K]&DJQK<2";
M01\[6B<7?. JG"4F$XA *F%J]#!C$3,<"%T\A@,Q;D+:]E)>X1DK2)N9#\2:
M)QOS#>,RBM7(PDEFW,+.P,L<2,?.WKC>;'07;M&^PG@EF ,Y:>IHCWQ]E8"%
MV6$,G3$+WS?V9E%/"5=^L71B0QQC83UJW1@]<U MSQ.LF--Y7T/KL5T+/X_5
MG/W[6 T.Q*PU+C<.9&4!R@Y2/D& 8VNQ4^N83<N[PP^\JQ$ID.8:^IZPK4':
MUG->"KFV]I3-$,&X7>1 VKXA5_O2?9'RY;O]4L/S6.GN' CL$(9X%3NO_,M]
M#GQ_<5'JMQ?]EU-QYOB?T^S =H*7$V7&-(J[8V4J11^F3.DJ]"6%[\\X]J\>
M*_K7)QW_ATI$YP.8+F8TFP.184,!+&D^LVY>I[[G'EJK2]_JVFJ"GG)8LNWV
M\]$F0Y#F]E71=;G?R+SRJ!J@U%2+X7$E\B\OB)_W@YL4T*ZOAM^TF[4/:M2L
M>+-C-/2%P-P6VYG[0N:,U?_&E3_@BF@MRO<K$TI[R(>;*\>R=KN7OQ>CX)E1
M1'%0ZS<VA34N,H8'.89FQG,@558<B CF\"*L-88QSX$$2NI/PZJ(JQT95LCX
M3T=_8 )-8@UM?R2S?7%$3\94QZ09BPX^%*$1?JGMD^-7W.)?7-'%>='!9HH5
M6DIC,S!$DZI(5M"UN\#X'M5ZS+6V;MQ" U('T0&V*9P9;P:;VP5CAXH&Z*)P
M/<DS*$_QKJ#/WAZF<P7+:+ W.K#D*__B.<7_ZIF5?TKY>U*S::+TWH_W\3MN
M)&PF;,'5]SB9?RS&BDT!1T]'%%YSP:#)A+/+OTE ^8_/[J- 9YQ'#K105T@8
M!M@1\_S*2YV$$QS(:!IF\;2^&@=R!<=*5D '(&90,#:Y\L)2Z0(%Q"VDN7_-
MK\$84[W,79GL4R-X\.8PV/*E.RL.J.R_@J1(9\+"]T!X3AV&=V^G=2?BA2^.
MZP]HXYC^^_EOM$<X6Y]U@;GVB@,AV'$@NYA@[[VW:?G9WOX*.[_,?&>4*$&%
M8? *&%A1E:/L2LI&4[C:84)!>.7)! UP!69]2]Y6EB%L*RQUFKFM73D$ .5&
M_GXCE+ZM%(0_Y_(<$EH/%"E96B@KZ =L^4)6-M6B?1ET3E>_PLC8">SGK_M3
M"*KW<40:8 E";_C/G[$.H_.#59U69 6!:-U.QK]1G@)KK<BV2,/1^7$<B%%X
MI32!-2.;V>@=SWQR"$-RF6*!39B*JS_Q1Y&OJI?)I1" _0AF '"8Q<"-RP3X
MNS"Z,>]#4\'^JZ@'&D']J31L_S6CG/*? (9)^5.FEMI6V'!O-L694..86=YA
M+$H+_?*?)8OYMRL**B)<:R":\A@"B30+NWP,_RP4E-./:)E^OX06T&T1#_R@
M,RB^R1;U/E4!QU[#=U6JL8\7_Y(#:#?(M^UAOTD"E/Z728#^_R9A6_\@].]G
M2I&1A$73BBL<R.4-I+FAA!)>-M GL!:Q0.I:ZJ(&*(/-29.K3+0(:$/V_CQ_
M6(5E!6'&RD"[>QE4U>4CN9-_U@M3T)P$A&;3WESG0/9N1P(7UF%@(TY-TG;\
M-_WZ3TMG]9VW?%9([AM$JDV$LS,-^53_ #62T0#E8ZIE<2#.,X[*P98G;U>_
MU3#=Z8@0%/?IB%&XYTU?#48Y9/BMU@:8AFG:8XNF)?/>W8LK&(V@?4Y^0<FO
MF1YXH#V%3R#<@ XL3H[B(BH4J$LU(SMBFC@0X0K+C_#K*::^'PYZ[<>,E.]L
M?X'R)>OH4A(]^]WI[X+ICY"[70>:0E51NRAX_F%6S,5VU0GAESZ)'^4?"'PU
M_S!=@SS!#UE=5Z9@PJ%4*\*V*5BA2QTQQ)#/0D@"_MY]AUM :Z9 A[H;^^:T
M\+N;;\/DI=Y$O=F^_X<WW0""LOB?(]<_'-@M% 7[$X1-(7\.3,,\AOTM+HUE
M$3JP'K[BTDHA/*O=((H3#FWZH&'5C?<"92KR^M#_YJ2XS6.VR,^3X@?_/"EN
M^OM)\1DF4037HSC3-CG7JC9;5,CXCV"NFVV'8^G@CZ?JXX%!O^JV+6-V(Z3K
M['BMVBO7?V1VW!<M@C'I N1 UL@$E2'Z* 7*X!G"3!6#R@V/Q('*[?2K<M_X
MO7)K;RAWPCT80>[(8AYH8-*=$?KW0;@P?NG35/I'@H<B(4W9-=!%!WGP/&B
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M&:N<#7+L4)_3M1KPT:_HB]3SC*?*Q7Y?C',_X*73#G)5 *?Q)\!'#5QI.B9
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M6UEV'GJ-7GYXKO/VR%%GN$$N;W;@+)1\JA8L(;[+^TME]MG8H].+_.!<Z!S
MOO+6O??1O:&9W!U]/4@U/<<W(I+,#5W?CKE.>>%.4$ SS,6X1_W+OLW78;YR
MHV:[?8V*MF#\!.5N9ZU%K3>8OOOYX 1(3ZX9V>^"R)3RR1V<QXKEH_]K?70$
MUR+4L0O)Y&@/E6F'B&=W[%]APQ@NXU*L@DNO"AMDA-LV,6+"R57/$8L&LR?
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M<SYT>]8*:#Q5H2.)FGFP57+U8WG]ZQS#VFNV]EVJ$BGMVXL3Q.C\SJ('2K>
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MQ7QEG(#B'>J%_:X2[^ 3&ZMZ;#N^@I]FKKU./'51NJ7O4UT6(!;_BA9&=B?
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M2>ZQP&B@?.,;[V%H^C@#O'SASPB9[Z)4 I&'\-1*=$:BV['EZ%SS*6_Z_1.
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M?7;K!9\.+L#C_UM,0XRJ@?=/@/O1* IW_@&,S .AWD[?0%&">VB48/$W_?X
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MO0&9]3@]I#W-YCSM =_%B:\IS^&7IIK($B1/9(!@!"[TU:F?7!(Y+9CKN,J
MD@[K^LMVVHG1(SO]I.O4N1. 5HV]D8PQ%N"/NE4G'QWA/)/R=W-[]]<N>+L
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M53]HV>+\1+PK]?<-69,UHQ_DG?'=BI*FWY^E,F>2A&+N@0PD/5\Q2<)1PM(
M6M/[G%"4L\YK7YWCTN@P&U;>)N/!@,DK'W\5'](<5D/F6;.@5+>S0D1 ?@QZ
M;7B^8-LCV#T"(QVP;C5D'!/S[C+F^GI"1@8+Z0N-FOA-M]%BW"XQAK^,(X3$
M>5:_<HAS\<)SA->HO$6B7(NB*;]EQKU4924E@^B%'7I::9F;UV$!T9!4!&]U
M1\F0VNO)HDK'J5\*#5E5CCZ5(EHO/ $:(WGY+ .>8:D+84/T6Y\ 7M 41!LT
MKH?=!W\T,(&1ZU6T*O5]S[W%),B%96G06K"(%$W56NB #T!9R29X7Z(C'OI4
MRZ4F4W%0(\8.\K"5QTB]P/6G V] 1KZ4+_)&)#*:AB]2B(<GP/=DK-%@]M*[
M[9%243R"6/BTZ5#[\@]5U3D_<9LL@<89J\_[C,*W X9G<\Y<+::XO4D#I/]_
M.&];31L D@J\%G0&_V]-206 U\KJ*^U+43G#F[1;@*/,55-=!E[+_Q>GG2+A
M*N92)K[LH\9>AI:^IM-OM&K]RG+WY9_HBD3+E1<YY5&YNJ(ZWL@1"B,QCM+P
MW])PJ?*\W8;GF[Y3^*R7_;"=SHOS LHF!@6;,@4F API5YX<&2%HU-BC5XK8
M"VH29@=6><!Z&@XP3PTTNFH^+W'*NA\A+V$:*9G9@ZF7W0VU)YQ'AP=-2M/O
MU<GMTV,Z1_;0^AA.W")FZBF$ RXQ]OJXN'VHJ<@O^(>!+UO@QYE\^8MAI)9.
M-Y/&O10$%]0_^_O6))0?''&<[0E=)X7;?+@OHFX[UM6L-6R/>74=&WBL=_\E
M7IK^,"F- %D4)I9/(WPYGQ:L7IY5*+D]=^'YXE:W^_M@W\=US"QK@QD"RAV,
MC(PY!C%Z)!_X"JT2')K"Q!S(<OB?51N<=*"IE9^4#:$A]XG*WX9/W,VM[+5L
M+]E+R@0DJH-T(6_;[,8A^#N<*:628!5)$G0:U%&8;VJG^/N6?*]"]<3.=(\$
M7[ST<R_1XOI!$R.5A8_T*")A77LON4^8?+7#] 1([9.T\5XIYXE-DT)<OI@"
MMRTP8N-5TT6;B&3$Q7:5!IG"BM2@[Y"X;Y2R (P'^,N7,>5'@(89__;=_(H,
MKE>5D>S,]R*^G[NW,Y)&D9^=#VWM/'=;"#MF*2/*ZO[LXV$YJ_7_DXOB157(
M*20HOY82ZL*X#DE M*K*3:A/$2XV5,^$IWQ^@W[,UY&;P\'!&833A93'37>C
M+B+67\#:PE/[>,G^*/ JX=S=;I)83^Y855.-)G1QC\W-^)M@]DJIE-69R/MB
M@'SP;RC>>NKLPV)SG Q)VVGQH5U!H%D(6Z[3Y.\F^"(P!D1BXJ!FS!6A\!A$
MOU=[X__$WGN&-=5M:\-!%)0J76H0$%":=*4%5)J(%*67B* T 9$6(!"4W@4>
M0$&*($U*:*%#Z"B(]%X3>D]H1@C)%_>S]]E[/_N4?<[9[W>]U_5]/U9^S&NL
MM<88\QYCWF.N.6?NJN.8%B-EMDZ++PE@>4V<S=+X.K:KN+@_N>OC]<\JLH[=
M2&-1 %2(E0WIC(M&PZ@FV_)]OUMKO:Z-T?'&+V_3[B>-]1X!!BG7O7USE9T/
MUD@5H$$A@52% _"/L'WH[_#BKY^=%"S *AG^,C''WCJG789Q"UMY+@64YY]I
M6D[T9P(J<*A?&R!P"?"Y31ZQ.HQ;!^>E.Y;FYE_ZG5^4J.A 4(8MT+Q79LN+
M=IGIAD$@.U1CV)K*@XI>MK#)UJ4MPUWXM]B[A(LSA1"Y8=U'J-INY4?:V'LB
M#9?$Q6(;M#2OTKQM63[_^CMGP?V3@NX6,MQ4:6#7<2#C,/0N2U:WF<P,ITZI
MXQX5F7#:50^A#\4?WH5D214)"7$EJ +O(48E>Q.4"BN1<W=:F0Y9Q#?Q3\\^
MDX+YO8H #HAQ,\ 5^V(UP*S.#6IA+O<5H\T8TJ%%'$V/JDLZ<Q7.4 /6DE$G
M581+#-C&KBQ6%2I(DC;6.L^]%!2&N+)3 H<+2#UXDJC<+OCJU0S5!T:/,/+R
M;/JF#>GO(IB9Q;VV.=OCZC.$RG6(A#Z6T(S:\G=N!AM8%)ME/C^;V^]F<GPI
M&:D(\S3))PS"JH1ZLB9!&GH11 !]RTUG%3Y,5TQ"Z;9'8_%TV)//=J_GT"E2
M/>>QL1TK>ZI >+7)F\ N4'5[X!B87(8(N*+C3)=5JJ:4%EAL[WJ:J/@.HR/N
M2[7^99$G'9L4D^6??2Y*^%][-:4?IYWEX&^?2N!%D%AX1(I.<FS*?-_#VB?7
MFNM>[,1J+[ZD9IHRBE<BWY+]R4F"1@,V^1M! >>,4D]\5H48*?/2B+\5NYQB
MP/C!/L6 VFN=:ZDHFYH'>%:&=,F:=G&%:F.*VXY/P*$Y[W-#S,TL?'7C40=E
M,S]*)-_HDR4-OA396IB,/P[#P;&V!"80#=0&HXW)BH:*B]D=C$_M#!_?[FPT
MY6>\1,%_P.]RFXO&I!Y*BU%)_=4IP4K2N:TU)X'IGV947VM0,W"D>!\]?VJ:
MN9RV4V"P_$5US7$-DTW_)8L\< &)*.@>B.3AP_1TQ#)U-.RLIAU\&R]ZQO5<
MQ#/UB<OPM^S%RKCZLBX2F/+ 0!*1<6,VW2 "@ 0FB[:\N8PBCX+6\:J;EFX.
MLU\PWS0T>ZF.-J4MY?&,$@0]<C3L[(T$Z+#AQFD2@4I[L9F_&U@QT,DV)KI4
MEZ6-T+W?_=RRB:F'#_7V^)K.]2,:=8!?=58U_1LB *7>CWW%K6\)N:$L=F3@
MPY'1SQ'\&S41H"Q_+AW6W!7HY8!$K.TDG)I:.EOSXZZC_,6 ;=.>JQ?1]ZK$
MM\]EE(J-!.ZK%KCOMP?1*2S=6J@$A4,-L$F$2S[8]#8_!9VBA>G-1)7WSTT3
M>XM=7F&Z)<>BOMR)*SFK^K7$7@GF-A!&!%3IM04\:B6 PDU&$(H!YLYUUL-?
MOE\S>7S!U([%RX[_O&V!LBK@Q(=PZ?34"Q)\'(*EC CDPFL-[QS"(_S.ZXE\
M=6,/L1)]%9%G$I&5:#I9IKJXC)$$WR6, GD.%Z;@B_ ()8_"&_VRGP*-0G.Y
M O)W]OFBU_6$AHQB XT"O\)8Q (%86W&I4U6J#Z+.1$MK'CNY]F N!TC04GE
MD'T&OER&C$W@&PW5VW /W)"7!)Z9_Q@]W,+FN.,EWYX5_DKY>[W[)1O:;YNM
M]^7II/I/D_=>BT@PDR6?7B-9>%?E-M3PK*B)';/78YPFFY)>*M*GW.1GJW8K
MLL1ZD]+0<E$J8M*.J]A_8C,T4$?V P<,S[H_/?YK(]*ECU'"N?HL#%"%;&'N
MH'-(<X=_YJBA?]D%CP MEO/PM0P2 7:7Q$11B5JR 8&]W=C!MWP1E^QI9E_1
MO-5HPJ8 [QZ?06IW0C$*>M,BQ]Y8V!LQI8IBJ]:JC0$1%P,OZDC^\\<T)C8J
M<0[D/;#%Q'G@R&'\9$_'1(T[GY530^S9V!+<),&5AT5H@\L@QM]DZA:\*WYR
MX7AI#&9S <O6OA=E33>^H!=V5I8X?[G8UT9:V,2 J^3S4,N831BY0$+&V+%)
M*Q)W/2]\1PQ[T&%-CA$*D@T=VDWT/;("&]N95$7=$GCV)$&ZD$*-8]>>H&0K
MH$_9NT +6Y%E(P*.@6.@PSGEP&(\>,B3"&# W\"FI'YNX_Z>[I,[U^'.W,IB
MYV#)1> ^?8KD@-IBLS3/,F&+GWE$L 2D?4# I_63HU,]M_P<F;U5<VVJ';K>
M@M4$/=%;%,VIQV&_-EY:!@[R7!P-Y,1S8.0C1LRP K0VU^9Z^:TN?F!)N!K&
M"JT2U$!W !)O P;/@S%W9V8^HO6BC6W>3<GF9XA(*-Y[O7LNJXPZT.A('L]B
MSA)^S(=]=\^(XD#O*;-MDC^#T$$NX5+1J> FN(JM;68FGMFBRVT)Q*3+/7=X
M\:YLB7!=V-R[EV8^7_J#@RQC/ICT@S &;CAAM@YX))*:P(N_,BR3Q5@067(4
M4N$_4ZS%V)4YC(4.EPA)N:A8N'Q[DBEU 1 @0:J^2.0S20 3?A:X"3HQ$2,Q
M.7M(<)<Y#,_",;W7;DZC<AW[,//DY5!U^NN&V_:LGX=2.,.I=I")E'U?N9W'
MD(OOP;7R04W7%H$ *$WS,/[.O&CS:-F3N&-.!XY6F9&FR%3I2Y)A ,(>O%:V
M[U>P5 ? CKW.&I28L',R?<5(&AVQV(XYB]?5_91?92MNHZ99SML#PF^!1)Z0
MVR_)[QB=.@3VBI%H B/T_DB3I ]J[L[:EWVQ[%"THUS*3>G.F82HXLNO-'O]
MEEA.]##A:.7PKKTPE2O8LG3.-MNR2?4 +BFN:O]1QI ?-UZ!J/#E9\U(5WI:
MPA0/!2:^G0@(:5"I+]E,"RNE/<3VV]88;G%%I*QG5X@UZ':E!C&%\::=B9^]
M4V&?PW.>94$O+/;M%^@/RQ1^;)A^=;Y'@I>RCJY?E2?O7UGE@#/ & N]G[R!
M%XB BG>P#8&C$Q'P>5B;C1(YV@V(I\5XU88I*7_&Q:W.=.K(##K*&5HI.;CD
MZW\K_/0ZA5SEDSYE$*SM3@M@;@-$&4@'#<#4)XX8#E<'"/89);)T7#7-E4N]
MO6U$!'AK'\4/U]-/YR[UU^[PHR6F0-W8BTLM=5XUH]DQ6-IEGYHMJ=-S+SN4
M=KS@8WHT4.4J;.WVS$><1.>TOVSF1U2TB\+)]U7ELO32Y"LL_.&/MK[<4!;!
MFH%L83%@TL#B*$;?WK\XP+CE)QB/A@C4C+VHGEHN3V%R!YYHO;T>*R_@8"'$
M[T"Y.T@YF_4G>S//D^Q-)P)<[.'AL@Y>H&#0%9#] A#ZN,*-'4(50*[>/)(C
M/-1>XSZ3\T[5FKKMZ@$5K$_OM_+.$)-U>CPK4ZN*(/9'ZP)E&RJ+WBF3KPZ!
MO9@&\2R^+6Y]J[^IKSF9[.JK5OO1J V\VJD@<)J:<&GOUT$7?OV_-8!B/+-H
M3?7R$<L:MTOV<FL,5AK*>\-6Y2CSMX^8R09A;?>\UO%&IP#<J2FF?]DO-/0L
M)<OKPEAQF+:+]?'4^]\.IVW%<,^;3@D7?PAF"6W'%FE^"M$UDST=J-D;.%EB
M5C$#;?\,!#^\I7Q@28]GRI_HL;Z&<UZ"3_4MT;]6TK1!>55\, -O*KP8U.1R
M15VK8:S<^?+\P)8W,WZ4S%H-!0Z'5??@F730&K42(4UB[ECJ5K9]BO1MXTK+
MF7F-3Q%SXY*K:E)A;;=ZP$V2JMSV.[38OF/4V7NH"&4DU!$-HFW[-#L?+9S6
M/OS=6TJJBJRV[_O-\+0SQK-WT(!BTJB520!":JT3;R,R;#5K&QL3KW0Z#$NM
M1!BTLF^+[/<<YYU]5+E%F+5F'&ZBM\=06PZB$"U6:I_"QG=14V/< -$A/C[4
M@.4AU\1D"R@>O=":A1-<"/,$4SHH). 2G',G'1]9.+Y$C,W%X2]EL(I->8%3
M13+RJJ:#E, $*M_3Q\C.OG60O428/BA2MOG.L?!1D:C:;S\_MR7V [AJ%DNV
MZ=@<@/,]$\CRO>UV9&56ZPR0QDJ/92T"GN^B8UH?^C(,U1XO]M#7=,Q(>O;-
M)'LKON8L":^-=3LV'I?5#5PXML=*1#>9^76*UWYV.(E(FQ<D?\5[^2TU5XIK
M :_GUHGB*0]A#,@2J )IM!IN"L"X&>(\;)[9U<J=A*X@OEV726]_APS@6%Y,
M^:G'^="!?,D-)T2/_Y2.)@+.7D[ #E=H T,),VS&QEF5H*XIB7F9()S3L:Q4
M0K#(/>.;TK/U#_P3P*E@.C<5F<!>).)'YP"/ RG=0HW0HRU-8R^>JGV:%Z5G
MGL@Q2A:($Z2Y&&/+Q3WG/$B0<EY [.VL78A_@T29S$(5,$;?*KYZIK[]ZLR$
M>LUHJ7N3KC=\E2'GG-9IB6HK90$II3*Z[#$MKG5J+_A,VDWDF%;>.KC0D,H?
MKQ'?')A@$D_H7:AJ23V5@+(/*U'GS[7DRES8=8//>9_EK]ZAB6/#/7YR(Z[1
MZ)7V5Y6V?_V$2: 'K,V6 ' BJ.!\4;"(-)8//_9Q9@6UH]FU,8W4VMXWWP5)
MU\C?S5*[JEQ\^#PW429-3E/_2P=-B=3%75I H/>O<A)C! \=@G)C"-'8N\;-
MI+"-JO:_56)?KP"=D 3[.E<\>T0E=^7SF[8W^P^E% *NGMXB3//0G'UNTEQ2
MEF^3,T]WS.0.FTLW;@[_&K>2)P5@N#0+8%A;;5-LH#% @W!"1,#V*3KV:8#A
M*2HL+O51A:]*SZJ%QK>''I5R1L @N G.'9/:AKSHR92#$^E0L ^3&8=)Z03(
M33UE;!EL7.9/?0&0EQ1ZK0J,06+T%J:96K.J4G>DL=1@+*'R1##9U][G&<U7
M1]FOCK&SKFPOM#JAA;,)<2)32-<!G/!:>(LR7BD5!6KKT]6SSNJ4[KJP<VJJ
MP&Y#PW77C?T,Y>.EKVVP'P;P2#@F?#P%$ ;\RCYZ^'MA:C435U>-TTQHI<*>
M7WNW>(L\T>^E2-.?9IEOXD#NQUD7</1JF)V]%#[Y%&^MV@N@AF>\]<!'_0!(
MS[8M)@XX67 ,2EOKSBN16'RSU4G@GZ3)7V#8E2PT?&5X)4'+<B78MM0CD_>L
M$F8;'4\_L&2VVR14NH ?+A%#+4Y_&%XK2!7@4]6!,=GXKY$"?SH_U;[,T<?/
M.]>1]CC+EVEFUGR6%Y(?VV:B:7C3Z#5O<-OYB0$D9G=A:N)4"PQK+QMN6I#N
MWV_ZVO1A[=;^CYV>&LF=*,!/)L*E@L4SBZ74'76LT''DF*?&\*%.>'VPEN$[
M-9GO%)-?@3>C+DQJ+4G@C(&AR,449'5\1WJL%N[N$I2'2V>CJ>^]3 98O](Y
MY]+T?L1OKJYZANYU!^#/@4#,;BI*F75 <\ASQDKH?E7,71=;6ZH.&N%;5!'9
M ,KR4@X GKP.1X_U \VT0J5AD6QB6/M^T@@9,G!JN-<_ZXFZ!7(D JP(N0QG
M*M;)IZ68@;OC4&G,6OLT*.+H$1P2K#>\4^I%:Q IN(OB,THTU -)A[GZKJ6M
M61Q[XEP7V) HA]J0[?AX#.7Q*O@[&BC Y3J3);+\73KJ,.K_W8-T[NJH U[-
M2^# BT1 !"TY+KV]03["+N2IT)@H7YU#VQJ5E39YW)A'>PLEYL?K%^9]'6ET
MZ=GFTJX.,C-:.X-9AI=ILDI=AU2Y FLQP:V9UT;S1[WB+T!\C$:%^/L;FX>S
MTTQ: :[>=_0 7LK%)ATMU*10#;FZ[RE&_6#(9NV'G]>'EQ("2>W"N[HN0ZJ7
M+*WS,&#4,:+0$NS$<Q[3?W;4\?YY0\/0SG**B="U]U%VB?Y)5J7,9-T;0$HE
M<M39?5I-'0PH[+#_SEQMAX_]IYDN4<TKO0W9O(O'9>&6&$(Z.D \0-YTI%36
M2L6]QD)GTMCA@Y]4.2_!*)=D-0\33G,11F:M[8N"7W3PNS ;7;$VXKF>_:HE
M-%FMI\89_G_!E/K_?_U__:J'1:9UK84'<N%RC496+H/-'%/EY?:EPJCY[GTK
M.'_9ESQ8E5N=Y6"B'4D#U<&N=8"I<7%;2SREM./%!6J^HN[K:0Y&CI<ER6]Z
MLI?!"2S@3KT3T9,!PB7/!8*D*@]"W5<"?P,9D75H=I2%9]Q XI_&XXQ@#*#U
MJBT0[MH(#-<%\!MC649B/A/X8$/VXS",3CX1@(T"H8SP]XB G(%?GS-2=8F
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M"(@A78=5C?B]_">"F\@_XJ@X"ZN=M?G\:\W$75W+\AOJZIY\?/Q5YMNP"C-
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MZWYE/;<+)<762;64^3UB^EH*4OM>VD4Y2-U)51355-AS/;14LLJQ2*$.9>A
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M0FU=;DNQ)%75VG+C%6FWJH*(WY<UZNXZZF!6[#'FD[1MG;B5+.QRN&YZ"_X
M-6.-Q4G^\PH$M$MXM]\A#2ZH.PR(I&U(BCHH/?@\N7 9=O#Z_ @=TJVA\+G[
M0(\H23+RJ[3!NE,B_>2D8..\H77U5T%D1R[-YRVAC--Y'\,IWX*1 "AWM8_Z
M4)ZR %+ EC?(\-MO_33V7@JZ*%_+T[)#^7'4Y-EW=D7[EC?4(M,HND#]$)Z
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M/6WGCK?ZK9<!A?HV,^[4/JT_[FFM2>Y:)@Q/A#PKXDH)(JCEU?N;?N"TTCX
MOGO+8. &1_9=\(AI:0I[TZ8C4',)T)APBNOCM4\G>9OX/YTB',?UZN^/M$%8
M# 6GNB-N##7"/X"7^*L\(<(7UVX9?G#(=%)QKK%Q"(-+5&S_;X4^XBIID776
M9B_[(&^-W,L1A6"=480XV%#E9V6/NQ7[  T9LQXV#NT+^=5WU).6+:X-F-K.
MUO!ELI;7'NYMODSCWA2Y'BS*/J('AZ<!14-%RWUVM01O+61HWU3*%5)9,C<
M^+OG;_^YO$ ] "*1\AV>@LOXMU+3KXX$Z%]-"6T/E79>J/@Y?OG'"OT"+:>P
M]H5D7I$IL_K164DWVB&*F3WL[=C*Y^83$,>:I.UY R8J_,B]"_)58-X^1(H*
MT]P:P.-*(\F-.A^6C5-(7NJQCMZLO19O]'QU4H^+$ZN#B$;N@2:\25<NN23<
M"VV0RR$2LJ[YBS8#*R7SGJ?5-;5\ W8N<#'%S/68L.QR%'BV_?C1>0'$=A/^
M['X*Z19X](R(PJ.Q2XIJRC78JPBMDA<':;_[G-X5_W1O\\.;I_810;-S5$QD
MN]<7W0\ [&T3_+.1$":# .VCFNBGM13"J6:P-BF]@==H$:Y>RA&M=W1G9"CR
M5D1P4,M(84M^]F7T/UYW]BJCL,3C8:$H"'P6UM@CH"G!QR(_5-'W,;+-W"K^
M<N-&=V!ER+#C/).LLGZ2N>8RV&H%[31J@,>2KFP^(PL-PIR\.%I->R)>M?>.
M067,F'(9L1RP=E20_WL!<CV4F%^P-W9IL]=Q$=.!=:I[_,8#);Y!_#DFF&@3
MRI137'CW^U8:^V_8/ !P9\)HP-.'9:<W/(12F14F"M,=KIT!@[&FO&_F;\9>
M?6A^!TQ7QZF9V=)Y /R+T$OTGX1>>.[^ \"F&F,5?4^^LT0Q"C^LYB'+4.2Q
M3,6*\F*#^<H'3N71&(@^L5\YPE[8;+&?E%YWO:MK_4_B+\ WP./?+DPI?0#\
M.^_W?][LDWX!C_;^C.%H9Z"6MK4/_$I@X',VV,!O ^/;_>H2TPG4^Z8;F0[H
MY-MB0K9TP!]=EC_U0_#\>8\M[5R2B6-RZG@]$0Y9?+07OAI;Z"$$)NGWS'L
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MKZN-^T[)\_.L,T'G.A;AUJ1.V50.,TS' X<O@*KET@[?%9O?E<12'<G:G;=
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M;%IL,D7%J><>TM>!\RZ5R3&NR0F*1@X,?DKUVZ6_M@(?QR^.JMHYH2TH^QQ
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M3;N8H%F&PYO_R1UU^=_<4:WG)&HPJ]++ESMG#4NSBPQ8FVDID@7?PQ<3S+<
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M$L$5CY/R-J[C"YE&NSI;9$4&R"EGQ<_1](=+8B;4Q*/5)^L>,&^QN!D5M]A
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M>SW8V33M?>?@)M6WJL/S<QF 6X D)F8U,%22%\0B<$R6MEK)]SKNP*=PRF!
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M=N\!)%9HC\L?V+<H4LD>?M<;U2;H-,RAN?Z&^J"WK(!2<C6=VO-ID,OW?M^
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M]GI\LNYJRX]56U5$LT9(JQ;9I.?\:+-T**G,*FKVY48<":2O4(3,9\3T2L@
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M>0[MNC+RMX#'S.(WK5_O? U\.TW"*+\W6-:U47J_-S48N52,$5*2Y?,$L]B
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M#_D"98F3\&+5;@#=])7+:@\:TA=NV3!3ORM,^GT[GFX%]]T#P'X*[^,_S+\
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M2%JR^/,3X.HR';0F__[IO>%_W>__NSCY.0'Z,3>HM7T6TR%M_^PX-XBS7S&
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MX'(_6G7GKT\#'."Y[ /;.+ Z@:6P =$YAG^2G('LUY$KGR<'HIU"KL\D43Z
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M3QN27^7O%Z/\!OQ&D2-[:DZRTKH&9GC'OKO[KKZ9UZ!5?C,-!L?3"5!-N"6
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M!.M/!RXT"6>I5>^L<OT4,M@#S^O>@S08LF=D@/;@VQFU9XSHO3@&Q>SJ(H]
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MP=:IIM&&M:D7J\+6S*P&&SB^OI)Y1MIWDX51ZR/X(DXI5-V:,K<BC \P.;A
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M=#8N5#=(IIUFVQKU?.O"PRV>&/MR3XCDOX*X7)7RJ!")Z\G;F-[E4ZXBSVA
MFO] FX+7QV&/$&O$8>OK2P$7JE@XBM-.ZPM&]NRSFKQP_^!0O3O_"K^\ :L!
M?BSPK D'69VXDT\,[G)UO=*JYN;'\_YF<&M_P'G("8F4#H:G*?<-)3,7M??!
M L_B^>*H<OKY"\/N>;@YDDNW+>\1ION#<4GO&A6S>V_F9]057_2<%:B=#3F#
MBKBK!, /?L^R&W#-C38I5?)[32EQJ(S8=_N3E#1[\EP[>T"$0+$2=F!% 9=E
M3K3!DHP@,78\[ZN1!K6),O9]DW=]G:SV,OH:2L9N%05BMJ/K]"=KUUCLG-4F
M<(EV'PD]SC@]\0>MT^FF?/R?)?&C PWH"O RBJ0%Y\#5O1C 5"9N5Z7S*3$-
M9(L%ZL=T<?9?N#E^BRGQU$+B)@/!;WF"!D@R8]8H(725W#0?R+7,HG9,_#X\
M\3]#B1\%9AF'F,;#&6C [=8\&O#R%LH'Q8;W(&<KA8"7K7K1FZZJJX_HM/Y(
M#N@I#7#FGX[&2D<JUFEA)WB=M-7=U-9/>=, Y@7>FH26O@?IC/(I>5_*C01/
M1^QS/5S/5\BZ"0ZQ[FNMGA15VV@)0,=Y8.HRQQ?G['K$>E!N,WI--NU,)UH+
MKE#&SS)+'C"1>&TS"K^-MRC"HO:Z:,Q%^9BP!:&:<(LQPK7#T L&',U[!,[?
MT5>1?6%^B /M+&MS!EEFW)&V%K*V*A%T9RGIK6T"#!9ZVZ:E]UKC1?X+FN]R
M9%W7J5=$&I6??F<N_C4M[L?7595B!NP8\7XAWI'?.RC(6!^OEY7/"17QUH8$
MF[A(<:VW=R1MCK=]V8?I= %67SGS2I^0+0_A*N@H/S1X*#PTFXA2)B+PRLV"
M52T@+J)0<\WE+ ]$[H*%8..XT[:Y,8/1$T7[ _6;YI)77"\C8FX<5KK84DG)
M*?:)(SE6?K?H;,Q,K/;$Q($.&ON*G$<<3FGZ4.2;-/H$X\U^=-1 5(99M0AG
M@O&+JQ>J?#LNA8_*P"Y4'+->G"5,G$MI7 R,DIA+[N@MN&;*9-7'+5L0^K$%
M"*B 09H.TTG;%;@]';VU1&F KJ$=%-^.45K9/RZ+5X_U!@\S7\99AEU+^*JF
M;FWPZ/JYU^K[@HEB3TG]ELM"/D5V\,O$$JD/>-YV;-3SF87G%4O[V4\<7Y]N
MON79AZ#SZOP_DTOW9XN=(<D:\;D*?H$&O+LP\>6#^[]S?(I8.W$T@!Q"=Z((
M231 AP>^F0-BIN1KKH"OXO:A<NWTLN7*ZJN3+O5$10W7534:^1X2;Y2.=BEX
M;7_$,Z% G:-9W0QWJ&48%:<)+D"X&[NJ!LI-N7G9<T8J)BL\7^]*DXPUBMGF
MM> 4ACA;W CH5X\1%(V''%1RU3P=6# O.!'BN)X44V0?.LFGSCN_;O5XAF/V
M393!G=M\K+ZWJO8PT8"RW"15=#SGV]U:6)<J0LE.\,M(88QNG9W)(SIW]IM^
MS*[+NM'NOK-MRES2]<L<O$<#N.%!0;@-DZXU-V_EMR/C+OT:;E^14*N]!:-C
MNNY'&YBJ]YF>"_UV6JX_Y$S 1I!TFYUT)?$E%(,XX!QPP6+W6>08Y5&-[7*J
M$>M9><.8OBE(O;2Y &SO=?^/TD)MD')).S:\XDLW2@QAC/'"AQYOBH<%WRW!
M;]"Y"Q&29T"/^3HBD8KOKY]E2.)1:A*-H)[$12?5G<6:'"2VZ>'/+''"^Z.;
M4(X^AXV:>1=.U"9?.!$V(9,TZWA7VHM+1\NW[A"VC?P,W #>G2I$+&CTT "G
M-;IC*Z MMFBMB6:CRMC M2NJ8OK7A1+ *U*8&"$KD4$!?M1C;4YPPA'*NWK1
MZ["F*?<,O#6V7]C\B,,MAVG5\ ?W6HAMDO:X'%!7P/_O#.U!&O!G+.T-RY;.
M!WBR NY.YL"@9!_J:&U%CZL*\:F>N_NJHX%8?#63^!-)VX[PT-0PF)BH'$R$
MU*8MV%>^-";:DJU91M1412J.;SH'"%WW]_"]<KL5GU51X2SD\OXTZ\<0;D:(
MAV5[L"K17)N_*DK5\%NM_Z1:?TYMOZ;ROEIJ^"M;8T^!1(.7QW=2;?*^AL;;
MW2X(V7]#<7@W,83W'VWS^JGL\X=NW-/V^-!F=TPBX9;IZ^?<]WCT]AK2F>!&
MTDH&9DS?&J>[W!^L^EU3Z;"@+2:EQZIG9=6ACC)TYK;S9=.II$=^/)L^\!Z2
ML8&F,0;"TU1(YJO#BSL/!V&O+ZESW)D/_R+=8=R]9O80I /+ 5VF9*&G0\A:
M=!WF05)CK#=C-SR&:G]\*6GBMR\EH0S_I;C_:0&Q_L$D56#LZ-J5VH)CIL0)
M9E 3HC[TA[">4S:B&S3;MB;16+N]_14PJA#L9=-!F..U.J29AD>L=VW<$WE%
MQX>?3X09."9YNTEH9MO$A\VQ,_-,P*6)?DI-"/9.Y\#"=BP'U+0NZTJ?JN%M
MJ_H>GV/MC^(/Z\7N>2%UF8>;JTV2T/LKDMU0:DZ*+B/.V1"#@CBF?0LQR ,)
M+E>3C00>7;<=\7?1/Y^5YIK]!5I#=Z#4]2E('RWUJSWE;U2SCI'9\HB9")[K
MU[,L^ HU2SL\IY57AV;RFM?$;M:^XS$Y9U)-M\OW:< A20,R(TJS,B#J.7_Y
MPXKBE.?%>3O!RSKQ'EIEX_7.E/A788AX4=[L$3T\;Z1 M!&='> O.&78;]^'
M-\NT]@Q_H '8[205)5:8.[;-'%^/G'0S,HLR6/81&I+8I]ZJ7E#=Q"/]',5"
M>>@A64_LPKM?#Q8[BS]&3I!'N-NT"<H%KYJ,896KY%9T1*V[_LGAPO]-L4P)
M[D>NNZ$/@I</JJ^C;%"2E"+P]$BP.&)0W&-&1R0#0W=G@86_;$0T_2O\Q_V
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M8QZ8\0KU"+B- Z9#>\*PSNW<^)()GX)WO=G.M;+U>_L7QD,T4$-5/W\F#F6
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M*CG/RHY:M@7XQ6H>*@P>1')X3[#">)<:_30"%KML;QB_8-M?K!,A,XC1?\S
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MAO01]JIYI>+ Z^=#O@63#.D22Q#+ZV/G7UNW>+FI^/&NOX;-Q(1+O)D^F=S
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M[QZ\XP,?46YBIR71>')%#5\$,;KVOOQJ:M2!O-)')Q]9W/@LY\>_Z/D<?XC
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MB&4C;G;P&55!LVJKO2I/]=YYZB,]>-\0L)REK)&YXZ8R5@2PA6/2A'M$JZJ
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M'I$6,9+NO6PBIZYG@E8^8#RXK=N]<HG*;0&1=5>TRE-LYKF.&Q[ ?-_H%>$
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M^H?>M32\_ZYC^=R;WSL;G/\A5+6**?38;3)"]0$JWHCT8[W3<L)I/-_95%/
M4?=E+D7[(CN[89=--<=+58-2<&#J;%-.P_A/,*_CDK9/+82@075%2]%:B7=C
M<C6'*5X(3_D)[T$ZKUM$O#4BZZ;G1FF,W2\K7B_WL^CU28Z[I(@1B>EM#4[M
M-1=1$Z&XY XL\)X_@Y7/PFYT>CH'/KQW\&!0=7&VK_507ZS_2'&M<89O"BZ%
MBRHI]M<^",<^@[E-;M;P>JV#Z3[!W?,R[S:^G?Y\<%"A<:G%R$/+^XKFUQZC
MP49?0A; FRL]5';P86^&0EPA.''+2F@"_77.^*[F\I?[B.5>X4-P1+92\2D
M6UJ3B#>WP<*VFTBSI'Y2S\P/$N;SWEV8-S#(<R-C@SRE"]$'CB/PFH788^/*
M8JMYEQ 04B']QDP2W<RG>#9;>:9#970382@B@_TPYH65EZY4R$R^"]MJ&L&I
M@SL@G$;\Q@!IZWE([?P##2!=R#"LR@X/TL5[N&$QNA,^E<"X_;@L'5E$0/CT
MN+QX=%@H!Z?<H49OP:4+-8!9@@D_=A*5EH2%:R-'91V;P$&#MS!&;^8&?BAD
MRFQ#>.@E \]CAV9D,#76YT:$L%^ST)4H"7.5.Q/""+92-EFP=*DO-J7/A=/"
M]]OSI H!#O-C]Z_KW 13=[<EL[(?FLE*S,M6.E3,P;0YC"9="W0OH!?]-SH0
MXJW@@G%5>2?Y6YR^79 Q6L(D4($R0=,25Q2ZO\ G^;HIY5Z>[MC63POH50,8
M(K(JLV'9>\S$0!/@51]"QP%B?;'#GEGWT*G0L"@XW;DS(+F'L+>N6@'B^@%"
M94.D#H;H9H^:$C-1,QM;6@,GPHGR6_G2.YBD]]R4KSVM\S0!$$["BY"^AX8$
M-2*(' 8ZY[C-< PKD3]7EVOK$@R5;]*7#\H@*1455^K VVY\"M&Z50F:8E?;
M8OL#PR_8<S7J:YP;:=RPH7(Y"%$<@YAP&YX40>W.PJ1KWL<-1"[97_'L=#3N
M&RKPMN&I"89:8LLBZR+XRM3E+MDCXVZ/149BIC]Z#?#TW&F7J.9__GD03!2<
MK!EB@RA@#S[E6;IR*#MT%]=(NX[4U/MS4COXBINU4[$U+"44?0)LA!;]![?9
M3%JJ(^[7)D^O7]J66#:JTA0]:VQSBXG*9!"&[4%<P@GW,G'[9W;- RLR;XY)
ME-J.H*K2].VXM5[J-_*+*@EX;]D8#&L I?%.![SX(#":B=V@&._C-.HNB0D6
ME1N3U(UB.2]V[63EX65O_&2&"[*"!$-[? ^06/PF,*(N-&M181&W08AT7N*@
MH:XXP?!E=0</Z&H 62 :)Z%;/QD4>LZAFB^);[O;CJ1K.XZ5:X3EV7KH'IT"
M7MOMPK-4#0AJFHL+^&LT+XGLGVC4S^"H0"ZUP^@QX6O+I?2EW"NS3.]* _>Z
M0VHF& [#B*!/^.2A+HY B?BOC8Y1*FY:%CXNJ(>_17I)TP@7E0$"3'[ES5HX
MOC!$HID]!>#ZM4]BU9G<%+%%BI@3=<PI(,&DR83W$T2W>B2$?Q7! +L[AI@L
ML1CR=/M(.[H):SS_-3)N>RZ*YB5_=@W%(H@:^11$ZXPX!_;@74U:S]B9<;?G
M8'%5$%>-2GVMGX5)O46#NHM3V!1&B<'CLIG'9,M8%54YW=Q>-+6FN"I<*4P-
M/Q(_2XJ+VIE'5'T(5;\W\6NX05Q*9V!\5 Q/"$V$85.B4:5R_-<U]TOPY$6/
MU1R%D)\=O03VM>G>>(2<RP3I4F-EI;QQ'TJ_)&XC[,S7;_('MY$YP8V#P>/Z
M&L"+YJ2V)M?U!7H^-^6+U16CA8E=&R<%GIG-$>>+E8E$M(8AQD8A9 1957L*
M:%N(.N!:)M#&=Y-B"F,D?+BC/.0*/;UTI ZM?!,[D&9B_%W6[,.0IW:\V?4%
MTZX32?W5I0IO2E]57>NOH/+AJZ' '"Q4VK2O2:#M4/?,*$!KA^JPGR._,NI?
MPZN< F[EDO^"D$A2LEXLO@ X"UBS7'E-M))Z*6Z\#F):GSZF#A"PNO94@O4C
M575 58\R6VA^2D28!E"9*'7RD@@L6,"W$\UR>X,\?$KUY1,JUQ4$VAT?W](*
M\?RL@E1VZAJ:TN\P3W_5PB 5^4)G\\6 @<772;N4!PUGT4,#3Y?#D.5;15AX
M$5$%;H8OZ3PF1ZG&=,.Q,MN6^J2WGYR7-%9UMMYTU*Q2+MO$G@(JX.$_W8"Z
MB>W37"Z'E>L'*58M&9%M3([P]Q@@R-A:C*X;6(E\:7>2J\KA5H17WVIA$4H-
MG,XLV.I-EJ2P$5#8D?G-O4=L\]EY<P >IGD2)KZ8HJ5P#&'-#Q%O;F[I*?#R
M6Z,7W+U,. 4$Z"8F'H"7=V9N'^CC.-H-OQ\:XC2S^J>LI\#I-M,*%Z??+B_5
M9MR7L /4J3_^"OZ)KH+HHPRX>\P?KF4<I+N4NGSM'P0'G1_@?.(OJ-/>#8 0
ML+T'ZGC#<H@BMBXO )66O;NC5YOM8D["2.ZPIMD1OB[!OC9!\;:P".3^-1B1
ML>$4@$G=,O:M,#7O='-C;?<X3XN)E>OX$!8*X 4 C)UB(3=!T<^HORA+YI81
MI_Q?8  O[DN;'HWT-& JA_AC 4?EP"G##CI<U8I1,*/,HORP,>TFJ$;2CVY!
M-BV%^_C"99\MXY ;(1TDV@EU[@W?D'/?'AK@[E1^K&I*N=](QTUCI*LRA(W:
MFD?$8Z&QSR">* -@E_+3I)HMXQ&Q&3OI"U#)._3-;_<5^6._DVF%NF1(1PCK
M..G"_)2_C&;B/5Q$-VWXKH'6HFC%BSU&O^QB[OK 07PD@1-_:[)GX3QJN(7?
M6S)=*%<4'[:(:!"Y<K'\4>.>^MH;*4-7 ILSV=T$QY%/Q'1;5'#6W"JT_&,_
MN;/FV=ZNFRA6Q]DRE.UA_<Z"XKU"Y$\BW&4SRYS,HVBO?BNC+EAXVY3Z%44O
M[W900.EG_/8LSP'\FVO4CVFQ@8 GV7)IG(_R>C"B_5JT_-_"G2D7@7CA^LV=
M1:DX))DL1;?HHP>O6H$M&AN:=#V$$ WT[8X.]Y\OO@"$L._#_KHOL3.1]R4H
MKO\GDL'?1!OKGG(Q/=<E+4,]DU,\K>Y^Z8-/PLGL6A1R!;)]5!X"KRM[(KQ5
M>  T1H8% $@1VI"\&@I CA;ACRX9 L_])>='UN3 _!]GHS(<9Y8JN(\EN9&!
M:Q 7 C-$N@4;5>^1Z^]L 3;Z?C=-1NZDC>7K_5<SZDZ.[7 3_$.<Q6U\'VH@
MRZ_S%.#B)L^]5FH$?GE>Z(:\ZE@G3T];E-%SG<N+)F!R2/ ''G#CH7;8%9WJ
MR1;5>FOA1$.=[>WT^XVBAQ37OS*2(AOAPKBB36TW%.R[QFV::*=QQ+69F:XJ
MR[7#0_K=ST[<L<O' ?8D+<1>/AFWU<*F5.ZTXJIM7*;O^,X#H><'GM4EDB=@
M]3CFVC7N8T P.!DGO$GQO,FX>,(8JPDB7L9-:RQ,^P$EZQH60 N$%CZH'F'^
M':XT]G&H:"<5WS[%T?M3 -4 G@YE$P<[!WG@@YGA;+E9NM:T7W<&;7&T6_P*
M*=*9()."GYR"8;M!--#51R \T)/,_,3&B5*+K33M\M4SJUQJ:?%4N^^7$WJH
M8^S?_'0$T*=L6(BW7ZA4!-AG (X,T8>;PHLG=KK#>5CK&+[,H(N58+6-OH^S
M88(9R)T\H-)RI!]K2!?L;#F_\S(V<( [>"GY /66P&R39+70 8U-@EAAY[*1
M3U%S3CK#\+*\ELKF\9 OU+-&#/W]E0;\4@,1T8]58[<_GE'QYZ^-4K2]G]23
MRZ[]1/',OW>Q1&S%\/5"%2(%9X)>":UUV5>[C@??Y1@LT>9S^Y&ARTP[\\+?
ML9-^%[S:I$>6O M6 8]P5Q?SUR+<_8:)[K@X<0@N^5Z7Y\7EPJD1&H;$WPLZ
M+%V@)/4@Z#,QH"Y3'RBME53DU41#91G]8,_EBS>0L(JC]QOU2CNQQX0+;A<H
M<#S "MZ*!JR=;E&;;6WKN(TY<-H$A(S22M_44X<NG@41?B!<3BJ1CD$+H0L4
M"%97:SNSC3P+TA".>KP\3X4;+A?SBKY>HWB.IB"D<4(JI@68ZS_R54P-JETY
MX78UU2F!&W_17I=&FR*LDS$@AXEW%&2[\Y*#RRT_$77+"JUE=T#(SC\#72XP
M_W/DF4\J=677.'\6P$OMQ:>,?V]'1G;&V-;X@\Q/5HG,KM<*;_HXG9>5WU/J
M>/_^-S>:NF]=B[CV'":64>A3&$4O3L6\M>D;.U%8,@O,GIHS)JF@[057^&W)
M8_7Q!R"6*P5MLRE''M (&SR.C&Q1K5.>T3\7ZS0FJ7%>\/9EPLFWZT3P6K\(
MY1+R]4)%8J0<G'[MN3^W5N+=<;OQ9\M-:59:BS0U9A19ZD?+Z?RXTB'ND!X2
M2S2FOK-!%D8S!Z/I<X/XI"<<8/I8J6SXH3O**[XW;.Q&[M-TU,.PAA,I*%CL
MLYR:,-7'GF@V[X(YLM=:ND7?VQM^>6=[8SD*&/\(7TM@GO(/V;#"\<:_-)[G
MJ@A?WRJ;-&J<Y[>@%Z&$/E"4F$#\+#Y,>^XJGV(^=RO]XNB5!!V'^_WK6K27
M?U+YYC"]!MDAOT-1]5T>WXO:K/EQ9R.%BDK7N?S3?FSK;\2/*#DNH7 P+-SQ
MSWKO_K"J[!>UWQRLH%=9/_J"X/.=H:Q4G\<3_N'CI3,Y.*%:]8C"S!(WOE.
M5>;S!TZ%1]8NB[_],&,!8)H9R=NT/7E$-FPZ48II"[2I<PI 49"Z=]7;3_(\
MD5OS[I O'FO5";50],[FC44K&Q3\E3B1(T<R"_V^+';MT,B5XXIM.C_]O;T9
MM9(%(@4F2P:M_7*SY7;>^Y#.%_8&*3EF5Y.5^*[9/3]'D7SGA:* @Z'0+[\8
MF3FX@K=%L"2<@T@S5A^P<!N<Y'HG@@;:GQW!YN'7\5D$]E5SJ78;^NX\O#GZ
ML,=S?NV&J]%W&TL9Y0 <7=$/P^;Z$/]50SV"8RP OX'6WN3(6??CNZ[.,?*A
M*G:C\Y-'WLZ8^\T((U8]\X=[^Z)VQ)(AQ-60]CT7$%.(B(U9.T,K&N\Z7&.6
M_A F/_FFPWS]]AZLY6:/]S3RYGKK>*E"VN[,[)V4FZ+OEA(TJ<UTVJGX<A+&
M*([(M)UJ^22[A0$7<> PJJJ)89!T\[!()JUS2@DA?I,1[8OD45P56SL%_ $#
M;(1P8@OC%^<D7LS1Z%4/U_QT]*FM#'OZ6H8GF5V#4ZA@TN=:3;RD17.P_(YI
MZHVZKUT]0BD"3&_[5W]S:F9\2['7&W\*>#H4G;XP!9I2Y[7P$'X<;G$R'?EY
M3P+@<0,TX2, 7[92^!7@YD'HE%- WP:,;!:YBR"N*>)M;&MY<]%M;P\WV>I;
M3UM>"U3VT0_1Q[:Q*OK/.NA2 6Y>_M&D##B"MMM4+(26M@C[>)3C ]QKHQJ;
MG0NM;BV%<=_]09%%9FB<-_$FZ?Y%!U?JL+V;!<'G\8%N-NC7S-<MXM5)J'EM
M&6*SU\D=>]\M&_\'-?=I/AO;5,"C'/&YN:Y>SJ[9S#9,[SS$@0\:YZ?#'*Y\
M7I@ZRQLT21E,UN;AF#W>J=#L)D.5?YG0V.#@][%MWRIE/8FS?J< RDNG@)T,
MPG8L@+AS\NX4X 0\ZY^"Z>T!T?EGZJ<\B.BTTX^B-2 2KB25[=UXB,Q3' )%
M!H/^DL[7CQ0)(L+^JOL,:.1^,/^C,3D57NF1T0=CG.;;ZY<>.S2(7B^8HJ^C
MN3M1"X 4X%(.+F!]*U%!.JHLN;V%ZQN?S ?$1]85+LL5?Z;O.QP2STGL:2XX
MB0UA<@/B=/=. 3:'0*)7<R(%T7HXY*H_O'N:,94:F]GY\#9#]WB77H4EIVK[
MNTLWQ(N'=?)3K1]A^#.VR?B7Z26R A:QGVG# G]=H_CS7-%$N=.HN9K6TI'Q
M7>U4SJ/CCT,K)A ) CV>=:B'3[IAG*A>SR4X^(4I[U939,^35Q8?/N=[[(CX
M[DP@<LF>RX-EVM0NW%B@(?(=DG@R#7%W _L'BD^:CE%6FQ.HPUR*XYJ@P$<@
M[,[$*>!E^,@#)\!H>H_1_ #P(+7G7JPMQ2^0[*]^3VR[6(1RM^C #4]98!,R
MM\"A#O3OX/0QH+N;H-^J8$CZ]J[7@ZV_C)E*48FE*B)EP\8+VGGAU[W<W/NG
M@,7@WE, #]RX&FL8O;_#,K=QT"01B6CVS;;J*6!ODN@JOM&I+JW-.^0ZD\,$
M4]4DL!#%&["D(L;WJ+"S!8*E,6!^FUE \MLKYTY6'-N)8@JHH4T5[,X]+%^8
M"QK*6+;SZFE5K-HME!Q=LN [$<:VG=5[029P/!/:'LH,K]6L^B8'MI+OV=WN
M]@$CJ^G []VV^>9O7M+-N.L1C[7BN.PTTAP(^!'"1U3!'G8,T<W@_3JF[0/O
M)5*J)LW<T:7(BKO1I]0GD%T[^G\AR61 44*MF[<V_A,6+6;EJ%/C9G[\HW]'
MW_3J-<D9[D^=Z:(V5SXD4NCP\*RH!@A'DF3\.W (3O\FS..T8)6>$&DD=KDW
MFF_B"F]6$]TI0' X_)SJF+QN2W6%RD)8CWKB.$2F"&Q>'O=Q7L.^>7@E^4=?
M9]61EZKTK5[ X@\ERR?'*V7>@3;M-K0N?-<2;>I'>6QN^WA"/2ZD&[76EGU!
M=>UU4MCQ>.D(I'B+AD-Z2;C/-)JHA7-KUFQ6=UR,P[^Y*I"-7$-%X;WGM;/:
M1S$].CST3*[?_P'N[#)--W=97\%ZM$'9_>,ZN68S&.'Y,R=EDE?K8VU1_E-W
M8OLIQ,\I#EWB];9,[QZ*L1:OQ$EU';T(=C?@&VCCXZF>R*U(F+X&JA5Z,Z>S
M<>V%Q/*%.M/) 5$_F=^P-[;F%;#623BVCD!8U$^"8\OP3Y&['/?%XSE?"+ J
M7*-7]I5+1 ]%D"[BZNJ:ZDJ*!B36HE1<OB@8M:4_[[V2IEC.<DG\<[E9>,-E
M#^B.O(9TBPP!A!?K(,DWX:+274K,-_PFO5TY!#:.(V;T57.B?>M<O@@L+IYY
M9RD)F+ZQ]LCHV]\?7">$3/)=Q0'#D4Y0'O_TCJ;-;+Z)%U;RP;?$/I9]R'K7
MR\W\+M5,0Z(F^1&6=B>C'3^,.06PKS6M=/'G;D3?J<=JO[R*X_%%3U]C>]#@
MV^*6(O/I*6M9VJS6HQ_/MA=-*OTWVI5!78DT&WP<..IJ:^>,UI+O\Q:E<)9D
MX4L.]/G7,0U*I7!.R!5L?:*/ '*B5*"A@: P5;B[71 C6788O>MTYTFU=@-;
M;3NEMZ_C9ZI P\Y$!E>^JS6XEHQ'\>5#K);\5E8&XKZ[L@[ZO71*"=?.5QJM
MYKY2%(C=OE:<^PAPG>;FO;_GCCE?CQWRM/-DK^W]+FDM;[HR!1RP9>1V65S<
MBUBSIK3#L75+8!?:?3W*9OM*-A!RK=BEZ97ON7NV]5';^.B9Y:.;7XS!S"JT
MLXL8N7U-STF;\Q %'Y0W"N,D:^XWDS^&N3ZGSS-LI=9I*5O97\K+/>C[Y-%K
M)\H$$<H8/.BC+JX$Y1<C:\-5=#!B"CZ&1Y=+TNZJS[$7;"9I7]L]0,5^<+\6
MUF@!H(P]>"+&T:'.,@)AR+V9[YP6WM^AD*R1^?[]4M*TKH"OK5G6W/OW[Y+-
M8E0S9OX^-2JY/6LX3J;'FA>!GW3TP01)II:NUG&ICGSO.OM;.GJ.LZXX'BWS
MW&)%6"4 $WMLW+"Q$\EW:0S67>97>+32;6UR4+>6WS7_2)_''K)PY?'C]KL\
MH8%[&GP!*%XUA"#X%,"B>@XCUHQDGO8W-*N]J/S6C\G!4\#;[#8H76;Z79B#
MB[T1 )!W^8F7]^;QO12''!??#,=,,$,"S(7,_<'N8?RQ<@#1X@0 P+:*"%QT
MXVZK.ZQTD=_5%CSI:VEI;,A:R5ZWC<VV3U82WZIDT3*DN,!(_4+VG^;_,.:(
MAU@Y+8+.KYN3<AF6![->6C]+6CN >ZMXG;TH2Y6M<T I\(9"KMDT6[JB8;SE
M2KGIM'"FC_=3U1M7KOBI:+5K&5(F*W^C82@.&;;F&%451!D$JEC9&=FPKMF9
M5XW6;%QL:+&X<L&K3Z4G'V5G]M#WG$!5<90C8'ZLAE/5C>P'T>IRP]MNY2^X
MN576S)\L<1K]$&E)NYEPDRY;9UULH 84A0#AH:B%2*[R)!2!#)=&5&FS6<;V
M VJI(C;W:GQ?5Y]C?)"G*_'=QD7\<9C&S//@9E3T2PL4&7- Z?QM=;O',N33
MP44U&,4WW:RY[D&LK2?.E)_^]OFML)K*R/#FUCTRN94=)8'\[8RP"=5HD=QQ
MHU&#<:WX Y=-/NZ2S,(;M",B-@SI,MKUSZT;%7DF%3!P9GP*1CM,_#*6-YQ,
M@2TM3?'QDC_9BM8OQO#9I0W?X-Y,A8E\O<1^7X_5S-0!#*,E&O@4^2<<TU&G
M&]7@PYCB9&>D:C_0X:_&4HM8"(A)ES8P);XW(0\=@ 6U':='['NP6&^PG*0\
MQ@DU^\$M34L_/*[>\[UZZQ)KHRDFT7>>+IU?38?& S5C4X&'WJTCT)O;I( O
M0)^&'?9ZO*0<,&[K+Y>/"/OM19GHOZ5\>H.5T=?5X /3].Z<[T,AF3>2X_6^
M#MT9&]5)$VOFO-K0T)CT]'K^]8KY'L.:.Q>8STF,\DSPM:+II!*S:<;WP8:T
MVJ6T3F &NULX!HS+I')PVYUD.:B$_5))7K36ZJ-/SW"1F,2(><')+:*#GP.8
M8P:#FTA'#PK-6X1^@O(6M(8ZOX_RY7 6NME SYR/&_2!44.XR];FK^ .7[?<
M+LIBNH^+RO/P;9*Q%-AQH+_X?.;J9UP*9]+K9[UVUSD?-&!D*6;]*6^/0106
MH4QKRH@<.2OCG@XZ<,FRP8< (SF3%-YZ9D.,%?4_Y,!@ ';/L1K&F0 9B5FW
MU-P91 V>E@O5.&_1BV#SJ%(K>,,:$LD&KB/ K.G%@-FA#QFQ!DZH<CP-@CO?
M=YT N=:.(7HJH"ZFYQ[;9XP7:.M>=6>I%U$1?/A:^48]VB,Z$-%(N#6%#[78
MQ.X0KYBG1<NA^W.3T>!F799;*W[7+D0_OW04N,(>B7U(-L37^ZUV[9_0P4*3
M.K584%0^=I;#^/##TQ*5VH\*M!'O,-\=7YY3#QZIZ.'P!OC84(9P@D'TF\0'
M'B5@KPW*!Y.2'ELM79&^=Y;8A?MC +;JNXMA8?5G6F_]0^*Z-SCMKCGA#FM)
M+#):ZLD8%Z'+1 +L(BN?,+%VM5.\(=F:7==4H"/<%%,H#8;5XG^BLL#=PIT3
MS^=G!0[3N0SJR@2X7\R4X!]_J0,K@)2/O,[H;0GRWA0_/SX4R\<^KJJ-]HA2
M"/2IR%[0Q-T8\YCZ7+)\\R0S^.SBN2-D@*H=7<J>TR6JR61_[458W'YCB]QB
MR9R\+'8HBN@0@)YJT>==!]9VRPW.?3%&\QR%/P[**3=]-OTR2F 1X(>D56>;
M\^?H.295@G-72>>P)S_CR_+5.;\52+BM=.VF-XE^3,J35G5Y>??->]N0^XC.
M?[:9A=26=.:L*63$]UOJ,Y0:R/2"*8?$J#D[M$*K*S>+S\GEZ@3>IWG72]#P
M#\2@#J,A)FX.)5;P5P7RQ\:)#%69A$^A21ERKQ'?VFV3$E8 U$I7/^#<WN''
M44/1TSM1DD]A]^HG-WWJDKV&4Z@L#C]:VNN<ZQE-N,ECDNT,HX58H:"41)YQ
M_F'2 AI(96-CZ),KN*0SR3S;[4WW[$U]>NN=CPLR%*&=2NA6C\7$,'<2#T1V
MI$;MUN/T^V:2'I(M]9(Q<MU=]:Q7V<8?%SCP]2ORBE"V_&VKRB_X$*JZIX]?
M1KGIV?#%.+2,2K2P$GR"6O7&M]"/=U\7WIG;DZ:F^='#*-U(Q=:_8<.N>ANG
MW7Z<E=CIIHS1P]U5N(BSML"GR5<T5E>_UX][EYHT_OX;<V84)5N+HWQ"-<0
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M4P QY%?Z5X3;+DD5.OP0[T?66A%9'_L!4#[0ZB>B"EFY#T\!N&/ L5[L4?T
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M<)S^F+H4/OH15JW8''\.<N7#6@J=,_UUJ&N[!'J Q9)B19/N)L]O[I97L[4
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M88'^VZ>">M+O@-DW&H-_5J/SWXZZ(7\[Z@9_%R/CL&<>1W+P6. !11-YU1@
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M'H?#&&C59K^\K4;<#I^\J]Z:,1B)2N>G![-%9P!KQ/RC=PN1RA*M39FY.7-
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M:E^9/)M0 +TL@-^FBY4,(8PY'PW0?8P#JV%F"H[]:CKSYWL=D^1%FU*!@"S
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MW133F\Y'G$+G__3!;T)_^#O4\S%+H,FK&^?J>FJ;ZMNQU#VST@=9<WR&,Y\
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MOWD68F,3X"F@#S]YS:UN\\#ECQ^7RKV#7B-$PLLYN*/0YLQZ.LLSK]KBV]+
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M]Y4WTF+7U$,@C>!A0NK'A*43PB%CJ@%"X(I1LKX0Z>]=RC9'S%] YRJ=\=T
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MPOR8#'B^D&+V)S6C..]*G" CNCED+F\_6HDXWE/3_*C[]ATXF&A2./S:Z5.
MMSOTO-W^^5\ ?#.$<+*9#U<J9#04\&'B_T>$.\_=OQ'N"7\!BL KO7];<EF?
M_%/$CC[?"0?JU^*\RT!_ :2VV'5<T=[KAD8L=QKSV7)J+G-I8[QR@\_2 7]<
M:*KQY1\SP'7__B)ZT/OH\9ZI:DK^H ,JR%";=$X?<_:K80JV'L^;^_N3B$91
M7R+*SI"/A180'Y;&PH1E[6NGP>7J9_9?K)!/U3$[082UJB><*V+"'O\ ;::B
MZ8UK9>2I?4KH=OVJRL^]L/+YY8[!SS"'9;.UJS@EJ]Q7X#T9KX9X[(,W2ZH2
MW\(^R*AZ?$Q1D> G!TC^(#/_WT0\P@AN*Q!$5=!D5&X47%NXGV$LHG)?S*PO
M4W=JEH-ZA=T>N?FM@8VBDQF\ MYN1YZ@O"_BY)F@"89P;%L[JK%NF09;.'5:
MFFB-8#$3Y\+74:5;9W;$@]WFW+P!PL+ER>JG(1')E>(QKOR@&BV8R&=>Y60.
MG!G>2:6@YYM:G%Z>8S,D.]G"Q-+IV0=*].DS7:GY6I>O23C.FQ\;V]&ZGY.,
MD3?"F&]3LA0Z&<QY]AYEPZS?$,FW2W?4+M=][DM0A&,:"_,T5TW$XL%>E=CC
M6;90M3?7M0@R10N*BT*ONI6N,TG^$0]7(EP09\-T\8QS4L!T\JL9P=>TM(E\
M,@\%DXFR"U\2TO&1V%5]026PX+BG>G]>&]5IOW(LJ&90EZE+UW(,U^@1Z:27
M>DZ ES.ST(TZ4.BY8\CM]=\L;(AQR1E%.6].52ZP:#Z3MZ;DEUBUZQA5-=T,
M5,8HZ6,E0H\J98&P719:^(PU_%'>:A\QC=O/F_-K\@C\?I(3EK.=5X5R64T6
M%\\WZTLT8530?*59^#5CG)+2W(VBG;V+F +WJ$H&;^A2UV;_$(P](8UNV.%^
MO4L;K[IO <ZAQ].XFVIYD=""%+UCC8BW9VOBS&[1E]M_EX""R6"5XXLK%#ZY
MWIBXW#W!K*3:M#8UPM_/ZC)\4*A=.J8W*^H;9)5:!Z:C6\%:F) 8("OQC5S#
M>-VWYMI8\[THCF7Y7'I]&E3GY<M[T0"Z)'.J7J^^STYB22W'B[4S05N4V2F;
M#>G3>Z87D7=/%W??+F0+WY'CG+G;&J+IBI-4$UD4J2JPS%7$D70_3R(ZJ7_C
MC RQS/')/Y>@U[H!@J\&_@)ZVE]-"?;VGG7PO6YZ-Z!&]_S83U\*V,J%R*'(
M59ZZT<523OX%J&+QHW=$_NS9=E@01+U,%&=-4DF,$H!VDVG-$G9* >-4M!UZ
M,CPU/=$0H8=B,L,)5+_K#YZI>ZP/T8NN45_&,"_Z^U:N%TJ9SEXC&D*B,C\+
M%:4,F6Y'(_AI/Y^%$+='P%WO6RSW(3V6G"Y>"!:0L:='KK:XX%7=^^,A8Y3;
MD"#01K^;PU(](W@ 9&R$A$(95E!L7X?I$D8CF^:-'.D[D4OHYERDROEV+XWT
M:$L9&/G:4%Q4LQB4JC?,&>I$\5N31OO[TOCAVQ8VIB!P+I:GYT"X%\GZQ<7[
M+^"!:@4HF)7<U&JU*).]LSI%-P7O,K2\:NW^+[;$:?=<79(G/PJF0$<P*^[K
M'$/N%(WX(8A\SNLV86QQ&) , /74F0A4#"A<!F<@PF'<61I?V0PHHYY@$@_Y
MC]^S\/-W7<1@VKNNP@];2Q1+_K2QV<-KIREG'8D],\.%"%^5?#2)1]UPL'SY
M.7EX>B"\GI+S\2_@H6!JH8VOVX7/7%HB$<C:K<3P0^$OGPV\CN6/_=11ZY6,
M[Z9.%\Y8:<&T#'WE+(N77IHQWT=2*L#^/UY)+K>[>%#[4P:W>'1K:/\Y.YD#
M^X.:-G4^YSU 82'MVNUK?]Y#F^7>JD]7>1V108NUJC&IV9OI<#H;&\"WNQ/G
MQ8]^MFPWA7(/R_R%H[PR!PLS#H_!FHS#ZOGP1@G1WL?/OQ*7,\9K5LNIN)'X
MAI#?\0FP,&>[W(@6K@A6'IO!OMCH3Y@,8 \;TC/#W'2,L0U5<GNC@?<J!U:X
MQN&ZY#B?KA 2IZM,>('V!WJMZT_4>EMDO'8JSW659NN*:0V32V8*4F!S=ZQ*
M8SW6F_I>F_2F2+GKD-R@P(17$/EN+8SEQY^@N5GIP?;:S'=)7JW68)(><&,)
MXT5@GDG[&D%;((ZQ7"@/Q8C;LC"\>-,6L,A1 IR/7A*_@'RM=],\9 (&6/5P
MU^-:*O:N(K+Q[R(SE&/#@0;9-C7X-@N""-'PZRKSC4.>Q^"1OP![_G\A5M/"
M]H5.(0%OVC,@^MM:S5-#(FK=*=9/7GOLOOOZ6X7(MR3O^EM60^WRS4@.#65L
M/L'9HJ[P[U5,2'<[%52W)T/Y9)!K,X-:8L<?1F7*Y]G((6*B2+C9(=4;,!99
M88--BS7O+.DMWFFV%0]^=Y5G$CR>)M!RL!EV:ZO5CZ]S#XT8,\$LE:\?Z%#[
M"0<J@?.U'5<89YS-AC1Y$[5<Q3YI)0T1N>@-D\ZT8"SG###M$2X(33_9'-8I
M[TR[J!_&LM=?2#O9O(?MZ,W#Z-Z_?.G'\Z1\#(DLED!4M)U,=Z%N,P,/ZEL#
M@E83QZV4K-%$%E9Z,X$2%4YMS)BM?+GZE" P=+:BWNF'!DJ=0)&1WXOIH'^.
MM9?F3@&7^CYDOQ$A 78O5878VSXC/%R*8IZ)(C[AZVN7SA*Q[_>?P+5[%D$U
MU\@^YQR9SPC# _RJGB;TS(H\2R4_D4SAC"NT:GN>?:E1O<8:>\<4@\IHRRS<
M>PM54J^]&Y+(84MA_SRZ9*=!*%-?:_NQ[YU-QD9"W:;!>YC]Y!UB]"_ 0>>;
MOFOMJBON8?]<ZI[2K&Q ^5[&[Q-<_3/.+]W(I^D4IC0=#1E/LVMX7_64CBV?
ME02SXK9827&6#\6RQ2%O^X@XXRH=C\>H2WR@]4??!D3>\O!ODHLH*Z+,M!TL
MJVG:'LX(($ .A8C95(R%"?"WB-E0A")C+;4='W4^27+V?$=YZATA'*.\U5#F
MU&QW$0F#FX$U[6M3!RHK1%.UYI^N)LN_--C&PP-6Y!,TV1_.:2X.C8"*+7[;
M/6LZZ7]]&U*>8Q*R#E%0C3&!R+QJ'-\_>^^%<Q&R>R$81?G,K<;&N>0EI/'R
MB^SZDQTAH"9KU 5#3J3P6'B=:CRV,J\QU6LAW.-8G7Y3C5NK>N?X^NV-C'@M
MUF']OO&.M$5$8OG.7 )7^O1T:I3- (6:RKO$W&9:6#")3P(JX)9*?496HG0!
MG&LSR_7-Z17C_!#1]XVGI+?YH@/O'.(EO*AWWZ5(0]X&P%?;;Q[XG95K\"/E
MA)L/KI;&)#*.>BK)5# N.;::)BY%;7=S:9Z[9*Y-F2./"R3UC6,IIJB'XEX%
MT9JU8]J_','-8IHJ,_JNMJS/0?7E-*2&BBULVY(<GUY8Z(;=/;/:N6IVHACQ
M1K523O2(-QB=HRHK#[Z1[]ZWBXU?^W$0O9&'E0CWYH^Z4?2EJ:ZJD_8JG-VR
M^Z;"HE_.%)]G)DM9)NW"-"?[<_&;'2,7O+G%>_&P"87F,(R5VI3PF5QU;9S
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MM&+C^<>">;]AQO:7_U&0I"GKI3IY^?,AH(6]L7,'AHJA\*1G1L,+[!H]0CV
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MGBAOQ,26*JR7S[50",7Z/LK97 >YS1@Q5V>(P94WB1(;W;HHUNFCUIPDV8K
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MRDP4^R'&W8&L<(7><MK2\EA>Q23;OHO0.GO_ND<"Y8I!/JW?*.F,KML[U:O
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MB?4X/]WQ(47J$&O[B;6-+GC/#D.$1/GFC;NL+5U)%]U%Q3.3K/1<U-YLORG
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MN]]_,"17R]_Z</_5V&/I%I'@]?R+^ X^+D'[#X8Q2>Z3ZU DQM%7-CR:T9;
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M\10BTC/3/;J-_B::>RS#Q"BXCFW91PFSTUS<+E3T-8_O^43]U\BWN^Q*M9V
M,^);1/P.##0X7_I.-WX4>3^7?;ZWWS[I4O),([AJ!7)[N O^;=WM'EYXF/5
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MV?8E@^WW.J^V+FL63]WD.?:0NGPY,NM[!*RYJ%6'<PG&DE88H2H$!=$CK3W
MS>"SFK,I3"U%>ODL,>D#@HF;PI>_4[+4=<5>]'LC6#[S!&!X@A-)_ FFWVT;
MCDJ36(A%NUL.)I?-/RQ4CK;G7K][)Y<ZTE0@.2!6][6\T1")&+P[N2A9#8_P
M!'FV!==7WTV:.4;1VY8OZ?9M7DBDC]\<?WO[S-.,Y*5%X4(3'#]:$\_D-IO5
MQ,,KKKW5 F=R?;3XOO';BM$]G8NQ&0L!]G/8W32&KZBGB$.^\NE]5A*J+S8Y
MR#FL(% ?6#I^(?Q4Y2TME:<<HJU91LL_H2[/'_!EXP!?!;KHO07_OY$N_]?$
MRX'>.E26#$;MB]NACJ1I#A0QW6SP]EF8"A$HLGY !'J_&57UD$$ / 1G,0OA
M="]!.S9SK8&"20 &$[DJT^25MC8&*UGE# UD](MU>A4D](%Q@2(BLA TU4Z^
M[AB9>K4.YX@);S6_W&]OL*/?6YJ4M,SW_GS@Y\@/K,"23>O=,S.<VZ (%/T+
M%R+PYO4TH_! J;UIFSES,6<C+M>@-R_3_DYCY,5&(E!SR-A.=D?=^&[C68TS
M5+WE9P6*_9IU 9N!D"3_Y+,,?7F#4*Z@ZN**Q-N)5+%RKR.KLR^<SUIY^!N"
M @66:)D55@+#@(3KALF6>I_X<&<5LA@9.V2H[TG-S]<@X/?F#Y'+>H@%AR#)
MYT!1U;Y#92!&S4QW@P[S?MF:=%"<K82<M$7@/:.@8V5C,9WS"@Z^SE/4/0FM
M$,8RO6!>V9HD-"@8/,O1"S/E'NLUOB._W>G*%'>9DA'Y)N8<'=]D!> +J$!G
M[* ]>)5R^#G5- >ARLK*TN"'3X>_&2,CAGH?2RE(YZF3LPK,<\=Z%*QLY>^_
MM8Y6(5@8U_%B4A-F>01L/>72OA5-_+P8^<&W+9NC$R:.=210=V+6&GOM>$50
M6*-F*-;5Y>=^HOK$JTI;]HH?>1K,S@,]5'W@8N/N-["GUT_#&Z'YW-%'AYX'
MVH=>!.JE#&-W^(Q@U\<O93LC)N[1#X(H![#[G\(5@(Z 2-Q:M.=1T/].4?\/
M25D4G85//FB '\WEP5<4AZN' V&&1.!=*DZ2"#QVA9\(FQR8_+9,F.@Q_J:Y
MEJE+F*B$S&7.+T7HS*#MU:'%IN9A11ICTTN!0K82%U0M)KIIWM",*BA3Y'>/
M=NM7O&LRV8^;7XOW' K/;;?,-8:.;;26"+#QWI$6"5NT?FZ3>(DO1JU5/CFG
M?+6]LH=J@ZP0%VNOJ:>H'ASD^*5O5QRB.^B0+\?_,DV\7^E&>SGKD]R%>"5D
M;3-# A.AP]G4!*?7[ .R9^5A:S8'#5OW[W4+;9JV(&ND6D2J=Q:$M)2_6_FA
MW-TD)Y9]>ZC*_C=@WJ4UP\"@!T7K&)=^WQ1':DI5#EI\*,GL_\ ?(*AU@4&"
M?9C6;WLI6R"5"G,V$+.D0>C G+PS,2D-,C:WG:],]3@#M(OUE6B)SCYP>"U,
M0_F2PL5%_Y31#TB%<.,)M'6*"37HLD7C;OVXK+_4JSSQX%%5JFC2"SZ%T/L+
M3X'ODQ,T1V751NWPLO(LS'&K.1/6 'H.5^6:(JR+]">WM/[:8O>,,=7XLY[X
M,/\64X1U&>!-_H<K5:$;KT6RB-K#MH^-&EY/8MXU3$0?GC;9)0(%HF;Y_U'$
M##O$)!#NELQIGG@LDU#:9>TCFCIOG X)N1EC/Q.0N_ 3%D%OJM]ZC%&71H^K
M[:)83'7<,]?35Y3/75^E]V"-/N;'"_? #.2.]:@U)/H@JEQ:6P[/O_FK76=@
M2?K^)-(/\(^)8(P),&_Y2Z/O2_4I9<V9^M*'RNP?&>="5LLQ8^;?U[M*U-D^
M+F3?>.VK/*I(EC*Q=*H83XZI:)RFL]],QPS%5K^L>=FOD*B5\42F6&5;YDHD
M&1\_U5/R0$-N(]-?.U7 I:BF6B.T9L"+%[+1]#:J0I5!:UU>CN<>=YZ^G<[N
M>)^Q:SW9N4VH-A&I-!=?-0-FO(09#IO%7C_FHO4=$XQ/RZU,)S\H7_&_HL=5
M*T+.MD_;/]]'!)Z?L/9!W>VM_(_U0],JGO:VJ@_XYL1J75:D.S+J==U!K?/S
ME$)*"F+CGUH\KPY*XSO6V))Y4O-68F/ZZKJEPM)07<A_%L'08MWPJ6Q-6\>L
MKGHG'!1>F>[6?V8\$\NG+J7KA$PI,#Z+;'BHP4''<)IQPBC&%EP,;K1G:+D)
M*<.\A]MIP7!YB\BJ)#W_._Z\HL)OQUOK?:_?;CWSO:'PZ2??\_%_./_(.<$T
MMO?6QKX4BPV6\=SMH^6J,OL8_\C"-E%6Y.X$N9/\]7>HY!E+R7HPK;(XIG5J
M$T1OJY-%6T$O4]IW9YWRM0:OQG/&- &!)V_47N9\#ENS23M]4"AQDH9GRL:K
MX>!"<9DVBI(AFY$_7WF'FZ<^LO\F$R\.ZHPY&LXV>@M[-83G\GZN+(6N1&H\
M3;#JVCC;A4NE!CCL!^;2#YU7-M2X(>O\GR=(NG6_\(N9\=C*\-742X/IL7TM
MHS.!;^:9-2PKOZ[KR>VFP%:.S]ZTL,<@'H=KL]W4U6-9[7"0A'6#.]BH'(B
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M?6Y!(Z,*@.543<Z,C[@=KV+?[IEG&-;HS#7.CPE,-W/-RI ZK'U:=%2/Y\*
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M">:5"-8M'Q3$='ZI<G3+T+P0:K_%B:8,C9L,5]8CA\WXS@;_J$P[NS4S'5%
MN CCP\B'R[&G5:"&741Y#-"B3QH%8KU<XN+(!#8HNJ2U6A4*BE>"1S,;NG_
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M./O2N<>W,E(9/\X] 6:"5=;V3M6=(X$ "T*[CQ!._@ON,UJO6>=J,;8M_.Y
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MEIFKV-$)4(SOP_:N_N0Y[AE]*N%CRO3H?><^EM3-&Y)[@/G)ZPGYHP?)WY7
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M5*Q?% &"^B$;STNE<;8=9T\$5LMMON=N9! R#$34<Z9"BXQZ4VK3O=L.#S(
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MD*=U'T*99&G''YL7*,+D7+-K_SUK>YO14J3!1:4B5'V>]K<972[ .>/4Y(<
M'L?9>( F+92(G2<+P=N+!9[.N-NH$@6+"Z^_2!Z8XY9\^QGDL]2^HE;$1=BP
M-?W^QX!%OM:A:)^;*VZ>S K NSL[P2=&E3"*Y00O2DLC=B=?^SO/T8NBP8"
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MH>2JW[H-7?VAKO21T('*P>/"*:%3@ Y;1_D[(*)!?B5Q"5T'YAFXG7\F#*0
M]V"9^H3& L..F'P*D-,_4LB9=[ZE<O;[EF,^%MG^?-+NX*SRO&RH&,[@\NGL
MKX]F*RZG@'2'W0.3CVE$?<1-V=!"8=\(1(%.2PYC/A;,=?*"$T1FS,9: =O@
M+Y1$V\6@FK&OW>S-)Z3D[%>FNP]3K@'KK5CJ9![!AK+9I1H8L#S(8[J#B=$N
MW@]5[6N#OD4;'DF:-I:?[GF;W# "0)PA8\?KFS#>#3](.G8^2B[DW<CZ^J$>
MJC;#I2UL1T77:N$IR]LL6H!OEC*9/0\RV@4[B\Y0#F''9DYYT3:8E*?62;,B
M[(E#U$FQS43ZA>7HQ8\$LGN()>M'=\Z#;S+37=!YB< M#*(N$!;>>)Y",,O'
M9"&T+3(@:1&"ERW/L2##0F_JV5Z&CBK_*"VEDPFC B8XKH$J/",+RB+0^#B%
M(^&Z\9/2 OPS"ED5A)X^\U1;/_<0-,NQ39$55X>"7]P!O@41'K%,Z0ZVP"NK
MVZ=V,S,_Z&ZT\R+3-OCEW6Q^>GZZ6:DVG)WB0KUAFP=C)C2]GF,?UELEB2_W
M"K1,Y]R>K,5;WT<1']8[O!*Q6F',B0U>8&2FUP7\H-@K2XU30(X&XD]RF_(5
M''$./Y^/M=B.IVU$EA1-6IIE7JU"],5]=V4F^+Q'G<#""\G8+Q"$/CG4^X03
M?(_)0J]/L6FTP/S*;&<#DQ]W39*0OZ.3&?2'HX$B#MG$N3Z\,4<]XB6,]CQZ
MP*V=4.3&^<7=Y_HKX?RO22(^,;,\YN<WK2[>YND'>)FO!L.R9=(FNJ:G[\FG
M17$\V7]ANN;RWQ?L\QVWQ\;>O*2>"%,9Q4:W@H6Q$]DE&"7UXJ;"K];KVW+C
M#8YC@]=>?_+IH5EPJLE$3"6BM<CTBP9G7%F<@SZ[ZWS6\0H- O/&+-4Z77Y(
M/_MXOB"46I/> D XW)[J-B"*MH.B3P3&FOJ<0[#U"?(D5SPXWTXEK5Y/5'BK
MG/X7A];=XY3GDLS;>N]M&!#?R)\V.G)M1B[Q]_.)OH8<QO()KTK,HQ)Q24;2
M=^B'#.E;X175K8<&T<W56MVA<GC8?*'5-&:^6VX\(Z;] >[>JZ[Y=!]^F-P>
MUY'0M,+QF?]0V9S<$YK>L0)UWPS/'8R]H>HEYV-)<3@@\[J2^>@FO@D#OM+\
M0>"K8TIP*@51\>/ :-OSSPTH="+\6:OX4'*P)B]C'O>E))]%JH.AL6;=QPS(
M0'&#X">XZDYK!ILQ_&\&25Y2W^%-97>9/R41?N.R\KL/M3S/@FZW& 8@3')8
MY$9AYU?30!S^"-ZS)4NAZ@^J1_5?H1"]\?>W,*W=<^"5'0Y@%.RL2Q,?<2^^
MX:%0=1V<E>\Q6*0*X5@;)2W-T*U<]\OF ]+;I__JD!)C *4LJK <7BMI;FUD
M:(-=2NYB.+[5 <1H+G?-<FL7!_SZZ"PQ5$PK-TX^)+D.'?F#$JP+$SO(F;JH
M46X-5Y[#&Y&SU9^TYL#DE2%3))B?<)N4[[)%3Y';@4?WR=)>A%%2U_$'9(BR
M?=':SGI=4[Z/M\<;\7?CD\*IW&VD_M#C4\#9TK@_YY0#C^@,",5X1@,A92$N
MV[K.N\*K;NIW^ =CCJCS-NKH"C]]D.]E05GJ>"V75#@J?+%*5(H_24TB=&.9
M7Q%6L"<OL/ZHJK&H%%>!G/JLB1L[>.Z9&7^Y"**P%=$Y"B8"N;&FM*F JNOZ
ME,:$=:Z,IT.>M5C>&%B^,TS5X'OAIV'"#]Y&SS"5D<&%Q%=>1-_#;C7C^L:)
M),Y4$K4[,"WWBJM*B\]>(@Y$]=B]F7;7VAVG%04U>8IZ@=26RK&4JT(XG 07
M_4P$1;MT3S0"+X)).2P<<0LJIC9BY&R_(+H/G.]P<<KNENI,%>\N3=$D]72P
MMO9%D$UO!1[RK)IF6,]FD]X9@%J'R=HUR)C7GWVE@D-WW%=_&S:&Y;OL7J0B
ML."O$9A'VYNK]C;Q.(QL2,U*G37O\HBRW [KY9CJC"7FKY8U>%M_Z<CG5O">
M_S#6$IK:PJ^+55Q^%(J;44?@'P_1Z4%,-:;AN$=V?RN[+J@:630/ C0A1A*B
MY@Y/V)B,J^1UP/9GSMC?%ZL14'MP<K7\1 )2W&'#07ZU\''D]Y?%RK'?$N[G
M=OL2;@BHY@4*F29O>SX.+;JOS>_YC,ID-I5$F\-RD_R* +I/W*I:V" E,K"0
MM?P=QVF\,9H:76,..QA$_:^ 70[GCFRZ78,+$$R;X.4=R1),>_]SC0I+S<=P
MI1LO%8#M\8B2X*O#Z(O/PE1N/22?>;((ZC!@G6DM*(W&20J.&E1%*5[L8TSZ
M&+N=4,,S)X/0K<\]Z9^^&H?-CIK6_<[10G#X(O1CHMRS 4/S.NPH\!>#S\QY
MTM\W/P3#*=7P% #VFO(=Q (W1Q<E#72S0IWV#&NB6,]/?5J:#[W2*E$5Z+,,
MWA@Z?UB&'8S<32.'8".DDAQ$E*Q+\1/?W^]+O">BY:;T:9Z43@GK< V_837@
M-@2LW>&);JN3_D](U)2=.6(?5N'"&7"OYTF$S).U?W.,,=Z<[J*MO? QY.+B
MIPL446ITG .[:D7F:GL\Z6(Z,9$E/2ZYQ?Q^[[P .$UD7G(T5U&"6R*,4AW1
MY.*O9-M2 QPBZH1C0FI%+[-17;>J+LL!0)^$-?$+ P!E5*AB <M-(G_N:5RR
M)>O^S*^FB/UO<I#?3U]/=VFTWD^B\9#9>WA$7+T&N_GG1Y)04!.A-79>F\N
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M?SC[PW)9E%K@YW\Y60Q^.O4_ %!+ P04    "  -@G]4\N+5!BI+ P!\C@,
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M!(4$_VW"P$3_##,+.PL+NR W)[?@?WG0.@'^8TRS+# FAE, (S\#$S\#K0>
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MY#ZG\T7>OUO!FCV8U_SF[[<<$9_\U;3FM_RN,(T[W<ZQI4QF&HAL*,6WE]&
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MQLQ%NAQE4UG"S+NH@I..ZJ*^SS@%IS5UYR,CP_ "WU![8RE*L>GG-22?P"[
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M.#/\2$M-ZOS0@8"DL.W(8-;9@2T7;WKE#M" 9^M=-."0- 7=4W8$?M/_1AV
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MD*O4P9XJ#SPR#,:4M(IA;;IPUSURYZ? L#WI,F)'^VDQ@7J#=N'KCZ7NC#1
MB_A?)!E1=YN44@=2$F:O.'W=(H@?M);!AGBA*3NHL\TVC5DP$P-'U_HJ);^N
M!I/M=)-MV637*+A^>$L?.3#!:5J9]DJ]H/ZPE8D(7=M#H *+SX) 4.O)EDO.
M*M?08C$?MP3YE%O2A_SOV(;R<OJI6YRWM3[ULB%0PYK\;9M,_ "(O84#>TL-
MS5);:H%]?S$Y4*/7*5L0\:@SX#Y-3+J&^>EL02I3?/Q;YK<T]^,3:*L!4'GD
M():_I^/G8V^WVLR9>V*@)D <+V92MMQ:Y)5THLBDI*5=)?"\N3JQV_6C;RV@
M4S@!=UI83Y."Z#=4A(:5+)#43[_MF<3I@0/-LB4^5AFT("J(YK\'?8 ["\E?
MTGJ5D]V0_K'C(IZ)Z+LXCE$#XS^"IX:2CN"T;(N<S4,'8ZJVN TV%PY3OM:X
M7TFK &2&_ABT3#\?&*AY]7_W[2AE*83,S%JL%,LZT<,1O=,88I%#Z\;X-M2\
MY8JITMV,C;NPW"H6ZY$N=WY >//G(?<RQI807Z_!L$\VP0BL&=JP56%\Y9A2
MVIC!C>7HWDW3>*KXKQ>,=&^6*U^3>)9Z8HM1/"U7,CHQA31VUBZB@BVQVHB=
MF->@Z=JCK 6+WF0O^-&;^T*,0*&0V+SZKD"UP%PSYW<JTP[N?I5)^TB3GE'>
MXN*'3$+!'R\ B 'W2)<FMR=/])Q@!/*W T9+=:7B0PK ]%8?\G,I%64U\[1X
M\%=OR>*>D)#8EO4)3_]Z#I]XF1;'])2;%;'6D1$Z4Q.R]$,LIZ&AJ6G!P![P
MVO_#3$6N)KEKCL<CIM@GPAB*5QZJ/-R$KJO!?=OVY&I;WG:*:4C;L6AW#G3"
M(S3@2SR/_S13.J7*3F;Z"WOX)=!29D9-^K.31\X\9'5#3<J%CI29:OY<O05:
MG&^AR^3G?;U[7GMEZ-LT/S8L(%ZAG1K$H(=@3E&N)AT-K"\.8Q2..A1$3!B4
M9[N'YYC/78N\C^J,E9I525KQA:/,]LB<GD*3%X2P=LA VLZ)K1I7&6O9&X)$
ML_48A>CC#^ #QW'.?EK=,4$SMVU1-SN;AOV;I1WKFIFT7\6G;B$R8N&.&;.&
MQJ?9AV4T_8A%*@TO'QA)"H6^?;*C-5M6U$7_9[;0RF=QK[V22]5![,ZP<C\<
M$U^/M3PV#6&E9S'L4U1R8[L:['B4R#RVX.+9/G!3BN2"K$YK=/E.R,FUHJH'
M3X0X&Z_(D-V5NZ;A0>D3^Y@J?Y,:$"2&GP2QD^*8BI!^P5!%5$CK3%-**B1Y
MP55;_QF?D.!COO['8GP1YZ08^N>6GN+[L $ZB>I#TKWD]N"WKJXYS[ZY?9+,
M-.C95'<.$)4=O1OUM;(F;$)I[3']"\OC)8KJ_]W[.D$&L#8-N/TB$"=QFEFU
M."..2(J9Q^Z7E.[AN^C3MMTOWBOB4Y>_UL!+W$U$G=$D?.CV:HCTFW'<SU>8
MC+@?@,'N6"..KL4H_F@-C*+VBB-_!EM[6MA=QEFGZX>EC9A1M$-TBP"L[=H:
M&ACC39P)R3X&"Q?-BUWAD7"&NW$2&0NDK$RG];1 -FR@/=E3-R"3'F86&KZ+
M3[U#;V44V<I ?IZCG,:#EO)3@:V@Z;UV&#4?-J 4DF,SHO:-9P I'>F;O!D0
M2B%;^40 @&N.<8$R8RG1MICUTX_%+5(X$]08G@%EG:(D-3LU?Q/UHZ)=VV*F
M/0':UU@^> G 52/O0CM13(C*;R!"TXC90.UM^Q=@G0<M40-%937U3".=QP'=
M470QK^BZ!OGWN(6_!V! I^72H.E&3"PZOS/0Y,:8C"O(NJ*Y*O+K@.:$:=_1
MJP%*ENNMIB^7ZYE/3M0 D(Q.V$R()M;CY-HL%-PX=*C8S!,HI3?6G42GUF#4
M>.V%^I<9BA\=?DJN,MB=$[6@:07:[KB9HU8X*X'3T&XJ^"8A-J1KW^G6)T@I
MP>T:G6:=2!WGR(B5MXX&744!4)GBH%&._)W^$Q:<32/6, O,00-W8)UB6$ ,
M]7O6:0EJOB7_D0J4 &PE WS*8LX MO XFW-X!NB5!M1DA JU):1W66^VE/>Y
MO/=U=X>Z^! A]3A!:^I@5SNC07Y$Q/73XEDCDSN5VM^:+#19T&$<2[=)7CQE
MZ78D_GZ")RO*6<#"K+']'YQE1\P6IWKMP%[N0HCL)!Z$%><<G0;"IK":H[.B
MDMG(H+^^7")Q$W;IQ_W7_W=F\W_C_\;_C?\?1UB3^W)X]VD (C^B20"Q1PV1
MQ]D40U[,O<ED!;L5E&?:"[QY2J_*TZL&W3L#4!8MPT[I*L\ (5A0>PJ>5:^;
MT,)><C@#D*)@H8! 6C4HFB"4_[M0* D0<0,[CH;C7YJ= =IP0(0J\-:PC>(9
MH'T3NW@&N"U"H)%X6E0>0?27E W>DN[W>?Y=61S6"L0%6@\#XH!M!/Y[H,:\
MWX,3^PG2![= W^&D6 /"K.N_9I4Z PC_6@[U7Y9#(.4AZ[^FL>&$KX?!5H-H
M49FT6>MEZ2"$#]3]#)!-Z(>3L/\H 4-X0]U[<*\&<64=>*8,5$.0W!E@F.H,
M\/4/DY1@OUOTNVX@JD%%#O;O(AN_1*[]9G3.'][+^&$3@KM"O/Y4>"T$_<OD
MW_3\VY1_]RY!I.U/D9]3'O]ICS?N"<$>UK_8<P;XY;E;/SVG_+OG%@]NT>)I
M,\\ %#^O< ?M$_S83(J]1SIT8#((_,-($!84@KOZRP-_^BA8)2R[!4+8M5%T
M(_ZE ]YDB3"+WA^*")X#$M:2?>6?U@+Z#^\3=!,DV& H&.G/%[[\U;X_%_NO
M;?Y-PO\,D/IS+>L_UQ+^GVNQ(L:$H;=M& @1'<>&$T]LQRSPI@8$!!R.\]93
MH&^.O#+2R(['1@*..2*=U[@.\_^+6V]&8V(M'4[*W7)D.0ZS<TN,I\+?XDCQ
MHT"6)G]$(S7L%E;PR-SHF-WU0Z GD]B[EU0F[#]?U\\AO/;+4((O0C-^A>OB
M3]<<P]JC_HB'V[_B81V+^#,)<G^9\-=4N:W_9]"(_RNN?FT+Y:]M^2UH8+_[
M_7==<%1#RY\[]YO(WV*:$'@FOP(OG)"V0P2M_XJLHF6_OR;*?V[5/R8*(:YN
M_%M<_5-"_E)$_8>B/S(2]F=\_JDI+1<[C:Z1$5DD?GYEI1+R'$!:?_TC##6T
MR I:CR.X!Z'GJ@J\,VPC ^NX!;4DK$C9B3"[<LEEG+1&U^ QWP0,:SA[CW1D
MS*3?!D6P\,_+-'#2H"[X,1_F=XFJ7Q)_F5?[#$!-C?;"OSS,P#-AQH@.\ICW
M[YUFX<5@PSP$)&I/GTG$<_ A%T_I3T"XJSN.Q!O.PM_*L(ZPJ(P#C>(S "J_
MAK"182^Q]02[GPX20C' ''!L'OFC",_!B5P[I=_Z>9D3#)'5\L>4J3/!*J^S
M6WX^$AC^U\M ?Y%)GPA62?I-)NS?9/ZRM%\R3K_4U_Y+QAF$R%81L\5K_F%1
M-?.^"P@8)#$G7 4ZGY7Q*%E%[^7.%'K[_-.4UL5(6G04(CT16>B=/YS7+%DT
MU?3\%B-_##MG.&F2--$ZD[X:X#^'-0C=NVS=B.JU086%(LK(0%&'&?1:3\IG
M16<L2$SO*3+T*=-NJ/*T_0-^;?Q1!Q W?H>> 8(3?XO@WX/\C^+PU[SX64(V
M?F7/GXG1<AWV9UY$_LH+T)^!E?='>CW\2R7Z!]@.^D_8_G>1EG\2F?^W6?ZK
M O$+JH'_EH2PO^;@/Z3&WZ$[X]_1$*:'U?]+%?E[8OY79:3H[V5D_C_+R&_9
M3@#FP-\4%?U7P$PH(UF_EQ&WOQ:)?P'SGV[7^!N8_ZO6_(%8*N%_[O?/*P[^
MW<6_+_&7^_;^5CO_@-S?&<)?]^1O(/</Y?.OKOF-=Q"6G<KRJR(9EST/DL'=
M&&L*R%WG$<<^7F"L&LM.RVRV,E!\W^3(Z3;.ON*0"CA2N)(=3/$_'L6%2GHY
M'<4?7AV71#H/R(F&6&:^CV:,Y_&C#PZX=^'=RM6+CY>?V5RT@8SVJ B>EN#9
M++!EK<OM#3YOQ[MBUENT\%,M!M%)0+]5P/Z6S0.3YU#K,T!B*E;T#&!YZ'Y*
M]YIH#YQ^4/7?L3Z3N* 1.%.3'BJGHX4=COH01?O2?:_Z\_;:Z&,!ZP!]DOV[
MY>^7[A@0URHQ!C]%$6WU\Y89$V\Z[N?@C_$^WV%=93.2UP\?%JU+;1R'AZV@
M8DKAKC[RKO#FL:S:1YW76NF_3I.22.Z/,H]#%)'&;]$DD+CNAIL69>WNM!;S
M86-)?4?FQ4./>_F%RD[JZ/AL(?.7+@8SG@]6"?VEP-M_^ PPJ(;K@MB$XF6A
MU]'2GOTR+26(== G&CA8K!$LD-DR.NFV]=*/*\E@(^GB]86WEM<$,]KA+Y]
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M?1&>A-L"?\C!:0AH^>OG8.7N_T!'85&H3JY*E;?/N$ML:8Y_.2OY6FBWI^W
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MQ\,3G0M?.==WV=X:V(7>$DX(0O&1SG$ #@Q4-SVLR=$0QI.[.);KR_;%4F<
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MNK#U[3Q[AH0(>-:F8?%#L1QOTJ2@@FL*Q'-/_%62\@2.^\$M"[?%EMX</78
ME@I'EX\+5D*RTLQ*IJ%OTJ;\[31)& ]D[BR;!UC):O:5,.\T3:M;EMM=)A'/
M)/YAI$!C,)0.6;PUI)O'.JVTTI=/F:3JYZGAWIWF YG8SNEUB".IBOIL&0 +
M]6Q0J73-7T^<R_LZI[M5_]#W%,$7#>SY7A2_F?BN=:*?>_ M<.^2@87+FZW&
M3+9B*]FT8J.!R &,\)9W.NL\8W21=Y',P/2B9<\3O\X(%Z +F)S4\UDO\$&@
M,O@I^^WAHM@7?L4KQ=U::DQI79J$#OYGLQX+_8<./O9_UL$O?K=2.0^;LKAW
M!A@A=R2>,\'AO3?5]@[S_N&0^RIG'@ BMV.8V_71\=@TL77A"OK#XO47J(EB
MC"AI[U'NK) [Z6CJT&ET]^)T%&)I:MA6A]CV?=*/V>CCN W+Q9U+I5 )M%+/
M3;1;,U)9[$1'XY5&=N GNMF4'"6MZC!E785)C1..CSTG$CAE\D8'C//._/ND
MA:G+FZ T0(#^]5SC?GNMDEEJAQ/A@,#R5K=SVRXN5*R*%=$KL5*I[<-0*SL'
M9U<WGZM[NUEP!6AB<\X'>_YRR_/=0[G4';$*H_KNF=Q) C*6MOS+S9)>+:Q&
M@;$WB,+(N7QRB3O<+C.E/SJ>" H!>SS\<.O\ZI8SZY5K1S21H0->[XGBOM8#
M6:TM=)8'R<T"PPT;&\WLZQBF*T58MLI+?YP!0E.N$WF]?X\LO?8MY:K<J&'S
MOLE$G#RH^;!,M'9<Q*U%>N&+*\PW73W]09KQIKRH&[>%1XSM%[OD:WY<--%2
MU@^7 P*NMXS[(-Q9<A7$&OEGTHN^.4O*YEK/_0@3OA+1_CW/3'//ZCZJZ;N^
MV^*E.Y8%Q[>,T;))F?ZP&?.8DO WW(D[#!_=*.1DI=;E99YROOP6P1\SH3E_
M2_CJYXO1*P$F?9[0^T/X2Q -C0;T9#C#YLPWUL;1:DX!*8LP!R'1MS]FQ5J)
M=R_I]0DE5Z"]NCE<,1GNB&8U'VX^O>H$X1=-M=K@?EU=+8LKD3&###OKLN]I
MFH]9; RT!.#IB_XI-3';@3<^;*4&U5-]FK*^$<!E("TVI,DE7-AQM>=)P'V_
MIZLEZ46V^5]WQ=Q)8LA,ITKISG66LW%K&/9#97+Q0QGT[MYLWJ#SCBPU#?!W
M,@/5,FDO Z+L]@&,FL';#-?F-+L]:>\L8M-.C&P<C4<@X"[C6I:9O$0R\>Q*
MZG.;-2.!TR4K)\.2!<9;(?7AHSDGO'"0T.1:64$Z+X6<RL0^XT3]B0TSM3I8
MRM;!R\]5:?2&0'?[<V*>)6WAA^5FFI^YNZ"&2)O8A8LH>.2>S*F<V? 9H(;O
MN;+D\>+.B*6YPIW6#GXR79**[+356(7)+$@4)K@%E1'BAA-&2 3"EOEK$W:5
M;QE-;<G:B?,7#8RTF$E>!5YDXU:_DFQH+KL%ZQC3IB>_[%"QM7 1S;P-HQ-S
MQ6GGZS@AP)>K,S3'1._FY3?,K Y/2"7D$(>Q*?F4;*A<<=J'/%V[/R):6GUE
MY[8XO[6A!7.L*J>_9/"UPGVY#\*K:0&8]^C%<"@IV$WI!F+>PJKA4X07Q0^3
MH?D[VU_[.8-#F54MEPM)L]9DEY%KG;1 #<2IAE9E77-3[6A+%Y+I64Y=],[[
MB!<UK>^%-?8OZ">^IU@\$<O-SI-.,'?//^C:64HK#73*Q!ZKH?.ZHXIL3#6/
MG\DI2!L3K3A4D9'[6W#>3QZ@40]P2-T;#RD%KRD#D54<R;GBHDW*!5B?8K&L
MX<LC8KQA[&X/4J+\:^6I^.ZVG'N_&I?W-*,]YA'E(,V<Z:R%E<6-W 7M_$LM
M]68K*;T7W<7(M])Q:&MU/EHA<.J$ I_P^\6=)[!E=KP ;(IBZPR@6IJ_5(M+
M !$@BF/T#' [SU]NQPGI3N<,KQSLFE7DIBZF#LO@?[1E@.2LH[#7B'+:O."1
M?K@.J]Q.K82*HK!CQM.N$]U3IC\X:SEAO,H?[IX!>+S>>UB6T@CMO'YJQZ1_
M[]J__IA\'AN5AW7OS*@R3LO'#E!RSO.*DUI;FLXX?RUQ_1;X4:#^E3 N;T*"
M;'[<:):-9++91&+9/9R'$9MBZVJ+W*/:X+E26?-NAVYVBT7"2H,IF([;6.VB
M+#D[=P2!D2]PCS6)?@SZG,X3AQ2KFTB];0TL;QZ+LI8V['7)X[@D2+/&L'U?
M^ P@ZB=)YT>O#Q7 6J:+5&.??:2M@E#>1L.F$A8[GE+W^8Z:6=PLIOKD?[M8
MCI6BRZ:W0XC?UO?P,P;(2+#6(>920U0G#^.PS.?2I<@9A RWPM4)QVPO?OTZ
M'\4DKF0CI7.>\A^PK C0<Q6VJ$'LK29@%L1DIU%E]#3J0X?3VO9 /]X\9M9/
M5FK4(Y,&B)'Q3<088>_O]NTN\%2*]'EJ?>_AGZPT]@W/=EK@''&5+A%LG]4>
MV5XV=2TN1I@^#&5ZP,N[)!2G*F$N_5>F2(2&=>S]T&+MCCMAVH8EF)3ANT'?
MW5MXS@"ED_!C(U%_TH[11CS%+73F&6 LWQ:7T S#2)P!$@-11Z>^S82Z5$BH
M2X[_UC;?-1A6 TC>BG:8:+DXZOVF&.9B$UZ9_PQJB A+6#,9R"IU'O1Q]3MY
MCT=*";N0[CTA):$XD>I<X*U ?0CW*W(V4))E*?IV=X/QCBHWID $!@ O4S/0
MAE<&361050-)P4&7QF4HIWVTW) 3 @T2MZF(X+Z5F8#'&8T[!.8Y:O;\,&]
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M$0%45XHXY]WN1=:FNK'\+UJH@@Q-?VL0L[$XG2.E%N_RSX(RA'RVE=_IR+V
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M2@%O5!.&.ON!$[".DIR9,.+K"WET%2%["SC=W2(FL'O"S.P*7I-3ZPR2'54
M)T4]PM7W&"UR3%2VUP[G@,AB_R#+UU\@7BI(#(3B=(E0Y>/IF>U>_^_A1%3J
MTW_8S(9&G<6TXDS)R^_7MO[YW@FMB)SLH=_[H(Z.V9&OA<+U5$Y^$RCPOY_Q
MR5='U2Z\4XI""XB1"7U(/9@OO9Y.IHY(?>G^^.0$NE.0-TO2RU-5.%A&\IYL
MD) PT%580=IQX15F:99WE0C_Y#(M/?&3MNJ%_JREA869Q3>]^(<F2G/NW1IW
MG\2_1WI!*TRUT.XW%)CAG%Q<F(F3@.AN(_KSKP8OU60$ _.A"7Z**83!<2?
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MX8TKP$U!T$HUIIWVF?K(I_69*GIG.1PV7YD\ZKF_ #E)_<[*2RW!0 9DT42
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M3!2P+OJ;\9D02Z$AGL70Q+7E%2USP<.$"[SW"MX*"FP\#)\6D'"JC(TEM^U
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M0-"RULDT@BL+V[SBTL;AXQNZ)-<N8D97D,!70W4WQXS?/;<MP(F3FD6K'_>
MYVW1[YB%@84J"ZG%"AK^L-R]?[XYLK#>#;6=^H!JD'\"C0)W\RR._R.-9N9S
MP+\7 V;_Y^+_BJK1-[UQ$*(?=V:3L&]:!FSXEDCBPLU83 !1:N,U]P"R.<Z4
M5$MPX5RNK:F?F@'/5%*B8C& 0IU[,=U<4_4GZGNL@$KO_#7/EOI&[#YG@NXK
M*55 +!V0-59%LG3ZP=*4.'6UF9E&RN5)GCI'U3-]94!B]R6 M 8+KS1O]B %
M;%=BM+!/'3UX^&!*DY?:@#B_%%N$%EON(5Z,J>K/F9K?O\1D&/Q5.CWG!,JG
M-/G=A/+XB,DOJ 9@8IB-5:%H74?UU1RJO58NL(QE(SULX?;;5B=EGZ(5C+QC
MWI^OZ1LQD!@J\?)$/S.EE65<])!T7N6,F4E\6F \@W91$4!P/;TDH?IS/"]+
M](;!Z7%]VA&7J;V!,$>%VZDX8$AXLW(SO<6XL2_< TE67C)UP: E::Y=B[H'
M.*6]/[.!--$[L[LS,O)LCN$EOYN#LG0U0L(%$0=:^*]K9@13K:^_4"<4#/]P
MC9]XL*@ZV *TW#.=>H,O_ ,F=I+2 %<MWY>G'H<COD9^F1+\P);HN7"E%E]Q
M).-N+O??\<+Z""*QMLIZA"U/M<IXBD4>:]R!@?TW,IZX55E?2- M^7?[5LZI
M<]-C0ONA7)-]U![ED  \Z;$V$Y/&$81+ I>4#E\GW@^)AU'5.B'[7 ,AL?_)
MX,^N5A/9.\'UON=]C"(/OP\WP#H;4:<,L-N7UBK,/5LT>>FR2XI*X?S@>L2W
M3D8"4YZ"F=]80<F C1%YM9.C/^*/3P[VNL([/W+PO\H#>%!=6;?M+PC46,$+
M8 IY"[LN=[/+ '^A=<1QW!$3PDH^U=4ML2+K!O%;CV<#GP]Y98]S1-6+OZ.=
M;Q&4\K^.(J*('$1S^);-OQ[( SZH_:;QVVU)Q3KFA643[T/N?_Y?5SNKL2MG
M ICLW(*+G7R=(^W&1/L1X%<:D0*%7U\5$ $.FZ:(,_T,7ZKI25A\X1X\PH^#
M9ABA#;OD#+OI6RJ2?-;-L4%<E^]F7N;7_0X:HFI^Z<M+,HOD2)\\N807+$+Q
M#="2]8W/+/H$\PV-/M.!#9T-Q., (;H-A$#?\Z(8Q7,X 0+CN19(O@Q-0'@Z
MX4TUJ]:N"V\KBE$^$F"T?@X;&OA0B+5@?KY%F'!5@ZC=5VJ<1=\#L ?6RH&7
MD8G;=I_MZ8NZBIJ;DZQ,R[(])T7A-95\2?7Q)*[SMKFYM\IHO(3O2H%^)1@?
M!"551:Z?AZ G2W4R5OD\,4D\1=ZV<W#V16 WO44J>N'RK'J2__R/RNA09R._
M@^>5 $I!<+7J]C,3N@XGVF7Z"$0A!L&#*4Y>( D<TD?B0CP7_)5N%&C(PZE/
ME=]L4[PD'O_YCG0R&W%@:5NLOB33$MBULVTE,P2_I=P&A;0*ZLTTOV1N*%G(
M(3R(!SJ5+8+R>J1E6</S.7(NCA.]@D?)"MYA,M9"#@>3;'[,8E*(MIV6GANG
M79H-$+\)9G^&5 ;P,'UEG#&'PPS0T0'T45J3'C*!1+M7U'Y: WJ)\RJU,L:'
MFS9_9N,I0]WF)#N.S?HZ5QY!34T::B?$V@@MH*F:=4XQV@,*""J;JIJ.YP38
MQ8LO===4GJ=?#[IE2I5RGAH$;L&1UE#)2%ZO:",,S-QFC4G-X4HZJZ>&NI0D
MN=F0_*2V0XGN!4ZH+7NY)XT%O_'7 <(.\?"AR@M*5JQ\#MZ0NTL@5;LY)G*F
M6]B\-B:?(<IV*GR2;8HPS1;QI*XWX*/@,^AZ8Q9--[7A6!\$8@=Q*C -?R<\
MQ#JLVX3-MC>MSGY@)H4BT>L<K7FZ["P^?0_HV@^PL1 I,C@]AH/XKB3R5_CD
M41^*V $;10HI/)KUJ&L\R><E!CA>2[.RB8&"R>_7I=C3P+IK2M7.UIY]:?OX
M<B^*>],Y4M0_@[<:L%30"0>QTH9G =Q/RFE\"G_#"[+O 7QYJ*)H$S</[L;N
MNNA3S0@6D=KE\"47L@#AR8EO]=&BO*=J+_9=1_$Y& ,O]K-;&,6IG_]!;"5P
M1 3-PX=[7G#$X\N$R\4Y-CBR!6V+UR7'JSMR4']0617!^^79T;_O5(??6;$X
M8BYPVW38TE:N;/H\J?F-XO@(HZL5=.UN/#% 47Z7;F_$QBE)];$0I C1G4H]
MQ-0=/[<ID=Q&[!J<\!%*9:OY%";!GWHE\8-B^UEENZ%+[(N\!RH^^/A;URB+
M-#2-5DN<7E,8L%XO5OAQ8UBB5PK=8#+^1[*6@*2N3.EBKLV*!OAVD^,U)'?#
ML!M([J>J%^WOO4X5%L&A!K9*7P!59;9\D:#>^E[_3OS0/:%N2V!FH@#R^<31
M@N[$^KF#5J[%055*0[JG4Y@+APQGY+.7':.T.)U@L2%HM>[4DTIZL1IOW^PT
M5T:3BF*PE5E[?M80R^#K=\3^&Z@6]TMWM%>1>YD9QFNT-Y#"/AV>F4IO6]$-
M,NZM'63C"HABC%0,>FR%U_:Z6WG-?CER/- B;'%SUH8V?V;?5Z$S!X"Y4CK)
M3X\+]50@=/)NC!DT6OQ%?#)KW&N]A#W0)HBG]^ P:0">*T^+80>>C*9" JGC
M\.)^+,^;%OP2/Z/3>>UZJ&_ '9_'2K\T<>['8(XGP_$S#%AKKRA7!IU/>T.X
M2>HB.6(^[F&JA:->-5G&=LI_^-[(,LX5_.,;0$3;%PO5)MV]OA7N_">P'-A8
M1*ILI9*8$GDV HR3)[H'#*JT2M\#9O$U[P%C!JU=\+B ?RZJRLL$SN*_OM,$
M6?Y7F_GGL-@[S:)V^ V1(\OU2P&_+*A=[_%OP1SLME]"Q8%[N#581^Q%&W\<
M_@W:\J5BLG+A$:T,&+B:O\.M9.JU_G2I$WF]2B49Y=-,8?8'6$N9<4U3ACIF
M<3U(W &TT!HP1O8)U?RLYCH)]96Z9I'B 1$0IYNQF)V59E1$^@U^3^/A7YW=
MUXWR8N;$F)_4*D^?RYCC:-S-HOVS$)$<0+8( 5VCU]FOHR1M8]X\&L3;67QX
M UH+#*F0)3M9Z5QF:I@B+7<O<$BYU 6Q_'8>[_UA9GTN>03< #W!:*[C?5I;
MH8)VJ:)I(@+(H:F],[Z<H<%%1A4M-5J<]2GLCUL_O'ZO<B;Q6'?'Q5FJ_WIG
M#?BY H9S@NP,H&]NNYMJFA M-26 OV!]C7Y5/(K%\5&M'S<IVOT%D\T_MJ^;
M;US7$,G;/M!)XI+:F=1XX;AUU;N_DJ,J/QH(N_UZWE%1%0DX@X?> _ .Y9GV
ML6_W4].7%NFMZ3DSZW*Q$)4A:8E/:H@3C9S=A\ @C7.Z/&,KGD$FHW>EQ,&Z
M?Q6>=,!4]K.,M8"HPM:8]Y4,';SJEQ 2\:)X&M9'T4WX#7 <C-!:N=#;/U_/
M8TS59BQ11[:3*)( N?<'XO,>UDWL#S\N,A'^C,:9'O%GOWEKLEM'+YCQIQIM
M<+46CPUY6BZHRU++E+<E$R9Y>0'GP+ 7%#;</,,0&8[)NMKDSAKMK2--($\)
MD3?#M\.^FO'?GN/$;+<0/_[-92?FX?TZO3VNT]N^;5;\NB]4=P)"@23P.W
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M;-;F&Y80R.8D0F^*.]RG[D>3-=$V(_B-#,\ [K5A5N1:NM.C.X28H!-?W;$
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MT".CO>IE92=/)_*0PZ+3Y#1-K!9H!_[LAN%JV>2MUY\?LEIHN/KD!8E,>VT
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MK@2$GTV5,13,N-''FO1,UAH?\P^)^L')X\1K\H;]"C[2+?F([H2>>'2T+7+
M)]^8/53])/N?MFC_U:CBKEEO /UO%,5N ']+K2_36\)/1&X J<&XTRO?EAO
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M&K!1X#/BEK->1_H+E,1JNMY5.;C*M2+?U1&+L35*&QGH[7>?JI'WMG%M5B\
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M7[(.9%C%@!.SV4 5.1 \?4;A/C=HFG.<!FF$$MRWP?=4A)+&" LPS4G4_%N
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MO0TO'MY7<WN^<5@8.4$9V0A-IDNMV/38V'>UE=>;WK_0XQ[4[7V>J\*WN,]
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M&?!T*<5E^B9=ZA;V8BMNC]7.F,+K6NO'ESBP)])]Y,^Y2'0[+DJE%3MK):@
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M#(7OXY%FKC3T*]<0P HL\@VWBK?L\#TV#P5**PLU#,*Y^Q?B];A^PB[N<]W
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M?9V;7[,Z02PCV&-%#UWPN2)[G%HW\NTT>[+1^HQEK9@3R.Z!\F.SQ WG]RG
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MD!UT30>75L#(SU2^'?+0]S!1@:*]3927UL5+0+H9EVHP"E$K@(/=[40"86;
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MD @-/EE733I%G')3B-9S6<;B*:6YDDQ.6\.1^K :'TFUP9][O$B#+&NMW!*
M+//AL^/H&K>1AWV5S&]N:3L!:"B064U1T^[C]_GN80(.>L1\%DPWZ[U92P3B
MB'VJ\G[J_&)P8 _!>U)O1ZGMD9=5<WK+]K^YX<,T(S:N<@-7I*\C=*4'N?Y
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M"V1Y 8(6@/S/LDC_2Q?Z6.S36(QYQM^+O\GS!SHY_3^(R4#U2O_SZF_*(W&
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MT28TTL8%JF7Z*G'M$\W#_XNW]PQH:MO:A1<"(EWI/6P!$6FB($4@@-)$0%1
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MQ('"@";+YF5>N^40P@V2;R+-S:M&RG<]:,9#9!X^-MK2S9Z+.413U<1@&^)
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M^-&G>J9U=5F<[9O<U?2(K(8KR0(J\K<[Z*.E-_.8KB<I?ZMY*N@5HK1_&-Q
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M!%U8&.4=GWD'(,X"K1_$P_R6&FXQ"EV4,%?*/H7ZYZ7_^O]\Z1_49GGH!]'
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MX\31K[GT?B!:#F@M]&A./]T3CGE%IO"FS?G9OVNG8Q]AW.BLOGG6T,WBG,#
M5T\D>7Y$:D;J<N$B:0+"3A5WO7J2S9HI3"%LM#Z^/FXG$0NK[M(WHA<,3\R5
M:Z<]CN3W$_.$\QE>^P7K>4?(S0#=6+?XUD(:=?=0S]KOCS:U%Y.,-6U[YANH
MK/P\VF:D<#2*[ 9>"Q)%RUG*<I67F1@9GN%_TU3?YVXUCJQ$GC%O:=Y9"_38
ML'DX>R^V4V0YB4O,M"[!$/!;*B0&D-3[-[(.;@_"K!XX1MSM\\HV^L!X&A 7
M[%&!3W7/'Q7]R/LTJ1N;4U7[#>\'T:ABEAE(G93KI;,V+X(]()@[X!"-Z&"N
M8??W9175J;R64+NHD\I<&G3#'PKJ90A>O@NLT2!6C#[MFB9T'H6F+YJ@=WF&
MS866XYMLO=<UA+0:L+>V(]EN?BY"1:>;U5ZA.AFE;.=)=>ZTW$$[_91I!8(@
M0==LS+JZ#O_(>GI\O+SG$9J;3[XSTE3TDKO(]@D6W9)B_!3>9L#-IU!-V\=J
M5PP=FX\+*YX/]SJKPG,8]%69%.''3>+@QGLE'>!-AA\]H1G>?Z-KC&.'OK"T
MTEWJDDI3%.W,TR 6B+EGO:1:KVQ *X9N"\?X/9'E,:#Y()J@1U+SO";Q_?33
M@X7\WZ>L^1%C_3^FK#7!G D_RT02I_UJ3-MJ:?A67R D4N?TAPN:6W(V1MNI
M(>J>(#0\Q.HV],P[O]K-6.[,T6-@G)N_F3UD?&I(F3??=1;]OF63T3CUX-:@
MJI6#T^FOR=/.W RQR>U&L[?I%FU'0*'2[PB)X#C:K[/0C)N&TD5=1S.M*;G,
M9/R]$8]8)/,CLBP,/ (3A_NHO<G*+B@U=-?99UA;!,7$ +AO!OA]0M#;B:(1
M<LI"MZ2C@W9ZT(GYNV4"%Y8%]55O3Y-GD*P;^_Q0^B<(KH[ )SQ-[H<T\]\G
MJ1Z^XQ6F3FX+Z&L]!B*N0#@P(.@\<;TVUBHPL-M@))4Z2MKC;&<V4NNNXP="
M[?R;Y>?J<GZ,[6<@VLS(J(?U"5 S+5L[U0<<'U<NZBIGLTHGDQFHL N2DK'H
M(=)M:;<EHFK9&P;/Q.XJF7:EN2UA.[6V.YC?>?>%(?<MZ>(%G&!%6_VVBL03
MBY%D5[I'<4_O5!&];5$?8(Q#%:PT4#)OD-:&%92O#S]<9N^AKSX@0#0_>C,0
MNG<.@\1''J5MR,HCGV>IE&"&B_=7-Q08J\I7-!R2+.2/@3(:QKC,@H0W/8#K
MRC'PR_"!ANAA^4WQMC2\(F,]?X;;2=\$[7TSZCR;O_EZAO)OS;\70D7&XPB]
MAGZX R2*[VFADUIDCEO>I\=3UCGZIR/=>8VOV<YU<%#M/@R>F66U'\D='+N!
M>S L\OPF/EPS\\L'(^J4=HUS\59X/,$_>R*C3O<&SB'^L\,UA?9PS]CJ5Q?B
M$H=+@,#T_6YP1*49G+N"];F!K^=DQ%:*4!(^%R%AI\\823TF.DBZ3["RP\4V
M7?+S,*FM*JU,6IO<Z'ZD$=1_,_G\(5M(L#S5=PI!13N%E-?RHF3V/+BG+)LC
M]<4S6@X8GF?;EPEB@ MU8YL_L5OMDLKN3_HX-3DWHCG+NK*GJ22KOA3@NM1*
M;!=QC)3RXHPJ;;&?Y9:+VZ8"5$(J+UW*P]2'0E::BF47G)HR4+PN<):](_#M
MA$%9AO6G*IGQGG'M?IMCM"=5Y.@^[F6SJM13_!D!DQLDC^&[C=FM@A(7$Q9[
M^I<A8KG$F&E/JTK7_(^4['N6H/MV:L;:%81]<:_)265R6M_KW<U8IEQ[D20E
M#]<]R'-0V95X' VA\=M:6C^\V2 P?Z;OQ__B[,OCH>SZ_R\41;:R[R&2K;)F
ME^PARLY(DF5"0@;#6+)O(12%LB<F,60=^Y)D-T66(62?D64P9GZC[N[G[G[N
M[_-]OK\_O%XN/M<YG_-9WY]SSG4.XW[!V\ZTDDZM3IE9&&)G)=%^1C(8QI)M
M5#\B*<,-PD-2Q4]?FRN[%7OK2DG"C</CL'TY[%;G2'C 9F@5OGG VXZJ,C\K
M&#%#2XY.UA3@*^[D&T'^K,-^K(J4D>JP)=7;MA([5PZ>$-@M7&4K+.VLG<W*
M#3SNA=^.#SU1(NFP"JKMY#6R G;?SAZND8!?6;L,D:JJ&,*<Y715(*6G8$SN
MX1($%7NQM&3"F':'9!S/B; K U -\$$V]V9%[RN7Z]97*"XST:Y<2#;P+XQ2
M8?J$BYTIC%#R$?^*M?LF6RW[QOH%SXW0FQ0L.P#U&BH?4/C_^!S[2*[SX8(L
M^*Q\5^%U6U\1X)&1IQI-TU?SYWC7840\?>N>2G[N4E_!$\3$N<D9Z7#>54:C
M(NOQ^MMOY(^>"0J[U'&L'1*/C%'2?(F3! V:MW-4:'MB353I#%Y/V596RU9=
M- "<!R_#'MADG]%SL'_&3,&\1 2H[YJW!_%BM4+*]+W*7,9X8_*JR[,(Z+FG
M:6,6[GSB0KZ78HRKQ715S'NS[I,MW[R5=GB!0+LX$W"=X_R$F@!<+Y )&%G\
M)IJ&2P1S-3+59WF<[$.?%3?ORS0/>21]K+[\8/KVXL&<JMX&$6!8KET/Q3M@
M1_>-AK>XK0)5FT<5/CXOG+1AYPM=X'@QS@0]1WG^"AVEM7.W?)EU*X%FB" (
MO3(:Q(W+O38"=4 S8T;#9U+!I59?E:P>5DP**/1PQ:"YU+E"SX\SE=V@!K:1
M80H=-7#HI4$?>H;2)F2-E"ZG[7A@!GHU#K[ME"%&+V$6V>-TE?;UA_,70KZ,
M2C[$BQ1"1"^'Z0R&]Y<'EZO[!<A\04JQ7$IS\E5*&4F@HH@S&P&8,EV<<X[D
M.9ZXQ%YH<HV<3M&<"ON2UK.>5;DS,@_%:EKE(2N/5ZF*]Q0B4]2I4;&T"7D&
MG4R=45'&%D8'\73OZTZZ9 D,\]B*&@ZYKP@/%\@Q+ HY%WP72I!59!;@K1^C
M4K'X:.#+PXXQ38R&VLYZ' 6S[B&CI&E/5X[O7RK; J=X,@UI"F?R9I4)GKTL
M>E=,2TB 4X>)[!OR.-22"!R?:J4_CGLX.;YT<<G*MN%#M5E2I:>N@%;!Y:*I
MB_'CC69?O95BEI<2$G,_?>.P+7A:,*;A4#AVY8WUV'B.SDR\&O6KW&" V3^8
MVGW,AZ13O8@E*<,\:2#S\B9S*_X6+LD#4]',JM"6I5N3-#K8[9Y_OLE=L,M(
M5HT^G8VO0O8XP$5^CSX; K=!006PU1TH!9_M_))=$$6*.6) N/9.%:MQ+__+
M3I;+Q6[!+!V&_K-LD=-"-:_HF9VK[D-B]MNV_5&AKZ'JOKZ^]X?XZI,OEPJJ
MI<P)OG@2A:)6*J.R"08'==DQP E"T%.($1D8@^:,FQ6MG7GYNV'[> %+%FZM
M&?D@4S:*;@O/X4?J@LFZV[4=&/C#S>PCI&SQV5\\^9-%8,'\>K?9'9Z[W[N5
M^M($Y_)3QPE'0T+:[_:3&8QG52Z=)1-AU[BGY3)\C4*;NZ$D 5?C,$.K@5Z#
MTX>#('BUKI>#^BZ,@I=M-2X^I4]_=_H6!3XO),G&*1Z.,*#9?HBI^[SD_WB[
MNI$5Y<ZK+4>[K9TQ::#XWIYANGK]-F>"T0>U#G"?RI'> "R--H8IB _EXQ8T
MWAE$9L2X[-E=K/>2<W7[:L&4 V653=_%E:BB@RZ"6#+9BAT%5$VF[YBMNE!I
MJ6MM0FI17\$4+X/VW>JT[R],!BY5&9\"V'4</VK0&?@KWX8XM>R9AU5"I!LX
MWBO2'(L]'Z/TK.+DAY6VN:=/DBVC24*1@?_'W8RTXWI,U%9G@0+LHB&<Z^"%
MA RMPG=TZ59$>;'+9VQ0MI-R0^J0!NVP29=&W@O/AGM([V?W(8O!]#?OKLK+
M*\?[P9M(?@VN'5:1J4(A[HR626>?G'#IMY&IO\=(W4[S:C5>K4GBR[-G/D+U
MXZU!@J/S6+D()5WA*(2(#ZU#IU5UI(>TI41TI?[9HWN='-8+K@JEKT_N!GLH
MC@M&L.U1:& F,]&HX4Q#!$MIT43#P8"9P_Q'M.FSK\]N\\?1R>?0NAZ>VL-4
M21J*7$ZA>7K0D#XD&X &^!8N[:5%!CKDVDZJ^^7;9/J-S(9/>/+M/G:G6'L$
M(<'8K*#4.8ZL&O@G_+W^33>I-G.%!L1@C\^K;[V.])^]>\Y$M]W??1^J^73A
MPKF2FLF7)JS'=+ZKQD]*8\]DQZ@(@3XM9<0_[POU-A"XWN\]KE\0P;D?/5]#
M]S;G9L7Q$RX ?>KU+K(:N,.@"@5.2AT[MQ"W(N:QBE</N(_RE8J_L]DN_3J3
M1HG20^1-/7"=@H*M*8?^\N'>&1%G4OAWOS#Y'"2W;V/CR@%K,CJY9&567NR<
M/N;?[L7<D7Y_=./D&=,QVR"W0E\^QF=>'>K MMA"G'DRSJDM2"!V]B,</:%A
M@DS1"I2PO3R&NH% V'XU.DE9F0RPM87$O'NR_B$IJ0,<@24"45OO\.JS,(;F
M&66M]T2@%20R(.TFIQ/S+3^O"D79]EXP4M'1)?[+-_9FT;EB&P:O59Y3.#MT
M-L62;VU$8D$E:[7#W?137WKO+3WM>QQA[B&A]'VN@%5I5IIL]/!\+:;'E=?(
M# CG?.XA.5^\RT2SQED-F30.NM\<+',7J!MR.F\8ER057W;))I6KF(K[V+(:
M=\?2;L?L]B..]%7E')Q67QM'8&)DFOZ!T(+A(Y':^L;X:Y&"95\U;SE<R_/@
MOPRA>09CQ.7:CN;V;_8D,BY9R>2GMUY2,F >*9UME9G;.Y;>ZT?A.,H8<?MN
M"6=(G3P<@GD>QW.^'\\^\_Q6DP22[EE*[LGW;E^SF+X_!NYYQ=U7O$9E_VMS
MHX'TTE<5\?$^3PRRG7_J6OW@@H&LG\FZT9-6I;M1-LR>[Q?<+UYJEN?[KL;]
M8 D;'T 2/&:]8YRQ#*PP^A2M;++'+:=551':HD_S-+ZBJUN1K7>P[J)NZ&O6
MKR _F04KWR@$G&61E]8[4+N]MB#11;B5!<N5GE;=1SLRMW'FY>ZZ[.K'\N/L
M3ZW/S3N*/[O5 $.G/_3./K6HPH0++W$I,&*96I3U]3)0VJC5D!H_^R!!R('+
M4.-BFN8)[2,SP<HR+L[_8>O;X7%?1R\\OL#.7CC,>BTSUN^6Y>V0/"UU,8LO
M#^/<;4(O*G><);<=F<]F4U(O@_A:X^Z/&19OBXIKM#U:' N'?\Y-6;V@=/&-
M[8?C5]DZ)YJ5O% JNCFN&2,[D4$<.*WE-H79Q3%4G))!P1)'S7"^]:X](MO$
MF6]?A_]*7W*V9P@-W4!(N[]Y,Z_43&2+ZG'7++%PA+BV ?)=QN":T^E\<,#3
MU=4UPO7N9#YX'V]]#CWH<%-9WIB(<PYYQGO.HEZ%Y& .I*3KG(KP1,'SZ?'E
MQ7ICR;#24O./F::A9\\D,5%LO/J0\#!9BW+02+T;3H$MC,/K3TLR! VB#J5^
MW$ZOW[M!PU"!A'VE:X3T^RY:O!3D?WG4[!P5_^EG&4MBC:S.68K8]!@H[8SB
MJE,[#_= 1$J9A?(DPF=A'*13?>Y3QB7F+G+I1R)W1=+/4?4$TU_'&07.B%]'
M(R,E\-;4UKB$F?>7)!VN?(X^UB>*%X]S#. *L0V\#;%NE>4YT>_F'2AF$\OI
M-FE15Y^Q9O>TAWOPP\IJ#V]])P5P$Q %!5-?EM+7!,[(/.+)E=[36E2C;0*%
MUJ-FMU"QTLC(G;'(,-6J.Z.KN:EHQ$#IRKR?X*</$9HURVR.0!01@/A"<X?>
M0S5FZ!D@YH;8M4R/&?%;,XJ)T0HJ,6/Q(^-*H[*^]Q:S[K=]:E-[FF?\AK;
M)L&OK Z-#%MIY%]L%.V'7JO>(\7:1%+P]C>=&\V_=R=K6/-(^)G'NHTWX8*/
MJI]8^Z9\OQ.L;-?4R&?$#)%4&WU9%[JGK-5"4^[C&I=DT"CC]JWT^]%+752/
M%$:W3-^45PW>=5MYO3I;65D=?ROBV(US6C& J2D70 4$F+X"1&3#2&-E&JRK
M'2K*H2P:'PH!!6#A,_GPEBF:\2^Z7AXN1:Z^ D9O,C;/5\7<,7,0_*"RQ%]R
MH9LSBOJ2/<BO#!<)PM@EJ#K3U'$[F SG#4$Y"Y<YW%)7YBW$W?66"ADZ6W(\
M^/GN71QG]90OE7S(49";AW?%RCUDM1U64G^AC7;CM-%%<!;40-S+A!H2KI6U
M/4I(P\JK/8 KJE$QD0T0>E44:G#Q&/-6JXGMMUFGA\\DZ)3YG)W1:1L4+ NO
MZGA!MJM-?0&4;QG$C5E[CE9F&=<;=$L;,JH^P1]B\<:FW*%;<$MP:]WJ,7#]
M 6F 1UX$"R1E6.D!FF00\G=&\<:0CMFFB^W3EHYA=@'C2KWNXA^ZP=M/X@<2
M5X'V>3_R:W4=<HQ;<#E<_(P1 TY@9B%^BU;4>!BA%8F>FR]W>M&KLFQ:&Z$F
MP-C>LG:KOKQ[MZN+C3PR6!J)TU/A<P51CVP]MVXC\&2W^*M&C<VX&4[K,F\.
M3@A4WL^-C+^M,U*/N)E+Y0PDJ?$T8"+;CL]XD(]-T.J;C A'!,0J1F]!;D9\
M,SJQSE3>]>9<^V-OQ_<GN&NZEVT1=W"PUCV/<.\ 6V'M\DC#H5+SV[*CWY@9
M[AOQY'U-]A-,!NO]?VS&S<LY^C*#4WG12XU&5\NY%_"J@*IBYCJ27KO<_S::
M[++7WCHQ-5[KZ"YTOR[/_F#EY;.$<'6ND74ZG(<^)BN5[FGN9XW"3U<LTXZQ
MTM0\J;BP=>>61?E7$NHISK "SN;U,@&5)K>-,P K$2DM9PH%92JC1+.&$9:/
M9Y -U3&C\X$U+K?BN@9R_<.E=(E 8$8?)C$8JCS-&? $JIP[MGC!YEVR8]55
M#SXWFVQ- % @:P+,-74S !'GO%Y G.GQG6"6F*L#&4 '#^. &1&PK%=PK/BR
M?$&;\N7'D,81#M%S><$8-7/[4(53QA#]ICWZX,W=N_6J^=:+9H/=\UUIRV$"
MJZ8GVC9T3$W9E8Y>DR>OKM!R)OOYE=O+%.G#UO7.4B@2& _D(<'+V0ZQ^Y:E
MFDGUG7U?(R4$^G9\N49]'Q)X<5Y-O9 QRGB7?)EQB@M5<1+XDZ:!CUEN,=V3
MDP6ZRV)_MB.E1J/)])34;HP>\/$=AI#M4V8)EK+2%BIV.#*ZC;H"Q6J+:CE>
M"V1KY8%]87Z.AD=.<F+<Y@XFHU]^7O25ZZV=T7<.3=]]BEV14ZRBI+1,- &_
M[!4'F$SNQ+>.'G9@]3^<OY7B0Y+4TUQI )%>"O$RP)[\3*OW4;39T9=[Z\UC
MI_=94H\?P2KSGIEE.>?0N?:A^R*DB0"K#2YK_')Y6!NK8MS8PWLAHFFF6K=@
M]::,^CZGF4X%B^;G_Y#_8:N5)G?2@JE?E#E7J9P9@%<^-QQ5G%#8HZJNJ7KL
M>"8>!1:@OWR<-QY$$BE=@"6&/A*J6;JXUYB?:P5:>L 9U.LC=K,^P-H_;H>Z
M]=['>WYL2BB2?@]E)>3<=2BLJ_WDHW91^$L%N#K-ND&96'D$M^SBY5[P^?<Z
M9%1' M5*E4CJGX<W<D'L;F!MJZ/+*CEI$AFL7XE9Q3TJ?G)DJB)K3JE;-F7'
MM^I"BNU9ICLQ)$L\V_5+O:^6K'RJR@MM/X%:TEE\C:5/:?"][^8D?UWX*51[
MUJQ82HVKJ@:#;,D2&JJLH[VN]A99,72JIR+">:-<NU)$?2G<5/UZ\]A%.M$B
M4^H<LF!YP&0^KI]\0/>GZ9.,Z!5J]+RKF3FI:;%1%&.E2=OLZ8$(-MY;QTO8
M<Z7)NI95C^-Y9[BI] 9\).D^@1:M;ER>?#\*"1-D/,*XZZKZ[MK1<Q ^0+VL
M3'Y4FOH5\XV;Y^* HZH_[.GJH/M"Z?\PRR$B1_W3WWZ:,MT=(H!&1OB(4^R?
M7-!$9.KOVZ2W3*2'OTLV3YV[/GS!C_LM79#7LG7&@VQP[N+VMJP9=LQR7.M-
MJP=UN,X J4*E4@,ZE%]-G/FE\<.SWTGMZZNQE4P?,/L8.!@3/E2!)VZQK2*.
MVU)P%N72,7+Q4(<(Q,$J7>FI</2M4_0K3I68M41PGG6?\/.+XT(G$IBOL2CK
MDHI?X</#G,AK3PSVDY%4_J=11:2E2).%^4T'4AE7C*Y*5&9:Q[JY&ZOD,D6Q
MN]]F[&1[P/."/XYB_-9.2095Y.8Z]>*]Q5J#9V:RY]-$3@@ ++<^&-W7/ZFK
M1(I#^3_%<.@IQG^PS>Z)\[B::#$L8UK^T)4CO%ZVVI?S_I FXZ..^"6F7DG>
MU8S<:2( X'S1!Z6]R$AOL $_9_21"O&W;I/-E\L"4]6N*0  &P5S/TG;9/JZ
M6NA#UWY\Z EQ_90.$%^#P(!]E]<S"O#/!NEC4;OX4/0'/\+:--VYQ(=0"O0Z
M6;L7:^1F@*V(Q#/=\]6DX&:OKCIAW +7Y *.>M]X^L,V,R.+<JC^KR>@F?'&
M;8UBD ^WXNU/L](6?N[U+K_0=#_*VCW B;D&I+&O90M90C4I-&&RLE],6E8]
M]=F>'RES#$^"%A !,T8Z0ZGAA&&R1,S.#&M[7U0653_>R#$'IS(Y9%:9L'&V
M8-A=G[\V@OI3;!$5PMO.'=='!-0\CL*F U%$@"-WVUJ8P(Y"?_0G O9C"X2#
M4O]\P,^B\4^JEL.-<\;;ZW$3FQY'B<#/9_-7QFH\YJ0_3FU28NP()R20N!'A
M\</E@G[.9CO<^5HB,&NZ5'F-*O6@;E;U@*R>E0B$T< ),MHD(AB)!O:+YO$A
M#7)6CD3#_!]I?K2#_\_MU/UHYW<:WG_Q\_B?^?G!]#]T]A<BPN^=792/O]\&
M*"1[7N/6^P3K@1"!]7*"--E\P?ZO]T)V[/"NB=50D@?GR(4B,?8^A]\J#2(K
M2Y$+];"=3R3)JU:6PG[]#GRWJX8Z_96V:-^W TH$NO[5ZZ+=F!GR^Z3J_BJL
M(W%5U&YWG?=@6[4C6 FU>K@<]XU^&HYGLX5A7ZE,8#,)P8?;FYK##U4,UR,,
M5A&!+%+M.J6!=YD:8YDZ;&8I6*F/]&8Y$>#[4\\F,.>_L_PQ'TP$E&>)0&.X
MY'8\'+^32-AC(IO/=L?U_K"07R9A_+LU^-MMQU?_),[^@^\56#S@!_^;E=P(
M)"DM\%]&LPC[%[7P=NJ/_O9Y9]5XP-M$X$<'YC\[X/UIR+!?K)OGPURLB$#?
M'\KX[8%L'OF37;N_L/M'<[_X-?]79Y;5!.E^Z;I$_AVKH97Y,<Z>K"7INSR1
M1W9RZ'A)$D-^H_V?1%TV.MX)XFI\;E^%VNR)?A9N,5L?_R2E'^"H3JVF!C;Z
M?AJ$Y"_I%O]ZGW>'X3>7D57]2CN-_-G'0M!IZ&5<-6:]:6\A>KV2]YB-Y:)L
M,LB B2.^Z\&-(X]J8MF;UD&K(,M]$R+077-XG=";,RA"L#-%O]*E5[+5Z ,Y
M8V^+L;6Q2^]%NFS?<[+CP89OE"B( +]J)'*%UX,(O!RM_O:/GR31ZV''D5&-
M2J.-9R EK4', YO'W;R/5GYWEP%_SO6S<OX01AT% 1Q20$]G7! ZWM:= [<0
MF:863\;: P4$Q85OKI"=#@J3F9FJF.B,7FN4A-JFM%=E.&:5U^G2\B0I]E).
M5:@,U8P8PJB!Y4-)>.!#_O0YM49<;_8N!422"%"RDGRIP20&V$#^E)]J*!'X
MEY? ]OZ-"O_3AO]*Y4&B$OTK%?P7U2]=!$UALTFZH/Y3%W^$ID./9EXD J?_
M&G=^BRF!/\/%K_BE?Q@L5<O_' JH6!/PL_L]8-T@.9K3+R95_A)2_S1RJ@F2
M[H_N_!B>Z-^$X/1OP_LWJBHD[D,)R;7_] \SYLXV)._G7D%65ACMS2S9,:QN
MZ<?7>3Y'V#HO43;4O.-OO'N0K4(-H6DG4-2-^" IOV64%<K6E1QW7Q=S2+.\
M ),_^C1$&"##7:-2)P(TUSMY-QEP)$;"%I&X&%6T*V2!$,I[@L13H!P18+3U
MQ4OYMO3M"3=RDGSCMAU:&R\%^_',\>,9;P#<5\4@E#R)@#I]! RGDDD$HO*)
M0'CI;/8N$?BSX648.I/  AM0QDP1:/C_V$[B@;,D E=V6F$XL5@B$)U#ITU@
M*4R ?3N-(44$JB$8E@G6,HSMPQ,!/"G6-&\B\9H^4QB2_].H?LO"'9[UF?3C
M-BPYO!C)^ /0<#R+)A%HZZ<2()&8=ZK^QX%Y_#XPO $OIG?JMX;)NF$M(]B/
M%TBZ_#6R7 (+_*\,,H\2@58YZ,_ND3^[/[S"Z]\X.D/BR+I3]3NI^W^-;?0O
M8YLBC2W[[QP@_QPL^!=/743@\+V#(RJD7#&]YT'@3R>P5">H+I @9C:!G@0D
M9D1?_Y"M]0_9VI%DBS_[N[ C?PA;_U#8?WV/1!5>,IN]=PSZ)T?_+NU_X_%0
M2G]3$B_)(+S^:A!E=01V)-KIX-04+6SZK21!*.7/9R="\X]6/KH0 085 5<4
MS=$X))V'DWO2^/+U.AZI)L;M4KM05::MOBC_Q'CO!MC5\B$$+ZUKKL&#H3(>
MBSL?=(6F+=5G@Q0>P),:12"BK0121 Q-A]*^Q<S'.KZPLG'QTA?D@(I2*][R
M3#-E$P9\-N%YL#O(71$[;MC*7;L#P8A@9<(_K47")7"[6'U3G/6+;U+?:MT*
M"HM<]T;*DIA\AY2,3S^-FOSPRI!2@0R4==!8 W^,=(V%<\M%*QVE7<M^(?Q0
M%2T]^('UVH2>1ZR'/"V[08Z3,N=@L++7OL:LJ/< G@FV=OJGQ\-^!+0_PYZF
M:NSRP5&58*77=M!_CWW_$"'_@<KC'^+HOP>:6[!_9:8M4HW]GC#U>PK,)67(
MVL,[%O\Y:/T%WM@3@?/_ "E;"3=_;XV$;?[6)2E75,7_^A,I<V3_!G=NO Q6
M.MR.^]N+)*HG1.##/R/&OR)/DJN=_!,/_6#*3+)1BGXW%/=K0(E_#\ E(V=S
MZ$7_)NC$7_FE\Z#M!\#PKC964TLVC:LVZ&0O(@*_H3^C?TM&/X$!]5\Q'.(/
M#.> =X']>CN'7OIO_88$8K-)POD#H&S"_X44_PTT(G\3S]_ZXX@O)@)IA_W=
M2M_70A$".HE X#6JC$.\9K3R6V6 (P*/_B(-4B"K%/\!<_MS][7&?WO3[3?@
M]U>0#4H]R'?[ VFV\_X=,GK^52N'?9+B1EOF/Z!&D[\#/X]_PZFD%$L$?D=^
M/Y#J/M._@\;?JJ ;'!X)2H'YD._J U#3/%P0C;BEA%)=O-":BZ!6-,4&G&TZ
M;*S!C+-HH2]M";=<.5\_VSFU8=[(B1TW)@*#GFH\F?_],1&/ 43JC.2I;P3&
MP2D3E ]8G-50ZP:XX3*:+TJ*Z^QDVXED-9Z\$5'Z*![.8;QN"2ZHS^9-S6AE
M5&ZV<7F,CXN;0. XAWKV8^Y2U. [20Y<13,18*H7.-J16+P4Q!?::1)JFMF\
M[RXA/G^LCRGNG>KI(PQZCWQ%]NN#Z4T&M\#< 8;5P]+C73(TG ^_GZY%I-Z.
MT51FMSAY;,]<&>L"FQG%(5'[_"29:,IH8\:600B<Q\N^6:V(<9"^9J!ZM.DQ
M+4.;XC%.=SFW75_W3K;7'C$@)<Q<9ZLJBU8&X<G:F&D_F?NLL!!+!Z4S.7*E
MF@@(+6.6"4T/D'MBYL6H5$(/E/ 120=;H0+W'518;>G]CR?4G\LJEAI;K/8Z
MW9;4\J&0Z[:(0$R-Z7HIX;.CIT>=4R:GT(IW5X<SQ6SBT:!AD 1*U0G<@=7_
M/ ;53.C1&T$GGP5(P^P9+S(6CM?IF#.'Y!GOV*I_Z['*D.Q<3N2&S"^@W2.%
MLEUFA5$(L-]69J8,RYY/?.DX?SN;Z-N 5KH6_CYJ:,=LV"C)9+:OOL%2-:L"
M.'/"R>,K6QY'VAUHJZJ/<!JTG:]4\;ZHC7PRQRC9\PZ=ROG\G;)LS;[<X6G2
M]%MN)Y5O?@;#9VCZ2+KFBQBX.F: KSYIP%64A]]7:N4DU]H4*R0K(J^.;I1U
MSJ(;J3=WD@M#!!H98F"?(^K*U&FK4]R36RK\7BBU^Y$+4 9&-U'%+*A(0&WK
M!X-$H2J8A8>5^]H#[DH&+GFXR.MIGVVE/#VD!\9:8 LY.@\3/#<B8[.S8W94
M*: !LXG<4.,AA!&34.HTDE&W<'S)LS.?0JB8>G$4:\-I>6+J&_KS[?AJL2>\
MOBZ<"3MM1I^JT5,)B%4J\TB],+WZ<NP)_ZWO'6=@U:FZ%%I-.N0L3F9?R/:?
M=$J3I?MA7?=O'!34GT:["1A4)C:97U@:K38?'"\.6.[1>>G$4(W?B,X[9N'C
MXXE7VIRDP!U@EF>HVMP<6JP<)U.5MB?5WB8+?4'5S;APG5ME^\2T<^F5*J8C
MF]Z;",2 CF&SHO,U7E9'Y-5GKYR/MG2_\_2&P-I%:":[Y1NFB*E>_ZW$AY4'
MPM:C6YEGXZS27I?3/-4_R=86+M"RR79D<UF-6<G1+Q<GW,*Q$.6^^6VN<O"N
M$S)#?L;V0Y+6QZ: 1XBOO'2;L&C0>8Q=&-Z/"!RG3':7>5(JHPBG[BZP+GUH
MEN+V($8Q7$,N(TF5SJ+DXD$_/4\=FIO7HA874+B8)9,Q938J]'9#1COAC$[A
M'1.NNUR >C-%PCOXN0&8$R_3HG]0(II=1;!7N%6<Q]EJ2"OR*L.2@0<-9<2@
M-5JREWK5=-?!W/%:?B.6CZW6#9Y8'_@:>OW= -3>*1?6HEC:5["8<7>/N7+[
MP\G1XS?T/ED>$S]-14<GVINY_7@4"O8K!'MVED!$FU4QT8O^[?,O"B"F/O+B
M985^A$''YRCRLZG\^SG/I"X %(FW:@^R\ %4T?4N$I%80V6*5A71X2GCNO(J
MS(9N(!W.(7Q4M/#)J^3RQ"=M.MV=\C(J#?LR2R4YR(=*HK-^E?21J PE!>;M
M,-_;'E:B%K,7+E0\[FJ\DJRE5Z?0=;P5H+M/-H<\J>K\=*AS4G%P4]E86I'W
M&">GO3^!,^! PO).J&+$.V1-@NR^<K%E$L7IHP]T%N;(&U2O'^0U<KFHLE8B
M*7I]<]?>O:U+F\?HP0;6[#..I4VY?]3?+?-U(EANSN=B82LE!\5RT953=) D
MJ R:GLW*^A,N4W>?:NS,NQA1GZH)\(5'?G3;WY(NW'YDSQQLUJU""CK'Z&(:
MSPU"KXA'C4@WJ+A)C*HMN%J_QU24?9E^ULPKG!2VY$R1@BO%<K82 >IYS$%^
M1XP,MX;MN^3)]Q-GJA"7!UXD5>LK1;/)<TFL=BJ=(-> *F)%6R?YL"HAZ&W,
M*B']U=(>;5_4R:EKE3H9QW*RC@DFJ#^+G+CWI.-&L(Y\ASO4&6=?##4<N+NR
M>6!]M<+BMI=GX?*8M']59B"GQ&#*>,6+,X;LEK;WM!5#VN]QV*U4OX+(HIH&
M<:H=W2^7)GD&):5%UMPK0[Q.;*=?[_0\&\,K TW3Y3>2G/<Q)=-[DT,7H'7P
M,OL:-CUZ?17*6@0&45=AJI)FSC9V'GVE[\#5@2WCN+PADE2ER<[XPF&_NO-F
M@'YB8M I&*=JI'<BG2UXGFTE_UW-&Y:Y9,6<4J:DIL'C!7$")5(=<4RGNL\U
M>=7:K>3.J)Y8%-;O;Q1$E(;O1)(<\L12CT_NZS[EAK<?XJ6%>\E%)IP\WT4:
M=YB^N? ">VJ;E <?+IL-YACX&H:U;).WN[U>]Y9?\]ALOGN-?F5_XMOHW C3
MR1XA.IT.9_*/L?LZ$ $;K&E9.F5<3^&DZ\:W!_ZY!LYF,VNR2<<8HJ^^C\,J
MO(YG.Q(,,3-QQM,.X!7W-7"R.^U!EW"^.8T5/(A7+KKBO>'U^3F(QJQC'?<[
MYRQ:GF596B0^#C.OY]Z_\ 4BUY&V(UM+2">90FE!H6R)VZU&GH>N 5^=4KJ2
M\37BU-T"%V=DH$=L<29&GAAKM!NJ19G>:B#;TM;!L&9T?0O,N&TDI&^QML:#
M1C^8;+G\5E^([>AT2,)%-16C@ZH@3LAU]'HBTJD8?P'=*]DZ] 4R/RB2-R1N
M0IETL1#,3"&@@MAYQ.EEQW;X 0<1^/K@X!ER);"2<*NQCS*8Y<<M,Q7;I (K
MQ0M'*G-OZL,/6,##RSVJKAZ[<JI14]M'2-!GX$ZPHAT9K"L1O;Y/-4X"O(C2
MI28,/3Z*P$,$W@0B";%64W\K442IVGCD,"1%K'MG*CM9OAWRD &'@.T]O"[F
MI9ND49^4$1:[_UZ>MTW9F<*_9IT6JH9!QI5)3)/>B-I\?A^L$1NU.?ZIT-E0
MI_7A+?-'VLK-!2!2^FL=G13DX0P$C>\'SCH9R CR!-CK3].O,Q\-S;IW_!NM
M7_H*"=\N$5A&UC<#9:=L*W$>]@7CUBYO(!EL,[4)BR!C?LU@0>=0/YCTTQ[Z
MQV^Z<^CO\?G"3^/NY!)8=SJD^O#-^]F[V_Z;HGT<S@J!K>,3RPJ!I2U<TE*V
M_&^Q6>HJJ?.P8UN*!N:SA1TTL:)%'GP.>62")ZE XMEQ8:/_W:U/E-7&(,U]
M$LKO/I=.:*WM)#P3AMMZU(MV(1UANV=,B, G7PLB,/1PD\QW5BY123UGF><X
M)CM<I<<#CJLP3AN0$?WVX<TGZU:*/J7):X[?>5WOFGZA7#B"R>,QZMR;:C>*
M"#HUTMM'$J*EA PW3Y_>Z,<G_._"R^"YU>\L<VC+MTLBM$QJ)D*1$D8Y4 N<
MU=1)<6EP"2W(C@Z7K=9 &!C8BGIA2>B]$#_C \F,%H!\]7;L$I0[PD![+V-A
M97^&"+!!O*Q4^' QU5EB#=E&::,;M(+M!1;BSP=M.HH=%Y+;GQONN/@RJ!TY
M2AXL:8&K[K2C)X@Y@YBPLOD.L]R2;6FL*8L[:57\+?.32Y^-QUCM+J0.7KFO
M$5^GQ^#U")R1/5N84*K" +5$(0S.H:YBY2(14RNE*JV&$0;ZW9:GWSJ'G0.&
MWLE=>:/>/7V/3!D92J #OX$LH3I 2MA02*?=4.F=MX.#/5=M%=YW7(IA?WKK
MNZ!3$K[RZ&<<33"EH8<N)GEOZBKVJ[]1C(1WH%%;QOMEL[WP2@I9$S&6 ;&[
M=4C_R!7D^3.^8G'U/CGT?#4'+Q$&DDUR*.'V=9]7UKB8'NWA;!/,LSV?[22F
MGCK_3XKL$NPAMID4%&GR;G&4V9$P,)B>'G^L'IL=A^ 67[]5/YPSY' R5D0&
M'  .X]#_6BY^(BZ</=<^5;R+O>ES]C88Y2.NCK<MP@U.SL[<<C7;BR\KY4F^
M;E#-H"Y3JR:&W^AE3YB'ILBN#KH? 5AJX330XV\K,)+1E9*GIK(9)R %:^ #
M][6S0=U<0SI%#S4YRB_PZ0RH?>F,2[NEFT.WT\IS=A#JF-M<XIP1WEA<:) M
ML32JAJVBHV/S:3YB_@Q7T98EB=5N7X32H&U!0ZUF_J!X2GCQTMO/-#5?P=&%
M,<?XM6Z^HOJ<[_2 MEF-2C!AW;@"I8H6Z;<SJHV84H]0)-5Z#^+U/[1?TT#4
MQA=ZRB_;I+=)AF<02F<Y/=@@PNW7<.9ML;=K':?&-P>*+*>L2NHZDJ\(QK=J
M;>B\[^$C A9-H?0 EUGIC&2L;.-I'&QZ50,TX!WO8%8STOX1;E\8^$+";375
M:E*=!KGV/#5BZTL3PSW/.$?P%#?4:1I.BS?'$ K/-);.2AXK>"Z34%JP:*(
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M4;P#;X2WKBKZ7-T@J\TPY[&T15]?)G$NAF#+9[O/+8.O'>^69_X&.ZDB#W%
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M)84JC\4V>^G-0S^V+,E>3FD;?=23G=K=?=']&^4H*/Z1[.&<X)DP--)=AO=
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M4M&9P="W\3Y$H+P<MIG,@<E.),6\E+[@J9]5X>J^#!'X:UDH3;:^^?NE"3'
MKG7KU F\W?2$)-J,5#(>F^LH5<G$+"VTI(]=-=&<'P?IB>5IN7U@*G#+T[K9
MR7X]]'AG/R\-7E(UA,"!TV]-OYY94LJK4SDTEWWI.\=9,]F[LS4F_KYE!3'
MAN08Y[83!K9ZX:5+AET<79ZX]VYOF^KGZOB[X^]3+_%QQ9VR.PJIV-8::#R"
M#\"<V8G<%([4J<::91]1>+X0;3#2&F'_:/33K+#2/O6!40I7('B:")! A9L;
M=KE%81$'R[$4S#H_9$XX&>43NO/=,9AZ]-,TEP/<7HT70JKI<-<7BZ>6#T3^
MZ^ODR%+D\''],%0%[-ME1 F_W2[["R( OT,$^L/!/P(7N9R>^XS"T")\A^1,
M&V[@[2>8H,@96B?#-&703.>5NH16,Y2;]TZZP= :EPAC[_EOYOX>? R9C;<0
MJO&JSNO'(;S6(][[PR/N+P<<8MR<3-Z\\7N]F??(7>O=XWM(R8^7O[YZU!OL
M92<$O1MJ=QQG-]L94G]F-E[HXU#;7OQ")AH\(6'IL^MCC;MVK!1(H7>3JI7+
MG$N.N4U8T[9]#=ZS:_6@"!IJ9,!*Y!Y1$1X53%Z^6OZTW+-8T_/EF%53U5*0
MBVX6N\#84[X#9XH595C;F%UXO2(,[HK"6'P;9>GS]0J0"N&Z]S+-2;B?+&,&
M3X.=5<<N1%]7BS5"2=N:S+3NFWSD]C!,'@:-19A>;#,Z0MZ=*GC^2UY1+Z1Z
ME>S%4OP^P[(=[>NR(4M<^$N<E$'6CGXT?KG8(:J#1X-7[/W\Y#VIY^T67B90
M;I1 Q4&.M+AB,XP!H1H-8A_UIFDP:CNY9)6\1%-@$QEL+6V0N.DA!YU=63)5
MBV+(=0,";37_=:<X60_.EZ %9X"AKI!4H^D5I$**2TC,[&(1*<:'V I'JGYU
MP5(=>!M]%<W [N#3Z".(@($V$=!M!_S=_H^WU1R;\D9U9",6$NJI9E17)UC;
M[:B5C&8")G@&9Q0-S&@O?$7$9_#[ED1\H[O4B<G8%R_I@CDC3T*J-3&4Y?21
M4,%&@:IL@UI6+\[-JOV+NW<O4IRH9E]48R&AF6>P5@7HI:8F0BMBEO!9W#_?
MS^[''HA5S'(<K"UA>*L/7\&\]/@_VNMS."F]\2\<#.#;08D'5@>BCW&E,T7U
M])A]2]2=D+);%5&*EQ^2?_:QH< 14D<N$V[K?.K0<B;7^Q55#%Z2_-^="G0@
M\B!1S^J/+ZC_&G(D#P\V@76M[E\B I_V7?"CC7W<R[.\N+-V^(2IBL2?*7H%
M/?F_KU0A_URI,OI]I6KO?UFI^OE#SWWP4D7(F7!BP&% 9HH2/'EA2.;=[8B
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M&I.4%!06_"N)$[F5<P@V994_XC*_/7+,/793,#Z5\NBJ.OF+1Y6!QY52IP,
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M+:@MO2M!$"10C/VO)MID7.SR]TN2W.BO7YQA9HVIXUKC*+N(>7,QS\KE,WW
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M]JM XUMN6G;+65D#^RUQKL<3@<>91A$!@^V'X/\RO'\[:O4?HSI$'&4!W3<
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M:'K@I];GO4)@F1QB\^U3P\[>G87*<#N@D-1?^SMZO*7XT'FB5H /ZTY-QPW
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MC-H,9CB:0$I8NMII:$,<@?@;''_CAP:K;_>S==L4)#B:#L1WQ@^6T6G=T3<
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M>&_JNV;LVK&:G))H#*"3 ["WQF#IT@*$'1#2JT&<J<)9FN(JQD'>[7? 2Y_
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M1P"KS)44EI,+XN[Q($SX/@IA.W?Z#)FY71 L[K4%VEGW:DR-]+1DQ+L?"A,
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M:;8KFV8B@)>LU?.RJ71635=H_53\*T*%*7%#RLIL_]X2"SQK^19 MY5-C0P
M%H&+3&<=_59%'%W-3$WF%4G473L%NAL.@]N:[GUW)[/]"R8_4H4,#BU/@J8$
MA&SJD'!M$809O#G_\;. J\A?SBMCZXC:X$@+[ND *>O?FZE0_:FRD[0R^*4"
MQ* %KD+2-!3TI^#,F06:OK-::Y*Q;NF!,K=HE(\@9VG-/HURJKOPG:]3_NT@
MSX 4$#?GZ+'@K:UN2%]WMEH@,:]1+);H?ORG/XWXR?I=4=$YG&ECRC6T>\]*
MO'),K*H$[ ZL'<IBV=-4M"\,H0=]TCW82R#XJ !VFVAN4L-ZQR\(.+-L:U60
M 7&.XXC9B3$BJ"W7CXB15;Z'=.\2?F2BZK=9J+&@*RY#Z?FXB2'G4J!>#)D?
MZJUW^N&>->;9I/=\KL]5:##1[^;KV.D#V)[M[TD[K\EN'II?%?]X@<1N1P94
MEVE"E"5%V0W#K.FL^<R W/5":5F[%:U3;5;L$<!\8+.O4)7,"QW4MFQ<+O@Y
M0 L$=,8,"Y8+O+\%O*F/!T#B9Q&$I%12#Y@H+$V69'F\<L&S7=+:.;$!4L*1
M;X@%]BPF<.E&FH>C,C1SF:O4]'L]$F==P:3RW)N-\S=I^7T%._PE+^$(TV+C
M\H]AZMZ?,]F7XC-Q9G#?)V^+N6'HB<!KOSWKX=*X4ZR'GH83-%CK1/QD-#9;
M$GN:4.'0:#(#_>8\:)2E(<2@K23C&_F0W18A0_BQ@;G'C0:[G7X+^&J5H804
M)Y,J;&307@BQ8D>R]6B*167-//6AUSSY3)YBJ8S GN84.Z3K1L5PK4V7.3L'
M,JIG?#QZ&,6^D51.<I^#A_JOB:/];CKL"@V;!.IIQTF:A!YD&QD2<Z1<-$8L
M3F47-C?K!&K=X:%_[WB@QF4KA#[S3]1]S#NVT5H%;U%0%EX>#?$:#NYF>8[:
M]2+$]M9 T]9^;NVQ0[[7!<"5AWI7OT)ZYT+X\_#FRZR5^&1%G'RRCQ-5T+-6
M,O&X8PVW8)<B[Y'',QM. PT>FX1NAA=M,5<O/,H<%6:3MM)+^0I.KD)K]68?
M4A,E]B_/?']%\#71I(UB-:%#7JBIV2;ZU($2<Z!M-%-;UU[D@!F@D\F?#WM0
M55Z\ C1H+M*60$*0.UK;>ZO'5O%<BCO^+1G:0<'3(P=FDG4Y#T_$PC>ZY>]&
M:")9)LA>OUDGLOY:IY3TS(4@S=?F'F5FLHD?M$>7T4$PKZ]B%GBQ$?ENI2TN
MFE\.DOT]<E_HMPVKR/>R^+M)L[J:(SCS*58JSKJFRJF3')HA*KX M:7@YZ5_
M?H70<\P]?YTA?_#Y: <U:^ZP0(\UCV4(@Y3:^R]/AV.<'4T?W0+^OAM])FQ'
MG\#X-!G(\?+=CJEJ&0^1E.J^R=[BQ7F.KJ9.OMQ0 6C'8L/^7[Z(Z7)\PE*M
M-FNW) /B;Q[$&L23)3A.K.@>T)%Y=X5^]^6611I%=X91A=BEG&;OD4;3E,LJ
MO#H>''-^>=]G391:_>:4O^]* 0OM3!>.8 G4[9!X<0OX/'<=YR5(]FKX1X:Q
M?>*AA) :5V#IYLRR^HK^N\Y88FR5I6%L>F'&HK=?K:V4HI2#.BSEW@G40"VJ
M=O9:3[D5/BE.L5MZ_IN7;+N7\WG5YJSN@S:3%EO2[[.]20/K@R4$&K$N'"$S
M9Q42:+--P7_)$%C)/1(Q@T6L'NC+X3"?4LY?RB(@$8& /2!0@X,%?F!9HS':
MG1 /O2G\3[V%TT8P.J+K5)[W'W_X_>KQ!)P(;>H41_/1NT'U/>F?LC)RY;NB
M1+*/+95N_B2>LSZ2E^RD3[/"*:G2SU2]K(THWM9M@!8T=P<2JE"]IU\-KC5(
M*;X%? +;=S?:U?QRJ,;K&M_,)(&>O,$::]#7-L!M@(8_1R\,EKH?IQ PH4;;
M[NT&R.&>="B0-M,O"S^ZDFE#!;R "57 MEN9IVG6]\5"5H;GB2.G5Y-67W!6
MBP >)!^X]/BG[@E;,Z.N^*,.KL2+P!6*E3CIA6V3H!RH^#D:8ACT)N'1 [Z:
MGXQ04JI3ZLXK?9Q[@ Y.LHN_@@)/T$O3RC$>8/C)C:4T<'E@SP Y,-<#9C!X
M%^K W"4<)$<("/SO'^,$G'LG%?^89J"VQ_)Q&V,S,_2O4Q![:N_0"K/8*%1;
M<'DRQ>.(VH!%YQ7'?O;&0BL:E=\6H=8:*$17+LX5-ERF5_7!5RFII*^2AQ46
M8(I+-<.CBATMR59P&V&RPOD.SBMDXND[&LU)P*N.I^CG:LK#@,#<4DMC(+)"
M/E=6XK3CB[!KAQ[G%RF><C>3Q]?CQV4YC\'V;W!VZ1=!%;;DN78CY6,C3:GN
MWP?=MHFHYH7UDFX.;V9W#6EB[-FB.-->:=0_<&?5<1O-+8%/HQ0E[3^ALID1
MC2B8>'CZIAFZ&\<)E"%2_VQ3&^R5P$3Y<KVRE;K+C3RJB"3M4UH\U%,QY*3\
MR_L-0 T+T<WFDB>UU4)?=[KV8 4:@WQ:/Y6N0=K/+E%71OY8Y"SZN_2A>R"A
M!D^()TQ2M;ZZ,G1+8M0=57'*+9+,&[C;_6UDG2D^(M%DWC2E9?>%K6?&2R]>
M+ZJZ2,LAALXSQE?>*IPER?%?:IC\4=D!JEA$E*Q%>J;H'!""%OQ]CAR;5ZKA
MFB3Z^>WYI\-[WSGNRO'*<JP,?,3.+9DM@B?61V;W@EW@=>KI.Y[5S^*><*R;
M_]RHH)["_W"21#&8PPJS@%[YYB]Z2DB@3R<HLQ[Y<&)5@-32XD*W@(IF4Q@%
M*S9]E">R%A2EY\A]>' I*DAB7EV;-+^L:B#@8MZU_):I[LX(72#_6 #_LJF#
M.)G)M%<&L\[(H6E,:8L$/_B'Z&A(1ONVQ+<CUI;TE0#>9<MP"WILRRD$+7;#
M6!7.>^!%QGWYAVO97B2-RZSN1$9U+OL^?UGEY)5"'OYP]-V$%Z/,8U\GYJS>
M+!!Q;:I@C<3N7EP_-?67!P2'Y8W5ZR#(+<!GS@X2O<Z2L"P#HIC7ML=X(NJF
MO) 9FN.8<4$T=TUUG(8ZC2>]98JR^RM2'=Z-[E$H/D)C2CR81(6ID+IF@KVA
M/G0[)@OS?G:14/W#97YR$W>EK%'C?IS;BKE>EW1VN9#GC$(-6TU+BBU"*RI3
MZ[3S3Q]1B')6UQ=H?,K4M@6E+@,XN3.J; ;(T-*; SU'^/WP^-$(S_KA#%;*
MIHZT8HS]:%T@ 4G*:+D%#-W0!44\E>PK'8TT&3X+KS4U?Z9!5=0(2<$0K87;
MU'#8MBL(]7[<  VJ2U$'Z=+OY#RZH?TIQJBMT#4@?KCE-K]=1/D 0?JA^7';
M ALIX4=IAN0>2@?O!=K+#Z>TC30-MJT3R$#-,;.%A8[/&#M]'IEO84O)F>D#
M> _KXBM3'%=+7_S5)NC8'S*U=TPO&#+K*_KKD7I%0F:NWL _LFYAJD%JA9'K
MZ!80T;9D"Y1R]#&!=C<)4^"3._\@#BTW:?LO/!9,?+7MJ=OYE/N7KJ#$0U_[
MAG?,@Y(Y3>0KKA.L?VLY0W^:["YT%]7=6$L)U#_P/DJ:YQ\YV6%]@+?79:&:
M] QD _LA3Z7@0[QY@94":0ZK^@2DO:^R=K1>X;CVHU;FP>; 5#_[,+3#BKGR
MNW0U25H=I=^SA>I&E6IO/,Q>%!8P]@1W_',).Y:GH4P#5,=!LF\:J?3^>$GX
MYCW. -Y=9R.YNO3&TOFLIW8TMK8$7A>3MQ44Y@C")V'-E?4.Y6RR>?'N1 \>
M<!3)E3"["36;D_!$P%<*=&V]K1H3G9%*ZA;63R-*>4?AKGZGJ1@*LIT+A0P,
MS&#G_;1GW3@2_"O2M,.]*5\R@?[EG)\S /D.2E^NGW?4,MBP)2T<(];VR'(;
M>>HRZE:H?>K4)LJM#:N5('A\1,KR"U,OS!"@AATIAG%_+<#_EF/L$5[["4J:
M'+E+<[WS:7#OF3ZYZ4LFNPI\GG8C/@L+?XJ]!<383?XIC3KQUW)E\7SU.IKJ
M:T@WBXIO1 <%(S@(1 X4 <,^CWL!A<7FV7T%D531*/>2F8;VZV6FE5;I9',Q
M!]6)XE(GK>"NWUR"OL:[?@9-&)F"L9Z#T]?:8"$&:Y"K*9]4V.^5]7XVN"]W
M#G?,I\*ZA)4LU8<!_HS50N6-D>]1HE7?E1F?'CU-6%7Y!%>3/PDVP!<OD\B]
M$[^/K8.SY"S-:H573W^,Y*I/<.SNH*KD9*)F3&7EK<A1C5AR]N].G0"BUTM_
M+SI4-:=OQ(B;WFNL:P)FF<NV=R]7*U4,78EO?G(MUVC@H5YM&UK+S8261]28
M@-.UI8]N'A\P;]%<7._#B@K^F+2&L1,Q'%)3<M7^H7NTJ?_.)W")MM4QT+*;
MP;Y+(9S!,BJUDX&48=O\>6/E9!Z[>M)RFI%JAWOYLB%7Y4OYZ8%;0*<&*!__
MK9N%$C[MB;^?>YU3@MYF_1AG7]_(R)FT,J0@](=?O:?2\ $S_P\<)+=@6^'O
M@CC.)IL-FUU1Q#D<_,EF6*Z\LN[RC4,979CJ7J\4".:M3%[ %=A<49[5!HOW
MG?KA%?//YW(B1?$(K*95<UT@2W*_%*,6+7- /BJX'E'L"/,6%$K\479GR)GG
M#WK6;(6]09@%O&B1W-58$0:ZXK4GG*/E/MUYW_@A>TVRB+'Y3TX:5OZC1^R=
MB>)M-'D,SA3#G8&1N[\]I/IC<]BG(AC$/7,SY?*=UZ"C<W!XVL_#E.4Y HZ"
M)SS)4G;)"";=XB[(_]M?^+#;\;72].@?I;6H=]?+/?[USSHT)WP0@R,;4;'=
M.KR:?*ASQ"$[WN?WCC>MB9E)80&HQ"%YJQQGVO(7PF7XWD!,>4+%%4JW'#*%
M-/!I)9FTG2H3'@07DO2$;!M357EEW5'D796::]\?>-KZX])<X1U*5A+T>U#P
M_9"VKCRR]YF^<*K__:>9I.$?I3A/J7/S%M".+ +-C7</T<*[:[0,KQ-70^*)
M(<R23/=W%L5;3(:5WH=HWS $IV'Q91T-<$V+ R=?QC;K]$NM&-WI?8NU@!1!
MC@:02+71ZL8OEQS-LE9:;5V+ENS#%_(9:WRPHL0H7RI;&^MLXAQE=)WGRUZX
M%XBTDBC)@-"Z\=R[E(7J,A[>%EA04)[C(_$]5;29O'/_ P\WVZO.A$:/;^>&
M1W:!O71ES+[+4TD_LNO&!1OWL\:WUHS%JF@JJ+=0AF/=M=@YZ>,)@F='=L1E
MG(G=FJKJ(S+9?O%32$0T[0.K\V%6B*%#/^#K=[>Q%42!242W(5JHT+H6/B,D
MJ+6O^E2V\A6;".N.2#Q%<>D%/-8PO2[/PTH>:>T9E6CTW:;W;BY/$6"5&&_"
MI&+BM:+[6,'M!'30MMAP@A^AK CMO+82N]ZOJT/!;ZX3N/%AA>9]^7.;=0RA
MR%,$BE]\K3:TF<6!LX\S[EO-@U@*Q3V+9"S&R3\FCE\O7MNM^9,MW<3GLF-&
MHVPD[0>KB=<>-4-\Y,I>W*5.)DZ.?O*Y^2H/3GV;YE*U$:0=54V"^$ T1M#S
MYS$KI406%'^C>[>/<X?LCW1 ]4_V=RR$W;%$L^OR?^X&QZ).Y#42"M+7QK/X
M2\W]9UO@XXZ-?JR\J8.N)44?(*6HBT;[^2!ZK$6>UZ\91X1A' @S0"F>\:&^
M)LJE=823DM&>Y'"%WH+"[[C_9K,B0_XA7B>83"*")^[JDW_1SKKW-QT$8HH;
M@G[[ME[ 3]U8YR#CZ_?[(I8:?4?/Q(_J^^NG'<\L()?-"1.\IHE&2='/RE^\
M_;=+957WK\^-[I/3G_]HEDO6:RJGV?\7.OP_X(FG_P.>F&0]N07\%WCB?\A1
MSP@F_T^<LBY<Q#=/X4@6YJ:Q *U\XYU&P85QN; K?@'1O8]##>H=7<\4WO*/
M>@;_95R"1IR8RNEJX_6799B51FRS%[;)N*G!^>_IS746B-@>6[2H -P5'LL_
MP4MB%E)H,E9T28%!W%515_VY4WOO/S'ZE:LJ7N@GW+UZB45TR9$Z+#S!WF0M
M#S]C7K29=(90"8 %E.)U&S:BMXI^4=!GG(KCJ=U># EW*CP8X(PUSJH%/^3,
M3 HR.=&EP >_P69'V>8Y(&DN+%*L*3N<[(%T\<^LWX7IOVLG&#-(^?^B\N+.
MM'T5]A[^PN?HX_UA \NW@"?*OTR["LT9BPHF)U9'6O68[@M(X+*_M?AU_5O4
MGG>L0+=]<V=Z%=L7O2<KXW0_S1/TM&%2?LJ%=M"% &2>23#&4GM'<K<O&.1T
M*7<E%NT4F0=QIIRV5G,E2:3$YC5<&&K@&#&0-"Q24$);B;$IK#G#;O;EFT(Q
MND7^)==HHH&S"I+KE+V3X*B<FM&O![8Q*I,'QTX.[.,GSQ2;GI5$5[LH&3HE
MIBR=#?NE1IT\!)T,#5NA>I%H[Y1EI!&<4:*:DB_Y&YOWB/L0@H[) ]EDK2J2
M([!8L07O!VGE02VI3< ^VLT-*%EED ]K-K,Q.]%8'R_+>]%BGGK&R/4RO,R;
M[*&N0J0_O[,@&A@9WA/U"L91&9!X]I.Y;PYI'UG>+/C/?-9&R@(]G"@9?UI+
M/NFAMV\@%J&\,Y?YY>4^?P:6(JHVAWQ;=?(#3NP(#.U>Q(E':$P;]6(Y"*HY
M=9>([T^.<FGKUJQ_<[-$7=W9';'L92C""Y=N!C%CYW]<0*.\YC)@/@;6["I.
MC#)VOFZQO,YY<G<N[(5O:&SG)V) -'CO3DLZX&_3H0?8N6"0N<2+._RR:2\)
M&_3I-Z(W98$KP@_!DQU51GC,Q=CB[%R:T+$VS='(D]#OPI 9>L^N/-%3#G3S
M*,8R5$PAHDZZ+<'3\M&"V7G,-:21*]K7.X?M4,.A;2TW6E1GPI<?V9+^*.YU
MWCL3\Y/IB].JH?<Z0IN[]CB+&!Q_-X-.:<&K/OTT4UV(H+U$I6.=)G5A&D??
M >F;/D#F79-F!*8WL0*\B#F).PB!S_Z55?RM:$]>]3#KHWD2]<>GL4]"[HIX
MC18XSX%9#2*6H>B3"N96Z"<H4%?R+^-K]9-W3KP\0QI:606GY'UA%>S-V*S1
M;F;Y6T"//'UM\WBS*0-ZWA*MWHE\%NS=J57[WH/-M:?I(\V.13EYBCC/LR&5
MPB:GA=---RM^?\2^XY49-JNU9D7XB:-)+,GRK+:5F]@[+:_6;7H2*JWB3[<
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MGAL;R@(^N!P/NTD:IN>+;(L8F5R'G*DWF+O;-_[4$,)(G#O4$[@8,=G_$K]
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MH $G2_OXX_][5B'XP<UKT/]F%2(IOK3];U:A"?($0/6C]NV#8>\;&:QEYRT
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M9:K3+/_AO2_L*9?$+8".2W<J^CP=OJV)X&(P=:+UYS67$V[:!_^,_F!U\.#
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MG#14U#2:\GWH:7LZ8Z&*<.GZQS%RQ/@KL5M E[;</:N;3Q-!W+L+MP#;G%L
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MOU;,%7Q:VOHSW:^RU205;AUJ./"EOT'@6[DUH&E+2$_1DZG3BJ$L5$):RR6
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MQVJ$18J\&<.I0?D94X@<,E'W&9,BWD9]@H3N%N+47^5>FNYH&CA-O.$N_Z)
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M#'2!?PJ \XYEX..QD@&9.;9/[8;\^M^W/@F:D8NXEA%D$$A'ASU:Z7S,>&'
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M6G5'18.M7/(NL3#QW)M[=<M@IM7\LT7ZBPW];RJ;*+7309]-+?OG\\I(LNA
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M,UOKXYP6[Q\$L9B+G_?']+S7IG:HJ3OPCZX6_U7Q2LFA2KG@M)=7!)D^MU&
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M]Q+1F![D;<OL!3+[[K\5D/^_*Q)?20?Y )[_F0_@K:7U@;4#!6!63D*0XR*
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MYBZ4@W2$.HL_DJ2(3?B?8 F4\3R(>7,OG/%$2WXQGW6RD+?ETV:L:(" FHZ
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MTDW)F,ENZB*>UR,N:,$98!*$UU5RV;G- Y$HKQ+=H!ZETY-.A+2(0S2BOJU
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M>:WNW6U/Q(\_I3QQ,;L@5($G\$3(G.2@>N6#SD'*?' UF'!T#T0>2C54UMV
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MV>6RQI 7?C57ZWXG4(%- ,?Y?^W]O[2I.1G$.57-*EV9$*L1N/=*]2V]F_H
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M^/]__6\7Z&+^_P)02P$"% ,4    "  -@G]4126*K73$!0#E6DX %0
M        @ $     8V5L=2TQ,&M?,C R,3$R,S$N:'1M4$L! A0#%     @
M#8)_5"3V#M>#*   ^.\! !$              ( !I\0% &-E;'4M,C R,3$R
M,S$N>'-D4$L! A0#%     @ #8)_5)-:0+":%   J#\! !4
M ( !6>T% &-E;'4M,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (  V"?U2>
M7!?K_VD  /Q=!P 5              "  28"!@!C96QU+3(P,C$Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    "  -@G]4U-PJM9?<  ">\PP %0
M@ %8; 8 8V5L=2TR,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ #8)_5$*8
M' 5ZB   &3T* !4              ( !(DD' &-E;'4M,C R,3$R,S%?<')E
M+GAM;%!+ 0(4 Q0    (  V"?U07O$6R0#X  -NN 0 3              "
M <_1!P!C96QU+65X,3 R,%\Q,C@N:'1M4$L! A0#%     @ #8)_5.G^397O
M @  'PL  !,              ( !0! ( &-E;'4M97@R,S%?,3$X-RYH=&U0
M2P$"% ,4    "  -@G]4L)6-K"()  !240  $               @ %@$P@
M8V5L=2UE>#,Q,5\Y+FAT;5!+ 0(4 Q0    (  V"?U0YP;)=#0D  +U/   0
M              "  ; <" !C96QU+65X,S$R7S<N:'1M4$L! A0#%     @
M#8)_5*1\V#8C!0  [B,  !               ( !ZR4( &-E;'4M97@S,C%?
M-BYH=&U02P$"% ,4    "  -@G]4_>+;"^L$  !1(   $
M@ $\*P@ 8V5L=2UE>#,R,E\X+FAT;5!+ 0(4 Q0    (  V"?U0K,5*PB"0
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M:7IT=&-U8W!L;6(P,# P,#<N:G!G4$L! A0#%     @ #8)_5( +2^HS.P$
M:7P! !8              ( !0Y 0 &=I>G1T8W5C<&QM8C P,# P."YJ<&=0
M2P$"% ,4    "  -@G]44,%9\E%4 0!$>P$ %@              @ &JRQ$
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M[!D 9VEZ='1C=6-P;&UB,# P,#$U+FIP9U!+ 0(4 Q0    (  V"?U0PESV
M1IH! #7) 0 6              "  :"8&@!G:7IT=&-U8W!L;6(P,# P,38N
M:G!G4$L! A0#%     @ #8)_5$?P&H:;R   3]X  !8              ( !
M&C,< &=I>G1T8W5C<&QM8C P,# Q-RYJ<&=02P$"% ,4    "  -@G]4>@S.
M) 4/ 0 D1 $ %@              @ 'I^QP 9VEZ='1C=6-P;&UB,# P,#$X
M+FIP9U!+ 0(4 Q0    (  V"?U2VR7?2LR4! )5) 0 6              "
M 2(+'@!G:7IT=&-U8W!L;6(P,# P,3DN:G!G4$L! A0#%     @ #8)_5*B.
M&4&O! $ YB8! !8              ( !"3$? &=I>G1T8W5C<&QM8C P,# R
M,"YJ<&=02P$"% ,4    "  -@G]4:.]*Q>OO 0!A) ( %@
M@ 'L-2  9VEZ='1C=6-P;&UB,# P,#(Q+FIP9U!+ 0(4 Q0    (  V"?U3)
MHB_\L8\" #5$ P 6              "  0LF(@!G:7IT=&-U8W!L;6(P,# P
M,C(N:G!G4$L! A0#%     @ #8)_5 LC[R?UOP$ -V4" !8
M ( !\+4D &=I>G1T8W5C<&QM8C P,# R,RYJ<&=02P$"% ,4    "  -@G]4
MJE'[<:V+ 0"9\P$ %@              @ $9=B8 9VEZ='1C=6-P;&UB,# P
M,#(T+FIP9U!+ 0(4 Q0    (  V"?U0)1X-BJ2T! #9- 0 6
M  "  ?H!* !G:7IT=&-U8W!L;6(P,# P,C4N:G!G4$L! A0#%     @ #8)_
M5!O<PP/W\0  NT,! !8              ( !UR\I &=I>G1T8W5C<&QM8C P
M,# R-BYJ<&=02P$"% ,4    "  -@G]4V-YP(G1& P "BP, %@
M    @ $"(BH 9VEZ='1C=6-P;&UB,# P,#(W+FIP9U!+ 0(4 Q0    (  V"
M?U3RXM4&*DL# 'R. P 6              "  :IH+0!G:7IT=&-U8W!L;6(P
?,# P,C@N:G!G4$L%!@     I "D MPH   BT,     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
